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Word of Welcome
We are proud that this year we can, together with you, celebrate 20 years of the annual congress of
the European Hematology Association. On behalf of the EHA Board and the Scientific Program
Committee we are therefore pleased to introduce to you this year’s anniversary Abstract Program.
The Scientific Program Committee has compiled an exciting and topical program of Simultaneous
Oral and Poster Sessions from over 2200 submitted abstracts. The poster sessions have a slightly dif-
ferent setup this year. A selection of posters will be presented in the traditional Poster Walks. More time
will be dedicated to discussion of the important research presented there, so look out for the Poster
Walk Moderators in their fashionable red baseball caps! There will also be E-posters available on the
E-poster screens, for which a specific time is allocated during the Poster Browsing Time at the end of
each Walk. The simultaneous oral sessions have now been spread over three days (Friday to Sunday),
with the five Best Abstracts to be presented during the Presidential Symposium on Friday afternoon.
For the second year running, we have invited “late breaking abstracts” for “hot” data that were not
available by the time of the regular submission deadline. The most exciting results have been selected
and will be presented in the two dedicated sessions on Sunday morning. There are also late breaking
posters that will be included in the poster walk of the relevant topic. 
All posters can be viewed on the E-poster screens from Friday morning to Saturday evening and are
also available on the EHA Learning Center, for which delegates have complimentary access after the
congress: learningcenter.ehaweb.org.
On behalf of the EHA Board, the committees and all the people involved in this years’ EHA congress,
we thank you for coming to Vienna and wish you a good meeting.
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Multiple myeloma: Clinical studies 1
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IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION
VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY
DIAGNOSED MYELOMA: A PHASE 3 TRIAL
F. Gay1,* M. Genuardi1, R. Hajek2, M.T. Petrucci3, L. Pour4, A.P. Falcone3,
M. Offidani3, F. Patriarca3, P. Corradini3, M. Gilestro1, N. Pescosta3,
A.M. Carella3, P. Finsinger3, A.M. Liberati3, D. Petrò3, S. Pulini3, S. Oliva1,
F. Di Raimondo3, A. Spencer5, M. Boccadoro1, A. Palumbo1
1Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy, 2Fac-
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Background: High-dose chemotherapy followed by autologous stem cell trans-
plantation (ASCT) improves survival in multiple myeloma (MM) patients. The
introduction of novel agents has challenged the role of ASCT at diagnosis.
Aims: We conducted a multicentre international randomized phase 3 trial to
compare ASCT with conventional chemotherapy plus lenalidomide in patients
≤65 years with newly diagnosed MM. The primary endpoint was progression-
free survival (PFS), the secondary endpoints included safety and overall sur-
vival (OS).
Methods: Eligible patients ≤65 years of age with newly diagnosed MM were
enrolled. All patients received lenalidomide-dexamethasone induction (four
28-day cycles of lenalidomide 25 mg day 1–21 and low-dose dexamethasone
40 mg day 1, 8, 15, 22) followed by stem cell mobilization. Patients were ran-
domized to receive consolidation with 2 cycles of MEL200-ASCT (melphalan
200 mg/m2 with stem-cell support) or cyclophosphamide-lenalidomide-dex-
amethasone (CRD) [six 28-day cycles of cyclophosphamide (300 mg/m2 day
1, 8, 15), dexamethasone (40 mg days 1, 8, 15, 22) and lenalidomide (25 mg
days 1–21)].
Results: Three-hundred and eighty-nine patients were enrolled in the trial.
Patient characteristics were well balanced between MEL200-ASCT and CRD.
After a median follow-up of 4 years, the median PFS was 42 months for
MEL200-ASCT and 28 months for CRD (HR 0.67, 95% CI 0.48-0.93, P=0.014).
The 4-year OS was 87% for MEL200-ASCT and 71% for CRD (HR 0.51, 95%
CI 0.28-0.93, P=0.028). The advantage in PFS and OS for MEL200-ASCT vs
CRD was noticed in most of the analysed subgroups. The rate of grade 3-4
hematologic (84% vs 26%, P<0.001) and non-hematologic (39% vs 22%,
P=0.008) adverse events (AEs) was higher in the MEL200-ASCT arm com-
pared with the CRD arm. The main non-hematologic AEs were infections (19%
with MEL200-ASCT vs 6% with CRD, P=0.004) and gastrointestinal AEs (20%
with MEL200-ASCT vs 5% with CRD, P<0.001). Toxicities were however man-
ageable. Despite the increase in grade 3-4 AEs with MEL200-ASCT, the rate
of serious hematologic (0% vs 2%, P=0.49) and extra-hematologic AEs (7% vs
10%, P=0.393) was similar between MEL200-ASCT and CRD arms. No toxic
deaths were reported in the MEL200-ASCT arm; 1 patient died of septic shock
in the CRD arm. Four patients who went off protocol before consolidation devel-
oped a second primary malignancy (SPM): 1 renal cancer, 1 breast cancer, 1
squamous cell carcinoma, 1 gastrointestinal cancer. Eight patients randomized
to MEL200-ASCT developed a SPM: 6 squamous cell carcinomas, 1
melanoma, and 1 prostate cancer. Five patients randomized to CRD developed
an SPM: 1 squamous cell carcinoma, 1 renal cancer, 1 breast cancer, 1 gas-
trointestinal cancer and 1 glioblastoma.
Summary and Conclusions: MEL200-ASCT significantly prolonged PFS and
OS in comparison with CRD. No increase in serious AEs, toxic deaths, and
SPMs were reported with MEL200-ASCT.
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SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH
RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN
THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS
BORTEZOMIB AND DEXAMETHASONE
H. Einsele1,* P. Richardson2, V. Hungria3, S.S. Yoon4, M. Beksac5,
M. Dimopoulos6, A. Elghandour7, W. Jedrzejczak8, A. Guenther9,
T. Na Nakorn10, N. Siritanaratkul11, R. Schlossman2, J. Hou12, P. Moreau13,
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Background: Panobinostat (PAN), a potent pan-deacetylase inhibitor (pan-
DACi), targets aberrations in multiple myeloma (MM) biology, including epige-
netics and protein metabolism. In the PANORAMA 1 phase 3 clinical trial, the
addition of PAN to bortezomib (BTZ) and dexamethasone (Dex; PAN-BTZ-Dex)
led to a clinically relevant and statistically significant increase in median pro-
gression-free survival (PFS) of ≈ 4 months compared with placebo (Pbo) + BTZ
and Dex (Pbo-BTZ-Dex) in patients (pts) with relapsed or relapsed and refrac-
tory MM.
Aims: To better characterize the efficacy and safety of PAN-BTZ-Dex within pt
populations with limited treatment options by presenting a subgroup analysis
of pts from the PANORAMA1 trial based on prior treatment.
Methods: The study design was described previously (San-Miguel JF, et al.
Lancet Oncol. 2014;15:1195-1206). For this subanalysis, pts were analyzed
for efficacy and safety based on prior treatment characteristics, including receipt
of prior immunomodulatory drugs (IMiDs); BTZ + IMiDs; and BTZ + IMiDs and
≥2 prior lines of therapy.
Results: A summary of efficacy based on prior treatment is provided in the
Table. Consistent or better efficacy benefit for the PAN arm was observed
across all subgroups analyzed. The benefit in median PFS was particularly
noteworthy among the largest subgroup in this analysis, pts who received prior
IMiDs. A total of 485 pts (63%) received prior IMiDs (PAN-BTZ-Dex [n =245] or
Pbo-BTZ-Dex [n =240]). Among these pts, the median PFS as determined by
investigator assessment for the PAN arm was 12.3 months (95% CI, 10.25-
13.83) vs 7.4 months (95% CI, 6.01-7.89) for the Pbo arm (hazard ratio [HR]
0.55; 95% CI, 0.44-0.70). The overall response rate for these pts was 62%
(95% CI, 55.6%>68.1%) vs 50% (95% CI, 43.3%>56.5%), and ≥near complete
response (nCR) rate was 29% (95% CI, 23%>34.7%) vs 13% (95% CI,
8.9%>17.8%) in the PAN and Pbo arms, respectively. Common grade 3/4
adverse events and laboratory abnormalities in each arm included thrombocy-
topenia (67% vs 36%), lymphopenia (54% vs 41%), neutropenia (37% vs 13%),
diarrhea (26% vs 8%), and asthenia/fatigue (25% vs 12%). The percentage of
on-treatment deaths in each arm was 7.1% vs 4.2%. The safety profile was
consistent among the other subgroups analyzed.
Tabella 1. Efficacy of PAN-BTZ-Dex and Pbo-BTZ-Dex among patient
subgroups classified by prior treatment history
Summary and Conclusions: PAN-BTZ-Dex demonstrated efficacy, with con-
sistent increases in median PFS and nCR/CR rates compared with the Pbo
arm among pt subgroups with a clear unmet need, including an increase in
PFS of nearly 5 months among pts who received prior IMiDs. The safety profile
across these subgroups was consistent with that in the overall PANORAMA 1
population, with the exception of the frequency of on-treatment deaths, which
was more similar between treatment arms across each subgroup.
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A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND
DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
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Background: Elotuzumab, an immunotherapeutic monoclonal antibody (mAb),
recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein
highly expressed on myeloma cells and natural killer cells. Elotuzumab targets
and kills SLAMF7-expressing myeloma cells by direct activation of natural killer
cells with minimal effect on normal tissues. Elotuzumab demonstrated
enhanced activity when combined with bortezomib in a preclinical myeloma
model,1 and elotuzumab/bortezomib showed encouraging clinical activity in a
Phase 1 study.2
Aims: This Phase 2 open-label study (NCT01478048, CA204-009) aimed to
investigate the efficacy and safety of elotuzumab + bortezomib/dexamethasone
(Bd) compared with Bd alone in patients (pts) with relapsed/refractory multiple
myeloma (RRMM).
Methods: Pts with RRMM who had received 1–3 prior therapies were given
elotuzumab + Bd (EBd) or Bd in 21-day (Cycles 1–8) or 28-day Cycles (9+)
until disease progression or unacceptable toxicity. Dosing schedule: elotuzum-
ab (10 mg/kg IV) weekly Cycles 1–2, Day 1 and 11 Cycles 3–8, then Day 1 and
15; bortezomib (1.3 mg/m2 IV/SC) Day 1, 4, 8, and 11 Cycles 1–8, then Day 1,
8, and 15; dexamethasone 20 mg on non-elotuzumab days, 8 mg PO + 8 mg
IV on elotuzumab days. The primary endpoint was progression-free survival
(PFS; ITT population) according to IMWG criteria. In this proof-of-concept study,
a 2-sided 0.30 significance level was specified to test for PFS difference
between arms; p≤0.3 was considered significant. The study had 80% power to
detect a hazard ratio (HR) of 0.69 with 103 events. Informed written consent
was obtained for all participants.
Results: In total, 152 pts (median age 66 years) were randomized to either
EBd (77) or Bd (75). At data cut-off (12 Sep 2014), 18% of pts treated with
EBd vs 10% of pts treated with Bd remained on therapy. The median number
of treatment cycles was 12 with EBd and 7 with Bd. Discontinuation was mainly
for disease progression (52%). HR for PFS was 0.71 (70% CI 0.58, 0.87;
p=0.08). One-year PFS rate was 39% (95% CI 28%, 50%) in the EBd group
vs 32% (95% CI 21%, 44%) in the Bd group, and 2-year PFS rate was 24%
(95% CI 13%, 36%) in the EBd group and 6% (95% CI 1%, 19%) in the Bd
group (Figure). PFS HR (EBd vs Bd), adjusting for prognostic factors, was
0.58 (70% CI 0.47, 0.72; p=0.01). The median PFS observed with EBd was
9.7 months, vs 6.9 months with Bd. Overall response rate was 66% with EBd
vs 63% with Bd. Early overall survival (OS) results revealed a HR of 0.61
(70% CI 0.43, 0.85); 1-year OS rate was 85% (95% CI 75%, 92%) in the EBd
group vs 74% (95% CI 62%, 83%) in the Bd group (Figure). Forty deaths (17
EBd, 23 Bd) were observed at the time of analysis, mainly due to disease
progression. Follow-up for OS continues. Grade 3/4 adverse events (AEs)
were reported in 51 (68%) pts with EBd treatment vs 45 (60%) with Bd. AEs
≥Grade 3 that occurred in ≥15% of pts in each group were thrombocytopenia
(7 [9%] in EBd group; 13 [17%] in Bd group) and infections (14 [19%] in EBd
group; 11 [15%] in Bd group). Infusion reactions (IRs; all Grade 1–2) occurred
in 7% of pts treated with EBd. There were no IRs at the maximum planned 5
mL/min infusion rate.
Figure 1. Progression-free survival (PFS) and overall survival (OS)
Summary and Conclusions: This study met the primary endpoint: PFS was
longer with EBd than with Bd. More pts continued on EBd than Bd and early
OS data favor EBd. Rate of IRs was low with EBd, and IRs were manageable
with premedication. In pts with RRMM, elotuzumab, an immunotherapeutic
mAb, provides clinical benefit with limited added toxicity when combined with
Bd vs Bd alone.
References
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NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER
RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AL AMYLOIDOSIS
AND PERSISTENT ORGAN DYSFUNCTION
M. Liedtke1,* H. Landau2, R. Comenzo3, D. Seldin4, B. Weiss5, J. Zonder6,
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Background: Light chain (AL) amyloidosis results from an accumulation of
misfolded proteins that cause the dysfunction of vital organs (eg, heart and
kidneys). Current therapeutic approaches target the plasma cells that produce
the pathogenic light chain proteins and are typically associated with significant
adverse effects. There is a substantial need for a safe and effective therapy
that specifically targets the misfolded proteins responsible for the underlying
organ dysfunction. NEOD001, a monoclonal antibody that targets these mis-
folded proteins, is hypothesized to neutralize circulating soluble protein aggre-
gates and to clear insoluble aggregates from organs. We report data from a
phase 1/2 dose-escalation/expansion study of NEOD001 in patients with AL
amyloidosis and persistent organ dysfunction (NCT01707264).
Aims: The primary aims of this study were to determine the maximum tolerated
dose/recommended phase 2 dose (RP2D) and the safety and tolerability of
single-agent NEOD001 when administered to patients with AL amyloidosis.
Secondary and exploratory objectives included pharmacokinetics (PK),
immunogenicity, and hematologic and best organ responses based on con-
sensus criteria.
Methods: Patients who completed ≥1 previous anti–plasma cell systemic ther-
apy, had partial response or better, did not require additional chemotherapy,
and had persistent organ dysfunction received NEOD001 intravenously every
28 days (q28d). Dose levels of 0.5, 1, 2, 4, 8, 16, and 24 mg/kg were evaluated
in a 3+3 study design. Informed consent was obtained from all patients.
Results: As of September 30, 2014, 27 patients in 7 cohorts received 209 infu-
sions. Mean treatment duration was 8 months. No deaths, drug-related serious
adverse events (AEs), discontinuations due to drug-related AEs, dose-limiting
toxicities, or antidrug antibodies were reported. The most frequently reported
AEs were fatigue, cough, and dyspnea. 24 mg/kg was selected as the RP2D.
PK data support intravenous dosing q28d. Of the 14 patients evaluable for car-
diac biomarker assessment, 50% met criteria for cardiac response (NT-proBNP:
30% reduction), and 50% achieved disease stabilization (Figure). Of the 14
renal evaluable patients, 43% met criteria for renal response (24-hour urine
protein: 30% reduction), and 57% achieved disease stabilization (Figure).
Figure 1. Change from baseline of cardiac response (NT-proBNP) and
renal response (24-hour urine protein) in organ-evaluable patients.
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Summary and Conclusions: Monthly infusions of NEOD001 were safe and
well tolerated. 24 mg/kg was the RP2D. The cardiac response rate was 50%,
and the renal response rate was 43%. These organ response rates compare
favorably to those reported with traditional chemotherapy. The phase 2 expansion
phase is ongoing. A phase 3 study has been initiated. Antibody therapy may
represent a new therapeutic platform for the management of AL amyloidosis.
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Background: The combination of melphalan, prednisone, and thalidomide
(MPT) is considered a standard treatment (Tx) option in many countries for
patients (pts) with newly diagnosed multiple myeloma (NDMM) who are inel-
igible for stem cell transplant (SCT). The FIRST trial is the largest prospective
phase 3 trial conducted in pts with NDMM ineligible for SCT. In this study,
patients were treated with lenalidomide plus low-dose dexamethasone admin-
istered until disease progression or unacceptable toxicity (Rd continuous),
Rd for 18 cycles (Rd18), or MPT for 12 cycles. At the planned primary analysis
for OS, Rd continuous was associated with improved progression-free sur-
vival (PFS) and an overall survival (OS) advantage vs MPT (Benboubker, N
Engl J Med, 2014).
Aims: This abstract presents an updated analysis of OS and other efficacy
measures that was not initially planned but was requested by regulatory
authorities.
Methods: Pts were randomized 1:1:1 to 1 of 3 Tx arms: Rd continuous (28-
day cycles), Rd18 (28-day cycles), or MPT for 12 cycles (42-day cycles). Eligible
pts (aged ≥18 yrs) had symptomatic NDMM and an Eastern Cooperative Oncol-
ogy Group performance status of 0-2 and were ineligible for SCT. Pts were
excluded if they had received prior anti-myeloma Tx, had specified laboratory
abnormalities, or had a history of malignancy, other than multiple myeloma,
within the past 3 yrs. The primary endpoint was PFS (Rd continuous vs MPT;
primary comparison). Secondary endpoints included OS, overall response rate,
and safety. Time from randomization to second disease progression (PFS2) or
death was included as an additional analysis.
Results: A total of 1623 pts were randomized; 535 pts received Rd continuous,
541 received Rd18, and 547 received MPT. At the time of data cutoff (March 3,
2014), 91 pts remained on Tx with Rd continuous. Across all Tx arms, 697 pts
(42.9%) died; 38.9% of pts treated with Rd continuous died compared with
42.1% and 47.7% of pts treated with Rd18 and MPT, respectively. With a medi-
an follow-up of 45.5 mos, median OS was 58.9 mos (95% CI, 56.0-not evaluable
[NE]) with Rd continuous vs 56.7 mos (95% CI, 50.1-NE) for pts treated with
Rd18 and 48.5 mos (95% CI, 44.2-52.0) for pts treated with MPT. For compar-
ison of OS with Rd continuous vs MPT, the hazard ratio (HR) was 0.75 (95%
CI, 0.62-0.90). For the updated PFS analysis based on investigators’ assess-
ment, the median was 26.0 mos for pts treated with Rd continuous compared
with 21.0 mos with Rd18 and 21.9 mos with MPT. The HR between Rd contin-
uous and MPT was 0.69 (95% CI, 0.59-0.80). The majority of second-line Tx
were bortezomib-based (55.7%). PFS2 events occurred in 58% of pts, and the
median PFS2 was extended with Rd continuous vs Rd18 and MPT (42.9 vs
40.0 and 35 mos, respectively), with an HR for Rd continuous vs MPT of 0.74
(95% CI, 0.63-0.86). The mean durations of Tx for pts who received Rd contin-
uous, Rd18, and MPT were 22.5, 12.6, and 11.9 mos respectively. Updated
safety data will be presented.
Summary and Conclusions: The OS and PFS benefits observed in the orig-
inal analysis were maintained with Rd continuous. Rd continuous was better
tolerated than MPT. The safety profile remained consistent with the interim
analysis. Improvements in PFS2 suggest that the benefit of Rd continuous is
retained through second-line therapy without inducing resistance. These find-
ings confirm Rd continuous as a new standard of care for pts with NDMM inel-
igible for SCT.
Treatment and outcome in non-Hodgkin
lymphomas
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Background: In spite of the improvement of the disease control obtained with
the intensive chemo-immunotherapy in adult patients with MCL with or without
autograft (ASCT) the rate of relapse and death is still high. Recent data showed
that a therapeutic strategy including a maintenance in responding patients to
chemoimmunotherapy can prolong the response duration and clinical outcome
of MCL patients
Aims: In 2008 the Fondazione Italiana Linfomi (FIL) designed the phase III
trial MCL0208, to evaluate the efficacy and safety of lenalidomide as mainte-
nance therapy in patients with MCL achieving at least a Partial Response (PR)
after an upfront intensive chemotherapy with rituximab (R) and ASCT
(NCT02354313). This trial was approved by the Ethical Committee of all parte-
cipating centers. Herein, we present the analysis of clinical and molecular
response after the chemotherapy with Rituximab (R) and ASCT, one of the sec-
ondary objectives of MCL0208 study.
Methods: Adult patients aged<66 years, with advanced stage MCL without
clinically significant comorbidities are enrolled. The primary end-point of the
study is the 2-year PFS from randomization. Patients receive 3 cycles of R-
CHOP-21, followed by R-HDS which includes: R-high-dose cyclophosphamide
(R-HD-CTX) (4g/m2), 2 cycles of R-high-dose Ara-C (R-HD-Ara-C) (2g/m2
q12x3 d), followed by BEAM and ASCT. CD34+ cell harvest is performed after
the first course of R-HD-Ara-C. A second harvest will be performed after the
second course of R-HD-Ara-C, if prior harvest is PCR+. After ASCT, responding
patients are randomized between maintenance with lenalidomide (15 mg days
1-21 every 28 days) or observation for 24 months. Minimal Residual Disease
(MRD) is examined at diagnosis, after R-HDCT, before and after ASCT, during
maintenance/observation and during follow-up every six months. The total num-
ber of patients to be enrolled is 300.
Results: From May 2010 to November 2014, 260 patients have been enrolled
by 48 italian and 1 international (Lisboa, Portugal) cancer centers. The median
age was 57 years (IQR 51-61), predominantly male (80%) and the majority of
patients presented with adverse features such as: advanced stage (98%), poor
ECOG-PS (24%), bulky disease (>5 cm) (33%), elevated LDH (31%), BM infil-
tration (76%) and intermediate-high MIPI (53%). Nine percent of patients had
blastoid variant. Among the 260 enrolled patients, 187 completed R-HDS (72%).
Ultimately, 168 patients (65%) proceed to ASCT and 146 (56%) have been ran-
domized between lenalidomide or observation. At the time of the present analy-
sis according to Cheson (JCO 2007) of 202 patients evaluable for final response
haematologica | 2015; 100(s1) | 3
Vienna, Austria, June 11 – 14, 2015
137 (68%) reached CR after RHDS and 156 (77%) after ASCT. Regarding
MRD a molecular marker was found in 87% of cases. Before ASCT a complete
molecular response (CMR) on PB and BM were 72% and 53% by nested PCR
and 80% and 67% by RQ-PCR. After ASCT CMR on PB and BM were 79%
and 50% by nested PCR and 86% and 73% by RQ-PCR. After a median fol-
low-up of 19 months the 2-year PFS and OS were 77% and 88%, respectively.
As expected with intensive regimens there was an hematological toxicity, par-
ticularly CTC grade 3-4 neutropenia (38% of cycles) and thrombocytopenia
(31% of cycles), but the infections were recorded only in 17% of patients and
the treatment-related deaths (TRD) were 1.6%.
Summary and Conclusions: RHDS with ASCT is a feasible regimen with lim-
ited toxicity in a multicenter setting and produces an high rate of durable
responses. These promising results are supported by the high rate of molecular
responses by RQ-PCR.
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Background: Clinically meaningful and statistically significant improved activity
was shown for lenalidomide, an immunomodulator with antineoplastic and
antiproliferative effects, over single-agent investigator choice (IC) treatment in
the MCL-002 (SPRINT) study of relapsed/refractory (R/R) patients with mantle
cell lymphoma (MCL).
Aims: Evaluate the potential impact of prior therapy on progression-free sur-
vival (PFS) in R/R MCL patients randomized to lenalidomide vs IC.
Methods: Patients were randomized to lenalidomide (25 mg/day PO on days
1-21/28 days) or single-agent IC (rituximab, gemcitabine, fludarabine, chlo-
rambucil, or cytarabine). The primary endpoint of this phase II study was PFS;
prespecified exploratory analyses of PFS by subgroups were conducted.
Results: Following a median of 2 prior therapies, 254 R/R MCL patients were
randomized 2:1 to lenalidomide (n=170) or IC (n=84). The preferred single-
agent IC therapy was selected for each patient prior to randomization. Overall,
the median PFS was significantly improved for lenalidomide vs IC (8.7 vs 5.2
months; HR=0.61, P=0.004). Exploratory analysis of PFS by central review
based on selected IC treatment showed that lenalidomide provided a reduction
in the risk of progression or death vs each IC treatment. Compared with
lenalidomide and taking into account small patient numbers per IC group, the
risk reduction in PFS was 22% vs rituximab (n=27), 56% vs gemcitabine
(n=20), 42% vs fludarabine (n=18), 43% vs chlorambucil (n=11), and 8% vs
cytarabine (n=8). Subgroup analysis of PFS by central review based on prior
treatment-related subgroups favored the use of lenalidomide overall. Several
subgroups showed statistically improved PFS for lenalidomide over IC, includ-
ing patients with ≥2 prior systemic antilymphoma therapies, >1 prior relapse,
refractory to last prior treatment, prior rituximab exposure, no prior hyperC-
VAD±rituximab or stem cell transplantation, ≥6 months time from last therapy
(≥230 days from last prior rituximab), and <3 years from diagnosis to study
treatment. The only category without risk reduction (but statistically insignifi-
cant) was ≥4 prior systemic antilymphoma therapies, partly explained by low
patient numbers in each arm. Treatment group was the main effect associated
with significantly better PFS by univariate Cox regression analysis (HR=0.619;
P=0.004), and was highly significant in the multivariate analysis (HR=0.384).
Other factors associated with significantly better PFS by both univariate and
multivariate analysis were <3 prior systemic antilymphoma therapies, and
≥230 days from last prior rituximab.
Summary and Conclusions: Subgroup and regression analyses of the pri-
mary study endpoint PFS showed superiority for lenalidomide over IC therapy
in providing consistent clinical benefit in patients with R/R MCL irrespective of
prior treatment history.
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Background: Localized early-stage extra-nodal marginal zone lymphoma
(MZL) presents with heterogeneous organ involvement and is treated with var-
ious modalities, including resection, radiotherapy, and, infrequently, systemic
therapy. We report the long-term outcome of a large cohort of extra-nodal MZL
and assess the impact of patient and disease characteristics, organ site, and
treatment strategy on disease control and survival.
Aims: To study patient characteristics and long-term outcome of a large cohort
of patients with early-stage localized extra-nodal marginal zone lymphoma
Methods: We identified 490 consecutive patients with stage IE or IIE MZL
referred between 1992 and 2012 to Memorial Sloan Kettering Cancer Center.
Pathology was confirmed by hematopathologists at our institution. Patient and
disease factors as well as treatment types were analyzed for association with
relapse-free survival (RFS), overall survival (OS), and cumulative incidence
of relapse.
Results: Median follow-up was 4.8 years. Median patient age was 60 years
and 57% were female. Ann-Arbor stage was IE in 89%. Most common sites
were stomach (32%), orbit (14%), lung (12%), skin (12%), and parotid (5%).
Radiotherapy alone (RT) was the initial treatment in 50% of patients, followed
by surgical resection (30%), observation (9%), immunotherapy (4%), and
chemotherapy (2%). Five-year OS and RFS were 90% and 64%, respectively;
10-year OS and RFS were 73% and 45%. Disease-specific death was 1.3% at
5 years and 1.8% at 10 years. Cumulative incidence of progression/relapse
was 29% by 5 years and 39% by 10 years. Amongst the 384 patients with com-
plete response (CR), 99 patients experienced relapse. On multivariable analy-
sis, initial treatment type and primary disease site were independently associ-
ated with RFS and relapse (all p<0.005). All disease sites (HR>2.0, p≤0.01)
except for thyroid (p=0.8) had worse RFS relative to stomach. Compared with
RT, chemotherapy or immunotherapy had worse RFS (HR 2.2, p=0.004) while
surgery was no different (p=0.52). After RT, only 11 patients experienced in-
field failure, with a 5-year cumulative incidence of 2.4%. Most common location
of relapse after CR was distant; relapses were also observed in paired untreat-
ed organs, such as the orbit, salivary gland, and breast. Crude rate of trans-
formation to pathologically-confirmed large-cell lymphoma was 2% (11
patients). Second tumors in irradiated sites developed in 3 patients: 2 of these
were breast ductal carcinoma in situ cured with surgical resection.
Summary and Conclusions: Overall and cause-specific survival are excellent
in early-stage extra-nodal MZL. Treatment with RT or surgery was associated
with longer RFS and reduced the need for salvage. Relapses are common
after initial remission, and most frequently occur in distant sites. Transformation
to large cell lymphomas is rare. Stomach cases are less likely to relapse than
other anatomic primary sites, perhaps in part because the entire organ is irra-
diated, versus other sites that are either bilateral or where only part of the
organ is treated, such as the skin and lung. This study supports the use of
local therapies to treat stage IE and IIE MZL. 
S109
A DOSE-ESCALATION STUDY OF THE BCL-2 INHIBITOR VENETOCLAX
(ABT-199/GDC-0199) PLUS BENDAMUSTINE (B) AND RITUXIMAB (R) IN
PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN’S
LYMPHOMA (NHL)
S. de Vos1,* C. Flowers2, D. Wang3, L. Swinnen4, N. Fowler5, E. Reid6, 
J. Cordero7, M. Gifford7, D. D’Amico7, M. Dunbar7, M. Zhu7, A. Salem7, 
S.H. Enschede7, J.L. Ricker7, D. Chien7, R. Humerickhouse7, M. Kozloff8
1Department of Medicine, University of California Los Angeles, Los Angeles,
2Winship Cancer Institute, Emory University, Atlanta, 3Hematology/Oncology,
Henry Ford Hospital, Detroit, 4Johns Hopkins University, Baltimore, 5The Uni-
versity of Texas MD Anderson Cancer Center, Houston, 6University of California
San Diego, La Jolla, 7AbbVie, North Chicago, 8Ingalls Hospital, Harvey, United
States
Background: Venetoclax is a selective, potent, orally bioavailable BCL-2
inhibitor that has shown single agent activity in patients with R/R NHL. The
current study evaluates venetoclax in combination with an immunochemother-
apy regimen, BR, an active regimen widely used to treat patients with NHL.
Aims: The primary objectives were to assess safety, pharmacokinetics (PK),
and determine the maximum tolerated dose (MTD) and recommended Phase
2 dose of the combination. Secondary objectives evaluated preliminary efficacy. 
Methods: Dose escalation used a 3+3 design on a 28 day (d) cycle (C) with 3
venetoclax schedules: 3, 7, and 28 d/C. The BR regimen was 6 C: B (2 d/C,
90mg/m2) and R (1 d/C, 375mg/m2). DLTs for dose escalation were assessed
during C1. Responses were first assessed on C3 d1. Patients who completed
venetoclax + BR with continued tolerability and without disease progression
could continue venetoclax monotherapy up to 2 yrs. 
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Results: As of January 9 2015, 33 patients were treated: 20 (61%) FL, 10
(30%) DLBCL, and 3 (9%) MZL. The median age was 62 (29-90) yrs. All had
prior R or R-combination, of which 32 (97%) had R-based chemotherapy and
8 (24%) had prior B or BR. Sixteen (48%) patients are active; 17 discontinued
(12 PD, 2 AE, 1 withdrew consent, 1 non-compliance, and 1 completed the
induction regimen). Median time on study was 90 d (1–876); 15 (45%) com-
pleted 6 C of the combination. The most common AEs (in >25%) were nausea
(58%), anemia, neutropenia (each 42%), thrombocytopenia, diarrhea (each
39%), hyperglycemia (36%), and vomiting, hypokalemia, fatigue (each 27%).
The most common grade 3/4 AEs (in >10%) were neutropenia (30%),
leukopenia, thrombocytopenia, lymphopenia (each 21%), and anemia (18%).
The most frequent SAE was febrile neutropenia (9%). There were no drug-
related AEs that led to death. DLTs are summarized in the table. Preliminary
PK results suggest that co-administration of BR did not significantly impact
venetoclax PK. Twenty-nine patients were evaluable for objective response:
6 (21%) CR and 13 (45%) PR. The ORR was 66% in all patients and 74% in
patients with FL.
Tabella 1.
Summary and Conclusions: Preliminary data demonstrate a tolerable safety
profile of venetoclax + BR. Early responses were seen across all cohorts in
this heavily pretreated patient population. The MTD has not been reached;
cohort 9 is enrolling at 600 mg 28 d/C. 
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Background: Extranodal natural killer/T-cell lymphoma (ENKTL), nasal type,
is a rare type of non-Hodgkin lymphoma with poor prognosis because tumor
cells are frequently resistant to anthracycline-containing chemotherapy such
as CHOP due to expression of the multidrug-resistant p-glycoprotein. As a
result, the treatment strategy for ENKTL has changed to non-anthracycline
based regimens such as SMILE (steroid, methotrexate, ifosfamide, L-asparag-
inase, and etoposide) with or without radiotherapy. Thus, concurrent chemora-
diotherapy followed by non-anthracycline based chemotherapy is recommend-
ed for localized disease whereas intensified chemotherapy such as SMILE is
for advanced disease. However, there is no proven prognostic model for ENKTL
in the era of this new treatment strategy because previous prognostic models
were developed by analyzing patients who were treated with CHOP or CHOP-
like regimens.
Aims: This study is to explore risk factors for poor progression-free survival
(PFS) and overall survival (OS) in ENKTL, and establish a prognostic model
for ENKTL patients treated with non-anthracycline based treatment. 
Methods: This is a retrospective cohort study using anonymized information from
patients with ENKTL. The following criteria are required: (1) Patients diagnosed
with ENKTL, nasal type between January 1, 1995 and December 31, 2012; (2)
Patients treated with non-anthracycline based therapy as an initial treatment. The
pathology of initial diagnosis was reviewed by designated pathologists.
Results: The data of 557 patients were from 32 hospitals from six Asian coun-
tries (Korea, Japan, Hong Kong China, Singapore, Taiwan, and Malaysia) and
6 hospitals from five Western countries (France, Germany, Denmark, Sweden,
and USA). Thirty cases were excluded from the analysis due to following rea-
sons: Missing follow-up data, different pathology from ENKTL, and different
treatment regimens containing anthracycline. Thus, 527 patients were analyzed,
and male (n =341) was predominant compared to female (n =186). 70% of
patients were ≤60 years at diagnosis whereas 30% was older than 60 years.
Two-thirds of patients had stage I/II (n =346) and nasal tract was most com-
monly involved extranodal site (n =421, 80%). Bone marrow involvement was
observed in 83 patients (16%), and distant lymph nodes were involved in 86
patients (16%). With a median follow-up of 45 months (IQR: 22-65 months),
306 patients (58%) were alive at the time of analysis and the event of progres-
sion-free survival occurred in 272 patients including relapse or progression (n
=187). The median OS was 76 months (95% CI: 51-101 months) and PFS was
32 months (95% CI: 20-45 months). The multivariate analysis for OS and PFS
showed a significant association of four parameters with survival outcomes:
age >60, stage III/IV, distant lymph node involvement, and non-nasal tract
involvement (P <0.001). Thus, the prognosis of patients with age >60, stage
III/IV and distant lymph node involvement was poor, and patients who did not
involve nasal tract also showed worse OS and PFS than patient with nasal
tract involvement. Thus, we gave one score for each parameter. According to
the sum of scores, patients with score 0 or 1 were grouped as low risk, score
2 was intermediate, and score 3 or 4 was high risk. This new risk model showed
a strong association with OS and PFS (Figure 1). Among 328 patients who
were initially evaluated for EBV DNA in blood, 189 patients (58%) showed
detectable level of EBV DNA. The multivariate analysis including EBV DNA
titer focused on these 328 patients showed that aforementioned four parame-
ters and the presence of EBV DNA were independently associated with OS
and PFS. Thus, we proposed another risk model for patients who had EBV
DNA data with these five parameters consisting of low (score 0/1), low-inter-
mediate (score 2), high-intermediate (score 3), and high risk (score 4/5).
Figure 1.
Summary and Conclusions: Our multinational, multicenter retrospective study
proposed a new prognostic model for newly diagnosed ENKTL patients who
were treated with non-anthracycline based treatment. It consists of age >60,
stage III/IV, distant lymph node involvement, and no involvement of nasal tract.
Our finding will be validated by currently ongoing study with an independent
cohort including China.
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Background: Relapsed/refractory pediatric acute lymphoblastic leukemia
(ALL) poses a substantial therapeutic challenge. Targeted immunotherapy
using chimeric antigen receptor (CAR)-modified T cells combines the specificity
of an antibody’s single chain variable fragment (scFv) with intracellular T cell
signaling domains, delivering T cells with potent cytotoxicity to antigen-express-
ing tumor cells. We previously reported complete remissions and prolonged
persistence in children and adults with ALL treated with CD19-specific CART
cells (CTL019). We now report on outcomes and longer follow-up of the first
40 patients with relapsed/refractory ALL treated on the pediatric trial of CTL019
in the largest cell therapy experience reported to date.
Aims: Establish the safety and efficacy of CTL019 for patients with
relapsed/refractory CD19+ ALL.
Methods: After informed consent, T cells collected from the patient were trans-
duced with a lentiviral vector encoding a CAR composed of anti-CD19 scFv,
CD3z, and 4-1BB domains, activated/expanded ex vivo with anti-CD3/anti-
CD28 beads, cryopreserved, and then infused. 35/40 patients received lym-
phodepleting chemotherapy the week prior to cell infusion.
Results: Of 40 patients aged 5-22y (median 11y) with CD19+ ALL, 33 had
detectable disease prior to CTL019 cell infusion, while 7 were negative for min-
imal residual disease (MRD). 28 had relapsed after prior stem cell transplan-
tation (SCT). A median of 3.6x106 CTL019 cells/kg (0.98-17x106/kg) were
infused in 1-3 fractions. At assessment 1 month after infusion, 37/40 (93%)
were in a complete remission (CR). MRD <0.01% by flow cytometry was
achieved in 34 patients. A CR rate of 86% was achieved in 22 patients with an
M3 marrow (>25% marrow lymphoblasts) at infusion. With median follow-up 7
mo (1-31 mo) as of January 1, 2015, 26 patients had ongoing CR, with only 5
receiving subsequent therapy (1 donor lymphocyte infusion [DLI], 4 SCT), 6-
month EFS was 72% (95% CI, 59-89%), and OS was 77% (95% CI, 64-92%).
CTL019 cells were detected in the CSF and 4 patients with CNS2a disease at
infusion have experienced ongoing CRs in CSF. Ten patients subsequently
relapsed, 5 with CD19(-) disease. CTL019 persistence was accompanied by
B cell aplasia, which continued up to 30 months in patients with ongoing CR.
Cytokine release syndrome (CRS) was seen in almost all (37) patients. Dra-
matic elevations in ferritin were observed, suggesting an association of
macrophage activation syndrome with CRS. Severe CRS requiring hemody-
namic or respiratory support occurred in 33% of patients, was associated with
high pre-treatment disease burden and with elevations in CRP and IL6 after
infusion. Severe CRS was rapidly reversed in each case with the anti-IL6R
agent tocilizumab, demonstrating the importance of IL6 in driving CRS.
Summary and Conclusions: Single-agent CTL019 immunotherapy can
induce potent and durable responses in patients with relapsed/refractory ALL.
CRS was effectively controlled with IL6 blockade. Long-term disease control
is possible without subsequent stem cell transplantation.
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Background: Adult patients with relapsed or refractory (R/R) acute lym-
phoblastic leukemia (ALL) have dismal prognosis. We previously reported high
anti-tumor activity of autologous T cells genetically modified to express 19-28z
chimeric antigen receptor (CAR) targeting CD19 in adult patients with ALL. 
Aims: Herein, we report the long-term outcome of our phase I clinical trial in
adults with R/R ALL (NCT01044069).
Methods: Adult patients with R/R B-ALL underwent leukapheresis, and T cells
were transduced with a gammaretroviral vector encoding a CAR construct
composed of anti-CD19 scFv linked to CD28 and CD3ζ signaling domains (19-
28z). All patients received conditioning chemotherapy followed by 1–3x106 19-
28z CAR T cells/kg. 
Results: 33 patients have been treated, and 32 patients are evaluable for
response. The median age was 54 years (range, 22-74). 12 patients (36%)
had Ph+ ALL, 11 patients (33%) had prior allogeneic stem cell transplant (allo-
SCT), and 14 patients (42%) had ≥3 prior lines of therapy. At the time of CAR
T cell infusion, 16 had morphologic disease (>5% blasts in BM) and the remain-
ing 16 patients had minimal residual disease (MRD). 13/16 patients with mor-
phologic disease (81%) and 16/16 patients with MRD (100%) were in complete
remission (CR) after 19-28z CAR T cell infusion, yielding an overall CR rate of
91% (29/32). Of the 28 MRD evaluable patients, MRD negative CR rate was
82%. 11 patients underwent allo-SCT following the CAR T cells. As of 1/25/15,
the median follow-up was 5.1 months (range, 1.0-37.6+), with 14 patients hav-
ing ≥6 months of follow-up. 6-month overall survival (OS) rate of all patients
was 58% (95% CI: 36-74). Among the patients who achieved CR, OS rate at
6 months for patients who had allo-SCT vs no allo-SCT following CAR T cells
was 70% (95% CI: 33-89) vs 61% (95% CI: 29-82; p=0.30). Severe cytokine
release syndrome (sCRS) requiring vasopressors or mechanical ventilation for
hypoxia was observed in 7 patients, effectively managed with IL-6R inhibitor
and/or corticosteroids.
Summary and Conclusions: 19-28z CAR T cells can induce a high CR rate
of 91% in adult patients with R/R ALL. The risk of sCRS correlates with disease
burden and can be effectively managed. These findings strongly support the
use of 19-28z CAR T cells in adults with R/R ALL and warrants investigation in
a phase 2 trial.
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Background: Tyrosine kinase inhibitors such as imatinib induce a high rate of
complete hematologic remission (CHR) in Philadelphia positive (Ph+) acute
lymphoblastic leukaemia (ALL), but the overall prognosis particularly in elderly
patients (pts.) remains poor, primarily due to relapse. Nilotinib is a potent ABL
kinase inhibitor (TKI) approved for treatment of CML. Data on its efficacy in
Ph+ ALL are limited. 
Aims: The EWALL (European Working Group for Adult ALL) initiated a prospec-
tive, investigator-initiated multicenter European clinical trial to examine the effi-
cacy and safety of nilotinib in conjunction with a chemotherapy backbone in
elderly patients (above 55 years of age) with newly diagnosed Ph+ ALL. 
Methods: Male or female pts. >55 years with untreated Ph+ and/or BCR-ABL1
positive ALL were eligible if they had a WHO performance status of 0-2, ade-
quate organ function and had signed written informed consent. The trial was
conducted in accordance with the principles of the Declaration of Helsinki and
was approved by the ethics committees of all participating centres (registered
under NCT01528085). After a pre-phase with dexamethasone (Dex) and
cyclophosphamide (optional), nilotinib was administered at 400 mg BID and
given continuously thereafter. During induction, nilotinib was combined with
vincristine (VCR) and Dex, repeated weekly for 4 weeks. Consolidation cycles
consisted of nilotinib 400 mg BID, methotrexate (MTX) and asparaginase for
cycles 1, 3 and 5 and cytarabine for cycles 2, 4 and 6. Maintenance phase
consisted of nilotinib, 6-MP, MTX and Dex/VCR. The primary end-point is the
rate of pts. without an event (defined as relapse, death, SAE or study treatment
discontinuation) at 12 months, secondary endpoints were the rate of CHR after
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induction, death during induction or in CHR, event free (and overall) survival,
the rate of molecular response defined by BCR-ABL/ABL ratios <0.1% (MMR)
and <0.001% (CMR), respectively.
Results: As of December 2015, 56 pts. (25 male, 31 female) have been
enrolled. Median age is 65 years (55-85 years), twelve pts. are older than 70
years of age. To date, all pts. are evaluable for safety and 47 pts. are evaluable
for efficacy. The CHR rate is 87 %, one pt. was refractory (2%), one pt. had a
partial remission (2%). One pt. died during induction therapy (2%), three pts.
discontinued therapy before CR evaluation. With a median follow-up of 5.5
months, 34 of the 41 pts. who achieved CR are in CCR and 3 pts. relapsed,
two of whom had discontinued study treatment to undergo allogeneic SCT. 11
pts. with documented induction response have discontinued study treatment
prematurely because of transfer to allogeneic SCT, as explicitly permitted by
the protocol. 9 pts. of them are transplanted. 11 pts. discontinued for various
other reasons. The rate of molecular remission (MMR) after induction (25 pts.
evaluable) was 45.5 %, with 5 pts. having undetectable BCR-ABL1 transcripts.
During consolidation, 30 of 40 pts. (80%) had a MMR, and BCR-ABL transcripts
were undetectable in 10 of 40 pts. (20%). Tolerability has been acceptable.
Infectious events and neutropenic fever predominated, individual SAEs included
metabolic, cardiovascular, neurologic, renal and hepatic events.
Summary and Conclusions: Nilotinib in conjunction with chemotherapy
according to the EWALL-PH-02 protocol is highly effective and well tolerated
in elderly pts. with newly diagnosed Ph+ ALL. Molecular response rates are
high and MRD levels in responding pts. continue to decrease with time. 
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Background: Older patients (pts) with ALL have a significantly worse outcome.
This is primarily due to poor tolerance of intensive chemotherapy. Addition of
targeted non-myelosuppressive therapy to effective low-intensity chemotherapy
might improve outcome. CD22 expression occurs in >90% of pts with ALL. Ino-
tuzumab ozogamicin (INO) is a CD22 monoclonal antibody bound to a toxin,
calecheamicin, and has shown single-agent activity in relapsed/refractory ALL
(Kantarjian et al. Lancet Oncology 2012).
Aims: To determine the efficacy of INO in combination with mini-hper-CVD
assessed by objective response rate, progression-free, and overall survival
and to assess the side effects of this treatment.
Methods: Pts ≥60 years (yrs) with newly-diagnosed B-cell ALL were eligible.
The chemotherapy was lower intensity than conventional hyper-CVAD and
referred to as mini-hyper-CVD (cyclophosphamide and dexamethasone at 50%
dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytara-
bine at 0.5 g/m2 x 4 doses). Rituximab and intrathecal chemotherapy were
given for first 4 courses. INO was given on Day 3 of each of the first 4 courses.
The first 6 pts received 1.3 mg/m2 for cycle 1 followed by 0.8 mg/m2 for sub-
sequent cycles; Pts 7 onwards received 1.8 mg/m2 for Cycle 1 followed by 1.3
mg/m2 for subsequent cycles.
Results: Thirty-three pts (20 men, 13 women) have been treated so far. Pts
characteristics and outcome are summarized in Table 1. Median age is 69
yrs (range, 60-79). Median follow-up is 15 months (mos) (range, 2-35). Of
the 30 pts evaluable for response (three pts started in CR; two achieved
with single-agent steroids and one with one course of HCVAD), 29 pts (97%)
achieved CR/CRp (24 CR, 5 CRp). All pts achieving CR have also achieved
flow-cytometric MRD negative status, in 79% at the time of CR achievement.
Grade 3-4 toxicities included infections (n=29; 88%), prolonged thrombocy-
topenia (n=25; 76%), hyperglycemia (n=17; 52%); hypokalemia (n=11; 33%);
increased bilirubin (n=8; 24%); increased ALT (n=7; 21%), and intracranial
hemorrhage (n=4; 12%). Grade 2 veno-occlusive occurred in 2 (7%) pts
(7%). At the last follow-up, 24 (73%) pts are alive, and 23 (70%) are in CR.
Nine (27%) pts died: 1 had primary refractory ALL and died after the first
salvage; 2 relapsed after receiving 3 and 2 courses only due to prolonged
myelossuppression and died of disease progression; and 6 died in CR from
pneumonia complications (n=1), sepsis and multiple organ failure (n=1),
gun-shot wound (n=1), renal failure and metabolic encephalopathy (n=1),
complications due to dementia (n=1), and unknown (n=1). One pt received
allogeneic stem cell transplantation. The 2-year progression-free survival
and overall survival rates were 85% and 70%, respectively. The mini-hyper-
CVD (n=33) appears superior to the historical HCVAD +/-rituximab (n=46)
in similar patient population (2-year survival rates 78% and 38%, respec-
tively; Figure 1).
Figure 1. Survival with mini-HCVD-INO vs HCVAD +/-Rituximab in frontline
ALL
Tabella 1. Patient characteristics and outcome
Summary and Conclusions: The combination of INO with low-intensity mini-
hyper-CVD chemotherapy is safe and shows encouraging results (96%
CR/CRp) in the frontline setting in older pts with ALL. These results appear to
be better than those achieved with a chemotherapy alone approach and may
become the new standard of care for frontline treatment of older pts with ALL.
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Background: Treatment options for older patients with relapsed/refractory
acute lymphoblastic leukemia (ALL) are limited. Blinatumomab is a bispecific
T-cell engager (BiTE®) antibody construct that directs cytotoxic T cells to CD19-
expressing B cells, and is approved in the US for treatment of Ph-negative
relapsed/refractory ALL. In two phase 2 adult studies of blinatumomab (Topp
MS, et al. J Clin Oncol. 2014;32:4134-40; Topp MS, et al. Lancet Oncol.
2015;16:57-66), 69% and 43% of patients, respectively, achieved complete
response (CR) or CR with partial hematologic recovery (CRh*).
Aims: We report pooled data for the combined subsets of older patients (≥65
years).
Methods: Patients with relapsed/refractory, Ph-negative B-precursor ALL
received open-label blinatumomab by continuous intravenous infusion (4 weeks
on/2 weeks off). Patients achieving CR or CRh* after two cycles could receive
three consolidation cycles. Response was assessed by bone marrow aspiration
and complete blood count with differential. CR required blasts <5%, ANC
>1000/μL and platelets >100,000/μL. CRh* required blasts <5%, ANC >500/μL
and platelets >50,000/μL. Minimal residual disease (MRD) was detected by
ASO-PCR of Ig heavy chain loci.
Results: A total of 36 older patients (median age 70 years, range 65-79)
received blinatumomab for a median (range) of 2 (1-6) cycles. Twenty (56%)
patients achieved best response of CR/CRh* within two cycles, including 14
(39%) CR and 6 (17%) CRh*. Among patients who responded to blinatumomab,
16 (80%) had an MRD response; of these, 12 (60%) had complete MRD
response (undetectable MRD) and 4 (20%) others had detectable MRD but
with <10-4blasts. With median follow-up of 18.2 months, median (range)
relapse-free survival was 7.4 (1.0-34.0) months. With median follow-up of 29.4
months, overall survival among patients was 5.5 (0.3-41.9) months. Ten (28%)
patients were alive at last follow up, including 6 in sustained remission. Two
(10%) of the patients who responded to blinatumomab underwent allogeneic
hematopoietic stem cell transplantation (HSCT) after blinatumomab therapy.
Treatment-emergent adverse events (AE) CTCAE grade ≥3 were reported for
31 (86%) patients, most commonly febrile neutropenia (22%) and neutropenia
(19%). Neurologic AE occurred in 26 (72%) patients, including grade ≥3 events
for 28%. One (3%) patient had grade ≥3 cytokine release syndrome. Of 7 fatal
AEs reported in patients, none were considered related to treatment.
Summary and Conclusions: Older patients (≥65 years) with relapsed/refrac-
tory ALL in two phase 2 studies of single-agent blinatumomab had similar treat-
ment responses and tolerability compared with patients in the overall study
populations.
Molecular pathogenesis of AML
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Background: Mutations in epigenetic regulators such as DNMT3A, TET2, and
ASXL1 have been shown to occur with ageing, leading to clonal pre-leukemic
hematopoiesis, which may evolve into acute myeloid leukemia (AML) once
additional lesions have accumulated. Studies of clonal architecture and pre-
leukemic hematopoietic stem cells (HSCs) of AML with normal karyotype sug-
gest that DNMT3A mutations, but not other sub-clonal mutations, are the pre-
leukemic initiating events and the hallmark of relapse reservoir.
Aims: It is unknown whether AML carrying other mutations or chromosomal
lesions have a clonal architecture and reservoirs of pre-leukemic HSCs similar
to those of DNMT3A mutant AML. To address this point we analyzed the clonal
architecture and evolution at relapse of a series of AML with both normal and
abnormal karyotype, i.e. MLL rearrangement, t(8;21), inv(16), del(20q), +8,
del(7), and complex karyotype (CK).
Methods: Molecular and cytogenetic analyses were performed at time of diag-
nosis (n=58 patients) and relapse (n=20). Exome analysis (n=9) and targeted
sequencing (122 genes, n=53) were performed using Illumina platforms. Vari-
ants were validated by Sanger sequencing. Somatic mutations were assessed
using remission samples or T cells. Cells from 14 patients (8 with abnormal
karyotype) were grown in methylcellulose and individual colonies were picked
for genotyping and FISH analysis.
Results: We found 234 lesions (median=4/patient) including 190 mutations in
60 genes. 36% of lesions target epigenetic regulators (DNMT3A, TET2/3,
IDH1/2, MLL, polycombs, del(20q)), with a frequent (34%) occurrence of mul-
tiple epigenetic events. 24 % of lesions involve proliferative events (FLT3, RAS
signalling, +8), and 17% affect transcription or splicing factors, NPM1, and
ubiquitin ligases. Mutations in other pathways (NOTCH, WNT, DNA repair,
cohesin), CBF translocations, and other chromosomal abnormalities account
for 22% of the total. FISH and genotyping analysis of 1,873 individual colonies
revealed that lesions involving epigenetic regulators, including MLL and 20q
rearrangements, occur frequently as first events (11/14). Analysis of variant
allele frequencies (VAF), FISH results, and relapse samples allowed us to build
the clonal phylogeny for 38 of the 44 remaining AML. Overall, a recurrent order
of events was observed, with CBF translocations and epigenetic abnormalities
as first events (37/52) and signalling or proliferation lesions as last ones (29/52).
In 17 cases this order was not observed, suggesting a distinct mechanism of
leukemogenesis, especially in patients with CK or chromosome 7 abnormalities
(n=7). Clonal composition changed in 14/20 samples at relapse. In one patient,
a second AML occurred on donor transplanted cord blood HSCs. In another
patient, a chronic myelo-monocytic leukemia developed after 9 years on an
ASXL1-mutant minor clone already detected at time of diagnosis. Changes in
relative VAF of IDH1, IDH2, TET3, WT1, NF1, and ZRSR2 variants were
observed in 5 patients. Seven samples carried events not detected at diagnosis
(t(1;6), gain of chromosome 8, and ZRSR2, SETBP1, RUNX1, PTPN11,
KDM6A, CEBPA variants), while in 9 cases, lesions were lost at relapse
(KDM6A, NPM1, PTPN11, WT1, DSCAM, POLR2A, TET2, UBEJ1, RUNX1,
IDH1, BCOR, FLT3, trisomy8). In all 14 patients harbouring an initial epigenetic
lesion, the event persisted at relapse.
Summary and Conclusions: Our results identify 2 groups of AML suggesting
2 ways for leukemogenesis. The 1st group includes cases with CK and chro-
mosome 7 lesions, which may result from chromosome or DNA maintenance
defects. For instance, TP53 mutations are frequent in CK AML. The 2nd group
is characterized by early epigenetic events, including DNMT3A, TET2, and
ASXL1 mutations, which always persist at relapse. These events may lead to
an over-expansion of mutant HSCs. In these pre-leukemic cells the increased
mitotic rate may result in a faster accumulation of replication errors and muta-
tions than in normal HSCs.
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Background: RUNX1/ETO is a driver leukaemic fusion protein produced by
the translocation t(8;21) and accounts for 10-12% of Acute Myeloid Leukaemia
(AML) cases. RUNX1/ETO is required for maintaining the leukaemic phenotype
influencing both leukaemic clonogenicity and growth. Currently the molecular
mechanism(s) by which it regulates leukaemic self-renewal and propagation
are just beginning to be unravelled. In our previous work, we characterised the
core-transcriptional network driven by RUNX1/ETO required to maintain the
t(8;21) AML phenotype (Ptasinska et al., 2014).
Aims: We have now functionally characterised the significance of individual
members of this network for leukaemic self-renewal by performing targeted
RNAi screens both in tissue culture and in a xenotransplant setting.
Methods: To that end, we intersected RNAseq, CHIPseq and microarray data
and identified a set of 103 genes comprising both direct RUNX1/ETO target
genes and genes potentially cooperating with such targets. For the RNAi
screens, we used a Doxycycline (Dox)-inducible lentiviral RNAi library covering
each gene of this set with at least 3 shRNAs. We transduced two t(8;21)-positive
AML cell lines (Kasumi-1 and SKNO-1) with this library and performed parallel
screens employing colony formation and long-term suspension culture assays
in the in vitro arm, and intrafemoral transplantation of highly immunodeficient
NSG mice for the in vivo screen. Both test series contained Dox and no Dox
groups. RNA and genomic DNA were isolated from transduced cells and sub-
jected to targeted Next Generation Sequencing. Changes in shRNA pool com-
positions were identified by comparison of the corresponding Dox and no Dox
groups using DESEQ.
Results: The analysis of the in vitro screen demonstrated that l RUNX1/ETO
shRNA constructs rapidly disappeared upon induction under all in vitro condi-
tions, confirming the central role of RUNX1/ETO in maintaining t(8;21) AML,
while levels of non-targeting control shRNA genes did not change during the
course of the experiments. Moreover, RUVBL1 (Pontin) shRNAs were depleted
in agreement with our previous finding of a dependence of t(8;21) AML cells on
this factor. In addition, shRNAs targeting KIT which in both cell lines carries the
activating mutation N822K, disappeared. These combined results demonstrate
the functionality of this targeted screen. Most importantly, the top hits of this in
vitro screen identified a group of self-renewal genes including those encoding
the ubiquitin ligase gene SKP2 and Cyclin D2 (CCND2). The more stringent in
vivo screen confirmed CCND2 as a RUNX1/ETO target gene relevant for
leukaemic propagation. Notably, this screen also identified several new genes,
which had not scored in the in vitro setting. This included several genes involved
in ubiquitination (UBASH3B, UBE2L6), regulation of G proteins (GPRC5C,
ARHGEF12, ARHGEF3), transcriptional control (ID1, KLF2, ERG) or glycolysis
(SCL2A3, PFKP). Importantly, several shRNAs targeting genes such as
NOTCH2, SLA or LAPTM5, which are repressed by RUNX/ETO, were also
depleted in the in vivo screen emphasising our previous observation that
leukaemic self-renewal and propagation is driven by a dynamic equilibrium
between RUNX1 and RUNX1/ETO.
Summary and Conclusions: We are now further characterising the contribu-
tion of these different target genes to the leukaemic self-renewal and propaga-
tion both in vitro and in vivo. The ultimate aim of our studies is the identification
of RUNX1/ETO dependent pathways, whose combined inhibition may pheno-
copy the loss of this hard-to-target initiator and driver of leukaemogenesis.
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Background: The finely tuned regulation of haematopoietic stem and progen-
itor cells (HSPCs) is crucial to ensure a normal haematopoiesis. Its dysregula-
tion can generate leukaemic stem cells (LSCs) which are difficult to eliminate
with current therapies, placing a focus on identifying novel therapeutic targets
to eradicate LSCs. Emerging studies have described that key oncometabolites
(such as succinate and fumarate) are main inhibitors of 2-oxoglutarate depend-
ent dioxygenases (2-OGDO), a family of enzymes that have been reported to
play an important role in leukaemogenesis. Here two of these 2-OGDO, Jmjd6
(a jumonji protein associated with alternative splicing) and Phd2 (a prolyl
hydroxylase that controls hypoxic response), were investigated in normal
haematopoiesis and acute myeloid leukaemia (AML).
Aims: The aim of this study is to investigate the role of two 2-OGDO (Phd2
and Jmjd6) in the development and/or maintenance of AML LSCs.
Methods: To elucidate the role of Jmjd6 in normal haematopoiesis, we gener-
ated a Jmjd6 conditional knock-out within the haematopoietic system
(Jmjd6fl/fl;Vav-iCre) and fully characterized it. To study the role of Jmjd6 and
Phd2 in leukaemogenesis, purified HSPCs from Jmjd6fl/fl;Vav-iCre and
Phd2fl/fl;Vav-iCre mice were transduced with retrovirus expressing respectively
Mll-AF9 and Meis1/Hoxa9. These transformed cells were characterized in vitro
(e.g. colony forming cell assay) and their leukemic potential was assessed by
transplantation. The Mll-AF9 knock-in (Mll-AF9KI/+) transgenic model was also
used to determine levels of mRNA expression.
Results: In normal haematopoiesis studies, mice lacking Jmjd6 specifically
within the haematopoietic system presented hyposplenism and reduced spleen
cellularity. Although these mice have normal numbers of stem and progenitor
cells (namely Lin-Sca-1+c-Kit+ (LSK)), the distribution within this compartment
is perturbed, leading to an accumulation of more committed progenitor cells.
This phenotype functionally correlates with the reduced engraftment exhibited
by mice transplanted with cells lacking Jmjd6 upon transplantation with either
Jmjd6fl/fl;Vav-iCre HSCs or total bone marrow (BM) when compared to con-
trols. Preliminary data from the leukaemic studies showed that the absence of
Jmjd6 does not impact on the generation of pre-leukaemic stem cells (pre-
LSC). Conversely, LSCs from the transgenic Mll-AF9KI/+ mouse model have
decreased Jmjd6 mRNA transcript levels. in vitro, Meis1/HoxA9 transformed
Phd2-deficient cells showed increased proliferation and lower apoptosis how-
ever, in vivo, mice transplanted with cells lacking Phd2 developed disease
later than the respective controls.
Summary and Conclusions: Deletion of Jmjd6 in the haematopoietic system
leads to an accumulation of committed progenitor cells that have a decreased
self renewal capacity and, therefore, a compromised repopulating capacity.
The deletion of Jmjd6 did not affect the in vitro generation of pre-LSC cells.
With regard to Phd2, it was observed a delay in AML initiation in mice trans-
planted with Phd2 KO pre-LSCs. Taken together, these data unravel a new role
for Jmjd6 as a player in normal haematopoiesis and suggest that Phd2 may
act as tumor suppressor in AML. 
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CONVERGENCE OF SOMATIC MUTATIONS WITHIN THE JAK-STAT
SIGNALLING PATHWAY IN A NOVEL RUNX1-MUTATED PEDIGREE
K. Tawana1, J. Wang1, P. A. Király2, K. Kállay3, G. Benyó3, G. Kriván3, 
J. Csomor2, J. Fitzgibbon1, C. Bödör2,*
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melweis University, 3Pediatric Haematology and Stem Cell Transplantation
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Background: Germline mutations in the transcription factor RUNX1 confer an
autosomal dominant predisposition to familial platelet disorder (FPD) and
myelodysplasia/acute myeloid leukaemia (MDS/AML). The penetrance of muta-
tions varies with approximately 40% of carriers developing overt malignancy,
whilst others remain asymptomatic or manifest mild to moderate FPD. We
describe a novel RUNX1-mutated family, where 3 young siblings presented
with secondary AML, providing a rare opportunity to compare the molecular
events initiating disease (Figure 1A).
Aims: To genetically profile somatic aberrations in multiple cases of MDS/AML
from a novel FPD/AML pedigree
Methods: We performed whole exome sequencing (WES) on bone marrow
(BM) DNA from 4 siblings with MDS/AML with an average exonic coverage of
96x. Peripheral blood (PB) DNA samples from both healthy parents were also
sequenced to enable exclusion of inherited variants in the 4 children. Acquired
mutations, copy number aberrations (CNA) and loss of heterozygosity (LOH)
were then defined across the four siblings. Key mutations were confirmed with
Sanger sequencing, whilst further verification of CNA was performed using mul-
tiplex ligation-dependent probe amplification (MLPA).
Results: Direct Sanger sequencing of the 4 siblings (II.1-II.4) and their mother
(I.1) revealed the germline RUNX1 mutation, p.R201X. Figure 1B summarises
the clinical timeline, with the key molecular and cytogenetic lesions detected in
MDS/AML from each sibling. Their mother (45y) remains an asymptomatic car-
rier, with no peripheral cytopenias. The dizygotic twins (II.1 and II.2) presented
within a period of 2 weeks at 5y, both with hepatosplenomegaly and pancy-
topenia. BM morphology of each twin revealed AML with dysplastic and
myelomonocytic features. Significant somatic chromosomal aberrations includ-
ed gain of 21q (II.1), monosomy 7 and deletion of chromosome 9q (II.2). Ten
years later, sibling II.4 also presented at 5y with monocytosis. BM examination
revealed myelomonocytic AML with dysplastic features and a normal cytoge-
netic profile. Sibling II.3 is now 14y, her BM examination revealed multi-lineage
dysplasia and normal cytogenetics. WES revealed molecular addiction to JAK2
signalling in 3 siblings (II.1, II.2 and II.4). II.2 and II.4 both acquired JAK2 V617F
mutations, with homozygosity of the mutant allele observed in II.2 due to 9p
acquired uniparental disomy (aUPD). In II.1, we detected a somatic mutation
in SH2B3 (p.R392Q), with apparent homozygosity caused by aUPD of 12q.
The p.R392Q mutation was localised to the SH2 domain, which normally binds
both mutant and WT isoforms of JAK2, inhibiting their phosphorylation. Further
somatic mutations occurred in CDC27 (anaphase promoting complex, II.2 and
II.4), RBBP8 (DNA double-strand break repair, II.2) and U2AF2 (spliceosome
complex, II.4). Notably, all 3 siblings with somatic JAK2-signalling lesions had
aggressive disease. Both twins died within a year of presentation, II.1 due to
relapse and II.2 from chemotherapy-refractory disease. Sibling II.4 relapsed
after 13 months and is currently in CR2 following allogeneic HSCT. 
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Figure 1.
Summary and Conclusions: We describe a novel FPD-AML pedigree demon-
strating convergence of lesions within the JAK-STAT signalling pathway in 3
siblings with MDS/AML. Since JAK2 mutations are reported in <5% of sporadic
RUNX1-mutated AML, our findings suggest somatic mutations in FPD/AML
may be enriched within distinct signalling pathways, often associated with
aUPD to increase the mutant allele burden within tumours. 
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HIF-2Α IS A TUMOUR SUPPRESSOR IN AML
M. Vukovic1,* A.V. Guitart1, K. Kranc1
1MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh,
United Kingdom
Background: Normal and malignant haematopoiesis occur under hypoxic con-
ditions. Hif-1α and Hif-2α regulate gene expression to facilitate adaptation to
low oxygen tension. Several studies investigated the role of Hif-1α and Hif-2α
in acute myeloid leukaemia (AML). These studies used shRNA knockdown in
human AML samples to show that HIF-1α and HIF-2α knockdown compromised
the ability of AML samples to reconstitute AML upon transplantation into recip-
ient mice, suggesting that HIF-1 and HIF-2 are potential therapeutic targets for
AML. However, a recent study demonstrated that conditional genetic deletion
of Hif-1α did not compromise the development and maintenance of mouse
leukaemic stem cells (LSCs) and on the contrary, accelerated the development
of AML, indicating that Hif-1α is a tumour suppressor in AML. To date, the effect
of conditional deletion of Hif-2α has not been examined in AML. 
Aims: To investigate the requirement of Hif-2α in the development and main-
tenance of AML leukaemic stem cells.
Methods: We generated Hif-2αfl/fl;Vav-iCre mice that lack Hif-2α specifically
within the hematopoietic system. We retrovirally co-transduced BM c-Kit+ cells
with oncogenes Meis1a and Hoxa9 and serially re-plated them to establish
pre-leukaemic stem cells (pre-LSCs). Retrovirally transduced cells were sub-
jected to in vitro assays in normoxia and hypoxia or transplanted into lethally
irradiated primary recipients, and subsequently into secondary recipients. We
next generated Mll-AF9KI/+; Hif-2αfl/fl;Vav-iCre mice and controls and trans-
planted Lin-Sca-1+c-Kit+(LSK) cells from these mice into primary recipients,
and Lin-Sca-1-c-Kit+(LK) cells into secondary recipients. 
Results: Hif-2α-deficient and control cells displayed similar re-plating capacity
and generated comparable numbers of colonies, but had increased proliferative
capacity. Thus, Hif-2α is not required for in vitro transformation and generation
of pre-LSCs but suppresses their proliferation. Transplantation of pre-LSCs to
primary recipients demonstrated that a smaller proportion of recipients of Hif-2α-
deficient pre-LSCs remained leukaemia-free, and therefore succumbed to AML
faster than recipients of control pre-LSCs. However, secondary recipients of both
Hif-2α-deficient and control LSCs generated aggressive AML with similar latency.
In concordance with these data, recipients of Mll-AF9KI/+; Hif-2αfl/fl;Vav-iCre suc-
cumbed to AML faster compared to recipients of control LSK cells, whereas, sec-
ondary recipients of both genotypes generated AML with similar latency.
Summary and Conclusions: Deletion of Hif-2α in pre-LSCs accelerates devel-
opment of LSCs and shortens AML latency induced by Mll-AF9 and its down-
stream effectors Meis1 and Hoxa9. Surprisingly, established LSCs lacking Hif-
2α efficiently propagate aggressive AML. We conclude that while Hif-2α sup-
presses the development of AML, it is not required for LSC maintenance. There-
fore, HIF-2 is unlikely to be a broad therapeutic target in AML and the benefit
of HIF inhibition should be carefully re-examined in all subsets of AML.
CLL - Biology: Interacting determinants of CLL
ontogeny and evolution
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DISSECTING RESISTANCE MECHANISMS IN CHRONIC LYMPHOCYTIC
LEUKEMIA USING WHOLE-EXOME SEQUENCING: IMPACT OF
RECURRENT RPS15 MUTATIONS ON P53 DYSREGULATION
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ratory, Uppsala University, Uppsala, Sweden, 2Department of Molecular Med-
icine, CEITEC, Masaryk University, 3Department of Internal Medicine-Hema-
tology and Oncology, University Hospital Brno and Faculty of Medicine,
Masaryk University, Brno, Czech Republic, 4Hematology Department and HCT
Unit, G. Papanicolaou Hospital, Thessaloniki, Greece, 5Division of Molecular
Oncology and Department of Onco-Hematology, San Raffaele Scientific Insti-
tute, 6Università Vita-Salute San Raffaele, Milan, 7Division of Hematology,
Department of Translational Medicine, Amedeo Avogadro University of Eastern
Piedmont, Novara, Italy, 8Department of Medical Sciences, Section of Hema-
tology, Uppsala University, Uppsala, Sweden, 9Department of Haematology,
Royal Bournemouth Hospital, Bournemouth, United Kingdom, 10Laboratory of
Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere,
Paris, France, 11Second Medical Department, University Hospital Schleswig-
Holstein, Kiel, Germany, 12Department of Medicine, Hematology and Clinical
Immunology Branch, Padua University School of Medicine, Padova, Italy,
13Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
Background: Fludarabine, cyclophosphamide and rituximab (FCR) is the gold-
standard first-line regimen in medically fit patients with chronic lymphocytic
leukemia (CLL); however, despite good response rates most patients will even-
tually relapse. Besides TP53 aberrations, the mechanisms leading to relapse
after FCR treatment are currently poorly understood.
Aims: To characterize the genetic mechanisms underlying relapse following
treatment with FCR using whole-exome sequencing (WES).
Methods: Forty-one CLL patients receiving FCR with either a partial response
(PR, with ≥4 cycles of treatment completed) or a complete response (CR, ≥1
cycle of treatment completed) were selected. Pre-treatment and relapse sam-
ples (mean time to relapse 3.2 years, range 0.7-10.9), together with matched
germline DNA for 28 patients, were analyzed by WES. Well-established bioin-
formatics tools and pipelines were used to process raw sequencing reads,
enabling the identification of somatic mutations and also facilitating the analy-
sis of copy-number aberrations (CNA) and absolute cancer cell fractions
(CCF).
Results: Amongst the 28 patients with matched germline DNA, 1191 somatic
variants (>10% allele frequency) were found in the pre-treatment samples
and 1334 in the relapse samples, with an average of 15.2 (range, 3-24) and
17.6 (range, 2-32) non-silent mutations per case, respectively. Mutations
were predominantly missense substitutions (81%) and less frequently
frameshift or in-frame insertions/deletions (14%) or nonsense mutations (5%).
As expected, at relapse, a high proportion of cases harbored mutations in
genes previously linked to adverse prognosis in CLL: TP53 (n=8; 19.5%),
NOTCH1 (n=8; 19.5%), ATM (n=7; 17%), SF3B1 (n=6; 14.6%), NFKBIE (n=4;
9.8%), EGR2 (n=4; 9.8%) and BIRC3 (n=3; 7.3%). Intriguingly, a large pro-
portion of cases also harbored mutations in RPS15 (n=8; 19.5%), a gene
encoding a component of the 40S ribosomal subunit. High allele frequencies
were observed for RPS15 mutations at both time points (range, 29%-56%),
and all mutations were missense variants residing within a 7 amino-acid evo-
lutionarily conserved region. Besides its role in protein translation, RPS15
has been shown to stabilize p53 by interfering with the MDM2-p53-MDMX
network and inhibiting MDM2-mediated p53 degradation. Characterization
of two recurrent RPS15 mutations in the HCT116 colorectal cancer cell line
transiently expressing either wild-type (wt) or mutant RPS15 revealed
impaired ability of RPS15P131S and RPS15G132A in regulating endogenous
p53. As both mutations map within the region that interacts with MDM2, this
finding strongly suggests that binding of RPS15P131S and RPS15G132A to
MDM2 is less efficient compared to wt protein thus leading to more pro-
nounced p53 degradation. Finally, by calculating the absolute CCF for all
mutations at both time points allowed monitoring of clonal heterogeneity over
time. All 24 cases with available exome-derived CNA data showed mutations
expanding ≥0.3 in CCF between the time points (mean 7.4 mutations, range
1-21). Among recurrently mutated genes, i) RPS15 remained stable over
time, ii) TP53, EGR2, NOTCH1 and BIRC3 mutations expanded or remained
stable, and iii) for SF3B1 and ATM mutations both increasing and decreasing
CCFs were observed.
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Figure 1.
Summary and Conclusions: We provide novel insights into the heterogeneous
genetic landscape of CLL relapsing after FCR treatment with our most prominent
finding being recurrent RPS15 mutations (19.5%) and with in vitro studies of
RPS15 mutations pointing to a novel mechanism for p53 dysregulation in CLL.
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IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN
CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION
OF THE NOTCH1 PATHWAY 
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Background: In chronic lymphocytic leukemia (CLL), NOTCH1 is constitutively
expressed promoting leukemia cell survival and resistance to apoptosis (Rosati
et al, Blood 2009). Additionally, NOTCH1 PEST mutations have emerged as
one of the most frequent somatic alterations in CLL, affecting up to 20% of
patients (Sportoletti et al, Leukemia 2014). Thus, inhibiting NOTCH1 activity
represents a potential therapeutic opportunity for this disease and the incorpo-
ration of NOTCH1 pathway antagonists may improve standard CLL treatment.
Targeting NOTCH1 has been a therapeutic strategy of interest in many cancers.
However, the use of gamma secretase inhibitors (GSI) evaluated in clinical
trials showed on target toxicities suggesting the need for the discovery of more
selective NOTCH1 pathway antagonists that preferentially target NOTCH1 ver-
sus NOTCH2 or that target mutated receptors compared to wild-type. Recently,
an expression-based screen identified several calcium modulators as a potential
strategy to target NOTCH1 (Roti et al, Cancer Cell 2013). Among numerous
ion flux modulators validated to induce a NOTCH1 off signature, one of the top
hits was the clinically relevant calcium channel blocker, bepridil, used to treat
patients with cardiac disease. Bepridil demonstrated anti NOTCH1 modulating
activity in T-ALL by a mechanism unique from GSI (Roti et al, ASH 2009).
Aims: The goal of the study was to evaluate whether bepridil exerts antitumor
activity in primary CLL cells in vitro and in a xenotransplant model and whether
these effects are associated with NOTCH1 inhibition.
Methods: in vitro, we evaluated NOTCH1 expression in primary CLL cells after
24 hours of bepridil treatment using western blot and flow cytometric analysis.
We also measured apoptosis using annexin V/propidium iodide staining and
by assessing PARP, MCL-1 and NOXA expression. in vivo, CLL cells were
transplanted into NSG mice and engraftment was evaluated after 28 days of
bepridil treatment.
Results: Bepridil treatment reduced the viability of primary CLL cells at a 2.5
μM concentration. In treated CLL cells, viability significantly decreased to
23.8±20.2% compared to 41.5±21.8% of the vehicle control (N=40, p <0.0001).
Conversely, bepridil did not affect viability of normal T cells from CLL patients
nor the viability of B and T cells from healthy donors, demonstrating that bepridil
selectively impairs the viability of B neoplastic cells compared to normal
hematopoietic cells. Bepridil significantly increased the percentage of annexin
V/propidium iodide positive apoptotic CLL cells compared to vehicle treated
cells (49.2±20.9% vs 29.3±15.3% N=34 p<0.0001). These apoptotic effects
were supported by the detection of increased PARP degradation (p<0.05), sig-
nificant reduction of MCL-1 protein expression (p<0.001) and a 5-fold up-reg-
ulation of NOXA transcript levels. Induction of apoptosis with bepridil treatment
in cultured CLL cells was not correlated with ZAP-70 expression, IGVH
rearrangement or NOTCH1 mutation status. However, the NOTCH1 pathway
was inhibited at concentrations of bepridil that induced apoptosis. Specifically,
flow cytometric analysis of cultured CLL cells (N=15) demonstrated that bepridil
significantly reduced the surface expression of NOTCH1 compared to vehicle
(32.8±19.2% vs 50.6±18.9% respectively, p<0.05). As previously reported in T-
ALL bepridil treatment lead to down regulation of the trans-membrane bound
portion of NOTCH1. Notably, NOTCH2 protein level remained unchanged in
bepridil treated CLL samples compared to vehicle (N=3), supporting a prefer-
ential effect of bepridil on NOTCH1. Interestingly, we observed that CLL cells
co-cultured with different stromal layers (including primary mesenchymal cells,
HS5 and OP9 cell lines) fail to apoptose upon bepridil treatment. The addition
of a CXCR4 antagonist restored bepridil efficacy, suggesting a synergistic
effects against the survival stimuli of the stroma. Finally, we established CLL
NSG primagrafts and tested bepridil in this leukemia model. Strikingly, flow
cytometry analysis revealed a statistically significant decrease in human
CD45+CD19+CD5+ percentage in the spleen of bepridil-treated mice compared
to vehicle (1.9±1% vs 10.8±10%, N=13, p<0.05). As anticipated by our results
in vitro bepridil treatment did not have a major effect in the neoplastic bone
marrow cell population of treated animals.
Summary and Conclusions: In conclusion, we showed that bepridil reduced
viability and increased apoptosis in primary CLL cells in vitro. This antileukemic
effect is associated with the inhibition of the NOTCH1 signal. Moreover, this
clinically relevant drug demonstrated efficacy in controlling splenic disease in
a mouse model of human CLL, suggesting a potential for rapid translation to
clinical testing.
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PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET #4:
FURTHER EVIDENCE OF ANTIGENIC STIMULATION
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Background: Chronic lymphocytic leukemia (CLL) is characterized by a
remarkably restricted immunoglobulin (IG) gene repertoire, mainly attributable
to the existence of subsets of patients with stereotyped B-cell receptor (BcR)
IGs strongly implying clonal selection by a restricted set of antigens. Our pre-
liminary high-throughput, next-generation sequencing studies of the T-cell
receptor beta chain (TRB) gene repertoire in CLL cases from various subsets
indicated repertoire skewing, pointing to antigenic selection of the T cells as
well, which is relevant in view of the bidirectional CLL-T cell interactions. 
Aims: We performed in-depth profiling of the TRB gene repertoire in CLL subset
#4 which became our focus for the following reasons: (i) it is the most indolent
subgroup of CLL patients identified thus far; (ii) previous studies have strongly
supported ongoing antigenic stimulation attested by the intraclonal diversifica-
tion of the clonotypic IG.
Methods: We studied 11 untreated CLL subset #4 cases and a healthy control.
RNA was isolated from peripheral blood mononuclear cells (n=12) or purified
CD4+ and CD8+ T cells (n=2 CLL cases). Two patients were studied overtime.
TRBV-TRBD-TRBJ gene rearrangements were amplified on cDNA according
to the BIOMED2 protocol and subjected to paired-end NGS (MiSeq Illumina
Platform). The experimental design allowed sequencing of the complementarity
determining region 3 (CDR3) twice/read, so as to increase the accuracy of
results. Computational processing of raw data was performed using a purpose-
built algorithm and a bioinformatics platform was developed for IMGT/HighV-
QUEST metadata clustering and analysis.
Results: Overall, 12,261,280 TRBV-TRBD-TRBJ reads were produced (median
397,035 reads/sample, median Q-score 38.4). Poor quality, incomplete, out-
of-frame and unproductive rearrangements were filtered out. For repertoire
analyses, clonotypes (i.e. TRB rearrangements with identical TRBV gene usage
and amino acid CDR3 sequence) rather than single rearrangement reads were
considered (median 77020 distinct clonotypes/sample, 54733 singletons versus
22287 expanded). Among the 53 functional TRBV genes identified, 5 predom-
inated: TRBV12-3/12-4 (9.9%), TRBV29-1 (8.6%), TRBV19 (7.5%), TRBV5-1
(5.5%), and TRBV6-5 (4.9%), collectively accounting for 36.4% of the TRBV
repertoire. Comparison of the TRBV gene repertoire of CD8+vs CD4+ cells
showed that TRBV19 was overrepresented in the CD4+ compartment (9.4%
versus 6.9%, p<0.001). The TRB repertoire was significantly more oligoclonal
in CLL compared to the healthy control (median frequency of the predominant
clonotype: 3.6% versus 0.47%, respectively, p<0.001), and this skewing
stemmed mainly from the CD8+ rather than the CD4+ compartment (median
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frequency of the predominant clonotype 10.7% versus 1.0%, respectively,
p<0.001). Cluster analysis of all CLL cases identified 37303 different clonotypes
(excluding singletons) shared by different patients and not present in the healthy
control. The longitudinal analysis of 2 cases showed contrasting results, with
14.6% of all expanded clonotypes persisting over time in one case, but only
0.06% in the other. In the former case, 5 of the persisting clonotypes ranked
among the 10 most expanded within the patient’s T cell repertoire, whereas in
the latter case only minor clonotypes persisted.
Summary and Conclusions: Our study provides large-scale evidence of TR
repertoire skewing and oligoclonality in CLL subset #4, strongly supporting
antigenic selection. The nature of selecting antigens remains to be elucidated.
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Background: Genome-wide association studies have identified 37 SNPs in
26 loci that confer risk of CLL. Here, we analyse genomic DNA from a prospec-
tive cohort of CLL patients that have an MBL sibling for the presence of these
CLL risk alleles.
Aims: To investigate whether CLL risk loci are also prevalent in MBL cells
found in a sibling.
Methods: Whole blood of siblings of patients with confirmed CLL patients was
screened with informed consent and ethical approval for presence of a distinct
CD19+CD5+CD20lowCD79blow population by flow cytometry. If such an MBL
population was present, genomic DNA from granulocytes of both CLL patient
and MBL sibling was isolated from the same blood sample. All cases with suffi-
cient available DNA were subjected to whole exome sequencing (WES) based
on SureSelect Human All Exon V4 kit (Agilent) capture on the HiSeq2000 (Illu-
mina) platform to an average coverage of 40x. Sequence reads were filtered
and mapped to the human reference genome (GRCh37). Analysis of gene copy
numbers and heterozygosity was performed by either 10K, 250K, SNP6, or
CytoscanHD arrays (Affymetrix). In addition, PCR was performed on 35 reported
CLL susceptibility alleles and analyzed by direct Sanger sequencing of gel-puri-
fied amplicons (PCR Clean-Up System, Promega). The frequency of all risk alle-
les was compared to healthy individuals from the literature by Fisher’s exact test.
Results: Screening of 160 siblings of CLL patients identified 19 MBL siblings
(MBL prevalence: 11.9%) from 16 CLL patients. In all but 2 MBL, the clonal B-
cell count was <100/ul. Genomic data from 13 CLL and 14 MBL cases, including
12 complete CLL/MBL pairs are described in this report. Nine of total of 37
CLL susceptibility SNPs could be called on WES data obtained from 5 CLL
and 4 MBL cases. 18 CLL risk SNPs could be analyzed on SNP arrays as indi-
cated by a median call rate of at least 98%. The combined SNP array and
WES data permitted analysis of 23 SNP of 15 loci. By targeted re-sequencing
on 10 CLL and 6 MBL cases, the total number of analyzed risk SNPs was
increased to 35 of the 37 known CLL risk alleles. 16 risk alleles were statistically
overrepresented in combined CLL and MBL compared to the healthy population
(Table). Out of these 16 SNPs, 11 were significantly overrepresented in CLL
and nine in MBL, respectively. SNP rs11083846 was significantly overrepre-
sented in MBL only but not in CLL or in the combined CLL and MBL cases.
Tabella 1.
Summary and Conclusions: Our data provide an independent validation of
16 of 35 previously reported CLL risk loci using combined SNP array, WES,
and Sanger sequencing data on a unique prospectively assembled cohort of
co-occurrence of CLL and MBL in siblings. No discrepancies were observed
between the various analysis platforms. Besides providing genetic correlates
for a familial susceptibility in CLL, the shared presence of these risk loci in CLL
and their MBL siblings indicate a causal role for clonal premalignant B-cell
expansion. These risk alleles therefore appear to contribute to the initiation of
a CLL-like phenotype, but further endogenous or exogenous triggers are
required to drive MBL to CLL.
S125
GENETIC PROFILE OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
WITH ULTRA-STABLE DISEASE
S. Raponi1,* M. Marinelli1, I. Del Giudice1, S. Bonina1, J. Wang2, L. Cafforio1,
C. Ilari1, M. Messina1, S. Tavolaro1, A. Bonafede1, F. R. Mauro1, D. Rossi3, 
G. Gaidano3, A. Guarini1, R. Rabadan2, R. Foà1
1Cellular Biotechnologies and Haematology, Sapienza University of Rome,
Rome, Italy, 2Biomedical Informatics, Center for Computational Biology and
Bioinformatics, Columbia University, New York, United States, 3Translational
Medicine, Amedeo Avogadro University of Eastern Piemont, Novara, Italy
Background: Chronic lymphocytic leukemia (CLL) shows an extremely het-
erogeneous clinical course. Beside cases with aggressive disease requiring
immediate treatment and those with an initial indolent phase followed by pro-
gression, there are patients who do not progress for decades. Next generation
sequencing (NGS) technologies have allowed a further understanding of the
molecular complexity of CLL. In the present study, we characterized 41 ultra-
stable CLL cases by whole exome sequencing (WES), ultra-deep NGS and
copy number aberration (CNA) analysis. Ultra-stable disease was defined as
absence of progression for at least 10 years from diagnosis.
Aims: To investigate the so far unexplored mutational profile and CNA load of
ultra-stable CLL patients.
Methods: Peripheral blood samples from 20 ultra-stable CLL patients were
used for WES analysis (Illumina HiSeq2000), including paired germline DNA in
14. Sanger sequencing (ABI PRISM 3100) was used to validate WES mutations
and to screen the recurrency of mutated genes identified in ≥2 cases by WES,
in a second cohort of 21 ultra-stable CLL samples. Bad prognosticator genes
(NOTCH1-BIRC3-SF3B1-TP53) were also investigated. Subclonal TP53 muta-
tions were examined by ultra-deep NGS (Roche-454 GS Junior) in 36 cases.
CNA analysis (Affymetrix Cytoscan HD arrays) was performed in 30 cases.
Results: WES analysis of the 14 cases having paired germline DNA predicted
83 non-silent somatic mutations in 81 genes, with a mutation load of 6 muta-
tions/case (range: 1-12). The remaining 6 cases without germline DNA were
analyzed to assess the recurrence of mutations identified in the former cohort
and to investigate those with known significance. Three genes were recurrently
mutated: RBM46, KLHL6, UBR5. Since RBM46 was the most recurrent among
ultra-stable CLL (3 cases, 15%) and never reported in other CLL WES studies,
Sanger sequencing of the whole codifying region was performed on the screen-
ing cohort with no additional mutated case identified. Interestingly, none of the
genes with known adverse prognostic impact was found mutated in 41 ultra-
stable CLL, including ATM and MYD88 in the WES cohort. Unexpectedly, ultra-
deep-NGS of TP53 revealed subclonal mutations in 2/36 cases (5.5%). One
case after 19 years from diagnosis showed 4 mutations with a median allele
frequency (AF) of 1.55% (range 0.9-1.79), corrected for tumor representation,
and developed a clinical progression soon after the inclusion in the study; after
therapy, a clonal TP53 mutation expansion occurred. The second case showed
1 subclonal mutation (AF 5.2%) after 29 years from diagnosis; for the subse-
quent 4 years she remained in clinical spontaneous regression of CLL but
developed a breast cancer. AS-PCR validation of these subclonal mutations is
ongoing. CNA analysis identified 31 lesions represented by 90% of losses and
10% of gains, giving a CNA load of 1/case. Twelve cases (40%) showed no
lesion, 9 (30%) showed isolated del(13q), 5 cases (17%) del(13q) with addi-
tional non-canonical CNAs and 4 cases (13%) a median of 1 non-canonical
CNAs. There was no recurrent CNA beside 13q deletion, as well as no CNA
with known poor prognostic significance.
Tabella 1. Biological and clinical features of 41 ultra-stable CLL patients
Summary and Conclusions: Ultra-stable CLL show no driver mutations or
CNAs. No new recurrent lesion associated to a highly stable course was iden-
tified. We found two cases with TP53 subclonal mutations with an extremely
divergent clinical history, which could be due to the subclonal architecture
complexity and to the chemotherapy selective pressure in the case with clonal
evolution.
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Background: Reduced Intensity conditioning (RIC) is increasingly offered to
older patients who are to undergo a stem cell transplant. We have previously
shown that a RIC allograft, particularly from a sibling donor is beneficial in inter-
mediate risk patients between the ages of 45-64, and may have advantages
over myeloablative conditioning in patients aged 35-44. Based on this analysis
of the UK NCRI AML15 trial in younger patients, the current recommendation
within the NCRI AML trials is to transplant intermediate risk patients with a RIC
allograft if a sibling is available excluding those who are NPM1+/ FLT3 wt. 
Aims: We here present similar analyses from the UK NCRI AML16 trial extend-
ing this experience to older patients.
Methods: The UK NCRI AML16 trial ran from 2006-2012 and randomised
patients, generally aged 60+, suitable for intensive chemotherapy between
Daunorubicin/Ara-C (DA) and Daunorubicin/Clofarabine (DClo), both with or with-
out Mylotarg, or between DA with or without etoposide and with or without ATRA.
Patients could be randomised between 2 or 3 courses of therapy and mainte-
nance or not with azacitidine. Because only 4/225 transplants took place in
patients over the age of 70, attention was restricted to patients who were aged
less than 70 years, achieved remission, and did not have core binding factor
leukaemia. A total of 963 patients were studied, with transplant in first remission
given to 162 patients (sibling allograft n=51, MUD n=93; other/unknown n=18).
Follow-up is complete to 1st January 2014 with median follow-up for survival
from CR of 46.3 months. Comparisons of confirmed allogeneic transplant in 1st
remission versus not are carried out using Mantel-Byar analysis to allow for time
to transplant, with patients censored at the time of non-RIC allo transplant.
Results: Among the 144 allografts, 93 had intermediate risk cytogenetics, 19
adverse risk, and 32 were unknown. In transplanted patients, survival from
transplant was 36% at 5 years, and while the survival for sibling allografts (42%)
was better than that for MUDs (37%) this did not reach statistical significance
(p=0.2), and 84% of transplants in adverse risk cytogenetics were from an unre-
lated donor. In analyses adjusted for Wheatley risk group there was no signif-
icant difference in outcome (HR 1.27 (0.80-2.03) p=0.3). When comparing allo-
graft versus no allograft, survival was significantly improved (35% vs 20%, HR
0.75 (0.61-0.93) p=0.006). When stratified by Wheatley risk group, there was
no evidence of any interaction (p-value for trend 0.5), and the adjusted hazard
ratio, allowing for differences in Wheatley group between transplant and no
transplant was 0.76 (0.61-0.94), p=0.008 reflecting the consistent benefit. When
considering type of transplant, sibling allograft performed consistently better
than MUD in Mantel-Byar analyses across the risk groups (overall sibling 41%,
MUD 35%, no SCT 20%; good risk 47% vs 42% vs 26%; standard risk 38% vs
34% vs 25%; poor risk, not reached vs 23% vs 8%). 
Summary and Conclusions: The results are consistent with those seen in
our analysis of AML15 While, particularly as patients get older, there will be
selection for transplant on the basis of fitness, the analysis adjusted for clinical
features of the disease shows that RIC transplant in first remission appears an
attractive option for older patients with AML. While no significant difference was
seen between sibling and MUD allograft, even after adjusting for Wheatley risk,
outcomes are better in all Wheatley groups with sibling allografts. 
S127
REDUCED INTENSITY CONDITIONING (RIC) ALLO TRANSPLANTATION
IS ASSOCIATED WITH SUPERIOR LONG-TERM DISEASE CONTROL IN
RELAPSED/REFRACTORY GRADE I/II (G-I/II) FOLLICULAR LYMPHOMA
E. Klyuchnikov1,* U. Bacher2, N. Kröger1, P. Hari3, K. W. Ahn3, D. Maloney4,
S. Smith5, A. Sureda6, J. Carreras3, M. Hamadani3
1Department for Stem Cell Transplantation, University Cancer Center, Ham-
burg, 2Department for Hematology/Oncology, University of Göttingen, Göttin-
gen, Germany, 3CIBMTR, Medicine, Medical College of Wisconsin, Milwaukee,
4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, 5Section
of Hematology/Oncology, The University of Chicago, Chicago, United States,
6Servei d’Hematologia, Institut Català d’Oncologia, Hospital Duran i Reynals,
Barcelona, Spain
Background: We compared long-term outcomes of allogeneic transplantation
(alloHCT) vs autologous (auto) HCT in pts with G-I/II follicular lymphoma (FL)
in the rituximab-era.
Aims: To compared survival outcomes following autoHCT vs alloHCT in G-I/II
FL, when either modality is used as the first transplantation approach.
Methods: Adult pts with relapsed/refractory G-I/II FL undergoing 1st RIC allo-
HCT or 1st autoHCT reported to Center for International Blood and Marrow
Transplant Research during 2000-12 were eligible. Pts with large cell transfor-
mation and those not receiving rituximab before HCT were excluded. 
Results: Characteristics of 518 pts included in this analysis are shown in
Table 1. AlloHCT pts were younger, more heavily pretreated, had more
advanced stage disease, had longer interval between diagnosis and HCT,
more extranodal involvement and were chemotherapy resistant compared with
auto-HCT pts. The 5-year adjusted probabilities of non-relapse mortality
(NRM), relapse/progression, progression-free survival (PFS) and overall sur-
vival (OS) of autoHCT vs alloHCT groups were 5% vs 26% (p<0.0001); 54%
vs 20% (p<0.0001); 41% vs 58% (p<0.001) and 74% vs 66% (p=0.05), respec-
tively. Cumulative incidence of second malignancies at 5 years did not differ
significantly (alloHCT=8%; autoHCT=5%). On multivariate analysis (MVA)
autoHCT was associated with reduced NRM (RR=0.21; p<0.0001) and time
varying effects were seen on other outcomes. Within the first 5 and 11months
post HCT, auto-and alloHCT had similar relapse/progression and PFS. Auto-
HCT was associated with a higher risk of relapse/progression beyond 5 months
post HCT (RR=4.4; p<0.0001), and worse PFS (RR=2.9; p<0.0001) beyond
11 months post HCT, respectively. In the first 24 months post HCT, autoHCT
was associated with improved OS (RR=0.41; p<0.0001), but beyond 24months
with inferior OS (RR=2.2; p=0.006). A landmark analysis of pts alive and pro-
gression-free at 2-years post HCT confirmed these observations, showing no
difference in NRM between the auto-and alloHCT groups, but significantly
higher risk of relapse/progression (RR=7.3; p<0.0001) and inferior PFS
(RR=3.2; p<0.0001) and OS (RR=2.1; p=0.04) following autoHCT.
Tabella 1.
  AlloHCT N=268 AutoHCT N=205 P
Median age, years 52 (27-74) 54 (22-79) 0.01
KPS ≥90 193 (72) 168 (67) 0.06
Stage III-IV at diagnosis 217 (81) 185 (74) <0.0001
Extranodal disease at HCT 10 (26) 40 (16) 0.002
Prior rituximab-resistance 118 (44) 161 (64) <0.001
Chemosensitive at HCT 202 (75) 226 (90) <0.001
Median lines of therapy 4 (1-5) 3 (1-5) 0.001
Duration of 1st response 0.76
   <1 year 79 (29) 68 (27)
   ≥1 year 173 (65) 164 (66)
Time from diagnosis to HCT 43mon (4-352) 34mon (6-315) 0.001
   Matched sibling Donor 143 (53) N/A -
   ≥7/8 unrelated donor 125 (46) N/A -
Median follow up 61 (3-154) 61 (3-169) -
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Background: Primary refractory AML is associated with a dismal prognosis.
Approximately one third of patients younger than 60 years, and 50 % of older
patients, with newly diagnosed AML fail to achieve complete remission (CR)
with standard induction chemotherapy. Allo-SCT in the setting of active disease
is an alternative but highly debatable strategy. The increased availability of UD
and the use of reduced-intensity conditioning (RIC) regimens have opened the
possibility for transplantation to a larger number of patients in comparison to
standard myeloablative regimens (MAC).
Aims: The current study aimed to assess outcomes in a cohort of 381 primary
refractory AML patients who received allo-SCT from an UD (10/10 or 9/10).
Primary refractoriness was defined as failure to achieve CR within 60 days
after starting induction.
Methods: Patients with primary refractory AML reported between 2000 and
2013 to the registry of the Acute Leukemia Working Party of the EBMT were
included in this study. The major endpoints were to assess overall survival
(OS), leukemia-free survival (LFS), relapse incidence (RI), and non relapse
mortality (NRM).
Results: Median age was 50.5 (range, 18-74) years and 56% were males.
Median time from diagnosis to allo-SCT was 111 (range, 60-178) days. 51 %
received a MAC regimen, and 49% a RIC regimen. Peripheral blood stem cell
(PBSC) was the main stem cell source (94.8%). The median follow-up was
18 months(range, 1.2-153). 296 patients received a matched UD (10/10) and
85 a mismatched UD (9/10). Engraftment was achieved in 95.2% of cases.
70.4% patients reached CR after allo-SCT. At 2 years, the cumulative inci-
dences of acute GVHD≥2 and chronic GVHD (cGVHD) were 35.5% and
25.8%, respectively. At 2 years, OS and LFS rates were 34.3% and 28.3%. RI
was 46.4% and NRM 25.1%. In multivariate analysis, 2 predictive factors were
associated with lower OS: cytogenetics (poor vs intermediary; HR=2.00,
95%CI,1.25-3.18, p=0.004) and positive CMV status of the recipient (HR=1.52,
95%CI,1.09-2.11, P=0.01), whereas Karnofsky status at transplant ≥80% (KS)
was associated with better OS (HR=0.65, 95%CI,0.43-0.98, p=0.04) (Fig1).
The same factors were predictive for LFS: cytogenetics (HR=1.86,
95%CI,1.19-2.92, p=0.01) and positive CMV status of the recipient (HR=1.46,
95%CI, 1.07-1.99, p=0.02) were negative predictive factors, whereas KS was
a positive one (HR=0.61, 95%CI,0.41-0.91, p=0.02). In multivariate analysis
for RI, cytogenetics was the only risk factor associated with increased relapse
(HR=1.92, 95%CI,1.15-3.19, p=0.001). As for NRM, patient gender (female
vs male) and KS were factors associated with lower NRM (HR=0.49,
95%CI,0.29-0.84, p=0.01; HR=0.41, 95%CI,0.22-0.76, p=0.004), while CMV
positive status was the only factor associated with higher NRM (HR=1.96,
95%CI=1.11-3.43, p=0.02).
Figure 1.
Summary and Conclusions: Unrelated donor transplantation (10/10 or 9/10)
may rescue about one third of the patients with primary refractory AML. More-
over, this study identifies cytogenetics, KS, and CMV status as major prognostic
factors. Finally, these data pave the way not only for improving patients’ selec-
tion, but also for investigating more intensive additional approaches relying on
sequential conditioning regimens (debulking phase followed by RIC) and/or
post-transplant treatments such as 5-azacytidine, prophylactic donor lympho-
cytes infusions, or targeted therapy which further improve results in this dev-
astating group of patients.
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Background: ALL is rare in patients older than 60 years, and is associated
with poor prognosis with chemotherapy alone, with reported leukemia-free sur-
vival (LFS) rates below 20%. When feasible, allogeneic stem cell transplanta-
tion (allo-SCT) is an attractive treatment option for those patients. However
due to comorbidites, non-relapse mortality (NRM) can be a limiting factor.
Aims: This study aimed to evaluate the results and risk factors associated with
outcome of allo-SCT in ALL patients older than 60 years, and who received a
reduced-intensity conditioning (RIC) regimen prior to allo-SCT between 2001
and 2012.
Methods: 117 patients with fully documented data could be identified and ana-
lyzed. Median age at time of allo-SCT was 63 (range, 60-75) years, with 34
patients (29%) being older than 65. 57% of patients had a Karnosky perform-
ance status ≥90%. Median year of allo-SCT was 2009. Median follow up was
37 (range, 10-134) m. 82 patients (70%) were transplanted in CR1, 19 (16%)
in CR2 and CR3, and 16 (14%) in more advanced disease. Of 109 patients
with available cytogenetics data, 53 (49%) harboured t(9;22) at diagnosis. Con-
ditioning regimen included fludarabine and busulfan (Bu-Flu) for 34% of
patients, 26% had a low-dose TBI-based regimen, while 20% received fludara-
bine and melphalan. ATG was used in 41% of cases. Fifty-two (45%) of patients
were transplanted with an HLA-identical-sibling donor (MSD). Graft source was
peripheral blood stem cells in 95% of cases.
Results: At 2 years the probabilities of LFS, and overall survival (OS) were
35% and 47%, respectively. The cumulative incidences (CI) of NRM, relapse
incidence (RI), and chronic GVHD were 22%, 43%, and 38%, respectively. In
univariate analysis, disease status was associated with LFS, RI and OS: LFS
rate was 25% for CR2 and 13% for advanced vs 41% for CR1 (p<0.01), RI
rate was 70% for CR2 and 63% for advanced vs 33% for CR1 (p<0.01), OS
rate 40% for CR2 and 19% for advanced vs 54% for CR1 (p<0.01). Patients
transplanted from a MSD had a higher RI (56% vs 33%) compared to those
transplanted from unrelated donors (UD, p<0.01). Factors associated with NRM
were the use of Bu-Flu (NRM was 13% for Bu-Flu vs 26% in other regimens)
(p=0.05)) and Karnofsky-score ≥90% (NRM was 14% for KPS<90% vs 31%
KPS ≥90%) (p<0.05)). In multivariate analysis, factors associated with LFS
were disease status (advanced disease, HR=3.6, p<0.01) and CR2, HR=1.90,
p=0.04), and the use of unrelated donors (HR=0.60, p=0.03). Disease status
was associated with better OS (HR=0.28, p<0.001). On the other hand,
advanced disease status, use of a MSD, performance status <90% was asso-
ciated with a higher RI (HR=4.64, p<0.01, HR=2.38, p=0.06, HR=2.25, p<0.05
respectively). NRM was lower for patients with performance status ≥90% and
for those receiving the Bu-Flu regimen (HR=0.48, p=0.06 and HR=0.33, p<0.05,
respectively).
Summary and Conclusions: Allo-SCT after RIC is a feasible and effective
option for patients with ALL older than 60 years with LFS of 35% and OS of
47%. The results were better for patients transplanted in CR1, and with good
performance status.
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Background: The use of unrelated donors (URD) in patients aged of 60 years
or more has drastically increased in the past few years. To date, there are only
limited data on URD allo-HSCT in elderly patients (60 years or more). 
Aims: The purpose of the current study is to describe outcomes in a large
cohort of patients aged 60 years or older, who received a RIC URD allo-HSCT
in recent years. 
Methods: Between 2008 and 2012, 516 consecutive patients aged of 60 years
or more, who received a first allo-HSCT for hematological malignancies from an
URD after a RIC regimen in France were included. Conditioning regimen was
fludarabine-based in 91% of the patients. Two groups of patients were defined:
patients with age at allo-HSCT less than 65 years old (“URD<65 group”, n=374)
and patients who were aged of 65 years old or more (“URD ≥65 group”, n=142).
Results: Patient characteristics were similar between the 2 groups. The medi-
an follow-up was 36 months (range, 0.36-73.5) for URD<65 group and 32
months (range, 0.03-72) for URD≥65 group. During evolution, the cumulative
incidence (CI) of grade II–IV acute GvHD was 32% in URD<65 group and
32% in URD≥65 group (p=0.975) while the CI of chronic GvHD at 2 years was
25 % and 26%, respectively (p=0.701). CI of non-relapse mortality (NRM),
disease free survival (DFS) and overall survival (OS) were not different
between the 2 groups Multivariate analysis for NRM, DFS and OS show that
age by itself has no influence on outcomes.
Summary and Conclusions: These data suggest equivalence of outcome
between URD<65 group and URD≥65 group after RIC URD allo-HSCT. Age by
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Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of hematopoietic neoplasms characterized by bone marrow dysplasia and one
or more peripheral blood cytopenias. Underlying this heterogeneity is a variety
of genetic abnormalities. Within the bone marrow and blood of an individual
patient, several clones of cells with their own set of mutations may be present
simultaneously. During the course of the disease, the clonal composition may
change and additional genetic defects can be acquired. Patient-specific
(sub)clonal architectures may contribute to the heterogeneity of MDS, both in
terms of clinical manifestations and response to treatment.
Aims: We studied the clonal composition of MDS on the basis of somatic muta-
tion profiles, the long-term diachronous changes in clonal architecture through-
out the course of the disease, and the correlations between clonal
architecture/evolution and clinical parameters and treatment response.
Methods: Bone marrow and blood samples from 12 patients with low-to inter-
mediate-risk MDS with long follow-up times (2.5-11 years) were collected at
regular intervals (5-19 sampling moments/patient). Whole-exome sequencing
was applied on the first and last and several intermediate time points for each
patient. In total, 64 samples were used for whole-exome sequencing, to an
average depth of 110x. Cultured T-cell DNA was used as reference. In addition,
the same samples were analyzed using high resolution SNP-arrays. From this,
in total 348 different acquired somatic mutations were identified in 300 different
genes. In order to be able to quantify the presence of these mutations with
high accuracy, for all mutations specific assays were developed for amplicon-
based deep sequencing (IonTorrent, with a coverage of ≈ 10,000 x). This was
used to measure the mutational burden at the different sampling time points.
Results: The median number of validated cancer-associated gene mutations
per patient was 14 (range 10-26) and 3 (range 0-5) for well-known, recurrently
mutated driver mutations in MDS. Integrated analysis revealed the clonal archi-
tecture and its evolution over time. Both linear and branched evolution were
present in different patients. Diverse patterns of clonal evolution, ranging from
a single clone remaining stably dominant for many years, to cases with highly
dynamic shifts in the subclonal composition were observed. Five patients were
treated with lenalidomide, four of which achieved complete remission. In one
of these patients, clinical complete remission was accompanied by molecular
remission (mutations <1%), followed by a relapse after acquisition of a TP53
and RELN mutation in the original clone, containing six other mutations. One
doubly-TET2-mutated patient, treated with EPO and G-CSF displayed a
branched evolutionary process with two competitive subclones: an initially major
NRAS-mutated subclone and a minor RRAS-mutated subclone. Over the
course of two years, the RRAS-mutated subclone became dominant with sub-
sequent transformation to AML.
Summary and Conclusions: Our study demonstrates that great diversity in
clonal composition and evolution underlies the clinical heterogeneity of MDS.
In some patients, clonal composition was very stable over time, whereas in
others, a highly dynamic pattern was observed. Our findings emphasize the
importance of genetically unbiased disease monitoring and the development
of therapeutic strategies aiming to eradicate multiple different clones.
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Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic
stem cell disorders characterized by dysplastic hematopoiesis in the bone mar-
row and peripheral blood cytopenias. The splicing factor SF3B1 is the most
commonly mutated gene in MDS and is mainly found in refractory anemia with
ring sideroblasts (RARS). SF3B1 mutations are missense, heterozygous and
clustered, suggesting they are gain-of-function with a causal link to the devel-
opment of RARS. Nevertheless, in vitro studies are hampered by the inability
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to clone the full length SF3B1 cDNA and model the effect of its mutation in cell
lines. Few reports on Sf3b1 knock-down mice have not convincingly recapitu-
lated the features of its somatic mutations in RARS. 
Aims: We therefore targeted the Sf3b1 locus of mouse embryonic stem cells
(ESC) to create a conditional allele encoding the most common mutation
Sf3b1K700E to assess the phenotypic consequences of its expression in vitro
and in vivo.
Methods: The C57BL/6N ESC line JM8 was targeted by homologous recom-
bination. Albino pseudopregnant females were injected allowing for chimera
screening based on coat color. One mouse carrying germline transmission was
selected and its heterozygous offspring was crossed to Tg(Mx1:Cre) mice.
Sf3b1K700E expression was then elicited in the bone marrow with pIpC injection
to activate the Cre recombinase. In parallel, Cre was overexpressed in ESC to
generate clones with constitutive Sf3b1K700E expression to perform in vitro
work. WT and mutant ES cells were analyzed in basal conditions and after dif-
ferentiation into haematopoietic cells. For the latter procedure, cells were
allowed to grow into embryoid bodies that were subsequently dissociated with
trypsin and cultured in a hematopoietic cytokines mix. 
Results: WT and mutant Sf3b1 ESC showed proliferation rates and colony
morphologies similar to native ESC. Upon differentiation, >80% of cells
expressed the pan-hematopoietic marker Cd45, with no difference between
genotypes. Erythroid differentiation in particular was efficient as confirmed by
an increase in transcription levels of the globin genes, that was reduced in
Sf3b1 mutant cells. Nevertheless, gross morphology was similar in WT and
mutant cells. Flow cytometry showed a marginal decrease in the percentage
of Cd71low/Ter119hi cells for the mutant genotype, but no major differences in
the frequency of expression markers of stem and progenitor, myeloid and
megakaryocytic cells. By unsupervised clustering of gene expression profiles,
we found that WT and mutant cells cluster closely together in the undifferenti-
ated state, whereas differentiation causes mutant cells to acquire a dramatically
different expression profile than WT cells. Mutant differentiated cells showed
an excess of downregulated genes, among which known players in congenital
sideroblastic anemias (Abcb7, Glrx5, and Scl25A38). Gene ontology analysis
showed downregulation of several biological processes, including the respira-
tory electron transport chain and regulators of mitochondrial ion transport as
shown previously, but also processes involved in RNA metabolism like trans-
lation initiation and pre-mRNA splicing. Initial analysis of conditional Sf3b1K700E
expression in mice showed that heterozygous animals display no overt sign of
disease at our median follow-up of 116 days. In turn, peripheral blood counts
post-pIpC injection show that hemoglobin is significantly decreased at one
(17.2 vs 14.2 gr/dl, p=0.001) and two months (16.7 vs 15, p=0.006) in mutant
animals, with no difference in white cell and platelet counts. Analysis of bone
marrow cells by flow cytometry showed a 2-fold decrease in Cd71low/Ter119hi
(p=0.02) cells for the mutant genotype, suggestive of a late maturation defect.
Lastly, iron stain of bone marrow cells showed an increment of iron-laden
macrophages and occasional ringed sideroblasts in the mutant animals.
Summary and Conclusions: Our data closely recapitulates initial observations
in human samples and suggests mutated Sf3b1 expression leads to defective
erythroid maturation. Our mouse model will allow better characterization of the
molecular pathways altered by the mutation and the analysis of modifiers of
this phenotype.
S133
IN VIVO TREATMENT BY LENALIDOMIDE CHANGES THE CLONAL
EVOLUTION OF HEMATOPOIETIC STEM PROGENITOR CELLS OF NON
DEL(5Q) LOW RISK MDS PATIENTS
V. Chesnais1,* A. Renneville2, A. Toma3, M. Passet4, A. Gauthier4, A. Lefèvre1,
J. Delaunay5, C. Rose2, A. Stamatoullas6, O. Beyne-Rauzy7, P. Fenaux8, 
F. Dreyfus9, C. Preudhomme2, M. Fontenay14, O. Kosmider14, E.L. Groupe
Francophone des Myelodysplasies9
1Institut Cochin, Paris, 2CHRU Lille, Lille, 3Hematology, Hopital Henri Mondor,
Creteil, 4Hematology, AP-HP Hopitaux Universitaires Paris Centre, Cochin,
Paris, 5CHU Nantes, Nantes, 6Centre Henri Becquerel, Rouen, 7CHU Toulouse,
Toulouse, 8Hopital Saint louis, 9AP-HP Hopitaux Universitaires Paris Centre,
Cochin, Paris, France
Background: Recurrent somatic mutations are thought to support MDS initiation
and progression. Recently, studies have highlighted the clonal evolution of MDS
which could be affected by treatments. Lenalidomide (Len) is designated as a
second line treatment in non-del (5q) transfusion-dependent (TD) ESA-resistant
low/int-1 MDS patients, which achieve an erythroid response in 30% of cases.
Aims: To investigate whether mutations may represent molecular markers of
sensitivity to Len, we used next generation sequencing to examine 26 recur-
rently mutated genes in non-del(5q) MDS patients treated by Len. We also
investigated the clonal evolution of hematopoietic stem progenitor cell (HSPC)
following this therapy.
Methods: Bone marrow mononuclear cells (BMMC) were collected in 99
patients at screening, in 15 patients (6 non responder and 9 responder) after
4 cycles of treatment within 4 to 8 months after treatment initiation. For 8 respon-
der, 3 to 5 sequential samples were collected until the 26th month of follow-up.
Samples were genotyped by next generation and Sanger sequencing
approaches. Clonal architecture of CD34+CD38-HSPC was determined by the
genotyping of single cell-derived clones expanded on murine MS5 stromal cells,
in 5 patients at screening and was also monitored after 4 cycles of treatment.
Results: On the global cohort, four genes had a mutation frequency over 10%:
SF3B1 (73%), TET2 (46%), ASXL1 (20%), DNMT3A (20%). As judged on vari-
ant allele frequencies (VAF), SF3B1 and DNMT3A mutations were mostly clonal
while TET2 and ASXL1 mutations were clonal or subclonal. The presence of
DNMT3A mutations was linked to the response to Len. Among the 15 patients
with a follow-up after 4 cycles, VAF were stable in 5/6 non-responder, while a
subclonal NRAS mutation became visible in one case. Among responder
patients, a significant decrease of VAF was observed in 5/9 cases. VAF detect-
ed in total BMMC mirrored the mutation representation in HSPC compartment.
Furthermore, genotyping of recurrent mutations in individual HSPC described
the clonal hierarchy. In some cases, the founding clone was the dominant
clone, while in other cases it preceded its appearance. Subclonal mutations
either colonised the dominant clone or defined a new independent clone. After
4 cycles of treatment, the dominant clone collapsed in 3/5 patients. In two
responder patients, the dominant SF3B1/DNMT3Amut clone either completely
disappeared in favor of the founding DNMT3Amut pre-leukemic clone or obvi-
ously decreased in favor of a minor SF3B1ex14mut/DNMT3Amutclone. In a 3rd
case, the dominant SF3B1/TET2mut clone decreased in favor of founding
SF3B1mut clone. In the two other cases, dominant clones SRSF2/TET2mut or
SRSF2/TET2/ASXL1mut remained stable. Long term follow-up of VAF in 8
responder until 26 months after the beginning of treatment identified an
increase of the dominant mutations and/or the emergence of mutations in
EZH2, TP53 or ASXL1 genes in 4/5 patients concomitantly with the loss of
response.
Summary and Conclusions: Len is able to modify the clonal evolution of non
del(5q) low/int-1 MDS by targeting the dominant clone in HSPC compartment,
in cases affected by DNMT3A and SF3B1 mutations. Conversely, emergence
of subclones can be observed before or at the time of treatment failure. Extend-
ed analysis to a larger number of patients will confirm that the clonal evolution
under treatment must be monitored.
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SRSF2 P95H MUTATION RESULTS IN IMPAIRED STEM CELL
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Background: Recent genetic studies have revealed frequent and specific path-
way mutations involving multiple components of the RNA splicing machinery
in myelodysplasia. Among these, SRSF2 mutations are more prevalent in
CMML subtype and are associated with poor prognosis. Mutations showed a
prominent hotspot involving proline 95, causing either P95H, P95L, or P95R
conversion. The molecular mechanism by which SRSF2 mutations lead to
myelodysplasia remains largely unknown.
Aims: This study aimed to clarify the role of SRSF2 mutations in the development
of myelodysplasia through the analysis of Srsf2 P95H conditional knock-in mice.
Methods: We first generated a heterozygous conditional knock-in mouse mod-
el of Srsf2 P95H mutation and crossed them with Vav1-Cre transgenic mice.
We then performed detailed analysis of hematological phenotype of Srsf2 P95H
knock-in mice and also evaluated their reconstitution ability in competitive trans-
plantation experiments. 
Results: Heterozygous Srsf2 P95H conditional knock-in mice exhibited no sig-
nificant change in total peripheral blood (PB) counts compared to wild-type
mice at 8-15 weeks after birth. Bone marrow (BM) cellularity and spleen weight
showed no obvious difference between Srsf2 P95H and wild-type mice. Analy-
sis of hematopoietic stem and progenitor cells fractions showed significant
decrease of the frequency of HSCs in Srsf2 P95H mice compared to wild-type
mice. On the other hand, there were no significant differences in the number
of more differentiated progenitor cells including multipotent progenitor (MPP)
cell fractions, myeloid progenitors (MEPs, CMPs, and GMPs) and lymphoid
progenitors between Srsf2 P95H and wild-type mice. We next performed non-
competitive transplantation experiments to assess the cell intrinsic effects of
Srsf2 P95H mutations. 3 months after transplantation, recipient mice trans-
planted with Srsf2 P95H BM cells showed significant leukopenia due to
impaired lymphopoiesis and anemia. Flow cytometrical analysis revealed
decreased numbers of HSCs and MPPs fractions, whereas there were no sig-
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nificant changes in MEPs, CMPs, and GMPs in BM. The frequency of erythroid
progenitor populations was significantly reduced in Srsf2 P95H mice in BM and
spleens. The population of B cell lineage also decreased at as early as pre-pro
B cell stages. These observations suggested that SRSF2 P95H mutations lead
to impaired stem cell functions and ineffective hematopoiesis, resembling the
phenotype of MDS. Subsequently, we assessed the reconstitution capacity of
whole BM cells from SRSF2 mutant mice in competitive transplantation exper-
iments. The donor chimerism of Srsf2 P95H-derived cells in PB was significantly
lower than that of wild-type cells. At 4 months post transplantation, chimerism
of Srsf2 P95H-derived cells was remarkably lower than that of wild-type cells
in the fractions of HSCs, MPPs, CMPs, MEPs, GMPs and CLPs. Furthermore,
the reduced donor chimerism for Srsf2 P95H mutants was recapitulated in sec-
ondary transplantation experiments. Finally, we have not observed overt MDS
phenotypes in none of these Srsf2-mutant mice or transplantation models.
Summary and Conclusions: Our results demonstrated that heterozygous
P95H mutation of Srsf2 lead to deregulation of hematopoietic stem cells that
was evident from reduced competitive repopulation in lethally irradiated mice
and impaired hematopoietic differentiation. SRSF2 mutation by itself does not
seem to be sufficient to develop MDS but to require additional genetic and/or
epigenetic events for overt MDS phenotype.
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CSNK1A1 BEHAVES LIKE A TUMOR SUPPRESSOR GENE AND
MUTATIONS IN CSNK1A1 ASSOCIATE WITH MUTATIONS IN SPLICEOSOMAL
GENES IN MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q)
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K. Wolfgang1, T. Felicitas2, H. Torsten1
1MLL Munich Leukemia Laboratory, Munich, 2Hematology, Hemostasis, Oncol-
ogy and Stem Cell Transplantation, Hannover Medical School, Hannover, Ger-
many
Background: Deletion of 5q is one of the most frequent cytogenetic aberrations
in myelodysplastic syndromes (MDS). The WHO category of myelodysplastic
syndrome with isolated del(5q) describes an own entity showing good prognosis
and also demonstrating response to specific treatment such as lenalidomide.
However, in some patients the disease evolves to secondary AML. The under-
lying pathogenic mechanisms are still under debate. Recently, CSNK1A1 was
found to be frequently mutated in MDS with del(5q) irrespective of the presence
of additional cytogenetic lesions. CSNK1A1 is located on 5q32 in the commonly
deleted region.
Aims: To analyze mutations in CSNK1A1 in correlation to other gene mutations
as well as to clinical data and prognostic information in MDS with isolated del(5q).
Methods: We investigated 115 patients (82 female, 33 male) presenting with
MDS with isolated del(5q) that were strictly diagnosed according to WHO clas-
sification 2008 with respect to cytomorphology and cytogenetics (blasts below
5% in the bone marrow and 5q deletion sole). All patients were analyzed for
mutations in ASXL1, BCOR, BRAF, CBL, CSNK1A1, DNMT3A, ETV6, EZH2,
FLT3-TKD, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, NRAS, KRAS, MPL,
NPM1, PHF6, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, and WT1. The
libraries were generated with the ThunderStorm (RainDance Technologies, Bil-
lerica, MA) and the Access Array System (Fluidigm, San Francisco, CA) and
both libraries were sequenced on a MiSeq instrument (Illumina, San Diego,
CA). Missense variants not yet described in any public database were excluded
from statistical analyses.
Results: In the total cohort the most frequently mutated genes were DNMT3A
and TP53 (21/115, 18% each), followed by SF3B1 (18/115, 16%), TET2
(13/113, 12%), CSNK1A1 (11/115, 10%), ASXL1 (9/115, 8%), and JAK2 (7/115,
6%). The mutation frequencies of all other analyzed genes were below 5%,
respectively. In only 35/115 patients (30%) no gene mutation was identified.
Therefore, CSNK1A1 is the fifth most frequently mutated gene in MDS with
isolated del(5q). All CSNK1A1 mutations were missense mutations in either
amino acid Glu98 (n=9) or Asp140 (n=2). Investigating concomitant gene muta-
tions with CSNK1A1 mutations resulted in two cases showing no additional
gene mutation. The other nine cases showed mutations in ASXL1 (n=2),
DNMT3A (n=2), SF3B1 (n=3), SRSF2, TET2, or U2AF1, respectively. Interest-
ingly, five of the eleven cases (46%) presented with an additional mutation in
one of the spliceosomal genes SF3B1 (n=3), SRSF2 (n=1), or U2AF1 (n=1)
(vs only 16% in CSNK1A1 wildtype, p=0.034). No correlation of CSNK1A1
mutations with age, sex, white blood cell count, hemoglobin level, platelet count,
as well as bone marrow blast count were found. There was also no prognostic
impact of CSNK1A1 mutations on overall survival. Furthermore we raised the
question if the CSNK1A1 mutations occur more likely in the del(5q) cell clone
or in the remaining cells. Therefore, we compared the percentage of del(5q)
positive cells by evaluation of the corresponding FISH data with the mutation
load of CSNK1A1 and found a significant correlation (r=0.761, p=0.006), sug-
gesting that CSNK1A1 mutations occur more likely in the del(5q) cell clone and
is therefore affected on both alleles.
Summary and Conclusions: 1) CSNK1A1 is the fifth most frequently mutated
gene in MDS with isolated del(5q). 2) Cases with mutations in CSNK1A1 fre-
quently associate with mutations in one of the spliceosomal genes SF3B1, SRSF2,
or U2AF1. 3) CSNK1A1 mutations are most likely present in the del(5q) clone.
Red cells: Novel clinical aspects
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LUSPATERCEPT (ACE-536) INCREASES HEMOGLOBIN AND DECREASES
TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN ADULTS
WITH BETA-THALASSEMIA: PRELIMINARY RESULTS FROM A PHASE 2
STUDY
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Background: Luspatercept, a fusion protein containing modified activin recep-
tor, is being developed for the treatment of beta-thalassemia (β-thal). Luspa-
tercept binds to GDF11 and other ligands in the TGF-β superfamily to promote
late-stage erythroid differentiation. Luspatercept corrected the effects of inef-
fective erythropoiesis in a thalassemia mouse model (Suragani R, Blood 2014)
and was well tolerated and increased hemoglobin (Hb) in a phase 1 clinical
study (Attie K, Am J Hematol 2014).
Aims: This is an ongoing, phase 2, multicenter, open-label, dose-finding study
to evaluate luspatercept in adults with transfusion-dependent (TD) or non-trans-
fusion dependent (NTD) β-thal. Efficacy outcomes include Hb increase in NTD
patients, reduced RBC transfusion burden in TD patients, and liver iron con-
centration (LIC) by MRI.
Methods: Inclusion criteria included age ≥18 yr and either being TD or NTD β-
thal with baseline Hb <10.0 g/dL. Luspatercept was administered SC every 3
wks for up to 5 doses with a 2-month follow-up. Six sequential cohorts (n=up
to 6 each) were treated at escalating doses from 0.2 to 1.25 mg/kg. An expan-
sion cohort (n=30) is ongoing; patients who complete the core study may be
eligible to enroll in a 12-month extension study.
Results: Preliminary data (as of 16-Jan-2015) were available for 35 patients
treated for 3 months. Median age was 35 yr, ranging from 20-57 yr, and 86%
had prior splenectomy. TD β-thal patients (n=11). Transfusion burden prior to
treatment ranged from 4 to 8 units/12 weeks. All 10 (100%) evaluable patients
achieved the primary endpoint of >20% decrease in transfusion burden over
12 weeks (includes 1 patient with only 8 weeks) compared with the 12 weeks
prior to treatment (median 67%, ranging from 43 to 100%). The 5 TD β-thal
patients in the higher dose groups with baseline LIC ≥5 mg/g dw who were on
chronic iron chelation therapy (mean duration 2.5 yr) had a mean LIC decrease
of 17% by week 16; this decrease in LIC correlated with a decrease in transfu-
sion burden. NTD β-thal patients (n=24). Mean baseline Hb was 8.3 g/dL, rang-
ing from 6.5 to 9.6 g/dL. Three of 7 (43%) patients in the higher dose groups
achieved the primary endpoint of increase in Hb >1.5 g/dL sustained for ≥2
weeks (mean duration 9 weeks) compared with 0 of 17 (0%) patients in the
lower dose groups. The 5 NTD β-thal patients in the higher dose groups with
baseline LIC ≥5 mg/g dw (includes 3 patients on iron chelation therapy) had a
mean LIC decrease of 18%; this decrease in LIC correlated with an increase
in hemoglobin. All 3 β-thal patients with chronic leg ulcers at baseline (2 NTD,
1 TD) had substantial, rapid healing, beginning 4-6 weeks after the first dose
of luspatercept. Luspatercept was generally well tolerated, with no related seri-
ous adverse events reported to date. Adverse events were mostly mild-moder-
ate and the most frequent related adverse events (>10% patients) were bone
pain, headache, myalgia, and pain in extremity.
Summary and Conclusions: Luspatercept treatment for up to 3 months was
well-tolerated, increased Hb levels in NTD patients, and decreased transfusion
requirement in TD patients with β-thalassemia. Both TD and NTD β-thal patients
had decreases in LIC at therapeutic doses, and healing of leg ulcers occurred
in 3 of 3 patients. These changes represent a significant reduction in disease
burden for patients with β-thalassemia. Phase 3 studies of luspatercept in β-
thalassemia are planned.
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Background: Beta-thalassemias are characterized by ineffective erythro-
poiesis leading to anemia, iron overload, and organ failure. Sotatercept (ACE-
011) is a novel and first-in-class activin type IIA receptor fusion protein that
acts on late-stage erythropoiesis to increase the release of mature erythrocytes
into circulation (Carrancio S, et al. Br J Haematol 2014;165:870-82). RAP-011,
a murine version of sotatercept, was effective in a mouse model of beta-tha-
lassemia, thereby supporting the clinical development of sotatercept for beta-
thalassemia (Dussiot M, et al. Nat Med 2014;20:398-407).
Aims: To determine a safe, tolerable, and effective dose of sotatercept in pts
with transfusion-dependent (TD) beta-thalassemia major (TM) and pts with TD
or non-transfusion-dependent (NTD) beta-thalassemia intermedia (TI). 
Methods: In this ongoing phase 2a, multicenter, open-label, dose-finding study,
pts received sotatercept subcutaneously once every 3 weeks; enrollment up
to 1.0 mg/kg is complete and analysis ongoing. Efficacy was assessed by
hemoglobin (Hb) increase from baseline for NTD pts and RBC transfusion bur-
den reduction for TD pts. Safety was assessed by NCI-CTCAE v4.0. All pts
provided informed consent. ClinicalTrials.gov identifier: NCT01571635.
Results: 30 of 46 pts (65%) in the sotatercept 0.1, 0.3, 0.5, 0.75, and 1.0
mg/kg dose groups were NTD (28 TI, 2 Hb-E/beta-thalassemia) and 16 (35%)
were TD (12 TM, 4 TI). Of 30 NTD pts, 6, 6, 6, 7, and 5 were included in the
different dose groups, respectively; mean baseline Hb for NTD pts was 8.3
g/dL (range 5.9–10.7). Rates of Hb response for NTD pts are shown in the
Table. Area under the curve and peak concentration of sotatercept increased
with dose (data not shown). Increased exposure was associated with higher
mean Hb increases over 9 weeks for NTD pts (r =0.78, P <0.0001) and with
reduced transfusion burden over 24 weeks for TD pts (r =0.74, P <0.01). Among
TD pts evaluable for efficacy, 8 of 14 pts (57%) showed a ≥20% reduction in
transfusion burden on treatment versus 6 month transfusion burden at baseline,
whereas ≥50% reduction was observed for 1 of 5 pts in the 0.75 mg/kg dose
group and 1 of 2 pts in the 1.0 mg/kg dose group; treatment of the 0.3, 0.5,
0.75, and 1.0 mg/kg groups is ongoing. Overall, sotatercept was well tolerated
and 25 of 46 pts (54%) remain on treatment; 19 (41%) pts have been on treat-
ment for ≥1 year, 8 (17%) for ≥22 months, and 2 (4%) for ≥2 years. Grade ≥3
treatment-related adverse events leading to discontinuation were seen in 4
pts: worsening grade 3 bone pain in 1 TD pt in the 0.1 mg/kg group; grade 3
ventricular extrasystoles in 1 NTD pt in the 0.5 mg/kg group; and grade 3 hyper-
tension in 2 NTD pts in the 0.75 mg/kg group. Overall, 3 pts discontinued due
to lack of efficacy: 1 pt in each of the 0.1, 0.3, and 1.0 mg/kg dose groups.
Updated safety and efficacy data will be presented.
Tabella 1. Rates of Hb response for NTD pts.
Summary and Conclusions: These preliminary data suggest long-term treat-
ment with sotatercept can increase Hb levels and decrease transfusion burden
with a favorable safety profile in pts with beta-thalassemia. These data suggest
an exposure-dependent effect for sotatercept. MDC, JP, and OH contributed
equally to this abstract.
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TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF
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Background: Pyruvate kinase (PK) deficiency is a rare genetic disorder of
metabolism resulting in chronic hemolytic anemia, with comorbidities including
iron overload and multi-organ dysfunction. Approximately 180 mutations in the
PKLR gene are recognized to cause functional deficiency of the PK-R isoform.
Defective glycolysis in red blood cells leads to increases in the metabolic pre-
cursor, 2,3-diphosphoglycerate (2,3-DPG), and deficiency of the product,
adenosine triphosphate (ATP). AG-348 is an oral allosteric activator of both
wild type and multiple mutant PK-Rs. We report here a multiple ascending
dose (MAD) trial of AG-348.
Aims: To assess safety, tolerability, and pharmacokinetics/pharmacodynamics
(PK/PD) of AG-348 in healthy volunteers and identify a dosing schedule for
future trials in patients with PK deficiency.
Methods: A phase 1, single-center, randomized, double-blind, placebo-con-
trolled MAD study (NCT02149966) was conducted in healthy men and women
(18–60 years) in 6 sequential cohorts (each cohort: n=6 AG-348, n=2 placebo
[P]). Subjects gave informed consent and received oral AG-348 at 15–700 mg
twice daily (q12h) or 120 mg once daily (q24h) for 14 days with follow-up to
Day 29. Adverse events (AEs), laboratory parameters, ECGs, and vital signs
were monitored. Plasma AG-348 concentrations and whole blood 2,3-DPG
and ATP levels were measured in serial blood samples for PK/PD assessment.
Hormone levels were monitored due to pre-clinical data suggesting potential
modulation.
Results: 48 subjects (42M/6F), mean age 41.5 (range, 25–60) years, enrolled.
Final, un-blinded safety data showed ≥1 AE in 16/36 (44%) AG-348-treated
and 4/12 (33%) P subjects. Treatment-related AEs (≥1) were noted in 11/36
(31%) AG-348-treated and 3/12 (25%) P subjects. All treatment-related AEs
were mild or moderate in severity (only one grade 3 event) and often reversible
despite continued dosing. The most frequent AG-348-related AEs were nausea
and headache, 5/36 (14%) for each (P: nausea 0/12 [0%]; headache 1/12
[8%]). Gastrointestinal AEs occurred in AG-348-treated subjects only at the
highest dose, 700 mg q12h. One grade 3 AE occurred (AG-348 700 mg q12h,
elevated liver function tests [LFTs], which resolved after treatment discontinu-
ation). There were 4 AG-348 discontinuations: due to AEs in 2 subjects (grade
2 drug eruption, 60 mg q12h; grade 3 elevated LFTs, 700 mg q12h), and 2
subjects withdrew consent (both had grade 1/2 nausea and grade 1/1 vomiting;
both at 700 mg q12h). The highest well-tolerated dose was 360 mg q12h (doses
between 360 and 700 mg were not explored). Plasma AG-348 exposure was
dose dependent, with low to moderate variability in the PK parameters of AG-
348 and its metabolite AGI-8702. There was a dose-dependent decrease in
2,3-DPG and increase in ATP with the effects plateauing at 360 mg q12h.
Decrease in 2,3-DPG was robust after Dose 1, while the increase in ATP
occurred gradually and was strongly evident at Day 8. Change from baseline
in 2,3-DPG and ATP plateaued at ~300 µg/mL (~50% decrease) and ~175
µg/mL (~50% increase), respectively. After final Day 14 dose, 2,3-DPG returned
to levels similar to baseline between 72 and 120 hours. ATP levels remained
elevated through 120 hours post dose (Figure). Details of all un-blinded data
will be presented.
Figure 1.
Summary and Conclusions: AG-348 showed a robust 2,3-DPG/ATP PD gly-
colytic profile at well-tolerated doses in healthy volunteers. The results support
proceeding with a planned phase 2 trial in patients with PK deficiency.
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THE SINGLE-UNIT BLOOD TRANSFUSION: EXPERIENCE AND IMPACT
IN HAEMATOLOGY PATIENTS
A. Allameddine1,* M. Heaton2, H. Jenkins2, S. Andrews2, B. Sedman2, 
C. Poarada2
1Pathology department, Royal Oldham Hospital, Oldham-Manchester, 2Royal
Oldham Hospital, Oldham, United Kingdom
Background: The Pennine Acute Trust (PAT) is one of the largest non-teaching
general hospitals in the UK with an average 30.000 units of blood products are
transfused yearly. The Hospital Transfusion Team (HTT) overseeing the trans-
fusion practice, conducted few audits to assess the appropriateness of blood
transfusion. These showed that an average of 15-25% of blood transfusion is
given inappropriately for various reasons, including the lack of intervention,
prevention and diagnosis of anaemia. This has been similarly confirmed by the
National Comparative Audits of blood transfusion(1).
Aims: The introduction of the Patient Blood Management (PBM) as a patient-
focused model, along with the adoption of a restrictive transfusion triggers,
resulted in one of the most effective measures to reduce the inappropriate
blood usage, with consequent major benefit for the health care system. The
implementation of the single-unit transfusion can considerably reduce the total
RBC requirement, as shown in a study of Berger et al (2012), where a change
from a double to single-unit transfusion resulted to be safe and achieved a 25%
reduction of transfusion requirements(2).
Methods: The HTT introduced the single unit policy for patients without active
bleeding in all hospital wards. This involved dispensing one RBC unit at a time.
Clinicians were asked to consider each unit transfused as an independent clinical
decision and to request the 2nd unit if clinically indicated, after the patient been
re-assessed. Recommendations were given to all clinicians to consider alternatives
to transfusion, especially, those known with iron deficiency or those with expected
transient drop of their haemoglobin level, following treatment, bleeding or sepsis.
The main indications suggested for the 2nd unit either the Hb remains<70g/l or
patient with on-going chest pain or rise of the haemoglobin less than 8g/l.
Results: The single-unit transfusion policy was introduced in PAT in January
2014. The data analysis within the haematology inpatient ward on the first 12
months of introduction of the policy, and compared with same period of 2013
and matched with the same number of patients, are very encouraging. The
analysis revealed an average 31% compliance to single unit policy compared
to 10% in 2013. This has resulted in the reduction of the number of RBC units
transfused by patient from an average of 3.71 units per patient in 2013 to 3.03
in 2014, with consequent saving of 18% of total units of blood, equivalent to
260 units with a saving of around 40.000 euro/year. 
Summary and Conclusions: The introduction of the single unit transfusion
policy could result in up to 18% reduction in red blood cell usage in a population
with haemato-oncological disorders. These data are very encouraging and
demonstrate that the long-standing concept of two RBC units transfusion nec-
essary for an adequate increase of the haemoglobin level must be critically
revised. The introduction of this policy will help reducing blood usage, maintain
adequate blood supply and optimise healthcare resources. However, further
work is needed to improve compliance among clinicians. The introduction of
the single unit policy did not have significant impact on the frequency of trans-
fusion. The 72 hours pre-transfusion compatibility specimen expiry allows
enough time to consider further transfusion without performing further tests.
Although more transfusion events may have occurred in some cases, the overall
reduction in transfusion requirement would compensate for the extra work
undertaken within the transfusion laboratory.
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RAPID REVERSAL OF RED BLOOD CELL SICKLING PROMOTED BY
PEGYLATED CARBOXYHEMOGLOBIN BOVINE GAS TRANSFER
PROPERTIES
R. Jubin1,* P. Buontempo1, C. Buontempo1, R. Yglesias1, Y. Chen1, 
A. Abuchowski1
1Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, United
States
Background: Sickled Red blood cells (RBCs) have increased rigidity restricting
their passage through the microvasculature and cause vasoocclusive crisis
(VOC). PEGylated carboxyhemoglobin bovine (Sanguinate™; SG) was
designed to release carbon monoxide (CO) to reduce vasoconstriction, coun-
teract inflammatory responses as well as deliver O2 to hypoxic tissues. Early
intervention of VOC with SG treatment could limit the crisis event and reduce
pain severity while providing a timely crisis resolution.
Aims: SG treatment effects were evaluated under controlled conditions to
determine its capacity for gas exchange with RBCs obtained from healthy and
Sickle Cell Disease (SCD) volunteers. 
Methods: Carboxyhemoglobin and oxyhemoglobin levels were monitored to
determine dose and time effects as well as the repetitive capacity of SG to
facilitate gas transfer processes. RBC treated samples were analyzed by light
microscopy and image capture flow cytometry to visualize and quantify the
effects of SG treatment on reversing sickled SCD RBC. PEG bovine serum
albumin (PBSA) product was used as a control.
Results: SG addition to normal oxygenated RBC resulted in CO and O2
exchange between RBC and SG that followed mass balance and reached equi-
librium in closed system. Kinetic analysis revealed SG rapidly transferred its
CO component to oxygenated RBC with concomitant O2 loading of SG. Using
experimentally loaded RBC with CO and SG with O2 produced similar reciprocal
gas exchange results. Additionally the primary RBC/ SG reaction products were
isolated and cycled demonstrating the ability of SG to continually facilitate gas
transfer through multiple exposure events. Similar studies using SG, oxygenat-
ed SG (produced by an RBC exchange reaction) or PBSA control were con-
ducted with SCD RBC. Sickling was induced by incubation of RBC in a hypoxic
chamber for 3 hours prior to SG or control treatments. After 2 hours of treatment,
cells were fixed by addition of glutaraldehyde. Photomicroscopy showed a
marked reduction in the sickled RBC population with both SG or oxygenated
SG treatments but not with the PBSA control (Figure 1). Results from imaging
flow cytometry further supported the microscopy findings and revealed a sig-
nificant quantitative reduction in the percentage of sickled RBC levels. 
Figure 1. SG Treatment of Sickled RBC. Hypoxic SCD RBC treated with
SG, oxygenated SG or PBSA for 2 hrs prior to fixation and image capture
(40X mag).
Summary and Conclusions: RBCs are negatively impacted by repetitive HbS
polymerization/de-polymerization cycling and treatments that reverse RBC sick-
ling during a VOC event could be expected to provide broad clinical benefits.
SG was designed to promote CO and O2 transfer in a concentration dependent
manner providing physiological supplementation of O2 transport/delivery in con-
ditions of hemolytic or ischemic anemia. Additionally since ASH 2015, anti-
inflammatory activity on LPS activated samples has been quantified by qPCR
and flow cytometry of a selected panel of inflammatory markers. SG pre-treat-
ment of normal and SCD whole blood significantly decreased inflammatory
cytokine RNA and protein levels. Studies are ongoing examining the effect of
SG on hypoxia induced inflammation. These ex vivo data demonstrated for the
first time that under controlled conditions, a therapeutic agent serves as an
active gas transport agent providing either CO or O2 to sickled RBCs, prompting
rapid unsickling and significant decrease in inflammation markers. Furthermore,
image capture flow cytometry provided a quantitative measurement of sickled
RBC fraction decrease. This mechanism may provide a useful biomarker test
in future clinical studies to monitor SG treatment effects on SCD patients.
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THE THROMBIN INHIBITOR DABIGATRAN IMPAIRS CANCER CELL
GROWTH AND PROGRESSION
F. Vianello1,* L. Sambado2, P. Prandoni3, A. Goss4, F. Fabris2
1Medicine, Haematology and Clinical Immunology, 2Medicine, 3Department of
Cardiothoracic and Vascular Sciences, University of Padova, Padova, Italy,
4Department of CardioMetabolic Disease Research, Boehringer Ingelheim Phar-
ma GmbH & Co. KG,, Biberach an der Riss, Baden-Württemberg, Germany
Background: Advanced malignancy often correlates with activation of the
coagulation system, termed cancer coagulopathy, which is associated with
increased mortality rates. Thrombin, a blood-derived serine protease, is the
main effector of the coagulation cascade. There is convincing evidence that
thrombin, by PAR-1 receptor, regulates numerous critical cellular events, includ-
ing cell proliferation, cell adhesion, angiogenesis, and invasion. Dabigatran is
a selective direct thrombin inhibitor that reversibly binds to thrombin. Dabiga-
tran-bound thrombin is unable to cleave and activate PAR-1.
Aims: The purpose of this study is to explore if dabigatran may affect mechanisms
favouring tumor growth by interfering with thrombin-induced PAR-1 activation.
Methods: The U87 glioblastoma cell line, the MCF-7 breast adenocarcinoma
cell line and the endothelial cell line HUVEC, all expressing PAR-1, have been
used for our experiments. Cell proliferation was measured by a colorimetric
assay suitable for determining the number of viable cells. Cell death was quan-
titated by FACS analysis with PI/annexin. For RNA analysis, Real Time PCR
was performed on a ABI PRISM 2600 instrument using SYBR Green. Protein
expression was measured by WB analysis. Chemotaxis was studied using
transwell plates. Endothelial cord formation was evaluated on Matrigel by enu-
merating branching points (tube formation) with an inverted microscope.
Results: Exposure of tumor cells to thrombin significantly increased cell pro-
liferation as measured by MTS conversion. Using this approach, dabigatran
was effective in antagonizing thrombin-induced proliferation in a dose-depen-
dent manner. In our experimental system, U87 cells underwent cell death when
cultured in starving medium. As thrombin has been shown to activate protein
kinases interfering with caspases-dependent cell death, we thought to evaluate
this property in U87 starved cultures. We found that the fraction of double pos-
itive annexin/PI cells was significantly lower in presence of thrombin and this
protection was lost when dabigatran was coincubated with thrombin. We then
evaluated the regulation of cell cycle proteins by thrombin and dabigatran. In
particular, we evaluated the expression of cyclin D1 (promoting cell cycling)
and p27 (inhibiting cell cycling) in U87 and MCF-7 starved cultures. Thrombin
led to down-regulation of p27 with concomitant induction of cyclin D1. When
dabigatran was added to cultures, the pattern of inhibition of growth observed
in presence of starving medium was restored (Figure1 A). Treatment of MCF-
7 cells with thrombin determined a slight but significant increase of the fraction
of cells in S phase. The effect of thombin on cell cycle was completely antag-
onized by dabigatran. We then evaluated the expression of pro-angiogenetic
proteins, Twist and GRO-a, in MCF-7 cells and HUVEC cells following exposure
to thrombin and dabigatran. We found that thrombin was significantly effective
in inducing up-regulation of Twist and GRO-a mRNA in MCF7 and HUVEC cell
lines. Expression of Twist was brought down to control levels when dabigatran
was added to colture. WB analysis confirmed RT-PCR results (Figure1 B). We
also found that the chemoattractant effect of thrombin on tumor cells was lost
in presence of dabigatran, and this effect was directly related to dabigatran
concentrations. Finally, vascular tube formation in HUVEC cells was increased
in presence of thrombin and the induction of tube formation was progressively
lost with dabigatran (Figure1 C).
Figure 1.
Summary and Conclusions: Our data support a role of thrombin in inducing
the proliferation, migration and pro-angiogenetic effects of tumor cells in-vitro.
Dabigatran has shown activity in antagonizing all these effects, thereby impair-
ing tumor growth and progression. In-vivo models may help to understand the
relevance of this pathway.
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OPTIMAL DURATION OF ANTICOAGULANT THERAPY FOR THE
TREATMENT OF CANCER-ASSOCIATED THROMBOSIS
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Hospital de Igualada, Barcelona, Spain, 6Emergency Internal Medicine,
Ospedale St. John, Rome, Italy, 7Internal Medicine, Hospital General Univer-
sitario Santa Lucía, Murcia, 8Internal Medicine, Hospital Universitari Germans
Trias I Pujol, Barcelona, Spain
Background: Cancer-associated thrombosis is associated with a high risk of
recurrent thrombosis despite “usual intensity warfarin”; anticoagulant therapy,
specifically low-molecular weight heparin, reduces the risk of recurrent throm-
bosis compared with warfarin. However, the optimal duration of treatment in
patients with cancer associated thrombosis remains unclear. 
Aims: To evaluate the effects of treatment duration on the outcomes in patients
with cancer-associated thrombosis. 
Methods: Consecutive patients with symptomatic venous thromboembolism
[VTE] (deep vein thrombosis or pulmonary embolism) were prospectively
enrolled in the RIETE registry. The patient were categorized into 2 group
according to received treatment duration (<6 months vs ≥6 months). All the
patients were followed up to 5 years from treatment start date. The primary
outcome was recurrent VTE and the secondary outcomes were all-cause mor-
tality, VTE-related death and major bleeding.
Results: A total of 4,460 patients with cancer-associated thrombosis were
enrolled in the analysis. Of these, 2,937 patients received anticoagulant for
less than 6 months, and 1,523 received anticoagulants for more than 6 months.
Patients receiving anticoagulant therapy for less than 6 months had an
increased risk of recurrent thrombosis (hazard ratio [HR] 2.86, 95% confidence
interval [CI] 2.22 to 3.70) when compared to patients received anticoagulant
for more than 6 months. The risk of all-cause mortality and VTE-related death
were significantly increased higher in patients treated for less than 6 months,
HR 5.88 (95%CI 5.00 to 6.67) and HR 6.25 (95% CI 3.03 to 14.29), respectively.
We did not observe increased major bleeding in patients who were treated for
more than 6 months, HR 0.26 (95% CI 0.19 to 0.38).
Figure 1.
Summary and Conclusions: We demonstrate that patients with cancer-asso-
ciated thrombosis patients have a higher risk of recurrent VTE, VTE-related
death and all-cause mortality if their anticoagulants are not continued beyond
six months from diagnosis. 
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DEVELOPMENT OF A PREDICTIVE SCORE FOR THE IDENTIFICATION
OF LYMPHOMA PATIENTS AT RISK FOR THROMBOEMBOLISM
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Background: There is a paucity of data that pertain to thrombosis in patients
with lymphoproliferative diseases. In few published studies the rate of throm-
botic complications in lymphoproliferative disease is highly variable ranging
from 1.5% up to 59.5% because of the different study types (prospective or ret-
rospective, with hospitalized or ambulatory patients), types of disease (indolent
vs aggressive) and the disease stage, there are few prediction tools for esti-
mating the risk of thrombosis but they are based on studies performed on hos-
pitalized medical patients without cancer or on hospitalized neutropenic cancer
patients without special consideration to hematological malignancies
Aims: Aim of our study was to determine incidence of thromboembolic (TE)
events in patients with non Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL)
and chronic lymphocytic leukemia (CLL) who were treated in our institution.
Also, we assessed predictive model for chemotherapy-associated thrombosis
developed by Khorana and create new model for the identification of lymphoma
patients at risk for thromboembolism
Methods: We reviewed all medical records of patients with with NHL, HL and
CLL diagnosed according to the World Health Organisation classification and
treated at our institution between January 2006 and December 2014. 
Results: A total of 1054 patients, with malignant lymphoma were eligible for
analysis: 576 patients were men (54.6%) and 478 were women (45.4%), and
mean age was 54.0 years. A total of 510 patients (48.4%) had high-grade lym-
phoma, 211 had low-grade lymphoma (20.0%), 153 had Hodgkin lymphoma
(14.5%), and 75 (7.1%) had other forms of lymphoma; HLL had 105 (10.0%)
patients. In group of our lymphoma patients, 72 (6.8 %) had at least one TE. A
total of 40 patients were men and 32 women. Thromboembolic events included
deep vein thrombosis (38.9%), jugular vein thrombosis (12.5%), pulmonary
embolism (11.1%), CNS thrombosis (6.9%), superficial vein thrombosis (2.8%),
acute myocardial infarction (1.4%) and other (26.4%). In total of 49 pts (68%)
thrombosis occurred during treatment or up to 3 months after completion of
therapy, whereas in 23 pts (32%) thrombosis was diagnosed prior to therapy.
Patients with aggressive NHL had significantly higher incidence of TE (8.6%)
compared to all other types of lymphoma patients (RR=2.1; 95%CI for RR 1.2-
3.6; p=0.009) (incidences of TE in low NHL, HL and other forms of limphoma
were 4.3%, 3.3% and 6.7%). Pts with HLL had 8.6% incidence of TE. Patients
with high grade lymphomas, overweight patients (BMI>25 kg/m2), patients with
reduced mobility (ECOG>2), and patients with recent operative procedure (<4
weeks) had increased risk for thrombosis (p<0.05 for all). No difference regard-
ing age, gender or disease stage was found. Based on previously mentioned
risk factors a new TE risk model was developed for patients with lymphoma
(excluding HLL). Patients who had at least two out of four risk factors fall into
high risk group for TE (RR=13.0; 95%CI for RR 7.4-23.0; p<0.001). Predictive
model for chemotherapy-associated TE developed by Khorana was also eval-
uated on this group of patients (RR=7.0; 95%CI for RR 3.3-14.7; p<0.001). In
multivariate analysis our newly developed model for TE events in lymphoma
patients were predictor of TE events and independent from Khorana model.
Summary and Conclusions: Prediction tools for estimating the risk of TE
events in lymphoma patients have not been established but our newly devel-
oped model should be used in addition to chemotherapy-associated model in
guiding best practice in the prevention of thromboembolism in patients living
with lymphoma.
S144
PRESENCE OF JAK2V617F MUTATION IN ENDOTHELIAL CELLS FROM
BUDD-CHIARI SYNDROME PATIENTS IS NOT CORRELATED WITH
PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
R. Helman1,2,* F. Santos P.S.1, P.V. Campregher1, L.C. Marti1, T.S. Datoguia1,
N. Hamerschlak1, M. Miyaji1, E. Matta HA1, C.S. Chiattone2, W.O.Pereira1
1hematology, Hospital Israelita Albert Einstein, 2hematology, Irmandade Santa
Casa São Paulo, Sao Paulo, Brazil
Background: The role of the endothelial cell in the pathogenesis of Ph-negative
MPNs is still not elucidated. Some have reported the presence of the
JAK2V617F mutation in endothelial colony forming cells (ECFC) isolated from
peripheral blood in patients with Ph-negative MPNs (Teofili L et all, Blood 2011).
Others, however, did not find such an association (Piaggio G et al, Blood 2009).
In patients with Budd-Chiari Syndrome (BCS), the JAK2V617F mutation has
been found in endothelial cell (ECs) isolated by micro dissection from liver biop-
sies in patients both with and without MPN (Sozer S et al, Blood 2009). Besides
the JAK2V617F mutation, other mutations (e.g. ASXL1, TET2, DNMT3A,
SRSF2) have been described in patients with Ph-negative MPNs, but their
presence has not been evaluated in patients with BCS who carried the
JAK2V617F mutation.
Aims: 1. To evaluate the presence of the JAK2V617F mutation in CECs from
patients with BCS both with and without concomitant Ph-negative MPNs; 2. To
determine the mutational landscape of granulocytes in patients with BCS who
harbored the JAK2V617F mutation but did not have the clinical diagnosis of a
Ph-negative MPN.
Methods: We identified 10 patients from our institution who had a diagnosis of
BCS and harbored the JAK2V617Fmutation in granulocytes. Three patients died
from hepatic failure before they could be evaluated by bone marrow biopsy, so
7 patients remain for the analysis. All patients were investigated for the presence
of Ph-negative MPNs with bone marrow trephine biopsy. ECs assays were per-
formed according to the method of Hill. Briefly, Ficoll-Paque density gradient–
isolated mononuclear cells were plated on fibronectin coated 6-well dishes with
EndoCult medium (Stem Cell Technologies) for 48 hours, when non adherent
cells were recovered and re-plated in a new dish at 106/mL concentration. After
an additional 5 days, adherent cells were plucked and analyzed by flow cytom-
etry. The ECs population was sorted using a FACS Aria BD Biosciences sorter
according to the following phenotype: CD45-PerCP-negative, CD31-FITC-
positve, VEGFR2-PE-positive, CD34-PECy7-positive, CD133-APC-negative.
The presence of the JAK2V617Fmutation was investigated by allele-specific
PCR. Paired DNA (sorted CD66b-granulocytes/skin biopsy) from 3 patients with
JAK2V617F-positive BCS without a clinical diagnosis of Ph-negative MPN was
subjected to whole exome sequencing on a Illumina HiSeq 2000 platform using
Agilent SureSelect kit. Tumor coverage was 150x and germline coverage was
60x. Somatic variants calls were generated by combining the output of Somatic
Sniper (Washington University), Mutect (Broad Institute) and Pindel (Washington
University), followed by in-house filters to reduce false positive calls.
Results: We were able to obtain CECs from all 7 patients. The purity of the
CECs populations obtained was over 96% in all cases. Among the 7 patients
with BCS, five did not have any clinical feature of a Ph-negative MPN, with a
normal bone marrow biopsy. The JAK2V617F mutation was positive in the
CECs from 5 cases, including 3 patients who only had BCS. In one patient with
BCS solely the reaction did not work, and in another the JAK2 was wild-type in
the ECs. The mutation was positive in CECs from both patients with myelofi-
brosis and BCS. Three patients with BCS solely were evaluated by whole
exome sequencing. The only known pathogenic abnormality found was the
JAK2V617F mutation, albeit at a low allele fraction (5%, 6%and 12.6%). 
Summary and Conclusions: The presence of the JAK2V617F mutation in
CECs from patients with BCS who did and did not have a diagnosis of Ph-neg-
ative MPN suggest that the mutation plays an important role in the development
of vascular complications in these patients. Further studies with a larger number
of patients are needed to precisely define the importance of CECs in the patho-
genesis of MPNs. The sole presence of the JAK2V617F mutation in circulating
granulocytes at a very low allele fraction in patients with BCS without Ph-neg-
ative MPNs suggest that these patients have a pre-malignant clone that would
probably remain undiagnosed had it been not for the development of hepatic
venous thrombosis. 
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HIGH-DOSE CORTICOSTEROID ASSOCIATED WITH CATHETER-RELATED
THROMBOSIS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
X.H. Zhang1,* F.E. Feng1, Q.M. Wang1, X.L. Zhu1, J.M. Zhang1, F.R. Wang1,
W. Han1, Y. Wang1, H. Chen1, Y.H. Chen1, L.P. Xu1, K.Y. Liu1, X.J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing, China
Background: Allogeneic haematopoietic stem cell transplantation (Allo-HSCT)
recipients are at increased risk of thrombotic complications, most of which are
catheter related. Catheter-related thrombosis (CRT) remains challenging in
allo-HSCT patients. On one hand, the incidence of CRT varies considerably
depending on clinical factors. CRT has major consequences for patients who
are already vulnerable, including pulmonary embolism. On the other hand, the
benefit of anticoagulation must be weighed against the substantially increased
risk of bleeding. However, the underlying pathogenesis of CRT remains unclear.
From a clinical perspective, it would be helpful to identify the risk factor of CRT
in allo-HSCT patients.
Aims: The aim of this study was to examine the incidence and risk factors of
CRT in allo-HSCT recipients.
Methods: We performed a retrospective nested case-control study in patients
following allo-HSCT. Patients were reviewed retrospectively from all recipients
who underwent allo-HSCT between July 2007 and June 2014 at Peking Uni-
versity People’s Hospital, Beijing. Transplantation protocols (donor selection,
HLA typing, stem cell harvesting, conditioning therapy, and GVHD prophylaxis)
were conducted according to our previously protocols. Thrombotic episodes
were diagnosed based on the clinical suspicion of the physician (pain, swelling,
etc.) with subsequent central venous catheter (CVC) or peripherally inserted
central catheter (PICC) thrombosis confirmed by duplex ultrasound. Cases with
CRT and controls were matched for time of HSCT (±5 days), age at HSCT (±5
years) and type of insertion (CVCs or PICC).
Results: During the 6-year period, CVC and PICC were placed in 923 patients
undergoing allo-HSCT. A total of 38 patients (4.11%) developed catheter-related
thrombosis, among which 12 were associated with CVCs, and 26 were asso-
ciated with PICCs. The median duration from catheter insertion to thrombosis
was 97 days. Among patients with CRT, 20 patients were classified as high risk
before transplantation, and 7 experienced relapse. On average, patients
received 4.5 rounds of pre-HSCT chemotherapy. Despite reports of an associ-
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ation between thrombosis and infection, no patient with CRT experienced a
central line-associated bloodstream infection in our study. No significant differ-
ences were noted in terms of primary disease, donor type, conditioning regimen
and catheter type between cases and controls. On univariate analysis, high-
risk classification and relapse were associated with CRT. Grade III-IV GVHD
is strongly correlated with CRT. Exposure to high-dose corticosteroids and
cyclophosphamide is also related to thrombotic complications. No correlations
between CRT and blood counts, coagulation markers, hyperlipidaemia or
hypoalbuminaemia were noted in the laboratory values analysed. Multivariate
regression analysis identified grade III-IV GVHD and exposure to high-dose
corticosteroids as independent risk factors for the development of catheter-
related thrombosis after allo-HSCT.
Summary and Conclusions: In conclusion, we demonstrate that CRT occurs
among patients following allo-HSCT. The use of high-dose corticosteroids is
correlated with the onset of CRT. However, the efficacy and safety of thrombo-
prophylaxis in this population requires further discussion.
Quality of life and health economics
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LEVELS OF DISCORDANCE BETWEEN PATIENTS’ AND PHYSICIANS’
PERCEPTIONS OF PATIENTS’ HEALTH-RELATED QUALITY OF LIFE IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA-A CROSS-CULTURAL
PERSPECTIVE
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Background: Patients’ Health-Related Quality of Life (HRQoL) is important,
particularly in the relapsed/refractory multiple myeloma (RRMM) setting. Explor-
ing levels of concordance between physicians’ and patients’ perceptions of
HRQoL could improve physicians’ understanding of patients’ feelings and help
in daily patient management. Findings of our study previously published for
the overall population showed no major discordance between ratings of
HRQoL/functioning domains, but major discordance between the perceptions
of physicians and patients for symptom domains.
Aims: To compare between countries the difference in physicians’ and patients’
perceptions of HRQoL and symptoms.
Methods: An observational study was conducted in Italy, Germany, France,
UK/Ireland and Belgium in RRMM patients starting 2nd or 3rd line treatment.
Patients and physicians completed three EORTC questionnaires: Quality-of-
Life Core Questionnaire (QLQ-C30), with 15 domains (Global Health
Status/QOL, Physical Functioning, Role Functioning, Emotional Functioning,
Cognitive Functioning, Social Functioning, Fatigue, Nausea and Vomiting, Pain,
Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea and Financial Diffi-
culties); QLQ-Multiple Myeloma (QLQ-MY20), with four domains (Disease
Symptoms, Side-Effects of Treatment, Body Image and Future Perspective);
QLQ-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) with three
domains (Sensory scale, Motor scale and Autonomic scale). Intra Correlation
Coefficients (ICC) were calculated to compare patient and physician scores
(ICC<0.40 showing major discordance). The difference in patient and physician
scores was compared across countries using ANOVA.
Tabella 1. Comparison of EORTC scores reported by physicians and
patients at baseline, overall and by country
Results: The population included 33 physicians who enrolled 258 patients
(mean age=70; 54% male; mean time since diagnosis=3 years). At baseline,
251 (97%) sets of EORTC questionnaires were completed by patients and 252
(98%) by physicians. Based on ICC (Table 1), most of the domains with major
discordance observed between patients and physicians were symptom
domains, in all countries but Italy. In almost all cases, physicians underesti-
mated the level of symptoms experienced by their patients. However, major
discordance was not observed on the same symptom domains across coun-
tries. The number of domains showing major discordance also differed, ranging
from none (Italian sites) to nine (UK/Irish sites). Variations across countries
were observed on the level of patient-physician discordance, with statistical
significance reached for four out of 14 symptom domains. For HRQoL/func-
tioning domains, major patient-physician discordance was also not observed
on the same domains across countries. Furthermore, the number of domains
showing major discordance differed, ranging from none (French sites) to five
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(Belgian sites). Depending on domain and country, physicians either underes-
timated or overestimated their patients’ HRQoL/functioning. Variations across
countries were observed on the level of patient-physician discordance, with
statistical significance reached for six out of eight domains. The highest varia-
tions (p<0.001) were observed for Physical Functioning, Social Functioning,
Pain and Future Perspective domains.
Summary and Conclusions: Major discordance was observed across coun-
tries on symptom domains, with physicians consistently underestimating their
patient’s symptoms. However, the specific symptom domains concerned varied
between countries. An even more variable picture was observed for
HRQoL/functioning domains. This supports the importance to also consider
patients’ view of their own health.
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ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT
PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK
MYELODYSPLASTIC SYNDROMES
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Background: Higher-risk myelodysplastic syndromes (MDS) are rarely curable
and have a poor prognosis, with short life expectancy. Thus it becomes essential
for physicians to accurately evaluate the patients’ wishes and preferences in
light of the risks, benefits and appropriateness of treatment.
Aims: The primary aim was to investigate the accuracy of physicians’ percep-
tion of patients’ health status and the patients’ preferences for involvement in
treatment decisions. A secondary objective was to investigate physicians’ atti-
tude toward patient involvement in treatment decisions and to examine factors
influencing physicians to be more patient inclusive or exclusive in the shared
decision-making process.
Methods: We investigated 280 high-risk MDS patients paired with 68 physi-
cians to evaluate physician-patient agreement on preferences for involvement
in treatment decisions and self-reported health status. Control Preferences
Scale (CPS) and the questionnaire EORTC QLQ-C30 were used to evaluate
these parameters, respectively. Simple and weighted κ-coefficient was used to
assess the degree of physician-patient agreement. The following variables were
ascertained: physician gender and age; the overall number of years in practice;
the number of years of experience in treating MDS patients.
Results: The median age of the physicians was 44 years (range 28-64) and
their median duration of medical practice was 16 years, with a median of 11
years of expertise in MDS. Analysis was based on 280 patient-physician dyads.
Overall concordance was 49% for physician perception of patient preferences
for involvement in treatment decisions, with a weighted K-coefficient indicating
poor concordance. In 36.4% of comparisons there were minor differences and
in 14.6% there were major differences. In 44.7% of the patients preferring a
passive role, physicians perceived them as preferring an active or collaborative
role. The only factors independently associated with the physicians’ attitude
toward less involvement of their patients in clinical decisions were absence of
the patient’s request for prognostic information (P=0.001) and judging the
patient as having a poor health status (P=0.036). The degree of agreement
between physicians and patients in evaluating overall health status was low.
Agreement on health status was found in 27.5% of cases. Physicians most fre-
quently tended to overestimate health status of patients who reported low-level
health status (Figure)
Figure 1.
Summary and Conclusions: Physicians treating MDS patients often have dif-
ficulty in understanding what their patients’ preferences are and some do not
consider the patients’ preferences to be important. General concordance on
physicians’ perception and patients’ health status was present in slightly less
than one third of comparisons. In particular, physicians tended to overestimate
the health status of patients reporting low levels for this parameter. Physicians
need to improve their perception of patients’ health status in view of the impor-
tant implications associated with assessment of patient eligibility for inclusion
in clinical trials. Moreover, clinicians need to be provided with decision aid tools
that can improve their perceptions and communication skills.
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AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE
MYELOMA (PREAMBLE): A PRELIMINARY REPORT OF DISEASE IMPACT
ON QUALITY OF LIFE
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Background: Multiple myeloma (MM) is associated with high morbidity and
mortality. In recent years, immunomodulatory drugs (IMiDs) and proteasome
inhibitors (PIs) have been approved for MM treatment based on their ability to
improve patient (pt) survival. However, a greater understanding of quality of
life (QoL) in patients treated with IMiDs and PIs is needed. 
Aims: PREAMBLE (Prospective REsearch Assessment in Multiple Myeloma:
an oBservationaL Evaluation; NCT01838512) is an ongoing, prospective, multi-
national, observational cohort study designed to better understand the real-
world clinical effectiveness of IMiDs, PIs, and IMiD+PI in pts with
relapsed/refractory MM (RRMM). We report QoL data for pts enrolled with ≥6
months’ follow-up.
Methods: PREAMBLE includes pts with RRMM aged ≥18 years who have
received ≥1 prior therapy and who initiated treatment with an IMiD, PI, or
IMiD+PI <90 days prior to or 30 days after enrollment. Administration is accord-
ing to standard clinical practice. Data are collected at baseline (BL) and every
3 months during Year 1, then every 6 months in Years 2 and 3, or until discon-
tinuation. Data extraction for the present analysis was performed on 12 Decem-
ber 2014. The EuroQol 5 Dimensions (EQ-5D) questionnaire and the European
Organisation for Research and Treatment of Cancer (EORTC) QoL Question-
naire-Core 30 (QLQ-C30) were used to assess disease burden. Minimally
important differences for EQ-5D and QLQ-C30 have been estimated at 0.06–
0.09 (for all cancers)1 and 6–17 (for MM),2 respectively.
Results: At the time of data extraction, 273 pts had ≥6 months’ follow-up (96%
completion rate at BL). Median BL EQ-5D score was 0.69, compared with 0.8
in the general US population3 and 0.6–0.7 in other MM studies.4,5 At BL, there
was no difference in median EQ-5D score regardless of number of prior lines of
therapy. At Month 6, there was a trend towards improvement in median EQ-5D
score with increasing numbers of prior lines of therapy (1: 0.69; 2: 0.69; >2:
0.76; 3: 0.76; >3: 0.76). At BL, pts reported some or severe pain and discomfort
(63.4% [some] and 14.1% [severe]), anxiety and depression (45.5% [some] and
5.3% [severe]), and inability to conduct usual activities (52.9% [some] and 10.6%
[severe]). More pts receiving IMiDs (19.4%) reported severe pain and discomfort
at BL than those receiving PIs (8.3%) or IMiD+PI (11.1%). Median QLQ-C30
global health status (GHS) score at BL and Month 12 was 58.3 and 66.7, respec-
tively, compared with 75 (general population), 66.7 (colorectal cancer pts), 66.7
(all cancer pts),6 and 57–68.7 (previous MM studies).4,5 Median QLQ-C30 GHS
improved over time in pts treated with 3 prior lines of therapy or with IMiDs
(Table; higher score=better QoL). At BL, fatigue and pain placed the greatest
burden on pts, but improved over time (Table; higher score=worse symptoms).
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Tabella 1. Patient-reported QoL outcome measures
Summary and Conclusions: Preliminary analysis suggests that MM continues
to place a high burden on pts despite new therapies. Although functional scores
show a high level of function, pts are particularly troubled by pain, discomfort,
and fatigue. As data mature and more pts are enrolled, PREAMBLE will shed
light on MM burden and its management.
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HOSPITAL VERSUS HOME CARE FOR PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES IN CURATIVE OR TERMINAL PHASE: USE OF THE
RESOURCES ANALYSIS, SYMPTOM BURDEN AND COST-EFFECTIVENESS
STUDY
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Background: Hospitalization of patients with hematological malignancies often
is an inappropriate setting of care since the economic and clinical advantage
of the home care is not established.
Aims: To compare the costs, the use of resources, the effectiveness of hospi-
talization versus a program of hematologic home care, funded in partnership
by charity and public health service.
Methods: Prospective, observational study. According to disease status two
groups of patients were analyzed for 6 weeks: i) in curative phase, for supportive
care or for early palliative simultaneous care; ii) in terminal phase, for end of life-
care. A mean weekly cost (MWC) for the provider was built of health professional,
laboratory, drugs and transfusions costs. Use of resources and costs for families
were evaluated, as well as a MWC for the families. To evaluate an economic
advantage between settings of care, cost-minimization analysis (CMA) was per-
formed as well as incremental cost-effective analysis (ICER), comparing the rel-
ative costs and outcomes (occurring infections). Patient-reported symptoms
over time (once per week) were measured with the M.D. Anderson Symptom
Inventory (MDASI). This brief self-reported questionnaire consists of 19 items
assessing symptom severity (13 items) and symptom interference (6 items).
Results: Out of 119 patients, 60 were cared at hospital, 59 at home, with a
prevalence older age, worse anemia, performance status and self-efficiency
score in the home care group (<0.001). Infections at first second and third
week occurred more frequently in the hospital than in the home-care group
(p<0.05). Mean No. of transfusions was similar in both groups. Hospital care
was significantly related to a higher MWC (3,830.6 €) and lower cost for families
(78.7 €), compared to home care (MWC 931.4 € and 123.2 €, respectively). At
home the highest cost driver was for health providers, at hospital for drugs.
Compared to hospitalization, CMA showed for home care a weekly-2899.2 €
save for the health provider and +44.5 € charge for the family. Patients’ families
in terminal phase suffered of a mean weekly extra charge of 126.1 €. Cost-
effectiveness analysis showed an advantage for home care, with an ICER –
11,315.1 € of prevented days of care for infection for all patients. No statistically
significant changes in the two groups (hospital versus Home care) over time
were found in the mean scores for symptom severity (p=0.139) and symptom
interference (p=0.284).
Summary and Conclusions: Although patients at home were older and in
worse clinical conditions, in this study the actual determined standard cost of
home care resulted one-third of the hospital cost regardless of the phase of
disease. In this setting home care resulted also cost-effective by saving money
because of a lower number of occurring infections. Also, symptom burden was
not different between groups suggesting that symptom management at home
is feasible.
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Background: MM is an incurable condition associated with high Tx costs.
NDMM resource consumption is driven by Tx-related hospitalization, which is
highest during periods of uncontrolled disease, such as after diagnosis and
during relapses (Arikian SR, ASH 2014 [abstract 2656]; Gaultney JG, J Clin
Pharm Ther, 2013). In the pivotal FIRST trial, continuous Tx with lenalidomide
plus low-dose dexamethasone (Rd continuous) was compared with fixed-dura-
tion Rd (Rd18) or fixed-duration Tx with melphalan, prednisone, and thalido-
mide (MPT), each for 18 mos, in NDMM pts aged ≥65 yrs and ineligible for
stem cell transplant (SCT).
Aims: This analysis quantified the rates of hospitalization and medical utiliza-
tion with Rd continuous based on data collected in the FIRST trial.
Methods: The FIRST trial (N =1623) is a pivotal, multinational, randomized,
open-label phase 3 study. Resource utilization data was collected until patients
discontinued study Tx, presented here with a median follow-up of 37 mos (data
cutoff =May 24, 2013). The rates of hospitalization and medical utilization for
patients treated with Rd continuous (n =535) were plotted for up to 48 mos to
assess whether Rd continuous increased resource utilization over time. Pro-
cedures during the Tx period (18 mos) were compared between the 2 fixed-
duration Tx arms using negative binomial regression.
Results: Resource utilization among pts treated with Rd continuous declined
over time (Figure). The annualized hospitalization rate in the first 3 mos was
3.2 times higher than the average rate for the remaining 45 mos of follow-up
(2.02 vs 0.62); medical utilization was 4.2 times higher than average (5.66 vs
1.34). After 4 yrs of Rd continuous Tx, hospitalization and medical utilization
rates were estimated to be 83% and 84% lower, respectively, than those
observed in the first 3 mos of Tx, reflecting the long-term disease control
observed with Rd continuous. The highest hospitalization rates (per pt-yr) were
associated with infections (0.20), musculoskeletal disorders (0.06), cardiovas-
cular disorders (0.06), and respiratory and thoracic disorders (0.05). The mean
length of stay per admission was 14.08 days (SD, 21.19). The highest medical
utilization rates (interventions per pt-yr) were associated with blood transfusions
(0.76), general imaging procedures (0.21), respiratory and thoracic imaging
procedures (0.20), and therapeutic interventions (0.09). Hospitalization rates
were 0.91 (Rd18) and 0.79 (MPT) per pt-yr of follow-up during the Tx period of
18 mos, adjusted rate ratio (RR) of 1.11 (95% CI, 0.92-1.35; P =0.27). The
equivalent rates for medical utilization were 3.00 (Rd18) and 2.85 (MPT) inter-
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ventions per pt-yr (RR =0.99 [0.81-1.22]; P =0.95). A comparison between the
2 fixed-duration arms showed no significant difference in the rates of medical
procedures and hospitalizations.
Figure 1.
Summary and Conclusions: The rates of resource utilization among pts treat-
ed with Rd continuous dropped substantially after the first 3 mos of Tx and
gradually declined thereafter. The findings suggest that Tx with Rd continuous
does not require a consistently high use of medical and hospital resources.
Note that data on resource utilization were collected only while pts were receiv-
ing Tx. Additionally, future analysis should include all costs generated by health-
care resource utilization throughout pt Tx, including costs associated with
relapses and Tx-free intervals.
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DISTINCTIVE GENOTYPES WITH PRENATAL ORIGINS IN INFANT T-CELL
ACUTE LYMPHOBLASTIC LEUKAEMIA
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Background: ALL in infants is often associated with MLL rearrangements (MLL-
r), a high leukocyte count at diagnosis, an immature or pro-B-cell lineage
immunophenotype (CD10-) and an in utero origin. Infant T-ALL (iT-ALL) is a
very rare and poorly defined entity with a poor prognosis.
Aims: The overall aims of this study were to determine the molecular profile of
iT-ALL (CNAs, LOH) and to investigate the possible prenatal onset of genetic
abnormalities in iT-ALL.
Methods: The availability to us of a unique series of thirteen iT-ALL cases (≤12
months) allowed us to perform matched Genome-Wide SNP6.0 arrays accom-
panied by NGS (WES). Q-PCR and FISH were used to confirm the SNP-array
findings and a ‘Backtracking’ approach with neonatal blood spots was used to
investigate the early onset of these abnormalities.
Results: At diagnosis the median age was nine months, there was no predom-
inance of gender and a high leukocyte count (≥50.103) was observed in 12/13
cases. Immunophenotype analyses revealed that six patients presented a T-IV
profile, five T-III, one presented T-I and another a T-II profile. The T-I case (BR4)
also expressed classical myeloid markers that, according to previously pub-
lished criteria, suggest an Early T-cell Progenitor (ETP) leukaemia. All samples
were analysed at diagnosis for various classical T-ALL abnormalities. Results
showed four cases were mutated for NOTCH1, patient BR1 presenting a com-
bined NOTCH1/FBXW7 mutation, while one case (FR5) harboured a sole
FBXW7 mutation. Three cases presented PTEN alterations and all patients
were IL7R WT. MLL-r was confirmed in three cases. Distinct from childhood T-
ALL, we observed no infants with either STIL-TAL1+ or TLX3+. All diagnostic
samples were analysed by SNP-array to identify CNAs/LOH. A recurrent somat-
ic chr3 deletion was observed in 3/13 cases. These losses result in the complete
deletion of MLF1 and have not previously been described in ALL. Case FR4
harboured a large 11q14.1-11q23.2 deletion that includes the important ‘driver’
gene ATM, while patient BR5 presented a 13q14.2 deletion that involved RB1.
Akin to non-infant paediatric T-ALL we observed a PTEN deletion in patient
BR6 and two further cases with an 11p13 deletion that could lead to LMO2
activation. However, we observed a lower frequency of CDKN2A/B deletions
(38%) than found in paediatric T-ALL (70%). WES analyses for BR4 showed
mutations in 22 genes previously described to play a relevant role in tumouri-
genesis and all tested mutations were found in the patients’ Guthrie card DNAs,
so confirming their presence before birth. For patient BR6 MLL-r, NOTCH1
mutation and PTEN deletion (usually considered a postnatal event) were also
detected as prenatally acquired alterations.
Summary and Conclusions: In summary, we have genetically analysed a
unique series of a rare subtype of paediatric leukaemia; iT-ALLs. We find the
genotypes are varied but, overall, different from those of T-ALL in older children
and adults. A novel aberration (for acute leukaemia), MLF1 deletion, was pres-
ent as a recurrent abnormality in 3/13 cases. Finally, we have provided evidence
that some of the genetic abnormalities, including a PTEN deletion, were pre-
natally acquired.
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DETAILED GENOME ANALYSES REVEAL EXTENSIVE RAG-MEDIATED
REARRANGEMENTS IN ADULT ACUTE LEUKEMIA SUBSETS
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Background: Acute leukemia is characterized by a multi-step accumulation of
genetic alterations in hematopoietic stem or progenitor cells. Recent next-gen-
eration sequencing (NGS) efforts led to the identification of novel genetic alter-
ations in pediatric acute lymphoblastic leukemia (ALL) subsets, however, their
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frequencies, co-occurrence in adult ALL and mutational origin remain unknown.
Recent deep-sequencing efforts in pediatric ETV6-RUNX1-rearranged ALL
cases demonstrated RAG-mediated deletions as the dominant underlying
mutational process (Papaemmanuil et al., Nature genetics 2014), however,
this analysis was not extended to other ALL subgroups.
Aims: Our goal is to determine novel mutational patterns and to reveal novel
mechanisms underlying adult ALL subgroups through integrative analyses of
DNA mapping array and NGS data.
Methods: We generated genome-wide copy number profiles of 53 adult B-cell
ALL (B-ALL), 20 adult T-cell ALL (T-ALL) cases using Affymetrix 6.0 DNA map-
ping arrays and 100 adult acute myeloid leukemia (AML) cases using Affymetrix
500K DNA mapping arrays. In addition, 5 B-ALL cases were selected for whole
exome sequencing and targeted resequencing of the breakpoint boundaries
with the Illumina HiSeq2500.
Results: In comparison to array-based genome characterization studies per-
formed on ALL cohorts, we observed a substantial higher frequency of genetic
lesions of well-known lesions in pediatric ALL, e.g., CDKN2A/B (44%), IKZF1
(23%), and PAX5 (11%). Strikingly, we demonstrated that all T-ALL cases
acquired copy number alterations perturbing the CDKN2A/B pathway. Interest-
ingly, joint analysis of ALL and AML cases revealed a recurrent deletion affecting
both the genes encoding NF1 and SUZ12 in 3 T-ALL and 5 AML cases, an aber-
ration recently shown to be recurrent with concomitant mutations in melanoma
and gliobastoma multiforme. We selected 5 representative B-ALL cases with
extensive genetic deletions of promoters or gene bodies of genes involved in
lymphoid development. Strikingly, all cases belong to the BCR-ABL1 or BCR-
ABL1-like ALL subgroup. In total 102 somatic mutations were detected, however,
no recurrent somatic mutations were detected. In total, we detected 64 genetic
deletions resulting in 128 breakpoints. De novo motif detection revealed the
RAG-affiliated heptamer sequence CACAGTG (E=5.68x10-91) for 121 out of
128 breakpoints (94.5%). Cryptic recombination signal sequence (cRSS) detec-
tion revealed that 58 out of 64 deletions (90.6%) had a 12-bp or 23-bp spacer
cRSS on one or both sides of the deletion. We observed that 54 out of the 64
(84.3%) resolved rearrangements demonstrated the incorporation of non-tem-
plated sequences at the breakpoint boundaries. Chip-Seq data from the B-lym-
phoblastic cell line GM12878 revealed that the breakpoint boundaries are
enriched for H3K4me3, H3K27ac and RNA polymerase II binding. These epi-
genetic alterations are typical for V(D)J-foci undergoing RAG-mediated
rearrangements. Strikingly, we detected complex insertions or deletions (in-
dels) in cRSS sequences located in promoters of genes associated with leuke-
mogenesis, e.g. BTLA, often in addition to large deletions. Further screening
for these open-and-shut joints in the BTLA promoter revealed 8 additional B-
ALL cases in which at least one BTLA allele was affected, comprising 6 BCR-
ABL1/BCR-ABL1-like and 2 B-ALL cases with unknown affiliation.
Summary and Conclusions: We demonstrated in a B-ALL subgroup com-
prising mainly BCR-ABL1/BCR-ABL1-like ALL cases extensive RAG-mediated
rearrangements, as previously shown in ETV6-RUNX1-rearranged ALL. Fre-
quently, these cases acquired kinase-activating lesions (Roberts et al., NEJM
2014), providing further grounds for researching associations between these
lesions and RAG-mediated rearrangements.
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Background: MLL gene rearrangements (MLL-t) define a unique subgroup in
5-10% patients with ALL. However, there is still heterogeneity in clinical out-
comes and genetic composition. The incidence of MLL-t varies by age account-
ing for 80% infant, 3% children and 10% adults. Patients harbouring MLL-t
have a poor outcome relative to their age-matched counterparts and are typi-
cally assigned to high risk treatment protocols. The frequency and clinical rel-
evance of the partner gene and cooperating lesions is unclear.
Aims: We investigated the age-specific frequency of partner genes and the
spectrum of additional abnormalities in 368 MLL-t cases treated on UK clinical
trials over a 20 year period.
Methods: Cytogenetic and FISH analysis was performed on pre-treatment
bone marrow samples using the Vysis MLL break apart probe, Kreatech Posei-
don MLL fusion probes [t(4;11)(q21;q23), t(11;19)(q23;p13), t(9;11)(p21;q23)
and t(6;11)(q27;q23)] and a home-grown AF10 break-apart probe. Copy num-
ber alterations (CNA) were assessed by high resolution Affymetrix arrays: SNP6
(n=14) or CytoscanHD (n=12).
Results: Among the 368 patients the most prevalent translocations were t(4;11)
n=225 (64%), t(11;19) n=61 (17%), t(9;11) n=28 (8%), t(10;11) n=12 (3%) and
t(6;11) n=10 (3%). Seventeen patients harboured other rare partners while the
partner gene could not be determined in 15 patients. The presence of t(4;11)
was age-dependent: infant (<1 year) 78/137 (57%); young children (1-9 years)
35/77 (48%); older children (10-14 years) 19/33 (58%); young adults (15-24
years) 27/30 (90%); and adults 66/76 (87%). The majority of MLL-t cases had
B-cell precursor ALL (93%) but 24 (7%) patients had T-ALL and these were
commonly older children and younger adults (11/24, 46%) and included 11
(46%) cases with t(11;19). In order to address the question of outcome hetero-
geneity by partner gene, we examined the outcome data for 47 patients (1-24
years) treated on UKALL2003 where patients with MLL-t were treated on the
high risk arm. There was no evidence that the t(4;11) conveyed an inferior out-
come compared with other MLL-t: 5 year event-free and overall survival rates
were 74% v 70%, p=0.7 and 74% v 83%, p=0.5, respectively. Among 347 cases
with successful cytogenetics, 116 (33%) cases had at least one additional chro-
mosomal abnormality (ACA) whilst in the remaining 225 cases only the 11q23
abnormality was observed. A total of 299 ACA were counted, averaging 0.8
per case but with some variation by age (0.43, 0.70, 0.51, 0.83 and 0.32 in
infants, young children, older children, young adults and adults, respectively)
as well as partner gene (0.48 in t(4;11) and 1.34 in non-t(4;11)). The most com-
mon ACA were gain of chromosomes X, 6, and 8 as well as loss of 17p and
i(7q). CNA analysis of 14 children and 12 adults with t(4;11) (n=22) and t(11;19)
(n=4) revealed a total of 87 CNA, mostly gains (n=58). SNP array analysis of
24 patients revealed at least one CNA per case and an average of 3.3 per
case. This average is fewer than that reported in other cytogenetic subgroups
using lower resolution arrays (6-7 per case). Although the number of CNA was
low and many were private, the increased resolution offered by the CytoscanHD
array identified several regions of the genome which were recurrently affected
by CNA and warrant further investigation, including 2q26~31 and 15q26.
Summary and Conclusions: In conclusion, although the number of secondary
abnormalities in MLL-t is low there is evidence that it is related to both the part-
ner gene and the age of the patient. In addition, when treated as high risk on
a contemporary protocol all children and young adults with a MLL-t can achieve
good OS rates.
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PATHWAY MUTATIONS IN DIFFERENT AGE COHORTS OF B-LINEAGE
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Background: We previously reported (Messina et al, EHA19 ABSSUB-4428)
that 27% of B-lineage acute lymphoblastic leukemia without known fusion tran-
scripts (B-NEG ALL) carries RAS/RTK pathway mutations. In particular, FLT3
mutations were specific of patients older than 15 years, being detected in 9.8%
of adolescents/young adults (AYA) and 12.3% of adult cases, while only in 2%
of children. On the contrary, KRAS and NRAS mutations clustered in the pedi-
atric cohort: indeed, they collectively accounted for 30% of pediatric cases and
only 14.7% of AYA and 14% of adults. The prognostic role of these mutations
has been investigated only in specific ALL subgroups with contrasting results.
Moreover, being druggable, these mutations represent an attractive target also
from a therapeutic perspective.
Aims: 1) To determine the prognostic impact of RAS/RTK pathway mutations
in children, AYA and adult B-NEG ALL. 2) To assess the sensitivity of B-NEG
ALL primary cells to gene or pathway specific inhibitors.
Methods: The impact on overall survival (OS) and disease-free survival (DFS)
of RAS/RTK pathway mutations was evaluated in 150 B-NEG ALL patients (49
children, 55 AYA, 46 adults) with a median follow-up of 65 months and by
grouping AYA and adults, whose mutational profile and therapeutic regimens
were comparable. OS and DFS curves were estimated by Kaplan-Meier prod-
uct-limit method and compared using the log-rank test (SAS software v9.4).
Annexin V/7AAD apoptotic test (BD Bioscience), MTT (Sigma Aldrich) and 3H-
thymidine (Perkin Elmer) proliferation assays were performed to assess the
sensitivity of ALL cells carrying mutations of FLT3, KRAS, NRAS to increasing
doses (0.1-10 μM) of selected inhibitors of tyrosine kinases (dasatinib, pona-
tinib), FLT3 (quizartinib, crenolanib) and of the PI3K/mTOR/MEK pathway
(rapamycin, BEZ235, selumetinib). Drugs were added at time 0 and viability
was measured after 72 hours. Cells were plated at 1x106/ml and each condition
was run in triplicate.
Results: Survival analyses showed that AYA and adult B-NEG ALL patients
harboring RAS/RTK gain-of-function mutations (i.e.ITD and D835 FLT3 muta-
tions and KRAS/NRASG12-13 mutations)displayed a shorter OS at 4 years
when compared to WT cases (18% vs 49.5%, 95% CI 5.4-59.3 and 38.1-64.4,
p=0.074) and also a significantly shorter DFS (p=0.020), being 20% at 4 years
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(95% CI 5.8-69.1) compared to 49% (95% CI 35.8-67) for WT cases. At vari-
ance, in the pediatric cohort the survival of RAS/RTK mutated cases resembled
that observed in WT cases.in vitro sensitivity experiments showed that quizar-
tinib and crenolanib (0.1 μM) reduced the proliferation rate of B-NEG ALL pri-
mary cells from 3 patients carrying FLT3 ITD mutations. Indeed, after 72 hours
of treatment, quizartinib reduced the percentage of proliferating cells to
31.4±7.9% and crenolanib to 44.1±23.1%. Interestingly, also the 3rd generation
multi-target TK inhibitor ponatinib was highly active. Similarly, primary cells
from 3 samples harboring NRAS or KRAS mutations were sensitive to
PI3K/mTOR/MEK inhibitors (0.1 μM): in particular, BEZ235 reduced the per-
centage of proliferating cells to 18.3±12%, rapamycin to 37.3±25.9% and
selumetinib to 54.1±12.3%. The same inhibitors also exerted a pro-apoptotic
effect in all the samples tested. On the contrary, the non-specific compounds
(ruxolitinib and tofacitinib) proved ineffective.
Summary and Conclusions: RAS/RTK pathway mutations are a common
event in B-NEG ALL with a different distribution across age cohorts. We con-
clusively show that these mutations negatively impact on AYA and adult out-
come. Our results indicate that the routinary screening of RAS/RTK signaling
members in B-NEG ALL may i) improve the risk stratification of AYA and espe-
cially adults, whose outcome is still unsatisfactory; ii) open the way to targeted
therapeutic strategies, as suggested by in vitro experiments.
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DUAL SMALL MOLECULE INHIBITORS TARGETING G9A AND DNMTS: A
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Background: The indisputable role of epigenetics in hematological malignan-
cies, along with the fact that unfavorable epigenetic alterations might be
reversible, has favored the development of novel epigenetic drugs. Although
according to the Structural Genomics Consortium there are 377 known epige-
netic proteins, currently most epigenetic drugs are inhibitors of DNA methyl-
transferases (DNMTS) and histone deacetylases (HDACS). Therefore, many
epigenetic targets remain to be discovered and exploited.
Aims: The overall goal of our study is the identification of new epigenetic targets
and design new small molecules against these targets in Acute Lymphoblastic
Leukemia (ALL), with the final aim of improving the treatment and life quality of
ALL patients.
Methods: We carried out a screening using a panel of small interfering RNAs
(siRNAS): we interfered the expression of 134 genes belonging to the main pro-
tein families implicated in the epigenetic mechanism regulation in several cell
lines of ALL and determined the effect of the interference in cell proliferation.
Results: In this way, we identified the histone H3 Lysine 9 (K9H3) methyltrans-
ferase G9a as a potential target in hematological malignancies. In order to cor-
roborate the results obtained, we nucleofected a greater number of cell lines
with two different siRNAs against G9a. As expected, inhibition of G9a expression
induced a significant decrease in cell proliferation. Besides, treatment of ALL
cell lines with the G9a inhibitors BIX01294 and UNC0638 induced a decreased
in cell proliferation. All these data suggest that G9a is an ideal epigenetic target
for the treatment of ALL. As DNMT1 and DNMT3B were also overexpressed in
ALL cell lines and patient samples and DNTM1 and G9a directly cooperate in
coordinated DNA and H3K9 methylation during cell division, we designed and
synthesized small molecules with dual activity against G9a and DNMTs. We
selected those compounds that presented an optimal affinity against G9a and
DNMTs (biochemical assay) and a good in vitro G9a-DNMT activity inhibition,
decreasing H3K9me2 and 5-methylcytosine (5mC) marks. CM-272 was select-
ed as the lead compound, showing an important in vitro anti-tumoral effect with
GI50 values lying in the nanomolar concentration range. In fact, CM-272 was
significantly more active than reference compounds BIX01294 and UNC0638
(G9a inhibitors) or 5-azacytidine and decitabine (DNMTs inhibitors). Moreover,
the dual small molecules induced apoptosis in addition to decrease cell prolif-
eration. In order to elucidate the mechanism of action of CM-272 we performed
a genome wide RNA-sequencing analysis with and without CM-272 treatment
in ALL derived cell lines. In this analysis we observed that CM-272 induces type
I interferon response and immunogenic cell death in ALL cell lines. Finally, we
performed ADME, toxicity and pharmacokinetic studies in order to carry out the
in vivo analysis in human CEMO-1 ALL mouse model. Treatment of mice
engrafted with CEMO-1 cells with CM-272 induced an in vivo decrease of the
H3K9me2 and 5mC marks, which was accompanied with a significant prolonged
overall survival of treated mice (90.8 days) in comparison with control group
(57.3 days). This is the first evidence of in vivo efficacy of G9a inhibitors.
Summary and Conclusions: In conclusion, we have identified and validated
G9a as an epigenetic target for the treatment of ALL and we have developed
dual small inhibitory molecules against G9a-DNMTs. Finally, our results show
the therapeutic activity of G9-DNMT small inhibitory molecules in models of
ALL and suggest that these compounds may be of clinical value in the treatment
of patients with ALL.
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Background: B-cell directed immunotherapies turned out to be effective in the
treatment of adult patients with B-cell precursor acute lymphoblastic leukemia
(BCP-ALL). However, a lack of target antigen expression in ALL subpopulations
may constitute a potential mechanism of relapse and persistence.
Aims: To gain inside in potential mechanisms of resistance to B-cell specific
immunotherapies by tracing the distribution of driver mutations within relevant
immunophenotypic compartments differing in target antigen expression in a
cohort of 27 BCR-ABL-fusion positive (BCR-ABL+) adult BCP-ALL cases.
Methods: Cryo-conserved samples from initial diagnosis of 27 adult BCR-
ABL+ BCP-ALL patients treated within the GMALL 07/2003 trial were flow sorted
onto slides and screened for BCR-ABL and concurrent CDKN2A/B and PAX5
deletions by fluorescence in situ hybridization (FISH) using one customized
(PAX5) and two commercial probes (Vysis LSI BCR/ABL Dual Color, Dual
Fusion Translocation probe, Vysis LSI CDKN2A/CEP 9; both Abbott Molecular,
Illinois, USA). The following populations were investigated: CD34+38-19-10-3-,
CD34+38+19-3-, CD34+19+20-3-, CD34+19+20+3-, CD34-19+20+3-, CD34-
19-20-3+, CD34+19-13/33+10-3/16-, CD34-19-13/33+10-3/16-, CD34-19-
13/33+10-3/16+.
Results: Cells with a BCR-ABL fusion were detected not only in the B-cell
compartment but also in CD19-negative multipotent progenitors (MPP) and in
myeloid precursor cells in 8/9 cases expressing the M-BCR-ABL transcript,
2/12 patients carrying the m-BCR-ABL variant, in 2/3 with both transcripts and
in 2/3 cases with unknown BCR-ABL transcript. In the remaining patients BCR-
ABL+ cells were found exclusively within the CD19+ compartment. In 8/10 cas-
es with concurrent CDKN2A/B deletions the latter were only found within the
CD19+ compartment including one patient with BCR-ABL+ MPP. One patient
with a unique BCR-ABL+ CD16+ compartment showed CDKN2A/B deletions
also in the MPP and the myeloid compartment. In 4 patients distribution patterns
of concurrent PAX5 deletions resembled the affection patterns of their
CDKN2A/B deletions. Examination of copy number alterations (CNA) of ABL,
BCR and BCR-ABL suggested an evolution of diverse BCR-ABL+ subclones
in 8/27 patients. The onset of subclonal diversification was observed within the
B-determined CD34+19+ compartment in 6/8 cases. However, in two cases
diverse BCR-ABL+ subclones were detectable within the multipotent CD34+38-
19-compartment. Also 6/10 cases with CDKN2A/B deletions showed subclonal
patterns regarding CNA of 9p21 and the centromeric region of chromosome 9.
In these patients we observed the highest burden of CDKN2A/B deletions within
the CD20+ leukemic compartment.
Summary and Conclusions: Our findings reveal distinct patterns of subclonal
evolution in adult BCR-ABL+ BCP-ALL. They confirm that the t(9;22) frequently
represents an antecedent event in the genesis of BCP-ALL which may occur
prior to B-lineage determination. Conversely, leukemic clones were exclusively
detected within the CD19+ compartment in other patients. Concurrent deletions
of CDKN2A/B and PAX5 are frequently restricted to the CD19+ compartment
but may also originate from preleukemic MPP in patients with a BCR-ABL+
CD16+ compartment. In the context of B-cell directed treatment, these obser-
vations may account for both: resistance and effectiveness. A lack of target
antigen expression in leukemic subclones may lead to resistance against CD19
or CD20 directed therapy, however, targeted treatment may eradicate clones
with the most complex genetic profile. Our observations may help to define
new stratification markers in future chemo-immunotherapeutic regiments for
BCR-ABL+ BCP-ALL patients.
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Background: Ikaros (IKZF1) is a master regulator of hematopoietic differenti-
ation and functions as a tumor suppressor. High-risk acute lymphoblastic
leukemia (ALL) characterized by Ikaros deletion and/or mutation has a very
poor prognosis and high relapse. Treatment is challenging for the high-risk
leukemia with Ikaros deregulation because its tumor suppressor mechanisms
are not well understood and targeted therapies are not available. Casein Kinase
II (CK2) activity is dramatically increased in ALL. CK2 directly phosphorylate
Ikaros and suppress Ikaros function. We hypothesize that CK2-mediated down-
regulation of Ikaros function also plays an important role in ALL leukemogen-
esis, and CK2 inhibition will restore Ikaros leukemia suppressor activity.
Aims: To understand the mechanism underlying restoring Ikaros tumor sup-
pressor activity in B-ALL and the therapeutic effect of CK2 inhibition for
leukemia therapy. 
Methods: Chromatin immunoprecipitation coupled with next generation
sequencing (ChIP-SEQ) was used to identify the Ikaros binding targets in B-
ALL cells and also the chromatin state of Ikaros targets by characterizing the
binding profiling of histone modification markers. Microarray and RNA-seq were
used to determine gene expression profiling. The qChIP assay was used for
further analysis of protein-DNA association in leukemia cell line and primary
leukemia cells. The Ikaros shRNA knockdown and retroviral transduction were
used for its function analysis on gene expression and cell proliferation. Human-
derived leukemia xenograft mouse model was used to observe the effect of
CK2 inhibition on restoring Ikaros tumor suppressor activity and leukemia devel-
opment with Xenogen IVIS 50 living imager.
Results: The genome-wide Ikaros and histone deacetylase 1 (HDAC1) binding
sites were identified in the B-ALL leukemic cells. Ikaros controls cellular prolif-
eration in leukemia by repressing cell cycle regulatory genes and the phos-
phatidylinositol (PI3K) pathway. Ikaros represses its target genes by forming
heterochromatin through two distinct epigenetic mechanisms, one via recruit-
ment of HDAC1 histone deacetylase (results in H3K27me3) and the other an
HDAC1-independent mechanism (results in H3K9me3). CK2 inhibition result
in the increase of more suppressive chromatin in promoter of Ikaros targets for
cell cycle progress and PI3K pathway. Moreover, CK2 inhibitor has effect on
gene suppression of Ikaros targets and result in cell proliferation arrest of B-
ALL cells in an Ikaros-dependent manner. These data indicates CK2 inhibition
restore Ikaros function in B-ALL cells. Targeted CK2 inhibition has a strong
therapeutic effect on high-risk leukemia cells in vivo with both leukemia cell
xenograft mouse model and patient-derived leukemia xenograft mouse model
through restoring Ikaros leukemia suppressor activity.
Summary and Conclusions: We found the novel, Ikaros-mediated mecha-
nisms of epigenetic regulation that contribute to tumor suppression in leukemia,
demonstrated that cellular proliferation is controlled by the CK2-Ikaros axis
and identified therapeutic efficacy of a novel therapeutic approach for high-risk
leukemia-restoration of Ikaros tumor suppressor activity via inhibition of CK2.
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THE STEMNESS INHIBITOR, BBI608, REDUCES THE SELF-RENEWAL OF
BCR-ABL1 POSITIVE LEUKEMIA CELLS
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Background: Hematopoietic stem cells and leukemic stem cells share com-
mon features, including self-renewal, the capacity to differentiate, resistance
to apoptosis, and limitless proliferative potential. Despite these similarities,
several stemness factors, such as Hedgehog, Wnt, Notch, and b-catenine
show differential activation in normal versus leukemia stem cells. BBI608 is an
oral first-in-class stemness inhibitor which inhibits the Stat3, b-catenine and
Nanog patheways. In a phase I study, BBI608 demonstrated telerability as well
as signs of anti-cancer activity in patients with solid tumors.
Aims: We investigated the molecular mechanisms by which BBI608 regulates
the self-renewal of primary BCR-ABL1 positive leukemia cells in vivo.
Methods: To identify the leukemia-propagating cell fraction of BCR-ABL1-pos-
itive leukemia, we serially transplanted human leukemia cells from patients with
chronic myeloid leukemia blast crisis (n=1; T315I BCR-ABL1) or ponatinib-resis-
tant Ph-positive acute lymphoblastic leukemia (n=2, Y253H/E255K/T315I BCR-
ABL1 and T315I BCR-ABL1) into NOD/SCID/IL-2gc-/-mice. The cell fractions
with CD34+CD38-CD19+ and CD34+CD38+CD19+ could self-renew and
transfer the leukemia in NOD/SCID mice. To investigate the effects of BBI608
on self-renewal and the relevance as a therapeutic target in ABL-tyrosine kinase-
resistant BCR-ABL1 positive leukemia, we examined the activity of BBI608
against CD34+CD38-CD19+, CD34+CD38+CD19+ fractions transferred
NOD/SCID mice in vivo. NOD/SCID mice were injected intravenously with BCR-
ABL1 positive cells then treated with BBI608 (20 mg/kg; p.o.) for 28 days.
Results: All mice demonstrated the engraftment of leukemia by flow cytometry.
However, the treatment with BBI608 reduced the population of CD34+CD38-
positive cells. We isolated human CD45+ cells from the spleen of mice from
each treatment group and injected equivalent numbers of leukemia cells into
secondary recipients. Following 30 days, all mice received BCR-ABL1 cells
from vehicle treated mice engrafted with leukemia. In contrast, leukemia
engraftment was not detected in recipient mice (n=6) from BBI608-treated
donors. These results demonstrate the persistent effects of BBI608 on long
term self-renewing BCR-ABL1-positive leukemia cells. We further examined
the effects of Stat3/Nanog pathway modulation on in vitro clonogenic growth.
CD34+CD38-CD19+ cells from T315I BCR-ABL1 (n=2) and WT-BCR-ABL1
(n=1) cells were treated with 2 mM of BBI608 for 72 hrs, washed free of drugs,
and plated in quadruplicate in methylcellulose. At 14 days, colonies were count-
ed as initial plating. The representative plate was then washed and cells were
re-suspended and re-plated. After an additional 14 days, colonies were counted
as secondary re-plating. Clonogenic recovery of untreated cells was normalized
to 100% and plating results from all treatment groups were expressed as %
control. BBI608 had only minimum effects on colony formation after initial plat-
ing over control cells. However, upon serial re-plating, secondary colony for-
mations were significantly inhibited by BBI608 (p<0.001). To identify the mech-
anisms that limit the self-renewal of BCR-ABL1-positive cells by BBI608,
NOD/SCID mice engrafted with T315I-BCR-ABL1-positive CD34+ CD19+ frac-
tions were treated with BBI608 (20 mg/kg; p.o.) for 14 days. BBI608 induced
the expressions of p21Cip1, cleaved PARP and reduced the expression of
BMI-1, phospho-Stat3, c-Myc, Sox-2, and Bcl-XL.
Summary and Conclusions: Our preclinical results indicate that BBI608 have
potential as an important option for controlling the drug-resistant leukemia ini-
tiating cells in BCR-ABL1 positive leukemia. It is expected that the BBI608 may
become extremely useful therapeutic interventions in a number of hematolog-
ical neoplasms, including BCR-ABL1 positive leukemia, where the persistence
of cancer stem cells.
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Background: The Prognosis of adult patients with Acute Lymphoblastic
Leukemia (ALL) is estimated at diagnosis on the basis of conventional clinical
and biological characteristics and during treatment by the molecular or
immunophenotypic evaluation of Minimal Residual Disease (MRD). New bio-
logical and molecular features are needed at diagnosis to guide prompt ther-
apeutic strategies. Recently, few studies on heterogeneously treated cohorts
of adult ALL patients reported that TP53 mutations are frequent and correlate
with poor response to induction therapy and short survival, but their real impact
on ALL outcome is still undefined.
Aims: To investigate the incidence of TP53 alterations at diagnosis and corre-
late them with the clinical outcome of 171 adult Philadelphia-negative ALL
patients homogeneously treated in the context of a prospective clinical trial
(NILG 09/2000, ClinicalTrials.gov identifier:NCT00358072)(Bassan R et al,
Blood 2009 and BJC 2014).
Methods: One hundred fourteen B and 57 T-ALL patients were studied (median
age 34,6 years, 97 male). Exons 4 to 11 of the TP53 gene were analyzed on
diagnostic DNA and in 3 cases also on relapse DNA by Next Generation
Sequencing (NGS, 454 Roche platform). Results were validated, when possi-
ble, by Sanger sequencing. Disease-free survival (DFS) and Overall survival
(OS) were estimated by the Kaplan Meier method. The log-rank test was used
to compare survival probabilities between subgroups of patients.
Results: TP53 mutations occurred in 8% of patients (14/171) with a higher
prevalence in B lineage ALL (9,6 vs 5,3% in T-ALL). The allele burden ranged
from 5 to 97% pointing out that TP53 alterations can be present at diagnosis
in minor leukemic clones. All alterations were identified in the DNA binding
domain region and led to missense or frame-shift mutations introducing a pre-
mature stop codon. The found alterations were 12 single nucleotide changes,
2 duplications (4 and 8 nucleotides) and one 11 base pair insertion. The same
TP53 mutations were seen at diagnosis and relapse in three patients for whom
DNA was available at both time points, suggesting the presence of a clone
bearingmutatedTP53 since disease onset. By univariate analysis, TP53 muta-
tions were strictly related to older age (p=0.0003) but not to other clinical fea-
ture. In our cohort, the presence of a TP53 mutation did not affect CR achieve-
ment but relapse rate was significantly higher in mutated cases (p<0.0001)
(Figure1a). Moreover, patients with mutated TP53 showed a significantly short-
er DFS and OS compared to wild-type patients (DFS p=0.0007, OS p=0.0011)
(Figure 1b-c). NGS analysis also revealed single nucleotides changes that
were reported as polymorphism (SNP) in IARC and dbSNP databases. One
patient bearing a TP53 mutation also revealed an unbalanced SNP distribution
along the TP53 sequence confirming the known karyotypic monosomy of chro-
mosome 17. Similarly, other 3 patients showed a TP53 SNP unbalance without
a karyotipic evidence, thus suggesting a cryptic TP53 gene deletion.
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Figure 1. Relapse Incidence (a), Disease Free Survival (b) and Overall Sur-
vival (c) in TP53 mutated vs Wild-type Ph-negative adult ALL. Percentages
are indicated at 4 years.
Summary and Conclusions: In our adult ALL cohort, mutated TP53 does not
impair CR achievement, but it identifies a group of patients with higher relapse-
rate and dramatically shortened DFS and OS. Therefore, TP53 aberrations
detection must be included in the diagnostic work up of adult ALL to guide treat-
ment strategies. The use of highly sensitive NGS is crucial to identify also minor
TP53 mutated clones that may lead to disease recurrence and to reveal TP53
gene deletions not detected by conventional karyotype.
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TUMOR SUPPRESSOR GENES IKZF1 AND BTG1 COOPERATE IN ACUTE
LYMPHOBLASTIC LEUKEMIA DEVELOPMENT AND GLUCOCORTICOID
THERAPY RESISTANCE
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Background: Previously, we and others have shown that IKZF1 (IKAROS)
gene deletions and mutations independently predict poor prognosis in children
with BCP-ALL, and IKZF1 gene alterations have now been incorporated in the
risk stratification of Dutch pediatric BCP-ALL patients. However, it remains to
be established whether loss of IKZF1 function has a direct impact on
chemotherapy responses. Our recent findings show that loss of IKZF1 function
promotes resistance towards glucocorticoid-induced apoptosis in normal and
leukemic B-cells, which correlates with attenuation of the transcriptional
response to glucocorticoids. Furthermore, the effect of other genetic aberrations
on therapy outcome of IKZF1-deleted patients has not been fully addressed.
Our analysis has revealed that the event-free survival of IKZF1-deletion positive
patients is negatively affected by the co-occurrence of BTG1 deletions. In addi-
tion, BTG1 deletions appear to occur more frequently in patients with IKZF1
gene alterations (19%) compared to an unselected cohort (9%).
Aims: Westudied the genetic interaction between IKZF1 and BTG1 in leukemia
development and glucocorticoid therapy responses using knockout mouse mod-
els and human leukemia cell lines.
Methods: Mice haplodeficient for Ikzf1 were crossed onto a C57BL/6J Btg1
knockout background and mice were monitored for spontaneous leukemia
development over a time period of 18 months. Additionally, glucocorticoid
response was determined in lymphoid cells isolated from compound Ikzf1+/-
;Btg1-/-mice by MTS assay and AnnexinV staining and compared to Ikzf1+/-,
Btg1-/-and wild-type B cells. Additionally, sensitivity towards glucocorticoid
induced apoptosis was determined in human leukemia cell lines displaying loss
of IKZF1 and BTG1 function.
Results: We observed a significant acceleration in the onset of T acute lym-
phoblastic leukemia in mice heterozygous knockout for both Ikzf1 and Btg1,
which was even further enhanced in Ikzf1+/-;Btg1-/-animals. These leukemias
were characterized by clonal TCRb rearrangement and aggressive infiltration
into secondary organs. B-cells isolated from 8 to 14 weeks-old Ikzf1+/-;Btg1-/-
animals without any signs of leukemia disease were highly resistant against
glucocorticoid-induced apoptosis. Similarly, human leukemia cell lines display-
ing loss of IKZF1 and BTG1 function showed a glucocorticoid-resistant pheno-
type that was even stronger than by loss of IKZF1 alone.
Summary and Conclusions: Together, our findings establish BTG1 as a tumor
suppressor gene that genetically interacts with IKZF1 during leukemic trans-
formation and strongly potentiates the IKZF1-mediated glucocorticoid resist-
ance phenotype in normal and leukemic B cells.
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INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS)
WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC
LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB
M.S. Topp1,* N. Gökbuget2, S. O’Brien3, A. Stein4, C. Jia5, S.J. Forman4, 
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Background: Blinatumomab is a bispecific T-cell engager (BiTE®) antibody
construct with dual specificity for CD19 on B-lineage cells and CD3 on T cells.
Blinatumomab showed efficacy in Philadelphia-chromosome-negative (Ph–) R/R
ALL in a large, multicenter, single-arm, phase 2 study (Topp et al. Lancet Oncol.
2015;16:57-66) and is now approved in the United States for this indication.
Aims: To evaluate associations between pt baseline characteristics and out-
comes in the phase 2 study.
Methods: Pts (≥18 years) with Ph– B-precursor R/R ALL (primary refractory
after induction; relapse <12 months after 1st remission; relapse <12 months
after HSCT; relapse or refractory after 1st salvage), ≥10% bone marrow blasts
[BMB], and ECOG performance status ≤2 were included in the study. All pts
provided informed consent. Blinatumomab was given by continuous IV infusion
(4 weeks on, 2 weeks off) for ≤5 cycles (cycle 1: 9µg/d days 1–7, then 28µg/d;
subsequent cycles: 28µg/d). The primary endpoint was complete remission (CR,
≤5% BMB, ≥100 000 platelets/μL, absolute neutrophil count [ANC] >1000/μL)
or CR with partial hematologic recovery (CRh, ≤5% BMB, >50 000 platelets/μL,
ANC >500/μL) within 2 cycles. Associations of baseline factors (platelet count,
prior salvage, BMB, peripheral blood blasts, age, geographic region, prior HSCT,
number of prior relapses, and lactate dehydrogenase [LDH]) with CR/CRh and
overall survival (OS) were assessed using the Cochran-Mantel-Haenszel test
and univariate and multivariate logistic regression.
Results: Of the 189 pts treated with blinatumomab, 81 (43%) achieved
CR/CRh within 2 cycles. Median (95% CI) relapse free survival was 5.9 (4.8–
8.3) months; median (95% CI) OS was 6.1 (4.2–7.5) months. CR/CRh was
seen in all groups, including 11 of 25 pts (44%) ≥65 years of age, 29 of 64 pts
(45%) with prior HSCT, 52 of 125 pts (42%) without prior HSCT, and 11 of 32
pts (34%) with ≥3 prior salvages. Pts with <50% BMB at baseline were more
likely to respond to blinatumomab treatment; 43 of 59 pts (73%) with <50%
BMB achieved CR/CRh, while 38 of 130 pts (29%) with ≥50% BMB achieved
CR/CRh. In the final multivariate model, lower BMB and higher platelet count
were associated with CR/CRh; higher platelet count and lower LDH were asso-
ciated with longer OS (Table).
Tabella 1.
Summary and Conclusions: In this analysis, low baseline BMB count was
associated with response to blinatumomab. This supports administration of bli-
natumomab when disease burden is low. For pts with higher tumor burden,
cytoreduction/higher blinatumomab doses may be considered. Responses to
blinatumomab have been observed in pts in remission with minimal residual
disease (Gökbuget et al. Blood. 2014;124:379), suggesting that pts have low
biologic resistance to blinatumomab even after intensive chemotherapy.
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CHARACTERIZATION OF LEF1 HIGH EXPRESSION AND NOVEL
MUTATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
Z. Ge1,* X. Guo1, R. Zhang1, J. Liu1, M. Li1, C. Song2, S. Dovat2, J. Li1
1The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
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Background: Aberrant activation of the Wnt pathway plays pathogenetic roles
in tumors and has been associated with adverse outcome in acute lymphoblas-
tic leukemia (ALL). Lymphoid enhancer binding factor 1 (LEF1), a key mediator
of Wnt signaling, has been linked to leukemic transformation, and LEF1 muta-
tions have been identified in T-ALL.
Aims: To characterize the LEF1 high expression and novel mutations in Chi-
nese adult ALL.
Methods: Bone marrow (BM) samples from 131 newly diagnosed patients (82
male and 49 female) with ALL (87 B-ALL, 43 T-ALL and 1 T-/B-ALL) were col-
lected between June 2008 and July 2013 at the First Affiliated Hospital of Nan-
jing Medical University. All the patients provided their written informed consent
in accordance with the Declaration of Helsinki before enrollment in the study.
The study was approved by the Institutional Review Board of the Nanjing Med-
ical University. We screened mutations ofLEF1exons 2 and 3, the hotspot
regions in T-and B-ALL with the pretreatment BM samples of the cohort. The
LEF1 mutations were created by site-direct mutagenesis and confirmed by
sequencing.The transient luciferase assay was performed in HEK293T cells
using the Promega’ luciferase assay reagents and measured with luminometer
following the manufacture’s instruction. The colorimetric cell proliferation assay
(WST-1 reagent from Roche Applied Science) was performed in Nalm6 and
Molt4 leukemia cells stably expressed LEF1-WT or its mutants. The Whitney
U –test for quantitative parameters, a χ2 test for qualitative parameters, and
Kaplan –Meier survival analysis were used in the cohort study. All statistical
analyses were performed using the SPSS 17.0 and p<0.05 was considered
statistically significant.
Results: Patients were divided into high and lowLEF1expression groups (Q4
vs Q1-Q3). We found LEF1 was highly expressed in 25.0% adult ALL patients
and LEF1 high expression was associated with high-risk leukemia factors (high
WBC, Philadelphia chromosomepositive and complex karyotype), shorter
event-free survival (EFS), and high relapse in patients with B-ALL. In addition,
LEF1 high expression was observed to associate with high mutation rate of
Notch1 and JAK1 in T-ALL. Moreover, we identified 2 novel LEF1 mutations
(K86E and P106L) in 4 of 131 patients with ALL, and those patients with high-
risk ALL (high WBC, complex karyotype). These results suggest a role for LEF1
mutations in leukemogenesis. We further explored the effect of the mutations
on cell proliferation and found both mutations significantly promoted the prolif-
eration of ALL cells. We also observed the effect of LEF1 and its mutations on
the transcription of its targets, c-MYC and Cyclin D1. We found LEF1 increased
the promoter activity of its targets c-MYC and Cyclin D1, and LEF1 K86E and
P106L mutants further significantly enhanced this effect. We also observed
that the c-MYC and Cyclin D1 mRNA levels were significantly increased in
patients with LEF1 high expression compared with those with low expression.
Summary and Conclusions: Our findings indicate high LEF1 expression and
mutations are associated with high-risk leukemia. Our data also revealed that
LEF1 high expression and/or gain-of-function mutations are involved in leuke-
mogenesis of ALL.
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Background: Tyrosine Kinase Inhibitors (TKI) have been shown to be very
effective for the treatment of Acute Lymphoblastic Leukemia (ALL), with a Com-
plete Hematologic Response (CHR) rate close to 100%, and a high rate of
Complete Cytogenetic and Molecular responses (CCgR and CMR). However,
when they are used alone, as single agents, most patients relapse, so that they
are currently used in combination with chemotherapy and as a preparation to
allogeneic stem cell transplantation (SCT). Since Ph+ ALL is more frequent in
the elderly, many patients cannot tolerate intensive chemotherapy and are not
eligible for SCT. We have explored if the administration of two TKIs, Nilotinib
(NIL) and Imatinib (IM) can improve the results without increasing the toxicity.
Aims: To evaluate the response and the outcome of Ph+ ALL patients treated
with the sequential administration of NIL and IM, and to investigate the type
and number of BCR-ABL kinase domain mutations developing during and
after the study.
Methods: We have designed a study (ClinicalTrials.gov. NCT01025505) in
which patients more than 60 years old or unfit for intensive chemotherapy and
SCT where treated with two TKIs, NIL 400 mg twice daily, and IM 300 mg twice
daily, alternating for 6 weeks for a minimum of 24 weeks (study core) and indef-
initely in case of response. The 6-weeks rotation schedule was respected, irre-
spectively of temporary discontinuations. The primary end-point was the rate of
Disease Free Survival (DFS) at 24 weeks (4 courses of treatment); the second-
ary end points included the evaluation of CHR, CCgR and CMR rates. Mutation
analysis was performed by nested RT-PCR amplification of the ABL kinase
domain of the BCR-ABL transcript (codons 206 through 421). Amplified products
were screened by denaturing-high performance liquid chromatography (D-
HPLC). Samples scored positive for the presence of sequence variations were
then subjected to direct automatic sequencing to characterize the mutation.
Results: 39 patients have been enrolled in 15 Italian hematologic Centers (medi-
an age 66 years, range 28-84, M/F=19/20). Among these, 8 patients were unfit
for standard chemotherapy or SCT (median age 50 years, range 28-59). 27
patients were p190, 5 were p210 and 7 were p190/p210. After 6 weeks of treat-
ment, 37 patients obtained a CHR (95%) and 2 a PHR (5%). All the patients
were evaluable for response after 12 weeks of treatment: 35 patients were still
in CHR (90%), 2 relapsed (5%) and one patient died. 25/26 patients who have
completed the study core (24 weeks), were in CHR, and 22 continued therapy
in the protocol extension phase.Thus, the OS at 1 year is 82%, and 64% at 2
years (median follow up 34.9 months, range 3.5-42.4 months). Overall, 25
patients relapsed, with a median time to relapse of 9.2 months (range 1.2-28.4
months), for a DFS of 48.7% at 12 months. Most of mutations detected at relapse
were T315I, E255K, E255V and Y253H. Further details about Cytogenetic and
Molecular responses, and about Adverse Events will be provided on site.
Summary and Conclusions: In this small cohort of Ph+ ALL elderly/unfit
patients, the rates of relapse and progression were not likely to be different
from the rates observed with Imatinib alone. It’s important to notice that the
mutations that occurred at the time of relapse were sensitive to other TKIs
(Dasatinib and Ponatinib).
Acknowledgements. ELN, AIL, AIRC, progetto Regione-Università 2010-12
(L. Bolondi), FP7 NGS-PTL project.
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INTERNATIONAL MULTI-LABORATORY NEXT-GENERATION SEQUENCING
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Background: Amplicon-based next generation sequencing (NGS) of
immunoglobuline (IG) and T-cell receptor (TR) gene rearrangements to quantify
minimal residual disease (MRD) in lymphoid neoplasms is already the focus of
intense research, development, and application. This is mainly due to its poten-
tial to overcome limitations of the current molecular gold standard, real-time
quantitative (RQ)-PCR, as it avoids laborious design and testing of patient spe-
cific assays and allows quantification of MRD with a more specific readout than
RQ-PCR. However, standardization, quality control and validation of the tech-
nology in a multicentre, scientifically controlled and independent setting is highly
warranted, but currently lacking.
Aims: To investigate an optimized IG/TR based NGS approach (including qual-
ity controls and calibrators) for sensitive and quantitative MRD assessment in
lymphoid neoplasms within the EuroClonality NGS Consortium.
Methods: Within a European Multicentre trial a newly designed quality con-
trolled one-step IGH NGS approach was tested in seven institutes (Kiel, Sala-
manca, Milano, Bristol, London, Prague, and Torino). Serial dilutions of diag-
nostic DNA and follow-up samples of thirty B-cell precursor ALLs with known
complete IGH rearrangements as well as a set of positive and negative controls
were analysed. All samples were spiked with pre-defined copy numbers of five
reference IGH sequences. One-step PCR was used for library preparation with
sets of FR2 primers harbouring sample specific barcodes and 500ng DNA per
sample (75.000 copies), subsequently being sequenced with the Illumina V2
kit on the Illumina MiSeq NGS platform. Purpose-built bioinformatics methods
were used to analyse data. MRD results of ALL follow-ups were compared to
results of EuroMRD based RQ-PCR.
Results: A total of 312 samples were sequenced within 24 deep sequencing
runs producing 168 million reads. Regression analysis of reference IGH allele
reads was used to calculate the read coverage per copy, and correct for different
B-cell content per sample. Ratios of reads between pairs of reference IGH alle-
les were highly consistent in intra-and inter-centre analyses, independent of
the total number of reads in the sample. This high consistency in the usage of
the reference IGH alleles was confirmed through redundancy analysis based
on normalized reads (adjusted p-value=0.24). When outliers were identified,
indicating poor assay performance, those were excluded from further analysis.
The IGH gene rearrangements of all 27 pooled positive B-cell line controls were
identified in all centres with a high intra-and inter-centre consistency. NGS
based MRD analysis in 116 ALL follow-up samples revealed MRD positivity in
69/116 samples, and RQ-PCR in 66/116 samples, with a good overall concor-
dance between both approaches (R2=0.81). Discrepancies mainly affected
samples with low MRD levels being consistent with Poisson sampling.
Summary and Conclusions: The approach newly developed by the Euro-
Clonality NGS Consortium shows great promise to allow for quality controlled
NGS based MRD analysis in a multicentre setting with a high intra-and inter-
laboratory reproducibility. The critical next step, as part of the Consortium´s
strategy, involves validation of this technology, prior to its implementation into
routine practice, within multicentre clinical trials, in a scientifically controlled,
independent, and multidisciplinary setting.
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Background: Blinatumomab is a bispecific T-cell engager (BiTE®) antibody
construct designed to link CD19-positive B cells to cytotoxic T cells and induce
tumor cell lysis. Blinatumomab recently showed efficacy in Philadelphia-chro-
mosome-negative (Ph–) R/R ALL in a large, multicenter, single-arm, phase 2
study (Topp et al. Lancet Oncol. 2015;16:57-66).
Aims: To determine the potential benefit of retreatment with blinatumomab
among patients with R/R ALL who had previously responded to blinatumomab.
Methods: In this combined analysis, we evaluated outcomes among patients
with R/R ALL enrolled in 3 open-label, phase 2 studies (NCT01471782: pediatric
and adolescent R/R ALL, study 205; NCT01209286: adult R/R ALL, study 206;
and NCT01466179: adult R/R ALL, study 211) who had a CD19-positive hema-
tological relapse after initial response to blinatumomab and were retreated with
blinatumomab. Patients were <18 (study 205) or ≥18 (studies 206 and 211)
years of age with Ph– R/R B-precursor ALL. All patients or their legal represen-
tatives provided informed consent. Blinatumomab was given by continuous IV
infusion for up to 5 cycles. A cycle was 4 weeks on, 2 weeks off. The primary
endpoint of the 3 studies was complete response or complete response with
partial recovery of peripheral blood counts within the first 2 cycles. Patients who
relapsed following a response that lasted ≥3 months could receive up to 3 cycles
of retreatment; patients with GVHD or CNS involvement were ineligible.
Results: A total of 11 patients received retreatment with blinatumomab (study
205, n=2; study 206, n=5; study 211, n=4). Seven patients (64%) were male;
mean (range) age was 31 (4–77) years. At the time of initial treatment, 9 patients
(82%) had ≥1 line of prior salvage chemotherapy; 7 (64%) had prior HSCT.
Among the 10 patients who achieved hematological remission during the 2
cycles of initial treatment, the median (range) duration of response prior to
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relapse was 9 (3–11) months. Five patients (45%) had HSCT between the first
blinatumomab response and relapse. Outcomes and adverse events (AEs)
during retreatment are shown in the Table. Four of 11 patients (36%) with R/R
ALL who relapsed following an initial response to blinatumomab responded to
retreatment with blinatumomab. One patient was retreated a second time and
achieved a complete response.
Tabella 1. a≤5% marrow blasts and full, partial, or incomplete recovery of
peripheral blood counts. bThere were no grade 4 or grade 5 neurologic
AEs.
                                                                                   Retreated Patients (n=11)
Median (range) duration of retreatment, days                                 28 (4–85)
Hematological remission (responders), n (%)                                 4 (36%)a
Minimal residual disease (MRD) responses
among responders, n (%)
   MRD<10-4                                                                               4 (100%)
   Complete MRD responses                                                           1 (25%)
Patients with any AEs, n (%)                                                          10 (91%)
   Grade≥3 AEs                                                                              8 (73%)
   Grade≥3 neurologic AEs                                                            3 (27%)b
   Cytokine release syndrome                                                          0 (0%) 
Summary and Conclusions: Our results suggest that patients with R/R ALL
who have responded to treatment with blinatumomab and have then relapsed
may respond to retreatment. Overall, rates of AEs during retreatment were in
line with recent clinical experience with blinatumomab.
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Background: Central nervous system acute lymphoblastic leukemia (CNS-
ALL) is a major clinical problem. Prophylactic therapy is neurotoxic and a third
of the relapses involve the CNS. We have previously reported that increased
expression of interleukin 15 (IL-15) in leukemic blasts is associated with
increased risk for CNS-ALL. As IL-15 is a strong activator of natural killer (NK)
cells we hypothesized that NK cells may be involved in regulating CNS
leukemia.
Aims: To characterize the role of IL-15 and NK cells in CNS-ALL.
Methods: We have created two in-vivo mouse models: Syngeneic S49 T lym-
phoma leukemia in BALB/c and human ALL cell lines and primary human ALL
xenografts in NOD/SCID and NOD/SCID/IL2Rγ null (NSG) mice. NK cells were
manipulated in-vivo by antibody mediated depletion and by human peripheral
blood NK (PBNK) cell therapy of xenografted mice. In-vivo studies were com-
plemented by in-vitro killing assays and NK ligand and receptor characteriza-
tion. Results from mouse models were verified by a case-control study involving
RNA and flow cytometry analyses of diagnostic bone marrow leukemia samples
from prospective BFM trials of childhood ALL. Ethical approvals were obtained
for all mouse and human experiments.
Results: Transplantation of IL-15 expressing S49 leukemia cells in neonatal
mice caused marked isolated CNS and ophthalmic leukemia and activation of
NK cells. A human B-cell precursor ALL cell line, 018Z, expressing endogenous
IL-15 caused isolated CNS leukemia in NOD/SCID, an immunodeficient mouse
strain with proficient NK cells. Yet it caused systemic CNS/peripheral leukemia
in NSG mice that lack NK cells. Antibody mediated depletion of NK cells in
NOD/SCID mice resulted in aggressive combined systemic and CNS leukemia,
suggesting that induction of NK cells prevented peripheral but failed to control
CNS leukemia. Therapeutic experiment with human PBNK confirmed that NK
cells do not enter the brain even in the presence of leukemic infiltration. The
killing of human leukemia lymphoblasts by NK cells depended on the expres-
sion of the NKG2D receptor. These findings were confirmed in primary human
ALLs. The degree of peripheral/CNS leukemia of seven independent primary
human ALL xenografts in NOD/SCID mice significantly correlated with IL-15
expression and in-vivo activation of NK cells (P<0.04). Expression of NKG2D
receptor evaluated by qRT-PCR and by flow cytometry of NK cells infiltrating
diagnostic bone marrows of children treated by BFM protocols for ALL corre-
lated with subsequent CNS involvement (P=0.001). Conversely, the expression
of secreted inhibitory “decoy” NK ligands ULBP1 and ULBP3 inversely corre-
lated with CNS positivity (P<0.0001)
Summary and Conclusions: The CNS may be an immunological sanctuary
for ALL cells protected from NK cell activity. Markers of activation of NK cells
(higher IL15, NKG2D and lower (ULBP1+ULBP3)/ULBP2 ratio) at the time of
diagnosis of ALL may be biomarkers for increased risk of CNS relapse. Addition
of CNS prophylactic therapy should be considered in NK based therapeutic
protocols for hematopoietic malignancies.
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Background: Clinical significance of CD20 expression in adult acute lym-
phoblastic leukemia (ALL) has been evaluated previously, showing that the
expression of CD20 was correlated with a bad prognosis in ALL. The addition
of rituximab to the conventional treatment showed a promising result in a
prospective observational study in a center, although no well-designed prospec-
tive interventional study has been performed until now.
Aims: This prospective study has been performed to find out the efficacy and
safety of rituximab plus multiagent chemotherapy for patients with CD20-pos-
itive acute lymphoblastic leukemia.
Methods: Subjects with newly diagnosed ALL who aged ≥15 years old and
were in their good condition were eligible when their leukemic blast cells of
bone marrow aspirate express ≥20% of CD20 antigens at time of diagnosis.
All patients received induction treatment composed of vincristine/pred-
nisolone/daunorubicin/L-asparaginase (for Ph-neg) or imatinib (for Ph-pos)
plus rituximab (375mg/m2) at day 8. After achieving hematologic complete
remission (HCR), subjects received five cycles of consolidation therapy with
concomitant rituximab followed by 2 years of maintenance (non-alloHCT). Allo-
geneic hematopoietic cell transplantation (alloHCT) could be performed when-
ever after achieving HCR. All subjects received 8 times of rituximab during the
whole treatment, irrespective of the adoption of alloHCT-if he/she continued to
alloHCT during the consolidation, rituximab was administered monthly from
day 90 of alloHCT. Data from 103 patients who were treated with the same
cytotoxic drug combination without rituximab in Asan Medical Center from 1997
until 2010 were collected as a historical control group. Toxicity was graded
according to National Cancer Institute Common Toxicity Criteria (version 4.0).
Data were frozen up in May 2014 for this interim analysis.
Results: Thirty six subjects were eligible for interim analysis-3 subjects were
excluded for various causes. The median age of subjects was 42.0 (range 18-
71), 31% of them were Ph-positive and 75% were high risk. The median value
of CD20 expression was 52.5%. Hematologic CR (HCR) rate was 97% and
only one subject failed to achieve HCR owing to death in aplasia during induc-
tion. Fourteen subjects received allogeneic hematopoietic cell transplantation
(alloHCT) after achieving HCR. Median number of consolidation therapy was
3, and rituximab was introduced 5 times (median) to each subject-rituximab
was skipped only 3 times during the cytotoxic chemotherapy schedules of all
subjects. After 11.5 months of median follow-up for surviving subjects, the 1-
year and 21 –month relapse-free survival (RFS) were 71.5% and 49.1%,
respectively, which were significantly higher than those of historical control
(55.5% and 38.9%, p=0.041). The overall outcomes were not significantly dif-
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ferent by the risk group, Ph-status, and the performance of alloHCT. Whereas,
the 1-year RFS of subjects with high CD20 expression level (the same or more
than the median value) was superior to those with low level (91.7% vs 46.4%,
p=0.033), and this difference of outcome was not observed among the historical
control group. Hematologic/non-hematologic toxicity profiles were all tolerable.
Only 10 times of infusion-related adverse events associated with rituximab hap-
pened, except 1 episode of grade-3 anaphylaxis. Especially, the incidence of
acute graft-versus-host disease (GVHD) of ≥grade 2 was 21%, and that of
chronic GVHD was 21%, which were all tolerable.
Summary and Conclusions: In this interim analysis of the prospective study,
combination of rituximab with multiagent chemotherapy was feasible; all
adverse events were tolerable, and all the outcomes were not inferior to the
results of our historical control. Based on these results, we will continue to
recruit subjects up to a total of 77 ones. (Clinicaltrials.gov NCT01429610).
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Background: B-cell acute lymphoblastic leukaemia (B-ALL) in adults is a very
challenging disease. Most patients will go into complete remission, but relapse
often occurs. Relapse following remission induction chemotherapy remains the
major barrier to patient survival, and relapse is an important part of overall mor-
tality in B-ALL patients after haematopoietic stem cell transplantation. Many
relapse patients are currently stratified as standard risk; therefore, additional
more accurate biomarkers for relapse and prognosis are needed to improve
patient stratification. ADAM28 is an ADAM (a disintegrin and metalloproteinas-
es) metalloproteinase that can cleave myelin basic protein. Studies have
demonstrated that ADAM28 is overexpressed in several human tumours and
is related to cell proliferation and lymph node metastasis (Takashi Ohtsuka, et
al. Int. J. Cancer 2005). To date, no information is available on the prognostic
role of ADAM28 in B-ALL.
Aims: The aim of this study was to assess ADAM28 expression levels with
regard to the potential role of ADAM28 as a prognostic biomarker in B-ALL.
Methods: In total, 50 consecutive patients with de novo B-ALL and 23 healthy
donors were enrolled in this study. After obtaining informed consent, ADAM28
expression levels were analysed by flow cytometric assessment and real-time
quantitative polymerase chain reaction. Relapse-free survival (RFS), event-free
survival (EFS) and overall survival (OS) data after a 2-year follow-up were prospec-
tively collected for prognostic evaluation. in vitro, B-ALL cells were isolated from
the bone marrow of patients to assess the effect of arsenic trioxide (ATO) on
ADAM28 expression. Using selective pharmacologic inhibitors, the PI3K/Akt path-
way was demonstrated to be involved in the regulation of ADAM28 expression.
Results: Our data are the first to demonstrate that ADAM28 expression in
leukaemic cells from B-ALL patients was significantly increased compared with
donor bone marrow cells (P=0.0003). A significant inverse correlation was
observed between ADAM28 levels in bone marrow cells and serum expression
levels (r2=0.7512; P=0.0025). Despite considerable variability in expression lev-
els in B-ALL cells, ADAM28 levels were not associated with established risk fac-
tors, such as white blood cell count at diagnosis, immunophenotype and kary-
otype. However, patients experiencing disease relapse or death exhibited sig-
nificantly increased ADAM28 expression compared with those with a favourable
outcome (p=0.0043). Notably, ADAM28 overexpression was associated with a
lower probability of relapse-free survival and event-free survival (P<0.001) and
was a significant prognostic factor (P=0.010, 0.003, respectively) in a multivariate
analysis. in vitro, the expression of ADAM28 in leukaemic cells from B-ALL
patients was inhibited by ATO in a time-and dose-dependent manner. A signifi-
cance increase in migratory activity was noted in B-ALL cells overexpressing
ADAM28 using the Boyden chamber method. The PI3K/Akt pathway inhibitor
down-regulated ADAM28 expression and decreased cell migratory activity.
Summary and Conclusions: Our results are the first to indicate that ADAM28
overexpression in B-ALL patients is correlated with poor outcome. ADAM28
overexpression in B-ALL identifies patients with a high risk of early relapse and
reduced RFS, EFS and OS. ADAM28 overexpression enhances cell migration,
which is potentially regulated by the PI3K/Akt pathway. These data suggest
that ADAM28 might serve as a novel biomarker to evaluate the prognosis of B-
ALL and a potential therapeutic target in B-ALL patients.
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Background: The prognosis for adult acute lymphoblastic leukemia (ALL)
patients with central nervous system (CNS) involvement (CNS+ patients) who
received allogeneic hematopoietic stem cell transplantation (allo-SCT) remains
unclear.
Aims: We compared the clinical outcomes of allo-SCT in CNS+ patients with
those in CNS-patients, and also evaluated prognostic factors for CNS+ patients.
Methods: Clinical data for patients were collected from the Japan Society for
Hematopoietic Cell Transplantation database (TRUMP). The eligibility criteria
for this study were as follows: diagnosis of ALL or acute biphenotypic leukemia,
aged more than 16 years, allo-SCT between 2005 and 2012, and first SCT.
Burkitt leukemia or lymphoblastic lymphoma and secondary leukemia were
excluded from this study.
Results: Data for 2582 patients including 136 CNS+ patients and 2446 CNS-
patients were used for analysis. As compared with CNS-patients, CNS+ patients
were younger (median age: CNS+ 36.5 years vs CNS-40 years, P=0.02), higher
frequency of T-cell phenotype (P=0.03), had worse disease status at SCT (CR
at SCT: CNS+ 55.9% vs CNS-80.5%, P<0.01) and had worse performance sta-
tus (PS) at SCT. A myeloablative dose of total body irradiation was more fre-
quently used for CNS+ patients. Other characteristics were not different
between the two groups. Incidence of neutrophil engraftment was marginally
worse in CNS+ patients (Gray, P=0.07), and mortality rate before engraftment
was significantly higher in CNS+ patients (Gray, P=0.04). Incidences and sever-
ity of acute graft-versus-host disease (GVHD) and chronic GVHD were not dif-
ferent between CNS+ patients and CNS-patients. Incidence of relapse was
higher in CNS+ patients (Gray, P=0.02), and the rate of CNS relapse was also
higher (9.7% in CNS+ patients vs 2.3% in CNS-patients, P<0.01). CNS+
patients developed CNS complications more frequently than CNS-patients
(P=0.02). Incidences of other transplant-related complications and transplant-
related mortality were not different between the two groups. At the median fol-
low-up day of 1000 after SCT (range: 15-3137 days), 3-year overall survival
(OS) rates were 41.2% in CNS+ patients and 55.8% in CNS-patients, and the
difference was statistically significant by univariate analysis (log-rank, P<0.01).
However, in patients who received SCT in CR, there was no difference in OS
rates between CNS+ and CNS-patients (log-rank, P=0.38). We performed mul-
tivariate analysis (MVA) using Cox’s proportional-hazards regression model to
adjust the differences of variables. In the MVA, CNS involvement at diagnosis
had not an unfavorable effect on OS (hazard ratio: 1.08, 95% confidence inter-
val: 0.85-1.38, P=0.53), on the other hand, age, disease status and PS at SCT
remained significant prognostic factors for OS. In the MVA focusing in patients
who had CNS involvement at diagnosis, disease status and PS at SCT were
significant risk factors for OS, and age of the patient was marginally significant.
Summary and Conclusions: Patients who had CNS involvement showed
unfavorable OS due to poor disease status and poor PS at SCT. Patients who
achieved CR and/or good PS before SCT showed preferable OS even if they
had CNS involvement.
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Background: Excellent outcome in childhood acute lymphoblastic leukemia
(ALL) treatment has been achieved by using risk-stratified therapy. Children
with ALL are currently stratified based on various clinical and molecular char-
acteristics to a specific risk group in order to receive an appropriate therapeutic
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regimen. Post induction Minimal Residual Disease (MRD) has been used rou-
tinely to identify higher risk patients that previously resided in standard risk
group by clinical classification. However, the use of MRD is still limited in most
developing countries due to the high complexity and high cost of MRD testing.
Therefore, a new basic clinical marker is needed to facilitate a better risk clas-
sification for children with ALL in resource-limited countries. Absolute lympho-
cyte count (ALC) during and post induction therapy which is a routine clinical
testing has recently been found to associate with treatment outcome in children
with ALL.
Aims: To define the level of ALC during induction chemotherapy that has a
meaningful correlation to ALL treatment outcomes in Thai children.
Methods: A retrospective cohort of 200 newly diagnosed pediatric ALL patients
treated at King Chulalongkorn Memorial Hospital during January 1996-August
2012 were reviewed.The study was approved by Chulalongkorn University
Institutional Review Board. ALC level during and post induction period was
documented together with other established risk factors. Lowess smoothing
Martingale residuals plot was used to determine the optimal cut-point of ALC
level. Univariate analysis was performed using Cox proportional hazards model.
Multivariate models were developed including covariates with P<0.1 in univari-
ate models and hazard ratios (HR) were estimated with 95% confidence inter-
val. Overall survival and event free-survival were analyzed using the method
described by Kaplan and Meier.
Results: High ALC at induction Day 1 (ALC-1) and/or Day-28 (ALC-28) were
associated with favorable outcome in ALL treatment. Children with ALC-1≥800
cells/µL or ALC-28≥1,860 cells/ µL had a significantly better 10-year overall
survival (10Y-OS) [ 85% (ALC-1≥800 cells/µL) versus 60% (ALC-1<800
cells/µL), P<0.001 and 90% (ALC-28≥1,860 cells/ µL) versus 75% (ALC-
28<1,860 cells/ µL), P=0.02] and 10-year event free survival (10Y-EFS) [ 80%
(ALC-1≥800 cells/µL) versus 55% (ALC-1<800 cells/µL), P=0.005 and 80%
(ALC-28≥1,860 cells/ µL) versus 76% (ALC-28<1,860 cells/ µL), P =0.63]. We
can define prognostic subgroups in more details when combining ALC-1 and
ALC-28. Children with ALC-1<800 cells/ µL and ALC-28<1860 cells/µL dis-
played the worse treatment outcome compared to other groups (10Y-OS=52%,
HR=6.9, P=0.001 and 10Y-EFS=48%, HR=4.3, P=0.002). Furthermore, ALC
can sub-classify the treatment outcome of patients in each established clinical
risk group. Standard risk patients with high ALC-1 had a significantly better 10-
Y OS [90% (ALC-1≥800 cells/µL) versus 60% (ALC-1<800 cells/µL), P=0.01]
(Figure1A) and 10-Y EFS [80% (ALC-1≥800 cells/µL) versus 45% (ALC-1<800
cells/µL), P=0.002] (Figure1B). Similarly, High ALC-1 in high risk patients also
predicted better 10Y-OS [77% (ALC-1≥800 cells/µL) versus 50% (ALC-1<800
cells/µL), P=0.05] and 10-Y EFS [80% (ALC-1≥800 cells/µL) versus 62% (ALC-
1<800 cells/µL), P =0.14].
Figure 1. Kaplan-Meier estimate of overall survival (A) and event free sur-
vival (B) among standard risk group with high and low ALC-1.
Summary and Conclusions: Unlike most studies which focused mainly on
the end of induction ALC, our finding indicated that ALC-1 and/or ALC-28 are
new powerful independent prognostic factors in pediatric ALL. ALC; which is a
simple and readily available clinical tool, can potentially be used as an additional
clinical factor to improve risk classification for children with ALL in resource-
limited countries.
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Background: Acute Myeloid Leukemia (AML) is a heterogeneous group of
diseases characterized by uncontrolled proliferation and survival of hematopoi-
etic stem and progenitor cells. An important characteristic of AML blasts is their
ability to avoid terminal differentiation into mature cells. The chemokine
CXCL12 and its receptor CXCR4 are key players in the retention of AML blasts
in the protective bone marrow (BM) microenvironment. The CXCL12/CXCR4
axis is also critical for the survival and maintenance of AML blasts in their stem-
ness state. In addition, CXCR4 overexpression is associated with poor prog-
nosis in AML patients. We have studied the effect of BL-8040 (BKT140) on the
survival, proliferation and differentiation of human AML blasts, using in-vitro
systems, AML mice model and correlative studies in human samples obtained
from the ongoing relapsed/refractory AML clinical trial (NCT01838395). 
Aims: Tostudythe effect of BL-8040 on the survival, proliferation and differen-
tiation of human AML blasts.
Methods: The ability of BL-8040 to induce differentiation of AML blasts was
tested in-vitro using MV4-11, HL-60, THP-1, NB4 and U937 cells. The in-vivo
effect of BL-8040 on differentiation, survival and apoptosis of human AML MV4-
11 cells was tested using AML model of NOD scid gamma (NSG) mice. In
humans, as part of an ongoing Phase IIa clinical trial (NCT01838395) samples
from subjects who signed informed consent, were evaluated for differentiation
and survival of AML blasts following two days of BL-8040 monotherapy.
Results: We have studied the signaling pathways involved in the survival of
AML blasts. Our results revealed that these cells are dependent on both,
increased survival factors mediated by the PI3K/mTOR/AKT axis and reduced
apoptotic potential attributed to increased BCL2 expression. Treatment of AML
cells with BL-8040 directly inhibited cell growthand increased cell death. This
BL-8040 effect was mediated by inhibition of the mTOR and AKT signaling and
by down regulation of BCL2 expression in vitro and in vivo. Moreover, the treat-
ment with BL-8040 distinctively induced myelomonocytic and granulocytic dif-
ferentiation in vitro and in vivo. In the clinical setting, two days of BL-8040
monotherapy triggered a dramatic decrease in the amount of leukemic blasts
in the BM in the majority of patients (9/10 patients tested). This decrease was
accompanied by an increase in the number of blasts positively stained for
apoptosis using cleaved caspase 3 antibody (6/8 patients tested). Furthermore,
in the majority of treated patients (7/10 patients tested) the reduction in the
number of leukemic blasts in the BM was associated with induction of monocytic
and granulocytic terminal differentiation.
Summary and Conclusions: Treatment with BL-8040 as a single agent rapidly
and efficientlyinduces cell death of AML cells both in-vitro andin-vivo. This effect
is mediated by reduction of the expression of BCL2 and by blocking the survival
signals through the PI3K/mTOR/AKT pathway. Furthermore, the present study
demonstrates for the first time that CXCR4 inhibition is associated with terminal
differentiation of AML blasts in patients. By relieving the differentiation block
that characterizes AML blasts along with blockade of survival signals, BL-8040
affects AML blasts survival. Moreover, the current study highlights an important
role for BL-8040 as a differentiation therapy which has the potential to translate
into clinical benefit.
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Background: Acute myeloid leukemia (AML) is a heterogenous disease of the
hematopoietic progenitor cell driven by the subsequent acquisition of genetic
alterations. Although new technologies (e.g. NGS) have substantially con-
tributed to our understanding of the genetic complexity of the disease, cellular
consequences often remain elusive. Approximately 20% of AML patients show
strong expression of CD56 (neural cell adhesion molecule; NCAM), a cell sur-
face marker typically found in natural killer cells. Expression of NCAM is asso-
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ciated with poor overall survival, however, the functional role of aberrant NCAM
expression has not been investigated to date.
Aims: The goal of this study is to examine the biological role of NCAM in AML
and to explore whether NCAM represents a potential therapeutic target.
Methods: The function of NCAM was investigated in several human AML cell
lines. Cells were infected with lentivirus expressing a Doxycyclin-inducible shRNA
directed against NCAM or scrambled shRNA. Genetically modified cells were
analyzed for proliferation, cell death and downstream signaling pathways. In addi-
tion, we performed xenotransplantation experiments to explore the role of NCAM
as a therapeutic target. Upstream regulatory mechanisms were investigated by
DNaseI-hypersensitive assays and modified qRT-PCR mapping. To analyze
NCAM effects at the stem cell level we made use of a well-established murine
MLL-AF9 leukemia model using C57BL/6 wild-type or NCAM-/-mice and per-
formed serial replating assays and bone marrow transplantation experiments.
Results: NCAM was expressed in several human cell lines (NOMO1, MOLM-
14, THP1, SKM1 and others) at high levels and correlated with MLL-rearranged
leukemias. Knockdown of NCAM using three different shRNA clones caused
diminished proliferation, G1-arrest and finally apoptotic cell death. Suppression
of NCAM sensitized leukemic blasts to genotoxic stress in vitro and prolonged
survival of mice in xenotransplantation experiments. Applying DNaseI-hyper-
sensitivity assays we demonstrate accessible binding sites for the transcription
factors MEIS1, MEF2c and STAT1. shRNA-mediated knockdown of MEIS1,
MEF2c and MLL-AF9 resulted in downregulation of NCAM cell surface expres-
sion, suggesting an upstream regulatory role for MLL-AF9. Analysis of down-
stream signaling pathways upon knockdown of NCAM demonstrated activation
of SMAD2/3, p38 and upregulation of CDKN1a. To analyze NCAM expression
in leukemia-initiating cells (LICs), we infected wild-type and NCAM-/-derived
bone marrow cells with MLL-AF9 expressing viral particles and transplanted
syngeneic recipient mice. Analysis of wild-type LICs (Lin-c-Kit+CD34+FcgR+)
demonstrated strong surface expression of NCAM, whereas normal HSCs (Lin-
c-Kit+Sca1+) were NCAM-negative. Recipients of NCAM-/-MLL-AF9_cells devel-
oped acute leukemia with prolonged disease latency, and in colony assays
replating activity was diminished. NCAM-/-MLL-AF9 cells had lower CD117 and
Gr-1 expression, but higher expression of Mac-1 and, in some samples, aber-
rant B220 co-expression. To analyze whether aberrant NCAM-expression is
essential to maintain self-renewal activity we currently perform serial bone mar-
row transplantation experiments.
Summary and Conclusions: Targeting aberrant expression of NCAM by
shRNA-mediated gene knockdown demonstrated strong antileukemic activity
in vitro and sensitized leukemic blasts to genotoxic stress. in vivo, depletion of
NCAM resulted in prolonged disease survival in syngeneic and xenotransplan-
tation experiments and diminished self-renewal capacities. Our data suggest
that NCAM represents a promising therapeutic strategy and likely targets AML
cells at the LIC level.
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GENETIC AND EPIGENETIC EVOLUTION DURING THE PROGRESSION
OF CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (CN-AML)
S. Vosberg1,2,3,4,* P.A. Greif1,2,3,4, L. Hartmann1,2,3,4, K.H. Metzeler1,2,3, 
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Background: Clonal evolution in acute myeloid leukemia (AML) has been pre-
viously described either in studies of large patient cohorts with focus on only a
restricted number of AML-associated genes or in smaller series of relapsed
patients studied by genome-wide techniques.
Aims: To better understand the genetic and epigenetic mechanisms of relapse
and therapy-resistance of AML, we performed exome sequencing and DNA-
methylation profiling of matched bone marrow or peripheral blood samples tak-
en at diagnosis, remission and relapse from 47 patients with cytogenetically
normal AML (CN-AML) with a median age at diagnosis of 65 (range 21-89).
Methods: Paired-end sequencing (Illumina) with a mean target coverage of
>100x resulted in an average of 95% of the exome covered at least 10-fold.
Variants at diagnosis or relapse were called with a minimum variant allele fre-
quency (VAF) of 20%. Mutations with a VAF≤5% at remission were defined as
somatic, whereas mutations in known AML-associated genes (n=40, e.g.
DNMT3A, IDH2, SRSF2) with VAF>5% at remission were considered as per-
sistent during remission. After exclusion of common germline polymorphisms
(dbSNP 138; MAF≥1%) and known error-prone genes (e.g. MUC4), we filtered
for mutations with translational consequences and validated them by custom
genepanel sequencing (HaloPlex, Agilent) with a mean target coverage of
>300x. On average, 94% of the target region was covered at least 20-fold.
DNA-methylation was analyzed using Illumina Infinium HumanMethylation450
BeadChip technology.
Results: Overall, 104 genes were recurrently mutated, while 7 genes were
recurrently altered only at diagnosis (e.g. CBL) and 16 genes were recurrently
altered only at relapse (e.g. KDM6A, SRSF2, SF3B1). The median number of
somatic mutations per patient was 7 at diagnosis and 8 at relapse, whereas a
gain or loss of mutations could be detected in 41 patients (87%). A median of
1 mutation is lost in relapse (e.g. FLT3 point mutations, range 0-5), a median
of 2 mutations were acquired during AML progression (e.g. WT1, range 0-5)
while mutations in several AML-associated genes (e.g. DNMT3A) remained
stable during the course of disease. In 60% of patients, the major clone at diag-
nosis remained predominant at relapse whereas expansion of a subclone during
disease progression was observed in 40% of patients. A total of 5 patients
acquired chromosomal alterations at relapse, with trisomy 8 as the only recur-
rent chromosomal abnormality present in 3 patients. A total of 22 patients (47%)
had persistent mutations at remission with 40/54 (74%) mutations showing a
dynamic pattern in their VAFs (relative change ≥20%). DNMT3A was the most
frequently affected gene (Figure 1A), and patients with persistent DNMT3A
mutation had a significantly shorter relapse-free survival compared to patients
with not-persisting DNMT3A mutation (Figure 1B, n=13, median 270 days,
range 81-586 vs n=7; median 508 days; range 235-1697; p=0.012). DNMT3A
R882 mutations correlated with a specific DNA-methylation profile, character-
ized by hypomethylation of HOX genes at diagnosis. Of note, even at remission
we were able to measure the DNMT3A R882 mutation-specific DNA-methyla-
tion pattern in patients with persistent mutations at VAF≥25%. These results
suggest altered DNA-methylation at the pre-leukemic stage.
Figure 1.
Summary and Conclusions: In summary, our findings provide insights into the
genetic and epigenetic evolution during the course of disease in a large cohort
of relapsed CN-AML. Information about the dynamics of genetic lesions (e.g.
persistent or relapse-specific mutations) may have prognostic applications and
provide the basis for tailored approaches to treat or to prevent relapse of AML.
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GENOTOXIC STRESS MODULATES EVI1 INTERACTION WITH CTBP1 IN
ACUTE MYELOID LEUKAEMIA CELLS
M. Schneider1,* R. Paredes1, D.J. White1, A. Pierce1, A.J. Williamson1,
A.D. Whetton1, S. Meyer1,2,3
1Stem Cell and Leukaemia Proteomics Laboratory, Institute of Cancer Sciences,
University of Manchester, 2Department of Paediatric Oncology, Royal Man-
chester Children’s Hospital, 3Department of Paediatric and Adolescent Oncol-
ogy, University of Manchester, Manchester, United Kingdom
Background: EVI1 proto-oncogene overexpression is associated with adverse
prognosis in acute myeloid leukaemia (AML). EVI1 is a DNA binding transcrip-
tional regulator. It forms complexes with multiple protein partners including
chromatin re-modellers and transcriptional repressors, such as C-terminal bind-
ing protein (CtBP). Understanding EVI1 protein interaction dynamics will be
important for novel therapeutic approaches.
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Aims: The identification and characterisation of EVI1 protein interactions mod-
ulated by EVI1 phosphorylation.
Methods: EVI1 phosphorylation was detected by MIDAS mass spectrometry
in EVI1 overexpressing AML SB1690CB cells. Flag-tagged wild type EVI1 and
phosphorylation site mutated constructs were generated. Mouse bone marrow
or HEK293T cells overexpressing the constructs were used for re-plating exper-
iments, co-immunoprecipitation and immunofluorescence. Genotoxic stress
was induced by 2Gy radiation and hydrogen peroxide(H2O2) treatment.
Results: We detected EVI1 phosphorylation at the C-terminal SQSP motif
(serine858 and860). EVI1 constructs with alanine-mutated phospho-sites
(A/A-EVI1) maintained the EVI1 transforming capabilities in transduced mouse
bone marrow serial replating experiments. Proteomic interactome studies com-
paring WT-and A/A-EVI1 in an overexpression system confirmed interaction
with co-repressor CtBP1. Co-immunoprecipitation showed significantly reduced
CtBP1 binding with A/A-EVI1 compared to WT-EVI1 after induction of DNA
damage. Higher levels of co-immunoprecipitated CtBP1 bound to EVI1 in dam-
aged versus undamaged cells were confirmed in SB1690CB cells. Immunoflu-
orescence analysis showed significantly higher co-localisation of WT-EVI1 with
CtBP1 and reduced co-localisation of A/A-EVI1 with CtBP1 after DNA damage
compared to undamaged cells.
Summary and Conclusions: Genotoxic stress induces EVI1 C-terminal phos-
phorylation and modulates EVI1 interactions with the co-repressor CtBP1. This
links the DNA damage response to transcriptional repression in EVI1 overex-
pressing AML.
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Background: Bispecific T-cell engaging (BiTE®) antibody constructs are very
efficient in recruiting and activating T cells. Through the strong T-cell activation,
proinflammatory conditions are generated, favouring the upregulation of
immune checkpoint molecules on cancer cells. Blockade of immune-suppres-
sive receptor-ligand interactions could potentially enhance BiTE® mediated
cytotoxicity.
Aims: In this study we tested the relevance of immune checkpoint molecules
on CD33/CD3 BiTE® antibody construct (AMG 330) mediated lysis of primary
AML cells in ex vivo cytotoxicity assays.
Methods: The expression profiles of PD-L1 (n=123), CD277 (n=70) and ILT3
(n=55) were assessed by flow cytometry (Specific fluorescence intensity, SFI)
in newly diagnosed AML patient samples. A long-term culture system supporting
the growth of primary AML cells for up to 36 days ex vivo was used to determine
the functional relevance of immune checkpoint molecules on AMG 330 mediated
lysis. The long-term culture system enabled us to analyze the dynamic process
of inhibitory molecule expression and receptor-ligand interaction over time.
Results: No constitutive expression could be detected for PD-L1 at primary
diagnosis in 83.7% of the cases. In contrast, constitutive expression of CD277
and ILT3 was detected in 77% and 100% of patient samples respectively. As
has been reported previously, the expression pattern of immune checkpoint
molecules can be modulated through proinflammatory conditions. Therefore,
the expression profile of the inhibitory molecules on different AML cell lines and
primary AML cells after addition of IFN-γ and TNF-α was analyzed. PD-L1 was
strongly induced on AML cell lines and primary AML cells (mean fold change
SFI: AML cell lines 3.5, n=6; primary AML cells 9.2, n=6). In contrast, no further
increase in ILT3 expression levels was detected (mean fold change SFI: AML
cell lines 0.7, n=5; primary AML cells 1.2, n=3). The cytokine-mediated upreg-
ulation of other immune checkpoint molecules including CD277 on AML cells is
currently being evaluated. In several studies it was shown, that BiTE® antibody
constructs induce strong T-cell activation, which is accompanied by secretion
of IFN-γ and TNF-α. Using our long-term culture system we observed a consid-
erable upregulation of PD-L1 on primary AML cells after 1-4 days of ex vivo
cytotoxicity assay (SFI control BiTE® (cBiTE®) vs AMG 330 1.8: 9.4, p<0.0001;
n=27). Blocking of the PD-1/PD-L1 interaction significantly enhanced AMG 330
mediated lysis efficacy (% lysis: AMG 330 58% vs AMG 330+α-PD-1/PD-L1
blocking antibody 75%, n=9, p=0.03) which was accompanied by a significant
increase in T-cell proliferation (fold change CD2+ cells: cBiTE® 0.8 vs cBiTE®+α-
PD-1/PD-L1 blocking antibody 1.0, p=0.06; AMG 330 8.0 vs AMG 330+α-PD-
1/PD-L1 blocking antibody 11.1, n=9, p=0.008). In addition, IFN-γ secretion was
significantly enhanced (IFN-γ secretion: cBiTE® 7.8 pg/ml vs cBiTE®+α-PD-
1/PD-L1 blocking antibody 16.5 pg/ml, p=0.03; AMG 330: 1573 pg/ml vs AMG
330+α-PD-1/PD-L1 blocking antibody: 2060 pg/ml, n=8, p=0.008). The functional
relevance of other immune checkpoint molecules in AMG 330 mediated lysis
efficacy is currently being evaluated in analogous experiments.
Summary and Conclusions: AMG 330-mediated cytotoxicity is modulated by
blockade of inhibitory molecules on AML cells. Our results support the use of
combinatorial approaches of BiTE® antibody constructs with PD-1/PD-L1
immune checkpoint blockade.
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DIFFERENTIAL RESPONSIVENESS OF PML-RARA CARRYING VARIOUS
POINT MUTATIONS TO ARSENIC TRIOXIDE
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Background: Expression of the fusion gene, promyelocytic leukemia (PML)–
retinoic acid receptor-α (RARA), initiates acute promyelocytic leukemia (APL)
and plays a crucial role in APL pathogenesis. Arsenic trioxide cures APL through
targeting PML-RARA oncoprotein for degradation and further eradicating the
malignant cells. A growing amount of evidence supports arsenic trioxide as a
front-line drug in APL treatment and the overall survival of APL patients has
been improved dramatically. Unfortunately, there are not a few patients devel-
oped arsenic resistance during therapy and their outcomes were extremely
dismal. Previous study has reported that A216V and L218P mutation in the
PML moiety of PML-RARA were detectable in two APL patients at relapse.
More recently, we identified a mutational hot spot (including previously reported
A216V, newly identified S214L, A216T, L217F and S220G) within PML-RARA
transcripts from 9 of 13 patients with relapsed APL. Whether all these acquired
mutations play a role underlying the mechanism of clinical arsenic resistance
are still unknown.
Aims: To explore if each of the identified mutations virtually plays a role and
functions similarly underlying the mechanism of arsenic-resistance.
Methods: The recombinant plasmids of wild type and mutant PML-RARA were
transfected into cultured Hela cells followed by the treatment with or without
As2O3. The protein levels and cellular localization were detected by
immunoblotting and immunofluorescence analysis. A retrospective analysis
was performed to validate whether various point mutations of PML-RARA func-
tioned distinctly in APL patients. The morphological characteristics and the
expression levels of PML-RARA transcripts in bone marrow of included patients
were monitored before and after reinduction treatment with arsenic.
Results: Immunoblotting analysis showed that total protein levels of PML-
RARA mutants with L217F or S220G were significantly decreased upon As2O3
treatment (regular dose), similar with the phenotype of wild type PML-RARA.
This finding was in parallel with the enhanced nuclear matrix association and
SUMOylation of L217F and S220G mutant proteins triggered by As2O3. Where-
as mutants with A216V, S214L or A216T did not respond to As2O3 treatment
in the same experimental conditions. Importantly, the varying responsiveness
of different point mutations to arsenic observed in vitro was conserved in the
clinical setting. Relapsed APL patients respectively with A216V, S214L or A216T
mutation had strong resistance to the reinduction therapy with arsenic. Tem-
porarily moderate drug resistance was found in a patient with S220G mutation.
In contrast,one patient with L217F mutation achieved a complete remission
after reinduction treatment. Furthermore, we showed that high dose of As2O3
was capable to reverse the primary arsenic resistance driven by indicated
mutations in the PML B2 domain of PML-RARA in cultured cells.
Summary and Conclusions: Our results reinforce the correlation of genetic
mutations found in the PML part of PML-RARA transcript with arsenic resist-
ance during APL therapy. We also propose a novel insight regarding that the
acquired mutations exhibited varying responsiveness to arsenic treatment both
in vitro and in vivo. Our findings may help in predicting the prognosis and select-
ing more effective strategies for the management of relapsed APL.
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SURVIVAL PREDICTION AND IDENTIFICATION OF KEY PROGNOSTIC
PROTEINS IN ACUTE MYELOID LEUKEMIA USING REVERSE PHASE
PROTEIN ARRAY 
E. Joffe1,* Y.H. Qiu2, N. Zhang3, S.E. Neely4, Y. Suk-Young3, K.R. Coombs5,
S.M. Kornblau2
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Background: Novel proteomic technologies, allow for accurate and rapid pro-
filing of the cellular protein ecosystem in Acute Myeloid Leukemia (AML). The
high throughput data they generate could be used to build better prognostic
models, to identify new targets for therapy, and to individualize treatment.
Aims: To use high-dimensional survival models to identify key prognostic pro-
teins in AML and to compare the performance of proteomics based survival
models to that of commonly used prognostic factors.
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Methods: We used reverse-phase protein array (RPPA) to measure the level
of total and phosphorylated expression of 230 proteins in leukemia-enriched
cell samples from 384 newly diagnosed AML patients. We used Cox regressions
with the Least Absolute Shrinkage and Selection Operator regularization to
construct multivariate prediction models for overall and relapse-free survival
(OS&RFS) and to identify the key prognostic proteins. To calculate coefficients
and evaluate model performance we employed a 100 iteration bootstrapping
procedure. We repeated the analyses for the subset of patients with normal
karyotype AML and younger patients (≤60).
Results: Multivariate prognostic models based on proteomics performed at least
as well as models based on commonly used prognostic covariates including age,
sex, performance status, prior malignancy or hematological disease, cytogenetics
and FLT-ITD mutation analysis (C-Index 0.71 vs 0.69 respectively for RFS). Mul-
tivariate survival models highlighted multiple proteins associated with survival.
Of these, the most pronounced were ARC, IGFBP2, INPP5D, TP53 and CCND3
which appeared in univariate and multivariate analyses. STAT3, XIAP, and CDK2
were identified only by multivariate models, suggesting they are of relevance only
in the context of the expression of other proteins. In younger patients we further
identified SMAD5, phospho-ERBB2, phospho-MTOR, and CCNE2. Genetic alter-
ations associated with many of these proteins have been previously implicated
in the pathogenesis of AML and provide an external validation to our results. For
most however this work is the first evaluation of their prognostic significance.
Finally, using proteomics based risk scores we were able to discern subgroups
of patients with differing survival. This risk stratification outperformed stratification
based on cytogenetics. Further, we identified distinct subgroups among patients
with a normal karyotype (RFS not-reached, 150 and 39 weeks, p<0.0001). Our
results bare a considerable similarity to risk stratification based on genetic alter-
ations presented in other studies, though the validity of such a comparison is lim-
ited due to variability in patient populations and a lack of standardized reporting.
Figure 1.
Summary and Conclusions: RPPA is an efficient tool for rapid and high
throughput proteomic profiling. Using the proteomic data with advanced survival
modeling can reliably identify multiple proteins with a significant prognostic val-
ue as targets for future research and novel therapeutics.
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MICRORNA-182, C/EBPΑ AND E2F GENERATE AN AUTOREGULATORY
FEEDBACK NETWORK WHICH IS DYSREGULATED IN ACUTE MYELOID
LEUKEMIA
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Background: The transcription factor CCAAT enhancer binding protein alpha
(C/EBPα) is a master regulator of granulopoiesis and is inactivated in approx-
imately 50% of all acute myeloid leukemia (AML) cases. MicroRNAs, a class
of small non-coding RNAs, were identified as important regulators of normal
hematopoiesis and leukemia development. We have already shown that
microRNAs, such as miR-223, miR-34a and miR-30c, are essential elements
in C/EBPα triggered granulocytic differentiation.But to our knowledge nothing
is known about inactivation of C/EBPα by microRNAs in acute myeloid
leukemia.
Aims: Functional characterization of miR-182 in AML.
Methods: We used Next Generation Sequencing to detect novel C/EBPα relat-
ed microRNAs. To investigate the function of miR-182, we used several in vitro
and in vivo systems, including cell lines, primary AML cells and a transplantation
based mouse model.
Results: In this study, we identified a novel network between C/EBPα, miR-
182 and E2F. In a next generation sequencing approach based on inducible
K562-C/EBPα-ER cell line, we found miR-182 strongly downregulated by wild-
type C/EBPα. We could further demonstrate an inverse correlation between
C/EBPα protein amount and miR-182 expression level in several biological
systems, including leukemic cell lines, G-CSF treated primary human CD34+
progenitor cells in vitro and sorted murine bone marrow subpopulations in vivo.
Additionally, we found elevated miR-182 expression levels in lineage-negative,
c-kit-positive myeloid progenitors of CEBPA Knock-Out mice. To discover the
mechanism how miR-182 is blocked by C/EBPα, we analyzed the minimal pro-
moter region of miR-182 and performed chromatin immunoprecipitation (ChIP).
Here, we could demonstrate a strong binding of C/EBPα to the miR-182 pro-
moter, particularly to a conserved E2F binding site. Because E2F is a well
known inhibitor of C/EBPα function, we tested whether E2F also effects miR-
182 expression. An overexpression of E2F1 in U937 cells leads to an elevated
miR-182 expression level. In addition, we measured the expression of miR-
182 in bone marrow from AML patients regarding to their CEBPA mutation sta-
tus. We could show that only patients with mutations in the C-terminal region
of C/EBPα showed increased miR-182 expression levels, while patients with
N-terminal CEBPA mutations revealed no abnormal miR-182 expression com-
pared to healthy donors or AML patients with no CEBPA mutation. The C-ter-
minal domain of C/EBPα is necessary for E2F inhibition. These findings illustrate
the importance of C/EBPα-E2F interaction during miR-182 regulation. Next,
we found a highly conserved binding site of miR-182 in the 3’UTR of CEBPA
itself, suggesting a possible negative feedback loop. To test this, we performed
overexpression of miR-182 in U937 cells, umbilical cord blood mononuclear
cells (UCB-MNCs) and primary blasts from AML patients. Here, we observed
a strong reduction of C/EBPα protein after miR-182 overexpression in all cell
types. Furthermore, we could demonstrate a direct binding of miR-182 to the
3’UTR of CEBPA via luciferase activity assay. Finally, we were interested in the
functional impact of miR-182 in myeloid differentiation and leukemia develop-
ment. We showed that stable overexpression of miR-182 blocks granulocytic
differentiation in G-CSF treated 32D cells and enhances replating capacity of
primary mouse bone marrow mononuclear cells. Moreover, we could demon-
strate that enforced expression of miR-182 in mouse Lin-Sca-1+c-Kit+ early
hematopoietic progenitors by lentiviral infection leads to a strong reduction of
mature Mac1+Gr1+ granulocytes in the peripheral blood in vivo.
Summary and Conclusions: Taken together, we identified miR-182 as novel
oncogenic microRNA that directly blocks C/EBPα during myeloid differentiation
and leukemia development. Thus, our data display a potential new strategy for
therapeutics in C/EBPα dysregulated AML.
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THE LEUKEMIA-ASSOCIATED RUNX1/ETO ONCOPROTEIN CONFERS A
MUTATOR PHENOTYPE
V. Forster1,* M. Nahari1, N. Martinez-Soria1, A. Bradburn2, A. Ptasinska3, 
S. Assi3, H. McNeill1, C. Bonifer3, O. Heidenreich1, J. Allan1
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon
Tyne, 2Institute for Cancer Research, London, 3Cancer Cell Biology and Epi-
genetics, University of Birmingham, Birmingham, United Kingdom
Background: One of the key processes in oncogenesis is the transition from a
premalignant to a fully malignant state. The chromosomal translocation (8;21)
is an initiating event in acute myeloid leukaemia (AML) and generates the
RUNX1/ETO fusion gene.RUNX1/ETO drives self-renewal, but is insufficient for
leukaemogenesis, requiring further mutations for transformation. We postulated
that this leukaemic fusion protein may affect the acquisition of mutations.
Aims: In this project, our aims were to investigate whether and how
RUNX1/ETO impacts on the acquisition of secondary mutational hits, thereby
promoting the generation of fully developed leukaemia.
Methods: We investigated the effect ofRUNX1/ETOexpression on susceptibility
to spontaneous and exposure driven mutation in TK6 cells. After lentiviral trans-
duction with RUNX1/ETO, we isolated TK6 clones withvarying levels of
RUNX1/ETOexpression. We used the PIGA assay as an initial measure of
spontaneous and exposure-induced mutation. Loss of this glycosyl-phos-
phatidylinositol(GPI) anchor protein results in an absence of GPI-linked proteins
from the cell membrane, including CD55 and CD59.Cells that are simultane-
ously negative for two GPI-linked proteins are considered to bePIGAmutants
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and are detected using fluorochrome-conjugated antibodies and analysed by
flow cytometry. We also used thethymidine kinase(TK) gene as a second muta-
tional target for exposure-induced mutation. 
Results: We determined the PIGA mutation frequency (Mf) in several inde-
pendent RUNX1/ETO-expressing and vector control clones 8-10 weeks after
initial cloning. The mean PIGA Mf in RUNX1/ETO clones (7.5 x 10-4) was 5
times higher than in vector control clones (1.5 x 10-4) (p=0.032). We next inves-
tigated whether RUNX1/ETO cells were sensitive to mutagenesis following
exposure to genotoxic agents. Fusion protein positive and vector control clones
were exposed to sub-cytotoxic doses of doxorubicin (100nM) or ionising radi-
ation (3Gy), and Mf was measured 2 weeks after treatment. The mean treat-
ment-induced PIGA Mf was strongly increased in RUNX1/ETO clones com-
pared to vector control clones following doxorubicin (Mean Mf =6.5 x 10-4 vs
2.1 x 10-4, p=0.09) or radiation treatment (Mean Mf =5.9 x 10-4 vs 2.1 x 10-4,
p=0.008). This was confirmed by assaying at the TK locus, where mean treat-
ment-induced Mf was also significantly higher in RUNX1/ETO cell clones com-
pared to vector control clones following either doxorubicin (Mean Mf =3.5 x 10-
6 vs 4.3 x 10-7, p=0.014) or radiation treatment (Mean Mf =6.4 x 10-6 vs 1.5 x
10-6, p=0.002). For both PIGA and TK, the Mf in vector control clones following
doxorubicin or radiation treatment was not significantly different from mock-
treated cells. Additionally, using ChIP, we showed that RUNX1/ETO directly
binds to and represses the OGG1 base-excision repair DNA glycosylase and
that RNAi mediated depletion of RUNX1/ETO in t(8;21) cell lines significantly
increases OGG1 transcript and protein levels, providing a plausible reason for
the increased Mf shown in RUNX1/ETO cells.
Summary and Conclusions: We have shown that RUNX1/ETO predisposes
to the acquisition of mutations, both spontaneously and after treatment with
genotoxic agents. RUNX1/ETO actively promotes the acquisition of secondary
mutations thereby expanding genetic heterogeneity in the population from
which malignant clones can emerge. We also suggest that late-relapse in
t(8;21) AML may be due to the presence of RUNX1/ETO positive, genetically
unstable pre-leukaemic clones in the bone marrow, which are prone to mutation
acquisition, leading to leukaemia relapse.
P180
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Background: Acute myeloid leukemia (AML) with t(8;21)(q22;q22) or
inv(16)(p13q22) chromosomal rearrangement corresponding to the RUNX1-
RUNX1T1 or CBFb-MYH11 fusion transcripts respectively, belongs to the core
binding factor (CBF) AML, a favorable-risk subgroup of AML. Nonetheless,
30% of patients with CBF-AML relapse. Prognostic factors have been identified
in adult studies to detect patients at higher risk of relapse, such as older age,
high white blood cell count, additional cytogenetic abnormalities or gene muta-
tions, and minimal residual disease response to therapy. Especially in adult
CBF-AML patients, it has been shown that a log reduction under 3-log in tran-
script level after 2 courses of chemotherapy, was associated with a significant
increased risk of relapse. In children CBF-AML accounts about 20% of de novo
AML with an unexpected relatively high incidence of relapse in the RUNX1-
RUNX1T1 subgroup. There is need to identify factors able to predict a high
risk of relapse. Few studies have reported the prognostic relevance of minimal
residual disease in pediatric CBF-AML.
Aims: The main aim of the study was to quantify and follow the minimal resid-
ual disease of CBF fusion transcripts during therapy in order to determine its
prognostic relevance and to identify patients who might benefit of allogeneic
hematopoietic stem cell transplantation in first complete remission in the future
protocol.
Methods: 438 children were treated between 2005 and 2011 in the French
pediatric ELAM02 trial. We focused on 97 patients with CBF-AML including 61
AML with t(8;21)(q22;q22) and 36 AML with inv(16)(p16q22). RUNX1-
RUNX1T1 and CBFb-MYH11 transcripts were quantified by real-time PCR at
diagnosis, and after each course of chemotherapy (MRD1, MRD2, MRD3,
MRD4) according to the trial design.
Results: Patients with inv(16)(p16q22) AML had higher WBC and more fre-
quent CNS involvement than those with t(8;21)(q22;q22). N/K-RAS mutations
were more frequent in the inv(16)(p16q22) subset, ASXL2 mutations more fre-
quent in t(8;21)(q22;q22) subset, whereas KIT gene mutations were equally
frequent in both subsets. At diagnosis, the median fusion transcript ratio was
higher in RUNX1-RUNX1T1 patients [258.7, range 20-1685] than in CBFb-
MYH11 patients [94.4, range 31.5-447]. Incidence of relapse was 39.3% and
16.7% in t(8;21) and inv(16) respectively. In the RUNX1-RUNX1T1 subset,
MRD log reduction evaluation shows that 19 (41%) of 46 patients at MRD2
and 8 (21%) of 38 patients at MRD3 did not reach 3-log reduction in fusion
transcript ratio level. In the CBFb-MYH11 subset, MRD log reduction evaluation
shows that 20 (67%) of 30 patients at MRD2 and 18 (67%) of 27 at MRD3 did
not reach 3-log reduction in fusion transcript ratio level. The 5-year DFS was
not significantly different at any point between MRD positive and MRD negative
in both subgroups: 48±11% versus 49±12% at MRD2 and 48±10% versus
37±17% at MRD3 in RUNX1-RUNX1T1 subset and 100% versus 79±9 at
MRD2 and 89±10% versus 75±11% at MRD3 in CBFb-MYH11 subset. The 5-
year disease free survival (DFS) was 53±2% in all-ELAM02, 53±7% in t(8;21)
and 80±7% in inv(16). Similarly the 5-year overall survival (OS) did not shown
any significant difference and was 71±2% in all-ELAM02, 87±4% in t(8;21) and
100% in inv(16) subgroups.
Summary and Conclusions: In the ELAM02 trial we confirmed how frequent
CBF-AML patients are slow-responders to chemotherapy but we were unable
to confirm the prognostic impact of 3-log MRD reduction to predict relapse as
in adult. Of note, children did not received anti-CD33 for chemotherapy as it
was in published adult trials. Furthermore comparison between flow-cytometry
and fusion transcript MRD could be helpful in CBF-AML.
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HIGH PROGNOSTIC VALUE OF PRE TRANSPLANT MINIMAL RESIDUAL
DISEASE ASSESSMENT BY COMBINED WT1 EXPRESSION AND FLOW
CYTOMETRY IN ACUTE MYELOID LEUKEMIA PATIENTS
F. Guolo1,* F. Galaverna1, P. Minetto1, L. Giannoni1, C. Ghiggi2, D. Guardo1,
S. Bagnasco1, M. Clavio1, C. Di Grazia3, A.M. Raiola3, N. Colombo1, 
R. Grasso1, A. Kunkl4, M. Miglino1, R.M. Lemoli1, M. Gobbi1, A. Bacigalupo3
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2First Division of Hematology and Bone Marrow Transplantation, 3Sec-
ond Division of Hematology and Bone Marrow Transplantation, 4Department
of Pathological Anatomy, IRCCS AOU San Martino-IST, Genoa, Italy
Background: Allogeneic bone marrow transplantation (BMT) offers the greatest
chance of cure for most patients affected by acute myeloid leukemia (AML). Per-
sistence of disease or high levels of pre BMT minimal residual disease (MRD)
have been reported to predict relapse risk after BMT. WT1 expression levels and
multicolor flow cytometry (MFC) are the most widely used tools to evaluate MRD.
Aims: We recently reported that combined MRD evaluation by WT1 and MFC
after induction therapy strongly impacts on relapse risk in AML patients.The aim
of the present study was to perform the same MRD assessment in the pre BMT
setting in order to evaluate its reliability in predicting relapse after transplant.
Methods: We retrospectively analyzed outcome of 257 AML patients with both
WT1-based and MFC-based MRD evaluation on bone marrow samples before
transplant. Median age at transplant was 44 years. One hundred thirty-three
patients were transplanted in first, 54 in second and 72 in third or subsequent
complete remission. Induction regimens included fludarabine-containing regi-
mens or standard “3+7” induction. Median follow-up was 48 months (95% CI
37.5-50.5 months). Relapse-free survival (RFS) was calculated from the time of
transplantation until last follow-up or documented leukemic relapse. Overall Sur-
vival (OS) was calculated from the time of transplantation until death by any
cause or last follow-up. A positive MFC MRD was defined by the presence of no
less than 25 clustered leukemic cells/105total events (threshold of 2.5x10-4resid-
ual leukemic cells) at four-color flow-cytometry. Real-time PCR for WT1 was
performed on DNA Engine 2 (Opticon®, MJ Research®). WT1 copy number/Abl
copy number 500x104 was used as cut-off value for abnormal WT1 expression.
Results: Eighty-nine relapses (35%) were reported. Median RFS was 84
months. The probability of disease relapse was significantly affected only by
disease status (first or subsequent CR, p<0.001) and MRD status before trans-
plantation, measured with any method (p <0.001). Specifically, MFC-MRD was
the strongest predictor of longer relapse free survival (p <0.001) since only two
relapses occurred in the eleven MFC-MRD negative patients. Among MFC-
MRD positive patients a further stratification of risk is obtained by the evaluation
of WT1 MRD status that was able to identify patients with significantly worse
RFS (p <0.01, Figure1). Multivariate RFS analysis revealed that the combined
MRD evaluation was the only independent predictor of RFS (p <0.001). The
predictive value of MRD resulted independent from induction schedules, donor
type, disease status at BMT and risk group. Similarly, univariate OS analysis
showed that BMT year, disease status at BMT and MRD evaluation with any
methodic significantly influenced OS duration (p <0.001, <0.001 and <0.001,
respectively). Multivariate OS analysis confirmed that combined MRD evalua-
tion was an independent strong predictor of long survival, alongside with BMT
year and disease status at BMT (p <0.003, <0.001 and <0.002, respectively)
Figure 1. RFS according to risk group
Summary and Conclusions: Pre transplant MRD evaluation by WT1 and MFC
on bone marrow samples is a reliable predictor of relapse risk. Patients with
both negative pre-BMT MRD markers have a significantly longer DFS, while
patients with both positive MRD markers display an higher risk of relapse. Iden-
tifying patients who are at higher relapse risk may allow to modulate post BMT
follow up, with the aim of detecting disease recurrence earlier and/ or applying
pre-emptive therapeutic strategies in order to delay or prevent AML relapse.
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A COMPARISON OF DAUNORUBICIN/ CLOFARABINE AND FLAG-IDA IN
HIGH RISK ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI
AML17 TRIAL
A. Burnett1,* N. Russell2, L. Kjeldsen3, D. Milligan4, A. Hunter5, R. Clark6, 
M. Dennis7, R. Hills8
1Blackwaterfoot, Isle of Arran, 2Department of Haematology, Nottingham Uni-
versity Hospitals, Nottingham, United Kingdom, 3Rigshospitalet, Copenhagen,
Denmark, 4Birmingham Heartlands Hospital, Birmingham, 5Leicester Royal
Infirmary, Leicester, 6Royal Liverpool University Hospital, Liverpool, 7Depart-
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Background: We have previously shown that consolidation of high risk patients
with high dose ara-c was less effective than combination chemotherapy (including
etoposide amsacrine and mitoxantrone) (Burnett AK et al. J.Clin.Oncol. 31,3360-
3368, 2013). In the NCRI AML17 Trial (ISRCTN55675535) 3215 untreated non-
APL adults, generally <60 years, were given an initial induction course of Daunoru-
bicin/Ara-C with or without Etoposide and/or Gemtuzumab Ozogamicin (GO). On
recovery patients were assigned a risk group. To be high risk patients required to
fulfil one of the following criteria: 1) Group A: in CR but with adverse features assim-
ilated into a validated risk score (based upon cytogenetics, age, presenting WBC,
secondary disease and response to course 1 of therapy) predicting an expected
survival of around 24% (Burnett AK et al Blood 108 (11):10, 2006) ; 2) Group B:
not in CR after a second induction course; or 3) Group C: relapsed disease.
Aims: We compared Daunorubicin/C.lofarabine with FLAG-Ida in a randomised
fashion in patients who were high risk.
Methods: 393 patients were identified (311 group A; 5 group B; and 77 group
C) and randomised 2:1 between Daunorubicin (50mg/m2 days 1,3 and 5) +
Clofarabine (20mg/m2 days 1-5) or FLAG-Ida (Fludarabine 30mg/m2 d2-6, Ara-
C 2g/m2/day d2-6, G-CSF days 1-7 and Idarubicin 8 mg/m2 on days 4,5,6). All
high risk patients were candidates for allo-BMT. For the purpose of this analysis
groups B & C are combined. 
Results: Overall 393 patients entered the comparisons of DClo vs FLAG-Ida:
311 in group A and 82 in groups B+C. The characteristics of group A and of B+C
were: median age 55 (18-69) and 47 (19-63); de novo 221 and 78; secondary
disease or high risk MDS 90 and 4; performance score >1 13 and 3; cytogenetics
favourable 0 and 14; cytogenetics intermediate 151 and 58; cytogenetics adverse
160 and 3. The median follow up is 25.8 months for group A and 12.7 months
for group B+C. In group A, the median number of courses received was 1 for
FLAG-Ida and 2 for DClo. The overall survival at 4 years for group A was 35%.
RFS was 46% in the FLAG-Ida patients vs 34% in those on DClo (HR 1.25 (0.89-
1.75) p=0.2). Survival was non-significantly superior in the FLAG-Ida patients
(48% vs 30%, HR 1.30 (0.95-1.79) p=0.10). The objective of the chemotherapy
was to deliver patients to allograft. 53% of FLAG-Ida and 56% of DClo received
a transplant. When the RFS and OS are censored at time of transplant the RFS
was FLAG-Ida 22% vs DClo 18%, and OS was 22% vs 22%. The overall survival
at 3 years for group B+C was 20%. CR was achieved in 2/2 refractory and 18/25
relapsed patients allocated FLAG-Ida vs 1/3 and 41/52% for DClo. Survival was
non-significantly better in the FLAG-Ida patients (35% vs 11%, HR 1.26 (0.73-
2.17) p=0.4). 56% of FLAG-Ida and 65% of DClo received a transplant. When
the OS are censored at time of transplant the OS at 18 months was FLAG-Ida
38% vs DClo 30%. If groups A, B+C are analysed together using standard meta-
analytic approaches, the hazard ratio for survival favours FLAG-Ida (HR 1.29
(0.98-1.70) p=0.07). Although FLAG-Ida resulted in slower count recovery and
required significantly more supportive care (RBC and platelets/ antibiotics/ hos-
pital days), it resulted in survival which was not inferior to DClo.
Tabella 1.
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Summary and Conclusions: FLAG-Ida resulted in at least as good survival
when compared with DClo for high risk patients in remission or relapsed or
refractory patients.
Acknowledgements: This study received research support from Cancer
Research UK. Genzyme/Sanofi provided Clofarabine for the trial.
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FLUDARABINE-CONTAINING INDUCTION INCREASES MINIMAL RESIDUAL
DISEASE CLEARENCE AND IMPROVES SURVIVAL IN AML PATIENTS
WITH CONCOMITANT NPM1 AND FLT3-ITD MUTATIONS
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Background: The negative prognostic impact of FLT3-ITD mutations in acute
myeloid leukemia (AML) patients is well known. This unfavorable effect is most-
ly due to high relapse rate and short disease free survival (DFS). On the con-
trary, NPM1 gene mutation has been shown to confer a good prognosis. The
co-existence of both mutations is common with most groups reporting a pre-
dominant negative prognostic impact of FLT3.
Aims: We performed a retrospective analysis of the outcome of 124 de novo
AML patients carrying FLT3 and/or NPM mutation receiving a fludarabine con-
taining regimen or conventional daunorubicin and cytarabine (3+7) schedule
as front line treatment, with the aim of evaluating whether the combination of
fludarabine to Ara-C and anthracycline may increase DFS in FLT3 or NPM
mutated patients, especially in double-mutated patients.
Methods: One-hundred twenty four consecutive FLT3-ITD and/or NPM1 pos-
itive non M3 AML patients (age 17-78 years) treated in two Hematology centers
of Northern Italy were retrospectively included in this study. In center 1, all
patients received FLAI-5 regimen (fludarabine 30 mg/sqm and ARA-C 2g/sqm
on days 1 to 5 plus idarubicin 10 mg/sqm on days 1-3-5), whereas in center 2
patients were given either FLAI or 3+7 induction. Overall 90 patients received
FLAI, and 34 patients received 3+7 regimen. In both centers, patients with
FLT3-ITD mutation underwent allogeneic bone marrow transplantation (BMT)
in first complete remission if feasible. Minimal residual disease was evaluated
on marrow samples in most patients using multicolor flow-cytometry (MFC)
and NPM expression levels. Demographical, cytogenetic and molecular char-
acteristics were comparable in the series of patients treated in the two centers
and in patients receiving the two induction regimens.
Results: Two patients (5.9%) died during first induction in the 3+7 arm,whereas
two patients (2.2%) died in the FLAI arm, mostly due to infections. One further
patient in the FLAI arm died during second cycle. Overall 60-days mortality
was therefore 4%. After two induction cycles, 105 patients achieved CR (88%)
and 14 did not respond (16%). Forty-two/105 (40%) CR patients underwent
BMT in first CR. CR rate after cycle 1 was significantly higher in FLAI-5 cohort
(86% vs 69%, p<0.05). Patients treated with FLAI-5 had significant higher prob-
ability of achieving MRD clearance, both on NPM and MFC-based evaluation
(p<0.001 and p<0.05, respectively, Figure 1A and D). After a median follow up
of 51 months, 2-year DFS was 53.4% (median 101 months). DFS duration was
significantly influenced by induction type (p <0.001, Figure1 B), risk group, sta-
tus for FLT3 and NPM1, NPM-MRD and MFC-MRD status (p <0.03, p<0.05,
p<0.05, p<0.001, p<0.01, respectively). Survival did not significantly differ
between patients achieving MFC-MRD negativity with FLAI 5 or “3+7”. Among
patients with FLT3-ITD and concomitant NPM mutation, the difference between
FLAI and 3+7 cohorts in term of DFS was higher (p <0.0001, Figure 1 C). No
significant DFS difference was observed in FLT3-ITD/NPM wild type patients.
Overall Survival analysis led to similar results.
Figure 1. A: Multicolor Flow Cytometry MRD levels after cycle 1
Figure 1. B: DFS in All Patients according to induction therapy.
Figure 1. C: DFS in NPM1 Patients according to induction therapy.
Figure 1. D: NPM1 MRD levels after cycle 1.
Summary and Conclusions: Despite the small size of patients cohorts and
the potential bias due to the retrospective nature of the analysis, our study
seems to indicate that fludarabine containing induction improves quality of
response in patients carrying NPM1 mutation compared to 3+7 regimen. It is
possible that the favorable impact of adding Fludarabine to Ara-C and anthra-
cycline in double mutated AML patients may overcome the negative prognostic
impact of FLT3-ITD.
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THE EFFECT OF AZACITIDINE ON HEALTH-RELATED QUALITY OF LIFE
(HRQL) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE
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Background: Older patients (pts) with AML generally have a poor prognosis.
While treatment (Tx) may extend overall survival (OS) for pts with AML, it may
also cause significant toxicity and impairment of HRQL (Cheng, Leukemia, 2014).
In the large, international, phase 3 AZA-AML-001 study, median OS for older pts
with AML treated with azacitidine (AZA) was 10.4 months vs 6.5 months for pts
who received conventional care regimens (CCR; HR=0.85; p=0.1009) (Dombret,
EHA, 2014). HRQL was a prespecified secondary endpoint of the study.
Aims: To evaluate changes in HRQL during Tx among pts in AZA-AML-001.
Methods: Pts were aged ≥65 years with newly diagnosed de novo or secondary
AML (>30% bone marrow blasts). Before randomization, pts were preselected
to receive 1 of 3 CCR per investigator choice: induction chemotherapy, low-dose
cytarabine (LDC), or best supportive care only. Pts were then randomized to
AZA or CCR, in which case, they received their preselected Tx. Most pts (n=312,
64%) were preselected to receive LDC. HRQL was assessed by EORTC QLQ-
C30 questionnaire at baseline, day 1 of every other Tx cycle, and at the end-of-
study visit, which occurred at different time points for individual pts. Analyses
included only pts who completed the baseline and at least 1 post-baseline HRQL
assessment. An HRQL-specific statistical analysis plan (SAP) was finalized
before database lock. HRQL changes were evaluated prospectively for the AZA
and CCR cohorts, and post hoc for the pt subgroup preselected to LDC who
received AZA or LDC. Four of the 15 QLQ-30 domains were prespecified in the
SAP as most relevant: Fatigue (primary), Global Health Status/QoL, Physical
Functioning, and Dyspnea (secondary). HRQL was evaluated through cycle 9
(~32 to 34 weeks) due to subsequent small cohort sizes. A prespecified 10-point
minimally important difference (MID) threshold represents meaningful change.
Results: Rates of HRQL assessment compliance were fairly high overall (>77%
both Tx groups) except at the end-of-study visit (AZA=42%, CCR=37%). Over-
all, 157 AZA pts and 134 CCR pts were evaluable for HRQL (the AZA-AML-001
ITT population included 488 pts, AZA N=241, CCR N=247). The rate of attrition
of evaluable pts during early Tx was higher in the CCR arm than in the AZA
arm. During Tx, mean change from baseline scores with AZA or CCR showed
general improvement in the 4 relevant domains (Figure). Few changes were
statistically significant (p<0.05) and fewer met the MID threshold. Pts receiving
CCR achieved meaningful improvement in Fatigue (cycles 7, 9) and Global
Health Status/QoL (cycle 9). No HRQL detriment was seen with AZA or CCR
during Tx. Notably, scores varied substantially among individual pts in both Tx
groups. Within the LDC preselection group, HRQL outcomes with AZA and
LDC were largely consistent with the primary HRQL analysis (Figure). Pts
receiving AZA achieved meaningful improvement in Fatigue (cycle 9).
Figure 1. Mean Changes from Baseline EORTC QLQ-30 Domain Scores.
Summary and Conclusions: During Tx, AZA and CCR were associated with
general improvement in HRQL in the 4 relevant domains, but improvements
were not consistently meaningful. Importantly, for these 4 domains, there was
no meaningful HRQL deterioration at the group level during Tx. Results were
largely similar for AZA vs LDC.
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DEFINITION OF CURE IN ADULT PATIENTS WITH ACUTE MYELOID
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Background: Advances in diagnosis, treatment, and supportive care have
improved rates of complete remission (CR) in adult patients (pts) with newly
diagnosed acute myeloid leukemia (AML). Unfortunately, disease relapse is
common, accounting for the majority treatment failure, and explaining the mar-
ginal improvements in long-term survival. However, there are subsets of pts
who achieve CR and continue to maintain very long term remissions, without
relapse-the so-called ‘cure-fraction’. Although long-term follow-up of AML pts
is standard, the time point after which a patient is considered ‘cured’ of AML is
a critical piece of information for both pts and physicians.
Aims: The aim of the current study is to clarify the definition of cure in adult pts
with AML in 1stCR.
Methods: For the purposes of the study, cure was defined as the point after
which the probability of relapse (POR) was ≤5%. In subgroups where this prob-
ability was not achievable in the first 5 yrs, a threshold of ≤10% was applied. Pts
who had received an allogeneic stem cell transplant were excluded. Pts with
acute promyelocytic leukemia (APL) were analyzed separately and not included
in the larger AML cohort. We evaluated the cumulative risk of relapse, time to
relapse, relapse-free survival, and overall survival in a cohort of pts treated at
our institution from 2000-2012, with a median follow up of 26.2 months.
Results: A total of 1096 pts were analyzed (median age 57, range [18-88]), of
whom 159 (14.5%) had APL. Of the remaining 937 pts, 493 (53%) were age
≥60 yrs, and 444 (47%) were <60 yrs. In pts with APL, the POR after 1 and 2
yrs was ≤5% and ≤1%, respectively. In the entire (non-APL) cohort, the POR
level of ≤5% was achieved after 4 yrs in CR. In pts <60 yrs, the POR of ≤5%
was achieved after 3 yrs in CR. In pts ≥60 yrs, the POR of ≤5% was not achieved
in the time of follow-up. In these pts, we observed a POR of ≤10% after 4 yrs in
CR. In pts with core-binding factor (CBF) AML, the POR was ≤5% at 2 yrs and
≤1% at 3 yrs after CR. In pts with diploid karyotype a POR of ≤5% was achieved
after 3 yrs in CR and in the non-diploid pts after 5 yrs in CR.(Figure 1).
Figure 1. The illustration shows the correlation between the probability
of relapse and the time passed from achieving the 1st complete remission
for the each subgroup of patients. Abbreviations: AML (acute myeloid
leukemia), CBF neg (core-binding factor negative AML), CBF pos (core
binding factor positive AML), APL (acute promyelocytic leukemia).
Summary and Conclusions: Although late relapses were observed, using a
threshold of ≤5% for POR, pts with APL and CBF AML may be considered
‘cured’ 1 and 2 yrs after achieving a CR, respectively. In younger pts with AML,
cure may be considered after 3 yrs in CR, while older pts did not achieve a
POR ≤5% during our follow-up. Using a POR of ≤10%, a ‘cure’ in older pts may
be considered after 5 yrs in CR.
Conflict of interest: This work was funded by a Conquer Cancer Foundation
of ASCO Long-term International Fellowship. Any opinions, findings, and con-
clusions expressed in this material are those of the authors and do not neces-
sarily reflect those of the American Society of Clinic Oncology or the Conquer
Cancer Foundation.
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RESIDUAL HEMATOPOIETIC STEM CELLS REFLECT MINIMAL RESIDUAL
DISEASE AND PREDICT OUTCOME IN ACUTE MYELOID LEUKEMIA
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Background: It has been demonstrated that functionally normal hematopoietic
stem cells (HSC) can be separated from leukemic cells in a subgroup of patients
with acute myeloid leukemia (AML) using the CD34+CD38-ALDH+ phenotype.
Our recent studies further showed that patients suitable for this separation can
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be identified prospectively by their low percentages of cells with high ALDH
activity (ALDH+ cells) (<1.9%; ALDH-rare AML) and that these patients repre-
sent a cohort with favorable outcome. However, frequencies of residual HSC
varies within this subgroup and individuals with very low numbers appear to
have extremely poor survival.
Aims: In this study we sought to investigate the relationships of residual HSC
to survival and disease status in diagnostic AML and follow-up samples. We
further aimed to test if HSC numbers correlate to leukemia initiation potential
in xenotransplantation assays.
Methods: Between 2012 and 2013 bone marrow (BM) aspirates of 73 ALDH-
rare AML patients were collected after written informed consent and patients
stratified according to HSC frequencies determined by 34+38-ALDH+ cells in
HSC-AML (0.01% of total MNC) and HSC+ AML (≥0.01% of total MNC). HSC
numbers were determined by FACS-analysis at diagnosis and various follow-
up time-points. Engraftment potential was evaluated by transplantation of
2x10e6 bulk AML cells in immune deficient NOD/SCID-IL2Rγnull (NSG) mice.
Results: Survival analysis showed that HSC-AML represents a subgroup of
patients with significantly worse overall survival (OS) (mean: 455 days) and
disease-free survival (DFS) (mean: 209 days), compared to HSC+ AML (mean
OS: 878 days; mean DFS: 896 days). Survival analysis of patients with cyto-
genetic intermediate-risk also showed significantly worse OS and DFS for HSC-
AML with mean OS of 439 days, compared to 872 days for HSC+ AML and
mean DFS of 218 days, compared to 848 days. We also analyzed matched
sample series from diagnosis, various remission time points and relapse (if
available), and found that HSC recovered after chemotherapy in cases that
achieved complete remissions. However, in cases of persistent disease HSC
remained rare. Correlation of disease status to HSC numbers during therapy
revealed that residual HSC are a reliable qualitative marker of minimal residual
disease with a negative correlation to frank or molecular relapse. To test if HSC
numbers correlate to leukemia initiation potential we transplanted 44 AML cases
in NOD/SCID-IL2Rγnull (NSG) mice and observed only abnormal engraftment
(47% AML-and 53% no engraftment) upon transplantation of HSC-cases. In
contrast HSC+ cases mostly lead to normal, multi-lineage engraftment (79%).
Summary and Conclusions: Frequency of residual HSC reliably predicts out-
come in AML patients and the quality of NSG mouse engraftment. Our AML
stratification strategy is especially helpful in identifying cases with poor prog-
nosis in the intermediate-risk group with HSC-AML representing patients with
poor overall and disease free survival. In addition HSC frequency can also be
used as a qualitative marker of MRD status tabling it as indicator of BM-niche
occupation of persistent leukemic cells.
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Background: Increasing numbers of older patients with acute myeloid
leukemia (AML) receive allogeneic hematopoietic cell transplant (HCT) due to
wider donor availability and improvements in supportive care that reduce trans-
plant-related morbidity/mortality. HCT in patients ≥60 y/o with first relapsed or
refractory (R/R) AML were examined from VALOR, a large phase 3 adaptive
design, randomized, double-blind, placebo-controlled trial evaluating vosaroxin
plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt) [NCT01191801].
Aims: The aim of this posthoc subgroup analysis was to assess outcomes of
HCT in patients ≥60 y/o with R/R AML.
Methods: Patients were randomized 1:1 to receive cyt (1 g/m2 IV over 2 hr, d
1-5) plus either vos (90 mg/m2 IV over 10 min, d 1 and 4; 70 mg/m2 in subse-
quent cycles) or placebo. We assessed complete remission (CR) rates prior to
HCT, posttreatment HCT rates, HCT outcomes, and overall survival (OS) by
treatment arm in R/R AML patients ≥60 y/o.
Results: Overall, 451 patients ≥60 y/o received vos/cyt (n=226) or pla/cyt
(n=225). Posttreatment HCTs were performed in 47 (20.8%) patients on vos/cyt
and 44 (19.6%) patients on pla/cyt. Of the 91 HCT patients, 27 had achieved
CR after vos/cyt vs 16 after pla/cyt. An additional 7 patients (vos/cyt) and 6
patients (pla/cyt) received subsequent therapy and went on to achieve CR,
resulting in totals of 34 vos/cyt vs 22 pla/cyt patients who achieved CR prior to
transplant. Median OS for patients who underwent posttreatment HCT on the
vos/cyt arm was 20.2 mo vs 12.2 mo on the pla/cyt arm (HR 0.699; one sided
P=0.088). There were no clinically meaningful differences between treatment
arms with respect to transplantation type, complications associated with HCT
(including graft-vs-host and veno-occlusive disease), 100-day mortality, or
achievement of engraftment.
Summary and Conclusions: While HCT rates were comparable between
treatment arms in this older R/R AML population, higher pretransplant CR rates
in the vos/cyt arm enabled more patients ≥60 y/o to undergo transplant while
in CR as compared to the pla/cyt arm. With median OS lengthened by 8
months, a trend toward an OS benefit was observed for vos/cyt-treated patients.
Additional follow-up is being conducted to further assess the impact of vos/cyt
treatment on posttreatment HCT. Funded by Sunesis Pharmaceuticals, Inc.,
South San Francisco, CA.
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RELAPSE CHARACTERISTICS AND RISK FACTORS FOR CENTRAL
NERVOUS SYSTEM INVOLVEMENT IN ACUTE PROMYELOCYTIC
LEUKAEMIA IN THE ORAL ARSENIC TRIOXIDE ERA-A 13-YEAR
FOLLOW-UP STUDY
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Background: Arsenic trioxide (As2O3)-based regimensareeffective in inducing
a remission in more than 90 percent of relapsed APL. Treatment failure follow-
ing As2O3 and central nervous system (CNS) involvement is associated with
a poor prognosis. The optimal post-remission therapy in relapsed APL is unde-
termined. Identifying the clinicopathologic characteristics and risk factors for
CNS relapse will be a useful guide to stratify patients to the most optimal post-
remission therapy.
Aims: The aim of this study was to prospectively evaluate the clinicopathologic
characteristics and risk factors for CNS involvement in patients with relapsed
APL treated with oral arsenic trioxide-based therapy.
Methods: A total of 188 patients with APL were prospectively followed for 13
years, of whom 71 patients had relapsed APL. The clinicopathologic charac-
teristics at relapse were determined. Prognostic factors for CNS involvement
at relapse were determined.
Results: There were 41 men and 30 women, at a median age of 43 (21–78)
years. The leukemia was de novo in 68 patients (five of which were of micro-
granular variant morphology), and therapy-related in 3 patients. Additional kary-
otypic abnormalities were seen in 11 patients (15.5%). Internal tandem dupli-
cation of the fms-like tyrosine kinase 3 gene (FLT3-ITD) was detected in 13
patients. During prior first complete remission (CR1), only 15 patients (21.1%)
had received oral-As2O3 based maintenance. A second complete remission
(CR2) was achieved with an oral-As2O3-based re-induction in all patients in
first relapse, who then received oral As2O3-based consolidation and mainte-
nance. At relapse, the median leucocyte count and peak leucocyte count was
2.7 (0.4–94.7) x 109/L and 9.2 (0.6–130.4) x 109/L, and the median platelet
count was 59 (7–281) x 109/L. APL differentiation syndrome (DS) occurred in
11 patients (15.5%) during relapse. At a median follow up of 93 (21–392)
months, 28 patients (39.4%) had two or more relapses. In the whole cohort of
patients, the patterns of relapses were: isolated bone marrow (BM), N=54
(76.1%); concurrent BM and CNS, N=9 (12.7%); and isolated CNS, N=8
(11.3%). In total, 22 patients relapsed during oral As2O3-based maintenance
at various disease stages. On univariate analysis, factors significantly associ-
ated with CNS relapse included peak leucocyte count at diagnosis >20 x 109/L
(P=0.03), oral As2O3-based maintenance at CR1 (P=0.004), leucocyte count
at R1 >10 x 109/L (P=0.04), 2 or more relapses (P<0.001), and relapse during
oral As2O3-based maintenance (P<0.001). On multivariate analysis, peak leu-
cocyte count at diagnosis >20 x 109/L (P=0.04) and relapse during oral As2O3-
based maintenance (P=0.01) were significantly associated with CNS involve-
ment at relapse. CNS involvement at relapse predicted worse overall survival
(HR=4.19; P=0.002; 95% CI:1.72-10.19).
Summary and Conclusions: CNS involvement was associated with a poor
prognosis. High peak leucocyte count at diagnosis and relapse during oral
As2O3-based therapy were the main risk factors. 
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Background: Neutropenic enterocolitis (NEC) is a life threatening complication
of leukemic and solid tumors patients (pts) treated with chemotherapy (CHT)
with mortality rate up to 50-100%. It’s a clinical syndrome in neutropenic patients
(pts) characterized by abdominal pain (AP), fever (F) and diarrhoea (D). Ultra-
sound (US) was used to evaluate bowel-wall thickening (BWT), and >4 mm is
considered diagnostic of NEC. Perforation occurs in 5%>10% of cases. Early
diagnosis is crucial to start conservative medical management (CMM) which
appears the optimal strategy for most cases.
Aims: To evaluate prospectively if Bed-side-US(BUS) can detect early signs
of NEC and guide a prompt treatment (CMM or surgical) in order to reduce
mortality and to evaluate the impact of different CHT regimens on mucosal
damage and NEC occurrence
Methods: in the last 7 years all AML pts admitted in Our Hematology Unit
wards at University of Pisa (Italy), undergoing chemotherapy (CHT) were
enrolled (n=109). Abdominal US was performed, baseline before treatment,
and as only one symptom (or a combination) appeared within 12h from onset:
F and/or D and/or AP in CHT-related neutropenic pts.
Results: N=220 chemotherapy-related neutropenic episodes (NE) occurred in
109 pts. N=17 episodes of NEC were diagnosed (7.7 %incidence rate). N=2
pts had 2 separate episodes of NEC and both survived. CHT regimens received
(total number of cycles/NEC episodes) was: 3+7 (Idarubicin+ARAC) N=62/10,
Idarubicin (AML-M3) N=9/1, 3+3+5 (Idarubicin,VP-16,ARAC) N=48/3; 2+5
(Idarubicin+ARAC) N=24/1; Clofarabine (40mg) N=5/0; Clofarabine (20mg)
14/0; Clofarabine+ARA-C (Cofa 20mg) N=18/1; FLANG N=13/1; HD-ARA-C
(3gr/mq for 3 consecutive days) N=26/0. Overall 3 pts died out of 17 NEC
episodes (mortality rate 17.6%). All pts were promptly treated as soon as BUS
was diagnostic of NEC. Overall 3 pts died /17 NEC episodes (17.6% mortality
rate).Median time to response from beginning of CMM was 24h and the first
sign of was a decrease in AP followed by F, D and BWT. Amelioration of symp-
toms occurred with pts still neutropenic. Symptoms at Dx were:F+AP+D N=9,
F+D N=1, F+AP N=1, Dia+AP N=4,D N=0, F N=0, AP N=2. Fever at Dx was
absent in N=6 episodes (35%). Statistically (St) CHT regimens mostly associ-
ated with NEC were: 3+7 odds ratio (OD) 6.00 (P<0.0001), 3+3+5 OD=1.75
(P<0.0001). There was not a St significant association of the following CHT
regimens with NEC occurrence: Clofarabine (20 or 40mg) N=0 NEC, 2+5
(P=0.125), Idarubicin (AML-M3) (P=0.111), Clofa 20mg+ARAC (P=0.167), HD-
ARAC N=0 NEC, FLANG (P=0.143). The association of ARAC to Clofarabine
vs Clofarabine (20 or 40mg) alone was not St significant in NEC occurrence
(P=0.9). The likelihood of NEC Dx in a discriminant model (Bayes theoreme)
for pts with BWT and AP=100%, AP+D=100%, AP+D+F=100%,AP+F=100%.
Summary and Conclusions: BUS allowed to detect early signs of NEC and
to start prompt treatment in this life threatening complication, with a 76% survival
rate. With BUS pts do not live the isolation room. Early diagnosis and interven-
tion allowed to reduce mortality. Images of BUS and CT were superimposable.
Fever is not a condition sine qua non for NEC diagnosis. Different chemother-
apy regimens do have a different impact on mucosal damage. A prompt BUS
in neutropenic patients as just one symptom presents allows to make early
diagnosis of this life threatening complication and guide prompt treatment (con-
servative or surgical) eventually reducing mortality.
Acute myeloid leukemia - Clinical 2
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MGA GUIDED INTENSIVE INDUCTION WITH HIGH DOSE CYTARABINE
PLUS IDARUBICIN IN 149 AML ELDERLY PATIENTS
D. Capelli1,* F. Saraceni1, M. Chiarucci1, A. Poloni1, G. Discepoli2, P. Leoni1,
A. Olivieri1
1Department of Haematology, Ospedali Riuniti di Ancona, 2Department of Cyto-
genetic, Ospedale Salesi, Torrette di Ancona, Italy
Background: The poor outcome of elderly AML patients is mainly due to the
biological properties of the disease and their frailty. To improve both the efficacy
and the tolerance of chemotherapy, different approaches have been tried and
tested in this setting.
Aims: We explored the feasibility and efficacy of an intensive induction regimen
in elderly AML patients evaluated by a simplified Multidimensional Geriatric
Assessment (MGA).
Methods: 149 consecutive AML patients older than 59 years, have been
prospectively evaluated by MGA: 91 patients (61%) who resulted fully or partially
fit, were eligible forintensive induction chemotherapy; the remaining 58 frail
patients received best supportive care (BSC). Frail patients turned out to be old-
er, have a poorer PS score and significantly more secondary and poor prognostic
karyotype AML than the fit subgroup of patients. In this latter group only 6.2% of
patients had favourable-risk cytogenetics while 40.7% had unfavourable-risk
cytogenetics. Thirty-six patients had a secondary disease and 3 patients had a
3 WHO performance status (PS) score. The induction chemotherapy consisted
in the association of High-Dose Aracytin, combined with a single high-dose of
Idarubicin, combined with Amifostine, in order to reduce the toxicity.
Results: Among the 91 patients who received intensive treatment the overall
chemotherapy-related mortality rate (TRD during induction and consolidation)
was 14.2% while the induction TRD rate was 5.5%. The main toxicity of the
intensive induction chemotherapy consisted in myelosuppression with neu-
trophils (>1,500/μl) and platelets (>20,000/μl) recovery was achieved on days
+15 and +16 respectively, with a median duration of hospitalization of 30 days
(range: 15-69); we did not observe severe extrahematological toxicities. Sixty-
seven (73%) patients achieved the Complete Remission (CR) and 61 received
intensive consolidation, followed by ASCT, SCT or Gemtuzumab Ozogamicin,
depending on mobilization outcome and donor availability.On intention to treat
basis the 8-year OS of the 91 patients receiving intensive induction, was 20%,
with a median duration of 11.4 months, significantly higher than that observed
in the 58 BSC patientssince all died within 18 months with a median OS of 1.5
months (p<0.001). Patients with poor cytogenetic, no hyperleukocytosis and
those with hyperleukocytosis ≥50,000/μl had respectively a 1.8and 3 relative
risk of dying when compared with other patients (p=0.005) (Figure 1).
Figure 1. OS in 91 AML elderly patients by prognostic score.
Summary and Conclusions: Our simplified MGA selected 60% of elderly AML
patients eligible for an intensive, feasible and effective protocol, making tailored
post-consolidation possible in 53.8% of patients with long term survival double
that reported in the literature.
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CD200 EXPRESSION IS ASSOCIATED WITH INFERIOR RESPONSE AND
POOR SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
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Background: The evasion of immune system by neoplastic cells is emerging
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as a mechanism of survival after conventional chemotherapy both in cells of
hematologic and solid tumors. Many molecules with “immune attenuator” activ-
ity have been identified over the last years; among them, CD200 has a central
role by inhibiting different effectors in immune response and has been asso-
ciated with poor prognosis in several cancers, including acute myeloid
leukemia (AML).
Aims: In the present work we investigated the aberrant expression of CD200
in 244 adult AML (173 “de novo” and 71 secondary) to evaluate its impact on
response to therapy and on survival. Secondary aim was to evaluate the pos-
sible association of CD200 expression with particular subsets of disease.
Methods: Two hundred forty-four patients with non-promyelocytic AML treated
at our two Institutions were included in this analysis. Blast cells immunopheno-
type and CD200 expression were evaluated by multiparametric flow cytometry.
Results: CD200 aberrant expression was found in 137/244 cases (56%), with
significantly higher frequency in secondary compared to “de novo” AML (52/71,
73% vs 85/173, 49%; p=0.0006). No association was found according to age
and FAB classification, but CD200 positivity was higher in CD34+ cases
(99/129, 77% vs 36/113, 32%; p<0.0001). CD200 expression was associated
with FLT3 unmutated status (105/170, 62% vs 17/46, 37%; p=0.004) and with
NPM wild-type status (99/145, 68% vs 19/65, 29%; p=0.001). Considering cyto-
genetic profile, CD200 expression was more frequent in the unfavorable group
(44/67, 66%) than in favorable/intermediate ones (74/153, 48%; p=0.01). Com-
plete remission (CR) was obtained in 73% of CD200 negative and in 58% of
CD200 positive patients (p=0.01). The negative impact of CD200 expression
on CR was confirmed also in multivariable analysis (HR: 0.49, 95%CI: 0.20-
0.95; p=0.04). With a median follow-up of 56 months, 107 patients (44% of the
total) were alive. Overall survival (OS) was significantly lower in CD200 positive
patients, with 3-year OS of 45%, compared to 31% in the CD200-negative
group (p=0.01) [Fig 1]. Moreover, a strong association was observed between
intensity of CD200 and survival, as patients with high CD200MFI (>11) had a
3-year OS of 10% compared to 40% in CD200 negative or low-expressing cas-
es (p=0.03). In multivariable analysis CD200 expression intensity retained its
negative impact on OS (HR: 0.59, 95%CI: 0.32-98; p=0.04). Finally we evalu-
ated the effect of CD 200 expression in patients with unfavorable karyotype: 3-
year OS was 39% in CD200 negative and 12% in CD200+ patients (p=0.045).
Figure 1.
Summary and Conclusions: Aberrant CD200 expression is associated with
low remission rate and poor survival in AML. The negative effect is particularly
evident in the unfavorable cytogenetic group. New therapeutic strategies direct-
ly targeting CD200 or modulating the tolerant microenvironment induced by
CD200 should be explored to improve the still largely unsatisfactory results of
conventional chemotherapy.
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Background: Specific genetic alterations in AML represent a critical information
for both diagnosis and treatment choice.
Aims: 20 AML patients at diagnosis were subjected to RNA-Seq to identify gene
fusions; mutations and indels in a predefined set of 45 genes were also evaluated.
Methods: RNA sequencing data were generated using an Illumina Genome
Analyser IIx following standard library-prep protocols. Alignment to the refer-
ence GRCh38/hg38 genome was performed using STAR. Alignment data were
processed using Samtools. Single nucleotide and small indels detection was
performed using in-house software and applied to the following list of genes
involved in AML pathogenesis (CEBPA, NPM1, FLT3, RUNX1, MLL, WT1,
EZH2, NF1, MECOM(EVI1), KIT, H-RAS, K-RAS, TET2, IDH1, IDH2, DNMT3A,
BCOR, BCORL1, NUP98, ASXL1, ABCB5, BAALC, CEP72, DIP2C, ROBO1,
KLC1, TP53, IGFBP7, SETBP1, JAK2, NRAS, NOTCH1, CDKN2A, MPL,
SF3B1, BRAF, PTPN11, SRSF2, IKZF1, GATA1, MYD88, ATM, CBL, PHF6,
BCL2). The presence of fusions was assessed using FusionAnalyser.
Results: We identified a total of 10 fusions and 29 single nucleotide variants
with a median number of 1 single nucleotide variant per patient (range 0-4). 5
patients had fusions that were previously detected with standard techniques
(1AML-ETO, 3 PML-RARA and 1 CBFB-MYH11); for all these patients known
fusions were confirmed by RNA-sequencing. In 5 patients previously unreport-
ed fusions were detected. Two of them were already known from the literature
(ZMYM2-FGFR1 and MLL-MLLT10) and 3 were new (ETS2-ERG, WDFY3-
WAS and KDM2B-ETV6). Thus the number of fusions present in this cohort of
patients was doubled when compared to fusions identified by standard tech-
niques. The ZMYM2-FGFR1 is particularly interesting, because it is potentially
targetable by using drugs such as ponatinib, dovitinb or nintedanib; indeed, in
vitro treatment of patient cells with nanomolar concentration of ponatinib caused
a potent and specific growth inhibition (see figure). Among the patients in whom
point mutations were identified, new treatment options could have been select-
ed in 14 out of 20 cases, harboring mutations in genes such as NOTCH1,
IDH1/2, RAS, KIT, TET, EZH2 and KMT2A.
Figure 1.
Summary and Conclusions: NGS technologies, such as RNA-Seq, can result
useful to identify genetic lesions and to tailor treatment in AML patients.
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SALVAGE REGIMENT WITH FRACTIONATED GEMTUZUMAB OZOGAMICIN,
INTERMEDIATE DOSE CYTARABINE AND MITOXANTRONE (MYLODAM)
FOR REFRACTORY AND RELAPSED AML: A SINGLE CENTER
EXPERIENCE
A.C. Mamez1,* P. Hirsch1, F. Isnard1, S. Lapusan1, M.T. Rubio1, E. Grignano1,
C. Marzac2, A. Vekhoff1, M. Mohty1, O. Legrand1
1Hématologie clinique, 2Laboratoire d’hématologie, Hôpital Saint Antoine, Paris,
France
Background: Gemtuzumab ozogamicine (GO, mylotarg ®) has been used for
44 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
refractory or relapsing AML with a response rate of 30% when used alone and
60% when used in combination with other chemotherapy. In the largest pub-
lished study reporting the combination of a single dose of mylotarg® 9mg/m2
with mitoxantrone and intermediate dose of cytarabine in relapsed AML, the 2
years OS and EFS were 41% and 33% respectively. Concerns about hepatic
toxicity have limited mylotarg® use, particularly for patients who had previously
received SCT. Several studies have shown good results and reduced toxicity
when using mylotarg® in a fractionated dose schedule.
Aims: In this study, we report a one center experience of a new association
with fractionated mylotarg® 3mg/m2on day 1, 4, 7, mitoxantrone 12mg/m2on
day 1 to 3 and cytarabine 1g/m2/12h on day 1 to 5 (MYLODAM), for refractory
or relapsed CD33+ AML.
Methods: Twenty-four patients were treated with MYLODAM between January
2012 and December 2014. Median age at time of treatment was 55 years old (range
19-67). Seven patients received the MYLODAM salvage course for primary refrac-
tory CD33+ AML, 7 for relapsed AML after chemotherapy and 10 for relapsed AML
after stem cell transplant (2 auto-SCT, 8 allo-SCT, in a median time between trans-
plant and MYLODAM of 300 days). Cytogenetic risk groups were distributed as fol-
low: 7 adverse karyotype, 9 intermediate risk and 7 favorable risk. Among the 12
patients with normal karyotype, 6 had NPM1 mutation and 5 had FLT3 ITD mutation.
After reaching CR or CRp, 8 patients received at least one consolidation containing
GO and 19 underwent allogeneic transplant (3 second allo-SCT, 16 first allo-SCT).
Results: Overall response rate was 19/24 (79%), including 6 CR and 13 CRp
(with incomplete platelet recovery). One year estimated OS and EFS were 62
% and 60% respectively. Median OS and EFS were not reached, with a median
follow-up of 12 months (figures 1A and 1B). We found no significant difference
in terms of EFS and OS whether patients had refractory disease, post transplant
or post chemotherapy relapse (p=0.41). Minimal residual disease was under
the threshold of detection after salvage therapy for 11/ 15 responding patients
with molecular evaluation (5/6 with NPM1 mutation, 5/6 with WT1 over expres-
sion and 1/3 for AML1-ETO transcript). The median duration of thrombopenia
(<50G/L) and neutropenia (<500/mm3) were 49 and 42 days respectively, for
patients reaching CR or CRp. Early death (<30 days) occurred for one patient.
Liver toxicity was frequent (elevation of transaminase levels: grade 0-1: 38%,
grade 2-3: 54%, grade 4: 8% and hyperbilirubinemia ≥grade 2 in 2 cases). We
report 2 cases of sinusoidal obstruction syndrome, none of them having
received previous SCT; one patient died 18 days after the beginning of
chemotherapy, the other patient was treated with defibrotide and is still alive.
Figure 1.
Summary and Conclusions: MYLODAM is an efficient salvage regimen for
refractory and relapse CD33+ AML. This combination based on fractionated
mylotarg® has an acceptable safety profile, even for the 10 patients who were
treated after SC transplant.
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EARLY PERIPHERAL BLAST CELL CLEARANCE PREDICTS MINIMAL
RESIDUAL DISEASE STATUS AFTER INDUCTION IN ACUTE MYELOID
LEUKEMIA
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Background: Identification of patients (pts) with acute myeloid leukemia (AML)
having high likelihood to respond to standard therapy and those with low prob-
ability to do well and being candidates for more aggressive treatment is of major
clinical importance. Most prognostic factors are surrogate for disease’s
chemosensitivity; among them, genetics is the most relevant, representing the
framework of European Leukemia Net (ELN) risk stratification. It defines sub-
groups with relatively good survival (ELN-favorable) and at the opposite a cat-
egory with poor prognosis (ELN-adverse). However, in the absence of genetic
determinants, ELN system merges pts with heterogeneous diseases. At any
rate, the response to induction therapy remains a powerful prognostic param-
eter, expressing actual chemosensitivity of AML cells. In responsive pts, minimal
residual disease (MRD), usually evaluated after induction or consolidation
cycles, is an accurate tool to refine risk category. We have previously demon-
strated that an earlier assessment, based on the speed of peripheral blast
clearance (PBC) as assessed by flow cytometry during induction therapy, strictly
correlated with AML outcome.
Aims: To correlate PBC after the first 3 days of induction therapy with MRD
assessment after induction at hematopoietic recovery.
Methods: Eligible pts had untreated non-M3 AML according to the World Health
Organization criteria and were treated according to a standard induction ther-
apy. At diagnosis, bone marrow (BM) aberrant leukemia-associated immuno-
phenotypes (LAIP) were identified by flow cytometry. We quantified LAIP+ cells
by single platform before treatment on day 1 and then following the first 3 days
of therapy (day 4). PBC of each individual pt was expressed as the ratio
between absolute LAIP cell count on days 1 and 4 converted to a logarithmic
scale. By ROC curves we identified 1.5 log as the most accurate cut-off sepa-
rating pts with high and low PBC index, respectively (PBC-hi, PBC-lo). In pts
achieving CR after a single induction cycle, we searched for LAIP+ cells in BM
expressing MRD as percentage on overall BM cellularity; pts were considered
MRD+ when LAIP+ cells were detected as at least 0.01% of total BM cells.
Results: Between 2007-2013, 104 pts achieving CR had available LAIP and
were studied both by PBC and MRD after induction. As concerns PBC, 34
(32.7%) pts were PBC-lo and 70 (67.3%) were PBC-hi. PBC status significantly
correlated with ELN prognostic stratification of patients (p=0.0007). Regarding
MRD, 50 (48.1%) pts were classified as MRD+ and 54 (51.9%) as MRD-. MRD
status correlated with ELN categories as well (p=0.0067). Both PBC and MRD
influenced disease-free and overall survival in univariate analysis. Most impor-
tant, PBC was able to predict MRD status after induction; specifically, 45/70
(64.3%) PBC-hi and 9/34 (26.4%) PBC-lo pts were MRD-negative, respectively
(Fisher’s test p=0.0004). The combination of both parameters separated two
categories of patients with favorable (PBC-hi/MRD-) and very poor (PBC-
lo/MRD+) outcome, as depicted in Figure 1. Discordant cases showed inter-
mediate prognosis.
Figure 1.
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Summary and Conclusions: PBC is very early and powerful outcome predic-
tor in AML, providing a real time quantification of AML burden reduction in the
first days of chemotherapy. PBC well correlated with MRD status after induction
and the combination of both parameters identified pts with strikingly different
outcome.
P195
MICRODUPLICATION 17Q21.31 AND 17P11.2 ASSOCIATE WITH AML
DIAGNOSIS OR RESPONSE TO THE THERAPY
E. Jaskula1,2, M. Mordak-Domagala2, A. Sobczynska-Konefal2, M. Sedzimirska2,
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Background: Genetic work on leukemia documented the predictive power of
chromosomal abnormalities as to the response to treatment. GTG and FISH
techniques are of clinical value. More recently, it became apparent that heritable
or acquired characteristics of non transcribing portion of the genome may influ-
ence the risk of cancer and the response to the treatment.
Aims: In the present study we looked at the copy number variations (CNV) to
document the possible relations between the pattern of CNV in some regions
of the genome and the risk of AML course in patients with normal karyotype
(NK). This approach is supported by the observation that CNV pattern influences
the expression of genes being in their vicinity; therefore, their examination offers
better inside into genetic potential of leukemic cells. In an advent of the wide
use of specific kinase inhibitors in the treatment of AML patients with Flt3 muta-
tion we investigated the relation between the presence of this mutation and the
CNV abnormalities to find out whether Flt3 internal tandem duplication (ITD)
mutation associates with a more complex genetic background in NK patients.
Methods: 82 patients with AML (median age: 57,5 years old (range 21-81
years), 79 primary and 3 secondary AML) were investigated. GTG karyotyping
was technically valid in 70 patients and in 25 FISH analysis was performed
(XY, inv(3),-5/5q-,-7/7q-,+8, MLL, RUNX1, PML/RARA or RARA, inv(16) and
MLL). Patients without abnormalities (46 patients) were classified as those with
NK. Twenty six patients were Flt3 ITD positive. All fit patients received
chemotherapy with intention to treat. Unfit patients were on the low dose AraC.
All patients who proceeded to the consolidation therapy phase and those unfit
having a stable number of blasts at three month after the treatment started
were classified as good responders all others as poor. DNA was extracted from
mononuclear cells (Ficoll separation) of the marrow aspirated at the diagnosis.
One microgram portions of DNA were subtracted to the analysis employing
WG Catalog NimbleGene 12x270K (Roche) and Catalog Agilent Cancer
CGH+SNP 180K microarrays according to the manufacturer’s instruction then
were scanned in the Roche NimbleGene MS 200 instrument. Data was ana-
lyzed with the use of Nexus 7.5 (BioDiscovery) program.
Results: The difference in CNV was compared between Flt3 ITD positive and
negative NK AML patients. It was found that the difference in the number of
CNV was statistically significant only in the analysis of chromosome region
chr17q21.31: 41576590-41682478. Flt-3 negative but not Flt3 ITD positive
patients had CNV gains in that region (25% vs 0%, p=0.03). The presence of
these microduplications barely affected their response to the treatment (37%
vs 16%, n.s.). Working further on the relationship between the response to the
treatment and CNV gains in chromosome 17. We found that NK patients with
CNV gains in 17p11.2: 19065233-19083457 responded poorly to the induction
therapy (66% vs 13%, P=0.013) and suffered from poor survival (p=0.037).
Notably, none of the 7 patients having gains in the 17p11.2 region had TP53
mutation evaluated by the FISH technique.
Summary and Conclusions: From the present study we cannot conclude
whether CNV abnormalities found in two chromosome 17 regions are inherited
or acquired; however, these genetic traits may affect either the risk of leukemia
(NK patients) or response to the treatment and survival in NK AML patients.
Supported by INNOMED/I/1/NCBR/2014 CellsTherapy grant
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THE SIGNIFICANCE OF RELATIVE MUTANT LEVEL FOR C-KIT MUTATION
IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA BY
ALLELE-SPECIFIC REAL-TIME PCR
E. Han1,* W. Jang1, A. Kwon1, M. Kim1, Y. Kim1
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Background: The chromosomal aberrations such as t(8;21)(q22;q22), which
result in RUNX1-RUNX1T1 translocation, and inv(16)(p13q22)/t(16;16)(p13;q22),
which result in CBFβ-MYH11 translocation are collectively referred to as core
binding factor acute myeloid leukemia (CBF AML). CBF AML is associated with
a relatively good prognosis although some CBF AML cases are difficult to man-
age due to relapse. Recently, c-KIT mutations have been identified as a poor
prognostic factor. However, the prognostic impact of c-KIT mutation still remains
controversial. In this study, we investigated the relationship between c-KIT
mutations and prognosis in CBF AML patients using highly sensitive detection
method, quantitative allele-specific real-time PCR.
Aims: We performed this study to evaluate the prognostic impact of qualitative
and quantitative determination of c-KIT mutations in CBF AML using highly
sensitive method, although there have been few studies on detection of c-KIT
mutations using allele-specific real-time PCR.
Methods: We analyzed the c-KIT mutations in 111 newly diagnosed adult CBF
AML patients (74 with t(8;21) and 37 with inv(16)) in St. Mary’s Hospital from
April 2009 to July 2013. DNA isolated from paired bone marrow samples at the
time of disease relapse and complete remission was also investigated. We used
allele-specific real-time PCR to detect D816 and N822 mutations in c-KIT exon
17 and determined exon 8 mutations using direct sequencing analysis.
Results: Of the total 111 patients, 62% (69/111) and 8% (9/111) had c-KIT
mutations in exon 17 and 8, respectively. CBF AML patients with a c-KIT exon
17 mutation showed significantly higher percentage of blasts in bone marrow
aspirates at diagnosis (77.0% vs 73.0%, P =0.031), and significantly lower
WT1 expression (0.5 vs 0.7, P =0.048) than those without a mutation. CBF
AML patients with c-KIT exon 17 mutations had worse event free survival (EFS)
than patients without mutations. The estimated 5-year EFS rates were 86.1%
for patients without mutations and 61.5% for patients with mutations (P =0.022).
The estimated 3-year EFS was the lowest in patients with high mutant allele
level (37.5%, P =0.003). In multivariate analyses, the high level of c-KIT exon
17 mutant alleles was associated with a statistically significant adverse impact
on both OS (HR, 7.4, P =0.001) and EFS (HR, 4.6; P =0.004). Of the 17
relapsed patients, 15 had c-KIT mutations at diagnosis. C-KIT mutations were
lost at relapse in 5 patients, and 2 patients who harbored double c-KIT muta-
tions at diagnosis lost the major mutations while retaining the minor at relapse.
C-KIT mutations showed the mutation disappeared at complete remission.
There was a similar trend between the level of c-KIT mutant and the fusion
transcripts in serial analyses.
Summary and Conclusions: The small populations of leukemic cells with c-
KIT mutations could be detected by high sensitive quantitative method and
high mutant level was associated with poor outcome. The quantitative meas-
urement of the c-KIT exon 17 mutant allele burden could be a valuable tool in
evaluation of prognosis at diagnosis and for subsequent patient monitoring.
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IMPROVED SURVIVAL IN PATIENTS ≥60 WITH FIRST RELAPSED/
REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN
PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM
THE PHASE 3 VALOR STUDY
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Background: Prognosis for older patients with relapsed or refractory (R/R)
acute myeloid leukemia (AML) is poor, with lower response rates and shorter
survival compared with younger patients. Safe and effective salvage regimens
are urgently needed. Vosaroxin is a first-in-class anticancer quinolone derivative
that is active in AML, is minimally metabolized, evades P glycoprotein recep-
tor–mediated efflux, and has activity independent of p53 status. VALOR, a
phase 3, randomized, double-blind, placebo-controlled trial, evaluated vosarox-
in plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt) in patients with
R/R AML (NCT01191801).
Aims: To evaluate the efficacy and safety of vos/cyt vs pla/cyt in patients ≥60
yrs of age enrolled in the VALOR trial.
Methods: Patients were randomized 1:1 to receive cytarabine (1 g/m2 IV over
2 hr, d 1-5) plus either vosaroxin (90 mg/m2 IV over 10 min d 1 and 4; 70 mg/m2
in subsequent cycles) or placebo. Up to 2 induction and 2 consolidation cycles
were administered. Eligible patients had refractory disease (persistent disease
after induction, or first complete remission [CR1] duration <90 d) or were in
first relapse (early relapse: CR1 duration of 90 d to 12 mo; late relapse: CR1
duration of 12 mo to 24 mo). Patients had 1-2 cycles of prior induction
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chemotherapy including at least 1 cycle of anthracycline/anthracenedione and
cytarabine. Randomization was stratified by age (<60, ≥60 yrs), disease status
(refractory, early relapse, late relapse), and geographic location (US, non-US).
Primary endpoints were overall survival (OS) and 30-and 60-day mortality. Here
we report results of predefined subgroup analyses in patients ≥60 yrs.
Results: Between Dec 2010 and Sept 2013, 711 patients were randomized at
101 sites; 63% (n=451) were ≥60 yrs (n=226 randomized to vos/cyt and n=225
to pla/cyt). At final analysis, OS was improved with vos/cyt in patients ≥60 yrs
(7.1 mo vs 5.0 mo with pla/cyt; HR=0.75; P=0.003) (Figure). Event-free survival
was also improved (2.1 mo vs 1.3 mo with pla/cyt; HR=0.61; P<0.0001). CR
was achieved in 31.9% of patients ≥60 yrs treated with vos/cyt vs 13.8% treated
with pla/cyt (P<0.0001). Responses were durable; median leukemia-free sur-
vival among patients ≥60 yrs who achieved CR was 10.3 mo with vos/cyt vs
6.5 mo with pla/cyt (P=0.20). The rate of subsequent allogeneic transplant in
patients ≥60 yrs was 20.2%. In a predefined sensitivity analysis in which patients
were censored at allogeneic transplant, the survival benefit in patients ≥60 yrs
was maintained (6.7 mo with vos/cyt vs 5.0 mo with pla/cyt; HR=0.75; P=0.009).
Thirty-day and 60-day all-cause mortality in patients ≥60 yrs was similar
between treatment arms (30-day: 10.2% vs 9.0%; 60-day: 20.4% vs 22.6%
with vos/cyt vs pla/cyt, respectively). Serious AEs in the ≥60 population were
more common with vos/cyt treatment (57% vs 33% with pla/cyt); most common
serious AEs were febrile neutropenia (9.3% with vos/cyt vs 5.9% with pla/cyt),
sepsis (9.3% vs 5.0%), pneumonia (7.5% vs 4.5%), bacteremia (7.5% vs 2.3%),
and stomatitis (4.4% vs 1.8%). Serious and non-serious cardiac, renal, neuro-
logic, and hepatic AEs were comparable between treatment groups.
Figure 1. OS in patients age ≥60 years, by treatment arm (n=451).
Summary and Conclusions: The addition of vosaroxin to cytarabine improved
OS and increased CR rates without increasing early mortality in older patients
with R/R AML, a population with few treatment options. The additional toxicity
observed in the vosaroxin arm was acceptable in light of the benefit received.
VALOR results support the use of vos/cyt as a standard of care in patients ≥60
yrs of age with R/R AML.
CLL - Biology: Microenvironmental interactions
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AND FUNCTIONAL RESPONSES IN B CELLS FROM PATIENTS WITH
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E. ten Hacken1, S.O’Brien2, W.G. Wierda1, A. Ferrajoli1, Z. Estrov1,
M.J. Keating1, C. Scielzo3, P. Ghia3, F. Caligaris-Cappio3, J.A. Burger1,*
1Leukemia, 2MD Anderson Cancer Center, Houston, United States, 3IRCCS
Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milano, Italy
Background: B-cell receptor (BCR) signaling is a central pathogenetic mech-
anism in chronic lymphocytic leukemia (CLL). CLL cells express immunoglob-
ulins of both IgM and IgD isotypes, but the relevance of these isotypes for sig-
naling and functional responses remains incompletely understood.
Aims: The aim of the present study is to characterize functional differences
between IgM and IgD signaling.
Methods: Purified CLL cells from 73 CLL patients (40 M-CLL and 33 U-CLL)
were stimulated with anti-IgM and anti-IgD; phosphorylation levels of the BCR-
related molecule HS1 and of the downstream kinase ERK was analyzed in
serial samples after 2, 5, 15, 30, and 60 minutes of stimulation by Western Blot
and flow cytometry; BCL6 expression were analyzed after 3, 6, 9, 12, 24 hours
of stimulation by Western Blot. 48-hour cell viability was analyzed by flow cytom-
etry; CCL3 and CCL4 chemokine production was measured by ELISA after 3,
6, 9, 12, and 24 hours of stimulation.
Results: sIgM and sIgD levels were significantly higher in U-CLL. Relative sur-
face expression of IgM was 34.81±5.346 in M-CLL, as compared to
85.71±10.51 in U-CLL (p<0.0001). Relative surface expression of IgD was
32.30±4.463 in M-CLL, as compared to 59.74±8.054 in U-CLL (p=0.0048). Anti-
IgM stimulation protected CLL cells from in vitro apoptosis to a greater extent
than anti-IgD and this difference was more evident when considering the U-
CLL subset of patients, which showed a mean relative viability after anti-IgM
stimulation of 178±21.79% as compared to anti-IgD stimulation, which only
reached 114.6±7.171% (p=0.0023). IgM stimulation induced protracted HS1
and ERK phosphorylation, up to 30 minutes following receptor engagement. In
contrast, IgD stimulation induced short-lived phosphorylation of both proteins.
CCL3 and CCL4 chemokines were secreted only after IgM stimulation, and
surprisingly low, if any, induction was noted after IgD stimulation. When U-CLL
cells were stimulated with 10 mg/mL anti-IgM, CCL3 levels in the surnatants
were 2155±719.1 pg/mL, as compared to 96.70±23.38 pg/mL after 10 mg/mL
anti-IgD. CCL3 and CCL4 chemokine secretion peaked after 9-12 hours of IgM
stimulation, and was concomitant to BCL6 down-regulation, in particular in U-
CLL cases. Interestingly, when CLL cells were co-cultured for 14 days with
NLCs, relative surface IgM levels were down-modulated from 47.36±18.95 to
41.39±16.08 in M-CLL (p>0.05), and from 80.01±18.19 to 43.45±7.824 in U-
CLL (p=0.0195). Consistent to this finding, CCL3 and CCL4 chemokines were
secreted in CLL-NLC cocultures, in particular in U-CLL cases. The mean CCL3
levels in U-CLL surnatants were 923.9±250.8 pg/mL, as compared to
256.7±117.3 pg/mL for M-CLL (p=0.0062); CCL4 levels were also higher in U-
CLL, but did not reach statistical significance.
Summary and Conclusions: IgM stimulation induces more durable signaling
responses, increased CLL-cell survival, CCL3 and CCL4 secretion, and con-
comitant BCL6 down-regulation, in particular in U-CLL. In contrast, IgD respons-
es are more transient and have no effect on CLL-cell survival or chemokine
secretion. BCL6 is a known transcriptional repressor of the CCL3 gene in nor-
mal B cells, and our findings suggest that this mechanism is also recapitulated
in CLL cells. In addition, stimulation provided by NLCs is associated with IgM
receptor downmodulation and CCL3 and CCL4 chemokine secretion in U-CLL.
Taken together, these evidences support the prevalence for IgM signaling in
CLL pathogenesis.
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UNIQUENESS VERSUS EQUIVALENCE
A. Agathangelidis1,* V. Bystry2, A. Hadzidimitriou3, L.A. Sutton4, E. Minga3,
D. Kienle5, Z. Davis6, X.J. Yan7, T. Shanafelt8, M. Boudjogra9, K. Plevova2,10,
M. Gounari1, A. Xochelli3, A. Navarro11, M. Chatzouli12, L.B. Pedersen13,
P. Baliakas4, L. Scarfò1, D. Rossi14, S. Veronese15, M. Facco16, V. Bikos2,
T. Karan-Djurasevic17, S. Pavlovic18, L. Mansouri4, C. Poiron19, C.C. Chu7,
E. Stalika3, V. Giudicelli19, P. Panagiotidis20, A. Sudarikov21, A. Anagnostopoulos22,
L. Trentin16, M. Catherwood23, M. Montillo15, G. Gaidano14, E. Campo11,
C.H. Geisler13, A.W. Langerak24, S. Pospisilova2,10, M.P. Lefranc19,
N. Chiorazzi7, D. Oscier6, D.F. Jelinek25, S. Stilgenbauer5, C. Belessi12,
F. Davi9, R. Rosenquist4, P. Ghia1, N. Darzentas2, K. Stamatopoulos3,4,22
1Division of Experimental Oncology and Department of Onco-Hematology, San
Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy,
2Masaryk University, Central European Institute of Technology, Brno, Czech
Republic, 3Institute of Applied Biosciences, CERTH, Thessaloniki, Greece,
haematologica | 2015; 100(s1) | 47
Vienna, Austria, June 11 – 14, 2015
4Department of Immunology, Genetics and Pathology, Science for Life Lab-
oratory, Uppsala University, Uppsala, Sweden, 5Department of Internal Med-
icine III, Ulm University, Ulm, Germany, 6Department of Haematology, Royal
Bournemouth Hospital, Bournemouth, United Kingdom, 7Feinstein Institute
for Medical Research, North Shore-Long Island Jewish Health System, Man-
hasset, 8Department of Hematology, Department of Medicine, Mayo Clinic,
Rochester, Minnesota, United States, 9Hematology Department and Uni-
versity Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France, 10Uni-
versity Hospital Brno, Brno, Czech Republic, 11Unidad de Hematopatología,
Servicio de Anatomía Patológica, Hospital Clínic, Universitat de Barcelona,
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Barcelona, Spain, 12Hematology Department, Nikea General Hospital,
Piraeus, Greece, 13Department of Hematology, Rigshospitalet, Copenhagen,
Denmark, 14Hematology Department, Amedeo Avogadro University of East-
ern Piedmont, Novara, 15Molecular Pathology Unit and Haematology Depart-
ment, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milan,
16Department of Medicine, Hematology and Clinical Immunology Branch,
Padua University School of Medicine, Padova, Italy, 17Institute of Molecular
Genetics and Genetic Engineering, University of Belgrade, Belgrade, 18Uni-
versity of Kragujevac, Kragujevac, Serbia, 19IMGT®, the international
ImMunoGeneTics information system®, Université d Montpellier, LIGM, Insti-
tut de Génétique Humaine IGH, Montpellier, France, 20First Department of
Propaedeutic Medicine, University of Athens, Athens, Greece, 21Department
of Molecular Hematology, National Hematology Research Center, Moscow,
Russian Federation, 22Hematology Department and HCT Unit, G. Papani-
colaou Hospital, Thessaloniki, Greece, 23Department of Hemato-Oncology,
Belfast City Hospital, Belfast, United Kingdom, 24Department of Immunology,
University Medical Center Rotterdam, Erasmus MC, Rotterdam, Nether-
lands, 25Department of Immunology, Mayo Clinic, Rochester, Minnesota,
United States
Background: Studies of the B cell receptor immunoglobulin (BcR IG) in chronic
lymphocytic leukemia (CLL) revealed that ~30% of cases can be assigned to
stereotyped subsets. In our previous publication of 7,596 CLL BcR IG gene
sequences, we focused on 19 major subsets, collectively accounting for 12%
of the cohort. This process was based on the implementation of stringent criteria
focusing on high sequence relatedness. However, we have been aware of BcR
IG sequences similar to those in or even between major subsets, yet set apart
due to not fulfilling the adopted criteria.
Aims: We systematically searched for previously obscured sequence relatives
of major BcR IG stereotypes with the aim of obtaining a wider, better connected,
and thus more insightful view into IG repertoire restriction in CLL.
Methods: Sequence relatives of major subsets were sought for through apply-
ing a series of criteria in reference to each respective subset: (i) usage of the
same IGH genes, (ii) VH CDR3 length difference ranging from-2 to +2 amino
acids (aa); and, (iii) expression of the same VH CDR3 sequence motif. A total
of 20331 productive IGHV-IGHD-IGHJ gene rearrangements from a multi-insti-
tutional series of CLL patients were evaluated, with assignment to major sub-
sets performed with purpose-built bioinformatics methods.
Results: Overall, 2450/20331 (12.1%) CLL sequences formed the 19 major
subsets, each containing 44 to 548 sequences. The relative frequency of each
major subset was highly similar between the present and the previous analysis,
justifying their consideration as major. The quest for sequence relatives to
major subsets was performed individually for each subset. For major subsets
with mutated IGHV genes (M-CLL), generally, very few non-subset sequences
showed adequate VH CDR3 similarity, and even these utilized different IGHV
genes, thus not satisfying our search criteria. Amongst subsets with unmutated
IGHV genes (U-CLL), a striking case of relatedness was observed between
major subsets #1 (501 cases) and #99 (70 cases), characterized by the usage
of the same IGH genes and the presence of a shared QWL motif at the same
positions within VH CDR3. Their single important difference concerned VH
CDR3 length (subset #1: 13 aa, subset #99: 14 aa). For the remaining major
U-CLL subsets, certain subsets remained “unique”, contrasting others for which
we identified closely related sequences we now deem as “satellite” subsets. In
particular, in the case of subset #8 (IGHV4-39) we identified two “satellite” sub-
sets that consisted of 35 and 10 cases and displayed relative sizes of 37.6%
and 10.8% (compared to subset #8), respectively. Even more pronounced was
the case of subset #31 (IGHV3-48), with its “satellite” comprising of 51
sequences and a relative size of 86.4% compared to subset #31, thus almost
equal to its established relative.
Summary and Conclusions: Major M-CLL stereotyped subsets remained iso-
lated, with unique sequence characteristics. In contrast, a clear trend was evi-
dent for many major U-CLL subsets in having “satellites”, potentially functionally
equivalent, and often large in size. These findings could be attributed to the
intrinsic differences between M-CLL versus U-CLL subsets in terms of IG gene
repertoire and VH CDR3 features. Considering that major stereotyped subsets
may indeed represent distinct disease subgroups, our highlighting of higher-
order sequence relations has implications for clinicobiological research aimed
at dissecting the heterogeneity of CLL towards identifying distinct profiles that
would assist in clinical decision making.
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Background: The etiology of chronic lymphocytic leukemia (CLL) remains elu-
sive, but there is growing evidence indicating a role of autoimmunity as well as
relevance of antigen stimulation in pathogenesis of CLL. Appearance two
groups of patients with mutated and unmutated status of the rearranged
immunoglobulin heavy variable (IGHV) genes and more frequent occurrence
of B-cell receptor (BCR) gene sequences, that are virtually-identical in unmu-
tated CLL suggest that an unknown antigen could be involved in development
of CLL. Recent studies proved occurrence of monoclonal antibodies directed
against cytoskeletal proteins including non-muscle myosin heavy chain IIA
(MYHIIA), vimentin, and cofilin-1, that are exposed on the surface during apop-
tosis. These molecules could represent autoantigens recognized by the specific
BCR of the CLL cells.
Aims: Current study aimed to characterize response of T cells specific to epi-
topes derived from three autoantigens including MYHIIA, VIM and CFL1.
Methods: MYH9, VIM, and CFL1 genes expression was analyzed using qRT-
PCR in 212 CLL patients. HLA-A2-restricted epitopes derived from MYHIIA,
cofilin-1 and vimentin were selected in silico using 2 independent prediction
algorithms. The affinity of MHC class I-restricted peptides was determined by
cellular-peptide binding affinity assay utilizing T2 cell line. Mixed lymphocyte
peptide cultures (MLPC) were performed to define immunogenicity of synthe-
sized peptides in vitro. To detect specific immune response ELISpot assays
for specific IFN-γ release were evaluated. Finally, the frequency of the specific
T cells directed against selected peptide with the highest along with detailed
phenotypical characteristics was assessed using dextrameric peptide-specific
complexes in 7-colour flow cytometry panel ex vivo.
Results: In CLL patients analyzed with qRT-PCR CFL1 overexpression in com-
parison with healthy volunteers was found, while there were no differences in
MYH9 and VIM expressions between CLL and HV. The in silico analyses fol-
lowed by in vitro HLA-A2 cellular-peptide binding assay enabled to define 9
immunogenic peptides derived from MYHIIA, vimentin and cofilin-1. MLPC with
ELISpot assays revealed higher specific cytotoxic immune response for pep-
tides derived from MYHIIA in 4/6 (66.7%), vimentin 7/8 (87.5%) and cofilin-1
5/8 (62.5%) in CLL patients in comparison with healthy volunteers 3/8
(37.5%).Multicolor flow cytometry panel demonstrated low frequencies of
autoreactive peptide-specific T cells against MYHIIA, vimentin and cofilin-1 in
CLL patients ex vivo; most of detected cells presented effector-memory phe-
notype. Results obtained from functional assays were compared with muta-
tional status of IGHV genes in CLL patients including subset analysis. Interest-
ingly, we found 6 CLL patients with stereotypic BCR represented subset clones
subset no.2 [IGHV3-21M], subset no.4 [IGHV4-34M], subset no.5 [IGHV1-
69UM], subset no.34 [IGHV1-69UM], subset no. 59 [IGHV1-58UM] and subset
no. 64B [IGHV3-48UM]. All of these patients demonstrated reactivity against
peptides derived from MYHIIA, vimentin or cofilin-1. Interestingly, we found
presence of autoreactive cofilin-1-derived peptide specific cytotoxic T lympho-
cytes in patient characterized by subset no. 5 [IGHV1-69UM] ex vivo.
Summary and Conclusions: The presence of autoreactive T lymphocytes
that might be involved in pathomechanism of CLL during stimulation of an
autoreactive B cells in proliferative compartment, indicate on important role of
autoimmunity in the pathogenesis of CLL. Autoantigenic stimulation through
apoptotic cells could lead to the proliferation of leukemic cells, possibly main-
tained or at least accompanied by autoreactive T cells.
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STEM CELL FACTOR KLF4 IS EPIGENETICALLY INACTIVATED AND
REPRESSED BY NOTCH SIGNALING IN CLL
D. Mertens1,2,* K. Filarsky2, R. Claus3, C. Plass4, H. Döhner1, P. Lichter5,
S. Stilgenbauer1
1Internal Medicine III, University Ulm, Ulm, 2Mechanisms of Leukemogenesis,
DKFZ, Heidelberg, 3Internal Medicine I, University Freiburg, Freiburg, 4Epige-
nomics, 5Molecular Genetics, DKFZ, Heidelberg, Germany
Background: Whole genome sequencing revealed CLL as a disease of the
genome and epigenome characterized by somatic mutations and aberrant DNA-
methylation. A number of genes have already been identified that show aberrant
DNA methylation in CLL cells. Examples are e.g. ZAP70 that is involved in B
cell and T cell signaling and whose promoter DNA-methylation is correlated with
its decreased expression. Of note, DNA-methylation of a single CpG dinucleotide
is important for ZAP70 expression and predictive of prognosis. Similarly, the
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MYB proto-oncogene is directly methylated in CLL, WNT signaling activation
has been related to hypermethylation of WNT inhibitor genes and also miRNA
transcriptional deregulation in CLL has been linked to aberrant DNA-methylation.
DNA-methylation has been reported to be stable over time in leukemic cells of
CLL patients and to be similar in resting and proliferative compartments. Of
interest, in addition to comparison with healthy tissue, recent publications have
shown intratumor heterogeneity of DNA methylation. We therefore focused on
identifying functionally relevant aberrant DNA-methylation of promoters in CLL
that correlates with transcriptional activity and is therefore most likely to impact
on gene regulation. With this approach we could identify the stem cell factor
KLF4 to be epigenetically deregulated in CLL, and could further show that this
defect is possibly caused by aberrant activation of NOTCH1.
Aims: To identify genes that: display an aberrant DNA-methylation in their pro-
moter in CLL cells; whose promoter DNA methylation correlates with their tran-
scriptional activity; to understand their functional role in the cellular pathome-
chanism of CLL.
Methods: In order to uncover the impact of aberrant DNA-methylation on the
transcriptional profile of CLL cells, gene expression and methylation array pro-
filing was performed in CLL-and B-cells using standard and custom microarrays.
Methylated DNA was precipitated using a methyl-cytosin binding fusion protein
(MCIp) and detected with arrayed 60bp oligonucleotides that span all RefSeq
human gene promotors-3.8 to +1.8kbp from the transcriptional start sites. Func-
tional analyses of candidate epigenetically deregulated genes were performed
using transient transfections in primary CLL cells and subsequent phenotypic
analysis of target gene expression and apoptosis of transfected cells. In addi-
tion, NOTCH1 signaling was inhibited in primary CLL cells using g-secretase
inhibitors to assess the impact on KLF4 levels.
Results: 1866 genes were differentially expressed in CLL (log2FC≤|1|, p≤0.05).
DNA-methylation covered a greater heterogeneity in CLL cells compared to
the healthy counterpart. In total, 2191 genes displayed aberrant methylation
within their promoter (log2FC≥|0.5|, p≤0.05). However, only 33 of these genes
also showed a significant negative correlation between expression and methy-
lation, including CBX7, ADRB2, CXCR3, LILRA4 and KLF4. We focused on
the transcriptional regulator KLF4 that was recently shown to play an important
role in B cell development and maturation and to act as tumor suppressor in
NHL and cHL. KLF4 downregulation was correlated in CLL with hypermethyla-
tion in a region downstream of its TSS. Expression was also correlated with
levels of BCL2 family members BAK, BAX, BCL2 and with the cell cycle regu-
lator CCND1. Inhibition of NOTCH1 signaling, which is constitutively activated
and frequently mutated in CLL patients, led to re-expression of KLF4 in 8 patient
samples and 6 leukemia-and lymphoblastoid cell lines, indicating regulation by
NOTCH1 in B cells. Intriguingly, ectopic overexpression of KLF4 in CLL cell
lines resulted in the deregulation of genes involved in signaling pathways includ-
ing BCR signaling.
Summary and Conclusions: The detected epigenetic deregulation of the stem
cell factor KLF4 is possibly caused in CLL by aberrant activation of NOTCH1.
It underlines a defect in the developmental program of CLL and suggests aber-
rant arrest of CLL cells in a terminally differentiated state.
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NOTCH2 AND NOTCH3 HAVE OPPOSITE ROLES IN THE REGULATION
OF APOPTOSIS IN CLL CELLS
R. Hubmann1,* M. Araghi1, S. Schnabl1, M. Hilgarth1, E. Ponath1, M. Reiter1,
D. Demirtas1, U. Jäger1, M. Shehata1
1Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Background: Chronic lymphocytic leukemia (CLL) cells express constitutively
activated NOTCH2. We have recently shown that the NOTCH2 transactivation
inhibitor gliotoxin induces apoptosis in CLL cells by a mechanism involving the
induction of NOTCH3. However, the regulation and possible functions of
NOTCH3 in resting and activated CLL cells remain to be clarified.
Aims: To elucidate the different roles of NOTCH2 and NOTCH3 in CLL cells
we compared the effects of gliotoxin and the clinical relevant γ-secretase
inhibitor (GSI) RO4929097 on CLL cells in vitro.
Methods: The dose and time dependent effects of these compounds on CLL
cell viability and on the induction of apoptosis, respectively, was determined by
MTT-assays and by FACS analysis. The influence of gliotoxin and
RO4929097on the expression of NOTCH and apoptosis related genes was
analysed by RT-PCR.
Results: Gliotoxin rapidly induced apoptosis in all CLL cases whereas
RO4929097 affected CLL cell viability only in a subgroup of cases after a pro-
longed incubation time. All NOTCH1 mutated CLL samples clustered in the
RO4929097 sensitive group. Chronic activation of CLL cells with low doses of
PMA (1ng/ml) enhanced NOTCH2 signaling, inhibited spontaneous apoptosis,
and strongly induced the proliferation marker MYC mimicking the proliferative
compartment in the lymphoid microenvironment. Inhibition of NOTCH2 by
gliotoxin led to the concomitant induction of homotypic NOTCH3 signalling as
indicated by the induced mRNA expression of NOTCH3 and its ligands JAG2
(in unstimulated CLL cells) or DLL1 (in PMA activated CLL cells) together with
an upregulation of the activation induced cell death (AICD) mediator NR4A1.
In contrast, RO4929097 inhibited NOTCH3 signalling, NR4A1 transcription,
and counteracted gliotoxin mediated apoptosis in GSI resistant CLL cases indi-
cating a tumour suppressive role for NOTCH3 in the leukemic cells. In line with
this hypothesis, the downregulation of NOTCH2 activity in unstimulated CLL
cells in vitro was associated with upregulation of NOTCH3 mRNA expression
and increased spontaneous apoptosis especially in CLL samples derived from
Rai/Binet I/A patients. In this context, RO4929097 inhibited NOTCH3 and
NR4A1 expression an inhibited spontaneous apoptosis depending on the GSI
sensitivity of NOTCH2.
Summary and Conclusions: In summary, these data indicate that NOTCH2
and NOTCH3 have counteracting roles in the regulation of CLL apoptosis which
should be considered in therapeutic approaches aimed to target NOTCH signaling
in CLL. Constitutive active NOTCH2 might inhibit tumour suppressive NOTCH3
signaling in CLL cells thereby enabling the activation dependent progredient
expansion of the malignant clone. Thus, gliotoxin selectively targets oncogenic
NOTCH2 signalling in a wide spectrum of CLL cases while GSIs may be effective
onlyin a subgroup of CLL patients including NOTCH1 mutated cases.
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EXPRESSION AND FUNCTIONAL ROLE OF CORTACTIN IN AGRESSIVENESS
AND DIFFUSION OF CHRONIC LYMPHOCYTIC LEUKEMIA
V. Martini1,* C. Gattazzo1, F. Frezzato1, V. Trimarco1, G. Chiodin1, F. Severin1,
M. Pizzi1, F. Marino1, A. Visentin1, G. Semenzato1, L. Trentin1
1University, Padua, Italy
Background: Cortactin is an actin-binding protein involved in several cell func-
tions, i.e. the assembly and the organization of cytoskeleton. Its overexpression
was observed in several human cancers and experimental data support the
role of cortactin in metastatic capability through the regulation of cell motility
and the release of matrix metalloproteinase-9 (MMP-9). The activity of this pro-
tein is regulated by its phosphorylation in Tyr residues by Src kinase family. We
previously demonstrated that in leukemic cells from CLL patients the Src kinase
Lyn is overexpressed, activated and involved in the resistance to apoptosis.
Recently, we found that cortactin is overexpressed in patients with CLL.
Aims: Here we investigated the involvement of cortactin in the release of MMP-
9 and, therefore, in the progression of CLL.
Methods: Blood samples were collected from 7 controls and 17 CLL patients.
Informed consent was obtained according to the Declaration of Helsinki.
Untouched peripheral blood B cells were purified using the RosetteSep for
human B cells isolation kit. The samples that were used had at least 95% of
normal CD19+ or neoplastic CD5+/CD19+ cells, as assessed by flow-cytom-
etry (FC). Purified B cells (2×106cells/ml) were cultured in RPMI medium with
or without CXCL12 (100ng/ml) for the evaluation of MMP-9 production. MMP-
9 release by neoplastic B cells was also investigated after cortactin silencing
in 4 patients expressing high level of cortactin. The protein was silenced by
SMARTpool siRNA collection (Dharmacon, Thermo Scientific), according to
the manufacturer’s instructions. Immunohistochemical (IHC) staining was
performed on formalin-fixed, paraffin-embedded tissue sections using a fully
automated platform.
Results: By IHC and FC we confirmed the increased expression of cortactin
in CLL patients with respect to controls. Moreover, we identified to groups of
patients: one characterized by high expression the other by low expression of
protein. By gelatin zymography we found that the release of MMP-9 by neo-
plastic B cells correlated to the expression of cortactin after 5 and 24-hrs culture.
To investigate whether cortactin was involved in MMP-9 secretion in CLL, a
cortactin-targeted siRNA silencing system was used to knockdown this protein
in 4 patients with high cortactin expression. We found that following cortactin
knockdown, leukemic cells showed a defect in MMP-9 secretion, as assessed
by ELISA test. This protease also showed a decreased gelatinolytic activity in
culture medium, confirming the hypothesis that cortactin is involved in the reg-
ulation of MMP-9 secretion in CLL malignant cells. Finally, we found that the
incubation of leukemic cells with PP2 or other kinase inhibitor, decreased Tyr
phosphorylation level of cortactin and shut down the release of MMP-9 in culture
medium, also following CXCL12 triggering.
Summary and Conclusions: The overexpression of cortactin in neoplastic B
cells and the correlation between cortactin levels, activity and MMP-9 release
suggest a role of this protein in metastatic invasion and in the CLL aggressive-
ness. In addition, cortactin might represent a biomarker for diagnosis and prog-
nosis as well as target for new therapeutic strategies.
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ROLE OF HAUSP/PTEN NETWORK IN CHRONIC LYMPHOID LEUKEMIA
PATHOGENESIS AND THERAPY
G. Carrà1,* C. Panuzzo1, D. Torti1, G. Parvis1, S. Crivellaro1, A. Guerrasio1,
G. Saglio1, A. Morotti1
1Department of Clinical and Biological Sciences, University of Turin, San Luigi
Hospital, Turin, Italy
Background: PTEN tumor suppressor was shown to play a role in Chronic
Lymphocytic Leukemia (CLL). In particular, it was demonstrated that PTEN is
phosphorylated in the tail by Casein Kinase II, favoring its inactivation. Further-
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more, it was also proposed that PTEN levels are significantly reduced in some
CLL patients. PTEN tumor suppressive functions are also regulated by proper
cellular compartmentalization through mono-ubiquitination. In particular, PTEN
mono-ubiquitination promotes PTEN nuclear localization, while PTEN de-ubiq-
uitination by HAUSP promotes PTEN nuclear exclusion with dramatic conse-
quences on the tumor suppressive function.
Aims: Assessment of the biological role of CKII/HAUSP/PTEN network in CLL
in order to evaluate HAUSP as a rheostat in the regulation of PTEN. Evaluation
of the therapeutic role of HAUSP inhibitors in CLL.
Methods: Primary CLL cells were collected from untreated and informed
patients accordingly to ethical committee approved protocol, during routinely
diagnostic procedures. Cells were enriched in CD19 fraction using the Miltenyi
anti CD19 kit. CLL CD19 cells were used for different analyses. Immunofluo-
rescence was performed to investigate PTEN cellular compartmentalization.
Protein samples were used for HAUSP and PTEN protein levels quantification
and evaluation of those proteins regulated by HAUSP (p53, p21, MDM2). The
same material was used for PTEN ubiquitination, PTEN phosphatase assay
and Casein Kinase II kinase assay. Transfected CLL cell lines with GFP-PTEN
and mutant constructs were used to evaluate the contribution of PTEN in pro-
moting growth arrest and/or apoptosis induction. HAUSP inhibitors were used
in CLL cell lines and proliferation and apoptosis were evaluated with MTT tech-
nology and Annexin V-FITC/Propidium PE detection by flow cytometry.
Results: By immunofluorescence we observed that a portion of CLL patients
is characterized by PTEN nuclear exclusion. PTEN protein levels did not cor-
relate with cellular compartmentalization, suggesting that the two phenomena
are regulated by different mechanisms. Forcing PTEN expression into the
nucleus of a CLL cell line, with a PTEN-NLS expressing vector, was associated
with strong apoptosis induction and growth arrest. These observations suggest
that PTEN is functionally inactivated in CLL. Next, we assessed PTEN ubiqui-
tination in CLL primary cells. We observed that PTEN is de-ubiquitinated, clearly
demonstrating a direct role of HAUSP in PTEN nuclear exclusion of CLL cells.
Our data suggested a dual regulatory mechanisms that activate HAUSP
towards PTEN. HAUSP could be either over-expressed and/or regulated by
Casein Kinase II, which phosphorylates HAUSP on serine residues. Interest-
ingly, treatment of CLL cells with HAUSP small molecule inhibitors is associated
with re-localization of PTEN into the nucleus, which in turn promotes cell growth
arrest and apoptosis induction.
Summary and Conclusions: Our data demonstrate that (1) PTEN is func-
tionally inactivated by nuclear exclusion in CLL; (2) PTEN can be reactivated
in CLL through HAUSP and Casein Kinase II inhibitors, with significant thera-
peutic implications.
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UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH
INFERIOR PROGNOSIS
H. Plesingerova1,2,* P. Janovska3, L. Poppova1,2, A. Shaik3, Z. Jurcickova4,
A. Libra4, K. Plevova1,2, J. Machac5, I. Slapak5, S. Pavlova1,2, P. Ovesna6,
J. Kotaskova1,2, M. Doubek2, S. Pospisilova1,2, V. Bryja3
1Molecular Medicine, Central European Institute of Technology, Masaryk Uni-
versity, 2Center of Molecular Biology and Gene Therapy, Department of Internal
Medicine-Hematology and Oncology, University Hospital Brno, 3Institute of
Experimental Biology, Faculty of Science, Masaryk University, Brno, 4GENERI
BIOTECH, s.r.o., Hradec Kralove, 5Clinic of Pediatric Ear, Nose & Throat Dis-
eases, Faculty of Medicine, University Hospital Brno, Masaryk University, 6Insti-
tute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Background: Chronic lymphocytic leukaemia (CLL) is a heterogeneous dis-
ease; patients are stratified into two prognostic groups with either mutated (M-
CLL) or unmutated (U-CLL) IGHV. CLL cells are also characteristic by upreg-
ulated expression of a transmembrane tyrosine-protein kinase (ROR1), a mem-
ber of Wnt/planar cell polarity (PCP) pathway, which influences migration of
CLL cells and chemotaxis. We have identified recently Cordon-bleu protein-
like 1 (COBLL1) as a ROR1 binding partner. The significance of COBLL1 for
CLL patient stratification remains unknown.
Aims: Our aim was (i) to examine expression of COBLL1 in CLL cells and (ii)
to analyse COBLL1 expression in relation to the patients’ prognosis.
Methods: We analysed COBLL1 expression in 174 previously untreated
patients (82 U-CLL, 92 M-CLL) by qRT-PCR and correlated the results with
prognostic markers (TP53 defect, IGHV status, del 11q, del 13q, trisomy 12,
ATM, BIRC3, MYD88 and NOTCH1 mutation). We also examined how
chemotaxis of CLL cells towards chemokines CCL19 and CXCL12 differs
depending on COBLL1 expression (11 M-CLL, 10 U-CLL COBLL1-low, 6 U-
CLL COBLL1-high).
Results: COBLL1 expression in CLL cells is heterogeneous. COBLL1 is upreg-
ulated in all M-CLL (M-CLL vs U-CLL, p<0.0001, Mann Whitney test), whereas
its expression in U-CLL shows a bimodal pattern and distinguishes two prog-
nostically different subgroups. Intriguingly, the U-CLL COBLL1-high patients
suffer from more aggressive disease than the U-CLL COBLL1-low patients,
which results in their shorter time to first treatment (TTFT), time to second
treatment (TTST) and overall survival (OS) (TTFT: medians 20 vs 33 months,
p=0.0226; TTST: 36 vs 57, p=0.0055; OS: 75 vs 207, p=0.0037, Mantle Cox
test). Analysis of biological markers revealed lower somatic hypermutation load
in U-CLL COBLL1-high cells (p=0.0062, Mann Whitney test). No other genomic
differences which might result in survival differences within U-CLL patients
have been found. Frequency of TP53 defect was not statistically significant
(29% U-CLL COBLL1-high vs 22% U-CLL COBLL1-low). Therefore, we
analysed the cell migration abilities of U-CLL COBLL1-high towards
chemokines CCL19 and CXCL12 and found impaired migration compared to
M-CLL and U-CLL COBLL1-low cells (CCL19: M-CLL vs U-CLL COBLL1-high,
p=0.0182, Mann Whitney test). In basal migration, the trend was reversed, i.e.
basal migration of U-CLL COBLL1-high cells was increased compared to the
M-CLL and U-CLL COBLL1-low cells.
Summary and Conclusions: COBLL1 expression in CLL cells differs dramat-
ically and identifies a novel subgroup within U-CLL patients with inferior prog-
nosis. Their shorter survival cannot be explained by any other prognostic mark-
er tested. Aggressive disease course of U-CLL COBLL1-high patients can be
a result of a deregulated response to microenvironment stimuli caused by
deregulated Wnt/PCP pathway. Supported by MUNI/A/1180/2014, IGA
NT13493-4/2012, GACR P301/11/0747, 15-29793A, CZ.1.07/2.3.00/30.0009.
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EXTRACELLULAR VESICLES FROM MESENCHYMAL STROMAL CELL
MICROENVIRONMENT PROTECT CHRONIC LYMPHOCYTIC LEUKEMIA
B-CELLS FROM APOPTOSIS
E. Crompot1,* M. Van Damme1, H. Duvillier2, K. Pieters1, P. Mineur3,
N. Meuleman2, D. Bron2, L. Lagneaux1, B. Stamatopoulos1
1Jules Bordet Institute/ULB, 2Jules Bordet Institute, bruxelles, 3Grand Hopital
de Charleroi, Gilly, Belgium
Background: The interactions between chronic lymphocytic leukemia (CLL)
cells and the microenvironment (primarily composed by mesenchymal stromal
cells-MSC) play an important role in promoting the increased survival of
leukemic B cells. Extracellular vesicles (EVs) produced by leukemic cells and
the microenvironment may be implicated in this cross-talk. EVs, including
microparticles and exosomes, are small plasma membrane fragments with
sizes ranging from 0.01 to 1µm, and contain products specific to the original
cell, such as microRNA, mRNA and proteins.
Aims: Our objective is to assess the role of EVs in the cross-talk between
malignant cells and their microenvironment.
Methods: Ultracentrifugation at 150000 x g during 1h was applied to isolate
EVs from supernatant of MSC culture. Protein concentration was measured
by BCA kit and Nanodrop. Different concentrations of EVs were added to CLL-
B-cells to evaluate their impact on cell proliferation and survival. PKH67 labeling
and qRTPCR were performed to prove the inclusion of EVs in CLL B-cells (18
samples were analyzed).
Results: We first demonstrated that EVs from MSCs are able to enter in CLL
B-cells. By flow cytometry with PKH67-labelled EVs, we observed that 44.2,
93.8 and 100% of CLL B-cells had integrated fluorescent EVs after 1, 3 and
24h respectively. Two highly expressed mRNA (collagen and fibronectin) in
MSC, also detected in MSC-derived EVs by qRTPCR, were increased in CLL-
B cells after 24h of incubation with EVs confirming EV-mediated mRNA transfer
to target cells. Further analysis of apoptosis in CLL cells were assessed by
flow cytometry using an Annexin/7AAD staining: addition of increasing con-
centrations of EVs showed a protective effect on CLL B-cells from cell death
(mean increase of 11% of live cells, n=19/p-value=0.007).
Summary and Conclusions: We demonstrated, by two methods, that MSC-
derived-EVs enter into CLL B-cells. These vesicles protect CLL cells from spon-
taneous apoptosis and affect mRNA expression involved in CLL cell functions.
This study provides evidence of the critical role played by EVs in the interactions
between leukemic cells and their microenvironment.
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FUNCTIONAL INVOLVEMENT OF THE SRC KINASE LYN IN THE
SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS VIA
MAINTENANCE OF ANTI-APOPTOTIC B CELL RECEPTOR SIGNALING
V. Vondey1,* M. Kuckertz1, E. Göckeritz1, M. Hallek1, G. Krause1
1Dept. I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Background: The Src family tyrosine kinase Lyn shows high protein levels
and activity in chronic lymphocytic leukemia (CLL) cells and pharmacological
inhibitors of Lyn cause apoptosis.
Aims: In a chemical genetics approach using inhibitor-resistant mutant kinases,
the functional roles in CLL pathogenesis of the Src kinases Lyn and Lck and
of Abl were validated with the aid of Src/Abl inhibitors in current clinical use or
development. To dissect the effects of these inhibitors with relatively broad
selectivity and to unequivocally assign partial contributions to blocked Lyn activ-
ity, we monitored the protection from inhibitor effects by mutant Lyn with a mod-
ified binding pocket.
Methods: For this purpose the CLL-derived, EBV-transformed lymphoblastoid
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cell line JVM-3 was retrovirally transduced to express Lyn-T319I or wild type
(WT) in addition to endogenous Lyn. Cellular survival of JVM-3 cells and CLL
samples after inhibitor treatment was determined by annexin V/7AAD staining.
Signaling analysis was performed using Western Blotting and electrophoretic
mobility shift assays. Transient down-regulation of Lyn expression was achieved
after nucleofection with specific siRNA. In addition, the impact of Src/Abl
inhibitors on purified Lyn and Abl was determined in a FRET-based kinase
activity assay.
Results: The activity of purified Lyn and Abl was inhibited to similar degrees
by Src/Abl inhibitors at >5000-fold lower concentration as required for cytotox-
icity for malignant B cells and more strongly by dasatinib than bosutinib. JVM-
3 cells showed similar sensitivity for Src-Abl inhibitors as CLL cells isolated
from patients’ blood, e.g. approximately 2.5 times higher cytotoxicity of bosutinib
than dasatinib. The activating autophosphorylation of the activation loop tyrosine
of Src kinases was diminished by Src-Abl inhibitors in parental JVM-3 cells and
in transductants expressing Lyn-WT, but maintained with Lyn-T319I expression.
In the same manner survival of JVM-3 cells was reduced in the presence of
Src-Abl inhibitors and rescued by expression of Lyn-T319I, but not by Abl-
T315I. Src-Abl inhibitors as well as siRNA knock-down of Lyn led to phos-
phatidylserine exposure, increased poly(ADP)ribosyl polymerase cleavage and
reduced Mcl-1 levels. Stronger cell killing by siRNA knock-down of Lyn than of
Lck corresponded to a higher degree of protection from inhibitor-induced apop-
tosis by Lyn-T319I than by Lck-T316I. In the presence of Src/Abl inhibitors,
Lyn-T319I restored the activating phosphorylation of the direct Lyn substrates
Syk and phospholipase C-γ and of Akt at serine 473, as well as the DNA binding
activity of the transcription factors NFκB and STAT3. Lyn determined the main-
tenance of high levels of the anti-apoptotic protein Mcl-1 mainly via transcrip-
tional mechanisms.
Summary and Conclusions: The described chemical genetic approach per-
mitted to confirm a functional role of Lyn at nodes of anti-apoptotic signalling net-
works and to quantitatively compare the contributions of Lyn and other kinases.
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THE COMBINATION OF ARSENIC TRIOXIDE AND IBRUTINIB INDUCES
SYNERGISTIC APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
THAT IS POTENTLY ASSOCIATED WITH PI3K-AKT DOWN-REGULATION
X.H. Zhang1,* R. Feng2, Y. Kong1, S.M. Yang1, Q. Jiang1, H. Jiang1, M. Lv1,
L.P. Xu1, K.Y. Liu1, X.J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematol-
ogy, 2Departments of Hematology, Beijing Hospital, Ministry of Health, Beijing,
China
Background: Chronic lymphocytic leukaemia (CLL) is generally treated by
chemoimmunotherapy, and there is an unmet medical need for novel targeted
therapies or combination therapies. Ibrutinib is an efficient therapeutic agent
for CLL. However, some patients do not respond to ibrutinib, and the long-term
safety of ibrutinib has not been established. (Chung et al., Pharmacothera-
py2014) By combining ibrutinib with other agents, higher responses are expect-
ed in CLL patients. Our previous study also suggested that arsenic trioxide
(As2O3) induces CLL cell apoptosis and serves as an efficient therapeutic agent
for CLL alone or in combination with other agents.
Aims: The aim of the study is to investigate whether As2O3 combined with
ibrutinib inhibits CLL cell proliferation synergistically in vitro and in vivo.
Methods: The CLL cell line MEC1 and primary B lymphocytes (PBL) from CLL
patients were used to examine the effects of As2O3 and ibrutinib alone or in
combination on CLL proliferation and apoptosis. The combinatorial effects of
As2O3 and ibrutinib on the growth and apoptosis of MEC1 cells and PBLs were
evaluated. Chou–Talalay analyses were preformed to evaluate the combinato-
rial effects of As2O3 and ibrutinib on CLL cells in vitro. To identify the possible
signal pathway involved in the synergistic effect, microarray analysis was con-
ducted on PBLs from 5 independent patients with CLL before and after treat-
ment with As2O3 and ibrutinib alone or in combination. in vivo studies were
conducted using MEC1 cells xenografted in BALB/c nude mice. Human MEC1
cells were inoculated subcutaneously into nude mice to establish a human
leukaemia xenograft model.
Results: The effect of the As2O3 and ibrutinib combination is synergistic in CLL
cells. The combination of As2O3 and ibrutinib has a minor effect on the viability
of normal peripheral blood lymphocytes. The results from the gene expression
profiling analysis indicate that As2O3 causes the down-regulation of PI3K target
genes. Ibrutinib exerted only modest effects on PI3K-AKT signatures, whereas
the combination had an even more profound effect compared with As2O3 alone.
Signatures associated with NF-κB were strikingly down regulated by ibrutinib
and to a lesser extent by As2O3. Finally, STAT3 target genes were reduced by
treatment with ibrutinib; As2O3 had a lesser effect. The cytotoxicity of combina-
tion therapy was associated with increased Caspase-3,-8,-9 and Bax expres-
sion and a more effective reduction of PI3K-AKT. In an adoptive transfer MEC1
mouse model of CLL, As2O3in combination with ibrutinib affected disease pro-
gression. In this model, theAs2O3and ibrutinib combination resulted in tumour
regression and inhibited CLL progression more dramatically than either drug
alone. The combination of As2O3 with ibrutinib induces significantly more tumour
cell apoptosis. The expression of p-AKT proteins was significantly reduced,
whereas the expression of Caspase-3 and Bax increased in the combination
therapy group.
Summary and Conclusions: The combination of As2O3 and ibrutinib inhibits
tumour growth and induces apoptosis synergistically in CLL cells in vitro and
in vivo. The combination induces a minor effect on the viability of normal periph-
eral blood lymphocytes. The combinatorial effect against CLL cells is mediated
by Caspase pathway activation and the inhibition of PI3K-AKT. The combination
of As2O3 and ibrutinib may have clinical potential for CLL treatment.
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REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH
SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL
PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH
INITIATIVE ON CLL (ERIC) 
P. Baliakas1,* A. Hadzidimitriou1,2, M. Mattsson1, A. Xochelli1,2, L.A. Sutton1,
E. Minga2, L. Scarfò3,4, D. Rossi5, Z. Davis6, A. Agathangelidis3,4, N. Villamor7,
H. Parker8, J. Kotaskova9, E. Stalika2,10, K. Plevova9, L. Mansouri1,
D. Cortese1, A. Navarro Lopez7, J. Delgado11, M. Larrayoz8, A. Anagnostopou-
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Background: Chronic lymphocytic leukemia (CLL) patients with somatically
hypermutated IGHV genes (M-CLL) within their B-cell receptor immunoglobulin
(BcR IG) generally display favorable biological profiles with an indolent disease
course. However, neither the biological background nor the clinical presentation
and outcome of M-CLL is uniform, thus justifying the quest for parameters that
would assist in refining prognosis.
Aims: Development of a novel prognostic index tailored to M-CLL.
Methods: Cox-regression models were used to assess the impact of demo-
graphic, clinical, genomic and immunogenetic features on time-to-first-treat-
ment (TTFT) in 1359 M-CLL cases.
Results: Main features of the studied cohort were as follows: median age:
64 years (22-92); males: 810/1359 (60%), Binet A/B/C: 1169/79/53
(90%/6%/4%); CD38 expression (CD38+): 161/1225 (13%). Except for
del(13q) (494/836, 59%) and trisomy 12 (+12, 142/1072, 13%), other genomic
aberrations were relatively rare [del(11q): 49/1076 (4.5%), TP53 abnormality
(TP53abn) i.e. del(17p) and/or TP53 mutations: 52/1144 (4.5%), NOTCH1
mutations (NOTCH1m): 23/1333 (2%), SF3B1m: 33/897 (4%), MYD88m:
23/556 (4%)]. Borderline mutated IGHV genes (germline identity, GI: 97-
97.99%) were expressed by 101 cases (7%). Thirty-three (2.5%) and 26 (2%)
patients were assigned to stereotyped subsets #4 (IGHV4-34/IGKV2-30) and
#2 (IGHV3-21/IGLV3-21), respectively. All the aforementioned parameters
were evaluated for their impact on TTFT, using univariate regression analysis.
As expected, Binet stage C at diagnosis emerged as the most powerful mark-
er (HR: 9.44, 95% CI, 7.45-11.97, p<0.0001). Among the remaining cases
(Binet A/B), representing 96% of the cohort, the following parameters were
significantly associated with shorter TTFT: Binet B (HR: 7.35, 5.51-9.81,
p<0.0001), subset #2 membership (HR: 4.24, 2.32-7.76, p=0.0001), CD38+
(HR: 2.62, 1.98-3.50, p<0.0001), TP53abn (HR: 2.56, 1.64-4, p=0.0003), +12
(HR: 1.75, 1.27-2.41, p=0.002), male gender (HR: 1.52, 1.2-1.9, p=0.004).
In contrast, a trend for favorable outcome was observed for subset #4 mem-
bership (HR: 0.43, 0.16-1.18, p=0.06). Taking into consideration the above
HRs as well as median TTFT, we defined 4 groups among Binet A/B patients
(n=934) with different TTFT (Figure 1): (i) high risk (n=88, 9%): Binet B or
subset #2 membership (median TTFT: 2.1 years, 65% and 85% probability
of treatment initiation (TI) at 5 and 10 years from diagnosis, respectively); (ii)
intermediate risk (n=199, 22%): Binet A and occurence of one or more of:
CD38 expression/TP53abn/+12 (median TTFT: 12 years, 33% and 45% TI
at 5 and 10 years, respectively); (iii) low risk (n=619, 66%): Binet A with no
CD38+/TP53abn/+12 (median TTFT: not yet reached, 15% and 25% TI at 5
and 10 years, respectively); and (iv) very low risk (n=28, 3%): subset #4
membership (median TTFT not yet reached, 0% and 10% TI at 5 and 10
years, respectively).
Figure 1. Kaplan-Meier curves for time-to-first-treatment (TTFT) in M-CLL.
Summary and Conclusions: We report a simple prognostic index for M-CLL
capable of identifying patients who will experience short TTFT as well as
those who will probably never require treatment, applicable even within early
clinical stage CLL. At the ends of the clinical spectrum described by this novel
index lie stereotyped subsets #2 (aggressive) and #4 (indolent). This further
highlights the importance of distinct BcR IG configuration, likely linked to dis-
tinct immune signaling, for CLL ontogeny and evolution and indicates that
subclassifying M-CLL based on stereotypy is relevant in the context of every-
day routine practice.
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Background: Idelalisib (IDELA) (Zydelig™) is a first-in-class PI3Kδ inhibitor
approved in combination with rituximab for patients with relapsed CLL.
Aims: To determine the safety and clinical activity of idelalisib in combination
with 6 commonly used chemo-immunotherapeutic agents for the treatment of
R/R CLL.
Methods: Patients with R/R CLL were treated continuously with 150 mg BID
oral IDELA and a limited number of cycles (C) of CIT to evaluate safety and
efficacy of combination regimens. Patients could enroll in extension study after
48 weeks. Responses were evaluated by published criteria (Hallek 2008; Che-
son 2012).
Results: 114 patients (37F/77M) median age 65 (range 41-87) years enrolled
with: extensive prior therapies (median: 3, range 1-9), refractory disease (51%),
high-risk Rai (60%), del17p/TP53 mutation (29%), del11q (13%), unmutated
IGHV (79%). Median exposure was 14.6 (range 0-49) months. 61 patients (54%)
enrolled in extension study. 21 (34%) were continuing on study. Most common
and select AEs independent of causality (any Grade/Gr ≥3): diarrhea/colitis
(52%/19%), pyrexia (45%/4%), cough (37%/1%), nausea (29%/1%), fatigue
(32%/4%), pneumonia (23%/15%), dyspnea (22%/3%), rash (21%/4%), pneu-
monitis (4%/4%). AST/ALT elevation Gr ≥3 was seen in 12%. Most common rea-
sons for discontinuation were AEs (25%) or PD (25%). 2 patients discontinued
due to AST/ALT elevation, 1 due to Richter’s transformation. 20 (18%) deaths
were reported on study; 6 patients experienced PD before death. ORR was
82.5% in all patients, 70% in patients with del17p/TP53 mut, and 87% among
patients without. SD/PD was reported in 10%/3%. Median overall PFS was 26.1
months, 20.3 months for patients with del17p/TP53 mut, and 36.8 months for
patients without. Median OS for all patients or patients with del17p/TP53 mut
was not reached. Estimated OS at 36 months was 73.1% for all patients, 57.3%
for patients with del17p/TP53, and 78.3% for patients without.
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Tabella 1.
Summary and Conclusions: IDELA in combination with CIT shows a man-
ageable safety profile without increased toxicities and has substantial clinical
activity in heavily pretreated, refractory, and high-risk CLL including presence
of del17p/TP53 mutation. Phase 3 trials of IDELA with O or BR in patients with
R/R CLL are ongoing (NCT01659021, NCT01732926).
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Background: Fludarabine (F), cyclophosphamide (C) and rituximab (R) gave
superior progression free (PFS) and overall survival (OS) versus (vs) FC in the
CLL8 Study.
Aims: We aimed to assess the safety, tolerability and efficacy of FCR based
therapy in elderly patients (pts). 
Methods: Previously untreated pts with CLL aged≥65 were randomised to one
of 3 therapy arms: (i)FR5: F 24mg/m2po D1-5 + R (375mg/m2cycle 1,
500mg/m2cycles 2-6) iv D1, (ii)FCR3: F 24mg/m2po and C 150mg/m2po D1-3
+ R iv D1 or (iii)FCR5: F 24mg/m2po+ C 150mg/m2po D1-5 + R iv D1 all at 4
weekly intervals for an intended 6 cycles. Cycles could be delayed up to 2
weeks for grade 3+ toxicity, and if unresolved by 2 weeks were off study.
Results: The eligible cohort was 116. Median age was 71 (range 65-82) years; 78
males (67%) and 39 females (33%). Binet stage was progressive A-19 (16.2%), B-
55 (47.0%), C-43 (36.8%). Response and grade 3+ toxicity data are shown in the
table. All 6 protocol cycles were completed in 69% but less on FCR5 44% vs FR5
89% and FCR3 76% (p<0.001). FCR3 vs FR5 was not statistically significant (NSS).
Reasons for non-completion were death, intercurrent illness, withdrawn consent,
stable or progressive disease, unacceptable toxicity and doctor decision.
Tabella 1.
Toxicity was lower with FR5 compared to FCR3 and FCR5 (p=0.004) (FCR3
vs FCR5 NSS). Dose delay occurred in 43 pts (37%): FR5 32%, FCR3 34%,
FCR5 44% (p=0.653), but early cessation due to toxicity was more common
with FCR5 (p<0.001). 11/13 pts stopping early due to toxicity received ≥3 cycles
of therapy (mean 3.5). ITT full dose FCR5 CR rates were significantly higher
(79%), but also higher rates of incomplete marrow recovery, haematological
toxicity and earlier cessation of therapy.
Summary and Conclusions: Final analysis shows oral FCR therapy is gen-
erally safe and well tolerated in CLL pts aged ≥65 years requiring first-line treat-
ment, when early stopping is utilised if prolonged toxicity occurs. Toxicity was
mostly hematological and manageable. Response rates were very high with
ORR of 95% and 97% and CR rate of 44% and 45% with reduced dose and
full dose FCR. Full dose FCR is highly effective and while cessation due to tox-
icity appears important, a dose intensity effect may exist. Dose reduced FCR
provides a balance of effectiveness, safety and tolerability as first-line therapy
for fit elderly pts.
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Background: Somatic hypermutation (SHM), is an important process to
increase the affinity of immunoglobulin molecules. The presence of ≥2% SHM
is an important prognostic factor for CLL patients. The current method used to
determine SHM status requires two steps: a PCR/capillary electrophoresis (CE)
to detect clonality, followed by Sanger sequencing. This multistep approach is
labor intensive and time consuming. We developed the next generation
sequencing (NGS) LymphoTrack® assays to address these limitations. Here
we report the results of a pilot study of SHM detection using both the NGS and
CE/Sanger approaches from 50 anonymized, blinded CLL samples.
Aims: to assess the clinical performance of NGS SHM assay
Methods: LymphoTrack® SHM assays have been developed for both the MiS-
eq and PGM NGS platforms. Both assays and NGS platforms were used in
this study. The MiSeq SHM Assay employs two master mixes. One amplifies
genomic DNA between the upstream leader (VHL) region and the downstream
joining (J) region of the IGH gene. The other amplifies from the framework1
(FR1) to J region. Amplicon products from VHL/J primers span the entire vari-
able (V) region. Amplicon products from FR1/J primers encompass portions of
the FR1 region to the downstream J region. The PGM Assay only employs
FR1/J primers. The proprietary V and J consensus primers were designed and
adapted to enable the PCR products to be sequenced on either the MiSeq or
PGM platform. Multiplexed PCR was followed by amplicon purification using
the AMPureXP PCR system. Purified equimolar amounts of amplicons were
pooled to form a library which was loaded onto the MiSeq or PGM. The
sequencing data was analyzed using Invivoscribe LymphoTrack® bioinformatics
software, generating frequency distributions, DNA sequences, V-J assignment
and usage, and SHM status. DNA from clinical samples was obtained from
Memorial Sloan-Kettering Cancer Center.
Results: The analytical performance of the SHM assays was evaluated using
contrived samples, with known V-J rearrangement and SHM status. For limit of
detection (LOD), limit of blank (LOB), linearity, and precision and reproducibility
(P/R) the assay demonstrated excellent linearity (R2>0.99), sensitivity of 2.5%
for clonality, and reproducibility (<20% CV). In addition, good concordance
(R2>0.99) was demonstrated between the NGS assay and the traditional
method of using gel extraction and Sanger sequencing in evaluating the SHM
status of cell line DNAs. The clinical performance of the LymphoTrack® SHM
assays was evaluated on 50 CLL samples that have also been tested using
the traditional CE/Sanger method. NGS assays were able to detect all 50 sam-
ples while 2 samples were non-evaluable by CE/Sanger method and were
excluded from comparison. Between the LymphoTrack® FR1 MiSeq and
CE/Sanger, 100% concordance has achieved for SHM status with linear regres-
sion of R2=0.91 for SHM rates. The LymphoTrack SHM FR1 MiSeq assay is in
100% agreement with the LymphoTrack SHM FR1 PGM assay for both SHM
status and rates. Only one discordant sample between the FR1 MiSeq and
Leader MiSeq for SHM status, resulting a 98% concordance for SHM status
and linear regression of R2=0.98 for SHM rates.
Summary and Conclusions: A comprehensive NGS assay has been devel-
oped for both MiSeq and PGM platforms that identifies clonal IGH V-J
rearrangements, associated specific V-J region DNA sequences and deter-
mines the SHM status in CLL specimens. This NGS assay has demonstrated
excellent clinical concordance for determining SHM status with the traditional
method.
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Background: The randomized phase III PROLONG study in 474 relapsed
CLL patients in remission after 2nd or 3rd line induction treatment has demon-
strated a statistically significant improvement in PFS by ofatumumab main-
tenance treatment as compared to observation: 29.4 months versus 15.2
months respectively (HR=0.50, p<0.0001; van Oers, 2014).
Aims: However, given that a watch and wait strategy is the current standard
of care and patients were treated for up to 24 months with ofatumumab main-
tenance, it is important to assess the impact of maintenance therapy on
health related quality of life (HRQoL).
Methods: During the PROLONG trial, the QLQ-C30 and the QLQ-CLL16
patient questionnaires were administered in all pre-progression patients dur-
ing both treatment and during the follow up stage. Primary endpoints in
patient reported outcomes were health related quality of life as reported by
the QLQ-C30 questionnaire and a B-symptom index including patient report-
ed symptoms of fatigue, night sweats, temperature changes and weight loss
as reported by the QLQ-C30 and QLQ-CLL16 questionnaires.
Results: In HRQoL, there was no statistical difference (p=0.14) or clinically
relevant difference between the arms at any time point measured during
treatment with the ofatumumab arm demonstrating a mean 0.2 point decline
in HRQoL on a scale of 0-100 and the observational arm demonstrating a
mean 1.9 point decline in HRQoL. The B symptom index demonstrated a
minor worsening across all B symptoms in patients in the observation arm
(p=0.002): during treatment with ofatumumab no change occurred in B symp-
toms (0.0 on a 0-100 scale) whereas in the observation arm there was a 2.8
point worsening. There was a trend to a difference between the arms as to
the question about worry for future health, where patients on ofatumumab
reported to be less likely to worry (4 point difference on 0-100 scale, p=0.06).
Summary and Conclusions: These results clearly demonstrate that ofatu-
mumab maintenance therapy does not negatively affect HRQoL. At present
it is not known whether the observed differences in the B symptom index
and future health score are based on the psychological effects of being treat-
ed instead of watchful waiting, or reflect improved quality of remission upon
ofatumumab maintenance.
Reference: Van Oers, M, et al. (2014) Ofatumumab (OFA) Maintenance pro-
longs PFS in Relapsed CLL: PROLONG Study Interim Analysis Results.
Blood (ASH Annual Meeting Abstracts),124. Abstract 21
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Background: Patients with chronic lymphocytic leukaemia (CLL) experience
disease-related symptoms including fatigue, dyspnea, abdominal pain, weight
loss, lymphadenopathy and sleep disturbances. Robust data on health-relat-
ed quality of life (HRQL) in the form of utility scores for CLL patients are,
however, scarce. Longitudinal EQ-5D data were collected in a phase III ran-
domized controlled trial of idelalisib with rituximab versus rituximab monother-
apy for patients with previously treated CLL unsuited to cytotoxic therapy
(Study 116, ClinicalTrials.gov Identifier: NCT01539512). These data can pro-
vide further insight into the health-related quality of life (HRQL) of CLL
patients.
Aims: This study aims to analyse longitudinal EQ-5D data from Study 116 to
better understand the HRQL of previously treated patients receiving further
treatment for CLL, and more specifically to gain insight on the HRQL profile
associated with idelalisib with rituximab for previously treated CLL.
Methods: EQ-5D questionnaires were administered in Study 116 at baseline
and at regular intervals: Weeks 2, 4, 6, 8, 12, 16, 20, 24, 30, 36, 42, 48,
every 12 weeks thereafter prior to disease progression, and at the end of
treatment. A generalised estimation equation (GEE) regression was carried
out to determine absolute HRQL scores across treatment arms and whether
there was a difference in quality of life between idelalisib with rituximab and
rituximab monotherapy while patients were receiving treatment. GEE regres-
sion was used as this method accounts for potential autocorrelation of patient
quality of life scores.
Results: Compliance rates for EQ-5D completion were good (>70%) across
all time points and in total there were 1,667 observations over both treatments
arms. Table 1 shows estimated mean HRQL estimates for patients receiving
treatment in Study 116, across treatment arms. Estimated utility was high
across treatment arms, and a significant treatment effect was found
(p=0.031), with patients receiving idelalisib with rituximab having a better
quality of life than those receiving rituximab monotherapy (absolute difference
of 0.0652).
Tabella 1. EQ-5D estimates for patients receving treatment in Study 116
Summary and Conclusions: The tolerability and efficacy profile of idelalisib
with rituximab may provide previously treated CLL patients with high quality
of life, both in absolute terms and in relation to treatment with rituximab
monotherapy.
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Background: MD Anderson Cancer Center (MDACC) nomogram and prog-
nostic index is an easy prognostication system in chronic lymphocytic
leukemia (CLL) because it depends on routinely available parameters (Blood
2007; 109: 4679). External validation of this prognostication system has been
done recently (Br J Haematol 2014; 167: 224). Lactate dehydrogenase (LDH)
level has prognostic value in many lymphoid neoplastic disorders. However
to the best of our knowledge no routinely used prognostication system in
CLL uses the LDH level.
Aims: In this study we aimed to test the prognostic value of MDACC scoring
system in a multicenter CLL cohort and to investigate if incorporation of LDH
could improve the MDACC index.
Methods: All previously untreated CLL patients who were admitted between
1997 and 2014 with available lab and clinical data for MDACC prognostic
scoring and survival analysis and a baseline serum LDH level were included
in the study. Patients with comorbidities affecting survival expectation and/or
serum LDH level were eliminated. Survival analyses were done according to
the Kaplan Meier method. Cox regression analysis was done to determine if
MDACC index and LDH were independently associated with survival. If both
parameters were independently associated with survival, deriving an inte-
grated scoring method depending on Cox regression analysis odds ratios of
the MDACC index and LDH was intended. All statistical tests were done
using SPSS v17.
Figure 1. MDACC-LDH scores corresponded to survival durations.
Results: The cohort was composed of 326 patients (207 male, 119 female;
median age [range] =63 [31-93], median f/u duration=53.5 months). The
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patients in low, intermediate and high MDACC index categories at diagnosis
composed 16%, 68%, and 16% of the cohort, respectively. 112 (36.6%)
patients had an elevated LDH level at diagnosis. Both MDACC index (not
reached, 131.8 [14.9, 102.5-161], and 62.1 [3.8, 54.5-69.6] months median
[standard error, 95% confidence interval] survival durations in low, interme-
diate and high risk groups respectively, p=.000) and LDH level (not reached
versus 81.1 [12.7, 56-106.1] months, p=.000) were very closely and inde-
pendently (Exp(B)=2.59, p=.000 for MDACC score and Exp(B)=2.63, p=.000
for LDH) associated with overall survival. All 3 MDACC risk groups could be
effectively subdivided into 2 different prognostic subgroups depending on
associated normal or increased LDH level. Depending on these results 0, 1
and 2 points were assigned to the MDACC low, intermediate and high risk
groups, respectively. Normal and high LDH levels corresponded to 0 and 1
points. The cumulative MDACC-plus-LDH (MDACC-LDH) score divided the
patients into 4 distinct prognostic groups. MDACC-LDH scores 0 (17% of the
patients), 1 (48%), 2 (26%), and 3 (9%) corresponded to median (standard
error, 95% confidence interval) survival durations of not reached, 135.8
(incomputable), 122 (24.1, 74.7-169.3), and 33 (22.6, 0-77.4) months, respec-
tively (p=.000) (Figure 1). MDACC-LDH scores 1 and 2 could be merged
together for practical reasons leading to low (0 points), intermediate (1 or 2
points) and high (3 points) MDACC-LDH score levels.
Summary and Conclusions: In conclusion, MDACC index is a successful
prognostic index in treatment-naïve CLL. Serum LDH level can divide each
MDACC prognostic group into two different subgroups. MDACC index and LDH
can be successfully incorporated into a new score.
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Background: Hairy cell leukemia is a distinct B cell neoplasm with character-
istic morphological and immunophenotypic features. The somatically acquired
V600E mutation of the BRAF gene has been recently described as a molecular
marker of hairy cell leukemia. In those cases which are BRAF negative muta-
tions in MAP2K1 and RNA spliceosome encoding gene U2AF1 have recently
been described.
Aims: Identification of baseline frequencies of BRAFV600E, MAP2K1 and RNA
spliceosome encoding gene U2AF1 in a large series of HCL in our centre.
Methods: Genomic DNA was extracted from stained bone marrow aspirate
smears of hairy cell leukemia patients. DNA was subjected to a modified ARMS
PCR technique followed by capillary electrophoresis on an ABI3500 genetic
analyzer. The PCR was designed to amplify a 200bp control product, a 142bp
BRAF V600E specific amplicon and a 92bp wild type specific amplicon. Exons2
& 3 of MAP2K1 and exon2 of U2AF1 genes were sequenced in BRAF negative
cases by Sanger sequencing.
Results: Majority of patients 89.1% (41/46) with a morphological and
immunophenotypic diagnosis of HCL were positive for BRAF V600E mutation.
Of the five patients that were BRAF negative a single patient harboured P124L
mutation in exon2 of MAP2K1 gene. This mutation has been described in pap-
illary carcinoma of the thyroid but not in patients of HCL.
Summary and Conclusions: Conclusions: Our findings point that analysis
of BRAF mutations is a potential diagnostic tool to distinguish HCL from other
B-cell lymphomas with similar features such as the HCL variant and splenic
marginal-zone lymphoma. This distinction is clinically relevant, since HCL, but
not HCL-like disorders, responds to therapy with interferon or purine analogues.
Summary: BRAFV600E mutation present in 89.1% patients of HCL in our
cohort represents a reliable molecular marker for the accurate diagnosis of
hairy cell leukemia.
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LLC-LENAR-08 A PHASE I/II STUDY LENALIDOMIDE-RITUXIMAB IN
RELAPSE/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
A. De La Fuente1,* M. Gonzalez2, P. Giraldo3, F. de la Cruz4, M.J. Terol5, 
J.A. Perez Simon4, G. Rodriguez6, C. Montalban1, J.F. Toas7, R. de Oña1
1Hematology, MD Anderson CC Madrid Spain, Madrid, 2Hematology, H. U.
Salamanca, Salamanca, 3Hematology, H. U. Miguel Servet, Zaragoza, 4Hema-
tology, H. U. Virgen del Rocio, Sevilla, 5Hematology, H. U. Clinico de Valencia,
Valencia, 6Hematology, H. U. Reina Sofia Cordoba, Cordoba, 7Hematology,
Bupa-SLA Madrid, Madrid, Spain
Background: Phase II studies showed lenalidomide monotherapy is active in
relapsed and refractory CLL. A synergistic activity between rituximab and
lenalidomide against CLL has been suggested and a previous study has eval-
uated the combination of lenalidomide and rituximab in this population with
encouraging results (J Clin Oncol, 2012,31: 584), but the optimal dose and
schedule for this combination remains unknown.
Aims: The endpoint in phase I of this study is to define the optimum dose of
lenalidomide in combination with rituximab in R/R CLL patients. The endpoint in
phase II is to evaluate effectiveness and toxic profile of the resulted schedule.
Methods: We carried out a multicenter phase I/II study on R/R CLL patients,
in the dose finding phase we started with a continuous lenalidomide daily dose
of 2,5mg and rituximab (375mg/m2 cycle 1 and 500mg/m2 cycles 2-6/28 days)
with cohorts of 3 patients (if no DLT move to a higher dose; if one DLT occurred
in the cohort expand 3 more patients). In the second phase we evaluated effi-
cacy (NCI WGC criteria), toxic profile (CTCAE v3.0 scale) OS and TTP with
Kaplan Meier. Study registered in ClinicalTrials.gov:NCT01185262.
Results: We reported our completed Phase I/II study, 29pt from 7 Spanish
sites were enrolled, 4 of them were screening failures because criteria not ful-
filled, and 5 withdrew consent to participate before starting treatment. Median
age 75 yr (45-86), male/female 11/9, ECOG 0/1/2: 7/12/1, median time from
diagnosis 7.8 yr, median number of previous lines 2 (1-4) all but 2 pt had
received fludarabine. In phase I the MTD of lenalidomide was 15 mg. Effec-
tiveness: In phase II ORR 7 pt (53%), all PR, estimated TTP 15.4 months, esti-
mated OS 21.9 months. Toxicity: 34 SAE were reported, in 6 cases treatment
was discontinued definitively (infection 4 pt, progressive multifocal leukoen-
cephalopathy 1pt, amyotrophic lateral sclerosis 1pt). Grade 4 neutropenia was
the main adverse event associated with the regimen.
Summary and Conclusions: In our experience 15 mg is the MTD of daily
lenalidomide in combination with rituximab every 28 days in R/R CLL patients.
The combination was effective and well tolerated with a 53% ORR and 21.9
months estimated OS.
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IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY
TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC
LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED,
DOUBLE-BLIND, PHASE 3 STUDY
P. Cramer* A. Chanan-Khan1, F. Demirkan2, G. Fraser3, R. Santucci Silva4, 
H. Pylypenko5, S. Grosicki6, A. Janssens7, A. Pristupa8, J. Mayer9,
M.S. Dilhuydy10, J. Loscertales11, N. L. Bartlett12, A. Avigdor13, S. Rule14,
S. Sun15, M. Mahler15, M. Salman15, A. Howes16, M. Hallek17
1Mayo Clinic, Jackonville, FL, United States, 2Dokuz Eylul University, Izmir,
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da, 4Hemomed Oncologia e Hematologia, IEP SÃO LUCAS , São Paulo,
Brazil, 5Department of Hematology, Cherkassy Regional Oncological Center,
Cherkassy, Ukraine, 6Department of Cancer Prevention, Faculty of Public
Health, , Silesian Medical University, Katowice, Poland, 7Universitaire Zieken-
huizen Leuven, Leuven, Belgium, 8Regional Clinical Hospital, Ryazan, Russ-
ian Federation, 9Dept. of Internal Medicine, Hematology and Oncology, Uni-
versity Hospital Brno, Jihlavska, Brno, Czech Republic, 10Hopital Haut Lev-
eque, Bordeaux, Pessac, France, 11Hematology Dept, Hospital Universitario
La Princesa, IIS-IP, Madrid, Spain, 12Siteman Cancer Center, Washington
University School of Medicine , St. Louis, MO, United States, 13Division of
Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center,
Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-
Aviv, Israel, 14Department of Haematology, Derriford Hospital, Plymouth, Unit-
ed Kingdom, 15Janssen Research & Development, LLC, Raritan, NJ, United
States, 16Janssen Research & Development, High Wycombe, United King-
dom, 17Department I of Internal Medicine and Center of Integrated Oncology,
University of Cologne, Cologne, Germany
Background: Despite considerable therapeutic advances, virtually all patients
with CLL/SLL will relapse and bendamustine/rituximab (BR) is often used in
this case. Ibrutinib is a first-in-class, once-daily, oral covalent inhibitor of Bruton’s
tyrosine kinase, an essential enzyme in the B-cell receptor signaling pathway
and a key mechanism promoting disease progression in B-cell malignancies.
Clinical trials of ibrutinib have demonstrated a favourable benefit/risk profile in
several B-cell malignancies, including previously-treated CLL, leading to the
approval of ibrutinib single agent therapy in multiple countries.
Aims: The international, multicentre, double-blind, placebo-controlled phase 3
HELIOS study evaluated the efficacy and safety of ibrutinib in combination with
BR (ibrutinib+BR) compared with placebo plus BR (placebo+BR) in patients
with previously treated CLL/SLL. The preplanned interim analysis reported here
showed that the primary end point was met, upon which the Independent Data
Monitoring Committee recommended unblinding the study. 
Methods: Patients were randomized 1:1 to receive BR (≤6 cycles) with either
ibrutinib (420 mg daily) or placebo. Stratification factors included whether the
patient was refractory to purine analogs and the number of prior therapies.
Patients with del17p (>20% of cells) were excluded. The primary end point was
independent review committee (IRC)-assessed progression-free survival (PFS).
Secondary end points included IRC-assessed overall response rate (ORR) and
overall survival (OS). 
Results: In total, 578 patients were randomized (289 per arm); median age
was 64 yrs; 38% had Rai Stage III/IV disease; median of 2 prior therapies. Six
cycles of BR were completed in 81.9% and 77.4% of patients in the ibrutinib
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and placebo arms, respectively. At a median follow-up of 17.2 months, IRC-
assessed PFS was significantly longer with ibrutinib+BR vs placebo+BR (medi-
an not reached vs 13.3 months; HR: 0.203, 95% CI: 0.150-0.276, P<0.0001);
PFS results were consistent across all subgroups. IRC-assessed ORR was
82.7% vs 67.8% (P<0.0001) and the rate of complete response/complete
response with incomplete marrow recovery (CR/CRi) was 10.4% vs 2.8% with
ibrutinib+BR vs placebo+BR, respectively. Investigators reported ORRs of
86.2% vs 68.9%, P<0.0001, and rates of CR/CRi of 21.4% vs 5.9%, respec-
tively. Median OS was not reached (HR 0.628: 95% CI 0.385, 1.024; P=0.06).
Ninety patients (31%) in the placebo+BR arm with confirmed progressive dis-
ease crossed over to receive ibrutinib, as permitted per the protocol. The inci-
dence of most adverse events (AEs) was similar between arms. The most
common all-grade AEs with ibrutinib+BR and placebo+BR respectively were
neutropenia (58.2% vs 54.7%) and nausea (36.9% vs 35.2%); the most com-
mon grade 3/4 AEs were neutropenia (53.7% vs 50.5%) and thrombocytopenia
(15.0% each arm). Rates of grade 3/4 atrial fibrillation were 2.8% and 0.7%,
and major hemorrhage were 2.1% and 1.7%. 
Summary and Conclusions: The addition of ibrutinib to BR significantly
reduced the risk of progression or death by 80% compared with placebo+BR.
The ORR was also significantly improved with ibrutinib+BR vs placebo+BR.
Safety of ibrutinib+BR was consistent with the known profiles for ibrutinib and
for BR. The data further support ibrutinib as an important treatment option for
patients with previously treated CLL/SLL.
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OFATUMUMAB (O) IN COMBINATION WITH FLUDARABINE (F) AND
CYCLOPHOSPHAMIDE (C) (OFC) VS. FC IN PATIENTS WITH RELAPSED
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE PHASE
III STUDY COMPLEMENT 2
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Silesian Medical University, Katowice, 3Department of Hematology, Institute of
Hematology and Transfusion Medicine, Warsaw, Poland, 4Department of Med-
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Background: The addition of anti-CD20 monoclonal antibody (mAb) ritux-
imab to the FC chemotherapy combination has shown improved response
rates, progression free survival, and overall survival compared to FC alone
in previously untreated and relapsed CLL. Ofatumumab is a human anti-
CD20 mAb that is more effective than rituximab when used as monotherapy
in patients with CLL that is refractory to fludarabine and alemtuzumab, and
has shown activity in patients with rituximab-refractory CLL. Ofatumumab
has also shown activity in combination with chlorambucil and bendamustine
in patients with previously untreated CLL, as well as maintenance monother-
apy in patients with relapsed CLL.
Aims: This report describes the clinical effect of ofatumumab in combination
with fludarabine and cyclophosphamide (OFC) vs fludarabine and cyclophos-
phamide (FC) alone in a randomised phase III study in patients with relapsed
CLL (Study COMPLEMENT 2; OMB110913).
Methods: Patients with relapsed CLL (progressive disease after ≥6 month
response to at least one prior therapy) who required therapy per the 2008
NCI-WG guidelines were randomised (1:1) to receive either OFC or FC. F
and C were administered as intravenous (IV) infusions (F: 25mg/m2, Days 1-
3 every 28 days for 6 cycles; C: 250mg/m2, Days 1-3 every 28 days for 6
cycles). O was also administered as IV infusions (Cycle 1: 300mg day 1 and
1000mg day 8, subsequent cycles: 1000mg at day 1). O premedication includ-
ed acetaminophen, antihistamine and glucocorticoid. The primary endpoint
was progression-free survival (PFS) assessed by an Independent Review
Committee (IRC) and secondary endpoints included overall response rate
(ORR), time to next CLL therapy (TNT), overall survival (OS), and safety.
Results: 365 patients from 18 countries were randomized, 359 received
treatment. Baseline demographics and disease characteristics were balanced
between the two arms. Median age was 61 years. All Binet stages were rep-
resented (A 16%, B 55%, C 28%), and 6% of patients had 17p deletion. Medi-
an duration of treatment for both arms was 6 cycles. PFS assessed by the
IRC was prolonged in the OFC arm (28.9 months) compared to the FC arm
(18.8 months, HR=0.67 [95%CI=0.51, 0.89]; p=0.0036). The ORR (95% CI)
by IRC assessment was 84% (77%, 89%) for OFC and 68% (60%, 74%) for
FC (p=0.0004). Median OS was 56.4 months in the OFC arm and 45.8
months in the FC arm (HR=0.78; [95%CI=0.56, 1.09]; p=0.1404) with a medi-
an follow-up of 34 months. Grade ≥3 AEs from start of treatment to 60 days
post last dose occurred in 74% of patients given OFC and in 69% of patients
given FC. Grade ≥3 infusion reactions were reported in 9% of patients given
OFC and in 3% given FC. Grade ≥3 cytopenias in both arms included neu-
tropenia (OFC: 53%; FC: 39%), thrombocytopenia (OFC: 14%; FC: 25%),
and anaemia (OFC: 8%; FC: 12%). Grade ≥3 infections were reported in
19% of patients given OFC and in 14% given FC.
Tabella 1. Baseline Characteristics, Time to event Endpoints and Response.
Figure 1. Kaplan-Meier Graph of IRC-assessed Progression Free Survival.
Summary and Conclusions: The results of this randomised study of ofatu-
mumab added to FC demonstrate clinically important improvements in efficacy
compared with FC alone, and the combination of OFC showed a manageable
side effect profile in patients with previously treated CLL.
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NON GENOMIC LOSS OF FUNCTION OF TUMOR SUPPRESSORS IN CML:
BCR-ABL PROMOTES P53 NUCLEAR EXCLUSION THROUGH THE
INTERACTION WITH IKB-ALPHA
S. Crivellaro1,* C. Panuzzo1, G. Carrà1, A. Volpengo1, F. Crasto1, E. Gottardi1,
A. Guerrasio1, G. Saglio1, A. Morotti1
1Clinical and Biological Sciences, University of Turin, Orbassano, Italy
Background: The function of tumor suppressors (TS) can be tightly controlled
by various non-genomic mechanisms, such as epigenetic silencing, regulation
by non-coding RNAs and post translational modifications. The identification of
mechanisms that cause non genomic loss of function of TS could have tremen-
dous consequences from the therapeutic standpoint. Targeting pathways that
inactivates TS could indeed promote the re-activation of a specific tumor sup-
pressor with strong biological consequences. IκBα is commonly known as the
inhibitor of the transcription factor (TF) NFκB, which in turn regulates the tran-
scription of many genes involved in immune and inflammatory responses, as well
as genes regulating cell proliferation and survival, including IκBα itself. IκBα is
also able to physically interact with the tumor suppressor protein p53. In the 20%
of blast crisis Chronic Myeloid Leukemia (CML) patients, p53 is mutated, while it
was never found mutated/deleted during the chronic phase of the disease.
Aims: The aim of this study was to demonstrate that BCR-ABL promotes the
formation of a ternary complex with IκBα and p53 in the cytoplasm causing
loss of p53 tumor suppressive nuclear pool.
Methods: HEK293T and HeLa cells transfected with IκBα expression vector
alone or in combination with Bcr-Abl expression vector and primary cells col-
lected from CML patients at the diagnosis were analysed by immunofluores-
cence, immunoprecipitation and western blot in order to evaluate IκBα and p53
protein levels, interactions and cellular compartmentalization. Furthermore,
kinase assays have been performed with purified proteins to examine the phos-
phorylation status of IκBα. CML/healthy subjects and transfected cell line mRNA
were analysed for NFKBIA (IκBα) and p21 expression by Real-TimePCR
Results: While assessing the cellular compartmentalization of IkBα in BCR-
ABL transfected HeLa cells, we observed that IκBα is expressed mostly in the
cytosol, while in parental HeLa cells IκBα showed a cyto/nuclear localization.
Similarly, primary CML cells are characterized by IκBα expression exclusively
in the cytosol. Using BCR-ABL transfected cells, we demonstrate that BCR-
ABL physically interacts with IκBα through the BCR portion of the chimeric pro-
tein BCR-ABL. in vitro, BCR-ABL does not appear to directly phosphorylate
IκBα on tyrosine residues. Next, we investigated whether BCR-ABL regulates
IκBα expression and stability. RealTimePCR analysis does not show IκBα
mRNA expression differences between normal and CML BM, and between
empty and BCR-ABL transfected cell. Incubation of BCR-ABL positive cells
with proteasome inhibitor MG-132 shows that BCR-ABL regulates IκBα protein
stability at a post-translational level. IκBα is known to negatively regulate the
NFkB pathway through the interaction with p65 subunit. Importantly, it was also
reported that IκBα can interact with the p53, with consequent inhibition of some
of its functions. Interestingly, here we observed that in CML primary cells, p53
is also delocalized into the cytosol and that IκBα is physically bound to both
p53 and BCR-ABL in the cytosol of CML cells. The delocalization of p53 is
associated with impairment of its function. The p21 mRNA levels, a downstream
gene of p53, are indeed markedly reduced in CML primary cells, compared to
normal bone marrow.
Summary and Conclusions: In this work, we demonstrate that BCR-ABL pro-
motes p53 nuclear exclusion through the interaction with IκBα. Our data suggest
that expression of BCR-ABL could promote non genomic loss of function of the
tumor suppressor p53.
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TRANSCRIPTION FACTOR MEF2C IS UPREGULATED DURING CML
DISEASE PROGRESSION AND INHIBITS C/EBPΑ EXPRESSION
S. Chakraborty1,* S. Agatheeswaran1
1Institute of Life Sciences, Bhubaneswar, India
Background: Although tyrosine kinase inhibitors (TKI’s) have revolutionized
CML therapy, the disease progresses to advanced blast crisis which is charac-
terized by differentiation arrested blasts. The progression primarily happens
due to the presence of secondary mutations and/or C/EBPα down regulation.
MEF2C belongs to the MEF2 (Myocyte enhancer factor) family of proteins
which comes under MADS–box group of transcription factors. MEF2C expres-
sion is abundant in CMP (Common Myeloid Progenitors) and gradually decreas-
es with granulocytic commitment and differentiation. Earlier it was shown that
C/EBPα regulates the myeloid specific miRNA-223 and we have recently shown
that miRNA-223 negatively regulates MEF2C in CML.
Aims: Given that MEF2C antagonizes myeloid differentiation it may repress the
C/EBPα transcription and play a significant role in CML disease progression.
Methods: Affymetrix Genechip® Human exon 1.0 ST arrays (Affymetrix, Inc,
USA) were used for the hybridization. Blood samples were collected from CML-
BC patients with their consent and the study was approved by Institutional
human ethicalcommittee. RQ-PCR was performed in Light cycler 480 II with
LC 480 SYBR Green master mix reagent. ANOVA and correlation statistics
was performed by using Graphpad Prism software 5.0.
Results: MEF2C is a confirmed target of miR-223 and its expression was neg-
atively correlated with miR-223 expression in CML samples. To identify the
genes targeted by MEF2C, microarray experiment was performed in K562 cells
treated with scrambled and MEF2C siRNA. Among the differentially expressed
genes, a total of 21 genes which are known to have a role in myeloid differen-
tiation were detected using GO analysis. Four transcription factors including
the C/EBPα were among the 21 genes. C/EBPα up regulation was validated
by RQ-PCR in the cells. To understand the relationship between MEF2C and
C/EBPα in CML, we deduced their expression pattern from publicly available
Radich CML dataset GSE4170. We observed the existence of a negative cor-
relation between MEF2C and C/EBPα and found that MEF2C expression was
significantly up regulated whereas C/EBPα expression was significantly down
regulated with CML disease progression. C/EBPα mRNA expression was also
up regulated in imatinib treated 32D BCR-ABL cells. This shows that C/EBPα
can also be regulated at mRNA level in CML progression. MEF2C expression
also showed a positive correlation with the blast count, the clinical parameter
which is used to determine the stage of the disease. We have also isolated
peripheral blood mononuclear cells (PBMC) from a CML-BC patient and the
blast cells were treated ex-vivo with 2µM imatinib. Imatinib treatment was able
to reduce MEF2C protein and up regulate C/EBPα and CSF3R mRNA expres-
sion. We found the existence of a MEF-2 binding site in the C/EBPα promoter.
The MEF-2 binding site was found to be highly conserved between human and
mouse. Since role of mouse MEF2C α1 isoform is established in antagonizing
the myelopoiesis we cloned the mouse C/EBPα promoter and performed a
luciferase assay with MEF2C α1 isoform and found that MEF2C significantly
represses the C/EBPα promoter.
Summary and Conclusions: The study shows that MEF2C expression
increases with CML disease progression and it is BCR-ABL dependent since
addition of imatinib was able to reduce MEF2C protein. MEF2C also negatively
regulates the C/EBPα promoter as it affects the luciferase activity. Thus MEF2C
up regulation was associated with decreased C/EBPα mRNA expression which
can favour disease progression.
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MESENCHYMAL STEM CELLS FROM CML PATIENTS REGULATE
MYELOID DERIVED SUPPRESSOR CELLS ACTIVATION
C. Giallongo1,* N. Parrinello1, D. Tibullo1, P. La Cava1, A. Romano1, A. Chiarenza1,
F. Stagno1, P. Vigneri1, G.A. Palumbo1, F. Di Raimondo1
1Division of Hematology, Azienda Policlinico-OVE, University of Catania, Cata-
nia, Italy
Background: The complex interplay between cancer cells and immune system
allows neoplastic cells to evade immune surveillance and expand. Recently, it
has been demonstrated that a subpopulation of myeloid cells, defined as
“myeloid-derived suppressor cells” (MDSCs), plays an important role of immune
escape in chronic myeloid leukemia (CML) patients inducing T cell tolerance.
Mesenchymal stem cells (MSCs) are a heterogeneous population of stromal
adult stem cells with immunomodulatory properties that contribute to form a can-
cer stem niche where tumor cells are protected and sustained in their growth.
Aims: The aim of this study was to evaluate the influence of MSCs on expan-
sion and activation of MDSCs in CML patients.
Methods: In a first instance, using real time PCR, we evaluated the expression
of immune modulatory factors (arginase 1, NOS2, COX2, TNFα, TGFβ, IL6, IL10,
IL1β) by CML MSCs (n=8) compared with healthy donors (HD) ones (n=6).
Human peripheral blood mononucleated cells (PBMCs) isolated from healthy vol-
unteer donors were cultured alone and with CML or HD MSCs (1:100 ratio). After
one week, PBMCs were collected and MDSCs were then isolated using anti-
CD66b magnetic microbeads. The phenotype of MDSCs (identified as
CD11b+CD33+CD14-HLADR-cells) was confirmed by cytofluorimetric analysis.
Results: CML MSCs showed higher COX2,TGFβ and IL6 expression (p<0.05).
Subsequently, we investigated the capacity of MSCs from CML patients and
HD to generate MDSCs. The immunosuppressive capacity of the generated
MDSCs was analyzed. Myeloid cells were co-cultured with autologous CFSE-
labeled T cells stimulated by phytohaemagglutinin (PHA). Only MDSCs gener-
ated by co-culture with CML MSCs were suppressive, decreasing T cell prolif-
eration of 31±12% (p<0.01) while myeloid cells generated by co-culture with
HD MSCs and control (isolated from PBMCs cultured in medium alone) did not
show any suppressive effect on T cell proliferation. Analyzing the expression
of immune modulatory factors by MSCs after 48 h of co-culture with PBMCs,
we observed higher expression of IL10 and TGFβ (p<0.05) andIL6 (p<0.01) by
CML MSCs than HD ones. These data suggest that multiple mechanisms are
involved in MDSCs induction by CML MSCs.
Summary and Conclusions: From our experiments we can conclude that
MSCs from CML patients are able to generate and activate MDSCs and might
favor cancer immune evasion in CML patients.
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DO ENDOTHELIAL CELLS BELONG TO THE PRIMITIVE LEUKEMIC
CLONE IN CML? ROLE OF EXTRACELLULAR VESICLES
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ca-IBSAL, Salamanca, 3Servicio de Hematología, Hospital General de Segovia,
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Background: The expression of BCR/ABL in hematopoietic stem cells is a
well defined primary event in chronic myeloid leukemia (CML). Some reports
have described the presence of BCR-ABL on endothelial cells from CML
patients, hypothesizing that the disease may arise in a primitive hemangioblas-
tic cell. On the other hand, it has been described that extracellular vesicles
(EVs) released by CML leukemic cells are involved in angiogenesis modulation
in the disease and that endothelial cells can incorporate them.
Aims: To assess if EVs released from BCR-ABL+ cells carry inside the onco-
gene and if their incorporation into endothelial cells leads to the expression of
both BCR-ABL mRNA and the oncoprotein in the recipient endothelial cells.
Methods: For the study K562 cells and primary samples of newly diagnosed
CML patients were used (after signed informed consent was obtained) as well
as the endothelial EA.hy926 cell line. For EVs isolation and characterization,
EVs obtained from K562 cell culture medium and plasma from CML patients
were isolated by differential centrifugation and characterized by transmission
electron microscopy and Western blot. For incorporation assays, EVs from
K562 cells and from plasma of CML patients were incubated with the EA.hy926
cell line for 4, 24, 48 and 72h. The incorporation was analyzed by flow cytometry
and fluorescence microscopy. Total RNA from EVs or cells was extracted using
TRIzol Reagent and the expression was quantified by using commercial Taq-
Man Universal Mastermix and the Step One Plus Real-Time PCR System. The
polyclonal rabbit anti-human c-ABL (BCR-ABL) antibody was used and the
proteins were visualized using the enhanced chemiluminescence system.
Results: EVs from K562 cells and plasma from newly diagnosed CML patients
were isolated and characterized and they showed the typical cup-shaped mor-
phology and were positive for the exosome marker CD63. By RT-PCR, the
presence of BCR-ABL RNA in the Evs from both K562 cells and plasmatic EVs
of CML patients was demonstrated. Next it was verified by flow cytometry and
fluorescence microscopy that after 24h of culture K562-derived EVs were incor-
porated into EA.hy926 cells The presence of mRNA BCR-ABL on endothelial
EA.hy926 cells that incorporated the EVs-K562 for 4h, 48h and 72h was also
detected by RT-PCR. In addition, the presence of BCR-ABL mRNA in EA.hy926
cell line after incubation with plasma-derived EVs from CML patients was
detected. The presence of BCR-ABL on endothelial cells incubated with
Philadelphia+ EVs was also confirmed by Western blot.
Summary and Conclusions: Endothelial cells acquire BCR-ABL RNA and
the oncoprotein after incubation with EVs released from Ph+ positive cells
(either from K562 cells or from plasma of newly diagnosed CML patients). This
results challenge the hypothesis that endothelial cells may be part of the
Philadelphia+ clone in CML.
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PPAR-GAMMA LIGANDS INCREASE ANTILEUKEMIC ACTIVITY OF 2ND
AND 3RD GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC
MYELOID LEUKEMIA CELLS
E. Glodkowska-Mrowka1,* P. Mrowka2
1Department of Laboratory Medicine and Clinical Immunology of Developmen-
tal Age, 2Department of Biophysics and Human Physiology, Medical University
of Warsaw, Warsaw, Poland
Background: Introduction of imatinib into clinical practice revolutionized the
treatment of BCR-ABL1-positive leukemias and allowed for successful devel-
opment of new tyrosine kinase inhibitors (TKIs). So far several 2nd and 3rd
generation TKIs has been approved for the treatment of chronic myeloid
leukemia (CML). Unfortunately, a significant number of patients do not benefit
from the therapy because of TKIs resistance or severe drug toxicity. Recently,
the success of 2nd and 3rd generation TKIs in CML was shadowed by the
reports on serious side effects of these drugs including increased risk of car-
diovascular events in patients treated with nilotinib and ponatinib. Pioglitazone,
peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligand used
in the treatment of type 2 diabetes, reduces cardiovascular risk in various clin-
ical settings and is currently tested for secondary prevention after ischemic
stroke and transient ischemic attack in patients with diabetes. In addition,
although it is not classic anticancer drug, pioglitazone exerts antitumor activity
and is used to potentiate various anticancer therapies in pre-clinical and clinical
trials. Therefore we decided to study the influence of PPAR-gamma ligands,
including pioglitazone, on 2nd and 3rd generation TKIs efficacy.
Aims: Comprehensive analysis of the influence of PPAR-gamma ligands on
antileukemic properties of 2nd and 3rd generation TKIs in chronic myeloid
leukemia cell line K562.
Methods: To study the cytotoxicity of PPAR-gamma ligands (pioglitazone,
prostaglandin J2, rosiglitazone) and TKIs (dasatinib, nilotinib, bosutinib and
ponatinib) XTT and trypan blue exclusion assays were used. The influence of
the studied drugs on cell proliferation and clonogenic potential was studied
using APO-BRDU and clonogenic assays. Western blotting analysis was used
to study proteins involved in the regulation of cell cycle (p21, p27, cyclin D1)
and apoptosis (cleaved caspase 3 & 9). In addition, phosphorylation of CrkL
was measured as a marker of BCR-ABL1 kinase activity inhibition. Activation
of caspase 7 was measured using fluorescent microscopy. Cell cycle was
analysed using propidium iodide DNA staining (flow cytometry).
Results: PPAR-gamma ligands synergistically increased cytotoxicity of dasa-
tinib, nilotinib, bosutinib and ponatinib (Figure1A). In addition, pioglitazone
significantly enhanced the antiproliferative effect of the studied TKIs. Moreover,
the addition of pioglitazone induced cell cycle arrest in G0/G1 and sensitised
CML cells to TKIs as observed by increased number of cells in subG1 phase
in TKI + pioglitazone group (Figure1B). Cell cycle arrest was confirmed by
Western blotting analysis of p21, p27 and cyclin D1. In result of cell cycle
arrest, pioglitazone significantly increased proapoptotic activity of TKIs as
observed in Western blotting (cleavage of caspase 3 & 9) and microscopy
(caspase 7 activity).
Figure 1.
Summary and Conclusions: Reduction of cardiovasular risk after adminis-
tration of pioglitazone observed in patients with type 2 diabetes suggests that
this drug can be useful in prevention of severe complications related to admin-
istration of 2nd and 3rd generation TKIs. In addition to its influence on cardio-
vascular risk, pioglitazone may enhance therapeutic efficacy of 2nd and 3rd
generation TKIs through induction of cell cycle arrest and sensitization of CML
cells to TKI-induced apoptosis. Therefore, the addition of pioglitazone to stan-
dard CML therapy may become potent treatment modality for the patients treat-
ed with 2nd and 3rd generation TKIs and increased cardiovascular risk.
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IDENTIFICATION OF BRD4 AS A NOVEL MOLECULAR TARGET IN PH+
CML 
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ogy, 2Ludwig Boltzmann Cluster Oncology, Medical University of Vienna,
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Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell
disease defined by leukemic expansion of myeloid progenitor cells and the
BCR/ABL1 oncoprotein that promotes growth and survival of leukemic cells.
In most patients growth of clonal cells can be kept under control by BCR/ABL1
tyrosine kinase inhibitors (TKI), including imatinib. For patients who develop
resistance or intolerance against imatinib, second-line and third-line TKI (nilo-
tinib, dasatinib, bosutinib, ponatinib) are available. However, in advanced CML,
patients may develop resistance against most or all TKI. Therefore, current
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research is attempting to identify novel drug targets in CML, in order to over-
come TKI resistance. One class of promising targets may be epigenetic regu-
lators of cell growth. In acute myeloid leukemia (AML), the epigenetic reader
BRD4 has recently been introduced as a novel drug target; and the BRD4-tar-
geting drug JQ1 was found to induce growth inhibition in AML cells. However,
so far, little is known about the expression and function of BRD4 in CML cells.
Aims: In this study we examined the expression of BRD4 in CML cells and
asked whether BRD4 serves as a target of therapy in this leukemia.
Methods: BRD4 expression was determined by qPCR and immunocytochem-
istry and the effects of JQ1 on proliferation and survival of CML cells were eval-
uated by 3H-thymidine uptake and Annexin V staining.
Results: Both CML cell lines investigated, namely KU812 and K562, express
BRD4 mRNA and the BRD4 protein. The BRD4-targeting drug JQ1 was found
to inhibit proliferation in KU812 cells in a dose-dependent manner (IC50: 0.25-
0.75 µM). Interestingly, however, no substantial growth-inhibitory effect of JQ1
was seen in K562 cells (IC50: >5 µM). Moreover, we were able to show that
JQ1 inhibits growth of primary CML cells with IC50 values ranged between 0.1
to 5 µM. Corresponding results were obtained when analyzing cell survival. In
particular, JQ1 was found to induce apoptosis in KU812 cells but did not induce
apoptosis in K562 cells. In addition, we were able to show that KU812 cells
and K562 cells display MYC mRNA. Exposure to JQ1 was followed by a
decrease in expression of MYC mRNA levels in both cell lines. Similar results
were obtained by Western blotting where JQ1 was found to decrease the
expression of the MYC protein in KU812 and K562 cells. Moreover, we were
able to show that MYC expression in CML cells is BCR/ABL1-dependent. Ima-
tinib, nilotinib, ponatinib and dasatinib were found to decrease expression of
MYC mRNA as well as MYC protein expression in K562 cells and KU812 cells.
Finally, we were able to show that JQ1 cooperates with imatinib, nilotinib, pona-
tinib and dasatinib in producing growth inhibition in KU812 cells and K562 cells.
Summary and Conclusions: Together, our data show that BRD4 serves as a
potential target in CML cells, and that the BRD4-blocker JQ1 synergizes with
BCR/ABL TKI to induce growth-inhibition. Whether BRD4 inhibition is a phar-
macologically meaningful approach in patients with TKI-resistant CML remains
to be determined.
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Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved out-
comes of chronic myeloid leukemia (CML) patients. However, a fraction of
patients fail in TKI treatment. One of the major mechanisms of resistance to
TKIs is point mutations in the BCR-ABL kinase domain (KD). Alternatively-spliced
(AS) BCR-ABL transcript variants, such as retention of 35bp intronic nucleotides
at Exon 8/9 splice junction (Ins35) are important obstacles to achieve optimal
response to TKI (Gaillard JB, et al. Mol Cancer Ther 2010; T O’Hare, et al. Blood
2011). This BCR-ABL variant possesses a stop codon in KD residues, resulting
in generation of “function dead” BCR-ABL. However, this variant showed struc-
tural changes, resulting in a failure to TKI bindings. We hypothesized that the
emergence of these BCR-ABL variants may render such CML clones insensitive
to TKIs, contributing to the persistence of CML clones.
Aims: We evaluated both point mutated and AS BCR-ABL variants in pts with
suboptimal response (SoR) to Imatinib (IM) by highly-sensitive assay system.
Methods: In the Study to Evaluate Nilotinib (NIL) in CML Patients with Subop-
timal Response (SENSOR, NCT0104387), all pts with SoR—complete cytoge-
netic response but no major molecular response (MMR) after ≥18 months (mo)
of frontline IM, were switched to NIL 400mg BID. cDNA was synthesized from
extracted RNA samples, and BCR-ABL was amplified by long-range nested
PCR method. These amplicons were deeply sequenced to detect BCR-ABL
variants by using HiSeq 1500 (illumina) (Figure 1). The cumulative amounts of
AS BCR-ABL are defined as the area under the curve from baseline to 24 mo
after switching to NIL. These cumulative amounts are thought to be a potential
persistence of AS BCR-ABL.
Results: Of 45 pts enrolled in the main study, 41 pts were evaluated for BCR-
ABL variants. At 24 mo, 10 pts could not achieve MMR, whereas 27 pts could
achieve MMR, including 5 pts with MR4.0. The remaining 4 pts could not be
evaluated serially. The remaining 4 pts could not be evaluated serially. We ana-
lyzed 422 samples from 41 pts who have at least one sample: 412 samples
with an average sequence depth on ABL-1 exon 8 achieved over 1,000 were
considered as reliable for further statistical analysis. Two types of splicing vari-
ants became evident: the Ins35 and the Intron 8-retained BCR-ABL that pos-
sesses inappropriately spliced Intron 8 of ABL-1. AS BCR-ABL transcript vari-
ants were detected in all 41 pts and serially detected during NIL treatment. A
representative cumulative curve in a patient who could not achieved MMR is
shown in Figure 2. After switching NIL, AS BCR-ABL was serially detected at
any points fo treatment. In addition, various point mutations were detected all
along during NIL treatment at any depth of molecular response (Table 1). We
analyzed the relationship between the cumulative amounts of Ins35 for 0-24
mo and molecular response rate: These cumulative amounts had an impact on
the achievement rate of MMR (Table 2).
Figure 1.
Summary and Conclusions: Our highly-sensitive quantification system
revealed that cumulative amounts of Ins35 for 0-24 mo might correlate with
failure to achieve MMR after switching to NIL. Point mutations were detected
in only 1 patient (K219N) out of 10 pts who could not achieve MMR at 24 mo.
In contrast, AS BCR-ABL was detected in all 10 pts, suggesting that AS BCR-
ABL might be related to SoR to TKIs rather than point mutation. These data
suggest that CML clones with AS BCR-ABL may not be addicted to BCR-ABL
kinase activity and were difficult to eradicate by TKI alone. Thus, quantification
of AS BCR-ABL variants might be a beneficial method to predict clinical out-
comes and to find out the mechanism of TKI resistance in CML pts.
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TRANSCRIPTS IN ARCHIVED RNA FROM PHILADELPHIA POSITIVE
ONSET SAMPLES
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Background: The identification of the BCR-ABL transcripts for the purpose
of molecular diagnosis is actually based on conventional RT-PCR. The novel
RT-Q-LAMP molecular method represents a semi-automated alternative,
which allows rapid differential detection of BCR-ABL p190 and p210 fusion
transcripts in a close, single step format.
Aims: Evaluation of the Q-LAMP assay performances on archived RNA sam-
ples previously tested by conventional qualitative RT-PCR .
Methods: BCR-ABL RT-Q-LAMP is a fluorescent isothermal method for retro-
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transcription, amplification and differential detection of the Minor (p190) and
Major (p210) t(9;22) transcripts and the endogenous Gusb RNA, that acts as
internal control. The test result is obtained starting directly from patient RNA
in a single, sixty minute step. RT-Q-LAMP is carried out on the Liaison IAM
instrument that incubates at constant temperature, displays fluorescent signals
in real time and return final elaborated data. Overall 165 samples (111 BCR-
ABL positive, 54 negative) consisting of archived RNA (500ng per reaction),
have been tested and the results compared with one previously obtained by
RT-PCR. 11 samples presented a chemical contamination, showing
A260/A230 ration below 1 (0,24-1). Further 8 rare isoform samples (e19a2
n=3; e6a2 n=3; e8(-44nt)/+(intr abl1 30nt)/a2 n=1; p210 presenting a deletion
in the fusion region) have been also analysed.
Results: The RT-Q-LAMP and RT-PCR data resulted fully concordant (100%).
3 samples initially discordant (negative by RT-PCR, weakly positive by Q-
LAMP) have been further investigated by Quantitative PCR confirming the
positive status. The positive samples have been identified by Q-LAMP in, as
average, 22,7 minutes and 18,3 minutes for the p190 and p210 respectively.
The 11 samples presenting poor A260/A230 ratio have been detected in 20,8
min as average. The rare isoforms e19a2 and e6a2 have been amplified, as
well as the p210 positive sample presenting a deletion in the fusion region,
which prevents quantitative PCR from amplification. The rare isoform e8(-
44nt)/+(intr abl1 30nt)/a2, detectable by nested RT-PCR did not produce ampli-
fication in Q-LAMP.The negative samples presented amplification of the
housekeeping gene, validating the result. Q-LAMP also demonstrated robust-
ness to contamination by extraction chemical reagents. The close tube format
and the ready-to-use lyophilized reagents provided an easier the set-up that
may decrease the classical risks of multistep procedures. The software elab-
orates and stores the data ensuring traceability. The limitations identified are
the inability to distinguish the p210 b2a2 from the b3a2 isoform and to detect
the rare isoforms in which the exon 2 of ABL is deleted.
Summary and Conclusions: The Q-LAMP technique produced results con-
cordant with RT-PCR, in a much lower time-to-results (about 20 minutes). The
Q-LAMP method represents a valid option for reliable and rapid detection of
BCR-ABL and the one step, close tube format could easily be adopted in not
highly specialized centers for an effective diagnosis of Philadelphia Positive
Leukemias.
Acknowledgments: ELN, AIL, AIRC, PRIN, progetto Regione-Università
2010-12 (L. Bolondi), FP7 NGS-PTL project
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Background: Previous studies indicate that Natural Killer (NK) cells are defi-
cient in Chronic Myeloid Leukemia (CML) patients, although the mechanisms
behind the dysfunction are not completely understood. Current therapeutic
strategies influence these innate lymphoid cells and successful results may
be partially explained by the advantageous effects on their cytotoxicity against
cancer cells. Due to recent advances in the knowledge of NK cell´s biology,
there is an increasing interest in mapping NK-cell responses in cancer.
Aims: The aim of the present study was to analyze NK cells in CML patients
and the effect of therapy and dose-dependent mechanisms on essential fea-
tures of NK cells.
Methods: In this study, we analyzed blood samples from 67 CML patients
treated with IFN-α and/or different generations of tyrosine kinase inhibitors
(TKI). Extended analysis of NK-cell receptor repertoire and functional proper-
ties was performed by multiparametric flow cytometry, cell sorting, Luminex
xMAP technology and real-time quantitative PCR.
Results: Relative frequency of NK cells was found reduced at CML diagnosis
and recovered after treatment. CML therapy induces an increase of
CD62L+CD56bright NK cells, associated to the capacity of migration to sec-
ondary lymphoid organs. Activation of NK cells and the increased expression
of CD137 and CD137L were interpreted as a significant effect of therapy
response. Activatory (KIR2DS1) and inhibitory (KIR2DL1, KIR2DL2) receptors
were found altered in CML. The expression of KIR2DS1 by CD56dimCD16+
NK cells was highest in CML patients undergoing Dasatinib therapy. Treatment
also increased the NKG2C/NKG2A (activatory/inhibitory) ratio. Lower expres-
sion of NKp30 and NKp44 was compensated by the increase of NKp46+ NK
cells. Production of IFN-γ and suppression of TGF-β+ and IL-10+ NK cells
was also a beneficial effect of treatment protocol. IFN-γ production decreased
with an increased TKI dose. Dasatinib induced the expression of KIR2DS1
(activating receptor) on NK cells, improving NK cell ability to kill cancer cells.
Summary and Conclusions: NK cells are affected during CML and current
therapeutic protocols ameliorate NK-cell performance. In the future, combi-
nation of NK cell-based immunotherapy with pharmacological interventions
should be investigated in order to eradicate cancer cells and discontinuation
of therapy.
Financial Support: FEDER (Programa Operacional Factores de Competi-
tividade-COMPETE) and FCT (Fundação para a Ciência e a Tecnologia)
through project PEst-C/SAU/LA0001/2013-2014.
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Background: A sensitive and standardized monitoring of deep molecular
response (MR) based on BCR-ABL1 transcript level quantification is an essen-
tial part of CML tyrosine kinase inhibitor (TKI) stopping trials. Detailed labora-
tory recommendations, developed as a part of the European Treatment and
Outcome Study (EUTOS) for CML, to enable testing laboratories to score MR
in a reproducible manner based on reverse transcription quantitative PCR
(RT-qPCR) has been recently published (Cross et al. Leukemia 2015). A new
quantification technology droplet digital PCR (ddPCR) is tested in more and
more laboratories with promising high quantification accuracy and sensitivity.
Aims: To assess differences in accuracy and sensitivity of BCR-ABL1 tran-
script levels quantification using ddPCR and standardized RT-qPCR. In addi-
tion to that to compare the levels of BCR-ABL1 at mRNA and DNA levels
measured by ddPCR.
Methods: The RT-qPCR used in our EUTOS MR4.5 laboratory is standardized
having regularly validated conversion factors for data reporting in the interna-
tional scale (IS) using ABL1 or GUSB control genes. The system QX-200 (Bio-
rad) was used for ddPCR. The same RT-qPCR primers and probes were
applied for ddPCR. Unlike to singleplex RT-qPCR, TaqMan probes were dif-
ferently labelled for multiplex ddPCR. Using each method all samples were
analyzed in doublets.
Results: The WHO certified ERM-AD623 standards (n=6) were used to com-
pare the quantification accuracy of both methods. Obtained gene copies ratios
(BCR-ABL1/ABL1 and BCR-ABL1/GUSB) in the standards by singleplex RT-
qPCR were in range 0.63-1.11 (Me=0.85). Singleplex ddPCR determined
ratios in range 0.92-1.29 (Me=1.02). Multiplex ddPCR improved quantification
accuracy with ratios 0.93-1.0 (Me=0.99).
Samples of 31 CML patients treated with TKIs with BCR-ABL1 mRNA levels
ranging 0.01-10% IS were used for data comparison. The Bland-Altman bias
plot was used to determine bias between RT-qPCR and ddPCR showing
antilog bias 0.54-fold in 31 paired results.
To compare BCR-ABL1 detection sensitivity of both methods we tested 66
samples from the time of MR4.0 confirmation and after TKI discontinuation of
7 patients enrolled in the EURO-SKI study (Europe Stops TKI in CML). The
total number of paired results from RT-qPCR vs ddPCR of samples with BCR-
ABL1 mRNA levels below 0.01% IS was 37 with determined antilog bias 0.23-
fold. The number of BCR-ABL1 negative samples by RT-qPCR vs ddPCR
was 26/66 in MR4.5-MR5.0 sensitivity vs 6/66, respectively. Moreover, 26 sam-
ples of 4/7 EURO-SKI patients were assessed by ddPCR for the levels of
genomic BCR-ABL1 fusions using patient-specific assays. We found signifi-
cant correlation between DNA and mRNA BCR-ABL1 levels (r=0.9038,
P<0.0001).
Summary and Conclusions: We found a higher quantification accuracy of
ddPCR in contrast to RT-qPCR for which standard calibration curves need to
be performed to mathematically calculate cDNA copy numbers in unknown
samples. This probably represents an important variable. We found compa-
rable results of both methods for BCR-ABL1 mRNA quantification within the
range 0.01-10% IS. Approximately a log higher BCR-ABL1 mRNA levels in
EURO-SKI MR4.0-MR5.0 samples were detected by ddPCR in comparison to
RT-qPCR, assuming that higher sensitivity of ddPCR may be important for
TKI stopping treatment management. Interestingly, BCR-ABL1 DNA and
mRNA levels measured by ddPCR correlated significantly. A larger cohort of
samples needs to be analyzed to elucidate the clinical importance of DNA
measurement. Supported by MZCR project no. 00023736 and EURO-SKI
research consortium.
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Background: In the Evaluating Nilotinib Efficacy and Safety in Clinical Trials–
Newly Diagnosed Patients study (ENESTnd), nilotinib (NIL) demonstrated
improved efficacy vs imatinib (IM) throughout 5 y of follow-up (f/u), with higher
rates of major molecular response (MMR; BCR-ABLon the International
Scale[BCR-ABLIS] ≤0.1%) and MR4.5(BCR-ABLIS ≤0.0032%). The protocol
was amended in January 2012 to extend the f/u period to 10 y, from the initial
5 y, to collect further data on efficacy parameters, including deep molecular
response and survival, and on safety. Here, we report 6-y f/u data.
Aims: The efficacy and safety of NIL vs IM were evaluated in adult patients
(pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic
myeloid leukemia (CML) in chronic phase (CP).
Methods: Pts were randomized to NIL 300 mg twice daily (n=282), NIL 400
mg twice daily (n=281), or IM 400 mg once daily (n=283). “On core treatment”
analyses included all events that occurred during core treatment with the
assigned study drug. “On study” analyses included all events that occurred
during core treatment, extension treatment, or posttreatment f/u. Progression
and survival data were collected prospectively every 3 mo for 5 y, then every 6
mo, including after discontinuation of study treatment.
Results: After a minimum f/u of 6 y, more pts remained on core treatment in
the NIL 300 mg and 400 mg arms than in the IM arm (53.5%, 55.2%, and
44.9%, respectively). In both NIL arms, cumulative rates of MMR and MR4.5 by
6 y were higher than in the IM arm (Table). In all 3 arms (NIL 300 mg, NIL 400
mg, and IM), MR4.5rates by 6 y were highest in pts with BCR-ABLIS ≤1% at 3
mo (73.6% [106/144], 75.0% [102/136], and 72.1% [31/43], respectively) and
lowest in pts with BCR-ABLIS >10% at 3 mo (8.3% [2/24], 21.4% [6/28], and
15.9% [14/88], respectively); more pts on NIL vs IM achieved BCR-ABLIS ≤1%
and fewer pts on NIL vs IM had BCR-ABLIS >10% at 3 mo. By 6 y, fewer pts on
NIL vs IM had progressed to accelerated phase/blast crisis (AP/BC) on study
and on core treatment (Table). Since the 5-y data cutoff, 1 new progression to
AP/BC on study (NIL 300 mg arm, ≈5 y after discontinuation of core treatment)
was reported; no new progressions on core treatment were reported. Fewer
deaths due to advanced CML occurred in the NIL arms than in the IM arm.
Since the 5-y data cutoff, 5 deaths were reported, including 3 on core treatment
and 2 on study after discontinuation of core treatment (Table); no new deaths
due to advanced CML occurred in any arm. The safety profiles of NIL and IM
were consistent with previous reports. Very few events of pleural effusions,
pericardial effusion, or pulmonary edema occurred in any arm (Table). More
pts in the NIL arms than in the IM arm had cardiovascular events (CVEs); CVEs
were reported at a consistent frequency within each arm throughout the study
(Table). A recent protocol amendment allowed for a dose reduction to NIL 300
mg twice daily in pts in the NIL 400 mg twice daily arm, and a subsequent dose
increase to the originally assigned 400 mg twice daily dose, based on a pt’s
individual benefit/risk assessment.
Tabella 1.
Summary and Conclusions: NIL continued to demonstrate improved efficacy
over IM, with higher rates of molecular response, fewer progressions, and fewer
deaths due to advanced CML. No new safety signals were detected. Results
from ENESTnd continue to support use of NIL 300 mg twice daily as a standard-
of-care frontline therapy option for pts with newly diagnosed Ph+ CML-CP.
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Background: ENESTcmr has demonstrated that switching to NIL results in
higher rates of deep molecular response vs continued imatinib (IM) in pts with
CML-CP with residual disease after long-term IM treatment; among pts without
major molecular response (MMR; BCR-ABL1 ≤0.1% on the International Scale
[IS]) after ≥2 y of IM, substantially higher rates of MMR were also observed
with switching to NIL vs continuing IM.
Aims: Here we present results with 4 y of follow-up.
Methods: The phase 3 ENESTcmr study evaluated pts with Philadelphia chro-
mosome–positive (Ph+) CML-CP with complete cytogenetic response but with
detectable BCR-ABL1 by real-time quantitative polymerase chain reaction (RQ-
PCR; sensitivity of ≥4.5 logs) on the IS after ≥2 y of treatment with IM. Pts were
randomized to receive NIL 400 mg twice daily (BID; n =104) or continue IM
(400 or 600 mg once daily [QD]; n =103). Crossover to the NIL arm was allowed
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for pts in the IM arm with detectable BCR-ABL1 transcripts after 2 y on study
or with treatment failure/confirmed loss of response (≥2 consecutive assess-
ments) at any time.
Results: Of 103 pts randomized to the IM arm, 46 crossed over to NIL, most
commonly due to detectable BCR-ABL1 after 2 y (n =41/46; 89%). The 4-y
cumulative incidence of MR4.5 (BCR-ABL1IS ≤0.0032%) among pts without
MR4.5at baseline (intention-to-treat analysis; NIL, n =98; IM, n =96) was 52%
(51/98 pts) in the NIL arm and 42% (40/96 pts) in the IM arm (nominal P =.1318;
Table). Among the 46 pts who crossed over to NIL, 20 (43%) achieved MR4.5by
the end of the study (13 achieved MR4.5for the first time [5 of these pts did not
have an RQ-PCR evaluation at the crossover visit], 4 maintained MR4.5, and
3 regained MR4.5 that was lost prior to crossover). When excluding responses
achieved after crossover to NIL, 52% of pts in the NIL arm vs 28% of pts in the
IM arm (nominal P =.0004) achieved MR4.5 by 4 y. Median time to MR4.5 was
24 months in the NIL arm and was not reached in the IM arm by 48 mo. At 2 y,
78 pts were eligible for crossover to NIL due to molecular detectable disease;
of these, 13/41 pts who switched to NIL vs 5/37 pts who remained on IM
achieved undetectable disease by 4 y. The safety profiles of NIL and IM were
consistent with previous reports. By 4 y, cardiovascular events were reported
in 13 pts in the NIL arm (ischemic heart disease [IHD], 4; cerebrovascular event
[CVE], 4; peripheral arterial disease [PAD], 7), 3 pts who crossed over from IM
to NIL (IHD, 1; CVE, 1; PAD, 1), and 2 pts in the IM arm (excluding events after
crossover; IHD, 1; CVE, 1). The median time on treatment was 3.9 y in the NIL
arm and 4.0 y for pts in the IM arm who did not cross over; for pts who crossed
over from IM to NIL, median time on treatment was 2.1 and 1.8 y before and
after crossover, respectively.
Tabella 1.
Summary and Conclusions: Results from ENESTcmr showed that for pts
with Ph+ CML-CP and residual disease after ≥2 y of IM treatment, more pts
achieved MR4.5with switching to NIL (52%) vs continuing IM (42%; when
accounting for confounding effects of crossover, 28%) by 4 y. In addition, more
pts with detectable disease at 2 y who switched to NIL than those who remained
on IM were able to achieve undetectable disease by 4 y. Overall, results from
ENESTcmr suggest that an earlier switch to NIL (at randomization) allows ear-
lier achievement of MR4.5 vs remaining on IM or delaying switch to NIL (at
crossover) and enables a larger proportion of pts to achieve deeper molecular
responses and become eligible for treatment-free remission trials sooner.
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Background: In the ENESTnd trial, nilotinib (NIL) showedsuperior efficacy
compared to imatinib (IM); based on these results, NIL has been approved for
frontline treatment of chronic myeloid leukemia (CML). The treatment-free
remission (TFR) is an emerging treatment goal in CML and a sustained deep
molecular response (DMR, MR4 or better) is a pre-requisite to achieve TFR.
The 5-year update from the ENESTnd trial showed a superiority of NIL over IM
in terms of achievement of DMR, but differences concerning the stability of
DMR have not been reported yet. Independent studies are extremely relevant
to confirm and to extend the results of company-sponsored trials.
Aims: To assess the efficacy of NIL as first-line treatment in terms of achieve-
ment of DMR and stability of DMR
Methods: A phase 3b study was conducted by the GIMEMA CML WP
(CML0811; NCT01535391). The primary endpoint was the rate of MR4 at 24
months. Key secondary objectives: evaluation of the kinetics of molecular
response and stability of DMR, assessment of the safety profile, evaluation of
the outcome. The starting NIL dose was 300 mg BID, with dose escalation to
400 mg BID (in absence of safety issues)in case of suboptimal response or
failure (ELN 2009 criteria), with the exception of progression to ABP or BCR-
ABL mutations insensitive to NIL. The molecular response was assessed in
GIMEMA standardized molecular laboratories (Labnet network). The MR4 was
defined as either detectable disease ≤0.01% BCR-ABL or undetectable disease
with ≥10.000 ABL copies; the MR4.5 was defined as either detectable disease
≤0.0032% BCR-ABL or undetectable disease with ≥32.000 ABL copies. Sus-
tained MR4 or MR4.5: MR4 or MR4.5 for at least 1 year a, with at least 3 evalu-
able analysis. A prospective evaluation of glucose metabolism and serum lipids
was performed. All the analysis were performed according to the ITT principle.
Results: 130 CML patients in early chronic phase have been enrolled in 32
italian hematologic centers; median age, 50 years (range 18-85); high risk
patients, 22%, 6% and 8% according to Sokal, Euro and EUTOS scores,
respectively; clonal chromosomal abnormalities in Ph+ cells at baseline, 5%;
e13a2 BCR-ABL transcript, 34%. The median follow-up is 29 months (24-37
months). At the last contact, the patients still on treatment with NIL were
100/130, 77% (86 with 600 mg, 9 with 300 mg or less, 5 with 800 mg daily),
while 30/130 patients, 23%, permanently interrupted the study drug for the fol-
lowing reasons: 3% progression to ABP, 5% failure or suboptimal response
(dose escalation not feasible or not effective), 8% adverse events, 1% TFR,
5% other reasons (including consent withdrawal and pregnancy). At 3 months,
80% of patients had BCR-ABL transcript levels <10%; at 6 months, 78% of
patients had BCR-ABL transcript levels <1%. The major molecular response
rates at 12 and 24 monthswere 57% and 65%, respectively. The rates of MR4
at 6, 12, 18 and 24 months were 12%, 28, 31% and 46%, respectively. Seven-
ty-six patients (58%) achieved a MR4 at least once; the patients with a sus-
tained MR4 were 39/76 (51%, or 30% of the total). The rates of MR4.5 at 6,
12, 18 and 24 months were 2%, 7%, 11% and 17%, respectively.Eleven
patients achieved a sustained MR4.5. A significant increase of glycosylated
hemoglobin was not observed. The total cholesterol, and both LDL and HDL
cholesterol fractions significantly increased during treatment. Triglicerid con-
centrations had not significant variations. Six patients (5%) had a cardiovascular
event, including myocardial infarction and arterial thrombosis. All the patients
are still alive.
Summary and Conclusions: The molecular response rates seem to be supe-
rior to the historical data of IM. NIL 300 mg BID as frontline treatment of BCR-
ABL+ CML, with dose optimization in case of non optimal response, may
improve the proportion of patients able to discontinue TKI treatment. Due to
the metabolic effects, a baseline selection is important to maximize the thera-
peutic benefit and to minimize the cardiovascular risks.
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Background: Currently available therapies may have limited potential to elim-
inate leukemic stem cells (LSCs). LDE225 is an antagonist of the transmem-
brane protein SMO, which plays a role in the Hedgehog (Hh) pathway. Inhibition
of the Hh pathway diminished survival signals in LSCs and increased the sen-
sitivity of LSCs to tyrosine kinase inhibitors (TKIs).1Preclinical studies2 have
shown synergistic effects between SMO inhibitors and BCR-ABL TKIs. This
combination is being explored in early phase clinical trials.
Aims: We evaluated the feasibility of the combination of nilotinib (NIL), a potent
BCR-ABL TKI and LDE225 in patients with Philadelphia chromosome-positive
CML in chronic phase R/I to at least 1 prior TKI.
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Methods: This phase 1b, single-arm, multicenter study had the primary objec-
tive of determining the maximum tolerated dose (MTD) and/or the recommend-
ed phase 2 dose (RP2D) of LDE225 (planned doses of 400/600/800 mg once
daily) in combination with NIL 400 mg twice daily. Dose-limiting toxicities (DLT)
were identified during the first 8 weeks of dosing. An adaptive Bayesian logistic
regression model guided by the escalation with overdose control principle was
used. Secondary objectives included safety, pharmacokinetics, and efficacy
(as measured by the kinetics of molecular and cytogenetic responses).
Results: Eleven patients (cohort 1 [LDE225 400 mg + NIL]: n=4; median age 58
years; cohort 2 [LDE225 600 mg + NIL]: n=7, median age, 46 years) were enrolled.
The median duration of exposure to study treatment in cohort 1 and cohort 2 was
11.27 and 8.25 months, respectively. Two patients in cohort 2 experienced 1 DLT
(elevated creatine phosphokinase [CPK]: n=1, grade [G] 3; n=1, G4). One patient
in cohort 1 experienced 1 serious adverse event (SAE; G4 elevated CPK), and 2
patients in cohort 2 experienced 2 SAEs each (G4 elevated CPK + G1 elevated
troponin T and G3 appendicitis + G2 sepsis). The most frequently occurring (>30%)
adverse events (AEs; all grades) in the overall patient population included alopecia
(73%), elevated CPK (64%), dysgeusia (64%), muscle spasms (64%), folliculitis
(46%), and weight loss (37%). AEs leading to study discontinuation included 1
patient in cohort 1 (G1 elevated CPK) and 4 patients in cohort 2 (G1 folliculitis, G3
folliculitis, G2 dysgeusia, and G2 alopecia). No deaths occurred during the study.
No other clinically significant laboratory abnormalities were observed during the
study. One patient in cohort 1, who had a major molecular response (MMR; ≤0.1%
BCR-ABLIS) at baseline, achieved deep molecular response (MR4.5; ≤0.0032%
BCR-ABLIS) temporarily at 2 months and 1 patient who had no MMR at baseline
achieved MMR post baseline (from 1 month until 9 months). In cohort 2, 1 patient
who had no MMR at baseline achieved MMR at 12 months. The study was termi-
nated early, as the benefit of addition of LDE225 to NIL did not appear to outweigh
additional risks in patients with CML.
Tabella 1.
Summary and Conclusions: The MTD was not determined; no RP2D for the
combination of NIL and LDE225 was found with respect to an acceptable risk/ben-
efit ratio for patients with CML. No evidence of clinical benefit or impact of the
combination was observed. The SAEs of elevated blood CPK were consistent
with the safety profile of LDE225. No significant AEs were seen due to NIL. Study
outcomes were similar to another phase 1 study, which showed lack of efficacy
and tolerability when a SMO inhibitor was used in combination with dasatinib.3
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Background: LASOR is the only randomized study evaluating IM dose esca-
lation vs switch to NIL in pts with Philadelphia chromosome–positive (Ph+)
CML-CP and suboptimal response to frontline IM. When accounting for
crossover, results from the 1-y analysis demonstrated an overall benefit of
switching to NIL vs IM dose escalation.
Aims: Here we present final results from LASOR with 2 y of follow-up.
Methods: Adult pts (N =191) with CML-CP and a complete hematologic
response but suboptimal CyR, defined per 2009 European LeukemiaNet (ELN)
criteria (no CyR ≥3 to <6 mo [Ph+ >95%], no partial CyR ≥6 to <12 mo [Ph+
36%–95%], or no complete CyR [CCyR] ≥12 to <18 mo [Ph+ 1%–35%] on IM
400 mg once daily [QD]), were randomized to receive NIL 400 mg twice daily
(BID; n =96) or IM 600 mg QD (n =95). The primary endpoint was CCyR at 6 mo
after randomization. Consistent with standard of care at the time of the study,
pts were allowed to cross over to the alternate treatment arm for failure to achieve
CCyR by 6 mo or development of intolerance/loss of response at any time. As
a result, additional analyses were performed to evaluate the effects of crossover.
Results: Crossover was more frequent in the IM arm (56 pts [60%] crossed over
to NIL) than in the NIL arm (13 pts [14%] crossed over to IM). Among pts who
crossed over, median time to crossover (from 1 day after randomization to the
last known date a pt took randomized study drug) was 6 mo in each arm; the
most common reasons for crossover were lack of CCyR after 6 mo (IM, 31%;
NIL, 6%), intolerance (IM, 17%; NIL, 5%), and loss of best CyR (IM, 8%; NIL,
1%). The median time on randomized treatment (including time to crossover for
crossover pts and time on treatment for pts who did not cross over) was 22 mo
with NIL and 8 mo with IM. Median time on alternative treatment after crossover
was higher for pts who switched to NIL (16 mo) vs IM (6 mo). Accounting for
crossover by considering pts who crossed over without achieving response by
the time point as nonresponders, 66% of pts on NIL vs 40% on IM achieved
CCyR by 1 y (nominal P =.0005; Table). Overall, the CCyR rate by 1 y was 67%
in the NIL arm vs 63% in the IM arm (nominal P =.6509; intention-to-treat [ITT]
analysis). When considering pts who crossed over without achieving response
by the time point as nonresponders, 42% of pts on NIL vs 19% of pts on IM
achieved a major molecular response (MMR; BCR-ABL1 ≤0.1% on the Interna-
tional Scale) by 1 y (nominal P =.0009; by 2 y, 51% and 26%, respectively [nom-
inal P =.0006]). MMR was achieved by 42% of pts randomized to the NIL arm
and 28% of pts randomized to the IM arm by 1 y (nominal P =.0688; ITT analysis)
and by 51% and 48%, respectively, by 2 y (nominal P =.7729). Estimated rates
of 2-y event-free survival (EFS) are reported in the table. The safety profile of
both drugs was similar to that reported at 1 y. Cardiovascular events occurred in
5 pts on NIL (ischemic heart disease, n =4; peripheral arterial occlusive disease
and arteriosclerosis, n =1) and 0 pts on IM.
Tabella 1.
Summary and Conclusions: With 2 y of follow-up and accounting for crossover,
final results from LASOR demonstrated clinically meaningful improvements in
CCyR and MMR in pts who switched to NIL following suboptimal CyR (2009 ELN
criteria) with frontline IM. Although the primary endpoint (ITT analysis) was not
met, data accounting for crossover suggest such pts (classified as warning/failure
according to current ELN recommendations) may be more likely to achieve rec-
ommended ELN treatment milestones with switch to NIL vs IM dose escalation.
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Background: For chronic myeloid leukemia (CML), many treatment options
have been established. So far, none of them provided a statistically significant
and clinically relevant survival advantage as compared with the others. Thus,
endpoints like health-related quality of life (HRQoL) move into focus. HRQoL
might become essential for deciding on treatment strategies. Data on HRQoL
in CML are rare (Efficace et al., 2011), especially for patients receiving second
generation tyrosine kinase inhibitor treatment.
Aims: We evaluated HRQoL in German patients of the ENEST1st study (Eval-
uating Nilotinib Efficacy and Safety in clinical Trials as First-Line Treatment,
NCT01061177). Main interest was the comparison of HRQoL between diagnosis
and during treatment and the presence of adverse events and symptoms.
Methods: The EORTC QLQ-C30 questionnaire (including global health status
and five functioning scales) and an ad-hoc 15-item symptom scale were sent
out to German participants of the study after informed consent was given at
diagnosis (visit 1, V1), month 3 (V2), month 6 (V3), month 12 (V4), month 18
(V5), and at the end of the study (month 24, V6). Patients with completed ques-
tionnaires at visits 1 and 6 were included in this analysis; patients ending the
study prior to 24 months were counted as visit 6 at their last QoL assessment.
Incomplete questionnaires were not considered. Functional scales and global
health status of the EORTC questionnaire were calculated in accordance with
Aaronson (1993) and Fayers (2001). With functional scales and global health
status ranging from 0 to 100, 8 points are regarded as a minimally important
difference suggesting benefit or harm (Efficace et al., 2013). Results at V1 and
V6 were compared with the Wilcoxon signed rank test handling zeros and ties
as suggested by Pratt (1959). Level of significance was 0.05.
Results: A total of 133 patients consented to the sub-study, 53 patients were
included in this analysis. The median age was 50 years (range 19-83), 40%
were female, and 7.6% had a high Euro score (Hasford et al., 1998). This was
comparable with the total study cohort (n=1164) with a median age of 53 (range
18-91) and 9.1% Euro-high risk. The results of all patients of the EORTC-QLQ-
C30 items are summarized in Table 1. For most items, the score at diagnosis
did not substantially decrease or increase over time. However, there was an
increase of social and role functioning for all patients. Despite minimally impor-
tant differences in social and role functioning, results of global health status
and the functional scales at V1 and V6 were not statistically significantly differ-
ent. Regarding symptoms there was a substantial change in skin problems. At
diagnosis patients scored skin problems not at all (n=32), a little (n=10), quite
a bit/very much (n=6), whereas at last visit the numbers were 12, 17 and 19
respectively. Other symptoms like edema, joint pain, weight loss, sexual func-
tion and headache were scored equally. Skin adverse events were documented
according WHO as grade 1 in 22, grade 1 or 2 in 7 and grade 3 in 2 patients.
Tabella 1.
Summary and Conclusions: The HRQoL of CML patients increased over
time under first-line treatment with nilotinib with the exception of cognitive func-
tioning. However, the differences were not statistically significant which might
be due to low patient numbers. Regarding the ad hoc symptom scale, skin
problems showed the most notable changes.
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Background: Ponatinib is an approved oral tyrosine kinase inhibitor (TKI) with
potent activity against native BCR-ABL and resistant mutants, including the
T315I mutant.
Aims: The phase 2 PACE trial evaluated the efficacy and safety of ponatinib
(starting dose 45 mg once daily).
Methods: Patients with chronic myeloid leukemia (CML) or Philadelphia chro-
mosome–positive acute lymphoblastic leukemia (Ph+ ALL) resistant/intolerant
to dasatinib/nilotinib or with T315I were enrolled in PACE (NCT01207440) and
gave informed consent. Of 449 patients, 58% received ≥3 prior TKIs. Arterial
occlusive events (AOEs) led to recommended dose reduction in October 2013.
Exposure-adjusted incidence rates of new AOEs were calculated as (number
of first events in interval)/(total exposure for interval in patient-years) x 100.
Rates for later intervals exclude patients with prior events.
Results: As of October 6, 2014: 33% of all patients and 45% of chronic-phase
(CP)-CML patients remained on study. Median follow-up was 34.2 (0.1–48.6)
months overall and 38.4 (0.1–48.6) months for CP-CML patients. Main reasons
for discontinuation were progression (21% overall, 9% CP-CML) and adverse
events (AEs) (15% overall, 17% CP-CML). Among CP-CML patients, 59%
achieved major cytogenetic response (MCyR), 39% achieved major molecular
response (MMR) or better, and 22% achieved MR4.5. Responses were durable,
with an estimated 83% of responders maintaining MCyR at 3 years; estimated
rates of progression-free survival and overall survival at 3 years were 61% and
82%, respectively. Among accelerated-phase CML, blast-phase CML, and Ph+
ALL patients, estimated rates of overall survival at 3 years were 59%, 9%, and
16%, respectively. Treatment-emergent AEs in ≥25% of patients were throm-
bocytopenia (43%), abdominal pain (42%), rash (41%), constipation (37%),
headache (37%), dry skin (36%), fatigue (30%), pyrexia (29%), arthralgia
(29%), hypertension (28%), nausea (28%), and neutropenia (25%). Rates of
AOEs (any/serious) were 22%/17%, including cardiovascular (12%/8%), cere-
brovascular (8%/6%), and peripheral vascular (8%/6%) events. Rates of
venous thromboembolic events (VTEs; any/serious) were 5%/4%. Of the 99
patients with AOEs, 42 remained on study and 33 were still in MCyR. Expo-
sure-adjusted incidence rates of new AOEs (events per 100 patient-years)
were 14.5 in Year 1, 14.1 in Year 2, and 10.8 in Year 3. Exposure-adjusted inci-
dence rates of new VTEs (events per 100 patient-years) were 3.5 in Year 1,
1.8 in Year 2, and 1.8 in Year 3. One year after recommended dose reduction,
61 (95%) of 64 CP-CML patients maintained MCyR, 44 (94%) of 47 CP-CML
patients maintained MMR, and 5 (7%) of 70 ongoing patients without a prior
AOE had an AOE.
Summary and Conclusions: Ponatinib continues to provide deep, durable
responses in heavily pretreated patients, particularly those with CP-CML. One
year after recommended dose reduction, responses were maintained and inci-
dence of new AOEs was low. A dose-ranging trial of ponatinib in refractory
CML to evaluate benefits and risks is currently planned.
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Background: Ponatinib is a potent approved oral tyrosine kinase inhibitor (TKI)
active against native and mutant BCR-ABL, with substantial activity in pts resist-
ant or intolerant to dasatinib or nilotinib or with the T315I mutation. In pts treated
with TKIs in the first-and second-line settings, responses at early (landmark)
time points correlate with positive long-term outcomes.
Aims: Since landmark analyses are limited for populations treated with multiple
prior TKIs, this analysis describes the impact of achieving early landmark
responses with ponatinib on long-term outcomes in CP-CML pts in the ongoing
PACE trial.
Methods: Retrospective landmark analyses of CP-CML pts (n=267) excluded
pts who: dropped out before landmark time, had response at baseline, had
missing or unevaluable assessments (<20 [13] metaphases examined for CCyR
[MCyR]) at landmark time, or progressed before landmark time (for PFS). Pts
gave informed consent. Molecular responses (International Scale; BCR-ABL
≤0.1% [MMR], ≤1%, and ≤10%) and cytogenetic responses (Ph+ metaphases
≤35% [MCyR] and 0% [CCyR]) at 3 and 6 months and their association with
outcomes are reported. Log-rank test was used to calculate P values. Data
cutoff: 6 Oct 2014; median follow-up: 38.4 (0.1–48.6) months.
Results: Of 267 CP-CML pts, 60% received ≥3 prior TKIs. Median age: 60
(18–94) years; median time from diagnosis: 7 (0.5–27) years. At 3 months,
48%, 39%, 49%, 34%, and 14% had achieved MCyR, CCyR, BCR-ABL ≤10%,
BCR-ABL ≤1%, and MMR, respectively. These pts typically had better PFS and
OS after 2 years, compared with those not achieving responses, although PFS
and OS were high in general (Table 1). Molecular response at 3 months was
also associated with achievement of MR4.5 over time. At 6 months, 62%, 52%,
55%, 49%, and 29% had achieved MCyR, CCyR, BCR-ABL ≤10%, BCR-ABL
≤1%, and MMR, respectively. Achievement of these responses was positively
associated with PFS/OS after 2 years (Table 1).
Tabella 1. Association of Early Responses With 2-Year PFS and OS
Summary and Conclusions: Rapid, deep reduction in BCR-ABL levels with
ponatinib was associated with improved long-term outcomes in this heavily
pretreated population. These data demonstrate that achieving early cytogenetic
and molecular responses with ponatinib treatment has a significant prognostic
value in heavily pretreated pts.
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Background: Ponatinib is the only oral tyrosine kinase inhibitor (TKI) approved
for use in refractory CML or Ph+ ALL pts that inhibits the BCR-ABL T315I
mutant, which is uniformly resistant to other approved TKIs.
Aims: The long-term efficacy and safety of ponatinib in pts with the T315I muta-
tion is reported based on pooled data from the ongoing phase 1 and PACE tri-
als.
Methods: The phase 1 trial (NCT00660920) evaluated safety and antileukemic
activity of ponatinib (2–60 mg qd) in pts with resistant/refractory hematologic
malignancies (N=81), and the PACE trial (NCT01207440) evaluated efficacy
and safety of ponatinib (45 mg qd) in pts with CML or Ph+ ALL who were resist-
ant/intolerant to dasatinib/nilotinib or who had the T315I mutation (N=449). All
pts gave informed consent. The T315I mutation was detected at baseline by
Sanger sequencing at a central laboratory. PFS and OS data were collected in
PACE only.
Results: Pooled data from 147 pts with T315I in the phase 1 (n=19) and PACE
(n=128) trials are reported. Among 76 CP-CML, 19 AP-CML, 26 BP-CML, and
26 Ph+ ALL pts, median age was 50, 52, 47, and 62 y, respectively; median
time since diagnosis was 4.6, 6.3, 2.3, and 1.3 y; and 86%, 84%, 96%, and
73% received ≥2 prior TKIs. At the time of analysis (26 September 2014 for
phase 1; 6 October 2014 for PACE), median follow-up for pts with T315I was
36 (1.5–70) mo, 21 (3.1–45) mo, 2.9 (0.4–9) mo, and 2.7 (0.1–40) mo for CP-
CML, AP-CML, BP-CML, and Ph+ ALL pts, respectively; 50%, 26%, 0%, and
4% remained on study. Pts discontinued primarily for disease progression (13%,
26%, 62%, and 46% in CP-CML, AP-CML, BP-CML, and Ph+ ALL, respectively)
and AEs (12%, 16%, 15%, and 4%). Median dose intensity was 34, 38, 44, and
45 mg/d in these groups. Among CP-CML pts, 75% achieved MCyR; 72%,
CCyR; 61%, MMR; 45%, MR4; and 37%, MR4.5. Responses were durable;
83% and 81% of CP-CML pts were estimated to maintain MCyR and CCyR,
respectively, for 3 y. Among AP-CML, BP-CML, and Ph+ ALL pts, MaHR rates
were 58%, 27%, and 38%, respectively. In phase 1, 11/12 CP-mo and median
OS was not reached (3-y OS rate was 63%); for 24 BP-CML and 22 Ph+ ALL
pts in PACE, median PFS/OS was 4.1/6.9 mo and 2.6/6.5 mo, respectively.
Treatment-emergent AEs in ≥30% of all T315I pts were generally grade 1/2
and included: rash, 42%/55% (of total/CP-CML pts); abdominal pain, 39%/42%;
headache, 39%/46%; nausea, 36%/41%; dry skin, 34%/49%; fatigue,
34%/39%; constipation, 33%/36%; and pyrexia, 32%/26%. Arterial occlusive
events (AOEs) occurred in 21%/32% of total/CP-CML pts and included cardio-
vascular (13%/18%), cerebrovascular (8%/12%), and peripheral vascular
(8%/13%) events. Venous thromboembolic events (VTEs) occurred in 8%/7%
of total/CP-CML pts. Exposure-adjusted incidence rates of new AOEs and VTEs
(events per 100 pt-years) were 13.0 and 5.0, respectively, among total pts, and
12.8 and 2.7, respectively, among CP-CML pts.
Summary and Conclusions: Ponatinib continues to provide deep and durable
responses with up to 6 y of follow-up in CP-CML pts with the T315I mutation,
in whom effective treatment options are limited. The response rates and safety
profile observed among T315I pts were comparable to, if not better than, those
observed among all pts with refractory CML or Ph+ ALL in the phase 1 and
PACE trials.
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Background: Ponatinib, an approved oral tyrosine kinase inhibitor (TKI), has
potent activity against native BCR-ABL and resistant mutants, including the
T315I mutant.
Aims: The safety and antileukemic activity of ponatinib were evaluated in
patients with resistant/refractory hematologic malignancies in this phase 1 trial.
This analysis includes a minimum follow-up of 4 years for ongoing patients, the
longest follow-up of ponatinib-treated patients to date.
Methods: Patients (N=81) received ponatinib (2–60 mg once daily) in this ongo-
ing, open-label, dose-escalation trial (NCT00660920; enrollment, 2008–2010;
data cutoff, 26 September 2014). All patients gave informed consent. The medi-
an follow-up for all 43 CP-CML patients was 49.9 (1.7–69.9) months; minimum
follow-up for the 22 CP-CML patients who remained on study at data cutoff
was 50.2 months.
Results: Data for CP-CML patients are reported. Median age was 55 years;
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time since diagnosis was 6.6 years. 60% of patients had received ≥3 prior
TKIs; 63% had BCR-ABL mutations (28% had T315I). At the time of analysis,
22 (51%) of 43 CP-CML patients remained on study. The most common rea-
sons for discontinuation were adverse events (AEs; 26%) and progression
(9%). Among the 43 treated CP-CML patients, major cytogenetic response
(MCyR) was 72%; complete cytogenetic response (CCyR), 65%; major molec-
ular response (MMR), 56%; MR4, 42%; and MR4.5, 28%. Responses were
durable (Table 1). Median durations of response (MCyR, CCyR, and MMR)
were not reached. Of the 22 ongoing patients at data cutoff, 18 (82%) were in
CCyR, and 17 (77%) had MMR or better (6 had MMR, 1 had MR4, and 10 had
MR4.5). The most common treatment-emergent AEs were rash (65%), fatigue
(60%), abdominal pain (58%), headache (58%), and arthralgia (53%). Rates
of arterial occlusive events (AEs/serious AEs) were 40%/30%, including car-
diovascular (30%/21%), cerebrovascular (9%/7%), and peripheral vascular
(14%/9%) events. Rates of venous thromboembolic events (AEs/serious AEs)
were 5%/0%.
Tabella 1. Stability of Response in CP-CML Patients Treated With Pona-
tinib.
Responders Lost Response Maintain Response
n na at 4 Years,% (95% CI)b
MCyR 31 8 68 (44–84)
CCyR 28 8 70 (48–84)
MMR 25 11 52 (30–70)
aFailed to meet criteria for response at any single time point after initial response
bKaplan-Meier estimate
Summary and Conclusions: These data in CP-CML patients represent the
longest follow-up with ponatinib. With 4-year minimum follow-up for ongoing
patients, ponatinib continues to provide benefit to CP-CML patients with prior
TKI failure. Risks and benefits should be evaluated when using ponatinib in
this population.
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Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of hematologic malignancies characterized by clonal expansion of bone marrow
(BM) myeloid precursors with impaired differentiation. It remains unclear
whether hypoplastic MDS (h-MDS) is a distinct clinicopathologic entity that dif-
fers from normo-/hypercellular MDS (NH-MDS) in terms of clinical and biolog-
ical features.
Aims: We aim to investigate the clinic-biologic features of h-MDS and its prog-
nostic relevance in a large cohort of MDS patients.
Methods: A total of 369 de novo MDS patients diagnosed according to the
2008 World Health Organization (WHO) criteria at the National Taiwan Univer-
sity Hospital who had complete clinical data and cryopreserved BM cells for
study were recruited into the analysis. Hypoplasia was defined as less than
30% of the cellularity in the BM biopsy specimen. The clinical features, cyto-
genetics, molecular mutations of 17 genes, and treatment outcomes were com-
pared between h-MDS and NH-MDS patients.
Results: Among the 369 patients, 103 (27.9%) were diagnosed as having h-
MDS. The patients with h-MDS had lower WBC count, peripheral blood and
BM blast percentage than those with NH-MDS (P=0.024, P=0.001 and
P<0.0001, respectively). Refractory anemia (RA) was more common in h-MDS
patients, whereas RA with excess blasts (RAEB) occurred more frequently in
NH-MDS patients. h-MDS was associated with lower risk MDS, including low
and intermediate-1 risk by International Prognostic Scoring System (IPSS)
(34.2% vs 14.8%, P<0.0001), or very low and low risk by revised IPSS (IPSS-
R) (41.1% vs 20.9%, P<0.0001). Clonal chromosomal abnormalities were
detected in 154 (45.2%) of 341 patients who had chromosomal data. There
was no difference in the distribution of karyotypes between patients with h-
MDS and NH-MDS. To investigate the interaction of genetic alterations in the
pathogenesis of h-MDS, a mutational screening of 17 genes was performed.
The patients with h-MDS had lower incidences of RUNX1, ASXL1, DNMT3A,
EZH2 and p53 mutations than those with NH-MDS (3.9% vs 14.4%, P=0.003;
6.9% vs 22%, P<0.0001; 2.9% vs 12.8%, P=0.003; 0% vs 5.3%, P=0.013,
2.9% vs 11%, P=0.013, respectively).
With a median follow-up duration of 46.9 months (range, 0.1-250.7 months),
the cumulated incidence of acute leukemic transformation at 5 years was 18.5%
for h-MDS patients and 41.1% for NH-MDS patients (P=0.001). Further, the
patients with h-MDS had longer median overall survival (OS) than those with
NH-MDS (113.7 months vs 29.1 months, P<0.001). In subgroup analysis, the
survival difference between h-MDS and NH-MDS patients was more significant
in lower-risk group. In multivariate analysis, h-MDS was an independent favor-
able prognostic factor for OS (relative risk 0.651, 95% CI, 0.427–0.992,
P=0.046) irrespective of age, IPSS-R, and gene mutations.
Summary and Conclusions: Our findings provided evidence that h-MDS is a
distinct clinico-biological subgroup of MDS and is inversely associated with
RUNX1, DNMT3A, ASXL1, P53 and EZH2 mutations. Patients with h-MDS
have better leukemia-free survival and OS.
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Background: Up to-50% of lower risk MDS patients respond to ESA, with a
median duration of response of 2 years, most responders relapsing and becom-
ing RBC transfusion dependent (TD). In a previous work on 253 such patients,
we found that outcome was largely dependent on whether ESA failure occurred
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early (primary failure or relapse <6 months), or later (Kelaidi, Leukemia 2013).
However, only few patients in that cohort had received, after ESA failure, treat-
ments other than RBC transfusions.
Aims: In this larger study, gathering the data from the French (GFM), German
(GMDS) and Spanish (GESMD) registries, we also analyzed whether second
line treatments could influence survival.
Methods: 991 lower risk MDS patients included in French (GFM), German
(GMDS) and Spanish (GESMD) registries between 1999 and 2013, and treated
by ESA were analyzed. Median age was 76.5y, with 55.9%males, WHO diag-
nosis: RA (11.6%), RCMD (31.8%), (12.9%) RAEB-1, RARS(24.7%),RCMD-
RS (7.9%), (3,2%) MDS-U, del 5q (1.9%), Median Hb level at onset of ESA
was 9.4g/dl, and 36.8% patients were RBC-TD, median EPO level was 57.8
IU/l (range 0-28000). IPSS-R was very low (20.2%), Low (57,8%), Int (18.7%)
High (0.03%) pts. OS was evaluated from ESA failure. 
Results: Erythroid response (HI-E, IWG criteria) was 66.5%. 331 pts had pri-
mary resistance and 277 relapsed after a response. Median response duration
in relapsing patients was 17 months. 27 patients out of 108 had progressed at
ESA failure (26%). After ESA failure, 195 patients received second, third and
fourth line treatments other than RBC transfusions, including azacytidine (AZA)
(n=131), lenalidomide (LEN) (n=62) thalidomide (n=27), LD araC (7),
ATRA+EPO (n=18), HSCT and ATG in 4 pts each. Considering only the second
line treatments after ESA failure (called TX1), 82 pts received AZA (ORR 41,6%)
and 37 LEN (ORR 29,7%). 18 pts received AZA and (after AZA failure) LEN
(seq 1), and 10 LEN and (after LEN failure) AZA (seq2). There was an ORR of
8/18 (44%) in seq 1 and 4/10 (40%) in seq 2 (with no response to LEN but sub-
sequent response to AZA). Among the patients who progressed at TX1 (n=26),
18 received AZA, 2 LEN and the others low dose chemotherapy. Baseline WHO
diagnosis (RARS and RARS-T vs others, HR 0.58, p=0.002) and IPSS-R (very
low and low vs int/high, HR 0.71, p=0.04) predicted better OS. In a multivariate
Cox model, receiving a second line treatment (considered as time-dependent
variable) did not influence OS, but second line treatment with AZA (and not
with LEN) was associated with improved OS and lower AML progression risk
in patients with ESA response >1 year (HR 0.158, p=0.02 for OS, HR 0.18,
p=0.03 for AML progression risk). Among the patients receiving AZA at TX1
(n=82), 18 had progressed either to RAEB-2 or AML.
Summary and Conclusions: Baseline RARS(-T) and lower IPSS-R predicted
better outcome after ESA failure. AZA, as second line treatment, improved OS
and AML risk in pts with ESA response >1 year, a finding requiring confirmation
in prospective studies. 
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Background: Dysplasias are a hallmark of MDS, they are mandatory for diag-
nosis, define classifications, and may play a role in prognosis and prediction.
Their relative and combined impact regarding other and newer parameters also
on different endpoints (leukemic vs non-leukemic mortality) remains to be defined.
Aims: Aim of the study was to redefine the role of dysplasias in MDS using a
larger multicenter database by evaluating correlations with other parameters,
characterising diagnostic and prognostic entities according to dysplasias includ-
ing their specific prognostic impact.
Methods: Patients: 1979 primary MDS patients without disease modifying treat-
ment were analysed retrospectively: median age: 73 years, 53% male, median
survival: 32 months, median follow up: 66 months. Statistical methods: besides
correlations, relative dominances of each dysplasia are described by odds of dis-
cordant pairs as they are less sample dependent than marginal proportions. Mul-
tiple regressions and Cox-models including interactions were used to quantify
their impact on cytopenias and prognosis, particularly on non-leukemic mortality.
Results: Dysplasias were found in 90.3 % for erythroid, 75.7% myeloid and
70.4% for megakaryocytic lineages, respectively. Unilineage dysplasia was found
in 18.0%, bilineage in 27.6%, trilineage in 54.4% of patients. Correlations between
dysplasias were generally weak, most prominently a positive correlation between
dysmeylo-and dysmegakaryopoiesis was noted. Anemic patients had significantly
more erythrodysplasia whereas myeloid and megakaryocytic dysplasia coincided
with neutropenia and thrombocytopenia, respectively, although details regarding
age, sex, and monocyte count remain to be explored. Dominance of erythroid
dysplasia becomes less pronounced in subentities (FAB, WHO) associated with
higher risk. Dysplasias are evenly distributed among different LDH and Ferritin
levels as well as in cytogenetic risk groups (IPSS 1996 and IPSS-R 2012 defini-
tions) and IPSS. Bone marrow blast categories and IPSS-R, IPSS-R-age, and
WPSS risk groups show fading dominance of erythrodysplasia with higher risk.
Regarding prognosis, dysplasias without adjustment for other parameters showed
marked differences between uni-, bi-and trilineage dysplasias (Dxy =0.15), espe-
cially in low risk cases and with normal cytogenetics. In Cox models myeloid and
megakaryocytic dysplasias had more impact on leukemic transformation than on
overall survival, erythrodysplasia was dominant regarding non leukemic mortality.
Inclusion of an interaction term for joint erythroid and myeloid dysplasias
enhances prognostic models. Inclusion of dysplasias in Cox models using patients
stratified according to IPSS-R shows no significant impact for single or combined
dysplasias or dysplasia interactions.
Summary and Conclusions: Dysplasias play an important independent role
in MDS, which is more pronounced in low risk and normal karyotype cases.
Dichotomisation in uni-vs multilineage dysplasia may not be justified given the
differences between bi-and trilineage cases. Although dysplasias do not provide
additional prognostic power for IPSS-R stratified patients as their prognostic val-
ue is already included in parameters and cutpoints used in this system, they
may support specific models for different mortality risks (leukemic versus non
leukemic) and consequently provide more meaningful classifications for this het-
erogeneous disease. Dysplasias may contribute to a multidimensional model of
MDS composed of anemina, proliferation, and infection/bleeding.
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THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (EPAG) IN
THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC
SYNDROMES (MDS)
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F. Mannino6, Y. Mostafa Kamel6, S. Dougherty6, G. Chan6, A. Giagounidis7
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Background: EPAG, an oral thrombopoietin receptor agonist, increases
platelets (PLTS) in chronic immune thrombocytopenia (TCP), hepatitis C virus-
associated TCP, and severe aplastic anemia. In patients (pts) with advanced
MDS or acute myeloid leukemia (AML) and severe TCP, EPAG has shown to
improve PLTS compared to PBO, leading to potential improvements in morbidity
of severe TCP, progression-free survival (PFS), and overall survival (OS).
Aims: To explore the safety, tolerability, and efficacy of EPAG in pts with advanced
MDS (baseline bone marrow [BM] blasts <20%) from study PMA112509.
Methods: Informed consent was provided. Pts with relapsed/refractory MDS, inel-
igible for antileukemic therapies, with 10–19% BM blasts and PLTS <30×109/Lwere
randomized to EPAG 50 mg once daily (increased every 2 weeks in pts without
PLT response, up to 300 mg [East Asian pts, 150 mg]) or PBO for 6 months. Stan-
dard supportive care and disease-modifying treatments were allowed.
Results: Overall, 32 pts with MDS (EPAG, n=18; PBO, n=14) were enrolled.
All pts received ≥1 prior therapy, including hypomethylating agents (HMAs) or
induction chemotherapy. Fewer EPAG than PBO pts had poor prognosis kary-
otype, but median baseline BM blast % was similar (Table). Most pts received
the maximum dose (EPAG, n=10 [56%]; PBO, n=8 [57%]). Adverse events
(AEs) (EPAG, n=17 [94%]; PBO, n=13 [93%]), Grade ≥3 AEs (EPAG, n=13
[72%]; PBO, n=8 [57%]), drug-related AEs (EPAG, n=10 [56%]; PBO, n=6
[43%]), and AEs leading to withdrawal (EPAG, n=5 [28%]; PBO, n=4 [29%])
were reported. The most common AEs on therapy or <30 days from the last
dose were diarrhea (n=6; 33%), constipation (n=5; 28%), and pyrexia (n=5;
28%) for EPAG pts and pyrexia (n=6; 43%), back pain (n=4; 29%), epistaxis
(n=4; 29%), and febrile neutropenia (n=4; 29%) for PBO pts. The most common
Grade ≥3 AEs on therapy or <30 days from the last dose in either arm were
febrile neutropenia, anemia, pneumonia, and sepsis. A total of 5 EPAG (28%)
and 6 PBO (43%) pts died on therapy or <30 days from the last dose; primary
cause of death in both arms was disease under study. Of 14 (EPAG, n=9; PBO,
n=5) pts with post-baseline BM exam results, 8 (5 [56%] and 3 [60%], respec-
tively) developed ≥20% BM blasts during treatment. PLT transfusion independ-
ence for ≥8 weeks was reported for 5 EPAG (28%) and 3 PBO (21%) pts. Grade
≥3 hemorrhages were reported in 2 EPAG (11%) and 3 PBO (21%) pts. More
EPAG vs PBO pts started HMAs during the study (4 [22%] vs 2 [14%], respec-
tively). Median PFS (Figure) was 16.1 weeks for EPAG vs 7.7 weeks for PBO
(hazard ratio [HR]=0.61; P=0.1531). Median OS was 34.0 weeks for EPAG vs
15.4 weeks for PBO (HR=0.70; P=0.3844).
Tabella 1. Baseline Characteristics.
EPAG (N=18) PBO (N=14)
Poor prognosis karyotype, n (%) 5 (28) 8 (57)
Median (Range)
BM blast, % 11 (10–18) 12.8 (10–19)
Platelets,a×109/L 19.8 (2–60) 13.5 (5–38)
aBaseline PLT count was derived using an average of PLT counts during screening, except within
3 days of PLT transfusion.
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Figure 1. Progression-Free Survival
Summary and Conclusions: EPAG ≤300 mg was well tolerated in pts with
advanced MDS. No obvious differences in blast % change were noted in pts
receiving EPAG vs PBO. Pts receiving EPAG showed a trend toward fewer
Grade ≥3 hemorrhages. Differences in PFS and OS may be influenced by the
direct effect of EPAG, MDS treatments initiated, or imbalances in the proportion
of pts with poor prognosis karyotype. Additional studies with EPAG in MDS and
AML are ongoing. This study (NCT00903422) was funded by GlaxoSmithKline.
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Background: Health-related quality of life (HRQoL) is compromised among
patients with transfusion-dependent anemia due to myelodysplastic syndromes
(MDS). In the phase 3 MDS-005 study, significantly more lenalidomide-treated
patients with MDS achieved RBC transfusion independence (TI) versus place-
bo (26.9% vs 2.5%; P<0.001; Santini V, et al. Blood 2014;124:abstract 409);
assessment of HRQoL was a pre-specified secondary endpoint.
Aims: The current analysis evaluated changes in HRQoL between treatment
arms in the MDS-005 study.
Methods: In MDS-005, transfusion-dependent patients with International Prog-
nostic Scoring System-defined Low or Intermediate-1-risk MDS without del(5q),
unresponsive or refractory to erythropoiesis-stimulating agents, were random-
ized to lenalidomide (n=160) or placebo (n=79). Patients with RBC-TI ≥56 days
or erythroid response by Day 168 (24 weeks) continued double-blind treatment
until erythroid relapse, disease progression, unacceptable toxicity, or consent
withdrawal. HRQoL was assessed using the European Organization for
Research and Treatment of Cancer QLQ-C30 questionnaire at baseline, Week
12, Week 24, every 12 weeks thereafter, and at discontinuation. Analyses were
performed among patients who completed a baseline HRQoL assessment and
had ≥1 post-baseline assessment (lenalidomide, n =122; placebo, n =56).
Changes from baseline were analyzed; 5 HRQoL domains were pre-selected
as clinically relevant: Fatigue, Dyspnea, Physical Functioning, Emotional Func-
tioning, and Global Quality of Life. Between-group comparisons were limited
to weeks 12 and 24 due to low patient numbers after 24 weeks. A post hoc
analysis assessed the impact of RBC-TI on pre-selected HRQoL domains.
Clinically meaningful improvement in HRQoL was defined as a score difference
of at least 10 points versus baseline.
Results: Questionnaire compliance rates were high (>72% in almost all visits)
and not significantly different across all assessment visits (P>0.05). At Week
12, mean changes in HRQoL scores from baseline were similar between treat-
ment arms across pre-selected domains. At Week 24, lenalidomide was asso-
ciated with benefit versus placebo in all pre-selected domains; after adjusting
for baseline scores, benefit was only significant for Emotional Functioning
(P=0.047). For lenalidomide patients with RBC-TI and/or erythroid response
at Week 24 who continued treatment, an improving trend in all pre-selected
domains was observed. In a post hoc analysis, RBC-TI was associated with
significant improvement (P<0.01) across all pre-selected domains, with benefit
also exceeding the pre-specified threshold for clinically meaningful improve-
ment in all 5 domains.
Summary and Conclusions: At Week 24, treatment with lenalidomide was
associated with benefit compared with placebo across all 5 pre-selected
HRQoL domains relevant to MDS; however, after adjusting for baseline scores,
benefit was only significant for Emotional Functioning. Further improvement
versus baseline was observed after Week 24 for patients continuing treatment
with lenalidomide. RBC-TI was associated with statistically significant (P<0.01)
and clinically meaningful improvement in all 5 pre-selected domains. These
data may be important given the superior effect of lenalidomide over placebo
in achievement of RBC-TI and highlight the beneficial effects of lenalidomide
on HRQoL in this patient population.
P243
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Background: A prospective, multicenter European Registry (EUMDS) for newly
diagnosed IPSS low and intermediate-1 Myelodysplastic Syndromes (MDS)
was initiated by the European Leukemianet (ELN) to assess demographic data,
disease-management and clinical course. Health-related quality of life (HRQoL)
has become an important patient reported outcome (PRO) to address patients’
needs and to tailor individualized therapy planning.
Aims: To analyze the impact of MDS on HRQoL as compared to a reference
population.
Methods: The EQ-5D (European quality group 5 dimensions) descriptive sys-
tem was introduced in EUMDS at initial diagnosis and at follow-up visits every
six months. EQ-5D data from MDS-patients were compared with population
norms published by the Euroquol Group (www.euroqol.org).
Results: So far, 1814 EUMDS patients from 17 European countries diagnosed
between December 2007 to December 2014 were included in the EUMDS.
1490 (82.1%) patients with a median age of 74.2 years (range 18.7-95.3) and
61.9% male, completed an EQ-5D questionnaire at the time of inclusion to the
registry. Moderate or severe restrictions in HRQoL were observed in a signifi-
cant proportion of MDS patients in the different dimensions of EQ-5D: mobility
in 41%, self-care in 13%, usual activities in 36%, pain/discomfort in 49%, and
anxiety/depression in 40%, respectively. Mean visual analog scale (VAS) in
EUMDS patients was 69.6±20.3 (mean, standard deviation). Population norms
were available for nine European countries: age and sex-matched analysis
reveal a significantly (p<0.05) higher proportion of restrictions in MDS in the
dimensions anxiety/depression in eight, in usual activities in six, and in mobility
and in self-care in four out of nine countries. Remarkably, problems in the
dimension pain/discomfort were significantly more often observed in the refer-
ence population than in MDS in two countries; in one country a trend towards
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significance was observed (p=0.07). It was possible to compute an index score
for seven countries, which translates the five dimensions of EQ-5D into a single
value, ranging from a score of 1 indicating no problems to a score of 0 indicating
death. Compared to age-and sex-matched simulated populations using the
population norms, EUMDS patients from France (n=340; mean [sd]: 0.69 [0.29];
p<0.001), Germany (26; 0.82 [0.28]; p<0.05), the Netherlands (48; 0.79 [0.20];
p<0.001) and Spain (120; 0.75 [0.32]; p<0.001) were characterized by signifi-
cantly lower EQ-5D index scores than the corresponding reference populations.
Visual analogue scores (VAS) in MDS ranged from 62.1 [20.5) (mean [sd]) in
France to 73.4 [16.8] in Denmark. Four out of nine countries revealed signifi-
cantly (p<0.05) lower VAS-values in MDS as compared to age-and sex-matched
simulated populations based on the reference values. Significant differences
were observed in France: n=340; VAS 62.08 [20.52]; p=0.02; The Netherlands:
48; 71.19 [16.61]; p=0.04; Sweden: 100; 67.45 [20.91]; p<0.001 and the United
Kingdom: 252; 71.31 [20.14]; p=0.01.
Summary and Conclusions: This study demonstrates for the first time pro-
found restrictions in self-reported health in VAS as well as in all dimensions of
the EQ-5D, with the exception of pain/discomfort, in MDS-patients at diagnosis
as compared with reference populations. Thus, the relevance of HRQoL in
treatment algorithms and as an endpoint in clinical studies and registries is
supported. This analysis will form the basis for the design of MDS-specific
assessment scores.
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Background: Anemia is the most frequent cytopenia in lower-risk MDS. Ery-
thropoietic-stimulating agents (ESAs) are commonly used in these patients.
Aims: The aims were (1) to collect the largest lower risk (IPSS low and int-1)
series of MDS patients with anemia treated with ESAs, describe their results,
and (2) to compare the outcomes of this ESA cohort (in terms of progression
to AML and OS) with those of a cohort of lower risk RBC transfusion dependent
untreated patients from the Spanish MDS Registry (SUPP cohort).
Methods: Data from 959 patients with MDS according to FAB and WHO criteria
were recorded in Spresas (SPanish Registry of Erythropoietic Stimulating
Agents Study). 237 cases were excluded from the study (23 treated with poten-
tial modifier agents, 38 with secondary MDS, 24 with IPSS >int-1 risk, 97
patients with Hb level >11 g/dL, 31 diagnosed after Dec 31, 2011 (pre-fixed
end of recruitment period), and 24 with incomplete data). The remaining 722
anemic patients with low/int1 risk IPSS de novo MDS and sufficient follow-up
data available (530 in ESAs and 192 in SUPP cohort) were included in the
analysis and are the basis of this report. Response to treatment was evaluated
according to IWG 2006 response criteria and a multivariate logistic regression
analysis was used to identify independent predictors of erythroid response. OS
and AML evolution (WHO criteria) were defined as the time between EPO intro-
duction (or diagnosis in SUPP arm) and the corresponding event or last follow
up (July 2014) and were analyzed using univariable and multivariable Cox pro-
portional hazards regression methods.
Results: In the ESAs-treated population median age was 77 years (interquartile
range [IQR] 25%>75%: 21-95 y), according to WHO 2008 there were 48 RCUD
(9.2%), 176 RCMD (33.8%), 101 RARS (19.4%), 18 RAEB-1 (3.5%), 2 RAEB-
2 (0.4%), 32 CMML (6.2%) and 3 MDS-U (0.6%) and the IPSS risk group was
low in 66% (N=308) and Int-1 in 34% (N=158). Median Hb level at start of treat-
ment was 9.6 g/dL (4-10.9). Among 329 patients with this data available, 185
patients (56%) were RBC transfusion dependent before ESAs treatment. Medi-
an time from diagnosis to ESAs treatment was 92 (1-5683) days. Among 484
with this data available 27.5% of patients received epoetin α, 19.9% epoetin β,
49.6% darbepoetin α, and 3%other epoietin. Doses and schedules were those
usually employed in MDS. Among 470 patients (88.6%) evaluable for response
the rate of erythroid response was 64.6%. To determine whether treatment with
ESAs had an impact on disease progression and OS, outcome of ESAs cohort
was compared to that of the SUPP cohort. After a median follow up of 3.12
years, 72 patients had developed AML (14%) and 209 had died (40%). Median
overall survival (OS) was 6.7 and 2.6 years, for ESAs and SUPP cohorts,
respectively (p<0.001). Response to treatment significantly improved outcome
(data not shown). Median time to progression to AML was similar in both cohorts
(p=NS), with 1, 2 and 5 years AML-free survival (LFS) of 95%, 92%, and 82%
for ESAs patients and 96%, 92% and 88% for the SUPP group.
Summary and Conclusions: The present study, the largest retrospective
series regarding ESAs treatment in lower risk MDS patients reported so far,
shows that, using conventional survival statistical analysis, treatment with ESAs
results in improved OS and does not increase the risk of AML evolution. Spresas
study was partly supported by Janssen
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Background: In the phase 3 MDS-005 study, lenalidomide treatment was asso-
ciated with significant achievement of RBC transfusion independence (TI) for
≥8 weeks in 26.9% of RBC transfusion-dependent patients with International
Prognostic Scoring System (IPSS) Low or Intermediate-1-risk myelodysplastic
syndromes (MDS) without del(5q), unresponsive or refractory to erythropoiesis-
stimulating agents (ESAs; P <0.001 vs placebo) (Santini V, et al. Blood
2014;124:abstract 409).
Aims: This analysis evaluated the impact of baseline erythropoietin (EPO) lev-
els on RBC-TI in lenalidomide-treated patients with MDS.
Methods: Patients were randomized 2:1 to oral lenalidomide 10 mg once daily
(5 mg for patients with creatinine clearance 40–60 mL/min) or placebo. Rates
of RBC-TI for ≥8 consecutive weeks were analyzed according to baseline EPO
levels prior to randomization (≤500 vs >500 mU/mL) in patients treated with
lenalidomide.
Results: Of 160 lenalidomide-treated patients, 5 had missing baseline EPO
data, 97 had EPO ≤500 mU/mL, and 58 had EPO >500 mU/mL; 125 (78.1%)
of all patients and 94 of 97 (96.9%) patients with EPO ≤500 mU/mL received
prior ESAs. Patients with EPO ≤500 mU/mL were slightly older than those with
EPO >500 mU/mL (median age: 72 vs 68 years), had a longer duration of MDS
(median: 3.7 vs 2.2 years), and lower RBC transfusion burden (median: 3.0 vs
3.8 packed RBC units/28 days). Among patients with EPO ≤500 mU/mL and
prior ESA use, 35.1% achieved RBC-TI ≥8 weeks, whereas only 9.4% of
patients with EPO >500 mU/mL and no prior ESA use had a response. Overall,
there was an increasing linear trend in rates of RBC-TI ≥8 weeks across patients
with decreasing EPO levels: 15.5%, 23.3%, 33.3%, and 42.5% for EPO levels
>500 (n =58), 200 to ≤500 (n =30), 100 to ≤200 (n =27), and ≤100 mU/mL (n
=40), respectively (Fisher’s exact P =0.023; linear trend test P =0.002). A similar
trend was seen in patients who had received prior ESAs.
Summary and Conclusions: In patients with IPSS lower-risk MDS without
del(5q), response to lenalidomide correlated with endogenous serum EPO lev-
els in a linear fashion. Baseline EPO ≤100 mU/mL was associated with RBC-
TI ≥8 weeks in >40% of patients. Patients with EPO ≤500 mU/mL had higher
response rates versus EPO >500 mU/mL. Patients with higher EPO levels may
be less responsive due to intrinsic defects in erythroid signaling pathways,
including STAT5, JAK2, and lipid raft assembly, which are believed to be
restored or stimulated by lenalidomide (Ximeri M, et al. Haematologica
2010;95:406-14; McGraw KL, et al. PLoS One 2014;9:e114249). These results
suggest it may be possible to identify a subset of patients with lower-risk MDS
without del(5q) who can be more sensitive to lenalidomide.
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Background: Chromosomal translocations are an uncommon finding in
myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemias
(CMML). Whether translocations other than t(3q) have a specific prognostic
significance in these entities has never been examined in detail.
Aims: To analyze the prognostic impact of translocations in the context of the
IPSS-R cytogenetic scoring system.
Methods: We evaluated 2014 patients from the Spanish Registry of MDS with
a diagnosis of MDS or CMML (WHO 2008) and an abnormal karyotype by con-
ventional cytogenetic analysis. The main study outcomes were survival from
diagnosis and transformation into acute myeloid leukemia (AML). Survival
curves were drawn using the Kaplan-Meyer method and compared by the log-
rank test. The Cox regression model was used for the multivariate adjustment
of factors predicting survival. The cumulative incidence of AML was estimated
by taking non AML-related death as a competing risk, and adjusted for other
predictive factors by means of the Fine and Gray regression method. Statistical
comparisons were done by the Mann-Whitney U-test for continuous data, and
the chi-square test for categorical factors. Stata, version 11, software (www.sta-
ta.org) was used for the statistical analysis.
Results: Translocations were identified in 168 patients (T-group). As com-
pared with the 1484 patients with abnormal karyotype without translocations
(non-T group), patients in the T-group were younger, had lower Hb, neutrophils
and platelets in peripheral blood and more blasts in bone marrow. The T-group
included a significantly larger proportion of patients with refractory anemia
with excess of blasts and higher scores in both the cytogenetic and the global
IPSS-R (p<0.0001). At the time of analysis, 905 (55%) patients had died.
Median follow-up for survivors was 1.3 years (range, 0.2 to 20 years). The
actuarial survival for all patients was 2.6 years (95% C.I, 2.4 to 2.9). Median
survival for the T-group was significantly shorter compared to the non-T group
(0.98 years [95% CI, 0.82 to 1.2] versus 2.86 years [95% CI, 2.58 to 3.32]),
respectively (p<0.001) (figure1A). After adjustment for the IPSS-R cytogenetic
category, no significant difference between the two groups was found (1.16
years [95% CI, 0.95 to 1.42] versus 1.65 years [95% CI, 1.55 to 1.75]), (ns)
(figure 1B). Three-hundred and forty-three patients (20.75%) had developed
AML after a median follow-up of 1.52 years (95% CI, 0.2-11.2) from the diag-
nosis of MDS, while 605 patients had died without progression to AML. Seven
hundred and five patients were censored alive at the time of analysis. Pres-
ence of translocations was associated with an increased incidence of AML at
the univariate analysis (subhazard rate (SHR): 1.5, 95% CI: 1.1-2.1;p=0.008)
(figure 1C). Nevertheless, this association dissapeared after the multivariate
adjustment for the IPSS-R cytogenetic risk category (SHR: 0.95, 95% CI:
0.68-1.35; p=0.78) (figure1D).
Figure 1.
Summary and Conclusions: In our study, the presence of translocations
clearly identified a subgroup of patients with a more aggressive MDS and with
a poorer IPSS-R cytogenetic prognosis. When a raw analysis of the prognostic
impact of translocations was made, a significant worse survival and an
increased risk of AML transformation were found in the T group. However,
translocations lost their prognostic impact after adjustment for the IPSS-R cyto-
genetic category. This results suggest that translocations are a surrogate mark-
er for other poor prognosis cytogenetic aberrations instead of being causally
related to the poorer outcomes.
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SUPERIOR LONG-TERM OUTCOMES OF LOWER RISK MDS PATIENTS
WHEN TRANSPLANTED IN RESPONSE COMPARED TO RELAPSED OR
REFRACTORY TO HMA
Y.J. Lee1,* J.H. Moon1, S.K. Sohn1, J.S. Ahn2, H.J. Kim2, M.K. Song3,
H.J. Shin3, W.S. Lee4, S.M. Lee4, Y.D. Joo5, H. Kim6, D.Y. Kim7, H.S. Lee8,
Y.S. Kim8, Y.Y. Cho9
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sun, 3Hematology/Oncology, Busan National University Hospital, 4Hematol-
ogy/Oncology, Inje University Busan Baik Hospital, 5Hematology/Oncology,
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8Hematology/Oncology, Kosin University Gosper Hospital, Busan, 9Hematol-
ogy/Oncology, Daegu Catholic University Medical Center, Deagu, Korea,
Republic Of
Background: Allogeneic hematopoieic cell transplantation (Allo-HCT) is gen-
erally recommended for lower-risk myelodysplastic syndrome (LR-MDS)
patients with relapsed or refractory to HMA treatment. It is still under debate
when LR-MDS patients should be transplanted in response or at the time of
loss of response.
Aims: This study retrospectively evaluated the outcomes of allo-HCT who
transplanted in response or relapsed/refractory to HMA treatment.
Methods: The data of 307 patients diagnosed with LR-MDS from Oct 1992 to
Jul 2013 were retrospectively evaluated. To address the time dependence of
allo-HCT, the methods of Simon and Makuch and the Mantel-Byar test was
used.
Results: Among 307 patients with LR-MDS, 200 patients were treated with
HMA. Sixty-three (31.5%) patients showed response (CR/PR/HI) to HMA and
119 (59.5%) were relapsed/refractory (SD/PD). Prior to Allo-HCT, 7 patients
were in response and 26 patients in relapsed/refractory. Median time to allo-
HCT were 2.8 years in responders and 1.9 years for patients with
relapsed/refractory. Among HMA responders, the 5-year overall survival (OS)
rate were 83.3% with allo-HCT (n=7) and 34.2% with continued HMA treatment
(n=53) (p=0.07). Among patients with relapsed/refractory, the 5-year OS rate
were 47.0% with allo-HCT (n=26) and 29.4% with BSC after HMA treatment
(n=93) (p=0.45). There showed a trend in the benefits of OS for patients treated
with allo-HCT in response compared to allo-HCT in SD/PD (p=0.17). In the
multivariate analysis, ECOG-PS 2-3 (HR 3.030, p=0.006), IPSS blast ≥0.5%
(HR 2.003, p=0.018), poor cytogenetic risk group (HR 12.362, p<0.001), and
non-response to HMA (HR 2.487, p=0.001) were unfavorable factors for OS
among LR-MDS patients.
Figure 1.
Summary and Conclusions: Allo-HCT in response to HMA showed superior
OS compared to allo-HCT in relapsed/refractory after HMA for patient with LR-
MDS. To elucidate best time points of allo-HCT for LR-MDS patients, a large
scale study will be needed.
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ABERRANT EXPRESSION PROFILES OF HLA-G AND IMMUNOGLOBULIN-
LIKE TRANSCRIPTS (ILTS) IN ACQUIRED APLASTIC ANEMIA
Y.X. Sun1,* Q. Feng1, Y.Y. Yu1, J. Ma1, X. Li1, J. Peng1
1Qilu hospital, Shandong University, Jinan, China
Background: Human leukocyte antigen-G (HLA-G) is a non-classical MHC
class I molecule characterized by low polymorphism, restricted tissue distribu-
tion and spliced transcripts which encode four membrane-bound (HLA-G1-G4)
and three soluble (HLA-G5-G7) isoforms. HLA-G interacts with multiple cell
subsets such as T cells and B cells, and exerts powerful immune suppressive
effects by binding to its receptors immunoglobulin-like transcripts (ILTs). As a
paradigm of bone marrow failure syndrome, acquired aplastic anemia (AA) is
thought to be a specific autoimmune disease for the aberrant T-cell immune
homeostasis, whereas the function of humoral immunity in acquired AA remains
elusive. It is reported that humoral immune responses to hematopoietic antigens
can be detected in AA patients, and these humoral immune responses may be
useful in unraveling the disease pathophysiology of AA. However, there has
been no data referred to the role of HLA-G in acquired AA.
Aims: The study was performed to investigate whether HLA-G and its two main
receptors (ILT2 and ILT4) were involved in acquired AA.
Methods: Human bone marrow mononuclear cells (BMMCs) and bone marrow
plasma were obtained from 20 severe AA (SAA) patients, 13 moderate AA
(MAA) patients and 16 healthy control subjects. All the AA patients were newly
diagnosed and had not received any specific treatment. The concentration of
soluble HLA-G in bone marrow plasma was determined by enzyme-linked
immunosorbent assay. The relative expression level of HLA-G, ILT2 and ILT4
in BMMCs was quantified by real time polymerase chain reaction. Besides,
the percentages of membrane-bound HLA-G+, ILT2+ and ILT4+ cells amongst
CD4+, CD8+, CD14+ and CD19+ BMMCs were analyzed by flow cytometry.
Results: The concentration of soluble HLA-G in the marrow plasma of AA
patients was much higher than that in healthy controls but no difference was
found between SAA and MAA patients. At transcriptional level, the ILT2 mRNA
expression on BMMCs in AA group was elevated compared with control group
while the HLA-G mRNA level was similar in the two groups. In addition, the
percentage of CD19+lymphocytes among BMMCs was increased in AA group,
and the proportion of ILT2-expressing cells among CD19+ BMMCs in AA
patients was significantly higher than that in healthy controls. In AA group the
percentage of CD19+ BMMCs was negatively correlated with the counts of
neutrophils, platelets or reticulocytes in peripheral blood. No significant differ-
ence was observed for the expression of membrane-bound HLA-G, ILT2 and
ILT4 on the surface of CD4+, CD8+ or CD14+BMMCs between AA patients and
healthy controls.
Summary and Conclusions: Together, our data demonstrated that HLA-
G/ILT2 was aberrantly expressed in AA patients’ marrow cells especially in the
CD19+ lymphocytes, which indicated HLA-G/ILT2 may play a role in the abnor-
mal humoral immunity in AA. Blocking HLA-G/ILT2 interaction might be a novel
therapeutic strategy for acquired AA.
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THE MTOR SIGNALING PATHWAY IS ACTIVIVED IN T CELLS OF APLASTIC
ANEMIA
H. Zhu1, W. Shen1, K. Miao1, J. Li1, G. He1,*
1hematology, the first affiliated hospital of nanjing medical university, nanjing,
China
Background: Aplastic anemia (AA), an unusual hematologic disease, is the
paradigm of the human bone marrow failure syndromes, The pathophysiology
is immune mediated in most cases, with activated cytotoxic T cells implicated.As
known to all, there are two signal transduction pathways for T cells’ activation,
TCR/CD3 as signal 1 heralds antigen recognition whereas cosignal
molecules(such as CD28, CTLA-4) as signal 2 refers to the integrated sum of
environmental cues. MTOR is an evolutionarily conserved PI3-kinase family
member that plays a central role in integrating environmental cues in the form
of amino acids, energy, and growth factors. Recently, an increasingly important
role for mTOR in directing T cell activation and differentiation has become
apparent.
Aims: To explore the roles of the positive and negative factors of mTOR (Mam-
malian target of rapamytin) signal pathway of the pathogenesis of aplastic ane-
mia (AA).
Methods: (1) To analyze the expression of the positive factors (p-Akt, p-mTOR,
p-TSC, p-P70S6K, p-S6, p-4EBP1) and the negative factor (Sirt1) in CD3+ T
cells selected by immunomagnetic beads of 21 aplastic anemia patients’(AA
group) and 16 healthy persons’ (control group) peripheral blood samples by
flow cytometry. (2) To compare the difference of Sirt1/p-Akt, Sirt1/p-TSC, Sirt1/p-
mTOR, Sirt1/p-4EBP1, Sirt1/p-P70S6K, Sirt1/p-S6 between the AA group and
the control group. Analyze the correlation of absolute neutrophil count (ANC)
and lymphocyte count (Ly) with the ratios.
Results: 1.The expression of p-Akt, p-TSC, p-mTOR, p-P70S6K, p-S6, p-
4EBP1 in CD3+ T cells of the aplastic anemia patients were (8.31±2.28),
(41.68±23.72), (14.02±11.51), (14.10±9.46), (20.17±11.75), (137.49±108.58),
respectively. The expression of p-Akt, p-TSC, p-mTOR, p-P70S6K, p-S6, p-
4EBP1 in CD3+ T cells of the control group were (3.11±0.85), (15.74±9.14),
(3.17±1.06), (3.81±1.49), (3.02±0.79), (29.91±17.78), respectively. So, the
expression of all the phosphorylated molecules in aplastic anemia patients
were obviously higher than the control group, (P<0.05, Figure1, Table 1).2. The
expression of the negative factor Sirt1 in CD3+ T cells of aplastic anemia
patients was (10.85±6.15) which had no significant with the control group
(9.67±2.91), (P=0.52, Table 1).3. The ratios of Sirt1/p-Akt, Sirt1/p-TSC, Sirt1/p-
mTOR, Sirt1/p-4EBP1, Sirt1/p-P70S6K in the AA group were much lower than
the control group, (P<0.05, Table 2).4. There were positive correlation between
ANC and the ratios of Sirt1/p-TSC, Sirt1/p-mTOR, Sirt1/p-4EBP1, Sirt1/p-
P70S6K and negative correlation between Ly and the ratios of Sirt1/p-mTOR,
Sirt1/p-4EBP1 in AA group, (P<0.05, Table 3).
Figure 1.
Tabella 1. The expression of the factors in the three groups (Mean±SD)
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Tabella 2. The rations of Sirt1/mTOR in the control and AA groups (Mean±SD)
Tabella 3. The correlation of Sirt1/mTOR with ANC and Ly in AA group
Summary and Conclusions: (1) The mTOR signal pathway in T cells of aplas-
tic anemia is activated, and the expression of Sirt1 in AA group relatively insuf-
ficient. (2) the ratios of Sirt1 with the phosphorylated molecules of mTOR signal
pathway showed: the mTOR pathway in AA group migrated than the normal,
which resulted in increased lymphocyte percentage and inhibition of
hematopoiesis.
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THE PREVALENCE OF GATA-2 MUTATION AMONG PEDIATRIC PATIENTS
WITH MYELODYSPLASTIC SYNDROME IN CZECH REPUBLIC
M. Novakova1,* M. Zaliova1, E. Fronkova1, M.W. Wlodarski2, A. Janda2,
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Background: Germline mutation in GATA-2 transcription factor was recently
identified in patients with immunodeficiency, familiar and sporadic myelodys-
plastic syndrome (MDS) and lymphoedema. Germline mutation in GATA-2 rep-
resents the most frequent genetic cause of MDS among children. Detailed
prevalence of GATA-2 mutation among pediatric patients with MDS or aplastic
anemia (AA) was not so far estimated.
Aims: Our aim was to define the prevalence of GATA-2 mutation among chil-
dren with MDS or aplastic anemia in Czech Republic.
Methods: Since 1998 there were 27 Czech pediatric patients diagnosed with
MDS refractory anemia with excess blasts (RAEB) or RAEB in transformation
(RAEBt). The final diagnostic algorithm including histopathological investiga-
tion for discrimination of MDS subtype refractory cytopenia (RCC) and AA
was introduced in 2005. Therefore only RCC/AA patients diagnosed in 2005-
2014 were included: 32 RCC patients and 41 AA patients. Fanconi anemia as
a cause of bone marrow failure was excluded in all patients. The coding part
and the intronic enhancer region of GATA2 gene was sequenced in all patients
with available material, except for 2 patients with RAEB emerging on the back-
ground of Fanconi anemia and morbus Recklinghausen (in total 22 patients
with RAEB/RAEBt, 31 RCC and 38 AA were analyzed). Immunophenotyping
using flow cytometry was performed in bone marrow and peripheral blood.
Levels of intronRSS-Kde recombination excision circles (KREC) were meas-
ured in peripheral blood and bone marrow with the aim to describe the level
of B cell production.
Results: GATA-2 mutation was found in 9 patients with MDS: in 3 RAEB/RAEBt
and in 6 RCC patients. As expected there was no AA patient with GATA-2 muta-
tion. Patients with GATA-2 mutation frequently harbored cytogenetic abnor-
malities including monosomy 7 and trisomy 8. Interestingly one patient did not
have any cytogenetic abnormality, however her father died of MDS harboring
monosomy 7. In total 7 patients had monosomy 7, 1 patient had trisomy 8 and
one patient had simultaneously monosomy 7 and trisomy 8. The prevalence of
GATA-2 mutation within patients with monosomy 7 and trisomy 8 was 41% and
29%, respectively. Considering patients with monosomy 7 only, patients with
GATA-2 mutation had significantly lower KRECs in peripheral blood and tend
to have lower number of B cells in bone marrow. However, at the time of birth
there was no major decrease in KRECs in 3 out of 4 analyzed Guthrie cards
from GATA-2 mutated patients, indicating postnatal impairment of B cell pro-
duction. The only one patient with low KRECs at birth developed MDS RAEB
at the age of 4 and is the youngest patient in our cohort. Except for this patient,
all other GATA-2 mutated patients were older than 11 years at time of diagnosis
(median 17y). Two patients with GATA-2 mutation died: one of CMV pneu-
monitis, another one of AML with a phenotypic switch to BCP ALL.
Summary and Conclusions: So far published cohorts of patients were mainly
identified based on clinical symptoms (i.e. immunodeficiency, familiar AML/MDS
or lymphoedema). The incidence of GATA-2 mutation among pediatric MDS
RCC, MDS RAEB/RAEBt and AA patients is 19%, 14% and 0%, respectively.
However, the real prevalence could be higher since not all the introns are
sequenced. Interestingly mutation in GATA-2 transcription factor can be iden-
tified even in patients without any cytogenetic abnormality. Diagnosis of GATA-
2 mutation is important for genetic counselling and potential identification of
GATA-2 mutation in a family donor before stem cell transplantation. Supported
by GAUK 802214, IGA NT/14534-3, UNCE 204012
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EVALUATION OF BONE MARROW MICROVESSEL DENSITY IN PATIENTS
WITH APLASTIC ANEMIA AND ITS ROLE IN PREDICTING OUTCOME TO
THERAPY
S. Venkatesan1,* A. Purohit1, M. Aggarwal1, M. Mahapatra1, P. Manivannan1,
S. Tyagi1, H. Pati1, R. Saxena1
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Background: Bone marrow (BM) microenvironment plays a crucial role in the
growth of hemopoietic cells and BM function, which in turn depends on an
intact microvasculature. Our study assesses the microvessel density (MVD) in
the BM biopsy of aplastic anemia (AA).
Aims: To examine BM angiogenesis by assessing MVD in patients with aplastic
anemia (AA), to compare these values with those obtained in control BM, to
correlate the MVD values with the severity of AA and with the response to ther-
apy (Anti Thymocyte Globulin (ATG), cyclosporine (CSA), and androgens).
Methods: Bone marrow biopsy specimens from 60 patients with AA and 17
controls were studied. There were 33 patients with non severe AA (NSAA), 12
patients with severe AA (SAA) and 15 patients with very severe AA (VSAA).
MVD was calculated on sections stained immunohistochemically for CD34. 35
patients (58.33%) received only androgen (Stanazolol 2 mg/kg/day in three
divided doses) due to poor socioeconomic status of patients, 22 patients
(36.66%) were treated with androgen and CSA (5 mg/kg/day in two divided dos-
es) while 03 patients (05%) were given ATG (40mg/kg for four days) and CSA.
Results: The patient age ranged from four to 72 years with median age at
presentation being 22 years. Majority of the patients were males (40/20); male
to female ratio was 2:1. The duration of symptoms ranged from one to sixty
months (median =two months). The commonest symptom being weakness/
fatigability noted in all cases followed by bleeding manifestations (66.66%) and
fever (40%). 53 patients (88.33%) gave transfusion history at presentation with
a range of one to 50 transfusions (median=four). Patients with AA exhibited
reduced BM cellularity which ranged from 5% to 20%. As assessed by CD34
immunohistochemistry, the mean BM MVD in AA group was 1.28±0.36, being
significantly lower than that in control group (6.80±1.59, P<0.001). MVD of
SAA and NSAA patients were 1.16±0.35 and 1.49±0.27, respectively, being
significantly different (P=0.003). MVD of VSAA was 0.93±0.25 and the differ-
ence with NSAA is significant, however there was no significant difference
between SAA and VSAA. Response was assessed in those patients (n=31)
who had a minimum follow up of six months. Of those cases, four had partial
response (PR) while four patients had complete response (CR) at the end of
six months follow up. It was found that MVD was higher among responders
(mean MVD 1.96±0.16) as against non responders (mean MVD 1.26±0.25).
The difference in mean MVD between these two groups was statistically sig-
nificant with a p value of (P<0.001).
Summary and Conclusions: Our study is unique in the sense it is one of the
largest to study the BM MVD in 60 cases of AA. In addition we compared the
mean MVD count of those cases that had shown either PR or CR with mean
MVD count of non responders. Our study shows that AA is associated with
reduced BM angiogenesis. Upon quantification of angiogenesis, it is seen that
the BM MVD reduces with the severity of the disease. Also the patients
responded to therapy had significantly higher MVD than the non responders at
presentation and hence may predict the behavior of the disease. This particular
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finding was not reported in the earlier studies. This observation advances our
knowledge about the role of microenvironment in the pathogenesis of AA and
this critical finding may have implications for new concepts relating to therapy
and outcome of this disease. It may guide future research towards looking at
the option of using pro-angiogenic drugs in treatment of AA. The promotion of
MVD in bone marrow and the improvement of microenvironment may induce
hemopoiesis and create a new way to cure aplastic anemia.
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Background: Diamond-Blackfan Anaemia (DBA) is a rare inherited pure red
cell aplasia. Patients with DBA exhibit a macrocytic normochromic anaemia
and reticulocytopenia. Erythroid progenitors (BFU-E and CFU-E) in bone mar-
row (BM) show a proapoptotic phenotype and their number is reduced. DBA is
considered as the prototype of ribosomopathies. Heterozygous mutations in
one of 13 ribosomal protein (RP) genes have been found in about 65% of
patients. Diagnosis of DBA is hampered by the overlapping clinical presentation
with other BM failure syndromes such as Fanconi Anaemia (FA), Shwachman-
Diamond syndrome (SDS), Dyskeratosis Congenita (DC) and Transient Ery-
throblastopenia of Childhood (TEC). The absence of unique diagnostic features
for the disease makes DBA a diagnosis of exclusion, finally confirmed by muta-
tion analysis.
Aims: As an alternative strategy for developing a more inclusive assay for pos-
sible use in DBA diagnosis we turned to the study of extracellular vesicles (EVs)
whose presence may be altered as a consequence of the loss of erythroid pro-
genitor cells in the marrow of these patients.
Methods: EVs have been isolated from plasma of patients with DBA and appro-
priate controls by differential centrifugations and analysed by flow cytometry.
Three markers have been used to characterise EVs derived from cells of the
erythroid lineage: CD34, CD71 and CD235a. EV immunophenotypic profiles of
8 patients with DBA, 22 healthy controls and 10 patients with other congenital
or acquired anaemias (non-DBA) have been performed.
Results: Among the three EV clusters we found, only the CD34+/CD71low pop-
ulation showed a statistically significant difference between DBA patients and
controls (p<0.05). This population, representing late erythroid progenitors, is
substantially less represented in DBA patients as compared to controls. This
finding is in agreement with the low level of erythroid progenitors in the patients’
BM. The assessment of Receiver Operating Characteristic (ROC) curves
demonstrated the potential use of the CD34+/CD71low population as a diag-
nostic tool. Area under the ROC curve (AUC) values suggest that this test has
an excellent accuracy to discriminate DBA patients from healthy controls, from
non-DBA patients and also from all other individuals under study.
Summary and Conclusions: These data overall suggest that the EV assay
we devised may be useful to improve DBA diagnosis as a quicker and less
invasive alternative to erythroid cultures. It should be noted that this assay is
performed from peripheral blood, is amenable to transfused patients and
requires two working days, whereas erythroid progenitors growth requires 15
working days and needs to be performed using a bone marrow sample in DBA
patients.
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DIAMOND-BLACKFAN ANEMIA
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Background: Diamond-Blackfan anemia (DBA) is a congenital pure red cell
aplasia often associated with skeletal malformations. Mutations in ribosomal
protein coding genes, mainly in RPS19, account for the majority of DBA cases.
The molecular mechanisms underlying DBA pathogenesis are still not com-
pletely understood. Alternative spliced isoforms of FLVCR1 (Feline Leukemia
Virus subgroup C Receptor 1) transcript coding for non-functional proteins have
been reported in some DBA patients. Consistently, a phenotype very close to
DBA has been described in animal models of FLVCR1 deficiency. FLVCR1
gene codes for two proteins: the plasma membrane heme exporter FLVCR1a
and the mitochondrial heme exporter FLVCR1b. Loss of FLVCR1a causes
heme accumulation in cytosol while the lack of FLVCR1b leads to mitochondrial
heme overload. The coordinated expression of both FLVCR1 isoforms regulates
an intracellular heme pool, necessary for proper expansion and differentiation
of erythroid precursors.
Aims: The aim of the work is the investigation of the role of FLVCR1 isoforms
in a cellular model of DBA.
Methods: TF1 cells expressing two different inducible shRNAs against RPS19
were compared to that expressing an inducible shRNA against a scramble
sequence. Cells were examined after 4 days of doxycycline treatment which
causes the downregulation of RPS19. FLVCR1 isoforms levels and heme con-
tent were evaluated. K562 cells stably expressing a shRNA against FLVCR1a
or both FLVCR1a/1b isoforms were compared to that expressing a shRNA
against a scramble sequence. To stimulate erythroid differentiation, K562 cells
were stimulated with 0.5 M sodium butyrate for 72 hours. Heme content, in
vittro erythroid differentiation, cell proliferation, cell cycle, apoptosis and oxida-
tive stress were analyzed.
Results: RPS19-downregulated TF1 cells show a reduction of both FLVCR1a
and FLVCR1b mRNA levels. Consistently, RPS19-downregulated TF1 cells
accumulated heme in both cytosol and mitochondria. It has already been report-
ed that RPS19-downregulated TF1 cells showed reduced proliferation, a G0/G1
arrest and increased apoptosis. To investigate whether the loss of FLVCR1 iso-
forms could affect these processes, we took advantage of K562 cells with a
specific downregulation of FLVCR1a or both FLVCR1a/1b. FLVCR1a-down-
regulated K562 cells showed cytosolic heme overload, reduced proliferation
and increased in vitro differentiation whereas loss of both FLVCR1a and
FLVCR1b causes mitochondrial heme overload, reduced proliferation and
decreased in vitro differentiation. Both FLVCR1a-and FLVCR1a/1b-downregu-
lated K562 cells showed cell cycle arrest at G0/G1 and increased apoptosis,
following the stimulation of in vitro erythroid differentiation.
Summary and Conclusions: Taken together, these data indicate that the
downregulation of FLVCR1 isoforms in K562 cells leads to a phenotype similar
to DBA. Thus, we proposed that alteration of heme metabolism could contribute
to defective proliferation and apoptosis of DBA erythroid progenitors. Further
work is needed to completely define the role of FLVCR1 isoforms in the patho-
genesis of DBA.
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AUTOIMMUNE NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN
NEUTROPENIA REGISTRY
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Background: Neutropenia is a disorder characterized by a reduction of
absolute neutrophil count (ANC) below the lower limit, which is 1.0x109/L in
Caucasian children up to age 1y, whereas from >1 year to adulthood it is 1.5
x109/L. Neutropenia is defined as mild if ANC is between 1.0 and 1.5x109/L,
moderate if between 0.5 and 1.0x109/L, and severe if <0.5x109/L. Autoimmune
neutropenia of infancy (AIN) is a disorder characterized by mild bacterial infec-
tions and a tendency to resolve spontaneously.
Aims: To provide clinical, biochemical and hematological insights through the
analysis of a reasonably sized cohort of patients.
Methods: a retrospective analysis of all patients diagnosed with AIN, enrolled
between 1.01.2002 and 1.06.2014 in the Italian Neutropenia Registry of AIEOP
(Associazione Italiana Onco-Ematologia Pediatrica). The Indirect Granulocyte
Immunofluorescence Test (GIFT) was used to detect circulating auto-antibodies
reacting with purified granulocytes from donors who were not genotyped for
Human Neutrophil Antigens. Italian Guidelines recommend repeating GIFT at
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least 4 times if negative at first; after 4 negative tests neutropenia is defined as
“idiopathic”.
Results: We analyzed 157 AIN patients. The sensitivity of GIFT after 1, 2, 3,
and 4 assays was 61.8%, 73.1%, 78.7%, and 81.8% respectively. The charac-
teristics of the patients are shown in Table I. The median age at onset was
0.70y (range 0.005–4.59): 82% of the children were under 18 months of age
at presentation. Three patients (1.9%) were under one month of age at onset,
and 13.2% of all patients born preterm. Median ANC at onset were 0.45
1x109/L, with the following distribution: 56.0% <0.500x109/L, 38.2% between
0.501 and 1.0x109/L, and 5.7% >1.0x109/L. Diagnosis of AIN was made by
chance in 29.3%, and in 70.7% on the basis of a suspected immunodeficiency
or during a hospitalization due to fever or infections. 89% of the cohort recov-
ered spontaneously and the median age of resolution was 2.14y, with a median
disease duration of 1.30y: 85% of the children recovered at less than 5y, and
13 patients recovered spontaneously at 5-11y of age. Among all the analyzed
parameters in the Cox model only age of appearance (p=0.00029) and
absence of monocytosis (p=0.015) were statistically associated with higher
recovery percentage. Lower age at presentation was also associated with
reduced duration of disease (p=0.028). Recovery was abrupt in 67.4% of
patients; in the remaining 32.5% there was an intermittent neutropenia, with
a median time of definitive healing from the first normal blood count of 0.65
year. Bone marrow was examined in 53 children and was normal in all but 2
patients who showed a moderate decrease of myeloid cellularity. A transient
positivity of direct antiglobulin test (DAT) and a selected IgA deficiency were
present in 6.8% and 3% respectively: both associations did not impact the
probability of spontaneous recovery. 44% of children were hospitalized for
fever or infectious, but only 15 patients (9.6%) suffered from severe infections
(sepsis, pneumonia, skin/soft tissue abscesses, or meningitis/encephalitis),
without long-term consequences. G-CSF was administered “on demand” only
in severe infections in 11 patients.
Tabella 1. Clinical characteristics of AIN cohort
Summary and Conclusions: This is the second largest cohort of AIN patients
ever reported. Our analysis confirms that GIFT assay has a reasonable sensi-
tivity on repeated testings and shows the following new findings that may affect
clinical management of the disease: (i) AIN is frequently found in children born
preterm; (ii) lower age at presentation is associated with reduced duration of
the disease. (iii) AIN can be associated with other immunological abnormalities
like transient positivity of DAT and low IgA serum level; (iii) AIN patients are
often hospitalized for infections but severe infections occur in less than 10% of
patients; (iv) recovery from AIN may be after age of 5 years and in one third of
patients ANC normalizes alternating normal to neutropenic values over a times-
pan >6 months.
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Background: Dyskeratosis congenita (DC) is an inherited telomeropathy char-
acterized by mucocutaneous features (oral leukoplakia, nail dystrophy, abnor-
mal skin pigmentation), bone marrow failure and organs’ compromision (main-
lylung and gastrointestinal tract). Haematopoietic Stem cell Transplantation
(HSCT) is the only definitive treatment to restore hematopoiesis, but increased
organ toxicity has been reported after transplant. To the best of our knowledge,
extensive reports on its outcome are lacking.
Aims: To collect data on the outcome of HSCT in DC by analyzing data from
the European Society for Blood an Bone Marrow Transplantation (EBMT)
Methods: All patients registered in the EBMT data base and affected with DC
were considered eligible to the study. Data about type of HSCT, characteristic
of donors, source of cells, incidence of acute and chronic GvHD were collect-
ed.
Results: A total of 84 patients affected with DC who underwent HSCT from
1979 to 2013, entered the study. Females were 23% of the cohort. Median
age at diagnosis of DC was 5.7 years (0-33y), while median age at HSCT
was 12.3 years (range 0.56-41y). Median time from diagnosis to HSCT was
22 months (0.62-278 mo). The cell source was bone marrow (BM) in 60%,
peripheral blood (PB) in 26% and cord blood (CB) 14%. Thirthy-three percent
of patients were engrafted from a matched related and 50% from an matched
unrelated donor. Fourteen percent were mismatched related and unrelated
HSCT. Engraftment was documented in 88 % of subjects: 6.5 % had primary
graft failure and 4% lost the engraftment. Overall 25 patients (33 %) died, and
59 were alive (67%). Causes of death were: rejection graft/ loss of graft 28%,
infections 24%, non-infectious interstitial pneumonia 16%, multi-organ failure
12%, secondary malignancies 12%, GvDH in 8%. Lung injury was present in
more than one third of the subjects who died. Transplant related mortality of
the whole cohort was 18% . Acute GVDH occurred in 67% of the cohort, mainly
of grade I and II (31%) and grade III in 6% of the cohort. No grade IV aGvHD
has been documented. The 5-year OS and EFS (death, relapse, second
tumours, primary and secondary graft failure being the events) were 63 %
and 51% respectively. Of note EFS curve did not show a plateau. Analyzing
data during the first 12 months of follow up, OS was 87% for patients aged 0-
12 years and 75% for subjects who underwent transplant at age >12 years
(p=0.23). The time between the diagnosis and transplant (>24 months and
<24 months) did not significantly impact on the 5 years-OS which was
assessed respectevely at 72% and 53% (p=0.14). Again, looking at the first
12 months of follow up, OS and EFS according to source of cells seemed not
significantly differ, even if a precocious fall in the curve was observed for CB
and PB rather than for BM.
Summary and Conclusions: HSCT may be an option in DC patients, but the
never reached plateau for the EFS curves points out the high risk morbility of
this disease. Lung involvement represents the main cause of death for both
GvHD and infections. Lung status before HSCT, irrespective to bone marrow
failure, has to be weighted regarding the choice of HSCT. Future data compar-
ing outcome of DSK transplanted and non transplanted patients will be useful
to definitely understand if any patients’ risk stratification regarding HSCT can
be applied.
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SOLUBLE CD163 AS A MARKER FOR MACROPHAGE ACTIVATION IN
CHILDREN AND ADOLESCENTS WITH GAUCHER DISEASE: RELATION
TO PULMONARY AND BONE INVOLVEMENT 
A.A. Adly1,* E. Ismail2
1pediatrics, 2clinical pathology, Ain Shams University, cairo, Egypt
Background: Bone and lung involvement are two major causes of morbidity
in Gaucher disease (GD). The soluble form of CD163 (sCD163) is a valuable
diagnostic biomarker for monitoring diseases with increased macrophage acti-
vation.
Aims: We determined sCD163 levels in 30 children and adolescence with GD
compared with 30 healthy controls and assessed the relation to phenotypes,
disease severity and complications.
Methods: Thirty GD patients (10 had type 1 and 20 had type 3) were recruited
from the regular attendants of the Pediatric Hematology Clinic, Pediatric Hos-
pital, Ain Shams University. All patients were under regular enzyme replace-
ment therapy (ERT) using recombinant glucocerebrosidase. Patients were
studied stressing on skeletal, pulmonary or neurological manifestations and
history of splenectomy. All studied patients were clinically asymptomatic for
pulmonary hypertension. Screening for pulmonary hypertension was done by
the non-invasive Doppler echocardiograpghy. Measurement of bone mineral
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density (BMD) was performed by dual energy X-ray absorptiometry (DXA).
Hematological profile, plasma chitotriosidase activity, D-dimer and sCD163
levels were assessed.
Results: The mean Z score for GD patients with normalBMD was-0.7±0.1.
Patients with osteopenia had a mean Z score of-1.9±0.9 while the mean Z
score for those with osteoporosis was-3.4±1.1. Patients with GD had signifi-
cantly higher sCD163 than healthy controls (median [IQR], 7750 [4000] ng/mL
versus 980 [460] ng/mL; p<0.001). Comparison between patients with type 1
and type 3 GD revealed that the incidence of squint, dysphagia, develop-
mental delay and pulmonary hypertension risk was higher among type 3 GD
patients (p<0.05). D-dimer, chitotriosidase activity and sCD163 levels were
significantly increased in type 3 GD patients compared with type 1 (p<0.05).
Severity score index (SSI) was higher among type 3 GD than type 1
(p<0.001). Other variables including DXA findings were similarly distributed
among both GD groups (p>0.05). sCD163 was significantly elevated in GD
patients with dysphagia (p=0.026), developmental delay (p=0.033), pul-
monary hypertension risk (p<0.001) or abnormal BMD (p=0.031) than those
without. GD patients receiving ERT every 2 weeks had lower levels than
those under ERT more than 2 weeks (p<0.001). sCD163 was positively cor-
related to age, disease duration, SSI, WBC count, D-dimer and chitotriosidase
activity. Multiple regression analysis showed that TRV, D-dimer and chitotriosi-
dase activity were independently related to sCD163 in GD patients (r2=0.768;
p<0.001). The cutoff value of sCD163 at 9400 ng/mL could differentiate GD
patients with and without pulmonary hypertension risk with a sensitivity of
90% and specificity of 95% %, area under the curve 0.975 and 95% confi-
dence interval 0.681-1.0; p<0.001.
Summary and Conclusions: sCD163 is a biomarker for clinical assessment
of macrophage proliferation and activity that would help in risk prediction of
bone and lung involvement. Assessment of sCD163 levels may provide a poten-
tially valuable tool for monitoring the response to ERT in GD patients.
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CYTOSIS IN ADULTS IS HEAVILY AFFECTED BY A COEXISTING VIRAL
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Background: Hemophagocytic lymphohistiocytosis (HLH) is a often fatal hyper-
inflammatory syndrome, mainly occurring on a genetic basis in the paediatric
population. In adult patients (pts) acquired HLH can develop as a complication
of many disorders, which may lead to similar deregulated immune response of
the paediatric form. Early diagnosis is essential in order to avoid a fatal outcome.
HLH-04 criteria have been validated in the paediatric setting, but are often dif-
ficult to apply to the adult population, since they include genetic and immuno-
logical parameters difficult to obtain in due time. Indeed, a readily applicable
diagnostic score (HScore, Fardet 2014) has been recently proposed in order
to facilitate the clinical diagnosis of acquired HLH.
Aims: To confirm the diagnosis of acquired HLH made in a single institution
series of adult pts with HLH-04 criteria, by applying the HScore and to identify
prognostic factors associated with clinical outcome.
Methods: Hscore diagnostic criteria were applied to a series of 35 pts with
HLH diagnosed according to HLH-04 criteria during a 11-year period. The fol-
lowing variables of potential prognostic significance were considered: sex, age,
underlying haematological disease, severity of anemia (<9g/dl), neutropenia
(<1000/mcl) and thrombocytopenia (<100000/mcl), hypertrigliceridemia (>265
mg/dl), hypofibrinogenemia (<150 mg/dl), ferritin >10000 ng/ml, bilirubin >2
mg/dl, LDH>2N, morphological signs of HLH, concomitant viral infection,
response to treatment.
Results: Median age of the 35 pts was 54 (range 17-81), M/F ratio was 20/15.
In 26/35 (74.3%) pts an underlying haematological disease was present (2 Mul-
ticentric Castleman Disease, 10 B-cell Non Hodgkin Lymphoma [NHL], 14 T/NK-
cell NHL); an autoimmune disorder was observed in 4 (11.4%) patients (1 Still
Disease, 1 undifferentiated connective tissue disease, 2 haemolytic anemia);
in 5 (14.3%) no underlying disease was identified. A concomitant infection by
EBV was observed in 10 pts, CMV in 8, HHV8 in 6 and HIV in 1. Hyperferritine-
mia, fever and splenomegaly were present in more than 90% of pts, whereas
bone marrow hemophagocytosis in 51% of cases only. According to HScore,
34/35 patients had a >75% and 32/35 >93% probability of HLH. Two pts did
not receive any treatment; the remaining 33 pts were treated with different
schemes, including steroids (30), i.v. Ig (20), antiviral agents (15), rituximab
(9), chemotherapy (14), HLH-04 protocol (3), cyclosporine (2). Ten of the 29
evaluable pts responded. After a median follow-up of 649 days, 8/35 pts are
alive. Four-year overall survival (OS) and HLH-free survival (HFS) were
17±7.9%SE and 23±8.2%SE, respectively. By univariate analysis, age >50y,
treatment failure and a concomitant viral infection were predictive of fatal out-
come. Notably, median OS of pts with and without a concomitant viral infection
was 35 and 930 days, respectively (p=0.0054).
Figure 1.
Summary and Conclusions: Acquired HLH is not rare in adults and may be
a dangerous but not uniformly fatal syndrome. HScore could be easily applied
and showed high concordance with HLH-04 criteria for its diagnosis. An under-
lying haematological diseases, particularly T/NK-cell, but also B-cell NHL was
the most frequent cause of acquired HLH. However a diagnosis of lymphoma
did not influence HLH outcome, whereas, in addition to older age and lack of
response to treatment, the presence of a concomitant viral infection, particularly
herpetic, was a dismal prognostic factor and predicted a rapid fatal outcome. A
better control of coexisting viral infections is warranted to improve the outcome
of acquired HLH.
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A COMPREHENSIVE GENOME-WIDE COPY NUMBER ALTERATIONS
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Background: Array-based technology has been showing a great impact on
clinical cancer cytogenetic, especially on genetically heterogeneous disease,
such as Multiple Myeloma (MM), where relevant lesions might be the hallmarks
of different patients’ subgroups, thus becoming of clinical relevance as well.
The phase III EMN02 study was designed to compare Bortezomib, Melphalan,
Prednisone with high-dose Melphalan and autologous stem cell transplantation
after a bortezomib-based induction, for newly diagnosed MM patients.
Aims: Here we present the comprehensive, high throughput genomic profile
performed at diagnosis in a subset of patients, in order to perform correlations
with response to induction therapy.
Methods: Data obtained from 170 patients, treated with bortezomib-
cyclophosphamide-dexamethasone (VCD) as induction therapy prior to ran-
domization, have been analyzed. Highly purified CD138+ bone marrow plasma
cells were profiled by SNPs array (Affymetrix 6.0 and CytoScanHD® chip).
ChAS (Affymetrix) and Nexus Copy NumberTM 7.5 (Biodiscovery) software
were used to perform CNAs analyses and clinical correlations, respectively.
Results: Presenting MM cases were studied by SNPs array in order to compute
CNAs and acquired loss of heterozygosity (LOH) in the tumor. The frequency
distribution of the more relevant CNAs among the 170 MM cases is summarized
in table 1. A subgroup of 13/170 (7.6%) cases is characterized by the absence
of any macro CNAs (either gains or losses): these cases are mainly character-
ized by LOH events on chr. 1, 8 and 16, where putative tumor suppressor
genes are located (e.g. PLEKOH1 and SIAH1 on chr.1 and 16, respectively).
In order to identify novel chromosomal lesions impacting the response to ther-
apy, we compared the CNAs profile of the extreme response categories, i.e.
³CR and SD. Either the absence of CNAs, or the presence of any of the renown
prognostically relevant ones does not significantly impact on the response to
induction therapy. On the contrary, two novel lesions resulted highly significant:
(1) a 42.9Kb CN gain on chr.11q22.1-22.2, which only includes the Hippo path-
way mediator YAP1, which significantly characterizes 6% of ³CR patients, as
compared to 54% of SD ones (p=0.002); (2) an extended CN loss on
chr.14q13.1-13.3, including genes implicated in the progression on cancer (e.g.
NKX2-8), which significantly characterizes 62.5% of £CR patients, as compared
to 4% of SD ones (p<0.001).
Tabella 1.
Summary and Conclusions: The reconstruction of high-throughput virtual
karyiotype by SNPs array in a cohort of homogeneously treated, newly diag-
nosed MM cases offered the opportunity to obtain a comprehensive overlook
of each patient’s sub-chromosomal anatomy. This allowed both to perform a
detailed patients’ stratification at diagnosis and to identify, among the whole
spectrum of CNAs, those having an impact on the response to therapy.
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PROTEASOME SUBUNITS AND CYTOTOXIC ACTIVITY OF PROTEASOME
INHIBITORS IN MULTIPLE MYELOMA
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Background: The use of proteasome inhibitors (PI) with the first-in class drug
Bortezomib (Btz) has improved the outcome of multiple myeloma (MM) patients.
However, Btz resistance frequently emerges in patients with advanced disease.
The second generation PI Carfilzomib (Cfz) and additional PI (including ixa-
zomib, delanzomib, oprozomib, ONX-0914 (PR-957)) are in advanced clinical
development. All these PI by design target the β5 subunit of the proteasome,
the rate-limiting protease, except for ONX-0914, which targets the β5i immuno-
proteasome subunit. The proteasome in addition contains β1 and β2 protease
subunits that differ from β5 in their substrate specificity. The degree of cytotox-
icity of PI varies with the degree of co-inhibition of proteasomal subunits β1/1i
and/or β2/2i, in addition to β5/5i. Btz-refractory MM cells upregulate activity of
β2, the subunit not targeted by Btz. The “optimum” pattern of proteasome inhi-
bition to reach maximum cytotoxicity in MM, either Btz-sensitive or Btz-resistant
is unknown, as well as the individual patterns of proteasome subunit
inhibition(i.e. co-inhibition of β1 and/or β2) of the non-approved PI in MM.
Aims: (I) To assess the impact of co-inhibition of proteasome subunits activity
(β1i, β1/1i, β2/2i, β5i, β5/5i) on cytotoxicity in Btz-sensitive and Btz-resistant MM
cells; (II) to analyse the subunit inhibition pattern of PI in clinical development
in relation to their cytotoxic activity.
Methods: We developed a set of subunit-selective proteasome inhibitors as
well as fluorophore-labelled activity-based probes (ABP) capable to visualize
the individual activities of the β1, β2, β5-subunits of the constitutive and immuno-
proteasome in intact cells. Equimolar concentrations of PI were used to assess
the inhibition profiles of the different drug candidates. Btz-resistant MM cell
lines were generated by continuous drug exposure from AMO-1 cells
(AMOaBtz,). Viability was estimated by MTS and plotted against the inhibition
of the individual β-subunits (alone or with various combinations of proteasome
inhibitors). In addition, recently synthetized inhibitors with dual specificity for
β2/2i/β5/5i (Xin550, Xin551) were used to improve the efficacy of proteasome
inhibition in PI resistant cells.
Results: Table 1: Cytotoxic effect of selective inhibition of individual subunits
of the proteasome (β1, β2, β5) or immunoproteasome (β1i, β5i,) alone or in com-
bination, in intact MM cells, either sensitive or resistant to Btz (wt/aBtz); no (-)
low (+), intermediate (++), high (+++) effect.
Tabella 1.
Summary and Conclusions: ABP is a reliable tool for analysis of proteasome
subunit activity in intact cells. Viability of Btz-sensitive MM cells can be maxi-
mally reduced by selective inhibition of β5-type activity, so that additional β1
and/or β2-targeted proteasome inhibition does not increase cytotoxicity. In con-
trast, co-inhibition of β2/2i in addition to β5 is required to achieve meaningful
cytotoxicity in Btz-resistant MM cells. Inhibition of β1/1i, either with β5 or β2/2i,
has no additional cytotoxic effect (Table 1). Further, Xin550/ Xin551, inhibitors
of β2/β5 are able to overcome resistance to Btz in vitro. Novel PI drug candi-
dates showed considerably less co-inhibition of either β1 or β2 subunits, com-
pared to Cfz or Btz, which correlated with a lower cytotoxic activity, in particular
against Btz-resistant MM cells.
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Background: Lysine-specific demethylase 1 (LSD1), a FAD-dependent histone
demethylase which selectively removes mono-and di-methyl groups from H3K4,
H3K9 residues leading to either repression or activation of transcriptome. LSD1
forms a co-repression complex with HDAC1, HDAC2, mSin3a and MMSET,
while the IMIDs cause cell cycle arrest in Multiple Myeloma (MM) by modifying
the chromatin structure of the p21WAF-1 promoter through LSD1 demethyla-
tion.
Aims: Here, we study the functional role of LSD1 in MM pathogenesis and its
contribution in aggressive traits of myeloma disease.
Methods: The expression level of LSD1 transcript and its prognostic role was
evaluated in publically available datasets of MM patients (GSE2113,
GSE16122). We utilized MM.1S, OPM2, LP1 and RPMI-8226 human myeloma
cell lines (HMCLs). Osteoclastogenesis was evaluated by using double
TRAP/ALP staining and by estimating the mRNA expression levels of osteoblast
markers (APL, BSP, OC). Cell viability and proliferation was evaluated by
CellTiter Glo and 3[H]Thymidine uptake assays. Immunoblot analysis was per-
formed using antibodies against LSD1, HDAC1,2, H3K4me2/3, H3K9me2/3.
We evaluated the expression of LSD1 in bone marrow paraffin embedded spec-
imen from 10 newly diagnosed MM patients. The epithelial-mesenchymal tran-
sition (EMT) was evaluated by using the transwell migration assay, invasion
and wound healing assays.
Results: First, we observed significant overexpression of LSD1 in patients with
symptomatic MM and Plasma Cell Leukemia (PCL) (p<.001). The expression
of LSD1 in a panel 45 HMCLs was also pronounced. We confirmed the expres-
sion and both its nuclear and cytoplasmic localization in HMCLs and primary
bone marrow plasma cells from newly diagnosed, relapsed MM and PCL
patients (N=10). LSD1 was highly expressed in bone marrow specimen of MM
patients and the higher expression was positively correlated with presence of
bone fractures at diagnosis. LSD1 knockdown in LP1 and MM1S cells resulted
in modest cytotoxicity. After a combination silencing of JARID1 members and
LSD1 we were able to observe a further significant decrease in survival of MM
cells lacking JARID1C and LSD1, indicating that the overlapping demethylation
of H3K4 is of high importance for the cell survival. We examined the post-trans-
lational histone modifications after LSD1 knockdown and as expected, we
observed significant increase of K4me2/3 and K9me2 marks, but more inter-
estingly, alteration of acetylation status of K9. Moreover, we observed that LSD1
depletion enhances significantly the cytotoxicity effect of LBH589. LSD1 deple-
tion resulted in significant reduction of mRNA levels by using real-time PCR
and protein expression by immunoblotting of HDAC1 and HDAC2. Furthermore,
we sought to investigate the impact of LSD1 in EMT. LSD1 depletion in MM1S
and LP1 cells inhibited significantly the migratory potency. More importantly,
MM cells lacking LSD1 expressed significant lower levels of E-cadherin, N-
cadherin and Vimentin evaluated by immunoblotting and immunocytochemistry.
We confirmed the suppression of EMT-involved gene expression by performing
a PCR-microarray assay. Finally, given the presence of osteolytic lesions as a
hallmark of disease, and consequent impact on outcome, we evaluated the
impact of LSD1 on osteoblast differentiation and osteoclastogenesis. LSD1
depletion and pharmacological inhibition (S2101) resulted in significant inhibition
of osteoclastogenesis and RANKL-induced resorption and survival of OCs. In
contrast, LSD1 overexpression confirmed the upregulation of Wnt/b-catenin
pathway suggesting a possible underlying mechanism for the osteoclastogen-
esis potency in MM patients with high expression of LSD1.
Summary and Conclusions: Our data suggest a promising epigenetic
approach in myeloma therapeutics by targeting the deregulated LSD1-methy-
lome in MM patients.
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S1P MODULATOR FTY720 TARGETS OSTEOCLASTOGENESIS IN
CXCR4-BASED MULTIPLE MYELOMA SYSTEMIC XENOGRAFT MODEL
K. Beider1,* E. Rosenberg1, H. Bitner1, A. Shimoni1, M. Leiba1, M. Koren-
Michowitz1, S. Klein2, D. Olam2, L. Weiss2, M. Abraham2, A. Peled2, A. Nagler1
1Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, 2Goldyne
Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital,
Jerusalem, Israel
Background: Bone disease is one of the hallmarks of multiple myeloma (MM)
leading to substantial morbidity and disability. Bone lesions result from abnor-
mally increased osteoclast (OC) formation and activation. Studying the under-
lying mechanism may help to develop new therapeutic targets to treat MM
associated osteolytic lesions and related complications.
Aims: Sphingosine-1-phosphate (S1P) was shown to play important role in
osteoclast biology. Previously we reported that S1P modulator FTY720 exhibits
potent anti-myeloma effect in vitro and in vivo in novel disseminated xenograft
model of MM. We report now the effect of FTY720 on formation and activation
of OCs and their functional sequel in MM model.
Methods: The in vitro effect of FTY720 was tested onOCsandOCprecursors
from healthy donors, and on bone marrowmesenchymalstromal cells (BMSCs).
in vivo model of BM-disseminated humanmyelomawas used to evaluate
FTY720 anti-MM andboneactivities.
Results: The generated OCs expressed the genes encoding for S1P1 and
S1P2 receptors and enzyme SPHK1, tested by RT-PCR. Treatment with
FTY720 significantly reduced in vitro formation of TRAP+ OCs, resulting in
90% inhibition following 1 µM treatment, and complete abolishment of OC for-
mation at 2.5 µM FTY720 (p<0.0001). Furthermore, FTY720 significantly
reduced the expression of genes associated with OC activation. Thus, expres-
sion of osteoactivin, cathepsin K, NFATc1, OSCAR, RANK, RANTES, MT1-
MMP and MMP9 genes were significantly down-regulated in FTY720-treated
OC cultures (p<0.001). Mechanistically, FTY720 abrogated RANKL-induced
Erk1/2 phosphorylation in OC progenitors. In addition, FTY720 targeted the
microenvironment components-MM cells and BMSCs, suppressing the expres-
sion of osteoclastogenic factors. mRNA levels of MIP1a, RANTES, MCP-1
and RANKL were significantly reduced in both MM cells (RPMI8226, CAG,
OPM-2) and BMSCs upon FTY720 treatment (p<0.001). Moreover, FTY720
altered the ability of myeloma and stroma cells to promote OC formation, and
concomitantly FTY720 overcame OC-mediated support and drug resistance
of MM cells. Thus, FTY720 was able to disrupt the deleterious cross-talk
between the MM tumor cells and the OCs. Next, we evaluated the effect of
FTY720 on OC activation in vivo taking advantage of our novel xenograft mod-
el of CXCR4-overexpressing MM cells that results in typical BM involvement
accompanying by significant increase in number of TRAP+ murine OC. Treat-
ment of MM-bearing mice with FTY720 (10 mg/kg) effectively targeted the MM
cells in the BM milieu. Correspondingly, FTY720 significantly reduced mRNA
levels of murine OC differentiation marker genes in BM, including those encod-
ing cathepsin K, integrin β3, OSCAR, RANTES and RANKL (p<0.001). This
effect correlated with increased numbers of circulating CD11c+ and F4/80+
monocytes, with OC precursors in both cell populations. Concomitantly, sig-
nificantly increased numbers of TRAP+ OCs were generated in vitro from
PBMCs of FTY720-treated animals in comparison to vehicle-treated controls
(p<0.001). To investigate whether OC precursor migration is affected by
FTY720, we evaluated the in vitro migration of human monocytes toward
CXCL12, well-known chemo-attractant of OC precursors. FTY720 completely
blocked CXCL12-induced migration of CD14+ cells and significantly reduced
their surface CXCR4 expression. These results suggest novel mechanism of
action of FTY720, affecting both S1P and CXCR4 pathways, reducing the
attachment of the OC precursors to the bone and thus leading to their mobi-
lization to the blood.
Summary and Conclusions: Our observations uncover new roles of S1P
pathway in OC formation and activation in MM, delineating a novel mechanism
of FTY720 targeting OC formation and migration in vitro and in vivo and pro-
viding preclinical rationale for its therapeutic application in patients with MM
bone disease.
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PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF
BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO
A. Bolomsky1,* H. Ludwig1
1Department of Internal Medicine I, Wilhelminenspital, Wilhelminen Cancer
Research Institute, Vienna, Austria
Background: BMI-1 is a putative oncogene reported to be overexpressed in
multiple myeloma (MM) compared to normal bone marrow plasma cells. Silenc-
ing of BMI-1 was shown to induce apoptosis, to impair proliferation and to sen-
sitize malignant plasma cells to bortezomib. However, therapeutic agents specif-
ically targeting BMI-1 were not available so far.
Aims: Here we investigated PTC-209, a novel transcriptional repressor of BMI-
1, for its activity in MM.
Methods: We confirmed overexpression of BMI-1 in MGUS (n=44), SMM
(n=12) and MM (n=414) compared to normal BM plasma cells (n=22) in a pub-
lically available gene expression dataset (Zhan et al., 2006). Preclinical activity
of PTC-209 was analysed in a panel of 8 human MM cell lines (HMCLs) as well
as in human umbilical vein endothelial cells (HUVECs) and during osteoblast
development.
Results: BMI-1 expression was significantly elevated in all 7 GEP-defined
molecular subgroups analysed (median expression value 12409 in MM vs 8183
in BM plasma cells, P<0.0001). Interestingly, BMI-1 expression was especially
increased in the CD2 (median expression value: 15965) and lower in the poor
prognostic proliferation (median expression value: 9759) and MMSET (median
expression value: 10860) associated molecular subgroups. Treatment with
PTC-209 significantly decreased viable cell numbers in MM cells with IC50 val-
ues <2 µM in 6 of 8 HMCLs tested (range: 0.21-5.68 µM). The combination of
PTC-209 with either pomalidomide or carfilzomib led to additive and synergistic
drug activity, especially in the PTC-209 resistant HMCL U266. Mechanistically,
PTC-209 induced a G1 cell cycle arrest in MM cells which was accompanied
by a significant downregulation of cyclin D1 and MYC as well as upregulation
of p16, p21 and p27. Induction of apoptosis was confirmed by Annexin-V/7-
AAD staining and increased levels of PARP cleavage. We observed upregula-
tion of NOXA after 5h (up to 3.23±1.06 fold induction at 2.5µM, P=0.02) and
downregulation of MCL-1 after 20h (up to 0.84±0.07 fold reduction at 1 µM,
P<0.0001) suggesting that these molecules mediate the apoptotic pathway of
PTC-209. Importantly, the pro-apoptotic activity of PTC-209 was upheld in co-
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culture of MM cells with BM stromal cells. In the MM microenvironment, PTC-
209 impaired tube formation (>90% reduction at 1 µM, P<0.0001) of HUVECs
in a dose dependent manner. Similarly, PTC-209 led to a dose-dependent
decrease of osteoblast formation evidenced by a reduction in alkaline phos-
phatase activity (62% reduction at 1 µM, P<0.0001) and matrix mineralization.
The latter might be attributed to the close interaction of BMI-1 and the Wnt sig-
naling pathway. We indeed observed a strong induction of the Wnt signaling
inhibitor DKK-1 after treatment of MM cells with PTC-209 for 5h (up to
6.86±3.23 fold induction at 2.5 µM, P=0.03).
Summary and Conclusions: Our data reveal therapeutic targeting of BMI-1
by PTC-209 as a promising novel therapeutic intervention for MM. We con-
firmed overexpression of BMI-1 in MM highlighting its role as attractive drug-
target. In line with this, PTC-209 showed potent anti-MM activity in 7 of 8
HMCLs tested. Moreover, PTC-209 demonstrates synergistic activity with
pomalidomide and carfilzomib, overcomes BM stromal support, impairs angio-
genesis and affects the expression of several prominent “MM-genes” known
for their essential role in the proliferation and survival of MM (e.g. CCND1,
MYC, MCL-1). Upregulation of DKK-1 suggests that the osteoblast suppressive
effect of PTC-209 might be overcome by concurrent antibody treatment. Further
studies will clarify the role of PTC-209 in bone remodelling and corroborate its
potent anti-MM activity.
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POMALIDOMIDE ENHANCES THE ACTIVATION OF ANTI-MYELOMA
SPECIFIC T CELLS IN HEALTHY DONORS AND MULTIPLE MYELOMA
PATIENTS
J. Dai1,* B. Neuber1, M. Engelhardt1, S. Medenhoff1, M. Schmitt1, A.D. Ho1, 
H. Goldschmidt1,2, M. Hundemer1
1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Ger-
many, 2National Center for Tumor Diseases, University of Heidelberg, Heidel-
berg, Germany
Background: Pomalidomide is an IMiD® (immunomodulatory drug)that main-
tain the immune modulating as well as anti-tumor effects similar to the parental
compounds thalidomide and lenalidomide. It has been reported to be the most
potent IMiD® compoundso far. The immune modulating effects of pomalidomide
include activation of NK cells, enhancement of dendritic cell function, and con-
trol of regulatory T cells. Pomalidomide has been used in clinic for the treatment
of multiple myeloma (MM). However, the exact mechanism of this IMiD® is still
unclear.
Aims: The aim of our study was to investigate the immunmodulatory effects of
pomalidomide especially on anti-myeloma specific T cells, which are able to
recognize and kill the myeloma cells.
Methods: For our study we have applied an in vitro model using autologous
dendritic cells to facilitate the expansion of antigen-specific T cells against the
MM-antigen HM1.24. The expansion of the antigen-specific T cells from 16
healthy donors and 6 patients with plasma cell dyscrasias (symptomatic MM,
smoldering MM and monoclonal gammopathy of undetermined significance)
were conducted in the presence or absence of pomalidomide. The cells were
incubated with pomalidomide for 12 or 21 days. We analysed the number of
the anti-myeloma specific T cells by IFN-y ELISpot, and quantified the secretion
of granzyme B and IL-6 from the specific T cells by ELISA.
Results: We found that pomalidomide was able to enhance significantly the
number of anti-myeloma specific T cells of healthy donors (p ≤.05) and patients
with plasma cell dyscrasias (p ≤.05). In addition, a longer duration of the IMiD®-
exposure on T cells (21 days vs 12 days) induced a higher frequency of the
specific T cells. We observed a significantly enhanced secretion of granzyme
B in 7 healthy donors (p ≤.05) and in 4 patients with plasma cell dyscrasias (p
≤.05); thus providing evidence for pomalidomide´s effects on cytotoxicity of
anti-myeloma specific T cells. Exploring the role of immune modulating
cytokines by ELISA, we found that pomalidomide significantly enhanced the
IL-6 secretion from anti-myeloma specific T cells of 16 healthy donors (p ≤.05)
and 4 patients with plasma cell dyscrasias. Interestingly, the IMiD® lenalidomide
has been reported to induce a blockade of IL-6 release. Accordingly, our pre-
vious work showed that IL-6 inhibited the activation of anti-tumor specific T
cells. However, in the present study, pomalidomide demonstrated an enhance-
ment of IL-6 release from anti-myeloma specific T cells.
Summary and Conclusions: In conclusion, we have provided evidence that
pomalidomide was able to enhance activation and cytotoxicity of anti-myeloma
specific T cells. In addition, we have defined the role of pomalidomide on the
enhancement of IL-6 secretion. This knowledge might explain partly the mech-
anism of activity of this drug in patients with MM.
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LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION
MODULATING BOTH MONOCYTE DIFFERENTIATION AND
MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES
F. Costa1,* M. Bolzoni1, R. Vescovini1, D. Toscani1, F. Accardi1, P. Storti1,
V. Marchica1, D. Guasco1, B. Dalla Palma1, F. Aversa1, N. Giuliani1
1Clinical and Experimental Medicine, Università degli Studi di Parma, Parma,
Italy
Background: The immunomodulatory drugs (IMiDs®) have several mecha-
nisms of action including the activation of T lymphocytes and natural killer cells,
direct anti-tumor effect on myeloma cells and anti-angiogenic and osteoclas-
togenic effects. However their use to reverse tumor-mediated immune sup-
pression and amplify multiple myeloma (MM)-specific immunity is currently
being explored and particularly the effects of Lenalidomide (LEN) on antigen
presenting cells is not yet fully known.
Aims: In order to clarify this issue in this study we investigated the potential
effect of LEN on maturation of both human progenitors and mature Dendritic
Cells (DCs) and on the immunosuppressive properties of human mesenchymal
stromal cells (hMSCs) on DCs.
Methods: DCs were differentiated in vitro from CD14+ cells, purified either
from peripheral blood (PB) of 6 healthy donors (HDs) or both PB and bone
marrow (BM) samples of a cohort of 9 patients with MM including 5 with symp-
tomatic MM and 4 with smoldering MM (SMM). Differentiation of monocyte-
derived DCs (mo-DCs) were induced by the treatment with granulocyte
macrophage colony-stimulating factor and Interleukin (IL)-4 for 8 days and
tumor necrosis factor (TNF) α for the last 24hrs. We added LEN at different
concentrations (0,1-2 µM) during all the differentiation period or for the last
48hrs of culture. LEN concentrations were chosen according to the serum
levels found in pharmacokinetic studies on patients treated withLEN ranging
from 5 mg to 25 mg. At the end of culture period, non-adherent cells were ana-
lyzed for DC maturation markers (CD83, HLA-DR, CD80, CD86 and CD209)
by flow cytometry. Circulating mature DCs were also obtained by an immuno-
magnetic kit and treated with LEN for 48hrs. Moreover mo-DC differentiation
was performed in the presence of conditioned media (CM) of hMSCs treated
for 5 days with LEN (0,1-2µM). The expression of soluble factors involved in
DC development was tested in hMSCs treated with LEN for 24hrs by both gene
expression profiling (Affymetrix® gene chips) and real time PCR. Finally PB
CD3+ cells were in vitro activated by ionomycin and phorbol myristic acetate
for 72hrs, and then treated with LEN for 48hrs. CM was collected either to
measure pro-survival DC cytokine levels or to treat precursors or mature mo-
DCs for 48hrs.
Results: LEN treatment induced a reduction of both number and % of mature
mo-DC as compared to untreated controls, either in HD’s and in patient’s sam-
ples. On the other hand, LEN treatment significantly increased the median
intensity expression of CD86 (LEN 0,1µM vs control, p=0,008) and CD209
(LEN 0,1µM vs control p=0.0004) but not of CD80 by mo-DCs derived from
BM. This effect was observed either in symptomatic MM or SMM patients but
not in HDs. Similarly increased CD209 expression has been also seen in mo-
DCs derived from PB (LEN 0,1µM vs control p=0,0014) in both MM and SMM
patients. The possible indirect effect of LEN on DCs was further investigated.
Interestingly LEN blunted the inhibitory effect of hMSCs on mo-DC differentia-
tion and down-regulated IL6 but not TGFB1, IL8, TNF and HGF gene expres-
sion. Moreover LEN increased the production of the pro-survival DCs factor
receptor activator of nuclear factor κB ligand (RANKL) by activated T cells com-
pared to controls.
Summary and Conclusions: LEN reduces the number of DCs but increases
the expression of mature DC markers both directly and indirectly, reducing the
immunosuppressive properties of hMSCs. These evidences underline a pos-
sible new effect of IMiDs® on the alloreactivity against MM cells.
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P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA
(MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL
TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4
ALLOSTERIC INHIBITORS
M.T. Fulciniti1,* S. Oliva1,2, N. Amodio3, A. Roccaro1, R. L. Bandi1, H. Daisy1,
A. Cagnetta1, W. Senapedis4, E. Baloglu4, K.C. Anderson1, I. Ghobrial1,
N.C. Munshi1
1Jerome Lipper Multiple Myeloma Disease Center,, Dana Farber Cancer
Instiute, Harvard Medical School, Boston, MA, United States, 2Myeloma Unit,
Division of Hematology, University of Torino, Torino, 3Departement of experi-
mental and clinical medecine, Magna Graecia University, Salvatore Venuta
campus, Catanzaro, Italy, 4Karyopharm Therapeutics Inc, Newton,MA, United
States
Background: PAK4 is a member of p21-activated kinase (PAK) family of ser-
ine/threonine kinases. It is activated in cancer cells, where it regulates a wide
range of cellular processes including cytoskeleton reorganization, cell prolifer-
ation, survival and motility. However, the role of PAK4 in multiple myeloma
(MM) is not established yet.
Aims: To investigate the expression and functional role of PAK4 in MM cells
and to evaluate impact of orally bioavailable PAK4 allosteric modulators (PAMs)
on MM cell growth and survival, providing evidences for a novel therapeutic
approach for the treatment of MM
Methods: The expression of PAK4 and phosphorylated(p)-Pak4 Ser474 was
assessed by immunoblot analysis. Both gain of-and loss of function studies
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were performed to investigate functional and molecular impact of PAK4 on MM
cells. Apoptotic cell death was analyzed by flow cytometry following Annexin-
V and propidium iodide (PI) staining. Cell proliferation and viability were meas-
ured by [3H]-thymidine and CellTiter-Glo (CTG) assays, respectively. TOP/FOP-
flash reporter assays were performed to examine B-catenin-mediated TCF/LEF
transcriptional activity.
Results: We have demonstrated a differential expression and sub-cellular local-
ization of PAK4 and (p)-Pak4 Ser474 in different multiple myeloma cell lines,
primary MM cells and PBMCs. In a gain-of-function study, over-expression of
PAK4 in deficient MM cells (RPMI8226 and U266) significantly increased cell
proliferation and survival in vitro and in vivo. Conversely, in a loss-of-function
study, conditional knock-down of PAK4 expression decreased MM cell prolifer-
ation and survival. With a significant impact of PAK4 on MM cell growth, we
identified a class of orally bioavailable PAK4 allosteric modulators (PAMs). We
observed inhibition of MM cell growth and survival after treatment with PAMs
even in the presence of bone marrow microenvironment with no significant
effect on normal PBMCs, suggesting a favorable therapeutic index in MM treat-
ment. Furthermore, time and dose dependent induction of both intrinsic and
extrinsic apoptotic pathways and G2/M arrest was observed after treatment
with PAMs. Importantly, orally bioavailable PAMs given daily were able to inhibit
tumor growth and prolong overall survival in vivo in two murine models of human
myeloma. PAK4 is a nucleo-cytoplasmic shuttling protein that is imported into
the nucleus, promoting TCF/LEF transcriptional activity and leading to B-catenin
stabilization. Furthermore, nuclear import of PAK4 accompanies the import of
B-catenin and increases TCF/LEF transcriptional activity. TOP/FOP-flash
reporter assays were performed to examine whether B-catenin-mediated
TCF/LEF transcriptional activity was modulated through PAK4 in myeloma cells.
The results showed that PAK4 silencing significantly reduced TCF/LEF tran-
scriptional activity in MM cells, highlighting the vital role that PAK4 plays in
mediating the nuclear localization and oncogenic activity of B-catenin. Further-
more, after PAK4 inhibition we also observed a decrease expression levels of
two B-catenin targets, cyclin D1 and c-myc, which are known to play a critical
role in the myeloma pathobiology.
Summary and Conclusions: PAK4 plays an important cellular and molecular
function in myeloma and its inhibition with a new class of PAK4 allosteric mod-
ulators provides a novel therapeutic approach for the treatment of MM. Further
experiments are ongoing, to clarify the pathway and downstream effectors of
PAK4 both in the nucleus and cytoplasm.
P266
BONE MARROW-MEDIATED DRUG RESISTANCE IS PROMOTED BY
JAGGED-INDUCED NOTCH PATHWAY IN MULTIPLE MYELOMA
S. Garavelli1,* E. Lazzari1, M. Colombo1, A. Paoli1, N. Platonova1, S. Galletti2,
K. Todoerti3, A. Neri2, R. Chiaramonte1
1Department of Health Sciences, University of Milano, 2Department of Clinical
Sciences, University of Milano, Fondazione IRCCS Policlinico, Milano, 3Labo-
ratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Can-
cer Center of Basilicata, Rionero in Vulture, Italy
Background: Multiple myeloma (MM) rapresents 10% of all hematological
malignancies and is caused by the accumulation of malignant plasma cells in
the bone marrow (BM). Although treatments with new drugs (immunomodula-
tors and proteasome inhibitors) are increasing patients’ survival, MM is still
incurable because of the development of endogenous or BM mediated drug
resistance. Therefore it is crucial to find new therapeutic targets. The dysregu-
lated expression of two Notch ligands, Jagged1 and 2, hyperactivates Notch
pathway  both in MM cells and in bone marrow stromal cell (BMSC). Several
Notch downstream effectors support MM cell growth, survival and proliferation,
i.e. IL-6, SDF-1alfa, CXCR4, NF-kB, VEGF and IGF.
Aims: The aim of this study was to investigate the role of Notch signaling in
endogenous and BMSC-promoted drug resistance in MM.
Methods: U266 and OPM2 MM cell lines were cultured alone in complete
RPMI-1640 medium or co-cultured with murine (NIH3T3) or human (HS5)
BMSC cell lines in DMEM medium supplemented with 10% V/V FBS. MM cells
were either kept in suspension for 24 hours or plated on BMSC monolayer for
24h, then the MM cell lines were treated with drugs (Mitoxantrone, Bortezomib
or Melphalan) for additional 24 hours. Apoptosis assay: HS5 cells were stained
with PKH26 red fluorescent dye (Sigma-Aldrich) before co-culturing to allowed
flow-cytometric detection of MM cells co-cultured with BMSCs. Cells were
stained with Annexin V-FITC and processed with Cytomics FC500 software
(Beckman Coulter). RNA interference: Silencing of Jagged1 and Jagged2 was
obtained by transient expression of two specific siRNAs (Stealth Select RNAiTM
siRNA system, Life Technologies). Quantitative PCR reactions were carried
out on a 7500 Fast Real-time PCR system (Applied Biosystems) using the
MaximaTM SYBR Green/ROX qPCR Master Mix (Dasit). Anti-apoptotic protein
such as SDF-1alfa, CXCR4, Bcl-2, Survivin and ABCC1 were analyzed by flow
cytometry using appropriate antibodies.
Results: Jagged1 and 2 silencing in OPM-2 and U266 cells is able to reduce
the expression of anti-apoptotic genes i.e. SDF-1alfa, CXCR4, Bcl-XL, Bcl-2,
Survivin and ABCC1. At the same time, MM cells with reduced levels of Jagged1
and 2 showed an increased sensivity to different drugs commonly used in MM
therapy such as Bortezomib, Mitoxantrone and Melphalan. We investigated
the underlying mechanism showing that MM cells and BMSC interaction result-
ed in the activation of Notch signaling in both cell types. When co-coltured with
human or murine BMSCs, we observed that MM cells showed increased drug
resistance due to: first of all, an increased expression of anti-apoptotic genes
in MM cells among which SDF-1alfa, CXCR4, Bcl-XL, Bcl-2, Survivin and
ABCC1; secondary, BMSC release of soluble factors, i.e. SDF-1alfa and VEGF,
relevant for MM cell growth and survival.  Interestingly, Jagged1 and 2 silencing
in MM cells could reverse all gene and protein expression changes and BMSC
protective effect. All these results were confirmed both at gene expression and
protein level.
Summary and Conclusions: The evidence that Jagged-1 and 2 silencing
affect endogenous and BMSC-induced drug resistance in MM cells supports
the use of a Jagged-targeted approach in MM therapy alone or in a combination
with common drugs.
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FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A
NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE
MYELOMA INTO SYMPTOMATIC DISEASE 
E. Zamagni1,* C. Nanni2, F. Gay3, A. Pezzi1, F. Patriarca4, M. Bellò5,
I. Rambaldi6, P. Tacchetti1, J. Hillengass7, B. Gamberi8, L. Pantani1, V. Magarotto3,
A. Versari9, M. Offidani10, B. Zannetti1, F. Carobolante4, M. Menga5,
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Bologna, Italy, 7University of Heidelberg, Department of Hematology and
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Background: The probability of progression of smoldering multiple myeloma
(SMM) into symptomatic disease (MM) is highly variable and therefore the
identification of sub-groups of patients (pts) at different risk of progression is
a relevant end point. FDG-PET/CT is a reliable technique for assessing early
skeletal involvement and the presence of osteolytic lesions identified by this
imaging technique has been recently incorporated in the updated criteria for
the diagnosis of MM. However, no data are available regarding the impact of
PET/CT FLs in the absence of underlying osteolyses in SMM on time to pro-
gression (TTP) into MM.
Aims: To address this issue, we prospectively studied a cohort of 120 pts
with SMM with PET/CT.
Methods: By study design, all the pts were studied with PET/CT at presen-
tation of the disease. Bone marrow involvement was described as negative,
diffuse or focal. The number of FLs, as well as size and associated stan-
dardized uptake values (SUV) were recorded. For each FL, the presence of
eventual underlying osteolytic lesion was investigated by the CT part of the
scan; pts with osteolytic lesions were excluded from the study, as they were
considered as having MM. Laboratory follow-up took place every 3-4 months.
Skeletal progression was defined by the appearance of one or more sites of
osteolytic bone destruction, pathological fractures and/or soft masses at
PET/CT or MRI. The start of systemic therapy was defined as the date of
event for the analysis of TTP.
Results: Baseline patient characteristics were as follows: median age 61
years, IgG isotype 73%, median M component 2.4 g/dL, ISS stage I 77%,
median bone marrow plasma cell (BMPC) 27%, median serum involved/unin-
volved FLC ratio 14.27. PET/CT was negative in 101/120 pts (84%) and pos-
itive in 19/120 (16%) of them; 8 pts had 1 FLs, 3 pt 2 FLs, 6 pts more than 3
FLs and 2 pt a diffuse bone marrow involvement. Median SUV max value
was 4.7 (range 2.5-10.7). BMPC was significantly superior for patients with
positive PET/CT (p=0.024). In 91 pts a baseline axial or WB-MRI was avail-
able as well and resulted positive in 27% of them. Ten per cent, 11% and
13% of the pts were having more than 60% BMPC, FLC ratio ≥100 and more
than 1MRI FL, respectively. With a median follow-up of 2.2 years, 62% of the
pts remained in the asymptomatic phase while 38% of them progressed to
MM, in a median time of 4 years, including 21% with skeleton involvement,
with/without the appearance of other CRAB symptoms, and 17% with exclu-
sive serological signs of progression. The relative risk of progression of the
pts with a positive PET/CT was 3.00 (95% CI 1.58-5.69, P=0.001). Moreover,
the relative risk of skeletal progression was 4.44 (95% CI 1.97-10.02,
P<0.001), with a median TTP of 2.2 years for pts with positive PET/CT vs 7
years for those with negative PET/CT (Figure 1). The probability of progres-
sion within 2 and 3 years for pts with positive PET/CT was 58% and 66%,
respectively, vs 33% and 42% for negative pts. Results did not significantly
differ after pts with early MM according to the updated criteria were excluded
from the analysis. A multinomial logistic regression analysis showed that PET
positivity was significantly related to progression with skeletal involvement
while BMPC superior than 60% to the exclusive serological one.
Figure 1.
Summary and Conclusions: In conclusion, approximately 16% of the pts with
SMM have a positive PET/CT, mainly with few FLs, with a low FDG uptake.
PET/CT positivity significantly increased the risk of progression of SMM into
MM. PET/CT could become a new risk factor to define high risk SMM. Further
studies are warranted to find and optimal cut off point of FLs and/or SUVmax
to capture the higher risk of progression at 2 year and to merge with other
prognostic factors.
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Background: Panobinostat (PAN) is the first pan-deacetylase inhibitor (pan-
DACi) to demonstrate a statistically significant and clinically relevant increase
in median progression-free survival (PFS) in a phase 3 clinical trial of patients
(pts) with relapsed or relapsed and refractory multiple myeloma (MM). In the
PANORAMA 1 trial, pts randomized to receive PAN + bortezomib (BTZ) and
dexamethasone (Dex; PAN-BTZ-Dex) demonstrated a median PFS of 12.0
months vs 8.1 months for pts who received placebo (Pbo) + BTZ and Dex
(Pbo-BTZ-Dex; hazard ratio [HR], 0.63; P<.0001).
Aims: To determine the effect of clinical outcomes based on the level of
response achieved.
Methods: Overall response rate, including rate of near complete/complete
response (nCR/CR) and partial response (PR) per modified European Society
for Blood and Marrow Transplantation (mEBMT) and stringent CR
(sCR)/CR/very good PR (VGPR) per International Myeloma Working Group
(IMWG) and duration of response (DOR) were analyzed. A landmark analysis
at 6, 12, 18, and 24 weeks by response status using a Cox regression model
was conducted to determine PFS in pts who achieved nCR/CR vs PR per
mEBMT or sCR/CR/VGPR vs PR as per IMWG criteria.
Results: The rate of nCR/CR was significantly higher for PAN-BTZ-Dex vs
Pbo-BTZ-Dex (27.6% vs 15.7%; nominal P=.00006). Per IMWG criteria, the
rate of sCR/CR/VGPR was also higher for the PAN-BTZ-Dex arm (36% vs
24%; nominal P=.00001). The DOR per mEBMT criteria for pts with nCR/CR,
≥PR, and PR was 18.4, 13.1, and 9.0 months, respectively, in the PAN-BTZ-
Dex arm and 14.5, 10.9, and 8.8 months, respectively, in the Pbo-BTZ-Dex
arm. The landmark analysis by mEBMT and IMWG criteria is shown in the
Table. At the 12-week landmark, a median PFS of 16.5 months was observed
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for pts with CR/nCR and 10.3 months for pts with PR in the PAN-BTZ-Dex arm
(hazard ratio [HR], 0.40; 95% CI, 0.25-0.65) and a median PFS of 14.1 months
for pts with CR/nCR and 9.7 months for pts with PR in the Pbo-BTZ-Dex arm
(HR, 0.62; 95% CI, 0.36-1.07). By IMWG criteria, the landmark analysis at 12
weeks demonstrated a median PFS of 15.9 months for pts with ≥VGPR and
8.1 months for pts with PR in the PAN-BTZ-Dex arm (HR, 0.36; 95% CI, 0.21-
0.62) and a median PFS of 14.4 months for pts with ≥VGPR and 7.6 months
for pts with PR in the Pbo-BTZ-Dex arm (HR, 0.39; 95% CI, 0.22-0.68).
Tabella 1. Landmark Analysis of Progression-Free Survival
Summary and Conclusions: A higher proportion of deep responses (≥nCR or
≥VGPR) was achieved with PAN-BTZ-Dex, and the DOR was longer and was
associated with a prolonged PFS. Results were consistent by mEBMT or IMWG.
Overall, these data further support achievement of deeper responses as a treat-
ment goal in pts with relapsed/refractory MM.
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Background: Carfilzomib is a selective proteasome inhibitor that is approved
in the United States for the treatment of relapsed and refractory multiple myelo-
ma. The approved dosing schedule for carfilzomib is a 2–10 minute IV infusion
on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle (starting dose: 20mg/m2 [cycle
1]; escalated to a target dose of 27mg/m2 in cycle 2). 
Aims: Herein we present updated results from a multicenter, single-arm, phase
1/2 study (CHAMPION-1; NCT01677858) evaluating the safety and efficacy of
weekly carfilzomib with dexamethasone (Kd) in patients with relapsed or refrac-
tory multiple myeloma (RRMM).
Methods: Patients who received 1−3 prior regimens were eligible. All patients
provided informed consent. In the phase 1 portion, patients received carfilzomib
as a 30-min IV infusion on days 1, 8, and 15 of a 28-day cycle using a 3+3
dose-escalation scheme. All patients received carfilzomib at 20 mg/m2 on day
1 of cycle 1; subsequent dose cohorts received 45, 56, 70, or 88 mg/m2 in suc-
cessive cohorts until the maximum tolerated dose (MTD) was reached for use
in the phase 2 portion of the study. Patients received dexamethasone 40 mg
(IV or oral administration) on days 1, 8, 15, and 22 of cycles 1–8; dexametha-
sone was omitted on day 22 in cycles ≥9. In the phase 2 portion, patients are
receiving carfilzomib at the recommended dose from the phase 1 portion (carfil-
zomib dose of 20 mg/m2 on cycle 1, day 1 escalating to the MTD for subsequent
doses) with the same dose and schedule for dexamethasone. Kd is being
administered until disease progression or unacceptable toxicity.
Results: Results are presented for patients treated at the MTD (70 mg/m2) in
the phase 1b and phase 2 portions of the study. As of January 7, 2015, 104
patients (phase 1, n=15; phase 2, n=89 patients) were enrolled at the MTD;
the study is fully enrolled. Median patient age was 68.5 years (range, 41–88).
Patients received a median of 1prior regimen (range, 1–3); 48% of patients
had received 2 or more prior regimens. A total of 82% of patients had received
prior bortezomib (BTZ), 48% of patients were BTZrefractory, 28% were lenalido-
mide (LEN) refractory, and 16% were refractory to BTZ and LEN. Preliminary
median carfilzomib treatment duration was 5.3 months (range, 0.03–18.8). The
overall response rate (≥partial response) was 72% (95% confidence interval
[CI]: 63%–81%); the clinical benefit rate (≥minimal response) was 80% (95%
CI: 71%–87%). Kaplan-Meier median PFS was 10.6 months (95% CI: 7.2–not
estimable). Seven patients (7%) discontinued treatment due to an adverse
event (AE). The most common hematologic AEs (all grade) were anemia (24%),
thrombocytopenia (18%), and neutropenia (8%). The most common nonhema-
tologic AEs (all grade) were fatigue (48%), nausea (32%), and insomnia (30%).
The most common grade ≥3 hematologic AEs were thrombocytopenia (6%),
anemia (5%), and neutropenia (4%). The most common grade ≥3 nonhemato-
logic AEs were fatigue (9%), dyspnea (6%), and back pain (6%). Four patients
died on study: 1 patient had sepsis, respiratory distress, pneumonia, and acute
renal failure; and 1 patient each had acute renal failure, cardiopulmonary arrest,
and disease progression.
Summary and Conclusions: At the MTD (70 mg/m2), weekly Kd is demon-
strating acceptable safety and tolerability with promising efficacy in patients
with RRMM. Updated results will be presented at the meeting.
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Background: Early mortality in elderly multiple myeloma (MM) patients is usu-
ally attributed to combined effects of active disease and co-morbid factors.
Before the introduction of novel agents, toxic deaths within 60 days from start
of conventional treatment occurred in 10% of patients (Augustson BM. J Clin
Oncol 2005, 36:9219), mainly due to infection and renal failure. The use of
novel agents has considerably improved MM outcome at the expense of newer
toxicity.
Aims: The aim of this analysis is to study early deaths not related to disease
progression during treatments with lenalidomide or bortezomib. We analyzed
individual patient data from two large multicenter randomized trials to assess
the rate and the causes of death, their predictability and whether current man-
agement strategies have reduced their frequency.
Methods: A total of 1,173 newly diagnosed MM patients ineligible for autolo-
gous transplantation due to age or co-morbidities enrolled in the Gruppo Ital-
iano Malattie EMatologiche dell’Adulto (GIMEMA) and European Myeloma
Network (EMN) trials from May 2006 to September 2012, were studied.
Patients in the GIMEMA MM-03-05 trial (N=511) received bortezomib-contain-
ing regimens (Palumbo A. J Clin Oncol 2014, 32:634) and those in the EMN01
trial (N=662) lenalidomide-containing regimens (Magarotto V. Blood 2014, abs
ASH).
Results: A total of 1146 patients could be evaluated for this analysis. Within
24 months from start of therapy, 207/1146 patients (18%) died for any causes,
61/1146 (5%) died due to adverse events. Toxic deaths within 60 days occurred
in 12 patients (1%) with a linear increase over time of 1% every 6 months
(Figure 1). There was no difference in the incidence of toxic deaths between
patients receiving bortezomib-containing regimens (31 pts, 6%) and those
receiving lenalidomide-containing regimens (30 pts, 5%, p=0.32). The inci-
dence of toxic deaths was significantly higher in patients older than 80 years
(11/107 [10%], p=0.005). Twenty-nine percent of deaths were attributable to
cardiac complications (18 pts), 18% to infections (17 pts) and 15% to vascular
complications (9 pts). By comparing the cause of toxic deaths between the 2
different treatment regimes, there was no significant difference in the propor-
tions of cardiac events, infections, vascular events or other causes. In a mul-
tivariate analysis, age (HR 1.09 per 1 year increase, p=0.002) and ISS score
(HR 3.81, p=0.01 ISS 2 vs ISS 1; HR 5.69, p=0.002 ISS 3 vs ISS 1) did
increase the risk of death but poor performance status did not (HR 1.25,
p=0.59). Greater tumor burden and activity (ISS) increased the risk of death
because such deaths occurred before the maximal beneficial effect of therapy
in reducing tumor load: 92% of patients dying from toxicity within 2 months of
start of therapy had achieved a suboptimal response (8 not available, 3 SD, 1
PR, ORR 8%).
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Figure 1. Cumulative incidence of death due to AEs or due to any other
causes
Summary and Conclusions: Novel, more effective and more rapid therapies
have reduced the risk of toxic deaths as compared to conventional treatments.
Nevertheless one-third of early deaths occurred primarily due to cumulative
specific drug-related toxicities. Improvement in supportive therapy together
with prevention and prompt recognition/treatment of complications are urgently
needed to reduce the risk of toxic deaths. The 2-fold higher risk of toxic mortality
in octogenarians indicates the need for a careful assessment of frail patients
who may benefit from a gentle or even palliative approach.
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Background: Lenalidomide maintenance showed to be effective in terms of
progression free survival (PFS) in patients with newly diagnosed multiple
myeloma (NDMM) ≥65 years or not eligible for autologous stem cell transplan-
tation. Recently, the geriatric assessment has emerged as a fundamental strat-
egy to evaluate patients’ frailty and consequently to select the most appropriate
treatment for elderly MM patients [Palumbo A, et al. Blood. 2015].
Aims: In a post-hoc analysis, we classified patients enrolled in the EMN01
trial according to the new geriatric assessment in order to evaluate safety and
efficacy of Lenalidomide-containing maintenance in fit, unfit and frail NDMM
patients.
Methods: In the EMN01 phase III trial, patients with NDMM were randomized
to receive induction treatment with Lenalidomide-dexamethasone or Melpha-
lan-Prednisone-Lenalidomide or Cyclophosphamide-Prednisone-Lenalidomide.
After induction, patients were randomized to receive maintenance with
Lenalidomide alone (10 mg on days 1-21 in 28-day cycles) or plus Prednisone
(25 mg every other day in 28-day cycles), until disease progression or intoler-
ance. The geriatric assessment was performed and included age, comorbidities
(according to Charlson Comorbidity index), Activity of daily living and Instru-
mental Activity of Daily Living scores.
Results: Six-hundred-forty-three patients started induction treatment. Patients
were classified as fit (n=280), unfit (n=202) and frail (n=161). During induction,
30 patients (11%) discontinued treatment due to adverse events (AEs) in the
fit group and 38 patients (23%) in the frail group (p=0.0006). Deaths not related
to progressive disease were 4 in the fit group (mainly due to stroke [n=2]) and
17 in the frail group (mainly due to cardiologic AEs [n=7] and infections [n=3]).
Four-hundred-two patients started maintenance treatment: 192 in the fit, 121
in the unfit, and 89 in the frail groups. During maintenance, at least one grade
≥3 hematologic AE was reported in 24 patients (13%) in the fit and 13 patients
(15%) in the frail groups. At least one grade ≥3 non-hematologic AE was record-
ed in 12 patients (6%) in the fit and 12 patients (13%) in the frail groups
(p=0.04), and were mainly cardiologic AEs and infections. After a median fol-
low-up of 30 months since the beginning of maintenance, median PFS was 24
months in fit and 27 months in frail patients (HR=1.136, CI 0.808-1.596,
p=0.464). Median overall survival (OS) was not reached; at 24 months, OS
was 90% in fit and 76% in frail patients (HR 2.804, CI 1.665-4.723, p=0.0001).
In the frail group, 101 patients (63%) did not reduce any drug doses during
induction, and 49 (49%) of them started maintenance; whereas 60 patients
(37%) reduced drug doses during induction, and 40 (67%) of them started
maintenance. The difference between the two groups of frail patients who
began maintenance was statistically significant (P=0.02).
Summary and Conclusions: The benefit of maintenance therapy in frail
patients is controversial. Frail patients who reduced doses at induction tolerated
therapy better and had a higher probability to start maintenance. Therefore, an
induction treatment tailored to the frailty status allows a higher number of
patients to complete induction, and to start and benefit from lenalidomide main-
tenance.
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Background: The survival of patients (pts) with multiple myeloma (MM)
decreases with increased age (Pulte et al, Oncologist, 2011), and those with
advanced disease who have exhausted treatment (Tx) options with newer
agents have a poor prognosis (Kumar et al, Leukemia, 2012). The oral agent
pomalidomide (POM) has anti-myeloma, stromal cell inhibitory, and immune
modulatory effects (Quach et al, Leukemia, 2010; Mark et al, Leuk Res, 2014).
In the pivotal MM-003 trial, Tx with POM + low-dose dexamethasone (LoDEX)
prolonged progression-free survival (PFS) and overall survival (OS) vs high-
dose DEX and had a tolerable safety profile in pts with refractory or relapsed
and refractory MM (RRMM; San Miguel et al, Lancet Oncol, 2013). In MM-003
and in the pivotal phase 2 trial, MM-002, Tx with POM + LoDEX provided sig-
nificant PFS and OS benefits across various age groups; tolerability and dose
intensity were unaffected by age (Weisel et al, Blood, 2013; Jagannath et al, J
Clin Oncol, 2013).
Aims: STRATUS is a multicenter, single-arm, open-label, European phase 3b
trial designed to further evaluate safety and efficacy of POM + LoDEX in a
large pt population. This analysis examined pt outcomes by age (≤65 vs >65
yrs and ≤70 vs >70 yrs).
Methods: RRMM pts with progressive disease (PD) during or within 60 days
of their last line of Tx (refractory to their last prior Tx) were included. Other eli-
gibility criteria included age ≥18 yrs, measurable M-protein in serum or urine,
lenalidomide and bortezomib failure after ≥2 consecutive cycles of each (alone
or in combination), and adequate prior alkylator therapy. Pts with absolute neu-
trophil count <800/μL, platelets <75,000 or <30,000/μL for pts in whom <50%
or ≥50% of bone marrow nucleated cells were plasma cells, respectively, or
creatinine clearance <45 mL/min were excluded. Pts received POM 4 mg D1-
21 + LoDEX 40 mg (20 mg for pts aged >75 yrs) D1, 8, 15, and 22 of a 28-day
cycle until PD or unacceptable toxicity. Thromboprophylaxis was required for
all pts. Primary endpoint was safety; key secondary endpoints included overall
response rate (ORR; ≥partial response), duration of response (DOR), PFS,
and POM exposure. Outcomes were analyzed by pt age at baseline (≤65 vs
>65 yrs and ≤70 vs >70 yrs).
Results: As of Sep 15, 2014, 604 pts have been enrolled. 599 received POM
+ LoDEX; 46% were ≤65 yrs, 54% were >65 yrs, 69% were ≤70 yrs, and 31%
were >70 yrs. Pts were heavily pretreated (median 4-5 prior Tx). Median fol-
low-up was 9.3 mos. Median relative dose intensity was similar independent
of pt age (range, 0.93-0.94). The most frequent grade (Gr) 3/4 treatment-emer-
gent adverse events (TEAEs) across age groups were neutropenia, anemia,
thrombocytopenia, and infections (Table). Discontinuation of POM due to
TEAEs was infrequent in pts aged ≤65 (7%), >65 (11%), ≤70 (7%), and >70
(14%) yrs. ORRs ranged between 32% and 38% for all age groups. Median
PFS was also similar, regardless of age (4.1-4.7 mos; Table). Updated data
will be presented at the congress.
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Tabella 1. Safety and Efficacy Outcomes
Summary and Conclusions: The results show that POM + LoDEX is effica-
cious and tolerable in RRMM pts regardless of age (≤65 vs >65 yrs and ≤70 vs
>70 yrs). Across the age groups, the safety profile and relative dose intensity
were similar. PFS and response rates were also similar and consistent with
previous findings. The data support the use of 4 mg of POM as an effective
starting dose, and the use of POM + LoDEX, regardless of age, in RRMM pts.
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Background: Survival outcomes of patients (pts) with relapsed/refractory mul-
tiple myeloma (RRMM) have improved with introduction of newer agents
(Kumar, Leukemia, 2014). However, there are few effective treatment (Tx)
options for pts with RRMM who failed Tx with bortezomib (BORT) and lenalido-
mide (LEN). As a result, these pts have shortened overall survival (OS; Kumar,
Leukemia, 2012). Pomalidomide (POM) is a distinct oral immunomodulatory
agent with direct anti-myeloma, stromal cell inhibitory, and immune modulatory
effects (Quach, Leukemia, 2010; Mark, Leuk Res, 2014). Pivotal trials demon-
strated higher overall response rates (ORRs) with POM + low-dose dexam-
ethasone (LoDEX) vs POM alone and significantly extended PFS and OS vs
high-dose DEX (San Miguel, Lancet Oncol, 2013; Richardson, Blood, 2014).
Refractoriness to LEN and/or BORT (including LEN as last prior Tx) did not
affect outcomes with POM + LoDEX.
Aims: STRATUS is a multicentre, single-arm, open-label, phase 3b trial
designed to further evaluate safety and efficacy of POM + LoDEX in RRMM pts.
Methods: Pts with refractory or relapsed and refractory disease (progressive
disease [PD] on or within 60 days of last prior Tx), prior BORT and LEN Tx failure,
and adequate prior alkylator therapy were eligible. Pts with absolute neutrophil
count <800/μL, platelets <75,000 or <30,000/μL (for pts with <50% or ≥50% of
bone marrow nucleated cells as plasma cells, respectively), creatinine clearance
<45 mL/min, hemoglobin <8 g/dL, and peripheral neuropathy (PN) grade (Gr) ≥2
were excluded. POM 4 mg was administered D1-21 of a 28-day cycle in combi-
nation with LoDEX 40 mg/day for pts aged ≤75 yrs or 20 mg for pts aged >75 yrs
on D1, 8, 15, 22 until PD or unacceptable toxicity. Thromboprophylaxis was
required for all pts. Follow-up continued for Tx, OS, and second primary malig-
nancy until 5 yrs post-enrollment. Primary endpoint was safety, and key second-
ary endpoints included ORR (≥partial response), duration of response (DOR),
PFS, OS, POM exposure, and cytogenetic analyses. STRATUS is registered
with ClinicalTrials.gov (NCT01712789) and EudraCT (2012-001888-78).
Results: As of Sep 15, 2014, 604 pts were enrolled. Median age was 66 yrs
(range, 37-88); median time since initial diagnosis was 5.2 yrs (range, 0.5-
27.1). Pts were heavily pretreated with a median of 5 prior Tx (range, 2-18);
95% of patients were LEN refractory, and 78% were refractory to both LEN
and BORT. Median follow-up was 9.3 mos. The most frequent Gr 3/4 Tx-emer-
gent adverse events (TEAEs) were hematologic, including neutropenia (42%),
anemia (29%), and thrombocytopenia (22%); Gr 3/4 non-hematological toxici-
ties included pneumonia (11%) and fatigue (5%). Gr 3/4 venous thromboem-
bolic events were infrequent (1%), and Gr 3/4 PN was 1%. 5% of pts withdrew
due to adverse events. Median PFS and OS were 4.2 and 11.9 mos, respec-
tively (Figure). ORR was 35%; 7% pts achieved ≥very good partial response,
and 1% achieved a complete response. Median DOR was 6.8 mos. In pts
refractory to prior LEN or LEN and BORT, similar PFS (4.2 and 4.1 mos), OS
(12 mos each), and ORR (34% and 35%) were observed. Updated data will be
presented at the congress.
Figure 1.
Summary and Conclusions: Safety and efficacy of POM + LoDEX in the
STRATUS trial was consistent with results from pivotal trials of POM + LoDEX.
Efficacy outcomes were similar regardless of prior refractoriness to LEN, BORT,
or LEN + BORT. This study confirms previous analyses demonstrating that
POM + LoDEX is a standard of care for RRMM pts in whom LEN and BORT
Tx has failed.
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Background: Renal impairment (RI) is reported in ≈ 20% to 40% of patients
(pts) with multiple myeloma (MM) at diagnosis and is associated with a negative
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impact on survival (Rajkumar, Mayo Clin Proc, 2005). The pivotal phase 3
FIRST trial represents the largest data set in transplant-ineligible newly diag-
nosed MM (NDMM) pts with various levels of RI. In this pt population, contin-
uous lenalidomide plus low-dose dexamethasone (Rd continuous) improved
progression-free survival (PFS; HR =0.72; P <0.01) and provided an overall
survival (OS) benefit (HR =0.78; P =0.02) vs melphalan-prednisone-thalidomide
(MPT; Benboubker, N Engl J Med, 2014).
Aims: This subanalysis was conducted to determine the impact of RI on PFS,
OS, and time to second anti-myeloma Tx (AMT) in NDMM pts treated with Rd
continuous or MPT.
Methods: NDMM pts ineligible for transplant were randomized to 3 Tx arms:
Rd continuous until progression (n =535); Rd for 18 cycles (Rd18; 72 weeks;
n =541); or MPT for 12 cycles (72 weeks; n =547). Enrolled pts were catego-
rized according to their renal function; pts requiring dialysis were excluded.
The starting dose of lenalidomide was modified based on renal function: 25
mg once daily (QD) for normal renal function (creatinine clearance [CrCl] ≥80
mL/min) or mild RI (CrCl ≥50 and <80 mL/min), 10 mg QD for moderate RI
(CrCl ≥30 and <50 mL/min), and 15 mg QD for severe RI (CrCl <30 mL/min).
The melphalan dose was reduced by 50% in pts with moderate or severe RI.
The primary endpoint was PFS in pts treated with Rd continuous vs MPT. Sec-
ondary endpoints included OS, time to second AMT, safety, and improvement
in renal function. Improvement in renal function was defined as a positive shift
in renal function subgroup from baseline to the most extreme post-baseline
CrCl value during active Tx. Renal response as defined by IMWG criteria
(Dimopoulos, J Clin Oncol, 2010) was also assessed to show similar results
across both CrCl and estimated glomerular filtration rate (eGFR).
Results: The median follow-up was 37 mos (data cutoff, May 24, 2013). PFS
benefit was seen with Rd continuous vs MPT (HR =0.66-0.76) or Rd18 (HR
=0.66-0.82) in all RI groups. OS results showed a benefit of Rd continuous vs
MPT (HR =0.59-0.81) or Rd18 (HR =0.74-0.88) in all groups except severe RI
(HR =1.03 vs MPT and 1.31 vs Rd18). Rd continuous compared with MPT
extended time to second AMT in all renal groups (HR =0.54-0.83). Improvement
in renal function was observed across all Tx groups, but appeared greater in
pts treated with Rd continuous than those treated with Rd18 or MPT. Per IMWG
criteria 24%, 28%, and 20% of pts had a renal response with Rd continuous,
Rd18, and MPT Tx, respectively. Rate of complete renal response was 20.0%
with Rd continuous, 27.4% with Rd18, and 14.3% with MPT. Most common
grade 3/4 adverse events for these Tx were anemia, neutropenia, and throm-
bocytopenia.
Tabella 1. PFS, Interim OS, and Time to Second AMT in Renal Subgroups
Summary and Conclusions: PFS, interim OS, and time to second AMT out-
comes generally improved across all Tx groups in pts with normal renal function
and those with mild or moderate RI. Rd continuous was well tolerated, with a
consistent safety profile across renal subgroups. Renal function also improved
more in pts treated with Rd continuous vs Rd18 or MPT. Results of this analysis
support the use of Rd in NDMM pts in most RI subgroups.
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Background: Daratumumab (DARA) a human anti-CD38 IgG1κ MAb has
shown robust, durable, single agent activity with deep responses and favorable
safety in patients with multiple myeloma (MM) relapsed from or refractory (RR)
to ≥2 prior therapy lines as well as in combination with lenalidomide (LEN) and
dexamethasone (D) in relapsed or RRMM.
Aims: This ongoing open-label, 4-arm, multicenter, phase 1b study
(NCT01998971) evaluated the safety and tolerability of DARA combined with
pomalidomide (POM)-D and three backbone MM treatments: bortezomib (V)-D,
V-thalidomide(T)-D, V-melphalan (M)-prednisone (P).
Methods: Patients (up to 100) in the DARA+POM-D arm were RR to ≥2 lines
of therapy including 2 consecutive cycles of LEN and V. Newly diagnosed
patients were included in the DARA+VD (n=6) and DARA+VTD (n=12) arms
(irrespective of transplant eligibility) and DARA+VMP arm (transplant ineligible;
n=12). Patients received DARA 16 mg/kg and approved label or standard of
care of each treatment: POM-D (DARA qw, 2 cycles; q2w, 4 cycles; q4w remain-
ing cycles); VD and VTD (DARA qw, 2 cycles; q3w, 16 cycles); VMP (DARA
qw, 1 cycle; q3w, 8 cycles). Data were evaluated by an independent data safety
monitoring board.
Results: Data from 49 patients with RRMM (DARA+POM-D [n=24]) and new-
ly diagnosed MM (DARA+VD [n=6], DARA+VTD [n=11], DARA+VMP [n=8])
are presented. Median (range) durations of follow-up in days: DARA+POM-
D, 29 (1-286); DARA+VD, 193 (151-218); DARA+VTD, 164 (9-274);
DARA+VMP, 267 (63-295). There was little additional toxicity when DARA
was added other than DARA-specific infusion related reactions (24/49
patients). Most occurred on Cycle 1 Day 1 and were mainly grade 1/2 (3/53
grade 3, no grade 4). All infusions were completed except 1 discontinuation
(grade 3 hypoxia possibly DARA-related). Median (range) numbers of DARA
infusions were: DARA+POM-D, 4 (1-20); DARA+VD, 13 (8-15); DARA+VTD,
8 (2-13); DARA+VMP, 16 (6-18). Other adverse events (AEs) were consistent
with the non-DARA agents. 6 patients had serious AEs: pneumonia (n=3;
possibly DARA-related; 1 likely POM-related), indirect Coombs test interfer-
ence (n=1; DARA-related), and 1 each of non-DARA-related soft tissue infec-
tion, diarrhoea, pre-renal failure, hyperviscosity syndrome, cardiac failure,
mental status change. The most common AEs were hematologic toxicity,
likely related to POM or backbone therapies. Study discontinuations were 3
in the DARA+POM-D arm (death after disease progression [PD], physician
decision, disease progression) and 1 in the DARA+VD arm (death; neu-
tropenic sepsis, 60 d post-ASCT). Patients were not on study treatment at
time of death. Efficacy dataset (n=35) had >1 post-baseline assessment:
DARA+POM-D (n=11); DARA+VD (n=6); DARA+VTD (n=10); DARA+VMP
(n=8). The overall response rates were 54.5% in the DARA+POM-D arm and
100% in the newly diagnosed groups. Responses deepened with continued
treatment. In the DARA+POM-D arm there were 2 stringent complete
responses, 1 very good partial response (VGPR), 3 partial responses (PR),
2 minimal responses, 2 stable disease, and 1 PD. In the DARA+VD arm there
were 3 VGPRs and 3 PRs and in the DARA+VTD arm there was 1 complete
response, 2 VGPRs and 7 PRs. In the DARA+VMP arm there were 4 VGPRs
and 4 PRs. Median (range) times to first responses in days were:
DARA+POM-D, 31 (29-57); DARA+VD, 23.5 (22-44); DARA+VTD, 22 (21-
43); DARA+VMP, 22.5 (22-135).
Summary and Conclusions: DARA plus POM-D or with backbone MM ther-
apies was well tolerated, with little significant additional toxicity, encouraging
efficacy and deepening responses.
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Background: With the introduction of new drugs and use of multidrug combi-
nations, lack of initial response to therapy in patients with newly diagnosed
multiple myeloma (NDMM) has decreased considerably. Previous studies have
shown that high dose therapy, in those eligible, is able to overcome resistance
to conventional drugs, though long-term outcomes remain inferior among the
rest of the patients. It is not clear if the outcomes of patients with primary refrac-
tory disease have changed with uniform introduction of newer therapies.
Aims: We performed this retrospective review to compare outcomes of patients
with primary refractory multiple myeloma with outcomes of primary responders,
specifically in the era of novel therapies. We also sought to identify character-
istics predisposing to primary refractory disease.
Methods: We identified 816 patients with NDMM who started treatment after
January 1, 2006, were seen at Mayo Clinic within 30 days of initiating treatment,
and in whom details of the initial treatment regimen were available. Only patients
who had consented to participation in research were included, and the study
was performed with the approval of the Mayo Clinic IRB.
Results: The median age of the study cohort was 67 years; 59% were male.
The median estimated follow up for the entire group was 4.3 years; 41% had
died at the time of the analysis. The median overall survival (OS) for the entire
group was 5.7 years from the beginning of treatment. Either a proteasome
inhibitor or an IMiD was part of the initial induction therapy in 84% patients,
with both an IMiD and a proteasome inhibitor combination used in 9%. The
remaining 7% received steroid-based treatment, in most cases along with mel-
phalan or cyclophosphamide. Response could be assessed in 669 (82%)
patients, with a PR or better seen in 557 (83%) patients. Primary refractory dis-
ease (SD or progression) was seen in 112 patients (17%) overall, and was
seen in 16% of those receiving a novel agent compared with 28% of those not
receiving a novel agent (P <0.01). The median OS from start of therapy was
significantly shorter for the primary refractory group at 3.6 years (95% CI 2.8-
4.8) compared with 7.6 years (95% CI 6-8.6) for the responding patients (P
<0.001). In a multivariable analysis including age >65 years, ISS stage 3, abnor-
mal LDH, BMPC% >60%, PCLI >1%, serum creatinine >=2 mg/dL, high-risk
FISH and primary refractoriness, only primary refractory disease, age >65,
high-risk FISH and high LDH were independently prognostic for OS. Other than
the lack of use of a novel agent, only a high-risk FISH was associated with pri-
mary refractoriness.
Figure 1.
Summary and Conclusions: In the current era, primary refractoriness to induc-
tion therapy with proteasome inhibitor or IMiD containing regimens is associated
with significantly inferior outcomes among patients with NDMM. These patients,
when identified, should be studied in clinical trials specifically designed for this
high-risk condition.
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Background: Treatment (Tx) with melphalan, prednisone, and thalidomide
(MPT) is a standard option for patients (pts) with newly diagnosed multiple
myeloma (NDMM) who are ineligible for autologous stem cell transplant (SCT;
Facon, Lancet Oncol, 2007; Fayers, Blood, 2011; NCCN Guidelines, Multiple
Myeloma, V3.2015). The pivotal phase 3 FIRST trial assessed the efficacy of
lenalidomide plus low-dose dexamethasone administered until disease pro-
gression or unacceptable toxicity (Rd continuous) vs Rd for 18 cycles (Rd18)
and MPT in pts with NDMM ineligible for SCT. Rd continuous improved overall
survival (OS), progression-free survival (PFS), and response rate vs MPT (Ben-
boubker, N Engl J Med, 2014).
Aims: This analysis examined PFS and OS in pts treated with Rd continuous
vs MPT and Rd18 by quality of response (ie, ≥very good partial response
[VGPR]).
Methods: Pts with symptomatic NDMM who were not candidates for SCT
were randomized 1:1:1 to Tx with Rd continuous (n =535), Rd18 (n =541), or
MPT for 12 cycles (72 weeks; n =547). The primary endpoint was PFS. Sec-
ondary endpoints included OS, response rate (as assessed by International
Myeloma Working Group criteria), time to response, duration of response
(DOR), time to Tx failure, time to next antimyeloma Tx, health-related quality
of life, and safety.
Results: As of the data cutoff date of May 24, 2013 for the final PFS analysis,
the median follow-up was 37.0 mos. In pts who achieved a complete response
(CR), greater benefit was observed with Rd continuous compared with MPT or
Rd18 (Table); median PFS with Rd continuous was not reached vs 44.6 mos
with MPT (HR =0.28; P <0.01) and 45.2 mos with Rd18 (hazard ratio [HR]
=0.29; P <0.01). For pts who achieved ≥VGPR, PFS with Rd continuous (NR)
was longer than with MPT (34.7 mos; HR =0.55; P <0.01) or Rd18 (31.0 mos;
HR =0.46; P <0.01). Across all response categories (including CR), pts treated
with Rd continuous vs MPT or Rd18 achieved longer DOR. The DOR in pts
who achieved ≥partial response in the intent-to-treat population was 35 mos
with Rd continuous, nearly a year longer than the DOR observed with MPT
(22.3 mos; HR =0.63; P <0.01) or Rd18 (22.1 mos; HR =0.60; P <0.01). Pts
who achieved a CR with Rd continuous had a longer DOR than whose who
achieved a CR with Rd18 (NR vs 43.6 mos; HR =0.29; P <0.01), and results
were similar for pts who achieved ≥VGPR (NR vs 29.9 mos; HR =0.46; P <0.01).
A higher proportion of pts who achieved a CR were progression-free after 36
mos with Rd continuous (88%) vs Rd18 (55%) or MPT (62%). OS data for pts
treated with Rd continuous vs MPT or Rd18 showed no significant differences
by response.
Tabella 1.
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Summary and Conclusions: For all responders, PFS and DOR were longer
in pts treated with Rd continuous vs MPT or Rd18. The benefits of Rd contin-
uous were more pronounced in pts who achieved a greater depth of response
(≥VGPR). These data suggest that continuing Tx after achieving best response
aids in delaying disease progression, particularly for those pts achieving a
VGPR or CR. Longer follow-up may be required to assess the impact of con-
tinuous treatment on OS for good responders in pts receiving Rd continuous
vs MPT or Rd18.
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Background: Patients with multiple myeloma (MM) achieving complete remis-
sion (CR) have a significant longer survival than patients who obtain less than
CR. This is particularly established after high-dose chemotherapy followed by
autologous stem-cell transplantation (ASCT). The response evaluation is usu-
ally done at day +100 after ASCT. Of interest, recent observations have shown
that improvement in the response can be observed beyond day +100 after
ASCT and that these late responders would have a better outcome than
patients without this improvement.
Aims: The objective of the present study has been to evaluate the rate and
outcome of patients who improve their response beyond day +100 after ASCT,
with and without maintenance therapy.
Methods: One hundred and forty-four patients (63M/81F, median age 55 years;
range 29 to 69) from Hospital Clínic de Barcelona (90) and Hospital Universi-
tario de Salamanca (54) who underwent ASCT with melphalan-based condi-
tioning between October 1992 and November 2013 were studied. The entry
criteria were: 1) chemosensitive disease at the time of ASCT, 2) have received
single ASCT, 3) less than CR at day 100 post-ASCT, and 4) minimum follow-
up of one year. Medical records of all patients were reviewed. Responses were
determined at 3, 6, 9 and 12 months after ASCT, according to the EBMT criteria.
27 (18.8%) of the patients had extramedullary disease at diagnosis.
Results: At day +100 post ASCT, 52.1% of the patients had achieved partial
response (PR), 39.6% very good partial response (VGPR) and 8.3% were in
minimal response. After a median follow-up of 66 months, the median OS for the
whole series was 6.8 years (IC 95% 4.5 to 9) and the median PFS was 2.9 years
(IC 95% 2.4 to 3.4). There were no significant differences in outcome between
the two centers. Seventy four patients (51.4%) did not receive any maintenance
and only one of them showed any upgrade in her response. This patient improved
their response from VGPR to CR beyond 100 days after ASCT. The remaining
70 patients (48.6%) received maintenance therapy, mainly interferon (53; 36.8%),
with glucocorticoids in 29 cases (20.1%); thalidomide (4.9%) or thalidomide plus
bortezomib (6.9%). Twelve patients (8.3%), improved response beyond day +100
after ASCT: five of them with interferon (two associated with glucocorticoids), 4
bortezomib plus thalidomide and 2 single agent thalidomide. The outcome of
these patients was better than those who did not upgrade their response in terms
of PFS and OS (p=0.024 and p=0.01, respectively).
Summary and Conclusions: A minority of patients receiving maintenance
therapy after ASCT upgrades their response and this finding is associated
with better outcome. In contrast with previously published data, in our series
the improvement in response beyond day +100 after ASCT in patients non
receiving maintenance therapy is exceedingly rare. This fact must be taken
into account when making treatment decisions based on the response status
after ASCT.
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Background: Ricolinostat, an oral selective HDAC6 inhibitor, is well tolerated
as monotherapy (Raje Blood 2012;120:4061) and demonstrates potent syner-
gistic activity with lenalidomide (Len) and pomalidomide (Pom) in preclinical
models (Quayle Blood 2013;122:1952). Pan-HDAC inhibitors vorinostat
(Dimopoulos Lancet Oncology 2013;14:1129-40) and panobinostat (San-Miguel
Lancet Oncology 2014;15:1195-206) are active in multiple myeloma (MM) in
combination with bortezomib (Btz) and Len, but have toxicities (thrombocy-
topenia, fatigue, and gastrointestinal events) which limit dosing exposure. Ricol-
inostat, in combination with Len and dexamethasone (Dex) demonstrates clin-
ical activity and a manageable safety profile at doses up to 160 mg twice daily
(BID) for 21 consecutive days (Yee Blood 2014;124:4772).
Aims: ACE-MM-102 is a phase 1b/2 trial in relapsed and refractory MM patients
who have received at least two cycles of a proteasome inhibitor and Len con-
taining regimen and who have progressed on or within 60 days of the last ther-
apy.
Methods: Phase 1b was a 3+3 design which explored ricolinostat 160 mg daily
(QD) orBID combined with Pom (4 mg) for 21 days of a 28 day cycle with Dex
(40 mg) on days 1, 8, 15 and 22. Patients had measurable disease, adequate
bone marrow reserve and hepatic function with creatinine clearance >45
mL/min. Patients with non-secretory MM, prior Pom or HDAC inhibitor therapy
were excluded. Bone marrow cytogenetics were obtained at entry. Peripheral
blood samples were obtained for pharmacokinetic (PK) and pharmacodynamic
(PD) assessment of acetylated tubulin and histones. Patients with serum free
light chain-only disease were excluded from phase 2.
Results: 7 patients were treated in phase 1b: 3 at 160 mgQD and 4 at 160
mgBID. Median age was 66 and the majority received >3 lines of prior therapy.
No dose limiting toxicities (DLTs) were observed. At 160 mg QD, 1 patient had
grade 3 fatigue and 1 patient had grade 3 neutropenia both attributed to Pom.
In the 160 mgBID cohort, all 4 patients had grade 2 diarrhea and 2 of 4 patients
had grade 4 neutropenia attributed to Pom. 1 patient continues on study after
10 cycles; the other 6 phase 1b patients were withdrawn for progressive dis-
ease at 2-4 cycles. Following safety review committee (SRC) review, phase 2
opened at a dose of 160 mg BID, with SRC review to occur after 6 patients
had completed one cycle of therapy. 3 of the 6 patients had grade 3 diarrhea
requiring ricolinostat dose reduction in cycle 2. Other treatment emergent tox-
icities included fatigue, neutropenia, hypertension, thrombocytopenia and ane-
mia that were mostly low grade. Although no DLTs were observed, reduction
of the dose from 160 mgBID toQD for ongoing and future patients was recom-
mended to maintain treatment at a therapeutic exposure for as long as possible.
PK of ricolinostat was similar to that observed in combination with Btz and Len.
There was no evidence of ricolinostat accumulation or drug-drug interaction
with Pom.As of February 2015, 27 patients have been enrolled in phase 2; 11
were dose reduced toQD after initial 160 mgBID dosing and 16 started at 160
mg QD. 6 patients have withdrawn due to progressive disease (2), low-grade
AEs (2), physician decision (1) or patient decision (1). 21 phase 2 patients
remain on study after a median of 2 (1-5) cycles.
Summary and Conclusions: Ricolinostatappears well tolerated and can be
safely administered in combination with Pom and Dex in patients with relapsed
and refractory MM.Updated safety, PK, PD and preliminary clinical activity data
will be presented as phase 2 enrollment continues.
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PROGRESSION-FREE SURVIVAL 2 (PFS2) IS THE MOST SIGNIFICANT
PROGNOSTIC FACTOR OF LONG-TERM SURVIVAL IN THE ERA OF
NOVEL AGENTS: A SINGLE GREEK MYELOMA CENTER EXPERIENCE
E. Katodritou1,2,* S. Papadaki1, G. Polychronidou1, N. Spyridis1, N. Karabatzakis1,
A. Pentidou1, S. Palaska1, K. Kokoviadou2, E. Vlachaki2, D. Markala2,
E. Yiannaki2, V. Perifanis2, E. Verrou1, V. Gastari1, P. Konstantinidou1, E. Terpos2
1Hematology, Theagenion Cancer Center, Thessaloniki, 2Greek Myeloma
Study Group, Athens, Greece
Background: The term “long-term survivor” (LTS) in Oncology refers to patients
alive for more than 10 years and according to published studies conducted
before the use of novel agents, 3-4% of Multiple myeloma (MM) patients belong
to this group. The current literature include very limited data regarding LTS in
the era of novel agents.
Aims: The aim of this study was to described the incidence, disease charac-
teristics and prognostic factors of LTS MM patients.
Methods: We checked the database of a single Greek myeloma center for the
presence of LTS. Pearson’s χ2test, Mann-Whitney U test, and One-way ANOVA
were used for comparisons; p<0.05 was considered statistically significant. Pro-
gression Free Survival (PFS) was estimated from the time of MM diagnosis until
progression or death from any cause; OS was estimated from the time of MM diag-
nosis until the last follow up or death; PFS2 was defined as the time from MM diag-
nosis to second objective disease progression, or death from any cause whichever
first. Prognostic factors for LTS were determined with a cox regression model.
Results: Among 648 consecutive MM patients diagnosed and treated between
1989-2013, we identified 50 LTS (7.7%; M/F: 23/27, median age: 65 years,
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range: 47-72 years). LTS were younger and most of them presented with ISS
stage I/II compared to all others who served as controls (p<0.001). In addition,
LTS had higher hemoglobin, lower creatinine and lower β2 microglobulin at diag-
nosis compared to controls (p<0.05). Bence Jones proteinuria and immuno-
paresis at diagnosis presented less frequently in LTS; recovery of immunoparesis
after 1st line treatment was more common in LTS (p<0.05); 72% of LTS received
novel agent-based combinations (NAC) during the course of MM. The number
of patients treated with NAC and the response rate after 1st line therapy, did not
differ between LTS and the control group; LTS received more frequently autol-
ogous transplantation at 1st line, NAC at 2nd line and IMiD-based regimens at
any line, compared to controls (p<0.05). After a median follow up of 12 years
(range: 2-180 months), 28/50 LTS vs 84/598 MM patients were alive (p<0.001);
13 LTS patients died from MM and 9 patients died from irrelevant causes. The
median PFS and OS for LTS vs controls was 81 months (95% CI: 56-105) vs 17
months (95% CI: 15-19) and 200 months (95% CI: 180-219) vs 33 months (95%
CI: 30-36), respectively (p<0.05). In the univariate analysis PFS, PFS2, period
of diagnosis (i.e. before or after 2000), 1st line treatment, 2nd line treatment
and treatment at any line with conventional therapy vs NAC were independent
predictors of long-term survival (p<0.05). Baseline disease characteristics or
quality of response did not predict for LTS. In the multivariate analysis, PFS2
was the only positive predictor for long-term survival (p<0.001; HzR: 0.98. 95%
CI: 0.96-0.99); 28% of patients with PFS2 ≥4 years were alive after 10 years
compared to 0.2% of those with PFS2 <4 years.
Summary and Conclusions: The percentage of LTS has increased in the era
of novel agents. LTS present with more favorable disease characteristics at
diagnosis compared to other MM patients, but none of those predicted for long-
term survival. PFS2 proved to be the most significant prognostic factor of long-
term survival, whereas quality of response failed to show a prognostic value,
suggesting that disease control during the initial phase of MM, where sensitive
clones still prevail and there is no drug resistance, should be the main goal of
the treatment strategy. Finally, 1/3 of patients who displayed disease control of
≥4 years after 2 treatment lines, enjoyed a long-term survival and most impor-
tantly, more than 20% of them could be considered as “cured” from MM, chal-
lenging the dogma of incurable disease.
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OBESITY AND RISK OF MONOCLONAL GAMMOPATHY OF
UNDETERMINED SIGNIFICANCE: A POPULATION-BASED STUDY
M. Thordardottir1,* E. Lindqvist2, S.H. Lund1, R. Costello3, D. Burton3,
N. Korde4, S. Mailankody3, G. Eiriksdottir5, L.J. Launer6, V. Gudnason1,5,
T.B. Harris6, O. Landgren2,4, S.Y. Kristinsson1,2
1Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 2Department of
Medicine, Division of Hematology, Karolinska University Hospital and Karolinska
Institutet, Stockholm, Sweden, 3Multiple Myeloma Section, National Cancer
Institute, National Institute of Health, Bethesda, MD, 4Myeloma Service, Division
of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York,
NY, United States, 5Icelandic Heart Association, Kopavogur, Iceland, 6National
Institute on Aging, National Institute of Health, Bethesda, MD, United States
Background: All multiple myeloma (MM) cases are preceded by the premalig-
nant state, monoclonal gammopathy of undetermined significance (MGUS), an
asymptomatic condition that needs no treatment. The etiology of MGUS and
MM is to a large extent unknown. Two studies on the association between obe-
sity and MGUS have been conducted with conflicting results, despite a reported
association between obesity and MM.
Aims: The aim of this study was to determine if obesity is associated with an
increased risk of MGUS and light-chain MGUS (LC-MGUS) in a population-
based screened cohort of individuals above the age of 65 years using extensive
number of markers for current and early life obesity. Secondly, the aim was to
examine whether progression to MM was affected by obesity.
Methods: This study was based on participants from the Age, Gene/Environ-
ment Susceptibility-Reykjavik Study (AGES-RS), consisting of 5764 men and
women above the age of 65 years. Serum protein electrophoresis (SPEP) and
serum free light-chain assay were performed on all subjects to identify MGUS
and LC-MGUS. Obesity measures were performed at baseline, and participants
were additionally asked about their weight at the age of 55 and 25 years and
their lifetime max weight. The measures at baseline included were weight (kg),
body mass index (BMI) (kg/m2), percent body fat, fat (kg), fat-free mass (kg),
waist circumference (cm), total body fat area (cm2), and visceral and subcuta-
neous fat area (cm2). Weight was measured using a digital scale and height
using a stadiometer, measures were performed multiple times and a mean
number found. Percent body fat, fat and fat free mass were calculated from
bioelectric impedance, a commonly used method for estimating body compo-
sition. Computed tomography imaging of the abdomen was performed to cal-
culate total body fat area, visceral fat area, subcutaneous fat area, and abdom-
inal circumference. Abdominal circumference was additionally measured mul-
tiple times and a mean number found. The participants were followed prospec-
tively until 2013 and information on MM diagnosis was collected through hos-
pitals, nursing homes, and mortality records. The association with MGUS and
LC-MGUS was analyzed using logistic regression and Cox proportional-hazard
regression was performed to test whether progression to MM was affected by
obesity. Adjustment was made for age and gender.
Results: A total of 299 (5.2%) MGUS cases and 33 (0.6%) LC-MGUS cases
were identified. No association was found between any of the obesity markers
and MGUS or LC-MGUS. Results for MGUS, presented as OR with 95% CI,
were: BMIbaseline 0.99 (0.97-1.02), BMI55y 1.01 (0.97-1.05), BMI25y 0.99 (0.94-
1.04), weight 1.00 (0.99-1.01), max weight 1.00 (0.99-1.01), percent body fat
0.99 (0.97-1.02), fat 1.00 (0.98-1.02), fat free mass 1.00 (0.98-1.02), total body
fat 1.00 (1.00-1.00), visceral fat 1.00 (1.00-1.00), subcutaneous fat 1.00 (1.00-
1.00), CT waist circumference 1.00 (0.99-1.01), and measured waist circum-
ference 1.00 (0.99-1.01). BMI ≥25 at the age of 55 affected MM progression
(HR 3.20; 95% CI 1.15-8.88) (Table).
Tabella 1. Effect of obesity on MGUS and risk of progression
Summary and Conclusions: In this large population-based cross-sectional
study aimed at evaluating the association between obesity and MGUS, we did
not find an association between several obesity markers and MGUS or LC-
MGUS. However, BMI ≥25 at the age of 55 years seemed to affect progression
from MGUS to MM. Future studies are needed to clarify underlying mechanisms
for this finding. Taken together, we were unable to confirm the previously report-
ed association between MGUS and obesity.
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POST AUTOLOGOUS STEM CELL TRANSPLANTATION MAINTENANCE
IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE OF 18 YEARS:
A MARKED SURVIVAL ADVANTAGE WITH INTERFERON
G. Varga1,* D. Lévai1, P. Reményi2, G. Mikala2, M. Réti2, L. Gopcsa2, Á. Bátai2,
Z. Csukly2, L. Lengyel2, É. Torbágyi2, A. Barta2, J. Fábián2, T. Masszi1,2
1Haematology, 3rd Department of Internal Medicine, Semmelweis University,
2Department of Haematology and Stem Cell Transplantation, St. Istvan and
St. Laszlo Hospital, Budapest, Hungary
Background: Interferon (IFN) maintenance was widely used in multiple myelo-
ma (MM) during the 90s and early 2000s but then was mostly abandoned. The
reasons of its decline were side effects, trials showing only marginal or no ben-
efit and the emergence of new, highly effective drugs. However maintenance
still has a very significant role in MM, and in this setting, drugs modulating the
immune system play the most important part.
Aims: To study the effect of maintennce on post ASCT survival we analyzed
the outcome of post-ASCT maintenance in 548 MM patients transplanted in
our centre over 18 years.
Methods: Progression free survival (PFS) was calculated from the day of ASCT
and overall survival (OS) from the first chemotherapy. The analyses were car-
ried out using the SPSS (version 20.0) software package.
Results: 93 (17%) patients had IFN, 127 (23.2%) thalidomide (thal) at the dis-
cretion of the treating physician. 42 (7.7%) had both drugs as maintenance for
a period of time mostly subsequently, but sometimes parallel. Maintenance
strategies changed over the years. Between 2001 and 2008 half of the patients
had maintenance. IFN was used from 1998 to 2011, but the majority of the
patients had it between 2002 and 2008. Thal was increasingly used from 2000
until 2008, and then it was only occasionally employed in patients with poor
response. Post-ASCT maintenance was more common after no-novel agent
and thal based protocols. Thal was used in 34.1% after thal based, 12.2% after
bortezomib and in 33.1% following no-novel agent based induction. IFN was
employed in 20.5% after thal, 9.2% after bortezomib and 24.8% after no novel
agent containing protocols. Patients with any maintenance had a 7 month PFS
benefit [33 (28.9−37.1) vs 25.9 (22.6−29.2) months; p=0.044] and a 15 month
OS advantage [101.4 (91.3−111.5) vs 86.1 (71.5−100.7); p=0.070]. With thal
the difference was not significant, however with IFN there was a significant
PFS [35.5 (31.3−39.7) vs 25.9 (22.6−29.2); p=0.017] and an even more pro-
nounced OS [122.4 (79.6−165.1) vs 86.1 (71.4−100.8); p=0.006] benefit (Figure
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1). The patients having the best results were those who had both maintenance
drugs [PFS 38.7 (15.5−61.9), OS 150.4 (102.2−198.6)]. The positive effect of
IFN maintenance was more prominent in patients with PR (OS benefit 52.8
months; p=0.01) than those in CR (OS difference 39.7 months; p=0.088). IFN
maintenance was confirmed as a highly significant independent protective fac-
tor in multivariate analysis (PFS p=0.030; OS p=0.003) while thal was not (PFS
p=0.736; OS p=0.165).
Figure 1.
Summary and Conclusions: The marked survival advantage in the IFN treat-
ed patients was beyond what the randomized interferon trials conducted back
in the nineties indicated. Although, patient selection might have had a role in
this, analyzing the distribution of presentation prognostic markers and post
ASCT responses revealed no detectable imbalances. One possible explanation
could be an interplay between thal and IFN, two drugs both exploiting the
immune system in different ways.
P283
WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS
WITH MYELOMA. INCIDENTAL FINDINGS-THE ROYAL MARSDEN
EXPERIENCE
A. Wale1, C. Pawlyn2,* M. Kaiser2, C. Messiou1
1Department of Radiology, 2Royal Marsden NHS Foundation Trust, Sutton,
United Kingdom
Background: The recent consensus statement from the International Myeloma
Working Group has introduced the role of whole body MRI in the management
pathway for patients with multiple myeloma. Whole body MRI is now recom-
mended for all patients suspected of having smouldering or asymptomatic
myeloma (Dimopoulos JCO 2015). The speed, coverage and high sensitivity
of whole body diffusion weighted MRI (WB DW-MRI) and the capability to quan-
tify both burden of disease and response to treatment has led to increasing
implementation at leading centres worldwide for imaging malignant marrow
disease. We have been offering a WB DW-MRI service for patients with myelo-
ma since 2011. However the high sensitivity of this imaging technique will
undoubtedly lead to detection of incidental findings.
Aims: The aim of this study was to determine the incidence of incidental and
extramedullary findings from WB DW-MRI studies performed in myeloma
patients.
Methods: Between January 2012 and October 2014 177 WB DW-MRI exam-
inations were performed for 80 patients with myeloma at the Royal Marsden
Hospital, UK. Scans and reports were retrospectively reviewed to determine
whether the patient had active marrow involvement, extramedullary disease
and if incidental findings were identified. Advice for management of equivocal
findings was also documented.
Tabella 1.
Results: 132/177 (75%) WB DW-MRIs showed evidence of active marrow
involvement (80 focal, 45 diffuse, 7 both). 18/177 (10%) examinations in 9
patients identified extramedullary myeloma in the liver in 7 examinations, in
muscles in 12 examinations, in the retroperitoneum in 4 examinations and in
the dura in 1 examination. This was confirmed by response to treatment at fol-
low up in all cases. 67/177 (38%) examinations in 47 patients had incidental
findings. Some examinations identified multiple incidental findings so a total of
70 incidental findings were documented. 14/70 incidental findings (20%) were
indeterminate. Guidance on further management of indeterminate lesions was
given in 13/14 examinations in 14 patients (93%). Half of these indeterminate
findings were addressed by clinical correlation and the remaining half required
further investigation. The incidental findings are summarised in the table:
Figure 1.
Summary and Conclusions: Incidental findings are common in WB DW-MRI
examinations but only a minority are equivocal requiring further action. The
use of WB DW-MRI in patients with myeloma is likely to increase and hence
we will need to develop strategies to manage incidental findings. The reporting
radiologist should facilitate this by specifically expressing a level of concern
and making suggestions regarding the need for further investigations. WB MRI
is also likely to increase detection of asymptomatic extramedullary myeloma
which may change our perspective of the disease.
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PATTERNS OF TOTAL COST OF CARE BY AGE GROUP FOR PATIENTS
WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
S. Arikian1,* G. Binder2, C.J. Gibson2, H. Hu2, Y. Nagarwala2, M. Hussein2,
F.A. Corvino1, A. Surinach1, S. Usmani3
1Genesis Research, Hoboken, 2Celgene Corporation, Summit, 3Levine Cancer
Institute/Carolinas Healthcare System, Charlotte, United States
Background: Clinical evidence supporting longer treatment (Tx) durations for
patients (pts) with newly diagnosed multiple myeloma (NDMM) raises economic
questions. Previous analysis showed that relapsed myeloma pts incurred higher
monthly costs once they advanced to later lines of Tx (Gaultney, J Clin Pharm
Ther, 2013). There is limited information on the cost patterns of MM pts by age
group, before and after their first relapse.
Aims: This claims analysis evaluated patterns of total costs of care, from Tx
initiation until progression, for NDMM pts and for newly relapsed pts by age
group, across Tx, using time to next therapy (TTNT) as a proxy measure for
progression.
Methods: Using a large US claims database, NDMM pts were identified based
on the first claim associated with a diagnosis of MM (ICD-9-CM code 203.0X)
between 2006 and 2013. Pts with claims for stem cell transplant (SCT) were
excluded. This cost analysis focused on NDMM and relapsed MM pts, aged
<75 and ≥75 yrs, receiving lenalidomide (LEN)-or bortezomib (BORT)-based
Tx, where complete claim history was available from Tx onset to initiation of
subsequent Tx. Using methods similar to those described by Gaultney (J Clin
Pharm Ther, 2013), pts’ average monthly drug and medical costs were deter-
mined, and differences in baseline measures between pt groups were evalu-
ated using the Charlson Comorbidity Index (CCI).
Results: 2843 NDMM pts (1862 pts aged <75 yrs; 981 pts aged ≥75 yrs) and
1361 second-line MM pts (978 pts aged <75 yrs; 383 pts aged ≥75 yrs) were
identified. For 41% and 29% of NDMM and second-line pts, respectively, com-
plete data through initiation of subsequent Tx was available and used for cost
determination. Monthly total costs for NDMM pts were $15,734 in the first 3
mos of Tx and declined each quarter to approximately $5000/mo at 18+ mos.
For second-line therapy, initial monthly costs were more than $13,876 and also
declined quarterly (Figure 1). Quarterly cost reduction patterns were consistent
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across Tx, lines of therapy, and age groups. TTNT for NDMM pts was 28.1,
24.7, and 33.6 mos for the overall, age <75 yrs, and age ≥75 yrs populations,
and TTNT was longer in pts initiated on LEN-based regimens compared with
those initiated on BORT. We compared cohorts of pts initiated on each Tx and
followed them for a common time period equal to the longer median TTNT of
the 2 Tx (LEN): 35 mos in pts aged <75 yrs and 39 mos in pts aged ≥75 yrs.
Monthly costs averaged $7941 in the LEN cohort vs $12,261 in the BORT
cohort of pts aged <75 yrs. For pts aged ≥75 yrs, monthly costs averaged
$6879 in the LEN cohort vs $7544 in the BORT cohort. Cost differences were
due to higher average monthly medical costs for pts treated with BORT; average
monthly drug costs were similar. CCI scores were similar across Tx.
Figure 1.
Summary and Conclusions: For a population of NDMM pts receiving either
LEN-or BORT-based Tx without SCT, followed until TTNT, total monthly drug
and medical costs per pt declined steadily over time, decreasing by two-thirds
over the TTNT period. Costs returned to near-baseline levels when pts began
second-line therapy, then declined similarly. This pattern of cost decline was
consistent regardless of age, Tx, or line of therapy. This may suggest that further
extending the time to progression for NDMM pts may yield economic benefits
for each month of extension before relapse. Average monthly total costs over 3
years were lower for NDMM pts initiated on LEN-based Tx due to longer periods
with below-average costs prior to initiating second-line therapy.
P285
ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE
1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND
*DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND
RELAPSED-REFRACTORY MULTIPLE MYELOMA
V. Magarotto1,* P. Sonneveld2, P. Voorhees3, C. Paba-Prada4, T. Plesner5,
U.H. Mellqvist6, C. Byrne7, J. Harmenberg8, E. Nordström8, A. Palumbo1,
P. Richardson4
1Turin University Hospital, Turin, Italy, 2Erasmus, Rotterdam, Netherlands,
3University of North Carolina, Chapel Hill, NC, 4Dana Farber Cancer Institute,
Boston, MA, United States, 5Vejle Hospital, Vejle, Denmark, 6Södra Älvsborgs
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Background: Melflufen is a potent and highly lipophilic alkylator designed for
efficient targeting of tumor cells. In contrast to other alkylating agents that are
hydrophilic, the lipophilicity of melflufen leads to rapid and extensive distribu-
tion into tissues and cells where it can bind directly to DNA or is readily metab-
olized by intracellular peptidases into melphalan. With targeted delivery of
alkylating metabolites to tumor cells (such as multiple myeloma) melflufen
exerts a higher anti-tumor activity compared with standard of care alkylator
melphalan but with a similar safety profile.
Aims: To study the safety and efficacy of melflufen and dexamethasone (dex)
in combination for patients with relapsed-refractory multiple myeloma (RRMM).
Methods: Melflufen is evaluated in combination with low dose dex in a Phase
1/2 study in RRMM. Phase 1 evaluated 4 dose levels of melflufen on day 1
with dex on days 1, 8 and 15 of 21 day cycles in a standard 3+3 design, with
an additional 20 patients added at the MTD in Phase 2.
Results: Phase I was completed in September 2014. No dose limiting toxicities
(DLTs) were observed in the first three dose cohorts (15, 25 and 40 mg
melflufen). 4 of 6 patients at the highest dose, 55 mg, experienced DLTs of
prolonged and severe neutropenia and thrombocytopenia, manageable with
dose delays and appropriate treatment. The maximum tolerated dose (MTD)
was established at 40 mg melflufen every 21 days combined with 40 mg dex
weekly. As of 16 Jan 2015, 16 patients were treated at the MTD. Median time
from initial diagnosis to first dose of melflufen was 5.5 years (1-15). Median
number of prior therapies was 4 (2-11). All patients had been exposed to IMiDs,
proteasome inhibitors and alkylators and 15 were at least single-refractory. 8
were double-refractory and 6 were alkylator-refractory. Treatment-related
Grade 3 and 4 adverse events were reported in 69% of patients; neutropenia
50%, thrombocytopenia 44%, fatigue and leukopenia 12% each, anemia,
febrile neutropenia and lymphopenia each occurred in 6% of patients. 10
patients were evaluable for response (defined as received ≥2 cycles with
appropriate assessments). The overall response rate (≥PR) was 60%. The
clinical benefit rate (≥MR) was 70%. Time to initial clinical benefit and response
was rapid with 70% of patients achieving MR or better after only 1-2 cycles,
and 50% of patients responding (≥PR) after 1-3 cycles. Of note, 1 patient that
only achieved SD to previous melphalan 200 mg/m2 with ASCT responded
with a PR following only 1 cycle of 40 mg melflufen. Four patients discontinued
treatment following 10, 6, 4 and 2 cycles for reasons other than progression.
Three continue to maintain response off therapy, at time of data cut for 9.5,
9.2 and 4.6 months respectively. The fourth patient continues to maintain SD,
9.6 months at time of datacut. Median time on treatment was 3.4 months (1.3-
7.8) with 5 patients still ongoing.
Summary and Conclusions: Melflufen plus low dose dex is tolerated and
has promising activity in this advanced RRMM population. The MTD was
established at 40 mg every 21 days with dex 40 mg weekly. In the first 10
evaluable patients treated at the MTD, all heavily pre-treated, 6 responded to
treatment with PR. Responses are rapid and durable. Based on these early
results the protocol will be amended to include 55 patients in Phase 2 to further
characterize response. Updated information will be presented at the time of
the conference.
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ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND
REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT
TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN
THE PHASE 3B STRATUS TRIAL (MM-010)
K. Weisel1,* M.A. Dimopoulos2, A. Palumbo3, P. Corradini4, M. Cavo5,
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Background: Overall survival (OS) of patients (pts) with refractory or relapsed
and refractory multiple myeloma (RRMM) has been extended by treatment
(Tx) with newer agents, such as lenalidomide (LEN) and bortezomib (BORT);
however, shortened OS is observed in pts who relapse on or who become
refractory to Tx (Kumar et al, Leukemia, 2012). Renal impairment (RI), a major
cause of death in this pt population, (Korbet et al, J Am Soc Nephrol, 2006)
occurs in ≈ 20% to 40% of MM pts (Kastritis et al, Haematologica, 2007). In
RRMM pts who failed LEN and BORT Tx, pomalidomide + low-dose dexam-
ethasone (POM + LoDEX) extended progression-free survival (PFS) and OS
vs high-dose dexamethasone in the phase 3 MM-003 trial. This included pts
with moderate RI (creatinine clearance [CrCl] <60 mL/min; Weisel et al, J Clin
Oncol, 2013). Efficacy of POM + LoDEX was similar across renal function sub-
groups in the MM-002 trial, in which pts with serum creatinine ≥3 mg/dL were
excluded (Vij et al, Clin Lymphoma Myeloma Leuk, 2013).
Figure 1.
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Aims: STRATUS is a multicenter, single-arm, open-label phase 3b trial
designed to further evaluate the safety and efficacy of POM + LoDEX in RRMM
pts, including those with varying degrees of renal insufficiency.
Methods: RRMM pts (progressive disease [PD] during or within 60 days of
last line of Tx), aged ≥18 yrs, with measureable M-protein levels in urine or
serum and ≥2 prior Tx, who failed LEN and BORT after ≥2 cycles of each
(alone or in combination), and who received adequate prior alkylator Tx were
eligible. Pts with CrCl <45 mL/min were excluded. POM 4 mg was adminis-
tered D1-21/28-day cycle and LoDEX 40 mg/day (20 mg for pts aged >75 yrs)
on D1, 8, 15, and 22 until PD or unacceptable toxicity. Thromboprophylaxis
was required for all pts. Primary endpoint was safety, and key secondary end-
points included, overall response rate (ORR; ≥partial response), duration of
response (DOR), PFS, OS, and POM exposure.
Results: As of Sep 15, 2014, 604 pts were enrolled; 599 received POM +
LoDEX, and 36% had moderate RI (CrCl <60 mL/min) at baseline. After a
median follow-up of 9.3 mos, the most frequently reported grade (Gr) 3/4
hematologic treatment-emergent adverse events (TEAEs) in pts with moderate
RI vs those without moderate RI (CrCl ≥60 mL/min) were neutropenia (39%
vs 44%), anemia (33% vs 27%), and thrombocytopenia (22% vs 21%). The
most frequent Gr 3/4 non-hematologic TEAE was infection (29% vs 30%).
Dose reductions due to TEAEs were similar in pts with moderate RI vs those
without moderate RI (19% vs 17%); 12% vs 7% discontinued POM due to
TEAEs. Gr 3/4 venous thromboembolic events and peripheral neuropathy
were infrequent, regardless of renal status. Median relative POM dose inten-
sity was similar between subgroups (0.94 in pts with moderate RI vs 0.93 in
pts without moderate RI). In pts with moderate RI vs those without moderate
RI, ORR was 37% vs 33%, median DOR was 6.0 vs 7.9 mos, and median
PFS was 3.7 vs 4.6 mos (P =0.1142; Figure). The median Tx duration for pts
with moderate RI vs without moderate RI was 3.7 vs 4.3 mos. Updated data
will be presented at the congress.
Summary and Conclusions: This analysis demonstrated that in pts with mod-
erate RI, POM + LoDEX has a manageable safety profile and is efficacious.
Tolerability and efficacy were similar in pts with or without moderate RI and
consistent with results from the pivotal MM-002 and MM-003 trials. There was
a trend toward longer PFS in pts without moderate RI. Two ongoing trials, MM-
008 (US) and MM-013 (EU), are evaluating RRMM pts with severe RI.
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PROGNOSTIC VALUE AND USEFULNESS OF SERUM-FREE-LIGHT-
CHAINS-RATIO (SFLCR) AND SERUM HEAVY-LIGHT-CHAINS-RATIO
(SHLCR) IN SYMPTOMATIC MULTIPLE MYELOMA IN THE CONTEXT OF
THREE GEM/PETHEMA CLINICAL TRIALS
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Background: Several studies have analysed the prognostic impact of high
values of sFLC or sHLC and their abnormal ratios in Multiple Myeloma (MM),
most of them retrospectives. Currently, the normalization of sFLC or HLCr after
treatment has been proposed as a good response biomarker.
Aims: To investigate the prognostic impact of sFLCr and sHLCr at diagnosis
and after treatment in MM patients in the context of three GEM/PETHEMA clin-
ical trials (GEM2005MENOS65, GEM2005MAS65 & GEM2010MAS65).
Methods: Among a total of 819 patients, treated according to the
GEM2005MENOS65, GEM2005MAS65 & GEM2010MAS65 GEM/PETHEMA
trials, serum samples for sFLC and sHLC analyses were available at diagnosis
in 623 and 183 of the patients, respectively. After induction, regardless of the
achieved response, it was available in 308 cases for sFLCr and 89 for sHLCr.
All patients in which sHLC assay was analysed were IgG or IgA-MM. The sHLC
and sFLC assays (HEAVYLITE® and FREELITE®, The Binding Site, Birming-
ham, UK) were performed on an automated nephelometer (BNII, Dade
Behring/Siemens, Marburg, Germany). The sPE assay was performed by cap-
illary electrophoresis (V8, Helena Biosciences Europe), and sIFE was performed
for γ, α, μ, κ, and λ Ig chains (SAS-3 & SAS-4, Helena Bioscience Europe).
Results: At diagnosis, 92% of the sFLCr and sHLCr were abnormal, which
had no impact in prognosis; even when we considered “very pathological” (VP)
sFLCr values (0.03-32)[FIGURE 1A]. Establishing several cut-offs, we note
that VP-sHLCr values (<0.29 or >73) at the time of diagnosis showed an
increased risk of progression (p=0.006)[FIGURE 1B], confirmed by multivariate
analysis ― age [p=0,003; OR 1.04 (1.01-1.06)]; LDH [p=0.03; OR 0.4 (0.26-
0.94)]; VP-sHLCr [p=0.01; OR 1.78 (1.14-2.78)]; high vs low risk FISH [p=0.02;
OR 1.75 (1.11-2.74)]. Interestingly, absolute HLC-involved-Ig values show linear
correlation with absolute values of MP by sPE (p=0,000; Pearson’s r=0.676)
and the presence of uninvolved HLC pair suppression had no prognostic impact
in our series (OS p=0.89; PFS p=0.57). After treatment, regardless of the
achieved response, a normal sFLCr or a normal sHLCr do not imply a better
prognosis in our series. Concerning the sFLCr, among the 130 patients in CR
after induction no prognostic differences were observed between patients with
a normal (0.26-1.65) vs pathological sFLCr.
Figure 1 A.
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Figure 1 B.
Summary and Conclusions: VP-sHLCr values (<0.29 or >73) at diagnosis
could suggest a greater risk of progression. Since the HLC-involved-Ig values
show a strict linear correlation with values of MP by sPE,its clinical utilityis
debatable.The sHLC non-involved pair suppression at diagnosis wasn’t related
to worse prognosis, nor did a normal sFLCr or sHLCr at diagnosis seem to
imply differences in prognosis. However, in CR, a normalization of the sFLCr
doesn’t correlate with a better prognosis in our series, what opens up contro-
versy about the value of the current IMWG criteria for sCR.
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Background: Patients with multiple myeloma have an increased risk of vari-
cella-zoster virus (VZV) infection, which has been established, especially with
the use of bortezomib. However, few studies have discussed the risk of VZV
infection in myeloma patients without bortezomib treatment.
Aims: We conducted a nationwide population-based study to investigate the
risk of VZV among myeloma patients and the association between non-protea-
some inhibition therapies and development of VZV.
Methods: We recruited patients with newly diagnosed multiple myeloma from
Taiwan’s National Health Insurance database between January 1, 2000 and
December 31, 2011. Patients who were aged under 20 years or with antecedent
VZV were excluded. Each myeloma patient was matched with four age-, sex-
, and comorbidity-matched individuals. All participants were followed up until
VZV development, death, dropout from the National Health Insurance program,
initiation of bortezomib treatment, or the end of 2011. The Kaplan-Meier method
was employed for estimation of cumulative incidence. Hazard ratios (HRs) of
VZV risk compared between the two cohorts were calculated by Cox propor-
tional regression analysis. In addition, therapeutic agents were put into Cox
models as time-dependent covariates to avoid immortal time bias.
Results: This study consisted of 3,677 patients with multiple myeloma and
14,708 matched individuals, with a median age of 67 years (interquartile range
58–75). Four hundred eighteen VZV infections developed among 3,677 myelo-
ma patients, with a follow-up of 6083.8 person-years. The incidence of VZV
infection was 5.93 times higher in the myeloma cohort than in the matched
cohort (68.7 vs 12.0 per 1,000 person-years), with an age-, sex-, and comor-
bidity-adjusted HR of 6.02 (95% confidence interval [CI] 5.30–6.83; P <0.001).
The multivariable Cox proportional hazard models showed thalidomide treat-
ment (adjusted HR 1.33; 95% CI 1.04–1.69; P =0.022), cytotoxic chemotherapy
(adjusted HR 1.34; 95% CI 1.02–1.77; P =0.036) and hematopoietic stem cell
transplantation (adjusted HR 2.80; 95% CI 2.09–3.75; P <0.001) as independ-
ent risk factors determining the subsequent VZV in myeloma patients.
Summary and Conclusions: Our study reveals an increased risk of VZV infec-
tion among myeloma patients without bortezomib therapy. Treatment with
thalidomide, cytotoxic chemotherapy, or hematopoietic stem cell transplantation
is associated with a higher risk of VZV infection in myeloma patients.
Figure 1.
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BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY
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Background: The anti-apoptotic proteins BCL-2 and MCL-1 promote multiple
myeloma cell survival. Bortezomib (BTZ) can inhibit MCL-1 activity by increasing
the MCL-1 antagonist, NOXA. Venetoclax is a selective, orally bioavailable,
small-molecule BCL-2 inhibitor, which enhances BTZ efficacy in multiple myelo-
ma xenograft models. This Phase 1 study evaluates venetoclax with BTZ and
dexamethasone (Dex) in patients with relapsed/refractory multiple myeloma.
Aims: Objectives include safety, pharmacokinetics, preliminary efficacy, and
maximum therapeutic dose of venetoclax with BTZ and Dex.
Methods: Patients received venetoclax (50-500 mg PO daily) in cycles 1-11
per designated dose escalation cohorts (continual reassessment method); BTZ
(1.3 mg/m2 SC, days 1, 4, 8, 11) and Dex (20 mg PO, Days 1, 4, 5, 8, 9, 11,
12) in cycles 1-8 (21 days), BTZ+Dex days 1, 8, 15, 22 in cycles 9-11 (35 days),
and venetoclax alone in cycle 12 and beyond.
Results: 32 patients were enrolled as of 12/18/2014: median age 65; 12/20
female/male. 12 were ISS stage I, 7 stage II, 10 stage III. Median (range) prior
therapies: 5 (1–15). 26 patients received prior BTZ (10 were refractory), 26
had prior lenalidomide, and 20 had autologous hematopoietic stem cell trans-
plant. Adverse events (AE; all grades) occurring in ≥20% patients: constipation
(41%), diarrhea (38%), peripheral edema (28%), thrombocytopenia (31%),
peripheral neuropathy (28%), insomnia (28%), dyspnea (25%), and anemia
(22%). Grade 3/4 AEs (≥10%): thrombocytopenia (25%) and anemia (13%).
14 patients had serious AEs: none were assessed as venetoclax-related. Rea-
sons for discontinuation (n=17): disease progression (PD; n=14), AEs (n=2:
adenocarcinoma, cardiac and respiratory decompensation), consent withdrawal
(n=1). 3 deaths occurred (due to PD); 1 dose-limiting toxicity at 300 mg (cardiac
decompensation attributed to Dex). No tumor lysis syndrome occurred. Dose-
normalized venetoclax exposure when given with BTZ+Dex (n=30) was similar
to venetoclax alone.
Summary and Conclusions: Venetoclax with BTZ and Dex has an acceptable
safety profile in heavily pretreated multiple myeloma patients. This combination
targeting BCL-2 and MCL-1 resulted in anti-tumor activity and longer time on
study in patients naïve or sensitive to prior BTZ. Dose escalation continues at
600 mg.
haematologica | 2015; 100(s1) | 91
Vienna, Austria, June 11 – 14, 2015
Tabella 1.
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Background: With the recent publication of updated criteria for the diagnosis
of multiple myeloma by the IMWG, a subset of patients formerly diagnosed as
having asymptomatic MM (SMM) or monoclonal gammopathy of undetermined
significance (MGUS), should be reclassified.
Aims: To retrospectively discriminate the subset of patients that present today
diagnostic discrepancy and to evaluate eventual damage, if any.
Methods: 286 patients (147 diagnosed as SMM and 139 as MGUS), diagnosed
and followed-up in our section, were studied. Patients were re-diagnosed
according to factors susceptible to change the diagnosis according to the new
IMWG criteria, namely the existence of IgA or IgG >30g/L or urinary moclonal
protein of 500 mg/24h or more, that could shift MGUS to SMM and, with regard
to an eventual shift from SMM to MM, the existence of plasma cell infiltration
equal or more than 60% and the presence of at least one osteolytic lesion on
more sensitive methods than x-rays. Anemia, hypercalcemia and renal impair-
ment were already taken in account initially and are not reassessed. Statistical
analysis was performed by standard methods with the SPSS v21.0 software.
Results: No MGUS patient had IgA or IgG >30g/L or urinary moclonal protein
of at least 500 mg/24h, so no change were made. The new criteria did not
taken into account serum free light chain (FLC) measurements or ratio (FLCR).
Five patients had an FLC value >100mg/L and 6 an FLCR >8 but although
Kaplan-Meier curves separated well, the statistical difference in evolution rates
for patients with the aforementioned FLC/FLCR values was not significant per-
haps due to the small number of patients. With regard to SMM patients, 25 of
them had at least one osteolysis by sensitive radiology methods (CT, MRI) in
the absence of bone pains or other end-organ damage-related symptomatol-
ogy; they should however be considered as having symptomatic MM. Their
median time to treatment initiation was 34 months (range 15-53) and their
median overall survival since diagnosis was 80 months (range 36-124). In addi-
tion, other 9 patients had more than 60% bone marrow plasma cell infiltration
and should also be considered as suffering from symptomatic MM, although
presenting no other symptoms. This second patients’ subgroup had a shorter
median time to treatment initiation of 6 months (range 5-7) and their median
overall survival since diagnosis was 60 months (range 10-110). In total, the
diagnosis of 34 patients (23%) of the present series should change according
to the IMWG updated criteria for the diagnosis of multiple myeloma.
Summary and Conclusions: The diagnosis of MGUS patients did not change
with the application of the new IMWG updated MM criteria, on the contrary the
diagnosis of 23% of SMM patients changed. This was totally justified for patients
with more than 60% bone marrow plasma cell infiltration, but is somewhat con-
troversial in the case of patients with existing but not extensive skeletal disease.
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Background: Several authors have highlighted the importance of a deep
response to chemotherapy in multiple myeloma (MM), especially in first line.
Aims: The objective was to assess which patient/treatment/disease charac-
teristics are prognostic for a deep response. Also, to assess whether the deep
response is prognostic for overall survival (OS) independent of treatment, treat-
ment line and patient/disease characteristics.
Methods: A retrospective analysis was performed on 2960 MM-patients from
24 hospitals in Denmark, Finland, Norway and Sweden. The database con-
tained information on patient baseline characteristics such as age, gender, ISS
stage, albumin, creatine, and MM type, which were recorded at start of first
line therapy. The following outcomes were considered; response, time to next
line of treatment (TTNT) and OS. The following categories of response were
differentiated: progressive disease (PD), no response (NR), partial response
(PR), very good PR (VGPR) and equal or better than near complete response
(>=nCR). To identify prognostic factors for response, univariate and multivariate
multinomial regression were conducted with response as dependent and
patient baseline characteristics and type of treatment as independent variables.
To assess whether response is an independent predictor of OS, multivariate
cox-proportional hazard models were run for the first four lines of treatment.
Results: Patients in the dataset were on average 67 years old, 48% were
male, 28%, 41% and 31% in ISS stages I, II and III, respectively. Multinomial
regression showed that type of treatment, age, ISS type and MM type were
significant prognostic factors for response in first line. In second line, first line
response, type of treatment and age were significant prognostic factors for
response in second line. Multivariate cox-regression showed that in first line
patients with NR, PR, VGPR and >=nCR had significant lower hazard ratio’s
(HRs) 0.61 (0.43-0.85), 0.56 (0.41-0.78), 0.34 (0.22-0.51) and 0.36 (0.24-0.54)
respectively compared to PD. Age, Albumin, Calcium and Beta-2-microglobulin
levels were also significant prognostic factors for OS with HRs of 1.03 (1.01-
1.04), 0.98 (0.96-0.99), 1.41 (1.11-1.79) and 1.02 (1.01-1.03) respectively. The
following categorical variables also were significant prognostic factors for first
line OS; type of treatment, ISS-stage and MM type. For second line OS multi-
variate cox-regression showed that patients with PR, VGPR and >=nCR had
significant lower HR’s 0.58 (0.46-0.73), 0.42 (0.3-0.58), 0.4 (0.27-0.6) compared
to PD respectively. Age also had a significant HR of 1.02 (1.01-1.03). For third
line OS multivariate cox-regression showed that patients with NR, PR, VGPR
and >=nCR had significant lower HR’s 0.67 (0.5-0.89), 0.37 (0.27-0.51), 0.32
(0.21-0.5), 0.18 (0.1-0.34) compared to PD respectively. Age also had a signif-
icant HR of 1.01 (1.00-1.02). For fourth line OS multivariate cox-regression
showed that patients with PR, VGPR and >=nCR had significant lower HR’s
0.45 (0.31-0.64), 0.31 (0.19-0.52) and 0.39 (0.21-0.73) compared to PD respec-
tively. Age was also identified as a significant prognostic factor.
Summary and Conclusions: Type of treatment, age, ISS type and MM type
were significant prognostic factors for response in first line. For second line
response, the significant prognostic factors were response in first line, type of
treatment and age. Moreover, multivariate cox-regressions shows that in the
first four lines of treatment, response is an independent prognostic factor for
OS. Future research should include genetic prognostic factors, which were not
collected in our dataset and could therefore not be assessed.
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WITH A SUPERIOR SURVIVAL IN MULTIPLE MYELOMA: A
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Background: Multiple myeloma (MM) is characterized by a neoplastic prolif-
eration of plasma cells in the bone marrow and overproduction of monoclonal
immunoglobulins in serum or urine. MM is preceded by a premalignant condi-
tion called monoclonal gammopathy of undetermined significance (MGUS).
Familial aggregation of MM and MGUS has been reported by several authors.
The role of genetic factors in the pathogenesis of multiple myeloma is also
indicated by emerging data. However, the underlying genetic cause of the dis-
ease is uncertain and the impact of family history on survival is unknown. 
Aims: The aim of our study was to compare survival in MM patients with family
history of lymphoproliferative disorders (LPD) to MM patients without family
history of LPD.
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Methods: MM patients and their first-degree relatives were identified using the
nationwide Swedish Registries. Information on malignancies in relatives of MM
patients was obtained by record-linkages to the Swedish Cancer Registry. A
positive family history of LPD was defined as MM patients having at least one
first-degree relative diagnosed with MM, chronic lymphocytic leukemia (CLL),
non-Hodgkin’s lymphoma (NHL), Waldenström’s macroglobulinemia (WM), or
Hodgkin’s lymphoma (HL). We performed a cox proportional hazard model and
adjusted for age, sex, and year at diagnosis.
Results: A total of 13,947 MM patients diagnosed in 1958-2005 were included
of whom 332 had a linkable first-degree relative with LPD. When compared to
MM patients without family history of LPD, MM patients with a family history
had a borderline significant decreased risk of death (HR 0.89; 95% CI 0.79-
1.00, p=0.0549). When stratified by age there was a significant difference in
patients 70 years of age or younger (0.83; 0.71-0.98, p=0.0298), but not older
(Figure 1). A better survival was also found in male MM patients with family his-
tory than with sporadic disease (0.83; 0.71-0.98, p=0.0297). There was no sta-
tistical difference by family history among female MM patients (Figure 1).
Figure 1.
Summary and Conclusions: In this large population-based study we showed
for the first time that there is a trend toward superior survival in MM patients
with family history of LPD, compared to MM patients without family history.
Interestingly, survival in MM patients younger than 70 years was significantly
better in the familial group (compared to sporadic). Lastly, male patients with
family history of LPD had a significantly lower risk of death. Our findings suggest
that familial MM may be associated with less agressive nature or better
response to therapy, at least in subgroups of patients. The underlying molecular
explanations for our findings are yet unknown and need to be established by
further research.
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Background: In the general population, parental longevity is associated with
an increased life expectancy. However, studies on specific diseases and
parental longevity have shown conflicting results. A few studies on multiple
myeloma have identified host characteristics that have an influence on the
patient’s prognosis, such as socioeconomic status, poor performance status,
and co-morbidity. Longevity as a host factor among patients with multiple myelo-
ma has never been studied in relation to outcome. Recent studies focusing on
the myeloma precursor, monoclonal gammopathy of undetermined significance
(MGUS), have implied that host biology plays an important role in relation to
malignant transformation.
Aims: Our aim was to study the effect of parental longevity on the survival of
patients with multiple myeloma and MGUS.
Methods: A total of 1,815 patients with multiple myeloma, 1,407 MGUS patients
as well as 8,267 population-based controls for multiple myeloma patients and
5,595 controls for MGUS were included in the study. We compared the risk of
death, using Cox’s proportional hazards regression (adjusting for age, gender,
and year of diagnoses), among multiple myeloma and MGUS patients with a his-
tory of parental longevity to those patients without a long-lived parent. Longevity
was defined as exceeding 90 years of age or living to the 90th percentile.
Results: Among multiple myeloma patients, a history of parental longevity was
not associated with a decreased risk of death (hazard ratio (HR=0.92; 95%
confidence interval (CI) 0.81-1.05, Table). Having one long-lived parent or both
did not have an effect (HR=0.91; 95% CI 0.80-1.04 and HR=1.02; 95% CI 0.72-
1.44, respectively). A history of parental longevity among MGUS patients was
associated with a significant decrease in risk of death (HR=0.69; 95% CI 0.53-
0.91, Table). The risk of death decreased when one parent was long-lived
(HR=0.69; 95% CI 0.52-0.91). However, based on few numbers, when both
parents were long-lived the risk of death was decreased but not statistically
significant (HR=0.72; 95% CI 0.34-1.53).
Tabella 1. Relative risk of death for patients with multiple myeloma and
MGUS in relation to parental longevity.
Summary and Conclusions: In this first, to our knowledge, study on parental
longevity and survival among multiple myeloma and MGUS patients, we con-
clude that a history of parental longevity is associated with superior survival
among MGUS patients, which may reflect the impact of host biology in relation
to overall survival. However, parenteral longevity does not decrease the risk of
death for patients with multiple myeloma. This finding probably reflects the poor
outcome of the malignancy itself which seems to outweigh the positive effects
of parental longevity.
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SERUM B-CELL MATURATION ANTIGEN IS A NOVEL PROGNOSTIC
INDICATOR FOR MULTIPLE MYELOMA PATIENTS AND CORRELATES
WITH CLINICAL STATUS AND SURVIVAL
J. Berenson1,* M. Ghermezi1, S. Vardanyan1, N. Harutyunyan1, M. Spitzer1,
J. Gottlieb1, A. Berenson1, C. Andreu-Vieyra2, M. Li1, C. Wang1, E. Sanchez1,
R. Swift3, H. Chen1
1Institute for Myeloma & Bone Cancer Research, 2Oncotherapeutics, 3James
R. Berenson, MD, Inc., West Hollywood, United States
Background: B-cell maturation antigen (BCMA) is a tumor necrosis factor
receptor family member that is expressed on normal and malignant B-cells.
Our group has recently shown that BCMA is present in the serum of multiple
myeloma (MM) patients (pts) and that its levels may correlate with their clinical
status and overall survival (OS).
Aims: We analyzed the relationship between serum BCMA levels and mono-
clonal (M)-protein levels as well as the relationship of BCMA to response status,
progression-free survival (PFS) and OS in a large cohort of MM pts.
Methods: Serum was obtained on 227 MM pts following informed consent.
Enzyme-linked immunosorbent assay (ELISA) was used to determine serum
BCMA levels (R&D Systems). The Mann-Whitney test was used to assess the
differences between clinical status groups. Kaplan-Meier analysis and multi-
variate Cox regression models were also used. Kaplan-Meier survival of MM
pts was determined from the time of initial serum BCMA measurement to death
or the date of last follow-up. PFS of MM pts was evaluated from the time of
serum BCMA measurement to date of first disease progression. Cox-propor-
tional hazards regression was utilized to determine the predictive influence of
serum BCMA and various other factors including age, creatinine, hemoglobin,
ISS stage, and bone disease on OS and PFS. P-values less than 0.05 were
considered statistically significant. Changes in serum BCMA levels were cor-
related with serum M-protein levels for 44 MM pts during their course of disease.
Similarly, serum BCMA levels were correlated with bone marrow and PET scan
findings for non-secretory disease (NSD) pts.
Results: Serum BCMA levels correlated with the patient’s clinical status at the
time of its determination (P <0.0001). Specifically, pts with ≥PR had significantly
lower serum BCMA levels (median, 52.49 ng/mL) than those with stable and
progressive disease (median, 124.8 ng/mL; P <0.0001). Changes in serum
BCMA levels highly correlated with changes in serum M-protein levels among
44 consecutive MM pts that had multiple determinations made during their
course of disease. Notably, pts with NSD showed a direct correlation between
changes in serum BCMA levels and their clinical status as reflected by PET
scan and bone marrow findings during their course of disease. PFS was
markedly longer among pts with serum BCMA levels below than among those
with levels above the median (P =0.006). We divided pts into quartiles based
on their serum BCMA levels. Pts in quartiles 1-3 had a longer PFS compared
to pts in quartile 4 (P <0.0001). Among all 227 pts, the 36-month OS of pts
whose serum BCMA levels were above the median (≥102 ng/mL) was signifi-
cantly lower than among those whose levels were below the median (P =0.02).
In the multivariate regression analyses, serum BCMA levels significantly cor-
related with only OS (P =0.0003). In contrast, age, bone disease status, serum
creatinine, hemoglobin, and ISS staging did not correlate with OS. Lastly, serum
BCMA levels were independent of ISS staging and serum creatinine levels.
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Summary and Conclusions: BCMA is a novel serum marker that can be used
to follow the course of disease in MM patients. Serum BCMA levels are elevated
in patients with MM. Levels of this marker also correlate with clinical status,
predict PFS and OS, and provide patients with NSD a way to follow their dis-
ease course.
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THE NOTCH LIGANDS JAGGED1 AND 2 ARE A POTENTIAL THERAPEUTIC
TARGET IN MULTIPLE MYELOMA-ASSOCIATED BONE DISEASE
M. Colombo1,* S. Garavelli1, K. Todoerti2, A. Paoli1, N. Platonova1, S. Galletti3,
A. Neri3, R. Chiaramonte1
1Dept. Health Sciences, Università degli Studi di Milano, Milano, 2Laboratory
of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer
Center of Basilicata, Rionero in Vulture, 3Dept. Clinical Sciences and Commu-
nity Health, Università degli Studi di Milano, Milano, Italy
Background: Bone disease is still a relevant issue in multiple myeloma (MM),
since it not only affects patients quality of life but it also promote tumor growth
and survival, finally contributing to the fatal outcome of this disease. The Notch
oncogenic pathway is dysregulated in MM, due to the hyperexpression of the
Jagged 1 and 2 ligands. This alteration improve the ability of MM cells to estab-
lish pathological interactions with the bone marrow (BM) niche, finally promoting
tumor progression. Notch is also a key regulator of bone tissue remodeling
and skeletal development.
Aims: The aim of this work was to provide a rationale for the targeting of the
two Notch ligands Jagged 1 and 2 in MM-driven bone disease. To address this
issue we assessed: the role of the Notch pathway in MM-associated osteo-
clastogenesis; the effects of Jagged1/2 silencing on the ability of MM cells to
activate the Notch pathway in OCLs and boost bone resorption.
Methods: OCL differentiation of Raw264.7 cells was induced by treating them
with 50ng/ml mRANKL or co-culturing with MM cells or their conditioned medium
(CM). After 5-7days cells were stained using the TRAP Kit and counted. DAPT
was used at a concentration of 50μM. Select RNAiTM siRNA system (Invitrogen)
was used according to the manufacturer’s guidelines for the selective knock-
down of Jag1 and Jag2. Jagged1 recombinant peptide was used at 0.5μg/ml.
anti-RANKL neutralizing antibody was used at 0.1μg/ml.Total RNA was isolated
using TRI-Reagent. cDNA was prepared through MMLV reverse transcriptase,
then quantitative PCR (qPCR) was performed by Maxima SYBR Green qPCR
Master Mix.RANKL was quantify by ELISA Assay and flow cytometry.
Results: Our findings indicate that the autonomous release of RANKL (Recep-
tor activator of nuclear factor kappa-B ligand) by MM cells is essential for their
ability to boost osteoclastogenesis. Interestingly, RANKL release is Notch-
dependent, since Jagged1/2 silencing in MM cells causes the inhibition of the
Notch pathway and impairs their ability to secrete RANKL and to stimulate
osteoclasts (OCLs) differentiation and activity. MM-derived Jagged are also
able to directly activate the pro-osteoclastogenic Notch signaling in neighboring
pre-OCLs, boosting their differentiation. Moreover, Jagged1/2 are essential for
the interaction of MM cells with BM stromal cells (BMSCs), that can further
enhance the osteoclastogenic potential of tumor cells. Jagged1/2 withdrawal
blocks the cross-talk between MM cells and the surrounding BMSCs and pre-
OCLs, finally causing a decrease in the formation of mature OCLs and in bone
resorption.
Summary and Conclusions: Our study provided the first evidence that two
Notch ligands dysregulated in MM, Jagged 1 and 2, play an essential role in
myeloma-induced osteoclast differentiation and bone resorption activity. Jagged
ligands can trigger Notch signaling in the same MM cells, resulting in the
release of the key osteoclastogenic factor RANKL, and may also activate Notch
signaling in the neighboring osteoclast progenitor further promoting their dif-
ferentiation. Finally, we demonstrated that MM cells are able to crosstalk with
BMSCs which are able to stimulate low-RANKL expressing myeloma cells, to
release higher amount of RANKL and acquire osteoclastogenic ability. Impor-
tantly, BMSC support can be prevented by silencing Jagged ligands on myelo-
ma cells. All together, our results demonstrate that the two Notch ligands
Jagged1 and 2 represents two new promising therapeutic targets in MM-asso-
ciated bone disease.
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BORTEZOMIB, DEXAMETHASONE, THALIDOMIDE AND MELPHALAN
(VDT-MEL) PREPARATIVE REGIMEN RESULTS IN A VERY HIGH
STRINGENT CR (SCR) RATE IN MULTIPLE MYELOMA (MM)
K. Nadiminti1,* L. Dozeman1, A. Schultz2, A. Tricot2, S. Bell3, F. Zhan1,
K. Abbi1, G. Tricot1
1Hematology,Oncology and Bone marrow transplant, 2Holden Cancer Center
clinical trials support core, 3Biostatistics core alliance, University of Iowa Hos-
pitals and Clinics, Iowa City, United States
Background: The role of autologous stem cell transplant (ASCT) in the treat-
ment of myeloma has been well established and Melphalan 200mg/m2 has
been the standard preparative regimen of choice. Although the introduction of
novel agents improved the treatment of myeloma significantly, data about their
role in preparative regimens are very scarce.
Aims: The purpose of this study is to understand the toxicity and efficacy of
novel agents used in combination with high-dose melphalan as a new prepar-
ative regimen.
Methods: Retrospective analysis was performed on all patients who received
an ASCT with the VDT- Mel during 2012- 2014. IRB approval was obtained. To
determine which variables were significantly associated with the odds of achiev-
ing a sCR post-transplant, logistic regression models were applied. All statistical
testing was two-sided and assessed for significance at the 5% level using SAS
v9.4 (SAS Institute, Cary, NC). Clinical end points were treatment- related tox-
icity and quality of response
Results: 97 patients underwent 149 transplants and toxicity was analyzed at
100 days; 45 patients underwent single and 52 had tandem transplants (TT),
respectively; 66 patients received early and 31 salvage transplantation. Median
age was 59 y. Best responses were 58% sCR, 20%CR, and 9.5% VGPR. For
patients receiving early transplantation, the sCR rate was 61%, and for TT
patients, 62%. Only early versus salvage transplantation was significant for
achieving sCR with a hazard ratio: 3.18 (P =0.02). Grade 3 and 4 non-hema-
tologic toxicities were related to infections in 54%; 100 day mortality was 2%
and 3.8% for single and TT, respectively. Median time to ANC>500/µL was 12
days in both early and late transplantation.
Summary and Conclusions: This study shows that VTD-Mel is a well-toler-
ated preparative regimen. Importantly, the sCR rate was significantly higher
than in other published studies. Since sCR is an early surrogate marker for
progression-free and overall survival, it appears likely that this regimen will be
superior to melphalan alone and may become the new standard preparative
regimen for ASCT in myeloma. This is the largest study performed to date eval-
uating this novel preparative regimen.
Email address: kalyan-nadiminti@uiowa.edu
LB297
SIGNIFICANT IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) STATUS
ON SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA
(MM) WHO ACHIEVE COMPLETE RESPONSE (CR): A META-ANALYSIS
N. Munshi1,* H. Avet-Loiseau2, A. Rawstron3, R. Owen3, A. Thakurta4,
P. Sherrington5, A. Georgieva6, K. Anderson1, W. Gregory7
1Dana-Farber Cancer Institute, Boston, United States, 2Unit for Genomics in
Myeloma, Institut Universitaire du Cancer, Toulouse, France, 3St James’s Uni-
versity Hospital, Leeds, United Kingdom, 4Celgene Corporation, Summit, NJ,
United States, 5Celgene International, Boudry, Switzerland, 6Excerpta Medica,
Amsterdam, Netherlands, 7University of Leeds, Leeds, United Kingdom
Background: Most patients with MM eventually relapse, suggesting that a
residual disease which cannot be detected by conventional assessment per-
sists, even in patients achieving CR with treatment. 
Aims: To assess the impact of MRD status on survival outcomes in patients
with MM who achieved CR.
Methods: A PubMed search was performed to identify studies published
between January 1990 and September 2014, with ≥20 newly-diagnosed
patients with MM. Patients requiring treatment and who had MRD evaluation
results were included in this meta-analysis. Analysis was restricted to tech-
niques with a limit of detection of 0.01% or lower. If primary data were not
accessible, survival graphs were used to derive individual survival and cen-
soring times. Data were adjusted for the different proportions of MRD patients
in different studies using a method that considers time-dependent effects (Gre-
gory WM, Br J Cancer 1988). P-values are for adjusted log-rank χ2 tests. 
Results: A total of 302 published articles were retrieved and 25 articles were
identified through the reference sections of recently published articles. Of these,
18 reported overall survival (OS) or progression-free survival (PFS) results, as
well as MRD status. Overall, 2,208 pts were evaluated for MRD by methods
including multiparameter flow cytometry (n=1,606), PCR (n=492), or high-
throughput sequencing (n=110). Nine publications reported conventional CR
at the time of MRD measurement; however only 4 represented unique data
sets. In total, there were 496 evaluable patients (362 were MRD-negative and
134 MRD-positive). The presence of MRD predicted shorter PFS (odds ratio
[OR] 0.36; 95% confidence interval [CI] 0.26–0.50; P < 0.0001). Median PFS
was 60 months for MRD-negative patients versus 36 months for MRD-positive
patients; PFS at 3 years was 72% versus 50%, respectively and at 5 years
was 50% versus 29%. MRD-negativity reduced the odds of death by 59% (OR
0.41; 95% CI 0.26–0.63; P <0.0001); median OS was not reached for MRD-
negative patients versus 82 months for MRD-positive patients. OS was higher
for MRD-negative patients versus MRD-positive patients at 3-years (93% vs
79%) and 5-years (78% vs 60%). Presence of MRD was predictive of outcome
in patients with adverse cytogenetic proﬁles. Overall, 37% of MRD-negative
patients versus 7% of MRD-positive patients were progression-free at 8 years.
There was no significant difference between studies in the impact of achieving
MRD-negativity on outcome, indicating that the predictive value of MRD status
does not depend on the type of treatment.
Summary and Conclusions: These results show that MRD negativity, as
determined by various high-sensitivity methods, predicted for substantially bet-
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ter PFS and OS in patients with MM who had achieved CR. Furthermore, nearly
all MRD-positive patients had disease progression within 8 years, whereas a
third of MRD-negative patients remained progression-free. This large cohort,
meta-analysis confirms that MRD status is a crucial marker of long-term out-
comes in patients with MM. It is, therefore, a key endpoint in MM clinical trials
and clearly also has an important role as a surrogate marker of OS.
Biology of MPN
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INCREASED AND PROLONGED STAT5 ACTIVATION DETECTED FOR A
JAK2 E846D GERMLINE MUTATION IN THE SPECIFIC CONTEXT OF EPO
RECEPTOR
K. Kapralova1,2,3,* M. Horvathova3, C. Pecquet1,2, J. Kucerova3, D. Pospisilova4,
E. Leroy1,2, B. Kralova3, S.N. Constantinescu1,2, V. Divoky3
1de Duve Institute, Université catholique de Louvain, 2Ludwig Institute for Can-
cer Research, Brussels, Belgium, 3Department of Biology, Faculty of Medicine
and Dentistry, Palacky University, 4Department of Pediatrics, University Hospital
and Faculty of Medicine and Dentistry, Olomouc, Czech Republic
Background: Somatic mutations of a gene that encodes the Janus kinase 2
(JAK2) are the most observed disease-causing events of the myeloproliferative
neoplasms (MPN). Recently, germline JAK2 mutations have been described in
cases with familial MPN, exhibiting hereditary thrombocytosis.
Aims: To characterize a novel JAK2 germline mutation found in a patient with
erythrocytosis.
Methods: The effect of JAK2 E846D mutation was functionally analyzed using
Ba/F3-EPOR cells (immunoblots, BrdU, MTT, inhibitors assays) and JAK2-defi-
cient γ2A cells (reporter luciferase assay).
Results: The patient was diagnosed with increased red cell mass, facial pletho-
ra and splenomegaly at the age of 15. The bone marrow aspirate showed fea-
tures typical for MPN. Two heterozygous mutations were found by targeted
analyses; E846D in JAK2 inherited from the mother and Q157H in PHD2 (SNP
rs61750991) inherited from the father. Erythroid progenitors derived from the
patient and his parents were hypersensitive to erythropoietin (EPO), however
only the patient exhibited the erythrocytosis phenotype. In silico modeling of
JAK2 showed that the substitution of Glu by a residue one CH2 shorter, namely
Asp, in the kinase domain might result in a formation of a tighter salt bridge to
residue K926, more difficult to disrupt upon returning of JAK2 to its inactive
state. This leads to a prolonged activation of JAK2 kinase.
Ba/F3 JAK2 E846D stable transfectants have revealed EPO-induced increased
and prolonged JAK2 and STAT5 activation detected by immunoblots assessing
active forms of JAK2 and STAT5. This was subsequently confirmed by
luciferase assay in γ2A cells that detected higher and prolonged cytokine-
induced levels of STAT5 transcriptional activity. Surprisingly, among the STAT
family members, the E846D substitution significantly increased only STAT5
transcriptional activity and only in the presence of EPO receptor but not with
TPO or G-CSF receptors. Two JAK2 inhibitors (Ruxolitinib, AZ-960) reduced
the prolonged STAT5 activation; the E846D variant exhibited similar sensitivity
as oncogenic JAK2 V617F. Although the E846D did not support growth factor
independence of Ba/F3 cells as V617F, increased STAT5 activity was detected
also in the condition without cytokines in transcriptional assays. In addition,
Ba/F3 JAK2 E846D transfectants showed improved survival in EPO-limiting
conditions when compared to JAK2 wild-type (wt) cells. Cell cycle studies
demonstrated that upon growth factor starvation JAK2 E846D cells re-enter
faster into S phase in low EPO concentrations, when compares to JAK2 wt.
Summary and Conclusions: The germline JAK2 E846D mutation emerged
as the main disease causing event in our patient. It causes EPO hypersensitivity
and erythroid hyperproliferation due to increased and prolonged JAK2/STAT5
signaling. This mutation gives this phenotype only in the context of the EPO
receptor, explaining the erythrocytosis in vivo. We propose that the disease is
a hereditary myeloproliferative disorder with incomplete penetrance; we
observed full clinical phenotype in the patient and intermediate phenotype in
the mother, the genetic background likely contributing to the extent of disease
expression. Grants support: P301/12/1503, NT13587-4,
CZ.1.07/2.3.00/20.0164, CZ.1.07/2.3.00/30.0041 from Czech Republic;
MEXP31C1, ARC10/15-027, FRIA PhD fellowship from Belgium.
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PH-NEGATIVE MPN RED BLOOD CELLS DISPLAY DEREGULATION OF
IQGAP1-RHO GTPASE SIGNALING DEPENDING ON CALR/JAK2 STATUS
N. Socoro-Yuste1,* A. Gonzalez de Peredo2, M.C. Dagher1, J. Mondet1,
A. Zaccaria3, M. Court4, B. Monsarrat2, J.Y. Cahn15, P. Mossuz16
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France, 3Department of clinical proteomics, University of Geneva, Geneva,
Switzerland, 4Plateforme d’Analyses Protéomiques EDyP-Service, CEA Greno-
ble, 5Clinique Universitaire d’Hématologie, CHU Grenoble, 6Laboratoire d’Hé-
matologie cellulaire, Institut de Biologie et Pathologie-CHU Grenoble, Grenoble,
France
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Background: Polycythemia Vera (PV), Essential Thrombocythemia (ET) and
Primary Myelofibrosis are myeloproliferative neoplasms (MPN) characterized
by a clonal proliferation of hematopoietic progenitors that results in an over-
production of mature blood cells. Several molecular abnormalities have already
been described in progenitor cells such as JAK2 or CALR mutations which
activate the STAT signaling pathway causing an enhanced and uncontrolled
proliferation of progenitor cells. In parallel, leucocyte and platelet functional
alterations have been reported in MPN patients. Nevertheless, little is known
about functional and protein alterations of erythrocytes despite their implications
in PV. Initial studies showed that abnormal red blood cell (RBC) adhesion to
endothelial cells in PV, which can cause vascular complications, could be due
to the activation of Lu/BCAM by the JAK2V617F/Akt/Rap1 pathway.
Aims: In this context, we have developed an integrative study of RBC proteome
in PV and ET looking for protein deregulations that could be related to functional
RBC alterations and MPN physiopathology.
Methods: Seeing as hemoglobin is a big impediment to the study of the RBC
proteome, we developed one technique based on the capture of low abundant
proteins by ferromagnetic beads surrounded by chemical surfaces. This hemo-
globin depletion was used on 48 samples (PV, ET and controls) before MS
analysis which allowed us to select, according to their proteomic profile, the
five most representative patients of each subgroup for LC MS/MS analysis
(LTQ Orbitrap).
Results: Quantitative comparative analysis distinguished 1019 proteins among
which 51 were upregulated in PV and 86 in ET compared with controls. Fur-
thermore, functional comparison using Ingenuity Pathway Analysis software
showed that the Ras GTPase family pathway was deregulated in both MPN
patients. Specifically, Ras GTPase-activating like protein IQGAP1 was over-
expressed in ET and PV compared with controls (p<0.05). Additionally, mass
spectrometry result verification by westernblot not only highlighted IQGAP1
overexpression in PV and ET compared with controls (p<0.01) but also depend-
ing on patient genotype (JAK2V617F>CALR+,p<0.05; JAK2->CALR+, p<0.05).
IQGAP1 is a scaffold protein that regulates several pathways including Ras
GTPase ones. Therefore, we explored connections between IQGAP1 and Rho
GTPases (Ras GTPase subfamily) demonstrating direct links between IQGAP1
and Rac1, Cdc42 and RhoA in patient RBCs. Moreover, we found that the Rho
subfamily protein recruitment profile by IQGAP1 was different between JAK2+
patients where it linked activated Rac1 but not RhoGDI (Rho GTPase inhibitor).
Conversely, in CALR+ patients, IQGAP1 co-precipitated with RhoGDI but didn’t
with Rac1, underlining a different impact of IQGAP1 overexpression between
CALR+ and JAK2+ patients. We also found that calreticulin protein was
expressed in erythrocytes independently of JAK2 or CALR mutation but it didn’t
interact with IQGAP1. Finally, we showed that p21 activated kinase 1 (PAK1),
a Rho GTPase effector implicated in cell motility, and its phosphorylated form
(PAK1-P), co-precipitated with activated Rac1 as well as with IQGAP1.
Summary and Conclusions: Our data showed a deregulation of IQGAP1-
Rho-GTPase signaling that could be implicated in erythrocyte adhesion alter-
ations and thereby in vascular complications via the activation of the cytoskele-
ton motility protein PAK1. Differential recruitment of RhoGDI and Rac1 between
CALR+ and JAK2+ patients might induce variations of PAK1 activation and
thereby take part in variations of vascular risk among different genotypes.
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CRITICAL ROLE OF HIS499 IN REGULATING THE DIMERIZATION AND
FUNCTION OF THE HUMAN THROMBOPOIETIN RECEPTOR AND
RESTRAINING THE REPERTOIRE OF ASPARAGINE PATHOGENIC
MUTATIONS
E. Leroy1,* J.P. Defour1, T. Sato2, S. Dass2, V. Gryshkova1, S. Myat Marlar1,
J. Staerk3, S.N. Constantinescu1, S.O. Smith2
1Ludwig Cancer Research, Belgium De Duve Institute, Université Catholique
de Louvain, Brussels, Belgium, 2Department of Biochemistry and Cell Biology,
Stony Brook University, Stony Brook, United States, 3Stem Cell Group, Nordic
EMBL Partnership and Center for Molecular Medicine, Oslo, Norway
Background: The thrombopoietin receptor (TpoR) is a member of the type-I
cytokine receptor family that regulates the proliferation and differentiation of
megakaryocytes, as well as stem cell homeostasis. Tpo binding mediates
dimerization of the extracellular domain of the receptor, which imparts a specific
orientation on the receptor’s transmembrane (TM) and intracellular (IC)
domains. TpoR can autonomously dimerize in the presence of asparagine sub-
stitutions in its TM domain leading to its activation, as it is the case with the
Essential Thrombocythaemia associated mutant «TpoR S505N».
Aims: We aim to determine the molecular mechanisms regulating TpoR dimer-
ization and function in the context of the asparagine mutant S505N, and
whether TM asparagine mutations other than S505N could be identified in
MPNs.
Methods: First, we took advantage of differences in the murine and human
TpoR sequences and we performed asparagine-scanning mutagenesis on the
receptors TM domain. We used a combination of transcriptional activity and
cellular growth to map out the inactive and active orientations of the trans-
membrane helices. Second, we assess TpoR dimerization by using a split
luciferase reporter. Third, we used protein segments corresponding to the
receptor transmembrane and juxtamembrane domains in order to complete
polarized IR and solid-state NMR spectroscopy.
Results: Asparagine mutants in the transmembrane domains of the murine
and human TpoR did not display the same biologic effects; while mTpoR exhib-
ited several active conformations; only one variant of hTpoR (S505N) was con-
sistent with constitutive signaling. Our studies indicate that this discrepancy
could be attributed to the eltrombopag (Promacta/Revolade; GlaxoSmithKline,
London, UK) target, His499, only present in the human TpoR TM domain.
Indeed, by point mutational studies, we showed that His499 was responsible
for protecting the human receptor from activation by several Asn mutations.
By spectroscopy, using short peptides, we showed that His499 accounts for a
change in the conformation and secondary structure of the transmembrane
helix and shifts the monomer-dimer equilibrium toward monomer for the human
TpoR. Strikingly, replacement of His499 by Leu, the residue at the correspon-
ding position in the murine TpoR induces dimerization of these peptides. When
His499 is replaced by Leu in the human TpoR, asparagine substitutions at sev-
eral different TM positions activate oncogenic signaling, like in the case of the
murine TpoR.
Summary and Conclusions: We show that His499 is critical for dimerization
of human TpoR and orientation-dependent activation. Using alignments of
TpoRs from different species and other cytokine receptors we show His499 in
TpoR evolved from primates and we discuss its possible role in evolution in
preventing oncogenic activation by multiple asparagine substitutions.
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COMBINED CONSTITUTIVE CANONICAL AND NON-CANONICAL HH
SIGNALING CAUSED BY DEPLETION OF PATCHED 2 INDUCES A
MYELOPROLIFERATIVE PHENOTYPE AND TRANSFORMS CHRONIC
MPNS INTO ACUTE LEUKEMIAS
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Background: MPNs frequently transform into leukemias, but the factors driving
this process are not understood. Aberrant Hedgehog (HH) ligand secretion, as
frequently found in MPN and CML, not only induces constitutive Smoothened-
dependent canonical HH-signaling causing GLI1 transcription, but also causes
PTCH1-dependent non-canonical HH signaling leading to constitutive ERK
activation. HH-ligands do not only act on malignant cells, but also stimulate
the surrounding niche cells, driving dual pathway activation in both compart-
ments. Previous results in CLL show, that HH ligand induced dual pathway
activation causes primary resistance to SMO-inhibitors. Combined canonical-
and non-canonical pathway activation was so far never investigated regarding
hematopoietic development and leukemic transformation.
Aims: Evaluate the effects of combined activated canonical and non-canonical
HH signaling within hematopoietic and niche cells in normal and malignant
hematopoiesis, especially regarding acceleration of myeloproliferative diseases
into leukemias.
Methods: Human PB samples of CML (BCR-ABL), AML and MPN
(Jak2V617F+) patients were analyzed concerning canonical-and non-canonical
HH signaling activation. The phenotype of Ptch2-/-mice mimicking over-acti-
vated canonical and non-canonical HH signaling was described and this model
was used for in vivo transplantation experiments. Therefore hematological or
niche Ptch2-/-was analyzed and combined with Jak2V617F or BCR-ABL regard-
ing disease development.
Results: Our investigations show, that excess HH ligand secretion is present
in MPNs and CMLs, while absent in AML, and constitutively activates canoni-
cal-and non-canonical HH-signaling. Furthermore 70% of MPN-and CML-cases
display loss of the Ptch1-competitive Ptch2 receptor. Depletion of the Ptch2
receptor in vitro and in vivo recapitulates overactivation of both pathways
(canonical-and non-canonical HH signaling), while depletion of Ptch1 only
reflects constitutive Gli1 activation (canonical). Ptch2-/-mice develop a pro-
nounced hematopoietic phenotype with leukocytosis driven by an increase in
neutrophils and monocytes, anemia, loss of B-and T-cells combined with a
strong increase of cKit+ progenitors in the peripheral blood and increased
extramedullary hematopoiesis causing splenomegaly reflecting a MPN phe-
notype. LKS (lin-cKit+Sca1+) cells residing within the BM (bone marrow)
showed enhanced cycling properties causing exhaustion and loss of LKS cells
over time, but improved stress hematopoiesis after 5-FU treatment. Niche
change experiments show that cytopenias and loss of LKS cells are caused
by overactivated HH signaling within the niche cells, causing depletion of
osteoblasts and alterations of essential niche factors like Cxcl12, Scf, Angiopoi-
etin or Jagged1. In contrast, the hematopoietic Ptch2-/-is responsible for leuko-
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cytosis and even promotes LKS expansion and replating capacity in vitro. Inter-
estingly, depletion of Ptch2 in the niche or within hematopoietic cells dramati-
cally altered Jak2V617F driven pathogenesis causing transformation of a non-
lethal chronic myeloproliferative disease into an agressive AML-like disease
with up to 30% blasts in the peripheral blood. In contrast, the BCR-ABL-driven
leukemia was exclusively accelerated by the cell intrinsic Ptch2-/-, but not by
cell extrinsic HH activation.
Summary and Conclusions: Combined constitutive canonical and non-canon-
ical HH activation induced by depletion of Ptch2 causes a MPN phenotype driv-
en by cell intrinsic, but mainly cell extrinsic mechanisms and accelerates myelo-
proliferative diseases caused by Jak2V617F and BCR-ABL into acute
leukemias. These finding suggest combined canonical-and non-canonical HH
pathway inhibition as a potential treatment option to prevent disease progres-
sion in myeloproliferative diseases.
P300
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF
MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-
ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-
BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
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Background: In Primary Myelofibrosis (PMF), mutations in the JAK-STAT path-
way result in clonal myeloproliferation and abnormal megakaryopoiesis.
Increased low-ploidy/immature megakaryocytes (MKs) are a diagnostic hall-
mark, and aberrant MK expression of fibro-angiogenic cytokines mediates BM
fibrosis. The increased MKs in PMF have been attributed to increased MK pro-
liferation, inhibited endoreduplication and apoptosis. MKs and erythroid (E)
cells arise from a common progenitor (MEP). Due to lack of precise immunophe-
notypic definitions of both MEP and early committed MK progenitors (MKP),
whether biased commitment to the MK lineage also contributes to aberrant
megakaryopoiesis in PMF has not been properly explored.
Aims: Using current strategies, immunophenotypic MEP are a negatively
defined, heterogeneous population. To enable detailed investigation of
megakaryopoiesis in PMF we sought 1) To determine whether MEP cells
primed/poised for MK differentiation and early committed MKs could be identi-
fied by their surface antigen expression 2) To prospectively isolate and compare
these populations in PMF and controls.
Methods: Peripheral blood CD34+ progenitors from healthy mobilized donors
(n=7) and JAK2+PMF (n=10) were analysed using previously validated
immunophenotyping (Weissman et al). A novel strategy was then developed to
examine expression of MK and E-associated antigens CD71, CD41 and CD42
within CD123-CD45RA-CD34+CD38+MEP. Specific MEP populations were
FACS-isolated for functional/molecular studies at population and single-cell lev-
el using lineage-specific liquid cultures, clonogenic assays and transcriptional
profiling (Taqman/Fluidigm).
Results: To capture the earliest stages of megakaryopoiesis, we first examined
myeloid progenitor populations and found a higher % of immunophenotypical-
ly-defined MEP in PMF vs controls (P<0.05). Three MEP fractions were iden-
tified by their expression of CD71 and CD41. Prospective isolation of these
populations demonstrated that CD71+CD41+MEP had highest MK colony form-
ing activity (“MK-MEP”), while CD71+CD41-MEP showed highest E colony
forming activity (“E-MEP”). Notably, MK-MEP, although MK-“primed”, retained
the ability for erythroid differentiation, giving rise to BFU-E colonies and
GlyA+CD71hi mature erythroblasts, and CD71+CD41-MEP gave rise to MKs.
Isolating populations from earlyin vitro MK cultures confirmed that CD71hiCD41-
CD42-and CD71+CD41+CD42-cells were bipotent and could give rise to either
MK or E, and CD71loCD41hiCD42+MKP were the first identifiable committed
MKP with no E potential. Single cell and population transcriptional profiling with
a panel of 43 mega-erythropoiesis genes confirmed that MK-MEP and E-MEP
possessed MK and E gene expression signatures. Bivariate Pearson correlation
analyses suggested that gene expression was strongly correlated between sin-
gle cell E-and MK-MEP replicates (>0.7), with greater heterogeneity among
total MEP. Comparing PMF and control MEP ex vivo demonstrated higher
%MK-MEP in PMF (P=0.01). Further, a higher % of MK-MEP expressed CD42
in PMF(P=0.003) and MK-MEP from PMF patients showed more pronounced
MK bias with reduced E colony forming activity and higher expression of MK-
vs E-associated genes (increased Fli1/PF4 in tandem with reduced EKLF).
Summary and Conclusions: Co-expression of CD71 and CD41 allows for
prospective identification of bipotent MEP cells that are primed/poised for MK
vs E differentiation, while CD42 marks commitment to the MK lineage. Func-
tional/molecular profiling indicate that MK-MEP and E-MEP represent homo-
geneous populations within the more heterogeneous MEP. In PMF, although
the frequency of immunophenotypically-defined MEP appears higher, this is
due to increased MK-committed CD42+MKPs. Together with reduced BFU-E
output, this suggests a bias towards megakaryopoiesis at the expense of ery-
thropoiesis at the level of the MEP. Abnormal regulation of mega-erythropoiesis
in PMF may underlie the pathologically expanded MKs and refractory anaemia,
and the ability to prospectively identify these populations enables further
detailed molecular characterization in PMF and related disorders.
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HIGH RESOLUTION CYTOGENETIC MAPPING AND WHOLE EXOME
SEQUENCING REVEAL A COMPLEX PATTERN OF CHROMOSOME 6P
ABERRATIONS IN PATIENTS WITH MYELOID MALIGNANCIES
A. Pudja1,* J.D. Milosevic1, T. Klampfl1, A. Harutyunyan1, T. Berg1, K. Bagienski1,
D. Chen1, B. Gisslinger2, E. Rumi3, L. Malcovati3, D. Pietra3, C. Elena3,
M.G. Della Porta3,4, L. Pieri5, P. Guglielmelli5, M. Doubek6,7, D. Dvorakova6,7,
N. Suvajdzic8, D. Tomin8, N. Tosic9, Z. Racil6,7, M. Steurer10, S. Pavlovic9,
A.M. Vannucchi5, M. Cazzola3,4, H. Gisslinger2, R. Kralovics1
1CeMM-Research Center for Molecular Medicine of the Austrian Academy of
Sciences, 2Division of Hematology and Blood Coagulation, Department of Inter-
nal Medicine I, Medical University of Vienna, Vienna, Austria, 3Department of
Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 4Department
of Molecular Medicine, University of Pavia, Pavia, 5Section of Hematology, Uni-
versity of Florence, Florence, Italy, 6Department of Internal Medicine, Hema-
tology and Oncology, University Hospital Brno, Masaryk University Brno, 7CEIT-
EK-Central European Institute of Technology, Masaryk University Brno, Brno,
Czech Republic, 8Clinic of Hematology, Clinical Center of Serbia, University of
Belgrade, School of Medicine, 9Institute of Molecular Genetics and Genetic
Engineering, University of Belgrade, Belgrade, Serbia, 10Division of Hematology
and Oncology, Innsbruck University Hospital, Innsbruck, Austria
Background: Chromosomal aberrations, together with somatic mutations,
contribute to disease onset and progression in myeloid malignancies. The
detection of these aberrations in patients has allowed identification of genes
involved in the disease pathogenesis. Chromosome 6 shows high complexity
of aberrations detected in patients. We previously showed that JARID2 is a
target for deletions amplified to homozygosity by 6pUPD (uniparental disomy).
However, JARID2 is not mutated in the rest of the patients with 6pUPD. This
implies that other genes are possibly targets of chromosome 6p (chr 6p) aber-
rations.
Aims: Identification of target genes of chromosome 6p aberrations in patients
with myeloid malignancies, using cytogenetic mapping and whole exome
sequencing.
Methods: Peripheral blood samples (n=913) were collected from patients with
myeloproliferative neoplasms (MPN), post-MPN acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS) post-MDS AML, de novo AML
(dnAML) and chronic myeloid leukemia (CML), along with written informed
consent, in compliance with local ethics committees. Genomic DNA was iso-
lated from whole blood, granulocytes or mononuclear cells. Affymetrix
Genome-Wide Human SNP 6.0 arrays and Genotyping Console software were
used for detecting deletions, gains and UPDs. Whole exome sequencing was
performed, using the TruSeq DNA sample prep kit and exome enrichment kit
(Illumina), on the Illumina HiSeq2000 instrument. Data was analyzed with the
GATK Haplotype Caller code. Variants were filtered for exonic and splice site
variants, located in the affected region of chr 6 (individually defined for each
sample). An allelic frequency filter of >50% was introduced in samples with
UPD and gains of chr 6p. All variants were validated by Sanger sequencing.
For 2 patients T lymphocyte DNA was used as control tissue DNA.
Results: We combined all chr 6 aberrations, detected by SNP microarrays,
from 913 patient samples. A total of 41 chromosomal aberrations were detected
on chr 6p in 25 patients (7 MPN, 2 progression phase MPN, 7 post-MPN AML,
2 post-MDS AML, 6 dnAML, 1 CML). Deletions represented 54% of events
(n=22). Six patients harbored 6pUPD, two of which had focal deletions of
JARID2 amplified to homozygosity by UPD. An additional small deletion
mapped to JARID2. Two independent UPD events were detected in one patient.
The aberration map was complemented with exome sequencing data from 4
selected patients: 1 with a deletion (post-MPN AML), 2 with a UPD (post-MPN
AML, dnAML) and 1 with a chr6 trisomy (secondary myelofibrosis). One somat-
ic, 8 germline and 9 mutations of unknown origin were validated. None of the
mutations were found in multiple patients. The somatic L521R mutation in
FAM65B was amplified by the trisomy. Overlap of the mutations with chromo-
somal aberrations identified a commonly affected region containing genes
NCR3 and PSORS1C1. Trisomy amplified a germline PSORS1C1 P38
frameshift mutation, whereas the NCR3 R96Q mutation was amplified by UPD.
A focal gain overlapped with a UPD-amplified UHRF1BP1 S506P mutation.
Summary and Conclusions: Intersecting microarray data from a large pan-
myeloid cohort of patients with exome sequencing data of 3 accelerated phase
MPN/post-MPN AML and 1 dnAML patient resulted in identification of 4 novel
genes, in addition to JARID2, as putative targets of chr6p lesions. As the posi-
tion of the genes does not overlap with all 6pUPDs, it remains possible that
mutations in regulatory regions or epigenetic events are targets amplified by
6pUPD in patients with myeloid malignancies.
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DNA METHYLATION PROFILING OF SORTED CELLS FROM
MYELOFIBROSIS PATIENTS REVEALS ABERRANT EPIGENETIC
REGULATION OF IMMUNE PATHWAYS AND IDENTIFIES EARLY MPN
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Background: Primary myelofibrosis (PMF) belongs to the heterogeneous
group of chronic myeloproliferative neoplasms (MPN) together with essential
thrombocytosis (ET) and polycythemia vera (PV). It has been suggested that
these neoplasms represent a biological continuum from early cancer stage
(ET, PV) toadvancedMF. Multiple studies report frequent mutations in epigenetic
regulators. However, the association to epigenetic changes and the role of epi-
genetic aberrations in different cell populations is still unknown.
Aims: We therefore performed DNA methylation profiling of sorted cells from
MF patients to unravel pathways contributing to disease phenotype and gain
insight into MF pathogenesis. As an aberrant DNA methylation pattern may be
an early event in tumorigenesis and may be crucial for progression of the malig-
nant clone towards the more aggressive forms of MPN, we further aimed to
identify candidate driver genes.
Methods: Peripheral blood samples from 16 MF patients and BM (bone mar-
row) and peripheral blood from 3 healthy age matched controls were sorted in
CD34+ cells, granulocytes and mononuclear cells, and analysed for differential
methylated regions using Illumina Infinium HumanMethylation 450K BeadChip.
Candidate genes were validated by pyrosequencing in a second cohort of 30
MF patients where DNA was extracted from full blood (PB). To identify potential
driver genes, the DNA methylation status of candidate genes was likewise ana-
lyzed in PB from a larger cohort consisting of 60 ET and PV patients.
Results: The number of differentially methylated CpG sites between MF cells
and the respective counterparts from healthy donors differed extensively among
the three cell populations analyzed. In MF CD34+ cells 1628 CpG sites were
differentially methylated compared to normal CD34+ cells, and 519 and 213
differential methylated CpG sites were observed in MF granulocytes and MF
mononuclear cells, respectively (Δβ was set to 0.2 with an adjusted p-value
<0.05, T-test). Differentially methylated genes were mainly involved in cancer
and embryonic development pathways in both the MF CD34+ cells and gran-
ulocytes, while mononuclear cells also showed aberrant methylation of genes
involved in the inflammatory disease pathways. MF granulocytes showed sig-
nificant aberrations in pathways involving immunological diseases, cell death
and survival. Candidate genes have been identified and validation is ongoing.
Interestingly, a gradual increase of the DNA methylation level ofTRIM59was
observed from the healthy controls (31%) over ET (53%) to PV (64%) and MF
(65%). ET patients could be distinguished from both healthy controls
(P=0.0004, Mann-Whitney test) and from the more progressed stages PV and
MF (P=0.0132, Mann-Whitney test) based on theTRIM59DNA methylation lev-
el.TRIM59promoter methylation could, however, not discriminate between PV
and MF (P=0.4721, Mann-Whitney test).
Summary and Conclusions: Genome-wide DNA methylation profiling of sort-
ed MF blood cells provided an exclusive insight into the pathways that con-
tribute to the MF phenotype at a cell specific level. The MF CD34+ cells had
the highest number of differential methylated CpG sites (n=1628) when com-
paring to granulocytes (n=519) and mononuclear cells (n=213) and should be
cells of choice when exploring new treatment strategies. Interestingly, the
mononuclear compartment show aberrant methylation of inflammatory genes
supporting a role of aberrant immune regulation in the pathogenesis of MPN.
Earlier studies have failed to identify aberrant methylation in early ET and PV,
however, our preliminary data on the methylation of individual genes
(TRIM59promoter methylation) shows that early MPN driver genes may be
identified. Further studies are ongoing to unravel the power by which DNA
methylation can discriminate between reactive thrombocytosis and ET. These
data will be presented at the meeting.
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Background: Recently, somatic mutations of CALR, encoding calreticulin,
have been found in most patients with essential thrombocythemia (ET) or pri-
mary myelofibrosis (PMF) with nonmutated JAK2 and MPL. Previous studies
have reported that most CALR mutations are heterozygous. Data regarding
sequential evaluations of CALR mutant burden are still lacking.
Aims: We studied the variation of CALR mutant burden during follow-up in a
large cohort of CALR mutated myeloproliferative neoplasms (MPN) compared
to JAK2 (V617F) mutated patients matched for diagnosis.
Methods: Inclusion in the current study required availability of clinical data at
diagnosis and during follow-up and at least two DNA samples to assess vari-
ations of mutant allele burden. A total of 94 CALR mutated patients (60 ET, 29
PMF, 5 post-ET myelofibrosis) were collected from our database at the Depart-
ment of Hematology Oncology Pavia, Italy. This cohort was compared with a
cohort of 218 JAK2 mutated patients with similar diagnosis (170 ET, 44 PMF,
4 post-ET MF). The evaluation of CALR mutant burden was done comparing
the height of the mutated and wild type picks. A quantitative real-time poly-
merase chain reaction (qRT-PCR)-based allelic discrimination assay was
employed for the quantification of the JAK2 (V617F) allele. For each patient
we calculated the variation from first to last evaluation and the slope between
sequential assessments (i.e. the slope of the regression line with allele burden
as outcome and time as covariate).
Results: 91 of 94 CALR mutated patients remained positive at the second
evaluation, except for three of them who underwent bone marrow transplanta-
tion, that were indeed excluded from further analyses. All of the 3 leukemic
evolutions were still CALR mutated. Statistical analysis was carried on ET and
PMF, due the low number of post-ET MF.Considering first and last evaluation,
we observed a significant increase in the median value of mutant CALR in ET
patients (45.5% vs 49%, Wilcoxon signed-rank test P=0.007), while it remained
stable over time in PMF (51% vs 51%, P=0.428). Median values of slope were
positive both in ET (0.05% increase of CALR mutant alleles/month) and in PMF
(0.02% increase of CALR mutant alleles/month). Mann Whitney U test showed
a trend toward a difference between natural and therapy-related slope in ET
(P=0.09) but not in PMF (P=0.126). Then we calculated the slope in a corre-
sponding cohort of JAK2 mutated ET and PMF: the slope was 0.01% (0.01%
increase of JAK2 V617F alleles/month) both in ET and in PMF, with a significant
difference between natural and therapy-related slope in ET (P=0.031). To eval-
uate the effect of the type of mutation (CALR vs JAK2) on the slope of mutant
burden adjusting for the effect of diagnosis (PMF vs ET), we performed a mul-
tivariate linear regression in all untreated patients (to avoid the potential influ-
ence of cytoreduction). Among patients with a positive slope (n=71, 14 ET
CALR; 7 PMF CALR; 41 ET JAK2; 9 PMF JAK2), the increase of mutant burden
was significantly higher in CALR vs JAK2 (β=0.26, p=0.009) with no difference
between diagnosis (p=0.603).
Summary and Conclusions: The increase of mutant burden during time is
higher in CALR patients respect to JAK2 regardless of diagnosis.
P304
NDEL1-PDGFRB FUSION GENE IN JUVENILE MYELOMONOCYTIC
LEUKEMIA ASSOCIATED WITH RESISTANCE TO TYROSINE KINASE
INHIBITORS
K. Byrgazov1,* R. Kastner1, G. Hoermann2, M. Gorna3, M. Koenig4,
O. Hantschel5, O. Haas4, P. Valent6, M. Dworzak7, C. Urban8, T. Lion1
1Molecular Microbiology, Children’s Cancer Research Institute, 2Department
of Laboratory Medicine, Medical University of Vienna, 3CeMM Research Center
for Molecular Medicine, 4Cytogenetics and FISH, Children’s Cancer Research
Institute, Vienna, Austria, 5School of Life Sciences, Ecole Polytechnique Fed-
erale de Lausanne, Lausanne, Switzerland, 6Department of Internal Medicine
I, Medical University of Vienna, 7Department of Pediatrics, St. Anna Children’s
Hospital, Vienna, 8Department of Pediatrics and Adolescence Medicine, Med-
ical University of Graz, Graz, Austria
Background: A novel fusion gene NDEL1-PDGFRB was identified in a child
with juvenile myelomonocytic leukemia (JMML) with no mutations in
NF1/RAS/PTPN11/cCBL. Malignant disorders displaying fusion genes involving
PDGFRB are generally sensitive to imatinib (IM) (Chan et al., 2014), but the
patient relapsed on IM and subsequently on nilotinib (NIL) treatment after initial
response.
Aims: Unravel molecular mechanisms underlying acquired resistance to tyro-
sine kinase inhibitors (TKIs), and determine in vitro sensitivity to different TKIs.
Methods: Cytogenetic, FISH and 5’-RACE analyses were used to identify the
translocation. A point mutation in the PDGFRB TKD was detected by Sanger
sequencing of overlapping amplicons in peripheral blood specimens from the
time of relapses and diagnosis. Protein modelling was done on SWISS-MODEL
and I-TASSER servers using available crystal structures of VEGFR2 and CSF-
1R TKDs. To test the TKI responses, BaF3 cells constitutively expressing retro-
virally introduced NDEL1-PDGFRB constructs (BaF3-N-Pb) were tested in via-
bility assays against a panel of TKIs.
Results: Reciprocal translocation t(5;7)(q33;p11.2) encoding a novel fusion
gene NDEL1-PDGFRB was identified in the patient. The chimeric mRNA con-
tains the 5´exons 1-5 of NDEL1 encoding the dimerization domain fused in
frame to the PDGFRB exons 10-22 encoding the transmembrane (TM) and
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tyrosine kinase (TKD) domains. Point mutation converting Asp850 into glutamate
(D850E) in the activation loop (A-loop) was identified from the time of both relaps-
es, but not diagnosis. Modelling of PDGFRβ TKD suggested that the mutation
D850E may result in higher activity of the TKD and resistance to type II TKIs, in
line with the observed failure of IM and NIL treatment. However, the model sug-
gested sensitivity to type I TKIs such as dasatinib (DAS) and midostaurin
(PKC412). BaF3-N-PbWT cells were sensitive to IM (IC50 =60 nM), NIL (100
nM), sorafenib (SOR; 20 nM), DAS (5 nM) and PKC412 (20 nM). Conversely,
BaF3-N-PbD850E cells exhibited high IC50 to the type II TKIs IM (>2500 nM), NIL
(1000 nM) and SOR (2500 nM), but retained sensitivity to the type I TKIs DAS
(20 nM) and PKC412 (5 nM). Activating mutations in the A-loop of RTKs such
as PDGFRA (D842V), FLT3 (D835V) or c-Kit (D816V) associated with resistance
to type II TKIs were described in different tumor entities. However, the mutation
D850E in the PDGFRβ TKD with apparent insensitivity to IM, NIL, and SOR
revealed a different pattern of resistance than the same amino acid exchange
at the corresponding site of PDGFRα (D842E) in the FIP1L1-PDGFRA fusion
gene which had been previously shown to be sensitive in vitro to IM (4 nM), NIL
(12.5 nM), and SOR (0.25 nM) (von Bubnoff et al., 2011). Protein modelling of
PDGFRβ TKD suggested that the distinct properties of PDGFRβ TKD carrying
D850E may be attributed to the poorly conserved residue in +3 position to the
mutated D850. In PDGFRβ, it is arginine (R853), as opposed to histidine (H845)
in PDGFRα. Mutation R853H in PDGFRβ carrying D850E reduced its kinase
activity and restored in vitro sensitivity to type II TKIs.
Summary and Conclusions: To our knowledge, this is the first observation of
an exchange between two negatively charged amino acids in a tyrosine kinase
PDGFRβ associated with a major change in responsiveness to TKI treatment.
The ongoing further investigation of this finding may extend our understanding
of structural interactions leading to TKI resistance and activation of tyrosine
kinases in MPNs.
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Background: Leukemic stem cells (LSCs) have been identified as an important
therapeutic target in human leukemia and other related hematologic disorders.
Systemic mastocytosis (SM) is a rare hematopoietic neoplasm characterized
by abnormal growth and expansion of mast cells (MCs) in the bone marrow
(BM) and other organ systems. Whereas patients with indolent SM (ISM) have
a normal life-expectancy, patients with more advanced forms of SM have a
grave prognosis. In these patients, neoplastic MCs are usually resistant against
conventional drugs and various targeted drugs. MC leukemia (MCL) is the rare
leukemic variant of advanced SM, defined by a rapid expansion of immature
MCs in various hematopoietic organs and a poor prognosis with short survival.
Although MCL is considered a stem cell disease, little is known about the origin
and phenotype of MCL-initiating LSCs.
Aims: We examined the phenotypic and functional characteristics of putative
LSCs in patients with aggressive SM (ASM, n=12) and MCL (n=6) by flow
cytometry.
Methods: Highly enriched, sorted LSCs were injected into NOD-SCID-IL-2Rg-
/-mice exhibiting human membrane-bound SCF (NSGSCF).
Results: We found that disease-initiating and propagating LSCs reside within
a CD34+fraction of the MCL clone. Whereas cell fractions containing CD34+
cells as well as highly enriched CD34+ cells engrafted in NSGSCF mice with a
MCL-like disease, no substantial engraftment was produced by MC-rich but
stem cell-depleted, KIT+/CD34─ cell fractions obtained from the same patients.
Moreover, we were able to confirm long-term engraftment by successful serial
transplantations into secondary recipient mice. As assessed by flow cytometry,
the CD34+/CD38─ MCL LSCs were found to co-express several stem cell mark-
ers, including aminopeptidase-N (CD13), leukosialin (CD43), Pgp-1 (CD44), the
IL-3R alpha-chain (CD123), AC133 (CD133) and CXCR4 (CD184). In addition,
in several of the patients examined, MCL LSCs were found to display IL-1RAP,
a surface antigen that is otherwise expressed in CML LSCs but is not expressed
in normal stem cells. In addition, MCL LSCs were found to express various cell
surface targets, including CD33 and CD52. By contrast, MCL LSCs did not
express CD2, CD25, CD26 and CLL-1. In patients with ISM and ASM, the
CD34+/CD38─ stem cells exhibited a similar surface marker profile compared
to MCL, but expressed higher levels of CD117, lower levels of CD133, and did
never express IL-1RAP. Subsequently, we examined the effects of target-specific
antibodies. As assessed by flow cytometry, the CD52-targeting antibody alem-
tuzumab was found to induce lysis of CD34+/CD38─cells in all MCL samples
analysed. Furthermore, pre-incubation of MCL cells with alemtuzumab prior to
injection into NSGSCF mice resulted in a significantly reduced engraftment.
Summary and Conclusions: In conclusion, our data show that the MCL clone
originates from a primitive hematopoietic stem cell. In addition, our data indicate
that MCL LSC express a number of clinically relevant surface targets, including
CD33, CD52 and CD117 (KIT). These observations may lead to the develop-
ment of novel LSC-eradicating treatment concepts in this highly aggressive
and drug-resistant form of leukemia.
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Background: Comorbidities are frequent in patients with myeloproliferative
neoplasms (MPNs), and studies show increased comorbidity already at time of
diagnosis. Furthermore studies in different cancer types, show an impact of
comorbidity on all-cause mortality. Neither the overall comorbidity, nor the
impact of it on all-cause mortality, have been widely investigated in large epi-
demiological studies including both MPN patients and matched controls.
Aims: To describe comorbidity in myeloproliferative cancer patients in Denmark
compared with matched controls and assess impact of comorbidity on all-cause
mortality in different MPN subgroups.
Methods: We conducted a population based cohort study, including all patients,
age 18+ or older, with a first listed diagnosis of MPN: essential thrombocythemia
(ET), polycythemia vera (PV), myelofibrosis (MF), unclassifiable MPN (MPN-U)
and chronic myeloid leukemia (CML) in the Danish National Registry of Patients,
between 1994-2013. Follow-up status was determined through linkage to the
Danish Civil Registration System, and started 30 days after the first diagnosis
date of MPN =index date, and continued until death, emigration, or end of 2013,
whichever came first. Comorbidity prevalence at the index date was measured
using an adapted version of the Charlson comorbidity index (CCI), within a ten-
year period preceding index date. Codes corresponding to MPN diagnosis were
excluded to allow comparison of overall non-MPN cancer comorbidity. To com-
pare CCI with the background population, we identified ten sex and age matched
individuals, without MPN, for each corresponding MPN patient. Patients and
matched controls were classified into four diagnostic calendar periods (1994-
1998, 1999-2003, 2004-2008, 2009-2013) and in five groups by CCI score (0,
1, 2, 3, ≥4). Prevalence of comorbidity in MPN patients and controls were com-
pared using chi-square test and t-tests for average CCI score. Impact of comor-
bidity on all-cause mortality was analysed by Kaplan-Meier plots and Cox regres-
sion. Patients and controls with CCI score 0 in each group was used as reference
in all analyses. We adjusted for period of diagnosis, smoking related and alcohol
related conditions (yes/no) and for CML patients before/after year 2000 to allow
for the introduction of tyrosine kinase inhibitor treatment.
Results: We included 9,868 patients (ET=2,735, PV=3,324, MF=603, U-
MPN=1,849, CML=1,357) and a total of 98,627 matched controls. Our results
show a higher percentage of patients than controls with CCI score >0 and dif-
ferences between MPN patients and controls were observed for mean CCI,
with significant higher CCI score in all MPN subgroups (p<0.0001) (table 1).
All-cause mortality for CCI score 0, was significantly increased in all MPN sub-
groups compared to controls, except for ET (p=0.12) (table 1). Furthermore
data showed increased all-cause mortality with increasing CCI score for both
MPN patients and controls, but the influence of increasing CCI had lower impact
in all MPN subgroups than in controls (P<0.05) and ET and PV patients with
comorbidity had lower mortality than corresponding controls.
Tabella 1. Percentage of CCI score >0, mean CCI (± standard deviation)
and hazard ratios of all-cause mortality between patients and controls
without comorbidity (95%-confidence intervals).
Summary and Conclusions: MPN was associated with significantly increased
comorbidity compared to the general population and patients with no comor-
bidity had higher all-cause mortality, except for ET patients. Comorbidity was
associated with increased all-cause mortality in all MPN groups and controls,
but impact of increasing CCI was different within the groups. Remarkably ET
and PV patients with comorbidity had lower mortality than controls.
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IMPACT OF JAK2, CALR OR MPL MUTATION STATUS ON PREGNANCY
OUTCOME IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA 
E. Rumi1,* I. Bertozzi2, I.C. Casetti1, C. Cavalloni1, E. Sant’Antonio1, M. Bellini1,
V.V. Ferretti1, C. Milanesi1, E. Peroni2, D. Pietra1, C. Astori1, M.L. Randi2,
M. Cazzola1
1Department of Hematology Oncology Fondazione IRCCS Policlinico S. Mat-
teo, Pavia, 2Department of Medicine-DIMED, University of Padua, Padua, Italy
Background: Essential thrombocytemia (ET) may occur in women of child-
bearing age. Pregnancy may therefore be an issue in the clinical management
of young women with ET. Previous studies have reported live birth rates of 50
to 70% and spontaneous abortion rates of 25% to 50%, mostly during the first
trimester. The pathogenesis of pregnancy complications is poorly understood.
Indeed, the association between JAK2 (V617F) mutation and poor pregnancy
outcome is uncertain, while data regarding the impact of the other MPN-asso-
ciated driver mutations are lacking.
Aims: We studied the impact on pregnancy outcome of the three MPN driver
mutations (JAK2, MPL, CALR) in a large cohort of pregnant ET patients.
Methods: Inclusion in the current study required availability of clinical data at
diagnosis and during pregnancy, and at least one DNA sample to assess muta-
tion status. A total of 155 pregnancies that occurred in 94 patients with ET were
collected from 2 centers (Department of Hematology Oncology Pavia, and Divi-
sion of Internal Medicine Padova). All patients were screened for JAK2, MPL
and CALR mutations with previously reported methods.The 4 genotypic sub-
groups (JAK2 mutated, MPL mutated, CALR mutated, and triple negative) were
compared in terms of pregnancy outcome. Pregnancy complications included
fetal loss (first-, second-or third-trimester miscarriage), intrauterine growth retar-
dation (IUGR), and maternal complications.
Results: Of 94 ET patients studied, 59 (62.8%) carried JAK2 (V617F), 19
(20.2%) carried CALR mutations, 2 (2.1%) carried MPL mutations, and 14
(14.9%) were triple-negative. The hemoglobin value at diagnosis was the only
hematological parameter that differed according to mutation status, being higher
in JAK2 (V617F)-mutated patients (P<0.001). Three pregnancies that were ter-
minated with voluntary abortion were excluded from this analysis. Overall, 72 of
152 pregnancies (47.4%) were complicated: 46 (30%) by fetal loss (37 during
the first trimester, 6 during the second, 3 during the third), 18 (11.8%) by maternal
complications, and 13 by IUGR (8.6%). The rate of complications (including both
fetal and maternal complications) was not influenced by mutation status (Fisher’s
exact test P 0.134). When we restricted the analysis to late pregnancy losses, a
relationship with JAK2 (V617F) mutation (P 0.027) was found: second-and third-
trimester miscarriage occurred in 9.4% of JAK2 (V617F) pregnancies vs none of
MPL/CALR/triple-negative pregnancies. Considering the potential role of calendar
year at pregnancy, we observed that the rate of pregnancy complications before
2007, was higher than that reported after 2007 (54% vs 35%, P 0.028). Then,
we performed a multivariate analysis considering calendar year (before or after
2007) and mutation status (CALR vs JAK2/MPL/triple negative). In multivariate
analysis we found that the occurrence of pregnancy before 2007 correlated with
a poorer outcome (OR 2.4, P 0.024), and the presence of CALR mutation showed
a trend toward a lower rate of pregnancy complications (OR 0.4, P 0.059).
Summary and Conclusions: The presence of JAK2 (V617F) mutation is asso-
ciated with late pregnancy losses. The outcome of pregnancy seems to be influenced
by calendar year, suggesting an improvement in our management strategy. Preg-
nancies occurring in CALR-mutated patients show a trend toward a better outcome
than those occurring in JAK2-mutated or MPL-mutated or triple negative patients.
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QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE
NEOPLASMS COMPARED TO NORMAL INDIVIDUALS-CASE-CONTROL
EVIDENCE OF SIGNIFICANT IMPAIRMENT 
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Background: The myeloproliferative neoplasms (MPNs) including poly-
cythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofi-
brosis (PMF) arediseases of hemopoietic stem cell originthat causesignificant
morbidity and mortality. Comparisons betweensymptom burdenof MPN cases
and those of the general population have not previously been reported.
Aims: The aim of the study was to compare the quality of life experienced by
patients with classic MPNs (PV, ET, PMF) with that of age and sex matchedin-
dividuals with no evidence of MPN.
Methods: The myeloproliferative neoplasm symptom assessment form (MPN-
SAF) is a reliable and validated clinical tool used for assessing MPN patient
symptom burden. A pilot case-control study of MPN, called the ‘MyelOprolif-
erative neoplasmS: An In-depth Case-Control study’ (MOSAICC), recruited
MPN patients and controls in Belfast, Northern Ireland and Southampton,
England. The MPN-SAF was completed by cases and, for the first time, by
non-blood relatives andindividuals from primary care centres all without evi-
dence of MPN to act as controls. Mean symptom scores were compared
between cases (n=106) and controls (n=124). Mean scores in cases were
then compared to published data on 1446 MPN patients from the Mayo Clinic,
USA. Mean scores in cases from the UK and USA studies were then combined
and compared with controls.
Results: MPN cases had significantly higher mean scores than controls for 26
of the 27 symptoms measured (p<0.05). Fatigue was the most common symp-
tom in cases and controls (92.4% and 78.1% respectively). Patients with PMF
reported the worst symptomatic burden (88.3%) which was significantly higher
than that reported by PV cases (p<0.001). Female MPN patients suffered worse
symptomatic burden than males (p<0.001). Compared to MPN cases in the
USA, UK cases reported similar symptom burden in all categories exceptlower
satiety (p=0.046).Combining the UK and USA cases resulted in an increase in
significance of reported symptoms compared with the controls. Interference
with work was reported in 77.4% of cases compared with 54.8% of controls
(p<0.001). Abdominal pain occured in 46.4% of cases versus 20.3% of controls
(p<0.001). Sexual problems were experienced by 60.9% of cases against
27.9% of controls (p<0.001). Bone pain occurred in 49.3% of cases compared
with 19.7% of controls (p<0.001).Overall QoL was impaired in 78.4% compared
with 57.4% of controls (p<0.001).
Summary and Conclusions: This novel study demonstratesthe significant
morbidity experienced by MPN patients compared to controls and the similar-
ities between patients in the UK and USA highlighting the common need to
manage disease burden. For the first time the MPN-SAF has been shown to
be a good discriminatory tool to assess the extent of symptoms in MPN patients
compared to normal individuals.
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PREDICTORS OF SURVIVAL IN PATIENTS WITH ESSENTIAL
THROMBOCYTHEMIA
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Background: Standard risk stratification for overall survival (OS) in patients
with essential thrombocythemia (ET) is based on advanced age and history of
thrombotic events. Recently, International Prognostic Score for ET (IPSET)
incorporated also leukocytosis in prognostic model.
Aims: was to establish additional risk factors for OS in ET patients.
Methods: The study was conducted on 244 consecutive patients with ET who
were diagnosed according to WHO criteria and treated at the Clinic for Hema-
tology, CCS, from January 2000 to January 2012. The following parameters at
diagnosis of ET were taken into consideration to find prognostic risk factors for
OS: age, sex, leukocyte and platelet count, hemoglobin level, JAK2 mutational
status, splenomegaly and thrombotic events (previous and during the follow-
up). We also analysed influence of cardiovascular (CV) risk factors on survival.
We considered as main CV risk factors presence of arterial hypertension, dia-
betes mellitus and hyperlipidemia while smoking attitude was considered as
additional CV risk factor.
Results: Mean age at the time of diagnosis was 56 years (range: 18-85 years)
and 68% of patients were women. After the median follow up of 7 years, 32
deaths were documented (13.2%). The 5-and 10-years OS was 95.9% and
79.7% respectively. Patients with CV risk factors had increased risk of death
(HR=2.33). In present study, univariate Cox analysis identified following risk fac-
tors as unfavorable predictors of survival: age≥60 years (p<0.001), leukocyte
count ≥10x109/L (p=0.004), previous thrombosis (p=0.002), presence of CV risk
factor (p=0.048) and CV risk factor ≥1 plus active tobacco use (p=0.012). Accord-
ingly, we assigned risk scores based on hazard ratios (HR) to age≥60 (HR=7.2;
2 points), 1 previous thrombosis (HR=1.19; 1 point), ≥2 previous thrombosis
(HR=5.7; 2 points), leukocyte count ≥10x109/L (HR=3.15; 1 point), presence of
main CV risk factor (HR=2,33; 1 point) and CV risk factor ≥1 plus active tobacco
use (HR=2,08; 2 points). A final 4-tiered prognostic model named Cardio-IPSET
was thus developed, as low (score 0-1), intermediate-1 (score 2-3), intermedi-
ate-2 (score 4) and high risk (score 5-7) with median survivals were: not reached
for the low risk group (81 patients), not reached for the intermediate-1 risk group
(92 patients), 122 months for the intermediate-2 (47 patients) and 97 months for
the high risk group (24 pts) (log rank=52.154, p<0.001). Multivariate regression
analysis confirmed the statistical significance of new Cardio-IPSET prognostic
model (p<0.001, HR 3.169, 95%CI 2.186-4.594) as only independent predictor
of OS in ET patients. This new model displayed a better hazard ratio profile com-
pared to the standard risk stratification (log rank=23.262, p<0.001) and IPSET
(log rank=40,010, p<0.001). In addition, patients who developed arterial throm-
bosis during the follow-up had significantly shorter survival then those who did
not develop the arterial thrombosis (97 months vs 140 months, p <0.001).
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Summary and Conclusions: The addition of CV risk factors allows better
prognostic assessment by delineating the intermediate risk category and
improved identification of the high-risk patients. Accordingly, inclusion of CV
risk factors is essential for individualizing assessment and optimizing the treat-
ment of ET patients in term to improve their outcome.
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Background: Patients with polycythemia vera (PV) and elevated hemoglobin
(Hb) concentration are at an increased risk of cardiovascular disease and
venous thromboembolism (VTE). In earlier studies, patients without PV but ele-
vated Hb were at increased risk of cardiovascular events. However, these stud-
ies were carried out before the discovery of JAK2V617F in the year 2005 and
a number of patients with idiopathic erythrocythosis were later diagnosed with
PV. Thus, there is paucity of data on the risk of vascular events in persons with
an elevated Hb concentration with no known PV diagnosis.
Aims: To assess the risk of acute myocardial infarction (MI) and VTE in relation
to Hb concentration among healthy blood donors without PV.
Methods: The study was based on the Scandinavian Donations and Transfusions
(SCANDAT2) database, which includes nationwide data on blood donations
including donor identity, date of donation, as well as current Hb from Sweden
and Denmark since the 1960’s and 1980’s, respectively. From SCANDAT2, all
donors who had performed at least one donation between 1987 and 2012 were
identified. Through the nationwide Swedish and Danish Patient and Cancer Reg-
isters, information on events of MI and VTE (deep venous thrombosis and pul-
monary embolism) as well as relevant co-morbidities was obtained. Patients with
a diagnosis of PV were excluded. The association between Hb concentration
and risk of MI or VTE was assessed using pooled logistic regression adjusted for
age, sex, calendar period, country of birth, and co-morbidity. We also fitted con-
ditional, person-adjusted models, where each individual was compared to him-
/herself. Hb concentration was considered time-dependently, allowing values to
change with time. Separate analyses were carried out for men and women.
Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Results: In total, 1.6 million blood donors with a total of 22.5 million Hb meas-
urements were included. Median age at first donation was 33.2 years, 50% of
donors were women and 65% were from Sweden. The risk of MI increased
gradually with higher Hb in both men and women. In the standard, adjusted
model, women with Hb ≥16.5 g/dL were at 3-fold increased risk of MI (OR=3.00;
95% CI 1.95-4.62) compared to women with an Hb of 12.0-13.4 g/dL (Table).
Similarly, the OR for MI in men with Hb ≥17.5 g/L was 3.49 (95% CI, 2.81-4.33)
compared to those with Hb 13.0-14.4 g/dL. In the conditional model, where
each subject serves as his or her own control, risks were attenuated. A slight
increase in risk of MI remained in men with Hb ≥17.5 g/L (OR=1.29, 1.05-1.57)
but no significantly elevated risk in women with Hb ≥16.5 g/L (OR=0.91, 0.56-
1.48). For VTE, the standard model revealed a pattern with elevated risks both
at subnormal Hb in men with Hb <13.0 (OR=1.61, 1.33-1.95), and a gradually
increasing risk with higher Hb (Table). Again, the association largely disap-
peared in the person-specific conditional model. For women there was no asso-
ciation between current Hb and VTE risk in the standard model and an inverse
association in the conditional model.
Tabella 1. Relative risk of myocardial infarction and venous thromboem-
bolism among female and male blood donors in relation to hemoglobin
concentration.
Summary and Conclusions: These findings imply that an elevated Hb can
serve as a marker of an increased risk of MI and VTE. In addition, a subnormal
Hb can indicate an elevated risk of VTE. However, when each subject served
as his/her own control, the risk elevations largely disappeared, indicating that
the risk is most likely driven by additional underlying co-morbidities and cannot
exclusively be attributed to the Hb elevation itself. Nonetheless, an elevated
Hb signals the need for thorough assessment of cardiovascular risk factors.
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COMPLICATIONS IN 217 PV PATIENTS
A. Enblom1,* E. Lindskog2, F. Girodon3, H. Hasselbalch4, D. Hersby4, M. Bak4,
P. Johansson2, B. Andreasson2
1Sunderby Hospital, Luleå, 2NU hospital group, Uddevalla, Uddevalla, Sweden,
3Laboratoire d’hématologie CHU, Dijon, France, 4Hematology,Roskilde Uni-
versity Hospital, Roskilde, Denmark
Background: Vascular complications and are risks for patients with poly-
cythemia vera (PV).
Aims: To investigate if blood counts, with respect to different treatments, influ-
ence the complication rate and/or survival during the course of the PV disease.
Methods: 217 PV patients from Uddevalla Sweden, Luleå Sweden, Roskilde
Denmark and Dijon France were included. The mean follow-up time was 6.2
years per patient. Blood values and co-morbidity were recorded at diagnosis,
during treatment and at the time of any complication were retrieved.
Results: At the time of diagnosis the median age 70 years, hemoglobin (Hb)
level was 17.6 g/dL, hematocrit (Hct) 55%, white blood count (WBC) 10.9 x109/L
and platelets (Plt) 512x109/L. LDH was elevated in 136 of 156 patients. 38
patients (median age 77 years) experienced vascularevents during follow-up,
40 patients (median age 72 years) had non-vascular complications and 139
patients (median age 66) had no complications. Both complication groups had
significantly higher age compared to the patients without complications
(p<0.01). No significant differences were found in Hb, Hct, WBC or Plt. Elevated
LDH at diagnosis was significantly more frequent in the patient group with vas-
cular complications compared to the patients without (p<0.01). The main treat-
mentswere Hydroxyurea (HU) (139 patients), Phlebotomy (Phl) only (55
patients) and other (interferon, busulfan or pipobroman in 23 patients). No sig-
nificant survival differences were found between the HU and Phl groups (p=0.6),
even though the median age was 72 and 66, respectively. A total of 78 PV
patients (36%) had recorded complications during the observation time. There
were 35 vascular complications, 16in the139 HU patients compared to 15in
the 55 patients on Phl (p=0.013). Blood values at the time for complication
were compared to the mean for the yearly controls for the patients without com-
plications, 41% with vascular events compared to 20 in the group without had
WBC >10 x109/L(p=0.042). The differences between the groups as regards
Hct and Plt were not significant.The survival for HU treated patients with need
for, at least, one phl per year was significantly better than for HU treated patients
without or need for less than one Phl per year (p=0.019). Fig 1
Figure 1. Survival of 139 Hydroxyurea treated PV patients, with and with-
out need for phlebotomy.
Summary and Conclusions: We did not find any association between blood
counts at the time of diagnosis and complication rate during follow-up, where-
asLDH was found in a larger proportion of the patients with vascular events.
Complications appeared in 36% of the patients. Vascular events were recorded
in 16 % of the patients, being significantly more frequent in the group of patients
treated with Phl only as compared to the patients treated with HU (p=0.013),
despite the fact that that their median age was significantly lower (66 and 72
years, respectively). ELN criteria for HU resistance/intolerance have been
established, including need for Phl, WBC >10 x109/L and Plt >400 x109/L. In
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this study we found a significantly better survival for patients on HU with need
for Phl compared to patients with less than one Phl per year, comparison with
findings for “masked PV” could be made.We also found that elevated WBC
seemed to be a risk factor for complications, whereas Plt levels did not influence
complication rate. We conclude that elevated LDH at the time of diagnosis and
high WBC during the corse are risk factors for future vascular complications in
PV. HU therapy is associated with, at least, equal survival compared to treat-
ment with Phl only. Need for complementary Phl to HU treated patients is safe.
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AND VALIDATION ON 792 PATIENTS
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Background: Spleen enlargement is present in about 10-20% of Essential
Thrombocythemia (ET) patients at diagnosis and is a feature clinically easy to
assess, confirmable by echography and with a very low chance of misinterpre-
tation. Nonetheless, the clinical and prognostic role of splenomegaly has been
seldom evaluated.
Aims: The present study aimed to correlate spleen enlargement with baseline
disease characteristics and outcome, with particular focus on thrombotic risk.
Methods: From 1979 to 2010, 1097 ET patients retrospectively collected in
the database of the Lazio Cooperative Group were evaluable for spleen
enlargement at diagnosis and were included in the primary analysis. The results
of the main Lazio cohort were validated in 792 ET patients who were diagnosed
and followed in the Bologna University Hospital between 1979 and 2013.
Results: In the Lazio cohort, spleen was enlarged in 213/1097 (19.4%)
patients; in most cases (92%) splenomegaly was mild (<5 cm). Patients with
splenomegaly were predominantly male, with higher platelet count, lactate
dehydrogenase levels and JAK2V617F mutation load. Despite comparable
use of cytoreductive/antiplatelet therapies in the two groups, the cumulative
risk of thrombosis at 10 years was significantly higher in patients with baseline
splenomegaly (23% versus 11% in patients without splenomegaly, p=0.007)
(Figure 1a). In multivariate analysis exploring risk factors for thrombosis,
splenomegaly retained its negative prognostic role, together with older age
and previous thrombosis. In the validation Bologna cohort, 55 out of 792 (7%)
ET patients carried baseline splenomegaly. Overall, 113 (14.3%) patients expe-
rienced a thrombotic event during follow-up. At 10 years, the cumulative inci-
dence of thrombosis was 31.5% and 17.4% in patients with or without
splenomegaly, respectively (p=0.039) (Figure 1b); splenomegaly confirmed its
impact on thrombosis also in multivariable analysis.
Figure 1.
Summary and Conclusions: Baseline splenomegaly seems to be an inde-
pendent additional risk factor for thrombosis in non-strictly WHO-defined ET
patients. This data could be useful in the real-life clinical management of these
patients.
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Background: Until now, due to less reliable method based on physical exam-
ination (PEx) to measure spleen size, prognostic clinical value of splenomegaly
have been devalued. Therefore, several clinical studies failed to demon-
stratethe significant prognostic value of spleen enlargement in primary myelofi-
brosis (PMF), although splenomegaly is a major characteristic associated with
the adverse clinical features.
Aims: We evaluated whether spleen volume (SV) in computed tomography
(CT) would accurately predict clinical outcomes in PMF.
Methods: A total of 188 patients with PMF who received abdomen CT at diag-
nosis, were enrolled. SV was quantitated from the cross-sectional images by
using 3-dimensional analytical volume software (Voxar, Ltd., Edinburgh, United
Kingdom). The computer automatically contoured the spleen in each CT slice
and calculated the SV in cubic centimeter (cm3). In order to evaluate prognostic
significance of SV by CT, we compared the prognostic values of several prog-
nostic factors present at the time of diagnosis: sex (male or female), age (≥or
<65 years), the presence of constitutional symptoms, hemoglobin (Hb) level
(≥or <10 g/dL), platelet (PLT) counts (≥or <100×109/L), white blood cell (WBC)
counts (≥or <25×109/L), presence of peripheral blood (PB) circulating blasts
(≥or <1 %), red blood cell (RBC) transfusion dependency, the presence of
JAK2-V617F mutation, MF grading according to the ECSS (MF-3 or <MF-3),
and the presence of unfavorable cytogenetic abnormalities such as complex
karyotype or sole or two abnormalities including +8,-7/7q-,-5/5q-, i(17q), 12p-
, inv(3), or 11q23 rearrangement.
Results: In ROC curve, SV by CT more accurately predicted prognosis than
spleen length by PEx (p <0.001). Ideal cut-off value, 378.1 cm3 of SV divided
with high and low volume status. Low SV status had superior leukemia-free sur-
vival (LFS) and overall survival (OS) compared with high status (p <0.001, p
<0.001). In univariate and multivariate analyses, old age (LFS, HR =1.864, 95%
CI =1.217-3.056, p =0.004; OS, HR =2.102, 95% CI =1.381-3.190, p =0.001),
low Hb level (LFS, HR =1.793, 95% CI =1.302-2.923, p =0.023; OS, HR =1.786,
95% CI =1.053-3.029, p =0.021), high WBC counts (LFS, HR =2.051, 95% CI
=1.287-3.269, p =0.003; OS, HR =1.892, 95% CI =1.197-2.989, p =0.006), PB
circulating blasts ≥1 % (LFS, HR =1.590, 95% CI =1.024-2.469, p =0.029; OS,
HR =1.699, 95% CI =1.064-2.598, p =0.020), unfavorable cytogenetic abnor-
malities (LFS, HR =1.808, 95% CI =1.371-1.987, p =0.025; OS, HR =1.802,
95% CI =1.104-2.945, p =0.028), and high SV status (LFS, HR =2.633, 95% CI
=1.368-5.069, p =0.004; OS, HR =2.641, 95% CI =1.404-4.967, p =0.003) were
independently associated with survivals. By using the independent prognostic
factors, each patient was assigned according to sum of 0-6 adverse points. The
six score groups were consolidated into 5 risk groups according to intergroup
survival differences ; low risk group (0 risk factor), intermediate-1 risk group (1
risk factor), intermediate-2 risk group (2 risk factors), high risk group (3 risk fac-
tors), and very high risk group (≥4 risk factors, Figure A and B).
Figure 1.
Summary and Conclusions: High SV status measured by CT had a qualifi-
cation as a remarkable risk factor at diagnosis to predict survivals in PMF.
Therefore, we could develop the novel prognostic scoring system model includ-
ing splenomegaly by the imaging modality in PMF.
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PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST
AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF),
POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL
THROMBOCYTHEMIA MF (PET-MF)
C. Harrison1,* A. Szoke2, A. Suvorov3, M. Egyed4, R. Prasad5, J. Mayer6,
J. Jakucs7, A. Elinder8, C. Recher9, P.A. te Boekhorst10, S. Knapper11,
T. Somervaille12, F. Ciceri13, F. Quddus14, N. Straetmans15, D. Niederwieser16,
J.P. Dean17, T. Granston17, J.J. Kiladjian18, A. Vannucchi19, J. Nangalia20,
A. Mead21, R. Mesa22
1Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom,
2Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Szeged,
Hungary, 3First Republican Clinical Hospital of Ministry of Health of the Udmurt
Republic, Izhevsk, Russian Federation, 4Kaposi Mor Teaching Hospital, Kapos-
var, Hungary, 5Royal Hobart Hospital, Hobart, Australia, 6University Hospital
Brno, Brno, Czech Republic, 7Békés Megyei Pándy Kálmán Kórház, Gyula,
Hungary, 8North Shore Hospital, Takapuna, New Zealand, 9Institut Universitaire
du Cancer Toulouse, Toulouse, France, 10Erasmus University Medical Center,
Rotterdam, Netherlands, 11Cardiff University, Cardiff, 12The Christie NHS Foun-
dation Trust, Manchester, United Kingdom, 13San Raffaele Scientific Institute,
Milan, Italy, 14Upstate Oncology Associates, Greenville, United States, 15Centre
Hospitalier Jolimont-Lobbes, Haine-Saint-Paul, Belgium, 16Universitatsklinikum
Leipzig, Leipzig, Germany, 17CTI BioPharma Corp, Seattle, United States,
18Hôpital Saint Louis, Paris, France, 19University of Florence, Florence, Italy,
20University of Cambridge, Cambridge, 21Oxford University, Oxford, United
Kingdom, 22Mayo Clinic, Scottsdale, United States
New Information: Submitted to ASCO 2015. New information includes addi-
tional safety data such as dose reductions, dose interruptions and reason for
dose modification.
Background: Treatment options for patients (pts) with MF are limited. A signif-
icant proportion present with disease-related thrombocytopenia, an independent
survival risk factor. Others develop treatment-emergent thrombocytopenia on
currently available therapies. These pts represent an underserved population.
PAC is a potent multikinase inhibitor of JAK2/FLT3 and has exhibited minimal
myelosuppression in early phase MF studies.
Aims: The open-label PERSIST-1 (NCT01773187) trial compared the efficacy
and safety of oral PAC vs BAT in PMF, PPV-MF, and PET-MF.
Methods: JAK inhibitor naïve pts were randomized 2:1 to oral PAC 400mg
once daily or BAT stratified by DIPSS risk (Int-1 or Int-2 vs High) and platelet
(plt) count (<50,000/µL vs 50,000 to <100,000/µL vs ≥100,000/µL). Eligibility
criteria included: DIPSS Int-1, Int-2, or High risk; ANC >500/µL; no restriction
on plt or hemoglobin; palpable splenomegaly ≥5 cm; and baseline total symp-
tom score (TSS) ≥13 using the MPN Symptom Assessment Form (MPN-SAF).
The primary endpoint was the proportion of pts achieving ≥35% spleen volume
reduction (SVR) at Week 24 (WK24) by centrally-reviewed MRI or CT. The sec-
ondary endpoint was the proportion achieving ≥50% reduction in TSS at WK24
using MPN-SAF. 
Figure 1.
Results: 327 pts were enrolled (PAC: 220, BAT: 107), 62% with PMF; 32%
had plt counts <100,000/µL and 16% had plt counts <50,000/µL; 75% were
JAK2V617F-positive. Median time from diagnosis was 1.0 y (PAC) and 1.6 y
(BAT). Median baseline spleen volumes were 2006 cm3(PAC) and 2153 cm3
(BAT) and TSSs were 20 (PAC) and 23 (BAT).Estimated median duration of
treatment was 16.2 mo (PAC) and 5.9 mo (BAT). SVR rates at WK24 were
19% for PAC vs 5% for BAT (p=0.0003) in intent-to-treat (ITT) and 25% vs 6%
(p=0.0001) in pts evaluable at baseline and WK24 (figure). Progressive dis-
ease was not required for crossover after week 24. 79% of BAT pts crossed
over to PAC (median 27 weeks). TSS (V1+V2) response rates were 25% for
PAC vs 7% for BAT (p<0.0001) by ITT, and 41% vs 10% in evaluable pts
(p<0.0001). Patient Global Impression of Change improvement on PAC (81%)
was significantly higher than on BAT (21%) in evaluable pts (p<0.001). PAC
significantly improved SVR rates irrespective of baseline plt counts. In pts with
<100,000 and <50,000 plt/μL, SVR rates were 17% for PAC vs 0% for BAT
(p=0.009), and 23% vs 0% (p=0.045) by ITT, respectively, and 24% vs 0%
(p=0.007) and 33% vs 0% (p=0.037) in evaluable pts, respectively. In baseline
RBC transfusion-dependent pts (PAC: 35, BAT: 15), 26% of PAC pts became
RBC transfusion independent vs 0% of BAT pts (p=0.043). The most common
adverse events (AEs) through WK24 for PAC were gastrointestinal (GI): diar-
rhea, nausea, and vomiting. Grade (Gr) 3 GI AEs rates were 5%, <1%, and
<1% respectively (no Gr 4). Gr 3-4 hematologic AEs occurring in >2% were
similar for PAC vs BAT: anemia (17% vs 15%) and thrombocytopenia (12% vs
9%). PAC AEs were similar in thrombocytopenic and non-thrombocytopenic
pts. 90% of PAC pts did not require any dose reduction. AEs leading to dose
reduction included diarrhea (3%) and anemia (2%). Dose interruptions
occurred in 22% (median duration 7 days) with 6% due to diarrhea, 3% throm-
bocytopenia, and 2% anemia.
Summary and Conclusions: PAC dosed 400mg once daily was well tolerated
with minimal dose modifications and induced clinically and statistically signifi-
cant and meaningful SVR and meaningful symptom control even in pts with
severe thrombocytopenia. PAC therapy also resulted in RBC transfusion inde-
pendence in a significant proportion of pts.
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DYNAMIC ROLE OF THE IRF4-PU.1 AXIS IN IBRUTINIB-RESISTANT
WALDENSTRÖMS MACROGLOBULINEMIA
K. Chitta1,* A. Paulus1, S. Akhtar1, M. Kuranz-Blake1, A. Novak2, S. Ansell2,
M. Gertz2, R. kyle2, C. Rivera1, V. Roy1, J. Foran1, P. Martin3, M. Coleman3,
T. Sher1, S. Ailawadhi1, A. Chanan-Khan1
1Mayo Clinic, Jacksonville, 2Mayo Clinic, Rochester, 3Weill Cornell Medical
Colleage, New York, United States
Background: Waldenströms macroglobulinemia (WM) is a rare and incurable
non-Hodgkin’s B-cell lymphoma that is defined by lymphoplasmacytic infiltration
of the bone marrow and lymphoid tissue with increased monoclonal IgM protein
production. Aberrant activation of B-cell receptor (BCR) signaling, results in neo-
plastic transformation of B-lymphocytes. Recent investigations using small mol-
ecule inhibitors have validated Bruton’s tyrosine kinase (BTK), one of the com-
ponents of the BCR signaling hub, to be a druggable target. Ibrutinib (PCI-
32765), an irreversible BTK inhibitor has shown clinical efficacy in CLL, mantle
cell lymphoma (MCL) and Waldenströms macroglobulinemia (WM). Ibrutinib
binds to cysteine-481 of the BTK protein and blocks its phosphorylation, resulting
in termination of BCR-mediated activation of cells, leading to tumor cell death.
Despite the clinical success of ibrutinib, WM patients achieve only partial
response and invariably acquire resistance to the drug, resulting in aggressive
relapse of the disease. A mutation of Cys481-Ser in BTK (ibrutinib-BTK binding
site) has been reported to be one of the reasons for the development of ibrutinib
resistance (IR). To understand the mechanisms resulting in acquisition of IR,
we established and characterized several models of IR-WM.
Aims: To evaluate the significance of IRF4-PU.1 axis in the development of
ibrutinib resistance
Methods: Ibrutinib was obtained from Pharmacyclics, CA. Validated human
WM models (BCWM.1, RPCI-WM1 and MWCL.1 cell lines) were used for the
study. shIRF4 clones of WM cell lines. qRTPCR, Western blotting, MTS assay,
Flow cytometry.
Results: Exposure of WM models for prolonged periods of time with progres-
sively increasing concentrations of ibrutinib resulted in outgrowth of IR tumor
clones. IR cells displayed 2-20 fold resistance to ibrutinib compared to their
respective parental cell lines as determined by MTS assay. Sequence analysis
of the BTK gene in all the IR cell lines revealed no mutation at Cys481 suggest-
ing that in an acquired IR state, resistance to ibrutinib can be developed inde-
pendent of BTK Cys481 mutation. BTK was constitutively phosphorylated at
Y223 and Y551 in all the cell lines tested and this was inhibited by ibrutinib at a
concentration as low as 1mM. Phosphorylation of other kinases in the cascade
such as SYK (Y323 and Y525/526) and PLCg2 (Y759 and Y1217) were also inhib-
ited while AKT phosphorylation at both Ser473 and Thr308 was consistently
increased in presence of ibrutinib. Interestingly, we found p-BTK levels to be
markedly reduced in IR cells. Ibrutinib reversal experiments suggested that
while continuous presence of ibrutinib was needed for the inhibition of BTK
phosphorylation, a stable IR state was maintained for ≥1 month with no loss of
cell viability upon reintroduction of ibrutinib, suggesting the cells reliance on a
parallel survival pathway, independent of BTK phosphorylation. Focused mRNA
(Nanostring nCounter assay) and immunoblot analysis revealed significant
changes in the expression profiles of several cellular elements. These included
transcription factors such as PU.1, IRF4, STAT1 and 3 suggesting a repro-
gramming of critical cellular networks, with IRF4 emerging as central in IR cells,
indicated by altered expression of its downstream targets. We assessed the
significance of IRF4 in IR cells by silencing IRF4 expression through IRF4-
shRNA. The results indicated that down regulation of IRF4 by itself has minimal
effect on ibrutinib sensitivity of IR cells. However, treatment of WM cells with
all trans retinoic acid (ATRA), which is known to upregulate PU.1, induced dose
dependent cytotoxicity in these cells suggesting involvement of PU.1 (and its
shifting partnership with IRF4) in ibrutinib-resistance.
Summary and Conclusions: Here we demonstrate that in the absence of
BTK Cys481 (ibrutinib binding site) mutation, an IR state is associated with
reprogramming of transcriptional networks to overcome ibrutinib-induced tox-
icity. Moreover, this results in activation of parallel survival pathways directed
by an altered IRF4-PU.1 axis, which is associated with sensitivity of WM cells
to Ibrutinib.
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KDM5 INHIBITION LEADS TO INCREASED H3K4ME3 LEVELS AND CELL
DEATH IN GERMINAL CENTRE LYMPHOMA CELL LINES INDEPENDENT
OF MLL2 MUTATION STATUS 
L. Koniali1,* J. Heward1, C. Loveday1, L. Wilkins1, M. Ishfaq2, J. Wang1,
J. Okosun1, G. Packham2, J. Fitzgibbon1
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University
of London, London, 2Cancer Sciences Unit, University of Southampton Faculty
of Medicin, Southampton, United Kingdom
Background: Follicular lymphoma (FL) and the germinal centre B-cell (GCB)
subtype of diffuse large B cell lymphoma (GCB-DLBCL) account for nearly 40-
50% of cases of Non-Hodgkin lymphomas (NHL). Whole exome and targeted
resequencing studies demonstrated an epigenetic addiction in these germinal
centre lymphomas with many biopsies harbouring mutations in histone methyl
(MLL2, EZH2) and acetyltransferases (CREBBP). Loss of function mutations
in MLL2 (also referred to as KMT2D) are detected in >30% of GCB-DLBCL
and 90% of FL cases and are expected to lead to a reduction in levels of the
chromatin mark H3K4me3 (histone 3 lysine 4 trimethylation), which is associ-
ated with active transcription. We therefore set out to assess whether stabilising
this H3K4me3 mark, by directly targeting the KDM5 family of H3K4me3
demethylases (KDM5A/B/C/D), offers a means to ameliorate the effects of
these mutations and provide a rationale for a therapeutic opportunity.
Aims: EpiTherapeutics have developed a specific inhibitor against the KDM5
family of demethylases (EPT001). The aim of this study was to determine the
potency of KDM5 inhibition in GCB-DLBCL lymphoma cell lines based on their
MLL2 mutation status and restoration of H3K4me3 levels.
Methods: The mutational profile of 10 GCB-DLBCL cell lines was characterised
via targeted deep sequencing, using Fluidigm-MiSeq and further validated by
Sanger sequencing. Expression of the KDM5 isoforms and downstream targets
of KDM5 were assessed by qRT-PCR. Cell lines were exposed to increasing
concentrations of EPT001 and cell proliferation and apoptosis were assessed
using the Guava EasyCyte Plus system. In parallel, cell cycle analysis was
performed by propidium iodide staining and flow cytometry. Immunoblotting
was used to establish the effect of treatment on a range of epigenetic histone
marks (H3K4me1/2/3, H3K27me3/Ac, and H3k36me2). 
Results: MLL2 mutations were detected in 6 of the 10 cell lines tested. All 4
KDM5 isoforms (A-D) are expressed in these cell lines with a predominance of
A and C. Exposure to EP1001 in all 10 lines resulted in a concentration depend-
ent increase in global H3K4me3 (range 1.4-4.8 fold at 48 hrs). Of note, elevation
of H3K4me3 was independent of MLL2 mutation status. A striking reduction in
proliferation and an induction of apoptosis were observed in 2 cell lines (SU-
DHL-6, OCI-LY-18) both at low nanomolar concentrations (GIC50: <5nM) and
this was accompanied by a concentration dependent accumulation of cells in
the G1/S-phase and a concomitant loss of G2/M phase. Treatment did not
result in any measurable differences in expression of established KDM5 targets
as assessed by qRT-PCR.
Summary and Conclusions: Inhibition of KDM5 family of demethylases is
sufficient to induce cell cycle arrest and induction of apoptosis in at least some
GCB-DLBCL cell lines. This appears independent of MLL2 mutation status
even in cell lines harbouring homozygous mutations. RNA-seq and ChIP-seq
are in progress to assess changes in gene expression that accompany KDM5
inhibition and H3K4me3 elevation in sensitive and resistant cell lines. 
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MICRORNA 203 CONTROLS T-CELL LYMPHOMAGENESIS BY TARGETING
IL-2 RECEPTOR SIGNALING
U. Ralfkiaer1,* M. Jansson2, K. Kopp3, A. Willerslev-Olsen3, F. Asmar1,
T. Krejsgaard3, P. Brown1, R. Gniadecki4, A. Woetmann3, A. Lund2, N. Odum3,
K. Gronbaek1
1Hematology, Copenhagen University Hospital, 2Centre for Epigenetics,
Biotech Research and Innovation Centre, University of Copenhagen, 3Inter-
national Health, Immunology and Microbiology, University of Copenhagen,
4Dermatology, Copenhagen University Hospital, Copenhagen, Denmark
Background: The pathogenesis of primary cutaneous T-cell lymphoma (CTCL)
is poorly understood, and early CTCL lesions are difficult to diagnose. We have
previously identified and validated a 3 microRNA (miR) classifier (miR-155, miR-
203 and miR-205), which can separate CTCL from benign inflammatory skin
disorders with >95% accuracy. Subsequently, we showed that miR-155
enhances proliferation and is induced by STAT5a. MiR-203 has been shown to
repress stemness during normal keratinocyte differentiation, and in solid tumors,
miR-203 has been shown to be silenced by promoter hypermethylation.
Aims: The role of miR-203 in CTCL pathogenesis has not previously been
described, however since miR-203 down regulation is a hall mark of CTCL,we
have investigated the transcriptional regulation and function of miR-203 in pri-
mary CTCL biopsies and cell lines.
Methods: Two IL-2 independent CTCL cell lines (MyLa2059 and PDB2B), and
two IL-2 dependent CTCL cell lines (SeAx and SeZ4) were analyzed in this
study. In addition, biopsies from 21 primary CTCL (Mycosis Fungides (MF),
Sezary syndrome, cutaneous T-cell lymphoma, NOS, and cutaneous anaplastic
large cell lymphoma) from 21 patients were included. Promoter hypermethyla-
tion of miR-203 was studied by methylation specific melting curve analysis,
and miR-203 expression by RT-qPCR. CTCL cell lines were treated by
hypomethylating agents (HMAs), and were transfected with miR-203 mimic or
non-template-control by electroporation. Proliferation was measured by 3H-
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Thymidine and apoptosis by MMT assays. Cells transfected with miR-203 mimic
and non-template-control were examined by Affymetrix RNA expression arrays
(GeneChip Human Gene 2.0 ST). Cloning was done according to the manu-
facturers’ recommendation and luciferase reporter assays were performed
using the Dual-Glo system (Promega). Protein levels were analyzed by flow
cytometry.
Results: We found that a member of our CTCL classifier, miR-203, is epige-
netically silenced by DNA methylation in all examined CTCL cell lines and in 9
of 21 (43%) of primary CTCL samples. MiR-203 expression can be up-regulated
by HMAs in vitro, and induction of miR-203 reduces cell viability and decreases
cell proliferation. Affymmetrix array analysis of miR-203 mimic vs non-template-
control cells identified 19 significantly differentially expressed genes (P<0.5/log
fold change>2), including the novel miR-203 target molecule IL2RB, which is
essential for IL-2 induced JAK/STAT signaling. QPCR and FACS analysis con-
firmed this up-regulation both at the mRNA and protein level. The IL-2 depend-
ent cell line SeAx showed significantly more profound down-regulation of IL2RB
in miR-203 transfected cell lines. Luciferase reporter assays of a construct con-
taining the IL2RB 3’ untranslated region confirm that IL2RB expression is reg-
ulated by miR-203. Thus, we suggest that targeted down regulation of miR-
203 in CTCL promotes IL-2/STAT driven T-cell lymphomagenesis
Summary and Conclusions: We provide the first evidence that miR-203 is an
epigenetically silenced tumor suppressor in primary CTCL, including early MF
lesions. Our functional studies show that miR-203 keeps the level of IL2RB in
check. Thus, we suggest that epigenetic down-regulation of miR-203 and IL2RB
up-regulation are important early and driving events in CTCL pathogenesis.
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ANALYSIS OF MECHANISMS OF MALIGNANT TRANSFORMATION IN
TP53 WILD-TYPE BURKITT´S LYMPHOMA BY INTEGRATION OF
MOLECULAR AND FUNCTIONAL GENOMICS DATA
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Background: Burkitt´s lymphoma (BL) is an aggressive mature B-cell lym-
phoma. The hallmark genetic lesion of BL is a translocation of the MYC gene
to an IG-locus. In addition, recent studies identified recurrent mutations of TCF3
and ID3 in a large proportion of BL. Oncogenic activation of MYC promotes
cell growth, but also activates a stress response via the TP53 pathway. Similarly,
aberrant mitogenic signaling induces oncogene-induced senescence. There-
fore, all BL depend on cooperating lesions that promote survival and cell growth.
Up to 50% of BL carry mutations in the tumor suppressor p53 leading to an
impaired response to the stress signals from oncogene activation. In the pres-
ence of functional TP53alternative mechanisms of TP53inactivation are fre-
quently observed in cancer, including loss of p14ARF locus or overexpression
of the main p53 inhibitors, MDM2 or MDM4. In BL, aberrations in the p53-path-
way have not been systematically investigated and their role in the pathogen-
esis of MYC-driven lymphoma is not known.
Aims: Our aim was to identify driver lesions specific to BL without TP53 muta-
tion promoting tumor survival and growth.
Methods: We analyzed differential copy number changes (CNA) and gene
expression in 67 BL and 205 diffuse large B cell lymphoma (DLBCL) from the
Molecular Mechanisms of Malignant Lymphoma (MMML) consortium according
to their TP53 mutation status. For an unbiased functional analysis, we per-
formed an RNAi drop-out screen on a panel of representative BL cell lines
(n=8) with defined genetic background.
Results: In order to identify TP53-dependent viability genes, we chose 4 BL
cell lines that carry mutations in TP53 and show impaired p53 pathway
response and 4 cell lines with wild-type TP53 and an intact p53 pathway. These
cells were infected with a pooled shRNA library targeting ~5000 genes with 5-
6 shRNAs per gene. Toxic shRNAs were identified by comparison of the shRNA
counts on day 2 and day 14 after infection as determined by high-throughput
sequencing (Figure 1A). As expected, shRNAs targeting common viability
genes as ribosomal and proteasomal proteins showed the strongest depletion
in all cell lines. We identified 81 genes that showed increased toxicity in cell
lines with wild-type TP53 (Figure 1B) and 88 genes that were significantly
enriched for toxicity in mutant TP53 cell lines. The strongest genes classifying
wild-type TP53 were involved in the p53 pathway and cell cycle control. Inte-
gration of our RNAi viability data with CNA and gene expression analysis from
BL patients showed, that the gene with the highest p53-dependent toxicity was
located within a minimally gained region associated with wild-type TP53
patients. Validation studies confirmed the p53-dependent cytotoxicity in single
gene knock-down experiments and demonstrated that toxicity was caused by
strong cell cycle arrest (Figure 1C).
Figure 1.
Summary and Conclusions: BL is known to be driven by the oncogene MYC
and mitogenic signaling. Cooperating lesions as mutation of TP53 are needed
to escape oncogene-driven apoptosis and senescence. In the presence of func-
tional p53, we identified an alternative disease driver in BL with wild-type TP53
controlling cell cycle progression, which may be exploited therapeutically.
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COMBINED 3D IMMUNO-FISH ANALYSIS OF PRIMARY HODGKIN (H) AND
REED-STERNBERG (RS) CELLS REVEALS DISRUPTION OF TELOMERE-TRF2
INTERACTION AND IDENTIFIES HODGKIN’S LYMPHOMA SHELTERIN
ASSOCIATED DISEASE
H. Knecht1,* N. Johnson1, T. Haliotis2, D. Lichtensztejn3, S. Mai3
1Medicine, 2Pathology, Jewish General Hospital, McGill University, Montréal,
3Cell Biology, University of Manitoba, Winnipeg, Canada
Background: In Hodgkin’s lymphoma (HL) derived H-cell lines the transition
from H-to RS-cells is associated with progression of 3D telomere dysfunction,
major changes in the telomere protecting shelterin complex, chromosomal
rearrangements and formation of giant “zebra” chromosomes. Analogous find-
ings are observed in a post-germinal center B-cell in vitro model for Epstein-
Barr-virus (EBV)-associated HL. In this experimental system the EBV encoded
oncogene LMP1, also expressed in EBV-associated HL, mediates multi-
nuclearity through downregulation of TRF2. (Blood 2015 Jan 7.[Epub ahead of
print]). Thus, the 3D interaction of telomeres and TRF2 appears to be primordial
in the formation of H-and RS-cells.
Aims: Our previous findings obtained with H-cell lines and diagnostic, deparaf-
fined lymph node biopsy slides were consistent with a shelterin-associated
pathogenesis of HL (reviewed in Cancers 2013, 5:714). These findings were
reinforced by our recent in vitro model for EBV-associated HL. The aim of the
present investigation is to test our results and hypothesis on primary H-and
RS-cells allowing the 3D analysis of the entire nuclear content.
Figure 1.
Methods: Combined TRF2-Telomere 3D immuno-FISH analysis (Blood 2015
Jan 7. data supplement) was performed on cultured BJ-5ta normal diploid
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fibroblasts and B-cell rich suspensions (negative selection) of diagnostic lymph
nodes for HL, cultured for 24-36 hours after thawing. Quality of H-and RS-cells
was assessed by Wright-Giemsa staining. Lymphocytes, H-and RS-cells of six
classical HL were analyzed, one of them with LMP1 positive tumor cells.
Results: Whereas all BJ-5ta normal diploid control fibroblasts and many lym-
phocytes showed an intact 1:1 quantitative and qualitative tight 3D interaction
of TRF2-Telomeres, with mainly mid-to large-sized telomeres, H-cells displayed
a variable pattern of disruption of steric interaction ranging from few to many
TRF2-deprotected and often short telomeres. These changes were more pro-
nounced in RS-cells. By far the most important loss of TRF2 expression, grad-
ually progressing from H-to RS-cells, was identified in the LMP1-expressing
case. In one further case of clinically aggressive disease, some lymphocytes
had already lost TRF2 signals. In this case huge multinucleated RS “ghost”
cells without any telomeres but inter-nuclear DNA-bridges (image) were
observed. Interestingly, in these RS cells TRF2 was still identified. In a third
case bi-nucleated RS-cells with grossly different nuclear telomere content of
nucleus one and nucleus two were present.
Summary and Conclusions: The 3D TRF2-Telomere interaction is disrupted
in primary H-and RS-cells and this process starts in B-lymphocytes. The iden-
tified changes are major and analogous to those of the telomere-shelterin com-
plex reported in H-and RS-cells of H-cell lines. Advanced TRF2-associated
telomere deprotection is observed in EBV-associated HL and confirms the
hypothesis of our in vitro model for EBV-associated HL. The unique 3D cyto-
logical appearance and behavior of H-and RS-cells is best explained by the
designation of HL as a shelterin associated disease. The telomere-shelterin
complex is a “plaque tournante” in the pathogenesis of HL and a potential ther-
apeutic target.
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A NOVEL ULTRA-DEEP SEQUENCING METHOD FOR TRACKING OF
DRIVER MUTATIONS IDENTIFIES THE MYD88 L265P MUTATION IN EARLY
HAEMOPOIETIC PRECURSORS IN DIFFUSE LARGE B CELL LYMPHOMA
Y. Jeelall1, A. Ziolkowski2, D. Andrews3, M. Field3, S. Jain4, C. Goodnow3,
M. Cook3, D. Talaulikar25,*
1Australian National University, 2Haematology, Canberra Hospital, 3John Curtin
School of Medical research, Australian National University, 4Anatomical Pathol-
ogy, Canberra Hospital, 5Haematology, Australian National University, Canber-
ra, Australia
Background: Activated B cell diffuse large B-cell lymphoma (ABC-DLBCL) is
characterised by a poorer clinical outcome compared to patients with germinal
centre (GC-DLBCL) with >50% patients failing standard first line chemo-
immunotherapy. The NFkappaB signature is upregulated in patients with ABC-
DLBCL with gain-of-function somatic mutations identified in genes involved in
this pathway including the MYD88 gene. However, the exact point in ontogeny
at which this mutation arises is not known.
Aims: We investigated the cellular origin of the MYD88 L265P mutation using
a novel ultra-deep sequencing assay as the presence of somatic mutations in
earlier haemopoietic precursors could potentially account for treatment failure
and act as a reservoir for future relapses.
Methods: We identified an initial cohort of 46 DLBCL samples from the ACT
Haematology Research Tissue Bank and screened them for somatic mutations
using a custom next-generation sequencing approach. A Haloplex custom
library preparation kit was used to develop an automated library and samples
were sequenced using the MiSeq and HiSeq2500. We identified 5 patients
with MYD88 L265P mutations. For each case, we then performed bulk cell
sorting on 3 non-clonal populations-T cells characterised by CD3 expression,
myeloid cells characterised by CD13/CD33 expression and non-clonal B cells
with the opposite light chain to that expressed by the lymphoma clone. For all
cases, single cell sorting and whole genome amplification was also performed.
An ultra-deep sequencing assay was developed based on Kinde’s approach
to screen for rare cells bearing somatic mutations amongst normal non-clonal
populations[Kinde et al,Proc Natl Acad Sci U S A,2011 Jun 7;108(23):9530-5].
By the addition of nucleotide barcodes in forward and reverse primers during
the PCR amplification process, we have eliminated processing and sequencing
errors, and have developed an assay capable of identifying very low numbers
of non-lymphoma cells with gain-of-function MYD88 mutations (~ 0.001%)-cell
line titration experiments.
Results: We have tested the assay on5 cases presenting with ABC DLBCL
heterozygous for the MYD88 L265P mutation. In 3 cases, the MYD88 mutation
was limited to the clonal population; it was not identified in bulk sorted non-
clonal B cells, T cells or myeloid cells. In the remaining 2 cases, the mutation
was identified in non-clonal B-cells and T cells but not in myeloid cells. Whole
genome amplificationfrom non-clonal single B-cells in both cases was subjected
to Sanger sequencing for MYD88 and IgHV.This analysisconfirmed thatnon-
clonal B cells lacking expression of the lymphoma specific IgHV (IgHV 4-39*01)
were heterozygous for the MYD88 mutation,indicating thepresence of the muta-
tion in early precursors. We postulate that the MYD88 mutation arises in the
CD20 negative common lymphoid progenitor pool in 2 casesfrom our cohort
but is limited to the lymphoma clone in others.
Summary and Conclusions: Varying cellular origin of the MYD88 L265P
mutation may account for some of the disease heterogeneity seen in MYD88-
driven DLBCLs. Further, early origin of MYD88 L265P driver mutation in CD20
nagetive early precursors is a likely cause of treatment failure with Rituximab.
Such cases may potentially respond better to Ibrutinib as the bruton’s tyrosaine
kinase is expressed in CD20 nagteive B-cell precursors.
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TRANSLOCATIONS AND CLONALITY DETECTION IN
LYMPHOPROLIFERATIVE DISORDERS BY CAPTURE-BASED
NEXT-GENERATION SEQUENCING. A PILOT STUDY BY THE
EUROCLONALITY-NGS CONSORTIUM
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Background: Detection and characterization of clonal IG/TR rearrangements
and translocations in lymphoproliferative neoplasms provides critical informa-
tion in the diagnostic pathway in several clinical scenarios and is a valuable
tool to address research questions around B and T cells. This includes ascer-
taining the clonal nature of lymphoid proliferations, characterization of translo-
cations in lymphomas and leukemias, characterization of CDR3 regions for
MRD target identification and stereotyping analysis, amongst others. Until now,
collecting this information required a combination of different methodologies,
such as Gene-scanning/heteroduplex analysis, FISH and Sanger sequencing.
Aims: This is a pilot study to assess the feasibility of a comprehensive IG and
TRgenes NGS protocol to detect IG and TR rearrangements in lymphoprolif-
erative disorders as a new tool for clonality diagnosis. Additionally, the pilot
aims to assess the feasibility of discovering novel translocation partners in lym-
phoma and leukemia patients, potentially leading to more accurate diagnostic
classification and novel therapeutic options.
Methods: As part of the EuroClonality-NGS consortium, we have designed a
capture-based protocol covering the coding V, D and J genes of the IG/TR
regions, as well as switch regions in the IGH locus. The assay uses Nimblegen
(Roche Molecular Systems) capture baits spanning a total of 180kb and the
products are analyzed on a MiSeq Illumina sequencer and MiSeq v3 sequenc-
ing chemistry with 2 x 120bp pair-end reads. This design allows the identifica-
tion of D-J and V(D)J rearrangements as well as chromosomal translocations
involving IG/TR genes by Next-generation sequencing (NGS). We piloted this
approach for clonality and translocation detection in a cohort of 21 peripheral
blood, bone marrow and fresh-frozen samples (3 precursor B-cell acute lym-
phoblastic leukemias [B-ALL], 4 Burkitt lymphoma [BL], 5 chronic lymphocytic
leukemias [CLL], 2 splenic marginal zone lymphomas [SMZL], 2 diffuse large
B cell lymphomas [DLBCL], 2 follicular lymphomas [FL], 2 precursor T-cell lym-
phoblastic leukemias [T-ALL] and 1 T-cell non-Hodgkin lymphoma [T-HNL])
with well-characterized translocations by FISH/Karyotype and/or clonal
rearrangements by PCR and Sanger sequencing.
Results: We were able to detect the described IG/TR translocation in 18/21
samples, including translocations into the J, D and switch regions of the IG/TR
genes. Three samples failed to produce results, two concerned fresh-frozen
lymphomas with low quality DNA, and one concerned a technical error in a B-
ALL case. The translocation partner and the breakpoint was identified in 15/18
evaluable cases, including CRLF2, MYC, BCL11A, BCL2, CCND3, IRF4,
BCL11B, and TLX1. In three cases with only karyotyping data available, a
translocation involving the IGH locus was identified with no clear leukemia/lym-
phoma-related genes in the neighboring regions of the reciprocal chromosome,
suggesting the potential for new translocation partners and/or mechanism of
disease. In all 14 samples with well-characterized D-J/V(D)J rearrangements
by PCR and sequencing, NGS was able to detect the same rearrangements.
These included IGH and IGK/IGL rearrangements in B-cell proliferations and
TRB, TRG and TRD in T-cell proliferations. Additionally, aberrant clonal
rearrangements were seen that were not detected with conventional PCR-
based approaches (e.g. IGKV to IGK intron).
Summary and Conclusions: The EuroClonality NGS IG/TR capture-based
approach is a promising tool for the simultaneous detection and characteriza-
tion of IG/TR translocation and rearrangements in a clinical setting. A formal
pan-European validation study is underway within the EuroClonality-NGS con-
sortium.
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MORAXELLA CATARRHALIS-A BACTERIAL INVOLVEMENT IN THE
ORIGIN OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN
LYMPHOMA OF IGD TYPE? 
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Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
is a rare type of Hodgkin lymphoma. In contrast to Hodgkin-Reed-Sternberg
cells in classical Hodgkin lymphoma, lymphocyte predominant (LP) cells, the
tumor cells in nodular lymphocyte predominant Hodgkin lymphoma, show func-
tional variable region genes of immunoglobulins with ongoing somatic hyper-
mutation. Chronic B cell receptor (BCR) stimulation has been proposed to play
a central role in the pathogenesis of NLPHL. However, the mechanisms under-
lying this stimulation are poorly understood.
Aims: Aim of the study was to identify potential target antigens of B cell recep-
tors of LP cells, with emphasis on autoantigens and bacterial structures.
Methods: Recombinant Fabs were constructed of corresponding variable
region heavy and light chain genes from LP cells isolated by laser capture
microdissection from cryopreserved specimens.
Results: Fabs of 9 cases were constructed. When tested on a protein macroar-
ray derived from human fetal brain to detect autoantigenic structures as the
targets of the LP cell BCR, ribosomal protein S27a and pyruvate carboxylase
(PC) were identified as target antigens of two individual Fabs. When tested on
the lysates from 10 bacterial strains, the recombinant BCR of 2 additional
patients reacted with the lysate from Moraxella catarrhalis (MC), a common
bacterium colonizing the upper respiratory tract, which expresses a 200 kD
IgD-binding protein (MID/hag) enabling MC to bind to the Fc part of IgD and
thus activate IgD carrying B-cells. Interestingly, the BCRs of the two patients
reactive with MC were derived from LP cells of IgD+ NLPHL, which are known
to represent a peculiar clinical subgroup of NLPHL, affecting the cervical lymph
nodes of young people (median age: 21 years) with a strong male predomi-
nance (23:1). Analysis of additional IgD+ NLPHL cases revealed that the LP
cell BCR of 4/5 IgD+ NLPHL cases reacted specifically with the DNA-directed
RNA polymerase subunit beta’ of MC (rpoC), a protein of 155 kD. Serum was
available from 1 patient with rpoC-specific LP cell-BCR and was shown to con-
tain polyclonal antibodies reactive against rpoC.
Summary and Conclusions: This study shows an association between MC
and IgD+ NLPHL, suggesting a causal role of MC in the pathogenesis of IgD+
NLPHL. MC is capable of binding to the Fc fragment of LP-BCR of the IgD type
via its IgD-binding domain and can mediate chronic antigenic stimulation of B-
cells with specificity of MC-rpoC. The presence of polyclonal serum antibodies
against MC-rpoC in patients with IgD+ NLPHL suggests that NLPHL is the
result of a clonal evolution from a polyclonal B-cell response against MC-rpoC.
Our findings are fundamental for the understanding of the pathogenesis of this
peculiar clinical subtype of NLPHL and might have relevance for the prophylaxis
and treatment of this disease.
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COMBINED CHEMOIMMUNOTHERAPY (R-CVP) IS AN EFFECTIVE TREAT-
MENT FOR HIV-NEGATIVE, HHV-8 POSITIVE PATIENTS WITH
MULTICENTRIC CASTLEMAN’S DISEASE 
A. Fragasso1,* C. Mannarella1, A. Ciancio1, O. Scarciolla1
1UO Ematologia Matera, Matera, Italy
Background: Castleman disease is a rare and heterogeneous lymphoprolifer-
ative disorder: the unicentric type includes hyaline vascular and plasma cell
variants, while the multicentric disease (MCD) is predominantly of the plasma
cell or mixed variant. The aetiology is poorly understood; the potential roles of
HHV-8 are suggested in several studies. MCD is also associated with HIV infec-
tion. No standard treatment has been established for MCD patients: steroids,
chemotherapy, rituximab, thalidomide, bortezomib, antiviral therapy, and IL-6
inhibitors have been used.
Aims: We have reported a complete hematologic remission and virologic
response to chemoimmunotherapy R-CVP in a HIV negative, HHV-8 positive
patient (Leukemia Lymphoma, 2008); in the following years we have treated
MCD patients with R-CVP in order to assess the effectiveness of this treatment.
Methods: Six HIV negative, HHV-8 positive patients (5 men, 1 woman, median
age 77 years, range 69-80 years) with MCD were diagnosed in our Hematology
Unit over a eight-year period. The patients’ characteristics are described in
Table 1. Five patients were initially treated by chemoimmunotherapy R-CVP
combination (cyclophosphamide 750mg/m2 on day 1, vincristine 2mg on day
1, prednisone 40mg/m2 per day orally on days 1 to 5, rituximab 375mg/m2 on
day 8 of the first cycle and then on day 1 of each cycle) every 3 week for 6-8
cycles. Patient n° 3 was initially diagnosed with a associated thrombotic throm-
bocytopenic purpura (TTP) and treated with steroids, plasma exchange and
rituximab.
Results: Four patients out of five, four completed the planned treatment. In
patient n°1 to clear residual disease (on immunofixation electrophoresis a per-
sistent monotypic IgG kappa was found) a maintenance treatment with rituximab
375mg/m2 once every 2 months for 4 cycles was made. In the 4 patients CT
scan and PET scan documented a complete remission (CR); the HHV-8 clearance
was also obtained. Patient n° 1 died after a 63 months follow up with a ischemic
cardiopathy. Patients n°4, n°5, n°6 are alive with a follow up respectively of 2, 1
and 62 months. Patient n° 2 initially refused treatment; 1 year later chemoim-
munotherapy was started because of the disease worsening with transfusion-
dependent anemia. After the first cycle this treatment was stopped for hematologic
toxicity. With his informed consent the patient was treated with bortezomib and
valganciclovir, but she died one month later with pseudomonas aeruginosa sep-
sis. Patient n° 3 obtained a partial remission with 9 plasma exchange and ritux-
imab, but refused further therapies and died one month later.
Tabella 1.
Summary and Conclusions: In HIV negative HHV-8 positive MCD patients
the illness can be fatal if not or lately treated. Chemoimmunotherapy is an effec-
tive treatment for these patients and is able to attain a clinical response with
associated undectectable HHV-8 viral load.
LB324
GENETIC ALTERATIONS OF IMPORTANCE FOR THE TRANSFORMATION
OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
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New Information: CGH array data was published at Genes Chromosomes
Cancer. 2014 Sep;53(9):750-68. New NGS data has never been submitted
before. None of these results has ever been submitted or presented at another
event. 
Background: Transformation of low malignant follicular lymphoma (FL) to the
more aggressive diffuse large B-cells lymphoma (DLBCL) has been associated
with new genetic events during the disease course. The number of recent evi-
dences suggests that mutations in several genes such as p53, EBF1, MYD88
are acquired during transformation. In studies of genomic copy number alter-
ations associated with transformation from FL to DLBCL, gains involving 2p,
12q13-14, 18q21, Xq as well as losses of 1p36, 6q, 17p were earlier described.
Aims: To identify further genetic alterations of importance for transformation
by analysis of sequential tumor samples from FL-DLBCL transformation using
array comparative genomic hybridization (array-CGH) and whole-exome
sequencing (WES).
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Methods: Material: 81 tumours from 60 patients í29 de novo DLBCL (dnDLB-
CL), 31 transformed DLBCL (tDLBCL), 21 concordant FL including 15 paired
tumours (FL and tDLBCL). Methods:Immunohistochemistry, 1 Mb array-CGH,
NGS Illumina HiSeq2000
Results: Using array-CGH, we identified a gain of 2p15-16.1 as a potential
prognostic marker of transformation as it was more commonly found in tDLBCL
in comparison with dnDLBCL (p<0,001). This chromosomal region encompass-
es, among others, genes involved in NFkB pathway such as REL, USP34,
COMMD1, OTX1, and of known importance for lymphomagenesis as BCL11A.
Notably, a high level amplification of 2p15-16 was also detected in FL prior to
transformation, indicating an early event of importance for this process. Fur-
thermore, we compared CGH-array data with WES results in a smaller group
of patients with available consecutive lymphoma samples and had access to
a multiple sample case with four subsequent FL (FL1-FL4) and two tDLBCL
(D1-D2) tumours. We focused on alterations appearing in the FL tumour just
prior to the DLBCL transformation i.e. FL4-D1, thus in the peri-transformation
phase. A number of mutations were identified affecting genes such as CHD4,
WDR33, FOXO4, PPP1R15B, DOCK4, SERPINI2, NPY5R, and MROH5. 
Summary and Conclusions: Having access to subsequent samples from
patients with consecutive FLs and tDLBCLs we were able outline the sequential
order of genetic alterations of importance for the transformation process. Using
array-CGH we found copy number changes that by WES were found to encom-
pass mutated genes, showing that these two methods complement and
strengthens each other in pinpointing crucial genetic events. Our studies
revealed that clonal evolution of transformed tumours occurs rather according
to branching than linear model.
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THE TYK2 PATHWAY AS A NOVEL THERAPEUTIC INTERVENTION SITE
IN AGGRESSIVE T-CELL LYMPHOMA
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Background: Anaplastic large cell lymphoma is a CD30 positive, aggressive
Non-Hodgkin T-cell lymphoma mainly affecting children or young adults.
Anaplastic lymphoma kinase (ALK) inhibition has shown remarkable success
in targeted therapy of non small cell lung cancer and in ALCL where ALK kinase
fusion proteins have initially been identified in 60% of ALCL patients (ALCL,
ALK+). However, treatment with ALK inhibitors inevitably leads to resistance
development. Moreover, the tumour drivers in ALK- ALCL remain still elusive
making the identification of new therapeutic targets an imperative.
Aims: We have recently identified Tyrosine kinase 2 (TYK2) fusion proteins in
the context of ALCL. Here we describe high expression of TYK2, a member of
the Janus kinase family (JAK1, JAK2, JAK3, TYK2) in human ALCL samples
and pathway dependence on TYK2 in all ALCL subtypes. By using TYK2 knock
down as well as TYK2 kinase inhibitors we demonstrate the therapeutic rele-
vance of our findings. 
Methods: TYK2 immunohistochemical stainings were performed in human
ALCL tissue microarrays (ALK+, ALK-). Lentiviral transduction mediated shRNA
knock-down of TYK2, JAK1 and STAT1 was performed in human ALCL cell
lines. Knock-down and activation of downstream targets was shown by Western
blot and IHC. Efficacy of JAK1 and TYK2 inhibitors (Bay-18, Symansis; TYK2_1
and JAK1_1, Genentech) was analysed by XTT and cell titer glow assays as
well as Western blot analysis. The in vivo relevance of TYK2 was assessed via
straight TYK2 knockout (TYK2 -/-) in a CD4-NPM-ALK ALCL mouse model.
Results: Tumor cell specific IHC staining revealed strong TYK2 expression in
both ALK+ and ALK- ALCL patient samples. ShRNA mediated TYK2 or JAK1
gene knockdown resulted in strong induction of apoptotic cell death. Analysis
of TYK2 downstream targets (STAT1, STAT3, STAT5) revealed distinct p-STAT1
reduction after small molecule TYK2 inhibition. Accordingly, shRNA mediated
gene knockdown of STAT1 revealed an essential function for ALCL cell survival.
Treatment with selective small-molecule inhibitors of TYK2 resulted in dramat-
ically reduced cell proliferation in ALCL cell lines but not in peripheral blood
mononuclear (PBMC) and JURKAT T-ALL control cell lines, suggesting novel
therapeutic options through TYK2-pathway inhibition in T-cell lymphomas.
TYK2 knockout in CD4-ALCL mice resulted in a complete rescue of the early
lethality phenotype.
Summary and Conclusions: Our results indicate a strong TYK2-pathway
dependence in ALCL (ALK+ and ALK-). We identified a novel therapeutic strat-
egy by taking advantage of recently developed small molecule inhibitors. Ongo-
ing in vivo experiments using CD4-NPM-ALK transgenic ALCL mice in which
TYK2 is conditionally knocked out in T-cells as well as treatment of patient
derived ALCL tumor cells with these inhibitors will systematically assess the
therapeutic potential of our findings.
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SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN
COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE
FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER’S SYNDROME
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Background: Transformation of Chronic Lymphocytic Leukaemia (CLL) to dif-
fuse large B cell lymphoma (DLBCL) (Richter’s syndrome, RS) is rare (2-15%)
(1–3) but associated with a very poor prognosis. Despite dose-intense
chemotherapy (4–8), little has improved outcomes, with the median overall sur-
vival (OS) remaining approximately 8 months. These regimens can also cause
significant toxicity. Patients are often elderly, immunosuppressed, and co-mor-
bid. Ofatumumab is a fully human anti-CD20 IgG1κ monoclonal antibody that
targets a B-cell epitope which is distinct from that targeted by rituximab. It dis-
plays increased binding affinity and a longer dissociation time compared to rit-
uximab, improving complement dependent cellular cytotoxicity (9,10); a mech-
anism with the potential to overcome apoptosis-resistance. Given the preva-
lence of TP53 disruption in RS (11), ofatumumab is a non-toxic agent with a
sound rationale to test (off label) with CHOP (CHOP-O).
Aims: To evaluate the safety, feasibility and activity of CHOP-O in induction
and maintenance for newly diagnosed RS. The primary objective was overall
response rate (ORR) according to standard criteria (12) after 6 cycles of CHOP-
O. Secondary objectives include progression free survival (PFS), OS, safety
and tolerability.
Methods: This single arm, multi-centre, non-randomised phase II NCRI feasi-
bility study recruited 43 patients with newly diagnosed RS across 10 UK centres.
Eligibility included: ≥18 years, PS 0-3, known or newly diagnosed CLL and
newly diagnosed, untreated RS. Eligible patients received CHOP-O for 6 cycles,
followed by 6 cycles of O-maintenance (8 weekly). The trial was run in accor-
dance with the Declaration of Helsinki. All patients gave informed consent. His-
tology results were reviewed locally for study inclusion to replicate ‘real life’,
and later for central review.
Results: Characteristics: 43 patients were recruited of which 36 patients are
currently evaluable (1 pending). Table 1 summarises in detail their main char-
acteristics. 73% were over 60 years, and most were male. Over half of patients
had received a fludarabine and cyclophosphamide based regimen as prior
treatment for CLL. Baseline PET CT was performed in 42% of enrolled patients,
with no clear change of scanning frequency occurring over recruitment.
Response: The ORR to induction was moderate. 66% responded (PR or CR)
after four cycles of CHOP-O, although this reduced to 44% ORR (CR 25%, PR
19%) at the end of induction. 17 patients started maintenance with 8 completing
maintenance, and 5 currently still continuing. The median PFS was just over
six months (95% confidence interval (CI) 4.87-14.96 months), with no clear
plateau on the survival curve. The current median OS was 11.4 months (95%
CI 6.38 months-NR), consistent with outcomes described in the literature using
R-CHOP and platinum-based regimens (6–8,13). Five patients received plat-
inum-containing salvage at progression, but none completed a stem cell trans-
plant. Safety: CHOP-O was typically well tolerated. 15 episodes of neutropenic
fever were reported and grade 3-4 neutropenia was noted on 14 occasions. 46
additional non-neutropenic infections were noted, of which 21 were serious
adverse events (SAE). A single SAE as the result of an ofatumumab-induced
infusion reaction was reported. There were no treatment related deaths. Further
Evaluation: The diagnostic tissue is currently undergoing further molecular
genetic testing, and central review analysis. This data will be presented along-
side an update on patient outcome. Within this study we also plan to prospec-
tively validate the two scoring systems devised in RS (1,7). Feasibility: This
was the first UK-wide prospective study in RS and is the largest ever prospec-
tive study performed to date. It therefore proves the feasibility of studying novel
combinations in a rare disease when national collaboration is successful. The
study was completed in 3.5 years, only just behind the predicted schedule. It
is important that further studies are performed in a collaborative manner to
study novel agents in this difficult-to-treat disease.
Tabella 1. Patient Characteristic at baseline
Summary and Conclusions: This study proved that it is feasible to perform
clinical trials in RS and answer important questions. It is likely that CHOP-O
does not considerably improve outcomes compared with R-CHOP in RS.
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A PHASE 1 TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL
INHIBITOR OF HDAC AND PI3K, IN PATIENTS WITH REFRACTORY OR
RELAPSED LYMPHOMA AND MULTIPLE MYELOMA
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Background: The importance of histone deacetylase (HDAC) and phos-
phatidylinositol 3-kinase (PI3K) pathways in lymphoma coupled with anti-tumor
synergy observed in preclinical studies by concurrent inhibition of both enzymes
support clinical testing of CUDC-907, an oral inhibitor of class I and II HDAC
as well as class I PI3K enzymes. Anti-tumor effects of CUDC-907 have been
demonstrated in cultured cells and xenograft models of B-cell lymphoma and
multiple myeloma via inhibition of PI3K/AKT, JAK/STAT and MAPK pathways
as well as modification of the tumor microenvironment.
Aims: The primary objective of this ongoing trial is to determine the maximum
tolerated dose (MTD) or biologically effective dose (BED) and recommended
Phase 2 dose (RP2D) of CUDC-907 in subjects with relapsed/refractory (RR)
lymphoma and multiple myeloma (MM). The secondary objectives are to assess
the safety and tolerability, pharmacokinetics, biomarker activity, and preliminary
anti-cancer activity of CUDC-907.
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Methods: This first-in-human trial used a standard Phase 1 3+3 design to
examine CUDC-907 in patients with RR lymphoma or MM. CUDC-907 was
orally administered using 3 different dosing schedules; once daily (QD), inter-
mittent twice (BIW) or thrice weekly (TIW), and five days on/two days off (5/2)
in 21-day cycles. Dosing started at 30 mg for the QD schedule and 60 mg for
the other schedules, escalating in 30 mg increments.
Results: 51 subjects received CUDC-907 up to a maximum of 60 mg for the
QD and 5/2 schedules and 150 mg for the intermittent schedules. Dose lim-
iting toxicities occurred in 3 subjects: G4 hyperglycemia and G3 diarrhea
(both in the same patient) at 60 mg QD, G3 hyperglycemia at 150 mg BIW
and G3 diarrhea at 150 mg TIW. The most common treatment-related adverse
events (AEs) were diarrhea (45%), fatigue (31%), nausea (20%) and throm-
bocytopenia (14%). The most common treatment-related AEs of Grade ≥3
intensity included thrombocytopenia (14%), neutropenia (4%) and diarrhea
(4%). Among 41 subjects evaluable for disease response, 4 objective
responses were observed: 1 subject with diffuse large B-cell lymphoma (DLB-
CL) achieved complete response (CR) in Cycle 2 (60 mg 5/2), 2 subjects
with transformed follicular lymphoma (t-FL/DLBCL) achieved partial response
(PR) in Cycles 4 and 26 (30 mg QD and 150 mg BIW, respectively), and 1
subject with DLBCL achieved PR in Cycle 4 (60 mg QD). To date, stable dis-
ease (SD) lasting for a median of 101 days (40-717) has been observed in
22 (54%) subjects including Hodgkin Lymphoma (HL) (n=9); DLBCL and t-
FL/DLBCL (n=3); and MM (n=3).
Figure 1.
Summary and Conclusions: The safety profile of CUDC-907 is similar to that
of other HDAC and PI3K inhibitors. Reversible gastrointestinal, hematologic,
endocrine and other AEs have been managed with standard interventions or
dose interruption. In this first-in-human trial, CUDC-907 has achieved objective
responses and durable disease control across multiple tumor types and dosing
schedules. MTD was not reached in the 5/2 schedule, which was selected for
expansion in patients with DLBCL and MM based upon CUDC-907’s toxicity
and efficacy profile across various schedules tested in this study population.
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A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY
B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR
(INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1
INHIBITOR (INCB039110)
T. Phillips1, A. Forero-Torres2, T. Sher3, C. Diefenbach4, M. Talpaz1,* P. Scherle5,
R. Schaub5, L. Zhou5, J. Pulini5, L. Leopold5, M. Spear5, P. Barr6
1University of Michigan, Ann Arbor, MI, 2University of Alabama at Birmingham,
Birmingham, AL, 3Mayo Clinic, Jacksonville, FL, 4New York University Perl-
mutter Cancer Center/New York University School of Medicine, New York, NY,
5Incyte Corporation, Wilmington, DE, 6University of Rochester Medical Center,
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Background: Inhibition of the PI3K and JAK-STAT pathways may be effica-
cious in B-cell malignancies because of their contribution to tumor growth and
survival both directly and through modulation of the tumor microenvironment.
Furthermore, inhibiting both pathways may result in synergistic efficacy due to
JAK-STAT augmentation of B-cell receptor activation of the NFκB pathway.
Aims: To determine the safety, efficacy, and pharmacodynamics of
INCB040093 alone or in combination with INCB039110 in patients with relapsed
or refractory B-cell malignancies.
Methods: Adults with relapsed/refractory B-cell malignancies were eligible for
this ongoing dose escalation study with expansion cohorts. Patients received
INCB040093 monotherapy (100 mg once daily, 100 mg twice daily, 150 mg
twice daily, or 300 mg once daily) or INCB040093 in combination with
INCB039110 (INCB040093: 150 mg daily, 100 mg twice daily, or 150 mg twice
daily; INCB039110: 400 mg or 600 mg once daily). Safety, efficacy, and phar-
macodynamics were evaluated.
Results: A total of 83 patients have been enrolled, including patients with fol-
licular lymphoma (n=19), classical Hodgkin lymphoma (cHL; n=17), diffuse
large B-cell lymphoma (DLBCL; n=15), chronic lymphocytic leukemia/small
lymphocytic lymphoma (n=13), and other subtypes (n=19). At baseline, the
median age was 61 years and 70% of patients were men. The median number
of prior regimens received was 4 and 24% of patients had undergone prior
hematopoietic stem cell transplantation. The median exposure during the study
was 185 days (range: 5–491+ [ongoing]) for INCB040093 alone and 99 days
(range: 6–337+ [ongoing]) for INCB040093 + INCB039110. The most common
adverse events were fatigue(28%), headache(19%), and pyrexia(19%) and
the most common grade ≥3 adverse event was pneumonia(6%). The most
common laboratory abnormalities were liver enzyme elevations and cytopenias.
One patient had a dose-limiting toxicity of gastrointestinal bleed secondary to
gastric DLBCL regression on INCB040093 100 mg twice daily. INCB040093
100 mg twice daily and INCB040093 100 mg twice daily + INCB039110 400
mg once daily were selected as the dosing regimens for expansion cohorts
based on the incidence of liver enzyme elevations with INCB040093 and
cytopenias with INCB040093 + INCB039110 at higher doses. At the selected
doses, pAKT was decreased by ≈90% at trough on INCB040093 and IL-6–
induced pSTAT3 was decreased an average of 65% on INCB039110. Of 75
evaluable patients, 28 responses have been reported. In evaluable patients
with cHL (n=15), the objective response rate was 60%, which included 3 com-
plete responses. Both patients enrolled with the non-germinal center B-cell–
like subtype of DLBCL experienced complete responses.
Summary and Conclusions: Treatment with INCB040093 alone or in combi-
nation with INCB039110 was tolerable and resulted in partial and complete
responses in this heavily pretreated population of patients with relapsed or
refractory B-cell malignancies. Based on these results, the study was expanded
to enroll additional cohorts of patients with relapsed/refractory B-cell malignan-
cies such as DLBCL and cHL, and a phase 2 study was initiated in patients
with relapsed/refractory cHL.
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UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE
SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND
HIGH-RISK CLL
M.A. Lunning1,* J.M. Vose1, N.H. Fowler2, L. Nastoupil2, J.A. Burger3,
W.G. Wierda3, M.T. Schreeder4, T. Siddiqi5, C.R. Flowers6, J.B. Cohen6,
S. Blumel1, M. Miguel2, E.K. Pauli4, K. Cutter4, B. Phye5, P. Sportelli7,
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de-Fonds, Switzerland, 9Incozen Therapeutics, Hyderabad, India, 10University
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Background: Ublituximab (UTX) is a novel anti-CD20 mAb that has been gly-
coengineered for enhanced ADCC. TGR-1202 is a novel once daily oral PI3Kδ
inhibitor with demonstrated clinical activity in B-cell lymphoma and notably
absent hepatotoxicity associated with similar agents. The combination of UTX
+ TGR-1202 showed strong synergistic activity in-vitro (Lugano 2013).
Aims: This Phase 1 trial evaluates the safety and efficacy of the combination
of UTX + TGR-1202 in patients with heavily pre-treated rel/ref NHL and CLL.
Methods: A 3+3 designwas utilized with rel/ref NHL and CLL patients accruing
independently. Informed consent was obtained on all patients. There were no
limits on number of type of prior therapies. Patients refractory to prior PI3K or
BTK inhibitorswere eligible. UTXwas administered D 1, 8, 15 of Cyc 1 & 2, fol-
lowed by D 1 of Cyc 4, 6, 9 & 12. TGR-1202was administered orally once-
daily. Primary endpoints: Safety and dose limiting toxicities (DLT). Secondary
endpoints: Efficacy (ORR, CR rate) with criteria as follows: CLL per Hallek
2008 and NHL per Cheson 2007.
Tabella 1.
Results: 37 patients were enrolled and evaluable for safety: 13 CLL/SLL, 12
FL, 9 DLBCL, 2 MZL and 1 Richter’s transformation. Med age 64 yo (range 29-
86); 24 M/13 F; median # prior treatment regimens =3 (range 1-9). Day 1 infu-
sion reactions (3% G 3/4), neutropenia (32% G 3/4), diarrhea (3% G 3/4) and
nausea (0% G 3/4) were the most commonly reported adverse events, regard-
less of causality. To date, TGR-1202-related hepatotoxicity has not been
observed. One DLT occurred: a patient with Gr 3 neutropenia at study entry
which worsened (cohort 1). A dose-response relationship was observed with
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TGR-1202; greater clinical activity was observed at higher doses. 29/37 were
evaluable for efficacy (7 too early and 1 was ineligible) with best response to
treatment as follows: To date, of the 29 patients evaluable for response, 87%
(13/15) in the higher dose cohorts remain progression-free compared to 43%
(6/14) in the lower dose cohorts. All but 1 of the CLL patients remain progres-
sion-free with a median follow up time of 9 months (range 2-12+ mos).
Summary and Conclusions: The chemotherapy free combination of UTX +
TGR-1202 is highly active and well tolerated in patients with both indolent and
aggressive rel/ref NHL and CLL. Dose escalation continues with enrollment
ongoing at the highest dose cohort and in recently opened expansion cohorts.
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BENDAMUSTINE COMBINED WITH RITUXIMAB (BR) IN ELDERLY FRAIL
PATIENTS WITH NEWLY DIAGNOSED DLBCL
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Background: Rituximab (R) in combination with cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP) is currently the most widely used
first-line therapy for Diffuse Large B-cell Lymphomas (DLBCL). However, many
patients, including elderly and/or frail patients, may not tolerate the toxicities
associated with this regimen. Recent data suggested that bendamustine plus
rituximab (BR) was superior in effectiveness and tolerability compared to R-
CHOP in the treatment of indolent and mantle cell lymphomas. Preliminary
data have shown a promising activity in DLBCL, both in the relapsing and
upfront setting.
Aims: We investigated the safety and efficacy of BR combination in elderly
patients affected by diffuse large B-cell lymphoma and defined as frail according
to CGA.
Methods: Eligible patients were elderly patients (>70 years) with a newly diag-
nosed DLBCL not suitable for R-CHOP-based chemotherapy. All patients were
evaluated by Comprehensive Geriatric Assessment (CGA) according to ADL,
IADL and CIRS-G and were considered FRAIL if the following criteria were
met: in patients aged 70-80 ADL<4 or IADL<5 or 1 grade 3 comorbidity or >8
grade 2 comorbidities; in patients older than 80 years ADL>5 or IADL>6 or 5-
8 grade 2 comorbidities. Patients received bendamustine at a dose of 90 mg/m2
daily on days 1 and 2 of each 28-day cycle along with rituximab on day 1 for
up to 6 cycles. The study evaluated the complete response rate (CRR), and
treatment safety. Secondary end points included progression free survival (PFS)
and overall survival (OS).
Results: From February 2012 to February 2014, 49 patients were enrolled in
24 Italian centers. The majority (both 59%) were male and stage III-IV. The
median age was 82. Overall, 83% (38) of the patients was older then 80 years
and at CGA evaluation showed unfavourable 3 (68%, 26), 2 (26%, 10), and 1
(5%, 2) criteria. 25 patients completed all planned cycles of chemotherapy. The
most frequent comorbidities were cardiovascular (37%) metabolic (11%) and
respiratory diseases (7%). 24 patients discontinued the treatment (12 progres-
sions of disease, 8 adverse events, 4 deaths). The adverse events that led to
treatment discontinuation were: persistent cytopenia (3), worsening general
condition (2), coronary acute syndrome (1), second tumor (1), febrile neutrope-
nia associated to infection (1). Among four patients not receiving at least2 cours-
es of BR, 2 progressed. The overall response rate in 47 evaluable patients was
64%, with 26 patients (55%) achieving a complete response. At the last analysis
performed with a median follow up of 10 months (1-31), 13 progressions and
4 relapse have been observed. The 2-years PFS and OS were 43% and 59%.
Summary and Conclusions: Combination therapy with BR demonstrates low
toxicity profile in this high risk population. The promising results on activity can
encourage clinicians to considered BR for the treatment of FRAIL elderly
patients with DLBCL not eligible for R-CHOP.






CD56 NEGATIVE EXTRANODAL NK/T CELL LYMPHOMA SHOULD BE
REGARDED AS A DISTINCT SUBTYPE WITH POOR PROGNOSIS
L. Wang1,* Z.J. Xia1, H.Q. Huang2, Y.J. Zhang3
1Hematologic Oncology, 2medical oncology, 3Sun Yat-sen University Cancer
Center, Guangzhou, China
Background: The majority cases of extranodal NK/T cell lymphoma (ENKTL)
have a natural killer cell origin, and a small minority has clonal T cell receptor
rearrangements and appears to be derived from cytotoxic T cells, which usually
featured by CD56 negative expression. Previous results about the clinical and
prognostic significance concerning CD56 expression status are controversial
due to small sample size and the heterogeneity nature of this disease.
Aims: We aimed to define the prognostic value of CD56 expression in ENKTL.
Methods: The complete data of 288 patients with early stage upper aerodi-
gestive tract ENKTL were retrospectively reviewed.
Results: 183 patients (63.5%) had stage I disease, and the primary tumor site
of 204 patients (70.8%) was in nasal cavity. 60 patients (20.8%) were catego-
rized to CD56 negative ENKTL group. There were more patients with primary
tumor site in extranasal upper aerodigestive tract (43.3% vs 25.4%, P =0.011)
and poor ECOG score (8.4% vs 2.2%, P =0.036) in CD56 negative group.
There were no significant correlations between CD56 expression status and
gender, age, lactate dehydrogenase (LDH) level, Ann-Arbor stage, B symptoms
and IPI score (P >0.05). At a median follow-up time of 69 months, the 5-year
and 10-year PFS rate were 52% and 41% respectively, and the 5-year and 10-
year OS rate were 69% and 68% respectively. Patients with primary tumor site
located in nasal cavity or CD56 positive expression had significantly superior
PFS and OS (P <0.05). In multivariate Cox regression model that included age,
Ann Arbor stage, LDH level, primary tumor site, and CD56 expression status,
all these five factors remained to be independent prognostic factors. In subgroup
analysis according to primary tumor site location, CD56 expression status sig-
nificantly correlated with survival outcomes in patients with primary nasal cavity
involvement, however, it lost the prognostic value in patients with primary
extranasal upper aerodigestive tract involvement (P >0.05).
Summary and Conclusions: In this largest cohort of early stage ENKTL ever
reported, we found that CD56 negative ENKTL had significantly inferior survival
outcomes, indicating CD56 negative ENKTL should be regarded as a distinct
phenotype and optimal treatment strategies need to be evaluated further for
this entity.
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DEFINING IMMUNOGLOBULIN SOMATIC HYPERMUTATION IN DE NOVO
DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: POTENTIAL
APPLICATION FOR PROGNOSIS AND RISK STRATIFICATION
I. Kirsch1,* Z. Xu-Monette2, T. Snyder1, K. Young2
1Adaptive Biotechnologies, Seattle, 2University of Texas MD Anderson Cancer
Center, Houston, United States
Background: Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group
of diseases with variable clinical presentation, morphologic features, genomics,
gene expression signature and prognosis. Some of the variability in patient
course and response to therapy is likely to represent a function of develop-
mental stage and/or specific pathway of transformation. We have been engaged
in a detailed investigation of the molecular and clinical features of a large cohort
of patients with DLBCL at the MD Anderson Cancer Center. Through these
analyses we have begun to subcategorize this patient population based on
these distinctive clinical and biological parameters. In this current aspect of our
investigation we have explored the prevalence of somatic hypermutation (SHM)
of the immunoglobulin loci in these de novo DLBCL patients using the platform
of multiplex PCR and high-throughput sequencing (immunoSEQ) developed
by Adaptive Biotechnologies, Inc. It has previously been established that the
presence or absence of somatic hypermutation is an independent prognostic
factor in patients with chronic lymphocytic leukemia (CLL). The ultimate goal of
this collaborative effort is to determine if a similar biological mechanism between
somatic hypermutation and prognosis exists within the population of DLBCL
patients or subset and to relate the presence of SHM to clinical, pathological,
and molecular aspects of this disease.
Aims: In this study, we investigated whether the immunoSEQ (Adaptive
Biotech) assay could be used to reliably discriminate dominant clones in diag-
nostic specimens from patients with DLBCL with regard to rearrangement status
of the immunoglobulin heavy and light (kappa and lambda) chains and the
presence or absence of SHM.
Methods: The study group consisted of 200 DLBCL patients treated with R-
CHOP. Patients with primary mediastinal large B-cell lymphoma, primary cuta-
neous DLBCL, primary central nervous system DLBCL, and DLBCLs trans-
formed from a low-grade B-cell lymphoma or associated with HIV infection
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were excluded. Genomic DNA was extracted from FFPE sections of diagnostic
lymph node specimens of patients with DLBCL. Immunoglobulin heavy and
light chain sequences were then independently amplified using multiplex PCR
with optimized primer sets. Following high-throughput sequencing, a bioinfor-
matics pipeline clusters the sequences into distinct clonotypes to determine
overall frequencies and to identify diagnostic clones. V, (D,) and J genes are
also identified for each clonotype, and point mutations that are not known germ-
line allele variants are assigned as somatic hypermutation events.
Results: Using both the IgH and IgL (kappa and lambda) we have been able
to identify an index trackable sequence in 90%+ of the samples (we identify an
index diagnostic sequence or sequences in about 70% of the cases using each
assay individually). Using a definition of SHM as >2% point mutations in the
observed V gene, the samples can be split into three distinct categories: 1,
V(D)J or VJ rearranged with SHM (50-55%); 2, V(D)J or VJ rearranged without
SHM (10-25%) and 3, DJ only evident (20-40%). The vast majority of complete
V(D)J rearrangements are in-frame.
Summary and Conclusions: The IgH and IgL immunoSEQ assays are robust
in their ability both to identify dominant sequences in diagnostic lymph node
specimens from patients with DLBCL and to distinguish those clones in which
evidence of somatic hypermutation is present. The distribution of SHM in these
samples lends itself to potential correlative and stratifying analyses on this
well-characterized patient cohort, and likely have significant application in other
aggressive B-cell lymphoma patients.
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Background: Efficacy of treatment options for patients with relapsed or refrac-
tory classical Hodgkin lymphoma (cHL) is limited. Preclinical and early clinical
evidence suggests that blocking the JAK-STAT or PI3K pathways may be effi-
cacious in cHL, both directly and through modulation of the tumor microenvi-
ronment. Furthermore, blocking both pathways may provide synergistic effica-
cy.
Aims: To determine the safety, efficacy, and pharmacodynamics of
INCB040093 alone or in combination with INCB039110 in patients with relapsed
or refractory cHL.
Methods: Adult patients with relapsed or refractory B-cell malignancies, includ-
ing patients with cHL, were enrolled in this ongoing, open-label, dose escalation
study. Patients received INCB040093 monotherapy (100 mg once daily, 100
mg twice daily, 150 mg twice daily, or 300 mg once daily) or INCB040093 in
combination with INCB039110 (INCB040093: 150 mg daily, 100 mg twice daily,
or 150 mg twice daily; INCB039110: 400 mg or 600 mg once daily). Safety,
efficacy, and pharmacodynamics were evaluated. Results from patients with
relapsed or refractory cHL are reported herein.
Results: A total of 17 patients with relapsed or refractory cHL have been
enrolled. At baseline, the median age was 34 years and 59% of patients were
men. The median number of prior treatment regimens was 5, 82% of patients
had undergone prior hematopoietic stem cell transplantation, and all patients
had received brentuximab vedotin therapy prior to study entry. The median
exposure to treatment in this study was 209 days (range: 22+ [ongoing]–388).
The most common nonhematologic adverse events (all grades) in patients with
cHL were fatigue (41%), headache(35%), and decreased appetite(35%). Pneu-
monia(12%) was the only nonhematologic grade ≥3 adverse event to occur in
>1 patient. All-grade neutropenia, thrombocytopenia, and anemia occurred in
47%, 47%, and 41% of patients, respectively. Grade ≥3 thrombocytopenia
occurred in 18% of patients. No patients with cHL experienced a dose-limiting
toxicity. Of 6 evaluable patients receiving INCB040093 monotherapy, the objec-
tive response rate (ORR) was 50% (including 1 complete response [CR]); of 9
evaluable patients receiving INCB040093 + INCB039110, ORR was 67%
(including 2 CRs). In this limited dataset of proximate dose cohorts, a dose
response in efficacy was not evident. INCB040093 100 mg twice daily and
INCB040093 100 mg twice daily + INCB039110 400 mg once daily were select-
ed for expansion based on pharmacodynamics and the safety profile of higher
dose levels in the overall study population. At the selected doses, ORR in the
cHL cohort was 50% for INCB040093 monotherapy and 75% (including 1 CR)
for INCB040093 + INCB039110.
Summary and Conclusions: INCB040093±INCB039110 was generally well
tolerated in this heavily pretreated population of patients with relapsed or refrac-
tory cHL. Although the number of evaluable patients is limited, efficacy com-
pares well to approved therapies and investigational agents for cHL. This activ-
ity warranted further investigation of INCB040093 alone and in combination
with INCB039110 in patients with relapsed or refractory cHL, and a phase 2
study has been initiated.
P334
ROUTINE BONE MARROW BIOPSY IN PET/TC ERA FOR HODGKIN
LYMPHOMA STAGING
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Background: Accurate staging is crucial in stratifying treatment in Hodgkin
Lymphoma (HL). Bone marrow involvement (BMI) detection traditionally
requires a BM biopsy (BMB), an invasive procedure. Some studies have shown
that 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed
Tomography (FDG-PET/TAC) scanning is more sensitive than BMB in detecting
BMI in HL. Although baseline FDG-PET-CT is recommended, it is not consid-
ered mandatory as a staging tool.
Aims: To determine whether BMB is still providing useful staging information
now that FDG-PET/CT is available at baseline.
Methods: We retrospectively identified all patients with newly diagnosed HL
between January 2008 and December 2014 in our center and evaluated those
with a baseline staging with FDG-PET/CT and BMB. 70/83 BMB were bilateral.
We classified the bone FDG uptake patterns as: negative (negative and reac-
tive, [those with diffuse symmetrical uptake]) and positive (focal). Clinical stage,
risk evaluation and treatment plan were determined with and without the con-
tribution of BMB results according to the Ann Arbor classification and the guide-
lines from the German Hodgkin Study Group.
Results: 91 new cases of HL were identified. Eighty three patients (91%) had
both FDG-PET/CT and BMB at baseline. The median age was 36 years and
the male/female ratio was 1.77. 43, 13 and 17 patients had stage II, III and IV,
respectively. Fifteen (18%) had BMI by FDG-PET/CT and 5 (6%) by BMB. BMB
underestimated 11 patients (13.2%) which had focal positive uptake by FDG-
PET/CT. None of the patients with BMI by BMB was assigned to stage I to II
disease by FDG-PET/CT. We identified one case with positive BMB but no
FDG skeleton uptake by FDG-PET/CT, although this case was already stage
IV on the basis of liver uptake. Therefore, none of the 83 patients would have
been allocated to another treatment on the basis of BMB results. However,
3/15 patients assessed to stage Ito II by CT where upstaged to stage IV by
FDG-PET/CT. Skeletal FDG-PET/CT lesions identified patients with positive
and negative BMBs with a sensitivity and specificity of 80% and 85.9%, respec-
tively. The positive and negative predictive values of skeletal FDG-PET/CT
lesions for BMB results were 26.7% and 98.5%, respectively.
Summary and Conclusions: In this retrospective analysis of patients staged
by FDG-PET/CT and BMB, the omission of BMB would not have changed the
treatment strategy in any case. Our results suggest that FDG-PET/CT may be
an appropriate method to replace BMB to assess bone marrow infiltration in
newly diagnosed HL. We should confirm in further studies that BMB has little
to offer in staging patients with HL in the FDG-PET/CT era and becomes an
unnecessary and painful procedure.
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Background: The outcome in pediatric classical Hodgkin’s lymphoma (cHL)
is excellent when combined modality therapy is used. Over the last two decades
it has been tried to identify prognostic factors that allow the identification of
children who are likely to benefit from reduced intensity treatment and patients
at higher risk of treatment failure. Many biological and inflammatory markers
at diagnosis have been proposed as having a prognostic value, but very few
have been validated in childhood.
112 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Aims: To explore the significance of biological and inflammatory markers in a
large population of 769 children affected by cHL.
Methods: By using the database of patients enrolled in A.i.e.O.P. (Associazione
Italiana di Emato-Oncologia Pediatrica) trial LH2004 for pediatric cHL, we iden-
tified 769 patients treated from June 1, 2004 to April 1, 2014 with ABVD (dox-
orubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV
(cyclophosphamide, vincristine, prednisone, procarbazine, doxorubicin,
bleomycin and vinblastine) regimens. We considered the following data at diag-
nosis: age, sex, stage, white blood cell count, absolute lymphocyte count (ALC),
absolute monocyte count (AMC), absolute eosinophil count (AEC), absolute
neutrophil count (ANC), platelet count (Plts), 1-hour erythrocyte sedimentation
rate, ferritin, albumin, hemoglobin; ALC/AMC ratio, ANC/ALC ratio, and
AEC/ALC ratio were also considered. All prognostic factors were first analyzed
as continuous variables, except for the A-B categorization, sex and stage. How-
ever, since these continuous variables are more likely to be of clinical signifi-
cance if categorized in binary form, we performed a ROC analysis to find some
reasonable cutoff value. Bivariate survival analysis was performed using Kaplan
Meier curves and log-rank test. Multivariate survival analysis was performed
using a Cox proportional hazards model. We also performed an Internal Boot-
strap Validation (IBV) of the model with 800 repetitions.
Results: There were 361 female patients (46.9%), and 408 males (53.0%);
454 patients (59.0%) were in category A and 315 (40.9%) in category B. There
were 27 stage I patients (3.5%), 397 stage II (51.6%), 177 stage III (23.0%)
and 168 stage IV (21.8%). Histologically, 636 patients (82.7%) were classified
as nodular sclerosis, 81 (10.5%) as mixed cellularity, 7 (0.9%) as lymphocyte
depleted, 8 (1.0%) as lymphocyte rich, and in 37 (4.8%) no histological subtype
was reported. There were 108 (14.0%) events: 71 were relapses, 37 progres-
sions (pathologically-confirmed recurrence within 3 months of the end of ther-
apy). On bivariate analysis with variables in binary form, under the identified
cutoffs, 5-year freedom from progression (FFP) survival was significantly lower
in patients with stage IV or elevated values of ferritin (≥209 ng/ml), AEC
(≥0.493x109/L) and Plts (≥537 x109/L): 73.4% vs 83.9% for stage IV, 66.0% vs
86.5% for ferritin, 71.6% vs 84.9% for AEC and 66.3% vs 82.4% for Plts. More-
over in the Cox multiple regression model for FFP with variables in binary form
the hazard ratios were 2.08, 2.72, 3.05 and 2.65 for Stage (IV vs others), Fer-
ritin, AEC and Plts respectively. The IBV showed that the model based on these
4 Risk Factors (RFs) was not over-fitted. A different Cox regression model for
the total number of RFs in each child is shown in table I.
Tabella 1. Cox regression model for total number of RFs from our cate-
gorical model (vs 0 risk factors).
Summary and Conclusions: Using the combination of 4 simple RFs it is pos-
sible to classify the patients into subgroups with very different outcomes.
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EVI1 EXPRESSION ASSOCIATES WITH HIGHER CUMULATIVE
INCIDENCE OF RELAPSE IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION
WITH NON-MYELOABLATIVE CONDITIONING
M. Bill1,* M. Jentzsch1, K. Schubert1, T. Lange1,2, J. Grimm1, M. Knyrim1,
S. Leiblein1, G.N. Franke1, V. Vucinic1, W. Pönisch1, M. Cross1, G. Behre1, 
D. Niederwieser1, S. Schwind1
1Hematology, University of Leipzig, Leipzig, 2Hematology, Asklepios clinic,
Weißenfels, Germany
Background: Prognosis of acute myeloid leukemia (AML) patients (pts) is still
dismal. Therefore, more personalized therapeutic strategies are required. Allo-
geneic hematopoietic cell transplantation (HCT) represents a therapy offering
potential cure. Non-myeloablative conditioning (NMA) is increasingly used in
pts that are ineligible for conventional conditioning. The ecotropic viral integration
site 1 (EVI1) gene maps to chromosome 3q26 & encodes a transcription factor
that has an important role during embryogenesis. In AML, the gene is well known
as a part of a fusionprotein in pts with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) that
are recognized as a distinctive entity in the WHO classification.
Aims: The presence of EVI1 expression has been described as a predictor of
poor outcome. Whether the expression of EVI1 also associates with outcome
in AML pts undergoing NMA-HCT, with a therapeutic approach mainly based
on an immunological graft-versus-leukemia effect, remains unknown.
Methods: We analyzed 136 pts (median age, 64 years [y]; range 22–75y) who
received NMA (Fludarabine 30mg/m2 at day-4 to-2 & 2Gy total body irradiation
[TBI] at day 0 [n=131; 96.3%] or Fludarabine 30mg/m2, Cytarabine 2g/m2 &
Amsakrine 100mg/m2 at day-12 to-9, Cyclophosphamide 40mg/kg at day-4 to-
3, ATG/TG day-3 to-1 & 4 Gy TBI day-5 [n=4; 2.9%])-HCT at the University of
Leipzig between May 2000 & August 2012, with pretreatment bone marrow
material available. Donors were human leucocyte antigen (HLA)-matched related
(n=23, 16.9%) or HLA-matched (n=81; 59.6%) or mismatched (>=1 antigen;
n=32; 23.5%) unrelated. 26.5% (n=36) had acute graft-versus-host disease
(GvHD; >=grade 2) & 44.1% (n=60) (14.3% (n=15) limited; 33.1% (n=45) exten-
sive) chronic GvHD. The mutation status of NPM1 & CEBPA gene & FLT3-ITD
status were assessed at diagnosis. Pts were grouped according to the European
LeukemiaNet (ELN) classification in favorable (n=32; 23.5%), intermediate-I
(n=36; 26.5%), intermediate-II (n=26; 19.1%) & adverse (n=38; 27.9%). Pres-
ence of selected surface markers was assessed using flow cytometry at diag-
nosis. EVI1 expression was measured by RT-PCR & normalized to 18S. The
normalized expression of EVI1 in the cell line SKOV3 was used to define EVI1
positive (EVI1+) expressers, i.e. pts with an expression higher than 0.1 relative
to the EVI1 expression of SKOV3 in the ddCT method were labeled EVI1+.
Results: Median follow-up for pts alive was 4.3y. 21.3% (n=29) pts were EVI1+.
At diagnosis EVI1+ pts’ blasts were more often CD7 (P=.001) & CD56 (P=.023)
positive. Regarding cytogenetics, EVI1+ pts had more often a monosomal kary-
otype (P<.001) & a monosomy 7/del7 (P=.003), but less frequent a normal kary-
otype (P=.024). Two pts in the set had an inv3 and were both EVI1+. EVI1+ pts
were less often NPM1 mutated (P=.014). Furthermore, EVI1+ associated with
a lower white blood cell count at diagnosis (P=.016). Regarding the cumulative
incidence of relapse (CIR), EVI1+ pts had a significant higher CIR (P=.010; Fig-
ure 1B). EVI1+ associated with shorter overall survival (OS; P=.063; Figure1B),
by trend. The median 2y-OS was 34.7% for EVI1+ pts compared to 51.8% for
EVI1 negative pts. Analyzing the ELN groups, these findings could only be recov-
ered in the adverse group by trend (P=.089 and P=.095, respectively).
Figure 1.
Summary and Conclusions: In conclusion, the EVI1 expression associated
with worse outcome and higher CIR in NMA-HCT treated AML pts. Pretreatment
EVI1 expression may refine the risk stratification for AML pts undergoing NMA-
HCT.
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SUPPORTIVE CARE AND INFECTIOUS COMPLICATIONS IN CORD
BLOOD AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN
ADULTS WITH HIGH RISK HEMATOLOGIC DISEASES
J. Elcheikh1,* R. crocchiolo2, A. vai2, S. furst1, S. bramanti2, B. sarina2,
A. granata1, R. devillier1, C. faucher1, B. mohty1, S. harbi1, R. bouabdallah1,
N. vey1, A. santoro2, C. chabannon1, P.J. weiller1, L. castagna2, D. blaise1
1transplantation, INSTITUT PAOLI CALMETTES, marseille, France, 2trans-
plantation, humanitas, rozzano, Italy
Background: Infections due to post transplant immune deficiency are a major
problem following allogeneic stem cell transplantation, particularly in patients
receiving cord blood (CBT) or haploidentical transplants (haplo-SCT).
Aims: To our knowledge, there are only some heterogeneous studies compar-
ing this important issue in this setting.
Methods: We evaluated the incidence and type of infectious complications
that occurred in these two types of transplant for 150 patients, 81 cord blood
and 69 haploidentical, who received the same conditioning regimen: fludarabine
(Flu), cyclophosphamide (Cy) and low dose TBI (2 Gy) combination in the two
groups. The GVHD prophylaxis consisted of Cyclosporine A (CsA) and MMF
in all patients in the two groups. In the Haplo group all patients received also
50 mg/kg Cy at day 3 and 4 post transplant. Of note, supportive care was the
same during the whole study period. CMV infection management was also
homogeneous.
Results: The median times to neutrophil and platelet recovery were 20 d (14-
39) and 29 d (14-50) after Haplo and 22 d (6-67) and 41 d (18-80) after CBT.
All supportive care measures included red blood cell, platelet transfusions,
antibiotics days, parenteral nutrition days and hospitalization time were signif-
icantly increased in CBT group. (p=0.0001). While incidence of infections
appeared similar in both types of transplant, viral infections were more frequent
than bacterial or fungal infections and were the most common cause of death
in both groups. During the first year after stem cell transplant, the CBT group
had 154 episodes of infection (31 infection episodes per 1,000 patient-days)
versus 125 of the haplo patients (39 per 1,000 patient days). Viral infections
were most common in both groups (83 vs 60 episodes) in CBT vs haplo group
respectively. Patients in the haplo group were 1.2 times (95% CI: 1.1 to 2.5)
more likely to have a viral infection (p=0.07). Pneumonia was the most common
clinical syndrome and was higher in the haplo group 28% vs 11% in CBT. Both
pneumonia and bacteremia prevalence occurred within the first 100 days in
the majority of CBT patients while haplo patients had a bimodal distribution
with more than one third of bacteremia episodes after 6 months post-transplant.
Survival analysis showed that transplant source (CBT versus Haplo) did not
have a significant effect on the probability to have an infection episode. (p=0.10)
Bacterial, fungal and CMV infections still quite frequent and contributed to high-
er mortality in CBT vs haplo (p=0.06). The first cause of mortality was the viral
infection (12 (15%) 3 (4%) p=0.060) followed by the bacterial infection cause
(4 (5%) vs 3 (4%)) and the fungal infection (1 (1%) vs 0) in CBT and haplo
group respectively.
Summary and Conclusions: Our study is unique in comparing adult patients
with advanced hematologic malignancies who received the same reduced-
intensity conditioning regimen, which offers a common base for comparing
the infections in these two types of transplant. In our hands, outcome is better
for haplo donor decreasing the need of supportive measures and facilitating
to perform the transplant in time. Haploidentical transplants are a good and
promising alternative option for high risk hematologic patients who lack an
HLA-matched donor. Collectively, the impact of infectious complications after
haplo-SCT was different from that in CBT patients, suggesting that a more
intensive strategy for infection control in haplo patients is required to reduce
infectious mortality.
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AUGMENTED CONDITIONING WITH TARGETED MOLECULAR
RADIOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN MYELOMA: RESULTS OF A PHASE II RANDOMISED CONTROL TRIAL
WITH IMPROVED CR RATE POST ASCT
K. Orchard1,* S. MacKinnon2, J. Langford3, R. Chakraverty2, D. Richardson1,
M. Guy4, J. Thom5, P. Lloyd-Evans6, M. Jenner1, T. Maishman7, K. Cozens7,
L. Stanton7, A.M. Quigley8, D. McCool8, P.S. Chan8, C. Wickham9, P. Johnson10
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ical Biotechnology Centre, Bristol, 7Southampton Clinical Trials Unit, University
of Southampton, Southampton, 8Dept of Nuclear Medicine, 9Dept of Medical
Physics, Royal Free Hospital, London, 10Cancer Sciences, University of
Southampton, Southampton, United Kingdom
Background: Autologous stem cell transplantation (ASCT) remains important
as consolidation therapy for patients with myeloma, improving rate and duration
of response. The standard conditioning treatment with high dose melphalan
has remained unchanged for 3 decades, further increase in the intensity of
therapy is limited by toxicity to non-haematopoietic organs. We developed
TMRT with a radiolabelled monoclonal antiCD66 that targets bone marrow,
plasma cells and lymphoid tissue as a vector for delivering high dose radiation
to sites of disease. We report the results of a Phase II RCT demonstrating
improved sCR/CR responses using the radiolabelled mAb.
Aims: Trial Design:A randomised, multi-centre, non-blinded Phase II study
comparing two treatment conditioning schedules prior to ASCT. Arm A TMRT
plus high dose melphalan vs Arm B high dose melphalan alone. Primary objec-
tive:To determine the efficacy of TMRT delivered by an Yttrium-90 (90Y)-radi-
olabelled murine antiCD66 monoclonal antibody given in addition to high dose
melphalan (200mg/m2) in terms of disease response in patients undergoing
ASCT for multiple myeloma. Secondary objectives: Engraftment, time to dis-
ease progression, time to next treatment, overall survival, HAMA formation.
Methods: Twenty-five patients were recruited out of a planned 90. All patients
had confirmed multiple myeloma, were in PR/vgPR following chemotherapy
and were scheduled to receive autologous stem cell transplantation. Randomi-
sation was stratified by disease risk (low/high). Patients randomised to receive
TMRT received an infusion of indium-111 labelled antiCD66 to allow imaging
and organ dosimetry calculation. Patients with favourable dosimetry received
an infusion of 90Y-labelled antiCD66, at an activity of 37.5MBq/kg lean body
weight as outpatients 14 days prior to scheduled ASCT. Patients in both arms
were admitted two days before ASCT and given high does melphalan. All
patients were managed post ASCT as per centre protocols. Disease response
was assessed pre-ASCT and at 3, 6, 9 and 12 months using EBMT response
criteria. Logistic regression, adjusting for risk group, was used to analyse the
primary endpoint (alpha 15% 1-sided).
Results: Twenty-five patients were randomised: 12 to Arm A; 13 to Arm B.
Twelve patients in each arm were available for analysis. Myeloma sub-type,
gender, patient’s age and risk group numbers were similar in each arm. Median
infused 90Y-activity 2.31GBq, range 1.61-2.74GBq. Median radiation doses to
organs BM 32.10Gy (17.2-34.7), liver 4.70Gy (1.7-12.0), spleen 28.55Gy (7.4-
34.0), renal 2.90Gy (2.1-3.6), pulmonary 3.45Gy (1.2-4.0), whole body 0.85Gy
(0.8-1.2). Toxicities were similar in each arm.
Tabella 1.
All Arm A patients showed a response improvement, 3 Arm B patients had sta-
ble disease with no change (2 PR, 1 vgPR).
Summary and Conclusions: The study achieved its primary endpoint demon-
strating a statistically significant improvement in the complete response rate
for patients in Arm A compared to Arm B (50% vs 25%, odds ratio [85% 1-
sided CI]: 0.277 [0.102, 0.753]). This is the first demonstration in an RCT of
effective augmentation of the conditioning prior to ASCT that improves the
response rate post transplant without additional toxicity. Eudract: 2006-003424-
12. The study was managed by Southampton Clinical Trials Unit Sponsor: Uni-
versity of Southampton NHS Foundation Trust Funding: Leukaemia & Lym-
phoma Research;ECMC core funding.
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ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS REQUIRING
INTENSIVE CARE: DELAY BETWEEN ORGAN DYSFUNCTION AND
REFERRAL TO THE INTENSIVE CARE UNIT AND TIME SPENT ON ORGAN
SUPPORT IMPACT SURVIVAL 
C. Orvain1,* F. Beloncle2, S. Thépot1, A. Kouatchet2, S. Francois1, P. Guardiola3,
A. Corby1, P. Asfar2, M. Hunault-Berger1, N. Ifrah1, A. Schmidt-Tanguy1
1Maladies du Sang, 2Réanimation Médicale, 3Plateforme SNP, Transcriptome
et Epigénomique, CHU Angers, Angers, France
Background: Although the prognosis of patients with hematological malignan-
cies admitted to the intensive care unit (ICU) has improved over the past years,
it remains poor in allogeneic stem cell transplantation (SCT) recipients and
thus admission of these patients to the ICU remains controversial.
Aims: We aimed to assess the prognostic factors of survival in ASCT recipients
with a special interest on graft-versus-host disease (GVHD), the requirement
for organ support, the timing between the occurrence of organ dysfunction and
ICU referral, the time spent with each organ support, and the time since ICU
admission at initiation of each organ support.
Methods: All allogeneic SCT recipients between 2002 and 2013 who were
admitted to the medical ICU in our center were included. Details on patients,
graft procedures, GVHD, ICU admission, and outcome were collected from
individual medical records. The need for oxygen therapy, the presence of low
blood-pressure (systolic arterial pressure <90 mmHg), altered mental status,
elevated serum creatinine (≥1.5 times baseline or ≥0.3 mg/dL increase), and
total bilirubin (>34 µmol/l) defined respiratory, hemodynamic, neurological,
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renal, and liver dysfunctions, respectively. Potential prognostic factors were
explored by logistic regression analysis for ICU and hospital discharge. Cox
regression analysis was performed for overall survival (OS).
Results: Of 344 patients who underwent ASCT during the study period, 92
patients (27%) were admitted to the ICU. No demographic or SCT parameter
was associated with ICU or hospital discharge, or with overall survival. 66%
patients could be discharged from the ICU and 46% from hospital whereas
one-year survival was 24%. At the time of referral to the ICU, 12 patients had
3 or 4 organ dysfunctions and only 4 of these patients (25%) could be dis-
charged alive from the hospital versus 57/80 patients (71%) with 0 to 2 organ
dysfunctions (OR: 12, 95% CI: 1.5-94, p=0.02). Patients who were admitted
until 3 days following the first signs of organ dysfunction were more likely to be
discharged alive from the hospital (41/80 patients, 51%) than those who were
presenting with symptoms for more than 3 days before admission to the ICU
(1/12 patients, 8%) (OR: 1.3, 95% CI: 1-1.8, p =0.03). Grade 2-4 acute GVHD
(37%) had a significant impact on hospital discharge (11/34 patients alive, OR:
2.4, 95% CI: 1-5.8, p=0.05) but not with ICU discharge (20/34 patients alive,
p=0.25). Mortality was greatly associated with the number of organ failures:
one-year OS rates were 31%, 27%, 23%, and 0% among patients with 0 (26
patients, 28%), 1 (26 patients, 28%), 2 (26 patients, 28%), and 3 to 4 (14
patients, 15%) organ failures, respectively (HR: 1.7, 95% CI: 1.4-2.1, p<0.001).
Neither time spent with invasive mechanical ventilation nor time from ICU
admission to the initiation of this life-supporting intervention was associated
with hospital survival. There were no survivors in patients for whom vasoactive
drugs and/or renal replacement therapy were initiated after day 1. There were
no survivors for those who received vasoactive drugs for more than 2 days and
for those who received renal replacement therapy for more than 5 days. The
Sepsis-related Organ Failure Assessment (SOFA) better distinguishes outcome
of patients when performed day 2 onward. Patients who had a stable or wors-
ening SOFA at day 2 had greater hospital mortality (OR: 2.8, 95% CI: 1.1-7,
p=0.03).
Summary and Conclusions: ASCT recipients, even with GVHD, might be
considered for transfer in the ICU as soon as they present first signs of organ
dysfunction and before they have too many organ dysfunctions. A reappraisal
should probably be performed after 48 hours of ICU.
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OUTCOME AND PROGNOSTIC FACTORS IN FLAMSA SEQUENTIAL
CHEMOTHERAPY FOLLOWED BY RIC AND HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR HIGHER RISK AML AND MDS PATIENTS
A. Sutra Del Galy1,* S. François1, V. Seegers2, A. Schmidt-Tanguy1, A. Bouvier3,
L. Baranger4, M. Hunault-Berger1, N. Ifrah1, P. Guardiola2, S. Thépot1
1Service des maladies du sang, 2Plateforme SNP, Transcriptome,
Epigénomique, 3Laboratoire de Biologie Moléculaire, 4Laboratoire de
Cytogénétique, C.H.U., Angers, France
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the
only potentially curative approach in refractory or relapse acute myeloid
leukemia (AML) and higher risk myelodysplastic syndrome (MDS). Sequential
cytoreductive chemotherapy including fludarabine, aracytine and amsacrine
(FLAMSA) followed by reduced intensity conditioning (RIC) and HSCT gives
promising results in this unfavorable group. However, little is known concerning
prognostic factor associated with this treatment approach.
Aims: This study aims to defined prognostic factors of overall survival (OS)
and early relapse after FLAMSA-based conditioning in higher risk AML or MDS
patients.
Methods: We retrospectively reviewed consecutive patients (pts) in our insti-
tution undergoing an SCT for high-risk myeloid malignancy after FLAMSA-RIC
between March 2006 and June 2014. We evaluated transplantation related
mortality (TRM) and early relapse defined before 90 days after transplantation.
The uniformly used conditioning regimen was 4 days of Fludarabine (30
mg/m2/d), Amsacrine (100 mg/m2/d) and Aracytine (2 g/m2/d) followed by 4
days of Busulfan (13,6 mg/kg/day) after 3 days of rest. Antithymocyte globulin
(Genzyme® 6 mg/kg), ciclosporin and mycophenolate mofetil were use for graft-
versus-host disease (GvHD) prophylaxis.
Results: Among 73 pts with a median age of 54 years (19-69), 51 (70%) were
AML and 22 (30%) pts were MDS. In AML pts, transplantation indication was
refractory disease for 24 (47%), secondary AML for 19 (37%), relapse for 8
(16%). In MDS pts (including 7 RAEB-T), 18 (81,8%) were high or very high R-
IPSS and 9 (41%) were previously treated with demethylating agents, 4 (18%)
with intensive chemotherapy and 9 (41%) were untreated and transplanted
upfront. Median leucocytosis and bone marrow blast before conditioning was
3,41 G/L (0,21-39) and 5% (0-90) respectively. Cytogenetics was adverse in
22 (30%) and intermediate in 51 (70%) pts and among them 15 had
unfavourable genotype (FLT3-ITD). Sorror score before transplantation (HCT-
CI) was higher or equal to 3 in 34 (47%) pts. Thirty-seven (51%) pts received
HLA-identical sibling transplantation and 36 (49%) pts received transplantation
from unrelated donors. Source of stem cells was mobilized peripheral blood
stem cell for 64 (88%), bone marrow for 5 (7%) and cord blood for 4 (5%) pts.
Eighteen (25%) pts experienced grade III-IV acute GvHD and 9 (12%) severe
chronic GvHD according to NIH classification. After a median follow-up of 58,8
months, OS at 24 and 48 months was 38,4% and 27% respectively. The 2-
years TRM was 31,5%. In univariate analysis, performans status >2 (p=0,041),
adverse cytogenetics (according to MRC classification, p<0,001), pre transplant
leucocytosis >10 G/L (p=0,015) and pre transplant bone marrow blasts
(p=0,011) were associated with poorer overall survival. Neither age, HCT-CI
nor number of CD34+ transfused were associated with outcome. Only inter-
mediate cytogenetics (p=0,02) was associated with superior overall survival in
multivariate analysis. Thirteen (18%) pts relapsed before the 90 days. In uni-
variate analysis, leucocytosis >10 G/L, higher bone marrow blast and adverse
cytogenetic were associated with early relapse (p=0,003; p=0,001; p=0,021
respectively). The pre transplant leucocytosis >10 G/L (p=0,042) and higher
bone marrow blasts (p=0,01) remains prognostic factors of early relapse in
multivariate analysis.
Summary and Conclusions: Despite median age of 54 years, high HCT-CI
and high-risk diseases, FLAMSA-based HSCT was feasible with acceptable
TRM. The 2-years overall survival (38,4%) is encouraging for this very high-
risk population and only adverse cytogenetics remains prognostic factor for
survival. Proliferative diseases before conditioning are associated with a high
risk of early relapse. New therapeutic approaches, for those pts need to be
tested in order to improve the HSCT outcomes.
P341
PRE-TRANSPLANT QUANTITATIVE MONITORING OF NPM1 MUTATION
SIGNIFICANTLY PREDICTS OUTCOME OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN NORMAL KARYOTYPE AML IN
COMPLETE REMISSION
M. Karas1,* K. Steinerova1, S. Vokurka1, A. Jungova1, M. Hrabetova1,
D. Lysak1, P. Jindra1
1Hematology and Oncology dpt., Charles University Hospital Pilsen, Pilsen,
Czech Republic
Background: detection and the level of minimal residual disease (MRD) affects
prognosis of AML patients (pts) treated with intensive chemotherapy alone. But
impact of MRD in the setting of allogeneic hematopoietic stem cell transplan-
tation (alloHSCT) especially in pts with normal karyotype AML in complete
remission (CR) is less clear.
Aims: with the aim to evaluate the potential role of pre-transplant MRD we
studied impact of pre-transplant MRD level on outcome of alloHSCT in 60 con-
secutive pts with normal karyotype AML harboring NPM1 mutations in complete
remission. MRD level was determined using quantitative real-time polymerase
chain reaction (qPCR) for detection of NPM1 mutations.
Methods: from 2/2005 to 9/2014 60 consecutive pts with median of age 54
years (range, 30-66 years) with normal normal karyotype AML harboring NPM1
mutations (53% FLT3/ITD positivity) in 1st CR (45 pts) and 2nd CR (15pts)
underwent myeloablative (16 pts) or reduced-intensity (44 pts) alloHSCT (27%
HLA identical related, 50% HLA matched unrelated, 23% HLA mismatched
unrelated). Source of stem cells was in 80% peripheral blood and in 20% bone
marrow. MRD level was determined using real-time qPCR for detection of NPM1
mutations before start of conditioning regimen from bone marrow. Pre-transplant
prognostic factors (age, type of donor, donor recipient sex combination, CMV
status, type of conditioning regimen, source of stem cells, number of CR,
FLT3/ITD status, MRD level) were included in the univariate and multivariate
statistical analysis.
Results: all pts fully engrafted with ongoing CR after alloHSCT. 36 pts (60%)
developed aGVHD and 24 pts (40%) developed chGVHD. With median follow-
up 52 months (range, 4-101 months) 35 pts (58%) are alive. 16 pts (27%)
relapsed and 13 of them died. 12 pts (20%) died due to NRM. The estimated
probabilities of 3-years EFS and OS are 54% and 59%. Statistical analysis
showed that only age over 63 years and MRD level affected alloHSCT outcome
in multivariate analysis. Pre-transplant MRD level 10 NPM1mut/10000 ABL
copies had the strongest statistical significance. The estimated probabilities of
3-years relapse incidence, EFS and OS were for pts with low MRD level (≤10
NPM1mut copies) 6%, 72% and 75% and for pts with high MRD level (>10
NPM1mut copies) 31%, 35% and 40%.
Summary and Conclusions: our data show that pre-transplant quantitative
assessment of NPM1 mutation in pts with normal karyotype AML harboring
NPM1 mutation in CR provides important prognostic information, which as an
independent prognostic factor predicts transplant results.
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EARLY RELAPSE FOR FOLLICULAR LYMPHOMA (FL) AFTER AUTOLOGOUS
STEM CELL TRASPLANTATION (HDT/ASCT) CARRIED OUT IN 1ST OR
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Background: Despite gains in survival with immunochemotherapy and
HDT/ASCT intensification, a considerable number of patients with FL die from
the lymphoma. A strong correlation between quality of response and better
progression-free survival (PFS) and overall survival (OS) in FL patients is well
known. Early relapse of disease within 24 months of HDT/ASCT has been sug-
gested as defining a group of patients with very low survival.
Aims: In this retrospective analysis, our interest is to study patients undergoing
HDT/ASCT in CR at the moment of transplantation, in order to analyze survival
and basal characteristics of patients relapsing early; within the first 24 months
from the procedure.
Methods: FL patients undergoing HDT/ASCT in 1st or subsequent CRs from
1989 to 2007 and reported to the GELTAMO registry were studied .Two groups
were defined: patients with relapse or and/or death ≤2 years from HDT/ASCT
(early relapse group) and a reference group without relapse or death within 2
years of diagnosis. Survival probability was estimated by the Kaplan-Meier
method. A Cox model evaluated the effect of early relapse on OS.
Results: A total of 405 patients were analyzed (mean age 47 years, female
sex 53%). Two hundred and three patients received HDT/ASCT in 1st CR, 43%
of them requiring more than one therapy line to achieve CR and 202 in subse-
quent CRs (174 in 2nd CR and 28 in 3rd CR). Median follow-up from HDT/ASCT
was 11, 8 years. An early relapse was observed in 20, 5% (83/405) of patients.
For patients undergoing HDT/ASCT in 1st CR, 16% (33/203) had early relapse
compared to 25% (50/202) of patients who underwent ASCT in subsequent
CRs (P=0.02). Early relapse following HDT/ASCT was dramatically and signif-
icantly related to worsened OS, both in transplanted in 1st CR (HR of 15.5;
95% CI 14.9—16.1), and in subsequent CRs (HR of 8; 95% CI 7.6—8.4), com-
pared with those not progressing so soon. Median OS for patients with early
relapse was 44 months compared to OS median not reached in the reference
group (P<10-5). OS was 39% vs 96% at 5 years, 28% vs 88% at 10 years and
21% vs 82, 5% at 15 years for the early relapse and the reference group,
respectively. OS curves for patients transplanted in 1STCR and in subsequent
CRs are shown in the figure. Multiple logistic regression analysis showed that
older age (P=0.05), male sex (P=0.05), high LDH (P<0.1), high B2 microglob-
uline (P<0.1) and the presence of more than 4 nodal areas affected were asso-
ciated with early relapse (P<0.1).For patients undergoing ASCT in 1st CR male
sex (p=0.05), high LDH (P=0.04), more than 4 nodal areas affected (P=0.01),
age adjusted IPI (P<0.1) and FLIPI (P<0.1) were associated with early relpse.
The poor outcome of these FL patients was independent of the use of Rituximab
previously to ASCT. For patients undergoing HDT/ASCT in 2nd/3rd CR duration
of first remission less than 12 months selected a subgroup of patients at high
risk for early relapse (P=0.02).
Figure 1.
Summary and Conclusions: Relapse of FL within 2 years after HDT/ASCT
intensification carried out at 1st or subsequent CR is associated with really
poor outcomes. Male sex, older age, high B2 microglobuline, high LDH, the
presence of more than 4 nodal areas affected and duration of first remission
less than 12 months conferred a significantly high risk for early relapse. Patients
undergoing HDT/ASCT at first CR relapsed early less frequently that those
transplanted at subsequent CRs (P=0.02), however relapsing within 2 years of
HDT/ASCT defines a unique category of patients at substantially increased
risk of death, independently of having been transplanted in 1ST or in subsequent
CRs. These high-risk patients need further study in directed prospective studies
of FL biology and clinical trials.
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Background: Large Granular Lymphocyte (LGL) leukemia is a rare lympho-
proliferative disorder characterized by clonal expansion of either CD3+ cytotoxic
T lymphocytes or CD3-NK-cells. Although usually considered as an indolent
disease, most patients will require therapy based on immunosuppressive drugs
such as methotrexate, cytoxan or ciclosporin. Treatment of rare aggressive
forms and refractory patients remains elusive and prognosis is dramatically
poor. For such patients, high-dose intensification may be proposed. However,
the feasibility and efficacy of both allogeneic (allo) and autologous (auto)
hematopoietic stem cell transplantation (HSCT) in LGL leukemia has not been
evaluated so far and data are only limited to few sporadic case reports.
Aims: The aim of the present study was to investigate the feasibility and effi-
cacy of allo-HSCT and auto-HSCT in T-cell LGL leukemia.
Methods: Fifteen patients treated by allo-HSCT or auto-HSCT for T-cell LGL
between January 2004 and November 2011 were included in this EBMT mul-
ticenter registry-based retrospective study. Baseline information and transplan-
tation characteristics of selected patients were downloaded. Centers were then
contacted to provide written diagnostic reports in order to confirm the diagnosis
of LGL and additional data. Probabilities of disease-free survival (DFS) and
overall survival (OS) were calculated using the Kaplan-Meier estimate.
Results: Most patients had an advanced disease with multi-organ involvement
(n=9) and were heavily pretreated with poly-chemotherapy (n=11). Median time
from diagnosis to transplantation was 15 months (range: 7-211). Ten patients
received an allo-HSCT at a median age of 49 years (range 29-66): at transplan-
tation, 3 patients were in complete remission, 6 in partial response and 1 pre-
sented with refractory disease. Conditioning regimen was reduced intensity in 6
patients and peripheral blood progenitor cells were used in all but one patient.
Engraftment was obtained for all patients. Grade II-IV acute GVHD was observed
in 4 patients. Of the 7 patients surviving past day 100, 2 developed extensive
and 1 limited chronic GVHD. The main cause of death after allo-HSCT was infec-
tion whereas relapse accounted only for a single death. Five patients were still
alive after a median follow-up of 30 months (range: 19-95), translating into a 2-
year DFS and OS of 50% (95%CI, 18% to 75%). Auto-HSCT was performed in
5 patients with a median age 49 years (range: 38-57): 3 of them were in complete
remission and 2 in partial remission at the time of transplantation. Conditioning
regimens were BEAM (carmustine, etoposide, cytarabine and melphalan) in 4
patients and TAM6 (cytarabine, melphalan, Total Body Irradiation 12 Grays) in 1
patient. Two patients relapsed at 1 and 31 months post auto-HSCT and died.
One patient did not obtain a complete remission after HSCT but is still alive after
a follow-up of 40 months. Two patients remain alive and disease-free 27 and 52
months post HSCT, respectively. For the entire group, 2-year DFS and OS were
43% (95%CI, 16% to 67%) and 60% (95%CI, 32% to 79%), respectively.
Summary and Conclusions: Here, we report the first cohort of patients treated
by HSCT for T-cell LGL leukemia. Despite the small number of patients, HSCT
appears as a potential therapeutic option in rare aggressive and relapsing
forms of T-LGL leukemia.
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Background: The likelihood of successful mobilization has improved with the
addition of Plerixafor to G-CSF in ASCT. Due to its high cost, risk adapted algo-
rithms were instituted to identify patients who would benefit from plerixafor.
Aims: We aimed to assess the appropriateness of our risk adapted algorithm
in selecting appropriate patients to receive plerixafor.
Methods: The current algorithm was instituted in December 2009. Mobilization
commences with GCSF alone; plerixafor is added if day 4 PBCD34 is <10/μL
for single transplant, <20/μL for multiple transplants, day 1 yield is <1.5 million
CD34/kg, or subsequent yield is <0.5 million CD34/kg. Goal of collection varied
by disease and by number of intended transplants (3-5 million CD34/kg/trans-
plant). The results of this mobilization strategy are presented here.
Results: We studied 1080 mobilizations in 1068 patients using the current pro-
tocol between June 2010 and December 2013; 548 MM (51%), 327 NHL (30%),
144 amyloidosis or light chain deposition disease (AL/LCD; 13%) and 61
Hodgkin’s (6%). Overall, 55.4% of patients required plerixafor (MM 58%, NHL
61%, AL/LCD 35%, HL 46%). The majority (77%) of patients initiated plerixafor
on day 4 for low PB CD34 count; 23% started beyond 4 days for suboptimal
CD34 collection. There was no difference between the diagnoses in terms of
the need to initiate plerixafor for low PB CD34 or for suboptimal CD34 collection.
Median days of plerixafor was 2 (IQR 1-3); 42% and 22% required >2 days
and >3 days, respectively. More patients with NHL (50%) needed >2 days of
plerixafor vs MM (41%), HL (40%) and AL/LCD (23%); p =0.004. The median
number of CD34 cells collected was 7.4 million/kg (IQR 5.2-9.9). Median CD34
collection was highest for MM and AL/LCD, reflecting the practice to collect for
more than one transplant. Overall 9 (<1%) and 22 (2%) patients collected <2
million and <2.5 million CD34 cells/kg, respectively. More patients with NHL
(4%) collected <2.5 million/kg compared with MM (1%), AL/LCD (2%) and HL
(0%), p=0.02. The median number of days of apheresis was 2 (IQR 1-3) and
was higher in the NHL group (p=0.002). The median CD34 collected per day
was 3.6 million/ kg (IQR 2-5.8); higher in MM and AL/LCD vs NHL and HL (p
<0.001). The median CD34 collection was very similar for those patients getting
plerixafor versus those not requiring plerixafor (p=0.26). The median time to
ANC and platelet engraftment were 14 days (IQR 13-16) and 13 days (IQR 12-
15), respectively. While there was no difference in ANC engraftment, platelet
engraftment was longer among patients requiring plerixafor.
Summary and Conclusions: This data confirms the effectiveness of this risk
adapted algorithm in over 1000 patients over 4 years. The mobilization failure
rate remains low. Approximately 45% of patients did not require plerixafor, sup-
porting the use of this risk adapted algorithm to select appropriate patients who
require plerixafor.
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Background: PT-Cy has been developed as GVHD prophylaxis after T-cell-
replete Haplo-SCT. Initially, bone marrow has been considered as the preferred
stem cell source because of the known higher risk of GVHD after PBSC tran-
plantation. However, there is no evidence that this observation is applicable
after Haplo-SCT using PT-Cy. For practical reasons we early decided to use
PBSC rather BM in this setting.
Aims: The objective was to evaluate the outcome of patients receiving PBSC
from a related haploidentical donor, using PT-Cy as GVHD prophylaxis.
Methods: Patients receiving a Haplo-SCT between March 2012 and December
2014 from 2 centres were included with following criteria: 1) high risk haema-
tological disease requiring Haplo-SCT in the absence of matched related and
unrelated donors; 2) PBSC as graft source; 3) PT-Cy 50 mg/kg at day +4 and
+3 used as part of GVHD prophylaxis. Study end points were the cumulative
incidences of acute and chronic GVHD, non-relapse mortality (NRM), cumula-
tive incidence of relapse (CIR) as well as progression free (PFS) and overall
survival (OS). Additionally, we analysed the composite endpoint GVHD and
relapse free survival (GRFS) for which the occurrence of relapse, death or
sever chronic GVHD were considered as relevant events.
Results: We analysed 102 patients (pts) with a median age of 57 years (range:
22-73). Fifty-two (51%) and 50 pts (49%) had myeloid and lymphoid diseases,
respectively. Seven pts (7%) with refractory AML received sequential RIC reg-
imen after intensive chemotherapy. Thirty-seven pts (36%) had high or very
high according to Disease risk index (DRI), while 64 pts (63%) had a HCT-CI
of 3 or more. Sixteen (16%) previously relapsed after a first allogeneic trans-
plantation. Conditioning regimens were classified as non-myeloablative
(cyclophosphamide (Cy)+fludarabine (Flu)+2 Gy TBI [n=69, 68%]), reduced
intensity (Cy + Flu + busulfan at 200 mg/m² total dose (Bu200) [n=4, 4%] or
Bu200+Flu+ thiotepa (TT) [n=10, 10%]) and myeloablative with reduced toxicity
(Bu at 400 mg/m² total dose + Flu + TT [n=12, 12%]). CSA+MMF or FK+MMF
were started on day +5 for additional GVHD prophylaxis to PT-Cy in 96 (94%)
and 6 (6%), respectively. All but 2 pt engrafted (2%). Median time to ANC and
PLT reconstitution was 21 (14-47) and 35 (10-134) days, respectively. The
median CD34+ and CD3+ infused cells were 5.1x10e6/kg (range 1.9-14.8) and
262x10e6/kg (range 59-587), respectively. Day-100 grade II-IV and III-IV acute
GVHD was 31% and 8%, respectively; 2-year all grades and sever chronic
GVHD was 18% and 2%, respectively. CD34+ and CD3+ cell dose did not influ-
ence the incidence of acute and chronic GVHD (median cut off). After a median
follow-up of 15 months (1-31), NRM at 100 days and 2 years were 12% and
23%, respectively. Relapse occurred in a median time of 3.3 months (0.5-14)
after Haplo-SCT, resulting in a 2-year CIR of 24%. PFS, OS and GRFS esti-
mation at 2 years were 53%, 55% and 48%, respectively (Figure 1). Among
the 17 AML patients who were transplanted in CR, the 2-year NRM, CIR, and
OS were 27%, 15% and 58%, respectively.
Figure 1.
Summary and Conclusions: Our results suggest the feasibility of Haplo-SCT
using PBSC and PT-Cy for high risk haematological malignancies. Notably, no
increased incidence of GVHD and NRM was observed comparing to bone mar-
row grafts. Importantly, for healthy donors, this source graft avoids risks related
to the use of general anaesthetic, necessary for bone marrow harvest. With
regard to the advanced pt characteristics our results are encouraging but need
further evaluation with longer follow-up.
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Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
is a curative therapy in some non-malignant pediatric diseases including bone
marrow failure, metabolic disease, immune deficiency, and so on. However,
allo-HSCT is still challenging in these disease due to the risk of TRM and GVHD.
Therefore, we analyzed the outcomes of allo-HSCT in pediatric non-malignant
disease, and compared the outcomes according to donor types.
Aims: We performed this study to estimate transplant outcomes of pediatric
non-malignant diseases, to analyze the efficacy of HSCT from alternative
donors in pediatric non-malignant diseases. and to find the fators affecting
transplant outcomes of pediatric non-malignant disease.
Methods: We retrospectively reviewed the medical records of 55 pediatric
patients with non-malignant disease who received allo-HSCT at Asan Medical
Center Children’s Hospital from January 2009 to November 2014. Thirty-six
patients had SAA, 7 had inherited bone marrow failure syndrome (1 Fanconi
anemia, 2 CAMT, 1 CDA, 1 Pearse syndrome, 1 PRCA, 1 Kostmann syndrome),
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6 had primary immune deficiency (1 IPEX, 2 WAS, 3 CGD), 5 had HLH, and 1
had Krabbe disease. To analyze the efficacy of HSCT, we investigated overall
survival (OS), event-free survival (EFS), incidence of TRM, cumulative inci-
dence (CI) of acute and chronic GVHD, incidence of graft failure (GF).
Results: Of the 55 patients, 40 were male and 15 were female. Median age at
HSCT was 12.9 years (range, 0.7-21.7). Seventeen patients received HSCT
from MSD (MSD-HSCT), 16 patients from URD (URD-HSCT) and 22 patients
from haploidentical family donor (HFD-HSCT). Six patients (11%) experienced
graft failure (GF). Of the 6 patients, 5 patients achieved engraftment after addi-
tional HSCT, and the remaining 1 survived with autologous recovery. Four
patients died of TRM, and one died of disease. TRM at 1 year and 2 years for
all patients were 4% and 6%, respectively. TRMs at 2 years were not different
according to the donor type (0% for MSD-HSCT, 14% for URD-HSCT, 5% for
HFD-HSCT; P=0.06). The CIs of aGVHD grade І-IV and cGVHD were 40% and
20%. However, CIs of severe aGVHD grade≥III and extensive cGVHD were
just 15% and 9%. There was no differences in incidences of acute GVHD and
chronic GVHD according to the donor type. At a median follow-up of 34.7 months
(range, 1.6-69.3), the 3-year OS were not different according to the donor types
(93% for MSD-HSCT, 87% for URD-HSCT, 95% for HFD-HSCT; P>0.05).
Summary and Conclusions: Given the high survival outcomes and low TRM,
our study suggests that allogeneic HSCT could be safe treatment modality to
the children with non-malignant disease. Especially, HSCT from alternative
donor could be beneficial to patients who lack MSD. However, a larger multi-
center study is needed to verify our results.
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Background: In recent year, reduced intensity conditioning (RIC) is developed
and increasingly used in allogeneic hematopoietic stem cell transplantation
(allo-HSCT) for elderly acute myeloid leukemia (AML) patients. Increasing age
is a repeatedly found significant risk factor for worse prognosis after allo-HSCT
among AML patients. However recent studies showed conflict results regarding
the association between age and outcome in the setting of RIC.
Aims: We conducted a large-scaled, nationwide retrospective study to examine
the impact of age on RIC transplantation outcomes for elderly AML patients
and other prognostic factors.
Methods: Clinical data were collected from the registry database of the Japan
Society for Hematopoietic Cell Transplantation. Patients with AML (excluding
acute promyelocytic leukemia) aged 50 years or older who underwent RIC
allo-HSCT from related or unrelated donor between January 2008 and Decem-
ber 2012 were extracted from the database. Patients who underwent second
or more HSCT were excluded. We retrospectively analyzed the clinical impact
of patient age on outcome of allo-HSCT. Patients were divided into the following
four group for analysis: 50 to 54, 55 to 59, 60 to 64 and ≥65 years old. Out-
comes after allo-HSCT of four age groups were compared. Overall survival
(OS) was estimated by the Kaplan-Meier method and was compared using a
log-rank test. Relapse and nonrelapse mortality (NRM) were considered com-
peting risk events for each other and were compared using Gray’s test. In a
multivariate analysis, the Cox proportional hazard model and Fine-Gray meth-
ods were used for OS and cumulative incidence of relapse and NRM respec-
tively, using the following variables: gender, donor source, disease status at
allo-HSCT, graft versus host disease (GVHD) prophylaxis, donor-recipient gen-
der mismatch, ABO mismatch, cytogenetic risk category and hematopoietic
cell transplant comorbidity index (HCT-CI).
Results: Of the 757 patients, 89 patients (11.8%) were 50-54 years old, 249
patients (32.9%) were 55-59 years old, 301 patients (39.8%) were 60-64 years
old and 118 patients (15.6%) were 65 years old or older. Higher proportion of
patients aged 60-64 years received graft from ABO matched donor, although dif-
ference was not significant (P=0.06). There was no difference in other factors,
including gender, disease status, cytogenetic risk category, HCT-CI, donor
source, gender mismatch and GVHD prophylaxis. The 3-year OS (47.8%, 45.2%,
37.9% and 36.6% for patients aged 50-54, 55-59, 60-64 and ≥65, respectively,
P=0.24) and NRM (24.0%, 22.8%, 29.2% and 27.6% for patients aged 50-54,
55-59, 60-64 and ≥65, respectively, P=0.49) were not significantly different among
4 age groups. In multivariate analysis, age had no significant effect on both OS
and NRM after adjusting for covariates. On the other hand, a multivariate analysis
showed mismatched related donor (HR 1.80; 95%CI 1.13-2.87; P=0.01) and
HCT-CI ≥3 (HR 1.51; 95%CI 1.04-2.17; P=0.03) were associated with higher
NRM; non-CR at allo-HSCT (HR 2.51 95%CI 2.01-3.14; P<0.001), mismatched
related donor (HR 1.44; 95%CI 1.04-1.97; P=0.03) and HCT-CI ≥3 (HR 1.46;
95%CI 1.14-1.87; P=0.003) were risk factors for worse OS.
Summary and Conclusions: The current study showed increased age had
no significant adverse impact on RIC allo-HSCT outcome and pre-transplan-
tation comorbidity has more impact than age in older AML patients.
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Background: Acute graft-versus-host disease (GVHD) is the most important
cause of death after allogeneic hematopoietic stem cell transplantation (allo-
HSCT), and antithymocyte globulin (ATG) has been used in the conditioning
regimens to prevent the severe GVHD in this setting. But the role and potential
efficacy of ATGin patients receiving cord blood transplantation (CBT) remains
controversial.
Aims: In the present study, we retrospectively compared the outcomes of routine
GVHD prophylaxis (cyclosporine-based regimens) plus pre-transplantation ATG
(ATG group) to routine GVHD prophylaxis alone (non-ATG group) in children
with high-risk or advanced hematological malignancies receiving unrelated CBT.
Methods: The study included patients younger than 18 years at transplantation
with hematological malignancies who received unrelated CBT between Febru-
ary 2000 and August 2013 at 8 child blood disease centers in China. Total of
207 patients enrolled in the study, and patients were divided into 2 groups:
those who received ATG (n=98) and those who received no ATG in the condi-
tioning regimens (n=109).
Results: The cumulative incidence of platelet recovery on day 100 was signif-
icantly lower in the ATG cohort as compared with the non-ATG cohort (77.3%
vs 89.8%) (p=0.046). There was no significantly difference in the incidence of
grade II–IV acute and chronic graft-versus-host disease (GVHD), and trans-
plant-related mortality (TRM) between the two groups (p =0.76, 0.57, 0.46).
The incidence of CMV infection was significantly higher among the ATG group
patients compared with that among the non-ATG group patients (p=0.003). The
5-year cumulative incidence of relapse was significantly higher in the ATG
cohort (30.7% vs 15.4%) (p=0.009). The overall survival (OS) in the non-ATG
group was slightly higher than the ATG cohort (64.1% vs 52.1%, p=0.093), and
the leukemia-free survival (LFS) in the non-ATG cohort was significantly higher
than the ATG cohort (56.6% vs 37.7%, p=0.015).
Summary and Conclusions: Our study demonstrated that, for high-risk or
advanced childhood hematological malignancies receiving unrelated CBT, the
omission of ATG in the conditioning had a faster platelet recovery, a comparable
GVHD and TRM, a significantly lower relapse risk, and an improved long-term
survival compared to the inclusion of ATG in the conditioning.
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TCR REPERTOIRE DIVERSITY ASSESSED WITH IMMUNOSEQUENCING
IS ASSOCIATED WITH PATIENT MORTALITY FOLLOWING CORD BLOOD
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Background: Immunosequencing represents a promising, fast and relatively
inexpensive method to assess the reconstitution of effective cellular immunity
following stem cell transplantation and has the potential to identify patients at
higher risk of developing life-threatening complications and treatment-related
mortality.
Aims: Diversity of the T-cell repertoire can provide a measure of immune com-
petence. We hypothesized that restoration of TCR repertoire diversity would
be associated with overall survival after UCBT. 
Methods: In order to study the clinical impact of T-cell receptor (TCR) diversity
in the setting of umbilical cord blood transplantation (UCBT), we retrospectively
analyzed samples from 76 patients in 2 independent study cohorts at separate
institutions. At Fred Hutchinson Cancer Research Center (FHCRC), we followed
34 patients with hematological malignancies who underwent myeloablation and
primarily double UCBT (2 single cord). This cohort was composed of 11 pediatric
and 23 adult patients (median age, 26.5yrs), primarily with acute leukemia
(n=26), 50% of whom had evidence of MRD at UCBT. They received fludara-
bine, cytoxan or treosulfan, and total body irradiation (TBI) with cyclosporine
and mycophenylate mofetil as GvHD prophylaxis. At Dana-Farber Cancer Insti-
tute (DFCI), we followed 42 adult patients (median age, 52.3 yrs), 19 with acute
leukemia, 18 of whom had evidence of disease at UCBT. All patients receive-
dreduced-intensity conditioning with fludarabine, melphalan, and anti-thymocyte
globulin (ATG) followed by double UCBT with tacrolimus and sirolimus as GvHD
prophylaxis. DFCI participants were selected to have predominantly cord T cell
chimerism. We analyzed peripheral blood pre-transplant, and at 1, 2, 3, 6 and
12 months after UCBT, based on sample availability. We performed high-
throughput sequencing of rearranged (TCR) loci to track presence and fre-
quency of individual T cell clones in each patient across time-points, as well as
to calculate estimated diversity of the TCR repertoire as a whole. We correlated
our measure of TCR repertoire diversity with clinical outcome, using one-year
survival as our primary endpoint.
Results: For the combined group of 63 patients with samples available 3
months after UCBT, 19 subsequently died within 1 year of transplant. Patient
with treatment-related mortality had significantly lower TCR repertoire diversity
at 3 months than other patients; when analyzed as 2 independent cohorts, the
29 patients at FHCRC with samples at 3 months after UCBT demonstrated sig-
nificantly lower TCR repertoire diversity in TRM patients (p=0.04), as did the
34 patients with samples available 3 months after transplant at DFCI (p=0.02).
In a univariate survival analysis using both cohorts, low TCR diversity at 3
months post-transplant was significantly associated with treatment-related mor-
tality (TRM; p=0.0006 by logrank test; see Figure). This result remained signif-
icant at p=0.006 in a multivariate analysis including several other clinical vari-
ables (patient age and CR2+ at transplant were associated with TRM in the
multivariate analysis; %CD3+ at 3 months and GVHD were not).
Figure 1.
Summary and Conclusions: In this study, we demonstrate that measurement
of TCR repertoire diversity generated using high-throughput sequencing genes
at 3 months after UCBT is significantly correlated with subsequent TRM mor-
tality within the first year. Low T cell diversity in the peripheral blood as soon as
3 months may therefore be an early indicator of inadequate immune reconsti-
tution and could potentially be used to tailor monitoring and therapy after UCBT
in several clinical contexts.
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G-CSF FOLLOWED BY MOBILIZED PERIPHERAL BLOOD
MONONUCLEAR CELLS IN CHILDREN WITH CEREBRAL PALSY
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of Translational Medicine, Hanyang University Graduate School of Biomedical
Engineering, 3Blood and Marrow Transplantation Center, 4Department of Radi-
ology, 5Department of Nuclear Medicine, 6Department of Rehabilitation Medi-
cine, Hanyang University Medical Center, Seoul, Korea, Republic Of
Background: Up to now most of the cells used in cell therapeutics have been
mesenchymal stem cells (MSCs). However, mononuclear cells from cord blood
or granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood
mononuclear cells (mPBMCs) may be an alternative option. In addition, cellular
components other than purified HSCs and MSCs could play important roles in
tissue regeneration.
Aims: We performed a randomized, double-blind, cross-over study to assess
the neuroregenerative potential of intravenous infusion of G-CSF followed by
mPBMCs in children with cerebral palsy (CP).
Methods: Children with the non-severe type of CP were enrolled in this study.
G-CSF was administered for 5 days, when mPBMCs were collected by aphere-
sis and cryopreserved. One month later (M1), recipients were randomized to
mPBMCs or placebo infusion, and switched at 7 months (M7). We assessed
the efficacy of treatment over 13 months after the G-CSF injection using various
tools for evaluating motor and cognitive function, as well as brain magnetic res-
onance imaging-diffusion tensor imaging (MRI-DTI) and brain positron emission
tomography (PET).
Results: Fifty-seven patients aged 4.3±1.9 (210) years and weigh-
ing16.6±4.9 (11.656.0) kg were enrolled; data for the mPBMCs collected
from them were total nucleated cell counts 5.97±1.99×108//kg, CD34+ cells
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3.07±2.1×106/kg. Forty-seven patients for whom serial data were available
were included in this analysis. After randomization, functional changes noted
by parents and neurodevelopmental tests showed tendencies to improve
with no significant differences between the mPBMC group and the placebo
group. Brain MRI-DTI revealed that fractional anisotropy (FA) in the splenium
of mPBMC group (p=0.048) and the right corona radiata of placebo group
(p=0.045) comparatively increased to similar extents, although increasing
tendencies in FA values in most regions of interest after infusion of mPBMCs
or placebo were noted without statistical significance. Additionally, in a sub-
group analysis, in the diplegia children, FA values in the mPBMC group were
significantly higher than in the placebo group in the left midbrain (p=0.044)
and right temporal lobe (p=0.05), and lower in the right midbrain (p=0.022).
In the brain PET analysis, we noted increased metabolism in 9 patients
(19.1%) in the mPBMC group and in 8 patients (17.0%) in the placebo group,
though the increases were not statistically significant. Interestingly, the par-
ents noted functional improvements between the time of G-CSF infusion (M0)
and the time (M1) when the children were randomized to the two groups in
27 (57.4%) of the total of 47 patients. Furthermore, there were significant dif-
ferences in score changes of neurodevelopmental tests between a span of
M0-M1 and M1-M7 or M7-M13 in both groups.
Summary and Conclusions: Although we did not detect any additional effect
of mPBMC reinfusion, functional and anatomical changes were noted in the
brains of CP children after receiving G-CSF followed by mPBMCs. Interest-
ingly, we observed significant differences in score changes of neurodevelop-
mental tests between a span of M0-M1 and M1-M7 or M7-M13, which sug-
gests that G-CSF administration on its own, without mPBMC collection and
reinfusion, may be beneficial in countering neurological impairment in children
with CP.
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PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD
TRANSPLANTATION: THE CLINICAL CHARACTERISTICS AND
STRATIFIED INTERVENTION TREATMENT
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L. Zhang1, Z. Sun1
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Background: Pre-engraftment syndrome (PES), a clinical entity of unknown
pathogenesis, has been described in patients receiving umbilical cord blood
transplantation(CBT). Although a uniform definition is lacking, PES is commonly
defined as noninfectious fever and various other clinical findings before neu-
trophil engraftment, including skin rash, pulmonary infiltrates, and diarrhea,
jaundice, or weight gain. However, PES remains poorly characterized, the prog-
nosis and appropriate management of PES are also unclear.
Aims: The aim of this study was to investigate the incidence, risk factors, clin-
ical outcomes of PES in CBT recipients and establish a prognosis assessment
score system to guide the stratified intervention treatment.
Methods: Between June 2006 and April 2014, a total of 204 consecutive hema-
tological malignancies patients underwent UCBT in Anhui Provincial Hospital
were analyzed. All the patients received TBI-based(n=119) or BuCY2
based(n=85) myeloablative conditioning. Cyclosporine and mycophenolate
mofetil were used as GVHD prophylaxis. A retrospective analysis of 94 patients
between June 2006 and March 2012 was first done to find out the poor prog-
nostic risk factors of PES. Then we made a PES score system according to
the high risk factors, and between April 2012 and April 2014, 88 patients with
PES in 110 patients were given stratified intervention treatment.
Results: In all 204 patients, PES developed in 154 patients (75.5%) at a medi-
an of 7 days after UCBT. Risk factors for developing PES included TBI-based
myeloablative conditioning and double units CBT. The age, sex, weight, under-
lying malignancy, BM status at CBT, HLA match, ABO compatibility, total infused
TNC dose and total CD34+ cell dose had no impact on PES incidence. Of the
94 patients in the period of June 2006 and March 2012, the cumulative inci-
dence of grade II to grade IV acute GVHD by 100 days after CBT was higher
in patients with PES than in those without PES (52.5% versus 20.3%, P <0.01).
The cumulative incidence of neutrophil engraftment at 42d after CBT was also
higher in patients with PES than in those without PES (97.5% versus 78.0%,
P <0.05). PES occurrence did not impact chronic GVHD, treatment-related
mortality, relapse, overall survival(OS) or disease-free survival(DFS). But we
found that PES occurred in 7 days (<7days), over three or more clinical symp-
toms, poor effectiveness of MP (ineffectiveness within in one week) were the
poor prognostic risk factors of PES. So we made a PES score system according
to 3 high risk factors, the existence of one risk factor was defined as 1 point,
and no risk factors with 0 score. We found that the higher the PES score, the
lower the OS(P<0.001). Then between April 2012 and April 2014, 88 patients
with PES in all 110 patients were given stratified intervention treatment, patients
with 1 high risk factor were treated with MP 1 mg/kg/d, and patients with 2 or
more high risk factors were treated with MP 2 mg/kg/d. If MP was invalid or the
disease progressed, anti-CD25 antibody was timely used. After the stratified
treatment according to the PES score system, the prognosis of severe
PES(score 2+3) was significant improved by 1-year OS between the two dif-
ferent periods (June 2006 to March 2012 and April 2012 to April 2014) (26.4%
versus 65.1%) (P<0.05).
Summary and Conclusions: PES seems to be common after CBT and may
be associated with enhanced engraftment and aGVHD incidence. We have
established a prognosis assessment score system according to poor prognostic
risk factors of PES and for the first time put forward a new insight for PES strat-
ified intervention treatment. Severe PES patients could be benefit from active
treatment.
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Background: Hematopoietic stem cell transplantation (HSCT) has contributed
to improved outcome in childhood acute leukemia (AL). However, post-HSCT
relapse is associated with a dismal prognosis and its optimal treatment remains
unclear.
Aims: We aimed to compare patients’ related factors and treatment strategy,
in case of relapse or progression postallogeneic HSCT in children with AL in a
recent ten-year period.
Methods: A total of 334 children who received a first allogeneic HSCT for ALL
or AML from January 2000 to December 2009 experienced a relapse or pro-
gression thereafter. They were treated in the 33 centers of the SFGM-TC,
among them 286 cases were analysable. Primary endpoint was overall survival
(OS) after diagnosis of relapse or progression post first HSCT whatever the
treatment post relapse was.
Results: 286 patients (113 females and 173 males) with a median age of 8.9
years at transplantation (range: 0.52-17.99) were included. Diseases were 151
ALL (B-ALL, n=125; T-ALL n=29), 123 AML. At transplantation, 234 patients
were in complete remission (CR) (CR1 n=122, CR2 n=94, CR3 n=18) . Donors
were matched related siblings (36%), mismatched related (4%), matched unre-
lated (18%), mismatched unrelated (24%), unrelated without precision (16%)
or syngenic (2%). Stem cell source was bone marrow, peripheral stem cells,
umbilical cord blood in 65%, 12%, 23% of cases, respectively. Median time
from diagnosis to first HSCT was 263 days. 91% children received myeloabla-
tive conditioning and 55% received TBI. Acute GVHD after first HSCT occurred
in 157 patients (grade I n=62 grade II to IV n=94). Median delay from first
HSCT to failure was 182 days. Treatments for relapse after first HSCT consisted
in chemotherapy alone (n=107), chemotherapy followed by second HSCT
(n=70), supportive and palliative care (n=68), combination of chemotherapy
and DLI (n=28), or DLI only (n=13). With a median follow up of 1315 days
(range 58;4182), median OS duration after relapse was 149 days. Median sur-
vival duration in days according to therapy was as follows [confidence interval]:
DLI after chemotherapy =407 [156;658], Second allograft: 391 [264;518],
chemotherapy: 174[118;239], DLI alone: 140 [10;270], Palliative care: 43
[33;53] . Cox model analysis showed the following hazard ratio, when compar-
ing to the best line of treatment, ie chemotherapy+DLI; second allograft HR
1.41, (p=0.20), chemotherapy alone; HR 2.05, (p=.008), DLI HR 2.00 (p=0.08),
palliative care HR=5,7, (p<.001). The time interval from transplantation to
relapse was also associated with prognosis: when comparing to relapses occur-
ing within the first 90 days, day 90-179, day 180-269,and ≥270 days yielded
hazard ratios of respectively .549, .479 and .293 (p ≤.003). There was no impact
on outcome from the following variables: gender, age at transplant, leukemia
subtype,type of conditioning, TBI, GVHD occurrence after thefirst
transplant,stem cell source.
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Figure 1.
Summary and Conclusions: The therapeutic choice after post transplant
relapse is a sensitive decision influenced by several factors. However, this
study highlights the positive role of immunotherapy: the longest survival was
achieved either through a second HSCT or through a combination of
chemotherapy and DLI, both yielding similar long-term results.
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Background: The major pitfall affecting clinical trials of high-dose therapy
(HDT) followed by autologous stem cell transplant (ASCT) in lymphomas is the
high heterogeneity of histological entities. As a consequence, the statistical
power is reduced when we focus on a specific histological subset, and data
are often not conclusive. We previously demonstrated (Visani et al, Blood 2011)
the safety of a new conditioning regimen with bendamustine, etoposide, cytara-
bine, and melphalan (BeEAM) prior to ASCT in resistant/relapsed lymphoma
patients (EUDRACTnumber2008-002736-15). The regimen showed long-last-
ing significant anti-lymphoma activity, with a 3-year PFS of 75%. However, that
study enrolled both Hodgkin and non-Hodgkin lymphoma patients.
Aims: We designed a phase II study to evaluate the efficacy of the BeEAM
conditioning in resistant/relapsed diffuse large B-cell non-Hodgkin lymphoma
(DLBCL) patients.
Methods: The study was registered at European Union Drug Regulating
Authorities Clinical Trials (EudraCT) N. 2011-001246-14. Until now, 57 patients
(median age 54 years, range 19-69) were enrolled. At the time of writing,44
patients with resistant/relapsed diffuse large B cell non-Hodgkin lymphoma are
evaluable. The primary end-point of the study is to evaluate the 1-year complete
remission rate. Fixing the lowest acceptable rate as 55% and the successful
rate as 70%, with a significance level alpha=0.05 and a power 1-beta =0.90,
the sample size was estimated in 88 patients.
Results: Briefly, 33/44 patients had advanced stage disease (III-IV), 14 were pri-
mary refractory and 30 had relapsed after a median number of 2 lines of therapy
(range: 2-3). Eleven patients had 1 or more relevant comorbidities (range: 1-5).
22 patients were in II or subsequent CR after salvage therapy, whereas 19 were
in PR and 3 had progressive disease. A median number of 5.90x106CD34+/kg
cells (range 2,8-9,42) collected from peripheral blood was reinfused to patients.
All patients engrafted, with a median time to ANC>0.5x109/l of 10 days. Median
times to achieve a platelet count >20x109/l and >50x109/l were 12 and 16 days
respectively. Ten out of 44 patients presented a fever of unknown origin (23%),
whereas 21 patients (47%) presented a clinically documented infection. All patients
received G-CSF after transplant for a median time of 8 days (range: 8-13). One
patient died due to an incomplete hematological recovery after transplant, pro-
ducing an overall transplant related mortality of 2.7%. Thirty-eight out of 44 patients
are evaluable up to now for response to treatment. 31/38 (81.5%) obtained a CR,
3/38 a PR, whereas 4/38 did not respond to therapy. After a median follow-up of
12 months after transplant (range 2-30), 4/38 patients were refractory, 7/38
relapsed, and 27/38 (71%) are still alive, in continuous CR.
Summary and Conclusions: The stringent inclusion criteria at enrollment allowed
theevaluation ofthe impact of HDT with Bendamustine followed by ASCT in a highly
selected population of patients with DLBCL only. Accordingly, our data preliminary
provide the evidence that the Benda-BEAM regimen is safe and has promising
high efficacy in resistant-relapsed aggressive diffuse large B cell lymphoma patients.
Acknowledgements: The study was supported in part by AIL Pesaro Onlus.
Mundipharma Italy is grateful acknowledged for providing Bendamustine free
of charge.
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Background: Chronic Graft Versus Host Disease (cGVHD) affects about 60%
of all patients receiving an allogeneic HSCT and surviving beyond day 100.
Incidence of cGVHD is rising because of the widespread use of Peripheral
Blood Stem Cells (PBSC) as stemcell source. Patients with cGVHD have high
morbidity and mortality rates. Patients require long term use of immunosup-
pressive drugs, mainly corticosteroids, which lead to development of severe
side effects. Therefore new therapies are urgently needed.
Aims: We tested whether the sequential therapy of the anti CD20 antibody rit-
uximab followed by a 6 month treatment period with the tyrosine kinase inhibitor
nilotinib is a good treatment strategy for patients with sclerotic cGVHD.
Methods: We treated 19 patients with a combination of 4 weekly infusions of rit-
uximab followed by a 6 month period of treatment with nilotinib (300mg b.i.d.).
Patients were evaluated monthly for 13 months and sequential blood samples and
skin biopsies were analyzed. All patients gave informed consent before enrollment.
Results: 3 patients experienced severe side effects from either rituximab or
nilotinib treatment and therefore were taken off study. Of the remaining 11
patients who thus far have completed the study protocol, 65% showed a
response (4 patients went from NIH scoring ‘severe’ to ‘moderate’, 1 patient
went from NIH scoring ‘moderate’ to ‘no cGVHD’). There is also a significant
decrease in cGVHD affected body surface area (Figure 1). Moreover, two out
of four patients who suffered from severe ulcerations at the start of the study
had a complete resolution of ulcers at the end of the treatment period. Patients
with a (partial) response also showed a decrease in self attributed severity of
cGVHD and their immunosuppressive drugs could be tapered.
Figure 1. Percentage of total body surface area affected by chronic Graft
versus Host Disease is plotted against time in months after start of the
study. Each dot represents 1 patient. P-values are calculated by means
of Wilcoxon matched-pairs signed rank test.
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Summary and Conclusions: The sequential therapy of B-cell depletion and
tyrosine kinase inhibition provides a new and interesting alternative treatment
option for this difficult and heavily pretreated patient category.
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Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is the only curative treatment options to hematologic malignancies. However,
majority of patients with refractory or resistant hematologic malignancies can
not achieve remission before transplantation. It is necessary to design a safe
and affective conditioning regimento reduce the tumor burden, improve there-
mission rate, decrease thetransplantation related mortality andimprove dis-
ease-free survivalin patients with advanced acute myloid leukemia(AML) and
myelodysplastic syndrom(MDS). One of the promising drugs of epigenetics is
decitabine (DAC), which has a significant effect on a variety of hematologic
malignancies including MDS and advanced AML. Furthermore, decitabine can
not only up-modulate the tumor-associated antigen express on surface of
leukemia cells to increase graft-versus-leukemia (GVL) effect but also can
reduce the incidence of graft-versus-host disease (GVHD) by increase the
number of regulatory T Cells (Tregs).
Aims: Therefore, this clinical study will investigate the security and efficacy of
conditioning regimen containing low-dose decitabine combined with modified
BUCY regimen for advanced AML/MDS patients and explore the role of
immunomodulatory activity post transplantation.
Methods: 20 cases of patients with advanced AML/MDS underwent allo-HSCT
with low-dose decitabine (integral dose100mg/m2) combined with modified
BUCY conditioning regimens.
Results: 19/20 (95%) patients achieved complete remission and hematopoietic
reconstitution after transplantation.The median time of neutrophil and platelet
recovery were 12 (10-22) and 14.5 (12-35) days respectively. The transplan-
tation-related mortality (TRM) rate was 0.The cumulative rate of aGVHD and
cGVHD were 25.6% and 48.3%.And the cumulative rate of aGVHD for grade
III and IV were 10.6%. The cumulative relapse rate was 26.7%. During a medi-
an follow-up of 246 (19-613) days,15 patients weredisease free survival.The
estimated 2-year overall survival (2yr-OS) rate was 78%.The 2 year disease-
free survival (2yr-DFS) rate was 62.6%. Furthermore, Therewasnosignificant-
differenceof the estimated 2-yr OS and DFS between patients with or without
DNMT3A mutations or abnormalities of chromosome 7 and complex chromo-
somal karyotype.
Summary and Conclusions: 1.It is feasible to use conditioning regimen con-
taining low-dose decitabine combined with modified BUCY regimen before allo-
HSCT.The treatment were well tolerated and transplantation-related mortality
(TRM) rate was 0. 2..The incidence of aGVHD and cGVHD were not increased
in this setting. 3. 92.3% patientsachieved complete remission with salvage allo-
HSCT with ralative high 2-yr rate of OS and DFS. 4.Theprognosisand survival
of the patients with complex chromosomal karyotype or chromosome 7 abnor-
malities or DNMT3A mutation may be improved by treating with decitabine
containing conditioning regimen.
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STUDY OF PERIPHERAL STEM CELLS MOBILIZATION AS A TREATMENT
LINE FOR PEDIATRIC IDIOPATHIC DILATED CARDIOMYOPATHY
M. El-Shanshory1,* S. abdou2, W. El-Shehaby3, A. Fathey4
1Pediatrics, Faculty of Medicine, 2Clinical pathology, 3Pediatrics, Faculty of
Medicine, Tanta University, Tanta, 4Pediatrics, Ministry of Health, Fayom, Egypt
Background: Mobilizing hematopoietic stem cells may be a promising inter-
vention to the treatment of idiopathic dilated cardiomyopathy (IDCM) in infant
and children.
Aims: Evaluating the efficacy of granulocyte-colony stimulating factor (G-CSF)
as a therapeutic modality in pediatric idiopathic dilated cardiomyopathy (IDCM).
Methods: This randomized clinical trial was conducted on 15 pediatric patients
with IDCM admitted at Cardiology Unit, Pediatric Department, Tanta University
Hospital. They were subjected to history taking, clinical examination, total CPK,
CK-MB isoenzyme, and peripheral blood CD34+ cell assessment before and
at day 6 after subcutaneous G-CSF injection for 5 consecutive days. Echocar-
diography was done before and one month after therapy.
Results: Clinical improvement in the form of regression of patients ROSS heart
failure classes. Increased percentage of CD34+ mobilized cells from the bone
marrow, and significant increase in blood counts especially white blood cells 6
days after G-CSF injection. Significant improvement in echocardiographic data
evaluating systolic function of the heart (Ejection fraction, Fractional shortening
and systolic velocity at mitral annulus. But, with no significant correlation
between increased percentage of CD34+ cells and improvement in echocar-
diographic parameters.
Tabella 1. Modified Ross H.F Classes before and after one month from
receving G-CSF therapy.
Tabella 2. Systolic functions of the heart among studied group before &
one month after receving G-CSF therapy.
Summary and Conclusions: Administration of G-CSF may be beneficial in
improving systolic functions of the heart in pediatric idiopathic dilated cardiomy-
opathy.
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IKAROS CONTRIBUTES TO B CELL TOLERANCE BY MODULATING
MAPK ACTIVITY
B. Heizmann1,* A. Macias-Garcia1, M. Sellars1, H. Dali2, J.L. Pasquali2,
S. Muller2, P. Kastner1, S. Chan1
1Hematopoiesis and leukemogenesis in the mouse, Institut de Génétique et
de Biologie Moléculaire et Cellulaire (IGBMC),, Illkirch, 2Institut de Biologie
Moléculaire et Cellulaire (IBMC), Strasbourg, France
Background: B cell differentiation is a multiple process that involves the
dynamic activation and silencing of hundreds of genes. The Ikaros transcription
factor is a key regulator of B cell differentiation and function. The IKZF1 gene,
which encodes the Ikaros transcription factor, was recently identified as a sus-
ceptibility locus for systemic lupus erythematosus (SLE), and leukocytes from
SLE patients have reduced IKZF1 mRNA levels, suggesting a possible link
between Ikaros loss and SLE development.
Aims: How Ikaros deficiency may contribute to SLE is presently unknown.With
this study, we want to understand the biological processes influenced by Ikaros
resulting in defectiveB cell tolerance associated with autoimmune disorders.
Methods: To study the function of Ikaros transcription factor as a regulator of
peripheral B cell maturation, activation, and tolerance, we used hypomorphic
and B cell conditional knock-out models for Ikaros.
Results: We show that mice with Ikaros null B cells spontaneously produce
high levels of IgM autoantibodies associated with SLE (against chromatin/nucle-
osomes, double-stranded DNA, all histones), demonstrating a direct role for
Ikaros in generating autoreactive B cells. Naive Ikaros null B cells are hyper-
reactive to B cell receptor (BCR) induced stimulation and show a diminished
requirement for secondary co-stimulatory signals, with enhanced survival and
increased proliferation. Unexpectedly, Ikaros deficiency induces gene expres-
sion changes in naive B cells that render them poised for activation. Freshly
isolated Ikaros null B cells show defects in the MAPK signaling pathway that
result in enhanced and sustained phosphorylation of p38 and ERK-1/2 upon
activation. Inhibition of p38 and ERK activity rescues the hyper-reactive phe-
notype. Interestingly, Ikaros deficiency in B cells is not sufficient for progression
to a pathological state as mutant mice do not develop clinical signs of lupus,
suggesting that Ikaros deficiency functions as a trigger for disease initiation
but is not sufficient for SLE progression.
Summary and Conclusions: Altogether, our results implicate Ikaros as a novel
negative regulator of BCR signaling which helps to maintain B cell tolerance to
self-antigens during maturation by modulating MAPK events downstream of
the BCR.
P358
HIGH-THROUGHPUT SIRNA SCREENING REVEALS GATA-2 UPSTREAM
TRANSCRIPTIONAL MECHANISMS IN HEMATOPOIETIC CELLS
Y. Saito1,* T. Fujiwara1,2, M. Kobayashi1, M. Suzuki1, Y. Okitsu1, N. Fukuhara1,
Y. Onishi1, K. Ishizawa1, H. Harigae1,2
1Hematology and Rheumatology, 2Molecular Hematology/Oncology, Tohoku
University Graduate School of Medicine, Sendai, Japan
Background: Hematopoietic stem cells (HSCs) are capable of self-renewing
and differentiating into all blood cell types. The transcription factor GATA-2 is
expressed in HSCs and progenitor cells and is essential for cell proliferation,
survival, and differentiation. Recently, studies of aplastic anemia, MonoMAC
syndrome, and lung cancer demonstrated a mechanistic link between GATA-2
and human pathophysiology. GATA-2-dependent disease processes have been
extensively studied; however, GATA-2 upstream transcriptional mechanisms
remains poorly understood.
Aims: We conducted high-throughput screening analysis of siRNA libraries to
identify novel factors involved in GATA-2 regulation.
Methods: Human hematopoietic cell lines, YN-1 (Endo et al, 1993), K562,
KG1a, Jurkat, U937, and NALM6 were analyzed. GATA-2 regulatory element
was cloned into luciferase plasmid (pGL4.20, Promega) and mutation within
the cis-element was introduced using a site-directed mutagenesis kit (Agilent).
For siRNA screening, we targeted 995 genes encoding transcription factors
from the siPerfect transcription factor library (RNAi Co., Ltd.). YN-1 cells stably
expressing GATA-2 +9.9/1S-luciferase were transfected with each siRNA
duplex by 96-well plate GenomONE-Si (Ishihara Sangyo), and luciferase activity
was analyzed using a ONE-Glo Luciferase Assay System (Promega). siRNA-
mediated knockdown (Dharmacon) and CRISPR/Cas9-mediated knockout
(Invitrogen) were conducted with nucleofector (Lonza).
Results: GATA-2 transcription involves two different exons, a distal (1S) and
proximal (1G) promoter, with the former being considered important in
hematopoietic cells (Pan et al, 2000). We first demonstrated that GATA-2 1S
transcript was most abundantly expressed in YN-1 cells. Next, using transient
luciferase analysis to determine the optimal configuration for siRNA screening,
we demonstrated that 1S promoter fused to a +9.9 kb intronic enhancer and
involved in MonoMAC syndrome pathogenesis (Johnson et al, 2012), exerted
the highest promoter activity. Disruption of the GATA binding motif within the
+9.9 kb enhancer resulted in a significant decrease in +9.9 kb/1S luciferase
activity. Next, we established a stable YN-1 cell line expressing GATA-2 +9.9
kb/1S-luciferase and demonstrated significantly diminished luciferase activity
following knockdown of BRG1, a previously reported GATA-2 regulator (Sanalku-
mar et al, 2014). Following siRNA library screening, 10% of genes with the high-
est luciferase activity repression after their knockdown were initially selected
from each 96-well plate (n =83), which included potential GATA-2 regulators of
GATA1, GFI1B, and ERG. The list of candidate genes was further refined based
on their potential importance in hematopoiesis. CITED2, previously reported as
a CBP/p300-dependent transcriptional co-activator involved in pathogenesis of
bone marrow failure (Chen et al. Blood 2007; Kranc et al. Cell Stem Cell 2008),
and EGR1, a transcription factor involved in HSC homeostasis as well as leuke-
mogenesis (Min et al. 2008; Stoddart et al. 2014), were subsequently identified.
siRNA-mediated knockdown of CITED2 and EGR1 led to significant GATA-2
downregulation. Further, CRISPR/Cas9-mediated knockout of CITED2 resulted
in significant GATA-2 downregulation. We are currently performing a molecular
analysis how CITED2 and EGR1 affect GATA-2 expression.
Summary and Conclusions: Our approach represents a powerful tool for
identifying GATA-2 regulatory mechanisms and may lead to the development
of novel therapeutic approaches for human diseases, including bone marrow
failure syndromes.
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FUMARATE HYDRATASE IS AN ESSENTIAL REGULATOR OF EMBRYONIC
AND ADULT HAEMATOPOIETIC STEM CELL
A.V. Guitart1,* M. Vukovic1, Z. Sas1, M. Vila1, C. Sepúlveda1, T. Panagopoulou1,
L. Allen1, P. Pollard2, N. Morton3, A. Finch2, K.R. Kranc1,2
1MRC Centre for Regenerative Medicine, 2Edinburgh Cancer Research UK
Centre, 3Queen’s Medical Research Institute, Edinburgh, United Kingdom
Background: Lifelong adult haematopoiesis critically depends on rare multi-
potent haematopoietic stem cells (HSCs). HSCs reside in niches within the
foetal liver (FL) during embryogenesis and the bone marrow (BM) after birth.
These specific microenvironments allow HSCs to maintain a particular meta-
bolic status that is essential to preserve their properties. Quiescent long-term
HSCs rely on glycolysis but switch to oxydative phosphorylation in order to
comply with the energetic demands of self-renewing or differentiation. However,
the tricarboxylic acid (TCA) cycle’s contribution to HSC metabolism remains
poorly understood. 
Aims: The aim of this study is to elucidate the role of the TCA cycle in
haematopoiesis by deleting one of the key enzymes, fumarate hydratase (FH),
that drives the hydration of fumarate into malate.
Methods: In order to determine the role of FH within the haematopoietic sys-
tem, we opted for an in vivo genetic loss of function approach. We crossed
floxed Fh1 conditional mice with Vav-iCre mice to induce a constitutive
haematopoiesis-specific Fh1 deletion.
Results: We demonstrate that Fh1 is indispensable to the haematopoietic sys-
tem as its deletion is embryonic lethal. Indeed, Fh1 deletion leads to complete
foetal liver failure resulting in a severe defect in differentiation coupled with an
expansion of the most primitive cell compartments. Using a different mouse
model, we validated these results in the adult by reproducing the phenotype
after conditional deletion (Mx-Cre). Metabolic analysis of haematopoietic cells
lacking Fh1 (combining LC/MS and SeaHorse approach) revealed that in addi-
tion to harbouring a compromised TCA cycle, Fh1-deficient cells exhibit a higher
cellular concentration of fumarate. In order to discriminate which of these two
metabolic changes triggers the observed phenotypes we reintroduced the
cytosolic isoform of Fh1 thereby restoring intracellular fumarate concentration
while maintaining the TCA cycle impairment. We demonstrate that this genetic
addition is enough to rescue the embryonic lethality, the multilineage differen-
tiation potential and the self-renewing capacity of HSCs upon transplantation.
Summary and Conclusions: With this study, we demonstrated an absolute
requirement for Fh1 for embryonic and adult haematopoiesis. From the dual
function of Fh1 we established that while the mitochondrial isoform of Fh1 is
largely dispensable for HSC maintenance and multilineage differentiation, effi-
cient clearance of fumarate from the cytoplasm by the cytosolic isoform of Fh1
is fundamental.
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DECODING THE CENTRAL ROLE OF RCOR1 IN PROLIFERATION AND
DIFFERENTIATION OF HAEMATOPOIETIC STEM AND PROGENITOR
CELLS IN ZEBRAFISH
C. Labalette1, K. Georgopoulou1, D. Stemple2, G. Jarvis3, A. Cvejic1,*
1Haematology, University of Cambridge, 2Wellcome Trust Sanger Institute,
3Department of Physiology, Development and Neuroscience, University of
Cambridge, Cambridge, United Kingdom
Background: The corepressor Rcor1 was initially discovered as a novel genetic
determinant of platelet number in meta-analyses of genome wide association stud-
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ies (GWAS) for mean platelet volume and platelet count. More recently, it has
been suggested to play a role in terminal differentiation of murine erythrocytes.
Aims: However, the mechanisms by which rcor1 affects haematopoiesis during
development and what transcription factors it mediates its effect through remain
unclear.
Methods: To address this lack of knowledge, in this study, we used already
validated methods of reverse genetics in zebrafish.
Results: Here we report on the novel role of Rcor1 in proliferation of
haematopoietic stem and progenitor cells (HSPCs) during zebrafish embryonic
development. Indeed, knock down of Rcor1 activity resulted in enhanced pro-
liferation of HSPCs after their migration to the caudal haematopoietic tissue,
which is the zebrafish equivalent to the mammalian foetal liver. This expansion
of HSPCs was accompanied by a block in differentiation. Interestingly, the loss
of transcription factor gfi1aa (gfi1aasa18719/sa18719) completely phenocopied
the rcor1 defect in proliferation of HSPCs. However, analysis of
gfi1aasa18719/sa18719 mutant HSPCs revealed that they had normal differenti-
ation capacity. We further show that inhibition of Notch signalling partially res-
cued the ability of rcor1-depleted HSPCs to undergo differentiation.
Summary and Conclusions: Taken together, our data suggest that Rcor1
mediates the complex interplay between HSPC proliferation and differentiation
by modulating the activity of diverse transcription factors.
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DUVELISIB (IPI-145) INHIBITS MALIGNANT B-CELL PROLIFERATION
AND DISRUPTS SIGNALING FROM THE TUMOR MICROENVIRONMENT
THROUGH MECHANISMS THAT ARE DEPENDENT ON PI3K-DELTA AND
PI3K-GAMMA
M. Peluso1, K. Faia1, D. Winkler1, S. Sharma1, N. Patel1, K. White1,
V. Palombella1, K. McGovern1, J. Kutok1,*
1Infinity Pharmaceuticals, Cambridge, United States
Background: In indolent non-Hodgkin lymphoma (iNHL) and chronic lympho-
cytic leukemia/small lymphocytic lymphoma (CLL/SLL), the neoplastic B cells
rely upon support from non-neoplastic cells within their microenvironment for
proliferation and survival. Support cells include T cells, myeloid-derived cells,
and mesenchymal stromal cells, which provide phosphoinositide-3 kinase
(PI3K)-dependent survival and growth signals for the neoplastic cells, as well
as signals that maintain the tumor microenvironment (TME). Duvelisib (IPI-
145) is an oral dual inhibitor of PI3K-δ and PI3K-γ in clinical development for
iNHL and CLL/SLL.
Aims: To better understand the roles of the PI3K-δ and PI3K-γ isoforms in
mediating signaling between the tumor and TME cells in B-cell
malignancies,Infinity’s potent PI3K isoform-selective compoundsthat targetei-
ther PI3K-δ or PI3K-γ with >100-fold selectivity over other PI3K isoforms were
utilized in in vitro experiments.
Methods: A mixture of cytokines (CD40L/IL-2/IL-10) was utilized in an assay
that recapitulated TME-induced malignant B-cell proliferation.
Results: Duvelisib inhibited CD40L/IL-2/IL-10-induced proliferation of primary
CLL cells with an average EC50 in the sub-nanomolar range. The use of PI3K
isoform-selective inhibitory compounds revealed these proliferative signals are
PI3K-δ dependent, as the PI3K-δ-selective inhibitor was more active than the
PI3K-γ-selective inhibitor. While these experiments established the PI3K-δ
dependence of TME-derived cytokines on CLL cell proliferation, the role of
PI3K-γ in key functions such as the directed migration of non-malignant immune
cells of the TME was also tested. The stromal chemokine, CXCL12, resulted
in upregulation of phospho (p)-AKT in the CD3+ T cell populations in CLL
patient PBMCs. Using isoform-selective inhibitors, the increase in CXCL12-
induced pAKT in CD3+ T cells was found to be mediated by PI3K-γ. Chemo-
tactic assays demonstrated reduced migration of total CLL PBMCs towards
CXCL12 in the presence of the PI3K-δ and PI3K-γ inhibitor duvelisib. Flow
cytometric analyses of these migrating cells revealed that duvelisib had the
greatest effect on CXCL12-induced migration of T-cell population. Utilizing PI3K
isoform-selective compounds, the inhibition of T-cell migration toward CXCL12
was found to be a PI3K-γ mediated process, as the PI3K-γ-selective inhibitor
was more potent than the PI3K-δ-selective inhibitor in blocking T-cell migration.
Myeloid-derived cells can also support CLL cell survival as components of the
TME. Murine bone marrow cells were polarized in vitro into M2-macrophages
with MCSF and IL-4. This polarization was blocked by the PI3K-g-selective
inhibitor but not the PI3K-d-selective inhibitor. Finally, co-cultures of M2
macrophages with CLL cells led to extended CLL cell survival. These data
show that macrophage polarization toward an M2 phenotype is dependent
upon PI3K-γ and that M2-cells can support CLL cell survival.
Summary and Conclusions: T cells and myeloid cells provide a survival and
proliferative advantage to malignant CLL cells within the TME. The role of PI3K-
γ in the migration and polarization of these cells supports the potential for ther-
apeutic benefit from inhibition of PI3K-γ. By inhibiting both the PI3K-δ and
PI3K-γ isoforms, duvelisib is uniquely positioned to inhibit key signals important
in the pathogenesis of B-cell malignancies.
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BONE MARROW ADIPOGENESIS BY ACTIVATING PPARΓ SIGNALING
INHIBITS POSTINJURY RECOVERY OF MOUSE HEMATOPOIETIC
STRESS MODEL
W. Lu1,* R. Zhu2, W. Wang1, S. Wang1, Y. Feng1, K. Liu1
1Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Institute
of Hematology, Peking University People’s hospital, 2Centre of Excellence in
Tissue Engineering, Peking Union Medical College hospital, Beijing, China
Background: Adipocytes have been considered as passive tissue filler of bone
marrow(BM) niche for a long time.However, recent reportsshow thatadipocyte-
rich BM harbored a decreased frequency of progenitor cells. Furthermore, “fat-
less” mouse BM cells exhibit improved engraftment after transplantation. Our
previous studies alsoreveal that hematopoietic recovery is accelerated by using
PPARγ inhibitor BADGE after chemotherapy. However, it is still unclear how
adipocytes affect hematopoietic recovery under stress conditions. In our study,
we set out to test the hypothesis that adipocytes could affect the function and
migration of hematopoietic stem cell(HSC) following hematopoietic stress.
Aims: To investigate the effect of BM adipogenesis on the function and migra-
tion ofHSC in response to stress in mice.
Methods: For induction of hematopoietic stress, C57BL/6J female mice(6-8
weeks, 18-20g, n=90) were administrated once by intraperitoneal injection with
250mg/kg 5-Fu. Rosiglitazone group animals were fed 5g chow/d containing
0.15mg/g.d rosiglitazone before 5-Fu. BADGE group animals were adminis-
tered 60mg/kg/d BADGE following chemotherapy. To observe the level of BM
adipogenesis, tibias were collected and detected by histopathology. PPARγ,
aP2, adiponectin mRNA level was evaluated by RT-PCR. Peripheral blood
cells(PB) and BM mononuclear cells(BMMNC) were counted using the hema-
tology analyzer. The number of progenitor cell in BM were analyzed by colony-
forming cell assay. Immunophenotype and cell cycle of hematopoietic stem
cells were quantitatively estimated by flow cytometry.
Results: We found that BM adipogenesis could be successfully induced by
rosiglitazone treatment under homeostatic condition. Rosiglitazone treatment
mice exhibited normal hematopoiesis compared with control group, as indicated
by normal levels of blood and BM cellularity. In response to 5-Fu induced
hematopoietic stress, mice exhibited hypocellular BM with dilated sinus. Com-
pared to control group, adipocytes number in BM of rosigolitazone group mice
was increased and the expression of PPARγ, adiponectin was also significantly
higher in rosiglitazone group. After treatment with 5-Fu, all groups showed sim-
ilar nadirs of WBC and BMMNC. On recovery, however, WBC and BMMNC
increased more slowly in rosiglitazone group mice. HGB and platelet counts
didn’t show similar pattern of delayed recovery after 5-Fu treatment in rosigli-
tazone group. As a cytotoxic agent, 5-Fu induces a multistep BM stress
response by killing actively cycling cells, causing the number of BM cells to
decline, followed by proliferation, differentiation and mobilization of HSPCs.
We observed that rosigalitazone group mice had increased percentage of LSK
compared to control groups while a decreased percentage of GMP and CLP
cells at d14 after 5-Fu. Meanwhile, we found a 1.5-fold reduction of CFU-G
counts in rosiglitazone group BM. However, we didn’t find any difference of
LSK cell counts in PB and spleen, and cell cycle of LSK cells was also not
affected by treatment of rosiglitazone. These results indicated that BM
adipocytes maintain the number of LSK cells in BM while impair myeloid and
lymphoid differentiation, which may explain the delayed hematopoietic recovery
in rosiglitazone group. Finally, we treated rosiglitazone mice with an PPARγ
inhibitor BADGE for 2 weeks to check if such effects were reversed. Surpris-
ingly, there was a twofold increase in the proportion of LSK cells in the spleen
at d14. Moreover, WBC and BMMNC counts of BADGE groups were elevated
compared to rosiglitazone group and the proportion of LSK of BADGE treated
BM was decreased compared with rosiglitazone group at d14.
Summary and Conclusions: Our studies revealed that PPARγ induced BM
adipogenesis could inhibit the differentiation of HSC while maintain them in
undifferentiated state. These results may suggest a plausible mechanism for
the impaired hematopoiesis in patients with fatty bone marrow and provide
new evidence for benefits of PPARγ inhibitor treatment to improve hematopoi-
etic recovery.
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A CROSSTALK IS MEDIATED BY THE NOTCH PATHWAY BETWEEN THE
HAEMATOPIETIC STEM CELLS AND THEIR STROMAL
MICROENVIRONMENT
A. Audia1,* F. Anjos Afonso1
1Cancer Research UK, London, United Kingdom
Background: The very well conserved Notch pathway is known to be important
in many aspects of haematopoiesis. The Notch ligands are expressed in the
stromal bone marrow microenvironment and interact with Notch receptors
expressed on the haematopoietic stem cells and progenitors (HSCs/HSPCs)
in order to maintain their immature and quiescent phenotype (Anjos Afonso et
al., 2013).
Aims: The cell autonomous role of the Notch pathway has been recently elu-
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cidated in human HSCs/HSPCs maintenance. However little is known about
the non-cell autonomous role played by the Notch pathway in the stromal
microenvironment.
Methods: The long-term culture (LTC) assay has been used as a model to
study the interaction mediated by the Notch pathway between the HSPCs and
the MS-5 stromal cell line in vitro and in vivo. For in vivo studies it has beenused
a technique recently established in the laboratory. MS-5 stroma and HSPCs
cells were pre-seeded in gel-foam scaffolds that were, after few days, implanted
in the back of mice for 8 or more weeks.
Results: In this study, for the first time, is shown that the HSPCs activate the
Notch pathway in the MS-5 stromal cells through Notch2 receptor (Fig1 A). The
activation of the pathway induces an increase in the expression of Notch ligands
Jag1, Jag2 and Delta4 and of Notch2 receptor in the stromal cells (Fig1 B).
Thus, enhancing in a positive feed-back loop the activation of the Notch path-
way in the HSPCs and in the MS-5 cells (Fig1 C and D). These data suggest
that a cross-talk mediated by the Notch pathway is happening between the
HSPCs and the stromal cells. Interestingly, in absence of Notch activation in
the stroma, the HSPCs are pushed to proliferate and differentiate loosing their
LTC-IC and in vivo engraftment potentials after co-culture (Fig2). However, the
inhibition of the cross-talk mediated by Notch inhibitors (GSIs) trigger a stronger
phenotype, confirming the cell autonomous role played by Notch in HSPCs
maintenance ex vivo (Fig3). These results have been confirmed using human
primary Mesenchymal Stem Cells (MSCs).
Figure 1.
Figure 2.
Summary and Conclusions: These results show that a crosstalk mediated
by the Notch pathway between the HSCs and the stromal microenvironment is
fundamental to maintain the properties of the HSPCsex vivo.A better under-
standing of the molecular mechanism involved in the crosstalk mediated by
the Notch pathway between the haematopoietic cells and the stromal microen-
vironment would not only help in the optimization of their in vitro expansion for




A CRITICAL ROLE FOR O-GLCNACYLATION IN MURINE FETAL LIVER
AND ADULT HEMATOPOIESIS
S. Soma1,* Y. Fukuchi2, S. Okamoto1, H. Nakajima1
1Division of Hematology, Department of Medicine, Keio Univeisity School of
Medicine, 2Department of Pathophysiology, Hoshi University School of Phar-
macy and Pharmaceutical Sciences, Tokyo, Japan
Background: Posttranslational modifications such as phosphorylation or gly-
cosylation are crucial for regulating protein function. Among these, glycosylation
of serine or threonine residues with O-linked N-acetylglucosamine (O-GlcNA-
cylation) by O-linked N-acetylglucosamine Transeferase (OGT) is particularly
important, as this modification regulates various cellular processes through
numerous targets including signaling molecules or transcription factors. Dys-
regulation of O-GlcNAcylation is critically linked to metabolic or degenerative
diseases (i.e. diabetes, Alzheimer disease), tumorigenesis and aging. However,
a role of O-GlcNAcylation in hematopoiesis still remains elusive.
Aims: To investigate the role of O-GlcNAcylation by Ogt in normal hematopoiesis.
Methods: We utilized Ogt conditional knockout mice (Ogt-cKO) to delineate
the role of O-GlcNAcylation in hematopoietic system. To accomplish hematopoi-
etic-specific or inducible deletion of Ogt, Ogt-cKO mice were crossed to Vav-
Cre transgenic (Tg) or Mx-Cre Tg mice, respectively. Since Ogt is located on
X-chromosome, Ogtflox/Y or Ogtflox/flox mice were considered to be equivalent.
Results: Since both Ogtflox/flox Vav-Cre+and Ogtflox/YVav-Cre+ mice were
embryonic or perinatal lethal, we analyzed E14.5 fetal liver cells (FLs) to exam-
ine the effect of Ogt loss in FL hematopoiesis. Quantitative RT-PCR and western
blot analysis showed that Ogt-mRNA and OGT protein were absent in Ogtflox/Y
Vav-Cre+or Ogtflox/flox Vav-Cre+ FL cells, indicating that floxed-alleles created
a null mutation. Interestingly, the number of FL cells was remarkably decreased
in Ogtflox/Y Vav-Cre+or Ogtflox/flox Vav-Cre+ embryos as compared to the wild-
type (WT) counterparts. In contrast, the percentage of lineage-Sca-1+c-kit+
(LSK) cells was significantly increased in Ogtflox/Y Vav-Cre+or Ogtflox/flox Vav-
Cre+ FLs. Surprisingly, these Ogt-deficient LSK cells completely lacked clono-
genic activity in methylcellulose culture in vitro, and a few surviving cells did
not form secondary colonies in serial replating assays. Furthermore, when
3,000 LSK cells from either Ogt+/YVav-Cre+ or Ogtflox/YVav-Cre+were trans-
planted into lethally irradiated recipient mice along with 200,000 recipient-type
whole BM cells, Ogtflox/YVav-Cre+donor-derived cells were scarcely detectable
in peripheral blood(PB) of recipient mice at 3 weeks after transplantation, while
more than 50% of PB cellswere donor-derived in mice recieving Ogt+/YVav-
Cre+LSK cells. These data suggest that Ogt is critical for proliferation, differen-
tiation and self-renewal of FL hematopoietic progenitors (HPCs).
We next examined Ogtflox/YMx-Cre+and Ogt+/YMx-Cre+ mice to investigate the
role of Ogt in adult hematopoiesis. Ogt deletion was initiated via five intraperi-
toneal injections of polyinosinic–polycytidylic acid (pI-pC) at dose of 400
µg/body, and then complete blood cell counts were monitored every 2 weeks.
Interestingly, the number of white blood cells, red blood cells and platelets were
decreased over time in Ogt-deleted mice. At four weeks after pI-pC injection,
the percentages of hematopoietic stem cells (HSCs) (CD48-LSK, CD150+CD48-
LSK) in Ogt-deleted mice were significantly decreased as compared to those
of WT mice.We then evaluated competitive repopulating activity of Ogt-deficient
cells. 1,000,000 bone marrow (BM) cells from either Ogtflox/Y Mx-Cre+ or Ogt+/Y
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Mx-Cre+ mice (CD45.2+) were transplanted with the equal number of competitor
cells (CD45.1+CD45.2+) into lethally irradiated CD45.1+ recipient mice. 4 weeks
after transplantation, pI-pC was administered to the recipient mice to delete
floxed alleles. The result showed that the percentage of Ogt-deleted cells was
remarkably decreased at 2 weeks after pI-pC injection and it progressively
decreased over time. These data suggest that Ogt is essential for competitive
and long-term repopulating capacity of BM-HSCs.
Summary and Conclusions: The O-GlcNAcylation by Ogt plays a critical role
for maintaining homeostasis of FL and BM hematopoiesis in mice.
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EXPLORING THE ROLE OF KIT LIGAND AT THE ONSET OF
HEMATOPOIESIS
E. Azzoni1, C. Nerlov1, M. De Bruijn*
1MRC Molecular Haematology Unit, Weatherall Instititute of Oxford, University
of Oxford, Oxford, United Kingdom
Background: Hematopoietic stem cells (HSCs) are generated during mam-
malian development from hemogenic endothelium in the major arteries through
a process called endothelial-to-hematopoietic transition. The extrinsic and intrin-
sic factors that orchestrate this process are poorly understood. Kit ligand (KitL;
also known as Stem Cell Factor/SCF) is a cytokine that plays a pivotal role in
the adult bone marrow HSC niche, and it is thought to act on several cell types
during embryogenesis. It is known that the absence of KitL causes a significant
reduction in the fetal liver HSC pool and leads to death in utero with severe
anaemia. However, it is currently unclear where, when and how the hematopoi-
etic defect originates in embryos lacking KitL, and what is the precise role of
this cytokine in the first steps of hematopoiesis.
Aims: Here we use a novel KitL transgenic reporter mouse line to map expres-
sion of this cytokine in the microenvironment of the Aorta-Gonad-Mesonephros
(AGM) and yolk sac hematopoietic sites in the developing embryo, and inves-
tigate the effect of loss of KitL in these pre-liver sites of hematopoiesis. 
Results: We show that KitL expressing cells are found in the microenvironment
of all hematopoietic sites of the E8.5-E10.5 mouse embryo. Loss of KitL as
assessed in Steel mutant (Sl/Sl) embryos showed smaller and less proliferative
hematopoietic clusters in the dorsal aorta and in the yolk sac. Already at E10.5,
homozygous Steel mutants show a reduction in pre-HSC numbers, yolk sac
erythropoiesis, and fetal liver cellularity. At E11.5 these mutants display
decreased progenitor numbers in all hematopoietic sites. 
Summary and Conclusions: Our data suggest that, contrary to earlier reports,
Kit signalling plays a role in early pre-liver hematopoiesis. In addition, our data
identified a previously unrecognized role for KitL in the maturation and/or expan-
sion of hematopoietic progenitors originating from the yolk sac, that could con-
tribute to the anaemia observed later in development. Ongoing studies aim at
elucidating the mechanism by which KitL exerts its role in early hematopoiesis.
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DEREGULATION OF GENES RELATED TO IRON AND MITOCHONDRIAL
METABOLISM IN REFRACTORY ANEMIA WITH RING SIDEROBLASTS
M. Del Rey1,2,* R. Benito1,2, C. Fontanillo1,2, F.J. Campos-Laborie1.2,
K. Janusz1,2, M. Abáigar1,2, M. Hernández-Sánchez1,2, R. Cuello3,
D. Borrego3, J. De Las Rivas1,2, K.I. Mills4, J.M. Hernández-Rivas1,2,5
1IBMCC, Centro de Investigación del Cáncer (CIC), Universidad de Salaman-
ca-CSIC, 2IBSAL, Instituto de Investigación Biomédica de Salamanca, Sala-
manca, 3Servicio de Hematología, Hospital Clínico de Valladolid, Valladolid,
Spain, 4Centre for Cancer Research and Cell Biology, Queen’s University
Belfast, Belfast, United Kingdom, 5Servicio de Hematología, Hospital Univer-
sitario de Salamanca, Salamanca, Spain
Background: The presence of SF3B1 gene mutations is a hallmark of
Myelodysplastic Syndrome with ring sideroblasts (MDS-RS) and could be relat-
ed to the iron accumulation in these patients. However, the mechanisms under-
lying that characterize the MDS-RS are not completely understood.
Aims: In order to gain insight in the molecular basis of MDS-RS, an integrative
study of the expression and mutational status of genesrelated to iron andmito-
chondrial metabolism was carried out.
Methods: A total of 231 low-risk MDS patients (50,3% MDS-RS, 49,7% refrac-
tory cytopenia with unilineage dysplasia patients-RCUD) and 81 controls were
studied. The gene expression profile was analysed using the Human Genome
Expression Array (U133 Plus 2.0) from Affymetrix. Array-based sequence cap-
ture (Roche NimbleGen) followed by next-generation sequencing (Roche GS
FLX Titanium sequencing platform) was used to analyze 39 genes related to
iron and mitochondrial metabolism. The genes were selected according to our
previous gene expression data. Spliceosome-related genes were studied using
an amplicon sequencing design in GS Junior Instrument (Roche Applied Sci-
ence). In addition, Sanger sequencing was carried out.
Results: Patients with refractory anemia with ring sideroblasts (RARS) showed
a differential expression of 1145 genes compared to controls. Interestingly, 38%
(266 genes) of the over-expressed genes were related to iron and mitochondrial
metabolism. The comparison between RARS and RCUD patients showed a set
of 192 differentially expressed genes: 33% (42 genes) of the over-expressed
genes were also related to iron and mitochondrial metabolism. ALAD and mito-
chondrial transporters SLC25 (SLC25A37 and SLC25A38) genes were over-
expressed in RARS. Most of the MDS-RS patients (94,3%) carried mutations in
any spliceosome-related gene. In addition, our analysis of the ALAD gene iden-
tified two polymorphisms (rs8177807 and rs2228083) in exon 6 and located 49
bases from each other. The occurrence of both polymorphisms (“variant haplo-
type”) was more frequent in MDS-RS (12%) than in members of the other groups
analyzed (5%). (p=0.07). Furthermore, an un-described variant in the exon 7
was found in the ALAD gene in one RARS patient with a mutation in SF3B1.
The positively charged arginine residue (R174) was replaced by an uncharged
cysteine residue. The three-dimensional structure showed that R174 residue is
completely buried into the monomeric structure and the protein was predicted
to be potentially damaging. The variant was not found in any of the control sam-
ples or in those analyzed from RCUD patients. An over-expressed gene-signa-
ture of 71 genes was identified between patients with SF3B1 mutations and
patients without the mutations. Interestingly, GDF15 was overexpressed in
patients showing SF3B1 mutations. In addition, other genes such as PPP2R5B,
PPP1R16A and DDIT4L, related to SF3B1 and GDF15, were up-regulated in
the mutated group. A functional analysis with this gene set showed two dereg-
ulated pathways: porphyrin biosynthesis and heme biosynthesis (p<0.001).
Summary and Conclusions: The deregulation of genes involved in iron and
mitochondrial metabolism provides new insights in our knowledge of MDS-RS.
Our study revealed mutations in spliceosome-related genes in almost 100% of
the MDS-RS. The presence of variations identified in ALAD gene could have
a possible role in the predisposition to disease (as a first event) as well as con-
tributing to the pathogenesis of MDS-RS where spliceosome-related genes
mutations could be the trigger cause.
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THE PRESENCE OF HEMOGLOBIN S IS ASSOCIATED WITH MIRNA
DEREGULATION IN CD34+-DERIVED ERYTHROID CELLS
T.A. Fornari1,* C. Lanaro1, K.Y. Fertrin1, N. Conran1, S.T. O Saad1, F.F. Costa1
1Hematology and Hemotherapy Center, State University of Campinas, Camp-
inas, Brazil
Background: Sickle cell disease (SCD) is a recessive genetic abnormality-
caused by a point mutation of the HBB gene (Glu6Val) that results in thepro-
duction of hemoglobin S (HbS), leading to chronic hemolysis andvaso-occlu-
sion. In addition to its ability to polymerize under hypoxicconditions, HbS may
give rise to increased oxidative stress caused by freeheme and iron secondary
to its intrinsic instability. MicroRNAs (miRNAs) canmodulate post-transcriptional
erythroid-specific regulators.
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Aims: The aim of thisstudy was to investigate miRNA expression profiles and
the possiblepost-transcriptional role of these molecules associated with the
presence ofHbS in sickle cell trait and in compound heterozygosity for HbS
and δβ-thalassaemiaSicilian type.
Methods: We obtained samples from individuals from the same family with
sickle cell trait (βS/βA),two sickle-δβ-thalassaemia Sicilian type patients (βS/βδβ),
two δβ-thalassaemia Sicilian type heterozygotes(βδβ/βA) and normal control
(βA/βA).CD34+-derived erythroid cells werecultured for 13 days and used to
determine the miRNA expression profile.miRNAs were hybridized using an Agi-
lent miRNA microarray platform and theprofiles were subjected to bioinformatics
data analysis using GeneSpringsoftware (v11.0). Different databases, such as
miRBase (Release 21),TargetScan (Release 6.2) and microRNA.org (Release
2010) were used todetermine the predicted targets of miRNAs. The RNAhybrid
tool (BiBiServ) wasused to find the minimum free energy hybridization of each
miRNA and apossible target gene.
Results: Twenty five miRNAs were up-regulated inβS/βδβ and in βS/βA com-
pared to βA/βA and βδβ/βA. In silico analysis showedthat eight miRNAs target
genes involved in cellular adhesion (CD36, ICAM4,and ITGB1), antioxidant
defense mechanisms (CAT, catalase), and hemoglobinaffinity for oxygen
(BPGM and MINPP1, 2,3-bisphosphoglycerate mutase andphosphatase,
respectively). CD36, ICAM4, and ITGB1 are possible targets ofthe miR-17, 20a
and 20b and the latter is additionally targeted by miR-29b,29c and 30e. The
CAT gene is also targeted by miR-30e as well as by miR-148aand 148b. BPGM
is targeted by miRs 20a and 20b, while MINPP1 is onlytargeted by miR-30e.
We also found hemopexin (HPX), a major heme-bindingprotein, is a possible
target of miR-26b.
Summary and Conclusions: Our data suggest that,in an in vitro model, the
presence of HbS is associated with miRNAderegulation that may be associated
to pathologic processes found ex vivo in reticulocytes and mature erythrocytes
from SCD patients. Financial supportby FAPESP and CNPq/INCTS.
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ORAL IRON SUPPLEMENTS INCREASE HEPCIDING AND DECREASE
ABSORPTION FROM DAILY OR TWICE DAILY DOSES: STUDIES WITH
STABLE IRON ISTOPIC LABELS IN YOUNG WOMEN
D. Moretti1,* J. Goede2, C. Zeder3, T. Harold4, M. Alida5, B. Gary6, S. Dorine7,
Z. Michael1
1Laboratory of Human Nutrition, ETH Zürich, 2Hematology, Unioversity Hospital
Zürich, 3ETh Zürich, Zürich, Switzerland, 4Radboud University Medical Centre,
Nijmegen, 5Wageningen University, Wageningen, Netherlands, 6College of
Physicians and Surgeons, Columbia University, New York, United States, 7Lab-
oratory Medicine, Translational Metabolic Laboratory, Radboud University Med-
ical Centre, Nijmegen, Netherlands
Background: Oral iron supplementation is used to treat iron deficiency, but
absorption is often low and correction is variable.
Aims: Determine the duration and magnitude of the plasma hepcidin (pHep)
response induced by oral iron (Fe) supplements and concomitantly measure
bioavailability in healthy iron depleted young women.
Methods: After randomization of 42 subjects with plasma ferritin<20 µg/L, pHep
(measured by C-ELISA), iron status and inflammation markers were monitored
at regular intervals. On day 1, no supplements were given (control day). On
days 2 and 3, subjects received iron supplements containing 40, 60, 80, 160
or 240 mg Fe as FeSO4 as either single or two consecutive daily doses extrin-
sically labeled with stable iron isotopes 54FeSO4, 57FeSO4 or 58FeSO4. Iron
bioavailability was measured by assessing the isotopic enrichment of erythro-
cytic iron 14 days after administration.
Results: Both Fe dose (P<0.05) and time of day (P<0.05) were associated
with increase in pHep. Compared to control days, pHep was significantly higher
at 8h and 24h after administration for 60, 80, 160 and 240 mg (P<0.05) but not
for 40 mg Fe. Total Fe absorption from the Fe dose on the second day of the
consecutive administration compared to a single Fe dose on the first day was
not significantly decreased for 40 mg, but was decreased by 37% for 80 mg,
31% for 160 mg and 45% for 240 mg (for all, P<0.01). Fractional absorption
was highest from the 40 mg dose. With twice per day dosing (60 mg Fe) the
afternoon dose was less bioavailable (P<0.05).
Summary and Conclusions: In Fe-depleted women, consecutive day doses
of supplemental Fe at 60 mg or above increase pHep and decrease fractional
Fe bioavailability, while a dose of 40 mg does not. These important new data
will help guide optimal dosing regimens for Fe supplements in women.
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RED BLOOD CELL GLYCOLYTIC INHIBITION ALTERS INTRACELLULAR
ION CONCENTRATIONS, LEADS TO DECREASED DEFORMABILITY, AND
UPREGULATES EXPRESSION OF CLEARANCE SIGNALS
R. Huisjes1,* L. Verhagen1, B. van Oirschot1, W. van Solinge1, R. Schiffelers1,
R. van Wijk1
1Department of Clinical Chemistry and Haematology, UMC Utrecht, Utrecht,
Netherlands
Background: enzymopathies is group of metabolic disorders of the erythrocyte
that leads to decreased intracellular energy production. Energy deprivation ulti-
mately results in premature clearance from the circulation in the spleen
(extravascular hemolysis). The precise mechanism by which energy-deprived
cells are recognized and cleared is largely unknown. One candidate mechanism
could involve disturbed ion balance due to defective function of ATP-dependent
ion channels in the red cell membrane, with consequent expression of clearance
signals, and loss of red blood cell deformability.
Aims: To investigate the effect of energy-depletion on ion channel function,
the exposure of clearance signals on the surface of the red cell, and red blood
cell deformability in a model for energy-depleted red blood cells.
Methods: Isolated erythrocytes were resuspended in HEPES buffered Ringers
solution (pH=7.4) and incubated overnight at 37ºC with 1mM D-glucose and
various concentrations (5-10mM) of 2-deoxy-D-glucose. 2-deoxy-D-glucose
(2dDg) is a glycolytic inhibitor acting on hexokinase, thereby serving as a model
for energy-depleted red blood cells. Intracellular calcium was analysed by flow
cytometry with fluo-4 AM as a fluorescent calcium probe and intracellular sodium
and potassium concentrations were measured by flame photometry. ATP was
measured using the CellTiter-Glo Luminescent Cell Viability Assay. Deforma-
bility of erythrocytes was measured using osmotic gradient ektacytometry by
LoRRca. Expression of phosphatidylserine (Annexin-V) and CD47 on the ery-
throcyte membrane was examined by FACS.
Results: Upon incubation with various concentrations of 2-deoxy-D-glucose
(2dDg) sodium levels (39 mM vs control 8 mM) were increased in a dose-
dependent manner. Potassium (51 mM versus control 82 mM) and ATP con-
centrations (23 nM versus 7 nM) were decreased following treatment with 2dDg.
FACS analysis revealed increased intracellular concentration of calcium and
increased expression of CD47 and phosphatidylserine after incubation with
2dDg. Osmotic gradient ektacytometry showed decreased deformability after
incubation with 2dDg, reflected by a decreased EImax (maximal Elongation
Index, Figure). When compared with ektacytometry curves from a patient with
either hexokinase or pyruvate kinase deficiency, similar curves were obtained.
Importantly, osmotic gradient ektacytometry curves of erythrocytes incubated
with 2dDg are comparable (Figure).
Figure 1.
Summary and Conclusions: Glycolytic inhibition alters intracellular red blood
cell ion concentrations, and causes decreased deformability of erythrocytes.
The decreased deformability as seen in 2dDg-incubated erythrocytes is com-
parable with the decreased deformability seen in patients with hexokinase and
pyruvate kinase deficiency. Moreover, glycolytic inhibition is associated with
upregulation of removal signals CD47 and phosphatidyl serine on the erythro-
cyte membrane. Loss of deformability and upregulation of removal signals in
energy-deprived red blood cells may play a role in the premature removal of
erythrocytes in red blood cell enzymopathies.
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MODIFIED ACTRIIB-MFC FUSION PROTEIN (RAP-536) INCREASES
FUNCTIONAL RED BLOOD CELLS AND IMPROVES SICKLE CELL
DISEASE PATHOLOGY WITH OR WITHOUT HYRDOXYUREA IN A MURINE
MODEL
R.N. Suragani1,* R. Li1, S. Cawley1, S. Pearsall1, R. Kumar1
1ACCELERON PHARMA, Cambridge, United States
Background: Sickle cell disease (SCD) is characterized by the presence of
the sickle hemoglobin variant (HbS) of the b-globin gene. Under hypoxic con-
ditions, HbS polymerizes, causing irreversibly sickled red blood cells (RBC).
Manifestations of SCD include increased reticulocytes, splenomegaly, impaired
blood flow due to intravascular sickling, and vaso-occlusive crises. The only
approved therapy for SCD is hydroxyurea (HU), which decreases irreversibly
sickled cells and painful events.. However, myelosuppression is a dose limiting
toxicity and ~1/3 of patients do not respond to HU therapy, thereby highlighting
the need for alternative treatment strategies
Aims: Luspatercept (ACE-536) is a modified type IIB activin receptor-Fc fusion
protein1 which acts as a ligand trap for members of the TGF-b superfamily to
promote late-stage erythroid differentiation. In a murine model of b-thalassemia,
RAP-536 (murine ortholog of ACE-536) corrected anemia and mitigated disease
complications of b-thalassemia2. In this study, we evaluated RAP-536 as a
monotherapy and in combination with HU in a murine model of SCD
Methods: SCD mice3 (βS/βS, 6 and 12 weeks old) were dosed with RAP-536
(10 mg/kg, twice weekly SC) or TBS (VEH) control (N=4-6/group). Combination
treatment with HU (100 mg/kg, i.p.) and RAP-536 (10 mg/kg SC) twice weekly
for 3 months was compared with vehicle or HU monotherapy. Non-symptomatic
compound heterozygote (β/βS) littermates were used as controls (N=5/group).
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Results: RAP-536 significantly decreased spleen weight (-16.4%) and serum
bilirubin (-40.8%, P<0.01) compared to VEH, indicating decreased hemolysis.
RAP-536 increased RBCs (+20%, P<0.01) and decreased reticulocytes (-30%,
P<0.05). Blood smears from RAP-536 treated SCD mice displayed a 40-60%
decrease in number of irreversibly sickled erythrocytes. In 6-week old SCD
mice, RAP-536 treatment resulted in increased oxy-hemoglobin (+41.3%,
P=0.06), functional oxygen saturation (+40.9%, P=0.06), oxygen content
(+65.2%, P=0.05), and oxygen carrying capacity (+14%, P<0.05), and reduced
carboxy-hemoglobin (-25.2%, P<0.05) compared to VEH. Histologic analysis
of RAP-536 treated SCD mice showed substantial reduction in vascular con-
gestion and damage in lung, spleen and kidneys, as well as reduced thickening
of the alveolar wall compared to VEH. These data are consistent with reduced
RBC sickling and qualitative improvements in SCD pathology in mice treated
with RAP-536 monotherapy. We then evaluated RAP-536 in combination with
HU in SCD mice. Treatment with HU alone reduced spleen weight (-20.2%,
P<0.05), reticulocytes (-23.7%, P<0.05), phosphatidyl serine exposure on RBC
membranes (-22.2%, P<0.05), and hemolysis (-48.4%, P<0.05) compared to
VEH. The addition of RAP-536 to HU therapy further decreased splenomegaly
(-50.7%, P<0.05), phosphatidyl serine exposure (-35.6%, P<0.001) and hemol-
ysis (-55%, P<0.01) compared to VEH. The combination also further reduced
vascular damage and congestion compared to VEH or HU monotherapy.
Summary and Conclusions: RAP-536, alone or in combination with HU, sub-
stantially improves RBC morphology and sickle cell disease pathology in SCD
mice. Luspatercept (ACE-536) is currently being tested in Phase 2 clinical trials
in MDS and β-thalassemia, and merits evaluation in SCD patients.
References
1. Suragani RN et al; Nature Medicine 2014; 20: 408-14
2. Suragani RN et al; Blood 2014; 123: 3864-72
3. Wu LC et al; Blood. 2006; 108:1183-8
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QUANTIFICATION AND VISUALIZATION OF DIETARY IRON UTILIZATION
UNDER ERYTHROPOIETIC STIMULATION BY USING STABLE IRON
ISOTOPE 57FE AND MASS SPECTROMETRY
Y. Matsuo-Tezuka1,*, Y. Sasaki1, M. Noguchi-Sasaki1, K. Yorozu1, M. Kurasawa1,
K. Kondo1, M. Kihara1, Y. Shimonaka1
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Japan
Background: Epoetin beta pegol (C.E.R.A.) is a novel, long-acting erythro-
poiesis-stimulating agent; once-monthly administration of C.E.R.A. effectively
maintains hemoglobin levels in renal anemia patients. We previously demon-
strated that C.E.R.A. promotes iron absorption through the reduction of serum
hepcidin levels and subsequent up-regulation of the iron transporters, divalent
metal transporter 1 (DMT1) and ferroportin. However, utilization of dietary iron
following C.E.R.A. administration has not yet been fully quantitatively analyzed.
Aims: In this study, we used the stable iron isotope 57Fe as a tracer of dietary
iron incorporation. The primary objective was to quantify the utilization of dietary
iron for erythropoiesis and its distribution into hematopoietic and iron storage
tissues under C.E.R.A. stimulation by using inductively coupled plasma mass
spectrometry (ICP-MS). We also attempted to visualize the incorporation of
dietary iron into newly synthesized heme in the spleen by using high-resolution
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).
Methods: To trace the incorporation of dietary iron into hematopoietic and iron
storage tissues, we used a diet containing 200 ppm of the stable iron isotope
57Fe instead of natural iron (57Fe-diet). As a control, we used a diet containing
200 ppm of natural iron (control diet). C57BL/6NCrl mice fed the control diet
were switched to the 57Fe-diet immediately after being intravenously injected
with 10 µg/kg of C.E.R.A. or vehicle. On Day 2, 5, 8, and 14 after administration,
mice were killed by exsanguinations under anesthesia with isoflurane, and iron
parameters and hematological parameters were analyzed. To quantify dietary
iron incorporation, the content of hemoglobin containing 57Fe in red blood cells
and 57Fe levels in bone marrow cells, spleen and liver were measured by ICP-
MS. To visualize newly synthesized heme containing 57Fe (57Fe-heme), on
Day5 after C.E.R.A. administration we spatially mapped 57Fe-heme in the
spleen by FT-ICR MS imaging.
Results: Compared with the vehicle-treated group, the C.E.R.A.-treated group
showed a reduction in hepcidin levels from Day 2 to Day 8 and higher levels
of hemoglobin. On Day 14, the content of hemoglobin containing 57Fe in red
blood cells was significantly higher in the C.E.R.A.-treated group than in the
vehicle-treated group (3.6±0.7 g/dL vs 1.5±0.2 g/dL). 57Fe levels in hematopoi-
etic tissues (e.g. bone marrow cells and spleen) and iron storage tissues (liver)
were also increased until Day 14 after C.E.R.A. administration. On Day 5,
newly synthesized 57Fe-heme in the spleen was more obviously detected in
the C.E.R.A.-treated group than in the vehicle-treated group.
Summary and Conclusions: The present study focused on the effect of
C.E.R.A. on dietary iron incorporation and utilization for erythropoiesis. We
demonstrated that C.E.R.A. stimulated the effective use of dietary iron for ery-
thropoiesis both in a quantitative manner with ICP-MS and in a visible manner
with FT-ICR MS. Using these tools, we could trace dietary iron dynamics from
incorporation to utilization for erythropoiesis or to retention in hematopoietic
tissues such as bone marrow and spleen. It is well-known that abnormal iron
metabolism contribute to the development of renal anemia. Therefore, our
methods can not only provide useful information to understand iron metabolism
under hematopoietic stimulation in basic research, but could be helpful in clin-
ical applications.
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FIVE NEW CASES OF HEXOKINASE DEFICIENCY: BIOCHEMICAL AND
MOLECULAR CHARACTERIZATION OF A NOVEL SPLICE SITE
MUTATION AND 2 NOVEL MISSENSE MUTATIONS IN HK1
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Background: Hexokinase (HK) deficiency is a very rare cause of hereditary
nonspherocytic hemolytic anemia (HNSHA). Hexokinase is one of the key reg-
ulatory enzymes of glycolysis, on which the red blood cell is totally dependent
the production of ATP. Deficiency of HK disrupts cellular metabolism, which
ultimately results in HNSHA. To date, 24 cases of hexokinase deficiency have
been described. Only four of them have been characterized on the DNA level.
We here describe five new cases and 3 novel mutations in HK1.
Aims: Characterize a genetic defect in patients who were found to be HK-defi-
cient by spectrophotometrically determined red blood cell HK and pyruvate
kinase (PK) enzymatic activities.
Methods: PK/HK ratio was applied to evaluate the effect of age-related increas-
es in enzymatic activity. To confirm the diagnosis, DNA sequence analysis of
HK1 was performed by Sanger sequencing. Novel mutations were character-
ized by biochemical methods (Km for glucose and Mg.ATP, pH stability and
thermolability) and molecular studies (RT-PCR, quantitative RT-PCR, and
Western Blot analysis on ex vivo cultured patient erythroblasts).
Results: DNA sequence analysis of HK1 of 5 patients with suspected HK defi-
ciency revealed a total of 5 different mutations in HK1. Three of them were
novel (Table, novel mutations in bold). In silico analysis of mutations
p.His868Tyr and p.Thr601Met by Polyphen-2 and SIFT predict that both sub-
stitutions are not tolerated. Both are located in the catalytic region, and kinetic
properties are likely to be impaired upon mutation. Kinetic studies of the
p.His868Tyr HK mutant showed that its affinity for ATP was indeed markedly
decreased (3.2-times), whereas the affinity for glucose was slightly increased
(Table). The molecular effects of the novel splice site mutation c.876-2A>G in
intron 7 was studied on mRNA isolated from ex vivo cultured erythroblasts from
the patient’s father, who was heterozygous for this mutation. RT-PCR analysis
showed the presence of normal as well as two aberrant mRNAs species. The
aberrantly spliced transcripts lacked either exon 8 or both exons 8 and 9. Quan-
titative RT-PCR analysis showed that expression levels of the normally spliced
mRNA variant were down-regulated 3-times compared to normal. These find-
ings were confirmed on the protein level by Western blot analysis of HK from
nucleated erythroid cells (Figure).
Tabella 1. Biochemical and molecular data of HK-deficient patients
Summary and Conclusions: We report 5 mutations in HK1 in 4 unrelated
families. Three of them, c.876-2A>G, Thr601Met, and p.His868Tyr have not
been previously reported. The pathogenic nature of novel mutations was con-
firmed by molecular and biochemical studies. Our results contribute to a better
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understanding of the genotype-to-phenotype correlation of HK deficiency, a
very rare enzyme disorder of the red blood cell. Supported by Ministry of Health
of Czech Republic, grant NT/13587 and IGA_LF_2015_015.
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CHRONIC PSYCHOLOGICAL STRESS STIMULATES MEDULLARY
ERYTHROPOIESIS BY MODULATING LOCAL NITRIC OXIDE PRODUCTION
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G. Jovčić3
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Background: Stress elicits an integrated neuroendocrine response disturbing
the homeostasis of different physiological systems. Thus, the experimental
studies have shown that chronic psychological stress stimulates erythropoiesis
but molecular mechanisms underlying this stress response remain to be eluci-
dated. There is evidence that stress increases nitric oxide (NO) synthesis as
well as that NO can modulate hematopoiesis.
Aims: This study was undertaken to investigate whether NO is involved in the
regulation of erythropoiesis during chronic psychological stress using restraint
experimental model and NO synthase (NOS) inhibitor Nw-nitro-L-arginine-
methyl ester (L-NAME).
Methods: Adult male CBA mice were randomly assigned to following groups:
1) restraint group exposed to 2 h daily restraint stress during 7 consecutive
days; 2) L-NAME + restraint group, treated with L-NAME (50 mg/kg, s.c.) 30
min prior to daily restraint; 3) L-NAME group, received only the daily dose of L-
NAME; and 4) control group, simply handled daily. In the bone marrow, the
number of erythroid progenitors burst forming units-erythroid (BFU-E) and
colony-forming unit-erythroid (CFU-E) was determined using colony assays.
The expression of neuronal NOS (nNOS) and endothelial (eNOS) in the bone
marrow cells was evaluated by both Western blot and immunohistochemistry.
In addition, the expression of nuclear factor kappa B (NFκB) subunit p65 was
assessed by Western blot in the nuclear fraction of bone marrow cells.
Results: Chronic psychological stress significantly increased the number of
BFU-E and CFU-E cells in the bone marrow. Inhibition of NOS activity by L-
NAME completely abolished the effect of repeated restraint on erythroid pro-
genitors. Similar to restraint stress, L-NAME alone induced a significant
increase in the frequency of erythroid progenitor cells compared to controls. To
further investigate a role of NO in regulation of erythropoiesis during chronic
stress, we evaluated the expression of nNOS and eNOS in bone marrow cells.
The results, obtained by Western blot analysis, demonstrated significantly
decreased expression of nNOS in cytoplasmatic fraction of bone marrow cells
following chronic restraint stress. Although not statistically significant, a similar
trend was observed for eNOS in restrained mice. In accordance, a few nNOS-
and eNOS-immunoreactive cells were detected within the bone marrow of
chronically stressed animals. Furthermore, the activation of NFkappaB, known
to induce the expression of NOS isoforms, was evaluated by its active nuclear
component p65. Consistent with decreased expression of nNOS, the data
showed that chronic psychological stress significantly attenuated the expression
of p65 in the nuclear fraction of bone marrow cells.
Summary and Conclusions: Taken together, obtained results demonstrate
for the first time that signal molecule NO modulates medullary erythropoiesis
during chronic psychological stress. These findings are of importance because
chronic psychological stress, as a part of modern style of life, may be involved
in the pathogenesis of hematological malignancies.
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RECOMBINANT HUMAN ERYTHROPOIETIN-INDUCED ERYTHROPOIESIS
REGULATES HEPCIDIN EXPRESSION OVER IRON IN A RAT MODEL
S. Ribeiro1,* P. Garrido2,3, J. Fernandes2, S. Rocha1, P. Rocha-Pereira4,
E. Costa1, L. Belo1, F. Reis2,3, A. Santos-Silva1
1UCIBIO, REQUIMTE, Department of Biological Sciences, Laboratory of Bio-
chemistry, Faculty of Pharmacy, University of Porto, Porto, 2Laboratory of Phar-
macology & Experimental Therapeutics, Institute for Biomedical Imaging and
Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, 3CNC.IBILI,
University of Coimbra, Coimbra, 4Health Sciences Research Centre, Faculty
of Health Sciences, University of Beira Interior, Covilhã, Portugal
Background: Iron has essential roles in several physiological processes,
including red blood cell formation. Stimulation of erythropoiesis increases iron
demand in bone marrow. Hepcidin, a small peptide produced by hepatocytes,
plays a central role in regulating iron by promoting internalization and degra-
dation of ferroportin, the only known cellular iron exporter. Several factors reg-
ulate hepcidin expression, as erythropoiesis, erythropoietin (EPO) and iron lev-
els; however, the impact of each factor is not well established.
Aims: We aimed to study the effect of recombinant human erythropoietin (rHuE-
PO) therapy on erythropoiesis and on iron metabolism in a rat model.
Methods: Male Wistar rats, 12 weeks old, were divided in 5 groups: control
group and rHuEPO-treated groups (100, 200, 400 and 600 IU/kg bw/week)
during 3 weeks. Hematological and iron data were evaluated, as well as, the
expression of several genes involving iron metabolism. Mann-Whitney test was
used to evaluate differences between groups.
Results: One week rHuEpo treatment to healthy rats caused a dose-dependent
increase in erythrocyte count, hemoglobin concentration, hematocrit and retic-
ulocyte count. At the end of the protocol (3 weeks), rHuEPO-treated groups
(200, 400 and 600 IU) showed higher values for these parameters, as compared
to control group, except for the reticulocyte count that was reduced in the 200
IU rHuEPO-treated group. After 3 weeks of treatment, iron and ferritin levels do
not differ between groups, transferrin levels reduced in the 100, 200 and 600
rHuEPO-treated groups, whereas transferrin saturation increased in the 200,
400 and 600 rHuEPO-treated rats. Liver hepcidin mRNA levels increased in the
200 IU rHuEPO-treated animals, as well as, the mRNA levels of the up-regulatory
hepcidin mediators (tfr2, hjv, bmp6); in contrast, reduced mRNA levels of matrip-
tase-2, an inhibitory modulator, were found. The 400 and 600 IU treated groups
presented reduced levels of hecpidin mRNA and of the up-regulatory hepcidin
mediators, and an increase in mRNA levels of matriptase-2. Serum EPO rat lev-
els increased in the 200 IU rHuEPO-treated group, at the same extent we found
an increase in liver EPO and EPO receptor mRNA levels. Extramedullary ery-
thropoiesis was found in the spleen of 600 IU rHuEPO-treated group.
Summary and Conclusions: An increasing EPO stimuli leads to a rise in retic-
ulocyte/erythrocyte production, which seems to be supported by an increase in
iron absorption and mobilization, as suggested by the increase in transferrin
saturation. However, the erythropoiesis stimuli triggered by the 200 IU rHuEPO
dose seems to overwhelmed the bone marrow capacity, as showed by the
decrease in reticulocyte production. Strengthening this hypothesis we found
an increased serum EPO levels and liver mRNA expression of EPO and EPO
receptor. At higher EPO stimuli, such as 600 IU rHuEPO dose, the increase in
erythrocyte production is also supported by extramedullary erythropoiesis. The
increase in hepcidin expression in the 200 IU rHuEPO-treated group seems to
result from the reduction in erythropoiesis (an inhibitory stimuli for hepcidin pro-
duction), as the transferrin saturation presents a similar value in the 600 IU
rHuEPO-treated group. Actually, it seems that erythropoiesis prevails over iron
regulation on hepcidin production. Supported by FCT (PTDC/SAU-
TOX/114253/2009 and SFRH/BD/79875/2011) and POPH/FSE.
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MICRO-RNA CANDIDATES FOR REGULATION OF FETAL HEMOGLOBIN
IN SICKLE CELL ANEMIA
C.R. Bonini-Domingos1,* G.C.S. Carrocini1, W. Araujo Jr2, C.C. Lobo3
1Biology, UNESP, Sao Jose do Rio Preto, 2Medicine, USP, Ribeirao Preto,
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Background: Due to the important role of maintaining the hemoglobin in the
metabolic activity, many factors are known to regulate the expression of globin
genes, specifically gamma-globin genes. MicroRNAs (miRs) are endogenous
regulatory elements, non-coding, small size, that act on gene regulation in post-
transcriptional level. The miRs differential expression in sickle cell anemia and
beta thalassemia homozygous has been studied and identified differences in
miRNA expression in individuals with sickle cell anemia in relation to individuals
without anemia.
Aims: We aimed to evaluate differential expression of miRNAs selected from
in silico analysis and characterized as candidates for regulation of gamma-glo-
bin genes (HBG1 and HBG2) in subjects with sickle cell anemia in order to
identify novel components involved in modulating levels of Hb F.
Methods: Peripheral blood samples from 20 individuals adults-10 with Hb AA
and 10 with Hb SS (Bantu haplotype and HU use) were collected, regardless
of gender. The quantification of the hemoglobin fractions was performed by
HPLC-Ultra 2 (Trinity Biotech®). The homozygous for Hb S and the Bantu hap-
lotype was confirmed by PCR-RFLP. MicroRNAs were selected from in silico
analysis, through databases miRNApath (http://lgmb.fmrp.usp.br/mirnapath),
Diana Lab (http://diana.cslab.ece.ntua.gr/microtiter /), Ferrolab (The miR ontol-
ogy database) (http://ferrolab.dmi.unict.it/miro/), TargetScan (http://www.tar-
getscan.org/), miRecords (http: // mirecords .biolead.org /) and miRBase
(http://www.mirbase.org). Were considered candidates for regulation of Hb F
levels the elements listed in at least three of the databases used.Reticulocytes
were isolated and the microRNA extraction was performed with use of the kit
miRvana miRNA Isolation Kit (Ambion®). CDNA synthesis (RT-PCR) was per-
formed using the High Capacity cDNA Reverse Transcription Kit Kit (Applied
Biosystems). For analysis of expression of microRNAs (qRT-PCR) reactions
were performed by TaqMan MicroRNA Assay Detection System (Applied
Biosystems). Statistical analyzes were performed with Statistica 8 software
(Statsoft®), GraphPad Prism version 5 (GraphPad Software, San Diego, USA)
and R version 3.1.1 Statistics (http://www.r-projet.org). We considered Statis-
tically significance was p <0.05.
Results: The in silico analysis shown 20 miRNA indicated as a candidates for
regulation of Hb F. Quantitative analysis showed that 14 miRNAs showed sig-
nificant differential expression: miR-449th, miR-449b, miR-34c-5p, miR-4795-
3p, miR-96, miR-26b, miR-151-3p, miR-210, miR-15a, miR-16-1, miR-451, miR-
144, miR-221 and miR-222. Only miR-34c-5p showed higher expression levels
in the group with sickle cell anemia. Higher levels of expression of miR-221 and
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miR-222 in the control group enhancing the performance of these two elements
as possible negative regulators of the Hb F levels. miR-449th, miR-449b and
miR-4795 were highly expressed in the control group.The miR-34c-5p, was
more expressed in the group with sickle cell disease and was correlated with
miR-26b (ρ=0.7). The miR-221 and miR-222 were correlated with each other
(ρ=0.7) and miR-151-3p (ρ=ρ=0.72 and 0.98, respectively). Furthermore, miR-
96 showed more correlations in the group with sickle cell anemia.
Summary and Conclusions: Our results shown the presence of differentially
expressed miRNAs predicted the regulation of gamma-globin genes among
Hb AA individuals with low levels of Hb F and individuals with sickle cell anemia
with increased Hb F induced by treatment with HU. Some of these elements
have validated and compared with the erythropoiesis regulation of gamma-
globin genes, whereas other miRNAs have not yet been associated with these
procedures.
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POSSIBLE INTERPLAY OF MICRORNA AND TRANSCRIPTION FACTORS
DURING IN VITRO ERYTHROID CULTURE OF CD34+ CELLS IN SICKLE
CELL ANEMIA
R. Ferreira1,* C. Lanaro1, M.A.C. Bezerra2, A. da Silva Araujo3,
D.M. de Albuquerque1, F.F. Costa1
1Hematology and Hemotherapy Center, University of Campinas, Campinas,
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Background: The clinical severity of the sickle cell anemia (SCA) can be affect-
ed by a number of modifying factors including HbF levels and the coinheritance
of alpha-thalassemia. Furthermore, key regulators such as microRNAs (miRs)
and transcription factors (TFs) are involved in the regulatory mechanism of
HbF production, however this regulatory mechanism is unclear.
Aims: To investigate miRs and TFs expression during in vitro erythroid differ-
entiation in normal and SCA erythropoiesis.
Methods: Peripheral blood CD34+ cells were isolated from 4 patients who pre-
sented homozygous HbS genotype (HBSS) and from 4 healthy subjects (CON).
The cells were cultured in a liquid system stimulating erythropoiesis and col-
lected on days 7, 10, and 13 to analyze miRs and the TFs expression profile.
In silico prediction was performed by TargetScanHuman software v 6.2 to verify
possible interactions between miRs and TFs.
Results: Quantitative PCR showed that two miRs were down-regulated during
HBSS erythropoiesis: miR-223 on days 7 and 10, and miR 486-3p on day 10
(P<0.05). Seven miRs were up-regulated: 146a-5p, 221 and 222 on day 10,
and 15a, 144-3p, 150-5p and 155-5p on day 13 (P<0.05). NFE2, SP1, ETO2
and FOXO3 were decreased on day 13 (P<0.05), while LMO2 and LDB1 were
up-regulated on days 10 and 13, respectively (P<0.05). Increased levels of
TAL1 were observed on days 10 and 13 (P<0.05). GATA1 expression did not
change significantly. In silico analysis predicted miR interactions for the 3’
untranslated region of TFs : 146a-5p–NFE2, miR-155-5p– SP1, miR-221–
FOXO3, miR-222 – FOXO3, miR-486-3p–LDB1, and miR-486-3p–TAL1. Stud-
ies have shown that mice lacking the transcription factor NF-E2 present
hemolytic anemia, while the downregulation of ETO2 and SP1 contributes to
the activation of TFs involved in the GATA1-complex, such as LDB1, TAL1 and
LMO2. Based on our preliminary results, the upregulation of these TFs may be
associated with the decreased expression of ETO2 and SPI1 in HBSS cultures.
We also suggest that the miRs-targets 155, 15a, 486-3p and 146a-5p may be
contributing to changes in the expression of these TFs. Studies demonstrated
that miRs 15a and 150-5p regulate the TF cMYB and its downregulation leads
to an increase in HbF levels. Our results of low levels of cMYB with concomitant
increases in these miRs in HBSS cultures are in agreement with the previous
studies. An association of high miR-144-3p expression with a severe anemia
phenotype in SCA, oxidative damage and hemolysis of HBSS erythrocytes
cells has been previously described. Additionally, up-regulation of FOXO3 cor-
related to an antioxidant gene expression response, which protects erythroid
cells from cellular stress. We also found the high levels of miR-144-3p in HBSS
cultures and also showed a downregulation of FOXO3, which may be associ-
ated with upregulation of its miRs-target 221/222. 
Summary and Conclusions: Our data show relevant associations between
miRNAs and their possible targets during in vitro erythroid differentiation. These
results suggest that miRNAs represent a class of molecules that may contribute
to hematopoietic process and may have a role in physiopathology of SCA.
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CATEGORIZATION OF CLINICAL SEVERITY IN PYRUVATE KINASE
DEFICIENCY (PKD) IN AN INTERNATIONAL, OBSERVATIONAL COHORT
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Background: PKD is the most common glycolytic defect causing congenital
non-spherocytic hemolytic anemia. An international, multicenter Natural History
Study (NHS) has been established to collect retrospective and prospective
clinical data on PKD patients (pts).
Aims: To categorize PKD clinical severity based on degree of anemia, trans-
fusion history, and splenectomy status and to identify predictors and prevalence
of complications in the severity groups.
Methods: 105 pts with PKD enrolled on the PKD NHS at 14 IRB approved sites
from March 2014 to January 2015. Pts were randomly assigned to either the
test set (n=75) or future validation set. For this analysis, baseline and retro-
spective enrollment data were included from the 75 test set pts. PKD pts were
categorized into 4 distinct severity groups (Gp1-Gp4), with increasing severity
of the disease: Gp1. Never regularly transfused +/-prior acute transfusions; Gp2.
Regular transfusions prior to splenectomy (SPL), post-SPL baseline hemoglobin
(hb) >8.7 g/dl; Gp3. Regular transfusions prior to SPL, post-SPL baseline hb
≤8.7 g/dl; and Gp4. Splenectomized and currently regularly transfused. Gp2
and 3 were regularly transfused prior to SPL and transfusion independent after
SPL and are distinguishable by post-SPL baseline hb. The median hb (8.7 g/dl)
from Gp2 and 3 was used to discriminate between pts who were less anemic
versus more anemic. Ordinal logistic regression models were used to test for
association between clinical characteristics and severity group.
Results: The Table shows the characteristics of Gp1-4. In Gp1, only 42% of pts
were splenectomized. Younger age at diagnosis (p=0.04) was significantly asso-
ciated with increased severity of disease. There were no significant differences
in groups based on gender, ethnicity, or race. There was a significant trend for
increasing ferritin (p=0.03) and liver iron concentration (LIC, p=0.04) with
increasing PKD clinical severity, and more severe groups were more likely to
have received chelation therapy (p<0.01). Some Gp1 pts developed iron over-
load despite the absence of a history of regular transfusions. There was also a
trend for higher rates of cholecystectomy (p=0.01) with increasing clinical sever-
ity. For certain complications, there was no evidence to support an association
with clinical severity, including aplastic crises (overall rate 16%), extramedullary
hematopoiesis (12%), and pregnancy complications of the affected mother
(55%), as well as the requirement for exchange transfusion in the newborn peri-
od (44%). The reticulocyte count was incrementally higher with increasing clinical
severity in the non-regularly transfused groups from Gp1 to Gp3 (p=0.02), even
after controlling for splenectomy status. As expected, multiple genotypes were
found in this cohort. Pts with the common, Amish, homozygous 1436G>A muta-
tion were found in Gp1, 2, and 3, which may indicate a contribution of other
genetic or environmental factors to clinical severity.
Tabella 1. Demographyc and Clinical Features of the Classification
Groups of Clinical Severity in PKD.
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Summary and Conclusions: The PKD NHS represents the largest cohort of
pts with PKD assembled to date. We have identified 4 distinct severity groups,
based on transfusion history, degree of anemia, and splenectomy status. Com-
plications, such as cholecystectomy and iron overload, are correlated with
severity of disease. Categories of severity will be validated in the next 75 PKD
pts enrolled on the PKD NHS, and prospectively followed in this cohort for at
least two years. This classification may be helpful for determining monitoring
and treatment practices in this rare anemia.
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EFFICACY AND SAFETY OF VITAMIN C AS AN ADJUVANT TO IRON
CHELATION THERAPY IN YOUNG PATIENTS WITH Β-THALASSEMIA
MAJOR: A RANDOMIZED PROSPECTIVE TRIAL 
M. Elalfy1,*, A.A. Adly1, E. Ismail2, O. Elalfy1
1pediatrics, 2clinical pathology, Ain Shams University, cairo, Egypt
Background: Ascorbate deficiency is common in iron overloaded subjects and
may modulate iron distribution. Animal studies showed that ascorbate replace-
ment in the presence of desforaxamine (DFO) can markedly improve urinary
iron elimination.
Aims: To investigate the effects of vitamin C as an adjuvant therapy to the
three used iron chelators in moderately iron overloaded young vitamin C-defi-
cient β-thalassemia major (β-TM) patients in relation to tissue iron overload.
Methods: This randomized prospective study was registered in the ClinicalTri-
als.gov (NCT02083575). Inclusion criteria were moderately iron overloaded β-
TM patients who had vitamin C deficiency, without clinical symptoms of cardiac
dysfunction and with serum ferritin (SF) >1000-2500 ng/mL and cardiac T2*
>10 ms. Of two-hundred ninety β-TM patients screened for eligibility, 180 were
enrolled. Patients were randomly assigned into 3 groups (60 patients in each
group) receiving DFO, DFP or DFX. Patients in each of the 3 chelation groups
were further randomly divided into 2 subgroups according to vitamin C supple-
mentation. Thirty patients in each chelation group received morning oral vitamin
C in a dose of 100 mg daily. All patients received vitamin C (group A) or no vita-
min C (group B) were followed-up for one year with assessment of transfusion
index, hemoglobin, iron profile, liver iron content (LIC) and cardiac magnetic
resonance imaging (MRI) T2*.
Results: Baseline clinical, laboratory and radiological variables were similarly dis-
tributed among β-TM patients with and without vitamin C supplementation and
also, among patients on the three used chelating agents. Transfusion index, serum
iron, serum ferritin (SF), transferrin saturation (Tsat) and LIC were significantly
decreased among group A β-thalassemia patients after vitamin C supplementation
compared with baseline levels (p<0.05). Hemoglobin and vitamin C levels as well
as cardiac MRI T2* were significantly increased at the end of treatment (p<0.001).
No significant difference was found between baseline and study end as regards
any of the studied variables among thalssemia patients who did not receive vitamin
C therapy (group B). After vitamin C supplementation, DFO-treated patients had
significantly lower transfusion index (p=0.004), serum iron (p<0.001), SF (p<0.001),
Tsat (p<0.001) and LIC (p<0.001) while hemoglobin (p<0.001) and cardiac MRI
T2* (p=0.017) were increased compared to baseline levels. Patients on DFP or
DFX showed non-significant improvement in hematological variables. Cardiac
MRI T2* was significantly higher among DFP-treated patients (p=0.002) while LIC
was significantly decreased in patients receiving DFX after vitamin C supplemen-
tation (p<0.001). When the three thalassemia subgroups were compared post
therapy, DFO-treated patients had the highest hemoglobin (p=0.046) and vitamin
C levels (p=0.038) with the lowest iron (p=0.032), SF (p=0.021) and Tsat (p=0.033)
compared with the other two subgroups. No significant difference was found
between the 3 groups as regards LIC or cardiac MRI T2*. Baseline vitamin C
levels were negatively correlated to SF and LIC (p<0.001).
Summary and Conclusions: vitamin C supplementation to patients with β-
TM represents a potential therapeutic adjuvant agent increasing the efficacy of
iron chelation therapy, decreasing transfusion frequency and elevating hemo-
globin levels. Vitamin C in a dose of 100 mg possibly potentiates the efficacy
of DFO more than DFP and DFX in reducing iron burden in the moderately iron
overloaded vitamin C-deficient β-TM patients, with no adverse events.
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Background: Conferring the World Health Organisation (WHO) statistics, iron
deficiency anaemia (IDA) is the most common nutritional deficiency disorder in the
world, affecting at least two billion people, with pregnant women and young children
at particularly high risk. If IDA in pregnancy is not managed properly, it may have
a significant effect on mothers and babies with serious maternal and neonatal con-
sequences. Therefore, we are proposing a pragmatic solution by employing in our
trial intravenous iron that is considered an effective and safe tool in replenishing
the iron stores and hence, eliminating serious consequences of IDA.
Aims: To assess the improvement in predelivery haemoglobin and iron stores
after treatment with the standard care with oral iron versus the standard IV iron
formulation “iron polymaltose” (long duration infusion) versus newly available
IV “iron carboxymaltose“ (short duration infusion) therapy in pregnant Tasman-
ian women, Australia.
Methods: A three arm randomised controlled trial (RCT) that aims to evaluate
the treatment effects on Tasmanian pregnant women with iron deficiency
anaemia, with (A) standard treatment with oral iron sulphate 325mg (elemental
105 mg) daily until delivery versus (B) a single dose of IV 100 mg iron polymal-
tose (IPM) administered over 60 minutes versus (C) a single dose of IV ferric
carboxymaltose (FCM) administered over 15 min. We recruited 246 pregnant
women after informed consentbetween September 2013 and August 2014 at
our tertiary referralcentre. Median age was 28 years (range, 18-47) with a medi-
an and mean gestational age of 27 weeks. Median baseline serum ferritin level
was 9 mcg/Lwith a median serum transferrin saturation of 13%.
Results: The ferritin level was significantly higher in FCM group against both
Oral iron andIPM group (p<0.001) with a difference of 73.9 mcg/L. However,
no difference was noted between the IVgroups with each IV iron showing sig-
nificantly higher ferritin at 4 weeks and pre-delivery compared to oral iron.The
ferritin is significant in FCM group against both oral and iron polymaltose groups
(p<0.001) but there were no significant differences against FCM and IPM groups
in terms of Hb or ferritin increment. Hb levels increased significantly at 4 weeks
in FCM group compared to oral iron group (p=0.05) however the difference
declined in pre-delivery Hb (p=0.07) with more apparent increase in terms of
ferritin compared to the oral group at both 4 weeks and pre-delivery time points
(p<0.0001). Cord blood ferritin was significantly higher in both IV iron groups
against oral iron groups with p values of 0.05 in FCM and 0.03 in IPM without
such difference in terms of cord Hb increment (p=0.2 and 0.8 respectively).A
cost effectiveness analysis showed the total cost of administration of 1000mg
of FCM is less than a similar dose of IPM and both were more economical than
oral iron in terms of effectiveness.No blood transfusion was recorded in the IV
iron groups, however two patients in the oral group received 2 units of blood
each, however statistically not yet significant (p=0.2)
Summary and Conclusions: We compared two different single IV iron infusion
in set of 1g versus 4 weeks of oral iron sulphate 325mg daily (total dose 9.1g)
for the treatment of moderate IDA of pregnancy. It is of interest that IV dose
compromise 1/9 of the oral dose and showed significant superior results than
oral iron at 4 weeks of treatment in both ferritin and Hb levels. Even the benefits
extended in terms of ferritin increment till the delivery time point (p<0.001),
where the patients received in average a total of 27 g of oral iron versus 1g for
the IV groups. Our data indicate thatFCM application during pregnancy is safe
and leads to improved efficacy and improvement of iron stores compared to
oral iron in pregnancy-related ID. There were no significant difference between
FCM and IPM groups. However, FCM is considered cost effective and more-
convenient to the patients. Trial registration: (http://www.ANZCTR.org.au/
ACTRN12613000853741).
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Background: Hydroxyurea (HU) is widely recommended for treatment of chil-
dren with Sickle Cell Disease (SCD) in developed countries, but information
about its use comes mainly from studies performed in adults or in the United
States. The National Guidelines for the Management of SCD in Childhood in
Italy issued in 2012 by the Italian Association of Pediatric Hematology Oncology
(AIEOP; www.aieop.org) strongly recommend HU treatment for specific disease
complications; a chapter dedicated to HU therapy is included in the Guidelines.
In Italy, where newborn screening is not available in most Regions, children
can receive HU free of charge from Pharmacies or Hospitals located near home
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upon presentation of the rare disease certificate and a HU prescription made
by a physician. The only formulation available in Italy is the 500 mg capsule,
not divisible. Data regarding the use of HU for children with SCD in our country
are lacking.
Aims: To evaluate HU prescription, availability and use in children (<19 yrs)
with SCD in Italian Pediatric Centers through a national survey.
Methods: The 22 Pediatric Hematology Oncology Units of the AIEOP were
invited to participate to the survey. Eight Centers in 4 different Regions respond-
ed. Data were retrospectively collected from clinical charts in each center and
included in a dedicated excel database for analysis.
Results: Out of 441 Children followed in 8 Centers, 173 (39%) were prescribed
HU: 98 M, mean age at diagnosis 30 months (range 0-198 months). 72% are
African, 18% European, the remaining from Middle East/South America. 94% are
SS/Sβ°, 3% SC, 3% SB+/Other. Mean age at HU beginning is 90 months (range
11-221) but is higher in SC patients (120 months, range 46-165). While in 70% of
the children the diagnosis of SCD is made before 3 yrs of age, less than 10%
begins HU before 3 yrs. Indications for HU therapy are: 29% recurrent Vaso-occlu-
sive crisis, 20% recurrent Acute Chest Syndrome, 16% both, 24% anemia <7 g/dl,
1% retinopathy, 1% refusal of transfusion, 9% various causes. Mean starting dose
is 16 mg/kg (range 6-30), mean dose reached after 6 months is 21 mg/kg (range
10-32). 87% of the patients use the 500 mg Oncocarbide capsule, 6% a galenic
prepared according to patients’ weight and drug dosage pro kg, 2% the 100 mg
Siklos tablets, purchased from abroad. Frequently, parents had to split the capsule
or change to non-daily drug schedule (2-3 times weekly) due to the limited avail-
ability of a pediatric formulation adequate for low weights. 62% of the HU pre-
scriptions by pediatric hematologists occurred after 2012. Surprisingly, 6 Centers
(36/173 patients) use combination of HU treatment coupled with chronic transfu-
sion (exchange or top up). Most children (>95%) achieved good hematological
and clinical response after 6 months of HU treatment and 158/173 are still on HU
with a mean FUP of 4 yrs (range 2 months-10 yrs); reasons for interruption were
lack of clinical response with start of a transfusion program or bone marrow trans-
plantation. No major complication have been reported.
Summary and Conclusions: This is the first survey regarding the use of HU in
children with SCD in Italy, a European country with a recent increase of SCD
patients. Among other results, we underline the significant number of children
receiving treatment, the majority having begun HU after 2012, year of the National
Guidelines publication. Some criticisms have been identified, mainly associated
with no pediatric formulation available (low dose tablets or syrup), the relative
high age of HU beginning, and a maximum dose lower than recommended.
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NOVEL SICKLE CELL DISEASE DIAGNOSTIC DEVICE DEMONSTRATES
HIGH PERFORMANCE AT THE POINT OF CARE
J. Kanter1,* C. Roberts2, X. Yang2, J. Kim2
1Pediatrics, Medical University of South Carolina, Charleston, 2BioMedomics
Inc, Durham, United States
Background: Sickle cell disease (SCD) is one of the most common inherited
blood disorders in the world1,2. Although newborn screening for SCD has become
standard of care in many high-resource countries, many low-resource areas
remain unable to diagnose patients at early age due to the expense and difficulty
of current testing mechanisms3. Furthermore, current standard of care testing
methodology (hemoglobin electrophoresis, iso-electric focusing, and high-per-
formance liquid chromatography) take time to perform and results are often deliv-
ered to affected families (or individuals) weeks after the initial testing is performed.
To improve the diagnosis of individuals worldwide with SCD, a point of care test
is needed. According to the College of American Pathologists, a point of care
(POC) test is designed to be used where the patient is located, does not require
permanent dedicated space, and can be performed outside the physical facilities
of the clinical laboratories. Having a low cost, portable POC test for SCD will a).
Greatly enhance the capacity for diagnosis in rural or low-resource areas b).
Reduce the time between testing and diagnosis and c). Improve the ability to
deliver results, counseling, and education at the time of testing.
Test: To address this gap in technology, we have developed a novel, innovative
point of care (POC) test for sickle cell disease (SCD) or sickle cell trait (SCT).
This Sickle SCAn™ test kit is a rapid, qualitative lateral flow immunoassay kit
for the identification of sickle cell disorder of hemoglobin A, S, and C. The test
requires five microliters of blood added to a provided, buffered loaded Module
to release hemoglobin by lysing erythrocytes. The resulting hemolyzed solution
is dropped on to the sample inlet of the Sickle SCAn™ cartridge. The treated
sample flows through the test cartridge in order to interact with antibody-con-
jugated colorimetric detector nanoparticles and travel to the capture zones. A
total of four detection lines are possible including hemoglobin variants A, S, C
and a control (compound heterozygotes will show all hemoglobin present, see
Figure). Prior to this clinical study, an ex-vivo laboratory testing using venous
blood samples was performed. Sickle SCAn™ was compared to hemoglobin
electrophoresis and HPLC using guidelines. Patient samples (n=126) were
collected and measured in duplicate on both systems. Sickle SCAn™ perform-
ance compared to hemoglobin electrophoresis based diagnosis demonstrated
>99% specificity and sensitivity for samples of HbAA, HbAS, HbSS, HbSC,
and HbAC. The Sickle SCAn™ limit of detection for hemoglobin A, S, and C
was determined to be 20%, 1%, and 2%, respectively.
Aims: To assess the level of agreement between sickle cell disease genotype
measured using the Sickle SCAn™ device by finger stick at the true point of
care compared to known genotype of affected individuals.
Methods: IRB approval was obtained from the Medical University of South
Carolina to test current SCD patients and their families using a POC device.
75 patients provided informed consent to undergo capillary sampling at the
MUSC SCD clinic. Blood was obtained using a standard lancet and was col-
lected using the capillary sampler provided in the testing kit and added to the
buffered loaded module. After inverting the module x 2, the hemolyzed samples
were dropped onto the inlet of the Sickle SCAn™ cartridge. Results were read
within 120 seconds. Patients of all ages were included in the trial. Those who
had received a blood transfusion within the last 60 days or family members
whose hemoglobin genotype was not confirmed were excluded. Patients on
Hydroxyurea were included in sample analysis. 43 patients met inclusion/exclu-
sion criteria and are included in the results below.
Results: Forty-three patients with HbAA, HbAS, HbAC, HbSS and HbSC were
included. Patients ranged in age from 5 weeks-72 years. The majority of individuals
were 16-32 years of age. Hemoglobin of individuals tested ranged from 5.9g/dL
to 14g/dL. Sample results are shown below with confirmed genotypes (table 1).
Tabella 1.
Number of Samples Sickle SCAn™ test result Confirmed Genotype
16 S 14 HbSS
2 HbSB0
1 HbSB+
7 SC 7 HbSC
12 AS 1 HbSD
11 HbAS
3 AC 3 HbAC
5 A 5 HbAA
The Sickle SCAn™ test performed favorably with only 1 false negative result
(patient with confirmed HbSD disease). In 43 subjects, this test detected the
correct A, S, C presence with an overall diagnostic accuracy of 97.7%. Detailed
data is shown in table 2 below.
Tabella 2.
Sensitivity (95% CI) Specificity (95% Cl)
SCD (HbSS, HbSC, HbS+-thal, HbS 0-thal) 100% (87-100) 100% (84-100)
Sickle trait (AS 100% (74-100) 96.9% (84-99)
C trait (AC) 100% (44-100) 100% (91-100)
Normal (AA) 100% (57-100) 100% (91-100)
Figure 1.
Summary and Conclusions: Results indicate the Sickle SCAn™ test is highly
specific and sensitive for the diagnosis of SCD at the point of care using a cap-
illary blood samples. The Sickle SCAn™ test is especially innovative in its use
of lateral-flow immunoassay technology which favors its use for large-scale
screening efforts in low-resource settings. In practice, this means the test does
NOT require electricity or high-level equipment. The results are easily inter-
preted with the naked eye with detection lines that are interpreted visually (sim-
ilar to a home pregnancy test). Our goal is to make POC testing widely acces-
sible with the same level of sensitivity and quantitation specificity as complex
and expensive central lab tests. The Sickle SCAn™ test kit includes everything
needed for performing SCD diagnostics outside of the laboratory setting. Fur-
ther testing in children less than 6 months of age is in progress to assess the
feasibility of Sickle SCAn™ test for newborn screening.
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TRANSCRANIAL DOPPLER IN A EUROPEAN COHORT OF SICKLE SC
PEDIATRIC PATIENTS
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Ospedaliera Università di Padova, 7Department of Child and Maternal Health,
Azienda Ospedaliera-Università di Padova, Padova, Italy
Background: Sickle Cell Disease (SCD) is the most frequent severe genetic
disease worldwide. It’s the most prevalent genetic disorder in France and the
UK; its frequency is steadily rising in several European countries, including
Italy and Ireland. Sickle SC disease (HbSC) is the second commonest form of
SCD after sickle cell anaemia (HbSS/HbSB°) and accounts for 25–30% of cas-
es. Neurological events are among the most frequent and disabling complica-
tions in children with SCD with an important impact on quality of life, health and
educational system costs. Overt stroke, silent infarcts and psycho-cognitive
impairment are reported to occur also in HbSC disease, although at a lower
frequency than in HbSS. Studies suggest that the life-time risk of stroke in
HbSC is 2–3%. At present, a screening program is available for stroke preven-
tion using Transcranial Doppler (TCD) according to the Stroke Prevention Trial
criteria, but only for HbSS/HbSB° patients. There is no specific evidence to
guide stroke prevention in HbSC. TCD ranges of velocities in the Middle Cere-
bral Artery (MCA) and in the distal Internal Carothid Artery (dICA) used to stratify
patients with HbSS/HbSB° in risk categories might be inappropriate for HbSC
patients. The Sickle Cell Anaemia transcranial Doppler Educational Study
(SCATES) is a Multicenter European Educational Study to facilitate a screening
program with the purpose to achieve systematic evaluation of stroke risk in
children. It has the objectives to standardize TCD application in different Euro-
pean Settings and make TCD a common practice in routine health care of chil-
dren with SCD across United Kingdom, Ireland and Italy.
Aims: To determine mean reference values of velocities in MCA and dICA in a
European prospective cohort of children with HbSC. To evaluate possible clin-
ical and hematological risk factors of high velocities in HbSC disease.
Methods: TCD was performed at least once a year in children with HbSC dis-
ease aged 2-18 years. TCD, clinical and hematological data were prospectively
collected in clinical charts and transferred in a web based dbase for statistical
analysis. Descriptive statistics and regression analysis were performed.
Results: 227 HbSS and 61 HbSC were enrolled in SCATES. In HbSC patients
mean MCA velocity was 95.70 cm/sec (range 54.3-132, SD 19.07) and dICA
was 79.81 cm/sec (range 29-138, SD 19.29), while in SS patients velocities
were much higher: MCA was 122.47 cm/sec (range 57-190, SD 24) and dICA
was 107 cm/sec (range 61-176, SD 22.21). Bootstrap analysis allowed to define
a mean velocity in the MCA of 98.68 cm/sec (95%CI 93.75-103.60 (N), 94.00-
103.77 (P), 94.06-103.92 (BC)). There was no significant correlation between
high velocities in the MCA or dICA in HbSC patients and any clinical or hema-
tological parameters except for Diastolic Blood Pressure (p 0.030, 95%CI
0.0939-1.593). Evaluation of Magnetic Resonance Imaging (MRI) available for
15 patients did not show any correlation between stenosis and TCD velocities
of the corresponding vessels.
Summary and Conclusions: This is the largest cohort of pediatric patients
with HbSC disease evaluated for stroke risk using a standardized protocol,
reproducible across Europe. Mean velocities are lower than the reported ones
for HbSS/SB° patients and could aid in defining stroke risk categories for this
group. Diastolic Blood Pressure is an important risk factor and prompts to a
regular Blood Pressure monitoring and control in children with HbSC.
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INTRAVENOUS IRON CARBOXYMALTOSE VERSUS STANDARD CARE IN
THE MANAGEMENT OF POSTOPERATIVE ANAEMIA: A PROSPECTIVE
RANDOMIZED CONTROLLED TRIAL
A. Khalafallah1,2,3,* V. Khelgi4, R. Al-Badri5, E. Robinson4, C. Yan4, J. Tan4,
R. Khan5, H. Nguyen5, B. Krikby5
1Menzies Research Institute, 2Faculty of Health Sciences, University of Tas-
mania, 3Haematology, 4Medicine, 5Surgery, Launceston General Hospital,
Launceston, Australia
Background: Data from literature suggest that by having postoperative normal
Haemoglobin (Hb), patients will recover significantly better after major surgery.
There is growing evidence that improving the recovery period after surgery will
impact on overall outcome of the surgical procedures. Despite the significant
efforts in management of the preoperative, it has been found that there is a
significant, although unknown, number of patients who have postoperative iron
deficiency anaemia. Furthermore, there is no data regarding prevalence and
management of postoperative iron deficiency anaemia and the requirement of
blood transfusion in patients who undergo different surgeries. 
Aims: This study is aiming to show that repleted iron stores and hence
improved haemoglobin post-operatively, will improve outcomes of major sur-
gery. Furthermore, this approach is aiming to minimise requirement for blood
transfusion and the patient’s stay in hospital and to lower the overall cost of
procedures and to relieve the extra burden on health systems.
Methods: A prospective randomized controlled study was offered after an
informed consent to adult patients who are 18 years old and above with docu-
mented Hb level at day 1 postoperatively between 70 and 120 g/L and reduced
iron stores with ferritin <100 or iron saturation <20%. Patients were randomized
between standard care versus active intervention with a single intravenous iron
carboxymaltose infusion. Assessment during hospital stay and at 4 weeks was
conducted to measure patients’ outcomes. During the period between Decem-
ber 2014 and March 1st 2015, we have recruited 106 patients postoperatively
after major surgery at the Launceston General hospital, a tertiary referral hos-
pital for Northern Tasmania, Australia. Male to female ratio was 52:54 with
median age of 65 years (range, 22:90). Vast majority of patients underwent
major orthopaedic surgery (68), then come abdominal (18) and genitourinary
surgery (12), and others (8).
Results: Mean day 1 postoperative Hb was 103 g/L with a median of 105 g/L.
At four weeks assessment of Hb, there was a significant increase of mean Hb
in the intervention group to 131 g/L with reduction in transfused blood units
versus Hb of 116 g/L in the standard care group (p<0.01).Intravenous single
iron carboxymaltose was commenced in average of 1000 mg as short infusion
over 15 minutes and was well tolerated by the patients postoperatively.
Summary and Conclusions: Our data show the feasibility and safety of apply-
ing iron carboxymaltose in the postoperative anaemia setting. Delays in the
identification of patients with preoperative anaemia may delay both, proper
anaemia management and the operative procedure. We employed a pragmatic
alternative or complementary approach to preoperative assessment for
anaemia at day 1 postoperatively. A significant number of surgical patients who
lost blood during surgery with an underlying iron deficiency could benefit from
postoperative management with iron infusion. The new therapy with iron car-
boxymaltose was well tolerated. Further trials to assess our novel approach in
treatment of the post-operative anaemia are warranted.
Trial registration: The study was approved by the Tasmanian Human Research
Ethics Committee, Australia and registered in the Australian New Zealand Clinical
Trials Registry (http://www.ANZCTR.org.au/ACTRN12614001261606).
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ORAL HIGH DOSE LIPOSOMIAL IRON SUPPORT IS SAFE, FAST, WELL
TOLERATED AND COST-EFFECTIVE AS INTRAVENOUS IRON IN
SIDEROPENIC ANEMIA. MULTICENTRIC RANDOMIZED STUDY
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Paul II”, campobaso, 3Regional Hospital “A. Cardarelli”, 4family medicine, Cam-
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Background: In iron deficiency anemia support with intravenous iron allows a
faster anaemia correction and a faster ferritin increase than iron sulfate. Fre-
quently iron sulfate and intravenous iron generate adverse events as hypoten-
sion, urticarioyd reactions, shock, epygastralgia, constipation or diarrhea. High
doses of oral iron frequently are poorly tolerated because of adverse events.
Aims: Aim of this study is to verify if high doses of oral liposomial iron are safe,
cost-effective and well tolerated as standard doses of intravenous ferrigluconate
in patients with iron deficiency anemia.
Methods: We considered two group of patients (RANDOMIZED 1:1) with iron
deficiency anemia without other relevant comorbidities. In group A M/F was
2/3, 7 patients had haemorragic gastritis, 3 hemorragic enteric bleeding
angiodysplasia, 10 hypermenorrhaea, median level of hemoglobin (Hb) was 8
g/dl (R 7-10), median ferritin level was 10 ng/ml (R 3-20), with a normal level
of CRP or ESR, and received liposomial iron 30 mg 4 tablet/day. In group B
M/F was 1/3, 9 patients had haemorragic gastritis, 1 hemorragic enteric bleed-
ing angiodysplasia, 10 hypermenorrhaea, median level of Hb was 8.5 g/dl (R
8-9.5), median ferritin level was 8 ng/ml (R 2-18), with a normal level of CRP
or ESR, and received iv sodium ferrigluconate 62.5 mg iv in NS 100 ml in 3
h/day. The median treatment costs in each group were calculated considering
the monthly global treatment cost for each patients in the treatment period.
This provided an estimate of the costs, independent of the precise cost of the
drug, but tied to the final outcome (efficacy) of the therapeutic strategy used
during the observation period.
Results: In group A, 1 g Hb increase was observed after a median of 8 days
(R 7-12), a target Hb level of 12 g/dl was achieved in a median time of 4 weeks
(R 2-4) with a median cost of € 110/months (R 92-162), 6 (30%) patients showed
adverse events (3 epigastralgia, 3 diarrhoea). In group B, 1 g Hb increase was
observed after a median of 7 days (R 6-10), a target Hb level of 12 g/dl was
achieved in a median time of 3.5 weeks (R 1.5-4) with a median cost of
€326/months (R 250-360), 4 (20%) patients showed adverse events (2 hypoten-
sion, 2 urticaria and headhace).
Summary and Conclusions: Oral high dose liposomial iron support is safe,
fast, well tolerated and cost-effective as intravenous iron in sideropenic anemia.
This study needs confirmation on a larger cohort of patients.
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SURVIVAL AND CAUSES OF DEATH IN PATIENTS WITH ΑLPHA-AND
ΒETA-THALASSAEMIA IN A DEVELOPING COUNTRY: THE FIRST
REPORT FROM THAILAND
V. Viprakasit1,* S. Jansutjawan2
1Department of Pediatrics and Thalassemia Center, 2Department of Pediatrics,
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Background: α-and β-thalassemia (thal) syndromes are the most common
genetic condition found in Thailand and other Southeast Asian countries. It is
expected that >40% of Thai population are carrier for thal and haemoglo-
binopathies resulting in >600,000 Thai people expected to have thalassemia dis-
eases. With recent advances on thalassaemia management i.e. stem cell trans-
plantation, transfusion support, iron monitoring and chelation, survival of trans-
fusion dependent thalassaemia (TDT) in particular; β thal major have increased
significantly in developed countries in the past recent years. However, there was
limited data of thalassaemia survival and the causes of death in developing coun-
tries and none from Thailand. Additionally no data on survival of a less severe
thalassaemia; Non Transfusion Dependent Thalassaemia (NTDT) is available.
Aims: To evaluate survival and causes of death of Thai patients with β thal
major,β thal/Hb E and α thalassaemia (Hb H and Hb H/Hb CS) who received
their treatment under standard health care system in Thailand.
Methods: We retrospectively analysed our hospital registry for patients who
were diagnosed at our department since 1974 until December 2013. The diag-
nosis of thalassaemia syndromes was performed based on the standard clinical
evaluation, haematology, haemoglobin and/or molecular analyses. After our
diagnosis, most patients were referred back to be treated locally at their primary
or secondary health care centers. All patients from our registry were verified
and determined their survival through our National Health Registry database
(started in 1996). Their death rate and causes of death were evaluated and
compared with those of age-sex matched general Thai population during 2004-
2013. Survivals were analysed by the Kaplan-Meier and compared by different
syndromes, sex, decade of birth cohort (<1990, 1991-2000 and >2001) using
the log-rank test. A statistically significant difference was defined at p<0.05.
Results: Total 4,303 thalassemia patients with the oldest patientborn in 1961
were registered in which 2,623, 317, 691 and 672 wereβ thal/Hb E,β thal major,
Hb H and Hb H/CS, respectively. Sixty five percentage of these patients
(n=2,570) could be identified using the National database at Ministry of Public
Health, Thailand. The ratio of male: female was around 50:50 across all syn-
dromes. The mean ages±SD of alive patients were 22.35±10.61, 17.63±7.71,
24.86±12.16 and 20.83±9.54 in β thal/Hb E (n=1,650), β thal major (n=165),
Hb H (n=386) and Hb H/Hb CS (n=414), respectively. Patients withβ thal major
(28 death; 17%) had the highest death rate (7.5 times over matched population
controls) followed byβ thal/Hb E (146 death; 9.1%) (3.1 times compared to
controls) while patients with α-thalassaemia (Hb H (6 death; 1.6%) and Hb
H/Hb CS (9 death; 2.2%) who were all NTDT had the same mortality as general
population. The majority of β thal major died from anemia and very few due to
heart failure suggesting most patients received inadequate transfusion and
only 20% of patients could reach their forth decade of life (Figure 1A). Up to
50% ofβ thal/Hb E patients that around 70% of them were NTDT phenotype
could live to the age of 50 (Figure 1A). Infection was the major cause of death
inβ thal/Hb E possibly related to splenectomy that widely practiced for such
condition in Thailand. The majority of Hb H patients died from accidents and
other natural causes not related to underlying disease similar to general pop-
ulation. Increasing survival was observed, although not statistically significant,
inβ thal major patients who born in recent birth cohorts (Figure 1B) suggesting
an improvement of thalassaemia care in general. There was no difference on
survival by different sex for all thalassemia syndromes.
Figure 1. A) Kaplan-Meier srvival curves for all types of thalassaemia syn-
dromes in Thailand; and B) by birth cohort in β thal major.
Figure 1. A) Kaplan-Meier srvival curves for all types of thalassaemia syn-
dromes in Thailand; and B) by birth cohort in β thal major.
Summary and Conclusions: For the first time, our data suggest that survival
and causes of mortality were different among thalassaemia syndromes; α-tha-
lassaemia had a comparable survival to general population while the survival
of β-thalassaemia was remarkably poor compared to those of developed coun-
tries. This suggests that management of severe thalassaemias in a developing
country remains suboptimal and an improvement on standard of care is urgently
required to enhance a long –term survival of these highly prevalent conditions.
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Background: The oral iron chelator, deferasirox (DFX), is approved for the treat-
ment of transfusional hemosiderosis in both adult and pediatric patients. Safety
data from 52 pediatric patients, aged 2–<6 years, who received DFX for 1 year,
in registration studies were consistent with other age groups. Majority of adverse
events (AEs) were transient in duration and of mild to moderate in severity. In
order to collect long-term data on the safety and efficacy of DFX in young children,
a 5-year observational multinational registry study was initiated.
Aims: To evaluate the long-term safety and efficacy of DFX in an unselected
population of children aged 2–<6 years at enrollment and with transfusional
hemosiderosis.
Methods: Pediatric patients (2–<6 years of age) receiving DFX according to
local prescribing information were enrolled and followed for up to 5 years. The
primary objective was to evaluate the safety profile of DFX, specifically, renal
and hepatic function. Growth and sexual development, and long-term efficacy
measured by serum ferritin, were also assessed. This interim analyses reports
data for up to 61 months since study initiation.
Results: Of 268 evaluable patients, 99 completed, 107 (mean age, 3.3±1.2
years) patients had ≥4.5 years of clinical data, 126 discontinued, and 43 were
ongoing at time of data cut off. Diagnoses included: β-thalassemia (n=177,
66.0%), sickle cell disease (n=52, 19.4%), Diamond–Blackfan Anemia (n=12,
4.5%), and other anemias (n=27, 10.1%). Most common reasons (>5%) for
study discontinuation were “others” (20.1%), lost to follow up (7.5%), and pro-
tocol deviation (5.2%), while 11 (4.1%) patients discontinued due to AEs. There
was one fatal event due to graft versus host disease. Mean±SD of DFX expo-
sure was 43.1±21.5 months and average±SD actual dose was 25.9±6.6
mg/kg/day. Median serum ferritin decreased from 1708 to 1050 ng/mL after 61
months. Most common AEs related to DFX for the overall population and for
those completing ≥4.5 are presented in Table 1. Serious AEs (SAEs) regardless
of relationship to study drug were seen in 86 (32.1%) patients, most common
(≥5%) being pyrexia and pneumonia in 24 (9%) and 15 (5.6%) patients, respec-
tively. Of 107 patients, 31 (29.0%) had SAEs. Of these 3 SAEs in 2 (1.9%)
patients were suspected to be related to study-drug, including accidental over-
dose, increase in aspartate aminotransferase (AST) and increase in ala-
nineaminotransferase (ALT). At data cut off, 227 (85%) patients had serum
creatinine (SrCr) ≤upper limit normal (ULN); 7 (2.6%) patients had SrCr increas-
es >33% and >ULN on 2 consecutive measurements. In patients completing
4.5 years, 2 (1.9%) patients had SrCr increases >33% compared to baseline
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and >ULN on 2 consecutive measurements. These cases were resolved without
dose adjustments. Increases in ALT >5xULN and 10xULN were observed in 6
(2.2%) and 4 (1.5%) patients, respectively. In patients completing ≥4.5 years,
elevated ALT >5xULN on 2 consecutive post-baseline assessments was seen
in 1 (0.9%) patient and resulted in drug interruption. Elevated ALT >10xULN on
2 consecutive post-baseline assessments was observed in 2 (1.9%) patients
and drug was not interrupted.
Tabella 1. Most common investigator-assessed drug-related AEs (≥4
patients, from the overall population).
Summary and Conclusions: The results show a favorable safety profile of
DFX with long-term treatment in pediatric patients of 2–<6 years age. Reported
increases in ALT parameters above 5 times ULN were consistent with previous
studies. Conversely, increases in SrCr were lower than those observed in pre-
vious studies. These results continue to support that DFX is effective in decreas-
ing serum ferritin levels in the pediatric population.
Infectious diseases, supportive care 1
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COMPARISON OF MICAFUNGIN AND LIPOSOMAL AMPHOTERICIN B FOR
EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC
PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED
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Background: Invasive fungal infections (IFIs) incur significant morbidity and
mortality among neutropenic patients after chemotherapy. The risk for IFIs is
related to the intensity and duration of neutropenia, and varies from 2 to 40%.
Mortality rates associated with documented IFIs are considerable, reportedly
ranging from 30% to 60%. Empirical antifungal therapy is the standard care for
neutropenic patients with hematological malignancies (HEM) who remain febrile
despite broad-spectrum antibacterial treatment. Several antifungal agents
including voriconazole (VRCZ) or liposomal amphotericin B (L-AMB) have been
studied as empirical therapies for febrile neutropenia (FN). However, limited
data are available concerning the efficacy of micafungin (MCFG) in febrile neu-
tropenic patients with HEM.
Aims: We conducted a randomized, cooperative group, open-label trial com-
paring MCFG (150 mg once daily) with L-AMB (2.5 mg/kg once daily) as first-
line empirical antifungal treatment for FN patients with persistent fever of HEM.
Methods: Eighty hospitalized FN patients with persistent fever of HEM (AML
56, ALL 8, MDS-AML 7, MDS (RAEB) 3, NHL 4, MM 2 cases) were randomized
to each drug group (MCFG, 40; L-AMB, 40). The study drug was started to
administer as empiric antifungal therapy at least for 5 days without severe drug
toxicity, and the efficacy and safety were evaluated.The efficacy end point was
a favorable overall response, as determined by a five-component end point
according to the criteria of Walsh et al (N Engl J Med 2004; 351: 1391).
Results: At the time of enrolment, there were no significant differences in the
demographics or baseline characteristics between the two groups. The mean
treatment duration for MCFG and L-AMB was 16 and 15 days, respectively.
There were no significant differences in clinical efficacy between the two treat-
ments (MCFG group, L-AMB group), evaluated based on: (1) successful treat-
ment of baseline fungal infection (no evaluation), (2) absence of breakthrough
fungal infection (90.0% vs 92.5%, p=0.692), (3) survival for ≥7 days after study
completion (87.5% vs 85.0%, p=0.745), (4) premature study discontinuation due
to poor efficacy (22.5% vs 20.0%, p=0.784), and (5) resolution of fever during
neutropenia (55.0% vs 52.5%, p=0.822). However, discontinuation due to drug-
related adverse events occurred less frequently in the MCFG group (12.5% vs
35.0%, p =0.018). In safety evaluation, total adverse events were less often in
the MCFG group than in the L-AMB group (25.0% vs 47.5%, P=0.036).
Summary and Conclusions: MCFG was as effective as L-AMB, and better
tolerated than L-AMB as empirical antifungal therapy in FN patients with HEM.
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CAN THERAPEUTIC DRUG MONITORING OPTIMISE EXPOSURE OF
PIPERACILLIN IN FEBRILE NEUTROPENIC PATIENTS WITH
HAEMATOLOGICAL MALIGNANCIES? A RANDOMISED CONTROLLED
TRIAL 
F.B. Sime1, M. Roberts 1, I. S. Tiong2, J. Gardner 2, S. Lehman 2, S. Peake2,
U. Hahn2,* M. Warner2, J. Roberts3
1University of South Australia, 2The Queen Elizabeth Hospital, Adelaide, 3The
University of Queensland, Brisbane, Australia
Background: Conventional antibiotic doses may recurrently fail to offer ade-
quate exposure in febrile neutropenic patients due to disease-related pharma-
cokinetic (PK) changes. Therapeutic drug monitoring (TDM) guided dose opti-
misation is recommended to improve antibiotic exposure although this has not
been described for piperacillin in febrile neutropenic patients.
Aims: To describe piperacillin exposure in febrile neutropenia patients and
determine whether TDM can be used to increase the achievement of piperacillin
pharmacokinetic/pharmacodynamic (PK/PD) targets at PK ‘steady state’
Methods: In a two-arm prospective randomised controlled study (Australian
New Zealand Registry, ACTRN12615000086561), patients were subjected to
TDM for three consecutive days. Dose was adjusted in the intervention group
to achieve a free drug concentration above the minimum inhibitory concentra-
tion for 100% of the dose interval (100% fT>MIC) which was also the primary
outcome measure. The secondary PK/PD target was 50% fT>MIC. Duration of
fever and days to the recovery from neutropenia were recorded.
Results: Thirty-two patients were enrolled. Initially, patients received 4.5g
piperacillin-tazobactam eight or six hourly along with gentamicin co-therapy in
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30/32 (94%) patients. At the first TDM, 7/32 patients (21%) achieved 100%
fT>MIC and 12/32 patients (38%) achieved 50% fT>MIC. Following dose adjust-
ment, 69% of the intervention versus 19% of the control patients (p=0.012)
attained 100% fT>MIC, and 94 % of intervention versus 31% of control patients
(p=0.001) achieved 50% fT>MIC. After the third TDM, the proportion of patients
attaining 100% fT>MIC improved from a baseline 19% to 73% in the intervention
group while it declined from 25% to 7% in the control group. No difference was
noted in the duration of fever and days to recovery from neutropenia.
Summary and Conclusions: Conventional doses of piperacillin-tazobactam
may not offer adequate piperacillin exposure in febrile neutropenic patients.
TDM provides useful feedback of dosing adequacy to guide dose optimisation.
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PREDICTORS OF MORTALITY IN 100 PATIENTS WITH NEUTROPENIC
ENTEROCOLITIS AFTER CYTOTOXIC AGENTS FOR ACUTE MYELOID
LEUKEMIA
N. Pugliese1,* P. Salvatore2, D. V. Iula2, M.R. Catania2, F. Chiurazzi1,
M. Raimondo1, G. Beneduce1, R. Della pepa1, F. Pane1, M. Picardi1
1Hematology, 2Molecular Medicine and Medical Biotechnology, University of
Naples Federico II, Naples, Italy
Background: Neutropenic enteroclitis (NEC) is a life-threatening complication
of intensive chemotherapy regimen in patients with acute myeloid leukemia
(AML) and the optimal treatment of patients with NEC remains controversial.
Aims: This retrospective study analyzed the predictors of mortality for NEC
occurring in AML patients undergone to intensive chemotherapy, in order to
evaluate the optimal management and the risk factors.
Methods: From January 2002 to December 2012, among 100 patients devel-
oping NEC, 30 received chemotherapy protocols based on standard doses of
cytarabine (CY) (100 mg/m2 daily), 19 intermediate doses (1000 mg/m2 daily)
and 51 high doses (6000 mg/m2 daily). Empirical treatment regimen was
defined as the initial antibiotic therapy of neutropenic fever while post-US treat-
ment regimen was the antibiotics used at the time of ultrasonographic (US)
diagnosis of NEC. The outcome measured was death within 30 days of the
NEC onset. Survivor and nonsurvivor groups were compared.
Results: The overall mortality rates at 30 days after the diagnosis of NEC was
23%. We observed no significant differences in the clinical, ultrasonographic
and microbiological characteristics of NEC episodes between survivors and
unsurvivors. Patients in the latter group were more likely to have received cyto-
toxic agent schedule based on high-dose CY (p<0.001). Front-line tigecycline
(TYG)-sparing antibiotic regimen (p=0.006) was associated to a higher mortal-
ity. Among the 37 patients, whose post-US antibiotic regimens were classified
as 2-drug combinations, 13 (35%) died whereas 10 of the 63 patients (16%)
who received 3-drug combination regimens died (p=0.02). Mortality rates within
the post-US antibiotic combination regimen sub-groups were: 14% (1/7) for
those treated with TYG plus piperacillin-tazobactam; 20% (1/5) for those treated
with TYG plus meropenem; 33% (2/6) for those treated with meropenem plus
daptomycin; 43% (3/7) for those treated with meropenem plus amikacin; 50%
(6/12) for those treated with piperacillin-tazobactam plus amikacin; 0% (0/17)
for those treated with TYG, meropenem and daptomycin; 14% (2/14) for those
treated with meropenem, amikacin and teicoplanin; 22% (4/18) for those treated
with ceftazidime, amikacin and teicoplanin; and 29% (4/14) for those treated
with piperacillin-tazobactam, amikacin and teicoplanin. The only multidrug reg-
imen of the post-US phase that was significantly more common in the survivor
group (p=0.036) was the combination of TYG, meropenem and daptomycin.
Overall, the 30-day survival distributions were also significantly different in
patients treated with regimens including TYG vs regimens sparing TYG in the
empirical, post-US and/or post-antibiogram phases of treatment [21/23 patients
(91%) vs 56/77 (73%) patients, respectively; p=0.01]. Logistic regression analy-
sis indentified cytotoxic schedule based on high-dose CY for hematological
remission induction (p<0.0001) and 2-antibiotics combination (p<0.0001) as
independent predictors of 30-day mortality, whereas front-line TYG-including
regimens (p<0.0001) and post-US combination therapy with TYG, meropenem
and daptomycin (p=0.013) were associated with a lower risk of mortality.
Summary and Conclusions: Our study represents the largest cohort of
patients with NEC analyzed to evaluate the impact of several factors on mor-
tality. High-CY doses are associated with higher incidence and mortality for
NEC in AML patients. Prompt administration of TYG in patients with neutropenic
fever as empirical therapy, preceding US diagnosis of NEC, seems to be effec-
tive. As for post-US antibiotic therapy, treatment with 3 drugs and overall TYG
including regimen seems to improve survival for NEC.
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THE ASSOCIATION OF COMBINED ANTIBODY DEFICIENCY AND
CHEMOTHERAPY REPRESENTS A HIGH-RISK FACTOR OF
NON-NEUTROPENI MAJOR INFECTION IN CLL
A. Visentin1,2,* N. Compagno1,2, S. Imbergamo1, F. Frezzato1,2, F. Cinetto1,2,
R. Zambello1,2, F. Piazza1,2, G. Semenzato1,2, C. Agostini1,2, L. Trentin1,2
1Hematology and Clinical Immunology brach, Department of Medicine, Padua
University School of Medicine, 2Venetian Institute of Molecular Medicine, Pad-
ua, Italy
Background: Chronic lymphocytic leukemia (CLL), the most common
leukemia in western is still an incurable disease and infections are the major
cause of morbidity and mortality. Susceptibility to infections in CLL patients
can be an intrinsic characteristic of the disease or due to chemo-immunother-
apy.
Aims: In this study we will identify a clinical subset of patients characterized
by a very high risk of major infectins, in which Ig replacement therapy (IgRT)
should be appropriate.
Methods: We retrospectively analyzed clinical and biochemical data of 706
patients referred to the Hematology and Clinical Immunology Unit of Padua
University Hospital. In this series, we identify patients with at least one episode
of major infections (MI), defined as those events requiring inpatient manage-
ment and/or intravenous antibiotic treatment; we excluded chemotherapy relat-
ed neutropenic MI. FISH analysis (n=450), CD38 expression (n=529), ZAP70
(n=502), IGHV (n=473), TP53, NOTCH1, BIRC3, SF3B1 (176 genes tested)
mutational status, were evaluated at diagnosis or before starting treatment.
Staging and Ig levels were collected at the time of the MI; for patients who
didn’t complain any MI we recorded the last available data. We used ROC
curve analysis, Mann-Whiney, Fisher exact or Chi-square, Log-rank test,
Kaplan-Meier method and Cox model when appropriated. Time to MI (TTMI)
was calculated from the date of initial presentation to the MI event or last known
follow-up (censored).
Results: 79 patients had 98 MI events, 67 were pneumonia (5 pulmonary
aspergillosis), 27 sepsis, 2 meningitides, 1 uveitis and 1 endocarditis. Ig levels
were significantly lower in patients with a history of MI with respect to patients
who did not experience any serious infections (p<0.0001). Some clinical and
biological markers were more common in patients with a history of MI (del 17p
[p<0.0001], unmutated IGHV [p<0.0001], CD38+ [p=0.0205], Rai stage III-IV
[p<0.0001] and needed treatment [p<0.0001]) than patients without any MI
event. No differences were found for ZAP70 expression, TP53, NOTCH1,
BIRC3, SF3B1 gene mutations. Using ROC analysis we identified the best Ig
isotype cut-offs to identify patients at high risk to development a MI event i.e.
7.44g/L for IgG, 0.79g/L for IgA and 0.21g/L for IgM. In the univariate analysis,
pretreated patients and subjects with combined antibody deficiency (CAD, i.e.
low levels of IgG and IgA or IgM) had a shorter TTMI with respect to patients
who did not need a specific CLL therapy (239 months vs not reached,
p<0.0001) or those with only IgG deficiency or Ig within normal range (239
months vs 270 vs not reached, p<0.0001), respectively. By multivariate analysis
the HR in treated patients and those presenting a CAD were 2.98 and 3.10
respectively (p<0.0001 in both cases). We evaluated the importance of the
presence of a combination of these two markers using a unique model. Median
TTMI was significantly shorter in patients who had both a history of treatment
and a CAD than in subjects presenting only one of this prognostic marker (i.e
treatment history or CAD presence) (217 months vs 258 vs not reached,
p<0.0001). These data were also confirmed in multivariate analysis.
Summary and Conclusions: We, herein, demonstrated that previously treated
patients with CAD carried the highest risk of contracting a major infection during
their clinical history. Furthermore, we described the half of incidence of MI
(0.044 vs 0.019 MI/people-year) in a small cohort of patients with such clinical
phenotype after IgRT.
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EMERGING RESISTANT BACTERIA STRAINS IN ACUTE LEUKAEMIA
PATIENTS: IS THERE STILL A ROLE FOR FLUOROQUINOLONE
PROPHYLAXIS? RESULTS OF A PROSPECTIVE STUDY BY THE RETE
EMATOLOGICA LOMBARDA (REL)
C. Cattaneo1,* P. Zappasodi2, S. Ferrari3, F. Pavesi4, C. Annaloro5, C. Skert6,
E. Todisco7, A. Ferrario8, V. Saccà9, L. Verga10, A. Passi1, E. Borlenghi1,
M. Da Vià2, V. Mancini3, G. Mometto5, C. Basilico8, R. Cairoli3, A. Nosari3,
G. Rossi1
1Spedali Civili, Brescia, 2Fondazione IRCCS Policlinico San Matteo, University
of Pavia, Pavia, 3A.O. Ospedale Niguarda Ca Granda, 4San Raffaele Scientific
Institute, 5Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Uni-
versity of Milan, Milano, 6Chair of Hematology, Unit of Blood Diseases and
Stem Cell Transplantation, University of Brescia, Brescia, 7Humanitas Cancer
Center, Rozzano-Milano, Milano, 8Azienda Ospedaliera Universitaria,
Ospedale di Circolo e Fondazione Macchi, Varese, 9Department of Internal
Medicine, Hematology, Ospedale Valduce, Como, 10San Gerardo Hospital,
Monza, Italy
Background: Multiresistant (multiR) bacteria are emerging pathogens in
haematologic cancer patients (pts). The antibiotic pressure, including fluoro-
quinolones (Fq) prophylaxis, may be one of the factors responsible for this
phenomenon.
Aims: In order to better define the very recent epidemiology and outcome of
bloodstream infections (BSI) in a real-life setting, we planned a prospective study
collecting all consecutive febrile/infectious episodes occurring in acute leukaemia
(AL) pts admitted to 9 haematological institutions participating to REL.
Methods: From Dec-12 to Dec-14, all febrile/infectious episodes were record-
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ed. The following data concerning BSI were analysed: age, gender, type/phase
of leukaemia, neutropenia, Fq prophylaxis or other antibiotic treatment, pres-
ence of central venous catheter (CVC), concomitant pulmonary infiltrates, antibi-
otic resistance.
Results: In 293 AL pts (M/F 174/119; median age 55y, range 18-80; AML/ALL
238/55), 433 BSI were diagnosed. In 246 (56.8%), BSI occurred in pts on Fq
prophylaxis and in 72 (16.6%) in pts already receiving systemic antibiotic ther-
apy. In 94 (21.7%) pneumonia was also present. Gram-positive cocci (GPC)
were isolated in 194/433 BSI (44.8%), Gram-negative rods (GNR) in 164
(38.3%), polymicrobial (PMB) aetiology in 68 (15.7%) and fungi (F) in 5 (1.1%).
Coagulase-negative staphylococci (CoNS) were the most frequent GPC
(130/433, 30%); S. aureus, S. viridans and enterococci were observed in 10
(2.3%), 24 (4.6%) and 52 (12%) cases, respectively. Methicillin-resistant strains
accounted for 76.4% of all staphylococci and vancomycin-resistant for 1.9% of
enterococci. Fq resistance was detected in 50.2% of all GPC. GPC aetiology
was associated with CVC-related BSI (OR 1.7, CI 1.1-2.6, p=0.009), and was
typical of pts not in complete remission (OR 0.7, CI 0.4-0.9, p=0.04). Consid-
ering GNR, Enterobacteria were isolated in 155 BSI (35.8%) and P. aeruginosa
in 37 (8.3%). GNR occurred more frequently during consolidation cycles (OR
1.8, CI 1.2-2.8, p=0.003). Frequency of Enterobacteria BSI was also higher
during consolidation cycles in comparison with other AL phases (OR 2.5, CI
1.7-3.9, p<0,0001) and neutropenia was a risk factor (OR 2.2, CI 1.1-4.5,
p=0.04). Fq resistance was observed in 88/155 (56.8%) Enterobacteria; in
84.1% of cases it was detected during Fq prophylaxis. ESBL+ strains, which
accounted for 21.3% of Enterobacteria, were also associated with previous
antibiotic exposure, including Fq prophylaxis (OR 4.05, CI 1.3-12.4, p=0.01).
Carbapenemase producing (CP) strains occurred in 9% of Enterobacteria.
Among P. aeruginosa strains, 21.6% were multiR. Thirty-day mortality was 8.5%
(37/433); it was lower, although not significantly so, for GPC (6.7%) in compar-
ison with GNR (9.1%) and PMB BSI (13.2%). CP Enterobacteria or multiR P.
aeruginosa BSI but not ESBL+ strains were independent predictors of death
(30d mortality: 30.8%; OR 5.7, CI 1.9-16.8, p=0.002). Furthermore, having
relapsed/resistant AL (18.3%; OR 4.7, CI 2.1-10.4, p=0.0002) and the presence
of concomitant pulmonary infiltrates (26.6%; OR 7.5, CI 3.4-16.1, p<0.001) sig-
nificantly correlated with the risk of death.
Summary and Conclusions: The proportion of multiR GNR is becoming a
major problem in our real-life prospective study and negatively impacts on prog-
nosis of AL pts, as well as a concomitant diagnosis of pneumonia during BSI.
Fq prophylaxis is not protective against multiR pathogens and it is associated
to Fq resistance and to ESBL+ strains. The role of Fq prophylaxis in AL
leukaemia patients should be reconsidered.
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PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND ACUTE
RESPIRATORY FAILURE FROM UNDETERMINED ETIOLOGY ARE AT
HIGHEST RISK OF DYING: A GRRR-OH STUDY
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Background: Acute respiratory failure (ARF) is the most frequent complication
in patients with hematological malignancies (HM), occurring in 20% to 50%,
and is associated with high morbidity and mortality. ARF etiologies are numer-
ous, and despite extensive diagnostic investigations, some patients remain
with undetermined ARF etiology.
Aims: We sought to appraise the relation between an undetermined ARF eti-
ology and mortality in a large cohort of critically ill patients with HM, and sec-
ondary, the yield of the bronchoalveolar lavage (BAL) in this population as com-
pared with non-invasive tests.
Methods: A post-hoc analysis from a prospective multicenter study of 1011
critically ill hematological patients performed by the French and Belgian
research network on critical respiratory diseases in patients with malignancies
(Groupe de recherche en réanimation respiratoire en onco-hématologie,
GRRR-OH) was conducted. All patients with ARF were included in the statistical
analysis. ARF etiology was sought by noninvasive diagnostic tests or bron-
choscopy and BAL. Relationship between ARF etiology and hospital mortality
was assessed using a multivariable model adjusting for confounders.
Results: Seven hundred and one patients with respiratory symptoms were
reviewed and 604 patients with ARF were included. There were mainly males
(61%) with a median age of 60 [50-70]. The most prevalent HM were acute
myeloid leukemia (AML, 28%) and non-Hodgkin lymphoma (NHL, 27%). Twenty
three percent of the patients were in complete or partial remission. One hundred
and seven patients (17.7%) were allogeneic hematopoietic stem cell transplan-
tation recipients. Twenty percent of the population had a performans status of
more than 1, 47% had a SOFA score over 7 and 30% were neutropenic. At ICU
admission, the median respiratory rate was 32 [26-38]/min and two-thirds of
the patients had 2 or more quadrants involved on chest radiography. Two hun-
dred and fifty patients (41.4%) needed invasive mechanical ventilation at day
1. Patients were classified into four etiological categories: infectious etiologies
(44.4%), non-infectious diagnoses (32.6%), opportunistic infection (10.1%) and
undetermined (12.9%), with corresponding mortality rates of 39.2%, 35%,
55.7% and 60%, respectively. Overall hospital mortality was 42.2%. One hun-
dred and fifty five patients had BAL (25,6%), with no impact on hospital mortality
or rate of undetermined diagnosis as compared with non-invasive tests (16.8%
vs 11.8% respectively, p=0.10). By multivariate analysis, factors associated
with hospital mortality were invasive pulmonary aspergillosis (OR =7.57 (95%
CI 3.06-21.62); p<0.005), invasive mechanical ventilation in the first 24 hours
(OR =1.65 (95% CI 1.07-2.55); p=0.02), a SOFA score >7 (OR =3.32 (95% CI
2.15-5.15); p<0.005) and an undetermined ARF etiology (OR =2.92 (95% CI
1.71-5.07); p<0.005) (Figure).
Tabella 1. Multivariate analysis of risk factors for hospital mortality.
Summary and Conclusions: In patients with hematological malignancies and
ARF, up to 13% remain with undetermined ARF etiology despite comprehensive
diagnostic workup. Undetermined ARF etiology is independently associated
with hospital mortality. Studies to better guide second line diagnostic strategies
are warranted.
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APREPITANT PREVENTS NAUSEA AND VOMITING AFTER A
HIGH-EMETOGENIC DOSE OF CYCLOPHOSPHAMIDE FOR PBSC
HARVESTING: A PHASE III, DOUBLE-BLINDED, RANDOMIZED,
PLACEBO-CONTROLLED TRIAL 
L. Flenghi1,* E. Bonifacio1, G. Reboldi2, C. Muzi1, S. Ballanti1, F. Falcinelli1,
F. Lotti1, M. Capponi1, E. Agliani1, B. Falini1
1Medicina Clinica e Sperimentale, Hematology, 2Medicina Clinica e Sperimen-
tale, MISEM, Perugia, Italy
Background: Peripheral blood haematopoietic stem cells for autologous trans-
plantation are often mobilized by means of highly emetogenic, intermediate
doses of cyclophosphamide which are administered in an out-patient regimen.
As prophylaxis of chemotherapy induced nausea and vomiting (CINV) Aprepi-
tant, a 5-HT3 receptor antagonist, is recommended in combination with dex-
amethasone and a 5-hydroxytryptamine 3 (5-HT3) receptor antagonist. Since
aprepitant moderately inhibits CYP3A4, concomitant administration with
cyclophosphamide might decrease cyclophosphamide clearance, thus impair-
ing efficacy of autologous stem cell mobilization.
Aims: This study was designed to determine whether the aprepitant-
palonosetron-dexamethasone regimen was better than palonosetron-dexam-
ethasone therapy in preventiing CINV and to assess its impact upon stem cell
harvesting and toxicity.
Methods: This single centre, randomized, double-blinded, placebo-controlled
phase III trial was conducted in patients who received a highly emetogenic
cyclophosphamide IV chemotherapy (3 g/m2) for autologous PBSC harvesting.
Efficacy of retching and vomiting, rescue medication, severity of nausea and
overall quality of and safety data were obtained from the patient’s daily diary
(days 1-5) which reported episodes life. The Functional Living Index-Emesis
questionnaire was completed on days 1 (before starting chemotherapy) and 6
(after chemotherapy). All side effects were recorded daily.
Results: A total of 122 patients were enrolled and randomized. The analysis was
performed according to the intention-to-treat principle. Primary endpoint: When
the 2 groups were compared, the number of patients with no emetic episodes and
no rescue medication in the first 120 hours post-chemotherapy, was significantly
lower in the aprepitant group (p.0114). Secondary endpoints: Acute (p.0272) and
delayed (p.0039) complete response rate, complete control rate (p<.0001), number
of emetic events (p.0003) and the impact of nausea and vomiting on daily life
(p<.0001) were also significantly better in the aprepitant group. The adverse event
rate and stem cell harvest (p.821) were not significantly different.
Summary and Conclusions: The aprepitant regimen more effectively pre-
vented CINV and weakened its impact on daily life without impairing the efficacy
of autologous PBSC mobilization and harvesting in patients treated with highly
emetogenic, intermediate doses of cyclophosphamide.
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A PROSPECTIVE STUDY ON BED-SIDE ULTRASOUND IN
NEUTROPOENIC ENTEROCOLITIS (NEC): 76 NEC OUT OF 1680
NEUTROPENIC EPISODES. EARLY ULTRASUOND DIAGNOSIS REDUCES
MORTALITY 
E. Benedetti1,* B. Bruno2, M. Petrini1, I. Bertaggia1
1Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina
e Chirurgia, Hematology Unit Ospedale S. Chiara Pisa, Pisa, 2U.O Ematologia
Trapianti di midollo Torino, University of Torino, Torino, Italy
Background: Neutropenic enterocolitis (NEC) is a life threatening complication
of leukemic and solid tumors patients (pts) treated with chemotherapy (CHT)
with mortality rate up to 50%. It’s a clinical syndrome in neutropenic patients
(pts) characterized by abdominal pain (AP), fever (F) and diarrhoea (D). Ultra-
sound (US) was used to evaluate bowel-wall thickening (BWT), and >4 mm is
considered diagnostic of NEC. Perforation occurs in 5%>10% of cases. Early
diagnosis is crucial to start conservative medical management (CMM) which
appears the optimal strategy for most cases.
Aims: Aims:to evaluate prospectively if Bed-side-US(BUS) can detect early
signs of NEC and guide a prompt treatment (CMM or surgical) in order to
reduce mortality.
Methods: In the last 7 years all pts admitted in Our Hematology/BMT Unit
wards at University of Pisa (Italy), undergoing chemotherapy (CHT), autologous
or allogeneic transplant (AutoTx,AlloTx) were enrolled. Abdominal US was per-
formed, baseline before treatment, and as only one symptom (or a combination)
appeared within 12h from onset: F and/or D and/or AP in CHT-related neu-
tropenic pts.
Results: Out of 1680 neutropenic pts 76 episodes were identified (4.7%). Sev-
en pts had 2 separate episodes of NEC. Disease diagnosis were HD (N=10),
ALL (N=8), AML(N=21),MM (N=9) and NHL (N=28). Treatment received was
intensive CHT (N=35), AutoTx (N=37) and AlloTx (N=4). At time of diagnosis
(Dx) symptoms were: F+AP+D 48%, F+D 4%, F+AP 1%, AP+D 34%,D 3%,AP
9%. F alone were never present at diagnosis of NEC. At Dx, F was absent in
35/76 NEC episodes (46%) and in 17/76 F never developed and 18/76 had
delayed onset of F (from 10h to 72 h) from NEC Dx. There is a trend but not a
statistical (St) significant difference in mortality among the 3 F groups (P=0.09).
As control group (CG) we considered pts with CHT related mucositis and pts
restaged with US during neutropenia in absence of symptoms. A total of N=509
pts were randomly chosen in the CG. None of them had BWT. Overall 11 pts
died (14.5%) without a St difference between 1 or 2 episodes (P=0.309) of
NEC. Treatment was CMM in 92% of pts, and was promptly started as BUS
diagnosis was made. Mortality in pts treated with CMM was 11.5%. Six pts
underwent surgery, guided by US features, during neutropenia, and 50% are
alive. Median BWT was 8.6 mm in surviving pts (range 4.2-30mm) and 11mm
in deceased (range 9.3-15mm). Authors have suggested BWT to be prognostic
of outcome; in our study pts with >10mm had 60% survival. Median time to
response from beginning of CMM was 24h and the first sign of was a decrease
in AP, while median time to death was 26h (range 10.5-72h). The likelihood of
NEC Dx in a discriminant St model (Bayes theoreme) for pts with BWT and
AP=98.8%, AP+D=99.9%, AP+D+F=100%, AP+F=99.9%, D+F=5%.
Summary and Conclusions: BUS allowed to detect early signs of NEC and
to start prompt treatment in this life threatening complication, which was CMM
in 92% with a 88.5% survival rate. With BUS pts do not live the isolation room.
Early diagnosis and intervention allowed to reduce mortality. US guided surgical
intervention with 50% survival rate. Images of BUS and CT were superimpos-
able. Fever is not a condition sine qua non for NEC diagnosis. A prompt BUS
in neutropenic patients as just one symptom presents allows to make early
diagnosis of this life threatening complication and guide prompt treatment (con-
servative or surgical) reducing mortality.
Transfusion medicine
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STREAMLINING THE MANAGEMENT OF BLOOD GROUP O RH NEGATIVE
BLOOD STOCK: A SINGLE CENTRE IRISH EXPERIENCE
E. Groarke1,* L. O’Brien2, M. Kiely2, S. Joyce2, J. Gleeson3, A. Korobeinikov3,
C. Fell3, M. Golding3, I. Kubat3, T. Jetka3, E. Lynch3, A. Magdalina3,
S. Mitchell3, N. Smith2, E. Cahill2, S. Quane2, J. Power4, D. O’Keeffe1,
M. Leahy1, H. O’Leary1
1Department of Haematology, 2Blood Transfusion Laboratory, University Hos-
pital Limerick, 3MACSI, Department of Mathematics, University of Limerick,
Limerick, 4Munster Regional Transfusion Centre, Irish Blood Transfusion Serv-
ice, Cork, Ireland
Background: Group O Rh D negative blood is an important resource as it is
can be transfused to patients of all blood types. According to most recent figures
from the Irish Blood Transfusion Service, 8% of the general population are
blood group O Rh D negative, but 14% of all blood used in clinical practice is
group O Rh D negative. Inappropriate usage (use of O Rh D negative blood
for non O Rh D negative patients on an elective rather than emergent basis
that is greater than 3 days from expiry of the red cell concentrate (RCC)) and
use of short dated group O Rh D negative blood (RCC less than 3 days to
expiry) frequently occurs. This should be minimised given both the importance
of this blood group and its scarcity. However, the use of short-dated O Rh D
negative blood is acceptable to avoid wastage when all reasonable efforts have
been made to give it to O Rh D negative patients.
Aims: To develop a system to minimise inappropriate use of group O Rh D
negative blood within the UL Hospitals.
Methods: In 2011, a strategy was adopted within the UL Hospital group in Ire-
land to streamline stock management of group O Rh D negative blood supply.
The UL Hospital group is made up of the main university hospital (the hub) and
5 other clinical sites. The Munster Regional Transfusion Centre, a branch of the
Irish Blood Transfusion Service (IBTS), supplies blood to the UL Hospitals (ULH).
Currently, ULH maintains 16 units of emergency O Rh D negative blood in the
5 satellite off site hospitals. Prior to 2011, these were supplied via the hub. In
2011, a mathematical model developed by the Mathematics Applications Con-
sortium for Science and Industry (MACSI) in the University of Limerick deter-
mined that replenishing the oldest emergency stock in any of the six hospital
sites (the hub plus 5 satellite sites) from the source as opposed to from the hub
and moving the oldest stock in the satellite sites to the hub would improve O Rh
D negative stock management and reduce inappropriate use. Stochastic simu-
lation was used to prove that the mathematical model would work in real time.
Use of group O Rh D negative blood was then audited before (2009), immedi-
ately after (2011) and 3 years after (2014) implementation of this model.
Results: The breakdown of usage of our group O Rh D negative red cell con-
centrate was audited, paying particular attention to inappropriate usage and
use of short dated group O Rh D negative blood. The initial audit (2009) showed
that the rate of inappropriate use was 22% and the rate of transfusion of short
dated O Rh D negative units to non-group O Rh D negative patients was 21%.
Following implementation of the model (2011), the rate of inappropriate use
and short dated use had markedly improved at 8% and 6%, respectively. A
repeat audit performed 3 years later (2014) showed that the rate of inappropri-
ate use was 0% and rate of short dated use was 13.7%.
Summary and Conclusions: Our audit shows that the rate of inappropriate
use of group O negative Rh D negative blood has reduced to 0 with our current
group O Rh D negative blood stock management system. The use of short
dated group O Rh D negative blood did increase from 6% to 13.7%. This
remains well below the pre 2011 figure of 21% and illustrates the improved
management implemented. In conclusion, this audit shows an effective blood
stock management system for O Rh D negative blood that minimises wastage
and is likely to be directly applicable to other hub and spoke model hospital
networks. Future efforts may include requisition of newer blood to the hub to
prevent short dating.
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CELL SALVAGE DURING CARDIAC SURGERY MAY DECREASE RED
BLOOD CELL TRANSFUSION: A SYSTEMATIC REVIEW AND
META-ANALYSIS
M. Al-Khabori1,* A. Al-Riyami1, S. Siddiqi2, H. Al-Sabti2
1Hematology, 2Surgery, Sultan Qaboos University Hospital, Muscat, Oman
Background: Red blood cell transfusion in cardiac surgery is known to be
associated with increased morbidity and mortality. The use of the cell salvage
(CS) as a blood conservative strategy in cardiac surgery has been under debate
with conflicting results from different studies.
Aims: We examined the current evidence behind the use of the CS by performing
a systematic review and meta-analysis of existing randomized clinical trials that
assessed the impact of the CS use on red blood cell (RBC) transfusion.
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Methods: We searched MEDLINE, CENTRAL, American Society of Hematol-
ogy and bibliographies of relevant studies (all searched July 2014) for random-
ized clinical trials comparing CS versus non-CS strategies in cardiac surgeries.
We performed a meta-analysis using random effects model (DerSimonian-
Laird) to estimate the pooled odds ratio and used I2 statistic to assess the het-
erogeneity.
Results: Total of 587 citations were retrieved, out of which 14 trials were eligible
for inclusion with a total of 1661 patients (899 in the CS group and 762 in the
non-CS group). The vast majority of patients had coronary artery bypass graft
surgery. All trials used shed blood for CS. In the CS group, 345 patients (38%)
received RBC transfusion compared to 340 patients (45%) in the non-CS group.
The odds of receiving blood transfusion were lower in the CS group (odds ratio
of 0.66, 95% confidence interval [CI]: 0.45-0.96; Figure). Nevertheless, there
was substantial heterogeneity between the trails in the outcome [I2 of 60%
(95% CI: 19-87%) which was statistically significant (P<0.01).
Tabella 1.
Summary and Conclusions: Available evidence suggests that the use of CS
during cardiac surgery as a blood conservative strategy may decrease RBC
transfusion with a reasonable effect size. However, these findings need to be
taken with caution, given the substantial between-study heterogeneity in the
outcome. We therefore recommend a large randomized controlled clinical trial
to confirm these findings.
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IMMUNOGLOBULIN PROPHYLAXIS AGAINST HUMAN T CELL
LYMPHOTROPIC VIRUS TYPE I PREVENTS INFECTION IN A HUMANIZED
MOUSE MODEL
T. Mizukami1,* K. Nojima1, C. Matsumoto2, W. Kuribayashi1, R. Sobata2,
M. Kuramitsu1, K. Furuhata1, S. Matsuoka1, K. Okuma1, S. Masahiro2,
K. Tadokoro2, K. Yamaguchi1, I. Hamaguchi1
1Department of Safety Research on Blood and Biologicals, National Institute
of Infectious Diseases, 2Central Blood Institute, Japanese Red Cross Society,
Tokyo, Japan
Background: Adult T-cell leukemia (ATL) is a malignant disease caused by
infection with human T-lymphotropic virus type 1 (HTLV-1). Only about 2–5%
of HTLV-1-infected patients develop ATL, but prevention of HTLV-1 infection is
the most effective strategy to eradicate ATL. After the introduction of HTLV-1
antibody screening of blood donations by the Japanese Red Cross, detection
of HTLV-1 infections caused by transfusion has ceased. However, HTLV-1 infec-
tion continues to spread via breastfeeding and sexual intercourse. In Kyushu,
an endemic area of Japan, pregnant HTLV-1 carriers are recommended against
breastfeeding, and this policy has successfully reduced the number of HTLV-1
vertical infections. Despite this recommendation, 3–5% of HTLV-1 infections
are still due to the virus passing from mother to child, and the number of HTLV-
1 infections in non-endemic areas is increasing. Thus, an effective anti-viral
agent is still needed to inhibit HTLV-1 infection. At present, there is no effective
vaccine or anti-viral agent for HTLV-1, although it has recently been shown that
anti-HTLV-1 antibody is effective in preventing mother to infant infection in a
rabbit model of HTLV-1.
Aims: In this study, we aimed to develop an effective HTLV-1 immunoglobin
isolated from HTLV-1 carriers that were screened at the Japanese Red Cross
and to test whether HTLV-IG can prevent HTLV-1 infection in a humanized
mouse model.
Methods: First, we developed and standardized effective screening methods
to evaluate and characterize the anti-viral effect of HTLV-1 positive plasma. To
monitor the infectivity and the ability to form syncytia we used MT-2, a HTLV-
1-harboring T-lymphoblastoid line that can infect normal cells. Cocultures of
103 MT2 and 105 Jurkat cells treated with mitomycin C (MMC; 50 µg/mL) were
successfully used to evaluate HTLV-1 infectivity.
Results: We found that HTLV-1 positive plasma, which was isolated from an
HTLV-1 carrier who had a proviral load over 4, can effectively inhibit both HTLV-
1 infection and syncytia formation. We purified HTLV-IG from the HTLV-1 positive
plasma and evaluated its effect in a humanized mouse model, NOG (NOD.Cg-
Prkdcscid Il2rgtm1Sug/Jic). Mice were treated with HTLV-IG for 5 days before
HTLV-1 infection. HTLV-1 infection of 6-week-old NOG mice was carried out by
injection with MMC+ MT-2 (105) 3 days after the mice received a transfer of
human peripheral blood mononuclear cells (PBMC; 107). At day 11 post-infection,
more than 80% of human CD45+ cells were found in the PBMC from the abdom-
inal cavity and spleen. In those tissues at day 11 post-infection, HTLV-1 infection
was observed in the untreated infected mice, but not in the HTLV-IG-treated
mice. HTLV-1-infected cells, CD3+/CD4+/CCR4+/CD25+, were detected in the
spleen, liver, and lung in the control MT-2-treated mice, but no HTLV-1-infected
cells were observed in these tissues in the HTLV-IG-treated mice, even though
their T cells (CD3+/CD4+ and CD8+) were normally colonized. These data sug-
gest that HTLV-IG inhibits both HTLV-1 infection and the infiltration of HTLV-1-
infected cells to the target tissues in a humanized mouse model.
Summary and Conclusions: We developed a screening method for evaluating
the anti-viral effect of HTLV-IG. Our results show that HTLV-IG effectively inhibits
both HTLV-1 infection and the infiltration of HTLV-1-infected cells into various
types of tissues in a humanized mouse model. Our model is suitable for eval-
uating and confirming the anti-viral effect of HTLV-IG.
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ENDOGENOUS THROMBIN POTENTIAL FOLLOWING HEMOSTATIC
THERAPY WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE:
A 7-DAY OBSERVATIONAL STUDY OF TRAUMA PATIENTS
G. Papakitsos1,* A. Kapsali2, T. Papakitsou3
1Anesthetic, Gharta, 2Private Clinic, ARTA, 3GHMessologi, Messologi, Greece
Background: Purified prothrombin complex concentrate (PCC) is increasingly
used as hemostatic therapy for trauma-induced coagulopathy (TIC). 
Aims: However, the impact of PCC administration on coagulation status among
patients with TIC has not been adequately investigated.
Methods: In this observational, descriptive study, data relating to thrombin gener-
ation were obtained from plasma samples gathered prospectively from trauma
patients upon emergency room (ER) admission and over the following 7 days. Stan-
dard coagulation tests, including measurement of antithrombin (AT) and fibrinogen,
were performed. Three groups were investigated: patients receiving no coagulation
therapy (NCT group), patients receiving fibrinogen concentrate only (FC group), and
patients treated with PCC and fibrinogen concentrate (FC-PCC group).
Results: The study population (77 patients) was predominantly male (84.4 %);
mean age was 40 +/-15 years and mean injury severity score was 25.6 +/-
12.7. There were no significant differences between the three study groups in
thrombin-related parameters upon ER admission. Endogenous thrombin poten-
tial (ETP) was significantly higher in the FC-PCC group compared with the NCT
group on days 1 to 4 and the FC group on days 1 to 3. AT levels were signifi-
cantly lower in the FC-PCC group from admission until day 3 (versus FC group)
or day 4 (versus NCT group). Fibrinogen increased over time, with no significant
between-group differences after ER admission. Despite ETP being higher, pro-
thrombin time and activated partial thromboplastin time were significantly pro-
longed in the FC-PCC group from admission until day 3 to 4.
Summary and Conclusions: Treatment with PCC increased ETP for several
days, and patients receiving PCC therapy had low AT concentrations. These find-
ings imply a potential pro-thrombotic state not reflected by standard coagulation
tests. This is probably important given the postoperative acute phase increase in
fibrinogen levels, although studies with clinical endpoints are needed to ascertain
the implications for patient outcomes. We recommend careful use of PCC among
trauma patients, with monitoring and potentially supplementation of AT.
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HIGH LEVEL OF UNDERSTANDING FOR BLOOD TRANSFUSIONS IN
PATIENTS CAN BE ACHIEVED BY EXPERT STAFF FROM THE
TRANSFUSION UNIT
H. Furumaki1,* C. Yamada1, H. Fujihara1, M. Tuduki1, S. Nagai1, H. Shibata1,
K. Ishizuka1, M. Kaneko1, H. Watanabe1, A. Takeshita1
1Transfusion and Cell Therapy, Hamamatsu University School of Medicine,
Hamamatsu, Japan
Background: Enough understanding for blood transfusion is essential for
patients treated with a blood transfusion. The American Association of Blood
Banks (AABB) and other societies concerned with blood transfusions have rec-
ommended the minimum acceptable requirements for obtaining informed con-
sent (IC). Specifically, the doctor should give each patient a sufficient amount
of information on the procedure as well as the opportunity to ask questions.
We have recently initiated a new service in which expert staff from the transfu-
sion unit provide patients with basic information on the blood transfusion pro-
cedure. This new system has drastically improved patient understanding of
blood transfusion.
Aims: The difference in the level of understanding for each basic fact related
to blood transfusion was assessed between two groups of patients that were,
or were not, provided with information from staff of the transfusion unit.
Methods: Expert staff from the transfusion unit started to provide patients with
basic information on blood transfusion before further disease-specific explana-
tion by the primary doctor (transfusion group; n =253). The effectiveness of
this approach was assessed by comparison with a group of patients that were
furnished with information by the doctors only (doctor group; n=74). We carried
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out a questionnaire survey of patients to analyze the depth of understanding
of blood transfusion from July to October 2013 and October to December 2014.
The level of understanding in patients before blood transfusion was compared
between the two groups. Statistical analyses were performed by the Chi-square
test using the SAS analysis suite (Tokyo, Japan). Probability values less than
0.05 were considered statistically significant.
Results: The level of understanding for each issue was as follows. For pre-
cautions during blood transfusion, 88% of patients answered “Completely” or
“Mostly” in the transfusion group, but only 26% in the doctor group. For require-
ment of tests for post-transfusion-transmitted infections, 90% answered “Com-
pletely” or “Mostly” in the transfusion group, but only 33% in the doctor group.
For the scheme of blood transfusion, 90% answered “Completely” or “Mostly”
in the transfusion group, while 36% in the doctor group. For agreement for
signing a consent form, 94% answered “Completely” or “Mostly” in the trans-
fusion group, but only 50% in the doctor group. For a sense of ease in receiving
a blood transfusion, 86% answered “Completely” or “Mostly” in the transfusion
group, but 45% in the doctor group. Patients were also asked for ten risks
associated with blood transfusion after being given the explanation. The results
are summarized in the figure, and the representative results were shown as
follows. In the transfusion group, a good understanding was obtained in 94%
of patients for “Allergenic reaction”, 90% for “Fever”, 85% for “Hepatitis virus”
and 74% for “HIV”. By contrast, in the doctor group, a good understanding was
obtained in 49% of patients for “Allergenic reaction”, 30% for “Fever”, 42% for
“Hepatitis virus” and 39% for “HIV. Notably, TRALI, TACO and GVHD were
understood by only about 10% of patients in the doctor group. There were sig-
nificantly higher degrees of understanding in the transfusion group (P <0.001).
For the other issues, the degree of understanding was significantly higher in
the transfusion group than in the doctor group (P <0.001). The significances
were more prominent than our previous smaller study.
Figure 1.
Summary and Conclusions: Providing patients with information on blood
transfusion by expert staff from the transfusion unit prior to further explanation
by the primary doctors was found to be useful. All of the issues related to blood
transfusion were significantly better understood by the patient after input from
the transfusion unit staff. Intervention by the transfusion unit in this field will be
useful for the process of obtaining IC and achieving high-quality transfusion
therapy.
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INTRAVENOUS HIGH-DOSE IRON SUPPLEMENTATION FOR BLOOD
DONORS WITH IRON DEFICIENCY
S. Macher1,* C. Drexler1, T. Stojakovic2, I. Lindenau3, M. Schröck3,
C. Reinprecht3, N. Sareban1, K. Amrein3
1Department of Blood Group Serology and Transfusion Medicine, 2Clinical
Institute of Medical and Chemical Laboratory Diagnostics, 3Division of
Endocrinology and Metabolism, Department of Internal Medicine, Graz, Aus-
tria
Background: Iron deficiency (ID) is one of the most common nutritional defi-
ciencies worldwide. It is highly prevalent in premenopausal women and also
frequently found in industrial countries. About 2 3% of the population participates
in blood donation programs. Blood donations often contribute to ID, but for
donor clearance, only a capillary hemoglobin (Hb) threshold is required. How-
ever, Hb does not reliably predict iron stores. ID is associated with restless
legs syndrome, cognitive and physical symptoms and an increased risk for
preterm birth. Currently, only in anemic donors, iron supplementation is routinely
recommended. Oral iron substitution is often associated with significant gas-
trointestinal side effects and poor compliance. 
Aims: In our ongoing study, we compare the effect of a single intravenous high-
dose iron carboxymaltose preparation (1000mg) for blood donors with iron deficiency
(IV) with the effect of a corresponding dose (10g) of oral iron over 10 weeks (PO).
Methods: In our randomized, controlled clinical trial we include male and
female blood donors (whole blood and platelet apheresis) who fulfill the criteria
of a predonation hemoglobin value of ≤13.5g/dl and a ferritin value of ≤30ng/ml
(target sample size 160 in total). Stratified by gender, participants are random-
ized with a web-based randomization tool to IV or PO in a 1:1 ratio. 12 weeks
after the first visit hemoglobin and ferritin values of both groups are determined.
Results: Out of 306 donors with Hb ≤13.5g/dl, 187 (61%, 166 female, 21 male)
had a ferritin value of ≤30ng/ml and of these, 112 had a ferritin ≤15ng/ml.
To date, 32 participants (27 female, 5 male) have completed the trial. Hb and
ferritin levels after treatment are shown in the Table. No serious adverse events
occurred. Before iron treatment, but after donation, mean Hb and ferritin levels
were 11.5±0.7g/dl and 6.5±3.9ng/ml.
Tabella 1. Hb and ferritin values (mean±SD) 12 weeks after iron supple-
mentation
IV, n=16 PO, n=16 P value
Hb (g/dl) 13.5±0.5 13.5±0.5 n.s.
Ferritin (ng/ml) 116.1±70.7 27.6±15.5 <0.01
In the IV group, 2/16 participants (12.5%) still had ferritin values <30ng/ml after
iron supplementation (both of whom donated blood after their first visit) com-
pared to 8/16 (50%) participants of the PO group.
Summary and Conclusions: Iron deficiency is common in blood donors, espe-
cially in females. Both IV and PO iron supplementation improves iron stores
but IV iron is more effective. The diagnosis and treatment of this common con-
dition could be useful both for donors and transfusion medicine services.
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MORTALITY REDUCTION WITH A MASSIVE TRANSFUSION PROTOCOL
IN A NON-TRAUMA UNIVERSITY MEDICAL CENTER
N. Martinez Calle1,2,* F. Hidalgo1, A. Alfonso2, R. Leucumberri2, M. Hernández2,
J.A. Paramo2
1Anaesthesia and Critical Care, 2Hematology, Clínica Universidad de Navarra,
Pamplona, Spain
Background: Management of massive bleeding requires rapid hemostatic
control and timely blood product support. Our center has developed a non-
trauma massive transfusion protocol (MTP) that includes blood product supply
and use of adjuvant pro-coagulant agents.
Aims: We aimed to evaluate the impact of a MTP on patient outcome.
Methods: Retrospective-observational study in patients treated with our MTP
between January 2006-December 2012, and an historical cohort (year 2005)
as control. MTP consisted in a goal-directed transfusion strategy with early
use of adjuvant procoagulant medications (fibrinogen, aFVII, prothrombin com-
plex concentrates or antifibrinolytics). Primary endpoints were 24-h and 30-
day mortality. Secondary endpoints were: 1) Fresh frozen plasma/Red blood
cells (FFP:RBC) and platelet/RBC transfusion ratios, 2) Time to first FFP unit,
and 3) Pro-coagulant agents frequency of use. A multivariate logistic regression
model was used to establish associations with 30-day mortality.
Results: 324 patients were included (67% male, median age 61yr). Analysis
was divided into two periods (2006-2009 and 2010-2012). RBC use remained
stable, with a progressive increase in FFP and pro-coagulant agents use after
MTP implementation. A statistically significant increase in FFP:RBC ratio was
observed after the MTP (p=0.03), without differences in PLT:RBC ratio. Time
to first FFP showed a tendency to reduction (p=0.08). A significant reduction in
30-day mortality was seen (25% in 2006-2009; 20% in 2010-2012; 38% in
2005, p=0.037), with unchanged 24-h mortality. Multivariate logistic regression
model showed an independent effect of MTP on 30-day mortality.
Figure 1. (A) 30-day Mortality reduction after massive bleeding protocol
implemetation. (B) Results of the multivariate logistic regression model
for 30-day mortality.
Summary and Conclusions: An independent association between the non-
trauma MTP implementation and 30-day mortality has been found, with a par-
allel improvement in transfusion ratios. MTP might be valuable for non-trauma
patients, and may have an effect on survival not entirely dependent on the
improved transfusion ratios.
140 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Platelet disorders
P400
THE TAIL MUTATIONS OF MYH9 INHIBIT THE DISASSEMBLY OF
NON-MUSCLE MYOSIN IIA
K. Miyazaki1,* S. Komatsu2, H. Jung3, M. Higashihara1, R. Craig3, M. Ikebe2
1Department Of Hematology, Kitasato University School of Medicine, Sagami-
hara, Japan, 2Department of Cellular and Molecular Biology, The University of
Texas Health Science Center at Tyler, Tyler, 3Department of CellBiology, Uni-
versity of Massachusetts Medical School, Worcester, United States
Background: MYH9 disorders include autosomal dominant macrothrombocytope-
nias with leukocyte inclusion bodies. These disorders were caused by heterozygous
mutations in MYH9, the gene encodes non-muscle myosin heavy chain-IIA. How-
ever, It has yet remained to be clarified how these mutations make an impact on
the molecular property of myosin. In order to address this issue, we need to examine
the whole myosin hexamer, consisting of a pair of heavy chains, essential light
chains and regulatory light chains, because it has been known that interaction
between the tail and the head-neck domain is critical for regulation of non-muscle
myosin filament formation. We have overcome difficulties and successfully produced
the recombinant non-muscle myosin hexamer as a whole molecule.
Aims: To clarify the effects of the tail mutations on the molecular property of
non-muscle myosin IIA.
Methods: We used Baculovirus expression system, and successfully produced
functional recombinant myosin hexamer, and analyzed the Mg2+-ATPsase activ-
ities and ability of filament formation, wild type and two representative tail
mutants, namely p.Asp1424His and p.Glu1841Lys.As in vivo analysis, we over-
expressed GFP-tagged MYH9, wild type and tail mutants in NIH3T3 cells, and
examined the localization.
Results: The ATPase activities of these mutants were essentially the same as
the wild type, indicating that these tail mutations don’t influence the motor activ-
ity of non-muscle myosin IIA. Non-muscle myosin forms large head to head
aggregation in the absence of ATP. However, both mutants failed to disassemble
to monomers upon the addition of ATP in contrast to the wild type. Additionally
electron microscopic analysis also revealed that they impaired the ATP-induced
disassembly of myosin filaments, and produced large aggregates. For further
investigation on the single molecule, we studied at reduced protein concentra-
tion using rotary shadowing. In the presence of ATP, the wild type myosin
monomers predominantly presented a compact shape with two folds in the tail.
On the other hand, two tail mutants predominantly formed an extended confor-
mation. Additionally the p.Glu1841Lys mutant proned to stick to each other
even at low protein concentration in the presence of ATP. Next we over-
expressed GFP-tagged MYH9, wild type and two tail mutants in NIH3T3 cells.
Wild type MYH9 diffusely localized in cytoplasm. In contrast, both tail mutants
accumulated to the myosin filaments, where the regulatory light chains were
phosphorylated, suggesting that these mutants were unable to disassemble
once they formed filaments.
Summary and Conclusions: These tail mutations hampered the ATP-induced
formation of folded conformation thus stabilizing the myosin aggregates. They
disturbed the normal assembly-disassembly dynamics of myosin filaments,
thus inhibiting dynamic actomyosin cytoskeletal rearrangements. These effects
may cause the clinical features of MYH9 disorders to some extent.
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PLATELET PROGENITORS AFTER LEAVING BONE MARROW
S. Kowata1,* K. Murai2, T. Oyake1, S. Ito3, Y. Ishida1
1Hematology/Oncology, Iwate Medical University School of Medicine, 2Hema-
tology, Iwate prefecture hospital, 3Oncology, Iwate Medical University School
of Medicine, Morioka, Japan
Background: in vitro observations have indicated that preplatelets, which are
anucleate discoid particles that can reversibly into proplatelet fragments, are
one of platelet progenitos from cultured megakaryocytes (MKs) (Thon JN, et
al. JBC 2010). Recently, we identified that bone marrow (BM) MKs form and
release two types of platelet progenitors, using intra-vital imaging and ultra-
structural analysis of mice BM (Kowata S, et al. Thrombosis and Haemostasis
2014). However, in vivo, how the platelet progenitors translate into individual
platelets after leaving BM remains poorly understood.
Aims: To elucidate whether platelet progenitors have an ability of conversion
into individual platelets in vivo and in vitro.
Methods: We isolated platelet progenitors from whole blood of green fluores-
cence protein (EGFP) transgenic mice by the centrifugation (100 g, 15 min)
after the intra-peritoneal injection of anti-platelet antiserum (APS). Mature
platelets were isolated from whole blood of GFP mice by the centrrifugation
(100 g, 15 min). in vivo: The freshly enriched progenitor isolates or mature
platelets, both of which were positive for EGFP, were transfused into wild type
mice. The peripheral blood was obtained and analyzed by flow cytometry con-
tinually. The EGFP positive platelets in platelet gate were counted. in vitro: The
freshly enriched progenitor isolates were cultured in IMDM medium at 37°C.
The continual change of their characteristics in the shape and size were
assessed using fluorescent microscopy with high resolution. Time lapse images
of the processes were also captured.
Results: During an acute thrombocytopenic period after the APS injection,
platelet progenitors increased remarkably in whole blood from vena cava. The
length and size of platelet progenitors was extremely varied (Figure 1). The
maximum length of platelet progenitor was more than 200 μm. These data were
confirmed by our previous study of intra-vital imaging of BM MKs (Thrombosis
and Haemostasis 2014). in vivo: Flow cytometric analysis showed that there
was a time-dependent increase in EGFP platelet number in the gate of mature
platelet, after the injection of EGFP positive platelet progenitors. The control
was carried out using EGFP positive platelets instead of platelet progenitors.
(0 h: 100%, 6h: 111±10.4%, 12h: 105±6.3% n=3, control 0 h: 100%, 6h:
86±8.8%, 12h: 73±5.3% n=3, Data were shown as % of the number of EGFP
positive platelets at 0 h). These data suggest that the infused platelet progen-
itors convert into mature platelets in vivo as time passed. in vitro: The platelet
morphogenesis from platelet progenitors was observed as highly dynamic
process, shown as follows. (1) A long proplatelet made several formation cleav-
age furrows, where it snapped, making short proplatelets. Then, they snapped
to become the platelet-sized particle. (2) Oval proplatelet, which was several
times bigger in diameter than mature platelet, extended to short proplatelet.
Then it snapped to become the platelet-sized particle.
Figure 1.
Summary and Conclusions: These data indicated that, after leaving BM sinu-
soid, these platelet progenitors convert into individual platelets in the blood
stream.
P402
HELICOBACTER PYLORI INFECTION INFLUENCES THE SEVERITY AND
TREATMENT RESPONSE IN CHRONIC HEPATITIS B COMPENSATORY
CIRRHOTIC PATIENTS WITH THROMBOCYTOPAENIA
X.H. Zhang1,* Y. He1, Q.M. Wang1, F.E. Feng1, X.L. Zhu1, Y.D. Xie2, H. Ma2,
H. Wang2, L.P. Xu1, K.Y. Liu1, X.J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking University People’s Hospital, Peking University Institute of Hepatology,
Beijing, China
Background: Thrombocytopaenia is a frequent complication of liver cirrhosis,
and ITP is closely related with H. pylori infection. Several studies illuminate the
associations between H. pylori and viral hepatitis, but most of the studies focus
on hepatitis C and H. Pylori infection.There is no information availableon the
association between H. pylori infection and hepatitis B compensatory cirrhosis
with thrombocytopaenia.T. Umemura et al. reported that H. pylori seropositivity
potentially contributes to thrombocytopaenia in patients with HCV infection.
Therefore, we wanted to determine whether H. pylori infection plays a role in
compensatory cirrhosis in chronic hepatitis B patients with thrombocytopaenia.
Aims: The aim of this projectis to explore the role that H. pylori infection plays
in chronic hepatitis B compensatory cirrhotic patients with thrombocytopaenia.
Methods: A total of 255 patients were enrolled in the study. All of the patients
were received nucleoside analogs (NA) therapy and were screened for H. pylori
infection. Patients were divided into three groups according to the different ther-
apy administered and the state of H. pylori infection: patients without H. pylori
infection and receiving NA therapy alone (N=146); patients with H. pylori infec-
tion and receiving NA therapy alone (N=48); patients with H. pylori infection
and receiving H. pylori eradication treatment combined with NA therapy (N=61).
Clinical laboratory parameters and platelet response to the treatment were
compared between three groups.
Results: In hepatitis B patients experiencing compensatory liver cirrhosis who
were infected with H. pylori, platelets counts were significantly reduced com-
pared with non-infected patients (31 vs 60×109/L, respectively, P<0.01).For
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long-term follow-up, the platelet count was significantly increased in HBV/H.
pylori co-infection patients who received NA combined H. pylori eradication
treatment compared with the other two groups who received NA alone (P<0.01).
The titre of anti-H. pylori IgG was significantly correlated with thrombocytopae-
nia severity and inversely correlated with platelet count. H. pylori infection is
an independent risk factor of thrombocytopaenia (P<0.01).
Summary and Conclusions: In conclusion, we are the first to report that
thrombocytopaenia is significantly correlated with H. pylori infection in com-
pensatory liver cirrhosis of chronic hepatitis B patients. The platelet response
after 2 years follow-upis markedly increased in HBV/H. pylori co-infection
patients who received NA combined H. pylori eradication treatment. H. pylori
infection is an independent risk factor of thrombocytopaenia. Therefore, H.
pylori may partly contribute to thrombocytopaenia in HBV patients. NA com-
bined with H. pylori eradication treatment may prove beneficial in chronic hep-
atitis B compensatory cirrhotic patients infected with H. pylori.
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ELEVATED PLATELET AGGREGATION AND ACTIVATION ARE
ASSOCIATED WITH PROLONGED ISOLATED THROMBOCYTOPAENIA
VIA REDUCED Β2-GPI AFTER ALLO-HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
X.H. Zhang1,* J.Z. Zhao2, Y. Zhou1, J.M. Zhang1, X.L. Zhu1, J. He3, F.R. Wang1,
L.P. Xu1, K.Y. Liu1, H. Wang2, X.J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking University People’s Hospital, department of clinical laboratory, 3Peking
University People’s Hospital, department of Rheumatology and Immunology,
Beijing, China
Background: Prolonged isolated thrombocytopaenia (PT) remains a serious
complication after allogeneic haematopoietic stem cell transplantation (allo-
HSCT). Recent studies have demonstrated that several risk factors, including
the stem cell source, disease status, graft-versus-host disease (GVHD), and
cytomegalovirus (CMV) infection, are proposed to be associated with PT after
allo-HSCT. PT is an independent risk factor for a poor prognosis after allo-
HSCT. The pathogenesis of PT after allo-HSCT remains unknown. Our previous
studies demonstrated that recurrence and engraftfailure are strongly associated
with PT; increased platelet turnover from impaired platelets and increased
platelet consumption have been demonstrated. β2-GPI is a major target for
antibodies in Apl, and β2-GPI antibodies contribute to decreased platelets in
APS patients. Hulsteinet al. revealed that β2-GPI inhibits the vWF-dependent
functions of platelet adhesion and aggregation. In present study, the function
of β2-GPI was investigated in PT after allo-HSCT. Minimal data are available
on β2-GPI involvement in platelet activation and aggregation in this setting.
Aims: The aim of this study was to explore whether decreased β2-GPI levels con-
tribute to the enhanced of platelet activation and aggregation in PT after allo-HSCT.
Methods: A total of 56 consecutive patients with PT and 60 control patients
after allo-HSCT were enrolled at our centre. β2-GPI Ag and anti-β2-GPI anti-
body levels were measured by ELISA, and vWF Ag and vWF activity levels
were detected using an automated coagulation analyser. Platelet aggregation
and CD62p and PAC-1 expression were confirmed using a Chrono-log aggre-
gation analyser and flowcytometry.
Results: The β2-GPI antigen in PT was significantly decreased compared with
control (164.2±12μg/ml vs 234.2±16μg/ml; P<0.01), and the β2-GPI antigen
was negatively correlated with platelet aggregation(P<0.01). The aggregation
ratio in PT was significantly increased compared with control(39±7.5% vs
23±8.5%; p=0.0317). A significant difference was noted after 90 days of allo-
HSCT (P<0.01). Additionally, anti-β2-GPI IgG in PT was markedly increased
(1.78±0.46vs 0.94±0.39 U/ml; P<0.01). No significant differences were noted
between the two groups regarding vWF antigen levels, and vWF activity was
increased in PT (133.06±30.50% vs 102.17±25.90%; P<0.01). β2-GPI antigen
levels and vWF activity were negatively correlated (P<0.01). Platelet aggrega-
tion was induced by ADP in combination with various concentrations of β2-
GPI. The aggregation ratio gradually decreased in PTwith increasing β2-GPI.
CD61, CD62p and PAC-1 expression in platelets was higher in the patients
with PT after allo-HSCT(33.6±11.6%vs 8.5±3.5%,p=0.000; 42.4±7.6% vs
6.8±2.2%, p=0.000; 20.6±7.9% vs6.1±2.0%, p=0.000; respectively).
Summary and Conclusions: β2-GPI antigen is obviously decreased in
patients with PT and is closely related to increased platelet activation and
aggregation. β2-GPI significant inhibit platelet aggregation in patients with PT,
suggesting that it may be involved in the pathogenesis of PT after allo-HSCT.
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OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT
FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED
IN A RETROSPECTIVE AND MULTICENTRIC STUDY
P. Noris1,* E. Civaschi1, C. Klersy2, F. Melazzini1, N. Pujol-Moix3, C. Santoro4,
M. Cattaneo5, C. Lavenu-Bombled6, L. Bury7, P. Minuz8, P. Nurden9,
A.R. Cid-Haro10, A. Cuker11, V. Latger-Cannard12, R. Favier13, I. Nichele14,
C.L. Balduini1
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Technologique et d’Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac,
France, 10Unidad de Coagulopatias Congenitas, La Fe University Hospital,
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gies Plaquettaires” from the frame of the Reference French Centre and Service
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Armand Trousseau Children Hospital, Haematological Laboratory, French Ref-
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U1009,94000, Villejuif, France, 14Department of Cell Therapy and Hematology,
San Bortolo Hospital, Vincenza, Italy
Background: Pregnancy and delivery represent hemostatic challenges to
women with inherited platelet function disorders (IPFD). Information on out-
comes and management of IPFD in pregnancy is scarce, and the limited data
available in literature, mainly deriving from case reports or small case series,
suggest that major bleeding is very common.
Aims: To improve knowledge on this matter we performed a retrospective,
multicentric study aimed at systematically collecting and analyzing pregnancy
outcomes in a series of women with IPFD. The study was promoted by the
SWG on Thrombocytopenias and platelet function disorders of the EHA.
Methods: Twelve centers around the world took part in the study, and 34 women
with 5 different forms of IPFD confirmed by specific diagnostic criteria were
enrolled, obtaining data on a total of 65 pregnancy and 48 newborns. Data on
spontaneous bleeding tendency, way of delivery, hemostatic prophylaxis, bleed-
ing at delivery and its management, as well as newborns’ status, were recorded.
Results: Spontaneous bleeding diathesis did not worsen during gestation, and
no severe bleeding episodes were reported during this period. Miscarriage and
preterm birth incidence was similar to that observed in the normal population.
Prophylactic platelet transfusions were given in 30% of cases and 73% of deliv-
eries were vaginal. Severe bleeding events requiring blood transfusion were
observed in 12.5% of deliveries, in all cases occurring in women with Glanzmann
thrombasthenia (GT). Of note, 50% of deliveries in women with GT needed
therapeutic blood transfusions, while no women with delta storage pool disease
(delta-SPD), Hermansky-Pudlak syndrome, P2Y12 defect or defect of throm-
boxane A2 receptor required this treatment. However, mild bleeding was report-
ed also in some women with the latter diseases. More than half of women with
GT who received prophylactic platelet transfusions experienced severe hemor-
rhages at delivery, suggesting that platelet transfusion alone may be inadequate
and better preventive treatments are required in this condition. No women died
of delivery-related causes or received hysterectomy to stop bleeding. Neither
the 9 neonates who inherited the mothers’ illness nor the unaffected infants
experienced bleeding at birth. Statistical analysis found significant association
between excessive bleeding at delivery requiring transfusion and a history of
grade 3 or 4 (OR 23.4) of WHO bleeding scale. The risk of bleeding was also
significantly increased in women with GT compared with delta-SPD (OR 41.6).
No significant correlations were found between severe bleeding requiring blood
transfusion at delivery and the way of delivery, the age of the mother, severe
bleeding at previous surgical interventions and the status of primipara; no sig-
nificant correlation was found with prophylactic platelet transfusion as well.
Summary and Conclusions: The risk of bleeding at delivery in women with
IPFD varies according to diagnosis and previous spontaneous bleeding diathe-
sis. Prophylactic platelet transfusions in women with GT do not ensure that
childbirth occurs without major hemorrhages in the mother, this indicating the
need for better regimens of preparation to delivery in this condition.
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PREDICTION OF SEVERE ADAMTS13 DEFICIENCY IN PATIENTS WITH
THROMBOTIC MICROANGIOPATHIES
J.M. Nieto1,* F. De La Fuente-Gonzalo1, A. Villegas1, F.A. Gonzalez1,
M.P. Martin1, C. Trujillo1, L. Garcia-Paredes1, M. Saez1, R. Martinez1,
P. Ropero1
1Hematology, Hospital Clinico San Carlos, Madrid, Spain
Background: Thrombotic microangiopathies (TMA) are a rare and heteroge-
neous group of diseases that include Thrombotic Thrombocytopenic Purpura
(TTP), Hemolytic Uremic Syndrome (HUS) and other TMAs secondary to sev-
eral conditions (ie, cancer and hematopoietic stem cell transplant). TTP is char-
acterized by an extreme ADAMTS13 deficiency. Plasma exchange therapy and
immunosuppression are the current treatment for TTP but are ineffective for
most other forms of TMA. Assays exploring ADAMTS13 activity are limited to
only some specialized reference laboratories. We performed an analysis of
our TMA registry to identify clinical features which may allow a rapid and reliable
prediction of an acquired ADAMTS13 deficiency.
Aims: The primary goal was to identify cut-offs for variables that would prove
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useful in excluding the possibility of TTP, in order to facilitate a more suitable
therapy based on the etiology of the TMA.
Methods: The Registry included 242 patients with TMA. All the statistical analy-
ses were performed on a final cohort of 174 adults (including secondary TMAs)
in which all the data for subsequent analyses were available. Secondary TMAs
were included in the study because it provides a real-world setting for the analysis.
A subset of variables was considered from a clinical standpoint as potential pre-
dictors of low ADAMTS13 activity. Patients with severe acquired (<5% of normal
activity) ADAMTS13 deficiency (n=55) were compared to patients with detectable
(≥5%) ADAMTS13 activity (n=119). Then, for the statistically significant variables
(age, platelet count and creatinine), we generated receiver operator characteris-
tics (ROC) curves and compared area under the curve (AUC) values to find cut-
offs helping in the prediction of a severe ADAMTS13 deficiency (thresholds of 68
years old for age, 2.0 mg/dL for creatinine and 44×109/L for platelet count). Finally,
we conduct multivariate logistic analysis to test if a model with combined variables
improves the prediction capability of the variables taken alone. A fourth variable
(absence of Hematopoietic Stem Cell Transplant (HSCT) in the patient) performed
well in the multivariate analysis and was included in the final model.
Results: The combined model (table 1) had an AUC of 0.925, thus improving
the prediction capability of the individual variables. The percentage of correct
predictions of the model was 89,7%. Patients with severe ADAMTS13 deficien-
cy had platelets ≤44×109/L, creatinine ≤2,0 mg/dL, age ≤68 years old and did
not undergo HSCT (Odds Ratio 64,0; p <0,001). If all the four criteria are met,
the probability of TTP is 82,5%. If any of the conditions is not met, the probability
of TTP drops to 6,8%.
Tabella 1.
Summary and Conclusions: TTP share features of atypical HUS and sec-
ondary TMAs. Our results may enable the rapid exclusion (if any of the condi-
tions is not met) and accurate diagnosis of TTP (if all the four criteria are met)
using readily available laboratory data and this could help to choose the suitable
therapy for different pathophysiological groups. Three out of 8 false negatives
were TTP relapses that were misclassified due to a high platelet count. This
could be explained because the patients were already diagnosed and advised
that they have to be promptly hospitalized in a relapse. Within the 10 false pos-
itives, 30% of the cases were shown to be associated to gastric or breast tumors
days after ADAMTS13 testing. Therefore, if ADAMTS13 test results normal in
a patient who met all the four conditions, a diagnosis of TMA secondary to can-
cer should be suspected.
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PDGF-BB PROTECTS BONE MARROW MESENCHYMAL STEM CELLS
AGAINST APOPTOSIS AND SENESCENCE THROUGH THE P53/P21
PATHWAY IN PATIENTS WITH IMMUNE THROMBOCYTOPAENIA
X.H. Zhang1,* J.M. Zhang1, Q.M. Wang1, F.E. Feng1, X.L. Zhu1, M. Lv1,
H.X. Fu1, L.P. Xu1, K.Y. Liu1, X.J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
Beijing, China
Background: Immune thrombocytopaenia (ITP) is characterized by platelet
destruction and megakaryocyte dysfunction resulting from autoantibodies induced
by the polarization of Th1 and deficient regulatory T cells. Mesenchymal stem
cells (MSCs) display not only stem cell multipotency but also robust immunosup-
pressive properties. However, MSCs from ITP patients do not exhibit conventional
proliferative abilities and thus exhibit defects in immunoregulation, suggesting that
MSCs impairment might be a mechanism involved in ITP. In addition, reversal of
the defects in MSCs may represent an attractive therapeutic alternative. Platelet-
derived growth factor (PDGF) improves growth and survival in various cell types.
Moreover, PDGF promotes MSCs proliferation. However, the effects of PDGF on
MSCs in patients with ITP have not been fully characterised.
Aims: The aim of this study was to investigate the molecular pathways under-
lying the increased apoptosis and senescence and to analyse thein vitroeffect-
sofPDGFon MSC from patients with ITP
Methods: Bone marrow MSCs were derived from primary ITP patients and
healthy donors. Gene expression profilechanges in MSCs from ITP patients
and controls wereinvestigated by DNA microarray analysis. RT-PCR and West-
ern blot were employed for molecular expression analyses. Cellular senescence
was detected using the CCK-8 assay, cell cycle analysis and senescence-asso-
ciated β-galactosidase (SAb-gal) assay. Apoptosis was assessed by nuclear
staining and flow cytometry. Mitochondrial membrane potential (MMP) was
investigated by JC-1 staining.
Results: Microarray analysis revealed that the expression of p53, p21, and
the apoptosis regulators Caspase-3,-9, and-8 were increased in ITP MSCs
compared with controls. ITP MSCs expanded more slowly and appeared larger
in size and flattened. ITP MSCs exhibited increased senescence as demon-
strated by decreased proliferative capacity and increased SAb-gal positive cells
and G0/G1 cells. The increased apoptosis rate was detected in ITP MSCs com-
pared with normal controls. Molecular changes involving the intrinsic apoptosis
pathway were assessed. A decreased Bcl-2/Bax ratio and MMP levels were
observed, which leads to cytochromeC release from mitochondria and conse-
quently activates Caspase-9 and Caspase-3 in ITP MSCs. Moreover, Fas and
FasL expression and Caspase-8 activation, which are associated with the
extrinsic apoptosis pathway, were up-regulated in ITP MSCs, suggesting that
both the intrinsic and extrinsic pathways account for enhanced apoptosis. p53
and p21 mRNA and protein expression were up-regulated in ITP MSCs, where-
as the inhibition of p53 with PFT-αmarkedly inhibits apoptosis and senescence.
PDGF-BB treatment significantly decreased p53 and p21 expression and
increased surviving expression in. In addition, the apoptotic rate and number
of senescent cells in ITP MSCs were reduced after PDGF-BB treatment.
Summary and Conclusions: Increased apoptosis and senescenceare noted
in ITP MSCs. Both the intrinsic and extrinsic pathways participate in excessive
apoptotic induction. For the first time, we demonstrate that PDGF-BB protects
MSCs against apoptosis and senescence in patients with ITP. This protective
effect of PDGF-BB is likely mediated via the p53/p21 pathway, thus potentially
providing a new therapeutic alternative for immune thrombocytopaenia.
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EFFICACY OF PROPHYLACTIC SINGLE DONOR PLATELETS (SDP)
TRANSFUSION IS RELATED TO THE TIME OF STORAGE AND NOT TO
THE ABO COMPATIBILITY IN CHILDREN WITH MALIGNANCY
D. Adamidou1,* A. Markantonatou1, E. Avramidou1, M. Oikonomou1, A. Filippou1,
A. Chroni1, C. Papadopoulou1, E. Abatzoglou1, V. Sidi-Frankandrea1, M. Kourti1,
E. Papakonstantinou-Athanasiadou1, T. Karafoulidou1, D. Koliouskas1,
S. Theodoridou1
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Background: The prophylactic transfusion of apheresis platelets remains the
gold standard in order to avoid spontaneous bleeding in children undergoing
intensive chemotherapy protocols. Due to inventory constrains, several times
transfusion services are issuing ABO mismatched platelets.
Aims: To provide descriptive data based on our centre’s experience with regard to
platelet increments post prophylactic transfusions in children with malignancy and
investigate for factors that could be related to the effectiveness of SDP transfusion.
Methods: We retrospectively analysed data from a 3 years period (2011-2014)
on the prophylactic SDP use on 48 children (25 boys/23 girls) with a median age
of 7(2.5-14)years diagnosed with haematologic or solid malignancies (29 ALL, 3
AML, 4 NHL, 2 Wilms’ tumor, 4 Ewing sarcoma, 3 myeloblastoma, 2 neuroblas-
toma and 1 rhabdomyosarcoma). Transfusion efficacy was assessed based on
the corrected count increment (CCI) that takes into consideration the difference in
platelet counts pre and post transfusion together with the number of platelets trans-
fused as well as the patients’ body surface area. Response was evaluated at 24
hours post transfusion and any CCI <5x103 was considered inadequate. Patient
related (age, gender, disease, ABO/D, previous exposure to SDP or random
platelets, status at last follow up) as well as product related (duration of storage,
ABO/D, apheresis machine) factors were recorded and included in the analysis.
Results: In total 228 transfusions, meeting the inclusion criteria were analysed.
In 146 (64%), patients received ABO identical SDPs whereas in 48 (21%) and
34 (15%) children received SDPs with major or minor ABO mismatch respec-
tively. The mean value of CCI was 17.9 (0-66.4)x103and transfusion refractori-
ness was noticed in 35 SDPs administration (15%). The median SDP age was
2.59 (0.5-5) days and each child received 3(1-21) prophylactic transfusions.
Previous exposure to SDP was recorded in 207 transfusions (136 with major
mismatch) whereas random platelets transfusion had preceded the current
transfusion in 189 cases (37 with major mismatch). In a univariate analysis a
strong negative correlation was found between the time of SDP storage and
the transfusion efficacy (p<0.002). In case of refractoriness (CCI <5x103) the
mean product age was 3.35 days, significantly longer compared to that of the
efficacious transfusions (2.47 days) (p<0.003). At the contrary the ABO com-
patibility between the patient and the transfused SDP did not influence the CCI
(18.5, 16.7 and 17 x103forΑΒΟ identical and with major and minor mismatch
respectively). When CCI was analysed by the patients’ ABO blood type signif-
icant differences were found between groups with patients on group B showing
the modest response (CCI 12.8 x103).
Summary and Conclusions: Based on our findings, prophylactic transfusion
of fresh SDPs (<48 hours) leads to bigger platelet increments while transfusion
of older SDP is related to refractoriness. Interestingly enough, opposite to lit-
erature, we found no correlation between the ABO compatibility status and the
SDP transfusion efficacy. This could partly be explained by the strong immuno-
suppression that our study population suffers due to both the underlying disease
as well as the chemotherapy received. In summary for children with malignancy,
should a prophylactic platelet transfusion is needed the first choice should be
to provide fresh SDP ideally of the same ABO, without though firm restrictions
on the use of other ABO blood types if the first are not available.
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Procoagulant states
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IMPACT OF HIGH ON-TREATMENT PLATELET REACTIVITY ON 5-YEAR
MORTALITY IN PATIENTS AFTER MYOCARDIAL INFARCTION
M. Jakl1,2, R. Sevcik3, I. Fatorova4, J.M. Horacek2,4,*
11st Department of Internal Medicine-Cardioangiology, University Hospital and
Charles University, Faculty of Medicine, 2Department of Military Internal Med-
icine and Military Hygiene, University of Defense, Faculty of Military Health
Sciences, Hradec Kralove, Czech Republic, Hradec Kralove, Czech Republic,
3Hjärtkliniken NÄL, NU-Sjukvården, Trollhättan, Sweden, 44th Department of
Internal Medicine-Hematology, University Hospital and Charles University, Fac-
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Background: High on-treatment platelet reactivity (HTPR) is expected to be
a negative prognostic factor in patients with coronary artery disease. However,
long-term results in patients with acute myocardial infarction are lacking.
Aims: The aim of the study was to assess the relationship between HTPR and
five-year mortality in patients with acute myocardial infarction.
Methods: We performed a prospective cohort study of 198 patients with acute
myocardial infarction. In these patients, the response to aspirin and clopidogrel
was assessed by impedance aggregometry. According to their response to
antiplatelet treatment, the patients were divided into groups with adequate
response, dual poor responsiveness (DPR), poor responsiveness to aspirin
(PRA) and poor responsiveness to clopidogrel (PRC). After five years, the
myocardial infarction recurrence and overall mortality were assessed.
Results: Five-year mortality was significantly higher in all groups of patients
with HTPR compared with patients with sufficient response to antiplatelet treat-
ment: in PRA patients 38.1 % vs 19.2 %, p <0.01, in PRC patients 45.2 % vs
17.3 %, p<0.001 and in DPR patients 50.0 % vs 19.9 %, p<0.05. Risk of repeat-
ed myocardial infarction was also increased (HR 4.0, 95 % CI 1.25-11.5, p<0.05
for DPR, HR 4.37, 95 % CI 1.51-12.77, p<0.01 for PRA, HR 3.25, 95 % CI
1.11-9.36, p<0.05 for PRC). In a multivariable analysis, HTPR and left ventricle
systolic dysfunction were proven to be independent predictors of mortality.
Figure 1.
Summary and Conclusions: PRA, PRA and DPR are independent predictors
of increased five-year mortality and risk of repeated myocardial infarction.
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PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM
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ogy, ICPMR, Pathology West, 3School of Medical Sciences, 4Centre for Vas-
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Background: The procoagulant subset of highly activated platelets has been
associated with increased pathological thrombotic states such as ischemic
stroke and sepsis. Increased generation of reactive oxygen species has been
implicated in procoagulant platelet formation, thus we postulated a role for acti-
vated neutrophils, and in particular neutrophil myeloperoxidase (MPO), in pro-
coagulant platelet associated occlusive thrombosis. We have shown a novel
marker for procoagulant platelets, trivalent arsenical GSAO, identifies proco-
agulant, necrotic platelets in a whole blood flow cytometry assay and enables
direct visualization of fibrin supporting platelets in occlusive thrombi after 8%
FeCl3 injury.
Aims: We aimed to use GSAO to study the role of activated neutrophils and
MPO in generation of procoagulant platelets in vitro and in vivo.
Methods: Thrombus formation in the 8% FeCl3 model of thrombosis in the
murine cremasteric arterial circulation was visualized using high speed confocal
intravital microscopy in presence of GSAO and fluorochrome-conjugated anti-
fibrin, and anti-CD42b antibodies. 1A8 anti-Ly6G antibody administered via
intraperitoneal injection was used to achieve neutrophil depletion, which was
confirmed by flow cytometry after 48 hours. Thrombus formation was induced
by 8% ferric chloride.
Results: Compared with controls, neutrophil–depleted C57Bl6 mice demon-
strated decreased GSAO+ platelets, decreased occlusive thrombi and reduc-
tion in fibrin formation indicating a role for neutrophils in formation of procoag-
ulant platelets in vivo. We examined whether the mechanism for this neutrophil
effect involved MPO and downstream oxidants. However, ex-vivo addition of
hypochlorous acid to washed human platelets did not induce formation of pro-
coagulant platelets. In murine models, there was no difference in generation
of procoagulant platelets at rest or after agonist stimulation in MPO-/-mice ver-
sus wild type C57Bl6 controls. There was also no difference in stimulus-induced
procoagulant subset when mice were exposed to increased circulating MPO
via 30 day continuous intravenous infusion of human MPO using a small animal
pump compared with saline control mice.
Summary and Conclusions: Thus, neutrophils are important for the genera-
tion of procoagulant, fibrin supporting platelets in vivo. However, the mechanism
is not via MPO.
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RELEVANT ROLE OF VON WILLEBRAND FACTOR IN EXPERIMENTAL
SEPSIS BY CECAL LIGATION AND PUNCTURE IN MOUSE
S. Kasuda1, H. Matsui2, K. Hatake1, M. Sugimoto2,*
1Legal Medicine, 2Regulatory Medicine for Thrombosis, Nara Medical Univer-
sity, Kashihara, Japan
Background: Sepsis is a serious inflammatory response syndrome, in which
systemic activation of both inflammatory and coagulation pathways are pro-
voked by severe microbial infection. In addition to the known hemostatic func-
tions, von Willebrand factor (VWF) is assumed to participate in a cross-talk
between inflammation and thrombosis. However, little is known about the
detailed mechanisms or relevant role of VWF functions in inflammation.
Aims: We therefore studied the physiologic relevance of VWF-dependent
inflammatory responses in a mouse model of experimental sepsis by cecal lig-
ation and puncture (CLP).
Methods: The mouse CLP was performed according to the established stan-
dard protocol (Rittirsch D, et al., Nat Protoc, 2009). Briefly, mouse cecum was
ligated distal to the ileocecal valve under laparotomy, punctured with 18 gauge
needle and gently pressed until a small drop of stool appeared. The cecum
was returned to the peritoneal cavity and 200 mL of saline was injected into
the cavity to avoid dehydration before body wall and skin incision were closed
with a 4-0 Sofsilk. We compared20 wild-type (WT) and 20 VWF-gene deleted
(knock-out; KO) mice (from The Jackson Laboratory, Bar Harbor, ME), all of
which were 10-12 weeks of age, healthy and fertile. Excess blood loss was not
observed in all (WT or KO) mice during the CLP operation.
Results: Kaplan-Meier analysis revealed the significantly (p <0.05) lower sur-
vival rate of KO mice than that of WT (KO; 20.0% vs WT; 60.0% at the Day 7 of
CLP). The impaired survival rate of KO mice was restored by the bolus admin-
istration of human VWF (n=22, 2.5 U/mouse) to an extent comparable to that of
WT. Peripheral blood analysis at 24 hours after CLP showed the severe leuko-
cytopenia and neutrophil decrease in KO mice, as compared to WT. In addition,
formation of walled-off abscess was confirmed at the peri-cecal space in all the
WT and KO mice alive even at the Day 7 of CLP, while such focal abscess for-
mation was not found in mice died before the Day 3 of CLP.
Summary and Conclusions: Our results altogether indicate that VWF could
play a role on the recruitment or accumulation of neutrophils for microbial killing at
the local inflammatory focus. VWF-mediated platelet aggregate formation in periph-
eral capillary vessels then could shut down the local microcirculation, thereby block-
ing systemic microbial expansion as a crucial biological defense mechanism.
P411
A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE
INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY
WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND
ANTI-COAGULANT THERAPY
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Research Laboratory, St Vincent’s Centre for Applied Medical Research, 5St
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Background: Procoagulant platelets are a subset of activated platelets that sup-
port thrombin generation. Excess procoagulant platelets are involved in patho-
logical thrombosis. Study of procoagulant platelets is hampered by the lack of
specific and sensitive marker. Recently, we have developed a novel assay for
procoagulant platelets using a cytoplasmic necrosis marker, GSAO that identifies
necrotic/procoagulant platelets in whole blood flow cytometric assay.
Aims: We postulated that platelets from patients with coronary artery disease
(CAD) have heightened propensity to stimulus-induced procoagulant pheno-
type, which may be modified by antiplatelet agents (APA).
Methods: Following an informed consent, 216 blood samples from 60 patients
were collected during coronary angiography from radial/femoral and coronary
arteries. Thrombin (2 U/mL) or a combination of thrombin (2 U/mL) and collagen
(10 µg/mL) were used to induce procoagulant platelet in diluted re-calcified
whole blood. Previously, we established a normal response profile to thrombin
and thrombin/collagen stimulation in healthy controls. Linear mixed effects mod-
els were used to explore the effect of antiplatelet agents and the presence of
angiographically-confirmed CAD on platelet procoagulant propensity.
Results: Compared to healthy controls, study participants undergoing coronary
artery angiography had higher proportion of procoagulant platelets at baseline
(4.1% vs 0.4%, P<0.0001) and in response to thrombin/collagen (31.7% vs
13.3%, P<0.0001). Controls and patients without CAD showed a marked syn-
ergistic increase in procoagulant platelet generation with dual agonist (throm-
bin/collagen) stimulation compared to either agonist alone. In contrast, patients
with angiogram-confirmed CAD reached maximal procoagulant potential with
thrombin stimulation alone. Aspirin alone had no effect on stimulus-induced
procoagulant platelet subset, however patients on dual antiplatelet therapy
(DAPT) demonstrated reduced thrombin/collagen-induced procoagulant
platelets compared to no APA (OR 0.61, P=0.0295). Patients receiving intra-
venous unfractionated heparin showed marked reduction in procoagulant
platelets regardless of the stimulus: thrombin (OR 0.32, P<0.0001) thrombin/col-
lagen (OR 0.38, P=0.0001).
Summary and Conclusions: Compared to healthy volunteers, platelets in
patients undergoing coronary angiography showed increased procoagulant
potential, which was favorably modified by DAPT but not aspirin alone. Novel
cytoplasmic necrosis marker, GSAO has potential as a biomarker in coronary
disease.
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SUITABILITY OF THE CAPE BABOON IN HUMAN-TARGETED
ANTI-PLATELET STUDIES
W. Janse Van Rensburg1,* P. Badenhorst2, J. Roodt3
1Haematology and Cell Biology, 2Internal Medicine, UNIVERSITY OF THE
FREE STATE, 3Haematology and Cell Biology, National Health Laboratory
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Background: Animal models play an integral part in the drug development
process and are among other things used to test the pre-clinical safety and effi-
cacy of anti-platelet agents. Non-human primates are considered to be the most
suitable animal model for anti-platelet studies. However, limited data exist on
the molecular make-up of some commonly used non-human primate species,
such as the Cape baboon (Papio ursinus). For this reason, concerns are raised
regarding the translatability of results obtained with these models to humans.
Aims: The aim of our study was to compare four commonly targeted platelet recep-
tors (P2Y12, GPIIb/IIIa, GPVI, and GPIbα) between the Cape baboon and human.
Methods: We performed light transmission aggregometry (LTA), surface-recep-
tor quantification, and Sanger DNA sequencing on baboon platelets and com-
pared it with normal human results.
Results: Baboon ADP-, arachidonic acid-, and collagen-induced platelet aggre-
gation results were significantly different compared to normal human results,
even with increased agonist concentrations. However, the differences in colla-
gen-induced aggregation results were not clinically relevant because all except
one result (at 8-μg/ml) fell within the normal human reference range. At double
the highest human concentration for ristocetin (2.5-mg/ml) baboon platelets
gave statistically similar results.
Baboon quantification results showed a 37%, 27% and 25.5% increase in GPIIb,
GPIIIa, and GPIbα, respectively. GPVI quantification failed due to non-reactive
monoclonal antibodies. P2Y12 quantification was not possible, as no commer-
cial monoclonal antibodies were available at the time of the study.
The P2Y12 protein sequences were 98.8% similar. It differed by four amino
acids, none of which have been described as functionally essential. The GPVI
protein sequence showed 95% similarity. It included a 14 amino acid difference
and a three amino acid deletion. One change was in a region where an amino
acid change has been implicated in reduced collagen-induced platelet aggre-
gation in humans. Two differences were directly adjacent to a collagen-binding
amino acid. The deletion was within the signaling area of GPVI. Exon 28 of
GPIIb failed to sequence. The GPIIb protein sequence for exon 1-27 was 98.2%
similar and for exons 29-30 there was 98.3% similarity. There was an 18 amino
acid difference. Only one conservative amino acid change was in the ligand-
binding region. The GPIIIa protein sequence was 99.6% similar, with three
amino acid changes. Again, only one conservative substitution was in the lig-
and-binding region. 54 amino acid changes were found in GPIbα. The protein
sequences of the signal peptide, vWF-binding-, PEST/macroglycoprotein-,
transmembrane-and cytoplasmic domains showed 93.8%, 89.4%, 57.9%,
90.5% and 95.0% similarity, respectively. 246 bases in the PEST/macroglyco-
protein domain of GPIbα failed to sequence. However, they were in a notoriously
variable region. However, no radical amino acid substitutions were found at
functionally vital sites.
Summary and Conclusions: Sequentially and functionally baboon P2Y12,
GPIIb/IIIa, and GPIbα is comparable to humans. Non-reactive antibodies and
changes in critical amino acids caused the baboon GPVI to be not comparable
to humans. For this reason, the Cape baboon is deemed a suitable animal
model for the evaluation of human-targeted anti-platelet agents directed against
P2Y12, GPIIb/IIIa, and GPIbα, but not against GPVI.
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CHARACTERIZATION OF PROCOAGULANT PLATELETS IN WHOLE
BLOOD USING A NOVEL CELL DEATH MARKER
L. Pasalic1,2,* H. Campbell1, P. Hogg1, V. Chen1,3
1Prince of Wales Clinical School, University Of New South Wales, 2Haematol-
ogy, ICPMR, Pathology West, 3SEALS Pathology, Prince of Wales Hospital,
Sydney, Australia
Background: Procoagulant platelets are implicated in the pathogenesis of
arterial thrombosis disorders including coronary events, ischaemic stroke and
sepsis outcomes. However, our understanding of the contribution this platelet
subset has been hampered by the lack of a suitable marker for clinical studies.
We have previously reported that a novel cell death marker, GSAO, identifies
the procoagulant platelet fraction in assays using washed human platelets.
Aims: Here we present a flow cytometry-based, non-lyse assay for detection
of procoagulant platelets in whole blood, which reduces volume of blood
required, improves throughput, and enables the interactions between platelets
and leukocytes within a physiological matrix.
Methods: Following informed consent, blood was collected from healthy vol-
unteers.15 µL of citrated blood was diluted in 96-well plate wells with a buffer
(HBSS, pH 7.35) containing GPRP (2.5 mM), CaCl2 (2.5 mM)±various
agonist(s) to 50 µL. Incubation at room temperature was stopped after 10 min
by adding 150 µL of HBSS. 20 µL aliquots were stained for 15 min at room
temperature with GSAO AF647 (2 µM), CD62P PE (KO2.3), CD45 BUV395
(HI30), and CD41a BV510 (HIP8) in 100 µL final volume. Fixation with 2 vol-
umes of PamFix for 5 min was followed by a single wash step with 10 volumes
of HBSS with 0.35% HSA (HBSS/HSA). Resuspended cells were analysed on
an LSRFortessa flow cytometer. The lowest FSC threshold was used to acquire
10,000 platelets defined as CD41a+/CD45-.
Results: At baseline, <1% of platelets showed the procoagulant phenotype.
Thrombin (EC50 0.8 U/mL) consistently induced largest PP subset (12.6%±5.1%)
whereas collagen (EC50 37 µg/mL) was significantly less potent (1.5%±0.4%).
Compared to collagen, GPVI agonist, CRP induced somewhat stronger proco-
agulant response. However, the maximal procoagulant platelet response
(15.8%±7.1%) was induced by a synergistic combination of submaximal doses
of thrombin and collagen (Figure 1). The thrombin-induced response was repli-
cated fully by PAR1 agonist TFLLR-NH2 (EC50 10.2 µM), and only partially by
PAR4 stimulation with AYPGKF-NH2 (EC50 66.9 µM) indicating that the thrombin
effect is PAR1 mediated. Stimulation with ADP up to 200 µM failed to induce any
increase in PP subset consistent with the concept that the procoagulant response
is induced by strong agonists.
Figure 1.
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Summary and Conclusions: The whole blood procoagulant platelet assay
makes it feasible to investigate the pathological roles of procoagulant platelets
in in mouse models of disease and to explore the potential of GSAO as a bio-
marker of disease in large scale clinical cohorts including cardiovascular and
sepsis settings.
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NO DIRECT ASSOCIATION BETWEEN ON-TREATMENT PLATELET
REACTIVITY AND BLEEDING EVENTS FOLLOWING CORONARY
INTERVENTION AND DUAL ANTIPLATELET THERAPY: A POST HOC
ANALYSIS OF THE PRASFIT-ACS STUDY
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H. Yokoi7, M. Nakamura8, S. Saito9
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8Toho University Ohashi Medical Center, Tokyo, 9Shonan Kamakura General
Hospital, Kamakura, Japan
Background: Few studies have examined the relationship between the phar-
macodynamics of antiplatelet drugs and the risk of clinically significant bleed-
ing following percutaneous coronary intervention for treating acute coronary
syndrome (ACS).
Aims: We examined the associations between the pharmacodynamics of pra-
sugrel and clopidogrel and the incidence of bleeding events in the acute and
chronic phases after PCI.
Methods: We performed a post hoc analysis of the PRASFIT-ACS (PRASugrel
compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) study
of patients in whom platelet reactivity was determined as P2Y12 reaction units
(PRU; VerifyNow® P2Y12 assay) or vasodilator-stimulated phosphoprotein-platelet
reactivity index (VASP-PRI). Japanese patients were randomized to prasugrel
(loading/maintenance dose: 20mg/3.75 mg/day) or clopidogrel (300mg/75mg/day),
both in combination with aspirin, for 24–48 weeks. The bleeding outcome was a
composite of TIMI major, minor, and clinically relevant bleeding.
Results: Overall, 66/685 (9.6%) and 65/678 (9.6%) of prasugrel-and clopido-
grel-treated patients, respectively, experienced major, minor, or clinically relevant
bleeding. PRU and VASP-PRI at 5–12 h or in steady state conditions (at 4
weeks) were not associated with the risk of bleeding in the acute (to day 3) or
chronic (from day 4 to 14 days after treatment discontinuation) phases of treat-
ment, respectively. The incidence of bleeding was not increased in patients with
very low on treatment platelet reactivity (defined as PRU <85 or VASP-PRI <16).
Summary and Conclusions: No direct association observed in the pharma-
codynamics of prasugrel and clopidogrel with the risk of bleeding in this cohort
of Japanese ACS patients following PCI.
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CYSTATHIONINE BETA SYNTHASE (CBS) GENE 844INS68
POLYMORPHISM IN SICKLE CELL DISEASE PATIENTS: FREQUENCY OF
VASO-OCCLUSIVE CRISIS
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Background: Sickle cell disease is (SCD) is a chronic hereditary hemolytic
anemia characterized by a hypercoagulable and inflammatory state which can
lead to vaso-occlusive episodes. Increased serum homocysteine level is an
independent risk factor for thromboembolism and cardiovascular disease and
is therefore of interest in sickle cell disease. The 844ins68 polymorphism,
occurring on the Cystathionine Beta Synthase (CBS) gene which controls the
CBS enzyme activity, is accompanied by hyperhomocysteinemia. This muta-
tion, in homozygous or heterozygous state, lowers CBS enzyme activity and
is thus considered an independent risk factor for artery occlusion.
Aims: To determine the frequency of the 844ins68 CBS gene polymorphism
and its contribution to hyperhomocysteinemia and vaso-occlusive episodes
in sickle cell anemia and sickle beta thalassemia patients. 
Methods: Nineteen sickle cell anemia, 32 sickle beta-thalassemia and 2 sickle
trait subjects together with 42 age and sex matched healthy controls were
included after approval of the institutional ethical committee. All
patients/guardians signed an informed consent. Fasting serum homocysteine
level was measured using immunonephlometry. The CBS 844ins68 polymor-
phism was detected using conventional PCR. 
Results: A significant increase in fasting serum homocysteine level (p-value
<0.001) was found in subjects with either thehomozygous or heterozygous
variant compared to wild type subjects. A significant increase in the frequency
of vaso-occlusive crisis (VOC) was found in SCD patients exhibiting these
variants (p-value =0.05). Positive correlation was found between fasting serum
homocysteine level and frequency of VOC (r=0.36, p-value=0.009). 
Summary and Conclusions: The 844ins68 polymorphism of the CBS gene
is a risk factor for VOC and hyperhomocysteinemia in sickle cell disease.
Quality of life, palliative care, ethics and health
economics
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THE DANISH LYMPHOMA REGISTRY HAS A HIGH COVERAGE AND HIGH
DATA QUALITY
B. Arboe1,* T.C. El-Galaly2, M.R. Clausen3, M.K. Nygaard2, P.S. Munksgaard2,
D. Stoltenberg4, J. Soenderskov1, P. Brown1
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Background: The Danish Lymphoma Registry, LYFO, prospectively includes
all lymphoma patients that are diagnosed at Danish hematology departments.
It was founded in 1982, and became nationwide from January 2000. It contains
detailed information on more than 20,000 patients and is characterized by a
very high coverage (>90%); however, the validity of LYFO has not previously
been assessed in detail.
Aims: The purpose of this study is to validate data quality and coverage of LYFO.
Methods: A random sample of 3% (N=364) was made from all the patients in
LYFO. In addition, four subtypes of lymphomas were validated in detail; CNS
lymphomas (N=370), Diffuse Large B-Cell Lymphomas (N=159), Peripheral
T-Cell Lymphomas N=141), and Hodgkin Lymphomas (N=672). For all patients
date of diagnosis, histological subtype, ECOG performance status and Ann
Arbor stage were validated. For each subgroup additional variables were
included, i.e. treatment, relapse and lab test results. A total of 1,706 patients
from the period 2000-2012 were included. The positive predictive values
(PPVs) of selected variables were calculated for each subgroup and for the
entire cohort of patients. Information from medical records was used as ref-
erence standard. Data coverage was tested by merging of LYFO with the Dan-
ish Cancer Registry (DCR) for the period 2000-2011.
Results: Table 1 shows the joined cohort validation (N=1706). PPV’s were
above 90% both in the joined cohort and for each subgroup, except for SR
and Albumin, which only were validated for Hodgkin Lymphomas. DCR and
LYFO contained information on 13,100 lymphoma patients; 11,350 patients
appeared in both registries, 12,084 in LYFO and 12,366 in DCR, giving a
coverage of 93.9% for LYFO, and 91.8% for DCR. For the 1,016 patients not
registered in LYFO, 469 patients were never referred to a hematology depart-
ment. For 357 patients without clinical lymphoma diagnosis, 105 patients
had an unconfirmed pathology diagnosis and 82 patients were diagnosed by
autopsy. Registration was missing in the remaining 190 patients. For the 734
patients only registered in LYFO, 56% had indolent lymphoma. Overall sur-
vival (OS) was significantly better for patients not registered in DCR, whereas
patients not included in LYFO had significantly worse OS. For 10,452 of the
11,350 patients registered in both LYFO and DCR the date of diagnosis +/-
one month was consistent (92.1%), in 581 patients the difference was 1-6
months, in 75 patients 6-12 months, and finally in 242 patients the difference
exceeded one year.
Tabella 1. Validation for the joined cohort, N=1706
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Summary and Conclusions: The information registered in LYFO is charac-
terized by high validity with PPV’s of 77-100% and a high coverage of more
than 93%. The fact that only patients in contact with specialized hematology
departments are registered in LYFO explains the majority of the discrepancy
between LYFO and DCR, since only 190 patients referred to a hematology
department, were not registered. For patients missing in DCR it is a plausible
explanation that the majority had indolent lymphomas with sparse inpatient
contacts. This is supported by the fact that the median OS was dismal for
patients registered in DCR only. In conclusion, LYFO is a unique nationwide
clinical database characterized by high validity, good coverage and prospective
data entry. Therefore LYFO is a valuable resource for future lymphoma
research.
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LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS
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Background: Measurement of health-related quality of life (QoL) is especially
important in patients with relapsed/refractory (R/R) mantle cell lymphoma
(MCL), as they generally receive multiple lines of therapy over the course of
their disease. The European multicenter MCL-002 (SPRINT) phase II study
was the first randomized study of lenalidomide vs investigator’s choice (IC) in
R/R MCL patients with ≤3 relapses on prior therapy and who were ineligible
for intensified treatment or stem cell transplantation.
Aims: Examine health-related QoL in R/R MCL patients receiving lenalidomide
vs IC.
Methods: Patients were randomized 2:1 to receive lenalidomide (25 mg/day
on days 1-21 of each 28-day cycle until progressive disease or intolerability
vs single-agent IC (chlorambucil, cytarabine, fludarabine, gemcitabine, or rit-
uximab). As a planned secondary study endpoint, QoL was measured using
the EORTC QLQ-C30 at baseline, after cycles 2, 4, 6, and 8, and at treatment
discontinuation. EORTC QLQ-C30 included 5 functional domains, 9 symptom
scales, and 1 global health status/QoL scale. Changes from baseline QoL
score at each visit for the primary (global health status/QoL) and secondary
domains (physical function and fatigue) and their 95% confidence intervals
were calculated. A mixed model was employed to analyze differences in mean
domain/scale scores between the treatment arms to account for repeated
measurements of QoL during follow-up visits. Patients with ≥10 percentage
point change (clinically meaningful) for each domain/scale at one or more
visits were compared between the two groups using the Chi-square test.
Results: 254 patients (lenalidomide n=170, IC n=84) were enrolled in the trial.
QoL data completion declined from 93% at screening to 51% at treatment dis-
continuation during the course of the study, with higher non-compliance rates
typically seen among IC than among lenalidomide patients. QoL was main-
tained (non-deterioration: no worsening >10 points) with lenalidomide from
baseline through last treatment cycle for evaluated primary and secondary
QoL domains. Patients treated with lenalidomide reported similar QoL vs IC
single agents across all domain/scale scores and at each follow-up visit. A
trend towards higher rates of clinically meaningful improvement in QoL was
observed in lenalidomide treated patients across most function and symptom
domains/scales at one or more follow-up visits. Statistically significant QoL
differences (≥10%) comparing lenalidomide vs IC treatment arms were iden-
tified for physical function (24% vs 8%, P=0.003) and pain (29% vs 18%;
P=0.047).
Summary and Conclusions: Patients with R/R MCL maintained their QoL
while receiving lenalidomide despite a longer duration of treatment compared
with single agent IC therapy. In addition, patients receiving lenalidomide expe-
rienced higher rates of clinically meaningful improvement in QoL for physical
function and pain.
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QUALITY OF LIFE AND SYMPTOM PROFILE IN LYMPHOMA PATIENTS
IN COMPLETE REMISSION AFTER AUTOLOGOUS HAEMATOPOIETIC
STEM CELL TRANSPLANTATION (AHSCT)
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Background: It is now clearly established that cure or control of the underlying
malignancy is not necessarily accompanied by full restoration of health or
quality of life (QoL) in long-term survivors. Self-reported QoL and symptom
assessment may be a useful tool to identify patient benefits and risks of AHSCT
at long-term follow-up.
Aims: We aimed to examine QoL in lymphoma patients in complete remission
at long-term follow-up after AHSCT as compared with population norms and
to evaluate symptom profile in this patient population.
Methods: A total of 80 patients with lymphomas (non-Hodgkin lymphomas-
36, Hodgkin lymphoma-44) in complete remission after AHSCT with the fol-
low-up of at least 12 months were enrolled in the study. Mean of follow-up
period was 18 months. Mean age-34.6 yrs (SD=9.9); male/female 38/42. QoL
was assessed using generic questionnaire SF-36; for symptom assessment
MDASI was used. To compare patient population with normative data the sam-
ple from population norm (PN) data base adjusted to age and gender (n=72)
was used. For comparisons t-test for independent samples or Mann-Whitney
test was used. Distribution of patients according to the grades of QoL impair-
ment was analyzed: no QoL impairment (Integral QoL index similar to the one
in normative population sample), mild (25% decrease from a PN), moderate
(25-50% decrease), severe (50-75% decrease) and critical (>75% decrease).
Results: QoL parameters in lymphoma survivors were similar to the ones in
normative population for the majority of scales: physical functioning-85.4 vs
85.3, role-physical functioning-74.0 vs 77.0, bodily pain-80.4 vs 80.0, general
health-63.9 vs 64.0, vitality-68.9 vs 65.3, social functioning-86.8 vs 86.0, role-
emotional functioning-85.6 vs 87.0, mental health-74.0 vs 70.0. No statistically
significant differences between patient group and normative population were
obtained. In the most cases patients experienced mild (ratings-1–4) symptoms;
22 % of patients experienced at least one moderate-to-severe (ratings ³5)
symptom. QoL parameters were significantly lower (p<0.001) in the patient
group with moderate-to-severe symptoms as compared with the ones who did
not have moderate-to-severe symptoms. The majority of patients (n=58;
73.4%) had no QoL impairment; 7 patients (8.8%) exhibited mild QoL impair-
ment, 7 patients (11.4%)-moderate QoL impairment; and 5 patients (6.4%)-
severe QoL impairment. There were no patients with critical QoL impairment.
The common symptoms in lymphoma survivors were sleep disturbance (70%),
fatigue (67%), memory loss (55%), shortness of breath (52%), numbness
(49%), and sadness (39%). Severity of fatigue and sleep disturbance was 1.1
and 1.4 in patients with no QoL impairment, and 5.1 and 4.5 in the group with
different grades of QoL impairment, respectively.
Summary and Conclusions: In conclusion, lymphoma patients in complete
remission at the mean follow-up of 18 months after ASHT had QoL parameters
similar to normative data. The vast majority of patients exhibited either no or
mild to moderate QoL impairment. The most common symptoms in lymphoma
survivors were sleep disturbance, fatigue, memory loss, and shortness of
breath. In the majority of cases they were of mild severity. The subgroup of
patients with moderate-to-severe symptoms was identified; these patients
experienced significant QoL impartment. Clinical self-reported symptom
assessment in lymphoma patients in complete remission after ASHCT provides
an important opportunity to promote proactive management of transplant-relat-
ed side effects and maintain or improve their QoL.
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GERMAN PATIENT AND PHYSICIAN PREFERENCES FOR
RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATMENT
OUTCOMES: A DISCRETE CHOICE EXPERIMENT 
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Background: Despite the availability of a wide number of treatments for
relapsed/refractory (r/r) mantle cell lymphoma (MCL), no standard of care has
emerged. There are no studies evaluating preferences for treatment outcomes
for r/r MCL.
Aims: This study was a discrete choice experiment (DCE) designed to elicit
preferences for r/r MCL treatment outcomes among patients and physicians
experienced in treating MCL in Germany.
Methods: 6 treatment attributes with 3 levels each were identified through lit-
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erature review and qualitative interviews with 6 hematologists and 5 r/r MCL
patients; overall survival (OS; Levels: 3,2,1 years), progression-free survival
(PFS; 2,1,0.5 years;), fatigue (no to mild, mild relieved by rest, mild not relived
by rest), nausea (no, mild, moderate), risk of serious infection (low, moderate,
high), treatment administration (oral pill daily at home, monthly infusion at
hospital, weekly infusion at hospital). The mean relative attribute importance
was assessed in a DCE using a Hierarchical Bayes model. Patients were
asked to base choices on their own preferences. Physicians were asked to
make their choices as if they were patients. 19 r/r MCL patients and 50 physi-
cians completed the online DCE survey.
Results: The analysis of mean relative attribute importance revealed that OS
(38%), treatment administration (17%) and risk of serious infection (16%) were
the most important treatment choice attributes to r/r MCL patients, followed
by PFS (11%), fatigue (10%) and nausea (8%). The most important attributes
to physicians were OS (44%), risk of serious infection (16%) and PFS (15%),
followed by fatigue (11%), treatment administration (8%) and nausea (7%).
Summary and Conclusions: OS is the most important treatment attribute to
both German r/r MCL patients and treating physicians, however, the relative
importance of the other attributes differ between patients and physicians. Our
results suggest the importance of mode of administration to patients may be
underestimated by physicians. The results may be used to guide what treat-
ment endpoints to include in clinical trials for the purpose of designing trials
that reflect the needs of the patients.
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COST EFFECTIVENESS OF BORTEZOMIB, RITUXIMAB,
CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR THE
FIRST-LINE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS NOT
ELIGIBLE FOR STEM CELL TRANSPLANTATION
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Background: Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin’s
lymphoma, incorporating the worst aspects of aggressive and indolent lym-
phoma subtypes; it progresses quickly and is typically incurable. In the UK,
patients unsuitable for haematopoietic stem cell transplantation (HSCT) pri-
marily receive rituximab, cyclophosphamide, doxorubicin, vincristine and pred-
nisone (R-CHOP). Although most patients initially respond to this therapy, the
durability of these responses is limited, and the majority of patients relapse
within 2 years. The LYM-3002 trial demonstrated that the use of bortezomib,
rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) close
to doubled progression-free survival (PFS) relative to R-CHOP (24.7 vs 14.4
months; HR=0.63, p<0.001). Duration of overall response for VR-CAP was
more than double that of R-CHOP (median of 36.5 vs 15.1 months), resulting
in an increase in treatment free interval of almost 20 months vs R-CHOP
(median of 40.6 vs 20.5 months).
Aims: To assess the cost effectiveness of VR-CAP compared with R-CHOP
as first-line treatment for patients with MCL unsuitable for HSCT, from the per-
spective of the UK National Health Service (NHS).
Methods: A cost-effectiveness model was constructed based upon line of
treatment, progression status and survival. The model has a 20-year time
horizon, extrapolating LYM-3002 clinical trial data using parametric models
that were fit to PFS and overall survival (OS) Kaplan–Meier curves. The patient
population was assumed to be the same as in the LYM-3002 trial with demo-
graphic data taken from US, Canadian and Western European patients. Util-
ities were derived from EQ-5D data from the clinical trial, supplemented with
data from published literature for long-term health status. Costs were included
for drugs, administration, adverse events and medical resources such as blood
transfusions and haematologist visits. Drug dosing and concomitant medica-
tions, adverse events, blood transfusions and second-line treatment informa-
tion were taken from the LYM-3002 trial data. Other resource use, such as
blood tests and haematologist visits, was based upon UK clinician advice.
Probabilistic and structural sensitivity analyses were conducted to assess the
uncertainty of the results.
Results: Total lifetime costs in the VR-CAP arm were £45,185 compared to
£27,460 in the R-CHOP arm. Treatment with VR-CAP resulted in an increase
in life years (7.67) compared to R-CHOP (6.66). The same is seen for quali-
ty-adjusted life years (QALYs), 4.14 and 3.35 for VR-CAP and R-CHOP,
respectively. Thus the additional cost associated with VR-CAP is partially
offset by additional benefit; resulting in an incremental cost-effectiveness ratio
of £22,227. In probabilistic sensitivity analysis, there was an 83% chance that
VR-CAP was cost effective at the standard UK threshold of £30,000 per QALY
gained. The model was most sensitive to assumptions regarding the extrap-
olation of PFS and OS and utility associated with post-progression from sec-
ond-line treatment.
Tabella 1.
Summary and Conclusions: Based upon data from the LYM-3002 trial, VR-
CAP is a cost-effective treatment for previously untreated patients with MCL
who are unsuitable for HSCT in the UK.
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TION AND CONVENTIONAL THERAPY FOR PATIENTS WITH THA-
LASSEMIA MAJOR IN CHINA
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Background: The conventional therapy (CT) for b-thalassemia major (TM)
consists of regular transfusion and iron-chelating therapy for lifetime. However,
the high cost of CT can lead to poor compliance. Hematopoietic stem cell trans-
plantation (HSCT) provides an alternative option for TM patients. To our knowl-
edge, recent data of China has not been available in the literature on cost com-
parison between HSCT and CT, leading to debate on selection of treatment for
patients with TM.
Aims: To compare the lifetime undiscounted mean cost (UMC) of HSCT with
UMC of CT in the TM patients and to investigate the relationship of the clinical
features to cost outcomes of HSCT.
Methods: We estimated UMC of 93 TM-HSCTs in 2011 with a median age of
6 years (range, 3-16) and a median follow-up time of 3.6 years (range, 3.1-
4.1). The relationship between the UMC of HSCT and patient characteristics
were analyzed. The UMC of 93 TM-HSCTs was compared with UMC of CT
based on total 1526 TM patients. Age was used as matching variant, and the
mean cost of each age was calculated, then cumulative cost was further adjust-
ed for age in patients.
Results: UMC of TM-HSCT was CNY (Chinese Yuan) 235,254/USD 37,664
(95% confidence interval (CI) CNY208,081-262,719/USD 33,293-42,035) with
mean hospital stay of 60.5 days (95% CI 49-71). With the addition of the UMC
of CNY 345,317/USD55,251 for 20 years of follow-up, total undiscounted life-
time (55 years) cost of TM-HSCT were CNY 465,975/USD 74,602. However,
the corresponding costs of patients undergoing CT were CNY 2,101,488/
USD336,238 and CNY 7,489,519/ USD1,198,323 respectively. Patient char-
acteristics were helpless to predict the costs. HLA-mismatched transplants
increased significantly UMC of HSCT than matched transplants (USD 35,818
vs USD 52,771; p<0.001). The development of GVHD were associated with
higher costs (USD 63,933 vs USD 44,547; p =0.001).
Figure 1.
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Summary and Conclusions: Cost comparison of HSCT and CT suggests that
HSCT is an efficient and high cost-effective treatment for TM patients. Mis-
matched donor transplant increases the cost of HSCT.
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Background: Advances in the management of patients with lymphoma or
chronic lymphocytic leukaemia (CLL) have changed the survival outcomes dra-
matically the last two decades. The number of new agents for these patients is
increasing and quality of life (QoL) is becoming a primary objective. Unfortu-
nately, questionnaires to assess disease-specific QoL among patients with
Hodgkin lymphoma (HL), high-grade non-Hodgkin lymphoma (HG-NHL), low-
grade non-Hodgkin lymphoma (LG-NHL) and CLL are lacking.
Aims: This study describes the combined development of four disease-specific
QoL questionnaires for patients with HL, HG-NHL, LG-NHL and CLL to supple-
ment the European Organization for Research and Treatment of Cancer
(EORTC)-QLQ C30 core cancer questionnaire.
Methods: Questionnaire development was conducted according to guidelines
from the EORTC Quality of Life Group. Phase I comprised generation of QoL
issues relevant to patients. Phase II included operationalization and assessment
of item relevance. In phase III, items were pretested in a cross-cultural sample
representing all four malignancies to assess issues such as comprehensibility
and intrusiveness of items. Data were analysed per malignancy.
Results: Seventy-five QoL issues were identified through focus groups and
systematic literature searches. Semi-structured interviews with 80 health-care
professionals and with 245 patients (75 HL, 66 HG-NHL, 41 LG-NHL and 63
CLL) resulted in a provisional module of 39 items representing items relevant
for all or at least one of the four malignancies. In phase III this was further
tested in 67 HL, 117 HG-NHL, 67 LG-NHL and 86 CLL patients with different
phases of disease and treatment from five European countries. Results from
the interviews, clinical experiences and statistical analyses resulted in a ques-
tionnaire with 27 items for HL (EORTC QLQ-HL27), 29 items for HG-NHL
(EORTC QLQ-NHL-HG29), 20 items for LG-NHL (EORTC QLQ-NHL-LG20)
and 17 items for CLL (EORTC QLQ-CLL17). The items are conceptualized in
several multi-item scales: symptom burden, physical condition/fatigue,
worries/fears health and functioning, emotional impact (not in the CLL module),
neuropathy (only in the HG-NHL module).
Summary and Conclusions: This study provides four modules for use in clin-
ical trials and observational research in conjunction with the EORTC QLQ-C30
for assessment of QoL for patients with HL, HG-NHL, LG-NHL and CLL. Phase
IV of the questionnaire development will start in 2015 and comprises interna-
tional field testing of the four questionnaires, i.e. EORTC QLQ-HL27, QLQ-
NHL-HG29, QLQ-NHL-LG20 and QLQ-CLL17.
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Background: While recent advances in the treatment of mantle cell lymphoma
(MCL) have increased remission rates and time to relapse, the cost of treatment
has not been well described.
Aims: This study evaluated the cost of care across the first, second, and third
treatment lines (1L/2L/3L) in patients with MCL.
Methods: MCL patients were identified in the IMS PharMetrics Plus database
containing de-identified health plan claims on >100 million U.S. lives. All patients
had ≥2 MCL claims (ICD-9-CM: 200.4X) at least 30 days apart between 2008
and 2012, no MCL claim 6 months prior to the initial claim (index), and contin-
uous enrollment in the health plans for ≥3 months post-index. Monthly costs
were calculated from the beginning of each line of therapy and up to 24 months
post-index. Patients receiving autologous stem cell transplant (ASCT) during
1L treatment were analyzed separately. The 1L was defined as a MCL treatment
with all agents administered within 90 days of the index and a new line was
determined when restarting therapy following a 90 day gap in a previous line,
or addition of a new agent >90 days from the start of the previous line.
Results: A total of 872 patients (mean age 63 years, 72.0% male) were select-
ed, of whom 172 (19.7%) received ASCT, 334 (38.3%) and 119 (13.6%) were
followed to the end of 2L and 3L, respectively. For patients who relapsed/were
refractory while on 1L treatment, the median TTNT was 350 days for pts after
ASCT (n=54) and 422 days for non-ASCT pts from initiation of 1L treatment to
the beginning of 2L (n=280). For patients receiving ASCT, the mean monthly
cost between diagnosis and the start of 2L treatment was $12,565 with the
highest mean monthly cost occurring between months 4 and 6 ($43,703). Phar-
macy, inpatient, and outpatient costs accounted for approximately 26%, 47%,
and 27%, respectively. For non-ASCT patients, the mean monthly cost following
diagnosis to the next line treatment was $5,964, with the highest mean monthly
cost occurring in the first 3 months ($24,363). For these patients, pharmacy,
inpatient, and outpatient costs accounted for approximately 43%, 27%, and
30%, respectively. For all patients, monthly 1L costs stabilized at about 16
months to approximately $4,000. Upon initiating 2L and 3L therapy, monthly
costs rose to $21,660 and $22,718 over the first three months, respectively,
then followed by a pattern of reduction similar to what was seen in 1L treatment.
For 2L and 3L therapy, pharmacy costs made up approximately 45% of all
costs, with inpatient and outpatient costs each accounting for 25%>30% of
remaining costs. Inpatient costs rose to 47% of total costs during months 4-6
after the initiation of 3L therapy.
Summary and Conclusions: Treatment costs for MCL were the highest during
the first 3 months of treatment in each line of therapy then declined and stabi-
lized to about 25%>30% of the initial costs. This pattern suggests that prolon-
gation of time to progression may yield economic as well as humanistic benefits.
Patients receiving ASCT incurred more than twice the expense compared with
those not receiving ASCT during 1L therapy.
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Background: Ponatinib is a potent oral 3rd-generation tyrosine kinase inhibitor
(TKI) with evidence of better efficacy than 2nd-geneation TKIs in 3rd-line treat-
ment of CML (Lipton 2014), but with potentially higher risk of vascular occlusive
adverse events (AEs). Bosutinib, a 2nd-generation TKI, differs in both efficacy
and characteristic AEs.
Aims: A model was developed to quantify the benefit-risk difference between
ponatinib and bosutinib for CP-CML patients after failure of 2 previous TKIs, in
terms of survival and quality-adjusted survival.
Methods: The Excel-based model uses estimates of treatment response, in
terms of complete cytogenic response (CCyR) at 12 months, and AEs to quan-
tify the overall benefit-risk difference with ponatinib vs bosutinib using common
metrics: outcomes of survival and quality-adjusted survival are measured in
life-years (LYs) and quality-adjusted life-years (QALYs) accrued over patients’
remaining lifetimes. Quality of life (QoL) is quantified using health-state utilities,
where each health state is assigned a value from 0 (death) to 1 (perfect health).
A decision tree captures the risk of transient AEs, assumed to occur immediately
upon start of treatment that may cause death or short-term decrements to QoL,
but if not fatal, have no long-term consequences. Chronic AEs occur either
immediately or over time and have both short-and long-term consequences.
AEs of interest are grade 3 or 4 affecting survival and/or QoL that differed
between treatments in clinical trials, including cardiovascular, hematologic, and
gastrointestinal AEs, as well as blindness and amputation. In an ensuing Markov
model, patients are assigned to health states based on treatment response
and their most serious previous chronic AE. In each 3-month Markov cycle,
patients are at risk of incident chronic AEs and of dying from prior or incident
chronic AEs, CML, or age-specific other causes. Each cycle, patients accrue
LYs, and QALYs reflecting response status, less any QoL loss for their most
serious chronic AEs. In the base case, the model applies an evidence-based
difference in utility between responders and non-responders, but assumes no
survival advantage for responders. Treatment response was estimated from a
recent synthesis of CML studies, estimating 60% response for ponatinib and
22% for bosutinib. Rates of AEs were derived from published literature and
prescribing information. Utility decrements for responders/non-responders and
AEs, and mortality for AEs were estimated from published literature. Extensive
sensitivity and scenario analyses were conducted.
Results: In the base case assuming response confers no survival advantage,
patients receiving ponatinib vs bosutinib accrue 0.43 fewer LY (9.5 vs 9.9,
respectively) of survival. When LY are adjusted for QoL, ponatinib provides an
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additional 0.24 QALYs vs bosutinib (Figure). In scenario analyses where
response is assumed to confer a 5% survival advantage, patients on ponatinib
are estimated to survive an additional 0.37 years (10.8 vs 10.4 LY, respectively)
vs bosutinib and accrue 7.9 vs 7.0 QALYs.
Figure 1. Estimated lifetime quality-adjusted life-years (QALYs) for 3rd-
line CP-CML patients treated with ponatinib versus bosutinib.
Summary and Conclusions: Given the assumptions and limitation of this
analysis, we found that in 3rd-line CP-CML patients, the positive effect of pona-
tinib’ s higher efficacy on quality of life more than offsets losses due to AEs,
even if no survival advantage for treatment responders was assumed. This
analysis highlights the need to consider the negative effect of non-response
as well as AEs on patients’ quality of life and survival when evaluating alterna-
tive treatments in CML.
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Background: In thalassemia major (TM) three chelators are available to treat
chronic iron overload due to blood transfusions: subcutaneous desferrioxamine
(DFO), oral deferiprone (DFP) and oral deferasirox (DFX).
Aims: This study evaluated the relative cost effectiveness of the three chelators
in monotherapy.
Tabella 1.
Methods: Patients enrolled in the MIOT (Myocardial Iron Overload in Tha-
lassemia) project and who received monotherapy with a single iron chelator
for at least 18 consecutive months were evaluated for assessment. The cost-
effectiveness model was adapted from the previously published UK model
(Bentley A et al. Pharmacoeconomics 2013;31:807–22). Based on literature
data, it was assumed that all three iron chelators had comparable efficacy in
controlling serum ferritin and liver iron concentration, wherea 4 different effica-
cy-based scenarios were explored in respect to cardiac morbidity and mortality
using Markov-type models. Treatment costs reflect the Italian market: Incre-
mental costs and quality-adjusted life-years (QALYs) were calculated for each
iron chelator, with cost effectiveness expressed as incremental cost per QALY.
Results: Within the MIOT project, none of the adverse events (AE) considered
in the UK model (neutropenia, agranulocytosis, Franconi syndrome, hepatitis)
were detected for the 193 TM patients who had been received the same chela-
tor for at least 18 months and were considered as reference group. The table
shows costs and QALYs in the different modelled scenarios. For the first three
scenarios a 5-year period was considered per patient while for the last scenario
a 1-year time horizon was used and the discount rate of 3.5% was not applied.
DFP was the dominant strategy in all scenarios, providing greater QALY at a
lower cost.
Summary and Conclusions: The results of this analysis indicate that, from
an Italian perspective, DFP is the most cost-effective treatment available for
managing chronic iron overload in β-thalassaemia patients. Use of DFP in
these patients could therefore result in substantial cost savings.
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Background: HDT followed by ASCT remains the gold standard for treatment
of NDMM patients who are able to tolerate the procedure. Following ASCT,
consolidation with novel agents for a fixed time period (or number of cycles)
can improve outcomes. However, there are currently few published data on
BTZ consolidation therapy, although a study by the Nordic Myeloma Study
Group has reported results in BTZ-naïve patients (Mellqvist et al. Blood 2013).
Aims: The results from two large randomized controlled phase 3 studies were
combined to investigate BTZ consolidation or OBS in patients with NDMM both
with and without prior BTZ treatment.
Methods: MMY3012 (NCT00416273; 222 patients aged ≤60 yrs) and
MMY3013 (NCT00416208; 158 patients aged 61-75 yrs) recruited adults with
NDMM who underwent induction therapy followed by ASCT. Patients were ran-
domized 1:1 to receive BTZ consolidation (1.6 mg/m² IV days 1, 8, 15, 22;
4x35-day cycles) or OBS, 60-120 days after ASCT. The primary endpoint was
progression-free survival (PFS) from the start of induction; secondary endpoints
included response rate, overall survival (OS), and safety. Factors affecting PFS
were also assessed by post-hoc multivariate analysis. Responses were
assessed per EBMT response criteria, with VGPR as an additional category.
Adverse events (AEs) were graded per NCI-CTCAE v3.0.
Results: In 371 randomized patients, median age was 59 yrs (35-76); 62%
were male, 14%/84% were Durie-Salmon stage II/III. Of the 278 patients
assessed for cytogenetics, 37% were classified as high-risk (32% del13q, 10%
t(4;14), 6% del17p). Overall, 50% of patients had received prior BTZ therapy;
the most common induction regimen was VCD (40%). Others included dexam-
ethasone/idarubicin (14%), dexamethasone (13%), VAD (9%), adriamycin/dex-
amethasone (6%) and VD (6%). In the overall study population, patients who
received BTZ-based induction showed a trend towards improved PFS (HR
1.24; 95% CI: 0.97, 1.59; p=0.084) by unadjusted Cox regression analysis.
Outcomes for patients receiving BTZ consolidation or OBS only are shown in
the Table 1 (median follow-up 50 months from start of induction). PFS was sig-
nificantly improved by approximately 6 months, but there was no improvement
in OS. In a post-hoc exploratory multivariate analysis, BTZ consolidation
remained a predictor for PFS (HR 0.69; 95% CI: 0.51, 0.93; p=0.016). There
appeared to be an increased risk of progression in patients with high-risk cyto-
genetics (HR 1.45; 95% CI: 1.05, 1.99; p=0.025) or those with <VGPR at base-
line (HR 1.44; 95% CI: 1.05, 1.98; p=0.024). Age >60 had no effect on PFS
(HR 1.24; 95% CI: 0.87, 1.77; p=0.240); neither did the use of non-BTZ induc-
tion (HR 1.17; 95% CI: 0.83, 1.66; p=0.375).
Table 1.
Summary and Conclusions: These data indicated that a fixed period (4
cycles) of BTZ consolidation was beneficial in NDMM patients with or without
prior BTZ exposure. A higher proportion of patients achieved ≥VGPR after BTZ
consolidation than OBS. PFS was significantly improved, but there was no
improvement in OS at data cutoff, possibly related to limited follow-up and the
use of effective salvage options. Subgroups that seemed to benefit from BTZ
consolidation were patients with <VGPR and those with high-risk cytogenetics;
age and BTZ pretreatment did not affect PFS. The BTZ dosing regimen was
generally well-tolerated.
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Background: Previously reported results from ASPIRE (NCT01080391; N=792
patients) showed that carfilzomib, lenalidomide, and dexamethasone (KRd)
significantly improved progression-free survival (PFS) vs lenalidomide and dex-
amethasone (Rd) in patients with relapsed multiple myeloma, with a favorable
benefit-risk profile (Stewart et al. N Engl J Med 2015;372:142-52).
Aims: A secondary analysis of efficacy and safety results from patients treated
with KRd or Rd after first relapse (1 prior line of therapy) vs ≥2 prior lines of
therapy in the ASPIRE study is presented.
Methods: Adults with relapsed multiple myeloma who received 1-3 prior lines
were eligible. Patients were randomized (1:1) to KRd or Rd. All patients
received lenalidomide (25 mg) on days 1-21 and dexamethasone (40 mg) on
days 1, 8, 15, and 22 of a 28-day cycle. Patients in the KRd arm received carfil-
zomib as a 10-min infusion on days 1, 2, 8, 9, 15, and 16 during cycles 1-12
(20 mg/m2 [days 1 and 2 of cycle 1]; 27 mg/m2 thereafter). Carfilzomib was
omitted on days 8 and 9 during cycles 13-18 and was not administered beyond
18 cycles. All patients provided informed consent.
Results: Median PFS for patients receiving 1 prior line (n=341) was 29.6
months (95% confidence interval [CI]: 23.2-33.5) for KRd vs 17.6 months (95%
CI: 15.0-22.2) for Rd (hazard ratio [HR]: 0.694; P=.0083). Median PFS for
patients receiving ≥2 prior lines (n=451) was 25.8 months (95% CI: 22.2-31.0)
for KRd vs 16.7 months (95% CI: 13.9-22.0) for Rd (HR: 0.688; P=.0017). Best
overall responses in patients who received 1 vs ≥2 prior lines of therapy are
presented in the Table 1. Overall response rates (partial response or better)
were 87.0% (KRd) vs 70.1% (Rd) in patients with 1 prior line and 87.3% (KRd)
vs 64.4% (Rd) in patients with ≥2 prior lines. In patients with 1 prior line, 33.7%
(KRd) vs 7.0% (Rd) achieved a complete response (CR) or better, including
12.5% (KRd) and 3.2% (Rd) who achieved a stringent complete response
(sCR). In patients with ≥2 prior lines, 30.2% (KRd) vs 10.9% (Rd) achieved a
CR or better, including 15.6% (KRd) and 5.0% (Rd) who achieved a sCR.
Adverse events (AEs) grade ≥3 were reported in 85.7% (KRd) and 79.9% (Rd)
of patients who received 1 prior line of therapy and 81.9% (KRd) and 81.3%
(Rd) of patients who received ≥2 prior lines. AEs of interest (grade ≥3; grouped
terms) included dyspnea (1 prior line: 2.7% [KRd] and 2.6% [Rd]; ≥2 prior lines:
3.3% [KRd] and 1.7% [Rd]); cardiac failure (1 prior line: 3.3% [KRd] and 1.9%
[Rd]; ≥2 prior lines: 4.3% [KRd] and 1.7% [Rd]); ischemic heart disease (1 prior
line: 4.9% [KRd] and 1.3% [Rd]; ≥2 prior lines: 1.9% [KRd] and 2.6% [Rd]);
hypertension (preferred term; 1 prior line: 3.8% [KRd] and 0.6% [Rd]; ≥2 prior
lines: 4.8% [KRd] and 2.6% [Rd]); and acute renal failure (1 prior line: 3.3%
[KRd] and 3.2% [Rd]; ≥2 prior lines: 3.3% [KRd] and 3.0% [Rd]).
Table 1. Best overall responses by prior line of therapy (1 vs ≥2).
Summary and Conclusions: The use of KRd led to a 1-year improvement in
median PFS vs Rd after first relapse, and a 9-month improvement in median
PFS vs Rd in patients with ≥2 prior lines of therapy, with similar HRs. KRd had
a favorable benefit-risk profile compared with Rd after 1 and ≥2 prior lines of
therapy in patients with relapsed multiple myeloma.
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Background: Triplet regimens containing an immunomodulatory agent (IMiD),
proteasome inhibitor (PI) or both, are standard induction therapy for myeloma
(MM) patients. Attempts to improve responses with quadruplets containing
bortezomib and lenalidomide led to increased toxicity without improving out-
comes. New generation PIs such as carfilzomib, with less off-target activity
and better toxicity profiles are now available and recent data from the ASPIRE
trial demonstrate that the triplet carfilzomib, lenalidomide, dexamethasone is
safe and effective at relapse. Therefore, it is important to define whether a
quadruplet combining carfilzomib and lenalidomide at induction can improve
outcomes whilst minimising additional toxicity. The UK NCRI Myeloma XI trial
is the first large, phase III study aiming to answer this question with the addition
of the quadruplet carfilzomib, cyclophosphamide, lenalidomide and dexam-
ethasone (KCRD) experimental arm to the transplant eligible (TE) pathway.
Overall the trial seeks to establish the optimum induction and maintenance
approaches for all newly diagnosed MM (NDMM) patients with almost 4000
recruited to date. 
Aims: To assess the safety and tolerability of KCRD in TE, NDMM.
Methods: In 2013, the TE pathway of the NCRI Myeloma XI trial was amended
to include an assessment of the quadruplet carfilzomib (20/36mg/m2 IV D1-
2,8-9,15-16. 20mg/m2 only cycle 1 D1-2), cyclophosphamide (500mg PO D1,8),
lenalidomide (25mg PO D1-21), dexamethasone (40mg PO D1-4,8-9,15-16).
This up-front quadruplet is being compared to the sequential strategy of triplet
IMiD combinations (with thalidomide or lenalidomide) followed by additional PI
triplet therapy (with bortezomib) for those with a suboptimal response (<VGPR)
prior to ASCT. Treatment is given to max. response/unacceptable toxicity before
proceeding to ASCT, followed by a maintenance randomisation. Here we report
a safety analysis for the KCRD regimen.
Results: Following informed consent 257 patients have commenced KCRD
treatment to date. KCRD is well tolerated with patients completing a mean of
4.2 cycles (±1.17), median 4 (range 1-7) prior to transplant. Dose modifications
have been required in 63% of KCRD patients (55% with modifications to carfil-
zomib, 38% to lenalidomide). Data for study drug-related toxicity in patients
who have completed at least one cycle of KCRD show a low incidence of grade
2-4 neuropathy (sensory 1.2%, motor 4.4%), all grade infusion reactions (4.4%)
and thrombo-embolism (5%). Grade 3-4 haem toxicities were: 14.5% neutrope-
nia, 6.9% thrombocytopenia, 7.5% anaemia. There were few reported cases
of cardiac or renal failure so we looked for ARs suggestive of these previously
reported side effects, finding grade 3-4 dyspnoea in only 1.3%. Serious adverse
events suspected to be due to trial medications have occurred in 41% of
patients receiving KCRD with the majority due to infections or cytopenias. Over-
all the toxicity profile is similar to that reported previously for patients receiving
the CRD triplet, despite the addition of carfilzomib.
Summary and Conclusions: These results suggest that KCRD, an outpatient
delivered 4-drug regimen combining second generation IMiD and PI drugs, is
well-tolerated and safe in TE NDMM patients. With no significant additional
toxicity over 3-drug combinations and a favourable profile when compared to
other 4-drug regimens, KCRD represents a highly promising induction option.
Longer follow-up is awaited to assess the efficacy and tolerability compared to
a sequential IMiD/PI strategy.
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Background: Combination therapy with melphalan-prednisone-thalidomide
(MPT) is considered a standard treatment (Tx) option for patients (pts) with
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newly diagnosed multiple myeloma (NDMM) who are ineligible for stem cell
transplant (SCT; Facon, Lancet Oncol, 2007; Fayers, Blood, 2011; NCCN
Guidelines, Multiple Myeloma, V3.2015). The pivotal, randomized, international,
multicenter phase 3 FIRST trial demonstrated that first-line use of lenalidomide
continuous plus low-dose dexamethasone (Rd continuous) improved progres-
sion-free survival (PFS) compared with MPT (HR=0.72; P <0.001). An overall
survival (OS) analysis also showed improvement, with a 22% reduction in risk
of death with Rd continuous vs MPT (HR=0.78; P=0.02) (Benboubker, N Engl
J Med, 2014).
Aims: To determine PFS, OS, and DOR outcomes stratified by age of patients
with NDMM in the FIRST trial.
Methods: NDMM pts ineligible for SCT were randomized 1:1:1 to Tx with Rd
continuous (28-day cycles) until disease progression (n=535); 18 cycles (72 wks)
of Rd (Rd18; n=541); or 12 cycles (72 wks) of MPT (n=547). Starting doses were
reduced in pts aged >75 vs those aged ≤75 yrs: dexamethasone (20 vs 40 mg),
melphalan (0.20 vs 0.25 mg/kg), and thalidomide (100 vs 200 mg). The primary
endpoint was PFS. Secondary endpoints included OS, overall response rate
(ORR), time to response, duration of response (DOR), time to Tx failure, time to
second anti-myeloma Tx, health-related quality of life, and safety.
Results: This analysis based on the final PFS analysis using a data cutoff of
May 24, 2013, with a median follow-up of 37 mos. The proportion of pts aged
≤75 yrs and >75 yrs was 65% (n=1056) and 35% (n=567), respectively. Pt
characteristics, including rate of adverse cytogenetics, were well balanced
across all Tx arms. In pts ≤75 yrs, ISS stage III disease was detected in 37%
of those treated with Rd continuous or Rd18 and 36% of pts treated with MPT.
In pts >75 yrs, these rates were 47% with Rd continuous or Rd18 and 50%
with MPT. Severe renal impairment (CrCl <30 mL/min) was observed in 6%,
8%, and 8% of pts ≤75 yrs vs 13%, 11%, and 15% of pts >75 yrs (Rd continuous,
Rd18, and MPT, respectively). PFS and OS outcomes favored Rd continuous
over MPT in both age groups. Median PFS was 27.4 mos in Rd continuous pts
vs 21.8 mos in MPT pts aged ≤75 yrs (HR=0.68; P <0.001); HR for pts aged
>75 yrs was 0.81 (P=0.11; Table 1). PFS for Rd continuous vs Rd18 pts was
also increased in both age groups (HR=0.68; P <0.001 and HR=0.75; P=0.03,
respectively). OS showed an improved trend for Rd continuous vs MPT in pts
aged ≤75 yrs (HR=0.77; P=0.06) and >75 yrs (HR=0.80; P=0.16). ORR was
consistently higher with Rd continuous vs MPT in pts aged ≤75 yrs (77% vs
66%) and >75 yrs (71% vs 55%). Median DOR with Rd continuous was longer
vs MPT in pts aged ≤75 yrs (40 vs 22 mos) and pts >75 yrs (31 vs 24 mos).
Hematologic and non-hematologic adverse events (AEs) were as expected for
Rd and MPT, with no relevant differences in Grade 3/4 toxicity between pts
≤75 yrs and >75 yrs. Tx discontinuation due to AEs was comparable across Tx
and age groups.
Table 1. PFS, OS, and response.
Summary and Conclusions: Regardless of age (≤75 vs >75 yrs), Rd contin-
uous extended PFS with an OS benefit vs MPT in NDMM pts. Rd continuous
was generally well tolerated in both age groups. DOR was improved with Rd
continuous vs MPT and Rd18, irrespective of age. Rd continuous represents a
new standard of care for pts in the first-line setting independent of age.
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Background: Novel agents including proteasome inhibitors (PI) and
immunomodulatory agents (IMiDs) have provided improved treatment out-
comes for patients with multiple myeloma (MM). The majority of patients with
MM still unfortunately relapse, with very limited options after PI and IMiD-based
treatment. Daratumumab (DARA) is a human anti-CD38 IgG1κ mAb and has
previously shown single agent activity and good tolerability in relapsed/refrac-
tory MM (Lokhorst HM et al. ASCO 2014).
Aims: This ongoing phase 2 study (NCT01985126) evaluated DARA monother-
apy in the FDA breakthrough therapy designation population: MM patients with
≥3 prior lines of therapy including a PI and an IMiD, or double refractory to a PI
and IMiD. Preliminary results are reported.
Methods: MMY2002 is a 2-part, open-label, international, multicenter study. In
part 1 stage 1, 34 patients were randomized to DARA 8 mg/kg (n=18) q4w or
16 mg/kg (n=16) qw for 8 weeks, q2w for 16 weeks, then q4w in a Simon-2-
stage design to determine the most effective dose. Subsequently, 90 additional
patients were enrolled in the 16 mg/kg DARA group. The primary endpoint was
overall response rate (ORR) by independent review (IRC).
Results: Data for the 16 mg/kg DARA group are presented (n=106). The medi-
an time from diagnosis was 4.8 years and patients received a median of 5 prior
treatment lines. A total of 80% of patients received prior autologous stem cell
transplants. Seventy five percent of patients were ISS stage 2 or higher. Nine-
ty-six percent of patients were refractory to their last line of therapy and 95%
were refractory to their last PI and IMiD. The proportions of patients refractory
to other to agents included pomalidomide (63%), carfilzomib (48%) and alky-
lating agents (78%). Adverse events (AE; ≥20%) included fatigue (39.6%), ane-
mia (33.0%), nausea (29.2%), thrombocytopenia (25.5%), back pain (22.6%),
neutropenia (22.6%), cough (20.8%). Infusion-related reactions (IRR, 42.5%)
were mainly grade 1/2 during the first infusion with 4.7% of patients with grade
3 IRRs. No grade 4 IRRs were reported and no patients discontinued the study
due to IRRs. Five patients (4.7%) discontinued treatment due to AEs and none
of these AEs were assessed by the investigator to be DARA-related. The ORR
(IRC assessed) was 29.2%, with 3 stringent complete responses, 10 very good
partial responses, and 18 partial responses. The ORR was consistent across
clinically relevant subgroups. The median duration of response was 7.4 months.
The median time to progression was 3.7 months. Median overall survival (OS)
has not been reached and the estimated 1-year OS rate is 65%. After a median
follow up of 9.4 months 14/31 (45.2%) of responders remain on therapy.
Summary and Conclusions: In a heavily pre-treated MM population (95%
refractory to last PI and IMiD), DARA at 16 mg/kg showed meaningful durable
single agent activity, with deep responses and a favorable safety profile.
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Background: Venetoclax is a selective, orally bioavailable BCL-2 inhibitor.
Single agent venetoclax induces responses in ~80% of pts with relapsed/refrac-
tory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Pts were enrolled in a phase 1b, open-label, dose-escalation, multicenter study
of venetoclax plus rituximab (R), to determine safety, PK and efficacy. We have
previously reported the recommended phase 2 dose for venetoclax in this com-
bination to be 400 mg/day. 
Aims: The goal of this analysis was to determine the response rate and minimal
residual disease status and to update the safety profile for the combination.
Methods: Eligible pts began treatment with 20 or 50 mg venetoclax daily,
increasing weekly to final cohort doses of 200-600 mg. After the weekly lead-
in phase, monthly R was added (at 375 mg/m2 and then 500 mg/m2) for 6 dos-
es. Responses were assessed using iwCLL criteria, including CT scan and
bone marrow (BM) biopsy at the end of combination therapy (7 months). MRD
was assessed in local laboratories using ≥4 color flow cytometry on cells in
BM and blood (minimum sensitivity of 0.01%).
Table 1.
Results: Accrual is complete with 49 pts (48 CLL/1 SLL) of median age 68 (50-
88) years enrolled in 5 dose escalation cohorts (n=41) and a safety expansion
cohort at 400 mg/day (n=8). The median number of prior regimens was 2 (1-5).
Forty-five (92%) had prior R; 14/49 (29%) were R-refractory. Twenty-eight (57%)
had prior fludarabine (F); 9/49 (30%) were F-refractory. Of 46 pts with available
data, 9 (20%) had del17p; 19/27 (70%) with available data had unmutated IGVH.
Eleven pts have discontinued the study: 6 due to PD, 2 due to AEs (neuropathy,
TLS), and 3 withdrew consent. The median time on study as of Jan 21, 2015
was 13 (0.03-28) months. The overall response rate (ORR) was 84% (41/49),
with 20 (41%) achieving either a complete response (CR) or CR with incomplete
marrow recovery (CRi). MRD was evaluable in 40 pts. MRD-negativity in BM
was achieved in 13/20 (65%) pts with CR/CRi and in 24/49 (49%) pts overall.
Responses are summarized in the Table 1. Only 3/41 (7%) responders have pro-
gressed (at 5, 8 and 12 months). Six pts stopped daily venetoclax after achieving
CR/CRi. These pts continue in follow up and all have maintained a response
after a median time of 12 months (0-21) off venetoclax. Treatment-emergent AEs
in >25% were neutropenia (53%), diarrhea and nausea (each 47%), upper res-
piratory tract infection (41%), pyrexia (37%) and fatigue, headache and cough
(each 33%). Grade 3/4 AEs in >10% were neutropenia (51%), thrombocytopenia
(16%) and anemia (14%). There was 1 treatment-emergent AE that led to death
(TLS) and there were 2 deaths after PD. 
Summary and Conclusions: The combination of venetoclax and R has a tol-
erable safety profile and induces deep and durable responses, with 41% of pts
achieving CR/CRi and 49% of pts achieving MRD negativity in BM. A phase 3
trial comparing venetoclax and R versus bendamustine and R in pts with pre-
viously treated CLL is underway.
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Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor which
lacks the hepatotoxicity associated with other PI3Kδ inhibitors and is active in
patients (pts) with advanced heme malignancies (ASH 2014). 
Aims: Herein we present updated safety and efficacy results from a Ph I study
of TGR-1202 in pts with rel/ref CLL and B-cell lymphoma.
Methods: TGR-1202 administered orally once-daily following a 3+3 dose esca-
lation design. Eligible pts have rel/ref B-cell non-Hodgkin lymphoma (NHL),
chronic lymphocytic leukemia (CLL), or other B-cell malignancy and an ECOG
PS ≤2. Endpoints: safety, PK/PD, and efficacy.
Results:As of Feb 2015, 58 pts evaluable for safety including CLL, FL, Hodgkin’s
(HL), DLBCL, MCL, and MZL. Median age 63 yo (range: 22-85), 72% male, ECOG
0/1/2: 19/38/1, median prior Tx: 3 (range: 1-14), 48% refractory to prior Tx. Safety:
The only Gr≥3 AE in ≥10% of pts was neutropenia (10%). AEs (all grades, all
causality) in >20% of pts were limited to diarrhea (34%), fatigue (31%), nausea
(29%), and cough (26%). All diarrhea events Gr1/2, except one Gr3 event occur-
ring in a pt in Cyc 1, which persisted for 2 days and resolved without dose inter-
ruption. Notably, in contrast to similar agents, no drug-related hepatotoxicity or
colitis has been observed to date (ave time on study 7 Cyc). 2 episodes of Gr3
fatigue at 1800 mg of a new micronized formulation met the criteria for DLT. Expan-
sion cohorts are open at 800 mg (CLL) and 1200 mg (NHL). Efficacy: A strong
exposure-response relationship has been observed. Of 14 evaluable CLL pts, 13
(93%) achieved a nodal PR (median nodal ↓ of 76%), of which 7 (50%) achieved
a PR per Hallek 2008 criteria. Responses have been limited in pts with DLBCL
and HL. Of the 12 evaluable FL pts, 8 (67%) remain on study progression-free
(range 7-99+ weeks), with 3 achieving a PR, notably being the 3 pts exhibiting the
highest TGR-1202 plasma concentrations. 
Summary and Conclusions: TGR-1202 is well tolerated in pts with rel/ref
heme malignancies with no reported hepatotoxicity or colitis (41% of pts on





EARLY CLINICAL ACTIVITY AND PHARMACODYNAMIC EFFECTS OF
DUVELISIB, A PI3K-DELTA, GAMMA INHIBITOR, IN PATIENTS WITH
TREATMENT-NAÏVE CLL
S. O’Brien1,* K. Faia2, K. White2, M. Douglas2, K. Allen2, J. Kutok2, J. Sweeney2,
V. Kelly2, I. Flinn3, J. Byrd4, H. Stern2
1MD Anderson Cancer Center, Houston, 2Infinity Pharmaceuticals, Cambridge,
3Sarah Cannon Research Institute, Nashville, 4The Ohio State University Med-
ical Center, Columbus, United States
Background: Signaling via PI3K-δ and PI3K-γ has distinct and complementary
effects on malignant B-cells and nonmalignant immune cells in chronic lym-
phocytic leukemia (CLL). Duvelisib, an oral dual inhibitor of PI3K-δ,γ, has
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shown clinical activity in a phase 1 study, IPI-145-02 (O’Brien, ASH 2014; Flinn,
ASH 2014; Horwitz, ASH 2014).
Aims: The activity of duvelisib monotherapy in patients with treatment-naïve
CLL from this study are reported here.
Methods: Following dose escalation, an expansion cohort of treatment-naïve
CLL patients was enrolled (n=18). Response was based on iwCLL (2008) cri-
teria. Safety included AEs and laboratory assessments. Pharmacodynamic
assessments included peripheral blood (PB) flow cytometry for phospho-S473
AKT (pAKT) and Ki67, and measurement of serum chemokines and cytokines.
Numbers of PB T-cell subsets were also monitored.
Results: As of Oct 2014, 18 treatment-naïve CLL pts received duvelisib 25 mg
BID. The best ORR per iwCLL was 82% (PRs in 14/17 evaluable patients) with
a median time on treatment of 53 weeks (range 8-69). Ten patients remain on
treatment, while 8 discontinued, including 6 patients due to AEs. AEs overall
were mostly Grade 1 or 2. The most common ≥Grade 3 AEs were neutropenia
(7/18) and ALT/AST increase (3/18). Inhibition of pAKT in CLL cells was rapid
following a single dose and sustained through Cycle 2 Day 1 (C2D1). A reduc-
tion in the Ki67 proliferative fraction in both CLL and T-cells was also observed.
Duvelisib resulted in reductions in the median serum levels of CCL3, CCL4,
CCL17, CCL22, CXCL10, CXCL13, IL-10, IL-12p40, MMP-9, IL-16, and TNFα
to ≤50% of baseline at C1D8 and/or C2D1 (p <0.01).
Summary and Conclusions: Duvelisib 25 mg BID shows clinical activity in
treatment-naïve CLL pts. The inhibition of pAKT and Ki67 in CLL cells suggests
duvelisib inhibits the PI3K pathway and suppresses malignant cell proliferation
in treatment-naive CLL patients. In addition, the effect of duvelisib on serum
chemokines, cytokines, and T-cell proliferation suggests that modulation of the
tumor microenvironment may contribute to the observed early clinical activity
of duvelisib in patients with treatment-naïve CLL. These data support the further
development of duvelisib in treatment-naïve CLL, including combinations with
other targeted therapies.
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ADHERENCE AND DOSE INTENSITY FOLLOWING ADMINISTRATION OF
THE IBRUTINIB 420 MG DOSE IN PATIENTS WITH PREVIOUSLY TREATED
CLL 
U. Jaeger1,* P.M. Barr2, J.R. Brown3, P. Hillmen4, S. O’Brien5, J.C. Barrientos6,
N.M. Reddy7, S. Coutre8, S.P. Mulligan9, R.R. Furman10, F. Cymbalista11,
M. Montillo12, C. Dearden13, T. Robak14, C. Moreno15, J.M. Pagel16, J.A. Burger5,
S. Suzuki17, J. Sukbuntherng17, G. Cole17, D.F. James17, J.C. Byrd18
1Medical University of Vienna, Vienna, Austria, 2Wilmot Cancer Institute, Uni-
versity of Rochester, Rochester, 3Dana-Farber Cancer Institute, Boston, United
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Background: Ibrutinib is a first-in-class, once-daily, oral, covalent inhibitor of
Bruton’s tyrosine kinase (BTK). Pharmacokinetic analyses have shown that
ibrutinib is rapidly absorbed, extensively distributed, and rapidly eliminated from
systemic circulation after oral administration (Advani, JCO 2013, Poggesi,
AACR 2014). In a study of BTK occupancy in peripheral blood, ibrutinib
achieved complete or near complete occupancy of the BTK active site (median
>90%) at 4 hours which was maintained at 24 hours following administration of
the 420 mg once-daily dose (O’Brien, Lancet Oncology 2013). PK/PD analysis
of BTK engagement at different dose levels predicted that at the lower doses
of 140 or 280 mg fewer patients would attain complete BTK occupancy (Pog-
gesi, AACR 2014).
Aims: To evaluate the effect of the ibrutinib 420 mg once-daily dose adherence
on independent review committee-assessed progression-free survival (PFS)
in patients with previously treated CLL from the phase 3 RESONATE trial.
Methods: Dose intensity was defined as the proportion of actually administered
vs planned doses of ibrutinib 420 mg. Dose intensity was also defined in the first
8 weeks to compare statistically with post-week 8 PFS. Steady-state AUC/Cmax
was estimated per NONMEM modeling using 2 timepoint samples (weeks 1 and
4). Missed doses had to be consecutive. Mean duration of missed doses was
based on the sum of all consecutive days of missed dose for each patient.
Results: Patients treated with ibrutinib (n=195) had a mean dose intensity of
95% (median 100%) with 8.3 months of treatment. Of all patients with dose
reductions (4.1%), 3.6% had 1 dose reduction and 0.5% had 2 dose reductions
due to adverse events. Only diarrhea led to dose reduction in >1 patient in the
ibrutinib arm (n=3). The majority of dose interruptions were restarted at 420
mg as per protocol. There were fewer PFS events in patients not missing ibru-
tinib doses (n=136) vs those missing (n=59) ibrutinib doses for ≥8 consecutive
days (13% vs 31%, respectively), with median PFS of NR vs 11 months, respec-
tively. The mean duration of missed doses was 26 days for patients missing ≥8
days. For patients missing ≥2-7 days consecutively (n=33), the mean duration
of missed doses was 6 days; 103/195 patients did not miss >1 day. Patients
with higher dose intensity experienced longer PFS compared to those with
lower dose intensity (median NR vs 11 months). This trend was confirmed
(HR=0.4 [P=0.0127]) using an adjusted mean dose intensity of 96% in the first
8 weeks and post week-8 PFS. In patients with del17p CLL (n=63), p53 mutation
(n=61), or del11q CLL (n=63), those with higher dose intensity also had a lower
rate of progression or death events compared to those with lower dose intensity
(18% vs 42%, 9% vs 29%, 14% vs 16%, respectively). Dose reduction due to
diarrhea, infection, and arthralgia occurred in patients with del17p (n=2), p53
mutation (n=3), but not del11q CLL. No difference was seen in median PFS
with lower vs higher ibrutinib exposure (AUC or Cmax) in the 179 patients receiv-
ing ibrutinib 420 mg with PK assessment at weeks 1 and 4. Patients receiving
ibrutinib without concomitant CYP3A inhibitors had similar outcomes.
Summary and Conclusions: Improvement in PFS is associated with a higher
mean dose intensity of ibrutinib, with patients missing more than 1 week of
treatment experiencing more PFS events. This improvement in PFS is seen
regardless of del17p, del11q, or p53 mutation status. These results support
sustained adherence to the once-daily ibrutinib 420 mg dose in patients with
previously treated CLL.
haematologica | 2015; 100(s1) | 155
Vienna, Austria, June 11 – 14, 2015
Translational studies in ALL
S436
TYROSINE KINASE FUSION GENES IN PEDIATRIC BCR-ABL1-LIKE
ACUTE LYMPHOBLASTIC LEUKEMIA
J.M. Boer1,* J.R. Marchante1, A. Boeree1, G. Escherich2, H.A. de Groot-Kruseman3,
R. Pieters1,3,4, M.L. den Boer1,3
1Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Chil-
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Background: Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) with the BCR-ABL1 fusion gene forms a small high-risk patient group
with a poor prognosis. Approximately 15% of BCP-ALL shows gene expression
similar to BCR-ABL1-positive disease and a similar unfavorable prognosis.
This group shows a high frequency of B-cell development gene aberrations,
especially IKZF1 deletions and tyrosine kinase activating lesions (Den Boer et
al. Lancet Oncol 2009; Mullighan et al. N Engl J Med 2009; Roberts et al. Can-
cer Cell 2012, N Engl J Med 2014; Van der Veer et al. Blood 2013).
Aims: To detect the clinical value (frequency, prognosis and drugability) of
tyrosine kinase fusions in childhood B-cell precursor ALL.
Methods: This study comprised 204 children with BCP-ALL in 3 Dutch trials
(DCOG ALL-8, 9, 10) and 2 German trials (COALL 06-97, 07-03) including 92
previously described BCR-ABL1-like cases identified by hierarchical clustering
and 112 non-BCR-ABL1-like B-other cases. Characterization included RT-PCR
and FISH to detect fusions involving ABL1, PDGFRB, JAK2 and CSF1R, copy
number analysis, and Sanger sequencing of JAK1 exons 13, 14 and JAK2
exons 16, 20, 21.
Results: We identified 12 tyrosine kinase activating fusion genes among 73
BCR-ABL1-like cases tested (16%) and none among 87 B-other cases. Four
EBF1-PDGFRB, two PAX5-JAK2, ZMIZ1-ABL1, and SSBP1-CSF1R fusions
were confirmed by RT-PCR. Four cases showed split FISH and/or breaks on
DNA copy number arrays for PDGFRB, ABL1, or JAK2 with unknown fusion
partners. IKZF1 deletions occurred more frequently in tyrosine kinase fusion
cases compared with B-other (55% vs 32%), and were enriched for rare, i.e.
other than exon 4-7 or full deletion, variants (46% vs 18%). JAK2 mutations
(mainly in exon 16) were present in 7/70 B-other and 2/82 BCR-ABL1-like cas-
es. JAK2 mutations co-occurred with high CRLF2 expression and had no prog-
nostic impact. The cumulative incidence of relapse (CIR) in the BCR-ABL1-
like group with tyrosine kinase fusions (5-yr CIR 25%±13%) was comparable
with the remaining BCR-ABL1-like group (5-yr CIR 33%±5%), and worse than
the B-other group (5-yr CIR 18%±4%; overall Gray p-value 0.06). Of the 12
tyrosine kinase fusion cases, 4 were late responders who only achieved remis-
sion after day 33 of induction therapy. Of 8 patients receiving a prednisone
window before start of induction therapy, 3 showed a poor prednisone response
on day 8. Day 15 punctures showed M2 or M3 marrows in 7/9 cases. Minimal
residual disease PCR at the end of induction was high (TP1 and TP2 ≥10-3) in
5 and intermediate (TP1 ≥10-3, TP2 <10-3) in 2/8 cases. Leukemic cells from
3 EBF1-PDGFRB patients were sensitive to imatinib in ex vivo cultures, com-
pared with lack of cytotoxic response in 4 EBF1-PDGFRB-negative samples,
2 of which even showed growth on imatinib. Combination of imatinib with pred-
nisolone resulted in further growth inhibition in ex vivo cultures from 2/3 EBF1-
PDGFRB patients.
Summary and Conclusions: Tyrosine kinase fusion genes were found in 16%
of DCOG/COALL BCR-ABL1-like cases, representing ~3% of total BCP-ALL.
JAK2 mutations were infrequent and not associated with BCR-ABL1-like in our
cohort. Tyrosine kinase fusion cases were characterized by poor initial response
to treatment, had an unfavorable clinical outcome compared to remaining non-
BCR-ABL1-like B-other ALL cases but had a comparable unfavorable outcome
to BCR-ABL1-like ALL without tyrosine kinase fusions. Imatinib worked additive
to prednisolone in EBF1-PDGFRB patient cells, indicating that this inhibitor
may be clinically used in combination with at least prednisone.
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THE PREDICTIVE STRENGTH OF NEXT GENERATION SEQUENCING MIN-
IMAL RESIDUAL DISEASE DETECTION FOR RELAPSE COMPARED WITH
CURRENT METHODS IN CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA
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Background: Minimal residual disease (MRD) monitoring using antigen recep-
tor-based quantitative PCR (qPCR) became a gold standard in the manage-
ment of acute lymphoblastic leukemia (ALL), despite being technically and
financially demanding. MRD detection based on next generation sequencing
(NGS) of antigen receptor genes rearrangements allows for a highly specific
and sensitive detection of MRD without the need for labourious optimization of
patient-specific assays.
Aims: To establish MRD detection by NGS of immunoglobulin heavy chain
(IGH) rearrangements and compare MRD levels at BFM-protocols stratification
timepoints with qPCR and flow cytometry (FC).
Methods: The libraries for sequencing were prepared from 450ng of diagnostic
bone marrow DNA and 50ng of polyclonal DNA. Two-round PCR was used for
library preparation: in the 1st round the IGH rearrangements were amplified
with Biomed-2 FR3 primers. In the 2nd round of PCR sequencing adaptors and
barcodes were attached. Libraries were sequenced on Ion Torrent PGM/Ion
Proton sequencers. For detection of reads containing the clonal sequence from
diagnosis we used our own bioinformatics algorithm.
Results: We sequenced 213 samples from 63 patients with childhood ALL
treated according to the AIEOP-BFM-ALL 2000 protocol and 14 more patients
with relapse from previous and current frontline treatment protocols with the
median coverage 719,904 reads per sample. Eighty-four (39.4%) samples
were negative by both methods. Sixteen (7.5%) samples were positive by NGS
and negative by qPCR, and 16 (7.5%) samples were positive by qPCR and
negative by NGS. This caused a shift in risk group stratification in 30% of
patients, mainly between standard risk and intermediate risk group patients.
The overall correlation of both methods was good (R2=0.71). NGS approach
detected significantly higher MRD than qPCR at day 33 in patients who later
relapsed (p=0.001). NGS-MRD positivity at day 33 seems to provide a more
accurate prediction of relapse than qPCR-MRD positivity (Figure 1A). At day
78, the predictive value of NGS was comparable to qPCR (Figure 1B). Com-
bined day 33 and 78 MRD used for defining of SR, IR and HR (+SER) groups
on BFM trials gave again similar results as qPCR (Figure 1C). Similarly to FC,
low NGS MRD defined a group with excellent prognosis at day 15.
Figure 1.
Summary and Conclusions: NGS will speed up the process of MRD detec-
tion and provide results at early time points, which is currently not possible
due to the long time needed for qPCR preparations. The correlation of NGS
and qPCR was good with the majority of the differrences below the repro-
ducible sensitivity of methods, which caused shifts mainly between SR and
IR groups. We showed that day 33 NGS MRD levels were higher than qPCR
MRD levels in patients who subsequently relapsed, which was reflected in a
slightly better prediction of relapse based on d33 NGS. The outcome of
patients stratified into risk groups by combined d33/d78 MRD was similar for
NGS and qPCR, despite the 30% of patients being differently stratified by
NGS. At present, the main drawback of the Ig/TCR-exploring NGS methods
is the lack of standardization both in the experimental setting and in data
analysis. Therefore, the European network “EuroClonality NGS Consortium”,
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has been formed to optimize and standardize NGS workflow..Before NGS
based MRD can safely replace qPCR for treatment guiding in ALL, robust
results on comparability of both methods by standardized methodology should
be validated within prospective clinical trials. 
Supported by IGA NT14343, GAUK 394214 and CZ.2.16/3.1.00/24022OPPK.
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HIGH THROUGHPUT SEQUENCING AS A MEASURE OF EARLY
RESPONSE TO THERAPY IN CHILDHOOD ALL
I. Kirsch1,* D. Williamson1, B. Wood2, M. Loh3, H. Robins4
1Adaptive Biotechnologies, 2University of Washington, Seattle, 3University of
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Background: Early response to induction chemotherapy has been demon-
strated to be one of if not the most significant prognostic factors in the outcome
of children with acute lymphoblastic leukemia. Multiparametric flow cytometry
(mpFC) has been the routinely used methodology in the US for the determina-
tion of this response. New high throughput sequencing (HTS) technologies of
rearranged immune receptor (TCR and Ig) genes have raised the possibility of
a more accurate, sensitive, and standardizable approach to determination of
early response to therapy in ALL patients.
Aims: In this study, we investigated whether the Adaptive Biotechnologies
immunoSEQ assay of IgH (immunoglobulin heavy chain (VDJ/DJ) and TCRG
(T-cell receptor gamma) would be able to quantify residual disease at the end
of induction therapy for children with ALL and be of prognostic value with regard
to outcome (relapse free survival and overall survival) in these patients.
Methods: This study involved a total of 432 patients enrolled on COG clinical
trials AALL0331 and AALL0232 for whom mpFC measurement of residual dis-
ease was <0.1% and for whom outcome data are available. 
MpFC was performed at the University of Washington and Johns Hopkins as
part of the evaluation for MRD. Genomic DNA was extracted from frozen bone
marrow specimens collected at diagnosis and at day 29 post the start of induc-
tion therapy. High throughput sequencing of CDR3 regions of IGH and TCRG
was performed on all samples. Diagnostic and d29 matched samples from a
given patient were sequenced and dominant (>5%) clonal CDR3 sequences
from diagnosis were searched for in the corresponding d29 sample. An exact
100 base pair match was required for identification of the sequence as residual
disease in the follow-up sample. Both the presence and the frequency of the
MRD clone relative to the total IGH repertoire and total nucleated cell population
were determined.
Results: The assays defined the dominant clonal sequences in >90% of the
patients. Approximately 60% of this subgroup was found to have residual dis-
ease present at d29. Clones from some of the patients demonstrated a single
“trackable” sequence while clones from other patients demonstrated multiple
trackable sequences either within or between the two immune receptor loci
being assessed. Approximately, 50% of the residual disease detected by HTS
was beneath the level of sensitivity of mpFC and therefore previously read out
as MRD negative. Correlations between mpFC and HTS and independent cor-
relations of each of these two methodologies with outcome will be presented.
Summary and Conclusions: This is the largest patient cohort studied to date
for which mpFC, HTS, and outcome data are all available. This study allows an
informative assessment of the capability of HTS to determine early response
to induction chemotherapy and the relevance of that determination to patient
outcome.
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GENOMIC DNA BREAKPOINTS IN MLL AND TRANSLOCATION PARTNER
GENES IN A LARGE COHORT OF INFANTS WITH ACUTE LEUKEMIA
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Background: Acute leukemia (AL) in infants is characterized by high incidence
of MLL gene rearrangements.
Aims: To evaluate the relation between genomic DNA breakpoints in MLL and
translocation partner genes (TPGs) and clinical parameters of infant AL.
Methods: 87 infants (32 boys (37%) and 55 girls (63%), median age 4.9 mo)
with MLL-rearranged acute lymphoblastic leukemia (ALL) (n=63), acute myeloid
leukemia (AML) (n=22) and mixed phenotype acute leukemia (MPAL) (n=2)
were included in the current study. Genomic DNA breakpoint detection in MLL
gene and translocation partner genes (TPGs) was performed by long-distance
inverse PCR (LDI-PCR). Exon-intron numbering of MLL gene was done accord-
ing to I. Nilson et al., 1996.
Results: Majority of ALL cases was characterized by presence of MLL-AF4
fusion gene (FG) (n=35;55%), less frequently MLL-MLLT1 (n=12;22%), MLL-
MLLT3 (n=8;13%) and others were found (Table 1). The most common break-
point location within MLL gene in ALL patients was intron 11, detected in 31
cases (49%), less frequently breakpoints in intron 10 (n=13;21%) and intron 9
(n=9;14%) were found. The highest variability of MLL breakpoints was found in
MLL-AF4-positive patients: only 15 of 35 (43%) had breakpoints in intron 11.
The most stable pattern of MLL genomic DNA breakpoints was observed in
MLL-MLLT1-positive patients: 9 of 14 (64%) had breakpoints in intron 11. In
AML patients the most prevalent FG was MLL-MLLT3 (n=8;36%). The remain-
ing ones are listed in Table 1. The most frequent breakpoint location was intron
9 (n=10;45%), less often they were found in intron 10 (n=5;23%) and 11
(n=4;18%). The most stable pattern was revealed for MLL-MLLT10 FG: MLL
breakpoints in 4 of 5 (80%) cases were found in intron 9 (Table 1). In TPGs the
most frequent breakpoint locations were as follows: in AF4-intron 3 (n=25;69%)
and intron 4 (n=7;19%); in MLLT1-non-coding region between ACER1 and
MLLT1 (n=9;60%) and intron 1 (n=5;33%); in MLLT3-intron 5 (n=13;81%); in
MLLT10-intron 8 and intron 9 (n=2;33% each); in EPS15-intron 1 (n=3;75%).
The pattern of breakpoints locations in TPGs was similar in ALL, AML and MPAL
cases. Distribution of DNA breakpoints in MLL gene was similar in boys and
girls and did not depend on type of TPG. ALL patients who had breakpoints in
intron 11 were significantly younger (median 3.0 mo, range 0.03-11.6) than all
others (median 5.6 mo, range 0.7-11.9) (p=0.025) and than patients with MLL
breakpoints in intron 9 (median 6.6 mo, range 3.1-11.9) (p=0.017). For AML
cases we did not find any relation between age and breakpoints locations. We
estimated prognostic significance of MLL breakpoint locations in 46 cases of
infant ALL homogenously treated by MLL-Baby protocol. 5-year EFS was sig-
nificantly lower in patients with breakpoint in intron 11 (n=29) in comparison to
patients with breakpoints localized from intron 7 to exon 11 (n=17) (0.16±0.07
vs 0.38±0.14 p=0.035). While cumulative incidence of relapse was remarkably
higher in the first group of patients (0.80±0.33 vs 0.56±0.20 p=0.020). Median
follow-up time was 36 months. Although in Cox regression model including
breakpoint position together with age, immunophenotype, initial WBC count,
initial CNS involvement, type of MLL rearrangement, absolute blast number at
day 8 of dexamethasone profase, minimal residual disease (MRD) at time point
4 (TP4) of MLL-Baby protocol, the only significant covariate was the presence
of MRD at TP4 (HR 3.160, 95% CI 1.159-17.815, p=0.021).
Table 1.
Summary and Conclusions: Our data provide additional information of molec-
ular genetic features of MLL-rearranged infant AL.
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Background: Asparaginase is a cornerstone in the treatment of ALL, but its
utility is limited by toxicities including hypersensitivity. Clinical allergy is asso-
ciated with inactivation of asparaginase by antibodies (A-Abs), which can also
neutralize asparaginase without any clinical signs of hypersensitivity (silent
inactivation). ERY001 improves pharmacokinetics, tolerability and maintain cir-
culating asparaginase (ASPA) activity due to the protective barrier of the ery-
throcyte membrane.
Aims: The study aimed at evaluating the efficacy and safety of ERYASP
Methods: This open, randomized international Phase 3 study enrolled pts with
relapsed ALL. The co-primary endpoints were the duration of ASPA activity
>100IU/L and the incidence of ASPA hypersensitivity during induction. Key sec-
ondary endpoints were complete remission (CR), minimal residual disease
(MRD), event free survival (EFS) and overall survival (OS).The study was pow-
ered to detect 3-fold difference in the incidence of allergic reactions between
treatments. Pts (n=80), aged 1-55 years were randomized to ERY001 (150 IU/kg,
n=26 or L-ASP (10,000 IU/m², n=28), or to ERY001-exp (prior allergy, n=26).
Results: In the non-allergic pts, ERY001 significantly reduced the incidence
of ASPA hypersensitivity (0% vs 43%; p<0.001). ASPA activity >100 IU/l was
21±5 vs 9±8 days in ERY001 and L-ASP, respectively (p<0.001). The CR rate:
ERY001 (65%, 95% CI: [51.6:89.8]) vs L-ASP (39%, 95% CI: [23.3:63.1];
p=0.026). Allograft was successfully performed in 65% of ERY001 vs 46% of
L-ASP. The proportion of patients who achieved MRD<10-3 in F1-F2/VANDA
was 35% and 25% in ERY001, and L-ASP arms, respectively. At 12 mo, EFS
rate was 65% and 49% in ERY001 and L-ASP arm, respectively. Treatment
with ERY001 was well tolerated.
Summary and Conclusions: ERY001 provides an alternative option for
patients with relapsed ALL, which is well tolerated and efficacious.
Stem cell transplantation: Clinical 2
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DROPLET DIGITAL PCR FOR DNMT3A AND IDH1/2 MUTATIONS TO
IMPROVE EARLY DETECTION OF ACUTE MYELOID LEUKEMIA RELAPSE
AFTER ALLOGENEIC HSCT
C. Brambati1,* E. Xue1,2, C. Toffalori1, S. Galbiati3, L. Crucitti2, R. Greco2,
A. Crippa4, L. Chiesa1, N. Soriani3, B. Mazzi1, C. Tresoldi4, J. Peccatori2,
M.G. Carrabba2, M. Bernardi2, M. Ferrari3, V. Lampasona3, F. Ciceri2, L. Vago1,2
1Unit of Molecular and Functional Immunogenetics, 2Hematology and Bone
Marrow Transplantation Unit, 3Genomics for the Diagnosis of Human Patholo-
gies Unit, 4Immunohematology and Transfusion Medicine, IRCCS San Raffaele
Scientific Institute, Milano, Italy
Background: Despite the considerable improvement documented over the last
two decades in the outcome of allogeneic Hematopoietic Stem Cell Transplan-
tation (allo-HSCT) for Acute Myeloid Leukemia (AML), disease relapse still rep-
resents a major unsolved issue, and efforts are aimed to anticipate relapse detec-
tion and treatment to the Minimal Residual Disease (MRD) stage. Recent studies
demonstrated that mutations in the DNMT3A and IDH1/2 genes occur very early
during the step-wise process of leukemogenesis, possibly representing disease
founder mutations and thus optimal markers for MRD tracking.
Aims: To investigate the clinical utility of ultra-sensitive tracking of DNMT3A,
IDH1 and IDH2 mutations as post-transplantation MRD monitoring technique.
Methods: By conventional Sanger sequencing, we screened for 6 mutations of
interest (DNMT3A R882H and R882C, IDH1 R132C and R132H, IDH2 R140Q
and R172K) 86 AML diagnosis samples from patients who underwent allo-HSCT.
113 bone marrow samples collected longitudinally over time from the 23 patients
who carried at least one of the mutations were analyzed by ultra-sensitive droplet
digital PCR (ddPCR) assays. As controls, we tested bone marrow samples col-
lected at diagnosis from 11 patients typing negative for the mutations, and periph-
eral blood samples from 19 healthy individuals. ddPCR assays were performed
using the Bio-Rad QX100 system: each sample was tested in duplicates, employ-
ing 25 ng of genomic DNA in each reaction well. Samples with a mutant-to-wild-
type ratio above 0.1% were considered positive. ddPCR results were compared
to those obtained testing the same samples by quantitative PCR (qPCR) assess-
ment of the WT1 gene transcript and of hematopoietic chimerism.
Results: All the samples which resulted positive by conventional sequencing
were confirmed by ddPCR, and in all of them the population carrying the mutant
allele, quantified by ddPCR, consistently exceeded the morphological count of
leukemic blasts, suggesting the presence of the mutation also in apparently
normal bone marrow hematopoietic cells. All the samples tested at post-trans-
plantation relapse remained positive for the mutations present at diagnosis,
except for one case, originally carrying both DNMT3A and IDH2 mutations and
typing negative for the latter at relapse. This observation might argue against
the putative role of IDH mutations as leukemia-founder events, and suggests
that, when present, DNMT3A could represent a more reliable MRD marker.
When post-transplantation remission samples were tested, 55/60 (92%) of
those harvested from 7 patients who remained long-term leukemia-free (median
follow-up after allo-HSCT: 24 months) resulted negative for the mutations of
interest. 4/5 of the samples which resulted positive belonged to the early time-
points of a single patient who progressively decreased the mutation burden
until becoming negative. 6/7 patients who relapsed presented at least one
sample harvested during apparent disease remission which resulted positive
by ddPCR, anticipating hematological relapse of at least one month. Of notice,
only 3 of those relapsed patients had displayed WT1 transcript overexpression
and only one had displayed host chimerism above the 1% threshold.
Summary and Conclusions: Although the small number of patients included
in this preliminary analysis warrants for caution, ddPCR for DNMT3A and
IDH1/2 mutations appears extremely promising, displaying very high specificity
and sensitivity in relapse prediction, and comparing favorably with current
qPCR-based post-transplantation monitoring techniques.
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KIR2DS4 AND ITS VARIANT KIR1D ARE ASSOCIATED WITH AGVHD, CMV
AND OS AFTER SIBING RELATED HLA MATCHED TRANSPLANTATION
FOR PATIENTS WHOSE DONORS BELONG TO KIR GENE HAPLOTYPE A
X. Wu1,* Y. Yao1, X. Bao1, X. Tang1, H. Zhou1, Y. Han1, C. Fu1, A. Sun1, X. Ma1,
J. Chen1, Y. Xu1, J. He1, D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Hematopoietic stem cell transplantation (HSCT) outcomes of
donor and recipient KIR genotypes have been extensively studies. However,
the association of KIR2DS4 and its variant KIR1D with outcomes in patients
who transplanted from a donor for KIR haplotye A after sibing related HLA
matched transplantation has not been explored. 
Aims: To the association of KIR2DS4 and its variant KIR1D with outcomes in
patients who transplanted from a donor for KIR haplotye A after sibing related
HLA matched transplantation.
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Methods: To study this, 165 patients transplanted from KIR gene haplotype A
were genotyped and divided into three groups: 2DS4+/1D- (two intact KIR2DS4
alleles), 2DS4+/1D+ (heterozygous), 1D+/1D+ (homozygous for the deletion
variant KIR1D). No difference of the recovery of neutrophils and platelets was
observed in the three groups.
Results: The cumulative incidences of Grade III-IV acute GVHD were 28.94%,
14.11% and 44.44%, respectively, in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+
groups within day+100 (P=0.0159). Multivariate analysis identified 1D+/1D+ was
an independent risk factor for aGVHD (HR=4.221, 95%CI 1.470-12.124,
P=0.007). In contrast, the cumulative incidences of chronic GVHD, 3-year cumu-
lative relapse, and treatment-related mortality displayed no significant difference.
The rate of CMV reactivation were 46.96%, 20.16% and 53.25% in the 2DS4+/1D-
, 2DS4+/1D+ and 1D+/1D+ groups (P=0.0017). Multivariate analysis identified
2DS4+/1D+ was an independent protective factor for CMV reactivation
(HR=0.268, 95%CI 0.125-0.574, P=0.001). Although the overall survival (OS)
showed no difference in the first year, the OS of 2DS4+/1D- group showed a sig-
nificant superiority over the other groups after one year (P=0.0361). In the disease
stage of advanced patients, the 3-year probability of DFS were 51.06%, 34.01%
and 0% in the 2DS4+/1D-, 2DS4+/1D+ and 1D+/1D+ group (P=0.0314).
Summary and Conclusions: Collectively, our data suggest that the KIR
2DS4/1D allelic variance is associated with the outcome of sibling related HLA
matched HSCT, and donor subclassification of KIR 2DS4/1D alleles should be
consider in this setting.
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HUMAN ATRIAL NATRIURETIC PEPTIDE (HANP) THERAPY IN THE EARLY
PHASE AFTER ALLOGENEIC STEM CELL TRANSPLANT (ALLO-SCT)
PREVENTS DEVELOPMENT OF CHRONIC KIDNEY DISEASE (CKD):
RESULTS FROM A PHASE 2 STUDY
H. Shimizu1,* T. Ishizaki1, N. Hatsumi2, S. Takada2, A. Yokohama1, T. Saitoh1,
T. Sakura2, H. Handa1
1Hematology, Gunma University, 2Leukemia Research Center, Saiseikai Mae-
bashi Hospital, Maebashi, Gunma, Japan
Background: Reducing late complications in allo-SCT recipients is an urgent
issue in the field of transplant. One of the most serious complications is renal
impairment, which reportedly develops in around 20% of long-term survivors.
hANP is commercially available in Japan, and preserves postoperative renal
function in patients undergoing cardiovascular surgery. These findings inspired
us to investigate the renoprotective effects of hANP administration in allo-SCT
recipients.
Aims: The primary objective was to determine the safety, toxicity, and efficacy
of hANP administration in the early phase after allo-SCT.
Methods: A prospective phase II study of hANP therapy for preventing renal
impairment in allo-SCT recipients was conducted with the permission of the insti-
tutional review board. Eligible subjects underwent allo-SCT for the first time
between 2009 and 2013 without any restrictions on underlying disease, donor
source, or conditioning regimen. After obtaining written informed consent, hANP
administration was started the day before transplant at a dose of 0.025 μg/kg/min.
This dose was adjusted according to blood pressure and urine volume. Results
were compared between the study group and control group who had undergone
allo-SCT between 2006 and 2013. We selected a control cohort at the rate of
one to three, using an optimal matching method for the following nine factors:
age; sex; underlying disease; disease status; conditioning intensity; conditioning
with or without total body irradiation (TBI); human leukocyte antigen disparity;
donor type; and estimated glomerular filtration rate (eGFR) at baseline.
Results: Eighteen patients (9 men, 9 women; median age, 45 years; range, 18-
64 years) were enrolled in this study. Underlying diseases were acute leukemia
(n=6), myelodysplastic syndrome (n=6), and others (n=6). Eight, seven, and three
patients received transplants from related donors, unrelated donors, and cord
blood, respectively, and most patients were conditioned with TBI-containing mye-
loablative regimens. Median duration of hANP administration was 16 days (range,
3-46 days). Two patients experienced grade 2 hypotension attributable to hANP
administration, but both cases resolved immediately upon discontinuation of
hANP administration. In addition, hANP administration was discontinued in two
patients, due to grade 4 bacterial meningitis and grade 4 sepsis, respectively.
For matched-pair analysis, 54 patients were selected, and no significant differ-
ences in clinical characteristics were identified between the study and control
groups. Although mean eGFR kept declining after transplant in both groups,
hANP administration maintained eGFR at a significantly higher level until 30 days
after transplant (p <0.001). Incidences of acute kidney injury within 30 days after
transplant did not differ significantly between groups, but that within 90 days was
significantly lower in the study group (11.1%) than in the control group (40.7%;
p=0.023). The incidence of CKD by 1 year after transplant was significantly
reduced in the study group (0%) compared to the control group (42.9%; p=0.005).
Two-year cumulative incidence of non-relapse mortality and 2-year overall survival
rates were similar between groups.
Summary and Conclusions: Our findings demonstrated that hANP adminis-
tration in the early phase after allo-SCT offers excellent renoprotective effects,
resulting in a significant reduction in CKD development, without any serious
adverse events in allo-SCT recipients. These findings should be confirmed in
a prospective, randomized manner in the near future.
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ALLOGENEIC TRANSPLANTATION FOR MYELOFIBROSIS: HIGH DOSE
INTENSITY AND EARLY DISEASE STATE ARE FAVORABLE PROGNOSTIC
FACTORS.
U. Popat1,* R. Bassett1, J. Chen1, A. Alousi1, P. Anderlini1, S. Ahmed1,
S. Ciurea1, C. Hosing1, R. Jones1, P. Kebriaei1, I. Khouri1, Y. Nieto1, A. Olson1,
B. Oran1, M. Qazilbash1, G. Rondon1, E. Shpall1, S. Verstovsek1, B.S. Andersson1,
R. Champlin1
1The University of Texas MD Anderson Cancer Center, Houston, United States
Background: The Best conditioning regimen, i.e. one that is both safe and
efficacious for treatment of patients with myelofibrosis (MF) is not known. After
observing a higher relapse rate in the initial cohort receiving a reduced intensity
regimen, we increased the intensity of the conditioning regimen for subsequent
patients, hypothesizing that increased dose intensity delivered with pharmaco-
kinetic- (PK-) dose guidance will reduce the relapse rate without increasing
non-relapse mortality (NRM), and thereby improving overall outcome.
Aims: To report final results of a prospective phase II clinical trial of Fludarabine
(Flu) and busulfan (bu) conditioning in MF patients with a median follow-up of
5 years.
Methods: Patients with advanced MF were eligible if they had adequate organ
function and at least 9/10 HLA matched related or unrelated donor. All 46 patients
received fludarabine 40 mg/m2x4 (day -5 to -2), and in the first 15 (bu low group)
IV busulfan 130 mg/m2/dayx2 was given after the Flu dose on days -3,and -2).
Of the remaining 31 (bu high group), 27 received IV busulfan dose to a target
daily systemic exposure, AUC, of 4000 μmol-minx4, given on day -5 to -2, (total
course AUC of 16,000 μmol-min) and 4 patients received a fixed dose of 100
mg/m2/dayx4 (days -5 to -2), each Bu dose was preceded by the day’s Flu dose. 
Results: 23 males and 23 females with a median age of 58 years (27-74) had
intermediate (27 Int-2, 1 Int-1) or high-risk (18) disease as per Dynamic inter-
national prognostic scoring system plus (DIPSS plus) criteria. Donors were
matched sibs (19), matched unrelated (23), or mismatched unrelated (4).All
patients engrafted with a median time to neutrophil engraftment of 13 (0-27)
days and a median time to platelet engraftment of 24 (0-268) days. The Cumu-
lative incidence (CI) of grade II-IV, grade III, and IV acute GVHD, and Chronic
GVHD were 22%, 7%, and 40%, respectively. With a median follow up of sur-
viving patients of 5.1 years (range 1-8.3 years), 3 year overall survival (OS),
event-free survival (EFS), cumulative incidence (CI) of non-relapse mortality
(NRM), and CI of relapse were 69%, 48%, 13%, and 39%, respectively. Multi-
variate Cox regression analysis showed that Bu-high dose (HR 0.44; P=0.07)
was associated with lower relapse rate. Bu-high dose (HR 0.5; P=0.09), DIPSS
plus high (HR 2.69; P=0.02) and Age (HR 1.05; P=0.08) were predictors of
EFS (Figure 1). DIPSS plus high (HR 5.99; P=0.001) and Age (HR 1.07;
P=0.03) were adverse predictors of OS.
Figure 1.
Summary and Conclusions: Allogeneic transplantation results in long-term sur-
vival in patients with myelofibrosis with better outcome seen in earlier phase of
the disease. PK guided myeloablative busulfan (AUC 16,000 μmol.min) appears
promising in reducing relapse rate without increasing non-relapse mortality.
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UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF CTLA4
BLOCKADE WITH IPILIMUMAB FOR RELAPSED HEMATOLOGIC MALIG-
NANCIES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
M.S. Davids1,* H.T. Kim1, C. Costello2, D. Avigan3, Y.B. Chen4, P. Armand1,
E.P. Alyea1, J. Hedlund5, P. McSweeney6, R. Liguori1, J. Ritz1, E.D. Ball2,
A. Bashey7, R.J. Soiffer1
1Medical Oncology, Dana-Farber Cancer Institute, Boston, 2Division of BMT,
University of California San Diego Moores Cancer Center, La Jolla, 3BMT Pro-
gram, Beth Israel Deaconess Medical Center, 4BMT Program, Massachusetts
General Hospital, Boston, 5New England Cancer Specialists, Scarborough,
6Colorado Blood Cancer Institute, Denver, 7Blood and Marrow Transplant
Group of Georgia, Northside Hospital, Atlanta, United States
Background: Patients with hematologic malignancies (HM) who relapse after
alloHCT often have a dampened graft versus tumor (GVT) effect and limited
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treatment options. Immune checkpoint modulation with CTLA4 blockade could
be a novel pharmacologic strategy to augment GVT to restore the anti-tumor
activity of the graft.
Aims: This is an ongoing multicenter phase I/Ib study of the CTLA4 blocking
antibody ipilimumab to treat patients (pts) with HM of any histology who relapse
after alloHCT. The primary aims are to determine the MTD and evaluate safety.
Secondary aims include assessments of efficacy and changes in immune cell
phenotype. 
Methods: After informed consent was obtained, ipilimumab was given off-label
at 3 mg/kg or 10 mg/kg IV every 3 weeks for 4 cycles of induction, followed by
maintenance dosing every 12 weeks up to 1 year. Disease-specific response
criteria were assessed at the mid-point (7 weeks), end of induction (13 weeks),
and throughout maintenance. Immunophenotyping was performed by 8-color
flow cytometry and analyzed by FACSDiva.
Results: Twenty-seven pts have received treatment to date. In phase I, 6
pts were treated at 3 mg/kg and 7 pts were treated at 10 mg/kg. An MTD was
not reached, and 14 pts subsequently enrolled in the phase Ib expansion
cohort at 10 mg/kg. The median number of prior therapies excluding trans-
plant was 3 (range 2-11), and 19/27 (70.4%) of pts had received prior therapy
for post transplant relapse. Histologies included AML (n=11), cHL (n=7), NHL
(n=4), and MDS (n=2), and 1 pt each had MM, MPN, and ALL. The median
age at enrollment was 58 yrs. (range 22-75). Immune-related adverse events
(irAEs) were observed in 4 pts, including pneumonitis (n=1 gr2, n=2 gr4),
diarrhea (n=2 gr 1), ITP (n=1 gr2), and colitis (n=1 gr 3), and were reversible
with steroids, with 3 pts able to resume ipilimumab. Four DLTs leading to dis-
continuation have been observed, including cGVHD (n=2, both liver, gr 3),
aGVHD (n=1, gut, gr 2), and TRM (n=1) due to presumed sepsis in the con-
text of severe irAEs. Seventeen patients discontinued due to progressive
disease, and 6 patients remain on active treatment. In an interim efficacy
analysis, while none of the 5 evaluable pts treated at 3 mg/kg responded, 8
of the 20 (40.0%) evaluable pts treated at 10 mg/kg had anti-tumor activity.
Six pts achieved formal response by disease-specific criteria, including a
cHL patient with a PR with dramatic reduction in nodal and extranodal disease
and a marrow CR at 7 weeks (see Figure 1), a MM pt with a PR with near
resolution of a lung plasmacytoma, and four pts with AML who achieved CR,
including two with leukemia cutis and one with myeloid sarcoma. The median
follow-up time among survivors is 5.5 mo., and 6 mo. OS is currently 66%.
Immunophenotyping studies revealed that while the absolute numbers of
both Treg and Tconv cells increased slightly after ipilimumab, the ratio of
Treg/Tconv decreased (range 24% to 41% decrease).
Figure 1. Baseline and week 7 re-staging studies in a classical Hodgkin
lymphoma patient after 2 doses of ipilimumab at 10 mg/kg. A. PET/CT
scan and B. bone marrow (CD30 stain).
Summary and Conclusions: While some toxicity including irAEs and GVHD
was seen with ipilimumab 10 mg/kg in pts with relapsed HM after alloHCT,
substantial anti-tumor activity was also observed in pts with both lymphoid and
myeloid malignanices, including highly chemorefractory diseases such as
leukemia cutis and myeloid sarcoma. The Treg/Tconv cell ratio decreased with
treatment, consistent with enhancement of GVT. Immune checkpoint modula-
tion with CTLA4 blockade may be a promising new therapeutic approach for
post alloHCT relapse, and is worthy of exploration in future studies.
MPN: Prognosis and treatment
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RISK FACTORS FOR THROMBOHEMORRHAGIC AND TRANSFORMA-
TION EVENTS IN 3649 HIGH-RISK PATIENTS WITH ESSENTIAL THROM-
BOCYTHEMIA: RESULTS FROM THE PROSPECTIVE LONG-TERM
OBSERVATIONAL EXELS STUDY
G. Birgegård1,* C. Besses2, M. Griesshammer3, L. Gugliotta4, C. Harrison5,
M. Hamdani6, H. Achenbach7, J.-J. Kiladjian8
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Background: The observational EXELS study (NCT00567502) is the largest
prospective cohort of high-risk patients (pts) with essential thrombocythemia
(ET) reported to date.
Aims: Study objectives included safety, pregnancy outcomes, and efficacy
(measured by incidence of thrombohemorrhagic events and platelet reduction)
of anagrelide (ANA) compared with other cytoreductive therapies (CRTs). The
multivariate (MV) analysis aimed to identify risk factors for thrombohemorrhag-
ic/transformation events.
Methods: Eligible pts were enrolled across 13 European countries between
2005 and 2009. Data were collected every 6 mo for 5 yrs. Event rates are pre-
sented as number of pts per 100 pt-yrs exposure and by treatment at registra-
tion. A Cox proportional hazards model was used for the MV analysis to predict
events based on certain risk factors. All pts provided informed consent. This
study was sponsored by Shire Pharmaceutical Development Ltd.
Results: 3649 pts were categorized according to treatment at registration:
ANA (n=804), ANA+other CRT (n=141), other CRT (n=2666), and no CRT
(n=38). More than 80% of pts received either hydroxycarbamide (HC) or ANA.
Median age was lower in the ANA (55.5 yrs) vs other CRT group (70.0 yrs).
Thrombohemorrhagic and malignancy event rates are displayed in Table 1.
Median platelet counts in the ANA vs other CRT group were 443 vs 428x109/L,
respectively, at baseline, and 402 vs 430x109/L, respectively, at the time of
major thrombotic event. Median white blood cell (WBC) counts in the ANA vs
other CRT group were 8.8 vs 6.0x109/L, respectively, at baseline, and 9.0 vs
6.2x109/L, respectively, at the time of major thrombotic event. 64 pts trans-
formed to myelofibrosis (MF) and 31 to acute leukemia (AL). In pts who had
only ever received either ANA or HC, the rate of transformation to MF was
higher in the ANA vs HC group (0.78 vs 0.17), whereas transformation to AL
was higher in the HC vs ANA group (0.22 vs 0). Non-hematological malignancy
event rate was higher in the other CRT vs ANA group. MV analysis identified
both a history of thrombohemorrhagic events and age ≥65 yrs at baseline as
risk factors for predicting thrombohemorrhagic (hazard ratio [HR] 1.91 and
1.67), major thrombotic (HR 2.05 and 2.14), arterial thrombotic (HR 1.81 and
1.90), venous thrombotic (HR 3.70 and 3.27), and transformation to
AL/myelodysplasia (MDS) events (HR 2.17 and 3.36). Presence of baseline
cardiovascular risk factors increased the risk of major thrombotic (HR 1.38)
and arterial thrombotic events (HR 1.65), while baseline hypertension was a
risk factor for thrombohemorrhagic events (HR 1.33). ET diagnostic criteria
(WHO vs PVSG) and aspirin at registration were not identified as risk factors
for thrombohemorrhagic events. Time since diagnosis (5-<10 yrs; ≥10 yrs) and
baseline platelet count increase of 100 units above normal (≤450x109/L) were
both identified as risk factors for transformation to MF (HR 3.38; 4.38 and 5.34).
Table 1.
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Summary and Conclusions: In this large prospective study population, MV
analysis identified the following baseline risk factors for thrombohemorrhagic
events: history of thrombohemorrhagic events, age ≥65 yrs, cardiovascular risk
factors, and hypertension. In contrast, within each treatment group, the baseline
platelet and WBC counts do not appear to be significantly different at the time
of major thrombotic events. A history of thrombohemorrhagic events, age ≥65
yrs, time since diagnosis, and platelet count increase of 100 units above normal
were identified as baseline risk factors for transformation to AL/MDS/MF.
S447
RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH
POLYCYTHEMIA VERA: 80-WEEK FOLLOW-UP FROM THE RESPONSE
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Background: RESPONSE, an ongoing, multicenter, open-label, phase 3 trial,
compared the efficacy and safety of ruxolitinib (Rux) with best available therapy
(BAT) in patients with polycythemia vera who are resistant to or intolerant of
hydroxyurea. Primary analysis results - at 48 weeks from last patient first treat-
ment (LPFT) - have been published (Vannucchi. NEJM 2015;372(5):426-435).
Aims: To perform a second preplanned analysis assessing the long-term effi-
cacy and safety of Rux 80 weeks after LPFT.
Methods: Patients ≥18 years of age, who were resistant to or intolerant of
hydroxyurea per modified ELN criteria, with splenomegaly, and phlebotomy
requirement to control hematocrit (Hct) were eligible. Patients were randomized
1:1 to receive open-label Rux 10 mg BID or BAT; the latter was selected based
on investigator’s choice. Patients randomized to BAT could cross over to Rux
from week 32. The primary response was a composite of (1) achieving a ≥35%
reduction from baseline in spleen volume by imaging at week 32 and (2) Hct
control without phlebotomy through week 32 (defined as no phlebotomy eligi-
bility between weeks 8 to 32 with no more than 1 phlebotomy eligibility from
randomization to week 8). Durability of the primary response, Hct control, spleen
volume reduction, complete hematologic remission (CHR), as well as long-
term safety, were evaluated.
Results: Overall, 222 patients were randomized (Rux, 110; BAT, 112). At the
week 48 analysis, 93 (84.5%) patients randomized to Rux (Rux arm) were still
receiving treatment (median exposure, 81 weeks); at the data cutoff for the
week 80 anaysis, 91 (82.7%) patients in the Rux arm were still receiving treat-
ment (median exposure, 111 weeks). No patients remained on BAT at the data
cutoff for the week 80 analysis, compared with 3 patients at the week 48 analy-
sis. The primary endpoint was achieved in 23 (20.9%) patients in the Rux arm
vs 1 (0.9%) patient in the BAT arm (P <0.0001). Among the responders in the
Rux arm, only 1 patient lost this response (Figure 1). Overall, 60.0% of Rux
patients vs 19.6% of BAT patients achieved Hct control without phlebotomy
through week 32; patients achieving Hct control in the Rux arm had an 89%
probability of maintaining this response for 80 weeks from the time of initial
response. Of the 98 patients on Rux at week 32, 89.8% did not have a phle-
botomy between weeks 32 and 80. At week 32, 38.2% vs 0.9% of patients in
the Rux vs BAT arm achieved a ≥35% reduction in spleen volume; all Rux
patients maintained their response. At week 32, CHR was achieved in 23.6%
of Rux patients and 8.9% of BAT patients, with Rux responders having a 69%
probability of maintaining CHR for 80 weeks. Among patients who discontinued,
5 of 10 in the Rux arm with available data for the Pruritus Symptom Impact
Scale at their end-of-study visit rated their pruritus as “very much improved.”
Nonhematologic adverse events were mainly grade 1 or 2; the most common
in the Rux arm included headache (21.8% at the week 80 analysis [ie, entire
follow-up] vs 20.9% at the week 48 analysis), diarrhea (20.0% vs 19.1%), pru-
ritus (20.0% vs 17.3%), and fatigue (17.3% vs 17.3%). Grade 3 or 4 anemia
and thrombocytopenia in the Rux arm did not increase from the week 48 analy-
sis, occurring in 1.8% and 5.5% of patients, respectively. Treatment discontin-
uation due to adverse events remained low in the Rux arm (4.5%).
Figure 1. Durability of primary response with rux.
Summary and Conclusions: In the RESPONSE study, Rux benefit was
durable and treatment remained generally well tolerated, with 82.7% still receiv-
ing Rux at a median exposure of 111 weeks.
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RUXOLITINIB (RUX) IN COMBINATION WITH 5-AZACYTIDINE (AZA) AS
THERAPY FOR PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
N. Daver1,* J. Cortes1, L. Zhou1, N. Pemmaraju1, E. Jabbour1, G. Borthakur1,
Z. Estrov1, G. Garcia-Manero1, H. Kantarjian1, S. Verstovsek1
1Leukemia, The University of Texas MD Anderson Cancer Center, Houston,
United States
Background: AZA is a DNA methyltransferase (DNMT) inhibitor with a modest
response rate (20-25%) and duration (4 months) in MF. Ruxolitinib and azacytidine
may target distinct clinical and pathological manifestations of myelofibrosis.
Aims: To determine the efficacy and safety of the combination in pts with MF.
Methods: A sequential approach with single-agent RUX 15 mg orally twice
daily (if platelets 100-200) or 20 mg twice daily (if platelets >200) continuously
in 28-day cycles for the first 3 months followed by the addition of AZA 25 mg/m2
on days 1-5 of each 28-day cycle starting cycle 4 was adopted. The AZA dosage
could be gradually increased to a maximum of 75 mg/m2. Pts would be treated
on study for 15 months followed by continuation of the combination off-study at
the discretion of the treating physician.
Results: 35 pts were enrolled between March 2013 and October 2014. 22
(63%) had received a median of 2 (1-3) prior therapies for MF. 31 pts remain
alive after a med follow-up of 15.4 (3.4-22.8) months. Study is ongoing. 28 pts
have been on the study for at least 6 months and are evaluable for response.
International Working Group for Myelofibrosis Research and Treatment 2013
(IWG-MRT) objective responses were noted in 23 (82%), including PR in 1, CI
for spleen and total symptom score (TSS) in 5 (18), CI for TSS and hemoglobin
in 2 (7), CI for TSS only in 9 (32), and CI for spleen only in 6 (21). Responses
occurred in 14 of 18 (78%) previously treated patients and 9 of 10 (90%) untreat-
ed pts (P=0.42). Median time to all responses was 1.0 month (0.8-7.5 months).
Median time to CI in spleen size was 1.9 months (0.9-6.6), to CI TSS was 1.0
months (0.8-7.5), and CI Hb was 2.1 months (1.1-8.9). A reduction in the base-
line JAK2V617F allele burden was noted in 11 of 13 serially evaluable responders
with 2 of the responders demonstrating a >50% reduction in allele burden.
Serial evaluation of bone marrow fibrosis revealed a documented reduction in
EUMNET fibrosis score in 6 of 22 (27%) evaluable responders, after a median
of 8 months (5-13) on therapy. Only 5 of the 35 (14%) pts have not required a
dose interruption/dose adjustment. The med time to first dose interruption/dose
adjustment was 28 days (6-634). Among the 30 pts who needed a dose inter-
ruption/adjustment, 27 needed it within 3 months of initiation of the combination.
The first change was a dose reduction in 17 pts and a dose interruption in 5
pts. AZA was the agent interrupted in 4 of these pts: 1 never started AZA, 1
didn’t resume AZA and 2 resumed AZA at same dose. The reasons for the first
dose interruption were thrombocytopenia (n=2), neutropenia (n=1), knee
replacement (n=1), and pneumonia (n=1). The first change was a dose increase
in 8 pts. AZA was the first drug to be increased in 1 and RUX in 7. The reasons
for dose increase were leukocytosis (n=3), progressive splenomegaly (n=1),
thrombocytosis (n=2), and suboptimal response (n=3). At the time of submis-
sion, 8 patients completed the predefined 15 months on the study, and 20 pts
remain on study. Reasons for discontinuation in the remaining 7 pts included
AML transformation (n=2), toxicity (n=2), lack of response (n=1), death (n=1),
and patient preference (n=1). 4 pts experienced grade 3/4 non-hematological
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toxicity including fatigue (n=2), nausea (n=1), pneumonia (n=1), respectively
(Table 1).
Table 1. Baseline characteristic (N=35).
Summary and Conclusions: Administration of RUX with AZA was feasible and
resulted in improved response rate. The sequential addition of AZA was well tol-
erated with a lower incidence of early discontinuation than what has been seen
with other ruxolitinib combination therapies. A sequential rather than concomitant
approach may be considered when administering ruxolitinib combinations.
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EXCELLENT LONG-TERM PROGNOSIS OF IMATINIB-TREATED FIP1L1-
PDGFRA POSITIVE EOSINOPHILIA-ASSOCIATED MYELOPROLIFERA-
TIVE NEOPLASM IN CHRONIC OR BLAST PHASE 
G. Metzgeroth1,* J. Schwaab1, M. Jawhar1, N. Naumann1, W.-K. Hofmann1,
N.C. Cross2,3, A. Fabarius1, A. Reiter1
1III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany,
2Wessex Regional Genetics Laboratory, Salisbury, 3Faculty of Medicine, Uni-
versity of Southampton, Southampton, United Kingdom
Background: FIP1L1-PDGFRA (FP) is the most common fusion gene in
eosinophilia-associated myeloproliferative neoplasms (MPN-eo) and is exquis-
itely sensitive to treatment with imatinib. The vast majority of FP positive (FP+)
patients (pts) are diagnosed in chronic phase (CP) but rarely also in myeloid
or lymphoid blast phase (BP).
Aims: To evaluate the long-term prognosis of FP+ pts in CP or BP on imatinib.
Methods: Here we present the long-term follow-up of 62 imatinib-treated FP+
pts in CP (n=50) or BP (n=12). Median age was 49 years (range 19-70) with a
striking male predominance (61/62, 98%). All pts were treated with imatinib
(100-400mg/d) for a median of 79 months (range 2-140).
Results: In CP, complete molecular remission (CMR) was observed after 6,
12 and 24 months in 26/48 (54%), 35/42 (83%) and 38/39 (97%) of pts, respec-
tively, as investigated by qualitative nested RT-PCR. The median duration of
CMR was 73 months (range 3-129). Imatinib was reduced to 2-3x100mg/week
in 15 pts for a median of 28 months (range 1-96) and no relapse has yet been
observed. Imatinib was stopped in 4 pts with 3 pts remaining in CMR for 2, 19
and 20 months, respectively. One patient relapsed after 12 months but rapidly
achieved second CMR after rechallenge with imatinib. In BP, imatinib was used
as monotherapy (n=7) or after intensive chemotherapy (n=5). All pts achieved
durable CMR (median 95 months, range 66-132). Overall, imatinib was well
tolerated and no grade III-IV toxicities were observed. At the time of analysis,
3 pts had died (CP, n=1; BP, n=2) but no death was disease- or treatment-
related. Two pts developed a secondary resistance, 7 and 10 months after
start of imatinib. A T674I point mutation in the ATP-binding domain of FIP1L1-
PDGFRA was identified in one patient while the mechanism of resistance in
the second patient remained unknown. Because treatment with nilotinib and/or
sorafenib did not result in significant remissions, both pts received an allogeneic
stem cell transplantation (SCT) 5 and 8 months, respectively, after detection
of imatinib-resistance. Both pts achieved a rapid complete hematologic remis-
sion. One patient has been in stable CMR for 48 months while the second
patient died 18 months after SCT in ongoing CMR.
Summary and Conclusions: Treatment with imatinib in FP+ MPN-eo is asso-
ciated with an excellent long-term prognosis, even if pts are initially diagnosed
in myeloid or lymphoid BP. Complete remissions are rapidly achieved, are
durable and can be maintained with low-dose imatinib. Discontinuation of ima-
tinib may be feasible in some cases. Primary resistance has not yet been
reported and secondary resistance seems to be very rare. If it occurs, the effi-
cacy of second-generation tyrosine kinase inhibitors seems to be poor. Eligible
pts should therefore be offered an allogeneic SCT.
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION (HCT) IN PATIENTS WITH MYELOFIBROSIS (MF) EXPOSED TO
JAK1/2 INHIBITORS
M. Shanavas1,* U. Popat2, L.C. Michaelis3, V. Fauble4, D. Mclornan5, R. Klisovic6,
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Louis, United States
Background: JAK1/2 inhibitors (JAK#) have the potential to effectively control
MF-related symptoms, and improve the clinical status prior to HCT. However,
the clinical experience is limited, and data are conflicting. (Robin et al., Blood,
2013, ASH abstract 306; Stübig et al., Leukemia, 2014). Additionally, the rela-
tionship between the response to JAK #, and outcomes of HCT is not clear.
Aims: To report outcomes of HCT in MF patients exposed to JAK#
Methods: In this multi-institutional retrospective study, we evaluated the out-
comes of 93 MF patients (pts.) who had exposure to JAK# prior to HCT. A
working definition of response to JAK# was established inspired by International
Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-
MRT) criteria. (Table1). The primary end point was overall survival (OS) from
the date of HCT.
Table 1.
1. Gp-A: Clinical improvement: 50% reduction in palpable spleen length for spleen palpable
by 10 cm, or complete resolution of splenomegaly for spleen <10 cm).
2. Gp-B: Stable disease: spleen response not meeting the criteria of clinical improvement.
3. Gp-C: New onset anemia requiring transfusions, or increase in blast to 10-19%.
4. Gp-D: Progressive disease: Loss of spleen response or progression of splenomegaly.
5. Gp-E: Progressive disease: Leukemic transformation (blast 20%).
Figure 1. Probabilities of survival at 2 years and (95% CI).
Results: Median age at HCT was 59 years (range 32-72 years). Diagnosis
was primary-MF (n=53), post polycythemia-MF (n=20), or post essential throm-
bocythemia-MF (n=20). DIPSS-plus score at the time of HCT was low in 2
(2%), INT-1 in 19 (22%), INT-2 in 47 (52%), high-risk in 22 (24%), and not
available in 3 pts. Conditioning was full intensity in 42 (45%), and reduced
intensity in 51 (55%). Donors were matched sibling in 36 (39%), matched unre-
lated in 47 (51%), and mismatched or haplo-identical in 10 (11%). JAK# used
were ruxolitinib (n=84), momelitinib (n=6), or others (n=3). Sixty-five (70%) pts
used JAK# leading to HCT, and stopped 0-16 days prior to conditioning regi-
men; 23 (25%) pts had discontinued the medication at least 4 weeks prior to
HCT due to progression or intolerance, and in 5 pts this information was not
available. Among pts who used JAK# leading to HCT, “withdrawal symptoms”
were reported in 10 (15%), and were more common in pts who stopped JAK
inhibitors ≥6 days prior to conditioning regimen compared to those who stopped
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within 0-6 days (26% vs 11%, p=0.06). Withdrawal symptoms were non-severe
in nature except in one pt. this resulted in rebound splenomegaly and pulmonary
infiltrates necessitating splenectomy and delaying the HCT for 3 months. Pri-
mary graft failure was reported in 3 pts (3%). The cumulative incidence of grade
≥2, and ≥3 acute GVHD at 100 days were 44% and 16% respectively. Cumu-
lative incidence of chronic GVHD at 2-years was 53%. Median follow-up of sur-
vivors were (2-53) months, and during this period, 12 (13%) pts had relapse/pro-
gression and 31 (33%) died. Probability of 2-year OS of whole cohort was 62%
(95% CI, 50%>73%). Patient in group-A (n=22) had significantly superior sur-
vival p=0.01 (Figure 1) Other factors with significant effect on survival in uni-
variate analysis were DIPSS-plus score, donor type, and performance status
at HCT. In a limited multivariate analysis, response to JAK# was the strongest
independent factor for survival (p=0.004). DIPSS-plus high-risk category
(p=0.04), and mismatched/haplo donor groups (p=0.04) were other independent
factors for survival.
Summary and Conclusions: Our data suggest that use of JAK# prior to HCT
does not have adverse effects on early transplant outcomes. Continuation of
JAK# until HCT appears to reduce the risk of “withdrawal symptoms”. The HCT
outcomes in patients responding to JAK# are particularly encouraging. 
Molecular markers in AML
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DNMT3A MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML): MONITOR-
ING OF MINIMAL RESIDUAL DISEASE (MRD). A STUDY OF THE AML
STUDY GROUP (AMLSG)
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Düsseldorf, Düsseldorf, 7Städtisches Klinikum Karlsruhe GmbH, Karlsruhe,
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versitätsmedizin Mainz, Mainz, 10Universitätsklinikum Hamburg-Eppendorf,
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Background: DNMT3A is frequently mutated in AML and associated with a
poor overall (OS) and relapse-free survival (RFS). The presence of DNMT3A
mutations (DNMT3Amut) in early preleukemic stem cells and in apparently
healthy elderly highlight its pathogenic role as a founder mutation and as pre-
disposing event in leukemia. Within our clinical AMLSG trials we addressed
the question if MRD monitoring in DNMT3Amut patients (pts) has clinical impact
and delivers further information for risk-adapted therapy and clonal
hematopoiesis.
Aims: To monitor MRD for the most common DNMT3Amut (DNMT3Amut-
R882H, n=111 and -R882C, n=48) in a large cohort of AML pts entered on three
AMLSG treatment trials [AML HD98A (n=14; NCT00146120), AMLSG 07-04
(n=87; NCT00151242), AMLSG 09-09 (n=58; NCT00893399)].
Methods: DNMT3Amut MRD monitoring was performed using a cDNA-based
RQ-PCR-assay by TaqMan technology with a sensitivity between 10-3 and 10-4.
MRD levels have been reported as normalized values of DNMT3Amut transcripts
per 104 ABL1 transcripts (DNMT3Amut/104 ABL1).
Results: In total, 1,168 samples [bone marrow (BM), n=615; peripheral blood
(PB), n=553] from 159 DNMT3Amut pts were analysed [diagnosis, n=256; during
therapy, n=719; follow-up, n=193]. Median BM DNMT3Amut transcript level (TL)
at the time of diagnosis was 12690 (range, 0-54280); TL were not associated
with known clinical characteristics or mutations in NPM1 or FLT3; there was no
impact on OS and RFS. DNMT3Amut TL during therapy were significantly higher
in BM after induction I, consolidation I and II (p=0.01; p=0.0003; p=0.01) than in
PB. After double induction therapy (DI) there was no difference in the median of
TL between 102 pts in complete remission (CR) and 12 pts not in CR (12694 and
11309, respectively). There was no prognostic impact of BM DNMT3Amut TL as
log 10 transformed continuous variable during therapy with regard to death and
relapse. Strikingly, the greatest TL reduction was seen after induction I (one log)
whereas subsequent therapies did not significantly influence TL. Next, we eval-
uated the impact of DNMT3Amut MRD monitoring for the clinical endpoints OS,
cumulative incidence of relapse (CIR) and remission duration (RD) after DI and
after end of therapy (ET). After DI and ET, only 7/75 and 4/63 BM samples became
MRD negative. At these two time-points MRD positivity did not significantly impact
OS (p=0.89; p=0.73), CIR (p=0.74; p=0.29) and RD (p=0.61; p=0.30). Then we
investigated the MRD DNMT3Amut log10-reduction (compared to level at diag-
nosis) using the median as a cut-off after DI and ET. Again, there was no signif-
icant correlation for pts with a higher TL reduction compared with a lower TL
reduction for OS and RD after DI and ET (p=0.87; p=0.38; p=0.67; p=0.57, respec-
tively). Finally, we evaluated the BM DNMT3Amut TL as 4 increasing equally sized
intervals according to the quartiles of the distribution. There was no prognostic
impact after DI on OS and RD (p=0.24; p=0.85) and ET (p=0.38; p=0.44). To
increase the number of samples, we also performed the analyses for BM and PB
samples, but again, there was no significant impact on prognosis.
Summary and Conclusions: In our study neither the absolute BM DNMT3Amut
TL at the time of diagnosis nor the reduction of TL or the increasing quartiles
after DI and ET showed prognostic impact. In contrast to AML with NPM1 muta-
tion or associated gene fusions, most pts had persistent DNMT3Amut TL sup-
porting the role of persistent clonal hematopoiesis. Serial investigation of
DNMT3Amut and its concurrent mutations will provide further insights into the
clonal evolution of AML.
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LEUKAEMIA-ASSOCIATED SOMATIC MUTATIONS DRIVE DISTINCT PAT-
TERNS OF AGE-RELATED CLONAL HAEMOPOIESIS
T. Mckerrell1,* N. Park2, T. Moreno3, C. Grove1, H. Ponstingl1, J. Stevens4,
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Background: Clonal haemopoiesis driven by leukaemia-associated gene
mutations can occur without evidence of a blood disorder.
Aims: To investigate the incidence, target genes and age distribution of age-
related clonal haemopoiesis (ARCH).
Methods: We performed targeted ultra-deep re-sequencing for hotspot muta-
tions at 15 gene loci recurrently mutated in myeloid malignancies in the blood
DNA of 4219 individuals including a large number of elderly people.To do this
we developed and validated a robust methodology, employing barcoded mul-
tiplex PCR of mutational hotspots followed by next-generation sequencing
(MiSeq) and bioinformatic analysis. This reliably detected mutation-associated
circulating blood cell clones with a variant allele fraction (VAF) ≥0.008 (0.8%).
Results: Using only the hotspots studied, we identified clonal haemopoiesis
in 0.8% of individuals under 60, rising to 19.5% of those ≥90 years; predicting
that clonal haemopoiesis is much more prevalent overall than was previously
realized. Indeed, using our findings as a basis for projection, we estimate the
overall prevalence of age related clonal haemopoiesis (ARCH) to be >70% in
those older than 90 years. DNMT3A-R882 mutations were most common and,
although their incidence increased with age, were found in individuals as young
as 25 years. By contrast mutations affecting spliceosome genes SF3B1 and
SRSF2, closely associated with the myelodysplastic syndromes, were only
identified in those aged >70 years, with several individuals harboring more
than one such mutation.This indicates that spliceosome gene mutations drive
clonal expansion under selection pressures operating in the ageing haemopoi-
etic system and explains the high incidence of clonal disorders associated with
these mutations in advanced old age. Finally, despite using a very sensitive
method and a mutation-calling script written specifically for this purpose, no
samples with NPM1 mutations of VAF ≥0.008 were identified.
Figure 1. The prevalence of clonal haemopoiesis driven by only 9 hotspot
mutations by age.
Summary and Conclusions: Our results demonstrate that the incidence of
clonal haemopoiesis is much higher than suggested by exome sequencing
studies, that splicesome gene mutations drive clonal outgrowth primarily in the
context of an aging haematopoietic compartment, and that NPM1 mutations
do not drive ARCH, indicating that their acquisition is closely associated with
frank leukemia.
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JAM-C: A NEW LEUKEMIC STEM CELL BIOMARKER IN ACUTE MYELOID
LEUKEMIA
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Background: Acute myeloid leukemia (AML) is a clonal hematologic malig-
nancy arising from a rare population of leukemic stem cells (LSCs) that initiate
and propagate the disease. LSCs are enriched within the CD34+CD38low/-
compartment expressing the IL-3 receptor α-chain, CD123. In contrast, normal
hematopoietic stem cells do not express CD123. Several studies have recently
shown that a fraction of LSCs, residing in particular niches of the bone marrow,
resists to chemotherapy and is associated with poor clinical outcome.
Aims: We were interested to explore cell-adhesion and migratory properties
of LSC aiming at identification of new cell-surface marker able to define a
Leukemic Initiating Cell population within the LSC compartment.
Methods: AML patient samples were analyzed by flow cytometry to character-
ize protein expression profile in the LSC compartment and then engrafted in
NOD scid gamma chain deficient (NSG) mice. Clonogenic and cobblestone-
area forming cell (CAFC) assays in vitro and gene-expression profiling were
performed to characterize stemness and regenerative potential of defined LSCs
subsets.
Results: We confirmed in a large cohort of 34 AML de novo patients results
showing correlation between mouse engraftment and poor AML disease prog-
nosis. Engrafting patients had a significant poorer overall survival as compared
to non-engrafting. Searching for molecular factors that could affect AML engraft-
ment, we found that the junctional adhesion molecule-C (JAM-C) was
expressed by a fraction of LSCs. JAM-C is an adhesion molecule that we have
previously shown to be expressed by mouse and human hematopoietic stem
cells. Functionally, JAM-C interaction with JAM-B expressed on stromal cells
was involved in HSC retention in the bone marrow. Here, we showed that per-
centages of JAM-C expressing cells in CD34+CD38low/-CD123+ leukemic
cells at diagnosis were significantly increased in engrafting AML patient sam-
ples as compared to non-engrafting samples. Since engraftment was correlated
to survival, we then tested if the frequencies of circulating CD34+CD38low/-
CD123+JAM-C+ cells could provide prognostic information. 60 AML de novo
patient samples at diagnostic were analyzed. We found that high frequencies
of JAM-C positive cells in the LSC compartment were correlated to poor overall
survival and significant reduced leukemia-free survival. Along this line, the
study of 10 paired AML samples at diagnosis and relapse revealed a significant
increase of JAM-C positive cells in the LSC compartment in all patient samples
at relapse as compared to diagnosis. Functional properties of these cells were
then tested. Clonogenic and CAFC assays showed that JAM-C+ LSCs grow
into colonies whereas JAM-C- cells do not. Moreover, JAM-C+ LSCs estab-
lished leukemia in vivo whereas JAM-C- cells didn’t engraft in mice. Finally we
showed that JAM-C+ cells are predominantly in G0 phase and have a more
immature gene expression profile compared to JAM-C- cells.
Summary and Conclusions: All together, these data indicate that JAM-C is
a unique marker for primitive leukemic stem cells and strongly suggest that
JAM-C expression defines a Leukemic Initiating Cell population within the LSC
compartment. Given the increased expression of this adhesion molecule by
LSCs during relapse, we propose that targeting JAM-C should be a promising
adjuvant therapeutic strategy to inhibit retention of leukemic stem cells within
bone marrow stromal niches.
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Background: Exosomes are microvesicles that play important roles in inter-
cellular communications in both normal and tumor cells via their cargoes, which
include microRNA (miRNA) and proteins. miRNAs play critical regulatory roles
in hematopoiesis, and their abnormal expression is correlated with several
hematological malignancies, including acute myeloid leukemia (AML). Exo-
some-derived miRNAs and proteins are increasingly recognized for their prog-
nostic biomarker potential. Exosomes are being evaluated for their potential
as novel drug-delivery vehicles due to their endogenous nature and ability to
carry small molecule drugs.
Aims: We aim to characterize HSC-derived exosomes, investigate the biomarker
potential of exosomes derived from AML patient samples (by examining their
proteomic and miRNA profiles) and utilize exosomes as innovative drug delivery
vehicles with the ability to eliminate leukemic stem cells in a targeted manner.
Methods: Secreted exosomes from murine bone marrow HSCs were isolated
from conditioned medium and visualized using confocal microscopy. We iso-
lated exosomes and performed miRNA profiling, using qPCR, and LC-MS/MS
proteomic analysis to characterize the constituents. We also isolated exosomes
from the CD34+ cells of three AML patient samples and profiled 372 of the
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most abundantly expressed miRs in these cells compared to normal CD34+
cells. We analyzed the proteome of these exosomes as well. In order to assess
the utility of exosomes as drug carriers, exosomes from bone marrow-derived
OP9 stromal cells were transfected with Daunorubicin (1ug/ul). Normal CD34+
cells and patient-derived AML samples (from n=2 patients) were treated with
varying doses of the drug-loaded exosomes. Drug-loaded exosomes uptake
was tracked with a Texas Red siRNA. After 24 hours, cells were screened for
apoptosis. To test the feasibility of targeted exosomes, OP9 cells were exposed
to AML patient samples for 48 hours. The patient cells were then removed and,
24 hours later, “trained” stromal cell-derived exosomes were isolated from the
media and transfected with Daunorubicin. These patient-specific, exosomes
were plated with both the corresponding patient’s CD34+ cells as well as normal
CD34 cells (Figure 1A). After 24 hours, apoptosis was measured.
Results: miRNA profiling of murine bone marrow showed miR-21a, miR-92a
and miR-25 were most abundant in exosomes. Proteomic LC-MS/MS analysis
revealed presence of exosome-associated novel proteins such as Syntenin-1.
Syntenin-1, which is known to bind IL-5R and promote myelopoiesis, was pres-
ent in significantly higher levels in HSCs compared to myeloid progenitors,
implying a functional role for exosome derived Syntenin-1. miRNA profiling in
AML samples revealed distinct signature profiles. Importantly, exosome derived
miRs such as -1290, -375, -205 and -21—that are known prognostic markers
in cancers such as prostate, ovarian and hepatocellular carcinoma—were sig-
nificantly upregulated in all the three exosome-derived AML samples. The drug-
loaded exosomes were successful in inducing significant apoptosis in two
patient samples tested. These drug-loaded exosomes also induced cell death
in CD34+ normal cells when compared to control exosomes. However, the
patient-trained exosomes specifically eliminated 92% of CD34+ patient cells,
while causing significantly less cell death (44%) of normal CD34+ cells exposed
to drug-loaded, patient-trained exosomes (Figure 1B).
Figure 1. Trained loaded exosomes specifically target leukemic cells. A]
Schematic diagram illustrating the experimental design for the generation
of the trained loaded exosomes (TLE). B] Cell death analyses of the AML
patient CD34+ cells compared to normal CD34+ cells upon exposure to
TLE are graphen (mean +/- SEM, *p<0.05).
Summary and Conclusions: Taken together, our data predict important func-
tional roles for exosome-derived Syntenin-1 in regulating lineage specific
hematopoietic differentiations. Furthermore, for the first time, we have identified
highly upregulated select exosome-derived miRs from AML patient samples
whose prognostic value has been recently reported for other cancers, making
these miRs promising candidates for AML biomarkers as well. Finally, stromal
cell-derived, drug-loaded exosomes are not only able to induce apoptosis in AML
patient samples, but they can effectively be trained by leukemic cells to favor
uptake resulting in targeted elimination of leukemic over normal CD34+ cells.
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Background: Recent advances in omics technologies allowed for affordable
generation of large scale molecular data including microRNA expression pro-
filing. These data are expected to serve as an invaluable source for molecular
based classification and prognostication of genetically heterogeneous diseases
such as acute myeloid leukemia (AML). Besides, the integration of various lay-
ers of omics data may serve for the generation of novel testable hypotheses
regarding disease pathogenesis.
Aims: Here, we aimed to develop a novel microRNA expression based prog-
nostic score using data from two different platforms-microarrays and RNA-Seq
data from adult patients with de novo AML and to investigate the underlying
biological pathways.
Methods: We used microRNA microarray expression data from 91 adult
patients with de novo AML enrolled into the AMLSG treatment protocol AML
HD98A (ClinicalTrials.gov Identifier: NCT00146120) (training dataset). Another
group of 177 AML patients with microRNA expression profiling data (RNA-Seq)
from the Cancer Genome Atlas (TCGA) served as a validation set. A scoring
system was built using the Robust Likelihood-Based Survival Modeling with
Microarray Data method. The selected model included 7 microRNAs (miR-100,
miR-132, miR-185, miR-186, miR-302a, miR-330, and miR-422a). A total con-
tinuous score was calculated for each patient sample using the Cox regression
coefficients obtained for the training dataset multiplied by the expression levels
in each sample and summed afterwards. Discrete scores (low vs high) were
defined using Receiver Operating Characteristics (ROC) curve analysis. In
addition, bioinformatic analysis of the GEP, RNA-Seq and DNA methylation
data from the TCGA was performed.
Results: For both the training and validation dataset the discrete scores were
significant prognostic factors in univariate analysis (p=0.001 and p=0.002, respec-
tively). The continuous score, which performed almost identically, was also a sig-
nificant factor in multivariate analysis (p<0.001 and p=0.022, respectively). In an
analysis restricted to cytogenetically normal (CN) AML the discrete score was a
significant adverse prognostic factor in the training dataset based on the log-rank
test (p=0.045), and it appeared as independent prognostic factor in the validation
subset of younger CN-AML patients in a multivariate model including age, gender,
FLT3-ITD and NPM1 mutational status (p=0.001). Next, we performed a network
analysis of the 7 microRNAs and their known and putative targets and found an
enrichment with nucleic acids binding proteins. Using the TCGA GEP data we
identified 850 probe sets that were differentially expressed between Low and
High Score patients at the level of p<0.01. GO analysis showed that “General
transcription regulation” was the most significantly overrepresented pathway.
Similarly, when Gene Set Enrichment Analysis (GSEA) was used for the subset
of CN-AML <61 years the 7 top scoring gene signatures were associated with
RNA metabolism and processing. The top scoring gene set was the “RNA SPLIC-
ING” signature. The differential exon usage (DEU) analysis between Low and
High Score patients showed a total of 7500 differentially expressed tags at a
level of significance of 0.05. Finally, we obtained the TCGA DNA methylation data
and found a total of 1218 CpG sites differentially methylated between the Low
and High Score patients and hierarchical clustering showed a very good corre-
lation with the miRNA score.
Summary and Conclusions: We demonstrated the feasibility to integrate
microRNA expression data from different platforms (microarray and RNA-Seq
data) for building prognostic scores in AML. Moreover, the integrated analysis
of omics data from microRNA expression score-defined subgroups provided
further evidence for the potential biological relevance of these subgroups and
a role of the RNA splicing machinery deregulation in the pathogenesis of AML.
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Oncogenic mechanisms and novel targets
in non-Hodgkin's lymphoma
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Background: Adult T-cell leukemia/lymphoma (ATL) is one of the most aggres-
sive peripheral T-cell malignancies, which is etiologically associated with human
T-cell leukemia virus type 1 (HTLV-1) infection. Although HTLV-1 can effectively
immortalize infected T cells, there is a long latency period of 30~50 years before
the onset of ATL, suggesting that HTLV-1 infection alone may be insufficient
for the development of ATL, but additional genetic lesions that accumulate dur-
ing the later life are essential. However, such somatic alterations underlying
the pathogenesis of ATL remain elusive.
Aims: The aim of this study is to elucidate the landscape of genetic alterations
in ATL.
Methods: We performed an integrated molecular study, in which whole-
genome/exome and transcriptome sequencing were performed together with
array-based methylation and genomic copy number analysis among a cohort
of 81 paired ATL samples, followed by extensive validation using targeted cap-
ture sequencing of detected mutations in 370 follow-up samples.
Results: Compared with other hematologic malignancies, ATL cells harbored
higher numbers of sequence mutations, copy number alterations, and structural
variants, suggesting the presence of global genomic instability in ATL. In addi-
tion to previously reported mutational targets in ATL (TP53, FAS, and CCR4)
and known targets frequently mutated in other lymphoid malignancies
(CARD11, GATA3, IRF4, POT1, CD58, STAT3 and RHOA), we identified a
variety of recurrent mutations affecting previously unknown mutational targets,
many of which are involved in development, activation and migration of T-cells,
immune surveillance, transcriptional regulation, and histone modification.
Molecular and functional analysis using human cell lines showed that some of
these novel mutations actually enhance T-cell function, validating their biolog-
ical significance in ATL. A comparison of mutations among disease subtypes
revealed several subtype-specific mutations, including TP53 and IRF4 muta-
tions in acute and lymphoma types, and STAT3 mutation in chronic and smol-
dering types, suggesting that there is a difference in the underlying oncogenic
mechanisms between indolent and aggressive forms. Moreover, several muta-
tions, including those in TP53, IRF4 and CCR4, independently predicted worse
clinical outcomes. ATL cells showed a distinct pattern of copy number changes
and genomic rearrangements. Interestingly, their gene targets showed a sig-
nificant overlap to mutational targets. Intriguingly, somatic focal deletions involv-
ing the 14q31.1 locus were observed in all the cases examined by whole-
genome sequencing and therefore are thought to characterize ATL genomes,
although their gene targets remained to be identified. Conspicuously, pathway
analysis demonstrated that multiple genes involved in the Tax interactome were
systematically altered in ATL, although Tax itself underwent gene silencing in
most cases. These data suggested that ATL cells can escape from immune
surveillance by silencing immunogenic Tax expression, while developing alter-
native oncogenic mechanisms through acquiring somatic mutations or copy
number alterations in the Tax-related pathway.
Summary and Conclusions: Our findings suggest that the deregulation of T-
cell functionalities caused by genetic alterations, especially those related with
HTLV-1 Tax oncoprotein, are pivotal to ATL pathogenesis, and provide a novel
clue to contrive new diagnostics and therapeutics to combat this intractable
disease.
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NPM-ALK MIMICS THYMIC PRE-T CELL RECEPTOR (TCR) EXPANSION BUT
REQUIRES TRANSIENT TCR EXPRESSION FOR THYMIC EGRESS AND
PERIPHERAL ANAPLASTIC LARGE CELL LYMPHOMA DEVELOPMENT
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Background: Anaplastic Large Cell Lymphoma (ALCL) is a peripheral T cell
lymphoma of children and adults which is characterized by aberrant ALK
expression and signaling, usually driven by the NPM promoter resulting from
the t(2;5)(p23;q35). Although ALK+ ALCL cells commonly express T cell acti-
vation (CD30) and cytotoxic (Granzyme, perforin, TIA1) markers and have
clonal TCR gene rearrangements, the TCR/CD3 signaling complex is strikingly
absent. It is also not clear at what stage of T lymphoid development lymphoma-
genesis initiates, but since NPM expression is ubiquitous it is possible that this
may occur before thymic egress.
Aims: We undertook a combined human and murine approach to evaluate the
place of TCR rearrangement in ALCL development and the timing of NPM-
ALK driven lymphoma onset.
Methods: Human ALCL were analyzed by multiplex TCR PCR from DNA (d,
g and b loci) or cDNA (a locus), with Sanger sequencing and TCRa/d Agilent
CGHa analysis for cases with available material. We used the murine model
of T cell lymphomagenesis in which NPM-ALK is expressed from the CD4 pro-
moter and following back-crosses to the RAG deficient and/or OTI TCR trans-
genic lines assessed tumor development and phenotype.
Results: Of 57 human, ALK+ ALCL (48 pediatric, 9 adult) with at least 40% tumor
involvement, cases with predominantly in-frame TCRa and TCRb rearrange-
ments were the most common category (56%), followed by 19% with predomi-
nantly in-frame TCRg and TCRd rearrangements and 14% with no clonal TCR
rearrangements. More surprisingly, 6 cases (11%) demonstrated clonal out-of-
frame TCRg but in-frame TCRa rearrangements in the absence of apparent clon-
al TCRB rearrangement, suggesting that NPM-ALK may in some way replace
TCRb mediated signaling. In keeping with this, CD4 driven NPM-ALK rag com-
petent transgenic mice (CD4NA/rag2+/+) demonstrated a block in thymic T lym-
phoid development at the Double Negative (DN)3 stage, which was not observed
in the CD4NArag2-/- mice, which developed cortical thymic tumors composed of
CD4/8 DP and CD4 SP cells, but no peripheral tumors. Crossing these mice with
the ovalbumin (ova) TCR transgene allowed thymic egress (in the absence of
ova) and the development of peripheral ALCL, pathologically similar to those
observed in humans. Intriguingly, this only occurred in a RAG competent context
and in the absence of ova and was associated with loss of the TCR transgene,
since CD4NA/OTImice exposed to ova and CD4NA/rag2-/- mice only developed
non-hematopoietic hepatic or gastro-intestinal sarcomas, although TCR trans-
gene expressing T cells were seen in the peripheryin the former.
Summary and Conclusions: These data demonstrate that NPM-ALK (and
ALK signaling) allows replacement of the thymic proliferative process of TCR
beta-selection, mediated by the pre-TCR, and development of thymic tumors,
but that TCR expression is required for thymic egress and development of
peripheral lymphoma resembling human ALCL. However, the latter is depen-
denton loss of TCR signaling, suggesting that simultaneous NPM-ALK and
TCR activities are not permissive of ALCL development and/or survival. In this
context, TCR signaling (but not unstimulated TCR expression) appears to act
as a tumor suppressor. These data also represent the first murine model resem-
bling human ALCL and provide proof of concept of an explanation of the path-
ogenic role for the long recognized “missing TCR” in peripheral T cell lym-
phomas, which may have implications beyond ALCL.
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Background: SOX11 is an SRY-related HMG-box transcription factor (TF)
family member aberrantly expressed in the majority of mantle cell lymphoma
(MCL) cases. The transcriptional program regulated by SOX11 and its poten-
tial oncogenic mechanisms in MCL pathogenesis have recently started to be
elucidated. However, the mechanisms underlying its aberrant expression in
MCL remain unclear. No mutations, genetic aberrations or direct correlations
with differential DNA methylation at the promoter region related to its expres-
sion have been found in MCL. As it is becoming increasingly clear that remote
enhancers may regulate gene expression, we hypothesized that distant reg-
ulatory regions might be involved in regulating aberrant SOX11 expression
in MCL.
Aims: In this study, we aimed to identify and characterize distal regulatory
elements associated with aberrant SOX11 expression in MCL.
Methods: We analyzed the 3-dimensional structure of the SOX11 genomic
region and its chromatin architecture by combining 4C- and ChIP-sequencing
in Z-138 and JVM-2, a SOX11-positive and a SOX11-negative MCL cell line,
respectively. Additionally, we analyzed the DNA methylation status of distant
enhancers that potentially regulate SOX11 expression by bisulfite pyrose-
quencing in normal naive B cells, SOX11-positive and SOX11-negative pri-
mary MCL cases. Finally, we performed TF motif enrichment analysis to iden-
tify TFs that potentially regulate aberrant SOX11 expression in MCL.
Results: By 4C-sequencing in the SOX11-positive cell line Z-138, we identi-
fied two genomic regions that show high contact frequencies with the SOX11
locus in 3-dimensional space. These regions were located between 500KB
and 1MB from the SOX11 locus. In Z-138, these regions were enriched for
histone marks H3K4me1 and H3K27ac, indicative of enhancer activity. In the
SOX11-negative MCL cell line JVM-2, neither high contact frequencies with
the SOX11 locus, nor enrichment of H3K4me1 and H3K27ac were observed
at these loci. Next, we investigated whether enhancer activity and DNA methy-
lation levels are inversely associated at the identified distant regulatory
regions, as described for other loci. We observed that DNA methylation levels
in these regions were significantly lower in SOX11-positive (n=12, average
methylation levels 13-21%) than in SOX11-negative primary MCL cases
(n=10, average methylation levels 51-85%) (P-value <0.01). Furthermore, in
normal naive B cells these regions were highly methylated (n=4, average
methylation levels 76-92%). These data support our 4C-seq findings in MCL
cell lines and suggest that these regions harbour active enhancers only in
SOX11-positive primary MCL cases. Next, we investigated the binding of 161
TFs (as identified by the ENCODE project) at the SOX11 locus and its poten-
tial distant enhancers. In total we identified binding sites of 13 TFs bound
both to the SOX11 locus and to one or both potential distant enhancers. None
of these were significantly higher expressed in SOX11-positive compared to
SOX11-negative primary MCL cases. Surprisingly, one of the distant enhancer
regions is bound by many TFs involved in B-cell development. However, it
remains to be elucidated how these B-cell related TFs play a role in SOX11
expression in MCL, as in normal B cells SOX11 is not expressed.
Summary and Conclusions: Altogether, our data suggest a model in which
SOX11 expression in MCL is associated with looping of the SOX11 locus to
two newly-identified distant enhancer regions. Further experiments, however,
are necessary to elucidate the mechanisms underlying their aberrant activa-
tion in SOX11-positive MCL cases.
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W. Béguelin1,* M. Teater1,2, K. Hatzi1, Y. Jiang1,2, R. D. Gascoyne3, O. Abdel-
Wahab4, R. Shaknovich1, V.J. Bardwell5, O. Elemento2, A.M. Melnick1
1Medicine, Weill Cornell Medical College, 2Institute for Computational Bio-
medicine, Weill Cornell Medical College, New York City, United States, 3Cen-
tre for Lymphoid Cancer and Departments of Pathology and Experimental
Therapeutics, British Columbia Cancer Research Centre, Vancouver, Canada,
4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering
Cancer Center, New York City, 5Developmental Biology Center, Masonic Can-
cer Center, and Department of Genetics, Cell Biology, and Development, Uni-
versity of Minnesota, Minneapolis, United States
Background: The majority of B cell lymphomas arise from germinal center
(GC) B cells, which form part of the humoral immune response to T cell-
dependent antigen stimulation. Understanding how B cells impose and main-
tain the GC phenotype may thus provide important clues to explain the patho-
genesis of GC B cell-derived lymphomas and inform the design of rational
therapeutic strategies for patients with diffuse large B cell lymphomas (DLB-
CLs) and follicular lymphomas (FLs). Upon activation, GC B cells upregulate
EZH2, a histone methyltransferase that forms part of Polycomb Repressive
Complex 2 (PRC2). EZH2 is targeted by gain-of-function somatic mutations
that enhance its ability to trimethylate histone 3 lysine 27 in DLBCLs and
FLs. We previously found that EZH2 mediates the GC phenotype through de
novo formation of bivalently marked chromatin domains (characterized by
overlapping H3K27me3 repressive mark with the H3K4me3 activation mark)
at the promoters of target genes involved in cell cycle regulation and in GC
exit, to transiently suppress GC B cell differentiation. Mutant EZH2 reinforced
these effects through enhanced silencing of these bivalent genes. EZH2
mutation induced GC hyperplasia in mice, and DLBCL patients with mutant
EZH2 displayed more profound repression of the GC bivalent genes, sug-
gesting that mutant EZH2 contributes to human lymphomagenesis through
repression of bivalent chromatin domains.
This scenario is reminiscent of the role of the transcriptional repressor BCL6,
which is also required for GC formation and survival of DLBCL cells. Notably
BCL6 represses its targets by associating with BCoR, which forms a variant
of Polycomb Repressive Complex 1 (PRC1).
Aims: We hypothesized that EZH2, BCL6, and PRC1-BCoR cooperate to
mediate the GC B cell phenotype and when aberrantly active may cooperate
to form GC-derived B cell lymphomas.
Methods and Results: Using transgenic animal models we found that EZH2,
BCL6, and BCoR are mutually dependent to induce formation of GCs. ChIP-
seq studies revealed that EZH2 bivalent promoter genes significantly overlap
with BCL6 targets only when is associated with BCoR in primary human GC
B cells and lymphoma cells (hypergeometric test, p=2.9e-20). Treatment of
DLBCL cells with EZH2 or BCL6-BCoR inhibitors or siRNA partially dere-
pressed these genes, indicating that these factors cooperate and are required
to mediate full repression of these crucial bivalent loci. Accordingly, ChIP
assays in DLBCL cells treated with EZH2 inhibitor showed impaired binding
of PRC2 complex proteins (EZH2, EED and SUZ12) and PRC1-BCoR com-
plex proteins (BCoR, RNF2 and KDM2B) to bivalent promoters. This was
accompanied with corresponding loss of H3K27me3 and H2AK119ub1, the
histone repressive marks catalyzed by PRC2 and PRC1, respectively. Similar
results were obtained when cells were exposed to a small molecule that dis-
rupts BCL6 recruitment of BCoR.
Conditional expression of mutant EZH2 in mice accelerated lymphomagen-
esis driven by BCL6. Accordingly, the combination of EZH2 inhibitor with
BCL6-BCoR inhibitor, suppressed DLBCLs proliferation and tumor growth in
xenografted mice more effectively than either agent alone. The combination
also yielded further killing of primary human DLBCL cells growth. 
Summary and Conclusions: We identified the first epigenetic mechanism
of lymphomagenesis involving aberrant repression of GC-specific bivalent
domains by PRC2 and BCL6 in cooperation with PRC1-BCoR complex, as
well as a rational epigenetic-based and molecular targeted therapeutic
approach with the potential to eradicate lymphomas without harming normal
tissues.
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Background: Chronic antigenic stimulation may has been hypothesized to
play an important role in the pathogenesis of malignant lymphomas. We have
previously shown that a hyperglycosylated version of neurabin/SAMD14, a
protein strongly expressed in the CNS, is the antigenic target of the B-cell
receptor (BCR) of 2/3 of all primary CNS lymphomas, but antigenic targets of
peripheral DLBCL-BCRs have not been defined to date.
Aims: To identify the antigenic targets/stimuli of BCR derived from peripheral
DLBCL.
Methods: BCRs were expressed as recombinant Fabs based on correspon-
ding pairs of functional variable region heavy and light chain genes, which
had been amplified from isolated genomic DNA of snap-frozen lymphoma
specimens and DLBCL-derived cell lines. The purified BCR-Fabs were
checked for binding to proteins expressed on macroarrays of human cDNA
expression libraries. 
Results: The BCR from 10 DLBCL cell lines (5 of the germinal center type
and 5 of the activated B-cell type) were tested on the protein macroarray.
None of the GC-type BCR reacted with any of the proteins expressed on the
protein macroarrays, but the BCR from 3/5 (60%) of the ABC-derived cell
lines reacted with ARS2 (arsenite resistance protein 2), a conserved mam-
malian protein which is important for microRNA biogenesis. Isoelectric focus-
ing and phosphatase treatment of ARS2 derived from ABC cell lines with a
BCR specific for ARS2 revealed that ARS2 was hypophosphorylated (hypo-
ARS2) in the respective cell lines. Analysis of peripheral blood lymphocytes
from patients with DLBCL of unknown cell of origin and healthy controls
revealed that 5/100 patients (5%), but only 1/200 controls (0.5%) were carriers
of hypo-ARS2, resulting in a 10x increased risk for healthy carriers of hypo-
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ARS2 to develop DLBCL. All patients with BCRs targeting ARS2 had poly-
clonal antibodies against ARS2 in their serum.
Summary and Conclusions: Hypo-ARS2 is the first molecular defined risk
factor for DLBCL identified to date. The increased risk for healthy carriers of
this posttranslational modification to develop DLBCL supports the hypothesis
of chronic antigenic stimulation as an important factor in the pathogenesis of
DLBCL of the ABC subtype and indicates that posttranslationally modified
autoantigens are a frequent target and stimulus for ABC-DLBCL-BCR. That
antibodies against ARS2 are found in the respective patients suggests that
the hypo-ASR reactive DLBCL evolves from a polyclonal B-cell response
against this autoantigen. Investigations into the mechanism underlying the
hypophosphorylation of ARS2 are underway and therapeutic options will be
discussed. Supported by Wilhelm-Sander-Stiftung.
Novel actors in chronic myeloid leukemia biology
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SECOND GENERATION TYROSINE KINASE INHIBITORS SUPPRESS THE
CIP2A/C-MYC/E2F1 PATHWAY
C. Lucas1, R. Harris1, A. Holcroft1, L. Scott1, N. Carmell1, E. McDonald1,
R. Clark1,*
1Haematology, University of Liverpool, Liverpool, United Kingdom
Background: Impairment of PP2A activity by its negative regulators SET and
cancerous inhibitor of PP2A (CIP2A) plays an important role in the pathogen-
esis and progression of chronic myeloid leukaemia (CML). CIP2A is associated
with increased proliferation in several human malignancies and its over-expres-
sion can cause cellular transformation. High levels are an adverse prognostic
indicator in many malignancies. In CML a high CIP2A protein level at diagnosis
in imatinib treated patients may be a biomarker for subsequent blast crisis.
However, its role in CML patients receiving second generation tyrosine kinase
inhibitors (2G TKIs) is not known.
Aims: Our aim was to investigate if the superior clinical outcome seen in
patients treated with 2G TKIs could be explained by modulation of the CIP2A
pathway.
Methods: CIP2A, PP2A, PP2AY307, c-Myc and E2F1 proteins were assessed
by FACS. CIP2A, c-Myc and E2F1 were depleted in K562 and CD34+ cells
using siRNA.
Results: In mononuclear cells taken at diagnosis from 20 chronic phase CML
patients, those with high CIP2A levels significantly decreased following dasa-
tinib or nilotinib treatment (p=0.007 and p=0.001 respectively) and this was
accompanied by a significant decrease in c-Myc, (p=0.002). Y307 phosphory-
lated (inactive) PP2A also decreased in dasatinib (p=0.03) and nilotinib (p=0.04)
treated cells, thus increasing PP2A activity, but imatinib had no significant
effect. These differences in TKI effects are not mediated by differential sup-
pression of BCR-ABL activity (as assessed using the pCrKL assay). E2F1 tran-
scriptionally regulates both c-Myc and CIP2A and has previously been shown
to be over-expressed in CML. E2F1 is high in patients with high diagnostic
CIP2A protein levels compared to those with low CIP2A protein levels (p=0.04).
Following 1 month of clinical 2G TKI treatment, E2F1 protein levels significantly
decreased (p=0.01) and this was accompanied by a decrease in mRNA levels
of its transcriptional target CIP2A. In sharp contrast, imatinib did not suppress
E2F1, and thus CIP2A mRNA levels remain unchanged. Our data demonstrate
that E2F1 is stabilised in CML as a result of PP2A inactivation. CIP2A acts to
inhibit PP2A leading to stabilisation of E2F1, creating a positive feedback loop
generating constant transcription and stabilisation of both CIP2A and c-Myc
(Figure 1). The positive feedback loop was interrogated by sequentially deplet-
ing CIP2A, c-Myc and E2F1 in K562 and CD34+ CML cells. Depleting CIP2A
in CD34+ CML cells reactivates PP2A, resulting in the dephosphorylation of
E2F1, and thus a decrease in E2F1 and c-Myc. This may occur by two mech-
anisms; firstly the decrease in CIP2A level means that CIP2A can no longer
stabilise c-Myc, and secondly the reduction in E2F1 removes its drive to tran-
scribe c-Myc. In CD34+ cells, c-Myc knockdown resulted in a decrease in
CIP2A (p=0.04) and E2F1 (p=0.04). This is consistent with our model, whereby
decreased CIP2A will reactivate PP2A, leading to the dephosphorylation of
E2F1 and therefore a decrease in E2F1. Finally E2F1 was depleted in CD34+
cells. This resulted in a decrease in CIP2A (p=0.002) and c-Myc.
Figure 1. CIP2A/c-Myc/E2F1 pathway.
Summary and Conclusions: In summary, we have shown that a positive feed-
back loop occurs between CIP2A, E2F1 and c-Myc which inhibits PP2A activity
and that only the 2G TKIs and not imatinib are able to supress it. Our study
highlights a role for E2F1 in the CIP2A pathway, although it cannot be assumed
that E2F1 is the only transcription factor regulating CIP2A and others may influ-
ence this dynamic process. Thus, CIP2A remains an attractive therapeutic tar-
get since high levels are only found in malignant cells.
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MYC-MAX HETERODYMER POSITIVELY REGULATES BCR AND BCR/ABL
EXPRESSION
V. Magistroni1,* N. Sharma1, R. Piazza1,2, C. Mezzatesta1, C. Gambacorti
Passerini1,2
1Dept. Health Sciences, University of Milano Bicocca, 2Clinical Research Unit,
San Gerardo Hospital, Monza, Italy
Background: Chronic Myeloid Leukemia(CML) is caused by the BCR/ABL fusion
gene. Both the presence and the levels of BCR/ABL expression seems critical for
CML progression from Chronic phase(CP) to Blast crisis(BC). At the molecular
level BC is a heterogeneous disease. Regardless of the additionally secondary
changes, one common feature during the evolution from CP to BC is a marked
increase in BCR/ABL expression. After the oncogenic translocation, the BCR/ABL
gene is under the transcriptional control of BCR promoter but the molecular mech-
anisms involved in the regulation of oncogene expression are mostly unknown.
Aims: The aim of this study is the identification of molecular mechanisms
responsible for BCR promoter regulation and BCR/ABL expression.
Methods: To identify the transcription factors directly acting on BCR promoter, we
studied in-silico a region of 1443bp upstream of the human BCR gene coding
sequence(Gene ID:613). Chromatin Immunoprecipitation was used to confirm in-
silico data. The role of transcription factors on BCR and BCR/ABL expression
have been determined through transfection of the K562 cell line with selected
expression vectors and through specific silencing in K562, LAMA-84 and KCL-22
cells. mRNA and protein expression levels of BCR and BCR-ABL were detected
by quantitative PCR(RT-qPCR) and western blot. BCR reporter activity was also
analyzed by reporter luciferase assay in the 293T cell line. The role of the identified
transcription factors in CML progression was investigated with in-vitro experiments.
Results: These data demonstrate that MYC-MAX heterocomplex binds to the
BCR promoter at four different binding sites(PBS1-4), leading to up-regulation
of BCR and BCR/ABL at both transcriptional and protein levels in the K562
cells. We found that both MYC and MYC-MAX overexpression significantly
upregulate BCR/ABL compared to control cells, as assessed by RT-qPCR
(MYC_BCR/ABL fold induction: 2.27±0.48,p=0.01; MYC-MAX_BCR/ABL fold
induction: 2.55±0.34,p=0.002) and western blot. Accordingly, silencing of
MYC(shMYC) expression in various BCR/ABL+ cell lines causes significant
down-regulation of BCR and BCR/ABL compared to the negative controls(BCR
fold change: KCL-22shMYC 0.49±0.07, p=0.013; LAMA-84shMYC 0.07±0.03,
p=0.0003. BCR/ABL fold change: KCL-22shMYC 0.58±0.02, p=0.0007; LAMA-
84shMYC 0.38±0.006, p<0.0001). In addition, MYC silencing in these cell lines
leads to decreased proliferation and induction of cell death as assessed by cell
cycle analysis and PARP-1 cleavage. In order to assess the effect of MYC-
MAX on BCR promoter, we tested the activity of the luciferase reporter assay
in presence of MYC expression and in a lentiviral MYC silencing model, showing
that MYC silencing significantly decreases BCR promoter activity in all of the
constructs analysed(p<0.0001). Notably, deletion of PBS1 and PBS2 and/or
deletion of PBS3 and PBS4, dramatically decreases the promoter strength,
therefore confirming the critical role of these region in controlling BCR promoter
activity. Interestingly, the deletion of PBS3 and PBS4 induces a greater down-
modulation of luciferase activity compared to PBS1 and PBS2 deletion (BCR-
promoter: 6.11±0.11; PBS3-4deleted: 1.86±0.14; PBS1-2deleted: 3.92±0.07).
Summary and Conclusions: This is the first description of a new pathway
which places BCR and BCR/ABL under the transcriptional control of the MYC-
MAX heterodimer. Since MYC is frequently over-expressed in BC, this phe-
nomenon could play a critical role in BCR/ABL up-regulation and blast aggres-
siveness acquired during CML evolution.
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CORRECTION OF MUTATIONS OF THE EPIGENETIC MODIFIER ASXL1 IN
MYELOID LEUKEMIA CELLS BY CRISPR/CAS9 GENOME EDITING
S. Valletta1,* H. Dolatshad1, E. Bello1, B.H. Yip1, M. Bartenstein2, S. Gordon2,
J. Shaw1, S. Roy1, L. Scifo1, A. Pellagatti1, T. A. Fulga3, A. Verm 2, J. Boultwood1
1LLR Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sci-
ences, Radcliffe Department of Medicine, University of Oxford, Oxford, United
Kingdom, 2Albert Einstein College of Medicine, Bronx, NY, United States,
3Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
University of Oxford, Oxford, United Kingdom
Background: The CRISPR/Cas9 genome editing system has recently emerged
as a powerful tool for genome engineering, and has been used for gene cor-
rection in cultured cells from patients with monogenic hereditary defects. We
reasoned that this technology could be employed to correct acquired gene
mutations in human cancer cells. Recurrent somatic mutations of the epigenetic
modifier ASXL1 are common in myeloid malignancies, including myelodysplas-
tic syndromes and chronic myeloid leukemia (CML). Loss-of-function ASXL1
mutations are strongly associated with a poor prognosis in these disorders.
We studied the CML line KBM5 which lacks wild-type ASXL1 protein expression,
due to a homozygous nonsense mutation (G710X) in the ASXL1 gene. 
Aims: We used CRISPR/Cas9-mediated homology directed repair (HDR) to
correct the ASXL1 mutation in KBM5 cells and performed functional studies to
determine whether the wild-type function of ASXL1 was restored.
Methods: We used three synthetic guide RNAs (sgRNAs) targeting the genom-
ic region overlapping the ASXL1 mutation and a single-stranded oligonucleotide
as a repair template. We sequenced 1,027 colonies expanded from single
FACS-sorted KBM5 cells to determine successful HDR-mediated correction of
ASXL1 mutation. Each sgRNA generated heterozygous precise correction (yield
0.46-2%). Importantly, homozygous precise correction was observed for two
sgRNAs (yield 1.13-1.63%). The frequency of correction obtained is consistent
with previous studies using the CRISPR/Cas9 system for precise genome edit-
ing through HDR. 
Results: Western blot analysis showed restoration of full-length ASXL1 protein
expression in heterozygous and homozygous corrected KBM5 clones. ASXL1
plays an important role in Polycomb Repressive Complex 2 (PRC2) recruitment
to specific target loci, including the HOXA cluster. Loss of ASXL1 is associated
with increased expression of HOXA genes. We observed significant downreg-
ulation of HOXA5, 6, 7, 9, 10 and 13 in ASXL1 mutation-corrected KBM5 clones.
The PRC2 plays a critical role in the deposition of H3K27me3 histone repressive
marks, and ASXL1 mutations are associated with H3K27me3 loss in myeloid
cells. Western blots on purified histones showed a marked increase in global
H3K27me3 levels in ASXL1 mutation-corrected KBM5 clones. ASXL1 forms a
protein complex in vitro with the chromatin deubiquitinase BAP1. This interaction
is reduced in cell lines carrying ASXL1 mutations. Immunoprecipitation studies
showed that the interaction between ASXL1 and BAP1 was restored in ASXL1
mutation-corrected KBM5 clones. Moreover, we observed growth suppression
and a significant increase in the expression of the myeloid marker CD15 in ASXL1
mutation-corrected cells. No sequence alterations were detected in any of the
off-target sites examined in all ASXL1 mutation-corrected clones identified, sug-
gesting high specificity of CRISPR/Cas9 system in our experiments. Preliminary
in vivo data show that mice xenografted with ASXL1 mutation-corrected KBM5
clones have a longer survival compared to mice xenografted with uncorrected
KBM5 cells (p=0.046) (Figure 1). A larger cohort is in progress.
Figure 1. Evaluation of ASX1 mutation correction in KBM5 cells using
Sanger sequencing. The arrows in the middle and bottom panel indicate
silent nucleotides changes that were introduced in the single-stranded
oligonucleotide (repair template) sequence to avoid undesired Cas9 activ-
ity in mutation-corrected cells.
Summary and Conclusions: In summary, we have corrected a specific ASXL1
point mutation in a leukemia cell line using CRISPR/Cas9 technology, resulting
in restored protein function. This study presents a new strategy to illuminate
the impact of oncogenic mutations on cellular function and may lay the foun-
dations for a new approach to leukemia therapeutics (e.g. modified autoSCT).
We provide proof-of-concept for gene correction via CRISPR/Cas9 technology
in leukemic cells from patients with a myeloid malignancy.
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MUTATION ANALYSIS OF EPIGENETIC MODIFIERS IN CHRONIC PHASE
CML USING NEXT GENERATION SEQUENCING
G. Nteliopoulos1,* G. Gerrard2, H.E. Foong2, L. Foroni2, J.F. Apperley1, A. Bazeos1
1Centre for Haematology, Faculty of Medicine, 2Imperial College Healthcare
NHS Trust, Hammersmith Hospital, Imperial College London, London, United
Kingdom
Background: Chronic myeloid leukaemia (CML) originates from a single genetic
aberration (BCR-ABL1); however the clinical disease is remarkably heteroge-
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neous and the genetic mechanisms of resistance to tyrosine kinase inhibitors
(TKI) are still poorly understood. Recently, we have identified consistent differ-
ences in genome-wide DNA methylation patterns in patients with chronic phase
CML (CML-CP) compared to healthy controls, indicating an involvement of epi-
genetic mechanism in CML pathogenesis. Several epigenetic modifying enzymes
have been found frequently mutated in other haematopoietic neoplasms.
Aims: The aim of this study is to analyse a panel of mutations in epigenetic
modifiers in chronic phase CML using Ion Torrent next-generation sequencing.
The panel design was based on a combination of gene expression analysis
we generated and literature search for frequently mutated enzymes in
leukaemia. Potential mutations involved in epigenetic deregulation of CML may
be used as novel prognostic biomarkers for TKI response.
Methods: 53 samples from untreated patients with newly diagnosed CML-CP
(CD34+) who started treatment with imatinib were included in the study. Patients
were classified as responders (n=26) /non-responders (n=27) based on 10%
BCR-ABL1/ABL ratio at 3 months. 6 samples from GCSF mobilised healthy
donors (CD34+) were used as negative controls, to exclude false positive vari-
ants and 2 samples from CML-BC (blast crisis) as positive controls. A custom
panel of 71 epigenetic enzymes was designed, containing 2002 amplicons.
We used the Ion AmpliSeq Library, the Ion PGM Template OT2 200 and the
Ion PGM Sequencing 200 kits, running 8 samples on a 318 Chip. Data were
analysed using Ion Reporter (Life Technologies), while the web-based appli-
cation Mutation Taster was used for the evaluation of the disease-causing
potential of a variant.
Results: A mean of 636,170 mapped reads per sample with mean depth of 273
and mean coverage (at x20) of 95.9% was obtained, detecting mutations with
high sensitivity. The filtering steps included exclusion of UCSC common SNPs,
use of healthy controls for excluding false positive variants, exclusion of intronic
variants, exclusion of variants called as polymorphisms by Mutation Taster, quality
control including all variants with frequency of the mutated allele>20% and some
variants with lower frequency based on QC, and exclusion of synonymous vari-
ants. 59 disease causing variants were identified in 34 genes including missense,
nonsense and frameshift insertions. No difference of overall number of variants
between responders/non-responders, however nonsense variants in ASXL1,
IKZF1 and EP300, similar to ones found in CML-BC samples, were found only
in non-responders. No variant was present in frequency more than 2/53 samples
and were mutually exclusive between R-NR except for a missense variant in
HDAC2, RUNX1 and a TET2 found in 5, 4, 3 samples respectively. At least one
variant was present in 85% of NR and in 67% of R. The findings were validated
using Sanger sequencing. For some genes, there was correlation of gain or loss
of function mutation with differences in gene expression.
Summary and Conclusions: We demonstrate the feasibility of using the Ion
Torrent PGM platform for mutation analysis of epigenetic modifiers in CML. The
findings may be the first report for the presence of these mutations in CML-CP,
which will allow a better understanding of the abnormal epigenetic changes in
CML. Some mutations found in high frequency can be considered characteristic
for CML whereas some others (found only in responders or non-responders) can
be considered as novel prognostic biomarkers for IM response.
S465
RUNX1 MUTATION AND/OR DISRUPTION OF THE C-TERMINAL DOMAIN
MAY BE CRITICAL FOR CHRONIC MYELOID LEUKAEMIA (CML) BLAST
CRISIS TRANSFORMATION 
L. Wang1,2,* G. Austin2, R. Clark2
1Department of Haematology, Royal Liverpool University Hospital, 2Section of
Haematology, Department of Molecular ans Clinical Cancer Medicine, Univer-
sity of Liverpool, Liverpool, United Kingdom
Background: Runt-related transcription factor 1 (Runx1)/ AML1 plays a crucial
role in haematopoiesis and its dysfunction may contribute to leukaemogenesis.
RUNX1 is frequently involved in chromosomal translocations including t(8;21),
t(3;21), and t(16;21). Normal RUNX1 function is repressed by all truncated
variants of RUNX1 that retain the entire Runt domain and lack the C-terminal
domain. RUNX1 with various point mutations also has a dominant-negative
effect on wild type and exhibits decreased transactivation activity; these have
been found in AML, myelodysplastic syndromes and accelerated phase/blast
crisis (AP/BC) of CML. 
Aims: To explore the role of RUNX1 lesions in disease evolution of CML, we
investigated RUNX1 splice variants and point mutations in CML chronic phase
(CP) and BC.
Methods: The cases studied included 54 cases of Philadelphia chromosome
positive (Ph+) acute leukaemia (22 cases of myeloid, 21 lymphoid, 3 bi-pheno-
typic and 8 unknown lineage of leukaemia). Of these 54 cases, 35 evolved
from previous CP CML and 19 were de novo Ph+ acute leukaemia. Twenty
cases of newly diagnosed CP CML were also studied. RNA was extracted and
cDNA synthesised from whole blood white cells. First round PCR primers were
designed to amplify the full length cDNA of the longest RUNX1 isoform 1c.
Then two overlapping fragments were amplified by nested PCR primers. For
several cases, it was found that there were PCR products of different size in
addition to the PCR product of wild type RUNX1 1c. All PCR products of various
sizes for each sample were gel-purified and subject to Sanger sequencing.
Results: A total of 18 types of transcript variant were found. Of these, 2 types
(39 bp spliced out from exon3 and 99 bp spliced out from the end of exon10)
were universally present and were excluded from this analysis. The 16 other
types each had either all or the majority of the RUNT domain spliced out (named
as Group 1 variants, 8 types) or had apparent aberrant C-terminal alteration
(named as Group2 variants, 8 types). Group 2 variants were detected predom-
inantly in Ph+ acute leukaemia cases, i.e. 8 of 54 Ph+ acute leukaemia cases.
In contrast, Group 2 variants were only found in 1 of 20 CP cases and this one
case was the only case that could not be controlled by imatinib treatment. The
presence of Group1 variants was not significantly different between Ph+ acute
leukaemia cases and CP cases. There were 35 types of nonsynonymous muta-
tion and 14 types of synonymous mutation detected. All nonsynonymous muta-
tions have been aligned to various single nucleotide polymorphism databases
to exclude known polymorphisms. Nonsynonymous RUNX1 mutations were
detected in of 20 of 54 cases of Ph+ acute leukaemia (37%). In contrast only
2/20 (10%) cases of CP CML had a nonsynonymous RUNX1 point mutation
(p=0.025). Combining RUNX1 splicing variant Group 2 and point mutation
together, 23/54 (43%) Ph+ acute leukaemia cases had either a Group 2 splice
variant or point mutations, which were only present in 3/20 (15%) CML CP
(p=0.03). 5/8 cases of CML who had transformed had point mutations at the
BC stage. In 4 of these 5 cases new point mutations were only detected at the
BC stage; 1 case had mutations that were present in the earlier CP sample.
6/8 cases of CML who had transformed had variants detected, and 3 of these
had Group 2 splice variants that were not present in CP.
Summary and Conclusions: RUNX1 splicing variants with disrupted C-ter-
minal domain and RUNX1 point mutations are predominantly found in Ph+
acute leukaemia and at the transformation of CML, but are uncommon in chron-
ic phase; these lesions may therefore be crucial transformation events, and
candidate biomarkers of transformation.
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Gene therapy, cellular immunotherapy
and vaccination
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OUTCOMES OF GENE THERAPY FOR Β-THALASSEMIA MAJOR AND
SEVERE SICKLE DISEASE VIA TRANSPLANTATION OF AUTOLOGOUS
HEMATOPOIETIC STEM CELLS TRANSDUCED EX VIVO WITH A LENTIVI-
RAL BETA GLOBIN VECTOR
M. Cavazzana1,* J.-A. Ribeil1, E. Payen2, F. Suarez3, Y. Beuzard2, F. Touzot1,
R. Cavellesco4, F. Lefrere5, S. Chretien2, P. Bourget1, F. Monpoux6, C. Pondarre7,
B. Neven1, M. Schmidt8, C. von Kalle9, F. Kuypers10, L. Sandler11, S. Soni11,
O. Hermine1, S. Blanche1, M. de Montalembert1, S. Hacein-Bey-Abina1,12,
P. Leboulch2,4,13
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Background: In patients with hemoglobinopathies, hematopoietic stem cell
(HSC) gene therapy has the potential to induce production of functional β-
globin in the red blood cell lineage with the aim of reducing or eliminating the
symptoms of disease. Results for 2 subjects with β0/βE-thalassemia major treat-
ed in clinical study HGB-205 that were previously presented (EHA 2014, ASH
2014) suggested that transplantation with autologous CD34+ cells transduced
with the self-inactivating LentiGlobin BB305 lentiviral vector containing an engi-
neered βA-T87Q-hemoglobin (Hb) and early transfusion independence.
Aims: Herein, we provide additional follow-up data on these two subjects as
well as early safety and efficacy data on the first subject with sickle cell disease
(SCD) treated with gene therapy.
Methods: After obtaining informed consent, subjects with β-thalassemia major
undergo HSC collection via peripheral blood apheresis, while subjects with severe
sickle cell disease undergo HSC collection via bone marrow harvest. CD34+ cells
were selected and transduced with LentiGlobin BB305 lentiviral vector. Estimation
of the mean ex- vivo vector copy number (VCN) was obtained by quantitative
PCR performed on pooled colony-forming progenitors. Subjects underwent mye-
loablation with intravenous busulfan, followed by infusion of transduced CD34+
cells. Subjects were monitored for overall safety including hematological engraft-
ment, βA-T87Q-globin expression (by high performance liquid chromatography)
and transfusion requirements. Integration site analysis (ISA, by linear amplifica-
tion-mediated PCR and high-throughput sequencing on nucleated cells) and repli-
cation-competent lentivirus (RCL) assays were performed. Prophylactic pRBC
transfusions are continued in sickle cell subjects who are transfusion dependent
pre-treatment to maintain HbS <30%, followed by gradual tapering over time.
Table 1. Demographics and transplantation outcomes.
Results: As of February 2015, 2 subjects with β0/βE thalassemia major (Sub-
jects 1201 and 1202) and 1 subject with βS/βS severe sickle cell disease (Sub-
ject 1204, who was on prophylactic transfusion therapy for multiple veno-occlu-
sive crises and acute chest syndrome) have undergone treatment. The outcome
of these subjects to date is shown in Table 1. No subject has experienced a
drug product related adverse event, and ISA analyses demonstrate highly poly-
clonal reconstitution without clonal dominance. Both β-thalassemia major sub-
jects remain transfusion-free for 14 and 11 months respectively, post-treatment.
Subject 1204, at his most recent visit (Month 4.5 post-treatment), has a total
hemoglobin of 12.0 g/dl, of which 24% is HbAT87Q (from 9.6% at Month 3) and
33% is HbS (from 14.7% at Month 3), with increasing levels of transduced cells
detected in peripheral blood (PBL VCN of 2.4 at Month 4.5). This subject has
not had a post-treatment hospitalization for a SCD-related event and his trans-
fusion support is being tapered.
Summary and Conclusions: The subjects with β-thalassemia major remain
transfusion-free for 14 and 11 months. The subject with SCD demonstrates
increasing production of HbAT87Q over time. Gene therapy using autologous HSC
transduced with LentiGlobin BB305 lentiviral vector ex vivo is a promising approach
for the treatment of patients with both β-thalassemia major and severe SCD.
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GENERATION OF EBV-SPECIFIC AND EBV-SPECIFIC, TCR-REPRO-
GRAMMED HUMAN CD8+ CYTOTOXIC T LYMPHOCYTES WITH STEM
CELL MEMORY AND CENTRAL MEMORY PROPERTIES BY MODULATING
GLYCOLYTIC T CELL METABOLISM 
I. Weber1, S. Khan1, M. Theobald1, U.F. Hartwig1,*
1III. Dept. of Medicine-Hematology, Internal Oncology & Pneumology, University
Medical Center Mainz, Mainz, Germany
Background: Adoptive transfer of virus-specific and TCR- or CAR-repro-
grammed cytotoxic T lymphocyzes (CTL) has advanced as a valuable cellular
therapy for opportunistic viral infections, Epstein-Barr Virus (EBV)-mediated
lymphoma and leukemia relapse. However, durable clinical responses are often
hampered by limited capability of terminally differentiated, high avidity effector
T cells (TEFF) to establish sustained antileukemic immunity whereas less dif-
ferentiated stem cell memory (TSCM) and central memory (TCM) T cells could
be shown to elicit potent antitumor responses, prolonged survival and memory.
Moreover, TSCM and TCM depend less on glucose consumption to drive oxida-
tive phosphorylation (OXPHOS) as their primary source of adenosine triphos-
phate (ATP) production whereas TEFF require additional aerobic glycolysis to
generate the ATP needed. 
Aims: In the current study, we therefore investigated means of modulating T
cell metabolism to generate EBV-specific TSCM and TCM as well as EBV-specific
TSCM/CM TCR-reprogrammed T cells.
Methods: Naïve CD8+CD45RA+ T cells isolated from peripheral blood mononu-
clear cells (PBMC) of healthy HLA-A2+ donors using the Naive T cell isolation
kit® (Milenyi Biotec, Bergisch Gladbach, Germany) and unselected (total) CD8+
T cells were primed by autologous dendritic cells loaded with EBV-peptides
followed by restimulation with peptide loaded autologous PBMC in the presence
of low (1 mM) glucose, glutamine, an optimized cytokine cocktail and 1 mM of
the non-metabolizable glucose analogue 2-deoxy-glucose (2-DG). Moreover,
either galactose or 9-oleic acid was added to glucose deprived cultures. In
addition to phenotypic and functional in vitro analyses by FACS, IFN-g
ELISPOT- and 51Cr-release assays, glucose uptake and lactate production
was determined. OXPHOS and aerobic glycolysis were assessed by measuring
oxygen-consumption rate (OCR) and extracellular acidification rate (ECAR),
respectively, using a Seahorse Analyzer. Finally, the biological activity of EBV-
reactive TSCM/CM was tested in vivo in NSG mice.
Results: We obtained strong expansion of EBV-reactive CTL expressing a
CD8+CD45RA+CD45RO-CD95+ CD27+CD28+CD62L+CCR7+TSCM and
CD8+CD45RA- CD45RO+CD95+CD27+CD28+CD62L+CCR7+ TCM phenotype
upon repetitive stimulation of naïve T cells in the presence of low glucose, glu-
tamine and 2-DG when compared to CTL stimulated without 2-DG. This effect
was also seen in total CD8+ T cells although less pronounced. In contrast, sup-
ply of galactose or oleic-acid to glucose free (but glutamine containing) medium
did not result in reduced TEFF differentiation, suggesting OXPHOS by galactose
converted to glucose and fatty acid oxidation. Moreover, 2-DG treated TSCM
and TCM as well as total CD8+ CTL showed less lactate production and ECAR
as compared to untreated controls, confirming that differentiation to TEFF
requires aerobic glycolytic ATP production. Functional assays in vitro did not
only reveal cytolytic activity of 2-DG treated EBV-TSCM and TCM comparable to
controls but elicited superior migration properties of these cells when tested to
untreated naïve or total CD8+ T cells in a transwell- migration assay. We further
showed that EBV-TSCM/CM can be successfully TCR-reprogrammed to recog-
nize primary acute myeloid leukaemia (AML) blasts.
Finally, first adoptive transfer studies into NSG mice indicated that EBV-TSCM/CM
generated in low glucose can persist and mount an immune response to EBV-
transformed B cells engrafted into NSG recipients.
Summary and Conclusions: These studies demonstrate that modulation of T
cell metabolism may be a promising approach to generate stem cell memory
and central memory T cells in vitro for virus-specific and redirected immunity in
adoptive cellular therapy. 
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A THERAPEUTIC NKT CELL ADJUVANT-BASED VACCINE INDUCES AN
EFFECTIVE ANTITUMORAL IMMUNE RESPONSE IN B-CELL LYMPHOMA
L. Escribà-Garcia1,* C. Alvarez-Fernández1, J. Sierra1, J. Briones1
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Background: Type I natural killer T (NKT) cells are lymphocytes with unique
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specificity for glycolipid antigens presented by nonpolymorphic CD1d receptor
on dendritic cells (DCs). NKT cells play a central role in tumor immunology
since they coordinate innate and adaptive immune responses. Activation of
NKT cells with the prototypic lipid α-galactosylceramide (α-GalCer) stimulate
INF-γ production and cytokine secretion (eg, IL-12, IL-17, IL-21) which con-
tribute to the enhancement of T cell activation. 
Aims: We evaluated the antitumor effect of a combination of DCs and irradiated
tumor cells with the NKT cell agonist α-GalCer in a mouse model of B cell lym-
phoma.
Methods: The murine B cell lymphoma line 4TOO was used as tumor model.
A therapeutic vaccine was generated by mixing DCs and irradiated 4TOO tumor
cells (106 cells in a 1:1 ratio) in the presence of α-GalCer (2μg/mouse). A single
dose of the therapeutic vaccine was injected iv. into Balb/c mice (n=10 per
group) two days after tumor challenge (4x105 cells/mouse, iv), and mice were
followed for survival. NKT cell expansion was analyzed by flow cytometry using
a PE conjugated CD1d: α-GalCer analogue (PBS-57) loaded tetramer (NIH
Tetramer Core Facility, Atlanta GA). Intracellular IFN-γ production on NKT cells
and CD4+ and CD8+ T cells was detected by flow cytometry. One-way ANOVA
was used for comparisons between different experimental groups. Differences
in survival were analyzed using the log-rank test.
Results: Therapeutic vaccine eradicated B cell lymphoma in all treated mice,
and was superior to any vaccine combination, including α-GalCer alone, irra-
diated tumor cells with DCs, and DCs with α-GalCer (100%, 10%, 0% and 50%
of survival at day 100, respectively; p<0.001). Importantly, 90% of treated mice
with the vaccine were resistant to a tumor rechallenge, suggesting the devel-
opment of a memory immune response. In addition, the immune response was
tumor-specific since all the mice were unable to reject a syngeneic A20 B cell
lymphoma. A significant NKT cell expansion in the spleen and liver of vaccinat-
ed mice was observed compared with control groups (4.8 vs 1.2 fold expansion;
p=0.02, and 3.8 vs 1.4 fold expansion; p=0.04, respectively). Moreover, this
vaccination strategy induced an increase of IFN-γ secreting NKT cells (58.4%
vs 39.5% (p=0.05) and of IFN-γ secreting T cells compared to control groups
(25.7% vs 16.8% in CD8+ cells (p=0,04), and 31.2% vs 14% in CD4+ cells
(p=0,04).
Summary and Conclusions: A therapeutic vaccine consisting of dendritic
cells pulsed with tumor cells plus the NKT agonist α-GalCer efficiently eradi-
cates B cell lymphoma in a therapeutic setting. This immune response is long-
lasting, tumor-specific, and it is associated with an expansion of NKT cells in
lymphoid organs and with an increase in IFN-γ secreting NKT and T cells.
These data support the development of immunotherapy strategies in patients
with B cell lymphoma using DCs and NKT cell agonists.
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ALLOGENIC ADOPTIVE IMMUNOTHERAPY OF ACUTE MYELOID
LEUKEMIA (AML) BY TARGETING CD123 WITH CAR T-CELLS
R. Galetto1,* C. Lebuhotel1, P. Francon1, A. Gouble1, J. Smith1
1Cellectis, Paris, France
Background: Adoptive immunotherapy using autologous T-cells endowed
with chimeric antigen receptors (CARs) has given rise to long-term durable
remissions and remarkable objective response rates in patients with refrac-
tory leukemia, raising hopes that a wider application of CAR technology may
lead to a new paradigm in cancer treatment. However, a limitation of the cur-
rent autologous approach is that CAR T-cells must be manufactured on a
“per patient basis”.
Aims: To overcome this limitation we have developed a standardized platform
for manufacturing T-cells from third-party healthy donors to generate allogeneic
“off-the-shelf” engineered CAR+ T-cell-based frozen products.
Methods: This allogenic platform utilizes Transcription Activator-Like Effector
Nuclease (TALEN) gene editing technology to inactivate the TCRa constant
(TRAC) gene, eliminating the potential for T-cells bearing alloreactive TCR’s
to mediate Graft versus Host Disease (GvHD). We have previously demon-
strated that editing of the TRAC gene can be achieved at high frequencies,
yielding up to 80% of TCRab negative cells and allowing efficient production
and purification of TCR-deficient T-cells that no longer mediate alloreactivity in
a xeno-GvHD mouse model. As a safety feature, T-cells are engineered to co-
express the RQR8 gene, with the aim of rendering them sensitive to the mon-
oclonal antibody rituximab.
Results: Here, we have adapted this allogeneic platform to the production
of T cells targeting CD123, the transmembrane alpha chain of the interleukin-
3 receptor, which is expressed on tumor cells from the majority of patients
with Acute Myeloid Leukemia (AML). In a first step, we have screened multiple
antigen recognition domains in the context of different CAR architectures to
identify effective CAR candidates displaying activity against cells expressing
variable levels of the CD123 antigen. In addition, experiments in an orthotopic
AML mouse model using UCART123 cells demonstrate important anti-tumor
activity in vivo.
Summary and Conclusions: The ability to carry out large scale manufacturing
of allogeneic, non alloreactive CD123 specific T-cells from a single healthy
donor can offer the possibility of an off-the-shelf treatment that would be imme-
diately available for administration to a large number of AML patients.
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Background: Autologous T-cells engineered to express chimeric antigen
receptors (CARs) that target specific tumor antigens are known to be of high
potential in treating different kinds of cancer. However, they must be generated
on a “per patient” basis, thereby limiting the population of patients that could
benefit from this approach. In particular, immune homeostasis may be affected
in heavily pre-treated patients, such that autologous T-cells may be low in num-
ber, not fully functional, or unable to expand, thereby restricting the amount of
cells that could be manufactured.
Aims: The use of allogeneic T-cells isolated from healthy third party donors
could constitute an easy-to-scale-up alternative, producible in advance, with
potential for standardized quality controls, better batch consistency, and imme-
diate availability for administration to a larger number of patients.
Methods: We have developed a standardized platform for manufacturing T-
cells from third-party healthy donors to generate allogeneic “off-the-shelf” engi-
neered CD19-CAR+ T-cell-based frozen products. Our platform involves the
use of transcription activator-like effector nucleases (TALEN), which mediate
the simultaneous inactivation of two genes through genome editing. The knock-
out of the TCR alpha gene eliminates TCR expression and is intended to abro-
gate the donor T-cell’s potential for graft-versus-host disease (GvHD), while
knocking out the CD52 gene makes donor T-cells resistant to the lymphode-
pleting agent alemtuzumab. In addition, our T-cells are engineered to co-
express the RQR8 gene as a safety feature, with the aim of rendering them
sensitive to the monoclonal antibody rituximab.
Results: We have obtained proof-of-concept for the application of this
approach by manufacturing TCR/CD52-deficient RQR8+ and CD19-CAR+ T-
cells (UCART19) using a good manufacturing practice-compatible process and
have demonstrated that the resulting UCART19 cells were functional using in
vitro assays. Furthermore we have demonstrated that the ability of UCART19
cells to engraft into an orthotopic human CD19+ lymphoma xenograft immun-
odeficient mouse model. UCART19 cells exhibited antitumor activity equivalent
to that of standard CD19 CAR T-cells. We also demonstrated that UCART19
cells did not mediate alloreactivity in a xeno-GvHD mouse model. Finally, the
effectiveness of the rituximab-induced depletion mechanism of RQR8+ cells
was shown in an immunocompetent mouse model.
Summary and Conclusions: This valuable dataset supports the development
of allogeneic CAR T-cells, and UCART19 will be investigated in an exploratory,
first-in-human, clinical trial where refractory/relapsed CD19+ B-cell leukemia
patients are to be enrolled.
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Background: Elotuzumab, an immunotherapeutic monoclonal antibody (mAb),
recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein
highly expressed on myeloma cells and natural killer cells. Elotuzumab targets
and kills SLAMF7-expressing myeloma cells by direct activation of natural killer
cells with minimal effect on normal tissues. Elotuzumab showed encouraging
activity with lenalidomide/dexamethasone (Ld) in a Phase 1b/2 study in patients
with relapsed/refractory multiple myeloma (RRMM).
Aims: ELOQUENT-2, a Phase 3 study (NCT01239797) compared efficacy and
safety of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld.
Methods: Patients with RRMM and 1-3 prior therapies were randomized 1:1
to ELd or Ld in 28-day cycles until disease progression or unacceptable toxicity:
elotuzumab (10 mg/kg IV) was given weekly during Cycles 1 and 2 and then
biweekly; lenalidomide (25 mg) was given on Days 1-21; dexamethasone was
given weekly (40 mg or 28 mg PO+8 mg IV on elotuzumab dosing weeks).
Written informed consent was obtained for all patients. Response/progression
was assessed by an independent review committee using European Group for
Blood and Bone Marrow Transplant criteria. Primary endpoints were progres-
sion-free survival (PFS) and overall response rate (ORR). Results of a pre-
specified interim analysis are reported.
Figure 1. Progression-free survival (PFS).
Results: 646 RRMM patients were randomized (321 to ELd, 325 to Ld; median
age 66 years [20% of patients ≥75 years old]; refractory to last therapy 35%).
Median number of prior therapies was 2, including bortezomib 70%, thalidomide
48% and lenalidomide 6%. High-risk patients were included: del(17p) in 32%;
t(4;14) in 9%. At the data cut-off (4 Nov 2014), 35% (ELd arm) and 21% (Ld
arm) of patients remained on therapy; discontinuation was mainly due to dis-
ease progression (42% in the ELd arm, 47% in the Ld arm). Median number of
cycles was 19 and 14 in the ELd and Ld arms, respectively. After a median fol-
low-up of 24 months, PFS rate was superior in the ELd over the Ld arm: 68%
vs 57% at 1 year and 41% vs 27% at 2 years. Hazard ratio for PFS was 0.70
(95% CI 0.57, 0.85; p=0.0004). Median (95% CI) PFS in the ELd arm was 19.4
(16.6, 22.2) months vs 14.9 (12.1, 17.2) months in the Ld arm (Figure 1). PFS
benefit with ELd was consistent across key subgroups. ORR (95% CI) was
79% (74, 83) in the ELd arm vs 66% (60, 71) in the Ld arm (p=0.0002). Very
good partial response or better was seen in 32.7% and 28.0% of patients in the
ELd and Ld arms, respectively; partial response was seen in 45.8% and 37.5%,
respectively. Grade 3-4 adverse events in ≥15% of patients include neutropenia
(25% in the ELd arm, 33% in the Ld arm) and anemia (15% in the ELd arm,
16% in the Ld arm). Infections (any grade) occurred in 81% of patients in the
ELd arm and 74% in the Ld arm. Exposure-adjusted infection rates were the
same in both arms (incidence rate/100 person-years of exposure, 197). Infusion
reactions occurred in 10% of patients with ELd (mostly Grade 1-2). There were
210 deaths (94 in the ELd arm, 116 in the Ld arm).
Summary and Conclusions: This is the first positive randomized Phase 3 trial
with an immunotherapeutic mAb, assessing Ld with or without elotuzumab in
RRMM. It showed a 30% reduction in risk of progression or death with ELd vs
Ld. More patients remain on ELd vs Ld, and follow-up for long-term outcomes
is ongoing. Infusion reactions were manageable. Elotuzumab, a mAb with a
novel mechanism of action, showed improved PFS at 1 year and 2 years, with
minimal added toxicity in combination with Ld vs Ld alone in patients with mul-
tiple myeloma.
^Equal contribution: M. Dimopoulos and S. Lonial.
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Background: Follicular lymphoma (FL) is an incurable B-cell malignancy char-
acterized by the t(14;18) and mutations in one or more components of the
epigenome in virtually all cases. Whilst frequent gene mutations in signalling
pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined,
the spectrum of these mutations typically overlaps with the closely-related dif-
fuse large B cell lymphoma (DLBCL). Through a combination of discovery
exome and extended targeted sequencing, we reveal recurrent somatic muta-
tions in components of the mTOR pathway in FL patients.
Aims: We sought to identify novel gene mutations in FL that might serve as
therapeutic targets.
Methods: Whole exome sequencing (WES) was conducted on 24 FL matched
tumour/normal samples (mean coverage: 133x) from 5 patients that had mul-
tiple episodes of FL but have not transformed to a more aggressive disease.
Prevalence screening and clonality assessment were performed by targeted
deep sequencing of candidate and FL-associated genes, using Fluidigm-Miseq,
in an extension cohort of 176 FL cases, with further Sanger sequencing in 329
related mature B-cell NHLs and 51 B-cell lymphoma cell lines. Functional analy-
ses were carried out by expressing wild-type and mutant RRAGC in HEK-293T
for signalling and co-immunoprecipitation experiments and purified wild-type
and RagC mutant proteins were used in nucleotide-binding assays.
Results: Novel somatic mutations in RRAGC encoding a Rag GTPase protein
(RagC) were identified in 4 out of the 5 untransformed FL patients analysed by
WES. Clonal density plots demonstrated the RRAGC mutations resided within
the dominant clone, with temporal analyses of multiple biopsies from the same
individual showing stability of the RRAGC mutations during disease progres-
sion. Coding RRAGC mutations were identified in 28 of 176 cases (16%) from
our FL extension cohort with mutations rare or absent in other mature B-NHL
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entities. Mutations were heterozygous, predominantly missense (93%) and
clustered within the nucleotide binding domain of RagC. The somatic origin of
10 of these mutations was confirmed by sequencing of matched constitutional
DNA. A search for additional mutations in regulatory components upstream
and downstream of the pathway uncovered co-occurring mutations in 2 sub-
units of the vacuolar H+-adenosine triphosphate ATPase (v-ATPase) complex,
in more than half of RRAGC mutated cases. Together, Rag GTPases form a
super-complex with the v-ATPase, Ragulator and SLC38A9 on the lysosomal
surface and promote amino acid-mediated activation of the mechanistic target
of rapamycin complex 1 (mTORC1). By transiently expressing RagC mutants
(RagCmuts) in HEK-293T cells, we showed increased co-immunoprecipitation
with a key regulatory component of mTORC1, raptor, compared to wild-type.
Furthermore, stable overexpression of the RagCmuts not only activated
mTORC1 but rendered it resistant to leucine or arginine deprivation, as indi-
cated by phosphorylation of a canonical mTORC1 substrate. Moreover, whilst
all RagCmuts were activating, mutations at amino acid residue Serine-75 led to
mTOR activation by specifically disrupting nucleotide binding.
Summary and Conclusions: We report novel recurrent mutations in RRAGC
and associated v-ATPase subunits, uniquely enriched in FL. The RRAGC muta-
tions lead to activation of mTORC1 in the absence of amino acids. Overall, the
emergence of frequent, gain-of-function RRAGC mutations that are clonally
represented and maintained during progression provides an excellent candi-
date to be therapeutically exploited.
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Background: Although most patients with AML initially respond to anti-leukemic
chemotherapy, the majority subsequently relapse and die of relapsed, refractory
disease. Recent studies have suggested that therapeutic relapse is due to per-
sistent, chemoresistant AML cells that survive initial therapy, and serve as a
reservoir for genetic/epigenetic evolution and subsequent clinical relapse.
Although many AML patients have evidence of residual leukemia at clinical
remission, the mechanisms leading to chemoresistance and to the survival of
AML cells in response to chemotherapy have not been delineated.
Aims: Investigate the link between specific mutations and minimal residual
disease (MRD); deliniate molecular mechanism of therapeutic resistance in
DNMT3A-mutant AML.
Methods: MRD was assessed by multi-parameter flow cytometry at day 28 in
patients in clinical/pathologic complete remission. Novel genetic mouse model
was used to study the role DNMT3A R882 mutation in AML pathogenesis and
chemoresistance.
Results: Multivariate analysis revealed that DNMT3A R882 mutations were
associated with an increased risk of MRD at the time of complete remission
(p=0.007). By contrast, non-R882 mutations in DNMT3A did not predict for
MRD, nor did other recurrent AML mutations. These data suggest an important
role for DNMT3A R882 mutations in chemoresistance in AML, consistent with
studies suggesting that DNMT3A-mutant, pre-leukemic stem cells persist after
anti-leukemic chemotherapy. Next we generated a mouse model that condi-
tionally expressed Dnmt3a(mut) from the endogenous locus. In agreement
with clinical observations, Dnmt3a(mut) animals were characterized by expan-
sion of the stem-cell-enriched Lineage- Sca1+ cKit+ (LSK) compartment. Con-
sistent with enhanced clonal stem cell fitness in clonal hematopoiesis, we
observed robust serial hematopoietic repopulation ability of Dnmt3a(mut) cells
over 3-4 rounds of retransplantation in vivo. Notably, expression of
Dnmt3a(mut) in hematopoietic cells from the endogenous locus did not induce
AML in vivo. By contrast, we found that co-expression of mutant Dnmt3a, Flt3-
ITD and Npm1c mutations, the most common “triad” of mutations observed in
AML, resulted in a fully penetrant, short latency AML phenotype capable of
propagating disease in secondary recipients. We next investigated the basis
for DNMT3A R882 mutant-induced chemoresistance. Cells expressing
Dnmt3a(mut) showed a survival advantage compared to wild-type controls and
preserved clonogenic potential after in vitro and in vivo exposure to daunoru-
bicin, but not in response to other DNA damaging agents. Of note, although
DNMT3A mutant cells had attenuated pro-apoptotic signaling through the p53
pathway in response to anthracyclines, we observed increased single strand
breaks and increased mutagenesis in DNMT3A-mutant cells consistent with
impaired DNA-damage sensing in response to DNA strand torsion induced by
daunorubicin. Most importantly, Dnmt3a(mut) cells fail to remodel their chro-
matin after anthracycline-induced DNA damage, with impaired nucleosome
remodeling and reduced recruitment of the FACT chromatin remodeling com-
plex subunit SPT-16 in response to anthacycline induced DNA torsion. This
results in defective sensing of DNA breaks, attenuated pro-apoptotic signaling
and reduced DNA repair, leading to increased mutagenesis in response to AML
chemotherapy.
Summary and Conclusions: These data provide a novel mechanism by which
mutant DNMT3A promotes chemoresistance in AML, and suggests the possi-
bility of unique vulnerabilities in DNMT3A-mutant cells that can be exploited
therapeutically to this common AML subset.
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Background: Recently, we found that a heterozygous mutation in Growth Fac-
tor Independence 1B (GFI1B) causes an autosomal-dominant bleeding disor-
der characterized by gray platelets.1 Affected individuals exhibited thrombocy-
topenia and suffered from mild to severe bleeding episodes. Their platelets
appeared gray in blood films, as they contained reduced numbers of α-gran-
ules. GFI1B is an essential transcription factor for megakaryocyte differentia-
tion. It contains six C terminal zinc fingers (Znfs), of which 3-5 are essential for
DNA binding. The mutation that we reported caused a truncation of Znf 5. The
mutant protein lost its repressive function and inhibited the repressive capacity
of the wild type GFI1B protein (dominant-negative effect). Platelets from affect-
ed individuals expressed CD34, which had not been reported for bleeding and
platelet disorders (BPD) caused by other genetic aberrations.
Aims: Here, we study eight new GFI1B variants that we identified in cases
with inherited BPD. We assessed platelet α-granule numbers and CD34
expression of these patients and CD34 expression of BPD cases with proven
pathogenic mutations in FLI1, GATA1, NBEAL2 and RUNX1. We also investi-
gated the repressive capacity of the GFI1B variants.
Methods: Variants found in GFI1B in 529 whole exome-sequenced BPD cases,
enrolled by the BRIDGE-BPD consortium, were compared to ~60,000 reference
genomes (1000 genomes and ExAC databases).2 Platelet α-granule numbers
were assessed by electron microscopy. CD34 expression was measured on
GPIbα/CD42B positive platelets by flow cytometry. Luciferase repression
assays using GFI1B binding sequences were performed as described before.1
Informed consent was obtained from all patients.
Results: Eight new GFI1B variants were found in patients with BPD.2 Four
variants were located upstream of the Znfs (D23N, Q89fs, G139S and C168F).
The other four variants were located in or close to Znfs 1 and 2 (H181Y, R184P,
R190W and G198S). All variants were heterozygous except for C168F being
homozygous. Most variants were extremely rare (<2 hits/121,198 alleles) or
absent in the reference samples. Approximately half of the patients had throm-
bocytopenia. Reduced platelet α-granule numbers were found for patients car-
rying Q89fs and H181Y, but normal α-granule numbers were found for patients
carrying R184P and R190W. Platelets from all tested individuals with GFI1B
variants (H181Y, R184P and R190W) exhibited CD34 expression. NBEAL2,
GATA1, RUNX1 and FLI1 mutated platelets were CD34 negative. We tested
the repressive capacity of Q89fs, G139S, C168F, H181Y, R184P and R190W.
Q89fs lacked all Znfs and did not repress in a luciferase reporter assay, where-
as all missense variants did repress.
Summary and Conclusions: We found eight new GFI1B variants in families
with BPD. Platelet α-granule numbers were reduced for two out of four variants,
while all tested variants had platelet CD34 expression. The latter seems unique
to GFI1B variants. Only the frameshift variant lacking the DNA binding Znfs
lost its repressive capacity. Therefore, distinct molecular mechanisms may
cause platelet abnormalities. The frameshift variant might inhibit the function
of wild type GFI1B by quenching co-factors, whereas the missense variants
might do this by occupying DNA while lacking the ability to bind certain co-fac-
tors. The identification of these new variants opens new avenues to understand
how GFI1B dictates megakaryopoiesis at the molecular level.
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Background: The hemoglobinopathies, such as beta-thalassemia and sickle
cell anemia (SCA), are characterized by mutations of the beta-globin gene
resulting in either decreased or functionally abnormal hemoglobin (Hb) produc-
tion. As bone marrow transplant is the only curative option for these patients,
there is a strong need for new therapeutic approaches. Both beta-thalassemia
and SCA represent ideal targets for gene therapy since introduction of a normal
beta-globin gene can ameliorate the phenotype, as we and others have shown
previously. In addition, overcoming the developmental silencing of the fetal
gamma-globin gene represents an additional approach for the treatment of
hemoglobinopathies. Here, we directly compare a recently established
approach to activate the gamma-globin gene using forced chromatin looping
with pharmacologic approaches to raise gamma-globin expression.
The beta-type globin genes are activated through dynamic interactions with
the distal locus control region. This region physically contacts the developmental
stage appropriate globin gene via chromatin looping, a process partially depend-
ent on the protein Ldb1. We have shown that tethering Ldb1 to the human
gamma-globin promoter with a custom designed zinc finger protein (ZF-Ldb1)
can redirect loop formation from the beta- to gamma-promoter and potently
reactivate gamma- globin gene expression in adult human erythroid cells (Deng
et al., Cell, 2012 and 2014).
Aims: Our objective is to compare this recently established approach to phar-
macological induction of fetal hemoglobin (HbF) in cells with abnormal beta-
globin function, as in Sickle Cell Anemia (SCA).
Methods: We isolated hematopoietic stem cells from blood of 11 SCA patients.
These cells were expanded and differentiated into mature erythroid cells in
vitro, and treated with a lentivirus expressing the ZF- Ldb1 transgene. 10 of
these specimens were also treated with hydroxyurea, the only FDA-approved
HbF inducer used in SCA patients, or with the experimental inducers decitabine,
tranylcypromine, pomalidomide and butyrate.
Results: ZF-Ldb1 increased HbF synthesis in SCA erythroid cells up to 86%
and, concurrently, reduced sickle Hb (HbS) below 15%, showing a balanced
synthesis between alpha and beta like globins, and consistent with additional
studies with healthy erythroid cells. In addition, the induction of HbF in cells
treated with ZF-Ldb1 was roughly three times higher (+34%, at a dose of ~ one
transgene copy per cell) than that observed using pomalidomide (+12%, 10μM).
Decitabine and tranylcypromine had an intermediate effect (+9% for both drugs,
0.5 μM and 1.5 μM, respectively). Hydroxyurea and butyrate showed the lowest
HbF increase (+2% and +3%, respectively, both 100μM). Importantly, poma-
lidomide treatment lowered to 46% cell viability, which remained unaltered in
ZF-Ldb1 expressing cells. In related experiments, we compared the expression
of a battery of genes known to regulate HbF levels (BCL11A, SOX6, KLF1 and
C-Myb) in normal and SCA derived erythroid cells treated with ZF-Ldb1 or HbF
inducers and compared to controls. Quantitative PCR analyses indicate
reduced expression of KLF1 in and SOX6 in SCA specimens, in line with a
higher HbF synthesis at steady state.
Summary and Conclusions: Given its efficacy and safety, lentiviral-mediated
ZF-Ldb1 gene transfer has great therapeutic potential for SCA erythroid cells and
appears superior to drug induction. Moreover, a reduced expression of HbF
repressors in SCA cells might facilitate ZF-Ldb1-induced expression of HbF 
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EXOME SEQUENCING POINTS TO DIFFERENCES IN GENETIC INSTA-
BILITY LEVEL IN MGUS COMPARED TO MM
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Background: Malignant transformation of normal to tumour cells is a multistep
process followed by sequential aggregation of hits at different molecular levels.
Genetic events including single nucleotide variants (SNVs), insertion-deletion
changes (indels) as well as copy number alterations (CNAs) affect the pheno-
type of the tumour population and consequently patient prognosis. Transfor-
mation from a symptomless state, monoclonal gammopathy of undetermined
significance (MGUS) to multiple myeloma (MM) can be used as a unique
model for cancer development studies. To date, there is very little data regard-
ing the mechanisms leading to disease progression at molecular level.
Aims: To perform exome sequencing together with SNP array analysis in
MGUS patients to describe the premalignant phenotype and compared these
to advanced tumour cells at the DNA level.
Methods: Overall, 33 and 69 MGUS patients were included in a WES and SNP
array study, respectively. Plasma cells (PC) were isolated from bone marrow
by FACSAria (BD Biosciences) system using CD138, CD19 and CD56 markers
to obtain a pure abnormal PC population with a purity >90%. For WES, NEB-
Next kit and SureSelect Human All Exon V5 (Agilent) were used, samples were
sequenced by HiSeq2000 (Illumina). Copy number alterations (CNAs) were
tested by SurePrint G3 CGH+SNP, 4x180K (Agilent). Results were compared
to 463 and 91 MM patients analysed by WES and SNP arrays, respectively.
Results: CNAs and acquired somatic gene mutations (SNVs) were detected
in 68% (47/69) and 100% (33/33) of MGUS patients in comparison to 100%
(91/91, p<10-4) and 100% (463/463) of MM patients, respectively. However,
the overall number of both CNAs and SNVs per patient was significantly lower
in MGUS (CNAs: median 2, range 0-15; SNVs: median 89, range 9-315) than
in MM (CNAs: median 16, range 2-49, p<10-18; SNVs median 123, range 1-
897, p<10-4). Non-synonymous SNVs (NS-SNVs) were present in 97% (32/33)
cases with a median 19 (range 0-70) NS-SNVs per patient. Overall, 42 genes
were recurrently mutated in at least 2 patients and 2 non-large protein coding
genes were mutated in at least 3 cases including KLHL6 and NPIPL2. We iden-
tified 7 genes which were significantly mutated in MM in our previous study
including KRAS (n=2), HIST1H1E (n=2) and NRAS, DIS3, EGR1, LTB, PRKD2
(all n=1). IGH translocations were identified in 27% (9/33) of patients: t(11;14)
in 12% (4/33), t(4;14) in 9% (3/33), t(14;16) in 3% (1/33) and t(14;20) in 3%
(1/33). As previously described in MM, only one type of IGH translocation was
found per patient and all 9 cases with IGH translocation did not have additional
hyperdiploidy. We did not find any translocations involving MYC (8q24.21) or
the light chain loci IGK (2p12) and IGL (22q11.2) and any mutations in TP53,
ATM, ATR and ZNFH4 genes involved in DNA repair pathway alterations which
were identified as unfavourable factors to MM patients survival.
Summary and Conclusions: We have performed the first comprehensive
analysis of MGUS patients using exome sequencing together with SNP arrays
and described the main genetic events that are already present in this prema-
lignant state. We proved that complex genetic instability is formed before clin-
ical manifestation first at the gene level then at the chromosome level. Then,
a number of random genetic hits increases to form a landscape for significant
oncogenic hits driving the transition to a malignant state.
This study was supported by grants IGA MHCZ NT13492, OPVK CZ.1.07/2.3.00/
20.0183.
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EXPRESSION LEVELS OF CD38 AND COMPLEMENT INHIBITORY PRO-
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Background: Daratumumab (DARA), an anti-CD38 monoclonal antibody,
induces lysis of multiple myeloma (MM) cells through complement dependent
cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Immunotherapy with DARA is clinically effective, but there is a significant vari-
ability in quality of response among patients.
Aims: We examined potential determinants of DARA sensitivity before start
of treatment, and mechanisms of resistance during therapy, with special
emphasis on the target protein CD38. Since several studies have stressed
the importance of CDC for therapeutic efficacy of antibodies, we also focused
on the complement inhibitory proteins (CIPs), including CD46, CD55, and
CD59. 
Methods: We investigated a panel of cell lines, as well as patient samples by
flow cytometry for CD38, CD46, CD55, and CD59 and assessed their sensi-
tivity to DARA-mediated CDC in vitro. We also evaluated samples from
relapsed/refractory MM patients treated with DARA as a single agent (GEN501
study).
Results: MM and lymphoma cell lines (n=33), as well as primary MM cells
(n=31) expressing high levels of CD38 and low levels of CD55 and CD59
were significantly more sensitive to DARA-mediated CDC, compared to cells
with low CD38 expression and high levels of CD55 or CD59. However, CD46
expression was not associated with CDC sensitivity. We also analyzed the
expression of CD38 and CIPs on MM cells from 21 relapsed/refractory MM
patients directly before start and during DARA treatment. The CD38/CD59
and CD38/CD55 ratios prior to treatment were predictive of clinical response.
Also the sensitivity of pretreatment MM cells towards DARA-mediated CDC
ex vivo, correlated positively with clinical response to DARA, expressed as
maximum reduction in tumor load (R=0.70, P=0.005). At the time of pro-
gression during DARA therapy, there was a significant reduction of CD38
expression and significant increase in CD59 and CD55 expression on both
bone marrow-localized and circulating MM cells, whereas CD46 levels did
not change. As expected, at the time of relapse, a significant decrease in
DARA-mediated CDC was found when compared to baseline values. Inter-
estingly, before start of DARA therapy, two out of 21 patients had two coex-
isting populations of MM cells based on differential expression of CD55
and/or CD59. In both cases, the dominant relapsing clone was strongly pos-
itive for both CD55 and CD59, whereas these clones were present as minor
populations before initiation of DARA treatment. Altogether, these data sug-
gest that elevated CIP expression results in reduced sensitivity to DARA-
mediated CDC, and that upregulation of CD55 and CD59 during DARA treat-
ment may contribute to the development of resistance. With the intention to
improve CDC sensitivity, we evaluated phospholipase C, which enzymati-
cally removes the GPI-anchored CD55 and CD59 molecules from the cell
surface. Indeed, loss of CD55 and CD59 improved DARA-mediated CDC
sensitivity in vitro. Similarly, all-trans retinoic acid (ATRA) enhanced CD38
expression levels and reduced CD55 and CD59 expression resulting in a
significant enhancement of CDC in MM cell lines and primary MM cells. Also
in a humanized mouse model, ATRA significantly enhanced the anti-MM
effect of DARA.
Summary and Conclusions: These results show that baseline CD38/CD55/
CD59 expression may be useful to predict response to DARA, and that tar-
geting CIPs could be a potential adjuvant therapy for DARA or other mono-
clonal antibodies with CDC activity. 
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Background: Current prognosis in multiple myeloma (MM) is based on Inter-
national Staging System (ISS) and the presence of chromosomal abnormali-
ties detected by Fluorescent in situ Hybridization (FISH). However, their ability
to stratify patients is still suboptimal and novel biomarkers are required to bet-
ter predict survival. We identified circulating miRNAs as a non-invasive bio-
marker to stratify MM patients.
Aims: To evaluate the role of circulating miRNA in combination with usual
prognostic factors in MM. In details: 1) to confirm the prognostic value of cir-
culating miRNAs in MM; 2) to investigate their relationship with classical prog-
nostic parameters; 3) to evaluate the addition of circulating miRNAs into a
prognostic model together with ISS and FISH.
Methods: Circulating miRNA expression has been evaluated in newly diag-
nosed MM patients enrolled in the GIMEMA clinical trial NCT#01063179.
Patients were randomized to receive VMP (Velcade-Melphalan-Prednisone)
or VMPT-VT (Velcade-Melphalan-Prednisolone-Thalidomide with Velcade-
Thalidomide maintenance). We used NanoString assay to screen more than
800 miRNAs in serum at baseline and qRT-PCR to validate significant miRNAs
as reported elsewhere (Rocci A et al., Leukemia 2014). High and low expres-
sion of miRNAs were defined using the 233 patients median value as a cut-
off. We defined high risk FISH as the presence of del(17p) or t(4;14) or t(14;16)
and standard risk as all other patients. Proportional hazard regression model
was used, stratified by maintenance (to remove the effect of different
chemotherapy regimens), with ISS treated as time-dependent covariate.
Results: We analyzed serum from 233 evaluable patients, with a median fol-
low-up of 71 months. Patient’s characteristics are reported in Table 1 and are
balanced by age, treatment received and maintenance. Ten miRNAs were
significantly expressed in serum (≥100 counts in at least 20% of patients) and
confirmed by miRNA qRT-PCR. High expression of circulating miR-16 was
confirmed as a strong predictor of better PFS (median PFS 32 vs 26 months,
p=0.020) and OS (median OS unreached vs 58 months, p=0.006) when com-
pared to low miR-16 in univariate analyses. High expression of miR-25 showed
a trend for improved survival (PFS p=0.063; OS p=0.064). In multivariate
analysis including age (>75 yrs vs ≤75 yrs), FISH (standard vs high risk), iso-
lated Del17 by FISH, and ISS (I vs II and I vs III), miR-16 was a strong predictor
of OS (p=0.014). Grouping miR-16, ISS and FISH identified those patients
with a poor prognosis (miR-16 low, ISS 3, high risk FISH) versus good prog-
nosis (miR-16 high, ISS 1, standard risk FISH) with a median OS of 18.4
months vs unreached respectively (p=0.0003). MiR-16 expression divides
patients with standard FISH (n=127) into those with good outcome (high miR-
16, 5 yrs OS: 68%) and those with poor outcome (low miR-16, 5 yrs OS: 47%,
p=0.012). High miR-16 identifies patients with better outcome independently
from treatment arm, however its effect was strongest in patients receiving
VMPT-VT: patients with high miR-16 have a better 5-years PFS (38% vs 21%,
p=0.07) and 5-year OS (76% vs 47%, p=0.0009).
Table 1.
Summary and Conclusions: Circulating miR-16 is a strong prognostic factor
in newly diagnosed MM patients. It independently predicts overall survival in a
model that includes ISS and FISH abnormalities. MiR-16 is independent from
ISS and FISH and these three covariates together dichotomize the population
in terms of overall survival.
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TARGETING EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)
THROUGH CXCR4 BLOCKADE IN MULTIPLE MYELOMA
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Background: Multiple osteolytic lesions are one of the main clinical features
of patients with multiple myeloma (MM), thus suggesting the ability of clonal
plasma cells to disseminate from bone to bone. The bone marrow (BM) homing
process of MM cells is supported by the CXCR4/CXCL12 axis activation. Nev-
ertheless, the role of CXCR4 in mediating MM cell bone metastasis, and the
role of CXCR4-targeted therapy in inhibiting MM cell dissemination has not
been previously reported.
Aims: 1) To define the pro-metastatic role of CXCR4 in vivo; 2) to investigate
the mechanisms of CXCR4-mediated EMT both in vitro and in vivo; 3) and to
test the anti-CXCR4 monoclonal antibody (Ulocuplumab) in inhibiting CXCR4-
mediated EMT phenotype in vivo.
Methods: Gene set enrichment analysis and Atlas of Cancer Signaling Net-
works were used to study publically available gene expression dataset of pri-
mary BM-derived MM plasma cells (GSE24080; n=577; FDR<0.25; P<0.05).
The functional relevance of CXCR4 in mediating MM cell dissemination was
studied by generating CXCR4-gain and -loss-of-function expressing cell lines,
using an in vivo model of MM cell dissemination from bone to bone. Modulation
of EMT-related genes and proteins was tested both in vitro and ex vivo, using
qRT-PCR, western blot, confocal miscroscopy, IHC and flow cytometry. The
anti-tumor effect of Ulocuplumab was tested both in vitro and in an in vivo
model of MM cell bone metastasis, bioluminescence imaging (BLI) and intravital
confocal miscroscopy.
Results: We categorized BM-MM-derived CD138+ cells (GSE24080; n=577)
according to their CXCR4 mRNA expression; and identified an EMT-related
pathway to be significantly activated in high-CXCR4- versus low-CXCR4-BM-
MM CD138+ cells. We next performed CXCR4-gain-of-function studies and
demonstrated that CXCR4+ cells presented with changes in actin cytoskeleton,
with protrusion of cell pseudopodia, sustained by modulation of EMT-related
markers (Slug/Snail/Twist up-regulation; E-cadherin down-regulation), com-
pared to control cells. These findings were recapitulated using an in vivo model
of MM cell bone-to-bone metastasis: CXCR4+ MM cells showed higher levels
of bone-to-bone metastasescompared to control cells, as confirmed on har-
vested host femurs. Lower expression of human (h)-E-cadherin, and higher
expression of h-Twist/h-Snail/h-Slug was confirmed within the BM of the host
femurs. The monoclonal antibody, anti-CXCR4 (Ulocuplumab) exerted an anti-
MM activity in situ, within the s.q. implanted bones; and also reduced MM cell
dissemination from the implanted bone to the host bone. Importantly, Ulocu-
plumab modulated EMT-related genes in the MM cells that metastasized to the
host bones, with enhanced mRNA expression of human (h)-E-cadherin, and
reduced expression of h-Twist/h-Snail/h-Slug and h-CXCR4 in the BM cells
harvested from the host bones of Ulocuplumab-treated mice. Similar findings
were confirmed in an in vivo breast cancer model (MDA-MB-231 intra-cardiac
injected). CXCR4-loss of function in MM cells led to inhibited BM homing and
tumor growth in vivo; with prolonged survival compared to control mice injected
with scramble-transfected control cells. Moreover, Ulocuplumab led to inhibition
of MM tumor growth in vivo, using MM.1S- and RPMI.8226- xenograft s.q.mod-
els; with a synergistic effect when used in combination with lenalidomide or
bortezomib.
Summary and Conclusions: Our study supports the pro-metastatic role of
CXCR4, due to its effect in mediating EMT in both MM and breast cancer in
vivo models, thus suggesting the potential role for using CXCR4-neutralizing
agents in order to delay or prevent tumor cell metastasis to bones.
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Background: Multiple Myeloma (MM) is a plasma cell malignancy with a well
documented immune dysfunction. However, the function of neutrophils in MM
and monoclonal gammopathy of undetermined significance (MGUS) has been
poorly investigated.
Aims: The objective of this investigation was evaluating the activation status
of peripheral neutrophils (N) isolated from MM and MGUS patients.
Methods: Using oligonucleotide microarrays we first evaluated the gene expres-
sion profile (GEP) of granulocytes at the steady state in 10 MM, 5 MGUS and 8
healthy subjects matched for sex and age, identifying Arg-1 and PROK-2 among
the first 10 genes differentially expressed in MM versus healthy granulocytes.
Thus, we validated Arg-1 and PROK-2 by RT-PCR in a series of 60 newly-diag-
nosed MM patients, 30 MGUS and 30 healthy subjects. Activation status on N
was then investigated in the same series, evaluating phagocytic and burst activity
by commercial kit, surface expression of CD64, CD16, CD62L and CD11b, mark-
ers of neutrophil activation and reactive oxygen species (ROS) by flow cytometer.
Finally, we tested the immunosuppressive properties of N isolated from MGUS
or MM patients, through functional assays, based on in vitro co-culture of N iso-
lated from patients and T-lymphocytes from healthy subjects. 
Results: MM-N exhibit an increased expression of ARG-1 compared to MGUS
and healthy subjects (25.5 vs 6.2 vs 1 fold changes in gene expression,
p=0.003), confirmed by functional assay of enzymatic activity of ARG-1, posi-
tively correlated with advanced disease. PROK-2 expression was two times
higher in MGUS than healthy subjects (p=.02) and up to ten times higher in
MM (p=.001). In MM patients, increased levels of PROK-2 were positively asso-
ciated with advanced bone disease and unfavourable cytogenetics. The phago-
cytic activity was reduced in MM-N compared to HS-N and MGUS-N (46% ver-
sus 75% versus 72%, p<0.0001 and p<0.0001 respectively). Oxidative burst
was 71% in MM-N, lower than HS-N (85%, p=0.01) and MGUS-N (86%,
p=0.01). The MM-N exhibit higher levels of ROS (MFI 113±9) compared to HS-
N (MFI 46±7) and MGUS-N (MFI 62±8, p<0.0001 and p=0.0001 respectively).
Expression of CD64 was significantly elevated in MM-N compared to MGUS-
N or healthy subjects-N (p=0.01 and p=0.007 respectively) and was inversely
correlated with phagocytic activity (p=0,01). After 72 hours, MM-N were able to
reduce T-cell proliferation at both tested 1:2 and 1:8 ratios, while MGUS-N
could induce a similar effect only at the highest ratio 1:8. This effect was partially
reverted with the treatment of 200 μM nor-NOHA, an Arg-1 inhibitor.
Summary and Conclusions: Compared to controls, neutrophils obtained from
MM patients have a reduced phagocytic activity, a greater expression of Arg-1
and PROK-2 and exhibit an immunosuppressive function on T lymphocytes.
These features are only minimally present in neuthophils from MGUS patients
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Background: B cell antigen receptors (BCR) control important cell fate deci-
sions of the B-lineage such as differentiation, proliferation and B cell survival.
Recently, it was demonstrated that major subgroups of Burkitt lymphomas (BL)
critically depend on BCR expression. The current treatment regimens consist
of intensive chemotherapy in combination with anti-CD20 antibodies and show
significant toxicity. Pharmacological interference with critical BCR signaling
pathways might open up the possibility for targeted therapies in BL that are
needed in particular for elderly patients and patients with endemic BL in devel-
oping countries.
Aims: Our study aims (i) to identify drug targets in BL, (ii) to validate selected
drug targets in vitro and in vivo and (iii) to elucidate BCR induced processes.
Methods: We performed mass-spectrometry-based phosphoproteomics, tran-
scriptome sequencing and bioinformatic analyses to elucidate BCR signaling net-
works in BL cell lines and patient-derived BL cells. Moreover, we validated identified
drug targets using a compound library and BL xenograft models. Detailed func-
tional analyses were performed for identifying the role of HSP90 in BL.
Results: We identified and quantified about 10.000 phospho-sites in various
BL cell-lines and patient-derived BL cells, of which more than 1000 phos-
pho-sites in almost 600 proteins were regulated in a BCR-dependent manner
leading to dynamic transcription of more than 100 genes. The identified BCR
signaling effectors belong to various functional groups, of which kinases,
transcription factors and cytoskeleton regulators are most represented and
bioinformatic analyses revealed that 83% of the identified BCR effectors were
not described in the context of B cells or lymphoma before. Our data-sets
allowed to investigate the dynamic interplay between receptor-triggered
kinase activation, phosphorylation events and mRNA-/protein expression
changes. While BCR-proximal signaling networks were concordantly regu-
lated among genetically distinct BL cell-types, BCR-distal signaling turned
out to be genotype-specific. Based on the detailed signaling information we
established genotype-specific kinase/substrate/transcriptome networks that
provide functional insights and information about druggable BCR-signaling
pathways in BL. Predicted drug targets were furthermore validated in more
than twenty BL cell lines using a compound screen that allowed us to correlate
BCR signaling profiles with responsiveness to compounds targeting BCR
signaling. For instance, heat shock protein 90 (HSP90) inhibition by small
molecule inhibitors such as AT13387 induced apoptosis in most analyzed BL
cell models and BL xenografts. This was achieved by disruption of BCR signal
initiation due to destabilzation of spleen tyrosine kinase expression that
turned out to critically depend on HSP90 function in BL. In contrast, com-
pounds like Bruton’s tyrosine kinase and protein kinase B inhibitors targeting
the more heterogenous BCR-distal signaling networks induced apoptosis
only in certain BL cell-types.
Summary and Conclusions: Taken together our study is a considerable com-
plement to recent genetic studies that elucidated the mutational landscape in
BL as it reveals mechanisms of signaling addiction to non-mutated druggable
BCR effector proteins. Their further (pre)clinical evaluation as drug targets
seems warranted.
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Background: The introduction of intensive cycles of high-dose immunotherapy
with rituximab has improved the outcome and survival rates in patients with
Burkitt lymphoma (BL). However, early relapse and refractoriness are current
limitations of BL treatment and new biological factors affecting the outcome of
the patients treated with dose-intensive chemotherapy including Rituximab
have not been explored. 
Aims: To characterize by array-based comparative genomic hybridization
(aCGH) and next generation sequencing (NGS) the presence of genetic changes
that could be predictive of the clinical response to Rituximab in a selected group
of BL patients included in the Dose-Intensive Chemotherapy Including Rituximab
(Burkimab trial) from the Spanish PETHEMA cooperative group.
Methods: Forty adolescent and adult BL patients were included. All of them
were homogeneously treated according to Burkimab trial established by the
PETHEMA group. The inclusion criteria were: a) diagnosis of BL or Burkitt-like
lymphoma according to WHO criteria, b) MYC-rearrangement demonstrated
by karyotype and/or fluorescence in situ hybridization c) age greater than 14
years. The segmentation analysis was performed using CGHweb tool. In addi-
tion, amplicon-based NGS was carried out to investigate the mutational status
of TP53 gene (4 to 11 exons). The 454 Life Sciences, a Roche company GS
Junior system was used. The variant analysis was performed using Amplicon
Variant Analyzer (AVA-Roche 454) and Sequence Pilot (JSI Medical Systems)
software. The genomic alterations were associated with clinical, biological and
survival parameters.
Results: CNAs were present in 97.5% of patients. The most common aber-
rations were gains on chromosomes 1q (33%), 7q (31%) and 8q (18%),
whereas the losses predominantly involved chromosomes 9p (23%), 13q
(23%), 15q (21%), 11q (15%) and 6q (10%). The losses on 11q, 13q, 15q or
17p (p=0.028) and poor performance status (ECOG≥2) (p=0.016) was asso-
ciated with the poor response Burkimab. These losses were also associated
with shorter four-year progression free survival (PSF) (50% vs 93%, p=0.012).
Shorter DFS was observed in BL patients with losses on 11q (p=0.003), 15q
(p=0.002) or 17p (p=0.03). The four-year DFS of patients with these losses
was 56% versus 93% for patients without losses. Likewise, BL patients with
losses on 11q (p=0.001) or 15q (p=0.02) had shorter OS than patients without
these abnormalities; the four-year OS of patients with these losses was 60%
vs 96% for patients without them. The ECOG≥2 was associated with a shorter
PFS (p=0.02), DFS (p=0.036) and OS (p=0.012). The losses on 11q, 13q,
15q or 17p (HR, 5.506; 95%CI, 1.283-23.624; p=0.022) and ECOG≥2 (HR,
8.605; 95%CI: 1.044-70.900; p=0.045) were independent risk factors asso-
ciated with shorter PFS. Losses in 11q, 15q or 17p were identified as risk
factors independently associated with shorter DFS (HR, 4.921; 95%CI: 1.0-
22.4; p=0.040) and OS (HR, 7.2; 95%CI: 1.2-41.5; p=0.026). In addition, the
integrative analysis of aCGH and NGS showed that 26% (5/19) of patients
carried at least one alteration in TP53 gene, two cases had loss of 17p and
three cases had missense mutations. TP53alt was associated with a poor
response to Burkimab therapy (p=0.044) and a shorter four-year PFS: 84.6%
vs 25% (p=0.022).
Summary and Conclusions: Losses of 11q, 13q, 15q, or 17p, as well as
TP53alt are associated with a poor response to Dose-Intensive Chemotherapy
Including Rituximab (Burkimab trial). These non-random losses could be used
for the risk stratification of BL patients treated with Rituximab.
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Background: Subcutaneous rituximab (RSC) offers improved patient (pt) con-
venience and healthcare resource savings versus intravenous R (RIV), with
similar efficacy and safety outcomes in the SABRINA study in follicular lym-
phoma (FL). RSC is approved in Europe and other countries for use in FL and
diffuse large B-cell lymphoma (DLBCL).
Aims: To confirm the efficacy and safety of RSC versus RIV plus CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone) for the treatment
of DLBCL.
Methods: The open-label, randomised MABEASE study (NCT01649856)
investigated the efficacy of RSC versus RIV plus CHOP in untreated DLBCL.
Pts were randomised 2:1 to receive RSC (RIV 375 mg/m2 cycle 1; RSC 1400
mg fixed dose cycles 2-8) or RIV (RIV 375 mg/m2 cycles 1-8), plus 6 or 8
cycles of CHOP every 14 or 21 days. Responses (complete response [CR],
unconfirmed CR [CRu], partial response [PR], progressive disease [PD]) were
determined by investigator assessment (Cheson 1999 criteria). Administra-
tion-related reactions (ARRs) were defined as R-related adverse events (AEs)
that occurred ≤24 hours of administration. The primary endpoint was response
rate at end of treatment (EOT). Safety was a secondary endpoint.
Results: In total, 576 pts were randomised (RSC n=381; RIV n=195; intent-
to-treat [ITT] population); baseline characteristics were balanced between
arms. A total of 572 pts (RSC n=378; RIV n=194) received ≥1 dose of R. Nine
RSC pts discontinued after cycle 1, due to AE (n=5), withdrawn consent (n=2),
PD and protocol violation (both n=1); as both arms received RIV during cycle
1, these pts were included in the RIV arm for safety analyses (RSC n=369;
RIV n=203). At EOT (RSC n=342; RIV n=177), response rates were similar
between arms in the ITT population overall (RSC 52%; RIV 51%) and when
pts were stratified by age (~50% for all groups; Table 1). AE rates were com-
parable between the RSC and RIV arms overall (92% vs 91%) and during
cycle 1 (61% vs 64%); the most common AE overall was neutropaenia (RSC
36%; RIV 33%). During cycles 2-8, RSC and RIV pts had similar rates of grade
≥3 AEs (53% vs 50%) and serious AEs (SAEs; 34% vs 31%); the most fre-
quent grade ≥3 AE was neutropaenia (RSC 22%; RIV 20%) and the most com-
mon SAE was febrile neutropaenia (RSC 11%; RIV 6%). ARR rates were sim-
ilar between RSC and RIV pts overall (28%/arm), during cycle 1 (11% vs 14%)
and cycles 2-8 (22% vs 20%). From cycle 2-8, the most common ARR by
System Organ Class (SOC) was general disorders and administrative site
conditions (RSC 10%; RIV 4%). Rates of grade ≥3 ARRs was similar between
arms overall (2% vs 5%), during cycle 1 (0% vs 2%) and cycles 2-8 (2% vs
4%); from cycles 2-8, the most common grade ≥3 ARR by SOC was blood
and lymphatic system disorders (RSC 1%; RIV 3%). In total, 52% (RSC) and
54% (RIV) of pts had R-related AEs; the most frequent R-related AE was neu-
tropaenia (RSC 14%; RIV 16%). Overall, 8% (RSC) and 9% (RIV) of pts dis-
continued R due to AEs, most commonly infections (RSC 2%; RIV 3%). In
total, 63 pts (11%) died (RSC 10%; RIV 13%). AEs led to death in 6% (RSC)
and 7% (RIV) of pts, most commonly due to infections (2%/arm).
Table 1. Response rates at EOT.
Summary and Conclusions: RSC and RIV plus CHOP had similar efficacy
and safety outcomes in previously untreated DLBCL. RSC offers convenience
for pts and efficient utilisation of healthcare resources.
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Background: A significant proportion of primary CNS lymphoma (PCNSL)
patients is refractory or relapses after first line therapy. Clinical presentation
and therapeutic management of patients with relapsed/refractory (R/R) PCNSL
are heterogeneous.
Aims: The aim of this study was to analyze the characteristics, management,
and outcome of R/R PCNSL patients after first-line therapy.
Methods: We analyzed patients with R/R PCNSL who had been prospectively
registered in the database of the French LOC network between 2011 and 2014.
Results: Among 563 PCNSL patients registered in the LOC database, we
identified 256 patients with relapsed (N=93, 16.5%) or refractory (N=163,
29.0%) disease after a median follow-up of 9 [0.3-43.0] months. Median age
was 68 [26-93] years. Most patients (92.6%) had received a methotrexate-
based chemotherapy as first line treatment. First relapse/progression
occurred after a median progression-free survival from diagnosis (PFS1) of
5.1 [0.3-35.8] months. Relapse/progression was asymptomatic in 25.5% of
the cases, mostly diagnosed on systematic neuroimaging. Overall survival
after relapse/progression (OS2) was 3.5 [0-29.6] months for the entire cohort.
At first relapse/progression, 28.2% of the patients received palliative care.
All of them died within 5 months with a median OS2 of 0.6 months. The
remaining patients (71.8%) received salvage chemotherapy (methotrexate,
cytarabine or ifosfamide-based regimens) without (79.5%) or with (20.5%)
consolidation therapy consisting in radiotherapy (14.7%) or intensive
chemotherapy followed by autologous stem cell transplantation (ICT+ASCT)
(85.3%). Survival was significantly longer in patients receiving consolidation
therapy with a median PFS2 (PFS from first relapse/progression) of 13.5 vs
2.6 months and a median OS2 not reached vs 6.7 months (p<0.01). In
patients receiving ICT+ASCT, 44.8% (13/29) experienced a PFS2 longer than
their PFS1. Survival was significantly worse in refractory patients and in
relapsed patients with a PFS1<1 year (median OS2=2.1 and 3.7 months,
respectively) compared to relapsed patients with a PFS1>1 year (median
OS2 not reached, p<0.01) (Figure 1). Other prognostic factors were age (<vs
>60 years), Karnofsky index (KI, >vs <70%), administration of a salvage ther-
apy, and administration of Rituximab. In multivariate analysis, three prognostic
factors remained statistically independent: performance status (KI), duration
of first remission (PFS1) and administration of a salvage therapy.
Figure 1.
Summary and Conclusions: One fourth of R/R PCNSL are asymptomatic
underlining the need for systematic neuroimaging in surveillance. Duration of
first remission (PFS1) is a strong prognostic factor. Salvage chemotherapy fol-
lowed by consolidation with ICT+ASCT is associated with prolonged remission
in a subset of patients.
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Background: The nuclear export protein XPO1 (CRM1) is overexpressed in
all types of malignant lymphoma including DLBCL. Selinexor is a selective
inhibitor of nuclear export (SINE) that inhibits XPO1 to force nuclear retention
& activation of >10 tumor suppressor proteins such as p53, IkBa, FOXO &
p21. Selinexor also reduces levels of c-myc, BCL2 & other oncoproteins. Cur-
rent therapy for DLBCL leads to cures in >50% of patients (pts) after 1-2 lines
of therapy. Pts with relapsed/refractory DLBCL have a very poor prognosis
with expected median survival <1 year.
Aims: We previously reported efficacy & safety of selinexor in pts with relapsed/
refractory Non-Hodgkin’s Lymphoma (NHL) (J. Kuruvilla et al. ASH 2014). Here
we correlate response to selinexor with progression-free (PFS) & overall (OS)
survival of pts with heavily pretreated DLBCL.
Methods: Selinexor was administered orally (3-80 mg/m2) for 8 or 10 doses
in a 28-day cycle in this phase 1 study (NCT01607892). Response evaluation
was performed in cycle 1 and 2 & then every 2 cycles. Comparison of survival
rates was done by Kaplan Meier analysis using 10-weeks timepoint as land-
mark. All pts had heavily pretreated DLBCL (prior R-CHOP & additional thera-
pies) with documented progressive disease on study entry.
Results: In 31 (of 33) pts with heavily pretreated DLBCL, the median number
of prior therapies was 3 (range 1-11). The most common adverse effects (Grade
1/2) occurring after cycle 1 are fatigue (43%), anorexia (38%), nausea (29%),
& dysgeusia (24%). Grade 3/4 adverse events occurring in ≥2 pts are throm-
bocytopenia (62%), neutropenia (24%), anemia (24%), fatigue (10%), hypona-
tremia (10%), syncope (10%), & confusion (10%). These are managed with
dose interruption, platelet stimulators and/or standard supportive care. Among
31 pts treated with at least 1 cycle of selinexor, the overall response rate was
39% (12/31) with a median duration of response of ~7 months. 8 pts (26%)
achieved partial response (PR), & 4 pts (13%) complete response (CR) con-
firmed by PET scan. Selinexor showed similar activity in GCB & non-GCB sub-
types of DLBCL. The overall median PFS & OS for pts on study ≥10 weeks
were 104 days & 155 days, respectively. In order to determine if best response
of CR or PR to selinexor was associated with improved clinical outcomes, the
PFS & OS of responding pts were compared with those of pts with stable (SD)
or progressive (PD) disease. Comparison of OS & PFS for pts with objective
responses vs those with SD & PD revealed a strong correlation between
response & survival (N=24): Median PFS of pts with CR/PR vs SD/PD were
329 & 49 days respectively (p<0.001). Median OS of pts with CR/PR vs SD/PD
were 571 & 108 days, respectively (p<0.01). Furthermore, 4 pts with CR
remained on study for 217, 505+, 525+, & 650+ days.
Summary and Conclusions: Selinexor monotherapy shows significant anti-
cancer activity in pts with heavily pretreated relapsed/refractory DLBCL. Objec-
tive responses to selinexor are durable & correlate with improved OS & PFS
compared with pts who achieve SD or PD, suggesting that these responses
are associated with clinical benefit. Clinical & molecular predictors of objective
response to selinexor are being evaluated. A study of selinexor monotherapy
(pts randomized to high versus low dose) in pts with heavily pretreated DLBCL
is ongoing & combination studies are being initiated.
CML: Clinical trials
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Background: The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as
First-Line Treatment (ENEST1st) study evaluated the efficacy and safety of
nilotinib in a large population of pts with newly diagnosed CML-CP using a net-
work of 14 European Treatment and Outcome Study (EUTOS) standardized
laboratories to monitor molecular response (MR).
Aims: Final results of ENEST1st, evaluated after all pts completed 24 mo of
treatment or discontinued early, are reported.
Methods: ENEST1st was a phase 3b, open-label, multicenter study of nilotinib
300 mg twice daily in adults with newly diagnosed CML-CP. The primary end-
point was the rate of MR4 (BCR-ABL ≤0.01% on the International Scale [BCR-
ABLIS] or undetectable BCR-ABL in cDNA with ≥10,000 ABL transcripts) at 18
mo. Results from 11 ancillary substudies, driven by national investigators and
local study groups, will help shape the future management of CML. All pts pro-
vided written informed consent before entering the study.
Table 1.
Results: In 26 European countries, 1089 pts were treated. Median age was
53 y, 59.0% of pts were male, 90.3% were Philadelphia chromosome positive,
97.0% had typical b2a2 and/or b3a2 BCR-ABL transcripts, and 16.9% were
previously treated with imatinib for ≤3 mo. EUTOS scores were low in 82.6%
and high in 8.6% of pts (8.7% missing). Sokal risk scores were low, intermedi-
ate, and high in 34.6%, 37.5%, and 18.1% of pts, respectively (9.8% missing).
A total of 80.9% of pts completed 24 mo of treatment; 19.1% discontinued
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early, most frequently due to adverse events (AEs; 11.7%). The MR4 rate at 18
mo in all treated pts with typical transcripts and ≤3 mo of prior imatinib (n=1052)
was 38.4% (95% CI, 35.5%-41.3%). Among pts with typical transcripts and
without prior exposure to imatinib, 70.5%, 16.6%, and 2.6% of pts, respectively,
achieved BCR-ABLIS ≤1%, >1% to ≤10%, and >10% at 3 mo. MR rates are fur-
ther detailed in the Table 1. Six pts (0.6%) progressed to accelerated
phase/blast crisis (AP/BC) on study; 13 pts (1.2%) died by 24 mo, including
one due to CML progression (16 mo after study drug discontinuation). The most
common AEs of any cause were rash (21.4%), pruritus (16.5%), and headache
(15.2%). Peripheral artery disease occurred in 1.9% of pts, ischemic heart dis-
ease in 3.4%, and ischemic cerebrovascular conditions in 0.8%; 0.6% of pts
had pleural effusions. Grade 3/4 AEs related to hepatotoxicity and pancreatitis
occurred in 0.4% and 0.6% of pts, respectively. Grade 3/4 thrombocytopenia
and neutropenia occurred in 6.0% and 4.8% of pts, respectively. The most fre-
quently observed grade 3/4 biochemical abnormalities were decreased phos-
phate (14.3%) and increased lipase (7.2%); glucose and lipid monitoring was
not mandated in the study protocol.
Summary and Conclusions: In this large study, frontline nilotinib yielded rapid
and high rates of response and a very low rate of progression to AP/BC; how-
ever, some pts discontinued treatment by 24 mo. As assessed with multicenter
molecular monitoring, MR rates in this study provided prospective confirmation
of the centrally reviewed MR rates in the pivotal ENESTnd study. This process
contributed to the development of standardized definitions for deep MR. Despite
the higher median age of pts in ENEST1st than in prior studies, safety results
were consistent with the known safety profile of nilotinib. Relatively low rates
of the most common AEs may reflect improvements in the management of nilo-
tinib-treated pts. These results support the use of frontline nilotinib 300 mg
twice daily in pts with CML-CP.
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Background: Most of the knowledge about treatments and outcomes of
patients with chronic myeloid leukemia (CML) originates from clinical trials. To
get new and unbiased insights the European Treatment and Outcome Study
(EUTOS) for CML collected population based data in 20 European countries.
Aims: The population-based registry was set up inside the infrastructure of the
EUTOS to further explore the epidemiology, patient and disease characteristics,
treatment and outcomes of CML in Europe. This work focuses on the treatment
and early outcomes of CML in Europe.
Methods: The population-based registry aimed to identify and to document all
newly diagnosed adult patients with Ph+ and/or BCR-ABL+ CML at any stage of
disease in whole countries or specified regions in Europe. First-line treatment and
treatment changes were documented. Cytogenetic responses are analyzed using
cumulative incidences considering death and progression as competing risks.
Results: Overall 2904 Ph+ and/or BCR/ABL1+ adult CML-patients were regis-
tered. 94% of the patients were diagnosed in chronic phase (CP), 3.5% in accel-
erated phase (AP) and 2% in blastic phase (BP). 57% of patients were male. The
median age was 56 years (18-99). Clonal chromosomal abnormalities (CCAs) in
Ph+ cells were found in 11% of patients. 12% of the patients were at high risk of
not achieving CCyR 18 months after start of therapy according to the EUTOS
score. According to the Euro score 38% of patients were low risk, 51% interme-
diate risk and 11% high risk. The follow-up data of 2499 and the first-line therapy
of 1986 patients were documented, for 1954 patients both, first-line therapy and
follow-up is known. As first-line therapy 81% of patients received imatinib, 12%
nilotinib, 3% dasatinib and 4% a treatment based on HU. Patients with high
EUTOS or Euro risk and patients in AP and BP did not receive second generation
tyrosine kinase inhibitors (TKIs) as a frontline therapy more often than patients
with low EUTOS risk or Euro low and intermediate risk or in chronic phase (16%
EUTOS low risk vs 13% EUTOS high risk, 16% euro low risk vs 14% Euro high
or intermediate risk, 16% in CP vs 12% in AC or BP received second generation
TKIs). Patients with CCAs in Ph+ cells, however, received more often second
generation TKIs (22% vs 15%). Median time to first complete cytogenetic remis-
sion (CCyR) was 8 months for all patients. There were major differences observed
between different EUTOS classes (high: 13 months vs low: 8 months), CCAs in
Ph+ cells (with CCAs: 10 months vs without CCAs: 8 months) and treated with
different medications first-line (Imatinib: 8 months vs second generation TKIs: 5
months). Survival probabilities 12 and 24 months after diagnosis were 95% and
92%, respectively. Stratified by Euro score the survival probability at 12 months
was 97% for Euro low and intermediate risk patients and 96% for Euro high risk
patients. At 24 months the survival probability was 96%, 93% and 91%, for Euro
low, intermediate and high risk, respectively.
Summary and Conclusions: This is the first analysis of the treatment and
outcome data from the EUTOS population-based registry, which provides an
unselected sample of Ph+ and/or BCR/ABL1+ adult CML patients in Europe.
Imatinib is the first choice in treatment of CML, while second generation TKIs
as a first-line treatment are not very common. Median time to CCyR in the pop-
ulation is comparable to the one reported in patients enrolled in prospective
randomized trials, while survival at 12 and 24 months are lower probably due
to the selection of patients that are included in clinical trials.
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Background: Imatinib (IM) is the standard treatment for Ph+ Chronic Myeloid
Leukemia (CML) in early Chronic Phase (ECP). Nilotinib (NIL) has demonstrat-
ed superior efficacy to IM (phase 3 ENESTnd trial). The treatment with more
than one TKI, according to the principles of cancer poly-chemotherapy, may
improve the response rates and may decrease the frequency of drug-resis-
tance. The combination of different TKIs is potentially toxic, difficult to be
explored in the ECP setting, while the alternating administration of IM and NIL
could be better tolerated.
Aims: To evaluate the response (either cytogenetic and molecular) and the
long-term outcome of ECP Ph+ CML pts treated with the alternating adminis-
tration of NIL and IM.
Methods: Phase 2 study (ClinicalTrials.gov. NCT00769327). Schedule: NIL
400 mg twice daily for the first 3 months; IM 400 mg daily for the next 3 months;
then, NIL and IM rotating every 3 months, for a total duration of 24 months
(study core). The primary end-point was the Complete Cytogenetic Response
(CCyR) rate at 12 months. The pts remained on study unless both drugs were
discontinued. Definition of failure: according to 2013 ELN recommendations;
event: failure, permanent discontinuation of both drug for any reason, patient
refusal of alternating schedule during the study core. All the analysis was per-
formed according to the ITT principle.
Results: 123 pts were enrolled in 38 Italian hematologic Centers; median age
56 years (range 18-84); 33% low, 45% intermediate and 22% high Sokal score;
94% low EUTOS score; median follow-up 60 months. The CCyR rates at early
milestones were: 68% at 3 months, 73% at 6 months and 67% at 12 months
(primary efficacy variable). The cumulative CCyR rate by 60 months was 93%.
The cumulative MMR rates by 12 and 60 months were 82% and 84%, respec-
tively. The cumulative MR4.0 rates by 12, 24 and 60 months were 43%, 61%
and 62%, respectively. At the end of the 60 months, 69% of pts were on study,
being the majority on monotherapy with NIL (35%) or IM (23%), and only 11%
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still on alternating schedule. Events were observed in 52 (42%) pts: 22 failures,
13 adverse events; 14 patient refusal; 3 others. Failures included: 7 (5.6%)
progressions to accelerated/blast phase (AP/BP); 5 primary resistances; 9 sec-
ondary resistances. The progressions to AP/BP occurred after a median time
of 10 months (4-25 months); 4 pts had an ABL mutation (2 T315I, 1 Y253H, 1
F359V); all pts subsequently died. Athero-thrombotic adverse events (AAE)
were observed in 6 (4.8%) pts: 3 acute myocardial infarctions, 1 unstable angi-
na, 1 peripheral arterial occlusive disease and 1 aortic atherosclerosis. All pts
discontinued permanently NIL and were treated with IM (4 pts) or dasatinib (2
pts). Overall, 12 pts died: 7 for progression to AP/BP, 2 for a second malignancy,
1 after ASCT, 1 for pulmonary embolism, and 1 for cerebral hemorrhage. The
5-year overall survival, progression-free survival, failure-free survival and event-
free survival were 90%, 90%, 78% and 57%, respectively.
Summary and Conclusions: The early response rates achieved with the alter-
nating administration of NIL and IM seem to be higher compared to historical
data with IM alone; however, no difference seems evident in the long-term.
Moreover, we observed a high number of progressions to AP/BP, which can be
only partially justified by the relevant proportion of pts at intermediate or high
Sokal risk. If compared to the results of NIL as monotherapy in ECP CML, this
final analysis, despite the lower rate of AAE, does not support the alternating
schedule of NIL and IM as first-line treatment of ECP CML.
Acknowledgements: European LeukemiaNet, BolognAIL.
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Background: SPIRIT 2 is the largest trial comparing imatinib 400mg with dasa-
tinib 100mg daily. 
Aims: The primary end point of the study is event-free survival at 5 years. A
key secondary endpoint is rate of a major molecular response (MMR, MR3,
BCR-ABL1/ABL ratio <0.1% international scale).
Methods: 814 patients were recruited from 144 hospitals in the UK between
August 2008 and March 2013. 812 patients were randomised, 406 in each arm. 
Results: With a median follow up of 37.4 months, 236 imatinib and 276 dasatinib
patients still received study treatment. 133 patients discontinued due to non-
haematological toxicity. 53/406 (13.1%) on the imatinib arm (predominantly gas-
trointestinal toxicity) and 80/406 (19.7%) dasatinib patients (predominantly
thrombocytopenia). 45/814 patients discontinued due to sub-optimal response
as assessed by the treating physician (not defined by the protocol). These were
predominantly patients on imatinib (42 of 406, 10.3%) as compared to dasa-
tinib-3 of 406, 0.7%. Pleural effusions occurred in 90/406 (22.2%) patients on
dasatinib and 13 required drainage. There was no significant difference in arterial
cardiovascular events: imatinib 3/406 (0.7%); dasatinib 9/406 (2.2%). The MR3
rate at 12 months was significantly (p<0.001) higher with dasatinib 237/406
(58.4%) compared to imatinib 175/406 (43.1%) patients. In contrast to previous
studies, pleural effusion was not associated with a significantly higher rate of
MR3. Accelerated phase (imatinib 1/406; dasatinib 2/406) and blast crisis (ima-
tinib 7/406; dasatinib 4/406) were observed in 14 patients. 38 patients died and
there was no significant difference in deat rate in the two arms (Figure 1).
Figure 1.
Summary and Conclusions: In conclusion, dasatinib-treated patients have a
significantly higher rate of molecular response at 1 year but so far there is no
significant difference in rates of disease progression or overall survival. More
patients abandoned imatinib than dasatinib due to investigator and/or patient
concerns about sub-optimal responses. Further follow up will evaluate differ-
ences in the primary endpoint: event free survival at five years.
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Background: For patients (pts) with CML, achieving and maintaining a deep
molecular response (MR4 ≤0.01% or MR4.5 ≤0.0032%) is necessary to min-
imize the risk of relapse after tyrosine kinase inhibitor (TKI) discontinuation,
which is desirable for long term management of side effects, pregnancy and
for economic reasons. For most pts, TKI therapy achieves an initial rapid
BCR-ABL reduction, followed by a slow decline over many years. Thus,
attaining a deep molecular response requires a long time. More potent TKIs
administered as first line or after switch from imatinib (IM) yield higher rates
of MR4.5. IM treated pts who switched to nilotinib were indeed more likely to
achieve MR4.5 in the subsequent 2 years compared to continuing on IM
(Hughes Blood 2014). However, decisions on treatment switch warrant careful
consideration for a responding patient tolerating IM, who risks toxicity of sec-
ond-line therapy. We analyzed BCR-ABL levels during IM therapy to deter-
mine the probability and timing of subsequent deep molecular response. This
information could guide decisions on treatment switch if certain BCR-ABL
response levels are associated with slow achievement of deep molecular
response.
Aims: We 1) determined the probability of achieving MR4 or MR4.5 on IM,
based on BCR-ABL levels attained; 2) assessed the time to reach these
responses; and 3) identified subgroups where a switch to a more potent TKI
may be warranted if timely TKI discontinuation is the goal.
Methods: 528 consecutive first line IM treated pts were examined. Pts were
grouped by their BCR-ABL level at 12, 18, 24 and 36 months (mo) of IM and
cumulative incidence of confirmed MR4 and MR4.5 by 8 years were calculated.
The BCR-ABL groups were >0.01-0.1% and >0.1-1% for subsequent achieve-
ment of MR4, and >0.0032-0.01%, >0.01-0.1% and >0.1-1% for MR4.5.
Figure 1. Cumulative incidence of MR4 and MR4.5 according to the molec-
ular response level at landmark timepoints of imatinib therapy.
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Results: By 8 years, the overall cumulative incidence of MR4 and MR4.5 were
66% and 53%. At landmark timepoints the subsequent rates of MR4 or MR4.5
were significantly associated with the BCR-ABL level, Figure 1. Rates at 8 years
ranged from 91% MR4.5 for pts with >0.0032-0.01% (MR4) at 36 mo to 15%
MR4.5 for pts with >0.1-1% (no MMR) at 36 mo, P<.0001. The majority of pts with
MR4 at any of the landmarks achieved MR4.5 within the subsequent 2 years with
continued IM. The median time to achieve MR4.5 for pts without an MMR at ≥12
mo was not reached with up to 7 additional years of IM. A substantial temporal
lag in attaining the deep molecular responses was evident between the BCR-
ABL groups for each landmark analysis. For example, for patients with MR4 at
12 mo the median time to MR4.5 was 23 mo after start of IM. However, for pts
with BCR-ABL >0.01-0.1% at 12 mo (MMR) the median time to MR4.5 was 69
mo after start of IM, a difference of >3.5 years (Figure 1B).
Summary and Conclusions: BCR-ABL levels are a powerful predictor of long
term response. Whether switching therapy to achieve timely deep response
will be associated with higher rates of treatment free remission compared with
continuing on IM is currently unknown. Nevertheless, our data show that pts
with <1% BCR-ABL without an MMR by 18-36 mo have a low chance of attain-
ing MR4.5, even with up to 6.5 additional years of IM, whereas most pts with
MR4 at any time achieved MR4.5 with ~2 additional years of IM. These data
provide timelines for the achievement of molecular response levels to clinicians
and their IM-treated pts, and will guide decisions for potential therapy switch to
optimise TKI discontinuation opportunities in pts where this is the goal of long
term management.
Stem cell transplantation: Experimental
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Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
can cure Acute Myeloid Leukemia (AML) thanks to the synergistic combination
of chemotherapy and antitumor immunity. Still, relapse after transplantation
remains an unsolved issue for a large proportion of patients, warranting further
investigation on the immunobiology of AML. Our group demonstrated that, after
partially HLA-compatible HSCT, AML relapse is frequently due to the genomic
loss of the HLA determinants targeted by alloreactive donor T cells (Vago, N Engl
J Med, 2009; Crucitti, Leukemia, 2014), suggesting that relapse might represent
an expression of immune veasion from the donor-derived immune system.
Aims: To identify and characterize novel mechanisms of post-transplantation
leukemia relapse.
Methods: Serial AML samples purified from 9 patients at diagnosis, relapse
after chemotherapy and relapse after allo-HSCT were employed for whole tran-
scriptome profiling using Illumina microarrays. Deregulated genes were iden-
tified by pair-wise LIMMA analysis and used in an unsupervised gene ontology
enrichment analysis. Results obtained by gene expression microarrays were
confirmed in a validation cohort of 21 patients by ad hoc optimized molecular
and cellular assays, including qPCR, immunophenotypic analysis, and func-
tional ex vivo and in vivo experiments.
Results: A 110-gene signature (p<0.1) was able to discriminate between AML
collected at disease diagnosis and at relapse after allo-HSCT. Most of the tran-
scripts deregulated at post-transplantation relapse were involved in immune-
related processes, and in particular in T cell costimulation and in the antigen
presentation machinery. Conversely, no significant enrichment in immune-relat-
ed processes was documented when comparing diagnosis with relapses after
sole chemotherapy. We validated the significant upregulation of the PDL1 and
B7H3 coinhibitory ligands on leukemic cells, accompanied by high levels of
PD1 on the respective donor-derived T cells. Blocking this inhibitory axis by
the usage of an anti-PDL1 monoclonal antibody, we rescued the ability of donor
T cells to proliferate in response to the patient AML blasts. Even more evident
were the de novo changes observed in the antigen presentation machinery at
post-transplantation relapse: selective loss of surface expression of all HLA
class II molecules and downregulation of their master regulator CIITA were
detected in 4 out of 14 patients analyzed, occurring exclusively in patients trans-
planted from partially HLA-incompatible donors. SNP arrays documented no
genomic rearrangement in HLA Class II genes or their regulators, suggesting
an epigenetic origin of the alteration: accordingly, surface expression could be
recovered upon culturing AML blasts in the presence of interferon-γ. Notably,
loss of HLA-II expression on AML blasts abolished their recognition and killing
by donor-derived T cells both in vitro and in vivo, which was recovered upon
exposure of AML blasts to γ-interferon.
Summary and Conclusions: Our results demonstrate that the deregulation
of immune-related processes, and in particular of the pathways involved in T
cell-mediated allorecognition, is a distinctive feature of AML relapses after allo-
HSCT. Identification of patient-specific mechanisms of immune evasion and
relapse might be rapidly translated into personalized therapeutic approaches.
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Background: In spite of the efficacy of allogeneic Hematopoietic Stem Cell
Transplantation (allo-HSCT) in curing Acute Myeloid Leukemia (AML), post-
transplantation relapse remain a major issue. According to the “leukemia immu-
noediting” hypothesis relapse may be due to the outgrowth of immune-resistant
leukemic variants upon the selective pressure of the transplanted immune sys-
tem. Immunodeficient mouse models might represent a precious tool to provide
insights into the immunobiology of this phenomenon. 
Aims: In the present study, we set up a novel mouse-human chimeric model
to characterize the biology of AML engraftment into mice and to model its inter-
actions with adoptively transferred human T cells. 
Methods: AML samples harvested at diagnosis from 26 patients were purified
and infused into non-irradiated immunodeficient NOD/SCID γ-chain null (NSG)
mice. Upon leukemia engraftment mice were sacrificed and purified leukemic
cells were reinfused in serial recipients. To mimic immune pressure, mice
received serial infusions of human T cells, either autologous or allogeneic (HLA-
identical, HLA-matched, HLA-haploidentical or HLA-disparate) to the AML. At
sacrifice, leukemic cells were FACS-purified and gene expression profile was
analyzed using Illumina microarray. Deregulated genes were identified by pair-
wise LIMMA analysis. Gene Ontology and Gene Set Enrichment Analysis curat-
ed databases were interrogated to identify deregulated processes.
Results: Twelve out of 26 primary samples (46%) generated AML xenografts.
Engraftment into mice significantly correlated with poor patient prognosis, and
in particular with relapse after allo-HSCT (p=0.005). Infused leukemic cells
reproducibly engrafted and exponentially expanded in mice, displaying a stable
gene expression profile amongst littermates and upon serial transfer. Notice-
ably, serially transplanted AML exhibited an accelerated and more aggressive
growth kinetic, with selective deregulation of genes involved in cell proliferation,
myeloid differentiation and sister chromathide organization during mythosis.
Four selected AML xenografts were challenged in vivo with serial injection of
T cells. We observed rapid and complete eradication of AML after treatment
with HLA-disparate and HLA-haploidentical T cells from 20/20 treated mice. In
all the cases, HLA matched cells harvested from unrelated donors were effec-
tive in controlling disease outgrowth. On the contrary HLA-identical T cells
granted only temporary control in 6/10 mice, while autologous T cells were
completely inefficacious in 14/14 mice. Leukemic blasts subjected to T cell-
mediated immune pressure showed a specific and reproducible gene signature,
with selective deregulation of genes involved in immune processes. Among
the top-ranked upregulated genes we identified those related to response to
interferons, comprising proteasome and immunoproteasome subunits, as well
as molecules involved in antigen processing and presentation, comprising HLA
Class I and II molecules. This data were further validated in vivo, observing in
real-time the activation of this transcriptional program during the antileukemic
immune response. Interestingly, in several experiments upon initial eradication
we documented AML recurrence, with patterns which were highly reminiscent
of post-transplantation relapses in human.
Summary and Conclusions: The model we set up represents a precious
asset to mimic and decipher the complex dynamics of allo-HSCT, and thus to
provide novel insights into the mechanisms of graft-versus-leukemia effect and
relapse.
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Background: To date, many studies investigating acute graft-versus-host dis-
ease (aGVHD) have focused on seeking potential biomarkers to initiate early
intervention. MicroRNAs (miRNAs) have been reported to be promising diag-
nostic biomarkers for various types of diseases. A few studies have also demon-
strated roles for miRNAs in the pathogenesis of aGVHD. However, data regarding
the function of these miRNAs in human GVHD are limited. Using a miRNA poly-
merase chain reaction (PCR) chip, miR-153-3p was detected as a potential bio-
marker of aGVHD. Interestingly, indoleamine-2,3-dioxygenase (IDO) was found
to be a potential target of miR-153-3p. Many previous studies have demonstrated
that IDO plays important roles in the immunosuppression. Increased IDO expres-
sion may serve as a protective mechanism during aGVHD.
Aims: This study was aim to confirm the regulation of miRNA-153-3p on IDO
both in vitro and mice model experiments, and to elucidate its role during GVHD
development.
Methods: Plasma samples from 70 patients who underwent allogeneic
hematopoietic stem cell transplantation (allo-HSCT) from Sep 2012 to Jun 2013
were prospectively collected at fixed time points from Peking University Institute
of Hematology. RQ-PCR analysis was performed to examine the miRNA expres-
sion of plasma. BALB/c (H-2d) and C57BL/6 (H-2b) mice were used to establish
the GVHD model. Antagomir and its control of miRNA-153-3p were administered
via tail vein injection after allo-HSCT. Clinical and histological assessment of
GVHD was performed. The expression levels of miRNA-153-3p and IDO in mice
organs were also examined by Western Blot and RQ-PCR analysis. 
Results: In this study, elevated plasma miR-153-3p levels at +7 d after trans-
plant appeared to be a good predictor for subsequent aGVHD. IDO was found
to be a potential target protein of miR-153-3p using bio-informative analysis.
In vitro experiments confirmed that miRNA-153 could bind directly to the pro-
moter region of IDO gene and affect its transcription and protein expression
(above data have been reported on 2014 ASH meeting as a poster). In addition,
the expression of plasma IDO was also lower in the aGVHD group at +7d com-
pared to that of control group after allo-HSCT. To confirm the relationship
between miR-153-3p and aGVHD, we established the MHC-mismatched
murine GVHD model. Two groups received antagomir-control and antagomir-
153-3p injection, respectively. The incidence and severity of the aGVHD were
significantly decreased in the recipients of antagomir-153-3p infusion, as evi-
denced by the clinical GVHD scores (p<0.0001). Recipients of the antagomir-
153-3p infusion survived longer compared to those of the antagomir-control
infusion (log-rank test, p=0.0089). The pathological severity of aGVHD at day
+21 in the liver and colon was also reduced in recipients who received
antagomir-153-3p with positively stained granzyme B cell proportions as a
marker. Besides, recipient mice of antagomir-153-3p displayed relatively higher
IDO expression at the early stage after transplantation.
Summary and Conclusions: This is the first study to demonstrate, using in
vitro and animal model experiments, that IDO can be directly regulated by miR-
153-3p and that this miRNA might participate in aGVHD development by down-
regulating IDO. Therefore, miR-153-3p may be a putative bio-target for a novel
strategy for aGVHD intervention.
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Hospitalier Universitaire de Nice, Hôpital de l’Archet, Service d’Hématologie
Clinique, Nice, France, Nice, France
Background: One major problem of allogeneic hematopoietic stem cell trans-
plantation (HSCT) is acute Graft versus Host Disease (aGVHD). aGVHD has
been managed until now with HLA matching and a constant evolving repertoire
of immunosuppressive drugs. One alternative would be to generate in the host
a permanent tolerance state toward the graft. Tolerant inducing cell therapy
has been proposed with adult mesenchymal stromal cells (MSCs). Ex vivo iso-
lated somatic MSCs have been implicated in immunoregulatory functions on
cells from both the innate and adaptive immune system. They were proposed
for cell therapies for treatment of aGVHD, Nevertheless, their use is restricted
because of the few number that can be recovered from adult tissues, their lim-
ited in vitro expansion, and the absence of a full phenotypic characterization.
Therefore other sources of well-defined and unlimited number of MSCs are
needed, and MSCs derived in vitro from human Induced pluripotent stem cell
(huIPS) would be a valuable tool for therapeutic approaches. 
Aims: Because of our expertise in pluripotent stem cell differentiation, we gen-
erated huiPS-MSCs that present a strong immunosuppressive activity on allo-
geneic T cell responses. Our objectives are: 1) To evaluate and characterize
in vitro this immunosuppression. 2) To validate in vivo these results using a
xenoGVHD model.
Methods: To characterize the huIPS-MSCs in vitro, FACS phenotyping and
multipotency were tested. Their immunogenicity in vitro was monitored in co-
cultures with allogenic peripheral blood mononuclear cells (PBMC). The in vivo
immunosuppressive activity of huiPS-MSCs was evaluated using a xenoGVHD
model in immunodeficient NSG (NOD/SCID/IL2rγKO) mice in which human
PBMC were injected intra-peritonally. We established 3 groups: 1) huIPS-MSCs
(control) 2) PBMC 3) PBMC+IPS-MSCs. We repeated huIPS-MSCs injection
weekly with median number of injection n=3 (range 2-3). The activation state
of human allogeneic T lymphocytes recovered from mice between 5 to 8 weeks
after initial injection was evaluated and indicated the level of the xenoGVHD
process and the efficiency of huiPS-MSCs to prevent it.
Results: a) In vitro characterization of huIPS-MSCs - As expected, the huiPS-
MSCs were positive for CD73, CD90, CD105, HLA-I Ags and negative for CD45,
CD34, HLA-II Ags and they were capable of differentiation into the classical mes-
enchymal-derived cells (osteoblast, chondrocytes and adipocytes). To test their
immunosuppressive properties, we analyzed their action on the proliferation of
human T lymphocytes stimulated in an allogeneic manner (Figure 1). The stim-
ulation of PBMC in mixed lymphocyte reaction resulted in CD4 and CD8 T cell
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proliferation (28±7% and 47±8%, respectively), which was significantly reduced
in co-culture with huiPS-MSCs (4±2% and 10±2 respectively, n=3 p<0,05). We
were able to demonstrate using blocking antibodies that part of the inhibition
exerted by the iPS-MSCs is due to a) B7H1, a membrane receptor for the B7
family, known for its inhibitory action on the activation of T lymphocytes b) and
B7H3 (from the same family) whose role remains controversial. b) In vivo char-
acterization of huIPS-MSCs - After sacrifice of mice, human circulating cells,
those present in the peritoneal cavity and in the spleen were analysed by FACS.
Mostly T lymphocytes were detected, and their number was significantly reduced
in mice treated with huIPS-MSCs p<0,05. Intracytoplasmic labelling of recovered
T cells showed that untreated mice displayed high percentages of human differ-
entiated T cells producing IFN g and TNF a (typical of a inflammatory Th1 cytokine
polarization profile), while little or none produced low inflammatory (IL-4) or anti-
inflammatory (IL-10) cytokines. In contrast, in mice treated with the huiPS-MSCs,
the proportion of T cells of the Th1 type was substantially reduced, while that of
T cells producing IL-4 and/or IL-10 was slightly increased. In parallel, T cells
expressing FoxP3 appeared (Figure 1). 
Figure 1.
Summary and Conclusions: We were able to generate immune-modulatory
huiPS-MSCs that can be used to reduce activation of T cells in a xeno-aGVHD
model through a switch from a Th1 inflammatory differentiation pathway to a T
cell regulatory pathway. Our results may favor the development of new tools
and strategies based on the use of pluripotent stem cells and their derivatives
to prevent aGVHD but also for the induction of specific tolerance.
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IN VITRO-GENERATED MYELOID-DERIVED SUPPRESSOR CELLS
(MDSC) PREVENT MURINE GRAFT-VERSUS-HOST DISEASE (GVHD) BY
INDUCING TYPE 2 T CELLS WITHOUT DISABLING ANTI-TUMOR CYTO-
TOXICITY
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Background: Allogeneic bone marrow transplantation (BMT) is a curative treat-
ment modality for hematopoietic malignancies such as acute and chronic
leukemias and lymphomas. Mature donor T cells in the allograft support engraft-
ment, promote early T cell immunity of the recipient and mediate the graft-ver-
sus-tumor (GVT) effect. However, these donor T cells are also responsible for
the induction of graft-versus-host disease (GVHD) by destroying recipient tissue
such as liver, skin, and bowel. Myeloid-derived suppressor cells (MDSCs) are
a population of immature myeloid cells preventing T cell activation, proliferation
and functions.
Aims: Therefore, we tested whether and how in vitro-generated MDSCs suppress
GVHD development without disabling the GVT effect in allogeneic BMT models.
Methods: MDSCs were generated in vitro by culturing BM cells in the presence
of GM-CSF and G-CSF. After 4 days more than 90% of the cells exhibited the
CD11b+Gr-1+ MDSC phenotype. To test, whether and how MDSCs prevent
GVHD, we transplanted allogeneic BM and spleen cells in lethally irradiated
recipient mice in combination with in vitro-generated MDSCs and analyzed sur-
vival and allogeneic T phenotype and functions. By co-injection of syngeneic
tumor cells, the effect of MDSC-treatment on the anti-tumor capacity of allo-
geneic T cells was analyzed.
Results: In-vitro generated MDSCs efficiently suppressed alloantigen-specific
T cell proliferation in vitro. Transplantation of 1x107 MDSCs together with allo-
geneic BM and spleen cells efficiently prevented clinical GVHD and attenuated
histological GVHD. MDSCs expanded in vivo and invaded lymphatic and GVHD
target organs and were still detectable 30 days after BMT. MDSC-mediated
GVHD suppression was antigen-independent since transplantation of MHC
class I deficient MDSCs prevented GVHD development comparable to wild
type MDSCs. Inhibition of GVHD required the presence of MDSCs during T
cell priming because transplantation of MDSCs one week after BMT was inef-
fective in GVHD prevention. Interestingly, MDSC treatment did not significantly
reduce allogeneic T cell numbers in lymphoid and GVHD target organs or
change their homing behavior. However, MDSCs skewed allogeneic T cells
towards type 2 T cells up-regulating Th2-specific transcription factors and
cytokines. Polarization towards type 2 T cell immunity was indispensable for
GVHD prevention since MDSC-treatment failed to prevent GVHD when allo-
geneic STAT6-deficient T cells, which are unable to differentiate into Th2 cells,
were transplanted. However, MDSC-mediated type 2 T cell polarization did not
abrogate anti-tumor cytotoxicity of alloantigen-specific T cells since syngeneic
thymoma tumor cells were efficiently eradicated.
Summary and Conclusions: Therefore, MDSC-induced Th2 polarization might
be exploited in clinical settings for GVHD prophylaxis while simultaneously
maintaining anti-tumor cytotoxicity.
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DOWN-REGULATED BETA2-GPI IS ASSOCIATED WITH A REDUCED ABIL-
ITY TO MITIGATE COMPLEMENT ACTIVATION BY INHIBITING JNK/BID-
DEPENDENT PLATELET DESTRUCTION IN THE PATHOGENESIS OF
IMMUNE THROMBOCYTOPAENIA
X.-H. Zhang1,* X.-L. Zhu1, J.-M. Zhang1, J.-Z. Zhao2, Q.-M. Wang1, F.-E. Feng1,
H.-X. Fu1, M. Lv1, L.-P. Xu1, K.-Y. Liu1, X.-J. Huang1
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking University People’s Hospital, Department of clinical laboratory, Beijing,
China
Background: It is widely accepted that immune complex-mediated classical com-
plement pathway activation represents an important mechanism of platelet
destruction in immune thrombocytopaenia (ITP) (Peerschke at al. Br J Haematol.
2010). However, not all patients diagnosed with ITP have detectable antibodies,
suggesting a potential mechanism of complement activation in the plasma of ITP
patients. Moreover, the mechanisms involved in complement-mediated platelets
lysis are elusive. β2-glycoprotein I (β2-GPI) is a plasma glycoprotein that functions
as a complement regulator (Gropp et al. Blood. 2011); however, there is no infor-
mation available on the role of β2-GPI in patients with ITP to date.
Aims: The aim of the present study was to assess the contribution of β-GPI
in complement activation and the details of its underlying mechanism.
Methods: Twenty-four consecutive patients with primary ITP and 24 healthy
donors were enrolled in this prospective study. The levels of plasma β2-GPI
and serum C1q, C4d, C3b and C5b-9 were determined by ELISA in ITP patients
and healthy donors. The deposition of the fore-mentioned complement com-
ponents on immobilized heterologous platelets was quantified. The levels of
C3 convertases in plasma and the phosphorylation of MAPKs (phospho-ERK,
phospho-JNK, phospho-p38MAPK) and Bid in C5b-9 mediated platelet lysis
were determined using Western blot. To study the effect of β2-GPI on comple-
ment activation, β2-GPI was added to ITP plasma, C3 convertase activity was
assayed via the determination of C3a generation, and serum levels of C5b-9
and its deposition and signalling proteins were re-evaluated.
Results: We first explored the significantly lower concentrations of β2-GPI in
plasma from patients with ITP (80±21 ng/ml) compared with healthy donors
(180±22 ng/ml) (p<0.05). Increased deposition of C5b-9 was observed, indi-
cating the complement activation in ITP plasma. Evidence for enhanced clas-
sical complement pathway activation (C1q and/or C4d deposition) was noted
in 45.8% of patient plasma samples, and alternative pathway activation (C3b)
was observed in 37.5% of plasma samples. Additional evidence for enhanced
complement activation was noted with increased serum levels of C3 conver-
tases (C4b2b and C3bBb). β2-GPI plasma levels and C5b-9 serum levels were
negatively correlated. The intensity of phospho-MAPKs bands revealed the
over-expression of phospho-JNK, and detection of Bid exhibited similar results.
SP600125 (JNK) and BI-6C9 (Bid) inhibitors significantly reduced complement-
mediated JNK/Bid-dependent platelet lysis. Treatment of ITP plasma with β2-
GPI in vitro resulted in a dose-dependent reduction of serum C5b-9 generation
and platelet deposition as well as reduced phospho-JNK and Bid. Moreover,
β2-GPI inhibited C3a generation and formed complexes with C3 in plasma.
Summary and Conclusions: This original observation highlights the role of
β2-GPI in ITP in harbouring complement activation at the level of the C3 con-
vertase and inhibiting JNK/Bid-dependent platelet destruction. The first mention
of decreased β2-GPI in ITP is suggestive of abnormal complement activation.
Our data provide important insights into immune dys-regulation via decreased
plasma β2-GPI, which may be exploited in the pathogenesis of ITP.
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Background: IPFD are a heterogeneous group of rare mucocutaneous bleed-
ing diseases of variable clinical severity. Excessive bleeding at surgery is a
feared complication for bleeding disorders. While studies on the bleeding risk
of surgical procedures in other hemorrhagic disorders, like hemophilia or von
Willebrand disease, have been conducted, very few and small studies have
evaluated the bleeding risk associated with surgery in IPFD.
Aims: Our aim was to evaluate the bleeding complications of surgical proce-
dures in patients with IPFD, the therapeutic approaches adopted for the pre-
vention/treatment of hemorrhage and their efficacy.
Methods: Retrospective, multicentre worldwide study involving clinical centers
managing IPFD. Participants were asked to examine retrospectively their
patient records and to enroll all cases who had undergone surgery fulfilling
strict inclusion criteria. Patients had to have a definite IPDF diagnosis, con-
firmed according to well-defined laboratory and/or molecular genetic criteria.
All types of surgical procedures, including biopsies and dental extractions,
were admitted. Bleeding tendency before surgery was scored by the WHO
bleeding scale, while the extent of bleeding at surgery was assessed by the
BARC classification, subjective evaluation from the surgeon, and/or duration
of bleeding at surgery. Information about prophylactic antihemorrhagic prepa-
ration and emergency treatment of bleeding was requested.
Results: 205 patients (Age 5 to 86, 56.6% females) from 36 centers with 13
different forms of IPFD were enrolled: 43.4% had Glanzmann Thrombasthenia
(GT), 22.4% Primary Secretion Defect (PSD), 6.8% combined α-δ granule defi-
ciency (αδ-SPD), 5.4% Hermansky-Pudlak syndrome (HPS), 4.4% Gray
platelet syndrome (GPS). Data from 389 surgeries were collected, the most
frequent being dental extraction (26.7%), adenotonsillectomy (3.3%), appen-
dectomy (2.8%), endoscopic polipectomy (2.8%). Major procedures, like chole-
cystectomy (2.6%), hernia repair (2.6%), gastrectomy (2.3%), hysterectomy
(1.8%), were also reported. The frequency of excessive bleeding at surgery
was 19.8% by subjective evaluation, 19.7% by the BARC classification and
23.1% by the combination of the two. High frequency of excessive bleeding
was observed in GT (29.5% of 183 procedures), HPS (27.3% of 22) and α-δ
SPD (12.5% of 32). Frequency of excessive bleeding in some forms remains
uncertain due to the low number, but some of them (thromboxane A2 receptor
defect, CalDAG, platelet-type von Willebrand Disease) appear to be at high
risk. Excessive bleeding at surgery was significantly predicted by presurgical
WHO bleeding score=3 (OR 8.1, 95% CI 1.1-61.8) and=4 (OR 28, 95% CI:
2.9-270.5). Prophylactic platelet transfusions were given in 38.5% of proce-
dures and antifibrinolytic agents or DDAVP in 32.9%, and reduced significantly
the risk of excessive bleeding (OR 0.3, 95% CI: 0.2-0.5). Emergency treatment
was administered in 85.5% of the procedures with excessive bleeding (platelet
transfusions in 50.6%, antifibrinolytic agents in 23.4%, FVIIa in 7.8%, DDAVP
in 3.9%, other in 14.3%), and was successful in 81.8% of cases.
Summary and Conclusions: IPFD are associated with a significant surgical
bleeding risk. The risk of excessive bleeding varies according to the diagnosis,
with GT having the highest risk, and is predicted by the preoperative WHO
bleeding score. Preoperative prohemostatic prophylactic treatments prevent
excessive bleeding in most cases. Treatment of excessive bleeding with platelet
transfusions and/or other measures stops excessive bleeding in most, but not
all, treated cases.
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Background: Inherited platelet disorders (IPDs) cause bleeding diathesis with
varying severity. Due to their rarity and extreme heterogeneity, the diagnosis is
complex, poorly standardized, time consuming and expensive. Based on clinical
and laboratory findings, gene mutations may be assessed by means of con-
ventional Sanger sequencing to diagnose the disease. However, in many cases
a proper diagnosis and the genetic cause for the disease remain unknown.
Next generation sequencing (NGS) enables the simultaneous analysis of large
groups of candidate genes in IPDs and may be useful for rapid genetic diag-
nosis and allow optimal disease classification and understanding of the patho-
genesis of the disease.
Aims: To improve the diagnosis of IPDs by using a next generation sequencing
panel.
Methods: Forty patients with suspected IPDs were analysed by NGS panel to
identify a pathogenic mutation causes them. Patients had abnormal bleeding
symptoms, normal coagulation factors levels, platelet function testing pathological
or thrombocytopenia without evidence of acquired causes. Two groups were estab-
lished, first group, 19 patients with specific phenotype and 21 without a proper
diagnosis or unknown phenotype. For the 70 genes associated with IPDs (figure1)
baits were generated to tile 400 kb DNA, corresponding to the exons and splice
sites of all known transcripts of the candidate genes. The bait library was tested
by enriching candidate genes from 50 ng DNA using the Nextera Rapid Custom
Enrichment system followed by massive parallel sequencing (Illumina).
Results: Genotype were determined in 16 of 19 patients with specific pheno-
type, therefore IPDs diagnosis were confirmed: 4 Von Willebrand Disease
(VWD), 1 Glanzmann Thrombastenia (GT), 4 Bernard Soulier syndrome (BSS),
2 MYH9-related disease, 1 Hermansky Pudlack Syndrome, 1 Prekalicrein
defiency, 2 Dysfibrinogenemia, 1 Signalling defect (GP6). Patients with
unknown phenotype, were subdivided in patients with or without thrombocy-
topenia. In patients with thrombocytopenia diagnosis were indentified in 7/10:
2 BSS (GP1BA; c.463C>; c.1280_1291delCCTCAGAGCCCG); VWD-PT
(GP1BA; c.733G>A); Bening Mediterranean macrothrombocytopenia (GP1BB;
c.1A>T), Gray Platelet syndrome (NBEAL2; c.3422_3423insC), Wiskott-Aldrich
Syndrome (WAS; c.802delC) and Thrombocytopenia FLNA-related (FLNA;
c.3695C>T). In IPD patients without thrombocytopenia diagnosis were identified
in 6/11: GT (ITGA2B; c.2063C>T); VWD 2N (VWF; c.2561G>A), mild Hemo-
philia A (F8, c.6623A>G), GATA-related disease (GATA1; C.865C>T), RUNX1-
related disease (RUNX1; c.167T>T), and Defect ADP receptor (P2YR12,
c.835G>A). No mutations were found in 3 patients with “Aspirin-like” syndrome.
In fact, genotype were determined in 13 of 21; and 22 mutations have not pre-
viously been described in the literature. Types of mutations described were 33
missense and 8 frameshift (3 insertion, 5 deletion). All mutations identified by
NGS were confirmed by Sanger sequencing. Once, diagnosis was determined,
functional testing, flow cytometry and electron microscopy were done to estab-
lish a proper diagnosis of IPDs (Table 1).
Table 1.
Summary and Conclusions: NGS by amplicon-based capture enables a fast
diagnosis of IPDs. This tool cold be used ina clinical setting to facilitate the
diagnosis of IPD displaying an unclear phenoptype.
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Background: Although cerebral complications and causes after allogeneic
haematopoietic stem cell transplantation (allo-HSCT) are well documented,
assessment of incidence rates and risk factors of intracranial haemorrhage
(ICH) following allo-HSCT are less frequently reported (Najima et al., Am J
Hematol 2009).
Aims: The aim of this study is to determine the clinical characteristics, risk fac-
tors and prognosis of ICH following allo-HSCT.
Methods: A nested case-control study was conducted that included 175 sub-
jects obtained from 2165 subjects who underwent HSCT in Peking University
People’s Hospital between Sept. 2004 and Jul. 2014. In total, 35 patients with
ICH and 140 controls matched for age, sex, transplantation type and time after
transplantation were identified (total n=175). The incidence of ICH was identified
by searching hospital records of CT and MRI scans.
Results: Among the 2165 patients, 35 patients (1.6%) developed intracranial
haemorrhage, including 29 cases (82.9%) of intraparenchymal haemorrhage
(IPH), 2 cases (5.7%) of subdural haematoma (SDH), 1 case (2.9%) of sub-
arachnoid haemorrhage (SAH), and 3 cases (8.6%) of multiple haemorrhage
lesions in the brain parenchyma. The median time of appearance for cerebral
haemorrhages was 129 days (range, 1-450 days). ICH patients exhibited unique
characteristics compared with controls, including systemic infections, severe
graft versus host disease (GvHD), and coagulation disorders. Multivariate analy-
sis revealed that systemic infections, III-IV acute GvHD, lower platelet count
and fibrinogen levels are independent risk factors for ICH among HSCT
patients. The risk of ICH increases when platelet counts are below 13.2×109/L
and fibrinogen is below 129.5 g/L. However, in addition to the causes indicated
above, chronic GvHD, hypertension, central nervous system leukaemia, and
INR were identified as risk factors by universal analysis. Transplantation-related
mortality rates in the intracranial haemorrhage and control groups were 50%
and 22.2%, respectively. The cumulative survival rates in the intracranial haem-
orrhage and control groups were 47.1% and 75.7% (P<0.001).
Summary and Conclusions: ICH is one of the most common cerebral com-
plications after HSCT and is associated with a high mortality and reduced overall
survival rate. Systemic infections, III-IV acute GvHD, lower platelet count, and
lower fibrinogen levels are individual independent risk factors. To prevent ICH,
it is useful to increase platelet counts and fibrinogen to safe levels.
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OF ELTROMBOPAG (EPAG) TREATMENT ON BONE MARROW (BM) IN
PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: FINAL
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Background: EPAG, an oral thrombopoietin receptor agonist (TPO-RA), is
approved for treating thrombocytopenia in adults with chronic immune throm-
bocytopenia (cITP) with insufficient response to prior therapy. TPO-RAs are
associated with varying degrees of BM reticulin increases.1 Due to lack of pre-
treatment evaluations, the incidence and clinical significance of these findings
have not been established. Inconsistencies in specimen preparation, staining,
and analysis across institutions further confound conclusions.
Aims: To assess the degree of BM fibrosis (reticulin and/or collagen) in cITP
patients (pts) treated for up to 2 years with EPAG.
Methods: Informed consent was provided. BM biopsies were collected at base-
line (prior to study treatment) and at 1 and 2 years on treatment. Specimens
were centrally processed, stained for reticulin (silver) and collagen (trichrome),
and reviewed by central independent hematopathologists for cellularity;
megakaryocyte, erythroid, and myeloid quantity and appearance; trabecular
bone quality; reticulin grade (European Consensus scale of marrow fibrosis
[MF]2); and presence of collagen.
Results: Of 162 pts analyzed, the median age was 42 years (range, 18-80),
104 pts (64%) were female, 50% were White, 20% East Asian, and 29% South
Central Asian. A total of 77% were diagnosed with ITP ≥12 months before study
entry. Prior ITP therapy was reported by 70%, and 8% received prior TPO-RA
treatment. Of 162 pts, 44 withdrew from the study, 118 completed the study,
and 93 had all 3 on-treatment biopsies. MF grades at each time point are shown
in the Figure 1. Of the 3 pts with MF-2 at 1 year, 1 completed 2 years of treat-
ment and had MF-2 at 22 days post-treatment and MF-1 at 288 days post-
treatment. Another pt received 17 months EPAG and had MF-0 at 44 days
post-treatment. The third pt did not have a follow-up biopsy. Of the 2 pts with
MF-3, 1 had an on-treatment MF-0 biopsy 31 days after the MF-3 biopsy and
at 2 years and 1 had MF-0 at 184 days post-treatment. At 2 years, no pt on
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treatment had ≥MF-2. When comparing biopsies at 2 years vs baseline, 80 pts
(86%) had no change in MF grade, 9 (10%) had a 1-grade increase from MF-
0 to MF-1, and 2 (2%) had a 1-grade decrease from MF-1 to MF-0. All pts were
negative for collagen at baseline. At 1 year, 5 pts (4%) were positive for colla-
gen, 3 of whom had MF-2 or MF-3. At 2 years, 1 pt (1%) with MF-1 had collagen
present. None of the on-treatment biopsies were prompted by an abnormal
peripheral blood smear or done at the investigator’s discretion for clinical symp-
toms suggestive of BM dysfunction. Cellularity was normal in 80%, 80%, and
76% of pts at baseline, 1 year, and 2 years, respectively. Trabecular bone thin-
ning was found in 73 pts (50%) at baseline, 61 (50%) at 1 year, and 33 (38%)
at 2 years, likely the result of prior steroid therapy.
Figure 1. Maximum reticulin gradea.
Summary and Conclusions: After 2 years of treatment, no increase in reticulin
was observed in the majority of pts (86%) while few pts (10%) had a mild
increase in reticulin. No pt had an on-treatment biopsy of ≥MF-2 at 2 years or
clinical signs/symptoms indicative of BM dysfunction. Results were similar to
those reported for EXTEND, an EPAG extension study (treatment duration up
to 5.5 years3). These data suggest that treatment with EPAG is generally not
associated with clinically relevant increases in BM reticulin or collagen. This
study (NCT01098487) was funded by GlaxoSmithKline.
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TP-0184 LOWERS HEPCIDIN LEVELS AND IS A POTENTIAL THERAPEU-
TIC FOR ANEMIA OF CHRONIC DISEASE
P. Peterson1, B. Bahr1, K. Soh1, J. Bearss1, W. Kim1, C. Whatcott1, A. Siddiqui-
Jain1, D. Bearss1, S. Warner1,*
1Tolero Pharmaceuticals, Inc., Lehi, United States
Background: The liver peptide hormone, hepcidin, is known as a master regu-
lator of bioavailable iron and red blood cell formation. Hepcidin expression is in
part regulated by pro-inflammatory cytokines that ultimately signal through the
activin-like kinase receptor 2 (ALK2) and SMAD transcription factors leading to
the expression of hepcidin. In chronic inflammatory conditions, such as chronic
kidney disease, rheumatoid arthritis, colitis, and in some forms of cancer, hepcidin
levels remain high, lowering bioavailable iron leading to anemia. Hepcidin func-
tions by binding to and inhibiting ferroportin, an iron pump that functions in
macrophage-based iron recycling and intestinal iron uptake. Several studies
demonstrated that lowering hepcidin could provide a novel approach for targeting
this complicated clinical challenge. Current clinical strategies for these patients
focus on red blood cell transfusions and the use of erythropoetin-based therapies.
Neither of these approaches target the underlying mechanism behind the anemia
associated with chronic inflammation and cancer. 
Aims: The aim of this work is to develop a small molecule inhibitor of ALK2 for
the treatment of hepcidin-driven anemia of chronic diseases. 
Methods: Two animal models were primarily employed for these studies. First,
turpentine oil (TO) was used to induce an acute inflammatory response in
C57BL/6 mice with associated hepcidin-driven anemia. The animals were orally
administered TP-0184 1 hour prior to TO treatment and then 8 hours later.
Plasma and livers were collected 16 hours after TO treatment. Second, a TC-
1 lung cancer syngeneic model was used in C57BL/6 mice. The TC-1 cells
were injected intraperitoneally and allowed to establish for about 1 week. The
mice were then administered TP-0184 repeatedly for 3-5 days, after which,
plasma and livers were collected. Liver hepcidin levels were determined by
RT-qPCR and plasma hepcidin levels by mass spectrometry. Iron levels were
measured by ELISA. 
Results: TP-0184 is a small molecule inhibitor of the kinase activity of ALK2
with an IC50 value of 5 nM. It has minimal activity against JAK2 (IC50=8540
nM), compared to other analogs within the same series. TP-0184 is effective
at targeting hepcidin expression in a HepG2 cell culture model with an EC50
lower than 100 nM. It achieves this activity in HepG2 cells with no observable
toxicities and in a pathway-specific manner. Furthermore, TP-0184 has been
evaluated in multiple animal models of inflammation and anemia. TO was used
to induce an acute inflammatory response in mice resulting in a 14-fold increase
in liver hepcidin levels. Two oral doses of TP-0184 at 100 mg/kg, separated by
8 hours, was able to almost completely reverse the induction of hepcidin that
was stimulated by the TO treatment. In this same TO model, TP-0184 was
evaluated at doses as low as 25 mg/kg to further explore the lower limits of its
efficacy and to establish a therapeutic window. Similarly, TP-0184 was tested
in an anemia of cancer model utilizing TC-1 lung cancer cells. Tumor-bearing
animals experienced a 3-fold increase in liver hepcidin expression, which was
again completely reversed by dosing with TP-0184 at 25 mg/kg. In addition to
the activity observed in these models, TP-0184 demonstrates favorable phar-
macokinetic properties and good drug-like characteristics making it a viable
candidate molecule to move into advanced preclinical testing, IND-enabling
studies and formal clinical development.
Summary and Conclusions: TP-0184 is a potent and selective inhibitor of
ALK2 with good activity in preclinical models of anemia associated with inflam-
mation. We anticipate a clinical development strategy that focuses on anemia
of chronic disease where an erythropoetin-sparing approach might offer signif-
icant clinical benefit both to patients and to health management institutions.
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HEME AND IRON CONTROL OF MACROPHAGE PLASTICITY IS PRE-
VENTED BY THE HEME SCAVENGER HEMOPEXIN AND THE IRON
CHELATOR DFO: LESSON FROM SICKLE CELL ANEMIA
F. Vinchi1,* M. Costa Da Silva1, G. Ingoglia2, S. Petrillo2, E. Tolosano2,
M. Muckenthaler1
1Molecular Medicine Partnership Unit (MMPU), University of Heidelberg &
EMBL, Heidelberg, Germany, 2Department of Molecular Biotechnology and
Health, Molecular Biotechnology Center, University of Torino, Torino, Italy
Background: Hemolytic disorders are associated with recurrent events of
intra- and extra-vascular hemolysis. Under these conditions, circulating heme
levels and erythrophagocytosis are increased resulting in heme and iron accu-
mulation in macrophages of the reticuloendothelial system (RES). The heme
scavenger Hemopexin limits heme accumulation in RES macrophages in
heme-overloaded Hx-null mice, a model mimicking heme release in hemolytic
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events. As a consequence cell activation as well as cytokine and ROS produc-
tion is reduced.
Aims: Here we investigated, both in vitro and in vivo, whether heme and/or
iron affect macrophage activation and polarization (e.g. M1 inflammatory vs
M2 anti-inflammatory macrophages) and, whether this is prevented by
heme/iron scavengers.
Methods: We characterized bone marrow-derived macrophages treated with
aged RBCs (Red blood cells), heme or iron and analyzed the expression of
iron-related genes and cytokines, ROS production and polarization markers.
Additionally, we evaluated the effect of co-treatment with the heme scavenger
Hemopexin or the iron chelator Desferrioxamine. Macrophage polarization was
further assessed in vivo, in mice injected with heme or iron-dextran as well as
in a mouse model of sickle cell disease, which is hallmarked by enhanced
macrophage heme/iron retention. Finally the effect of Hemopexin administration
on macrophage polarization was evaluated in vivo.
Results: Macrophages treated with RBC, heme or iron increase mRNA expres-
sion of HO-1, L-Ferritin and FPN and decrease TfR1 mRNA levels. This corre-
lates with an increase of M1 markers (MHCII/CD86/TNFa) and a decrease of
M2 markers (CD206/Arg1), indicating that heme and iron drive macrophage
polarization towards a M1-like pro-inflammatory phenotype. Interestingly,
heme/iron treatment further potentiates M1 polarization and shifts M2
macrophages to the M1 phenotype. Similarly, heme and iron affect macrophage
plasticity in vivo, promoting macrophage polarization towards a M1 phenotype.
These effects are reversible by the co-treatment with Hemopexin or Desfer-
rioxamine both in vitro and in vivo. Additionally, the treatment with heme together
with the anti-oxidant N-acetyl-cystein or the TLR4 inhibitor, TAK-242, rescued
the up-regulation of some M1 markers and the down-regulation of some M2
markers, likely suggesting that both oxidative stress (induced by both heme
and iron) and the activation of the TLR4 pathway (activated by heme) are
responsible for heme-induced M1 polarization of macrophages. Interestingly,
hepatic macrophages from sickle mice show an enhanced M1-like phenotype,
correlating with increased iron accumulation in these cells and Hemopexin
depletion. The administration of Hemopexin to sickle mice rescued the expres-
sion of M1 markers in liver macrophages to levels similar to control mice, indi-
cating that heme scavenging reduces the pro-inflammatory state of
macrophages, by reducing cell heme-iron loading.
Summary and Conclusions: Here we show that heme and iron induce the
polarization of macrophages towards the M1 pro-inflammatory phenotype. This
finding is of pathophysiological relevance in disorders associated with heme
and iron loading in RES macrophages, such as sickle cell disease. We expect
that the heme/iron-induced increase in cytokine production and ROS will sig-
nificantly contribute to the enhanced inflammatory status of some hemolytic
diseases. The administration of anti-oxidant and hemoglobin/heme scavenger
could be beneficial to counteract the heme-induce pro-inflammatory status of
macrophages in these disorders.
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FUNCTIONAL CHARACTERIZATION OF NOVEL ABCB6 MUTATIONS AND
THEIR CLINICAL IMPLICATIONS IN FAMILIAL PSEUDOHYPERKALEMIA
I. Andolfo1,* C. Auriemma1, R. Russo1, F. Manna1, M.L. Salve1, F. Vallefuoco1,
A.K. Sharma2, S. L. Alper2, L. De Franceschi3, A. Iolascon1
1Dept. of Molecular Medicine and Medical Biotechnologies, University Federico
II of Naples, Ceinge, biotecnologie avanzate, Naples, Italy, 2Division of Nephrol-
ogy, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard
Medical School, Boston, MA, United States, 3Department of Medicine, Univer-
sity of Verona, Piazzale Lo Scuro 10, Verona, Italy
Background: Isolated Familial Pseudohyperkalemia (FP) is a dominant red
cell trait characterized by cold-induced slow ‘passive leak’ of red cell K+ into
plasma, first described in a large Scottish family from Edinburgh (Stewart GW,
et al., 1979). Although in freshly obtained blood samples plasma [K+] was nor-
mal, it was increased when measured in blood stored at or below room tem-
perature. This trait was unaccompanied by clinical symptoms or signs except
for mild abnormalities of red cell shape. Functional gene mapping and sequenc-
ing analysis of the candidate genes within the 2q35-q36 critical interval in three
multigenerational FP families with 20 affected individuals identified two novel
heterozygous missense mutations in the ABCB6 gene that cosegregated with
disease phenotype (Andolfo I. et al., 2013). The two genomic substitutions
altered two adjacent nucleotides within codon 375 of ABCB6, a porphyrin trans-
porter that in erythrocyte membranes bears the Langereis blood group antigen
system (Krishnamurthy PC, et al., 2006; Helias V, et al., 2012).
Aims: In this study we analyzed three additional families and report the first
functional characterization of ABCB6 mutants towards understanding the path-
ogenic mechanism of FP.
Methods: DNA was obtained for genetic analysis from affected and unaffected
family members, after signed informed consent, according to the Declaration
of Helsinki. The search for mutations was performed by direct sequencing of
the ABCB6 gene. cDNAs encoding full-length wildtype ABCB6 were cloned in
pcDNA3.1 vector. The novel point mutations found in our patients: c.1361T>C,
p.V454A; c.826C>T, p. R276W; c.2168G>A, p.R723Q were introduced into
pcDNA3.1-ABCB6 by site-directed mutagenesis. WT and mutants constructs
were transfected into HEK-293 cells for 72h. The cells were maintained at 30°C
to evaluate the effects of reduced temperature. After transfection, the cells were
incubated in a medium containing 86rubidium (86Rb+) as a tracer for K+. 86Rb
was determined in cell lysate, and K was determined in the supernatant by
atomic absorption spectrometry.
Results: In one Bolivian patient we found the homozygous mutation c.1361T>C,
p.V454A. In one patient from Cardiff we found two heterozygous mutations in
trans: c.826G>T, p. R276W and c.2168G>A, p.R723Q. In Ireland family we found
the heterozygous mutation c.826G>T, p. R276W. All these mutations are anno-
tated in public databases as single nucleotide variants (SNVs), suggesting that
many patients with FP could be present in donor blood population and are pre-
dicted to be damaging by in silico analysis by PolyPhen2 and SIFT tools. V454A,
R276W, and R723Q as well as the previously identified, R375Q and R375W,
were expressed into HEK-293 cells. Expression analysis of all mutants showed
no alterations in levels of expression of mutant RNA or polypeptide, and molecular
modeling predicted minimal structural changes resulting from the novel missense
mutations. However, measurement of ouabain- and bumetanide-resistant net
cation flux demonstrated a greater loss of cell K from ABCB6 mutant-expressing
cells compared to ABCB6 WT-expressing cells. The coexpressed R276W/R723Q
mutations, in particular, elicited greater efflux of cellular K+ into extracellular medi-
um than did the other mutants studied.
Summary and Conclusions: Our findings demonstrate that missense muta-
tions in ABCB6 lead to increased cellular K+ efflux as exhibited in RBCs of FP
patients. Storage of FP blood can cause a significant increase in blood K+ lev-
els, with serious clinical implications mostly in neonates and infants receiving
large-volume transfusions of whole blood. Furthermore, the prevalence of FP
might be underestimated, since patients with FP can be asymptomatic and
thus undetected in the donor population. In the future, genetic tests for FP could
be added to blood donor prescreening. 
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DISSECTING THE CONTRIBUTION OF UNREGULATED MACROPHAGE
IRON RECYCLING AND DIETARY IRON UPTAKE IN GENERATING SYS-
TEMIC IRON OVERLOAD
M. Muckenthaler1,2 S. Altamura1,2,*
1Pediatric Oncology, Hematology and Immunology, University of Heidelberg,
2MMPU-Molecular Medicine Partnership Unit, Heidelberg, Germany
Background: Dysregulated iron homeostasis causes a wide spectrum of dis-
eases including hepatic fibrosis and cirrhosis, endocrinopathy and cardiac fail-
ure. This is evident not only in hereditary hemochromatosis, a genetically inher-
ited primary iron overload disorder, but also in many dyserythropoietic syn-
dromes (e.g. beta-thalassemia or congenital dyserythropoietic anemias) in
which the ineffective eyrhtropoiesis drives an abnormal request for iron causing
secondary iron overload.
Systemic iron levels are balanced by the hepatic iron hormone hepcidin and its
“receptor” ferroportin (FPN) to prevent the pathological consequences of iron
overload or iron deficiency. Hepcidin binding to the iron export channel FPN
reduces dietary iron uptake in duodenal enterocytes and iron recycling from
aging erythrocytes in reticuloendothelial macrophages. Despite the importance
of these two cell types as iron exporters, their single contribution in maintaining
systemic iron content has not yet been elucidated.
Aims: The aim of this study is to quantify the individual contributions of
macrophage iron recycling and dietary iron uptake to systemic iron levels. This
knowledge is an important prerequisite to develop specific pharmacological
strategies to limit iron export in iron-related disorders.
Methods: Central to this study is a novel mouse line that expresses a FPN
mutant protein that is unable to bind to hepcidin FPN(C326S) (Altamura et al.,
Cell Met. 2014). Constitutive disruption of the hepcidin/FPN regulatory loop
causes increased serum and hepatic iron levels and a dramatic decrease in
the splenic and duodenal iron content. By using the cre/lox technology, we gen-
erated mice expressing the FPN(C326S) mutation only in duodenal enterocytes
(Villin-Cre/FpnC326S) or in macrophages (Lyz-Cre/FpnC326S) to dissect the
contribution of the two iron-exporting cell types in generating systemic iron
overload. 10-week old C57BL6/J congenic male mice have been analyzed.
Hematological parameters have been measured using the Scil-Vet blood ana-
lyzer while serum iron levels have been assessed using the SFBC and UIBC
iron kits (Biolabo). Gene expression analysis has been performed using SYBR-
green qRT-PCR. All mouse breeding and animal experiments were approved
by and conducted in compliance with the guidelines of the EMBL Institutional
Animal Care and Use Committee.
Results: Mice carrying the FPN(C326S) mutation specifically in the duodenum
have the same alterations in hematological parameters found both in hemochro-
matotic patients and in constitutive FPN(C326S) mice, showing increased
hemoglobin (Hb), hematocrit (HCT) and mean corpuscular volume (MCV).
Serum iron content and transferrin saturation are strongly increased mirroring
a hemochromatotic phenotype. Interestingly, Lyz-Cre/FpnC326S mice of unreg-
ulated macrophage iron export failed to show both hematological and serum
iron alterations, providing the first indication that dietary iron uptake could be
the major responsible mechanism in causing systemic iron overload in
hemochromatosis. Hepatic iron measurement revealed a strong iron accumu-
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lation only in Villin-Cre/FpnC326S mice. This, together with the systemic iron
overload, causes an increase in circulating hepcidin levels triggering the FPN
degradation in reticuloendothelial macrophages and causing splenic iron over-
load. Lyz-Cre/FpnC326S mice, instead, have splenic iron deficiency due to the
presence of the FPN(C326S) unregulated iron channel that continuously
exports iron from reticuloendothelial macrophages.
Summary and Conclusions: Our results show for the first time that unregu-
lated duodenal iron export is the major contributor in the generation of systemic
iron overload. This finding opens new insights in developing pharmacological
strategies aimed to specifically limit dietary iron import for the treatment of pri-
mary and secondary iron overload diseases.
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REGULATORY NETWORK GATA1-MEDIATED ON SEC23B GENE IN ERY-
THROID CELLS
R. Russo1,* I. Andolfo1, A. Gambale1, F. Wandroo2, M.G. Bisconte3, A. Iolascon1
1Molecular Medicine and Medical Biotechnologies, University “Federico II”,
Naples, CEINGE-Biotecnologie Avanzate, Naples, Naples, Italy, 2Department
of Haematology, Sandwell and West Birmingham Hospital, Birmingham, United
Kingdom, 3Dipartimento Oncoematologico, Azienda Ospedaliera di Cosenza,
Cosenza, Italy
Background: Mutations in SEC23B gene cause the congenital dyserythropoi-
etic anemia II (CDA II), an autosomal recessive disorder with ineffective ery-
thropoiesis. Most of patients show biallelic mutations, according to the pattern
of autosomal recessive inheritance. However, the 14% of the cases exhibit an
incomplete pattern of inheritance, with a monoallelic SEC23B mutation. Muta-
tions in deep regulatory regions of the SEC23B gene as well as in CDA-related
loci could be hypothesized as further pathogenetic mechanisms of CDA II.
In SEC23B monoallelic patients we postulated the occurrence of a second
mutation in GATA1 gene, assuming that it could be involved in the regulation
of SEC23B expression. GATA1 transcription factor is a key regulator of the
erythro- and thrombopoiesis. Indeed, mutations in this gene have been already
associated to specific CDA variants, as X-linked dyserythropoietic anemia and
thrombocytopenia (XLTDA).
Aims: Our aims are: (i) to perform a mutational screening of GATA1 genomic
sequence in SEC23B monoallelic patients, as well as in those without SEC23B
mutations; (ii) to characterize the promoter region of SEC23B and (iii) to analyze
GATA1-mediated regulation of SEC23B expression.
Methods: Genomic mutational screening, gene and protein expression analy-
ses were performed as described (Russo et al., 2014; Russo et al., 2013). In
order to characterize SEC23B promoter region, 10 overlapping fragments cov-
ering a 3500 bp upstream region of the gene were cloned upstream the
luciferase gene into PGL3 vector. Putative binding sites for GATA1 (GATA1bs)
in the promoter sequence of SEC23B were predicted by MatInspector and
PROMO web server tools. GATA1 cDNA was cloned into the expression vector
pcDNA3.1. All mutants were obtained by site-direct mutagenesis. Direct binding
of GATA1 to the GATA1bs was assayed by chromatin immunoprecipitation
(ChIP) in both K562 and HEL cells at 6 days of erythroid differentiation.
Results: In our cohort we found one XLTDA patient with the hemizygous muta-
tion GATA1-Gly208Arg. Two SEC23B monoallelic patients showed the single
nucleotide variant rs113966884 G/A in GATA1 5’upstream region. Both GATA1
variants resulted in a reduced gene expression, which in turn correlates with a
decrease of SEC23B expression. By luciferase assay of the deletion mutants
we identified the promoter region of the SEC23B gene (HuSEC23B/3.44). Ten
putative GATA1bs were predicted. However, direct GATA1 binding were con-
firmed for only two sites, GATA1bs/HuSEC23B-2475 and -463. The co-trans-
fection of GATA1bs/HuSEC23B-2475 and -463 mutants and GATA1 WT
showed a reduction of 30-40% luciferase activity respectively, compared to
WT sequence. Finally, we analyzed the GATA1-mediated regulation of SEC23B
expression by co-transfection of several GATA1 mutants (GATA1/G208R,
GATA1/R216W, GATA1/D218G, and GATA1/V205M) and the HuSEC23B/3.44
in HEK-293 cell line. We demonstrated a marked reduction of HuSEC23B/3.44
luciferase activity induced by the mutants G208R and R216W, which are the
causative variants related to XLTDA and congenital erythropoietic porphyria
(CEP), respectively.
Summary and Conclusions: This study provided new insights into the molec-
ular mechanisms of SEC23B regulation. We also suggested an explanation of
the variability of phenotypes GATA1-related by means of the crosstalk of this
gene with SEC23B. Moreover, the identification of transcriptional regulatory
elements in SEC23B promoter could allow the definitive diagnosis of CDAII
patients with peculiar clinical phenotypes or those with incomplete mutation
pattern in SEC23B. 
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PROGRESSIVE ANEMIA CAN BE DETECTED MORE THAN 2 YEARS PRI-
OR TO THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME: RESULTS
FROM THE PRIMARY CARE SETTING IN DENMARK
J.W. Hansen1,* H. Sandholdt2, V.D. Siersma2, A.D. Ørskov1, H. Hasselbalch3,
O.W. Bjerrum1, N.D.F. Olivarius2, K. Grønbæk1, C.L. Andersen3
1Department of Hematology, Rigshospitalet, University of Copenhagen, 2The
Research Unit for General Practice and Section of General Practice, Department
of Public Health, University of Copenhagen, Copenhagen, 3Department of Hema-
tology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark
Background: Myelodysplastic syndrome (MDS) is a clonal hematopoietic
disorder, characterized by inefficient hematopoiesis and peripheral blood
cytopenias. Cytopenias are frequently observed in the primary care setting,
where the clinical presentation of the patient determines further investigations
instituted by the general practitioner (GP). Cytopenias have diverse origins
such as inefficient hematopoiesis due to hematological malignancy, but also
carcinomatosis, vitamin deficiency, immune dysfunction and viral infections.
In primary care, MDS is a rare cause of cytopenias. However, if untreated
they are persistent, and important predictors of survival in MDS according to
the revised international prognostic scoring system (IPSS-R).
Aims: The aim was to investigate the association between pre-diagnostic
cytopenias in primary care patients and the characteristics and prognosis of
subsequently occurring MDS with focus on the hemoglobin concentration.
Methods: Between 2000 and 2010, GPs in the Copenhagen area were all
served by one laboratory, The Elective Laboratory of the Capital Region
(ELCR). The Copenhagen Primary Care Differential Count (CopDiff) database
based on ELCR data contains information on all complete blood cell counts
requested by GPs for 555,039 individuals during this period. Cancer occur-
rence within the CopDiff population has been obtained by linkage to the Dan-
ish Cancer Registry, which is known to have valid and almost complete reg-
istration of cancer cases in Denmark. For the present study, we included cas-
es of MDS (ICD-10=D46) between 2000 and 2010Consecutive hemoglobin
counts obtained prior to diagnosis were modeled using linear regression
models. An estimate of the time point at which hemoglobin levels fell below
the sex specific threshold, was derived from this regression. In this model
patients with secondary MDS were excluded, n=3.
Results: We identified 284 patients with MDS of whom 221 had undergone
primary care laboratory work-up in the preceding 10 years. The remaining
patients (n=63) only had laboratory workup performed after diagnosis and
were excluded from the present study. Hence, we included 221 patients with
an average of four prediagnostic complete blood counts measured (SD=4,5).
Anemia prior to MDS diagnosis was observed for 69% of men and 84% of
women (p=0.01). Using the linear regression model, we estimated that male
patients in average dropped below the hemoglobin reference range 780 days
prior to diagnosis. The corresponding estimate for women was 250 days. At
diagnosis women had estimated hemoglobin levels of 5.5 mmol/L (8.8 g/dL)
and men of 5.1 mmol/L (8.3 g/dL). The proportion of patients presenting with
prediagnostic thrombocytopenia and neutropenia were similar between men
and women (Table 1).
Table 1.
Summary and Conclusions: Cytopenia is a cardinal finding in MDS. In this
study we demonstrate that men on average are anemic two years prior to
diagnosis. This is significantly longer than for women. According to the IPSS-
R we know that the severity of anemia is a risk factor, and we speculate that
this risk factor is an indirect marker of disease duration. If so, it would empha-
size the need for earlier diagnosis to improve prognosis, especially in male
patients. We are currently performing subgroup analysis according to bone
marrow histology, cytogenetics and IPSS-score. This will elucidate if the dura-
tion of prediagnostic anemia per se has prognostic impact. Furthermore we
will investigate these patterns in subgroups of low- and high-risk MDS and
estimate prediagnostic neutro-and thrombocytopenia as well. These data will
be presented at the meeting.
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CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERY-
THROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS
PATIENTS 
O. Kosmider1, M. Passet2, V. Santini3, U. Platzbecker4, V. Andrieu5, G. Zini6,
O. Beyne-Rauzy7, P. Fenaux8, F. Dreyfus9, M. Fontenay9, S. Park10,*
1Hôpital COCHIN, 2Hopital COCHIN, PARIS, France, 3AOU Careggi, University
of Florence, Firenze, Italy, 4Dresden, Dresden, Germany, 5Bichat, Paris, France,
6Catholic University of Sacred Heart, Roma, Italy, 7Toulouse, Toulouse, 8Saint
Louis, 9Cochin, Paris, 10Hematologie Clinique, CHU de Grenoble, 38043
GRENOBLE Cedex 09, France
Background: Up to 50% of lower risk MDS respond to ESA. While response
can be predicted by serum(s) EPO level and transfusion dependence (TD), it
is unknown if molecular findings are also prognostic.
Aims: We studied prognostic factors of erythroid response (HI-E, IWG 2006
criteria) to ESA in 90 lower risk MDS treated with ESA in France (GFM), Italy
(FISM) and Germany (GMDS) with a focus on molecular mutations.
Methods: We studied prognostic factors of erythroid response (HI-E, IWG 2006
criteria) to ESA in 90 lower risk MDS treated with ESA in France (GFM), Italy
(FISM) and Germany (GMDS) selected on the availability of all the following:
sEPO, serum ferritin (SF), marrow slides for review (especially of dysplasia).
In 79 of them, mutational analysis of 39 genes recurrently mutated in myeloid
malignancies was performed on marrow cell DNA collected before ESA treat-
ment, using an AmpliSeq approach (Life Technologies), and confirmed by
Sanger method when the variant allele frequency was found upper than 20%.
Results: Median age was 74 years, with 56% males, 26% RBC TD patients,
median Hb level 9.5 (range 6.2-11) in non RBC-TD patients, median sEPO
level 59 U/l (range 9-402), median SF 411 µg/l (range 11-1856), WHO diagno-
sis: 21% RA; 24.4% RAEB-1; 24.6% RARS; 24.4% RCMD; 2% del(5q); 3.6%
MDS-U. IPSS was low (45.3%) and int-1 (54.7%), IPSS R: very low (6.6%),
low (59.7%) and int (33.7%). 85% pts had dyserythropoiesis, 62% dysgranu-
lopoiesis, 67% dysmegakaryopoiesis. HI-E, was 64.5% and median response
duration 19.8 months. Clonal and subclonal mutations were found in: SF3B1
(40.5% patients), TET 2 (35.4%), ASXL1 (31.4%), DNMT3A (20.2%), U2AF1
(10.1%), SRSF2 (8.8%), IDH1/IDH2 (7.4%), RUNX1 (2.5%), STAG2 (11.4%),
NRas (3.7%), KRas (3.7%), BCOR (3.7%), Jak2, PHF6, and CBL in 1 pt each.
86.1% patients had at least one mutation (median number 2,range 0-6). As
previously described by others, SF3B1, DNMT3A and TET2 co-occurred fre-
quently. ASXL1 and DNMT3A seemed to be mutually exclusive and SRSF2
never co-occurred with SF3B1.The number of mutations was not correlated
with the degree of dysplasia. By univariate analysis, male gender, sEPO level
>100U/L, IPSS-R (int vs very low and low) were correlated with worse HI-E.
Patients with ≤2 mutations had better HI-E (OR: 0.32, p=0.02), but none of the
most frequent mutations (SF3B1, ASXL1, TET2, DNMT3A), age, karyotype
and importance of dysplasia had any impact on HI-E. In an adjusted logistic
regression model, male gender, sEPO level>100U/L and RBC- TD, but not
number of mutations, were significantly correlated with poorer HI-E.
Summary and Conclusions: Presence of >2 mutations predicted worse HI-E
to ESA in lower risk MDS. However, in multivariate analysis, mutational analysis
lost its prognostic value compared to more conventional factors, especially
RBC-TD and sEPO level.
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Background: Prognostication in myelodysplastic syndromes (MDS) has
recently been improved by the revised International Prognostic Scoring System
(IPSS-R). However this score, as the original IPSS, was developed analyzing
primary, untreated patients (pts) only. Data on its usefulness in pts with thera-
py-related MDS (tMDS) is limited.
Aims: We analyzed 615 pts from Spanish, German, Swiss, and Austrian cen-
ters diagnosed 1975-2015. 
Methods: Complete data to calculate the IPSS/-R was available in 446 pts.
Prognostic impact of features was analyzed by uni- and multivariable models
and estimated by a measure of concordance for censored data (Dxy).
Results: Median age was 67 years. According to WHO classification 2% of pts
had 5q-syndrome, 6% RA, 3% RARS, 27% RCMD, 9% RCMD-RS, 16% RAEB-
1, 18% RAEB-2, 6% CMML-1, 2% CMML-2, 3% MDS-U, and 8% AML (RAEB-
T). Cytogenetics were 47% good, 14% intermediate, and 39% poor according
to IPSS, and 2% very good, 44% good, 17% intermediate, 16% poor, and 21%
very poor according to IPSS-R. Regarding prognostic risk groups 19% exhibited
IPSS-low, 33% int-1, 30% int-2, and 18% high, while the IPSS-R was very low
in 8%, low in 26%, intermediate in 16%, high in 22%, and very high in 27%.
Regarding the primary disease most frequent diagnoses were NHL 19%, breast
cancer 16%, myeloma 10%, Hodgkin’s disease, and AML 6% each. 75% of pts
received chemotherapy and 47% received radiotherapy. Most pts received
combination regimen containing alkylating agents in 59%, topoisomerase
inhibitors in 35%, antitubulin agents in 28%, and antimetabolites in 38%. Laten-
cy periods varied broadly (≤3 yrs 22%, >3-≤6 yrs 26%, >6-≤12 yrs 31%, >12
yrs 21%). Median follow-up from MDS diagnosis was 56 months, median sur-
vival 17 months. After MDS diagnosis 30% of pts received disease altering
treatment, including stem cell transplantation in 17%. Features with influence
on survival and time to AML in univariable analysis included age, FAB, WHO,
IPSS, IPSS-R, cytogenetic risk, platelets, marrow and peripheral blasts, ferritin,
fibrosis, year of primary diagnosis. Predominantly influence on survival was
seen for year of MDS diagnosis, hemoglobin, LDH, and use of alkylating agents.
A latency period >12 years showed higher risk of AML. Neutrophil count, use
of chemo or radiotherapy as well as other chemotherapeutic agents had no
influence on both outcomes. Our results indicate that both the IPSS (Dxy 0.26
for survival, 0.35 for AML), and IPSS-R (Dxy 0.32 for both) perform moderately
in tMDS, but not as well as in primary MDS. Adjusting prognostic models to
tMDS seems therefore required. Score versions including peripheral blasts per-
form somewhat better. Separate score versions for survival and time to AML
would give differing weights to most features. Hemoglobin and cytogenetics
would get more weight for survival, while marrow blasts would be more impor-
tant regarding AML. Another issue is the possible integration of data on primary
disease/therapy (Figure 1).
Figure 1. Survival by IPSS-R.
Summary and Conclusions: In contrast to early publications on tMDS, where
aberrant cytogenetics were described in >90% of pts and prognosis was seen
uniformly poor, surprisingly we find good risk karyotypes in a relatively large
number. Although some cases might be unrelated to previous therapy and poor
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risk cytogenetics are still overrepresented, this indicates, different types of
tMDS exist. Our analysis shows that indeed many variables exhibit a prognostic
influence in tMDS. About one third of our pts were treated for MDS. However,
censoring/leaving them out would not show a representative cohort. Further
analyses are performed to propose an optimized scoring system for tMDS.
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SION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK
MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS
FROM THE PHASE 2 PACE-MDS STUDY
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Background: Luspatercept (ACE-536) is a fusion protein (modified activin
receptor IIB-IgG Fc) being investigated for the treatment of anemias with inef-
fective erythropoiesis. MDS patients have increased GDF11 levels (Suragani,
Nat Med 2014) and aberrant Smad2,3 signaling in the bone marrow. Luspater-
cept binds TGF-β superfamily ligands, including GDF11, inhibits Smad2,3 sig-
naling, and promotes late-stage erythroid differentiation, distinct from ESAs. In
a healthy volunteer study, luspatercept was well-tolerated and increased hemo-
globin (Hb) levels (Attie, Am J Hematol 2014).
Aims: This is an ongoing, phase 2, multicenter, open-label, dose-finding study
to evaluate the effects of luspatercept on anemia in patients (pts) with low/int-
1 risk MDS (IPSS classification). Study outcomes include erythroid response
of increased Hb in low transfusion burden (LTB) pts (<4 RBC units/8 weeks),
reduced transfusions in high transfusion burden (HTB) patients (≥4 RBC units/8
weeks), safety, PK, and PD biomarkers.
Methods: Inclusion criteria include age ≥18 yr, anemia, defined as being HTB
or LTB with Hb <10.0 g/dL, EPO >500 U/L or nonresponsive/refractory to ESAs,
no prior azacitidine or decitabine, and no current treatment with ESA, G-CSF,
GM-CSF, or lenalidomide. Luspatercept was administered by SC injection once
every 3 weeks in sequential cohorts (n=3-6 each) at dose levels ranging from
0.125 to 1.75 mg/kg for up to 5 doses with a 3-month follow-up. Treatment of
an expansion cohort is ongoing, with individual pt dose titration allowed.
Patients completing this study may enroll into a 12-month extension study.
Results: Enrollment is complete for 27 pts in the dose escalation cohorts and
31 pts in the expansion cohort. Preliminary safety and efficacy data (as of
23Feb2015) were available for 44 pts (19F/25M, 15 LTB/29 HTB). Mean age
was 68.1 yr, 61% had prior EPO therapy, and 21% had prior lenalidomide. 35
(80%) patients had ≥15% ring sideroblasts (RS) in bone marrow. The mean
baseline Hb for LTB patients was 8.6 g/dL, ranging from 6.8 to 10.1 g/dL. LTB
pts treated at 0.75-1.75 mg/kg (n=13) had a 77% response rate for the primary
endpoint (Hb increase ≥1.5 g/dL for ≥2 weeks) and a 69% IWG HI-E response
rate (Hb increase ≥1.5 g/dL over 8 weeks). The mean (SD) maximum change
in hemoglobin was 2.7 (1.1) g/dL in the higher dose groups compared with 0.9
(0.1) g/dL in the lower dose groups. HTB patients treated at 0.75-1.75 mg/kg
(n=22) had a 50% HI-E response rate (reduction of ≥4 RBC units over 8 weeks).
Higher response rates were observed in pts with ring sideroblasts and/or muta-
tions of SF3B1 (data to be presented). Of the patients with RBC transfusions
during the 8 weeks prior to treatment, 10/28 (36%) patients were transfusion-
free for ≥8 weeks during treatment. Luspatercept was generally well-tolerated.
Adverse events were mostly mild-moderate. The most frequent related adverse
events (>10% patients) were bone pain, headache, diarrhea, myalgia, and pain
in extremity.
Summary and Conclusions: Based on preliminary data in Low/Int-1 MDS
patients, luspatercept treatment at therapeutic dose levels for 3 months led to
HI-E response for increased Hb levels and/or decreased transfusion require-
ment in the majority of patients, with a favorable safety profile. Higher response
rates were observed in patients with ring sideroblasts and/or SF3B1 mutations.
These data strongly support further evaluation of luspatercept in patients with
low to intermediate risk MDS.
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Background: Anemia, a hallmark of MDS, is challenging to treat, particularly
after failure of erythropoiesis-stimulating agents (ESAs). Sotatercept (ACE-
011) is a novel and first-in-class activin type IIA receptor fusion protein that
acts on late-stage erythropoiesis to increase release of mature erythrocytes
into circulation (Carrancio S, et al. Br J Haematol 2014;165:870-82).
Aims: This phase 2, open-label, dose-finding study aims to determine a safe,
tolerable, and effective dose of sotatercept in anemic pts with lower-risk MDS. 
Methods: The primary endpoint was erythroid hematological improvement (HI-
E; modified International Working Group 2006 criteria). Secondary endpoints
included rate of RBC transfusion independence (TI) ≥8 weeks and safety. Eli-
gible pts had International Prognostic Scoring System-defined Low or Inter-
mediate-1-risk MDS (Greenberg P, et al. Blood 1997;89:2079-88) and anemia,
with no response, loss of response, or low chance of response to ESAs. Pts
received subcutaneous sotatercept at 0.1, 0.3, 0.5, 1.0, or 2.0 mg/kg every 3
weeks for up to 8 doses; pts with clinical benefit may receive treatment beyond
8 doses until meeting protocol discontinuation criteria. Informed consent was
obtained from all pts. ClinicalTrials.gov identifier: NCT01736683.
Results: As of February 4, 2015, a total of 59 MDS pts were enrolled: 7, 6, 21,
20, and 5 in the 0.1, 0.3, 0.5, 1.0, and 2.0 mg/kg groups, respectively. Overall,
66% of pts were male, median age was 71 years, and median time from diag-
nosis 4 years. Pts received a median 6 RBC units (range 0-16) in the 8 weeks
prior to treatment; 50 (85%) received ≥4 RBC units (high transfusion burden;
HTB) and 9 (15%) received <4 RBC units (low transfusion burden; LTB). In
this heavily pre-treated cohort, 56 (95%) pts were previously treated with ESAs,
31 (53%) with hypomethylating agents, 27 (46%) with lenalidomide, and 26
(44%) with other MDS treatments. Of 53 pts evaluable for efficacy, 23 (43%)
achieved HI-E: 0 of 7 (0%), 4 of 6 (67%), 9 of 20 (45%), and 10 of 20 (50%)
pts in the 0.1, 0.3, 0.5, and 1.0 mg/kg groups, respectively. Review of efficacy
data for the 2.0 mg/kg dose group is ongoing. Of 45 evaluable HTB pts, 6
(13%) achieved RBC-TI ≥8 weeks; median duration of longest response was
67.5 days, 107 days, and 122.5 days in the 0.3, 0.5, and 1.0 mg/kg dose
groups, respectively. Of 8 evaluable LTB pts, 5 (63%) achieved RBC-TI ≥8
weeks and a mean hemoglobin increase of ≥1.5 g/dL sustained for ≥8 weeks;
duration of RBC-TI for responders ranged from 175-472+ days. Sotatercept
was generally well tolerated. The most common adverse events (AEs), all
grades, were asthenia/fatigue (n=24), peripheral edema (n=12), and diarrhea
(n=12). Eighteen (31%) pts had ≥1 grade 3 or 4 AE; of these, 3 (5%) were
reported as suspected to be study drug-related (1 each with grade 3 pain in
extremity, grade 3 hypertension, and grade 4 acute myeloid leukemia, all in
the 0.5 mg/kg dose group). Overall, 4 pts discontinued due to suspected treat-
ment-related AEs: 1 each with grade 2 hemolytic anemia, grade 2 hypertension,
grade 2 muscular weakness, and grade 2 increased blood pressure with grade
2 diarrhea in the 0.3, 0.5, 1.0, and 2.0 mg/kg groups, respectively.
Summary and Conclusions: Data from this ongoing study suggest sotatercept
was well tolerated, with promising evidence of clinical activity in this cohort of
heavily pre-treated, anemic, lower-risk MDS pts who had failed or were refrac-
tory to prior ESAs.
PF and AFL contributed equally to this abstract as senior co-authors.
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Background: Survival in acute myeloid leukemia (AML) is increasing, but most
survival data come from clinical trials. National registries provide population-
based survival data. Relative survival ratios (RSRs) provide a measure of total
excess mortality associated with AML irrespective of whether the excess mor-
tality is directly or indirectly because of AML. A new statistical method, loss in
expectation of life (LEL), has recently been developed and provides an alter-
native for presenting survival.
Aims: We previously evaluated RSRs in Swedish AML patients 1973 -2005
and found a large improvement in survival for younger patients, while less
improvement was seen among those 71+ years.1 We now extend the study to
include patients diagnosed -2011 aiming to investigate whether there was a
continuous improvement in survival and whether any improvement was seen
among elderly. The aim was also to present trends in survival using LEL.
1 Derolf et al., Blood 2009
Methods: AML patients in the Swedish Cancer Registry 1973-2011 were
included. Date of death was obtained from the Register of Causes of Death.
RSRs and LEL were used to quantify survival. RSR is defined as the all-
cause survival of the patients under study divided by the expected survival
of a comparable group from the general population. LEL is calculated by sub-
tracting the life expectancy for a patient from the life expectancy of a matched
subset of the general population. This is interpreted as the number of life
years lost due to an AML diagnosis. 5-year conditional LEL measures the
LEL for patients conditional on the fact that they have survived 5 years since
diagnosis.
Results: 11598 AML patients (51% males; 2212 diagnosed 2006-2011) were
included. Median age was 69 years. 10 and 69 allogeneic SCTs were per-
fomed in patients 61-70 years (EBMT register data) in the two last calendar
periods, respectively. The increase in RSRs for 1973-2005 continued into the
additional 6 years for all ages except patients 81+ years (Figure 1). The
increase was most pronounced for patients 61-70 years; 0.16 (95% CI: 0.13-
0.19) and 0.28 (95% CI: 0.23-0.33) in 1997-2005 and 2006-2011, respectively.
Among patients 41-60 years RSRs increased from 0.39 (95% CI 0.35-0.43)
to 0.47 (95% CI 0.41-0.52). The greatest improvement in survival 1973-2005
was seen among patients ≤40 years; now the increase in survival was modest.
LEL decreased for all AML patients 1973-2011 but most for those aged 35
and 50 years (Figure 1). A 35-year old male diagnosed in 1973 lost, on aver-
age, 41.6 (95%CI: 40.7-42.5) life years whereas a 35-year old male diagnosed
in 2011 is predicted to lose 19.5 (95%CI: 16.4-22.5) life years. 5-year condi-
tional LEL decreased for younger patients during the study period suggesting
less long-term complications of applied treatment and fewer relapses. How-
ever, young patients surviving 5 years still have their lives shortened by about
two years.
Figure 1. Temporal trends in survival of AML patients illustrated by a) rel-
ative survival rations stratified by age category over calendar period; and
b) temporal trends in the life expectancy of the general population and
AML patiens.
Summary and Conclusions: AML survival continued to improve except among
patients 81+ years. Most improvement was seen among patients 61-70 years.
In Sweden at least 85% of patients of this age are treated with induction
chemotherapy. Our results suggest clear benefit from intensive treatment includ-
ing allogenic SCT. Posakonazol profylaxis was introduced during the last cal-
endar period and risk stratification has improved, both are factors that may also
contribute to increased survival in all age groups.
RSR is useful for comparisons of survival but we believe that using the LEL
and comparing survival in terms of years, rather than proportions, is more intu-
itive and useful for communicating survival statistics.
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Background: Comparative population-based outcome data in AML of older
patients not fit for intensive chemotherapy are rare. Currently available treat-
ment options outside clinical trials are best supportive care (BSC), decitabine
(DAC), azacitidine (AZA), and low-dose cytarabine (LDAC).
Aims: To assess clinical outcome in patients older than 60 years not fit for
intensive chemotherapy within the registry/molecular-screening trial AMLSG
BiO (NCT01252485).
Methods: Between 2011 and 2014 a total of 2651 patients (median age 72
years, range 60- 94) have been registered. Molecular screening was performed
within 48hours for NPM1 and FLT3 mutations as well as for the fusion-genes
PML-RARA, RUNX1-RUNX1T1, MYH11-CBFβ. Treatment and outcome data
were documented based on medical records and case record forms.
Results: Of the 2651 patients, n=1104 (42%) received intensive chemotherapy,
n=88 (3%) AZA, n=162 (6%) DAC, n=250 (9%) LDAC, n=229 (9%) BSC, n=818
(31%) unknown. Of the 729 patients treated non-intensively n=176 (LDAC,
n=134; DAC, n=40; AZA, n=1) were treated in clinical trials. Of the remaining
553 patients, the distribution according to treatment was n=116 LDAC, n=122
DAC, n=87 AZA and n=228 BSC. There was no difference in the age distribution
between the groups BSC, AZA, DAC, LDAC (p=0.22, median 76 years, range
60-92), cytogenetic risk group according to ELN recommendations (high, 26%;
intermediate, 72%; low, 2%; p=0.35), HCT-CI score <3 (p=0.50), but significantly
more patients with ECOG performance status >1 (p<0.001) were in the BSC
group, however, without difference between the treatment-groups AZA, DAC,
LDAC (p=0.76). Patients with a NPM1 mutation were more frequently (p<0.001)
found in the BSC (23%) and the LDAC (22%) group compared to AZA (5%)
and DAC (10%). Overall, FLT3-ITD and FLT3-TKD were detected rarely and
mutually exclusive (3% each) without a difference between the groups (p=0.87,
p=0.89). Significantly (p<0.001) higher white blood counts (WBC) at diagnosis
were present in the BSC (median, 27/nl) and LDAC (median, 29.6/nl) compared
to AZA (median, 3.5/nl) and DAC (median, 5.0/nl), no differences between
groups were present for platelets (p=0.97) and hemoglobin (p=0.60). Median,
one-year and two-year survival according to the 4 groups (BSC, AZA, DAC,
LDAC) are given in the Table 1.
Table 1.
                                                              BSC                AZA                DAC             LDAC
Median survival (months)                            0.9                 9.7                10.1              3.5
One-year survival                                        12%               45%               46%             29%
Two-years survival                                        2%                13%                8%              14%
In a Cox regression model including all patients receiving therapy (AZA, DAC,
LDAC), overall survival was significantly influenced by cytogenetic high-risk
category (HR, 1.8; p=0.006), ECOG performance status <2 (HR, 0.5;
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p=0.0008), treatment (reference LDAC) with AZA (HR, 0.37; p=0.00003), DAC
(HR, 0.38; p=0.00008), but not by NPM1 (p=0.72) and FLT3 (p=0.40) mutational
status. In univariable comparisons, treatment with AZA and DAC resulted in a
significantly better survival of patients with high-risk cytogenetics (p=0.001),
normal cytogenetics (p=0.03), ECOG performance status <2 (p=0.0007), HCT-
CI score <3 (p=0.0006) and low WBC (<4.0/nl).
Summary and Conclusions: In older patients with AML treatment with AZA
or DAC is in the short-term perspective of one to two years superior to LDAC.
However, results beyond 2 years are still dismal for all treatment options.
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Background: In older patients (>60yrs) with AML or high risk MDS (>10%
marrow blasts), the UK NCRI AML16 trial compared two induction courses
of DA vs DClo +/- gemtuzumab ozogamicin (GO). The benefit of GO has
been reported (Burnett et al. J Clin. Oncol 30(32); 3924-31, 2012). The trial
also compared adding etoposide or ATRA to DA induction in a 2x2 design,
and considered the optimal number of courses of treatment and the use of
maintenance therapy.
Aims: Following 2 courses of induction patients with at least a partial remis-
sion (<15% marrow blasts) after course 1, and in CR after course 2 were eli-
gible to be randomised to one course of consolidation (Dauno 50mg/m2 d 1,
2+ara-C 100mg/m2 bid d 1-5) or not; patients in remission after course 2
could be randomised to maintenance (Azacitidine 75mg/m2 for 5 d x9 every
6 wks) or not.
Methods: From 8/2006-5/2012, 1880 patients entered the intensive induction
options: 573 patients were randomised between 3 vs 2 courses in total, and 530
between maintenance and not. Of those randomised for consolidation 474
entered CR after course 1 and 99 achieved PR after course 1 and were in CR
after course 2. Of the 530 patients entering the maintenance randomisation, 421
were in CR post course 1. A total of 453 patients entered both questions. Ran-
domisations were stratified by induction chemotherapy and other demographics
to ensure balance. The demographics of those entering the post induction options
were: median age 67y (53-84); 77% de novo, 14% secondary, 8% high risk MDS;
4%, 82%, 14% favourable, intermediate, poor risk cytogenetics: 18% FLT3-ITD
and 30% NPM1 mutant: 32%, 40%, 28% Wheatley good, standard, poor risk.
Follow-up is complete to 1st January 2014 (median 50.4 months).
Results: For all trial entrants the overall response rate was 69% (CR 59%,
CRi 10%) and 5-yr OS was 14%. There were no significant outcome differences
between induction arms. There was no difference in 5-year survival by consol-
idation randomisation (consolidation 25% vs not 22% HR 0.92 (0.75-1.12)
p=0.4). Similarly, there was no difference in 5-year OS in those who did (24%)
or did not (20%) receive maintenance (HR 0.93 (0.76-1.14) p=0.5). In the 226
patients allocated consolidation there was no difference in 5 year survival
whether they received maintenance (26%) or not (21%) (p=0.7). Of 227 patients
allocated no consolidation there was a non-significant benefit of maintenance
(5yr OS 27% vs 18%, p=0.15), but no significant interaction (p=0.5). During
the study marrow samples were tested for MRD by immuno-flow analysis (Free-
man S. et al. J Clin. Oncol. 31; 4123-4131, 2013) with a sensitivity of 1 in 104.
This showed that for patients in CR after course 1, MRD positivity was the
most powerful predictor of survival in multivariable analysis. In the 74 MRD -
ve patients who received consolidation or not, there was a trend for improved
OS (36% vs 26%) for recipients of consolidation (p=0.09); however, in the 74
patients who were in CR but MRD +ve, survival was significantly inferior with
consolidation (11% vs 27%; p=0.03). In the 73 MRD -ve patients in the main-
tenance randomisation, there was a significant survival benefit for maintenance
(40% vs 13%, p=0.003), but no difference for MRD +ve patients (20% vs 23%,
p=0.9). There was no additional benefit from both consolidation and mainte-
nance irrespective of MRD status. 
Summary and Conclusions: Overall, neither a 3rd course nor demethylation
maintenance improved survival. However in the ~50% of patients who achieved
CR with course 1 who were MRD -ve, OS was improved by consolidation or
maintenance but not incrementally by both. MRD appears to identify chemo-
sensitive patients who benefit from additional treatment whereas the chemo-
insensitive do not.
Acknowledgements: This study received research support from Cancer
Research UK. Celgene provided Azacitidine for the trial.
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Background: In older patients (>60yrs) the UK NCRI AML16 trial compared
two courses of DA vs DClo induction with or without gemtuzumab ozogamicin
(GO). The benefit of the addition of GO has been reported (Burnett et al. J
Clin. Oncol 30(32);3924-3931, 2012). 
Aims: Based on a feasibility study a schedule of Clofarabine 20mg/m2 d 1-5
was combined with Daunorubicin (Dauno) 50mg/m2 d 1-3 for two courses, and
compared with Dauno 50mg/m2 d 1,3,5+ara-C 100mg/m2 bid d 1-10 (course
1) or d 1-8 (course 2). Subsequently, patients with at least a partial remission
(<15% marrow blasts) after course 1, and CR after course 2 were eligible to
be randomised to one course of consolidation (Dauno 50mg/m2 days 1, 2+ara-
C 100mg/m2 bid days 1-5); patients in CR could be randomised to azacytidine
maintenance or not.
Methods: From 8/2006-12/2009, 806 patients were randomised between DA
and DClo, of whom 683 entered the GO randomisation. The median age was
67y (56-84); 72% had de novo, 17% secondary, and 11% high risk MDS; 4%,
73% and 23% had favourable, intermediate, poor risk cytogenetics; 14% were
FLT3-ITD and 20% NPM1 mutant; 30%, 34%, 36% had good, standard, poor
Wheatley risk. Following the two courses of induction, 263 patients were ran-
domised to 2 vs 3 courses (138 from DA and 125 from DClo; 42% were Wheat-
ley good risk, 37% standard risk, 21% poor risk). 274 were randomised to
maintenance or not (137 from DA and 137 from DClo). The post induction inter-
ventions will be reported separately, but are taken into account in this assess-
ment of induction treatments. Follow-up is complete to 1/1/2014 (median FU
66 months). 
Results: In the DA vs DClo randomisation, the overall response rate (ORR) was
68% (CR 61%, CRi 7%) and 5-year OS 14%. The ORR was not different between
DA: 71% (CR 64%, CRi 6%) and DClo 66% (CR 58%, CRi 8%), OR 1.26 (0.94-
1.70) p=0.12, with 60 day all-cause mortality of 15% and 14% respectively.
Remission rates after course 1 were higher with DA (54% vs 47%, OR 1.33 (1.01-
1.76) p=0.04). There were no significant differences between DA and DClo at 5
years in RFS (14% vs 15%, HR 0.98 (0.82-1.18) p=0.9), CIR (78% vs 71%, HR
0.92 (0.76-1.12) p=0.4), death in CR (8% vs 14%, HR 1.50 (0.90-2.49) p=0.12),
survival from CR (20% vs 22%, HR 0.96 (0.79-1.16) p=0.6), survival from relapse
(4% vs 7%, HR 0.92 (0.75-1.13) p=0.4) or OS (15% vs 14%, HR 1.04 (0.89-
1.21) p=0.6). The schedules were equi-toxic, and although neutrophil and platelet
recovery was quicker in the DA arm in both courses DClo patients received sig-
nificantly less transfusion support, days on antibiotics and hospitalisation. There
was no evidence of interaction between the two induction randomisations, or
between the DA vs DClo randomisation and any demographic feature. There
was no evidence of interaction between the number of courses (3 vs 2) or receipt
of maintenance or not. 135/410 patients in the clofarabine induction randomisa-
tion who achieved CR post course 1had information for MRD by immuno-flow
analysis (Freeman S. et al. J Clin. Oncol. 31; 4123-4131, 2013), Of patients in
morphological CR after the first induction course 48% of DA and 47% of DClo
patients were MRD -ve which resulted in a survival of 25% and 37% respectively.
For those who were in CR but were MRD +ve the survival was 14% for DA and
19% for DClo patients.
Summary and Conclusions: DA and DClo in induction give similar outcomes in
older patients, with equivalent toxicity, and slightly lower resource usage on the
DClo arm. Of patients in CR after course 1, as defined by immunoflow MRD +ve.
Acknowledgements: This study received research support from Genzyme
and Cancer Research UK.
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Background: The outcome in CBF-AML [AML with t(8;21)(q22;q22) or
inv(16)(p13.1q22) or t(16;16)(p13.1;q22)] has been largely improved by using
repetitive cycles of high-dose cytarabine (HiDAC) for postremission treatment.
However, still only half of the CBF-AML patients (pts) have a favorable long
term outcome, indicating the need for improved therapeutic approaches. Dasa-
tinib (DAS) is a multikinase inhibitor with activity against the KIT kinase, which
is highly expressed in CBF-AML and mutated in around one third of the cases.
In preclinical studies DAS inhibited growth and survival of AML progenitor cells,
enhanced the sensitivity to chemotherapy and induced in vitro differentiation of
AML cells (Dos Santos et al., Blood 2013; Fang et al., PLoS One 2013). Anec-
dotally, DAS also induced differentiation of blasts in an AML patient with t(8;21)
after single-drug treatment (Chevalier et al., Leukemia 2010).
Aims: The primary endpoint in the open-label AMLSG 11-08 study
(NCT00850382) was to assess the feasibility of DAS after intensive induction
and postremission chemotherapy, and as single agent in 1-year maintenance
therapy in pts with newly diagnosed CBF-AML.
Methods: Adults [≥18 years (yrs)] with CBF-AML received induction with
daunorubicin (60 mg/m2/d, d1-3) and cytarabine (200 mg/m2/d, d1-7); DAS
100 mg/d was added on days 8-21; pts with partial remission could receive a
second induction cycle. Pts achieving a complete remission (CR) or CR with
incomplete hematologic recovery (CRi), were intended to receive four cycles
of HiDAC [cytarabine 3 g/m2 (in pts >60 yrs 1 g/m2) q12h, d1,3,5); DAS 100
mg/d was added on days 6-28 of each cycle. Maintenance with DAS 100 mg/d
was continued for 1 year after completion of chemotherapy or until relapse.
Results: Eighty-nine pts [median age 48.5 yrs; males, n=47; t(8;21), n=37;
inv(16), n=52] were included in the study. The median baseline WBC in AML with
t(8;21) and inv(16) was 9.2 Giga (G)/l and 34.1 G/l, respectively. The current
median follow-up is 2.9 yrs. The overall CR/CRi rate was 93% (83/89); CR/CRi
rate in AML with t(8;21) and inv(16) was 94% and 92%, respectively. Overall,
there were 2 cases with refractory disease and 5 cases with early/hypoplastic
death. The median time until recovery of neutrophils (>0.5 G/l) and platelets (>20
G/l) after induction cycles was 27d and 23d, respectively, and after the consoli-
dation cycles 22d and 21d, respectively. To date, a total of 64 serious adverse
events (SAEs) with suspected causal relationship to DAS have been reported.
Among them the most frequent SAEs were infection-related (n=23); they only
rarely occurred during maintenance phase (n=2). Pleural/pericardial effusion and
liver toxicity CTC ≥3° was reported in 11% (10/89) and 10% (9/89) of the pts,
respectively. There was no significant difference in event-free (EFS) and relapse-
free survival between AML with t(8;21) and inv(16), but overall survival (OS) was
superior (P=.04) in AML with inv(16) (OS at 3-yrs: 80.5% vs 63.4%). When com-
pared with an AMLSG historical control group, there was an improvement in EFS
(P=.04), but so far not for OS (P=.4).
Summary and Conclusions: There was no unexpected excess in toxicity by
the addition of DAS to intensive induction and postremission therapy as well
as of single-agent maintenance. The preliminary data indicate efficacy of the
treatment when compared to historical controls. Based on the favorable toxicity
profile and the encouraging efficacy data, a confirmatory phase III trial with
DAS (AMLSG 21-13; NCT02013648) has been initiated.
Biological pathway deregulation
in B Cell Precursor ALL
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Background: MicroRNAs are essential regulators of normal and malignant
hematopoiesis. We previously described the function of miR-126 in HSC
where it regulates the balance between quiescence and self-renewal (Lech-
man et al., 2012). 
Aims: We aimed at studying the role of miR-126 in induction and maintenance
of high-grade B cell malignancies in mouse and humans.
Methods: We exploited the following techniques: Transduction of murine bone
marrow (BM) cells and human primary ALL blasts with lentiviral vectors (LV);
LV integration site (IS) analysis by linear amplification mediated PCR and map-
ping on the murine genome; RNA sequencing; Immunofluorescence staining
Results: We here report a novel role for miR-126 in the induction and maintenance
of high-grade B cell malignancies. By ectopically expressing miR-126 in trans-
planted BM cells, we observed that up to 60% of mice (n=71) developed B cell
tumors. LV IS analysis revealed that all tumors were monoclonal. We then tracked
back the leukemic clone to different hematopoietic lineages prospectively purified
from the mice 2-6 months before disease onset. IS sharing between normal line-
ages and the leukemic clone suggests a stem or multipotent progenitor cell origin
for most tumors. Importantly, we show that miR-126 is the direct cause for the
induction and maintenance of leukemia, since (i) leukemogenesis is abolished
when miRNA expression is inhibited by doxycycline (doxy) using a tetracycline-
repressible miR-126 cassette, and (ii) established symptomatic leukemia com-
pletely regresses when miR-126 is switched off by doxy. We then performed RNA
sequencing on blasts purified ex vivo before and 24 to 72h after doxy administra-
tion. Gene sets that changed were significantly enriched in migratory functions,
cancer pathways and cell cycle regulators. Strikingly, there was a near-complete
overlap with pathways that resulted significantly regulated by miR-126 in a second
RNAseq dataset obtained from human cord blood (huCB) CD34+ cells following
lentiviral miR-126 overexpression or knockdown. Many genes converged on the
p53 pathway in both murine B-ALL and huCB CD34+ cells. Indeed, overexpression
of miR-126 in huCB CD34+ cells physically displaced p53 from the nucleus and
caused a significant reduction of its transcriptional activity. We identified a dozen
of genes involved in p53 regulation that were directly targeted by miR-126 or miR-
126*, suggesting extensive cooperative regulation of this central tumor suppressor
pathway by miR-126. We further studied the function of miR-126 in Philadelphia+
human primary B acute lymphoblastic leukemia (Ph+ B-ALL) where miR-126
expression ranges from low to high in individual patients. We stably knocked down
miR-126 in primary blasts from five Ph+ B-ALL patients using a miR-126 sponge
LV. Following xenotransplantation, we observed increased apoptosis and impaired
engraftment after primary and secondary transplantation in 4 out of 5 diseases
(miR-126/KD: n=32 mice; Ctrl: n=37 mice), demonstrating the relevance of miR-
126 in human B-ALL. 
Summary and Conclusions: Down-regulation of miR-126 could be exploited
as therapeutic strategy in ALL, since it would deplete leukemic cells while
expanding normal HSC, two ways to restore normal hematopoieis.
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Background: Somatic genetic abnormalities are key initiators and drivers of
disease in acute lymphoblastic leukaemia (ALL). Several chromosomal abnor-
malities have proven clinical utility as prognostic and predictive biomarkers at
initial diagnosis. However, the role of genetic biomarkers in relapsed ALL is
less well understood and has rarely been studied comprehensively within a
clinical trial.
Aims: To evaluate the role of genetics in predicting outcome among children
with relapsed B-cell precursor ALL treated on the international trial, ALLR3.
Methods: We analysed cytogenetic, copy number alteration (CNA) and
sequence mutation data at relapse in representative cohorts of patients.
Patients with a very early relapse (<18 months from first diagnosis) and those
patients with an isolated marrow relapse who had an early relapse (<6 months
from stopping frontline therapy) were treated as clinical high risk (HR) whereas
all other patients were treated as clinical standard risk (SR).
Results: Clinical HR patients accounted for 25% of the cohort and had a sig-
nificantly inferior overall survival (OS) compared to SR patients: 25% (95% CI
15-37) v 65% (57-72), p<0.0001. A total of 427 patients were assigned to pre-
defined cytogenetic risk groups which were predictive of survival post-relapse
in both univariate and multivariate analysis adjusting for clinical risk: good risk
(GR) cytogenetics (ETV6-RUNX1, high hyperdiploidy) 5 years OS 68% (60-
75); intermediate risk (IR) cytogenetics (TCF3-PBX1, IGH translocations, B-
other ALL) 47% (38-55); and HR cytogenetics (BCR-ABL1, MLL translocations,
near haploidy, low hypodiploidy, iAMP21, TCF3-HLF) 26% (14-40), p<0.001.
However, the prognostic effect of cytogenetic risk group was strongest within
the clinical SR group. A representative cohort of 240 patients with marrow
involvement was screened for CNA and mutations affecting key genes in ALL.
Over 75% patients harboured at least one CNA or mutation: CDKN2A/B (39%),
IKZF1 (22%), PAX5 (20%), TP53 (17%), ETV6 (16%), KRAS (12%), NRAS
(12%), NR3C1 (9%), PAR1 (8%), PTPN11 (8%), RB1 (4%), EBF1 (4%), BTG1
(4%), FLT3 (4%), CBL (1%). Cox models adjusted for clinical risk revealed that
only four genes were associated with outcome. Patients with a TP53 alteration
or a deletion of either NR3C1 or BTG1 had an inferior progression free survival
(PFS) with hazard ratios of 2.07 (95% CI 1.20-3.58), p=0.009 and 2.26 (1.38-
3.70), p=0.001, respectively. In addition, cytogenetic GR patients with a NRAS
mutation had an inferior PFS compared with other GR cytogenetic patients
2.54 (1.24-5.22), p=0.01. The integration of clinical and cytogenetic risk groups
with TP53, NR3C1, BTG1 and NRAS gene status revealed three groups: (1)
Favourable-clinical SR patients with GR cytogenetics and without a TP53,
NR3C1, BTG1 or NRAS abnormality; (2) Intermediate-clinical SR patients with
GR cytogenetics and a TP53, NR3C1, BTG1 or NRAS abnormality plus clinical
SR patients with IR cytogenetics; and (3) Adverse-all clinical and cytogenetic
HR patients. The three groups accounted for 35%, 35% and 30% patients,
respectively, and had markedly distinct OS rates: 78% (61-89), 56% (46-65)
and 27% (19-35), p<0.001, respectively. Multivariate Cox models including
variables for treatment and minimal residual disease did not materially alter
the results. Receiver operating characteristic (ROC) curve analysis revealed
that the new index had significantly greater predictive power than clinical risk
alone for both PFS and OS: area under the curve (AUC)=0.73 v 0.67, p=0.02
and 0.75 v 0.69, p=0.03, respectively.
Summary and Conclusions: In conclusion, we have integrated key genetic
information with clinical risk to improve risk prediction in relapsed ALL and pro-
pose a three-tier index which could be used to develop risk-directed therapy in
future trials.
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Background: In acute lymphoblastic leukemia (ALL), involvement of the central
nervous system (CNS) is associated with adverse prognosis. Despite non-
detectable CNS involvement in many cases, CNS-directed therapy is indis-
pensible for relapse free survival indicating subclinical CNS manifestation in
many patients. However, CNS therapy coincides with increased risk for sec-
ondary neoplasms and impaired cognitive skills in ALL survivors.
Aims: In this study, we aimed to characterize mechanisms mediating CNS
involvement in ALL and to identify targets for CNS leukemia directed treatment.
Methods: Primary B-cell precursor (BCP) ALL cells were transplanted onto
NOD/SCID mice. At onset of disease related morbidity, human ALL engraftment
was analyzed in bone marrow (BM), spleen (S), peripheral blood (PB), and
meninges of the recipients by flowcytometry staining for huCD19. Transcrip-
tome profiles of ALL cells isolated from meningeal and BM infiltrates (8 pairs
of 8 CNS+ ALLs) were analyzed. Gene expression was validated by qPCR.
Proliferation, survival and trans-endothelial migration was analyzed in geneti-
cally modified (down-regulation or overexpression) ALL cells and in response
to recombinant protein or an antagonizing antibody. In an in vivo model of
CNS+ ALL, inhibition of CNS manifestation was evaluated.
Results: At onset of leukemia manifestation in recipients transplanted with
BCP ALL, meningeal infiltration was detected along with ALL engraftment in
BM, S and PB in a subset of samples (CNS+) in contrast to absent CNS involve-
ment despite full-blown leukemia in BM, S and PB in others (CNS-). In line,
magnetic resonance imaging revealed meningeal enhancement in CNS+ recip-
ients. By expression profiling, the gene coding for vascular endothelial growth
factor A (VEGF) was identified to be highly expressed in leukemia cells isolated
from CNS as compared to BM-derived cells. Interestingly, VEGF was reported
to mediate cell survival, vascular permeability and trans-endothelial cell migra-
tion and increased levels of VEGF protein were described in cerebrospinal
fluid collected from CNS+ ALL and AML patients. Differential VEGF expression
was confirmed in independent cohorts. VEGF receptor 1 expression was
detected on all ALL cells. However, ALL cell proliferation and survival was not
affected by VEGF overexpression, down-regulation, or exposure to VEGF or
the antagonizing antibody bevacizumab. Further, we addressed the paracrine
effect of VEGF on endothelial cells mediating trans-endothelial leukemia migra-
tion. Upon VEGF incubation, brain endothelial cells (bEND.3) showed induction
of downstream VEGF receptor 2 signaling activity mediating cellular perme-
ability. In a transwell assay, we identified VEGF-dependent trans-endothelial
migration of BCP ALL cells (Nalm-6) with significantly increased or decreased
migration in the presence of VEGF or bevacizumab through bEND.3 monolay-
ers. Moreover, we investigated the effect of VEGF inhibition by bevacizumab
on CNS leukemia manifestation in 3 patient-derived primografts (4 experiments
including 1 replicate) in vivo. Most interestingly, in all 4 experiments anti-VEGF
treatment significantly reduced the leukemia load exclusively in the CNS but
not in BM, S and PB organ compartments indicating that the CNS+ phenotype
is mediated by VEGF and can be controlled by VEGF inhibition.
Summary and Conclusions: We identified VEGF as a mediator of trans-
endothelial leukemia cell migration and CNS manifestation in ALL. Most impor-
tantly, in vivo inhibition of VEGF by bevacizumab significantly decreased
involvement of CNS ALL indicating a novel therapeutic strategy to control CNS
leukemia.
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Background: “ERG-related” childhood B cell precursor acute lymphoblastic
leukemias (BCP-ALL) are characterized by a specific gene expression signa-
ture and by recurrent ERG intragenic deletion. ERG-related patients have a
favourable outcome, despite a high incidence of IKFZ1 deletions. Nothing is
known about non-coding (nc) RNA regulation in this leukemia subtype.
Aims: To investigate the main features of ERG-related patients by integrative
genomic and gene expression analysis in an Italian cohort of B-others ALLs
enrolled in the AIEOP ALL 2000 therapeutic protocol with emphasis on ncRNAs.
Methods: 143 BCP-ALL patients lacking known genomic aberrations or a
hyperdiploid karyotype (”B others”) were assigned to the ERG-related subtype
according to their gene expression profile (GEP) and ERG and IKFZ1 aberra-
tions were assessed by genomic analyses. A representative sub-cohort of “B
others” including 8 ERG-related and 16 non-ERG-related samples were profiled
by ncRNA microarray (Mirna1.0, Affymetrix) and validated by qRT-PCR.
Results: Non supervised clustering of 143 B-others patients identified a cluster
of 35 samples (24.5%) in which 15 (45.5%) carried the ERG intragenic deletion.
None of patients outside this “ERG-related” GEP cluster had ERG deletions.
Similar to previous reports from BFM and EORTC childhood ALL protocols for
the ERG deleted subgroup, our GEP defined ERG-related patients were char-
acterized by more common IKZF1 deletions (35.3% compared with 26.2% in
non-ERG related) and a favourable outcome, with a cumulative relapse inci-
dence at 5 years of 6%±4.1 vs 25.7%±4.3, p-value 0.03; (3/35 vs 29/108 relaps-
es). Analysis of ncRNAs revealed two interesting findings: Upregulation of the
oncogenic miR-125b-2 cluster (hsa-miR-125b, -125b-2*, -99a, let-7c) and the
related hsa-miR-100, hsa-miR-125a-3p, and a specific signature of snoRNAs
tightly clustered within the ERG-related group. Strikingly the differentially
expressed snoRNA probe sets (adjusted p-value <0.05) were located mainly
in the Prader-Willi syndrome (PWS) locus at chromosome 15q11.2, a locus
controlled by genomic imprinting. These snoRNAs are processed from a pater-
nally expressed transcript that includes the PWS imprinting center upstream
from SNURF/SNRPN. Specifically, there was up-regulation of SNORD109a,
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SNORD64, SNORD107 and 11 snoRNAs of the SNORD116 cluster
(SNORD116-11, 14, 15, 16, 17, 20, 21, 22, 23, 24, 25) and downregulation of
a subset of SNORD116 snoRNAs (SNORD116-4, 6, 10, 12, 13, 26) in ERG-
related patients. Validation by qRT-PCR confirmed microarray findings.
Figure 1.
Summary and Conclusions: ERG-related GEP defines a phenotypically
unique subgroup in which only half carry ERG deletions, suggesting another
underlying pathogenic mechanism beyond ERG intragenic deletion. We have
identified a ncRNA signature specific of ERG-related BCP-ALL that can be
used for differential diagnosis of these patients. While loss of imprinting asso-
ciated with modified snoRNA expression was reported in acute promyelocytic
leukemia, this is the first report of abnormal expression of snoRNAs in childhood
BCP-ALL. The specific clustering of these snoRNAs within the imprinted PWS
locus suggests a potential epigenetic mechanism underlying ERG-related ALLs. 
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GENOMIC AND DRUG RESPONSE PROFILING OF FATAL TCF3-HLF-POS-
ITIVE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIES
RECURRENT MUTATION PATTERNS AND NOVEL THERAPEUTIC
OPTIONS
J.-P. Bourquin1,* U. Fischer2, M. Forster3, A. Rinaldi1, T. Risch4, S. Sungalee5,
W. Hans-Jörg4, B. Bornhauser1, G. Michael2, K. Christina2, S. Adrian5,
S. Marc4, W. Catherine4, V. Amstislavskiy4, A. Baruchel6, B. Thies7,
B. Giuseppe8, C. Gunnar7, C. Hélène9, D. Dardane1, D. Mauro10,
M.P. Dobay10, C. Eckert11, E. Ellinghaus3, S. Eugster1, V. Frismantas1,
S. Ginzel2, O. Haas12, O. Heidenreich13, G. Hemmrich-Stanisak3, K. Hezaveh14,
J. Höll2, S. Hornhardt15, P. Husemann2, G. te Kronnie8, H. Lehrach4, B. Marovca1,
F. Niggli1, A. McHardy16, A. Moorman17, R. Panzer-Grümayer12,
B.S. Petersen3, B. Raeder5, M. Ralser4, P. Rosenstiel3, D. Schäfer2,
M. Schrappe7, S. Schreiber3, M. Schütte18, B. Stade3, J. Tchinda1, R. Thiele19,
A. Vora20, M. Zaliova21, T. Zichner5, M. Zimmermann22, A. Borkhardt2,
A. Franke3, J.O. Korbel5, M. Stanulla22, M.-L. Yaspo4
1Pediatric Oncology, University Children’s Hospital, Zurich, Switzerland, 2Clinic
for Pediatric Oncology, Hematology, and Clinical Immunology, Heinrich-Heine-
University, Düsseldorf, 3Institute of Clinical Molecular Biology, Christian-
Albrechts-University, Kiel, 4Department of Vertebrate Genomics, Max Planck
Institute for Molecular Genetics, Berlin, 5Genome Biology Unit, European
Molecular Biology Laboratory, Heidelberg, Germany, 6Department of Pediatric
Hemato-Immunology, Hôpital Robert Debré and Paris Diderot University, Paris,
France, 7Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel,
Germany, 8Department of Pediatrics, University of Padova, Padova, Italy,
9Department of Genetics, Hôpital Robert Debré and Paris Diderot University,
Paris, France, 10SIB Swiss Institute for Bioinformatics, Ludwig Center for Can-
cer Research, University of Lausanne, Lausanne, Switzerland, 11Pediatric
Hematology and Oncology, Charité University Hospital, Berlin, Germany, 12St.
Anna Children’s Hospital and Children’s Cancer Research Institute, Vienna,
Austria, 13Department of Molecular Haematology, Northern Institute for Cancer
Research, Newcastle, United Kingdom, 14Clinic for Pediatric Oncology, Hema-
tology, and Clinical Immunology, Medical Faculty, Heinrich-Heine-University,
Düsseldorf, 15Federal Office for Radiation Protection, Oberschleissheim,
16Department of Algorithmic Bioinformatics, Heinrich-Heine-University, Düssel-
dorf, Germany, 17Northern Institute of Cancer Research, Newcastle University,
Newcastle, United Kingdom, 18Alacris Theranostics GmbH, Berlin, 19Depart-
ment of Computer Science, Bonn-Rhine-Sieg University of Applied Sciences,
Sankt Augustin, Germany, 20Sheffield Children’s Hospital, Sheffield, United
Kingdom, 21Department of Pediatric Hematology/Oncology, Charles University
Prague, Prague, Czech Republic, 22Pediatric Hematology and Oncology, Han-
nover Medical School, Hannover, Germany
Background: The translocation t(17;19)(q22;p13) results in the fusion of the
transactivating domain of the B cell transcription factor TCF3 and the DNA bind-
ing domain of the hepatic leukemia factor HLF. TCF3-HLF defines a rare sub-
type of ALL that is currently incurable. In contrast, the fusion of the same portion
of TCF3 to the PBX1 gene (t(1;19)) results in a leukemia subtype with a favor-
able prognosis. TCF3-HLF ALL constitutes a paradigm of treatment refractory
leukemia in which the oncogenic fusion protein drives programs that are fun-
damental for the malignant process. However genetic engineering experiments
in mice did not recapitulate disease, suggesting that the cellular context in
which the translocation occurs is critical for transformation. 
Aims: We explored the genetic landscape of ten TCF3-HLF positive ALL cases
in comparison to TCF3-PBX1 positive ALL using primary diagnostic samples
and corresponding patient derived leukemia xenografts in order to analyze
whether TCF3-HLF is associated with characteristic patterns of genomic lesions
and to establish a well characterized humanized mouse model for functional
investigations.
Methods: We used an integrated multi-OMICs approach to identify mutation
and gene expression patterns in TCF3-HLF- and TCF3-PBX1-positiveALL. To
compare drug response profiles of treatment resistant TCF3-HLF-positive and
responsive TCF3-PBX1-positive ALL we established a xenograft model of
patient derived leukemia. At least two biological replicates per case were
xenografted in NOD/SCID/IL2rγnull (NSG) mice. Drug response profiles to a
customized library of >100 therapeutic compounds were obtained and in vivo
validation studies were performed using this model.
Results: In TCF3-HLF-positive ALL, intragenic deletions in the lymphoid tran-
scription factor PAX5 or somatic mutations in the non-translocated allele of
TCF3 (acting upstream of PAX5), but not in any of the IFKZ family members,
were recurrent and frequently observed in conjunction with RAS pathway aber-
rations. The pattern of co-occurring mutations was not overlapping in TCF3-
PBX1 ALL, supporting the notion that completely different genetic interactions
may be required for disease pathogenesis. The profile of mutations was main-
tained in the corresponding xenografts. Sequence features at the translocation
breakpoints suggested RAG mediated recombination and an already lymphoid-
committed cell of origin, but the TCF3-HLF-positive ALL transcriptome was
enriched for stem cell and myeloid features, consistent with reprogramming
towards a hybrid, more drug-resistant hematopoietic state. This gene expres-
sion signature was maintained in matched patient-derived xenografts. TCF3-
HLF-positive ALL revealed a distinct drug-response profile with resistance to
some agents commonly used in ALL therapy, but sensitivity towards glucocor-
ticoids and some therapeutic agents in clinical development. Striking on-target
sensitivity was achieved with the BCL2-specific inhibitor ABT-199 indicating
BCL2-dependency of TCF3-HLF-positive ALL. Our results show, that ABT-199
acts synergistically with conventional chemotherapeutic agents, including dex-
amethasone and vincristine, providing a rationale for experimental therapy.
Summary and Conclusions: The molecular portrait of TCF3-HLF-positive ALL
indicates that the initiating event occurs in cells committed to the lymphoid lin-
eage and that leukemogenesis requires a restricted pattern of additional genetic
lesions. Maintenance of dominant genomic and transcriptomic patterns of both
TCF3-translocated subtypes in the corresponding xenografts provides the basis
for systematic functional investigations. Integration of drug response profiling
revealed recurrent patterns of resistance and new options for the treatment of
this deadly disease.
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SPHINGOSINE KINASES ARE REQUIRED FOR IL-7-MEDIATED SIGNAL-
ING IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
A. Melão1,* J. Matos1, H. Cadilha1, J.T. Barata1
1Cancer Biology Unit, Instituto de Medicina Molecular, Lisboa, Portugal
Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric
malignancy. T-cell ALL is associated with high risk and poor prognosis. We have
shown that IL-7, produced in the leukemia milieu by stromal cells, can accelerate
leukemia progression in vivo and has a relevant contribution to the viability and
proliferation of T-ALL cells (Silva et al., Cancer Res 2011). Moreover, IL-7/IL-7R-
mediated signaling may partake in leukemia development, as demonstrated by
the identification of IL-7Rα gain-of-function mutations in around 9% of T-ALL
patients (Zenatti et al., Nat Genet 2011). Sphingosine Kinases (SPHKs), of which
2 isoforms have been described (SPHK1 and 2), are lipid kinases that promote
cell viability by phosphorylating sphingosine and thereby regulating the
ceramide/sphingosine 1-phosphate (S1P) rheostat. SPHKs play a fundamental
role in many signaling pathways associated with cancer, although their involve-
ment in leukemia development is not fully understood.
Aims: The aim of this study was to elucidate the crosstalk of SPHK isoenzymes
and IL-7-mediated effects on pediatric T-ALL leukemogenesis.
Methods: SPHKs expression was determined by qRT-PCR, and activity meas-
ured by a luminescence-based assay. To test the involvement of SPHKs on IL-
7-mediated signaling we incubated D1 (IL-7-dependent, thymocyte-like), TAIL7
(IL-7-dependent, T-ALL), HPB-ALL (IL-7-responsive, T-ALL) and DND-41 (IL-
7Rα mutant, T-ALL) cell lines in the presence of IL-7 and/or SPHK1- or SPHK2-
specific pharmacological inhibitors, SKi-II and K145 respectively. Cell viability
was determined by flow cytometry analysis (FSCxSSC distribution and Annexin
V/7AAD staining). Maintenance of mitochondrial membrane potential was
measured by TMRE staining. Caspase 3 cleavage and activation of signaling
pathways were measured by western blot. Proliferation was determined by
evaluation of DNA synthesis upon 3H-thymidine incorporation. 
Results: We first observed that SPHK1, but not SPHK2, is increased in T-ALL
patient samples as compared to normal controls. Analysis of SPHK activity
revealed that IL-7 positively regulates SPHK activity without significantly affect-
ing its expression. Furthermore, inhibition of SPHK1 or SPHK2 prevented the
activation of both PI3K/AKT and JAK/STAT pathways in all cell lines studied,
as determined by the phosphorylation status of key members of each pathway.
These results suggest that SPHK activity is fundamental for the activation of
pro-survival pathways derived from IL-7/IL-7R-dependent activation. In accor-
dance, signaling downstream from IL-7 stimulation or IL-7Rα mutant activation
was not able to improve leukemia cell viability upon SPHK inhibition. The antag-
onistic effect of SPHK inhibition on IL-7-mediated effects associated with
increased apoptosis, decreased mitochondrial membrane potential and
increased caspase-3 cleavage. Importantly, we found that both inhibitors com-
pletely prevented IL-7 viability effects not only in T-ALL cell lines but also in pri-
mary leukemia cells collected from patients at diagnosis. Moreover, T-ALL
patient samples were significantly more sensitive to SPHK inhibition than their
normal counterparts. Finally, we observed that T-ALL cell line proliferation upon
IL-7 stimulation or IL-7Rα mutational activation was abrogated in the presence
of SPHK inhibitors. 
Summary and Conclusions: Our study identifies SPHK1 and 2 as essential
modulators of IL-7-dependent activation of pro-survival and proliferative path-
ways in T-ALL, opening new possible therapeutic avenues in this pathology.
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MIR-146B IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A POSSIBLE
TUMOR SUPPRESSOR ROLE
N.C. Correia1, R. Fragoso1,* V. Póvoa1, F.J. Enguita2, J.T. Barata1
1Cancer Biology Unit, 2Instituto de Medicina Molecular, Lisboa, Portugal
Background: Regardless of improved therapy regimens, acute lymphoblastic
leukemia from T-cell origin (T-ALL) is still not a curable disease. Therefore, the
field currently faces the challenge of creating more efficacious therapies, ration-
ally-designed and less toxic. A better understanding of the pathogenesis of the
disease, namely molecular analysis of the common genetic alterations in
leukemic cells, may be the solution to understand why some cases fail to
respond to chemotherapy and to improve selective targeting of leukemic cells
without long-term effects on the normal tissues. The transcription factor TAL1
is down-regulated early in T-cell development and over-expressed in more than
60% of pediatric T-ALL cases. TAL1 is able to either activate or repress the
expression of downstream targets as part of a transcriptional complex.
Aims: This work aimed to contribute to a better comprehension of the biology
of T-ALL, namely in relation to the means by which TAL1 exerts its oncogenic
functions. Having shown previously that microRNA genes are regulated by
TAL1 at the level of transcription (Correia et al., Leukemia 2013), we hypothe-
sized that some of these miRNAs may be part of the oncogenic network trig-
gered by TAL1 ectopic expression in leukemia. We focused on miR-146b-5p
and evaluated the functional and molecular effects of its deregulation by TAL1
in the context of T-ALL.
Methods: The expression of miR-146b-5p in T-ALL cell lines was determined by
real time-PCR using LNA primers, whereas in T-ALL patients and normal coun-
terparts it was analyzed from publicly available data (GSE51908 and Mets et al.,
Leukemia 2014). To verify the functional effects of miR-146b aberrant expression
in T-ALL we manipulated its levels in T-ALL cells using lentiviral transduction. In
vitro functional assessment of the effects of miR-146b-5p modulation in T-ALL
cell lines was performed by analysis of proliferation by cell counts, of viability by
flow cytometry, and of migration and invasion by transwell assays. For the in
vivo experiment ten NOD/SCID mice were either injected with CCRF-CEM cells
over-expressing miR-146b or with mock transduced cells.
Results: The miR-146b-5p was found to be down-regulated by TAL1 in cell
lines (Correia et al., Leukemia 2013). We now further verified that pediatric T-
ALL patients over-expressing TAL1 display significantly lower miR-146b-5p
levels than other T-ALL patients (p=0.002). Moreover, T-ALL patients signifi-
cantly express lower levels of miR-146b-5p compared to normal cells
(p<0.0001). This led us to hypothesize that miR-146b-5p has a tumor suppres-
sor role in this disease. Our results point to a direct down-regulation of miR-
146b-5p by TAL1. Although no clear differences were found concerning cell
viability or proliferation, miR-146-5p reduced expression improved the migration
and invasion capacities of T-ALL cells. Moreover, we showed that over-expres-
sion of miR-146b in human T-ALL cells significantly increased the survival of
recipient mice (p=0.039) in a xenotransplant model of human leukemia.
Summary and Conclusions: We have shown that miR-146b-5p is a functionally
relevant TAL1 microRNA target gene, whose down-regulation may contribute to
T-ALL by modulating leukemia cell motility and disease aggressiveness.
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IL-7 ACTIVATES THE JAK/STAT5/PIM1 KINASE AXIS THEREBY MEDIAT-
ING VIABILITY AND GROWTH OF T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA CELLS
D. Ribeiro1,* A. Melão1, R. van Boxtel2, C.I. Santos1, M.C. Silva1, A. Silva1,
B.A. Cardoso1, L.F. Moita1, P.J. Coffer2, J.T. Barata1
1Instituto de Medicina Molacular, Lisboa, Portugal, 2UMC Utrecht, Utrecht,
Netherlands
Background: T-cell acute lymphoblastic leukemia (T-ALL) constitutes, in general,
an aggressive subset of ALL, the most frequent childhood malignancy. Although
risk-adjusted chemotherapeutic regimens are currently extremely effective, their
efficacy is associated with significant long-term side effects and those cases that
relapse have dismal prognosis. New, more specific, therapies are therefore
required. To achieve this goal it is essential to have a better understanding of T-
ALL biology, including the contribution of tumor microenvironmental factors for
leukemia progression. Interleukin 7 (IL-7) is produced in the bone marrow and
thymus. While IL-7 is essential for normal T-cell development, there is also con-
siderable evidence that it can partake in leukemia expansion. Previously, we
have shown that IL-7 promotes T-ALL expansion in vivo (Silva et al., Cancer
Res. 2011) and leukemia cell survival and proliferation in vitro by activating
PI3K/Akt/mTOR signaling pathway (Barata et al., J Exp Med. 2004), consequently
downregulating p27kip1 and upregulating Bcl-2. However, it is also known that T-
cell lymphomas arising spontaneously in IL-7 transgenic mice depend on STAT5
activity and IL7R gain-of-function mutations, found in around 10% of T-ALL
patients (Zenatti et al., Nat Genet. 2011), drive JAK/STAT5 pathway activation.
Aims: To investigate whether the JAK/STAT5 pathway may be involved in the
IL-7/IL-7R pro-leukemia effects in human T-ALL.
Methods: We used an IL-7-dependent leukemia T-cell line (TAIL7), an IL-7-
responsive T-ALL cell line (HPB-ALL) or primary T-ALL samples collected at
diagnosis as cellular models. We used pharmacological inhibitors of JAK3
(WHI-P131), STATs in general (parthenolide), STAT5 in particular (N-((4-Oxo-
4H-chromen-3-yl)methylene)nicotinohydrazide) and PIM1 (Smi-4a). Analysis
of viability, cell size, cell cycle, surface CD71 and Bcl-2 expression was per-
formed by flow cytometry. Signaling pathway activation, STAT5, PIM1 and cell
cycle protein expression was performed by western blot analysis. Proliferation
was assessed by 3H-Thymidine incorporation. STAT5 ChIP-seq and RNA-seq
were performed on TAIL7 cells.
Results: We show that IL-7 induces JAK1/3-STAT5 pathway activation, STAT5
DNA binding and transcriptional activity. To test the potential clinical applicability
of these findings, we treated TAIL7 cells or primary T-ALL samples with
inhibitors of JAK3, STATs in general or STAT5 in particular. All inhibitors abro-
gate IL-7-mediated T-ALL cell viability, growth and proliferation, with complete
inhibition of IL-7-induced downmodulation of p27kip1, upregulation of cyclin A
and increased transferrin receptor (CD71) surface expression. Interestingly,
IL-7-dependent Bcl-2 upregulation is not affected by STAT5 inhibition. To under-
stand how STAT5 mediates the survival effects of IL-7 in T-ALL cells without
affecting Bcl-2, we performed STAT5 ChIP-seq together with RNA-seq. Cross-
analysis of the data revealed that IL-7 drives transcription of the serine/threo-
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nine kinase PIM1 via STAT5. Notably, inhibition of PIM1 kinase activity abro-
gates IL-7-mediated T-ALL cell growth, viability and proliferation.
Summary and Conclusions: Overall, our results indicate that a
JAK/STAT5/PIM1 axis is mandatory for IL-7/IL-7R-mediated T-ALL cell survival.
Furthermore, these results indicate that JAK/STAT5 pathway inhibitors can
eliminate T-ALL cells and that STAT5 plays a major role in mediating IL-7/IL-
7R signaling effects in T-ALL cells, therefore constituting a promising target for
therapeutic intervention in this malignancy.
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JAK2 MUTATIONS ARE HIGHLY ENRICHED IN CRLF2-REARRANGED B-
ALL CASES WITH A PH-LIKE GENE SIGNATURE
T. Sadras1,2,* S. Heatley1,2, E. Nievergall1, C. Kok1,2, P. Dang1, D. Yeung3,4,
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Background: High expression of CRLF2 occurs in 5-15% of adult and pediatric
B-ALLs, and commonly results from a cryptic deletion that juxtaposes CRLF2
to the promoter of P2RY8 (P2RY8-CRLF2), or from the translocation of CRLF2
to the immunoglobulin heavy chain locus (IGH-CRLF2), bringing CLRF2 under
the control of IGH enhancer elements. CRLF2 overexpression alone is not suf-
ficient for leukemic transformation, requiring additional oncogenic lesions, and
a large proportion of CRLF2-rearranged cases harbor activating mutations in
JAK2, and less commonly in JAK1. To date, the prognostic significance of
CRLF2 rearrangements (CRLF2-r) remains debatable, although recent reports
demonstrate that CRLF2-r are enriched in Ph-like ALL, a high-risk sub-type. In
this study we show that Ph-like B-ALL cases with CRLF2-r represent a distinct
genetic sub-group that may reflect underlying differences in secondary coop-
erating lesions and disease progression.
Aims: The aims of this investigation are to characterize the genetic and bio-
logical differences between Ph-like and non-Ph-like CRLF2-r B-ALL cases, to
better understand the prognostic significance and targetable pathways in these
patients that have previously been grouped in one class.
Methods: Patients with high CRLF2 expression detected by Taqman Low Density
Arrays (TLDA), were screened for P2RY8-CRLF2 and IGH-CRLF2 rearrange-
ments by RT-PCR and FISH, respectively. Ph-like ALL cases were identified by
TLDA analysis using a customized 9-gene signature. gDNA from CRLF2-r sam-
ples was analyzed for JAK1/2 mutations by Sanger sequencing, and where pos-
sible, phospho-flow cytometry detecting pathway activation of downstream kinase
targets was used to assess sensitivity to JAK inhibitors in vitro. 
Results: We have screened >300 B-ALL samples from our Australian cohort
(age between 0.5 and 75 years) and identified 27 CRLF2-r cases (P2RY8-
CRLF2 n=14 and IGH-CRLF2 n=13). Interestingly, the frequency of IGH-CRLF2
rearrangements increased with age. Activating JAK2 mutations were found in
10/27 cases (R683G/S n=4; F694L n=1; D873N n=1 and D875N n=4) and con-
sistent with prior reports all cases harboring JAK2 mutations that were tested,
responded to JAK inhibitors in vitro. No JAK1 mutations were identified in this
cohort. Importantly, TLDA analysis showed that 20/27 cases classified as Ph-
like, and these samples also expressed significantly higher levels of MUC4 and
GPR110 than the non-Ph-like CRLF2-r cases, despite no significant difference
in CRLF2 levels. Most strikingly, the activating JAK2 mutations were restricted
to the Ph-like patients. Of note a rare non-synonymous polymporphism in JAK2
(R1063H) was detected in one of the non-Ph-like patients. Importantly, these
results suggest that JAK2 mutations are highly enriched in Ph-like CRLF2-r
cases, likely indicating differences in disease etiology, and highlighting the het-
erogeneity of ALL which can be observed within a subset of patients that harbor
identical translocations, and which have previously been analyzed as one
group. We are currently using NGS approaches to further elucidate the genetic
landscape of CRLF2-r patients, with a particular focus on the Ph-like patients
lacking JAK2 mutations and the non-Ph-like subset of B-ALLs. 
Summary and Conclusions: We propose that Ph-like and non-Ph-like CRLF2-
r cases compose prognostically and biologically distinct groups of B-ALL
patients that should be studied as independent entities, possibly addressing
some of the discrepancies previously observed in large studies of CRLF2 dereg-
ulation in ALL. Importantly, further study of these sub-groups may provide critical
leads for the development of novel targeted therapies. 
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CLONAL ORIGINS OF HIGH-HYPERDIPLOID ACUTE LYMPHOBLASTIC
LEUKEMIA
D. Alpar1,* D. Wren2, M.B. Mansur1, N.E. Potter1, C.M. Bateman1, T. Szczepanski3,
D. Gonzalez de Castro2, A.M. Ford1, M. Greaves1
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Oncology, Zabrze, Medical University of Silesia, Katowice, Poland
Background: Monozygotic twins with concordant leukemia provide a unique
model to analyze the timing and early genetic steps of leukemogenesis. Our
previous studies on twins and cord blood samples revealed that pre-leukemic
clones of high-hyperdiploid acute lymphoblastic leukemia (HHD ALL) are pre-
natal in origin.
Aims: Identification of the fetal cell type which is transformed in HHD ALL.
Methods: Diagnostic bone marrow samples from three monozygotic twin pairs
concordant for HHD B-cell precursor ALL were screened for all varieties of
immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements, which
are hallmarks of lymphoid cell development, using a combination of targeted
next-generation sequencing and conventional screening approaches. Identical
rearrangements shared by twin siblings and indicative of the IG/TCR status of
the cells giving rise to pre-leukemic clones were identified. Previous genome-
wide SNP-array analysis indicated trisomy of chromosome 14 in all six patients.
The study was conducted in accordance with the Declaration of Helsinki.
Results: In total, 23 rearrangements were identified in the three twin pairs.
Clonal rearrangements were detected in IGH, IGK, IGL, TCRD, TCRG and
TCRB genes in 6, 2, 1, 3, 1 and 2 patients, respectively. At least two different
rearrangements were found in each child. Seven identical junctions shared by
the siblings were observed with the following distribution: twins 1A/B IGH VDJx2
(non-functional); 2A/B IGH DJx2 and 3A/B IGH VDJx1 (non-functional), IGK
VKdex1 and TCRD VD2-DD3x1. All these rearrangements must have occurred
in the pre-leukemic cell population formed in utero. The majority of clonal mark-
ers proved to be patient-specific and is likely to have arisen post-natally in twin-
specific sub-clones.
Summary and Conclusions: To date, only conventional screening of IG/TCR
gene rearrangements was reported in a limited number of twins with concordant
HHD ALL. We have carried out a comprehensive screen for these rearrange-
ments in a cohort of twin pairs, also using advanced genomics. Our data sug-
gest that the pre-leukemic clone spawned in utero, and shared by the twins,
has the IG and TCR feature of precursor B-cells in all twin pairs tested. These
results add to the accumulating evidence that the formation of the hyperdiploid
karyotype can arise in utero, probably as an initiating mutation and it most likely
occurs in early B-lineage progenitors at the stage of or after RAG-dependent
IGH rearrangement. Therefore, the pre-leukemic clone expands preferentially
in the pro- or pre-B lineage compartment, initially in one twin and spreads into
the sibling via shared circulation. Clonally descendent cells with self-renewal
stem cell activity are sustained in both twins after birth as independent targets
for a number of secondary genetic hits - copy number changes and sequence
mutations - essential for clinical development of ALL.
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INTEGRATED ANALYSIS OF JAK/STAT, RAS/AKT AND NOTCH1 PATH-
WAYS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PROGNOSTIC
AND THERAPEUTIC IMPLICATIONS
V. Gianfelici1,* S. Chiaretti1, N. Peragine1, F. Di Giacomo1,2, M. Messina1,
F. Paoloni3, V. Apicella1, A.M. Testi1, A. Vitale1, J. Cools4,5, M. Vignetti1,3,
A. Guarini1, R. Foà1
1Department of Cellular Biotechnologies and Hematology, “Sapienza” University
of Rome, Rome, 2Department of Molecular Biotechnology and Health Science,
and Center for Experimental Research and Medical Studies (CeRMS), Univer-
sity of Turin, Turin, 3Fondazione GIMEMA Onlus, Rome, Italy, 4Center for
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Background: We previously reported a high rate of mutations in the JAK/STAT
and RAS/AKT pathways in refractory/early relapsed T-cell acute lymphoblastic
leukemia (T-ALL) cases analyzed by RNAseq (Gianfelici et al., ASH 2013).
Conversely, the NOTCH1/FBXW7 pathway was less frequently affected.
Aims: Screening of JAK/STAT, RAS/AKT and NOTCH1/FBXW7 was performed
to confirm their prognostic impact in T-ALL. In vitro assays were carried out to
assess the sensitivity of primary cells to specific inhibitors.
Methods: The study included 49 adult T-ALL cases (median age 37 years,
range 16-59) enrolled in 2 consecutive Italian GIMEMA ALL protocols, for which
genomic material was available. Both refractory and responsive cases were
included. Hotspot mutations of JAK3, JAK1, IL7R and STAT5B for JAK/STAT
signaling, N/K-RAS, PTEN and FLT3 for RAS/AKT and NOTCH1/FBXW7 were
analyzed by Sanger sequencing. Overall survival (OS) and disease-free survival
(DFS) were estimated using the Kaplan-Meier method. The JAK1/2 inhibitor
Ruxolitinib and the JAK3 selective inhibitor Tofacitinib were tested on primary
diagnostic cells. Following 72 hours of incubation, proliferation and cytotoxicity
were determined using the MTT assay.
Results: Eight T-ALL cases (16%) harbored JAK/STAT mutations, namely JAK1
(n=3), JAK3 (n=3), STAT5B (n=2) and IL7R (n=3). All STAT5B mutants carried
concomitant mutations in JAK3 (1 of them also had a JAK1 mutation), whereas
the IL7R positive patients had no additional mutations of the same pathway.
RAS/AKT alterations were found in 10 cases (20%), namely PTEN (n=5), N/K-
RAS (n=4) and FLT3 (n=1). NOTCH1/FBXW7 mutations were found in 28 cases
(57%), in 16 without additional alterations, while in 12 a concomitant mutation in
JAK/STAT (n=8) or N/K-RAS (n=4) was documented. We observed an enrichment
of JAK/STAT and RAS/AKT alterations within the group of patients developing
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an early relapse or refractoriness: 6/8 and 7/10, respectively. A significantly shorter
OS and DFS was observed in patients harboring JAK/STAT mutations compared
to patients without alterations in the pathway: 15.7 vs 27.3 months (p=0.04) and
11 months vs median not reached (p=0.002), respectively. Similarly, a significantly
shorter OS and worse DFS were observed in cases with RAS/AKT alterations
compared to patients without alterations in the pathway: 7.9 vs 27.3 months
(p=0.0108) and 4.3 vs 33.2 months (p=0.0005), respectively. Conversely, OS
and DFS were significantly better for cases harboring NOTCH1/FBXW7 muta-
tions alone compared to wild-type patients or cases with concomitant JAK/STAT
or RAS/AKT mutations: median not reached vs 18.7 vs 15.7 months, respectively,
(p=0.0325), and median not reached vs 14.5 vs 9.8 months, respectively
(p=0.0015). Primary cells from JAK1 mutated patients proved sensitive to Rux-
olitinib, whereas viability was not affected by Tofacitinib, documenting a selective
sensitivity to Ruxolitinib. Furthermore, primary cells carrying JAK1 and JAK3
mutations in association with a STAT5B alteration were poorly sensitive both to
Ruxolitinib and to Tofacitinib. 
Summary and Conclusions: This study documents the negative prognostic
impact of JAK/STAT and RAS/AKT mutations in T-ALL, at least when standard
chemotherapy regimens are used. Notably, the favorable impact of
NOTCH1/FBXW7 was overcome by the presence of concomitant JAK/STAT
or RAS/AKT mutations. Finally, in vitro experiments demonstrate that inhibitors
directed specifically against the underlying lesions may be effective on primary
T-ALL cells.
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DISTINCT ALL-ASSOCIATED JAK3 MUTANTS EXHIBIT DIFFERENT
CYTOKINE-RECEPTOR REQUIREMENTS AND JAK-INHIBITOR SPECI-
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Background: JAK1 and JAK3, which are intracellular tyrosine kinases asso-
ciated to cytokine receptors, are recurrently mutated in acute lymphoblastic
leukemia. These mutations are activating and scattered through the kinase
and pseudokinase domains, which contrasts with the unique pseudokinase
V617F mutation in JAK2 that is prevalent in myeloproliferative neoplasms.
JAK1 and JAK3 associate with heterodimeric receptors such as IL-7R or IL-
9R, in which JAK1 is appended to the specific chain and JAK3 to the common
gamma chain. 
Aims: To study the role of cytokine receptor complexes in mediating the onco-
genic activity of JAK3 mutants. 
Methods: STAT5 transcriptional activity downstream JAK3 mutants was
assessed by measurements of luciferase expression in HEK293 cells or JAK1-
deficient U4C cells upon transient co-transfection of appropriate cDNA con-
structs with a reporter construct harboring STAT5-responsive elements
upstream a luciferase gene. Same experiments were conducted for JAK1 and
JAK2 mutants. In vivo transforming characteristics of JAK3 mutants were stud-
ied by transplantation of mouse bone marrow progenitor cells transduced with
retroviral vectors expressing JAK3 mutants in irradiated Balb/c mice. JAK3
mutants’ sensitivity to JAK inhibitors was assesed by treating growth factor-
independent Ba/F3 cells obtained after stable transduction with JAK3 mutants
with increasing JAK inhibitors concentrations and measuring their proliferation
using a tritiated thymidine incorporation assay. Phosphorylation of STATs and
JAK proteins in these cells was also analyzed by western blotting.
Results: Our study demonstrated that JAK3V674A and the majority of other
JAK3 mutants need to bind to a functional cytokine receptor complex in order
to constitutively activate STAT5. However, one mutant, JAK3L857P, was unex-
pectedly found to not depend on such receptor complexes for its activity, which
was induced without receptor or JAK1 co-expression. Introducing a mutation
in the FERM domain that abolished JAK-receptor interaction did not affect
JAK3L857P activity, while it inhibited the other receptor-dependent mutants. The
same cytokine receptor independence as for JAK3L857P was observed for
homologous L857 mutations of JAK1 and JAK2 and for JAK3L875H. This different
cytokine receptor requirement correlated with different functional properties in
vivo and with distinct sensitivity to JAK inhibitors. Transduction of murine
hematopoietic cells with JAK3V674A led homogenously to lymphoblastic
leukemias in mice. In contrast, transduction with JAK3L857P induced various
types of lymphoid and myeloid leukemias, illustrating a broader oncogenic
potential related to the absence of cytokine receptor restriction. Ruxolitinib,
which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells
transformed by JAK3V674A, which requires a functional JAK1-JAK3 associated
receptor complex, yet proved much less potent on cells expressing JAK3L857P.
These particular cells were, in contrast, more sensitive to JAK3-specific
inhibitors. 
Summary and Conclusions: Altogether, our results have demonstrated that
different JAK3 mutations can induce constitutive activation through distinct
mechanisms, suggesting that an improved understanding of these mechanisms
could offer new therapeutic perspectives.
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XIAP EXHIBITS AN ESSENTIAL ROLE FOR PATIENTS’ ALL CELLS GROW-
ING IN VIVOAS SHOWN BY A NOVEL TECHNIQUE FOR STABLE KNOCK-
DOWN IN PATIENT-DERIVED XENOGRAFT (PDX) ALL CELLS
M. Carlet1,* J. Vergalli1, C. Finkenzeller1, M. Grunert1, I. Jeremias1,2
1Department of Gene Vectors, Helmholtz Zentrum Muenchen, 2Oncology, Dr.
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Background: Acute lymphoblastic leukemia (ALL) is a frequent disease in
children and adults. XIAP, the X-linked inhibitor of apoptosis, is an anti-apoptotic
protein which is frequently and highly overexpressed in hematological malig-
nancies. Up-regulation of XIAP was shown to be associated with inferior prog-
nosis of patients in various different types of tumors. No data exist so far on
XIAP’s role for growth and survival of hematological malignancies in vivo.
Aims: We aimed at characterizing the role of XIAP for survival and growth of
patient-derived xenograft (PDX) acute lymphoblastic leukemia (ALL) cells in
vivo. Towards this aim, we had to establish a novel technique allowing stable
knockdown in PDX ALL cells.
Methods: Primary tumor cells from ALL patients were transplanted into severe-
ly immune-compromised NSG mice. PDX ALL cells were lentivirally transduced
with a construct allowing stable knockdown in these cells. We decided to embed
the shRNA in the context of a miRNA background using miR30 as it allowed
expressing the shRNA under a Pol II promoter and coupling it to the expression
of transgenes. We expressed different fluorochromes such that expression of
blue indicated cells with control knockdown and expression of green cells with
knockdown of XIAP. Additionally, we expressed either a codon optimized ver-
sion of Firefly luciferase or a membrane bound form of Gaussia luciferase
which require different substrates, Luciferine and Coelenterazine, respectively.
Expression of luciferases enabled in vivo imaging for highly sensitive, reliable
and continuous follow up of the growth of each subpopulation in vivo. Several
established B-ALL and T-ALL cell lines were transduced in the same way.
Taken together, we expressed the different luciferases and colors such that
control cells and cells with knockdown of XIAP could be distinguished in vivo
using dual luciferase imaging and post mortem using flow cytometry. We finally
injected both populations into a single mouse and monitored the distribution of
the two populations over time.
Results: Knockdown of XIAP in PDX ALL cells lead to the reduction of the
XIAP protein by more than 90% as shown by Western Blot. Knockdown
remained stable over three passages indicating a highly stable knockdown by
our novel technical approach. In cell lines, down-regulation of XIAP expression
did not affect proliferation of different T- and B-ALL cell lines in vitro, nor engraft-
ment and development of preB-ALL NALM6 cells in NSG mice. In contrast,
down-regulation of XIAP expression significantly reduced tumor load of PDX
ALL samples in vivo, as measured both by dual luciferase imaging in vivo and
by ex vivo quantification of the leukemic subpopulations using flow cytometric
analysis of the different colors.
Summary and Conclusions: We established a technique allowing efficient
silencing of target genes in PDX ALL cells growing in mice together with con-
venient readout systems. Our data show that the role of XIAP is highly different
in cell lines and in PDX ALL cells. Targeting XIAP by knockdown significantly
reduces leukemia burden in PDX ALL cells in vivo. Our novel technical
approach for knockdown in PDX ALL cells in vivo enables the preclinical testing
of the role of putative therapeutic targets in PDX cells. Cell lines represent
unsuitable models for predicting the role of XIAP in PDX ALL cells in vivo.
Upregulation of XIAP constitutes an essential oncogenic alteration in PDX ALL
cells; XIAP represents a promising target for treatment of ALL.
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EXPRESSION OF GATA3 DEPENDS ON GENOTYPE VARIANT AT
RS3824662 AND IS ASSOCIATED WITH CLINICAL COURSE OF B-CELL
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Background: Polymorphic site at rs3824662 in GATA3 gene is a susceptibility
locus for newly identified subtype of BCP-ALL associated with poor outcome
called BCR-ABL1-like. 
Aims: The main purpose of the study was to investigate an association between
the genotype variant at rs3824662 of GATA3 gene and GATA3 expression level
in leukemic cells at diagnosis of childhood ALL as well as genetic and clinical
features of pediatric ALL.
Methods: Between November 2010 and January 2015, 452 pediatric patients
(median age 8.5 yrs; median follow-up 2.3±1.7 yrs), with newly diagnosed BCP-
ALL treated according to ALL-IC BFM09 protocol in 15 centers of the Polish
Pediatric Leukemia/Lymphoma Study Group were enrolled into the study.
Patients with BCR/ABL gene fusion, MLL rearrangements, hypodiploidy, Down
syndrome were excluded from analysis. MRD was measured at day 15 of induc-
tion therapy using FCM with EuroFlow 8-color antibody panels (n=358). Tar-
geted copy number screening of selected 23 loci was performed on available
DNA samples (n=448) by using the MLPA methods. Determination of genotype
at polymorphic locus rs3824662 was performed in all the patients’ samples
using allelic discrimination assay. GATA3 mRNA expression was quantified by
Q-PCR using FAM-MGB probe.
Results: Genotype distribution in studied group: AA: n=26 (6%); CA: n=148
(33%); CC: n=278 (62%). Genotype variant AA at rs3824662 was associated
with higher level of GATA3 mRNA expression compared to CA and CC variant,
with mean -0.11; -1.45 and -3.88 respectively (p=0.02).
We have not succeeded in defining microdeletion profile specific for polymorphic
variant. Among AA homozygotes 27% are IKZF1 deletion carriers, whereas
among CA and CC genotypes 16% and 13% respectively. However, after exclu-
sion of TEL/AML rearrangements and hyperdiploidy AA homozygous were more
likely to be carriers of IKZF1 deletion risk allele compared with patient without
this defect (p=0.03). Homozygotes AA showed higher WBC level at diagnosis
of childhood ALL compared to CA and CC variant, with median 13.8 [1000/µL]
(quartiles: 7.3-50.0); 13.2 (q: 4.90-44.70); 9.7 (q: 4.40-25.00) respectively,
p=0.05 and were older with median 7.6 (q: 4.20-12.11); 5.0 (q: 3.11-9.31); 4.3
(q: 2.75-7.68) and with p=0.05). There was no difference in terms of MRD level
at day 15 between patients with specific genotype in GATA3 gene.
Summary and Conclusions: The expression of GATA3 gene in leukemic cells
was associated with genotype variant at rs3824662 in the study cohort. Fur-
thermore, carriers of AA variant at rs3824662 of GATA3 showed clinical features
at ALL diagnosis related with poor treatment outcome.
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Background: Acute lymphoblastic leukemia (ALL) consists of heterogeneous
cell populations and the most aggressive subpopulation determines prognosis
and outcome in each patient. Each subpopulation relies on a different ALL stem
cell and a better understanding of challenging subclones is intensively required.
Aims: We aimed at functionally characterizing single stem cell clones in vivo
regarding growth behavior and drug resistance and at correlating clone-specific
functional characteristics with genetic features using a sample from a child with
ALL growing in mice.
Methods: Primary tumor cells from a 5-year old girl with hyperdiploid ALL at
first relapse were transplanted into severely immune-compromised mice and
lentivirally modified to express the fluorochromes red, green and blue at different
amounts and combinations (RGB marking, Weber et al., 2011). Single cell
clones were generated by limiting dilution transplantation and their uniqueness
was verified by LM-PCR. Single cell clones were re-mixed for in vivo assays
and analyzed one-by-one by flow cytometry where they could be distinguished
from each other using their unique color expression. In vivo experiments were
performed to evaluate spontaneous growth rate as well as drug resistance.
Single cell clones and bulk cells were genetically analyzed for their exome,
methylome and gene expression (RNA sequencing).
Results: 8 single stem cell subclones were generated and compared between
each other and bulk cells. When several combinations of two clones were mixed
within the same recipient mice, one clone overgrew the other in different
amounts indicating that different clones grow at different rates. In vitro,
chemosensitivity differed between several clones tested, especially regarding
stimulation with glucocorticoids, including resistant clones. Two clones were
mixed and transplanted into several mice and some mice were treated with
glucocorticoids while others received buffer. One clone showed a significantly
reduced sensitivity towards in vivo glucocorticoid treatment compared to the
second clone indicating selective drug sensitivity in single cell clones. Exome
sequencing and DNA methylation profiling revealed that passaging a bulk sam-
ple results in few changes only, while recurrent additional mutations in two
clones suggest a common ancestor subclone. Individual clones showed diver-
gent mutational and methylation signatures compared to the parental bulk sam-
ple. Glucocorticoid resistant clones show more alterations compared to sensi-
tive clones.
Summary and Conclusions: Taken together, combining the individualized
xenograft mouse model with genetic engineering allowed multicolor marking
and generating viable single cell clones for functional characterization in vivo.
Within the heterogeneous tumor bulk, aggressive subclones exist showing slow
tumor growth or drug resistance which is associated with inferior genetic char-
acteristics. Our studies allow the functional characterization of challenging sub-
clones in vivo in order to develop efficient novel treatment approaches to elim-
inate aggressive stem cell clones in ALL.
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CELLS IN PATIENTS’ ALL CELLS GROWING IN MICE
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Background: While ALL cells display major genetic heterogeneity upon clonal
evolution, leukemia initiating potential is homogenously shared between many,
if not all ALL cells. Nevertheless, drug resistant residual disease might persist
after successful treatment cycles suggesting functional heterogeneity in ALL in
response to therapy. We decided using quiescence as benchmark in searching
for a clinically relevant subgroup of ALL cells.
Aims: We aimed at evaluating whether patients’ ALL cells growing in mice
exhibit differences in proliferation rate, drug sensitivity and stem cell behavior
and whether a challenging subpopulation of stem cell might exist which is qui-
escent and drug resistant.
Methods: We engrafted patients’ primary ALL cells in NSG mice. To monitor
ALL growth patterns, we established a technique allowing for unbiased re-iso-
lation of small numbers of human ALL cells from murine bone marrow. Towards
this aim, we lentivirally transduced patient-derived ALL cells to express NGFR,
a red fluorochrome and luciferase. A combined MACS/FACS procedure based
on the expression of the transgenes enabled more than 10.000-fold enrichment
of human ALL cells from murine bone marrow.
Results: CFSE labeling revealed a rare subpopulation of in vivo long-term qui-
escent cells which had not divided, even if tumor mass had increased by 3
orders of magnitude and 50% of the time from cell injection to animal’s death
by leukemia had passed. Re-transplantation into secondary recipients revealed
that quiescent cells converted into cycling cells and vice-versa suggesting a
major plasticity of patients’ ALL cells in vivo. Limiting dilution transplantation
assays revealed that both quiescent and cycling cells exhibited similar, high
stem cell frequencies which were not further increased in quiescent cells. In
vitro, quiescent and cycling cells displayed similar sensitivity towards cytotoxic
drugs after 3 days of stimulation. In contrast and clinically most importantly,
quiescent ALL cells displayed severe resistance against in vivo treatment of
mice with cytotoxic drugs used in routine treatment of ALL patients; while the
amount of cycling cells was decreased by more than 1 order of magnitude, the
amount of quiescent cells remained completely unchanged.
Summary and Conclusions: Our data suggest that ALL consists of functionally
heterogeneous cells. Non cell-autonomous factors and stimuli determine impor-
tant functions of ALL cells. As the study was restricted to analysis of bone mar-
row, bone marrow niche factors determine both growth rate as well as drug
sensitivity of patient-derived ALL cells in vivo. We conclude that uncoupling
ALL cells from the bone marrow niche might represent an attractive approach
for bringing these cells back into the cell cycle and sensitizing them towards
chemotherapy. In summary, genetic engineering of ALL xenograft cells enabled
the sensitive isolation and enrichment of ALL cells from murine bone marrow.
We identified a small subpopulation of in vivo long-term quiescent and drug
resistant cells in patient-derived ALL cells which obtain their phenotype from
external stimuli exerted from the bone marrow niche. These cells might be
important targets for therapy and should be considered when evaluating novel
therapeutic approaches to treat ALL.
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Background: The knowledge of treatment results in older patients with acute
lymphoblastic leukemia (ALL) is modest and derives mostly from clinical stud-
ies where selection mechanisms are present.
Aims: The aim of this study was to assess the outcome of treatment accord-
ing to national guidelines in an unselected cohort of older/elderly ALL
patients.
Methods: Data regarding all patients aged 55-85 years diagnosed with ALL
from 2005 to 2012 in Sweden was obtained from the Swedish Acute
Leukaemia Registry and the Swedish Acute Lymphoblastic Leukaemia Reg-
istry. Both are truly population-based registries with prospectively reported
information including: date of diagnosis, phenotype, WHO performance status
(WHO 0-4), treatment intention (induction therapy or palliative treatment),
stem cell transplantation and dates of morphologic complete remission
(CR)/relapse/death. Statistical analysis was carried out with SPSS v 22 (IBM).
Overall survival (OS) was defined as time from diagnosis until last follow up
or death. OS was calculated by the Kaplan-Meier method. Univariable and
bivariable analyses regarding prognostic factors were performed using the
Cox proportional hazards regression. Logistic regression was used to deter-
mine factors related to treatment decisions. Vital status was obtained until
the 22nd of August 2014.
Results: In total, 182 patients (90 males and 92 females) with a median and
mean age of 68 years were reported. Median follow up time of survivors was
61 (range: 20-115) months. Immunophenotype was reported for 172 patients;
B-ALL 142 (82%), Burkitt-leukemia 17 (10%), and T-ALL 13 (8%). The median
age in these groups was 67, 74 and 70 years, respectively. Induction therapy
was given to 144 (79%), resulting in CR for 110/144 (76%) patients. Three
year OS was 27 (95% CI, 20-33)% for all patients, 33 (95% CI, 25-41)% for
patients receiving induction therapy, and 3 (95% CI, 0-8)% for patients report-
ed as receiving palliative treatment (p<0.001, logrank test). The correspon-
ding median OS was; 10 (95% CI, 6-14), 15 (95% CI, 11-19), and 1 (95% CI,
0-2) months respectively. Allogeneic stem cell transplantation was performed
upfront in 19 patients (mean age 60; range: 55-66 years). CR frequency and
OS for different age and WHO performance status groups are displayed in
Table 1.
Treatment intention, age (as continuous variable), WHO performance status
(0-1 versus 2-4), and gender were identified as significant prognostic factors
for OS. The proportion of patients receiving induction treatment was neg-
atively correlated to age and WHO performance status (p<0.001). Among
14 patients >80 years only three received induction therapy and none sur-
vived beyond one year. Although a significant difference in OS was found
for the whole population regarding gender, sub-group analysis revealed
that the difference was mainly located in the 55-64 year cohort (p<0.01,
adjusted for WHO status) and was demonstrated also within the B-ALL
cohort separately.
Table 1.
Summary and Conclusions: We conclude that intensive ALL treatment could
be given successfully to an older population up to at least 75 years of age. Age
and performance status are important factors for decisions regarding treatment
intensity and outcome. The difference in OS between males and females aged
55-64 years is striking and will need further evaluation. Elaborate studies
regarding given treatments and risk factors are ongoing.
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GENOME-WIDE ANALYSIS OF WDR5 BINDING REVEALS ITS EFFECT ON
TUMORIGENESIS IN ACUTE LEUKEMIA
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Background: Mixed-lineage leukemia (MLL) fusion proteins are potent inducer
of leukemia. It is reported that MLL fusion proteins lost their histone modification
activity. WD repeat domain 5 (WDR5) is the conserved component in the mul-
ti-subunit complex of SET1 family enzymes with direct methyltransferase activ-
ity. WDR5 itself may also have histone H3 trimethyl Lysine 4 (H3K4me3)
methyltransferase activity. We observed that WDR5 was significantly increased
in the patients with acute leukemia.
Aims: To identify the global binding profiling of WDR5 and H3K4me3 in
leukemia cells and to explore the role of WDR5-mediated H3K4 methylation in
the leukemogenesis.
Methods: Bone marrow samples from 120 patients with newly diagnosed acute
leukemia, including 60 cases of acute lymphoblastic leukemia (ALL) and 60
cases of acute myeloid leukemia (AML), were collected between June 2008
and July 2013 at the First Affiliated Hospital of Nanjing Medical University. All
the patients provided their written informed consent in accordance with the
Declaration of Helsinki before enrollment in the study. The study was approved
by the Institutional Review Board of the Nanjing Medical University. Quantitative
PCR was performed to detect the expression of WDR5 in the patients and 40
normal controls. ChIP-Seq analysis for WDR5 and H3K4me3 were done and
ChIP-seq libraries were sequenced in two MLL-rearranged leukemia cell lines
RS4:11(MLL-AF4) and THP-1(MLL-AF9). The peaks were called using
Cisgenome 2.0 and SISSRS. The overlapping of WDR5 peaks and H3K4me3
peaks was analyzed.
Results: We found more than 10,000 H3K4me3 peaks in two detected MLL-
rearranged leukemia cell lines RS4:11 and THP-1 which express MLL fusion
proteins. This result indicated that H3K4me3 is highly genomic enriched in the
cells and suggested that there is a mechanism responsible for the genomic
recruitment of H3K4me3. Moreover, we examined the expression of the WDR5
in patients with acute leukemia and found WDR5 high expression in this cohort
of patients. We also observed the interaction of WDR5 with the MLL protein in
the MLL-rearranged cells by co-immunoprecipitation. We further identified the
global genomic binding of WDR5 in RS4:11 and THP-1 cells by ChIP-seq and
detected more than 2000 binding peaks in the two leukemia cells. Importantly,
we found the genomic co-localization of WDR5 binding with H3K4me3 enrich-
ment and WDR5 with H3K4me3 binds to the promoter regions of important genes
involved in leukemogenesis and hematopoiesis. Our data suggested that WDR5-
mediated H3K4 methylation plays an important role in the leukemogenesis. 
Summary and Conclusions: WDR5 expression significantly increased in adult
ALL and AML patients. We demonstrated global enrichment of H3K4me3 bind-
ing around WDR5 binding peaks and co-existence of WDR5 and H3K4me3
binding in promoter region of oncogenes in MLL-rearranged leukemia cells. 
P534
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Background: Previous studies have demonstrated apoptosis induction effect
of high dose methylprednisolone (MPZ) on lymphoblasts. In a previous study,
high dose MPZ (900 mg/m2) during induction therapy of children with acute
lymphoblastic leukemia (ALL) was compared with standard dose prednisolone
(60 mg/m2) and increased cure rates were shown with high dose MPZ therapy. 
Aims: Aim of the study is to compare effectiveness of two different high doses
of MPZ, both doses being higher than the standard doses, during induction
phase of therapy.
Methods: Pediatric patients newly diagnosed with ALL between 2008 and 2014
were enrolled. Patients were randomized for high doses of MPZ treatment,
which was given for 7 days before commencement of induction phase of St
Jude Total XV protocol, at doses of 10 mg/kg/day or 20 mg/kg/day, po. The
steroid dose was tapered to 5 mg/kg/day and 10 mg/kg/day, in each group
respectively by the 2nd week and concomitant chemotherapy was initiated. By
the 3rd week of diagnosis, steroid dose was tapered to 2 mg/kg/day in both
groups and continued at this dose upto the end of induction phase. Minimal
residual disease (MRD) levels were measured by flow cytometry at 15th, 22nd,
and 42nd days of induction. Event-free (EFS) and overall survival (OS) rates
were calculated with Kaplan-Meier analyses.
Results: A total of 154 pediatric patients with newly diagnosed ALL were
enrolled in the study. When the patients who were initiated full dose chemother-
apy earlier, without a 1 week steroid only course, were excluded, a total of 141
patients were randomized to each dose group (n=78 and n=63 patients in 10
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and 20 mg/kg/day groups, respectively). Patient characteristics of the study
group were summarized in Table 1. Median age of patients was 5 (1-19) years,
male/female ratio was 1.4. Majority of the patients were CALLA+ B cell ALL
(80.5%) and t(9;22) positivity was detected in 7 (4.5%). CNS involvement was
present in 6 (3.9%) of the patients . The two dose groups were similar in terms
of age at diagnosis, gender, flow type, CNS and t(9;22) positivity. The MRD
levels on 15th, 22nd, and 42nd days between two groups were statistically indif-
ferent (Table 1). To investigate the effect of MPZ dose on MRD of 42nd day,
effects of age, initial white blood cell count, t(9;22) positivity and neutropenic
fever were adjusted using ANCOVA test, and still there wasn’t statistical differ-
ence between these groups (p=0.83). Median follow-up was 33 (1-85) months.
Five year OS of patients treated with 10 and 20 mg/kg/day MPZ were 85±5%
and 92±4%, respectively (p=0.29). Five year EFS of patients treated with 10
and 20 mg/kg/day MPZ were 83±6% and 86±7%, respectively (p=0.34).
Table 1. Comparison of MRD levels based on initial MPZ dose
                                      10 mg/kg MPZ*             20 mg/kg MPZ                         p
MRD on 15th day                    1 (0-814)                       1 (0-896)                           0.92
MRD on 22nd day                    0 (0-323)                      0.5 (0-378)                         0.14
MRD on 42nd day                  0.5 (0-959)                   0.5 (0-1449)                        0.80
* Median (range); MPZ, methylprednisolone; MRD, minimal residual disease.
Summary and Conclusions: Related to our published institutional previous
experience of the better outcomes of patients at higher doses of steroid at
induction; we aimed to find out whether lesser doses MPZ were still effective,
although still higher than the standard recommended doses. Our study indicates
that the survival rates and MRD levels are similar among patients treated initially
with 10 mg/kg/day MPZ compared to 20 mg/kg/day.
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Background: The role of IKZF1 deletions is extensively-evaluated in children
with ALL and is the most common genetic maker associated with a poor prog-
nosis. Few data are available on the role of IKZF1 deletions in adults with com-
mon B-cell ALL.
Aims: To Interrogate the impact of IKZF1 deletion on therapy-outcomes of
adults with common B-cell acute lymphoblastic leukemia.
Methods: 144 adults with common B-cell ALL achieved complete remission
were tested for IKZF1 deletion. Deletions in IKZF1 were detected using multi-
plex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex lig-
ation-dependent probe amplification (MLPA). All subjects received chemother-
apy and some also received an allotransplant and tyrosine kinase-inhibitors,
especially those with BCR/ABL. Multivariate analyses were done to identify
associations between IKZF1 deletion and other variables on cumulative inci-
dence of relapse (CIR), leukemia-free survival (LFS) and survival.
Results: IKZF1 deletion was detected in 66/144 subjects (49%). Amongst sub-
jects achieving complete remission those with IKZF1 deletion had a higher 5-
year CIR (39% [38-40%] vs 19% [18-20%]; P=0.010) and worse 5-year LFS (34%
[16-52%] vs 60% [42-74%]; P=0.009) and survival (48% [32-62%] vs 76% [58-
87%]; P=0.001, Figure1). In multivariate analyses IKZF1 deletion was independ-
ently associated with an increased relapse (relative risk [RR]=2.8, [1.4-5.8];
P=0.005), a higher risk of treatment-failure (inverse of LFS; RR=2.3, [1.3-4.2];
P=0.007) and a higher risk of death (RR=3.0, [1.5-6.3]; P=0.003). The adverse
impact of IKZF1 deletion on outcomes was stronger in subjects without vs with
BCR/ABL and in subjects receiving chemotherapy-only vs an allotransplant.
Figure 1. A) Cumulative incidence of relapse (CIR), B) leukemia-free sur-
vival (LFS) and C) survival of subjects with and without IKZF1 deletion.
Summary and Conclusions: IKZF1 deletion was independently-associated
with a higher relapse risk and worse LFS and survival in adults with common
B-cell ALL after adjusting for other prognostic variables and differences in ther-
apies. These data suggest IKZF1 deletion may be a useful prognostic variable
in adult common B-cell ALL, especially in persons without BCR/ABL and those
receiving chemotherapy-only.
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DUCTION OF WHOLE BLOOD AT DAY 29 OF INDUCTION CHEMOTHERA-
PY FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
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Background: Despite significant improvements in cure rates, recurrent acute
lymphoblastic leukemia (ALL) causes 10% of childhood cancer deaths and the
need for new treatment strategies has not diminished. Although ALL has long
been viewed as a poor target for immune therapy, it has recently been reported
that the peripheral blood absolute lymphocyte count (ALC) at completion of
induction chemotherapy (Day 29) is prognostic for outcome. This finding sug-
gests that the immune environment during therapy may play a role in protecting
against disease progression. It is currently unknown, however, whether ALC is
simply a marker of bone marrow recovery or whether particular immune cell
subsets at this early time-point confer a beneficial effect.
Aims: To address this question, we have initiated a study to evaluate the lym-
phocyte composition as well as cytokine production after stimulation of whole
blood with a panel of Toll-like receptor (TLR) ligands. Peripheral blood was
obtained at Day 29 from children undergoing therapy for precursor B cell ALL
at BC Children’s Hospital. The goal of this study is to correlate the size and
responsiveness of the immune cell subsets with ALC in order to identify potential
immune-mediators of the high ALC-associated favorable outcome. 
Methods: The study was approved by the University of British Columbia Ethics
Board. Freshly collected whole blood was immediately processed for i) multi-
colour flow cytometry and ii) 24 hour stimulation with a panel of Toll-like receptor
(TLR) ligands. We next performed an extensive phenotypic characterization of
20 immune cell subsets and also measured cytokine production in the super-
natant of TLR ligand-stimulated whole blood. 
Results: To date we have evaluated 11 patients for T cells (5 subsets), B cells
(6 subsets), NK cells (3 subsets), NKT cells (2 subsets), dendritic cells (2 sub-
sets), monocytes, and granulocytes. Although we have not yet identified a single
lymphocyte population that significantly correlates with ALC, clear trends, most
notably with myeloid dendritic cells, have emerged that suggest that ALC may
be indicative of specific immune activity. TLR ligand-induced cytokine production
is currently being quantified to determine whether higher ALC correlates with a
specific pattern of response. 
Summary and Conclusions: While a large-scale prospective study to validate
prognostic significance of ALC in children with high-risk ALL is underway, to
our knowledge our ongoing study is the first to investigate the specific immune
cell composition of Day 29 peripheral whole blood for significant links with ALC.
The identification of the mechanism(s) underlying ALC-associated outcomes
may reveal novel strategies for enhanced immune-mediated control of ALL
after chemotherapy.
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ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ACCORDING TO NON-
INTENSIVE BUT NON-INTERRUPTIVE PROTOCOL ALL-2009: RESULTS
OF THE RUSSIAN ALL STUDY GROUP
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Background: T-cell ALL is a distinct subgroup of ALL with better prognosis
than B-cell ALL, especially with high-dose chemotherapy and allogeneic HSCT
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in the majority of high risk patients (pts). RALL has initiated a prospective mul-
ticenter trial for adult Ph-negative ALL based on non-intensive but non-inter-
ruptive protocol “ALL-2009” (ClinicalTrials.gov public site; NCT01193933). The
therapy was unified for all pts, but in T-cell ALL autologous hematopoietic stem
cell transplantation (auto-HSCT) after non-myeloablative BEAM conditioning
followed by prolonged maintenance was scheduled as late intensification. Allo-
HSCT was planned to be an option for high risk pts with sibling donors.
Aims: Assess risk factors significance in T-cell acute lymphoblastic leukemia
treated according ALL-2009 protocol.
Methods: From Jan 2009, till Dec 2014, 30 centers enrolled 263 ALL pts,
including 90 (34,2%) T-cell ALL cases. Median age was 28 years (15-56 years),
33f/57 m; early T-cell (TI/II) phenotype was verified in 44 (49%), mature (T-IV)
- in 11 (12%), thymic (TIII, CD1a+) ALL - in 35 pts (39%). T-lymphoblastic lym-
phoma (T-LBL) was diagnosed in 18,4%, CNS disease - 13,4%, mediastinal
tumor - 57,3%. Cytogenetics was done in 61% of pts (n=55): 9% (n=5) had no
mitosis, 45,5% (n=25) - normal karyotype, 45,5% (n=25) - different aberrations.
23% of pts (n=21) were in the standard risk, 77% (n=69) - in the high risk group
(WBC >100; EGIL T-I-II-IV; LDH >2N; late CR). MRD levels by PCR analysis
for clonal TCR rearrangements (10-3) before auto-HSCT were studied only in
the minority of pts (n=7). The analysis was performed in Dec 2014. The median
follow-up was 27,4 mo.
Results: CR rate in 86 available for analysis patients was 89,5% (n=77), induc-
tion death was registered in 5,8% (n=5), resistance - in 4,7% (n=4). CR was
achieved after prephase in 16% (n=12) and after the 1st phase of induction -
in 56% of pts (n=43). There was 28% of late responders (n=22). CR rate was
higher -100% - in 34 thymic T-ALL pts in comparison with 85,7% in 42 early T-
ALL and 70% in 10 mature T-ALL pts due to higher early death rate (7,1% and
10%, respectively) and more resistant forms (4,2% and 20%, respectively).
Allo- HSCT was done in 6 pts (TI/II=4, T-IV=2) at a median of 7,2 mo from CR,
all are alive without relapse. Only 28 of 77 (36%) CR pts underwent HSCT due
to logistics problems and refusals. Auto-HSCT was done at a median time of
6 mo from CR and pts proceeded to further maintenance. We compared dis-
ease-free survival (DFS) and probability of relapse incidence (RI) in transplant-
ed pts and those who survived in CR ≥6 months (land-mark) receiving only
chemotherapy (n=27). Land-mark analysis demonstrated the essential benefit
of auto-HSCT: DFS from time of transplantation was 100% and from land-mark
for chemotherapy group - 66% (p=0,03). There were no relapses after auto-
HSCT. RI at 5 years in the chemotherapy group constituted 21% (p=0,047).
The MRD before HSCT was negative in 6 of 7 evaluated pts. At 5 years overall
survival (OS) for the whole group constituted - 66%, DFS - 76% (Figure 1). In
a multivariate analysis no relation was found between OS or DFS or RI and
age, gender, initial risk group, T-LBL, leukocytosis, immunophenotype, late
response, CNS disease, treating center.
Figure 1.
Summary and Conclusions: Though small our data demonstrate that non-
intensive, but non-interruptive treatment approach is effective. Auto-HSCT after
BEAM conditioning followed by maintenance provides an adequate alternative
to allo-HSCT. OS and DFS were not found to be depended on various common
risk factors. 
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OSTEONECROSIS IN AIEOP ALL 2000 AND 2006R TRIALS
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Background: Osteonecrosis (ON) is a potentially disabling complication in
children and adolescents treated for acute lymphoblastic leukaemia (ALL), that
could negatively impact on the quality of life (QoL). 
Aims: We retrospectively assessed the incidence of ON and sequelae on
patients enrolled in 2 consecutive ALL trials (ALL 2000 and 2006R) of the Italian
Association of Pediatric Hematology and Oncology (AIEOP), from September
2000 to December 2011.
Methods: Using ad hoc report forms, data on 3691 ALL patients were reviewed
in AIEOP participating centers in order to identify ON occurrence, ON-related
symptoms, radiological findings, treatment, risk factors and outcome. Patients
with Ph+ ALL, infants or who underwent an hematopoietic stem cell transplant
(HSCT), in first remission or after relapse, were excluded from the study.
Descriptive statistics and chi-square test for association were used. Cumulative
incidence of ON were estimated adjusting for competing risks and compared
with the Gray test. 
Results: Overall, 99 ON (2.7%) were identified of whom 82% were sympto-
matic. ON was diagnosed during induction/consolidation therapy in 12% of
patients, during reinduction in 24% and during maintenance or after therapy
discontinuation in 64% of cases. The 5-year cumulative incidence of ON was
significantly different by age, being 9.9% (n=77) in 781 patients ≥10 years vs
0.8% (n=22) in those under this age (p <0.001). Within each of these two age
groups, the incidence of ON did not differ by gender, white blood cell count at
onset, immunophenotype B or T lineage, type of steroid induction (dexametha-
sone or prednisone) and was not greater in patients treated in the high risk
arm or in patients who received cranial radiotherapy. Table 1 summarizes the
characteristics of patients aged ≥10 years. ON incidence in our study does not
seem related to other risk factors such as obesity or thyroid dysfunctions.
Involved-site was single in one-third of cases; the most frequent sites were
hip, knee, ankle and shoulder. ON (unilateral or bilateral) in these sites was
diagnosed in 64%, 51%, 35% and 9% of patients, respectively. ON-related
treatment was performed in 34 (41%) patients, including: arthroprothesis’ inter-
vention (n=21), therapy with bisphosphonates (n=9) or other non-invasive pro-
cedures, such as physiokinesitherapy (n=4). At the last follow-up visit, 81% of
patients were asymptomatic, 12% had persistent pain without functional limi-
tations and 7% had pain with limitations of daily activities.
Table 1. Characteristics of patients aged ≥10 years.
Summary and Conclusions: This study confirms that ON is a challenging
problem, with possible consequent morbidity that could compromise the QoL.
ON occurrence was not related to the type of treatment but closely influenced
by older age at diagnosis. An early detection of ON symptoms and the intro-
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duction of innovative therapies to prevent sequelae for children or adolescents
treated in ALL trials are needed.
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Background: Altered expression of histone deacetylases (HDACs) is a com-
mon feature in cancer, including hematological malignancies. Thus, HDAC
inhibitors have rapidly emerged as promising targets in cancer therapeutics
(Stubbs, 2015). However, expression patterns of HDACs in childhood leukemia
have been scarcely studied.
Aims: To analyze the expression of HDAC isoforms in different subtypes of pedi-
atric leukemia and correlate them with prognosis and clinic-biological features.
Methods: We evaluated the mRNA gene expression profile of class I, II and IV
HDAC genes (HDAC 1-11) by quantitative PCR in 54 leukemic pediatric sam-
ples and a pool of non-neoplastic samples as control. Samples were obtained
from the Biobank of our hospital after appropriate informed consent was signed
by patients and/or legal tutors. Our series included 35 boys and 19 girls diag-
nosed with acute leukemia (median age 5.4 years, range 0-16.7), treated
according to Spanish Pediatric Hemato-Oncology Cooperative Group protocols
in a single center. Nineteen (35%) cases were B-cell precursor acute lym-
phoblastic leukemia (pre-B-ALL), 22 cases T-cell ALL and 13 patients had acute
myeloblastic leukemia (AML). The HDAC expression levels in different groups
of patients were compared by the Mann-Whitney test. The level of significance
was set up at p<0.05. The analyses were performed with SPSS 22.0.
Results: We found high expression levels of class I HDAC isozymes (HDAC
1, 2, 3 & 8) in leukemic samples compared to non-neoplastic samples, as pre-
viously reported (Gruhn, 2013; Moreno, 2010). We also noted a trend towards
a downregulation of HDAC10 in all leukemia subtypes. A higher expression of
HDAC1, HDAC2, HDAC3, HDAC4 & HDAC11 and a lower expression of
HDAC5 and HDAC9 was observed in T-ALL compared to pre-B-ALL. HDAC11
was significantly overexpressed in AML cases. The class I HDACs HDAC1 &
HDAC3 expression correlated with age, with patients >10 years old expressing
the highest levels. In contrast, infant patients (<1 year-old) had a significant
lower expression of HDAC7 (p=0.022). Interestingly, 3/4 cases with a pro-B
phenotype had low levels of HDAC7, in line with our recently published data
(Barneda-Zahonero, 2015). Of note, patients with MLL rearrangement had sig-
nificantly higher expression of HDAC9 (p=0.001). Male patients had higher
expression of HDAC4 (p=0.008). We did not find a correlation between HDACs
expression and WBC count levels at diagnosis. In general, overexpression of
all HDACs isoforms was associated with worse outcome. Noticeably, in T-ALL
patients HDAC5 and HDAC9 expression levels above Q3 upper quartile signif-
icantly correlated with worse overall survival (OS) (p=0.03 and p=0.04, respec-
tively). T-ALL cases with high HDAC1 had inferior OS (91% vs 51%), but the
low number of patients precluded the finding of statistical significance. In sum-
mary, high expression of HDACs isoforms in leukemic patients correlate with
worse outcome and older age. In addition, some isozymes associated with
specific features. Thus, T-cell phenotype cases overexpressed HDAC1-4 &
HDAC11 and underexpressed HDAC5 & 9. However, those T-ALL cases with
high HDAC5 & 9 levels did worse, with inferior OS. HDAC7 levels were lower
in infant patients and in those pre-B-ALL cases with pro-B phenotype. Finally,
MLL rearranged cases showed higher expression of HDAC9.
Summary and Conclusions: We have observed a different pattern of HDACs
expression in different subtypes of pediatric leukemia. Some of these profiles
identified high risk patients who could benefit from a targeted treatment with
HDAC inhibitors.
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Background: Previously we developed next generation sequencing assays
for the detection and characterization of clonality in B-cells, targeting the IGH
locus with single step PCR approach followed by sequencing and analysis.
These IGH assays were shown to be both sensitive and robust in a number of
different laboratories and have demonstrated utility for tracking residual disease.
IGK is also an important locus that can be used for the identification and tracking
of clonality, as IGK rearrangements are stable markers that are retained even
in lambda light chain expressing B-cells, as Kde rearranges to Vk elements as
well as to the recombination signal sequence (RSS) in the Jk5-Ck intron (INTR)
prior to rearrangements within IGL. Accordingly, IGK is an ideal marker for
tracking residual disease in B-lineage ALL.
Aims: The development of an assay for IGK that can be combined with IGH
that will increase the chance of identifying clonal populations in lymphoid malig-
nancies such as non-Hodgkin’s Lymphoma and tracking a variety of B-cell
tumours.
Methods: Genomic DNA from peripheral blood, tonsil and bone marrow aspi-
rates were tested for IGK gene rearrangements. Optimized V and J consensus
primers targeted all IGK V and J region gene segments that are rearranged in
lymphoid cells as well as the Kde rearrangements that precede lambda selec-
tion. Multiplex PCR master mixes simultaneously amplified IGK V-J gene
rearrangements and incorporated sample identifying indices into amplicons,
which facilitated combining and sequencing libraries generated testing up to
12 samples and controls in each run. Amplicon products were purified, quanti-
fied, the concentrations adjusted, pooled, and the harmonized libraries were
loaded into the OneTouch 2. The enriched emulsion PCR libraries were
sequenced using Ion 316 Chip Kit v2s and Ion PGM Sequencing 400 Kits. Data
were analysed using Invivoscribe’s proprietary bioinformatics software (included
with the test kits) on a standard personal computer. The bioinformatics package
allows for IGH and IGK libraries with the same barcodes to be analysed on the
same run. The PGM platform allows a sustainable, rapid turn around time, less
than 36 hours from primary sample to result.
Results: Data generated with the LymphoTrack® IGK assay and bioinformatics
package reproducibly identified clonality and DNA sequences of IGK Vk-Jk, as
well as Vk-Kde and INTR-Kde, gene rearrangements. Automated data outputs
include frequency distributions and V-J gene usage. DNAs from cell lines serially
diluted into polyclonal tonsil DNA, confirmed the linearity (R2 >0.99) and low
run-to-run variance of the assay. This assay may be used with genomic DNA
from peripheral blood, bone marrow and FFPE. In addition to the assay devel-
opment, the break point of the INTR element was also identified.
Summary and Conclusions: We have previously developed IGH and TRG
assays for the IonTorrent PGM. We now add an NGS clonality assay for IGK
that identifies clonal IGK Vk-Jk, as well as Vk-Kde and INTR-Kde, rearrange-
ments and associated specific rearranged DNA sequences to the repertoire
that can either be used in reflex testing to further characterise samples that are
difficult to characterize by IGH alone. Alternatively, a more time and cost efficient
approach would be to run both assays at the same time on samples to be run
on the same sequencing run. These assays can be used to both detect and
monitor lymphoproliferative disease. A further advantage is that the assays
identify clonal lymphocyte populations by their unique DNA sequences that can
subsequently be used to track clones in residual disease testing.
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Background: Minimal residual disease (MRD) assessment is now established
as an important predictor of outcome in both pediatric and adult patients (pts)
with acute lymphoblastic leukemia (ALL). Availability of novel agents able to
eradicate MRD is a further factor emphasizing the need for MRD monitoring in
these pts.
Aims: To determine the significance of MRD relapse as detected by multi-para-
meter flow cytometry (MFC) in pts with ALL after achieving an MRD negative
status following induction and consolidation therapy.
Methods: Between January 2003 and August 2013, 585 newly diagnosed pts
with ALL (excluding Burkitt’s leukemia/lymphoma) were treated with regimens
including the hyperCVAD backbone or Augmented BFM. 540 (92%) achieved
complete remission (CR), of whom, 490 (91%) became MRD negative as
assessed by MFC. 47 pts (41 with B-ALL, 6 with T-ALL) developed recurrence
of MFC detectable disease while still in morphological CR and are subjects of
this study. MRD was assessed by 4-color (and since 2009, 6-color) flow cytom-
etry at CR and multiple time points thereafter, as clinically indicated.
Results: Median age was 43 years (yrs)(range,18-72 yrs), 27 (57%) were male.
Median laboratory values at initial presentation were: WBC 7.3 K/uL (range,
0.6-303.8) and bone marrow (BM) blasts 89% (range, 26-98). Cytogenetics at
initial presentation were: 11 diploid, 14 Philadelphia positive (Ph+), 6 insufficient
metaphases/not done, 15 miscellaneous, and 1 with 11q23 rearrangement.
Chemotherapy regimens included: 42 HCVAD +/- other (10 HCVAD, 8
HCVAD+Dasatinib, 10 HCVAD+Rituximab, 6 HCVAD+Imatinib, 5
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HCVAD+Nelarabine, 3 HCVAD+Ofatumumab) and 5 Augmented BFM. Median
Event-free survival (EFS) of the whole group was 24 months (mos) (range,
3.7-138 mos); median OS, 30 mos (range, 3.7-138 mos). Thirty-nine (83%)
pts subsequently developed morphological relapse (32 BM, 3 BM+ central
nervous system (CNS), 3 CNS, and 1 non-CNS extramedullary), after a median
of 110 days (range, 3-540 days) from detection of MRD recurrence. Median
EFS for this group was 24 mos (range, 7.6-72 mos), and median OS was 30
mos (range, 9-82 mos). Eight pts did not have morphological relapse including
5 pts who died in complete morphological remission, with only 3 pts alive in
continued CR. Of the 5 pts who died prior to relapse, 4 had undergone stem
cell transplantation (SCT) (2 related, 1 cord, and 1 haplotype), and died of
post-SCT complications. 3 pts (2 B-ALL, 1 T-ALL,) are still alive and in CR
despite having had MRD recurrence, all with normal karyotype and all having
undergone matched unrelated donor(MUD) SCT with a median OS of 3.8 yrs
(range, 3 -11.5 yrs).
Figure 1. Overall survival for pts with MRD relapse with no morphological
relapse (n=8) versus pts with MRD relapse followed by morphological
relapse (n=39).
Summary and Conclusions: In this single institution retrospective analysis,
the vast majority of pts with ALL who achieved MRD negative CR, followed by
MRD relapse at any time point, subsequently experienced morphological
relapse, suggesting that MRD relapse at any time point during a patient’s fol-
low-up is associated with a high risk for relapse. Although allogeneic SCT res-
cued some patients with ongoing long-term remission, it was associated with
mortality in others. Prospective studies of long-term MRD assessments
throughout a patient’s treatment course, together with less toxic strategies to
eradicate MRD, are warranted.
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IMPROVED SURVIVAL IN ADULT PATIENTS WITH ACUTE LYMPHOBLAS-
TIC LEUKEMIA (ALL) IN THE NETHERLANDS: A POPULATION-BASED
STUDY ON TREATMENT, TRIAL PARTICIPATION AND SURVIVAL, 1989-
2012
A. Szabo1,* A.G. Dinmohamed1, M. van der Mark2, O. Visser2, J.J. Cornelissen1,
P. Sonneveld1, M. Jongen-Lavrencic1, A.W. Rijneveld1
1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University
Medical Center, Rotterdam, 2Department of Registration and Research, Com-
prehensive Cancer Centre the Netherlands, Utrecht, Netherlands
Background: Pediatric ALL has shown an impressive improvement in survival
over the last decades. The outcome in adult patients is far less optimistic with
current survival rates in several published trials reaching 60% only. Large, com-
prehensive population-based studies among unselected adult ALL patients are
lacking.
Aims: We conducted a population-based study to assess trends in treatment,
trial participation and survival among adult ALL patients diagnosed in the
Netherlands from 1989-2012.
Methods: We identified 1833 over 18-year-old ALL patients (median age 49
years) from the nationwide Netherlands Cancer Registry (NCR) with follow-up
until February, 2014. Patients were categorized into 4 calendar periods (1989-
1994, 1995-2000, 2001-2006 and 2007-2012) and 5 age groups (18-24, 25-
39, 40-59, 60-69 and ≥70 years). Data on treatment (ie, supportive care only,
chemotherapy (CT) and stem cell transplantation (SCT)) were retrieved from
the NCR. We obtained data on the type of SCT (ie, autologous (autoSCT) or
allogeneic SCT (alloSCT)) from the HOVON SCT working party, and data on
trial participation from the HOVON and EORTC cooperative groups. To correct
for the life expectancy of the general population, relative survival rates (RSRs)
were computed as a measure of patient survival. Overall survival (OS) accord-
ing to treatment by calendar period was estimated by the Kaplan-Meier method.
Results: The annual age-standardized incidence remained stable over time
at around 0.6/100,000 with a consistent male predominance (54% males).
Overall, 38%, 41%, 49%, 72% and 43% of the patients in the 5 age groups
received CT, 22%, 15%, 10%, 1% and 0% received autoSCT, 38%, 41%, 31%,
10% and 0% received alloSCT, while 2%, 3%, 9%, 17% and 57% received
supportive care only, respectively. The application of alloSCTs increased over
time among patients up to 70 years and was steadily introduced in the treatment
of patients aged 60-69 years during the mid-1990s. Treatment remained essen-
tially unchanged over time among patients aged ≥70 years. 
When clinical trials were open for accrual, the inclusion rate was 67%, 66%,
55% and 58% in the first 4 age groups, respectively. No trials were available
for patients aged ≥70 years. 
Relative survival (RS) improved over time as 5-year RSRs (95% CI) were 19%
(15%>23%) in 1989-1994 and 37% (32%>42%) in 2007-2012 (Figure 1A). This
improvement was confined to patients up to 70 years, and was most pro-
nounced among patients up to 40 years, especially in the most recent calendar
period (Figure 1B). RS worsened sharply with age. 5-year RSRs (95% CI) for
patients diagnosed in 2007-2012 were 75% (63%>84%), 57% (44%>68%),
37% (27%>47%), 22% (13%>31%) and 5% (1%>18%) for the 5 age groups,
respectively. Among 18-39-year-olds, 5-year OS was 25% and 68% for those
who received CT (Figure 1C) and 46% and 66% for recipients of an alloSCT
(Figure 1D) in the first and last calendar periods, respectively.
Figure 1.
Summary and Conclusions: We show that survival of unselected adult ALL
patients up to 70 years of age improved over time in the Netherlands. The
intensification of adult chemotherapeutic approaches based on more intensive,
pediatric protocols implemented since 2007 and the increased application of
alloSCT along with improved supportive care, are most likely important factors
contributing to this improvement. The accrual into clinical trials slightly
decreased with age, with no trials available for patients aged ≥70 years yet.
Novel, and more targeted treatment options with a tolerable toxicity profile are
needed to further improve outcome, particularly in the elderly.
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A DISTINCTIVE LONG-NON CODING RNA SIGNATURE CHARACTERIZES
ACUTE MYELOID LEUKEMIA WITH TRANSLOCATION T(8;16)(P11;P13)
AND MYST3-CREBBP REARRANGEMENT
M. Diaz-Beya1,*A. Navarro2, A. Cordeiro2, M. Pratcorona1, J. Castellano2,
M. Nomdedeu1, R. Risueño3, M.A. Torrente1, M. Camós4, M. Monzo2, J. Esteve1
1Hematology Department,, Hospital Clínic, IDIBAPS, Barcelona, Spain, 2Mol-
ecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of
Medicine, University of Barcelona., 3Josep Carreras Leukaemia Research Insti-
tute, 4Hematology Laboratory, Hospital Sant Joan de Deu, Fundació Sant Joan
de Deu, Barcelona, Spain
Background: Long Non-coding RNAs (lncRNAs) have recently emerged as
important actors in the regulation of multiple cellular processes including cancer.
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) (t(8;16) AML)
is a subtype with specific clinical and biological characteristics including a spe-
cific gene (Camós et al., 2008) and a microRNA (Díaz-Beyá et al., 2013) expres-
sion profile. In this translocation, MYST3 on chromosome 8p11 fuses with
CREBBP on chromosome 16p13.3. The MYST3-CREBBP fusion protein is
able to interact with multiple transcription factors producing a disturbed tran-
scriptional program. However, the lncRNA expression pattern of t(8;16) AML
has not been described yet.
Aims: The main objective of this study was to characterize the expression pat-
tern of lncRNAs in t(8;16) AML in comparison to other AML subtypes.
Methods: Forty six AML patients, 4 normal bone marrow (NBM) and 3 CD34+
NBM samples were included in the study. Patient samples included a wide diver-
sity of different AML subtypes: intermediate-risk cytogenetics AML (IR-AML,
n=18), acute promyelocitic leukemia (APL, n=4), t(8;21) AML (n=4), inv(16)
AML(n=2), t(6;9) AML (n=7), monosomal karyotype AML (n=4), t(3;3) AML (n=1),
t(9;11) AML (n=1) and t(8;16) AML (n=5). Within IR-AML, 7 harbored an FLT3-
ITD, 5 NPM1, 7 CEBPA and 6 DNMT3A mutations. The lncRNA expression was
studied using Affymetrix® Human Gene 2.1 ST platform which includes 9698
lncRNAs transcripts. The filtering and normalization of the array data was per-
formed using oligo package from Bioconductor. Statistical analyses were per-
formed with TiGR MultiExperiment Viewer, BRB tools and R. The Transcription
factor Affinity Prediction Web Tool was used to determine the putative transcription
factors binding to the differentially expressed lncRNAs promoters.
Results: The hierarchical cluster analysis showed that all 4 NBM clustered
together, as well as all 3 CD34+ NBM according to their lncRNA expression.
Interestingly, all 5 t(8;16) AML samples clustered together, as well as the 3
APL, the 7 t(6;9) AML and 5 out of 7 cases with CEBPA mutations. Afterwards,
we focused on t(8;16) AML and the supervised analysis identified an specific
113-lncRNA signature. Interestingly, when we analyzed which transcription fac-
tors (TF) had motifs overrepresented in the promoters regions of the t(8;16)
AML lncRNA signature, we identified motifs for GATA2 (p<0.001) and Evi1
(p=0.04). These two TFs have been described to interact with CREBBP, one of
the partners involved in t(8;16) AML. Of note, 4 overexpressed lncRNAs of the
signature (linc-HOXA11, HOXA11-AS, HOTTIP and NR_038120) were located
in the HOXA genomic region, previously found upregulated in t(8:16) AML.
Since several studies suggest an active crosstalk between microRNAs and
lncRNAs, we correlated the expression of these lncRNAs with the microRNA
profile. We found significant correlations between linc-HOXA11 and miR-222*
(R2=0.996, p=0.003), HOXA11-AS and miR-let-7c (R2=0.994, p=0.006), HOT-
TIP and miR-196b*(R2=0.958, p=0.041), NR_038120 and miR-486-3p
(R2=0.999, p=0.0004), and miR-19a (R2=0.953, p=0.04). 
Summary and Conclusions: t(8;16) AML harbors a characteristic lncRNA sig-
nature. Some of the lncRNAs of this signature are located in the HOXA genomic
region, and correlate with several of the distinctive microRNAs of this entity.
Interestingly, we have identified in silico GATA2, which interacts with CREBBP,
as the most significant TF that could regulate this lncRNAs signature. Further
investigation is warranted to determine the importance of this lncRNA signature.
Acknowledgements:ISCII Rio Hortega CM13/00205,PI13/00999.
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NEW JAK2 HETEROZYGOUS LOSS: A ROLE IN OVERALL SURVIVAL IN
ACUTE MYELOID LEUKEMIA PATIENTS 
V. Guadagnuolo1,* M.C. Fontana1, C. Papayannidis1, I. Iacobucci1, M. Manfrini1,
A. Padella1, G. Simonetti1, A. Ferrari1, G. Marconi1, A. Ghelli Luserna di Rorà1,
S. Paolini1, M.C. Abbenante1, S. Parisi1, C. Sartor1, E. Ottaviani1, M. Cavo1,
G. Martinelli1
1Department of Hematology and Medical Sciences “L. and A. Seràgnoli”,,
Bologna, Italy
Background: Acute Myeloid Leukemia (AML) is a hematologic malignancy that
originates in hematopoietic stem and myeloid progenitor cells. Age and karyotype
have been recognized as the most prominent prognostic factors in AML patients.
Novel array-based technique-single-nucleotide polymorphism (SNP) microarray
can detect cytogenetic lesions involve mostly structural alterations with losses or
gains of chromosomic material. Those chromosomic abnormalities are predictive
of response and are very important to define therapeutic strategies. SNP microar-
ray can detect copy-neutral loss of heterozygosity (CN-LOH), which plays a role
in oncogenesis by duplicating oncogenes, inhibiting tumor suppressors, and stim-
ulating improper epigenetic programming.
Aims: Our objective is to evaluate the prognostic impact of these genetic alter-
ations on clinical outcome.
Methods: We analyzed 58 AML patients by high-density CytoScan HD Array
(Affymetrix, Inc). The results obtained by SNP Array, were analyzed by Chro-
mosome Analysis Suite (ChAS) v1.2 (Affymetrix Inc.) and Nexus Copy Num-
ber™ v7.5 (BioDiscovery). 
Results: We treated 58 AML patients (pts) with a median age of 52 years, of
which 9 were insensitive pts and 49 sensitive to therapies. The median age
at diagnosis was 51,3 years (range: 19-89 years), and they have a
female/male ratio of 53% and 47%, while the median follow up is of 28,5 and
34,4 months respectively. Copy Number Alterations (CNAs) were detected in
all patients affecting all the chromosomes, in particular our cohort of pts pres-
ent a percentage of CNA, divided as follow: 42% of LOH, 19% of Copy Num-
ber (CN) gain, 39% CN of loss. By SNP array analysis we found that several
important genes were preferentially deleted: ADAM3A (62,2% pts; Chr 8),
JAK2 (34,5% pts; Chr 9), HRAS (8,6% pts; Chr11), WT1 (20,7% pts; Chr 11),
FLT3 (13,8% pts; Chr 13), SIRPB1 (41,4%; Chr 20) and CRLF2 (50% pts;
Chr X). We observed a significant involvement of the Chromosome X, infact
in several leukemia-related genes as ATRX (43,1% pts), BCOR (34,5% pts),
GATA1 (39,7% pts), KDM6A (43,1% pts), PHF6 (29,3% pts), ZRSR2 (31%
pts), STAG2 (29,3% pts) are concurrent events of loss and LOH: this double
lesion may inactive their function as transcriptional regulators. While genes
preferentially involved in amplifications are PRDM16 (12% pts), KIT (24,1%
pts), IKZF1 (12% pts), MYC (8,6% pts), KRAS (8,6% pts). Moreover we
focused on a particular heterozygosis loss of JAK2, detected in 5/58 (8,6%)
pts, which goes from 5080280 bp to 5098786 bp, involving half of exon 17
and exons 18, 19, 20, 21 and 22. This region include the second tyrosine-
kinase domain required for a correct function of the protein. We showed that
a group of patients which present this deletion have an overall survival rate
better than the group with an amplification of the gene (p-value <0,01) (Figure
1). None CNV in this region of JAK2 had been described in hematopoietic
tissue before.
Figure 1.
Summary and Conclusions: By SNP arrays we have identified Copy Number
Alterations involving important cancer genes in AML and we showed that a
new deletion involving JAK2 may have a role in overall survival. Future prospec-
tive will be to correlate other cancer genes alterations and mutations with the
prognosis of AML, in order to identify new biomarkers relevant for the disease.
Acknowledgement: ELN, AIL, AIRC, PRIN, progetto Regione-Università 2010-
12 (L. Bolondi), FP7 NGS-PTL project.
P545
SELECTIVE DEATH OF LEUKEMIC STEM CELLS INDUCED BY
DEFERASIROX
S. Shapira1,* P. Raanani1,2, I. Lubin1, A. Nagler3, N. Arber4, G. Granot1
1Felsenstein Medical Research Center, Beilinson Hospital, 2Institute of Hema-
tology, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah
Tikva, 3Department of Hematology and Bone Marrow Transplantation, Chaim
Sheba Medical Center, Tel-Hashomer, 4Integrated Cancer Prevention Center
and Department of Gastroenterology, Tel- Aviv Sourasky Medical Center, Sack-
ler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
Background: Despite high remission rate after therapy, only 30-40% of acute
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myeloid leukemia (AML) patients survive 5 years after diagnosis. The main
cause of treatment failure is thought to be insufficient eradication of leukemic
stem cells (LSC). Identifying drugs that can efficiently eradicate LSCs is there-
fore imperative. HIF1α is essential for LSC maintenance and targeting HIF1α
selectively eliminates LSC. Deferasirox is an iron chelator used to reduce
chronic iron overload in patients receiving long-term blood transfusions.
Aims: To study the ability of deferasirox to induce apoptosis and to target
HIF1α in AML LSCs.
Methods: We isolated CD34+CD38- LSC-like cells from the leukemic progen-
itor CD34+ KG1a cell line using CD38 magnetic separation. We isolated the
phenotypically primitive leukemic CD34+CD38-CD123+ cells and the progenitor
CD34+CD38+CD123+ cells from bone marrow samples of newly diagnosed
AML patients using a double CD34 & CD38 magnetic separation. Cell prolifer-
ation and apoptosis were analyzed by WST-1 and FACS assays, respectively.
Synergism was calculated by Chou.T.C combination index. HIF1α expression
was measured by real-time PCR and Western blot assays.
Results: CD34+CD38- LSC-like cells, sorted from the KG1a cell line, exhib-
ited increased sensitivity to deferasirox with an IC50 of 1.3μM compared to
8.9μM calculated for the more mature CD34+CD38+ cells. The LSC-like cells,
which were more sensitive to deferasirox, were less sensitive to ARA-C com-
pared to the CD34+/CD38+ cells. Deferasirox was >2-fold more efficient in
inducing apoptosis in the CD34+CD38− cells, compared to the CD34+CD38+
cells (74±7.2% & 32±6.2% apoptosis, respectively). Deferasirox demonstrat-
ed a synergistic cytotoxic effect with ARA-C on both the CD34+CD38− and
CD34+CD38+ KG1a cell fractions. Similar results were observed with
CD34+CD38-CD123+ LSCs and CD34+CD38+ CD123+ progenitor cells iso-
lated from AML patients. As shown with the cell line, AML patient LSCs were
2-fold more sensitive to deferasirox treatment showing a 62±15% induction
of cell death compared to only a 34±9% induction in leukemic progenitor cell
death. The increase in cell death was accompanied by an increment of reac-
tive oxygen species (ROS) levels which was more prominent in the LSCs
compared to the progenitor cells. Furthermore, deferasirox enhanced the
cytotoxic effects of ARA-C on both the LSCs and the leukemic progenitor
cells. These data indicate that deferasirox is highly cytotoxic to AML cells;
however, it is significantly more specific to AML stem cells. Since deferasirox
is an NFkB inhibitor which regulates HIF1α levels, and since HIF1α is selec-
tively activated in AML stem cells and is essential for maintenance of these
cells, we studied the effect of deferasirox on HIF1α expression. We found
that HIF1α was downregulated transcriptionally (~40% reduction) and trans-
lationally (~55% reduction) in the LSC-like cells while it was upregulated in
the CD34+CD38+ KG1a cells following deferasirox treatment. These data
hint that AML-LSCs are selectively targeted by deferasirox.
Summary and Conclusions: We describe a novel and unique anti-LSC prop-
erty of deferasirox, which was originally developed as an iron chelator. We
found clinically relevant concentrations of deferasirox to be cytotoxic in vitro to
AML cells but even more potent against LSCs. We believe that deferasirox
exerts its cytotoxic effect, at least in part, by downregulating HIF1α levels in
the LSC population. Pending further characterization, deferasirox can be con-
sidered as a potential therapeutic agent for eradicating LSCs.
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ADDITIONAL MOLECULAR ABERRATIONS LEADING TO LEUKEMIC
TRANSFORMATION IN PATIENTS WITH FAMILIAL PLATELET DISORDER
N. Duployez1,2,* I. Antony-Debré3, M. Bucci1, S. Geffroy1,2, N. Boissel4,
C. Berthon2,5, N. Dhédin4, T. Leblanc6, D. Réa4, P.G. Heller7, R. Favier8, V. Latger-
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Lille, 3U1009, INSERM, Gustave Roussy Institute, Villejuif, 4Hematology
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Médicas Alfredo Lanari, Buenos Aires, Argentina, 8French Reference Center
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Background: Familial platelet disorder with predisposition to acute myeloid
leukemia (FPD/AML) is a rare autosomal dominant disorder characterized by
quantitative and qualitative platelet abnormalities and considered as a model
of genetic predisposition to hematological malignancies. FPD/AML syndrome
is caused by inherited RUNX1 mutations (21q22) reported so far in less than
40 pedigrees. However, evolution remained very heterogeneous since only
30-40% of such patients develop hematopoietic neoplasms, usually after a
long period.
Aims: In this context, it is likely that the acquisition of secondary molecular
events functions as a driver to promote malignant transformation, thus the
FPD/AML syndrome constitutes a unique multi-step leukemogenesis model in
vivo. Recently, acquired mutations of CDC25C and GATA2 have been reported
in 53% and 23% of FPD/AML patients respectively (Yoshimi et al., Nat Com-
mun, 2014), particularly during disease progression.
Methods: We studied 24 patients from 15 FPD/AML families identified from
2005 to 2014. Twelve of them progressed to leukemic stage: 9 patients devel-
oped AML and 3 patients developed T-ALL. Cytogenetics and next-generation
sequencing (MiSeq, Illumina®) of 44 genes (including CDC25C and GATA2)
were performed for all patients. For patients who progressed to leukemic stage,
samples were collected at the time of diagnosis and during complete remission
allowing to confirm the acquired status of mutations.
Results: Characteristics of the patients studied are presented in the following
Table 1.
Table 1.
Summary and Conclusions: Acquisition of a secondary genetic or molecular
event was identified in all patients of our cohort. Acquired mutations involved
genes implicated in tyrosine kinase pathway, epigenetic, spliceosome and tran-
scription regulation. In addition to germline RUNX1 mutation, a second aber-
ration of RUNX1 was found in all patients who developed AML, in line with our
previous report (Preudhomme et al., Blood, 2009). Four patients acquired muta-
tion in the second allele and 4 patients had duplication of the abnormal copy
by uniparental disomy (n=2) or acquired trisomy 21 (n=2). On the other hand,
patients who developed T-ALL were younger and did not acquire second aber-
ration of RUNX1. Interestingly, CDC25C or GATA2 mutations were not identified
in our cohort, in contrast with Yoshimi et al.
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LEUKEMOGENIC MLL-ENL FUSIONS INDUCE ALTERNATIVE CHRO-
MATIN STATES TO DRIVE A FUNCTIONALLY DICHOTOMIC GROUP OF
TARGET GENES.
M.-P. Garcia-Cuellar1, C. Büttner2, E. Füller1, K. Hetzner1, J. Steger1, R. Slany1,*
1Genetics, 2Human Genetics, University Erlangen, Erlangen, Germany
Background: MLL fusion proteins provoke leukemogenic transformation by
inappropriate activation of downstream target genes.
Aims: To identify MLL-ENL subordinate transcripts with importance for malig-
nant development, primary hematopoietic precursor cells containing a condi-
tional MLL-ENL knock-in were used in NGS experiments to monitor the molec-
ular process driving the transition from a transformed, self-renewing to a normal,
differentiating cell.
Methods: Nascent RNA-seq and ChIP-seq identified 165 high confidence MLL-
ENL target genes.
Results: Correlation of individual transcription rates with cellular physiology
suggested that about 40% of MLL-ENL targets play an important role in trans-
formation thus assigning them a “driver“ status with the remainder likely to act
mainly as “bystanders“. Next to well-known MLL-fusion targets like the HoxA
cluster hitherto unknown MLL-ENL controlled regulatory units could be identi-
fied. Many of those supported pro-transformation traits like accelerated prolif-
eration, reduced differentiation and inhibition of apoptosis. In addition mecha-
nistic insight was gained from ChIP patterns that were linked to activation by
MLL-ENL. MLL-ENL targets fell in two distinct clades characterized by unique
MLL-ENL binding arrangements and chromatin configurations. In an “ME5”
group the fusion protein bound at the transcription initiation site, RNA synthesis
rates were directly proportional to H3K79 methylation and extensive transcrip-
tional pausing was suggested by RNA-PolII Ser2-P distribution. In contrast,
hallmarks of an “ME3” group were a location of MLL-ENL downstream of the
transcription termination site, transcription rates that were inversely correlated
to H3K79 methylation and an unusual RNA PolII accumulation associated with
the occurrence of non-coding transcripts. This chromatin-based dichotomy was
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mirrored by a functional separation into DNA and RNA related activities for ME5
and ME3 genes respectively.
Summary and Conclusions: As current small-molecule approaches aim to
eliminate exclusively H3K79 methylation they may not be sufficient for complete
leukemia eradication. Our results suggest that targeting both subsets of MLL-
ENL subordinate genes may be potentially more efficient for treatment of MLL
fusion induced leukemia.
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GENOMIC LANDSCAPE OF CORE-BINDING FACTOR ACUTE MYELOID
LEUKEMIA
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Laboratory, Cochin Hospital, APHP, Paris, 6Department of Hematology, Angers
University Hospital, Angers, 7Department of Hematology, Nîmes University
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France
Background: Core-binding factor (CBF) acute myeloid leukemia (AML)
includes AML with t(8;21)/RUNX1-RUNX1T1 chromosomal translocation and
AML with inv(16)/t(16;16)/CBFB-MYH11 chromosomal rearrangement. These
recurrent genetic abnormalities are both associated with the disruption of the
CBF, a heterodimeric transcription factor involved in hematopoiesis. Although
the fusion proteins appear to be crucial for the leukemogenic process, consid-
erable experimental evidences indicate that they are no sufficient to induce
AML on their own. CBF-AML accounts for about 15% of de novo AML and is
associated with a relatively favorable prognosis due to the high sensitivity to
standard chemotherapy with high complete remission rates. Nonetheless,
relapse incidence may reach 40% in such patients.
Aims: In this context, identification of additional molecular events is considered
of great interest to improve our understanding of CBF-AML leukemogenesis,
better predict clinical outcome and identify novel therapeutic approaches.
Methods: This study focused on 123 patients with CBF-AML including 68 AML
with t(8;21) and 55 AML with inv(16)/t(16;16). Patients were enrolled in the 2
French therapeutic trials ELAM02 (n=68; median age: 10 years [4-17]) and
CBF2006 (n=55; median age: 40 years [18-60]). All patients were studied at
the time of diagnosis by next-generation sequencing (MiSeq, Illumina®) inclund-
ing 57 genes well-known in hematological malignancies.
Results: Identified mutations are indicated in the Figure 1 according to the
CBF-AML subtype. Mutations involving genes from the tyrosine kinase path-
ways (i.e KIT, NRAS, KRAS or FLT3) were the most frequent aberration and
were found in both subtypes as previously reported. Interestingly, mutations
involving genes that control chromatin modifications (i.e ASXL1, ASXL2, EZH2,
KDM6A) or implicated in the cohesin complex (i.e. RAD21, SMC1A, SMC3,
STAG2, NIPBL) were frequent especially in the t(8;21)-AML subtype, whereas
they were nearly absent in the inv(16)/t(16;16)-AML subtype. Finally, the two
CBF-AML subtypes showed greatly distinct mutational profiles.
Figure 1.
Summary and Conclusions: Due to similarities between their molecular and
prognostic features, t(8;21) and inv(16)/t(16;16)-AML are usually grouped
and reported together in clinical studies. However, considerable experimental
evidences have highlighted that they represent two distinct entities and should
be considered separately for further studies. Particularly, t(8;21)-AML is char-
acterized by the high frequency of mutations of genes involved in the epige-
netic machinery and the cohesin complex. It is currently known that polycomb
proteins functionally interact with cohesin to control transcription. Together,
these results suggest an important pathway in t(8;21) leukemogenesis.
Note: Increase of our cohort size and correlations with clinical outcome are in
progress to identify prognostic markers.
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Background: The reversible phosphorylation and dephosphorylation of tyrosine
residues on proteins is mediated by protein tyrosine kinases (PTKs) and protein
tyrosine phosphatases (PTPs). This process regulates a wide range of signalling
pathways and dysregulation of these signalling pathways are common biochem-
ical phenomena in cancer cells. Protein-tyrosine phosphatase of regenerating
liver 3 (PRL-3, encoded by PTP4A3 gene) is a member of VH1-like PTP family
with dual-specificity. Elevated expression of PRL-3 is associated with metastasis
in solid tumors. Acute myeloid leukemia (AML) arises from abnormal clonal
hematopoietic cells characteristic with uncontrolled proliferation and blocked dif-
ferentiation of immature myeloid cells. A larger body of evidence supports the
notion that leukemia stem cell (LSC), a distinct subpopulation of AML cells with
self-renewal capacity, initiates and sustains the bulk leukemia. The molecular
mechanisms underlying the transformation of LSC are not fully understood yet.
We and others identified that PRL-3 is over expressed in patients with acute
myeloid leukemia (AML) and serves a poor prognostic factor.
Aims: The aims of this study were to explore the role of PRL-3 in transformation
of LSC in AML and to investigate the molecular mechanism by which PRL-3
was regulated.
Methods: Whole genome microarray was used to compare the transcriptome
of a pair of iosgeneic cell line TF1-pEGFP vs TF1-hPRL-3. Colony formation
assay and serial replating assay were employed to examine the in vitro self-
renewal capacity of AML cells. To assess the in vivo function of PRL-3 in leuke-
mogenesis, we performed limited serial dilution and bone marrow transplanta-
tion of TF1-hPRL-3 cells in nonobese diabetic/severe combined immunodefi-
ciency (NOD/SCID) mice.
Results: We first show that ectopic expression of PRL-3 promotes proliferation,
colony forming capacity of AML cells in vitro and leukemogenicity in vivo. Next,
we conduct gene expression profiling of TF1-pEGFP and TF1-hPRL-3 cell lines
and reveal upregulation of some stemness factors such as LIN28B, c-KIT,
IGF2BP1 and downregulation of mature cell surface marker CD36 and CD38 by
PRL-3. Importantly, gene-set enrichment analysis (GSEA) of this microarray result
revealed a significant enrichment of genes identified in a previously defined gene
expression signature of leukemia stem cell (LSC SIGNATURE_SAITO) and
hematopoietic stem cell (HSC SIGNATURE_EPPERT). Notably, we unravel that
LIN28B, a stem cell reprogramming factor, represses let-7 microRNA family in
TF1-hPRL-3 cells. Furthermore, we identify IGF2BP1 as a novel target of let-7
miRNA. Through combination of shRNA targeting with serial replating assay and
xenotransplantation mouse models, we validate that this regulatory axis is critical
to PRL-3-medidated LSC phenotype. We also demonstrate SOX4 is a mediator
to elevate LIN28B expression. LIN28B overexpression is associated with poor
prognosis in a cohort of AML patients. 
Summary and Conclusions: In conclusion, our investigation has identified a
critical regulatory PRL-3/SOX4/LIN28B/let-7 networks, which play an important
role in transformation of LSC and development of AML. Thus, we believe the
novel regulatory uncovered in our study may represent the “Achilles’ heel” of
LSC in AML and apprises the possibility of eliminating LSC in a molecular
subset of AML in which PRL-3/LIN28B appears pivotal for the transformation.
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RATIONAL TARGETING OF NOTCH SIGNALLING IN ACUTE MYELOID
LEUKAEMIA
P. Takam Kamga1,* G. Bassi1, A. Cassaro1, R. Stradoni1, M. Midolo1, M. Di Trapani1,
F. Canella1, R. Carusone1, A. Gatti1, O. Perbellini1, M. Gottardi2, M. Krampera1
1Medicine, University of Verona, Verona, 2Ematologia, Azienda Ospedaliera
ULSS 9, Trevise, Italy
Background: Growing evidences from both preclinical and clinical investiga-
tions reveal Notch signalling as critical for the development of many cancers,
and for their response to chemotherapy. Our lab has previously showed that
Notch inhibition was efficient to abrogate stromal-induced chemoresistance in
CLL and B-ALL. In contrast, the role of Notch in AML and its contribution to the
crosstalk between AML cells and bone marrow stroma remains controversial:
that makes unclear which could be the best therapeutic strategy (activation or
inhibition) to target Notch in AML. 
Aims: In this study, we sought to validate Notch signalling as potent successful
therapeutic target in AML. We tested different modulators for their ability to
influence Notch signalling at different levels, including the interaction ligand-
receptor, the transactivation of the receptors and the transcriptional activation
of the pathway. We then analysed the effects of Notch modulators, alone or in
synergy with chemotherapeutic agents, on AML cells in culture or co-culture
with bone marrow mesenchymal stromal cells (BM-MSCs).
haematologica | 2015; 100(s1) | 209
Vienna, Austria, June 11 – 14, 2015
Methods: AML blast cells were obtained from bone marrow samples (33) and
peripheral blood (22) of AML patients. BM-MSCs were expanded from bone
marrow of 20 healthy donors (BM-MSCs) and of 20 AML patients (BM-MSCs*).
In silico analysis, RT-qPCR, FACS analysis and western immunoblotting were
used to study the expression of Notch receptors and ligands, as well as Notch
activation status, in AML cells and BM-MSCs. AML cells were cultured or co-
cultured with BM-MSCs or BM-MSCs* at 10:1 (AML:BM-MSCs) ratio in pres-
ence or absence of Notch modulators including: recombinant human Jagged-
1 and Jagged-2; anti-Notch-1, -2, -3, -4, anti-Jagged-1, -2 and anti-DLL-3 block-
ing antibodies; gamma secretase inhibitor-IX, -XII (GSI-IX, GSI-XII) and Notch
transcription factor inhibitor (SAHM1). The chemotherapeutic agents used
were: cytarabine, etoposide and idarubicin. Cell viability was evaluated by
Annexin-V/Propidium Iodide (PI) and MTT assays; proliferation and cell cycle
were assessed through CFSE dilution and PI method, respectively.
Results: In vitro and in silico analysis showed that disregarding FAB classifi-
cation or molecular pattern, AML cells expressed Notch receptors and ligands.
Notably, 50% of AML samples showed basal Notch signalling activation as
demonstrated by the detection, at mRNA and protein level, of HES-1. The acti-
vation of Notch signalling using recombinant Jagged-1 or Jagged-2 did not
lead to any changes neither in AML cell survival nor in cell proliferation. On the
contrary, the pan blockade of Notch, at the membrane level by GSIs or by the
combination of Notch blocking antibodies, or, at the transcriptional level using
SAHM1, inhibited AML cell proliferation in culture. Notably, BM-MSCs* showed
higher level of Notch1 and Jagged1 as compared to BM-MSCs. Interestingly,
we observed that BM-MSCs*, but not BM-MSCs, stimulated AML proliferation
and the pan Notch inhibition was sufficient to revert this phenomenon. In addi-
tion BM-MSCs* were more efficient to rescue AML cells from apoptosis induced
by chemotherapeutic agents. Pan Notch signalling blockage by either GSI-XII
or combination of Notch receptor-blocking antibodies in presence of chemother-
apeutic agents, significant lowered the supportive role of BM-MSCs towards
AML blasts; conversely SAHM1 has a slight effect. The specific blockade of
Notch-1, -2, -3 or Jagged-1, -2 reduced partially the chemoresistance, while
blockade of Notch-4 or DLL-3 rescued totally the chemosensitivity of primary
AML cells in co-culture with BM-MSCs.
Summary and Conclusions: These results suggest that the inhibition of Notch
signalling may represent a potential therapeutic strategy to improve AML treat-
ment, overcoming bone marrow stromal-mediated anti-apoptotic and chemore-
sistance effects. Clinical application of GSIs is limited due their toxic and mul-
tiple off targets. In this study we showed that blocking antibodies were sufficient
to recapitulate GSIs effects, making them a useful and less harmful strategy to
target Notch signalling. 
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ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1
MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-
MUTATED AML CELLS
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Background: Acute myeloid leukemia (AML) is the most common acute
leukemia in adults and a molecularly heterogeneous disease. Standard
chemotherapy±hemopoietic-stem-cell transplantation can cure about 40-50%
of younger adults and 10-15% of elderly patients (>60 years old). Thus, it is
clearly needed to develop novel therapeutic approaches. At present, the only
highly effective molecular targeted therapy for AML is based on all-trans-retinoic
acid (ATRA) and/or arsenic trioxide (ATO) in acute promyelocytic leukemia
(APL) with promyelocytic leukemia (PML)-retinoic acid receptor a (RARa) gene
rearrangement. Nucleophosmin (NPM1) gene mutations represent the most
frequent genetic lesion in AML accounting for about 30% of adult AML. NPM1
is an ubiquitously expressed nucleolar phosphoprotein with nuclear-cytoplas-
mic shuttling activity, involved in multiple cellular functions and essential for
life. NPM1 mutations in AML are heterozygous and lead to NPM1 wild-type
haploinsufficiency and cytoplasmic accumulation of the leukemic NPM1 mutant
protein. Because NPM1 mutations are common, stable and represent a founder
genetic lesion in AML, they are an appealing therapeutic target. However,
whether and how the NPM1 mutant oncoprotein is druggable remain to be
established.
Aims: Here we explored whether NPM1 mutant protein levels could be affected
by treatment with drugs such all-trans-retinoic acid (ATRA) or arsenic trioxide
(ATO) which have been shown to target specific oncoproteins (i.e. PML-RAR-
alpha, Bcr-Abl) and display some anti-leukemic activity in vitro and in patients
in AML cells carrying NPM1 gene mutations.
Methods: For these purposes, we treated in vitro either AML cell lines
(OCI/AML3 and IMS-M2, carrying NPM1 gene mutation A, and OCI/AML2 and
U937, with wild-type NPM1) or primary AML cells from patients (25 NPM1-
mutated and 19 NPM1-wild type AML) with ATRA, ATO or combination of either
drug and analyzed their effects on cell growth and apoptosis and on levels of
NPM1 either mutant or wild-type protein. To explore the underlying mecha-
nisms, we used pretreatment with the proteasome inhibitor MG132, to analyze
the role of the proteasome machinery in protein degradation, and with N-Acetyl-
L-Cysteine (NAC), to analyze the role of reactive oxygen species (ROS) which
are known to be elicited by treatment with ATO.
Results: We found that whilst ATRA exerts a more general anti-leukemic effect
in non-APL AML cells including NPM1-mutated AML, ATO displays a peculiar
anti-leukemic activity in NPM1-mutated as compared to NPM1-wild type AML,
and that this activity can be potentiated by ATRA. Interestingly, we found basally
a partially altered PML nuclear bodies (NBs) organization in NPM1-mutated
AML, which can be restored by treatment with ATO. Strikingly, ATO, as well
ATRA, induced proteasome-dependent NPM1 mutant oncoprotein degradation
in either cell lines or primary AML patients cells, relocalized NPM1 wild type
protein in the nucleus with rearrangements of nucleoli, and increased daunoru-
bicin-sensitivity. All these events resulted to be dependent on ROS, being pre-
vented by pretreatment with the ROS-scavenger NAC. Collectively, these find-
ings are reminiscent of the ATRA/ATO-induced PML/RARα degradation in APL.
Summary and Conclusions: Altogether, our data show that NPM1 mutant is
targeted by ATO and, at least in some cases, also by ATRA and, although prob-
ably not the only mechanism, its downregulation might contribute to the pro-
apoptotic and/or anti-proliferative effects of these drugs in NPM1-mutated AML.
This suggests that ATO and ATRA are potential drugs for a molecular target-
ed-based therapy in NPM1-mutated AML leading to NPM1 mutant oncoprotein
degradation. These findings provide experimental evidences for further explor-
ing ATO/ATRA in preclinical NPM1-mutated AML in vivo models and a rationale
for exploiting these compounds in chemotherapic regimens in clinics.
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RUNX1 AND RUNX3 IN LEUKEMOGENESIS
D. Chin1,* C. Wang2, J.Y. Chooi1, B. Cirovic1, V. Tergaonkar2, I. Tanuichi3,
M. Osato1,4,5,6
1Cancer Science Institute of Singapore, National University of Singapore, 2Insti-
tute of Molecular and Cell Biology, Agency for Science, Technology and
Research, Singapore, Singapore, 3RIKEN Research Center for Allergy and
Immunology, Yokohama, 4International Research Center for Medical Sciences,
Kumamoto University, Kumamoto, Japan, 5Department of Paediatrics, National
University of Singapore, 6Institute of Bioengineering and Nanotechnology, Sin-
gapore, Singapore
Background: Chromosomal translocations associated with RUNX family tran-
scription factors, such as t(8;21) and inv(16), are frequently observed in human
acute myeloid leukemia (AML). These chromosomal abnormalities produce
fusion proteins which suppress function and/or expression of both RUNX1 and
RUNX3. We previously reported that Runx1fl/fl;Runx3fl/fl;Mx1-Cre+ [double
knockout (DKO)] mice exhibited two paradoxical lethal phenotypes: bone mar-
row failure and myeloproliferative disorder. These contradictory manifestations
were shown to be caused by defect in DNA repair pathway. Accumulation of
non-repaired DNA damage leads to massive cell death, while occasional acqui-
sition of oncogenic mutations result in leukemia development.
Aims: In this study, we aim to identify cooperative genetic hits which cooperate
with Runx1 and Runx3 deficiency in leukemogenesis.
Methods: To identify such cooperative genetic alterations, retroviral insertional
mutagenesis (RIM) was performed on Runx1;Runx3 DKO mice. DKO and their
control mice were injected with Moloney murine leukemic virus (MoMuLV) and
monitored for disease presentation. Bone marrow transplantation and colony
forming assay were conducted to validate the cooperativity. To correlate findings
in mice to human AML, publicly available gene expression datasets were also
analyzed. 
Results: Runx1;Runx3 DKO mice showed shorter disease latency in RIM as
compared to the control mice. Although MoMuLV inoculation commonly induce
T cell leukemia/lymphoma, majority of the Runx1;Runx3 DKO mice developed
biphenotypic leukemia with myeloid features. Retrovirus integrations into inte-
grin α9 (Itga9) locus, which resulted in Itga9 overexpression, were exclusively
found in Runx1;Runx3 DKO mice. We confirmed that overexpression of Itga9
in Runx1;Runx3 DKO cells increased the incidence of leukemia. In human
AML, high expression of ITGA9 was found in AML cells with t(8;21) and inv(16)
and associated with a poor prognosis.
Summary and Conclusions: We identified Itga9 as a cooperative hit with
Runx1 and Runx3 deficiencies in leukemogenesis. This synergism was con-
firmed in human RUNX-related leukemias. Better understanding of the coop-
erating mechanism between abnormalities in ITGA9 and RUNX transcription
factors will give further directions in developing therapies for human leukemias.
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EUROPEAN NETWORK NGS-PTL PRELIMINARY DATA: WHOLE EXOME
SEQUENCING IDENTIFIES MUTATIONS OF ALDH2, RETSAT, HSPG2,
CHPF, AND OTHER METABOLIC GENES AS A NOVEL FUNCTIONAL CAT-
EGORY IN ACUTE MYELOID LEUKEMIA
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Background: Next Generation Sequencing studies identified 9 functional cat-
egories of mutations in acute myeloid leukemia (AML), with >99% of cases
having at least one of those mutations (Ley et al. NEJM 2013). However, mul-
tiple genetic hits participate to AML pathogenesis, and metabolic dysregulations,
as the one induced by IDH1/2 mutations, play oncogenic functions (Ward et al.
Cancer Cell 2010).
Aims: To define novel functional categories of AML mutations affecting rele-
vant and druggable biological processes, with focus on genetic determinants
of metabolic plasticity.
Methods: Out of 455 whole exome sequencing (WES) cases from onco-
hematological patients collected in the NGS-PTL project, we analyzed 37
AML cases, belonging to our cohort of 239 FLT3-WT samples (886 AML total).
We performed 100 bp paired-end WES (HiSeq2000, Illumina) and mapped
the sequenced reads with Burrows-Wheeler Aligner. Variants where called
with MuTect or GATK for single nucleotide variant (SNV) and indels detection,
respectively (>90% confidence). Gene expression profiling (GEP) was per-
formed using HTA2.0 microarray (Affymetrix) on 56 bone marrow samples,
including AML (≥80% blasts) and healthy controls. 
Results: We detected an average of 26 somatic variants per patient (range
7-65) by WES. Gene ontology annotation identified 8 novel relevant func-
tional categories of mutated genes: transcription, translation and post-trans-
lational modifications, protein degradation, cytoskeleton, cell cycle, DNA
damage, cell survival and metabolism. Since metabolic pathways are prom-
ising targets for tailored therapies (e.g. IDH1/2 and glutaminase inhibitors),
we focused our analysis on them. We identified 82 variants (74 SNVs, 2
frameshift and 4 nonframeshift deletions, 2 stopgains) targeting 70 genes
involved in metabolism, with 78% of patients carrying at least one mutation
in a metabolic gene and 35 variants rated as damaging by CONDEL algo-
rithm. Among mutations in metabolic genes, the most represented pathways
were amino acids, lipids, CoA and nucleotides metabolism, transport and
bioenergetics pathways. Notably, IMPDH2, a mediator of MYC-induced pro-
liferation involved in nucleotide interconversion, was mutated and overex-
pressed in our AML cohort (p=0.01), suggesting a potential oncogenic func-
tion. Moreover, ALDH2, a regulator of hematopoietic stem cell functions
which is involved in multiple metabolic pathways and associates with meta-
bolic remodeling, was mutated and 2-fold downregulated in AML blasts. Sev-
en genes were mutated in 5-8% of samples: RETSAT, HSPG2, CHPF,
ABCA2, ND1, APOBR, NAAA. RETSAT, HSPG2 and CHPF mutations were
predicted as “drivers” by DOTS-Finder tool. Bioenergetic pathways were
affected by mutations in glycolysis and gluconeogenesis (GPI, ITPA), oxida-
tive phosphorylation (ND1, ND4, ND5, CYTB), pentose phosphate pathway
(H6PD, PGLS).
Patients carrying mutations in the bioenergetic pathway showed a strong
trend towards reduced overall survival, which did not associate with unfa-
vorable molecular mutations.
Summary and Conclusions: Metabolism is the most represented class of
mutated genes (8.6% of variants) in our FLT3-WT AML cohort after signaling,
leading us to propose a novel functional category. Our data suggest that, along
with mutations in established oncogenes and tumor suppressors involved in
metabolic control (KRAS, TP53, MYC pathway), a number of genetic determi-
nants participate to leukemia metabolic plasticity and oncogenic mutations of
metabolic enzymes may drive leukemogenesis, impact on patients’ survival
and become novel targets for personalized therapies.
Acknowledgements: ELN, AIL, AIRC, progetto Regione-Università 2010-12
(L. Bolondi), FP7 NGS-PTL project.
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THE PAN-CLASS I PI3 KINASE INHIBITOR, NVP-BKM120, DEMON-
STRATES ANTI-LEUKEMIC ACTIVITY IN ACUTE MYELOID LEUKEMIA
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Background: Aberrant activation of PI3K/Akt/mTOR pathway is a common
feature of acute myeloid leukemia (AML) patients contributing to chemoresis-
tance, disease progression and unfavourable outcome. Therefore, inhibition of
this pathway may represents a potential therapeutic approach in AML. NVP-
BKM120 (BKM120) is a pan-class I PI3K inhibitor which exerts anti-proliferative
and cytotoxic effects on several solid tumors and hematological malignancies
by inhibiting PI3K/Akt/mTOR activity.
Aims: To evaluate the pre-clinical activity of BKM120 on AML cell lines and pri-
mary samples.
Methods: BKM120 (Novartis) was tested on AML cell lines (U937, NB-4, HL-
60/Mx2, OCI-AML2, HL-60, OCI-AML3, THP-1, MOLM-13 and KG-1) and on
15 primary AML samples. Given the role of PI3K/Akt/mTOR in cell metabolism,
BKM120 was then combined with dichloroacetate (DCA), a glycolitic modulator,
on selected AML samples. Cell cycle and apoptosis were analyzed by Acri-
dine-Orange and AnnexinV (AnnV)/PI staining, respectively. Signaling modu-
lations and metabolic changes were evaluated by western blot and by the XF24
Flux analyzer, respectively. In vivo experiments were performed on non-obese
diabetic severe combined immunodeﬁcient interleukin-2 receptor g-null mice.
Results: Basal expression and phosphorylation levels of PI3K/Akt/mTOR path-
way components were initially assessed on AML cell lines and primary samples.
Despite some heterogeneity, all cell lines shared the constitutive activation of
PI3K/Akt/mTOR axis. Moreover, 7 of the 9 primary samples tested showed a
higher phospho/total Akt ratio than normal mononuclear cells (MNCs) and dis-
played p-mTOR (S2448 and S2481) and p-4EBP1 (T37/46) overexpression,
suggesting the aberrant activation of PI3K/Akt/mTOR pathway. BKM120 expo-
sure resulted in a dose-dependent dephosphorylation of Akt (S473) and
Gsk3α/β (S21/9) in all cell lines tested and affected, at higher doses, mTOR
activity inducing the dephosphorylation of mTOR (S2448 and S2481), p70S6K
(S371) and 4EBP1 (T37/46). Blockade of PI3K/Akt/mTOR signaling inhibited
cell growth (IC50s: 0.7-1.2μM) and induced a significant (p<0.005) dose- and
time-dependent apoptosis in all cell lines. Cytotoxicity was preceded by a tem-
porary G2/M block that was rapidly followed by induction of apoptosis, as
demonstrated by the increase of the subG0/G1 peak at 72h. Efficacy of BKM120
was then confirmed on primary samples: at 144h, AnnV+ cells increased from
19.5±9.6% (vehicle) to 48.0±23.6% (p<0.001) at 5μM. Dephosphorylation of
Akt (S473), achieved in 3/3 primary samples, supported the target inhibition.
Conversely, BKM120 failed to show considerable cytotoxicity on normal and
PHA-activated MNCs (8.0% and 4.4% apoptosis net increase at 5µM, respec-
tively). Metabolic perturbations induced by BKM120 were then assessed on
AML cells demonstrating a dose-dependent reduction of basal and maximal
respiration as well as ATP production in both cell lines and primary samples.
Furthermore, BKM120 strongly synergized (CI<0.6) with DCA to trigger apop-
tosis at lower doses on AML cell lines and primary samples. Finally, in vivo
administration of BKM120 in a xenotransplant mouse model of AML markedly
inhibited leukemia progression and induced a significant (p<0.001) improve-
ment of overall survival.
Summary and Conclusions: Our data demonstrated that BKM120, as single
agent or in combination with other drugs (i.e. glycolytic modulators), has a sig-
nificant anti-leukemic activity towards AML cell lines and primary samples, thus
supporting its clinical evaluation as a therapeutic agent for AML patients.
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ACUTE MYELOID LEUKEMIA DERIVED MACROPHAGE MIGRATION
INHIBITORY FACTOR DRIVES INTERLEUKIN-8 PRO-SURVIVAL SIGNALS
IN THE TUMOR MICROENVIRONMENT
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Background: Despite recent significant advances in the understanding of the
biology of acute myeloid leukemia (AML) the clinical outcomes for the majority
of AML patients, particularly the elderly, remain poor. There is increasing evi-
dence that the AML microenvironment plays an important role in AML survival
and proliferation. The bone marrow microenvironment is composed of multiple
cell types that via direct cell-to-cell interactions and soluble factors promote
the survival of leukemic cells and affect their response to therapy. In vitro, pri-
mary AML blasts rapidly undergo spontaneous apoptosis, however we and oth-
ers have shown that the same primary AML cells survive when cultured on
bone marrow derived mesenchymal stem cells (BM-MSC). Furthermore dis-
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ruption of the interaction between AML cells and BM-MSC increases AML cell
sensitivity to chemotherapy. These observations indicate that the pro-survival
apoptotic defect in AML is not cell autonomous but highly dependent on extrin-
sic signals derived from the microenvironment.
Aims: Our aim is therefore to investigate the bidirectional interaction of AML
cells and BM-MSC.
Methods: Primary AML blasts and primary AML BM-MSC were obtained from
patient’s bone marrow. Primary AML blasts 1x106 were co-cultured on confluent
primary BM-MSC. Conditioned medium was then collected from these cultures
and analyzed using Proteome Profiler Human XL Cytokine Array and target
specific ELISAs. Real-time PCR was also used to verify the array data.
Results: Using the XL Cytokine array we found that IL-8 and MIF increased
significantly in the media from AML/BM-MSC co-cultures compared to media
from either AML or BM-MSC alone. The observed changes in IL-8 and MIF
were confirmed by ELISA assays. RT-PCR was used to measure MIF and IL-
8 gene expression from RNA extracted from AML or BM-MSC cultured alone
or in combination. Results indicate that MIF is upregulated in AML in response
to BM-MSC co-culture and IL-8 was upregulated in BM-MSC in response to
co-culture with AML. Next we used recombinant MIF and IL-8 as well as
inhibitors of MIF (ISO-1) and IL-8R (SB225002) to define their specific role in
BM-MSC/AML co-cultures. Recombinant human MIF increases IL-8 mRNA
and protein expression in BM-MSC but not in AML. Moreover, the MIF inhibitor,
ISO-1, inhibits AML induced IL-8 expression and secretion by BM-MSC. Finally,
we report that IL-8 protects primary AML from spontaneous apoptosis in vitro
which is reversed by the IL-8R inhibitor, SB225002.
Summary and Conclusions: BM-MSC respond to signals from AML cells
which results in changes in the expression of pro-survival cytokines. Hence,
BM-MSC and AML cells act together in the formation of the pro-tumoral
microenvironment. MIF/IL-8 regulated BM-MSC/AML crosstalk may represent
a novel target for future AML therapies.
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APY IN ACUTE MYELOID LEUKEMIA (AML) BY TARGETING DNA REPAIR
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Background: Targeting nuclear exporter receptors such as Exportin 1
(XPO1) is a novel approach to restore tumor suppressor function in AML.
Selinexor, a selective inhibitor of XPO1, is currently being tested in a Phase
1 clinical trial in AML. Preliminary data indicate that selinexor is well tolerated,
safe and active in AML patients. However, considering the molecular com-
plexity of AML, it is unlikely that this disease can be cured with monotherapy
and therefore we asked whether adding already established effective drugs
such as Topo IIα inhibitors to selinexor will enhance or improve its anti-
leukemic effects in AML.
Aims: To investigate the anti-leukemic activity and mechanisms of selinexor in
combination with Topo IIα inhibitors in AML cell lines and patients blasts.
Methods: IC50 values for selinexor and Topo IIα inhibitors were determined
using MTS assays in AML cells lines and patients. Synergy was calculated
using the Chou-Talalay method.
Results: To evaluate whether the combination of selinexor and Topo IIα
inhibitors (idarubicin, etoposide and mitoxantrone) induce synergy, we treated
the AML cell lines MOLM-13 and MV4-11 with selinexor and each of the Topo
IIα inhibitors separately at two-fold dilutions of their individual IC50 values,
and measured cell proliferation at 48 hours. Concomitant treatment of selinex-
or with Topo IIα inhibitors resulted in synergy (combination index (CI) values
<1) in all cell lines. Treatment of AML patients blasts (n=3) with selinexor and
idarubicin at 4-fold dilutions of their individual IC50 values showed synergy
as well. High-throughput studies on protein expression in tumor cells after
selinexor treatment indicate that several DNA damage repair proteins are
down-regulated. Based on these data, we reasoned that the synergistic
effects of selinexor with Topo IIα inhibitors could be explained in part by
selinexor induced down-regulation of DNA repair proteins thus preventing
leukemia cells from repairing chemotherapy-induced DNA damage. A dose
dependent reduction in mRNA (RT-PCR) and protein levels (WB) of the DNA
damage repair genes Chk1, Rad51, MSH2 and MSH6 were observed as
early as 6 hours after selinexor treatment and before apoptosis was observed
(50 to 200 nM). Chk1 and Rad5 mRNA and protein levels decreased the
most (2 and >10 fold decrease respectively) and was caused by decrease
MYC binding to these genes promoters which resulted in reduced transcrip-
tional activation. Similar depletion of these DNA repair proteins was also
observed in 4 AML patient samples incubated with selinexor at IC50 concen-
trations. Topo IIα inhibitors cause double stranded DNA breaks which can be
repaired by the homologous repair (HR) pathway. HR is governed by multiple
proteins that include Rad51. To measure the ability of cells to carry out HR
in the presence of selinexor, we used the HeLa DR cells with an HR integrated
plasmid. These cells carry two copies of inactive Green Fluorescent Protein
(GFP) genes integrated into the genome. The cells are treated with an
enzyme ICSE1 that cuts at 1 site within the GFP. If HR occurs then there is
repair of the double strand break and GFP events are observed. Using this
assay, when Hela DR cells are treated with selinexor, we observed a 7 fold
decrease in the number of GFP expression compared to control cells
(P<0.05). Animal studies are currently undergoing.
Summary and Conclusions: Our data showed that selinexor synergizes with
anthracyclines to kill AML blasts by targeting DNA repair. Therefore, we propose
to combine selinexor with Topo IIα inhibitors in a Phase 1 clinical trial. 
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MAPPING WHOLE-EXOME SEQUENCING DATA OF ACUTE MYELOID
LEUKEMIA PATIENTS INTO KEGG PATHWAYS
A. Padella1,* G. Simonetti1, I. Iacobucci1, I. DoValle2, E. Zago3, F. Griggio3,4,
M. Garonzi4, M. Manfrini1, V. Guadagnuolo1, S. Bernardi5, C. Papayannidis1,
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Background: Acute Myeloid Leukemia (AML) is a highly heterogeneous dis-
ease and a complex network of events contribute to the pathogenesis. Recently,
functional categorization of mutated genes in AML identified 9 classes of affect-
ed genes. However, how genomic alterations cooperate to induce AML, the
pathways affected by the mutated genes and their prognostic value are still
unknown.
Aims: To better stratify AML patients and identify novel molecular biomarkers
based on the mapping of genomic alterations in biological pathways and cor-
relation with clinical outcome.
Methods: We sequenced the exome of 33 cases of AML at diagnosis using
the Illumina Hiseq2000 platform. We usedthe GATK and MuTect tools to call
mutations and we selected variants with a minor allele frequency (MAF) lower
than 0.05. We mapped variants in biological pathways using KEGG database
and we identified putative driver genes with DOTS-finder and MutSig.
Results: A validation rate equal to 89% (26 validated variants out of 29) was
obtained by Sanger sequencing analysis of variants. Our cohort included 16
patients belonging to the intermediate risk cytogenetic prognostic group and
17 patients belonging to the high-risk one (p=0.002). For each patient, we
mapped the mutated genes into KEGG pathways and we performed unsu-
pervised clustering analysis based on the represented KEGG pathways. We
identified 4 groups of patients characterized by significant differences in the
number of mutated pathways (p=0.032), with an average of 74 (group 1), 58
(group 2), 28 (group 3) and 9 (group 4) mutated pathways per patient. We
identified the PI3K-Akt signalling as the top mutated pathway (23 out of 33
patients). Notably, the frequency of patients with mutations in that pathway
differed among groups: 100% of patients in group 1 and 2, versus 62% and
20% of patients in group 3 and 4, respectively. Moreover, we were able to
identify a common mutated gene in group 1, KRAS, which was defined a
putative driver gene by both DOTS-finder and MutSig tools. On the other
hand, 6 out of 8 patients of group 2 had TP53 mutations . Group 3 and 4
showed a heterogeneous distribution of mutated pathways: the top mutated
pathways in group 3 were the PI3K-Akt signalling and the Metabolic path-
ways, with 6 patients with mutations out of 8; whereas the top mutated path-
way in group 4 counted 5 out of 10 patients with mutations in the Metabolic
pathway. Klapan-Meier survival curves showed a significant correlation of
the 4 groups with clinical outcome (p=0.047), with group 2 having an extreme-
ly unfavourable prognosis, as expected from TP53 mutated patients. Sub-
classification of group 3 and 4 patients according to molecular characteriza-
tion and correlation with clinical outcome are ongoing.
Summary and Conclusions: In summary, by mapping WES data into KEGG
pathways, we were able to distinguish 4 groups of patients. Two of them were
characterized by distinct molecular biomarkers able to stratify patients with dif-
ferent prognosis. KRAS was identified as putative driver gene in AML by two
different tools, underling its importance in the disease pathogenesis. Interest-
ingly, our analysis defined a potential association between two patients lacking
TP53 mutations and TP53-mutated cases (in group 2), in terms of KEGG path-
way clusterization, which could be defined only by omics analysis. Our results
confirm the different prognostic risks of AML patients with KRAS or TP53 muta-
tions and highlight the relevance of WES data interpretation according to mutat-
ed pathways for patient stratification at diagnosis.
Acknowledgements: ELN, AIL, AIRC, progetto Regione-Università 2010-12
(L. Bolondi), FP7 NGS-PTL project.
AP and GS: equal contribution.
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PBX3 AND MEIS1 COOPERATE THROUGH MULTIPLE MECHANISMS TO
SUPPORT HOX-INDUCED MURINE LEUKEMIA
M.-P. Garcia-Cuellar1, J. Steger1, E. Füller1, K. Hetzner1, R. Slany1,*
1Genetics, University Erlangen, Erlangen, Germany
Background: Hox homeobox transcription factors drive leukemogenesis effi-
ciently only in the presence of Meis or Pbx proteins.
Aims: In this study we investigated the importance of a cooperation of Meis1
and Pbx3 for Hoxa9 mediated transformation.
Methods: Protein-protein interactions, protein-stability and half-life as well
as DNA binding capability and transformation efficiency were tested in vitro
and in vivo.
Results: A biochemical analysis of the Meis1-Pbx3 cooperation revealed that
in the absence of Pbx3, Meis1 stability was greatly reduced. As shown by a
deletion analysis Meis1 degradation was contingent on a motif coinciding with
the Pbx-binding domain. Either deletion of this sequence or binding to Pbx3
prolonged Meis1 survival by preventing poly-ubiquitination and proteasome
mediated decay. Meis1 break-down could be also blocked directly by inhibition
of the ubiquitin proteasome system indicating a tight posttranscriptional control.
In addition, Meis1 and Pbx3 cooperated genetically as overexpression of Pbx3
induced endogenous Meis1 transcription. These functional interactions trans-
lated to in vivo activity. Blocking Meis1/Pbx3 dimerization abrogated the ability
to enhance proliferation and colony forming cell numbers in primary cells trans-
formed by Hoxa9. Furthermore, expression of Meis1 target genes Flt3 and
Trib2 was also dependent on Pbx3/Meis1 dimerization. This correlated with the
requirement of Meis1 to bind Pbx3 in order to form high affinity
DNA/Hoxa9/Meis1/Pbx3 complexes in vitro. Finally, kinetics and severity of dis-
ease in transplantation assays indicated Pbx3/Meis1 dimers as rate-limiting
factors for Hoxa9 induced leukemia.
Summary and Conclusions: Here we show that Pbx3 and Meis1 form stable
dimers and we present evidence that this dimers are the actual functional units
whose formation is rate limiting for efficient leukemia induction by Hoxa9.
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THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LAND-
SCAPE OF ACUTE MYELOID LEUKEMIA
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Background: The development of acute myeloid leukemia (AML) is associated
with accumulation of acquired genetic alterations in hematopoietic progenitor
cells. The study performed by the TCGA consortium has enabled for the dis-
covery of recurrent mutations in 23 genes in AML. However, many patients
with normal karyotype carry no mutations in any of the currently recognized
driver genes associated with leukemogenesis, suggesting that AML has relevant
changes not yet defined. 
Aims: We performed whole-exome sequencing (WES) of tumor-normal
matched samples to identify new driver mutations in AML patients with normal
karyotype lacking NPM1, CEBPA and FLT3-ITD mutations. Novel candidate
genes, together with other previously described,1 were resequenced in an inde-
pendent cohort of intermediate-risk AML patients. . The obtained results were
further in silico analysed. 
Methods: WES was performed on matched samples from 7 de novo AML
patients, lacking cytogenetic alterations, NPM1, CEBPA and FLT3-ITD muta-
tions (discovery cohort). Library preparation and exome capture were performed
according to the manufacturer protocol for sequencing with an Illumina platform.
WES data were analyzed using and in-house bioinformatic pipeline. Candidate
variants were validated using an Ion AmpliSeq™ Custom Panel in an Ion Torrent
platform (Life-Technologies). Furthermore, a custom panel of 87 genes (55
genes from in-house results and 32 genes reported to be mutated in ≥2% of
patients in the TCGA study1) was analysed in an independent validation cohort
of 100 patients with intermediate-risk AML using SureDesign Tool (Agilent). To
prioritize the best candidate genes we studied the significance of the network
in which they participate. Samples were provided by the Hospital La Fe Biobank.
Results: In the discovery cohort, we identified 94 SNVs non-synonymous coding
mutations and 8 small indels, with an average of 30 mutations per sample (range
22-37). We confirmed 60% of the candidate variants affecting 56 genes. Among
them, 15 genes had been shown previously to be recurrent. Over the validation
cohort we detected a mean of 6.81 mutations per sample (range 1-17). We iden-
tified a total of 193 variants affecting 65 different genes, been 41 mutated in more
than one patient. After prioritization we found 9 individual genes with a a higher
frequency in our cohort than expected in the 1000g database and with a strong
potential of being involved in AML pathogenesis (P≤0.01). To improve our knowl-
edge of the interactome of AML, these genes were also analyzed for functional
enrichment of gene ontology terms and grouped according to their biological
function. As a result, we defined a network in which 27 out of the 41 genes select-
ed by harboring recurrent deleterious mutations were significantly more connected
that the random expectation (P <0.05). 
Summary and Conclusions: This study shows a comprehensive analysis of
AML combining WES with a custom panel of targeted genes by NGS. We iden-
tified recurrent deleterious mutations in 9 genes with a strong potential to be
involved in AML pathogenesis and have defined a functional module in the
interactome of intermediate-risk AML patients. 
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Background: Most patients diagnosed with acute myeloid leukemia (AML) die
of the disease despite currently available chemotherapy. The bone marrow
(BM) microenvironment is a key player supporting AML blast survival. The BM
microenvironment consists of many cell types not directly of the hematopoietic
lineage, including bone marrow adipose tissue (MAT). MAT accounts for approx-
imately 50% of BM volume in the axial skeleton of adult humans. Adipocytes
store energy primarily as triglyceride which can be released following lipolysis
as free fatty acid (FFA) and are taken up by cells for conversion into energy.
How this energy source is utilised locally in the bone marrow by AML has not
been well characterised to date.
Aims: The aim of this study is to determine the role of human bone marrow
adipocytes in the support of AML blast survival in vitro and their protection
against chemotherapy-induced apoptosis.
Methods: Primary AML blasts and primary AML BM mesenchymal stem cells
(MSC) were obtained from patients’ bone marrow. BM derived MSC were dif-
ferentiated in vitro into adipocytes (MSC-Ad) and co-cultured with primary AML
blasts. BrdU incorporation, annexin V and PI staining were used to determine
proliferation and apoptosis of AML blasts. Lipolysis was measured by deter-
mining free fatty acid and glycerol release. Dodeconic acid fluorescent fatty
acid analog (DFFAA) was used to measure uptake of FFA by AML blasts. West-
ern blot analysis was used to determine the level of proteins associated with
triglyceride breakdown; hormone sensitive lipase (HSL), phosphorylated HSL
and fatty acid binding protein 4 (FABP4). Cytarabine and daunorubicin were
used to determine the chemotherapy-induced apoptosis.
Results: Our results show AML blasts co-cultured with MSC-Ad have increased
proliferation and reduced apoptosis by day 6 compared to AML blasts in mono-
culture. Cell cycle analysis shows a higher percentage of AML blasts from MSC-
Ad co-culture in the M and G2 phase compared with monoculture. Furthermore
we found that MSC-Ad had enhanced lipolysis in response to AML co-culture.
We observed increase in free fatty acid and glycerol release in AML/MSC-Ad
co-culture media compared to media from MSC-Ad alone. The uptake of FFA
was then examined in AML blast co-culture with MSC-Ad. Flow cytometry analy-
sis shows an increase in fluorescence (DFFAA) within AML blasts when co-
cultured with MSC-Ad loaded with DFFAA. In addition, Western blot analysis
of HSL, an enzyme that hydrolyzes triglycerides of the lipids, shows an increase
in phosphorylation. FABP4 which is a lipid transport protein is also increased
in MSC-Ad when cultured with AML blasts. Finally, chemotherapy induced apop-
tosis was significantly reduced in AML/MSC-Ad co-culture compared to AML
blasts on their own. 
Summary and Conclusions: Here we report that MSC-Ad upregulate lipolysis
in response to co-culture with AML blasts. Furthermore MSC-Ad support the
survival and proliferation of AML blasts and provide a protective microenviron-
ment against standard cytotoxic chemotherapy. We hypothesize that pro-sur-
vival metabolic activity in AML blasts is supported by AML directed transfer of
free fatty acid from adipocytes in the bone marrow microenvironment and that
targeting this interaction may provide the foundation of novel micro-environment
directed treatment strategies for AML in the future.
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COMPARATIVE FUNCTIONAL ANALYSIS OF THE MOLECULAR NET-
WORK OF 7 SELECTED MLL FUSION PROTEINS
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Background: The Mixed Lineage Leukemia gene (MLL) is a frequent target of
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chromosomal rearrangements in human malignancies. Many MLL-rearrange-
ments are associated with pediatric leukemias with poor clinical outcomes.
Balanced translocations result in the fusion of the MLL gene to over 65 different
fusion partner genes, leading to the production of novel chimeric proteins. Crit-
ical effectors of distinct MLL fusion proteins have previously been identified,
and some of them were shown to hold great potential for targeted therapies.
However, it is not clear if these effectors are conserved among all MLL fusion
proteins or if different molecular mechanisms of transformation exist for distinct
MLL fusion proteins. 
Aims: We aim to delineate common critical effectors of 7 selected MLL fusion
proteins that are presumed to differ in their oncogenic mechanisms (MLL-AF1p,
MLL-AF4, MLL-AF9, MLL-CBP, MLL-EEN, MLL-ENL, MLL-GAS7). 
Methods: Stable cell lines allowing for inducible expression of 7 selected, affin-
ity-tagged MLL fusion proteins were prepared and expression of transgenes
was verified by qRT-PCR and Western Blotting. Affinity purification coupled to
mass spectrometry (AP-MS) identified novel interactors of 7 MLL fusions protein
complexes. To assign functional information to the candidate genes we
employed a pooled RNAi screening approach. The MLL-AF9-positive MOLM-
13 cell line was transduced with pools of viral vectors allowing for the expres-
sion of 6 shRNA targeting the same candidate gene. Using this setup we have
established a screening methodology that is suitable for positive and negative
selection readouts. This dual read-out highly increases the significance of true
hits and strongly decreases the false positive rate.
Results: Advanced statistical filtering using a novel, improved algorithm devel-
oped by us yielded a densely connected protein-protein interaction network of
>950 proteins around 7 MLL fusions, including many known MLL-interactors.
128 proteins were found to interact with ≥5 of the 7 MLL-fusions. This list of
conserved MLL-interactors is highly enriched for proteins with a function in
chromatin metabolism and transcriptional control. RNAi screening performed
in a ‘mini-pool’ format was used to functionally dissect the conserved MLL-
fusion interactome. As a result, 35 novel interactors of MLL fusion proteins
were selected for further validation experiments.
Summary and Conclusions: In conclusion, we developed a robust experi-
mental pipeline allowing for the functional characterization of cellular effects of
MLL fusion proteins in a comprehensive and comparative manner, which will
contribute to further insight into the molecular mechanisms of MLL-fusion
dependent leukemogenesis.
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RETINOIC ACID AND ARSENIC TRIOXIDE TRIGGER DEGRADATION OF
MUTATED NPM-1 RESULTING IN APOPTOSIS OF AML CELLS
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R. Hleihel1, U. Sahin2, N. Tawil1, A. Salameh1, K. Zibara4, N. Darwishe1,
M. Mohty3, H. Dombret2, P. Fenaux5, H. De The6, A. Bazarbachi1,*
1American University of beirut, Beirut, Lebanon, 2Saint Louis, 3Hopital Saint
Antoine, Paris, France, 4Lebanese University, Beirut, 5Saint Louis, Paris, 6Saint
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Background: Nucleophosmin-1 (NPM-1) is the most frequently mutated gene
in acute myeloid leukemia (AML). Addition of retinoic acid (RA) to chemotherapy
was proposed to improve survival of some of these patients. 
Aims: Investigate the efficacy and molecular mechanism of action on arsenic
and retinoic acid (RA) combination on NPM-1 mutated AML
Methods: AML derived cell lines and freshly isolated blasts from AML patients
were treated in vitro with Retinoic acid, arsenic trioxide and their combination.
Five elderly AML patients with normal karyotype, NPM-1 mutation, without FLT-
3 ITD, who were judged unfit to chemotherapy, received RA/arsenic on a com-
passionate basis. 
Results: We found that in AML cell lines or primary samples, RA or arsenic tri-
oxide synergistically induce proteasomal degradation of mutant NPM-1, leading
to differentiation and apoptosis. NPM-1 mutation not only delocalizes NPM-1
from the nucleolus, but also disorganizes promyelocytic leukemia (PML)
nuclear bodies. Combined RA/arsenic treatment significantly reduced bone
marrow blasts in three patients and restored the sub-nuclear localization of
both NPM-1 and PML. 
Summary and Conclusions: These findings could explain the proposed ben-
efit of adding RA to chemotherapy in NPM-1 mutant AMLs, and warrant a
broader clinical evaluation of regimen comprising a RA/arsenic combination. 
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CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS,
POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1
STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC
MALIGNANCIES
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Background: Somatic mutations in the metabolic enzymes isocitrate dehy-
drogenase (IDH) 1 and 2 occur in a spectrum of solid and hematologic malig-
nancies. Mutant IDH1/2 in cancer cells results in the neomorphic production of
the oncometabolite, D-2-hydroxyglutarate (2-HG), which impairs cellular dif-
ferentiation via an epigenetic mechanism. AG-120 is a first-in-class, oral, potent,
reversible and selective inhibitor of mutated IDH1 protein. In IDH1-mutant pri-
mary human blast cells cultured ex vivo, AG-120 lowered 2-HG and restored
cellular differentiation. We report preliminary results from the ongoing, first-in-
human, phase 1, open-label, single-arm study of AG-120 (NCT02074839).
Aims: Primary objectives are to evaluate the safety, tolerability, and maximum
tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and
clinical activity.
Methods: Patients with advanced, IDH1-mutant, hematological malignancies
including relapsed or refractory (RR) acute myeloid leukemia (AML), elderly
untreated AML who are not candidates for standard therapy, and recurrent or
refractory myelodysplastic syndromes, are eligible to receive continuous, sin-
gle-agent, oral AG-120 once (QD) or twice (BID) daily in 28-day cycles.
Informed consent is obtained prior to entry. Sequential cohorts are being
enrolled, with expansion cohorts planned. Blood and bone marrow samples
are collected for PK/PD assessment. Response is assessed on Days 15, 29,
and 57, and every 56 days thereafter. Objective responses are investigator
assessed using International Working Group criteria.
Figure 1. Duration of AG-120 treatment and best overall response.
Results: As of 17 October 2014, 17 patients had received AG-120 and 11
remained on study. All had RR AML (8 men/9 women), median age 73 years
(range, 42-87) and median number of prior chemotherapy regimens 2 (range, 1-
5). Doses administered were 100 mg BID (n=4), 300 mg QD (n=4), 500 mg QD
(n=4), and 800 mg QD (n=5). Median treatment duration at data cut-off was 1.6
months (range, 0.4-5.7). Therapy has been well tolerated and the MTD has not
yet been reached. Fourteen patients experienced adverse events (AEs), the
most common (>20% of patients) were nausea, fatigue, dyspnea, vomiting, pyrex-
ia, and cough. Serious AEs occurred in 8 patients: 1 differentiation syndrome, 1
tongue edema and grade 3 QT prolongation (dose-limiting toxicity; 800 mg QD),
and 6 non-drug-related deaths, 5 of which occurred after discontinuation of AG-
120 due to progressive disease and 1 due to disease-related intracranial hem-
orrhage while on treatment. Preliminary PK analyses showed high plasma expo-
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sure and drug accumulation following oral administration and a mean half-life of
>32 hours. PD analyses showed up to 98% inhibition of plasma 2-HG at all dose
levels. Objective responses were observed in 7/14 efficacy-evaluable subjects
(4 CR, 2 marrow CR, 1 PR), with durable responses of up to 5.7 months, and all
responders remain on treatment (Figure 1). Six patients had stable disease and
1 had disease progression. Consistent with preclinical data, responses were
associated with differentiation of myeloblasts into mature cell types. Dose esca-
lation continues and updated safety, efficacy, and PK/PD data will be presented.
As of 20 February 2015, 41 patients have been treated in 5 dose escalation
cohorts from 100 mg BID to 1200 mg QD.
Summary and Conclusions: AG-120, a first-in-class, oral, potent, selective
inhibitor of mutant IDH1, has been well tolerated to date. Durable single-agent
responses of up to 5+ months have been observed. IDH1 inhibition resulted in
reduced 2-HG and profound cell differentiation effects in some patients. Updat-
ed data from this ongoing study will be presented.
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TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH
RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFIL-
ING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY
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Background: Elderly patients with acute myeloid leukemia (AML) have an
extremely poor outcome. In addition, intensive induction chemotherapy is often
unsuitable. Tosedostat is a new, orally bioavailable inhibitor of members of the
M1 and M17 classes of aminopeptidases that includes the zinc-dependent
aminopeptidases. Tosedostat was proven to be effective as single agent, with
a manageable safety profile, in both de novo and relapsed AML.
Aims: We assumed that the addition of tosedostat to low-dose cytarabine may
improve the response rate and remission duration over what is expected with
chemotherapy or tosedostat alone.
Methods: This was a phase II, prospective, multicenter study, designed according
to Fleming’s method. Fixing the lowest acceptable rate as 10% and the successful
rate as 25%, with a significance level a=0.05 and a power 1-b=0.80, the sample
size was estimated in 33 patients. Thirty-three patients (median age 75 years)
received Tosedostat 120 milligrams orally once daily from day 1 to day 240, cou-
pled with intermittent low-dose cytarabine given subcutaneously at 20 milligrams
twice/day from day 1 to day 10 of each cycle. Courses of cytarabine were repeat-
ed every 4 weeks in the absence of disease progression or unacceptable toxicity,
up to 8 cycles. To identify possible biomarkers associated to sensitivity/resistance,
global gene expression profiling (GEP, Affymetrix Transciptome Array 2.0) was
performed on purified AML cells obtained from 29 patients.
Results: Median white blood cell count at diagnosis was 3.05x109/l (range:
0.26-24.53x109/l). Seventeen out of 33 patients had an intermediate karyotype,
13/33 an unfavorable karyotype and 3/33 were not evaluable. Sixteen patients
had a de novo AML, whereas 17 had a secondary AML. Induction-period mor-
tality was 12%, with 4 deaths occurring in aplasia. According to intent-to-treat,
the CR rate was 45.4% (15/33 patients). Interestingly, 3/33 additional patients
obtained a partial response, translating in an impressive overall response rate
of 54.4%. In addition, 4/33 patients remained in stable disease for a median
time of 9 months (range: 4-14). Seven patients did not respond at all and died
with progressive disease after having received a median of 2 cycles of cytara-
bine and 45 days of tosedostat. In responding patients, the median time for the
achievement of best response was 74 days (range 22-145). Statistical analysis
showed that responding patients (CR+PR) had a longer median overall survival
than non-responders (P=0.018). Ten out of 18 (55%) responding patients are
still in remission (8CR, 2 PR) after a median follow-up of 319 days (range: 47-
548); 2 patients are still alive with stable disease. Twenty-one patients died
[while in aplasia (4), due to resistant disease (7) or due to progressive disease
(8)] after a median CR duration of 5 months (2-17). As far as GEP analysis was
concerned, we studied 29 cases and identified a molecular signature associated
with the clinical response (CR vs no CR). Based on that, an algorithm to predict
the clinical response was developed and validated.
Summary and Conclusions: The tosedostat and low-dose cytarabine combo
produced a CR rate superior to what expected (45.4% versus 25%), and thus
met the primary endpoint of study. Moreover, the achievement of CR could be
efficiently predicted by the gene expression pattern. Further, potential biomark-
ers were identified by GEP. The study was registered at European Union Drug
Regulating Authorities Clinical Trials (EudraCT) n.2012-000334-19.
Acknowledgements: Chroma Therapeutics and CTI Biopharma are gratefully
acknowledged for providing Tosedostat for the patients free of charge.
The study was supported in part by AIL Pesaro Onlus.
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Background: Outcome for patients aged ≥70 years with acute myeloid
leukemia (AML) is extremely poor. Intensive induction chemotherapy is fre-
quently unsuitable. Thus, novel therapies are needed.
Aims: We designed a prospective phase II study to assess the efficacy of the low-
dose lenalidomide and cytarabine combo in patients with AML aged ≥70 years.
Methods: The study was designed according to the MiniMax design. The pri-
mary outcome was the complete remission rate (CR+CRi) according to the
SWOG criteria. Fixing the lowest acceptable rate (P0) as 17% and the suc-
cessful rate (P1) as 30%, with a significance level alpha=0.05 and a power 1-
beta=0.90, the sample size was estimated to be 66 patients. Sixty-six patients
(median age 76 years) were enrolled in the study. Median white blood cell count
at diagnosis was 3.9x109/l (range: 0,45-49,7x109/l). Thirty-six out of 66 patients
had an intermediate karyotype, 25/66 an unfavorable karyotype and 5/66 were
not evaluable. Twenty-eight patients had a de novo, whereas 38 patients had
a secondary AML. Patients received low-dose lenalidomide (10 mg/day orally,
days 1-21) and low-dose cytarabine (20 mg/m2 twice daily subcutaneously,
days 1-15). Therapy was repeated every 6 weeks, up to 6 cycles. To identify
possible biomarkers associated to sensitivity/resistance, global gene and miR-
NA expression profiling (Affymetrix Transciptome Array 2.0) was performed on
purified AML cells obtained from 26 patients.
Results: After the first cycle of therapy, 8/66 patients died in documented apla-
sia. One patient died during cycle 1 (acute heart failure). The cumulative induc-
tion-period mortality was 13%. Three patients are too early. According to intent-
to-treat, the CR rate was 36.3% (24/66 patients), the PR rate was 3% (2/66)
with an overall response rate (ORR) of 39.3%. Four patients died in CR, one
in PR, whereas 6/26 responding patients are still in CR after a median follow-
up 358,5 days (range: 89-1787). The remaining 15 patients who achieved a
CR/PR relapsed after a median time of 12 months and died due to progressive
disease. Statistical analysis showed that responding patients had a longer
median overall survival than non-responders (P <0.0001). Interestingly, cyto-
genetic risk and bone marrow blats at diagnosis were not predictive of CR.
Conversely, by studying the miRNA and gene expression profile in 26 patients,
we identified a molecular signature, including 306 genes and 3 miRNA associ-
ated with the clinical response (CR vs no CR). Noteworthy, the involved genes
belonged to relevant functional categories such as NF-kB cascade, protein
kinase signaling and immune response. Based on the expression of such
genes/miRNA, treatment response could be predicted with high accuracy
(88.5%, 23/26 samples correctly classified), with 87% sensitivity, 91% speci-
ficity, and 93% positive predictive value for responders. Moreover, we developed
an algorithm to predict response based on the expression of 16 genes only,
that correctly identified 14/14 CR patients.
Summary and Conclusions: The low-dose lenalidomide and cytarabine combo
produced a CR rate superior to what expected when designing the trial (36.3%
versus 30%), and thus met the primary endpoint of study. Moreover, the achieve-
ment of CR could be efficiently predicted by the gene expression pattern. The
combo warrants further investigation in a randomized, phase III trial. The study
was registered at EMA with the EUDRACT no 2008-006790-33.
Acknowledgements: Celgene is acknowledged for providing Lenalidomide
for the patients.
The study was supported in part by AIL Pesaro Onlus.
P566
OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER
PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH
AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-
AML-001 STUDY
H. Döhner1,* D. Selleslag2, J. Cavenagh3, J.F. Seymour4, M. Minden5, C. Récher6,
G. Martinelli7, J. Mayer8, P. Font López9, H.-J. Kim10, W.-C. Chou11, A. Kew12,
Y.H. Min13, S. Songer14, L.M. Lucy14, C. Beach14, H. Dombret15
1Universitätsklinikum Ulm, Ulm, Germany, 2Algemeen Ziekenhuis Sint-Jan,
Brugge, Belgium, 3Barts Health NHS Trust, London, United Kingdom, 4Peter
haematologica | 2015; 100(s1) | 215
Vienna, Austria, June 11 – 14, 2015
MacCallum Cancer Centre, East Melbourne, Australia, 5Princess Margaret
Cancer Centre, Toronto, Canada, 6Institut Universitaire du Cancer de Toulouse
Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France,
7Institute of Hematology and Medical Oncology “L. e A. Seragnoli”,, Bologna,
Italy, 8Fakultni Nemocnice Brno, Brno, Czech Republic, 9Hospital General “Gre-
gorio Maranon”, Madrid, Spain, 10College of Medicine, The Catholic University
of Korea, Seoul, Korea, Republic of, 11National Taiwan University Hospital,
Taipei, Taiwan, ROC, 12Queen Elizabeth II Health Services Centre, Halifax,
Canada, 13Yonsei University College of Medicine, Seoul, Korea, Republic of,
14Celgene Corporation, Summit, United States, 15Hôpital Saint Louis, Institut
Universitaire d’Hématologie, University Paris Diderot, Paris, France
Background: There is no universally accepted approach to AML treatment (Tx)
for older pts. IC is recommended for pts aged ≥60 years with favorable prognostic
features (NCCN guidelines, 2014). However, many older pts can not tolerate IC.
Such pts often receive low-dose cytarabine (LDAC), which is associated with a
median OS of only ~5 months (Burnett, Cancer, 2007; Kantarjian, JCO, 2012).
There is an unmet need for tolerable Tx options that prolong OS to a similar or
greater extent than IC. The phase 3, randomized AZA-AML-001 study compared
AZA with conventional care regimens (CCR) in older pts with AML. Before ran-
domization, pts were preselected to receive 1 of 3 CCR per investigator choice
of preferred Tx option: IC, LDAC, or best supportive care only. Pts were then
randomized to receive AZA or CCR and received their preselected Tx.
Aims: To compare OS and clinical outcomes with AZA vs IC in the subgroup
of pts in AZA-AML-001 preselected to receive IC before randomization.
Methods: Pts aged ≥65 years with newly diagnosed de novo or secondary AML
(>30% bone marrow [BM] blasts) and ECOG PS 0-2, WBC ≤15x109/L, and inter-
mediate- or poor-risk cytogenetics were enrolled. Pts received IC (cytarabine IV
x7days (d)+an anthracycline IV x3d, with ≤2 subsequent cycles) or AZA (75
mg/m2/d SC x7d/28d cycle). OS and 1-year survival were estimated using
Kaplan-Meier methods. OS was compared between Tx groups by log-rank test.
Hazard ratios (HRs) and 95% CI are from an unstratified Cox proportional hazards
model. Rates and durations of complete remission (CR) and CR with incomplete
blood count recovery (CRi) (IWG 2003), and RBC transfusion independence (TI)
in pts transfusion-dependent at baseline, were assessed. Rates of grade 3-4
treatment-emergent adverse events (TEAEs), defined as new or worsening AEs
during Tx, were assessed. To account for differences in Tx exposure, TEAE inci-
dence rates (IR) per 100 pt-years of Tx exposure are reported.
Results: Of all pts in AZA-AML-001 (N=488), 87 (18%) were preselected to
receive IC (AZA n=43, IC n=44). Median number of Tx cycles of AZA was 8
(range 1-24) and of IC was 2 (1-3). At baseline in the AZA and IC groups, median
ages were 71 yrs (AZA range 65-79, CCR 65-81); 16% and 18% of pts, respec-
tively, had ECOG PS of 2; median BM blasts were 72% (7-100%) and 70% (6-
100%); median WBC count was 3.8x109/L (1-15) and 2.2x109/L (1-90); and 35%
and 34% of pts had poor-risk cytogenetics. Median OS was comparable in the
AZA and IC groups: 13.3 vs 12.2 months, respectively (HR=0.85 [95% CI 0.52,
1.38], p=0.5032) (Figure 1). One-year survival with AZA was 55.8% (95% CI
39.8%, 69.1%) vs 50.9% (35.2%, 64.6%) with IC (Δ4.9%; 95% CI -16.2%,
26.0%). In the AZA and IC groups, respectively, 30% and 36% of pts attained
CR, and 12% and 11% achieved CRi. Median durations of CR+CRi in the AZA
and IC groups were 17.3 (95% CI 3.7, not reached) and 19.8 (8.2, 26.3) months,
respectively. RBC TI rates with AZA vs IC were 57% vs 35%, respectively. Pro-
portions of pts with grade 3-4 TEAEs and [IRs] in the AZA and IC groups, respec-
tively, were: anemia 12% vs 14% [14 vs 45]; neutropenia 30% vs 33% [37 vs
99]; febrile neutropenia 33% vs 31% [40 vs 92]; thrombocytopenia 23% vs 21%
[29 vs 64]; and (any) infections 49% vs 50% [60 vs 149].
Figure 1. Overall survival in patients preselected to intensive chemotherapy.
Summary and Conclusions: AZA and IC were associated with comparable
OS, 1-year survival, and rate and duration of remission in these older pts with
AML. AZA was better tolerated than IC, with lower incidence rates of hemato-
logic TEAEs and infections. AZA may be a good option for older pts with AML
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Background: Elderly AML patients, deemed unsuitable for intensive therapy,
have limited treatment options. We previously reported a high initial response
rate in the first stage of a phase 2 study of P plus AZA in this population (ASH
2014). This report presents updated results, which include additional patients.
Aims: The study was designed to evaluate the efficacy and safety of the com-
bination of pracinostat and azacitidine in elderly patients with AML
Methods: Eligibility includes previously untreated AML (≥ 20% bone marrow
blasts), age ≥ 65 years, unsuitable for intensive therapy due to co-morbidities
and/or AML related features, and intermediate or high-risk cytogenetics. Study
therapy includes P, 60 mg p.o. 3 alternate days/week for 3 weeks plus AZA, 75
mg/m2 /day 1-7 or day 1-5 and 8-9 either s.c. or i.v. with cycles repeated every
28 days until progressive disease, lack of response, or intolerance. The primary
endpoint is CR+CRi+ morphologic leukemia free state (MLFS) per IWG criteria.
Response assessments occur at the end of cycle 1 or 2 then every other cycle
or when clinically indicated. A Simon 2-stage statistical design is utilized with
the following assumptions: null=0.10, alternate=0.25, α=0.10, power=0.90.
Stage 1 n=27 and total stage 2 n=40.
Results: Between 12/2013 and 12/2014 50 patients from 15 study sites were
enrolled. At this time, 47 are evaluable for efficacy. Baseline disease charac-
teristics for all patients include: median age 75 (range 66-84); 32 de novo AML,
13 evolved from AHD, 5 treatment-related; 28 intermediate-risk and 20 high-
risk cytogenetics and 2 unknown; baseline bone marrow blast counts ranged
from 20% to 89% with a median of 40%. The primary endpoint of CR +CRi
+MLFS has been observed in 22/47 evaluable patients (47%) to date, including
14/47 (30%) CR. Current median duration of response is 15+ weeks (range:
1- 48+ weeks). Disease progression has not been observed in any responders.
30 patients continue on study (range 11- 52+ weeks). The 60-day all-cause
mortality rate is 10% (5/50). Median overall survival has not been reached.
Treatment emergent adverse events (TEAEs) Grade ≥3 seen in >5% of
patients: febrile neutropenia 30%; thrombocytopenia 22%; neutropenia 10%;
cellulitis 10%; anemia 8%; fatigue 8%; sepsis 6%, and pancytopenia 6%.
TEAE’s leading to study therapy discontinuation: peripheral motor neuropathy
(1), parainfluenza (1), atrial fibrillation/prolonged QTc/(1), subdural hematoma
after a fall (1), and sepsis (3). 
Summary and Conclusions: P plus AZA produces a high rate of durable
responses in this AML population. Updated data, including EFS and OS esti-
mates, will be presented at the meeting. These phase 2 data warrant definitive
evaluation in a phase 3 study.
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Background: Somatic mutations in the metabolic enzymes isocitrate dehy-
drogenase (IDH) 1 and 2 occur in a spectrum of solid and hematologic malig-
nancies. Mutant IDH1/2 in cancer cells results in the neomorphic production
of the oncometabolite, D-2-hydroxyglutarate (2-HG), which impairs cellular
differentiation via an epigenetic mechanism. AG-221 is a first-in-class, oral,
potent, selective, reversible inhibitor of mutant IDH2. Data from the ongoing,
first-in-human, phase 1, open-label, dose escalation study (NCT01915498)
are reported.
Aims: To assess safety and define the maximum tolerated dose (MTD) of
AG-221 and inform the dosing schedule for expansion cohorts and future
phase 2 studies. Secondary objectives include preliminary evaluation of clin-
ical efficacy and measurement of pharmacokinetic/pharmacodynamic
(PK/PD) markers and cellular differentiation.
Methods: Patients with IDH2 mutation-positive advanced hematologic malig-
nancies (acute myeloid leukemia [AML] or myelodysplastic syndromes)
receive oral AG-221 once or twice daily in continuous 28-day cycles. Informed
consent is obtained prior to entry. Dosing began at 30 mg twice daily and
increased in subsequent cohorts. Response is determined by blood and bone
marrow examinations according to International Working Group criteria.
PK/PD analyses of AG-221 and 2-HG are conducted.
Results: As of 1 Oct 2014, 73 patients have received AG-221 (median age
67 years [range, 33-90], 53% men, 75% with relapsed/refractory [RR] AML)
and 38 (52%) remain on therapy, with 45 (62%) evaluable for efficacy. Median
treatment duration is 1.9 (range, 0.1-8.8) months, and 18 patients have been
on study for ≥4 months. There are 10 dose cohorts, MTD has not been
reached, and the highest daily cumulative dose is 300 mg. The most common
adverse events (AEs) were nausea, pyrexia, diarrhea and fatigue, with 81%
of patients experiencing any AE, including AEs that were not related to AG-
221. There have been 4 AEs leading to discontinuation. The majority of seri-
ous AEs (SAEs) were disease-related, with 13 patients experiencing 21 treat-
ment-related SAEs, including leukocytosis in 3 patients. Of 11 deaths report-
ed, 2 were assessed as possibly related to treatment. AG-221 demonstrated
adequate plasma exposure, with a mean half-life >40 hours. After multiple
AG-221 doses, plasma 2-HG was reduced from the elevated levels observed
at baseline, with inhibition of up to 98% in subjects with the IDH2-R140Q
mutation. Objective responses were observed in 25 (56%) efficacy-evaluable
patients, defined as having Day 28 bone marrow biopsy information available
(6 CR, 4 marrow CR, 5 CR with incomplete platelet or hematologic recovery,
10 PR). There were durable responses of up to 8.8 months and 5 responders
proceeded to transplant (Figure 1). As of 20 Feb 2015, 145 patients have
been enrolled, 104 in dose escalation and 41 in four expansion arms of 1)
age ≥60 years (y) with RR AML, or any age if relapsed after stem cell trans-
plant (SCT); 2) age <60 y with RR AML excluding relapse after SCT; 3) age
≥60 y with untreated AML declining standard therapy; 4) any hematologic
malignancy not eligible for arms 1-3.
Figure 1. Duration of AG-221 treatment and best overall response, all effi-
cacy evaluable patients as of 1 October 2014.
Summary and Conclusions: In patients with IDH2 mutation-positive
advanced hematologic malignancies, AG-221 therapy was well tolerated, dis-
played favorable PK/PD properties, and resulted in durable remissions of up
to 8.8 months. These results continue to validate mutant IDH2 as a thera-
peutic cancer target and demonstrate the safety of AG-221. Updated clinical
results will be presented.
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Background: The chromosomal aberration t(15;17) plays a central role in the
development of acute promyelocytic leukemia (APL) and results in the formation
of PML/RARa fusion protein. Arsenic trioxide (ATO) and all-trans retinoic acid
(ATRA) target the PML and RARa proteins respectively, which made APL changes
from a highly fatal disease to a highly curable disease. However, ATO must be
intravenously administered in a hospital setting. The development of an orally
active arsenic-containing formulation with comparable efficacy and adverse
effects is highly desirable. Increasingly clinical trials and articles demonstrated
that an oral tetra-arsenic tetra-sulfide (As4S4) treatment alone can serve as a
highly effective and safe remission induction and maintenance therapy.
Aims: To estimate the efficacy and safety of Oral As4S4 -containing formula
named the Realgar-Indigo naturalis formula (RIF), combined with ATRA therapy
in APL.
Methods: Cochrane Library, PUBMED, EMBASE, Chinese National Knowl-
edge Infrastructure, and WanFang Data were searched for randomized con-
trolled trials (RCT). Oral RIF+ATRA (RIF group) versus intravenous arsenic tri-
oxide (ATO)+ATRA (ATO group) as treatment of APL, the complete remission
(CR) rate and the incidences of adverse events of two groups were compared.
Meta-analysis was conducted to generate combined odds ratios (ORs) with
95% confidence intervals (CIs) by RevMan 5.2. 
Results: Data from 5 RCTs involving 343 APL patients were identified. For the
CR rate, the RIF group and the ATO group showed a similar efficacy in the dif-
ferent treatments (95.57% vs 93.33%). For CR rate of RIF group vs CR rate of
ATO group, ORs increased with the year of clinical trials (2008,OR:0.7;
2011,OR:2.97 and 2013 OR:3.72), which suggested RIF as the first-line treat-
ment of APL stabilized and improved year by year. Besides, time to CR, 2-year
DFS, 3-year DFS and mortality also showed that oral RIF+ ATRA had effect no
worse than intravenous ATO+ATRA. At the end of consolidation therapy, the
PML-RARα transcript was undetectable in any patient in both the RIF group
and ATO group (two RCT were involved which was 113 patients). Notably,
although there were no statistical difference in 3 articles which mentioned
adverse events affecting the liver, meta-analysis suggested remarkable differ-
ence: happening of hepatic dysfunction in RIF group were lower than ATO
group (OR=0.57, 95%CI 0.34-0.95, P=0.03). Moreover, rate of headache and
infection in RIF group were also lower than ATO group, (OR=0.06, 95%CI 0.01-
0.46, P=0.007) and (OR=0.34, 95%CI 0.14-0.32, P=0.02), respectively. Means
of medical cost for postremission treatment in 15 months was 10701.9 RMB
for RIF group, compared to 49957.5 RMB for ATO group. The cost of RIF group
was only less than a quarter to ATO group (P<0.00001). The rates of other
events were similar in the two groups.
Summary and Conclusions: Oral RIF plus ATRA is not inferior to intra-
venous ATO plus ATRA as treatment of APL. RIF as the first-line treatment of
APL stabilized and improved year by year.The security of oral RIF is better
than intravenous ATO, and the maintenance treatment costs of RIF is lower
than ATO therapy in APL. PML-RARα transcript for the treatment of
RIF+ATRA was 100%, suggested RIF+ATRA may be considered as a
postremession treatment. It may be considered as a new strategies therapy
in APL: oral RIF Replace intravenous ATO.
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Background: SGI-110 (guadecitabine) is a novel hypomethylating agent
(HMA) given subcutaneously (SC) and provides a prolonged in vivo exposure
to its active moiety decitabine. We previously reported results from a multicenter
randomized dose-response study of guadecitabine given at 2 doses in a 5-day
regimen in 51 treatment naïve elderly AML patients not eligible for intensive
chemotherapy (Yee et al., 2014). There was no significant differences in overall
composite complete response (CRc: CR+CRp+CRi) or safety between the two
doses; however 14 patients were still on treatment at the time of the analysis.
Aims: To report on long term follow up including additional late responders
and overall survival (OS).
Methods: Previously untreated elderly (≥65y) AML patients who were not eli-
gible to receive intensive chemotherapy were randomized 1:1 to either 60 or
90 mg/m2/d SC for 5-days in 28-day cycles. Overall composite CR (CRc:
CR+CRp+CRi) was the primary endpoint. OS, and Safety were secondary end-
points.
Results: Fifty one patients were treated (24 and 27 on 60 and 90 mg/m2 doses
respectively). Patients’ characteristics were generally balanced between the 2
doses and represented a poor prognosis population: 73% were ≥75 y old; 47%
had poor risk cytogenetics; 45% secondary AML; and 35% poor performance
status (PS 2). No differences in either CRc or CR were observed in the previous
and current analysis between the 2 treatment doses so data are presented
here for the overall patients treated. Two additional patients developed CR with
longer follow up (one on each arm) bringing total patients with CR to 19 (37%)
and the total patients with CRc to 29 (57%): 19 CR; 7 CRi, and 3 CRp. Median
follow up now reached 21.1 months (m) (range 17.2-30.0 m). Median number
of cycles administered was 5 (range 1-24). Of the 29 CRc patients, the majority
(20 or 69% of responders) occurred after at least 3 cycles and 6 of them (21%
of responders) occurred after at least 6 cycles. Two late responders occurred
after 8 and 9 cycles respectively. With death events reported in 34/51 patients
(67%) the median OS is 10.5 m (95% CI: 5.3-18.1 m). The most common
Grade≥3 Adverse Events (AEs) assessed as drug-related by investigators were
neutropenia and thrombocytopenia (35% each), febrile neutropenia (20%),
leukopenia (18%), and anemia (16%).
Summary and Conclusions: Unlike cytotoxic chemotherapy where responses
tend to occur in the first 2 cycles, AML responses with HMA guadecitabine tend
to occur after multiple cycles with potential for late responses even after 6
cycles. Clinical activity as demonstrated by 57% CRc including 37% CR and
median OS of 10.5 months in this elderly poor prognosis population is promis-
ing. A Phase 3 trial in previously untreated AML patients not eligible for intensive
chemotherapy has been initiated with 5-day regimen at 60 mg/m2/d SC.
Reference
Yee K, Daver N, Kropf P, et al: European Hematology Association Meeting,
June 12-15, 2104; Milan, Italy. Abstract S647.
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PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A
POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1
STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
B. Fan1,* Y. Chen1, F. Wang1, K. Yen1, L. Utley1, M. Prahl1, K. Colby1, K. Straley1,
C. Bowden1, S. Biller1, S. Agresta1, H. Yang1
1Agios Pharmaceuticals, Cambridge, United States
Background: Isocitrate dehydrogenase 1 and 2 (IDH1/2) are critical metabolic
enzymes, catalyzing the oxidative decarboxylation of isocitrate to produce
alpha-ketoglutarate (α-KG) in the citric acid cycle. Somatic IDH1/2 mutations
occur in multiple solid and hematologic tumors, including acute myeloid
leukemia. Mutant IDH1/2 proteins possess novel enzymatic activity, catalyzing
the reduction of α-KG to produce the oncometabolite, D-2-hydroxyglutarate (2-
HG). Accumulation of 2-HG drives multiple oncogenic processes, including
impaired cellular differentiation. AG-120 is a first-in-class, oral, potent,
reversible, selective inhibitor of the mutated IDH1 protein and has been shown
to lower 2-HG levels and restore cellular differentiation in IDH1-mutant primary
human blast cells cultured ex vivo. We conducted in vivo pharmacokinetic/phar-
macodynamic (PK/PD) studies in an IDH1-mutant xenograft mouse model to
assess the correlation between AG-120 exposure and 2-HG inhibition, and to
predict exposure required for efficacy in humans. AG-120 is currently being
assessed in a first-in-human, phase 1 study enrolling patients with IDH1-
mutant, advanced hematologic malignancies (NCT02074839).
Aims: To compare early PK/PD data from the ongoing, first-in-human, phase
1 study of AG-120 with PK/PD data from in vivo and in vitro models.
Methods: The AG-120 phase 1, open-label, dose-escalation study includes eval-
uation of safety, tolerability, maximum tolerated dose (MTD) of AG-120, PK/PD
(including 2-HG levels) and clinical activity. Single-agent AG-120 is administered
orally once (QD) or twice (BID) daily in continuous 28-day cycles. Informed con-
sent is obtained prior to entry. Patients included in this analysis received doses
of 100 mg BID, 300 mg QD, 500 mg QD, and 800 mg QD (N=17). Blood was col-
lected at multiple time points for determination of PK/PD. Concentrations of AG-
120 and 2-HG in plasma samples were determined using qualified LC-MS/MS-
based methods. Analyses were performed using WinNonLin®. PK/PD relation-
ships for AG-120 were also evaluated in vivo in an HT1080 IDH1-R132C-mutant
xenograft mouse model following oral administration, and potency was assessed
in vitro in a number of cell lines carrying IDH1 mutations.
Results: Preliminary analyses demonstrated a favorable PK profile for AG-
120 in humans following oral administration. Mean exposure was high at all
dose levels tested, and AG-120 displayed a long plasma half-life (>32 hours).
Following multiple AG-120 doses, substantial reductions in mean plasma 2-
HG concentrations to levels seen in healthy volunteers were observed at all
doses (up to 98% 2-HG inhibition). With exposure-response analysis, substan-
tial and constant plasma 2-HG inhibition was achieved from multiple AG-120
100 mg BID doses at the AG-120 AUC0-10hr value of 15.5 hrμg/mL (Figure 1).
These findings showed good correlation with PK/PD analyses in the HT1080
IDH1-R132C mutant xenograft mouse model. In vitro studies showed potent
inhibition of 2-HG production with AG-120 treatment in cells expressing IDH1-
R132C, -R132H, and -R132S mutations but not in those expressing the IDH2-
R140Q mutation, demonstrating selectivity for IDH1 mutations.
Figure 1. AG-120 plasma exposure and 2-HG inhibition correlation in
patients with IDH1 mutations.
Summary and Conclusions: AG-120 demonstrated a favorable PK profile in
humans following oral administration, with high plasma exposure and a long
half-life, supporting QD dosing. AG-120 inhibited plasma 2-HG to within normal
levels found in healthy volunteers. Inhibition of 2-HG production by AG-120
translated well from in vitro to in vivo and from pre-clinical models to humans.
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CHARACTERISATION OF TP53 MUTATIONS IN ADULT ACUTE MYELOID
LEUKEMIA (AML) PATIENTS: MUTUAL EXCLUSIVITY WITH FLT3 AND
NPM MUTATIONS STRONG ASSOCIATION WITH COMPLEX KARYOTYPE
AND POOR OUTCOME
A. Ferrari1,* C. Papayannidis1, C. Baldazzi1, I. Iacobucci1, E. Zuffa1, M. Perricone1,
V. Robustelli1, C. Venturi1, M.T. Bochicchio1, C. Sartor1, M.C. Abbenante1,
V. Guadagnuolo1, A. Padella1, G. Simonetti1, N. Testoni1, E. Ottaviani1, M. Cavo1,
G. Martinelli1
1University of Bologna, Institute of Hematology “L. e A. Seràgnoli”, Bologna,
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Background: AML is a heterogeneous disease with a variety of structural and
numerical chromosomal and genetic alterations that provided important prog-
nostic information capable to guide therapy and predict outcome. The reported
TP53 mutation rate in AML is low (2.1%). By contrast, the incidence of FLT3
disruption is frequent (20-30%) and is an independent predictor of unfavourable
outcome of acquired clinical resistance to FLT3 inhibitors. TP53 mutations in
AML with a complex karyotype (CK) is higher (69-78%), and patients (pts) with
complex karyotype (CK-AML) have generally a poor outcome but few data are
available for association between the most common AML associated lesions
such as FLT3, NPM1, DNMT3A, IDH2 and TP53 mutation or CK.
Aims: To investigate the frequency, the types of mutations, the associated cyto-
genetic, the molecular abnormalities, the correlation with known molecular alter-
ations (FLT3, NPM, etc.) and the prognostic role TP53 mutations in adult AML pts.
Methods: 236 adult AML pts AML pts with FAB-M0-7, miscellaneous cytogenetic
abnormalities and normal karyotype (nK) were examined for TP53 mutations
using several methods, including Sanger sequencing, NGS (20/236) and HiSeq
2000 platform (38/236) and were correlated with cytogenetic analysis. Analysis
was focused on coding sequences (RefSeq GRCh37/hg19 NG_017013.2).
Results: By PCR and subsequent Sanger sequencing, mutations of TP53 were
detected in 33 cases (14%). Nine pts revealed 2 mutations. 75.8% of all mutated
pts had CK (25/33) by contrast the frequency of mutations was lower in “no
CK-AML” pts (24.2%). Overall, between pts with CK, TP53 mutation frequency
is 43.1% (25/58). 38 TP53 point mutations and 4 TP53 deletions were found.
M237I mutation was found in 4 pts. This mutation was described to severely
compromised p53 expression level. The majority of alterations are located in
the DNA binding domain (38/42; 90%), 9 of these were located in hot spot sites.
Almost all mutations in coding regions were classified by the IARC database
(http://p53.iarc.fr/TP53GeneVariations.aspx) as deleterious. WES analysis done
in 38 pts (33 TP53 wt and 5 pts TP53 mutated) revealed no genes exclusively
mutated in the 5 TP53 mutated pts. 174 and 117 pts were analysed for con-
comitant presence of TP53 mutations and FLT3/NPM1 disruption/mutation
revealing a significant relation between pts with FLT3-ITD or NPM1 and TP53
wild-type (p=0.015 and 0.009 respectively). Of note, alterations of TP53 were
significantly associated with poor outcome in terms of both overall survival (Fig-
ure 1A; P <0.0001) and disease free-survival and that TP53 compare to FLT3
mutations have worse impact on prognosis (Figure 1B; P <0.0001).
Figure 1. A) Overall survival in AML adult patients considering TP53 muta-
tional status alone and B) in combination with FLT3 mutations.
Summary and Conclusions: Our data demonstrated that TP53 mutations
occur in 14% of AML with a higher frequency in the subgroup of CK-AML
(p<0.0001-Fischer’s exact test) and are mutually exclusive with FLT3 and/or
NPM1; they predicted to be deleterious and significantly correlated with worse
prognosis and may confer resistance to conventional and innovative therapy.
For these reasons, TP53 mutation screening should be recommended at least
in CK-AML pts.
Supported by: ELN, AIL, AIRC, progetto Regione-Università 2010-12 (L. Bolon-
di), FP7 NGS-PTL project.
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PHASE 1 TRIAL OF G-CSF, CLADRIBINE, CYTARABINE, AND DOSE-
ESCALATED MITOXANTRONE (G-CLAM) IN ADULTS WITH NEWLY DIAG-
NOSED AML OR HIGH-RISK MDS
A. Anwar1,* A. Halpern1, B. Scott1, P. Becker1, M. Othus1, P. Hendrie2,
E. Ranker3, A. Perdue3, T. Chen2, S. Buckley1, K. Orlowski1, M. Powell1,
F. Appelbaum1, E. Estey1, R. Walter1
1Fred Hutchinson Cancer Research Center, 2University of Washington, 3Seattle
Cancer Care Alliance, Seattle, United States
Background: Standard-dose cyarabine with an anthracycline (“7+3”) has
remained the mainstay of induction chemotherapy for newly diagnosed AML.
Recently, some randomized studies have demonstrated improved outcomes
with regimens containing high-dose cytarabine, cladribine, or escalated doses
of anthracyclines during induction.
Aims: Given these findings and the previously established tolerability and effi-
cacy of G-CLAM in relapsed/refractory AML, we aimed to determine the max-
imum tolerated dose (MTD) of mitoxantrone within G-CLAM in adults with newly
diagnosed AML or high-risk MDS (>10% blasts).
Methods: Eligibility included a treatment-related mortality (TRM) score of ≤6.9
(corresponding to a risk of early death with standard induction chemotherapy
of ≤3%) and adequate organ function (LVEF ≥45%, creatinine ≤2.0 mg/dL,
bilirubin ≤2.5-times upper limit of normal). Excluded were patients with con-
comitant illness with expected survival <1 year and those with active, uncon-
trolled infection. Cohorts of 6-12 patients were assigned to 1 of 4 total dose
levels of mitoxantrone (12, 14, 16, or 18 mg/m2/day on days 1-3, as compared
to 10 mg/m2/day used in standard-dose G-CLAM). Other drug doses were G-
CSF 300 or 480 μg/day (for weight <76 kg vs ≥76 kg; days 0-5), cladribine 5
mg/m2/day (days 1-5), and cytarabine 2 g/m2/day (days 1-5). A second identical
course of G-CLAM was given in the case of persistent disease. Dose-limiting
toxicity (DLT) was defined as: 1) any grade 3 non-hematologic toxicity lasting
>48 hours that resulted in >7 day delay of the subsequent treatment cycle, with
the exception of febrile neutropenia or infection; 2) any grade ≥4 non-hemato-
logic toxicity, with the exception of febrile neutropenia or infection or constitu-
tional symptoms, if recovery to grade ≤2 within 14 days.
Results: 31 patients (20M, 11F), median age 58 (range: 27-77) years, median
TRM score 2.83 (range: 0.15-5.54) with newly diagnosed AML (n=25), or high-
risk MDS (n=6) and cytogenetically favorable (n=1), intermediate (n=23), and
adverse (n=6) disease characteristics were enrolled (failed karyotyping: n=1;
MRC criteria). One DLT occurred each at dose levels 3 and 4 (respiratory failure
in both cases), establishing G-CLAM with mitoxantrone at 18 mg/m2/day as
the MTD in our study. One patient died within 28 days of treatment initiation
from thrombocytopenia-related intracranial hemorrhage. Overall, 29/31 patients
(93.5%, exact 95% confidence interval [CI]: 78.6-99.2%) achieved a CR (n=24
[77.4%, 95% CI: 58.9-90.4%]), CRp (n=2 [6.5%, 95% CI: 0.8-21.4%]), or CRi
(n=3 [9.7%, 95% CI: 2.0-25.8%]) with 1-2 cycles of chemotherapy; one patient
at dose levels 1 and 2 each had persistent disease. Only 2 patients required 2
cycles to best response. 26/29 (89.7%, 95% CI: 72.7-97.8%) had no evidence
of residual disease by flow cytometry at best response. After multivariable
adjustment, the CR rate was similar and overall response rate was favorable
as compared to 300 patients treated with 7+3 on the SWOG S0106 trial
(OR=1.25, p=0.64, and OR=4.68, p=0.045, respectively). Among responders,
median times to an absolute neutrophil count ≥500 and a platelet count of
50,000 were 25 (range: 19-38) and 24 (range: 18-45) days, respectively.
Besides infections and neutropenic fever, maculopapular rash, nausea, and
hypoxia (fluid overload/infection-related) were the most common grade ≥3
adverse events.
Summary and Conclusions: G-CLAM with mitoxantrone up to 18 mg/m2/day
is feasible, well tolerated, and effective in newly diagnosed AML/high-risk MDS.
A phase 2 study has been initiated.
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OVERALL SURVIVAL (OS) WITHOUT COMPLETE REMISSION (CR) IN
OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): AZACITI-
DINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN THE AZA-
AML-001 STUDY
A. Schuh1,* H. Dombret2, I. Sandhu3, J.F. Seymour4, R.M. Stone5, H.K. Al-Ali6,
G. Alimena7, I. Lewis8, S. Sang Kyun9, M. Geddes10, D. Cilloni11, L. Je-Hwan12,
S. Songer13, L.M. Lucy13, C. Beach13, H. Döhner14
1Princess Margaret Cancer Centre, Toronto, Canada, 2Hôpital Saint Louis,
Institut Universitaire d’Hématologie, University Paris Diderot, Paris, France,
3University of Alberta Hospital, Edmonton, Canada, 4Peter MacCallum Cancer
Centre, East Melbourne, Australia, 5Dana-Farber Cancer Institute, Boston, Unit-
ed States, 6Universitätsklinikum Leipzig, Leipzig, Germany, 7Policlinico Umberto
I - Università La Sapienza, Rome, Italy, 8Royal Adelaide Hospital, Adelaide,
Australia, 9Kyungpook National University Hospital, Daegu, Korea, Republic
of, 10Tom Baker Cancer Centre, Calgary, Canada, 11AOU San Luigi Gonzaga,
Torino, Italy, 12Asan Medical Center, Seoul, Korea, Republic of, 13Celgene Cor-
poration, Summit, United States, 14Universitätsklinikum Ulm, Ulm, Germany
Background: The international phase 3 AZA-AML-001 study compared treat-
ment (Tx) effects of AZA vs CCR on OS in older patients (pts) with AML; AZA
prolonged median OS by ~4 months (10.4 vs 6.5 months, overall p=0.10) (Dom-
bret, Haematologica, 2014:LB2433). AZA is known to improve OS vs CCR in
pts with higher-risk myelodysplastic syndromes (HR-MDS) who have not
achieved CR during Tx (Gore, Haematologica, 2013). MDS and AML are bio-
logically and clinically distinct; it is unknown whether OS benefits in the absence
of CR shown for AZA in HR-MDS extend to AML.
Aims: This post hoc exploratory analysis examined Tx effects on OS in sub-
groups of pts in AZA-AML-001 who did not attain CR on-study.
Methods: Eligible pts were aged ≥65 years with newly diagnosed AML with
>30% bone marrow blasts, and with ECOG PS of 0-2, WBC count ≤15x109/L,
and intermediate- or poor-risk cytogenetics. Before randomization, pts were
preselected to receive 1 of 3 commonly used CCR per investigator choice of
most appropriate Tx: intensive chemotherapy (IC; cytarabine IV x7days (d)+an
anthracycline IV x3d, with ≤2 subsequent cycles), low-dose cytarabine (LDAC;
20mg SC BID x10d/28d cycle), or best supportive care only. Pts were then ran-
domized to AZA (75 mg/m2/d SC x7d/28d cycle), or to CCR and received their
preselected Tx. CR (IWG 2003) was adjudicated centrally by an Independent
Review Committee blinded to Tx assignment. Median OS and 1-year survival
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were estimated using Kaplan-Meier methods. OS was compared between AZA
and CCR groups by log-rank test stratified by ECOG PS and cytogenetic risk.
OS was compared between AZA and LDAC and AZA and IC within preselection
groups by unstratified log-rank test. Hazard ratios (HR) and 95% CIs are from
a stratified Cox proportional hazards model. Results should be interpreted cau-
tiously, as OS comparisons of pt subgroups defined by post-randomization out-
comes may be biased. The current analysis did not control for time-dependency
of response or interactions between Tx and response that could influence OS.
Results: Of all pts in AZA-AML-001 (AZA n=241, CCR n=247), 47 (19.5%) in the
AZA arm and 54 (21.9%) in the CCR arm attained CR and were excluded from
these analyses. Median OS in the remaining pts in the AZA vs CCR groups was
6.9 (95%CI: 5.1, 8.9) vs 4.2 (95%CI 3.2, 5.1) months, reflecting a 23% reduced
risk of death with AZA; HR=0.77 (95%CI 0.62, 0.95), p=0.0171 (Figure 1). Esti-
mated 1-year survival was 33.8% with AZA and 20.4% with CCR (difference 13.4%
[95%CI 4.5%, 22.4%]). For pts with no CR who were preselected to receive LDAC,
median OS with AZA (n=126) vs LDAC (n=120) was 8.1 vs 4.2 months, respec-
tively (HR=0.75 [95%CI 0.57, 0.99], p=0.0390), and 1-year survival was 36.8% vs
16.4% (difference 20.4% [95%CI 9.4%, 31.3%]). For pts with no CR who were
preselected to receive IC, median OS with AZA (n=30) vs IC (n=28) was 8.0 vs
7.5 months, respectively (HR=0.81 [95%CI 0.46, 1.44], p=0.4765), with 1-year
survival of 40.0% vs 40.2%.
Figure 1. Overall survival for patients who did not achieve CR.
Summary and Conclusions: The relative benefit on OS seen with AZA vs
CCR for all pts in AZA-AML-001 was maintained in pts who did not attain CR
on-study. Similarly, median OS with AZA was almost twice that with LDAC in
pts preselected to receive LDAC who did not achieve CR. Clinically meaningful
improvements in 1-year survival rates with AZA vs CCR (13.4%) and with AZA
vs LDAC (20.4%) in this analysis are similar to those reported for all AZA-AML-
001 pts (12% and 15%, respectively; Dombret, Haematologica, 2014). These
findings suggest that CR is not necessary to gain a survival benefit with AZA
vs other commonly used Tx for older pts with AML.
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ABSOLUTE QUANTIFICATION OF THE PRETREATMENT PML-RARA
MOLECULAR TRANSCRIPT BY DROPLET DIGITAL PCR DEFINES THE
RELAPSE RISK IN ACUTE PROMYELOCYTIC LEUKEMIA
F. Albano1,* A. Zagaria1, L. Anelli1, N. Coccaro1, G. Tota1, C. Brunetti1,
C.F. Minervini1, L. Impera1, A. Minervini1, A. Cellamare1, P. Orsini1, C. Cumbo1,
P. Casieri1G. Specchia1
1D.E.T.O., Hematology - University of Bari, Bari, Italy
Background: The persistence of resistant leukemic cells after treatment is
responsible for relapse in 10-20% of acute promyelocytic leukemia (APL)
patients. Until now, the white blood cells count at diagnosis has been consid-
ered the most important prognostic factor in APL, able to better identify those
patients at higher risk of relapse.
Aims: In this study we performed absolute quantification of the PML-RARA
transcript by droplet digital polymerase chain reaction (ddPCR) in newly diag-
nosed APL patients to verify the the prognostic impact of the PML-RARA initial
molecular burden.
Methods: PML-RARA expression analysis was performed by ddPCR in 76
APL patients at diagnosis with Bio-Rad’s QX200 system. Primers and probes
for PML-RARA isoforms were selected according to the standardized protocol
for TaqMan based RT-qPCR analysis. After amplification, ddPCR data were
analyzed with QuantaSoft analysis software (version 1.7.4). Target concentra-
tion in each sample was expressed as PML-RARA copies/ng.
Results: ddPCR analysis revealed that the amount of PML-RARA transcript
at diagnosis in the group of patients who relapsed was higher than in that with
continuous complete remission (CCR) (272 vs 89.2 PML-RARA copies/ng,
p=0.0004, respectively). Moreover, considering the arbitrary cut-off of 124
PML-RARa/ng (the median value of our APL series), a higher proportion of
patients who relapsed (85.7%) had >124 PML-RARa/ng compared to the CCR
group (39.6%) (odds ratio 0.10; p=0.002). Further parameters (age, sex, WBC
count, M3/M3v, bcr transcript type, FLT3 mutation status, CD34 and CD2
expression, relapse risk score) were assessed to verify the presence of dif-
ferent amounts of the fusion gene transcript at diagnosis among these different
categories but yielded no statistically significant differences. ROC analysis
detected the optimal PML-RARA concentration threshold as 209.6 PML-
RARa/ng (AUC, 0.78; p <0.0001) for discriminating between outcomes (CCR
versus relapse). Among the 67 APL patients who achieved CR after the induc-
tion treatment, those with >209.6 PML-RARa/ng had a worse relapse-free
survival (RFS) (p=0.0006). At 5-year follow-up, patients with >209.6 PML-
RARa/ng had a cumulative incidence of relapse of 50.3% whereas 7.5% of
the patients with suffered a relapse (p <0.0001). There was no difference in
terms of overall survival (OS) between patients with ≤209.6 PML-RARa/ng
and those with >209.6 PML-RARa/ng. It is noteworthy that when the group of
patients with early death was excluded from the OS analysis, the difference
between the two groups was statistically significant (p=0.02). Cox proportional
hazards regression model analysis was performed for RFS identifying the
amount of PML-RARA before induction treatment as the sole independent
prognostic factor for APL relapse (HR 9.26, p=0.0009).
Summary and Conclusions: Our results identified the amount of PML-RARA
before induction treatment as the sole independent prognostic factor for APL
relapse. In our experience the experiments performed with the ddPCR tech-
nology were absolutely reproducible, allowing easy measurement of the
absolute copies number of the PML-RARA transcript, and with high precision.
We conclude that the pretreatment PML-RARA molecular burden defined by
ddPCR could therefore be used to improve risk stratification in order to develop
more individualized treatment regimens for high-risk APL patients.
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PREVALENCE AND CLINICAL CHARACTERISTICS OF SETBP1 MUTA-
TIONS IN MYELOID DISORDERS
N. Winkelmann1,* J. Reichert1, V. Schaefer1, A. Waldau1, J. Rinke1, A. Hochhaus1,
T. Ernst1
1Jena, University Hospital, Jena, Germany
Background: SETBP1 mutations have recently been discovered and charac-
terized in myelodsyplastic syndrome (MDS), secondary acute myeloid leukemia
(sAML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and aplas-
tic anemia. Even though they are infrequent (1-5% in the above mentioned
diseases), they are associated with a poor prognosis. The role of SETBP1
mutations during disease progression for individual patients has rarely been
investigated so far.
Aims: To address this subject, we have screened 401 patients with World
Health Organization-defined AML (n=48), sAML (n=95), MDS (n=93), classical
MPN (n=113), MDS/MPN (n=40), and aplastic anemia (n=12) in an unselected
single-center cohort. In addition, we analyzed 103 follow up samples of patients
during disease evolution at a median of 10 months (range, 3-65 months) from
diagnosis.
Methods: Mutational screening was performed from bone marrow samples or
peripheral blood using bidirectional Sanger sequencing of genomic DNA cov-
ering the entire SKI homology domain of SETBP1.
Results: In total, we found SETBP1 mutations in 10 patients (2.5%, MDS/MPN,
n=6; sAML, n=2; MDS, n=2) who were all included in our clinical follow up. The
median age of patients harboring SETBP1 mutations was 63 years (range, 48-80
years). The majority of patients had a normal karyotype (n=5), chromosomal alter-
ations were: monosomy 7 (n=2), trisomy 8, trisomy 21, loss of chromosome Y
(n=1 each). All mutations were located within known somatic hotspots according
to the COSMIC database (codons 868, 870, 871, 942). One patient showed a
novel 12 base pair deletion starting at codon 867, reaching into the known muta-
tional hotspot. Germline material was available in 5/10 patients and confirmed the
somatic origin of mutations. In our clinical follow up, 9 of 10 patients with SETBP1
mutations had progressive disease and underwent intensive chemotherapy with
consecutive allogeneic stem cell transplantation (ASCT, n=3), demethylating treat-
ment with azacytidine as a bridging therapy to ASCT (n=3), palliative chemother-
apy with cytarabine (n=2), or best supportive care with transfusion dependency
(n=2). One patient with a codon 942 mutation (271993G>GA:942R>R/Q) was
diagnosed with MDS RAEB II and had stable disease over 65 months under con-
tinuous cytoreductive/demethylating therapy. 2/3 transplanted patients had early
relapse after 6 and 2 months, respectively. In the first patient, the SETBP1-clone
dissolved for 6 months after allotransplant, but re-appeared in relapse. In the sec-
ond patient, the clone harboring the SETBP1 mutation persisted through engraft-
ment and was always detectable by Sanger sequencing. One patient has
remained in complete remission for 14 months after ASCT. 
Summary and Conclusions: Mutated SETBP1 is associated with rapid dis-
ease progression of early relapse in a variety of hematologic diseases, even
after ASCT. Since SETBP1 mutations were never lost during disease progres-
sion they may drive disease progression in subgroups of patients and their
presence may guide treatment/surveillance decisions in the future.
220 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
LB578
PRELIMINARY PHASE II RESULTS OF ARA-C AND IDARUBICIN IN COM-
BINATION WITH SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE)
COMPOUND SELINEXOR (KPT-330) IN PATIENTS WITH RELAPSED OR
REFRACTORY AML
W. Fiedler1,* M. Heuser2, O. Ottmann3, M. Kebenko1, F. Thol2, A. Trummer2,
C. Brandts3, C. Bokemeyer1, S. Theile4, A. Kranich5
1Department of Internal Medicine II and Clinic (Oncology Center), University
Medical Center Hamburg-Eppendorf, Hamburg, 2Department of Hematology,
Hemostasis, Oncology und Stem Cell Transplantation, Hannover Medical
School, Hannover, 3Department of Medicine II, University Hospital Frankfurt,
Frankfurt, 4GSO Hamburg, Hamburg, Germany, 5GSO Global, Amsterdam,
Netherlands
Background: Acute myeloid leukemia (AML) is one of the most common
leukemia’s affecting adults. Although 70-80% of patients achieve a complete
remission (CR), patients with AML who fail to achieve a CR after the first cycle
of induction therapy and those with relapsed disease have a bleak prognosis.
Currently no standard regimen exists for the treatment of patients with relapsed
AML and a great clinical need exists for new treatment options. Selinexor, an
oral first-in-class Selective Inhibitor of Nuclear Export (SINE) compound, inhibits
XPO1 mediated nuclear export to induce cytotoxicity in cells with genomic dam-
age such as tumor cells. In Vivo model with selinexor alone or combination
with AraC significantly prolonged the survival of leukemic mice from a median
survival of 24 days (APL+vehicle) to 39 days, respectively (P <0.0001). Com-
bination therapy prolonged survival (P <0.0001), with some mice being cured
of the disease. Phase I clinical study demonstrates encouraging results in AML
patient. The role of selinexor as a mono therapy is currently under investigation
in phase II.
Aims: This phase II trial explores the efficacy & tolerability of Ara-C and idaru-
bicin in combination with selinexor in patients with relapsed or refractory AML.
Methods: Patients with relapsed/refractory AML are treated with Ara-C (100
mg/m2, continuous infusion, day 1-7), idarubicin (10 mg/m2, day 1, 3, 5) every
4 weeks. In the majority of the patients selinexor is administered twice weekly
orally starting on day 2 (40 mg/m2). A small cohort of patients received selinexor
after registration and before first induction cycle for correlative studies. The pri-
mary endpoint is percentage of patients achieving a complete response or com-
plete remission without normalization of peripheral blood counts (CRi). Other
endpoints are partial response rate, percentage of patients undergoing subse-
quent allogeneic stem cell transplant, early death rate, overall survival (OS),
event-free survival and toxicity.
Results: As of 20-April-2015, 18 patients with AML have been enrolled in 3
sites. Informed consent was obtained from all patients. Median age was 56
years. Out of 18 patients, 17 patients received ≥1 induction and 15 patients (9
male, 6 female) were evaluable for efficacy at the time of analysis. In average,
patients received 2.4 therapies prior to study start. Overall response rate was
53% (13% of patients achieved CR, 40% of patients achieved CRi). Stable dis-
ease was observed in 13% of patients. Sixty-seven percent of patients received
or were planned for stem cell transplant or donor lymphocyte infusion. Drug
related AEs comprised 61% of all CTC Grade 3/4 and 46% of all CTC Grade
1/2 events. Grade 3/4 drug related adverse events (AEs) include febrile neu-
tropenia (71%), diarrhea (71%), anorexia (57%), thrombocytopenia (43%),
leukopenia (43%), anemia (29%) and nausea (29%). Grade 1/2 drug related
AEs include: diarrhea (86%), vomiting (71%), nausea (71%), anorexia (43%),
constipation (43%), fatigue (29%) and oral mucositis (29%). No drug-related
deaths occurred.
Summary and Conclusions: The prognosis of relapsed/refractory AML
patients is remarkably poor. Our findings suggest that treatment with Ara-C and
idarubicin in combination with selinexor might be a potentially effective strategy
for patients with relapsed/refractory AML without unexpected toxicities. Most
common AEs were of low CTC grade.
CLL - Biology: Cell-intrinsic defects
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NOTCH1 MUTATIONS ARE ASSOCIATED WITH LOW CD20 EXPRESSION
LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCE FOR A
NOTCH1-MEDIATED EPIGENETIC MECHANISM
F. Pozzo1,* T. Bittolo1, F. Arruga2, P. Bulian1, P. Macor3, E. Tissino1, B. Gizdic2,
F.M. Rossi1, R. Bomben1, A. Zucchetto1, D. Benedetti1, M. Degan1, G. D’Arena4,
A. Chiarenza5, F. Zaja6, G. Pozzato7, D. Rossi8, G. Gaidano8, G. Del Poeta9,
S. Deaglio2, V. Gattei1, M. Dal Bo1
1Clinical and experimental Onco-hematology unit, Centro di Riferimento Onco-
logico, Aviano, 2Immunogenetics Unit, Human Genetics Foundation (HuGeF),
Torino, 3Department of Life Sciences, University of Trieste, Trieste, 4Onco-
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da Ospedaliera Universitaria S. Maria Misericordia, Udine, 7Department of
Internal Medicine and Hematology, Maggiore General Hospital, University of
Trieste, Trieste, 8Division of Hematology-Department of Translational Medicine,
Amedeo Avogadro University of Eastern Piedmont, Novara, 9Division of Hema-
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Background: In chronic lymphocytic leukemia (CLL), NOTCH1 mutations have
been associated with clinical resistance to anti-CD20 immunotherapy (Stilgen-
bauer et al. Blood, 2014, Dal Bo et al. Ann Hematol, 2014).
Aims: To investigate whether NOTCH1 mutations could affect CD20 expression
in CLL.
Methods: NOTCH1 mutations were investigated by ARMS PCR, Sanger and next
generation sequencing. CD20 expression was evaluated by flow cytometry and
QRT-PCR. CLL-like MEC-1 cells were transfected with vectors containing the
NOTCH1 intracellular domain (NICD) carrying either the 7541-7542delCT (NICD-
mut) or a stop codon at the beginning of NICD sequence (c.5304G>A, NICD-null).
Results: i) In a cohort of 692 CLL, 87 were NOTCH1 mutated (NOTCH1-mut,
81 cases with the c.7541-7542delCT, 6 with other NOTCH1 mutations). In 495
CLL, evaluated with a FITC-conjugated anti-CD20, variable CD20 levels were
found, with the highest levels in trisomy 12 CLL. NOTCH1-mut expressed lower
mean fluorescence intensity (MFI) values than NOTCH1 wild type (NOTCH1-
wt) cases in both trisomy 12 (20 NOTCH1-mut, 69 NOTCH1-wt; mean MFI
1,893±196 vs.7,051±819; p<0.0001) and non-trisomy 12 (40 NOTCH1-mut, 366
NOTCH1-wt; mean MFI 1,858±203 vs 2,426±112; p=0.017) CLL. Superimpos-
able results were obtained in the remaining 197 CLL, evaluated with a PE-Cy7-
anti-CD20, both in trisomy 12 (6 NOTCH1-mut, 17 NOTCH1-wt; mean MFI
12,926±3,676 vs 28,216±5,228; p=0.027) and non-trisomy 12 (21 NOTCH1-mut,
153 NOTCH1-wt; mean MFI 10,207±1,310 vs 15,208±1,578; p=0.017) CLL.
Consistently, in 275 CLL (46 NOTCH1-mut), transcript levels of MS4A1, encoding
for CD20, were lower in NOTCH1-mut than in NOTCH1-wt cases both in trisomy
12 (p=0.006) and non-trisomy 12 (p=0.019) categories. ii) By cell sorting accord-
ing to CD20 expression in 3 NOTCH1-mut CLL, CD20low sorted cells always
had a higher NOTCH1 mutational burden than CD20high cells (i.e. 32% vs 15%,
38% vs 32%, 48% vs 39%). iii) CD20 expression was up-regulated in-vitro by
gamma-secretase inhibitors (GSI). iv) In keeping with CD20 levels, NOTCH1-
mut showed lower relative lysis induced by rituximab, in complement-depen-
dent-cytotoxicity assay, than NOTCH1-wt cells (6 NOTCH1-mut, 7 NOTCH1-wt;
mean relative lysis 2.5% vs 29.4%; p=0.045). v) The stable transfection of the
mutated NICD into MEC-1 cells resulted in a strong downregulation of CD20,
and, consistently, NICD-mut cells showed lower relative lysis by rituximab
(p=0.043). vi) We investigated the interactions of RBPJ, a transcription factor
acting either as activator or repressor of NOTCH1 pathway when respectively
bound to NICD or hystone deacetylases (HDACs). Compared to controls, NICD-
mut cells had RBPJ preferentially complexed to NICD, by co-immunoprecipitation
experiments, and showed higher levels of HDACs interacting with the MS4A1
promoter, by chromatin immunoprecipitation assay. vii) In NICD-transfected cells,
treatment with the HDAC inhibitor valproic acid (48 hrs) increased MS4A1 tran-
script (NICD-mut, mean increase (MI)=1.7, p=0.001; NICD-null, MI=1.5 p=0.003)
and CD20 protein (NICD-mut, MI=1.3, p=0.041; NICD-null, MI=1.4, p=0.029)
expression. Similar results were obtained in primary CLL both for MS4A1 tran-
script (7 NOTCH1-mut, MI=1.5, p=0.05; 6 NOTCH1-wt, MI=1.8, p=0.02) and
CD20 protein (NOTCH1-mut, MI=1.3, p=0.05; NOTCH1-wt, MI=1.3, p=0.005).
Summary and Conclusions: NOTCH1-mut CLL are characterized by low
CD20 levels that may confer resistance to anti-CD20 immunotherapy. The low
CD20 expression is due to an epigenetic dysregulation that might be reverted
by GSI and/or HDAC inhibitor therapy.
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MYD88 L265P SOMATIC MUTATIONS INFLUENCE GENE EXPRESSION
AND THERAPEUTIC RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
R. Improgo1,2, B. Tesar1,2, J. Klitgaard1,2, R. Magori-Cohen3,4, L. Yu1,2,
S.M. Fernandes1, D. Chaudhary5, W. Miao5, D.L. Romero5, W.F. Westlin5,
H.T. Kim3, J.R. Brown1,2,*
1Department of Medical Oncology, Dana-Farber Cancer Institute, 2Department
of Medicine, Harvard Medical School, 3Department of Biostatistics and Com-
haematologica | 2015; 100(s1) | 221
Vienna, Austria, June 11 – 14, 2015
putational Biology, Dana-Farber Cancer Institute, 4Department of Biostatistics,
Harvard School of Public Health, Boston, 5Nimbus Discovery, Inc, Cambridge,
United States
Background: Several driver mutations have recently been identified in CLL,
including the MYD88 L265P mutation. MYD88 L265P mutations are highly
recurrent in B-cell malignancies such as Waldenstrom’s Macroglobulinemia
(>90%) and ABC-DLBCL (29%). MYD88 is an adaptor molecule in the Toll-like
receptor (TLR) and Interleukin-1 Receptor (IL-1R) pathway. Upon TLR/IL-1R
stimulation, MYD88 forms a complex with IL-1R-associated kinase 4 (IRAK4).
IRAK4 then phosphorylates IRAK1 leading to its degradation and activation of
nuclear factor kappa-B (NF-kB) signaling. 
Aims: This study aims to understand the functional consequences of MYD88
L265P mutations in CLL.
Methods: We first profiled the expression of CLL samples with known MYD88
mutation status, using Affymetrix U133 Plus 2.0 arrays. We then used CellTiter-
Glo to assess how MYD88 L265P mutations influence response to therapy.
Finally, we performed Western blot analysis and ELISA to characterize TLR/IL-
1R signaling upon drug treatment.
Results: In our cohort of 160 CLL patients, we identified 10 patients harboring
MYD88 L265P mutations (6.25%), all with mutated IGHV status. To determine
gene expression changes driven by MYD88 L265P, we compared the expres-
sion of these MYD88 L265P samples (n=10) to MYD88 wild-type CLL cells
possessing IGHV mutated status (n=76). Using Prediction Analysis for Microar-
rays (PAM), we identified 28 differentially expressed genes between the two
groups. We next examined the expression of these 28 genes across all CLLs
(n=150) in relation to clinical features. Using a penalized Cox model, we iden-
tified 4 predictive genes, CHL1, UGT2B17, BCAT1, and PDE8A with active
coefficients 0.186, 0.174, 0.158, and -0.373, respectively. The composite sig-
nature of these 4 genes is strongly associated with overall survival (p=2.6E-
09, Cox proportional hazards) and is independent of high-risk clinical features
including unmutated IGHV, 17p deletion, and 11q deletion. We next evaluated
the response of MYD88 wild-type versus L265P CLL cells to pathway inhibition.
Inhibition of the B-Cell Receptor pathway with ibrutinib led to modest dose-
dependent cell death in both wild-type and MYD88 L265P cells (n=6 per group),
with the latter exhibiting slight resistance to ibrutinib (p=0.036). We then tested
a highly selective IRAK4 kinase inhibitor, ND-2158 (Nimbus Discovery), to
inhibit the TLR/IL-1R pathway downstream of MYD88. CLL cells exhibited dose-
dependent cell death upon single agent IRAK4 inhibition, with no difference in
sensitivity between MYD88 wild-type and L265P cells. Combination treatment
with ibrutinib and ND-2158 resulted in even more marked cell death in both
MYD88 wild-type (p=0.0009 vs ibrutinib alone; p=0.007 vs ND-2158 alone)
and L265P CLLs (p=0.003 vs ibrutinib alone; p=0.04 vs ND-2158 alone). To
characterize IRAK4 inhibition in CLL cells, we investigated IRAK1 and IkBa
levels by Western blot and evaluated production of the cytokine CCL3 by
ELISA, as a measure of TLR-mediated NF-kB signaling. As expected, activation
of the TLR pathway via CpG stimulation led to a decrease in IRAK1 levels,
increased phospho-IkBa over total IkBa ratio, and increased CCL3 production.
Conversely, treatment of cells with ND-2158 inhibited these processes in a
dose-dependent manner.
Summary and Conclusions: MYD88 L265P mutations drive expression
changes that influence clinical outcome in CLL. IRAK4 inhibition in CLL perturbs
TLR signaling downstream of MYD88 leading to inhibition of the NF-kB pathway
and resulting in cancer cell death in both MYD88 wild-type and L265P CLLs.
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THE GAIN OF THE SHORT ARM OF CHROMOSOME 2 (2P) IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) RESULTS IN XPO1 OVEREXPRESSION
AND DRUG RESISTANCE
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Background: CLL is a very heterogeneous disease in terms of response to
treatment, with some patients reaching complete and prolonged remissions,
while others relapsing early and requiring several lines of treatments. This highly
variable course is partly explained by the existence of a heterogenic panel of
genetic alterations (mutations, chromosomal abnormalities) that allow the devel-
opment of drug-resistant aggressive CLL subclones. Therefore, a functional char-
acterization of the cytogenetic alterations associated to CLL drug resistance may
provide new means of improving the current therapeutic strategies. We and oth-
ers have already reported that the gain of 2p (2p+) is recurrent in CLL. However,
the candidate gained gene(s) on the 2p remain to be identified.
Previously unpublished data: We have observed that the 2p gain is frequent
in previously untreated CLL Binet stages B/C (21/132, 15.9%), and is associ-
ated with bad prognostic factors, such as 11q deletion (p=0.0008) and unmu-
tated IGHV (p=0.02). Using a SNP-array approach, we have identified a mini-
mally gained region of 1.28Mb on 2p16.1-15. This region included the gene
CRM1/XPO1 (Chromosome Region Maintenance 1/Exportin-1), a gene also
recurrently mutated in CLL. A qPCR assessment confirmed that XPO1 was
over-expressed in the CLL 2p+ patients (1.4-fold increase compared to CLL
2p-; p=0.02). 
Aims: The objective of our work was to identify the potential role of XPO1 in
CLL drug resistance by using the selective XPO1 inhibitor Selinexor (KPT-330,
provided by Karyopharm Therapeutics), which is currently in Phase II human
clinical trials in hematological and solid cancers.
Methods: We have analyzed 36 CLL 2p+ and we have searched for XPO1
mutations in 436 CLL samples. CLL drug resistance associated to XPO1 over-
expression/mutation was assessed by measuring the rate of programmed cell
death (PCD) on cells from CLL 2p- and wildtype (wt) XPO1 (n=20), CLL
2p+/XPO1wt (n=8) and on CLL XPO1mut (n=6). After 24 hours treatment with
Fludarabin+Cyclophosphamid+Rituximab (FCR), Ibrutinib, Idelalisib+Rituximab
(Ide+R) and Selinexor, cells were stained with Annexin-V and propidium iodide
and PCD was assessed by flow cytometry. KPT-301 was used has a negative
control.
Results: (i) XPO1 was found mutated in 23/436 (5.3%) CLL and in 2/30 (6.7%)
CLL 2p+; (ii) Selinexor induced PCD in CLL 2p-/XPO1wt (35% of PCD). The
results were similar in all tested CLL, independently from prognostic factors
(del13q, tri12, del11q, del17p, IGHV status), while sparing the non leukemic
cells from CLL patients or B cells from healthy donors; (iii) CLL XPO1mut were
significantly resistant to PCD induced by Selinexor (p=0.003). In contrast, the
mutations in XPO1 had no effect in FCR and Ibrutinib PCD induction; (iv) CLL
2p+ cells were resistant to PCD induced by all tested drugs: FCR (p=0.01),
Ibrutinib (p=0.003), Ide+R (p=0.004) and Selinexor (p=0.0001).
Summary and Conclusions: Our data show that CLL 2p+ is associated to
FCR, Ibrutinib and Ide+R drug resistance. Strikingly, Selinexor, a new XPO1
inhibitor, is unable to induce PCD in CLL 2p+ and/or XPO1mut, which strongly
suggests a key role for XPO1 in the CLL drug resistance associated to the
2p gain. Altogether, our work provide substantial progress in the understand-
ing of the role of XPO1 in CLL drug resistance and suggests that the assess-
ment of the 2p gain and the mutations in XPO1 will be considered before to
decide a CLL therapy. As 2p gain could be observed in other B malignancies,
it is tempting to expand these recommendations before opting for a Selinexor
treatment.
P581
A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN
CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF
CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING
EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR
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United Kingdom
Background: Somatic mutations in multiple genes have been associated with
adverse outcome in CLL. However, the causes and interrelationships of such
mutations remain unclear.
Aims: To deepen our understanding of the causes and interrelations of the
somatic mutations throughout the disease course.
Methods: We analysed CLL samples obtained from 32 patients immediately
before (n=10) or after chemotherapy (n=22) for exon mutations in 15 genes
(TP53, ATM, NOTCH1, SF3B1, BIRC3, LRP1B, SAMHD1, FBXW7, PCLO,
HIST1H1E, XPO1, CHD2, MYD88, POT1 and ZFPM2) using HaloPlex enrich-
ment and Ion Torrent PGM (average depth:2200x, limit of detection:1%).
Results: With SNPs excluded, a total of 60 somatic non-synonymous SNVs
&11 indels (VAF:2-98%) from the first 12 genes were identified in 26 of the
32 samples. The most common mutated genes were SF3B1, ATM, TP53,
and PCLO found in 11, 10, 9 and 8 cases, respectively. ATM and TP53 muta-
tions did not co-exist in any sample, while most of the SF3B1 (9/11), PCLO
(5/8) and other (11/13) gene mutations were found in samples with mutations
in either TP53 or ATM. Moreover, both of TP53 and ATM appeared to be the
dominant mutant genes in 18 samples, being either the only mutation (in 5
samples) or the one with the highest level of mutant and/or deleted alleles
(in 13 multi-gene mutated samples). Strikingly, all but 2 of the 22 samples
(91%) from treated patients showed mutations in at least 1 gene compared
with only 60% (3/5) in the untreated group (P=0.08). Furthermore, among 15
samples bearing mutations in multiple (2-4) genes, 14 (93%) were from
patients who had received chemotherapy, compared with only 1 (7%) in the
untreated group (P=0.009). In a longitudinal study, 27 sequential samples
before (n=20) or post (n=7) treatment from 22 cases who had somatic muta-
tions already detected were used to study evolution of these mutant clones
using the same deep sequencing approach. Including those initially studied,
data from a total of 2-3 sequential samples with an average interval of 29
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months of each of these 22 cases were compared. Results showed that most
(92%) of mutations detected at time of disease progression/drug-resistance
existed in samples taken at early stages. But a mutation in ATM, FBXW7,
LRP1B and SF3B1 in 5 cases emerged only during disease progression or
development of drug resistance. Interestingly, except the one in SF3B1, all
other 4 mutations appeared following the expansion of pre-existed either TP53
or ATM mutation. A clear trend of expansion of the mutated subclones was
found in majority (94%) of cases. TP53 and ATM were still the most common
mutated genes before disease progression or treatment. They were dominant
over other mutated genes coexisting in the same clones during clonal evolu-
tion. Competition for expansion between subclones bearing mutations in dif-
ferent genes or different mutations in same genes was documented in some
cases, suggesting a convergent clonal evolution.
Summary and Conclusions: The observed association between prior treat-
ment and somatic mutations is consistent with the idea that DNA-damaging
chemotherapy can be mutagenic in vivo. Furthermore, the high frequency of
mutations in TP53 and ATM, their association with other mutations and their
dominance over these other mutations during the course of CLL progression
suggests the existence of a “snowballing effect” in which defective DNA repair
due to loss of ATM/p53 function facilitates the acquisition of additional muta-
tions. In addition, this study provided evidence supporting that convergent




TP53 MUTATIONS ARE EARLY EVENTS IN CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) DISEASE PROGRESSION AND PRECEDE CLONAL
EVOLUTION TO COMPLEX KARYOTYPES
F. Baran-Marszak1,2,* G. Lazarian1, E. Tausch3, A. Sebaa1, V. Bianchi1,
V. Eclache1, R. Letestu1, S. Stilgenbauer3, F. Cymbalista1
1Hematologie biologique, Hopital Avicenne APHP, 2INSERM U978, Université
Paris 13, Bobigny, France, 3Hematology, Universitätsklinikum, Ulm, Germany
Background: TP53 abnormalities lead to resistance to purine analogues and
are found in over 40% patients with refractory CLL. At diagnosis, no more than
5% of CLL carry 17p deletion and most cases harbour mutations within the
other TP53 allele. Incidence of TP53 mutations as sole alteration is also
approximately 5%, but dependent on the sensitivity of the technique. Complex
karyotype (more than 2 abnormalities) has recently been considered as a
stronger adverse prognostic factor than presence of TP53 alteration. However,
there are no longitudinal studies examining simultaneously the presence of
17p deletion, TP53 mutations and karyotype abnormalities in the same
patients.
Aims: Assess the sequence of events of clonal evolution through the longitu-
dinal study of a cohort of high risk patients. Determine the impact of minor
TP53 mutated clones by NGS in a routine setting.
Methods: We conducted a retrospective longitudinal study of 33 high risk CLL
(defined by either TP53 alteration at baseline or relapsed/refractory disease).
Del17p was detected by FISH and TP53 mutations by Sanger sequencing of
exons 4 to 9 as well as by NGS (Ion Torrent and Illumina). Two to five samples
per patient over 4.9 years (1.7-10.7 years) were studied. An excellent corre-
lation between Illumina and Ion Torrent technologies was obtained.
Results: A TP53 abnormality was found in 55% (17/33) of the patients at any
time point of progression. At diagnosis, only 7/17 patients carried a del17p
among which 5 harboured a TP53 mutation on the other allele. In 3 additional
cases, TP53 mutation was detected as sole alteration. The use of NGS tech-
nology allowed the detection of a minor TP53 mutated clone (3.5% to 20%
allele frequency) in 4 additional cases. At diagnosis, only 4/17 cases had a
complex karyotype, and all of them had a TP53 mutation. During progression,
clonal evolution was found in 11 patients: i) 17p deletion was detected at a
later time point in 7 patients, 5 of which had a previous TP53 mutation, ii) A
novel TP53 mutation was detected in 3 cases and an additional subclonal
TP53 mutation in 4 patients iii) in 8 patients with non-complex karyotype at
diagnosis, a complex karyotype was found during progression. All of them had
a TP53 mutation preceding the evolution to a complex karyotype. In this group
of TP53 mutated cases, 12/17 cases harboured a complex karyotype at some
point, as compared to only 4/15 cases in the group without TP53 alteration
(among these 2 had del11q)(p=0,01). Regarding treatment, two patients
showed clonal evolution while untreated. In 4/6 patients, we observed an
expansion of the TP53 mutated clone after fludarabine-based regimen. Inter-
estingly, in all 4 patients receiving ibrutinib, the allelic burden of TP53 mutation
remained the same after 1 year.
Summary and Conclusions: Presence of TP53 mutation identifies patients
with genomic instability. Small mutated clones are present at an early stage
of the disease and precede other signs of clonal evolution, most importantly
the development of a complex karyotype. 17p deletion is either a later event,
or detected later because of a lower sensitivity of the FISH technique. Complex
karyotype occurs as clonal evolution event in patients with preexisting TP53
mutated (sub)clones, and therefore in itself may not be associated with poor
prognosis when TP53 can be assessed by a sensitive technique such as NGS.
NGS allows early detection of TP53 mutated clones, and is achievable on a
routine basis with a dedicated sequencing assay. We strongly recommend
early and iterated detection of TP53 mutations in CLL progressive cases.
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EXPRESSION OF DNA HYDROXYMETHYLATION-RELATED GENES IS
ASSOCIATED WITH PROGNOSIS IN CHRONIC LYMPHOCYTIC
LEUKEMIA
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L. Lagneaux1, B. Stamatopoulos1
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Background: Epigenetics plays a crucial role in cancer physiopathology. DNA
hydroxymethylation is catalyzed from methylated DNA by Ten Eleven Translo-
cation (TET) enzymes requiring co-factors produced by Isocitrate Dehydroge-
nase (IDH) proteins. This modification could be a step in the demethylation
process and could thus have an impact on gene expression. TET2 mutations
have already been reported in several leukemias. However, little is known
about hydroxymethylation in B-chronic lymphocytic leukemia (CLL).
Aims: We intend to characterize the mRNA expression of enzymes (TET1, 2,
3, IDH1 and 2) involved in DNA hydroxymethylation in purified B cells obtained
from CLL patients.
Methods: Expression of TET1, 2, 3, IDH1 and 2 mRNA was assessed by
qPCR on purified leukemic B-cells from a cohort of 214 CLL patients with a
median follow-up of 75 (6-380) months and compared with those of purified
peripheral normal B-cells. The influence of CLL microenvironment on TET
enzyme expression, was investigated by culture of CLL cells (n=10) in the
presence or absence of bone marrow mesenchymal stromal cells (BMSC).
Results: TET1, 3 and IDH2 are underexpressed in leukemic B-cells compared
with healthy volunteers B-cells (P=0.0221, 0.0013, <0.0001 respectively) while
IDH1 is overexpressed (P=0.0037). Expression of TET2 is similar in both
groups. When we stratified patients according to low and high expression,
TET2 and IDH1 significantly predict treatment-free survival (TFS): patients
with high TET2/IDH expression had a median TFS of 110 months while patients
with low expression presented a median TFS of 78 months (P=0.0071/0.0123).
Finally, we observed a decreased TET1 expression (P=0.0371) and an
increased TET3 (P=0.0273) and IDH2 expression (P=0.0039) in CLL-cells
after co-culture with BMSC. Further analysis in 14 CLL patients shows that
ZAP70+ patients present higher hydroxymethylated DNA than ZAP70-
patients.
Summary and Conclusions: This is the first report that DNA hydroxymethy-
lation enzymes are deregulated in B-CLL compared to normal B cells: 1) TET2
and IDH1 overexpression have a good prognostic value; 2) TET1, TET3 and
IDH2 expression is modulated by microenvironment interactions, resulting in
CLL cells survival. Our observations suggest that DNA hydroxymethylation
plays a major role in CLL physiopathology and support the potential therapeutic
benefit of agents targeting epigenetics in CLL patients.
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SF3B1 MUTATIONS AND ALTERATIONS OF FOXP1 TRANSCRIPTION IN
CHRONIC LYMPHOCYTIC LEUKAEMIA
H. Roudot1,2,* F. Baran-Marszak1,2, V. Eclache1, J.-F. Collon1, V. Lévy3,
N. Varin-Blank2, F. Cymbalista1,2, R. Letestu1,2
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Paris 13, 3Hématologie, Hôpital Avicenne AP-HP, Bobigny, France
Background: Spliceosome mutations have been described in various myeloid
and lymphoid malignancies. In chronic lymphocytic leukaemia (CLL), SF3B1
is mutated in a variable proportion of cases, depending on the studies, ranging
approximately from 5 to 20% and the presence of these mutations correlates
with an adverse prognosis. Recently, a modification in the species of FOXP1
transcripts, consisting in the appearance of a truncated variant, has been
described in 3 patients with SF3B1 K700E or N626Ymutation (Quesada Nat
Genet 2012).
Aims: In this work, we aimed to study the transcription profile of FOXP1 in a
series of CLL patients, and in control samples. In a second step we investi-
gated a validation cohort, and studied the sensitivity of the technique.
Methods: Peripheral blood mononuclear cells (PBMC) were obtained from
10 normal subjects and 60 patients with CLL after informed consent. The
expression of the FOXP1 truncated and the full length transcripts was studied
by real-time quantitative PCR. SF3B1 mutations were detected by Sanger
sequencing of the exons 14, 15, and 16.
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Results: We selected 32 patients with at least one adverse prognostic factor
(unmutated IGHV, CD38 +, ZAP-70 +), explored SF3B1 by Sanger sequencing
and found 4 mutated cases. Then we studied FOXP1 transcription profile in
10 control samples, the 4 SF3B1 mutated samples and 6 additional CLL sam-
ples with wild type SF3B1. The FOXP1 truncated transcript was found at a
very low level of expression in the control samples contrasting with the high
level measured in the SF3B1 mutated samples, finally the expression of
FOXP1 truncated variant in unmutated samples was similar to that observed
in controls. In a validation cohort, including 28 patients with the same selection
criteria and/or the presence of 11q deletion, we performed the FOXP1 study
and SF3B1 sequencing. We found an overexpression of the FOXP1 truncated
transcript in 8 patients. SF3B1 mutations were identified in 7 of these patients
whereas no mutation was detected in samples with low FOXP1 truncated vari-
ant expression. Most of the cases with SF3B1 mutations and overexpression
of the FOXP1 truncated variant presented an 11q deletion, however the major-
ity of the samples tested with 11q deletion were not SF3B1 mutated. Overall,
in the 11 mutated samples, we identified five different mutations of SF3B1 (3
Y623C, 1 R625H, 3 K700E, 1 G740V and 3 G742D). Finally, using dilutions
of mutated sample in unmutated sample, we evaluated the sensitivity of the
test at approximately 5%.
Summary and Conclusions: In this study, we investigated a cohort of
patients and controls to evaluate the impact of various SF3B1 mutations on
the splicing of FOXP1 transcripts. A high expression of the FOXP1 truncated
variant was observed in any case with SF3B1 mutation. Therefore, FOXP1
transcription profile could become an alternative tool to identify functionally
relevant mutations in the SF3B1 gene. Moreover, we described 4 additional
mutations of SF3B1 (affecting the 3 exons tested) that impact FOXP1 splicing.
Finally, it is of major interest to explore the FOXP1 transcription variants
regarding their functions and their involvement in the mechanisms leading to
CLL progression.
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ADDITIONAL TRISOMIES AMONGST PATIENTS WITH CHRONIC LYM-
PHOCYTIC LEUKEMIA CARRYING TRISOMY 12: THE PARTNER CHRO-
MOSOME MAKES A DIFFERENCE
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Background: Trisomy 12 (+12), the second most frequent recurrent chromo-
somal aberration in chronic lymphocytic leukemia (CLL), is associated with
clinical and biological heterogeneity. We and others previously reported a
minor fraction of +12 cases with co-existence of trisomy 19 displaying distinc-
tive clinicobiological characteristics. However the respective cohorts were
small, precluding definitive conclusions.
Aims: Detailed characterization of cases with multiple trisomies in a large
series of CLL patients carrying +12, aiming to identify distinctive profiles that
would assist in further dissecting the heterogeneity of this major cytogenetic
subgroup.
Methods: Within a multi-institutional series of 4486 CLL patients with available
classic cytogenetic data, we identified 713 cases (16%) with trisomy 12, of
whom 87 (12%) harbored multiple trisomies. Sixty-eight of these 87 cases
(78%) had co-existing +19 (group A: +12,+19 CLL), while the remaining 19/87
cases (22%) had other co-existing extra chromosome(s) (group B: +12,+other
trisomy CLL). The median time from diagnosis to karyotype analysis was 1.5
months (range, 0-194); the great majority of cases with available
treatment/survival information were untreated prior to testing (73/78 cases,
94%). FISH data for the Döhner model aberrations was available in 67/87
(77%) cases. Within the same CLL series, we identified 68 cases with isolated
+12 and available clinicobiological data, which were used as a control group
for the survival analysis (group C).
Results: In group A, 43/68 (63%) cases also harbored +18. Extra structural
abnormalities were detected in 12/63 (18%) cases, mostly concerning dele-
tions and/or translocations involving the 13q chromosome in 7/12 (58%) cases.
Interestingly, the great majority of cases harboring extra structural abnormal-
ities (10/12, 83%) displayed +12+18+19 highlighting an association between
+18 and clonal evolution. In contrast, no structural abnormalities were
observed in group B, within which trisomy 3 predominated, being detected in
8/19 (42%) cases, followed by trisomies 18 and 22 in 6 (32%) and 4 (21%)
cases respectively Moreover, different clinicobiological profiles were observed
between the two groups. In particular, group A displayed (i) higher incidence
of M-CLL (42/45, 95% vs 6/8, 75%, p=0.045); (ii) younger median age at diag-
nosis (59 years vs 67 years, p=0.007); (iii) ubiquitous surface IgG expression
(23/23, 100% vs 2/8, 25%, p<0.0001); (iv) higher incidence of del(13q) (27/51,
53% vs 0/11, 0%, p=0.0002); and (v) higher incidence of monoclonal gam-
mopathy (23/37, 62% vs 2/8, 25%, p=0.05). Group B displayed higher inci-
dence of: (i) clinical/laboratory autoimmunity (5/10, 50% vs 2/33, 6% in group
A, p=0.0009); and (ii) other malignancies (6/11, 55% vs 4/48, 8% in group A,
p=0.0002). Furthermore, each group displayed significant differences (p<0.05)
when compared to control group C regarding the aforementioned features.
Regarding survival analysis, Groups A and B exhibited longer overall survival
compared to Group C (median OS: not reached for Groups A and B vs 8 years
in Group C; log-rank test, group A vs C, p=0.08, and group B vs C, p=0.036). 
Summary and Conclusions: The presence of extra trisomies defines sub-
groups of cases with distinctive clinicobiological profiles within +12 CLL cases,
further highlighting their heterogeneous biological background and clinical
outcome.
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MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPER-
MUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV
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Background: Introducing somatic hypermutations (SHM) into genes coding
for heavy and light chains of immunoglobulins (IGHV, IGLV) is a physiological
process indispensable during antibody maturation. SHM introduction is a two-
step process, which in the first step involves deamination of cytosine to uracil
by an enzyme Activation-Induced (Cytidine) Deaminase (AID). During the sec-
ond step, uracil and potentially also flanking nucleotides are removed and
error-prone DNA polymerases (mainly polymerase eta) are recruited to fill the
gap. Off-targeting of AID may result in mutations in non-immunoglobulin
genes, including tumor suppressor gene TP53. 
Aims: We explored the TP53 mutation patterns with regards to SHM features
emphasizing the differences between mutations occurring in IGHV unmutated
(U-CLL) and IGHV mutated (M-CLL) groups of patients.
Methods: In order to reduce the selection bias, we used the set of TP53 muta-
tions detected using ultra-deep Next Generation Sequencing (NGS) with high
sensitivity (0.2%) allowing to consider the minor subclonal mutations with less
prominent selective advantage. For NGS analysis, Illumina Miseq platform
has been used with average coverage 34788; (range 1674-177021). For vari-
ant detection, an in house bioinformatics pipeline was established. Statistical
evaluation was performed by shearwater algorithm computing Bayes classi-
fiers based on a betabinomial model. Only point substitutions were taken into
account. Altogether, 464 TP53 mutations in 73 high risk CLL patients were
analyzed. 121 mutations were found in M-CLL cases and 343 mutations were
detected in U-CLL patients. The high number of mutations should be attributed
to the high number of minor subclonal mutations detected mainly in patients
in relapse after treatment. In 60% of patients, results from repeated examina-
tions were included (2-4 examinations per patient; each mutation detected in
more than one consecutive sample was considered only once). 72.6% of
patients received treatment before the first or during consecutive analyses. 
Results: U-CLL showed a higher proportion of mutations in C:G pairs com-
paring to M-CLL (66% vs 51% of all mutations; P=0.003). Out of these,
G:C>A:T substitutions, the primary result of AID cytidine deamination, were
the prevalent events observed in U-CLL but not M-CLL (59.6% vs 40.3% of
all C:G mutations; P=0.009). Focusing on the AID-targeted sequence motif
RGYW/WRCY, no difference between the two subgroups was observed (2.5%
vs 3.1%; P=ns). However, we found a significant overrepresentation of muta-
tions in GNW motif in U-CLL (14.58% of all mutations vs 6.61% in M-CLL;
P=0.025). GNW is a strand-biased motif derived from RGYW most frequently
targeted by AID in IGLV genes. On the other hand, TP53 mutations detected
in M-CLL cases showed the features of targeting by polymerase eta: (i) fre-
quent targeting of A:T pairs (49% vs 34% in U-CLL; P=0.003); with prominent
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strand bias favoring A over T (13.8 fold vs 3.1 fold in U-CLL; P=0.002; (ii)
prevalence of mutations in WA/TW motifs (40.5% vs 23.91% in U-CLL;
P<0.0001) with strand bias favoring WA observed in both groups, but extremely
prominent in M-CLL (23.5 fold in M-CLL vs 4.37 fold in U-CLL; P=0.014).
Summary and Conclusions: We documented the significantly different pat-
terns of TP53 mutations in U-CLL vs M-CLL. Mutations detected in U-CLL
showed the features corresponding to the first step of SHM process: deami-
nation by AID with strand bias possibly attributable to AID activity on the tran-
scribed strand. In contrast, spectra of mutations detected in M-CLL cases sug-
gested the more prominent involvement of polymerase eta during the second
SHM step. Supported by CZ.1.07/2.3.00/30.0009, CZ.1.05/1.1.00/02.0068,
NT13519, NT13493, NT11218, MUNI/A/1180/2014, NGS-PTL/2012-
2015/no.306242, MSMT-CR (2013-2015, no.7E13008)
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Background: Idelalisib (Zydelig), a first-in-class, selective, oral inhibitor of PI3Kδ,
is approved in the US and EU for the treatment of chronic lymphocytic leukemia
(CLL) in combination with rituximab and as monotherapy for patients with follicular
lymphoma who have received at least two prior systemic therapies.
Aims: To further characterize the safety profile of idelalisib, we integrated
adverse event data from 8 clinical trials.
Methods: The analysis included 760 subjects with CLL, indolent non-Hodgkin
lymphoma, or other B-cell malignancy who received IDELA alone (doses=50
mg BID to 350 mg BID) or as part of a combination regimen (IDELA doses=100
or 150 mg BID). Most subjects were heavily pre-treated with relapsed disease.
Results: Common adverse events (AEs) are presented in the Table 1, along
with important laboratory results. AEs leading to dose modification included
transaminase elevations (13%), diarrhea/colitis (11%), and rash (5%); discon-
tinuations due to these AEs were infrequent (3%, 5%, and 2%, respectively);
dose interruption allowed successful re-challenge in most patients. Pneumonitis
occurred in 2.3% (monotherapy) and 3.9% (combo therapy) of subjects. Grade
≥3 diarrhea/colitis had a later onset (peak incidence of 9% between 6-12 mo.);
other AEs occurred most often in the first 6 months and declined thereafter.
Table 1.
Summary and Conclusions: As well-characterized in this large dataset, IDELA
has an acceptable safety profile.
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Background: BI 836826 is a novel Fc-engineered IgG1 type II antibody tar-
geting CD37, a tetraspanin predominantly expressed on normal and malignant
B-cells, with a dual cytotoxic mode of action by directly inducing apoptosis and
increasing antibody-dependent cellular-cytotoxicity. Ex vivo, BI 836826 treat-
ment results in a significantly greater depletion of CLL cells than rituximab,
irrespective of genetic risk. We report preliminary results of an ongoing Phase
I, first-in-human, dose-escalation study of BI 836826 in pts with R/R CLL
(NCT01296932; 1270.1).
Aims: To investigate the maximum tolerated dose (MTD), safety, pharmacoki-
netics, and efficacy of BI 836826 monotherapy in pts with R/R CLL.
Methods: Pts with R/R CLL after ≥2 prior therapy lines were eligible if they
had adequate organ function, neutrophils ≥1000/µL and platelets ≥25000/µL.
Increasing doses of intravenous (IV) BI 836826 (1-400 mg) were administered
as a rate-controlled IV infusion in a modified 3+3 design. In Course 1, 10% of
the total BI 836826 dose (not exceeding 10 mg) was administered on day 1
with the total dose remaining administered on day 2 of a 14-day course. In
subsequent courses, BI 836826 was administered on day 1. The MTD will be
determined based on dose-limiting toxicity (DLT; defined as any drug-related
non-hematologic adverse event [AE] ≥grade 3, except infusion-related reac-
tions [IRRs]) observed during the first treatment course. All pts provided written
informed consent.
Results: To date, 33 pts (mean age 66.2 yrs; 70% male) have been treated
with BI 836826 (1 mg [n=3], 3 mg [n=3], 9 mg [n=6], 25 mg [n=6], 50 mg [n=3],
100 mg [n=3], 200 mg [n=6], 400 mg [n=3]). Dose escalation is ongoing. At
screening, 12 pts (36.4%) were Binet stage C or Rai III/IV. Pts had received a
median of 4 (range 2-10) prior therapy lines. Molecular genetics at baseline
were del(17p) and/or TP53 mutation in 63.6%, and del(11q) in 29.0%; 72.7%
had unmutated IGHV. Four treatment courses were planned, 18 pts (54.5%)
completed 8 courses. Five pts (15.2%) stayed on therapy beyond 8 courses
due to sustained clinical benefit. One pt in the 200 mg cohort had a DLT of
grade 3 hypophosphatemia. Dose escalation is ongoing and the MTD has not
yet been determined. The most frequent AEs were IRRs (66.7%), chills (60.6%),
pyrexia (51.5%), anemia (42.4%), thrombocytopenia (42.4%), neutropenia
(39.4%), diarrhea (36.4%), and nausea (33.3%). Drug-related AEs included
IRRs (66.7%), chills (57.6%), pyrexia (48.5%), neutropenia (36.4%), and throm-
bocytopenia (27.3%). Serious AEs included pyrexia (9.1%), neutropenia,
leukopenia, cardiac failure, and IRRs (all 6.1%). PK exposure increased with
increasing doses and short half-lives were observed. Of 26 evaluable pts (i.e.,
received full intended dose) at ≥9 mg doses, the overall response rate based
on investigator assessment was 42.3% (all partial remission); 14 pts (53.8%)
had stable disease. Of 23 pts with elevated baseline counts at ≥9 mg doses,
a ≥50% lymphocyte reduction was observed in 78.3% and a reduction to
<4000/µL was observed in 52.2%, including pts with high-risk genetic features.
Summary and Conclusions: Promising responses have been observed with
BI 836826, even at low doses. The safety profile was acceptable with AEs pre-
dominantly IRRs and cytopenias which were manageable with routine sup-
portive care.
These data support further clinical evaluation of BI 836826 as a single agent
and in combination.
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Background: POT1 mutations in CLL have been reported to be functionally
relevant by a dominant negative effect, leading to uncapping of the telomeric
ends, thereby enabling telomerase to aberrantly elongate the telomeres, caus-
ing fusion events and chromosomal aberrations. However, their impact on
telomere length and outcome has not been established in a clinical trial cohort.
Aims: To study the impact of POT1 mutations on telomere length and disease
outcome in a clinical trial cohort.
Methods: We assessed telomere length associations with disease character-
istics, especially with that of POT1 mutations in the Complement 1
(OMB110911) trial (1st line chlorambucil (Chl) vs ofatumumab-Chl (O-Chl)) in
patients considered inappropriate for fludarabine-based therapy. Telomere
length was analysed using quantitative PCR from baseline samples of 368
patients (82.3%) with available DNA and this cohort was representative of the
full trial population with regard to baseline characteristics. Validation of the
technique was done using terminal restriction fragment length analysis (TRF)
(R2=0.859, P<0.001) in an independent control sample set (n=18) and 6 of
these samples were included in every batch as controls.
Results: Analysis of telomere length associations was performed by
dichotomizing the cohort based on the median telomere length (4.53kb). No
significant association of telomere length was found with the clinical charac-
teristics age, sex, Binet stage and ECOG status while short telomeres were
significantly associated with high WBC count (P<0.001), high β2-MG (P<0.001),
and high CIRS score (P<0.01). As previously reported in a similar trial (CLL8,
Jebaraj et al., ASH 2013), short telomeres were significantly associated with
other adverse prognostic factors namely, unmutated IGHV (P<0.001), 17p-
(P<0.04) and 11q- (P<0.001). Also gene mutations in NOTCH1 (P<0.001),
SF3B1 (P<0.02), TP53 (P<0.02), ATM (P<0.001) and BIRC3 (P<0.01) were all
significantly associated with short telomeres. POT1 mutations were found in
7.6% (n=28 of 368 cases) cases in Complement1 and the mutations were pre-
dicted to be dominant negative in function. POT1 mutations were not signifi-
cantly associated with any of the clinical characteristics or genomic aberrations.
Interestingly, there was also no significant association of telomere length with
POT1 mutations (4.76 kb vs 5.34 kb, P=0.68). At a median follow-up of 31.7
months, there were 245 (67%) events for progression free survival (PFS) and
60 (16.3%) events for overall survival (OS). Incidence of POT1 mutations (Chl:
n=16, O-Chl: n=12, P=0.70) and short telomeres (Chl: n=95, O-Chl: n=89,
P=0.83) were balanced in both treatment arms. Analysis of the impact of POT1
mutations showed no significant association with remission rate, PFS and OS.
In contrast, short telomeres were found to be significantly associated with
reduced overall response (72.0% vs 87.6%, P<0.001), shorter PFS (HR=1.98,
P<0.001, Figure 1) and OS (HR=1.88, P=0.02). To evaluate their independent
prognostic impact, we performed multivariable analysis by Cox regression
including as variables the treatment arms, 11q-, +12q, 17p-, mutation status of
IGHV, TP53, NOTCH1, SF3B1, BIRC3, MYD88, ATM, FBXW7, POT1 and
telomere length. For PFS, O-Chl (HR 0.43, P<0.001), 17p- (HR 3.01, P=0.001),
NOTCH1 (HR 1.45, P=0.04), TP53 (HR 1.78, P=0.04 and telomere length (HR
1.71, P=0.001) were identified as independent factors, while for OS, only 17p-
had an adverse prognostic impact (HR 3.90, P<0.01).
Figure 1. Progression free survival.
Summary and Conclusions: In the Complement1 trial short telomeres were
found to be significantly associated with various adverse clinical and biological
prognostic disease characteristics and poor outcome, including PFS and OS,
but had no association with POT1 mutations. There was no association
between POT1 mutations and clinical outcome.
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PREVALENCE AND CHARACTERISTICS OF CENTRAL NERVOUS SYS-
TEM (CNS) INVOLVEMENT BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
P. Strati1,* J.H. Uhm1, C.A. Hanson1, K.G. Chaffee1, S.J. Achenbach1, T.G. Call1,
T.D. Shanafelt1
1Mayo Clinic, ROCHESTER, United States
Background: Clinically significant “extramedullary” involvement by CLL is rare,
with only 192 cases reported in literature between 1975 and 2012. Although
the CNS has been the most commonly reported site, either as CLL or Richter
Transformation (RT), the available information is derived exclusively from case
reports of individual patients.
Aims: To determine the prevalence and characteristics of CNS involvement
in CLL.
Methods: We used the Mayo Clinic CLL database to identify all patients with
CLL/small lymphocytic lymphoma (SLL) who were followed at our center
between 07/1997 and 11/2014 and who underwent an MRI of the head or of
the spine because of neurological symptoms.
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Results: Of 4317 patients with CLL followed at Mayo between 07/1997 and
11/2014, 1115 (26%) had an MRI of the head or spine to evaluate neurologic
symptoms. Of these, 47 (1%) had radiological findings indicative of CNS involve-
ment by a lymphoproliferative neoplasm (21 leptomeningeal involvement, 26
parenchymal brain involvement). Of these 47 patients, 24 underwent concomitant
lumbar puncture (LP) and tissue biopsy, 5 tissue biopsy only, 13 LP only, and 5
had no tissue obtained. Tissue biopsy revealed CLL infiltration in 11 cases, infil-
tration by RT in 9 cases (diffuse large B-cell lymphoma [DLBCL] in 8 cases,
peripheral T-cell lymphoma in 1 case), other etiologies in 6 cases (2 progressive
multifocal leukoencephalopathy, 2 vasculitis, 3 primary brain tumors), and normal
brain tissue in 2 cases. Of the 13 patients with MRI abnormalities who underwent
a LP only, 4 demonstrated clinically significant CLL involvement. Collectively, 24
(0.5%) of 4317 CLL patients cared for at our center over a 17 year interval devel-
oped clinically significant CNS involvement by CLL or RT. 
Summary and Conclusions: Although neurologic symptoms are frequent in
patients with CLL/SLL and prompt diagnostic MRI imaging in up to 26% of
CLL cases, radiographic findings suggestive of CNS involvement by CLL or
RT are rare (about 1% of patients). Tissue confirmation with brain biopsy is
necessary to confirm the diagnosis of lymphoproliferative neoplasm and the
subtype (CLL vs DLBCL) in such cases. Clinically significant CNS involvement
by CLL or RT is a relatively rare event, observed in 0.5% of CLL patients (~1
of every 200 patients). 
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MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE
MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC
LEUKEMIA PATIENTS (CLL FITNESS STUDY)
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Background: While fludarabine+cyclophosphamide+rituximab (FCR) has
shown a survival advantage in CLL, it cannot be considered the standard of
care for all patients, due to prolonged cytopenias and increased susceptibility
to infections in particular among the elderly. For these reasons, FCR is the
treatment of choice for young fit patients with CLL, while recent studies have
demonstrated that elderly patients with comorbidities may benefit from chlo-
rambucil, in association with anti-CD20 antibodies. How these findings translate
into everyday care is still to be defined and several factors have been proposed,
but none validated, in helping physicians make better decisions.
Aims: We designed an investigator-driven, multicenter, observational, retro-
spective study based on the review of medical records. The study aimed at
defining the most relevant parameters when choosing the first-line treatment in
clinical practice and how these parameters associate with treatment tolerance.
Methods: The target population included patients with CLL, requiring first-line
treatment at participating centers between Jan 1, 2009 and Dec 31, 2010. Infor-
mation on global health status, disease parameters, treatment and follow-up
was collected.
Results: Four hundred and forty eight patients from 37 Italian sites were eval-
uated. Eight participating centers treated ≥10 CLL patients per year in the front
line setting, 12 centers 5-10 and 14 centers <5. The median age was 66 years,
with a male:female ratio of 1.5:1. The most frequent treatment choices -FCR
(195) and alkylating agent (AA) as monotherapy (79 patients)- were further
analysed. FCR- and AA-treated patients were significantly different in terms of
baseline features and, not surprisingly, FCR-treated patients showed younger
age, less comorbidities and better ECOG performance status. Investigators
reported age as the most relevant parameter in selecting treatment, followed
by ECOG PS, comorbidities (based on clinical evaluation) and disease burden.
Seventy one percent of FCR-treated patients received the planned number of
cycles, but 53% required dose reduction or delay. At multivariate analysis, age
was the only factor able to predict tolerance to FCR (p=0.032), with CIRS index
showing a trend to significance (p=0.058). In 70% of cases discontinuations
and reductions of FCR were related to toxicities. The most frequent AEs includ-
ed neutropenia (36%), general (17%) and gastrointestinal disorders (14%),
infections (11%), thrombocytopenia (8%) and anemia (5%). More than 90% of
physicians who chose FCR, after evaluating response and tolerance, would
choose again the same first-line therapy.
Summary and Conclusions: Our data suggest that age, together with the
comorbidity burden, is widely used for the treatment choice in both FCR and
AA-treated patients, remains the best predictor of tolerance to therapy and
accurately guides first-line treatment in CLL patients. In the AA-group functional
and mental status have also some relevance, while the biologic profile was
less significant. The use of FCR was associated with a lower frequency and
grade of infections than reported, reasonably due to a higher awareness of the
potential toxicity among hematologists. A broader use of infectious prophylaxis
as well as a younger median age of the patients receiving FCR in our study as
compared to CLL8 most likely accounts for the lower incidence of hematologic
toxicities recorded. In the general practice, the use of FCR is becoming safer
likely due to an improved a priori selection of the target population and a better
management of the side effects.
P593
EFFICACY OF PHOSPHATIDYLINOSITOL-3 KINASE INHIBITORS WITH
DIVERSE ISOFORM SELECTIVITY PROFILES FOR INHIBITING THE SUR-
VIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
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Background: Pharmacological inhibition of phosphatiylinositide-3-kinase
(PI3K)-mediated signaling holds great promise for treating chronic lymphocytic
leukemia (CLL). PI3K inhibitors exhibit various degrees of isoform specificity,
which influences their effectiveness on CLL cells. Specifically targeting the
p110-δ isoform, which dominates B cell receptor signaling and is preferentially
expressed in CLL cells is an attractive treatment option.
Aims: Three structurally related PI3K inhibitors were investigated that target
the PI3K-δ isoform for their ability to inhibit the survival of CLL cells in vitro.
The purely PI3K-δ-selective inhibitor idelalisib was compared to copanlisib (BAY
80-6946) and duvelisib (IPI-145), with isoform target profiles that additionally
include PI3K-α or PI3K-γ, respectively. In addition, the direct cell killing capacity
of PI3K inhibitors in combination with CD20 antibodies was assessed as well
as interference with antibody-dependent cell mediated cytotoxicity.
Methods: Freshly isolated B lymphocytes and PBMC’s from CLL patients as
well as CLL-derived JVM-3 cells were treated in vitro for 48 hours with copan-
lisib, duvelisib and idelalisib. Annexin/7-ADD negative cells were subsequently
determined by flow cytometry. In addition, migration of primary CLL cells
towards SDF-1 upon inhibitor treatment was determined as an index of migrated
cells in a two-chamber based assay. Survival-inhibition of inhibitor-treated CLL
cells in coculture with bone marrow stromal cell line HS-5 was also determined
by flow cytometry.as well as combination treatments with CD20 antibodies.
Interference of ADCC through inhibitors was assessed by measuring LDH
release after 4 hour co-cultivation of JVM-3 cells as target and healthy donor
PBMC’s as effector cells.
Results: The concentrations leading to halfmaximal reduction of the survival
of CLL cells were more than ten-fold lower for copanlisib than for idelalisib and
duvelisib. At concentrations reflecting the biological availability of the different
inhibitors, high levels of apoptotic response among CLL samples were attained
more consistently with copanlisib than with idelalisib. Copanlisib selectively
reduced the survival of CLL cells compared to T cells and to B cells from healthy
donors. In addition copanlisib and duvelisib impaired the migration of CLL cells
towards CXCL12 to a greater extent than equimolar idelalisib. Similarly copan-
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lisib and duvelisib reduced the survival of CLL cells in co-cultures with HS-5
cells more strongly than idelalisib. Survival inhibition by copanlisib and idelalisib
was enhanced by the monoclonal CD20 antibodies rituximab and obinutuzum-
ab (GA101), while antibody-dependent cellular cytotoxicity mediated by alem-
tuzumab and peripheral blood mononuclear cells was not substantially impaired
by both PI3K inhibitors for the CLL-derived JVM-3 cell line as target cells.
Summary and Conclusions: Among the investigated PI3K-δ-selective
inhibitors, the cytotoxicity for CLL cells of copanlisib by far surpassed that of
idelalisib and duvelisib. Targeting the α- and δ- p110 isoforms with copanlisib
may be therefore a useful strategy for the treatment of CLL and warrants further
clinical investigation. Taken together, targeting p110-δ showed promising clinical
efficacy for CLL treatment, but could be further improved by PI3K inhibitors
showing more potent direct tumor cell killing than idelalisib.
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HEALTH RELATED QUALITY OF LIFE AND PATIENT REPORTED OUT-
COMES OF OFATUMUMAB PLUS CHLORAMBUCIL VERSUS CHLORAM-
BUCIL MONOTHERAPY IN THE COMPLEMENT1 TRIAL
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Background: The COMPLEMENT1 study has demonstrated a statistically sig-
nificant improvement in PFS in patients who are treated with ofatumumab plus
chlorambucil in the first line setting for CLL over chlorambucil monotherapy
and the combination therapy was well tolerated. Given that ofatumumab was
added to chlorambucil, it is important to consider the impact of ofatumumab on
health related quality of life (HRQoL).
Aims: Given that ofatumumab was added to chlorambucil, it is important to
consider the impact of ofatumumab on health related quality of life (HRQoL).
Methods: During the COMPLEMENT1 trial, the QLQ-C30 and the QLQ-CLL16
patient questionnaires were administered in patients during treatment, during
the follow up stage and at the time that progression was identified. The primary
specified patient reported outcomes were health related quality of life and
fatigue from the QLQ-C30 questionnaire.
Results: In HRQoL, there was no significant difference (p=0.67) or clinically
relevant difference between the arms at any time point measured during treat-
ment. In the fatigue scale, there was similarly no significant differences noted
between the arms (p=0.17) during treatment. This trend of no clinically signif-
icant changes in HRQoL and fatigue continued during follow-up (p=0.49 and
p=0.10 respectively). A summary of HRQoL scores measured on a scale of 0
to 100 with 100 being the maximum HRQoL can be seen in Figure 1.
Figure 1.
Summary and Conclusions: These results demonstrate that adding ofatu-
mumab to frontline chlorambucil therapy do not result in any perceptible
changes in HRQoL or fatigue, with any adverse events having minimum impact.
This is consistent with the adverse event profile of ofatumumab in the COM-
PLEMENT1 study, which demonstrated high tolerability irrespective of age and
fitness.
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Background: Chronic lymphocytic leukemia (CLL) is the most common
leukemia in western countries, while it is extremely rare in Asian countries. Yet,
genetic profiles of CLL have not been reported in Asian.
Aims: Aim of our study is to characterize the genomic profiles of Korean CLL and
to find out ethnic differences in somatic mutations with prognostic implications. 
Methods: A total of 71 patients with CLL was enrolled (median age at diagnosis
61 year, range 23-81). We performed target exome sequencing for 87 gene
panel using next-generation sequencing (n=48). Targeted genes were
sequenced by IlluminaHiSeq 2500 and the sequencing reads were analyzed,
based on the pipeline of bioinformatics tool. Candidate mutations were con-
firmed by Sanger sequencing. Among 71 patients, G-banding (n=60) and flu-
orescent in situ hybridization (FISH) for RB deletion, 13q deletion, chromosome
12 enumeration, and TP53 deletion (n=51) were performed. 
Results: Overall, 43 out of 48 patients (89.6%) harbored at least one mutation
and mean number of mutation per patient was 2.8 (range 0 -9). Average cov-
erage of target regions was >800-fold. Aberrant karyotypes were observed in
28.3% by G-banding and 66.7% by FISH. The targeted exome sequencing
analysis revealed 136 substitutions and insertion/deletions. Most recurrent
mutation (>10% frequency) was ATM (21%) followed by TP53 (15%), FAT4
(15%), LAMB4 (13%), NFKBIE (10%), NOTCH1 (10%) and SF3B1 (10%).
Mutations of ITPKB, SF3B1, NFKBIE and TP53 was associated with adverse
prognosis (P=0.033, P=0.023, P=0.016, and P=0.023, respectively, by con-
ventional cox regression model, P<0.05). BRD2 and LAMB4 mutation was
mutually exclusive (r=0.55, P<0.05). Mutation of NOTCH1, TP53, and SF3B1
showed similar incidence with Caucasian, while mutation of ATM, BCOR,
SAMHD1, KLHL6, ITPKB and EGR2 was higher than Caucasian. Especially,
ATM mutation showed 2 fold higher incidence (20%) than Caucasian. MYD88
mutation (4%) showed lower incidence than Caucasian. Novel mutations in
Korean CLL was FAT4 (15%) and LAMB4 (15%) mutation, which was not
reported in CLL of Caucasian. 
Summary and Conclusions: Mutation profile of Korean CLL was different
with those of Caucasian, while profile of cytogenetic aberrations was similar to
those of Caucasian. Novel mutations discovered in the present study must be
validated through large cohort study, which might suggest a clue for an ethnic
difference in incidence. Future evaluation of therapeutic strategies should be
taken into account for these mutated genes. 
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THE CD37 ANTIBODY BI 836826 IN COMBINATION WITH CHEMOTHERA-
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Background: The Fc-engineered CD37 antibody BI 836826 showed promising
direct cell killing activity for chronic lymphocytic leukemia (CLL) cells in vitro
and is currently investigated in early phase clinical trials. 
Aims: To explore its potential for combination therapy, its direct cytotoxicity
was assessed in combinations with the DNA alkylating agents chlorambucil
and bendamustine, the nucleoside analogue fludarabine or the PI3K inhibitors
idelalisib and copanlisib.
Methods: Freshly isolated B lymphocytes from CLL patients were treated in
vitro for 48 hours with fixed concentrations of chemotherapeutic agents (3 and
10 µM) and monoclonal antibodies (mAbs, 10 µg/ml). The percentages of viable
cells, which were not stained by annexin V and 7AAD, were subsequently
determined by flow cytometry. The effects of binary combinations were calcu-
lated as fractional products of the separate single agent effects.
Results: Among the examined mAbs only BI 836826 and alemtuzumab signif-
icantly reduced the survival of CLL cells in a set of twelve CLL samples. The
mean relative survival of CLL cells after treatment with BI 836826 was approx-
imately 50%. The percentages of CLL samples, in which the relative survival
was reduced by more than 5%, after treatment with BI 836826, alemtuzumab,
obinutuzumab and rituximab were 83, 70, 25 and 17%, respectively. The three
investigated chemotherapeutic agents significantly reduced the survival of CLL
cells at a concentration of 10 µM and also of 3 µM in the case of fludarabine.
In combinations BI 836826 enhanced the cytotoxicity of chemotherapeutic
agents more efficiently than the other tested antibodies including alemtuzumab
and obinutuzumab.. By combinations of BI 836826 with 10 µM of the
chemotherapeutic agents the median relative survival of CLL cells was reduced
to 20%. In a different set of CLL samples BI 836826 enhanced the cytotoxicity
of the PI3K inhibitors idelalisib and copanlisib more efficiently than the CD20
antibodies rituximab and obinutuzumab. The mutual enhancement of cytotox-
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icity by BI 836826 in combination with PI3K inhibitors was slightly stronger than
that with chemotherapeutic agents. The apoptotic response to the combination
of BI 836826 with PI3K inhibitors was more evenly distributed among samples
than with chemotherapeutic agents.
Summary and Conclusions: In line with its remarkable capacity of inducing
apoptosis in CLL cells, combinations of BI 836826 with chemotherapeutic
agents and PI3K inhibitors consistently resulted in higher percentages of apop-
totic cells than correspondent combinations including the mAbs in current clin-
ical use.
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Background: Increased circulating levels of soluble calreticulin (sCRT) are
found in the sera of patients with autoimmune disease and in lung cancer they
correlate with the hystopathologic subtype. However, studies addressing the
issue in patients with hematologic malignancies are absent. 
Aims: We analyzed the correlation between well-established clinico-biological
parameters of prognostic relevance in chronic lymphocytic leukemia (CLL) and
serum levels of CRT by evaluating the impact of these variables on the time to
first treatment (TFT) in a series of 70 previously untreated CLL patients in Binet
stage A. 
Methods: For this purpose peripheral venous blood samples collected at the
time offirst diagnosis and stored at−70 ◦C were analyzed for the quantitative
determination of circulating CRT level using a commercial Human CRT ELISA
assay (CUSABIO, Biothech CO, LTD). 
Results: Circulating levels of sCRT of CLL Binet stage A patients did not differ
(median, 0.55 ng/mL; range, 0.1-2.9) from levels of healthy controls (median,
0.4; range 0.1-1.2)(P=0.09). The analysis restricted to the cohort of patients with
CLL revealed that levels of sCRT did not correlate with age (P=0.25), gender
(P=0.70), LDH (P=0.90), ß2-microglobulin (P=0.48), CD38 (P=0.41), ZAP-70
(P=0.50), mutational status of IGHV (P=0.65). In contrast, a positive correlation
with peripheral blood (PB) lymphocytosis (P=0.04) and Rai substages (P=0.03)
was observed. After a median follow-up time of 36 months (range, 1-204 months)
19 out of 70 (27.1%) patients experienced progressive disease requiring therapy
according to IWCLL criteria. Receiver operating characteristic (ROC) analysis
identified a serum concentration of 0.8 ng/mL as the threshold (area under curve
[AUC]=0.67; sensitivity 0.58; specificity 0.78) that best allowed the identification
of two subsets of patients with different clinical outcomes with respect to TTFT
(Hazard ratio [HR], 4.51; P=0.0002). Finally, in multivariate analysis along with
serum level of sCRT (P=0.003), Rai substages (P=0.02) and PB lymphocytosis
(P=0.02) entered the Cox model at a significant level. 
Summary and Conclusions: In CLL CRT, an antigen highly expressed by
stromal cells, may stimulate B-cell antigen receptor (BCR) therefore contributing
to the protective effect that stroma exerts on CLL cells. Our results shed a new
light on the role of CRT as predictor of disease-progression in early CLL.
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Background: IDELA is a selective oral PI3Kδ inhibitor approved in combination
with rituximab for previously treated patients with CLL.
Aims: This open-label study (NCT01659021) compared the safety and efficacy
of IDELA plus OFA vs OFA in patients with relapsed or refractory CLL.
Methods: Patients with CLL progressing ≤24 months from last therapy, and
who had received ≥2 cycles of a purine analogue or bendamustine, were ran-
domized 2:1 to either Arm A (IDELA 150 mg BID continuously plus OFA, 300
mg IV week 1, then 1 gm IV weekly x 7 and q 4 week x 4) or Arm B (OFA, same
as Arm A except 2 gm was substituted for 1 gm dosing). Stratification was per-
formed for relapsed vs refractory, del17p and/or TP53 mutation, and IGHV
mutation. Response and progression were assessed by an independent review
committee (IRC) based on clinical data and imaging using modified IWCLL
2008 criteria. The primary endpoint was PFS and alpha-protected secondary
endpoints were confirmed ORR, lymph node response (LNR), OS, PFS in
patients with del17p and/or TP53 mutation, and CR rate. Results are from the
final analysis of the primary endpoint.
Results: Patient characteristics were balanced in the 2 arms: median age 68;
Rai II/III/IV 18/13/51%, median number of prior regimens 3, refractory disease
49%, del17p/TP53 mut 40%, IGHV unmut 78%. The median exposure to IDELA
was 12.3 months (range: 0.2-23.9). Disposition and efficacy are shown in the
Table 1. There was a disproportionate dropout rate with an excess of Arm B
patients discontinuing prior to PD or death. Efficacy results, demonstrating
superiority of the combination, were consistent across risk groups. The median
duration of response was 14.9 months and 6.7 months in Arm A and B patients,
respectively. The most frequent non-haematologic Gr ≥3 AEs in Arm A patients
were diarrhea/colitis (20.2%), pneumonia (12.7%), and febrile neutropenia
(11.6%). Grade 3/4 ALT/AST elevation occurred in 12.9% of Arm A patients.
Infusion-related reactions of any Grade/Gr ≥3 were reported in 16.8%/ 2.3%
and 26.7%/1.2% of patients in Arms A and B, respectively. Deaths in Arm A
occurred in 16.8% of patients on-study (until 30 days post-discontinuation) and
6.9% off-study; and in Arm B in 9.3% of patients on-study and 16.3% off-
study. TEAEs leading to death were reported in 10.4% (exposure-adjusted
rate=0.10/yr) and 7.0% (exposure-adjusted rate=0.18/yr) of patients in Arms A
and B, respectively.
Table 1.
Summary and Conclusions: IDELA plus OFA yielded superior PFS, ORR,
and LNR compared to OFA in patients with previously treated CLL, including
within high-risk subgroups. Safety was manageable with a profile similar to that
previously observed with IDELA in CLL trials.
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INDIVIDUALIZED IMATINIB THERAPY BASED ON [C]MIN LEVELS MONI-
TORING IN NEWLY DIAGNOSED CML PATIENTS RESULTED IN HIGHER
MAJOR MOLECULAR RESPONSE RATES AT 12 MONTHS. RESULTS OF
THE OPTIM-IMATINIB STUDY
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Background: Imatinib mesylate (Gleevec, IM) remains a standard for chronic
phase CML (CP-CML) therapy. The recommended dose is 400 mg/d. Pharmaco-
kinetic studies pointed-out the inter-individual variability in IM exposure. The value
of IM dose optimization based on pharmacokinetic parameters is controversial.
Aims: We conducted the first prospective randomized trial to evaluate the effi-
cacy and the feasibility of IM daily dose optimization based on imatinib [C]min
(trough level) in newly diagnosed CP-CML patients (OPTIM-imatinib trial,
EudraCT 2008-006854-17).
Methods: Patients (pts) diagnosed with CP- CM for less than 3 months, not
previously treated or treated by IM 400 mg/d for less than 1 month were eligible
and treated with IM 400 mg/d. IM [C]min was determined at day 15 after enroll-
ment, 20 to 24h after intake. Pts with a [C]min <1000 ng/ml were randomized
between a dose-increase strategy to improve the [C]min ≥1000 ng/ml (C1) ver-
sus observation only (C2). Pts with adequate dosage (≥1000 ng/ml) were allo-
cated to the standart arm (C3). All pts were managed according to the ELN
2009 recommendations (amended for ELN 2013 recommendations). IM [C]min
levels were assessed monthly for pts in C1 and C2 and every 3 months in C3.
The primary end-point was major molecular response (MMR) at 12 months
(missing data were analyzed as failures). 
Results: 139 pts were enrolled in the OPTIM-imatinib trial from Oct 2010 to
Mar 2014. Median age was 64y (25 to 88y), sex ratio (M/F) was 1.4 and
Sokal score distribution was 21%, 41% and 38% for high, intermediate and
low categories respectively. Six pts were not randomized (3 were intolerant
to IM and 3 declined the dosage). In 86 pts (65%) [C]min was below 1000
ng/ml (median 619; 180 to 998). 43 pts were randomized in C1 and 43 in C2.
47 pts were allocated to C3 (median 1328 ng/ml; 1007 to 3294). At 3 months,
median [C]min was 838 ng/ml in the adapted C1 arm, 566 and 998 ng/ml in
the C2 and C3 arms respectively. These values were 987, 601and 996 ng/ml
at 6 months; 1062, 604 and 935 ng/ml at 9 months and 998, 653 and 930
ng/ml at 12 months. The corresponding mean daily doses of IM in C1, C2
and C3 were 540, 395 and 400 mg/d at 3 months; 614, 390 and 397 mg/d at
6 months; 621, 390 and 394 mg/d at 9 months and 628, 394 and 385 mg/d
at 12 months. A higher rate of dose reductions was recorded in C3 suggesting
that some of these pts may be over dosed. 19 pts (14%) out of the 133 ran-
domized pts were switched from IM to second generation TKIs during the
first 12 months based on the investigator decision, 11 for intolerance (4 in
C1, 3 in C2 and 4 in C3), 4 for failure and 4 for non-compliance. No SAE was
observed in the adapted arm as compare to 6 in C3. In an intent to treat
analysis, MMR was achieved in 27 out of 43 pts (63%; 95% CI, 49 to 77) at
12 months in the C1 dose-adaptation arm versus 16 out 43 pts (37%; 95%
CI, 23 to 51) in the C2 non-adapted arm (p=0,031), as compared to 22 out
of 47 pts (47%; 95% CI, 33 to 61) in C3 (p=0.12).
Summary and Conclusions: The dose adaptation strategy was successfully
applied in 95% of the pts recruited. Two third of them were considered under
dosed based on IM [C]min. The individualized dose adaptation strategy resulted
in a significant increase in the proportion of pts achieving MMR at 12 months
(63% versus 37%), a magnitude similar to the results reported in studies with
second generation TKIs first line. These results may influence the choice of
first line therapy and may provide a strong rational to optimize the use of IM
and IM generic formulations.
This study was sponsored by the Clinical Research Office of Hôpital de Ver-
sailles and supported by a grant from the Programme Hospitalier de Recherche
Clinique (PHRC-I).
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Background: The Optim dasatinib trial validated a dose optimization strategy
driven by dasatinib residual plasmatic level (EudraCT 2008-006854-17). We
reported that dasatinib dose individualization was associated with a lower risk of
pleural effusion and produced high levels of deep molecular responses (Rous-
selot et al. EHA2014). Dasatinib discontinuation was included in the trial and we
report the first prospective dasatinib STOP study in dasatinib first line patients.
Aims: The aim of the study was to test the value of early discontinuation of
dasatinib in early molecular responders. 
Methods: First line patients included in the OPTIM-dasatinib trial, in MR4.5 for
2 years and on dasatinib for at least 3 years were eligible. The OPTIM-dasatinib
trial started to recruit patients in Jun 2009, therefore no patient was eligible for
the discontinuation study until Jun 2012. Loss of major molecular response
(MMR) was used as the criteria to resart dasatinib as validated for imatinib
treated patients in the A-STIM study. 
Results: From Aug 2012 to Nov 2014, 20 patients were offered to discontinue
dasatinib in MR4.5. Median age (52y, range 32-70) and Sokal score distribution
(low, 45%; intermediate 30%; high 25%) was similar to the whole population.
Sex ratio was 1 (10 males; 10 females) as compare to 1.3 in the whole popu-
lation. Five patients were included in the adapted arm, 2 in the non-adapted
arm and 13 in the standard arm. All patients were early molecular responders
(BCR-ABLIS ≤10%) at 3 months and all except one were in major molecular
response at month 6 (BCR-ABLIS ≤0.1%). Mediane time for dasatinib therapy
was 43 months (range 36.3 to 56.5). Median time for the achievement of MR4.5
was 10 months (range 5.6 to 23.4). Median follow-up after discontinuation was
13.2 months. Ten patients (50%) restarted dasatinib after a median of 6.1
months (range 3.3 to 14.5). Median duration of treatment free remission (TFR)
was 11.4 months. At 12 months, the proportion of patients in TFR was 41% (95
CI, 17.5 to 65.7) (Figure 1).
Figure 1. Treatment free remission.
Summary and Conclusions: No published study has described the kinetic of
the molecular response before treatment discontinuation. For the first time we
report a prospective follow-up of patients included in a prospective clinical trial
testing dasatinib first line before discontinuation. Our patients were selected to
be early molecular responders and were discontinued after the shortest dura-
tion of therapy reported to date. Despite the use of dasatinib and with the lim-
itation of a short follow-up, we failed to improve TFR as compare to previous
studies with imatinib first or second line or second generation TKIs second
line. Our results suggest that early molecular response is not the path to cure
and that duration of therapy is probably the most important parameter to con-
sider before making the decision to discontinue tyrosine kinase inhibitors. 
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REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT
SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY
DISCONTINUED FOR INTOLERANCE: REPORT OF THE GROUPE QUÉBÉ-
COIS DE RECHERCHE EN LMC-NMP
L. Busque1,* M.-O. Gratton2, M. Harnois2, L. Mollica1, P. Laneuville3, H.J. Olney 4,
R. Delage5, S. Assouline6
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Background: Since the introduction of imatinib two decades ago, there has been
a continual evolution in the management of CML. With the advent of second-
generation tyrosine kinase inhibitors (TKI) and better molecular monitoring tools,
the decision making for CML patients has become increasingly complex. A variety
of treatment guidelines has emerged to help clinicians make decisions based on
evidence obtained from clinical trials. However, little is known about the utilization
of these guidelines in the real life setting, where patients have more co-morbidities
than in clinical trials, and where clinical decision-making may deviate from the
strict application of therapeutic guidelines due to diverse factors, such as drug
availability, patient choice, and the definition of tolerance and resistance.
Aims: To evaluate in an unbiased, population-based registry the patterns of uti-
lization of CML treatments in the second- and third-line setting in order to assess
the discordance between real life data and those expected from clinical trials.
Methods: The CML patient registry of CML-MPN Quebec Research Group
(www.gqr-lmc-nmp.ca) prospectively follows 590 patients with CML in 18 oncol-
ogy centers across the province of Québec. All patients have provided informed
consent to participate in the registry. For this interim analysis, 266 patients
diagnosed after 2002 and with complete clinical data have been analysed.
Results: The mean age of the cohort was 54 years (range 18-92). The most
frequently used front-line TKI included: imatinib (83%), dasatinib (8.6%), and
nilotinib (5.6%). In this cohort, a high proportion of patients (44%) needed sec-
ond-line treatment. The two main causes of first-line discontinuation were resist-
ance (45%) and intolerance (42%). The distribution of the second-line therapy
was: dasatinib (43%), nilotinib (29%), stem cell transplantation (8.5%), and
other treatments (14%). Thereafter, second-line TKI therapy was discontinued
at the following rates: dasatinib was discontinued in 48% of patients after a
mean of 9.6 months due mostly to intolerance (48%) and resistance (28%).
Similarly, nilotinib was discontinued in 55% of patients after a mean of 15
months, the main cause of discontinuation being intolerance (53%) and resist-
ance (26%). Third-line treatment was instituted in 60 of 100 patients. The most
frequent choices were: nilotinib (33%), dasatinib (29%), stem cell transplanta-
tion (16%), best supportive care (5%), interferon (2%) or other (11%). Surpris-
ingly, intolerance lead to less discontinuation in the third-line setting (nilotinib:
20%; dasatinib: 10%) and mean time on treatment was longer (nilotinib: 24
months; dasatinib: 25 months).
Summary and Conclusions: Registry-based real life data indicate that intol-
erance is a predominant trigger for switching therapy in first- and in second-
line treatment of CML. This is in contrast with clinical trial data where resistance
is the most frequent cause of treatment discontinuation, particularly in second-
line. We also observed a paradoxical tolerance benefit for nilotinib and dasatinib
when used in third-line. We hypothesize that the increased flexibility associated
with real life setting renders physicians more prone to change therapy in the
presence of lower grade side effects that would not justify therapy modification
in the setting of a clinical trial. Interestingly, in the third-line setting, which is the
last resort for most patients, they are more willing to endure their adverse effects
and continue on therapy.
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CARDIOVASCULAR (CV) AND PULMONARY ADVERSE EVENTS (AES) IN
PATIENTS (PTS) TREATED WITH BCR-ABL TYROSINE KINASE
INHIBITORS (TKIS): UPDATED ANALYSIS FROM THE FDA ADVERSE
EVENT REPORTING SYSTEM (FAERS)
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Background: The publicly available FAERS database includes AEs reported
to pharmaceutical companies and voluntary reports submitted from pts and
physicians. FAERS can be mined as part of postmarketing surveillance to iden-
tify potential safety signals based on exposure of a broader population than
clinical trials. A prior report of FAERS through Sept 2012 described CV and
pulmonary AE signals for pts treated with dasatinib (DAS), imatinib (IMA), and
nilotinib (NIL) (Cortes 2015, AJH).
Aims: As FAERS identifies potential signals emerging over time, a reanalysis
using the previous criteria was conducted through Dec 2013. Although data
may be sparse (potential ‘Weber effect’) on recently approved bosutinib (BOS),
and altered due to potential ‘notoriety effect’ of FDA suspension of ponatinib
(PON), due to interest in emerging safety signals associated with both agents,
they were included in the present analysis.
Methods: Data mining using the validated Multi-Item Gamma Poisson Shrinker
(MGPS) Bayesian method is an accepted tool to identify drug-event associations
in surveillance databases. MGPS provides a robust estimate of disproportionality
(reporting frequency of drug-event pair compared to expected frequency) referred
to as the Empirical Bayesian Geometric Mean, and the corresponding 90% CI
(EB05, EB95). EB05 ≥2 indicates a 95% chance an event is reported at least 2x
as frequently as expected. A threshold of EB05 ≥4 (4x expected reporting fre-
quency) was used to identify events more likely to be clinically relevant and attrib-
utable to drug. We assessed the frequency of preferred terms in 3 MedDRA sys-
tem organ classes (SOCs) with safety signals associated with DAS/IMA/NIL (car-
diac; respiratory, thoracic and mediastinal; and vascular) in pts ≥18 years (yrs)
and for age cohorts: 18-45, 46-64, and ≥65 yrs.
Results: Drug-event associations with an EB05 ≥4 were identified for
DAS/IMA/NIL (Table 1). Drug-event pairs that reached EB05 ≥4 for all 3 of
these agents included pleural and pericardial effusions. NIL was uniquely asso-
ciated with EB05 ≥4 for vascular occlusive events. While no events reached
EB05 ≥4 for BOS/PON, EB05 ≥2 was noted for pleural effusion with both, and
for pericardial effusion, peripheral arterial occlusive disease, and hypertension
with PON. In all age cohorts, pleural effusion with DAS/IMA and pericardial
effusion with DAS reached EB05 ≥4. Peripheral and cardiac vascular AEs were
noted with NIL with EB05 ≥4 in pts ≥46 yrs. Key limitations were the inclusion
of terms in only 3 MedDRA SOCs and the reclassification of preferred terms by
SOC since the last report; additionally, there was an inability to establish causal-
ity or to determine incidence of safety signals, and the possible effect of outside
influences on reporting frequency.
Table 1. Drug-event pairs with EB05 ≥4.
Summary and Conclusions: This analysis suggests a strong association of
pleural effusion with DAS, with a weaker association with IMA/NIL. An associ-
ation between NIL and multiple vascular events was identified. Due to limited
exposure and potential bias for BOS/PON, no signals reached EB05 ≥4; how-
ever, some events reached EB05 ≥2 and warrant monitoring in future analyses
with longer follow-up.
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LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC
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Background: Bosutinib (BOS) is a Src/Abl tyrosine kinase inhibitor for adults
with Ph+ CML resistant/intolerant to prior therapy.
Aims: We assess long-term efficacy/tolerability of BOS after ≥5 y vs ≥2 y fol-
low-up from last enrolled patient (pt).
Methods: Data were from an ongoing phase 1/2 study in chronic phase CML
pts on 2nd-line BOS (500 mg/d start dose) after imatinib failure (n=284).
Informed consent was obtained from all pts.
Results: 41% of pts remained on BOS at 5 y (54% at 2 y; per protocol, 1 y=48
wk); 60% and 50% had newly attained or maintained baseline major cytoge-
netic response (MCyR) or complete cytogenetic response (CCyR) (most in ≤2
y). Kaplan-Meier probability of maintaining MCyR or CCyR in responders was
similar at 2 y (76%, 79%) and 5 y (71%, 71%); 6 and 7 pts, respectively, lost
MCyR and CCyR >2 y. Cumulative incidence of on-treatment transformation
to accelerated phase (AP)/blast phase (BP) CML at 5 y was 4%; 55% discon-
tinued without transformation 2 y transformed to AP in y3-5. Kaplan-Meier over-
all survival was 84% at 5 y (91% at 2 y; 40% censored 37 pts discontinued
BOS y3-5 (vs 131 ≤2 y), mostly for disease progression (n=11), AE (n=7, y3:
coronary artery disease, scleroderma, renal failure; y4: ascites and serositis
[same pt], blood creatinine increased, pulmonary hypertension; y5: thrombo-
cytopenia), and unsatisfactory efficacy (n=7). Common newly occurring AEs
(in >5 pts) in y3 were cough (n=7), blood creatinine increased (n=7), pyrexia
(n=6), and blood creatine phosphokinase increased (n=6); y4: blood creatinine
increased (n=6), pleural effusion (n=6); y5, none in >5 pts. Newly occurring
AEs of interest (Table 1) were most common in y1-2; vascular AEs >y2 were
primarily hypertension (y3, n=5; y4, n=3; y5, n=2). Four on-treatment deaths
occurred y3-5, none BOS-related.
Table 1.
Newly Occurring AEs*
n (%)                           Year 1             Year 2             Year 3            Year 4           Year 5
                                  N=284            N=189            N=148           N=130          N=124
Diarrhea                     239 (84)             3 (2)                  0                 1 (1)                0
Cardiac                         23 (8)               7 (4)               8 (5)               7 (5)             4 (3)
Vascular                        11 (4)               8 (4)               5 (3)               4 (3)             5 (4)
Renal                           14 (5)               4 (2)               8 (5)               7 (5)             5 (4)
*Not experienced by same patient previously (denominator=patients on treatment each y; 1
y=52 wk).
Summary and Conclusions: BOS showed durable efficacy and manageable
toxicity; a large proportion of chronic phase CML pts with prior imatinib failure
remained successfully treated at 5 y.
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Background: The introduction of Tyrosine Kinase Inhibitors (TKIs) has dra-
matically changed the prognosis of chronic myeloid leukemia (CML). For
patients who maintain deep molecular remission for many years, it is now under
discussion the possibility to discontinue TKI therapy. In the last 8 years different
studies analyzed the outcome of patients who discontinued imatinib. For most
of these studies, the main criteria for discontinuation were the duration of com-
plete molecular response (CMR) and the depth of molecular response, defined
at least as MR4.
Aims: To present our experience with imatinib discontinuation in clinical practice.
Methods: We retrospectively analyzed the outcome of patients treated in 6
Divisions of Hematology in Piemonte and Lombardia, who discontinued ima-
tinib. All these patients had discontinued imatinib in CMR defined at least as
MR4. After discontinuation patients were monitored. In case of loss of response,
therapy was restarted. Only patients with a minimum follow-up of 6 months
were included. Statistical methods: We estimated MR4 relapse-free survival
and treatment-free remission (TFR) with the Kaplan-Meier method. Prognostic
factors for MR4 relapse-free survival were assessed by univariate Cox regres-
sion model analysis.
Results: We analyzed a total of 46 patients who discontinued imatinib from
August 2003 to October 2014. Median age was 53 year old (46-67). 24 were
male, 22 were female; 27 (61%), 13 (30%) and 4 (9%) were low, intermediate
and high Sokal score respectively; 43% (20/47) were pre-treated with interferon
α (IFN). Reasons for discontinuations were comorbidities for 3 patients, patient
request for 26 cases, intolerance for 13 patients, desire of pregnancy for 4
patients. Median time to CMR after the initiation of imatinib was 18 months
(10-40). Median duration of CMR was 37 months (31-56) before stop. Median
time of treatment with imatinib was 62 months (49-100). At 12 months, esti-
mated MR4 relapse-free survival was 57.7% (95%CI 44.7%>74.2%). After a
median follow-up of 37 months (14-77), estimated MR4 relapse-free survival
was 42.9% (95%CI 29.8%>61.7%) (Figure 1). Overall, 24% (11/46) of patients
lost major molecular remission (MMR). Only 2 patients lost Complete Cytoge-
netic Remission (CCyR). Median time to loss of MR4 was 4 months (2-7). Most
of the patients lost MR4 within the first 7 months (figure 1). 48% (22/46) restart-
ed treatment; median time to restart treatment was 6 months (4-12). 4 patients
lost MR4 but never restarted treatment. No patients progressed. We assessed
age, sex, Sokal score, previous IFN therapy, duration of imatinib therapy, time
to CMR, and CMR duration until discontinuation as potential prognostic factors
for MR4 relapse-free survival, but no statistically significant association were
found. Patients who had to restart the therapy were treated with imatinib
(19/22), nilotinib (2/22), vaccine (1/22). All of them regained at least an MMR
(14 patients re-achieved a response ≥MR4). All patients were alive at the last
follow up with the exception of one who died of colon cancer.
Figure 1. MR4 relapse-free survival.
Summary and Conclusions: Our experience, aligned to the literature, con-
firms that treatment discontinuation is feasible and safe for CML patients treated
with imatinib front-line or after INF. No progressions occurred among our
patients, considering that 75% of our population had a follow-up longer than
77 months. A close molecular monitoring is however required. 64% of patients
regained a deep response, and may be considered for a second attempt of
discontinuation.
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Background: A new prognostic score for differentiating cumulative incidence
probabilities (CIPs) of dying of chronic myeloid leukemia (CML) was developed
in the IN-study section of the European Treatment and Outcome Study
(EUTOS) registry. From 2002 to 2006, all patients were enrolled in prospective,
controlled clinical trials. They had Philadelphia chromosome-positive chronic-
phase (CP) CML and started first-line imatinib-based treatment within half a
year after diagnosis. In the OUT-study section of the registry, patients were
prospectively registered, but, as the only contrast to the IN-study, not part of
clinical trials.
Aims: To compare the performance of the Sokal, the Euro, the EUTOS, and
the new score in the OUT-study data
Methods: Survival was counted from start of imatinib treatment and censored
at the time of allogeneic stem cell transplantation (SCT) in first CP. Only death
after recorded disease progression was regarded as death due to CML. CIPs
of dying of CML were estimated, treating death due to any other cause as a
competing event. All prognostic scores were calculated at diagnosis of CML.
Overall level of significance was 0.05.
Results: Applying the same inclusion criteria as for the IN-study section, 1,120
patients of the OUT-study section were evaluable with regard to all prognostic
scores and survival. These patients came from registries in Russia, the Czech
Republic, Poland, Spain, and Romania. Median observation time was 5.6 years.
Allogeneic SCT in first CP was performed in 29 patients (3%, 7 died). Without
prior SCT in first CP, 116 patients died, 6-year CIP was 11% [95%>confidence
interval (CI): 9-14%]. In 56 cases (48% of 116), cause of death was CML. Six-
year CIP of death due to CML was 5% [95%>CI: 4-7%] and 6% [95%>CI: 5-
8%] for death due to other causes. The new prognostic score identified 681
low-risk (61% of 1,120), 302 intermediate- (27%), and 137 high-risk patients
(12%). Their 6-year CIPs of dying of CML were 3% [95%>C.I.: 2-5%], 6%
[95%>C.I.: 3-9%], and 17% [95%>C.I.: 11-25%]. In the corresponding risk
groups of the Sokal score the 6-year CIPs resulted in 3% [n=450, 95%>C.I.: 2-
5%], 5% [n=411, 95%>C.I.: 3-8%], and 11% [n=259, 95%>C.I.: 8-16%] and
with the Euro score in 4% [n=466, 95%>C.I.: 2-6%], 5% [n=523, 95%>C.I.: 3-
7%], and 15% [n=131, 95%>C.I.: 9-23%]. The EUTOS score found a 6-year
CIP of 5% [n=971, 95%>C.I.: 3-6%] for its low-risk and of 12% [n=149,
95%>C.I.: 7-18%] for its high-risk group. Each of the 4 prognostic scores pro-
vided significantly higher probabilities of dying of CML for the high-risk group
as compared with each of the non-high-risk group(s) (all p values <0.005). The
new prognostic score was also able to identify significantly different CIPs of
dying of CML between the low- and the intermediate-risk group (p=0.04).
Summary and Conclusions: Judging from the CIPs and the distribution of
the patients into the risk groups, the new score showed the best prognostic
performance also in the out-study patients. Only the new model identified three
risk groups with pairwise significantly different CIPs of dying of CML. With
similar CIPs, the new score identified a much larger group of low-risk patients
than the Sokal and the Euro score. Altogether, validation of the new score in
the out-study data was successful. In the 681 patients of the low-risk group
(61%), the new score showed an excellent long-term outcome when starting
treatment with imatinib. Due to the worse results, for the high-risk patients
(12%), an upfront comparison between different tyrosine kinase inhibitors would
be highly desirable.
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PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO
ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS
FROM THE SWEDISH CML REGISTER
S. Söderlund1,* T. Dahlén2, M. Creignou3, F. Sandin4, U. Olsson-Strömberg1,
A. Dreimane3, B. Markevärn5, A. Själander6, H. Wadenvik7, L. Stenke2,
J. Richter8, M. Höglund1
1Department of Medical Sciences, Uppsala University and Section of Hema-
tology, Uppsala University Hospital, Uppsala, 2Department of medicine, division
of hematology, Karolinska University Hospital Solna, Stockholm, 3Department
of hematology, Linköping University Hospital, Linköping, 4Regional Cancer
Center, Uppsala University Hospital, Uppsala, 5Department of hematology,
Umeå University Hospital, 6Department of public health and Clinical medicine,
Umeå University, Umeå, 7Section of Hematology and Coagulation, Sahlgrenska
University Hospital, Göteborg, 8Department of Hematology and Vascular Dis-
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Background: Chronic myeloid leukemia (CML) chronic phase (CP) patients
treated with tyrosine kinase inhibitors (TKIs) today have an excellent prognosis,
but those progressing to accelerated phase (AP) or blast crisis (BC) still have
a dismal outcome. The primary goal of CML treatment is therefore to prevent
disease progression, and with Imatinib treatment progression rates have been
reduced to less than 3% per year. By identifying risk factors for progression
already at diagnosis, and by early therapeutic intervention in patients showing
insufficient treatment response, the progression rates may be further reduced.
The Swedish CML register is population-based and contains data on Swedish
CML patients at diagnosis and follow up. The estimated coverage is >95% of
newly diagnosed CML patients. This gives us an opportunity to characterize
CML patients who are diagnosed in CP and progress to AP or BC during TKI
treatment in a population based material.
Aims: To characterize CML patients diagnosed in CP and treated with TKIs
who progress to AP or BC within 24 months from diagnosis with regard to base-
line characteristics, adherence to national guidelines for CML management
and to evaluate progression rates and outcome in a population based setting.
Methods: Patients diagnosed in CP and treated with TKIs between 1 Jan 2007
and 31 Dec 2012 were selected from the Swedish CML register database and
those who progressed within 24 months from diagnosis were further evaluated
through review of patient charts.
Results: In total, 437 CP CML cases, aged 61 (47-72) years, were registered
during the study period. Nineteen patients (4.6%), all treated with Imatinib first
line, progressed to advanced phases (5 AP, 13 BC, 1 unknown). Six of these
progressed within 6 months, seven between months 6-12 and six during the
second year from diagnosis. This corresponds to a cumulative probability of
progression of 3.1% at 12 months and 4.6% at 24 months. At baseline, 37% of
progression patients were EUTOS high risk, as compared to 13% of patients
who did not progress (p=0.014). Patients later progressing to AP/BC had a
higher percentage of blast cells in peripheral blood at diagnosis (median 2.4 vs
1.0%, p<0.001) and lower platelet counts (322 vs 429x109/l; p=0.022). No dif-
ference between progression and non-progression cases were observed with
respect to age, WBC, Hb, Sokal and Hasford score. Adherence to national
guidelines for monitoring was suboptimal in several progression cases. Thus,
at 6 months, 42% of the patients that later progressed to AP/BC were not
subject to genetic evaluation by cytogenetics or qRT-PCR. Clonal evolution
was noted in 5 patients (28%) as an early sign of progression.
First line treatment of AP/BC consisted of chemotherapy in combination with
TKI switch in 6 patients, TKI switch only in 7 patients, TKI dose increase in 2
patients and palliative chemotherapy in 2 patients. Eight BC patients and 1 AP
patient underwent allogeneic HSCT. Median survival after transformation to
AP/BC was 1.4 years (Figure 1).
Figure 1.
Summary and Conclusions: The cumulative probability of progression from
CML CP to AP or BC at 24 months from diagnosis in this Swedish population
based cohort[JR1] [SS2] was 4.6%, which is similar to findings in studies based
on more selected patient groups. Median survival for patients progressing to
AP/BC was poor. The proportion of patients progressing to AP/BC may be
reduced by more stringent monitoring and by earlier therapeutic intervention
as prescribed in national and international guidelines.
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INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULA-
TION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED
CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML
PATIENTS 
V. Polivkova1, P. Rohon2, N. Curik1, H. Klamova1, O. Cerna3, M. Divoka2,
J. Zach1, M. Novak2, I. Marinov1, S. Soverini4, E. Faber2, K. Machova Polakova1,*
1Institute of Hematology and Blood Transfusion, Prague, 2Department of Hema-
to-Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc,
3Department of Internal Medicine and Hematology, 3rd Faculty of Medicine,
Charles University in Prague, Prague, Czech Republic, 4Institute of Hematology
“L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
Background: CML patients in whom the tyrosine kinase inhibitor (TKI) therapy
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(imatinib, dasatinib, nilotinib) fails due to T315I BCR-ABL kinase domain muta-
tion, should be switched to ponatinib or for bone marrow transplantation. How-
ever, in individual cases these treatment scenarios cannot be applied. We used
treatment with interferon-α (IFN, given solo, sequentially or together with TKI)
assuming that TKI-independent mechanism of action may lead to T315I mutant
clone repression. 
Aims: To study an effect of IFN-based treatment on mutated BCR-ABL tran-
script level and overall response of CML patients who failed on TKIs. In addition
to that to assess the role of the sensitive measurement of BCR-ABL mutant
mRNA load dynamics and immune response induced by IFN in individualized
treatment.
Methods: Six CML patients who had failed on TKIs due to T315I or other highly
resistant mutational profile have been treated with individual IFN-based treat-
ment strategies. Kinase domain mutations in cDNA of BCR-ABL were analyzed
in total 54 samples (median 6 samples of each patient, range 5-15) of peripheral
blood leukocytes using next-generation deep sequencing (GS Junior, Roche
Applied Science). The T315I clone reactivity on lowering imatinib concentration
(2.0, 1.0, 0.4 and 0 µM imatinib) was studied in vitro on KCL22-R cell line
resistant to 4.0 µM imatinib with 45% of BCR-ABL T315I. KCL22-R were incu-
bated in each imatinib concentration for 14 days and checked for mutation.
The basic immune-profile was analyzed in 5/6 CML patients using flow-cytom-
etry detecting populations of CD4+, CD8+, regulatory T-cells (Tregs) and NK
cells in specific time points (e.g. before IFN initiation, during IFN-based treat-
ment). 
Results: The switch of TKI to IFN-based treatment resulted in decreasing of
mutated BCR-ABL mRNAs to undetectable levels in 4/6 patients. Three of
those patients achieved major molecular response (MMR). IFN has been
stopped, based on non-mutated BCR-ABL transcripts detection, continuing
with solo nilotinib in 1/4 patient who achieved complete cytogenetic remission
(CCgR). One case of MMR responding patient on solo IFN treatment showed
decreased levels of CD3+ T-lymphocytes and elevated levels of NK cells. Other
two patients who achieved MMR after IFN expressed elevated levels of NK
cells representing probably an immune activation on dasatinib pre-treatment
following with restoring immunological surveillance after application of com-
bined treatment IFN with TKI. In 2/6 cases TKI cessation and IFN introduction
did not contribute to the BCR-ABL mutations reduction and response improve-
ment.
No changes in the BCR-ABL T315I transcript levels have been observed after
14 days of incubation of KCL22-R upon easement of selective pressure of ima-
tinib. We assume that longer time of incubation, which is ongoing, would be
necessary to follow-up any changes. 
Summary and Conclusions: In this work we showed that CML patients with
TKI multi-resistant mutation T315I or other highly resistant BCR-ABL mutations
may achieve CCgR or MMR thanks to IFN-based individualized treatment.
These achievements may relate to immune-mediated anti-leukemic effects in
this specific group of patients resulting in BCR-ABL clones repression. The
sensitive measurement of mutated BCR-ABL transcript levels augments safety
of this individualized treatment strategy.
Supported by IGA NT1389, by the project for conceptual development of
research organization no. 00023736 of MZCR and IGA LF UP 01-2015.
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PREDICTION OF THE NUMBER OF CML- PATIENTS IN GERMANY: UP TO
20,000 ARE TO BE EXPECTED IN THE NEAR FUTURE
M. Lauseker1,* R. Gerlach2, M. Tauscher2, J. Hasford1
1Institute for Medical Information Sciences, Biometry, and Epidemiology, Lud-
wig-Maximilians-Universität, 2Kassenärztliche Vereinigung Bayerns, München,
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Background: Since introducing Tyrosine Kinase Inhibitors (TKI) into the treat-
ment of chronic myeloid leukemia (CML) the survival rates have increased
remarkably and thus the patient numbers are rising too. It has been estimated
that the prevalence of CML rises annually by about 10%, but exact figures are
missing. As the treatment costs are considerable, a prediction of the number
of patients in the future is of interest for a proper assessment of the economic
impact.
Aims: Our first objective was to estimate prevalence and incidence of CML by
using routine data from the Bavarian Association of Statutory Health Insurance
Physicians (Kassenärztliche Vereinigung Bayerns). Based on these estimates
the second objective was to find a model to predict patient numbers in Germany
for the future accounting also for the changes in demography.
Methods: Data on ICD-10 codes as well as prescribed medication were avail-
able for about 10 million people in the statutory health insurance system in
Bavaria for the years 2008 to 2013. Only patients with at least two recordings
of CML (ICD C92.1) and a CML-related treatment (TKI, Interferon, Hydrox-
yurea, Busulfan) were included to avoid misclassification bias.
As survival rates could not be estimated from our data base, corresponding
values were adapted from two recent publications, which both reported age-
specific relative survival rates (Nennecke et al., Bundesgesundheitsblatt 2014,
and Smith et al., BMJ open 2014), as well as current survival rates for the Ger-
man population, obtained from the German Federal Statistical Office (GFSO).
Data on the expected population projection - in twelve different scenarios,
structured by birth rate, life expectancy and migration balance - was provided
by the GFSO as well.
Results: The mean estimated raw incidence rate was 1.851 for women and
2.249 for men; the age-standardized (Old European Standard Population) rates
were 1.300 and 1.768 for women and men. For mid-2009, we estimated the
prevalence for men/women (each per 100,000 inhabitants): 0.100/0.285 (age 0-
19 years), 1.065/1.904 (20-29), 3.523/3.798 (30-39), 6.778/6.845 (40-49),
7.919/11.151 (50-59), 19.282/21.935 (60-69), 22.877/28.194 (70-79) and
15.419/26.440 (80 and older). Based on the population data described above,
we estimated a total number of about 7,000 CML patients in Germany for 2009.
The estimations of the number of patients in the future according to the twelve
population scenarios combined with the different survival assumptions (and the
average of both) are depicted in Figure 1. An increase of the prevalence is expect-
ed in every scenario. Differences were due to the chosen survival scenario rather
than due to the population scenarios. The number of patients in the most probable
average survival scenarios will increase for the next 25 to 35 years.
Figure 1.
Summary and Conclusions: The estimated incidence rates presented here
are comparatively higher than in recent publications. Using a restrictive defini-
tion for case patients we do not think that there is much overestimation.
We expect the number of CML patients to increase further for at least 20 years,
probably even longer. The survival estimate by Smith is based on relatively
few patients and might thus lead to an overestimation. Vice versa, the estimate
by Nennecke is in part based on patients known by death certificate only and
might be slightly too pessimistic. From our point of view, the mean survival
scenario seems to be the most realistic one, thus in Germany a maximum of
about 20,000 CML patients is to be expected.
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KILLER IMMUNOGLOBULIN-LIKE RECEPTORS CAN PREDICT TKI TREAT-
MENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS
G. Caocci1,* M. Greco1, R. Littera2, S. Lai2, S. Galimberti3, C. Baraté3, O. Mulas1,
C. Labate4, C. Carcassi2, B. Martino4, G. La Nasa1
1Hematology, Department of Medical Sciences, 2Medical Genetics, Department
of Medical Sciences, University of Cagliari, Cagliari, 3Department of Clinical
and Experimental Medicine, University of Pisa, Pisa, 4Division of Hematology,
Ospedali Riuniti, Reggio Calabria, Italy
Background: Discontinuation of Tyrosine Kinase inhibitors (TKIs) in chronic
myeloid leukemia (CML) patients is currently a much debated challenge. Sev-
eral drug-, disease- and patient-related parameters have been suggested to
be predictive of durable treatment-free remission (TFR). Despite the well known
anti-tumor effect of the innate immune system, few data exist on the role of
natural killer (NK) cells and their killer-cell immunoglobin-like receptors (KIRs)
in CML. In a previous report we found that a decreased frequency of the
KIR2DL2 inhibitory receptor and homozygosity for KIR A haplotype were sig-
nificantly associated to achievement of undetectable molecular response
(UMR4.5). A more recent report by other authors found that early disease
relapse after TKI discontinuation was associated to both low numbers and
impaired function of NK cells.
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Aims: The primary aim of this study was to investigate whether NK cells and/or
the KIR gene system could provide us with predictive immune-biomarkers of
stable TFR in CML. A second endpoint was to evaluate which other patient/dis-
ease factors were related to relapse/non relapse after stopping TKI treatment.
Methods: The distribution of KIR and human leucocyte antigen (HLA) gene
frequencies, KIR and HLA genotypes and KIR-ligand combinations were inves-
tigated in 22 chronic-phase CML patients who discontinued TKI treatment after
achieving UMR4.5. Age at diagnosis, gender, white blood cell (WBC) and platelet
(PLT) counts, Sokal risk, splenomegaly, previous interferon treatment, rapidity
in obtaining UMR4.5 and overall treatment duration were also included in the
binary logistic regression model in which TFR was considered as a dependent
variable.
Results: Median age at diagnosis was 68 years (range 37-88) and 16/22 of the
patients were males (72.8%); splenomegaly was detected in 13 patients (59%),
ranging from 1 to 16 cm below the costal margin. Sokal risk was low in 54.5% of
the patients, intermediate in 40,9% and high in 4.6%. Median follow-up was 11.5
years. Six/22 patients (27.3%) had been previously treated with interferon followed
in 5 cases by imatinib; 14 patients were treated upfront with imatinib and 2 with
nilotinib. All patients achieved UMR4.5 after a median of 17 months (range 3-96)
and, within the framework of a clinical protocol, discontinued TKI treatment at a
median of 72 months from the start of treatment (range 23-105). The 36-month
probability of TFR was 58.7%. The majority of relapses occurred within 8 months
of interrupting therapy. TFR was significantly higher in patients not carrying the
inhibitory KIR2DL2 receptor (81.4% vs 36.4%, p=0.039) (Figure 1). There was
also a trend toward better TFR in patients homozygous for KIR A haplotype (80%
vs 41.7%). Younger age, male sex and lower duration of treatment were signifi-
cantly associated with relapse. All relapsed patients regained UMR4.5 after restart-
ing treatment with the same TKI.
Figure 1.
Summary and Conclusions: Further investigation into innate immunity and
the modulation of NK cell function could represent an important step ahead in
the management and recovery from CML. Our results show that patients car-
rying the KIR2DL2 inhibitory receptor are at risk for not maintaining durable
TFR. Previous reports show that homozygosity for KIR A haplotype is associ-
ated to better immune response with resistance to viral infection and tumor
cells. Our findings suggest that this genotype could be a useful predictive mark-
er when deciding whether or not to withdraw treatment in CML patients. 
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AML1-EVI-1 FUSION GENE INHIBITED DIFFERENTIATION AND APOPTO-
SIS IN ZEBRAFISH MYELOPOIESIS
L.-J. Shen 1,*F.-Y. Chen1
1hematology, Renji Hospital,Shanghai Jiao Tong University School of Medicine,
Shanghai, China
Background: AML1-Evi-1 is a chimeric gene generated by the t(3;21)(q26;q22)
translocation, which leads into malignant transformation of hematopoietic stem
cells (HSCs) by many mechanisms which have not been thoroughly elucidated.
Aims: We established a stable line of zebrafish expressing the human AML1-
Evi-1 fusion gene under the control of a heat stress-inducible bidirectional pro-
moter, named as Tg(AE:HSE:EGFP) line, to study its roles in hematopoiesis
and hematologic malignancies.
Methods: Using Wright Giemsa stain detected the blood cell distribution in
peripheral blood and kidney. The changes of hematopoietic regulatory factors
were examined through RT-PCR and whole mount in situ hybridization. Agilent
microarray analysis was performed to find the most relevant Kyoto Encyclope-
dia of Genes and Genomes (KEGG) terms associated with differentially
expressed genes (DEGs) between wild type and Tg(AE:HSE:EGFP) F2 gen-
eration. Furthermore, we investigated the in vivo effects of histone deacetylase
inhibitor, valproic acid (VPA), on AML1-Evi-1-expressing cells.
Figure 1.
Results: Three of 146 (2.1%) mosaic F0 zebrafish embryos were identified as
the stable positive germline transgenic zebrafish, including 2 males and 1 female.
The Transgenic F1 generation were mated to create homozygous
Tg(AE:HSE:EGFP) line. Immature myeloid cells and hematopoietic blast cells
were accumulated in peripheral blood and single cell suspension from kidney in
adult Tg(AE:HSE:EGFP) zebrafish. AML1-Evi-1 presented an intensive influence
on hematopoietic regulatory factors. Consequently, primitive hematopoiesis was
enhanced by upregulation of gata2 and scl, erythropoiesis was downregulated
due to the suppression of gata1, while early stage of myelopoiesis was flourishing
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according to the higher expression of pu.1 but inhibited along with the lower level
of mpo expression. These characters closely resemble to the main aspects of
human myeloid leukemia. Therefore, this model facilitated dissection of AML1-
Evi-1-mediated pathomechanism in vivo, and enabled high-throughput scale
screens to identify the potential therapeutic targets. Microarray analysis demon-
strated that AML1-Evi-1 upregulated Proteasome, Cell cycle, Glycolysis/Gluco-
neogenesis, Tyrosine metabolism, Drug metabolism, and PPAR pathway. Mean-
while, transforming growth factor β (TGFβ), Jak-STAT, DNA replication, Mismatch
repair, p53 pathway, JNK signaling pathway, and Nucleotide excision repair were
distinctly suppressed. It’s worth noting that histone deacetylase 4 was dramati-
cally decreased. Factors involved in cell proliferation were obviously suppressed
after 3-day treated with VPA. Accordingly, higher proportion of G1 arrest and
apoptosis were manifested by the propidium iodide staining.
Summary and Conclusions: The phenotypes of Tg(AE:HSE:EGFP) fish
resemble to those of the human’s MDS-RAEB or AML. AML1-Evi-1 could pro-
mote the primitive hematopoietic cell proliferation and apoptosis resistant, inhib-
it myeloid cells differentiation through synergy of several pathway and factors.
We propose VPA to be an attractive choice in the molecular targeting therapy
of AML1-Evi-1-related leukemia. 
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THE INFLUENCE OF SF3B1 MUTATIONS ON THE RESPONSIVENESS OF
BLOOD CANCERS TO MOLECULAR THERAPEUTICS
F. Liberante1,* K. Lappin1, M.-F. McMullin1, K. Savage1, K. Mills1
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Belfast, United Kingdom
Background: In recent years, high-throughput sequencing has identified muta-
tions in the SF3B1 gene in a variety of blood cancers such as myelodysplastic
syndromes (MDS), acute myeloid leukemias (AML) and chronic lymphocytic
leukemias (CLL). The majority of mutations reported involved a single nucleotide
substitution that alters a lysine codon into a glutamate (K700E). This alteration,
along with all other known mutations, resides within the HEAT domains of the
protein. This narrow localisation of the substitutions in combination with the
absence of nonsense mutations suggests that SF3B1 mutations lead to alteration
of function rather than simple haploinsufficiency. Furthermore, their prevalence
implies the mutations are relevant to these diseases, if not disease-causing. In
terms of clinical utility, identifying therapies which target cells harbouring mutant
SF3B1 would be of great benefit, as there is pressing need to improve available
therapies for all these diseases; particularly MDS, a disease of the elderly. 
Aims: To explore the tractability of SF3B1 mutations by standard and advanced
molecular therapies; using isogenic pre-clinical models of myelodysplasia and
acute myeloid leukemia harbouring the mutant protein.
Methods: A lentiviral platform was used to introduce wild-type or mutant SF3B1
into cell lines representing the spectrum of MDS>AML, including MDS-L, SKM-
1 and OCI/AML-3. The system allows finely tuneable conditional expression of
the gene. The effects of variable gene expression, both mutant and wild-type on
the susceptibility of these cells to molecular agents was assessed by cytology,
proliferation, viability and apoptosis assays. Further genome-editing via
CRISPR/Cas9 nucleases is being used to create isogenic models. In addition,
other molecular effects, such as reduced DNA damage response were assessed.
Results: The conditional expression system was successful in producing titrat-
able levels of the mutant protein. Cells which over-expressed the mutant protein
had reduced proliferation compared to those harbouring only the wild-type
gene. Those cells also had higher rates of spontaneous death in culture without
further insult. Furthermore, the mutant expressing cells showed altered DNA
damage repair after exposure to DNA-damaging chemotherapies, such as
Etoposide. In line with this defect, they also demonstrated greater sensitivity
to Poly ADP Ribose Polymerase inihibitors (PARPi).
Summary and Conclusions: This study has shown that an altered spliceo-
some, via SF3B1 mutation, results in a DNA damage repair defect. In terms of
clinical applicability, this finding supports the idea that these mutant cells, with
resulting DNA repair defects, can be treated with compounds that target DNA
repair. One of the newest classes of small molecules in multiple clinical trials,
are Poly ADP Ribose Polymerase inhibitors (PARPi), which showed a selective
effect on mutant cells. In conclusion, these data suggest that this class of com-
pounds has great potential in the treatment of SF3B1 mutant blood cancers;
especially MDS or secondary AML.
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POLYMORPHISMS OF DNMTS AND FOLATE/METHIONINE METABOLISM
GENES INFLUENCE DNA METHYLATION, GENETIC SUSCEPTIBILITY
AND PROGNOSIS OF MYELOID NEOPLASIA PATIENTS
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Background: Global hypomethylation and targeted hypermethylation are con-
sidered defining characteristics of human tumors, including myeloid neoplasias
(MN). Folate, methionine and vitamin B12 can influence the supply of methyl
groups and, therefore, the biochemical pathways of methylation processes.
Moreover, single nucleotide polymorphisms in genes that encode DNA methyl-
transferases (DNMTs) as well as enzymes from folate/methionine metabolism
can influence the DNA methylation status, as well as the individual susceptibility
to develop MN, namely Acute Myeloblastic Leukemia (AML), Myelodysplastic
Syndromes (MDS) and Myeloproliferative Neoplasias (MPN), including Chronic
Myelogenous Leukemia (CML).
Aims: In this context, we analyzed the influence of the polymorphisms in
DNMT1, DNMT3a, DNMT3b, RFC1, CBS and MTRR genes in DNA methylation
status and its role as risk and prognosis factors for myeloid neoplasia.
Methods: This study enrolled 333 patients diagnosed with myeloid neoplasia
(80 AML, 106 MDS, 147 MPN, being 77 CML) and 261 healthy controls. The
genetic polymorphisms of DNMT1 (rs759920), DNMT3a (rs2289195), DNMT3b
(rs2424908), RFC1 (rs1051266), MTRR (rs162036), MTHFR (rs1801131,
rs1801133), and CBS (844ins68) were assessed by RFLP-PCR and Tetra-
primer-ARMS-PCR. The localized methylation status was analyzed through
p15, p16, DAPK, and KEAP1 methylation profile by MSP. Global methylation
status was assessed by 5-methylcytosine (5mC), 5-hydroxymethylcytosine
(5hmC) levels and LINE-1 methylation. The statistical analysis was carried out
by variance analysis, χ2 test, and Fisher exact test (p<0.05). 
Results: Our results show that CBS, MTHFR, DNMT1, and DNMT3b genes
influence the localized and global methylation status in a genotype-dependent
manner. Moreover, DNMT1 AA and DNMT3b CT genotypes were protector fac-
tors for MDS development [OR 0,49 (CI95% 0,27-0,90), p=0,03; OR 0,50 (CI95%
0,28-0,83), p<0,001]. The DNMT3a AG genotype was also a protector factor for
AML development [OR 0,16 (CI95% 0,05-0,52), p<0,001]. Besides that, individ-
uals with DNMT1 GG genotype have an increase risk for develop SMD about
1,78-fold (CI95% 1,03-2,01; p=0,04), while those with the DNMT3a GG and
DNMT3b CC genotypes have an increase risk for develop AML about 6,82-fold
(CI95% 1,22-37,95; p=0,03) and 2,01-fold (CI95% 1,07-11,48; p=0,03), respec-
tively. The RFC1 GG genotype also increases the risk of CML development about
2,65-fold (CI95% 1,53-4,57; p<0,001). Moreover, DNMT3a genotype can influ-
ence prognosis since MDS patients with DNMT3a GG genotype had lower sur-
vival (p=0,032). We also observed that allele C from MTHFR polymorphisms
(rs1801133) and the AC genotype from the same gene (rs1801131) significantly
increase 1,55-fold (IC95%: 1,08-2,23; p=0,031) and 2,01-fold (IC95%: 1,25-3,21;
p=0,012) the risk of MDS development, respectively.
Summary and Conclusions: These results suggest that genetic polymor-
phisms in DNMTs and folate/methionine metabolism genes can influence the
DNA methylation status, the susceptibility to develop MN and the prognosis of
MDS patients.
This work was supported by CIMAGO (Project 22/09) and R. Alves is supported
by the FCT fellowship FRH/BD/51994/2012.
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APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER
RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHRO-
POIESIS: A PRECLINICAL STUDY
A. Raimbault1, S. Bondu1, C. Pierre-Eugène1, C. Deudon1, L. Willems1, N. Chapuis1,
R. Sapena2, A. Rouquette3, C. Kunz4, H. Fricke4, O. Kosmider1, V. Bardet1,
M. Fontenay1,*
1Hematology, AP-HP Hôpitaux Universitaires Paris Centre, Cochin, Université
Paris Descartes, 2Hematology, AP-HP Hôpitaux Universitaires Paris Centre,
Cochin, 3Epidémiologie et Biostatistiques, AP-HP Hôpitaux Universitaires Paris
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Background: The production of red blood cells is negatively regulated by cas-
pase-dependent apoptosis of immature precursors mediated by death receptor
CD95 when activated by its ligand, CD95L, in the bone marrow. CD95 is over-
expressed at CD34+ progenitor cell surface in two thirds of patients with low/int-
1 risk myelodysplastic syndromes, and this contributes to anemia. CD95 over-
expression may depend on methylation level (1) and on single nucleotide poly-
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morphisms (SNP) at -1377 and -670 from ATG in the 5’UTR of CD95 gene pro-
moter. We have previously reported that resistance to erythropoiesis-stimulating
agents (ESA) was significantly associated with CD95 overexpression and poor
residual erythropoiesis.
Aims: In a preclinical study, we investigated an alternative therapeutic strategy
for anemia in lower risk MDS based on inhibition of CD95-dependent apoptosis
of erythroid precursors.
Methods: From a cohort of 250 MDS patients and 30 controls, CD95 and
CD95L expression was quantified by flow cytometry, and SNP rs2234767 (-
1377G>A) and rs1800682 (-670A>G) were determined by Sanger sequencing.
The effect of APG101, a fusion protein consisting of the extracellular domain of
human CD95 and Fc fragment of human IgG1, on erythropoiesis was investi-
gated in 20 low/int-1 MDS and 6 control bone marrow samples from patients
with another type of anemia in liquid cultures and/or clonogenic assays.
Results: CD95 and CD95L were overexpressed in 146/250 (58%) and in 48/82
(58%) MDS patients, respectively. In 147 samples, we showed that the -1377G
allele, to which the transcription factor SP1 can bind, is more frequent in MDS
compared to controls and that the -1377G/-670A haplotype is associated with
a higher CD95 expression level than the -1377A/-670G ancestral haplotype
(P=0.042). CD95L epigenetic regulation is currently under study. In liquid cul-
tures, APG101 increased the number of erythroid progenitors of BFU-E type
and the proliferation of erythroblasts by inhibiting apoptosis of immature pre-
cursors in 4 MDS samples, but not in 3 controls. In a series of 20 MDS with
high CD95 expression level, APG101 improved the growth of bone marrow
mononuclear cell (BMMC)-derived BFU-E in 15 MDS patients which erythro-
poiesis was initially collapsed with ≤15 BFU-E/105 BMMC, independently of
CD95L level. APG101 had no effect on BFU-E number of control samples.
More importantly, APG101 does not increase the expansion of non-erythroid
leukemic clusters counted at day 7 of clonogenic assays.
Summary and Conclusions: These results delineate a subgroup of lower risk
MDS with high CD95 expression and collapsed erythropoiesis that could benefit
from alternative strategy to ESA. This provides with arguments for a phase I/II
clinical trial in ESA-resistant lower risk MDS.
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AZACITIDINE IMPROVES THE T-CELL REPERTOIRE IN PATIENTS WITH
MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
WITH MULTILINEAGE DYSPLASIA
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E. Angelucci3, M. Longinotti1
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Background: Patients with myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML) with multilineage dysplasia show several immunolog-
ical abnormalities. Azacitidine represents a therapeutic option for these disor-
ders and, beside the well known effects on bone marrow precursors, has been
demonstrated to potentially influence T-cell polarization.
Aims: The aim of this study is to monitor the kinetic of the T-cell receptor (TCR)
repertoire during Azacitidine treatment in order to explore its potential ability,
not only to restore the hematopoietic function, but also to reverse the immune
derangement typical of these patients
Methods: Our study consisted in a flow cytometric and spectratyping analysis
performed on the peripheral blood of 11 patients (5 with MDS and 6 with AML
with multilineage dysplasia) and 30 normal controls. Each patient was evaluated
at baseline and then every 3 cycles of Azacitidine. The flow cytometry analysis
was based on a panel of 24 beta variable (BV) family-specific antibodies. The
profile of the third complementarity-determining-region (CDR3) in separated
helper and cytotoxic T-cells was then analyzed by spectratyping. After immuno-
magnetic CD4+/CD8+ cell separation, RNA extraction and reverse transcriptase
PCR, CDR3 fragment analysis was performed through capillary electrophoresis. 
Results: By flow cytometry, we first demonstrated a variable improvement from
baseline to the following evaluations in the frequency of CD3+ (mean 63.00% vs
68.24%, p=0.03), CD4+ (40.09% vs 42.05%, p=0.04) and CD8+ cells (20.27%
vs 25.10%, p=0.02), whereas the frequency of CD16+ CD56+ cells was stable
(8.50% vs 8.45%, p=0.22). Also the frequency of regulatory T-cells (0.53% vs
0.45%, p=0.84) and BV expansions was substantially stable in both CD4+ (mean
1.60% vs 2.53%, p=0.36) and CD8+ cells (5.20% vs 5.60%, p=0.79). Noteworthy,
when monitored by spectratyping during their treatment our patients showed sig-
nificant changes in their CDR3 profiles, which were much more evident in helper
T lymphocytes. In fact, the frequency of skewed BVs was significantly decreased
from baseline to the following evaluations in the CD4+ subset (mean 81.45% vs
70.17%, p=0.004). In more details the mean frequency of skewed subfamilies in
CD4+ cells decreased from 81.45% at baseline to 75.91% at 3 months, 80.86%
at 6 months, 58% at 9 months, 17% at 12 months and 22% at 18 months. This
pattern was even more pronounced in patients responding to Azacitidine (89.60%
vs 61.47%, p=0.002). Also in the CD8+ subset a slight but statistically significant
trend towards a reduction in the frequency of skewed CDR3 profiles (mean
99.27% vs 98.74%, p=0.01) was demonstrated. Beside our patients showed a
substantially stable frequency of oligoclonal profiles in both CD4+ (mean 3.00%
vs 2.74%, p=0.47) and CD8+ cells (11.82% vs 11.61%, p=0.19).
Summary and Conclusions: Our findings firstly confirmed in our patients an
overall derangement of the TCR repertoire. However this pattern seems to
gradually improve during Azacitidine treatment, as witnessed by the improve-
ment in T-cell counts observed on flow cytometry but much more by the pro-
gressive restoration of the CDR3 diversity detected by spectratyping, especially
within the CD4+ subset. Therefore our data suggest that Azacitidine could be
potentially able to reverse the immune derangement typical of patients with
MDS and AML with multilineage dysplasia.
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REPOPULATING PROGENITOR CELLS IN PRIMARY MDS BONE MAR-
ROW CELL CULTURE IN SEVERE HYPOXIC CONDITIONS
E. Masala1,* F. Buchi1, S. Pillozzi2, A. Valencia Martinez1, T. Rondelli3, A. Gozzini1,
A. Sanna1, A. Bosi1, P. Dello Sbarba2, V. Santini1
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Background: Myelodysplastic Syndromes (MDS) are clonal disorders. How-
ever, whether the transforming event occurs in a myeloid committed cell or in
earlier progenitor (stem cell ?) it is still not ascertained. Evidence have been
accumulated in both senses, but certainly, MDS initiating cells must be capable
of sufficient repopulating capacity to perpetuate the disease.
Aims: We evaluated the repopulating ability and stem cell potential of hypoxia
maintained primary bone marrow (BM) progenitors derived from Myelodysplas-
tic Syndromes (MDS).
Methods: Thirty seven BM samples were obtained at diagnosis from MDS
patients (WHO: 10 RA, 12 RCMD, 7 RAEB, 8 AL/post MDS). Mononuclear BM
cells were isolated and cultured with TPO, FLT3-L, SCF, IL-3 in severe hypoxic
conditions (0,3%O2, 5%CO2, 95%N2), for 10-13 days (LC1). The stem cell poten-
tial of these cultures was explored by transferring cells to growth-permissive sec-
ondary cultures in normoxia (LC2), in the presence of SCF, G-CSF, IL-6, IL-3,
and according to the Culture-Repopulating Ability (CRA) assay methodology, cell
proliferation was evaluated daily. Expression of CD34, CD38, CD117, CD133
was determined and when present, the persistence of chromosomal aberrations
was analyzed by FISH at various stages of cell culture. In parallel, MDS mononu-
clear BM cells were intravenously injected in sublethally irradiated NOD-SCID
mice before hypoxic culture and after LC1 (1x106 cells inoculated per mouse).
Mice were sacrificed at day 56 after graft. The presence of CD45+ human cells
in the peripheral blood of injected mice was evaluated by flow cytometry analysis
every two weeks, and quantified to evaluate the repopulating ability and the dif-
ferent engraftment capacity of cells before hypoxic culture and after hypoxic
selection. Mice marrow trephines as well as spleen and liver biopsies were also
evaluated morphologically to test the engraftment of human MDS cells. 
Results: In all 37 MDS cases studied, cultured cell number decreased of one log
or more after 10-13 days of culture in hypoxic conditions. Only 12/37 MDS cases
showed a significant repopulating ability at day 17 of LC2, all classified as Low/INT1
IPSS risk category. In IPSS high and INT-2 risk cases, repopulating ability accord-
ing to CRA method was absent. CD34+ cells were always decreased after hypoxia
and did not co-express CD38. We demonstrated the persistence of chromosomal
aberrations in CD34pos/CD38neg cells after hypoxic culture in 5 MDS cases
(del5q, +8, del20q, -Y, complex karyotype). We observed in sublethally irradiated
NOD-SCID mice transplanted with hypoxia cultured cells a significantly higher
percentage of CD45+ human cell that in mice transplanted with non hypoxia select-
ed cells, at days 28 after transplantation (5,5% vs 0,56%); at the same time, the
analysis of cells derived from mice spleen showed a significantly higher percentage
of CD45+ human cell (1,83%) in mice transplanted with hypoxia selected cells
than mice transplanted with non selected cells (0,16%); by the other hand, the
analysis of cells derived from mice bone marrow showed an higher percentage of
CD45+ human cells in mice transplanted with non hypoxia selected cells than
mice transplanted with selected cells (2,16% vs 1,26%).
Summary and Conclusions: Severe hypoxic culture conditions are maintain-
ing a sub-population of MDS cells endowed with increased repopulating capac-
ity in vitro and in vivo in sublethally irradiated NOD-SCID mice. Most importantly,
repopulating ability was observed exclusively in IPSS lower risk MDS cases.
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DIAGNOSTIC UTILITY OF MYELOID NUCLEAR DIFFERENTIATION ANTI-
GEN EXPRESSION AND OTHER FLOW CYTOMETRIC PARAMETERS IN
MYELODYSPLASTIC SYNDROME
S. Venkatesan1,* S. Soni2, M. Aggarwal1, A. Chopra2, R. Kumar2, H. Pati1
1Hematology, 2Laboratory Oncology, All India Institute Of Medical Sciences,
New Delhi, India
Background: Diagnosis of myelodysplastic syndrome (MDS) based on mor-
phology is particularly difficult in low grade MDS (i.e. <5% blasts, no ring sider-
oblasts and karyotypic abnormality). Hence, a more objective method is essen-
tial. Currently there are various guidelines for standardization of flow cytometry
(FCM) in MDS. However; their widespread applicability may be challenging
especially in resource limited settings, due to vast array of markers recom-
mended by these guidelines.
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Aims: This study was conducted to assess the utility of expression of MNDA
along with quantitative FCM approach using “mini-panel” of antibodies (CD34,
CD10, CD19, CD45, CD11b, CD15 and CD56) in MDS diagnosis.
Methods: Bone marrow aspirates (BMA) collected from 52 consecutive patients
with suspected diagnosis of MDS were divided into three groups: (1) proven
MDS (n=12) based on morphology and/or cytogenetics (2) suspected MDS (n=6),
non-contributory morphology and cytogenetics (3) non-MDS (n=34). Sixteen con-
trol BMA were also studied. 44 cases (12 MDS, 06 suspected MDS and 26 non
MDS)were analyzed for MNDA expression (on granulocytes, blasts, monocytes
and lymphocytes) and 52 cases were analyzed for seven quantitative parameters:
(1) CD34+ myeloblasts% in nucleated cells (2) CD34+ B-cell progenitor% in all
CD34+ cells (3) lymphocyte/myeloblast CD45 mean fluorescence intensity ratio
(4) granulocyte/lymphocyte SSC peak channel ratio and the proportion of CD34+
myeloblasts expressing (5) CD15 (6) CD11b and (7) CD56. ROC curves were
constructed for each parameter. A score of 1 was given to each of these param-
eters beyond the cut-off and score ≥3 was considered as FCM positive.
Results: MNDA expression in granulocytes and myeloblasts was significantly
lower in MDS cases as compared to controls (p=0.003 and 0.001 respectively).
The percentage of MNDA negative granulocytes (mean+SD, 79.9%+13.4%,
p<0.001) was higher in MDS cases as compared to non MDS (53.46%+19.6%).
Similar differences were also seen in myeloblasts (88.85%+7.3% in MDS Vs
60.3%+18.15% in non MDS, p<0.001). Monocytes, however; failed to show
any significant difference between these groups (p=0.802). ROC cut-off value
for granulocytes had sensitivity and specificity of 75% and 76.92%, respectively
and for myeloblasts 91.6% and 88.5%, respectively for discriminating between
MDS and non MDS. MNDA expression was significantly reduced in suspected
MDS as compared to non MDS cases in both: granulocytes (p=0.032) and
myeloblasts (p=0.004). On the basis of ROC cut offs, MNDA expression was
altered in either granulocytes or myeloblasts (single abnormality) in five/six
cases (83.3%) where four/six cases (66.7%) had dual abnormality (altered in
both granulocytes and myeloblasts). However significant difference between
the suspected MDS and non MDS was seen in the presence of dual abnor-
mality only (p=0.022) and not in case of single abnormality (p=0.336). In other
quantitative FCM parameters assessed, a score of ≥3 successfully distin-
guished MDS from non-MDS with a sensitivity of 100% and specificity of 95.2%.
After incorporating MNDA score into the quantitative FCM scoring (total 8
parameters), score ≥3 successfully discriminated suspected MDS from non
MDS cases (p=0.005) and MDS from non MDS (p<0.001) with a sensitivity
and specificity of 100% and 95.24%, respectively which is similar to those
obtained at a score of ≥3 with quantitative approach (Figure 1 and Figure 2).
Figure 1. Box and whisker plot showing MNDA expression in different
groups of patients. Percentage of MNDA negative granulocytes (A) and
percentage of MNDA negative myeloblasts (B) in non MDS, suspected
MDS and MDS cases.
Figure 2. MNDA analysis in non MDS and MDS cases. MNDA expression is
displayed for lymphocytes and granulocytes in a histogram. (A) Lympho-
cytes showing similar MNDA expression in both MDS and non MDS used
as internal negative control (B) MNDA expression in granulocytes in a non
MDS patient. (C) MNDA expression in granulocytes in a MDS patient.
Summary and Conclusions: Both MNDA analysis and quantitative FCM
approach using “mini panel” of antibodies are independently able to discrimi-
nate MDS from non MDS and controls and correctly categorize suspected
MDS as a distinct group. On merging the two approaches, the sensitivity and
specificity of flow cytometric analysis did not improve. More studies validating
this in a large cohort of patients are required before any conclusion can be
reached regarding superiority of any method.
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OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS
IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED,
CONTROLLED, PHASE III STUDY OF RIGOSERTIB
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Background: ONTIME was a randomized (2:1) study of rigosertib (RIG) vs
best supportive care (BSC, including optional low-dose ARA-C) in 299 pts with
higher-risk MDS who had relapsed after, failed to respond to, or progressed
during treatment with hypomethylating agents (HMAs). For MDS patients who
fail HMAs, there are no FDA-approved therapies. Thus an unmet medical need
exists for effective second-line therapies. ONTIME showed a significant treat-
ment effect with RIG in the subgroup of patients with “primary HMA failure”
(Garcia-Manero et al., Blood 2014).
Aims: To describe differences in overall survival (OS) after primary or second-
ary HMA failure in 299 patients treated with RIG (N=199) or BSC (N=100) in a
Phase III study.
Methods: We evaluated the correlation between baseline disease character-
istics and OS in pts with primary HMA failure (RIG N=117; BSC N=52) as ascer-
tained by a centralized, blinded reader.
Results: Pts with primary HMA failure were generally male (69%), age 50-86
years (median 73), at high or very high risk per IPSS-R (80%), with 5-19%
bone marrow blast count (92%). A meaningful difference in median OS between
RIG and BSC was observed not only in the overall population of pts with primary
HMA failure, but also in several subgroups (see Table 1). Overall, adverse
events (AEs) were reported in 99% of RIG pts and 88% of BSC pts. The fol-
lowing AEs >=Grade 3 were reported by ≥ 10% of pts: anaemia (16% RIG vs
10% BSC), thrombocytopenia (15% vs 6%), neutropenia (15% vs 8%), febrile
neutropenia (13% vs 10%), pneumonia (12% each).
Table 1.
Summary and Conclusions: Patients with primary HMA treatment failure and
certain subgroups identifiable on the basis of baseline disease characteristics
randomized to RIG showed an improvement in OS compared to BSC. Such
characteristics should be considered in the design of future trials in second-
line in primary HMA failure patients. 
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Background: Supportive care (BSC) including hematopoietic cytokines still
remains an important component of treatment for lower-risk myelodysplastic
syndrome (LR-MDS) including low or intermediate-1 risk by International
Prognostic Scoring System (IPSS) even in the era of hypomethylating
agents (HMA). The role of front-line HMA for LR-MDS has not been clearly
defined yet. 
Aims: We evaluated the long-term outcomes of patients with LR-MDS treated
with front-line HMA compared to those treated with supportive care.
Methods: The data of 353 patients diagnosed with LR-MDS from Oct 1992
to Jul 2013 were retrospectively evaluated. The prognostic factors affecting
overall survival were evaluated within all population. Then, we performed a
case-constrol study using 122 patients with propensity score matched (PSM)
population. 
Results: Initial patient population (n=353) included 110 patients treated with
BSC and 243 treated with HMA. Patients characteristics (age, gender, IPSS
risk groups, IPSS blast score, IPSS cytopenia score) were similar between
two groups, however, ECOG performance status (PS) and IPSS cytogenetic
score were biased between two groups. ECOG-PS 2-3 were 32 patients
(29.1%) in BSC and 20 (9.3%) in HMA group (p<0.001) and IPSS cytogenetic
score ≥0.5 were 27 patients (25.2%) and 33 (14.6%) in HMA group (p=0.032).
In the multivariate analysis, ECOG-PS 2-3 (HR 4.586, p<0.001), IPSS blast
≥0.5% (HR 2.549, p<0.001) and front-line HMA therapy (HR 2.019, p=0.006)
were unfavorable factors affecting OS. Using PSM population, we performed
a case-control study comparing the outcomes of 61 patients in each group
who treated with BSC and front-line HMA. Patient characteristics were well
balanced between two group. In the multivariate analysis, ECOG-PS 2-3
(HR5.036, p<0.001), IPSS blast ≥0.5% (HR 2.157, p=0.035), and first-line
HMA therapy (HR 2.213, p=0.026) were still unfavorable factors for OS. The
5-year OS rate was 62.5±10.8% in BSC group and 41.0±7.4 in HMA group,
respectively (p=0.049). Infection was the main cause of death among patients
who received HMA ≤4 cycles (61.3%) compared to those who received HMA
>4 cycles (22.2%, p=0.051) (Figure 1).
Figure 1.
Summary and Conclusions: Front-line HMA for patient with LR-MDS showed
inferior long-term outcomes compared to BSC in PSM population. Early infec-
tion-related mortality could compromise the favorable effect of HMA. The effect
of HMA on later leukemic transformation and resistance should be elucidated
in the future studies.
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Background: CC-486 has clinical activity in patients (pts) with IPSS-defined
lower-risk MDS (Garcia-Manero, ASH 2010, 2012). This ad hoc analysis
assessed CC-486 efficacy in a small group of pts with HR-MDS (IPSS Inter-
mediate [INT]-2 or High-risk) from 2 phase I/II studies. While all pts had HR-
MDS, CC-486 dosing schedules in these studies varied between administration
for 7 days (d) per 28d cycle and extended administration (CC-486 x14 or
x21d/28d cycle); prognostic disease variables at baseline differed; and, at study
entry, some pts were MDS Tx-naïve while others had progressive disease
despite prior Tx.
Aims: To explore whether differences in dosing schedules, prognostic disease
features, and receipt of prior MDS Tx influenced overall response rate (ORR)
with CC-486 in pts with HR-MDS.
Methods: Pts received CC-486 120mg to 600mg QD x7d/28d cycle (7D
cohort) or in an extended dosing schedule (ED cohort): 300mg QD x21d/28d
(21D); 300mg QD x14d/28d (QD-14D); or 200mg BID x14d/28d (BID-14D).
Dosing schedules in the ED cohort were analyzed collectively. Prognostic
Risk Index scores for this ad hoc analysis were calculated as 1 point each for
the following abnormalities at baseline: Hgb <11 g/dL, ANC <1.0x109/L,
platelets <100x109/L, BM blasts ≥5%, and transfusion of ≥4 RBC units or ≥2
platelet units in the 56 days before study entry. ORR (IWG 2006) included
complete or partial remission, RBC or platelet transfusion independence, and
any hematologic improvement. ORR was evaluated based on dosing cohort
(7D or ED), prior MDS Tx (yes/no), and prognostic Risk Index scores (≤3/>3
abnormalities).
Results: In all, 13 pts (50%) comprised the 7D cohort and 13 (50%) com-
prised the ED cohort (21D n=11, QD-14D n=1, BID-14D n=1). At baseline,
most pts had IPSS INT-2 MDS (n=24, 92%), were male (n=19, 73%), and
had ECOG PS of 0-1 (n=22, 85%). Pt diagnoses were RAEB-1 (n=11, 42%),
RAEB-2 (n=11, 42%), RCMD (n=3, 12%), and RA (n=1, 4%). Overall, 11 pts
(42%) had received prior MDS Tx (ESAs, growth factors, thalidomide,
lenalidomide, and/or hypomethylating agents [HMAs, n=7]). Median ages in
the 7D and ED groups were 69 (range 31-91) and 75 (47-87) years, respec-
tively. Median time since diagnosis was 3.9 months (range 0.7-40) in the 7D
group and 5.3 months (0.4-119) in the ED group. Median Hgb, ANC, and
platelet counts in the 7D group were 9.1 g/dL, 0.6x109/L, and 54x109/L,
respectively, and in the ED group were 9.0 g/dL, 0.4x109/L, and 19x109/L.
Most pts (n=17, 65%) had prognostic Risk Index scores >3. One pt (7D
cohort) was not evaluable for response (no post-baseline data). ORR for all
pts was 56% (14/25) (Figure 1), including 5/8 pts with poor-risk cytogenetics.
ORR in the 7D and ED cohorts were 46% (6/13) and 67% (8/12), respectively.
ORR in pts who had received prior MDS Tx was 40% (4/10, including 2/7 pts
who had received prior HMA Tx and responded to CC-486) and in pts who
had no prior MDS Tx was 67% (10/15). ORR in pts with prognostic Risk Index
scores ≤3 and >3 were 50% (4/8) and 59% (10/17), respectively.
Figure 1. CC-486 in patients with Higher-risk MDS.
Summary and Conclusions: More than one-half of these pts with HR-
MDS attained a hematologic response with CC-486. In this small patient
group, prolonged exposure to CC-486 resulted in a higher proportion of
response. Absence of prior MDS therapy was associated with better
response, though prior HMA Tx did not preclude response to CC-486. Base-
line prognostic Risk Index score did not influence ORR, suggesting that
underlying molecular pathways or genetic factors may have a greater influ-
ence on Tx response. 
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AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMO-
SOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE
STUDY FROM THE GFM AND GESMD REGISTRIES
M. Díez Campelo1,2,* J.I. Lorenzo3, R. Itzykson4, S. Rojas Porras1, R. Guièze4,
E. Luño1, C. Berthon4, J.M. Hernández Rivas1, O. Beyne-Rauzy4, J. Pérez de
Oteiza1, N. Vey4, B. Xicoy1, S. Park4, A. Bailén García1, D. Bordessoule4,
J. Bargay1, E. Gyan4, E. Such1, S. Visanica4, T. Cedena1, S. De Botton4,
M. Tormo1, S. Ame4, M. Calabuig1, A. Stamatoullas4, F. Ramos1, J. Delaunay4,
M.Á. Ruiz Guinaldo1, C. Salanoubat4, A. Fernández González1, F. Isnard4,
G. Sanz1, R. Guieze4, C. del Cañizo1, P. Fenaux4
1Hematology, GESMD, Valencia, 2Hematology, Hospital Universitario de Sala-
manca, Salamanca, 3Hematology, Hospital La Fe, Valencia, Spain, 4Hematol-
ogy, GFM, Paris, France
Background: Cytogenetic alterations are the most discriminative prognostic vari-
ables in MDS, complex karyotype (CK) and Abn7 having the poorest outcome.
Data from small series have suggested that non complex Abn 7 are associated
with relatively favorable response to AZA in MDS.The paradigm that CR or PR
is necessary to prolong OS with AZA treatment has also been challenged. 
Aims: We analyzed in a large series of higher risk MDS with Abn 7 treated with
AZA the impact of response on survival compared to best supportive care (BSC).
Methods: This study analyzed 235 patients with higher risk (IPSS Int-2 and
high) MDS with Abn 7 included in the French and Spanish MDS registries. 115
patients received AZA (75 mg/m2/d for 7 days [n=92] or 5 days [n=23] every 4
weeks; median number of cycles, 5 [range, 1 - 32]) and 120 received only BSC
(control group). The effect of response to AZA (IWG 2006 criteria) on outcomes
was evaluated by time-dependent multivariable methods.
Results: Baseline characteristics were similar in both groups (Table 1). 91
AZA-treated patients were evaluable for response. The ORR was 42.8%
(n=39), including 16.4% CR and 26.4% SD with HI. Among non-responders,
53.8% had SD without HI and 46.2% progressed. 11 (16%) of 67 RBC trans-
fusion dependent patients became transfusion independent. The ORR was
43% in pts with CK, 35% in pts with non complex and -7 and 50% in pts with
non complex and del(7q) (p=0.1 for complex vs non complex Abn 7). At last
follow up, 61 patients had relapsed or progressed (53%) and 92 (80%) had
died. AML-free survival and OS estimates at 1 and 2 years were 62 and
31% and 43% and 16%, respectively. In multivariable time-dependent analy-
ses in the overall series response to AZA, IPSS risk group, and CK had a
significant independent impact on OS and AML-free survival. Compared to
untreated patients, any type of response to AZA and SD without HI was sig-
nificantly associated with a reduced risk of mortality and AML progression
(Tables 2 and 3).
Table 1. Patients and disease characteristics.
Table 2. Cox OS. Multivariate analysis among R vs SD vs NR vs no treat-
ment.
Table 3. Cox LFS. Response vs no response vs SD vs no treatment mul-
tivariate analysis.
Summary and Conclusions: AZA yields a significant response rate in higher
risk MDS with Abn 7. Response to AZA, including SD without HI, translates




TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS)
WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM
BRITISH COLUMBIA, CANADA
M. Ankenman1,* D. Hogge1, S. Narayanan1, M. Power1, Y. Abou Mourad1,
M. Barnett1, S. Nantel1, H. Sutherland1, D. Forrest1, R. Broady1, C. Toze1,
A. Gerrie1, K. Song1, T. Nevill1
1Leukemia/BMT Program of BC, Vancouver, Canada
Background: MDS is a clonal disorder with propensity to transform to AML.
Prior to 2010, treatment was limited to supportive care or, in young patients
(pts), stem cell transplantation (SCT). Azacitidine (AZA), a hypomethylating
agent, produces hematologic improvement (HI) in 50% of higher-risk MDS pts
and prolongs overall survival (OAS; Fenaux, 2009). Health Canada approved
AZA in October 2009 after which the British Columbia Cancer Agency (BCCA)
began funding the drug for MDS pts in the province of BC.
Aims: The research objective was to review patterns of AZA use and to deter-
mine its efficacy in a population-based analysis.
Methods: An IRB-approved retrospective review of pts receiving AZA for MDS
in BC was performed by obtaining dispensing records from the BCCA pharmacy
data base and clinical notes from the Cancer Agency Information System. Final
analysis date was August 1, 2014.
Results: Between 01/2010 and 04/2014, 181 pts were treated with AZA in BC;
there were 127 males and 54 females with median age 71 years (range 1-90).
Diagnosis (WHO 2008) was (oligoblastic) AML (60 pts), RAEB-2 (45 pts),
RAEB-1 (24 pts), therapy-related neoplasm (19 pts), CMML (16 pts), RCMD
(14 pts) or MDS, unclassifiable (3 pts). IPSS karyotype was available in 136
pts - 34% were good-risk/normal, 40% were intermediate-risk and 26% were
poor-risk. Pts were treated at teaching hospitals in Vancouver (VAN, 72 pts),
BCCA sites outside Vancouver (BCCA, 44 pts) or one of 14 smaller hospitals
(OTHER, 65 pts) of which only 3 sites treated >5 pts. Starting AZA dose was
75 mg/m2/d in 78%, 50 mg/m2/d in 9%, 37.5 mg/m2/d in 6% or other in 7% of
pts. Overall, 50% of pts received 75 mg/m2/d throughout treatment; 36%, 29%
and 12% of pts required ≥1, 2 or 3 dose reductions. AZA doses were re-esca-
lated in 20% of pts and 9% of pts were increased to 100 mg/m2/d. Median
number of AZA cycles given was 5 (range 1-42) with 60% of pts receiving ≤5
cycles; 35 pts (19%) received only one cycle and 37 pts (20%) received 2-3
cycles. Pts receiving ≤3 cycles was similar at VAN, BCCA and OTHER (42%,
30% and 45% of pts, respectively). IWG responses were evaluable in 163 pts
and were CR (18 pts, 11%), PR (4 pts, 2%) or HI (47 pts, 29%); 14 pts (9%)
had stable disease. HI by lineage was 64% erythroid (73% major), 49% platelet
(79% major) and 34% neutrophil (85% major). Bone marrow exam follow-up
was done infrequently in responding pts making upgrading from HI to PR/CR
problematic and determination of cytogenetic response not possible. Respons-
es were independent of cytogenetic classification with overall response
(HI+PR+CR) similar in good- (52%) and poor-risk (44%) karyotypes. Reason
for stopping AZA could not be determined in 35% of pts; most common identi-
fiable reasons were lack/loss of response (43%), death from complications of
MDS/AML (36%), decision to proceed to SCT (10%) and AZA side
effects/patient discretion (10%). Median OAS for the entire cohort was only 7
months (range 1-37) with 43 pts (24%) alive at date of analysis. Including only
the 109 pts receiving ≥4 cycles, median survival was 13 months.
Summary and Conclusions: This population-based analysis of AZA treatment
outcomes in MDS suggests that many pts are not given adequate trials (≥4
cycles) at standard doses. This may explain why, despite IWG response rates
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in line with the pivotal randomized trial, median survivals were inferior to expec-
tations. Physician and patient education on the importance of adequate dosing
and duration of therapy is ongoing in BC. 
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ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE (COMBINATION VS
SEQUENTIAL TREATMENT) IN HIGH-RISK MYELODYSPLASTIC SYN-
DROMES. UPDATE OF THE RESULTS OF A RANDOMIZED PHASE II MUL-
TICENTER STUDY
C. Finelli1,* C. Clissa2, M.Y. Follo3, M. Stanzani1, S. Parisi1, S. Mongiorgi3,
P. Avanzini4, C. Bosi5, B. Castagnari6, A. Candoni7, M. Crugnola8, M.B. Giannini9,
M. Gobbi10, G. Leonardi11, G.M. Rigolin12, D. Russo13, P. Tosi14, V. Giuseppe2,
L. Cocco3, M. Cavo1
1Hematology, S.Orsola-Malpighi University Hospital, Bologna, 2Hematology,
S.Salvatore Hospital, Pesaro, 3Biomedical Sciences-Human Anatomy, Univer-
sity of Bologna, Bologna, 4Hematology, S.Maria Nuova Hospital, Reggio Emilia,
5Hematology, Guglielmo da Saliceto Hospital, Piacenza, 6Hematology, S. Maria
delle Croci Hospital, Ravenna, 7Hematology, S. Maria della Misericordia Uni-
versity Hospital, Udine, 8Clinical and Experimental Medicine, University of Par-
ma, Parma, 9Oncology, I.R.S.T., Meldola (FC), 10Hematology, S. Martino Uni-
versity Hospital, Genova, 11Hematology, University of Modena, Modena,
12Hematology, University of Ferrara, Ferrara, 13Chair of Hematology, University
of Brescia, Brescia, 14Hematology, Infermi Hospital, Rimini, Italy
Background: Azacitidine (AZA) is able to induce hematologic responses in
50-60% of patients (pts) with Myelodysplastic Syndromes (MDS) and moreover
to prolong survival in higher risk MDS pts. However the duration of therapeutic
response to AZA is limited, with a median survival advantage of only 9.5 months.
Recently, several studies have evaluated the efficacy and safety of combining,
in high-risk MDS pts, AZA with Lenalidomide (LEN), either administered con-
currently (Sekeres, 2010; 2012), or sequentially (Platzbecker, 2013), in both
cases showing promising results, although in a limited number of pts.
Aims: The aim of this study was to evaluate the efficacy and safety of the com-
bination vs the sequential use of AZA and LEN in high-risk MDS pts (IPSS
score risk: High or INT-2). Primary endpoint: ORR, defined as the Rate of Com-
plete Remission (CR), Partial Remission (PR), Marrow Complete Remission
(mCR), and Hematological Improvement (HI), following the International Work-
ing Group (IWG) criteria (Cheson, 2006).
Methods: A randomized, phase II, multicenter, open label study, including pts
with MDS (WHO 2008 classification) with International Prognostic Scoring Sys-
tem (IPSS) risk High or Intermediate-2, without previous treatment with AZA or
LEN. ARM 1 (combined treatment): AZA: 75 mg/m2/day (days 1-5) I.C.+LEN:
10 mg/day (days 1-21), orally, every 4 weeks. ARM 2 (sequential treatment):
AZA: 75 mg/m2/day (days 1-5) I.C.+LEN: 10 mg/day (days 6-21), orally, every
4 weeks. The induction treatment was planned for 8 cycles (32 weeks). For
responder patients (CR, PR, mCR, or HI) the same treatment will be continued
until disease progression or unacceptable toxicity. A sample size of 44 pts was
planned. At the time of this analysis, 44 pts have been enrolled, 22 pts are still
on therapy, and 7 of them have not yet completed 6 cycles of treatment.
Results: From March 2013, 44 pts (27 males), with a median age of 72 (48-83
yrs) were enrolled, from 13 hematologic italian Centers. At baseline, WHO diag-
nosis was: RCMD: 2 pts; RCMD-RS: 1 pt ; RAEB-1: 11 pts; RAEB-2: 30 pts;
IPSS risk was: Intermediate-2: 32 pts; High: 9 pts; not determined (N.D.) (because
of lack of cytogenetic data): 3 pts. (all with RAEB-2). IPSS cytogenetic risk was:
Good: 16 pts; intermediate: 12 pts; Poor: 13 pts. 21 pts were randomly assigned
to ARM 1, and 23 pts to ARM 2. At the time of this analysis, 44 pts have been
enrolled, 28/44 pts (63.6%) completed ≥6 cycles of treatment, and are evaluable
for response. 22/28 pts (78.6%) showed a favourable response to treatment, fol-
lowing the International Working Group (IWG) criteria (Cheson, 2006) : 9 pts
achieved Complete Remission (CR), 2 pts attained Partial Remission (PR), 2 pts
showed Marrow Complete Remission (mCR), and 9 pts obtained Hematological
Improvement (HI). Responder pts were: 11/13 (84.6%) in ARM 1 (2 CR; 2 PR; 1
mCR; 6 HI), and 11/15 (73.3%) in ARM 2 (7 CR; 1 mCR; 3 HI), respectively. A
grade >2 non hematologic toxicity was observed in 18/43 (41.9%) pts. 21/43 pts
(48.8%) had a dose reduction of LEN because of hematologic or non-hematologic
toxicity. 11 pts died; 6 pts showed progression to AML.
Summary and Conclusions: Our results, although preliminary, seem to con-
firm the feasibility of the association of AZA and LEN in high-risk MDS pts.
Ongoing analyses are aimed to assess possible relationships between
response to therapy and specific alterations affecting inositide signalling mol-
ecules, mutational status and microRNA profiling.
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CLINICAL IMPACT OF DEL (11Q) IN PATIENTS WITH DE NOVO AND SEC-
ONDARY MYELODYSPLASTIC SYNDROMES- A SINGLE INSTITUTION
EXPERIENCE
H. Alkhateeb1,* M. Damlaj1, A. Al-Kali1, N. Gangat1, K.H. Begna1, M.R. Litzow1,
W.J. Hogan1, M.A. Elliott1, R.P. Ketterling2,3, M.S. Patnaik1
1Hematology, 2Cytogenetics, 3Hematophatology, Mayo Clinic, Rochester, MN,
United States
Background: Del(11q) is an uncommon cytogenetic abnormality (<1%) in
patients with myelodysplastic syndromes (MDS), and when associated with dis-
ruption of the MLL gene portends an inferior survival. With the recent revision of
the IPSS, isolated del 11q (non-MLL) is considered to be a favorable karyotype.
Aims: To describe the incidence, clinical features and outcomes of 11q deleted
MDS and the impact of the MLL gene rearrangement.
Methods: After due IRB approval, patients diagnosed with MDS from 2000-
2015 at Mayo Clinic Rochester were screened. Consecutive cases of MDS
with del (11q) were identified and reviewed. Patients underwent a bone marrow
aspirate at diagnosis and all clinical and pathologic data including FISH studies
and cytogenetics were retrospectively reviewed. The cohort was stratified into
three groups according to the underlying karyotype; isolated del (11q), del (11q)
with an additional structural abnormality, and del (11q) with a complex kary-
otype. Survival analysis was estimated by Kaplan-Meier method and log ranks
was used to compare the curves.
Results: A total of 1550 MDS patients were screened and, 23 (1.5%) with del
(11)q were identified. Eleven patients (47%) were males. Four (17%) patients
had secondary MDS, while the remainder had de novo disease. The median
age at diagnosis was 70 years. Median presenting features included the fol-
lowing; absolute neutrophil count (ANC) of 1.8x109, hemoglobin (Hb) of 8.8
g/dl, platelets (Plt) 75x109, and bone marrow (BM) blasts of 3%. The median
follow up was 12 months and over all 17 deaths (74%) and 2 (%) leukemic
transformations were documented. The median OS for MLL rearranged versus
non rearranged patients was 16 vs 24 months, respectively (p=0.49). Patients
were then grouped based on additional cytogenetic abnormalities. Group 1:
Six pts had del (11q) as a sole abnormality, one of who had a MLL rearrange-
ment. IPSS-R stratification score included 4 with low risk and 2 with intermediate
risk. Median overall survival (OS) was 30 months (P=0.0094) comparing sur-
vival among the three groups and diminished to 28 months with MLL rearrange-
ment (P=0.0015). Group 2: Nine pts had del (11q) and an additional structural
abnormality, with only one of these demonstrating the MLL rearrangement.
None of the additional karyotypic abnormalities were considered poor prognosis
based on IPSS-R. As per the IPSS-R score, there were 5 intermediate risk and
3 low, 1 missing data. Median OS was 24 months vs 9 months without and with
MLL rearrangement, respectively (P=0.0015) comparing survival based on MLL
rearrangement among the three groups. Median OS of the group was 21
months. Group3: Eight patients with del (11q) with a complex karyotype, of
which three demonstrated the MLL rearrangement (2 with therapy related MDS).
Notably there were no patients with a monosomal karyotype. As per the IPSS-
R score, there were 6 very high risk and 2 high risk. Median survival of the
group was 7 months. Median OS again diminished with MLL rearrangement at
5.6 vs 10 months, respectively (P=0.0015) (Figure 1).
Figure 1.
Summary and Conclusions: Del (11q) is a rare karyotype in MDS with an
incidence of <2%, 25% with del (11q) have associated MLL gene rearrange-
ments. Although non-MLL rearranged isolated del (11q) is classified as a very
good cytogenetic aberration, the observed OS in our group was inferior to IPSS-
R predicted survivals. In subgroup analysis MLL gene rearrangements inde-
pendently impacted OS.
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A PROGNOSTIC MODEL FOR PREDICTING SURVIVAL AFTER STOPPING
HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME
H. Kim1,* J.H. Moon2, J.-C. Jo1, J.S. Ahn3, Y.-R. Do4, H.J. Shin5, W.S. Lee6,
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Background: Hypomethylating agent (HMA) is widely used for the treatment
of myelodysplastic syndrome (MDS) not only for hematopoietic cell transplan-
tation (HCT) ineligible patients but also HCT eligible patients for a bridging
therapy. However survival after HMA stop is very dismal although more inten-
sive therapy like HCT can expect longer survival. However, we don’t know
which patient can survive longer even after stopping HMA is still unknown. 
Aims: We wanted to know which clinical factors will be important for predicting
prognosis after HMA failure. Here we present a prognostic model for predicting
survival after stopping HMA in MDS.
Methods: Data were retrospectively collected. All MDS patients who had
received HMA were selected. For the analysis of prognostic model after stop-
ping HMA, we excluded patients with on-going HMA therapy, patients who
stopped HMA for planned HCT or patients who died during HMA therapy.
Results: We retrospectively collected 236 MDS patient who had received HMA.
We excluded on going HMA therapy, stopping HMA for planned HCT or stop-
ping HMA by death. Therefore total 187 patients were selected for this analysis.
Median survival after HMA stop was 11.4 (95% CI, 9.369-13.432) months. HCT
or supportive care had longer survival than chemotherapy (p=0.024) as a sal-
vage therapy after HMA stop. Many clinical factors were validated as prognostic
factors for predicting survival; gender (p=0.568), age<70y (p=0.034), ECOG 0
or 1 (p=0.065), prior cancer or multiple comorbidity (p=0.017), initial IPSS-R
very low/low/intermeidate (p=0.001), time to HMA start >4 weeks (p=0.067),
azacitidine as HMA (p=0.127), HMA treatment duration <3M (p=0.346), SD/HI
as best response to HMA (p=0.003), CR/PR/SD as final response to HMA
(p<0.001), HMA stop by progression/loss of response (p=0.002). Multivariate
analysis revealed that age<70 (HR 1.766, 95% CI 1.156-2.698; p=0.008), no
prior cancer or multiple comorbidity (HR 2.340, 95% CI 1.127-4.859; p=0.023)
or CR/PR/SD final response (HR 2.225, 95% CI 1.480-3.344; p<0.001) were
prognostic factors. Median survival for favorable (no risk factor; n=55), inter-
mediate (1 risk factor; n=97) or poor risk group (2 or more risk factors; n=34)
were 30.653 (95% CI 17.786-43.520), 10.349 (95% CI, 8.267-12.431) or 5.322
(95% CI, 2.757-7.888) months, respectively (p<0.001; Figure 1).
Figure 1.
Summary and Conclusions: Our data showed that survival after stopping
HMA was dismal, but some prognostic factors can predict longer survival
among them even with supportive care.
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CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW
BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLAS-
TIC SYNDROMES (MDS)
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1Icahn School of Medicine at Mount Sinai, New York, United States, 2Hospital
St Louis, Paris, France, 3Stanford Medical School, Stanford, United States,
4University of Florence, Florence, Italy, 5Peter MacCallum Cancer Centre and
University of Melbourne, Melbourne, Australia, 6Onconova Therapeutics, Inc.,
Newtown, 7MD Anderson Cancer Center, Houston, United States
Background: BMBL% is the prognostic variable with the greatest impact on
outcome in MDS patients at diagnosis and subsequent time points. Current
composite response criteria (IWG, Cheson 2006) do not consistently correlate
with OS. Treatment impact of BMBL as an independent response criterion has
not been adequately evaluated.
Aims: To evaluate the correlation between OS and BMBL in pts with higher-
risk (HR) MDS.
Methods: We accessed 4 datasets encompassing 7 studies with 887 pts and
evaluated the correlation of BMBL response/stabilization at 4- and 12-week
timepoints with OS. The 4 studies were: ONTIME, a Phase III randomized
study of 2nd-line rigosertib (RIG) vs best supportive care (BSC) (N=299; Sil-
verman, ASH 2014); 4 Phase I/II studies of RIG in pts with MDS/AML (N=39;
Silverman, Hematol Oncol 2014); AZA-001, a Phase III study of azacitidine
(AZA) vs 3 conventional care regimens (N=358; Fenaux, Lancet Oncol 2009;
Gore, Haematologica 2013); Cancer & Leukemia Group B (CALGB) Study
9221, a Phase II, randomized trial of 1st-line AZA vs BSC (N=191; Silverman,
J Clin Oncol 2002). Change in blasts was defined similarly in each of the 4
studies: BM complete response is BMBL ≤5%; BM partial response is ≥50%
decrease from baseline, but BMBL still >5%; stable disease is <50% decrease
or increase from baseline.
Results: In ONTIME, landmark time-dependent analyses showed correlation
of BMBL response/stabilization with OS at 4 wks (P=0.011) and 12 wks
(P<0.001). In the 4 Phase I/II studies, BMBL response/stabilization at 4-8 weeks
was associated with a quadrupling of median OS (P<0.001). In Study AZA-
001, time-dependent analysis of BMBL stabilization was associated with a sig-
nificantly reduced risk of death in both treatment cohorts (P<0.001) compared
to progression. In Study 9221, landmark analysis of BMBL response/stabiliza-
tion showed a 6-fold improvement in OS (P<0.001).
Summary and Conclusions: These studies, spanning more than a decade
with different therapeutic agents and settings, demonstrate a consistent positive
correlation between BMBL response and OS in pts with HR-MDS, including
pts on supportive care. This suggests that use of reduction/ stabilization in
BMBL can serve as a new early response parameter, as an intermediate clinical
endpoint for evaluation of new agents, and as a biomarker for disease pro-
gression in HR-MDS itself.
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THE INTERIM ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDY
WITH PNH-TYPE CELLS IN JAPANESE PATIENTS WITH BONE MARROW
FAILURE (THE OPTIMA STUDY)
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease deriv-
ing from an acquired mutation of the phosphatidylinositol glycan class A (PIGA)
gene in the hematopoietic stem cells. In some cases of aplastic anemia (AA)
or low-risk types of myelodysplastic syndromes (MDS), it is known that PNH-
type cells can be often detected through the high-resolution flow cytometry-
based method. Because these patient groups are reported to have a good
response to immunosuppressive therapies as opposed to the other patient
groups lacking PNH-type cells, detection of these cells is potentially useful in
determining a treatment plan for the cases of bone marrow failure syndromes.
To confirm this preliminary information, a large cohort study is needed.
Aims: In order to determine the prevalence and significance of PNH-type cells
in bone marrow failure patients, we conducted a nationwide multi-center
prospective 0bservational investigation, the OPTIMA study (Observation of
GPI-anchored protein-deficient cells in Japanese patients with bone marrow
syndrome and in those suspected of having PNH).
Methods: A nationwide multi-center prospective observational study (OPTIMA)
was started in July 2011 to determine the prevalence of patients with bone marrow
failure syndromes who carried PNH-type cells and to clarify the clinical signifi-
cance of the presence and quantitative changes of these cells with regard to the
clinical features. Each of the 6 laboratories in different universities was assigned
as a regional analyzing center. The percentage of PNH-type cells was measured
by the high-resolution flow cytometry-based method, originally established in
Kanazawa University. At the six individual laboratories, cross validations were
conducted to minimize the inter-laboratory variations in the detection sensitivities,
cutoff values, etc. For the detection of PNH-type granulocytes, the liquid FLAER
method (≥0.003%) was used, and cocktail method (≥0.005%) with CD55 and
CD59 antibodies was used for PNH-type erythrocyte detection.
Results: As of July 2014, flow cytometry data have been collected from 1739
patients and are included in this interim analysis. Of these patients, 67 (3.9%)
were diagnosed with PNH, 546 (31.4%) with AA, 475 (27.3%) with MDS, and
651 (37.4%) with bone marrow failure (BMF) of unknown etiology. Overall, 172
(9%) patients had ≥1% of both PNH-type erythrocytes and granulocytes: 66
(98.5%) patients with PNH; 66 (12.1%) with AA; 22 (4.6%) with MDS; and 18
(2.8%) with BMF of unknown etiology. In total, 607 (34.9%) patients had
≥0.005% PNH-type erythrocytes and ≥0.003% PNH-type granulocytes. These
consisted of the followings: all 67 (100%) patients with PNH; 295 (54.0%) with
AA; 85 (17.9%) with MDS; and 160 (24.6%) with BMF of unknown origin. No
patients with MDS-RAEB-1 or -2 had PNH-type cells. Lactate dehydrogenase
(LDH) levels ≥1.5 × upper limit of normal range were seen in 4% patients with
0.005-1% PNH-type erythrocytes, 37% patients with 1-10% PNH-type erythro-
cytes, and 97.4% patients with ≥10% PNH-type erythrocytes.Periodic blind val-
idation tests revealed that inter-laboratory differences in absolute measure-
ments of PNH-type cells were always within 0.02%.
Summary and Conclusions: A high-resolution flow cytometry-based method
that enables the detection of very low percentages of PNH-type cells was suc-
cessfully transferred to 6 laboratories across Japan. Our results demonstrated
that the proportion of patients identified as having small percentages of PNH-
type cells differed depending on diagnosis (PNH, AA, MDS, or unknown BMF)
and that elevated LDH levels (>1.5xupper limits of normal range) were more
frequently associated with higher percentages of PNH-type erythrocytes. PNH-
type cells didn’t detected in patients with MDS-RAEB-1 or -2. Our findings sug-
gest that the high-resolution method is helpful as a diagnostic tool in BMF syn-
dromes, including AA, MDS, and PNH, and may prove useful in understanding
the pathophysiology of these disorders.
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HYPOMEGAKARYOCYTIC THROMBOCYTOPENIA (HMT): AN IMMUNE-
MEDIATED BONE MARROW FAILURE CHARACTERIZED BY AN
INCREASED NUMBER OF PNH-PHENOTYPE CELLS AND PLASMA
THROMBOPOIETIN LEVELS
K. Ishiyama1,* H. Yamazaki2, C. Saito1,3, Y. Zaimoku2,4, H. Maruyama4, S. Nakao4
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Background: Chronic thrombocytopenia is one of the most common abnormal-
ities that are seen at hematology clinics. Although immune thrombocytopenic
purpura (ITP) is the most frequent diagnosis of chronic thrombocytopenia without
anemia and leukocytopenia, there are a considerable number of cases exhibiting
megakaryocytic hypoplasia which do not meet the diagnostic criteria for ITP,
aplastic anemia (AA), myelodysplastic syndrome (MDS), or paroxysmal nocturnal
hemoglobinuria (PNH). Patients with hypomegakaryocytic thrombocytopenia
(HMT) are usually followed without therapy when their thrombocytopenia is mild,
i.e., 50x109/L. However, some patients may progress to aplastic anemia (AA)
after a long observation period, which is often refractory to immunosuppressive
therapy (IST). It is therefore important to elucidate the pathophysiology of patients
with HMT at the time of diagnosis, even when their thrombocytopenia is not
severe. We previously conducted a retrospective analysis of 29 patients with
HMT and found that 55% patients possessed an increased number of glyco-
sylphosphatidylinositol (GPI) anchored protein (GPI-AP)-deficient blood cells
(PNH-type cells), which are often detected in patients with AA and are associated
with a better response to IST than patients not possessing PNH-type cells. Ten
of such 16 PNH(+) patients received cyclosporine (CsA) monotherapy and 60%
(6/10) responded to the therapy (unpublished observation). Prospective studies
may help to clarify the pathophysiology and prognosis of HMT.
Aims: To further characterize the clinical findings of HMT, we began a multi-
center prospective observational study in 2009 (UMIN-CTR 000002729). 
Methods: The inclusion criteria were WBC >3x109/L, Hb >10 g/dL and Plt
<100×109/L with a decreased number of megakaryocytes. The patients who
met the diagnostic criteria for well-established hematologic diseases including
ITP, AA, MDS and PNH were excluded. PNH-type cells were detected using a
high-sensitivity flow cytometry assay at the time of diagnosis and annually
thereafter. The cutoff values of the assay were >0.003% for granulocytes and
0.005% for erythrocytes. The plasma thrombopoietin (TPO) levels were deter-
mined at the time of enrollment using an ELISA. The therapeutic plans were
left to the discretion of each institution. The data were collected in January
2015 for this interim analysis.
Results: From August 2010 to March 2014, 25 HMT cases (male/female, 14/11)
were enrolled. The median of age was 65 years (range, 25-79). The mean of the
complete blood cell counts was as follows: white blood count (WBC) 4.1 (2.77-
8.50)x109/L; hemoglobin (Hb) 11.9 (10.0-14.8) g/dl, and platelet (Plt) 40.0 (1.0-
95.0)x109/L. PNH-type cells were detected in seven of the 25 cases (28%) and
the median clone size of the PNH-type cells in PNH(+) patients was 0.073%,
(range, 0.015% - 20.5%) in granulocytes and 0.069% (range, 0.0% - 3.8%) in
erythrocytes. The TPO level ranged from 0.4 - 42.8 fmol/ml (median, 8.4 fmol/ml).
Eleven (44%) patients showed TPO levels greater than 9.1 fmol/ml, which is the
lowest level observed in our patients with typical AA (Seiki, et al. Haematologica,
2013). The patients with high TPO levels (TPOhigh patients) showed significantly
lower Hb levels (11.0 vs 12.4, P<0.03) and a higher prevalence of increased
PNH-type cell numbers (64% vs 0%, P<0.001) than patients with low TPO levels
(TPOlow patients). A total of six patients were treated with CsA or prednisolone
(PSL) while the other 19 patients left untreated; four TPOhigh patients, including
three PNH(+) and one PNH(-) patient, were treated with CsA and all three PNH(+)
patients responded well to the therapy. Two TPOlow patients treated with PSL
improved. Among the 19 untreated patients, the hematological parameters of 11
patients remained unchanged during the median follow-up period of 30 months.
On the other hand, thrombocytopenia progressed in one TPOlow patient and four
of seven (57%) TPOhigh patients, which include two PNH(+) patients. Notably,
two TPOhigh PNH(+) untreated patients progressed to moderate AA in 15 and 12
months after the diagnosis of HMT. One TPOlow patient developed acute myeloid
leukemia in 18 months and one TPOlow patient demonstrated spontaneous res-
olution of the thrombocytopenia (Figure 1).
Figure 1. Changes of the platelet count in TPOhigh patients with
hypomegakaryocytic thombocytopenia (HMT).
Summary and Conclusions: This prospective analysis confirmed our previous
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observation that approximately 50% of all patients with HMT have an immune
pathophysiology similar to AA. Early treatment with CsA may therefore improve
the prognosis of HMT patients who are generally followed up without therapy
until their thrombocytopenia progresses. A long-term follow-up is needed to
clarify the influence of CsA therapy on the natural course of HMT.
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OUTCOME OF STEM CELL TRANSPLANTATION IN PATIENTS WITH
SHWACHMAN- DIAMOND SYNDROME WITH OR WITHOUT SECONDARY
MDS/AML: AN ANALYSIS OF THE GERMAN SHWACHMAN-DIAMOND
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Background: Shwachman-Diamond Syndrome (SDS) is a rare autosomal reces-
sive disorder characterized by exocrine pancreatic insufficiency, bone marrow
failure and a varying degree of congenital abnormalities including the skeleton,
liver, heart and the immune system as well as psychomotor retardation. It has
been documented that SDS patients have an increased risk to develop myelodys-
plasic syndrome (MDS), pancytopenia and leukemia, particularly acute myeloid
leukemia (AML). So far, stem cell transplantation is the only therapeutic option
for SDS patients with secondary bone marrow failure or leukemia.
Aims: The aim of this analysis is to evaluate the outcome on SCT in patients
with Shwachman-Diamond Syndrome.
Methods: In the SCNIR we have collected long term data on 41 German
patients with a clinical diagnosis of Shwachman-Diamond Syndrome. In 37
patients SDS diagnosis was confirmed by detection of compound heterozygous
SBDS gene mutations. Here we report on the outcome of stem cell transplan-
tation (SCT) in 9 patients with SDS in Germany, which were performed between
1999 and 2014. Reasons for SCT were MDS (1 patient), secondary leukemia
(2 patients), pancytopenia (4 patients), cytogenetic abnormality (deletion 20q)
(1 patient) and severe lung infections (1 patient).
Results: Patients’ characteristics are as follows: Gender (4 female, 5 male),
age at SCT (1.5 years - 30 years), median follow-up time post- SCT (52
months), G-CSF treatment prior to SCT (n=3), stem cell source (MUD: n=6,
MSD: n=2, haploidentical: n=1). The majority of patients received a Fludara-
bine/Treosulfan or Fludarbine/Melphalan based conditioning regimen in com-
bination with ATG or Campath. 2 patients received a second SCT due to graft
failure. Outcome: 3 patients received a SCT due to secondary hematologic
malignancy: AML (n=2) and MDS (n=1). Both patients with AML have died.
Patient 1 (AML) received a MUD SCT without anti-leukemic therapy and 37%
blasts in the bone marrow. The preparative regimen consisted of Busulfan,
Melphalan, VP-16 and ATG. After initial engraftment, the patient relapsed on
day +101 and died 1 month later due to disease progression. Patient 2 (AML)
received AML- induction therapy with Ara-C and Daunorubicin. He went into
prolonged aplasia and received a haploidentical SCT from this mother after
a conditioning regimen with Fludarabine, Thiotepa, ATG and total lymphoid
irradiation. He died due to severe bacterial infection on day+11. Patient 3
(MDS with complex karyotype) is alive and well 107 months after SCT. The
patient received a MUD SCT after a preparative regimen of Fludarabine, Tre-
osulfan, Melphalan and Campath. Patient 1 and 3 developed bacterial sepsis
and acute Graft versus Host Disease (GvHD) within the first 100 days after
SCT (grade I and II). 6 patients received a SCT (MUD: n=4, MSD: n=2) for
other reasons: pancytopenia (n=4), deletion 20q (n=1) and severe lung infec-
tions (n=1). Complications within 100 days post SCT included acute GvHD
grade II (n=2), bacterial sepsis (n=2), hepatic candidiasis (n=1) and primary
(n=1) and secondary (n=1) graft failure with successful second SCT. 1 patient
(pancytopenia) died due to idiopathic pneumonia syndrome on day+80 after
he had received a cord blood transplant (conditioning regimen: Fludarabine,
Treosulfan, Melphalan, ATG). The other 5 patients are alive 8-106 months
after SCT.
Summary and Conclusions: In summary, out of 9 patients with SDS who
underwent SCT, 6 have survived documenting that SCT is the treatment of
choice in patients who developed leukemia or pancytopenia.
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Background: Pearson syndrome (PS) was originally reported as a fatal dis-
ease in infancy characterized by sideroblastic anemia with vacuolization of
marrow precursors and exocrine pancreas dysfunction. In addition, involvement
of multiple other organs and subsequent development of Kearns-Sayre Syn-
drome (KSS) have also been reported. Both PS and KSS are associated with
single mitochondrial DNA (mtDNA) deletions. There are few systematic studies
on PS because of its rarity.
Aims: To characterize the clinical and hematological presentations and courses
of patients with PS.
Methods: We retrospectively reviewed clinical and laboratory data of 20
patients (12 M/ 8 F) with PS diagnosed between 1987 and 2012 in Germany. 
Results: The median hemoglobin level was 5.9 g/dl (2.2-9.8 g/dl) and the mean
corpuscular volume of red cells (MCV) was elevated or normal in 12 and 14
patients, respectively (unknown in 4). Some patients had normal neutrophil
and platelet counts at diagnosis (n=5/6), but all of them developed bi- or pan-
cytopenia later. The hemoglobin F level was elevated for age in 8 of 9 patients
examined. Bone marrow was normo- and hypocellular in 13 and 7 patients,
respectively. All patients had vacuolization of erythroid and myeloid precursors,
but ringed sideroblasts are only observed in 13 of 19 patients examined. Serum
lactate was elevated in 14 of 15 patients studied. The diagnosis of PS could
be confirmed by the detection of mtDNA deletion in all patients. The median
age at the time of the last follow-up was 39 months (6 months to 14 years).
Hematological recovery was observed in most patients with a longer follow-up
time. Ten patients became transfusion independent at a median age of 27
months (11 to 67 months), while one patient was still transfusion dependent
when he died at the age of 8 years. Various symptoms and organ dysfunctions
developed during clinical courses, including failure to thrive/short stature (n=8,
median age of presentation: 26 months (m)), liver dysfunction (n=2, 21 m),
renal tubulopathy/Fanconi syndrome (n=5, 32 m), pancreas insufficiency (n=6,
13 m), cardiac disease (n=3, 45 m), diabetes (n=1, 19 m), other endocrine
dysfunctions (n=4, 63 m), hearing loss (n=1, 115 m), ophthalmoplegia (n=1,
19 m), retinitis pigmentosa (n=1, 92 m), cataract (n=1, 39 m), muscle hypotonia
(n=4, 31 m), ataxia (n=2, 54 m) and encephalopathy (n=1, 74 m). Seven
patients died of acute metabolic acidosis with other complications at the median
age of 49 months (14-101 months). The longest survivor (death at 14 years of
age) suffered from KSS-like disease. 
Summary and Conclusions: These findings suggest that PS is a multisystem
mitochondrial disorder in infancy with bone marrow failure as the main pre-
senting feature. Because patients can initially present with only anemia, clini-
cians should consider PS as a differential diagnosis of hypoproliferative anemia
in early childhood. Although hematological improvement can be expected in
long survivors, patients have highly heterogeneous clinical courses with varied
extents of multi-organ involvement. Therefore, intensive monitoring and man-
aging of multisystem complications are crucial. 
P630
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Background: Pearson Syndrome is a multisystem disorder caused by mutation
of mitochondrial DNA (mtDNA). It typically consists of hypoplastic macrocytic
anemia with vacuolated marrow precursors, lactic acidosis and exocrine pan-
creatic dysfunction. Additional manifestations may include myopathy, neurologic
symptoms, skin lesions and renal tubular acidosis. 
Aims: To provide clinical, biochemical and hematological insights through the
analysis of a reasonably sized cohort of patients. 
Methods: A retrospective analysis via dedicated Case Report Form including
more than 160 items sent to all 55 A.I.E.O.P. (Associazione Italiana di Ema-
tologia ed Oncologia Pediatrica) Centers. Information was collected on all pre-
sumed PS patients diagnosed in Italy in the period 1993-2014.
Results: this series, with 11 enrolled patients, is one of the largest ever report-
ed. The principal characteristics of the patients are shown in Tables 1 and 2.
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The median age at diagnosis was 299 days. At onset, among the 11 patients,
pancytopenia was present in 5, anemia associated with leucopenia and/or neu-
tropenia in 5, isolated anemia in 1; the median value of Hgb was 5.7 gr/dL, the
lowest value of platelets was 72,000/µL and neutropenia (present in 10 children)
was severe (Absolute Neutrophil Count (ANC) <0.5x109/L) in 1, moderate (ANC
0.5-1x09/L) in 8, and mild (ANC of 1.3xx109/L) in another. HbF was assessed
in 5 patients outside the neonatal period and it was found elevated (>2%) in all
of them. BM examination was performed in all patients: a precursor vacuoliza-
tion associated with reduced cellularity was found in 6 children, isolated vac-
uoles in 2, mild dyserythropoiesis in 1, and hypocellularity in 2. One patient
evolved, after allogenic Bone Marrow Transplantation, into acute myeloid
leukemia. No solid tumor was observed. Exocrine pancreatic deficiency and
neurologic symptoms were observed respectively in 3 and 8 children. A hyper-
trophic cardiomyopathy was present in 4 out of 10 evaluated patients. Serum
lactate was dosed in all patients and found elevated in all but one. A plasmatic
amino acid analysis was performed in 10 children: in 9/10 alanine was high.
Urine organic acids were analyzed in 9 patients: in 7/9 an increased excretion
of lactate and fumaric acid was noted; interestingly an increase of malic acid
excretion was also found in 4/9 patients. All patients were transfused with
packed red blood cells (PRBC), 6 with platelets and 2 with plasma. A sponta-
neous improvement of the Hgb values was noted in 8 of the 9 evaluable
patients. Therapy with EPO was attempted, without any efficacy, in 3 children.
Granulocyte-colony stimulating factor (GCSF) was administered in 3 patients
with proven efficacy in one of them. After a median FUP of 5.7 years 8/11
patients died (two at less than 6 months of life), 1 was lost at FUP at 45 months
of age, and only 2/11 patients are alive (at the age of 2.9 and 6.6 years respec-
tively). In 3 cases sepsis was the cause of the death.
Table 1. Clinics and laboratory.
Table 2. Clinics and laboratory.
Summary and Conclusions: PS is a rare disease. Our report enables to esti-
mate the likely incidence of PS in our country as 1/million newborns. Further-
more it shows for the first time that an increased level of serum alanine along
with increased excretion of fumaric acid and hypertrophic cardiomyopathy, even
though never described in previous reports, are a common finding in PS
patients. Finally it seems that transfusion independency is highly probable in
case of survival after the first 2-3 years of life.
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Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clon-
al stem cell disorder with varied clinical manifestations, consequent to deficiency
of membrane-bound glycosylphosphatidylinositol (GPI) anchored protein. It is
known to be associated with other hematological conditions like aplastic anemia
(AA) and myelodysplastic syndrome. In the last few years fluorescent aerolysin
(FLAER) based flow cytometry analysis has become the gold standard for
screening of these abnormal PNH clones.
Aims: FLAER based flow cytometric screening for PNH clones in patients pre-
senting with pancytopenia, features of hemolysis or thrombophilia; and to cor-
relate the clone size with the clinical and laboratory parameters.
Methods: A total of 212 patients were screened between January 2014 to Feb-
ruary 2015 using FLAER based flow cytometry protocols. Stain -Lyse -Wash
technique was used. Neutrophils and monocytes were analyzed using a four
color antibody panel which included FLAER/CD24/CD15/CD45 and
FLAER/CD33/CD14/CD45 respectively. For red blood cell analysis a combination
of CD235/CD59 was used. A minimum of 5000 polymorphs and 3000 monocytes
were analyzed. The patients were divided into three groups based on clone size,
small (<10%), medium (11-49%) and large (≥50%). A correlation between the
clone size along with clinical and laboratory parameters was performed.
Results: The indication for screening included pancytopenia (n=172), evidence
of hemolysis (n=25) and as a part of thrombophilia workup (n=15). A total of
53/212 patients tested positive of which 45/172, 8/25 and 0/15 were for the
above mentioned indications respectively. Amongst the patients who underwent
a bone marrow examination at our centre, 43 showed features of aplastic ane-
mia whereas 10 patients showed variably cellular marrow with erythroid hyper-
plasia. Flow cytometric examination showed large clone sizes in 47% (25/53),
medium in 19% (10/53) and a small clone size in 34% (18/53) patients respec-
tively. The patients with features of hemolysis showed larger clone sizes (large
clone-6 and medium clone -2) as compared to pancytopenic/AA group. 3 of the
16 (18.8%) patients from the pancytopenia/AA group, who were on antothymo-
cyte globulin therapy, showed a clonal PNH evolution with large clone sizes.
On comparing the clone size with other laboratory parameters, larger clone
size was found to be directly and significantly correlated with a higher S. LDH
levels, S. creatinine and reticulocyte count.
Summary and Conclusions: Most common indication of the present study
was pancytopenia. FLAER appeared to be a sensitive technique for detection
of PNH clone in these patients. The clone size in patients presenting with
hemolytic features was higher as compared to those with pancytoepnia/AA. A
fair proportion of patients on ATG therapy showed clonal PNH evolution. 
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Background: Acquired aplastic anemia (AA) is a T-cell mediated suppression
of hematopoietic stem cells. Treatment options available in these patients as
an alternative to allogenic stem cell transplantation include weak androgens
(Stanozolol, Danazol) or immunosuppressive therapy [Cyclosporine(CsA)
and/or Antithymocyte Globulin(ATG)]. There is paucity of studies showing supe-
rior response rates for ATG+CsA as compared to other conventional treatments.
ATG is limited by its high cost.
Aims: To analyse and compare the response of ATG+CsA to other treatment
options in AA using the standard response criteria. 
Methods: Consecutive patients of AA (n=1430) were enrolled in this retrospec-
tive study. Patients were randomly allocated to different treatment protocols.
Response was measured as time to attainment of CR or PR. Response was
also assessed for relapse and clonal evolution with respect to treatment groups. 
Results: Patients with AA (mean age 22±16.9 years, 70% males) were followed
up for median of 4 months (range 0.5 to 132 months) of which 5% patients
died. Anemia (97%) was the major symptom followed by bleeding (70%) fever
(47%) and jaundice in 4.5% patients. In 5% patients the stress cytogenetics
was positive. Very severe (VSAA): Severe (SAA): Non-Severe (NSAA) were
15%: 76%: 9%, respectively. Treatment given to patients included; Stanazolol-
37.5%, CsA-8.5%, Stanazolol+CsA-35%, ATG+CsA-15.5% and others-3.5%.
The median time to PR and CR was 4 and 7 months respectively. There was
a significant difference in the overall response (OR) rates (CR+PR) of ATG+CsA
with respect to other treatment protocols (59% vs 30%; p<0.001). The OR rates
were also significantly different with respect to severity of AA i.e. (45%.vs 10%;
p<0.001) in VSAA, (61%vs 32%; p<0.001) in SAA but not in NSAA. (77% vs
48%; p=0.07). The rates of CR and PR were also significantly superior in the
ATG+CsA group as compared to others (34% vs 15%; p<0.001) and (25% vs
15%; p<0.001) respectively. The relapse even though non-significant was noted
more frequently in the ATG+CsA group as compared to others (3.2% vs 1.2%;
p=0.07). The rate of clonal evolution to acute leukemia was almost similar in
both the groups (0.8% vs 0.5%; p=0.64). 
Summary and Conclusions: Although matched sibling allogenic bone marrow
transplant is the gold standard treatment for aplastic anemia, but immunosup-
pressive therapy with ATG+CsA is a good alternative superior to other conven-
tional treatments. However, alternative immunosuppressive therapy can still
be considered for patients with non-severe aplastic anemia.
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Background: According to published data, current immunosuppressive therapy
(IST) proved to be effective in 70-90% of patients with AA. However, not all the
questions are solved, particularly, treatment of patients with AA refractory to
IST without HLA-compatible donor. 
Aims: The purpose of the study is optimization of treatment algorithm of
patients with AA
Methods: A total of 86 patients with AA were included in the study: 51 males
and 35 females at median age 23 years (range 17-65 years). The median peri-
od from AA diagnosis to IST was 4 months (range 1-25 months). Severe forms
of AA (SAA) were detected in 66 patients, non-severe (NSAA) in 20 pts. PNH-
clone was detected using flow cytometry before treatment and monitored during
of IST. The combined IST consisted of Antithymocyte Globulin (ATG 20
mg/kgx5 days in 81pts, rabbit ATG 3.75 mg/kgx5 days in 5 pts) and Cyclosporin
A (CsA) during 2 years (at least one year after achieving of remission).
Results: IST with several courses of ATG and long-term treatment of CsA was
effective in 73 from 86 pts (84.9%): 54 (81.8%) from 66 pts with SAA and 19
(95%) from 20 pts with NSAA. After one course of ATG+CsA positive response
was received in 53 (61.6%) from 86 pts and after two courses of ATG in 16
(18.6[LE1]%) . Three courses of ATG were conducted in 5 patients with SAA,
3 of them achieved partial remission. After 3 months from the beginning of IST
positive response was achieved in 52.8% and after 6 months in 83, 4% pts
with AA. Overall survival and 7 years event-free survival were 89% (95% CI:
83-96%) and 93% (95% CI: 88-97%), respectively. PNH clone was detected in
20 (60.6%) from 33 pts before IST: granulocyte PNH clone did not changed in
16 from 20 pts during period of observation, in 3 patients decreased more than
in 5 times and in 1 cases clone was eliminated. Response to IST attained in
17 (85%) from 20 PNH+ pts and only 8(61%) from 13 PNH- pts.
Summary and Conclusions: Thus, IST with repeated courses of ATG and
long-term treatment of CsA provided a positive response and long-term survival
in the most of patients with AA in the study, including SAA. The second course
of ATG significantly improves results of the IST, and the optimal period of time
to second course in patients with no answer to the first ATG course should be
3- 6 months from the start of treatment no longer. Patients with no response to
two courses of ATG could be assigned to a group of patients with refractory
AA. These patients require further intensive therapy and alternative methods
of treatment (thrombopoietin receptor agonist, alemtuzumab, chelation thera-
py). As well the results of our research support that PNH+ pts has a better
response to the IST than PNH-.
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PRELIMINARY DATA ON L-LEUCINE THERAPY OF DBA PEDIATRIC
PATIENTS
G.S. Ovsyannikova1,* M.A. Maschan1, G.A. Novichkova1, N.S. Smetanina1,2
1Hematology, Federal Clinical Scientific Center of Pediatric Hematology, Oncol-
ogy and Immunology named after Dmitry Rogachev, 2Hematology, Russian
National Research Medical University named after N.I.Pirogov, Moscow, Rus-
sia, Moscow, Russian Federation
Background: The first line of therapy for patients with Diamond-Blackfan ane-
mia (DBA) is oral corticosteroids. Initially respond only 80% of patients, less
than a half can keep it for extended periods. The majority of DBA patients
received regular blood transfusions. Animal models showed efficacy of L-
leucine, a translation enhancer, in the DBA and 5q- syndrome, which has the
same altered ribosome function as the DBA. It was observed that treatment
with L-leucine improves hemoglobin level and induce transfusion independence
in patients with DBA and 5q- syndrome.
Aims: To evaluate the overall safety and efficacy of L-leucine therapy transfu-
sion dependent DBA patients.
Methods: After approval by Local Ethics Committee and obtained signed
informed consent form six children (aged 2 - 8 years, 3 girls and 3 boys) were
enrolled in the study. The diagnosis of DBA in all patients was established
according to the criteria of the DBA Working Group of the European Society
for Paediatric Haematology and Immunology. L-leucine (700 mg/m2) was given
orally 3 times daily during 9 months. The criteria of efficacy of L-leucine therapy
were haemoglobin (Hb) levels, reticulocytes count (Retic) and soluble trans-
ferring receptor (sTFR).The safety was monitored by blood chemistry param-
eters, urine analysis, amount and severity of adverse events. Response criteria
were: complete response - Hb >90 g/L and transfusion-independence; partial
response - Hb <90 g/L and increased Retic >1% and any increase in transfusion
interval from baseline; no response - no change in transfusion requirements
and no significant change in Hb or Retic.
Results: Baseline Retic range in all cases was 0.1-0.5%; transfusions - every
3 weeks. Complete response was obtained in 2 (30%) cases (both girls 2
years old). One of these patients has mutation in geneRPL11 ex. 2 c.65delT
(p.Cys21Ser_fs*33) hetero. In the other case the whole genome sequencing
is in the progress. No response - in 4 cases; their genotype: RPS19ex. 2
c.3G>А (Met1Ile) hetero; RPL5ex. 3 c.187 C>T (Gln63*);RPS19 ex. 2 c.31
C>T (Gln11*) hetero. Increasing growth rate was noticed in all cases: twice-
higher compare to the same period of time before the study. No one showed
any kind of adverse events. The blood chemistry parameters were within ref-
erence range in all cases.
Summary and Conclusions: The L-leucine therapy might be perspective for
some DBA patients.
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GENETIC VARIANTS OF COMPLEMENT C5 AND POLYMORPHISMS OF
COMPLEMENT C3 IN CHINESE PATIENTS WITH PAROXYSMAL NOCTUR-
NAL HEMOGLOBINURIA
Q. Zhang1, B. Han1,* L. Wang1, Y. Du1
1Department of Hematology, Peking Union Medical Colleague Hospital, Beijing,
China
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal
hematopoietic stem cell disorder, which is characterised by intravascular hemol-
ysis, an abnormal tendency of thrombosis, and various degrees of bone marrow
failure. Eculizumab suppresses the terminal complement system, by inhibiting
the cleavage of C5,with subsequent decrease of cytolysis of PNH erythrocytes
. 3.2% of the Japanese PNH population did not respond to eculizumab,due to
a single missense C5 heterozygous mutation, c.2654G→A. The prevalence of
this mutation was similar to that of healthy Japanese population (3.5%) and
was also identified in the Han Chinese population(1/120). Mutant C5 did not
bound to and was not blocked by eculizumab. Meanwhile, eculizumab pre-
serves upstream components that culminate in C3b-mediated extravascular
hemolysis, which results in the permanent transfusion requirements. British
researchers found that eculizumab-treated patients who had homozygote
C3S/C3S allele had a significantly higher degree of C3 loading on PNH. But
the PNH complement C3 alleles screening was conducted mainly in Europe,
not in Asia.
Aims: We intend to study genetic variants of complement C5 and polymor-
phisms of complement C3 in Chinese patients with PNH in order to determine
its potential impact on Eculizumab efficacy. 
Methods: 220 patients with PNH (diagnosed by CD55/CD59, Flaer analysis)
and 259 normal controls were included. DNA was extracted from peripheral
blood mononuclear cells . Complement C5 exon 21 PCR products and C3
genotypes were analyzed by Sanger method, in order to search the gene muta-
tion of complement C5 gene (rs56040400),and to analyses the genetic poly-
morphisms of C3 (rs2230199). 
Results: For patients with PNH, there were 118 males and 102 females, with
a medium age of 39 years(4-75 years), mean LDH 1078 (IU/L), mean Hb 82
(g/L). 152 patients were classic PNH, 68 patients were aplastic anemia with
PNH clone, five patients had thrombosis. In normal control group, there were
138 male and 121 females with a medium age of 35 years(8-72 years). In both
the PNH patients and normal control subjects,we found no a single missense
C5 heterozygous mutation. When we analysed C3 genetic polymorphisms,they
were all homozygous SS allele, no F allele was found. 
Summary and Conclusions: In the small sample of Chinese PNH patients
and normal subjects,we found no C5 exon gene mutations that had been report-
ed before, and only SS polymorphism was seen in C3 polymorphismsin analy-
sis. These data suggest that Chinese patients will probably not affected by the
C5 mutation when exposed to Eculizumab, but may undergo C3 mediated
extravascular hemolysis.
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EFFECT OF IMID COMPOUNDS ON CD38 EXPRESSION ON MULTIPLE
MYELOMA CELLS: MOR202, A HUMAN CD38 ANTIBODY IN COMBINA-
TION WITH POMALIDOMIDE
R. Boxhammer1,* S. Steidl1, J. Endell1
1MorphoSys AG, Martinsried/Planegg, Germany
Background: MOR202 (MOR03087), a human CD38 antibody currently under
evaluation in a phase I/IIa trial, mediates antibody-dependent cell-mediated
cytotoxicity/phagocytosis (ADCC/ADCP) of multiple myeloma patient-derived
cells with high potency (EC50 ~200 pM). 
Aims: To evaluate in vitro the ability of the IMiD compounds lenalidomide and
pomalidomide, both of which are approved for multiple myeloma, to modulate
CD38 expression and enhance the cytotoxicity of MOR202.
Methods: CD38 expression +/- lenalidomide and +/- pomalidomide on multiple
myeloma cell lines was analyzed by flow cytometry. The antitumor activity of
pomalidomide combined with MOR202 was evaluated in vitro; analyses includ-
ed the induction of direct cytotoxicity on multiple myeloma cells and the activa-
tion of immune effector cells. On a functional level, the combinatorial effects of
MOR202 with pomalidomide were assessed in ADCC assays. Different incu-
bation schemes were used to separate the effect of pomalidomide on target
and effector cells, as well as in the evaluation of the combined effects. The
observed combination effects were analyzed for synergistic potential using the
fractional product concept.
Results: Pomalidomide and lenalidomide mediated a substantial CD38 upreg-
ulation on multiple myeloma cell lines. Pomalidomide as a single agent demon-
strated activation of effector cells with high potency (EC50 ~150 nM), and
demonstrated cytotoxic effects on multiple myeloma cell lines. Additionally,
pomalidomide dose-dependently induced an up to 3-fold CD38 upregulation
(EC50 ~20 nM) on CD38-expressing multiple myeloma cell lines. Pomalido-
mide-mediated effects were time-dependent, with the most pronounced effects
after 72 h incubation. Combining MOR202 with pomalidomide led to a syner-
gistic enhancement of cytotoxic activity. The synergic benefit ranged 1.2-3.1-
fold above theoretical additivity depending on the cell line used, and was most
prominent in the case of strong CD38 upregulation.
Summary and Conclusions: Upregulation of CD38 was mediated by both
lenalidomide and pomalidomide and may represent a class effect of IMiD com-
pounds. The cytotoxic activity of MOR202 on multiple myeloma cells was
enhanced by pomalidomide via multiple mechanisms: direct cytotoxicity, CD38
upregulation and activation of effector cells. These results provide a mechanistic
rationale for the combination of MOR202 with IMiD compounds and warrant
further clinical evaluation.
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CENTROSOME ASSOCIATED GENES PATTERN FOR RISK SUBSTRATI-
FICATION IN MULTIPLE MYELOMA
F. Kryukov1,2,* P. Nemec3, L. Radova4, E. Kryukova1,2, Z. Kufová1,2,
L. Sedlarikova3,5, S. Sevcikova3, R. Hajek1,2,3
1Department of Haematooncology, Faculty of Medicine, University of Ostrava,
2Department of Haematooncology, University Hospital of Ostrava, Ostrava,
3Babak Myeloma Group, Department of Pathological Physiology, Faculty of
Medicine, Masaryk University, 4The Central European Institute of Technology,
Masaryk University, 5Department of Clinical Hematology, University Hospital
Brno, Brno, Czech Republic
Background: Multiple myeloma (MM) is a lymphoproliferative disease char-
acterized by the clonal expansion of neoplastic plasma cells within the bone
marrow. The genome of the malignant plasma cells is extremely unstable char-
acterized by a complex combination of structure and numerical abnormalities.
Our previous study defined centrosome associated genes pattern with impact
in myeloma pathogenesis. Revealed molecular signature is related to OS as
well as to clinical parameters and ISS staging (Kryukov et al., 2013).
Aims: The objective of our study was to create and validate risk stratification
model based on previously described centrosome associated genes pattern
in MM.
Methods: One hundred and fifty patients were evaluated for this study. The
patients’ baseline characteristics were as follows: males/females 79/71, median
age of 67 years (range 38-90 years). Newly diagnosed (90/150) and relapsed
(60/150) patients were included in this study; most of them had advanced stage
of MM (DS II/III n=110; ISS II/III n=144). Interphase FISH with cytoplasmic
immunoglobulin light chain staining (cIg FISH) and gene expression profiling
(GEP) were performed on CD138+ plasma cells separated by MACS. Training
and validation cohort includes 72 and 78 pts, resp.
Results: Using multinomial logistic regression 12 candidate genes (BUB1,
BUB1B|PAK6, RAD51, PLK1, BRCA1, CENPA, BARD1, AURKA, MAD2L1,
CENPH, XRCC2 and CDC25C|FAM53C) for patients, risk stratification were
defined. Based on expression of these genes, patients can be stratified into three
groups - “High-”, “Mediate-” and “Low expressed”. The overall survival of patients
in “High” and “Medium” subgroups was significantly worse than in patients in
“Low” subgroup for both training and validation cohorts and was in concordance
with previously published results (Kryukov et al. 2013). To characterize the prog-
nostic significance of centrosome associated genes pattern (CAGP), multivariate
Cox proportional hazards survival model was used. Significantly worse prognosis
was found for united “High & Medium” group (HR=2.182; 3-year OS=28.3%)
compared to “Low” group (3-year OS=63.8%, p<0.01). Besides CAGP, the fol-
lowing parameters were used for multivariate Cox proportional hazards survival
model: ISS stadium, β2-microglobulin, del 17p13, t(4;14), amp 1q21. The vari-
ables in the multivariate model were the only variables, which remained statisti-
cally significant when potential predictors were combined together as well as
CAGP, which was forced into the model. Among all subsequently tested combi-
nations of predictors, the best results in risk of death assessment were obtained
for CAGP combined with del 17p13 (p<0.001). It is worth to mention that both
prognostic factors were independent. United “High & Medium” CAGP subgroup
as well as TP53 deletion had significantly higher risk of death assessment
(HR=3.189 and HR=3.699 resp. p<0.005). Survival characteristics for different
risk groups are presented in the Table 1.
Table 1. Survival characteristics for different risk groups (validation
cohort, n=69).
Summary and Conclusions: We have created a new GEP-based model for
classification of every patient into one of three prognostic subgroups, which
can be easily used in routine practice. This approach can be used independently
as well as in combination with other factors. Best results in risk of death assess-
ment are obtained when the new stratification model is used in combination
with detection of TP53 loss analyzed by FISH. Thus, the new model can be
used for substratification of prognosis in patients with TP53 loss. These findings
need to be confirmed on larger cohort with longer follow-up.
Acknowledgments: This work was supported by the Moravian-Silesian Region
- grant no. (MSK 02680/2014/RRC and MSK 02692/2014/RRC); grants by MH
CZ - DRO - FNOs/2014 and FNBr, 65269705; by The Ministry of Education,
Youth and Sports (Specific university research of the Faculty of Medicine, Uni-
versity of Ostrava) project no. (SGS01/LF/2014-2015, SGS02/LF/2014-2015,
SGS03/LF/2015-2016); and by grant IGA of The Ministry of Health (NT 13190-
3 and NT 14575).
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BONE MARROW MESENCHYMAL STROMAL CELLS FROM HEALTHY
DONORS SECRETE EXOSOMES THAT INHIBIT IN VIVO TUMOR GROWTH
AND ANGIOGENESIS IN MULTIPLE MYELOMA
T. Umezu1,* S. Imanishi2, K. Azuma2, S. Yoshizawa3, K. Ohyashiki3, J. Ohyashiki2
1Department of Molecular Science, 2Institute of Medical Science, 3Department
of Hematology, Tokyo Medical University, Tokyo, Japan
Background: The bone marrow microenvironment plays a key role in the
growth and survival of multiple myeloma (MM) cells. MM cells interact with
mesenchymal stromal cells (MSC) in the bone marrow, resulting in cell prolif-
eration and angiogenesis. The bone marrow derived MSC is one of the most
promising source of cell therapy. Resently, MSC-derived exosomes have been
found to be efficacious in animal models for the treatment of non-neoplastic
disease, such as cardiovescular disease and liver injury, because MSC-derived
exosomes carry and transfer their cargo, which promote therapeutic response.
Aims: We sought to determine the anti-tumor effect of MSC-derived exosomes
by nude mouse heterotransplant model, aiming to establish the exosome-based
theraputic approch using MSC-derived exosomal miRNAs.
Methods: Human MSCs obtained from bone marrow of healthy donors (BM-
MSC; age 19 to 72) were purchased from Lonza. BM samples were obtained
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from MM patients (age 62 to 77) in accordance with the Declaration of Helsinki
and using protocols approved by the research Ethics Committee of Tokyo Med-
ical University (IRB No. 2648), and MSCs derived form MM patients (MM-
MSCs) were isolated by the classical adhesion method. Hypoxia-resistant
myeloma cell line (RPMI8226-HR) established in our laboratory were cultured
at 1% O2. Exosome secreted from MSCs (MSC-exosome) were isolated from
conditioned medium using a Total Exosome Isolation Reagent (Invitrogen).
The size of MSC-exosomes was confirmed using a NanoSight LM10. To exam-
ine whether MSC-exosomes could be transferred into recipient cells,
RPMI8226-HR cells or human endothelial cells, were cultured with fluorescent
dye-labeled MSC-exosomes. Exosomal miRNA profiling was done using a Taq-
Man low-density array (ABI), and Student’s t-test was used to determine sta-
tistical significance for comparisons between MM patient and healthy donor
groups using R software. In Matrigel plug assay, BALB/c nude mice were inject-
ed subcutaneously with 400 µL Matrigel containing myeloma cell lines with or
without MSC-exosomes. After 3 weeks, the Matrigel plugs were harvested,
and stained with anti-CD31 antibody to analyze vessel density.
Results: BM-MSCs displayed long spindle shape, and there was no morpho-
logical difference between the BM-MSCs from non-aged donors (19 and 21
years) and that from aged donors (68 and 72 years). In contrast, MM-MSCs
displayed the flat cellular morphology. The nanoparticle size distribution of
MSC-exosomes was approximately 50 nm, and there were no significant dif-
ferences in size and amount of exosomes in BM-MSCs and MM-MSCs. We
found a diferential exosomal miRNA expression profile between BM-MSCs and
MM-MSCs. Then we could subdivide miRNAs as follows: (1) miRNAs upregu-
lated in BM-MSCs, (2) miRNAs upregulated in MM-MSCs. We also found the
transport of these exosomal miRNAs derived from BM-MSCs into either myelo-
ma cell or human endothelial cell via exosomes using in vitro model. MM-MSC-
exosomes enhanced angiogenesis and cell proliferation of MM cells in Matrigel
plug containing RPMI8226-HR cells. Of note is that BM-MSC-exosomes sig-
nificantly reduced the density of CD31 positive endothelial cells and the remark-
able decrease of myeloma cells in Matrigel plug, indicating the anti-tumor effect
of BM-MSC-exosomes. The growth inhibitory effect was more prominent in
BM-MSC-exosomes from non-aged donors.
Summary and Conclusions: Our results suggest that the BM-MSC-exosomes
is able to transfer the miRNAs, which have the ability to inhibit tumor growth
and angiogenesis in MM. The present study provide a theraputic potential of
exosomes derived BM-MSCs in MM.
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ANTITUMORAL ACTIVITY OF AMILORIDE IN MULTIPLE MYELOMA
THROUGH APOPTOSIS INDUCTION, REGARDLESS OF TP53 MUTATION-
AL STATUS
E. Rojas1,* I. Misiewicz-Krzeminska1, S. Hernández1, T. Paíno1, L.A. Corchete1,
I. Isidro1, M.V. Mateos1, E. Ocio1, N.C. Gutiérrez1
1Instituto de Biologia Molecular y Celular del Cancer, CSIC/Universidad de
Salamanca, Salamanca, Spain
Background: Multiple myeloma (MM) remains incurable despite the novel
agents with different mechanisms of action. Therefore, the investigation of the
potential antimyeloma activity in other therapeutic agents is stillneeded. The
antihypertensive agent, amiloride, has been demonstrated to inhibit tumor cell
proliferationin different experimental models. Here we explore the activity of
amiloride in myeloma cells.
Aims: To investigate the antimyeloma effect of amiloride in myeloma cell lines
and primary samples and to identify the potential mechanisms involved.
Methods: Seven human myeloma cell lines (NCI-H929, JJN3, KMS12-BM,
KMS12-PE, U266, MM1S and RPMI-8226) and 9 bone marrow (BM) samples
from MM patients were used for the experiments. Cell viability, apoptosis and
cell cycle analyses were carried out by CellTiter-Glo assay, annexin V staining
and PI/RNASE solution following manufacturer’s instructions, respectively.
Caspases 3/7, 8 and 9 activities were evaluated by luminescent Caspase-
Glo®Assays and the measuring of mitochondrial membrane potential (ΔΨm)
by flow cytometry analyses. The gene expression was quantified by Taqman
assay qRT-PCR. Synergy with bortezomib and dexamethasonewas calculated
with the “CalcuSyn” software program.
Results: To test the antiproliferative effect of amiloride, myeloma cells were treat-
ed with increasing concentrations of the compound (0.1mM-1mM) for 24, 48 and
72 hours. Amiloride displayed potent antimyeloma activity in the panel of 7 cell
lines. A substantial induction of apoptotic cell death (greater than 40% at 24 h
and 60% at 48 h) and cell cycle blockade (a 12% increase in G0/G1, and a 10%
and 5% decrease in the G2/M and S phases of cell cycle, respectively) was
observed in all MM cell lines. The apoptosis induced by amiloride was not related
to the TP53 mutational status, since amiloride was still able to induce cell death
through a p53-independent pathway in p53 mutated cell lines, such as U-266,
KMS12-BM and JJN3. Moreover, this drug caused a notable decrease in mito-
chondrial membrane potential (ΔΨm) and an activation of caspases 3/7, 8 and
9. Mechanistic studies showed that amiloridetriggered apoptosis was associ-
ated with the overexpression of BAX, BAK1, BBC3, TNFRSF10B, FAS, CDKN1B
and CDKN1A, even in those MM cell lines in which p53 gene was mutated. Fur-
ther, we evaluated the potential synergism of amiloride with other antimyeloma
agents. H929 and JJN3 cell lines were treated for 48 h with combinations of sub-
optimal doses of amiloride, and bortezomib and dexamethasone, in double com-
binations. Amiloride was synergistic with bortezomib in NCI-H929 and JJN3 cell
lines (CI=0.80 and 0.89, respectively). The combination indexes for dexametha-
sone were in the additive range. Finally, the antiproliferative/cytotoxic effect of
amiloride in BM cell subpopulations obtained from 9 patients with MM was
assessed. In vitro studies confirmed the antimyeloma efficacy of amiloride in
patient samples and showed a clearly lower cytotoxicity in the remaining cell
subpopulations compared to tumor plasma cells.
Summary and Conclusions: Our results demonstrate a potent and selective
antimyeloma effect of amiloride by p53-dependent and independent pathways.
The present data support the investigation of amiloride as a treatment option
for MM patients, either alone or in combination.
Funding: “Instituto de Salud Carlos III” (PI13/00111).
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BORTEZOMIB-RESISTANCE OF BONE MARROW FIBROBLASTS IN MUL-
TIPLE MYELOMA IS CLOSELY CONNECTED TO ACTIVATION OF
AUTOPHAGY AS SURVIVAL MACHINERY 
L. Di Marzo1,* V. Desantis1, D. Vergara2, K. De Veirman3, I. Catacchio1, L. Rao1,
M. Maffia2, K. Vanderkerken3, A. Vacca1, M.A. Frassanito1
1Biomedical and Human Oncology Sciences, Azienda Ospedaliero-Consorziale
Universitaria Policlinico di Bari, Bari, 2Department of Biological and Environ-
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ment of Hematology and Immunology, Myeloma Center Brussels, Vrije Univer-
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Background: Cancer-associated fibroblasts (CAFs) are a relevant cell type
within the stroma of many tumors entailed with high malignancy grade, pro-
gression, and poor prognosis. In multiple myeloma (MM), CAFs give a note-
worthy contribution in terms of growth, proliferation, and survival of tumor cells1.
Aims: Since drug resistance of MM cells depends on tumor microenvironment,
we analyzed the mechanism which involves CAFs in bortezomib-resistance of
MM cells.
Methods: Proteomic, phospho-proteomic, western blot, immunofluorescence
and flow cytometry studies were performed to demonstrate the effect of CAFs
on the bortezomib-induced apoptosis of MM cells. 
Results: CAFs purified from bone marrow of bortezomib-resistant patients
were in vitro insensitive to the bortezomib treatment, and protected MM cells
as RPMI8266 cell line and CD138+ plasma cells from bortezomib-induced
apoptosis. The effect was related to the ability of bortezomib-resistant CAFs
treated with bortezomib to secrete high levels of prosurvival cytokines/growth
factors, namely insulin-like growth factor 1 (IGF-1), interleukin-6 (IL-6), inter-
leukin 8 (IL-8), and transforming growth factor beta (TGFβ), compared to
CAFs purified from 1st diagnosed patients. Proteomic and phospho-proteomic
studies suggested that resistance of CAFs to bortezomib was related to a
cellular stress condition. Flow cytometry and immunofluorescence studies
showed that bortezomib-resistant CAFs had higher production of reactive
oxygen species (ROS) compared to CAFs purified from 1st diagnosed
patients. When treated with bortezomib cells increased the ROS expression
and activated the autophagy pathway. Indeed, the bortezomib treatment
induced an increase of microtubule-associated protein light chain 3 (LC3)-II
with a reduction of p62 proteins, two autophagic markers, and inhibited the
phosphorylation status of mTor, the major autophagic pathway. Finally we
demonstrated that TGFβ, which acts in autocrine way, activated prosurvival
autophagy and induced bortezomib resistance.
Summary and Conclusions: Our results highlight that CAFs from bortezomib
resistant patients are insensitive in vitro to the bortezomib treatment and protect
MM cells from bortezomib-induced apoptosis. The in vitro resistance of borte-
zomib-resistant CAFs to drug treatment is closely connected to activation of
autophagy as prosurvival machinery. Accordingly, we speculate that targeting
CAFs in MM patients may be envisaged as a cell-based therapeutic strategy.
Reference
1. MA Frassanito et al. Bone marrow fibroblasts parallel multiple myeloma pro-
gression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;
28(4):904-16.
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POLYMORPHISMS WITHIN THE CEREBLON AND BETA-CATENIN ENCOD-
ING GENES IN PATIENTS WITH MULTIPLE MYELOMA
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Background: The recent studies have suggested that cereblon (CRBN) is
essential for the anti-myeloma (MM) activity of immunomodulatory drugs
(IMiDs), such as thalidomide and lenalidomide and that dysregulation of Wnt/β-
catenin pathway may be one of the possible reasons of lenalidomide resistance. 
Aims: This prompted us to analyze the effect of the polymorphisms within the
genes coding for cereblon (CRBN (rs121918368, C>T)) and β-catenin
(CTNNB1 (rs4135385, A>G; rs4533622, A>C). 
Methods: MM patients (n=144) and healthy individuals (n=126) were geno-
typed using the Light SNiP assays.
Results: The CTNNB1 (rs4135385) AA homozygosity was more frequent
among patients with better response to CTD - cyclophosphamide, thalidomide,
dexamethasone (8/11 vs 42/72, p-=0.047) and were at lower risk of disease
progression after thalidomide treatment (22/31 vs 8/18, p=0.078). Patients car-
rying the CTNNB1 (rs4533622) AA genotype were better responders to the
first line therapy with thalidomide containing regiments (p<0.05). No significant
association was observed between the effect of lenalidomide therapy and poly-
morphisms studied. However, the occurrence of neutropenia during lenalido-
mide therapy was more frequent among the CTNNB1 (rs4135385) AA carriers
(p=0.019) while the CTNNB1 (rs4533622) AA homozygosity characterized
patients with high grade (3-4) neutropenia (p=0.044). No association was found
for the CRBN polymorphism. 
Summary and Conclusions: The response to chemotherapy in patients with
multiple myeloma is associated with the CTNNB1 polymorphism.
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A NEW NEXT GENERATION SEQUENCING STRATEGY TO EVALUATE
GENETIC ABNORMALITIES IN MULTIPLE MYELOMA
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Background: Approximately 60% of multiple myeloma (MM) patients harbor a
translocation predominantly involving the IGH locus at 14q32. IGH transloca-
tions are a primary event and determine the prognostic outcome of a patient.
These events are routinely assessed by FISH, which can easily detect the IGH
translocation, although the partner chromosome frequently remains unknown.
Next Generation Sequencing (NGS) techniques may overcome this limitation
with the additional advantage of identifying the precise localization of the break-
points. This would allow the subsequent design of patient specific PCRs for
monitoring the aberrant chromosomal translocation over disease evolution.
Moreover, this methodology may provide other relevant information, such as
the identification of the clonal V(D)J rearrangements, IgH isotypes or somatic
gene mutations.
Aims: To design a NGS-based strategy in order to investigate the landscape
of relevant chromosomal abnormalities and gene lesions in a series of MM
patients.
Methods: A custom pull down panel to identify IGH translocations, V(D)J
rearrangements and the most common somatic mutations in myeloma patients
(involving NRAS, KRAS, HRAS, TP53, MYC and BRAF genes) was designed.
Samples from 48 newly diagnosed MM patients, enrolled in GEM2005 clinical
trial, were included in the study. DNA was extracted from bone marrow CD138+
plasma cells separated by autoMACS®. Regions of interest of the aforemen-
tioned genes were captured with the NimbleGen strategy (Roche NimbleGen,
Inc., Madison, WI). Massive parallel sequencing was performed in a GS FLX+
System with a mean of 350 bp paired-end read length and a mean depth of
more than 23.000X per sample (>95% coverage). Results were correlated with
FISH, molecular and clinical data of the patients.
Results: In a preliminary analysis (with ≥40 bp overlap depth and ≥90% overlap
identity), we could confirm the presence of 9/17 IGH translocations that had
been detected by FISH (5 t(11;14), 2 t(4;14), 1 t(14;16) and 1 t with unknown
partner). Breakpoints in IGH were located in µ switch and enhancer regions
(67%) and in IGHJ region (33%). One unknown partner chromosome turned
out to be chromosome 12q24, and the breakpoint was located between
SCARB1 and UBC genes. Interestingly, this patient was the only one in this
series that had an associated amyloidosis. We also detected 6 potential addi-
tional translocations that will be further analyzed for confirmation. Regarding
IgH subclass, we could observe that the splice process occurred between µ
switch (S) region and Sγ1 (in 50% cases), Sγ2 (20%), Sγ3 (10%), Sγ4 (10%)
and Sα1 (10%). This preliminary analysis also allowed us to identify the V(D)J
rearrangement in 18 patients (38%). Finally, mutation analysis revealed the
presence of missense protein-coding alterations in 19/48 (40%) patients, dis-
tributed as follows: 7/48 (15%) NRAS, 7/48 (15%) KRAS, 7/48 (15%) MYC,
2/48 (4%) TP53, 0/48 (0%) HRAS and 0/48 (0%) BRAF.
Summary and Conclusions: Our capture-based NGS study allows the simul-
taneous identification of IGH translocations, V(D)J rearrangements, IgH isotype
switching and somatic mutations in myeloma patients. The precise location of
the breakpoints can be used as a target for minimal residual disease detection.
Lastly, it is also interesting the discovery of novel translocations, as it is the
case of the t(12;14) translocation that we have found here. Nevertheless, this
study still requires further optimization and standardization that will involve both
biological and bioinformatics evaluation.
Financial support: Grants PI1202311, GCB120981SAN and RD12/0036/0069.
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Background: Multiple myeloma (MM) remains a non-curable disease for
most patients, and novel therapeutic options need to be evaluated. The clonal
heterogeneity and plasticity of human MM disease emphasizes the need to
use primary human MM cell populations that reflect this in preclinical murine
MM models. However, the engraftment of primary human MM cells in immuno-
compromised mice is poor, likely due to the fact that murine hematopoetic
growth factors and in particular Interleukin-6 (IL-6), which is important for
intramedullary MM growth, share only little homology with their human coun-
terparts. This poor engraftment of human MM cells severely limits the useful-
ness of xenograft MM models for the assessment of novel therapies in the
preclinical setting in vivo.
Aims: To explore whether expression of human IL-6 in immunocompromised
mice would allow efficient engraftment and systemic bone marrow growth of
human MM cells in immunocompromised mice, providing the basis for an
improved MM in vivo model.
Methods: 2x106 human RPMI8226 and INA-6 (an IL6-dependent human MM
cell line) cells were injected into the femur of adult humanSIRAPα
transgenic/humanIL6 and humanTPO-knockin Rag2-/- gamma chain-/- mice
(TPO-IL6-SIRPα mice). Mice were sacrificed 38-54 days after injection and
analyzed by histology and immunohistochemistry, FACS and Mikro-CT. Para-
proteinemia was detected by ELISA for human light chains.
Results: 5/5 RPMI8226-injected mice developed a measurable paraproteine-
mia and showed infiltration by myeloma cells also at distant bone marrow sites
(sternum), as detected by histology. 3/5 mice developed a soft tissue tumor in
the parafemural tissue. Two mice showed a massive infiltration and systemic
bone marrow spread to vertebral column, tibia, contralateral femur, hip and
humerus with dense infiltration of the marrow cavity and often locally destructive
growth with myeloma cells invading the surrounding tissue. Both mice devel-
oped paraplegia due to infiltration of the spinal cord at day 54. Mikro-CT
revealed osteolytic lesions and generalized loss of trabecular structure, resem-
bling human MM. Hepatic involvement was noticed in both animals by histology.
One animal showed small foci of myeloma cells in the perirenal soft tissue.
Ongoing experiments likewise demonstrate engraftment of the IL6 dependent
cell line INA-6. Further experiments using human primary MM cells are ongoing
and will be presented at the meeting.
Summary and Conclusions: Our data suggest that human TPO-IL6-SIR-
PαRag2-/-γc-/- mice considerably support the systemic growth of human myelo-
ma cells in the bone marrow. TPO-IL6-SIRPα mice may therefore provide the
basis for a next generation xenograft MM model that allows studying primary
human cells from the intramedullary phase of MM in vivo.
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OVEREXPRESSION OF SALIVARY-TYPE AMYLASE REDUCES THE SEN-
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Background: Despite recent progress in treatments for multiple myeloma, a
complete cure remains elusive. Amylase-producing myeloma, mainly reported
in East Asian and European countries, exhibits refractoriness to chemotherapy
including bortezomib with a dismal prognosis. To overcome the obstacle, it is
critical to elucidate the mechanisms by which amylase-producing myeloma
cells survive after chemotherapy.
Aims: The aim of this work was to elucidate the mechanisms by which ectopic
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overexpression and production of amylase contributes to the chemoresistance
in myeloma.
Methods: We generated a human myeloma cell line in which the transfected
AMY1 gene was stably expressed. RPMI-8226 was lentivirally transduced to
express salivary type amylase (8226/AMY1) or lacZ (8226/mock) as mock con-
trol. Cells were treated with anti-myeloma drugs (dexamethasone, bortezomib
and lenalidomide). Cell viability and growth of treated cells were examined by
the MTS assay. Apoptosis was quantitated by flow cytometry using annexin V
- FITC staining. Gene expression changes associated with amylase expression
were analyzed by microarray gene expression profiling. Cells were subcuta-
neously injected to mice (n=3 mice, each group), and DMSO or bortezomib
(0.3 mg/kg) was administered twice a week for in vivo study. The tumor volumes
of mice were observed every 3 to 4 days.
Results: Cell proliferation after 48 hours exposure to dexamethasone (40 mM),
bortezomib (2 nM), and lenalidomide (1 mM) were significantly high in
8226/AMY1 compared with mock in vitro (Figure 1). The degree of apoptosis
was significantly reduced in 8226/AMY1 after exposure to bortezomib and
lenalidomide, but it was similar when treated with dexamethasone. In vivo,
tumor growth of 8226/AMY1 markedly increased compared with mock, but did
not show significance (Figure 2A). The ratio of tumor size treated with borte-
zomib to that with DMSO on days 46 was significantly high in 8226/AMY1 com-
pared with mock (p=0.017) (Figure 2A), indicating that bortezomib was less
effective in 8226/AMY1 compared with mock in vivo. Gene expression analysis
by microarray identified 5 genes differentially up-regulated in 8226/AMY1
including the TCL1A gene, which codes T-cell leukemia/lymphoma 1 oncopro-
tein to function as a coactivator of the cell survival kinase AKT, as well as 7 dif-
ferentially down-regulated.
Figure 1. 8226/AMY1 showed the reduced sensitivity to anti-myeloma
drugs in vitro.
Figure 2. 8226/AMY1 showed the reduced sensitivity to bertezomib in
vivo.
Summary and Conclusions: We demonstrated that 8226/AMY1 cells had
reduced susceptibility to dexamethasone, bortezomib and lenalidomide in vitro
partly through inhibition of apoptosis induced by these reagents. 8226/AMY1
also showed a weakened anti-tumor effect of bortezomib in exnografted mice.
Up-regulation of TCL1 may influence the anti-myeloma drug resistance by the
mechanism of promotion of Akt-induced cell survival and proliferation in
8226/AMY1. Our data provide clues for elucidating the molecular pathology
and developing treatment approaches for not only amylase-producing myeloma
but relapsed and refractory myeloma.
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Background: Commonly recommended standards of care for patients (pts)
with transplant-ineligible newly diagnosed multiple myeloma (NDMM) include
melphalan and prednisone (MP) combined with thalidomide (MPT) or borte-
zomib (VMP). The randomized, controlled phase 3 FIRST trial demonstrated
that continuous treatment with lenalidomide and low-dose dexamethasone (Rd
continuous) significantly improved progression-free survival (PFS, the primary
study endpoint) and overall survival vs MPT in pts with NDMM (Benboubker,
N Engl J Med, 2014). In the absence of a head-to-head comparison, an indirect
comparison of Tx across separate trials can be performed. However, cross-
trial comparisons may be biased by differences in pt populations, sensitivity to
modeling assumptions, and differences in the definitions of outcome measures. 
Aims: A mixed-Tx comparison (MTC), a type of network meta-analysis (NMA),
was used to evaluate the relative effect of Rd compared with VMP on overall
survival (OS) and PFS.
Methods: A systematic literature review was conducted in Embase, PubMed,
and CENTRAL using keywords for MM combined with Tx of interest: lenalido-
mide, thalidomide, bortezomib, interferon, and bendamustine as monotherapy,
combination Tx, and MP combination Tx. The search was then narrowed to
randomized trials of clinical efficacy in Tx-naive pts published between 1988
and September 2014. To avoid potential biases, quality assessments for each
study were conducted using key questions derived from the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins, BMJ, 2011). The
assessments were validated by independent investigators. Study comparability
and Tx relevance were assessed to compare VMP with Rd using MPT as a
common comparator. To reduce bias and better reflect the real-world situation,
the analysis network was further limited to studies evaluating MPT on a fixed-
dose schedule (per the thalidomide summary of product characteristics and
current clinical practice). Random- and fixed-effects Bayesian MTC meta-analy-
ses comparing Tx hazard ratios (HRs) for OS and PFS were conducted. The
comparison described herein was conducted for research purposes and does
not represent a validated hypothesis.
Table 1. Extracted data from studies in the primary analysis network.
Results: The network was composed of 5 trials (IFM 0101, IFM 99/06, Sacchi
2011, VISTA, and FIRST) evaluating Rd continuous, VMP, MP, and MPT (Table
1). An analysis of OS using fixed-effects NMA models documented a significantly
lower risk of death with Rd compared with VMP (HR=0.69 [95% credible interval
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(CrI), 0.48-0.98]), MPT (HR=0.78 [95% Crl, 0.64-0.95]), and MP (HR=0.48 [95%
Crl, 0.36-0.64]). A significantly lower risk of progression or death was detected
from a PFS analysis of Rd compared with MPT (HR=0.71 [95% CrI, 0.61-0.85])
or MP (HR=0.40 [95% CrI, 0.31-0.51]). A numerical trend in PFS in favor of Rd
was observed when compared with VMP (HR=0.72 [95% CrI, 0.51-1.02]).
Summary and Conclusions: A significant advantage in OS was associated
with Rd continuous compared with other first-line Tx (VMP, MPT, and MP). Pts
treated with Rd continuous had a lower risk of progression than those treated
with MPT and MP. Conclusions are focused on efficacy and do not consider
any potential differences in safety.
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Background: Preliminary findings from an open-label, phase 1b/2 study
(NCT01416428) investigating OPZ in pts with hematologic malignancies (includ-
ing MM) were presented previously (Vij et al., Blood 2014;124: abstract 34). In
the phase 1b portion of the study, the maximum tolerated dose (MTD) of OPZ
administered once-daily on days 1, 2, 8, and 9 of a 14-day cycle (2/7 schedule)
or on days 1-5 of a 14-day cycle (5/14 schedule) was 300 mg/day (mg/d) and
240 mg/d, respectively. In addition, results from 27 pts who were enrolled in the
phase 2 portion of the study on the 5/14 schedule at the MTD (240 mg/d) were
presented previously (Vij et al., Blood 2014;124: abstract 34).
Aims: We present updated data from the phase 2 portion of the study
(NCT01416428).
Methods: The study is enrolling adult pts with hematologic malignancies who
have relapsed after receiving ≥1 line of therapy. The primary objective of the
phase 2 portion of the study is to determine the best overall response rate (≥partial
response). Given the encouraging anti-MM efficacy of OPZ, in order to improve
the gastrointestinal tolerability of OPZ, the study protocol was amended so that
pts on both the 2/7 and 5/14 schedules could receive a reduced dose of OPZ
during cycle 1 (150 and 240 mg/d, respectively), followed by a higher dose of
OPZ during cycles ≥2, if tolerated (180 and 300 mg/d, respectively). Enrollment
of pts with MM is continuing in the phase 2 portion of the study in the 2/7 schedule
(240/300 mg/d) and 5/14 schedule (150/180 mg/d); the target enrollment is 94
pts with MM. Preliminary safety results are presented for pts with MM who enrolled
in the phase 2 portion of the study following modification of the treatment sched-
ules. All pts provided informed consent.
Table 1. Common AEs of interest.
Results: As of November 3, 2014, 19 pts with MM were enrolled in the phase 2
portion of the study on the modified treatment schedule, including 10 pts who
enrolled on the 2/7 schedule (240/300 mg/d) and 9 pts who enrolled on the 5/14
schedule (150/180 mg/d). Preliminary median treatment duration was 5.6 weeks
(range, 0.1-11.3) and 6.7 weeks (range, 3.0-16.7), respectively. Median patient
age was 69 years (range, 51-77) and 60 years (52-75), respectively. Response
data from the 2/7 schedule (240/300 mg/d) and 5/14 schedule (150/180 mg/d)
were not available due to limited treatment exposure. Common adverse events
(AEs) of interest are shown in the Table 1. No grade 4 AEs occurred in the two
schedules. Two pts (20%) in the 2/7 schedule (240/300 mg/d) and 0 pts in the
5/14 schedule (150/180 mg/d) discontinued treatment due to an AE. Two pts
(20%) in the 2/7 schedule (240/300 mg/d) and 1 patient (11%) in the 5/14 schedule
(150/180 mg/d) had ≥1 dose reduction due to an AE.
Summary and Conclusions: The gastrointestinal tolerability profile of OPZ
improved at dosing levels below the MTD in the 2/7 schedule (240/300 mg/d)
and 5/14 schedule (150/180 mg/d). Common grade ≥3 AEs in both treatment
schedules included diarrhea, nausea, and vomiting. Updated results from the
phase 2 portion of the study will be presented at the meeting.
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Background: The paradigm of multiple myeloma (MM) therapy has changed
markedly over the last 2 decades and continues to evolve, with varying practice
patterns across Europe. However, data describing patient management in clin-
ical practice are limited.
Aims: This cross-sectional study estimated the size of each line of treatment
for symptomatic MM patients in a real-world setting in Belgium, France, Ger-
many, Italy, Spain, Switzerland and the UK in 2014.
Methods: Data were collected using chart reviews by oncologists/haematologists
who manage ≥10 patients with MM per month and were personally responsible
for initiating treatments in MM. Data included patient characteristics and current
treatment for all patients with symptomatic MM seen during a 2-4-week observa-
tion period (depending on number of patients seen during this time) regardless
of time since diagnosis, disease stage and current treatment strategy.
Figure 1. Treatment statuses of patients with symptomatic multiple
myeloma.
Results: In total, 435 physicians collected data for 7635 patients. Physicians
were haematologists/onco-haematologists (68%) or oncologists (32%). Most
patients (62%) were ≥65 years and median time since diagnosis was 33
months. Overall, 23% of patients had an International Staging System (ISS)
score of I, 37% a score of II and 37% a score of III at diagnosis. Patient char-
acteristics were similar across countries, except for Spain, where fewer patients
had ISS III MM (24%). Figure 1 shows treatment statuses of patients. Nearly
half (47%) of patients were on active treatment, most of whom were on 1st line
therapy. For patients on treatment at the time of the study, bortezomib-based
regimens were the most commonly used at 1st line (48% of patients), except in
the UK where thalidomide was more frequently used (56%). At 2nd line, lenalido-
mide was most commonly used (59%), except in the UK, where bortezomib
was mainly used. Lenalidomide was also the most common agent overall at
3rd line (51%). Even though only recently reimbursed, the use of pomalidomide
was prominent in 4th and 5th line regimens (32% and 43%, respectively). Ben-
damustine was seldom used at 1st or 2nd line therapy; in later lines, this agent
was more commonly used in Germany, Spain and France than in other coun-
tries. Overall, 19% of patients currently receiving 1st line treatment had received
a stem cell transplant (SCT; this snapshot does not include patients for whom
SCT was planned in 1st line); 70% of patients receiving 5th line or later treatment
had previously received an SCT. Main reasons for discontinuing previous anti-
tumour therapy were remission and/or disease stabilised (61%) and completed
planned cycles (38%). Main reasons for never treating patients were lack of
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symptoms (62%) and waiting for biochemical progression (45%). However, in
Germany, patient refusal was a frequent reason (19%) and in Switzerland poor
life expectancy was selected for 27% of patients.
Summary and Conclusions: Half of patients seen were on active therapy.
However, data suggest that many do not receive subsequent treatment lines.
Those who reached later lines were more likely to have had a previous SCT.
Although treatment practices were broadly similar across countries, there were
some notable differences in the agents used. These real-world data provide
useful information for designing clinical trials and for health economic evalua-
tions of new and existing agents.
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Background: Multiple myeloma (MM) remains an incurable disease. Natural
killer (NK) cell infusions could be a novel treatment strategy. NK cells exert
cytotoxicity against MM cells. Moreover, it has been suggested that enhanced
NK cell cytotoxicity might be part of the mechanism of action of effective anti-
myeloma drugs such as lenalidomide or bortezomib. By co-culture with the
genetically modified cell line K562-mb15-41BBL it is possible to expand ex
vivo large numbers of activated NK cells from MM patients.
Aims: We are conducting a phase I clinical trial to evaluate feasibility, safety
and tolerability of K562-mb15-41BBL-expanded autologous NK cells (termed
“NKAEs”) infused in MM patients in combination with anti-myeloma drugs
(EudraCT 2012-000514-11). Patients eligible for this trial have MM and per-
sistent or progressing disease.
Methods: Five MM patients on 2nd or later relapse have been enrolled in this
phase I clinical trial to date. To activate and expand NK cell, peripheral blood
mononuclear cell (PBMCs) were co-cultured with K562-mb15-41BBL cells and
100 IU/ml IL-2. We collected 200 ml of peripheral blood (PB) from patients
every cycle (n=4) to produce autologous NKAEs under GMP conditions and
cells were harvested on day 14 and 21 for infusions. Four cycles of pharma-
cological treatment with 2 infusions of 7.5x106 autologous NKAEs/kg on day 1
and 8 of each cycle were performed. NKAEs purity was analyzed by multi-
parametric flow cytometry. NK cells presence in PB was also assessed by PB
smear examination before and after each infusion. C-Myc, telomerase and
BCR-ABL expression were determined by real time-PCR.
Figure 1. A) Results of NKAE expansion procedures (n=17) from patients
included on EudraCT 2012-000514-11 clinical trial. Results are shown as
mean ± standard deviation of 4 independent expansion procedures from
each patient. B) Summary of EudraCT 2012-000514-11 clinical trial.
Results: Of the 5 patients enrolled, 3 received lenalidomide-based treatment
and 2 bortezomib-based treatment. Patients received a total of 34 NKAEs infu-
sions. We have not observed any serious toxicity attributable to NKAE infusion.
One patient had grade II neutropenia, which did not require dose adjustment.
The 5 MM patients enrolled had 23% (±10%) NK cells of PBMCs. We collected
21x106 (±17x106) NK cells from PB. After 1 week NKAEs number increased
x17 fold, at 2nd week fold was x33. We collected 550x106 (±50x106) NKAEs
from culture for the first infusion. At 3rd week NKAEs number reached 992x106
and 92% (±7%) purity of NKAEs (Figure 1A). The expression of c-Myc and
telomerase were not altered in NKAE end products. The expression of BCR-
ABL disappeared from cultures after the first week, and was undetectable in
PB after NKAE therapy. PB smear examination showed an increase ofx2.5
fold of activated circulating lymphocytes: 7x105 lymphocytes/L before infusion,
reaching 1.75x106 lymphocytes/L after infusion. Patient 01 achieved a partial
response and maintained it for 13 months after NKAEs infusion. Patient 02
started NKAEs infusion while in relapse and, achieved stable disease, which
was maintained for 9 months before disease progression. Of note, bone marrow
infiltration by MM plasma cells decreased at least 50% at the end of NKAE
treatment in these two patients. Patient 03 had disease progression 2 months
after stopping treatment due to unrelated toxicity. Patients 04 and 05 recently
finished NKAEs treatment and achieved disease stabilization 4 months after
the first NKAE infusion (Figure 1B).
Summary and Conclusions: Clinical-grade NKAEs can be obtained from MM
patients undergoing treatment, and multiple infusions of NKAEs are feasible
without serious toxicities. NKAEs showed clinical anti-myeloma activity, with
one heavily treated patient achieving durable partial response. These results
and clinical observations warrant further development of NKAEs infusion as a
treatment modality for refractory MM.
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Background: Advances in therapy and management have improved survival
for patients with multiple myeloma (MM), many of whom live to receive several
lines of therapy. With increasing numbers of available therapies, it is timely to
examine real-world treatment practices and the course of patient journeys.
Aims: To investigate patient characteristics, treatment durations and outcomes,
treatment-free intervals (TFI) and symptom burden across the treatment path-
way in Belgium, France, Germany, Italy, Spain, Switzerland and the UK.
Methods: Data were obtained from chart reviews by physicians managing
patients with MM, who completed retrospective forms on patient characteristics
and treatment from diagnosis for up to 14 patients seen in the previous 3
months, with a quota for patients who had completed specific treatment lines.
Patients were included in reverse chronological order. 
Results: In total, 435 physicians retrospectively reviewed 4997 patient charts.
Median time from diagnosis in patients at 1st line was 19 months, at 2nd line
44 months and at ≥3rd line 65 months. Profiles of patients diagnosed in the last
12 months were similar across countries; common presentations were bone
pain (61%), anaemia (39%), vertebral fracture (21%), renal dysfunction (20%)
and hypercalcemia (19%). Almost all patients (95%) received ≥1 line of therapy,
61% received ≥2, 38% ≥3, 15% ≥4 and 1% ≥5. Of the 38% of patients eligible
for stem cell transplantation (SCT), 95% received SCT at 1st and/or 2nd line;
proportions of patients receiving SCT were similar across countries. Median
duration of 1st line therapy was 6 months, followed by a median TFI of 10
months. TFI was longer in patients who received SCT (16 months [n=444] vs
7 months in those who did not [n=935]). Time to progression (TTP) decreased
with later lines of therapy, from median 18 months at 1st line to 5 months at 4th
line. Depth of response, as assessed by treating physician, decreased with
each additional line of therapy: 74% of patients achieved at least very good
partial response (≥VGPR) in 1st line, while only 11% achieved ≥VGPR at 5th
line. Better response levels were associated with longer TTP; in 1st line, median
TTP for patients in complete response (CR) was 30 months, VGPR, 21 months
and PR, 13 months. At the end of each treatment line, patients who were not
planned to receive further treatment were significantly (p <0.05) more likely to
have had a worse response to treatment, a poor overall condition, more
adverse events (AEs), shorter life expectancy and to have received suboptimal
dosing owing to comorbidities or treatment-related AEs compared to patients
who were planned to or those who received a further line of therapy. The most
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common AEs at 1st line were neuropathy (45% of patients, all grades), anaemia
(23%), neutropenia (22%) and thrombocytopenia (15%). AEs affected optimal
treatment dosing in 23% of patients at 1st line, increasing to 45% at 3rd line.
Summary and Conclusions: Information on real-world patient outcomes may
be valuable to physicians when assessing treatment options and discussing these
options with patients. The data suggest that while over half of patients receive
2nd line therapy, only 15% receive ≥4 lines. Diminishing benefits with each line of
therapy, and increasing incidence of AEs leading to suboptimal treatment dosing,
highlight the challenges when making treatment decisions across the pathway.
The data also indicate which patients are most likely to discontinue therapy, which
may help physicians to plan MM treatment strategies.
P650
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Background: EU PASS is an observational, non-interventional post-authorization
study designed to investigate the safety of lenalidomide (LEN) and other agents
in the treatment (Tx) of RRMM patients (pts). Venous thromboembolic events
(VTEs) are recognized as possible adverse events (AEs) associated with the
administration of LEN+dexamethasone (DEX). Larocca (Blood, 2012) reported
that the incidence of grade 3/4 deep vein thrombosis (DVT) and pulmonary
embolism (PE) during the first 6 mos of Tx was similar in selected newly diag-
nosed MM pts treated with LEN+low-dose DEX randomized to receive either
acetylsalicylic acid (ASA) 100 mg/day (2.3%) or low-molecular-weight heparin
(LMWH) enoxaparin 40 mg/day (1.2%; P=0.452). In the observational MELISSE
study of pts treated with IMiD immunomodulatory drugs in 52 IFM centers, 443
pts received thromboprophylaxis at therapy initiation: 307 pts (59%) received
ASA, 88 pts (17%) received LMWH, and 81 pts (15.5%) did not receive VTE pro-
phylaxis (Leleu, Thromb Haemost. 2013). Through the first year of follow-up, the
cumulative incidence of VTEs was 6% (n=31). Overall, VTEs occurred irrespective
of whether pts were on ASA or LMWH prophylaxis (P=0.62).
Aims: To describe the incidence of VTE (DVT/PE) among RRMM pts enrolled in
the PASS, to identify risk factors for VTE, and to compare the incidence of VTE in
pts receiving different types of anti-thrombotic prophylaxis and no prophylaxis. 
Methods: RRMM pts who had received ≥1 prior Tx were enrolled at the inves-
tigator’s discretion into a LEN or background cohort (other regimens); this analy-
sis focused only on pts who were treated in the LEN cohort. Thromboprophy-
lactic medication was administered per local standard practice. Baseline risk
factors for VTE were extracted. Incidence rates of VTE were calculated for
events that occurred during the first 6 mos of follow-up based on pt-mos of
exposure to single agents (ie, LMWH, ASA) and pt-mos of no exposure.
Results: A total of 2164 pts received LEN therapy for RRMM. Pts in the LEN
cohort had a median age of 68 yrs (range, 25-95 yrs), and 54% were male. The
proportion of pts prescribed low-dose DEX (≤160 mg) was 74.2%. Among 1529
pts with new or continuing thromboprophylaxis at baseline, 36.5% received ASA,
24.9% received LMWH, 7.1% received other anti-platelet medications, and 5%
received warfarin. Over the entire follow-up interval, 123 pts (5.7%) experienced
a VTE. Only 2 pts experienced a VTE while receiving warfarin therapy. Baseline
risk factors associated with VTE were previous history of VTE (odds ratio
[OR]=1.71; 95% CI, 1.06-2.77), age (OR=2.10; 95% CI, 1.36-3.25), and body
mass index (OR=1.47; 95% CI, 0.98-2.21). Considering only single thrombopro-
phylaxis agent use during the first 6 mos of IMiD therapy, the incidence of VTE
was highest among pts not receiving prophylaxis during the month the VTE
occurred: 1.64 per 100 pt-mos. VTE incidence rates were similar among pts treat-
ed with either ASA (0.686 per 100 pt-mos) or LMWH (0.636 per 100 pt-mos). In
either case, a significant protective effect was noted for use of either ASA (relative
risk [RR]=0.42, P=0.003) or LMWH (RR=0.39; P=0.004).
Summary and Conclusions: The incidence of VTE among RRMM pts in the
PASS (5.7%) was similar to that previously reported in another large cohort
study (MELISSE). Identified VTE risk factors were similar to those previously
identified (age, prior VTE, BMI). Similar to previously reported results comparing
ASA and LMWH, equivalent reductions in VTE risk were identified for pts receiv-
ing thromboprophylaxis with either ASA or LMWH.
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Background: To allow for full-dose treatment (Tx) and maximize therapeutic
benefit, management of adverse events (AEs) in patients (pts) with
relapsed/refractory multiple myeloma (RRMM) must be optimized. Pts with
RRMM who have been exposed to multiple prior Tx may present with comor-
bidities and be susceptible to frequent AEs. In the pivotal MM-003 study of
pomalidomide+low-dose dexamethasone (POM+LoDEX) in pts with heavily
pre-treated RRMM, most pts did not have dose reductions and there were few
discontinuations due to AEs (Delforge, EHA 2013). Frequent grade (Gr) 3-4
AEs associated with POM+LoDEX were neutropenia, anemia, thrombocytope-
nia, and infections.
Aims: This sub-analysis examined the safety profile and management of AEs
for pts enrolled in the STRATUS trial.
Methods: Pts with refractory or relapsed and refractory disease (progressive
disease [PD] within 60 days of last prior Tx) who failed prior lenalidomide and
bortezomib Tx and had adequate prior alkylator therapy were included. Key
exclusion criteria were: absolute neutrophil count <800/μL, platelet count
<75,000 or <30,000/μL (for pts with <50% or ≥50% of bone marrow nucleated
cells as plasma cells, respectively), hemoglobin <8 g/dL, creatinine clearance
<45 mL/min, and peripheral neuropathy (PN) ≥Gr 2. POM 4 mg was adminis-
tered D1-21 of a 28-day cycle in combination with LoDEX 40 mg/day for pts
aged ≤75 yrs or 20 mg for pts aged >75 yrs on D1, 8, 15, 22 until PD or unac-
ceptable toxicity. Pts required mandatory thromboprophylaxis. AEs were graded
according to the National Cancer Institute Common Terminology Criteria for
AEs v 4.0. Pts were followed for subsequent anti-myeloma Tx, OS, and second
primary malignancy until 5 yrs post enrollment. The primary endpoint of this
sub-analysis was safety.
Table 1.
Results: 604 pts have been enrolled as of Sept 15, 2014; 599 pts were evaluable
for safety. Median follow-up was 9.3 mos. The most frequent Gr 3-4 hematologic
AEs were neutropenia (42%), anemia (29%), and thrombocytopenia (22%); 5%
of pts experienced Gr 3-4 febrile neutropenia. The most frequent Gr 3-4 non-
hematologic AEs included infections (30%) and fatigue (5%); 11% of pts experi-
enced Gr 3-4 pneumonia. Gr 3-4 venous thromboembolic events (VTEs) occurred
in 1% of pts and 4% had at least 1 VTE of any grade. PN of any grade occurred
in 15% of pts, with 1% of pts experiencing Gr 3-4 PN. Management of AEs was
primarily via dose reductions and/or supportive care (Table 1). 18% and 58% of
pts had POM dose reductions or interruptions, respectively due to AEs. The most
common AEs leading to dose reductions or dose interruptions, respectively were
neutropenia (4.7% and 19.4%), thrombocytopenia (3.3% and 9.7%), and pneu-
monia (1.5% and 7.3%). Discontinuation of POM due to AEs was infrequent (5%)
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and the most frequently occurring AEs leading to POM discontinuation included
pneumonia (0.7%), thrombocytopenia (0.7%), anemia (0.3%), and neutropenia
(0.3%). Updated data will be presented at the congress.
Summary and Conclusions: This is the largest study conducted to date with
POM+LoDEX in a heavily pre-treated RRMM pt population. POM+LoDEX was
generally well tolerated with an acceptable safety profile that was consistent
with the pivotal trials. There were few discontinuations due to AEs and most
AEs could be managed with dose reductions and/or supportive care.
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Background: In the last couple of years a heated debate developed between
supporters of first line autologous stem cell transplant (ASCT) in every multiple
myeloma (MM) patients whenever it is feasible and those who think that with
the arrival of novel agents (thalidomide, bortezomib and lenalidomide) we can
get comparable results without the toxicity of ASCT which we can therefore
delay and spare for relapse. Randomized studies from the nineties showed
conflicting results regarding the progression free survival (PFS) and overall
survival (OS) benefit associated with high dose treatment, and trials exploring
this question in the era of novel agents are currently running. These are expect-
ed to be reported within the next years, but until then our strategies should
mainly be based on retrospective comparisons.
Aims: We analyzed the outcome of 548 myeloma patients transplanted in our
centre over 18 years.
Methods: Transplants performed within 12 months from the start of the first
chemotherapy were counted as early, others as late. PFS was calculated from
the day of ASCT and OS from the first chemotherapy.
Results: The median time from first treatment to ASCT was 9.8 (3.4-192)
months in the whole cohort, 7.3 (3.4-11.9) in the early and 16.9 (12-192) in the
late ASCT subgroups. The overall response rate post-ASCT was higher in the
early group with significantly more CRs (58.1 vs 46.8%, p=0.016). The pre-
ASCT results were superior with novel agents both in the early and late cohorts,
but following the ASCT these differences disappeared. The PFS was signifi-
cantly longer in the early than the late group [30.2 (26.1-34.3) vs 23.3 (16.8-
29.8) months; p=0.036], but there was no OS advantage [95.5 (83.8-107.2) vs
100.4 (80.7-120.1); p=0.211] (Figure 1). The results were similar in subgroups
treated with novel agents [PFS in early vs late 31 (25.8-36.2) months vs 22.2
(14.9-29.4); p=0.105; OS 84.3 (70.9-97.7) vs 122.4 (90.5-154.3) respectively;
p=0.101] and without [PFS 27.8 (21.1-34.5) vs 27.8 (18.9-36.7) in early vs late;
p=0.138; OS 97.2 (84-110.4) vs 99.1 (93.4-104.8) respectively; p=0.772] how-
ever within the subgroups the differences were not significant.
Figure 1.
Summary and Conclusions: Our findings confirmed the results of prior retro-
spective studies: early ASCTs resulted in more CRs and VGPRs, and a signif-
icant post-ASCT PFS benefit, but no OS difference. However one has to be
careful with the interpretation of retrospective studies. Even with novel agents
there is a significant proportion of patients unsalvageable at relapse. For others
transplant becomes unfeasible due to deterioration of performance status or
comorbidity. As these patients have never had ASCT they remain unaccounted
for in any retrospective ASCT data sets. Another worry is that ASCT may be
less effective later in the disease course due to clonal drift resulting in increased
chemoresistance. Only prospective randomized studies can answer these
questions.
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Background: The oral proteasome inhibitor OPZ has shown promising anti-
tumor activity in pts with hematologic malignancies, including multiple myeloma
(MM; Vij, Blood 2014;121:abstract 34).
Aims: We present updated results from an ongoing, single-arm, phase 1b/2
study (NCT01832727) that is evaluating the safety and tolerability of OPZ with
DEX in pts with RRMM.
Methods: Pts with RRMM who have received 1-5 prior lines of therapy (≥1
regimen including lenalidomide and/or bortezomib) are eligible. Pts are receiv-
ing OPZ tablets (PO) on days 1, 2, 8, and 9 (2/7 schedule) or on days 1-5
(5/14 schedule) of a 14-day cycle. All pts are receiving DEX (20 mg PO) on
days 1, 2, 8, and 9. Treatment is being administered until pt withdrawal, disease
progression, or unacceptable toxicity. The starting OPZ dose was 210 mg on
both schedules. OPZ doses are being escalated in 30-mg increments using
standard 3+3 dose escalation. The primary objectives of the phase 1b study
are to determine the maximum tolerated dose (MTD), recommend the phase
2 dose (RP2D) of OPZ with DEX, and to evaluate safety and tolerability.
Response is being assessed by IMWG criteria, with minimal response (MR)
and near complete response defined by modified EBMT criteria. Safety is being
assessed by CTCAE, v4.03. All pts provided informed consent.
Results: As of January 19, 2015, 22 and 19 pts were enrolled on the 2/7 and
5/14 schedules, respectively. Preliminary data are available for a total of 35 pts
enrolled as of November 3, 2014 (2/7 schedule, n=19; 5/14 schedule, n=16), 31
of whom were evaluable for response (2/7 schedule, n=17; 5/14 schedule, n=14).
The median age of pts was 63 years (2/7 schedule) and 63.5 years (5/14 sched-
ule). Pts received a median of 3 (range, 1-5) prior regimens in the 2/7 schedule
and 2 (range, 1-5) prior regimens in the 5/14 schedule. Preliminary median OPZ
treatment duration was 15 weeks in the 2/7 schedule (range, 1.3-51.3 weeks)
and 5.7 weeks in the 5/14 schedule (range, 0.7-24.7 weeks). No dose-limiting
toxicities (DLTs) occurred in the 2/7 schedule. In the 5/14 schedule, 3 DLTs
occurred (210-mg/day dosing level: grade 2 subarachnoid hemorrhage; grade 3
transaminitis; and grade 4 thrombocytopenia); the MTD was 180 mg/day. The
MTD was not reached in the 2/7 schedule up to a dosing level of 300 mg/day. In
both schedules combined, the most common adverse events (AEs) of any grade
were diarrhea, nausea, and fatigue; the most common grade ≥3 AEs were ane-
mia, diarrhea, and thrombocytopenia (Table 1). Two grade 5 AEs of sepsis
occurred: 1 in the 2/7 schedule (240 mg/day) and 1 in the 5/14 schedule (210
mg/day). Three pts on the 2/7 schedule and 9 pts on the 5/14 schedule discon-
tinued treatment due to an AE. Five pts in each schedule had their OPZ dose
reduced due to an AE. On the 2/7 schedule, the overall response rate (ORR;
≥partial response [PR]) was 35.3% and the clinical benefit rate (CBR; ≥MR) was
41.2% (6 pts had a PR, 1 had an MR, and 8 had stable disease [SD]). On the
5/14 schedule, the ORR was 7.1% and the CBR was 35.7% (1 pt had a PR, 4
had an MR, and 6 had SD).
Table 1. AEs occurring in ≥25% of pts or grade ≥3 AEs occurring in ≥2 pts.
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Summary and Conclusions: In the 5/14 schedule, the MTD was 180 mg/day;
the MTD was not reached in the 2/7 schedule. Preliminary results suggest that
OPZ with DEX has promising antitumor activity in pts with RRMM receiving the
2/7 schedule; this schedule has been selected as the recommended phase 2
schedule. Dose escalation will continue in the 2/7 schedule until the MTD or
RP2D is determined. Updated data (including pharmacokinetics) for both sched-
ules will be presented at the meeting.
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Background: With the development of novel therapeutic agents, more than
30% of patients with multiple myeloma (MM) achieve complete response (CR)
as defined by the International Myeloma Working Group (IMWG) criteria. How-
ever, most of the patients that achieve CR ultimately die due to relapse, sug-
gesting the presence of minimal residual disease (MRD) in these patients. Mul-
ticolor flow-cytometry (FCM) allows the detection of < 10-4 clonal plasma cells
(PCs) in normal bone marrow and has been used for detecting MRD after treat-
ment. FCM-defined immunophenotypic response (iR, clonal PCs<10-4) has
emerged as a more relevant prognostic factor in patients with MM. However,
the relevance of the prognostic impact of IR and the normalization of serum
free light chain (sFLC) ratio remain unclear.
Aims: To investigate the impact of FCM-defined CR (iR), conventional
immunofixation negative CR (CR), and CR plus FLC κ/λ normal CR (sCR) on
the prognosis of patients with MM who obtained more than very good partial
response (VGPR) at Kameda Medical Center, Kamogawa, Japan.
Methods: Among the 265 patients treated at our hospital between April 2004
and February 2015, 102 patients that achieved more than VGPR (70 CR, 32
VGPR) were included in this study. The study population consisted of 64 males
and 38 females with a median age of 69 years. All patients received at least one
course of novel agent-containing therapeutic regimen. Treatment response was
assessed using the IMWG criteria. Best response to treatment during the course
of disease was evaluated by simultaneous analysis by immunofixation elec-
trophoresis (IFE), sFLC measurements, and FCM analysis of bone marrow PCs.
FCM defined MRD was evaluated by single tube 6-color FCM using CD45, CD38
gating strategy, with combination with CD19. iR was defined as less than 10-4
neoplastic PCs in bone marrow samples determined by FCM. Overall survival
(OS) and disease free survival (DFS); OS was defined from the day of diagnosis
to death from any cause, with censoring performed the date of last contact. DFS
was calculated from the date of achieve CR, sCR, or iR to relapse from the
respective response date. Survivals were analyzed by the Kaplan-Meier method,
and differences between curves were calculated by two-sided log-rank test. Sub-
jects were classified into four categories; MFC positive or negative and κ-λ ratio
normal or abnormal, and PFS and OS were compared between groups.
Results: Among 102 patients who achieved more than VGPR, iR, sCR, CR
and VGPR was obtained 43 (42%), 80 (78%), 70 (69%) and 32 (31%) of
patients, respectively. Normalization of FLC ratio with CR and VGPR was
observed in 61 (87%) and 19 (59%) of patients, respectively. iR was achieved
in 33 (49%) of the CR patients, in 8 (25%) of the VGPR patients, and in 39
(90.7%) of the iR patients who attained normal κ/λ. The patients with iR and
normal FLC showed significantly longer DFS compared to those without iR,
although OS was not different between patients with or without iR. However,
these survival differences were not translated to the OS among the groups due
to less. On multivariate Cox regression analysis, only achievement of iR
emerged as an independent prognostic factor for DFS (Figure 1).
Figure 1. Impact of iR on DFS in patients with CR and sCR.
Summary and Conclusions: Although both achievement of CR, normalization
of sFLC κ/λ, and iR appeared to confer on longer DFS and OS, obtaining iR
seems to have greater implications for longer survival compared to CR or FLC
κ/λ normalization. MFC is a rapid, affordable, and easy performable method
for measurement of MRD and iR could be considered as a goal of treatment
for patients with MM.
Multiple myeloma - Clinical 4
P655
A PRIOR CANCER DIAGNOSIS IS NOT A RISK FACTOR FOR THE DEVEL-
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Background: Patients with multiple myeloma (MM) have been shown to have
an increased risk of subsequently developing certain types of cancers, such as
acute myeloid leukemia, myelodysplastic syndromes, gastrointestinal and non-
melanoma skin cancer. With improved survival in MM patients the incidence of
subsequent cancers will increase in the future. Also we have previously shown
that the development of a subsequent cancer is associated with a decreased life
expectancy. Therefore it is of great importance to identify potential risk factors.
Treatment-related factors have been considered to be the main contributing factor
to the observed risk increase, but research regarding other risk factors is limited.
Prior studies have found genetic instability to be associated with carcinogenesis.
In this study we hypothesize that prior cancer is a proxy for genetic instability that
could be a potential risk factor for subsequent cancer development in MM patients.
Aims: To investigate whether any form of cancer diagnosis prior to MM diag-
nosis is an independent risk factor for developing a subsequent cancer after
the MM diagnosis.
Methods: All patients diagnosed with MM in Sweden from January 1st, 1958 to
December 31st, 2011 were identified from the Swedish Cancer Registry (SCR).
All prior and subsequent cancer diagnoses were identified through cross-linkage
with the SCR. Patients with a cancer diagnosis after MM diagnosis were classified
as cases. For each case, 1-3 controls without a cancer diagnosis after MM diag-
nosis, matched for age, gender, and date of MM diagnosis, were selected from
the cohort. The controls had to be alive when the corresponding case developed
subsequent cancer. The type of prior and subsequent cancer was classified
according to the International Classification of Disease version 7. Prior cancer
diagnosis was compared between cases and controls. Subgroup analysis was
performed for each subsequent cancer subtype according to appropriate organ
system. Conditional logistic regression was used for the statistical analysis in R.
Results: Results: A total of 26,627 patients were diagnosed with MM during
the study period. Of these, 1,645 (6.2%) developed subsequent cancer (cases)
and 4,334 MM patients were chosen as matched controls. MM patients with a
prior cancer diagnosis did not have a statistically significant increased risk of
developing a subsequent cancer compared to MM patients without a prior can-
cer (odds ratio (OR) 1.19; 95% confidence interval (CI) 0.97-1.46). In a sub-
group analysis, prior cancer in MM patients was not associated with increased
risk of developing the following cancers: breast (OR=1.21; 95% CI 0.52-2.77),
ear, nose and throat (OR=0.90; 95% CI 0.09-8.68), endocrine (OR=0.94; 95%
CI 0.18-5.01), female reproductive (OR=0.91; 95% CI 0.26-3.15), hematological
(OR=0.84; 95% CI 0.43-1.66), gastrointestinal (OR=0.89; 95% CI 0.56-1.43),
kidney and urinary tract (OR=1.86; 95% CI 0.92-3.75), male reproductive
(OR=0.58; 95% CI 0.31-1.12), melanoma (OR=1.35; 95% CI 0.52-3.47), nerv-
ous system (OR=0.72; 95% CI 0.15-3.38), non-melanoma skin cancer
(OR=1.52; 95% CI 0.98-2.36), and respiratory (OR=2.02; 95% CI 0.84-4.86).
Summary and Conclusions: In this large case-control study we report that a
prior cancer diagnosis is not associated with increased risk of developing a
subsequent cancer in MM patients. Our findings are of major clinical relevance
and suggest that the best available therapy should not be withheld from MM
patients due to concern for subsequent cancer, irrespective of a prior cancer
diagnoses. Further research is needed to shed light on the risk factors for sub-
sequent cancers in MM patients.
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MELPHALAN IN COMBINATION WITH BORTEZOMIB AND DEXAMETHA-
SONE (BMDEX) PRODUCES MORE DURABLE RESPONSES THAN
CYCLOPHOSPHAMIDE (CYBORD): A MATCHED CASE-CONTROL STUDY
P. Milani1,* A. Foli1, M. Basset1, G. Merlini1, G. Palladini1
1Department of Molecular Medicine, Amyloidosis Research and Treatment Cen-
ter, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Background: At present, the majority of patients with AL amyloidosis are treated
with combinations of alkylating agents, bortezomib, and dexamethasone. High
response rates and short times to response have been reported with these reg-
imens. Cyclophosphamide is used more commonly (CyBorD), but in some centers
melphalan is also prescribed (BMDex). At our center both regimens are used,
and cyclophosphamide is preferred in patients with potentially reversible con-
traindications to stem cell transplant and in subjects with renal failure.
Aims: In the present case-control study, we compared the outcome of patients
treated with CyBorD and BMDex.
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Methods: Eighty-seven newly-diagnosed consecutive patients treated with
BMDex were matched with 87 controls who received CyBorD. Matched vari-
ables were cardiac stage (with stage III patients having NT-proBNP >8500 ng/L
included in a separate stage, IIIb), revised Mayo stage, renal stage, systolic
blood pressure <100 mmHg, and bortezomib (1.3 mg/m2 in all patients) and
dexamethasone (40 mg in 26% of patients) dosages.
Results: Cardiac stage was I, II, IIIa, and IIIb in 14%, 42%, 22%, and 22% of
patients, respectively. Renal stage was I, II, and III in 53%, 30%, and 27% of
cases, respectively. There was no difference in plasma cell infiltrate (median
13% vs 12%, P=0.190) and dFLC (median 199 mg/L vs 212 mg/L, P=0.953)
between the BMDex and CyBorD groups. Patients treated with BMDex were
older (median 69 vs 60 years, P<0.001). Severe adverse events were observed
in 22% of patients treated with BMDex and in 13% of those receiving CyBorD
(P=0.108). Most common were cytopenia (6% vs 1%, P=0.054) and fluid reten-
tion (9% vs 8%, P=0.787). Hematologic response rate was 69% in the BMDex
group and 55% in the CyBorD group (P=0.061), and CR/VGPR was reached
in 55% of patients in the BMDex arm and in 39% in the CyBorD arm (P=0.033).
Differences in cardiac (16% vs 17%) and renal (29% vs 25%) response rates
were not significant. Projected overall survivals at 3 years in cardiac stages I,
II, IIIa, and IIIb were 100% vs 100%, 72% vs 51% (P=0.059), 42% vs 47%
(P=0.605), 12% vs 12% (P=0.352) in the BMDex and CyBorD arms, respec-
tively. In the overall population, time to second-line therapy was longer with
BMDex (74% vs 40% of responses maintained at 3 years, P=0.050). This was
due to a longer duration of CR/VGPR (89% vs 57% maintained at 3 years,
P=0.019), while duration of PR was similar in the two arms (median 9 vs 13
months, P=0.093). However, relapsing patients were efficiently rescued, and
there was no difference in overall survival of patients achieving CR/VGPR with
BMDex and CyBorD (83% vs 82% at 3 years).
Summary and Conclusions: Profound reductions in the concentration of the
amyloidogenic light chain can be obtained with both BMDex and CyBorD. How-
ever, responses are more durable in patients exposed to melphalan, and
BMDex may be preferred when there is no need to preserve stem cells.
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EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRES-
SION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELO-
MA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC
V. Sandecka1,2, R. Hajek3,4,5,6,* Z. Adam2,7, I. Spicka8,9, V. Scudla10,11,
E. Gregora9,12, J. Radocha13,14, L. Brozova15, J. Jarkovsky15, L. Rihova2,16,
A. Mikulasova5,16, D. Starostka17,18, L. Walterova19,20, D. Adamova21,22,
P. Kessler23,24, M. Brejcha25,26, I. Vonke27, J. Obernauerova28,29, K. Valentova30,
L. Pour1,2, J. Minarik10,11, J. Straub9,12, J. Gumulec4,31, V. Maisnar13,14
1Department of Internal Medicine, Hematology and Oncology, University Hospital,
2Czech Myeloma Group, Brno, 3Department of Haematooncology, University
Hospital and the Faculty of Medicine University of Ostrava, 4Czech Myeloma
Group, Ostrava, 5Department of Experimental Biology, Faculty of Science,
Masaryk University, 6Department of Pathological Physiology, Faculty of Medicine,
Masaryk University, Babak Myeloma Group, 7Department of Internal Medicine,
Hematology and Oncology, University Hospital Brno, Czech Republic, Brno,
8Department of Internal Medicine, University Hospital, 9Czech Myeloma Group,
Prague, 10Czech Myeloma Group, 11Department of Hemato-oncology, University
Hospital Olomouc and Faculty of Medicine and Dentistry of Palacky University,
Olomouc, 12Department of Clinical Hematology, University Hospital Kralovske
Vinohrady, Prague, 134th Department of Medicine - Hematology, University Hos-
pital, 14Czech Myeloma Group, Hradec Kralove, 15Institute of Biostatistics and
Analyses, Faculty of Medicine, Masaryk University, 16Department of Clinical
Hematology, University Hospital, Brno, 17Department of Clinical Hematology,
Hospital, 18Czech Myeloma Group, Havirov, 19Department of Clinical Hematol-
ogy, Hospital, 20Czech Myeloma Group, Liberec, 21Czech Myeloma Group,
22Department of Hematology and Transfusion, Hospital, Opava, 23Department
of Hematology and Transfusion Medicine, Hospital, 24Czech Myeloma Group,
Pelhrimov, 25Czech Myeloma Group, 26Department of Clinical Hematology, Hos-
pital, Novy Jicin, 27Department of Clinical Hematology, Hospital, Ceske Bude-
jovice, 28Department of Hematology and Transfusion, Hospital, 29Czech Myelo-
ma Group, Mlada Boleslav, 30Department of Clinical Hematology, Thomayer
Hospital, Prague, 31Department of Haematooncology, University Hospital Ostrava
and the Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Background: Two risk stratification models predict the progression from smoldering
multiple myeloma (SMM) to multiple myeloma (MM). i) the Mayo Clinic model uses
percentage of bone marrow plasma cells (BMPCs) and serum monoclonal protein
(M-protein) and free light chain (FLC) ratio, ii) the PETHEMA model uses immuno-
paresis and the percentage of abnormal PCs (aPCs) by flow cytometry.
Aims: The primary end point was to estimate the cumulative risk of MM occurring
during the follow-up of our cohort. The secondary end points were: to validate
known clinical models and to establish a new risk model by the Czech Myeloma
Group (CMG model) with better prediction of ultra high-risk SMM group.
Methods: Data for this study were obtained from the Registry of Monoclonal
Gammopathies (RMG) acquired from hematologic centers of the Czech Repub-
lic. In total, 361patients with SMM were enrolled in the RMG study from May
2007 to June 2013. In total, 79.5% (287/361) of patients were analyzed.
Results: 287 SMM patients were followed with median 2.4 years. MM was devel-
oped in 51.9% (149/287) of patients. The risk of progression was 16%, 31.2%,
54.8% and 73.4% at 1, 2, 5 and 10 years after diagnosis, respectively. The key
predictors factors of progression were as follows: serum (iFLC/uFLC) ratio >30
(HR 2.4 [1.4-4.1], p<0.001), BMPCs ≥15% (HR 2.1 [1.5-3.0]; p<0.001), immuno-
paresis (HR 2.0 [1.3-2.9]; p<0.001), M - protein concentration ≥2.3 g/dL (HR 2.00
[1.4-2.7]; p<0.001), beta2 microglobulin ≥2.0 mg/l (HR 1.8 [1.2-2.7]; p=0.001),
and thrombocyte count ≤250x109/l (HR 1.7 [1.1-2.4]; p=0.005). Distribution of
SMM patients according to risk groups based on the Mayo Clinic model (Dispen-
zieri 2008) confirmed predictive power of this model based on low and interme-
diate- risk group, but did not confirm high-risk group. The high-risk group was
represented only by 4 SMM patients. At 2 years, no-risk group had 20.2% risk of
progression compared to 23.2%, 45.4% and 25% in groups with 1, 2 or 3 risk
factors, respectively (p=0.014) (Figure 1). SMM group with 1, 2 and 3 risk factors
in comparison to the reference group had HR (1.14 [0.54- 2.41]; p=0.732, HR
2.58 [1.25- 5.35]; p=0.011, HR 2.18 [0.47-10.03]; p=0.317, n=146), retrospec-
tively. Immunoparesis and ≥95% aPC was used to validate the PETHEMA model
(Perez-Persona 2007). The rates of progression at 2 years were 5.9%, 20% and
41.4% for groups with 0, 1 or 2 risk factors, respectively (p=0.058) (Figure 1).
SMM group with 1 and 2 risk factors in comparison to the reference group had
HR (1.51 [0.40-5.69]; p=0.546, HR 3.31 [0.78-14.06]; p=0.104, n=62), retrospec-
tively. Based on the 3 parameters with independent predictive value in the uni-
variate analysis (immunoparesis, serum M-protein quantity ≥2.3 g/dL and
iFLC/uFLC >30) we proposed a new CMG model. The risk of progression from
SMM to MM at 2 years was 18.5%, 20.9%, 41.9% and 78.7% if 0, 1, 2 or 3 risk
factors are present (p<0.001) with HR of 1.4 [0.7-2.9]; p=0.28, 2.5 [1.2-5.0];
p=0.008, 6.7 [3.0-15.2]; p<0.001, n=139), respectively (Figure 1).
Figure 1. Comparison of 2 year risk of progression of CMG risk model (c)
with the existing models developed by Mayo clinic group (a) and PETHE-
MA group (b).
Summary and Conclusions: We confirmed the validity of previously consid-
ered clinical models by the Mayo Clinic group (except high-risk group) and the
PETHEMA group. New CMG model for the risk of progression from SMM to
MM was established. Better identification of ultra high-risk group with prediction
of 79% risk of progression to MM within two years based on easily accessible
clinical parameters is advantage.
Acknowledgments: NT13492-4, NT14575-3 and by EU FP7/2007-2013; grant
278570, IGA MZ CR NT14393.
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VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/
REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY
S. Kumar1,* R. Vij2, J. L. Kaufman3, J. Mikhael4, T. Facon5, P. Moreau6,
M. Amiot6, S. Alzate7, L. Morris7, J. Ross7, M. Dunbar7, M. Zhu7, S. Agarwal7,
J. Leverson7, S. Enschede7, R. Humerickhouse7, C. Touzeau6
1Mayo Clinic, Rochester, 2Washington University School of Medicine, St. Louis,
3Winship Cancer Institute of Emory University, Atlanta, 4Mayo Clinic Arizona,
Scottsdale, United States, 5CHRU Lille, Hopital Huriez, Lille, 6CHU de Nantes,
Hotel Dieu-HME, Nantes, France, 7AbbVie, North Chicago, United States
Background: The anti-apoptotic protein BCL-2 has been implicated in medi-
ating the survival of multiple myeloma (MM) cells. Venetoclax is a potent, selec-
tive, orally bioavailable small-molecule BCL-2 inhibitor. Venetoclax induces cell
death in MM cell lines and primary samples in vitro, especially in cells which
express a high ratio of BCL2 to MCL1, such as those with t(11;14). The current
Phase 1 study evaluates safety and efficacy of venetoclax in patients with
relapsed/refractory MM.
Aims: Primary objectives are to evaluate safety, pharmacokinetics (PK), and
recommended Phase 2 dose (RPTD); other objectives include preliminary effi-
cacy and impact of chromosomal abnormalities.
Methods: In dose-escalation cohorts, venetoclax was given orally daily at 300,
600, 900, or 1200 mg after a 2-week dose ramp-up. Patients were monitored
for tumor lysis syndrome.
Results: As of 12/19/2014, there were 28 patients with median age 65 (12/16
female/male); 9 were ISS stage I, 11 stage II, and 6 stage III. Median (range)
prior therapies: 6 (1-13). 23 received prior bortezomib-containing regimens (15
were refractory), 26 lenalidomide (12 were refractory), and 13 autologous
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hematopoietic stem cell transplant. 10 patients were t(11;14)-positive. Adverse
events (AE; all grades) occurring in ≥20% patients: diarrhea (32%), nausea (32%),
neutropenia (21%), and fatigue (21%). Grade 3/4 AEs (≥10%): thrombocytopenia
(18%), anemia (14%), and neutropenia (14%). 7 patients had serious AEs, with
1 (epigastric pain) possibly related to venetoclax. 17 patients have discontinued:
14 due to disease progression (PD), 2 for AEs (worsening shortness of breath,
hypokalemia), and 1 withdrew consent; 11 are still receiving therapy. 2 deaths
occurred (both due to PD). 2 dose-limiting toxicities were seen at 600 mg (cohort
was expanded): epigastric pain, nausea with abdominal pain. No patient had
tumor lysis syndrome. Preliminary PK (n=11; 300 and 600 mg): mean Cmax and
AUC24 were approximately dose-proportional with high intra-dose variability. 21
of 28 patients were evaluable for preliminary efficacy (Table 1).
Table 1. Best response by t(11;14) status.
Summary and Conclusions: Venetoclax monotherapy was well tolerated in
heavily-pretreated relapsed/refractory MM. Responses (including CR) and
longer time on study were observed in t(11;14)-positive patients. RPTD was
achieved; this study is now enrolling in the safety expansion cohort at 1200 mg
(with 2-week ramp-up). 
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IMPACT OF FISH ABNORMALITIES ON RISK OF PROGRESSION IN
PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIG-
NIFICANCE
S. Paul1, S. Kochuparambil1, S.V. Rajkumar1, A. Dispenzieri1, M. Gertz1,
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Background: Genetic abnormalities can be detected in the clonal plasma cells
in nearly all patients with myeloma, and remains the most important prognostic
factor in this disease. These abnormalities can be seen in the plasma cells at
all stages of the disease spectrum from MGUS to SMM to active MM. In SMM,
various abnormalities have been shown to increase the risk of progression to
MM. The relevance of these findings in MGUS is unknown. 
Aims: The study was performed to define the impact of common FISH abnor-
malities on risk of progression to multiple myeloma.
Methods: We reviewed the records of 10,244 patients with a diagnosis of MGUS,
and identified 382 in whom a FISH test was performed at some time during the
course of MGUS, but prior to any progression to SMM or MM. Impact of various
FISH abnormalities on the risk of progression to SMM or MM was analyzed.
Results: The median age at diagnosis was 62 years; 57% were male. The
estimated median follow up from MGUS diagnosis was 33 months for the entire
cohort, 20 patients (5%) had progressed at the time of analysis (5 SMM, 15
MM). FISH demonstrated at least one abnormality in 207 (54%) patients, was
normal in 58 (15%) and had insufficient plasma cells in 117 (31%). Among the
265 patients with a productive FISH, del13q was seen in 73 (28%), del17p in
6 (2%), any chromosome 14 translocation in 89 (34%), other chromosome 14
abnormality in 48 (18%), and trisomies of one or more chromosomes in 85
(32%). Considering only the 207 patients with an abnormal FISH, the distribu-
tion of the abnormalities above were 35%, 3%, 43%, 23% and 41%, respec-
tively. Presence of t(11;14), del17p and any trisomy were all associated with
increased risk of progression, while presence of any of the high-risk transloca-
tion (t(4;14, 14;16, or 14;20) did not affect the risk of progression. Overall, tri-
somy, t(11;14) or del17p were present in 146 (38%) of the patients and was
associated with a 6 fold increased risk of progression (95% CI; 2, 38). We
repeated the analysis excluding 7 patients who had progression to SMM or
MM within 1 year of FISH, and the results were similar with an increased risk
of progression in the presence of one of these three abnormalities. 
Summary and Conclusions: The spectrum of abnormalities in MGUS appear
similar to those in MM, except for presence of abnormalities in only a little over
half of the patients (compared to 97% in MM), likely a reflection of low plasma
cell burden. Interestingly, the FISH abnormalities associated with a better out-
come in patients with MM appear to increase the risk of disease progression in
MGUS. This raises the intriguing hypothesis that certain abnormalities are asso-
ciated with a faster transition to MM state but remain alive longer in the MM
phase, thus suggesting that the improved outcomes seen with these abnor-
malities reflect more of a lead-time bias in diagnosis of symptomatic disease. 
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POST RELAPSE OUTCOMES IN YOUNG PATIENTS WITH MULTIPLE
MYELOMA IN THE ERA OF NOVEL AGENTS
N. Vallumsetla1, S. Kumar1, M. Gertz1, U. Painuly1, A. Dispenzieri1, M. Lacy1,
F. Buadi1, R. Go1, D. Dingli1, N. Leung1, R. Kyle1, V. Rajkumar1, P. Kapoor1,*
1Hematology, Mayo Clinic, Rochester, United States
Background: About 10-15% of patients with multiple myeloma (MM) are ≤50
years of age at diagnosis. Age is known to impact survival outcome for patients
with MM. Young patients tend to have significantly longer overall survival (OS)
compared to their older counterparts. Our previous accounts have suggested
that in contradistinction to the observations in the elderly, young patients have
not demonstrated incremental survival improvement over the past decade.
Herein, we attempt to determine the disease course in young patients following
first relapse in the novel agent era, and compare outcomes with a matched
cohort of elderly patients (≥65 years of age) with relapsed MM.
Aims: To evaluate post relapse outcomes in young (≤50 years of age at diag-
nosis) MM patients, diagnosed between 01/01/2000-12/31/2011.
Methods: Of 242 consecutive young patients with active MM, diagnosed
between 2000-2011 and evaluated within 90 days of their diagnosis of MM at
Mayo Clinic, Rochester,149 (61.5%) had a documented first relapse prior to
our data cut-off date (12/31/2014). Patients were assigned to 2 year groups
based on the timing of the diagnosis: Group A (2000-2005; n=79) and Group B
(2006-2011; n=70). The outcomes from diagnosis were compared to a reference
cohort of elderly patients (≥65y of age), matched (1:1) by the timing of diagnosis,
using the Kaplan-Meier method and log-rank test. Additionally, post relapse
outcomes were compared to a similar reference cohort of elderly MM patients
that had a documented relapse. 
Results: The median OS from diagnosis for young MM patients (n=242) was
100.5 months [CI: 91- NR (not reached)]. The median estimated follow-up of
the entire cohort was 85 months from diagnosis. The median time to first pro-
gression was 33 months (CI 28-38) in 207 young patients for whom the com-
plete progression-related data were available. In Group A, young patients had
a superior OS from diagnosis [median 100 months (CI 81-NR) vs 38 months
(CI 25-49) in elderly; p<0.0001)] and from first relapse [median OS 59 months
(CI 38-75) vs 22 months (CI 15-33) in elderly; p<0.0001] (Figure 1A). In Group
B, OS from diagnosis was better in the young [median NR (CI 76-NR) vs 54
months (CI 37-71); p<0.0001]. However, OS from first relapse in the young
patient cohort in Group B was not different from that of the reference cohort of
elderly patients [median 43 months (CI 26-NR) vs 37 months (CI 20-54), respec-
tively; p=0.25] (Figure 1B). Similar observations were made for disease specific
survival in the 2 groups (data not shown). Therapy-related information stratified
by the year groups is provided in Table 1. While the use of novel agents at
relapse increased in the elderly (p<0.0001) as well as the young patients
(p=0.03) in the more recent period (2006-2011), a greater proportional increase
is evident in the older patient cohort.
Figure 1. Survival outcomes in young vs elderly from first relapse.
Table 1. Therapies utilized at first relapse.
Therapy                             Young                  Elderly       
                                              Group A (%)    Group B (%)        Group A (%)   Group B (%)
I)  Novel Agent-based                       74                  88                       49                 83
Immunomodulatory drug (IMiD)    57                  32                       39                 39
Proteasome inhibitor (PI)              16                  35                        5                   35
IMiD+PI combination                     1                   21                        5                    9
II) Conventional agents-based           26                  12                       51                 17
Summary and Conclusions: Although overall survival from diagnosis is supe-
rior for young patients with MM compared to the elderly, outcomes from first
relapse for the 2 age groups are similar in recent period (2006-2011). While
this observation may be attributed to improved survival in the elderly at relapse,
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likely related to increased use of novel agents at relapse, our results also under-
score that disease course for young patients is not different than that of the
elderly after first relapse, indicating that our current approaches for the young
patients with MM require substantial improvement. 
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SKY92 GEP, IFISH AND ISS COMPARISONS FOR RISK STRATIFICATION
IN MULTIPLE MYELOMA
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Background: Prognostic biomarkers are valuable for risk assessment in clin-
ical settings in Multiple Myeloma which is a heterogeneous disease with vari-
able outcome. Markers that have extensively and consistently been related to
prognosis are t(4;14), del(17), ISS, and GEP signatures. Ideally a prognostic
marker is robust across datasets, identifies a relevant fraction of patients and
captures as much of the risk as possible. We evaluated four risk models for
their clinical performance in two large datasets, HOVON65/GMMG-HD4 and
MRC-IX. We compare HR, p-value, proportion of high risk cases and concor-
dance between high risk models. Importantly, we show how individual patients
may or may not be high risk depending on the model used.
Aims: To provide insight in the prognostic value of four different high risk mod-
els A) iFISH t(4;14) and/or del(17); B) SKY92 [1]; C) iFISH+ISS [2] and D)
SKY92+ISS [3] in 2 different datasets. 
Methods: 230 cases from HOVON-65/GMMG-HD4 (GSE19784) and 169 from
MRC-IX (GSE15695) having GEP, iFISH, ISS data were analyzed. Kaplan
Meier analyses were used to calculate Cox proportional hazard ratios and p-
values. Venn diagrams visualize the overlap between the high risk models.
Note that HOVON65/GMMG-HD4 data is the trainingset for EMC92/SKY92 [3]
Results: iFISH high risk (A) and SKY92 high risk (B) were compared for hazard
ratio (p-value), proportion and overlap in two clinical cohorts. All hazard ratios
except for iFISH (A) in MRC-IX were significant with p<0.05. The largest HR
was observed for SKY92+ISS (D) for the highest risk category in comparison
to the lowest risk category of SKY92, namely HR=13,6 in HOVON-65/GMMG-
HD4 (Figure 1D) and HR=5,9 in MRC-IX (Figure 1). The two cohorts HOVON65
and MRC-IX have similar overlap of patients positive for iFISH, SKY92 or both
(14/12/12% and 12/10/10% respectively) suggesting the robustness of these
categories.
Figure 1. Shows four prognostic models applied to the (n=169) MRC-IX
dataset. OS Kaplan Meier analyses were performed using risk model A,
B, C or D (see aim). The overlap between high risk cases in model A and
B is given in the Venn diagram. The pie charts visualize - for model D -
the enrichment of iFISH t(4;14) (light grey) and del(17) (dark grey), or both
(black) in each of the four strata. E) table with hazard ratios between for
the extreme strata in each model.
Summary and Conclusions: SKY92 (model B) is a better prognostic marker
than iFISH (model A) or FISH+ISS (model C) with twofold higher HR. Besides,
addition of ISS to SKY92 (model D) is relatively easy to perform and is powerful
for the identification of a group of patients with favorable prognosis as judged
by the median OS which is not reached at 60 months in both cohorts.
References
1. Kuiper, R (2012) Leukemia, 26(11), 2406-2413.
2. Avet-Loiseau, H et al. (2013) Leukemia, 27(3), 711-717.
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MARKERS OF DISEASE EVOLUTION IN SMOLDERING MULTIPLE
MYELOMA (SMM)
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Background: SMM is an asymptomatic plasma cell dyscrasia that fulfills the
diagnostic criteria of MM, without end organ damage symptoms. Ten percent
of the patients are at risk of progression to symptomatic MM of which fewer will
evolve within the first 2 years. For these latest patients, it is wondered whether
they should be treated if they could be accurately recognized. Biomarkers pro-
posed for that purpose are increased serum free light chains (FLC) or ratio
(FLCR), plasma cell BM infiltration above 60% (that already categorizes
patients as symptomatic MM), at least one bone lytic lesion by sensitive imaging
techniques, etc.
Aims: To investigate prognostic markers of disease evolution in SMM, including
FLC/FLCR levels, BM infiltration, skeletal findings, serum syndecan levels and
other classical MM biomarkers.
Methods: We studied 147 SMM patients, diagnosed and followed -up in our
department. Median age was 69 years (31-86) while 42% were males. Seven-
ty-two percent, 21% and 7% were Durie-Salmon staged 1, 2 and 3 respectively,
while 63%, 18% and 19% were ISS staged I, II and III respectively. MM type
was IgG in 72%, IgA in 24% and light-chain in 3% of the population, while 2
patients (1%) were biclonal. Soluble syndecan-1 was measured by ELISA in
77 frozen samples collected at diagnosis. Serum FLCs were estimated by
nephelometry (FREELITE, The Binding Site Ltd., Birmingham, UK). Serum
FLC ratio (FLCR) κ/λ or λ/κ was calculated with the uninvolved LC as denom-
inator. Statistical analysis was performed with SPSS v21.0. Survival was cal-
culated with Log-rank test and depicted with Kaplan-Meier method. 
Results: During a median follow-up time of 64 months, 50 patients (36%) evolved
to MM. Median time to evolution was 15,5 months Factors highly statistically relat-
ed to the probability of evolution were LC type MM (p<0,001), IgM <25mg/dl
(p<0,001), the presence of at least 1 osteolytic lesion but also of diffuse osteo-
porosis (p=0,004), BM infiltration >60% and also BM infiltration 30-59% as com-
pared to 10-29% (all p<0,001), FLCR>100 (7 pts, p<0,001), FLCR>8 (48 pts,
p<0,001), involved FLC >100 mg/L (46 pts, p<0,001), IgA or IgG >30g/L (29 pts
p<0,002) and soluble syndecan-1>120pg/ml (20/77 pts, p=0,001). However none
of these factors alone could produce an 80% probability of evolution within two
years. This was only possible by combining factors in models, thus patients with
at least two factors of FLCR>100, soluble syndecan-1>120pg/ml and IgM
<25mg/dl (N-10), had a 90% probability of disease evolution within two years.
Summary and Conclusions: Serum FLC/FLCR, skeletal status, immunopare-
sis, BM infiltration, soluble syndecan-1 serum levels are all important prognostic
factors of disease evolution in SMM patients. The best models to recognize
high-risk SMM should still be found and carefully validated in retrospective
series because both the administration of an unneeded treatment and the
delayed therapy could be harmful. 
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Background: High dose chemotherapy (HD) with subsequent autologous stem
cell transplantation (ASCT) is the standard treatment for newly diagnosed mul-
tiple myeloma (NDMM) patients and has recently been shown to be effective
in the relapsed multiple myeloma (RMM) setting in a prospective phase III trial.1
Stem cell mobilization in NDMM patients is a safe procedure associated with a
low rate of failure to collect sufficient numbers of stem cells after stimulation
with chemotherapy and G-CSF. However, the number of preceding chemother-
apy cycles and exposure to melphalan have been identified as factors nega-
tively correlated with mobilization success.2
Aims: We report data on the efficiency and toxicity of cyclophosphamide based
stem cell mobilization in RMM patients from the ongoing phase III trial ReLApsE.
Methods: ReLApsE (EudraCT 2009-013856-61, ISRCTN 16345835) is a ran-
domized, open, multicenter phase III trial of continued lenalidomide/dexametha-
sone vs lenalidomide/dexamethasone induction followed by HD, ASCT and
lenalidomide maintenance in a planned study population of 282 MM patients up
to 75 years of age in their 1st to 3rd relapse. Patients without available stem cell
transplants from earlier apheresis undergo stem cell mobilization and apheresis
in both trial arms after three cycles of lenalidomide/dexamethasone to allow for
HD and ASCT either as part of the ReLApsE trial or as a subsequent treatment.
Mobilization consists of high dose cyclophosphamide (HD-CY; 2*2 g*m-2) followed
by G-CSF (filgrastim 10 µg*kg-1*d-1 or lenograstim 300 µg*m-2*d-1) from day 5
until the last day of apheresis. In patients who fail to harvest sufficient numbers
of stem cells, the administration of plerixafor is recommended.
Results: Until February 2015, 186 patients were randomized. Thirty patients
underwent stem cell mobilization of which 29 received HD-CY plus G-CSF. Two
patients died from HD-CY associated complications (sepsis) and one patient
was withheld from stem cell apheresis due to a coinciding myocardial infarction.
Of the 26 patients who underwent stem cell apheresis after HD-CY plus G-
CSF, 9 patients (34.6%) succeeded and 17 patients (65,4%) failed to collect
sufficient numbers of stem cells (≥2*106 CD34+ cells*kg bw-1). Additional appli-
cation of plerixafor was initiated in 16 patients and enabled successful apheresis
in 13 patients (81.3%). 
Summary and Conclusions: Stem cell mobilization with HD-CY plus G-CSF
in RMM allows for sufficient stem cell collection in only 35% of patients under-
going apheresis and is associated with marked toxicity. However, with addition
of plerixafor as a rescue strategy following HD-CY plus G-CSF, successful stem
cell collection is feasible in 85% of RMM patients undergoing apheresis. Our
data underline the importance of collection of additional stem cell transplants
during first-line treatment, as at this time-point stem cell mobilization is far more
efficient and less toxic. If mobilization is performed in the relapsed setting, HD-
CY administration and subsequent surveillance should be performed in an inpa-
tient setting to enable early detection of infections and treatment of any severe
adverse events.
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Background: The prognostic value of pre-transplant heavy light chain (HLC)
and free light chain (FLC) response over conventional electrophoretic response
in the post-transplant setting is not well understood.
Aims: We correlated FLC and HLC assays with conventional electrophoretic
response criteria to study their prognostic impact over 6 years of follow-up
among 497 patients enrolled in the BMT CTN0102 trial of tandem autologous
(autoHCT) versus tandem autoHCT-allogeneic (alloHCT) transplantation.
Methods: Pre-transplant serum samples prior to first autoHCT were analyzed
centrally for FLC (FreeliteTM) and HLC (HevyliteTM). Corresponding disease
status (IMWG uniform response criteria) was determined by independent data
review committee. An HLC-CR was defined as normalization of ratios across
all 3 measured HLC pairs or the normalization of clonal isotype with normal
ratios of uninvolved pairs. The demographics of the 497 patients with HLC and
FLC pre-transplant samples were concordant with the main study (Krishnan et
al. Lancet Oncol. Dec 2011; 12(13): 1195).
Results: 56 patients in conventional CR were also in HLC-CR. Comparing
HLC-CR vs conventional CR, sensitivity was 100%, specificity 39%, PPV and
NPV values 17% and 100% respectively. Of 211 pts in a conventional response
better than or equal to very good partial response (>VGPR), 188 were in HLC-
CR (Sensitivity=89%). Comparing HLC-CR vs conventional >VGPR: specificity
was 52%, PPV 58% and NPV 87%. FLC ratio normalization (FLC-CR) vs con-
ventional >VGPR disease state had a sensitivity of 47%, specificity 81% and
PPV and NPV of 64% and 67% respectively. Adjusted multivariate models
including baseline conventional response, myeloma stage and study arm were
used to compare the prognostic utility of HLC-CR and FLC-CR. HLC-CR was
an independent predictor of superior PFS (p-0.016), freedom from relapse (p-
0.035) and survival (p-0.012) (Figure 1) while FLC-CR was not. A pre-transplant
HLC-CR but not FLC-CR was associated with improved outcomes for patients
not in electrophoretic CR/VGPR.
Figure 1. Adjusted survival by HLC remission status.
Summary and Conclusions: We conclude that 1) HLC normalization, but not
FLC normalization, is additionally informative about patients not in elec-
trophoretic CR/VGPR and 2) achievement of pre-transplant HLC-CR is a pow-
erful predictor of improved post-transplant outcomes regardless of pre-trans-
plant conventional response.
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Background: Accurate diagnosis of essential thrombocythemia (ET) persists to
be a controversial and challenging issue and is usually performed by applying
either the 2014 British Committee for Standards in Haematology (BCSH) guide-
lines or the 2008 World Health Organization (WHO) criteria. The critical point is
that according to the WHO classification bone marrow morphology (BM) is rec-
ognized as a major feature, while the BCSH guidelines are more focused on an
exclusion of the other subtypes of myeloproliferative neoplasia (MPN) and thus
do allow ET diagnosis without BM examination. However, prefibrotic/early stages
of primary myelofibrosis (prePMF) may also present with thrombocytosis, while
failing to meet the diagnostic signs and symptoms characterizing overt PMF.
Since clinical outcome in prePMF patients is considerably worse than in ET
patients accurate diagnosis is pivotal to provide adequate management in these
cases. Moreover, a small fraction of polycythemia vera (PV) patients may present
with low hemoglobin and hematocrit levels, but a platelet count in keeping with
BCSH- and WHO-defined ET, thus mimicking phenotypically ET at onset. 
Aims: The aim of this study was to investigate the prognostic relevance of BM
morphology for ET diagnosis as underscored by the WHO classification versus
the first set of the BCSH criteria that do not include BM evaluation.
Methods:A clinic-pathological database including 350 MPN patients was created
by clinicians and hematopathologists from a major Austrian center. Treatment-
naive BM biopsies were centrally re-reviewed at a multiheaded microscope by
two of the authors, who were completely blinded to initial data (except for age
and gender). Follow-up data including clinical course and mutation status were
analyzed after the completion of the histopathology review. For purpose of this
study we selected two cohorts of ET patients presenting with a sustained platelet
count >450x109/L: (1) 164 ET patients in accordance with the diagnostic require-
ments of the BCSH (A1-A3) that included no BM biopsy examination. (2) 122
patients in strict agreement with the diagnostic guidelines of the WHO including
BM biopsy evaluation as major criterion. Both cohorts were compared and ana-
lyzed regarding their presenting clinico-pathological data, mutation status and
follow-up. Diagnosis of post-ET myelofibrosis or progression into overt myelofi-
brosis with myeloid metaplasia was made according to well-known criteria.
Figure 1.
Results: Following the BCSH criteria, 164 patients were diagnosed as ET.
When reclassifying those cases according to the WHO criteria including BM
morphology examination, 56 (34.1%) patients were diagnosed as prePMF and
17 (10.4%) as PV. Comparison of clinical features of BCSH-ET and WHO-ET
revealed significant differences in white blood cell counts, LDH levels, fibrosis
grades in the BM biopsy and in progression to overt myelofibrosis. Fibrosis-
free survival was significantly shorter in BCSH-ETs (Figure 1). When reclassi-
fying the BCSH cohort according to WHO criteria, overall survival and progres-
sion free survival were significantly shorter in WHO-confirmed prePMF.
Summary and Conclusions: Our results highlight the central role of BM biopsy
in the accurate diagnosis and differentiation of ET and prePMF. The differences
in clinical features and outcome underscore the importance of an accurate
initial diagnosis.
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Background: Patients with myeloproliferative neoplasms (MPNs) are at an ele-
vated risk of thrombosis and their life expectancy is shorter compared to the nor-
mal population. Survival has improved during recent years due more effective
disease management and new targeted treatments. There is however limited
information on morbidity and mortality due to infections in patients with MPNs.
Aims: To assess the risk of infections in MPN patients and matched controls
in a population-based setting in Sweden.
Methods:All patients with MPNs reported to the Swedish Cancer Register and/or
registered in the national Inpatient Register from 1987 to 2009 were included in
the study. For each MPN patient, four controls matched for age, sex, and county
of residence, were randomly selected from the Swedish Total Population Register.
End of follow-up was December 31st 2010. Information on type and date of infec-
tion was obtained from the Swedish Patient Registry which captures information
on all individual patient-based discharge diagnoses from inpatient (since 1987)
and outpatient care (since 2001) as well as from the Cause of Death Register
where all dates and causes of death are recorded. The risk of infection was ana-
lyzed using Cox regression where death was considered a competing risk. Sep-
arate analyses were performed for the overall risk of infection as well as subsets
of bacterial and viral infections. Results are presented as hazard ratios (HRs) and
95% confidence intervals (CIs). In addition, the cumulative incidence of infection
and death from any cause in MPN patients diagnosed during different calendar
periods are illustrated by cumulative incidence curves.
Results: In total, 9,655 MPN patients and 38,660 matched controls were iden-
tified. There was a statistically significant two-fold risk elevation for infections
(HR=1.9; 95% CI 1.8-2.0, p<0.0001) in MPN patients compared to controls.
The risks of bacterial and viral infections were significantly increased (HR=1.8;
1.6-1.9, p<0.0001 and HR=3.0; 2.7-3.3, p<0.0001, respectively). The HRs of
sepsis was 3.5 (3.2-4.0), pneumonia 2.2, (2.0-2.3), urinary tract infection 1.5
(1.2-1.6) compared to matched controls, all statistically significant. In addition,
there was an increased risk of viral hepatitis with a HR of 3.8 (2.8-5.2, p<0.0001)
in relation to controls. A significantly elevated risk of infections was observed
in patients of all MPN subtypes compared to matched controls.
The risk elevation remained stable over time when MPN patients diagnosed dur-
ing different calendar periods were analyzed separately (Figure 1). The overall
risk of infection were HR 2.1 (1.9-2.4), 2.1 (1.9-2.3), 1.9 (1.8-2.1), and 2.2 (1.9-
2.5) in MPN patients diagnosed during the years 1987-1992, 1993-1998, 1999-
2004, and 2005-2009, respectively, compared to matched controls.
Figure 1.
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Summary and Conclusions: MPN patients are at an increased risk of bacterial
and viral infections compared to matched controls. The findings are particularly
relevant since the JAK2 inhibitors have been shown to further increase the risk
of opportunistic infections and reactivation of viral infections. Taken together,
our results indicate that the risk of infection and possible immunosuppressive
effects need to be considered when choosing optimal treatment in MPN. In
addition, further studies are needed to identify subsets of patients that may
benefit from infectious prophylaxis.
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Background: Infectious complications represent one of the main causes of
morbidity and mortality in patients (pts) with Primary Myelofibrosis (PMF), Post-
Essential Thrombocythemia and post-Polycythemia Vera MF (PET/PPV-MF).
An increased infectious risk has been reported in pts treated with ruxolitinib
(RUX), a JAK1/2 inhibitor with potent immune-suppressive properties. However,
very few data are available on outcome and risk factors of this potentially fatal
complication.
Aims: To evaluate risk factors for severe infections in a large cohort of MF
patients.
Methods: Clinical and laboratory data of pts with MF were retrospectively col-
lected from the database of 3 Italian Hematology Centers in University Hospi-
tals. Severe infections were defined as grade 3/4 according to the CTCAE. The
study was approved by the Ethic Committee of each participating Centers.
Results: Between 1980 and Aug 2014, 426 pts with PMF (319 pts, 75%), or
PET-MF (13%) or PPV-MF were diagnosed and followed for a median follow-
up of 4 yr (0.5-30.1). Baseline characteristics were (median): age, 67 y (range,
26-87); ≥65 y, 55%; male, 57%; hemoglobin (Hb), 12 g/dL (4-17.9); Hb <10
g/dL, 24%; PLT, 372×109/L (15-2513); PLT <100×109/L, 8.0%; spleen enlarge-
ment, 69% (spleen length ≥5cm: 32.4%); constitutional symptoms, 15%. Inter-
national Prognostic Score System (IPSS) was low (11%), intermediate-1 (intm-
1, 21%), intermediate-2 (intm-2, 43%), high (24%). Molecular analysis was per-
formed on 253 pts (59%) and was positive in 84% (JAK2V617F), 14% (CALR),
3% (MPLW515K/L); 6 pts (2%) were triple negative. Karyotype was abnormal
in 34 (16.6%) out of 204 evaluable pts (unfavorable in 10 pts; 5%). Overall, 81
pts (19%) experienced 112 grade 3-4 infectious events, for an incidence rate
of 3.3% pt-y. The cumulative incidence was 16%, 26.8% and 43.6% at 5, 10
and 20 y, respectively (Figure 1). Infections were: bacterial (101 events, 90.2%;
pneumonia: 54 cases, 53.4%); VZV reactivations (7 events, 6.2%), nodal TBC
(2 events, 1.8%), fungal lung infections (2 events, 1.8%). Infectious complica-
tions represented the causes of death in 9 (8%) out of 126 deceased pt. Among
baseline features, age≥65 y (p=0.004), leukocyte ≥25x109/l (p=0.02), spleen
length>5 cm (p=0.03), high/intm-2 IPSS (p=0.01), unfavorable karyotype
(p<0.001) and JAK2/CALR/MPL negativity (p=0.002) significantly correlated
with higher infectious risk; in multivariate analysis, unfavorable karyotype and
molecular negativity confirmed their negative impact (p=0.008 and p=0.03,
respectively). Overall, 81 pts at intm-2/high IPSS risk were treated with RUX
for a median time of 16 mos (1-45). Infection-free survival at 5 y was significantly
worse in RUX-treated pts (66%) compared to non RUX-treated intm-2/high risk
pts (86%, p=0.01). Among RUX-treated pts, only age ≥65 y correlated with an
increased risk of infectious complications (p=0.015).
Figure 1.
Summary and Conclusions: This large study confirms severe infections as
frequent events involving 19% of MF pts and representing the ultimate cause
of death in 8% of the cases. Molecular/cytogenetic data identify a subset of
patients at higher infectious risk. In RUX-treated pts, a higher incidence of infec-
tions was observed; in this particular subpopulation, only older age represented
a significant risk factor for severe infectious complications.
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Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) that
may arise as primary (PMF) or result from progression of polycythemia vera
(PPV-MF) or essential thrombocythemia (PET-MF). Independent of subtype,
MF patients share a debilitating symptom profile and high mortality rate. His-
torically, all MF patients have been treated similarly without impact of subtype.
Recent data suggests perhaps a different natural history amongst subtypes of
MF (Passamonti et al., Blood 2014). 
Aims: We sought to evaluate impact of MF subtype on MPN total symptom
burden and symptom profiles.
Methods: Data was collected among an international cohort of patients with
MF including PMF, ETMF and PVMF as reported previously (Emanuel et al.,
JCO 2013). Subjects completed the Brief Fatigue Inventory (BFI) and Myelo-
proliferative Neoplasm Symptom Assessment Form (MPN-SAF) instruments.
Items were scored on a 0 (absent) to 10 (worst imaginable) scale. MPN-SAF
TSS items included fatigue, concentration, early satiety, inactivity, night sweats,
itching, bone pain, abdominal discomfort, weight-loss, and fever. For individuals
completing at least 6 of the 10 MPN-SAF TSS items, the survey was scored by
multiplying the average score across items by 10 to achieve a 0 to 100 scaled
score. Demographics, clinical variables and symptom scores were compared
between myelofibrosis groups using ANOVA F-tests or chi-squared tests. 
Results: Patient Population. A total of 835 MF subjects (PMF=488; PET-
MF=192; PPV-MF=155) were prospectively enrolled and administered the
MPN-SAF and BFI. Most patients were of expected age for MPNs (mean 60.9
years) with a mean disease duration of 8.7 years. Splenomegaly (68.9%) and
laboratory abnormalities (62.4%) including anemia (51.4%) and thrombocy-
topenia (31.3%) were common. Prior hemorrhage (8.7%), phlebotomy use
(12.9%) and prior thrombosis (13.2%) were infrequent. Clinical Features by
MF Subtype. MF subgroups differed by mean age (p<.001) and MPN duration
(p<0.001). PMF patients had significantly higher rates of anemia (p=0.005),
thrombocytopenia (p=0.006) and laboratory abnormalities (p=0.03) with the
lowest mean hemoglobin (p=0.0053) and platelet counts (p<0.001). PMF
patients also had the lowest rates of prior thrombosis (p<0.001) and prior hem-
orrhage (p<0.001). As expected, PPV-MF patients demonstrated the highest
rate of current/previous phlebotomies (p<0.001) along with the highest rates of
enlarged spleens (p=0.007). MF Symptom Burden by Disease Subtype. Mean
Total Symptom Scores were similar between PMF (27.2), PET-MF (26.4) and
PPV-MF (26.4; p=0.83; Figure 1), however individual symptom patterns differed
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by MF subtype. PMF patients had the most frequent and symptomatic fevers
(21%, p=0.03; TSS 0.6, p=0.049) and weight loss (45%, p=0.04; TSS 2.1,
p=0.007). Inactivity was least common (69%, p=0.01) in PET-MF whereas pru-
ritus was most common amongst PPV-MF patients (60%, p=0.02). No signifi-
cant differences were noted for items of worst fatigue, early satiety, abdominal
discomfort, inactivity, concentration, itching or bone pain (all p>.05) between
MF subtypes.
Figure 1. MPN-SAF TSS for individual items by myelofibrosis subtype.
Summary and Conclusions: The results of this study confirm recent reports
that that PMF, PET-MF and PPV-MF exhibit unique clinical and symptomatic
profiles. PMF patients demonstrate more significant constitutional symptoms.
No difference in scores for these items was noted between PET-MF and PPV-
MF, contrary to previous findings. Further research is needed to determine if
this finding is of clinical relevance in the determination of therapy.
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IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE
COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROT-
IC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO
THE WHO-CLASSIFICATION
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Background: In 2013, the landscape of myeloproliferative neoplasms (MPN)
was altered dramatically by the identification of somatic mutations in the cal-
reticulin (CALR) gene. With this discovery molecular information, in addition to
the JAK2V617F mutation, can be implemented as an affirmative variable for
discrimination of MPNs from reactive myeloid proliferations for the first time.
Previously, the clinical course of essential thrombocythemia (ET) or primary
myelofibrosis (PMF) in patients carrying the CALR mutation has been reported
to be more indolent than in JAK2 positive patients and was associated with
increased survival.
Aims: Our aim was to investigate the different impacts of CALR mutations on
the prognosis and clinical outcome in prefibrotic PMF (prePMF) and WHO-
classified ET (WHO-ET). Additionally, the same investigations were made con-
cerning ASXL1 (exon12) mutations, with ASXL1 being one of the most common
bystander mutated genes in MPNs.
Methods: In a cohort of 348 patients with the clinical diagnosis of either WHO-
ET or PMF, mutational analysis for CALR was available. For study entry, the fol-
lowing eligibility criteria had to be fulfilled: a) availability of mutation analysis for
JAK2, MPL and CALR; b) availability of representative, treatment-naive bone
marrow biopsy; c) availability of a histological and clinical consensus on the diag-
nosis; d) complete long-term documentation of clinical data and outcome.
Results: Consenting clinico-pathological findings were consistent with 115
cases of WHO-ET and 85 patients with prePMF. In contrast to the most recent
publications, the present study revealed a different CALR mutation frequency
in ET (Table 1). This discrepancy in the frequencies of CALR positivity in our
ET cohort may be due to our strict adherence to the WHO criteria for diagnosis
of ET. Regarding prePMF, we observed CALR mutations in 39% of the patients.
92% of the JAK2/MPL wt subgroup carried the CALR mutation, with JAK2,
MPL and CALR wt being observed in only 3% of prePMF. The most striking dif-
ferences between WHO-ET and prePMF were seen in the comparison of the
overall survival (Figure 1A, 1B). While the CALR mutation did not have any
beneficial influence on survival in WHO-ET, it was associated with a superior
overall survival in prePMF. Such a difference was not seen in the time to trans-
formation into overt MF, and there was only a slightly shorter time to progression
to fibrosis in CALR wt prePMFs. There was a trend showing that CALR mutated
prePMF patients have shorter thrombosis-free survival compared to CALR wt
prePMF patients. No impact of the CALR mutations on thrombosis-free survival
in WHO-ET was observed. ASXL1 (exon12) mutations revealed no impact on
overall survival (Figure 1C).
Table 1.
                              Total cohort (N=200)    WHO-ET (N=115)     prePMF (N=85)     P
Age at diagnosis, years                                                                                        0,04
Median (range)             58,85 (19-88)             56,4 (19-84)          60,7 (27-88)
Sex                                                                                                                    0,587
Male/female                      78/122                      43/72                    35/50
Observation period, years                                                                                    0,066
Median (range)                  8 (0-30)                   8,5 (0-28)              7,4 (0-30)
CALR positive                                                                                                     0,001
No. (%)                              54 (27)                    21 (18,3)               33 (38,8)
ASXL1(ex12) positive           (N=190)                     (N=108)                  (N=82)       0,0868
No. (%)                             17 (8,9)                     13 (12)                   4 (4,9)
Figure 1. Kaplan-Meier analyses for A) CARL analyzed WHO-ET, B) CARL
analyzed prePMF and C) ASXL1(ex12) analysed WHO-ET and prePMF.
Summary and Conclusions: The present data confirm that WHO-ET and
prePMF are biologically different sub-entities of MPNs. In prePMF, almost all
patients are now associated with known disease-causing mutations. Our data
support the classical approach in the diagnosis of thrombocytosis, using BM
histology to differentiate WHO-ET from prePMF and more accurately estimate
the outcome of the disease.
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RUXOLITINIB PROVIDES CONSISTENT HEMATOCRIT CONTROL IN
PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOL-
ERANT OF HYDROXYUREA
M. Griesshammer1,* F. Passamonti2, S. Durrant3, J.-J. Kiladjian4, S. Verstovsek5,
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Background: Ruxolitinib (RUX) is a JAK1/JAK2 inhibitor that has shown supe-
riority over best available therapy (BAT) in patients (pts) with PV who had an
inadequate response to or unacceptable side effects from hydroxyurea (HU).
In RESPONSE, a higher proportion of RUX-treated pts achieved hematocrit
(HCT) control without phlebotomy (PBT) than BAT-treated pts (60% vs 20%).
Pts with inconsistent HCT control may be at a higher risk for thromboembolic
events than those who have HCT aggressively targeted to ≤45%.
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Aims: Because HCT values can fluctuate over time, and given the importance
of a target HCT of ≤45% in PV, we performed an analysis to determine the per-
centage of time patients maintained HCT control on treatment (ie, HCT ≤45%)
in each study arm.
Methods: RESPONSE is a randomized (1:1) open-label phase 3 study to eval-
uate the efficacy and safety of RUX vs BAT in pts with PV who are resistant to
or intolerant of HU by modified ELN criteria. Pts with splenomegaly (≥450 cm3
by MRI) who required PBT for HCT control received RUX 10 mg bid or single-
agent BAT. The primary endpoint was the proportion of pts who achieved both
HCT control without PBT from wk 8 to 32 (with ≤1 PBT from randomization to
wk 8) and a ≥35% reduction from baseline in spleen volume at wk 32, as
assessed by MRI. The primary analysis occurred when all pts reached wk 48
or discontinued. In this preplanned analysis at wk 80 data cutoff, the total per-
centage of time pts had HCT >45% during randomized treatment was estimat-
ed. A linear relationship between HCT and time was assumed for any consec-
utive 2 assessments with no PBT in between. If any PBT was done between 2
assessments and HCT was ≤45% at later assessment, HCT was assumed to
be ≤45% immediately after the PBT, and the time patients had HCT >45% was
not calculated between the 2 time points; however, if HCT after the PBT was
>45%, the time between the 2 time points was assumed to be with HCT >45%.
Results: Pts were randomized to RUX (n=110) or BAT (n=112). Baseline char-
acteristics were well balanced between arms (median HCT, 43.3% vs 44.0%;
pts with HCT >45%, 25.5% vs 22.3%). At data cutoff, 82.7% of pts randomized
to RUX remained on treatment and no pts remained on BAT (median exposure,
111 and 34 wk). In the RUX arm, mean HCT decreased continuously from wk
2 to 12 and then remained relatively stable thereafter. A larger proportion of pts
in the RUX arm achieved HCT ≤45% than pts in the BAT arm (Figure 1). For
pts who had uncontrolled HCT (ie, >45%) at baseline despite PBT, mean HCT
in the RUX arm declined to <45% and was lower than that in the BAT arm over
the course of treatment. The mean change from baseline in HCT ranged from
−3.12% to −4.36% in the RUX arm (from wk 12 to 80) and from +0.06% and
+1.03% in the BAT arm (from wk 12 to 32). Over the duration of treatment, pts
in the BAT arm spent 12 times more in percentage of time with a HCT >45%
than pts in the RUX arm (median, 39.1% [Q1-Q3, 12.9-65.9] vs 3.0% [Q1-Q3,
0.0-16.7]). Pts who achieved HCT control without PBT from wk 8 to 32 with
RUX (n=66) had an 89% probability (95% CI, 0.78-0.95) of maintaining the
response for 80 wk from the initial response. From wk 8 to 32, more BAT pts
required PBT (≥1 PBT: 62% vs 20%; ≥3 PBT: 20% vs 3%); 90% of RUX pts did
not have a PBT from wk 32 to 80.
Figure 1. Plot of hematocrit over time for individual patients.
Summary and Conclusions: In RESPONSE, pts who received RUX experi-
enced more consistent control of HCT to ≤45% than those who received BAT.
Sustained HCT ≤45% is a key treatment goal for reducing the risk of throm-
boembolic events in PV, as supported by results of the CytoPV trial.
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OF ANAGRELIDE (GALE-401) IN SUBJECTS WITH MYELOPROLIFERA-
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Background: Despite advances in the diagnosis and management of MPNs,
treatment of essential thrombocythemia (ET) has remained largely unchanged
since the introduction of anagrelide in the US (1997) and Europe (2004). Ana-
grelide reduces platelet production by inhibition of megakaryocyte hypermatura-
tion, and also inhibits cyclic AMP phosphodiesterase III. Common drug related
adverse events (AEs; e.g., headache, palpitations, fluid retention, etc.) might be
due to this latter mechanism. As the marketed anagrelide product is an immediate
release (IR) formulation with peak plasma levels that may exceed that needed
for platelet reduction, an alternate formulation that modifies this pharmacokinetic
(PK) profile may improve patient tolerability and treatment outcomes. This led to
the development of a controlled-release (CR) formulation of anagrelide (GALE-
401). To-date, 98 healthy subjects were enrolled among 5 Phase 1 clinical trials
of anagrelide CR at doses ranging from 0.2 to 0.6 mg once or twice daily for up
to 42 days. Anagrelide CR induced significant reductions in platelet counts that
were not distinguishable from IR, despite Cmax and AUC0-τ values that were 29%
and 55% of IR. These trials supported the initiation of a Phase 2 study in MPN-
related thrombocytosis, preliminary results for which are reported here.
Aims: The primary objective of the study was to estimate the overall platelet
response rate (ORR). Secondary objectives included safety, tolerability, and
pharmacokinetics (PK).
Methods: This is an open-label, single-arm, Phase 2 trial. Eligible subjects include
those with chronic myelogenous leukemia (CML), polycythemia vera (PV), pri-
mary myelofibrosis (PMF) or ET, platelet count ≥600 K/μL, and not previously
refractory to anagrelide. Anagrelide CR was given at a starting dose of 0.5 mg
twice daily and individually titrated to maintain a target platelet count of 150 - 400
K/μL. Platelet response is defined as complete response (CR, ≤400 K/μL) or par-
tial response (PR, ≤600 K/μL or ≥50% reduction from baseline), and maintenance
of the reduction for at least 4 weeks. Safety evaluations include routine physical
and laboratory evaluations. The PK profile is assessed at the starting dose, weekly
sampling during dose titration, and at the final titrated dose level.
Results: Eighteen (18) subjects who provided written informed consent were
enrolled, median age 65 yrs (range 40-80), 10 females/8 males, 13 ET, 4 PV,
and 1 PV/ET. Prior treatments for thrombocytosis included hydroxyurea (n=8),
anagrelide (8), and none (7). Mean platelet count decreased rapidly to <600
K/μL at 4 weeks, at which time the mean dose was 1.8 mg/day. To-date, the
confirmed overall response rate is 67% (12/18) with 4 CR and 8 PR. A total of
151 AEs were reported, of which 69 were study drug related including headache
(8 subjects); palpitations (4); abdominal pain, AST increased, and nausea (3
each); and diarrhea, fatigue, hypotension and tachycardia (2 each). Most related
AEs were Grade 1-2 in severity. Study drug related serious AEs were reported
for 2 subjects and included Grade 3 headache and Grade 3-4 cholestatic jaun-
dice/increased creatinine. Six subjects discontinued treatment for reasons that
included study drug related AE (2), subject request (2), investigator decision
(1) and other (1). Plasma PK analyses are ongoing.
Summary and Conclusions: Anagrelide CR induced rapid platelet count reduc-
tions at daily doses and ORR as anticipated with the IR formulation. AEs were
mostly Grade 1-2 in severity and consistent with anagrelide’s known side effects,
however additional dosing experience in the current trial or comparative controlled
studies may be needed to further elucidate the safety profile. Study treatment is
ongoing and 6-month data are being collected for analysis and presentation.
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SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA:
RESULTS FROM THE CLINICAL TRIAL PROGRAM
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Background: Polycythemia vera (PV) is a myeloproliferative neoplasm that is
characterized primarily by erythrocytosis and an increased risk of thrombosis.
To control blood counts and manage PV-related symptoms, some patients may
require chronic therapy. The most common drug treatment is hydroxyurea (HU);
however, some patients may develop unacceptable side effects or have an
inadequate response to HU.
Aims: To evaluate the long-term safety of the JAK1/JAK2 inhibitor ruxolitinib
(Rux) in the PV clinical trial program.
Methods: This analysis of Rux safety included data from 3 clinical trials: (1) a
phase 2, single-arm, open-label study in patients who were resistant to or intol-
erant of HU (ClinicalTrials.gov identifier, NCT00726232); (2) RESPONSE, an
ongoing, randomized, open-label phase 3 clinical trial (NCT01243944) com-
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paring Rux with best available therapy (BAT) in patients who are resistant to
or intolerant of HU; and (3) RELIEF, a randomized, blinded, phase 3b compar-
ative trial (NCT01632904) of Rux vs HU in patients generally well controlled
on HU but reporting symptoms. Data were pooled for Rux-treated patients from
the 2 studies with HU-resistant/intolerant patients (phase 2 study and
RESPONSE), including patients in RESPONSE who crossed over to Rux fol-
lowing BAT treatment.
Results: Overall, the HU-resistant/intolerant group (n=241) included 457
patient-years of exposure (median Rux exposure [range], 19.5 months [0.3-
66.7 months]). The most common adverse events for patients treated with Rux
who were HU-resistant/intolerant included diarrhea (8.7 per 100 patient-years
of exposure), headache (8.5), and pruritus (7.4); most events were grade 1 or
2 (Table 1). Grade 3 or 4 thrombocytopenia and anemia each occurred in 3.7%
of patients over the duration of follow-up. The rate of herpes zoster was 5.0
per 100 patient-years. Nonmelanoma skin cancer occurred at a rate of 2.8 per
100 patient-years (vs 2.7 per 100 patient-years in RESPONSE patients ran-
domized to BAT during BAT treatment). There were 7 transformations to
myelofibrosis during Rux treatment; 3 of these occurred after crossover from
BAT. There were 2 transformations to acute myeloid leukemia (AML); 1 occur-
ring after crossover. These rates of transformation to myelofibrosis and AML
were consistent with those published for similar patient populations with PV
(Fiannzi. Blood 2005;105:2664-70; Passamonti. Am J Med 2004;117:755-61;
Alvarez-Larran. Blood 2012;119:1363-9). The thromboembolic event rate was
2.2 per 100 patient-years (vs 8.2 per 100 patient-years in RESPONSE patients
randomized to BAT during BAT treatment). In the RELIEF trial, median expo-
sure was 21.6 weeks in the Rux arm (n=54). Adverse events that occurred
during the blinded phase were generally consistent with those observed in
studies of patients who were HU-resistant/intolerant.
Table 1. Nonhematologic adverse events in ruxolitinib-treated patients
who were resistant to or intolerant of HU.
Summary and Conclusions: This long-term follow-up of Rux experience in the
PV clinical trial program provides evidence that supports the safety and tolerability
of Rux in patients who have an inadequate response to or are intolerant of HU.
Myeloproliferative neoplasms - Clinical 3
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EFFECT OF RUXOLITINIB ON MARKERS OF IRON DEFICIENCY: AN
ANALYSIS OF THE RESPONSE TRIAL
S. Verstovsek1,* C.N. Harrison2, J.-J. Kiladjian3, C. Miller4, A.B. Naim5,
D.C. Paranagama5, D. Habr6, A.M. Vannucchi7
1Department of Leukemia, The University of Texas MD Anderson Cancer Cen-
ter, Houston, TX, United States, 2Haematology/Oncology and Cellular Pathol-
ogy, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom,
3Department of Hematology, Hôpital Saint-Louis et Université Paris Diderot,
Paris, France, 4Saint Agnes Cancer Institute, Baltimore, MD, 5Incyte Corpora-
tion, Wilmington, DE, 6Novartis Pharmaceuticals Corporation, East Hanover,
NJ, United States, 7Department of Experimental and Clinical Medicine, Uni-
versity of Florence, Florence, Italy
Background: Patients with polycythemia vera (PV) often rely on phlebotomy to
control their hematocrit. Frequent phlebotomies may result in a state of iron defi-
ciency, which can be associated with various complications, such as restless leg
syndrome and cognitive dysfunction. The RESPONSE trial demonstrated that rux-
olitinib lowers hematocrit and reduces the need for phlebotomy in patients with PV
who have had an inadequate response to or are intolerant of hydroxyurea (HU).
Aims: A subanalysis of the RESPONSE trial data was conducted to evaluate
the effect of ruxolitinib on markers of iron deficiency. 
Methods: Total iron binding capacity (TIBC), ferritin, mean corpuscular volume
(MCV), and serum iron were Total iron binding capacity (TIBC), ferritin, mean
corpuscular volume (MCV), and serum iron were measured at baseline and
over time in patients randomized to ruxolitinib and best available therapy (BAT);
in the BAT group, these measures were assessed before and after crossover
to ruxolitinib. Transferrin iron saturation (TS) was calculated based on observed
iron and TIBC. Patients within each arm were stratified into 2 groups: patients
with baseline values within the normal range and patients with baseline values
outside of the normal range; this was determined for each patient based on
the normal ranges for each of the study sites. Values outside of the normal
ranges indicative of iron deficiency included TIBC above the upper limit of nor-
mal; and ferritin, MCV, serum iron, and TS below the lower limits of normal.
Table 1. Values for markers of Iron deficiency at baseline and week 32 in
patients with evidence of iron deficiency at baseline.
Mean(SD)       Ruxolitinib (randomized) BAT (randomized)
                                             Baseline         Week 32                Baseline          Week 32
Ferritin, pMol/L                       19.7 (8.0)     134.1 (99.2)            21.7 (7.2)       43.2 (64.0)
Serum Iron, μMoL/L                 3.7 (1.2)        16.4 (7.5)               3.9 (1.1)          6.4 (5.4)
MCV, FL                                  70.3 (6.5)       81.1 (8.9)              70.6 (6.6)       73.1 (10.6)
TS,%                                       6.00 (2.9)      31.1 (14.9)              6.6 (3.4)         10.6 (9.6)
TIBC, Mol/L                            82.5 (6.3)       60.2 (4.2)              79.8 (3.6)        75.5 (6.2) 
Increases in ferritin, iron, MCV, and TS=improvement; decreases in TIBC=improvement.
Figure 1. Mean (SE) total iron binding capacity over time for patients with
baseline values above the upper limit and below the upper limit of normal*.
Results: The majority of patients (in both study arms) had laboratory values out-
side of normal limits at baseline: TIBC, n=54 (24.3%); ferritin n=141 (63.5%);
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MCV, n=137 (61.7%); serum iron, n=181 (81.5%); MCV+iron, n=127 (57.2%);
TS, n=197 (88.7%). Among patients with evidence of iron deficiency at baseline,
use of iron supplementation was infrequent (<20% of patients) and balanced
between treatment arms. Changes in TIBC over time are shown in Figure 1 and
Table 1. In patients with elevated TIBC at baseline, mean TIBC improved (ie,
lowered) to levels within the normal range during ruxolitinib treatment (in patients
randomized to ruxolitinib and after crossover from BAT), but remained above the
normal limit during BAT treatment. Consistent with these findings, ferritin, MCV,
serum iron, and TS improved (ie, increased) in patients with low baseline levels
during ruxolitinib therapy, but remained outside of the normal limits during BAT
treatment (Table 1). Similar patterns were also observed when evaluating these
markers by gender. Mean values for patients with normal iron status at baseline
remained within normal ranges during ruxolitinib therapy.
Summary and Conclusions: In patients with PV who have had an inadequate
response to or are intolerant of HU, normalization of 5 markers of iron deficiency
was observed with ruxolitinib therapy, while in the BAT arm, there was little or no
change in these parameters.
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Background: The JAK2 c.1849G>T (p.V617F) mutation leads to constitutive
activation of JAK2 and contributes to dysregulated JAK signaling in myeloprolif-
erative neoplasms. COMFORT-I, a phase 3 study of ruxolitinib versus placebo in
patients with intermediate-2 or high-risk myelofibrosis (MF), demonstrated rapid
and durable reductions in splenomegaly and symptom improvement with ruxoli-
tinib versus placebo.
Aims: This analysis was a long-term (maximum of 4 years) follow-up of COM-
FORT-I to determine if ruxolitinib, an oral JAK1/JAK2 inhibitor, continued to reduce
allele burden in patients with the JAK2p.V617F mutation.
Methods: JAK2p.V617F-positive patients (n=236) were identified from the COM-
FORT-I dataset. Presence of this mutation was not an eligibility requirement of
the trial; but for patients having baseline data demonstrating a JAK2p.V617F
mutation, allele burden was assessed by genomic DNA isolation from peripheral
blood at baseline and weeks 24, 48, 120, 144, 168, and 216. Allele burden was
defined as the percentage of mutant allele relative to the total (wild-type+mutant).
Complete molecular remission (CMR), partial molecular remission (PMR), and
relapse of molecular remission were defined based on the IWGd spleen response
(≥ 35% reduction from baseline to week 24) were also assessed with respect to
JAK2p.V617F mutation.
Results: On average, allele burden decreased in ruxolitinib-treated patients and
increased during placebo treatment. The mean/median (range) maximal change
in the ruxolitinib randomized arm was −27%/−16% (−100%, 36%), and in patients
who crossed over from placebo to ruxolitinib was −19%/−11% (−100%, 12%). Of
the 28 patients (12%) achieving a > 50% decrease in allele burden, 20 achieved
a PMR and 6 achieved a CMR, with median times to response of 22.2 and 27.5
months, respectively. Allele burden reductions were independent of baseline allele
burden; patients with high and low allele burdens both had significant reductions.
Patients were grouped into tertiles of maximal percentage allele burden reduction
from baseline, with mean/median changes within tertile 1: −62.6%/−63.4%; tertile
2: −15.3%/−14.8%; and tertile 3: −0.5%/−2.2%. Patients with the largest decreases
(tertile 1) had the shortest mean/median times from diagnosis at baseline (tertile
1: 36.8/15.2 mo; tertile 2: 52.5/21.7 mo; tertile 3: 44.8/22.1 mo). Comparison of
clinical responses across tertile groups indicated that patients with greater allele
burden decreases had a larger percent reductions in spleen volume (mean/median
changes at week 24 for tertile 1: −41.2%/−45.2%; tertile 2: −38.3%/−37.1%; tertile
3: −23.4%/−22.7%) as well as a greater proportion of patients with a ≥ 35%
decrease in spleen volume at week 24 (tertile 1: 63.9%; tertile 2: 55.6%; tertile 3:
31.4%). Even patients with smaller decreases in JAK2p.V617F allele burden
(31.4% of 35 patients in tertile 3), as well as patients who were JAK2p.V617F-
negative at baseline (27.5%), had spleen responses.
Summary and Conclusions: Patients treated with ruxolitinib continued to show
reductions in allele burden independent of baseline allele burden with ongoing treat-
ment up to 4 years. JAK2p.V617F reductions correlated with reductions in spleen
volume; however, ruxolitinib is associated with marked spleen volume reductions
regardless of mutation status. Patients with shorter disease duration had greater
allele burden reductions, suggesting a potential benefit for earlier treatment.
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States, 17St. Paul’s Hospital, University of British Columbia, Vancouver, British
Columbia, Canada
Background: RUX is a potent JAK1/JAK2 inhibitor that has demonstrated reduc-
tions in splenomegaly and MF-related symptoms and improved survival in patients
(pts) with intermediate (Int)-2- and high-risk MF in the 2 phase 3 COMFORT stud-
ies. JUMP (JAK Inhibitor Ruxolitinib in MF Patients) is a phase 3b, expanded-
access trial in countries with no access to RUX outside a clinical trial and includes
pts with Int-1 MF. As of December, >2200 pts have enrolled in 25 countries.
Aims: To assess the safety and efficacy of RUX in a cohort of pts with IPSS
Int-1 MF (N=163).
Methods: Pts with MF classified as high risk, Int-2 risk, or Int-1 risk with a palpable
(≥5 cm) spleen were eligible. Starting doses were based on baseline platelet
(PLT) counts (5 mg bid [≥50 to <100×109/L], 15 mg bid [100 to 200×109/L], or 20
mg bid [>200×109/L]) and were titrated during treatment. The primary endpoint
was safety and tolerability of RUX. Additional analyses included changes in pal-
pable spleen length and symptoms using the FACT-Lymphoma Total Score
(FACT-Lym TS). The final analysis will be performed after all pts have completed
24 mo of treatment or ended due to commercial availability.
Figure 1. Best percentage reduction from baseline in spleen length by
week 72.
Summary and Conclusions: JUMP is the largest study to date of pts with MF
treated with RUX and includes the largest cohort of pts with Int-1-risk MF, a risk
group not included in the COMFORT studies. Pts with Int-1-risk MF achieved
spleen size reductions and symptom improvement consistent with those seen
in the overall JUMP population. The safety and efficacy of RUX in Int-1 pts in
JUMP is consistent with that in the phase 3 COMFORT studies.
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INTERIM ANALYSIS OF A PHASE II PILOT TRIAL OF RUXOLITINIB COM-
BINED WITH DANAZOL FOR PATIENTS WITH MYELOFIBROSIS SUFFER-
ING FROM ANEMIA
K. Gowin1, A. Dueck2, J. Mascarenhas3, R. Hoffman3, S. Nagi Reddy2, C. Reeder2,
J. Camoriano2, V. Fauble2, R. Tibes2, K. Gano2, V. Ghurye2, P. Koenig2, R. Mesa2,*
1Hematology and Medical Oncology, 2Mayo Clinic Arizona, Scottsdale, 3Mount
Sinai, New York, United States
Background: Approximately 75% of myelofibrosis (MF) patients develop ane-
mia during evolution of the disease process predicting decreased survival. Pre-
vious studies exploring the effect of danazol in the treatment of anemia in MF
demonstrate responses in anemia of 30-55%. In prior randomized, controlled
studies, ruxolitinib demonstrated improvements in splenomegaly, symptom bur-
den, and even survival yet improvements in cytopenias were uncommon.
Aims: We designed a phase II multicenter pilot study to evaluate the efficacy
and tolerability of combination therapy with ruxolitinib and danazol in MF
patients with anemia.
Methods: This is a pre-planned interim analysis of a Simon optimum two-stage
phase II trial, minimum of 10 and a maximum of 27 patients. Participants received
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ruxolitinib 10mg (plat >75x10x9) BID or 5mg (plat <75x10x9) BID with tapered
danazol up to 200mg orally TID. Dose escalation was allowed after completion
of 28 days for lack of response or for disease progression. Patients without pro-
gression were continued for 6 cycles at 56 days each. Treatment modifications
were based on adverse events (AE) including thrombocytopenia, leukopenia,
and elevation in creatinine and transaminases. Treatment responses were eval-
uated every cycle by the IWG-MRT response criteria (Blood 2006). Patient report-
ed outcome questionnaires (MPN-SAF and EORTC QLQ-C30) were adminis-
tered at baseline, prior to treatment cycles, and at study discontinuation.
Results: Patients: Ten of the 14 evaluable patients enrolled (median age 70.5,
range 57-78, M:F ratio 4:1) are included in this analysis. Eight patients had pri-
mary MF, 1 post essential thrombocytosis MF, and 1 post polycythemia vera
MF. Jak2 V617F mutation was positive in 30%. All were DIPSS Int-2 or higher
and 40% received an erythrocyte transfusion in the last month. Med baseline
hemoglobin was 9.0 g/dL (range 8.3-12.4), med platelet level 172x10 (9)/L
(range 56 - 346). Most (90%) had received prior therapy. Tolerability: Seven
patients completed treatment, with med duration of treatment received of 45
days (range 24-287). Treatment discontinuation was due to progression of dis-
ease in 2 patients, unrelated AE in 1, stem cell transplant in 1, unrelated death
in 1, comorbidity in 1, and decline of therapy in 1. Hematologic Grade 3 or >AE
included anemia (60%), neutropenia (20%), and leukopenia/thrombocytopenia
(10%). Non-hematologic Grade 3 or >AE included electrolyte abnormalities
(20%), edema (10%), infection (10%), and intracranial hemorrhage (10%). Effi-
cacy: Overall, treatment response per IWG-MRT response criteria included
stable disease in 60%, clinical improvement in 30% (all spleen responses),
and progressive disease in 10%. The median change in hemoglobin and
platelet count from baseline was 0.60 g/dL (range -0.3-1.8) and 35.5x10(9)/L
(range -143 - 140) respectively, however 7/10 (70%) had improvement at some
point during treatment in level of anemia and/or thrombocytopenia. Among
patients with a baseline and at least one post-baseline MPN-SAF TSS, 30%
of patients had at least 50% improvement from baseline. Responses might
have been confounded due to impact of prior therapies.
Summary and Conclusions: On interim analysis, an improvement in anemia
and/or thrombocytopenia was observed in some treated patients however; the
clinical improvement in 30% of patients treated was limited to spleen response.
Combination therapy was well tolerated with no major incremental toxicity attrib-
utable to the addition of danazol. Maturation of data is needed to fully evaluate
efficacy of ruxolitinib and danazol combination therapy for the treatment of MF
associated anemia. 
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BONE MARROW FIBROSIS BY WHO GRADE AND QUANTITATIVE IMAGE
ANALYSIS IS REDUCED BY PRM-151 IN PATIENTS WITH MYELOFIBRO-
SIS AND ASSOCIATED WITH IMPROVED BONE MARROW MORPHOLOGY
AND INCREASED PLATELET COUNTS
E. Trehu1, O. Pozdnyakova2,* R. Hasserjian3, M. Salama4, R. Mesa5, L. Foltz6,
V. Gupta7, J. Mascarenhas8, E. Ritchie9, R. Hoffman8, R. Silver9,
M. Kremyanskaya8, H. Kantarjian10, J. Gotlib11, S. Verstovsek10
1Research and Development, Promedior, Inc., Lexington, 2Pathology, Brigham
and Women’s Hospital, 3Pathology, Massachusetts General Hospital, Boston,
4Pathology, University of Utah, Salt Lake City, 5Hematology, Mayo Clinic,
Scottsdale, United States, 6Hematology, St. Paul’s Hospital, Vancouver,
7Hematology, Princess Margaret Hospital, Toronto, Canada, 8Hematology,
Mount Sinai Medical Center, 9Hematology, Weill Cornell Medical Center, New
York, 10Leukemia, MD Anderson Cancer Center, Houston, 11Hematology, Stan-
ford Cancer Institute, Stanford, United States
Background: PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endoge-
nous human protein that acts at sites of tissue damage, inducing macrophage
differentiation to prevent and reverse fibrosis. 27 patients (pts) with Primary
Myelofibrosis (MF), post-Polycythemia Vera MF, or post-Essential Thrombo-
cythemia MF and ≥Grade 2 MF received PRM-151 10 mg/kg IV QW (n=8) or
Q4W (n=7), or ruxolitinib plus PRM-151 10 mg/kg IV QW (n=6) or Q4W (n=6). 
Aims: This study investigates the reduction of BM (BM) fibrosis by quantitative
image analysis and WHO MF grading, and the changes in BM fibrosis and his-
totopography in pts treated with PRM-151. 
Methods: Morphologic analysis was performed on serial BM specimens from
25 pts: 4 at baseline (BL) and 12 weeks, 9 at BL, 12 and 24 weeks, 3 at BL,
12, 24, and 36 weeks, and 8 at BL, 12, 24, 36, and 48 weeks. Two
hematopathologists blinded to treatment assessed reticulin grade, collagen
quantity, osteosclerosis quantity, cellularity, megakaryocytic morphology and
topography, myeloid to erythroid (M:E) ratio and presence of erythroid islands.
Pts were divided into fibrosis responders by morphologic analysis (FR: ≥1
grade decrease or stable grade 1 at the last follow-up) and non-responders
(FNR: worsened grade or persistent grades 2 or 3 at the last follow-up), and
platelet (PLT) responders (PR: ≥12 week doubling or normalization in PLT in
pts with baseline PLT count <100x109/L and/or PLT transfusion independence
in pts requiring ≥2 PLT transfusions in prior 12 weeks) and PLT non-responders
(PNR). Computer assisted image analysis (CIA) was performed on whole slide
scans from serial BM specimens from 26 pts at the same timepoints as the
morphologic analysis (1 additional pt at BL and 12 weeks) for objective quan-
tification of overall fibrosis level and osteosclerosis of all post-treatment sam-
ples compared to baseline samples. Area occupied with bone trabeculae (%
of total core biopsy) and reticulin fibers (% of hematopoietic areas excluding
the fat) were calculated. Values of bone and reticulin fibers were compared
across serial sections of each patient to determine the trend. 
Results: At baseline 2 patients had WHO MF-1, 9 pts - MF-2 and 14 pts - MF-
3. There were 9 FR and 16 FNR; the baseline fibrosis grades in the FR group
were 1 pts - MF-1, 3 pts - MF-2, and 5 pts - MF-3. No differences in BM mor-
phology between FR and FNR or between PR and PNR groups were seen at
the baseline. The FR group had reduced collagen quantity (p=.007) and a trend
toward reduced osteosclerosis (p=0.1) at the last timepoint compared to the
FNR group. CIA revealed statistically significant decreased fibrosis in all treated
samples (p=0.003) but no significant difference in 12 weeks samples (p=0.28)
in treated patients compared to baseline (Figure 1). FR pts showed a trend for
fewer paratrabecular megakaryocytes (44% vs 81%, p=0.08). There were 8
PR and 17 NPR. PR was associated with normalization of the M:E ratio
(p=0.03) and borderline association with fibrosis reduction (p=0.09).
Figure 1. Fibrosis reduction by quantitative image analysis at baseline
and post-baseline (p=.0031).
Summary and Conclusions: Reduction in BM fibrosis and improved PLT
counts in pts treated with PRM-151 appear to be associated with reduction in
collagen and osteosclerosis, improvements in megakaryocytic topography, and
normalization of the M:E ratio. Post treatment fibrosis reduction is confirmed
by CIA analysis and may be a useful adjunct to conventional morphologic-
based grading, as it may more accurately assess fibrosis heterogeneity fol-
lowing therapy. Studies of intra- and inter-patient differences between CIA and
morphologic analyses are in progress.
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THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS
S. Merante1,* I. Neri2, D. Magliacane3, A. Belloni Fortina4, F. Ingeborg5,
E.A. Pastorello6, M. Mauro7, R. Minelli8, E.D. Elisa Difonzo9, E. Guggiari10,
A. Peserico11, I. Romani, 12M. Bocchia, 13E. Fontana, 14S. Di Nuzzo15,
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prensorio sanitario di Brunico Ospedale di Brunico, Brunico, 6Allergologia e
Immunologia, Dipartimento Medico Polispecialistico Ospedale Niguarda Ca’
Granda, Milano, 7Allergologia, Ospedale Sant’Anna, Como, 8Pneumologia e
Malattie Allergiche, ASL 8, Cagliari, 9Dermatologia, Dipartimento Chirurgia e
Medicina Traslazionale Università di Firenze, Firenze, 10Ematologia e Trapianto
Midollo, Dipartimento di Oncologia Ospedale San Raffaele, Milano, 11Clinica
Dermatologica Azienda Opsedaliera, University of Padua, 12Dermatology, Uni-
versiti of Padua, Padua, 13Hematology, University of Siena, Siena, 14Derma-
tology, University of Padua, Padua, 15Dermatology, University of Parma, Par-
ma, 16Hematology, San Gerardo Hospital, University of Milan, Monza, 17Hema-
tology, 18Dermatology, Fondazione IRCCS Policlinico San Matteo, 19Gastroen-
terology, Internal Medicine, 20Bone Metabolism, Internal Medicine, Fondazione
IRCCS Policlinico San Matteo,University of Pavia, 21Pediatric Clinic, Fon-
dazione IRCCS Policlinico San Matteo, 22Pathology, Fondazione IRCCS Poli-
clinico San Matteo, Pavia,University of Pavia, Pavia, 23Dermatology, Sant’Or-
sola-Malpighi Hospital,University of Bologna, Bologna, 24Immunology, Aller-
gology, University of Salerno, Salerno, Italy
Background: Mastocytosis is a rare disease characterized by abnormal pro-
liferation and accumulation of mast cells (MC) in several organs and tissues
(skin, bone marrow, liver, gastrointestinal tract, lymphnodes). WHO classifica-
tion includes mastocytosis into cutaneous mastocytosis (CM) and systemic
mastocytosis (SM) that is subdivided in indolent (ISM), “smoldering” (SSM),
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systemic mastocytosis-associated hematologic non-mast disease (SM-AHN-
MD), aggressive SM (ASM), mast cell leukemia (MCL), solitary mastocytoma.
Difference in incidence of CM and SM correlates with age at onset. While the
diagnosis of SM requires the presence of multifocal dense mast cell infiltrates
in one or multiple extra-cutaneous organs (mostly bone marrow, due to the ori-
gin of MCs), mastocytosis encompasses a wide range of clinical entities,
extremely heterogeneous for clinical course and prognosis. Due to its hetero-
geneity, mastocytosis is a multidisciplinary disease. Concerns remain about
the possible misdiagnosis or lack of identification of different subtypes of mas-
tocytosis due to different diagnostic procedures between various specialties.
For example, in pediatric cases, invasive procedures are not mandatory con-
sidering the good prognosis.
Aims: The Italian Mastocytosis Registry was set up in 2009 to collect data of
mastocytosis patients at a multidisciplinary and national level. 
Methods: Patient data are being routinely collected after written informed consent
in 18 Italian centers. An on-line database (www.registroitalianomastocitosi.it) has
been created for data collection. Patients’ features at onset of disease according
to age, type of mastocytosis and specialty are shown in Table 1.
Table 1. 
Table 2.
Results: Data on 431 patients have been collected from 5 hematology centers
(97 patients) and 11 multidisciplinary centers (334 patients). Clinical evaluations
were available at onset of disease in 134 patients. At diagnosis, 87% of these
134 patients presented systemic symptoms; 89 (66%) presented cutaneous
symptoms (CM: 35/63 (56%) ≤11 yrs, 3/3 (100%) 12-19 yrs, 46/56 (82%) ≥20
yrs; SM: 2/2 (100%) ≤11 yrs, 2/2 (100%) 12-19 yrs, 25/36 (69%) ≥20 yrs). 83
(62%) patients were asymptomatic at onset. Of these, 28 (34%) presented
symptoms in a median time of 15 months (range 3-271). SM was reported in
143 (33%) cases: 2 at ≤11 yrs, 3 at 12-19 yrs, 138 at ≥20 yrs. Of these, 65
(45%) had progressed from a CM: 0 (0%) at ≤11 yrs, 1 (2%) at 12-19 yrs, 64
(98%) at ≥20 yrs. First diagnosis was made <18 years of age in 183 (42%)
patients. Table 2 shows therapeutic options (total exceeds 100% because ther-
apy combination is allowed). 94 of 431 patients were evaluated for both bone
marrow percentage of mast cell infiltrate and tryptase serum level and there
was a significantly positive correlation between the two (Spearman rank corre-
lation=0.81; p=0.005). Number of bone marrow biopsies performed was com-
pared between hematology and other multidisciplinary centers and no statistical
difference was observed (p=0.345). We also compared the number of positive
bone marrow biopsies between the two types of centers; again, there was no
statistical difference (p=0.248). 
Summary and Conclusions: The on-line database is a useful tool for data
collection at a national level. In spite of the complexities of the multidisciplinary
context, our study confirms a homogeneous approach with a high level of knowl-
edge among Centers in terms of diagnostic algorithm and treatment, in keeping
with the recent guidelines
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HIGH RATE OF DISCORDANCY REGARDING DIAGNOSIS AND SUBCLAS-
SIFICATION OF SYSTEMIC MASTOCYTOSIS ON BONE MARROW BIOP-
SIES BETWEEN INITIAL LOCAL AND CENTRALIZED REFERENCE
HEMATOPATHOLOGY
M. Jawhar1,* J. Schwaab1, N. Naumann1, H.-P. Horny2, K. Sotlar2,
W.-K. Hofmann1, A. Fabarius1, G. Metzgeroth1, A. Reiter1
1Department of Hematology and Oncology, University Hospital Mannheim,
Mannheim, 2Department of Pathology, Ludwig-Maximilians-University, Munich,
Germany
Background: Advanced systemic mastocytosis (SM) is associated with a poor
prognosis. The median overall survival is approximately 0.5, 2 and 3.5 years in
patients (pts.) with mast cell leukemia (MCL), SM and associated non-mast cell
lineage hematologic neoplasm (SM-AHNMD) and aggressive SM (ASM), respec-
tively. AHNMD is usually a myeloid neoplasm such as chronic myelomonocytic
leukemia (CMML), myelodysplastic/myeloproliferative neoplasm unclassified
(MDS/MPNu) or chronic eosinophilic leukemia (CEL). A thorough histologic and
immunohistochemical examination, e.g. tryptase, CD117 (KIT) and CD25, of the
bone marrow (BM) is required for appropriate diagnosis and subclassification
including markers for characterization of AHNMD, e.g. CD34 for blasts or CD14
for monocytes. ASM is diagnosed through the presence of C-findings, e.g. cytope-
nias, liver function abnormalities, splenomegaly, ascites, hypoalbuminemia,
weight loss, or osteolyses. The KIT D816V mutation is present in >80% of SM
pts. and plays a pivotal role in the pathogenesis of SM.
Aims: We sought to retrospectively evaluate the concordance of diagnosis and
subclassification of SM between two consecutively performed BM trephine
biopsies.
Methods: Within the ´German Registry on Disorders of Eosinophils and Mast
Cells´, we retrospectively analyzed 65 pts. (median age 64 years, range 40-
85; male 65%) who had two consecutive diagnostic BM trephine biopsies (medi-
an time between biopsies 4 months, range 0-71). The initial biopsy was evalu-
ated by a local pathologist (LP) while KIT D816V+ SM was diagnosed in the
subsequent biopsy in all 65 pts. by reference pathologists (RP) of the ‘European
Competence Network on Mastocytosis (ECNM)’. 
Results: According to the WHO classification, final diagnoses by RP were SM
or aggressive SM [(A)SM (n=27)], (A)SM-AHNMD (n=34), MCL (n=3) and MCL-
AHNMD (n=1). In peripheral blood, the serum tryptase level (normal value
<11.4 ng/ml) was elevated in 59/59 (median 132 ng/ml, range 12-1690) pts.
and KIT D816V was detectable in 57/60 (95%, median allele burden 26%,
range 1-76) pts. in 15/65 (23%) pts., the initial diagnoses by LP were inconsis-
tent and included primary myelofibrosis (n=3), MDS/MPNu (n=3), indolent B-
cell lymphoma (n=2), autoimmune thrombocytopenia (n=2), CMML (n=1),
hypereosinophilic syndrome (n=1), anemia of chronic disease (n=1) or without
pathological findings (n=2). Twelve of those 15 (80%) pts. with discordant diag-
nosis had (A)SM-AHNMD with AHNMD being subclassified as MDS/MPNu,
n=6; CMML, n=3; MDS, n=2; CEL, n=1) (Figure 1). Immunohistochemical mark-
ers for qualitative and quantitative assessment of MCs, e.g. CD117 (KIT) or
CD25, were only used in 43/65 (66%) and 24/65 (37%) cases, respectively. In
50 concordantly diagnosed patients (median time between biopsies 6 months,
range 1-8), the extent of MC infiltration was quantified by LP in only 34/50
(68%, median 20%, range 5-90) pts., subclassification of SM was not consistent
because AHNMD was not diagnosed in 9/50 (18%) pts. and KIT D816V muta-
tion anaylsis was suggested or performed in only 13/50 (26%) correctly diag-
nosed SM pts. 
Summary and Conclusions: Adequate diagnosis and subclassification of SM
warrants an evaluation of BM histology/immunohistochemistry by reference
hematopathologists in combination with molecular genetics (KIT D816V) and
clinical parameters. A more frequent evaluation of serum tryptase would help
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CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH
SYSTEMIC MASTOCYTOSIS AND ASSOCIATED ACUTE MYELOID
LEUKAEMIA
S. Kreil1,* J. Schwaab1, M. Jawhar1, S. Schnittger2, H.-P. Horny3, N.C. Cross4,5,
W.-K. Hofmann1, A. Reiter 1
1Department of Hematology and Oncology, University Hospital Mannheim,
Mannheim, 2Münchner Leukämielabor, 3Department for Pathology, Ludwig-
Maximilians-Universität, Munich, Germany, 4Wessex Regional Genetics Lab-
oratory, Salisbury, 5Human Genetics, University of Southampton, Southampton,
United Kingdom
Background: In systemic mastocytosis (SM), the most aggressive clinical
course has been reported from aggressive SM (ASM) and mast cell leukaemia
(MCL) with median survival times of 2-3 years and less than 6 months, respec-
tively. A significant proportion of patients with indolent SM (ISM), ASM or MCL
may present with an associated haematological non-mast cell lineage disease
(AHNMD) which most commonly represents chronic myelomonocytic
leukaemia (CMML), myelodysplastic/myeloproliferative neoplasm unclassified
(MDS/MPN-U), myeloproliferative neoplasm unclassified (MPN-U) or chronic
eosinophilic leukaemia (CEL). Very rarely, an associated acute myeloid
leukaemia [(A)SM/MCL-AML] is diagnosed which can be either de novo or
secondary, e.g. evolving from CMML, MDS/MPN-U, MPN-U or CEL. A KIT
D816V mutation is present in >90% of patients with advanced SM and plays a
pivotal role in its pathogenesis. However, recent data have suggested that
additional mutations, e.g. in TET2, SRSF2, ASXL1 or RUNX1 etc., are
detectable at variable frequencies in >80-90% of patients with (A)SM/MCL-
AHNMD (Schwaab et al., Blood 2013).
Aims: To analyse the clinical presentation, genetic profile, treatment and prog-
nosis of (A)SM/MCL-AML.
Methods: Retrospective analysis of 11 patients (male, n=6; female, n=5) with
SM-AML recruited within the “German Registry on Disorders of Eosinophils
and Mast Cells”.
Results: SM was diagnosed prior to AML (n=8), concomitantly with AML (n=1)
or due to lack of durable remission following intensive chemotherapy of AML
(n=2).The median age at diagnosis of SM and AML was 55 years (range 26-
78) and 62 years (range 27-75), respectively. The subtype of SM was ASM
(n=9) or ISM (n=2) while AML was de novo (n=6) or secondary (CMML, n=3;
MPN-U, n=2, MDS/MPN-U, n=1). At time of diagnosis of AML, cytogenetic
analysis of 6 patients with available material/data revealed a complex karyotype
(n=1), monosomy 7 (n=1), trisomy 8 (n=1) or a normal karyotype (n=3). The
KIT D816V mutation was identified in 10 of 11 (91%) patients and additional
mutations in 8 of 8 (100%) patients with available material. The number of
additional mutations in individual patients was 1 (n=3), 2 (n=2) and >2 (n=3).
The most frequently identified mutations included RUNX1 (n=4), ASXL1 (n=3),
SRSF2 (n=3), and TET2 (n=2). Ten patients received intensive chemotherapy
according to disparate AML study protocols (e.g. daunorubicin/ara-C or mitox-
antrone/high-dose ara-C). Seven patients achieved a complete remission. Two
patients died as consequence of treatment or disease-related complications 2
and 12 months after start of chemotherapy. Six patients received an allogeneic
stem cell transplantation (ASCT) immediately after chemotherapy (n=1), in first
remission (n=3) or following relapse (n=2) after remission. Four patients died
a median of 13 months (range 1-36) after ASCT while 2 patients are alive 9
and 29 months, respectively, after ASCT. Of the non-transplanted patients
(n=5), 4 patients died within the first 13 months following diagnosis of AML
while only one patient is alive 70 months after diagnosis and conventional treat-
ment of AML. The single patient without intensive chemotherapy died 4 months
after diagnosis of AML. Overall, median survival after diagnosis of SM was 3
years (range 0.7-16.6) and 13 months (range 2-74) after diagnosis of AML,
respectively.
Summary and Conclusions: SM-AML is a rare entity with a very poor prog-
nosis. Diagnosis of SM may be missed when presenting simultaneously with
AML. The high frequency of additional mutations suggests a pathogenetic role
for the aggressive clinical course and poor prognosis. Long-term survival is
more likely in patients achieving complete remission following intensive
chemotherapy with or without subsequent ASCT.
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VALIDATION OF THE SIMPLIFIED PROGNOSTIC SCORE FOR SMZL OF
THE SMZLSG (SMZL STUDY GROUP) IN A SERIES OF PATIENTS TREAT-
ED WITH RITUXIMAB MONOTHERAPY, AND LONG TERM OUTCOME OF
RITUXIMAB RESPONDERS
C. Kalpadakis1,* G. Pangalis2, M. Angelopoulou3, S. Sachanas2, F. Kontopidou4,
M. Moschogiannis2, M. Ximeri1, A. Dimitrakopoulou5, P. Tsirkinidis2,
M.-C. Kyrtsonis6, T. Tzenou6, X. Yiakoumis2, E. Koulieris2, P. Panayiotidis6,
H. Papadaki1, T. Vassilakopoulos3
1Hematology, University of Crete, Heraklion, 2Hematology, Athens Medical
Center-Psychikon Branch, 3Hematology, 42nd Department of Internal Medicine,
University of Athens, 5Immunology Laboratory, Laikon General Hospital, 61st
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Background: Rituximab monotherapy is a highly effective therapy for SMZL.
However, there is a subset of patients not responding to rituximab with com-
promised survival. Several prognostic factors have been proposed without
reproducible results.
Aims: To assess the long term outcome of rituximab treated patients and val-
idate the reproducibility of the simplified risk stratification score of the SMZLSG
in a series of SMZL patients treated homogeneously with rituximab monother-
apy as a first line therapy. 
Methods: The study population included 76 patients who had received ritux-
imab as 1st line therapy for SMZL between 2003 and 2014. The prognostic
system is based on the on the combination of 4 factors: haemoglobin levels
<9.5 g/dL, platelet counts <80×109/L, elevated LDH and the presence of
extrahilar lymphadenopathy (outside the splenic and hepatic hilum). All vari-
ables were considered to have the same statistical weight and were assigned
the same value of one point each. The prognostic score was calculated as
the sum of the 4 variables (0 or 1; range 0-4). Three risk groups were identi-
fied: low (A) for patients with 0 points, intermediate (B) for patients with 1 or
2 points and a high risk group (C) for patients with 3 or 4 points. The Kaplan-
Meier method was used to estimate survival and the log-rank test to compare
survival curves.
Table 1. Main characteristics, stratification and outcome of our patients.
Results: Among 76 patients with SMZL included in the present study, 73 had
complete data for all four variables and were therefore analyzed for the prog-
nostic system (Table 1). The median age was 65 years (45-95). The main
clinical characteristics and the stratification of our patients in the three 3
groups are presented in table. Among the 76 SMZL patients, 3 did not respond
to or progressed during rituximab treatment, for an overall response rate of
96%. At 1, 2, 3, 4, 5, and 7 years, PFS was 95%, 88%, 83%, 74%, 69%, and
69% respectively. At the time of this analysis 6 deaths were recorded, 3 due
to the disease and 3 urelated. The 7-year overall survival and disease-specific
survival were 87% and 91% respectively. According to the simplified prog-
nostic score the stratification of our patients in the three risk groups at treat-
ment initiation were as follows: 27/73 (37%) were classified into group A,
42/73 (58%) into group B and 4/73 (5%) into group C. 7-year PFS were 83%
for group A, 48% for group B and 50% for group C (p=0.051). Difference in
7-year PFS was more prominent when groups B and C were analyzed togeth-
er (7-year PFS for group B+C was 49% vs 83% group Α, p=0.02). In order to
evaluate long term outcome of rituximab responders, 24 patients who had
received rituximab and remained in remission for ≥5 years were analyzed.
The 5-year PFS was 96%. At a further median time of 24.5 months (range,
4-72) beyond 5 years, 22 patients still remain in remission, while two relapsed
at 6 and 62 months, respectively. The subsequent 5-year PFS (10 years post-
treatment) was 96%.
Summary and Conclusions: This study validates the applicability of the
SMZLSG prognostic system regarding PFS, in a series of 73 SMZL patients
homogeneously treated with Rituximab monotherapy. The long-term disease-
specific survival exceeded 90%. This study confirms the efficacy of Rituximab
as first line treatment in SMZL and demonstrates the potential for a long-term
disease control, beyond the initial 5 years, in a substantial patient subgroup.
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Background: Follicular lymphoma (FL) may, over time, transform into an
aggressive lymphoma, usually diffuse large B-cell lymphoma (DLBCL). Trans-
formed follicular lymphomas (tFL) have a worse prognosis due to poorer
response to treatment than primary DLBCL. The incidence of transformation is
estimated in ~3% per year, although it varies largely between different studies
(24%>70% overall). These differences are mainly due to different criteria to
define tFL, to lack of evidence of tFL by biopsy, absence of clonality studies
discarding secondary de novo NHL, studies performed in the pre-Rituximab
era, or different follow-up times among studies. With all this pitfalls, the actual
incidence of transformation remains an open question.
Aims: The aim of the present study is to analyse the incidence and prognostic
impact of transformation in patients with FL in a large retrospective series of
the Spanish group of Lymphomas (GELTAMO).
Methods: A total of 1096 patients (grade I, II, and IIIa) from 8 Spanish centres
diagnosed of FL between 2000 and 2010 were included in the study. Data were
obtained from the database of centres willing to participate in this study. True
tFL (FL to DLBCL) were recorded. Composite FL+DLBCL, discordant tFL (FL
in bone marrow and DLBCL in adenopathy or viceversa), and downgrading tFL
(DLBCL at diagnosis and relapse of FL) were excluded from the preliminary
analysis. This study was approved by the Salamanca University Hospital Ethic
Committee.
Results: Seventy-one patients (median follow up of 6 years) were trans-
formed to DLBCL (6,5%). Cumulative incidence of transformation at 5, 10,
and 15 years was of 5%, 8%, and 14%, respectively. Median time to trans-
formation was 30 months, ranged 3-150. Considering survival from diagnosis
of FL, tFL patients had a shorter OS than non-transformed (20% vs 68%,
p<0,0001). Most of the tFL patients (92%) have previously received treatment
for FL, 56% of them with Rituximab. Median number of treatment lines before
transformation was 2 (1-6). Patients receiving Rituximab as first line therapy
showed decreased time to transformation at 15 years (10% vs 19%, p=0.025).
Other factors influencing risk of tFL included no response to first line therapy,
age at diagnosis >60 years, FLIPI, and Ann Arbor stage. Consolidation ther-
apy with autologous transplant for tFL showed an increase in OS (67% vs
8%, p=0.001). However, these results should be confirmed in prospective
studies.
Summary and Conclusions: High risk FLIPI, Ann Arbor stage III-IV, age >60
years, not use of Rituximab in first line therapy, and response to first line have
shown to predispose to a higher risk of transformation. Autologous transplan-
tation could have a benefit in terms of OS in transformed patients. Effort should
be made in order to clarify criteria for transformation, and biological studies on
tumoral samples at diagnosis and at transformation will help to determine patho-
genesis of transformation in helping to design clinical trials with new molecules
based on molecular characteristics of transformation.
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Background: Current first-line treatments for FL provide prolonged disease
control (median PFS ~7 years). Thus, studies evaluating first-line treatment
options based on the accepted regulatory endpoint of PFS require extended
patient follow-up, increasing the challenges associated with clinical develop-
ment of novel treatments by prolonging the evaluation process.
Aims: The Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH)
group conducted a prospectively planned meta-analysis with individual patient
data (IPD) to evaluate whether the treatment effect on clinical endpoints at
early landmarks, for example, complete response rate(s) at 24 (CR24) or 30
months (CR30), could accurately predict treatment effect on PFS.
Methods: Randomized controlled trials testing first-line treatments in FL, pub-
lished after 1990, with available IPD were eligible. Association between CR
rates and PFS was assessed at both the trial and patient level. Treatment
effects on PFS and binary CR endpoints were quantified by hazard ratios (HRs)
and odd ratios (ORs), respectively. The trial-level correlation of CR rate with
PFS was evaluated using linear regression (R2WLS) and copula bivariate
(R2Copula) models. Prespecified criteria for establishing surrogacy required
either R2WLS or R2Copula ≥0.80 with a lower bound of the 95% confidence inter-
val (CI) >0.60, and neither <0.70. The patient-level association between CR
status (at 24 and 30 months) and PFS was assessed using a stratified Cox
model with a landmark approach and by the global OR using a bivariate copula
model. The minimum treatment effect on CR needed to predict a significant
PFS difference was calculated.
Results: Of 13 eligible randomized first-line trials, 8 explored induction and 5
explored maintenance regimens; IPD was available for 3837 patients (Table
1). Nine trials included an experimental arm exploring a rituximab-based regi-
men. The prespecified threshold for CR30 surrogacy was met: R2WLS was 0.88
(95% CI, 0.77-0.96) and R2Copula was 0.86 (95% CI, 0.72-1.00), demonstrating
that treatment effect on CR30 predicted effect on PFS in previously untreated
FL. A minimum 10% improvement in CR30 over a control rate of 50% predicted
a significant improvement in PFS. Multiple sensitivity and IPD surrogacy analy-
ses supported the robustness of the primary CR30 analysis. Treatment effects
on CR24 also met prespecified surrogacy criteria for R2WLS 0.84 (95% CI, 0.63-
0.95), but not for R2Copula; CR24 analyses were influenced by one outlier study.
Table 1. Correlation of CR30 and CR24 with progression-free survival.
Summary and Conclusions: This large IPD meta-analysis of chemo/im -
munotherapy trials demonstrates that treatment effect on CR30 is a robust pre-
dictor of the treatment effect on PFS in first-line FL; the correlation of CR24 and
PFS treatment effects is promising but requires further confirmation. The use of
the CR30 endpoint may expedite the evaluation of, and thus improve the speed
of access to, promising novel therapeutics for this patient population.
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Background: CD5- CBL displays features consistent with marginal zone ori-
gin. This entity may be associated with monoclonal gammopathy, frequently
of the IgM type. Therefore differential diagnosis from Waldenstrom
macroglobulinemia (WM) /lymphoplasmacytic lymphoma (LPL) is mandatory.
The recently identified gain of function L265P MYD 88 mutation is considered
a sensitive and specific marker of WM and might be a valuable tool to differ-
entiate the two entities.
Aims: To determine the presence of L265P MYD-88 mutation in a well charac-
terized series of CD5- CBL pts along with an extended analysis of the morpho-
logic, clinical, immunophenotypic and histologic features in order to identify
whether some of these cases may be in fact WM/LPL.
Methods: We retrospectively evaluated 40 patients with CD5- CBL presenting
in the blood and/or in the bone marrow (BM), without evidence of any other
disease localization or signs of chronic and/or active inflammation, autoim-
munity, organomegaly or cytopenia. The identification of MYD 88 L265P muta-
tion was performed in blood/BM mononuclear cells with allele specific PCR.
For the purpose of the present analysis, patients were divided in 3 groups:
Group 1 included patients with a mutated MYD 88. Group 2 consisted of MYD
88 wild type patients with paraproteinemia, whereas patients with wild type
MYD 88 but without paraproteinemia were classified as group 3.
Table 1. Patients’ characteristics according to the presence of MYD-88
L265P mutation.
Results: All patients were asymptomatic at diagnosis presenting predominantly
with lymphocytosis, or more rarely with a paraproteinemia. Thirty-six patients
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had lymphocytosis, while circulating clonal B-cells were found in 93%. Blood lym-
phoid population consisted mainly of small lymphocytes, admixed with villous
lymphocytes and monocytoid cells in various proportions. Paraproteinemia was
evident in 20 cases. BM was invariably infiltrated with features of plasmacytic dif-
ferentiation in 15 cases, 12 of which were associated with the presence of para-
proteinemia. The L265P MYD-88 mutation was present in 8 cases (20%). The
laboratory, morphologic, immunophenotypic and histologic characteristics of the
three groups are shown in the Table 1. All MYD-88 (+) cases (group 1) had para-
proteinemia (5 IgM, 2 IgG and 1 IgM plus IgG) and 6 of them also displayed plas-
macytic differentiation in the BM. Regarding group 2 patients (N=12), 6 had an
IgM paraprotein and 6 plasmacytic differentiation in the BM. Among the 20 group
3 patients, only 3 showed plasmacytic differentiation in the BM. Thus, MYD-88
mutated cases had more frequently IgM paraproteinemia, higher percentage of
BM infiltration and plasmacytic differentiation, and CD38 expression. At a median
follow-up time of 41 months, 1 patient progressed to SMZL and 4 developed
cytopenias due to extensive BM infiltration. The limited number of patients in
each group and the relative short follow-up time prevent any correlation between
the MYD-88 and outcome.
Summary and Conclusions:Almost 2/3 (12/20) of pts with monoclonal gamopathy were
MYD-88 (-) and therefore these pts are still classified as CD5- CBL. Further on our study
shows for the first time, that 20% of CD5- CBL cases harbor the L265P MYD 88 mutation
- a marker that is WM specific. The L265P MYD mutated subgroup displayed more often
plasmacytic differentiation, CD38 expression, and a paraprotein of the IgM type. Whether
these cases represent true WM or borderline cases between these two entities remains
to be clarified.
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Background: Anthracyclines-based regimens remain the gold standard for the
treatment of Lymphomas, although the associated cardiac toxicity may limit
their use, especially in frail and elderly patients.
Aims: The aim of this study was to evaluate the efficacy and tollerability of
RCOMP inpatients with poor-risk lymphoma and cardiovascular comorbidity
Methods: From October 2008 to January 2015 we treated 44 newly diagnosed
patients with poor-risk lymphoma and cardiovascular comorbidity using the R-
COMP regimen (rituximab, cyclophosphamide, non-pegylated liposome-encap-
sulated doxorubicin, vincristine and prednisone)
Results: Median age was 74 years (range:46-83 yrs ; 45% ≥75 years). As
for histology, 22/44 (50%) were Diffuse Large B-cell Lymphoma; 8/44 (18%)
Mantle-cell Lymphoma; 5/44 (11%) Follicular Lymphoma; 3/44 (7%) Periph-
eral B-cell Lymphoma; 4/44 (9%) Nodal Marginal Zone Lymphoma; 2/44 (4%)
other B-cell indolent Lymphoma. IPI score was Intermediate-High/High in
61,3% of the patients, 75% had an advanced Ann-Arbor stage and 43% pre-
sented at diagnosis with extranodal involvement. The median age adjusted
Charlons comorbidity index was 6 (range: 3 to 9). Cardiovascular risk factors
were considered: hypertension (30/44pts: 68%), 14/44 pts (31,6%) had a his-
tory or recent acute myocardial infarction and 4/44 (10%) suffered of Atrial
fibrillation. Treatment was well tolerated and toxicities were limited grade
III/IV cytopenia. Complete remission was achieved in 30/44 (68%) and partial
response in 6/44 (14%). Progressive disease was present in 8/44 (18%).
After a median follow up of 18 months, the median OS (Overall Survival) was
not reached and 4/36(11%) responders relapsed. Cardiac toxicity was
observed in one patients who died for pulmonary edema, while two patients
developed arrhythmias.
Summary and Conclusions: This study confirm the efficacy and tolerability of
R-COMP regimen in elderly patients with cardiovascular comorbidities.
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Background: B-cell indolent non-Hodgkin’s lymphoma is typical manifestation
of chronic extrahepatic hepatitis C. The incidence of HCV infection in patients
with B-cell indolent non-Hodgkin’s lymphomas is approximately 15%.
Aims: In our study included 93 patients with indolent lymphoma and hepatitis C
markers (IL+C) and control group of 146 patients with indolent lymphomas without
markers of hepatitis C (IL-C). In patients with indolent lymphoma associated with
hepatitis с proteins of virus expression on tumor cells in 82% patients.
Methods: In 93 patients with IL+C 43 patients received antiviral therapy as the
first treatment. 50 patients with IL+C received polychemotherapy therapy as
first line of therapy. All patients with indolent lymphomas without markers of
hepatitis C received only chemotherapy.
Results: Antiviral therapy(AVT) in patients with IL+C received complete
remission(CR)-77%, partial remission(PR) - 11%, stabilization-4%, 8% pro-
gression. All patients, in whom antiviral therapy was not effective(stabiliza-
tion+progression), virus proteins of hepatitis C on tumor cells was not detect-
ed. On chemotherapy in patients with IL+C CR received in 64%, PR-23%,
stabilization-9%, 4%>progression. All patients with progression on chemother-
apy on tumor cells was detected proteins of hepatitis C virus. On chemother-
apy in patients in control group with IL-C received CR in 53%, PR-31%, the
stabilization-5%, 11%>progression. The median relapse-free survival(RFS)
in patients with IL+C on AVT was 36mth. The median RFS in patients with
IL+C on chemotherapy was 19 months. The median RFS in patients with IL-
C on chemotherapy was 33 months. 37 patients with relapse IL+C after
chemotherapy was conducted AVT. CR was received in 81% of patients, PR
was achieved in 11% and stabilization/progression+8% of patients. The medi-
an RFS in patients with IL+C recurrence after chemotherapy for AVT was 31
months.
Summary and Conclusions: The effectiveness of AVT was significantly higher
than chemotherapy in patients with IL+C. Median disease-free for patients with
IL+C significantly more on antiviral therapy. AVT should be the first line therapy
in patients with the IL+C.
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Background: Subcutaneous rituximab (RSC) offers improved patient (pt) con-
venience and healthcare resource savings versus intravenous rituximab (RIV).
The phase III SABRINA study (NCT01200758) investigated induction RSC or
RIV in combination with chemotherapy followed by maintenance RSC or RIV
in pts with follicular lymphoma (FL). With a median follow-up time of 14
months, the RSC and RIV arms had similar response rates and safety profiles,
without any new clinically relevant safety findings reported for RSC. However,
longer follow up is needed to define the safety of RSC versus RIV in the main-
tenance setting.
Aims: We present an updated safety analysis of RSC and RIV for the mainte-
nance phase of SABRINA (median follow-up time 26 months).
Methods: Pts with treatment-naïve CD20+ grade 1-3a FL (n=410) were ran-
domised to receive RSC or RIV (n=205/arm), stratified by FL International Prog-
nostic Index score, chemotherapy regimen and region. All pts received RIV 375
mg/m2 in cycle 1; for cycles 2-8, pts received RSC 1400 mg or RIV 375 mg/m2
every 3 weeks. Pts received ≤8 cycles of CHOP (cyclophosphamide, doxoru-
bicin, vincristine and prednisone) or 8 cycles of CVP (cyclophosphamide, vin-
cristine and prednisone). During maintenance, pts received RSC or RIV every
8 weeks. Non-serious AEs were reported for 28 days following the last dose of
rituximab. Serious AEs (SAEs) were recorded for 1 year post-treatment or until
the start of new anti-lymphoma treatment. SAEs considered possibly related to
study treatment were recorded indefinitely. 
Results: In total, 407 pts received ≥1 dose of rituximab (safety population).
Six RSC pts discontinued treatment after cycle 1 (RIV in both arms) and were
included in the RIV safety population (RSC n=197 [81 male, 116 female]; RIV
n=210 [109 male, 101 female]). In total, 86% of pts started maintenance (RSC
n=172, 87%; RIV n=178, 85%). During maintenance, the most common AEs
were of the system organ class (SOC) infections and infestations (RSC 41%;
RIV 42%); most were grade 1/2 upper respiratory tract infections, urinary tract
infections or nasopharyngitis. Grade ≥3 infections were reported in 8% (RSC)
and 3% (RIV) of pts. Other common AEs (≥15% pts) belonged to the SOCs
general disorders and administration site conditions (RSC 28%; RIV 19%; dif-
ference mainly driven by grade 1 injection site erythema [RSC 8%; RIV 0%]);
gastrointestinal disorders (RSC 24%; RIV 19%); musculoskeletal and connec-
tive tissue disorders (RSC 23%; RIV 21%); respiratory, thoracic and mediasti-
nal disorders (RSC 18%; RIV 17%); blood and lymphatic system disorders
(17% each; most were grade ≥3 [10% of pts/arm]); and skin and subcuta-
neous tissue disorders (RSC 16%; RIV 15%). SAEs reported during mainte-
nance (≥2% of pts) were: infections and infestations (RSC 8%; RIV 2%); gas-
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trointestinal disorders (RSC 1%; RIV 4%); musculoskeletal and connective
tissue disorders (RSC 2%; RIV 1%); blood and lymphatic system disorders
(RSC 1%; RIV 2%); and neoplasms (RSC <1%; RIV 2%). In both arms, grade
≥3 AEs were more common in females (RSC 27%; RIV 29%) than in males
(RSC 18%; RIV 19%) during maintenance. In total, 5% (RSC) and 3% (RIV) of
pts discontinued maintenance due to AEs. At data cut off, 27 pts (RSC n=11,
6%; RIV n=16, 8%) had died.
Summary and Conclusions: Maintenance RSC and RIV were well tolerated
in treatment-naïve pts with FL, with no new safety signals noted for RSC. Avail-
ability of RSC administration over approximately 6 minutes has positive impli-
cations for pt convenience and healthcare resource savings, without compro-
mising safety or efficacy.
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Background: Based on early evidence of cumulative toxicity of PoV at a dose
of 2.4 mg/kg (Morschhauser ASH 2014; NCT01691898), a dose of 1.8 mg/kg
dose was explored. 
Aims: To report updated results of the dose comparison. Safety and efficacy
of PoV after 8 treatment cycles were also analyzed.
Methods: Patients (pts) with R/R FL received PoV at 2.4 mg/kg or 1.8 mg/kg
with R 375mg/m2, q21d until progression or unacceptable toxicity. Five pts with
R/R FL from the Phase 1 study (Palanca-Wessels ASH 2013) treated with PoV
2.4 mg/kg were included in the analysis. Data at completion of PoV treatment
were compared with data after 8 cycles.
Results: Forty-five pts received PoV+R (25, 2.4 mg/kg; 20, 1.8 mg/kg). Medi-
an follow-up was 14 mo. for 2.4 mg/kg vs 8 mo. for 1.8 mg/kg. When limited
to the first 8 treatment cycles, median follow-up was similar at 6 mo. for both
groups. Baseline characteristics were balanced between the two cohorts,
except for age (median 68 yrs 2.4 mg/kg, 62 yrs 1.8 mg/kg) and tumor volume
(SPD 1824 mm2 at 2.4 mg/kg, 2655mm2 at 1.8 mg/kg). Overall, 40% (10/25,
2.4 mg/kg) and 50% (10/20, 1.8 mg/kg) of pts were refractory to their last
treatment. At data cut-off for this analysis, pts received a median of 10 and
9.5 treatment cycles in the 2.4 mg/kg and 1.8 mg/kg groups, respectively,
with median dose intensities after cycle 8 of 88% and 99%, respectively.
Safety is shown in the Table 1. Peripheral neuropathy (PN) was more frequent
with PoV 2.4 mg/kg, and discontinuation (d/c) rates due to all causes were
56% vs 30% with the 1.8 mg/kg dose. After 8 treatment cycles, d/c rates
were similar for both doses (28% vs 25%). An 84-year old pt in the 2.4 mg/kg
cohort died 2 mo. after cycle 12 due to pulmonary congestion.
Table 1. Safety profiles of PoV+R for all treatment cycles and truncated
after cycle 8                               
Adverse events, n (%)                      PoV                 PoV                 PoV                 PoV
(MeDRA SOC)                            1.8 mg/kg       2.4 mg/kg      1.8 mg/kg      2.4 mg/kg
                                                 all cycles         all cycles         8 cycles          8 cycles
                                                   (N=20)            (N=25)           (N=20)           (N=25)
Any AE Grade 3-4                          10 (50)            13 (52)           10 (50)           13 (52)
Neutropenia                                   7 (35)              4 (16)             7 (35)             4 (16)
Febrile neutropenia                         2 (10)               1 (4)              2 (10)              1 (4)
Serious AE                                      6 (30)              8 (32)             6 (30)             6 (24)
Deaths                                               -                   1 (4)                  -                      -
AE leading to study discontinuation 6 (30) 14 (56) 5 (25) 7 (28) Grade 2-4 periph. neuropathy1
8 (40) 18 (72) 5 (25) 10 (40) Grade 3+ infection 1 (5) 3 (12) 1 (5) 2 (8) AE per CTCAE V4.03.
AEs G3/4 10% reported; 1 MedDRA SMQ peripheral neuropathy (wide).
ORR was similar in for both levels: 19/25 (76%) at 2.4 mg/kg, 15/20 (75%) at
1.8 mg/kg. CRs were achieved in 11/25 (44%) patients at 2.4 mg/kg and 2/20
(10%) patients at 1.8 mg/kg. Duration of response was 12 mo. for 2.4 mg/kg
and not estimable for 1.8 mg/kg group. After 8 cycles, ORR remained similar;
64% for 2.4 mg/kg and 60% for 1.8 mg/kg. Median PFS was 15 mo. at 2.4
mg/kg and not reached in the 1.8 mg/kg group (Figure 1). 
Figure 1. PFS for PoV+R (PoV at 2.4 mg/kg and 1.8 mg/kg).
Summary and Conclusions: PoV+R in R/R FL showed high ORR at both
doses, with higher CR at 2.4 mg/kg. D/c rates, mostly due to cumulative PN,
were high. AEs and d/c rates were reduced at both doses if only the first 8
cycles are considered vs those reported through study completion. The safety
of PoV can be improved by shorter treatment and/or lower dose. Updated
PFS will be presented. 
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IDELALISIB EFFICACY AND SAFETY IN FOLLICULAR LYMPHOMA
PATIENTS FROM A PHASE 2 STUDY
P. Zinzani1,* G. Salles2, S.J. Schuster3, S. de Vos4, N.D. Wagner-Johnston5,
A. Viardot6, C.R. Flowers7, M. Will8, M. Breuleux8, W.R. Godfrey8, B. Sorensen8,
A.K. Gopal 9
1Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy, 2Hospices Civils
de Lyon, Université Claude Bernard, Pierre-Bénite, France, 3Abramson Can-
cer Center of the University of Pennsylvania, Philadelphia, 4David Geffen
School of Medicine at UCLA, Los Angeles, 5Washington University School
of Medicine, St Louis, United States, 6University Hospital of Ulm, Ulm, Ger-
many, 7Winship Cancer Institute of Emory University, Atlanta, 8Gilead Sci-
ences, Foster City, 9University of Washington School of Medicine, Seattle,
United States
Background: There is an unmet need for new treatment options in follicular
lymphoma (FL), particularly for heavily pretreated, high-risk patients refractory
to anti-CD20 and chemotherapy. Idelalisib, a PI3Kδ inhibitor, showed antitumor
activity and acceptable tolerability as monotherapy in a pivotal phase 2, open-
label study in indolent non-Hodgkin lymphoma (iNHL) refractory to rituximab
(R) and an alkylating agent (NCT01282424).
Aims: This post hoc analysis evaluated efficacy and safety in the FL patient
subset.
Methods: Double refractory patients with histologically confirmed iNHL
received oral idelalisib 150 mg BID until disease progression (PD) or unac-
ceptable tolerability; patients with FL (grade 1, 2, or 3a; n=72) were included
in this analysis; all patients provided informed consent. Responses were eval-
uated by an independent review committee using standardized criteria. The
primary endpoint was the overall response rate (ORR).
Results: At study entry, patients’ median age was 62 y, 54% had a high-risk
FLIPI score, 22% had bulky disease, and 17% had FL grade 3a. Median
(range) number of prior treatments was 4 (2-12); 86% were refractory to their
last therapy (32/50 to bendamustine). At data cutoff, median (range) treatment
duration was 6.5 (0.6-31.0) mo, with 65 (90%) patients off treatment (PD, 38;
adverse events [AEs], 15; investigator decision, 7; death, 5). Lymph node
size decreased during treatment by ≥50% SPD in 57%. The ORR (95% CI)
was 56% (43-67; P<0.001), including 10 complete responses (CR) and 30
partial responses. Kaplan-Meier (KM) - estimated median (range) time to
response was 2.6 (1.6-11.0) mo, median response duration was 11 mo (27
mo in patients with CR), and progression-free survival was 11 mo, substan-
tially longer vs the last regimen. Median overall survival (OS) was not
reached; KM-estimated OS at 1, 1.5, and 2 y was 87%, 74%, and 68%. The
most common AEs (any/grade ≥3,%) were diarrhea (51/14), cough (32/0),
pyrexia (29/4), fatigue (28/0), and nausea (28/3). Rates of grade ≥3 transam-
inase elevation, pneumonitis, neutropenia, anemia, and thrombocytopenia
were 14%, 4%, 22%, 3%, and 6%.
Summary and Conclusions: Idelalisib demonstrated rapid, durable responses
that were substantially longer than those with the previous regimen with accept-
able safety in highly refractory, relapsed FL patients with limited treatment options.
Supported by Gilead Sciences.
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IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN
PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM’S
MACROGLOBULINEMIA (WM)
S. Coutre1,* J. Leonard2, C. Flowers3, A. Davies4, W. Jurczak5, J. Byrd6,
S. Spurgeon7, S. Peterman8, L. Holes8, Y. Cho8, B. Sorenson8, W. Godfrey8,
A. Gopal9
1Stanford University Medical Center, Stanford, 2Weill Cornell Medical Center,
New York, 3Winship Cancer Institute at the Emory University School of Medi-
cine, Atlanta, United States, 4Southampton General Hospital, Southampton,
United Kingdom, 5Malopolskie Centrum Medyczne S.C., Krakow, Poland, 6Ohio
State University Comprehensive Cancer Center, Columbus, 7Oregon Health &
Science University, Portland, 8Gilead Sciences, Foster City, 9University of
Washington School of Medicine, Seattle, United States
Background: Idelalisib (Zydelig), a selective oral inhibitor of PI3Kδ, demon-
strated considerable anti-tumor activity in patients with relapsed/refractory iNHL
in phase 1 (Flinn, 2014; Study 02) and refractory iNHL in phase 2 (Gopal, 2014;
Study 09) trials. This analysis evaluates outcomes in the subset with WM.
Aims: To evaluate the combined safety and efficacy of idelalisib monotherapy
in pts with WM in 2 clinical trials.
Methods: Eligible patients (pts) with WM included those with relapsed/refrac-
tory disease (phase 1), or those with disease refractory to both rituximab and
an alkylating agent (phase 2). Idelalisib dosages were 150 mg QD, and 50 mg-
200 mg BID (phase 1), and 150 mg PO BID (phase 2) and were administered
continuously until disease progression. WM response was assessed by IgM
levels and CT imaging (Owen, 2013).
Results: Enrolled pts, (phase 1 N=9; phase 2 N=10), had a median age of 63
and 60 years [range 42-83] and 78% and 80% were male, respectively. Patients
had received a median of 4 prior regimens in both groups. Overall response
rate (ORR) was 5/9 (56%), and 8/10 (80%; Table 1). Median time to minor or
first response was 2 months, and most responses continued to improve over 6
months or longer. Median DOR was 32.8 months (phase 1) and not yet reached
(phase 2). 67% have continued response at 2 years (phase 2). Median PFS is
33.3 months, and 22.1 months, respectively. Interestingly, >3 gram/dL improve-
ments in hemoglobin were noted in 5/9 and 7/10 subjects, respectively, over 3-
6 month timeframe. Grade ≥3 adverse events included increased ALT/AST 5/9,
and 1/10, and diarrhea/colitis 1/9, and 3/10. One G3 ALT elevation and 1 G3
diarrhea resulted in study discontinuation.
Table 1.
Summary and Conclusions: These combined data suggest single-agent ide-
lalisib monotherapy is active in Waldenstrom’s macroglobulinemia. Durable
responses were seen in the majority of subjects. Marked improvements in
hemoglobin level are also associated with response. The safety profile was
acceptable and manageable, with no apparent disease-specific safety signals.
Phase 3 clinical trials of idelalisib with combination therapy are in progress for
pts with iNHL, including WM (NCT00710528, NCT01282424).
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GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINU-
TUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE
ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-
HODGKIN LYMPHOMA
L. Sehn1,* N. Chua2, J. Mayer3, G. Dueck4, M. Trněný5, K. Bouabdallah6,
N. Fowler7, V. Delwail8, O. Press9, G. Salles10, J. Gribben11, A. Lennard 2,
P. Lugtenburg13, N. Franklin14, E. Wassner-Fritsch15, G. Fingerle-Rowson15,
B. Cheson16
1Centre for Lymphoid Cancer, British Columbia Cancer Agency and the Uni-
versity of British Columbia, Vancouver, 2Cross Cancer Institute, University of
Alberta, Edmonton, Canada, 3University Hospital, Brno and Masaryk University,
Brno, Czech Republic, 4BC Cancer Agency, Kelowna, Canada, 5Charles Uni-
versity, General Hospital, Prague, Czech Republic, 6CHU Haut-Leveque, Pes-
sac, France, 7MD Anderson Cancer Center, University of Texas, Houston, Unit-
ed States, 8University Hospital, INSERM, Poitiers, France, 9Fred Hutchinson
Cancer Research Center, Seattle, United States, 10Hospices Civils de Lyon,
Pierre Bénite, France, 11Barts Cancer Institute, Queen Mary University of Lon-
don, London, 12Northern Institute for Cancer Research, Newcastle University,
Newcastle upon Tyne, United Kingdom, 13Erasmus MC Cancer Institute, Rot-
terdam, Netherlands, 14F. Hoffmann-La Roche Ltd, Welwyn Garden City, United
Kingdom, 15F. Hoffmann-La Roche Ltd, Basel, Switzerland, 16Georgetown Uni-
versity Hospital, Washington DC, United States
New Information: These data have been submitted to ASCO and ICML. The
EHA submission contains additional data describing NHL subtypes and median
duration of maintenance therapy, plus a PFS curve.
Background: Treatment options are limited and outcomes poor for patients with
rituximab-refractory (Rit-ref) indolent non-Hodgkin lymphoma (iNHL). Bendamus-
tine (B) has shown a median progression-free survival (PFS) outcome of 9 months
and response duration of 10 months in Phase II trials in Rit-ref iNHL. Obinu-
tuzumab (GA101/Gazyva [G]) is a glycoengineered type II anti-CD20 antibody
with activity and an acceptable safety profile in Rit-ref iNHL shown in Phase I/II
studies; obinutuzumab is not currently licensed in NHL. Preclinical studies have
shown that combining G and B increases their activity; thus, this combination
(GB) has potential for improved efficacy in comparison with B alone.
Aims: To evaluate efficacy and safety of GB versus B alone in patients with
Rit-ref iNHL.
Methods: GADOLIN (NCT01059630) is a randomized, open-label Phase III study
in patients with CD20-positive Rit-ref iNHL. In the control (B) arm, patients
received single-agent therapy with B 120mg/m2 (days 1 and 2, cycles 1-6); in the
test (GB) arm patients received B 90mg/m2 (days 1 and 2, cycles 1-6) in combi-
nation with G 1000mg (days 1, 8, and 15 of cycle 1 and day 1 of cycles 2-6) for
up to six 28-day cycles. All patients gave informed consent. Non-progressing
patients in the GB arm received further G monotherapy every 2 months for up to
2 years. The primary endpoint was PFS assessed by an independent radiology
facility (IRF), with 80% power to detect a 43% improvement in median PFS.
Results: At a protocol-specified interim analysis, 396 patients were randomized
to receive B (n=202 [198 were treated]) or GB (n=194). On February 4, 2015,
the IDMC recommended to unblind the study and release the data to the sci-
entific community as the primary endpoint (PFS) had been met. Baseline char-
acteristics were balanced between the treatment arms and follicular lymphoma
was the most common iNHL subtype (82.2% B vs 79.9% GB). The median age
was 63 yrs and patients had received a median of two prior therapies. The
median observation time was 20 months for B and 22 months for GB. IRF-
assessed median PFS was 14.9 months for B and not reached (NR) for GB
(hazard ratio [HR] 0.55, 95% confidence interval [CI]: 0.4-0.74; p=0.00011)
(Figure 1).
Figure 1. IRF-assessed median PFS in the GADOLIN study.
The median investigator-assessed PFS was 14 months for B and 29 months
for GB (HR 0.52, 95% CI: 0.39-0.70; p<0.0001). There were no significant dif-
ferences in IRF-assessed overall response rate (63.0% B vs 69.1% GB) or
complete response (12.2% B vs 11.2% GB) at the end of induction, in IRF-
assessed best overall response up to 12 months from the start of treatment
(76.6% B vs 78.6% GB), or in preliminary overall survival (OS; median OS NR
in either arm). The median duration of post-induction G monotherapy was 10.8
months, 74% of patients received at least one dose of G and 25% received all
12 doses. In the treatment period, there were fewer Grade ≥3 adverse events
with B than with GB (62.1% B vs 68.0% GB), notably neutropenia (26.3% B vs
33.0% GB) and infusion-related reactions (3.5% B vs 8.8% GB), but more
Grade ≥3 thrombocytopenia (16.2% B vs 10.8% GB), anemia (10.1% B vs
7.7% GB) and pneumonia (5.6% B vs 2.6% GB).
Summary and Conclusions: G combined with B (90 mg/m2) followed by G
maintenance significantly improved PFS vs B alone (120 mg/m2) in Rit-ref iNHL.
The clinically meaningful PFS improvement with GB is the first randomized evi-
dence of benefit for a novel anti-CD20 antibody in Rit-ref iNHL.
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RECURRENT TP53 ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLAS-
TIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
J. Hoell1,* S. Ginzel1,2, C. Eckert3, M. Gombert1, U. Fischer1, M. Stanulla4,
M. Schrappe4, U. zur Stadt5, P. Bader6, J. Alten4, B. Strahm7, A. Moericke8,
G. Escherich9, A. von Stackelberg3, C. Peters10, A. Borkhardt1, R. Meisel1
1Department of Pediatric Oncology, Heinrich Heine University Duesseldorf,
Duesseldorf, 2Department of Computer Science, Bonn-Rhine-Sieg University
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Charité University Hospital, Berlin, 4Pediatric Hematology and Oncology, Han-
nover Medical School, Hannover, 5Center for Diagnostic, University Medical
Center Hamburg Eppendorf, Hamburg, 6University Hospital for Children and
Adolescents, Frankfurt/Main, 7Pediatric Hematology and Oncology, University
Medical Center, Freiburg, 8Department of Pediatrics, University Medical Center
Schleswig-Holstein, Kiel Campus, Kiel, 9Clinic of Pediatric Hematology and
Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,
10St Anna Children’s Hospital, Vienna, Austria
Background: Survival rates of many childhood malignancies at relapse -includ-
ing patients relapsing with acute lymphoblastic leukemia (ALL) post allogeneic
hematopoietic stem cell transplantation (allo-SCT)- remain very poor. These
patient groups are the focus of the German-wide INdividualized therapy FOr
Relapsed Malignancies in childhood (INFORM) initiative. Our group is focusing
on post allo-SCT relapses since they exhibit a dismal prognosis despite various
therapeutic efforts.
Aims: Since ALL relapses post allo-SCT escape both chemotherapeutic and
immunologic therapies, they are assumed to display other genetic alterations com-
pared to ALL relapses following conventional chemotherapy. The aim of our present
study therefore is to identify the landscape of genetic alterations of ALL relapses
post allo-SCT by whole-exome sequencing (WES). This will result in a better under-
standing of the pathobiology of these specific ALL cases and in more personalized
treatment strategies through the identification of druggable targets. Achieving remis-
sion prior to secondary allo-SCT represents the primary clinical aim.
Methods: WES of germline and tumor DNA was performed on a HiSeq 2500 (Illu-
mina). Obtained sequence reads were aligned to the human reference genome.
Resulting variation calls were annotated by Variant Effect Predictor and imported
into an in-house MySQL database. MuTect and VarScan2 were employed for iden-
tification of somatic nucleotide variations (SNVs) of each oncogenome.
Results: To address the genetic landscape of relapsed ALL following both
chemotherapeutic and immunologic therapy, we sequenced five samples per
patient: initial leukemia, first remission, first relapse, remission post allo-SCT,
and relapse post allo-SCT. Since the latter generally occur in a situation of
hematopoietic chimerism, it is important to have two genetic germline back-
grounds (recipient=patient in first remission, stem cell donor=remission post
allo-SCT) available subtracted to uncover those mutations exclusively defining
the relapse post allo-SCT. To allow comparative analysis, we defined the fol-
lowing three “oncogenomes” (OGs): OG1 (initial leukemia), OG2 (first relapse),
OG3 (relapse post allo-SCT). We report the results of the first 5 patients of our
study. Patient age at initial diagnosis was 4-10 years (4x high, 1x medium risk;
3x B-, 2x T-ALL). Time from relapse diagnosis to allo-SCT (4x matched donor,
1x matched sibling donor) ranged from 3-5,5 months, relapse following allo-
SCT occurred between 3-7 months, all patients died 1-4 months thereafter.
Median numbers of leukemia-specific SNVs in OG1-3 were 25, 42 and 69,
respectively. More specifically, we identified 17 recurrently mutated genes pres-
ent in OG3s of ≥2 patients (e.g. NOTCH1, TOP2A, WNT2). Of these, 9 were
OG3 specific. Most notably, TP53 was mutated in 4/5 patients. One patient
carried a TP53 germline mutation; 3 had novel TP53 mutations only present in
their OG3s. Moreover, leukemic blasts showed plasticity concerning the muta-
tional status of the nucleoside exporter NT5C2. Activating mutations in this
gene were previously shown to drive chemotherapy resistance in relapsed
ALL. We found a total of 3 SNVs (1 known) in NT5C2 in the OG2s of 2/5 of our
patients, but these disappeared again in the OG3s once selection pressure of
maintenance chemotherapy employing nucleoside analogues had been with-
drawn.
Summary and Conclusions: Comprehensive genetic analysis of the first 5 chil-
dren with ALL relapsing post allo-SCT has shown leukemic cell plasticity (loss of
acquired NT5C2 mutations) as well as identified several recurrent genetic alter-
ations (e.g. NOTCH1, TOP2A, WNT2), most notably affecting TP53. Moreover,
we have successfully established a bioinformatic analysis pipeline addressing the
…two germlines” challenge in our post allo-SCT patient cohort. 
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MESENCHYMAL STROMAL CELLS STIMULATE PROLIFERATION AND
CYTOKINE PRODUCTION OF GROUP 3 INNATE LYMPHOID CELLS
M. Munneke1,* A. Cornelissen2, S. Omar3, M. Spruit3, J. Bernink3, M. Kleijer2,
H. Spits3, C. Voermans2, M. Hazenberg1
1Dept. of Hematology, Academic Medical Center, 2Dept. of Hematopoiesis,
Sanquin Research and Landsteiner Laboratory, 3Dept. of Cell Biology and His-
tology, Academic Medical Center, Amsterdam, Netherlands
Background: Graft-versus-host disease (GvHD) remains a challenging com-
plication after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Transplantation of mesenchymal stromal cells (MSCs) is a frequently used
secondary line of treatment for patients with steroid-refractory GvHD. The ben-
eficial effects of MSCs in this context are mainly ascribed to their ability to mod-
ulate inflammation by inhibiting proliferation of (alloreactive) T cells. In addition
MSCs might enhance tissue repair activities of other cells. We previously report-
ed on the association between the activation status of a novel family of lym-
phocytes, called innate lymphoid cells (ILCs), and a reduced susceptibility to
GvHD. Activated (CD69+) ILC3s expressed the gut-homing marker α4β7 and
represent potent producers of the tissue-protective interleukin (IL)-22.
Aims: To test the hypothesis that MSCs may potentiate the tissue protective
effects of ILC3s.
Methods: MSCs were harvested and expanded from bone marrow obtained
from otherwise healthy human adults undergoing cardiac surgery with median
sternotomy. ILC3s were freshly isolated from tonsils obtained from pediatric
tonsillectomies. Co-cultures were performed in the presence of IL-2, for 5 days
in a 1:1 ratio after which the cells were analyzed for proliferation (using a dye
dilution assay) and cytokine production (by means of qPCR and intracellular
cytokine stain).
Results: We observed an increased proliferation of ILC3s in the presence of
MSCs (+/- pre-incubation with IFN-γ) as compared to a condition without MSCs
(P=0.002). ILCs express CD127, the α-chain of the IL-7 receptor, which was
downregulated upon co-culture with IL-7 producing MSCs. When IL-7 was
blocked with neutralizing antibodies proliferation was significantly reduced. As
compared to NK cells, ILC3s were found to have a low expression of genes
encoding inhibitory cytokine receptors, such as the receptors for IL-10 and
prostaglandin E2. Co-culture with MSCs resulted in an enhanced production
of IL-22 (P=<0.0001) by NKp44+ ILC3s. Also NKp44- ILC3s, which ex vivo
express only low levels of IL-22, responded with a significantly enhanced IL-
22 production. After co-culture with ILC3s, MSCs showed expression of the
integrins vascular cell adhesion molecule 1 (VCAM1) and intracellular adhesion
molecule 1 (ICAM1).
Summary and Conclusions: IL-22-producing NKp44+ ILC3s represent the
dominant ILC subset in the intestinal lamina propria and have important func-
tions in mucosal homeostasis and immunity. IL-22 directly induces survival and
proliferation of epithelial cells and stimulates secretion of antimicrobial peptides.
Here we propose a mechanism for how MSCs may contribute to the control of
GvHD, by promoting expansion and IL-22 production of tissue-restoring ILC3s.
That MSCs and ILCs could serve as allies in combating GvHD is emphasized
by the induced expression of the integrin VCAM1, a ligand for α4β7, which we
observed to be expressed on circulating ILCs before allo-HSCT. Further studies
are needed to address the in vivo implications of these findings.
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ENDOTHELIAL CELL MICROPARTICLES-DELIVERY MIR-155 PROMOTES
THE DEVELOPMENT OF AGVHD BY MODULATING T CELLS
Q. Wu1,*H. Shen1, M. Hong1, L. Xia1
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China
Background: Elevation of endothelial cell microparticles (EMPs) has been
proved in acute graft-versus-host disease (aGVHD) patients after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) and recently found asso-
ciated with the onset of aGVHD. However, how EMPs regulate T cells function
and lead to the pathogenesis of aGVHD is rarely known.
Aims: We aimed to confirm that EMPs produced by injuried endothelial cells
can regulate T cells function through carrying microRNA-155 (miR-155) in
process of aGVHD by series of in vivo and in vitro experiments.
Methods: We first compared dynamic change of miR-155 of MPs in plasma of
aGVHD patients, pre-aGVHD patients (+7d, +14d, +21d and +28d after allo-
HSCT) and non-aGVHD patients using qRT-PCR. We then compared the
expression of miR-155 in EMPs derived from TNF-α-stimulated endothelial cell
line EA.hy926 cells and untreated EA.hy926 cells. Nextly, we transferred miR-
155 agomir into EA.hy926 cells, collected EA.hy926 cells derived EMPs and
co-cultured EMPs with T cells. Then we observed the fusion of EMPs and T
cells by confocal laser-scanning microscope and measured the change of miR-
155 level in T cells. Simultaneously, ELISA was used to detect secreted TNF-
α, IL-4, IL-10 of T cells, Annexin V-FITC/PI double-labeled flow cytometry was
used to detect apoptosis and Western blot was used to determine the cas-
pase-3 and bcl-2 expressions of T cells. Survival rates of mice were calculated
and scored clinical signs of aGVHD were determined in the C57BL/6 (H-2b+)
donor to BALB/c (H-2d+) recipient MHC-mismatched aGVHDmodel, then miR-
155 in MPs and in MPs-depleted plasma were examined in aGVHD mice.
Results: In this study, we found miR-155 level in MPs from peripheral blood
was significantly higher in pre-aGVHD patients (+7d, +14d, +21d and +28d
after allo-HSCT) compared with non-aGVHD patients and slightly decreased
at aGVHD point. Similarly, in aGVHD mice, miR-155 in plasma MPs was sig-
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nificantly higher on +3d, +7d, +14d after allo-BMT while slightly lower at aGVHD
point. In vitro, TNF-α can induce EA.hy926 cells damage to release EMPs rich
of miR-155, which was further demonstrated to be delivered into T cells and
resulted in the up-regulation of miR-155 in T cells and the activation of T cells
including decreased apoptosis and the transition from Th2 to Th1.This result
was confirmed by the observation that EMPs derived from TNF-α and
antagomir155 co-treated EA.hy926 cells increased caspase-3 expression and
decreased bcl-2 expression in T cells.
Summary and Conclusions: Altogether, our data suggest that EMPs-delivery
miR-155 is involved in the development of aGVHD through modulating T cell
function. MiR-155 in EMPs might serve as an early predictive index as well as
an early intervention target of aGVHD.
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PRESENCE OF KIR2DS1 RECEPTOR IN DONORS OF ALLOGENEIC
HEMATOPOIETIC TRANSPLANTATION DUE TO MYELOID MALIGNAN-
CIES IMPROVES OVERALL SURVIVAL IN RECIPIENTS WITH HLA-C2
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Background: Recognition of HLA-C2 antigen of recipient cells by the activating
killer immunoglobulin like receptor (KIR), KIR2DS1 receptor on donor natural
killer (NK) cell may lead to increased graft versus leukemia effect in patients
with myeloid malignancies treated by allogeneic hematopoietic transplantation
(HSCT) influencing disease free (DFS) and overall survival (OS).
Aims: The goal of the present study was to examine the effect of donor KIR
status in conjunction with recipient HLA-C type on the outcome of HSCT.
Methods: In our cohort, 249 consecutive adult patients, who underwent first
allogeneic HSCT (HLA-identical sibling n=117 and unrelated donor n=132) for
a malignant myeloid condition, namely acute myeloid leukemia (AML, n=157),
bi-phenotypic acute leukemia (n=10), chronic myeloid leukemia (n=24), myelo-
proliferative neoplasm (n=23) and myelodysplastic syndrome (n=35) at a single
center between 2007 and 2013, were retrospectively analyzed. Median follow-
up was 36 months (range 6-92 months). Genotyping for the presence of KIR
genes was performed by an allele specific multiplex PCR using archived DNA
samples. Low resolution HLA-C typing was performed by sequence specific
oligonucleotides as part of the routine work-up prior to HSCT.
Results: The frequency of the donor KIR2DS1 gene in the entire cohort was
36.5% (91/249) while the distribution of HLA-C1/C2 groups was as follows:
HLA-C1: 36.5% (91/249), HLA-C1/C2: 47.4% (118/249), HLA-C2: 16.1%
(40/249). There was no difference in DFS or OS between patient subgroups
stratified by the presence or absence of KIR2DS1 or HLA-C1/C2. As expected,
patients with sibling donors showed significantly better DFS and OS. Further
analyzes were performed exclusively focusing on the patient subgroup with
KIR2DS1 positive donors (n=91). Within this subgroup, we found improved
DFS and OS for patients carrying at least one copy of the HLA-C2 antigen (i.e.
HLA-C2 homozygous and heterozygous patients combined, n=54) compared
to those homozygous for the HLA-C1 antigen (n=47). DFS at 3 years for HLA-
C2 carriers was 55.9% compared to HLA-C1 homozygotes with 39.4% (p=0.14).
Similar comparison for OS showed 62.3% for the former and 42.3% for the
latter subgroup (p=0.068). Upon performing a further stratification, we per-
formed an identical comparison exclusively for the AML patient subgroup (HLA-
C2 carriers: n=36 and HLA-C1 homozygous: n=22) indicating a 3 years DFS
of 60.4% for HLA-C2 carriers compared to 45.1% for HLA-C1 homozygotes
(p=0.19) and a 3 years OS of 71.7% for the former and 45.7% for the latter
(p=0.047). In spite of the impressive differences of the above survival rates,
due to the low case numbers, only OS among AML patients with KIR2DS1 and
HLA-C2 combination was significantly better. Performing a multivariate analyzes
by Cox regression among AML-patients considering age, sex, the type of con-
ditioning (myeloablative or reduced intensity conditioning) and type of donor
as covariates, the association of a favorable OS with the simultaneous presence
of KIR2DS1 and HLA-C2 remained significant (hazard ratio=0.422, 95% con-
fidence interval: 0.179-0.995, p=0.049).
Summary and Conclusions: Our results indicate that the combination of donor
KIR2DS1 and recipient HLA-C2 may be a favorable genetic constellation in
allogeneic HSCT for AML with respect to overall survival.
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ENDOTHELIAL MICROPARTICLE IS INVOLVED IN THE DEVELOPMENT
OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
D. Nie1, Q. Wu1, L. Xia1, M. Hong1,*
1Hematology, Union Hospital, Tongji Medical College, Huazhong University of
Science and Technology, wuhan, China
Background: Endothelial microparticles (EMPs) are membrane-bound sub-
cellular microparticles produced by endothelial cells in response to activation
or apoptosis. Accumulating evidences have indicated that endothelial injury
and EMPs release are initial steps in the development of acute graft-versus-
host-disease (aGVHD) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT). However, the roles of EMPs in the feedback of endothelial injury
and the development of aGVHD are poorly understood.
Aims: To investigate the role of EMPs in the development of aGVHD through
evaluating their effects on endothelial cell survival and function.
Methods: Dynamic change of plasma EMPs was compared by flow cytometry
in aGVHD patients and non-aGVHD patients (7, 14, 21 and 28 days after trans-
plantation), aGVHD occurring point, and normal controls. Meanwhile, plasma
TNF-αwas measured by ELISA among aforementioned groups. Primary human
umbilical vein endothelial cells (HUVEC)and human umbilical vein endothelial
cell line EA.hy926 were both treated with different concentrations of TNF-αto
induce EMPs release. The level of EMPs in the supernatant was detected by
confocal laser scanning microscopy and FCM with PE-labeled CD62E and
FITC-labeled CD31. After treating EA.hy926 cells with 20μg/ml EMPs for 24h,
we evaluated their apoptosis rates by Annexin V-FITC/PI double-labeled flow
cytometry, intracellular nitric oxide (NO) production by Nitrate reduction enzy-
matic method, Fas and eNOS mRNA by Real-time PCR, and protein level of
Fas, eNOS and phosphorylation-eNOS by Western-blot. Moreover, the angio-
genic activity of EA.hy926 cells was measured by in vitro Matrigel tubulogenesis
assay.
Results: The level of both serum EMPs and TNF-αin aGVHD group showed
an increased tendency within 28d after allo-HSCT. Serum EMPs peaked at day
21, while TNF-αpeaked before EMPs. Moreover, the number of EMPs at day
21 was significantly higher in aGVHD group compared with non-aGVHD group
(13819±1513 vs 2208±363/μL,P<0.05) at day 21. Significantly higher was found
in the patients in aGVHD point group in comparison to the other groups includ-
ing control groups, pre-aGVHD group and non-aGVHD group. In vitro, TNF-
αwas found to stimulate endothelial cells to release EMPs in a dose-dependant
manner. After treated with 100ng/ml TNF-α, the levels of CD62E+EMPs
increased significantly in both primary HUVEC and endothelial cell lines
(HUVEC 27.7±0.54 vs 5.47±0.17; EA.hy926 36.5±0.63 vs 11.9±0.28%, P
<0.05). In addition, the ratio of CD62E/CD31 of EMPs indicating that TNF-αin-
duced activated EMPs release instead of apoptosis EMPs. After treated with
EMPs, EA.hy926 cells exhibited a significant increase of cell apoptosis rate
(48.9±3.2% vs 7.8±1.2%, P <0.05), accompanied with an increase of Fas
mRNA and protein expression. Meanwhile, they were found to produce less
NO (77.54±4.52 μmol/gprot vs 30.85±3.20μmol/gprot, P <0.05) with decreased
eNOS and phosphorylation-eNOS expression after treatment. And the tubule
formation function was found weakened because the endothelial tubule length
in EMPs-treated group were significantly shorter than that of control group (P
<0.05).
Summary and Conclusions: At the onset of aGVHD, TNF-αinduced the dam-
age of endothelial cells to release activated EMPs, which promote the devel-
opment of aGVHD through inducing the apoptosis of endothelial cells and impair
endothelial function.
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SIMPLE, EFFICIENT, AND SAFE PROCESSING OF FROZEN-THAWED
UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS APPLIED
FOR THE TREATMENT OF GVHD
T. Nagamura-Inoue1,* Y. Mori1, A. Takahashi1, T. Shimazu1, H. Tsunoda1,
A. Tojo1
1Department of Cell Processing and Transfusion, Research Hospital,The Insti-
tute of Medical Science, The University of Tokyo, Tokyo, Japan
Background: Human umbilical cord (UC) is a rich source for mesenchymal
stromal cells (MSCs), and UC-MSCs have been reported to have multilineage
potential including neural differentiation. In recent reports, MSCs have the ability
to migrate to inflammatory tissues and suppress adverse immune reactions.
BM-derived MSCs have been already applied for the patients with acute graft
versus host disease (aGVHD) with promising efficacy. To avoid the potential
risk of BM harvest from the donor, we intended to use umbilical cord (UC) as
an alternative source for MSCs, especially for the treatment of GVHD in clinic.
There were several problems in the processing of UC to be resolved. Here we
introduced the new device in the explant method and found a suitable cryop-
reservation method of UC for clinical use. 
Aims: The object of this study was to explorer an efficient and safe processing
and quality evaluation methods for UC-MSCs GMP-grade banking for clinical
use. 
Methods: UC was collected after informed consent from the mother. MSCs
(P1) were isolated from minimal size of fresh UC by an improved explants
method using Cellamigo® to protect the fragments floating during the culture.
The culture medium was refreshed every 3 days and the adherent cells and
tissue fragments were harvested using trypsin. P1 MSCs were submitted for
the quality control test including infection tests, chromosomal analysis, flowcy-
tometry analysis and mixed lymphocyte reaction (MLR) assay to evaluate the
immunosuppressive potency of the UC-MSCs. The remaining UC was cut in
cross-section and incised longitudinally, immersed in the cryoprotectant Stem-
Cellbanker® and cryopreserved. After confirmation of the unit quality including
6-month baby’s health, we thaw the UC and isolate MSCs by the above method
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and continue to culture for further expansion in 5-stack Cellstack® chambers
by P3. MLR was performed on UC-MSCs using CFSE-staining method, as in
vitro functional assay. CFSE-labeled responder cells were analyzed by FACS.
In vivo assay, we injected UC-MSCs into NOG mice with xenogeneic GVHD
triggered by human peripheral mononuclear cells (MNC).
Results: The number of UC-MSCs isolated from 1 g of UC using the explant
method with Cellamigo® was 2.9±1.4×106/g, which was significantly higher
than that obtained without Cellamigo® (0.66±0.53×106/g) (n=6, P <0.01) when
cells reached 80-90% confluence. In addition, the processing time and incu-
bation time required to reach 80-90% confluence were reduced in the improved
explant method compared to the conventional method. Next, we compared the
cryoprotectants to find a suitable cryopreservation method of UC tissue for
clinical use. The highest yield of cells was obtained from frozen-thawed UC
with serum- and xeno-free cryoprotectant, Stem-Cellbanker®, when compared
with others. We obtained 1.5±0.96 MSCs from of frozen-thawed UC with Stem-
Cellbanker® compared to those from fresh UC (n=4). UC-MSCs (P1) were fur-
ther expanded in a large scale culture until P3. The expected final products
showed more than 1×109 /g of original UC tissue, resulting in 30×109 per whole
UC at least. The UC-MSCs showed spindle-shaped plastic adherent with pos-
itive CD105, CD73, CD90, CD44 and negative for CD45, CD34, CD14, CD19,
and HLA -DR. They also have the ability of differentiation into adipocytes, chon-
droblasts in vitro, although osteoblasts differentiation was not enough. In MLR,
3rd party-derived UC-MSCs efficiently inhibited the responder T cells, triggered
by allogeneic dendritic cells (DC). Furthermore, we found the xeno-GVHD mice
treated with UC-MSCs showed a longer survival compared to the control.
Summary and Conclusions: We improved the explant method using stainless
mesh resulting in the efficient and safe processing for isolation of MSCs from
UC and developed the simple and safe cryopreservation method of UC tissue
for clinical use. We demonstrated UC-MSCs have the immunosuppressive
effect on the activated T cells in allogeneic 3rd party MLR setting. Conclusively,
UC-MSCs may be a feasible alternative non-invasive source of BM-MSCs for
GVHD treatment and can be considered for the prompt clinical applications.
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THE IMPACT OF NFAT INHIBITION ON NEUTROPHIL EFFECTOR FUNC-
TIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
K. Plein1, D. Teschner1,* C. Michel1, P. Stein2, E.M. Wagner1, M. Theobald1,
H. Schild3, M. Radsak1,3
1Department of Hematology, Medical Oncology, & Pneumology, 2Center for
Thrombosis and Hemostasis, 3Institute of Immunology, University Medical Cen-
ter of the Johannes Gutenberg-University Mainz, Mainz, Germany
Background: Patients after allogeneic hematopoietic stem cell transplantation
(HSCT) are threatened by opportunistic infection like invasive fungal diseases
(IFD) partly due to immunosuppressive medication e.g. by calcineurin inhibitors
like cyclosporine A (CsA). The nuclear factor of activated T cells (NFAT) is
known as an important transcription factor downstream of calcineurin in the
adaptive immune systems, but it also seems to play an important role in innate
immune response by polymorphonuclear neutrophils (PMN), as indicated by
recent data in rodent models.
Aims: The aim of our work is to elucidate the relevance of NFAT-dependent
signals in PMN and the significance for antifungal immunity in human.
Methods: Firstly, isolated PMN from healthy donors were analyzed in vitro in
absence or presence of CsA. In detail, we examined phagocytosis, L-selectin
shedding, degranulation, generation of reactive oxygen species (ROS) and
release of inflammatory mediators like IL-8 and TNF-α. After activation with
lipopolysaccharide (LPS) and zymosan, phagocytosis, degranulation and L-
selectin shedding were measured by flow cytometry using polychromatic
microspheres and surface markers (CD11b, CD62L, CD66b). In addition, gen-
eration of ROS was analyzed by dichlorofluorescein assay (DCF), whereas
activation-induced release of inflammatory mediators was measured by
enzyme-linked immunosorbent assay (ELISA) and intracellular flow cytometry.
Furthermore, migratory response of PMN was examined in a transwell migra-
tion assay. Secondly, blood samples of patients after HSCT under continuous
CsA medication (n=17) and healthy volunteer donors (n=8) were analyzed ex
vivo at two different time points after allogeneic HSCT (day 25-35 and 125-
135) concerning their PMN effector functions as described above.
Results: CsA had no significant influence on expression of activation markers
and shedding of CD62L in vitro. Moreover, no substantial influence of CsA on
generation of ROS was detected compared to untreated controls. Along with
that, activation-induced synthesis of IL-8 was not influenced in presence of
CsA. However, CsA rather enhanced phagocytosis of PMN (83.5% +/- 1.7
(CsA) vs 71.0 +/- 1.5 (control), after stimulation with LPS), whereas their migra-
tory capabilities were reduced (30.2% +/- 10.8 vs 40.1 +/- 0.9, spontaneous;
114.0% +/- 2.3 vs 79.8 +/- 0.6, yeast activated). Regarding the ex vivo analysis
of HSCT patient and healthy donor blood samples, production of ROS was
slightly decreased under CsA therapy (31.7% +/- 4.5 vs 41.4 +/- 7.0, zymosan).
In contrast, CsA medication showed a stimulating effect on PMN phagocytosis
which is in line with our in vitro data (54.2% +/- 4.1 vs 43.8 +/- 1.5, LPS), as
well as on PMN activation (CD11b: 11897 MFI +/- 983 vs 9321 +/- 1279, LPS)
and degranulation (CD66b: 22328 MFI +/- 2365 vs 9668 +/- 1359, LPS), where-
as L-selectin shedding was unaffected. Furthermore, an increased production
of IL-8 and TNF-α was detectable (IL-8: 18.7% +/- 4.3 vs 5.5 +/- 2.6; TNF-α:
20.9% +/- 3.4 vs 4.0 +/- 2.0, both zymosan).
Summary and Conclusions: We found an increased phagocytic activity in
vitro and ex vivo in human PMN upon NFAT/calcineurin inhibition, whereas
other effector mechanisms were unaffected or rather decreased in vitro. In
addition, HSCT patients under CsA treatment displayed enhanced degranula-
tion and inflammatory mediators production in PMN ex vivo. It is currently
unclear whether these findings are clinically relevant for the innate immune
response after HSCT and further studies are needed to distinguish this obvi-
ously multidimensional interaction of NFAT inhibition and innate immune
response.
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INHIBITION OF TRANSFORMING GROWTH FACTOR ΒETA-ACTIVATED
KINASE 1 SUPPRESSES ALLOREACTIVITY AND IMPROVES SURVIVAL
IN A MURINE MARROW TRANSPLANTATION MODEL
A. Kobayashi1,* S. Kobayashi1, Y. Osawa1, T. Maekawa1, T. Yamamura1,
J. Watanabe1, K. Miyai2, H. Tsuda2, K. Sato1, F. Kimura1
1Division of Hematology, Department of Internal Medicine, 2Department of
Basic Pathology, National Defense Medical College, Tokorozawa, Saitama,
Japan
Background: Acute graft-versus-host disease (GVHD) is a major complication
of allogeneic hematopoietic cell transplantation (HCT). Recently, much attention
has been given to the role of innate immune responses in its pathogenesis.
Host tissue damaged by HCT conditioning releases molecules that mediate
danger signals, which bind to pattern recognition receptors on antigen-pre-
senting cells, such as Toll-like receptors (TLRs), activate the innate immune
response, and induce the upregulation of cytokines, leading to the amplification
and maintenance of GVHD. The monocyte/macrophage is an important cell
component in the innate immunity system; IL-32 augments the GVH reaction
in contrast to the inhibitory effect of macrophage colony-stimulating factor (M-
CSF). We analyzed the gene expression profiles of IL-32 and M-CSF-induced
macrophages, and monocytes from HCT patients, and focused on transforming
growth factor β-activated kinase 1 (TAK1), which plays a key regulatory role in
various cytokine-mediated innate immunity signal transduction cascades,
including the downstream signaling of TLRs.
Aims: The aim of this study was to clarify the roles of TAK1 on GVHD patho-
genesis using TAK1 inhibitor in vitro and in an allogeneic mouse HCT model.
Methods: The present study was performed according to a protocol approved
by the ethics committee of our institute, and informed consent was obtained
from all the patients and healthy volunteers participating in the study. Tran-
scriptional profiles of cytokine-induced macrophages from healthy volunteers
and monocytes from post-HCT patients, as substitute for tissue macrophages
(N=9; seven experienced GVHD, while two did not), were examined by microar-
ray analysis and Gene set enrichment analysis (GSEA). Allogeneic mixed cell
reactions (alloMCRs) were performed in the presence of 5Z-7-Oxozeaenol
(OZ), a selective inhibitor of TAK1, or not. The impact of TAK1 inhibition by OZ
on the production of the pro-inflammatory cytokines by LPS-stimulated mono-
cytes was evaluated using a human proteome profiler array. In the MHC-mis-
matched mouse HCT model (donor, B6; recipient, BALB⁄c), recipient mice were
given 5 μg of OZ from day 12 to day 25 to validate the effect of TAK1 inhibition
on survival and GVHD severity.
Results: Gene expression signatures of M-CSF or IL-32 induced macrophages
revealed difference in the TLR signaling pathway. Although the number of ana-
lyzed post-HCT patients was insufficient to make a definite clustering of mono-
cyte gene expression, there were certain changes in the expression of TLR
signaling molecules, depending on GVHD, and particularly the expression level
of TAK1, a key molecule of the pathway, was elevated in monocytes from
GVHD patients, accompanied by upregulation of TNFα, IL-1β, and IL-6. The
TAK1 inhibitor, OZ, suppressed pro-inflammatory cytokine production in LPS-
stimulated monocytes, and reduced lymphocyte proliferation in alloMCRs. OZ
also reduced the donor T-cell response after dendritic cell (DC) stimulation in
both donor DC and recipient DC. Finally, post-conditioning alteration of TAK1
activity significantly improved the survival of recipient mice compared with con-
trols in the MHC-mismatched mouse transplant model (P <0.01) with a reduc-
tion in GVHD scores after day 16 (P <0.01).
Summary and Conclusions: Our findings suggest that TAK1 is a key molecule
in post-transplant innate immune and inflammatory responses, and this could
be a novel therapeutic target in GVHD.
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DISTINCT EXOSOMAL MIRNA EXPRESSION OF LATE ONSET GRAFT-
VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
S. Yoshizawa1,* T. Umezu2, Y. Saitoh1, M. Gotoh1, D. Akahane1, C. Kobayashi2,
J. H. Ohyashiki3, K. Ohyashiki1
1Department of Hematology, 2Department of Molecular Science, 3Institute of
Medical Science, Tokyo Medical University, Tokyo, Japan
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Background: Exosomes, small endosome-derived extracellular vesicles, are
present in various biological fluids, such as plasma. They contain a wide range
of functional proteins, mRNAs, and miRNA, thus have potential in facilitating
molecular diagnosis. A recent study by Xiao et al. demonstrated that specific
plasma miRNA signature could serve as an independent biomarker for the pre-
diction, diagnosis, and prognosis of classic acute GVHD. Unlike classic acute
GVHD, however, molecular mechanism of persistent, recurrent, late onset acute
GVHD has not fully elucidated.
Aims: We therefore set out to determine clinically relevant exosomal miRNAs
in patients developing late onset acute GVHD after HSCT.
Methods: We evaluated blood samples obtained from 10 patients who under-
went HSCT for treatment of hematologic diseases between February 2012 and
November 2013 at our institution. This study consisted of 5 patients with late
onset acute GVHD (gut, n=2, liver, n=2, skin and gut, n=1), and 5 patients with-
out GVHD (control). The diagnosis of acute GVHD was based on clinical symp-
toms or histologically proven by biopsy in the target organs. Patients with typical
manifestations of acute GVHD occurring beyond 100 days after transplantation
were considered as having late onset acute GVHD, according to the new clas-
sification made by NIH consensus criteria. Exosoms were isolated from plasma
using a Total exosome isolation kit for plasma (Life Technologies). To identify
exosomal miRNAs specific for late onset acute GVHD, we then compared exo-
somal miRNA expression between late onset acute GVHD and non-GVHD
using TaqMan miRNA Array (Life Technologies). The validation of the microarray
data was done by qRT-PCR. Expression levels of candidate miRNAs (miRNA-
A, and B) was analyzed sequentially in a subset of late onset acute GVHD
patients. Wilcoxon rank-sum test was used to determine statistical significance
for comparisons between late onset acute GVHD groups and non-GVHD
groups using R software. P values less than 0.05 were considered to indicate
statistically significant differences.
Results: We found that exosomal miRNA are differently expressed in late onset
acute GVHD compared to non-GVHD controls: a subset of miRNAs were sig-
nificantly up-regulated in the exosomes of late onset acute GVHD (p0.005)
when compared with non-GVHD. Accordingly, the predicted target genes of
the miRNA-A and B were obtained from MirTarBase: ERBB2, KLF13, CBFB
for miRNA-A and DCX, RELN, BMI1, FBXW7 for miRNA-B were validated by
luciferase reporter assay in the literature. The Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) Bioinformatics tools provided func-
tions of the target genes for miRNA-A and B linked inflammation, T-cell activa-
tion, and immune system development and nucleotide-binding. Notably, the
expression levels of the miRNA-A and B changed subsequently prior to the
occurrence of clinical manifestations.
Summary and Conclusions: Although the number of patients in the current
study is small, our study indicates that altered expression of certain exosomal
miRNAs may play an important role in the occurrence of GVHD, therefore, may
be helpful for as a potent predictive biomarker for managing patients with GVHD.
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B LYMPHOCYTES ARE IMPORTANT EFFECTOR CELLS IN ANTI-AML
RESPONSES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
M. Gillissen1,2,* E. Yasuda1, S. Levie1, A. Bakker1, M. Kedde1, Y. Claassen1,
C. Huisman2, T. Beaumont1, P. van Helden1, H. Spits1, M. Hazenberg2
1AIMM Therapeutics, 2Academic Medical Center (AMC), Amsterdam, Nether-
lands
Background: Unleashing the tumor-specific immune response by immunother-
apies such as checkpoint inhibitors or allogeneic stem cell transplantation can
result in long lasting tumor regression. It is thought that T cell responses are
responsible for tumor rejection. 
Aims: Here we tested the hypothesis that B cells contribute to tumor regression
following immunotherapy by analysing the tumor-specific antibody repertoire
in patients with acute myeloid leukemia (AML), a high-risk malignancy with a
poor prognosis. These patients received an allogeneic hematopoietic stem cell
transplantation (HSCT) that reset the immune system and led to potent graft
versus leukemia (GvL) responses. 
Methods: We selected three patients who despite the high-risk nature of their
AML remained disease free after allogeneic HSCT. Of these patients we estab-
lished antibody-producing clonal B cell lines following transduction of memory
B cells from peripheral blood with BCL-6 and Bcl-xL and screened those for
producing antibodies specifically binding to surface antigens on AML cell lines
and AML blasts. 
Results: A number of antibodies were identified that recognized various primary
AML blasts isolated from newly diagnosed AML patients, but did not bind to
healthy bone marrow, peripheral blood mononuclear cells or tissues such as
liver, skin and colon. Some of the antibodies induced complement dependent
cytotoxicity. Strikingly, other AML-specific antibodies (about 40% of the reper-
toire) induced direct cell death of cultured AML cell lines and of primary AML
blasts, independent of complement or effector cells. Cytotoxicity of the anti-
bodies was rapid, characterized by swelling and blebbing of the cells and
occurred both at 37oC and 4oC, suggesting activation of a non-apoptotic path-
way. Indeed, target cell death could not be prevented with pan-caspase
inhibitors Z-VAD or Q-VD. These characteristics of cell death fit with killing of
tumor cells through a necrotic pathway like oncosis. A possible target recog-
nized by a number of these antibodies will be discussed. 
Summary and Conclusions: Together, these data indicate that highly potent,
tumor selective antibodies can be elicited following allogeneic HSCT in AML
patients. The direct cytotoxic activities against tumor cells of a proportion of
these antibodies suggest that they contribute to the GvL response. 
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FEMUR TARGET CELL TRANSPLANTATION CAN BE ACHIEVED BY MAG-
NETISM-INDUCED CELL TARGET TRANSPLANTATION (MAGIC-TT) IN
MURINE TRANSPLANTATION MODEL 
H. Huang1,* Y. Ye1, Q. Jiang1, Q. Mai2, C. Yin1, Y. Lu2, J. Wang2, L. Liu2, Y. Zhou1,
X. Sun2, M. Zhang2, J. Qin2, L. Yuan2, Y. Yuan2, Q. Zhang2, J. Sun1, Q. Liu1
1Department of Hematology, Nanfang Hospital, 2Southern Medical University,
Guangzhou, China
Background: Organ target cell transplantation will improve stem cell homing
efficiency, as well as avoiding possible complications of cell diffused distribution.
Here we set up a novel cell transplantation system named Magnetism-induced
cell target transplantation (MagiC-TT). This work was supported by the National
Natural Science Foundation of China (No. 30901367, 31070866), Outstanding
Young Teachers’ foundation of SMU (C1031694).
Aims: To explore the distribution and survival of donor cells transplanted by
MagIC-TT in vivo and ex vivo.
Methods: 1) Magnetized cells: Two kinds of cells were used, C57BL/6 RFP+
mesenchymal stem cells (MSC-RFP) and C57BL/6 GFP+ CD45+ (CD45-GFP)
cells. MSC-RFPs was bought from Cyagen Biosciences Inc, China, and were
magnetized by self-made Au@Fe nano-particle, positive cells were sorted by
MACS column. CD45-GFPs were sorted from C57BL/6 GFP-transgenic mice
bone marrow by MACS anti-CD45 beads and column. 2) Ex vivo study: Both
magnetized MSC-RFPs and CD45-GFPs and their wild type controls were
study of cell morphology, cell proliferation, cell cycle and cell viability, as well
as cells’ migration to magnetism, transwell migration and matrigel migration
assays. 3) In vivo study: To MSCs-RFP study, fifty C57BL/6 female GFP trans-
genic mice were divided into 3 magnetized cell groups and 2 non-magnetized
cell groups, magnetized and wt MSCs were injected into the femur cavity of
the mice. To the CD45-GFP cell study, forty C57BL/6 female mice (4 groups)
were transplanted after 7.5Gy irradiation. At different time points after cells
injection, FACS, bioluminescence, pathologic observation with fluorescence
and confocal microscopy, together with real-time PCR were used to detect GFP
and RFP cells in peripheral blood, bone marrow, liver, spleen, thymus and lung,
etc. Femurs and humeri of recipients were decalcified with self-made semi-
solid decalcification (SSD) to clarify the distribution of donor cells and their rela-
tionships with the microenvironment.
Results: 1) Ex vivo study: There were no differences between magnetized and
non-magnetized MSCs or CD45 cells in cell morphology, cell proliferation, cell
cycle and cell viability. The Fe particles exist within or on the surface of mag-
netized MSCs or CD45 cells observed by electric microscope. Within the mag-
netic field, magnetized cells can migrate through matrigel and transwell mem-
brane much more efficiently, 174±22 vs 2±1 per 200X microscopic vision
(P<0.0001); they also can migrate horizontally towards magnetism in matrigel.
The most interesting is, magnetized MSCs even grow well on the roof of 24-
plate (grows against gravity) in the culture medium. 2) In early hours after trans-
plantation, lots of magnetized RFP+ or GFP+ cells exit within femur and knee
joint in magnetized cells groups while few in the control groups, while many
non-magnetized MSCs and CD45-GFP distributed in the lung while few in mag-
netized cell group. After few days without any magnetism, RFP+ or GFP+ were
observed to migrate to the spleen, kidney, gut and other organs, showing the
slowly release of target-transplanted-cells from femur.3) To the CD45-GFP
study, the blood recovery in MagIC-TT group is much faster than the controls,
especially for the platelet.
Summary and Conclusions: These results demonstrated that femur target
cell transplantation can be achieved by MagIC-TT, which can be widely used
for cell transplantation and cell therapy in the future.
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COMPLEMENT-BINDING DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND
RISK OF PRIMARY GRAFT FAILURE IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
S. Ciurea1,* P. Kongtim1, U. Popat1, F. Aung2, R. Champlin1, K. Cao1
1Stem Cell Transplantation, 2Pathology, The University of Texas MD Anderson
Cancer Center, Houston, United States
Background: Detection of donor-specific anti-HLA antibodies (DSA) has been
associated with graft rejection in all forms of transplantation. The mechanism
by which DSA increase the risk of graft failure remains unclear. 
Aims: We hypothesized that complement-binding DSA are associated with
engraftment failure in hematopoietic stem-cell transplantation.
Methods: We analyzed 122 haploidentical transplant recipients tested
prospectively for DSA. Retrospective C1q testing was done on 22 allosensi-
tized recipients.
Results: Twenty-two of 122 patients (18%) had DSA, 19 of which were females
(86%). Seven patients with DSA (32%) rejected the graft. Median DSA level at
transplant for patients who failed to engraft was 10,055 MFI versus 2,065 MFI
for those who engrafted (p=0.007). Nine patients with DSA were C1q positive
in the initial samples with median DSA level 15,279 MFI (range 1,554-28,615),
compared with 7 C1q negative patients with median DSA level 2,471 MFI (665-
12,254) (p=0.016). Of 9 patients, who tested positive for C1q in the initial sam-
ples, 5 patients remained C1q positive at time of transplant [all with high DSA
levels (median 15,279, range 6,487-22,944)] and experienced engraftment fail-
ure, while 4 patients became C1q negative pre-transplant and all engrafted
the donor cells (p=0.008) (Figure 1). 
Figure 1.
Summary and Conclusions: Patients with high DSA levels (>5,000 MFI) and
complement-binding antibodies (C1q positive) appear to be at much higher
risk of primary graft failure. C1q should be assessed in patients with DSA prior
to hematopoietic stem-cell transplantation. Reduction of DSA to non-comple-
ment binding levels might prevent engraftment failure in hematopoietic stem
cell transplantation.
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DURABLE REMISSIONS AFTER SEQUENTIAL TRANSPLANTATION USING
T-REPLETE NON-MYELOABLATIVE CONDITIONING FOR RELAPSED/
REFRACTORY ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
S. Hassan1,* J. Davies2, M. Smith1, D. Tsitsikas3, H. Oakervee1, S. Hallam1,
D. Taussig2, J. Gribben2, J. Cavenagh, 1
1Haemato-Oncology, St Bartholomews Hospital, 2Haemato-Oncology, Barts
Cancer Institute, 3Haematology, Homerton University Hospital, London, United
Kingdom
Background: Allogeneic transplantation remains the only curative treatment
for most patients with relapsed/refractory AML and high risk MDS. Conven-
tionally, patients are treated with intensive chemotherapy to induce remission
prior to transplantation. However, many patients cannot proceed to transplant
using this approach because of toxicities, delayed engraftment and failure to
achieve remission. The sequential allogeneic transplantation approach was
introduced to address these concerns by giving intensive chemotherapy to
reduce the leukaemic burden and then proceeding immediately to reduced
intensity conditioned transplantation to provide a long-lasting graft-vs-
leukaemia effect. To date, this approach has only been reported using T cell
depleted conditioning in the context of myeloid disorders.
Aims: Following the low toxicity associated with our T-replete transplantation
approach using non-myeloablative fludarabine cyclophosphamide conditioning
in other clinical settings, we performed a prospective single-centre study using
this transplant strategy as part of a sequential approach for patients with
relapsed/refractory AML and high risk MDS.
Methods: Patients received daunorubicin (45mg/m2 D-15-D-13) and cytarabine
(1500mg/m2 bd D-15-D-9) followed by fludarabine (25mg/m2 D-6-D-2) and
cyclophosphamide (1g/m2 D-3-D-2). GvHD prophylaxis was with methotrexate
and ciclosporin (CSA).
Results: 44 patients were enrolled on study between 2007 and 2014 after writ-
ten informed consent. Median follow-up was 51 months. Median age was 53
years (range 23-68). Patients had refractory AML(50%), relapsed AML(30%),
untreated AML(5%) and MDS(15%). Most patients (65%) had an intermediate
or high co-morbidity index. No patients were in remission pre-therapy. All
patients were transplanted from fully HLA-matched donors (50% sibling donors,
50% unrelated donors). All patients who survived beyond day 30 engrafted.
Median time to neutrophil engraftment was 21 days. 3 year NRM was 38%,
split equally between infection and GVHD. 35% developed acute GVHD (grade
II-IV) and 33% of all assessable patients had chronic GVHD requiring immuno-
suppression, half of whom died from GVHD-related causes. Early deaths were
more common in those over 60 years. Only one patient had CMV disease (col-
itis) and no other clinically significant viral complications occurred. No patients
received donor lymphocyte infusions. With a median follow up of 5 years, the
cumulative incidence of persistent or relapsed disease was 35%. 1 year and 3
year overall survival (OS) was 42% and 30% respectively. No factors impacted
upon overall survival. Patients with adverse cytogenetics had a significantly
higher risk of relapse (p=0.08). Patients with chronic GVHD demonstrated a
trend to reduced relapse. Patients with relapsed AML and MDS had excellent
outcomes with 5 yr OS of 42% and 67% respectively.
Summary and Conclusions: The rationale of using lower intensity chemother-
apy and non-myeloablative conditioning followed by T-replete transplantation
facilitated the treatment of an older, less fit patient group, whilst maintaining
comparable outcomes to more aggressive strategies. This treatment approach
is particularly effective in those with relapsed AML and MDS.
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SERUM FERRITIN IS INDEPENDENT OF DISEASE RISK INDEX FOR
OVERALL SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANS-
PLANTATION
L. Chee1,* M. Tacey2,3, B. Lim3, D. Ritchie1
1Department of Clinical Haematology and Bone Marrow Transplant Unit, 2Mel-
bourne EpiCentre, The Royal Melbourne Hospital, 3Department of Medicine,
The University of Melbourne, Parkville, VIC, Australia
Background: Elevated serum ferritin has been associated with inferior survival
and relapse outcomes following allogeneic stem cell transplantation (SCT).
Serum ferritin is commonly used as a surrogate marker for iron overload. How-
ever, a recent meta-analysis showed no impact of liver iron concentration
assessed by MRI on survival outcomes. The relationship between ferritin and
survival outcome may be related to either the direct effect of iron on organ
function or reflect the transfusion and/or comorbidities associated with pre-
SCT disease status.
Aims: Correlation of iron studies pre-SCT with clinical outcomes.
Methods: We undertook a retrospective analysis of all allogeneic SCT recipi-
ents for haematological malignancy between 2000-2013. Iron studies were
performed pre-SCT and Day 100, 12 months and 24 months post-SCT. We
assessed overall survival (OS), relapse free survival (RFS) and non-relapse
mortality (NRM) as a function of pre-transplant ferritin and transferrin saturation.
Co-variates included in univariate analysis and then multivariate analysis if
predictive of OS or RFS included age, gender, disease type, disease risk index
(DRI), conditioning intensity, graft source, donor type, cytomegalovirus status,
graft-versus-host disease (GVHD) prophylaxis and acute and/or chronic GVHD
treated as time-dependent covariates.
Results: 602 patients were identified (Male n=339, Female n=263). The medi-
an age was 49 years. The main underlying diagnoses were acute myeloid
leukaemia (AML) (n=223; 37%), Non-Hodgkin lymphoma (NHL) (n=96; 16%)
and acute lymphoblastic leukaemia (ALL) (n=89; 15%). The pre-SCT condi-
tioning regimen was myeloablative (n=372; 62%), reduced intensity (n=181;
30%) and non-myeloablative (n=49; 8%). Graft source was peripheral blood
(PB) (n=476; 79%), bone marrow (BM) (n=96; 16%), cord blood (n=27; 4%)
and both PB and BM (n=1; 0.2%). Donor type was sibling (n=362, 60%), unre-
lated (n=207; 34%), cord (n=26; 4%) and other family relation (n=7; 1%). Post-
SCT GVHD prophylaxis was primarily with Cyclosporin and Methotrexate for
the related and unrelated donor transplants and Mycophenolate mofetil for the
cord blood transplants. DRI was low (n=53; 9%), intermediate (n=371; 62%),
high (n=149; 25%), very high (n=5; 1%) and unable to be calculated in 24 (4%). 
The median ferritin levels were pre-SCT 1079ug/L, post-SCT D100 2074ug/L,
12 months 993ug/L and 24 months 740ug/L. A pre-SCT ferritin level above the
median was associated with inferior OS (HR 1.84, 95%CI: 1.41-2.39) and
increased relapse rates (HR 1.44, 95%CI: 1.07-1.93). High transferrin satura-
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tions (>50%) were associated with inferior OS (HR 1.44, 95%CI: 1.09-1.90)
but not with relapse outcomes (HR=1.10, 95%CI: 0.80-1.53). Univariate analy-
sis determined DRI (High: HR 3.91, 95%CI: 2.08-7.35 and Very high: HR 6.4,
95%CI: 2.03-20.19 when compared to Low), disease type (NHL: HR 0.42,
95%CI: 0.27-0.66 when compared to AML) and chronic GVHD (HR 0.46,
95%CI: 0.34-0.63) as the other most significant variables impacting OS. On
multivariate analysis, pre-transplant ferritin above median remained statistically
significant for inferior OS (HR 1.89, 95%CI: 1.42-2.52) but lost its association
with increased relapse risk (HR 1.28, 95%CI: 0.86-1.90) with DRI a strong con-
founding factor (High: HR=3.33, 95%CI: 1.44-7.71 and Very high: HR=10.35,
95%CI: 1.76-60.75). Pre-SCT ferritin level thresholds of 1000ug/L and 2500ug/L
remained a significant predictor for OS. The main causes of death in the
high/low ferritin groups were progressive disease (25%/14%), infection (7%/5%)
and GVHD (6%/5%).
Figure 1. Kaplan-Meier survival estimates: by median ferritin.
Summary and Conclusions: A high pre-transplant serum ferritin remains an
important prognostic variable in allogeneic SCT independent of DRI. Serum
ferritin was a better predictor of survival outcome in comparison to transferrin
saturation in our cohort of patients, although no significant prediction of relapse
risk was found after adjustment for DRI. 
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COMBINATION THERAPY WITH INOLIMOMAB AND ETANERCEPT FOR
SEVERE STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
L. Van Groningen1,* A. Liefferink1, A. de Haan2, N. Schaap1, P. Donnelly1,
N. Blijlevens1, W. van der Velden1
1Hematology, 2Epidemiology, Radboudumc, Nijmegen, Netherlands
Background: After allogeneic stem cell transplantation (SCT) the occurrence of
acute graft-versus-host disease (aGVHD) is an important cause of morbidity and
mortality. Treatment of aGVHD consists of high-dose steroids in first-line with
approximately a 50% response rate. However patients who prove refractory to
this therapy, especially those who suffer from grade III-IV aGVHD with gastroin-
testinal involvement, have a very poor prognosis. Different therapeutic strategies
have been used for second-line therapy, but responses have remained disap-
pointing. In literature both inolimomab (monoclonal antibody targeting the inter-
leukin-2 receptor subunit α that inhibits activated alloreactive T cells) and etan-
ercept (TNFα-receptor fusion protein that scavenges TNFα) have shown prom-
ising results when used as monotherapy. Therefore combination therapy with
these drugs might prove beneficial in patients with steroid-refractory aGVHD as
two pivotal pathways in aGVHD pathogenesis are inhibited.
Aims: In this study we evaluated the efficacy and safety of second-line combi-
nation therapy, inolimomab and etanercept, for patients with steroid-refractory
aGVHD. Primary endpoints were the overall response rate (ORR) on day 28 of
second-line therapy and the 6-month estimated overall survival (OS).
Methods: Second-line treatment with inolimomab and etanercept started when
steroid-refractory aGVHD was determined. Inolimomab was administered intra-
venously in a dose of 0.3 mg/kg daily from day 1 to 8 and a dose of 0.4 mg/kg
every other day from day 9 to 28. Etanercept was given subcutaneously twice
weekly at a dose of 25 mg during 4 weeks. Primary endpoints were overall
respons rate (ORR) on day 28 of second-line therapy and the 6-month esti-
mated overall survival (OS).
Results: From February 2010 to February 2014 21 patients with steroid-refractory
grade III-IV aGVHD received treatment with the combination therapy inolimomab
and etanercept. 19 had GI involvement and mean albumin levels at diagnosis
were 27 g/l. Of the 21 patients 6 achieved a complete response (CR) and 4
patients a partial response (PR), bringing the overall response rate on day 28 to
48% (10/21). On day 56, the overall response rate was 33% with 5 patients retain-
ing CR and 2 a PR. The estimated 6-month and 2-year overall survival were dis-
mal; 24% (5/21) and 10% (2/21). Statistical significant risk factors for treatment
response were determined namely aGVHD after donor lymphocyte infusion
(p=0.01) and GVHD involving the liver stage 2-4 (p=0.03). There were no infu-
sion-related adverse events. Infectious complications occurred frequently and
consisted predominantly of bacteriemias with gut residing pathogens, invasive
mould disease and CMV and EBV reactivation and disease.
Summary and Conclusions: Combination therapy with inolimomab and etan-
ercept in patients with steroid-refractory grade III-IV aGVHD was moderately
effective with regards to achieving a remission, but nevertheless overall survival
was dismal, with only 10% of patients being alive at last follow up. New strate-
gies are urgently needed with more effective drugs but also with approaches
directed at prevention of refractory GVHD and incorporation of biomarkers that
facilitate risk-adapted therapy.
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PURE RED CELL APLASIA IN MAJOR ABO MISMATCHED ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH
SEVERE PANCYTOPENIA
F. Aung1,* B. Lichtiger1, R. Gabriela2, A. Alousi2, S. Ahmed2, B. Andersson2,
Q. Bashir2, C. Stefan2, C. Hosing2, R. Jones2, P. Kebriaei2, I. Khouri2, Y. Nieto2,
O. Betul2, S. Parmar2, M. Qazilbash2, N. Shah2, E. Shpall2, R. Champlin2, U. Popat2
1Transfusion Medicine, 2Stem Cell Transplantation and Cellular Therapy, The
University of Texas MD Anderson Cancer Center, Houston, United States
Background: The persistence of anti-donor isohemagglutinins in Major ABO
mismatched allogeneic stem cell transplantation (HCT) leads to pure red cell
aplasia (PRCA). In our previous report of 12 patients with PRCA, severe pan-
cytopenia was observed in one patient who eventually had a second transplant
(Aung et al. B J Haematol 2013 Mar; 160(6):798-805). Furthermore, ABO anti-
gens are expressed on or adsorbed from plasma on granulocyte and platelets
and production of these may be impaired by isohemagglutinins.
Aims: To further investigate this observation we analyzed a larger cohort of
patients with PRCA to determine the frequency of pancytopenia and natural his-
tory of pancytopenia in patients with PRCA after major ABO incompatible HCT.
Methods: We reviewed 707 patients who received a major ABO-mismatched
HCT between January 2003 and December 2012 at our institution. Pure red
call aplasia was determined to be present when the bone marrow biopsy on
post-transplant day 30 demonstrated absent or nearly absent erythroid precur-
sors with absence of donor red cells on forward red cell typing of the recipient
and the recipient being red cell transfusion dependent. Pancytopenia was
defined as ANC <1.5x109/L or requiring G-CSF, Platelets <50x109/L or trans-
fusion dependent, and PRCA with red cell transfusion dependence as above
at 90 days after allogeneic SCT.
Results: 83 (11.7%) patients (29[35%] males: 54[65%] females) had PRCA and
of these 13 (16%) (10 [77%] males]: 3[23%] females), median age 53 [range 27-
66 years] had pancytopenia at day 90 after transplant. There was a female pre-
ponderance of PRCA patients, however a male predominance was noted in
PRCA patients with severe pancytopenia. None of these patients had any other
reason for persistent pancytopenia like CMV or other viral infection or use of
drugs like ganciclovir or disease recurrence. On post-transplant day 90, median
absolute neutrophil counts (ANC) was 0.93 K/UL with all patients having inter-
mittent G-CSF. The median platelet count was 14 KL/UL (range 6-34) and all
patients were platelet and red cell transfusion dependent. Of the 13 PRCA patients
with pancytopenia, 2 (15%) received a second transplant due to persistent pan-
cytopenia/graft failure, 4 (31%) patients did not recovered their platelet counts
despite red cell and ANC recovery and died (3 from disease recurrence/1 from
myocardial infarction). 1 (8%) patient was lost to follow up. In the remaining 5
(38%) patients, neutropenia and thrombocytopenia resolved after resolution of
PRCA. Red cell recovery occurred at a median of 188 (97-549) days post-trans-
plant, ANC recovered at median of 296 (145-743) days post-transplant, and
Platelets recovered at median of 296 (190-1250) days post-transplant.
Summary and Conclusions: Severe pancytopenia is frequently (16%) asso-
ciated with PRCA in major ABO incompatible HCT. Neutropenia and thrombo-
cytopenia resolve after resolution of red cell aplasia in the majority of patients.
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DONOR CHIMERISM AS MARKER OF RELAPSES AFTER BONE MARROW
TRANSPLANTATION.
I. Barkhatov1,* A. Evdokimov2, A. Shakirova1, V. Teplyashina1, S. Bondarenko1,
A. Chukhlovin1, L. Zubarovskaya1, B. Afanasyev1
1R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, 2R.M. Gorbacheva Memorial Institute of Children Oncology,
Hematology and Transplantation, FIRST PAVLOV SAINT PETERSBURG
STATE MEDICAL UNIVERSITY, St.Petersburg, Russian Federation
Background: Allogeneic hematopoietic stem cell transplantation is an effective
treatment for different hematological malignances. Efficiency of donor cell engraft-
ment is determined by donor chimerism evaluation, i.e. determining of genetically
different cell populations coexistence in patient. We assume that the kinetics of
chimerism in patients with hematologic malignancies, in turn, may be defined in
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terms of relapse probability, and it could be used as a marker of minimal residual
disease (MRD) after allogeneic transplantation of HSCs (allo-HSCT).
Aims: Evaluation of donor chimerism definition in assessing the likelihood of
posttransplant relapses.
Methods: We have analyzed 440 allo-HSCT’s in patients with various hemato-
logic malignancies. For the donor chimerism monitoring we used standard panels
of human DNA markers based on STR variability (short tandem repeats,
microsatellites). The ratios of donor and recipient cells were calculated according
to the data derived from fragment analysis, using the Genemarker program. The
study was performed on days +15, +30, +45, +60 and +100 after transplantation.
Results: Achieving of full donor chimerism (95%) significantly increases the 5-
year survival (p=0.001) and reduces the probability of disease recurrence
(p=0.01). Among patients with mixed chimerism the stability of donor chimerism
level is most important, being associated with lower risk of relapse (p=0.013).
Thus, in patients with stable mixed chimerism, the markers molecular markers
of MRD had no significant effect either on overall survival, or the likelihood of
relapse (p=0.55 and p=0.34 respectively). Meanwhile, we had found an inverse
correlation between the level of donor chimerism and expression of relapse
markers, i.e. WT1 (R=-0.4, p=0.0001) and EVI1 (R=-0.16, p=0.03). Similar
data were obtained when analyzing expression of the chimeric transcripts:
BCR-ABL (R=-0.26, p=0.0001), MLL-AF4 (R=-0.36, p=0.003), TEL-AML (R=-
0.37, p=0.003). Hovewer, this dependence with other markers (CBFB-MYH11,
PML-RARα, RUNX1-RUNX1T1) could be also obtained.
Summary and Conclusions: Monitoring of donor chimerism after allo-HSCT
adequately reflects the dynamics of donor cells engraftment and may be used
as an adequate method for predicting recurrence of the disease, but it can not
be used as a single method in MRD analysis.
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PERIPHERAL BLOOD EOSINOPHIL COUNT AT DAY 28 AS A PROGNOS-
TIC INDICATOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
K. Kawamoto1,* Y. Shibasaki2, H. Kobayashi1, T. Ushiki1, N. Sato3, T. Yano3,
M. Moriyama1, T. Kuroha3, J. Takizawa1, S. Hashimoto3, M. Narita1, T. Furukawa3,
H. Sone1, M. Masuko2
1Department of Hematology, Endocrinology and Metabolism, Niigata University
Faculty of Medicine, 2Division of Stem Cell Transplantation, Niigata University
Hospital, Niigata City, 3Department of Hematology, Nagaoka Red Cross Hos-
pital, Nagaoka City, Japan
Background: Peripheral blood eosinophilia has been reported as a favorable
prognostic indicator for patients with hematologic disease after allogeneic
hematopoietic stem cell transplantation (HSCT). It has been reported to be
associated with chronic Graft versus Host Disease (GVHD) and decreased
relapse rate. Eosinophils play an important role in alloimmune reactions after
HSCT. However, the relationship between eosinophilia after HSCT and acute
GVHD is still controversial, and the clinical relevance of peripheral blood
eosinophil count (PB-Eos) at the early phase after HSCT is not clear.
Aims: The purpose of this study was to clarify the clinical relevance of PB-Eos
at the early phase after HSCT.
Methods: We enrolled 180 adult patients with hematological neoplasms who
underwent their first HSCT between November 2004 and August 2013 at Niiga-
ta University Hospital and Nagaoka Red Cross Hospital in this study. Forty-
four of the 180 patients were excluded from the analysis because of graft
failure, using corticosteroids before day 28 after HSCT, or inadequate laboratory
data. We analyzed retrospectively 136 patients, including 55 with acute myel-
ogenous leukemia, 40 with acute lymphoblastic leukemia, 22 with myelodys-
plastic syndrome, 3 with myeloproliferative neoplasm, 2 with chronic myeloge-
nous leukemia, 3 with adult T cell leukemia, 1 with mixed lineage leukemia,
and 10 with malignant lymphoma. Median age of patients was 42 years (range:
16-66). Fifty-six patients received related stem cell transplantation, 50 received
unrelated stem cell transplantation, and 30 received cord blood transplantation.
Chi-squared analysis and Fisher’s exact test were used to assess the relation-
ship between PB-Eos and acute GVHD. Overall survival (OS) was based on
Kaplan-Meier estimates. Cumulative relapse rate (RR) was based on Gray’s
estimates. Multivariate Cox regression for OS and Fine-Gray regression for
RR were used to identify the independent risk factors.
Results: Median PB-Eos at day 28 was 48 /µl (range: 0-3078 /µl). We divided
the patients into 2 groups, those with PB-Eos of more than 50 /µl and those
with PB-Eos of less than 50 /µl at day 28. According to univariate analysis, PB-
Eos of <50 /µl at day 28 tended to indicate a poor prognosis of OS (p=0.096).
In multivariate analysis adjusting for age, grade 2-4 acute GVHD after day 28,
disease status and conditioning regimen, and PB-Eos of less than 50 /µl at
day 28 were independent poor prognostic factors for OS (HR: 1.86 (1.05-3.31),
p=0.034). In patients with acute GVHD of any grade, PB-Eos of <50/µl at day
28 was an independent prognostic factor for OS (HR: 3.14 (1.34-7.34),
p=0.0085) and RR (HR: 4.45 (1.65-12.06), p=0.003). In contrast, it was not a
prognostic factor for OS or RR in patients without acute GVHD. Next, we ana-
lyzed the relationship between PB-Eos and acute GVHD. PB-Eos was not
associated with development of grade 2-4 acute GVHD after day 28 by Chi-
squared analysis (p=0.55) and grade of acute GVHD by Fisher’s exact test
(p=0.37). Furthermore, in patients with grade 2-4 acute GVHD after day 28,
PB-Eos of <50/µl at day 28 was also an independent prognostic factor for OS
(HR: 3.87 (1.12-13.37), p=0.033) and RR (HR: 4.88 (1.26-18.82), p=0.021). 
Summary and Conclusions: PB-Eos at day 28 is an independent prognostic
indicator for OS in HSCT. In particular, lower RR may contribute to better OS
in patients with acute GVHD. The presence of eosinophils at the early phase
of HSCT could predict a good prognosis in HSCT.
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AUTOLOGOUS STEM CELL TRANSPLANTATION WITH HIGH-DOSE
MITOXANTRONE AND MELPHALAN IN PATIENTS WITH HODGKIN AND
NON-HODGKIN LYMPHOMA: LONG-TERM SURVIVAL AND TOXICITY DATA
B. Gungor1, M. Yeral2, M. Adam1, C. Unsal1, C. Boga2, H. Ozdogu2, Y. Koc1,*
1BMT Unit, MedicalPark, Antalya, 2BMT Unit, Baskent University, Adana,
Turkey
Background: In patients with high risk or relapsed lymphoma, a satisfying
response rate and long-term survival cannot be achieved by conventional
chemotherapy regimens. Despite reports of high-dose chemotherapy regimens
coupled with or without autologous stem cell transplantation (Auto-SCT), med-
ical literature reporting long-term survival and toxicity data beyond 10 years is
rare. In the autologous transplant setting, use of high-dose mitoxantrone cou-
pled with high-dose melphalan as conditioning protocol (HDMTZMEL) is rela-
tively less frequent, compared to the well known BEAM regimen.
Aims: In this study, we report disease-free (DFS), long-term overall survival (OS)
and long-term toxicity in patients with lymphoma treated with HDMTZMEL con-
ditioning regimen followed by Auto-SCT during the past 15 years (2000-2014).
Methods: 107 patients relapsed or resistant diffuse large B-cell NHL (DLBCL,
n=49) or Hodgkin lymphoma (HL, n=58) underwent Auto-SCT after adminis-
tration of the conditioning regimen consisting of high-dose mitoxantrone (60
mg/m2) and melphalan (180 mg/m2) following greater than 50% response to
the salvage regimens; DHAP or ICE or IIVP and/or HD-VP16. Treatment did
not include prophylactic cranial radiotherapy. Patients over 65 years of age
and with CNS involvement prior to salvage regimen and refractory to both initial
therapy and the salvage regimens were excluded. Patients had a median age
of 39 (16-63) and proceeded with Auto-SCT only after CR or PR was achieved.
Results: Following salvage chemotherapy, 68 (63.5%) patients achieved CR,
and 36 (36,4%) achieved PR. Transplant related mortality (TRM) rate at day
+100 was%0,9 in all patients, with an OS rate of 72.4% and 67,2% at 5 and 10
years, respectively. In patients with DLBCL, 5 and 10 year OS were 70.4%,
whereas patients with HL had 74.9% and 67.4% OS rates, respectively. Five-
year DFS was calculated as 62.9% (66.8% for DLBCL, 61.8% for HL) and did
not change at 10 years and beyond. No statistically significant difference in OS
and DFS rates was found between patient groups. In the DLBCL group, relapse
was not observed after 29 months, whereas late relapses were observed until
57 months in patients with HL. In both groups, OS at 15 years were identical to
OS at 10 years. Patients transplanted in CR had an OS rate of 80.4% at 5 yr
(78.8% for NHL, 82.7% for HL, 71.5% after 10 years) whereas patients trans-
planted in PR had an OS rate of 55.7% at 5 and 10 years (52.5% for NHL, 57.7%
for HL) and beyond (CR vs PR, p=0.01 for NHL and p=0.3 for HL). Patients trans-
planted in CR had an DFS rate of 72.9% at 5 yr and beyond (76.2% for NHL,
71.9% for HL) whereas patients transplanted in PR had an DFS rate of 42.4% at
5 and beyond (43.8% for NHL, 44.9% for HL) and beyond (CR vs PR, p=0.004
for all patients, p=0.2 for NHL and p=0.04 for HL). Late complications and toxic-
ities during the post-transplant period include; late relapses (>3 years post-trans-
plant) among patients with HL (n=3), secondary malignancy between 1-3 years
(n=2,1 AML, 1 MDS), delayed platelet engraftment (n=2), congestive heart failure
(n=1) corresponding to a late toxicity rate of 2.8% (Figure 1).
Figure 1. Kaplan-Meier cum. Survival plot for OS.
Summary and Conclusions: In patients with relapsed or resistant DLBCL
and HL sensitive to pre-transplant salvage chemotherapy, HDMTZMEL condi-
tioning regimen is capable of inducing high rates of OS and DFS rates with a
low toxicity profile. In the DLBCL group, patients undergoing transplantation in
CR have significantly higher overall survival and cure rate. In both DLBCL and
HL groups, DFS is significantly better if the patients are transplanted in CR.
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RISK FACTORS FOR TRANSPLANTATION-ASSOCIATED THROMBOTIC
MICROANGIOPATHY AND OUTCOME OF PATIENTS, FOLLOWING ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
K. Balassa1,* H. Andrikovics1, P. Remenyi2, A. Batai2, A. Bors1, K.P. Kiss1,
L. Lengyel2, E. Torbagyi2, A. Barta2, A. Szilvasi3, K. Rajczy4, D. Inotai3, A. Tordai1,
T. Masszi2
1Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion
Service, 2Department of Hematology and Stem Cell Transplantation, St. Istvan
and St. Laszlo Hospital, 3Laboratory of Transplantation Immunogenetics, 4Bone
Marrow Donor Registry, Hungarian National Blood Transfusion Service,
Budapest, Hungary
Background: Transplantation-associated thrombotic microangiopathy (TA-
TMA) is a feared complication of allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) due to its high mortality. Endothelial damage and activation,
attributed to multiple clinical factors, are thought to be the key elements in the
induction of TA-TMA.
Aims: Our work focused on the assessment of the frequency, risk factors and
prognostic impact of TA-TMA in allo-HSCT.
Methods: Data of 425 consecutive adult patients, who underwent first allo-
HSCT for a malignant hematological condition at a single centre between 2007
and 2013, were retrospectively analysed.
The median age at transplantation was 43 years (range 19-73 years). The most
common indications for the procedure were acute leukaemias. The donor stem
cells originated from a sibling donor in 217/425 (51%) patients. Myeloablative
conditioning (MAC) was administered to 267 (63%) patients, whereas 158
(37%) patients received reduced intensity conditioning. Graft-versus-host dis-
ease (GvHD) prophylaxis consisted of cyclosporin-, or tacrolimus-based regi-
mens.
Results: The cumulative incidence of TA-TMA was 19% (80/425) in the entire
cohort, and 65 (81%) patients developed TA-TMA within the first 100 post-
transplant days. The majority of TA-TMA patients (83%) also suffered from
acute GvHD (aGvHD), usually preceding TA-TMA. Several risk factors were
identified in association with the manifestation of TA-TMA: aGvHD grade II-IV
(p<0.001), unrelated donor type (p<0.001), MAC (p=0.003), tacrolimus-based
GvHD prophylaxis (p=0.003) and cytomegalovirus (CMV) reactivation/disease
(p=0.004). Overall survival rates of patients with TA-TMA were significantly low-
er compared to patients without the complication (p<0.001, 48-months overall
survival 20+/-5 vs 52+/-3%). Among those affected by TA-TMA, the survival
was poorer (p=0.05), if clinical signs of organ damage were present. Within the
TA-TMA group, severe (grade III-IV) aGvHD influenced the survival the most
adversely.
Summary and Conclusions: TA-TMA developed early following HSCT and
was precipitated by several patient, and transplantation related risk factors,
such as aGvHD, unrelated donor, MAC, tacrolimus administration and CMV
infection. The survival of patients with TA-TMA was significantly poorer com-
pared to patients without TA-TMA.
Our findings confirm that TA-TMA remains a severe complication of allo-HSCT,
with the contribution of multiple factors and poor prognosis.
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REITERATED THERAPEUTIC DRUG MONITORING (TDM) TO BETTER
CONTROL TARGETED EXPOSURE TO IV BUSULFAN IN INFANTS AND
OLDER CHILDREN UNDERGOING HEMATOPOIETIC STEM-CELL TRANS-
PLANTATION (HSCT)
P. Bourget1, B. Neven2, A. Amin1,* M. Chomton2, G. Cros2, E. Elkaim2,
M.-L. Fremond2, D. Moshous2, F. Touzot2, F. Ader1, A. Lalli1, A. Petain3,
L. Nguyen3, S. Blanche2
1Department of Clinical Pharmacy, 2Pediatric Hematology-Immunology and
Rhumatology Department, University Hospital Necker-Enfants Malades, Paris,
3Pharmacokinetic Department, Institut de Recherche Pierre Fabre, Toulouse,
France
Background: Busulfan (Bu) is the standard backbone for HSCT conditioning
regimens (CR) worldwide. It has a narrow therapeutic window (TW), and graft
rejection and toxicity may be related to Bu exposure. In infants, Bu exhibits
large pharmacokinetic (PK) variability, and its metabolic clearance is non-lin-
early related to body weight (BW). In this setting, Bu dosage is stratified accord-
ing to BW and commonly monitored once after the 1st of 16 total 2-hr infusions
(96-hr exposure).
Aims: To optimize Bu duration/intensity exposure in children undergoing HSCT,
we studied the possible contribution of double TDM of IV Bu in children receiving
Bu-based CR for HSCT, by comparing the targeted and calculated exposure
values after performing 1 PK (1st dose, PK1) and finally 2 PK (1st dose, PK1,
and 9th dose, PK2).
Methods: In this single-centre observational study (05/2012-02/2015), 50
patients (Pts) receiving Bu based myeloablative CR for HSCT were prospec-
tively included with median follow up of 12 months [0-33]. There were 33 males
and 17 females. Median age was 16.5 months [1-193] and BW 11.0 kg [3-59].
Most Pts had non-malignant diseases, received allogenic HSCT and Bu-based
CR in combination with fludarabine. The 1st dose and the tight and high TW
were set up according to EBMT-ESID recommendations [ΣAUC=20,706-23,180
μmol/L*min]. Bu PK was assessed on 3 plasma samples/PK (LC-MS2 analysis)
with area under the concentration-time curve (AUC) calculation from the 1st
and 9th doses, using the NONMEM® software. AUC calculated after the 1st
dose and extrapolated to the 16th one were compared by a Wilcoxon signed-
rank test to the targeted AUC and to the sum of AUC1-6 with TDM1 applied
from the 7th dose with or without TDM2 applied from the 14th dose; p≤0.025
was considered statistically significant.
Results: An initial median Bu posology of 1.16 mg/kgx4/day for 4 days was
given. We demonstrate that: (a) calculated total AUC obtained from 2 PK differ
significantly from those calculated after no PK (p=2.7006 E-6) or PK1 alone
(p=3.4750 E-7), (b) double TDM allows achieving no difference between the
targeted AUC desired by the medical staff in view of diseases vs calculated
AUC (p=0.8939), (c) calculated total AUC obtained after no PK or PK1 alone
significantly differed from targeted AUC. In 2/50 (4%) Pts, PK did not lead to
change Bu dosage. In 9/50 (18%) and 12/50 (24%) Pts, dosage was modified
after PK1 (TDM1 Group) or PK2 alone, respectively. In 27/50 (54%) Pts,
changes were required twice, after PK1 and PK2 (Double-TDM Group). The
median total doses of Bu were as follows: (a) a theoretical value of 220.8 mg
(20.2 mg/kg) would have been given without any TDM (16 consecutive doses),
(b) 194.7 mg (18.1 mg/kg) were administered in the TDM1 Group (16 doses),
(c) 242.8 mg (19.5 mg/kg) were administered in the Double-TDM Group, pre-
venting the unnecessary infusion of 20.0 mg of Bu vs PK1 alone in these Pts.
In 15/50 (30%) Pts, a decision of discontinuation of Bu exposure was taken as
the target desired by the medical staff was achieved after 13 (6 Pts) or 14 (9
Pts) doses; the mean total amounts of Bu were 273.2 mg (15.0 mg/kg) and
231.0 mg (15.6 mg/kg), respectively, vs 336.3 mg (18.5 mg/kg) and 278.2 mg
(19.5 mg/kg) theoretically after TDM1 alone.
Summary and Conclusions: In this pediatric series, the double TDM of Bu is
a relevant and feasible option to better achieve a narrow TW and to potentially
minimize the risk of overexposure. Correlations with toxicities (VOD, aGVH),
CR, OS are under analysis. Based on these data, the double-TDM procedure
is routinely applied in our centre.
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FACTORS DETERMINING THE EFFECTIVENESS OF ACUTE GRAFT VER-
SUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION WITH MULTIPOTENT MESENCHYMAL STRO-
MAL CELLS
N. Petinati1,* I. Shipounova1, A. Bigildeev1, N. Sats1, N. Drize1, L. Kuzmina2,
E. Parovichnikova2, V. Savchenko3
1Physiology of Hematopoiesis lab., 2High Dose Chemotherapy, Depressions
of Hematopoiesis and Bone Marrow Transplantation Department, 3National
Research Center for Hematology, Moscow, Russian Federation
Background: Currently acute graft-versus-host disease (aGVHD) is one of the
main problems after allogeneic bone marrow transplantation (allo-BMT) in
patients with hematological malignancies. The new method involving the use
of donors’ multipotent mesenchymal stromal cells (MSC) was developed (Clin-
icalTrials.gov NCT01941394). In some cases prophylaxis of aGVHD with MSC
failed. The reasons of failure could be either the result of particular qualities of
donor-recipient interaction, patient status or characteristics of MSC samples.
Aims: The aim of the study was to analyze the main characteristics of MSC
used for aGVHD prophylaxis based on the clinical outcome.
Methods: The study included 67 patients received allo-BMT from related
donors after informed consent. The patients were randomized into 2 groups:
first received standard prophylaxis of aGVHD (34) and the second (33) were
additionally infused with MSC from the bone marrow of corresponding
hematopoietic stem cells donor. MSC were cultivated in aMEM with 4%
donors’ platelet lysate. MSC were administered intravenously when the blood
counts indicated recovery (peripheral blood leukocytes reached 1x109/l). For
analysis MSC were cultivated in standard conditions (aMEM, 10% fetal calf
serum) for 3 passages. Relative expression level (REL) of 30 genes involved
in proliferation, differentiation and immunomodulation was estimated by RT-
qPCR in all MSC. 
Results: Observation of the patients for 100 days (typical time of aGVHD man-
ifestation) had revealed significant 3-time decrease in aGVHD development in
the group of patients who received MSC (9.4% aGVHD grade II-IV) when com-
pared to the standard prophylaxis group (29.4% aGVHD grade II-IV), p=0.041.
MSC injection did not affect the engraftment as well as the relapse frequency.
Overall survival of the patients was significantly higher in the MSC received
group p=0.048. Three of 32 MSC samples had been ineffective for preventing
aGVHD. Analysis of individual donor characteristics (gender, age, body mass
index), found no significant differences between the MSC, effective and inef-
fective for preventing aGVHD. The cumulative MSC production of ineffective
samples was 2 fold lower (p=0.05) than effective ones. REL of CSF1, FGFR1
and PDGFRB was 4 (p=0.0005), 2.5 (p=0.02) and 2.5 (p=0.02) fold decreased
correspondingly in ineffective samples. REL of other 27 studied genes involved
in proliferation, differentiation and immunomodulation did not differ significantly
in MSC effective and ineffective for aGVHD prophylaxis.
The combination of predictors that characterize the most suitable for the pre-
vention of aGVHD MSC samples was revealed by multiple logistic regression
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analysis. A model calculating the probability of the success of MSC samples
application was proposed:
logit(P)=2.5-0.26*CFH+0.02*IDO1-0.65*IGF1
where logit(P)=ln[P/(1-P)], P - probability of successful prophylaxis, CFH, IDO1
and IGF1 - REL of corresponding genes in tested MSC. Chi-square goodness
of fit test p=0.0053. The calculated efficiency of this model was 95%. CFH and
IDO1 are important for immunomodulation by MSC, while IGF1 is the gene
associated with aging. So this statistical model seems reasonable for primary
estimation of MSC efficiency for aGVHD prophylaxis.
Summary and Conclusions: The high variability of all analyzed characteristics
among MSC from different donors was shown. By means of the proposed mod-
els ineffective MSC samples could be discharged. Such strategy hopefully will
prevent the development of aGVHD in the maximum number of patients.
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IMPACT OF HISTOLOGIC GRADE ON THE OUTCOME OF ALLOGENEIC
STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMAS
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A. Pellegrinelli5, C. Micò6, L. Farina1, F. Spina1, A. Rambaldi6, L. Castagna3,
P. Corradini1,7
1Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori,
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Vicenza, 3Hematology Unit, Humanitas Cancer Center, Milan, 4Hematology
Unit, Santa Maria della Misericordia Hospital, Udine, 5Department of Pathology
and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan,
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Background: Allogeneic stem cell transplantation (AlloSCT) represents an
effective treatment for relapsed and refractory follicular lymphoma (FL) and it
is the only curative treatment approach in this particular clinical setting. Indeed,
graft versus lymphoma (GVL) effect is superior in patients affected by FL as
compared to those affected by diffuse large B-cell lymphoma (DLBCL). There-
fore, also patients with active disease at time of AlloSCT can achieve a long-
term survival. Grade 3B FL, both for its histological features and clinical behav-
ior, is generally considered as an aggressive lymphoma. However, it is com-
pletely unknown the outcome of patients with Grade 3B FL receiving AlloSCT.
Aims: We investigated the impact of histologic grade on the outcome of
AlloSCT in relapsed/refractory FL patients
Methods: In this study, we retrospectively analysed a cohort of 62 FL pts trans-
planted in 5 Italian Institutions between December 2001 and November 2014.
All patients fulfilled the following criteria: 1) confirmed histologic diagnosis of
FL including revised histological grading of each case; 2) pre-transplant disease
status and response evaluated by computed tomography (CT) and/or positron
emission tomography (PET) and assessed according to criteria established by
Cheson et al., JCO 2007. Fifty (80.6%) patients had a diagnosis of grade 1-3A
and 12 of Grade 3B FL. Twenty-eight (45%) patients were transplanted from
related, 28 (45%) from unrelated and 6 (10%) from haploidentical donors. Thir-
ty-three patients (53%) were characterized by the presence of active disease
before AlloSCT [20 partial remission, 1 stable disease and 11 disease progres-
sion (PD)]. No significant pre-transplant clinical differences (age, disease status,
previous chemotherapy lines, stem cell source and donor types) were observed
in patients with grade 1-3A versus 3B.
Results: Considering the whole patient cohort, we confirmed the favorable out-
come after AlloSCT with 5-years EFS, PFS and OS estimates of 83.6% (95% CI,
78.2% to 89%), 61.3% (95% CI, 54.7% to 67.9%) and 69.1% (95% CI, 63% to
75.2%), respectively. No differences in EFS, PFS and OS were observed among
Grade 1, 2 and 3A. Conversely, Grade 3B FL patients were characterized by a
worse outcome compared to the other FL in terms of 5-years EFS [24.2% (95%
CI, 21.5% to 26.9%) vs 90.7% (95% CI, 86.2% to 95.2%); p=0.0004], PFS [11.1%
(95% CI, 0.7% to 21.5%) vs 72% (95% CI, 65.3% to 78.7%); p<0.0001] and OS
[42.8% (95% CI, 27.2% to 58.4%) vs 74.7% (95% CI, 68.3% to 81.1%); p=0.02]
estimates. Among patients with active disease and grade 1-3A, AlloSCT con-
firmed its high efficacy with 5-years EFS, PFS and OS estimates of 75.2% (95%
CI, 67% to 83.4%), 55.9% (95% CI, 46.6% to 65.2%) and 63% (95% CI, 56% to
71%) respectively. Conversely, all grade 3B patients with active disease before
AlloSCT suffered an early relapse (p<0.01), suggesting a lower GVL efficacy
compared to other FL grades. Grade 3B histology retained its independence for
EFS, PFS and OS in multivariate analysis including: age, pre transplantation dis-
ease status, graft source (peripheral blood versus bone marrow), intensity of the
conditioning regimen (RIC versus MAC), acute and chronic GVHD occurrence
and previous autologous SCT.
Summary and Conclusions: Overall, these data confirm the favorable prognosis
of relapse/refractory FL patients Grade 1-3A undergoing AlloSCT, including those
with active disease. Conversely, our study suggests that 3B FL patients should
be treated like DLBCL rather than FL. This different approach might be particularly
important among patients with active disease before AlloSCT.
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ALPHA/BETA T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLAN-
TATION FROM MATCHED RELATED AND UNRELATED DONOR GRAFTS
IN PATIENTS WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES
M.D. De Witte1,* G. Fleurke2, L. van de Wagen2, I. Slaper3, J. Kuball1,2
1Hematology, 2Laboratory of Translational Immunology, 3Cell Therapy Facillity,
University Medical Center Utrecht, Utrecht, Netherlands
Background: The outcome of allo-SCT in patients with poor risk leukemia is
still hampered by GVHD and relapse. The innate immune system has been
reported to contribute to tumor control, with lower incidence of GVHD. Specific
depletion of αβ T- cells - key players in the development of GVHD - will render
NK cells and γδT cells within the allograft. Recently reported results have shown
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the great promise of this approach in haploindentical transplantations. Within
this study, we aim to extend αβT- cell depleted allo-SCT to patients with a
mathed related donor (MRD) or matched unrelated donor (MUD).
Aims: An “Innate-Tx” (αβ T cell depleted allograft from MRD/MUD) is aimed to
serve as a low toxicity allo-SCT platform for futee immune interventions. As
such it should have reduced levels of GVHD as compared to T cell replete allo-
SCT, withour an increase in clinical significant infections or relapse. 
Methods: All patients with hematological malignancies and an indication for
allo-SCT were eligible. Either HLA matched siblings or HLA matched (9 or
10/10) unrelated donors (MUD) were eligible. αβT-cell reduction was performed
by negative selection with anti-αβTCR antibodies in combination with magnetic
microbeads, using the automated CliniMACS device (Miltenyi Biotec, Bergisch
Gladbach, Germany). The maximal contamination with αβT-cells was 5x105/kg.
The conditioning regimen consisted of: ATG (Genzyme®) 4 or 6 mg/m2+flu-
darabine 120 mg/m2+busilvex AUC=90 followed by αβT- cell depleted grafts
from matched related or unrelated donors. No additional immune suppression
was given post allo-SCT.
Results: A ~4 log depletion of αβT-cells has been observed in the product with
a recovery of ~75% of CD34+ cells. The combination of ATG/fludarabine/busil-
vex was well tolerated with a hematological recovery within 3 weeks. Most
patients received a pre-emptive low dose DLI (1x105 T cells/kg). Primary
engraftment (chimerism >95%) was observed in all patients (n=14). Immune
reconstitution primarily consisted of NK cells, showing a contraction around 4
months post SCT. In addition, γδT cells were present at normal numbers up to
6 months post SCT, whereas the adaptive immune repertoire shows a delayed
reconstitution. Under this “innate control”, no increase in CMV or EBV reacti-
vations has been observed so far. Up to date, none of the patients developed
aGVHD >grade II, none of the patients developed a relapse and no treatment
related deads have been observed. 
Summary and Conclusions: Here we show that an conditioning regimen of
ATG/busilvex/fludarabin in combination with an αβT- cell depleted allo-SCT
from MRD/MUD results in a swift reconstitution of innate cells (NK cells and
γδT cells) the first 6 months post transplantation, followed by a subsequent
reconstitution of the adaptive immune repertoire. After a median follow-up of 5
months, we observed low levels of aGVHD, without a concomitant increase in
graft failure and infections. To address the incidence of cGVHD, relapse rate
and overall survival a longer follow-up is required. However, the low incidence
of aGVHD in this protocol suggests that this transplantation strategy can serve
as a platform for subsequent interventions such as administration of tumor spe-
cific drugs, vaccination or tranfer of tumor specific T cells.
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANT IN PATIENTS WITH MDS/MPN OVERLAP SYNDROMES- A SINGLE
INSTITUTIONAL EXPERIENCE
P. Sharma1, S. Shinde2,* N. Gangat3, A. Al-Kali3, S. Hashami3, M. Litzow3,
W. Hogan3, S. Khan4, V. Rodriguez4, M. Patnaik3
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Background: Clonal myeloid neoplasms with overlapping features of
myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN),
based on the 2008 WHO criteria, are categorized as MDS/MPN overlap syn-
dromes. This subgroup includes well-defined entities such as, chronic
myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML)
and atypical chronic myeloid leukemia (aCML), along with lesser-defined enti-
ties such as, refractory anemia with ring sideroblast and thrombocytosis (RARS-
T) and MDS/MPN- unclassifiable (MDS/MPN-U). Clinical outcomes are variable
and allogeneic hematopoietic stem cell transplant (allo-HCT) remains the only
potentially curative option. 
Aims: To describe transplant and survival outcomes in patients with MDS/MPN
overlap syndromes that underwent allo-HCT. 
Methods: After IRB approval, consecutive patients with MDS/MPN overlap
who underwent allo-HCT from 1990 to 2014 were identified and data was ret-
rospectively abstracted.
Results: Of 51 patients (males: 62%) with MDS/MPN overlap, 36 had CMML
(70%), 6 JMML (12%), 8 MDS/MPN-U (16%) and 1 aCML (2%). Median age was
54 years (range, 18- 68 years) in adult patients and 38 months (range, 3- 72
months) in JMML patients. (a) CMML: Of 36 patients (median age 51 years,
range 66-18 years), 19 (52%) had CMML-1 (13 myeloablative conditioning, MAC;
6 reduced intensity conditioning, RIC) and 17 had CMML-2 (9 MAC; 8 RIC). The
proportion that proceeded directly to transplant without prior chemotherapy was
similar between MAC (12 patients/ 55%) and RIC (8 patients/ 57%). Post-trans-
plant CR was achieved in 23 (64%) patients (MAC: 15, RIC 8). Median follow-up
was 21 months (range 0.7- 191) with 2 years overall survival of 44% (n=16) and
non-relapse survival of 36% (n=13). Common causes of non-relapse mortality
(NRM) were related to chronic GVHD (27%) and sepsis (27%). 27 patients (75%)
experienced acute-GVHD (grade 3/4: 9, 33%) and 22 (61%) had chronic-GVHD.
More patients with chronic-GVHD died due to non-relapse causes (71% NRM
versus 40% in those without chronic-GVHD). In multivariate analysis, engraftment
failure (n=1, p <0.001) and higher HCT-comorbidity index (HCT-CI) were inde-
pendent predictors of survival (HCT-CI >3, n=23; HCT-CI ≤3, n=13; p=0.03), and
importantly, none of the conventional risk stratifying models predicted survival
(Patnaik BJH 2014). (b) JMML: All 6 patients underwent MAC allo-HCT (5 periph-
eral blood stem cell transplant (PBSCT) and 1 umbilical cord blood transplant,
(UCT)). Acute-GVHD occurred in 1 (grade 2) and chronic-GVHD in 2 patients.
Median follow-up was 11 years and at last follow-up, 1 patient had died (1.8 years
post-transplant) due to sepsis following bowel obstruction. 2 patients relapsed in
the first year post-transplant and achieved remission with subsequent transplants.
(c) MDS/MPN-U: Of the 8 patients (5 PBSCT, 1 BMT, 2 UCT), 6 (75%) underwent
RIC allo-HCT. 7 patients (88%) experienced acute-GVHD (grade 3/4: 3, 43%)
and 4 had chronic-GVHD. Median follow-up was 15 months. At last follow up, 4
patients (50%) were alive, 3 died due to relapse (3 months, 5 months, 19 months)
and 1 died in remission due to immune mediated lung injury. (d) aCML: One
female with aCML received PBSCT following MAC. She died 6.7 years post-
transplant due to chronic-GVHD (Table 1).
Table 1. Clinical and laboratory features of CMML patients who have
undergone allogeneic stem cell transplant.
Summary and Conclusions: Allo-HCT is a viable treatment option for
patients with MDS/MPN overlap syndromes, with 3-year combined disease-
free survival rates of 32% in adults with CMML and aCML, 43% in JMML and
1-year disease-free survival rate of 62% in adults with MDS/MPN-U. In
patients with CMML, engraftment failure and co-morbidity index have prog-
nostic implications, while conventional prognostic models were unable to pre-
dict transplant outcomes.
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FEASIBILITY OF LENALIDOMIDE MAINTENANCE AFTER NONMYELOAB-
LATIVE ALLOGENEIC TRANSPLANTATION (NMAT) IN CHRONIC LYMPHO-
CYTIC LEUKEMIA (CLL)
I. Khouri1,* A. Gulbis2, C. Ledesma1, M. Korbling1, F. Turturro3, C. Bueso-Ramos4,
E. Jabbour5, R. Bassett jr6
1Stem Cell Transplantation and Cellular Therapy, 2Pharmacy Clinical Programs,
3Lymphoma/Myeloma, 4Hematopathology, 5Leukemia, 6Biostatistics, MD
Anderson Cancer Center, Houston, United States
Background: NMAT is an effective therapy for relapsed/refractory CLL patients
(pts). Results and safety using the FCR (fludarabine, cyclophosphamide, ritux-
imab) regimen were previously described (Khouri et al. Cancer 2011; 117:4679-
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88). About 50% of pts with refractory disease at study entry required immuno-
manipulation (IMM)[early immunosuppression withdrawal after NMAT and
donor lymphocyte infusion (DLI)]. This is a significant cause of morbidity and
graft-versus-host- disease (GVHD). Maintenance with lenalinomide post NMAT
may improve outcomes by promoting the immune-mediated graft-versus-tumor
effect and lessen the need for IMM.
Aims: To assess the feasibility (dose, toxicity and GVHD) of lenalidomide main-
tenance after NMAT in CLL.
Methods: This is a phase II randomized study that included relapsed/refractory
CLL pts who were eligible to undertake NMAT after FCR conditioning [later
replaced with the advent of the BFR regimen (bendamustine, fludarabine, rit-
uximab) in 2011 (Khouri et al. Blood 2014; 124:2306)]. Pts were randomized
at day 90-100 post NMAT to receive lenalinomide if they had persistent active
CLL, engrafted donor cells, and no active GVHD, with ANC≥1,500/μL and
platelets ≥70,000/μL. Lenalidomide was initiated at 5mg every other day (qod)
with an increase to 10mg/day if tolerated. 
Results: Of the 38 pts studied, 17 (48%) met the eligibility for randomization.
Characteristics of non-randomized pts (n=21; Group A), pts randomized to receive
lenalinomide maintenance (LM+) (n=8, Group B), or not (n=9, Group C) were sim-
ilar and included median age (60, 55 and 56 years in the 3 groups, respectively),
sex distribution, and percent of pts with ≥3 prior therapies (60% vs 38% vs 44%,
respectively), percent of pts with β2-microglobulin ≥3 mg/L at study entry, refractory
disease (75% vs 50% vs 67%, in the 3 groups respectively), unmutated status
(100% vs 67% vs 100%, in the 3 groups respectively), donor/recipient CMV, sex-
mismatched distributions and donor type (matched unrelated in 65%, 50% and
56%, in Groups A,B and C, respectively). Presence of 17p deletion was detected
in 30% of Group A and 22% in Group C; none of the pts randomized to LM+ had
17p deletion. FCR was the NMAT conditioning in 55%, 75% and 78% of pts in the
3 groups, respectively, and the remaining pts received BFR. One pt refused LM+
after randomization. Maximum tolerated dose for LM+ was 5 mg qod in one pt
due to dermatitis, 5 mg/day in 2 pts (cytopenia in one; liver toxicity and cytopenia
in the other), 10 mg/day in 4 pts (1 opted to stop at 2.5 months and one died of
pneumonia at 2 months; one achieved complete remission (CR) and stopped
LM+ at 4 months due to rash and pt later relapsed; and one took 10 mg/day for 1
year without achieving CR. The need for IMM was 53%, 57% and 56%, in groups
A, B, and C respectively. DLIs were needed in 10% vs 38% and 22%, respectively.
The incidence of acute grade 2-4 GVHD was 47% for group A, and 50% vs 11%
for groups B and C (P=0.11). The incidence of chronic GVHD was 40% vs 42%
vs 59% in the 3 groups, respectively. Treatment-related-mortality at 1-year was
30% vs 12.5%, and 11%, in Groups A, B and C, respectively. With a median fol-
low-up time of 31 months (range, 13-65), the 3-year overall survival rates for
groups A,B and C were 42% vs 56% vs 63.5%, respectively (P=0.6) and the pro-
gression-free survival rates were 30% vs 25% vs 67%, respectively. The use of
BFR resulted in a trend for a better OS (2-year 83% vs 54%) and PFS (64% vs
33%) than the FCR regimen.
Summary and Conclusions: This trial suggests that maintenance lenalido-
mide after NMAT for CLL is not feasible and that alternative strategies are
needed to treat persistent disease . The preliminary results after BFR condi-
tioning are encouraging and a larger trial is ongoing to confirm these findings.
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ENGRAFTMENT SYNDROME (ES) AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A HIGH INCIDENCE IN HAPLOIDENTICAL SETTING
Y. Chen1,* L.-P. Xu1, K.-Y. Liu1, H. Chen1, Y.-H. Chen1, X.-H. Zhang1, Y. Wang1,
X.-J. Huang1
1Peking University People’s Hospital, Institute of Hematology, Beijing, China
Background: Engraftment syndrome, a clinical entity presented with non-infec-
tious fever, skin rash within peri-engrfatment period, has been described in
patients receiving various types of allogeneic stem cell transplantation (SCT).
However, ES in haplo setting remains poorly characterized, and the prognosis
and appropriate management are unclear. 
Aims: Here, we attempted to determine the incidence, manifestations, and
outcomes of ES after haploidentical SCT.
Methods: We compared the incidence of ES in 516 patients received hap-
loidentical SCT and in 393 patients received HLA-identical sibling SCT, between
Octorber 2001 and Octorber 2012 were collected retrospectively. ES was
described as unexplained fever and skin rash within 24 h of the start of neu-
trophil recovery by Maiolino’s criteria.
Results: The incidence of ES was significantly higher in haploidentical type than
the other one (21.9% vs 2.0%, P < 0.001). Major symptomes included fever
(119/121, 98.3%), skin rash (98/121, 81.0%) and diarrhea (51/121, 42.1%), with
the median time of +10 (6-20) days. Significantly higher median increases in
CRP level were observed in 13 samples of ES group than in 38 samples of the
non-ES group (99.0 vs 13.9 mg/L, P <0.001). Similarly, the results showed higher
plasma concentration of C3 in the ES group compared with non-ES group (mea-
dian: 1.30 vs 1.16 g/L, P=0.003). ES patients had a significantly higher incidence
of grade II-IV aGVHD and than the non-ES group (42.1% vs 24.6%, P<0.001).
No difference of non-relapse mortality or overall survival were noted between
ES group and non-ES group in each transplant setting.
Summary and Conclusions: Higher incidence of ES was observed in hap-
loidentical type, but it did’t predict poor clinical outcomes.
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versity, Shanxi,China, 11The First Hospital of Peking University, Beijing,China,
12The First Affiliated Hospital of Zhejiang University, Zhejiang,China, 13Affiliated
Union Hospital of Fujian Medical University, Fuzhou,China, 14307 Hospital of
PLA, Beijing, China, 15Shanghai Ruijin Hospital, Shanghai,China, 16Jiangsu
Province Hospital, Jiangsu,China, 17Sanofi R&D, Shanghai,China, 18Sanofi
R&D, Beijing, China
Background: Plerixafor, a small molecule chemokine receptor 4 (CXCR4)
antagonist, has been shown to increase mobilization of CD34+ cells for Cau-
casian non-hodgkin’s lymphoma (NHL) patients in a Phase 3 trial.
Aims: This Phase 3 trial was conducted to confirm efficacy and safety of pler-
ixafor in Chinese NHL patients.
Methods: Patients in first or second complete remission or partial remission
received morning granulocyto colony stimulating factor (G-CSF, 10µg/kg/day).
Since Day 4 evening, patients started plerixafor 0.24 mg/kg/day or placebo
(1:1 ratio) in addition to G-CSF treatment for a maximum of 4 apheresis days.
Apheresis could be discontinued if optimal target (5x106 CD34+ cells/kg) was
reached earlier. 
Results: One hundred patients were randomized. A total of 12 patients (3 in
plerixafor arm and 9 in placebo arm) discontinued mainly due to adverse events
(1 in plerixafor arm and 7 in placebo arm). Patients’ demographics and baseline
characteristics were similar between groups. The primary endpoint was met
as 62% (31/50) patients in the plerixafor group, and 20% (10/50) patients in
the placebo group achieved optimal target (p<0.0001). 88% patients with pler-
ixafor and 66% patients with placebo reached minimum target (2 X 106 CD34+
cells/kg). Median time needed to achieve optimal target was 2 days in plerixafor
group and not reached in placebo group. Median time to engraftment of neu-
trophil (10 days for both groups) and platelet (19 days vs 17 days) were similar
between groups. The incidence of adverse events was similar between groups
(62.7% vs 63.3%). Neither unexpected adverse events nor serious adverse
events were observed in treatment period.
Summary and Conclusions: This study demonstrated that plerixafor plus G-
CSF was superior to G-CSF alone to mobilize CD34+ cells for autologous
transplantation in Chinese NHL patients. Patients who received plerixafor plus
G-CSF were statistically significantly more likely to achieve both optimal and
minimum CD34+ cells collection targets and in less time than patients receiving
G-CSF alone. Plerixafor plus G-CSF was a safe and well tolerated mobilization
regimen in this Chinese NHL population.
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INFLUENCE OF CYP3A5 GENE POLYMORPHISMS ON PHARMACOKI-
NETICS OF TACROLIMUS MODIFIED-RELEASE ONCE-DAILY AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
T. Yamashita1,* N. Fujishima2, M. Miura3, T. Niioka3, M. Abumiya3, K. Teshima1,
K. Ubukawa1, M. Nara1, M. Fujishima1, Y. Kameoka1, M. Hirokawa1,4,
N. Takahashi1
1Akita University Graduate School of Medicine, Department of Hematology,
Nephrology, Rheumatology, 2Akita University Graduate School of Medicine,
Department of blood transfusion, 3Akita University Hospital, Department of
Pharmacy, 4Akita University Graduate School of Medicine, Department of Gen-
eral internal medicine and Clinical laboratory medicine, Akita, Japan
Background: Modified-release, once-daily dosage of tacrolimus (Tac-QD) has
been developed to provide more convenient dosing and to improve patient
adherence. Tac-QD is confirmed to have equivalent safety and efficacy as
twice-daily tacrolimus (Tac-BID), and the renal dysfunction side effect of Taq-
QD is the same as Taq-BID. Tac-QD is strongly affected by cytochrome P450
(CYP) 3A4/5, which is expressed in the small intestine and hepatocytes. The
blood concentration of tacrolimus in a patient who has received renal trans-
plantation with CYP3A5 *3/*3 (poor metabolizer ; PM) is higher than CYP3A5
*1/*1 or *1/*3 (extensive metabolizer ; EM) patients. Furthermore, the azole
antifungal agents, fluconazole, itraconazole and voriconazole, are routinely
used as prophylaxis against Aspergillus infection and administered to HSCT
recipients receiving tacrolimus, and those azole antifungal agents potently
inhibit the activity of CYP3A. 24 patients who underwent allogeneic HSCT were
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enrolled. Before HSCT, CYP3A5 *3 allele was detected using a PCR-restriction
fragment length polymorphism method. After HSCT, continuous infusion of 0.03
mg/kg/day tacrolimus was administered to prevent acute graft-versus-host dis-
ease (aGVHD). On days 20-30 after transplantation, patients were switched to
Tac-QD administered about 4 times orally. We collected venous blood samples
just before (C0h) to determine the blood concentration of Tac-QD and check
the organs dysfunction. From day 7 after oral administration of Tac-QD, 21
patients were administered orally azole antifungal agent. After the co-adminis-
tration of azole antifungal agent, we were subjected to the same test. Before
and after the co-administration of azole antifungal agent and Tac-QD, blood
concentrations of tacrolimus were determined by the chemiluminescence mag-
netic microparticle immunoassay.
Aims: We identified influence of CYP3A5 gene polymorphisms on Tac-QD in
patients after hematopoietic stem cell transplantation (HSCT).
Methods: 24 patients who underwent allogeneic HSCT were enrolled. Before
HSCT, CYP3A5 *3 allele was detected using a PCR-restriction fragment length
polymorphism method. After HSCT, continuous infusion of 0.03 mg/kg/day
tacrolimus was administered to prevent acute graft-versus-host disease
(aGVHD). On days 20-30 after transplantation, patients were switched to Tac-
QD administered about 4 times orally. We collected venous blood samples just
before (C0h) to determine the blood concentration of Tac-QD and check the
organs dysfunction. From day 7 after oral administration of Tac-QD, 21 patients
were administered orally azole antifungal agent. After the co-administration of
azole antifungal agent, we were subjected to the same test. Before and after
the co-administration of azole antifungal agent and Tac-QD, blood concentra-
tions of tacrolimus were determined by the chemiluminescence magnetic
microparticle immunoassay.
Results: 14 patients have CYP3A5 *3/*3 (PM) and 10 patients have CYP3A5
*1/*1 or *1/*3 (EM). Before the co-administration of azole antifungal agent, we
did not recognize significant differences between CYP3A5-PMs and CYP3A5-
EMs about C0h and dose of tacrolimus. However, after the co-administration of
azole antifungal agent, although CYP3A5-PMs had a reduced dose of Tac-QD
than CYP3A5-EMs (p=0.041), C0h of tacrolimus was higher with a significant
difference (p=0.034). Additionally, acute renal dysfunction occurring in patients
with elevated C0h of tacrolimus was remarkable. The risk factors of acute renal
dysfunction were CYP3A5-PM (p=0.024) and C0h with azole antifungal agent
co-administration of tacrolimus (p=0.020). C0h of tacrolimus which is a measure
of the onset acute renal dysfunction was 10 ng/ml. The virus infection and
fungal infection showed no significant differences between CYP3A5-PMs and
CYP3A5-EMs.
Summary and Conclusions: In this study, we recognized that C0h of
tacrolimus with azole antifungal agent co-administration in CYP3A5-PMs was
higher than that of CYP3A5-EMs, and acute renal dysfunction was occurred.
Therefore, when we administer Tac-QD with azole antifungal agent co-admin-
istration in CYP3A5-PMs, Tac-QD dosage should be individualized based on




INTERFERONΑ: A POTENTIAL EFFECTIVE TREATMENT FOR MINIMAL
RESIDUAL DISEASE IN ACUTE LEUKEMIA/MYELODYSPLASTIC SYN-
DROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
X.-D. Mo1,* X.-H. Zhang1, L.-P. Xu1, Y. Wang1, C.-H. Yan1, H. Chen1,
Y.-H. Chen1, W. Han1, F.-R. Wang1, J.-Z. Wang1, K.-Y. Liu1, X.-J. Huang1,2,3
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking-Tsinghua Center for Life Sciences, 3Beijing Key Laboratory of
Hematopoietic Stem Cell Transplantation, Beijing, China
Background: Preemptive intervention with donor lymphocyte infusion (DLI)
based on minimal residual disease (MRD) status is one of the most important
methods for relapse prophylaxis in acute leukemia patients receiving allogeneic
hematopoietic stem cell transplantation (HSCT). However, some patients could
not receive further DLI because of provider refusal; in addition, some patients
disagree to receive DLI after HSCT. Interferon (IFN)-α may be the potential
alternative option for MRD positive patients after allogeneic HSCT.
Aims: The safety and efficacy of preemptive IFN-α were investigated and were
compared with those of preemptive DLI in patients who were minimal residual
disease (MRD) positive after allogeneic HSCT.
Methods: Patients receiving allogeneic HSCT were eligible if they had acute
leukemia or myelodysplastic syndromes and MRD turning positive after HSCT.
The patients who could receive DLI were assigned to a preemptive DLI group
(n=49). The patients who could not receive DLI or be disagree to receive DLI
after HSCT received preemptive IFN-α(n=25). MRD was monitored according
to leukemia-associated immunophenotypes and genes. Informed consent was
obtained from all patients, and the study was conducted in accordance with
the Declaration of Helsinki. The study protocol was approved by the Ethics
Committee of Peking University People’s Hospital.
Results: A total of 25 patients received preemptive IFN-α, and the median
duration of IFN-αtherapy was 35 days (4-180 days). Nine patients relapsed,
and 1 patient died from severe pneumonia. The 2-year cumulative incidence of
chronic graft-versus-host disease (cGVHD) after HSCT was 88.0% and 59.1%
in IFN-α and DLI groups (P=0.006). The MRD status after preemptive inter-
vention was comparable between IFN-α and DLI groups, and the 2-year cumu-
lative incidence of relapse was 33.7% and 39.4%, respectively (P=0.812). The
2-year cumulative incidence of non-relapse mortality was 4.0% and 2.1%,
respectively, in IFN-α and DLI groups (P=0.678). The 2-year probabilities of
disease-free survival was 67.5% and 58.5%, respectively, in IFN-α and DLI
groups (P=0.711). In multivariate analysis, early-onset MRD, persistent MRD
after intervention, and non-cGVHD after intervention were significantly associ-
ated with poorer clinical outcomes.
Summary and Conclusions: Preemptive IFN-α may be the potential alterna-
tive option for MRD-positive patients who could not receive preemptive DLI
after HSCT.
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INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC
COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER
STUDY OF 551 PATIENTS
Y. Han1,* W. Han1, L. Hu1, Y. Tang1, J. Wang1, H. Qiu1, A. Sun1, C. Ruan1, D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Hemostatic disorders are common and potentially fatal compli-
cations in patients undergoing allogeneic hematopoietic stem-cell transplanta-
tion. However, Limited data exists on early diagnosis and prevention of these
complications.
Aims: To explore the incidence, risk factors, and outcome of early hemostatic
complications in patients after allogeneic hematopoietic stem cell transplantation.
Methods: In this study, 551 allogeneic transplantation recipients were enrolled
to investigate the incidence, risk factors, and outcome of thrombotic or bleeding
complications in the first 100 days after transplantation.
Results: Of all the patients, 261 cases (47.4%) developed bleeding events,
the cumulative incidence of minor, moderate, and severe bleeding was 28.9%,
14.9% and 3.8%, respectively. The incidence of thrombotic complications was
4.5% (25/551 cases), consisting of 15 cases of veno-occlusive disease, 7
thrombotic microangiopathy, 2 pulmonary embolism, and 1 deep vein throm-
bosis. Risk factor analysis demonstrated that veno-occlusive disease, II-IV
acute graft-versus-host disease and cord blood transplantation were independ-
ent predictors for bleeding complications in multivariant analysis and platelet
counts less than 10×109/L were significantly associated with severe bleeding.
Meanwhile, mismatched donor, polyomavirus BK infection, cytomegalovirus
infection and II-IV acute graft-versus-host disease were potential risk factors
for late-onset hemorrhagic cystitis, while total body irradiation conditioning reg-
imen and high-risk disease status prior to transplantation were significantly
associated with the occurrence of thrombotic disorders. Severe hemorrhage
and early-onset of thrombotic disorders independently increased the mortality
of allogeneic transplantation recipients. However, late-onset hemorrhage cystitis
did not appear to affect the survival rate significantly.
Summary and Conclusions: Our study demonstrated that hemostatic com-
plications following transplantation have much high mortality. Therefore, early
diagnosis and therapeutic intervention of hemostatic complications are crucial
to improve the outcome of allogeneic hematopoietic stem cell transplantation
recipients. 
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A PROSPECTIVE CLINICAL TRIAL OF PROLONGED AUTOLOGOUS ERY-
THROPOIETIN (EPO) SECRETION FROM TARGTEPO IN EPO-DEPEN-
DENT END STAGE RENAL DISEASE PATIENTS SHOWED EPO INDE-
PENDENCE FOR OVER 8 MONTHS
S. Blum1,* N. Shapir2, R. Miari2, A. Liran2, B. Lerner1, K. Doenyas-Barak3,
S. Efrati3, D. Schwartz4, G. Chernin4, G. Neil5
1Clinical Department, 2R&D, Medgenics Inc., Misgav, 3Research & Develop-
ment unit and Nephrology unit, Assaf-Harofeh Medical Center, Zrifin, 4Nephrol-
ogy and Dialysis Department, The Tel Aviv Sourasky Medical Center, Tel Aviv,
Israel, 5R&D, Medgenics Inc., Wayne, United States
Background: Recombinant human Erythropoietin (rHuEPO) along with iron
supplementation corrects anemia in most patients with End Stage Renal Dis-
ease (ESRD) but is associated with supra-physiological peak serum concen-
tration (Cmax) of EPO and may cause thromboembolic complications in these
patients. The Transduced Autologous Restorative Gene Therapy system
(TARGT™) is an ex-vivo gene therapy platform that provides autologous,
continuous protein or peptide therapy in the physiological range. The system
consists of several 2x30 mm pieces of dermal tissue (Micro-Organ, MO),
extracted under local anesthetic in which its fibroblasts cells are transduced
with a viral vector containing a gene of interest. TARGTEPO refers to a TARGT
that provides EPO. After culture, and measurement of in-vitro EPO produc-
tion, one or more transduced MOs secreting EPO (TARGTEPOs) are re-
implanted subcutaneously as required for delivering the target dose. Patients
are treated with local steroid injection to stabilize secretion. The system allows
dose flexibility and the TARGTs may be added or removed according to the
in-vivo secretion levels. 
Aims: We present here initial results from an-ongoing open label ascending
dose exploratory clinical study of TARGTEPO in patients with anemia due to
ESRD. 
Methods: This study was approved by the Ethics Committees of the partici-
pating sites in Israel and the TARGTEPO product was cleared for clinical testing
by the Israeli Ministry of Health. All patients have signed an informed consent
prior to enrollment in the study. We have completed the enrollment of patients
in the first out of 3 cohorts (the low dose) with 6 EPO-dependent patients
treated with a total of up to 3 TARGTEPO units each, secreting a total of 25
IU/Kg/Day of autologous EPO. All patients continued their previous regimen of
intravenous supplemental iron. 
Results: Efficacy data in this ongoing study is being continuously assessed
as per protocol. Patient follow-up post implantation is ongoing, while the first
patient implanted has completed 8 months of follow up with stable EPO secre-
tion and stable Hb. Results obtained from the 6 patients enrolled thus far sug-
gest stabilization of serum EPO levels at the physiological range of ≤20 mIU/ml
and the resulting Hb levels between 9-12 g/dL without rHuEPO or transfusion
while TARGTEPOs are still functioning. Comparative analysis of serum EPO
levels revealed significantly lower Cmax with TARGTEPO compared to rHuEPO.
Also, comparison of extrapolated Area Under the Curve (AUC) of rhEPO vs
actual TARGTEPO AUC, revealed that TARGTEPO maintained Hb within the
desired range in these patients with an order of magnitude smaller exposure
to EPO compared to rHuEPO. This observation may have significant clinical
benefits. No treatment related serious adverse events have been reported. 
Summary and Conclusions: TARGTEPO is a promising novel therapy for ane-
mia and the TARGT platform may have promise for other diseases requiring
protein or peptide based treatment.
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ADOPTIVE IMMUNOTHERAPY OF MULTIPLE MYELOMA (MM) WITH
ALLOGENIC CAR T-CELLS TARGETING CS1: ENHANCEMENT OF CAR
ACTIVITY THROUGH CS1 GENE INACTIVATION IN EFFECTOR CELLS
R. Galetto1,* I. Chion-Sotinel1, P. Francon1, J. Smith 1
1Cellectis, Paris, France
Background: Chimeric antigen receptor (CAR)-redirected T-cells have been
successfully used in patients with refractory leukemia by targeting the CD19
molecule, yielding long-term durable remissions and raising hopes that a wider
application of CAR technology may lead to a new paradigm in cancer treatment.
Nevertheless, the CAR approach is restricted to targeting antigens expressed
at the tumoral cell surface but absent from T-cells, since CAR expression will
deplete antigen-expressing T-cells and thus reduce the chances to efficiently
produce CAR specific T-cells. Multiple Myeloma (MM) is a B-cell neoplasia
characterized by clonal expansion of malignant plasma cells in the bone mar-
row, and although currently available therapies can improve overall survival it
still remains incurable in most patients. Immunotherapy against MM is one
area in which extensive research is being made, with novel antigenic targets
being considered to drive eradication of plasma cells. Among these, the CS1
glycoprotein is highly expressed on tumor cells from most of patients with MM,
making it an attractive antigen for CAR targeting.
Aims: Expression of CS1 on normal CD8+ T-cells is potentially an obstacle for
the development of CAR T-cells targeting CS1. The objective of this work was
therefore to evaluate if CS1 expression on T-cells could have an impact on
CAR activity.
Methods: To address this limitation, Transcription Activator-Like Effector Nucle-
ase (TALEN) gene editing technology was used to inactivate the CS1 gene in
T-cells, prior to transduction with a lentiviral vector encoding an anti-CS1 CAR.
Results: We will present data showing that non-gene-edited T-cells express-
ing an anti-CS1 CAR display limited cytolytic activity against MM cells express-
ing the CS1 antigen as well as a progressive loss of CD8+ T-cells in the effec-
tor cell population. In contrast, CS1-gene-edited CAR cells display significantly
increased cytotoxic activity with the percentage of CD8+ T-cells remaining
unaffected. Experiments in an orthotopic MM mouse model are currently ongo-
ing, in order to investigate the impact of CS1 gene disruption on in vivo anti-
tumoral activity.
Summary and Conclusions: Gene editing technology can also be used to
manufacture T-cells from third-party healthy donors to generate allogeneic “off-
the-shelf” engineered CAR+ T-cell-based frozen products. We have previously
demonstrated that TALEn mediated inactivation of the TCRa constant (TRAC)
gene can be achieved at high frequencies and eliminate the potential for edited
T-cells to mediate Graft versus Host Disease (GvHD). Furthermore, multiplex
genome editing can lead to the production of double KO (TRAC and CS1) T-
cells, allowing large scale manufacturing of allogeneic, non alloreactive CS1
specific T-cells that display enhanced antitumor activity. This technology there-
fore offers the possibility of developing an off-the-shelf cell therapy product
that would be immediately available for administration to a large number of
MM patients.
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EVALUATING HUMAN T-CELL THERAPY OF CYTOMEGALOVIRUS
ORGAN DISEASE IN HLA-TRANSGENIC MICE
S. Thomas1,2,* N. Lemmermann3, S. Klobuch1, J. Podlech3, B. Plachter3,
M. Theobald4, M. Reddehase3, W. Herr1,2
1Department of Internal Medicine III, University Hospital of Regensburg,
2Regensburg Center of Interventional Immunology, University of Regensburg,
Regensburg, 3Institute for Virology, 4Department of Internal Medicine III, Uni-
versity Medical Center of the Johannes Gutenberg-University, Mainz, Germany
Background: Reactivation of human cytomegalovirus (HCMV) can cause
severe disease in recipients of hematopoietic stem cell transplantation.
Although preclinical research in murine models as well as clinical trials have
provided ‘proof of concept’ for infection control by pre-emptive CD8 T-cell
immunotherapy, there exists no predictive model to experimentally evaluate
parameters that determine antiviral efficacy of human T cells in terms of virus
control in functional organs, prevention of organ disease, and host survival
benefit.
Aims: Here we introduce a novel mouse model for testing HCMV epitope-spe-
cific human T cells. In this, we combined the well-described murine model of
mCMV infection of the immunocompromised host with the strong T-cell
immunogenicity of the HLA-A*0201 restricted HCMV epitope pp65495-503
NLVPMVATV (NLV). We generated a chimeric recombinant mCMV expressing
the NLV epitope (mCMV-NLV) during the infectious cycle to allow organ man-
ifestation of the infection in the natural host similar to that seen in immuno-
compromised patients.
Methods: For construction of the chimeric virus mCMV-NLV we integrated
the coding gene sequence of the HLA-A2.1 restricted pp65495-503 peptide
epitope NLVPMVATV (NLV) of HCMV into the immediate-early (IE)2/m128
gene of mCMV-Δm157. To determine in vivo antigenicity of mCMV-NLV and
protective activity of NLV epitope-specific T cells, we infected sublethally irra-
diated HLA-A2.1 transgenic NOD/SCID/IL-2Rγc-/- mice transgenic
(NSG/HHD) by intraplantar injection with 1x105 PFU of mCMV-NLV, a dose
that would be lethal after approximately 12 to 17 days. Shortly thereafter, we
adoptively transferred murine or human NLV-specific T cells in order to mimic
the clinical setting of pre-emptive therapy, and analyzed viral titers in spleen
and lungs as well as numbers of infected cells in livers of individual mice on
day 11.
Results: After infection of immunocompromised NSG/HHD mice, mCMV-NLV
resulted in a rapid systemic infection that could be effectively combated by
adoptively transferred murine and human NLV-specific CD8 T cells as well as
by human CD8/CD4 T cells transduced with an NLV-specific T-cell receptor.
Upon transfer, the T cells infiltrated host tissues in an epitope-specific manner,
confining the infection to nodular inflammatory foci. This resulted in a significant
reduction of viral load, prevention of organ pathology, and prolonged survival.
Collectively, these data demonstrated that NLV-specific human T cells mediate
HCMV NLV-specific immune control in mCMV-NLV infected NSG/HHD mice,
even across the human-mouse species barrier.
Summary and Conclusions: The model has proven its potential for a pre-
clinical testing of the protective antiviral efficacy of HCMV epitope-specific
human T cells in the evaluation of new approaches to an immunotherapy of
CMV disease.
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NOVEL HUMAN IL-15 SUPERAGONIST PROMOTES LONG-TERM PER-
SISTENCE AND REACTIVITY OF HUMAN EBV- AND LEUKEMIA-SPECIFIC
CD8+ T CELLS WITH STEM CELL MEMORY AND CENTRAL MEMORY
PROPERTIES IN HUMANIZED MICE
A. Mades1, S. Khan1, M. Theobald1, U.F. Hartwig1,*
1III. Dept. of Medicine - Hematology, Internal Oncology & Pneumology, Univer-
sity Medical Center Mainz, Mainz, Germany
Background: Adoptive cellular therapy (ACT) using leukemia-reactive T cells
has evolved as a promising strategy to improve antileukemic immunity. How-
ever, durable clinical responses are often hampered by limited sustained reac-
tivity of fully differentiated effector T cells or graft-vs-host disease when HLA-
matched donor-derived T cells are applied. In addition to the transfer of
leukemia-reactive stem cell memory (TSCM) and central memory (TCM) T cells,
IL-15 has emerged as a promising cytokine to improve ACT as it facilitates the
in vitro generation of leukemia-reactivity from naive CD8+CD45RA+ precursors,
supports engraftment of adoptively transferred CD8+ T cells in lymphopenic
hosts and promotes homeostasis and formation of T cell memory.
Aims: In the current study we therefore investigated whether a novel IL-15
superagonist could promote engraftment, expansion, persistence and cytolitic
acvtivity of human CD8+ T cells in humanized NSG mice.
Methods: A novel high affinity human IL-15 superagonist (IL15N72D-
IL15Rα/Fc referred to as ILR-Fc) was generated by exchanging asparagine
(N) to aspartic acid (D) at position 72 reported to increase the biological activ-
ity of IL-15. The modified IL-15 sequence was then linked to the IL-15-binding
Sushi-domain of IL-15Rα. To improve bioavailibility of the IL-15 complex the
truncated IL-15Rα was fused to the Fc-domain of human IgG1. HLA-A2 reac-
tive CD8+ T cells were generated by repetitive stimulation of human CD8+ T
cells isolated from peripheral blood mononuclear cells (PBMC) by MACS®
with HLA-A2 expressing K562 transfectants. To generate Epstein-Barr Virus
(EBV) and acute myeloid leukemia (AML)-specific T cells in vitro, naive
CD8+CD45RA+ T cells were isolated using the naive T cell isolation kit (Mil-
tenyi Biotec) and repetitively stimulated with autologous, EBV-peptide loaded
dendritic cells and peptide loaded PBMC or with HLA-matched primary AML
blasts and feeder cells in the presence of a optimized cytokine cocktail and
the Gsk3 inhibitor TWS119, which modulates the Wnt-signaling pathway
resulting in strong enrichment of T cells with a TSCM and TCM phenotype.
Phenotypic and functional analyses in vitro were performed by FACS and
IFN-g ELISPOT- or 51Cr-release assays, respectively.
Results: The Expi293 Expression System™ (Invitrogen) was applied to pro-
duce soluble ILR-Fc. Following transfection and expansion of modified 293T
cells growing in suspension protein-A affinity based purification of ILR-Fc
resulted in ≥1mg recombinant protein/25 ml culture. In vitro bioactivity analy-
ses of ILR-Fc as compared to IL-15 (N72D) produced in E coli revealed that
ILR-Fc was ≥10 fold more active when tested on M07e cells. To test for growth
promoting effects on T cells in a lymphopenic environment, we first injected
ILR-Fc into NSG mice previously humanized by engraftment of human CD34+
hematopoietic stem cells and observed robust expansion of primarily human
CD8+ T cells. Strong effects on expansion of splenic CD8+ T cells could be
further confirmed following injection of ILR-Fc into C57BL/6 mice. Moreover,
upon transfer of EBV- and AML-reactive CD8+ CTLSCM/CM into NSG mice
engrafted with autologous EBV-immortalized B cells or HLA-matched AML
blasts, resp., we observed prolonged persistence and superior reactivity in
mice receiving weekly i.p. injections of 60 ug ILR-Fc/mouse (equivalent to 10
ug IL-15) when compared to mice receiving T cells and 10 ug E. coli-derived
IL-15. This extended bioactivity was partially attributed to an increased half-
life of ILR-Fc in the serum as determined by IL-15 ELISA. In addition, ILR-Fc
treatment resulted in strongly reduced AML burden and regression of EBV-
lymphoma. Finally, adoptively HLA-A2-specific cytototxic CD8+ T lymphocytes
(CTL) caused xenogeneic GvHD in NSG mice in the presence of ILR-Fc when
compared to mice injected with CD8+ CTL alone.
Summary and Conclusions: These studies demonstrate that ILR-Fc has
potent and prolonged bioactivity to facilitate CD8+ T cell persistence and activity
in lymphopenic hosts and might thus serve as a valuable tool to improve selec-
tive CD8+ T cell-mediated immunotherapy.
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DENDRITIC CELL VACCINATION IN POSTREMISSION THERAPY OF AML:
RESULTS OF A CLINICAL PHASE I TRIAL AND OF PRECLINICAL STUDIES
TESTING COMBINATORIAL APPROACHES
F. Schnorfeil1,2,* F. Lichtenegger1,2, M. Rothe1,2, M. Schlüter1,2, J. Neitz1,2,
M. Brüggemann3, A. Moosmann4, B. Wagner5, R. Henschler5, T. Köhnke2,
V. Bücklein2, T. Altmann2, C. Geiger6, W. Hiddemann2, I. Bigalke7, G. Kvalheim7,
D. Schendel6, M. Subklewe1,2
1Clinical Cooperation Group Immunotherapy, Helmholtz Zentrum München,
2Department of Internal Medicine III, Klinikum der Universitaẗ Mun̈chen, Munich,
3Department of Hematology, University Hospital Schleswig-Holstein, Kiel, 4Clin-
ical Cooperation Group Immunooncology, Helmholtz Zentrum München,
5Department of Transfusion Medicine, Cellular Therapeutics and Hemostase-
ology, Klinikum der Universität München, 6Institute of Molecular Immunology,
Helmholtz Zentrum München, Munich, Germany, 7Department of Cellular Ther-
apy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Background: Immunotherapy is a promising treatment strategy to eradicate
residual chemorefractory leukemic cells in AML patients. We are currently con-
ducting a proof-of-concept phase I/II (6+14 patients) clinical trial using next-
generation dendritic cells for postremission therapy of AML (NCT01734304).
Besides therapeutic vaccination, immune checkpoint modulation represents
another strategy to enhance anti-tumor immune responses, which is now being
tested in various hematological malignancies.
Aims: The primary endpoint of the clinical trial is feasibility and safety, and sec-
ondary endpoints are immunological responses and disease control, with a
particular focus on MRD conversion. In preclinical studies we examine combi-
natorial approaches using DCs together with immune checkpoint modulation
to augment T cell activation and thus the efficacy of DC vaccination.
Methods: Next-generation DCs are generated in a GMP-compliant 3-day pro-
tocol including a TLR7/8 agonist containing maturation cocktail. DCs are loaded
with ivt-RNA encoding WT1 and PRAME as leukemia-associated antigens and
CMVpp65 as an adjuvant and surrogate antigen. Patients are vaccinated intra-
dermally with 5x106 DCs of each antigen up to 10 times within 26 weeks in
weekly to monthly intervals. To test the combinatorial approach, DCs and autol-
ogous T cells are cocultured in vitro with or without antibodies blocking inhibitory
ligand-receptor interactions (PD-L1, PD-1 or LAG-3) or an immunomodulatory
drug (lenalidomide). IFNγ secretion and proliferation are measured by FACS-
based assays.
Results: Eight patients have been enrolled into the trial so far. In 6/6 cases,
leukapheresis yielded sufficient monocytes to generate DCs for clinical appli-
cation. DCs secreted IL-12p70, migrated, expressed all three antigens and
activated antigen-specific T cells in vitro. Three patients have completed the
vaccination schedule. Delayed-type hypersensitivity (DTH) responses at the
vaccination site were observed in 4/4 patients, but no grade III/IV toxicities.
Multimer analyses revealed the induction of antigen-specific T cell responses
in 2/2 patients: a 10-fold increase of WT1-specific and a 6-fold increase of
CMVpp65-specific T cells in a CMV-seronegative patient were detected. TCR
repertoire analyses by next-generation sequencing revealed an enrichment
of particular clonotypes at DTH sites, supporting the induction of antigen-
specific immune responses. A patient with an impending relapse during the
vaccination schedule was treated with a combination of DC vaccination and
5-azacytidine, resulting in MRD conversion. In preclinical studies, the block-
ade of PD-L1, PD-1 or LAG-3 in DC-T cell cocultures resulted in 1.4-, 2- or
5.9-fold augmented IFNγ secretion. Addition of lenalidomide induced a 5.4-
fold increase in IFNγ secretion. All four agents additionally enhanced T cell
proliferation.
Summary and Conclusions: We conclude that next-generation DCs are capa-
ble to induce tumor-specific immune responses in vivo. Moreover, our in vitro
studies suggest that the efficacy of DC vaccination can be enhanced by con-
current immune checkpoint modulation.
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COMBINATION OF IBRUTINIB AND ANTI-CD19 CHIMERIC ANTIGEN
RECEPTOR T CELLS FOR THE TREATMENT OF RELAPSING/REFRAC-
TORY MANTLE CELL LYMPHOMA (MCL)
M. Ruella1,* S. Kenderian1,2, J. Fraietta1, O. Shestova1, S. Qayyum3, Q. Zhang3,
X. Liu3, M. Maus1,4, S. Lacey1, A. Mato4, S. Schuster4, C. June1, M. Wasik3,
S. Gill1,4
1Translational Research Program, University of Pennsylvania, Philadelphia,
PA, 2Hematology and Oncology, Mayo Clinic, Rochester, MN, 3Pathology and
Lab. Medicine, 4Hematology and Oncology, University of Pennsylvania,
Philadelphia, PA, United States
Background: The Bruton Tyrosine Kinase (BTK) inhibitor Ibrutinib displays con-
siderable activity in mantle cell lymphoma (MCL), yet approximately 30% of
patients do not respond and among responders only one third experience com-
plete remission (CR). Furthermore, the therapy invariably leads to drug resistance
and a median response of 17.5 months (Wang ML, NEJM, 2013). Infusion of
autologous T cells transduced with chimeric antigen receptors (CAR) against the
B-cell specific CD19 antigen (CART19 or CTL019) leads to dramatic clinical
responses in the majority of patients with acute lymphoblastic leukemia and
chronic lymphocytic leukemia (Maude SA, NEJM, 2014; Porter D, NEJM, 2011).
The role of CTL019 in MCL, where bulky disease may impair T cell infiltration,
has not yet been established. Ibrutinib has shown particular efficacy in reducing
tumor masses while mobilizing neoplastic B cells into the peripheral blood.
Aims: We sought to investigate the combination of two novel potent approach-
es, ibrutinib and CTL019, for treatment of MCL.
Methods: MCL cell lines were obtained from ATCC (Mino, Jeko-1, SP-49) while
MCL-RL was generated in our laboratory from a pleural effusion of a MCL
patient. CTL019 were produced as previously described by lentiviral transduc-
tion of healthy donor T cells using an anti-CD19-CD3zeta-41-BB construct
(Milone M, Mol. Ther., 2009). For in vivo experiments, ibrutinib was dissolved
in HP-beta-cyclodextrin/H20 and administered in the drinking water to mice
with established disease, usually from 7 days after tumor injection until the end
of the experiment.
Results: In vitro studies with established MCL-derived cell lines and MCL-
RL show a variable response to ibrutinib with an IC50 ranging from 10 nM to
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10 µM as determined in the MTT conversion assay. MCL-RL was the most
sensitive cell line with an IC50 of 10nM, similar to primary MCL. These dif-
ferent cell lines could therefore be used to model both ibrutinib-sensitive and
ibrutinib-resistant MCL. Both ibrutinib-sensitive and ibrutinib-resistant cell
lines, but not the CD19-negative control MOLM14 cell line, when exposed to
allogeneic CTL019 strongly activated the T cells as detected by CD107a
degranulation, cytokine production and CFSE proliferation assays. In vitro
assays with MCL cell lines and different doses of CTL019 with increasing
concentration of ibrutinib demonstrated an additive tumor killing with the com-
bination CTL019 and ibrutinib. However, supra-physiologic doses of Ibrutinib
(>/=1 uM) impaired cytokine production and T cell proliferation in vitro; these
concentrations of ibrutinib are not typically reached in the clinical setting. In
order to confirm these results in vivo we established a novel MCL model,
using the MCL-RL cell line. Intravenous injection of MCL-RL cell line trans-
fected with the GFP/luciferase gene into immunodeficient NOD/SCID-gamma
chain knockout (NSG) mice resulted in 100% MCL engraftment in liver and
spleen, with eventual dissemination into lymph nodes and bone marrow.
Treatment with three different doses of allogeneic CTL019 (0.5, 1 and 2 mil-
lion/mouse) led to a dose dependent anti-tumor effect. A similar dose
response to CTL019 was also observed in the ibrutinib resistant Jeko-1 cell
line. We treated MCL-RL xenografts in vivo with different doses (0, 25 and
125 mg/Kg/day) of ibrutinib, with a median overall survival respectively of
70, 81 and 100 days (p<0.001). Importantly, a direct in vivo comparison of
the highest ibrutinib dose (125 mg/kg) and CTL019 showed a significantly
improved tumor control for mice treated with CTL019. MCL-RL xenografts
were treated with vehicle, ibrutinib, CTL019 or the combination of CTL019
and ibrutinib. The combination resulted in an improved tumor control with
80% of mice achieving long-term disease-free survival (Figure 1A). In addi-
tion, we found that mice treated with ibrutinib had higher numbers of circu-
lating CTL019 cells (Figure 1B).
Figure 1.
Summary and Conclusions: This preclinical model demonstrates for the first
time that a small molecule inhibitor of B cell receptor signaling (ibrutinib) can
be combined with CTL019 in a rational manner that augments the anti-tumor
effect and leads to enhanced survival.
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INTERIM ANALYSIS OF PHASE I/II TRIAL IN HIGH-RISK PEDIATRIC
PATIENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) TREATED WITH EX VIVO EXPANDED DONOR-DERIVED
ADENOVIRUS-SPECIFIC T CELLS 
W. Ip1,2,* A. Stansfield3, A. Skulte3, K. Gilmour1, M. Brocklesby1, G. Ahsan1,
P. Amrolia4, P. Veys4, B. Gaspar1,2, W. Qasim1,2
1Department of Clinical Immunology, Great Ormond Street Hospital, 2Molecular
and Cellular Immunology Section, Institute of Child Health, 3Cell Medica Ltd.,
4Bone Marrow Transplantation Department, Great Ormond Street Hospital,
London, United Kingdom
Background: Adenovirus (ADV) is a cause of significant morbidity and mortality
after pediatric HSCT. Antiviral drug therapy is routinely given for ADV viremia
in HSCT patients, but can be associated with significant toxicity. While antiviral
drug therapy may attenuate viremia, T cell reconstitution is required for sus-
tained viral clearance. Adoptive virus-specific immunotherapy offers the pos-
sibility of durable viral control in the post transplant setting.
Aims: In order to assess the safety and tolerability of an ADV cell therapy
(ACT) Cell Medica is evaluating an expanded anti-ADV T cell product in a clin-
ical trial in three centers in children who reactivate ADV after T cell-depleted
transplantation. Here we report on the clinical experience of the first five patients
treated in the ASPIRE clinical trial (EUDRA CT 2011-001788-36).
Methods: Patients were consented to receive ACT on reactivation of ADV (defined
as two consecutive positive PCRs>1000 copies/mL) post-transplant, in addition
to routine antiviral drugs. Cell administration did not occur until 28 days post-trans-
plant due to continuing in vivo persistence of conditioning antibodies. The primary
dose was 1x104/kg total CD3+ T cells. Patients were monitored post adoptive
cellular therapy up to 180 days. If the patient exhibited significant levels of ADV
viremia requiring treatment ≥4 weeks post-infusion they were eligible to receive a
secondary maximum target dose of 1x105/kg total CD3+ T cells and were moni-
tored for a further 180 days. Lymphocytes for the expansion process were sourced
from the transplant donor either from peripheral blood or a 5 mL aliquot of the
original stem cell donation. The one-touch rapid expansion process for generation
of this ACT was based on exposure of T cells to overlapping peptides covering
the entire hexon V protein and 10 days expansion in the presence of cytokines;
cells were then harvested and cryopreserved. The ADV-specific T cells were for-
mulated in 4.5% human serum albumin and 10% dimethylsulfoxide with ≥1x102
ADV-specific T cells per kg body weight of recipient. Study endpoints included
incidence and severity of GvHD, cytopenias and grade 3-4 adverse events.
Results: Patients were consented to receive ACT on reactivation of ADV post-
transplant. All five patients analyzed cleared viremia post ACT. Two SAEs were
reported; one pancreatitis and one GvHD (skin GvHD stage III; gut GvHD stage
II). Additionally, one Suspected Unexpected Serious Adverse Reaction
(SUSAR) was reported which was subsequently downgraded following attri-
bution to astrovirus encephalitis.
Figure 1. Log PCR vs days from enrolment.
Summary and Conclusions: In a small number of initial subjects ADV viremia
in pediatric patients post HSCT was controlled following ACT. A number of AEs
and SAEs were reported, in keeping with expectations for this patient popula-
tion. The trial is ongoing.
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LIPOSOME-BASED SPECIFIC TARGETING OF A STAT3-INHIBITOR TO
CANCER-PROMOTING MACROPHAGES: A NOVEL THERAPUTIC PARA-
DIGM IN MULTIPLE MYELOMA
M.N. Andersen1,* A. Etzerodt1, M.B. Maniecki2, N.F. Andersen3, S.K. Moestrup1,
M. Hokland1, H.J. Møller2
1Department of Biomedicine, Aarhus University, Faculty of Health, 2Department
of Clinical Biochemistry, 3Department of Haematology, Aarhus University Hos-
pital, Aarhus, Denmark
Background: Tumor-associated macrophages (TAMs) play an important role
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in cancer by suppression of adaptive immunity and promotion of angiogenesis
and metastasis. In multiple myeloma, as well as other haematological malig-
nancies, there is an association between infiltration of CD163+ macrophages
in the tumor microenvironment and poor outcome. This association has also
been found for most other human cancers. Importantly, expression of the
haemoglobin scavenger receptor CD163 is increased on TAMs and other alter-
natively activated macrophages (M2). Activity of the transcription factor STAT3
is increased in both stromal and malignant cells, and inhibition of STAT3 in
tumor-associated myeloid cells has been proposed as a target for novel anti-
cancer therapy. Inhibiting STAT3 could potentially repolarize TAMs towards a
pro-inflammatory (M1) phenotype, and restore anti-tumor functions. In vivo,
ablation of the Stat3 gene, specifically in cells of the haematopoietic system,
has been shown to elicit a strong anti-tumor immune response in a mouse
model of melanoma. Therefore, CD163-targeted inhibition of STAT3 within
TAMs may be a novel treatment paradigm in malignant diseases.
Aims: We aimed to produce a novel drug, long-circulating liposomes (LCLs) con-
taining a STAT3 inhibitor, target this drug specifically to M2 macrophages with
high CD163 expression, and evaluate the effect on STAT3 activation in the cells.
Methods: In vitro, monocyte-derived macrophages (MDMs) were targeted
using a liposome-based system, in which the molecule/drug of interest was
packaged within LCLs. LCLs containing either green fluorescent protein calcein
(cal-LCLs) or a STAT3-inhibitor (STAT3i-LCLs) were produced using microflu-
idics technique. Subsequently, LCLs were modified by conjugation with anti-
human-CD163 antibodies (LCL-aCD163). MDMs were cultured in RPMI-1640
medium containing 10% foetal calf serum, 10ng/mL M-CSF, and 1ng/mL GM-
CSF, and were matured for 7-8 days before experiments were performed. For
confocal microscopy, MDMs were cultured on cover slips. For STAT3-activation
experiments, MDMs were first treated with the STAT3 inhibitor, and then stim-
ulated with 50ng/mL IL-10 for 15min to induce STAT3 activation. Cells were
then fixed, permeabilized, stained with anti-human-P-Y705-STAT3 PE conju-
gated monoclonal antibody, and analysed on a LSR Fortessa flow cytometer.
Results: Stable cal-LCLs and STAT3i-LCLs were produced, with a radius of 50-
80 nm (measured by dynamic light scattering). Here, we show that cal-LCL uptake
was markedly higher in MDMs with the highest CD163 expression (the 5-10%
most CD163 expressing cells). Using a validated flow cytometric assay for detec-
tion of activated (phospho-Y-705) STAT3, we evaluated the ability to inhibit this
activation in human MDMs. After stimulation with IL-10 the median fluorescence
intensity (MFI) for P-Y705-STAT3 PE increased from ~150 to 290. This increase
could only be partially reduced by free STAT3 inhibitor or non-targeted STAT3i-
LCLs, but with the targeted STAT3i-LCL-aCD163, we were able to reduce the
STAT3 activity to the unstimulated level, or below (MFI ~100 to 150).
Figure 1.
Summary and Conclusions: We have shown that LCLs can be effectively
targeted to the most CD163-expressing cells (which includes TAMs), and that
this delivery system can be used to effectively inhibit STAT3 within human
MDMs in vitro. 
In perspective, this may lead to the first in vivo experiments of targeted inhibition
of STAT3 specifically within TAMs.
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ANTIBODY-TARGETED CYCLODEXTRIN NANOPARTICLES DELIVER SIR-
NA AND ACHIEVE THERAPEUTIC GENE SILENCING IN BLOOD FROM
ACUTE MYELOID LEUKAEMIA (AML) PATIENTS
J. Guo1,* K.A. Fitzgerald1, E.G. Russell2, R. Darcy3, T.G. Cotter2, S.L. McKenna4,
M.R. Cahill5, C.M. O’ Driscoll1
1School of Pharmacy, 2Bioscience Research Institute, University College Cork,
Cork, 3Centre for Synthesis and Chemical Biology, University College Dublin,
Dublin, 4Cork Cancer Research Centre, University College Cork, 5Department
of Haematology, Cork University Hospital, Cork, Ireland
Background: Delivery of small interfering RNA (siRNA) using multifunctional
nanoparticles has been investigated to treat solid cancers; however the appli-
cation of this approach to blood cancers is at an early stage. Modified cyclodex-
trins have successfully delivered siRNA in a range of in vivo pre-clinical animal
models of disease including prostate cancer [1], inflammatory bowel disease
[2] and Huntington’s disease [3]. 
Aims: The aims of this study are: to formulate an antibody (Fab) targeted
cyclodextrin (CD) nanoparticle (NP) for siRNA delivery to treat AML, to assess
the efficacy of this NP in vitro using KG1 (AML) cells and ex vivo using AML pri-
mary patient samples, and to evaluate the NP as an adjuvant therapy for tra-
ditional chemotherapy.
Methods: An amphiphilic cationic CD was synthesised as previously described
[4]. This CD was complexed with siRNA and co-formulated with a PEGylated
lipid (DSPE-PEG). The resulting NP was tagged with a Fab to give
CD.siRNA.DSPE-PEG-Fab (NP-Fab) targeting the CD123 receptor overex-
pressed on AML stem cells. Incorporation of Fab was assessed by SDS-PAGE.
The NP-Fab was characterised for particle size, surface charge and stability
using a Malvern Zetasizer Nano ZS. Agarose gel retardation assay was per-
formed to determine the ability of nanoparticles to bind siRNA and protect it
from serum degradation. In vitro toxicity was examined in KG1 cells using the
MTT assay. In vivo toxicity was assessed in C57BL/6 mice using ELISA and
haematoxylin and eosin (H & E) staining. Competitive internalisation of nanopar-
ticles was evaluated using FACS. Confocal microscopy was used to investigate
intracellular trafficking of nanoparticles. Targeted gene knockdown was quan-
tified using real-time qPCR and western blotting. Anti-leukaemia efficacy was
investigated in KG1 cells and AML primary cells using a CCK-8 Kit and a colony-
formation assay. 
Results: The incorporation of DSPE-PEG into CD.siRNA NP significantly
increased the size and reduced the charge, further incorporation of Fab signif-
icantly increased the size but did not affect the charge. The NP-Fab had a size
of ~200 nm with a nearly neutral surface charge of 4 mV, and resisted aggre-
gation in OptiMEM. The NPs displayed minimal in vitro and in vivo toxicities.
Pre-treatment with free Fab significantly (P<0.05) reduced uptake of the anti-
body-targeted NP in KG1 cells, suggesting specific ligand-receptor mediated
internalisation. Confocal microscopy data indicated that endosomal escape of
antibody-targeted NP was time-dependent. The NP-Fab incorporating Bromod-
omain-containing protein 4 (BRD4) siRNA displayed significantly (P<0.05) high-
er gene knockdown efficiency in KG1 cells and AML primary cells compared to
the siRNA delivered by the commercial cationic lipid vector, Lipofectamine 2000.
Use of the Fab-targeted NP in combination with Cytarabine (Ara-C) resulted in
a synergistic therapeutic response, achieving up to 90% growth inhibition of
primary cells.
Summary and Conclusions: The antibody-targeted CD-based NP containing
therapeutic siRNA is a novel therapeutic strategy with potential to treat AML,
particularly when combined with chemotherapeutics. Future work is underway
to investigate pharmacokinetics, tissue distribution, and anti-cancer efficacy in
a pre-clinical AML mouse model.
References
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CLINICAL GRADE ACTIVATED NATURAL KILLER PRODUCTS FOR ADOP-
TIVE IMMUNOTHERAPY AGAINST HIGH-RISK MALIGNANCIES
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Background: Natural Killer (NK) cells may exert a graft-vs.-leukemia/tumor
effect without concomitant severe graft vs host disease. Different clinical-grade
highly active human NK cell products are being used against malignancies. 
Aims: Our study investigates the NK cell recovery, T cell depletion, phenotype
and cytotoxicity of three different ways of good manufacturing practice (GMP)-
grade NK cell products. 
Methods: In four different clinical trials, we have infused three different acti-
vated NK cell products obtained after: i) enrichment from healthy haploiden-
tical donors peripheral blood mononuclear cells (PBMNCs) collected by non-
mobilized apheresis by two steps procedure, depletion of CD3+ cells and
selection of CD56+ cells, using CliniMACS device and ex-vivo stimulation
with IL-15 overnight (NKIL15), EudraCT 2009-010016-15; ii) expansion from
autologous PBMNCs from multiple myeloma patients using as feeder K562
cells expressing interleukin (IL)-15 and 4-1 BB Ligand (K562-mb15-41BBL),
(NKAE), EudraCT 2012-000514-11; iii) or expasion from healthy haploiden-
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tical PBMNCs obtained by whole blood using the same feeder K562 cellular
line, EudraCT 2012-000054-63 and EudraCT 2012-005146-38. The final cell
products were analyzed for microbiological test and by flow cytometry for
CD3+CD56- and CD3-CD56+ cells. In addition, haploidentical NKAE products
were analyzed for the surface expression of CD25, CD69, NKG2D, DNAM
and NCRs by tye appropiate combination of flurochrome-conjugated mono-
clonal antibodies. The NK cytolitic activity was tested in a 2h BATDA release
assay against K562, A673, Jurkat and U266 in an 8:1 E/T ratio.
Results: Thirty-three activated NK cell products consisted on haploidentical
NKIL15 (n=8), haploidentical NKAE (n=11) and autologus NKAE (n=14) were
infused on 17 patients suffering from advanced malignancies (6 pediatric
refractory sarcomas, 7 pediatric refractory acute leukemias, and 5 adults
patients suffering from high risk multiple myeloma, respectively) on 4 different
clinical trials. Safety. No microbial contamination was detected in any product.
BCR-ABL1 quantification was negative after infusion in all patients treated
with NKAE activated with K562 feeders. From NKIL15 the median NK cell
recovery was 25% (range 10-41%) and the T cell depletion was 5.34x10-5
(5.1 log). From NKAE the expansion of CD56+CD3- cells after 14 days of
culture was 268.47-fold (range 28- to 1547-fold) after 14 days of coculture
from donors and 74.4-fold (range 13- to 551-fold) from multiple myeloma
patients. Expansion of CD3+ T cells was minimal (median recovery 2.31-
fold; range 0.13- to 5-fold from haploidentical donor and 0.36-fold; range
0.0001- to 1.7-fold from patients PBMCs). The CD56+CD3- cells, NK cells,
obtained from NKIL15 and NKAE products were similar. However, CD56-
CD3+ cells, T cells, were significantly lower in NKIL15 product, Figure 1.
Haploidentical NKAE product expanded higher NK cells but also significantly
higher T cells than autologous NKAE product (p=0.002). The surface expres-
sion of the activating receptors CD69, CD25, NKp44,NKp46, NKp30 and
DNAM was up-regulated, Figure 2. NKAE and NKIL15 products had a signif-
icantly higher lytic activity than unstimulated NK cells (97 and 75% versus
42%; 34 and 57% versus 23%, 40-60% versus 19% and 60-52% versus 21%)
in K562, A673, Jurkat and U266, respectively.
Figure 1.
Figure 2.
Summary and Conclusions: In conclusion, our results indicate that differ-
ent procedure of GMP-grade purification of highly activate NK cells with
extremely low T cell content are feasible for clinical use. The T cells con-
tained are lower in NKIL15 and autologous NKAE products than in hap-
loidentical NKAE products. 
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Background: Adoptive transfer of T cells retrovirally transduced with a tumor-
associated antigen (TAA) -specific T cell receptor (TCR) has shown promise in
the treatment of cancer patients. Mutation and overexpression of the p53 tumor
suppressor protein are the most common genetic alterations in human cancers.
We used HLA-A2.1 transgenic mice to generate a high-affinity CD8-indepen-
dent TCR specific to the widely expressed human p53(264-272) tumor-asso-
ciated antigen. However, a safety concern of TCR gene transfer is the pairing
of natural and introduced TCR chains resulting in the potential generation of
self-reactive T cells.
Aims: We aim at improving adoptive T cell-based immunotherapy by generat-
ing optimized specific TCR format with reduced potential for TCR mispairing-
associated self-reactivity and enhanced tumor recognition. 
Methods: To overcome TCR mispairing formation, we designed a single chain
(sc) TCR format by connecting the variable TCRa domain to the TCRb chain
via a short peptide linker co-expressed with a truncated TCRa constant domain.
The TCR sequences were cysteine-modified, codon-optimized and cloned into
one single 2A-based retroviral vector. The choice of target tumor antigens for
cancer immunotherapy is of central importance as the transfer of high-avidity
T cells may potentially induce severe on-target toxicity by damaging normal
cells expressing the antigen. Here, we evaluated the safety issues raised by
the risk of p53TCR gene transfer-associated on/off-target toxicities in A2.1
transgenic mouse models of adoptive transfer.The antitumor efficacy was
assessed in syngeneic and NodScid IL-2R gamma chain-null mice (NSG)
xenograft models.
Results: In vitro studies showed that, scTCR-modified CD4+ and CD8+ T cells
displayed similar high-avidity compared to the full-length TCR, as determined
by peptide titration in cytotoxicity assays and were able to mediate specific
lysis of p53 mutant A2.1+ tumor cells. However, in contrast to the full-length
TCR, the optimized scp53TCR did not result in mispairing-mediated lethal off-
target autoimmunity in vivo. We next assessed the potential of scTCR-modified
T cells to cause on-target autoimmunity, using A2.1Kb transgenic mice express-
ing human p53 (Hupki). We observed that transfer of scTCR-specific T cells
did not result in a depletion of hematopoietic compartment, as mice recovered
normal white blood cell counts and survived without any sign of toxicity. Impor-
tantly, high-avidity scTCR-modified T cells were able to eradicate established
tumors in syngeneic and xenograft mouse models.
Summary and Conclusions: Together, our study provided evidence that an
optimized high-affinity scTCR-specific for the broadly expressed tumor-asso-
ciated antigen p53(264-272) can eradicate tumor cells without inducing off/on-
target toxicities in murine models of adoptive T-cell transfer. These data demon-
strate the improved safety and therapeutic efficacy of high-affinity scp53TCR
for a broad-spectrum immunotherapy of malignant disease.
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HYDROXYUREA FOR Β-THALASSEMIA: A META-ANALYSIS
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Hematology/Oncology/BMT, Alberta Children Hospital, Calgary, Canada,
3Haematology, King Abdulaziz University, Jeddah, Saudi Arabia
Background: β-thalassemia is one of the most common inherited diseases
worldwide. Severe forms of β-thalassemia require life-long blood transfusions,
resulting in iron overload with multi-organ morbidity and mortality. Hydroxyurea
(HU), an oral chemotherapeutic drug, is anticipated to decrease the need for
transfusions, either completely or partially by raising hemoglobin levels and
thus decreasing the short and long term complications of chronic transfusions. 
Aims: To evaluate the clinical efficacy and safety of HU in β-thalassemic patients
of any age.
Methods: Search strategy: We searched MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials (CENTRAL), ongoing trials registers, and major pre-
ceding conferences. Hand searches were also conducted using reference lists
from primary studies. Selection criteria: Randomized controlled trials (RCTs) and
observational studies (sample size ≥5) assessing the clinical efficacy of HU alone
for three months or longer, for the treatment of patients with β-thalassemia were
included. Data collection and analysis: Two authors acted as reviewers and inde-
pendently assessed study quality and extracted data from the included studies.
β-thalassemia classification and response evaluation outlined in the following
Table 1. Effect size was estimated as a proportion (responders over sample size).
All data was analyzed using Stata, Version 13.0.
Table 1.
Disease                     Subgroup                   Key features              Response assessment
β-thalassemia    1) Classical β-TM; or      Life-long transfusion     1. Complete response (CR):
major (β-TM)            2) Severe E/                      needs                    complete cessation of
                              β-thalassemia                                                          transfusion
                                                                                                  2. Overall response (OR):
                                                                                                          50 reduction
                                                                                                           of transfusion
Severe                       1) Classical            4 transfusions/year              1. CR: as above
non-transfusion       β-Thalassemia            or every 3 months                2. OR: as above
dependent               intermedia; or               & not meeting
β-thalassemia        2) Moderate E/              β-TM definition
(severe NTDβT)        β Thalassemia
Mild NTDβT               1) Classical                     No or <4                   Response rate (RR):
                              β-thalassemia             transfusions/year               1g/dL increase
                              intermedia; or                                                    in Hemoglobin (Hb)
                                 2) Mild E/
                           β Thalassemia
Results: For β-TM, 11 observational studies involving 620 patients were includ-
ed. HU was associated with a significant decrease in transfusion need with CR
of 41% (95% CI, 25-58%) and OR of 71% (95% CI, 56-84%). In severe NTDβT,
8 (1 RCT & 7 observational) studies involving 305 patients were analyzed. HU
was associated with a significant decrease in transfusion need with CR of 55%
(95% CI, 34-75%) and OR of 79% (95% CI, 69-88%). For mild NTDβT, 14 (1
RCT and 13 observational) studies involving 344 patients were included. HU
therapy was effective in raising Hb by 1g/dL from baseline in 54% (95% CI, 43-
65%). All of the studies had several limitations, such as small sample size, lack
of comparison group, under-reporting of data and methods, and being mostly
observational studies. Adverse events (AEs) were transient and improved with
temporary cessation of the drug and/or adjustment of the dose. 
Summary and Conclusions: HU appears to be effective in the management
of β-thalassemia by decreasing the need for chronic blood transfusions com-
pletely or partially in a significant number of patients. It appears to be well tol-
erated and associated with mild and transient AEs. Patients with β-thalassemia
may benefit from a trial of HU, though large RCT assessing efficacy should be
done to confirm the findings of this meta-analysis.
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OF THE ROLE OF THE ENVIRONMENT AND SKIN MICROBIOME ON LEG
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C. Minniti1,* V. Bonham2, K. Findley3, K. Abdallah3, A. Buscetta4
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Background: There is extensive phenotypic variation in SCD, a monogenetic
inherited disorder that affects millions worldwide. Fetal hemoglobin and alpha
chain number have been identified as genetic disease modifier, but alone do
not explain the marked interpatient and intrapatient variability of acute and
chronic complications, which can affect every organ. Efforts have been ham-
pered by the difficulty in precisely defining clinical phenotypes, such as acute
pain crisis, and acute chest syndrome.Leg ulcers are a debilitating complication
of SCD, associated with severe anemia, chronic pain, elevated TRV, priapism,
thrombophilia, renal insufficiency, and a negative predictor of survival. They
are easy to identify and recall both by the patient and the health care provider.
Their prevalence in patients with SCD is 10 times higher than in the general
population and varies in different geographic locations
Aims: We hypothesize that leg ulcerations in SCD are multifactorial and include
contributions from the skin microbiome, genetic and environment factors, both
physical and social.
Methods: The study will recruit 60 adults with SCD, 30 with and 30 without leg
ulcers in a NHGRI sponsored trial. Clinical, laboratory, and social characteristics
are prospectively obtained. Samples for microbiome analysis are collected at
the center of the wound, the periwound, and the opposite leg. Microbial DNA
was extracted, the 16S rRNA molecular marker sequenced (V1V3 region), and
the PCR products purified and quantified for sequencing using the Illumina
MiSeq Benchtop Sequencer platform.
Results: Laboratory measures from the first 35 participants in the study were sig-
nificantly different between the leg ulcer and non-leg ulcer groups: lupus antico-
agulant, glucose, hematocrit, hemoglobin, platelet count, ferritin, hemoglobin retic-
ulocyte, ESR, and serotonin (p<0.1). The leg ulcer group had higher mean values
for absolute reticulocyte count, serotonin, and ESR (p=0.42, p<0.05, and p<0.1,
respectively), and significantly lower values for hemoglobin (Hb), hematocrit (hct)
and fetal hemoglobin (HbF) at p<0.05, p<0.05, and p<0.1, respectively. For the
first 12 participants who had their microbiome sequenced preliminary analysis of
the relative abundance of bacteria on the malleoli of SCD participants with and
without leg ulcers reveals that the bacterial community structure differs in partici-
pants with leg ulcer and non-ulcer. No significant differences were found for demo-
graphic characteristics between the active and no leg ulcer groups (Figure 1).
Figure 1.
Summary and Conclusions: Clinical and laboratory differences exist in patient
with SCD and leg ulcers, when compared to patients without ulcers. The micro-
biome of patients who have leg ulcers is different from patients that do not
develop them and could contribute to their occurrence. Stress levels are higher,
as demostrated by higher levels of serotonin and so are markers of inflammation
(ESR). Family and education variables do not seem to responsible for this end
organ complication.
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PERICARDIAL EFFUSION IS A MARKER OF INCREASED CARDIAC MOR-
TALITY IN THALASSEMIA MAJOR PATIENTS
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Background: In different types of not-hematological diseases the presence of
a small pericardial effusion (PE) was associated with worse survival even after
adjustment for patient characteristics, suggesting that it is a marker of under-
lying disease. In thalassemia major (TM) pericardial effusion was shown to be
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one of the manifestations of heart disease but its potential prognostic impor-
tance has never been investigated in the modern era. Cardiovascular Magnetic
Resonance (CMR) by cine SSFP sequences was demonstrated to be extremely
sensitive to even a small amount of PE.
Aims: This is the first prospective study evaluating if the presence of pericardial
effusion is associated with increased cardiac mortality in TM.
Methods: 1259 patients (648 females, mean age 31.02±8.64 years) enrolled
in the Myocardial Iron Overload in Thalassemia (MIOT) were prospectively fol-
lowed from their first Magnetic Resonance Imaging (MRI) scan. CMR was used
to quantify myocardial iron (MIO) overload by a multislice multiecho T2*
approach and to assess biventricular function parameters and to detect PE by
cine SSFP sequences.
Results: PE was present in 25 (2.0%) patients. Patients with and without PE
were comparable for age and ratio of men/women. At the baseline, the per-
centage of patients with MIO (global heart T2* value <20 ms) was comparable
between patients with and without PE (12.0% vs 28.7%; P=0.074) and left ven-
tricular and right ventricular ejection fractions were not significantly different
between the two groups. Mean follow-up (FU) time was 44.55±20.35 months
and there were 15 deaths. Nine death were due to cardiac causes. Cardiac
mortality was greater for patients with PE compared to those without an effusion
(8.0% vs 0.6%, P=0.013). PE was a significant predictive factor for cardiac
death (hazard ratio-HR=19.25, 95%CI=3.96-93.66, P<0.0001). PE remained
a significant prognosticator for death also in a multivariate model including MIO
(PE: HR=35.24, 95%CI=6.59-188.57, P<0.0001 and global heart T2* <20 ms:
HR=6.89, 95%CI=1.60-29.69, P=0.010) (Figure 1).
Figure 1.
Summary and Conclusions: PE is quite rare in TM patients and it is not relat-
ed to myocardial iron overload. An important role in the development of PE
could be played by the ‘iron-induced’ pericardial siderosis but, due to the limi-
tations of the current non-invasive CMR techniques, we were not able to
address this issue. PE was found to be a strong predictor for cardiac death,
independently by the presence of myocardial iron overload. The non-invasive
diagnosis of pericardial effusion is important for a more complete definition of
the cardiac involvement of TM patients. The increased risk of cardiac death
associated with PE may be used along with other clinical characteristics when
estimating a patient’s prognosis and monitoring.
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Background: Tissue damage due to iron overload is an ineluctable complica-
tion in chronically transfused children with hemoglobinopathies. Lifelong iron
chelation therapy is therefore necessary to reduce iron accumulation; however,
compliance issues associated with parenteral treatments remain a challenge.
Oral iron chelators (OIC) provide an attractive alternative due to their longer
half-life, which permits once daily or three times a day dosing regimens.
Aims: We aimed to investigate the outcomes of two oral iron chelators, namely,
deferiprone (DFP) and deferasirox (DFX) for transfusion dependent children
with hemoglobinopathies in Turkey. 
Methods: This multicenter, nation-wide, prospective, non-interventional, 3 year
follow-up study evaluated OIC for the treatment IOL. Patients aged 2-18 years
with beta-thalassemia major (bTM) or sickle cell anemia (SCA) who were suf-
fering from TIO and on OIC treatment were included. Recommended assess-
ments included demographics, laboratory and imaging results related to TIO,
and serious adverse events.
Results: Hereby, we present 3 year follow-up results of this prospective study.
Of 474 patients included from 30 centers, 450 (95%) (50.7% female, mean
[standard deviation-SD-] age: 9.3 (4.1) years) were diagnosed as bTM whereas
24 (5%) (33.3% female, mean [SD] age: 9.9 (4.2) years) as SCA. Of the
patients, 338 (71.3%) completed the study. Results of key laboratory parame-
ters are summarized in Table 1. There were 165 (48.8%) patients with hemo-
globin level of ≤9 g/dL at month 36. Serum ferritin (SF) levels significantly
decreased with DFX therapy; however, no significant change was observed
with DFP therapy. This discrepancy can be explained with the low patient num-
bers on DFP treatment (n=35). The rate of patients with SF levels of <1000
ng/mL was increased from baseline to month 36 (DFX: 19% to 37% vs DFP:
9% to 26%). Additionally, the mean DFX dose was increased from 26.3±6.1
mg/kg to 29.4±10.6 mg/kg on month 36. As compared to <20mg/kg dose,
patients who were on ≥20mg/kg of DFX had a significant decrease in SF level.
According to the Cox regression analysis, DFX alone was 2.23 times (95% CI:
1.281-3.867) more successful in reducing SF levels of patients below 1000
ng/mL as compared to DFP. There was a positive correlation between SF level
and alanine aminotransferase (ALT) for both DFX and DFP.
Table 1. Results of selected laboratory parameters.
Summary and Conclusions: This study comprises the overall prospective
largest pediatric cohort including bTM and SCA patients suffering from TIO and
under OIC treatment. In DFX treated patients receiving >20mg/kg, a decrease
in SF was observed; however, it was lower than that reported in randomized
trials most likely due to few patients receiving the recommended DFX dose of
over 30 mg/kg to gain negative iron balance. There was no clinically significant
change in liver or kidney function in these patients receiving DFX or DFP. About
half of the patients had a hemoglobin level of ≤9 g/dL after 36-month follow-up,
revealing that such patients still do not receive optimal transfusion regimens
according to current guidelines. Results of three-year follow-up of the study
demonstrate that in order to achieve optimal therapeutic goals, it is important to
personalize the treatment through active dose adjustments and address potential
compliance issues that can arise from multi-year oral treatments.
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Background: There is a substantial need for improved molecular-diagnostic
testing of patients with rare inherited anemias, whether isolated or in the context
of pancytopenia. Due to the rarity of these disorders, no routine testing is avail-
able. In practice, clinicians must refer patient samples to multiple specialist
centers for diagnostic investigations, which often leads to delays in diagnosis
and high costs without the certainty of obtaining a molecular diagnosis. Next
generation sequencing (NGS) methodology offers an avenue to overcome
many of these issues. Targeted resequencing panels have been used for
patients with rare anaemias in a research setting but technical and scientific
barriers have hampered the transfer of this technology into a routine diagnostic
setting. These include the extensive validation required for diagnostic tests and
bioinformatic validation of coverage to highlight regions where pertinent muta-
tions may have been missed. Finally, there is limited information regarding the
clinical utility of this type of resequencing strategy in this patient group.
Aims: To meet this need we developed and validated a method for the routine
diagnosis of congenital red-cell disorders by NGS with the aims of (1) demon-
strating the feasibility of achieving clinical-grade validation for a targeted rese-
quencing panel, (2) developing and providing an open-source tool for evaluation
of DNA sequence coverage in a clinical setting, (3) assessing the diagnostic
yield of the strategy in the diagnosis of congenital anemia/pancytopenia and
(4) assessing the clinical utility and impact on management of results generated
by this approach.
Methods: We designed a resequencing panel to target 34 genes known to
cause anemia and/or pancytopenia [Diamond-Blackfan anemia (DBA), dysker-
atosis congenital (DKC), Schwachman-Diamond syndrome (SDS), sideroblastic
anemia, congenital dyserythropoietic anemia (CDA) and the enzyme deficien-
cies G6PD, PKLR and pyrimidine 5’ nucleotidase] and used it to assess patients
with unexplained anemia in whom acquired causes have been excluded. We
also developed an open-source tool for evaluation of sequence coverage in a
diagnostic clinical laboratory setting that determines the discoverability of all
known mutations in each gene for every individual sample, a functionality cur-
rently unavailable in commercial software. 
Results: We validated diagnostic findings from NGS with Sanger sequencing
and microarray, and found 100% specificity and 99.7% sensitivity (95% CI 97.9-
99.9%). We then analysed 57 clinical samples. A molecular diagnosis was made
in 24 cases (42%), corresponding to a total of 34 mutations of which 21 were
novel. The clinical utility of our diagnostic approach is apparent as accurate molec-
ular diagnosis led to changes in patients’ therapies such as splenectomy for
patients with PK deficiency or trial of steroids for Diamond-Blackfan anemia.
Summary and Conclusions: We have developed a robust and useful platform
for routine molecular diagnosis across the spectrum of congenital anemias and
shown a high diagnostic yield, which translated into clinical utility by targeting
therapies appropriately.
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COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE IN
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Background: Sickle cell disease (SCD) is a hereditary disorder characterized
by abnormal β-globin chain synthesis leading to vaso-occlusion, hemolytic ane-
mia, recurrent infections and end organ failure. Vaso-occlusive effects on the
vascular eye bed may be detectable before patients report visual symptoms.
Aims: This study aims at determining the prevalence and risk factors of oph-
thalmological complications in a Lebanese SCD cohort and delineating the
importance of early detection of asymptomatic eye findings in this cohort.
Methods: This is a prospective observational ongoing cross-sectional study of
a SCD cohort in North Lebanon. Ophthalmologic examination consisted of bilat-
eral best-corrected visual acuity (BCVA) measurements, slit-lamp examinations,
direct and indirect ophthalmoscopy and wide-field retinal photographs. Fundus
fluorescein angiography (FFA) was performed in patients with reduced BCVA
or retinal photograph abnormalities. Frequencies and descriptive data were
generated using Statistica.
Results: 79 patients, 40 females, 39 males, mean age 15.6±10.5 years were
tested. 70%, 28.5% and 1.5% had HbSS, Sβ and SD. Mean steady state hemo-
globin, LDH, and ferritin were 8.6±0.87 g/dl, 520.1±203 U/L and 924±1028
ng/ml, respectively. 62% were on hydroxyurea and 86% had history of intermit-
tent blood transfusions. BCVA was >20/50 in 97% and between 20/50 and
20/100 in 3%. Anterior and posterior segment findings were detected in 44%
and 48% of patients respectively. The most common anterior segment findings
were comma shaped conjunctivae and pallor in 70% and 36%. Posterior seg-
ment manifestations included salmon patches in 10.5%, black sunbursts in
31.5%, retinal vascular tortuosity in 26.3% and disc sign in 10.5%. Proliferative
sickle retinopathy (PSR) was present in 39.5% of patients, mean age 17.5
years, age range 4 -35 years. Stages 1, 2, 3 and 4 were seen in 5%, 23.6%,
8% and 3% of patients. No patient had stage 5 PSR. Patients with anterior and
posterior segment findings had a statistically significant older mean age than
those who did not (19.6±10.4 and 18.6±11.5 years versus 12.3±9.6 and
13.2±8.7 years, p<0.05). Anterior manifestations were significantly more fre-
quent among patients who had cholecystectomy compared to those who did
not (63% versus 36.8%, p<0.05), those with a median hematocrit lower than
25.9% than those with higher hematocrit (59% versus 31.5%, p<0.05) and in
those with a higher transfusion load (60.8 versus 21.8 transfusions, p=0.02). A
significantly higher level of black sunbursts was found in patients who had
cholecystectomy compared to those who did not (32% versus 11%, p<0.05). 
Summary and Conclusions: Ophthalmologic complications are frequent
among young Lebanese patients with SCD and tend to increase with age.
Despite the small sample size, the high rate of PSR at a very young age is wor-
risome. The higher frequency of ophthalmic complications in patients with chole-
cystectomy, low hemoglobin and high transfusion rate suggest a possible under-
lying hemolytic etiology besides the well established vaso-occlusive etiology.
Early identification of affected patients particularly those at high risk for PSR
through effective screening can help introduce timely targeted treatment thereby
improving visual outcomes and preventing vision loss.
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DISEASE AND IMPACT ON DISEASE SEVERITY IN LEBANON
A. Inati1,* M. Noureldine2, G. Amhez2, M. Kahale2, H.A. Abbas3
1Nini Hospital, Tripoli, 2Lebanese American University, Beirut, Lebanon, 3MD
Anderson Cancer Center, Houston, United States
Background: Glucose-6-phosphate dehydrogenases (G6PD) and sickle cell
disease (SCD) occur due to defects in hemoglobin stability or structure, respec-
tively. Sickle cell trait and G6PD deficiency are found in 2.1% and 2.09% of the
Lebanese population. To date, the rate of co-inheritance of both SCD and G6PD
deficiencies in Lebanon has not been determined.
Aims: The primary objective is to determine the co-inheritance rate of G6PD
deficiency and SCD in Lebanon. The secondary objective is to delineate the
impact of G6PD deficiency co-inheritance on SCD related morbidity and mortality. 
Methods: Patients with SCD, followed in 2 comprehensive SCD referral centers
in mid and North Lebanon were tested for G6PD deficiency using spot test. All
abnormal tests were confirmed by repeat testing. High pressure liquid chro-
matography (HPLC) was utilized for diagnosis of SCD. Pertinent demographic,
clinical, and hematologic information was collected. Statistical analysis was
done using Statistica (v. 12.5). Statistical significance was set for p <0.05. 
Results: A total of 121 patients with SCD, 57% males, 43% females, mean
age 12.5±11.3 years, median follow-up 12.6 years, were screened for G6PD
deficiency. 72.5% had HbSS, 21.5% Sβ0T, 4.2% Sβ+T and 1.6% SD, respec-
tively. 6/121 (5%) patients were found to be deficient for G6PD. Hematologic
and clinical features are listed in Table 1.
Table 1. General clinical and laboratory characteristics of SCD patients.
Steady state hemoglobin, LDH, haptoglobin, and ferritin were 8.7±1 g/dL,
493±188 unit, 0.5±1.7 and 610±783 ng/dcl, respectively. Acute splenic seques-
tration (ASS), cholecystectomy and persistent splenomegaly beyond 6 years
of age were seen in 44.5%, 26% and 20% of patients, respectively. 40% of
patients had splenectomy (surgical in 13% and auto-splenectomy in 26%).
Mean HbA1 at diagnosis and steady state ferritin of SCD patients were signif-
icantly different among G6PD deficient and G6PD wildtype patients. Specifically,
HbA1 was 21.3% in G6PD deficient patients versus 5% in wild type (p=0.01);
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and steady state ferritin was 1410.9 unit in G6PD deficient patients, while it
was 568.6 unit in G6PD wildtype SCD patients (p=0.0002). Number of trans-
fusions, age at cholecystectomy, steady state hemoglobin, LDH, heptaglobin,
reticulocyte count or bilirubin were not statistically different between the two
groups. In Fisher’s exact test analysis, we did not find a correlation between
G6PD status and each of gender, splenomegaly, splenectomy, ASS, cholecys-
tectomy or hepatomegaly. Three SCD patients (2.5%) who had wildtype G6PD
died during the course of this study but was independent on G6PD status.
Summary and Conclusions: This is the first study on SCD and G6PD defi-
ciency co-inheritance in Lebanon. G6PD deficient SCD patients had signifi-
cantly higher steady state ferritin levels despite no increased rate of transfu-
sions. Hence, it is possible that G6PD deficiency can alter the iron regulatory
and storage pathways via mechanisms that are still to be elucidated. However,
this warrants that SCD patients with G6PD deficiency should be monitored
more closely for increased iron overload complications.
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Background: The mortality rate associated with invasive fungal disease (IFD)
remains very high (≥40%). Patients in haematology units are at high risk of
IFD, and more acurate data is needed on medical practice and use of antifungal
therapies.
Aims: An objective of this study was to describe the frequency and character-
istics of systemic antifungal prophylaxis strategy in French patients suffering
from haematological malignancy and hospitalized in a haematology unit in rou-
tine medical practice.
Methods: Multicenter, cross-sectional, prospective French observational study
conducted in 24 hematology units (717 beds including 368 sterile beds) over
5 consecutive days on adult or paediatric patients with hematological malig-
nancies and hospitalized during this period.
Results: Overall, 494 patients who signed a consent form were classified into
4 groups according to their risk of Invasive Fungal Infections (IFI). Group 1
includes patients who received allogeneic hematopoietic stem cell transplant
(HSCT) (N=147), Group 2 patients suffering from AML or MDS who did not
receive allogeneic HSCT (N=131), Group 3 patients suffering from ALL who
did not receive allogeneic HSCT (N=71) and Group 4 all the patients not includ-
ed in the groups 1, 2 or 3 (N=145). 246 patients received systemic antifungal
therapeutic strategy. Among them, the proportion of patients who received pro-
phylactic strategy was for Group 1: 95/119 (79.8%), Group 2: 56/78 (71.8%),
Group 3: 12/19 (63.2%), Group 4: 24/30 (80.0%). Half of the patients from
groups 2 and 3 presented neutropenia for at least 10 days when enrolled in
the study compared to 17% for groups 1 and 4. 82% (78/95) and 73% (41/56)
of the patients from groups 1 and 2 were placed in sterile room (either in laminar
flow sterile room or Immunair™ bed or in highly purified room) compared to
50% (6/12) of the patients from Group 3 and 54% (13/24) from Group 4. In
Group 1: 75% (71/95) of patients received an azole, mostly fluconazole (44/71);
13/95 received echinocandins, mostly caspofungin (11/13); 11/95 received
polyenes. In Group 2: 89% (50/56) of patients received an azole, mostly
posaconazole (35/56); 6/56 polyenes and 1/56 echinocandins. In Group 3:
33% (4/12) of patients received oral fluconazole; 3/12 posaconazole, 3/12 poly-
enes and 3/12 echinocandins. In Group 4: 92% (22/24) patients received an
azole, mostly posaconazole (16/24); 1/24 polyenes and 1/ 24 echinocandins.
Summary and Conclusions: Prophylaxis is now the leading strategy used in
hematology, whatever the disease conditions of the patients with overall 76% of
treated patients receiving it. Overall, prophylaxis is mainly based on oral azoles
: fluconazole and posaconazole. Fluconazole is still used in high risk patients
(allogeneic HSCT) and low risk patients (Group 4). Posaconazole is mainly used
in AML/MDS patients, but also in ALL patients not receiving HSCT where its use
is off-label. Echinocandins are mainly used in high risk patients. Caspofungin is
the most-used echinocandin although it is not licensed for prophylaxis.
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Background: Bone marrow (BM) involvement by non-hematopoietic neo-
plasms usually occurs as a late event during the course of oncologic diseases.
Most patients with BM metastases have hematological abnormalities, such as
one or more cytopenias.
Aims: BM biopsy is a key diagnostic tool to investigate unexplained persistent
cytopenias. Limited information is reported in the literature about the incidence
of BM metastasis during the course of solid malignancies, with considerable
variability depending on the different types of neoplasms.
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Methods: A total of 10736 BM trephine biopsies were examined at the
Hematopathology Laboratory of the Azienda Ospedaliero-Universitaria Poli-
clinico of Modena, from January 2004 to December 2014. After processing, all
samples were stained with Hematoxylin-Eosin (H&E), Giemsa and Silver
impregnation (Gomori reaction). After morphologic evaluation, the appropriate
immunohistochemical panel, including cytokeratin (CK) mix (AE1-AE3), was
performed. Further characterizations of non hematopoietic neoplasms were
carried out in collaboration with the Pathologic Anatomy laboratory.
Results: Solid cancer metastasis was documented in 107 of all 10736 BM
biopsy samples (0.99%). Concomitant BM aspirates and touch imprints were
evaluable in 92 (86%) cases. Median patient age was 68 years (range 7-88
years; excluding a pediatric case, the interval span was 37-88 years). Males
and females were 49 (46%) and 58 (54%) of the 107 cases, respectively. The
most frequent metastatic tumors were, in order of frequency, as follows: breast
(39.25%), gastrointestinal (16.82%), lung (13.08%) and prostate (12.15%)
carcinomas. Among them, a previous diagnosis of solid cancer was missing
in 25 cases (23.36%). Primary tumor site was determined in 16 out of these
latter 25 cases (64%), namely breast 5 (20%), lung 4 (16%), kidney 2 (8%),
prostate 1 (4%), neuroendocrine 2 (8%), gastro-intestinal 1 (4%) and cervix
1 (4%). In the remaining 9 cases (36%), the rapid deterioration of clinical
conditions contraindicated further diagnostic investigations. However, epithe-
lial origin was documented according to CK mix positive staining, without
other specific markers. Cytopenias were the most common hematological
finding, namely, in order of frequency: anemia (75.7%), thrombocytopenia
(64.5%), and more rarely, leukopenia (23.4%). Of note, pancytopenia was
present in 13.1% of patients only. The finding of BM metastases predicted
unfavorable outcome, with a median survival from observation of 7 weeks
(range 0-361 weeks). This wide range was conditioned by the presence of
few breast cancer patients still responsive to hormone therapy (15 women
(14%) surviving more than one year).
Figure 1. BM metastases patients (n=107).
Summary and Conclusions: BM biopsy is an invasive procedure mainly used
for the diagnosis of hematopoietic disorders. Involvement of the BM by non-
hematopoietic lesions can incidentally be observed by the hematopathologist.
Our case series highlighted that persistent unexplained cytopenias in solid can-
cer patients can be the first indicator of BM metastases. Although rarely, the
finding of BM metastasis can lead to the first diagnosis of solid organ malig-
nancies. However, patients with BM metastasis have a poor outcome and, for
most of them, only supportive care can be considered.
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Background: Febrile neutropenia (FN) is often observed in chemotherapy of
hematological malignancy (HEM) such as acute leukemia (AL). Carbapenem
antibiotics having a potent and broad antimicrobial activity against both gram-
positive and gram-negative bacteria including Pseudomonas aeruginosa, are
good candidates as the first-line therapy drug in high-risk FN patients. In the
IDSA guideline 2010 on the use of antimicrobial agents in FN, mono-therapy
with an anti-pseudomonal beta-lactam, such as piperacillin-tazobactam
(TAZ/PIPC), cefepime (CFPM) or carbapenem [only meropenem (MEPM) and
imipenem-cilastatin (IPM)], is recommended as an empirical therapy for high-
risk FN patients. Doripenem (DRPM) is a newer carbapenem with few data
available as for the efficacy and safety in the setting of FN patients. 
Aims: We conducted a randomized, cooperative group and open-label trial
comparing DRPM (1.0 g every 8 hours) with MEPM (1.0 g every 8 hours) as
the first-line empirical antibacterial therapy for high-risk FN patients with AL
and myelodysplastic syndrome (MDS).
Methods: One hundred and forty-six hospitalized high-risk FN patients with
HEM (AML 96, ALL 23, APL 13, MDS-AML 9, MDS (RAEB-2) 5 cases) during
or after chemotherapy were randomized to each drug group (DRPM, 72; MEPM,
74). The study drug was started to administer as a mono-therapy and continued
at least for 5 days without severe drug toxicity, and the efficacy and safety were
evaluated.
Results: The overall response rate at 7 days in DRPM and MEPM group were
not significantly different (DRPM: 67.6%, MEPM: 52.9%, respectively, P=0.098).
Both the resolution of fever by mono-therapy at day 3 to 5 (DRPM: 56.9%,
MEPM: 47.0%, respectively, p=0.26), and survival at day 30 (DRPM: 98.4%,
MEPM: 98.5%, respectively, p=0.312) were not significantly different in the two
groups. The cases needed for anti-MRSA agent and antifungal agent tended
to be observed less frequently in DRPM rather than in MEPM group [DRPM:
36.9%, MEPM: 50.0% (p=0.185), DRPM: 26.1%, MEPM: 32.3% (p=0.535),
respectively]. Only grade 1-2 adverse events were observed in both groups
(liver dysfunction, renal dysfunction, diarrhea and rash), and they were less
often in DRPM group significantly (DRPM: 29.8%, MEPM: 40.8%, respectively,
p=0.046). These adverse events were clinically acceptable in the two groups,
and most of patients could continue the treatment by both study drugs.
Summary and Conclusions: Our clinical study suggested that DRPM had the
non-inferiority of efficacy in comparison with MEPM as the first-line therapy in
high-risk FN patients with AL and MDS, and both drugs could be well tolerated
clinically.
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Background: Human herpes virus 6 (HHV-6) is increasingly detected in
hematopoietic stem cell transplantation (HSCT) recipients and in patients who
recover after chemotherapy courses. HHV-6 may cause serious complications
such as encephalitis, myelosupression, pneumonitis, hepatitis, cystitis, unex-
plained fever, rash and is associated with graft-versus-host disease. The virus
DNA is detected in blood of 40% to 60% patients after HSCT, HHV-6 infection -
in 10-15% of such patients. DNA polymerase chain reaction (qPCR) is the com-
mon method of HHV-6 detection. HHV-6 infection lacks specific clinical syndromes
and is often revealed with CMV infection/reactivation. On time diagnostics and
early beginning and prolonged antiviral treatment (ganciclovir, foscarnet or cido-
fovir) may favorably affect the patient survival and neurologic symptoms.
Aims: To estimate the frequency of HHV-6 infection reactivation in patients
(pts) with acute leukemias and aggressive lymphomas after chemotherapy and
auto-HSCT.
Methods: For the period from January 2013 to December 2014 in the Depart-
ment of Hematological Oncology and BMT 68 pts (23 ALL, 42 AML, 3 DLBCL)
were analyzed. Auto-HSCT was carried out in 6 cases. Blood, bone marrow,
cerebrospinal fluid and urine samples were collected in patients who had febrile
neutropenia and other infection complications after courses of chemotherapy
or auto-HSCT. HHV-6 DNA was detected in biological fluids by realtime PCR.
The lower limit of detection for the assay was 500 copies/mL.
Table 1.
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Results: HHV-6 DNA was detected in 35% cases (n=24; 9/24 ALL, 13/24 AML,
2/24 DLBCL). Four out of 24 pts were after auto-HSCT. Only in 8,8% (6/68) of
cases (including 4 pts after auto-HSCT) we associated the HHV-6 detection and
clinical symptoms (3 ALL, 2 DLBCL, 1AML). Prolonged cytopenia (more than 40
days) and febrile fever had 3 pts, cystitis 2 pts, encephalitis 1 pt. (Table 1). All 6
pts were treated with ganciclovir (10mg/kg iv) during 4 weeks with conversion to
valganciclovir (per os) during the next 2 weeks. The median ganciclovir treatment
time was 4 weeks but in 2 cases of recurrent infection the treatment was pro-
longed until 6 (6-9) weeks. Early cessation of therapy (after 2 weeks) caused
viremia reccurence and viral load increasing of HHV-6 in 2 pts. The clinical symp-
toms fully disappeared after 3-5 days of treatment. The median time to virus
clearance was 4 (4-8) weeks.
Summary and Conclusions: Our study showed high frequency of HHV-6
DNA detection (35%) in immunocompromised pts, only 8,8% had HHV-6 asso-
ciated infection, most of them were after auto-HSCT. Early conversion therapy
to valganciclovir per os caused reccurent HHV-6 infection (33%). Thus, HHV-
6 infection required long treatment.
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SIVE FUNGAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
M. Fischer1,* B. Spies-Weisshart1, K. Schrenk1, B. Gruhn2, S. Wittig2, A. Glaser3,
A. Hochhaus1, S. Scholl1, U. Schnetzke1
1Internal Medicine II/ Oncology and Hematology, 2Klinik für Kinder- und
Jugendmedizin, 3Institut für Humangenetik, Universitätsklinikum Jena, Jena,
Germany
Background: Patients with acute myeloid leukemia (AML) who undergo induc-
tion chemotherapy are at high risk for invasive fungal disease (IFD). Dectin-1
(Dendritic cell-associated C-type lectin-1), a C-type lectin family member rep-
resents one of the most important and intensively studied pattern recognition
receptor (PRR) of the innate immune system and single nucleotide polymor-
phisms (SNP) in the Dectin-1 gene have been associated with an increased
risk of infectious complications. In detail, the heterozygous Dectin-1 variant
Y238X coding for an early stop codon has been associated with invasive
aspergillosis (IA) in recipients of hematopoietic stem cell transplantation.
Aims: We sought to investigate the impact of two different Dectin-1 SNPs on
developing IA in 164 patients with newly diagnosed AML during anthracycline-
based induction chemotherapy (cytarabine combined with idarubicin or mitox-
antrone). The occurrence of infectious complications (sepsis, general pneu-
monia, IFD) were analyzed.
Methods: Genotyping of Dectin-1 SNPs (rs16910526 and rs7309123) was
performed by TaqMan method and pyrosequencing in 164 adult AML patients.
IFD was defined according to the EORTC/MSG consensus guidelines. Multiple
logistic regression analyses were applied to evaluate the association between
Dectin-1 polymorphism and infectious events.
Results: We could demonstrate that patients carrying the homozygous Dectin-
1 SNP rs7309123 (G/G genotype, n=43 patients) revealed a significantly higher
risk for developing both pneumonia in general (p=0.018, odds ratio (OR): 2.46;
95% confidence interval (CI): 1.2 - 4.9) and pulmonary IFD (p=0.023, OR: 2.3;
95% CI: 1.2 - 4.5). In detail, 24 patients harbouring homozygous Dectin-1 SNP
developed pneumonia in general whereas 18 of them fulfilled criteria for IFD.
No significant correlation was observed between the occurrence of sepsis and
either SNP. Importantly, no differences were found between patients with het-
erozygous Dectin-1 SNP rs16910526 (Y238X, T/G genotype, n=13 patients)
and wild type carriers with regard to all analyzed infectious complications. 
Summary and Conclusions: To our best knowledge, this study represents
the first analysis demonstrating that a haplotype containing the Dectin-1 SNP
rs7309123 influences the risk of developing invasive fungal disease in patients
with acute myeloid leukemia undergoing induction chemotherapy.
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Background: Patients diagnosed with acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) who receive intensive induction chemother-
apy to achieve complete remission (CR) are considered to be at high risk for
developing invasive fungal infection (IFI) during the neutropenic phase (NP).
IFI occurs in up to 10% of patients diagnosed with AML/MDS on induction treat-
ment, and is fatal in approximately 40% of cases. Moreover, IFI may compro-
mise the subsequent chemotherapeutic strategies. Difficulty of making a rapid
diagnosis of the fungal disease and the high mortality associated, have led to
use primary antifungal prophylaxis (PAP) to prevent the occurrence of IFI
Aims: To collect the experience with posaconazole as PAP in patients diag-
nosed with AML or MDS in hospitals from our environment (Madrid-Spain).
Specific goals of this study were to assess IFI rates in our patients (incidence
of proven or probable IFI during the NP) the efficacy of this prophylaxis, the
rate of adverse events, infection-associated mortality, and overall mortality
Methods: A multicenter, observational, retrospective study of incidence of IFI
in patients diagnosed with AML and MDS, who received posaconazole as PAP,
and treated with intensive induction chemotherapy, was carried out in 11 hos-
pitals in Madrid (Spain) between 2009 and 2012. In order to achieve a minimum
100 evaluable patients each hospital collected around 10 consecutive
AML/MDS patients showing deep neutropenia defined as <500 neutrophils/µL
for more than 7 days and <100 neutrophils/µL for more than 4 days. All patients
received posaconazole, oral suspension, 200 mg three times daily, at least for
one day. Patients follow-up was stopped when a new chemotherapy treatment
was started, after 30 days-off posaconazol, or if the patient died
Results: 102 patients fulfilled the inclusion criteria. 63% were male with a median
age of 61 years. Diagnosis was AML 94% (8% in first relapse) and MDS 6%.
Anthracycline-based chemotherapy was used in 92% of patients; CR was
achieved in 72% and partial remission in 10%. All patients developed <500 neu-
trophils/µL with a median duration of 23 days (range 8-99) and <100
neutrophils/µL for a median of 16 days (range 4-84). Posaconazole was used a
median of 19 days (range 1-90). In 48 patients (47%) PAP was successful, but
35 (34%) needed a change in antifungal therapy: empirical treatment due to
maintained fever in 21 patients (21%) and to treat IFI in 14 patients (IFI was
diagnosed as possible in 10, probable in 3 and proven in 1) In all cases, lung
was the organ involved. Switch from posaconazole a different intravenous pro-
phylaxis due to mucositis, or poor oral intake, was a further cause of PAP failure
in 13% of patients. Drug discontinuation because of liver or gastrointestinal tox-
icity, was observed in 5% of patients. Overall mortality was 6% (bacterial infec-
tions in 3 patients; thrombotic and hemorrhagic events in 2 patients, and 1 patient
due to progression leukemia) with no IFI attributable mortality in our patients.
Summary and Conclusions: Despite the limitations of this retrospective, mul-
ticenter, real-life study, PAP with posaconazole reduced the incidence of prob-
able and proven IFI to 4% of patients diagnosed with AML and MDS and treated
with intensive induction chemotherapy. Nevertheless empirical antifungal treat-
ment was maintained in a fever-driven approach in 21% of the patients. Poor
oral intake represents a further handicap with this PAP that might be solved in
the near future with the new upcoming drug presentation
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WITH HEMATOLOGICAL DISEASE: CLINICAL CHARACTERISTICS AND
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Background: Community-acquired respiratory viruses (CARV) are a frequent
cause of respiratory infections in immunocompromised patients with an
increased risk for progression to pneumonia and fatal outcome. The diagnosis
of these infections are moving from the classical techniques (virus isolation by
cell culture, direct antigen detection) to nucleic acid amplification test usually
directed to several viruses.
Aims: The aim of this study was to describe CARV infections in haematological
patients based on multiplex PCR DNA microarray platform, focusing on Res-
piratory Syncytial Virus (RSV) and Human Parainfluenza Virus (HPIV) infections
due to their higher frequency and clinical relevance.
Methods: We have analysed retrospectively 570 specimens from 211 consec-
utive haematological patients with clinical symptoms of respiratory infection
from November 2012 to April 2014. The collected samples, nasopharyngeal
exudates and/or bronchoalveolar lavages (BAL), were tested with the CLART®
Pneumovir assay (Clinical Array Technology, Genomica, Spain) that detect 19
CARVs. Patients were classified as upper (URTID) or lower respiratory tract
infection disease (LRTID) according to the published criteria of the Fourth Euro-
pean Conference Infections in Leukaemia (ECIL-4) (Hirsch HH, et al. Clin Infect
Dis. 2013;56(2):258-66).
Results: There were 195 positive cases (34%) in 570 specimens from 211
haematological patients. Ninety nine patients had a positive result at least once.
Viruses detected were: 64 RSV, 35 HPIV, 64 rhinovirus, 8 metapneumovirus,
2 enterovirus, 2 coronavirus, 2 bocavirus, 4 adenovirus and 14 patients with
several viruses isolate in the same sample. Fifty-nine patients were diagnosed
with RSV or HPIV URTDI/LRTID (Table 1).
All patients with RSV were diagnosed from November to April. Nevertheless,
HPIV were diagnosed during all the year with a maximum incidence in June (6
cases). Twenty-nine (49%) patients were treated with oral ribavirin, mostly
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when RSV was diagnosed. Patients with no treated RSV, had solved the symp-
toms when positive test was informed. Ribavirin dosage used was that recom-
mended in ECIL-4. Median ribavirin treatment duration was 14 days (1-35).
Treatment was well tolerated. There were two engraftment delays in two trans-
plantation patients with RSV and LRTD (one autologous and one allogeneic).
One of them died of Pseudomonas aeruginosa pneumonia without neutrophil
engraftment. There were two deaths (6%) due to RSV pneumonia. One death
occurred in an AML patient treated with chemotherapy without any other micro-
biological documentation. The other fatal case occurred in a T-NHL patient hos-
pitalized for autologous stem cell transplantation with CMV coinfection. Both
patients received ribavirin since RSV infection diagnosis. No deaths related to
HPVI were described. In the whole series time to solve symptoms was 14 (3-
59) days and time to achieve a negative test was 20 days (7-119).
Table 1. Patients with RVS or HPIV disease.
Summary and Conclusions: CARV infection is a frequent cause of respiratory
tract infectious disease. The most important CARVs by clinical relevance and
frequency are RSV and HPIV. In our series LRTID was diagnosed in 34%
patients with RSV and 22% patients with HPIV but fatal complications occurred
only in RSV infection (6%) in spite of treatment. Oral ribavirin is a treatment
option, but can be associated with engraftment delay. More studies are neces-
sary to established treatment criteria, dosage, duration and efficacy of ribavirin
treatment in this population. The value of follow-up PCR tests in this patient
population neither has been established.
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TICEMIA AND ITS PROGNOSTIC VALUE
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Background: In acute leukemia, sepsis is a potentially fatal complication. Pen-
traxin 3 is a protein rapidly produced in response to primary inflammatory sig-
nals. It shows high levels in sepsis, especially associated with vascular and
end organ failure.
Aims: The study aimed to measure the level of Pentraxin 3 in septicaemia in
patients with acute leukemia and correlate its level to higher risk of complica-
tions compared to C-reactive protein (CRP).
Methods: The study took place from January, 2012 to December, 2013 includ-
ing 60 acute leukemia patients with sepsis, during severe neutropenia
(ANC<500) and after receiving chemotherapy. Samples were analyzed for
serum CRP and plasma PTX3 on days 1, 2 & 3 by ELISA. Blood cultures were
done to all patients.
Results: The studied group had a male to female ratio of 1:1, age ranged from
18-62 years (median of 40 years). 41 patients had Acute Myeloid Leukemia
while 19 had Acute Lymphoblastic Leukemia. High Pentraxin 3 levels on first
day of sepsis is a strong indicator for poor prognosis (septic shock, mortality
and coagulopathy outcomes) compared to CRP (p<0.01). PXT3 showed sen-
sitivity of 100% and specificity of 70% for prediction of poor prognosis where
CRP showed 88.5% and 60.5% respectively (Table 1 and Figure 1).
Table 1. Area under the curve represents significance, sensitivity and
specificity of Pentraxin 3 and CRP in day 1 among patients in sepsis.
Figure 1. ROC curve to determine the sensitivity and specificity of CRP
and Pentraxin 3 at day 1.
Summary and Conclusions: PXT3 is highly recommended in diagnosis of
sepsis in patients with acute leukemia during neutropenia and shows high sen-
sitivity and specificity in prediction of poor prognosis (septic shock, mortality
and coagulopathy outcomes) in comparison to CRP.
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Background: Idiopathic hypereosinophilia (IHE) has been a disorder of uncer-
tain etiology, characterized by persistent elevation of blood eosinophil count
exceeding 1.5x103/uL. So far, the diagnosis has been made through the exclu-
sion of either reactive or clonal causes of hypereosinophilia. When end-organ
damage due to eosinophilic infiltration is present, idiopathic hypereosinophilic
syndrome (IHES) is diagnosed. IHE and IHES are heterogeneous diseases
and have not been studied well so far. The nature of eosinophilic proliferation
is still unclear, whether benign or clonal, but WHO classification of hematologic
neoplasm described IHE and IHES with defined diagnostic criteria in the section
of myeloproliferative neoplasm.
Aims: Purpose of this study was to investigate the frequency of somatic muta-
tions in patients with IHE/IHES through targeted exome sequencing.
Methods: Bone marrow was collected from a total of 20 patients fulfilling WHO
2008 criteria for IHE (n=8) and IHES (n=12) along with 15 patients diagnosed
with reactive eosinophilia as a control group. In all patients, fluorescence in
situ hybridization (FISH) for BCR/ABL1, PDGFRa, PDGFRb, and FGFR1 was
performed for excluding myeloproliferative neoplasms associated with
eosinophilia with known cytogenetic aberrations. We designed capture
sequencing for 88 genes known for recurring mutation in hematologic malig-
nancies using target capture by Sureselect (Agilent, Santa Clara, CA, USA)
followed by sequencing using IlluminaHiSeq 2500. The sequencing reads were
analyzed based on the pipeline of bioinformatics tool. Candidate mutations
were confirmed by Sanger sequencing and also sequenced using matched
saliva samples (germline) from patients.
Results: The average coverage of target regions was >800-fold. The targeted
exome sequencing analysis revealed 193 substitutions and insertion/deletions
(Indels), median 3 per patient (range 0-86). Of these 193mutations, we identi-
fied somatic mutations in 4 genes according to interpretation algorithm; MPL
(2/20, 10%), SCRIB (2/20, 10%), ASXL1 (3/20, 15%), and STAG2 (3/20,15%).
The findings above highly suggest that these genes are likely related to patho-
genesis of hypereosinophilia.
Summary and Conclusions: Four recurrent mutations were identified in 6
patients (30%) by targeted exome sequencing analysis. Due to a limitation of
small number patients enrolled in the present study, a future larger validation
cohort is needed to test the frequency of the identified variants. We suggest
that mutation analysis of the 4 genes (MPL, SCRIB, ASXL1 and STAG2) could
be help to unveil clonal proliferation of eosinophil and here we propose them
as a potential candidate for the diagnostic work-up for hypereosinophilia. Fur-
thermore, this discovery of somatic mutations in IHE/IHES will provide a base-
line data for the tailored treatment of hypereosinophilia.
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Background: A novel anti-Neutropenic factor (ANF) consisting of a pegylated
granulocyte colony-stimulating factor with improved pharmacokinetic/pharma-
codynamics (PK/PD) properties was developed through a combinatorial PEGy-
lation approach to create a clinical candidate ideally suited for treating condi-
tions of severe neutropenia. 
Aims: Analyze ANF and marketed therapeutic(s) in parallel to identify unique
properties of ANF thereby expediting selection of a superior clinical candidate
for specific human clinical trials.
Methods: A series of in vivo and in vitro pre-clinical studies were conducted in
comparison to marketed forms of filgrastim (F) or PEG-filgrastim (PF). Following
pre-requisite and unremarkable GLP-toxicology studies, a phase 1 clinical
study was conducted in healthy volunteers (signed, consenting) to assess safe-
ty and tolerability of ANF as well as the PK and PD. Subcutaneous, single dose
treatment of ANF (or PF) with ascending dose were evaluated in a double-
blind study that included PK, neutrophil and CD34+ analytical parameters to
determine if pre-clinical ANF findings could also be observed within healthy
human subjects. ANF was evaluated in a dose-escalation (5 - 50µg/Kg) study
with each cohort including randomized treatment and controls. PF was admin-
istered at the single 6mg dosage (80-100µg/Kg), single-use syringe as a stan-
dard of care supplied by manufacturer.
Results: Rat neutropenia model dosage study results indicated the blood
PD parameters of ANF were significantly superior to both F and marketed
PF. Area under the curve (AUC) kinetic analysis showed the absolute neu-
trophil count (ANC) of ANF was equivalent at 4X lower dosage (25 vs
100µg/Kg) and yielded significantly higher ANC than marketed PF when
administered at equivalent 100µg/Kg dosage. A follow-on in vitro human neu-
trophil maturation study was conducted to evaluate CD34+ stem cell matu-
ration effects of ANF compared to PF. Similar to rat study findings, ANF yield-
ed a 4-6 fold increase in de novo neutrophil (CD66+) counts. Phase I clinical
interim safety results were unremarkable, with no severe adverse events in
any cohorts (ANF or PF). The ANF PK/PD parameters within the phase 1
study were similar to pre-clinical findings. PD results (ANC and CD34+) were
markedly prolonged in the ANF treatment groups even at the lowest cohort.
Mean ANC counts for all ANF cohorts showed an ANC Cmax between 162 -
177hrs in contrast to PF that reached max concentrations at 52hrs. AUC
analysis showed that ANF at 10µg/Kg was equivalent to PF at 100 ug/Kg
(standard of care) demonstrating a >8-fold potency effect over PF in healthy
volunteers. Peripheral blood CD34+ counts also yielded similar results; aver-
age ANF Cmax was prolonged by 2 days over PF (7 vs 5 days). PK results
were prolonged with ANF in both the pre-clinical rat and phase-1 human
study that correlated with the PD results. 
Summary and Conclusions: Collectively these data showed that ANF, a novel
anti-neutropenic factor, has unique, prolonged PK/PD attributes as compared
to PF, and these qualities may provide an improved clinical benefit in further
clinical studies. Phase 2 efficacy studies in severe neutropenia are planned to
further understand the potential clinical applications and benefits of ANF. 
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PRECLINICAL PHARMACOKINETIC/PHARMACODYNAMIC RELATION-
SHIPS FOR AG-348, AN INVESTIGATIONAL SMALL-MOLECULE ACTIVA-
TOR OF PYRUVATE KINASE
Y. Chen1,*P. Kosinski1, G. Histen1, C. Kung1, H. Kim1, L. Dang1, J. Popovici-
Muller1, J. Hixon1, L. Silverman1, S. Biller1, H. Yang1
1Agios Pharmaceuticals, Cambridge, United States
Background: Pyruvate kinase (PK) deficiency is a rare, autosomal recessive,
inborn error of metabolism caused by a functional deficiency of the R isoform of
PK (PK-R). It is characterized by life-long hemolytic disease and serious long-
term comorbidities such as poor growth and development in children, iron over-
load, and multi-organ dysfunction. Current treatments are palliative only, and there
are no approved drugs that directly target the underlying enzyme defect. PK-defi-
cient red blood cells display metabolic changes related to defective glycolysis,
including a build-up of upstream intermediate, 2,3-diphosphoglycerate (2,3-DPG)
and a deficiency in the product, adenosine triphosphate (ATP). AG-348 is a first-
in-class, oral, small molecule allosteric activator of PK-R. AG-348 treatment of
PK-deficient red blood cells ex vivo increased PK-R enzyme activity and induced
metabolic changes consistent with increased glycolytic activity, including reduc-
tions in 2,3-DPG levels and increases in ATP levels. First-in-human, phase 1 trials
of AG-348 in healthy volunteers have recently been completed.
Aims: Pharmacokinetic/pharmacodynamic (PK/PD) studies were conducted
to evaluate the effect of AG-348 on red blood cell metabolism in vivo in PK-R
wild-type (WT) mice, rats, and monkeys.
Methods: PK-R WT C57/BL6 mice, Sprague Dawley rats, and cynomolgus
monkeys were administered single or multiple (twice daily) doses of AG-348
by oral gavage for 3 and 7 days (mice and rats) or 5 days (monkeys). Dose
levels tested were 1 mg/kg, 10 mg/kg, 50 mg/kg, and 150 mg/kg in mice and
rats, and 3 mg/kg, 10 mg/kg, 25 mg/kg, and 70 mg/kg in monkeys. After the
first and last dose, blood samples were collected to evaluate plasma drug expo-
sure and pharmacodynamic (PD) markers in whole blood, including 2,3-DPG
and ATP levels, and PK-R activity.
Results: In WT mice, rats, and monkeys, a single dose of AG-348 resulted in
AG-348 exposure-related increases in PK-R activity concomitant with a reduc-
tion in 2,3-DPG levels, but no significant change in ATP levels. After multiple
doses of AG-348, the increase in PK-R activity and decrease in 2,3-DPG was
comparable to that observed after a single dose. In contrast to the single-dose
study, ATP levels increased in an exposure-related manner after multiple doses
(Figure 1). In vitro IC50 values for purified red blood cell PK-R activity correlated
well with estimated in vivo potencies in mice, rats, and monkeys.
Summary and Conclusions: In vivo PK/PD studies in WT mice, rats, and
monkeys found no significant species-related differences in pharmacokinetics
following single and multiple oral doses of AG-348 and demonstrated an indi-
rect PK/PD relationship across all three species. In whole blood samples,
robust changes in all three PD markers (2,3-DPG, ATP, and PK-R activity)
were observed following multiple doses, which correlated with AG-348 plasma
exposure. Changes in PD markers showed good cross-species consistency,
and there was good correlation of in vivo and in vitro data. These studies in
mice, rats, and monkeys effectively predicted the changes in 2,3-DPG and
ATP levels observed in single and multiple ascending dose clinical studies in
healthy volunteers.
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Figure 1. Correlation of AG-348 plasma exposure and ATP, 2,3-DPG and
PK-R activity in WT mice, rats, and monkeys following multiple, twice
daily (BID) dosing.
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EFFICACY AND SAFETY OF ELTROMBOPAG IN PATIENTS WITH MOD-
ERATE, SEVERE AND VERY SEVERE APLASTIC ANEMIA
D. Nance1,* G. Rodgers1, M. Nuttall2
1Internal Medicine Division of Hematology, University of Utah Huntsman Cancer
Institute, Salt Lake City, 2Hematology and Oncology Department, Central Utah
Clinic, Provo, United States
Background: Aplastic anemia is a rare, life-threatening, bone marrow failure
disorder in adults with few treatment options, particularly for those who are not
bone marrow transplant candidates. Eltrombopag is an orally bioavailable, syn-
thetic, small molecule, non-peptide thrombopoietin-receptor agonist that inter-
acts with the transmembrane domain of the thrombopoietin receptor (TPO-R).
As with thrombopoietin, the binding of eltrombopag to the TPO-R initiates a
number of signal transduction events which leads to an increase in the produc-
tion of mature megakaryocytes and platelets. Eltrombopag has been shown to
be effective in a limited number of patients to increase platelet counts in patients
with moderate, severe, and very severe aplastic anemia, and to reduce the
need for frequent platelet transfusions. 
Aims: The primary aim of this study is to evaluate the efficacy of eltrombopag in
patients with moderate to very severe aplastic anemia. Efficacy is defined as a
stable platelet count of 50,000/μL or more during any 4 week period within the
possible 12 weeks while on study. The secondary aims include recording adverse
events, identifying maximal platelet counts, hemoglobin and absolute neutrophil
counts, odds of responding during treatment, and proportion of patients achieving
at least twice their baseline platelet value at any point during the study. 
Methods: This is a prospective, phase II, investigator-initiated clinical research
trial. After IRB approval, patients meeting inclusion criteria and having platelet
counts that dropped below 30,000/µL or with clinically significant bleeding were
enrolled with informed consent. Data collected included: serial complete blood
counts, peripheral smears, complete metabolic panels, pharmacokinetic testing
of eltrombopag, serum thrombopoietin levels and urinalysis.
Results: Nine patients have been enrolled in the trial, and 8 have completed
at least 12 weeks of therapy and 4 weeks of follow up. One patient withdrew
from the study due to a concomitant liver injury, not study related. Thrombopoi-
etin level at the time of study entry was available for 8 of the 9 patients; average
2,863pg/mL (range 1452-4000), reference range 7-99 pg/mL. Efficacy: 3
patients (38%) had a complete response (platelet count of >50 K/μL) and 1
patient (12%) had a partial response (decreased need for platelet transfusion)
during treatment and in the first 4 weeks of follow up. The minimum effective
eltrombopag dose was 150mg po daily. The average time to increase in platelet
count was 7 weeks, range 2-12 weeks. All patients who had a response main-
tained the response at time of censure (average 4-43 weeks. In the 3 patients
who responded, a mean increase in hemoglobin (9.5 to 10.6 g/dL) occurred
and liberation from red blood cell transfusions was observed and 2 had improve-
ment of neutrophil count to >1.5 K/μL. 2 additional patients showed improve-
ment in absolute neutrophil count; therefore, 4 of 8 patients had increases from
baseline to liberation from granulocyte colony stimulating factor therapy (0.9 to
3.0 K/μL). No serious adverse events were observed. No patient stopped the
drug due to side effects of the medication.
Summary and Conclusions: Eltrombopag at a dose of 150-300mg daily is safe
in individuals with aplastic anemia with 50% achieving reduction or elimination of
need for supportive platelet transfusions. An additional subset of 25% of patients
who did not meet the primary study endpoint experienced improvement in neu-
trophil count, and/or hemoglobin level, with an overall response rate of 75%. 
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HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE CENTER EXPE-
RIENCE
Y. Oymak1, E. Toret1,* Y. Ay1, T. Karapinar1, B. Demirag1, Y. Yaman1, O. Carti1,
G. Ozek1, M. Bulut1, F. Hazan2, C. Vergin1
1Pediatric Hematology-Oncology, 2Medical Genetics, Izmir Dr Behcet Uz hos-
pital, Izmir, Turkey
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder
which presents as prolonged fever, severe cytopenia and hepatosplenomegaly.
It is classified as primary (genetic) and secondary (acquired) HLH according to
the underlying etiology. If left untreated, patients with HLH survive for only a
few months. 
Aims: There were few studies related with HLH series. As the reported series
continue knowledge about this rare disease will increase and make a contribu-
tion to advence its prognosis. In this study we present our experience with
patients with HLH.
Methods: We retrospectively analyzed data of 46 HLH patients who were
admitted to the Pediatric Hematology Department of Dr. Behçet Uz Children’s
Hospital, Izmir, Turkey between July 2008 and October 2014. Patients were
diagnosed based on the revised diagnostic criteria criteria (HLH-2004) of the
International Histiocyte Society.
Results: Of 46 patients, six (M/F=3/3) were defined as primary and
40(M/F=23/17) were secondary HLH. Consanguinity rate was 35%. Perforin,
sytaxin, and RAB27A mutations were detected in three, two, and one of primary
HLH patients, respectively. Malignancy, infection and rheumatologic diseases
were related in 5 (11%), 29 (63%) and 12 (26%) of secondary HLH patients.
The mean age of primary and secondary HLH patients was 2.3(0.2-11.0) years
and 5.5(0.2-17.0) years respectively (p=0.074). Fever, organomegaly, hyper-
ferritinemia, hemophagocytosis, hypertrigylseridemia, hypofibrinogenemia were
seen 100.0%, 85.0%, 85.0%, 52.2% and 54.3% respectively. The central nerv-
ous system was involved in a total of 11(23.9%) patients; 10 had seizure and
one had visual loss. The median follow-up duration was 10(1-84) months. Five
year survival rate fort he patients was 79%. Hematopoetic stem cell transplan-
tation were performed in five primary HLH patients.
Summary and Conclusions: This study present clinical findings of patients
with primary and secondary HLH. We think that this study will contribute the
data related with HLH which is rare and fatal disorder. 
P754
MANAGEMENT OF CYCLIC NEUROPENIA: DIAGNOSIS AND THERAPY
C. Zeidler1,* U. Grote2, S. Mellor-Heineke2, A. Nickel2, K. Welte1
1Molecular Hematopoiesis, 2Medical School Hannover, Hannover, Germany
Background: Cyclic neutropenia (CyN) is a hematologic disorder characterized
by regular oscillations of the bone marrow maturation leading to peripheral
blood neutrophil counts with consistent, usually 21-day, periodicity. Other blood
cells, e.g. platelets, may also show a cyclic pattern. CyN is inherited as an
autosomal dominant disorder and mainly attributed to mutations in ELANE (for-
merly ELA2). Other gene mutations may also cause blood cell periodicity related
with regular fevers and infections, e.g. tumor necrosis factor receptor gene
(TRAPS) or MEFV (MEditerranean FeVer). ELANE mutations are also respon-
sible for a substantial proportion of congenital neutropenia (CN) with persistent
low neutrophil counts.
Aims: Investigation of the natural course and management of cyclic neutropenia.
Methods: The Severe Chronic Neutropenia International Registry (SCNIR) col-
lected data on 80 patients with CyN (37 with ELANE mutation, 9 ELANE neg-
ative, 34 not tested) since 1994. Eleven families with a total of 24 patients were
identified.
Results: Diagnosis: It is most important to discriminate between CN and CyN,
since patients with ELANE associated CN have a high risk of leukemic trans-
formation whereas patients with ELANE associated CyN do not, although some
mutations are associated with both phenotypes, even in the same kindred. To
document the cyclic pattern of blood counts 3 CBCs per week over a period of
six weeks are required to proof CyN. Depending on the cycle phase, bone mar-
row morphology may change between normal and maturation arrest of granu-
lopoiesis. Intriguingly, one patient harbored both ELANE- and TNFR1A-muta-
tions suggesting there is an overlap of patients suffering from Cyclic Neutrope-
nia and Periodic Fever Syndrome. Treatment: The efficacy of daily subcuta-
neous Granulocyte-Colony Stimulating Factor (G-CSF) has been proven in ran-
domized controlled trials with congenital, cyclic and idiopathic neutropenia. Six-
ty-seven patients (83,8%) received G-CSF at a median dose of 1,94 µg/kg/d.
Long-term follow-up indicates that these patients experience fewer mouth
ulcers, febrile events and (bacterial) infections when treated with recombinant
human granulocyte-colony stimulating factor (rHuG-CSF), despite a persistence
of the cycling of blood counts. However, the cycle length and duration of nadir
is shortened with treatment. G-CSF can be administered every day or every
other day for patients with cyclic neutropenia. Ordinarily it is easier to start with
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a very low dose, 0.5 to 3 mcg per kilogram per day given on a daily basis,
going up gradually to find the lowest effective dose. Both children and adults
respond well to G-CSF and adverse events are relatively infrequent. The most
common acute adverse events associated with G-CSF therapy are bone pain
and headache. Less frequent administration of larger doses can intensify bone
pain, so weekly or twice weekly injections are seldom tolerated, and increasing
the frequency of administration may ameliorate the bone pain. Treatment
responses tend to be quite stable once an effective dose for the individual
patient is found. The dose should be gradually adjusted for body weight in
growing children, with monitoring of the response. Supportive care: Chronic
periodontal disease may occur in untreated CyN. In addition to sufficient neu-
trophil counts, good dental hygiene and regular professional treatment are nec-
essary to prevent tooth loss. Psychosocial support can help alleviate the psy-
chological and financial burdens of a chronic illness, and can be provided both
by health professionals and by patient/parent groups which are established in
many countries already.
Summary and Conclusions: CyN patients benefit from G-CSF treatment.
Correct disgnosis is important for the long-term management and counseling.
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RELATION BETWEEN GLUTATHIONE S TRANSFERASE GENES (GSTM1,
GSTT1 AND GSTP1) POLYMORPHISMS AND CLINICAL MANIFESTATIONS
OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS
H. Ellithy1,* G. Shaheen2, S. Yousry2
1Internal medicine- clinical hematology unit, 2Clinical pathology, Kasr Al-ainy
school of medicine- Cairo university, Cairo, Egypt
Background: Sickle cell disease (SCD) is characterized by clinical manifes-
tations that resulted from sickling of Hb S, which is augmented by accumulation
of oxygen free radicals that cause oxidation of Hb S. Defective normal antiox-
idant protective mechanism predispose to clinical manifestations of SCD like
vaso-occlusive crisis (VOC) and acute chest syndrome (ACS). The glutathione
system plays an important role in the removal of endogenous products of per-
oxidation of lipids and so protects cells from the deleterious effects of oxidative
stress. Impairment of glutathione system due to genetic polymorphisms of glu-
tathione S transferases (GSTs) genes is expected to increase risk of SCD clin-
ical manifestations. GSTs genes polymorphisms may have ethnic-dependent
polymorphism frequencies. The association of GSTM1, GSTT1 and GSTP1
polymorphisms and various diseases such as cancer and inflammatory dis-
eases has been proved in various studies.
Aims: Understanding the impact of GSTs gene polymorphisms on severity
of SCD manifestations, may help to improve the quality of life of SCD patients,
by using prophylactic measures that decrease oxidative stresses, such as
antioxidants, in patients at risk of developing sever manifestations due to
impairment of their defense reductive mechanisms, namely patients who car-
rying the predisposing GSTs genotypes. So in this study, we aimed at outline
the relation between GSTs gene polymorphisms and severity of SCD mani-
festations.
Methods: In this study, we measured the frequency distribution of the 3 GSTs
genes polymorphisms (GSTM1, GSTT1 and GSTP1) in 100 Egyptian adult
SCD patients and 80 corresponding controls.GSTM1 and GSTT1 genotypes
was determined by multiplex polymerase chain reaction (PCR) with using a
housekeeping B globin gene as internal control. GSTP1 polymorphism were
determined with a polymerase chain reaction-restriction fragment length poly-
morphism assay [PCR-RFLP]. Patients were followed up prospectively between
June 2012 and June 2014 to evaluate the relation between GSTs genes poly-
morphisms and the frequency of complications of SCD, in the form of severity
of anemia, number of VOC attacks, acute chest syndrome and pulmonary
hypertension. The patients were assessed for the severity of anemia by the
average number of units of packed red cells (PRCs) transfused per year. The
average number of VOC per year was documented.
Results: In our study, the frequency distribution of the GSTs null genotypes
was found in 58% of SCD patients, with the highest prevalence for GSTM1
(42%), followed by GSTT1 (32%). Absence of both GSTM1 and GSTT1
genes was found in 16% of SCD patients. Regarding GSTP1 polymorphisms
distribution, highest prevalence was for wild genotype (59%), followed by
heterozygous genotype (35%) then homozygous genotype (6%). There was
no statistically significant difference in the distribution of the GSTs gene poly-
morphisms between SCD patients and the controls. GSTM1 null genotype
was significantly associated to ACS and VOC (P value=0.03 and 0.01 respec-
tively), it also associated to pulmonary hypertension and high requirement of
blood transfusion, but not of statistical significance. GSTT1 null genotype
was associated with significantly increased requirement of blood transfusion
(P value=0.01), however risk of pulmonary hypertension, ACS, and VOC
were not increased significantly (P value=0.1, 0.8 and 0.2 respectively).
Absence of both GSTM1 and GSTT1 genes significantly predisposed to pul-
monary hypertension (P value=0.04). Non wild GSTP1 polymorphism not
predisposed to clinical manifestations of SCD in the form of pulmonary hyper-
tension, ACS, frequent VOC or increased requirement of blood transfusion
(P value=0.7, 0.6, 0.9 and 1 respectively).
Summary and Conclusions: In this study, the null status of GSTM1 and
GSTT1 genes were identified as important risk factors for developing sever
clinical manifestations of SCD. Further studies are needed to confirm our find-
ings. Identifying GSTM1 and GSTT1 null genotype as risk factors for developing
sever manifestations of SCD may help to categorize SCD patients whom are
genetically at risk of developing sever manifestations due to defective anti-
oxidative defense mechanism, in order to minimize severity of their symptoms
by using prophylactic antioxidants and other measures that improve their reduc-
tive defense mechanisms.
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CASES OF SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS:
A SINGLE CENTER EXPERIENCE
S. Karaman1,* D. Demirkol2, I. Yildiz3, K. Nisli4, I. Bilge5, H. Aktürk6, A. Citak7,
S. Anak1, A. Unuvar1, G. Ozturk1, Z. Karakas1, O. Devecioglu1
1Pediatric Hematology, Istanbul University, Istanbul Medical Faculty, Istanbul,
2Pediatric Intensive Care Unit, Koc University School of Medicine, 3Ambulatory
Pediatrics, 4Pediatric Cardiology, Istanbul University, Istanbul Medical Faculty,
5Pediatric Nephrology, Koc University School of Medicine, 6Pediatric Infectious
Diseases, Istanbul University, Istanbul Medical Faculty, Istanbul/, 7Pediatric Inten-
sive Care Unit, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
Background: Hemophagocytic lymhohistiocytosis (HLH) is a life-threatening
hematologic disorder characterized by fever, hepatosplenomegaly or
splenomegaly, and cytopenias that accompany with elevated liver enzymes,
hyperferritinemia, hypertriglyceridemia, and hypofibrinogenemia. There are two
types as primary (congenital) and secondary. HLH may ocur secondary to
infections, malignancies, immun deficiency syndromes, and rheumatologic and
metabolic disease.
Aims: To describe the profile and the treatment of children with secondary
hemophagocytic lymphohistiocytosis (HLH).
Methods: Secondary HLH, who were admitted to the Department of Pediatrics,
Istanbul Faculty of Medicine Hospital, from January 2003 through December
2014, were retrospectively evaluated.
Results: There were 38 secondary HLH cases, of that 49% were females and
the mean age was 6.7±4.2 (range: 1-17.0) years. Primary causes were distrib-
uted among patients as follows: sixteen cases with rheumatological diseases,
eleven with malignancies, seven with infectious diseases, one with metabolic
disorder, one with epilepsy, one with hemolytic anemia, and one with chronic
granulomatous disease. Mean ferritin value was 22693.8±26312.3 (range:
1114-100 000) ng/mL. Six cases (15.7%) were treated with high dose methyl-
prednisolone (HDMP), three (7.9%) with intravenous immunoglobulin (IVIG)
only; four (10.5%) with HDMP+plasma exchange (PE); 10 (%26.3) with
HDMP+PE+IVIG; 12 (31.5%) with HDMP+IVIG; 2 (5.2%) PE+IVIG, and one
(2.6%) with standard steroid treatment.
Summary and Conclusions: HDMP is a very effective treatment especially
for macrophage activation syndrome. In case of progressive disease adding
PE +/- IVIG is an important issue.
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MYCHOPHENOLATE MOFETIL AND SIROLIMUS AS TREATMENT OF
AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE IN CHILDREN: A SIN-
GLE CENTER EXPERIENCE
M. Miano1,* K. Perri1, A. Todiere1, E. Palmisani1, C. Micalizzi1, J. Svahn1,
M. Calvillo1, P. Terranova1, T. Lanza1, C. Dufour1, F. Fioredda1
1Haematology Unit, G Gaslini Research Institute, Genoa, Italy
Background: Autoimmune Lymphoproliferative Syndrome (ALPS) is an erratic
disorder with wide phenotypic expressions that vary from asymptomatic pictures
to very severe clinical manifestations. Steroids and intravenous immunoglobulin
are commonly used to switch off the disease, although they may not be effective
or may require long-term administration to maintain remission, which may lead
to severe side effects. Mycophenolate mofetil (MMF) and sirolimus have been
used as alternative option in this setting but experiences are still limited. 
Aims: To evaluate the efficacy and toxicity of the use of MMF and sirolimus in
children for treatment of ALPS in a single center
Methods: ALPS was defined according to the revised criteria of the consensus
conference held in 2009. Clinical records of all ALPS patients followed at our
Center were revised. Complete and partial response (CR, PR) was defined as
follows. Lymphoproliferation: lymphonodes/spleen volume reduction with (CR)
or without (PR) return to normal size. Platelets >100.000 (CR), or 20-
100x103/mmc (PR) and doubled number compared to the baseline. Haemo-
globin: grade 2 but no need of transfusion (PR). Neutrophil: >1,5 (CR), or 0,5-
1,5x103/mmc (PR) and double number compared to the baseline.
Results: From January 2002 to December 2014, 26 subjects (50% females,
50% males) aged 0.1-40 yrs (median 10.5) with probable (35%) or definitive
(65%) diagnosis of ALPS were studied. 18/26 (70%) of patients showed
cytopenia, and the remaining 8 patients (25%) suffered from lymphoprolifer-
ation with or without other symptoms (fever, asthenia, headache). 6/26 (23%)
did not need any treatment. Sixteen out of the remaining 20 (80%) patients
were initially treated with steroids: 3/16 (19%) of them responded, 13 (81%)
did not. 4/20 (20%) patients received MMF (3) and Azatioprine (1) as first
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line therapy and achieved a CR and PR in 3 and 1 cases, respectively.12/13
non-responders to steroids received MMF as 2nd (8), or further line (4) ther-
apy and achieved a complete (7) or partial (5) response. The remaining child
received and responded to sirolimus. Three patients who partially responded
MMF where shifted to sirolimus with the aim to further improve the response.
Two of them achieved a CR and the remaining one maintained the PR. Over-
all, 16/16 patients who received MMF and 4/4 who received Sirolimus
responded to the treatment. Both drugs were well tolerated. Median age at
last follow-up (FU) was 17 years (range 6.3-49.6) and median duration of fup
was 5.2 years (range 0.4-12).
Summary and Conclusions: This is the largest report on children receiving
MMF and Sirolimus shows that they are safe and effective in ALPS. Results
must be validated by clinical trials.
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ADULT DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS IN THE US:
A POPULATION-BASED STUDY USING THE SURVEILLANCE, EPIDEMI-
OLOGY, AND END RESULTS (SEER) PROGRAM
M.V. Shah1,* C. Hook1, T. Call1, R. Go1
1Division of Hematology, Mayo Clinic, Rochester, United States
Background: Adult disseminated Langerhans Histiocytosis (AD-LCH) is an
extremely rare multisystem histiocytic disorder of the dendritic cells. Accurate
estimates of its incidence and survival are important for assessing optimal
patient care and prognosis. However, most of the current data are in the pedi-
atric population. Comparative epidemiologic study of AD- LCH in a large pop-
ulation is lacking and clinical studies remain limited to small series.
Aims: To investigate the epidemiology and outcomes of patients with AD-
LCH. using the Surveillance, Epidemiology, and End Results (SEER) Program
database.
Methods: SEER, a program of the U.S. National Cancer Institute, collects
cancer incidence and survival data from population-based cancer registries
covering approximately 28% of the US population. We identified AD-LCH cas-
es using ICD-O-3 histology code 9754/3 who were >18 years of age at the
time of diagnosis. We calculated the incidence rates (case/1,000,000) using
the 2000-2009 SEER 18 registries and age-adjusted those to the US 2000
standard population. Patient level data were analyzed to determine demo-
graphic findings and clinical outcome. To measure the relative risk of subse-
quent malignancies compared to the general population, we calculated a
standardized incidence ratio (SIR) for each type of second and higher primary
cancer (observed/expected). We used SEER*Stat (v 8.1.5) for incidence and
SIR statistical calculations.
Results: In the years 2000-2009, a total of 40 cases of AD-LCH were reported
in the SEER database with the overall incidence of 0.07 per 1,000,000 indi-
viduals (95% CI: 0.05 - 0.10). The incidence according to racial groups (adult
and pediatric cases combined) was: Whites 0.22 (95% CI: 0.18 -0.25), Black
0.08 (95% CI: 0.04-0.14), American Indian/Alaska Native 0.16 (95% CI: 0.03-
0.6), and Asian/Pacific Islander 0.21 (95% CI: 0.12-0.32). The incidence was
significantly lower among Black compared to White population (rate ratio:
0.35; 95% CI: 0.17-0.67; p<0.001). The incidence was similar among both
sexes (male/female ratio=1.03) and the median age at diagnosis was 46
years (range, 20-86 years). Males were more likely to be diagnosed at a
younger age compared to females (36 vs 51 years; p=0.01). After a median
follow-up of 83 months (range, 16-323), 19 patients have died. The causes
of death were malignancies (7 patients), vascular diseases (6 patients), acci-
dent (1 patient) and ‘other causes’ (5 patients). The median overall survival
was 255 months (Figure 1A). The relative survival was similar between
patients diagnosed in the 1978-1993 and 1994-2009 eras (Figure 1B). Nine
patients developed more than one malignancy including acute myeloid
leukemia (AML; 2 patients), lung cancer (1), and non-Hodgkin lymphoma (1).
Compared to the general population, AD-LCH patients had an increased risk
of developing AML (SIR 58.6; p<0.05).
Figure 1.
Summary and Conclusions: AD-LCH is a very rare malignancy that is less
common among the Black population. The prognosis is relatively good with
overall median survival of more than two decades after diagnosis. There is an
increased risk of subsequent development of AML.
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MULTICENTRE OBSERVATIONAL PROSPECTIVE COHORT STUDY LOOK-
ING AT CARDIOVASCULAR RISK AND PURE RED CELL APLASIA ASSO-
CIATED WITH EPOETIN THETA IN 1039 PATIENTS WITH CHRONIC KID-
NEY DISEASE
A. Lammerich1,* P. Balcke2, P. Bias1, M. Wiesholzer2
1Biosimilars Clinical Development, Teva ratiopharm, Merckle GmbH, Ulm, Ger-
many, 2, Department of Internal Medicine, University Hospital St. Poelten and
Karl Landsteiner Institute of Nephrology and Haematology, St Poelten, Austria
Background: In 2010 the EU Authorities recommended to limit haemoglobin
(Hb) levels within the range of 10 to 12 g/dL for adults when giving Erythro-
poiesis-Stimulating Agents (ESAs) to patients with chronic kidney disease
(CKD). In addition, rare cases of pure red cell aplasia (PRCA) have been report-
ed through post-marketing surveillance. 
Aims: The primary objective was to assess the incidence and severity of car-
diovascular events including ischemic stroke in patients treated with epoetin
theta (EPO θ) for anaemia associated with CKD. The secondary objective was
to monitor the safety of EPO θ, including PRCA.
Methods: In this observational, non-interventional, cohort study 55 study cen-
tres from 4 European countries observed 1039 consecutive patients with
advanced or end-stage renal disease who received EPO θ for at least 6 months.
Up to 4 visits could be documented at study start, month 2, 4 and 6 respectively.
Spontaneous as well as reportable adverse events (RAEs) were collected, the
latter being grouped as “cardiac disorders”, “cardiac failure”, “myocardial infarc-
tion”, and “ischaemic stroke” with respective defined subterms. Furthermore,
EPO θ doses and available Hb values were recorded. For a post-hoc analysis,
classification by 33.3% and 66.6% percentiles resulted in 3 tertiles for individual
mean Hb levels: low Hb level (≤10.7 g/dL), medium Hb level (>10.7 to ≤11.47
g/dL) and high Hb level (>11.47 g/dL) and for mean weekly EPO θ doses: low
dose (≤62 IU/kg per week), medium dose (>62 to ≤125 IU/kg per week) and
high dose (>125 IU/kg per week), respectively.
Results: 101 RAEs were documented in 89 patients (8.6%) with an event rate
of 0.0992 events per ½ person year. 64 patients died (6.1%), but none of the
deaths were related to EPO θ. Among the Hb classes, the lowest incidence of
RAE was found at medium Hb level (6.2%) compared to low (11.3%) and high
Hb level (7.8%). The incidence for ischemic stroke is more than double in the
high Hb level class (1.5% vs 0.6% for low and medium Hb level). The incidence
of any RAEs was higher in the high dose group (10.1%) compared to medium
(8.0%) and low dose group (7.6%). Constellations associated with higher risk
for any cardiovascular RAE or ischaemic stroke are high dose/high Hb (13.3%),
high dose/low Hb (12.6%), and low dose/low Hb (12.1%). Lower risk for RAEs
is associated with medium Hb (high dose/medium Hb: 3.8%, low dose/medium
Hb: 5.3%). The event rate for Adverse Drug Reactions (ADRs) that affected
terms other than the predefined reportable ADRs was 0.0081 events per ½
person year. No cases of PRCA were reported in this study.
Summary and Conclusions: This observational study confirmed that the low-
est approved effective EPO θ dosage and dose frequency should be used to
reach an individual target Hb level in the medium Hb range of 10 to 12 g/dL.
These results confirm the prescribing recommendations and support a
favourable risk-benefit ratio for treatment with EPO θ.
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ADJUSTED CORTICOSTEROID RISK FUNCTION OF SEVERE INFECTION
IN PRIMARY IMMUNE THROMBOCYTOPENIA ADULTS. A NATIONWIDE
NESTED CASE-CONTROL STUDY.
G. Moulis1,2,* L. Sailler2,3, M. Lapeyre-Mestre2,4
1Internal Medicine, Toulouse University Hospital, 2UMR 1027, INSERM-Uni-
versity of Toulouse, 3Toulouse University Hospital, Toulouse, France, 4Clinical
Pharmacology, Toulouse University Hospital, Toulouse, France
Background: Corticosteroid (CS)-related infection risk in immune thrombocy-
topenia (ITP) is unknown. 
Aims: The objective of this study was to assess the CS risk function of severe
infection in persistent or chronic primary ITP adults, adjusted on other immuno-
suppressive treatments (rituximab, splenectomy, immunosuppressants) and
intravenous immunoglobulin exposures.
Results: We identified 161 cases (including 9 opportunistic infections). The
model with the best goodness of fit was CS exposure during the month before
the index date (OR: 2.48, 95% CI: 1.61-3.83). The risk existed from doses ≥5
mg PEQ daily (vs <5 mg: 2.09, 95% CI: 1.17-3.71). No impact of previous
cumulative exposure was measured.
Summary and Conclusions: Maintaining supraphysiological CS dose is asso-
ciated with the risk of severe infection in persistent or chronic primary ITP patients.
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ELTROMBOPAG SAFETY AND EFFICACY FOR PRIMARY CHRONIC
IMMUNE THROMBOCYTOPENIA IN CLINICAL PRACTICE
T.J. González-López1,* C. Pascual2, M.T. Alvarez-Román3, F. Fernández-
Fuentes4, B. Sánchez-González5, I. Jarque6, J.A. Hernández-Rivas7,
S. Bernat8, M.M. Andrade9, M. Cortés10, S. Pérez-Crespo11, M. Gómez-
Nuñez12, P.E. Olivera13, G. Pérez-Rus2, V. Martínez-Robles14, A. Fernández-
Rodríguez15, C. Fernández-Miñano16, M.A. Fuertes-Palacio17, E. De Cabo18,
R. Fisac19, C. Aguilar20, M. P. Martínez-Badas21, M.J. Peñarrubia22, J. García-
Frade23, J.R. González-Porras24
1Department of Hematology, Hospital Universitario de Burgos, Burgos, 2Depart-
ment of Hematology, Hospital General Universitario Gregorio Marañón, 3Depart-
ment of Hematology, Hospital Universitario La Paz, Madrid, 4Department of
Hematology, Hospital universitario Insular de Gran canaria, Las Palmas de Gran
Canaria, 5Department of Hematology, Hospital del Mar, Barcelona, 6Department
of Hematology, Hospital La Fe, Valencia, 7Department of Hematology, Hospital
Infanta Leonor, Madrid, 8Department of Hematology, Hospital de La Plana,
Castellón, 9Department of Hematology, Hospital Universitario Miguel Servet,
Zaragoza, 10Department of Hematology, Fundació Hospital Asil de Granollers,
Barcelona, 11Department of Hematology, Hospital de Santiago de Compostela,
Santiago de Compostela (La Coruña), 12Department of Hematology, Hospital
Parc Taulí, Sabadell (Barcelona), 13Department of Hematology, Hospital Vall de
Hebron, Barcelona, 14Department of Hematology, Hospital de León, León,
15Department of Hematology, Hospital Universitario Central de Asturias, Oviedo
(Asturias), 16Department of Hematology, Hospital Vega Baja, Orihuela (Alicante),
17Department of Hematology, Hospital Clínico Lozano Blesa, Zaragoza,
18Department of Hematology, Hospital del Bierzo, Ponferrada (León), 19Depart-
ment of Hematology, Hospital de Segovia, Segovia, 20Department of Hematology,
Hospital de Soria, Soria, 21Department of Hematology, Hospital de Ávila, Ávila,
22Department of Hematology, Hospital Clínico de Valladolid, 23Department of
Hematology, Hospital Rio Hortega, Valladolid, 24Department of Hematology,
IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain
Background: Eltrombopag is a thrombopoietin receptor agonist (TPO-RA)
drug. It is considered effective and safe in chronic immune thrombocytopenia
(ITP) patients. However, the results from clinical trials could not accurately
reflect what happens in the clinical practice. 
Aims: To evaluate the efficacy and safety of eltrombopag in primary chronic
ITP in a real world setting. 
Methods: 164 primary chronic ITP patients from 33 Spanish centers who had
been treated with eltrombopag were retrospectively evaluated. Nevertheless
12 patients were excluded from the final analysis because they were not treated
for primary chronic ITP.
Results: The median age of our cohort (72% women) was 63 (IQR, 45-75)
years. The median months with ITP diagnosis was 81 (IQR 30 - 192). The
median number of therapies prior to administration of eltrombopag was 3 (IQR,
2-4), including splenectomy (68%) and rituximab (23%). At the time of eltrom-
bopag start, 45 of 152 (30%) patients were receiving concomitant treatment
for ITP, mainly corticosteroids and/or immunoglobulins (29%). Forty-six (30%)
patients had bleeding signs/symptoms the month before treatment start. The
median platelet count at eltrombopag initiiation was 22x109/L (IQR, 8-
39x109/L). Platelet responses were observed in 135 of 152 (88.4%) patients.
The proportion of patients achieving platelet response was quite similar regard-
less of age (86.7% and 91.4% for patients <65 years-old and ≥65 years-old,
respectively), gender (93.4% and 76.7% for women and men respectively),
splenectomy status (87.5% and 89.4% for splenectomised and nonsplenec-
tomized patients, respectively), use of concomitant ITP medication at baseline
(90.9% and 87.9% for patients with and without concomitant baseline treat-
ment), bleeding at eltrombopag initiation (82.6% and 91.5% for patients with
and without bleeding, respectively) and baseline platelet count (85.9% and
90.9% for patients with less than and more than 20x109/L platelets, respec-
tively). Demographic (age, gender), baseline disease characteristics (platelet
count, splenectomy status, concomitant ITP treatment or presence of bleeding)
were examined as possible predictors of platelet response. However, no pre-
dictive factor was statistically significant. The median of days to platelet
response was 12 (95%CI, 9-13). The proportion of cumulative platelet response
time observed during the 15-months period under examination was 75.2%.
28 patients (18.4%) experienced adverse events, mainly grade 1-2. The com-
monest adverse effects reported were diarrhea and headache. Seven patients
had hepatobiliary laboratory abnormalities. One patient had superficial venous
thrombosis and one patient had myelofibrosis grade II. 
Summary and Conclusions: This abstract describes the results of the Spanish
Eltrombopag ITP registry. To the best of our knowledge, this is the largest “real-
world” primary chronic ITP eltrombopag treatment reported study.
Here we describe eltrombopag efficacy and safety after a 15 months follow-up
for a clinical practice group of 152 adult primary chronic ITP patients. Our “real
-world” results are in line with the excellent results of eltrombopag in ITP clinical
trials11. Eltrombopag was well tolerated in our study. We only observed 18.4%
of adverse events. 98% of them were grade 1-2.
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IDENTIFICATION OF B CELL SUBSETS IN PATIENTS WITH IMMUNE
THROMBOCYTOPENIA
E.E. Schippers1,* N. Cooper2, C. Graham3, P. Kelleher3, V. Papalois2
1Erasmus University Rotterdam, Rotterdam, Netherlands, 2Hammersmith Hos-
pital, 3Chelsea and Westminster Hospital, London, United Kingdom
Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
characterised by antibody-mediated platelet destruction. The pathogenesis of
ITP remains poorly defined, resulting in untargeted treatment and additional
side effects. It has been evident that B cells have multiple functions in the reg-
ulation of immune responses, besides the production of allo-antibodies. 
Aims: We investigated the phenotype of B cells in ITP patients.
Methods: Using a twelve-colour flow cytometry, we identified the frequency of
CD19+ B lymphocytes, CD24+CD38+ transitional cells, CD24-CD38+ plas-
mablasts, CD27-IgD+ naïve B cells, CD27+IgD+ non-class switched, CD27-
IgD- class switched, CD21+CD27+ resting, CD21-CD27+ activated and CD21-
CD27+ exhausted memory B cells. We included 21 ITP patients and 10 healthy
controls after obtaining informed consent. Patients were separated into different
groups based on current and past treatment. 11 patients were not on any treat-
ment at the time of blood sampling, 8 patients had received rituximab treatment
and 4 patients used trombopoietin receptor agonists.
Results: When taken as a whole group, patients with ITP had a significantly
decreased (p<0.05) frequency of plasmablasts, CD27+ class switched, non-
class switched and resting memory B. Naïve B cells and exhausted memory
B cells were significantly increased in ITP patients compared to controls. ITP
patients who were on no treatment showed the same distribution of B cell
subsets. Patients who had received Rituximab between 1 and 7 years previ-
ously had significantly reduced plasmablasts, CD27+ class switched, non-
class switched and resting memory B cells when compared to ITP patients
who had never received Rituximab. Frequency of naïve B cells and exhausted
memory B cells was significantly increased in this group. In contrast, patients
who used thrombopoietin receptor agonists had almost normal B cell subsets.
There remained a significant increase in the frequency of exhausted memory
B cells in this cohort. All other subtypes were not significantly different to
controls.
Summary and Conclusions: Overall, there seems to be a shift from mature
B cell to immature B cells in ITP patients compared to controls. This might
suggest exhaustion of memory B cells, caused by constant stimulation of
memory B cells by auto-antigens. Our findings indicate a major role for med-
ication, in the change of B cell distribution, with an unexpected long term
effect on memory B cells many years after rituximab therapy despite no clear
evidence of increased infection, whilst trombopoietin receptor agonists may
have an improvement in B cell phenotype. Further understanding might give
a better insight in the effects of different therapies and this could cause the
need for revision of current therapeutic options. 
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BETA2 GLYCOPROTEIN I EXPRESSION IN MONOCYTES IS DECREASED
IN IMMUNE THROMBOCYTOPAENIA AND REGULATED BY IL-6
X.-H. Zhang1,* X.-L. Zhu1, J.-M. Zhang1, J.-Z. Zhao2, Q.-M. Wang1, F.-E. Feng1,
H.-X. Fu1, M. Lv1, L.-P. Xu1, K.-Y. Liu1, X.-J. Huang1
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1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking University People’s Hospital, Department of Clinical Laboratory, Beijing,
China
Background: Numerous reports have indicated dys-regulated expansion of
cytokine profiles from specific T-cell subsets in immune thrombocytopaenia
(ITP). In particular, elevated interleukin-6 (IL-6) levels inversely correlate with
platelet count. β2-glycoprotein I (β2-GPI) is a plasma glycoprotein that acts
as a complement regulator (Gropp et al. Blood. 2011) and might be involved
in the pathogenesis of ITP. Recent studies have proven the presence of β2-
GPI mRNA in human peripheral blood monocytes. Whether monocytes can
be ‘educated’ by IL-6 to regulate β2-GPI expression remains unknown. The
role of anti-IL-6R antibodies in controlling β2-GPI/IL-6 imbalance in ITP needs
to be exploited.
Aims: To elucidate the reciprocal relationship between β2-GPI and IL-6, and
evaluate the potential role of anti-IL-6R antibodies in regulating β2-GPI in
patients with ITP.
Methods: Twenty-four consecutive patients with primary ITP with 24 healthy
donors were enrolled in this prospective study. The levels of serum IL-6 and plas-
ma β2-GPIwere measured using ELISA. The purity of human peripheral blood
monocytes obtained from ITP patients and healthy donors was assessed by cyto-
fluorimetric analysis using FITC-conjugated anti-CD14 antibodies. Intracellular
β2-GPI and IL-6 expression was determined by Western blot and flow cytometry.
DNA fragmentation was assessed by propidium iodide staining followed by flow
cytometric analysis. β2-GPI and IL-6 mRNA expression in monocytes was
assessed by RT-PCR. To further determine the role of IL-6, monocytes were pre-
treated with IL-6 or anti-IL-6R antibodies in vitro. β2-GPI mRNA expression and
β2-GPI levels in monocytes and cell supernatants were determined.
Results: β2-GPI was down-regulated and IL-6 was up-regulated in both
peripheral blood samples and CD14+ monocyte lysates in patients with ITP
compared with healthy controls. Negative correlations were observed
between β2-GPI and IL-6 levels in peripheral blood samples and monocytes.
To further confirm the negative correlation between the expression of IL-6
and β2-GPI, flow cytometry with staining intracellular antigens revealed an
increased frequency and number of monocytes with lower β2-GPI expression
and positive higher IL-6 expression. To eliminate the possibility that increased
β2-GPI expression may be due to cell apoptosis, we analysed DNA fragmen-
tation by cytofluorimetric analysis in the two groups, and no significant
hypodiploid peaks were detected. Decreased β2-GPI expression in cell
lysates from healthy donors pre-treated with IL-6 in vitro was observed, and
this level did not significantly differ with the levels observed in ITP patients.
Down-regulated secretion of this protein in cell supernatant was also
observed. More importantly, β2-GPI mRNA expression was inhibited in mono-
cytes. Decreased expression of β2-GPI at the molecular and genetic levels
was reversed by the addition of anti-IL-6R antibodies.
Summary and Conclusions: Our results are the first to suggest that patients
with ITP may have decreased β2-GPI expression in monocytes, which was
inhibited by persistently high IL-6 expression. The effect of anti-IL-6R antibodies
in correcting imbalanced β2-GPI/IL-6 levels may suggest the promoting thera-
peutic potential of anti-IL-6R antibodies in ITP patients.
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THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (UK ITP) REG-
ISTRY: PRELIMINARY FINDINGS ON BLEEDING EVENTS EXPERIENCED
BY ITS PARTICIPANTS
U. Doobaree1,* R. Nandigam1, A. Newland1, D. Provan1
1Barts and The London School of Medicine and Dentistry, London, United
Kingdom
Background: Primary immune thrombocytopenia (pITP) is a rare bleeding
disorder in which platelets are destroyed through immune-mediated mecha-
nisms. This leads to a reduction in platelet count and at particular low level
there is an increased susceptibility to bleed. There is much heterogeneity in
outcome for individuals with low platelet counts, which can range from no
bleeding to severe intracranial haemorrhages. What influences its occurrence
and its severity is not well understood.
Aims: The Registry was set up to provide much required evidence on the nat-
ural history of ITP, occurrence of comorbidities and treatment effectiveness.
The main purpose of this study is to investigate the occurrence of bleeding in
this cohort and identify likely contributory and preventative factors.
Methods: The Registry relies on the contribution of haematology teams
across the country to provide adequate data to conduct its studies. To date,
it has 62 centres throughout the UK but aims to expand internationally to
increase recruitment and improve collaboration. The findings reported here
are from univariate analyses which were preliminary to a more in-depth study.
Results: These initial findings were obtained on a cohort of 1454 (58.2%
females; 76% European ancestry) participants with a median age at diagnosis
of 49.2 [interquartile range (IR) 30.8, 63.9; mean 47.9] years old. Their mean
platelet count at diagnosis was 38.8x109/L. Among participants who reported
bleeding episodes before and around diagnosis of pITP, 53% were cutaneous
bleed (e.g. petechiae, purpura, and haematoma), 24% were haematomas
affecting ‘not specified’ sites, 20% affected the eye, 20% occurred in the oral
cavity, 19% were epistaxis, 11% were ‘not specified’ mucocutaneous bleed
and 6% occurred in the gastrointestinal tract (exc. oral). Cutaneous bleed
continued to be one of the commonest complaints (36%) after ITP diagnosis
(at which point treatment may have been started) whereas the distribution of
the other sites’ bleed stayed almost the same as pre-diagnosis. Intracranial
bleed was experienced by 0.7% before and around ITP diagnosis and 1.3%
after. Advancing age and being female were found to be significantly associ-
ated with bleeding after ITP diagnosis.
Summary and Conclusions: Skin-related bleed appeared to be the most
complaint at and after diagnosis of ITP. Whether any types/sites of bleed
were related to different platelet counts levels and other characteristics
remained to be established. The associations depicted in this analysis were
noteworthy for further stratified analysis by certain characteristics (e.g. gen-
der) and treatments as well as for identifying likely confounders/proxy/expla-
nations (e.g. anticoagulation therapy used in the treatment of DVT) before
engaging in more elaborate multivariate analysis.
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THYROID DYSFUNCTION IN IMMUNE THROMBOCYTOPENIA: MORE
THAN AN ASSOCIATION
M. Aggarwal1,* M. Mahapatra1, R. Saxena1
1Hematology, All India Institute Of Medical Sciences, New Delhi, India, New
Delhi, India
Background: Immune thrombocytopenia is characterized by immune medi-
ated platelet destruction in addition to suppression of platelet production by
the bone marrow (BM) megakaryocytes leading to variable degree of throm-
bocytopenia and bleeding manifestations. It could be newly diagnosed, per-
sistent or chronic and primary or secondary. Primary ITP is an autoimmune
disorder characterized by isolated thrombocytopenia in the absence of other
causes or disorders that may be associated with thrombocytopenia. Second-
ary ITP includes those associated with antiphospholipid syndrome, infection
with Helicobacter pylori, hepatitis C, HIV, lymphoproliferative disorders, sys-
temic lupus erythematosis, thyroid dysfunction etc. In these cases, treatment
of the underlying condition helps in recovery of platelet counts and thus pre-
vents bleeding. Mild-moderate thrombocytopenia is found commonly in
patients with hyperthyroidism due to reduced non immune platelet survival.
Similarly, mild thrombocytopenia occurs in some patients with hypothyroidism
due to impaired production. 
Aims: To study the prevalence of thyroid dysfunction in Immune thrombocy-
topenia.
Methods: This was a prospective observational study, which included patients
with age >12 years, diagnosed as ITP on the basis of peripheral smear and/or
bone marrow examination. They were evaluated for secondary ITP. Serum
T4 and TSH levels and Anti thyroid peroxidise antibodies were done by elec-
tro-chemi-illuminence test. All patients were treated as per standard guide-
lines, with regular follow up for assessement of bleeding and platelet counts.
Those with treatable secondary causes like H. Pylori or thyroid dysfunction
were treated accordingly in addition to immunosuppressive therapy for ITP.
Females with severe thrombocytopenia and menorrhagia were also given
hormonal treatment.
Results: A total of 168 patients of immune thrombocytopenia were enrolled,
with thyroid function tests available in 146 patients. Mean age was 30.6 years,
with 67.8% females (n=114). Most of our patients were having either persist-
ent ITP (n=42, 25%) or chronic ITP (n=101, 60%), with a median duration of
symptoms being 2 years. Abnormal T4 levels were present in 29 patients (27
hypothyroid and 2 hyperthyroid). Total 26 patients had abnormal TSH. Of
these, antithyroid peroxidase antibodies were demonstrated in 9 patients
(31%) with abnormal T4. Raised antithyroid antibodies were present in 14
patients (54%) with raised TSH. These were significantly associated with both
abnormal T4 (p value 0.038) and TSH (p value 0.021). Subclinical hypothy-
roidism was present in 14 patients. Hypothyroidism (high TSH, or low T4)
were significantly associated with presence of anti-nuclear antibodies (p value
0.011). Presence was abnormal thyroxine levels (p value 0.04), abnormal
thyroid stimulating hormone levels (p value 0.039) and presence of anti thyroid
peroxidase antibodies (p value 0.02) were associated with chronic or persist-
ent ITP. None of these were associated with response to treatment.
Summary and Conclusions: Thyroid dysfunction was present in 43 patients
(29%). Both hypothyroidism (clinical and overt) and hyperthyroidism were
seen, latter being less common. Mildly raised T4 can be due to effect of estro-
gen containing pills prescribed frequently to females with menorrhagia. Estro-
gens bind to thyroid hormone binding protein and cause elevated total T4
levels, free T4 levels are likely to be normal in these cases. Disproportionately
low TSH can be seen with patients on glucocorticoids. Most of our patients
had been on steroids before they presented to us, thus explaining the abnor-
mal relation in T4 and TSH. Association of hypothyroidism and antinuclear
antibodies highlights that two autoimmune diseases tend to occur together.
Presence of antithyroid peroxidase antibodies in these cases suggests
autoimmune nature of thyroid dysfunction and perhaps common occurence
of multiple autoimmune disorders in these patients. Due to increased preva-
lence of thyroid dysfunction in ITP patients, thyroid function tests should be
a part of secondary ITP work up at diagnosis and periodically thereafter.
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Screening with TSH alone is likely to be insensitive in ITP patients and we
suggest combined T4 and TSH for this screening. Results of treatment of
thyroid disease and impact on platelet count have been variable.
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ELEVATED SERUM THROMBOPOIETIN LEVEL IN IMMUNE THROMBO-
CYTOPENIA IN PREGNANCY
X. Zhang1,* H. Zhou1, F. Jing1, Z. Kong1, M. Hou1
1Department of Hematology, Qilu Hospital, Shandong University, Jinan, Chi-
na
Background: Thrombopoietin (TPO), the ligand of c-mpl protein, is the major
regulator of megakaryocyte maturation and platelet production. Up to 10%
of all pregnancies would present thrombocytopenia, most of which are caused
by gestational thrombocytopenia (GT). Immune thrombocytopenia (ITP)
appears in 1 to 2 per thousand pregnancies, which may lead to bleeding
complications in both the mothers and their infants. Previous studies showed
that TPO levels were mildly increased or within the normal range in ITP
patients. However, little data is available about the TPO levels of ITP in preg-
nancy or gestational thrombocytopenia.
Aims: To determine the serum levels of TPO in ITP in pregnancy, gestational
thrombocytopenia, healthy pregnancy, age-matched nonpregnant ITP and
controls. And to assess the value of serum TPO levels for differential diag-
nosis of thrombocytopenia in pregnancy.
Methods: Blood samples were obtained from ITP in pregnancy, gestational
thrombocytopenia, healthy pregnancy, age-matched nonpregnant ITP and
nonpregnant healthy control at Qilu Hospital, Shandong University. Platelet
count was determined by complete blood count (CBC). Serum TPO concen-
tration was analyzed by a commercially available ELISA kit, according to the
manufacturer’s instructions. This study was approved by the Medical Ethical
Committee of Qilu Hospital, Shandong University. Informed consent was
obtained from each patient.
Results: The TPO result and the platelet count of different groups are sum-
marized in the Table 1. In all these five groups, ITP in pregnancy displayed
the highest TPO level (P<0.01). The serum TPO level in ITP in pregnancy
was significantly elevated compared with that in GT (P<0.01). It might be
helpful to differentiate the two disorders by TPO level since TPO level in
26/31 ITP in pregnancy was 500 pg/ml or higher, but none of the GT patients’
TPO level exceeded 500 pg/ml. Furthermore, the level in GT was mildly high-
er than healthy pregnancy (P<0.05). ITP in pregnancy presented a markedly
higher TPO level than nonpregnant ITP (P<0.01). Numerous studies over
the past two decades had documented that TPO levels were high when
thrombocytopenia was due to megakaryocyte deficiency, and low when due
to increased platelet destruction. Taken together the previously published
studies and our data, it could be inferred that the pathogenesis of ITP in
pregnancy might be different from nonpregnant ITP. The TPO level in non-
pregnant ITP was slightly higher than nonpregnant healthy control, which
was generally in consistence with most of the previous studies. The platelet
count in healthy pregnancy was mildly lower than nonpregnant healthy con-
trol. Meanwhile, the healthy pregnancy had slightly higher TPO level than
nonpregnant heathy control. We did not find a correlation between platelet
count and thrombopoietin level in any group.
Table 1.
Summary and Conclusions: TPO levels might be useful for differential diag-
nosing ITP in pregnancy from other causes of thrombocytopenia in pregnancy.
These findings need to be further explored.
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CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDHOOD: EVALUATION
OF THE DATA OVER 30 YEARS BASED ON THE REVISED CRITERIA OF
INTERNATIONAL WORKING GROUP
B. Koc1,* N. Ozdemir1, J. Alakbarlı1, H. Apak1, T. Celkan1, I. Yıldız1
1Pediatric Hematology and Oncology, Istanbul University, Cerrahpasa Medical
Faculty, Istanbul, Turkey
Background: Childhood immune thrombocytopenia (ITP) is usually a self-lim-
ited acquired bleeding disorder lasting from a few weeks to several months.
About 20% of children with newly diagnosed ITP develop a chronic course.
The International Working Group (IWG) recently standardized the terminology
and definitions of ITP. 
Aims: We evaluated the data of children with chronic ITP based on the
revised criteria to investigate the natural course of this disease.
Methods: The medical records of 564 children diagnosed with ITP from 1978
to 2014 were reviewed according to the IWG criteria and data of the patients
with chronic ITP were included. 
Results: Eighty-six patients (M/F: 1.09) with chronic ITP were included. Medi-
an age at admission was 6 years (range: 1-16 years). Median platelet count
at admission was 20x109/L (range: 1-4x109/L). The most frequent bleeding
symptoms at admission were petechia and/or echimosis (86%), followed by
mucosal bleedings (39.5%) such as epistaxis (24%), gingival/oral mucosal
bleeding (15%), severe menstrual hemorrhage (1%), gastrointestinal bleeding
(2.3%), hematuria (3.5%) and subconjunctival hemorrhage (1%). Intracranial
hemorrhage was not observed in none of patients at admission or on follow-
up. Bone marrow examination was performed in 65% of the patients;
megakaryocytes were increased in 80% and decreased in 1.7% and normal
in the remainder. Chronic infections were detected in two patients (Hepatitis
B carrier (n:1) and Helicobacter pylori infection (n: 1)), 1 patient was diag-
nosed with SLE and 1 patient was diagnosed with Evans syndrome. Labora-
tory results showed direct coombs test and anti-nuclear antibody positivity in
8% and anticardiolipin antibodies in 1% of the patients. Spontaneous remis-
sion (>100x109/L platelet count) was detected in 28% of the patients and the
mean duration time to spontaneous recovery was 3.5 years. Twenty patients
(23%) underwent splenectomy. The platelet counts increased to
>100000/mm3 in 90% of the patients after splenectomy. None of the patients
who had splenectomy had complication related to surgery. During follow-up
period treatment was given to patients with bleeding or platelet count
<20x109/L. Treatment options were steroids (n:68), IVIG (n:38), anti-D
immunoglobulin (n:12), rituximab (n:5), dapsone (n:3) and vincristine (n:1).
Summary and Conclusions: The etiology remains unknown in children with
chronic ITP. Our data of 30 years showed that platelet counts recovered
spontaneously in one-third of the patients about 3.5 years after the diagnosis.
Splenectomy is a safe and effective treatment option in children as in adults
and may be considered in selected cases.
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RESPONSE LOSS AND DEVELOPMENT OF NEUTRALIZING ANTIBOD-
IES DURING LONG-TERM TREATMENT WITH ROMIPLOSTIM IN
PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
M. Carpenedo1,* S. Cantoni2, V. Coccini1, E.M. Pogliani1, R. Cairoli2
1Hematology and Transplant Unit, A.O San Gerardo di Monza and University
of Milan Bicocca, Italy, Monza, 2Hematology and Oncology Department, A.O
Ospedale Niguarda Cà Granda, Milan, Italy
Background: In ITP patients (pts) failing immunosuppressants, an alternative
approach is to enhance platelet (plt) production stimulating thrombopoiesis.
Clinical development of first-generation thrombopoietic agents (TPO) was
halted due to induction of neutralizing antibodies (Abs) against both recom-
binant and endogenous TPO. Romiplostim (R) is a second-generation TPO
receptor agonist (TPO-RA) with no sequence homology to TPO, thus avoiding
the risk of eliciting cross-reacting Abs . However, Kuter et al. reported devel-
opment of neutralizing Abs to R in 2/291 treated pts. Both pts were tested
after their plt counts fell and in both cases these neutralizing Abs were no
longer present at re-testing after withdrawal of R. No pt had Abs that cross-
reacted with eTPO (1). 
Aims: To describe prevalence and time course of response loss to R and
the results of neutralizing Abs testing in a group of ITP pts treated at 2 Cen-
ters.
Methods: 44 pts received R between Sept 2009 and Dec 2014 for ITP not
responsive to immunosuppressants. All pts are enrolled in a local Italian data
base (REL-ITP data base), and informed consent to clinical data use is given
at enrollment. Whenever feasible, blood samples of pts losing response to R
were collected and sent for R neutralizing Ab testing (performed as
immunoassay), according to R manufacturer instruction.
Results: Among our pts, 5/44 (11%) were non responders to R. An additional
32% of pts (14/44) although responders, are not evaluable since: 2 lost to
follow up; 3 discontinuation due to SAE (1 bone marrow fibrosis; 2 thrombotic
events); 5 bridge to splenectomy; 3 late responders to either splenectomy or
rituximab. Therefore a total of 25 pts are evaluable for loss of response. Of
these pts: 11/25 discontinued R after achieving a stable response and are in
follow up, off any therapy; 8/25 are currently receiving R with stable response;
6/25 have lost response while on therapy. Outcome of these 6 pts is summa-
rized in Table 1. Neutralizing R Abs testing could be carried out in 4 of 6 pts
(#1 to 4) and 3/4 (# 1,2,3) tested positive. These Abs did not cross react with
eTPO. 4/6 pts went into long-term remission when switched to a different
therapy: #1 rituximab, #2 and #3 splenectomy, # 5 eltrombopag; 2/6 pts (#4
and 6) were heavily pre-treated, splenectomized pts and never regained a
response. Pts #2 and #3 were re-tested for Abs, at 9 and 7 mos from first
detection respectively and both tested negative.
Summary and Conclusions: The second generation TPO-RA romiplostim
is an effective and well tolerated therapy for ITP pts not responding to
immunosuppressants. Pts seldom discontinue treatment due to adverse
events but over time a fraction of responding pts need dosage increase in
order to maintain their plt count (1) or are unable to maintain a sustained
response (2). Response loss doesn’t seem to be so rare an event accounting
for 24% of pts in our series. Similarly to Kuter’s data (1), in 3 of our pts abrupt
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loss of response was associated with development of neutralizing Abs to R,
not cross-reacting with endogenous TPO and resolving after R withdrawal.
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LONG-TERM FOLLOW-UP SPLENECTOMY FOR IMMUN THROMBOPE-
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Background: Splenectomy was the first effective treatment for ITP, reported
nearly 100 years ago. At many centers splenectomy is still the second line
treatment for patients with ITP who have failed corticosteroids. The surgical
approach has been improved by laparoscopic splenectomy, offered to most
patients.
Aims: We report here the long-term outcome of a large cohort of ITP splenec-
tomized patients. Criteria for response were defined as follows: complete
response (CR), all post-splenectomy platelet counts>150×109/L without ever
receiving treatment after splenectomy; partial response (PR), all other patients
with platelet counts >50×109/L without therapy after splenectomy; failure,
platelet counts <50×109/L or patients who received therapy after splenectomy.
Methods: We retrospectively analyzed the data on 159 patients (64 males,
95 females) who underwent splenectomy for ITP between 1999 and 2014.
53 underwent laparoscopic splenectomy, introduced in our center from 2006.
Mean age was 31years (7→63 years), 43 were less than 16 years. Platelets
before splenectomy was de 27.000 (10.103 → 37.103/µl). The median interval
from diagnosis to splenectomy was 19 months with a range of 5-39 months.
Diagnosis has been reconsidered in 4 patients: splenic lymphoma 2, familial
thrombopenia 2.
Results: One hundred forty three patients (90%) achieved a complete remis-
sion the first month after splenectomy. There was 1 death in operative period.
The immediate postoperative complications: infection 3, thromboembolic
events in 4 patients. Accessory spleens were identified 11 cases, 9 from
laproscopic splenectomy. After the first year: CR 132(85%), partial remission
32 (20%), failure 23(16%). After the second year, among 113 patients fol-
lowed, we observed 24 cases of failure. After 5-year: 51 patients (32%) were
lost follow-up, Among 108 patients, 17 Failure, 15 PR. Seventy-six (70%)
remained in a prolonged complete remission with a persistently normal
platelet count, never having received any postsplenectomy treatment. Seven
patients of the complete responders to surgery relapsed after an initial com-
plete response. All 17 patients in the failure group received prednisone after
splenectomy, 2 received rituximab, 3 received cyclophosphamide, 1 received
high-dose dexamethasone. Any patients died of hemorrhage during neither
follow-up nor cases of overwhelming post-splenectomy infection.
Summary and Conclusions: This study shows that splenectomy is a safe
procedure and effective in approximately two thirds of patients with chronic
ITP. However, the durability of responses, the ability to predict who respond
will remain uncertain. Further studies are required to establish whether sur-
gery-sparing treatments of chronic ITP, such as high-dose dexamethasone,
anti-D and anti-CD20 immunoglobulins, thrombopoietin mimetics, have similar
or even superior efficacy, risk and cost ratios compared to splenectomy.
Bleeding disorders
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WHOLE EXOME-SEQUENCING TO IDENTIFY GENETIC RISK FACTORS
OF INHIBITOR IN KOREAN SEVERE HEMOPHILIA A PATIENTS
K. Yoo1,* E. Cho2, T. Lee2, Y. Park3, H. Kim4, S. Kim5
1Korea Hemophilia Foundation, 2Green Cross Genome, 31Kyung Hee Univer-
sity Hospital at Gandong, 4Sungkyunkwan University School of Medicine,
Seoul, 5Inha University college of medicine, Incheon, Korea, Republic of
Background: The development of inhibitor against factor VIII is a serious com-
plication in the treatment of hemophilia A. F8 mutation type plays an important
role in inhibitor development, however, patients who share the same F8 muta-
tion with discordant inhibitor status suggest the presence of other genetic risk
factors. Studies on genetic determinants other than F8 mutation yielded incon-
sistent results, therefore the genetic background of the risk remain largely
unknown.
Aims: This study was designed to investigate the genetic risk factors underling
the development of inhibitor in Korean severe hemophilia A patients by whole
exome sequencing with next-generation sequencing. 
Methods: A total of 89 severe hemophilia A patients (55 with inhibitors and 34
without inhibitors) underwent sequencing of the exome on NextSeq500 (Illumi-
na) following capture by SureSelect Human All Exon V5 UTR kit (Agilent). Map-
ping of reads was performed on reference genome (hg19) by BWA and variant
calling by GATK. Initially, we screened F8 mutations and the candidate muta-
tions were confirmed by Sanger sequencing, MLPA and intron22 inversion test.
Then we performed case(inhibitor)-control(non-inhibitor) association studies
using SNP-set Kernel Association Test (SKAT-O test, gene-based test) and
mixed-effect logistic regression analysis (EMMAX).
Results: A mean depth of 81X was achieved and the mean 63,103 variants
were identified per patient. Large deletion, nonsense, small insertion/deletion,
missense mutation and inversion 22 of F8 were found in 10, 11, 20, 18 and 22
patients, respectively. All the patients with large deletions and all except one
case with nonsense mutations developed inhibitors. We found the 8 immune
genes (IL28RA, SMARCAL1, HLA-B, TNFRSF10C, RAG1, PLXNC1, ITGAD,
LAIR1) at P<0.05 by SKAT-O test and 95 immune related variants at P<0.05
by EMMAX. When we narrowed the patients with inversion 22, we identified
ten immune related variants at P<0.05.
Summary and Conclusions: This study reveals new candidate genes asso-
ciated with the risk of development inhibitor in Korean hemophilia A patients. 
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Background: Acquired von Willebrand syndrome (AvWS) is a rare bleeding
disorders but it is particularly frequent in myeloproliferation. ET(essential
thrombocythemia), one form of myeloproliferation, is characterised not only
by thrombotic but also by bleeding complications. It is very important to know
if AvWS may cause bleeding tendency in ET patients. 
Aims: The aim of the study was to look for AvWS in ET patients using a
screening evaluation of vWF antigen and activity and factor VIII activity.
Methods: We have examined 106 patients with ET(80 females and 26 males,
mean age 54(23-82). In 22 patients(20,75%) bleeding episodes occurred .
We have evaluated factor VIII level (FVIII) and von Willebrand factor antigen
(VWF:Ag) and activity. In order to evaluate von Willebrand factor activity we
have used two reagents: von Willebrand Factor Activity kit HemosilTM, and
von Willebrand Factor Collagen binding kit Technoclone. In the first method
a specific anti -vWF monoclonal antibody directed against glycoprotein Ib
receptor reacts with the vWF in patient plasma. In the second method we
evaluated the ability of vWF in binding to collagen. If all values : VWF:Ag,
VWF:Activity and FVIII are within the normal range, AvWS may be excluded.
If at least one parameter is abnormally low diagnosis of AvWS is probable.
To differentiate the type of AVWS(1, or 2A, 2B or 2M) we calculate the ratios:
1:VWF Activity/VWF:Ag, 2:FVIII/VWF:Ag.
Results: We have detected: low level of VWF:Ag in 8 (8,42%) patients, low
VWF: activity measured by Hemosil reagent in 19 (20,43%) patients, low
VWF collagen binding activity in 27(27,42%) of patients. In a group of 12
patients low levels of both forms of vWF activities have been observed. We
haematologica | 2015; 100(s1) | 305
Vienna, Austria, June 11 – 14, 2015
have detected low factor VIII level only in 3 (3,13%) patients. Summing up,
we have discovered abnormalities in 34 patients. According to AvWS defini-
tion, the diagnosis is based not only on laboratory abnormalities but also on
clinical symptoms. Based on this we have diagnosed AvWS in 9 (41%)
patients from the group of ET patients with bleeding episodes.
Summary and Conclusions: In 41% of ET patients presenting bleeding
episodes this tendency may be caused by AvWS. We propose to use a
screening evaluation mentioned above, to avoid bleeding complication con-
nected with AvWS. 
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INTEREST OF A NEW RAPID COMMERCIAL ASSAY FOR THE ANALYSIS
OF VON WILLEBRAND MULTIMERS IN AGAROSE GEL 
G. Nouadje1, D. Francois2, T. Ligneel1, R. Bironien2, G. Beaulieu1, M. Vasse2,*
1Research & Development, Sebia, Lisses, 2Biology, Hopital Foch, Suresnes,
France
Background: The analysis of von Willebrand factor (vWF) multimers is nec-
essary for the classification of hereditary and acquired forms of von Wille-
brand disease (vWD). Only a few specialized laboratories are skilled enough
to perform this analysis due to the complexity of the method itself and to its
very slow turnaround time (2- 3 days). In fact, vWF multimers are usually
separated in “Home- made” discontinuous SDS agarose gel (difficult to pro-
duce) followed by a western blotting step. Multimers are then identified by
immunofluorescence or other staining techniques.
Aims: We present here the use of a new commercial method for multimer
analysis, which is rapid (6 hours), easy to perform (no western blot), repro-
ducible (ready to use SDS agarose gel). This method assesses the overall
size distribution of vWF multimers (low, intermediate, high and very high
molecular weight).
Methods: vWD were diagnosed on quantification of vWF by both immuno-
logical (vWF:Ag) and functional assays based on ristocetin cofactor activity
(vWR:Co), bleeding time (BT), platelet count, ristocetin induced platelet
aggregation (RIPA). Plasma from patients diagnosed with different von Wille-
brand disease (vWD) types were loaded and separated by the new assay, in
continuous SDS agarose gel system (no stacking and running gel) within 110
mn Multimers were probed in gel by immunofixation using horse-radish per-
oxide (HRP) conjugated to a rabbit anti-vWF (90 min). Visualisation of mul-
timers was achieved by colorimetry using commercially available TTF1/TTF2
reagents. Curves were produced using the manufacturer’s gel scanner and
interpretation software. 
Results: The results obtained with this new method are shown in the figure.
In normal plasma at least 9 to 12 main multimer bands can be detected (line
C). Line 1 corresponding to a type 1 vWD in basal conditions (vWF:Ag=49%;
vWR:Co=47%) shows a weaker coloration than controls, but all the multimers
were present. Coloration of all the multimer bands increased after desmo-
pressin infusion (lane 2; vWF:Ag=178%; vWR:Co=188%). Lanes 3 and 4
correspond respectively to the plasma of a patient with a suspected acquired
vWD (avWD) in basal conditions (vWF:Ag=49%; vWR:Co=28%) and after
purified vWF infusion (vWF:Ag=101%; vWR:Co=58%). There was an
absence of high molecular weight multimers (HMW) in both samples,
strengthening the hypothesis of an avWD with an accelerated turn-over of
HMW multimers of vWF concentrates. Line 5 shows the plasma of a pregnant
woman (38th week/1st gestation) who reported unusual bruises from child-
hood. BT was very prolonged, and a discrepancy was noted between vWF:Ag
(225%) and vWR:Co (86%). There was an absence of HMW multimers and
a large excess of vWF dimers, suggesting a type 2:C. Lane 6 corresponds
to the plasma of a pregnant woman who reported a familial history of vWD
(24th week/1st pregnancy). BT was very prolonged, vWF:Ag was 132% and
vWR:Co slightly slower 77%):Co. The absence of HMW multimers as well as
RIPA results suggested a type 2:A.
Figure 1.
Summary and Conclusions: The method for vWF multimer analysis
described here is simple to carry out, produces results within 6 hours, and is
performed on a commercially available instrument. This is particularly valu-
able in emergency situations such as preterm labor or urgent surgery, when
the patient has no document specifying its vWD type. This technique which
is the first line multimer analysis would also help for extensive screening and
studies.
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DENGUE VIRUS NONSTRUCTURAL PROTEIN 1-INDUCED ANTIBODIES
CROSS-REACT WITH HUMAN PLASMINOGEN AND ENHANCE ITS ACTI-
VATION
T.-M. Yeh1,* Y.-C. Chuang1
1Medical Laboratory Science and Biotechnology, NATIONAL CHENG KUNG
UNIVERSITY, Tainan, Taiwan, ROC
Background: Dengue virus (DENV) infection is the most common mosqui-
to-borne viral disease, which can cause life-threating dengue hemorrhagic
fever and dengue shock syndrome (DHF/DSS). Abnormal activation of the
coagulation and fibrinolysis system is one of the hallmarks associated with
DHF/DSS patients. However, the mechanism to cause hemorrhage in
DHF/DSS is still elusive. In previous studies, plasminogen (Plg) cross-reac-
tive antibodies which can recognize DENV nonstructural protein 1 (NS1)
were found in dengue patients. However, it is unclear whether these anti-
bodies are indeed induced by DENV NS1.
Aims: To test whether dengue NS1 indeed can induce antibodies crossreact
with human Plg and enhance its activation.
Methods: We immunized mice with recombinant NS1 from both bacteria and
drosophila to test whether NS1 can induce Plg-cross-reactive antibodies.
Results: Results from NS1-immunized mice sera indicated NS1 immuniza-
tion induced antibodies which could cross-react with Plg. To study the effects
of these NS1-induced Plg-cross-reactive antibodies on fibrinolysis, we iso-
lated several Plg cross-reactive anti-NS1 monoclonal antibodies (mAbs) from
these mice and found some of these mAbs could enhance Plg activation. In
addition, epitope mapping by phage-displayed random peptide library
revealed that one of these mAbs (2A5) could recognize NS1 C-terminal
residues 305-311 which share sequence homology with Plg region 609-616.
Synthetic peptide of NS1 305-311 could inhibit both 2A5 and its antigen-bind-
ing fragment (Fab) binding to and enhancing Plg activation.
Summary and Conclusions: Our results suggest that DENV NS1 can induce
Plg cross-reactive antibodies through molecular mimicry, which can enhance
Plg activation and contribute to the pathogenesis of DHF/DSS.
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GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELAT-
ED TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A
PATIENTS
A. Silveira Cassette1,* M. Moreira1, S. Béla1, H. Araújo2, A. Teixeira-Carvalho1,
F. Campos-Nunes3, D. Chaves2, O. Martins-Filho1
1Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de
Pesquisas René Rachou, 2Serviço de Pesquisa, Fundação Hemominas,
3Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Hor-
izonte, Brazil
Background: The cell activation in the blood is associated with plasma mem-
brane remodeling, resulting in the shedding of membrane-derived micropar-
ticles (MPs) rich in accessible phosphatidylserine and in specific cell-surface
antigens. There are limited data about the role of MPs in hemophilia A [HA]
and especially in FVIII inhibitors development.
Aims: This study aimed to assess the MPs dosage in patients with HA and
positive [HAα-FVIII(+)] (n=34) or negative [HAα-FVIII(−)] (n=68) for inhibitors.
Methods: The study was conducted in Fundação Hemominas, Belo Hori-
zonte, MG, Brazil. The recruitment of participants and the methodology of
the study were approved by the Brazilian ethics committees. MPs were ana-
lyzed by flow cytometry using the classical MPs marker, annexin, and fluo-
rochrome-labeled monoclonal antibodies against specific cell surface mark-
ers: T cells (CD3); platelets (CD41a); granulocytes (CD66); leukocytes
(CD45); erythrocytes (CD235a); and endothelial cells (CD51/61).
Results: The meaning of circulating MPs were markedly increased in HAα-
FVIII(-) when compared to HAα-FVIII(+) in T cells (33.58±15.08 vs
13.20±14.70; p<0.01); platelets (203.10±450.00 vs 50.86±54.64; p=0.03);
granulocytes (12.05±7.95 vs 6.78±6.08; p<0.01); leukocytes (241.10±419.30
vs 71.29±45.87; p=0.02); endothelial cells (31.57±11.42 vs 22.22±11.41;
p<0.01) (MPs/μL±standard deviation). In contrast, the meaning MPs/μL of
erythrocytes were higher in HAα-FVIII(+) (12.64±10.01 vs 8.58±9.53; p<0.01).
Summary and Conclusions: We found recently that HAα-FVIII(−) patients
has increased activation of all leukocytes and synthesis of pro-inflammatory
cytokines. These data could explain the increased presence of MPs in these
patients. Increases in circulating MPs counts may be a good prognostic for
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inhibitors clearance and could be used as an important biomarker for the
inhibitors development. More research is needed to fully understand the role
of MPs in hemophilia A. Financial support: Fundação Hemominas, Fapemig,
CAPES and CNPq.
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MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS
AND DIC IN ACUTE LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY
D. Gheldof1,* J.-M. Dogné2, C. Graux3, F. George3, A. Sonet3, B. Chatelain3,
F. Mullier3
1CHU Dinant-Godinne UcL, 2Unamur, Namur, 3CHU Dinant-Godinne UcL,
Yvoir, Belgium
Background: Thrombosis is a common complication of patients with malig-
nancies. Patients with hematological malignancies have a 28 fold increased
risk to develop venous thromboembolism (VTE). Among patients with acute
myelogenous leukemia (AML), the incidence of VTE is 5.2%, and among
patients with acute lymphoblastic leukemia (ALL), the incidence of VTE is
4.5% in the first two years of disease. Despite their influence on mortality
and morbidity, the mechanisms inducing a hypercoagulable state are not fully
understood to date. Multifactorial causes include physic immobility,
chemotherapy adverse effects and the overexpression of several procoagu-
lant substances by cancer cells (cytokines, cysteine protease and tissue fac-
tor). Recent studies strongly demonstrate that cancer cells shed microvesicles
(MVs) harboring tissue factor (TF-MVs). These TF-MVs have a primary role
in thromboembolism by expression of procoagulant phospholipids (PL) such
as phosphatidylserine, and TF. Tissue factor, the most potent initiator of the
coagulation cascade, plays a critical role in hemostasis. Moreover several
studies strongly suggest that TF-MVs and their activity may have prognostic
value in identifying cancer patients with increased risk of developing venous
thromboembolism (VTE) or disseminated intravascular coagulation (DIC)
Aims: The aim of this study is to find a link between procoagulant state in
patient with acute leukemia and MVs procoagulant activity (PCA). The other
aim is to assess if MVs-PCA could be a good biomarker to predict thrombotic
events.
Methods: Blood samples from 38 patients with acute leukemia newly diag-
nosed were obtained at Day-0 (before treatment), D-3 and D-7 (3 and 7 days
after treatment). Extracellular vesicles were isolated and concentrated by
ultracentrifugation. EVs-PCA and EVs associated tissue factor activity was
measured a commercial bio-immunoassay (Zymuphen MP-TF®), respectively. 
Results: Among acute leukemic patients, 3 patients have an increased EVs
PCA at D-0 and 2 of them developed a thrombotic event. The remaining
patients without thrombotic events (n=35) do not show an increased EVs-
PCA. One patient has an increased extracellular vesicles procoagulant activity
at D-3 and develop a DIC at D-5. Three patients have an increased EVs-
tissue factor activity (>2pg/ml), among these, two developed a thrombotic
event and one had haemorrhage. A plasma from patient with induced DIC
has no increased extracellular vesicles tissue factor activity from D-0 to D-7
(<2pg/ml). 
Summary and Conclusions: This study shows the link between thrombotic
events and MVs-PCA, and suggests the role of MVs derived from leukemic
blast and others cells in procoagulant state in AL. Moreover, MVs PCA could
have a predicting value for venous thromboembolism and DIC in patients
with acute leukemia and could inform haematologists for the thrombosis pro-
phylaxis.
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THERAPEUTIC APPROACH TOWARDS SYMPTOMATIC THROMBOCY-
TOPENIA IN DENGUE HEMORRHAGIC FEVER
T. Jameel1,*
1Faculty of Medicine Rabigh, King Abdul Aziz University Jeddah KSA, Jeddah,
Saudi Arabia
Background: Immune-mediated destruction of platelets is thought to be the
mechanism of thrombocytopenia seen after the viremic phase of dengue
haemorrhagic fever (DHF). Immuno-suppressants such as steroids, immune
globulin and Anti D immunoglobulin are effective in the treatment of this type
of immune thrombocytopenic purpura.
Aims: To evaluate the efficacy of oral Prednisolone in the rate of resolution
of thrombocytopenia and monitoring of complications in patients recovering
from Dengue haemorrhagic fever.
Methods: A controlled study was carried out on diagnosed cases Dengue
haemorrhagic patients presenting with sever thrombocytopenia and symp-
toms like confluent ecchymosis, epistaxis and purpuric rashes. This study
was conducted in Ittefaq hospital (trust) Lahore, during the period of October
to December 2013. Treatment group received steroids in two forms i.e. 1st
line therapy prednisolone (1mg/kg) orally or as 2nd line therapy of initial I/V
high dose (prednisolone) in pulse doses i.e. 40 mg bid for four days and later
oral prednisolone as in 1st line therapy with omeprazole 20 mg bid in addition
to standard treatment. Control group received standard supportive care only.
Results: A total of 341 suspected patients were admitted in hospital. Sero-
logical diagnosis was confirmed in 166 patients. CBC revealed platelet count
≤100x109/l in 106 patients. A group of symptomatic febrile patients have
platelet count <20x109/l was selected for therapeutic intervention. 1st line
therapy (oral prednisolone was stated in 43 patients. In Fourteen patients
2nd line therapy (high dose dexamethasone pulse) therapy was instituted.
Seven of them attained complete response whereas two patients achieved
partial response. Four patients were shifted to Anti D therapy. Three deaths
occurred during our study. Rest of all the patients improved and were dis-
charged in due course of time.
Summary and Conclusions: This small scale preliminary study shows prom-
ising results in reducing the morbidity of patients in a relatively serious stage
but large scale double blinded randomized controlled studies are needed
before making recommendations on use of steroids in symptomatic throm-
bocytopenic patients with dengue haemorrhagic fever.
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PREVALENCE AND PREDICTIVE MODEL OF MYELOPROLIFERATIVE
NEOPLASM-RELEVANT MOLECULAR MARKERS IN ISCHEMIC STROKE
PATIENTS
Y.-Y. Chen1,* C.-C. Chen1, C.-E. Huang1, H.-J. Chou1, H.-Y. Chou1, Y.-S. Chen1,
H.-Y. Ho1, C.-P. Li1, J.-D. Lee2
1Division of hematology oncology, 2Department of Neurology, Chang Gung
Memorial Hospital, Chiayi, Pu-Tz City, Taiwan, ROC
Background: Myeloproliferative Neoplasm (MPN) has three major clonal
molecular markers, including JAK2V617F, CALR and MPL mutation. MPN is
also highly correlated with thromboembolic disease including ischemic stroke.
However, the prevalence of these markers in patients with cerebral infarction
is little known and the clinical characteristics of these patients remain unclear. 
Aims: In this study, we aimed on the prevalence of JAK2V617F, CALR exon
9 and MPL mutation in patients with ischemia stroke. We also wanted to
know if the clinical characters were different from unmutated patients with
ischemic stroke.
Methods: In this study, more than 150 patients were enrolled. We used Allele-
specific PCR (AS-PCR), real-time AS-PCR and Illlumina paired-end sequenc-
ing to detect the mutation including JAK2V617F, CALR exon 9 and MPL in
the DNA of patients’ granulocytes. Clinical characteristics were also recorded
for comparison including age, gender, complete hemogram, thromboembolic
events and risk factors of ischemic stroke including hypertension, diabetes
mellitus, family history of stroke, atrial fibrillation, smoking history and hyper-
cholesterolemia.
Results: In this study, more than 8% of stroke patients carried JAK2V617F
mutation. two of these patients were homozygous for JAK2V617F mutation
and had phenotype of essential thrombocytosis. If we excluded these 2
patients, the prevalence of JAK2V617F mutation was still more than 7%, which
is higher than general population. Stroke patients harboring JAK2V617F muta-
tion were mostly low allele burden without clinical phenotype of MPN. Only 2
patients carried heterozygous CALR mutation but the mutation didn’t occur
inside exon 9 nor affect KDEL amino acid domain of the calreticulin protein.
No MPL mutation was detected in this study. We correlated patients’ clinical
parameters with their mutational status. Several characteristics were found
closely related to the status of JAK2V617F mutation, including age, hemogram
and stroke related risk factors. Using these parameters, we developed a scoring
system to predict stroke patients at risk of having JAK2V617F clonal mutation.
The scoring system composed of age older than 60 years, circulating white
blood cell count greater than 10x109/L, hemoglobin level greater than 14g/dL,
platelet count greater than 400x109/L and presence only 1 or no stroke factor.
Each item give a score of 1, minimal score 0 and maximal score 5. Higher
score, higher incidence of JAK2V617F mutation (Score 0-1: 2.8%; Score 2:
11.3%; Score 3: 20%; Score 4-5: 50%).
Summary and Conclusions: The prevalence of mutant JAK2V617F in
stroke patients was higher than general population. Using our scoring system,
identify stroke patients at risk of carrying JAK2V617F mutation is warranted.
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DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 INDUCES VASCULAR
LEAKAGE THROUGH MACROPHAGE MIGRATION INHIBITORY FACTOR
SECRETION AND GLYCOCALYX DEGRADATION
C. Chen1,* Y.-C. Chuang2, T.-M. Yeh3
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Kung University, 2Department of Medical Laboratory Science and Biotechnol-
ogy, Medical College, National Cheng Kung University, 3Department of Medical
Laboratory Science and Biotechnology, Medical College, National Cheng Kung
University, Tainan, Taiwan, ROC
Background: Dengue virus (DENV) is a member of flaviviridae and it causes
the most common mosquito-borne disease, including the life-threatening
dengue hemorrhagic fever (DHF) and shock syndrome (DSS). In the patho-
genesis of DHF/DSS, vascular leakage is the most characteristic feature, of
which the mechanisms remain unclear. DENV non-structural protein 1 (NS1)
is a highly conserved protein and its serum level is positively-correlated with
the severity of the disease. Cytokine secretion, autophagy and disruption of
endothelial barrier are factors cause vascular leakage, but how they are reg-
ulated by DENV NS1 has not yet been described.
Aims: The purpose of this study is to test whether DENV NS1 disrupted
endothelial barrier function through macrophage migration inhibitory factor
(MIF)-induced autophagy and glycocalyx degradation.
Methods: The E. Coli generated recombinant NS1 (rNS1) and Drosophila
generated recombinant NS1 (CTK-NS1) were used. The expression and
secretion of MIF in human microvascular endothelial cell line (HMEC-1)
were determined by RT-PCR and ELISA. Endothelial permeability was deter-
mined by real-time cellular analysis and transwell permeability assay. In vivo
permeability assay was demonstrated by Evans blue permeability assay
and abdominal lavage in mice. The distribution of junction proteins and
autophagy were observed by immunofluorescence assay and transfection
of tf-LC3 construct. The degradation of glycocalyx was determined by MMP-
9 expression in primary cultured human peripheral blood mononuclear cells
(PBMC), heparanase-1 (HPA-1) protein level in HMEC-1 cells and CD138
concentration in mice peritoneal lavage and human patient serum samples.
Results: We first demonstrated that rNS1 induced vascular leakage in vitro
and in vivo, and the permeability was rescued by treating heat-denatured
rNS1 or co-treating rNS1 neutralizing antibodies. CTK-NS1 could also induce
endothelial hyperpermeability. We then demonstrated that rNS1 induced the
secretion of MIF in various cell types including HMEC-1 and PBMC. MIF con-
centration was also increased in the peritoneal lavage of rNS1-injected mice,
and this phenomenon was rescued by co-treating NS1 neutralizing antibod-
ies. In addition, rNS1 induced the LC3-I-to-LC3-II conversion and phospho-
rylated mTOR reduction, which indicated autophagy formation. The conver-
sion of EGFP to mRFP in tf-LC3 transfected HMEC-1 cells further revealed
that rNS1 induced the formation of autophagolysosome and autophagic bod-
ies. The disarray of VE-cadherin and ZO-1 in HMEC-1 was induced by rNS1
and could be reversed by either MIF or autophagy inhibitors, which indicated
the involvement of MIF and autophagy. Atg5 knockdown HMEC-1 stable
clone could resist rNS1-induced hyperpermeability, indicating the importance
of autophagy in endothelial permeability. Both MIF inhibitors and autophagy
inhibitors rescued rNS1-induced endothelial hyperpermeability in vitro and
in vivo, which further confirmed the mediation of MIF and autophagy in rNS1-
induced vascular leakage. In patient serum samples, the increase in MIF and
CD138 concentration were observed, indicating the correlation of glycocalyx
degradation and vascular leakage. The glycocalyx degradation enzymes
MMP-9 and HPA-1 were increased by rNS1 in PBMC and HMEC-1, indicating
rNS1-induced glycocalyx degradation.
Summary and Conclusions: Taken together, these results suggest that NS1
may play pathogenic roles in DENV-induced vascular hyperpermeability
through MIF secretion and glycocalyx degradation.
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PROVOKED VENOUS THROMBOEMBOLISM IN NON-CANCER PATIENTS:
ARE THEY THE SAME?
C.C. Chua1,* H.Y. Lim1, M. Sleeman1, P. Ho1,2
1Clinical Haematology, Austin Health, Melbourne, 2Clinical Haematology, North-
ern Health, Epping, Australia
Background: Venous thromboembolism (VTE) can be classified as provoked
if there is a clear identifiable provoking factor. Collectively they have been
shown to be associated with a lower risk of recurrence, and are often treated
in a similar fashion.
Aims: To evaluate the association between different categories of provoked
VTE in our study population and their risk of recurrence
Methods: Retrospective evaluation of all non-cancer VTE from July 2011 to
December 2012 at Austin and Northern Health, Melbourne, Australia. The
follow up was continued through to December 2014.
Results: 779 VTE cases were identified during our study period of which
50.6% were female with a median age of 63 years. Cases with no provoking
factors (n=303, 39%) had a higher risk of recurrence at 11.9% (RR 2.4,
p<0.001) and were more likely to be subsequently diagnosed with malignancy
(3.3%, RR 3.2, p=0.03). Cases with provoking factors (n=476, 61%) included
surgery (35.1%), non-surgical causes of immobility or injury including hospi-
talizations (38.4%), travel greater than 4 hours (14%), estrogen-related (11%),
catheter-associated (1%) and local inflammatory processes such as cellulitis
(0.4%). Of the provoked cases, travel had the highest recurrence rate
(10.6%), comparable to unprovoked VTE (RR 0.89, p=0.771). Non-surgical
causes of immobility or injury had the second highest recurrence rate of 5.5%
(RR 0.46, p=0.024), followed by surgery at 3.6% (RR 0.30, p=0.005). Estro-
gen-related VTE had a lower trend of recurrence at 1.9% (RR 0.16, p=0.067).
None of the VTE associated with catheter or local inflammatory processes
recurred during our follow up period, however numbers were small (n=7).
Provoked VTE had a significantly shorter time to recurrence than unprovoked
VTE, with 76% occurring within the first 12 months of the initial event (median
8 months versus 18 months, p=0.02). Whether an episode of VTE was pro-
voked did not appear to influence the rate of VTE-related deaths (p=0.89).
Table 1. Provoking factors and risk of recurrence in VTE.
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Summary and Conclusions: Provoked VTE is not a homogenous group, and
recurrence rates depend on the identifiable provoking factor. Reversible factors
such as surgery, estrogen exposure, catheter or local inflammatory process
demonstrated lower risk of recurrence. The high risk of recurrence associated with
travel raises the question of the validity of travel as a “true” provoking factor. Further
studies are warranted to better define travel as a provoking factor, as this will influ-
ence the optimal treatment and future outcomes for travel related VTE. 
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COAGULATION PROCESS AND FIBRINOGEN GENETIC VARIABILITY ARE
STRONG RISK FACTORS FOR ATHEROGENESIS, MYOCARDIAL INFARC-
TION AND THE EXTEND OF THE DISEASE IN SUBJECTS SUSPECTED
FOR STABLE ANGINA
Z. Pallantza1,* M. Karagrigoriou1, M. Kozanitou1, G. Mallios1, E. Andronopoulou1,
P. Parigori1, N. Papageorgiou1, D. Tousoulis1
1Athens Ippokratio Hospital, Athens, Greece
Background: It is well known that altered coagulation as well as fibrinogen
genetic variability contribute to atherogenesis. In the present study we examined
the combined effects of the rs1800790, rs2070011 fibrinogen polymorphisms
on coagulation and endothelial function as well as the effect of coagulation on
atherosclerotic manifestations.
Methods: We enrolled 422 patients with stable angina (SA) and 277 controls.
The rs1800790 (G455A) and the rs2070011 (G58A) polymorphisms were esti-
mated by appropriate genotyping. Fibrinogen and D-Dimer levels, as well as
factors (f) V, X activity were measured by standard coagulometry techniques.
Flow-mediated dilation (FMD) was assessed by brachial ultrasound.
Results: We have found the 455AA homozygosity was associated with raised
fibrinogen levels in both groups (p=0.035 controls and p<0.001 SA). In addition,
homozygotes for the 58A allele had lower fibrinogen levels in controls (p=0.038).
Both the 58AA (p=0.027) and 455AA homozygotes (p=0.022) had higher levels
of D-Dimer in the SA group. The 455AA homozygotes had also increased fV
activity in the SA group (p=0.048). No effects were observed on fX activity and
FMD. Further analysis revealed that fibrinogen levels were strongly associated
with SA (1.005 [1.003-1.007], p<0.001) as well as the presence of MI (1.003
[1.001-1.005], p=0.001). Similarly, D-Dimer levels were also strong predictors of
CAD (1.001 [1.001-1.002], p<0.001), but not of MI (1.000 [1.001-1.001], p=0.083).
Surprisingly, when fV and fX activities were examined for possible associations
with clinical presentations, we found that fV activity was associated with increased
number of diseased vessels (1.016 [1.001-1.030], p=0.037), while fX activity was
strongly related to MI (0.985 [0.973-0.997], p=0.013).
Summary and Conclusions: The rs1800790 variant increases significantly
fibrinogen, D-Dimers levels and fV activity, contributing to atherogenesis. In
addition, fibrinogen and D-Dimers levels are strong predictors of SA and MI.
Interestingly, in our study we have shown for the first time to our knowledge
that fV and fX are associated with the number of diseased vessels and the risk
of MI respectively.
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LONGTERM CANCER RISK AFTER VENOUS THROMBOEMBOLISM 
L. Eischer1,* P. Kyrle1, M. Kammer2, S. Eichinger1
1Hamatology and Hemostasis, 2Core Unit for Medical Statistics and Informatics,
Medical University Of Vienna, Wien, Austria
Background: A venous thromboembolic event (VTE) may indicate an under-
lying cancer. In population based studies the likelihood of cancer is highest
during the first year but a persistent increase has been reported also in the
years thereafter. Data on the risk in patients who completed anticoagulant treat-
ment and recommendations regarding screening are lacking. 
Aims: To evaluate the long-term risk of cancer in a well-defined cohort of
patients with an unprovoked VTE.
Methods: We prospectively followed patients with a first unprovoked VTE after
discontinuation of anticoagulation and excluded those with long-term antithrom-
botic therapy, major thrombophilia or pregnancy. Study endpoint was diagnosis
of cancer. The ratio of the observed cases and the number of cases expected
based on national cancer incidence rates was calculated and expressed as
standardized incidence ratio (SIR). The study was approved by the local ethics
committee and all patients consented.
Results: 43 (3.6%) of 1188 patients (mean age 48 years, 638 women, median
duration of anticoagulation 7.2 months) were diagnosed with cancer (colon 8,
breast 7, lung 6, hematologic 6, prostate 4, skin 1, brain 1, others 10) during a
median follow up of 70 months (range 3-216). Cancer patients were significantly
older (57 vs 48 years, p<0,001) but did not differ from non-cancer patients
regarding proportion of women (49 vs 54%), blood cell counts (hemoglobin
14.2 vs 14.2 g/dl; platelets 232 vs 238 G/l; leukocytes 6.5 vs 6.8 G/l), body
mass index (both 27 kg/m2) or D-Dimer (469 vs 463 µg/ml). The probability of
cancer was 0.7% (95% CI 0.1-1.3%), 1.7% (95% CI 0.9-2.5%) and 3.0% (95%
CI 1.8-4.2%) after 1, 2 and 5 years. The corresponding SIR did not significantly
differ from expected rates in an age- and sex-matched general population (1.2,
1.3 and 1.0) (Figure1).
Figure 1.
Summary and Conclusions: In patients with unprovoked VTE the long-term
incidence of cancer after anticoagulation is low. Cancer types are heteroge-
neous and specific screening strategies do not seem to be warranted. 
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POLYMORPHISM OF GENES INVOLVED IN LIPID METABOLISM AS A RISK
FACTOR FOR VENOUS THROMBOEMBOLISM
S.P. Svitina1,* V. Shmeleva1, V. Soldatenkov1, V. Kargin1, L. Papayan1, S. Kapustin1
1FSBI “Russian Research Institute of Haematology and Transfusiology”, St.
Petersburg, Russian Federation
Background: Venous thromboembolism (VTE) is one of the leading causes of
morbidity and mortality in industrialized countries, and is known as a multifac-
torial disease. Along with the classic risk factors, significant role in the devel-
opment of VTE has been assigned to genetic predisposition. Although conven-
tional genetic risk factors have been involved in the disease process, VTE often
occurs in the absence of known risk factors. Doubtless, some forms of dyslipi-
demia are risk factors for arterial thrombosis. However, based on the recent
research, lipid metabolism disorders have a high probability to be implicated in
pathogenesis of VTE.
Aims: The aim of this study was to investigate the role of allelic polymorphism
of some genes involved in lipid metabolism: apolipoprotein E (ApoE),
apolipoprotein CIII (ApoCIII), lipoprotein lipase (LPL) and hepatic lipase (LIPC),
in patients with VTE.
Methods: We retrospectively analyzed DNA samples of 300 patients with VTE
(147 men and 153 women, average age 39,9±12,4 years), including 200 indi-
viduals with the debut of VTE under the age of 45 years. Isolated deep vein
thrombosis (DVT) has been diagnosed in 170 patients, whereas in 67 persons
DVT complicated by pulmonary embolism (PE) (“DVT+PE”), and 63 individuals
have had PE without signs of DVT (isolated PE). The control group consisted
of 100 sex- and age-matched healthy persons without history of thrombosis.
Polymorphism of the ApoE (E2/E3/E4), ApoCIII (C3175G and −455 T/C), LPL
(Asn291Ser) and LIPC (-514 T/C) genes was determined by polymerase chain
reaction with subsequent restriction digest. Statistical analysis was performed
using the program GraphPad Prism 5.0. Differences in the distribution of alleles
and genotypes were assessed by Fisher’s exact test. 
Results: The distributions of alleles and genotypes of analyzed genes in
patients with VTE had no significant differences from those in healthy controls.
Nonetheless, ApoE E3/E4 genotype was more frequently seen in men with
thrombosis when compared to group of women (24,5% vs 15,0%; OR=1,8;
95%CI: 1,0-3,3; p=0,043). Significant increase in proportion of homozygotes
for the LIPC −514T allele was observed in the “DVT+PE” group (69,2% vs
52,9% in patients with isolated DVT; OR=2,0; 95%CI=1,1-3,7; p=0,027). The
ApoCIII −455CC genotype was more prevalent in patients who had their first
episode of VTE after 45 years than in those with early-onset disease (26,5%
vs 14,9%, respectively; OR=2,0; 95%CI=1,0-4,1; p=0,043). On the other hand,
the proportion of homozygotes for the ApoCIII −455T allele was significantly
higher in young patients (37,4% vs 22,0% in the group with late-onset VTE;
OR=2,1; 95%CI=1,1-4,0; p=0,023).
Summary and Conclusions: Our data indicate that polymorphism of some
genes affecting lipid metabolism could influence the risk and course of VTE.
ApoE genotype E3/E4 is a potent risk factor for VTE development in men. Poly-
morphism −455 T/C of the ApoCIII gene could influence the age of VTE debut.
Furthermore, the risk of PE development in patients with DVT may depend on
their LIPC genotype.
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HIGH LEVELS OF FIBRINOGEN, BUT NOT FIBRINOGEN GENETIC VARI-
ANTS PREDICT CORONARY ARTERY DISEASE IN SUBJECTS WITH
HYPERTENSION AND DIABETES MELLITUS TYPE 2
Z. Pallantza1,* M. Karagrigoriou1, A. Vlachopoulou1, G. Papacharalampous1,
D. Gubini1, L. Plavoukou1, N. Papageorgiou1, D. Tousoulis1
1Athens Ippokratio Hospital, Athens, Greece
Background: It is well established that hypertension (HTN) and diabetes mel-
litus (DM) are strongly associated with coronary artery disease (CAD). In addi-
tion, controversial data exist related to the role of fibrinogen genetic variants in
atherosclerosis-CAD. Therefore, we examined the effects of the rs180070 and
rs2070011 fibrinogen polymorphisms on coagulation, inflammation and on the
risk for CAD in patients with DM and HTN admitted with stable angina pectoris
symptoms.
Methods: A total of 744 subjects were enrolled in 3-year period. Fibrinogen
polymorphisms were determined by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) technique. Fibrinogen, interleukin-6
(IL-6), high sensitivity C-reactive protein (hsCRP) CD40L, D-dimers and factors
V, X activity were measured with appropriate laboratory methods.
Results: The AA homozygosity of rs180070 was associated with significantly
higher levels of fibrinogen in both HTN and DM (p=0.05, p=0.04 respectively).
The presence of AA genotype (rs180070) was also significantly associated
with increased risk of CAD in the general population [OR: 3.2, 95% CI, (1.01-
10.1, p=0.049)]. While it was associated with higher IL-6 an D-dimers, but not
hsCRP levels in the general population. Interestingly, multivariate logistic
regression analysis showed that fibrinogen levels >443 mg/dl were associated
with higher risk for CAD [OR: 3.9, 95% CI, (1.7-9.4, p=0.002)] compared to
levels <347 mg/dl in the general population. Similar associations were observed
in HTN and DM patients. In hypertensive patients, higher fibrinogen levels
>443 mg/dl [OR: 3.5, 95% CI (1.14-10.9, p=0.029), but not the AA genotype of
rs180070 [OR: 3, 95% CI (0.78-11.9, p=0.11)] were independent predictors of
CAD. Similarly, in DM only fibrinogen remained an independent predictor of
CAD [OR 5.86, 95% CI (1.1-31.2, p=0.038)].
Summary and Conclusions: We have shown that the presence of AA geno-
type (rs180070) is associated with increased levels of D-dimers and IL-6 pro-
moting atherosclerosis, as well as risk for CAD. However, elevated fibrinogen
levels >443 mg/dl remain the most significant predictor of CAD both in HTN
and in DM subjects.
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VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUS-
TRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREAT-
MENT STRATEGIES IN THE WARFARIN ERA 
H.Y. Lim1,2,* C.C. Chua1, M. Sleeman1, P. Ho1,2
1Haematology, Austin Health, Heidelberg, 2Haematology, Northern Health,
Epping, Australia
Background: Venous thromboembolism (VTE) is associated with significant
morbidity, mortality and economic cost (approximately AUD$117 000 per per-
son, Access Economics 2008). Despite advances in thrombosis management,
management strategies remain heterogenous with a paucity of real-world VTE
data.
Aims: To provide a holistic evaluation of VTE management in the warfarin era
including identifying potential causal effects and complications.
Methods: Retrospective evaluation of VTE from July 2011 to December 2012,
at two major hospitals in Northeast Melbourne, Australia.
Results: 1003 patients, with a median age of 63 (range 19-97) years and an
overall male predominance (52%), presented with a total of 1025 episodes -
574 (56%) pulmonary embolism (PE), 422 (41%) deep venous thrombosis
(DVT). 23% (n=234) had active malignancy at time of diagnosis with 14 patients
(1.4%) subsequently being diagnosed. Median follow up was 33.5 (range 23-
53) months. Non-cancer patients: 63% had provoked VTE and thrombophilia
screen was performed in 41%. 20% had previous VTE and 7.5% reported pos-
itive family history. Median duration of anticoagulation was 6 and 7 months for
DVT and PE respectively. Majority (90%) was on warfarin for long-term antico-
agulation. 5% required other interventions - IVC filter (n=29) and thrombolysis
(n=13). 19% had end-of-treatment repeat imaging and residual clot was
observed in 56%. On extended follow-up, clot persistence was not associated
with increased recurrence (OR 1.9 [0.6-6.2]). 7% had recurrent thrombosis
with increased risk in unprovoked VTE (OR 2.2 [1.3-3.80], p=0.004). 60% of
recurrence occurred within 12 months of initial VTE. 5.6% reported grade III/IV
bleeding with 56% occurring within the first month of anticoagulation. Bleeding
risk was independent of duration of anticoagulation. All-cause mortality rate
was 14%. In the below knee DVT (BKDVT) sub-analysis, 1.5% was subse-
quently diagnosed with cancer, similar prevalence to those with major VTE
(1.7%), defined as proximal DVT and/or PE. BKDVT were more likely to be
provoked (71% vs 60%, p<0.001) and recurrence was similar to major VTE
(9% vs 7%, p=0.36). Mortality rate was 5.5% with no thrombosis-related deaths.
Cancer patients: These patients were older (67 vs 61 years, p<0.001) and had
higher clot burden with more PE (64% vs 53%, p=0.004), proximal DVT (63%
vs 46%, p=0.0008) and bilateral DVT (16% vs 5%, p<0.001). Metastatic cancer
was associated with increased unprovoked events (p=0.015). Cancer patients
were more likely to require IVC filters and lifelong anticoagulation (p<0.001).
Recurrence/clot extension (17%) and Grade III/IV bleeding (10%) were more
common (p=0.02). Mortality rate in this cohort was 68% with higher incidence
of complications-related deaths (p<0.001).
Summary and Conclusions: Recurrence rate was 4% in the first 12 months
with unprovoked VTE being a major risk factor. Cancer patients experience
more complications with higher clot burden and all-cause mortality rate. Inter-
estingly, BKDVT, often considered a minor VTE, had comparable rates of recur-
rence and subsequent cancer detection to major VTE suggesting that BKDVT
may not be as benign as it seemed. Further evaluation of new treatment strate-
gies as well as clinical and laboratory risk assessments are required to improve
the management for VTE. This data will serve as an important baseline for
future comparison in the new era of novel oral anticoagulants.
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IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTRÖM’S
MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE
RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION
STATUS
S. Treon1,* C. Tripsas2, K. Meid2, D. Warren2, G. Varma3, R. Green4,
K. Argyropoulos4, G. Yang2, Y. Cao2, L. Xu2, C. Patterson2, S. Rodig5, J. Zehnder3,
J. Aster5, N.L. Harris6, S. Kanan2, I. Ghobrial2, J. Laubach2, Z. Hunter2,
Z. Salman7, M. Cheng8, J. Li8, F. Clow8, T. Graef8, J. Castillo2, M.L. Palomba4,
R. Advani3
1Bing Center For Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute,
Boston, 2Dana Farber Cancer Institute, Boston, MA, 3Stanford University Cancer
Institute, Stanford, CA, 4Memorial Sloan Kettering Cancer Center, New York, NY,
5Brigham and Women’s Hospital, 6Massachusetts General Hospital, Boston, MA,
7Pharmacyclics Inc,, 8Pharmacyclics Inc., Sunnyvale, CA, United States
Background: MYD88L265P and CXCR4WHIM are highly prevalent somatic
mutations in Waldenström’s Macroglobulinemia (WM). MYD88L265P triggers
WM growth via Bruton’s Tyrosine Kinase, a target of ibrutinib. CXCR4WHIM
mutations confer in vitro resistance to ibrutinib. 
Aims: The primary aim of this study was to determine in a prospective, multi-
center study the overall and major response rates of ibrutinib monotherapy in
previously treated and symptomatic WM patients requiring therapy. Secondary
aims of this study included determination of progression-free survival, drug
safety, and impact of MYD88 and CXCR4 mutations on treatment outcome.
Methods: Symptomatic WM patients with >1 prior therapies were eligible. Ibru-
tinib (420 mg) was administered daily until progression, or unacceptable toxicity.
Dose modifications for toxicity were permitted. Central pathology review was
performed in all patients. Genotyping for MYD88 L265P and CXCR4 WHIM
mutation status was performed in 63 and 62 patients, respectively.
Results: 63 patients with a median of 2 prior therapies (40% with refractory
disease) were enrolled. Post-therapy, median serum IgM levels declined from
3,520 to 880 mg/dL; hemoglobin rose from 10.5 to 13.8 g/dL, and bone marrow
involvement declined from 60% to 25% (p<0.01 for all comparisons). Overall
and major response rates were 90.5% and 73.0%, and the median times to at
least minor and major responses were 4 and 8 weeks, respectively. Overall
responses were similar regardless of baseline age (<65 vs. ≥65 years), ECOG
status (0 vs. ≥1), pre-therapy WM IPSS score, serum β2-microglobulin levels
(<3.0 vs. >3.0 mg/L), hemoglobin (<11 vs. >11 g/dL), serum IgM (<4,000 vs.
≥4,000 mg/dL), BM disease involvement (<50% vs. ≥50%), prior relapsed or
refractory status, and prior lines of therapy (1-3 vs. >3). Fifty-six (88.9%) patients
expressed MYD88L265P, and 21 (33.9%) had CXCR4WHIM mutations. Overall
and major response rates were highest in patients with MYD88L265PCXCR4wild-
type(WT) (100% and 91.2%), followed by MYD88L265PCXCR4WHIM (85.7% and
61.9%), and MYD88WTCXCR4WT(71.4% and 28.6%) mutation status. The 2-
year PFS (Figure A) and overall survival rates (Figure B) were 69.1% and
95.2%, respectively. Subset analysis showed that >3 prior lines of therapy, high
pre-therapy IPSS score, and MYD88WTCXCR4WT mutation status associated
with inferior progression-free survival. Grade >2 treatment-related toxicities
included neutropenia (22.2%) and thrombocytopenia (14.3%) that were more
common in heavily pre-treated patients; atrial fibrillation in patients with a prior
arrhythmia history (3.2%); procedure-related bleeding (3.2%); and epistaxis
related to marine oil supplements (3.2%). Serum IgA and IgG levels were
unchanged, and treatment-related infections were infrequent.
Figure 1. A
Figure 1. B
Summary and Conclusions: Ibrutinib is highly active in previously treated
WM patients. An overall response rate of 90.5%, and 2-year progression-free
and overall survival rates of 69.1% and 95.2%, respectively, was achieved with
ibrutinib monotherapy. Ibrutinib responses were influenced by MYD88 and
CXCR4 mutation status. Overall, treatment toxicity was moderate and no unex-
pected toxicities were observed. 
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LOW IKZF1 EXPRESSION IS ASSOCIATED WITH FAVORABLE OUTCOME
IN LENALIDOMIDE TREATED NEWLY DIAGNOSED MULTIPLE MYELOMA
J. Krönke1, F. Kuchenbauer1, M. Kull1, V. Teleanu1, L. Bullinger1, A. Greiner1,
S. Kolmus1, S. Köpff1, L.O. Mügge2, C. Straka3, F. Bassermann4,
M. Engelhardt5, R. Bargou6, H. Einsele6, S. Knop6, C. Langer1,*
1Internal Medicine III, Ulm University, Ulm, 2Internal Medicine II, Friedrich
Schiller University, Jena, 3Hematology and Oncology, Schön Klinik Starnberger
See, Berg, 4Department of Medicine III, Klinikum Rechts der Isar, Munich,
5Hematology and Oncology, University of Freiburg, Freiburg, 6Department of
Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
Background: Lenalidomide is an immunomodulatory drug (IMiD) with high
activity in multiple myeloma (MM). IMiD binding to the CRBN E3 ubiquitin ligase
results in targeted ubiquitination and degradation of the lymphoid transcription
factors IKZF1 and IKZF3 and constitutes a unique mechanism of action for a
class of drugs.
Aims: To determine whether expression levels of CRBN, IKZF1, and IKZF3
are associated with outcome in lenalidomide treated patients (pts) with newly
diagnosed MM.
Methods: We analyzed mRNA expression levels of IKZF1, IKZF3, and CRBN
by real-time quantitative PCR (RQ-PCR) in CD138-selected pre-treatment sam-
ples from 60 pts with newly diagnosed MM uniformly treated within a phase II
clinical trial of the German Myeloma Study Group (DSMM). Additionally, all pts
were characterized for the presence of cytogenetic abnormalities using a com-
prehensive set of FISH probes. All patients received induction consisting of
four cycles of lenalidomide, adriamycin and dexamethasone followed by high-
dose melphalan (Mel-200) with autologous stem cell transplantation (aSCT).
Genetically defined low- and intermediate risk patients received a second aSCT,
while those pts with high-risk cytogenetics (presence of a del17p13, t(4;14) or
t(14;16)) underwent allogeneic stem cell transplantation if a donor was avail-
able. All patients received lenalidomide maintenance for 12 months.
Figure 1.
Results: Median expression levels normalized to plasma cells from healthy
volunteers of CRBN, IKZF1, and IKZF3 were 0.66 (range, 0.12 - 2.86), 0.66
(0.16-2.92), and 0.52 (0.19-5.13), respectively. Expression levels of CRBN,
IKZF1, and IKZF3 were not affected by the presence of chromosomal aberra-
tions (del13q14, del17p13, del9q34, +1q21, t(4;14), t(11;14), t(14;16)). Patients
achieving a complete response (CR) or very good partial response (VGPR)
had a trend towards a lower IKZF1 expression than patients achieving a partial
response (PR) (median IKZF1 expression: 0.62 vs 0.84, p=0.07). Consistently,
lower IKZF1 expression levels were associated with a better outcome: when
segregating IKZF1 expression levels into quartiles, pts with the lowest (Q1)
quartile of IKZF1 expression had a 3 year progression-free survival (PFS) of
86% compared to 51% in patients of the remaining quartiles (Q2-Q4)(Log rank
test, p=0.01). This translated into a better overall survival (OS) (IKZF1Q1:100%
vs IKZF1 Q2-4:74% after 3 years, log rank p=0.03). In contrast, CRBN and
IKZF3 expression levels had no impact on response, PFS, or OS. Factors also
associated with outcome included the presence of a del13q14 (PFS: p=n.s.;
OS: p=0.04), del17p13 (PFS: p=0.001; OS=0.03), t(4;14) (PFS: p=0.009; OS:
p=0.004) or +1q21 (PFS: p=n.s.; OS p=0.037).
Summary and Conclusions: In this cohort of uniformly treated newly diag-
nosed MM patients, IKZF1 but not IKZF3 or CRBN expression levels were
associated with outcome. Low IKZF1 mRNA expression levels seem to identify
a sub-group with a particularly good outcome.
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POST-TRANSPLANT CARFILZOMIB (KYPROLIS®), LENALIDOMIDE
(REVLIMID®), AND DEXAMETHASONE (KRD) CONSOLIDATION IN NEWLY
DIAGNOSED MULTIPLE MYELOMA (NDMM): EFFICACY AND
TOLERABILITY OF EXTENDED TREATMENT
A. Jakubowiak1,* K. Griffith2, J. Jasielec3, C. Rosenbaum1, K. McDonnell1,
J. Berdeja4, R. Vij5, N. Raje6, D. Reece7, D. Dytfeld8, T. Zimmerman1
1The University of Chicago, Chicago, 2University of Michigan, Ann Arbor,
3Northshore University Health System, Evanston, 4Sarah Cannon Cancer Cen-
ter, Nashville, 5Washington University, St. Louis, 6Massachusetts General Hos-
pital, Boston, United States, 7Princess Margaret Cancer Centre, Toronto, Cana-
da, 8Poznan University Medical Science, Poznan, Poland
Background: In a previous phase 1/2 study, extended treatment for 24 months
with KRd provided a high rate of stringent complete response (sCR) of 55%
and durable disease control with a 3-year progression-free survival (PFS) of
79% and overall survival (OS) of 96% after extended treatment (Jakubowiak
et al. Blood 2012; Jasielec et al.ASH 2013). In this Phase 2 study we evaluate
post-transplant extended treatment with KRd in NDMM (NCT01816971).
Aims: To assess the efficacy and tolerability of extended post-transplant treat-
ment with KRd in NDMM pts who have received KRd induction and ASCT.
Methods: Pts with symptomatic NDMM per IMWG criteria and transplant can-
didates were eligible for enrollment. After 4 cycles of KRd induction and ASCT,
pts received KRd consolidation treatment (70—90 days post-transplant) as 28-
day cycles for 4 cycles: CFZ 36mg/m2 IV on Days 1, 2, 8, 9, 15, 16; LEN PO
Days 1-21 starting at 15mg with option to escalate after 1 cycle of consolidation;
DEX PO 20mg Days 1, 8, 15, 22. After consolidation, KRd was given for additional
10 maintenance cycles, with modified CFZ schedule on Days 1, 2, 15, 16. LEN
single-agent was recommended off protocol at best tolerated dose after KRd
maintenance. Dose modifications were permitted to manage toxicities. The pri-
mary endpoint was sCR rate at the end of Cycle 8; an improvement of sCR from
30%, the rate observed at the end of 8 cycles without transplant, to 50% in this
study will be considered promising for strategy of combining KRd with transplant.
Results: As of Feb 1, 2015, 28 of a total 55 enrolled pts have completed at least
1 cycle of KRd consolidation: 25 pts have completed KRd consolidation and initi-
ated maintenance; 7 pts have completed KRd maintenance and initiated LEN sin-
gle-agent off protocol. After transplant prior to the initiation of KRd consolidation,
≥VGPR was 96%, ≥near CR (nCR) was 46%, and sCR was 29%. After 4 cycles
of consolidation, ≥VGPR was 100%, ≥nCR was 88% and sCR was 72%. The
rate of negative minimal residual disease by 9-color flow cytometry at the end of
8 cycles was 88%. Responses deepened in 25 pts treated beyond at least 4
cycles of KRd consolidation with an additional 1 pt converting to nCR and 3 to
sCR, resulting in ≥nCR 96% and sCR 84%. After a median follow-up of 14 months
from the start of the KRd treatment (range 8-24), all 28 pts were alive and pro-
gression free. There were no new or unexpected toxicities post-transplant com-
pared to the referenced above phase 1/2 trial of KRd without transplant. Enrollment
continues with a target of 70 pts; 55 have been enrolled and updated results of
pts receiving at least one cycle post-ASCT will be reported during the meeting.
Summary and Conclusions: Based on this analysis, extended post-transplant
treatment with KRd can be considered for future evaluation in pts who have
received induction regimens other than KRd. The preliminary data suggest that
KRd with transplant has high efficacy compared to standard single-agent main-
tenance therapy post-transplant.
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IMPACT OF STABLE DISEASE AS A RESPONSE TO POMALIDOMIDE
PLUS LOW-DOSE DEXAMETHASONE ON SURVIVAL OUTCOMES IN
PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY
MULTIPLE MYELOMA IN THE MM-003 TRIAL 
P. Moreau1,*K. Weisel2K. Song3C. Gibson4O. Saunders5L. Sternas4K.
Hong4M. Zaki4M. A. Dimopoulos6
1University Hospital Hôtel-Dieu, Nantes, France, 2University Hospital of Tue-
bingen, Tuebingen, Germany, 3Vancouver General Hospital, Vancouver, Cana-
da, 4Celgene Corporation, Summit, United States, 5BresMed Health Solutions,
Sheffield, United Kingdom, 6National and Kapodistrian University of Athens,
Athens, Greece
Background: Patients (pts) with refractory or relapsed and refractory multiple
myeloma (RRMM) have poor overall survival (OS) outcomes after failure of
bortezomib and lenalidomide treatment (Tx) regimens. Pomalidomide plus low-
dose dexamethasone (POM+LoDEX) has been demonstrated to significantly
extend OS in this pt population compared with high-dose DEX (HiDEX; hazard
ratio [HR]=0.74 [95% CI, 0.56-0.97]; P=0.0285; San Miguel et al, Lancet Oncol,
2013) in the phase 3 MM-003 trial (clinicaltrials.gov identifier NCT01311687).
Secondary analysis of MM-003 showed that the survival benefit of Tx with
POM+LoDEX extended to pts who achieved minor response or better (San
Miguel et al, ASH, 2013).
Aims: This post hoc analysis of MM-003 investigated OS based on response
status with a focus on pts who achieved stable disease (SD) but not a response
by certain landmark points in time.
Methods: Kaplan-Meier methods and unadjusted Cox regression models were
used for landmark analyses at the start of cycles (C) 3, 5, and 7. Response
status was captured over time by time-dependent survival analyses. For both
approaches, survival of pts with SD was compared with that of pts with pro-
gressive disease (PD) or overall response (OR; ≥partial response) at the same
point in their treatment.
Results: 302 pts randomized to POM+LoDEX were included in the analysis.
Response rates at C3 were 38.4% SD, 14.6% PD, and 19.2% OR, with no
response data for 27.8% of pts (mostly due to early discontinuation). The medi-
an OS from randomization by response status at C3 was 15.3 mos for SD
(n=116), 6.3 mos for PD (n=44; hazard ratio [HR]=3.83; P <0.0001 vs SD), and
17.5 mos for OR (n=58; HR=0.75; P=0.320 vs SD). Median OS at C5 was 16.6
mos for SD (n=57), 11.0 mos for PD (n=31; HR=2.81; P=0.004 vs SD), and
18.0 mos for OR (n=56; HR=0.74; P=0.462 vs SD). Median OS at C7 was not
reached for SD (n=40), 16.4 mos for PD (n=18; HR=2.66; P=0.080 vs SD),
and 18.0 mos for OR (n=47; HR=0.90; P=0.843 vs SD). The time-dependent
survival model showed a lower risk of death for pts with SD or OR vs PD
(HR=0.27 [95% CI, 0.17-0.44] and HR=0.06 [95% CI, 0.02-0.16], respectively).
The HiDEX Tx arm exhibited a lower response rate and shorter OS, which in
combination with a smaller number of pts overall resulted in response groups
too small for meaningful analysis.
Summary and Conclusions: POM+LoDEX–treated pts with SD at C3, C5,
and C7 had OS comparable to pts who achieved OR. The OS of pts with either
SD or OR at these time points was significantly longer than for those with PD.
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A PHASE I/IIA STUDY OF THE HUMAN ANTI-CD38 ANTIBODY MOR202
(MOR03087) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
M. Raab1,* H. Goldschmidt1, H. Agis2, I. Blau3, H. Einsele4, M. Engelhardt5,
B. Ferstl6, M. Gramatzki7, C. Röllig8, K. Weisel9, P. Klöpfer10, D. Weinelt10,
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Franklin, Berlin, 4University Hospital Würzburg, Würzburg, 5Medical University
Hospital, Freiburg, 6Fried-Alexander-University Erlangen-Nürnberg, Erlangen,
7University Hospital Schleswig-Holstein Division of Stem Cell Transplantation
and Immunotherapy, Kiel, 8University Hospital Carl Gustav Carus, Dresden,
9University Hospital of Tübingen, Tübingen, 10MorphoSys AG, Martinsried,
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Background: MOR202 is a HuCAL-derived fully human immunoglobulin G1
(IgG1) anti-CD38 antibody, with high efficacy in preclinical models of multiple
myeloma. 
Aims: To evaluate the safety and preliminary efficacy of MOR202 in adult
patients with relapsed or refractory multiple myeloma. 
Methods: This is an open-label dose-escalation study (3+3 design). The data
of patients previously treated with ≥2 prior therapies, including an immunomod-
ulatory drug and a proteasome inhibitor, are presented. Patients received 2-
hour intravenous MOR202 every 2 weeks (q2w; 8 dose levels from 0.01–16
mg/kg) without dexamethasone, or 4 or 8 mg/kg (dose levels 6 and 7) weekly
(q1w)+/-dexamethasone. MOR202 16 mg/kg (dose level 8) q1w+/-dexametha-
sone, and combination cohorts with lenalidomide+dexamethasone and poma-
lidomide+dexamethasone, are planned, as well as confirmation cohorts.
Results: As of December 31 2014, 38 patients had been treated; 29 and 9
patients in the q2w and q1w dose levels, respectively. Median age was 70 (44–
80) years. The median number of prior treatment lines was 4 (2–10) for all
patients. A total of 36 patients (94.7%) developed adverse events. The most
frequently reported adverse events (>10%) of any grade were anemia (31.6%),
fatigue (28.9%), white blood cell count decreased (21.1%), lymphocyte count
decreased (21.1%), diarrhea (21.1%), nasopharyngitis (18.4%), and leukopenia
(13.2%). Grade ≥3 hematologic adverse events were lymphocyte count
decreased (15.8%), white blood cell count decreased (7.9%), leukopenia
(5.3%), thrombocytopenia (2.6%), and lymphopenia (2.6%). Infusion-related
reactions occurred in 13 patients (34%) receiving MOR202 without dexam-
ethasone, mainly during the first infusion. All were grade 1–2 except for 1
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patient (grade 3). There have been no treatment-related deaths. Pharmacoki-
netic data demonstrate a significant target-mediated drug disposition effect for
most patients treated q2w. In 4 out of 6 patients in the q1w 4 mg/kg cohort,
MOR202 trough levels show the start of target saturation. Only 1 patient
(MOR202 0.15 mg/kg q2w) generated a transient anti-drug antibody response
to MOR202. 
Summary and Conclusions: The maximum tolerated dose has not been
reached. MOR202 is safe and well tolerated. Pharmacokinetic data show the
potential for full target occupancy in the majority of patients receiving 8 and 16
mg/kg q1w. These latter dose levels of MOR202 will be tested as monotherapy
or in combination with dexamethasone, lenalidomide+dexamethasone, and




SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR
IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM
RESULTS OF A PHASE 2 STUDY
J.A. Jones1,* L. Andritsos1, F. Ravandi2, R.J. Kreitman3, C. Schiffer4, T. Call5,
G. Lozanski6, J. Sexton7, P. Harris8, M.R. Grever1
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Background: Effective therapy for classical hairy cell leukemia (c-HCL) refractory
to purine nucleoside analog (PA) treatment is limited, and there is no accepted
treatment standard for either treatment-naïve or relapsed variant hairy cell leukemia
(v-HCL). Ibrutinib, an oral small molecule inhibitor of Bruton tyrosine kinase (BTK),
has shown single-agent efficacy and acceptable tolerability in patients with various
B-cell malignancies, including CLL, mantle cell lymphoma, and Waldenstrom
macroglobulinemia. However, while BTK is expressed in HCL cells, the clinical
activity of ibrutinib in this disease has not been previously assessed.
Aims: To characterize the overall response rate (complete+partial response)
and safety of single-agent ibrutinib treatment for hairy cell leukemia. 
Methods: This NCI/CTEP-sponsored, single-arm phase 2 study enrolled patients
with c-HCL (unfit for or relapsed after PA) and v-HCL (relapsed or treatment-
naïve). Eligible patients required treatment, had ECOG ≤2, no active infection,
and preserved end-organ function. Patients received continuous oral ibrutinib
(420 mg daily) in 28-day cycles. A second cohort at higher dose (840 mg daily)
has been accrued after a pre-determined response endpoint was not initially met
at the 420 mg dose. Response, including bone marrow biopsy with immunohis-
tochemistry for minimal residual disease (MRD), is assessed after 8 and 12
cycles. Soluble interleukin-2 receptor levels (sIL2R) were measured serially and
correlated with clinical outcome. Patients experiencing clinical benefit may con-
tinue ibrutinib indefinitely absent unacceptable toxicity or progressive disease. 
Results: Data are presented for the initial 420 mg/day cohort (n=13). Enrolled
subjects (1 treatment-naïve v-HCL, 1 relapsed v-HCL, 11 relapsed c-HCL)
included 12 male and 1 female patients with median age 64 years (range: 43-
76) and median 4 (range: 1-11) prior therapies. All relapsed patients had
received prior PA, 5 (45%) were splenectomized, and 9 (82%) had prior ritux-
imab. The most frequent (>20%) grade 3/4 adverse events (AEs) included lym-
phopenia (37%), hypophosphatemia (30%), neutropenia (23%), and infection
(23%). Common grade 1/2 AEs included myalgias (61%), headache (38%),
dizziness (38%), diarrhea (38%), arthralgias (30%), rash (30%), and fatigue
(30%). Other hematologic AEs included grade 1/2 anemia (38%) and grade
1/2 thrombocytopenia (38%). In general, response has improved with continued
treatment (Table). One MRD-negative complete response (c-HCL) and 5 partial
responses have been observed (ORR 46%). Four additional patients (30%)
with stable disease have experienced clinical benefit not meeting criteria for
PR and continue on treatment. At median follow-up of 14.5 months, 9 patients
(69%) remain progression-free on treatment, 3 patients (1 v-HCL, 2 c-HCL)
have progressed and 1 patient (c-HCL) discontinued in cycle 8 after failing to
resolve baseline neutropenia. Redistribution lymphocytosis (peaking at day 8)
occurred in both v-HCL patients and 1 c-HCL patient with circulating disease
at baseline. sIL2R levels were increased at baseline in all c-HCL patients for
whom data were available and normalized in responders.
Tabella 1.
Response Best Response Post-Cycle 8 Post-Cycle 12
Category (n=13) (n= 11) (n=11)
CR 1 0 1
PR 5 5 5
SD 6 6 4
PD 1 0 1
Summary and Conclusions: Ibrutinib is well-tolerated and can induce remis-
sions, including MRD-negative complete remission, in hairy cell leukemia
patients. The correlation between sIL2R levels and response will be investigated
further. Accrual continues to the second cohort.
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Background: Chronic lymphocytic leukemia (CLL) is a disease with a highly
heterogeneous course, ranging from mild to aggressive. Therefore, prediction
of outcome is important in clinical practice to avoid too aggressive treatment
in patients with a rather mild course of disease and to identify patients in whom
standard treatment is likely to fail. In the era of more effective treatments for
CLL, the established clinical staging systems [Binet/Rai] do not accurately dis-
criminate between prognostic subgroups. Despite the introduction of several
new prognostic markers, there is no system integrating the major clinical, bio-
logical and genetic variables into one widely accepted prognostic system.
Aims: To develop an internationally applicable prognostic index for CLL patients
[CLL-IPI], we performed a comprehensive analysis of 26 prognostic factors
including clinical, biological and genetic markers.
Methods: The data from 8 prospective randomized phase III trials from France,
Germany, UK, USA and Poland comprised our full analysis set including 3472
previously untreated patients at early and advanced clinical stage with a median
age of 61 years (yr) (range, 27 - 86) and a median observation time of 80
months. First line therapies included Fludarabine (F), F+Cyclophosphamide
(FC), FC+Rituximab, FC+Campath, C+Cladribine, Chlorambucil and watch &
wait. The full analysis set was randomly divided into training [2308 (67%)] and
internal validation dataset [1164 (33%)]. Methods of multivariable survival sta-
tistics were applied including proportional-hazards Cox regression analyses.
The main end point of all statistical analyses was overall survival (OS). Handling
of missing data was performed with complete case analysis using a 4 step-
down procedure accounting for the degree of completeness of data. C-statistics
were calculated to evaluate the discriminatory value of the model (c=1 indicates
perfect discrimination; c=0.5 is equivalent to chance). Subsequently, the model
was externally validated in a third dataset comprised of 845 newly diagnosed
CLL patients from Mayo Clinic [median age 62 yr (range, 25 - 89); 63 months
median observation time].
Results: Based on 1192 (52%) patients from the training dataset, 5 independ-
ent predictors for OS were identified: age [cut off, 65 yr], clinical stage [Binet
A/Rai 0 vs. Binet B-C/Rai I-IV], del(17p) and/or TP53mutation, IGHVmutation
status (MS) and serum β2-microglobulin (B2M) [cut off, 3.5 mg/L]. Applying
weighted grading of the independent factors based on the regression param-
eters, a prognostic index was derived separating 4 different risk groups [low
(score 0-1), intermediate (score 2-3), high (score 4-6) and very high risk (score
7-10)] with significantly different OS [93%, 79%, 64% and 23% OS at 5 yr for
the low, intermediate, high and very high risk group respectively, p<0.001; C-
statistic c=0.724 (95% confidence interval (CI), 0.69-0.76)] (figure 1A). This
multivariable model was confirmed on the internal validation dataset [575 (49%)
patients; 91%, 80%, 52% and 19% 5-yr OS, p<0.001; c=0.777 (95% CI, 0.73-
0.82)] (figure 1B). In the external Mayo dataset the 5-yr OS for the CLL-IPI risk
groups were 97%, 91%, 68% and 21% [p<0.001; c=0.790 (95% CI, 0.74-0.85)]
(figure 1C). Further, the CLL-IPI provided accurate estimation regarding time
to first treatment within this cohort [81%, 47%, 30% and 19% patients free from




Summary and Conclusions: We report the development and validation of a
weighted, integrated prognostic score and index derived from a broad number
of established prognostic markers. The resulting CLL-IPI combines the most
important genetic risk factors (IGHV MS, del(17p)/TP53) with traditional clinical
stage, age, and B2M into an easily applicable prognostic index for CLL patients.
Moreover, it both discriminates between prognostic subgroups and may help
to inform current treatment recommendations in the future.
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THE LLR TAP ICICLLE TRIAL ASSESSING BIOLOGICAL RESPONSE TO
IBRUTINIB IN CLL: IMMEDIATE DISEASE REDISTRIBUTION PRECEDES
CELL CYCLE ARREST BY 2 WEEKS WITH REDUCED BONE MARROW
INFILTRATION BY 6 MONTHS
A. Rawstron1,* T. Munir1, S. Dalal1, J. Thompson1, C. Yap2, K. Brock2, F. Yates2,
E. Ogburn2, C. Fox3, D. MacDonald4, C. Fegan5, A. Bloor6, P. Hillmen7
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Background: Ibrutinib is a Bruton’s tyrosine kinase inhibitor with efficacy in
CLL. The IcICLLe trial (ISRCTN 12695354) is a feasibility study to investigate
the biological response to ibrutinib and inform the design of subsequent ran-
domised phase II/III trial(s). Primary outcome measures include assessment
of the CLL cell levels and protein expression profile, particularly in relation to
cell cycle and other CLL treatment targets, in the peripheral blood (PB) and
bone marrow (BM). Toxicity, categorical response and survival are secondary
outcomes.
Aims: To understand the biological impact of ibrutinib treatment and identify
changes that may impact the design of therapeutic strategies or affect disease
monitoring.
Methods: 40 participants with CLL requiring treatment (20 treatment-naïve
and 20 relapsed/refractory) received ibrutinib (420 mg once daily) from regis-
tration until either achievement of <0.01% residual disease in bone marrow or
disease progression. PB & BM samples are taken -0.5 (screening), 1 & 6
months with additional PB samples at 0 (baseline), 4 hours, 1, 2, 7, & 14 days
and 2, 9, & 12 months (M). Markers assessed at each time point include CD19,
CD20, CD45, CD5, CD10, CD305, kappa, lambda, CD23, CD43, CD81,
CD79b, ROR1, CXCR4, CD49d, Ki67, CD62L, and CD38 with an additional
30 markers (including BCL2, ZAP-70 and IRF4) samples with paired PB & BM.
Results: Absolute peripheral B-cell counts increased immediately after the first
dose, peaking at two weeks, and returning to baseline by month 2 (median
1.25, 1.44, 2.1, 1.19 fold absolute B-cell count relative to baseline at 4hrs,
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24hrs, 2 weeks and 2 months after first dose respectively). There was no dif-
ference in bone marrow infiltration after 1 month of treatment but after 6 months,
7/8 evaluable patients had more than 50% reduction in PB CLL counts relative
to baseline and bone marrow involvement was reduced with 3/8 achieving
<30% BM CLL and 1 treatment-naïve patient achieving a CR. The proportion
of CLL cells expressing Ki67 at baseline was slightly lower in the peripheral
blood (median 3.5%, range 0.3-22.3%) than the bone marrow (median 3.9%,
range 0.8-42%) but the difference was not significant and blood was a suitable
site for assessing proliferative capacity. Ki67 expression initially increased,
peaking at 24 hours after first dose (PB CLL Ki67+median 5.1%, range 0.4-
16.4%), after which the Ki67 expression declined below quantifiable levels
(<0.5%) in 15% of patients by week 1 and in more than 90% of patients at sub-
sequent time points. Similarly in the BM, CLL Ki67 expression was not
detectable in most patients after 1 month of treatment. Other changes in protein
expression during treatment, including decreases in markers associated with
proliferation in CLL (CD5, CD23, CD38, CD49d and IRF4), and changes in
molecules involved in CLL cell trafficking and adhesion (increased CXCR4 and
CD24 expression; decreased CCR7, CD31 and CD11a) followed the same
kinetics as cell cycle arrest, i.e. differences emerged after 1-2 weeks of treat-
ment and then stabilised during subsequent treatment. Concerning molecules
involved in disease monitoring, CD19, CD5 & CD43 expression were mildly
reduced but overall expression remained strong; CD81/CD79b expression did
not change significantly; CD20/CD22 expression decreased, potentially enhanc-
ing discrimination from normal B-cells but this may affect optimal timing of anti-
CD20 therapy; CD200 expression was also consistently decreased and these
changes need to be considered when assessing residual disease levels.
Summary and Conclusions: The redistribution of CLL cells during ibrutinib
therapy happens much more rapidly than any changes in proteins associated
with proliferation, cell trafficking or adhesion. The majority of changes in CLL
cells correlate with the loss of the proliferative fraction, mostly stabilising after
one month of treatment.
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OVERALL SURVIVAL ANALYSIS ADJUSTING FOR TREATMENT EFFECT
AFTER CROSSOVER IN A PHASE 3 STUDY EVALUATING IDELALISIB IN
COMBINATION WITH RITUXIMAB IN RELAPSED CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)
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Background: A Phase 3 trial evaluated idelalisib (IDELA)+rituximab (R) vs
placebo (PBO)+R in patients (pts) with relapsed CLL (Furman, NEJM, 2014).
Using an extension study design, pts on the control arm were allowed to receive
IDELA after progression (PD). Estimating the true overall survival (OS) benefit
of the active arm of randomized studies with such a crossover design represents
a challenging statistical problem. Intent-to-treat (ITT) analyses considering data
from pts after crossover as well as the approach of censoring subjects at the
time point of crossover may significantly underestimate the OS benefit. Alter-
native analysis approaches like the rank-preserving structural failure time (RPS-
FT) model (Robins, 1991; Ishak, 2014) have successfully been used to estimate
the true treatment effect in similar trials designs with crossover.
Aims: Estimate the treatment effect in OS adjusted for the impact of crossover
Methods: Three methods of OS analysis were compared (data cut-off date
01July2014): 1) ITT analysis calculating the OS according to initial randomization
including data after crossover (as pre-specified), 2) Censoring subjects at the
time point of crossover, and 3) RPSFT. Methods 1 and 2 commonly underesti-
mate the true OS benefit. The RPSFT model estimates the counterfactual event
time of the control arm that would have been observed without crossover and
provides the estimate of treatment effect adjusted for the impact of crossover.
Results: 110 pts were randomized to each arm. 38% (n=42) of pts on PBO+R
crossed over to receive single-agent IDELA following PD according to the initial
study design. An additional 40% (n=44) of subjects on PBO+R crossed over to
receive idelalisib in the absence of prior PD according to an amended protocol
after the study was stopped due to overwhelming PFS efficacy. The median
follow-up for the presented analyses was 12.5 months (mos) for pts initially on
IDELA+R and 11.1 mos for PBO+R. There were 17 deaths in the IDELA+R
group, and 40 deaths in the PBO+R group. Analysis results from each method
are presented in the table below:
Tabella 1.
Summary and Conclusions: IDELA+R demonstrated significant and consis-
tent improvement in OS regardless of the analysis method. The median OS
and HR as estimated by the RPSFT model reduced the bias associated with
the idelalisib treatment effect compared to the ITT analysis or the censoring
approach.
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BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR
DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE
PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS
A. Rawstron1,* D. Cohen2, R. de Tute1, L. McParland2, L. Collett2, D. Phillips2,
A. Chalmers2, A. Varghese1, T. Munir1, W. Gregory2P,. Hillmen3
1St. James’s Institute of Oncology, 2Clinical Trials Research Unit, 3Institute of
Cancer and Pathology, Leeds, United Kingdom
Background: Minimal residual disease (MRD) in CLL is an independent pre-
dictor of progression-free (PFS) and overall survival (OS) with a high, interme-
diate and low risk of disease progression seen in patients with >1%, 0.01-1%,
or <0.01% MRD respectively. Evaluating novel treatments currently requires
assessment of PFS/OS in randomised controlled trials but the prolonged duration
of remission means that this approach is slow. Assessing MRD as a trial endpoint
could greatly speed the process; using peripheral blood (PB) would be preferable
but antibody therapies preferentially deplete circulating disease to a variable
extent and bone marrow (BM) is the more sensitive site for MRD detection.
Aims: To compare PFS/OS according to MRD level in PB and BM for different
treatment and patient groups and determine the optimum site for MRD assessment.
Methods: MRD was quantified using multi-parameter flow cytometry according to
ERIC consensus protocols with a limit of quantification of 10-4 / 0.01% or better.
Results: The MRD level in 609 paired PB & BM samples taken during or within
6 months of treatment (446 in clinical trials, see table) was concordant in 443
(72.7%) at MRD thresholds <0.01% / 0.01-1% / >1%. In 391 cases with <0.01%
PB MRD, 85/391 (21.7%) had 0.01-1% CLL and 14/292 (3.6%) had >1% CLL
in the paired BM sample. In 118 cases with 0.01-1% CLL in the PB, the paired
BM sample showed >1% CLL in 63/118 (53.4%). The PB MRD level would
have assigned a higher risk category than BM in only 4 cases, all of which had
detectable BM disease. Discrepancies between PB & BM MRD levels were
not consistent across treatment and patient groups. Refractory patients treated
with alemtuzumab-based therapies typically showed a high proportion of dis-
crepant results with >1 log differences while patients in CR/PR receiving alem-
tuzumab consolidation had few discrepancies; during Ibrutinib monotherapy
(IcICLLE trial) there have been no discordant cases to date. To determine
whether discrepant results impact on outcome, PFS/OS was evaluated accord-
ing to PB & BM MRD in different trials. In the ADMIRE/ARCTIC trials, PB & BM
MRD levels were discordant in 66/312 evaluable cases, all with ≥0.01% BM
but <0.01% PB MRD. After a median follow-up of 3 years, MRD level was con-
firmed as a strong predictor of PFS and OS, independent of categorical
response, with the presence of ≥0.01% MRD conferring a significantly poorer
outcome (PFS: HR 4.6, 95%CI 2.7 to 7.7, p=<0.001). For patients in CR, and
with ≥0.01% MRD (n=70), 3 year PFS was 68.7% compared with 86.6% for
patients with <0.01% MRD (n=176). There was no observable difference in the
PFS or OS for patients with <0.01% PB but ≥0.01% BM MRD compared to
those with <0.01% PB & BM MRD. However, for those patients with MRD
detected in the BM only, there was a median of 0.08% CLL and this would be
predicted to yield observable differences in PFS only after >3 years follow-up.
The results contrast with the outcome for 47 evaluable patients in the CLL202
CAMFlud trial where patients with <0.01% MRD in PB but ≥0.01% disease in
BM had a poor outcome that was similar to those with ≥0.01% in both PB &
BM, and both groups had significantly poorer PFS/OS than patients with
<0.01% MRD in both PB & BM (with median 55 months follow-up for patients
with ≥0.01% in PB & BM / <0.01% PB but ≥0.01% BM / <0.01% MRD in both
PB & BM patients respectively, median PFS was 1.6 / 6.5 / 44.7 months and
OS was 7.5 / 14 / not reached, P<0.001).
Tabella 1.
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Summary and Conclusions: Patients achieving <0.01% CLL have a better
outcome than those with detectable MRD but the power of peripheral blood
MRD eradication to predict outcome varies widely according to the type of ther-
apy received and is poor with more potent antibodies. The most robust tissue
and time-point for MRD assessment to predict long-term outcomes in CLL is
the bone marrow at 3 months post-treatment. Our work justifies the use of
MRD eradication from the marrow post-treatment as a surrogate end-point in
clinical trials.
AML: Molecular profile and targeting
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COMPREHENSIVE GENOMIC PROFILING OF A LARGE COHORT OF
ACUTE MYELOID LEUKAEMIA TO DISSECT ITS GENOMIC AND
PHENOTYPIC COMPLEXITY
E. Papaemmanuil1,* M. Gerstung1, R. Schlenk2, L. Bullinger2, P. Paschka2,
G. Verena2, N. Bolli1, V. Teleanu2, C.H. Köhne3, G. Held4, P. Brossart5,
M. Ringhoffer6, H. Horst7, M. Heuser8, F. Thol8, B. Schlegelberger9,
U. Germing10, G. Arnold11, K. Doehner12, H. Doehner12, P. Campbell1
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Stem Cell Transplantation, MH-Hannover, Hannover, 12Internal medicine, Uni-
versitätsklinikum Ulm, ULM, Germany
Background: The characterization of recurrent chromosomal abnormalities in
AML has paved the way for the incorporation of genetic lesions into clinical
diagnostics and prognostication tools. However, clinical outcomes vary greatly
and in the absence of informative lesions, a large proportion of patients are
given an intermediate risk score. Recent profiling studies have characterized
>50 recurrently mutated genes in AML. Considering the multitude of gene can-
didates, evaluations of the AML genomic landscape and its relationship to clin-
ical trajectory must extend beyond single/few biomarkers studies and, impor-
tantly, involve large well-annotated datasets.
Aims: We sought to comprehensively evaluate the known driver mutations in
AML; study molecular phylogenies that underpin AML transformation, and
investigate how the composite genetic architecture determines phenotype and
correlates to clinical response.
Methods: We study 1540 adult AML patients from three clinical trial cohorts of
the AML-SG (HD98A, HD98B and 07-04) using a targeted re-sequencing
approach. Taken together with cytogenetic analysis we identify 5,241 driver
variants across 55 genes and 23 recurrent cytogenetic alterations. We incor-
porate these to diagnostic and clinical outcome data (median follow-up=2169
days), perform classification analysis to determine molecular subgroups, and
apply variable selection models to characterize prognostic biomarkers.
Results: We find at least 1 driver mutation in 97% patients in the study, and
importantly at least 2 in 85%. There was a long tail of infrequently mutated
driver genes, with only 30% of the events seen in >10% of patients. The num-
ber of drivers increases with age and patients with normal karyotype have
more mutations than patients with cytogenetic abnormalities. Using the fraction
of reads reporting a gene mutation to distinguish subclonal from clonal muta-
tions, we identify 690 samples with at least 2 driver mutations and subclonal
heterogeneity and map recurrent preferences in order of mutation acquisition.
We survey the composite genomic architecture and define 10 classes, which
are broadly defined by inv(16); t(8;21), t(var;11q23), inv(3), t(6;9), bi-allelic
CEBPA, NPM1/DNA hydroxymethylation, TP53/aneuploidies,
chromatin/spliceosome and DNMT3A/IDH2 mutations, and collectively
account for 85% of patients. The definition of each class extends beyond a
single lesion and is rather determined by class-specific initiating events and
co-operative lesions that are ordered in time. Many of these interactions
extend to mutation clusters or hotspots within genes as evidenced by pairings
between FLT3 TKD/ITD, NRAS c.12-13/c.61, IDH2 c.140/c.172 and CEBPA
mono/bi-allelic mutations. As expected, evaluation of clinical phenotype and
outcome associations identifies broad correlations between class, phenotype,
response to induction chemotherapy and overall survival. Strikingly, we find
that specific molecular contexts within each class (as defined by secondary
and tertiary interactions) correlate with distinct and often opposing outcome
trajectories and clinical phenotype ranging from excellent to highly adverse
clinical outcomes. These relationships are underpinned by models of additive
risk or suggestive of genetic epistasis. Using overall survival as a primary
endpoint we evaluate the known landscape of driver mutations, and genetic
interactions. We derive a comprehensive set of significant factors and identify
at least three genetic interactions that retain significance (q<0.01) in the pres-
ence of other clinical and demographic variables. Importantly we identify at
least one prognostic predictor in 70% of the patients and observe a three-fold
increase in patients with 2 or 3 prognostic predictors relative to current molec-
ular prognostication guidelines.
Summary and Conclusions: Taken together, we study an extended and well-
annotated clinical cohort we demonstrate the potential of recent genetic findings
to deliver improved classification and risk stratification algorithms that extend
beyond single biomarker correlations, capture most AML patients and that are
tailored to the individual patients genomic profiles.
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AKT PHOSPHORYLATION AT SERINE 473 IS A POWERFUL NOVEL
BIOMARKER IN ACUTE MYELOID LEUKAEMIA, AND IS RELATED TO
PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION BY CIP2A AND SETBP1
C. Lucas1, N. Carmell1, L. Scott1, A. Holcroft1, R. Hills2, R. Clark1,*
1Haematology, University of Liverpool, Liverpool, 2Institute of Translation, Inno-
vation, Methodology & Engagement, Cardiff University School of Medicine,
Cardiff, United Kingdom
Background: Many malignancies are characterised by inappropriate substrate
phosphorylation which causes aberrant proliferation and decreased apoptosis;
this is often due to an overactive kinase e.g. BCR-ABL or FLT-3 in myeloid
malignancy, or ERK or ErbB2 in solid tumours. What is less clear is why this
effect is not simply countered by normal cellular phosphatases, of which the
most important is protein phosphatase 2A (PP2A). PP2A is normally inhibited
by SET, (which is stabilised by a binding protein SETBP1) and cancerous
inhibitor of PP2A (CIP2A). We have shown that high CIP2A levels confer a
poor outcome in chronic myeloid leukaemia (similar to findings in many solid
tumours), and also that high CIP2A levels are associated with stabilisation of
c-Myc and E2F1, as well as PP2A inactivation in CML. There are also data to
suggest that high SETBP1 levels may confer a poor outcome in AML, presum-
ably by PP2A inhibition via increased action of SET, though little is known of
CIP2A in AML. 
Aims: To investigate if CIP2A or network related proteins could predict clinical
outcome in AML patients. 
Methods: CIP2A and PP2A related proteins were investigated in 120 AML
patient samples collected in the UK MRC/NCRI trials AML15, 16 and 17. These
were stratified into intermediate or adverse risk, based on cytogenetics as pre-
viously defined (Grimwade et al, Blood. 1998: 92; 2322-33). Protein levels were
studied in diagnostic mono-nuclear cells samples by flow cytometry. CIP2A lev-
els in individual samples were then defined as either high or low based on
receiver-operator characteristics analysis as previously described.
Results: Diagnostic CIP2A levels were significantly higher in younger interme-
diate than in adverse risk patients (p=0.004). In the intermediate risk group,
overall survival was dominated by the survival from relapse. High diagnostic
CIP2A was associated with high levels of c-Myc (p=0.003), inactive PP2A
(PP2AY307, p=0.04) and activation of AKT as identified by its phosphorylation
on serine 473 (AKTS473) (p=0.0009). Interestingly, high diagnostic CIP2A was
strongly associated with the presence of a FLT3-ITD mutation (p=0.009). For
younger intermediate risk patients with high and low CIP2A levels, median sur-
vival from relapse censored at transplant was 56 days and 303 days respec-
tively, and multivariate analysis adjusted for FLT3-ITD showed that a high CIP2A
level predicted inferior survival from relapse (p=0.04, hazard ratio 4.02). Rates
of high levels of CIP2A were lower in adverse risk patients but instead we found
elevated levels of SETBP1, which acts via SET as an alternative inhibitor of
PP2A. In younger patients with adverse cytogenetics, high SETBP1 levels pre-
dict for an inferior overall survival (p=0.02). High SETBP1 was also associated
with secondary AML (p=0.06). In univariate analysis, high levels of AKTS473were
associated with poor survival in all patient groups. Multivariate analysis of known
predictors of outcome (age, cytogenetics, white count, secondary leukaemia,
FLT3-ITD) together with CIP2A and related proteins (PP2AY307, SET, SETBP1,
c-Myc E2F1, AKTS473, STAT5, and E2F1) was used to derive a prognostic
model for survival. This ranked high levels of AKTS473 as the third most impor-
tant predictor of outcome after age and cytogenetics. 
Summary and Conclusions: AKT phosphorylation at S473 is a surrogate
‘readout’ of PP2A inhibition by either CIP2A (intermediate risk) or SETBP1
(adverse risk patients). The diagnostic AKTS473 level appears to be a novel
biomarker for treatment outcome in AML. This should now be tested prospec-
tively as part of a clinical trial.
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ASSOCIATION OF MIR29 RNA WITH RESPONSE AND SURVIVAL IN
OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED
WITH AZACITIDINE (AZA) OR CONVENTIONAL CARE REGIMENS (CCR)
K.J. MacBeth1,* L. Tang1, J.F. Seymour2, R.M. Stone3, M.D. Minden4,
L.M. Lucy1, C. Beach1, H. Döhner5
1Celgene Corporation, Summit, United States, 2Peter MacCallum Cancer Cen-
tre, East Melbourne, Australia, 3Dana-Farber Cancer Institute, Boston, United
States, 4Princess Margaret Cancer Centre, Toronto, Canada, 5Universität-
sklinikum Ulm, Ulm, Germany
Background: DNA methyltransferases (DNMTs) mediate DNA methylation and
contribute to epigenetic aberrancy in myeloid malignancies. The miR29 family
of microRNAs directly inhibit the expression of DNMT-3A and -3B (Fabbri,
PNAS, 2007). In a small study (N=23) of older patients (pts) with AML, higher
levels of miR29b were significantly associated with response to decitabine
(Blum, PNAS, 2010). The large (N=488) phase 3 randomized AZA-AML-001
study compared AZA and CCR treatment (Tx) in older pts with AML. AZA pro-
longed median overall survival (OS) by ~4 months (mos) (10.4 vs 6.5 mos;
p<0.101) and improved 1-year survival (46.5% vs 34.2%) vs CCR (Dombret,
EHA, 2014).
Aims: To investigate the relationship between miR29 family RNA levels and
clinical endpoints (response and OS) in AZA-AML-001 pts.
Methods: Eligible pts were age ≥65 years with newly diagnosed AML (>30%
bone marrow [BM] blasts) and had ECOG PS of 0-2, WBC count ≤15x109/L,
and intermediate- or poor-risk cytogenetics. Pts received AZA (75mg/m2/day
[d] x7d/28d cycle) or a preselected CCR: intensive chemotherapy (standard
7+3 regimen), low-dose cytarabine (20mg SC BID x10d/28d cycle), or best
supportive care only. RNA was isolated from BM mononuclear cells collected
at screening from a subset of pts who gave informed consent for this exploratory
biomarker analysis and had adequate BM mononuclear cells for analysis.
Experimental miRNAs (miR29a, b, c) and control RNAs (RNU44, miR-16) were
quantified by qRT-PCR. Associations between miR levels and response (IWG
2003) were assessed, defining responders as pts who achieved complete
remission (CR) or morphologic CR with incomplete blood count recovery (CRi),
and nonresponders as pts with partial response (PR), stable disease (SD), or
progressive disease (PD) as their best response. Differences in baseline miRNA
expression were compared by T-test within the AZA and CCR Tx arms. A 2-
way ANOVA model was used to test the interaction between miR expression
and Tx. miR expression as a continuous variable was also fit in a Cox model
with and without strata in separate arms.
Results: The biomarker cohort comprised 156 of all 488 pts (32%; AZA n=83,
CCR n=73). Baseline characteristics were well-matched in the biomarker vs
non-biomarker groups, respectively, with median age 75 years in both groups,
median BM blasts 50.5% vs 52.0%, and cytogenetic risks of intermediate 63.8%
vs 66.5%, and poor 36.3% vs 33.5%. Baseline miR29a and miR29b expression
levels were significantly higher in responders (CR+CRi) vs nonresponders
(PR+SD+PD) with AZA Tx (p<0.004 & p<0.029, respectively), but not with CCR
Tx (Figure). This difference for miR29a was confirmed in the 2-way ANOVA
analysis of response and Tx (p<0.054). miR29a levels were also associated
with OS (p<0.044) in the AZA arm, but not in the CCR arm, in stratified survival
analysis. No significant associations between miR29b or miR29c levels and
OS were seen in either Tx arm.
Figure 1. miR29a, b, c RNA expression levels (mean ±SD) in responders
vs nonresponders.
Summary and Conclusions: In this exploratory analysis, higher expression
levels of miR29a and miR29b were significantly associated with response to
AZA Tx, and the association of miR29a levels with response was specific to
AZA. Higher miR29a levels were also associated with improved OS in pts treat-
ed with AZA, but not in pts treated with CCR. As miR29a is implicated in regu-
lating DNMT levels, an AZA target, these data are consistent with the concept
that reduced pretreatment DNMT levels due to higher miR29a expression can
improve response and survival with hypomethylating agents.
S798
RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A
SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH
RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA 
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Park Cancer Institute, Buffalo, 21University of South Carolina, Charleston, Unit-
ed States
Background: FMS-like tyrosine kinase-3 (FLT3) mutations, including internal
tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, are
present in acute myeloid leukemia (AML) cells in up to 30% of patients. FLT3
inhibitors have shown promise as a therapeutic option for AML patients with
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FLT3 activating mutations. in vitro analyses suggest that ASP2215 is a potent
inhibitor of FLT3 and AXL tyrosine kinases and demonstrates activity against
both FLT3-ITD and FLT3-TKD.
Aims: A Phase 1/2 trial investigated the safety, pharmacokinetics (PK), and
clinical efficacy of ASP2215 in patients with relapsed or refractory (R/R) AML. 
Methods: This open-label, first-in-human study, conducted in patients ≥18
years old with R/R AML, included 2 cohorts: dose escalation (Cohort 1) and
dose expansion (Cohort 2). Cohort 1 was a modified 3+3 with accelerated titra-
tion design that evaluated ascending oral doses of ASP2215 (20–450 mg).
Cohort 2 was a parallel multi-dose expansion cohort that was initiated based
on the efficacy observed during dose escalation and patients were stratified by
FLT3 mutation status. The primary endpoints included determination of the
maximum tolerated dose (MTD) and the PK profile; clinical efficacy and FLT3
phosphorylation were evaluated as secondary endpoints. All patients provided
informed consent. Data from an interim analysis are presented.
Results:: A total of 166 patients (Cohort 1, n=25; Cohort 2, n=141) with a medi-
an age of 64 years (range: 21–90) were enrolled between October 2013 and
December 2014. ASP2215 MTD was determined to be 300 mg after 2 out of 3
patients dosed with ASP2215 treated at 450 mg experienced dose-limiting tox-
icities (grade 3 diarrhea and ALT/AST elevation). Plasma concentrations of
ASP2215 increased with increasing dose, with tmax between 2 and 6 hours.
Accumulation was observed following repeat dosing, with estimated t1/2 values
of 45 to 159 hours based on accumulation index. Approximately dose-linear
PK parameters were observed over the dose range for both single and repeat
dosing. Fatigue (13%), constipation (10%), anemia (8%), nausea (8%), diarrhea
(7%), thrombocytopenia (6%), decreased platelet count (6%), vomiting (6%),
dizziness (6%), peripheral edema (5%), increased transaminases (5%), and
hypomagnesemia (5%) were the most commonly reported treatment-emergent
adverse events considered “possibly” or “probably” related to drug. Further, no
incidents of clinically significant QTc prolongation have been reported. Overall
response rate (ORR, defined by composite complete and partial remissions)
in patients with FLT3 mutations was 57% at doses between 20 and 300 mg,
and 65% at doses of ≥80 mg; a lower ORR (11%) was observed in patients
with wild type FLT3 (Table). In patients receiving doses ≥80 mg, a plasma
inhibitory activity assay confirmed effective, consistent, and sustained FLT3
inhibition. 
Tabella 1.
Summary and Conclusions: ASP2215, a potent oral inhibitor of FLT3/AXL,
was well tolerated at doses of 20–300 mg/d in patients with R/R AML and
showed a high degree of clinical activity in patients with FLT3-ITD and/or FLT3-
TKD mutations. ASP2215 demonstrated a predictable PK profile consistent
with once-daily dosing. Randomized phase 3 trials of ASP2215 dosed at 200
mg in newly diagnosed and R/R AML are planned.
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UPDATED RESULTS FROM THE SORAML TRIAL COMPARING
SORAFENIB VERSUS PLACEBO IN ADDITION TO STANDARD THERAPY
IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID
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Background: Sorafenib is a multi-kinase inhibitor with activity against several
oncogenic kinases that may play a role in the pathogenesis of acute myeloid
leukemia (AML). We present updated results from the randomized placebo-
controlled SORAML trial (NCT00893373) testing sorafenib versus placebo as
add-on to standard treatment in AML patients ≤60 years. 
Aims: The data focus on treatment adherence, efficacy in cytogenetic sub-
groups and relapse pattern.
Methods: The trial enrolled 276 patients with newly diagnosed AML from 18 to
60 years and suitable for intensive therapy. The treatment plan for all patients
included two cycles of induction with DA (daunorubicin 60 mg/m2 days 3-5 plus
cytarabine 100 mg/m2 cont. inf. days 1-7) or HAM (cytarabine 3 g/m2 b.i.d. days
1-3 plus mitoxantrone 10 mg/m2 days 3-5), followed by three cycles of high-dose
cytarabine consolidation (3 g/m2 b.i.d. days 1, 3, 5). Allogeneic stem cell trans-
plantation (SCT) was scheduled for all intermediate-risk patients in first complete
remission (CR) with a sibling donor and for all high-risk patients with a matched
related or unrelated donor. Patients were randomized to receive either sorafenib
(800 mg/day) or placebo as add-on to standard treatment in a double blinded
fashion. Study medication was given on days 10-19 of DA I+II or HAM, from day
8 of each consolidation until 3 days before the start of the next consolidation and
as maintenance for 12 months after the end of consolidation.
Results: Out of 276 enrolled patients, 267 received study treatment, 134 in
the sorafenib arm and 133 in the placebo arm. Demographic and disease char-
acteristics were equally distributed between the two arms; the incidence of
FLT3-ITD was 17%. Toxicity-related drop-outs were slightly more frequent in
the sorafenib arm with 32% vs 25% of patients commencing maintenance.
After a median observation time of 36 months, the median EFS was 9.2 months
in the placebo arm and 20.5 months in the sorafenib arm (p=0.013). Induction
mortality was 4% in both arms, but cumulative incidence of relapse was signif-
icantly higher in the placebo arm. Subgroup analyses on EFS suggest a ben-
eficial effect of sorafenib already after induction treatment. In multivariate analy-
sis, sorafenib exposure, favorable cytogenetics and NPM1 mutation were asso-
ciated with superior EFS whereas FLT3-ITD remained a negative prognostic
factor. Median RFS after standard treatment plus placebo was 23 months and
not yet reached after sorafenib treatment (p=0.017). The median OS had not
been reached in either arm; the 3-year OS was 56% with placebo versus 63%
with sorafenib (p=0.382). More placebo patients (N=66; 50%) than sorafenib
patients (N=39; 29%) received a SCT in relapse due to more and earlier relaps-
es with placebo, whereas relative SCT rates among relapses were similar
(sorafenib: 75%; placebo: 82%). Detailed subgroup analyses will be presented.
The risk for fever, diarrhea, bleeding events, liver toxicity, hand-foot syndrome
and rash was significantly higher in the sorafenib arm. 
Summary and Conclusions: In younger AML patients, the addition of
sorafenib to standard therapy is associated with significant EFS and RFS pro-
longation independent of FLT3-ITD status. After the current follow up, the RFS
benefit does not translate into an OS benefit, most likely due to potent salvage
strategies mainly based on SCT. Ongoing data collection on salvage treat-
ments, second CR and molecular profiling plus additional follow up will con-
tribute to further explain the mechanism of action of sorafenib in younger AML
patients.
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MONOTHERAPY TREATMENT WITH A SINGLE DOSE OF THE CXCR4
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HUMAN HSPC AND MSC; RESULTS OF A PHASE I HEALTHY
VOLUNTEERS STUDY
Y. Pereg1,* M. Abraham2, B. Bulvik2, O. Eizenberg2, R. Golan1, A. Vainstein1,
A. Aharon1, Y. Caraco3, R. Or4, A. Peled5
1BioLineRx Ltd., Jerusalem, 2Biokine Therapeutics Ltd, Ness Ziona, 3Clinical
Pharmacology Unit, 4Cancer immunotherapy and immunobiology research cen-
ter, Hadassah University Hospital, Jerusalem, 5Biokine Therapeutics Ltd and
Hebrew University Hospital, Ness Ziona, Israel
Background: Hematologic malignancies often require hematopoietic cell trans-
plantation (HCT). Randomized trials demonstrated the advantages of
hematopoietic stem/progenitor cells (HSPC) mobilized from the peripheral blood
(PB) compared to bone marrow (BM) for HCT. The most commonly used mobi-
lization regimen utilize GCSF (-/+Plerixafor), which requires 4-5 treatment
days and often involves several apheresis sessions. In addition, the graft com-
position; CD34+, mesenchymal stem cells (MSCs), NK and T cell subsets may
influence recipient outcomes in terms of engraftment, anti-tumor activity, GVHD,
morbidity and mortality. BL-8040 (BKT140) is a novel CXCR4 antagonist that
binds the receptor with high affinity and long receptor occupancy. Studies in
mice demonstrated that single BL-8040 injection mobilized long term repopu-
lating cells sufficient for transplantation. Results from a study in multiple myelo-
ma patients showed that BL-8040 when combined with G-CSF enabled the
collection of high number of CD34+cells in a single aphaeresis procedure. The
potential of BL-8040 monotherapy as a mobilizing agent and its derived graft
composition and quality is currently evaluated in a phase I clinical study in
healthy volunteers (NCT02073019). 
Aims: To test the potential of BL-8040 monotherapy as a mobilizing agent and
its derived graft composition and quality.
Methods: The first part of the study was randomized, double-blind, placebo-
controlled dose escalation. Each cohort included 8 subjects in a 6+2 design
(0.5, 0.75 and 1 mg/kg). After obtaining informed consent, BL-8040 was admin-
istered SC QD on 2 consecutive days. Frequent PB samples were tested for
the number of WBC, CD34+, B, T, and NK cells, MSC, MSC colony forming
cells and HPCs colony forming cells. In the second part, 8 subjects are receiving
single injection of BL-8040 (1mg/kg) and 4 hours later undergo a standard
leukapheresis (18 L) procedure. The composition of the collected graft is being
tested for the number of CD34+cells per kg, number and type of MSCs per kg,
number and type of T, B, NK and dendritic cells. 
Results: BL-8040 was found safe and well tolerated at all doses tested (0.5-1
mg/kg). The primary treatment related AEs were mild to moderate transient
injection site and systemic reactions. BL-8040 triggered substantial mobilization
of WBC to the circulation. The mean WBC count, of all patients receiving BL-
8040, rose from a baseline of 6.3 to 29.7 X 109/L at 4 hr post dose. Dramatic
mobilization of HSPC (CD34+cells) was observed across all doses tested. Mean
CD34+count at baseline was 5.8/µL; four hours post dose, the count rose to a
mean of 8, 37, 31 and 35 cells/µL and four hours post the second dose of BL-
8040, it further increased to 9, 38, 46 and 58 cells/µL (placebo, 0.5, 0.75 and 1
mg/kg, respectively). BL-8040 administration resulted in rapid mobilization of
MSC and HPC colony forming, T, B and NK cells. Preliminary results from the
second part of the study indicate the potential to collect sufficient amount of
CD34+cells following single apheresis session. Long receptor occupancy and
long pharmacodynamic effect (≥24 hours post dosing) were also observed.
Summary and Conclusions: The current data demonstrate that BL-8040 is
safe and well tolerated and induces rapid mobilization of HSPC and MSC.
These results support BL-8040 monotherapy as an effective strategy to shorten
the procedure length required to collect sufficient cells for HCT. In addition,
treatment with BL-8040 is expected to yield a potent hematopoietic graft with
unique cells composition and may also serve as a novel approach to collect
MSCs for diverse indications. The final study results will be presented. 
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Background: Vitamin D receptor (VDR) is expressed on activated immune cells.
Numerous preclinical studies, including models for solid organ transplantation,
have shown that vitamin D (VitD) has a potent immunomodulatory effect although,
by contrast, few reports have described an increased immune response upon
exposure to vitD. In the alloSCT setting scanty information is available although
an association between common polymorphisms of VDR and graft-versus-host
disease (GVHD) has been described. In addition, different studies have also
described the capability of vitD to induce differentiation of blasts in acute leukemia.
In spite of these properties no clinical trial has been carried out to evaluate the
role of VitD as an immunomodulatory agent after alloSCT.
Aims: Based on the potential benefit of vitD on the risk of GVHD but also con-
sidering previous studies describing an exacerbated immune response after
exposure to the drug, the main aim was to determine the safety and to assess
the effect of VitD supplementation after alloSCT on the incidence of GVHD.
Methods: We designed a multicenter prospective Phase I/II clinical trial with
three consecutive cohorts of patients (n= 50 each group), receiving no vitD
(control group, CG), 1000 IU/day po. VitD (low dose group, LDG) or 5000 IU/day
(high-dose group, GDA) from day -5 to +100 post alloSCT. In addition, we
measured plasma levels of VitD (on days -5, +1, +7, +14 and +21 after trans-
plant), of serum th1/th2 cytokines (on days +1, +7, +14, +21, +56 and +100)
and of WBC subpopulations including T cells (naive/memory/effector), activation
markers for T cells, Treg, NK cells, B cells and dendritic cells by flow cytometry
(on days +21, +56 and +100).
Results: Regarding characteristics of patients, we only observed significant
differences between the 3 subgroups in terms of age, patients in LDG being
slightly older. Calcineurin inhibitors plus methotrexate or MMF and FK506 plus
rapamycin were used as GVHD prophylaxis. No T-cell depletion was allowed
as GVHD prophylaxis. No significant differences were observed in terms of
cumulative incidence of global and grade II-IV of acute GVHD (CG= 55.9%
and 38.2%; LDG= 56.8% and 36.4% and HDG= 56.4% and 53.8%, respective-
ly). By contrast, a significantly lower cumulative incidence of chronic GVHD
(cGVHD) at 1 year was observed in LDG and HDG as compared to patients
who did not receive VitD (33.7%, 25.9% and 66.7% for LDG, HDG and CG,
respectively; p=0.04) (Figure 1). Multivariate analysis identified treatment with
VitD as the only variable which significantly decreased the risk of cGVHD
(p=0.03) (for LDG [HR=0.33, (95% CI=0.13-0.81), p=0.01] and for HDG
[HR=0.42, (95% CI=0.16-1.1), p=0.07]. No significant differences were
observed in terms of relapse or non-relapse mortality. With a median follow up
of 1 year, overall survival was 70,6%, 74.2% and 70.4% for CG, LDG and HDG,
respectively, p=0.76). Concerning the biological parameters monitored, plasma
levels of vitD were higher among patients receiving the drug as compared to
the control group, beyond day +21 (significantly for HDG). VitD modified the
immune response after alloSCT for parameters evaluated, the most significant
differences being a decreased percentage of B-cells for both LDG and HDG
(p≤0.05), a markedly modified ratio of naïve/central memory/effector T cells,
with a lower number of circulating naïve CD8 T cells for patients receiving vitD
(10.1%; 9.61%; 16%, p=0.02 for LGC, HGD and CG respectively, p≤0.025) and
a lower expression of CD40L as marker of activation upon exposure to vitD
(24.4%, 39.5% and 49%, for LGD, HGD and CG, respectively, p≤0.02). 
Figure 1.
haematologica | 2015; 100(s1) | 319
Vienna, Austria, June 11 – 14, 2015
Summary and Conclusions: This is the first prospective multicenter trial which
analyzes the effect of vitamin D administration after alloSCT. A significantly
lower incidence of cGVHD was observed among patients receiving vitD. Inter-
estingly, vitD markedly modified the immune response after alloSCT.
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Background: Allogeneic hematopoietic stem cell transplantation (HSCT) can
be curative in a subset of patients with advanced B-lineage acute lymphoblastic
leukemia (ALL), but relapse remains the main reason for treatment failure.
Donor-derived, non-specific lymphocyte infusions (DLI) have been ineffectively
infused and are associated with significant graft-versus-host-disease (GVHD).
Chimeric antigen receptor (CAR)-modified T cells directed toward CD19 have
demonstrated dramatic efficacy in patients with refractory ALL. However,
responses are often associated with life-threatening cytokine release.
Aims: We hypothesized that infusing CAR-modified, CD19-specific T cells
after HSCT as a directed DLI would be associated with less GVHD while pro-
viding cellular-based disease control, and may be associated with less cytokine
released when administered in a minimal disease state.
Methods: We employed a non-viral gene transfer using the Sleeping Beauty
(SB) transposon/transposase system to stably express a 2nd generation CD19-
specific CAR (designated CD19RCD28 that activates via CD3z/CD28) in donor-
derived T cells for patients with advanced CD19+lymphoid malignancies. T
cells were electroporated using a Nucleofector device to synchronously intro-
duce two DNA plasmids coding for SB transposon (CD19RCD28) and hyper-
active SB transposase (SB11). T cells stably expressing the CAR were retrieved
over 28 days of co-culture by recursive additions of g-irradiated activating and
propagating cells (AaPC) in presence of soluble recombinant interleukin (IL)-
2 and IL-21. The AaPC were derived from K562 cells and genetically modified
to co-express CD19 as well as the co-stimulatory molecules CD86, CD137L,
and a membrane-bound version of IL-15.
Results: To date, we have successfully treated 16 patients with advanced
CD19+ALL (n=13) or NHL (n=3); 7 patients had active disease at time of HSCT.
Donor-derived CAR+T cells (HLA-matched sibling n=9; haplo-family n=5; dou-
ble cord blood n=2) were infused at a median 64 days (range 42-91 days) fol-
lowing HSCT to prevent disease progression. Transplant preparative regimens
were myeloablative, busulfan-based (n=8) or reduced intensity, fludarabine-
based (n=8). All patients were maintained on GVHD prophylaxis at time of
CAR infusion with tacrolimus, plus mycophenolate mofeteil for cord, plus post-
HSCT cyclophosphamide for haplo donors. The starting CAR+T-cell dose was
106 (n=7), escalated to 107 (n=6), and currently at 5x107 (n=3) modified T
cells/m2 (based on recipient body surface area). Patients have not demon-
strated any acute or late toxicity to CAR+T cell infusions. Three patients devel-
oped acute grades 2-4 GVHD (liver n=1, upper GI n=1, skin=1) which was
within the expected range after allogeneic HSCT. Eight patients have relapsed
at a median of 90 days following HCT (range 68-185 days). Fifty percent of
patients (n=8) remain alive and in complete remission (CR) at median 7.2
months (range 2.1-21.3 months) following HSCT.
Summary and Conclusions: We report the first human application of the SB
and AaPC platforms to genetically modify clinical-grade cells. We demonstrate
that infusing donor-derived CD19-specific CAR+T cells in the adjuvant HSCT
setting as pre-emptive DLI may provide an effective and safe approach for
maintaining remission in patients at high risk for relapse. Modification of the
CAR construct is underway in efforts to improve CAR T-cell in vivo proliferation
and persistence. 
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Background: Invasive Aspergillosis (IA) is a life-threatening infection caused
by Aspergillus that mainly affects acute myelogenous leukemia and allogeneic
stem cell transplantation (allo-SCT) patients. Recent studies suggest that
immunomodulating single nucleotide polymorphisms (SNPs) may influence
on the risk of developing the infection.
Aims: The purpose of this study was to assess whether 36 SNPs within 14
immune-related genes (IL4, IL4R, IL8, IL8RA, IL8RB, IL10, IL12A, IL12B,
IL13, IFNg, IFNgR2, CCR5, MIF and VEGF) are associated with the risk of IA
and whether a predictive model built with these variants might help to predict
the disease risk.
Methods: We conducted a three-stage case-control association study of 742
high-risk patients, 146 of whom were diagnosed with proven or probable IA.
This is one of the largest populations recruited so far to conduct genetic asso-
ciation studies.
Tabella 1. Association of immunoregulatory polymorphisms and invasive
aspergillosis
Results: Overall, we found that the IL4Rrs2107356 and IL8rs2227307 SNPs were
associated with an increased risk of IA (P=0.007 and P=0.010, respectively)
whereas the IL12Brs3212227 and IFNgrs2069705 variants were significantly asso-
ciated with a decreased risk of developing the disease (P=0.046 and P=0.032;
Table 1). Importantly, an allogeneic stem cell transplantation (allo-SCT)-strat-
ified analysis revealed that the effect observed for the IL4Rrs2107356 and IFN-
grs2069705 SNPs was stronger in allo-SCT patients (P=0.0007 andP=0.0010,
respectively) compared with those patients without transplantation. Although
none of these associations remained significant after correction for multiple
testing (P=0.0004), the association ofIL4Rrs2107356 and IFNgrs2069705 SNPs
in allo-SCT patients remained marginally associated with the risk of IA infec-
tion. In vitro stimulation assays confirmed a relevant role of the IL4R2107356
and IL12Brs3212227SNPs in regulating IL4R and IL12 levels. We found that
CD19+B lymphocytes from carriers of theIL4R2107356A/A mutant genotype
(n=7) tended to have an increased expression of IL4R protein when compared
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with those B-cells from subjects harbouring the wild-type allele (n=7; P=0.08).
Although carriers of the IL4R2107356A/A genotype also tended to have higher
levels of IL4R in T-cells and monocytes, a substantial correlation could only
be detected in B-lymphocytes, a cell subset where IL4R is highly expressed.
We also confirmed that carriers of the IL12Brs3212227C allele showed an
increased production of IL12p70 after 24 and 48h of incubation with zymosan
alone or in combination with LPS when compared with carriers of the
IL12Brs3212227A/A genotype (IL12BMUT-ZYM-24h=44.0±8.5 vs. IL12BWT-ZYM-
24h=30.1±2.2, P=0.087 and IL12BMUT-ZYM-48h=81.9±9.4 vs. IL12BWT-ZYM-
48h=26.8±5.8, P=0.006 and IL12BWT-ZYM+LPS-24h=34.6±3.0 vs. IL12BMUT-
ZYM+LPS-24h=73.3±4.0,P=0.0017). In addition, we found that patients harbour-
ing the IL12Brs3212227C allele showed a substantially increased level of IFNg
after 48h of incubation with Zymosan when compared with those subjects har-
bouring the wild type genotype (IFNgMUT-ZYM-48h=501.4±38.1 vs. IFNgWT-ZYM-
48h=183.5±83.0, P=0.06). Finally, a predictive analysis also confirmed that a
prediction model including SNPs significantly associated with IA showed a
substantial improvement in the discriminatory ability to predict the disease
when compared with a reference model including only demographic and clin-
ical variables (AUC=0.659 vs. AUC=0.564; Figure 1).
Figure 1. Receiver operating characteristics (ROC) curve analysis.
Summary and Conclusions: These findings suggest that SNPs within
immuno-modulating genes influence on the risk of developing IA infection and
might be used to predict the disease risk and to implement risk-adapted pro-
phylaxis strategies.
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Background: High-risk Follicular Lymphoma (FL) patients intensified with high
dose therapy and autologous stem cell transplantation HDT/ASCT may achieve
prolonged remissions. The best timing for the procedure remains controversial.
Addition of rituximab to conventional chemotherapy has brought a significant
development, with several phase III randomized trials proving a benefit in favor
of a rituximab-containing chemotherapy up front. The vast majority of studies
of HDT/ASCT in FL have been performed in the pre-rituximab era, and its value
now remains to be elucidated.
Aims: To analyze the impact of previos Rituximab exposure in patients intensified
with HDT/ASCT in a retrospective study from the Spanish Geltamo Registry.
Methods: All FL patients undergoing HDT/ASCT from 1989 to 2007 and reported
to the Spanish GELTAMO registry (n=655, mean age 47 years, male sex 49,6%)
were eligible for this study. 203 patients (31%) received HDT/ASCT after
achievement of 1st CR, 43% of them requiring more than one therapy line to
achieve CR; 26% in 2ndCR, 5% in 3rdCR, 21,5% in 1stPR, 12,5% in chemo sen-
sitive recurrence, and 5% with active disease. Of the 312 cases who were evalu-
able for FLIPI, 125 (38%) were in the high-risk group. Of the 332 who were
evaluable for FLIPI II, 125 (40%) were in in the high-risk group. Of the 640
assessable for Rituximab exposure previously to ASCT, 184 (30%) had been
treated with the anti-CD20 monoclonal antibody (R+Group). Overall survival
(OS) and progression free survival (PFS) probabilities were calculated using
Kaplan-Meier estimates. The log rank test was used for univariate comparisons.
Results: Median follow-up from HDT/ASCT was 14, 5 years for the Rituximab-
naïve (R- Group) patients and 9 years for the R+Group. In the R+Group,
patients were older (P=0.01) and there were more with ECOG >1 (P=0.05),
with high LDH (P=0.02), with poor risk FLIPI II (P=0.05) and had a shorter
length of follow-up (P<0.0001). In patients transplanted in 1st CR, there were
more patients who received more than one line of therapy to reach CR in the
R+Group (P=0.02). Globally, R+Group showed a better outcome than R-Group
(median PFS not reached vs 74 months (P=0.0006); median OS not reached
vs 221 months, respectively; (P=0, 02)). For patients transplanted in 2nd/3rd
CR the benefit of Rituximab was remarkable: median PFS not reached vs 92
months (P=0.002); OS at 5 years 91%, OS at 10 years 86%, in the R+Group
vs OS at 5 years 76%, OS at 10 years 63% for the R- Group, respectively
(P=0.01). Surprisingly this benefit did not occur in patients transplanted in 1st
CR, where R- patients showed even a better outcome (no statistically differ-
ences on PFS and OS at 5 years 91% vs 83%, OS at 10 years 84% vs 72%
for the R- Group and R+Group, respectively;(P=0.02)).
Figure 1.
Summary and Conclusions: Follicular lymphoma patients undergoing
HDT/ASCT in 2nd / 3rd CR have a formidable outcome; treatment with rituximab
seems to have a synergistic effect with HDT/ASCT in this population. R+Group
transplanted in 1st CR, showed an excellent outcome, however it was no better
than the obtained in R- Group. Worse initial prognostic factors in the R+Group,
with more patients needing more than one line of therapy to reach the CR,
could explain these data. In the Rituximab era, HDT/ ASCT should be consid-
ered in the therapeutic approach at first relapse for FL patients. Very high risk
patients could, as well, benefit from a transplant in 1st CR. As well-balanced
randomized studies are not easily feasible in this setting, we think that updating
the results of the available studies could elucidate this question.
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Progess in Hodgkin lymphoma therapy: Incorporation
of novel agents and reduction of side effects
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Background: About 30% of all Hodgkin Lymphoma (HL) patients are ≥60 years
old. ABVD is standard of care for these patients, although outcome and feasi-
bility are poor, one limitation being bleomycin-induced pulmonary toxicity. 
Aims: We thus replaced bleomycin with lenalidomide (Revlimid®), and initiated
the AVD-Rev phase-I trial (NCT01569204) for 60-75 year-old patients with 1st
diagnosis of early unfavorable- or advanced-stage HL, good performance sta-
tus (ECOG/WHO ≤2), and no severe organ dysfunction.
Methods: Depending on stage and response at interim staging, patients
received 4-8 cycles of AVD-Rev followed by radiotherapy with prophylactic
anticoagulation (ASA or heparin). The daily lenalidomide dose for the first
patient was 5mg; possible dose levels ranged from 5 to 40mg. Thromboem-
bolism ≥CTC II°, hematological toxicity as severe cytopenia (ANC<500/μl
>7days with G-CSF and thrombocytopenia <25.000/μl), and complications as
neutropenic fever and prolonged therapy delay were considered as dose lim-
iting toxicities (DLT) if they occurred during the first 4 cycles.
Results: 25 patients (median age: 67, range 61-76) and a CIRS-G comorbidity
score of up to 7 points (range 0-7) were assigned to dose levels 5mg (n=1),
10mg (n=1), 15mg (n=1), 20mg (n=6), and 25mg (n=16). 15 patients were
male, 68% had advanced stage-HL, and 80% had B-symptoms. After DLT
evaluation of 20 patients, a pre-specified stopping criterion was reached with
a recommended dose for a phase II trial of 25mg. Dose delivery was high
with a median relative dose intensity of 97% (range 49%>104%; mean 91%).
However, CTC III°-IV° toxicities occurred in all 22 patients treated at the 20mg
and 25mg dose levels. DLTs were observed in 1 of 6 and 5 of 16 patients at
20mg and 25mg, respectively, and were mainly hematologic but included 3
thromboembolic events despite ASA prophylaxis. No DLT occurred in patients
receiving <20mg lenalidomide. Of note in these vulnerable patients, no treat-
ment related deaths occurred. Overall response rates were 80% for all patients
(20/25) and 86% (19/22) for patients receiving ≥20mg lenalidomide. At 19
months median observation time, 5 patients had disease progression and 4
patients died. The one-year estimates for progression-free (PFS) and overall
survival (OS) are 75% [95%>CI: 53-88%] and 92% [95%>CI: 71-98%], respec-
tively. Final results on PFS and OS with two years follow-up will be presented
at the EHA congress 2015.
Summary and Conclusions: AVD-Rev is toxic but feasible and highly effec-
tive in this vulnerable population of elderly HL patients. 
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Background: Salvage chemotherapy followed by high dose chemotherapy
with autologous stem cell transplant (ASCT) is the standard of care for refrac-
tory/relapsed Hodgkin’s lymphoma (HL r/r), leading to durable responses in
approximately 50% of relapsed patients. The pre-transplantation achievement
of CR is the strongest prognostic factor in this setting. The combination of
gemcitabine and vinorelbine and ifosfamide (IGEV) demonstrated to be an
highly active salvage regimen, with a high CR rate (48%) and low toxic profile.
Bendamustine, as single agent, has been reported to induce objective
responses in an high percentage of pts with HL recurring after autologous
stem cell transplant (ASCT).
Aims: This study has been conducted with the aim of improving the CR rate
of induction salvage chemotherapy in comparison to historical IGEV data by
combining Bendamustine with Gemcitabine and Vinorelbine (BeGEV).
Methods: This was a Fleming’s single-stage phase II multi-centric trial in HL
r/r patients before ASCT. Aim of the study was to assess the activity of BeGEV
in term of CR rate. Assuming an improvement of 15% (50 to 65%), with a
10% rejection error and a power of 85%, at least 35 CR out of 59 patients had
to be observed. Secondary end points were overall response, cell mobilization,
toxicity, progression free survival (PFS) and overall survival (OS). Patients
were eligible if they had relapsed or refractory classic HL after first line
chemotherapy. The treatment schedule was: Bendamustine (90 mg/sqm, days
2-3), Gemcitabine (800 mg/sqm, day 1 and 4) and Vinorelbine (25 mg/sqm,
day) every 3 weeks for a total of 4 courses.
Results: Between August 2011 and March 2014, 59 consecutive patients with
relapsed (45.8%) or refractory (54.2%) HL were enrolled. The median age
was 33 years (range 18-68). Out of 59 enrolled patients, 43 (72.9%) achieved
a CR, 6 (10.2%) a partial response (PR) for an overall response rate of 83.1%.
The remaining 10/59 patients (16.9 %) were evaluated as non responders
for: 1 (1.7%) stable disease, 8 (13.6 %), PD, 1 (1.7 %) toxicity. Adequate
CD34+cell collection was achieved in 55 out of 57 (96.5%) mobilized patients.
Considering the 49 responsive patients, 42 proceeded to ASCT (37/43 in CR,
5/6 in PR). The remaining 7 patients did not proceed to ASCT due failed mobi-
lization (2 cases), allogenic transplant (1 case), physician’s decision (2 cases),
early relapse (1 case), and patient refusal (1 case). With a median follow up
of 16 months, the PFS and OS at 2 years were respectively 50.9% and 68.8%
for all series, without significant difference among relapsed and refractory
patients. The 2-year PFS for the 49 responsive pts was 61% for CR and 63%
for CR+PR, respectively. The 2-year OS reached 85.5% for CR+PR vs 14.3%
induction failures (p value <0.001). Hematological and non-hematological side
effects were acceptable. Out of 204 evaluated cycles, 23 (11%) had to be
delayed and 4 (2%) reduced, respectively; only 1 patient stopped therapy for
toxicity. Three non-hematologic G4 toxicity (2 infection and 1 hepatic failure
unlikely related to treatment), were observed. No toxic death occurred. 
Summary and Conclusions: The BeGEV regiment achieved a CR (72.9%)
and overall response rate (83.1 %) overcoming the expected results. The
study highlights the activity of this combination as well as the good toxicity
profile and the high mobilizing potential. These data provide strong support
for further development of BeGEV.
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Background: In the phase 3, randomized, placebo-controlled AETHERA trial,
progression-free survival (PFS) was significantly improved with brentuximab
vedotin (BV) vs placebo (HR=0·57, P=0·001) in Hodgkin lymphoma (HL)
patients at risk of progression post-autologous stem cell transplant (ASCT). 
Aims: A multivariate analysis was performed to determine which factors sig-
nificantly influence PFS by investigator assessment.
Methods: After ASCT, 329 patients were randomized to receive BV 1.8 mg/kg
q3wk (n=165) or placebo (n=164) for up to 16 cycles. The primary endpoint
was PFS per independent review. Multivariate analysis using a Cox-propor-
tional hazards model was developed on the following factors: treatment, age,
sex, weight, geographical region, initial disease stage, time from diagnosis,
no. of treatments pre-ASCT, chemosensitivity, response to frontline (FL) and
salvage, type of FL therapy, prior radiotherapy, extranodal disease pre-ASCT,
ASCT conditioning regimen, B symptoms at pre-ASCT relapse, number of
risk factors, baseline ECOG, baseline lesions, and pre-existing peripheral
neuropathy. Significant factors (p<0.05) were determined after a stepwise
addition and elimination of nonsignificant factors from the model. 
Results: Multivariate modeling indicated that factors significantly associated
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with PFS by investigator assessment included: treatment (BV vs. placebo),
salvage response, gender, number of treatments pre-ASCT, type of FL therapy,
B symptoms pre-ASCT, and weight (see Table).
Tabella 1. Multivariate analyses of PFS by investigator assessment.
Summary and Conclusions: After adjustment for significant clinical factors
in a multivariate regression analysis, consolidation treatment with BV signifi-
cantly reduced the risk of treatment failure compared to placebo with a HR of
0.44. These results support the primary analysis.
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Background: The PD-1 pathway functions as a checkpoint which limits T-cell
mediated tumor immune responses. Nivolumab (NIVO), a fully human IgG4
monoclonal PD-1 blocking antibody, potentiates T-cell activity. Prior results
from this study (median follow-up 40 weeks) showed that NIVO was tolerated
and achieved an overall response rate of 87% in classical Hodgkin lymphoma
(cHL), 40% in follicular B-cell lymphoma (FBL), 36% in diffuse large B-cell
lymphoma (DLBCL) and 17% in T-cell non-Hodgkin lymphoma (T-NHL). The
stable disease rate in multiple myeloma (MM) was 67%.
Aims: Herein, we report the updated follow-up and safety profile of this study.
Methods: Patients (Pts) were treated using a dose-escalation design (1 and
3 mg/kg) of NIVO administered every 2 weeks (wks) for 2 years. Responses
were assessed using standard criteria. Primary endpoint was safety. The sec-
ondary endpoint was efficacy.
Results: 105 pts were enrolled (23 cHL, 31 B-NHL, 23 T-NHL, 27 MM and 1
chronic myelogenous leukemia). Pts were heavily pretreated with 88%, 78%,
68% and 66% of pts with cHL, T-NHL, B-NHL and MM, respectively, having
received ≥3 prior regimens. Previous ASCT was reported for 75% of pts with
cHL, 56% of MM, 13% of B-NHL and 9% of T-NHL. As of 1/8/2015, median
duration of follow-up was 62 wks (range: 2 to 106+wks). Drug-related adverse
events (DrAEs) occurred in 71 (67%) pts. The most common DrAEs occurring
in ≥5% were fatigue (15%), rash (11%), diarrhea, pneumonitis, pruritus (each
9%), pyrexia (8%), thrombocytopenia, decreased appetite (each 7%), hypocal-
cemia, lipase increased, leukopenia, lymphopenia (each 6%) and nausea
(5%). Serious DrAE in ≥5% of pts included pneumonitis (5%). Efficacy results
shown below. The rate of stable disease in MM (n=27) was 63%. Among the
20 responding cHL pts, 10 discontinued NIVO; 6 (1CR and 5 PR) to undergo
SCT, 3 for disease progression and 1 for toxicity (MDS, thrombocytopenia)
and 10 (7 PR and 3 CR) continue to respond. Among responding B- and T-
NHL pts, 1/4 DLBCL, 3/4 FL and 3/4 T-NHL pts remain in response. In this
updated analysis, median duration of response has not been reached in cHL,
B-NHL and T-NHL.
Tabella 1. Multivariate analyses of PFS by investigator assessment.
Summary and Conclusions: Encouraging, durable objective responses were
observed in cHL, DLBCL and FL, including CR and PR. NIVO treatment remains
safe and tolerable with a safety profile similar to that in solid tumors, and further
analysis is warranted in cHL and selected B-NHLs and T-NHLs.
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Background: Bleomycin induced pulmonary toxicity occurs in 20-46% of
Hodgkin lymphoma (HL) patients, treated with ABVD (doxorubicin, bleomycin,
vinblastin, dacarbasine) regimen. Bleomycin hydrolase (BLMH), an enzyme
that inactivates bleomycin, may be a potential candidate that influences pul-
monary function. Single nucleotide polymorphisms (SNP) of the BLMH gene
have been investigated previously in testicular germ-cell cancer (TC) patients
in parallel to survival data. Interestingly, homo- and heterozygous variants of
BLMH gene SNP A1450G were found to significantly affect survival of TC
patients. Yet, there is no available data of BLMH SNPs and bleomycin induced
pulmonary toxicity in correlation with HL patients.
Aims: We hypothesized, that BLMH gene SNP A1450G (rs1050565) influences
BLMH activity and by an altered metabolism of bleomycin, differences could
be seen at the risk of bleomycin induced toxicity appearance. 
Methods: Pulmonary functions of previously treated HL patients have been
collected by using St. George Respiratory Questionnaire (SGRQ), dynamic
inhalation lung scintigraphy and spirometry at the Department of Hematology,
University of Debrecen, retrospectively. After informed consent of these patients
genomic DNA was isolated from peripheral blood samples and TaqMan geno-
typing assay was used to determine genotype distribution. Local Research
Ethics Committee approved this investigation.
Results: A total of 131 patient samples have been collected of previously treat-
ed HL patients, with a median age of 29 years (14-73), median time elapsed
since treatment completion was 11 years (1-44). Genotype frequency was found
as follows: A/A 55.0%, A/G 33.6%, G/G 11.5%, where A is the wild allele (71.8%)
and G is the mutated allele (28.2%). Our results are comparable to the NCBI
SNP database for SNP A1450G. Patients were subdivided into subgroups con-
taining the mutated allele: A/G+G/G (45.1%) and those homogenous for the
wild allele: A/A (55.0%). All bleomycin treated patients (n=102) had more favor-
able lung function test result in the wild A/A genotype group, with significant dif-
ference in the forced vital capacity results (FVC), p=0.041. When narrowing
patients to those who received only ABVD regimen (n=68), significantly more
favorable results were seen in the wild A/A genotype group with every investi-
gated test method (SGRQ score: p=0.035, lung scintigraphy results: p=0.045,
spirometry results: FVC: p=0.020; forced expiratory volume in 1 s (FEV1):
p=0.028). Univariate analysis also confirmed these results. As control group
(n=29), patients treated with agents excluding bleomycin were tested with no
significant differences between the A/G+G/G and A/A groups. Other factors
(smoking, age, bleomycin dose, chest irradiation, kidney function, use of colony
stimulating factors) that could potentially affect lung function were equally rep-
resented in all investigated subgroups.
Summary and Conclusions: BLMH gene polymorphism significantly distin-
guished in retrospective pulmonary test results of ABVD treated patients. Based
on these results prospective trials could be designed to further evaluate its role
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in pulmonary toxicity of treating HL, and thus treatment could be adjusted indi-
vidually. One of its potential roles could be to identify those cases even in the
frontline setting, where brentuximab vedotin should be administered instead
of bleomycin, either in the standard care or considering expense issues.
Patients with multiple risk factors for lung toxicity should be particularly consid-
ered for this test method. Eventually, life expectancy and quality of life of HL
patients wouldn’t remarkably differ from the untreated healthy population.
CML: Molecular-cytogenetic diagnostics
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Background: Imatinib mesylate (IM) has been for many years the standard of
care for chronic myeloid leukemia (CML) in early chronic phase (CP). As first-
line treatment, IM produce high probability of long-term survival, but few patients
are able to achieve a stable deep molecular response (MR4.0 or better), that is
a pre-requisite to discontinue the TKI treatment. The treatment-free remission
(TFR) is an emerging CML treatment goal. The identification of patients with
higher probability of achieving a stable deep molecular response is important
for the optimization of treatment strategy.
Aims: The aim of the present study was to investigate the predictors of MR4.0
in CML patients treated frontline with imatinib.
Methods: We analyzed 559 patients enrolled within 3 multicentric prospective
studies conducted by the GIMEMA CML WP (NCT00514488, NCT00510926,
observational trial CML023). Definitions: major molecular response (MMR), BCR-
ABLIS ratio <0.1%; deep molecular response (MR4.0), detectable disease ≤0.01%
BCR-ABLIS or undetectable disease with ≥10,000 ABL transcripts; stable MR4.0:
MR4.0 lasting ≥24 months and ≥3 evaluable samples; unstable MR4.0: uncon-
firmed occasional positive samples <0.1% BCR-ABLIS in patients with a stable
MR4.0 (Rousselot et al. J Clin Oncol 2014). The intention-to-treat population of
each study was analyzed and all the 559 enrolled patients were included.
Results: Baseline demographics characteristics: median age, 52 years
(extremes 18-84 years); male/female sex, 60%/40%; high Sokal, high Euro
and high EUTOS scores, 22%, 7% and 7%, respectively; clonal chromosomal
abnormalities (CCA) in Ph+cells, 4% (not evaluable in 32% of patients for insuf-
ficient number of metaphases); e13a2 BCR-ABL transcript, 36%. The median
follow-up was 82 (60-105) months. The median time to MMR and MR4 was 8
and 42 months, respectively. The rate of MR4.0 at 24, 36, 48 and 60 months
was 18%, 27%, 30% and 33%, respectively. Overall, 61% of patients achieved
a MR4.0 at least once. According to the previously detailed criteria, at the last
contact 28% of patients had a stable MR4.0 and 12% had an unstable MR4.0
(stable+unstable MR4.0=40%). The median duration of stable MR4.0 was 36
months and the median duration of stable+unstable MR4.0 was 40 months. In
a multivariate Cox analysis including baseline variables, female sex, smaller
spleen size and e14a2 transcript type resulted independent good prognostic
factors on the probability to achieve a MR4.0. Female sex was the only baseline
variable able to predict a stable MR4.0. The reduction of BCR-ABL1 transcript
levels and the time to molecular response are influenced by baseline variables,
so the impact of the dynamics of molecular response on the probability of MR4.0
was analyzed separately: the time to MMR strongly predicted both the achieve-
ment and the stability of MR4.0.
Summary and Conclusions: As suggested by a previous report (Branford et
al. Blood 2013), in a large nationwide multicentric experience, the female sex
was confirmed as a predictor of the achievement of a stable deep molecular
response. Moreover, our results support strategies aimed to a rapid reduction
of BCR-ABL1 transcript levels to optimize potential suitability for imatinib dis-
continuation studies.
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Background: After the clinical success of TKIs in treating patients with CML,
the clinical management of these patients became the core of patient care. RT-
qPCR is the current gold standard for monitoring patients’ response to therapy.
Transcript levels are prognostic and capable of stratifying the patients in to risk
groups as early as 3 month after therapy induction. Several molecular milestone
have been introduced based on the log reduction of the transcript levels in
response to therapy. Optimal response has been defined by the recently revised
ELN guidelines as BCR-ABL1 levels to be ≤10% by 3 month, <1% by 6 month,
≤0.1% by 12 month then ≤0.1% at any time. However, these percentages huge-
ly vary from one centre to the other due to inherent limitations introduced by
the gold standard method of quantification, unless expressed on the Interna-
tional scale. Recently, dPCR has been introduced as a method of quantification
that promises simplified assay standardisation procedures mainly for being a
method of absolute quantification as opposed to the relative quantification
ascribed to the gold standard. In this study, we sought to optimize the use of
such a platform, the QS3D, for our routine practice in addition to a performance
comparison study with other dPCR platforms.
Aims: In this study, we sought to optimize the use of the dPCR platform, the
QS3D, for our routine practice in addition to a performance comparison study with
other widely used dPCR platforms, namely the Bio-Rad QX200 and RainDance.
Methods: For validating the EAC assay on the QS3D dPCR, we used the ref-
erence ERM-AD623 plasmid to assess the linearity metric of the platform by
running a series of dilutions that fell within, below and above the sweet spot of
the chip used. To assess the bias introduced to our measurements of BCR-
ABL1 transcript ratios in patient material using our in-house generated Wessex
plasmid, we ran a series of dilutions using the Wessex plasmid and compared
it against the reference plasmid. To assess the limit of detection, we ran 6 cat-
egories of patient material at different disease ranges on the IS: 20%, 10%, 1%,
0.1%, 0.01%, and 0.001% (10 samples per category). These 60 patient material
were also ran on the two other platform for comparing their performances.
Results: Linearity was maintained within the sweet spot and down to 3 mole-
cules per chip. Inte and intra experimental variations were insignificant indicat-
ing excellent reproducibility (p=0.2). Linearity above the sweet spot was main-
tained, However a systematic underestimation was observed (p=0.05). There
was a systematic bias introduce using out in-hour plasmid (p=0.001), and this
bias was factored into the quantification of the cNDA molecules collected form
the patients’ samples. The limit of detection of the platform was concordant
with that of the gold standard down to 0.1% IS (p=0.2); however dPCR demon-
strated better precision in quantifying molecules in samples at the 0.01% IS
level (p=0.07), and had improved sensitivity and precision in quantifying mole-
cules in samples at the 0.001% IS level (p=0.06). Platform comparison showed
reassuring concordance in sensitivity at all levels (p=0.16-0.4). 
Figure 1.
Summary and Conclusions: In conclusion, our investigations demonstrate
that the QS3D digital PCR platform demonstrates performance characteristics
to favour its implementation in routine clinical use with a one log increased limit
of detection compared to the gold standard.
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Background: Major route additional cytogenetic aberrations (ACA) at diagnosis
of chronic myeloid leukemia (CML) indicate an increased risk of progression and
shorter survival. Since all major route ACA are unbalanced it is unclear whether
other unbalanced ACA at diagnosis also confer an unfavourable prognosis.
Aims: Since major route ACA are unbalanced aberrations and since patients
with minor route ACA may also progress, the question arose whether a more
generally defined group of chromosomal abnormalities such as unbalanced
aberrations rather than only the specific major route ACA indicate progression.
Methods: On the basis of 1348 Philadelphia (Ph) chromosome positive chronic
phase patients of the randomized CML-study IV we examined the impact of
unbalanced minor route ACA at diagnosis in comparison to major route ACA
on prognosis. Cytogenetic analyses of at least 20 Giemsa(G)-banded or
Reverse(R)-banded bone marrow metaphases at diagnosis were interpreted
according to the International System for Human Cytogenetic Nomenclature
(2013). Patients with cytogenetic aberrations in Ph-negative clones at diagnosis
were excluded from this analysis. Patients with constitutional changes were
assigned to the group with standard translocation t(9;22)(q34;q11) or variant
translocation t(v;22). In patients showing a complex aberrant karyotype G- or
R-banding analysis was combined with m-FISH analysis. Cytogenetic remission
was defined according to the ELN recommendations. Progression-free survival
(PFS) was defined as the time from diagnosis until the beginning of accelerated
phase, blast crisis, or death from any cause whatever event came first. For
overall survival (OS), death from any cause was the only event. Probabilities
of PFS and OS were calculated by the Kaplan-Meier method and compared by
the log-rank test. Patients were censored at the date of last follow-up. P-values
lower than 5% were considered significant. Due to the explorative character of
this work, no adjustment of p-values was done and all p-values have to be
interpreted descriptively.
Results: At diagnosis, 1175 patients (87%) had a translocation t(9;22)(q34;q11)
and 74 (5.5%) a variant translocation t(v;22) only, while a loss of the Y-chromo-
some (-Y) was present in addition in 44 (3.3%), balanced or unbalanced minor
route ACA each in 17 (1.3% each) cases and major route ACA in 21 (1.6%)
cases. Patients with unbalanced minor route ACA achieved complete cytoge-
netic remission, major molecular remission, PFS and OS at similar rates as did
patients with t(9;22), t(v;22), -Y, and balanced minor route karyotypes. In con-
trast, patients with major route ACA had a shorter OS and PFS than all other
groups (p<0.005 for all pairwise comparisons with major route). Five year sur-
vival probabilities were for t(9;22): 91.4% (95% CI 89.5-93.1), t(v; 22): 87%
(77.2-94.3), -Y: 89.0% (76.7-97.0), balanced: 100%, unbalanced minor route:
92.3% (72.4-100), major route: 52.2% (28.2-75.5).
Summary and Conclusions: We conclude that only major route, but not unbal-
anced minor route ACA at diagnosis have a negative impact on prognosis of
CML. This observation may be of relevance also to other cancers.
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SECOND GENERATION TYROSINE KINASE INHIBITORS MITIGATE THE
HIGH RISK OF DISEASE PROGRESSION IN CHRONIC MYELOID
LEUKAEMIA PATIENTS WITH HIGH DIAGNOSTIC LEVELS OF CIP2A 
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Background: CML treatment has been significantly improved by the tyrosine
kinase inhibitor (TKI) imatinib, but at least one-third of patients will eventually
fail imatinib treatment2,3 and a significant proportion of these will progress
towards blast crisis (BC), which is usually rapidly fatal. Suppression of PP2A
activity by the inhibitors SET and CIP2A is important in the pathogenesis and
progression of chronic myeloid leukaemia (CML). We have previously shown
that CML patients with a high diagnostic CIP2A protein level who then receive
imatinib have a high risk of progressing to blast crisis.
Aims: The aim of this study was to investigate if high CIP2A also confers a
high progression rate in patients receiving a second generation (2G) TKI dasa-
tinib or nilotinib from diagnosis.
Methods: The diagnostic CIP2A protein level was assessed by flow cytometry
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in 74 newly diagnosed chronic phase patients, who were subsequently treated
with either imatinib or a 2G TKI. ROC analysis was used to define a CIP2A cut
off level to stratify cases into high and low CIP2A groups. All have been seen
since original diagnosis of chronic phase CML at our centre and have been fol-
lowed for at least 9 months (median follow-up: 50 months).
Results: For patients with high diagnostic CIP2A level treated with imatinib,
the overall and progression-free survival probability at 24 months was 41%
and 17% respectively, compared to 100% for patients in any other group
(p<0.001, Figure 1). Disease progression to blast crisis only occurred in those
patients with a high diagnostic level of CIP2A and treated with imatinib. All pro-
gressions occurred within 32 months from diagnosis with the median time to
progression being 12.5 months and disease progression was not associated
with the development of BCR-ABL kinase domain mutations. The cumulative
complete cytogenetic response (CCR) rate for low CIP2A level imatinib treated
patients was 85% at 18 months. In contrast, only a single patient with a high
diagnostic CIP2A level achieved CCR (cumulative CCR rate of 9% at 18
months; p<0.001); this patient subsequently progressed. This deleterious effect
of high CIP2A was not seen if patients were treated with a 2G TKI from diag-
nosis, where the estimated cumulative CCR rate at 18 months was 86% and
56% for the low and high CIP2A 2G TKI patients respectively. The cumulative
rate of MR4 (BCR-ABL1/ABL transcript ratio of ≤0.01%) for low CIP2A imatinib
treated patients was 16% at 18 months. No patient with a high diagnostic CIP2A
level and treated with imatinib achieved MR4 (p=0.001). High CIP2A patients
treated with a 2G TKI have a lower rate of MR4 compared to low CIP2A 2G
TKI treated patients, 11% and 48% respectively. High diagnostic CIP2A levels
in patients treated with a 2G TKI predicts for poor molecular response. Early
molecular response (EMR, BCR-ABL1/ABL ratio of <10% at 3 months) is an
excellent predictor of clinical outcome in imatinib treated patients. 55% of ima-
tinib treated low CIP2A patients achieved an EMR, compared to only 9% of
high CIP2A patients (p=0.01). 90% of low CIP2A patients treated with a 2G
TKI achieved an EMR compared to 44% of those with a high CIP2A level.
Figure 1. High CIP2A expressing patients do not progress if treated with
a second generation TKI. All 74 patients involved in the study are included
in the Kaplan-Meier estimate of progression free survival plots. The Log
rank was used.
Summary and Conclusions: In summary, patients with high diagnostic CIP2A
levels and treated with a 2G TKI at initial diagnosis do not progress to BC, sug-
gesting that if a patient has a high CIP2A level at diagnosis then they should
not be treated with imatinib due to the high risk of disease progression. A high
diagnostic level of CIP2A in patients treated with a 2G TKI can predict an
inferior deep molecular response. There is therefore now a case for routine
CIP2A testing at diagnosis. Further study to determine the true incidence of
high CIP2A patients in the general CML population is needed.
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Background: Point mutations in the BCR-ABL kinase domain are the most
frequently identified mechanisms of acquired resistance towards tyrosine
kinase inhibitors in chronic myeloid leukemia (CML). Although Sanger sequenc-
ing is still regarded as the gold standard technique for routine BCR-ABL muta-
tion screening, next-generation sequencing (NGS) has evolved rapidly and is
accessible to an increasing number of diagnostic laboratories. Thus far, data
is limited on the technical performance of NGS for BCR-ABL mutation screening
in a clinical diagnostic setting.
Aims: As an international consortium of 11 laboratories in 7 countries, we
sought to investigate the robustness, precision, and reproducibility of NGS for
BCR-ABL mutation analysis. The study was conducted as a subproject within
the Interlaboratory Robustness of Next-generation sequencing (IRON)-II study.
Methods: Optimized PCR protocols and preconfigured 96-well plates contain-
ing lyophilized primer pairs targeting the entire BCR-ABL kinase domain were
generated and distributed to each participating laboratory. To evaluate per-
formance, 22 blinded control samples were sent to each laboratory (a total of
242 samples). Seventeen control samples contained cDNA of Ba/F3BCR-ABL
cell lines harboring 12 different BCR-ABL kinase domain mutations that were
mixed with non-mutated Ba/F3BCR-ABL to produce dilutions ranging from 1%
to 100% of mutant alleles. Five control samples contained cDNA of non-mutat-
ed Ba/F3BCR-ABL. All control samples were diluted into HL60 cells to simulate
a BCR-ABL level of 10% on the International Scale. NGS was performed on
454 GS Junior sequencing instruments using 454 GS Junior Titanium chemistry
for amplicon sequencing.
Results: Overall, a median of 104,732 high quality sequencing reads were
generated across each of the 11 laboratories, where the number of sequenc-
ing reads ranged from 11,307 to 185,775. The mean read length obtained in
all runs was 356 bases (range, 346 to 363), indicating a homogenous read
length pattern across all centers. A combined number of % mixed and % dots
filtered reads of less than 10% on average indicated a robust performance
for each emulsion PCR (emPCR) reaction in this study. Concerning mutation
analysis, 203 of 242 samples (84%) were evaluated correctly. Hereby, 9 lab-
oratories showed an excellent performance with correct identification of 21
(2 laboratories), 20 (2 laboratories) and 19 (5 laboratories) of the 22 control
samples including novel artificial variants (e.g. E282K) and five low-level
mutations with less than 20% mutant alleles. The concordance of mutation
quantification was high in all laboratories. All non-mutated control samples
were reported correctly. The 1% T315I mutation dilution was not identified in
any laboratory, a 5% M244V mutation was not detected in 7, and a 1% F311L
mutation was not detected in 5 laboratories. Two laboratories failed to test 9
of the 22 control samples correctly, thereby reporting both false positive and
false negative results.
Summary and Conclusions: This multicenter analysis demonstrated that
amplicon-based deep sequencing is technically feasible, achieves a high con-
cordance across multiple laboratories and allows a broad and in-depth char-
acterization of BCR-ABL mutations in CML. However, data also illustrates that
expertise in NGS performance and characterization of BCR-ABL mutations is
advantageous and necessarily required for the report of accurate results.
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IDENTIFICATION OF FIP1L1-PDGFRA ASSOCIATING MOLECULE THAT
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FIP1L1-PDGFRA
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Background: FIP1L1-PDGFRA is a fusion tyrosine kinase that plays a patho-
genic role in chronic eosinophilic leukemia. This fusion kinase is constitutively
active and its kinase activity is essential for the development of chronic
eosinophilic leukemia. Therefore, a tyrosine kinase inhibitor, imatinib, is used
to treat FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Although the
C-terminal kinase portion of FIP1L1-PDGFRA is essential for activation of down-
stream substrates, the N-terminal FIP1L1 portion also plays a crucial role in
cellular transformation. We have reported that the FIP1L1 portion directs
FIP1L1-PDGFRA into the nucleus and is necessary for the higher proliferating
activity (Iwasaki et al.Ann Hematol. 93:1473-81, 2014). However, little is known
about the transforming pathway mediated by the FIP1L1 portion.
Aims: We tried to isolate a molecule interacting with FIP1L1-PDGFRA to elu-
cidate the leukemogenic role of the FIP1L1 portion. 
Methods: Yeast two-hybrid screening was performed, where FIP1L1-PDGFRA
was used as bait. One of the positive clones encoded Protein inhibitor of acti-
vated STAT1 (PIAS1). Expression vectors of FIP1L1-PDGFRA and PIAS1 were
constructed. Immunoprecipitation/immunoblotting analysis was performed to
analyze the association of two molecules. Immunostaining was also performed
to examine the intracellular localization of these molecules. In addition, a series
of biochemical analysis was performed to analyze pathological significance of
this association. Moreover, we established cells stably expressing FIP1L1-
PDGFRA. Using this cell line, we analyzed whether PIAS1 contributes the
FIP1L1-PDGFRA-dependent growth.
Results: PIAS1 was isolated as a FIP1L1-PDGFRA associating molecule by
yeast two-hybrid screening. The association between two molecules was con-
firmed by immunoprecipitation/immunoblotting analysis. In addition, FIP1L1-
PDGFRA associated with PIAS1 via the FIP1L1 portion. An immunostaining
analysis revealed that FIP1L1-PDGFRA and PIAS1 co-localized in the nucleus.
FIP1L1-PDGFRA, as a tyrosine kinase, and PIAS1, as a SUMO E3 ligase, cat-
alyzed each other, and this enzymatic catalysis resulted in the stabilization of
each molecule. Therefore, inhibition of PIAS1 activity by PIAS1-specific siRNA
or a sumoylation inhibitor, ginkgolic acid, resulted in the destabilization of
FIP1L1-PDGFRA. Ginkgolic acid and imatinib synergistically inhibit the kinase
activity of FIP1L1-PDGFRA.
Summary and Conclusions: Our results revealed a novel pathway in the patho-
genesis of chronic eosinophilic leukemia, where FIP1L1-PDGFRA associates with
PIAS1 in the nucleus. The interaction of two molecules seems to be crucial for the
pathogenesis of chronic eosinophilic leukemia. Moreover, sumoylation system
could be a potential target in the treatment of chronic eosinophilic leukemia.
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THE THROMBOPOIETIN RECEPTOR SUPPORTS PROLONGED JAK2
V617F DIMERIZATION AND ACTIVATION AND IS MORE SENSITIVE TO
LOW JAK2 V617F LEVELS DUE TO LONG HALF-LIFE WHEN COMPARED
TO EPOR AND G-CSFR 
V. Gryshkova1,* T. Balligand1, S. Najjar1, S.N. Constantinescu1
1Ludwig Institute for Cancer Research, Université catholique de Louvain, de
Duve Institute, Brussels, Belgium
Background: The activating mutation V617F in the pseudokinase domain of
JAK2 is prevalent in myeloproliferative neoplasms (MPN) such as Polycythemia
Vera (PV), Essential Thrombocytosis (ET) and Myelofibrosis (MF). Low JAK2
V617F allele burdens in ET together with evidence from transgenic and retro-
viral mouse models established that low expression of mutated kinase specif-
ically associates with an ET phenotype. The mechanism for this effect and how
this single mutation promotes three distinct diseases still remains elusive.
Aims: Our aim was to investigate the differences in the interaction between
JAK2 V617F and dimeric cytokine receptors for thrombopoietin (Tpo), erythro-
poietin (Epo) or granulocyte-colony stimulating factor (G-CSF) and to assess
biochemical reasons to any possible distinctions in these interactions. 
Methods:Gaussia princeps luciferase protein-fragment complementation was
utilized to study interaction between JAK2 V617F and the cytokine receptors
as well as dimerization of JAK2 V617F kinase co-expressed with these recep-
tors. Signaling assays in transiently transfected HEK293 and γ2A cells as well
as stably transduced Ba/F3 cells were used to validate the results of protein-
fragment complementation assay.
Results: We have shown stronger interaction between JAK2 V617F and TpoR
compared to EpoR or GCSFR at gradually decreasing dosages of the JAK2
V617F. Also, dimerization of JAK2 V617F appeared to be higher in presence of
TpoR compared to other receptors tested. Interaction of the JAK2 V617F kinase
with the cytokine receptors and its dimerization correlated with the half-lives of
the receptors. The more stable TpoR supported prolonged JAK2 V617F and
STAT5 activation compared to the less stable receptors EpoR or GCSFR. We
have identified the intracellular domain in these receptors responsible for the
distinction in their half-lives and made a shorter-lived TpoR and a longer-lived
EpoR mutant by adding or removing a lysine, which triggers ubiquitination and
degradation. As expected, the stability of the receptors was crucial for inducing
pathologic signaling from JAK2 V617F with the less stable TpoR mutant losing
its sensitivity to the low levels of JAK2 V617F, and, conversely, the more stable
EpoR mutant becoming more sensitive to low JAK2 V617F levels.
Summary and Conclusions: Our results suggest that due to its natural long
half-life in the cell and at the cell-surface, TpoR could support prolonged JAK2
V617F dimerization and activation even at the lower level of kinase expression
explaining the in vivo JAK2 V617F gene dosage effect, where low JAK2 V617F
levels are associated with thrombocytosis. 
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Background: Polycythemia vera (PV) and essential thrombocythemia (ET) are
characterized primarily by an excess production of erythrocytes and platelets,
respectively. Whilst it is accepted that somatic mutations in JAK2 and other
genes drive clonal proliferation, less is known about the factors that determine
the precise disease phenotype. Compared to ET, PV is characterized by higher
levels of the JAK2 V617F mutation and much more frequent outgrowth of
homozygous mutant clones, however mutation burden alone cannot distinguish
the two disorders and it is clear that other factors must also be important. The
finding that leukocyte counts in murine JAK2 V617F retroviral-mediated trans-
fection/transplantation models differ in a strain-dependent manner was the first
suggestion that host genetic factors may influence the disease phenotype.
Aims: Our aim is to identify inherited genetic factors that influence whether
JAK2 V617F positive MPN patients develop PV or ET.
Methods: We undertook a two stage genome-wide association study. At stage
1,556 ET patients and 556 PV patients that were positive for JAK2 V617F and
from the UK were genotyped. Following standard quality control, allelic chi-
square tests were used to compare SNPs between ET or PV cases against
controls (WTCCC2 n=5200). SNPs with subtype specific effects were identified
by using Breslow-Day tests to assess the homogeneity of effect sizes. SNPs
with significantly different effects in ET and PV cases were followed up at stage
2 by additional genotyping in two independent cohorts of JAK2 V617F negative
cases with either ET or primary myelofibrosis from the UK (n=524), Germany
(n=187) and Austria (n=99). At stage 2, controls from the UK (WTCCC2 NBS
n=2706) and Bavaria (KORA n=1805) were used for comparison. The final
effect size and significance of SNPs was determined by a fixed effects meta-
analysis of the 3 cohorts. To investigate SNP function, we used RT-qPCR to
analyse gene expression in myeloid progenitors cultured in vitro from a series
of healthy controls and MPN cases. 
Results: After quality control, 490,755 SNPs were tested in 499 ET and 505
PV cases, and 5200 WTCCC2 controls at stage 1. Excluding the JAK2 region
due to recurrent aUPD in PV and to a lesser extent in ET, rs9376092 in the
intergenic region between HBS1L and MYB was identified as having one of
the strongest subtype specific effects (Breslow-Day test p=4.4x10-5) which
increases the risk of ET (allelic chi-square p=6.1x10-7, OR=1.42) and may
reduce the risk of developing PV (allelic chi-square p=0.068, OR=0.87). After
testing stage 2 and using a fixed effects meta-analysis to combine evidence
across stages, rs9376092 achieved genome-wide significance (meta-analysis
p=1.8x10-11, OR=1.35) without heterogeneity between cohorts (Cochran’s Q
test p=0.50). Using RT-qPCR we associated the rs9376092 risk allele with
reduced expression of MYB (5.8-9.7 fold) and, less prominently, HBS1L (1.9-
2.4 fold) in healthy individuals. We also found that MYB expression in ET was
significantly lower in JAK2 V617F-heterozygous BFU-E colonies compared to
JAK2-wild type colonies from the same patient (Mann-Whitney test P=0.0009;
q=0.01) but this difference was not seen in colonies from PV cases. 
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Summary and Conclusions: We conclude that constitutional genetic variation
in the intergenic region between HBS1L and MYB influences whether JAK2
V617F mutant MPN develop ET or PV. In JAK2 V617F-negative MPN, the
same variation predisposes to the development of ET. Our findings thus link
constitutional differences in MYB expression to both predisposition to MPN
and to MPN phenotype.
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CALCIUM INFLUX IS SHAPED BY THE MUTATIONAL STATUS IN
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Background: Mutations of the JAK2, CALR, and MPL are detectable in the
hematopoietic cells of about 90% of patients with myelofibrosis. Whereas JAK2
and MPL mutations are represented by point mutations resulting in a gain of
function of the gene, CALR mutations are mainly represented by either a 52-
bp deletion or a 5 bp insertion, resulting in a novel C-terminal peptide sequence.
This domain regulates the Ca2+-binding activity of the protein and the two
mutations are predicted to modify the Ca2+storage capacity in the endoplasmic
reticulum (ER). The ER-Ca2+content of a cell depends on the balance between
the so-called Store Operated Calcium Entry (SOCE) and the ER-dependent
Ca2+release and, in turn, it regulates many important cell functions, such as
proliferation, apoptosis and gene expression. In physiologic conditions, most
of the ER-bound Ca2+is stored in the smooth-ER (s-ER). Little is known about
the effects of the mutations on intracellular Ca2+homeostasis in CD34+cells
of patients with myelofibrosis.
Aims: We have investigated the intracellular Ca2+release and SOCE in circu-
lating CD34+cells of patients with MF with either the V617FJAK2 mutation
(n=7) or a mutation of the CALR gene (n=7), and of healthy subjects (HS, n=4).
We have also studied the ultrastructural extension of the s-ER of CD34+cells
of the same subjects.
Methods: After loading CD34+cells with 4 mcM fura-2 acetoxymethyl ester,
depletion of intracellular Ca2+stores was induced by adding 10 mcM cyclopi-
azonic acid (CPA) to a 0 Ca2+bathing medium. Ca2+was then added to the
extracellular solution eliciting a rise in [Ca2+]i due to Ca2+influx through open
store-operated Ca2+channels. The amplitude of the peak Ca2+response to
CPA, was measured as the difference between the ratio at the peak and the
mean ratio of 1 min baseline before the peak. SOCE amplitude was measured
as the difference between the peak and the mean ratio of 1 min baseline record-
ed before the readdition of Ca2+. Extension of sER was assessed by electron
microscopy (EM) followed by analysis by ImageJ software. Data are expressed
as mean+/-SD.
Results: Resting levels of Ca2+of CALR-mutated CD34+cells were not statisti-
cally different from those of JAK2-mutated cells, but higher compared to those
of HS. CALR-mutated CD34+cells released more Ca2+from ER stores compared
to JAK2-mutated cells (60.6 nM±30.9 vs 26.7 nM±24.9, respectively, P=0.038)
and compared to HS (27.6±19.8 nM, P=0.041 compared to CALR-mutated cells).
SOCE of CALR-mutated CD34+cells (318.5 nM±206.1) was slightly increased
compared to JAK2-mutated patients (242.8±146.8) and lower than SOCE of
CD34+cells of HS (104.3 nM±66.5), without reaching a statistical significance.
At EM evaluation, the extension of vescicles of the sER was higher in CALR-
mutated CD34+cells compared to JAK2-mutated cells (0.82 vs 0.24 mcm, respec-
tively, P=0.0001) and to HS-cells (0.101 mcm, P=0.0007).
Summary and Conclusions: Our results show that CALR mutation in
CD34+cells of patients with PMF is associated with a rearrangement of intra-
cellular Ca++balance, with a significant difference in Ca++release compared
to that observed both in JAK2-mutated- and HS-CD34+cells. In keeping with
the higher Ca2+release, we observed an increased extension of s-ER. Con-
sidering the pivotal role of Ca2+in regulating many cell functions, including pro-
liferation and differentiation, these results seem to suggest that CALR mutation
could be implicated in the myeloproliferative phenotype that characterizes PMF
patients carrying CALR mutations by interfering with the signaling role of Ca2+.
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Background: Survival of essential thrombocytemia (ET) patients during the
first 10 years of their disease is similar to that of the general population. While
it is well known that alkylating agents (given alone or sequentially) increase
the risk of transformation into an acute myeloid leukemia, the specific role of
different therapies on the development of secondary malignancies (SM) in ET
patients is still under investigation.
Aims: To retrospectively evaluate the role of different treatments on the devel-
opment of SM in a large cohort of ET patients followed over a 30-year period.
Methods: Data from a series of 1026 ET patients diagnosed between 1980
and 2000, and followed at 11 Hematology Centers of the Lazio region in Central
Italy, were collected. The median age at ET diagnosis was 62 years (range 17-
93); there were 392 males, 634 females; the median follow-up of the entire
population is 6.2 years (range 0.1–32). Among the whole population, 39% of
patients carried the JAK2V617F mutation, while 27% were wild type; for 34%
of cases, this datum is missing. With regard to adjunctive risk factors (smoke,
diabetes, hypertension, dyslipidemia), 64% of patients presented at least one
risk factor (42%, 1; 22% >1); 28% of patients did not present adjunctive risk
factors and for 8% of cases this datum is missing. Smoke was present in 25%
of cases, hypertension in 43%, diabetes in 7%, dyslipidemia in 15%. Sixty three
of the 1026 patients (6%) developed 64 SM during the follow-up, after a median
time of 50 months (range 2-158) from diagnosis. The observed SM were
grouped as follows: genito-urinary 15, breast 14, non-melanoma skin cancer
5, lung 11, gastro-intestinal 8, hematologic 5, thyroid 3, central nervous system
1, soft tissue 1 and unknown 1. Taking into consideration the different treatment
approaches, we divided our population into 5 different groups: group 0, untreat-
ed patients; group 1, patients treated with hydroxiurea (HU) alone or in com-
bination/sequentially with interpheron α (IFN)/anagrelide (ANA); group 2,
patients treated with alkylating agents (ALK) alone or in combination/sequen-
tially with IFN/ANA; group 3, patients treated with ALK+HU sequentially; group
4, patients treated with ANA and/or IFN only.
Results: With regard to the exposure time to drugs, a statistically significant
difference was found between the groups HU vs ALK (p=0.036), HU vs
ALK+HU (p=0.006) and ALK+HU vs ANA/IFN (p=0.006). No differences were
found for the groups HU vs ANA/IFN, ALK vs ALK+HU, ALK vs ANA/IFN. In
univariate analysis, the following variables were considered: gender, age, dif-
ferent therapeutic approaches, exposure time, presence of adjunctive risk fac-
tors. A statistically significant difference was found only for gender (M vs F:
p=0.035) and age (>60 years vs <60years: p=0.0001). In multivariate analysis,
a statistically significant difference was maintained for both gender and age
[gender HR1.7 (CI 95% 1.037-2.818) p 0.035; age HR 4.190 (CI 95% 2.308-
7.607) p=0.0001)].
Table 1.
Groups Number of patients SM SM Median exposure Median FU
No Yes time to drugs (years) (years)
No therapy 220 (21.5%) 209 (95%) 11 (5%) - 5 (0.1-23)
HU 641 (62.5) 599 (93%) 42 (7%) 4 (0.1-30) 6 (0.1-32)
ALK 26 (2.5%) 24 (92%) 2 (8%) 8 (0.4-23) 12 (1-30)
ALK+HU 86 (8.5%) 79 (92%) 7 (8%) 9 (0.6-24) 10 (2-26)
ANA/IFN 53 (5%) 51 (96%) 2 (4%) 4 (0.1-20) 8 (2-21)
Summary and Conclusions: In our series of 1026 ET patients followed over
a 30-year period, the different therapies administered, comprising HU and ALK,
do not appear to have impacted on the development of SM. A similar prevalence
of SM was observed also in untreated patients. The only two variables which
showed a statistical significance were male gender and age >60 years.
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Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
malignancy resulting from the leukemic transformation of T-cell progenitors.
Despite progress in intensive chemotherapy, 25% of pediatric and over 50% of
adult patients with T-ALL show resistance to therapy and relapse. The patho-
physiology of T-ALL suggests a significant deregulation of cell migration and
tissue infiltration. Previously we showed that the serin-threonin protein phos-
phatase Calcineurin (Cn) regulates the physical and functional interaction that
T-ALL cells establish with other cells in the tumor microenvironment, notably
their adhesive and migratory properties, among other phenotypic traits including
increased apoptosis, inhibition of cell proliferation and ultimately inhibition of
Leukemia Initiating Cell (LIC) activity (Gachet et al., 2013).
Aims: The aim of this study is to dissect the molecular mechanisms underlying
the interactions between T-ALL cells and their microenvironment which are per-
turbed by Cn inactivation, and explore their therapeutic importance.
Methods: NOTCH-induced murine T-ALL in which Cn can be genetically inac-
tivated were used to study the effect of Cn deletion on leukemic cells migration
on stromal cells and on CXCR4 recycling. Retroviral mediated transduction of
T-ALL cells was used to perform rescue experiments with both CXCR4 and
Cortactin (Cttn). In vivo syngeneic transplantation studies were performed to
analyse LIC activity of T-ALL cells, and two-photon confocal microscopy to
study their homing ability. Sh-RNA lentiviral transduction of T-ALL cells was
used to study the effect of CXCR4 knock-down on murine and human T-ALL.
Results: We identify CXCL12/CXCR4 as a highly deregulated pathway in T-
ALL upon Cn deletion. Indeed, we demonstrate that Cn has a central role in
CXCL12 signaling by regulating CXCR4 recycling at the cell surface. Farther,
we link regulation of CXCR4 cell surface expression and CXCL12 responsive-
ness to the Cn-dependent expression of the actin binding protein Cttn in T-
ALL. Moreover, we demonstrate that CXCL12/CXCR4 pathway not only regu-
lates T-ALL migratory properties, but also their survival and proliferation ex
vivo, and their homing and LIC activity in vivo both in NOTCH-induced mouse
T-ALL and in human T-ALL xenografts.
Figure 1.
Summary and Conclusions: Our results reveal a Cn-dependent regulation of
CXCR4 surface expression and signaling, which plays a fundamental role in T-
ALL migration. Moreover, our findings identify CXCR4 as an important regulator
of T-ALL homing and transplantation and call for clinical trials targeting the cal-
cineurin-CXCR4 axis to interfere with leukemogenesis and to improve current
chemotherapy regimens in T-ALL.
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Background:
Pediatric T-cell acute lymphoblastic leukemia patients harbor mutations in IL7Ra
or downstream molecules encoded by JAK1, JAK3, N-RAS, K-RAS, NF1, AKT,
and PTEN. These mutated signaling molecules can contribute to leukemia by
disturbing a multitude of cellular processes such as the cell cycle, epigenetics,
apoptosis, or affecting other important signal transduction pathways.
Aims: We aimed to determine the overall incidence of mutations in IL7Ra and
downstream signaling components in a large cohort of T-ALL patients. Addi-
tionally, we were interested to know whether these mutations occur in a mutually
exclusive manner. In order to find better treatment options for patients with
these mutations, we analyzed the effect of selected IL7Ra-pathway inhibitors—
individually and in combinations—on downstream signaling and cytotoxicity for
each of the mutations using our expression system in Ba/F3 cells.
Methods: We screened 146 pediatric T-ALL patient samples for mutations in
the FERM, pseudokinase and kinase domains of the Janus kinase gene family
(JAK1-3, TYK2) and hotspot regions of N-RAS and K-RAS. The three-dimen-
sional JAK1 model was superimposed on the TYK2 pseudokinase-kinase crys-
tallographic structure. We developed a doxycycline-inducible system by adapt-
ing the IL3-dependent Ba/F3 cell line to express mutant or wild type genes
upon induction by doxycycline. Various IL7Ra-pathway inhibitors were tested
using this system, and the synergy of combined inhibitors was determined by
comparing the dose-response curve of different ratios of IC50-based inhibitor
concentrations to the curves for each of the single inhibitors. The Combination
Index was calculated using Calcusyn™ software.
Results: IL7Ra, JAK, RAS, AKT and PTEN mutations are present in 44% of
T-ALL patients and occur in a predominantly mutually exclusive fashion, sug-
gesting they represent a single mutant signal transduction route. We found
JAK1, JAK3 and RASmutations as previously reported, but also identified new
JAK1 mutations including V427M, L624YPILKV, E668Q, P815S, and T901G.
Our novel three-dimensional model of JAK1 provides insight on how these JAK
mutations result in constitutive kinase activity. Amino acid residues that regulate
or facilitate direct interactions between the pseudokinase and the kinase
domains are frequent targets of JAK1 and JAK3 mutations in T-ALL. In our
doxycycline-inducible IL3-dependent Ba/F3 system, expression of mutant
genes—in contrast to the wild type genes—transforms Ba/F3 cells by support-
ing IL3-independent growth, and by activating the RAS-MEK-ERK and PI3K-
AKT pathways. We used this system to test the sensitivity to pharmacological
inhibitors; IL7Ra and JAK mutant Ba/F3 cells are sensitive to JAK inhibition, so
JAK inhibitors such as Ruxolitinib may offer therapeutic potential for IL7Ra,
JAK1 or most JAK3 mutated T-ALL patients. However, IL7Ra and JAK mutants
are relatively resistant to downstream RAS-MEK-ERK or PI3K-AKT-mTOR inhi-
bition, indicating that inhibition of either of these downstream pathways alone
is insufficient. Inhibitor combinations of both pathways completely block IL7R
signaling irrespective of the level of activation by specific mutations. The RAS
and AKT mutants respond to RAS-MEK and PI3K-AKT-mTOR inhibition,
respectively, but are insensitive to JAK inhibition.
Summary and Conclusions: We show that the combined inhibition of MEK
and PI3K/AKT leads to strong and synergistic cytotoxic effects in the IL7Ra
and JAK mutants and efficiently blocks signaling downstream of both pathways.
Since leukemia often depends on one or both pathways, the cytotoxic efficacy
of synergistic MEK and PI3K inhibition should be further explored in clinical
trials for IL7Ra mutant leukemia.
S822
CONCURRENT CREBBP AND KRAS MUTATIONS ARE ASSOCIATED WITH
A DISMAL OUTCOME IN CHILDREN WITH HYPERDIPLOID LEUKEMIA
IMPLYING A SYNERGISTIC FUNCTION IN RELAPSE EVOLUTION
R. Panzer-Gruemayer1,* K. Malinowska-Ozdowy2, C. Frech2, C. Eckert3,
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Background: High hyperdiploidy (HD) denotes the largest B cell precursor
acute lymphoblastic leukemia (BCP ALL) subgroup in children and adolescents.
Patients usually present with low risk features and respond well to treatment.
The relative proportion of relapses (up to 15%) is small but constitutes the
largest genetically homogeneous fraction in the BCP ALL cohort. ≈50% of HD
ALL harbor activating mutations in RTK/Ras pathway genes, which, however,
haematologica | 2015; 100(s1) | 329
Vienna, Austria, June 11 – 14, 2015
do not qualify as relapse predicting factor based on their high instability at
relapse. By contrast, mutations in the transcriptional coactivator CREBBP
(CBP) occur particularly in ALL relapsing cases, attenuate the function of the
encoded protein and reduce acetylation of histone and non-histone proteins.
Previous studies have focused on conventional sequencing of selected
RTK/Ras pathway genes including small numbers of matched diagnosis and
relapse samples only.
Aims: Our aim was, therefore, to investigate the mutational landscape of HD
ALL using high throughput sequencing in a large cohort of such relapsing cas-
es, in order to infer and compare the clonal composition of diagnostic and
relapse samples, and test for clinical association.
Methods: We used whole exome sequencing (WES; n=19) and targeted
sequencing in these and additional 81 relapsing cases (including 50 cases
with matched diagnosis and relapse samples) as well as 51 non-relapsing
ones. Cases were treated according to AIEOP/BFM-ALL95 and 2000, CoALL-
08-09, and ALL-Rez BFM 2002 protocols.
Results: We detected at diagnosis 12 (median, range 3-23) and at relapse 25
(range 10-90) non-silent mutations per case. They target most frequently
KRAS, NRAS, PTPN11 and FLT3 as well as CREBBP. Ras mutations were
found in >80% of cases, frequently affecting only small clones with high inter-
and intragenic heterogeneity at initial diagnosis; ≈50% were lost at relapse.
RTK/Ras mutations were similarly frequent at relapse, when the vast majority
of them define the major clone. CREBBP mutations were present in 18% of
cases at diagnosis and 30% at relapse. They were already part of the major
clone in >50% of cases at diagnosis, but were virtually always confined to the
predominant relapse clone. Our most salient finding was the coexistence of
CREBBP and KRAS mutations in the major clone of HD ALL relapses
(P<0.001). Despite a similar frequency of KRAS and NRAS mutations, only
the KRAS ones concurred with CREBBP mutations. This observation implies
that these two mutations exert an interdependent function and cooperate in a
RAS isoform-specific and synergistic fashion under the selective pressure of
the applied chemotherapy. Clinically, RTK/Ras pathway and CREBBPmutated
relapses showed only a slight prevalence of occurring early while KRASmutat-
ed relapses usually did develop early; in line, relapses with concurrent CREBBP
and KRAS mutations appeared earlier than those in the remaining cases
(P=0.012). While cases with CREBBP or KRAS mutations or double mutant
leukemias had a significantly poorer outcome than wt cases, the cumulative
incidence of relapses of the double mutant cases tended to be associated with
an increased incidence of subsequent relapses.
Summary and Conclusions: KRAS and CREBBP double mutant HD ALL
relapse cases are amongst those with the highest risk and are therefore suitable
candidates for novel therapeutic approaches using histone deacetylase
inhibitors and Ras pathway inhibitors. Since somatic CREBBP mutations are
also present in a small number of non-relapsing HD ALL cases, they cannot be
used as prognostic markers.
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MEK INHIBITION IS A PROMISING THERAPEUTIC STRATEGY FOR
MLL-REARRANGED INFANT ALL PATIENTS CARRYING RAS MUTATIONS
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Background: Acute Lymphoblastic Leukemia (ALL) in infants is characterized
by a high incidence (~80%) of chromosomal rearrangements of the Mixed Lin-
eage Leukemia (MLL) gene. MLL-rearranged (MLL-r) infant ALL patients are
challenged by a very poor prognosis (i.e. 30-40% 5-year EFS), hence the need
for better risk stratification and improved therapeutic solutions is evident. We
recently screened a relatively large cohort (n=109) infant ALL patients (all
enrolled in INTERFANT treatment protocols) for the presence of KRAS and
NRAS mutations and found that the incidence of such mutations ranges
between 14-24%, depending on the type of MLL translocation. Moreover, these
mutations were found to represent independent predictors of exceedingly poor
prognosis; all RASmutation-positive MLL-r infant ALL patients deceased within
3 years from diagnosis.
Aims: We aimed to identify a therapeutic strategy to improve the prognosis of
MLL-r infant ALL patients carrying RAS mutations.
Methods: 8 small molecule inhibitors against different RAS-pathway compo-
nents were selected and tested for anti-leukemic activity against the MLL-r ALL
cell lines SEM and RS4;11 (RASwt) and KOPN8 (RASmut) using MTS cell via-
bility assays. Next, primary infant ALL samples (n=20) all carrying MLL translo-
cation t(4;11) (giving rise to the MLL-AF4 fusion protein) either with (n=6) or
without (n=14) RAS mutations were exposed to these inhibitors in MTT cyto-
toxicity assays. In addition, we assessed the RAS activity in RASmutated and
wild-type MLL-r infant ALL cells, and analysed downstream MEK and ERK acti-
vation both in the absence and presence of the MEK inhibitors. Furthermore,
combination treatment of MEK inhibitors and prednisolone, the spearhead drug
for ALL treatment regimes, was investigated in SEM and KOPN8 using the
MTS assay.
Results: We found that the MEK inhibitors MEK162, Selumetinib, and Tram-
etinib effectively reduced the viability of KOPN8 cells (RASmut), whereas SEM
and RS4;11 cells (RASwt) largely remained unaffected. In line with this, MLL-
AF4+infant ALL patient samples carrying RAS mutations were significantly
more sensitive to these MEK inhibitors when compared with patients carrying
wild-type RAS genes: LC50 values for MEK162 were 0.04 vs. 26.9 µM (p<0.01),
for Selumetinib 0.04 and 23.7 µM (p<0.01), and for Trametinib 0.01 vs. 26.5
µM (p<0.01), respectively. Furthermore, the presence of RASmutations in pri-
mary MLL-r infant ALL samples was associated with significantly increased
RAS activity, as determined by immunoprecipitation of GTP-bound RAS.
Remarkably, however, enhanced RAS activation was not demonstrated by
increased downstream ERK phosphorylation, while a slight increase of MEK
phosphorylation was observed. Yet, MEK inhibitor exposure in both KOPN8
and SEM cells resulted in nearly complete abrogation of ERK phosphorylation,
without affecting total ERK protein levels, suggesting that the loss of ERK acti-
vation plays an important role in the observed anti-leukemic effects. Further-
more, MEK162 and Selumetinib, seemed to induce accumulation of phospho-
rylated MEK. Additionally, MEK inhibitor treatment in both SEM and KOPN8
synergistically enhanced sensitivity towards prednisolone. Interestingly, a sub-
group of patient samples (n=5) with wild-type RAS also showed sensitivity
towards MEK inhibition, similar to the primary cells with RAS mutations. How-
ever, this observation could not be explained by increased RAS activation, nor
by the phosphorylation levels of either MEK or ERK.
Summary and Conclusions: Our data show that MEK inhibition represents a
promising therapeutic approach for MLL-r infant ALL patients carrying additional
RASmutations. Furthermore, the mechanism of action provoked by these MEK
inhibitors seems to involve abrogation of ERK phosphorylation, but the initial
levels of ERK phosphorylation did not correlate with MEK inhibitor sensitivity,
and has no predictive value. Moreover, the prednisolone sensitization induced
by MEK inhibitor exposure, further illustrates the potential value of MEK inhi-
bition for the treatment of MLL-r infant ALL. Currently we are in the process of
testing the efficacy of the above mentioned MEK inhibitors in vivo using a
xenograft mouse model, while further elucidation of the molecular mechanisms
underlying the anti-leukemic effects of these inhibitors in MLL-r ALL cells are
in progress.
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Medical University Berlin, Berlin, Germany
Background: Acute lymphoblastic leukemia (ALL) is the most common child-
hood cancer, and although current drug treatment is effective in most cases
there are few effective second-line drugs available for drug-resistant disease.
SMAC mimetics (SMs) are an emerging class of novel chemotherapeutics,
which activate cell death by inhibiting key anti-apoptotic cellular inhibitors of
apoptosis proteins (cIAP1, cIAP2, and xIAP). 
Aims: To elucidate the potency and mechanisms of cell death induction by
SMAC mimetics in pediatric ALL. 
Methods: Using an in vitro screening approach, we assessed the sensitivity
of 51 patient derived ALL xenografts to a preclinical SM compound (Birinapant).
We applied specific inhibitors of apoptotic and necroptotic cell death as well as
a CRISPR based genetic approach to map the mechanisms of cell death induc-
tion by SM treatment in patient derived ALL samples as well as ALL cell lines.
Finally, we examined the ability of SM to selectively kill ALL cells in an in vivo
xenograft model of refractory ALL.
Results: We show that a significant proportion of patient-derived ALL samples
are highly sensitive to SM-induced death. SM sensitivity does not correlate
with patient risk grouping and includes both relapsed and refractory samples.
Pharmacological inhibition of distinct cell death pathways indicates that SM
treatment induces both apoptotic and necroptotic cell death. While a minority
of ALL samples showed either apoptotic or necroptotic features, a majority of
cases had simultaneous induction of both cell death phenotypes. Examination
of distinct cell death parameters such as DNA-fragmentation and loss of plasma
membrane integrity by FACS and microscopy suggests that both apoptosis
and necroptosis occur simultaneously within a given cell population after SM
treatment. Lenti-CRISPR mediated gene disruption in ALL cell lines demon-
strates that irrespective of the cell death phenotype, induction of death requires
Rip1-kinase in all cases. Rip1 in turn activates Rip3-dependent necroptosis
and/or Caspase-8-dependent apoptosis. Blockade of both death pathways
through gene disruption or inhibitor treatment was required to restore cell via-
bility after SM treatment. Strong anti-leukemic activity of SM was confirmed in
vivo in a xenograft mouse model of refractory ALL. Treatment of transplanted
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mice with SM not only delayed leukemia progression, but also completely elim-
inated leukemia burden in established disease for several weeks following
treatment.
Figure 1.
Summary and Conclusions: This data shows that apoptotic and necroptotic
cell death pathways are not mutually exclusive phenomena, but can be acti-
vated simultaneously in chemotherapy-resistant ALL. Because SM can induce
both pathways of cell death in parallel, these agents have a strong potential for
anti-leukemic therapy in refractory childhood ALL.
Biology and clinics of bone marrow failure
syndromes and PNH
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CELLULAR AND MOLECULAR CHARACTERIZATION OF ERYTHROID
DEFECTS IN DIAMOND BLACKFAN ANEMIA
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S. Ellis4, J. Lipton2, N.I. Sequencing Center1
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Background: Diamond-Blackfan anemia (DBA) is a rare, congenital bone mar-
row failure syndrome with severe anemia, congenital anomalies, predisposition
to cancer and variable severity. Approximately 65% of DBA patients have het-
erozygous autosomal dominant mutations or deletions in one of >15 ribosomal
protein (RP) genes encoding both large and small subunit proteins. In addition,
recent studies have identified mutations in the GATA1 gene in three DBA fam-
ilies. Despite targeted sequencing of all 80 RP genes, the causal abnormalities
in the remaining ~35% of DBA patients are unknown as is the mechanism by
which RP defects cause erythroid failure.
Aims: 1. To develop an in vitro system to culture erythroid cells from DBA
patient peripheral blood CD34+cells. 2. To use transcriptional profiling of DBA
erythroid cells to determine the disrupted pathways. 3. To perform whole exome
sequencing on DBA patients without RP mutations to determine the genetic
defects.
Methods: We developed a 2-step culture system that expands CD34+cells (7
days), then induces differentiation of erythroid cells (7 days). This system
yields >107 CD235+erythroid cells from ~104 CD34+cells collected from 10
ml of healthy control peripheral blood. RNA isolated from CD235+erythroid
cells was profiled on Affymetrix GeneChip Human Gene ST Arrays and by
RNASeq. Whole exome sequencing (WES; Illumina HySeq; 80X coverage)
was performed on DBA probands, an unaffected sibling and their parents.
After filtering out common variants in the 1,000 Genomes and ClinSeq data-
bases we used the VarSifter program to evaluate candidate causal variants
for further study.
Results: In contrast to control cells, cells from 9 different DBA patients (5 RP
mutations, 3 unknown, 1 with a GATA1 mutation) exhibited a significantly
reduced growth rate, generating ~100-fold fewer CD235+erythroid cells, with
an ~2-day delay in the acquisition of the CD235 marker. Using flow cytometry,
we isolated populations of CD235+erythroid cells from both control and patient
cell cultures for RNA profiling. RNA from DBA patients showed a distinct tran-
scriptional profile compared to control samples and the sample from the GATA1
patient. Gene ontogeny analysis showed increased expression of genes asso-
ciated with cellular stress and decreased expressed expression of genes asso-
ciated with cell cycle progression and protein translation in the RP patients.
The GATA1 patient’s profile identified decreased expression of red cell structural
genes as well as genes in the heme biosynthesis pathway. In one DBA family,
we identified candidate autosomal recessive mutations in the MCM2 and
POLR3B genes. Normal CD34+progenitor cells expressing shRNAs targeting
MCM2 and POLR3B mRNA demonstrated 60-90% knockdown of each.
POLR3B knockdown cells showed no inhibition of erythroid differentiation, indi-
cating POLR3B is an unlikely DBA candidate gene. In contrast, knockdown of
MCM2 ddemonstrated a significant reduction in BFU-E (but not CFU-GM)
colony formation. Similar to DBA patient cells, the proliferation of MCM2 knock-
down cells was reduced and the differentiation of CD235+erythroid cells was
delayed. MCM2 knockdown cells were arrested at the G1/S checkpoint in the
cell cycle. As confirmation, mice deficient in Mcm2 have a severe bone marrow
failure syndrome with erythroid defects.
Summary and Conclusions: Our in vitro differentiation system is a powerful
tool to study erythropoiesis in DBA patients using small volumes of peripheral
blood. We have used this system to demonstrate that the common forms of
DBA, associated with defects in ribosomal genes, have defects in cell cycle
and protein translation that differ significantly from the defects observed in the
GATA1 DBA patient. Finally, we have shown that mutation in the MCM2 gene
is associated with DBA in at least one family, which represents the first autoso-
mal recessive mutation identified in DBA patients.
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Background: Immunosuppressive treatment (IST) for severe aplastic anemia
(SAA) has a 60-65% rate of overall hematologic response (OR), of which only
about 10% are complete (CR). Eltrombopag, a synthetic thrombopoietin recep-
tor agonist (TPO-RA), has activity in refractory SAA, producing multilineage
hematologic responses in about 40% of patients.
Aims: We conducted an investigator-initiated phase II, single-center trial to
test the efficacy of adding eltrombopag to h-ATG/CsA (clinicaltrials.gov,
NCT01623167).
Methods: Patients with treatment-naïve SAA were enrolled from July 2012 to
November 2014. All subjects received standard h-ATG and CsA. To determine
the optimum regimen, eltrombopag was administered at 150 mg daily to two
consecutively enrolling cohorts (see Table). The primary endpoint was CR at 6
months. Both cohorts were powered to detect a ≥30% CR rate at 6 months for
comparison with our historical rate of 10%. Our historical data suggest that CR
is a surrogate for late events since it is associated with a low rate of evolution
to monosomy 7/acute leukemia and correlates with excellent long-term survival.
Results: Thirty subjects enrolled in the first cohort had a median age of 39
years (12-72); thirteen (43%) had very severe disease (ANC<200/µl), and 8
(27%) had PNH clones ≥1%. Eltrombopag was well tolerated when combined
with CsA, and only three patients discontinued treatment before 6 months. CR
at 6 months was 33% (95% CI, 15-51%), significantly higher than our historical
rate of 10% (p<0.001). OR at 6 months was 80% (CI, 65-95%), exceeding the
historical rate of 60% (p=0.040). Median increases in blood counts among
responders at 6 months (n=24) were: absolute neutrophil count (ANC) +1240/µl;
hemoglobin +3.8 gm/dL; and platelets +87,000/µl. Median time to achieve trans-
fusion independence was 32 days for platelets and 39 days for red cells. Serial
BM biopsies showed improved cellularity in 25 cases without increased fibrosis.
Median increase in BM CD34+cells, as measured by flow cytometry, was 34-
fold from baseline to 3 months, and 23-fold from baseline to 6 months
(p<0.0001). Primitive hematopoietic progenitors were serially measured in 4
patients, detecting HSC (CD34+CD38-CD45RA-CD90+CD49f+Rholo) and MPP
(CD34+CD38-CD45RA-CD90-CD49f-) by flow cytometry. Undetectable at base-
line, these cells constituted 4-48 HSC and 1-27 MPP per 100,000 CD34+cells
6 months after therapy. The first cohort has been followed for median 24 months
(range 15-31m); there have been 3 clonal evolution events, all detected in
responders: one patient had complex cytogenetics (t(3;3)(q21;q26)) with BM
dysplasia followed by increased blasts, and deletion 13q in one subject and tri-
somy 15 in another, neither with BM dysplasia. Enrollment to the second cohort,
in which eltrombopag is stopped at 3 months, is complete and 23 subjects are
currently evaluable at 6 months. OR at 6 months is 87% (20/23) and CR rate at
6 months is 22% (5/23) confirming results observed in the first cohort. One
clonal evolution event (deletion 7p) occurred at 6 months in a responder and
relapse of pancytopenia soon followed.
Tabella 1. Hematologic Response.
Summary and Conclusions: The addition of eltrombopag to IST increases
overall and complete hematologic response rates. Marked increase in
CD34+cells, the appearance of multipotent progenitor cells, and rapid blood
count recovery support a mechanism of action of direct stimulation of stem
and progenitor cells by eltrombopag.
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Background: Acquired aplastic anemia (AA) is characterised by a hypo-cellular
marrow and peripheral blood cytopenias. Unfortunately, allogeneic bone mar-
row transplantation is limited by the availability of human leukocyte antigen
(HLA)-matched donors. Most AA patients receive immunosuppressive therapy
(IST) combining anti-thymocyte globulin (ATG) and cyclosporine A (CyA). The
presence of minor paroxysmal nocturnal hemoglobinuria (PNH) clones and a
short telomere length (TL) were identified as predictive biomarkers of IST
responsiveness. 
Aims: To assess whether combining minor PNH clones and TL could predict
IST response with greater accuracy.
Methods: We enrolled 118 children (67 boys and 51 girls) diagnosed with
acquired AA in Japan between July 2001 and November 2013. Fifty-three
patients received horse ATG (Lymphoglobulin, 15mg/kg/day for 5 days) and
65 received rabbit ATG (Thymoglobulin, 2.5−3.75 mg/kg/day for 5 days). All
patients received CyA (6 mg/kg/day) starting on day 1 for at least 180 days.
The dose of CyA was adjusted to maintain trough levels of 100–200 ng/ml.
Written informed consent was obtained from the parents of all patients. This
study was approved by the ethics committee of Nagoya University Graduate
School of Medicine. A flow cytometry assay was used to detect PNH-type gran-
ulocytes and red blood cells (RBCs). The presence of >0.005%
CD13+CD55−CD59− granulocytes and/or >0.010% glycophorin
A+CD55−CD59− RBCs was defined as PNH clones positive (PNH+). Cut-off
values were determined using receiver operator characteristic (ROC) analysis.
The telomere length of peripheral lymphocytes was measured by flow-fluores-
cence in situ hybridization (flow-FISH). According to ROC analysis, we defined
−1.21 SD of age-adjusted controls as the cut-off value.
Results: Patients’ median age when IST was administered was 9.7 years
(range, 0.9–16.0 years), disease was moderate-to-very severe, and all three
categories of disease severity were well represented. The causes of AA were
idiopathic in 103 patients and hepatitis-associated in 15 patients. Forty-eight
patients (41%) carried PNH+clones. The median TL of AA patients was −1.08
standard deviation (SD) (range, −4.01–+3.01 SD). Overall, 63 patients (53%)
responded to IST after 6 months. Multivariate logistic regression analysis iden-
tified WBC ≥2.0 × 106/L (OR, 2.82; 95% CI, 1.13–7.03; p=0.026), absence of
PNH+clones (OR, 4.66; 95% CI, 1.81–12.00; p=0.001), and a shorter TL (OR,
4.10; 95% CI, 1.66–10.10; p=0.002) as independent unfavorable predictors of
response to IST at 6 months. Accordingly, the cohort was stratified into unfa-
vorable group (PNH− and a shorter TL, n=41) and favorable group (PNH+and/or
a longer TL, n=77). The response rate at 6 months of the unfavorable group
was significantly lower (22%) compared with that of the favorable group (70%)
(p <0.001). Five-year transplantation free survival (TFS) and failure free survival
(FFS) were significantly lower in the unfavorable group compared with those
in the favorable group [TFS, 53% (95% CI, 34%–68%) vs. 73% (95% CI, 60%–
82%); p=0.010; FFS, 24% (95% CI, 11%–39%) vs. 53% (95% CI, 40%–65%);
p <0.001]. However, no difference was observed in 5-year overall survival (OS)
between groups [unfavorable group, 98% (95% CI, 84%–100%) vs. favorable
group, 96% (96% CI, 88%–99%); p=0.743], possibly because of effective sal-
vage hematopoietic stem cell transplantation (HSCT).
Summary and Conclusions: The current study reveals that PNH− patients
with shorter TL are less likely to respond to IST. Our findings suggest that com-
bining these two markers may help to provide the appropriate treatment option
to the patients and prevent adverse events due to unnecessary treatment.
Despite the risk of complications, unrelated or mismatched related donor trans-
plantation may be considered as a front-line therapy for patients in the unfa-
vorable group lacking HLA-matched sibling donors.
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Background: Uncontrolled complement activation plays a pivotal role in a vari-
ety of disorders such as PNH and aHUS.
Aims: ALN-CC5 is a subcutaneous (S.C.) investigational RNAi therapeutic tar-
geting complement C5 (C5) with the purpose of decreasing terminal comple-
ment activity and thereby protects against intravascular hemolysis and com-
plement mediated tissue damage.
Methods: Preclinical studies in rat and non-human primate (NHP) models were
used to investigate the ability of ALN-CC5 to reduce complement C5, inhibit com-
plement-mediated hemolytic activity and complement alternative- and comple-
ment classic pathway (CAP and CCP). Furthermore, ALN-CC5 was investigated
in a rat membranous nephropathy model, the anti-collagen antibody induced
arthritis model and in a passive myasthenia gravis model. A placebo controlled
double blind phase 1 clinical study in healthy volunteers and patients with PNH
is ongoing. Several cohorts in part A, a single ascending dose study have been
completed and Part B, a multiple ascending dose study is currently ongoing. Part
C will be a multiple dose study in patients with PNH. Primary endpoints are safety
and tolerability. Secondary endpoints are pharmacokinetics, reduction of circu-
lating C5, reduction in hemolytic and CAP as well as CCP activity.
Results: Pre-clinical studies demonstrated that ALN-CC5 resulted in mean
98.4±0.7% reduction of C5 levels in NHPs, mean 88±6.1%% reduction in
hemolysis and mean 95.1±0.93% reduction in CAP with every-other week or
monthly S.C. dosing. Furthermore, ALN-CC5 significantly reduced proteinuria
in a rat membranous nephropathy model, reduced disease activity in the mouse
arthritis model and reduced clinical disease score and improved grip strength
in the myasthenia gravis model. ALN-CC5 reduced disease manifestation com-
parable to treatment with C5 monoclonal antibody. In Part A of the phase 1
study, human volunteer subjects were randomized (3:1) to placebo or a starting
single subcutaneous dose of 50 mg ALN-CC5 and followed for at least 70 days.
Following safety review, additional single ascending dose cohorts were author-
ized. Part B multiple ascending cohorts are planned to start in parallel to Part
A. Up-to-date results on safety, tolerability and C5 knockdown, changes in CAP,
CCP and hemolytic activity from study will be presented.
Summary and Conclusions: Collectively, these data suggest that the use of
a novel RNAi therapeutic targeting C5 is a promising approach for inhibiting
complement in PNH, aHUS and other complement mediated diseases. The
subcutaneous route of administration and infrequent dosing make this a par-
ticularly encouraging potential therapy.
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Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, genetic,
and life-threatening blood disease. This illness is characterized by the destruc-
tion of red blood cells and hemolytic anemia [1]. The consequent intravascular
hemolysis, hypercoagulability, and bone marrow failure may result in several
clinical sequels as thrombosis or renal failure [2]. Although its treatment was
usually symptomatic, Eculizumab has recently shown efficient results for this
disease world-wide [3] and specifically in Spanish cohorts [4].
Aims: This study was planned to describe Acute and Chronic Renal Failure
(ARF and CRF) related values in PNH-patients and to assess how Eculizumab
affects these parameters.
Methods: From 128 registered patients (PNH Spanish Registry; April 2014),
60 were diagnosed with classic PNH (47%). 27 of these cases (45%) also suf-
fered ARF or CRF and were included in this retrospective and descriptive study.
Results: PNH studied patients were 12 males and 15 females with a mean
age of 48.5 (±16.2) y/o whom were diagnosed with PNH when they had a mean
age of 38.6 (±13.8) y/o. PNH clone values for analyzed patients was 71.7 %
(±23.4) granulocytes, 76.6 % (±28.1) monocytes and 42.3 % (±23.6) erythro-
cytes. All 27 patients presented renal failure. Specifically, 5 (18.5%) patients
were diagnosed with CRF without any previous ARF, 8 (29.6%) were diagnosed
with CRF and suffered ARF and 14 (51.9%) only presented ARF. In 20 cases,
ARF diagnosis was coincident with a hemolytic crisis. In addition, a patient pre-
sented 5 ARF episodes and 4 patients presented 2 episodes. ARF patients
showed these mean values at diagnosis: 3880.3 (±2253) UI/L for LDH, 8.1
(±1.9) g/dL for Hemoglobin (Hb), 7.6% (±7.2) Reticulocytes, 117.3 (±46.7) mg/dL
for Urea, 4.4 (±2.3) for Creatinine, 26.8 (±17.3) ml/min/1.73 m2 for Glomerular
filtrate and 534.8 (±492.1) mg/24 h for Proteinuria. In addition, 21 out of 22
patients showed Hemoglobinuria, 15 out of 16 Hemosideruria and 9 out of 15
Urinary casts. Finally, 6 ARF patients required dialyses and there were 18 com-
plete recoveries and 4 partial recoveries, with a mean time of 13.3 (±7.6) days.
Values for CRF-diagnosed patients were 41.7 (±27.2) mg/dL for Urea, 1.3 (±0.4)
mg/dL for Creatinine, 56.8 (±14.0) ml/min/1.73 m2 for Glomerular filtrate and
814.4 (±614.0) mg/24 h for Proteinuria. After PNH diagnosis, estimated prob-
ability to evade ARF at 5 years was 56.5% (IC 95%; 35.1, 73.3) and median
time without an ARF episode was estimated to be 7.3 (IC 95%; 2.2, 14.9) years.
Likewise, estimated probability to avoid CRF at 5 years was 60.9% (IC 95%;
37.8, 77.7) and median time without CRF diagnosis was estimated to be 14.5
(IC 95%; 3.8, ND) years. Finally, from 23 Eculizumab treated patients, 20 were
still continuing with a mean extent of 3.9 (±2.2) years. Creatinine and Glomerular
filtrate values for treated CRF patients were still very preliminary to statistical
evaluation. However, recorded data showed a trend towards improvement after
18 months. Considering all treated patients, only 1 (5.3%) suffered a septic
shock coincident ARF episode after treatment. All patients were alive at the
end of the study.
Summary and Conclusions: This study described ARF and CRF values of
Spanish PNH patients and estimated the probabilities to present these diseases
after PNH diagnosis. Also, preliminary results suggested that there might be a
low ARF incidence in Eculizumab treated patients and CRF related clinical val-
ues might have a positive development in time.
Bibliography: 1. Hillmen P et al. N Engl J Med. 1995; 2. Rachidi S et al. N
Engl J Med. 2010; 3. Hillmen P et al. N Engl J Med. 2006; 4. Muñoz-Linares C
et al. Eur J Haematol. 2014.
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Background: Survival for patients with APL has improved in the last 20 years.
The MRC AML15 trial delivered 80% 5 year survival using anthracycline and
All-trans retinoic acid (ATRA) and the exclusion of cytarabine and maintenance
which has become standard of care. Arsenic Trioxide (ATO) and Gemtuzumab
Ozogamicin (GO) are effective as single agents with the former approved for
relapsed disease. The next stage in de-intensification in this disease is the
“chemo-free” combination of ATO+ATRA. In low risk disease (WBC<10x109/L)
the GIMEMA-AMLSG-SAL trial, using a daily schedule of ATO+ATRA, indicated
this was at least as effective as chemotherapy containing protocols (Lo Coco
et al., NEJM 2013;369: 111-21). 
Aims: The NCRI AML17 Trial compared Anthracycline/ATRA (AIDA) vs the
chemo-free combination of ATO (in an attenuated schedule) +ATRA. Impor-
tantly high risk patients (presenting WBC>10x109/L) were also included with
the option to add a single dose of GO (6mg/m2) in induction.
Methods: From May 2009 to October 2013, 235 patients aged>16 who entered
the AML17 trial with molecularly confirmed APL were randomised to either
ATRA+ATO (8 week induction 0.3mg/kg d1-5 w1, 0.25mg/kgx2/w w2-8, fol-
lowed by 4 consolidation courses of 0.3mg/kgx2 w1, 0.25mg/kgx2/w w2-4 (63
ATO doses) OR AIDA schedule: Idarubicin (Ida)12mg/m2 d2,4,6,8 +ATRA to
d60) (induction) then Ida 5mg/m2 d1-4 +ATRA d1-15 (Course 2); Mitox.
10mg/m2d1-4 +ATRA d1-15 (course 3); Ida 12mg/m2 d1 +ATRA d1-15 (Course
4). ATRA was 45mg/m2/d. Follow-up is complete to 1/1/2014.
Results: The median age was 47y (16-77); 57 had WBC>10x109/L (27 AIDA,
30 ATRA+ATO) and 49 (24 AIDA, 25 ATRA+ATO) were >60y. 90% entered
morphological CR; overall day 30, 60 mortality was 5%, 7%. When a landmark
analysis is performed from day 30, 4-year OS is 96%. 20 patients have
relapsed. Survival at 4 years is 91%. For patients with a high WBC OS was
86%, and for patients >60 years OS was 77%. There was no significant differ-
ence in CR rate between the arms (Chemo 89%, Chemo-free 94%; OR 0.54
(0.21-1.34), p=0.18). The day 30, 60 mortalities were 6% vs 4% (p=0.6) and
9% vs 5% (p=0.2). One patient on ATRA+ATO experienced frank relapse com-
pared with 12 on AIDA plus a further 7 molecular relapses on this arm (cumu-
lative incidence of frank relapse 13% vs 1%, HR 0.16 (0.05-0.48) p=0.001).
Among patients who achieved molecular negativity cumulative incidence of
molecular relapse was 27% vs 0%. The OS at 4 years is 89% (Chemo) vs 93%
(Chemo-free), HR 0.60 (0.26-1.42) p=0.2, but EFS was significantly superior
with ATRA+ATO (91% vs 74%, HR 0.36 (0.19-0.70) p=0.003) due to the lack
of relapse after CR. There was significantly less alopecia, grade 3,4 liver and
GI toxicity on the chemo-free arm. Significantly fewer blood and platelet trans-
fusions were used and there were fewer days on antibiotics and in hospital.
The QoL and HADS assessments did not differ significantly. There was no het-
erogeneity of treatment effect by subgroup. Importantly, when considered by
WBC risk, for low risk patients (WBC<10x109/l) cumulative incidence of frank
relapse was 5% vs 1% (p=0.03) with 4-year survival of 90% vs 95% (p=0.17).
In high risk patients (WBC>109/L) CIR was 26% vs 0% (p=0.008), and OS
87% vs 84% (p=0.8). Of 30 high risk patients allocated to the chemo-free arm,
28 received GO as per protocol. The OS at 4 years for high risk patients given
GO was 89%. Of the 2 patients not treated with GO, one died on d12. Com-
pared with the GIMEMA-AMLSG-SAL trial, results were similar, but with less
liver toxicity (<10% vs 63%); less frequent dosing of ATO (63 vs 140); less ATO
required (151 vials vs 280 vials for a 70kg patient, which at an acquisition cost
of £350/vial represents a cost reduction of £46k/patient). 
Summary and Conclusions: The combination of ATO and ATRA represents
a new standard of care resulting in a very low risk of relapse resulting in sig-
nificantly better EFS and excellent survival. The attenuated dosing approach
is safe and effective in high risk patients particularly if combined with a single
dose of GO, is less toxic and less costly.
LB2068
IMPACT OF A GAIN-OF-FUNCTION MUTATION OF CXCR4 ON
HAEMATOPOIESIS IN MICE
C. Freitas1,2,* M. Wittner3, J. Nguyen1,2, V. Biajoux1,2, M.L. Aknin4,
F. Gaudin1,2,4, S. Beaussant-Cohen5, Y. Bertrand6, F. Bachelerie1,2,
A. Dalloul1,2, J. Donadieu7, F. Louache3, K. Balabanian1,2
1Laboratoire d’Excellence en Recherche sur le Médicament et l’Innovation
Thérapeutique, INSERM, 2Université Paris-Sud, Laboratoire Inflammation,
Chimiokines et Immunopathologie, INSERM U996, Clamart, 3Université Paris-
Sud, Laboratoire Hématopoïèse normale et pathologique, INSERM U1009,
Villejuif, 4Institut Paris Saclay d’Innovation Thérapeutique, UMS IPSIT- US31-
UMS3679, Chatenay-Malabry, 5Service d’Hémato-Oncologie Pédiatrique, CHU
Jean Minjoz, Université de Franche-Comté, Besançon, 6Service d’Hémato-
Oncologie Pédiatrique, Hospices Civils de Lyon, Université Claude Bernard
Lyon I, Lyon, 7Registre Français des Neutropénies Chroniques Sévères, Centre
de référence des Déficits Immunitaires Héréditaires, Service d’Hémato-Oncolo-
gie Pédiatrique, Hôpital Trousseau, Paris, France
Background: The Warts, Hypogammaglobulinemia, Infections and
Myelokathexis Syndrome (WS) is a rare immuno-haematological disorder char-
acterized notably by a chronic pan-leukopenia. It is mostly caused by inherited
heterozygous autosomal dominant gain-of-function mutations in CXCR4, which
engender a distal truncation in the carboxyl-terminal tail (C-tail) domain and
lead to a desensitization-resistant receptor. CXCR4 is widely expressed on
non-haematopoietic cells and virtually all leukocytes. Thus, we hypothesized
that WS-associated circulating lymphopenia arises from altered CXCR4-medi-
ated signalling that skews tissue distribution and differentiation of lymphocytes.
We recently produced major breakthroughs in the pathophysiology of the WS
by generating a knock-in mouse strain (Cxcr4+/1013) harbouring a WS-linked
heterozygous Cxcr4 mutation. Mutant mice displayed in vitro lymphocytes with
enhanced migration to Cxcl12, the sole ligand of Cxcr4, and phenocopied
severe circulating pan-lymphopenia. Analyses of primary lymphoid organs (i.e.
bone marrow [BM] and thymus) have unveiled defects in early stages of B-
and T-cell development, i.e. B-cell progenitors and Early T-cell progenitors.
The mechanisms underlying deregulation of lymphopoiesis process, and the
resulting chronic blood lymphopenia, are still unknown. 
Aims: Here we explore the biological impact of a gain-of-Cxcr4-function on
haematopoiesis in both BM and extra-medullary sites. 
Methods: We took advantage of our original knock-in model to investigate BM
and splenic haematopoietic stem and progenitor cells (HSPC) distribution,
clonogenicity, quiescence and in vivo migration by flow cytometry and clono-
genic assays. We further examined the capacity of mutant HSC to repopulate
the BM in long-term BM reconstitution experiments. To exclude any interference
of the Cxcr4+(WT) allele, we produced and investigated homozygous
Cxcr41013/1013 mice in parallel.
Results: We showed that the total number and homing properties of HSC, as
well as the clonogenicity of progenitors, were not altered in the BM of mutant
mice as compared to WT littermates. The quiescence status of LSK SLAM was
increased, whereas the total number of multipotent and common lymphoid pro-
genitors was decreased in an allele dose-dependant manner. Long-term BM
reconstitution experiments indicated that these defects were cell-autonomous
and further revealed a decreased capacity of Cxcr41013/1013 HSC to repopulate
the BM. Based on clonogenic assays, we reported a decrease in the total num-
ber of HSPC in the blood of mutant mice, an anomaly also found in four WS
patient carrying a heterozygous CXCR4mutation. This suggested an abnormal
HSPC circulation that was strengthened by the increased extramedullary
haematopoiesis observed in the spleen of mutant mice. This phenomenon was
allele dose-dependent, cell autonomous and associated with an increased
expression of Cxcl12 in the red pulp area.
Summary and Conclusions: These results provide new details about
haematopoiesis by establishing the C-tail in Cxcr4-mediated signalling as a
pivotal regulator of such process. Our current activities consist in investigating
in vitro the lymphoid differentiation of mouse and human HSPC and character-
izing BM and spleen HSC niches.
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Background: Both pre and postoperative anaemia are highly prevalent in sur-
gical patients. Depending on the type of surgery, underlying disease and the
definitions of anaemia, about 14% up to 76% of surgical patients may present
with pre-operative anaemia according to different studies. Recently, there has
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been increasing evidence to suggest that pre-operative anaemia can lead to
an increased risk of peri-operative adverse outcomes such an increase in the
requirement for blood transfusion, increase of hospital Length of Stay (LoS)
and increased overall morbidity and mortality. In addition, evidence has shown
that pre-operative anaemia increases the chance of receiving unnecessary
allogeneic blood transfusion with its consequences when compared to patients
with a normal haemoglobin level, preoperatively.
Aims: Assessment of safety of a single intravenous iron carboxymaltose dose
versus standard oral iron sulphate and the subsequent effect on the perceived
quality of life (QoL) in both treatment groups.
Methods: We conducted a prospective randomised controlled trial with two dif-
ferent iron therapies for the treatment of iron deficiency anaemia (IDA) patients
who were undergoing elective surgery. During the period between January 2012
and August 2014 at our tertiary referral Hospital for Northern Tasmania, Australia,
we recruited 125 patients 2-4 weeks preoperatively who were randomized to a
single intravenous ferric carboxymaltose (FCM) infusion (1000 mg standard
dose) versus oral daily iron sulphate (325 mg, equivalent to 105 elemental iron)
until the time of the surgery. Median age was 71 years (range, 38-94) with a
male to female ratio of 67:58. The vast majority of patients were Caucasian. All
patients gave an informed consent according to Helsinki guidelines. There were
70 patients who underwent major orthopaedic surgery, 23 abdominal surgery,
27 genitourinary surgery and 5 patients underwent general surgery.
Results: Average Hb level at recruitment was 113 g/L in the FCM intervention
group versus 120 g/L in the oral iron group that increased respectively to an
average of 122 g/L versus 124 g/L immediately prior to surgery and was main-
tained at 126 g/L versus 123 g/L at 3 months after treatment respectively. The
median baseline ferritin in the FCM group was 32 mcg/L versus 76 mcg/L that
increased immediately prior to surgery to 544 mcg/L in the FCM versus 107
mcg/L in the oral iron group and was maintained for 3 months at 176 mcg/L
versus 90 mcg/L respectively (p<0.001). Average LoS in the hospital was
reduced by 1 day in the FCM group as compared to the oral iron group. FCM
was well tolerated by all patients without serious adverse events.
QoL assessment using SF36 at baseline, immediately preoperative, and 3
months post operatively showed improvement in physical function, energy and
general health in favour of the FCM group.
Summary and Conclusions: Our data suggest that IV FCM was well tolerated
and was associated with improvement of both immediate preoperative Hb and fer-
ritin levels compared to oral iron. Accordingly, there was a reduction of length of
hospital stay and improvement of perceived QoL after surgery. Further trials that
aim to improve and optimize preoperative and postoperative Hb are warranted.
Trial registration: This study was registered prospectively in the Australian
New Zealand Clinical Trials Registry:
(http://www.ANZCTR.org.au/ACTRN12611001256965) and the World Health
Organization:
(http://apps.who.int/trialsearch/trial.aspx?trialid=ACTRN12611001256965).
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WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC
LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER
MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY
HISTORY IN CANCER PATHOGENESIS
E. Tausch1,* D. Landau2,3,4,5, A. Taylor-Weiner5, C. Stewart5, J. Reiter6,
J. Bahlo7, S. Kluth7, I. Bozic8, M. Lawrence5, S. Boettcher9, K. Cibulskis5,
D. Mertens1,10, C. Sougnez5, M. Rosenberg5, J. Hess5, S. Carter5,
J. Edelmann1, S. Kless1, A. Fink7,11, K. Fischer7,11, M. Ritgen9, M. Kneba9,
S. Gabriel5, E. Lander5, M. Nowak8, H. Döhner1, M. Hallek7,11,12,
D. Neuberg2,13, G. Getz5,14, S. Stilgenbauer1, C. Wu2,3,4,5
1Department of Internal Medicine III, Ulm University, Ulm, Germany, 2Harvard
Medical School, 3Department of Internal Medicine, Brigham and Women’s Hos-
pital, 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
5Broad Institute of Harvard and MIT, Cambridge, United States, 6IST Austria
(Institute of Science and Technology Austria), Klosterneuburg, Austria, 7Depart-
ment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn,
University Hospital Cologne, Cologne, Germany, 8Department of Organismic
and Evolutionary Biology, Harvard University, Cambridge, United States,
9Department of Internal Medicine II, University Hospital of Schleswig-Holstein,
Kiel, 10Cooperation Unit “Mechanisms of Leukemogenesis”, German Cancer
Research Center (DKFZ), Heidelberg, 11German CLL Study Group, Central
office, 12Cologne Cluster of Excellence in Cellular Stress Responses in Aging-
associated Diseases, Cologne, Germany, 13Biostatistics and Computational
Biology, Dana-Farber Cancer Institute, 14Cancer Center and Department of
Pathology, Massachusetts General Hospital, Boston, United States
Background: Massively parallel whole-exome sequencing (WES) studies have
uncovered cancer drivers in CLL and have provided new insights in disease
pathogenesis, evolution and prognostication.
Aims: To overcome limitations in size and the clinical heterogeneity of previous
cohorts, we performed WES on pretreatment tumor and matched germline
samples of 278 CLLs enrolled in the CLL8 trial of the GCLLSG treated with
FC/FCR and with full clinical annotation and mature follow up time. We
enhanced the power to detect putative drivers through integration with previ-
ously published WES data for a total discovery cohort of 538 CLL exomes.
Figure 1.
Results: This resulted in detection of 55 putative CLL driver events (44 sSNVs,
11 sCNVs), many of which have not been previously associated with CLL. At
least one potential driver event was found in 91.1% of samples, with 65.4%
harboring 2 or more. These putative drivers appeared to affect 8 major cellular
processes, including the MAP-ERK pathway (KRAS, NRAS, BRAF, MAP2K
mutations; affecting 5.6% of cases), and the MYC pathway (MGA, FUBP1,
PTPN1, IRF4 mutations; 8% of cases). For the majority of samples, two driver
events were found within the same sample, one at clonal and the other at sub-
clonal frequency. Such cases enabled us to infer a temporal sequence of acqui-
sition and built a network based on significantly recurrent temporally directed
events. Thus we found distinct points of origin restricted to few events such as
del13q and tri12, with early convergence to del11q and subsequent divergence
in diverse late-occurring driver events including mutated TP53 and KRAS. We
assessed the clinical impact of driver events in 278 patients from CLL8 in the
context of front line therapy. Mutated TP53 and SF3B1 cases had significantly
shorter PFS and OS. XPO1 (HR 2.02, P =0.02), BRAF (HR 2.05, P =0.05) and
EGR2 (HR 2.14, P =0.05) mutations were associated with reduced OS and
trend towards shorter PFS. ATM and BIRC3 mutations had no significant impact
on outcome. Both the presence of a pre-treatment subclonal driver (66.5% of
subjects) and clonal driver (84.2%) were associated with a significantly shorter
PFS (HR 1.64, p=0.003 and HR 1.78 p=0.009) with only subclonal drivers
achieving significance in the FCR arm. To directly observe clonal evolution fol-
lowing FC/FCR, we compared the cancer cell fractions (CCFs) of the putative
driver alterations in 59 of 278 samples for which a matched relapse samples
was available. We observed clonal shifts in 57 of 59 cases of which 21 showed
linear and 36 branched evolution with the latter significantly associated with
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FCR treatment. Neither type of evolution nor presence of the relapsed clone
at baseline (n=18) had an impact on outcome. Notably events inferred as early
events by our temporal network were stably clonal over time. Late events
demonstrated either increasing (i.e. in TP53) or shifting (i.e. in SF3B1, ATM)
CCFs after FC/FCR suggesting evolution in relation to therapy (figure). In addi-
tion, this temporal map suggests that the copy number loss in 11q precedes
point mutations in ATM or BIRC3 in cases with biallelic loss. By contrast, TP53
and 17p show a concordant rise of both events suggesting that biallelic inacti-
vation of TP53 is typically required for fitness advantage.
Summary and Conclusions: WES of a large, uniform cohort revealed several
novel putative drivers in CLL, enabled their categorization into 8 major func-
tional pathways and investigation of their prognostic impact within the CLL8
trial cohort. Furthermore we developed a network model of CLL evolution with
earlier initiating and late accelerating events.
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CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSION-
FREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND
DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE
MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
M. Dimopoulos1,* P. Moreau2, A. Palumbo3, D. Joshua4, L. Pour5, R. Hájek6,
T. Facon7, H. Ludwig8, A. Oriol9, H. Goldschmidt10, L. Rosiñol11, J. Straub12,
A. Suvorov13, C. Araujo14, E. Rimashevskaya15, T. Pika16, G. Gaidano17,
K. Weisel18, V. Goranova-Marinova19, A. Schwarer20, L. Minuk21, T. Masszi22,
I. Karamanesht23, M. Offidani24, V. Hungria25, A. Spencer26, H. Gillenwater27,
N. Mohamed27, S. Feng27, W.J. Chng28
1School of Medicine, National and Kapodistrian University of Athens, Athens,
Greece, 2University of Nantes, Nantes, France, 3University of Torino, Torino,
Italy, 4Royal Prince Alfred Hospital, Camperdown, Australia, 5University Hos-
pital Brno, Brno, 6University Hospital Brno and Faculty of Medicine, University
of Ostrava, Ostrava, Czech Republic, 7CHRU Lille Hopital Claude Huriez, Lille,
France, 8Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna,
Austria, 9Institut Català d’Oncologia, Institut Josep Carreras, Hospital Germans
Trias i Pujol, 10Heidelberg Medical University, 11Hospital Clínic de Barcelona,
Barcelona, Spain, 12Vseobecna fakultni nemocnice v Praze, Prague, Czech
Republic, 13First Republican Clinical Hospital of Udmurtia, Izhevsk, Russian
Federation, 14Centre Hospitalier de la Cote Basque, Bayonne, France,
15Semashko Central Clinical Hospital, Moscow, Russian Federation, 16Univer-
sity Hospital Olomouc, Olomouc, Czech Republic, 17Amedeo Avogadro Uni-
versity of Eastern Piedmont, Novara, Italy, 18Universitatsklinikum Tubingen,
Tubingen, Germany, 19University Multiprofile Hospital for Active Treatment
Sveti Georgi, Plovdiv, Bulgaria, 20Box Hill Hospital, Box Hill, Australia, 21London
Health Sciences Centre, Western University, London, London, Guam, 22St.
Istvan and St. Laszlo Hospital, Budapest, Hungary, 23Kyiv Center for Bone
Marrow Transplantation, Kyiv, Ukraine, 24Clinica di Ematologia, Azienda
Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi di
Ancona, Ancona, Italy, 25Irmandade da Santa Casa de Misericórdia de Sao
Paulo, Sao Paulo, Brazil, 26Alfred Health-Monash University, Melbourne, Aus-
tralia, 27Onyx Pharmaceuticals, Inc., an Amgen Subsidiary, South San Fran-
cisco, United States, 28National University Cancer Institute, National University
Health System, Singapore and Cancer Science Institute of Singapore, National
University of Singapore, Singapore, Singapore
Background: Bortezomib and dexamethasone (Vd) is a standard-of-care reg-
imen for RMM. Carfilzomib (20/27 mg/m2; 2–10 min intravenous [IV] infusion)
is approved in Argentina, Israel, Mexico, and the United States for relapsed
and refractory multiple myeloma and significantly improved progression-free
survival (PFS) when given with lenalidomide and dexamethasone for RMM in
the phase 3 study ASPIRE (NCT01080391; Stewart et al, N Engl J Med, 2015).
In study PX-171-007 (NCT00531284), carfilzomib (20/56 mg/m2; 30-minute
infusion) and dexamethasone (Kd) had promising activity in pts with RMM
(Papadopoulos et al, J Clin Oncol, 2015).
Aims: ENDEAVOR (NCT01568866) compares Kd with Vd in pts with RMM.
Results from a prespecified interim analysis are presented.
Methods: Adults with RMM (1─3 prior treatments) were eligible. Pts were ran-
domized 1:1 and stratified by prior K or V (yes vs no), prior lines of treatment
(1 vs 2–3), International Staging System stage (1 vs 2–3), and intended route
of V (IV vs subcutaneous [SC]). The Kd arm received K (30-min IV infusion) on
days (D) 1, 2, 8, 9, 15, 16 (20 mg/m2 on D1, 2 [cycle 1]; 56 mg/m2 thereafter)
and dexamethasone (20 mg) on D1, 2, 8, 9, 15, 16, 22, 23 of a 28-day cycle.
The Vd arm received V (1.3 mg/m2; IV or SC) on D1, 4, 8, 11 and dexametha-
sone (20 mg) on D1, 2, 4, 5, 8, 9, 11, 12 of a 21-day cycle. Cycles were repeated
until disease progression or unacceptable toxicity. The primary end point was
PFS assessed by an independent review committee. Secondary end points
include overall survival (OS), overall response rate (ORR), duration of response
(DOR), rate of peripheral neuropathy (PN), and safety. 
Results: In total, 929 pts (Kd: 464; Vd: 465) were randomized. In the Vd arm,
83.6% of pts received SC bortezomib. Median treatment exposure was 39.9
weeks (Kd) and 26.8 weeks (Vd). Kd led to a 47% decrease in the risk of pro-
gression or death (hazard ratio, 0.53; 95% confidence interval [CI], 0.44–0.65;
P<.0001), with a median PFS of 18.7 months (95% CI, 15.6–not estimable) in
the Kd arm vs 9.4 months (95% CI, 8.4–10.4) in the Vd arm. OS data were
immature (deaths: Kd=75; Vd=88); pts continue to be followed. Best overall
responses are presented in the table. The median DOR was 21.3 months (Kd)
and 10.4 months (Vd). Treatment discontinuation due to an adverse event (AE)
occurred in 14.0% (Kd) and 15.7% (Vd) of pts. An AE led to dose reductions of
K or V in 22.9% and 47.8% of pts, respectively; 61.9% of dose reductions in
the Vd arm were due to neuropathy-related AEs vs 6.6% in the Kd arm. Rates
of grade ≥2 PN (grouped term) were 6.0% in the Kd arm vs 32.0% in the Vd
arm (P<0001). The most common hematologic AEs (preferred terms; all
grades) in the Kd and Vd arms, respectively, included anemia (39.3% vs 27.0%)
and thrombocytopenia (20.5% vs 17.1%); the most common nonhematologic
AEs (preferred terms; all grades) included diarrhea (30.9% vs 38.4%), fatigue
(29.4% vs 28.5%), and dyspnea (28.5% vs 13.2%). Grade ≥3 AEs of interest
in the Kd and Vd arms, respectively, included hypertension (preferred term;
8.9% vs 2.6%), dyspnea (preferred term; 5.4% vs 2.2%), cardiac failure
(grouped term; 4.8% vs 1.8%), and acute renal failure (grouped term; 4.1% vs
2.6%). A total of 3.9% of pts in the Kd arm and 3.4% of pts in the Vd arm died
on study owing to AEs. 
Tabella 1. Best overall responses.
Summary and Conclusions: Carfilzomib and dexamethasone demonstrated
statistically significant and clinically meaningful superiority over bortezomib
and dexamethasone in RMM, with a 2-fold improvement in median PFS and a
favorable benefit–risk profile. These data suggest that carfilzomib could be a
best-in-class agent for RMM.
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PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED,
MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB
(PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
R. Mesa1,* A. Vannucchi2, A. Mead3, L. Wang4, Y. Yang5, C. Harrison6
1Mayo Clinic, Scottsdale, United States, 2University of Florence, Florence,
Italy, 3Oxford University, Oxford, United Kingdom, 4CTI BioPharma Corp., Seat-
tle, 5Baxter Healthcare Corporation, Deerfield, United States, 6Guy’s and St
Thomas’ NHS Foundation Trust, London, United Kingdom
Background: MF is a serious, life-threatening disease characterized by
splenomegaly and debilitating symptoms such as fatigue, night sweats, pruritus,
weight loss, and abdominal pain. MPN-SAF TSS is a PRO tool designed to
measure the burden of MF-related symptoms. The instrument was developed
and validated at Mayo Clinic for utilization in clinical practice. In agreement
with the FDA, the instrument was modified (MPN-SAF TSS 2.0) for use in PER-
SIST-1 and PERSIST-2, both, international, phase 3 randomized clinical trials
to support a PRO endpoint.
Aims: Compare symptom reduction of PAC vs BAT in the open-label PER-
SIST-1 (NCT01773187) trial in primary myelofibrosis (PMF), post-polycythemia
vera (PV-MF), and post-essential thrombocythemia (PET-MF).
Methods: JAK inhibitor naïve patients (pts) were randomized 2:1 to oral PAC
400 mg once daily or BAT stratified by DIPSS risk (Int-1/Int-2 vs High) and platelet
(plt) count (<50,000/µL vs 50,000 to <100,000/µL vs ≥100,000/µL). Pts had base-
line total symptom score (TSS) ≥13 using MPN-SAF TSS. Each symptom is
rated on a scale from 0 (absent) to 10 (worst imaginable) using MPN-SAF TSS
and MPN-SAF TSS 2.0 with core symptoms tiredness, night sweats, early satiety,
itchiness, bone pain, and abdominal pain. Other PROs included Patient Global
Impression of Change (PGIC), EORTC QLQ-C30, and EQ-5D-5L.
Results: 327 pts were enrolled (PAC: 220, BAT: 107), 62% with PMF; 32%
had plt counts <100,000/µL and 16% had plt counts <50,000/µL. 24.5% of pts
treated with PAC and 6.5% treated with BAT achieved a ≥50% decrease in
TSS at Week 24 (WK24; Figure; p<0.0001) in the intent-to-treat population. In
pts with baseline plt count <100,000/uL, 25.0% of pts treated with PAC and
8.8% treated with BAT achieved a ≥50% decrease in TSS at WK24 (p=0.0677).
There were significant reductions from baseline to WK24 in fatigue, early sati-
ety, abdominal discomfort, inactivity, night sweats, itching, and bone pain (MPN-
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SAF TSS), and tiredness, early satiety, abdominal discomfort, night sweats,
and pain under ribs on left side (MPN-SAF TSS 2.0). In the PAC group, 81%
of pts rated the change in their overall condition as very much improved, much
improved, or minimally improved by PGIC in pts who completed questions, vs
21% for pts in the BAT group (p<0.001). Among those with improvement in
PGIC, 40% had ≥50% reduction of TSS at WK24. On the EQ-5D-5L, overall
health scores were higher on average in patients treated with pacritinib and a
greater proportion reported improvement in the usual activities, pain/discomfort,
and anxiety/depression dimensions. Pacritinib-treated patients also reported
higher scores on functioning (physical, role and social) scales and lower scores
on symptom scales including fatigue, pain, insomnia, and loss of appetite on
the EORTC QLQ-C30.
Figure 1.
Summary and Conclusions: PAC treatment improved PROs across several
measures. Specifically, it resulted in significantly higher response rates based
on TSS which were associated with better PGIC and QoL.
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EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN (INO) VS
STANDARD OF CARE (SOC) IN SALVAGE 1 OR 2 PATIENTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL): AN ONGOING GLOBAL PHASE 3
STUDY
D.J. DeAngelo1,* M. Stelljes2, G. Martinelli3, H. Kantarjian4, M. Liedtke5,
W. Stock6, N. Goekbuget7, K. Wang8, L. Pacagnella9, B. Sleight9, E. Vandendries8,
A.S. Advani10
1Dana Farber Cancer Institute, Boston, MA, United States, 2Universität-
sklinikum Münster, Münster, Germany, 3Institute Seragnoli, University of
Bologna, Bologna, Italy, 4MD Anderson Cancer Center, Houston, TX, 5Stanford
Comprehensive Cancer Center, Stanford, CT, 6University of Chicago, Chicago,
IL, United States, 7Goethe University, Frankfurt, Germany, 8Pfizer Inc, Cam-
bridge, MA, 9Pfizer Inc, Groton, CT, 10Cleveland Clinic, Cleveland, OH, United
States
Background: The majority of cases of B-cell ALL express CD22. InO, a human-
ized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic antibi-
otic, showed initial efficacy and safety in ALL (Kantarjian. Cancer.
2013;119:2728).
Aims: To assess antitumor activity and safety of InO vs SOC (intensive
chemotherapy) in adults with relapsed/refractory ALL
Methods: In this phase 3 trial (NCT01564784), patients (pts) were randomized
to InO (starting dose 1.8 mg/m2/cycle [0.8 mg/m2 on d1; 0.5 mg/m2 on d8 and
15 of a 21–28 d cycle [≤6 cycles]) or SOC (either fludarabine/cytarabine [ara-
C]/granulocyte colony-stimulating factor [FLAG], ara-C plus mitoxantrone, or
high-dose ara-C). A split-α design was used for 2 primary endpoints: 1) complete
remission (CR) or CR with incomplete hematologic recovery (CRi) assessed in
218 pts; and 2) overall survival (OS) to be assessed in all 326 pts enrolled.
Secondary endpoints: duration of remission (DOR), minimal residual disease
negativity (MRD-neg; <0.01% by central flow cytometry) in pts with CR/CRi,
stem cell transplant (SCT) rate. Data as of October 2, 2014 are presented,
except for survival (not mature at this date).
Results: Per protocol, the first 218 of 326 pts randomized were included in the
primary intent-to-treat (ITT) analysis (for InO vs SOC [n=109 each]: CR1 dura-
tion ≥12 mo, 43% vs 35%; age <55 y, 61% vs 63%; Salvage 1, 67% vs 63%);
CR/CRi rate was significantly better in the InO vs SOC arm (see Table for effi-
cacy). Safety was assessed in 259 pts who received ≥1 dose of study drug; pts
received InO (n=139) for median 8.3 (range, 0.1–26.4) wks vs SOC (n=120)
for median 0.9 (0.4–15.1) wks; 83% vs 89% discontinued, primarily due to CR
in InO (35%) vs resistant ALL in SOC (40%) arms. Most common grade (Gr)
≥3 AEs were hematologic cytopenias. For InO vs SOC, Gr≥3 hepatobiliary AEs
occurred in 9% vs 3% pts; any grade veno-occlusive liver disease (VOD)
occurred in 15 vs 1 pts (Gr≥3, 13 vs 1 pts). More patients proceeded to allo-
geneic SCT with InO (n=48) vs SOC (n=20); in the InO arm, 5 VOD cases (2
in pts with prior SCT) occurred during treatment and 10 after subsequent SCT
(2 fatal).
Tabella 1. Best overall responses.
Summary and Conclusions: CR/CRi, DOR, and MRD-neg rates were signif-
icantly greater with InO vs SOC. InO safety profile is consistent with previous
studies; liver toxicities and VOD were more common with InO; additional VOD
analyses characterizing risk factors and management considerations will be
presented. Trial is ongoing to allow survival data to mature.
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FISH-BASED SCREENING FOR TYROSINE KINASE-ACTIVATING FUSION
GENES IN CHILDHOOD HIGH-RISK B-CELL PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA (BCP-ALL)
K. Nebral1,2,* M. König2, A. Attarbaschi3, G. Mann3, O.A. Haas1,2,3, S. Strehl2
1medgen.at GmbH, 2CCRI, Children‘s Cancer Research Institute, 3St. Anna
Children’s Hospital, Medical University, Vienna, Austria
Background: Tyrosine kinase (TK)-activating gene fusions define a biologically
and clinically distinct class of apparently high-risk BCP-ALL in children and
adolescents (Roberts et al, New Engl J Med 371:1005;2014). Because they
provide unique targets for therapeutic interventions with various fusion type-
specific tyrosine-kinase inhibitors, these abnormalities attain considerable inter-
est. Consequently, there is also a pressing need to identify all the respective
lesions in a fast and cost efficient way.
Aims: In consideration of these demands, we devised a hierarchical FISH-
based screening algorithm that enables the detection of the vast majority of all
relevant alterations. We used this approach to examine a careful selected
group of high-risk patients that were enrolled in the Austrian BFM-ALL 2000
treatment study with the aim to identify the respective TK-activating fusion
genes in order to determine their type, frequency and clinical relevance.
Methods: Our strategy consists of several hierarchical steps of FISH screening,
the first of which is required to define and exclude the preponderant proportion
(>60%) of cases with all known specific abnormalities, such as those with an
ETV6/RUNX1, BCR1/ABL1, KMT2A, TCF3 and IGH rearrangement as well as
those with a hyper- or hypodiploid karyotype, iAMP21 and dic(9;20), because
cases with the TK fusions of interest are almost exclusively found in the remain-
ing so-called “B-others” cohort. Next, we exploit the fact that one of the respec-
tive fusion partners is always one of a few TK-activating hub genes, namely
ABL1, ABL2, CRLF2, CSF1R, JAK2, PDGFRB or EPOR. The potential involve-
ment of the one or the other of these genes is then assessed with the respective
3’-5’ dual-color split apart FISH probes.
Results: So far, we have analyzed 50 high-risk “B-others” patients that were
selected according to the above criteria. These cases were screened for the
presence of TK-activating gene fusions with all currently available commercially
PDGFRB/CSF1R, JAK2, CRLF2 and (the non-TK) PAX5 split-apart FISH
probes. We identified specific rearrangements in 13/50 (26%) cases. Three had
a PDGFRB/CSF1R, two a JAK2, seven a CRLF2 and one an ABL1 gene
rearrangement, the latter of which became apparent during screening with a
BCR/ABL1 FISH probe. Moreover, with the help of metaphase FISH, CGH array
and RT-PCR analyses we were also already able to identify the fusion partner
in 11/13 of these cases. Six of the 13 patients were transplanted, two of them
in second remission, five experienced a late relapse and three died, two because
of septicemia and one after experiencing a third relapse after transplantation.
Summary and Conclusions: The results of our analyses confirm the efficiency
and validity of our FISH screening approach, which currently is supplemented
also with additional assays, in particular those identifying ABL1 and ABL2 gene
rearrangements. The presented strategy can be easily adopted in an analogous
fashion to identify such TK-activating gene fusions also in other forms of hema-
tologic malignancies. Their unambiguous identification is an essential require-
ment for choosing a suitable TK inhibitor, an option that is increasingly required
for the appropriate disease-specific treatment.
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CUSTOMIZED NEXT-GENERATION SEQUENCING PANEL FOR
IMPROVED CLINICAL DIAGNOSTICS OF HIGH-RISK B-CELL PRECURSOR
ACUTE LYMPHOBLASTIC LEUKEMIA OF CHILDHOOD
U. Zur Stadt1,* G. Escherich2, D. Indenbirken3, M. Adao1, M. Alawi4,
M.A. Horstmann25
1Center for Diagnostic, 2Clinic of Pediatric Hematology and Oncology, Univer-
sity Medical Center Hamburg Eppendorf, 3Virus Genomics, Heinrich-Pette-
Institute for Experimental Virology, 4Bioinformatics Core Facility, University
Medical Center Hamburg Eppendorf, 5Research Institute Children’s Cancer
Center, Hamburg, Germany
Background: Next generation sequencing (NGS) applications have recently
identified various recurrent kinase and cytokine receptor mutations in a sub-
group of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is char-
acterized by a Ph-like gene expression signature. Combined genome, exome
or transcriptome analyses have identified recurrent genetic alterations of kinas-
es and cytokine-receptors/adaptors, which often result in ligand-independent,
constitutive activation of downstream signalling pathways. The diversity of
mutation types including complex genomic rearrangements demands new
strategies for cost-effective, time-saving routine clinical diagnostics.
Aims: We report a feasible approach for the identification and characterization
of kinase and kinase-dependent pathway aberrations in BCP-ALL utilizing a
customized sequence enrichment capture panel for NGS.
Methods: Thirteen BCP-ALL patients with a high minimal residual disease
(MRD) level (≥1x10-2) after induction therapy from COALL studies 07-03 or
08-09 were applied to the panel. Four positive controls with known rearrange-
ments (BCR-ABL1 and ID4-JH) were included to test the general applicability
of the method. Genomic capture probes were specific for exonic and intronic
regions of ABL1, JAK2, PDGFRB, CRLF2 and for the IgH-JH region on chro-
mosome 14. These predefined genomic regions from recurrently mutated or
rearranged kinase and cytokine receptor genes were enriched from 50 ng of
initial genomic DNA without gene specific PCR amplification steps, followed
by paired end sequencing of the captured genomic fragments (Nextera Rapid
Capture Custom enrichment protocol with paired end sequencing on a MiSeq
benchtop sequencing platform; Illumina).
Results: All breakpoints from 4 positive controls were successfully identified
and verified by patient specific amplification of the genomic fusion sites. ABL1
and JH specific capture probes allowed the “fishing” of the genomic fusion
partner gene, here BCR and ID4, by paired end sequencing of overlapping,
breakpoint spanning reads. This approach also allowed the identification and
exact mapping of the genomic breakpoint for CRLF2 (P2RY8-CRLF2; CRLF2-
JH), PDGFRB (EBF1-PDGFRB) or EPOR (IgH-EPOR) in 7/13 BCP-ALL with
high level of post-induction MRD.
Summary and Conclusions: Rapid identification of kinase- or cytokine recep-
tor rearrangements in BCP-ALL offers new therapeutic options for the treatment
with target specific tyrosin kinase inhibitors (TKI’s). Our approach is applicable
for routine clinical applications with short turnaround times of less than 2 weeks.
Up to 12 samples can be processed in parallel on one MiSeq run. Bioinformat-
ical analysis follows a standardized, automated workflow. Despite limitations
in target gene selection, the method allows the identification of unknown fusions
partners from frequently rearranged kinase genes, providing the exact break-
point location. MRD guided NGS panel analysis is a feasible strategy for iden-
tification of patients suitable for targeted TKI intervention, which may reduce
the high risk for therapeutic failure/relapse.
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THE LNCRNAS MEG3 AND LINC-PINT REGULATE THE EXPRESSION OF
HMOX1 IN ALL, SHOWING A POTENTIAL AS A THERAPEUTIC TARGETS
FOR THIS DISEASE
A. Garitano Trojaola1, X. Agirre1, A. Vilas1, V. Segura2, P. Fortes3, F. Prosper1,*
1Oncology, 2Bioinformatics, 3Hepatology and Gene therapy, Centre for Applied
Medical Research (CIMA), Pamplona, Spain
Background: Long non-coding RNAs (lncRNAs) are functional RNAs longer
than 200 nucleotides in length. Compared to mRNAs, most lncRNAs are local-
ized preferentially to the nucleus, are more cell type specific and are expressed
at lower levels. The function of lncRNAs in the cell is primarily regulatory and
they have a clear impact in cell behavior. Furthermore, several lncRNAs are
deregulated in human diseases including several cancers. 
Aims: we aimed to analyze the expression and function of lncRNAs in ALL.
Methods: In order to identify aberrantly expressed lncRNAs in ALL, we used
the SurePrint G3 Human Gene Expression array that detects 27956 coding
genes and 7419 lncRNAs. The transcriptomes of primary ALL cells, ALL cell
lines and control samples were compared.
Results: In this analysis, we detected 37 lncRNAs differentially expressed, 24
of them down-regulated and 13 up-regulated in ALL cells compared to healthy
controls. We analyzed the expression of 21 deregulated lncRNAs by quantita-
tive RT-PCR (q-PCR) and we validated the data obtained by expression arrays
in 18 out of the 21 genes tested. We focused our study in MEG3 and linc-
PINT, and by q-PCR, we observed a decreased expression of these 2 lncRNAs
in 10 ALL-derived cell lines compared with B and T cells obtained from healthy
donors. Also, we detected a direct correlation between an inappropriate DNA
methylation and the decreased expression of MEG3 in ALL cell lines. Interest-
ingly, we observed that re-expression of MEG3 or linc-PINT in ALL cells led to
a decrease in cell proliferation, due to cell cycle arrest in G2 phase and induc-
tion of apoptosis. The transcriptome analysis of ALL cell lines after overex-
pression of MEG3 or linc-PINT, showed an increase expression of HMOX1.
Interestingly, the overexpression of HMOX1 on its own also decreased cell
proliferation, suggesting that HMOX1 could be a mediator of the phenotype
observed after re-expression of MEG3 or linc-PINT. Finally, we observed that
different drugs that affect proliferation of ALL cells, such as curcumin or panobi-
nostat, induced drastically the expression of linc-PINT and HMOX in these cell
lines. These results indicate that linc-PINT and HMOX1 could be interesting
therapeutic targets for improving the treatment of ALL patients.
Summary and Conclusions: The expression of several lncRNAs is altered in
primary samples and cell lines of ALL. In some cases, altered expression is
due to inappropriate DNA methylation. MEG3 and linc-PINT are decreased in
ALL cells and their re-expression affects cell cycle progression and induces
apoptosis in these cells. These effects could be mediated by HMOX. Curcumin
and panobinostat also induce linc-PINT and HMOX, which could drive their
effects in cell proliferation. Therefore, linc-PINT and HMOX1 could be thera-
peutic targets for improving the treatment of patients with ALL.
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THE ROLE OF NRARP IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
PATHOGENESIS AND CHEMOTHERAPY SENSITIVITY
M.L. Oliveira1, R. Cabrita1, J.T. Barata1, R. Fragoso1,*
1Cancer Biology Unit, Instituto de Medicina Molecular, Lisboa, Portugal
Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematological malignancy. Although the outcome of T-ALL patients has
improved over recent years, the poor prognosis of patients with resistant or
relapsed disease is still a major concern. Even though NOTCH is a known
driver in T-ALL, its inhibition cannot be efficiently achieved with the drugs cur-
rently available, due to their weak therapeutic effects and severe toxicity. Thus,
a better understanding of the mechanisms downstream of NOTCH oncogenic
signaling in T-ALL is necessary in order to develop NOTCH targeting therapies
more effective and less toxic. We have shown that loss of mir-181ab1 blocks
Notch-induced T-ALL development partly by de-repressing the expression of
NRARP (NOTCH regulated ankyrin repeat protein)(Fragoso R., PLOS Genetics
2012), a transcriptional target of NOTCH and a negative regulator of NOTCH
signaling. Interestingly, NRARP over-expression in murine hematopoietic stem
cells impairs T-cell differentiation. Since T-ALL originates from a block during
T-cell development, these results suggest that de-regulation of NRARP expres-
sion can contribute to the pathogenesis of T-ALL. Importantly, over-expression
of NRARP in thymoma cells displaying NOTCH-induced glucocorticoid resist-
ance was shown to sensitize the cells to this drug. This suggests that targeting
NRARP may further tackle chemotherapy-resistance in T-ALL.
Aims: To investigate the role of NRARP in human T-ALL cell growth and survival
and its potential to sensitize T-ALL cells to commonly used chemotherapeutic
agents.
Methods: NRARP mRNA and protein expression was determined by real time-
PCR and western blot analyses. in vitro functional evaluation of NRARP in T-
ALL cell lines was performed by flow cytometry analysis of proliferation and
viability upon NRARP over-expression. To determine the effects of NRARP in
chemotherapy sensitivity and resistance, T-ALL cells were exposed to Dexam-
ethasone (Dex), Asparaginase (APR) and Methotrexate (MTX). 
Results: We started by quantifying NRARP expression in human T-ALL cell
lines (n=10) and compared it with the expression of NRARP in human thy-
mocytes (n=10). We observed that NRARP expression is significantly
decreased in T-ALL cells (p=0.05). Moreover, quantification of NOTCH1 in
the same cells showed that NRARP expression is inversely correlated with
NOTCH1 levels. Of note, although NRARP is a downstream target of NOTCH
signaling, which is constitutively active in T-ALL patients, it is also a target of
mir-181ab1, which is highly expressed in T-ALL cells. Next, we over-
expressed NRARP in human T-ALL cell lines. Remarkably, NRARP over-
expression results in a block in leukemia cell expansion (4 out of 5 cell lines).
Proliferation and viability analyses revealed that NRARP over-expression
affects T-ALL cell proliferation (CEM and Jurkat cells) and survival (Molt4 and
DND41 cells). Importantly, NRARP overexpression sensitizes leukemia cells
to APR (CEM cells), MTX (CEM and DND41 cells) and Dex (CEM and
DND41). Moreover, over-expression of NRARP partly re-sensitizes Molt4
Dex-resistant cells to this drug.
Summary and Conclusions: Taken together our preliminary results suggest
that NRARP plays an important role in T-ALL pathogenesis and chemotherapy
resistance.
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THE INHIBITION OF CHECKPOINT KINASE 1 INCREASES THE
EFFECTIVENESS OF CONVENTIONAL CHEMOTHERAPY IN B-/T-ACUTE
LYMPHOBLASTIC LEUKEMIA
A. Ghelli Luserna Di Rora1,* I. Iacobucci1, E. Imbrogno1, E. Derenzini1, A. Fer-
rari1, V. Robustelli1, V. Guadaguolo1, M. Abbenante1, C. Papayannidis1, M.
Cavo1, G. Martinelli1
1Department of Hematology and Medical Sciences “L. and A. Seràgnoli,
Bologna, Italy
Background: During the last few years the efficacy of many Checkpoint Kinase
(Chk)1/Chk2 inhibitors has been assessed for the treatment of different type of
cancers but only few studies have been performed to evaluate their effective-
ness on hematological diseases.
Aims: In this study we evaluated the in vitro efficacy of the Chk1 inhibitor,
LY2606368, as single agent and in combination with other tyrosine kinase
inhibitors (imatinib and dasatinib) or chemotherapy drugs (clofarabine) in B-/T-
ALL cell line and in primary blasts. 
Methods: Human B (BCR-ABL1-positive: BV-173, SUPB-15; BCR-ABL1-neg-
ative: NALM-6, NALM-19, REH) and T (MOLT-4, RPMI-8402, CEM) leukemia
cell lines were incubated with increasing concentrations of drug (1-100 nM) for
24 and 48 hours and the cell viability was evaluated using WST-1 reagent. The
effect of the inhibition of Chk1 on cell cycle profile was analyzed using Propidium
Iodide (PI) staining. To deeply understand the effect of the compound on the
pathway of Chk1, different western blots analyses were performed on specific
downstream targets of Chk1. The Chk1 inhibitor LY2606368 was purchased
by ApexBio Technology.
Results: LY2606368 deeply reduced the cell viability in a dose and time
dependent manner in all the cell lines treated, with the BV-173 (6.33 nM IC50
24hrs) and RPMI-8402 (8.07 nM IC50 24hrs) cell lines being the most sensitive
while SUP-B15 (61.4 nM IC50 24hrs) and REH (96.7 nM IC50 24hrs) cell lines
being the less sensitive. In addiction the sensitivity was no correlated with the
different sub-type of ALL or with the mutational status of p53. The cytotoxic
activity was confirmed by the significant increment of the number of apoptosis
cells (Annexin V/Propidium Iodide), by the increment of γH2AX foci and by the
activation of different apoptotic markers (Parp-1 and pro-Caspase3 cleavage).
To better understand the relationship between the activation of apoptosis and
the effect on cell cycle, different cell cycle analyses were performed. The inhi-
bition of Chk1, even with a high heterogeneity among the different cell lines,
deeply changed the cell cycle profile. In all the cell lines the percentage of cells
in G1 phase and in G2/M phase were reduced by the treatment while the num-
bers of cells in sub-G1 and S phase were increased. Furthermore the cytotox-
icity of LY2606368 was evaluated in combination with imatinib, dasatinib or the
purine nucleoside antimetabolite clofarabine. The combination strongly reduced
the cell viability when compared to the cytotoxic effect of the single drugs. More-
over the combination showed an additive efficacy in term of induction of DNA
damages as showed by the increase number of γH2AX foci and the activation
of phospho-Chk1 (ser 317). 
Summary and Conclusions: LY2606368 as single agents showed a strong
cytotoxic activity on B-/T-All cell lines. Furthermore the compound was able to
increase the cytotoxic effect of imatinib, dasatinib and clofarabine in all the cell
lines treated. In our opinion this data are the basis for a future clinical evaluation
of this compound in the treatment of leukemia. Supported by ELN, AIL, AIRC,
progetto Regione-Università 2010-12 (L. Bolondi), FP7 NGS-PTL project.
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LEUKEMOGENICITY OF RCSD1-ABL1 OF PH-LIKE ACUTE
LYMPHOBLASTIC LEUKEMIA VARIES BETWEEN FUSION SITES
H. Tamai1,* H. Yamaguchi1, K. Miyake2, M. Takatori3, T. Kitano4, K. Dan5,
K. Inokuchi1
1Hematology, 2Biochemistry and Molecular Biology, 3Research Center for
Advanced Medical Technology, 4Research Center for Life Science, Nippon
Medical School, Tokyo, 5Medical Education Center, Ryotokuji University, Uraya-
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Background: The RCSD1 gene, located at 1q23 involved in t(1;9)(q23;q34)
translocation in acute lymphoblastic leukemia (ALL)ALL is known as a novel gene
fusion partner of ABL1 gene. RCSD1-ABL1-positive ALL is included in Philadelphia
chromosome-like (Ph-like) ALL. The leukemogenicity of RCSD1-ABL1 are unde-
fined. We found two types of fusion gene in a case of RCSD1-ABL1-positive ALL—
the first involved fusion of exon 2 of RCSD1/exon 4 of ABL1 (R2A4; 2952 bp) and
the other involved fusion of exon 3 of RCSD1/exon 4 of ABL1 (R3A4; 3042 bp).
Aims: The aim of this study is examine the leukemogenicity of two kinds of
fusion genes of RCSD1-ABL1.
Methods: We generated retroviral vectors expressing R2A4 or R3A4, which
we used to transduce Ba/F3 cells, and examined the IL-3 dependency of each
transduced Ba/F3 cell line. Secondly we examined the multiplication activity
and the IL-3 dependency of each Ba/F3. Thirdly we injected 2x108 of each
Ba/F3 to SCID mice and examined the overall survivals (OS) and histopathology
of each mice. Fourthly we examined phosphorylation receptor tyrosine kinase
activity of each Ba/F3 under no IL3 by Phosphorylation Antibody Array. Based
on the result of Phosphorylation Antibody Array, we examined the mechanisms
of leukemogenicity of RCSD1-ABL1 by Western Blotting. Finally we examined
the response of leukemogenicity of RCSD1-ABL1 to Tyrosine Kinase Inhibitors
Results: Only R3A4-Ba/F3 showed significant independence from IL3 (Control
vs. R3A4, P = 0.001; Control vs. R2A4, P = 0.90). In vivo, R3A4-Ba/F3-injected
mice showed significantly shorter survival times than Control or R2A4-Ba/F3-
injected mice (42 vs. > 100 days, respectively, P = 0.0009). Leukemic changes
were observed only in R3A4-Ba/F3-injected mice. Phosphorylation Antibody
Array showed that Tyk2 were activated only in R3A4-Ba/F3. Western Blotting
showed that the leukemogenicity of R3A4 consists of Tyk2-STAT2 pathway.
R3A4-Ba/F3 was resistant to Imatinib and Dasatinib but sensitive to pan-JAK
family including Tyk2 inhibitor.
Summary and Conclusions: Previous study reported that another R3A4 fusion
activated STAT5, which was inhibited by Dasatinib. Our findings, together with
this previous report, suggest that leukemogenicity of RCSD1-ABL1 of Ph-like
ALLvaries between fusion sites.
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TRD/TRA REARRANGEMENTS OCCUR INFREQUENTLY IN EARLY
THYMIC PRECURSOR SUBTYPE OF T LYMPHOBLASTIC LEUKEMIA BY
HIGH-THROUGHPUT SEQUENCING 
A. Sherwood1,* B. Wood2, K. Choi1, S. Winter3, K. Dunsmore4, M. Loh5,
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Hutchinson Cancer Research Center, Seattle, United States
Background: High-throughput sequencing (HTS) of T-cell receptor genes may
be useful for detecting minimal residual disease (MRD) in acute lymphoblastic
leukemia. We previously demonstrated application of high-throughput sequenc-
ing for the detection of minimal residual disease in T-lineage acute lymphoblastic
leukemia (T-ALL) (Sci. Transl. Med. 4(134):134ra63. 2012), and showed that
early thymic precusor T-ALL and a subtype which we termed “near-ETP” with
variable low CD5 expression frequently lacked a complete clonal rearrangement
of TRB. The absence of a pre-treatment clonal rearrangement of TRB limits the
potential for molecular monitoring by next-generation sequencing of this T-cell
receptor gene rearrangement for minimal residual disease in these subtypes of
leukemias. TRD gene rearrangements are expected to occur earlier in T cell
development than TRB, suggesting they are an attractive marker.
Aims: Given TRD is the first T-cell receptor to rearrange during T lymphocyte
development, we evaluated the feasibility of amplifying and sequencing of
TRD gene rearrangements to monitor MRD in ETP and “near-ETP” subtypes
of T-ALL.
Methods: We sequenced the TRD and TRA of residual samples from 33
patients enrolled in Children’s Oncology Group AALL0434 using an amplifica-
tion bias-controlled multiplex PCR. These 33 samples included 11 cases of
early thymic precursor (ETP) subtype, 12 so-called near-ETP sample (which
have similar immunophenotype with ETP but differences in CD5 expression)
and 10 non-ETP samples. We defined high-frequency clones as probable neo-
plastic if they exceeded 15% of the repertoire.
Results: We find that clonal TRD and TRA rearrangements can be identified
in only 2 of 11 of pre-treatment samples of ETP-TALL, using a cut-off of 15%
for defining clonality. By comparison, in a cohort of 12 “near-ETP” samples,
samples with leukemic blasts that have some but not all of the immunopheno-
typic features of ETP, we found 5 of 12 cases with TRD gene rearrangement.
Lastly, typical, “non-ETP” T-ALL subtypes showed evidence of clonal rearrange-
ment in 7 of 10 cases.
Summary and Conclusions: Our data suggest that clonal rearrangements in
ETP subtype of T-ALL are infrequent, suggesting that molecular monitoring of
TRD and TRA T-cell receptor gene rearrangements does not substantially
enhance the ability to follow ETP- clones through treatment for post-therapy
MRD detection.
E856
PROGNOSTIC VALUE OF DELETIONS AND PROMOTER METHYLATION
OF CDKN2A AND CDKN2B IN CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA
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Background: Alterations in CDKN2A and CDKN2B are the most common
molecular patterns in pediatric acute lymphoblastic leukemia (ALL). Deletions
in these genes occur in 30% of cases and are the leading mechanism in inac-
tivation of these genes. The available data for promoter methylation of CDKN2A
and CDKN2B is discrepant and the importance of this mechanism needs to be
answered.
Aims: To assess the prevalence and size of deletions and promoter methylation
of CDKN2A and CDKN2B and to ascertain the impact of these aberrations on
clinical and biological features in children with ALL.
Methods: We analyzed copy number variations in selected genomic loci using
MLPA (Multiplex Ligation dependent Probe Amplification; P202, P335, ME028
kits) on DNA extracted from bone marrow samples collected from patients at
diagnosis of childhood ALL. Promoter methylation of CDKN2A and CDKN2B
was examined by using Methylation-specific MLPA (MS-MLPA) method. Data
mining analysis technique was used for evaluation of coexistence of non-ran-
dom patterns of factors. We analyzed overall survival and event-free survival
with respect to genetic alterations as well as clinical features of these patients.
Results: Six hundred fifty two samples were analyzed. In 185 (28.4%) samples
deletions in 9p21 region were detected: 29 (4.4%) were positive for deletions
of CDKN2A, 151 (23.2%) of CDKN2A and CDKN2B and 5 (0.8%) of CDKN2B.
In 85 (13%) patients deletions of CDKN2A were homozygous. Methylation sta-
tus was determined in 208 samples. P15 promoter was methylated in 49
(23.5%) samples, p14 and p16 promoters were methylated in 9 (4.3%) and 11
(5.3%) cases, respectively. The deletion of MIR31 was significantly associated
with the deletion of both CDKN2A and CDKN2B (p<0.001). We detected asso-
ciations between deletions in 9p21 region and ETV6, IKZF1 and PAX5: con-
current deletions in 9p21 and ETV6 were found in 42 (7.0%) cases (p=0.04),
in 9p21 region and IKZF1 were found in 41 (6.3%) cases (p=0.008) and in
9p21 region and PAX5 were found in 44 (7.0%) cases. Homozygous deletions
in CDKN2A and CDKN2B genes were associated with worse event free survival
(p=0.03), but there was no significant impact on overall survival. Methylation
of p15, p14 and p16 promoters were not associated with other molecular alter-
ations. Methylation of p15 worsened overall survival (p=0.003) and the ten-
dency was seen regarding shortening event free survival.
Summary and Conclusions: Deletions in CDKN2A and CDKN2B are com-
monly associated with deletions of ETV6, PAX5 and IKZF1 genes. The co-
occurrence with deletions in IKZF1 may explain the fact of worse prognosis in
terms of both EFS and OS in patients with homozygous deletions of CDKN2A.
We found that the deletion of MIR31 is a valid indicator of large deletions in
9p21. Methylation of p15 promoter seems to be a frequent and biological impor-
tant occurrence in childhood ALL.
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MAJOR IMPACT OF AN EARLY CHECKPOINT FOR MINIMAL RESIDUAL
DISEASE IN FLOW CYTOMETRY IN CHILDHOOD ALL: A BICENTRIC
STUDY
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Background: Although childhood acute lymphoblastic leukemia (ALL) is of
good prognosis, about 15 to 25% of the patients relapse. The early persistence
of positive minimal residual disease (MRD) is considered as a poor prognostic
factor indicative of chemoresistance.
Aims: We report a study on the level of MRD assessed by multiparameter flow
cytometry (MFC) in the bone marrow samples used for morphologic assess-
ment of chemosensitivity at day 21 (D21) post induction.
Methods: This study enrolled 123 children (median age 5 years, range 6
months-21 years), treated between 2006 and 2014 in Nantes and Marseilles
University Hospitals with a median follow up of 30 months. On D8, 85 children
were corticosensitive and 21 were unassessable (<1G/L blasts at diagnosis).
On D21, 109 patients with less than 5% bone marrow blasts were considered
chemosensitive. Sixteen relapses were observed and 5 patients died.MRD
was investigated at D21 (MRD0) in MFC and at day 35 by RT-qPCR for
IGH/TCR rearrangements (MRD1). Antibody combinations (5 to 10) correspon-
ding to the specific Leukemia Associated ImmunoPhenotypes of the blasts at
diagnosis was used. A minimum of 10 clustered events allowed to assess a
positive result. Acquisition of at least 100,000 events were required for a neg-
ative result. A median of 537 816 events were analyzed per patient.Event-free
survival (EFS) and overall survival (OS) were studied according to the log-rank
test. A Chi2 test was performed to compare MRD0 to MRD1.
Results: Early MRD defines three risk groups: three risk groups were estab-
lished according to the level of MRD0 by MFC at D21: Level 1 (high risk,
n=25)>10-2, Level 2 (intermediate risk, n=46) 10-2 to 10-4 and Level 3 (low risk,
n=50) <10-4.OS (p=0.048) and EFS (p=0.00017, Figure 1) were significantly
different between the three MRD0 risk groups. These subgroups also allowed
to reclassify patients at high cytogenetic risk, those reaching level 3 presenting
no relapse (p=0.02). Early MRD levels are more discriminating than classically
defined early responses to therapy: evolution of the 14 corticoresistant patients
appeared to strongly depend on their MRD0 level (p=0.004), all low-risk level
3 patients still being in complete remission 1 (CR1) at 4 years while all high-
risk level 1patients had relapsed. Similarly, chemosensitive patients had a sig-
nificantly different evolution according to their level of MRD0, both for EFS
(p=0.004) and OS (p=0.02). MRD0 has more prognostic value than MRD1:
MRD0 and MRD1 levels were compared for 112 patients. Consistent results (-
/- or +/+) were observed in 57.2 % of the cases. Four patients had a low level
of MRD1 but undetectable MRD0. By contrast, the 44 MRD0+/MRD1- patients
had a significantly worse EFS (p=0.004) than the 33 with undetectable MRD
at both MRD0 and MRD1.Multivariate analysis for EFS, using the Cox model
analysis with age, corticosensitivity, chemosensitivity, MRD0 and MRD1, only
retained a significant prognostic value for age (p=0.01) and MRD0 (p=0.0001).
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Figure 1. Comparative EFS and OS according to MRD levels in MFC at
day Level 1, solid line, level 2 dashed line, level 3 dotten line.
Summary and Conclusions: This study confirms the usefulness and superi-
ority of MRD detection by MFC in day21 bone marrow in order to better dis-
criminate patients with less than 5% blasts in cytomorphology at this time point.
In addition, MFC MRD0 identifies a subgroup of patients with poorer prognosis
(MRD0+/MRD1-) who would be missed with MRD only performed on D35. MFC
thus provides valuable early information on the actual chemosensitivity of these
children.
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MDM2 ANTAGONIST NUTLIN-3A IN ADULT PHILADELPHIA POSITIVE
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Background: The human p53 tumor suppressor is functionally impaired in
nearly 50% of human cancers. Although its alterations are relatively infrequent
in B-ALL, wild-type TP53 remains dysfunctional due to overexpression of MDM2
and also to deletion of CDKN2A gene.
Aims: In testing novel therapeutic approaches activating p53, we investigated
the preclinical activity of the MDM2 antagonist, Nutlin-3a, in Philadelphia pos-
itive (Ph+) and negative (Ph-) leukemic cell line models, and primary Ph+B-
Acute lymphoblastic leukemia (ALL) patient samples.
Methods: Ph+(BV-173 and SUP-B15) and Ph- (NALM-6, NALM-19 and REH)
cell lines and primary Ph+ALL cells were incubated with increasing concentra-
tions of Nutlin-3 for different times. Methanethiosulfonate test was used to eval-
uate cell viability and flow cytometry was performed to analyze the apoptosis.
Gene expression profile (GEP) was performed using Affymetrix GeneChip
Human Gene 1.0 ST platform. p53, BMI-1, p21, caspase-3 and caspase-7 pro-
tein expression was evaluated by Western Blot (WB). BMI-1mRNA expression
was measured by quantitative real time PCR in ALL patient samples.
Results: In order to investigate the effects of Nutlin-3a treatment, we examined
cell viability of Ph+and Ph- cell lines and primary Ph+ALL cells. Nutlin-3a efficiently
reduced cell viability of Ph+(BV-173 and SUP-B15) and Ph- (NALM-6 and NALM-
19) ALL cells with wild-type p53, in dose-dependent manner. In contrast, no sig-
nificant changes in cell viability were observed in chronic myeloid leukemia p53-
null cell line K562 and in Ph- ALL p53-mutated cell line REH after incubation with
MDM2 inhibitor. Next, we observed that Nutlin-3a treatment, at 5 μM concentration
for 24 hours, induced a reduction of cell viability, ranging from 25% to 40%, on pri-
mary ALL cells compared to their untreated counterpart. Notably, the dose-depen-
dent reduction in cell viability was confirmed in primary blast cells from two Ph+ALL
patients with the T315I BCR-ABL kinase domain mutation. MDM2 inhibitor treat-
ment increased p53 protein expression in wild-type p53 cell lines activating p53
pathway, as demonstrated by increasing expression of p53 downstream target,
p21, and activation of the cleaved caspase-7 apoptotic marker. Nutlin-3a also
induced a dose- and time-dependent apoptosis in BV-173, SUP-B15 and NALM-
6 cell lines, with wild-type p53. By contrast, REH cells were not sensitive to Nut-
lin-3a. In order to better elucidate the implications of p53 activation and to identify
biomarkers of clinical activity, GEP analysis in sensitive cell lines showed 621
genes (48% down-regulated and 52% up-regulated) differentially expressed
(p<0.05) upon treatment. We found a strong down-regulation of BMI-1, repressor
of INK4/ARF and p21, after treatment as compared to control cells (fold-change -
1.11; p=0.03). This was validated in BV-173 and SUP-B15 cells after Nutlin-3a
treatment. Noteworthy, BMI-1 mRNA expression was down-regulated in Ph+ALL
patients after treatment (p<0.05), if compared with their untreated counterparts.
Summary and Conclusions: Inhibition of MDM2 efficiently reduces cell viability
and induces p53-mediated apoptosis in ALL cells. Therefore, targeting p53-
MDM2 could be able to overcome or synergize with conventional therapies in
Ph+ALL patients with wild-type p53. Our results suggest a new possible thera-
peutic strategy in resistant T315I mutated ALL patients. These findings provide
a strong rational for further clinical investigation of Nutlin-3a in Ph+and Ph-ALL.
Supported by ELN, AIL, AIRC, progetto Regione-Università 2010-12 (L. Bolon-
di), FP7 NGS-PTL project and Italian Ministry of Health, Current Research
funds to IRCCS CROB
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CHARACTERIZATION OF IMMUNOPHENOTYPING AND MOLECULAR
PROFILE OF FLT3 MUTATIONS IN CHILDHOOD T-CELL LEUKEMIA
E. Noronha1,* E. Pina1, F. Andrade1, M.S. Pombo-de-Oliveira1
1Programa de Hematologia e Oncologia pediatricos, Instituto Nacional de
Câncer, Rio de Janeiro, Brazil
Background: T-cell Acute Lymphoblastic Leukaemia (T-ALL) in childhood is
an aggressive and biological heterogeneous malignancy. T-cell immature
immunophenotype might identify settings of T-ALL with gene mutations. The
FMS-like kinase-3 (FLT3/CD135) and the stem cell factor receptor (cKit/CD117)
are members of the receptor tyrosine kinase family that contribute to normal
differentiation and proliferation of hematopoietic cells. Mutations in FLT3 -inter-
nal tandem duplication (ITDs) and single mutations in the tyrosine kinase
domain (TKD), results in constitutive activation of the FLT3 receptor in the
absence of ligand. 
Aims: To identify FLT3 mutations in a cohort of childhood T-ALL at diagnosis
at any point in time and in relapses; to test the possible correlation between
FLT3 mutation with cellular expression of CD135 and CD117
Methods: A cohort of 178 T-ALL (≤18 years) was evaluated throughout flow cytom-
etry and molecular techniques. Diagnostic samples (DS, n=157) prior to any onco-
treatment, and relapsed samples (RS, n=23) were selected. The levels of cellular
surface of CD135 and CD117 were quantified by multiparametric flow cytometry
(M-FCM). The monoclonal antibodies anti-CD135; CD117; CD135;CD34; CD127
were included in four or 6 colours to M-FCM analysis. These variables were cat-
egorized by percentage of cell positivity and median intensity fluorescence. Pos-
itivity was evaluated in CD45 intermediate/low gate in≥20% of blasts cells. DNA
and RNA were extracted from BM aspirate or PB blast cells to perform molecular
tests (SIL-TAL1, HOX11L2, IL7R and FLT3 mutations); FLT3-D835 mutations were
tested in exon 17 by restriction fragment length polymorphism PCR assay, where-
as, FLT3-ITD was examined by the amplification of the juxtamembrane domain in
exons 11 and 12. To compare the distribution of categorical variables Fisher`s
exact test was used and Mann-Whitney U test comparing two groups (positive/neg-
ative) and Kruskal Wallis test comparing more than two groups to test differences
in continuous variable. P-values of <0.05 were considered statistically significant.
Results: Fifteen out of 176 (8.5%) cases presented mixed phenotype- T /
Myeloid lineage. Early T cell precursors (ETP-ALL) were identified in 20 cases
(11.4%). Amongst the remaining 141 T-ALL cases, 30 T-II (18.6%), 78 T-III
(48.4%) and 33 T-IV (20.5 %) cases were found. CD127 was expressed in 55
out of 70 (78.6%) cases tested; whereas CD117 was expressed in 19 out of 86
(22%) and CD135 found in 10 out of 85 (11.7%) cases tested. FLT3-ITD were
founds in 8 out of 157 (5%) of DS and in 2 out of 23 (8.7%) in RS. There were
no statistical differences regarding demography (gender and age at the diag-
nosis), and clinical features (mediastinal mass, high white blood cell count or
SNC involvement) in T-ALL with FLT3-ITD. The frequencies of somatic aberra-
tions of SIL-TAL1, HOX11L2, IL7R and FLT3mutations were 24.8%, 12%, 10%
and 7%, respectively. Besides FLT3 and IL-7R mutation were also mutually
exclusive. No association was observed in CD127 and CD135 cellular expres-
sion and T-ALL subtypes, nor association with IL7R mutation (p=0.64). The
percentage of CD117 positive cells was greater in the ETP-ALL than other sub-
types (T II, T-III and T-IV) (p <0.001); The variation of CD117 expression accord-
ing to FLT3 and/or IL7R mutations demonstrated that high expression level of
CD117 were associated with FLT3 mutation (p=0.02), whereas CD117 lower
expression with IL7R mutation (p=0.03). The higher expression of CD135 was
associated with HOX11L2 alteration (p=0.012) and with FLT3 mutation (p=0.03).
The CD127 expression was higher in cases with SIL-TAL1 rearrangement
(p=0.04) and in cases with mutated FLT3 had a lower expression (p=0.04).
Summary and Conclusions: FLT3-ITD is important in the pathogenesis of T-
ALL and it seems to contribute to disease progression in cooperation with other
alterations. Preliminary results demonstrated that CD117 and CD127 could
predictive molecular aberrations in some T-ALL settings. 
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IMPACT OF SMALL MOLECULE INHIBITORS OF SKP2 IN T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
S. Colomer-Lahiguera1,* S. Strehl1
1CCRI, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung
e.V., Vienna, Austria
Background: T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10-
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15% of pediatric leukemias. NOTCH1 activating mutations are found in more
than 50% of T-ALLs and have been shown to induce transcription of the S
phase kinase-associated protein 2 (SKP2), which in turn decreases CDK
inhibitor p27KIP1 levels, thereby promoting cell cycle progression. During the
last years, efforts have been directed towards therapeutically targeting the
ubiquitin-proteasome system in order to reduce protein degradation. Recently,
small molecule inhibitors of SKP2, which showed different specificities, have
been developed. Compound C1 has been described to specifically target the
interface between SKP2 and CKS1, an accessory protein responsible for the
recognition of Thr187-phosphorylated p27KIP1 (Wu et al., 2012). A second com-
pound, C25, interacts with SKP2 and prevents its binding to SKP1, thus inhibit-
ing SKP2-SCF E3 ligase activity (Chan et al., 2013)
Aims: The purpose of this study was to evaluate the effects of these new
small molecule inhibitors of SKP2 in T-ALL.
Methods: To assess the impact of SKP2 inhibitors, we treated four different
T-ALL cell lines (Jurkat, DND-41, TALL-1, and Loucy) with the compounds C1
or C25 for 24 and 48 hours. Trypan blue exclusion assay was used to deter-
mine the number of viable cells. Apoptosis (Annexin V/PI double staining) and
cell cycle distribution were analyzed by flow cytometry. Equal amounts of cell
lysates were subjected to immunoblot analysis in order to evaluate the protein
levels of the main cell cycle regulators.
Results: As has been previously shown by others, we, too, observed that
SKP2 is up regulated in T-ALL, suggesting that SKP2 inhibitors may hold prom-
ise for therapeutic intervention. Applying compound C1 resulted in a decrease
of cell proliferation in a dose- and time-dependent manner in all cell lines. In
contrast, when using C25, only TALL-1 showed a slight reduction in cell growth.
To evaluate whether the observed growth inhibition was related to cell death,
we performed Annexin-V/propidium iodide staining and flow cytometry analysis.
Depending on the cell line used, compound C1 showed different effects with a
tendency towards a faster cell death in Loucy, as compared to Jurkat, and no
impact at all on the other cell lines. This observation was confirmed by western
blotting for cleaved PARP. In marked contrast, cells treated with the C25
inhibitor did not show any induction of apoptosis and cell death. Notably, in
TALL-1 and DND-41 cells, neither C1 nor C25 induced major changes in via-
bility, which - together with the observed growth inhibition - suggests an effect
on the cell cycle as the main impact of the inhibitors. To further substantiate
this notion, we assessed the influence of the two compounds on cell cycle pro-
gression. On the one hand, in TALL-1 and DND-41 C25 treatment resulted in
an accumulation of G0/G1-phase cells, reflected by an increase in p27KIP1
protein levels, which inversely correlated with SKP2 expression. However, no
effects at all were observed in Loucy or Jurkat. On the other hand, treatment
with C1 induced a significant accumulation of G2/M-phase in a dose- and time-
dependent fashion in all cell lines. Quite unexpectedly, also the cell line Loucy,
which lacks p27KIP1 expression, showed a decrease in cell proliferation,
increased cell death and achieved a G2 arrest, suggesting that cell cycle arrest
occurs independent of p27KIP1.
Summary and Conclusions: Our results indicate that T-ALL cell lines show
different sensitivities towards SKP2 inhibitors and that the two compounds
tested have distinct effects on the cell cycle, apoptosis, and cell death. Fur-
thermore, they raise the question whether the compounds C1 and C25 may
have so far unrecognized (off-target) effects.
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ANTI-CD47 AND METHOTREXATE INDUCE CELL DEATH BY
PHAGOCYTOSIS – PHAGOPTOSIS – OF LEUKAEMIA CELLS, SUGGESTING
NOVEL WAYS OF TARGETING CANCER 
L. Metayer1,*G. A. Burke2G. Brown1
1Biochemistry, 2Paediatrics, University of Cambridge, Cambridge, United King-
dom
Background: Antibodies to CD47 have been shown to increase clearance of
many types of cancer cells in vitro and in vivo, but the means by which they
cause cell death and clearance is not yet clear.
Aims: To explore the mechanism of action of anti-CD47 in a model of B-ALL/B
lymphoblastic lymphoma.
Methods: U937 cells were treated with 10 ng/mL PMA for 24 hours, then
allowed to mature for a further 48 hours. Phagocytosis was assayed with a
1:1 target:effector ratio, using either flow cytometry (2 hour co-incubation), or
fluorescent microscopy for live/dead cell phagocytosis of propidium iodide
stained target cells (1 hour co-incubation). Live cell imaging of the mitochon-
drial membrane potential measured with JC-1 stained target cells was per-
formed over 3 hours. The blocking CD47 antibody clone B6H12 was used at
2 μg/mL, with F(ab’)2 blocking in a 1:5 molar ratio. CD19 at 2-10 μg/mL, 4N1K
at 0.12 nM-30 μM, thrombospondin at 1.2-12 nM, methotrexate at 0.01 μM
and 6-mercaptopurine (6MP) 5 μM (24 hours for phagocytosis assays, up to
72 hours for direct cell death).
Results: Anti-CD47 strongly increased the phagocytosis of 697 cells, a pre-
B ALL cell line, by U937 macrophages. The leukaemia cells were alive when
phagocytosed by macrophages as indicated by their exclusion of propidium
iodide and their intact mitochondrial membrane potential. However, death rap-
idly followed as shown by mitochondrial depolarisation of leukaemia cells after
their engulfment. 2 μg/mL anti CD47 was sufficient to clear all leukaemic cells
within 3 hours. Inhibition of phagocytosis prevented clearance and death of
leukaemic cells, indicating that cell death was by phagoptosis. Phagocytosis
required the Fc domain of the anti CD47 antibody as blocking this domain
with F(ab’)2 prevented the phagocytosis. However, an antibody against CD19,
a B cell marker, did not increase phagocytosis, indicating that phagocytosis
required both antibody binding with an available Fc domain and blocking/acti-
vation of CD47. Alternative ligands for CD47, low dose 4N1K and throm-
bospondin, had little effect on phagocytosis, suggesting that activation of CD47
is not sufficient for phagocytosis. Finally, low doses of the maintenance phase
treatment methotrexate increased the phagocytosis and subsequent death of
live 697 cells. The same doses induced little or no death of the lymphoblasts
in the absence of macrophages.
Summary and Conclusions: CD47 is an exciting treatment for lymphoid
malignancies, and does induce death of live cells by phagocytosis (phagop-
tosis). This finding may explain the mechanism of action of the little understood
requirement for prolonged low dose maintenance phases, and this could
potentially be shortened by utilising the more effective pro-phagocytic treat-
ment anti-CD47.
E862
CD22 AS A TARGET FOR ELIMINATION OF THE LEUKEMIC BLASTS IN
B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
V. Kanderova1,* D. Kuzilkova1, M. Vaskova1, T. Kalina1, O. Hrusak1,
E. Mejstrikova1
1Department of Pediatric Hematology and Oncology, CLIP-Cytometry, 2nd
Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
Background: Epratuzumab is a humanized anti-CD22 monoclonal antibody
(mAb) derived from LL2 clone. Its B-cell suppressive effect was demonstrated
in autoimmune diseases (systemic lupus erythematosus), and some hemato-
logical malignancies (non-Hodgkin lymphoma). In current IntReALL study of
iBFM group, epratuzumab is included in post-induction treatment phase in
relapsed B-cell precursor acute lymphoblastic leukemias (BCP-ALL). CD22
function in mature B cells is partly known, the exact mechanism of action of
epratuzumab is not completely understood. Furthermore, the effect of the con-
comitant and proceeding chemotherapy on CD22 expression remains
unknown.
Aims: Optimize the detection of CD22 before and during epratuzumab treat-
ment. Assessment of the level of CD22 expression on leukemic blasts and its
correlation with BCP-ALL genetic subtype. Monitor CD22 expression on
leukemic blasts in BCP-ALL patients during treatment. Determine the effect
of epratuzumab to leukemic cell proliferation, cell cycle, apoptosis, and intra-
cellular signaling.
Methods: CD22 was detected with 2 different antibody clones (S-HCL-1 and
epratuzumab) by flow cytometry. Proliferation was determined by cellular
counting. Changes in cell cycle were monitored with Pyronine Y/Hoechst
33342 staining. Apoptosis was checked with Annexin V/propidium iodide or
DAPI staining. Intracellular signaling (phosphorylation of Syk, Akt and Erk1/2)
was measured by single cell phospho-flow cytometry.
Results: For optimal detection of CD22 three temperatures (4, 25, and 37°C)
and two antibody clones were tested. We observed reduction of epratuzumab
binding to cells with decreasing temperature (n=3): 41% at 25°C and 2% at
4°C. In contrast, S-HCL-1 binding did not differ at low temperature (34% at
25°C and 40% at 4°C). This reduction of LL2 affinity at 4°C was previously
described (Mattes et al, 1997). Moreover epratuzumab and S-HCL-1 partially
competed for CD22 binding but we were able to detect CD22 by S-HCL-1 at
25°C well when the cells were pre-incubated with epratuzumab. In vitro exper-
iments did not show any anti-proliferative effect of epratuzumab on leukemia
cell lines (n=5) probably due to their partial growing independence on external
stimuli. In contrast, we detected reduced numbers of viable B-cells isolated
from healthy peripheral blood after epratuzumab treatment (n=3, p<0.05). In
addition, cell cycle transition from G0 to G1 phase was inhibited after 24h
(n=2, p<0.05) and intracellular signaling led via phosphorylation of Syk and
Erk1/2 in healthy B-cells (n=4). Deeper proteomic profiling is in progress. In
our so far limited cohort of patients with BCP-ALL where the CD22 expression
was quantified with the two mAb clones (n=16), the CD22 levels varied greatly.
In contrast, CD22 expression on mature B cells was comparable among
healthy individuals (n=8). The only cases without detectable CD22 expression
were found among patients with pro-B BCP-ALL.
Summary and Conclusions: CD22 is detected by both clones of antibodies
at 25°C at diagnosis and relapse. During the epratuzumab treatment, CD22
can be monitored by S-HCL-1 clone. CD22 expression varies on leukemic
blasts among individuals. CD22 negativity is found within pro-B BCP-ALLs.
BCP-ALL cell lines are frequently resistant to epratuzumab treatment and can-
not be used as in vitromodel. In healthy B-cells, epratuzumab partially inhibits
cell cycle and proliferation in vitro, the signaling occurs via B-cell receptor
associated kinase Syk and via kinase Erk1/2. Supported by FP7 IntReALL,
IGA NT13462, UNCE 204012.
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BONE MARROW STROMAL PRECURSOR CELLS OF THE ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED ACCORDING TO THE
ALL-2009 PROTOCOL RESTORE THEIR FUNCTIONAL AND BIOLOGICAL
POTENTIAL DAMAGED BY THE DISEASE
T. Sorokina1,* I. Shipounova2, A. Bigildeev2, N. Petinati2, N. Drize2, L. Kuzmina1,
E. Parovichnikova1, V. Savchenko3
1High dose chemotherapy, depressions of hematopoiesis and bone marrow
transplantation, 2Physiology of Hematopoiesis laboratory, 3General director,
National Research Center for Hematology, Moscow, Russian Federation
Background: Stromal microenvironment essential for normal hematopoiesis,
as it forms niches for hematopoietic precursors, suffers during leukemia devel-
opment. High dose chemotherapy affects not only hematopoietic cells but also
stromal precursor cells.
Aims: The goal of this study was to analyze the alterations in the characteristics
of human multipotent mesenchymal stromal cells (MSC) and their more differ-
entiated progeny – fibroblastic colony forming units (CFU-F), derived from the
bone marrow (BM) of acute lymphoblastic leukemia (ALL) patients at the
moment of diagnosis and during treatment according to the protocol ALL-2009.
Methods: Fourteen newly diagnosed cases (8 B-ALL and 6 T-ALL) were
involved in the study after informed consent. BM was aspirated prior to any
treatment and at days 37, 100 and 180 since the beginning of the protocol.
MSC were cultured in aMEM with 10% fetal calf serum. Cumulative MSC pro-
duction was counted after 3 passages. CFU-F concentration was analyzed in
standard conditions. The ability of MSC to maintain hematopoietic precursor
cell was assessed by cobble-stone area forming cells (CACF-1-2 wk) method.
As a reference control MS5 cell line was used. The relative expression level
(REL) of different genes was measured by TaqMan RQ-PCR. As a control MSC
and CFU-F from 88 healthy donors of BM for alloHSCT were used.
Results: The CFU-F concentration in the BM of patients at the moment of ALL
diagnostics was about 1/7 of the donor’s (table, p<0.0001). BM blasts count
did not correlate reversely with CFU-F concentration in the BM of each patient,
thus the dramatic decrease in CFU-F concentration is caused by the damage
of this stromal precursor cells by leukemic cells. The treatment of patients
resulted in the restoration of CFU-F concentration in as little as 37 days. Cumu-
lative MSC production at the disease manifestation did not differ from donor’s,
while their ability to maintain normal hematopoietic cells had the tendency to
decrease. At the same moment in MSC the REL of PDGFRA and PDGFRB
increased in 3 and 2 fold correspondingly (p=0.01 and 0.03), while REL of
TGFB2 decreased 3 fold (p=0.002). Chemotherapy did not affect MSC produc-
tion and during treatment their ability to maintain CAFC 1-2wk normalized.
Table Main characteristic of stromal precursor cells from the BM of ALL patients.
Tabella 1.
CFU-F per 106 Cumulative MSC Frequency of 
BM cells production per 3 CAFC 1-2wk,
passages, x106 proportion to MS5
Donor 25.4±3.0 7.1±1.0 74.9±9.5
Before treatment 3.8±1.6 7.9±2.4 57.5±11.4
37 days of ALL-2009 30.3±6.8 9.7±2.5 62.1±8.2
100 days of ALL-2009 31.5±1.0 11.1±2.4 74.4±16.6
Summary and Conclusions: It was demonstrated that Protocol ALL-2009 was
highly effective for treatment adult ALL patients. Such treatment restores the
functional and biological characteristics of stromal microenvironment initially
damaged by leukemic cells.
E864
THE PAN-BCL-2-TARGETING DRUG OBATOCLAX (GX15-070) AND THE
PI3-KINASE/MTOR-INHIBITOR BEZ235 PRODUCE SYNERGISTIC
GROWTH-INHIBITORY EFFECTS ON LEUKEMIC CELLS IN PATIENTS
WITH PH+AND PH- ALL 
G. Stefanzl1,* D. Berger1, K. Blatt1, G. Eisenwort1,2, W.R. Sperr1, A. Hauswirth1,
U. Jäger1, S. Cerny-Reiterer1,2, P. Valent1,2
1Internal Medicine I, 2Ludwig Boltzmann Cluster Oncology, Medical University
of Vienna, Vienna, Austria
Background: Acute lymphoblastic leukemia (ALL) is a life-threatening stem
cell disease defined by abnormal expansion of lymphoblasts in hematopoietic
tissues. Despite improved therapy only a subfraction of patients can be cured.
Therefore, current research is attempting to identify new drug targets and novel
targeted drugs to improve therapy in these patients. A number of previous and
more recent data have shown that members of the BCL-2 family and compo-
nents of the PI3-Kinase/mTOR pathway are critically involved in the regulation
of growth and survival of leukemic cells in ALL.
Aims: We examined the effects of the pan-BCL-2-targeting drug obatoclax
(GX15-070) and the dual PI3-Kinase/mTOR blocker BEZ235 on growth and
survival in ALL cells.
Methods: The effects of obatoclax and BEZ235 on proliferation were examined
by 3H-thymidine-uptake, and drug-induced apoptosis was determined by flow
cytometry and Western blotting.
Results: Both drugs were found to suppress the in vitro proliferation of leukemic
cells obtained from patients with Ph+ALL (n=4) and Ph- ALL (n=9) in a dose-
dependent manner (obatoclax IC50: 0.05-0.1 µM; BEZ235, IC50: 0.01-0.5 µM).
In addition, obatoclax and BEZ235 suppressed the proliferation in the Ph+ALL
cell lines BV-173 (obatoclax IC50: 0.08-0.3 µM; BEZ235, IC50: 0.01-0.03 µM),
NALM-1 (obatoclax IC50: 0.1-0.5 µM; BEZ235, IC50: 0.05-0.1 µM), TOM-1 (oba-
toclax IC50: 0.1-0.3 µM; BEZ235, IC50: 0.01-0.03 µM), and Z119 (obatoclax
IC50: 0.05-0.1 µM; BEZ235, IC50: 0.03-0.05 µM) as well as in the Ph- cell lines
RAJI, RAMOS, REH, and BL-41 (IC50: <1 µM). The growth-inhibitory effects of
both drugs were accompanied by apoptosis in all cell lines examined, as evi-
dence by Western blotting using an antibody against cleaved caspase 3 as
well as by AnnexinV/PI-staining and staining for active-caspase 3 by flow cytom-
etry. We also confirmed that BEZ235 counteracts phosphorylation of pAkt and
pS6 in all cell lines tested. Since obatoclax and BEZ235 interact with a different
spectrum of molecular targets, we also determined drug-combination effects.
In these experiments, obatoclax was found to cooperate with BEZ235 in inhibit-
ing the growth of all Ph+ALL cell lines and all Ph- cell lines tested. Finally, we
were able to show that primary ALL cells, CD34+/CD38- leukemic stem cells
and all cell lines tested express major drug targets, including members of the
BCL-2 family (BCL-2, MCL-1, BCL-xL), the PI3-Kinase and mTOR.
Summary and Conclusions: Obatoclax and BEZ235 effectively counteract
growth and survival in ALL cells. Both agents exert synergistic anti-leukemic
effects on ALL cells which may have clinical implications.
E865
GDF15 MODULATES HEPCIDIN-FERROPORTIN AXIS IN LYMPHOBLAS-
TIC LEUKEMIC CELLS
J. Gao1,* J.-R. Wu1, L.X. Yuan2, Z. Wan3, Y.P. Zhu3
1Department of Pediatric Hematology and Oncology,West China Second Uni-
versity, 2Public Laboratory, West China Second University Hospital, 3Depart-
ment of Pediatric Hematology and Oncology, West China Second University
Hospital, Sichuan University, Chengdu, China
Background: Being a novel pleotrophic member of TGF-beta family, growth
differentiation factor 15(GDF15) is intimately involved in cancer development
and prognosis, and has been documented recently as an upstream negative
regulator of the iron regulatory hormone hepcidin, with its expression upregu-
lated remarkably in a variety of anemias characterized by ineffective erythro-
poiesis.
Aims: To investigate the expressions of GDF15, key iron regulators and trans-
porters, and oxygen sensing molecule hypoxic inducible factor 1 alpha
(Hif1alpha) in lymphoblastic leukemic cells, exploring roles of GDF15 on mod-
ulation of iron homeostasis in lymphoblastic leukemic cells.
Methods: Sixty newly diagnosed children with ALL and 19 age-and-sex
matched control children were enrolled in this study, together with 5 types of
leukemic cell lines. mRNA expressions of target genes were assayed by Eva-
Green real-time RT-PCR in triplicates. Relative gene expression was repre-
sented by the mean of target gene against housekeeping gene by delatdeltaCt
method. suppressed in ALL group as against controls (P=0.000) and was pos-
itively correlated both to hepcidin and GDF15. (4) There was no significant dif-
ference in terms of Hif1alpha expression in the two groups.
Results: (1) Hepcidin was expressed in both leukemic cell lines and clinical
sample of primary lymphoblastic cells. GDF15 expression in ALL group was
significantly increased as compared to controls(p=0.026), with median of
expression being 0.5 and 0.005 in ALL and control groups respectively; (2)
Expression of GDF15 was significantly higher in ALL group than that in controls
(p=0.003) and was positively correlated to hepcidin(P=0.000); (3) Expression
of ferroportin was remarkably suppressed in ALL group as against controls
(P=0.000) and was positively correlated both to hepcidin and GDF15. (4) There
was no significant difference in terms of Hif1alpha expression in the two groups. 
Summary and Conclusions: We demonstrated that GDF15 is remarkably
upregulated in ALL cells independent of Hif1alpha signaling pathway. More
importantly, we found that hepcidin is expressed by both leukemic cell lines
and primary cells. In addition, ferroportin, the only cellular iron exporter, is sig-
nificantly downregulated in lymphoblastic leukemic cell, which is consistent with
reduced expression in breast cancer cells (cell lines). And GDF15 expression
is positively correlated both to hepcidin and ferroportin. Taken together, our
study strongly indicates that upregulation of GDF15 stimulates induction of
hepcidin by leukemic cells themselves, with in turn mediates enhanced ferro-
portin internalization and degradation, resulting in reduced iron efflux from
leukemic cells, providing more iron available for leukemic cell proliferation. Fur-
ther studies are urgently needed to explore interrelationship between regula-
tions of cellular and systemic iron homeostasis in patient with lymphoblastic
leukemia.
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PROGNOSTIC SIGNIFICANCE OF THE CYTOGENETIC EVOLUTION
AFTER THE ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC ACUTE LEUKEMIA
T.L. Gindina1,* N. Mamaev1, N. Stancheva1, O. Slesarchuk1, E. Nikolaeva1,
I. Petrova1, A. Alyanskiy1, L. Zubarovskaya1, B. Afanasyev1
1R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, FIRST PAVLOV SAINT PETERSBURG STATE MEDICAL
UNIVERSITY, Saint-Petersburg, Russian Federation
Background: Cytogenetic abnormalities at diagnosis have significant impact
on disease outcome and clonal evolution at cytogenetic level is considered to
be associated with relapse and refractoriness to chemotherapy. Relapse of
acute leukemia was reported to be associated with cytogenetic clonal evolution
in 40% of patients who have received chemotherapy. The cytogenetic clonal
evolution in post-transplant relapse has been recently studied in adult acute
myeloid leukemia (AML) by Yuasa et al.,2013. They showed that the cytoge-
netic clonal evolution is an important predictor of resistance to therapy after
allogeneic hematopoietic stem cell transplantation (alloHSCT).
Aims: To study karyotypic changes in post-transplant relapses of pediatric
acute leukemia in order evaluate a prognostic impact of the cytogenetic clonal
evolution on survival.
Methods: We retrospectively reviewed children and adolescents with diagnosis
of AML or ALL who underwent allo-HSCT at our institute from 2009 to 2014
and analyzed the cytogenetic evolution patterns in patients (pts) at relapse of
acute leukemia after HSCT.
Results: Thirty children and fifteen adolescents with post-transplant relapse
were included in this study. The bone marrow karyotypic changes were ana-
lyzed before and after allo-HSCT. Twenty six (58 %) pts were male, and median
age at alloHSCT was 10 years (range, 1,2-21). Seventeen (38 %) pts are still
alive. Thirteen (29 %) pts received related transplantation, 15 (33 %) did unre-
lated HSCT, and 17 (38 %) did haploidentical HSCT. Four (9 %) pts had normal
karyotype, 22 (49 %) had one chromosomal abnormality, 4 (9 %) had two
abnormalities, and 15 (33 %) had more than three abnormalities before HSCT.
Median follow-up after HSCT was 500 days (40-861). Twenty-eight (62 %) pts
showed gain or loss of chromosomal abnormalities from original one (group
1), 16 (36 %) showed no karyotypic change between HSCT, and 1 (2 %)
showed totally different karyotype. We defined the cytogenetic evolution group
as group 1, and others as group 2. Median time from transplantation to relapse
was not different between group 1 and 2. Shorter survival after relapse was
observed for group 1 (8,9 % vs 51,5 % at 2-year post-relapse survival,
P=0,041)(Figure1). Moreover, survival after relapse was inferior for pts with 2
or 3 cytogenetic subclones (n=10) compared to pts with 1 cytogenetic clone
(n=35) (0% vs 32,5 % at 2 year post-relapse survival, P=0,016).
Figure 1.
Summary and Conclusions: Survival time of pediatric acute leukemia pts
was similar with those of the above-mentioned adult AML being significantly
shorter for group 1 than group 2. It supports that cytogenetic clonal evolution
may be an important predictor of resistance to therapy after allo-HSCT, and
needs novel therapeutic approaches.
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SEQUENCE ANALYSIS OF CLONAL IMMUNOGLOBULIN
REARRANGEMENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA:
PATHEGENESIS AND MECHANISM
K. Katsibardi1,* M. Braoudaki2, M.P. Le Franc3, F. Tzortzatou-Stathopoulou4,
A. Kattamis5, G. Chrousos5
1Hematology/Oncology Unit, First Department of Pediatrics, University of
Athens, “Aghia Sophia” Children’s Hospital, 2University Research Institute for
the Study and Treatment of Childhood and Malignant Diseases, University of
Athens, “Aghia Sophia” Children’s Hospital, Athens, Greece, 3International
imMunoGeneTics Information System, Université Montpellier 2, Laboratoire
d’ImmunoGénétique Moléculaire LIGM, Institut de Génétique Humaine IGH,
Montepellier, France, 4University Research Institute for the Study and Treat-
ment of Childhood and Malignant Diseases, University of Athens, “Aghia
Sophia” Children’s Hospital, 51Hematology/Oncology Unit, First Department
of Pediatrics, University of Athens, “Aghia Sophia” Children’s Hospital, Athens,
Greece
Background: Clonal immunoglobulin rearrangements are assembled from the
joining of (V) variable, (D) diversity and (J) joining gene segments (VDJ
rearrangement). This process takes place during the maturation of B-cells. 
Aims: Aim of the present study was to evaluate the clonal immunoglobulin
rearrangements in children with B-cell acute lymphoblastic leukemia (ALL), in
order to describe the underlying mechanism and ascertain whether it is influ-
enced by the stage of leukemogenesis and the clonal evolution. Furthermore,
characteristics of the VDJ rearrangement were evaluated as novel prognostic
factors.
Methods: DNA extracted from 80 bone marrow samples at diagnosis of ALL
patients was amplified by Polymerase Chain Reaction. Direct sequencing for
PCR products was carried out on a MJ Research PTC-225 Peltier Thermal
Cycler. The V, D and J segments were identified using the ImMunoGeneTics
Information System (IMGT, European Bioinformatics Institute, Montpellier,
France) and the software algorithm JOINSOLVER in order to characterize the
closest matching human germline counterparts. The rearranged IGH V-D-J
sequences were characterized as productive or non-productive.
Results: V region was identified in all VDJ rearrangements, involving 21 dif-
ferent gene segments, while 45% were in the 3’ terminus of chromosome 14.
V3 family (V3-13, V3-15, V6-1, V3-11) was the most common (55%). In pre-B-
ALL patients, V3-11 and V6-1 regions were used frequently (67%). D identifi-
cation was feasible at 84% rearrangements, distinguishing totally 24 different
sections. In 73% sequences, segments of the 3’ end of region D were associ-
ated with gene segments of the 5’ end of J region. In 9.7% cases, D irregular
recombination (DIR) signal sequences were recognized. In patients with pre-
B-ALL only J4 and J6 areas were observed. In 90% of the rearranged VDJ
sequences the CDR3 region was short. Insertion of N regions was recorded in
95% of rearrangements with a greater number of nucleotides in the region
between V and D. Most sequences (75.5%) were non-productive and were
associated with better prognosis, which means 97% of relapse-free events.
On the other hand, productive rearrangements counted for 24.5% of cases
and were linked to worse outcome that is 75% of relapse-free episodes.
Summary and Conclusions: The selective involvement of the V gene frag-
ments depending on their position on chromosome 14 reinforces the theory of
D-proximal model. The association of D and J for the creation of DJ complex
is selective depending on the stage of maturation of B-cells. The superiority of
V3-11 and V6-1 rearrangements in immature B-lymphocytes suggests that
possibly the leukemogenesis occurs at the initial stages of B-lymphocytes mat-
uration. Furthermore, the small size of the CDR3 region shows that malignant
transformation occurred in the early stages of differentiation of B-cell. The
increased risk of relapse in patients with productive VDJ rearrangements is
based on the fact that they are completed at the advanced phases of B-cell
maturation, which means they are more prone to mutations. Concluding, gene
rearrangements are subject to the influence of molecular mechanisms, the dis-
covery of which might give more information regarding leukemogenesis and
subsequently serve as a therapeutic target in acute lymphoblastic leukemia of
childhood.
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NUDT15 GENE POLYMORPHISM RELATED TO MERCAPTOPURINE
INTOLERANCE IN TAIWAN CHINESE CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
D.C. Liang1,* C.P. Yang2, H.C. Liu1, T.H. Jaing2,3, S.H. Chen2,3, I.J. Hung2,
T.C. Yeh1, T.H. Lin4, C.L. Lai4, C.Y. Lai3, L.Y. Shih3,5
1Mackay Children’s Hospital and Mackay Medical College, Taipei, 2Chang
Gung Children’s Hospital, 3Chang Gung University, 4Chang Gung Memorial
Hospital, Taoyuan, 5Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Background: It is well known that the European descent have higher risk allele
frequency of thiopurine methyltransferase (TPMT) gene than that of East Asian.
However, this can not explain why the East Asian are more intolerable to mer-
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captopurine than the European descent. A recent study identified a variant of
the NUDT15 gene (rs116855232 C>T) associated with intolerance to thiopurine
in Korean patients with Crohn’s disease.
Aims: We aimed to determine the prevalence of NUDT15 variant in a Taiwan
Chinese population and sought to clarify the reason why the East Asian tolerate
mercaptopurine poorly.
Methods: Four hundred and four Taiwan Chinese children with acute lym-
phoblastic leukemia (ALL) at achieving complete remission and 100 adult
patients with normal bone marrow (BM) were examined. Pyrosequencing for
NUDT15 (rs116855232) c.415 C>T (NM_018283.1) and genotyping for TPMT
(rs1142345) c.719 A>G (NM_0003673) by use of TaqMan assay were per-
formed.
Results: Of 404 ALL patients, 224 were boys and 180 girls. Five (3 boys and
2 girls), were homozygous for NUDT15 rs116855232 (TT), 84 (42 boys and 42
girls), were heterozygous (TC), and the remaining 315 were wild-type (CC),
with a risk allele frequency of 11.6 %. In 100 normal adult BM, one was homozy-
gous, 29 were heterozygous, and the remaining 70 were wild-type NUDT15,
with an overall risk allele frequency of 15.5%. There was no statistical difference
between pediatric ALL patients and normal adult BM in NUDT15 variant
(P=0.154). By contrast, of the 404 ALL patients, none was homozygous for
TPMT (GG), 13 were heterozygous (AG), and the remaining 391 were wild-
type (AA), with an overall risk allele frequency of 1.6%. In the 100 normal adult
BM samples, none was homozygous, one was heterozygous, and the remaining
99 were wild-type TPMT, with an overall risk allele frequency of 0.5%. No dif-
ference in the variant frequency of TPMT genotype was observed between
children with ALL and adults with normal BM (P=0.325).The high risk NUDT15
variant was closely associated with the intolerance to mercaptopurine in children
with ALL. The maximal tolerable daily doses of mercaptopurine, in which a
patient could maximally tolerated for at least several months, in NUDT15 TT,
TC and CC groups were 9.4±3.7 mg/m2 (mean±SD ), 30.7±11.7 mg/m2, and
44.1±15.3 mg/m2, respectively (P<0.0001). The maximal tolerable dose of mer-
captopurine in TPMT AG and AA were 31.4±10.2 mg/m2and 41.2± 15.8 mg/m2,,
respectively (P=0.034 ). The maximal tolerable daily dose of mercaptopurine
in double heterozygous for both NUDT15 and TPMT (n=4) was 32.7±14.3
mg/m2/day compared with single heterozygous for NUDT15 or TPMT of
30.0±11.7 mg/m2/day (P =0.655), the latter was significantly different from the
dose 44.6±15.3 mg/m2/day in wild-type for both NUDT15 and TPMT
(P<0.0001). The 5-years event-free survival (EFS) was 87.6%, 90.2%, and
50.0%, for NUDT15 CC, TC, and TT genotype, respectively (P=0.0118). The
patients with homozygous for NUDT15 (TT) had inferior EFS compared with
heterozygous TC (P=0.034). Neither heterozygous NUDT15 nor TPMT variant
alone affected EFS of children with ALL.
Summary and Conclusions: The high frequency of NUDT15 risk variant, but
not the low frequency of TPMT risk variant, was closely associated with the
intolerance to mercaptopurine in children with ALL in Taiwan.
Grant supports: MMH-E-99009, NSC101-2314-B-004-MY2, MOST103-2314-
B-182-052 and CMRPG4A0041.
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HTS COUPLED WITH A BIOINFORMATICS ANALYSIS IN ROUTINE
HOSPITAL PRACTICE FOR MULTICLONAL DIAGNOSIS AND MRD
FOLLOW-UP IN ALL
Y. Ferret1,* N. Grardel1, M. Salson2,3, A. Caillault1, M. Duez2,4,5, S. Sebda1,
C. Villenet6, C. Roumier1, M. Figeac6, B. Nelken7, B. Quesnel8, C. Preud-
homme1, M. Giraud2,3
1Hématologie, Centre de Biologie Pathologie CHRU Lille, 2INRIA Lille, 3Labo-
ratoire d’Informatique Médicale de Lille (LIFL), 4Laboratoire d’Informatique
Médicale de Lille, UMR CNRS 8022, Université Lille 1, 5SIRIC OncoLille, 6Func-
tional Genomic Platform, Cancer Research Institute, 7Hôpital Jeanne de Flan-
dre, 8Service des Maladies du Sang, CHRU Lille, Lille, France
Background: The molecular diagnosis in ALL allows, by the research of V(D)J
rearrangements on lymphoblast DNA, to find clonal markers in 95% of the cas-
es. These markers are also used to quantify the minimal residual disease (MRD)
by real time Q-PCR to adapt treatments. This strategy fails in some cases:
Absence of initial marker, failure of sequencing or emergence at relapse time
of a clone which was not observed at diagnosis time or in minority. Several
studies have asserted the usefulness of high-throughput sequencing (HTS). It
enables deep sequencing of a whole lymphoid population, bypassing some of
these problems. However, the huge amount of data raises two challenges.
First, hospitals must be able to store and process terabytes of data per year.
Second, the data must be nicely synthesized to ease clinician interpretation.
Aims: Here we report the use of HTS in a hematology lab for diagnosis and
follow-up of ALL, combined with a bioinformatics analysis and visualization of
the results with the new dedicated Vidjil software (Giraud, Salson, et al, BMC
Genomics 2014, http://www.vidjil.org).
Methods: In a first work we retrospectively studied the clonality of 8 pediatric
patients (5 B-ALL and 3 T-ALL, 2w-6m, 2-14 years) at diagnosis and follow-up
(37 follow-up time points). Since January 2015 we lead a prospective study of
pediatric ALL clonality at diagnosis in a routine hospital practice (15 patients in
mid-February: 11 B-ALL and 4 T-ALL, 2-22 and 10-25 years). 500ng of bone
marrow DNA are extracted on Qiagen® Kit and amplified by PCR systems for
TRG, TRD, IGKB and IGH targets (compared to only TRG and IGH for the ret-
rospective study). These systems are described or derived from the BIOMED-
2 works. The libraries are done with Ion Fragment Plus® Kit and sequenced
with an Ion Torrent® 318 or 316-V2 Chip system on PGM™. The Vidjil platform
clusters reads in clones, names the clones based on their V(D)J rearrangement
and tracks them along the time. Sequences can be aligned, merged and sent
to IMGT/V-QUEST or IgBlast. It exports medical results tailored to general lab-
oratory computer system or to a printable file.
Results: We identified a number of clones in the diagnosis samples and
observed their evolution at different follow-up time points. All the clones detected
by classic methods were also found by Vidjil. Moreover the software allows us
to look deeper at other clones appearing at lower concentrations. This way we
could easily notice emergence of minority clones or clones that were not detect-
ed at diagnosis: Relapses were detected, and for one patient two emerging
clones were observed. (See FIGURE 1 below.). No sequencing failure occurred
in the 15 prospective analyses compared to one Sanger failure in the usual
protocol. The whole analysis from the receipt of the sample to the end of the
validation by the clinician was several days faster than the current protocol,
with equal resources.
Figure 1.
Summary and Conclusions: Vidjil has been designed and tested for two years
in Lille and is now being tested in other French hospitals involved in ALL-MRD.
It opens the floodgates to the use of HTS in routine hospital practice. Now all





A NOVEL HOTSPOT FOR IKZF1 WHOLE GENE DELETIONS IN
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
B.A. Lopes1, C. Meyer2, T.C. Barbosa1, U.Z. Stadt3, M.S. Pombo-de-Oliveira1,
R. Marschalek2, M. Emerenciano*
1Pediatric Hematology-Oncology Program, Instituto Nacional de Câncer, INCA-
RJ, Brazil, Rio de Janeiro, Brazil, 2Diagnostic Center of Acute Leukemia,
Goethe University, Frankfurt am Main, 3Center for Diagnostic, University Med-
ical Center Hamburg Eppendorf, Hamburg, Germany
Background: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is
characterized by chromosomal translocations. Genome-wide studies have
revealed additional alterations, such as IKZF1 deletions (IKZF1del). The gene
is located at 7p12 and encodes the transcription factor Ikaros, which is involved
in the development of the B cell lineage. IKZF1del is independently associated
with relapse and dismal outcome in BCP-ALL. They are mainly characterized
by absence of exons 2-3, 2-8, 4-7, and 4-8. In a recent study, a multiplex PCR
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approach was able to detect the most frequent IKZF1del on chromosome 7p,
which could be used as markers for minimal residual disease monitoring. How-
ever, precise data concerning IKZF1whole-gene Δ1-8 deletions, which account
for approximately 30% of all IKZF1del, are still lacking.
Aims: We aimed at characterizing IKZF1 whole-gene deletions at the genomic
level in order to improve the current PCR methods for the analysis of the most
frequent IKZF1 deletions in pediatric patients with BCP-ALL.
Methods: Samples of BCP-ALL with IKZF1 whole-gene deletions (n=30) were
included. Deletions of exons 1-8 were first identified by the multiplex ligation-
dependent probe amplification (MLPA) kit (P335-A4), and confirmed using spe-
cific IKZF1 MLPA kit (P202). Six samples were analyzed with CytoScan HD
array (Affymetrix. Inc., Santa Clara, CA, USA), and the breakpoints were con-
firmed by multiplex PCR. Afterwards, 24 samples were screened for the hotspot
identified by the array (located within COBL gene) with a long distance PCR
(LDI-PCR) and sequencing approach.
Results: According to the comparative genome analysis, 2 out of 6 samples
with BCP-ALL (33.3%) and IKZF1 whole-gene deletions had a breakpoint on
COBL intron 5. They presented a ~1.7 Mb and ~18.8 Mb deletion (7p12.2-
COBL and 7p14.3-COBL). Further screening of 24 samples within COBL intron
5 led to the verification of three molecular alterations: a 1.1 Mb inversion of
COBL that also compromised IKZF1; and two chromosomal translocations
(Xp21.3-COBL and C20orf194-COBL). In sum, a hotspot on COBL intron 5
was found in 16.7% of the samples (five of thirty samples) with IKZF1 Δ1-8.
Summary and Conclusions: This study identified chromosomal transloca-
tions, deletions, and inversions involving COBL intron 5 on samples with IKZF1
whole-gene deletions. This clearly indicates that COBL intron 5 is a new hotspot
for IKZF1 whole-gene deletions. Genetic alterations starting on COBL intron 5
also promote IKZF1 deletions due to the proximity between IKZF1 and COBL
(~800 Mb). Further analyses covering a larger genomic area within COBL are




EXPRESSION ANALYSIS OF GENES LOCATED IN THE COMMON REGION
OF AMPLIFICATION IN PEDIATRIC B CELL PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA WITH INTRACROMOSSOMAL AMPLIFICA-
TION OF CHROMOSOME 21
J.C. Santoro1, G. Fuka1, M.S. Pombo-de-Oliveira1, M. Emerenciano*
1Pediatric Hematology-Oncology Program, Instituto Nacional de Câncer, INCA-
RJ, Brazil, Rio de Janeiro, Brazil
Background: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases
frequently present high hyperdiploidy (>50 chromosomes) or chromosomal
translocations resulting in chimeric gene fusions (ETV6-RUNX1, BCR-ABL1,
TCF3-PBX1, and KMT2A-AFF1). Recently, molecular cytogenetic studies
defined a subgroup among BCP-ALL with cryptic intrachromosomal amplifica-
tion features on chromosome 21 (iAMP21). The iAMP21 has been described
in 1.5-3% of BCP-ALL and is associated with a higher relapse risk when
patients are treated under standard regimens. Genomic analysis demonstrated
the presence of a common region of amplification (CRA), including genes such
as IFNGR2, GART, SON DSCR1, RUNX, DYRK1A, ERG, and ETS. These
genes are described to be involved in the leukemogenesis and/or in the ther-
apeutic response of some leukemia subtypes. Our hypothesis is that aberrant
expression of these genes could also contribute to the particularities of iAMP21-
BCP-ALL.
Aims: We aimed to identify genes that could be potentially relevant in the
leukemogenesis of iAMP21-BCP-ALL by evaluating the expression of genes
with functions previously described in leukemia and located in the CRA. 
Methods: From 368 bone marrow (BM) samples of patients with BCP-ALL
diagnosed between 2002 and 2012, 74 were suggestive for chromosome 21
copy number alterations by Multiplex Ligation-dependent Probe Amplification
(MLPA). In 9 patients an iAMP21 was confirmed by Fluorescence in situ hib-
ridization (FISH). Gene expression analysis of these samples was performed
by reverse transcriptase quantitative PCR (qPCR) and CT values of the select-
ed genes among BCP-ALL samples either with or without an iAMP21 were
calculated. The non-iAMP21 subgroups were: ETV6-RUNX1 fusion (n=9),
hyperdiploid karyotypes (n=3), no recurrent gene fusions (n=7), and non-
leukemic controls (n=7). Statistical analysis was performed using Student’s t-
tests, p values <0.05 were considered statistically significant (Unpaired t-test),
using the GraphPad Prism 1.5 software. 
Results: Patients with iAMP21-BCP-ALL had higher expression of IFNGR2
(*p=0.0331; **p=0.0147; ***p=0.0023), ERG (*p=0.0284; ***p=0.0115), ETS2
(*p=0.0343; **p=0.0058; ***p=0.0021) and DYRK1A (***p=0.0008) genes when
compared with ETV6-RUNX1 (*p), no recurrent gene fusions (**p), or with
hyperdiploid karyotypes (***p) groups.
Figure 1.
Summary and Conclusions: Our results suggest that there is a differential
expression of some genes in the CRA of samples from patients with iAMP21-
BCP-ALL. Thus, these data allow further studies in order to evaluate the con-
tribution of these genes in leukemogenesis and therapeutic response of
iAMP21-BCP-ALL.
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AKT REGULATION OF ONCOGENIC NOTCH PATHWAY IN T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
N. Platonova1,2,*, E. Vigolo1, G.C. Cermisoni1, D. De Simone1, M. Colombo1,
S. Garavelli1, E. Lazzari1, S. Galletti2, A. Paoli1, A. Neri2, R. Chiaramonte1
1Department of Health Sciences, 2Department of Clinical Sciences and Com-
munity Health, Università degli studi di Milano, Milano, Italy
Background: Notch and PI3K/AKT signaling are two key oncogenic pathways
closely associated in T-cell acute lymphoblastic leukemia (T-ALL). These path-
ways collaborate in controlling proliferation, survival and migration of T-ALL
cells and are deregulated in ~60% (Notch pathway) and 48% (PI3K/AKT) of T-
ALL patients. Recent evidences indicate that in T-ALL cells, Notch and
PI3K/AKT pathways collaborate through a reciprocal control.
Aims: of this work was to investigate the molecular mechanisms of PI3K/AKT-
dependent Notch1 activity regulation.
Methods: T-ALL cell line, Molt4, and HEK293T cell line were grown in RPMI-
1640 and DMEM respectively, supplemented with 10% heat-inactivated FBS.
1 mg RNA isolated from cells was retro-transcribed in 20 ml by M-MuLV reverse
transcriptase using random hexamer primers. RT-PCR analysis was performed
using primers for Notch1, HES1, preTCRa, GAPDH. Apoptotic cells were iden-
tified by Annexin-V and propidium iodide staining. Protein expression was
detected by Western blot analysis of whole cell lysates. HEK293T cells were
transfected with expression plasmid encoding the dominant negative mutant
form of AKT (DN-AKT) and with plasmid encoding full length Flag-tagged
NOTCH1 using the DMRIE-C reagent (Invitrogen), according to manufacturer’s
instructions. Molt4 cells were electroporated with 20 µg of pcDNA3.1 DN-AKT
or mock pcDNA3.1 using the Neon Transfection System (Invitrogen) according
to the manufacturer’s guidelines. After 72 h cells were harvested to prepare
protein lysates. Immunoprecipitation of ubiquitin-conjugated proteins was per-
formed using the UbiQapture-Q Kit (Biomol, Exeter, UK), as described by the
manufacturer. Co-immunoprecipitation analysis was performed using Protein
G Agarose beads, eluted immunoprecipitates were analyzed by Western blot.
Immunofluorescent staining was done on HEK293T cells incubated with anti-
Flag or anti-c-Cbl primary antibodies and the appropriate AlexaFluor-conjugat-
ed secondary antibodies. Images were acquired with a Leica TCS SP2 confocal
microscope. A colocalization area was determined based on a 2D cytofluoro-
gram and density analysis performed by Multicolor Analysis Leica Confocal
software.
Results: Both LY294002-mediated chemical inhibition of PI3K/AKT signaling
and transient transfection of a DN-AKT mutant strongly reduced Notch1 protein
level and activity, without affecting Notch1 transcription. We showed that down-
stream AKT regulator, GSK-3β, did not mediate the effect of PI3K/AKT with-
drawal on Notch1 protein. We demonstrated that Notch1 protein decrease
upon PI3K/AKT inhibition was due to lysosomal degradation of the Notch1
membrane-bound form. IP and Co-IP analyses revealed that PI3K/AKT with-
drawal in Molt4 cells resulted in an increased tyrosine phosphorylation of
Notch1 and monoubiquitination of Notch1 as detected by ubiquitin capture
assay. Co-immunoprecipitation assay and co-localization analysis further
showed that E3 ubiquitin ligase, c-Cbl, interacted with Notch1 in order to direct
it into the lysosome for degradation.
Summary and Conclusions: To our knowledge, our results provide the first
evidence of mechanism by which AKT pathway controls Notch1 activity reduc-
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ing the amount of protein undergoing to lysosomal degradation. Given the cru-
cial role of Notch1 in T-ALL, our findings suggest that hyperactive AKT signaling
in T-ALL may contribute to increase the oncogenic Notch signaling in T-ALL
independently from mutations in Notch1. Therefore a therapeutic strategy direct-
ed to PI3K/AKT signaling in T-ALL could provide advantages to inhibit the dys-
regulated NOTCH signaling.
Acute lymphoblastic leukemia - Clinical
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EVALUATION OF INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE
94 C>A, IVS2 +21 A>C POLYMORPHYSMS IN ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS TREATED WITH 6-MP AND PREDICTION OF ITS
MYELOSUPPRESSIVE EFFECTS
Y. Mortazavi1,* F. Azimi2, A. Ramazani3, M. Khalili2, S. Faghihzadeh4
1Pathology, 2molecular medicine, 3Biotechnology, 4Biostatistics, Zanjan Uni-
versity of Medical sciences, Zanjan, Iran
Background: 6- Mercaptopurine (6-MP) plays an importante role in treatment
of ALL. ITPA is one of the enzymes which is involved in 6-MP metabolism path-
way, catalyzes the pyrophosphohydrolysis of inosine triphosphate (ITP) to ino-
sine monophosphate (IMP) and prevents accumulation of toxic ITP metabolits. 
Aims: Our objective was to evaluate the ITPA 94 C >A, IVS2 +21 A >C gene
polymorphisms in patients with ALL under treatment with 6-MP and prediction
of its myelosuppressive effects.
Methods: In this case series study the population consisted of 70 patients
diagnosed with ALL in the Division of Hematology-Oncology of Tehran Mofid
Hospital. PCR was carried out to amplify exon 2, exon 3, intron 2 and intron 3
of ITPA gene. All the amplified fragments were subjected to directional sequenc-
ing, then association between genotype and 6-MP toxicity was studied.
Results: In this study two exonic variants including 94 C>A and 138 G>A
showed a prevalence of 8.5% and 36.4% respectively and two intronic variants,
IVS2 +21 A>C and IVS3 +60 G>A were found in 13.5% and 7% of the samples
respectively. The rate of myelosuppression in the presence of mutant homozy-
gote and heterozygote alleles (94 C>A, 138 G>A, IVS2 +21 A>C and IVS3 +60
G>A) was higher compared to wild type (CC, AA and GG) alleles during the
use of 6-MP (P<0.05). Hepatotoxicity in individuals with mutant homozygote
and heterozygote 94 C>A and IVS3 +60 G>A alleles was higher than individuals
with wild type alleles (CC and GG) during the use of 6-MP (P<0.05).
Summary and Conclusions: Our results indicate that individuals who have
aberrant ITPase genotype (mutant homozygous or heterozygous), more likely
to have myelosuppression and hepatotoxicity during the use of 6-MP. This
results also suggest that pre-therapeutic screening of ITPA 94 C>A, IVS2 +21
A>C and IVS3 +60 G>A may help in minimizing the myelosuppression and
hepatotoxicity induced by 6-MP in ALL patients.
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COMPARISON OF THREE DIFFERENT PRIMING REGIMENS BASED ON
IDARUBICIN, ACLACINOMYCIN OR PIRARUBICIN FOR REFRACTORY/
RELAPSE ACUTE LYMPHOBLASTIC LEUKEMIA
K. Miao1,* H. Zhu1, W. Shen1, S. Wang1, H. Wu1, J. Li1, G. He1
1the first affiliated hospital of Nanjing Medical University, Nanjing, China
Background: Refractory/relapse acute lymphoblastic leukemia (ALL) has very
poor clinical outcome for the resistance to routine chemical agents. Priming regimen
was a promissing choice for refractory/relapse ALL, especially for those eldly patients. 
Aims: We were interested and analyzed three different priming regimens based
on idarubicin, aclacinomycin or pirarubicin for refractory/relapse ALL. Both the
effectiveness and safety were investigated.
Methods: A total of 43 refractory and/or relapsed ALL patients were enrolled in
this study. These patients composed of 31 male and 12 female, with the medial
age of 26(8~ 85) years old. The salvage regimen was idarubicin, aclacinomycin
or pirarubicin combined with cytarabine (Ara-C) and granulocyte colony-stimu-
lating factor (G-CSF). The detailed three regimens were performed as, IAG
(idarubicin 10mg/d, d1,4,8,11; Ara-C 10 mg/m2 twice daily, d1-14; G-CSF 200
mg /m2 d0~14), CAG(Acla 10mg/d, d1-8; Ara-C 10 mg/m2 twice daily, d1-14; G-
CSF 200 mg /m2 d0~14) and TAG(pirarubicin 10mg/d, d1,4,8, 11; Ara-C 10
mg/m2 twice daily, d1-14; G-CSF 200 mg /m2 d0~14). There were 13 cases in
IAG group, 18 cases in CAG group and 12 cases were assigned to TAG group.
Effectiveness was measured using objective response and safety was measured
using the NCI classification system of common toxicity criteria for adverse
events. Some parameters which may influence the clinical outcome, such as
age, immunophenotype and white blood cell (WBC) count were also explored.
Results: The overall complete remission (CR) rate for all patients in three
groups was 46.5% (20 cases), partial remission (PR) rate was 16.2% (7 cas-
es), and 16 cases (37.2%) got no remission (NR). The overall response rate
(ORR) was 62.8%. In IAG group, the ORR was 69.2%, and the CR rate as well
as PR rate was 53.8% and 15.4%, respectively. There were 8 patients (44.4%)
got CR, 3 patients (16.6%) got PR, and ORR was 61% in CAG group. In group
TAG, a total of 5 cases (41.7%) got CR, and 2 cases (16.6%) got PR, with
ORR 58.3%. The response rate in three groups had no statistical difference
(P=0.837). Compared with patients 35 years old (ORR 71.4%), the ORR for
≤35 years old group was 54.5%, and no statistical difference was found between
two groups (P=0.347). There was also no significance about ORR between T-
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ALL and B-ALL groups (T-ALL group 68.4% Vs B-ALL group 54.1%, P=0.542).
No significance could be found between WBC decreased group and WBC nor-
mal or increased group (ORR, WBC decreased group 65% VsWBC normal or
increased group 60.9%, P=1.000). ORR in >60 years old group and ≤60 years
old group did not show any significant difference (ORR, >60 years old group
60% Vs ≤60 years old group 54.3%, P=0.272).If we define WBC≥100×109/L in
T-ALL or WBC≥30×109/L in B-ALL as high WBC group, there was also no sig-
nificance between high WBC group and non high WBC group (ORR, 50% Vs
64.9%, P=0.808). Further more, it was analyzed in every two chemotherapy
regimen groups, and no significance was found for response rate. Some com-
mon adverse events occurred during and after chemotherapy, including fever,
bone marrow suppression, gastrointestinal tract reaction and liver function
damage. These events were all well tolerated.
Summary and Conclusions: Three different priming regimen based on idaru-
bicin, aclacinomycin or pirarubicin for refractory/relapse ALL showed high
remission rate, good tolerance, and the non hematological toxicity was mild
and could be well tolerated. These regimens did not show any significance in
both response rate and side effects.
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INVESTIGATING THE PROGNOSTIC SIGNIFICANCE OF MICRORNA-335
EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA 
J.S.X. Lee1,* B.H. Lin1, W.J. Chng 1
1Department of Haematology-Oncology, National University Cancer Institute,
Singapore / National University Health System, Singapore, Singapore, Singa-
pore
Background: Acute lymphoblastic leukaemia (ALL) accounts for approximately
15% of all leukemias in adults. Unlike paediatric ALL, which has a 90% five-year
event-free survival, adult ALL tend to fare poorly, with a 20-30% five-year event-
free survival rate. While some of the issues related to poor outcome may be due
to host conditions, most patients die of refractory disease rather than treatment-
related complications. Prognostic factors and the treatment regimen for adult ALL
have not evolved in more than 15 years; it is therefore critical that we try to identify
better prognostic factors that not only identify high-risk patients, but may also pro-
vide insight into the use of therapeutic agents that can improve prognosis. MicroR-
NA has been shown to be dysregulated in cancer cells, and to be more powerful
prognostic factors in leukaemia. Low levels of miR335 have previously been found
to result in higher MAPK1-mediated survival of paediatric ALL and is associated
with prednisolone resistance. The use of MAPK inhibitors could overcome this
resistance. miR335 has not been studied in adult samples.
Aims: We aimed to determine the level of miR335 in samples of newly diag-
nosed Adult ALL patients. Our hypothesis is that low expression of miR335 in
adult ALL is associated with a poorer outcome. We also hoped to determine
miR335 association with known poor prognostic factors as well as the need for
Stem Cell Transplants.
Methods: We determined the level of miR335 in 37 newly diagnosed Adult ALL
patients who were treated uniformly on our institutional protocol over the past 5
years. Mononuclear cells were separated and harvested at diagnosis using
Ficoll-Paque density gradient centrifugation. Total RNA was extracted using
TRIzol Reagent and subsequently purified. cDNAs was then synthesized from
total RNA with miR335 specific primers and qRT-PCR quantification of miR335
was performed of the samples. Using the median expression of miR335 as a
cut off, we compared a number of parameters between the 2 populations, includ-
ing complete response rates, survival, known poor prognostic factors and need
for stem cell transplantation. The t-test is used for comparison of continuous
values, chi-square test for categorical values and log-rank test for survival.
Results: Those with a high level of miR335 were noted to have more poor prog-
nostic factors (94%) as compared to the group with a low level of miR335 (71%,
p=0.04). Despite this, those with a high level of miR335 had a higher rate of
remission after induction chemotherapy (71% vs 41%, p=0.046). Although fewer
patients with low miR335 had poor prognostic factors, they required more stem
cell transplants (47% vs 11%, p=0.03) compared to the high miR335 group.
This was mainly due to poor response to induction chemotherapy with 78% of
them not achieving remission then. Although the overall survival is the same in
both groups (High miR335 39%, Low miR335 42%, p=0.66), it is largely con-
founded by the high rate of stem cell transplant in the low miR335 group.
Summary and Conclusions: This data supports the hypothesis that miR335
in adult ALL confers a poorer outcome which is independent of traditional poor
prognostic factors. This may allow us to identify poor risk patients for which we
can tailor treatment using MAPK1 inhibition to overcome therapeutic resistance
as we have shown previously, at the beginning of treatment rather than at a
later stage based on minimal residual disease measurement.
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IDENTIFICATION OF DISTINCT PROGNOSTIC SUBGROUPS IN
HIGH-HYPERDIPLOID PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
BY MULTI-TARGET INTERPHASE FISH
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Background: Acute lymphoblastic leukemia (ALL) is the major malignancy in
childhood. Patients with high hyperdiploid (HeH) chromosome constellation
represent the largest genetic subgroup. Despite its generally favorable prog-
nosis, patients show heterogeneous clinical outcome.
Aims: The eight most commonly gained chromosomes (4, 6, 10, 14, 17, 18, 21,
X) were investigated by correlated way at single-cell level using multicolor inter-
phase fluorescence in situ hybridization (iFISH) in order to explore genetic het-
erogeneity and identify subgroups of patients with distinct prognostic features.
Methods: After exclusion of children with t(9;22)(q34;q11.2), t(v;11q23),
t(12;21)(p13;q22) or t(1;19)(q23;p13.3) a complete multi-target iFISH analysis
was successfully performed on bone marrow samples of 168 patients with pre-
B ALL. A minimum of 300 nuclei were aimed to be fully evaluated in each sam-
ple. Modal number (iMN8), defined as the chromosome number of the largest
subclone by iFISH, has been identified for each leukemia.
Results: iMN8 indicated a HeH ≥51 chromosome set in 28.5% (48/168) of cas-
es. As compared to non-HeH patients higher DNA index (p<0.001), lower WBC
at presentation, higher proportion of patients in the standard risk group, some-
what younger age and longer survival were all indicators of better prognosis in
the iMN8 ≥51 group. A subgroup of patients (n=20) with the highest modal num-
ber, iMN8 55-56, had an excellent 5-year pOS (95.2%) which was not only
higher compared to all other patients involved in the study (p=0.019) but also
considering HeH patients exclusively (p=0.046). iMN8 55-56 patients had sig-
nificantly lower WBC at diagnosis (p=0.010), more patients belonged to the
standard risk arm (p=0.007) and none of them had central nervous system
involvement at diagnosis. We scrutinized whether the pattern of specific numer-
ical chromosome aberrations has an association with the outcome heterogene-
ity observed in the HeH group. Improved survival was achieved by patients
gaining chromosome(s) 4, 4-6, 4-10, 4-17, 4-18 and 4-10-17. and 4-10-17.
Patients with 4-10-17 triple trisomy, a feature previously reported to be asso-
ciated with the best prognosis, showed a better pEFS but not pOS. The multi-
target iFISH approach allowed us to determine the copy number status of 8
chromosomes in single nuclei. Cells sharing identical alterations were grouped
during clonality identification and subclonal composition was then analyzed to
assess chromosomal heterogeneity. Amongst patients with iMN8 55-56 on
average 23.0 (SE 9.24) subclones were detected, which was significantly lower
(P=0.028) compared that in the iMN8 51-54 group.
Summary and Conclusions: We successfully performed a screening for
whole chromosome copy number changes at single-cell level using an exten-
sive panel of FISH probes on unselected leukemic cells of patients with child-
hood pre-B ALL. We were able to identify patients with HeH ALL with high reli-
ability as well as to explore chromosomal heterogeneity, reveal cytogenetic
patterns as predictors of outcome and classify HeH ALL patients into prognos-
tically distinct subgroups.
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EARLY CLEARING OF PERIPHERAL BLOOD BLASTS IS AN INDEPENDENT
PROGNOSTIC FACTOR IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA
L. Monteiro1, J. Schuh1,* R. Gerivaz1, S. Leocádio1, A. Tomé1, M. Fevereiro1,
N. Almeida1, F. Costa1, J. Caldas1, C. Gaspar1, M. Silva1, L. Checa1, A. Mon-
teiro1, G. Ferreira1, M.H. Sousa1, P. Ribeiro1, E. Cruz1, M. Prata1, I. Poças1,
A. Botelho de Sousa1
1Serviço de Hematologia, Hospital dos Capuchos, Lisboa, Portugal
Background: Although therapeutic regimens for acute lymphoblastic leukemia
(ALL) in use for adult patients achieve complete remission (CR) rates over
80%, most patients eventually relapse and long-term mortality is high. Steroid
resistance is known to be associated with aggressive disease in children, but
it has not been routinely evaluated as a prognostic factor in adults.
Aims: In order to evaluate the impact of steroid sensitivity at diagnosis, we ret-
rospectively analyzed the day 7 peripheral blood blast count (d7BC) in adult
patients treated in our department over a period of 11 years with the hyperCVAD
regimen, which includes a 7-day pre-induction phase with dexamethasone.
Methods: We evaluated 131 consecutive patients treated from January 2003
to December 2013 for the influence of the following variables on disease-free
survival (DFS) and overall survival (OS): age, sex, immunophenotype, hyper-
leukocytosis (defined as >30,000/ul for B and >100,000 for T subtypes), central
nervous system or testicular involvement at diagnosis, unfavorable cytogenet-
ics [t(9;22) or MLLrearrangements] and d7BC.
Results: Median age was 40 years (15-69) with 18% (23 patients) >60 years;
53% were male. The phenotype was B in 79% (104) patients and T in 21%
(27). Hyperleukocytosis was present at diagnosis in 22% of B and 30% of T-
ALL; median leukocyte count at diagnosis was 13300/ul. The CR rate was
88%. With a median follow-up of 60 months, DFS was 25,7 months and OS
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was 30 months. Among the 108 evaluable patients for circulating blasts, 36%
(39) had persisting d7BC. This subgroup of patients had a shorter OS (17,1 vs
38,8 months, P <0,01). In multivariate analysis, the Hazard Ratio was 2,0 for
persisting d7BC.
Figure 1.
Summary and Conclusions: Our results show that d7BC is an independent
risk factor, suggesting that early clearance of blasts has a major impact on the
outcome of ALL in adults. The potential of emerging novel therapies should be
explored in this particular group of patients.
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PHILADELPHIA CHROMOSOME MAY NOT BE AN ADVERSE PROGNOSTIC
FACTOR IN THE OLD-AGE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS IN THE ERA OF TYROSINE KINASE INHIBITOR
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Background: Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL) is approximately comprised of 25% of adult ALL, and has been
characterized by poor clinical outcomes, especially in the elderly patients. How-
ever, the prognosis in these patients might be improved with the advent of tyro-
sine kinase inhibitors (TKIs) as combination therapy to various chemothera-
peutic regimens.
Aims: The aim of this study is to analyze the prognostic significance of Ph+B-
cell precursor (BCP) old-age ALL treated with TKIs and compare its clinical
outcomes with Ph- BCP old-age ALL.
Methods: The clinical outcomes of 41 elderly patients with BCP, who were
treated at 5 university hospitals in Korea from Sep 2005 to Nov 2013, were ret-
rospectively analyzed.
Results: In this study, the median age of the patients was 65 (range, 60 to 82)
and median follow up duration was 58.3 months (range, 1.5 to 115.4 months).
Twenty-one patients (51%) were Ph+and treated with TKI combined chemother-
apy. Patients with Ph- ALL were treated with conventional chemotherapy iden-
tical to those for the Ph+patients. There were no differences in the patient char-
acteristics including age, white blood cell count, immunophenotype,
extramedullary involvement, and lactic dehydrogenase level according to the
presence of Philadelphia chromosome. Complete remission (CR) rate was sig-
nificantly higher in the Ph+ALL compared to the Ph- ALL elderly patients (80.0%
vs 50.0%, P=0.047). There was no difference in the treatment-related mortality
rate between two groups. Median overall survival was not different between
the Ph- and Ph+ALL (5.4 months vs 7.5 months). Among Ph+patients, Bcr/abl
subtypes at diagnosis and quantitative PCR analysis after induction therapy
did not show any prognostic values. Multivariate regression analysis demon-
strated that Charlson comorbidity score of less than 4 at diagnosis (Hazard
ratio (HR) 0.186, P=0.05), CR achievement after the first induction chemother-
apy (HR 0.188, P=0.001) and negative CD20 expression (HR 0.271, P=0.007)
remained as the independent prognostic factors predicting higher overall sur-
vival rate. In contrast to Ph- ALL patients (HR 1.462, P=0.481), CD20 expres-
sion level on the leukemic blasts was significantly associated with low overall
survival rate in the Ph+old-age ALL (HR 5.338, P=0.008).
Figure 1.
Summary and Conclusions: In this study, the survival rates of elderly BCP
ALL patients were very low as expected. However, no additive poor prognostic
value of the presence of Philadelphia chromosome was observed in the elderly
ALL patients treated with TKI-combined chemotherapy. In addition, the prog-
nostic relevance of CD20 antigen expression should be further evaluated for
the large number of elderly Ph+ALL patients. 
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NELARABINE IN CHILDREN WITH REFRACTORY AND RELAPSED
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
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Background: Nelarabine is a pro-drug of the deoxyguanosine analogue ara-
G. Accumulation of ara-GTP in leukemic blasts allows for incorporation into
deoxyribonucleic acid (DNA), leading to inhibition of DNA synthesis and cell
death. It is indicated for patients with T-cell acute lymphoblastic leukemia (T-
ALL) and T-cell lymphoblastic lymphoma whose disease has not responded to
or has relapsed following treatment with at least two chemotherapy regimens.
This use is based on the induction of complete responses by Nelarabine alone.
We used Nelarabine in combination with other agents in treatment of children
with refractory T-ALL.
Aims: To assess rational use of Nelarabine in children with T-ALL
Methods: In multicenter studies ALL-MB from 1991 to 2014 yy there were reg-
istered 506 pts with T-ALL, 81 of them (16%) didn’t respond to induction therapy
and were classified as high-risk group (HRG). There were no significant differ-
ences between responders and non-responders in terms of initial characteris-
tics, except immunophenotype – significantly more patients with CD1a expres-
sion <25% were refractory (p,0,01). Nelarabine was used in 26 cases – for 21
patients (80,8%) as postinduction therapy and for 5 pts (19,2%) with early
relapses as second-line treatment. For both groups we used two 5-days courses
of Nelarabine 650mg/m2, combined with Dexa, Cph, PEG-asp in the 1st block
and with Dexa, VP-16 and Ara-C in second.
Results: Among high-risk patients 16 (76,2%) responded after one or two
blocks. 13 of them were transplanted from MUD, MSD or haploidentical donor.
Among 5 relapsed T-ALL patients nobody responded to therapy. We also com-
pared those, who were treated by standard chemotherapy for HRG (12 pts) with
those with Nelarabine. There was no difference in initial data, and also in remis-
sion achievement rate (47% vs 34%, p=0,2). Patients with T3-ALL responded
significantly worse in Nelarabine group(p<0,0001). Severe reversible neuropathy
was observed in 2 patients, who achieved remission.
Summary and Conclusions: Nelarabine didnt show an advantage over stan-
dard HR-blocks in our non-randomized study. But the groups were small, and
we need further research to establish optimal dose regimen, possible drug
combinations and reasons for refractoriness in T3-variant of ALL.
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Background: Anthracyclines are effective agents used in the treatment of
hematological malignancies and form important part of induction chemotherapy
in Acute Lymphoblastic leukemia (ALL). However, they cause progressive
chronic cardiotoxicity resulting in heart failure and acute toxicity manifesting
as arrhythmia and diastolic dysfunction. This is due to irreversible cardiac
myocyte damage caused by topoisomerase II inhibition and iron free radical
induced DNA damage. The early detection of cardiotoxicity is important as it
may be useful in the prevention of heart failure. Left ventricular ejection fraction
(LVEF) has been the main indicator of cardiac dysfunction and a powerful pre-
dictor of mortality. However, impairment in LVEF is often detected only after
considerable myocyte loss has taken place. However, Doppler parameters and
tissue Doppler parameters can detect early cardiac changes and may help
predict later overt LVEF decline.
Aims: To study the acute cardiac toxicity of anthracycline infusion in ALL patients
by serial echocardiographic parameters during induction chemotherapy.
Methods: The study was conducted on newly diagnosed acute lymphoblastic
leukemia without any history of previous anthracycline exposure for any reason.
Patients were treated as per Augmented BFM protocol and during induction, they
were administered daunorubicin 25 mg/m2/week for 4 weeks, vincristine 1.4
mg/m2/week for 4 weeks, Prednisone 60 mg/m2/day for 28 days and L- asparag-
inase 6000 U/m2 on alternate day for 9 doses. Echocardiography was done in all
the patients before start of chemotherapy (baseline) and at end of induction
chemotherapy (post). One more echo was done after 2 weekly doses of anthracy-
cline (mid echo). Various parameters on 2D mode, Doppler and tissue Doppler
were recorded and ejection fraction and myocardial performance index calculated.
Results: A total of 20 patients of acute leukemia were enrolled in the study.
Median age was 16.5 year (4-42 year), with 17 males (85%). Baseline leucocyte
count was 6910/ul (range: 600-788,250), with 3 patients having high risk cyto-
genetics and two having CNS 3 status. Changes in echocardiographic param-
eters occurring during baseline, mid chemotherapy and post chemotherapy are
shown in table. 2 D Parameters: LVIDes/BSA showed a decreasing trend from
baseline to mid echo (p value 0.07). It returned to near baseline value in post
echo. LA dimensions, IVS thickness was not significantly altered at any point of
time as was the case with LVPW. Doppler Parameters: E velocity was showing
overall significant changes in ALL patients (p value 0.031). A velocity showed
trends towards overall changes during induction (p value 0.07), attaining signif-
icant difference in mid and post echo (p value 0.048). E/A ratio showed statistical
significant difference in post chemotherapy echo (p value 0.049). Deceleration
time showed a non significant dip after chemotherapy cycle and reverted back
to some extent in ALL patients. Tissue Doppler Parameters: Sm lateral was
insignificant during chemotherapy. Sm septal showed a significant dip from
baseline to mid echo (p value 0.02). Em lateral had significant decrease (p value
0.045). Em septal had non-significant decreasing trend (p value 0.08). Am septal
and lateral showed non- significant changes. Iso-volumetric relaxation and con-
traction time did not show significant variation during chemotherapy at any time.
Left ventricular ejection fraction did not show significant changes. Myocardial
performance index was also almost unchanged during induction.
Tabella 1. Changes in echocardiographic parameters during ALL induction.
Summary and Conclusions: Daunorubicin induced early cardiac toxicity caus-
es predominantly diastolic dysfunction, as is reflected by changes in various
Doppler and tissue Doppler indices. Systolic function of the heart as assessed
by LVEF is relatively preserved. Myocardial performance index (Tei index), pro-
posed as sensitive indicator of cardiac dysfunction, does not change either
during induction. These changes in echo parameters remain sub- clinical during
induction. Patients with changes in echocardiographic parameters need to be
followed up with repeated echo to find improvement or worsening of these
changes and their relation to clinical symptoms due to heart failure.
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APPLICATION OF SYSTEMS PHARMACOLOGY MODELING FOR
EVALUATION OF THERAPIES EFFECT ON BLAST DYNAMICS IN ACUTE
LYMPHOBLASTIC LEUKEMIA
A. Nikitich1,* O. Demin Jr1
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Background: Acute lymphoblastic leukemia (ALL) is an acute form of cancer
of the white blood cells, characterized by the overproduction of cancerous,
immature white blood cells. ALL is most common in childhood with a peak inci-
dence at 2–5 years of age, and another peak in old age. About 80% of ALL
patients will have complete remission, but the question about the most effective
therapy remains open. 
Aims: The aim of this work is to reproduce dynamics of ALL progression and
compare efficacy of several clinically accepted and potential treatments.
Methods: Systems pharmacology model of ALL progression and treatment was
developed. The model is a system of ordinary differential equations. It includes
description of B-lymphoblasts proliferation and distribution between cell cycle
phases with and without treatment, B-lymphoblasts and other blood cells dynam-
ics during ALL progression, pharmacokinetics of several compounds (vorinostat,
sorafenib) and its effect on B-lymphoblasts dynamics in ALL patients. Parame-
ters of the model were calculated on the basis of the literature data or fitted
against published experimental data. Treatment was simulated for two types of
virtual patients: with slow and high rate of disease progression.
Results: Model satisfactory reproduces in vitro data on B-lymphoblasts cell
lines proliferation and distribution between cell cycle phases with and without
drug treatment and in vivo blasts levels in blood measured during ALL pro-
gression. The model was validated against blast dynamics during treatment
with sorafenib. Model shows that for virtual patients with slow ALL progression
vorinostat is more effective than sorafenib. For virtual patient with fast ALL pro-
gression both compounds are ineffective.
Figure 1.
Summary and Conclusions: Model predicts that slow progression rate
patients have better respond to the therapy. Systems pharmacology model of
ALL progression and treatment could be used as a tool to compare different
clinically accepted and potential treatments. 
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LACK OF PROGNOSTIC IMPACT OF ABERRANT MYELOID ANTIGEN
EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
M. Alpoim1,* G. Brás1, R. Pinto1, A. Carneiro1, F. Príncipe1, J.E. Guimarães1
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Background: A subset of adult acute lymphoblastic leukemia (ALL) patients
have blast cells which co express myeloid associated markers. The expression
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of aberrant myeloid antigen (MyAg) in ALL differs considerably in independent
studies and its prognostic value is still controversial.
Aims: To analyze the incidence of MyAg in a group of adult ALL and its corre-
lation with clinical features, prognostic factors and outcome.
Methods: We retrospectively analyzed the expression of MyAg CD13 and/or
CD33 of 79 adult patients with de novo ALL in a single center, between 2006
and 2014. 
Results: The median age at diagnosis was 44 years [17-70]. The median white
blood count (WBC) was 9.6 x10^9/L [0.2-254] and 24 (30.4%) patients had
high WBC (>30x10^9/L in B-ALL and >100x10^9/L in T-ALL). Physical exami-
nation revealed hepatomegaly in 30 (38%) and splenomegaly in 27 (34.2%)
patients. The central nervous system (SNC) was involved in 9 (11.4%) and 31
(39.2%) had serum lactate dehydrogenase (LDH) >4xULN. Sixty-nine (87.3%)
patients had a B-lineage ALL (common-B ALL 63.8%, pre-B ALL 29%, pro-B
ALL 7.2%), while only 10 (12.7%) patients had T-lineage ALL (Thymic ALL 60%,
mature-T ALL 40%). MyAg expression (CD13 and/or CD33) was documented
in 25 (31.6%) patients. No differences were found between the MyAg +and
MyAg- groups with regard to median age, median WBC, high WBC, high LDH
(>4xULN), hepatomegaly and/or splenomegaly or involvement of SNC at diag-
nosis. MyAg expression was only found in B-ALL and none of the 10 cases of
T-ALL showed aberrant phenotype (31.6% vs. 0%; p=0.017). According to
immunophenotypic subtype B, no difference was observed (p=0.275). Kary-
otype was evaluated in 71 of 79 patients and 34 (47.9%) had an unfavorable
karyotype: t(9,22) in 32 (45.1%) patients, t(4,11) in 1 (1,4%) and hypodiploidy
in 1 (1.6%) patient. Fifty-one (64.6%) patients fulfilled criteria for High Risk
(HR) group, while the remaining 28 (35.4%) were classified as Standard Risk
(SR) group. In B-lineage ALL, the MyAg+group was more frequently associated
with unfavorable karyotype (47.1% vs 25%; p= 0.074) and with HR group
(41.3% vs 26.1%; p=0.215) but these differences were not statistically signifi-
cant. Patients were treated with the Hyper-CVAD protocol or HOVON 100
ALL/EORTC 06083 protocol (nonexperimental arm). Seventy-seven (97.5%)
patients achieved complete remission (CR) after induction therapy. The two
patients with resistant disease had MyAg+expression but this difference was
not statistically significant (p=0.097). The 5-year overall survival rates for
MyAg+group vs MyAg- group were 26.7% vs 39.7%, respectively, but again,
the difference was not statistically significant (p=0.555). The 5-year disease
free survival (DFS) rates were 29.5% for MyAg+group and 43.5% for MyAg-
group, difference not significant (p=0.567). We separately analyzed B-lineage
ALL cases and we found no differences in DFS (p=0.460) and OS (p=0.464)
between MyAg+and MyAg- cases. Additionally when cases with unfavorable
karyotype were analyzed as a separate group, we failed to observe any statis-
tical difference between the two groups in terms of DFS (p=0.978) and OS
(p=0.888). Again, when the HR group was evaluated as a separate group, no
differences were recorded between the two groups (DFS p=0.587; OS
p=0.583).
Summary and Conclusions: In our study we have found that there was no
prognostic impact of aberrant myeloid antigen expression in adult acute lym-
phoblastic leukemia. However, the evaluation of the expression of these anti-
gens remains valuable, as for example, in the monitoring of minimal residual
disease.
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OUTCOME OF OLDER ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA TREATED WITH HYPERCVAD
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Background: Older patients with acute lymphoblastic leukemia (ALL) have a
poorer outcome. Due to assumptions about a higher risk of complications and
toxic death, they are often denied potentially curative treatment approaches. 
Aims: To address the impact of known prognostic factors in older fit patients
offered intensive chemotherapy, we retrospectively analyzed the outcome of
patients ≥55 years of age who received HyperCVAD as a first-line treatment.
Methods: We compared the outcome of 35 consecutive older patients (age
55-69) who were treated in our center from January 2003 to December 2013,
and of the 96 younger patients (age 15-54) treated in the same period with the
same regimen. We evaluated the complete remission (CR) rate, the disease-
free survival (DFS) and the overall survival (OS) of these 2 groups, and we
analyzed the influence of age, performance status, immunophenotype, leuko-
cyte count at diagnosis (≤ or >50000/uL), presence of hyperleukocytosis
(defined as >30000/uL for B and >100000/uL for T subtypes) and unfavorable
cytogenetics (BCR-ABL1 or MLL rearrangements).
Results: Disease characteristics were similar in older and younger patients
(BCR-ABL1 being non-significantly more frequent in the former, 32% vs 20%).
The CR rate was lower in older patients (82% vs 90%). At a median follow-up
of 60 months (m), DFS was worse in older patients (7,8m vs 32,8m), as was
OS (9,8m vs 36,4m, p<0,01). In older patients, a T phenotype had a strong
negative impact on OS (1,8m vs 17m, p<0,05). In multivariate analysis, the 2
independent prognostic parameters for OS were a T phenotype (Hazard Ratio
2,1) and older age (Hazard Ratio 2,25).
Figure 1.
Summary and Conclusions: Older patients easily achieve CR, but CR dura-
tion and OS remain highly unsatisfying (in particular for T-ALL) even with an
intensive regimen such as HyperCVAD, underscoring the need for novel strate-
gies.
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INHIBITION OF AXL KINASE SUPPRESSES RETINOIC ACID
METABOLISM THROUGH REGULATION OF CYP26
K. Soh1, J. Bearss1, B. Bahr1, P. Peterson1, W. Kim1, C. Whatcott1,*,
A. Siddiqui-Jain1, S. Warner1, D. Bearss1
1Tolero Pharmaceuticals, Inc., Lehi, United States
Background: Retinoic acid (RA), a metabolite of Vitamin A (retinol), is a known
regulator of cell growth and differentiation, inducing expression of multiple
genes such as retinoic acid receptor responder 1 (RARRES1/TIG1). RAR-
RES1, and its associated binding partners such as AXL kinase, have been
shown to promote tumor growth and drug resistance in multiple tumor types.
RA has been used as a single-agent treatment in patients with acute promye-
locytic leukemia (APL) with roughly 90% of patients attaining a complete remis-
sion. However, remissions can be transient and resistance arises within a few
months following treatment. This resistance is thought to develop through
increased RA metabolism through upregulation of CYP26, a cytochrome P450
enzyme that plays a key role in the metabolism of RA.
Aims: We have sought to understand the role of AXL inhibition as a means of
restoring sensitivity to RA treatment. We hypothesize that treatment with our
AXL inhibitor, TP-0903, would disrupt RA metabolism by CYP26. 
Methods: RT-PCR was used to measure mRNA expression of CYP26 in cells
induced with RA and treated with TP-0903. Following treatment, changes in
CYP26 expression was assessed at the protein level, using standard western
blotting techniques. Endogenous RA levels were measured using a competitive
ELISA technique. To determine the effect of TP-0903 on tumor growth in an in
vivomodel, we tested TP-0903 treatment in a MV4-11 xenograft mouse model.
Results: Consistent with prior reports, we observe a robust induction in mRNA
expression levels of CYP26 following 1 mM RA treatment in MV4-11 leukemia
cells, reaching nearly 4.3-fold after 6 hours of treatment. However, treatment
of cells with TP-0903 at levels as low as 100 nM inhibited RA-mediated induc-
tion of CYP26 mRNA levels by 88.9% in MV4-11 cells at 6 hours. Interestingly,
TP-0903 also inhibited basal mRNA levels of CYP26 by 94.1% at 6 hours. Sim-
ilar trends are observed in additional cell lines (HL60, A549, and H1650), and
with an alternative AXL inhibitor, R428, although only at higher concentrations.
At time points greater than 24 hours, and without re-treatment with TP-0903,
CYP26 expression exceeded levels observed in induced samples. In TP-0903-
treated cells, we observed that RA levels are maintained at time points where
CYP26 expression is suppressed. TP-0903 strongly inhibited tumor volumes
by up to 100% at multiple dose levels and treatment schedules. Analysis of
CYP26 expression in fixed tissues, and RA levels in plasma will be assessed
to determine the effects of TP-0903 on physiological levels of CYP26 and RA. 
Summary and Conclusions: Our observations support our hypothesis that
inhibition of AXL kinase by TP-0903 disrupts RA metabolism by suppressing
CYP26. Taken together, our data suggest that AXL may serve as a suitable
therapeutic target for addressing cellular responses mediating RA resistance. 
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AN EFFICIENT COMPUTATIONAL APPROACH TO EVALUATE THE
EXPRESSION PROFILE OF INDIVIDUAL ACUTE LEUKEMIA PATIENTS
M.C. Hansen1,* C.G. Nyvold1, T. Haferlach2, M.O. Henriksen1,3, A.S. Roug1,
P. Hokland1
1Department of Hematology, Aarhus University Hospital, Aarhus, Denmark,
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Background: Microarray and sequencing studies have been instrumental in
the mapping of genome wide associations in hematological diseases. Thus, the
MILE Study (Haferlach et al, J Clin Oncol 2010) has taught us that it is possible
to robustly classify and predict leukemia subgroups. However, several factors
have impeded the general use of such data and methods in the everyday clinical
setting: (i) technical expertise may not be available and, (ii) inter-study variations
have hampered direct comparison of results between centers. As a conse-
quence, (iii) the practical implications of analyzing single patient samples have
to some extent been overlooked. Tools, which enable the singular patient omics
to be addressed in a clinically relevant fashion, are thus much needed. We
hypothesized that combining data from MILE Study and data mining at the single
patient level by novel scripts could delineate the unique expression signature.
Aims: (1) To develop an algorithm for implementing results from large profiling
studies (microarray or RNA-seq) without the need for normalization between
sample sets (2) to predict leukemia subtype of single samples in a timely fash-
ion, thus (3) enabling informative exploration within the private expression pro-
file of genes of interest.
Methods: We accessed the MILE Study data (2096 samples from Stage I
study), to generate a single compressed dataset for individual leukemia pre-
diction of 21 separately run samples (Aarhus, DK) derived from microarray
analysis (HG-U133A arrays, Affymetrix Inc., CA, USA) of bone marrow aspi-
rates (Figure 1A). This resulted in a reference matrix, which covered 2181 pre-
dictor genes in total and 15 leukemia subtypes, denoting genes as upregulated,
unaltered or downregulated (discrete values of 1, 0, -1), evaluated via the
Leukemia Gene Atlas (Hebestreit et al, PLoS One 2012). The patient samples
were comprised of three clinically defined subtypes (6 AML inv(16), 8 t(8;21)
and 7 ALL t(12;21)). The evaluation of individual molecular subtypes was sub-
sequently performed by entry-wise matrix multiplication followed by scoring.
Data mining was performed by coupling external sources and results, utilizing
Wolfram Mathematica as computational platform (Hansen et al, Br J Haematol
2015, in press).
Results: Prediction of leukemia subtype matched clinical diagnoses in all cases
(21/21). Consecutive data mining enabled us to evaluate and emphasize indi-
vidual expression patterns, which were otherwise masked by attempts to draw
parallels between samples. Setting an arbitrary threshold of e.g. eightfold
expression difference, the common gene set for each subgroups was low com-
pared to the total number of genes observed (Figure 1B). In contrast, evaluating
combinations of samples in each subtype showed a higher number of common
differentially expressed genes in-between patients. At the individual level a sub-
stantial part of the genes with increased or decreased expression was leukemia
associated (median values of 17–62 in sets of 74–230 genes, evaluated through
DisGeNET database, Bauer-Mehren et al, PLoS One 2011). Of these sets each
genes was found to have two or more MeSH term associated references in the
PubMed database (within the three clinically defined subtypes: 74/138, 97/178,
181/376). It was also observed that the vast majority of biological gene functions
matched potentially malignant functions, i.e. cell cycle, migration, defense
response and signal transduction.
Figure 1.
Summary and Conclusions: We have recently described how genomic analy-
sis on the single patient level can be utilized in the setting of exome sequenced
samples (Hansen et al, Br J Haematol 2015, in press). Here we show that this
data mining approach can also be utilized for expression profiling of single
patients. Hopefully, with shortened lab turn-over time for omic studies, the pres-
ent approach, which involves minimal computational effort, taken together with
standard molecular screening in acute leukemia patients, should result in
speedy information flow from research to the clinic with much more detailed
characterization of the single patient. Ultimately, this should in turn enable more
focused personalized medicine.
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MOLECULAR CORRELATES AND DRUG RE-PURPOSING SCREENING IN
HYPOMETHYLATING AGENT FAILURE IN AML AND MDS 
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Background: After initial response to the hypomethylating agents
(HMA)/DNMT inhibitors 5-Azacitidine (AZA) and Decitabine, ultimately all
patients with Myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML) progress/fail treatment. Subsequent therapies and outcomes are dismal.
Developing novel therapeutic approaches in HMA failure MDS and AML patients
is one of the largest clinical needs in this field.
Aims: The mechanisms of HMA failure are still poorly understood and effective
novel regimens are lacking. To address these deficiencies, we pursued several
approaches in parallel including extensive genomic characterization of AZA
resistant cells as well as in vitro drug re-purposing screens of FDA approved
small molecule libraries with the goal to define the molecular landscape and
novel therapeutic targets in HMA failure MDS/AML, as well as to identify novel
drugs that could be immediately translated into clinical use.
Methods: Over a 2-year period AZA resistant (RES) cell lines (TF-1, HEL) were
generated including non-clonal (NC, requiring continuous AZA exposure) and
clonal (C) sub-lines with 20-50 fold AZA resistance. Lines were extensively pro-
filed by various next generation assays including exome sequencing, RNA-
seq, Illumina 450K methylome and miRNA arrays; to identify differences in
molecular changes in resistant vs. parental (PAR) cells mimicking clinical sce-
narios cells were either AZA treated or left untreated prior to performing assays.
A 1,489 RNAi gene silencing screen for molecular vulnerabilities is available
as well. A ~ 2,216 drug library (i.e. Prestwick, Mayo customized selected
approved drugs) was run on RES and PAR cells. Lastly, we performed targeted
sequencing and RNA-seq in HMA failure MDS/AML patients to assess clonal
evolution and correlate findings with in vitro models.
Results: In RES cells no actionable new mutation were identified by exome
sequencing. RNA-seq showed several genes and regulators of the MAPK and
specifically RAS pathway activated in RES cells. Methylation analysis showed
shared genes with loss of methylation following AZA in PAR and RES cells.
Further, genes with methylation changes only in RES or PAR cells as well as
genes that were unmethylated at baseline in RES vs. PAR cells but became
methylated following AZA treatment, indicate a loss of response to epigenetic
regulation upon chronic HMA exposure. These genes represent novel genomic
therapeutic vulnerabilities and depict resistance mechanism. From the 2,216
compound screen, only 4 compounds were overlapping in >3 of 6 cell lines,
these 4 drugs are formally being validated now including primary HAM resistant
patient samples. In parallel we tested putative HMA/DNMT inhibitors based on
structural bioinformatics knowledge mining in the HMA resistance context. Sev-
eral drugs, including known drug entities such as antihypertensives, showed
similar activity in sensitive and resistant lines. Lastly, we have generated a
mutational landscape of HMA resistant clinical samples (Foundation Medicine
Heme Panel) and RNA-seq has been performed.
Summary and Conclusions: At the meeting our efforts and data will be pre-
sented to give an overview of our translational research platform and our
approach at HMA failure. We present and highlight results and data of our com-
bined integrated platforms of elucidating molecular mechanisms of HMA resist-
ance while providing drugs and therapeutic avenues for MDS and AML patients
who have failed AZA or Decitabine. 
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ABSOLUTE QUANTIFICATION OF EVI1 OVEREXPRESSION IN ACUTE
MYELOID LEUKEMIA BY RQ-PCR ANALYSIS: A STUDY OF THE ALFA
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Background: The Ecotropic viral integration site 1 (EVI1) gene is located on
chromosome band 3q26.2, and is composed of 16 exons. At diagnosis, EVI1
overexpression has been implicated in approximately 8% of patients harboring
acute myeloid leukemia (AML) and confers a poor prognosis. It is often asso-
ciated with adverse cytogenetic abnormalities, but can be found in normal kary-
otypes. Quantification of EVI1 expression is complex due to its various splice
variants and its 5 alternative mRNA 5’-ends. EVI1mRNA expression has been
mainly assessed by real-time quantitative PCR (RQ-PCR) using the house-
keeping genes Abelson (ABL) and the ΔCt method. The technique currently
used in our laboratory is based on the relative quantification of the EVI1-1D
alternative splice form. Although this assay provides good results at AML diag-
nosis, it is not powerful enough to monitor MRD.
Aims: In the present study, we developed a RQ-PCR assay to perform the
absolute quantification of EVI1 expression covering the different EVI1 splice
variants. This assay was applied in control samples to define threshold values
in normal bone marrow (BM) and peripheral blood (PB), and in AML diagnostic
and follow-up samples.
Methods: This study focuses on 64 patients with EVI1 overexpression included
in the ALFA-0701 and ALFA-0702 trials. BM and PB samples were collected at
AML diagnosis (n=67) and during follow-up (n=152). Using relative quantification,
EVI1 was considered as overexpressed at AML diagnosis if the ΔCt value
between EVI1 and the housekeeping gene ABL was less than 10. Reference
values of normalized EVI1 levels in normal PB and BM were established by
analyzing a total of 31 PB and 17 BM samples collected from healthy volunteers.
To achieve absolute quantification, we cloned a sequence of EVI1 localized on
exons 14 and 15, framing primers and TaqMan probe previously described by
Gröschel et al. The sequence was integrated into plasmids that were used to
determine the standard curve for the RQ-PCR. In parallel, the expression of the
housekeeping gene ABL was evaluated by RQ-PCR for each sample. The
results were expressed as a percentage of EVI1 copies by ABL copies.
Results: The median value of EVl1 expression in normal PB samples was
0.11% (range, 0.01 to 0.49%) and was 0.36% (0.01 to 0.96%) in normal BM
samples. The overexpression threshold was set at 0.5% for PB and at 1% for
BM. At diagnosis, we confirmed EVl1 overexpression for 62 samples out of 67
selected samples. We observed a good correlation between absolute and rel-
ative quantification, only 5 PB samples considered as low positive in relative
quantification were discordant. The median EVl1 expression was 23.3% (4.1
to 614.1%) in BM and 3.6% (0.53 to 80.7%) in PB samples. Patients with unfa-
vorable cytogenetics (n= 42) had a significantly higher EVI1 expression level
compared to patients with intermediate cytogenetics (n= 20) (P=.004), with an
average EVI1 expression of 43.1% versus 6.8%, respectively. The highest EVI1
overexpression was found in the AML subgroup with MLL rearrangement (n=
11), with an average EVI1 expression of 91.4% versus 18.3% in the absence
of MLL rearrangement (P=.006). MRD monitoring by EVI1 mRNA level quan-
tification was performed in diagnostic and follow-up samples from 48 patients.
EVI1 expression in BM varied from 21.6% in diagnostic samples to 3.56% in
post-induction samples. EVI1 expression in PB varied from 4.0% at diagnosis
to 0.22% in post-induction. Although reduction was significant (P <.001), it
remained insufficient for MRD follow-up on this parameter. Finally, among the
44 patients who achieved CR1, we observed a trend of higher EVI1 expression
in relapse group with an average expression of 163.1% in BM (n=6) and 11.5%
in PB (n=12) against 26.8% in BM (n=12) and 4.4% in PB (n=15) in relapse
free group (P=0.1). 
Summary and Conclusions: We developed a model of absolute quantification
of EVI1 expression correlating with routine relative quantification. Nevertheless,
the basal expression of EVI1 is high and variations are weak between diagnosis
and follow-up. However at diagnosis, we observed higher expression in patients
with MLL rearrangements, and thus, a trend of higher EVI1 expression in
patients who relapsed after having achieved CR1.
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THE D816V C-KIT MUTATION HAS HIGHER ABILITY OF JAK-STAT AND
SRC FAMILY KINASE THAN N822K C-KIT MUTATION, AND THEREFORE
PROLIFERATION ACTIVITY IS HIGH IN CORE-BINDING FACTOR ACUTE
MYELOID LEUKEMIA
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Background: Acute myeloid leukemia (AML) with the t(8;21) or inv(16)/t(16;16)
is defined as core-binding factor AML (CBF-AML) and has been considered an
AML group with favorable prognosis. In recent years, it has been reported that
CBF-AML with c-kit mutations show poor prognosis. Among these mutations,
D816V in exon 17 is the most frequent mutation in CBF-AML and confers higher
tumor growth and anti-apoptotic potential compared to other mutations of exon
8, 10 and 11. Interestingly N822K in exon 17 is reported at frequency similar to
D816V mutation in Asia. Our previous report (Leukemia. 2011;25(9):1423) sug-
gested the possibility that the prognosis of CBF-AML with the N822K mutation
was different from D816V and that D816V and N822K may differ functionally
even if this mutation is also in the same A-loop.
Aims: The aim of this study is to clarify a difference of the molecular biologic
function for leukemogenesis between D816V and N822K.
Methods: To analyze the molecular function of D816V and N822K, we gener-
ated amphotropic retroviral vector expressing c-kit (wild type, D816V, and
N822K). After transduction with human Interleukin 3 (IL-3) dependent TF-1
cells, we established c-kit expressed TF-1 cells (TF-1WT,TF-1D816V, and TF-
1N822K). In these three cells, we analyzed the proliferation rate by cell growth
assay and the erythropoietin (EPO)-related induction of differentiation by fluo-
rescence activated cell sorting. We also analyzed the signal pathways by West-
ern blotting, and examined responsiveness to protein kinase (PTK) inhibitors
which were Imatinib, Dasatinib, and CP690550 (JAK inhibitor).
Results: Cell growth assay showed IL-3 independent proliferation in TF-1D816V
and TF-1N822K but not TF-1WT. The proliferation rate of TF-1D816V was signif-
icantly higher than that of TF-1N822K (18610±6269 cells vs 4354±1109 cells in
day 10, p=0.026). The erythroid differentiation assay showed TF-1D816V inhib-
ited differentiation to erythroblast as compared with TF-1N822K and TF-1WT with
or without EPO. (The rates of CD71+CD235a+cells 72 hours after EPO addition:
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TF-1D816V 22.1%, TF-1N822K 84.6%, TF-1WT 82.8%) Subsequently, we inves-
tigated the difference of signal pathway for cell proliferation by Western blotting.
Under the condition starved from IL-3, the same levels of constitutive phos-
phorylation of c-kit protein were observed in the TF-1D816V and TF-1N822K, but
the TF-1WT hardly induced phosphorylation of it. We investigated about the
downstream of phosphorylated c-kit protein in the TF-1D816V and TF-1N822K.
We observed a strong phosphorylation of STAT3 and Src proteins in the TF-
1D816V, but phosphorylation of ERK protein in the TF-1N822K. Finally, we exam-
ined responsiveness to PTK inhibitors. Imatinib could inhibit cell proliferation
of TF-1N822K, but not inhibit it of TF-1D816V. In contrast, Dastinib could inhibit
cell proliferation of both TF-1N822K and TF-1D816V. We could demonstrate these
findings by Western blotting that half maximal inhibitory concentration (IC50)
of Dasatinib more strongly inhibited phosphorylation of c-kit and Src proteins
as compared with Imatinib in the TF-1D816V. CP690550 could also inhibit cell
proliferation of both TF-1N822K and TF-1D816V. We could also demonstrate
these findings by Western blotting that IC50 of CP690550 inhibited phospho-
rylation of STAT3.
Summary and Conclusions: We conclude that the D816V c-kitmutation con-
fers higher proliferation activity by JAK-STAT and Src family kinase compared
to N822K c-kit mutation. These findings suggest that biological functions of c-
kit mutations differ depending on the mutation site, which may affect respon-
siveness to treatments.
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Background: Telomeres shortening, a pro-apototic cellular event that occurs
at every round of DNA replication is prevented by human telomerase. This last
consists of two components, hTERT, a telomere specific reverse transcriptase
that catalyzes the addition of telomeric repeats, and hTERC, the RNA compo-
nent used as a template. Thus, telomerase activity mostly relies on hTERT
which activity depends on the spliced variant produced by an alternative splicing
process. This last can generate not only the full-length hTERT transcripts
(+α+β), but also transcripts carrying α and/or β deletions (transdominant neg-
ative isoform -α+β, inactive products +α-β and -α-β). Recent data provided evi-
dence that in AML hTERT over-expression may be associated with a poor clin-
ical outcome, but up to now no study has examined the frequency and prog-
nostic significance of spliced variant transcripts.
Aims: Our objectives were to estimate the frequency of hTERT isoforms in a
series of de novo AML patients (pts) and to establish whether the expression
of these isoforms varied between pts with a normal and a complex karyotype
and had any influence on clinical outcome.
Methods: The one-hundred and nine de novo AML patients included in the
present study came to our observation in the period January 2010 and January
2014. They were forty-three females and sixty-six males; their median age was
59 years (range 18-84). According to WHO classification 8 (7.3%) patients
were classified as M0/M1, 51 (46.7%) as M2, 42 (38.5%) as M4, 7 (6.4%) as
M5 and one as M6. Cytogenetic studies revealed a normal karyotype (NK) in
sixty-two (56.8%) pts, whose median age was 56 years (range 24-84), and a
complex chromosomal pattern (CK) with ≥3 defects in forty-seven (43.2%),
whose median age was 60 years (range 33-84). The two patients groups were
comparable by age. An internal tandem duplication (ITD) of the FLT3 gene and
a NPM1 mutation were revealed in 15 and 2 chromosomally normal patients.
No CK presented a FLT3 ITD. All patients received standard induction
chemotherapy followed by two courses of consolidation treatment. At the time
of the study 41 patients achieved a complete remission (CR) and 39 died.
Median follow-up was 22.7 months (range: 13.5-60.2). hTERT isoforms expres-
sion was determined in bone marrow samples by real-time reverse transcrip-
tase polymerase chain reaction, using SYBR Green I. hTERT transcript (+α+β)
primers design was made using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/),
while for the other primers we referred to Capraro et al. 2011. Specific ampli-
fications were confirmed by sequences analysis. In order, to estimate hTERT
isoforms expression levels in normal mononuclear cells, twenty-three umbilical
cord bloods (UCB) were examined (control group).
Results: At first, the expression of hTERT isoforms of NK pts was compared
to that of CK pts by applying the Kruskal-Wallis rank test, but no significant dif-
ference was observed (P=0.39, P=0.77; +α+β, -α+β respectively). Instead, Cox
univariate analysis revealed that independently from karyotype response to
treatment was significantly better in pts presenting an over-expression of the
trans-dominant negative isoform (-α+β) (P=0.03, HR=2.11; 95% CI:1,13-3,93).
In addition, leukemia-free survival was significantly worse in pts who over-
expressed inactive products (-α-β) (first group) than in those who presented a
low expression of these same products (second group) (P=0,003, HR=3,26;
95% CI:1,33-7,96). Pts who over-expressed the full-length hTERT transcript
(+α+β) and the trans-dominant negative isoform (-α+β) presented only a trend
towards significance. Moreover, the first group of pts presented a worse overall
survival (HR=1,66; 95% CI:0.94-2,91), whereas the second group a better
overall survival (HR=0,58; 95% CI:0,33-1,02).
Summary and Conclusions: Thus, in our study the over-expression of the
hTERT trans-dominant negative isoform identified low-risk AML pts, whereas
the over-expression of the hTERT inactive product (-α-β) identified high-risk
AML pts. Interestingly, this last isoform might control the expression of its trans-
dominant negative isoform. In conclusion, our results suggest an intriguing link
between the control of hTERT isoforms expression and AML outcome.
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Background: The heterogeneity of MCL1 and BCL2 expression in primary AML
samples, and likely even within individual patient isolates, suggests that it would
be difficult to establish cut-off points that would enable the clinician to select
patients for either MCL1 or BCL2-directed targeting, so the use of complemen-
tary agents may offer an ideal solution.TG02 is a novel CDK9-selective multi-
kinase inhibitor that down-regulates RNA Polymerase II causing the depletion
of the labile BCL2-family pro-survival protein MCL1, but not its stable paralogs
BCL2 or BCLXL. ABT-737 and ABT-199 are BH3 mimetics that inhibit BCL2.
Aims: We investigated whether ABT-737 and/or ABT-199 would co-operate with
TG02 to kill AML cells, and we studied the mechanisms of their interactions.
Methods: Cytotoxicity was measured by alamar blue in AML lines and flow
cytometry in patient samples. Apoptosis was determined using flow cytometric
assays for Annexin V binding, and active epitopes of BAX, BAK and caspase
3. In dynamic BH3 profiling assays, cells were treated with TG02 or ABT-199
for 4 hours and probed with BH3 peptide mimetics for a further hour. Mitochon-
drial outer membrane permeabilisation was then determined by Cytochrome
C release assays.
Results: In CD34+CD38- KG1-a cells, TG02 was strongly synergistic with
ABT-737 or ABT-199 with combination indices as low as 0.13. In a cohort of 18
patient samples treated in vitro, 50 nM TG02 +50 nM ABT-199 or ABT-737 was
significantly more toxic than 100 nM of each agent individually. Whereas the
agents were synergistic in some samples, others showed enhanced apoptotic
responses to TG02 but not to ABT-199/737 and vice versa. Normal CD34+cells
from stem cell harvests were not sensitive. In AML cells all three agents
exposed activation-specific epitopes of BAX, BAK and caspase 3. The sensi-
tiser protein BAD binds to BCL2, which can then release the apoptosis-activator
protein BIM, whereas the sensitiser NOXA releases BIM from MCL1. Following
treatment of AML cells with TG02 or ABT-199, the resultant dynamic BH3 pro-
files were found to be complementary: both agents sensitised cells to BIM,
TG02 sensitised to BCL2-targeting BAD and ABT-199 sensitised to MCL1-tar-
geting NOXA. Drug priming altered patient cell BH3 peptide sensitivity in a
manner that corresponded closely to the cells’ in vitro demise.
Summary and Conclusions: We conclude that this combinatorial approach
broadens the therapeutic potential of anti-survival signalling drugs in AML and
that dynamic BH3 profiling is a sensitive methodology for investigating com-
plementary mechanisms of chemoresponsiveness.
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COMBINED INHIBITION OF HEDGEHOG AND FLT3 SIGNALLING LEADS
TO EFFECTIVE ANTI-LEUKEMIC EFFECTS IN ACUTE MYELOID
LEUKEMIA 
E. Latuske1,* H. Stamm1, M. Klokow1, G. Vohwinkel1, M. Kebenko1,
C. Bokemeyer1, M. Jücker1, W. Fiedler1, J. Wellbrock1
1Hematology and Oncology, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
Background: The interaction of leukemic stem cells with the bone marrow
niche is dependent on stem cell activators implicated in normal stem cell biology
including the Hedgehog pathway. Recently, we revealed that expression of the
Hedgehog downstream transcription factors GLI1 and GLI2 represents a neg-
ative prognostic marker for patients with acute myeloid leukemia (AML) and
that targeted inhibition of GLI1/2 mediates anti-leukemic effects in vitro and in
vivo. Furthermore, the expression of GLI2 was correlated to the occurrence of
FLT3 mutations in AML patients. Activating FLT3 mutations represent one of
the most frequent aberrations in AML resulting in a constitutively activated
downstream signalling including the PI3K cascade. In addition to the Hedgehog
ligand-mediated, a non-canonical GLI activation via PI3K, TGF-β or Ras has
been described. Therefore, we propose also FLT3 as a non-canonical inducer
of GLI transcription in AML.
Aims: The aim of our study was to analyze the therapeutic potential of com-
bined GLI and FLT3 signaling inhibition in AML.
Methods: FLT3 mutated AML cell lines MV4-11 and MOLM-13 as well as the
non-mutated cell line OCI-AML5 were treated with combinations of the GLI
inhibitor GANT61, the FLT3 inhibitor sunitinib or the PI3K inhibitor PF-04691502
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and analyzed for cell proliferation. MV4-11 cells were also analyzed in colony
formation and apoptosis induction assays. Specific shRNA knockdown of all
targets have been performed to confirm the results.
Results: In proliferation assays, single agent treatment with sunitinib, PF-
04691502 or GANT61 was significantly less effective than double and especially
triple combinations. Growth inhibition of FLT3-mutated MV4-11 and MOLM-13
cells occurred at lower concentrations compared to non-mutated OCI-AML5
underlining the potential role of a non-canonical activation of GLI via FLT3-PI3K.
Investigating the induction of apoptosis in MV4-11 cells, combinations of two
inhibitors were more effective compared to the single agent treatments while
the triple combination of GANT61, sunitinib and PF-04691502 induced the high-
est apoptosis rate after 48h. Similar effects were observed in colony formation
assays of MV4-11 cells. The double combinations induced a slightly stronger
inhibition compared to the single agent treatments while the triple combination
resulted in most drastically reduced colony numbers. The impact of combined
treatment on colony numbers was also analyzed in CD34 positive hematopoietic
progenitor cells isolated from healthy donors. Interestingly, the reduction of
colonies upon double or triple inhibitor combinations was only slightly, but not
significantly increased compared to the single agent treatments possibly opening
up a therapeutic window for combination therapy. Targeted knockdown of GLI,
FLT3 and PI3K in MV4-11 cells using specific shRNA lentiviral constructs could
confirm our observations. The cells transduced with all shRNAs showed the
poorest proliferation rates and colony formation capacities. Upon transduction
with the FLT3 shRNA alone the mRNA expression of GLI2 was also reduced
supporting our hypothesis of GLI2 activation by FLT3 signaling in AML.
Summary and Conclusions: We propose that the Hedgehog pathway mem-
bers GLI1/2 are non-canonically activated by FLT3. Therefore, the combined
inhibition of FLT3, PI3K and GLI could represent a more effective, therapeutic
approach than targeting FLT3 alone in patients with FLT3-mutated AML.
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MATURATION-ASSOCIATED IMMUNOPHENOTYPIC CLASSIFICATION OF
BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
L. Martin1,2,3, A. López2,3, B. Vidriales3,4, D. Caballero3,4, A. Silva Rodrigues5,
S.I. Ferreira6, M. Lima7, S. Almeida8, B. Valverde9, P. Martínez10, A. Ferrer11,
J. Candeias12, F. Ruiz-Cabello13, J. Marco Buadesa14, A. Sempere15,
N. Villamor16, A. Orfao1,2,3, J. Almeida1,2,3,*
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Florianópolis, Brazil, 7Haematology, Hospital de Santo António, Porto, 8Haema-
tology, Hospital Universidade de Coimbra, Coimbra, Portugal, 9Hospital
Nacional de Niños Dr. Carlos Sáenz Herrera, San José, Costa Rica, 10Haema-
tology, Hospital 12 de Octubre, Madrid, 11Pathology, Hospital del Mar,
Barcelona, Spain, 12Immunology, Hospital São João, Porto, Portugal, 13Clinical
Analysis and Immunology, Hospital Virgen de las Nieves, Granada, 14Haema-
tology, Hospital General, Castellón, 15Haematology, University Hospital La Fe,
Valencia, 16Hospital Clinic, Barcelona, Spain
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare
subtype of leukaemia/lymphoma, whose diagnosis can be difficult to achieve
due to its clinical and biological heterogeneity, as well as its overlapping features
with other hematologic malignancies.
Aims: In this study we investigated whether the maturational stage of tumour
cells could be associated with particular clinico-biological and prognostic fea-
tures of the disease.
Methods: 46 BPDCN cases were analysed and classified into three matura-
tion-associated subgroups according to the expression of CD34 and CD117:
1) immature BPDCN (expression of CD34 in at least a fraction of blasts); 2)
intermediate BPDCN (partial positivity for CD117 in the absence of CD34), and;
3) mature cases (CD34- CD117- blasts).
Results: Blasts from cases with an immature plasmacytoid dendritic cell (pDC)
phenotype exhibited an uncommon CD56- phenotype, coexisting with CD34+non-
pDC tumour cells, typically in the absence of extramedullary (e.g. skin) disease
at presentation. Conversely, patients with a more mature blast cell phenotype
more frequently displayed skin/extramedullary involvement and spread into sec-
ondary lymphoid tissues. Despite the dismal outcome, acute lymphoblastic
leukaemia-type therapy (with central nervous system prophylaxis) and/or allo-
geneic stem cell transplantation appeared to be the only effective therapies.
Summary and Conclusions: Overall, our findings indicate that the matura-
tional profile of pDC blasts in BPDCN is highly heterogeneous and translates
into a wide clinical spectrum -from acute leukaemia to mature lymphoma-like
behaviour-, which may also lead to variable diagnosis and treatment.
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INVOLVEMENT OF HISTONE ACETYLTRANSFERASES IN
DEVELOPMENT OF ACUTE PROMYELOCYTIC LEUKEMIA AND
RESPONSE TO DIFFERENTIATION-INDUCING COMPOUND
Y. Sunami1,* M. Araki2, A. Ito3, Y. Hironaka1, A. Ohsaka2, M. Yoshida3,
N. Komatsu1
1Department of Hematology, 2Department of Transfusion Medicine and Stem
Cell Regulation, Juntendo University school of medicine, Tokyo, 3Chemical
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Background: In a model of acute promyelocytic leukemia (APL) development,
PML-RARA fusion protein suppresses transcription of RARA regulated genes
through recruitment of histone dedyacetylase (HDAC), which blocks granulo-
cytic differentiation. Differentiation-inducing compound all-trans retinoic acid
(ATRA) that is used for APL treatment induces granulocytic differentiation in
APL cells by modulating PML-RARA structure and subsequently dissociating
HDAC from PML-RARA. Although the HDAC involvement in APL development
and ATRA response is well documented, roles of histone acetyltransferases
(HAT) remain elusive.
Aims: This study aims to uncover involvement of HAT in APL development and
ATRA-induced granulocytic differentiation in APL cells.
Methods: mRNA expression levels of major HAT such as PCAF, GCN5, and
p300 were assessed in APL patients’ bone marrow by quantitative PCR (q-
PCR) at onset and complete remission of APL. RNA expression profiles in APL
and other hematologic malignancies were further analyzed with public data-
bases. Differential expression of HAT upon ATRA treatment was further exam-
ined in vitro with cell lines such as HL-60 and NB4, and primary cells from APL
patients. The protein levels of HAT were finally examined by immunoblot analy-
sis. For functional characterization, a loss-of-function assay was performed
using lentivirus vectors system with 3 independent shRNA sequences against
PCAF or GCN5, and a non-target shRNA. Granulocytic differentiation was
defined by CD11b expression.
Results: PCAF and GCN5 but not CBP/p300 showed differential expression
between onset and complete remission of APL. PCAF expression was sup-
pressed in APL bone marrow, while GCN5 expression was significantly elevat-
ed. When leukemic cells were induced for cellular differentiation by ATRA,
dynamic change of PCAF and GCN5 mRNA expression was observed in culture
cells NB4 and HL-60, and primary cells from APL patients. In cultured cells,
levels of PCAF and GCN5 proteins followed those of mRNA. In public data-
bases, reduced level of PCAF-expression in patients’ bone marrow compared
to healthy individuals was observed in not only APL but also other acute
leukemia such as acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) (healthy individuals; n=74, AML; n=505, ALL; n=750). While,
the reduction of PCAF-expression was not evident in chronic myeloid leukemia
(CML) and myelodysplastic syndrome (MDS). In Contrast, GCN5-expression
in AML and ALL was increased compared to that in the healthy individuals, and
even in chronic hematologic malignancies. These data suggest that in malignant
cells GCN5 expression was generally upregulated whereas PCAF expression
is coupled with normal differentiation, which was preferentially blocked in acute
leukemia cells. Potential of contradictory roles between PCAF and GCN5 in
leukemia cells were assessed by a loss-of-function assay. Knocking down
GCN5 induced massive apoptosis in HL-60 cells, suggesting that GCN5 harbors
oncogenic property. In contrast, when knocking down PCAF, cells failed to dif-
ferentiate into granulocytes after ATRA treatment. Furthermore, primary APL
blasts of which PCAF was knocked down became resistant to ATRA-induced
granulocytic differentiation, which implies that PCAF possesses a tumor sup-
pressor function.
Summary and Conclusions: Despite that functional redundancy between
PCAF and GCN5 in normal development was proposed, our data strongly sug-
gest that PCAF and GCN5 have opposing roles in the APL development and
ATRA-induced granulocytic differentiation in APL cells. More detailed under-
standing of HAT involvement in leukemogenesis and ATRA-induced cell differ-
entiation in APL may lead to a development of novel treatment strategy against
not only APL but also other AML.
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EFFECTS OF ARSENIC TRIOXIDE ON EVI-1 IN ZEBRAFISH AND IN
LEUKEMIA CELLS
F. Chen1,* L. Shen1
1Hematology department, Ren Ji Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, China
Background: The ecotropic viral integration site-1 (Evi-1) was first identified
as the integration site of the ecotropic retrovirus leading to myeloid leukemia in
murine model systems. In humans, Evi-1 is located on chromosome 3q26, and
rearrangements on chromosome 3q26 often activate EVI-1 expression in
myeloid malignancies. Arsenic trioxide (ATO), used in some traditional Chinese
remedies for a very long history, has been found to be an effective treatment
for acute promyelocytic leukemia (APL) and is being tested for treating other
malignancies. Therefore, in our study we chose Tg(EVI-1:HSE:EGFP) zebrafish
model (zebrafish embryos) and leukemia cells (both primary leukemia cells
and leukemia cell line THP-1) to examine the effect of ATO on Evi-1 gene
expression and clarify the mechanisms.
Aims: High expression of oncogene Evi-1 is an independent negative prog-
nostic indicator of survival in leukemia patients. The present study investigates
the effects of ATO on Evi-1 in zebrafish and in leukemia cells via apoptosis.
Methods: Embryos of Evi-1 transgenic zebrafish, tagged with Enhanced green
fluorescent protein (EGFP),were treated with different concentrations of ATO
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(50100 and 150μM) in vivo from 24 hours post fertilisation (hpf) to 72 hpf prior
Evi-1 mRNA quantification by RT-PCR. Meanwhile, we measured the Evi-1
expression in bone marrow mononuclear cells treated with 1 μM ATO for 24h,
72h or 120h in vitro, the specimen was donated by a patient diagnosed with
acute monocytic leukemia with high Evi-1 expression. Furthermore, THP-1 cell
line, the highest expression of Evi-1 out of four leukemia cell lines (K562, HL-
60, U937, THP-1),were treated with different concentrations of ATO (1, 3 and
5μM), or with a novel selective inhibitor of c-Jun N-terminal kinase (JNK),
named as SP600125 (10μM),for 24h, 48h or 72h, tested for cell viability by
CCK-8 kit, cell morphology by cytospin smear, cell apoptosis by flow cytometry,
Evi-1 mRNA expression by RT-PCR, protein quantity by western blot.
Results: ATO downregulated Evi-1 mRNA in zebrafish in vivo and in primary
leukemia cells in vitro. ATO treatment was shown to inhibit proliferation, induce
apoptosis, downregulate both Evi-1 mRNA and Evi-1 oncoprotein expression,
increase the expression of pro-apoptosis protein JNK, p-JNK, p-P53, PUMA,
Bax, caspase-9 and caspase-3, and decrease the expression of anti-apoptotic
protein Bcl-2 and Bcl-xL in THP-1 cell line in vitro. The pro-apoptotic activity of
ATO in THP-1 cells could be inhibited by SP600125 (a specific JNK inhibitor),
whereas SP600125 had little effect on the expression of EVI-1 protein.
Figure 1.
Summary and Conclusions: Together, the study results reveal that ATO can
downregulate Evi-1 mRNA as well as oncoprotein and block the repression of
Evi-1 to JNK pathway, so the JNK apoptotic pathway is activated, giving rise
to apoptosis of Evi-1 positive cell line THP-1. These novel findings provide the-
oretical basis for developing personalized medicine strategy to improve the
therapeutic efficacy of the treatment of Evi-1 positive leukemia.
E892
CLINICAL CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF
DNMT3A MUTATIONS IN ACUTE MYELOID LEUKEMIA
E. Petrova1,* I. Martynkevich1, L. Polushkina1, L. Martynenko1, M. Ivanova1,
N. Cybakova1, E. Kleina1, E. Shabanova1, A. Chechetkin1, K. Abdulkadyrov1
1Molecular genetics, Russian Research Institute of Hematology and Transfu-
siology, Saint-Petersburg, Saint-Petersburg, Russian Federation
Background: Gene mutations and epigenetic changes have been shown to
play a significant role in the pathogenesis of acute myeloid leukemia (AML). The
components of epigenetic machinery such as DNA methylation plays an essential
role in development, differentiation, genomic instability, specific regulation of
gene expression and may contribute to leukemogenesis. Recently, researchers
have been interested in investigating DNMT3A, because of the high frequency
of mutations of this gene in AML. Also, DNMT3Amutations are considered to be
independently associated with an unfavourable prognosis in adults with de novo
AML, however, there are still ongoing debates on this topic.
Aims: The aim of the research was to investigate the frequency and prognostic
impact of DNMT3A mutations in AML patients and to analyze its interaction
with other prognostic markers.
Methods: This retrospective study was performed in 143 previously un-treated
adult patients (135 pts with de novo and 8 pts with secondary AML). There
were 65 males and 78 females with a median age of 55 years (18-86). Accord-
ing to the results of cytogenetic analyses pts were separated in the following
groups: with favourable (9.8%), unfavourable (14.0%) prognosis, with normal
karyotype (NK) (49.0%) and other aberrations (27.2%). Mutation analysis of
DNMT3A R882 was performed by high-resolution melting curve analysis. Muta-
tions in FLT3 and NPM1 were analysed by PCR and in NRAS by sequencing.
Metaphase chromosomes were banded with the trypsin-Giemsa technique.
Results: Mutations of DNMT3A R882 were found in 23 (16.1%) de novo AML
patients: R882H (16 pts), R882C (6 pts) and R882S (1 pts). All but one pts
(with mutation R882S) were heterozygous and retained a wild-type allele.
DNMT3A mutations were detected in all morphologic variants (except M0 and
M3, extremely rare in M2 (p=0.006)) and were frequently noted in patients with
M5 (7/17, p=0.003) and M4 (11/38, p=0.012). It was revealed, that none of the
patients with favourable karyotype harboured DNMT3A R882 and only 1/20
pts with adverse karyotype had DNMT3A mutation. 17/23 pts (24.3%) with
DNMT3Amut had tumors with normal cytogenetic profiles (of a total of 70 NK
samples) (p=0.009). Patients with isolated DNMT3Amutations were seen in 5
cases; all 3 patients with genotype DNMT3Amut/NRASmut had the R882C vari-
ant of the mutation; 6 pts had genotype DNMT3Amut/FLT3-ITDmut/ NPM1mut.
DNTM3A mutations were significantly more prevalent in NPM1 positive cases
when compared to NPM1 wild type cases (p=0.005). DNTM3Amutations were
also more dominant in FLT3-ITD positive pts than wild type (p=0.001). Patients
who harbored the mutations in DNMT3A had a higher white blood cell count
(p=0.001) and platelets count (p=0.020) in peripheral blood, and blasts in bone
marrow (p=0.099) at diagnosis. There was no statistical correlation with other
parameters, including sex, age and hemoglobin between patients with and
without DNMT3A mutations (p>0.05). There was statistically significantly cor-
relation between overall survival (OS) and relapse-free survival (RFS) of AML
pts with DNMT3Amut and DNMT3Awt (p=0.031 and p=0.045, respectively).
Medians of OS and RFS were: 5.2 and13.0 months; 4.8 and10.0 months,
respectively.
Summary and Conclusions: AML with DNMT3Amutations represent a group,
which is homogeneous on a number of clinical and laboratory parameters,
associated with adverse prognosis and a high risk of relapse. Therefore, the
discovery of highly recurrent mutations in DNMT3Amay provide a new tool for
the classification of intermediate-risk AML.
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CRITICAL ROLE OF SOX12 IN LEUKEMOGENESIS IN AML 
H. Wan1,* H. Zhong1, B. Ni1, J. Cai1, F. Chen1
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Background: The SOX (Sry-related HMG box) genes belong to a family of
transcription factors containing a High-Mobility-Group box domain. In an initial
screen of SOX genes in human leukemias, SOX12 is uniquely up-regulated in
acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous
leukemia but down-regulated in most cases of normal individuals. 
Aims: The study is to examine the expression and function of SOX12 in acute
myeloid leukemia (AML).
Methods: Mononuclear cells (MNCs) were isolated from AML and fractionated
by immunomagnetic selection and fluorescence activated cell sorting (FACS).
SOX12 expression in different leukemia subsets was evaluated by RT-PCR.
To examine its function, SOX12 siRNA was nucleofected to K562 cells and
gene knock-down was confirmed by RT-PCR and Western Blot. Apoptosis and
cell cycle were analyzed by Annexin V/7AAD assay and flow cytometry. To
examine the leukemia stem cell (LSC) function in AML, SOX12 was knocked
down with siRNA, and K562 cells transduced with siRNA were subjected to in
vitro colony forming assay, and injected into NOD/SCID mice as well. 2 weeks
later, the number of colonies were enumerated, and 8 to 12 weeks later, the
mice were euthanized and bone marrow cells from the mice were analyzed.
Results: SOX12 was preferentially expressed in CD34+cells (CD34+vs CD34-
: P<0.015) but not CD34+CD38- cells which were considered stem/progenitor
cells in normal hematopoiesis. SOX12 knockdown in K562 cells with siRNA
could reduce the cell proliferation (scramble vs SOX12 at day 3, p=0.025),
induce the increase of cells in G1 phase (SOX12 vs scramble at day 3, p=0.03),
but had no effect on apoptosis. in vitro colony number was reduced with siRNA
transduced K562 cells compared to control group (P=0.032). Engraftment of
transduced K562 cells in NOD/SCID mice were significantly reduced 8 to12
weeks after transplantation (p=0.04).
Summary and Conclusions: SOX12 is preferentially expressed in human
CD34+cells of AML. SOX12 knock-down reduced cellular proliferation by arrest-
ing the AML cells in G1 phase of the cell cycle. SOX12 knock-down could also
reduce the repopulating ability of AML in NOD/SCID mice, indicating SOX12
was involved in the regulation of leukemogenesis in AML. Its mechanism of
action would have to be further evaluated.
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THE SYK INHIBITORS R788, R406 AND P505-15 COUNTERACT NEOPLASTIC
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Background: In acute myeloid leukemia (AML), relapse after high-dose
chemotherapy is frequent and the overall outcome is poor. Therefore, new ther-
apeutic strategies are warranted. Currently, the effects on leukemic cells of
novel targeted drugs, including signal-transduction inhibitors, have been exam-
ined. Syk is a tyrosine-kinase that has been shown to play a key role in onco-
genic signaling in AML cells.
Aims: In this study, we evaluated the effects of the Syk-inhibitors Fostamatinib
(R788), its active metabolite R406 and the more specific inhibitor P505-15 on
proliferation and survival of AML cells.
Methods: The inhibitors R788 and R406 were purchased from Selleck (Hous-
ton, TX), and P505-15 from Exon Medchem (Groningen, NL). The multikinase
inhibitor PKC412 (midostaurin; active against Flt-3) was purchased from
Chemietek (Indianapolis, IN). In this study, the Flt-3-ITD positive AML cell lines
MOLM-13 and MV4-11 were used. Primary AML blasts were isolated from the
peripheral blood or bone marrow from 13 AML patients. Neoplastic cells were
exposed to various concentrations of Syk-inhibitors alone or in combination
with PKC412. Thereafter, cell proliferation was measured by 3H-thymidine-
uptake. Cell cycle progression and induction of apoptosis were analyzed by
flow cytometry. Apoptosis was confirmed by light microscopy and by Western
blot analysis of cleaved caspase-3. Drug interactions (additive, synergistic)
were qualified with Calcusyn software. The enzymatic activity of Syk was eval-
uated by detection of autophosphorylated tyrosine on the position 348 by flow
cytometry.
Results: In a first step, MOLM-13 and MV4-11 cells were exposed to the three
Syk-inhibitors. As assessed by 3H-thymidine-uptake, all tested drugs were
found to inhibit proliferation in both cell lines in a dose-dependent manner (IC50:
0.1-5 µM). The underlying mechanisms of growth-inhibition were induction of
cell-cycle arrest in G0/G1 phase and induction of apoptosis, as assessed by
light microscopy, flow cytometry and Western blot analysis of cleaved caspase-
3. These effects were accompanied by a dose dependent decrease of the enzy-
matic activity of Syk. We next incubated primary AML-blasts (n=13 patients)
with R406, R788 and P505-15. Again, all compounds tested were found to
inhibit cell-proliferation with IC50 -values ranged between 0.1 µM and 5 µM in
all tested samples, including in primary cells expressing Flt-3-ITD. No difference
in IC50 -values were seen between samples isolated from newly diagnosed
patients and heavily pretreated patients, suggesting, that Syk-inhibition may
exert antileukemic effects even in relapsed patients. Finally, we combined the
Syk-inhibitors with the Flt-3-inhibitor PKC412 at suboptimal concentrations and
were able to demonstrate synergistic effects of these targeted drugs in produc-
ing growth-inhibition in Flt-3-ITD+AML cell lines.
Summary and Conclusions: Altogether, Syk-inhibitors act antineoplastic in
AML cell lines and primary AML blasts, including in samples isolated from
patients with relapsed AML. Further, Syk-inhibitors synergize with the Flt-3-
inhibitor PKC412 in blocking leukemic cell expansion. Our data suggest that
Syk-inhibitors may be implicated in the therapy of relapsed AML. However, the
therapeutic value of these agents alone or in combination with other drugs
remains to be investigated within the frame of clinical trials.
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ACCUMULATION OF THE NPM-1 SPLICE VARIANT R2 ACCOMPANIES
AML DEVELOPMENT
M. Zajac1,* J. Zaleska1, O. Jankowska-Lecka2, M. Hus2, L. Bullinger3,
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Background: The relevance of differential splicing in human cancer is an evolv-
ing area of cancer biology. The recent findings of frequent mutations of the
splicing pathways in MDS provide insight into the mechanism of alternative
splicing, which has been long associated with the development of cancer. The
genome-wide microarray analysis using Exon arrays discovered significantly
differentially spliced genes in AML. Moreover, the AML specific “splicing profile”
was normalized in remission and reappears with patient relapse, thereby sup-
porting a role of deregulated splice variants in the process of leukemogenesis.
A close cytogenetic and molecular deregulation between de novo MDS and
AML of elderly people suggests a common pathogenic mechanism for these
conditions. Although the full spectrum of leukemic progression has not yet been
completely clarified, recent clinical and biological studies indicate that MDS
and AML could be considered as part of the same continuous disease spectrum
rather than as distinct disorders. Recently, we found that high expression of
the NPM-1 splicing variant R2 may provide prognostic value for CN-AML
patients. As the R2 splicing variant represents a truncated form of NPM1 gene
this isoform mostly localizes in the nucleoplasm, and thus might also have a
biological impact in the malignant cells. 
Aims: Assuming the common origin of MDS and AML we aimed to characterize
the NPM1R2 splice variant expression as well as the influence of R2 expression
on NPM1 localization in groups with MDS, sAML and AML patient samples.
Methods: Since we found prognostic significance of the expression level of
R2 for the AML cohort of patients, therefore we decided to evaluate its signifi-
cance for MDS and sAML cases. For 61 samples (25 AML, 30 MDS and 6 sam-
ples with sAML) qRT-PCR was performed. Expression level of NPM-1 R2 was
assessed. To investigate whether R2 might disrupt localization of the NPM1
wild type protein, immunohistochemistry analysis for NPM1 in 23 AML bone
marrow smears was performed.
Results: We found significant differences in NPM-1 R2 expression levels
between cytogenetically normal (CN-AML), sAML, MDS and healthy volunteer
(HV) groups. Interestingly, expression of NPM-1 R2 tended to be elevated in
CN-AML compared to MDS (median 0.022 vs 0.015, p=0.061). The expression
of R2 was significantly increased in the CN-AML, sAML and MDS groups com-
pared to HVs (median 0.022 vs 0.005, p<0.001, 0.015 vs 0.005, p<0.001, and
0.022 vs 0.005, p<0.001, respectively). Moreover, we stratified MDS and AML
patients according to IPSS and genetic risk classification, respectively and
found significant differences in NPM-1 R2 expression between those groups.
The IHC stainings for AML samples revealed that in cases with high NPM-1 R2
expression we were able to determine a cytoplasmic localization of NPM1 even
in the absence of a concomitant NPM1mutation. Therefore, we provide further
evidence that the cytoplasmic localization of NPM1 might depend not only on
its mutational status, but might also be influenced by the distribution of its splice
variants.
Summary and Conclusions: In our study we found that the expression levels
of NPM-1 R2 were elevated in AML, sAML and MDS groups compared to HVs
suggesting that NPM-1 R2 might play some role in the process of the tumori-
genesis not only in AML cases but also in early stages of development of this
disease. As the NPM-1 R2 splice variant represents a truncated form of NPM1
gene this isoform mostly localizes in the nucleoplasm, and thus might also have
a biological impact in the malignant cells. The NPM-1 R2 might interact with
cellular proteins affecting signal pathways and by this have influence on out-
come or modulate treatment response. In summary, the expression of NPM-1
R2 might be of biological importance for CN-AML as well as for sAML and MDS
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Background: Next generation sequencing (NGS) studies have been instru-
mental in identifying novel and recurrent mutations in hematologic malignancies.
FoundationOne Heme© is a comprehensive NGS platform designed to provide
targeted assessment of the genomic landscape of hematologic neoplasms. It
interrogates the entire coding sequence of many genes, described to be somat-
ically altered.
Aims: We wished to report the frequency of somatic mutations and variants of
unknown significance (VUS) in myeloid neoplasms and their impact on clinical
care including timing of testing. 
Methods: After due IRB approval, patients with myeloid malignancies who
underwent FoundationOne Heme© analysis at Mayo Clinic Rochester were
identified. The complete coding DNA sequence of 405 genes, selected introns
of 31 genes as well as the RNA sequence (cDNA) of 265 genes was interro-
gated. Mutations identified were stratified as having prognostic or actionable
clinical impact. Actionable mutations were defined as potentially leading to a
treatment decision with clinical trials or off label therapies, whereas prognostic
mutations were those that helped with risk stratification. All data was retrospec-
tively abstracted. 
Results: A total of 45 patients were included in this analysis. The distribution
of underlying conditions was: AML (27), ALL (5), acute undifferentiated leukemia
(2), MDS (4), MPN (3), MDS/MPN overlap syndrome (3) and others (3). At last
follow up, 19 (42%) patients were alive. A. Somatic mutations: A total of 164
somatic mutations were identified with a median of 4 per patient (range: 0-8).
Of therapeutic relevance, the following mutations were most common:DNMT3A
(8%), RUNX1 (6%), TET2 (5%), FLT3 and KRAS (4% each), whereas TP53
(10%) and ASXL1 (8%) were the most common prognostic mutations. A total
of 58 (35%) aberrations were actionable; 53 via clinical trials and 38 through
off label therapeutics. Median number of potential therapies and clinical trials
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identified after testing were 2 (0-6) and 3 (0-7) per patient, respectively. Among
patients who succumbed to their disease, median time to death from sample
acquisition was 68 days (6-375), and 7 patients (16%) died within 1 month of
testing, 5 of whom died before results were available. In Patients surviving
beyond 2 weeks of available results, testing changed clinical management in
7/38 (18%); 5 received off label therapy and 2 were enrolled in phase I/II clinical
trials. B. Variants of unknown significance (VUS): A total of 286 somatic variants
were identified; 215 in AML and 71 in other myeloid neoplasms, with 29 over-
lapping variants. Most common variants observed were in the following genes;
MLL2 (3%), DNMT3A, EP300, FLT1, LRP1B, LRRK2, MAP2K6, PDCD11 and
ROS1 (2% each) in AML and HDAC7 (4%), ATRX, CRKL, DOT1L, EP300,
FLT1, FOXO3, MLL2, RICTOR, SPEN and STAT6 (3% each) in other myeloid
neoplasms.
Figure 1.
Summary and Conclusions: Targeted use of NGS potentially yields prognos-
tic and therapeutic information about somatic mutations in Hematologic malig-
nancies. This permitted the use of novel targeted therapies including clinical
trials in some patients. However, delayed testing until exhaustion of therapeutic
options limits the utility of this tool. Utilizing a larger cohort with functional stud-
ies is required to comprehensively investigate the potential pathologic nature
of recurrent VUS. 
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A COMPREHENSIVE ANALYSIS OF ACCESSIBLE BONE MARROW
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Background: Immunoconjugates are targeted agents that combine the tumor
homing properties of monoclonal antibodies with the cancer killing capacity of
effector molecules such as drugs, cytokines, toxins or radionuclides. There is
no therapeutic antibody approved for the treatment of AML to date, but several
are under clinical investigation. Well characterized antigens like CD33 and
CD123 are leukemia-selective, but lack true leukemia-specificity. New targets
are usually identified by comparison of the expression of membrane-bound
proteins in leukemic cells and their normal hematopoietic counterparts.
Aims: Here, we used a general chemical proteomics approach based on in
vivo protein biotinylation to identify bloodstream-accessible proteins as they
exist natively in the bone marrow in AML, a disease that is, despite therapeutic
improvements of the last decades, still lethal to the majority of patients.
Methods: Brown Norway (BN) rats bearing the syngeneic BNML acute myeloid
leukemia model and healthy control rats were subjected to in vivo protein
biotinylation by vascular perfusion with an aqueous solution of sulfo-NHS-LC-
biotin, a reactive ester derivative of biotin, that enables the covalent labeling of
proteins readily accessible from the blood-stream. Biotinylated proteins from
the perfused bone marrow were purified on streptavidin-resin, trypsinized and
subjected to LC-MALDI-TOF/TOF mass spectrometry and bioinformatic pro-
cessing for identification and relative quantification. The most promising AML-
associated targets were validated by APAAP-immunohistochemistry (IHC) on
rat and human AML bone marrow specimens.
Results: In total, almost 1500 bloodstream-accessible proteins were identified
in healthy and leukemic bone marrow. Among them, 181 proteins were more
than 100-fold up-regulated in AML as compared to normal bone marrow. Fifteen
of the most differentially expressed proteins were selected for further validation
by IHC. Of these, ECM1, Nucleolin, COL6A1 and AP3B2 showed the most dif-
ferential expression in rat and human AML as compared to normal bone marrow.
Summary and Conclusions: We provide an atlas of circulation-accessible
AML-associated bone marrow proteins that could serve as potential targets
for a site-specific antibody-mediated pharmacodelivery of cytotoxic drugs,
cytokines or radionuclides to the leukemia-infiltrated bone marrow in AML.
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Background: Acute myeloid leukaemia (AML) is a heterogeneous disease
with a sharp rise in incidence after the 3rd decade. A strong correlation between
specific genetic changes and gene expression patterns is well established,
and individual cytogenetic subtypes of AML, in particular t(8;21), t(15;17) and
inv(16) display distinct gene expression patterns1. Chronological age of the
patient is one of the most important markers for prognosis and clinical out-
come2. The impact of age on leukaemia prognosis is not understood in detail.
Differences in gene expression patterns between AML in younger and older
patients have been described, and suggests differential oncogenic pathway
activation in older patients (>55 years of age)3. We have recently defined dis-
tinct gene expression patterns associated with the developmental stages in
childhood; infancy, early and late childhood, and puberty. These gene expres-
sion patterns discriminate stages of childhood development and imply that
developmental stage impacts on gene transcription in a tissue-independent
manner4. We propose that age will affect gene expression patterns independent
and dependent on cytogenetic subtype in children and adults.
Aims: I) Identify genes and gene expression patterns that are age dependently
regulated in childhood and adult AML independent of cytogenetic subtype. II)
Delineate expression patterns that are regulated by age according to cytoge-
netic subtype.
Methods: We have used transcriptomic data from the age annotated dataset
of childhood AML (0 – 19 years of age n=237)5,6, normal children (0 – 19 years
of age, n=87)4 and from adult patients (16-84 years of age, n=436)7. We iden-
tified genes that showed age-related regulation in expression both dependently
and independently of cytogenetic subtype [focussing on t(8;21), inv(16),
t(15;17)]. The Isomap dimensional reduction approach to principal component
analysis (PCA) was used to define age and cytogenetic relationships within
AML patient data (Qlucore Omics Explorer software) using unsupervised time-
series clustering. Cross-validation of the PCA by sample exclusion was used
to identify robust relationships. Rank regression was used to define age-related
gene expression.
Results: The TPM1 gene, producing an actin binding protein involved in cal-
cium signalling, had differentially phased variation during childhood in AML
subtypes and normal children, but displayed age dependent variation only in
AML with t(15;17) (p<0.01). SPIRE2, a protein kinase involved in cytoskeleton
organisation, transcripts showed age dependent variation in normal children
and childhood AML (p<0.01) with patterns that suggest differential phasing in
adult AML; age-dependent variation was independent of karyotypic subtype.
TSPAN2, a component of the integrin signalling pathway, transcripts showed
different levels of expression in different phases of childhood in normal children
(p<0.01), however in AML age dependent regulation was differentially phased
dependent on cytogenetic subtype.
Summary and Conclusions: We have identified three examples of individual
transcripts where age and karyotype display very different effects. These data
imply that some age dependent changes in AML are karyotype specific.
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Background: Mutations in the CCAAT/enhancer binding protein alpha (CEB-
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PA) gene occur approximately in 5 – 10 % of acute myeloid leukemia (AML)
patients and can be used as molecular markers for monitoring of minimal resid-
ual disease (MRD). However, detection of MRD using quantitative real-time
PCR (qPCR) is complicated due to GC-rich regions and thus validation of
leukemia-specific and sensitive MRD assay can be technically difficult. 
Aims: The goal of our work was the application of next-generation amplicon-
based deep sequencing (NGS) as a quantitative detection method for MRD
monitoring.
Methods: Since 2010, we have performed mutational analysis of the CEBPA
gene coding region in 411 AML patients at the time of diagnosis using Sanger
sequencing. In patients with the CEBPAmutation/s as the only detected muta-
tion/s, i.e. the examined patients did not have other available MRD markers
after standard molecular analysis of fusion transcripts and mutations in hema-
tological prognostic genes, we designed leukemia-specific assays using qPCR.
However, in 5 patients the assay did not provide sufficiently sensitive and spe-
cific detection of residual leukemic cells. In these cases MRD was monitored
by NGS technology (GS Junior System, Roche). For MRD analysis starting at
first diagnosis and following the course of the treatment we analyzed bone mar-
row (n=36) or peripheral blood (n=2) samples. The result of the MRD assess-
ment was evaluated as a percentage of the mutated reads from all reads (reads
with mutation/all reads). 20 000 reads per sample was considered as a mini-
mum for valid MRD analysis. 
Results: From January 2013 to February 2015 we examined 38 samples from
5 AML patients. CEBPAmutations found in these patients and used as a marker
for MRD analysis were short insertions or deletions. The median of reads per
sample was 58 376 (mean 58 076, range 27 829 - 110 564). The assay detec-
tion sensitivity achieved the threshold of 10-4 to 10-5 (1 leukemic cell in 10 000
cells to 1 leukemic cell in 100 000 cells). The MRD levels of residual leukemic
cells correlated with clinical outcome. In patients with relapse (three out of five
patients), the occurrence of the CEBPAmutation/s was also confirmed by con-
ventional Sanger sequencing. 
Summary and Conclusions: Quantitative assessment of CEBPA mutations
using next-generation amplicon-based deep sequencing enabled MRD moni-
toring in AML patients, where the design of quantitative real-time PCR assay
didn not achieve sensitivity of at least four orders of magnitude. NGS technology
represents another approach for MRD assessment of the mutated CEBPA gene.
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GRANULOCYTE COLONY-STIMULATING FACTOR INHIBITS CXCR4/SDF-1Α
SIGNALING AND OVERCOMES STROMAL-MEDIATED DRUG
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Background: The outcome of acute myeloid leukemia in older and
relapsed/refractory patients is dismal, which is partially due to drug resistance.
The cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF)
protocol has been widely used in these patients and has been achieved dra-
matic therapeutic efficacy, while the underlying mechanisms are still not very
clear. Interaction with stromal cells may protect leukemia cells from sponta-
neous and drug-induced apoptosis. 
Aims: We tried to clarify the potential ability of G-CSF to overcome stromal-
mediated drug resistance through CXCR4/SDF-1α axis regulated by miR-146a
expression in the leukemia cells.
Figure 1.
Methods: HS-5/HL-60 co-culture model was established to imitate the interac-
tions between stromal and leukemia cells. The ability of G-CSF sensitize HL-
60 cells to chemotherapy through G-CSF→microRNA-146a (miR-
146a)→CXCR4 pathway was investigated. For all experiments, HL-60 cells
were divided into four groups: control group, blank plasmid, miR-146a over-
expression group and miR-146a interference group.
Results: An obviously inverse correlation between miR-146a expression and
CXCR4 expression was observed. In over-expression group, miR-146a was
significantly up-regulated and CXCR4 mRNA was decreased. In interference
group, miR-146a was down-regulated and CXCR4 mRNA was increased. The
levels of surface and total CXCR4 protein were also reduced in over-expres-
sion group, while increased in interference group. Then we verified that G-
CSF clearly up-regulated the levels of miR-146a in all groups compared with
medium, along with down-regulated CXCR4 mRNA and protein expression.
In function assays, we firstly found that HL-60 cells can be attracted and
adhered to HS-5 cells. The migration index and adhesion was decreased in
over-expression group, but increased in interference group compared with
control group. Then we also observed that G-CSF disturbed HL-60 cell migra-
tion and adhesion. Lastly, we observed that HL-60 cells were protected from
apoptosis (both spontaneous apoptosis and drug-induced apoptosis) when
co-cultured with HS-5 cells in all groups, while G-CSF partially inhibited this
protective effect. We also observed that the protective effect was more appar-
ent in interference group and less apparent in over-expression group than
control group.
Summary and Conclusions: Our data suggest that interfering with the
CXCR4/SDF-1α signaling axis by using G-CSF inhibited HL-60 cell migration,
adhesion and stromal-mediated protective effects. Our study also indicate that
G-CSF reduced CXCR4 expression by miR-146a up-regulation, that is to say,
there may be exist a G-CSF→miR-146a→CXCR4 pathway to explain how G-
CSF inhibits CXCR4/SDF-1α signaling and overcomes stromal cell-mediated
drug resistance in acute myeloid leukemia.
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THE ROLE OF CYBB IN MAINTENANCE OF MLL-REARRANGED
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Background: MLL (mixed lineage leukemia)-rearranged leukemia is caused
by the chromosomal translocation of the MLL and partner genes. Previous
studies demonstrated that the Cytochrome b beta chain (Cybb) gene is severely
down-regulated in Mll-rearranged leukemia. Cybb encodes the catalytic subunit
of NAPDH oxidase 2 (Nox2) complex and its expression is closely associated
with the reactive oxygen species (ROS) level. ROS has been shown to influence
stem cells maintenance and progenitors differentiation in hematopoietic system.
The down-regulation of Cybb may suppress intracellular ROS level and there-
fore enhance stemness of Mll-rearranged leukemia. 
Aims: To investigate the function of Cybb and Nox2-generated ROS in the
maintenance of MLL-rearranged leukemic cells.
Methods: We have established a novel Mll-Een cell line from an Mll-Een knock-
in mouse model. We compared the expression level of Cybb in the Mll-Een
cells and wild-type bone marrow cells isolated from C57BL/6 mice by qPCR
analysis. Intracellular ROS level was quantified by CellRox staining. Overex-
pression of Cybb in Mll-Een cells was done by lentiviral transduction. The ROS
level and leukemic features of Cybb overexpressing Mll-Een cells were
assessed by CellRox staining, colony forming assay and proliferation assay.
Results: We found that Cybb expression was severe down-regulated in the Mll-
Een cell line when compared with the wild-type bone marrow cells. Besides, the
intracellular ROS level of Mll-Een cells was also reduced. Overexpression of Cybb
in Mll-Een leukemia cell increased the intracellular ROS level by over 30%. The
colony forming number of Cybb overexpressing cells was sharping decreased by
89%, indicating that Cybb expression attenuates the colony forming potential of
Mll-Een cells. Importantly, the colony morphology of Cybb overexpressing cells
consists of mainly terminally differentiated cell colonies, which are 5 times higher
in number than the control sample (57% vs 11%). These results suggested Cybb
reduces self-renewal potential and promotes myeloid differentiation of Mll-Een
leukemia. Furthermore, proliferation ability of Cybb overexpressing Mll-Een cells
was greatly reduced by 87%, implying an impaired proliferative potential.
Summary and Conclusions: Overexpression of Cybb in Mll-Een cells increas-
es ROS level and attenuates leukemic feature, such as the self-renewal poten-
tial and proliferative ability. Cybb also promotes myeloid differentiation in Mll-
rearranged leukemia cells. 
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ANALYSIS OF ASXL1 MUTATIONS AND CORRELATION WITH
CHROMOSOMAL ALTERATIONS IN ACUTE MYELOID LEUKEMIA
K. Kakosaiou1, A. Daraki1, P. Apostolou1, S. Zachaki1, M. Pagoni2,
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Background: Additional sex comb-like 1 (ASXL1) is an enhancer of Trithorax
and Polycomb family, which is necessary for the maintenance of stable repres-
sion of homeotic and other loci. Recently, mutations of the ASXL1 gene were
identified in the hematopoietic cells from patients with a variety of myeloid
malignancies, including acute myeloid leukemia (AML). The vast majority of
these mutations, which are frameshift and nonsense, have been associated
with an aggressive phenotype and detrimental effects on overall survival, espe-
cially in patients with a normal karyotype.
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Aims: The purpose of this study is the identification of the ASXL1mutations in
de novo and secondary AML (s-AML) patients and their correlation with the
cytogenetic findings.
Methods: Our study included 275 AML patients (184 de novo AML and 91 s-
AML) and 10 healthy donors. Conventional cytogenetic analysis was performed
on unstimulated bone marrow cells. In order to detect ASXL1 exon 12 muta-
tions, molecular analysis was performed by PCR and subsequent direct Sanger
sequencing in all patients’ and controls’ samples.
Results: A successful karyotypic analysis was performed in all AML samples at
diagnosis. Among them, 201 patients (73.1%) exhibited clonal karyotypic aber-
rations and 74 (26.9%) showed a normal karyotype. ASXL1 mutations were
detected in 50 out of 275 patients (18.2%) while none ASXL1 mutation was
observed in the control group. A significantly higher frequency of ASXL1 muta-
tions was found in s-AML compared to de novoAML patients (26.4% vs 14.1%,
respectively; p=0.013). The most frequent ASXL1mutation was the c.1934dupG
(43/50, 86.0%). ASXL1 mutations were more frequently found in males than in
females (19.8% vs 15.8%, respectively), while stratification of patients according
to age revealed a higher frequency of ASXL1 mutations in patients ≥61years
than in patients <60years (p=0.003). Among the 50 AML patients with ASXL1
mutations, 28% exhibited a normal karyotype, 22% had trisomy 8 either as a
sole abnormality or in combination with others, 4% t(8;21), 4% trisomy 13, 4%
-7/del(7q), 2% t(15;17), 2% t(9;22) and 26% other chromosomal abnormalities.
Moreover, 8% of ASXL1 mutated patients revealed complex karyotypes.
Summary and Conclusions: These results suggest that ASXL1 mutations
are frequent in AML, especially in s-AML and are highly correlated with older
age, male sex and specific karyotypic aberrations. The most common chromo-
somal abnormality associated with ASXL1 mutations is trisomy 8, followed by
t(8;21) and trisomy 13. ASXL1 mutations are present in all AML cytogenetic
risk groups with good, intermediate and poor prognosis.
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Background: The existence of age-specific differences in the genetic mech-
anisms of myeloid leukemogenesis has long been observed and has been
the subject of numerous studies. However, only the introduction of new NGS
technology has allowed us to obtain, in a relative simple manner, a large
amounts of mutation data.
Aims: The aim of this study was to facilitate our understanding of the similar-
ities and differences in molecular pathogenesis between cAML and aAML by
application of parallel targeted NGS technology.
Methods: We analyzed DNA isolated from the bone marrow mononuclear
cells from 20 childhood (cAML) and 20 adult AML (aAML) unselected patients,
using TruSeq Cancer Panel with the MiSeq platform (Illumina) for the detection
of somatic mutations, consisting of 212 amplicons targeting mutational
hotspots in 48 cancer-related genes. Filtering and variant calling were per-
formed using GATK UnifiedGenotyper and VariantFiltration tools. Resulting
data were mapped against human genome b37. The average coverage of
high-quality sequences was 2981 × per amplicon. Nine genes were discarded
due to insufficient coverage, therefore a total of 188 amplicons from 39 genes
was used for subsequent analysis. FLT3/ITD and IDH2 mutations were
screened using PCR followed by direct sequencing.
Results: We identified 939 (467 cAML, 472 aAML) different mutations in both
coding and non-coding targeted regions, with substantial variation from patient
to patient. A total of 527 (260 cAML, 267 aAML) mutations in the non-coding
regions and 412 (207 cAML, 205 aAML) mutations in the coding regions was
detected, out of which only 122 (62 cAML, ranging from 0 –7 mutations per
patient; and 60 aAML, ranging from 1 –5 mutations per patient) were poten-
tially protein-changing, i.e. nonsense (N), frameshift (F) and missense (M)
mutations. Seven genes were found to have more than 5 NFM mutations,
namely NRAS, KIT, KDR, NPM1, MET, FLT3, and TP53. Out of these, TP53
and KDR were found to have more than 20 mutations in over 50% of AML
patients. Finally, the number of patients who harbored at least one mutation
in TP53 gene was 17 of 20 in cAML and 19 of 20 in aAML. As expected, the
prevalence of the most AML associated mutations including FLT3/ITD, NPM1,
IDH1 and IDH2 gene, differed in cAML and aAML patient cohorts. IDH1 (0%
cAML, 5% aAML), IDH2 (0% cAML, 10% aAML), NPM1 (10% cAML, 35%
aAML), FLT3/ITD (0% cAML, 10% aAML). This discrepancy in prevalence in
leukemia associated genes highlights the differences in the pathogenesis of
cAML versus aAML at the genetic level.
Summary and Conclusions: Our results confirm that AML contains relatively
small number of genetic alterations, suggesting that for the development of
AML fewer genetic alterations are required than for other malignancies. In our
study in which we used samples from unselected AML patients, we were not
able to determine previously unknown prevalence of some gene alterations.
Our results merely confirmed existing prevalence AML specific mutations in
aAML. Many of them are well known (FLT3, NPM1, CEBPA) and their detec-
tion has already entered standard clinical practice. Given that AML is extremely
heterogeneous in its clinical and genetic characteristics, more definite results
regarding similarities and differences in pathogenesis of these two entities
will be obtained in a parallel NGS analysis of the morphological and cytoge-
netic homogeneous groups of cAML and aAML patients.
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PROGNOSTIC SIGNIFICANCE OF CD34+CD38LOW/-CD123+ LEUKEMIC
STEM CELLS IN ACUTE LEUKEMIA - A PROSPECTIVE COHORT STUDY
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Background: It is believed that acute leukemia arises from stem cells called
Leukemic Stem Cells (LSC) and they are usually resistant to chemotherapy.
These are also implicated in relapse of the disease. They can easily be quan-
tified by flow cytometry by the presence of CD34+CD38low/-CD123+ clone.
Aims: To study the prognostic significance of CD34+CD38low/-CD123+
leukemic stem cells in terms of response to induction therapy and survival at
induction.
Methods: Prospective single-centre cohort study which included 76 patients
of acute leukemia. Bone marrow samples at diagnosis were analysed by flow
cytometry to quantify the LSC clone. Patients of both ALL and AML were given
the usual induction chemotherapy. Response was assessed by peripheral
blood blast clearance, interim bone marrow blast assessment, CR (complete
remission) status and survival at induction.
Results: All enrolled patients of acute leukemia were followed during the
induction chemotherapy phase. Of these 43% were ALL (median age 23 years;
70% males) and 57% were AML (median age 32 years; 61% males). Fever
(97%) and anemia (97%) were the major symptoms followed by bleeding
(40%). Amongst the clinical signs presence of lymphadenopathy (40% versus
5%; p<0.001), hepatomegaly (64% versus 12%; p<0.001) as well as
splenomegaly (64% versus 12%; p<0.001) were more commonly seen in
patients with ALL as compared to AML. Leucocyte counts at baseline and
blasts in the peripheral blood were also higher in the ALL group compared to
AML group (median of 29,000/mm3 versus 8900/mm3; p=0.06). Mortality was
significantly more in the AML group as compared to ALL group (49% versus
24%; p=0.03). There was a significant correlation of LSC clone size with ALL
type (p=0.002, r2=0.512), blast clearance (p=0.02, r2=0.397) and day 7 BM
blasts (p=0.01, r2=0.557). B-ALL had significantly higher LSC clone size com-
pared to T-ALL (5.2 versus 0.004; p=0.002). In patients with ALL, higher LSC
clone size was significantly associated with delayed blast clearance in periph-
eral blood (p=0.02) and less number of patients having M2 or M3 bone marrow
(p=0.013). Patients with high LSC clone had higher days of peripheral blood
blast clearance and had lesser number of patients clearing blast within 5 days.
Similarly, in patients with AML, there was a significant correlation of LSC clone
size with AML cytogenetics risk group (p=0.02; r2=0.352), blast clearance
(p=0.03; r2=0.328) and mortality (p=0.002; r2=0.452). High risk AML had higher
percentage of LSC clone. Patients with high LSC clone had not only delayed
clearance of blasts in the peripheral blood (P=0.03) but also higher risk of
death (P=0.002). 
Summary and Conclusions: Both ALL and AML had presence of LSC clone
expressed as CD34+CD38low/-CD123+ leukemic stem cells. Presence of high
LSC clone is associated with poor blast clearance in peripheral blood and
bone marrow and poor survival in patients with acute leukemia 
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COOPERATIVE MUTATION STUDY IN KOREAN PATIENTS WITH
MLL-REARRANGED ACUTE MYELOID LEUKEMIA USING TARGETED
NEXT GENERATION SEQUENCING
S.Y. Kim1,2,* J.J. Yang3, T.S. Park3, W.I. Lee3, E.H. Cho4, C. Meyer5,
R. Marschalek5, S.T. Lee6, H.J. Kim6, S.H. Kim6, Y.U. Cho7, S. Jang7, C.J.
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Kyung Hee University, 3Department of Laboratory Medicine, School of Medi-
cine, Kyung Hee University, Seoul, 4Green Cross Genome, Yongin, Korea,
Republic Of, 5Institure of Pharmaceutical Biology, ZAFES, Diagnostic Center
of Acute Leukemia, Goethe-University of Frankfurt, Frankfurt, Germany,
6Department of Laboratory Medicine and Genetics, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 7Department of Laboratory
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Background: Recent advancements of technologies including next generation
sequencing (NGS) have led to discovery of molecular pathogenesis of malig-
nant diseases of hematological malignancies, and these discoveries are now
enabling the beginning of molecular targeted therapy. The MLL-rearranged
fusion gene is among the main leukemogenic mutations which is found in both
acute myeloid leukemia (AML) and acute lymphoblastic leukemia with a fre-
quency of about 5-10%, and is associated with a poor clinical prognosis. Sys-
tematic studies analyzing cooperative genetic events of MLL-rearranged
leukemia based on NGS technology has mainly been conducted in western
populations, and has not yet been carried out in Asian ethnicity, such as the
Korean population.
Aims: The aims of this study are to evaluate the cooperative mutation profiles
of Korean MLL-rearranged acute myeloid leukemia patients using targeted
next generation sequencing and to determine the ethnic difference of molecular
basis of AML.
Methods: This study includes total of 24 MLL-rearranged AML patients who
visited two separate tertiary care hospitals between the period of January
2009 and May 2014. The patient group included twelve men and twelve women
(M:F=12:12), and also twelve children and twelve adult patients (A:C=12:12).
The number of each MLL fusion genes are as follows; MLL/MLLT3 n=12;
MLL/MLLT4 n=6; MLL/ELL n=2; other MLL fusion genes n=4. Mutation profile
study for 19 candidate genes for cooperative mutation (TET2, DNMT3A, IDH1,
IDH2, NPM1, FLT3, CEBPA, ASXL1, BRAF, CBL, KIT, KRAS, NRAS, PTPN11,
RUNX1, TP53, WT1, SETD2, JAK2) was carried out using a MiSeq sequencer
(Illumina, San Diego, CA).
Results: Among the twenty-four MLL-rearranged patients, 17 patients had no
additional mutations (~70%) found. Only 7 patients (29.2%) had positive results
for more than 1 gene mutations which were analyzed for (Table 2). Positive
gene mutations found were in order of their frequency; ASXL1 (n=4), FLT3
(n=2), CEBPA (n=2), KRAS (n=1), NRAS (n=1) and PTPN11 (n=1). Interest-
ingly, 4 out of 6 patients harboring MLL/MLLT4 were found to have additional
gene mutations. Two patients had multiple gene mutations while one patient
had four concurrently detected gene mutations (Table).
Tabella 1. Results of detected cooperative mutations by targeted sequenc-
ing in this study.
Summary and Conclusions: This is the first cooperative mutation study on
MLL-rearranged AML patients of Asian ethnicity using targeted NGS technology.
Small number of cases was a limitation in assuming the general mutational
spectrum of the representing population, however a higher incidence of gene
mutation among MLL/MLLT4 patient group (4/6) and relatively higher incidence
of ASXL1 mutation (4/24) being found could be carefully suspected as an eth-
nical difference in molecular basis of AML. Further study requires a larger num-
ber of MLL-rearranged MLL patients of equal ethnicity and additional mutation
profile study with ethnical comparison.
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ASSOCIATION BETWEEN CD117 (C-KIT) AND CD135 (FLT3) RECEPTOR
TYROSINE KINASES AND MUTATIONAL STATUS AND CLINICAL
FEATURES IN ADULT AML PATIENTS UNDER 60 YEARS
S. Bellesi1,* F. Corrente1, E. Metafuni1, P.L. Puggioni1, A.M. Ciminello1,
F. D’Alò1, D.G. De Ritis1, S. Giammarco1, L. Laurenti1, F. Sorà1, S. Sica1,
V. De Stefano1, P. Chiusolo1
1Hematology, Policlinico A. Gemelli UCSC, Rome, Italy
Background: Proliferation is one of the mechanism for AML pathogenesis.
Receptor Tyrosine Kinases have significant contribution in leukemogenesis
because of their proliferative role. For this reason we have evaluated CD117
(c-kit receptor) and CD135 (FLT3 receptor) in the setting of AML.
Aims: The purpose of this study was to investigate the association between
CD117 and CD135 expressions and FLT3-ITD, NPM1 mutations and clinical
features.
Methods: Percentages of expression and Median Fluorescence Intensity (MFI)
of CD117 and CD135, tagged with phycoerythrin (PE), were obtained from
flow-cytometric AML definition panels acquired on FACSCanto cytometer using
BDFACSCanto software. Levels of NMP1 mutation (NPM1m) and internal tan-
dem duplications of FLT3 (FLT3-ITD) were quantified in a RT-PCR assay. Com-
parison between two groups were performed using the Mann–Whitney U
(MWW) and Chi-square tests (CSQ) or Fisher exact test (FET) for continuous
and dichotomic variables, respectively; for comparison among different groups
Kruskal Wallis test (KW) was performed. Measure of association was expressed
by Odds Ratio (OR). Cut-off value for the marker was selected using receiver
operating curves (ROC). P values lower than 0.05 were considered statistically
significant (SPSS 15.0 version).
Results: 106 AML patients (pts) under 60 years with median age of 48 ys
(range 15-65; M/F 62/44), diagnosed in our lab from 2007 to 2015, were
included in this study. The incidence of FLT3-ITD and NPM1m was 28.9%
and 42.0%, respectively. Double FLT3-ITD/NPM1m was present in 18.8% of
cases. Pts with FLT3-ITD had higher median WBC (36.4 vs 10.5 x 10^9/L,
MWW, P=0.004), median percentage of bone marrow blasts (80% vs 43%,
MWW, P <0.001), peripheral blood blasts (72% vs 29%, MWW, P <0.001)
and median LDH value (761 vs 401 UI/L, MWW, P=0.010) than in FLT3 wild
type (FLT3wt) pts. FLT3-ITD cases showed a greater median percentage of
CD135 expression (86% vs 65%, MWW, P=0.009) than counterpart. NPM1m
pts did not exhibit significant differences in clinical features, but showed a
lower expression of CD117, both in percentage (61% vs 88%, MWW,
P=0.001) and MFI (298 vs 1458, MWW, P <0.001). By calculating ROC, a
MFI cut off value of 1125 provided a best sensitivity (89%) and specificity
(63%). Higher median MFI of CD117 were present in FAB M0 (1189), M1
(832), M2 (986) and lower in FAB M4 (394) and M5 (89) (KW, P=0.044). The
association between CD117 expression (categorized by ROC) and FAB M5
(FET, P=0.046) showed an OR of 0.14 (95% CI from 0.02 to 0.97) No differ-
ences were observed for CD135 expression levels in FAB subtypes. The
favorable NPM1m/FLT3wt status (48% of all NPM1m) was associated with
FAB M5 (FET, P=0.011), with an OR of 8.33 (95% CI from 1.68 to 41.29).
Adverse FLT3-ITD/NPM1 wild type (12% of all FLT3-ITD) correlated with FAB
M0 (FET, P=0.006) with an OR of 31.8 (95% CI from 2.77 to 365.53). Any
association was found between double NPM1m/FLT3-ITD status and FAB
subtypes. Pts with refractory AML were associated with an higher level of
CD117 expression (categorized by ROC) (CSQ, P=0.003, OR 4.47, CI 95%
from 1.57 to 12.72) and an adverse FLT3-ITD/NPM1wt status (FET, P=0.042,
OR 5.87, CI 95% from 1.13 to 30.45). 
Summary and Conclusions: High percentage of CD135 expression in pts
with the adverse FLT3-ITD status and high level of CD117 expression in refrac-
tory AML pts suggested a possible role of this combination for a bad prognosis.
In opposite, the strong correlation of CD117 low expression with the presence
of the favorable NPM1m can be predictive of a good prognosis.
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ROLE OF DNMT3A MUTATIONS IN INTERMEDIATE-RISK ACUTE MYELOID
LEUKEMIA PATIENTS: ASSOCIATION WITH PROGNOSIS AND TREAT-
MENT STRATEGIES
M.I. Prieto-Conde1,* M. Alcoceba1, C. Jiménez1, M. García-Álvarez1,
M.E. Sarasquete1, A. Balanzategui1, M. Hernández-Ruano1, E. Sebastián1,
R. Corral1, L. Marín1, F. Ramos2, P. Giraldo3, A. Bárez4, N. C. Gutiérrez1,
R. García-Sanz1, M.C. Chillón**1, M. González-Díaz**1
1Hematology Department, University Hospital of Salamanca-IBSAL, Salaman-
ca, 2Hematology Department, Hospital de León and Ibiomed, Universidad de
León, León, 3Hematology Department, Hospital Miguel Servet, Zaragoza,
4Hematology Department, Hospital Nuestra Señora de Sonsoles, Ávila, Spain
Background: Mutations impacting epigenetic mechanisms, such as DNMT3A
mutations, are recurrent in acute myeloid leukemia with intermediate-risk kary-
otype (AML-IR), although their prognostic value remains unclear. The prospec-
tive determination of DNMT3Amutations may provide an important step forward
individualized therapies using hypomethylating agents or high-dose daunoru-
bicin. However, the clinical benefit of allogeneic stem cell transplantation
(HSCT) has not been established.
Aims: 1) To evaluate the incidence of DNMT3A mutations, their prognostic
impact as well as the interaction with other molecular markers in AML-IR
patients; 2) To determine if allogeneic HSCT in first remission improves the
outcome of patients with somatic mutations in the DNMT3A gene. 
Methods: A cohort of 74 patients with AML-IR (median age 54 years) (PETHE-
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MA AML-99-2010). Analyses of DNMT3A mutations (exons 10 to 23) were
characterized by direct sequencing in diagnostic bone marrow (BM) samples.
Sixty-four patients achieved complete remission (CR) and 30 of them under-
went an allogeneic bone marrow HSCT. 
Results: Of the 74 patients included in this study, 31% (23/74) had mutations
in DNMT3A (78% had R882 mutations and 22% other missense mutations).
DNMT3A mutations were frequently detected in FLT3-ITD mutated patients
(48% vs. 19%, p=0,013). No significant differences were found in both groups
with regard to age, WBC counts or BM blast percentages. The median follow-
up time was 543 days (range, 20-2678). AML-IR patients with DNMT3A muta-
tions had shorter overall survival (OS) (36% vs. 54%, p=0,024) and relapse-
free survival (RFS) (23% vs. 53%, p=0,018) at 5 years than the non-mutated
subgroup. These differences were more evident when older patients (>65 y.)
were excluded (RFS: 15% vs. 55%, p=0,005) or only DNMT3A R882 mutations
were considered (RFS: 20% vs. 54%, p=0,012). In multivariate analysis,
DNMT3A R882 mutations (p=0.039) were independent factors for shorter OS,
and only FLT3-ITD mutations (p=0.004) had a negative prognostic impact on
RFS. We next examined the relapse risk after allogeneic HSCT in first CR in
order to elucidate if poor outcome of DNMT3Amutations was overcome. Again,
DNMT3A mutations identified a population of patients with substantially short-
ened RFS at 5 years (37% vs. 70%, p=0,020). 
Summary and Conclusions: Mutations in DNMT3A, especially R882 muta-
tions, identify a subgroup with poor prognosis in the intermediate-risk group.
Although based on small numbers of patients, these data suggests that muta-
tions in DNMT3A identify a significant fraction of HSCT recipients with poor
survival, for whom alternatives to standard transplantation options should be
considered. **Equal senior contribution. FINANCIAL SUPPORT: Grants
PI12/02321 from the Instituto de Salud Carlos III, BIO/SA44/14 from the Con-
sejería de Sanidad (JCYL), RD12/0036/0069 and Asociación Española Contra
el Cáncer (AECC).
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ACUTE MYELOID LEUKEMIA DISEASE MODELING VIA RNA-GUIDED
CRISPR–CAS9 SYSTEM INDUCED SOMATIC MUTATIONS
O. Brabetz1,* L. Angenendt1, W.E. Berdel1, M.F. Arteaga1, J.H. Mikesch1
1University of Münster, Münster, Germany
Background: Acute myeloid leukemia (AML) is a genetically heterogeneous
clonal disorder characterized by the accumulation of acquired somatic genetic
alterations in hematopoietic progenitor cells that alter normal mechanisms of
self-renewal, proliferation and differentiation. In the majority of AML patients
chromosomal aberrations and/or gene mutations that are involved in disease
development are detectable in the leukemic blasts. Disease models (incl. retro-
viral/lentiviral overexpression, transgene mouse models etc.) have largely con-
tributed to reveal key mechanisms of AML leukemogenesis and progression.
However, the current models face severe limitations since most of them induce
unphysiological gene expression and depend on external promoters for regu-
lation of gene expression/repression. Moreover, a significant proportion of AMLs
is based on gene mutations rather than chromosomal rearrangements or
up/down regulation of gene expression levels.
Aims: We sought out to develop a new effective methodology to reproduce
precise leukemia associated mutations required for improved disease modeling
and to gain insight into AML development. IDH2 mutations that occur frequently
in AML and are related with poor prognosis for the patients were chosen for
acute myeloid leukemia cell genome editing.
Methods: Using the clustered, regularly interspaced, short palindromic repeats
(CRISPR)/Cas9 system we induced specific DNA double strand breaks in the
IDH2 gene of K562 myeloid leukemia cells and introduced IDH2 R140Q point
mutation via homologous recombination introducing a specific DNA template.
Thus, integrated IDH2 R140Q mutation was regulated by the endogenous
IDH2 gene promoter.
Results: Correct insertion of the mutation was confirmed performing targeted
integration PCR as well as genomic DNA sequencing. K562 cells carrying IDH2
R140Q mutation showed significantly enhanced in vitro cell proliferation and
colony forming capacity as compared with controls carrying wt IDH2 introduced
analogously. in vivo studies in NSG mouse model are currently underway to
confirm differences in human leukemia development upon introduction of IDH2
mutation in leukemia cells.
Summary and Conclusions: Our data present a new strategy for generating
leukemia-related gene mutations at defined positions and under endogenous
gene promoters. Using this approach for leukemic cells as well as normal
hematopoietic progenitor cells will provide a promising new methodology for
leukemia disease modeling.
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VSTM-V1 IS A POTENTIAL MYELOID DIFFERENTIATION ANTIGEN GENE
THAT IS DOWNREGULATED IN BONE MARROW CELLS FROM PATIENTS
WITH MYELOID LEUKEMIA
J. Zhou1,* M. Xie1, T. Li2, N. Li1, J.L. Li1, Q.M. Yao1, W.L. Han2, G.R. Ruan1
1Peking University People’s Hospital and Institute of Hematology, Beijing Key
Laboratory of Hematopoietic Stem Cell Transplantation, 2Peking University
Center for Human Disease Genomics, Department of Immunology, Key Labo-
ratory of Medical Immunology, Ministry of Health, School of Basic Medical Sci-
ences, Peking University Health Science Center, Beijing, China
Background: Myeloid leukemia is a myeloid blood cell malignancy that shows
great heterogeneity. Leukocyte differentiation antigens often represent impor-
tant markers for the diagnosis, classification, prognosis and therapeutic tar-
geting of these malignancies. To find novel leukocyte differentiation antigens,
we used an immunogenomics approach and VSTM1 (V-set and transmem-
brane domain containing 1) was selected as a candidate.
Aims: To find novel leukocyte differentiation antigens and new targets for the
diagnosis and treatment of leukemia.
Methods: VSTM1 expression in cell lines, bone marrow samples from healthy
donors and myeloid leukemia patients were analyzed by qRT-PCR, western
blotting and flow cytometry. The promoter methylation of VSTM1 was assessed
by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS).
All-trans retinoic acid (ATRA) was used to induce APL cell line NB4 and bone
marrow cells from APL patients to investigate the relationship between VSTM1
expression and cell differentiation in vitro. To explore the effect of VSTM1-v1
on leukemic cell growth, VSTM1-v1 was overexpressed in K562 and MEG-01
cells and performed viable cell counting assays. Additionally, it was tested for
correlations between VSTM1 expression and patient characteristics.
Results: Herein, we report that the expression level of VSTM1 is downregu-
lated by qRT-PCR in bone marrow cells from leukemia patients (Table 1) and
showed a high degree of promoter methylation. The predominant splice variant
encoded by the gene, VSTM1-v1, encodes an ITIM-bearing type I membrane
molecule. By flow cytometry, we could divide bone marrow cells into subpop-
ulations by immunophenotyping and showed that VSTM1-v1 expression levels
were positively correlated with the maturation state of the myeloid cells (Table
2). Additionally, in vitroATRA treatment could restore VSTM1-v1 expression in
both bone marrow cells from APL patients and NB4 cells. The overexpression
of VSTM1-v1 in K562 or MEG-01 leukemia cells led to an inhibitory effect on
cell growth. When analyzing correlations between VSTM1 expression and the
clinical features of AML patients, we detected a higher expression level of
VSTM1 in the AML1-ETO-positive group.
Tabella 1. The expression level of VSTM1 in bone marrow cells from
leukemia patients and healthy donors.
Table 2. The expression of VSTM1-v1 at various stages of myelocytic
differentiation.
Myeloblasts Promyelocytes Myelocytes Metamylocytes
CD markers CD34+ CD34-CD117+CD16- CD34-CD117-CD16-CD13+ CD16+
VSTM1-v1-positive cells (%) 5.69±2.69 11.48±4.58 35.02±11.58 61.63±8.53
P-valuea <0.001 <0.001 <0.001
aThe P-value was calculated using Wilcoxon signed ranks test as compared with the next stage.
Summary and Conclusions: VSTM1-v1 could represent an important myeloid
leukocyte differentiation antigen and might provide a potential target for the
diagnosis and treatment of leukemia.
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THE PI3K GAMMA/DELTA INHIBITOR, IPI-145 (DUVELISIB) INHIBITS
ACUTE MYELOID LEUKEMIA BLAST PROLIFERATION AND ADHESION
G. Pillinger1,* R. Piddock1, M. Lawes2, S. Rushworth1, K. Bowles1,2
1Molecular Hematology, University of East Anglia, 2Hematology, Norfolk and
Norwich University Hospital Trust, Norwich, United Kingdom
Background: A number of non-receptor tyrosine kinases have been identified
as functionally important in the biology of acute myeloid leukemia including
protein kinase B (AKT), phosphatidylinositol 3-kinase (PI3K), signal transducer
and activator of transcription 5 (STAT5), mitogen-activated protein kinase
(MAPK) and Bruton’s tyrosine kinase (BTK), have all been shown to be consti-
tutively activated in AML. Tyrosine kinase inhibition is clinically effective and
well tolerated in chronic myeloid leukemia, chronic lymphocytic leukemia and
mantle cell lymphoma. Inhibition of selected tyrosine kinases seems an attrac-
tive strategy to assess in AML. PI3K is an enzyme group that generates phos-
phatidylinositol 3, 4, 5-triphosphate which provides membrane docking site for
the tyrosine kinase AKT. AKT itself is responsible for activation of the mam-
malian target of rampamycin (mTOR) pathway which plays an essential role in
the growth of malignant cells, stimulating glycolysis, driving cells to consume
glucose and promoting cell survival and cell-cycle progression. PI3K is known
to be constitutionally active in patients with AML. Recently PI3K/mTOR inhibition
has been shown to delay tumor progression, reduce tumor load and prolong
survival in MLL-AF9+/FLT3-ITD+xenograft mouse models. PI3K has different
isoforms, α β δ and γ.
Aims: To determine the functional effects of PI3K δ/γ inhibition on AML sig-
nalling, survival and adhesion.
Methods: To investigate the role of PI3K p110δ and p110γ isoforms in the reg-
ulation of AML survival, proliferation, migration and adhesion we inhibited PI3K
using different doses of IPI-145 (Duvelisib) (δ/γ inhibitor), CAL-101 (Idelalisib)
(δ inhibitor), and LY294002 (pan PI3K inhibitor). We used AML cell lines and
AML primary cells as well as primary bone marrow stromal cells derived from
AML patients to determine the role of PI3K inhibition in AML proliferation and
adhesion. We assessed survival using CellTiter-Glo and adhesion by Calcein
AM staining of AML cultured on fibronectin or bone marrow stromal cell (BMSC)
coated plates. Western blot analysis was used to assess phosphoAKT and
phosphoMAPK expression. The concentration range of IPI-145 used covers
the plasma steady-state concentration of 0.9uM for patient treated at a dose of
25mg twice a day.
Results: PI3K inhibition with IPI-145, CAL-101 and LY294002 inhibited prolif-
eration in 5/6 AML cell lines. We also observed similar anti-proliferative activity
in primary AML cells. Furthermore, we show that inhibition of PI3K with IPI-
145, CAL-101 and LY294002 results in a decrease in the activity of phospho-
AKT, but has no effect of the activity of phosphoMAPK, indicating that MAPK
is activated via a separate signalling pathway. Finally we report that pre-treat-
ment of AML cells with IPI-145 inhibits adhesion of both AML cell lines and pri-
mary AML cells to primary BMSC at nanomolar concentrations.
Summary and Conclusions: Here we report that IPI-145 (Duvelisib) inhibits
AML proliferation and adhesion through effects on downstream survival signals
including inhibition of AKT phosphorylation at concentrations achievable in
patients. Our results provide biological rationale for further evaluation of PI3K
δ/γ inhibitors in AML.
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IDENTIFICATION OF CYTOGENETIC AND MOLECULAR SUBGROUPS OF
ACUTE MYELOID LEUKEMIAS SHOWING L-ASPARAGINASE IN VITRO
SENSITIVITY
S.N. Bertuccio1,* S. Serravalle1, A. Astolfi1,2, A. Pession1, F. Melchionda1
1Pediatric Hematology and Oncology, O.U. Pediatrics, S.Orsola-Malpighi Hos-
pital Univeristy of Bologna, 2Giorgio Prodi Cancer Center, University of Bologna,
Bologna, Italy
Background: L-Asparaginase catalyzes the hydrolysis of L-Asparagine to L-
aspartic acid and ammonia and sustains reduction in serum asparagine, which
is required for rapid proliferation of leukemic cells. The gene coding for L-
Asparagine synthetase (ASNS) is located in 7q21.3 and its increased expres-
sion is correlated with resistance to L-Asparaginase in Acute Lymphoblastic
Leukemia (ALL). Monosomy of Chromosome 7, or partial deletion involving its
long arm [del(7q)], are recurrent aberrations in myeloid disorders, and it was
shown that these events lead to a significant down-regulation of the genes
located in the deleted regions, including ASNS. Moreover, methylation of CpG
islands in the promoter region is one of the epigenetic mechanisms for silencing
of genes, and some studies demonstrate that ASNS gene is often methylated
in ALL cells, thus explaining why ALL cells may be sensitive to L-Asparaginase.
Aims: The aim of the study is to analyze the in vitro sensitivity to L-Asparagi-
nase of human AML cell lines with different ASNS gene expression levels and
to identify cytogenetic and/or molecular events involved in the in vitro response
to L-Asparaginase. In particular this study investigates if the cytogenetic status
of chromosome 7q or, more generally the expression level of ASNS gene, could
predict the efficacy of L-Asparaginase in Acute Myeloid Leukemia.
Methods: FISH (Fluorescent in situ Hybridization) of Chromosome 7 was per-
formed with specific probes D7S522/CEP7 (Abbott Molecular) located at chro-
mosome 7q31 and 7p11.1-q11.1. In order to measure drug sensitivity we used
the WST-1 assay (Roche Applied Science, Monza, IT), testing eight concen-
trations of L-Asparaginase (Erwinia chrysanthemi, Jazz Pharmaceuticals). The
expression level of ASNS gene was evaluated with quantitative RT-PCR (Roche
LightCycler 480 instrument). For methylation analysis DNA was modified with
bisulfite, amplified by PCR and sequenced with specific primers.
Results: FISH analysis identified 3 out of 10 AML cell lines displaying Chr
7monosomy (UCSD, FKH-1, OCI-AML6). AML cell Lines carrying Chr 7 mono-
somy were more sensitive than the other AML cell lines to L-Asparaginase,
with P value <0.01 (Figure A, B). Moreover AML cell lines with Chr 7 mono-
somy showed a statistically significant lower expression of ASNS gene when
compared to the other AML cell lines. The four ALL cell lines (DND41, HPB-
ALL, MOLT-4 and RPMI-8402) displaying by WST-1 assay the highest sen-
sitivity to the drug, also showed a lower expression of ASNS gene with respect
to the other three ALL cell lines, that however did not display Chr. 7 abnor-
malities. We therefore analyzed the methylation status of the promoter region
of ASNS gene, as an alternative mechanism for gene silencing. ALL cell lines
DND41, HPB-ALL, MOLT-4 and RPMI-8402, that had a low expression of
ASNS gene indeed show hyper-methylation of the ASNS gene promoter
region. On the contrary none of the AML cell lines showed hyper-methylation
of the ASNS gene.
Figure 1.
Summary and Conclusions: The low expression of ASNS gene, found in AML
cell lines carrying Chr 7 monosomy and in ALL cell lines with hyper-methylation
of ASNSCpG island, significantly correlates with higher sensitivity to L-Asparag-
inase in vitro (Figure C, D). The study was supported by a research grant from
EUSAPHARMA (Europe) Ltd.
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AZACITIDINE FOR THE TREATMENT OF MDS, AML AND CMML: THE
SOUTH WALES (UK) EXPERIENCE
A.J. Mahdi1,* J. George1, G.A. Pitchers1, R. Al-meshhedani1, E.M. Bretherton1,
S. Seppings1, R. Jones1, S. Al-Ismail1, U. Mohite1
1ABM University Health Board, Swansea, United Kingdom
Background: The management of elderly patients with myelodysplastic syn-
drome (MDS) and Acute Myeloid leukaemia (AML) poses significant challenge
to the haematologist. Azacitidine (AZA) is a first-in–class hypomethylating agent
with activity in MDS and has shown significantly improvement in survival com-
pared with conventional care regimens. AZA was approved by the UK regulatory
body, the National Institute for Clinical Excellence (NICE) in 2011. Approval
was granted in non-transplant eligible patients with AML with 20-30% marrow
blasts, CMML with 10-29% marrow blasts and intermediate-2/ high risk MDS.
Aims: We report the results of the treatment with AZA at our centre in patients
with MDS, AML and CMML in a “real life” setting. We investigate the character-
istics and outcome of patients receiving AZA including tolerability, efficacy and
overall survival.
Methods: We conducted a retrospective analysis of patients receiving AZA
between 1st Jan 2011 to 31st Dec 2014 over 4 year period from three hospitals
in South Wales, UK within the Abertawe Bro Morgannwg University Health
Board (ABM UHB). Patients were included if they received one cycle of AZA.
Patients were identified from our electronic prescribing system (Chemocare)
and correlated with clinical notes. Disease status was defined by the World
Health Organisation (WHO) classification system. Patients with MDS were risk
stratified using the IPSS-R. Statistical analysis was conducted using SPSS.
Overall survival (OS) was estimated using Kaplan-Meier estimates.
Results: A total of 90 patients with AML and MDS were treated in ABM UHB.
Out of this 26 patients received AZA representing 28% of all patients with MDS
and AML. A median age 73.9 years (range 66-84 years) was observed. Median
follow up was 12.2 months (2-36 months). A male predominance (73.1%) and
a range of indications were seen (MDS n=14, 54 %; AML n=9, 35%; CMML
n=3, 11%). AZA was used outside NICE indications in 3 (11%) cases. AZA was
used as first line therapy in 17 cases (65%) and beyond second line therapy in
9 cases (35%). Out of those receiving 2nd line therapies, 3 (11%) had received
previous high dose therapy, 4 (15%) previous low dose therapy and 2 (7%)
were on only transfusion support. The median number of cycles received was
6.9 (range 1-26). Most patients tolerated AZA well. Grade I-2 skin toxicity was
observed in 9 patients (34%). Grade 1-2 gastrointestinal was common but did
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not prompt discontinuation of AZA treatment. At least one hospital admission
was required in 9 patients (35%) during treatment. Overall response including
stable disease was achieved in 17 patients (65%) out of which complete remis-
sion was achieved in 7 patients (26%) and cytogenetic remission in 2 cases
(8%). At present 7 patients (26%) are alive and continuing on AZA therapy.
Median overall survival (OS) was 8 months. No difference was observed
between disease (p=0.92) and IPSS-R classification in MDS patients (p=0.806).
Patients receiving >6 cycles (n=14, 54%) obtained transfusion independence
and blood count responses with significantly improved overall survival (5
months vs. 20 months, p=0.001).
Summary and Conclusions: AZA is well tolerated and deliverable in our insti-
tution. Patients receiving >6 cycles were most likely to achieve transfusion
independent, improvement in blood counts and have improved median OS
comparable to published data. Persistence with AZA is therefore vital to obtain-
ing a response.
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MIRNA SIGNATURES ASSOCIATED WITH MOLECULAR MARKERS IN
ACUTE MYELOID LEUKEMIA
M. Llop1,* F. Lluch1, C. Alonso1, M. Ibáñez1, E. Such1, I. Gómez1, M. López1,
J. Cervera1, S. Palanca1, I. de Juan1, R. Murria1, P. Bolufer1, M.Á. Sanz1,
E. Barragán1
1Hospital La Fe, Valencia, Spain
Background: Genomic characterization of normal karyotype acute myeloid
leukaemia (NK-AML) has provided in the last years novel molecular markers
(such as DNMT3A, IDH1/2 or TET2) that help refine classification and risk
assessment. miRNA profiling can also define new biological subtypes and
therefore it could complement NK-AML diagnosis and risk stratification. 
Aims: Our aim is to identify a miRNA profile in NK-AML, to find miRNA signa-
tures associated with established molecular markers (FLT3, NPM1, DNMT3A
and CEBPA), and to determine whether altered miRNA expression has prog-
nostic value in NK-AML.
Figure 1.
Methods: Five CD34+samples from cord blood obtained from healthy donors
and 7 de novo NK-AML samples (>70% blast count, CD34+and no mutations
in FLT3, NPM1, DNMT3A or CEBPA) were hybridized onto an array miRNA
3.0 chip (Affymetrix). Deregulated miRNAs in NK-AML were determined with
a hierarchical cluster analysis set at 10-fold change (FC) and p<0.001. The
most up- and down- regulated miRNAs were validated by qRT-PCR (miScript
system) in a cohort of 60 NK-AMLs. Mann-Withney U-test was used to deter-
mine differentially expressed miRNAs according to molecular alterations
Results: We found a miRNA signature characterized by 6 up- and 61 down-
regulated mature miRNAs in NK-AML compared with CD34+controls (Figure
1). By y qRT-PCR we validated 9 miRNAs in a cohort of 60 samples. MiR-20b
(p<0.001), miR-99a (p=0.006), miR-126 (p= 0.009), miR-146b and miR-151b
(both p=0.012) were downregulated; and miR-4668 and miR-494 were upreg-
ulated (p=0.004 and 0.005, respectively). NPM1 and/or FLT3 mutations signif-
icantly reduced miR-126, miR-424 and miR-4668 expression. CEBPA and
DNMT3a mutations did not modify any of the miRNAs expression. WT1 over-
expression was accompanied by a significant reduction of miR-424 expression.
We are currently increasing our patient series to establish the prognostic value
of the altered miRNAs/miRNA profile. Interestingly, miR-126 (downregulated)
targets PI3K (protooncogene), and miR-494 (upregulated) targets PTEN (tur-
mor suppressor gene). These two genes catalyze opposite reactions in cell
signalling pathways. We are currently analyzing the involvement of these two
miRNAs in PI3K/PTEN expression regulation in NK-AML.
Summary and Conclusions: In conclusion, NK-AML has a defined miRNA
profile that is altered by the presence of NPM1 and FLT3 mutations. miR-424
and miR-126 expression is altered in AML and they are predicted to target





VPA AND SAHA TREATMENT DIFFERENTIALLY IMPACT PROTEOME AND
ACETYLOME OF ACUTE MYELOID LEUKEMIA HL60 CELLS
X. Zhu1,* X. Liu2, J. Yan1, Q. Wu1, Z. Sun1
1Hematology, 2ANHUI PROVINCIAL HOSPITAL, Hefei, China
Background: Valproate(VPA) and Suberoylanilide hydroxamic acid (SAHA)
are both HDAC inhibitors. Previous studies indicated that both inhibitors
showed therapeutic effects on acute myeloid leukemia(AML), while the differ-
ential impacts of the two different HDACi on AML treatment still remain elu-
sive.
Aims: The aim of this study was to analyze the impact of VPA and SAHA treat-
ment on histone lysine acetylation and proteome in AML HL60 cells and explore
the differential impacts of the two different HDACi on AML treatment. 
Methods: In AML HL60 cells, by using 3-plex stable isotope labeling for cell
culture (SILAC)-based quantitative proteomics, biochemistry assay, and bioin-
formatic analysis, here we for the first time comprehensively identified and
quantified proteome and acetylome profiling on AML HL60 cells in response to
VPA or SAHA treatment.
Results: In total, we identified 5,775 proteins with 3,227 quantifiable proteins
in AML HL60 cells in response to VPA or SAHA treatment. Taking advantages
of anti-acetyllysine antibody based affinity enrichment followed by Nano-
HPLC/MS/MS analysis, we identified 1124 Kac sites in 702 Kac proteins in
response to VPA or SAHA treatment, among which 1,089 quantifiable Kac sites
in 686 Kac substrates were screened. Intensive bioinformatic analysis clearly
showed that VPA and SAHA treatment differently induced proteome and acety-
lome profiling in AML HL60 cells.
Summary and Conclusions: This study therefore for the first time revealed
the differential impacts of VPA and SAHA on proteome/acetylome in AML cells,
deepening our understanding of HDAC inhibitor mediated AML therapeutics.
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PIVOTAL BIOMARKER ALTERATIONS IN CYTARABINE-RESISTANT
ACUTE MYELOID LEUKEMIA CELL LINES
L.I. Lin1, J.W. Lu1,* P.P. Lim1, Y.L. Lai1, C.Y. Chen2, H.F. Tien2
1Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan Uni-
versity, 2Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan,
ROC
Background: Cytarabine is the backbone of acute myeloid leukemia (AML)
therapy. However, the majority of patients succumb to disease relapses.
Although several reports tried to unveil the mechanisms of cytarabine resist-
ance, such as diminished cytarabine import, increased cytarabine degradation,
decreased formation of active metabolized form of cytarabine, these mecha-
nisms failed to fully explain cytarabine resistance. Recent studies indicated
that molecules of signal transduction and apoptosis may be involved.
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Aims: To establish cytarabine-resistant leukemia cell lines, and further characterize
the pivotal biomarker alterations, on which future treatment may be developed.
Methods: We established a resistant derivative of the human leukemic line
MV4-11 by using stepwise dose-escalation method. The parental and resistant
MV4-11 cells were named MV4-11-P and MV4-11-R, respectively. Further, piv-
otal biomarker alterations were characterized by using human phospho-kinase
array, human apoptosis array, and human phospho-RTK array. Western blotting
was used to confirm those changes. Sanger’s sequencing and pyrosequenicng
were used to study the mutation status of p53.
Results: MV4-11-P and MV4-11-R showed cytarabine IC50 of 0.26μM and
3.37μM, respectively. MV4-11-R cells also showed higher IC50 to idarubicin
and CI-1040 (an MEK inhibitor). In contrast, they displayed no remarkable dif-
ference in response to MK-2206 (an allosteric AKT inhibitor), sorafenib (a mul-
tikinase inhibitor inhibits BRAF and VEGFR) and XL-184 (a multikinase inhibitor
inhibits c-MET, VEGFR, and FLT-3). There were no detectable differences
between MV4-11-P and MV4-11-R cells morphologically and immunopheno-
typically. By using human phospho-kinase array, there were significant differ-
ences between MV4-11-P and MV4-11-R cells in phosphorylated form of several
molecules, such as increased phosphorylated ERK1/2 and p53, as well as
decreased phosphorylated CREB. Slightly increased phosphorylation in MV4-
11-R included p38, JNK, and Akt; on the contrary, slightly decreased phospho-
rylation of STAT5 was noted in MV4-11-R. By using human apoptosis array,
substantial increased phosphorylation of p53 was found in MV4-11-R cells. In
addition, slight increase in HSP27 was found; on the contrary, slight decrease
in SMAC, survivin, TNF-R and XIAP were found in MV4-11-R cells. By using
human phospho-RTK array, increased phosphorylation of EGFR, AXL, HGF-
R, Tie-2 and Dtk were found in MV4-11-R cells; on the contrary, decreased
phosphorylation was only found in VEGFR. Western blotting confirmed these
changes. Exon sequencing revealed that a secondary p53 mutant (D281G) in
MV4-11-R cells in addition to the pre-existing p53 mutant (R248W) of MV4-11-
P cells. By using pyrosequencer analysis, no significant change of R248W bur-
den was noted, but D281G emerged from 1% to 41%.
Summary and Conclusions: We established a cytarabine-resistance cell line
MV4-11-R. This cell line possesses substantial higher phosphorylation of AKT,
ERK, MEK, p53 and lower phosphorylation of CREB and STAT5. Of them, an
emerging secondary p53 mutant (D281G) was noted. Further characterization
of the biologic significance of these molecular alterations may lead to the devel-
opment of novel therapeutics for AML.
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THE EXPRESSION OF THE DNA REPAIR GENE SETMAR IS HIGHLY
CORRELATED TO THE LEVEL OF THE MINIMAL RESIDUAL DISEASE IN
ACUTE MYELOID LEUKEMIA THROUGHOUT THE DISEASE
J.L. Jensen1,* H.B. Ommen1, P. Hokland1, C.G. Nyvold1
1HemoDiagnostic Laboratory, Aarhus University Hospital, Aarhus, Denmark
Background: Acute Myeloid Leukemia (AML) is characterized by accumulation
of malignant white blood cells in blood and bone marrow. The human fusion
protein SETMAR is interesting in the context of the disease, as high expression
in AML cells has shown inhibitory effects on Topoisomerase IIa (TOPO2A)
inhibitors that form a cornerstone as drug in this disease entity. SETMAR pro-
motes DNA double strand break (DSB) repair in the non-homologous end join-
ing pathway, thereby reducing migration of DNA fragments and suppressing
chromosomal translocation. We have previously shown that SETMAR is higher
expressed in patients without a chromosomal translocation compared to
patients with a translocation1.
Aims: The aim of this study is to explore the correlation of the expression of
SETMAR and the level of minimal residual disease (MRD) in patients with AML.
Furthermore the expression level of TOPO2A is correlated to the expression of
SETMAR to investigate whether a high expression of SETMAR has an up reg-
ulating effect on the expression level of TOPO2A.
Methods: Blood samples from 28 patients diagnosed with AML and treated with
TOPO2A inhibitors were collected from diagnostic samples and from subsequent
follow-up samples (n=82). For 10 patients the follow-up samples were drawn up
to seven years from diagnosis (n=28) while samples were drawn shortly after
treatment for 18 patients (n=54). The cell line K562 was used as a positive
control for the quantification of SETMAR and TOPO2A expression. A quantitative
PCR (qPCR) assay including primers and probes targeting transcript variant 1
of SETMAR was used as previously published [1]. Furthermore a qPCR assay
targeting TOPO2A, established prior to the study, was used for the quantification
of TOPO2A expression level (forward primer: CCCAAGAGCTTTGGATCAAC,
reverse primer: AACTTCACCCAGTTTAGTATGC, TaqMan probe: ATCAAAGCT-
GCCATTGGCTGTGGT). b-glucoronidase (GUS) and b-2-microglobulin (b2m)
were used as reference genes. The MRD level was routinely quantified for diag-
nostics purpose and correlated to the SETMAR and TOPO2A expression levels.
The MRD target was either WT1, inv(16), or t(8;21).
Results: We observed a close correlation (Sperman’s rho=0.57, P<0.01)
between the expression of SETMAR and the level of MRD for all 28 patients.
This is shown in Figure 1A. Likewise we found a trend towards a positive cor-
relation between SETMAR and TOPO2A expression (Spearman’s rho=0.1753,
P=0.0671, Figure 1B). When correlating the expression of SETMAR and
TOPO2A to the level of MRD only for the 18 patients with samples drawn shortly
after diagnosis a tighter correlation between the expression of SETMAR and
MRD level was observed (Sperman´s rho=0.6167, P<0.001). Longitudinally
sampling showed excellent correlation between variations in SETMAR expres-
sion level and disease state from time of diagnosis to follow up. This is depicted
in Figure 1C-D where two representative patient courses are shown. The
expression of SETMAR followed the pattern for MRD at time of relapse sug-
gesting a close relationship between SETMAR level and degree of disease in
patients with AML. For the 18 patients with samples drawn at three specific
time points 15 of these showed expression levels of TOPO2A that corresponded
to the changes in gene expression levels of SETMAR and the MRD level.
Figure 1.
Summary and Conclusions: We identified a positive correlation between the
expression of SETMAR and the MRD level as well as a positive correlation
between the expression of SETMAR and TOPO2A. Interestingly there seemed
to be very high concordance between the kinetics of SETMAR and MRD target
during follow-up. This might indicate that SETMAR is present in the malignant
compartment of the neoplastic cells. The mechanisms behind this remains to
be further explored but we speculate that the need for DNA repair in the malig-
nant population might be an issue here. The level of SETMAR followed the
level of TOPO2A over time in the majority of cases indicating that the inhibitory
effect of TOPO2A inhibitors could be an important subject to be considered in
choice of treatment strategy.
Reference 1. Jeyaratnam, D.C., et al., Exp Hematol, 2014. 42(6): p. 448-56
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CORRELATION OF GENOMIC ANALYSIS BY MYAML™ WITH IN VITRO
HIGH THROUGHPUT DRUG SENSITIVITY TESTING IN NEW DIAGNOSIS
AND RELAPSED ACUTE MYELOID LEUKEMIA 
P.S. Becker1,2,* M. Schmitt3, L. Loeb4, W. Gu5, Q. Wei5, Z. Xie6, A. Carson6,
T. Martins7, C.A. Blau8, V. Oehler2, K.Y. Yeung9
1Division of Hematology, University of Washington, 2Clinical Research Division,
Fred Hutchinson Cancer Research Center, 3Hematology and Medical Oncology,
4Pathology, 5University of Washington, Seattle, 6Invivoscribe, San Diego, 7Insti-
tute for Stem Cell and Regenerative Medicine, 8Institute for Stem Cell and
Regenerative Medicine and Center for Cancer Innovation, University of Wash-
ington, Seattle, 9Institute of Technology, University of Washington, Tacoma,
United States
Background: Whole genome sequencing has demonstrated tremendous het-
erogeneity in the mutations and chromosomal translocations associated with
acute myeloid leukemia (AML), yet we remain quite limited in our ability to pre-
dict specific chemotherapy drug sensitivity based on genomics with the excep-
tion of a few selected mutations or translocations, such as FLT3-ITD or PML-
RARA. The overall survival in AML remains poor, especially for patients who
are refractory to ≥2 regimens, or for those with brief duration of first complete
remission.
Aims: 1. To categorize the mutations identified by MyAML™ in new diagnosis
and relapsed AML, and correlate with clinical features.
2. To determine if specific mutations or patterns of mutations will correlate with
results of in vitro high throughput drug sensitivity testing in AML.
Methods: MyAML™ uses next generation sequencing to analyze the coding
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regions and potential genomic breakpoints within known somatic gene fusion
genomic breakpoints of 194 genes known to be associated with AML. Frag-
mented genomic DNA is captured (3.4Mb) with a customized probe design,
and sequenced with 300bp paired end reads on an Illumina MiSeq instrument
to an average depth of coverage >1000x. Using a custom bioinformatics
pipeline, MyInformatics™, single nucleotide variants (SNVs), indels, inversions
and translocations are identified, annotated, characterized, and allelic frequen-
cies calculated. Commonly associated variants in dbSNP and 1000 genomes
were eliminated, as well as variants with allele frequencies less than 5%. High
throughput drug sensitivity testing was performed against a panel of 160 drugs,
of which 56 are FDA approved and 104 are investigational. De-identified sam-
ples from 12 patients with de novo AML and 12 patients with relapsed AML
were analyzed. For 2 patient samples, Duplex Sequencing was also performed
to detect sub-clonal mutations below the detection limit of conventional next-
generation DNA sequencing. Statistical analysis was performed to examine
relationships between gene mutations and drug sensitivity profiles. Specifically,
we computed the Pearson’s correlation between all possible pairs of genes
containing missense mutations and the in vitro cytotoxicity response across
the same set of 24 patients.
Results: From the 24 patient samples analyzed to date, an average of 129
missense mutations were identified in each sample with an allelic frequency
>5%. Of these, an average of over 21 missense variants were observed in
COSMIC and less than 3 were novel (not in dbSNP). These samples also con-
tained an average of over 12 coding indels (~5 frameshift and 7 inframe indels
per sample). In addition, MyAML™ identified 3 samples with inv(16) and 6
samples with translocations, including the cryptic NUP98-NSD1 t(5;11) that
was not detected by karyotyping. For 2 of the samples, Duplex Sequencing
was performed at a depth of at least 6000X, and showed concordance of some
of the mutations, with each method identifying additional mutations not
observed by the other, an expected finding, as each method targeted distinct
regions, and Duplex Sequencing had a greater depth of coverage. The correl-
ative studies between mutations and the results of the high throughput drug
sensitivity testing are in progress.
Summary and Conclusions: Data from disease focused genomics and in
vitro chemotherapy sensitivity testing of individual patient AML samples will
likely lead to innovation in treatment, identification of novel targeted agents,
and improved outcomes in AML.
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ANALYSIS OF GENETIC POLYMORPHISMS IN DNA REPAIR GENES IN
ASSOCIATION WITH ACUTE MYELOID LEUKEMIA AND ITS SPECIFIC
CHROMOSOMAL ABNORMALITIES
A. Daraki1,2,* D. Koumbi1, P. Masoura2, S. Samara2, C. Sambani1, V. Aleporou-
Marinou2, K. Manola1, P. Kollia2
1Laboratory of Health Physics, Radiobiology & Cytogenetics, NCSR “Demokri-
tos”, 2Department of Genetics & Biotechnology, Faculty of Biology, National
and Kapodistrian University, Athens, Greece
Background: DNA damage repair mechanisms are vital to maintain the func-
tions of normal cells and genomic integrity. Alterations and a variety of poly-
morphisms in DNA repair genes have been associated with increased risk of
developing acute myeloid leukemia (AML). DNA double-strand break repair
pathway (DSB) represents the main pathway in maintaining genome stability
and is distinguished into two distinct and complementary pathways homologous
recombination (HR) and non-homologous end-joining (NHEJ), while the
nucleotide excision repair (NER) pathway constitutes the primary mechanism
for removal of bulky adducts from DNA. Essential components of the above
pathways represent the XPD23 proteins which participate in the opening of
the damaged DNA during NER, the Rad51 proteins in HR and Lig4 proteins
which are central components of the NHEJ. The genes that encode the above
proteins are subjected to a single-nucleotide polymorphism (SNPs) and have
been associated with hematological malignancies. 
Aims: The aim of this study was to assess the role of A23927C, G135C and
C26T germline polymorphisms of XPD23, RAD51 and LIG4 genes as genetic
risk factors for AML and its specific chromosomal abnormalities. 
Methods: Genotyping was performed in 83 AML patients and 91 controls by
PCR-RFLPs. Cytogenetic analyses were performed on unstimulated bone mar-
row cells cultured for 24 and 48 hours. 
Results: Concerning the polymorphic sites A23927C of XPD23 gene and G135C
of RAD51 gene, our analysis showed the same allelic and genotypic frequency
between patients and controls. However, the genotypic distribution for C26T
polymorphism of LIG4 gene revealed a statistically higher frequency of the
variant genotypes in patient’s group compared to controls (C/T: 50.6% vs
30.8%, T/T: 10.8% vs 6.6%, respectively, p=0.006). Allele frequency distribution
analysis showed that AML patients exhibited an almost 2-fold increased risk of
carrying at least one variant T allele compared to controls (p=0.004, OR [95%
CI]=2.100 [1.253-3.224]). After stratification of patients according to karyotype,
no statistically significant associations were found between the above poly-
morphisms and the cytogenetic subgroups. Nevertheless, an increased fre-
quency of the variant genotypes of C26T polymorphism of LIG4 gene (CT+TT)
was observed in patients with +8 (80.0%), -7/del(7q) (76%) and -5/del(5q)
(66.7%) compared to healthy donors. 
Summary and Conclusions: Our results showed that AML risk is not signifi-
cantly associated with RAD51 and XPD23 polymorphisms. However, our data
provide evidence for a possible role of the C26T polymorphism of LIG4 gene in
AML development and its specific chromosomal abnormalities.
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EXPOSURE TO ROS INDUCES DNA DAMAGE AND INFLUENCES DNA
METHYLATION IN NORMAL AND MALIGNANT HEMATOLOGICAL CELL
LINES
A.C. Gonçalves1,2,3,4,* R. Alves1,2,3,4, A. Pires1,2, J. Jorge1,2, L. Mota-
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Background: The pathogenesis of myeloid neoplasias is complex and involves
multiple genetic and epigenetic events. The oxidative stress and abnormal
DNA methylation have been implicated in some types of cancer, namely in
myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) and acute
promyelocytic leukemia (APL). Since both mechanisms are observed in some
of these patients, we hypothesize that oxidative stress may influence DNA
methylation. 
Aims: In this context, the present work aimed to analyze the influence of acute
and chronic exposure to OS in global and localized methylation, as well as in
the gene expression levels of epigenetic modulators and antioxidant enzymes.
Methods: In this study, normal lymphocytes (IMC cell line) and several hema-
tological neoplasia cell lines, the K-562 cells (CML), the F36P cells (MDS),
the NB-4 and the HL-60 cells (APL with and without t(15;17), respectively),
were exposed acutely (48h) and chronicle (± six months) to oxidative stress
inducers (hydrogen peroxide and menadione). Cell proliferation and death
were analyzed by trypan blue assay. ROS and GSH levels were analyzed
using fluorescent probes (DCFH2DA, DHR123, DHE, DAF, and MO, respec-
tively) by flow cytometry. DNA damage was analyzed through 8-hydroxy-2’-
deoxyguanosine (8-OHdG) levels (ELISA). The localized methylation status
was analyzed through p15, p16, DAPK, and KEAP1methylation profile (MSP).
Global methylation status was assessed by 5-methylcytosine (5mC), 5-hydrox-
ymethylcytosine (5hmC) levels, and LINE-1 methylation. Gene expression
levels of epigenetic modulators (DNMT1, DNMT3a, DNMT3b, p300, EZH2,
MBD1, MBD2, MECP2, and TET2), oxidative stress genes (GPX1, GSTM1,
NQO1, GSR, HMOX1, SOD1, KEAP1, and TXN), transcription factors (NF-
KB and NRF2), as well as tumor suppressors (p15, p16, p53, and DAPK),
were analyzed by real time PCR. The statistical analysis was carried out by
variance analysis (p<0.05).
Results: Acute and chronic exposure to hydrogen peroxide (H2O2) and mena-
dione (MND) increased intracellular ROS levels in all tested cells lines. Under
acute exposure to ROS, GSH content decrease, while in chronic exposure it
was increased, probably reflecting an adaptation to OS. Moreover, acute expo-
sure to ROS induces a significant increase of DNA damage, however chronic
exposure only significantly increases DNA damage in IMC cells. This oxidative
damage is followed by an increase in 5-mC levels and a decrease in LINE-1
methylation. Moreover, OS also conduced to hypermethylation of p15, p16,
and KEAP1 promoter genes in a cell type- and exposure-dependent manner.
In all cells lines, we observed that chronic exposure to H2O2 and MND induced
an increase in DNMT1, DNMT3a, GSR, GSMT1, and NQO1 gene expression
and a decrease in KEAP1, p15 and p16 genes. In cells, acutely exposed to
theses compounds, gene expression levels were cell line-dependent.
Summary and Conclusions: In summary, exposure to hydrogen peroxide and
menadione (a superoxide donor), especially chronic exposure, lead to DNA dam-
age, global hypomethylation and localized hypermethylation. These findings sug-
gest a relationship between oxidative stress and aberrant methylation status,
two common mechanisms involved in the development of hematological neo-
plasias. This work was supported by CIMAGO and R. Alves is supported by
the FCT fellowship FRH/BD/51994/2012.
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POLYMORPHISM OF FOLATE AND METHIONINE METABOLISM GENES
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC
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1Laboratory of biochemestry, 2FSBI “Russian Research Institute of Hematology
and Transfusiology of FMBA”, Saint-Petersburg, Russian Federation
366 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Background: Abnormal DNA methylation is often seen in patients with acute
myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Polymorphism
of folate and methionine metabolism (FMM) relating genes can influence the
methylation processes and, therefore, modify the risk of AML and MDS devel-
opment.
Aims: The aim of this study was to assess the features of alleles and genotypes
distributions of the FMM genes in MDS and AML patients.
Methods: Forty-eight patients with MDS (21 men and 27 women, mean age
61.3 yrs), 71 patients with AML (25 men and 46 women, mean age 51.2 yrs)
and 121 healthy controls (HC) (cancer-free 73 men and 48 women, mean age
54.1 yrs) were genotyped for the MTHFR C677T, MTHFR A1298C, MTR
A2756G, MTRR A66G and MTHFD G1958A polymorphisms by PCR-RFLP
technique. The differences in allele and genotype frequencies between patients
and HC groups were assessed by Fisher’s exact test with computation of odds
ratios (OR), their 95% confidence intervals (CI) and p-values.
Results: The frequency of the MTHFR 1298AC genotype was decreased in
MDS patients and increased in AML patients, when compared to HC group
(33.3% vs. 43.8% and 55.7% vs. 43.8%, respectively). The difference between
MDS and AML patients was statistically significant (33.3% vs. 55.7%, OR=0.4,
95%CI: 0.2-0.9, p=0.025). At the same time, the MTR 2756 GG variant was pres-
ent in 2 (4.2%) patients with MDS, none of AML patients (0.0%) and 8 (6.6%)
controls. The latter observation also was statistically significant (0.0% vs 6.6%,
OR=0.09, 95%CI: 0.01-1.6, p=0.027). It is interesting, that the MTR 2756 GG
genotype was detected in none of the male patients in MDS and AML groups
compared to men in the HC group (0.0% vs. 11.0%, respectively, OR=0.08,
95%CI: 0.01-1.5, p=0.023). The simultaneous presence of the MTHFD 1958GG
and MTRR 66GG genotypes was more often detected in MDS group than in HC
(14.6% vs. 4.1%, OR=4.0, 95%CI: 1.2-13.2, p=0.04), and in AML group compared
to HC group (8.5% vs. 4.1%, OR=0.5, 95%CI: 0.14-1.6, p=0.33).
Summary and Conclusions: We conclude that polymorphism of the FMM
genes could have an important role in pathogenesis of both MDS and AML.
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SK053, AN INHIBITOR OF ENZYMES INVOLVED IN ALLOSTERIC
DISULFIDE BONDS FORMATION, TARGETS EXPRESSION OF HISTONE
GENES, SHOWS POTENT ANTI-LEUKEMIC EFFECTS AND INDUCES
DIFFERENTIATION OF HUMAN AML CELLS
J. Chlebowska1,2,3,* P. Gaj1, M. Lazniewski4, M. Firczuk1, K. Furs1,
R. Sadowski1, P. Leszczynski1, P. Stawinski5, S. Klossowski6, R. Ostaszewski6,
K. Giannopoulos7, R. Ploski5, D. Plewczynski8, J. Golab1, D. Nowis2,3
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Background: All-trans retinoic acid and arsenic trioxide have revolutionized
management of acute promyelocytic leukemia. Right now targeting epigenetic
modifiers, such as histone deacetylases, bromodomain and extraterminal
domains or methyltransferases and differentiation-inducing agents are rising
hopes for development of effective therapeutic strategies for other types of
acute myeloid leukemia (AML). Numerous proteins involved in tumor develop-
ment have so-called allosteric disulfide bonds amenable to modifications affect-
ing protein structure and function (Hogg P, Nat Rev Cancer 2013). Targeting
allosteric disulfide bonds becomes a novel approach to cancer treatment. Our
interest in this field focuses on proteins with thioredoxin fold such as protein
disulfide isomerase (PDI). We have developed SK053, a small molecule
inhibitor of thioredoxin/thioredoxin reductase system (Klossowski S, Muchowicz
A et al., J Med Chem 2012) that is not a target-specific, but mechanism-selective
inhibitor of allosteric disulfide bonds formation that blocks the enzymatic activity
of PDI
Aims: The aim of this project was to evaluate anti-leukemic and differentiation-
inducing effects of SK053 and investigation of the potential mechanisms of its
activity.
Methods: We evaluated the biological effects on proliferation and differentiation
and the transcriptome changes determined by SK053 in the human myeloid
cell lines: HL60, NB4, KG1 and MOLM14
Results: Our results show that SK053 reduces cell proliferation evaluated by
trypan blue exclusion. SK053 induces cell differentiation along the monocytic
and granulocytic lineages as evidenced with May-Grünwald-Giemsa staining,
nitro blue tetrazolium reduction assay and flow cytometry analysis of CD11b,
CD14 and CD15 expression. Accordingly relative gene expression calculation
and RNA sequencing showed the up-regulation differentiation-related genes.
RNA-seq analysis revealed that 5 day incubation of HL60 cells with SK053
down-regulates mRNA for MYC and ID1 oncogenes as well as for histone pro-
teins. Expression of other genes of mature myeloid lineage such as adhesion
molecules (collagen type XV, fibronectin I, MAC-1), hydrolytic enzymes (car-
boxypeptidase, proteinase 3, CA12 anhydrase, ADAM19 metalloprotease), pro-
teoglycan 2 (core of eosinophilic granules) and PGLYRP3 (peptidoglycan recog-
nition protein 3) was significantly up-regulated. Moreover, the transcripts for
histone proteins: HIST1H3J, HIST1H2AB, HIST1H1B, HIST1H3H, HIST1H2AH
were strongly down-regulated. Drugs that disrupt histone modifiers are in clinical
trials with promising results but very little is known about direct targeting of his-
tone proteins. We also plan to analyze transcriptome of HL60 cells incubated
for shorter time with SK053 using RNA-seq techniques to estimate an early
response to that compound. Figure 1) Differential expression assesed with
RNA-seq after 5-day treatment of HL60 cells with SK053. HL60 cells were incu-
bated with 10 µM SK053, next RNA from control and SK053-treated cells was
transcribed to cDNA library using Illumina kit. Next-Generation Sequencing was
performed with Illumina HiSeq 1500. Transcriptome RNA-seq dataset was ana-
lyzed using Spliced Transcripts Alignment to a Reference (STAR) software and
HTseq software (short-read counts). The y-axis presents negative log of the p-
value from differential gene expression.
Figure 1.
Summary and Conclusions: We propose a new approach in AML treatment,
i.e. targeting of enzymes involved in formation of allosteric disulfide bonds
which has already been reported as novel promising strategy in other cancer
types.
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PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN
NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
J.E. Megías Vericat1,* P. Montesinos2, V. Bosó1, F. Moscardó2, M.J. Herrero1,
D. Martínez-Cuadrón2, R. Rodríguez-Veiga2, L. Rojas1, B. Boluda2,
J. Martínez2, J. Sanz2, F. López2, I. Cano2, A. Lancharro2, J. Cervera2,
J.L. Poveda1, S.F. Aliño3, M.Á. Sanz2
1Pharmacogenetic Unit, Medicament Clinical Area, Hospital Universitari i
Politecnic La Fe, Valencia, Spain, Instituto Investigación Sanitaria, Hospital
Universitari i Politecnic La Fe, 2Hematology Department, Hospital Universitari
i Politecnic La Fe, Valencia, Spain, Hospital Universitari i Politecnic La Fe,
3Pharmacogenetic Unit, Medicament Clinical Area, Hospital Universitari i
Politecnic La Fe; Clinical Pharmacology Unit, Hospital Universitari i Politecnic
La Fe and Pharmacology Department, Medicine Faculty, Valencia University,
Instituto Investigación Sanitaria, Hospital Universitari i Politecnic La Fe, Valen-
cia, Spain
Background: The intake of anthracyclines in blast cells could be affected by
several transporters, including influx transporters (SLC22A16 and SLCO1B1)
and efflux pumps of the ABC family. 
Aims: Previous studies have suggested that single nucleotide polymorphisms
(SNPs) of genes coding for anthracyclines transporters may influence their
effectiveness or toxicity, although their impact in acute myeloid leukemia (AML)
induction therapy remains undetermined.
Methods: The SNPs of anthracycline transporter genes (ABCB1: rs1128503,
rs1045642, rs2032582 and haplotype; ABCC1: rs4148350; ABCC2: rs8187710;
ABCG2: rs2231142, rs2231137; SLCO1B1: rs4149056; SLC22A16:
rs12210538, rs714368) were evaluated in 149 adult patients at initial diagnosis
from AML using a Sequenom (iPLEX) mass spectrometry–based multiplex
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genotyping assay (Sequenom, San Diego, CA). All patients received induction
chemotherapy consisting of idarubicin plus cytarabine (PETHEMA-LMA 99,
2007 and 2010 trials). Genotypes were grouped as dichotomous variables
(dominant and recessive model). Efficacy of first induction cycle was evaluated
comparing complete remission (CR) vs. partial remission or resistance. Patients
dying during induction were considered as no evaluable for efficacy. Based on
the WHO grading scale, toxicities were grouped as binary variables (grade 0-
1 vs. grade 2-4). The grade of toxicity assigned to an organ group was the
maximum grade of all the specific toxicities within that group. Overall toxicity
was grouped with grade 3-4 assessment. Hematologic toxicity was measured
with the time to neutropenia and thrombocytopenia recovery since first day of
chemotherapy. Categorical and continuous variables were assessed using χ2
test with Yates correction if needed and Mann–Whitney U test, respectively.
Significant values were reanalyzed with logistic regression (covariables: age,
gender, ECOG, leukocyte and platelet count).
Results: The median age of patients was 51.7 years (17-78 years). There
were lower CR rates among patients harboring ABCB1 G2677T variant allele
(rs2032582, GG: 60.0% vs. GT/TT: 78.6%, P=0.03; OR: 2.44; IC95%:1.08-
5.55; P=0.033), genotype previously associated with lower activity of ABCB1
pump, and lower anthracycline clearance. Cardiotoxicity was related with wild
type ABCB1 haplotype (32.0% vs. 11.3%, P=0.013; OR: 3.42; IC95%:1.19-
9.85; P=0.023) and variant allele of ABCG2 (rs2231142, CC: 17.0% vs. CA/AA:
50.0%, P=0.008; OR: 6.87; IC95%:1.89-24.96; P=0.003). Neurotoxicity was
associated with wild type ABCB1 haplotype (24.0% vs. 11.4%, P=0.041; OR:
3.00; IC95%:0.97-9.28; P=0.057). Skin toxicity was higher in wild genotypes
of ABCB1 G2677T (rs2032582 GG: 44.0% vs. GT/TT: 24.5%, P=0.015; OR:
0.41; IC95%:0.20-0.85; P=0.017) and ABCB1 haplotype (45.7% vs. 18.9%,
P=0.007; OR: 2.44; IC95%:1.02-5.88; P=0.046), as well as mucositis with vari-
ant allele of ABCC1 (rs4148350 GG: 34.8% vs. GT/TT: 7.1%, P=0.037; OR:
0.14; IC95%:0.02-1.09; P=0.060). Regarding hematologic toxicity, time to neu-
tropenia recovery was delayed with variant allele of SLCO1B1 (TT/CT: 26.8
vs. CC: 29.9 median days, P=0.033). 
Summary and Conclusions: This study shows a prognostic impact of trans-
porter genes polymorphisms in adult AML patients regarding induction
chemotherapy efficacy and toxicity. Further studies with larger population are




NQO1 C609T VARIANTS ARE ASSOCIATED WITH TYPE I AND II
MUTATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA
F.G. Andrade1, G.D. Brisson1, F.V.D.S. Bueno1, E. Pina1, E.P. Noronha1,
B.A.A. Gonçalves1, M.S. Pombo-de-Oliveira1,*
1Pediatric Hematology-Oncology Program, Instituto Nacional de Câncer, Rio
de Janeiro, Brazil
Background: Acute myeloid leukemia (AML) has long been recognized for its
biological heterogeneity, as well as the diversity of genetic and epigenetic mod-
ifications. The broad range of abnormalities across different subtypes is impor-
tant to stratify AML cases to different prognostic groups and choosing of an
appropriate therapy for the disease. However, there has been no recent com-
prehensive overview of the type I (FLT3, RAS) and II [RUNX1-RUNX1T1,
CBFb-MYH11, MLL rearrangements (MLL-r), PML-RARa] genetic alterations
in one large cohort of pediatric AML cases and examining the potential contri-
bution of inherited susceptibility to AML development. 
Aims: The purpose of this study is to evaluate the association of NQO1
rs1800566 polymorphism with pediatric AML risk presenting RAS and FLT3
gene mutations as cooperating events with the mainly fusion genes related to
AML in children. 
Methods: Samples from 601 AML cases aged ≤21 years-old ascertained from
2000-2014 prior to any treatment were included. Variables of reference were
type I/II mutations and NQO1 rs1800566 (C609T). Restriction fragment length
polymorphism and/or direct sequencing were used to screen FLT3 and K/N-
RASmutations. RT-PCR and/or FISH were performed to identify the most com-
mon partners of MLL gene, and the fusion transcripts RUNX1-RUNX1T1,
CBFb-MYH11, and PML-RARa. NQO1 polymorphism was detected by real-
time allelic discrimination technique. 
Results: Overall, type I mutations were identified in 42.2% of cases and type
II mutations in 45.5% (KRAS=6.9%; NRAS=11.6%; FLT3=23.7%; RUNX1-
RUNX1T1=16.9%; CBFb-MYH11=4.5%; MLL-r=12.4%; PML-RARa=11.7%).
Higher rate of KRASmutation was found in AML with MLL-r (42.9%) compared
with cases without this abnormality, as well NRAS in RUNX1-RUNX1T1 positive
cases (50.0%) and FLT3 with PML-RARa (56.7%), suggesting a non-random
association among these alterations. Children aged >2-10 years-old with at
least one NQO1 variant allele were at higher risk for developing AML with PML-
RARa than cases with no type II mutation (odds ratio (OR) 3.67, 95 % confi-
dence interval (CI) 1.01-13.40). Interestingly, we observed a reverse associa-
tion for those cases PML-RARa positives aged >10 years-old (OR 0.18, 95%CI
0.04-0.87). The presence of at least one NQO1 variant allele also provided an
increased risk for cases presenting RUNX1-RUNX1T1 or CBFb-MYH11 and
concomitant FLT3 mutations (OR 6.08, 95%CI 1.15-32.29). 
Summary and Conclusions: The identification of genetic subgroups in pedi-
atric AML may assist to improve the molecular-epidemiology, risk stratification
and etiopathology of AML worldwide. The NQO1 rs1800566 (C609T) polymor-
phism modified risk depending on genetic subtype and age range, suggesting
that lower NQO1 enzyme activity may play a synergistic effect with genetic
alterations and environmental exposures for leukemogenesis. 
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FAVORABLE PROGNOSTIC IMPACT OF NMP1 MUTATION IN ELDERLY
PATIENTS WITH NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA
M. Virijevic1,* I. Djunic1, N. Suvajdziv-Vukovic2, N. Tosic3, A. Novkovic4,
M. Mitrovic5, N. Colovic2, A. Vidovic2, S. Pavlovic3, D. Tomin2
1Department of acute leukemias, Clinic for Hematology, Clinical Center of Ser-
bia, 2Department of acute leukemias, Clinic for Hematology, Clinical Center of
Serbia, Medical Faculty Of Belgrade University, 3Institute of Molecular Genetics
and Genetic Engineering, University of Belgrade,, 4Clinical Hospital Center
“Zemun”, 5Clinic for Hematology, Clinical Center of Serbia, Medical Faculty Of
Belgrade University, Belgrade, Serbia
Background: The prognosis of acute myeloid leukemia (AML) in elderly
patients is poor. The prognostic impact of molecular mutations in these patients
is still unknown. Recent studies showed that NPM1 mutation have a favorable
prognostic impact in elderly patients with de novo AML.
Aims: The aim of this study was to investigate the impact of NPM1 and FLT3
internal tandem duplication (ITD) mutations as prognostic factors for overall
survival (OS), complete remission (CR) rate and disease-free survival (DFS) in
elderly patients with normal karyotype (NK) AML.
Methods: Diagnostics bone marrow samples from 138 de novo AML patients
aged ≥65years diagnosed between 2009 and 2014 were analyzed for NPM1
and Flt3 mutations by DNA PCR amplification/sequencing. Chemotherapy
received 110 patients and 28 patients treated by supportive care only. Co mor-
bidities were evaluated by using the hematopoietic cell transplantation-specific
comorbidity index (HCT-CI). Performance status (PS) was evaluated by Eastern
Cooperative Oncology Group (ECOG), ranged 0-4. Cytogenetic risk group was
assessed by recommendation of European LeukemiaNet. The following param-
eters were estimated as the risk factors for CR rate, DFS and OS: leukocytes
count (<30x109/L vs. ≥30109/L), level of serum lactate dehydrogenase (LDH)
more than 1.5 x upper limit of normal, ECOG PS (<2 vs. ≥2), ELN cytogenetic
risk group, HCT-CI (<2 vs. ≥3) and NPM1 and FLT3-ITD mutations. Risk factors
were identified using the univariate and multivariate analysis.
Results: NPM1 and/or FLT3-ITD mutations detected in 43.5% (60) of patients.
Patients with NPM1 mutations (NPM1+) and without FLT3-ITD mutation (FLT3-
ITD-) had higher CR rate than NPM1- patients (p=0.015). Also, NPM+/ FLT3-
ITD- patients had longer DFS than NPM- patients (p=0.023). Nevertheless, in
NPM1+/FLT3- patients multivariate analysis indicated HCT-CI <3 as the most
important risk factor for longer OS: p=0.02, relative risk (RR)=2.486; 95% con-
fidental interval (CI)=1.156-5.346.
Summary and Conclusions: NPM1 mutation was associated with higher CR
rate and longer DFS in elderly patients with NK-AML and without FLT3-ITD mutation,
but comorbidity remained to be the most important risk factor for OS of its patients.
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STUDY OF PLASMA ENDOSTATIN LEVEL IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA
R. Haggag1,* O. Hussein2, H. Abd El Moaty2, A. Omran2, H. Ebian2
1Medical Oncology, 2Clinical Pathology, faculty of medicine/ Zagazig Univerisity,
Zagazig, Egypt
Background: Endostatin is a naturally-occurring 20-kDa C-terminal fragment
derived from type XVIII collagen. It serves as an anti-angiogenic agent. Endo-
statin is a broad spectrum angiogenesis inhibitor and may interfere with the
pro-angiogenic action of growth factors such as basic fibroblast growth factor
(bFGF/FGF-2) and vascular endothelial growth factor (VEGF).
Aims: To evaluate the role and prognostic value of endostatin in AML patients
Methods: Sixty subjects were included in this study, 30 apparently healthy
adult subjects as control (group 1) and 30 adult patients with newly diagnosed
de novo AML(group2). Estimation of serum endostatin level by ELIZA, at the
onset of the disease and after 1 month of induction treatment
Results: Serum endostatin levels varied widely from 2.1 ng/mL to 7.1 ng/mL
(median, 4.1ng/mL), and the median level was higher in patients with AML com-
pared with patients in the control group (2.6 ng/mL; P =0.001). No significant
difference was found between pre-and post-treatment in group 2 (0.23).
Median overall survival of group 2 was 7 months (1 to 16 months), while the
disease free survival ranged from 2 to 15 months with a median of 8.5 months.
The overall survival of patients who had pre-treatment endostatin level ≤50%
percentile was significantly longer than patients with pre-treatment endostatin
level >50% percentile (p=0.007). According to change of endosatin levels, the
overall survival of patients with increased endostatin level was significantly
longer than patients with decreased endostatin (p=0.03). Also there were sig-
nificant association between change of endosatin level and age, performance
status, cytogenetics, response to treatment and the disease outcome.
Summary and Conclusions: Inhibition of the angiogenesis may have a role
in remission of AML patients. Levels of endostatin in patients with AML may be
effective in predicting the survival
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LONG TERM EFFICACY OF CONSOLIDATION TREATMENT WITH COURSES
OF HIGH-DOSE CYTARABINE AND LIMITED AUTOLOGOUS PBSC
SUPPORT IN A SERIES OF ADULTS WITH ACUTE MYELOID LEUKEMIA
NOT AT HIGH BIOLOGICAL RISK
E. Borlenghi1,* C. Pagani1, E. Cerqui1, A. Belotti1, C. Bottelli1, D. Dalceggio1,
S. Ferrari1, I. Nardiello1, A. Passi1, F. Schieppati1, M. Chiarini2, C. Lamorgese2,
G. Giuliani1, M. Enrico1, G. Ruggeri3, C. Cattaneo1, G. Rossi1
1UO Ematologia, 2Centro di Ricerca Emato-oncologico AIL (CREA), 3UO Lab-
oratorio di Analisi, Spedali Civili, Brescia, Italy
Background: In adult acute myeloid leukemia (AML) consolidation treatment
after complete remission (CR) is mandatory to improve remission duration.
Allogeneic stem-cell-transplantation (allo-SCT) is considered standard for
young pts but repeated cycles of high-dose cytarabine (HDAraC) or autologous
SCT may be as effective in standard risk (SR) pts. In these pts, the AML-00
NILG program (Bassan, ASH 2003) called for 3 consolidation cycles of idaru-
bicin (8 mg/sqm for 2 days) and HDAraC at 2g/sqm/bid for 5 days (A20). Small
doses (1-2x106/kg) of autologous CD34+peripheral blood stem cells (PBSC)
were reinfused after each A20 to minimize toxicity.
Figure 1.
Aims: To analyze, by intention to treat and according to cytogenetic/molecular
characteristics, the very long term outcome of SR pts who received A20 con-
solidation with PBSC support according to the AML-00 NILG program, adopted
as standard at our Institution. High risk (HR) pts, identified by high-risk cytoge-
netics, secondary AML, late CR or FLT3-ITD positivity, were addressed to allo-
SCT and analyzed separately.
Methods: Induction treatment consisted of ICE (3-7-5) followed by IC (2-7)
consolidation if CR was achieved, or by SPLIT (HD-AraC and HD-Idarubicin)
in patients refractory to ICE. AraC 1g/sqm/bid for 4 days (A8) was then given
to all patients achieving CR to allow collection of 3-6x106/Kg PBSC in three
aliquots. SR pts were treated with 3 cycles of A20 followed by reinfusion of 1-
2x106/Kg CD34+PBSC, at 1-2 months intervals upon hematologic recovery.
Pts with insufficient CD34 +PBSC yield received 2 courses of A10 (HD-AraC
1g/sqm/bid for 5 days +idarubicin 10mg/sqm day 1). HR pts received A20/A10
waiting for donor availability and allo-SCT. From January 2001 to December
2014, 234 consecutive AML pts were diagnosed at our Institution, (median age
53, range 15-65). According to molecular/cytogenetic data, available in 229
(97.8%), 118 were SR (51,5%) and 111 HR (48,5%). The CR rate after ICE
induction was 78,6% (180/229) and increased to 89,5% (205/229) after SPLIT
(SR 96,6% and HR 82%). Early/aplastic death rate was 3,9%. A8 course was
administered to 196/205 pts, and 160 (82%) successfully collected
CD34+PBSC (Fig1). 
Results: Of 118 SR pts, 109 actually received A20 (86,2% ) or A10 (13,7%).
Of 111 HR pts, 50 actually received allo-SCT and 32 A20/A10 consolidation
only. The TRM at 100-days after A20/A10 was 2/141 (1,4%) (Ps aeruginosa
sepsis and toxic megacolon). Neutrophil recovery occurred at a median of 10
days after reinfusion. After a median of 20 mo., the median OS of the entire
population was 37.8 mo.; 45+/-6% (IC 95%) of pts were alive 5 years and 42+/-
7% 8 years after diagnosis. Focusing on SR pts, median OS was 131 months
and 62+/-6% were alive after 5 years. According to ELN risk, 5y-OS was 86+/-
4% in CBF+, 100% in CEBPA+, 80+/-10% in NPM+, 54+/-15% in ELN Int-1,
and 30+/-12% in Int-2 risk groups, respectively. OS at 8 years did not change
except in NPM+pts, where it dropped to 53+/-18% because of late relapses
(Fig2). In HR pts, 5y-OS was 24+/-5% by intention to treat. It was 45+/-8% in
the 50 pts actually receiving allo-SCT and 25+/-9% in 32 patients actually com-
pleting A20/A10 because of allo-SCT refusal or lack of donor.
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Figure 2.
Summary and Conclusions: Repeated courses of HD-AraC with limited
PBSC support as consolidation was feasible, well tolerated and very effective
in non HR adult AML. After long term follow up, 86% of CBF+, and more than
50% of NPM+and ELN int-1 risk pts appear to be cured. In NPM+pts late relaps-
es can occur even after 5 years from diagnosis.
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HIGH CURE RATE OF YOUNGER AML PATIENTS WITH FLUDARABINE,
CYTARABINE AND IDARUBICINE INDUCTION AND RISK ORIENTED
CONSOLIDATION: TEN- YEARS REAL LIFE EXPERIENCE
P. Minetto1,* F. Guolo1, M. Clavio1, L. Giannoni1, D. Lovera1, D. Guardo1,
J. Agnelli1, S. Bagnasco1, F. Trovato2, M. Bado2, N. Colombo1, R. Grasso1,
B. Rebesco2, F. Ballerini1, M. Miglino1, R.M. Lemoli1, M. Gobbi1
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2Pharmacology Division, IRCSS AOU San Martino-IST, Genoa, Italy
Background: Conventional induction therapy of acute myeloid leukemia (AML)
is still largely based on the combination of cytarabine (ARA-C) and daunoru-
bicin. In the last two decades alternative drug combinations have been tested
in order to improve complete remission (CR) rate and quality of remission. Flu-
darabine has been shown to enhance ara-CTP accumulation in leukemic blasts
and to inhibit DNA repair mechanisms, thus providing a rationale for combina-
tion with DNA damaging agents.
Aims: In our institution a fludarabine containing induction regimen (FLAI-5) is
being used since more than 15 years. The aim of present study was to critically
rewiev feasibility and efficacy of our strategy.
Figure 1. Overall Survival according to risk group.
Methods: One hundred-five consecutive non M3 AML patients (age 17-72
years) treated in our center between 2004 and 2013 were retrospectively ana-
lyzed. Median age was 45 yy; 90/105 patients (86%) were de-novo AML while
15 (14%) had secondary disease. Fifteen patients (14%) had high risk kary-
otype; 35 patients had NPM-1 mutation (33%), and 24/105 (23%) carried FLT3-
ITD. Median follow-up was 48 months. Induction regimen included fludarabine
30 mg/sqm and ARA-C 2g/sqm on days 1 to 5 plus idarubicin (IDA) 10 mg/sqm
on days 1-3-5, with or without gemtuzumab ozogamicin (3mg/sqm) on day 6.
Patients achieving complete remission received a second course including
ARA-C 2g/sqm on days 1 to 5 and IDA at an increased dose of 12 mg/sqm on
days 1-3-5. Patients were stratified in prognostic risk groups according to a
comprehensive score based on karyotype, de-novo or secondary disease,
NPM and FLT3 status. High-risk and selected intermediate-risk patients under-
went allogeneic bone marrow transplantation (BMT) in first CR if a donor was
available. The other patients were scheduled to receive at least 2 and up to 4
courses of consolidation therapy with 4 days of ARA-C (2g/sqm, daily). 
Results: Five (4.8%) and nine patients (8.6%) died during the first 30 and 60
days, respectively, mainly because of infective or hemorrhagic events. After
1st induction cycle 83 patients achieved CR (79%) and 17 did not respond
(16%). After cycle 2, CR rate was 84% (88/105). FLAI-5 was generally well
tolerated, with negligible non-hematological toxicity; median time to neutrophil
and platelets recovery was 18 and 17 days, respectively. Most patients were
able to receive subsequent therapy at full dose and in a timely manner; 29/88
CR patients underwent BMT in first CR whereas 41 out of the 59 not scheduled
for an early transplant (70%) received the full programmed therapy. In the
whole cohort, 3 years DFS and OS were 42.8% and 48.3% (median 34 and
35 months, respectively). Patients not undergoing early allo-BMT and receiving
the full planned dose had a very good outcome, with a 3-year DFS of 56.7%
(median 63 months). The outcome was further improved if a third consolidation
cycle was given, with a 3-years DFS and OS of 71.2% and 100%, median not
reached.
Summary and Conclusions: In a large randomized trial Burnett et al showed
that FLAG-Ida favorably compared with other induction schedule. However the
longer disease free survival and the lower relapse rate observed in the FLAG-
Ida arm did not translate in a higher OS mostly due to the severe hematological
toxicities following the second FLAG-Ida course. Our results are comparable
to those recently published and show that delivering only one fludarabine con-
taining regimen may significantly reduce hematological toxicity therefore allow-
ing patients to proceed along the risk tailored consolidation program in a good
performance status. 
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IMPACT OF CYTOGENETICS ON CLINICAL OUTCOME IN PATIENTS WITH
FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS
CYTARABINE: RESULTS FROM VALOR
N. Vey1,* F. Ravandi2, E.K. Ritchie3, H. Sayar4, M.D. Craig5, R.K. Stuart6,
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anapolis, IN, United States, 5West Virginia University, Morgantown, WV, United
States, 6Medical University of South Carolina, Charleston, SC, United States,
7Moffitt Cancer Center, University of South Florida, Tampa, FL, United States,
8Vanderbilt-Ingram Cancer Center, Nashville, TN, United States, 9Sunesis
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zinische Klinik und Poliklinik im Städtischen Krankenhaus, Kiel, Germany,
11Hôpital Haut Lévêque-CHU de Bordeaux, Pessac Cedex, France
Background: Diagnostic karyotype is one of the most important predictors of
outcome in acute myeloid leukemia (AML). VALOR, a large phase 3 trial of
vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt) in
patients with relapsed or refractory (R/R) AML [NCT01191801], provided the
opportunity to evaluate the impact of karyotype on clinical outcomes in this dif-
ficult-to-treat patient population. 
Aims: The aim of this posthoc analysis was to assess efficacy outcomes by cyto-
genetic risk category and treatment arm in a large cohort of patients with R/R AML.
Methods: Patients were randomized 1:1 to receive cyt (1 g/m2 IV over 2 hr, d
1-5) plus either vos (90 mg/m2 IV over 10 min, d 1 and 4; 70 mg/m2 in subse-
quent cycles) or placebo. Complete remission (CR) rates, overall survival (OS),
and 30-day and 60-day mortality were assessed by treatment arm in R/R AML
patients based on cytogenetic risk category (an optional entry in the case report
form at screening) per NCCN guidelines.
Results: Overall, cytogenetic data were available for 479 of 711 (67%) of
patients on the VALOR study, of whom 133 (28%) had unfavorable risk, 330
(69%) had intermediate risk, and 16 (3%) had favorable risk karyotype as report-
ed at screening. CR rates by cytogenetic group were: 12.0% for unfavorable,
27.0% for intermediate, and 56.3% for favorable risk patients. Median OS was
4.0 mo, 8.1 mo, and 15.6 mo for unfavorable, intermediate, and favorable risk
groups, respectively. On the vos/cyt treatment arm, there were 58 patients with
unfavorable risk, 175 patients with intermediate risk, and 7 patients with favor-
able risk. For the pla/cyt arm, there were 75 patients with unfavorable risk, 155
patients with intermediate risk, and 9 patients with favorable risk (test for asso-
ciation, p=0.16). When CR was examined by treatment arm, there were
improved rates in the vos/cyt treatment arm compared with the pla/cyt arm for
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each cytogenetic risk group: 15.5% vs 9.3% for unfavorable, 34.3% vs 18.7%
for intermediate, and 71.4% vs 44.4% for favorable risk. In the intermediate risk
group, the difference in CR rate was statistically significant (P=0.0015, chi-square
test). Forest plots of OS hazard ratios (HR) reflected treatment benefit for all
categories of cytogenetic risk (Figure). When median OS was reported by treat-
ment arm, patients with unfavorable and intermediate cytogenetics who received
vos/cyt had improved survival compared with patients who received pla/cyt (for
unfavorable group: 5.0 mo vs 3.8 mo, respectively [HR 0.79; P=0.20]; for inter-
mediate group: 8.3 mo vs 7.1 mo, respectively [HR 0.88; P=0.32]). Between
cytogenetic risk groups there were no clinically meaningful differences between
treatment arms with respect to 30-day and 60-day mortality.
Figure 1.
Summary and Conclusions: These data further validate previous reports of
important prognostic value of cytogenetics in R/R AML. Improvement in CR
rate and OS benefit was observed for vos/cyt-treated patients with the poorest
prognosis, those with intermediate or unfavorable cytogenetics, without an
increase in early mortality. Funded by Sunesis Pharmaceuticals, Inc., South
San Francisco, CA.
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CLOFARABINE AND HIGH-DOSE CYTARABINE ARABINOSIDE (CLARA)
FOR PRIMARY REFRACTORY OR RELAPSED ACUTE MYELOID
LEUKAEMIA – A PROSPECTIVE FOLLOW-UP STUDY OF 60 PATIENTS
H. Gill1,* T. Chan1, Y.Y. Hwang1, A. Leung1, E. Tse1, Y.L. Kwong1
1Medicine, The University of Hong Kong, Hong Kong, Hong Kong
Background: Relapsed or refractory acute myeloid leukaemia (AML) is asso-
ciated with a poor prognosis with a remission rate ranging between 10 to 40
percent with conventional salvage regimens. Clofarabine was designed to incor-
porate the anti-leukaemic properties of fludarabine and cladribine, both of which
are active against AML. 
Aims: The aim of this study was to prospectively evaluate the efficacy and tol-
erability of the salvage regimen combining clofarabine and high-dose cytarabine
in patients with primary refractory or relapsed AML in the real-world scenario.
Methods: Patients with primary refractory or relapsed AML were prospectively
recruited between 1 June 2009 and 31 December 2013. All data was censored
on 30 June 2014. Patients were treated with Clofarabine at 40mg/m2/day from
day 1 to day 5) in combination with cytarabine arabinoside (AraC) at 2g/m2/day
from day 1 to day 5 (CLARA). Clinicopathologic features, treatment response
and survivals were determined. Prognostic factors for response and survivals
were determined using logistic regression and cox regression. 
Results: 60 patients with primary refractory or relapsed AML were recruited
(primary refractory,N=18; first relapse,N=31, second relapse,N=10, third
relapse,N=1). 29 men and 31 women with a median age of 48.5 (range: 18-66)
were recruited. They received a median of 2 (range:1-5) prior induction/re-
induction regimens for AML. 36 patients (40%) had normal karyotype at diag-
nosis while 24 patients (60%) had abnormal karyotype. 8 patients had fms-like
tyrosine kinase 3-internal tandem duplication (FLT3-ITD) and 5 patients had
mutated nucleophosmin 1 (NPM1). 8 patients achieved complete remission
(CR) and 25 patients achieved a complete remission with incomplete
haematopoietic recovery (CRi) making the CR/CRi rate of 55%. 17 patients
progressed after initial remission. 15 patients (25%) underwent allogeneic
haematopoietic stem cell transplantation (HSCT) after remission. Grade 3/4
haematological toxicity was seen in all 60 patients. Febrile neutropenia occurred
in 24 patients (40%) and grade 3/4 hepatotoxicity was seen in 5 patients (8%).
With a median follow-up of 6.5 months (range: 1-43), the median overall survival
was 8 months (95% confidence interval: 5.04-10.96). The overall survival at 12
and 24 months was 38.9% and 29.7% respectively. Patients who were suc-
cessfully bridged to allogeneic HSCT had a significantly better overall survival
(P<0.001). The overall survival at 36 months in patients who underwent HSCT
was 62.2%. The median progression-free survival following CLARA was 6
months.
Summary and Conclusions: Clofarabine in combination with high-dose
cytarabine was effective in inducing a response in a significant proportion of
patients with heavily-pretreated primary refractory or relapsed AML. Successful
bridge to subsequent curative allogeneic HSCT was the major determinant of
overall survival.
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IDH1 (BUT NOT IDH2) MUTATIONS CAUSE INFERIOR OUTCOME IN
PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETICS
J. Marková1,* P. Michková1, C. Šálek1, J. Březinová1, J. Soukupová
Maaloufová1, P. Soukup1, P. Cetkovsky1, K. Michalová1, J. Schwarz1
1Institute Hematology and Blood Transfusion, Prague 2, Czech Republic
Background: IDH1 and IDH2 are enzymes that catalyze the oxidative car-
boxylation of isocitrate to α-ketoglutarate in the Krebs cycle. Heterozygous
mutations at IDH1Arg132, IDH2Arg140 and IDH2Arg172 were found to cause
loss of normal enzymatic function. IDH1 mutations are described in 6-16% of
patients with cytogenetically normal AML, incidence of IDH2mutations is slightly
higher (15-20%). IDH2 mutations, particularly Asp140 are considered to have
an unfavourable prognostic impact.
Aims: Patients: Presence of IDH1 and IDH2 mutations was analysed in 296
patients with AML with an intermediate-risk cytogenetics (defined according to
Grimwade et al., Blood, 2010) diagnosed between years 1998-2012. Median
age at diagnosis was 55.1 years (range 16.0-81.7), the initial median WBC
count was 22.3 x 109/L (range 0.4-483.7). The male/female ratio was 147/149
and the median of follow-up was 10.8 months.
Methods: Exons 4 of both IDH1 and IDH2 genes were amplified by RT-PCR;
PCR products were treated by ExoSAP-IT reagent and directly sequenced.
Obtained sequences were compared with wild type ones and mutations were
identified.
Results: IDH1/2 mutations were detected in 81 (27.4%) from 296 patients, all
but one mutations were heterozygous. IDH mutations were more frequent in
female patients (P=0.055) and independent of age (P=0.395). IDH mutations
were associated with mutated DNMT3A (P=0.0008), but not with FLT3/ITD
(P=0.124). IDH1 mutations were found in 28 (9.5%) patients; 14/28 (50.0%)
patients had Arg132His mutation, 9/28 (32.1%) Arg132Cys, 4/28 (14.3%)
Arg132Ser and the remaining one had a Arg132Gly change. 6 of IDH1-positive
patients had also FLT3/ITD. 53/296 (17.9%) cases carried mutations in IDH2
gene; the majority of them (39/53; 73.6%) had Arg140Gln mutation, 13/53 (24.5%)
harboured Arg172Lys change and one patient carried a previously undescribed
alteration Gly145Trp. 11/53 cases were FLT3/ITD positive. None of the IDHmuta-
tions influenced WBC counts at diagnosis. Neither IDH1, nor IDH2 mutation wors-
ened the chance for reaching complete remission (CR): 15/27 (55.5%) IDH1-
positive cases receiving standard induction treatment achieved CR as well as
30/47 (63.8%) cases with IDH2 mutation and 126/208 (60.6%) without any IDH
alteration. 10/15 (66.7%) patients harbouring IDH1 mutation suffered a relapse,
while only 59/125 (47.2%; P=0.362) cases without any IDH mutation and 9/30
(30.0%; P=0.009) carrying IDH2 change relapsed. The difference was more obvi-
ous, when FLT3/ITD positive cases were excluded from analysis (66.7% patients
with IDH1 mutation relapsed vs. 37.5% relapsing cases with wt IDH and 26.1%
of IDH2-positive ones). Patients with mutated IDH1 had significantly shorter over-
all survival (OS) than cases without this mutation (P=0.048) or cases with IDH2
mutation (P=0.026). OS 2 years after the diagnosis was 18.8% in cases with
mutated IDH1, compared with 35.2% and 39.3% in patients without any IDH
mutation and IDH2-positive ones, respectively.
Summary and Conclusions: We detected IDHmutations in 27.4% of patients
with intermediate-risk cytogenetics. IDH1-positive patients had significantly
shorter OS in comparison with IDH negative ones as well as comparing to
IDH2-positive cases. This may result from a slightly lower CR rate on one hand
and higher incidence of relapses in IDH1 group on the other. IDH2 mutations
did not influence the prognosis of AML patients whatsoever. Supported by
Research project 00023736 of Ministry of Health of Czech Republic and grant
RVO VFN64165.
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DISTINCT EPIDEMIOLOGIC EXPOSURES AND PROGNOSTIC FACTORS
FOR SURVIVAL IN OLDER ADULTS AGE ≥70 YEARS RECEIVING LOW
INTENSITY THERAPY FOR ACUTE MYELOID LEUKEMIA (AML)
J. Foran1,* M. Heckman2, L. Sproat3, L.J. Jiang4, R. Ketterling5, R. Tibes3,
L. Finn6
1Mayo Clinic Cancer Center, 2Biostatistics, Health Services Research, Mayo
Clinic Florida, Jacksonville, 3Division of Hematology & Medical Oncology, Mayo
Clinic Arizona, Phoenix, 4Hematopathology, Mayo Clinic Florida, Jacksonville,
5Cytogenetics, Mayo Clinic Rochester, Rochester, 6Division of Hematology &
Medical Oncology, Mayo Clinic Florida, Jacksonville, United States
Background: Many older adults age ≥70 years with AML were not previously
candidates for intensive remission induction therapy and consequently the epi-
demiology and prognostic factors for overall survival (OS) have not been studied
systematically in this population. However many now receive lower intensity
treatment strategies, with distinct patterns of OS. We sought to study prognosis,
clinical outcome and role of epidemiologic risk factors for AML development in
this population.
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Aims: The primary study aim was to evaluate prognostic factors for overall
survival after AML and the incidence and contribution of epidemiologic expo-
sures in older (≥70yrs) versus younger adults, and following intensive vs. low
intensity therapy.
Methods: Epidemiologic exposures associated with AML development [includ-
ing family history of hematologic malignancy (FHx); prior myelodysplasia
(MDS); secondary AML (sAML); obesity (BMI ≥30kg/m2); smoking; history of
farm habitat or toxin exposure; and medical history, medications and prior
immunosuppressive therapy (IST)] and clinical risk factors associated with OS
were studied in a well characterized and non-selected cohort of n=295 con-
secutive AML patients diagnosed and treated at Mayo Clinic Florida & Arizona
from 2002-12. Patients were treated in accordance with existing institutional
algorithms, and central cytogenetics testing was performed at Mayo Clinic in
all cases. Single variable Cox proportional hazards regression models, testing
interaction p-values between groups (Age ≥70 vs. ≤69 yr.; intensive therapy
vs. non-intensive or supportive care), was performed to evaluate differences
in associations with OS. Fisher’s exact test (or Wilcoxon rank sum test) was
used for comparisons of patient characteristics.
Results: Older patients had a lower incidence of favorable risk cytogenetics,
and were more likely to have prior MDS (p=0.032); sAML (p=0.026); a comor-
bidity index score (HCTCI) ≥3 (p<0.001); ECOG performance status (PS) >1
(p<0.001); and history of aspirin (p=0.001), statin (p=0.004) and metformin use
(p=0.047) (but not acetaminophen). No other major difference in the incidence
of epidemiologic exposures was observed between groups. Older patients were
significantly less likely to receive intensive therapy (38% vs. 90%, P<0.001).
Significant differences in prognostic factors for OS were observed. sAML was
strongly associated with inferior OS in younger (Hazard Ratio (HR) 2.00, 95%
Confidence Intervals (CI) 1.32-3.03) but not older adults (HR 1.09, 95%CI 0.75-
1.58) (p interaction =0.030). In contrast, ECOG PS >1 was associated with OS
in older (HR 2.39, 95%CI 1.67-3.43) but not younger patients (HR 0.97, 95%CI
0.60-1.56) (p interaction =0.003). Intensive therapy had a similar effect on OS
in both groups (<70yr, HR 0.17, 95%CI 0.07-0.40; ≥70 yr, HR 0.21, 95%CI 0.13-
0.33) (p interaction =0.77). Poor risk cytogenetics was associated with inferior
OS in both groups, however cytogenetically normal AML was adverse in older
(HR 5.71, 95%CI 1.35-24.12) but not younger (HR 1.69, 95%CI 0.58-4.90)
adults. Other epidemiologic exposures (smoking, obesity, acetaminophen, IST,
Farm habitat) did not affect OS, with the exceptions of FHx and Toxin exposure
both associated with inferior OS after intensive therapy (HR 1.5, 95%CI 0.88-
2.54 and HR 2.33, 95%CI 1.30-4.15, respectively) but not after low intensity/sup-
portive care (HR 0.53, 95%CI 0.23-1.22 and HR 0.70, 95%CI 0.22-2.21, respec-
tively) (p interaction =0.047 and =0.085, respectively).
Summary and Conclusions: Patients age ≥70 years and those receiving low-
er intensity therapy demonstrate a distinct profile of epidemiologic exposures,
and prognostic factors for OS differ from younger adults. This suggests that
prognostic factors in younger patients receiving intensive therapy cannot be
directly extrapolated to this population, and prospective studies are needed to
evaluate unique etiologic and prognostic factors for older adults.
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CHARACTERISTICS OF ACUTE MYELOGENOUS LEUKEMIA PATIENTS
WITH GATA2 MUTATIONS
H. Maeng1,* M. Routbort2, J. Jorgensen2, T. Kadia1, K. Bhalla1, J. Cortes1,
H. Kantarjian1, C. DiNardo1
1Leukemia, 2Hematopathology, the University of Texas MD Anderson Cancer
Center, Houston, United States
Background: The zinc-finger transcription factor GATA2, located on chromo-
some 3q21, serves an essential role in the development and regulation of
hematopoietic stem cells and myeloid differentiation. Acquired and inherited
GATA2 mutations leading to decreased GATA2 transcription have been
described in patients with myeloid malignancies, often in the setting of a
hypocellular marrow with atypical megakaryocyte morphology. In addition to a
predisposition to myeloid malignancies, GATA2 deficiency is characterized by
deficiencies in B-lymphocyte, monocyte, NK and dendritic cells and a propen-
sity for mycobacterial, fungal and viral infections, as well as lymphedema and
pulmonary disease and propensity for venous thromboembolic disease among
other described clinical manifestations.
Aims: The aim of our present study was to investigate the frequency, charac-
teristics and outcome of acute myelogenous leukemia (AML) patients with
GATA2 mutations. 
Methods: We performed a database search for GATA2 mutations in AML
patients from 2013 to 2014; conveyed as part of our institutional Next-Gener-
ation Sequencing (NGS) platform. All patients signed an informed consent form
approved by the University of Texas MD Anderson Cancer Center institutional
review board. Medical records were retrospectively reviewed. 
Results: Among 233 patients with AML, 16 patients were identified to have
GATA2 sequence variations. Six patients with previously reported non-path-
ogenic population polymorphisms (2 P161A, 1 G237D and 3 P250A) were
excluded from further analysis. Data from 10 (4.3%) patients were collected
and analyzed; clinicopathologic characteristics of these 10 patients are pro-
vided in Table 1. Median age was 53 (range 22-79) years old, with 4 patients
under the age of 35 years. No patient had a prior known diagnosis or family
history of GATA2 syndrome or clinical history of frequent infections. Complete
blood count at diagnosis demonstrated a median WBC 29.3x10^3 (3.3-
215.9x10^3)/uL, peripheral blast 37(0-95) %, Hemoglobin 9.25 (5.8-11.30)
g/dL and platelet 72.5x10^3 (8-181x10^3)/uL. By bone marrow morphology,
4 patients were classified as AML without differentiation, 3 as AML with differ-
entiation, 1 myelomonocytic leukemia and 2 as AML with MDS-related
changes. Patient 4 with dysplastic changes had GATA2 L359V that was pre-
viously reported to cause myelomonocytic differentiation in blastic transfor-
mation of chronic myelogenous leukemia. Cytogenetics revealed a diploid
karyotype in all evaluable patients except one patient with isolated deletion
5(q22q35) in 10 out of 20 metaphases. GATA2 mutations were always found
in the presence of other somatic mutations, with a median number of 3 (range
2-6) mutations. Of significant interest, CEBPA mutations were identified in 6
(60%) of patients with double-CEBPA mutations in 5 of the 6 patients. With a
median of 9.5 (2-14) months, 7 patients are alive in first complete remission
status post high-dose cytarabine based induction chemotherapy; Patient 9
was additionally consolidated with a stem cell transplant in CR1. Patient 4 is
alive 10 months into decitabine therapy with stable disease not requiring trans-
fusion. Two patients have died; one of infectious complications after a cord-
blood stem cell transplant in remission and the other had multiorgan failure in
the setting of relapsed disease.
Tabella 1.
Summary and Conclusions: We identify the presence of GATA2 mutations
in approximately 4% of newly diagnosed AML patients. GATA2 mutations are
associated with younger age at AML diagnosis, diploid cytogenetics, an appar-
ently favorable outcome, and notably a strong correlation was seen with con-
comitant CEBPA mutations suggesting cooperativity. Evaluation for familial
inheritance of the presumed somatic GATA2 and/or CEBPA mutations is ongo-
ing in select families. 
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DAY-14 LAIP ON BONE MARROW PREDICTS COMPLETE RESPONSE
AND DRIVE EARLY SALVAGE CHEMOTHERAPY IN AML: RESULTS OF
MULTIPARAMETER FLOW CYTOMETRY AND WT1-RNA
QUANTIFICATION
C. Messina1,* M.G. Carrabba1, E. Sala1, P. Ronchi2, C. Tresoldi3, M. Tassara3,
F. Pavesi1, B. Gentner1, L. Vago1, F. Ciceri1, R. Milani2, M. Bernardi1
1Department of Onco-Ematology, Unit of Hematology and Bone Marrow Trans-
plantation, 2Immuno-hematology and Transfusion Medicine, 3Unit of Molecular and
Functional Immunogenetics, IRCCS San Raffaele Scientific Institute, Milan, Italy
Background: In acute myeloid leukemia (AML) response to induction
chemotherapy (CT) is evaluated by bone marrow (BM) morphology and cyto-
genetics. Real-time quantitative PCR (RQ-PCR) and multiparametric flow cit-
ometry (MFC) are sensitive techniques to assess minimal residual disease
(MRD). Early evaluation of response at day14 (d14) predicts the achievement
of complete remission (CR). Most studies rely on BM morphology at d14 but
this timepoint is often not evaluable for cytological blast count. Few data on
BM blast clearance by MFC and/or RQ-PCR are available; the correlation
between these two assays is unknown in this setting. Moreover, it is to be
established if early intensification with a second CT cycle could increase CR
rate or reduce the time to achieve CR in pts with disease persistence at d14
BM. 
Aims: Objective of the study were i) to compare the two assays to identify the
more sensitive/specific assay; ii) to compare the outcome of pts who received
or did not receive an early intensification for d14 disease persistence, if in
appropriate clinical conditions. 
Methods: We retrospectively evaluated 33 newly diagnosed AML pts who
received induction CT at our Center between 02/2009 and 02/2015, and for
whom analysis of BM both at d14 and after hematologic recovery was available.
We evaluated MFC (d14-LAIP) and WT1 quantification by PCR (d14-WT1) to
predict the response to induction at d14, in particular when morphologic blast
count is not evaluable. 
Results: 25 pts received “3+7” and 8 pts the ICE induction regimen. After d14
BM evaluation, 6 pts received early reinduction CT (FLAG-Ida) starting at d16
(median), 27 pts did not receive further therapy before d28 BM evaluation.
Overall CR rate was 64% (21 pts), PR/NR 36% (12 pts), d60 treatment related
mortality (TRM) 3% (1 pt). At d14, morphologic blast count was not evaluable
in 13 (39%) cases due to marrow aplasia, in 1 case (3%) blasts were <5%, in
5 (16%) <20%, in 14 (42%) ≥20%; by MFC (33 evaluable), in 15 pts (45%)
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blasts were ≤2%, in 18 (55%) >2%; by PCR (27 evaluable), in 7 pts (26%) WT1
was <250cp/104ABL, in 20 (74%) ≥250cp/104ABL. At d28 of the 13 pts with
d14 aplastic marrow, 10 (77%) achieved CR and 3 (23%) PR/NR, all the 6 pts
with d14 blasts 5-19% achieved CR, of the 14 pts with d14 blasts ≥20%, 5
(36%) achieved CR and 9 (64%) PR/NR. Analysis of the paired results from
nadir to recovery revealed that d14-LAIP 2% had a positive predictive value
(PPV) of 83% and negative predictive value (NPV) of 93%, with 90% sensitivity
and 87% specificity; d14-WT1 250 had a PPV of 53% and NPV of 86%, with
89% sensitivity and 46% specificity. The d14-LAIP was strongly associated with
CR after induction (p=0.00007). Considering the 14 pts with d14 blasts ≥20%,
5/6 (83%) who received d14 FLAG-Ida obtained CR after a median time of 43
days, 3 pts did not receive further therapies, 3/5 (60%) who received d30 rein-
duction CT obtained CR after a median time of 54 days (p=0.23).
Summary and Conclusions: D14-LAIP proved to be superior to morphology
and d14-WT1 in terms of feasibility and predictive value of subsequent CR.
Even in one-third of pts who had an early morphologic response not evaluable
due to marrow aplasia MFC proved to be a useful tool with a 100% applicability.
Correlation between the two assays was >90%. Our data confirm the prognostic
value of d14 BM evaluation and suggest that MRD detection, also in aplasia,
could drive early salvage CT. Our results with early intensification are promising;
clinical impact of this strategy will be investigated in larger studies.
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IDENTIFICATION OF PROGNOSTIC FACTORS RELATED TO THERAPEUTIC
OUTCOMES OF CHEMOTHERAPY AND ALLOGENEIC STEM CELL
TRANSPLANTATION IN 120 ACUTE MYELOID LEUKEMIA PATIENTS WITH
MONOSOMAL KARYOTYPE IN KOREA
H. Cho1,* J. Jang1, J. Yoon2, I. Kim3, J.H. Lee4, C.W. Jung5, H.J. Shin6,
W.S. Lee7, J.H. Lee8, D.S. Hong9, H.J. Kim10, H.J. Kim2, S. Park3, J.H. Jang5,
J.S. Chung6, S.M. Lee7, J. Park8, J.S. Ahn10, W.S. Min2, J.W. Cheong1,
Y.H. Min1
1Department of internal medicine, Yonsei University College of Medicine,
2Department of Hematology, Seoul St. Mary’s Hospital,College of Medicine,
The Catholic University of Korea, 3Department of Internal Medicine, Cancer
Research Institute, Seoul National UniversityCollege of Medicine, 4Department
of Medicine, Asan Medical Center, University of Ulsan College of Medicine,
5Department of Medicine, Samsung Medical Center, Sungkyunkwan University,
School of Medicine, Seoul, 6Department of Internal Medicine, School of Medi-
cine, Medical Research Institute, Pusan National University Hospital, 7Depart-
ment of Hemato-Oncology, Inje University Busan Paik Hospital, Busan, 8Depart-
ment of Internal Medicine, Gachon University Gil Medical Center, Gachon Uni-
versity School of Medicine, Incheon, 9Department of Internal Medicine,
Soonchunhyang University Bucheon Hospital, Bucheon, 10Department of
Hematology and Oncology, Chonnam National University Hwasun Hospital,
Hwasun, Korea, Republic Of
Background: Monosomal karyotype (MK) was known to be associated with a
dismal prognosis in acute myeloid leukemia (AML) and provide additive prog-
nostic value in AML patients with complex karyotype. 
Aims: In this study, we evaluated the prognostic significances of clinical char-
acteristics and additive chromosomal abnormalities, which are associated with
therapeutic outcomes of chemotherapy and allogeneic stem cell transplantation
in ML AML.
Methods: Clinical data on AML in Korea has been collected through AML reg-
istry managed by the AML/MDS Working Party of the Korean Society of Hema-
tology, and a total of 3,041 AML patients were registered at the time of analysis.
From Jan. 2007 to Dec. 2011, 184 patients who met the definition of MK-AML
were selected for this study, and 120 of 184 received induction therapy were
retrospectively analyzed. 
Results: The MK-AML accounted for 6.1 % of total AML in our registry, and the
median age of was 56 years (range, 17-82 years). Median follow up duration
for 120 patients was 40.5 months. The most frequent cytogenetic abnormality
was -7/7q deletion (46.7%), and -5/5q deletion (40.8%) and 17p abnormality
(17.5%) followed. MK defined by one single autosomal monosomy with at least
one structural chromosomal abnormality was shown in 45 patients (37.5%),
and MK defined by equal or more than two autosomal monosomies in 75
patients (62.5%). Fifty-two patients (46%) achieved complete remission (CR)
after 2 cycled of induction chemotherapy, and early mortality rate was 16% (19
patients). Univariate and multivariate analysis revealed that ≥10% cells with
normal metaphase was an independent good prognosis factor for CR achieve-
ment. Older age (≥60) and 17p abnormality were significant risk factors for
early mortality. The 3-years overall survival (OS) and progress-free survival
(PFS) for all patients was 20.8% and 7.9%, respectively. Univariate and multi-
variate analysis revealed that single monosomy, achievement of CR, and ≥10%
cells with normal metaphase were independent good prognostic factors for
PFS and OS. De novo type of AML and absence of 17p abnormality were anoth-
er good prognostic factors for PFS and OS, respectively. Total 44 patients were
finally received allogeneic hematopoietic stem cell transplantation (alloHSCT).
Thirty-three of 44 patients were in CR1 or CR2 status, and 11 in relapsed or
refractory status at alloHSCT. The 3-years overall survival (OS) and progress-
free survival (PFS) for these transplanted patients was 38.6% and 24.1%,
respectively. For 52 patients achieving CR, single monosomy, de novo type of
AML, and alloHSCT at CR1 were significant good prognostic factors for relapse-
free survival. Interestingly, as shown in Figure 1, MK-AML with one single mono-
somy receiving alloHSCT at CR1 showed better prognosis (3-yr OS and DFS
rate was 64.6% and 48.1 %, respectively) 
Figure 1. Overall survival according to type of MK and treatment modali-
ties.
Summary and Conclusions: MK-AML, one of subtypes of AML accounting
for about 6 % of AML in Korea, showed dismal prognosis with lower CR rate,
PFS, and OS. However, compared to patients showing equal or more than 2
monosomy or <10% cells of normal metaphase, MK showing single monosomy
or ≥10% cells with normal metaphase showed better prognosis in our analysis.
AlloHSCT at the first CR should be strongly recommended to MK-AML patients
with better prognostic factors, and for those without, more prudent decision is
required. Furthermore, biologic mechanism of these better prognostic cytoge-
netic features should be investigated. 
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NO INCREASE IN LEVEL OF FATIGUE AMONG LONG-TERM SURVIVORS
WITH ACUTE MYELOID LEUKEMIA
Å. Derolf1,* M. Hultcrantz1, E. Brånvall1, K. Bergmark2, E. Johansson1,
M. Björkholm1
1Division of Hematology, Karolinska University Hospital, 2Department of oncol-
ogy and pathology, Karolinska Institutet, Stockholm, Sweden
Background: At least 60% of patients <40 years and about 40% of patients
41-60 years of age can expect to become long-term survivors if diagnosed with
acute myeloid leukemia (AML). These survivors are at risk of potential long-
term disease- and treatment-related side complications due to intensive
chemotherapy treatment and hematopoietic stem-cell-transplantation (HSCT).
Most studies on long-term survivors have been performed in the HSCT popu-
lation. Impaired sexual function, increased fatigue and psychological distress
have been described among patients treated with HSCT when compared to
patients receiving conventional chemotherapy only. There are few comparisons
between AML survivors and the general population.
Aims: The aim of this study was to assess the impact of AML and its treatment
on fatigue in long-term survivors in a population-based setting and with a
matched control population.
Methods: Adult AML patients diagnosed 1973-2003 within the area of the
Leukemia Group of Middle Sweden were identified in the Swedish Cancer Reg-
istry and those who died within 5 years of their diagnosis were excluded from
the study using theCauses of Death Registry. Survivors were invited to partic-
ipate by letter. Participants for the comparison group were identified through
Statistics Sweden. For each survivor, 3 controls matched for sex, year of birth
and residence were identified. Fatigue was measured using the Multi-dimen-
sional Fatigue Inventory (MFI-20), a validated instrument consisting of five sub-
scales of fatigue: general fatigue, physical fatigue, reduced motivation, reduced
activity, and mental fatigue.
Results: 161 survivors were invited to participate; 100 accepted and were includ-
ed (response rate 62%; 55 women). 150 controls accepted participation
(response rate 31 %); 96 women. 27 patients had been treated with HSCT. AML
survivors did not report a higher level of fatigue than the comparison group. We
investigated whether there were any differences in the reported fatigue levels
associated with the treatment applied. Radio therapy (i.e. total body irradiation
as part of conditioning treatment prior to HSCT) was associated with an
increased level of reduced motivation (p=0.044). When adjusting for age and
co-morbidities using a linear regression analysis, radio therapy was associated
with reduced motivation (p=0.010) and mental fatigue (p=0.044). We did not
find any association between allogeneic HSCT and increased fatigue level in
any dimension, neither in crude analyses or when adjusting for age and co-mor-
bidities. Presence of chronic graft versus host disease (GvHD) or previous recur-
rence of AML was not associated with a higher level of fatigue. Among patient
characteristics, we found a strong association between the presence of co-mor-
bidities and general fatigue, physical fatigue and reduced activity. All five fatigue
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dimensions were also associated with anxiety and depressive symptoms. There
was no difference between male and female AML survivors.
Table 1. Five dimensions of fatigue among AML survivors and comparison
group.
AML survivors Comparison group p-value* Crombach’s
median (range) median (range)
General fatigue 11.00 (4-20) 10 .00 (4-20) 0.826 0.84
Physical fatigue 10.33 (4-20) 8.00 (4-20) 0.186 0.90
Reduced activity 9.00 (4-20) 9.00 (4-20) 0.637 0.89
Reduced motivation 7.00 (4-19) 7.00 (4-18) 0.362 0.72
Mental fatigue 8.00 (4-19) 9.00 (4-20) 0.800 0.76
Summary and Conclusions: In this cohort of long-term AML survivors, most
patients were treated with chemotherapy only. After more than five years after
diagnosis, this group of survivors did not experience increased fatigue when
compared to the general population.
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LONG-TERM REPORT OF A PILOT STUDY EVALUATING CLOFARABINE
COMBINED WITH INTERMEDIATE-DOSE CYTARABINE AS CONSOLIDATION
THERAPY IN PATIENTS WITH NON-FAVORABLE ACUTE MYELOID
LEUKEMIA IN FIRST REMISSION
L. Roulin1,* N. Boissel1, K. Celli-Lebras1, M. El-Amhri2, X. Thomas2, H. Dombret1,
E. Raffoux1
1Maladies Du Sang, Hopital St Louis, Paris, 2Hematology, CHU Lyon, Lyon,
France
Background: In younger patients with AML in first complete remission (CR),
a standard consolidation option relies on repeated cycles of high-dose cytara-
bine (HDAC), according to the CALGB schedule (Mayer, NEJM, 1994). Nev-
ertheless, relapse incidence remains high, especially in those with non-favor-
able AML. Combination of 40mg/m2/d clofarabine d2-6 with 1000 mg/m2/d
cytarabine d1-5 has been associated with promising response rate in high-risk
AML patients (Faderl, Blood 2005 & 2006). 
Aims: We conducted a pilot study to assess the feasibility of this “CLARA”
combination as first CR consolidation in younger patients with non-favorable
AML and no identified donor for allogeneic stem cell transplantation (SCT). We
report here on long-term outcome and safety of this experimental approach.
Methods: Between 2004 and 2007, 23 patients aged 22 to 63 years (median,
50) with non-favorable AML in first CR (10 intermediaire I, 2 intermediaire II,
and 11 adverse risk, according to ELN classification) received 3 CLARA cycles
as consolidation, without further maintenance. All had previously received
remission induction according to ALFA-9802 protocol (Thomas, Blood). All
received oral antibacterial prophylaxis with levofloxacin or amoxicillin, but none
received anti-fungal prophylaxis.
Results: Eight patients received the planned 3 CLARA cycles; 13 patients
received only 1 or 2 cycles because either they became eligible for SCT (5
patients) or presented severe complications (8 patients). Two patients received
a reduced clofarabine dose (30 mg/m2/d) from the first cycle. Six patients are
still in CR1 (26%) with a median follow up of 59 months, including 3 non-trans-
planted patients. In addition, 2 patients are still in CR2 with a median follow-
up of 51 months. Infectious adverse events were frequently reported: 10 non
documented infections, 7 sepsis documented with Gram-negative bacteria, 12
sepsis documented with coagulase-negative staphylococcus, 2 clostridium coli-
tis, 3 viral reactivation (CMV), 7 pulmonary invasive aspergillosis (4 possible
and 3 probable, according to EORTC classification) and 1 candidemia. Two
patients required ICU hospitalization and 1 patient died from infection after the
second CLARA cycle. Liver cytolysis was also frequently reported (7 Grade III
and 7 Grade IV episodes) in 12 patients. 
Summary and Conclusions: Administration of repeated CLARA consolidation
cycles is a promising approach in younger patients with non-favorable AML in
first CR. Nevertheless high rate of infections (especially pulmonary aspergillo-
sis) led us to reduced the clofarabine dose from 40mg/m2/d to 30mg/m2/d and
to introduce systematic anti-fungal prophylaxis in the following and not yet
reported randomised ALFA-0702 trial, which compared prospectively CLARA
to HDAC consolidation in similar patients. 
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RETRO-TRANSCRIPTION LOOP MEDIATED ISOTHERMAL AMPLIFICATION
(RT-Q-LAMP) AS A RAPID AND ROBUST MOLECULAR ASSAY FOR THE
DIAGNOSTIC DETECTION OF PML-RARA FUSION TRANSCRIPTS
F. Lo Coco1, G. Minnucci2, M.D. Divona3,* F. Rigo2, E. D’Agostini2, A. Brisci2,
C. Montrasio4, G. Amicarelli2, L. Cicconi5, C. Ciardi6
1Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata, Roma,
2Molecular Diagnostics, Diasorin Spa, Gerenzano, 3Policlinico Universitario
Tor Vergata Roma, Roma, 4Molecular Diagnostics, 4Università degli Studi
Milano-Bicocca Milano, Milano, 5 Dipartimento di Biomedicina e Prevenzione,
6Dipartimento di Biomedicina e Prevenzione Roma, Università Tor Vergata,
Roma, Italy
Background: The accurate and timely molecular identification of the Acute
Promyelocytic Leukemia (APL) associated PML-RARa fusion gene is manda-
tory to confirm the morphologic suspect of APL and rapidly initiate tailored ther-
apy, thus reducing the risk of potentially fatal hemorrhagic complications. The
molecular analysis is currently based on RT-PCR or RQ-PCR assays, which
can suffer from poor quality or insufficient amount of the extracted RNA, thus
delaying the diagnosis.
Aims: Improvement of the molecular diagnosis of APL by introducing a novel
ultra rapid and reliable screening test, robust for suboptimal RNA samples.
Methods: RT-Q-LAMP PML-RARa is an innovative, isothermal, non-PCR-
based method for direct RNA amplification, extremely sensitive and specific. It
consists of two fluorescent multiplex assays: one specific for the most frequent
transcript isoforms (bcr1 and bcr3) and one for the infrequent bcr2 type. The
reaction mix of both assays contains also additional primers to detect the
endogenous GUSb housekeeping RNA as internal control. The reaction is per-
formed in 40 minutes, with the amplification of positive samples requiring about
15 minutes, into the Liaison IAM instrument (DiaSorin) at constant temperature
with a real-time monitoring of fluorescence. The data obtained are directly elab-
orated by the instrument that returns objective results and the proper discrim-
ination of the transcript type.
Results: The triplex (bcr1-bcr3-GUSb) and duplex (bcr2-GUSb) RT-Q-LAMP
assays have been tested on 33 PML-RARa positive and 20 PML-RARa neg-
ative clinical samples. In all cases RNA was extracted with the phenol-chloro-
form method and RT-PCR for PML-RARa was performed according to the
Europe Against Cancer (EAC) protocol. All RNA samples presented heavy
chemical contamination (ratio of 260/230 in the range of 0.29-0.99). In addition
we tested 7 clinical samples that didn’t produce an acceptable amplification
result for the RT-PCR, due to strong RNA degradation (n=3), inhibition (n=2),
and very low RNA amount availability (5ng/ul, n=2).The RT-Q-LAMP PML-
RARa assays correctly amplified all the 53 samples with low 260/230 ratio,
giving concordant results with those of conventional RT-PCR. Moreover, the 7
samples for which RT-PCR analysis was not possible, were all successfully
amplified with RT-Q-LAMP in less than 30 minutes.
Summary and Conclusions: The fluorescent RT-Q-LAMP assays for PML-
RARa fusion transcript detection is highly specific, sensitive and rapid. The
rapidity and specificity of RT-Q-LAMP associated with the robustness for low
concentrated and degraded samples, allow to reach a timely diagnosis in all
cases, avoiding the need for analysis repetition or new sample extraction, as
actually required by conventional RT-PCR. In addition, RT-Q-LAMP PML-RARa
assays demonstrated to be not affected by the common PCR inhibitors, allow-
ing the rapid amplification of samples presenting chemical contamination.
These features increase the confidence in the results and make the assays
suitable for even not highly specialized laboratories.
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THE ROLE OF AZACITIDINE IN THE TREATMENT OF ELDERLY PATIENTS
WITH AML - RESULTS OF A RETROSPECTIVE MULTICENTER STUDY
A. Tombak1,* M.A. Ucar1, A. Akdeniz1, E.N. Tiftik1, D. Sahin2, O.M. Akay2,
M. Yildirim3, O. Nevruz3, C. Kis4, E. Gurkan4, S. Medeni Solmaz5, M.A. Ozcan5,
R. Yildirim6, I. Berber7, M.A. Erkurt7, T. Firatli Tuglular8, P. Tarkun9,
I. Yavasoglu10, M.H. Dogu11, I. Sari11, M. Merter12, M. Ozcan12, E. Yildizhan13,
L. Kaynar13, O. Mehtap9, A. Uysal14, F. Sahin14, O. Salim15, M.A. Sungur16
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2Internal Medicine - Hematology, Eskisehir Osmangazi University, Eskisehir,
3Internal Medicine - Hematology, GATA, Ankara, 4Internal Medicine - Hematol-
ogy, Cukurova University, Adana, 5Internal Medicine - Hematology, Dokuz Eylul
University, Izmir, 6Internal Medicine - Hematology, Ataturk University, Erzurum,
7Internal Medicine - Hematology, Malatya Inonu University, Malatya, 8Internal
Medicine - Hematology, Marmara University, Istanbul, 9Internal Medicine -
Hematology, Kocaeli University, Kocaeli, 10Internal Medicine - Hematology,
Adnan Menderes University, Aydın, 11Internal Medicine - Hematology, Denizli
Pamukkale University, Denizli, 12Internal Medicine - Hematology, Ankara Uni-
versity, Ankara, 13Internal Medicine - Hematology, Kayseri Erciyes University,
Kayseri, 14Internal Medicine - Hematology, Ege University, Izmir, 15Internal
Medicine - Hematology, Akdeniz University, Antalya, 16Internal Medicine -
Hematology, Duzce University, Duzce, Turkey
Background: Older patients with AML have significant comorbidities, poorer
performance status.Overall results of intensive chemotherapy remain
poor.Azacitidine (AZA) has significant activity in MDS.Use of AZA was associ-
ated with improved OS when compared to low dose cytarabine in patients with
high risk MDS, including those with marrow blast counts ranging from 20 to
30%. In untreated or relapsed/refractory AML, few studies have also shown
significant response rates of AZA.However, there is limited data showing effi-
cacy of AZA in AML patients with >30% bone marrow (BM) blasts.
Aims: In this retrospective multicenter study, we aimed to investigate the effi-
cacy and safety of AZA in elderly patients with AML (including patients with
>30% BM blasts) defined according to WHO.
Methods: Between 2009-2014,≥60 year-old patients with AML from 16 centers
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in Turkey were included.Eligibility criteria included ≥60 years-old AML patients
treated with at least one dose of AZA.Demographic data, comorbidities, ECOG
status, transfusion-dependency, cytogenetic risk status, blast ratios, treatment
prior to AZA, adverse events, treatment responses were recorded.Assessment
of response was performed after 4 cycles.
Results: 130 patients (72 men) receiving AZA were included into study.Median
age was 73 (60-88 years).ECOG performance status (ECOG-PS) was ≥2 in
54.6%, there were comorbidities in 66.2% of cases (89.5% had <3 comorbidi-
ties).LDH was ≥225 IU/L in %75.4 and 40.8% had WBC count>10x109/L/mm3.
80 patients (61.5%) had >30% BM blasts.112 patients were transfusion-depen-
dent. 50.8% had an intermediate karyotype.Patients received AZA for a median
of 4 cycles (range 1-21). Initial ORR (including complete remission CR/CRi/PR)
was 36.2%. Any hematologic improvement (HI) was documented in 37.7%.HI
was also documented in 27.1% of patients who were unresponsive to treat-
ment.Median overall OS was 18 months for responders, 12 months for non-
responders (p=0.005).In unresponsive patient group, any HI has also improved
OS compared to patients without any HI (median OS was 14 months versus 10
months, p=0.068).In univariate analysis of following parameters had significant
effect on both treatment response and OS: ECOG-PS, number of AZA cycles
and any HI. ECOG-PS≥2 was associated with a worse response to AZA (29.7%
versus 53.2%, p=0.012) and with a worse OS (10 [95% CI 8.1-11.9] months
versus 14.1 [95% CI 7.8-20.3] months,p=0.034).In patients receiving ≥5 courses
of AZA versus <5 courses, response rate and OS were higher (61.9% versus
28%, p<0.001 and 14.1 [95% CI 8.5-19.6] months versus 9 [95% CI 4.0-14.0]
months,p=0.011, respectively).Response rate and OS increased with any HI
versus without any HI (59.6% versus 27.1%,p<0.001 and 18 [95% CI 10.0-26.0]
months versus 10 [95% CI 5.1-14.9] months,p=0.002).OS was higher in patients
with LDH<225 IU/L compared to patients with LDH≥225 IU/L (19 [95% CI 12.1-
25.9] months and 11 [95% CI 8.6-13.4] months, respectively,p=0.018), but LDH
level had no impact on treatment response (ORR is 38.5% versus 41.9% for
LDH</≥225 IU/L, respectively,p=0.758).Transfusion-dependence prior to AZA
was associated with a worse response to AZA (36.3% versus 66.7%,p=0.025)
and with reduced OS, which was however not statistically significant (12.3 [95%
CI 9.8-14.8] months versus 20 [95% CI 4.2-35.9] months,p=0.077).ECOG<2,
increasing number of AZA cycles (≥5 courses) and any HI predicted better OS
(Figure1). Age, AML type, BM percentage had no impact.Grade 3-4 neutropenia,
thrombocytopenia anemia were documented in 34.6%,40.8%,39.2% of patients,
respectively.Non-hematologic toxicities were mild;most common adverse events
being mucositis, injection site pain, nausea.
Figure 1.
Summary and Conclusions: In conclusion; AZA is effective and well tolerated
in elderly, comorbid AML patients with fewer required erythrocyte and platelet
transfusions, irrespective of BM blast count. And HI should be considered suf-
ficient response to continue treatment and treatment should not be interrupted
since OS and response to treatment increase with the increasing number of
AZA cycles.
E939
CORE-BINDING FACTOR IN CHILDHOOD ACUTE MYELOID LEUKEMIA
O. Kassar1,* M. charfi1, F. kallel1, M. ghorbel1, M. mdhaffar1, N. abdejellil2,
H. bellaaj1, S. hdijji1, T. ben othmen2, M. elloumi1
1Hematology, University Sfax, Sfax, 2Bone Marrow Transplantation Center,
University Tunis, Tunis, Tunisia
Background: Core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21]
or inv[16]/t[16;16]) represents a favorable cytogenetic AML subgroup and have
favorable prognosis
Aims: We reported the results of therapeutic and prognostic pediatric AML with
rearrangement of CBF genes in a single center from Tunisia.
Methods: Our study is retrospective; it concerned patients under 20 years with
AML with rearrangement of CBF genes de novo during the period between
January 2006 and December 2013.The treatment protocol includes: a course
of 7 +3 induction ( Arac200mg/m2/day+DNR60mg/m2/day) followed in case of
complete remission (CR) by 3 courses of consolidation: *1st course: Arac
6g/m2/day (3d) +Mitoxantrone12mg/m2/day(3d), 2nd course:
Arac200mg/m2/day (7d) +DNR50mg/m2/day VP16100mg/m2/day (5d) * 3rd
course: Arac 6g/m2/day (3d) +L-asparaginase 6000UI/m2 in day 5. Allogenic
bone marrow transplantation is indicated for patients who have a HLA-compat-
ible family donor. Kaplan-Meier method is used to estimate overall survival
(OS) and event-free survival (EFS).
Results: Of the 33 patients under 20 year with acute myeloid, 10 patients
(33%) enrolled in our study with CBF genes. The sex ratio is 1,5. The mean
age is 12 years [6 -18 years]. Distribution according to the FAB classification is
as followed: 8 patients with AML2, 1 patient with AML4 and 1 patient with AML6.
Cytogenetic abnormalities are found in 9 cases and 1 case have normal kary-
otype. Eight patients (80%) have t(8,21), one patient has inv 16 and one case
has normal karyotype with positive CBF tanscript. Complete remission rate
(RC) is 100%, relapse rate is 30 %. The bone marrow transplantation was per-
formed in one patient in RC1. A second remission is achieved in 2 patients
(67%). Overall survival, event-free survival and relapse-free survival at 5 years
are respectively 89% and 65,5%. 
Summary and Conclusions: The cytogenetic t(8;21) is predominant in CBF
AML in our series (80%). Childhood CBF- AML are associated with a high CR
rate and a good long-term prognosis in our series similar the literature.
E940
PROGNOSATIC RISK SCORE FOR HAEMORRHAGIC EARLY DEATH IN
ACUTE PROMYELOCYTIC LEUKEMIA
M. Mitrovic1,2,* N. Suvajdzic1,2, A. Novkovic3, I. Djunic1, A. Vidovic1,2,
M. Virijevic1, N. Colovic1,2, I. Elezovic1,2, D. Tomin1,2
1Clinic of Hematology, Clinical Center of Serbia, 2Faculty of Medicine, University
of Belgrade, 33. Clinical Hospital Center Zemun,, Belgrade, Serbia
Background: Hemorrhagic early death (HED), w
ith reported rates between 5 and 26.52%, is a major impediment in the man-
aging of acute promyelocytic leukemia (APL). Although previous studies iden-
tified several prognostic factors for HED such as poor performance status (PS),
high white blood cell (WBC) count, high peripheral blast count, serum lactate
dehydrogenase (LDH), low fibrinogen level, platelet count and prolonged pro-
thrombin time (PT), a predictive model for HED has not yet been elaborated. 
Aims: To identify factors predictive of HED and to develop prognostic scoring
system.
Methods: We analyzed data on HED in 85 newly diagnosed PML-RARA positive
APL patients (median age 45 years, range 18-78; 36/49 female/male ratio) man-
aged in the Clinic of Hematology from 2004 to 2014 with all-trans retinoic acid
combined with anthracyclines. Central nervous system (CNS), retinal, pulmonary
or gastrointestinal haemorrhages were considered a severe bleeding event. HED
was defined as death from hemorrhage from the first day of hospitalization up to
the end of the induction treatment. The following parameters were evaluated as
risk factors for HED: age, ECOG PS, patient’s (time from the first symptoms to
seeking medical care), medical (time from the first medical contact to ATRA initi-
ation) and treatment delay (time from hospitalization to ATRA initiation), severe
bleeding, WBC count, peripheral blast count, platelet count, fibrinogen level, PT,
D dimer, ISTH DIC score, morphological disease type, CD15 and CD56 positivity,
additional cytogenetic abnormalities, PML-RARA isoforms and FLT3-ITD muta-
tion. Pearson chi test and Fisher test were used to analyze differences for cate-
gorical data. For multivariate analysis a binary logistic regression model was con-
structed for EHD adjusting for 6 variables. A backwards elimination procedure
was used to exclude redundant or unnecessary variables. Integer weights for
the risk score were derived from logistic regression model. Prognostic score was
validated via 10-fold cross validation.
Results: HED occured in 12/85 (14.12%) patients. Predictors of HED in uni-
variate analysis were: ECOG PS ≥2 (P=0.010), severe bleeding at diagnosis
(P=0.023), WBC >20x109/L (P=0.015), fibrinogen level <2 g/L (P=0.05), PT
<50% (P=0.005), and ISTH DIC score ≥7 (P=0.031) as the most statistically
significant cutoff points. Independent risk factors in multivariate analysis were:
severe bleeding at diagnosis (P=0.041), WBC >20x109/L (P=0.018) and ISTH
DIC score ≥7 (P=0.024). A clinical prognostic scoring system was then devel-
oped: absence of severe bleeding at diagnosis, WBC <20x109/L, ISTH DIC
score <7=0, WBC ≥20x109/L=1 point and ITSH DIC score ≥7=2 points. Accord-
ingly patients were classified in three groups: low risk=0 points, intermediate=1-
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2 points and high risk ≥3 points. The HED rate between these groups (low
2.4%, intermediate 26.1% and high 100%) was significantly different (p<0.001).
Summary and Conclusions: The prognostic model developed in this study
allows for the identification of the patients at high risk for HED, needing more
aggressive supportive measures. Further large population-based studies for
testing new score systems and refinements therapeutic approaches for APL
patients in high HED risk are needed. 
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THERAPY-RELATED ACUTE MYELOID LEUKEMIA IN ADULTS: IS AGE
YOUNGER THAN 40 CLINICALLY RELEVANT?
F. Rosenblum1, V. Parekh1, V. Reddy1, D. Peker1,*
1University of Alabama at Birmingham, Birmingham, United States
Background: Therapy-related myeloid neoplasms (t-MN) occur as the com-
plication of chemotherapy (CT) and/or radiation therapy (RT), and account for
approximately 10 to 20% of all cases of myeloid neoplasm in adults. t-MN rep-
resent distinct clinical entities, confer a worse prognosis when compared to de
novo counterparts and have a high prevalence of adverse-risk karyotypes. One
of the most serious entities comprising t-MN is therapy-related acute myeloid
leukemia (t-AML).
Aims: Most of the studies published in the past have focused on elder patients,
so we aim to investigate the features of t-AML in patients younger than 40
years of age as compared to their older counterparts.
Methods: A retrospective review of cases encountered between 2003 and
2013 was performed following IRB approval. All cases of AML with a prior his-
tory of CT/RT were included in the study (n=70). The clinical data including
age, sex, medical history and the time interval between the treatment for prior
solid or hematologic malignancy and the development of t-AML were recorded.
Cytogenetic, molecular and/or FISH data for t-AML were available for sixty-
one patients. The cases were divided into two groups. Group 1 consisted of t-
AML patients 40 years of age or younger and Group 2 consisted of patients
older than 40. A survival analysis was performed.
Results: Table 1 shows the summary of characteristics for groups 1 and 2.
Group 1 included 12 cases with a median age of 32 (20-40 years) and the M:F
ratio of 0.5. In this group, the most frequent prior malignancy was hematologic
cancers (n=5, 42%); Hodgkin lymphoma being the most common, followed by
sarcomas majority of which are Ewing sarcomas (n=3, 25%). Cytogenetic find-
ings were abnormal in 10 of 12 patients (83%), with MLL gene anomalies being
the most common finding (n=5, 42%), followed by 7q deletion (n=4, 33%).
Group 2 consisted of 58 cases with a median age of 61 (41-86 years) and the
M:F ratio of 0.7. In this group, the most frequent prior solid and hematologic
malignances were breast cancer (n=19, 33%) and follicular lymphoma (n=9,
16%), respectively. Cytogenetics and FISH (combined) revealed 7q deletion
as the most frequent abnormality (n=16, 28%) followed by MLL gene abnor-
malities (n=9, 16%). NPM1 and FLT3 internal tandem duplications were found
in 5% of cases. The median interval between the last CT/RT and diagnosis of
t-AML for groups 1 and 2 were not significantly different; 47 and 36 months,
respectively. There was no significant difference in cell counts or bone marrow
blast counts. The OS in two groups were significantly different; 28 vs. 9 months
in Groups 1 and 2, respectively (p <0.05) (Figure 1). There was no significant
difference in OS between patients >60 and =<60 years old; 8 vs. 9 months,
respectively (p=0.225).
Figure 1. Survival analysis between Group 1 and Group 2.
Summary and Conclusions: The results of the current study show that age
is an important prognostic factor regardless of the karyotypic abnormalities. In
the two groups we analyzed, group 1 (=<40 years) showed more frequent
association with poor prognostic karyotype when compared to group 2 (>40
years). There was no significant difference between two groups with regards
to interval between prior treatment and t-AML, cell counts or blast count. t-
AML being a dire complication in patients treated with cytotoxic therapy, prog-
nostication is important to accurately predict the outcome in this group. Large
scale studies are warranted to investigate other prognostic factors in addition
to cytogenetic sub-classifications.
Tabella 1. Summary of patient char acter ist ics and outcomes.
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AZACYTIDINE THERAPY IN PREVIOUSLY UNTREATED ELDERLY AML
PATIENTS: COMPARISON WITH CONVENTIONAL CHEMOTHERAPY IN A
MATCHED-PAIRED ANALYSIS
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L. Mitscheunig1, L. Del Corso2, A. Bellodi2, E. Balleari2, M. Miglino1,
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Genoa, 2Chair of Internal Medicine, Department of Internal Medicine (DiMI),
University of Genoa, IRCSS AOU San Martino-IST, Genoa, Italy
Background: The hypomethylating agent azacytidine (AZA) is increasingly
used in acute myeloid leukemia patients (AML) with low marrow blast count or
in elderly patients who are not eligible for intensive chemotherapy. We recently
performed a retrospective analysis of AZA front line treatment in elderly AML
patients and reported its efficacy and feasibility.
Aims: The aim of the present study was to compare the outcome of untreated
elderly AML patients receiving AZA or conventional chemotherap by performing
a matched-paired analysis.
Methods: We retrospectively analyzed the outcome of 42 elderly AML patients
who received AZA as front line treatment in our Centre from June 2010 to
December 2014. A control series of patients treated with conventional
chemotherapy was selected through a matched-paired analysis. Matching vari-
ables were white blood cells count at diagnosis, age, karyotype, disease onset
and sex. No significant differences were appreciable for those variables, where-
as median age was significantly higher in AZA cohort than in FLAI-3 cohort (74
yy and 70 yy, respectively, p <0.05). Relevant comorbidities (diabetes mellitus,
heart disease, hypertension, liver or lung diseases) were present in 70% of
patients receiving AZA. AZA was delivered at the dosage of 75 mg/sqm s.c.
with a 5+2 days schedule. Patients were given a median of 4 courses of treat-
ment (range 1-27). Twenty-five patients (75%) received concomitant recombi-
nant alpha erythropoietin therapy (40000 U once weekly). AZA therapy was
continued until unacceptable toxicity or disease progression, regardless of
response achieved. Conventional treatment consisted in a fludarabine-con-
taining regimen with age-adjusted doses (FLAI-3 schedule: fludarabine 25
mg/mq, cytarabine 1000 mg/mq, idarubicin 5 mg/mq, days 1,2,3). 
Results: Major infection during therapy were observed in 20/42 (47.6%) patients
in AZA group and 15/42 (35.7%) in FLAI-3 group (p=0.356). Four and two patients
died during induction in AZA and FLAI-3 group, respectively. Complete remission
(CR) rates were significantly lower in AZA-treated patients (7/38, 18%), compared
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to FLAI-3 (21/40, 53%) (p=0.002). Sex, disease onset, karyotype, WBC count
and age did not significantly influence CR rates in neither of the two cohorts. Of
note, none of the nine patients treated with AZA who presented with leukocytosis
achieved CR, compared with 6/15 (40%) patients in the FLAI-3 cohort. However,
this did not translate in a significant lower OS for patients with leukocytosis treated
with AZA (2yy OS 50.4% and 24.2% for patients with WBC count lower or higher
than 10.000/mmc, respectively, p=0,120). After a median follow-up of 25 months,
2-years overall survival (OS) was 36.2% in AZA group (median 14 months), sig-
nificantly higher than FLAI-3 group (11.2%, median 9 months, p=0.048, Figure1).
OS duration was significantly influenced only by achievement of CR in FLAI-3
cohort (p=0.000), whereas in AZA cohort was influenced only by younger age at
diagnosis (p=0.048). Achievement of CR had only a borderline effect on OS dura-
tion in AZA cohort (p=0.050).
Figure 1. Overall survival according to treatment.
Summary and Conclusions: AZA was generally well tolerated, with acceptable
toxicity profile, even in our cohort of very frail untreated AML patients. Even if
CR rates were significantly lower when compared to a matched-paired cohort
of conventionally-treated patients, OS rate were not inferior. Our data suggest
that Azacytidine is a safe first-line therapy for frail AML patients, with comparable
effectiveness with conventional intensive chemotherapy. 
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COMBINATION OF CLOFARABINE AND CYTARABINE IN THE
TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID
LEUKEMIA
B. Spassov1,* G. Balatzenko2, S. Angelova2, S. Toshkov2, M. Guenova3,
G. Arnaudov4, G. Mihaylov1
1Department of Clinical Hematology, 2Laboratory of Cytogenetics and Molecular
Biology, 3Laboratory of Hematopathology and Immunology, 4Department of
Stem Cell Transplantation, National Specialized Hospital for Active Treatment
of Hematological Diseases, Sofia, Bulgaria
Background: The use of combination chemotherapy is effective and curative
in some patients with acute myeloid leukemia (AML). However, some of the
newly diagnosed AML patients fail to achieve complete remission (CR) because
of resistance to treatment and 40% of CR patients will relapse within 2 years.
The prognosis of patients with primary refractory or relapsed AML is generally
unfavourable, with salvage chemotherapy giving a remission rate of merely
10–40%. Clofarabine is a new generation deoxyadenosine analog that has
shown some activity in relapsed or refractory AML. Because of the structural
similarity between purine analogues, a putative synergism between clofarabine
and cytarabine has been postulated. However data regarding efficacy and safe-
ty of clofarabine and cytarabine combination therapy in refractory and relapsed
AML patients is limited.
Aims: To examine the efficacy and safety of sequential clofarabine and high
dose cytarabine in adult patients with relapsed or refractory AML.
Methods: Data from 35 refractory or relapsed AML patients, at a median age
of 39.4 years (range, 21-60 years), diagnosed between 2010 and 2014, were
evaluated retrospectively. Clofarabine was administered as a 1-hour intra-
venous infusion at a dose of 40 mg/m2 daily for 5 consecutive days on days 2
through 6 followed 4 hours later by cytarabine at a dose of 1 or 2 g/m2 as a 2-
hour intravenous infusion daily for 5 consecutive days on days 1 through 5. On
day 1, only cytarabine was administered, and on day 6, only clofarabine was
given. Patients who achieved CR received further consolidation chemotherapy
with intermediate- (1.5 g/m2 every 12 h for six doses) or high-dose cytarabine
(3 g/m2 every 12 h for six doses) or allogeneic hematopoietic stem cell trans-
plantation (HSCT).
Results: All the patients had received at least one prior regimen. There were
29 primary refractory and 6 relapsed cases. Cytogenetic analysis was per-
formed in 91.4% (32/35) of the patients. Twenty one patients (65.6%) had inter-
mediate cytogenetic risk, whereas favorable and unfavorable cytogenetic find-
ings were detected in 3 (9.4%) and 8 (25%), respectively. Internal tandem dupli-
cations of FLT3 gene (FLT3-ITD) were found in 8 patients (22.9%). Eighteen
patients (51.4%) achieved CR, whereas thirteen patients (37.1%) had resistant
disease, and 4 (11.4%) died during induction. CR was achieved in 9 (60%)
patients with diploid cytogenetics whereas CR was observed in 3 (100%) and
1 (12.5%) patient with favorable and unfavorable cytogenetic findings, respec-
tively. Patients with FLT3-ITD achieved CR in 50% (4/8) of the cases. In patients
with CR, 55.6% (10/18) were able to proceed to allogeneic HSCT. The 24 month
overall survival (OS) for the whole patients’ cohort was 28.8%. For CR patients,
the 24 month OS and disease-free survival (DFS) were 33.8% and 40.8%,
respectively.
Summary and Conclusions: Clofarabine in combination with cytarabine is
effective in refractory and relapsed AML patients. In addition, it represents a
useful remission induction strategy to serve as a bridge to transplantation in
these patients.
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PROGNOSTIC IMPACT OF WT1 GENE EXPRESSION QUANTIFICATION
DURING MINIMAL RESIDUAL DISEASE MONITORING OF ACUTE
PROMYELOCYTIC LEUKEMIA
M. Mitrovic1,2,*, N. Tosic3, N. Suvajdzic1,2, I. Djunic1, A. Vidovic1,2, M. Virijevic1,
N. Colovic1,2, I. Glumac3, T. Kostic3, S. Pavlovic3, I. Elezovic1,2, D. Tomin1,2
1Clinic of Hematology, Clinical Center of Serbia, 2Faculty of Medicine, University
of Belgrade, 3Institute of Molecular Genetics and Genetic Engineering, Bel-
grade, Serbia
Background: Acute promyelocytic leukemia (APL) is characterized by the high-
est Wilms tumor gene 1 (WT1) expression levels in comparison to other types
of acute myeloid leukemia (AML). Several studies have reported the usefulness
of WT1 expression assessment as a molecular marker of minimal residual dis-
ease (MRD) in AML patients. However, data on prognostic significance of WT1
gene expression during MRD monitoring of APL is lacking.
Aims: To quantify WR1 gene expression during MRD monitoring of APL
patients
Methods: Data on WT1 expression in 22 de novo PML-RARA positive APL
patients were analyzed prospectively (median age 42 years; female/male ratio
12/10; median WBC count 1.5 x109/L (range: 0.4-88), median follow-up of 27
months (range: 5-78)). The patients were managed with all-trans retinoic acid
combined with anthracyclines. Fresh bone marrow (BM) samples were collected
at diagnosis, after the first consolidation and after that every six months. WT1
expression levels were quantified by RQ-PCR method, using TaqMan chemistry.
Abl served as a housekeeping gene. Relative quantification analysis was per-
formed using comparative Ct method (2-ddCt), where ddCt=dCt(sample) -
dCt(healthy(median)). A WT1 level of at least twice the maximum assessed in
healthy controls was defined as WT1 overexpression (≥18.00).
Results: A total of 89 BM samples were collected during diagnosis and fol-
low-up. Initially WT1 level was significantly higher in APL patients compared
to healthy controls (mean 3765.99, range 13.64-13988.95vs. 1.95±1.18, range
0.06-8.77, p<0,001), with overexpression in 21/22 (95.45%) of patients. After
first consolidation all patients reached molecular remission (MR). In 15/22
(68.18) patients MR was accompanied by WT1 levels ≥3 log reduction, in 4/22
(18.18%) by ≥2 log reduction and 1/21 (4.54%) <1 log reduction. Median WT1
gene expression after first consolidation was 24.34 (range: 0.95-72), with over-
expression in 6/22 (27%) patients. Six relapses (5 molecular) was observed
in 4/22 (18.18%) patients. The increase in WT1 expression was observed in
all samples during relapse (>1.5 log in 2/6 relapses (30%), >1 log in 3/6 (50%)
and <1 log in 1/6 (16.67%)) with mean level of 274.07 (range: 11.93- 1327.96).
Increased WT1 expression was combined with PML-RARA positivity in 5/6
(83.3%) samples. In one case WT1 level increment was registered 6 months
before PML-RARA positivity. Mean WT1 expression in patient with persistent
MR was 21.17 (range: 3.34-59.76), with high level of variability and overex-
pression in 11/30 (36.7%) samples. However WT1 expression increment >1
log wasn’t seen in patients with persistent MR. APL relapses were significantly
associated with WT1 overexpression after first consolidation (3/4 (75%) vs
3/18 (16.67%), p=0,003), and >1 log WT1 expression increment during fol-
low-up (5/6 (83.3%) vs 0, p=0,0001). No correlation was found with initial WT
expression level (2471/7 vs 3994/51, p=0,516).
Summary and Conclusions: 1. WT1 decreased rapidly after induction but
maintained residual levels in MR 2. WT1 expression was able to detect patients
at high risk of relapse 3. Quantitative analysis of WT1 as post-remission control
enables early detection of relapse. Further large prospective trials should eval-
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uate whether this parameter should be included in risk stratification and MRD
monitoring.
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CCAAT/ENHANCER BINDING PROTEIN ALPHA (CEBPA) NEW
MUTATIONS IDENTIFIED BY THE HEMATOLOGY OF FLORENCE 
V. Ponziani1,* F. pancani2, F. mannelli2, B. scappini2, S. di lorenzo1, A. bosi1
1hematology, 2careggi hospital, florence, Italy
Background: CCAAT/enhancer binding protein alpha (CEBPA) is a transcrip-
tion factor involved in lineage specification; it is crucial for the development of
myeloid progenitors to differentiated neutrophils. Mutations in CEBPA gene are
specific to AML and are not reported in other cancers. They are detected in 5-
14% of cytogenetically normal AML patients (CN-AML). Typical alterations
affect either the N-terminus with nonsense mutations leading to a dominant
negative protein, and/or C-terminus resulting in decreased DNA binding of
basic leucine zipper (bZIP) region. Several studies show that a single mutation
in CEBPA (CEBPAsm) is prognostically neutral, whereas double mutations
(CEBPAdm) have been associated with a relatively favourable outcome and
therefore are emerging as a prognostic marker at the diagnosis. In the majority
of CEBPAdm AML, the mutations are typically on different alleles and involve
a combination of a N-terminal and a C-terminal mutation.
Aims: In order to obtain a better insight into the distribution of the various types
of CEBPA mutations and evaluate their impact on clinical outcome, we
screened for CEBPA a cohort of 230 de novo AML patients.
Methods: We analysed the entire coding region of CEBPA using three over-
lapping PCR primer pairs designed by Pabst et al. (2001) with minor modifica-
tions. PCR products were sequenced in both directions on ABI-3100 Genetic
Analyzer (Applied Biosystems).
Results: By sequencing the entire CEBPA coding region, we identified a total
of 33 mutations in 23 patients (10%) in our cohort of 230 patients de novo CN-
AML. Within them, 10 patients had biallelic mutations (CEBPAdm) while 13
patients had single CEBPA mutation. Among these 33 mutations detected, 16
were already identified in previous studies, while the others (listed in table 1)
had not been described before. The results can be summarized as follows: 8
of the 17 alterations described were frameshift mutations, 8 were
insertions/duplications in-frame, 1 was a missense point mutation. According
to literature data, insertions/deletions mutations (3n+1 bp) out-of-frame were
concentrated in N-terminal region causing frameshift in the reading sequence
and involving the formation of a new stop codon. All new mutations identified
in the C-terminal region were in-frame and occurred between AA 301 and AA
318. We observed in four cases a “de novo” nucleotides insertion, while all the
other patients showed long existing sequences duplication to 36 bp. Patient #
9 showed a nonsense nucleotide substitution in position 992 of the C-terminus,
in which an thymine was replaced by a cytosine, corresponding to an Isoleucine
Proline amino acid substitution (I with P), creating a novel stop codon.
Summary and Conclusions: In this analysis on a cohort of 230 de novo AML
we identified 18 new CEBPA mutations not described before. Due to the rele-
vant role of CEBPA in leukemogenesis, the identification of novel mutations
aids to get more insight into the biology and prognosis of CEBPA-mutated AML
subset. A longer follow up is necessary to evaluate the impact of CEPBAdm
and particularly of these new mutation on the clinical outcome.
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CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS IN
PATIENTS WITH ACUTE MYELOID LEUKEMIA: RISK FACTORS,
TREATMENT AND OUTCOME
I. Djunic1,* N. Suvajdzic-Vukovic2, M. Virijevic1, N. Kraguljac-Kurtovic3,
V. Knezevic3, M. Mitrovic2, A. Novkovic4, N. Colovic5, A. Vidovic5, D. Tomin5
1Department of acute leukemias, Clinic For Hematology, Clinical Center Of
Serbia, 2Clinic For Hematology, Clinical Center of Serbia, Medical Faculty of
Belgrade University, 3Laboratoty for imunoflowcytometry, Clinic For Hematol-
ogy, Clinical Center Of Serbia, 4Clinical Hospital Center “Zemun”, 5Department
of acute leukemias, Clinic For Hematology, Clinical Center of Serbia, Medical
Faculty of Belgrade University, Belgrade, Serbia
Background: Central nervous system (CNS) involvement at diagnosis of acute
myeloid leukemia (AML) occurs in less then 5% of patients. It is rare but serious
complication of AML with significant influence on poor outcome of these
patients. Due to infrequency of CNS involvement (CNS+) in AML there is a
paucity of literature on the optimal management of CNS disease.
Aims: The aims of this investigation were to estimate the incidence of CNS+at
diagnosis AML, to determine risk factors for its occurrence and to define influ-
ence of CNS+on outcome of these patients: rate of complete remission (CR)
and remission of CNS+, relaps-free survival (RFS) and overall survival (OS).
Methods: This single-center study involved 402 adult patients with nonpromye-
locytic de novo AML during follow-up of 72 months. The following parameters
were estimated as risk factors for CNS+at diagnosis of AML: age, WBC
(<30x109/L vs ≥30x109/L), serum lactate dehydrogenase (LDH) concentration
>1.5x the upper limit of normal, expression of CD56 antigen on leukemic blasts
(<20% vs ≥20%), AML subtype according to the French-American-British (FAB)
Cooperative Group and cytogenetic risk group (assessed according to Euro-
pean LeukemiaNet recommendations). The presence of leukemic cells in cere-
brospinal fluid (CSF) detected by cytomorphological and/or flow cytometric
analysis of CSF is considered as CNS involvement. Patients were treated
according with follow chemotherapy (CT): induction CT ( daunorubicin 60
mg/m2 three days and 7 days cytarabin 200 mg/m2) following three CT of con-
solidations (high dose of cytarabine, eg. 3 g/m2 every 12 h on day 1,3,5). In
patients aged >60 years doses of induction CT were reduced for 50% and as
consolidations CT were applied cytarabine in intermediate dose (1.5 g/m2 day
1 to 3). Patients aged >75 years treated with paliative therapy (Hydroxiurea or
6-mercaptopurine per os). Patients with CNS+treated with intrathecal (i.t.) CT:
cytarabine 100 mg 2 x/week until clear of CSF. Patients who no achived remis-
sion of CNS+treated with radiotherapy of CNS with 18-24 Gy in total dose.
Assesment of remission of CNS+was performed after 8 i.t. CT.
Results: The CNS+was recorded in 4.7% (19 pts) of AML patients at diagnosis.
The mean age of CNS+patiens was 48 years (range 26-71 years) while the
mean age of CNS negative (CNS-) patients was 58 years (range 19-85 yeras).
Multivariate analysis identified CD56+as the most important risk factor for
CNS+at diagnosis in AML patients: p=0.001, relative risk (RR)=18.241; 95%
confidental interval (CI)=3.305-100.675. In group of CNS+patients, the CR rate
was 68% (13 pts) while CNS remission rate was 16% (3 pts). RFS was signif-
icance different among CNS+and CNS- patients: 8 vs 20 months (p=0.001),
as well as OS: 6 vs 18 months (p=0.002). Multivariate analysis indicated
CNS+as the most significant independent predictor of poor RFS: p=0.002,
RR=1.806, CI=1.241-2.628, and OS: p=0.008, RR=1.592, CI=1.130-2.243.
Summary and Conclusions: AML patients with CNS involvement at diagnosis
have a poor prognosis and further studies need to improved and optimized
their treatment.
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PHASE 1 STUDY: SAFETY AND TOLERABILITY OF INCREASING DOSES
OF CB-839, AN ORALLY-ADMINISTERED SMALL MOLECULE INHIBITOR
OF GLUTAMINASE, IN ACUTE LEUKEMIA
M.Y. Konopleva1,* I.W. Flinn2, E.S. Wang3, C.D. DiNardo1, M.K. Bennett4,
C.J. Molineaux4, M.H. Le4, M.B. Maris5, O. Frankfurt6
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Calithera Biosciences, Inc., South San Francisco, CA, 5Transplant Physician,
Colorado Blood Cancer Institute, Denver, CO, 6Dept of Medicine-
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Background: Glutaminase is a proposed tumor metabolism target implicated
in the growth and survival of a variety of tumor types. The enzyme is essential
to the utilization of glutamine by many tumor cells, converting incoming glutamine
to glutamate for use in the TCA cycle and for production of glutathione and
many other cellular constituents. Glutaminase is highly expressed in primary
tumors, including acute myeloid leukemia (AML). CB-839 is a highly selective,
reversible, allosteric inhibitor of glutaminase. Preclinial studies have demon-
strated in vitro and in vivo anti-tumor activity across a broad array of solid and
hematological tumor types and the compound was well tolerated in animals.
Aims: CX-839-003 is an ongoing Phase 1 study of escalating doses of CB-
839 in acute leukemia patients to evaluate safety and tolerability, and to identify
a recommended Phase 2 dose (R2PD) of the compound. Pharmacokinetics
(PK) and pharmacodynamics (PD) of CB-839, as well as an exploration of bio-
markers of tumor sensitivity, are being evaluated.
Methods: CB-839 was administered orally continuously in 21-day treatment
cycles from 100 to 1000 mg three times daily (TID) to patients with relapsed
and/or treatment-refractory acute leukemia. The plasma pharmacokinetics of
CB-839 was determined after the first dose given on Days 1 and 15. At the
RP2D, 11 patients will be enrolled in disease-specific treatment cohorts includ-
ing AML; additional patients will be added if there are responses.
Results: 15 patients enrolled during dose escalation have received CB-839
with doses up to 1000 mg TID. The steady state plasma concentration of CB-
839 on Day 15 was found to be above 250 nM continuously in most patients
using doses of 600 mg TID and higher. In a companion solid tumor trial, CX-
839-001, this plasma concentration was determined to result in >85% inhibition
of glutaminase activity in platelets and 75% in solid tumors. Peripheral blood
mononuclear cells (PBMCs) from three patients treated with 600, 800, and
1000 mg TID on the current trial were found to have between 10 and 58%
leukemic blast counts and showed >94% inhibition of glutaminase activity.
CB-839 has been administered TID 1 hr before breakfast, at 3 pm, and prior
to bedtime in all patients thus far. An increase in exposure was demonstrated
with increasing dose. When CB-839 was administered at 600 mg BID with food
in CX-839-001, the Cmax was reached in 2-6 hr; trough drug levels exceeding
450 nM in all patients. This schedule of administration will be employed for all
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patients going forward in this trial. There were no DLTs identified in this trial
and treatment-related AEs (all grades) that occurred in >10% of patients were
limited to increases in transaminases (4 patients) and bilirubin (2 patients).
There were no Grade ≥3 AEs that were considered treatment-related in >10%
of patients. Stable Disease (SD) for 4 – 10 cycles was observed in 5 (33%) of
15 efficacy-evaluable AML patients across all dose levels, with patients remain-
ing on study for an average of 134 days (>6 cycles). One of these patients
achieved a Complete Response in the bone marrow with incomplete recovery
of peripheral counts (CRi) after 6 cycles of dosing; therefore, enrollment will
continue with additional patients in the expansion cohort. All of these patients
with SD or better were >65 years of age and not eligible for high dose therapy.
Summary and Conclusions: The glutaminase inhibitor CB-839 is well toler-
ated in AML patients using doses up to 1000 mg TID. One CRi was observed
and 33% of patients enrolled during dose escalation showed stable disease
that was prolonged for 4-10 cycles. This trial will continue to enroll at the expan-
sion phase.
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PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EVALUATION OF
AG-221, A POTENT MUTANT IDH2 INHIBITOR, FROM A PHASE 1 TRIAL
OF PATIENTS WITH IDH2-MUTATION POSITIVE HEMATOLOGIC
MALIGNANCIES
B. Fan1,* Y. Chen1, F. Wang1, K. Yen1, L. Utley1, C. Almon1, K. Straley1, E.
Attar1, C. Bowden1, S. Biller1, S. Agresta1, H. Yang1
1Agios Pharmaceuticals, Cambridge, United States
Background: The isocitrate dehydrogenase 1/2 (IDH1/2) enzymes catalyze
the production of alpha-ketoglutarate (α-KG) from isocitrate. Mutant IDH1/2
enzymes are capable of novel enzymatic production of D-2-hydroxyglutarate
(2-HG) from α-KG. 2-HG is an oncometabolite implicated in cancer initiation
and progression that is found at highly elevated levels in several cancer types
expressing mutant IDH, including acute myeloid leukemia (AML). AG-221 is a
first-in-class, oral, selective, potent inhibitor of mutant IDH2. In vitro studies
have shown that AG-221 reduces 2-HG levels by >90%, reverses histone and
DNA hypermethylation, and induces cellular differentiation in leukemia cell mod-
els. In in vivo xenograft mouse models using U87MG and primary human AML
cells, oral AG-221 also demonstrated robust 2-HG inhibition. These pharma-
cokinetic/pharmacodynamic (PK/PD) correlations between AG-221 exposure
and 2-HG inhibition were used to project the efficacious dose in humans. Here
we present updated PK/PD analyses from the ongoing, first-in-human, phase
1 trial of AG-221 in patients with IDH2 mutation-positive advanced hematologic
malignancies (NCT01915498).
Aims: To model the human PK/PD profile of AG-221, to compare these results
with in vitro as well as pre-clinical studies, and to assess the PK/PD profile of
AG-221 across different IDH2 mutations.
Figure 1.
Methods: In the phase 1, open-label, dose-escalation trial, patients who pro-
vided informed consent received oral AG-221 once (QD) or twice daily (BID) in
continuous 28-day cycles. Dosing began at 30 mg BID and increased in sub-
sequent cohorts. Blood and bone marrow samples were collected at multiple
time points after a single dose at Day –3 and after multiple doses. AG-221 and
2-HG concentrations were measured using a qualified LC-MS/MS method for
PK/PD analysis, which was performed with WinNonLin®. In vitro activity was
assessed in cell lines carrying IDH2 mutations. Efficacy of oral AG-221 and
PK/PD relationships were also evaluated in U87MG and primary human AML
xenograft mouse models carrying the IDH2-R140Q mutation.
Results: Patients in this analysis received AG-221 at doses of 30, 50, 75, 100,
and 150 mg BID and 50, 75, 100, 150, and 200 mg QD (total N=64). Patients
bearing the two dominant IDH2 mutations, R140Q (88%) or R172K (12%),
were enrolled. AG-221 demonstrated excellent dose-dependent plasma expo-
sure with high accumulation after multiple doses and a half-life >40 hours. After
multiple AG-221 doses, substantial, sustained reduction of 2-HG in plasma and
bone marrow was observed. 2-HG inhibition in plasma was dose- and expo-
sure- dependent, with up to 98% inhibition in IDH2-R140Q and 93% inhibition
in -R172K mutation-positive patients. More than 30-fold different PD responses
were modeled for each of the mutations (Figure), with an AG-221 free fraction
50% inhibitory concentration (IC50) of 5 ng/mL for IDH2-R140Q (Emax model)
and 160 ng/mL for IDH2-R172K (sigmoidal Emax model). This correlates with
PK/PD analysis from in vitro studies, in which lower IC50 values were observed
in IDH2-R140Q cells than in IDH2-R172K cells.
Summary and Conclusions: AG-221 demonstrates a favorable PK profile that
supports oral QD dosing, based on the high plasma exposure and long half-life
observed in this study. AG-221 inhibition of 2-HG production was more potent
in IDH2-R140Q than in -R172K mutants, however, AG-221 reduces plasma 2-
HG in patients with both IDH2-R140Q and -R172K mutations to within the nor-
mal range seen in healthy volunteers, in a dose- and exposure-dependent man-
ner. The PK/PD findings translate well from in vitro to in vivo studies and from
pre-clinical to human studies.
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REDUCED MEDICAL COSTS AND HOSPITAL DAYS WITH ORAL ARSENIC
PLUS RETINOIC ACID COMPARED WITH INTRAVENOUS ARSENIC PLUS
RETINOIC ACID AS THE FRONT-LINE TREATMENT OF ACUTE
PROMYELOCYTIC LEUKEMIA
H.H. Zhu1, J. Hao1, G.W. Liang2, Q. Jiang1, S. Han2, L.W. Shi2, X.J. Huang1,*
1Peking University Institute of Hematology, Peking University People’s Hospital,
2Department of Pharmacy Administration and Clinical Pharmacy, Peking Uni-
versity Health Science Center, Beijing, China
Background: We recently demonstrated that oral arsenic (Realgar-Indigo nat-
uralis formula,RIF) plus all-trans retinoic acid (ATRA) is not inferior to intra-
venous arsenic trioxide (ATO) plus ATRA as the front-line treatment of acute
promyelocytic leukemia (APL). Howerver, the cost-effectiveness of oral arsenic-
based treatment has never been reported.
Aims: We aimed to compare the cost-effectiveness of between oral and intra-
venous arsenic.
Methods: we analyzed the results of 60 patients (30 patients in each group)
involved in a randomized controlled trial at our center. The direct medical costs
and hospital days for each patient were calculated.
Results: The median total medical costs were ¥83056 in the RIF group com-
pared with ¥152063 in the ATO group (p<0.0001). This difference primarily
resulted from the differential costs of induction therapy (p=0.016) and mainte-
nance treatment (p<0.0001). The hospitalization length for the RIF group was
significantly lower compared with the ATO group (24 vs. 31 days, p<0.0001)
during induction therapy. During maintenance treatment, the estimated medical
costs were ¥12897 for each patient in the RIF group treated at home compared
with ¥71025 for each patient in the ATO group treated in an outpatient setting
(p<0.0001).
Summary and Conclusions: We concluded that oral RIF plus ATRA signifi-
cantly reduced the medical costs and length of hospital stay during induction
and maintenance therapy compared with ATO plus ATRA in APL patients. Oral
arsenic plus ATRA should be incorporated into the front-line treatment of
patients with APL for medical and economic reasons.
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CLINICAL COURSE OF LEPTOMENINGEAL INVOLVEMENT OF ACUTE
MYELOID LEUKEMIA: 14-YEARS SINGLE CENTER EXPERIENCE
J.H. Kwon1,2,*, J. Park1,3, Y.I. Koh1, I.H. Kim1, S.S. Yoon1, S. Park1
1Seoul National University, College of Medicine, Seoul, 2Chungbuk National
University Hospital, Cheongju, 3Seoul Metropolitan Government Seoul National
University Boramae Medical Center, Seoul, Korea, Republic Of
Background: The leptomeningeal involvement of acute myeloid leukemia is
known to be rare in adult, and its prognostic importance is controversial. 
Aims: We investigated risk, clinical course and outcome of acute myeloid
leukemia patients with leptomeningeal involvement.
Methods: We examined medical records of the patients who were diagnosed
with acute myeloid leukemia (AML) at Seoul National University Hospital from
January 2000 to November 2013. Leptomeningeal involvement was defined
as the presence of atypical or malignant hematopoietic cells in cerebrospinal
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fluid. Molecular risk group was classify into three categories; good (t(8;21),
t(15;17), inv(16) & NPM1), Poor (t(9;22), MLL rearrangement, MDS-related
change, complex karyotype, FLT3-ITD) and Standard (normal karyotype and
other abnormalities). Information about demographical data, treatments and
outcomes, survival was also collected.
Results: Among 943 patients with acute myeloid leukemia, 155 patients
(16.4%) have had lumbar puncture and cerebrospinal fluid examination. Lep-
tomeningeal involvement of AML was confirmed in forty-three patients (4.6%).
Most common symptom was headaches (15 patients, 34.9%). Median age was
51 years old and 27 patients (62.8%) were male. Patients in good risk group
were fifteen (34.9%). Among these patients, t(15;17) was founded in 6 patients
(40%). Fifteen were standard and eleven were high risk group. Twenty-three
patients (53.5%) had involvements of extramedullary site except lep-
tomeninges, and sixteen patients (37.2%) had chloromas in their brain pare-
hchyma or spinal cord. Twelve patients (27.9%) discovered leptomeningeal
involvement simultaneously with the initial diagnosis of leukemia. Among these
patients, 3 (25.0%) belonged to good risk group. Thirty-one patients (72.1%)
developed leptomeningeal involvement at the relapsed or refractory status,
twelve (38.7%) of them were in good risk group. Thirty-six patients (83.7%)
received intrathecal chemotherapy, then leukemic cells were eliminated from
cerebrospinal fluid in thirty-one patients (86.1%). Whole-brain or spinal radio-
therapy was performed in 13 patients (30.2%). The complete remission-rate of
bone marrow after the first induction chemotherapy was 67.4%, and allogeneic
hematopoietic stem cell transplantation was performed in 14 patients (35.5%).
Median overall survival was 10.8 months. Radiotherapy and complete remis-
sion after the first induction chemotherapy were independent prognostic factors
for overall survival in multivariate analysis. 
Figure 1. Overall survival. A; radiotherapy, B; Complete remission after
1st induction chemotherapy.
Summary and Conclusions: Leptomeningeal involvement in acute myeloid
leukemia is rare condition, which are relatively common in relapsed or refractory
status. Whole-brain radiotherapy and complete response to induction
chemotherapy were thought to have contributed to improve their prognosis.
Active treatment using intensive induction chemotherapy and leptomeninges-
directed treatment including radiotherapy might be helpful improving their sur-
vival.
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A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS
LEUKEMIA
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Background: Vismodegib is a small molecule inhibitor of the hedgehog (Hh)
signaling pathway currently approved for treatment of advanced basal cell car-
cinoma. Increased expression of Hh ligand leading to activation of the Hh path-
way is thought to play a key role in the maintenance of the leukemic stem cell
in myeloid leukemias. Specifically, the Hh ligand may contribute to leukemic
stem cell self-renewal properties. Inhibiting the ability of leukemic stem cells to
self-renew by targeting the Hh pathway could eradicate the malignant clone.
Aims: To assess the safety and efficacy of vismodegib in the treatment of
relapsed/refractory acute myelogenous leukemia (AML) patients with a primary
endpoint of overall response rate at week 8 of study treatment.
Methods: Patients (pts) with relapsed or refractory AML who gave informed
consent were enrolled in a single arm treatment of vismodegib 150mg PO daily
for 8 weeks or until progression evaluated by using the International Working
Group criteria. Eligibility criteria included pts with documented relapsed/refrac-
tory AML (excluding APL), ≥18 years, ECOG ≤2, with adequate renal and hepat-
ic function. Pts were stratified by the following factors: poor risk cytogenetics
(based on NCCN guidelines), FLT3+mutation, or neither (patients who were
not poor risk or FLT3+).
Results: 38 pts were enrolled (poor-risk karyotype n=15, FLT3+n=4, and nei-
ther n=19). Most pts had relapsed AML (60.5%), were white (89.5%) and male
(55.3%) with a median age of 68.5 years. The ORR was 5.3% (1 CRi, 1 PR).
Both of the responders were in the “neither” group with no identified cytogenetic
abnormalities or other risk factors. The median duration of vismodegib therapy
was 49 days, with a range of 5 – 225. 37 patients (97.4%) had at least one
adverse event. The most common adverse events were pyrexia (39.5%), nau-
sea (39.5%), dysgeusia (31.6%), epistaxis 26.3%), febrile neutropenia (23.7%),
fatigue (23.7%), muscle spasms (23.7%), decreased appetite (23.7%), and
peripheral edema (21.1%). Serious adverse events occurred in 26 patients
(68.4%). The majority of serious adverse events were infections (53.8%). Most
patients died due to disease progression on study, 27 of 33 pt deaths.
Summary and Conclusions: Single agent vismodegib treatment produced
minimal clinical efficacy in pts with relapsed/refractory AML. However, this is
the first documented single-agent response in a disease thought to be driven
through the Hh ligand as opposed to a mutation in the pathway. The adverse
event profile was most likely driven by the underlying AML. Serious adverse
events were typically infections, which are common in relapsed/refractory AML.
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PHASE I/II STUDY OF DFP-10917 GIVEN BY CONTINUOUS INFUSION IN
PATIENTS WITH RELAPSED OR REFRACTORY ACUTE
LEUKEMIA: PHARMACOKINETIC, PHARMACODYNAMICS AND
PHARMACOGENOMICS PROPERTIES
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N. Jain1, G. Borthakur1, C. DiNardo1, J. Cortes1, B. Anderson2, K. Iizuka3,
C. Jin3, H. Kantarjian1
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Background: DFP-10917 is activated by deoxycytidine kinase (DCK) and inac-
tivated by cytidine deaminase (CDA) similar to the deoxycytidine analogs,
cytarabine and gemcitabine. Upon low dose administration DFP-10917 is con-
verted to its nucleotide form and incorporated into tumor DNA causing DNA
strand breaks and G2/M phase-arrest by cell-checkpoint regulators and ulti-
mately tumor cell apoptosis.
Aims: To determine the maximum tolerated dose (MTD), the recommended
phase II dose (RP2D) and dose-limiting toxicity (DLT) of DFP-10917 given by
continuous infusion (CI) in patients with relapsed or refractory acute leukemia.
To perform pharmacokinetic (PK), pharmacodynamic (PD) and pharmacoge-
nomic (PGx) analyses.
Methods: In phase I, DFP-10917 was administered by 7-day CI followed by
21 days rest (stage 1) or 14-day CI followed by 14 days rest (stage 2) in pts
with relapsed or refractory acute leukemia to determine the MTD. PK analysis
was performed to measure DFP-10917 (CNDAC) and the primary metabolite
at days 7 and 14. PD assessment utilized the comet assay to quantify DNA
strand breaks in whole blood and bone marrow samples. PGx assessment
was performed by DNA genotyping of CDA and DCK.
Results: In stage 1, twenty-seven pts received a 7-day CI of DFP-10917 at
eight escalating doses ranging from 4 to 35 mg/m2/day. At the 35 mg/m2 dose
level, one patient experienced a DLT of grade 3 diarrhea during cycle 1. The
starting dose for stage 2 was calculated as two-thirds the cumulative 7-day
DFP-10917 dose at the MTD of 30 mg/ m2/day divided by 14-day resulting in
a dose of 10 mg/m2/day x 14 days. The 10 mg/m2/day x 14-day CI dose result-
ed in DLTs of prolonged hypo-cellularity in 2 of 4 pts. At the 6 mg/m2/day x 14-
day dose level, 1 of 6 evaluable pts experienced a DLT of prolonged hypo-cel-
lularity, and the MTD/RD was defined as 6 mg/m2/day x 14-day CI. Initial effi-
cacy assessments include leukemia responses observed in 7 of 10 AML pts
(70%) receiving the 14-day DFP-10917 CI (3 bone marrow complete respons-
es, 4 partial responses). PK data indicates dose-proportionality for steady state
concentration (Css) of DFP-10917 and its primary metabolite. 2 of the 3 patients
with prolonged hypo-cellularity DLTs demonstrated CNDAC Css of >10 ng/ml
(0.0346 nM). The comet assay results indicate DNA strand breakage increased
following the 7 and 14 day CI of DFP-10917; however, the 14-day CI was asso-
ciated with a lower level of DNA strand breakage. DNA genotyping did not
detect genetic mutations associated with CDA and DCK.
Summary and Conclusions: The MTD/RP2D of DFP-10917 in relapsed AML
was established for 14-day CI at 6 mg/m2/day, and the phase II study is ongo-
ing. Prolonged myelosuppression was associated with CNDAC Css >10 ng/ml
among 2 of 4 pts treated at 10 mg/m2/day x 14 days of DFP-10917. PD data
demonstrated DNA strand breakage at the doses tested. No genetic mutations
associated with CDA or DCK were detected among leukemia patients treated
in the Phase 1 study.
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EFFICACY AND TOXICITY OF FLUDARABINE BASED INDUCTION
REGIMENS IN ACUTE MYELOID LEUKEMIA PATIENTS YOUNGER THAN
65 YRS
A. Candoni1,* S. Vassallo1, D. Lazzarotto1, E. Simeone1, G. Ventura1,
M.E. Zannier1, F. Zanini1, C. D’Odorico1, E. Lucchini1, R. Fanin1
1Hematology and BMT, Division of Hematology, University Hospital, Udine,
udine, Italy
Background: Fludarabine (Fluda)–Cytarabine combinations are commonly
used as salvage chemotherapy in Acute Myeloid Leukemia (AML). The role
and efficacy of Fluda based induction regimens in high risk AML younger than
65 yrs are still poorly understood.
Aims: To evaluate efficacy and toxicity of Fludarabine based induction regimens
in patients with AML and younger than 65 yrs.
Methods: We retrospectively evaluated the efficacy and toxicity following induc-
tion chemotherapy with Fluda based regimens in 286 pts, with previously
untreated Acute Myeloid Leukemia, followed over a 10 years period (2002-
2012) at our Center. All patients were younger than 65 with a median age of 52
years. Diagnosis of AML was confirmed in all cases and Cytogenetic, Multidrug
Resistance, FLT3 mutation analysis, were performed in all patients; 73% of
these were poor-risk at diagnosis [high risk factors: BC >30x109/L, secondary
AML, FLT3 ITD mutation, poor-risk karyotype]. The 286 Fluda based induction
courses included: 235 FLAI courses (Fludarabine, Cytarabine, Idarubicine) and
51 FLAIE courses (FLAI course plus Etoposide). Patients were evaluated for
response rate and treatment related adverse events. Toxicity was evaluated
and graded according to National Cancer Institute criteria.
Results: After Induction with a Fluda based regimen 213/286 (74%) of patients
achieved a Complete Remission (CR). Only a 3% of Death During Induction
(DDI) was reported. Non hematologic toxicity was acceptable with 54% of pts
presented FUO, 48 % bacteremia or sepsis and 20% grade II-III oral mucositis.
As expected, all pts experienced grade IV hematological toxicity and (in CR
pts) the median time to PMN (>1000/ml) and platelet (>50.000/ml) recovery
was 24 (range 17 to 40) and 26 days (range 18-43), respectively. Supportive
treatment consisted of a median of 13 RBC (range 5-26) and 7 platelet units
(range 3-18). Median time to hospital discharge was 31 days (range 22-61). 1
yrs Overall Survival and DFS was 68% and 64%, respectively.
Summary and Conclusions: This data, from a large serie of cases, confirm
that Fluda based induction regimens are effective and well tolerated in poor
risk AML patients younger than 65 yrs with a high CR rate, favourable safety
profile and very low DDI.
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OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER
PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH
AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE
AZA-AML-001 STUDY
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Background: There is no standard treatment (Tx) for older patients (pts) with
AML, who have especially poor OS due to adverse risk factors such as unfa-
vorable karyotypes and poor performance status (PS). Older pts may be unfit
for high-intensity induction chemotherapy (IC); such pts are often treated with
LDAC or best supportive care (BSC) alone, which are associated with very
poor outcome (Dombret, Semin Oncol, 2008). The international phase 3 AZA-
AML-001 study compared AZA with conventional care regimens (CCR) in older
pts with AML. Before randomization, investigators selected their preferred Tx
option for each pt from 3 commonly used CCR for AML Tx: IC, LDAC, or BSC
only. Pts were then randomized to receive AZA or CCR and received their pre-
selected Tx.
Aims: To compare effects of AZA vs LDAC on OS and clinical outcomes in
the subgroup of pts in AZA-AML-001 preselected to receive LDAC before ran-
domization.
Methods: Pts aged ≥65 years with newly diagnosed de novo or secondary
AML (>30% bone marrow [BM] blasts by local assessment), ECOG PS 0-2,
WBC count ≤15x109/L, and intermediate- or poor-risk cytogenetics were
enrolled. AZA dose was 75mg/m2/day SC x7 days/28-day cycle and LDAC
dose was 20mg SC BID x10 days/28-day cycle. OS and 1-year survival were
estimated using Kaplan-Meier methods. OS was compared between Tx groups
by log-rank test. An unstratified Cox proportional hazards model generated
hazard ratios (HRs) and 95% CIs. Overall response rate (ORR) included com-
plete remission (CR) +CR with incomplete blood count recovery (CRi) (IWG
2003). Proportions of pts with grade 3-4 infections and hematologic treatment-
emergent adverse events (TEAEs), and TEAE incidence rates (IR) per 100 pt-
years of Tx exposure, are reported.
Results: Of all pts in AZA-AML-001, most (312/488, 64%) were preselected to
receive LDAC (AZA n=154, LDAC n=158). Median number of Tx cycles
received was 7 (range 1–28) for AZA and 4 (1–25) for LDAC. At baseline in the
AZA and LDAC groups, respectively, median ages were 76 (range 64–90) and
75 (65–88) years; 25% and 22% had ECOG PS of 2; centrally read median BM
blasts were 70% (2–100) and 74% (4–100); and 29% and 34% of pts had poor-
risk cytogenetics. Median OS in the AZA and LDAC groups was 11.2 vs 6.4
months (mon), respectively (HR=0.90 [95%CI 0.70, 1.16], p=0.43; Figure), indi-
cating a 4.8-mon (95%CI 1.7, 7.9) longer median OS with AZA. The OS differ-
ence was not statistically significant due to convergence of the OS curves at
~20 mon. One-year survival rate was 48.5% with AZA vs 34.0% with LDAC, a
difference of 14.5% (95%CI 3.5%, 25.5%). ORR was 27% with AZA and 26%
with LDAC. Proportions [IRs] of AZA and LDAC pts, respectively, with grade 3-
4 TEAEs were: anemia 19% vs 23% [26 vs 42]; neutropenia 25% vs 25% [33
vs 46]; febrile neutropenia 27% vs 30% [36 vs 56]; thrombocytopenia 25% vs
28% [34 vs 51]; and infections 49% vs 46% [66 vs 84].
Figure 1. Overall survival in patients preselected to LDAC.
Summary and Conclusions: Analyzing outcomes within preselection groups
allows assessment of Tx effects in pts with generally similar prognoses and
clinical features, as preselection of the preferred CCR occurred before ran-
domization. AZA was associated with a longer median OS of 11.2 mon vs 6.4
mon with LDAC, in pts with similar features at study entry. At 1 year, almost
one-half of AZA-treated pts were alive, compared with approximately one-third
of LDAC-treated pts. Quality of life outcomes during Tx with AZA or LDAC in
this pt group are now being evaluated. AZA may offer potential advantages
over LDAC as first-line low-intensity Tx in difficult-to-treat older pts with AML
and high blast counts.
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RETROSPECTIVE ANALYSIS OF OUTCOMES BETWEEN PATIENTS WITH
ACUTE MYELOID LEUKEMIA WHO ARE TREATED WITH HEPARIN AND
RECOMBINANT HUMAN THROMBOMODULIN THERAPY
N. Takezako1,* N. sekiguchi1, A. nagata1, A. miwa1
1Hematology - National Hospital Organization Disaster Medical Center, DIS-
ASTER MEDICAL CENTER OF JAPAN, Tachikawa, Japan
Background: Recombinant thrombomodulin (rTM) is a promising anticoagulant
and rTM therapy more signiﬁcantly improves disseminated intravascular coag-
ulation (DIC) and relieves bleeding complications in DIC patients, when com-
pared with unfractionated heparin therapy. However, it is unknown as to whether
or not the treatment with rTM affects acute myeloblastic leukemia (AML)
patient’s outcome.
Aims: we retrospectively analyzed 103 patients with AML (except adult acute
promyelocytic leukemia), and compared outcomes between patients treated
with low-molecular-weight heparin and rTM.
Methods: We retrospectively analyzed 103 patients with AML and compared
the outcomes between the patients with low molecular weight heparin therapy
and with rTM. The diagnostic criteria for DIC previously proposed by the Japan-
ese Ministry of Health and Welfare. Comparisons between the qualitative vari-
ables were carried out using the χ2 test. The survival probabilities were esti-
mated by the Kaplan-Meier method, and differences in the survival distributions
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were evaluated using the log-rank test.
Results: 47 developed DIC in association with chemotherapy or disease status.
Fourteen patients were treated by rTM, and 33 patients were treated by low
molecular weight heparin (LMWH). The overall survival was worse in the DIC
group compared with the non- DIC group on the log-rank test (P=0.003). The
overall survival was superior in the rTM group compared with LMWH group
according to the log-rank test (P=0.016).
Figure 1.
Summary and Conclusions: Treatment with rTM is efficient compared with
LMWH because of improvement of overall survival.
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POST REMISSION MONITORING OF MINIMAL RESIDUAL DISEASE BY
WT1 AND LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE PREDICTS
RELAPSE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS
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Background: Although a complete remission (CR) can be achieved in 70-80%
of newly diagnosed acute myeloid leukemia (AML) patients, relapses occur in
up to the 50% of cases. Minimal residual disease (MRD) monitoring is a major
issue for early detection of patients at high-risk of treatment failure and relapse.
Aims: to perform a comparative sequential monitoring of MRD by RT-qPCR
on WT1 and by Multiparametric Flow Cytometry (MFC) on Leukemia Associ-
ated Immunophenotypes (LAIPs).
Methods: 104 newly diagnosed AML patients consecutively treated between
2010 and 2013 were monitored with RT-qPCR WT-1 from bone marrow (BM)
and peripheral blood (PB) and with MFC on the LAIP on BM at baseline, after
induction, after the first consolidation course and after the first intensification
course.
Results: All the patients were studied at diagnosis for a LAIP and this was
available in 80/104 (77%) cases. BM and PB-WT1 level at diagnosis was avail-
able in 92/104 (88%) and 70/104 (67%), respectively. Eighty-eight out of 104
patients (85%) achieved a complete remission (CR) after induction, 30/88
(34%) relapsed during follow up and 33/104 (32%) were addressed to allo-
geneic stem cell transplantation (allo-SCT). Univariate and multivariate analysis
on relapse free survival (RFS) were conducted, censoring allotransplanted
patients at the time of allo-SCT. By univariate analysis, after induction BM-WT
≥295x10^4/ABL (HR 7.8; p<0.0001) significantly identified patients at high risk
of relapse. After 1st consolidation BM-WT1 ≥121x10^4/ABL (HR 5.2; p>0.0001),
PB-WT1≥18x10^4/ABL (HR 7.9; p<0.0001), LAIP ≥0.2% (HR 3.3; p=0.002)
and LAIP-decrease <85% (HR 3.6; p=0.001) were significantly correlated with
adverse RFS. After 1st intensification cycle (before allo-SCT), BM-WT1
≥150x10^4/ABL (HR 7.8; p<0.0001), PB-WT1 ≥16x10^4/ABL (HR 12.2;
p<0.0001) ,and LAIP decrease <85% (HR 4.5; p=0.006) significantly affected
the RFS. By multivariate analysis, after 1st consolidation BM-WT1
≥121x10^4/ABL (HR 4.1; p=0.02) and LAIP decrease <85% (HR 3.0; p=0.0001)
and after 1st intensification PB-WT1 ≥16x10^4/ABL (HR10.2; p=0.0001) were
independently associated with averse outcome. Within the different ELN-risk
categories, BM-WT1 ≥121x10^4/ABL after the 1st consolidation cycle signifi-
cantly dissected the patients at high risk of relapse both in the ELN Int-1 [HR
14.4; 95% CI 1.7-118.6); p=0.01] and Int-2 risk category [HR 11.7; 95% CI 1.1-
124.9); p=0.04]. Similarly, LAIP decrease <85% after the 1st consolidation cycle
significantly identified the patients at high risk of relapse in the ELN Int-2 risk
group only [HR 10.1; 95% CI 1.1-93.9); p=0.04]
Summary and Conclusions: Our data, although retrospectively collected,
show that WT1 and LAIP MRD monitoring is useful to predict the relapse in
AML patients and may help to guide the post-remission treatment strategy. 
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TREATMENT WITH LOW-DOSE CYTARABINE (LD-ARAC) IN ELDERLY
PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID
LEUKEMIA (AML): A SINGLE INSTITUTION EXPERIENCE
M. Heiblig1,* M. El Ahmri1, I. Tigaud2, A. Plesa3, F. Barraco1, H. Labussière-
Wallet1, S. Ducastelle-Leprêtre1, M. Michallet1, F.E. Nicolini1, C. Plesa4, E.
Wattel1, G. Salles1, X. Thomas1
1Hematology Department, 2Laboratory of Cytogenetics, 3Laboratory of Cytol-
ogy and Immunology, Centre Hospitalier de Lyon Sud, 4Hematology Depart-
ment, Trarieux Clinic, Lyon, France
Background: The treatment outcome for patients with AML aged 70 years or
older is unsatisfactory and has not improved significantly over the last two
decades. Most of these patients do not receive intensive chemotherapy either
because they decline or because they are not considered fit enough for such
therapy. LD-AraC is still regarded as the standard of care in elderly patients
with AML ‘unfit’ for intensive chemotherapy, against which novel drugs may be
compared.
Aims: In this study, we compared the efficacy of LD-AraC with that of intensive
chemotherapy (IC), best supportive care (BSC), or lower intensity therapy (LIT)
based on hypomethylating agents in a single institution experience.
Methods: Three hundred and sixty six patients (aged 70 years or older) with
newly diagnosed AML have been seen in our institution between 2000 and
2014. Among them, 60 patients (16%) received LD-AraC at 20 mg once or
twice daily by subcutaneous injection for 10 consecutive days. Subsequent
courses were administered after intervals of 4 to 6 weeks. 
Results: They were compared to 85 patients treated by IC (anthracycline- and
cytarabine-based chemotherapy), 34 patients treated by LIT (12 received
decitabine and 22 azacitidine), and 43 patients receiving only BSC. The overall
complete remission (CR) rate with LD-AraC was 7% (4/60 patients). The medi-
an number of courses to CR was 4 courses (3-9 courses). The CR rate was
better in patients treated by IC (144/280 patients; 51%) and in patients treated
by LIT (7/34 patients; 21%). Median OS of patients treated with LD-AraC was
9.6 months (95% CI, 5.8-13.5 months) with 3-year OS of 12%. Survival with
LD-AraC was better than with BSC only (median OS: 9.6 months vs 3.4 months;
P=0.001). Although not statistically significant, IC tended to be better than LD-
AraC in terms of OS (median OS: 12.4 months vs 9.6 months; 3-year OS: 27%
vs 12%; P=0.07). However, differences in favor of IC were only confirmed for
patients aged less than 75 years (median: 12.7 months vs 9.2 months; 3-year
OS: 28% vs 10%). In patients aged >or=75 years, median OS was better with
LD-AraC (9.6 months vs 2.8 months). No significant differences were observed
between LIT and LD-AraC (median OS: 16.1 months vs 9.6 months; 3-year
OS: 22% vs 12%; P=0.1). There was no clear evidence that a beneficial effect
of LD-AraC was restricted to any particular subtype of patients, except for cyto-
genetics (favorable and intermediate-risk vs unfavorable-risk) (median OS:
11.4 months vs 4.3 months; P=0.03). Of the patients who received LD-AraC,
24 patients were treated inside clinical trials, while 36 patients were not. Median
OS was 13.2 months for the first ones vs 7.8 months for the others; 3-year OS:
18% vs 9%; P=0.21.
Summary and Conclusions: Overall, despite a trend in favor of IC and LIT
over LD-AraC, no real significant advantage could be demonstrated, while LD-
AraC showed a significant advantage comparatively to BSC. This tends to con-
firm that LD-AraC can still represent a baseline against which new promising
agents may be compared either alone or in combination.
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CLINICAL SIGNIFICANCE OF THE DAY 5 PERIPHERAL BLASTS
CLEARANCE RATE IN THE EVALUATION OF EARLY TREATMENT
RESPONSE AND THE PROGNOSIS FOR AML PATIENTS
B. Chen1,* C. Yu1, Q. L. Kong1, Y.X. Zhang1, S.J. Chen1
1State Key Laboratory of Medical Genomics,Shanghai Institute of Hematology,
Rui Jin Hospital, affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, China
Background: Acute myeloid leukemia (AML) is a group of clinically and genet-
ically heterogeneous diseases. In spite of the landmark progress in treating
acute promyelocytic leukemia (M3), current treatment of AML is still largely
based on chemotherapy. The standard induction chemotherapy consists of
anthracycline and cytarabine (“3+7” regimen) could achieve the complete
remission (CR) rate about 75%, but due to the variability of individual genetic
profile and drug sensitivity, the outcome is uncertain. Monitoring of the minimal
residual disease (MRD) could reflect the treatment response in time, and then
become the essential reference for AML patients to optimize chemotherapy
strategy. In the past decades, multiparameter flow cytometry (MFC) method
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has been used as a standard technique to track MRD in leukemia patients.
Aims: For AML patients, the MRD detection of bone marrow was usually per-
formed after one course of induction chemotherapy. To optimize the chemother-
apy strategies, it is essential to establish an earlier and easier method to monitor
the early treatment response during induction period. Peripheral blood (PB)
blasts clearance rate might serve as such a monitoring marker.
Methods: PB blasts were monitored using flow cytometry, the absolute counts
were calculated before treatment (D0) and on the 3rd, 5th, 7th, 9th days (D3,
5, 7, 9) of induction chemotherapy. The cut-off value of Day 5 peripheral blasts
clearance rate (D5-PBCR) was defined by a receiver operating characteristic
(ROC) analysis. Prognostic effect was compared between the different patient
groups according to D5-PBCR cut-off value.
Results: The D5 peripheral blasts clearance rate (D5-PBCR) cut-off value was
determined as 99.55%. Prognostic analysis showed that patients with D5-
PBCR≥99.55% were more likely to achieve CR (94.6% vs. 56.1%, P<0.001)
and maintain the relapse-free status (80.56% vs. 57.14%, P=0.027). In survival
analysis, both relapse-free survival (RFS) and overall survival (OS) were longer
in the D5-PBCR≥99.55% patients group (2-year OS: 71.0% vs. 38.7%, P=0.011;
2-year RFS: 69.4% vs. 30.7%, P=0.026). Moreover, in cytogenetic-molecular
intermediate-risk group, a subgroup with worse outcome could be further dis-
tinguished by D5-PBCR level (<99.55%) (OS: P=0.033, RFS: P=0.086).
Summary and Conclusions: In conclusion, our work established an effective
early treatment response evaluation method by monitoring PB blasts using flow-
cytometry. The D5-PBCR value (99.55%) could be a reliable reference to predict
the treatment response and outcome in very early stage of chemotherapy, which
may offer the opportunity of induction regimen modification, and help in optimiz-
ing the current cytogenetic-molecular prognostic risk stratification.
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PROPHYLACTIC USE OF SORAFENIB IN PATIENTS WITH
FLT3-ITD-POSITIVE ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Q. Liu1,* L. Xuan1, Z. Fan1, Q. Jiang1, M. Dai1, P. Shi1, C. Yin1, J. Sun1
1Department of Hematology, Nanfang Hospital, Southern Medical University,
Guangzhou, China
Background: Internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-
ITD) mutations have been reported in 20%>30% of patients with acute myeloid
leukemia (AML). FLT3-ITD-positive AML patients have an inferior survival, pri-
marily due to lower complete remission (CR) rate and higher relapse rate.
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT)
improves the outcomes of a proportion of FLT3-ITD-positive AML, a signiﬁcant
number will suffer disease recurrence after allo-HSCT. Sorafenib, an inhibitor
of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-
positive AML. Recent studies have shown that sorafenib monotherapy or in
combination with chemotherapy are effective in attaining CR, but they do not
have significant improvement in relapse. Currently, prophylactic use of sorafenib
after allo-HSCT has been rarely reported, and whether it can improve outcomes
of FLT3-ITD-positive AML remains unclear. 
Aims: To assess the feasibility and efﬁcacy of prophylactic use of sorafenib in
FLT3-ITD-positive AML after allo-HSCT for preventing relapse.
Methods: A total of 18 patients with FLT3-ITD-positive AML undergoing allo-
HSCT from January 2012 to March 2014 at our single institute were enrolled
in this retrospective study. The median age was 29 years (range 16-51 years),
with 10 males and 8 females. Thirteen patients received related (9 sibling and
4 family donors), 5 unrelated donor transplants; 8 received HLA locus matched,
10 mismatched transplants. Seven patients were in first CR at the time of trans-
plantation and all received standard conditioning. Eleven patients were not in
CR (NR) at the time of transplantation and all received intensified conditioning.
Sorafenib was used from day 30 to day 180 post-transplantation. The initial
dose of sorafenib was 400 mg orally twice daily and was adjusted in case of
suspected toxicity or resistance (dose range, 200-800 mg daily).
Results: Of the 18 patients, 7 patients received prophylactic sorafenib, includ-
ing 3 in CR and 4 in NR pre-transplantation; 11 did not receive prophylactic
sorafenib, including 4 in CR and 7 in NR pre-transplantation. The eleven
patients in NR at the time of transplantation all achieved CR and had complete
chimerism by day +30 post-transplantation. Of the 7 patients with prophylactic
sorafenib, one developed grade II acute graft-versus-host disease (aGVHD)
and 3 developed chronic GVHD (cGVHD, limited in 2 and extensive in 1). Of
the 11 patients without prophylactic sorafenib, 3 patients developed aGVHD
(grade II in 2 and III in 1) and 7 developed cGVHD (limited in 3 and extensive
in 4), including 1 grade III aGVHD and 2 cGVHD after donor lymphocyte infusion
(DLI). With a median follow up of 433 (range, 124-765) days post-transplanta-
tion, 7 patients with prophylactic sorafenib all had no recurrence and survived.
Of the 11 patients without prophylactic sorafenib, 5 experienced leukemia
relapse at a median time of 92 (range, 49 to 335) days post-transplantation,
including hematologic in 4 and central nervous system (CNS) in 1. The patient
with CNS relapse achieved CR after radiotherapy and DLI, and was still alive
now. Of the 4 patients with hematologic relapse, one abandoned treatment and
3 received treatment, including sorafenib combined with chemotherapy and
DLI. Two of the three patients achieved short CR after treatment and finally all
of them died of relapse within half a year. With a median follow up of 343 (range,
135-863) days post-transplantation, 6 patients survived and 5 died in the 11
patients without prophylactic sorafenib. Causes of death included leukemia
relapse (n=4) and cGVHD (n=1). The main side effect of sorafenib was rash,
and none of patients experienced bone marrow suppression. Of the 10 patients
with sorafenib treatment, 6 had hand-foot skin reaction and/or rash. Anti-allergy
therapy was ineffective, and glucocorticoid was usually required. In 4 of the 6
patients, the skin rash covered gradually after reducing the dose of sorafenib
and the use of glucocorticoid. Other two patients even required drug discontin-
uation, but sorafenib was tolerated after the reuse although the rash reap-
peared.
Summary and Conclusions: Early prophylactic use of sorafenib has an
acceptable toxicity profile and could reduce relapse of FLT3-ITD-positive AML.
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Background: Age is a dominant predictor of outcome in acute myeloid
leukemia (AML). It is unclear to which extent comorbidities contribute to this
effect. Unfortunately, data regarding the impact of pretreatment comorbidities
on prognosis and outcome are limited.
Aims: The object of this study was to determine the effect of relevant comor-
bidities on the survival of patients with AML and compare three validated comor-
bidity indices in predicting outcome.
Methods: In a single-center retrospective study 194 AML patients aged older
than 18 years treated between 1996 and 2012 were included. The Hematopoi-
etic stem cell transplantation comorbidity index (HCT-CI), the Adult Comorbidity
Evaluation-27 (ACE-27) score and the Cumulative Illness Rating Scale for Geri-
atrics (CIRS-G) at the time of initial AML diagnosis were evaluated to assess
the degree of pretreatment comorbidity conditions. Data on demographics,
cytogenetics, treatment and outcome were collected. Kaplan-Meier methods
and Cox regression were used to assess survival.
Figure 1. Survival curves according to HCT-CI, ACE-27 and CIRS-G.
Results: The study included 102 male and 92 female with median age at diag-
nosis of 60.9 years (range, 18-90). Median duration of follow-up was 9 month.
One hundred twelve (57.7%) patients died, and 173 (89,2%)received intensive
chemotherapy. Overall median survival was 17 month (range, 0-180). The most
frequent comorbidities included cardiovascular disease (59.8%), infection
(57.7%), hepatic disorders (45.9%) and prior malignancy (39.2%). In univariate
analysis, presence of cardiovascular disease, severe hepatic disease and renal
impairment were associated with inferior survival (26 vs 12 month, p=.005; 19
vs 4 month, p=.013; 17 vs 7 month, p=.016). Also, older age (≥60 years), poor
cytogenetics and higher ECOG score (≥2) were significantly associated with
reduced overall survival (25 vs 13 month, p=.003; 29 vs 12 month, p=.008; 21
vs 4 month, p=.000). For each index, the highest comorbidity burden was asso-
ciated with poorer overall survival (Figure 1). However, in Cox-analysis the
impact on overall survival was only significant for the ACE-27 score and the
HCT-CI. Median survival by ACE-27 score was 96, 18, 14 and 8 month for
patients with none, mild, moderate and severe comorbidities, respectively
(p=.006). Median survival by HCT-CI was not reached, 22 and 12 month for
patients in the lower- (0 points), intermediate- (1-2 points) and high- (≥3 points)
risk groups, respectively (p=.021). Although the HCT-CI appeared to separate
the risk groups better, in multivariate models only the ACE-27 score was sig-
nificantly associated with overall survival. Adjusted hazard ratios were 1.9, 2.3
and 4.2 for mild, moderate and severe comorbidities, respectively, compared
with no comorbidities (p=.004). Exploratory evaluations of the multivariate analy-
sis suggested that higher ECOG (≥2), poor cytogenetics and presence of severe
comorbidities according to ACE-27 had a significant impact on overall survival.
Interestingly, higher age (i. e. ≥60 years) had no significant impact in multivariate
analysis.
Summary and Conclusions: Comorbidities have a significant impact on sur-
vival of patients with AML. Patients with severe comorbidity had a greater than
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50% decrease in survival, independent of age, ECOG and cytogenetics. A pre-
treatment assessment of severity of comorbidities by comorbidity indices may
help to identify patients with poor outcome. It appears that age at least partially
impacts survival as a marker for comorbidities. Our data suggest that the ACE-
27 score is a suitable index to predict survival in patients with AML.
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Background: Acute erythroleukemia (AML-M6) accounts for 4% of all AML and
is often associated with high risk karyotypes and poor prognosis, with a median
survival of 3-9 months from diagnosis. When treated with intensive chemother-
apy (ICT), remissions last less than one year (Santos et al, Leukemia 2009).
Azacitidine (AZA) prolongs overall survival (OS) in patients with MDS and AML
who are not candidates for ICT (Fenaux et al, Lancet Oncology 2009) but there
is limited data of its efficacy in AML-M6 (Almeida, Leuk Res Reports 2013).
Aims: We report the clinical outcomes of 88 AML-M6 patients treated with AZA.
Methods: Data were pooled from registries and/or clinical files from multiple
nations. Survival was estimated using the Kaplan-Meyer method and log-rank
test for group comparison.
Figure 1.
Results: AZA was used as first line treatment in 41 patients (47%) and as ≥2nd
line treatment in 51% (treatment line unknown in 2%).
Median age was 69 (range 28-88) years. MRC cytogenetic risk was interme-
diate in 44% and poor in 51%. The median time from diagnosis to treatment
start was 21.9 days (1-552) and patients received a median number of 5 cycles
(1-37). At the time of last follow-up 22 patients were still alive, of which 9 were
still on AZA treatment; the main reasons for treatment discontinuation were
disease progression (52%), infection/toxicity (12%), death (11%) and allogeneic
transplantation (17%). At the time of writing, 66 patients had died from disease
progression (48%), infectious complications (12%), and other (12%) or
unknown causes (21%). Recorded grade 3-4 toxicities were predominantly
hematological, and only 32 hospital admissions due to toxicities were reported.
Overall marrow response was 34%, with 23% complete responses and 11%
partial responses (assessed according to IWG criteria). Time to first and best
response was 2.6 and 3.9 months, respectively. Progression free survival (PFS)
in the whole AZA cohort was 5.1 months (range 3.4-9.2), and 9.4 months (range
4.3-14.5) in those treated with AZA first line. The median OS was 16.8 months
(13.3-28.3) from diagnosis, 12.3 months (9.8-14.3) as of treatment start with
AZA. Median OS from start of treatment for patients treated with AZA 1st line
was 14.2 months (12.6-25.2) months, and 9.8 months (4.6 to 13.5) for those
receiving AZA ≥2nd line. Response to AZA showed a significant impact on OS:
18.3 months in patients achieving CR/PR/HI, 16.2 months in patients with mar-
row SD and 9.1 months in patients with PD (p=0.008) Of importance, patients
with poor-risk cytogenetics did not have an inferior survival when treated with
AZA (Fig1). The median OS from start of treatment in a group of AML-M6
patients (n=34) treated with ICT alone was 7.6 months (5.4-20.3).
Summary and Conclusions: AZA demonstrates efficacy and shows promising
response and survival results in our cohort of AML-M6 patients, not inferior to
that seen with ICT. The median OS of 14.2 months for those treated with AZA
1st line compares favorably with data for WHO-AML patients treated with AZA
1st line in a randomized trial (10.4 months; Dombert H, EHA 2014, LB-2433)
or from established patient registries (12.8 months; Pleyer L et al., ASH 2014,
#943). In addition, the observed median OS of 9.8 months in relapsed or refrac-
tory AML-M6 patients which generally confers a dismal prognosis (~3 months;
Ferrara F, Haematologica 2004;998; Roboz G, JCO 2014;1919), is promising.
Thus, AZA is a treatment option for 1st line treatment of AML-M6 patients inel-
igible for IC approaches, and also as salvage therapy for AML-M6 patients with
relapsed/refractory AML.
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Background: The hypocellular variant of acute myeloid leukemia (AML) is
defined as the presence of <20% of cellular bone marrow in a biopsy specimen
at presentation.
Aims: We performed a retrospective analysis to determine the clinical features
and survival outcomes of hypocellular AML in a Korean population.
Methods: We reviewed the medical records of all patients with AML who were
diagnosed from 2006 to 2012 at 9 hospitals participating in the AML registry.
Overall survival and event-free survival were calculated from the time of diag-
nosis until death or an event, respectively. An event was defined as relapse
after remission, failure to respond or death from any cause. 
Results: In total, 2110 patients were enrolled, and 102 (4.8%) were identified
as having hypocellular AML. Patients with hypocellular AML were older than
those with non-hypocellular AML (median age, 59 vs. 49 years, respectively; p
<0.001) and more frequently presented with leukopenia (mean white blood cell
count, 5,810/µL vs. 40,549/µL, respectively; p <0.001). There were no differ-
ences in the presence of antecedent hematologic disorders (5.9% vs. 5.3%,
respectively; p=0.809). No differences were seen between the hypocellular and
non-hypocellular AML groups with respect to the complete remission rate (53.9%
vs. 61.3%, p=0.139), early death rate (defined as any death before 8 weeks,
14.7% vs. 13.0%, p=0.629). Overall survival (OS) and event-free survival (EFS)
were not different between two groups (median OS, 16 vs. 23 months, respec-
tively; p=0.169; median EFS, 6 vs. 9 months, respectively; p=0.215).
Summary and Conclusions: Hypocellular AML is more frequently observed
in older age, but the clinical outcomes of hypocellular AML do not differ from
that of non-hypocellular AML.
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Background: Outcome of patients (pts) over 60 years of age with acute myeloid
leukemia (AML) treated only with intensive chemotherapy is poor. To improve
treatment results reduced-intensity transplantation (RIT) was establish as a
part of standard treatment strategy for pts aged 60 to70 years with AML (except
of pts with prognostically favourable AML) in our centre from 2003.
Aims: With the aim to evaluate transplant feasibility and the role of RIT in the
treatment of pts aged 60 to 70 years with AML we analysed outcome of such
pts in our centre from 2003.
Methods: From 1/2003 to 11/2014 AML was diagnosed in 188 pts aged 60 to
70 years. 120 pts were intensively treated and 61 pts with median of age 63
years (range, 60-68 years) with AML in 1st CR (35 pts), in 2nd CR (5pts), with
primarily resistant AML (9 pts) and with AML beyond CR (12 pts) underwent
RIT (30% HLA identical related, 41% HLA matched unrelated, 26% HLA mis-
matched unrelated, 3% haploidentical related). Source of stem cells was in
85% peripheral blood and in 15% bone marrow with the median of infused CD
34+cells 4,8x10^6/kg (range, 1,7-14,9x10^6/kg). The conditioning regimen con-
sisted of fludarabine (30mg/m2 for 4 days) and melphalan (140mg/m2 for 1
day), in 14 pts with ATG (ATG Fresenius 15mg/kg). CsA and methotrexate were
used as GVHD prophylaxis except haploidentical RIT where posttransplant
CPA and combination of CsA and MMF was used.
Results: The main reasons of impossibility to implement RIT in treatment of
older pts with AML were death during remission induction treatment (39%), resist-
ant or progressive AML (24%), non-availability of donor (16%), severe comor-
bidities (12%) and refusal of RIT (9%). However 51% of intensively treated pts
with AML eventually underwent RIT. All pts fully engrafted and achieved complete
remission (CR). 37 pts (60%) developed aGVHD (6 pts grade III-IV) and among
50 evaluable pts 22 (44%) of them developed chGVHD (9 limited, 13 extensive).
With median follow-up 46 months (range, 4-123 months) 27 pts (44%) are alive
(26 pts in CR). 14 pts (23%) relapsed and 13 of them died. 21 pts (34%) died due
to NRM, 2 (3%) of them till day 100 after RIT and 11 (18%) of them till day 365
after RIT. The estimated probabilities of 3-years EFS and OS are 44% and 47%.
3-years OS for all intensively treated elderly pts was 38%.
Summary and Conclusions: Our data show that half of intensively treated pts
aged 60 to 70 years with AML were able to undergo RIT and that RIT even in case
of unrelated or HLA mismatched donor is associated with acceptable NRM and
encouraging disease control of unfavourable AML (3-years OS 47%). The relatively
high percentage of transplanted pts undoubtedly influenced the overall results of
the group of intensively treated elderly patients with AML with a median survival
of 15 months and estimated 3-year OS of 38%. RIT should be considered as stan-
dard treatment option for consolidation therapy in elderly patients with AML.
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Background: Acute myeloid leukemia (AML) is the most frequent acute
leukemia affecting adults and its incidence increases with age. Leukemogenic
mutations affect hemopoietic stem cells resulting in leukemic clones. It has
been proven that leukemic stem cells reside in CD34+CD38- compartment of
the bone marrow. Several studies were conducted to include different markers
e.g. CD44, CD123, CD90 and CD133 for discriminating leukemic stem cell dur-
ing treatment (minimal residual disease) or for targeted therapy. The human
myeloid inhibitory C-type lectin-like receptor (hMICL) (also named CLL-1) was
reported as possible leukemic stem cell marker and for targeted therapy.
Aims: The aim of this work is to determine the diagnostic impact and the appli-
cability of the Human Myeloid Inhibitory C-Lectin (hMICL) in routine clinical flow
cytometry (FCM) in the diagnosis of AML in Egyptian patients.
Methods: Bone marrow samples were drawn from 40 de novo AML and 20 de
novo ALL patients. Mobilized peripheral blood was drawn from healthy donors
after granulocyte colony-stimulating factor (G-CSF) stimulation. An informed
consent in accordance with the Declaration of Helsinki was obtained. Bone
marrow samples were stained with hMICL PE (clone: 687317, R&D systems,
Minneapolis, USA) in combination with CD45 PE-PC5,CD34 ECD and CD38
FITC (Bechman Coulter,Maiami, USA) analysis done within 24 hours of sam-
pling. Sample analysis was done by multicolor flow cytometry (Coulter Epics
XL, Hialeah, USA). Gating strategy was applied using dim CD45/side scatter.
Data analysis was done on Winlist 6 (Verity Software House, Topsham, ME).
Results: In AML cases, hMICL was expressed in all studied patients ranging
from 20% to 95% (mean 60.3±19.9). This was found to be significantly higher
compared to the healthy control subjects who ranged from 0.8% to 9.5% (mean
3.5±2.4) (p<0.0001) and to ALL patients who ranged from 0.9% to 7.2% (mean
3.3±1.9) (p<0. 0001). In different FAB subtypes, expression of hMICL percent-
age was heterogeneous. The highest percentage was 95% in M1 and the lowest
was 20% in M4. This heterogeneity of hMICL % expression was found to be
significant (p=0.02). An interesting finding is that hMICL expression was also
found in all CD 34- cases with percentage that reached 87% which pave the
way for improved leukemia associated immunophenotype (LAIP) characteri-
zation and minimal residual disease (MRD) detection and quantification by mul-
ticolour FCM in the otherwise poorly described CD34- AML cases. hMICL
expression has no statistical significance regarding age, gender, hemoglobin,
platelet count, total leukocyte count, blast percentage, CD34, cytogenetic pro-
file, and FLT3 ITD mutation. Using the receiver operating characteristic (ROC)
curve, cut-off values for hMICL% and hMICL-MFI were identified which allow
the most significant separation and differentiation between AML cases and nor-
mal subjects. The hMICL % cut-off value was 9.5% showing sensitivity of 95%
and specificity of 100%. The hMICL MFI cut-off value was 2.3 showing sensi-
tivity of 100%, specificity of 85%
Summary and Conclusions: hMICL is unique novel discriminator of AML reli-
able for diagnosis and MRD detection and it is considered a goal for targeted
therapy.
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Background: Acute myeloid leukemia (AML) in elderly patients has a poor
prognosis when treated with intensive chemotherapy (IC) and there is a need
for new treatment options. Regardless of the blast count, elderly patients often
display more indolent disease behaviour, resembling that seen in high risk
myelodysplastic syndromes (MDS). Several studies have demonstrated the
efficacy of Azacitidine (AZA), approved for use in MDS, in patients with AML
unfit for IC.
Aims: We present a multi-centre retrospective analysis of efficacy of azacitidine
in AML patients unfit for IC or relapsed/refractory to IC. 
Methods: Retrospective data collection from clinical files was carried out fol-
lowing ethical committee approval. Survival was estimated using the Kaplan-
Meyer method, post-hoc pairwise comparisons using log-rank test were per-
formed and the p-values adjusted for multiple comparison using Hochberg
method. Responses were assessed according to the IWG-MDS-2006 response
criteria. [F1]Avaliação de resposta de acordo com que critérios.
Results: One-hundred and twenty three AML patients treated with AZA were
identified. Median age at diagnosis was 69 years; 67% were men. At diagnosis,
75% of patients were anemic, 38% neutropenic and 46% thrombocytopenic.
Secondary AML was diagnosed in 45% of patients. Karyotypes were normal in
40%, intermediate risk in 23% and poor risk in 21%. Patients started azacitidine
a median of 1.5 months following diagnosis. It was first line therapy in 57% and
second line following IC in 28%, unknown in 15%. Patients were treated until
progression, toxicity or bone marrow transplant and received a median number
of 5 cycles. Overall response rate was 27.6%, with 19.5% complete and 8.1%
partial responders. Stable disease at time of assessment was seen in 17.9%
and progression in 17.1%. Haematological improvement was achieved in 44.7%
of patients. Of the whole population, 4 (3.3%) were not evaluable for survival.
During the study period 86 deaths were reported. The main cause of death
was disease progression (64%). The other main identified cause was infectious
(12%). Median overall survival was 15.7 months. Response of any quality to
AZA had a significant impact in overall survival. The median survival observed
in patients achieving CR or PR was 19.2 months, in patients with SD was 24.6
months and in patients with PD was 6.4 months (p=0.006). Pairwise compar-
isons show a significant difference in overall survival between PD and CR+PR
and between PD and SD but not between CR+PR and SD. The median survival
was significantly higher in patients with haematological improvement (17 vs 13
months, respectively; log rank test: p=0.048).
The survival of the cohort treated with AZA was compared to that of a matched
pair group treated with IC. The median time from diagnosis to start of IC in this
comparator group was 0.13 months (range: 0-9.2 months). The median follow-
up was 5.4 months (range: 0.1-43.4). There were 48 deaths and only 2 patients
were still alive at the time of last follow-up. Median overall survival observed in
this comparator cohort was 5.4 months. This was significantly inferior to that
observed in the cohort treated with AZA (p<0.0001).
Summary and Conclusions: These results support the efficacy of AZA in AML
in a similar fashion to that demonstrated in high risk MDS, increasing treatment
options in these patients.
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Background: The prognostic relevance of epigenetic modifying genes
(DNMT3A, TET2, and IDH1/2) in patients with acute myeloid leukemia (AML)
has been investigated extensively.
Aims: However, the prognostic implications of these mutations following allo-
geneic hematopoietic cell transplantation (HCT) have not been evaluated com-
prehensively in patients with normal karyotype (NK)-AML.
Methods: A total of 121 patients who received allogeneic HCT for NK-AML
were evaluated for the FLT3-ITD, NPM1. CEBPA, DNMT3A, TET2, and IDH1/2
mutations in diagnostic samples and analyzed for long-term outcome following
allogeneic HCT.
Results: The prevalence rates for the mutations were: FLT3-ITDpos(32.2%),
NPM1mut (43.8%), CEBPAmut (double) (29.2%), DNMT3Amut (32.2%),
DNMT3A R882mut (19.8%), TET2mut (8.3%), and IDH1/2mut (15.7%). The 5-
year overall survival (OS) and event-free survival (EFS) rates were 57.9% and
56.2%, respectively, with a median follow-up duration of 69.2 months. A multi-
variate analysis revealed that FLT3-ITDpos (hazard ratio, [HR], 2.122; p=0.009)
and DNMT3A R882mut (HR, 2.198; p=0.012) were unfavorable prognostic fac-
tors for OS. In addition, both mutations were significant risk factors for EFS
and relapse risk. DNMT3A R882mut had high coincidence with FLT3-ITDpos
(p=0.038). Additionally, patients with both mutations showed the worst OS,
EFS, and higher relapse rates than those with the other mutations, which were
confirmed in a propensity score matching analysis.
Summary and Conclusions: These results suggest that the DNMT3A
R882mut, particularly when accompanied by FLT3-ITDpos, is a significant prog-
nostic factor for inferior transplant survival outcome by increasing relapse risk,
even afterallogeneic HCT. Thus, the association between DNMT3A
R882mutand FLT3-ITDpos will clarify the prognosis in the patients with NK-AML
after allogeneic HCT.
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LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS
PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR
HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A
RETROSPECTIVE SINGLE CENTER ANALYSIS
C. Jakob1,* S. Peinert2, F. Breywisch1, B. Guenther1, K. Dittberner1, L. Boger1,
F. Rothmann1, G. Maschmeyer1
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Background: The demethylating agents 5-azacitidine (5-AZA) or decitabine
recently became a standard of care for first line treatment of elderly or unfit
patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid
leukemia (AML) who are not eligible for intensive induction chemotherapy or
allogeneic stem cell transplantation. Although there is an improvement in overall
survival with epigenetic therapies, almost all patients eventually develop dis-
ease progression, for which no standard therapeutic option is available.
Aims: The aim of our retrospective analysis was to evaluate the clinical benefit
of low-dose cytarabine (ARA-C) treatment compared to best supportive care
(without chemotherapy) as second-line palliative treatment options after failure
of 5-AZA.
Methods: From 2009 to 2014 we treated 48 consecutive patients, 10 with
newly diagnosed high-risk MDS and 38 with de novo AML, with 5-AZA
(75mg/m2 s.c. d1-7, q-d29) as first-line therapy until progression. After failure
of 5-AZA, 15/31 patients received a 2nd-line treatment with subcutaneous low-
dose cytarabine (ARA-C, 2x 10 mg/m2/d, d1-10) and 16 patients received best
supportive care only, without chemotherapy.
Results: After first-line 5-AZA 37/48 (76%) patients achieved a partial hema-
tologic response (n=23) or stable disease (n=14). Median duration of response
was 14 (2-52) months. After a median follow-up of 18 months, 31 patients had
a disease progression, as defined by worsening of peripheral blood counts,
increase of blasts or increase in transfusion frequency. Four of 15 patients,
who were treated with ARA-C as second line therapy, achieved a partial hema-
tologic response and 5/15 had stable disease with a median response duration
of 4 months. The median overall survival from the time of progression on 5-
AZA (OS-2) was 6 months, with a trend for longer survival in patients achieving
at least a partial remission. There was no correlation between response and
cytogenetic risk. In comparison to the ARA-C group, in 16 patients who received
best supportive care only, the median OS-2 was 2.9 months and no objective
responses were observed.
Summary and Conclusions: In conclusion, our analysis show that second-
line treatment with ARA-C may add a survival benefit of approximately 3 months
compared to best supportive care alone. The second overall survival (OS-2) of
6 months is within the range achieved with low dose ARA-C as primary treat-
ment for this patient population. Our data indicate that ARA-C can be consid-
ered as a reasonable therapeutic option after failure of 1st-line treatment with
demethylating agents like 5-AZA. This clinical observation is supported by
recent pre-clinical data, showing that epigenetic modifications in AML cells can
have a sensitizing effect for the subsequent administration of ARA-C.
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Background: FLT3 internal tandem duplication (FLT3-ITD) is present in nearly
25% of patients with normal karyotype acute myeloid leukemia (NK-AML) and
have been associated with poor prognosis. Because of inferior outcome of
FLT3-ITD+ NK-AML patients when treated with standard chemotherapy regi-
mens like daunorubicin (DNR)-cytarabine (AraC) 3+7 induction (DA), this group
prompts the use of investigational therapy. Targeting the FLT3 receptor signal-
ing has recently become particularly attractive. However, so far clinical expe-
rience failed to demonstrate efficacy of such approach. 
Aims: We retrospectively evaluated the effect of the addition of cladribine to
induction regimen on patients outcome according to presence or absence of
FLT3-ITD.
Methods: 227 patients with NK-AML either enrolled in clinical trials or treated
with the same protocols outside prospective studies were included in the analy-
sis. 103 patients were treated with daunorubicine-cytarabine-cladribine (DAC)
while 124 patients received daunorubicine-cytarabine (DA). 
Results: Among FLT3-ITD+ patients the use of DAC was associated with
increased rate of complete remission rate (CR; 86% vs 61% in DA group;
p=0.04) and improved overall survival (OS; 37% vs 14%, respectively; p=0.05).
The effect on OS was most prominent when observations were censored at
time of allogeneic hematopoietic stem cell transplantation. In multivariate analy-
sis, DAC independently improved CR rate and predicted longer OS in the group
of FLT3-ITD+ patients after adjusting for age and NPM1 mutations (p=0.07 for
CR rate; p=0.009 for OS). Such an effect could not be demonstrated for FLT3-
ITD- patients.
Summary and Conclusions: Thus, our results suggest that DAC regimen
can abolish negative effect of FLT3-ITD on the prognosis of NK-AML patients.
Email address: marta.libura@gmail.com
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ELEVATED PIM-2 GENE EXPRESSION IS ASSOCIATED WITH POOR
SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
K. Kapelko-Slowik1,* T. Owczarek2,3, K. Grzymajlo2, D. Urbaniak-Kujda1,
B. Jazwiec1, M. Slowik4, K. Kuliczkowski1, M. Ugorski2,3
1Haematology, Wroclaw Medical University, 2Department of Biochemistry,
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Background: PIM-2 gene belongs to the PIM family which encodes the
serine/threonine kinases involved in cell survival and apoptosis. While PIM-1
is described as an antiapoptotic protein in acute myeloid leukemia (AML), much
less is known about the importance of PIM-2. The relations between PIM-2
gene expression and AML outcome have not been fully defined 
Aims: The aim of the presented study was to evaluate PIM-2 gene as marker
of AML malignancy. We also examined the role of PIM-2 expression in apop-
tosis and proliferation of blastic cells isolated from patients with AML.
Methods: Ninety-one patients were enrolled in this study: aged 18-84, median
age 50. Forty-eight patients reached complete remission (CR). For all patients,
bone marrow samples were collected at the time of diagnosis, only samples
with blastic cells for more than 80% of total cellularity were examined. In 20
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patients bone marrow in CR phase was assessed. The control group consisted
of 24 hematologically healthy bone marrow donors. External validation was
performed on TCGA AML dataset. PIM-2 expression levels assessed by
RNAseq and represented as z-score were downloaded from cBioPortal. Expres-
sion of PIM-2 gene was assessed by TaqMan RQ-PCRassay. Apoptosis was
measured using FITC-Annexin V and propidium iodide staining. The BrdU stain-
ing was performed using FITC BrdU Flow Kit. Inhibition of PIM-2 was performed
with RNAi and apoptosis rate of HL-60/PAC-GFP and HL-60/PAC-GFP-shPIM-
2 cells was analysed by standard methods. Expression of PIM-2, BAD, 4E-
BP1 p-BAD, p-4E-BP1 proteins was assessed by Western blot. All statistical
analyses were performed using GraphPad Prism 5 software.
Results: Median PIM-2 gene expression in AML patients was significantly high-
er than in healthy control group. AML patients with high expression levels of
PIM-2 gene (above median) had significantly shorter leukemia free survival
(LFS) than patients with low PIM-2 expression (p=0.0082). External data from
TCGA AML dataset was utilized to farther validate these observations. For
patients with AML, Kaplan-Mayer analysis of overall survival confirmed that
high PIM-2 gene expression level is associated with poor prognosis (p=0.038).
In addition, it was found that patients who achieved CR had significantly lower
expression of the PIM-2 gene than patients with no CR (p=0.0083). Importantly,
elevated PIM-2 gene expression assessed at presentation was restored to nor-
mal level in all patients in CR. Moreover we revealed overexpression of the
PIM-2 kinase and its downstream effectors: native BAD and 4E-BP1 proteins
as well as p-BAD (Ser112) and p-4E-BP1 (Ser65) in AML samples in compar-
ison to controls. Negative, moderate correlation between PIM-2 gene expres-
sion and the percentage of blastic cells in a total apoptosis was found
(r2=0.4332, p<0.0001). Cytometric analysis of HL60/PAC-GFP and HL60/PAC-
GFP-shPIM2 cells revealed increase in the number of spontaneously apoptotic
cells after inhibition of PIM-2 gene.
Summary and Conclusions: In summary, we showed that elevated expres-
sion of the PIM-2 gene in blastic cells is associated with poor prognosis of AML
patients and their resistance to induction therapy, what can be linked with
increase resistance of leukemic cells to apoptosis. We hypothesize that anti-
apoptotic effect of the PIM-2 kinase is mediated, at least in part, by increased
phosphorylation of BAD and 4E-BP1 proteins. Based on obtained data, we
speculate that AML patients with elevated PIM-2 expression more likely develop
resistance to induction therapy, what may negatively affect their survival.
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RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS
AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED
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Background: The LyMa (ClinicalTrials.gov, NCT00921414) is a prospective
randomised phase III trial conducted by the LYSA group. The study assessed
the potential benefit of Rituximab maintenance after autologous stem cell trans-
plantation (ASCT) in young previously untreated Mantle Cell Lymphoma (MCL)
patients (<66y).
Aims: The primary endpoint was EFS at 4 years after randomization, EFS
being defined as death of any cause, disease progression, severe allergic reac-
tion or severe infection to Rituximab. PFS and OS were secondary objectives.
Herein, we present the first planned interim analysis. Analysis was performed
by intention to treat.
Methods: Patients were enrolled at times of diagnosis. All patients received 4
courses of R-DHAP followed by ASCT (4 additional courses of R-CHOP was
given to patients who did not reach at least a PR after R-DHAP). The condi-
tioning regimen of ASCT was Rituximab (500mg/m2) plus BEAM. Patients
achieving a complete or partial response after ASCT were randomly assigned
between 3 years of Rituximab maintenance therapy (375mg/m2, one injection
every two months) versus wait and watch (WW) (1:1).
Results: From September 2008 to August 2012, 299 patients were included
(one patient withdrawn his consent, data of one patient with incomplete data at
time of the present analysis). Median age at registration was 57y (27-65) and
236 (78,9%) patients were male. MIPI score was low in 53,2% (n=159), inter-
mediate in 27,4% (n=82) and high in 19,4% (n=58). In all, 257 (86%) patients
proceeded to ASCT. The CR/CRu rates before and after ASCT were 81,4%
and 92.7%, respectively. Last update was performed in November 2014. Medi-
an follow-up calculated from time of inclusion is 40.6 months. For all patients,
median PFS and OS are not reached. The estimates 3y-PFS and -OS are 75%
(95%CI ; 69.5-79.6) and 83.4% (95%CI ; 78.5-87.3), respectively. Last ran-
domization was done in February 2013. Two hundred and thirty eight patients
were randomised: 119 patients were assigned to rituximab maintenance and
120 to WW. The mFU (n=238) calculated from date of randomization is 34.3
months. The 3y-EFS is 88.1% (95%CI, 79.5-93.2) in the Rituximab maintenance
arm versus 73.4% (95%CI, 62.6- 81.6) in the WW arm (p=0.0057). The 3y-OS
does not differ between the two groups (85.5 in the WW arm vs 93.1% in the
maintenance arm ; p=0.7175).
Summary and Conclusions: This planned interim analysis of the LyMa trial
shows that a 3 years of rituximab maintenance after R-DHAP plus ASCT as first-
line treatment for young patients with MCL significantly improves EFS and PFS.
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CLINICO-BIOLOGICAL CHARACTERISTICS AND OUTCOME OF
PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
CARRYING HEPATITIS B VIRUS OR C VIRUS RECEIVING
IMMUNOCHEMOTHERAPY
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Background: DLBCL patients carrying hepatitis B virus (HBV) or hepatitis C
virus (HCV) are a management challenge in the clinical setting, particularly
since rituximab-based treatments became the gold standard.
Aims: The aim of this study was to assess the HBV and HCV incidence and
their clinical and prognostic impact in a series of DLBCL patients treated with
immunochemotherapy.
Methods: 321 patients (161M/160F; median age 66) diagnosed with DLBCL
in a single center between 2002 and 2013. Primary central nervous system
lymphoma, primary mediastinal lymphoma and plasmablastic lymphoma were
excluded, as well as transformed cases from other lymphomas, post-transplant
lymphoproliferative disorders and HIV+patients. HCV+and HBV+were defined
by the presence of IgG anti-HCV and HBV core-antibodies, respectively. Main
clinico-biological characteristics and outcome were analyzed according to the
viral status.
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Results: 265 patients were virus negative, 32 HBV+(10%) and 29 HCV+(9%).
5 of the latter had HBV/HCV co-infection. Main initial features and outcome
are detailed in the table. Elevated basal bilirubin correlated with higher liver
toxicity during treatment (85% vs 40%, p<.001) and shorter overall survival
(OS). After a median follow up of 49 months (range 2-146), median OS was
not reached for patients without hepatitis, and was of 55, 38 and 14 months for
HBV+, HCV+and HBV+/HCV+patients, respectively (p=.005). HCV+patients
without liver cirrhosis showed an almost identical OS compared to hepatitis
negative patients. When the analysis was restricted to patients receiving cur-
ative intention regimens, 5 year OS for hepatitis negative, HBV+, HCV+and
HBV+/HCV+was 69%, 62%, 63% and 25%, respectively (p=NS).
Tabella 1. Summary of patient char acter ist ics and outcomes.
# These patients are also included in HBV and HCV columns;*p<,05; **p<,005;
$n= 64 patients
Figure 1.
Summary and Conclusions: The presence of HBV or HCV in DLBCL patients
entails higher number of complications; however, liver impairment and not the
hepatitis viral status is the key feature in the outcome of the patients.
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Background: Rituximab (R) plus CHOP (R-CHOP) is the standard of care for
patients with diffuse large B-cell lymphoma (DLBCL). The International Prog-
nostic Index (IPI) and revised IPI were reported as prognostic indicators for
DLBCL in 1993 and in 2007, respectively. Although they are widely accepted,
the performance status (PS) factor is sometimes ambiguous or subjective.
Therefore, we developed a new prognostic index, SIL, that includes only three
objective prognostic factors: clinical stage (S), soluble interleukin-2 receptor
level >2,500 U/mL (I), and elevated lactate dehydrogenase level (L) (Cancer
Sci. 2012).
Aims: To compare the SIL index with other risk factors that comprise the IPI
and to evaluate its utility in the risk stratification of patients with DLBCL. 
Methods: Between 2003 and 2012, we registered and treated 781 consecutive
patients with DLBCL, excluding those with mediastinal large B-cell lymphoma,
intravascular large B-cell lymphoma, and primary effusion lymphoma. All the
included patients were scheduled to undergo primary therapy with six cycles
of full-dose R-CHOP. Patients in whom the initial therapy dose was reduced by
>20% were excluded. Finally, 572 of 781 patients were retrospectively ana-
lyzed. Patients with partial remission (PR) after the initial four cycles underwent
eight R-CHOP cycles in total, whereas those who did not achieve PR after the
initial four R-CHOP cycles or those who exhibited disease progression at any
given time received salvage therapy. If deemed necessary by the attending
physician, additional local irradiation was performed in patients with PR or
complete remission.
Results: The median age at diagnosis was 63 years (range, 18-89 years). The
median number of therapy cycles was 6 (range, 1-8), and 90% of the patients
received ≥6 cycles. Sixty-one patients (11%) received radiation therapy as pri-
mary treatment, which was often used to treat sites of residual masses at the
end of chemotherapy. The median observation time for survivors was 55 months
(range, 1-131 months). For the 572 patients, the 5-year progression-free survival
(PFS) and 5-year overall survival (OS) rates were 70% and 81%, respectively.
According to the SIL index, 367 patients (64.2%) and 205 patients (35.8%) were
classified as having standard (SIL index: 0 or 1) and high (SIL index: 2 or 3)
risks, respectively. Five-year PFS rates in the standard and high risk groups
were 79% and 53%, respectively (P <0.0001). Five-year OS rates in the standard
risk and high risk groups were 90% and 66%, respectively (P <0.0001) (Figure).
Cox regression analysis of the SIL index, age (>60 years), PS (2-4), extranodal
involvement sites (>1), and sex showed that the SIL index (P <0.0001; hazard
ratio [HR]: 2.38) and PS (P=0.005; HR: 1.73) were independent risk factors for
PFS. Similarly, the SIL index (P <0.0001; HR: 2.62) and PS (P=0.006; HR: 1.89)
were independent risk factors for OS. When the patients were divided into two
groups by age (≤60 years and >60 years), the SIL index was a good prognostic
indicator for PFS and OS in both groups. When they were divided by the number
of extranodal involvement site (0-1 and >1), and sex, the SIL index was still a
good prognostic indicator for PFS and OS in both groups. Lastly, when they
were divided by PS (0-1 and 2-4), the SIL index was effective in the good PS
group. In the poor PS group however, the SIL index showed a statistically sig-
nificant difference in the OS, but not in the PFS.
Figure 1.
Summary and Conclusions: The SIL index is a simple and objective prog-
nostic indicator for DLBCL patients treated with R-CHOP.
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Background: Primary testicular lymphoma (PTL) is a rare type of extranodal
non-Hodgkin lymphoma. Because of its rarity, clinical features, and optimal
treatments remain uncertain.
Aims: To assess clinical features, outcomes and prognostic factors in patients
with PTL.
Methods: In total, 62 patients were diagnosed with PTL at 8 institutions of the
Yokohama City University Hematology Group from 1998–2014. Of 62 patients,
57 (92%) were diffuse large B-cell lymphoma (DLBCL). Our retrospective
analysis included these 57 patients with PTL-DLBCL. We defined stage IE as
mono or bilateral involvement of the testis, and stage IIE as the stage IE lesion
with concomitant regional lymph node involvement. Stage III or IV, although
undistinguishable from a nodal lymphoma in advanced stage, was defined as
testicular involvement with distant lymph nodes and/ or extra-nodal sites
involvements.
Results: The median age at diagnosis was 68 years (range, 42–85 years).
The clinical stage of PTL was stage I, II, III, and IV in 25, 15, 7, and 10 patients
respectively. The median observation period in the surviving patients was 53
months (range, 7–124 months). Fifty-five patients underwent orchiectomy. Fifty-
five patients received systemic chemotherapy; 46 with rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, 7 with
CHOP therapy, and 2 with other regimens. Of the remaining 2 patients, 1 had
orchiectomy and radiation, and 1 had best supportive care (BSC). Thirty-two
patients received contralateral testicular irradiation in addition to systemic
chemotherapy. Prophylactic intrathecal methotrexate (IT) or high-dose intra-
venous methotrexate (HdMTX) for central nervous system (CNS) relapse was
administered in 40 patients; IT for 32, and HdMTX for 8. Among the 56 patients
who underwent treatments other than BSC, 48 (86%) achieved complete remis-
sion, and 3 (5%) partial response. The 4-year progression-free survival (PFS)
and overall survival (OS) rates of all patients were 57% and 59%, respectively.
Twenty-one patients had disease progression after treatment for PTL. Extran-
odal recurrence was reported in 18. CNS was the most common site of extra-
nodal relapse observed in 6 patients, although 5 of them had prophylactic IT.
In total, 21 patients died: 13 of lymphoma, 2 of infection during chemotherapy,
1 of pneumonia in remission, 2 of secondary malignancy, and 2 of cardiopul-
monary arrest from unknown cause. Absence of B symptoms, normal levels of
serum lactate dehydrogenase, good performance status (PS), and addition of
contralateral testicular irradiation to chemotherapy were associated with better
PFS and OS at univariate analysis. Patients that received chemotherapy plus
contralateral testicular irradiation had a tendency to be in earlier stages
(P=0.03), and in better PS (P=0.008) than those who received chemotherapy
alone. However, even when the analysis was limited to the patients with stage
I and II, the benefit of radiation therapy added to chemotherapy remained sta-
tistically significant for PFS (P=0.015), and OS (P=0.002). The impact of addi-
tional radiation therapy diminished in advanced stages. In the multivariate analy-
sis, any prognostic factors were significant for OS, whereas only additional
contralateral testicular irradiation was associated with better PFS (HR 0.29;
95%CI 11-83; P=0.02).
Figure 1. PFS according to contralateral testicular irradiation.
Summary and Conclusions: PTL-DLBLC had poor outcomes, and a high fre-
quency of extranodal relapse, especially in CNS. Our study showed that
chemotherapy with contralateral testicular irradiation may improve the outcomes.
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siung Medical University Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan, ROC
Background: 3-Hydroxy-3-methylglutary–coenzyme A reductase (HMG-CoA)
inhibitors, also known as statins, are common cholesterol-lowering medications
that are widely used for the primary and secondary prevention of cardiovascular
disease and stroke. In addition to their cholesterol-lowering effects, several in
vitro and in vivo studies have suggested that statins may have anticancer prop-
erties via various mechanisms.
Aims: The purpose of this study was to investigate whether statin administration
was associated with a decreased risk of non-Hodgkin lymphoma (NHL).
Methods: This nationwide population-based case–control study was conducted
retrospectively using the National Health Insurance Research Database
(NHIRD) of Taiwan. The NHL group consisted of the patients with a first-time
diagnosis of NHL between 2005 and 2008. The cases of the control group were
pair-matched to the NHL group by sex, year of birth and index date. The usage
of statins was analyzed retrospectively in both groups since January 1, 1996
to the index day. The cumulative defined daily dose (cDDD) was estimated to
evaluate the statin exposure. Usage of other lipid-lowering agents, aspirin, non-
steroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors and angiotensin-
converting enzyme inhibitors was also identified. Adjusted odds ratios (ORs)
and 95 % CIs (95 % confidence intervals) were estimated using multiple logistic
regression.
Results: This study enrolled 1715 cases with NHL and 17150 controls for the
analysis. Compared with the group without the statin administration, the group
with any previous statin usage had an adjusted OR of 0.54 (95% CI=0.46-0.64).
In addition, the chemo-preventive effect of the statins was exerted in a dose-
response manner. The adjusted ORs were 0.69 (95% CI= 0.51-0.94), 0.56
(95% CI=0.42-0.76), 0.55 (95% CI=0.42-0.71), and 0.37 (95% CI=0.26-0.54)
for statin administration of fewer than 28, 28 to 90, 91 to 365, and more than
365 cumulative defined daily doses (cDDDs), respectively, relative to the group
without the statin administration.
Summary and Conclusions: The results of this study suggest that the admin-
istration of statins may reduce the risk of NHL.Further studies, especially
prospective randomized trials, to confirm our findings are warranted.
E973
HIGHLY SUSPECTED LYMPHOMA ASSOCIATED HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS WITHOUT PATHOLOGICAL EVIDENCE: PET-CT
FEATURES AND TREATMENT OUTCOME
J. Wang1,* H. Qiu1, S. Zhang1, D. Wang1
1Department of hematology, The first affiliated hospital of Nanjing medical uni-
versity, Nanjing, China
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening
syndrome of hyper-inflammation, caused by uncontrolled activation and prolif-
eration of lymphocytes and antigen-presenting cells. Up to now, few researches
have described the characteristic findings of PET/CT in patients with HLH,
especially for those with out known pathological evidences. Further studies
about identifying the causative agents and finding efficacious regimens to lym-
phoma associated HLH patients are seldom reported.
Aims: The aims of the present study were to: (1) investigate the characteristics
of PET-CT image in patients with sHLH; (2) find out the differences of PET-CT
characteristics between lymphoma associated HLH (LAHLH) and non-lym-
phoma associated HLH (non-LAHLH); (3) discuss the diagnostic performance
of PET-CT for the detection of underlying lymphoma, especially when patho-
logical evidences were unavailable; (4) compare the efficacy of different regi-
mens for sHLH without pathological basis.
Methods: A total of 44 adult patients first diagnosed with HLH who had under-
gone F-18 FDG PET-CT scanning before clinical treatment were enrolled in
this retrospective analysis. Their clinical manifestations, laboratory findings,
PET-CT characteristics, and received therapies or survival data were collected
and compared. PET-CT parameters were comparatively analyzed between
LAHLH patients and non-LAHLH patients. Moreover, the efficacies of initial
therapies to highly suspected lymphoma were compared by OS analysis.
Results: All of the patients had at least 3 organs involved, including 37 cases
(82.2%) showing splenomegaly, 35 cases (77.8%) with bone lesions, 34 cases
(75.6%) lymphadenopathy, 35 cases (77.8%) inflammatory changes in the lung
including pneumonia and/or atelectasis, 29 cases (64.4%) serous effusions,
26 cases (57.8%) pleura thickening and/or pleura adhesion, 17 cases (37.8%)
cholecystitis or cholelithiasis, 16 cases (35.6%) sinusitis, 15 cases (33.3%)
heart lesions, 13 cases (28.9%) brain tissue or cerebrovascular lesions, 10
cases (22.2%) hepatomegaly, 8 cases (17.8%) pericardium thickening. The
maximum SUV levels of the spleen (SUVSp), bone marrow (SUVBM), lymph
node (SUVLN), SUVmax, SUVLN/Li and SUVmax/Li in LAHLH group were signif-
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icantly higher than those in non-LAHLH group (p= 0.002, p=0.042, p=0.001,
p<0.001, p=0.041, p=0.022, respectively). However the level of SUVLi,
SUVSp/Li, SUVBM/Li in two groups revealed no significant difference. HLH
patients with an absolute SUVmax value >5.5, absolute SUVLN value >2.6, and
an absolute SUVsp value >4.8 were more like to be LAHLH (p<0.001, sensitiv-
ity=92.9% and specificity=82.4%, AUC=0.933; p=0.001, sensitivity=85.7% and
specificity=70.6%, AUC=0.851; p=0.001, sensitivity=71.4% and specifici-
ty=100%, AUC=0.836). The incidence of multiple lymphadenopathys with
increased FDG uptake in LAHLH patients was significantly higher than those
in non-LAHLH group (p=0.004); the incidence of multiple bone lesions in
LAHLH patients was significantly higher than those in non-LAHLH group
(p=0.016). Furthermore, OS analysis revealed that highly suspected LAHLH
patients treated with lymphoma-chemotherapy had better prognosis (365 days)
than those treated with non-lymphoma therapy (35 days) (p=0.003).
Figure 1.
Summary and Conclusions: PET-CT may play an important role in confirming
the diagnosis of LAHLH without pathologic evidence. Patient in LAHLH group
had remarkablely higher levels of SUVSp, SUVBM, SUVLD, SUVmax, SUVLD/Li,
and SUVmax/Li than those in non-LAHLH group. In addition, sHLH patients who
presented in PET-CT images with multiple lymphadenopathys and/or multiple
bone lesions accompanied by increased FDG uptake were more like to be
LAHLH. For the initial treatment of these highly suspected LAHLH, lymphoma
chemotherapy, rather than HLH-2004 protocol or immunosuppressive/cytokine-
regulating therapy, may have a relatively favorable effect and better clinical
outcomes.
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HIGH THROUGHPUT TCR SEQUENCING PROVIDES ADDED VALUE IN
THE DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA
I. Kirsch1,* D. Williamson1, J. Krueger2, J. Teague3, M. Tavallaee4, C. Elco3,
R. Clark3, J. Kim4, Y. Kim4, T. Kupper3, H. Robins5
1Adaptive Biotechnologies, Seattle, 2Rockefeller University, New York,
3Brigham and Women’s Hospital, Boston, 4Stanford University, Palo Alto, 5Fred
Hutchinson Cancer Research Center, Seattle, United States
Background: Diagnosis of early-stage CTCL can be challenging because skin
lesions contain a mixture of both diverse benign and clonal malignant T cells.
High throughput sequencing (HTS) of the TCR gamma (TCRG) and TCR beta
(TCRB) CDR3 regions provide markers of the total repertoire of T cell clones
in a specimen, the breadth of repertoire diversity, and an exact quantitation of
individual T cell clones.
Aims: Two independent sample cohorts from two different institutions have
been analyzed by HTS in an attempt to validate this approach and discriminate
benign from malignant skin disease.
Methods: The two independent studies together involve the analysis of >100
patients with CTCL and approximately 100 patients with benign skin disease.
Skin biopsies were studied from patients with histopathologically and clinically
suspicious or diagnostic CTCL (over 80% Stage I or Stage II), treated CTCL
patients, patients with benign inflammatory diseases, and normal skin. Genomic
DNA was extracted from FFPE or OCT sections of skin biopsy specimens of
patients. T cell receptor gamma (TCRG) and beta (TCRB) chain sequences
were then independently amplified using multiplex PCR with optimized primer
sets. Following HTS, a bioinformatics pipeline clusters the sequences into dis-
tinct clonotypes to determine overall frequencies and to identify diagnostic
clones. V, (D), and J genes are also identified for each clonotype.
Results: The assays defined the dominant clonal sequences in the majority of
malignant cases and distinguished likely gamma/delta from alpha/beta T cell
lymphoma. Using the fraction of the top two TCRG sequences divided by two
as a fraction of the total nucleated cell population defined a cut off of approxi-
mately 1/1000 above which the assay approached 100% specificity for malig-
nant disease and below which the assay approached 100% specificity for non-
malignant or treated malignant disease. TCR PCR was negative in a significant
fraction of lesions suspicious of CTCL—most of these were among those deter-
mined to be clonal by HTS. There was also a significant false positive rate for
TCR PCR.
Summary and Conclusions: HTS analyses of DNA extracted from skin biop-
sies of patients with skin disorders can provide important quantitative data of
T cell number, clonality, repertoire, and frequency and in so doing provide a
useful discriminator of benign versus malignant disease, extent of disease,
and disease response.
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THE CLINICAL IMPLICATION OF THE ACTIVATION OF NF-ΚB SIGNALING
PATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA: PRE- AND
POST-RITUXIMAB ERA
L. Lee1,* J.H. Liu2, C.H. Tzeng2, J.P. Gau2, P.M. Chen2, T.J. Chiou2
1Hematology-oncology, Veteran General Hospital of Taipei, Taoyuan branch,
2Hematology-oncology, Veteran General Hospital of Taipei, Taipei, Taiwan,
ROC
Background: The nuclear factor-κB (NF-κB) comprises a family of transcription
factors that control genes implicated in the activation, proliferation and resist-
ance to apoptosis in normal B lymphocyte and malignant lymphoma cells,
especially diffuse large B cell lymphoma (DLBCL). Gene expression studies
on DLBCL lines have discovered that several genes which are targets of NF-
κB are expressed on a subgroup of DLBCL (activated B-cell subtype). However,
the clinical implication of activated NF-κB was not fullly elucidated, especially
in the Rituximab era.
Aims: The aim of this study is through antibodies against the members of NF-
κB family to delineate the activation of NF-κB, and to evaluate the clinical impli-
cation of this signaling pathway.
Figure 1.
Methods: Seventy-six DLBCLs diagnosed between 2002~2009, treated with
antracycline containing regimen with (n=40; 53%) or without Rituximab (n=36;
47%) were evaluated with antibodies against phosphorylated p65(P-p65), phos-
phorylated IκBα (P-IκBα), p52, BCL-2, BCL-6, CD10, MUM-1 and c-MYC. IκB
phosphorylation and degradation results in liberation of NFκB dimers (p65/p50)
and its activation. Besides, there is evidence that phosphorylation of p65 on
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serine 536 leads to NFκB activation, independently of IκB degradation. There-
fore, activation of NFκB was defined as presence of positive P-p65 or P-IκBα.
The impact of activated NF-κB was analyzed comparing clinical features and
outcome including 4-year event free survival (4-year EFS) and 4-year overall
survival (4-year OS) of DLBCL patients. We also evaluate the association
between activated NF-κB and DLBCL subtypes, clinical features or other IHC
stain markers (includes BCL-2, BCL-6 and C-MYC).
Results: Seventy-six DLBCLs were enrolled, and 48 cases had activated NF-
κB. In the group with activated NF-κB, one case cannot be subdivided into
GCB or ABC subtype. Twenty (20/47; 43%) belonged to GCB subtype and
twenty-seven (27/47; 57%) belonged to non-GCB subtype (P=0.743). There
were no difference betweent NFκB activation (+) and NFκB activation (-) in Ann
Arbor stage, international prognosis index (IPI ≥3 vs. <3), and age (≥60 vs.
<60). Treatments (with or without Rituximab) given to patients with NFκB acti-
vation (+) or NFκB activation (-) also had no difference.
With a median follow-up of 58 months, the group of activated NF-κB had trend
toward better 4-year EFS(58.3 vs. 37%, P=0.075). 4-year OS was also better
in the group with activation of NFκB but with no significance (68.8% vs. 51.9%,
P=0.111). Because the gene expression studies on DLBCL cell lines suggested
NFκB is preferentially activated in ABC-like DLBCL. Subgroup analysis revealed
that in the no-GCB group, patients with activated NFκB had better 4-year EFS
(55.6% vs. 31.3%; P=0.045) and 4-year OS (75% vs. 66.7%; P=0.017). We
further analyzed if addition of Rituximab to chemotherapy could affect the clin-
ical outcome according to the activation status of NFκB. We found that patients
with activated NFκB who also received treatment with Rituximab containing
regimen had the best 4-year EFS and 4-year OS (P=0.036 and P=0.058,
respectively). Similarly, in non-GCB subgroup, patients with activated NFκB
who received treatment with Rituximab containing regimen also had the best
4-year EFS (P=0.024). In multivariate analysis, activated NFκB was correlated
with trend for better 4-year EFS (HR 0.521, P=0.056) and trend for better 4-
year OS (HR 0.479, P=0.062).
Summary and Conclusions: NFκB activation through classical pathway can
be detected through immunohistochemical stain of P-p65 or P-IκBα. Activation
of NFκB is associated with good prognosis. Besides, patients with activated
NFκB also had better outcome to Rituximab containing regimen. Subgroup
analysis revealed that in non-GCB DLBCL, patients with activated NFκB also
had better prognosis which is not observed in GCB DLBCL. NFκB activation is
not confined to non-GCB subgroup and is not correlated with other IHC markers
(BCL-6, BCL-2 or c-MYC).
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HISTOLOGICAL DISTRIBUTION, TREATMENT AND PROGNOSIS OF
PERIPHERAL T-CELL LYMPHOMAS: AN ANALYSIS OF 505 PATIENTS IN
TAIWAN
H.W. Kao1,* L.Y. Shih1,2, M.C. Kuo1, P.N. Wang1, T.L. Lin1, T.C. Tang1,
H. Chang1, Y.S. Hung1, P. Dunn1,2, J.H. Wu1, T.T. Kuo2,3
1Division of Hematology-Oncology, Chang Gung Memorial Hospital, 2College
of Medicine, Chang Gung University, Taoyuan, 3Department of Pathology,
Chang Gung Memorial Hospital, Taipei, Taiwan, ROC
Background: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group
of lymphoid malignancies. The distribution of pathological subtypes differs in
different geographic areas and the prognostic factors, optimal therapy and roles
of stem cell transplantation (SCT) remain to be defined.
Aims: We aimed to determine the clinical characteristics of PTCL in Taiwan.
Methods: We examined histological subtypes, patient characteristics, treat-
ment, and outcome among 505 consecutively newly diagnosed adult PTCL
patients from 1998 to 2014.
Results: PTCLs represented 14.3% (505/3539) of all non-Hodgkin lymphomas
(NHL). PTCL subtypes included NK/T-cell lymphoma (NKTCL) (21.0%),
angioimmunoblastic T-cell lymphoma (AITL) (20.2%), PTCL, not otherwise
specified (PTCL-NOS) (17.0%), anaplastic large cell lymphoma (ALCL)
(15.6%), adult T-cell leukemia/lymphoma (ATLL) (overall 7.3%, acute type
4.5%), others (3.0%), and cutaneous T-cell lymphomas (CTCL) (15.9%) includ-
ing mycosis fungoides (7.3%), primary cutaneous ALCL (4.6%), subcutaneous
panniculitis-like T-cell lymphoma (3.2%), and rare subtypes of CTCL (0.8%).
Median age was 56 (range 20-90) years, 53% had stage III/IV disease, 53%
had international prognostic index (IPI) ≥2, and 38% had prognostic index for
T-cell lymphoma (PIT) ≥2. 391 patients received chemotherapy: CHOP (77%),
COP (23%), proceeding to high-dose chemotherapy (ESHAP, VPBBM, MINE,
ICE or EPOCH regimen) (22%) and SCT (6%). The overall response rate was
61%, complete response (CR) rate was 51%, and 37% had primary refractory
disease. With a median follow-up of 63.7 months, 3-year progression free sur-
vival (PFS) and overall survival (OS) rates were 38% and 45% for all patients.
The 3-year OS rate for each subtype was 77% (CTCL), 63% (ALK-positive
ALCL), 52% (NKTCL), 39% (AITL), 39% (ALK-negative ALCL), 28% (PTCL-
NOS), 18% (ATLL), and 9% (others). Both IPI (HR 3.9, P<0.001) and PIT (HR
3.8, P<0.001) had significant impact on OS. In multivariate analysis, age ≥60
(HR 1.7, P<0.001), ECOG performance status ≥2 (HR 1.9, P<0.001), extra-
nodal sites ≥2 (HR 1.6, P=0.006), bone marrow involvement (HR 1.5, P<0.018),
elevated LDH (HR 1.4, P=0.017), and hypoalbuminemia (HR 1.5, P=0.02) were
independent poor pre-treatment prognostic factors for OS. OS benefit was
observed in patients who received CHOP-like compared to COP regimen (HR
0.6, P=0.004), and in patients who achieved CR (HR 0.2, P<0.001) or received
SCT (HR 0.5, P=0.052).
Summary and Conclusions: The overall frequency of PTCL among NHL and
the frequencies of NKTCL and ATLL in our cohort were higher compared to
western countries. The distribution of PTCL subtypes are mostly in line with
other Asian series except for a lower frequency of ATLL and higher frequencies
of ALCL and CTCL compared to Japanese series. IPI and PIT predicted OS.
Hypoalbuminemia was a poor prognostic factor for OS. Patients who received
CHOP-like regimen or achieved CR survived longer. SCT provided a trend of
improved OS in PTCL patients.
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THE INFLUENCE OF TREATMENT FACILITY VOLUME ON SURVIVAL OF
DIFFUSE LARGE B-CELL LYMPHOMA
R. Go1,* M. Al-Hamadani2, N. Shah3, E. Habermann3
1Hematology, Mayo Clinic, Rochester, 2Medical Research, Gundersen Medical
Foundation, La Crosse, 3Robert D. and Patricia E. Kern Center for the Science
of Health Care Delivery, MAYO CLINIC, ROCHESTER, United States
Background: Diffuse large B-cell lymphoma (DLBCL), the most common form
of non-Hodgkin lymphoma, is a relatively uncommon cancer with annual inci-
dence of ~21,000 cases in the US. 
Aims: The goal of this study was to determine the extent to which the number
of DLBCL patients treated annually in a facility (facility volume) affects overall
survival (OS).
Methods: We included DLBCL patients identified from the US National Cancer
Data Base (NCDB) from 1998 to 2011. NCDB, a joint program of the American
College of Surgeons and the American Cancer Society, is a nationwide oncol-
ogy outcomes database for more than 1,500 cancer programs in the US and
Puerto Rico capturing about 70% of all newly diagnosed cases of cancer in the
US. We classified treatment facilities by quartiles based on facility volume
(mean DLBCL patients/year): Quartile 1 (Q1; ≤2), Quartile 2 (Q2; 3-6), Quartile
3 (Q3; 7-11) and Quartile 4 (Q4; >11).
Results: 116,615 DLBCL patients were cared for in 1,547 facilities. The distri-
bution of patients according to facility volume was Q1 (2.0%), Q2 (14.3%), Q3
(23.0%) and Q4 (60.7%) and according to facility type was academic (30.3%),
comprehensive community (11.0%), community (54.1%) and other (4.6%). The
unadjusted median OS by facility volume was: Q1: 27.5 months, Q2: 38.5
months, Q3: 49.1 months and Q4: 61.3 months. After multivariable analysis
adjusting for demographic (sex, age, race, ethnicity), socioeconomic (education,
income, primary payor), geographic (area of residence), disease-specific (NHL
subtype, stage) and facility-specific (type and location) factors, we show that
facility volume remains an independent predictor of OS. Compared to patients
treated at Q4 facilities, patients treated at lower quartile facilities had a worse
OS (Q3HR: 1.03 [95% CI, 1.06-1.13]; Q2HR: 1.09 [1.06-1.13]; Q1HR: 1.21
[1.314-1.29]). We performed sensitivity analyses removing primary payor and
facility type (collinearity with age and facility volume, respectively) as well as
adjusting for Charlson-Deyo co-morbidity score (available for patients diag-
nosed after 2003) in secondary models and found similar results.
Summary and Conclusions: Patients who receive treatment at higher volume
facilities for DLBCL are likely to have longer OS than those who are treated at
facilities with a lower volume.
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CLINICAL SIGNIFICANCE OF CO-EXPRESSION OF MYC AND BCL2
PROTEIN IN AGGRESSIVE B-CELL LYMPHOMAS TREATED WITH A
SECOND LINE IMMUNOCHEMOTHERAPY
K. Miura1,* M. Nakagawa1, H. Takahashi1, Y. Hatta1, M. Sugitani2, S. Otake1,
M. Sakagami1, Y. Uchino1, S. Kiso1, H. Kodaira1, N. Iriyama1, S. Kobayashi1,
A. Hojo1, M. Yagi1, D. Kurita1, Y. Kobayashi1, M. Takei1
1Department of Hematology and Rheumatology, 2Department of Pathology,
Nihon University School of Medicine, Tokyo, Japan
Background: Recent studies have shown that concurrent expression of MYC
and BCL2 protein evaluated by immunohistochemistry (IHC) in de novo diffuse
large B-cell lymphoma (DLBCL) is associated with worse survival when stan-
dard R-CHOP is applied. However, little is known about the clinical significance
of concurrent expression of MYC/BCL2 protein in aggressive B-cell lymphomas
which failed to benefit from conventional, upfront immunochemotherapies.
Aims: We show the clinical impact of co-expression of MYC and BCL2 protein
among patients with relapsed or refractory aggressive B-cell lymphomas, who
were uniformly treated with a second line immunochemotherapy.
Methods: This is a retrospective analysis of patients with relapsed and refrac-
tory aggressive B-cell lymphomas, who were consecutively treated with the R-
IVAD regimen consisting rituximab (375 mg/m2, day 1), ifosfamide (1500 mg/m2
on day 3-7), etoposide (150 mg/m2, day 3-5), cytarabine (100 mg/m2, day 3-5)
and dexamethasone (40 mg/body, day 3-5) followed by consolidative high-dose
chemotherapies at Nihon University Itabashi Hospital from 2001 to 2009. MYC
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and BCL2 protein were analyzed by IHC assay using formalin-fixed paraffin-
embedded tissue specimens for all available cases. Cut-off values of positivity
for MYC and BCL2 protein were set as 40% and 50% of stained tumor cell,
respectively. Lymphomas showing concurrent positivity for MYC and BCL2
protein were defined as “Double expresser lymphoma (DEL)”.
Results: A total number of 27 patients with a median 61 years (range 38-79)
of age were analyzed. Nineteen patients were relapsed and the other eight
patients were refractory to upfront immunochemotherapies. Histological sub-
types consisted of 20 cases of DLBCL and seven cases of grade 3/transformed
follicular lymphoma. Totally, 12 cases (44%) were categorized into DEL. Clinical
characteristics such as risk factors consisting IPI or relapsed/refractory status
were generally balanced, whereas a histological form of DLBCL was more
common in the DEL group as compared with the non-DEL group (100% vs
53%, P=0.008). The overall response (OR) and the complete response (CR)
rate to R-IVAD for all patients was 70% and 56%, respectively. The DEL group
was less likely to respond to R-IVAD, as compared with the non-DEL group
(OR: 50% vs 87%, P=0.087, CR: 33% vs 73%, P=0.057). The numbers of
patients proceeding to consolidative therapies in the DEL group and the non-
DEL group was 4 (33%) and 9 (60%) (P=0.252), respectively. Within a median
47 months (range 2-152) of observation period, the 2-year EFS and the OS
rate for all patients was 33% and 59%, respectively (Figure a, b). As for the
status of MYC/BCL2 protein, both the 2-year EFS and the OS rate were sig-
nificantly lower in the DEL group than in the non-DHL group (Figure c, d). Mul-
tivariate analysis revealed that the negative impact of MYC/BCL2 expression
on OS was still significant (HR 3.05, 95%CI 1.05-9.65, P=0.040), after it was
adjusted for the other prognostic factors (i.e. high/high-intermediate risk for
IPI, and refractory disease).
Figure 1.
Summary and Conclusions: This analysis confirmed that dual expression of
MYC/BCL2 protein in IHC among relapsed/refractory aggressive B-cell lym-
phomas was common especially in DLBCL, and strongly associated with worse
clinical outcome. Our findings suggest that MYC/BCL2 related high-risk aggres-
sive B-cell lymphomas need highly discreet strategies in the context of second
line setting as well as upfront therapies. The standardization of diagnostic pro-
cedures for DEL should therefore be established.
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OUTCOMES OF SPLENECTOMY IN NON-HODGKIN’S LYMPHOMAS
COMPLICATED BY IMMUNE CYTOPENIAS
Y. Yevstakhevych1,* Y. Vygovska1, I. Yevstakhevych1, O. Vygovska1, V. Login-
sky1
1Hematology, SI “Institute of Blood Pathology and Transfusion Medicine, NAMS
of Ukraine”, Lviv, Ukraine
Background: Autoimmune hemolytic anemia (AIHA) and immune thrombocy-
topenia (ITP) complicate the clinical course of Non-Hodgkin’s lymphomas (NHL)
in 15-25% of patients. In cases of ineffective steroid- and chemotherapy and in
the presence of massive splenomegaly, such patients undergo splenectomy
(SE).
Aims: To retrospectively analyze the efficacy of splenectomy in patients with
NHL associated with AIHA and/or ITP.
Methods: Ninety seven patients with NHL underwent SE during 1986-2014.
In 49 out of them (50.5%), immune cytopenias were diagnosed. Warm-type
AIHA was observed in 7 (7.2%) patients: mantle cell lymphoma (MCL) in one,
splenic marginal zone lymphoma (SMZL) in 2, diffuse large B-cell lymphoma
(DLBCL) in 4. ITP was found in 28 (28.9%) patients: SMZL in 8, DLBCL in 13,
diffuse large T-cell lymphoma (DLTCL) in one, hepatosplenic T-cell lymphoma
(HCTCL) in one, and in 5 patients NHL were classified according to the Working
Formulation (WF). NHL with AIHA and ITP was diagnosed in 14 (14.4%)
patients: MCL in 2, follicular lymphoma (FL) in one, SMZL in 6, while one of
them had splenic lymphoma with villous lymphocytes (SLVL), DLBCL in 4, and
DLTCL in one. Splenomegaly was revealed in all patients, some of them devel-
oped a giant-size spleen weighing 6-8 kg. Patients were followed up to 1-270
months after splenectomy.
Results: SE has been effective in 25 (89%) out of 28 patients suffering from
NHL with ITP: a large tumor mass was removed, the platelet count was normal-
ized, and signs of hemorrhagic syndrome disappeared. In 3 patients (DLBCL –
1, DCTCL – 1, and HCTCL – 1), splenectomy proved ineffective. They died
within 4 months following surgery due to a thrombocytopenia relapse and dis-
ease progression. Mean post-splenectomy survival of patients with NHL with
ITP reached 67.3 months. SE performed in 14 patients with NHL associated
with AIHA and ITP proved effective in 9 (64%) patients: abdominal discomfort
was relieved, hemolysis was reverted, and the platelet count was normalized.
One patient died immediately after operation due to acute adrenal insufficiency,
and four patients died within 1-6 months following SE (DLBCL – 1, DLTCL – 1,
and SMZL with SLVL – 1 patient). Mean survival after SE reached 50.5 months.
The worst long-term outcomes of SE were observed in patients with NHL and
AIHA: 6 patients survived 2-22 months after operation, whereas only one has
been living for 270 months following SE. Mean survival after SE is 46.2 months.
Summary and Conclusions: SE remains to be an effective treatment option
in NHL associated with splenomegaly and immune cytopenias. The worst long-
term outcomes of SE are observed in NHL with AIHA. SE proved to be ineffec-
tive in DLTCL and HCTCL.
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LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE CELL
LYMPHOMA ASSOCIATED WITH HEPATITIS C (DLBCL+C)
S. Lepkov1,* I. subortseva2, S. kosyura1, G. Storojakov1, A. Kovrigina2,
P. Zeynalova3, O. kolomyetsev3, J. Rybuchina3, G. Tumyn3, N. kokosadze3,
T. Bulik3
1Therapy, Russian Research Medical University Moscow, 2hematology, Hema-
tology Research Center, 3oncology, Cancer Research Center NN Blokhin,
Moscow, Russian Federation
Background: Materials. 94 patients with diffuse large cell lymphoma and mark-
ers of hepatitis C (DLBCL +C) and 72 patients with diffuse large cell lymphoma
without markers of hepatitis C (DLBCL - C) were included in the study. All the
patients were under the supervision of an oncohematologist and therapist from
2003 to 2013.
Aims: The age of patients with DLBCL +C ranged from 21 to 76 years (mediana
47). In control group age ranged from 23 to 81 years (mediana 55) (p=0.02).
The ratio of men and women in the two groups was equal - in DLBCL +C -1:1.3
in the group DLBCL-C-1:1.7. Stage I and II were in 11% of patients in group
DLBCL +C, and 48% of patients in the control group; III and stage IV were in
89% of patients in the DLBCL +C, 52% in the control group (p=0.00002). Extra-
nodal lesions were 72% of patients in the DLBCL +C, 46% of patients with
DLBCL - C (p=0.006).
Methods: In the group of patients with GCB DLBCL+C was 55% non-GCB
was 45%; in the control group GCB DLBCL-C was 36%, non-GCB was 64%
of patients (p=0.001).
Results: In the group of patients with DLBCL+C antibodies to hepatitis C were
positive in all 94 patients. Positive PCR HCV was 78% (74 patients). Median
viral load at the start of chemotherapy was 2x104 copies / mL. 15 patients with
viral load was high - more than 1 x106 copies / mL. All patients received
chemotherapy CHOP / R-CHOP. After treatment in patients with DLBCL+C and
DLBCL-C complete remission was achieved in 60% and 63% respectively. Dis-
ease free survival in patients with DLBCL+C was 25 months in the control group
- 61 months. The median overall survival in DLBCL+C group was 40 months in
the control group it was 71 months (p=0.0003). Median progression free survival
in patients with GCB DLBCL+C was 40 months in the patients with GCB DLB-
CL-C - 60 months (p=0.003). Median overall survival in the group of patients
with GCB DLBCL+C was 45 months in the control group to 70 months (p=0.002).
Median progression-free survival in patients with non-GCB DLBCL+C was 10
months in the control group non-GCB DLBCL-C -60 months (p=0.00001). Overall
survival in the group of patients with non-GCB DLBCL+C was 18 months in the
patients with non-GCB DLBCL-C overall survival was 70 months (p=0.00001).
Summary and Conclusions: DLBCL with markers of viral hepatitis C is a sep-
arate group of lymphomas with characteristic clinical, morphological features.
This allows us to separate of a hepatitis C-associated DLBCL. Despite the lack
of differences in the effectiveness of the therapy, long-term results of therapy
was significantly worse in patients DLBCL+C.
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INTERIM 18F-FGD PET/CT MAY NOT PREDICT THE OUTCOME IN
PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS
TREATED WITH INTENSIVE METHOTREXATE AND CYTARABINE
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Background: 18F-fluoro-2-dexoy-D-glucose-positron emission tomography
(PET)/computed tomography (CT) is a useful imaging technique for monitoring
treatment response in cases of malignant lymphoma.
Aims: We investigated the value of interim brain PET/CT (I-PET/CT) for monitoring
the response to intensive methotrexate chemotherapy in primary central nervous
system lymphoma (PCNSL) patients with diffuse large B cell lymphoma (DLBCL).
Methods: Of 94 PCNSL patients treated with intensive methotrexate and
cytarabine chemotherapy between September 2006 and December 2012, 66
PCNSL patients with DLBCL underwent brain PET/CT at diagnosis, during ther-
apy (I-PET/CT), and at the end of therapy (final [F]-PET/CT) and were included
in this study.
Results: The patient cohort consisted of 66 individuals (43 men and 23
women), with a median age of 59 years (range, 17–75 years). During
chemotherapy, 36 patients (54.5%) showed a negative metabolism in the scan
of I-PET/CT, and 47 patients (71.2%) showed a negative F-PET/CT at the end
of therapy. The baseline characteristics were similar between I-PET/CT-nega-
tive (n=36) and I-PET/CT-positive patients (n=30). After a median follow-up of
27.5 months, there was no difference in the progression-free survival (PFS;
P=0.701) or overall survival (OS; P=0.620) between the I-PET/CT-negative and
I-PET/CT-positive groups. However, PFS in the F-PET/CT-negative group was
significantly longer than in the F-PET/CT-positive group (P <0.001) without sig-
nificant difference in OS (P=0.892)
Summary and Conclusions: Our findings suggest that I-PET/CT might not
predict the survival outcome of PCNSL patients with DLBCL treated with inten-
sive methotrexate and cytarabine chemotherapy. Prospective trials are required
to fully evaluate the role of I-PET/CT.
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CLINICAL RELEVANCE OF BONE MARROW HEMOPHAGOCYTOSIS IN
THE DIAGNOSIS OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN
ADULTS: A SINGLE CENTER, RETROSPECTIVE ANALYSIS
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Background: Hemophagocytic lymphohistiocytosis (HLH) is an immune-medi-
ated life-threatening condition diagnosed by the diagnostic criteria for HLH
(HLH-2004). However, the clinical relevance of HLH-2004 criteria is still not
clear in adult patients because it was mainly based on clinical experience in
pediatric patients. Thus, we analyzed bone marrow hemophagocytosis in adult
patients presenting suspicious hemophagocytic syndrome.
Aims: The primary objective was to analyze underlying causes, clinical features
and outcomes of adult patients with bone marrow hemophagocytosis, and the
secondary objective was to explore the feasibility and clinical usefulness of
HLH-2004 criteria in adult patients. 
Methods: We reviewed the electronic data base of medical records at the Sam-
sung Medical Center, and selected 264 patients who had evidence of hemo-
phagocytic histiocytosis in bone marrow aspiration and biopsy between January
2000 and June 2014.
Results: All patients had bone marrow hemophagocytosis, and their median
age was 53 years (range, 18-83). Malignant disorders were predominant under-
lying causes of adult HLH (n=170, 64%), especially aggressive T/NK-cell (n=82)
and B-cell non-Hodgkin lymphomas (n=45). Among non-malignancy associated
HLH (n=94, 36%), infectious disease (n=48) and idiopathic HLH (n=17) were
more common than autoimmune disease. There was no primary/familial HLH
in these patients. Fever (68%) and splenomegaly (55%) were most common
clinical manifestations, and more than 80% of patients had increased level of
serum ferritin and lactate dehydrogenase (89% and 84%, respectively) whereas
the frequency of hypofibrinogenemia, hypertriglyceridemia, and bicytopenia
were less common findings (<40%). Thus, only 45% of patients who had bone
marrow hemophagocytosis could be diagnosed with HLH based on the current
diagnostic criteria (≥five positive criteria). However, the remaining patients also
had clinically significant hemophagocytic syndrome. Malignancy was more
common cause of HLH than non-malignant disorders in patients who fulfilled
the diagnostic criteria (63% vs. 37%). After a median follow-up of 30 months,
the median overall survival (OS) was significantly worse in patients with malig-
nancy (9.0 months, 95% CI: 5.6-12.5) than patients without malignancy (71.8
months, 95% CI: 56.5-87.1, p <0.001). The presence of bi-cytopenia,
splenomegaly, and hypertriglyceridemia was not associated with poor OS (p
>0.05). However, the presence of fever, elevation of ferritin, and hypofibrino-
genemia was significantly associated with poor OS in malignancy-associated
hemophagocytosis. Especially, patients with very high ferritin level (>10,000
ng/mL) showed extremely worse OS than patients who did not.
Summary and Conclusions: Bone marrow hemophagocytosis might be a cru-
cial finding in the diagnosis of HLH in adult patients regardless of other diagnostic
clues. Considering high incidence of malignancy, especially lymphoma as pre-
disposing disorders for HLH in adults, immediate evaluation and management
should be done in adult patients with bone marrow hemophagocytosis.
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TOTAL BODY SURFACE AREA (TBSA) AS A NEW PROGNOSTIC
VARIABLE IN MYCOSIS FUNGOIDE AND SÉZARY SYNDROME
S. Novelli1,* P. Garcia-Muret2, A. Mozos3, J. Sierra1, J. Briones1
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Barcelona, Spain
Background: Mycosis fungoides and Sézary syndrome (MF/SS) are the most
common forms of primary cutaneous T cell lymphomas. There is no standard
chemotherapy regimen for advanced stages of disease. The only curative
option is allogeneic stem cell transplantation but it is limited to eligible patients.
Currently, it is still difficult to establish prognosis taking into account clinical and
biological features at diagnosis.
Aims: Our aim is to analyze the applicability of cutaneous lymphoma interna-
tional prognostic index (CLIPi) in our population with MF/SS and also evaluate
the total body-surface area (TBSA) at diagnosis and the type of skin lesions.
Methods: A retrospective analysis identified in our center 134 patients diag-
nosed with MF/SS between 1976 and 2013. (see table 1)
Tabella 1. Characteristics of MF/SS patients (n=134).
Results: The overall survival (OS) at median time of follow up (96 months) was
75.6% (CI 95%, 62.0-98.5%). In the univariate analysis, OS was analyzed by age
(≤60 vs. >60 years), advanced disease (<IIb vs ≥IIb) according to ISCL/EORTC,
presence of erythroderma, type of skin lesions and TBSA (<40% vs ≥40%) at
diagnosis; all showed differences in OS (p<0.01) (see figure 1). In the multivariate
analysis there was a significant increased relative risk of survival (p<0.05) in those
patients younger than 60 years, with TBSA less than 40% and early stage (<IIb).
Tabella 2. Independent prognostic factors for survival.
CLIPi was calculated for both early and advanced disease. There were differ-
ences in probabilities of survival in early and advanced disease, but patients
with CLIPi 0 and 1 in both groups were poorly discriminated.
Figure 1. Overall Survival at 5 and 10 years: (A) OS by Age. (B) OS by
Stage. (C) OS by TBSA. (D) OS in advanced.
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Summary and Conclusions: In conclusion, the CLIPi is a reliable tool to iden-
tify poor prognostic patients, but those with initially early stages were not fully
discriminated. The addition of the TBSA data is a simple, ready-to-use method
in the daily clinical practice that could improve the prognostic classification of
those patients with early-stage disease. This combined score, CLIPi plus TBSA,
may be used to identify early-stage patients that may benefit from new systemic
therapies.
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DIRECT ANTIGLOBULIN TEST POSITIVITY IS A PROGNOSTIC MARKER
IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
J. Tobin1, B. Shadbolt2, S. Jain3, Y. Gonzalez4, D. Talaulikar4,5,*
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Background: The revised International Prognostic Index (r-IPI) is convention-
ally used for prognostication of DLBCL patients but has limited ability to stratify
patients with a probability of survival less than 50%. There is thus a need to
identify readily available biomarkers to ifurther classify prognostic groups within
this category.
Aims: We investigated the prevalence of, and prognostic value of subclinical
autoimmunity directed against red blood cells [demonstrated by a positive direct
antiglobulin test (DAT)] in DLBCL
Methods: Eligibility criteria for inclusion in the study were: patients aged >18
years, histological diagnosis of DLBCL at the Canberra Hospital from 2004-14,
DAT performed at the time of diagnosis, and availability of relevant clinical and
laboratory data. In addition to descriptive statistics and Kaplan-Meier curves,
Cox proportional hazard regression (SPSSv22.0) was used to calculate the
prognostic effect of DAT positivity on progression free survival (PFS) at 5 years
and overall survival at 3 years (OS) controlling for R-IPI, gender, and anaemia.
Results: Of the 96 cases that fulfilled the eligibility criteria for inclusion in the
study, 77 were DAT negative (80.2%) and 19 DAT positive (19.8%). DAT pos-
itivity resulted in a poorer 5-year PFS (HR=2.3, p= 0.046) and 3-year OS
(HR=2.605, p=0.035). This effect was accentuated in the ‘poor prognosis’ sub-
set of patients identified by an r-IPI score of 3 or higher (OR=5.630, p=0.004).
Summary and Conclusions: The findings of this study demonstrate that the
prevalence of DAT positivity is much higher in DLBCL than the background
reported rate of 1:10,000. Further, it is a strong negative prognostic marker in
DLBCL and may be particularly useful in identifying patients with a very poor
prognosis. It is likely that the impact of subclinical autoimmunity on survival is
mediated by effects on the tumour microenvironment and further studies are
required to understand this epiphenomenon. 
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FEATURES OF EBV VIREMIA AND OUTCOMES IN PATIENTS RECEIVED
ALLOGENEIC STEM CELL TRANSPLANTATION: A CHINESE
MULTICENTER SURVEY
J. Chen1,* T. Song1, F. Chen1, Y. Xu1, Y. Wang1, Z. Zhu1, J. Xu2, X. Li3, C. Ye2,
X. Bao3, A. Sun1, D. Wu1
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Background: EBV reactivation and associated diseases have been well recog-
nized as one of the life threatening complications after SCT, which leads to the
establishment of prophylactic and preemptive treatment for EBV viremia. How-
ever since then, few epidemic data was shown in SCT recipients, especially in
China.
Aims: An observational data base study was conducted in patients with hema-
tological disorders who received allo-SCT from Jun 2011 through Jun 2014. 
Methods: EBV-negative status was confirmed before transplant for both donors
and recipients. EBV-DNA was screened weekly until Day 100 post SCT by
qPCR, and then every 2-4 weeks until 1 year. Additional tests were carried out
when clinically indicated. All patients received ganciclovir during conditioning
regimen, and then switched to acyclovir or valaciclovir after stem cell infusion
until 1 year post SCT. Ganciclovir and/or foscarnet were used when DNAemia
developed, as well as rituximab for high risk patients such as high viral load or
persistent DNAemia.
Results: This study recruited 892 evaluable cases, including 91 cases of
benign diseases and 801 cases of malignancies. EBV-DNA was detected in
165 cases with a median duration of 55 days (16-618days) post SCT, and the
long-term cumulative incidence of DNAemia was 21.3±1.5%. Totally 7 patients
developed probable or proven PTLD. Log-rank test showed EBV-DNAemia
had impact on neither 2 year-OS (67.2±6.3% vs 66.2±1.9%, P=0.341) nor 2
year-NRM (19.4±4.0% vs 25.1±1.8%, P=0.272). Cox model analysis revealed
that haploidentical donor (RR 1.973 [95%CI 1.383-2.814], P<0.001) and the
use of ATG/ALG (RR 4.831 [95%CI 2.469-9.524], P<0.001) were independent
risk factors (Figure 1). While focusing on leukemia patients, RIC regimen was
identified as an additional risk factor (RR 3.378 [95%CI 1.058-10.870]), with a
weaker association (P=0.040).
Summary and Conclusions: Reported EBV viremia incidence post SCT
ranged from 0.6 to 26%. A relatively higher incidence in this study was probably
due to higher proportion of haploidentical donor SCT. Fortunately, OS and NRM
were comparable between EBV-positive and EBV-negative patients, and PTLD
was rarely observed, which implied the efficacy of preemptive treatment. Pre-
viously described risk factors of EBV reactivation include unrelated or HLA-
mismatched donor, use of T cell depletion in vivo and onset of GVHD. Our
results were partially in accordance with those literatures. Acute GVHD had
not been identified as an independent risk factor, and a probable reason is that
physicians paid more attention to virus infection during the treatment of GVHD.
For haploidentical donor SCT recipients, the EBV prophylactic strategy needs
to be further explored.
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A MODIFIED-INTERNATIONAL PROGNOSTIC INDEX INCLUDING
PRETREATMENT HEMOGLOBIN LEVEL FOR EARLY STAGE
EXTRANODAL NK/T CELL LYMPHOMA
L. Wang1,* Z.J. Xia1, Y.J. Zhang2
1Hematologic Oncology, 2radiation oncology, Sun Yat-sen University Cancer
Center, Guangzhou, China
Background: Anemia is a common finding in cancer patients, even before
patients have received radiotherapy or chemotherapy and even when there is
no bone marrow infiltration. Recent studies have found that pretreatment ane-
mia status is correlated with shorter survival in patients with several hemato-
logical malignancies. 
Aims: We aimed to define the relationship between pretreatment hemoglobin
level and survival outcomes in patients of extranodal NK/T cell lymphoma,
nasal type (ENKTL). 
Methods: We retrospectively investigated the prognostic role of pretreatment
hemoglobin level in 352 patients with stage I/II ENKTL.
Results: Of 352 patients, 67% had stage I disease, and 79.8% had interna-
tional prognostic index (IPI) scores between 0 to 1. There were no significant
correlations between baseline hemoglobin level and age, ECOG performance
status score, lactate dehydrogenase (LDH) level, and Ann-Arbor stage. The
complete response rate in patients with anemia was 64.7%, slightly lower than
that in patients without anemia (75.6%, P=0.076). The overall response rate in
both groups were similar (84.1% and 88.7%, P>0.05). At a median follow-up
time of 83.8 months, the 5-year and 10-year PFS rate were 48.0% and 40.0%,
respectively, and the 5-year and 10-year OS rate were 63.0% and 60.0%,
respectively. Patients with pretreatment hemoglobin level<120g/L had signifi-
cantly inferior PFS and OS than those with hemoglobin level≥120g/L (P<0.05).
In a multivariate Cox regression model, age, ECOG performance status, LDH
level, Ann-Arbor stage, and pretreatment hemoglobin level were all independent
prognostic factors for PFS and OS (P<0.05). Using these five parameters, a
modified-IPI model (mIPI) was constructed and three prognostic groups were
classified: group 1, no adverse factors; group 2, one or two factor; group 3,
three or more factors. This mIPI could categorize three groups with significantly
different PFS and OS (both P<0.0001). Using the cohort of patients who
received asparaginase-based therapy as a validation set, this mIPI retained
its prognostic value. 
Summary and Conclusions: This large-cohort retrospective study confirmed
the independent prognostic role of pretreatment hemoglobin level in early stage
ENKTL, and a newly modified IPI including pretreatment hemoglobin level
could be used to further optimize treatments for patients with stage I/II ENKTL,
even in the era of asparaginase.
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CARBOPLATIN, ARACTYIN PLUS DEXAMETHASONE WITH OR WITHOUT
RITUXIMAB (DHAC+/-R) IS A FEASIBLE AND EFFECTIVE TREATMENT
FOR LYMPHOMA PATIENTS
B. Tessoulin1,* E. Deslandes2, J. Moynard2, T. Gastinne1, H. Maisonneuve3,
N. Blin1, B. Mahé1, V. Dubruille1, M. Voldoire1, P. Gallas1, P. Moreau1,
P. Thomaré2, S. Le Gouill1
1Clinical Hematology, 2Clinical Pharmacy Oncology Unit, Nantes University
Hospital, Nantes, 3Clinical Hematology, Hospital, La Roche sur Yon, France
Background: Salt platins (cisplatin, oxaliplatin, carboplatin) are used in
relapsed/refractory (R/R) lymphomas. The so-called DHAP regimen with or
without Rituximab (R) combines dexamethasone, cisplatin plus high-dose
cytarabin (AraC-HD). However, cisplatin-induced nephrotoxicity is a major con-
cern: 10-20% of tubular complication sometimes leading to persistent reduced
glomerular filtration that jeopardizes autologous stem cell transplantation
(ASCT). Oxaliplatin may replaces cisplatin but it is associated with neuropathy
toxicity. Carboplatin is widely used in solid tumours and combined with ifos-
famide (ICE regimen) in lymphomas. However, the carboplatin plus AraC-HD
and dexamethasone (DHAC+/-R) regimen has never been evaluated.
394 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Aims: Taken into account the potential benefice of carboplatin, we investigated
this regimen. Herein, we report the toxicity and efficacy of DHAC+/-R in lym-
phomas patients.
Methods: From September 2008 to September 2014, all R/R lymphoma
patients treated in our institution received DHAC+/R instead of DHAP+/-R. Only
patients with Mantle Cell Lymphoma (MCL) or contra-indication to anthracycline
was allowed to receive upfront DHAC+/-R. Rituximab (375mg/m2) was admin-
istrated only in CD20+lymphoma entities. DHAC consisted of: Carboplatin (tar-
geted AUC =5, Calvert’s formula [Dose (mg)= AUC x (GFR +25)]), AraC-HD
2g/m2 two times a day (day 2) and IV or oral dexamethasone from day 1 to 4.
Interval between courses was 21 days. Number of cycles was adapted to
patients and therapeutic program including or not ASCT.
Results: 182 patients received DHAC+/-R. Diagnoses were as followed: Diffuse
Large B Cell Lymphoma (DLBCL) in 97 cases (53%), Follicular Lymphoma (FL)
in 24 cases (13%), Hodgkin Disease (HD) in 22 cases (12%), MCL in 22 cases
(12%), Peripheral T Cell Lymphoma (PTCL) in 6 cases (3%) and 7 cases pre-
sented with low grade B lymphomas and 3 patients had plasmablastic lym-
phomas. Twenty-two patients received upfront DHAC+/-R while 54 were in
relapse (n=54, 30%), 61 in partial response (PR) (34%), 19 in stable
disease/refractory (SD) (11%) and 23 patients had progressive disease (PD)
(13%). The median number of treatments line before DHAC+/-R was 1 (range,
1-4). At time of first cycle, median age was 53 years (range, 18-75). Before
start of DHAC+/-R, ASCT was planned for 133 patients (73%). 48% of patients
received DHAC+/-R with overnight stay and 38% in day care hospital. For all
patients, a median of 3 cycles of DHAC+/-R was administrated. Median dosing
of carboplatin at cycle 1, 2, 3, 4, 5 and 6 were (mg/m²) 350, 350, 350, 350, 310,
315, respectively. Median dosing of AraC-HD was 4g/m² through all cycles.
78% of patients with advanced disease completed the scheduled number of
cycles. Major cause of arrest of DHAC+/-R was PD or SD (32 out of 41). In
term of toxicity, Grade >=3 haematological toxicities were reported mainly
thrombopenia (n=53) and anaemia (n=41). Transfusion support was used in
106 patients (58%), with a median of 2 red blood cell units (2-14) and 2 platelets
units (1-27) during the treatment period. 11 sepsis were reported. One patient
died of septic shock at day 8 of first cycle of DHAC. No grade >= 3 renal (4 cas-
es of grade 1/2), and only one grade 3 neurological toxicities were reported. In
term of response, Percentage of response after DHAC was as followed: com-
plete remission (CR) in 27%, PR in 42%, SD in 11% and 20% PD. 60% of the
patients at diagnosis reached CR, while 72% of patients with relapsed lym-
phoma reached PR. For the entire cohort, the median follow-up was 24m
(range, 2-71), median OS was not reached (estimated 2-year OS was 74%),
and median PFS was 46m. According to lymphoma entities, median PFS were
3.6m for PTCL, 21m for DLBCL, NR for FL, NR for MCL and 51m for HD. When
focusing on DLBCL with insufficient response before ASCT, the 2y OS was
85% and the 2y PFS was 64% (41-77). Among the 133 patients scheduled for
ASCT, 96 were in response after DHAC+/-R and they all underwent ASCT.
Summary and Conclusions: Herein, we show that DHAC+/-R is a safe
chemotherapy regimen associated with good clinical response in all lymphoma
entities and does not jeopardize ASCT when PR is reached.
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C-MYC AND BCL2 TRANSLOCATION FREQUENCY IN DIFFUSE LARGE B
CELL LYMPHOMAS
B. Akkaya1,* O. Salim2, H. Akkaya3, M. Ozcan1, O.K. Yucel2, R. Erdem2,
U. Iltar2, L. Undar2
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Background: Diffuse large B-cell lymphomas (DLBCLs) are a biologically het-
erogeneous group with varied clinical courses, histology, molecular and cyto-
genetic characteristics.
Aims: DLBCLs have been associated with multiple cytogenetic abnormalities
including MYC with BCL6 or BCL2 rearrangement. Three antibody panel of
immunohistochemical stains can be used to subclassify DLBCL into prognos-
tically significant germinal center B-cell like (GCB) DLBCL and activated B-cell
like (ABC) DLBCL subtypes. Both CD 10 and BCL6 are considered as germinal
center markers while MUM 1 is expressed in activated B-cells and plasma
cells.The aim of this study was to investigate the frequency and prognostic
impact of BCL2 and MYC rearrangements. 
Methods: In the present study, we evaluated the expression patterns of CD
10, BCL6 and MUM 1 by immunohistochemistry on contructed 121 cases (62;
GCB, 59 ABC), (60; female, 61; male) of DLBCL in tissue microarray. MYC,
BCL2 rearrangements were investigated by interphase fluorescence in situ
hybridization (FISH) on tissue microarrays in 97 DLBCLs.
Results: Mean age of patients was 54.8 year. There were 60 women ( 49,58%)
and 61 men (50,41%) patients. Tumors were located at lymph nodes in 59
patients (48,76%). Mean of survival time was 65,74 months. FISH was success-
fully performed in 97 cases. No significant differences were observed with regard
to age (<60 vs -60years), sex, primary site of presentation (nodal vs extranodal),
stage (I-II vs III-IV) among GCB and ABC subgroups. MYC rearrangements
were observed in 11 (11,3%) of 97 DLBCL patients. There was no association
with other clinical features, including age, sex, nodal/extranodal disease. MYC
rearrangement was associated with significantly worse overall survival (p=.00).
MYC rearrangement was more common in cases with GCB phenotype (9 cases
GCB; 2 cases ABC). BCL2 rearrangements were observed in 14 (14,4%) of 97
DLBCL patients. Six of them were extranodal lymphoma, eight cases were nodal
lymphoma. BCL2 rearrangements were more common in nodal than in extran-
odal presentations. There was no association with other clinical features, includ-
ing age, sex. BCL2 rearrangement had prognostic impact on outcome (p= .00).
No significant differences were observed with regard to age (<60 vs -60years),
sex, primary site of presentation (nodal vs extranodal), stage (I-II vs III-IV) among
GCB and ABC subgroups.No significant differences were observed with regard
to BCL2 rearrengement among GCB and ABC phenotype. MYC and BCL2
rearrangements were observed in 3 (3,09%) of 97 cases. There was no signifi-
cant difference between GCB and ABC phenotype cases with regard to MYC
and BCL2 rearrangements. Three cases were 53 (female), 53, 63 years years
old, respectively. Two of them were GCB type of DLBCL. The patients were died
in 24.,18. and 35. months after diagnosis. Double-hit lymphoma patients included
one female and two males with a median age of 56 years (range, 53-63). Two
cases had primary nodal and one case primary extranodal presentations. The
majority of patients had stage IV disease.
Summary and Conclusions: Cases in which clinical, morphological and
immunohistochemical diagnosis are not adequate to discriminate DLBCL-BL,
cytogenetic studies are beneficial. In this way, not only the patient will be able
to reach the correct diagnosis but also get the effective treatment. We concluded
that C-MYC and BCL2 may contribute to aggressive transformation, and more
mechanism-based therapy should be explored. Analysis of MYC gene
rearrangement along with BCL2 is critical in identifying high-risk patients with
poor prognosis.
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R-DA-EPOCH VS R-CHOP IN PATIENTS WITH PRIMARY MEDIASTINAL
LARGE B-CELL LYMPHOMA: INTERIM RESULTS OF RANDOMIZED
(PROSPECTIVE) MULTICENTER STUDY
I. Kryachok1,* I. Stepanishyna1, K. Filonenko1, O. Novosad1, I. Tytorenko1,
T. Skrypets1
1Oncohematology, National Cancer Institute, Kiev, Ukraine
Background: The standard frontline therapy of primary mediastinal large B-
cell lymphoma (PMBL) does not establish. Different anthracycline–based reg-
imens are applied. Therefore, the effort to determine the most effective and
well-tolerated treatment of such category of patients is reasonable.
Aims: To compare the treatment efficacy and toxicity of R-da-EPOCH and R-
CHOP regimens in patients with PMBL.
Methods: 57 patients with newly diagnosed PMBL from five Ukrainian centers
were included into the study. Median age was 30 years (range 17-45), 39
females (68.4%) and 18 males (31.6%). 70.2 % of patient had early stage (І-ІІ)
of disease, 80.7 % of patients had greatest size of the tumor mass in medi-
astinum more than 10 cm. The tumor pleurisy, pericarditis were revealed in
40.3% and 42.1%, respectively. Patients were randomized in two groups to
receive R-da-EPOCH (32 patients) or R-CHOP (25 patients). Primary and post
treatment assessment of disease included PET-CT or CT of the whole body.
The treatment efficacy in both groups was evaluated according to Cheson cri-
teria 1999, 2007 and Deauville criteria. All patients received 6 cycles of R-
chemo±mediastinal radiation therapy (30-36 Gy).
Results: The ORR was 100% in the group of R-da-EPOCH and 78% in group
of R-CHOP, p<0.01. CR rate (including CR unconfirmed) was 75% and 48%,
respectively, p<0.05. Primary refractory disease was diagnosed in 3 pts (12%)
of R-CHOP group. 1 patient from R-da-EPOCH-group had early relapse up to
6 months after treatment. All 57 patients had manifestations of treatment toxicity.
54 (94.7%) patients completed full treatment plan. There was no significant dif-
ference in toxicity rate in both groups. Treatment was complicated by anemia
grade 3-4 in one case in R-da-EPOCH group vs two cases in R-CHOP group.
FN was detected in 4 pts (12.4%) vs 3 pts (12%), respectively. Thrombocy-
topenia grade 3-4 was not observed. All cases of non-hematological toxicity
were grade 1-2.
Summary and Conclusions: The treatment of patients with PMBL with both
regimens was quite efficient, but ORR and CR rate was significantly higher in
R-da-EPOCH group. The treatment toxicity rate was comparable in both groups.
The study should be continued to evaluate and analyze long-term results.
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Background: A number of second-generation monoclonal antibodies (mAbs)
that target the antigens CD20 and CD19 have been evaluated across a range
of non-Hodgkin’s lymphoma (NHL) subtypes combined with chemotherapy, as
a single agent, or as maintenance therapy. Although these agents are usually
well tolerated and have demonstrated clinical activity in patients (pts) with NHL,
there remains a high unmet medical need for new therapies for pts with
relapsed or refractory (R-R) B-cell NHL. MOR208 is an Fc-engineered, human-
ized mAb that targets the B-cell-specific antigen CD19 and which possesses
significantly enhanced antibody-dependent cell-mediated toxicity, a key mech-
anism for tumor cell killing. 
Aims: To evaluate the preliminary efficacy and safety of MOR208 in adult pts
with relapsed or refractory NHL.
Methods: This is a non-randomized, open-label, multicenter, two-stage, phase
IIa study of MOR208 in pts with R-R NHL previously treated with rituximab who
were not candidates for high-dose chemotherapy with stem cell support. Adult pts
with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follic-
ular lymphoma (FL), or other indolent NHL (iNHL), were treated with single-agent
MOR208, at an intravenous dose of 12 mg/kg, weekly, over two 28-day cycles.
Pts with at least stable disease according to the 2007 International Response Cri-
teria were to continue treatment with MOR208 for another cycle. Pts achieving a
complete or partial response (CR or PR) could then receive maintenance MOR208
every two or four weeks, depending on the investigator’s decision, until progres-
sion. Overall response rate (ORR=CR +PR) was the primary endpoint.
Results: By 17 November 2014, all pts (N=89) had been enrolled (DLBCL, n=35;
FL, n=31; MCL, n=12; iNHL, n=11); median age was 67 (range 35–90) years. Of
these pts, 88% had stage III–IV disease and the median number of prior therapies
was 2 (range 1–4). The mean number of cycles completed was 2.2 (0–3). The
investigator-assessed responses across all NHL subtypes are shown in Table 1;
the highest ORR was recorded in the DLBCL cohort (26%). Preliminary median
duration of response was 7.7 months in the DLBCL group and 2.6 months in the
FL group. Grade ≥3 non-hematologic treatment-emergent adverse events
(TEAEs) were recorded in 30 pts (34%); disease progression, reported in 10 pts
(11%), was most common. Grade ≥3 hematologic TEAEs were recorded in 8 pts
(9%); neutropenia, reported in 5 pts (6%), was most common. Infusion-related
reactions, reported in 8 pts (9%), were all grade 1–2 except for one case of dys-
pnea, which was grade 4. There were no treatment-related deaths.
Tabella 1. Investigator-assessed responses in HHL subtypes (safety pop-
ulation).
Summary and Conclusions: MOR208 demonstrated encouraging single-
agent efficacy with CRs observed in pts with R-R DLBCL, FL, and iNHL.
MOR208 is well tolerated without significant infusional toxicity. Protocols are
being developed to investigate MOR208 in combination with other agents.
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PROPOSED PROGNOSTIC MODEL FOR PERIPHERAL T-CELL
LYMPHOMA: PSU-PROGNOSTIC INDEX FOR T-CELL LYMPHOMA
(PSU-PIT) SCORE
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Background: Peripheral T-cell lymphoma (PTCL) is an uncommon lymphoma
entity which is composed of various histological subtypes and unfavorable out-
comes. Compared with Western countries, the prevalence of PTCL is higher
in the Asian population and accounts for 15-20%.
Aims: This objective of the study was to identify prognostic factors and to pro-
pose a new prognostic model for PTCL patients.
Methods: The clinical characteristics, histopathology, treatment outcomes, and
survival of 182 newly diagnosed PTCL patients from 2001 to 2014 in Songk-
lanagarind Hospital were retrospectively reviewed. The clinical and outcome
data were analyzed to define the factors associated with the response rate
and survival outcomes. 
Results: The histological subtypes of our patients included PTCL, NOS (33.5%),
AITL (17.6%), nasal NKTCL (15.4%), CTCL (12.6%), SPTCL (12.1%), ALCL
(4.4%), and others (4.4%). Overall clinical characteristics of the patients included
a median age of 53 years (range 15-89 years), 70.3% male, 87.4% ECOG score
0-1, 80.2% extranodal lesions with 28.1% extranodal lesions >1, 48.4% Ann
Arbor stage III-IV, 50% had B symptoms, 63.7% had high LDH level, 23.5% had
bone marrow (BM) involvement, and 10.4% had thrombocytopenia (platelet
count <150x109/l). Eighty-five percent of the patients were treated with
chemotherapy and CHOP regimen was used in 77.4%. Of the 148 patients eval-
uated, the overall response rate was 69.6% with 47.3% complete remission
(CR). With the median follow-up time of 18 months, the median overall survival
(OS) was 23.9 months and the 3-year OS was 43.8%. From multivariate analy-
ses, 6 factors were significantly associated with poor OS including the ECOG
score 2-4 (p=0.000), extranodal >1 (p=0.013), Ann Arbor stage III-IV (p=0.005),
B symptoms (p=0.003), BM involvement (p=0.003), and platelet count
<150x109/l (p=0.001). A new prognostic (PSU-PIT) model was constructed by
combination of these prognostic variables: score 0-1 as low-risk group, score
2-3 as intermediate-risk group, and score >3 as high-risk group. The PSU-PIT
score was able to differentiate 3 risk-groups of PTCL patients with significantly
different response rates (p=0.016) and survival outcomes (p=0.000) as the table.
Tabella 1.
PSU-PIT risk group N (%) CR rate (%) Median OS (mo) 3-year OS (%)
Low 101 (55.5) 50 47 54.6
Intermediate 47 (25.8) 34 13 38.5
High 34 (18.7) 12 9 13.8
p value 0.016 0.000 0.000
Summary and Conclusions: A new prognostic model for PTCL was proposed.
The PSU-PIT score efficiently predicted the CR rate and 3-year OS among the
three risk groups of our PTCL patients.
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RESULTS OF TREATMENT OF LYMPHOBLASTIC LYMPHOMA AT THE
CHILDREN CANCER HOSPITAL EGYPT- A SINGLE CENTER EXPERIENCE
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Background: Lymphoblastic lymphoma (LL) and acute lymphoblastic leukemia
(ALL) and are neoplasms of immature B or T-cell precursors. They are considered
as a unique biological entity in the 2008 World Health Organization Classification
of Hematologic Neoplasm. Both entities are arbitrarily separated by a cut-off point
of 20-25% of blast cells in the bone marrow. Treatment of LL has evolved over
time from conventional high-grade NHL schedules to ALL- derived protocols.
Aims: The aim of this work is to estimate the EFS, OS, and common
chemotherapy toxicities of LL patients treated at the Children Cancer Hospital
Egypt during 5.5 years period.
Methods: A Retrospective review of patients charts diagnosed and treated as
LL during the period between July 2007 till end of December 2012 was done.
Patients were treated according to St. Jude Children Research Hospital ALL
Total Therapy XV protocol, standard risk arm.
Results: This study included 77 patients. T- cell LL patients were 87%, while
B-cell were 13%. The median age at diagnosis was 9 years (range 1–17 years).
The majority were males (70.1%). Stage III was the most common at presen-
tation (74%). Two patients were excluded from analysis as they died before
receiving chemotherapy. Complete remission post induction chemotherapy
was seen in 25.3% of the patients, partial remission in 72%. Progressive dis-
ease was the event in 6.6% of the patients, while 5.3% suffered from a disease
recurrence. The most common chemotherapy toxicities were cerebral venous
thrombosis (20%), followed by bone infarcts ((10.6%), and avascular necrosis
of head of femur (9.3%). One patient developed secondary AML after 3 years
of FU. Disease recurrence was local in 4% and systemic in 5% of the patients.
By the end of the study, 84% of the patients were alive, 16% were dead. Mean
duration of follow up was 48.6 months (range 1-89 months). The 4 years overall
survival was 82.7% while event free survival was 82.2%.
Summary and Conclusions: Disease progression and chemotherapy related
toxicity are the main causes of death in pediatric LL patients. While cerebral
vascular thrombosis and steroids induced musculoskletal complications are
the major chemotherapeutic adverse events.
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Background: The new NCCN IPI has been suggested as a better outcome
predictor than the classic IPI in patients with DLBCL in the Rituximab era (blood
2014). The MDA-LNH-2011-01 study analyzed the effectiveness and toxic pro-
file of R-COMP in patients 70 and above with diagnosis of DLBCL and grade 3
Follicular Lymphoma, G3FL (EHA 2013).
Aims: The aim of this study is to evaluate the new NCCN IPI in 70 yr old and
above aggressive lymphoma patients treated with R-COMP (Rituximab 375
mg/m2/day1, Ciclofosfamide 750 mg/m2/day1, Vincristine 2 mg/day1, Lipo-
somal non pegilated Doxorubicin 50 mg/m2/day1 and Prednisone 60
mg/m2/days 1-5).
Methods: We performed the analysis of the ORR, CRR (as Revised-Response-
Criteria-for-Malignant-Lymphoma v2007), OS and PFS (Kaplan meier) using
the new NCCN IPI as well as the classic IPI in the patients included in the
MDA-LNH-2011-01 study. This study was approved by the Spanish Medicines
Agency (AEMPS).
Results: The MDA-LNH-2011-01 study included 100 patients from 15 Spanish
sites, data to perform the new NCCN IPI were available in 84 pt. Mean age
77.3 (70-91), age >75yr 52pt (62%), M/F 46/38pt, DLBCL/G3FL 74/10pt, Ann
Arbor III/IV 54pt (64%), extranodal involvement 52pt (62%), ECOG≥2 38pt
(45%), LDH 1-3 49pt (58%), LDH>3 8pt (9.5%). NCCN IPI: int-low 14pt, int-
high 36pt, high 34pt. Classic IPI: low 10pt, int-low 23pt, int-high 19pt, high 32pt.
Effectiveness: CRR 55pt (65.5%), mean OS 24.6 months, mean PFS 22.7
months. Toxicity: Febrile neutropenia (FN) 29pt (34%). In the univariate analysis
ECOG≥2 predicts OS and PFS (p<0.01 and p 0.02) and extranodal involvement
predicts PFS (p0.02). The NCCN IPI index results in statistical significant dif-
ferences for OS (p0.01), classic IPI don’t (p0.07). Both index predict OS
(p<0.01) and have correlation with FN incidence, if we make two groups, low
and int-low versus int-high and high. We didn’t observed correlation between
other clinical baseline characteristics, age >80 yr, creatinine >1.3 mg/dL, Hb
<10g/dL and OS.
Summary and Conclusions: In our experience NCCN IPI is useful to predict
OS in 70 and above aggressive lymphoma patients treated with R-COMP. Mak-
ing two groups (low and int-low versus int-high and high) both index are useful
to predict OS and FN.
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Background: Angioimmunoblastic T-cell lymphoma (AITL) is one of the most
frequent subtypes of T-cell lymphoma encountered in Western countries. Its
optimal first-line treatment remains ill-defined with only 30% of patients expe-
riencing long-term disease free survival when treated with anthracycline-
based regimens. This disorder derives from the “follicular helper T cells” (TFH)
subset developing within a unique malignant microenvironment. Owing to the
importance of this microenvironment and given the promising activity of lenali-
nomide in a relapsed/refractory setting in AITL, we postulated that AITL
patients might benefit from a treatment with lenalinomide combined with a
classical CHOP regimen.
Aims: This multicenter, open label, phase 2 trial (NCT01553786) investigates
the combination of lenalidomide with CHOP in previously untreated elderly
patients with AITL.
Methods: Patients older than 59 years were treated with 8 cycles of lenalido-
mide +CHOP 21 (lenalidomide 25 mg/day (d), d1 to 14 - cyclophosphamide
750 mg/m², d1- doxorubicin 50 mg/m², d1- vincristine 1.4 mg/m², d1-prednisone
40 mg/m², d1 to 5, with pegfilgrastim at day 6) and received intrathecal
methotrexate as central nervous system prophylaxis with the first 4 cycles. A
thrombosis prophylaxis was mandatory. A dose adjustment of lenalidomide was
planned according to related toxicities. A PET was performed at diagnosis and
at the end of treatment. Histologic samples and PET were centrally reviewed.
The primary objective was to evaluate the complete response (CR) rate based
on a visual interpretation (Deauville five points scale) of PET according to the
Lugano 2014 Classification. Secondary endpoints were safety, progression free
survival and overall survival. Based on a Simon two-stage design comparing a
CR rate of 60% with treatment to an unacceptable CR rate of 45% (CHOP
alone), 17 or more CR out of 37 evaluable patients were required to declare
the treatment worthy of further testing.
Results: Between November 2011 and July 2014, 19 LYSA centers enrolled
38 patients, of whom 37 were evaluable. Median age at diagnosis was 68 (59-
79), 47 % were male, 68% had a performance status of 0 to 1, 97% an Ann
Arbor stage ≥III, 84% IPI≥3 and 82% a PIT score≥2. The mean number of
cycles delivered was 5.9. A total of 21 patients received the 8 planned cycles.
A metabolic CR was obtained in 17 patients (46% [IC95%:29.5-63.1]) and 3
patients achieved a partial response, providing an overall response rate of
54%, 12 patients progressed and 5 could not be evaluated (one death of a
septic shock after cycle 1, one withdrawal of consent, 2 patients with a major
protocol violation retrieved after one cycle and one patient who refused to
continue lenalidomide after one cycle). Toxicity was in the range of CHOP reg-
imen with 70% and 30% grade 4 neutropenia and thrombocytopenia, respec-
tively. Four episodes of thrombosis occurred during treatment. No second can-
cer was reported.
Summary and Conclusions: This pre-planned interim analysis shows that a
combination of 25 mg of lenalidomide for 14 days with CHOP cycles gives
acceptable activity and toxicity in AITL elderly patients. The study will continue
as planned for a total of 70 evaluable patients.
E995
SUVMAX ON 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION
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Background: Although 18F-fluorodeoxyglucose positron emission tomography
(PET) imaging for diffuse large B cell lymphoma (DLBCL) have been widely
utilized to evaluate the staging and response assessment after treatment with
high sensitivity, the relevance of the maximum standard uptake value (SUVmax)
on pretreatment PET scan to disease outcome has been poorly studied.
Aims: The aim of this study was to investigate relationships between SUVmax
on pretreatment PET scan and clinicopathological factors, and the prognostic
value of baseline SUVmax in patients with newly diagnosed DLBCL.
Methods: In the present study, 140 patients with newly diagnosed DLBCL who
had undergone pretreatment PET scan from 2004 to 2014 in single institute
using an identical protocol were reviewed and analyzed. Correlations between
SUVmax at the predominant lesion on PET scan and patient clinical features,
immunohistochemical parameters of glucose transporter-1 (Glut-1), Glut-3 and
Ki-67 reactivity were evaluated. SUVmax were evaluated for their association
with progression-free survival (PFS) and overall survival (OS).
Results: The median SUVmax was 12.2 (1.7–42.7). The median follow-up time
was 30 months (range, 4-124months). There was significant association
between high SUVmax and patient characteristics, including Ann-Arbor stage,
B symptoms, number of extranodal involvement, serum lactate dehydrogenase
level, and Prognostics Index (R-IPI). High SUVmax was significantly associated
with high expression of Glut-3 (immunoreactive score ≥6 vs <6: 16.7±10.1 vs
9.7±5.8P=0.008) and Ki-67 (%expression ≥50% vs <50%: 15.1±10.0 vs
9.4±4.9 P=0.001), but not with Glut-1 (P=0.668). The 3-year PFS rates in
patients with low SUVmax (SUVmax≤9) and those with high SUVmax
(SUVmax>9) were 92.2 and 63.6%, respectively (P=0.000). The 3-year OS
rates were 95.5 and 78.3%, respectively (P=0.003). This outcome advantage
was demonstrable in patients with very good prognosis group and poor prog-
nosis group according to the R-IPI categories (PFS, P=0.044 and P=0.011,
respectively). Multivariate analysis revealed that high SUVmax is a significant
poor prognostic factor for PFS (hazard ratio (HR) 4.784 [1.429–16.022],
P=0.011), independent of R-IPI. The combination of SUVmax and R-IPI risk
group provided a powerful discriminator of outcome.
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Figure 1.
Summary and Conclusions: In conclusion, for newly diagnosed patients with
DLBCL, there was significant relationship between SUVmax on pretreatment
PET and clinicopathological factors including R-IPI, Glut-3 and Ki-67. SUVmax
can provide prognostic information in DLBCL beyond that which can already
be obtained by the R-IPI. Therefore, the baseline SUVmax is an important
prognostic tool of disease progression in DLBCL.
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Background: Positron Emission Tomography combined with computerized
tomography (PET-CT) is increasingly used in non-Hodgkin lymphoma (NHL),
and its availability of a staging also improves the accuracy of subsequent
response assessment. Recently, interim PET-CT (iPET) that is often used to
assess the early response and to guide the subsequent treatment, although
its role is still controversial other than in Hodgkin disease.
Aims: The present study was performed to evaluate the prognostic value and
clinical significance of iPET with regard to NHL in assessment of early
response, and the usefulness for guiding subsequent treatment.
Methods: Between June 2006 and December 2014, 377 patients with NHL
who was had iPET after two to four courses of treatment and end of treatment
at Kameda Medical Center, Kamogawa-shi, Japan were retrospectively
analysed. All of the patients with CD20-positive B-cell lymphoma received rit-
uximab combined treatment. iPET was performed just before the next cycles
of treatment to avoid the post chemotherapeutic change due to previous
chemotherapy. A negative interim scan was defined as FDG uptake less than
or equal to liver uptake at any site of FDG-positive disease identified in the
baseline study. A positive scan was defined as any FDG uptake greater than
liver background activity with a corresponding structural abnormality on CT
scan. Overall survival (OS) and progression free survival (PFS) differences
between curves were calculated by two-sided log-rank test. OS and PFS were
compared between the patients with negative and positive results on iPET. 
Results: The study population consisted of 219 males and 158 females with
a median age of 63 years. The most frequent lymphoma diagnoses were diffuse
large cell lymphoma (DLBCL; n=225), followed by indolent lymphoma (n=83)
and T-cell lymphoma (n=69). Percentage of patients whose treatment was
modified by iPET results were 13% in patients with DLBCL, 39% with T-cell
lymphoma, and 5% of indolent lymphoma. iPET and at the end of treatment
PET-CT status correlated with conventional response criteria. With a median
follow up of 34 months, 2-year progression free survival rate was 81.2% for
iPET negative versus 45.7% for iPET positive (P<0.001). Percentage of patients
who became iPET negative was 70% (157/225), 71% (59/83), and 48% (33/69)
in patients with DLBCL, indolent lymphoma and T-cell lymphoma, respectively.
iPET status was associated with high serum LDH and soluble interleukin 2
receptor by Fisher’s exact test (p<0.01 and P<0.001, respectively). On the
whole, the patients who achieved the iPET negative showed significantly longer
OS and PFS compared to those with positive (P<0.001). In the analysis of lym-
phoma subtypes, patients with DLBCL and T-cell lymphoma who had iPET
negative showed significant longer PFS and OS (P<0.001), however, iPET did
not have a predictive values in patients with indolent lymphoma (P=0.7 for OS
and P=0.22 for PFS). We also analyzed maximal standardized uptake value
reduction (ΔSUVmax) at baseline and iPET. Using the receiver operating char-
acteristic (ROC) curve, ΔSUVmax between baseline and iPET of >85% was
predictable for better PFS and OS (sensitivity 55.2%, specificity 85.7%, area
under curve 0.719, 95% confidence interval=0.667-0.771).
Figure 1. Impact of interim PET-CT negative on OS.
Summary and Conclusions: iPET effectively predict outcomes of patients
with DLBCL and T-cell lymphoma, but it appeared to have a limited predictive
value in patients with indolent lymphomas. ROC analysis revealed theΔSU-
Vmax between baseline and iPET>85% is also predictable for better survival
in both PFS and OS.
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Background: Long-term outcomes of adults with first-relapsed or refractory
(R/R) systemic anaplastic large-cell lymphoma (ALCL) are not definitively
established and should be evaluated.
Aims: To evaluate long-term outcomes of adults with first R/R systemic ALCL.
Methods: We previously reported the long-term outcomes of adult patients treat-
ed at first diagnosis of systemic ALCL in three LYSA prospective clinical trials
(Sibon D et al, J Clin Oncol 2012). All patients had confirmed systemic ALCL
after immunohistopathologic review and defined ALK expression status. Here
we report the long-term outcomes of these patients with R/R systemic ALCL.
Results: Among the 138 (64 ALK+and 74 ALK-) adult patients treated at first
diagnosis in clinical trials, 40 (14 ALK+and 26 ALK-) had R/R systemic ALCL
after the frontline chemotherapy and their long-term outcomes were analyzed.
Median follow-up of R/R patients was 12.5 years (ALK+13.6 years; ALK- 12.1
years). The median age at first relapse/progression was 35 (19-76) years for
ALK+patients and 61 (34-82) years for ALK- patients. All patients relapsed/pro-
gressed after polychemotherapy with an anthracycline-based regimen. Five (4
ALK+and 1 ALK-) patients relapsed/progressed after planned high-dose ther-
apy/autologous stem-cell transplantation as first-line treatment consolidation.
Median time from initial inclusion in clinical trials to relapse/progression after
primary therapy was 6 months (46 days – 2.8 years) for ALK+patients and 11
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months (32 days – 5.6 years) for ALK- patients. Median progression-free sur-
vival (PFS) after the first relapse/progression (second PFS) was 5 months for
ALK+patients and 4 months for ALK- patients. Median overall survival (OS)
after the first relapse/progression was 11.9 months for ALK+patients and 7.7
months for ALK- patients, and 10-year OS rates were 14% for ALK+patients
and 15% for ALK- patients, without significant difference (p=0.99; figure). ALCL
was the main cause of death. Impact of treatments will be presented.
Figure 1.
Summary and Conclusions: Most patients with first R/R ALCL have poor out-
comes with short survival, without significant difference between ALK+and ALK-
patients. These results could be used as reference in the evaluation of new
drugs for R/R ALCL.
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HIGH-THROUGHPUT SEQUENCING OF BOTH IMMUNOGLOBULIN LIGHT
AND HEAVY CHAIN GENE REARRANGEMENTS IMPROVES DETECTION
OF NEOPLASTIC CLONES IN MATURE B-CELL LYMPHOMAS
A. Sherwood1,* J. Fromm2, D. Hospodsky1, H. Robins3, R. Emerson1,
M. Rieder1, B. Wood2, D. Wu2
1Adaptive Biotechnologies, 2University of Washington, 3Fred Hutchinson Can-
cer Research Center, Seattle, United States
Background: The detection of recurrent/persistent disease in mature B-cell
lymphomas is important for individualized patient care. Amplification and high-
throughput sequencing (HTS) of CDR3 sequences to describe the repertoire
of B-cell and T-cell receptors is emerging as a low-invasive and sensitive
method to identify and monitor minimal residual disease (MRD), and we have
previously applied this technology to MRD monitoring in precursor T- and B-
lineage acute lymphoblastic leukemias (Sci. Transl. Med. 2012; 4: 134ra63,
Clin. Cancer Res. 2014; epub). However applying this technology to mature B-
cell lymphomas present a unique challenge; some germinal-center derived
mature B-cell lymphomas may have somatic hypermutation (SHM) of the IGH
locus that may limit primer binding and amplification of these rearrangements.
Prior work suggests that analysis of multiple gene rearrangements, IGH, IGK,
and IGL, may increase the likelihood of identifying a tractable clone (Biol Blood
Marrow Transplant. 2014; S1083-8791(14)00257-2).
Aims: Here we evaluate the potential of sequencing immunoglobulin heavy
and light chains (IGH and IGK/IGL) in mature B-cell lymphomas by testing if
we could identify tractable B-cell clones using HTS of the IGH and IGK/IGL
repertoire.
Methods: First we defined tractable clones by defining the normal proportion
of reactive clones in lymphoid tissues and peripheral blood by measuring the
relative abundance of B-cell clones in healthy controls. We amplified the IGH
and IGK/IGL repertoire of 20 control samples using an amplification bias-con-
troled multiplex PCR assay and HTS sequencing. We defined clones as abnor-
mal and representing a neoplastic population in patient samples, if the clones
occurred at a proportion of >5 standard deviations above mean frequency of
the most abundant rearranged IGH, IGK/IGL in control samples. Next we used
the same assay to amplify the IGH and IGK/IGL repertoire of a cohort of 60
mature B-cell lymphomas assembled from residual material. This set included
cased from: 20 diffuse large B-cell lymphoma (DLBCL), 10 mantle cell lym-
phoma (MCL), 20 follicular lymphoma (FL), and 10 chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL). As described, we then used
the distribution of abundant clonal IGH and IGK/IGL CDR3 sequences in healthy
controls to define probable neoplastic clones.
Results: We detected a clonal IgH gene rearrangement suitable for disease
tracking in all MCL and CLL/SLL samples. By contrast, for many follicular lym-
phoma samples (11 of 20) and for some DLBCL samples (3 of 20), a clonal
IGH gene rearrangement was not detected, most likely due to SHM. Additional
high-throughput sequencing analysis of IGK or IGL, however, allowed a
tractable clone to be detected in nearly all samples (18 of 20 for follicular lym-
phoma and 19 of 20 for DLBCL). Taken together, in this cohort, ninety-five per-
cent of samples (57 of 60 cases) had at least one tractable clonal, immunoglob-
ulin gene rearrangement.
Summary and Conclusions: We conclude that high-throughput sequencing
of IGH is suitable for the majority of mature B-cell lymphomas. Lymphomas
that may undergo somatic hypermutation, such as diffuse large B-cell lym-
phoma and follicular lymphomas, benefited most from additional immunoglob-
ulin light chain gene sequencing. As high-throughput sequencing of antigen
receptors can describe the breadth of the B-cell repertoire and simultaneously
quantify the proportion of individual clones, this technology could contribute to




AN INHERITED MUTATION OF THE NOD2 GENE IS ASSOCIATED WITH
POOR SURVIVAL OF PATIENTS WITH DIFFUSE LARGE B CELL
LYMPHOMA
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J. Lubiński2, B. Zdziarska1
1Department of Hematology, 2Department of Genetics and Pathology, 3Depart-
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Szczecin, Poland
Background: The NOD2/CARD15 gene is involved in the regulation of immune
function through activation of the transcription nuclear factor – kappaB (NF-
kappaB). A single truncating mutation of NOD2/CARD15 gene, 3020insC is
present in the Polish population with a frequency of approximately 7%. This
allele has been shown to be associated with chronic inflammatory disease such
as Crohn’s disease and also with increased risk of colorectal cancer. The muta-
tion has also been found to confer an increased risk of gastric MALT lymphoma,
but not of other subtypes of lymphoma.
Aims: In the current study we analysed whether or not this mutation is associ-
ated with the risk of diffuse large B cell lymphoma (DLBCL), disease progression
and survival among patients with DLBCL.
Methods: We genotyped 141 patients diagnosed with DLBCL between the
November 2000 and the August 2009 for the 3020insC allele using PCR-RFLP.
We compared the frequency of this allele in DLBCL patients to that reported
previously in the general population of Poland using Fisher exact test. The
patients were followed from date of diagnosis (November 2000 to August 2009)
to the date of death (for deceased patients) or the date of last follow up (for
alive patients). The mean follow up time was 4.4 years (range 0.04 – 12.9
years). For clinical evaluation we used a retrospective analysis of: International
Prognostic Index (IPI) and its modifications, first full blood count (FBC) param-
eters at diagnosis (absolute lymphocyte count (ALC), presence of anemia or
thrombocytopenia), progression incidence. Progression free survival rates,
overall survival and disease specific survival were compared between carriers
of the allele and non-carriers.
Results: The 3020insC allele was present in 11 of 141 (7.8%) patients with
DLBCL, compared to 140 of 1910 (7.3%) population controls and the difference
was not significant (OR=1.1, 95%CI=0.6 - 2.0, p=0.9). In the univariate Cox
proportional hazards model carriers of the NOD2 mutation were found to have
2.7-fold increased risk of DLBCL progression (95%CI=1.1 - 6.5, p=0.02) and
3.1-fold increased risk of death because of the lymphoma (95%CI=1.1 - 9.4,
p=0.03), but association with death of any cause was not significant (HR=2.0,
95%CI=0.8 - 4.6, p=0.12). The analysis of survival curves showed that the
presence of 3020insC was associated with both a shorter progression-free sur-
vival (log-rank p=0.04) and disease-specific survival (log-rank p=0.045), but
not with overall survival (log-rank p=0.15). In multivariate Cox regression analy-
sis where age of onset, sex, aaIPI and thrombocytopenia at the time of diag-
nosis were included as covariates, the 3020insC mutation was associated with
increased risk of DLBCL-related death (HR=7.7, 95%CI=1.8 - 32.9, p=0.006).
Summary and Conclusions: Our study suggests that an inherited mutation
of the NOD2 gene is an independent factor associated with poor disease-spe-
cific survival in patients with diffuse large B cell lymphoma, however, further
studies are needed in this regard. 
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MYC/BCL2 DOUBLE EXPRESSION INCREASES A RISK OF RELAPSE OR
PROGRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
TREATED WITH INTENSIVE CHEMOTHERAPY M-NHL-BFM-90 PLUS
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Background: Diffuse large B-cell lymphoma (DLBCL) represents a highly
aggressive type of lymphoma. A potential role of MYC and BCL2 synergetic
interaction continues to be widely discussed in context of tumor chemoresis-
tance. Previously it was reported that MYC/BCL2 double expressor (DE) DLB-
CL had a poor prognosis in patients, treated with CHOP plus rituximab (R) and
in pts with non-GCB DCBCL who underwent R-(DA)-EPOCH chemotherapy. 
Aims: To investigate a prognostic significance of MYC/BCL2 double expression
in DLBCL patients treated with intensive chemotherapy m-NHL-BFM-90+R.
Methods: 62 DLBCL patients (35 males and 27 females) which underwent
modified protocol of intensive chemotherapy – m-NHL-BFM-90+R in National
Research Center for Hematology (Moscow) between 2004 and 2013 years
were included in current study. Hans algorithm was used to determine GCB or
non-GCB immunohistochemical subtypes of DLBCL. Tumor samples were
stained with antibody to BCL2 (clone 124, Dako) and MYC (clone Y69, Epito-
mics). We used a previously reported cut off for MYC expression ≥40% and
BCL2 ≥50% (N. Johnson et al., 2012). G-banding data were available in 19
patients. 1 patient had a translocation t(8;14)(q24;q32). In all other cases FISH
didn’t reveal c-MYC or BCL2 rearrangements with DNA probes Vysis LSI MYC
Dual color, Break Apart Rearrangement Probe, Vysis LSI BCL2 Dual color,
Break Apart Rearrangement Probe. We used Kaplan-Meyer and Cox regres-
sion analysis to estimate treatment results (SAS 9.3).
Results: By clinical characteristics patients corresponded to a high-risk group
according IPI (3-5) in 48 (78%) cases. According to MYC and BCL2 expression
status patients were divided into 4 groups: MYC+/BCL2- -9 (14,5%),
MYC+/BCL2+- 15 (24%), MYC-/BCL2+- 21 (34%), MYC-/BCL2- 17 (27,5%)
patients. All patients had comparable clinical characteristics, except of age.
Median age of DE MYC/BCL2 patients were statistically higher - 61 (25-73)
years old than in others - 47 (15-73) years old, (P<0,05). MYC/BCL2 double
expression was revealed more frequently in non-GCB (29%) than in GCB sub-
type (17%), (P=0,18). 45 (78%) of patients achieved a complete remission, 4
from them had second remission. Relapses and progression of DLBCL devel-
oped in 9 (15%) and 7 (11%) patients, respectively. 5 (8%) patients died because
of other reasons. There wasn’t significant differences in 4-year OS depending
on MYC and BCL2 expression: MYC+/BCL2- - 100%, MYC-/BCL2 – 78%,
MYC+/BCL2+- 57%, MYC-/BCL2+- 53% (P=0,09). Although DE DLBCL patients
had a statistically higher risk of relapse or disease progression within 4 years:
MYC+/BCL2- - 14%, MYC-/BCL2 – 14%, MYC+/BCL2+- 65%, MYC-/BCL2+-
24% (P=0,02) (Picture 1). If compare DE patients with all others statistical sig-
nificance increased (65% vs 15%, P=0,003). GCB/non-GCB subtype increases
a probability of DLBCL relapse or progression within 4 years (17% vs 39, P=0,
07). In multivariate analysis MYC/BCL2 double expression had an independent
prognostic power (HR 4,717, P=0,0024) from IPI, GCB/non-GCB subtype.
Figure 1.
Summary and Conclusions: MYC/BCL2 double expression is an independent
risk factor of DLBCL relapse or progression in patients treated with intensive
chemotherapy m-NHL-BFM-90+R, independently of IPI, GCB/non-GCB sub-
type.
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CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH EXTRANODAL
NK/T-CELL LYMPHOMA, NASAL TYPE: A PROSPECTIVE MULTICENTER
STUDY FROM THE THAI LYMPHOMA REGISTRY
T. Numbenjapon1 K. Prayongratana1, J. Julamanee2, A. Lekhakula2,
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Background: Extranodal NK/T-cell lymphoma (ENKTL), nasal type is a rare
subtype of lymphoma with a strong geographic predilection for Asian and South
American populations. At diagnosis, most of ENKTL, nasal type patients pres-
ent with destructive lesions in the nasal cavity and paranasal sinuses.
Aims: This study aims to describe the clinical features and treatment outcomes
of Thai patients with ENKTL, nasal type.
Methods: A clinical review of patients with ENKTL, nasal type according to
WHO 2008 classification obtained from The Thai Lymphoma Registry between
2002 to 2014 was performed. 
Results: Among 4,019 cases of lymphoma, there were 81 cases (2%) of ENK-
TL, nasal type. The median age was 45 years old (range, 21-91). The male:
female ratio was 2.5: 1. At diagnosis, approximately half of the patients had
stage I/II disease (55.6%), International Prognostic Index (IPI) score of ≤1
(51.9%), B symptoms (54.0%), and elevated serum LDH (54.0%). A majority
of the patients (92.6%) presented with good ECOG performance status. The
patients were treated with chemoradiotherapy in 34.6%, chemotherapy alone
in 35.8%, and radiotherapy alone in 11.1%. Fifteen patients (18.5 %) did not
receive any treatment. The most common first-line induction chemotherapy
regimen was CHOP (92.9%). Of the 66 evaluable patients, the overall complete
remission (CR) rate and overall partial remission (PR) rate was 39.4% and
6.1%, respectively. The CR rate was achieved in 71.4%, 27.6%, and 22.2% of
the cases treated with chemoradiotherapy, chemotherapy alone, and radio-
therapy alone, respectively. With the median follow-up time of 9.7 months
(range, 0.5-316.2), the median overall survival (OS) and progression-free sur-
vival (PFS) for the whole group was 10.8 months (95% CI: 0.2-21.5) and 8.2
months (95% CI: 3.0-13.5), respectively. The median OS of the patients treated
with chemoradiotherapy was significantly higher than those treated with
chemotherapy alone (5.8 years [95% CI: 1.2-10.4] vs. 0.4 year [95% CI: 0.1-
0.7]; P=0.002) and radiotherapy alone (5.8 years [95% CI: 1.2-10.4] vs. 0.3
year [95% CI: 0.1-0.5]; P=0.021). The median PFS of the patients treated with
chemoradiotherapy was significantly higher than those treated with chemother-
apy alone (17.1 months [95% CI: 8.7-25.5] vs. 4.1 months [95% CI: 2.2-5.9];
P=0.014) and radiotherapy alone (17.1 months [95% CI: 8.7-25.5] vs. 3.1
months [95% CI: 1.6-4.6]; P=0.024). Furthermore, the IPI score was of prog-
nostic significance to predict the median OS (IPI score=0 [6.4 years] vs. IPI
score ≥1 [0.4 year]; P=0.016) and 5-year OS (IPI score=0 [56.9%, 95% CI:
30.8-76.3] vs. IPI score ≥1 [25.2%, 95% CI: 14.5-37.5]; P=0.012) in this cohort.
Summary and Conclusions: ENKTL, nasal type is rare among Thai popula-
tion. At presentation, approximately half of the patients had early stage dis-
eases, B symptoms, elevated serum LDH, and low IPI score. Chemoradiother-
apy was the most effective treatment. In this cohort, the IPI score significantly
predicted the OS.
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CD30 EXPRESSION IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA:
CLINICAL FEATURES AND OUTCOME
F. Gaudio1,* F.E. Laddaga1, T. Perrone1, P. Pinto1, M.S. De Candia1, G.
Ingravallo2, G. Specchia1
1Hematology, University of Bari, 2Patology, University of Bari, Bari, Italy
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
and one of the most heterogeneous lymphomas. Therefore, it is critical to fur-
ther stratify cases of DLBCL into biologically similar and clinically meaningful
subgroups, which will not only guide prognostic assessment and facilitate ther-
apeutic decisions, but also stimulate further research to understand the patho-
genesis and develop potential novel treatments. One promising candidate is
brentuximab vedotin, an antibody-drug conjugate targeting CD30-expressing
cells. Previous observational studies have suggested that CD30 may be
expressed in 10 to 20% of DLBCLs.
Aims: The aim of this study was to determine the prevalence of CD30 expres-
sion in DLBCL by immunohistochemistry, and to explore possible relationships
with outcome.
Methods: We retrospectively identified cases of DLBCL diagnosed between
January 2010 and January 2013 at our Institution. The following large B cell
lymphoma subtypes were excluded from this analysis: post-transplant lympho-
proliferative disorders with a DLBCL morphology, Primary Mediastinal large
cell lymphoma and unclassifiable lymphomas with intermediate features
between either DLBCL and Burkitt’s lymphoma or DLBCL and Hodgkin’s lym-
phoma. Immunohistochemistry was performed as part of the routine workup
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and CD30 was considered positive when ≥30% of neoplastic cells stained pos-
itive. A total of 82 cases of de novo DLBCL treated with R-CHOP were included
in the training set for further analysis There were 45 men and 37 women with
a median age of 57 years (range, 16-84); 35 patients (43%) presented with B
symptoms, and 49 (60%) had advanced Ann Arbor stages. Most of the patients
had a good performance status (Eastern Cooperative Oncology Group score
0- 1, 87%), elevated serum lactate dehydrogenase level (61%), and low or low-
intermediate International Prognostic Index (IPI) risk (IPI score 0-2, 63%).
Involvement of multiple extranodal sites (>=2) was seen in 22% of cases, and
bulky disease in 32% of cases.
Results: The median follow-up time was 47 months. Among the 82 cases in
the training set, CD30 was positive in 24 cases (29%). No difference in response
rate was observed between CD30 positive and CD30 negative patients.
Patients with CD30+DLBCL showed a significantly superior OS and PFS com-
pared with those with CD30–. The 3-year OS was 79% in patients with CD30+vs
59% in CD30– (P <0.05); 3-year PFS was 73% in patients with CD30+vs 57%
in CD30– (P<0.05).
Summary and Conclusions: CD30 is expressed in approximately 29% of all
DLBCL and defines a novel subgroup of diffuse large B-cell lymphoma with a
more favorable prognosis. The advent of brentuximab vedotin and its well-
established effectiveness in other types of relapsed lymphomas opens the pos-
sibility of its application in this subset of patients.
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PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/
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Background: We previously reported that SMILE (Steroid, Methotrexate, Ifos-
famide, L-asparaginase and Etoposide) regimen is effective for newly-diag-
nosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal
type (J Clin Oncol 2011; 29: 4410-6). Because of the many similarities in extra-
nodal NK/T-cell lymphoma, nasal type and peripheral T-cell lymphoma (PTCL),
the SMILE regimen was applied for PTCL.
Aims: The aim of this study is to examine the efficacy and safety of SMILE
regimen for relapsed/refractory PTCL.
Methods: The phase II study of SMILE for PTCL was carried out according to
the Simon’s two-stage design. Patients with relapsed or refractory PTCL after
first-line chemotherapy, aged 15-69 years old, and with a performance status
of 0-2 were eligible. Eight subtypes of PTCL were subjected, comprising PTCL,
not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma
(AITL), ALK-positive and -negative anaplastic large cell lymphoma (ALCL),
hepatosplenic T-cell lymphoma, enteropathy-associate T-cell lymphoma (EATL),
primary cutaneous gamma-delta T-cell lymphoma (PCGDTL), and primary cuta-
neous CD8+aggressive epidermotropic cytotoxic T-cell lymphoma. The primary
endpoint was overall response rate (ORR) after 2 cycles of SMILE chemother-
apy.
Results: From November 2009 to February 2014, a total of 42 patients were
enrolled. The median age was 56 years (range, 28 to 69 years), and the
male:female ratio was 33:9. The diagnosis was PTCL-NOS in 19, AITL in 14,
ALK-positive ALCL in 1, ALK-negative ALCL in 4, EATL in 3, and PCGDTL in 1.
Twenty-six were relapsed PTCL, and 16 were refractory to initial treatment with
anthracycline-containing regimen. Complete and partial response was achieved
in 6 and 13 patients, respectively, with an ORR of 48% (90% confidence interval,
34-62%). The response was stable disease in 6, progressive disease in 15, but
was not evaluable in 2. The ORR was 64% (90% confidence interval, 46-80%)
for relapsed PTCLs, but was 27% (90% confidence interval, 10-51%) for relapsed
patients, and the difference was statistically significant (P=0.048). One patient
died of sepsis and another patient died of disease in the treatment period.
Summary and Conclusions: These results indicate that SMILE regimen is
effective for relapsed or refractory PTCL. The efficacy was lower than that for
extranodal NK/T-cell lymphoma, but the present T-SMILE study included more
relapsed patients. Further follow-up defined in the protocol is required to deter-
mine the duration of response and long-term efficacy.
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GASTROINTESTINAL TRACT POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISORDER (PTLD) AFTER KIDNEY TRANSPLANT: A 17-YEAR BRAZILIAN
SINGLE-CENTRE EXPERIENCE
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Background: Post-Transplant Lymphoproliferative Disorder (PTLD) is a well
recognized complication following both solid organ and allogenic hematopoietic
stem cell transplantation. This condition is characterized by the development
of lymphoid or plasma cell neoplasms in the setting of post-transplant immunos-
supression. Epstein-bar virus is considered the most important causative factor,
with EBV positivity observed within up 90% of tumor lymphocytes. Gastroin-
testinal (GI) involvement of PTLD is a relatively common life-threatening con-
dition, usually associated with aggressive presentation and high mortality rates.
Aims: To analyze the cases of PTLD with Gastrointestinal involvement dig-
nosed between 1998 and 2014 on our center.
Methods: From 1998 to 2014, a total of 11,284 kidney transplants were per-
formed at Hospital do Rim e Hipertensão/UNIFESP (Federal University of São
Paulo). We retrospectively analyzed cases of PTLD with GI tract involvement
diagnosed over the past 17 years. Only confirmed cases of PTLD with available
clinical and epidemiological data were included.
Results: PTLD was reported in 94 recipients. GI tract involvement was present
in 39% of the cases (37 patients). Two patients were excluded from the analysis
due to incomplete data. The median age at diagnoses was 41 (range 4 to 64).
The M:F ratio was 1,92:1. The median time from transplant to PTLD was 57
months. Twelve (32%) of our cases received induction therapy either with
antithymocyte globuline (ATG) (50%) or Basiliximab (50%) at the time of trans-
plant. The immunossupressive regimen the patients were receiving at the time
of diagnosis of PTLD were: Prednisone (100%), azathioprine (88%), tacrolimus
(62%), cyclosporine (37%), mycophenolate mofetil (8%) and 1 patient received
FTY720. Regarding EBV positivity, 28 patients (76%) were EBV positive, 4
patients (11%) were EBV negative and 5 patients (13%) were not tested or had
inconclusive results. Monomorphic PTLD was present in 32 patients (86%),
the majority (90%) was diagnosed as diffuse large B-cell non-Hodgkin lym-
phoma, Polymorphic PTLD corresponded to only 4 cases (11%) and 1 patient
could not be classified. Eight (22%) patients had multiple gastrointestinal tract
involvement, 11 (31%) patients had only small intestine involvement, followed
by 9 (24%) patients with stomach involvement, 8 (22%) with hepatic involve-
ment and 1 patient had esophageal involvement. Seventeen (46%) had con-
comitant non GI tract extranodal involvement (lung/pleura, CNS, bone marrow,
bone, skin and ovaries). After diagnosis, all patients had their immunossupres-
sion regimens reduced or suspended. Twenty-eight (76%) patients received
anti-CD20 based therapy with 21 (75%) patients receiving R-CHOP, 5 patients
(13.5%) did not received chemo/immune therapy, eleven patients (30%)
required surgery (gastrectomy or enterectomy) and in 4 (11%) cases surgery
was the only treatment. Nineteen (51%) of our patients achieved complete
remission (CR). 17 patients (46%) died, most of them (10 patients) from infec-
tious complications, 3 patients due to GI perforation, 2 patients from pulmonary
embolism and 2 from undetermined causes. At total, 6 (16%) cases of GI per-
foration were observed.
Summary and Conclusions: In our population, GI tract was the most common
PTLD involved site. EBV was positive in the majority of cases. Although 19
patients achieved CR, a high number of deaths were observed, mostly due to
infection. This unique condition should be considered in every transplant recip-
ient presenting with abdominal symptoms.
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THE ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION
FOR HIGH-RISK PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
H. Cho1,* S.J. Kim1, H. Park1, J.Y. Lee1, J.E. Jang1, Y. Kim1, J.W. Cheong1,
Y.H. Min1, J.S. Kim1
1Severance Hospital, Seoul, Korea, Republic Of
Background: Primary central nervous system lymphoma (PCNSL) is an
aggressive extranodal non-Hodgkin lymphoma. The patients with International
Extranodal Lymphoma Study Group (IELSG) score of more than one or those
who did not achieve complete remission (CR) after two courses of high-dose
methotrexate (HD-MTX)-based chemotherapy (non-CR1) have been shown
inferior treatment outcomes. Upfront autologous stem cell transplantation
(ASCT) as consolidation after HD-MTX-based chemotherapy has shown better
efficacy compared to whole brain radiotherapy consolidation.
Aims: To investigate the role of upfront ASCT for high-risk PCNSL patients
Methods: We retrospectively analyzed a total of 66 newly diagnosed high-risk
PCNSL patients between February 2003 and December 2014 in Severance
Hospital. Patients who were younger than 65 years of age with IELSG score
≥2 (n=56) and/or non-CR1 (n=37) were included in this study. All the patients
(n=66) were HIV negative, received HD-MTX-based chemotherapy as initial
treatment and achieved at least partial response (PR) after initial treatment.
Results: The median age at diagnosis was 52 (range 21-64) years and 43
(65.2%) patients were male. Median follow-up for surviving patients was 22
(range 2-123) months. The upfront ASCT group included more patients aged
50 or less (68.4% vs. 31.9%, P=0.007). Nineteen (28.8%) patients have
received upfront ASCT, and all of them received busulfan-based conditioning
regimens including busulfan plus thiotepa (n=18). The disease status at the
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time of upfront ASCT was CR in 17 (89.5%) patients and PR in 2 (10.5%)
patients. Transplant-related mortality occurred in 1 (5.3%) patient after upfront
ASCT. In non-upfront ASCT group (n=47), 28 (59.6%) patients achieved CR
after completion of therapy and 16 (34.0%) patients received whole-brain radio-
therapy as consolidation. Twelve patients in the non-upfront ASCT group under-
went ASCT after relapse. Non-upfront ASCT was associated with shorter overall
survival (OS) and progression-free survival (PFS) in multivariate analysis (haz-
ard ratio (HR) 8.24; 95% CI 1.31-51.99; P=0.025, and HR 4.26; 95% CI 1.49-
12.14; P=0.007, respectively). The 2-year OS and 2-year PFS of all patients
were 65.9% and 39.9%, respectively. The upfront ASCT group showed superior
OS and PFS compared to the non-upfront ASCT group (P=0.022 and P=0.005,
respectively). Among the 56 patients with IELSG score ≥2, upfront ASCT was
performed in 17 (30.4%) patients and showed survival benefit for OS and PFS
(P=0.036 and P=0.005, respectively). OS and PFS between the upfront and
the non-upfront ASCT group also showed similar results in patients with 37
non-CR1 patients (P=0.009 and P=0.021, respectively). 
Figure 1.
Summary and Conclusions: Upfront ASCT as consolidation after HD-MTX-
based induction chemotherapy in high-risk PCNSL showed better survival
results with acceptable toxicities. Upfront ASCT overcomes a negative impact
of IELSG score ≥2 and/or non-CR1 in PCNSL.
E1007
FAVORABLE OUTCOME IN PRIMARY MEDIASTINAL LARGE B-CELL
LYMPHOMA IN A SINGLE CENTRE: THE PADUA EXPERIENCE
S. Imbergamo1,* A. Visentin1, S. Bonetto1, C. Gurrieri1, F. Piazza1,2, C. Boso3,
R. Zambello1,2, G. Semenzato1,2, L. Trentin1,2
1Department of Medicine, Hematology and Clinical Immunology Branch,
2Venetian Institute of Molecular Medicine, Padua, Italy, Padua University School
of Medicine, 3Department of Radiotherapy, Veneto Istitute of Oncology, IOV-
IRCCS, Padova, Italy
Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct
clinical, pathological and molecular subtype of diffuse large B-cell lymphoma.
The optimal management of PMBCL is still unknown, however several retro-
spective analyses showed an improvement of outcome with dose-intensive
chemotherapy regimens and radiotherapy on residual mass.
Aims: In this study we evaluate activity, feasibility and safety of the third gen-
eration regimen R-VACOP-B and mediastinal radiotherapy (RT) in the treat-
ment of PMBCL.
Methods: We retrospectively evaluated data from 34 previously untreated
patients with PMBCL between September 2002 and January 2014, referred to
the Hematology and Clinical Immunology Unit of Padua University Hospital.
Patients were treated with R-VACOP-B+RT according to Todeschini G. et al Br
J Cancer 2004. Progression free survival (PFS) and Overall survival (OS) were
calculated as date of initial presentation to progression (event) or death for
any cause (event), respectively, or last known follow-up (censored). Survival
analyses were performed by Kaplan-Meier method and Log-rank test to com-
pare survivals. p values <0.05 were considered significant.
Results: Among recruited patients 50% of them were female, the median age
at diagnosis was 33 years, 79% had a mediastinal-limited disease, 88% had
IPI 0 or 1 and ECOG 0 or 1, and the median follow-up was 69 months. All
patients completed the planned 8 cycles R-VACOP-B followed by RT. Treat-
ment was well tolerated; neutropenia G3-4 occurred in 38% of patients, ane-
mia G3-4 in 3% but no piastrinopenia G3-4 was observed. 38% of subject
underwent a major infective event. Extrahematological toxicity mainly con-
sisted in transient neuropaty (21%) and catheter related thrombosis (12%).
Focusing on late cardiac toxicity, a decrease in left ventricular ejection fraction
(EF) was observed in 18% of the cohort but an EF<40% was reported only by
1 patients. Considering pulmonary toxicity 50% of subjects had a slight to
moderate reduction of CO diffusion, but none of them developed a life threat-
ening interstitial pneumonia. Finally, hypothiroidism and mammarian nodule
was observed in 6% of patients. Interim PET-CT was performed in 23 patients
(68%) and for 18 (78%) of them it was negative. Interestingly, all of these 18
subjects achieved a complete remission (CR) at the end of therapy. 14 patients
(41%) had partial response at interim analysis, 10 of them covered to CR after
the eighth cycle, the remaining 4 developed a relapse-refractory (R/R) disease.
The median PFS was not reached during the follow-up and the 5-year PFS
and OS were 82% and 100% respectively. 6 patients (18%) had a R/R disease
and all progressed within the first 15 months. All these 6 patients were suc-
cessfully saved by R-DHAP followed by autologous stem cell transplantation.
1 (3%) patient required allogenic bone marrow transplant due to acquired
bone marrow failure. All 34 subjects were still alive after 10 years of follow-
up. Furthermore, we observed that IPI and staging at diagnosis significantly
correlated with PFS (IPI 0-1 vs >1, 86% vs 50%, p=0.0385 and Stage II vs III-
IV, 89% vs 50%, p=0.0234 ).
Summary and Conclusions: In this single center retrospective study, R-
VACOP-B+RT induced a very-high remission rate with an acceptable toxicity
profile. IPI and ECOG correlated with PFS and all patients were still alive after
a follow-up of more than 10 years. We provide evidence that R-VACOP-B is a
safe and effective radio-chemo-immunotherapeutic protocol for the treatment
of patients with PMBCL. In the next future, we will compare R-VACOP-B+RT
vs R-DAEPOCH.
E1008
HUMAN T-LYMPHOTROPIC VIRUS TYPE I TAX SPECIFIC CYTOTOXIC
T-LYMPHOCYTE ANALYSIS OF AGGRESSIVE TYPES OF ADULT T-CELL
LEUKEMIA/LYMPHOMA PATIENTS WITH LONG-TERM SURVIVAL AND
COMPLETE REMISSION
T. Jo1,* K. Horio1, K. Shigematsu2
1Hematology, 2Pathology, Japanese Red Cross Nagasaki Genbaku Hospital,
Nagasaki, Japan
Background: Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell
malignancy caused by human T-lymphotropic virus type I (HTLV-I). Most ATLL
cells are CD4 and CCR4 positive, and CD8 negative. ATLL is classified into 4
clinical subtypes: smoldering, chronic, acute, and lymphoma. Acute and lym-
phoma type ATLLs, which are aggressive types, have a very poor prognosis. 
Aims: We report here the extremely interesting results of aggressive ATLL
patients with long-term survival and complete remission (CR) after activation
of cellular immunity against ATLL cells.
Tabella 1. A summary of HTLV-I tax specific CTL analysis and HTLV-I
provirus load in the peripheral blood.
Methods: We retrospectively evaluated 46 patients with aggressive ATLLs
diagnosed at our hospital between January 2001 and August 2011. Of these,
7 patients had long-term survival greater than 3 years with complete remission
(CR) after intensive chemotherapies. Four of these 7 patients had HLA-A02:01
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or HLA-A24:02, and were investigated using cytotoxic T-lymphocyte (CTL)
analysis. T-cell receptor (TCR) V beta (VB) repertoire and the HTLV-I provirus
load in peripheral blood were also analyzed.
Results: The Table summarizes the results. HTLV-I specific CTL analysis and
HTLV-I provirus load in the peripheral blood were performed twice, once in
2012 and once in 2014. HTLV-I tax specific CTLs were detected in all 4
patients. Although all patients maintained CR, HTLV-I proviruses were detected
in the peripheral blood in all patients. This phenomenon was observed both in
2012 and in 2014. TCR VB repertoire was analyzed using flow cytometry in
January 2015. Clonal dominance was present in all patients. In particular,
HTLV-I tax specific CTL expressing VB3 was found in a high percentage (71%)
in Patient No. 1.
Summary and Conclusions: The findings from this study suggest that HTLV-
I specific CTLs can be induced with clonal dominance in patients with aggres-
sive types of ATLL. In patients having long survival with CR, these CTLs can
contribute to treatment and may play a roll inhibiting the relapse of ATLL. The
development of efficacious methods to induce HTLV-I specific CTLs in individual
ATLL patients may leads to improved outcomes for aggressive types of ATLL.
E1009
PROPHYLACTIC USE OF ACETAZOLAMIDE REDUCES WEIGHT GAIN
AND AMELIORATES RENAL COMPLICATIONS ASSOCIATED WITH HIGH
DOSE METHOTREXATE
M. Ku1,* A. Bazargan1, S. O’Connor2, C. Tam1,3,4
1Haematology, 2Pharmacy, St Vincent’s Hospital, Fitzroy, 3Haematology, Peter
MacCallum Cancer Centre, East Melbourne, 4Medicine, University of Mel-
bourne, Parkville, Australia
Background: High dose methotrexate (HDMTx) is an effective drug in the treat-
ment of lymphoid malignancies such as CNS lymphoma, especially combined
with high dose cytarabine or radiotherapy. Adequate MTx levels in the CSF
require rapid infusion, with 2 - 4 hours deemed the optimal duration. HDMTx
toxicities include mucositis, hepatotoxicity, renal impairment and myelosuppres-
sion. HDMTx-induced acute kidney injury (HDMTx-AKI) is a rare complication;
it can range from asymptomatic serum creatinine (Cr) rise to life-threatening
AKI. HDMTx-AKI can increase the risk of other MTx related toxicities, and cause
a reduction of the optimal MTx dose administered. HDMTx-AKI is attributed to
tubular obstruction due to precipitation of MTx and its metabolite (crystal
nephropathy), which may be exacerbated by acidic urinary pH and hypovolemia.
Acetazolamide (AZL) is a carbonic anhydrase inhibitor in the renal proximal con-
voluted tubule. It causes increased bicarbonate excretion and therefore urine
alkalinization. Shamash et al found AZL 500 mg QID effectively alkalinized urine
in patients treated with HDMTx, with satisfactory plasma MTx elimination. Pro-
phylactic intravenous fluids are also essential in preventing HDMTx-AKI, and
hence fluid overload is a common complication of HDMTx therapy.
Aims: We conducted a dual centre, retrospective cohort study examining AZL’s
renoprotection effect in patients receiving HDMTx for haematological malig-
nancies. Parameters examined included AKI incidence, days of elimination and
urinary pH. Since 2010, the use of prophylactic AZL was recommended for
patients undergoing HDMTx therapy at our institutions.
Figure 1.
Methods: Data of patients who had HDMTx from 2007 to 2012 was analysed.
In total, 92 patients were given HDMTx, resulting in 256 cycles. The AZL group
(250mg q8h) and non-AZL group were comparable in the majority of variables
that could have impacted on the incidence of HDMTx-AKI. The primary endpoint
was AKI (Cr>100umol/L) or prolonged MTx elimination (>5 days).
Results: 1. AZL showed a strong trend in preventing either AKI (Cr>100umol/L)
or prolonged MTx elimination (>5 days). a) AKI or MTx elimination>5 days
occurred in 24/164 (14.6%) of the non AZL group, versus 4/68 (5.9%) of the AZL
group, p=0.063. There is a strong trend that AZL use reduced renal complica-
tions. A graph of a patient’s serial Cr in 4 cycles of HDMTx is shown (Fig 1),
depicting much higher Cr without AZL versus Cr levels with AZL. b) HDMTx
induced AKI was correlated with increased days of elimination (mean 6.5 days
for AKI versus 4.0 days for non AKI, p=0.001). c) AZL benefit on HDMTx-AKI or
prolonged MTx elimination was more obvious in males, who were more prone
to these effects. In the non AZL group, 4/64 (6.3%) females had either AKI or
prolonged MTx elimination, versus 20/100 (20%) males, p=0.015. AZL abolished
this gender disadvantage, with 2/29 (6.9%) females versus 2/39 (5.1%) males,
p=0.759. 2. AZL use resulted in significantly less weight gain and less acidic uri-
nary pH (pH<7) and was tolerated well a) weight gain - median weight gain of
3.0kg (range 0 - 13, n=151) in the non AZL group, compared to 1.0kg (0 - 6,
n=85) in the AZL group, Mann-Whitney p<0.001. b) urine pH <7.0 - 40/166
(24.1%) in the non AZL group had at least one episode of urinary pH<7, versus
10/86 (11.6%) in the AZL group, Chi-square p=0.029. c) AZL was well tolerated,
with mild hypokalaemia being the only common complication (48.5% of AZL
group). This was preventable by prophylactic oral potassium use.
Summary and Conclusions: This retrospective, dual centred cohort study
examined AZL’s renoprotection effect during HDMTx. AZL showed a strong
trend in preventing either AKI or prolonged MTx elimination, especially in males,
who appeared to be at higher risk. A larger patient sample is required to confirm
the significance of this finding. AZL use also resulted in significantly less weight
gain and less acidic urinary pH (pH<7) during HDMTx; these factors could influ-
ence patient management and length of hospital stay. In summary, this study
demonstrated that AZL could be used as an adjunct renoprotective treatment
in HDMTx regimens.
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CD30 EXPRESSION IN DLBCL, INCIDENCE AND PROGNOSIS VALUE: A
SINGLE-INSTITUTION EXPERIENCE
L. García-Sanchis1,* C. Martinez-Ciarpanglini2, A. Ferrández2, A. Teruel1,
J.L. Piñana1, C. Solano1, M.J. Terol1
1Hemathology, 2Pathology, Hospital Clinico de Valencia, Valencia, Spain
Background: DLBCL is the most common subtype of NHL, with R-CHOP, the
standard of treatment, we obtain CR and 5 years PFS in more than 50% of
patients. It has been identified biological markers with impact on the outcome
of these patients. CD30 is a cell-surface marker expressed by several types of
NHL, including a subset of DLBCL (±15%). A better outcome has been sug-
gested for CD30 positive patients.
Aims: The aim of this study is to analyze the incidence of CD30 in DLBCL and
to evaluate the prognostic impact and the possible correlation with clinical and
biological characteristics.
Methods: We carried out a single institution study with DLBCL samples from
patients diagnosed in the period 1994-2011 and treated with chemotherapy or
R-chemotherapy. DLBCL diagnosis was reconfirmed. Tissue fixation and pro-
cessing were performed using standard methods. Tissue microarrays (TMAs)
that contained two representative 2-mm cores from each tumor were prepared.
Internal control cores were present in each TMA. Immunohistochemical stain-
ings were performed using fully automated protocols. Sections were subjected
to staining protocols with the antibody CD 30(Dako). CD30 expression was
evaluated by an anatomopathologist and a hematologist and was considered
positive 20% and above. CD30 expresion was also evaluated using computer-
ized image analysis with Image Pro Plus 6.0. A mean number of 1000 cells
were evaluated per case. Both readings were compared and scoring discrep-
ancies (differences >10%) were resolved using a multi-head microscope. Cor-
relation with clinical and biological characteristics were analyzed with chi-square
test and OS and PFS with kaplan Meier (SPSS19). This study has been
approved by local ethic committee.
Results: Samples from 140 DLBCL patients (95/45pt R-chemo/chemo) were
analyzed, median age 70 (23-76), male/female 73/67pt, Ann Arbor stage III or
IV: 73pt (52%), high LDH 72pt (51%), high β2-microglobullin 62pt (44%) IPI
low 53 pt, int-low 26pt (19%), int-high 31pt (23%), high 28pt (20%) IPI ≥3: 59pt
(42.1%). All patients ORR 79pt (58%), CRR 53pt (39%). We observed CD30
overexpressed (>20%) in 14pt (10%). In univariate analysis patients with CD30
overexpression had better CRR, 91% versus 68% (p0.08). CD30 also appears
to predict a better outcome, OS p 0.1 and PFS p0.1. We didn’t observed cor-
relation between CD30 overexpression and clinical baseline characteristics.
Summary and Conclusions: In our experience the incidence of CD30 expres-
sion seems lower than the previous reported (10% versus 15%), these CD30
positive patients have a higher CRR, better OS and better PFS.
E1011
PROPOSAL OF NEW PROGNOSTIC INDEX FOR PATIENTS WITH DIFFUSE
LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
S. Yoon1,* D.H. Yoon1, S. Kim1, K. Lee1, E.H. Kang1, S.W. Lee2, C.J. Park3,
C.S. Park4, J. Huh4, C. Suh1
1Department of Oncology, 2Department of Radiation Oncology, 3Department
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versity of Ulsan College of Medicine, Seoul, Korea, Republic Of
Background: The International Prognostic Index (IPI) has been useful prog-
nostic tool to predict prognosis of aggressive non-Hodgkin lymphoma in the
last 20 years. Since the advent of R-CHOP (rituximab, cyclophosphamide, dox-
orubicin, vincristine, and prednisone) chemotherapy for diffuse large B-cell lym-
phoma (DLBCL), its utility has been challenged and other prognostic index
including revised IPI and National Comprehensive Cancer Network (NCCN)-
IPI were proposed, which are not popularly used yet. 
Aims: We aimed to develop new prognostic model for DLBCL in rituximab era.
Methods: Between March 2004 and June 2012, patients with DLBCL treated
with R-CHOP were identified in the database of the Asan Medical Center (AMC)
Lymphoma Registry. Primary end point was to devise a new prognostic index
for DLBCL. Secondary end point was to validate the NCCN-IPI in our cohort.
We tested new prognostic index model in the training set of AMC cohort con-
sisted of randomly selected 80% of the sample (503 patients). The remaining
20% (118 patients) was used as an internal validation set.
Results: The AMC cohort consisted of 621 patients. Median follow-up duration
was 43.3 months (6.2-122.5 months). Median age was 57 years (range, 16-85
years). Median ϐ-2 microglobulin (ϐ-2 MG) was 2.10 mg/L (range, 1.0-66.0
mg/L). The univariate analysis of baseline characteristics revealed that age (≤60
vs. >60 years), LDH (within normal vs. increased), ECOG performance (0 or 1
vs. ≥2), advanced stage (Ann Arbor stage I/II vs. III/IV), extra-nodal involvement
(≤1 vs. >1), B symptoms (no vs. yes), and ϐ-2 MG (≤2.5 vs. >2.5) could predict
overall survival (OS), whereas bulky disease and gender did not (p value 0.140,
0.621, respectively). In the multivariate analysis, age, LDH, ECOG performance
status, and ϐ-2 MG were significantly associated with OS (p value 0.001, <0.001,
0.004, and 0.019, respectively), while stage, extra-nodal involvement, and B
symptom did not (p value 0.057, 0.233, and 0.577, respectively). We developed
a new prognostic model with these 4 significant factors in the multivariate analy-
sis. One point is assigned for each of the risk factors without refined categoriza-
tion. Four risk groups were composed as followings: low (0 point), low-interme-
diate (1 point), high-intermediate (2-3 points), and high (4 points). The new prog-
nostic model showed better discriminative power compared with classic IPI (Fig-
ure 1A). Five-year OS of low- and high-risk subgroup in new scoring model and
classic IPI model in AMC cohort were 95% and 32% versus 89% and 45%,
respectively. Our model was validated in an internal validation set (Figure 1B).
NCCN-IPI also could stratify four risk groups (Figure 1 A and B). 
Figure 1.
Summary and Conclusions: We propose a new prognostic index model for
DLBCL in rituximab era with age, LDH, ECOG performance and ϐ-2 MG, which
has good discriminative power and convenient to apply. It warrants further val-
idation using an independent cohort.
E1012
AN INVESTIGATION OF RADIATION THERAPY FOR DLBCL AFTER
CHEMOTHERAPY FOR ACHIEVING COMPLETE REMISSION: A SINGLE
INSTITUTION EXPERIENCE
A. Ouchi1,* M. Yokoyama2, M. Oguchi3, K. Takeuchi4, Y. Kusano2, H. Nitta2,
K. Ueda2, N. Nishimura2, N. Tsuyama4, Y. Terui2, N. Usui1, K. Aiba1, K. Hatake2
1Department of oncology and hematology, Jikei university school of medicine,
2Department of hematology and oncology, 3Department of radiation oncology,
Cancer institute hospital, 4Department of pathology, Japanese foundation of
cancer research, Tokyo, Japan
Background: Radiation therapy (RT) for localized- refractory or -relapsed dif-
fuse large B cell lymphoma (DLBCL) after chemotherapy is a sort of standard
therapy. Some cases can achieve complete remission (CR) after RT for local
residual disease, but others cannot. If we can distinguish more radioactive
DLBCL from radio-resistant DLBCL in advance, more appropriate care could
be possible. 
Aims: To clarify which cohorts of patients (pts.) are more radiosensitive and
which cohorts aren’t.
Methods: We analyzed DLBCL receiving RT on the purpose of achieving
remission after chemotherapy at Cancer Institute Hospital from October 2005
to January 2014. All pts.’ histopathology samples were reviewed by expert
hematopathologists, according to the WHO classification. All 3-dementional
conformal RT were planned by an expert lymphoma radiation oncologist. 
Results: A total of 180 pts. were included in this study. Baseline pts.’ charac-
teristics were as follows; a median age of 65.2 years (range, 17.3-88.1 years),
105 male and 75 female. We classified them into four categories; 87 pts.
(48.3%) received RT as an adjuvant therapy after CR by R-CHOP therapy, 43
pts. (23.9%) received RT after partial metabolic response (PMR) at positron
emission tomography-computed tomography (PET-CT)-based response of the
Lugano classification by R-CHOP therapy, 38 pts. (21.1%) received RT for no
metabolic response (NMR) at the PET-CT-based response by R-CHOP therapy,
and 12 pts. (6.7%) received for progressive metabolic disease (PMD) after
previous chemotherapy. The median dose of RT for CR settings was 30.6Gy
(range, 16.2-45.0Gy), for PMR setting was 40.0Gy (range, 30.0-54.0Gy), and
for NMR/PMD were 40.0Gy (range, 20.0Gy-50.4Gy). Disease progression rates
within RT field were 0% of CR group, 2.3% (5 pts.) of PMR group, 43.2% (13
pts.) of NMR group, and 16.7% (2pts.) of PMD group. Disease progression
outside of the radiation fields were 5.8% (5 pts.) of CR group, 11.6% (5 pts.) of
PMR group, 50% (19 pts.) of NMR group, and 83.3% (10pts.) of PMD group.
There was no treatment related mortality during RT. At a median follow-up time
of 48.2 months (range, 6.5-78.8), the 2 year progression free survival (PFS)
after RT and overall survival (OS) rates of all the pts. are 75.9%, 83.0%, respec-
tively. In CR group, PFS and OS were 95.1%, 96.4%, in PMR group, 89.9%,
90.4%, in NMR group, 37.3%, 47.5%, and in PMD group, 16.7%, 72.7%,
respectively.
Summary and Conclusions: RT as an adjuvant therapy resulted in a good
prognosis as previously reported in the literature. RT for PMR after chemother-
apy also resulted in a good prognosis. However, RT for NMR and PMD after
previous chemotherapy showed poor prognosis and also revealed high rates
of disease progression outside the RT field, suggesting the limitation of local-
ized treatment for DLBCL. Because RT causes few severe adverse events, it
is tolerable even for elderly people and pts. with long history of chemotherapy.
Though such an advantage, it might be desirable for DLBCL of NMR and PMD
after chemotherapy to treat with a systematic therapy if their health conditions
allow for achieving remission.
E1013
UNDERWEIGHT AND LOW BODY SURFACE AREAS FOR
CHEMOTHERAPY DOSING ARE ASSOCIATED WITH INFERIOR SURVIVAL
IN MALE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A
STUDY OF 658 R-CHOP TREATED PATIENTS
P. Svenssen Munksgaard1,* M. Tang Severinsen1, E. Bekric2, C. Brieghel
Mortensen3, K. Buchardi Jensen4, M. Bøgsted5, M. Dahl Bendtsen5,
T. Christoffer El-Galaly1
1Department of hematology, Aalborg University Hospital, Aalborg, 2Department
of hematology, Odense University Hospital, Odense, 3Department of hematol-
ogy, Copenhagen University Hospital, Copenhagen, 4Department of hematol-
ogy, Holstebro Hospital, Holstebro, 5Department of Clinical Medicine, Aalborg
University, Aalborg, Denmark
Background: Chemotherapeutic drugs are usually dosed according to patient
weight or body surface area (BSA). Therefore, anthropometrics may influence
survival in patients with diffuse large B-cell lymphoma (DLBCL).
Aims: To examine the impact of body mass index (BMI) and BSA on overall
survival (OS) in DLBCL patients. 
Methods: This retrospective study included adult patients with newly diagnosed
DLBCL seen at the hematology centers of Aalborg (2003-2010), Holstebro
(2006-2012), Odense (2006-2012), and Copenhagen (Rigshospitalet, 2010-
2012). All patients had been treated with R-CHOP/CHOP-like regimens. Patient
lists were obtained from the Danish Lymphoma registry (LYFO). All medical
records were reviewed for information about weight and height at diagnosis,
disease-related weight loss (≤5kg, >5kg), and BSA values used for chemother-
apy dosing. Patients were grouped according to the WHO defined BMI cate-
gories for underweight (<18.5), normal weight (≥18.5, <25), overweight (≥25,
<30) and obesity (≥30). The 3-year overall survival (OS) fractions were esti-
mated using the Kaplan-Meier method. Cox regression analyses were used to
assess the prognostic impact of BMI and BSA.
Results: A total of 658 DLBCL patients were included in the present study.
The median age was 67 years (range 16-95 years) and the male:female ratio
was 1.3. Patients with full international prognostic index (IPI) scores (n=615)
were categorized as low-risk (27%), low-intermediate (26%), intermediate-high
(27%) and high-risk (20%). By the time of first chemotherapy, 4% of the patients
were underweight, 46% were normal weight, 34% were overweight, and 16%
were obese. BSA values used for chemotherapy dosing were <1.8 m2, 1.8-2.0
m2, and >2,0 m2 in 36%, 31%, and 33% of the patients, respectively. The used
BSA value was not reported in five patients. The Table shows the prognostic
impact of BMI and BSA on OS. There were no significant differences in the
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BMI-specific 3-year OS estimates with the exception of inferior OS for under-
weight patients vs. overweight patients. In the sex-stratified analyses, under-
weight was associated with a higher risk of death in male patients, but not in
female patients. BSA values between >1.8 m2were associated with a better
OS for male patients, but only BSA values ≥2.0 m2 retained significance in mul-
tivariate analysis.
Tabella 1.
Summary and Conclusions: Consistent with previous reports, being under-
weight at the time of diagnosis was associated with an inferior survival in male
DLBCL patients. Lower BSA values were also associated with a worse outcome
in male patients, which highlights the ongoing discussion of a possible inade-
quate dosing of immunochemotherapy in these patients. 
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18-F FDG PET/CT VERSUS BONE MARROW BIOPSY FOR ASSESSMENT
BONE MARROW INVOLVEMENT IN PATIENTS WITH NON-HODGKIN
LYMPHOMA
D. Vassileva1,* B. Spassov2, J. Dimitrov3, M. Guenova3, S. Toshkov4
1Laboratory of Nuclear Medicine, 2Department of Clinical Hematology, 3Labo-
ratory of Hematopathology and Immunology, 4Laboratory of Cytogenetics and
Molecular Biology, National Specialized Hospital for Active Treatment of Hema-
tological Diseases, Sofia, Bulgaria
Background: Bone marrow involvement is an important parameter that affects
the stage, prognosis and management of lymphoma patients. Bone marrow
involvement in patients with non-Hodgkin lymphoma (NHL) shows extensive
stage of the disease. The bone marrow biopsy (BMB) is the method of choice
for the detection of bone marrow infiltration, despite its technical limitations.
BMB may demonstrate high false negative results. In last years 18-F FDG
PET/CT imaging has become a very useful technique for diagnosis, staging
and therapy control in NHL patients.
Aims: To evaluate the value of 18-F FDG PET/CT and its concordance with
BMB in determining the bone marrow involvement in patients with NHL.
Methods: Data from 70 patients (39 men and 31 women), aged 21- 69 years,
with histologically verified non-Hodgkin lymphoma were analyzed retrospec-
tively. All the patients were investigated by 18-F FDG PET/CT, according to the
accepted protocol. Iliac crest BMB was performed according to standard pro-
cedure. The 18-F FDG PET/CT results were compared with the BMB results in
order to evaluate the bone marrow involvement.
Results: Both 18-F FDG PET/CT and BMB were negative in 52 (74%) patients.
In 18 patients (26%) 18-F FDG PET/CT was positive for bone marrow infiltra-
tion. The focal and diffuse bone marrow involvement was detected in 13 and 5
patients respectively. Of the eighteen 18-F FDG PET/CT positive patients, both
methods gave concordant data in 5 (28%) patients. Thirteen patients of the 18-
F FDG PET/CT positive patients showed a negative BMB. These patients had
multifocal 18-F FDG uptake but excluding the iliac crest biopsy site.
Summary and Conclusions: 18-F FDG PET/CT has a complementary role
with BMB for the detection of bone marrow involvement in patients with non-
Hodgkin lymphoma, especially in the focal bone marrow infiltration. 18-F FDG
PET/CT positive results may change the treatment in patients with negative
BMB.
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INTRAPLEURAL RITUXIMAB FOR THE TREATMENT OF MALIGNANT
PLEURAL EFFUSION DUE TO CD20-POSITIVE LYMPHOMA
M. F. Law1,*H. N. Chan2H. K. Lai2C. Y. Ha2C. Ng2Y. M. Yeung2S. F. Yip2
1Medicine, Prince of Wales Hospital, Shatin, 2Medicine, Tuen Mun Hospital,
Tuen Mun, Hong Kong
Background: Pleural effusion due to lymphoma can be massive and resistant
to chemotherapy treatment. When systemic therapy fails, local therapy has to
be considered. Rituximab was proven effective for the treatment of CD20-pos-
itive B cell lymphoma when given intravenously. The intrapleural route of admin-
istration was not explored. The intrapleural route might allow achievement of a
high enough concentration of the antibody for lymphoma cell killing in the pleural
cavity.
Aims: We assess the use of intrapleural rituximab in controlling malignant pleu-
ral effusion due to CD20-positive lymphoma. 
Methods: Patients with malignant pleural effusion due to lymphoma were iden-
tified. Immunophenotyping study of the pleural fluid was performed to confirm
CD20 positivity. They were given systemic chemotherapy and pleural tapping.
Those with persistent pleural effusion were recruited and given intrapleural rit-
uximab. Rituximab (50-100mg in 50ml saline as a bolus) was given intrapleu-
rally and the chest tube was clamped for two hours and then released. 
Results: Two patients with refractory pleural effusion were given intrapleural
rituximab. The first patient was a 61-year-old man with stage IV mantle cell
lymphoma. There was bone marrow and pleural involvement by lymphoma with
massive left pleural effusion. Immunophenotyping study of the pleural fluid
showed malignant B cell (CD20+) involvement. He was given two cycles of
standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisolone) chemotherapy three weeks apart but the pleural effusion per-
sisted. At the third cycle of chemotherapy, rituximab (100mg in 50ml saline as
a bolus) was added and given intrapleurally. Repeat chest X-ray on day two
showed resolving pleural effusion. There was no untoward side effect. After
the fourth cycle of R-CHOP, the patient had lymphoma progression with central
nervous system involvement. Further salvage chemotherapy including high
dose methotrexate and cytarabine was given. The lymphoma did not respond
to salvage chemotherapy. Despite this, there was no recurrence of the pleural
effusion. The second patient was a 44-year-old man suffering from marginal
zone B-cell lymphoma. He presented with extensive lymphadenopathy and left
massive pleural effusion. Immunophenotyping study of the pleural fluid also
confirmed malignant B cell (CD20+) involvement. Two cycles of R-CHOP
chemotherapy at standard dosing was given but there was persistent massive
effusion that required repeated chest drainage. Rituximab (50mg in 50ml saline
as a bolus) was then administered intrapleurally together with the first day of
intravenous chemotherapy and rituximab at the third cycle of chemotherapy.
Two more doses of rituximab (100mg in 50ml saline) were given intrapleurally
three weeks apart in subsequent cycles. The patient tolerated the intrapleural
rituximab and the effusion subsided gradually. 
Summary and Conclusions: Intrapleural rituximab has an adjuvant role in the
control of malignant pleural effusion due to CD20-positive lymphoma. Our
patients demonstrated a good response to rituximab given through this route,
with resolution of the effusion. This route of administration was well tolerated.
It is worthwhile exploring further this novel route of administration.
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LOCALLY ADMINISTERED HAEMOSTATIC DRUG TREATMENT OF
DIFFUSE LIFE-THREATENING PULMONARY BLEEDS, REFINING
TECHNICAL APPROACH
A. Selmeczi1,* A. Szücs2, M. Udvardy1
1Department of Haematology, 2Intensive care Unit, Debrecen Medical Univer-
sity, Debrecen, Hungary
Background: Fulminant diffuse, critically severe pulmonary bleedings, partic-
ularly diffuse alveolar haemorrhage (DAH) might be treated with iv. recombinant
Factor VIIa (rFVIIa) and quickly stopped by intratracheal application of suitable
sized haemostatic compounds, including rFVIIa (Orphan Drug Status in DAH:
Europe, UK and FDA).
Aims: DAH is well known, sometimes critically severe complication of bone
marrow (or organ) transplantation and might also be the consequence of sys-
temic pulmonary vasculitis. There is limited, anecdotic experience on intrapul-
monary rFVIIa administration, which had been summarised by Hesley, 2012
(Biologics 6:37). Intratracheal rFVIIa might powerfully stop DAH bleeding, with-
out unwanted systemic coagulatory effects. However, the optimal dose, applied
volume, way of application is far from being elucidated. Limited data are avail-
able on systemic or intrapulmonary tranexamic acid in DAH. Our aim was first
of all stop life-threatening DAH bleeds, and try to improve our skills in intrapul-
monary haemostatic drug delivery (timing, combinations and sequence).
Methods: Three fulminant DAH cases will be presented on the poster. All three
cases received intrapulmonary rFVIIa and or tranexamic acid first iv, but due
to refractoriness locally, by bronchoscopy or inhalation or both. The dose of
intrapulmonary rFVIIa was 50 ug/kg and tranexamic acid was applied as 500
mg in 5 ml. Bronchoscopic administration was followed, if needed by a second
inhalatory administration one day later. The control of bleeding was assessed
by bronchoscopic lavage, and measuring respiratory parameters, along with
haemodynamics and haemostasis monitoring.
Results: Pulmonary bleeding was stopped or significantly decreased in all of
our cases, within a few minutes. The most complex and relapsing case was a
young male patient, in whom DAH developed following autologous bone mar-
row transplantation therapy of AL amyloidosis. His fulminant DAH needed com-
plex systemic therapy including repeated iv 40 ug/kg rFVIIa and tranexamic
acid, which measures could not stop the progression of DAH. Following that
intrapulmonary rFVIIa administration (with quick cessation of bleeding), but lat-
er, when restrictive heart failure became even more serious it turned to be
refractory and the patient died. In the other two patients (case 2: liver failure
with DAH, case 3: DAH following acute leukaemia chemotherapy) intrapul-
monary rFVIIa +tranexamic acid proved to be effective quite promptly, achieving
durable responses. We used the recommended rFVIIa dosing schedule
(50ug/kg), however, we found critical over flood phenomenon if we applied the
originally suggested 50 ml volume –divided into the two lungs, so at the end
we reduced the volume to 5-10 ml/lung. We did not observe any systemic
haemostatic changes or thrombotic events following our intrapulmonary treat-
ments.
Summary and Conclusions: Careful intrapulmonary administration of rFVIIa
or probably tranexamic acid is safe and effective way to stop otherwise refrac-
tory, massive pulmonary haemorrhage and DAH. This form of treatment is safe,
feasible, but needs well trained and instrumented intensive care unit, and
should be available and applicable in transplant and larger oncohaematological
centres. However, the optimal technique, mode of application, dosage seems
to be uncertain, e.g. the volume recommended by the literature seemed to be
critically oversized. It is not clear weather intrapulmonary administration could
be the first approach instead of iv route or not. It would be important to collect
and summarise anecdotic experiences, until then each treating unit should
develop an own protocol and improve skills. 
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THE USE OF PROTHROMBIN COMPLEX CONCENTRATE FOR
INDICATIONS OTHER THAN VITAMIN-K ANTAGONIST REVERSAL: AN
ALTERNATIVE AND EFFECTIVE MEANS OF CORRECTING ACQUIRED
COAGULOPATHIES 
M. Scott1,* R. Ramsey2, J. Thachil3
1Department of Haematology, Central Manchester NHS Foundation Trust, 2Uni-
versity of Manchester School of Medicine, 3Central Manchester NHS Founda-
tion Trust, Manchester, United Kingdom
Background: In accordance with a number of national guidelines, prothrombin
complex concentrate (PCC) is widely used for the emergency reversal of the
anticoagulant effect induced by vitamin-K antagonists. The licenced use also
includes the treatment and prophylaxis of bleeding in all situations where there
may be an acquired deficiency of coagulation factors. Despite this, fresh frozen
plasma (FFP) is preferentially used in these scenarios, partly because of clinician
familiarity, but also because of lack of data supporting PCC use in this context.
Aims: To determine the frequency of PCC utilisation at Central Manchester
NHS Foundation Trust (CMFT) for indications other than the emergency rever-
sal of vitamin K antagonists; the indications for this use and it’s efficacy in
terms of correction of routine coagulation parameters.
Methods: Data was collected retrospectively for two 13-month periods, January
1st 2012 – January 31st 2013 and January 1st 2014 – January 31st 2015. Using
electronic records held by the CMFT transfusion laboratory, all patients that
had been issued PCC during these periods were identified. These records
were cross-referenced with electronic request forms and discharge documen-
tation to determine which patients had been anticoagulated with vitamin K
antagonists at the time of PCC issue and excluded. Besides laboratory results
and demographic information, the following data was collected: Patient sex;
coagulopathy aetiology; Liver function test and albumin results; PCC indication;
dose issued; pre and post-PCC administration PT and APTT.
Results: A total of 41 patients were identified to have received PCC for indi-
cations other than vitamin-K antagonist reversal. This included 20 males and
21 females. The average PCC dose issued was 2463 iu (equivalent to 35iu/kg
for a 70kg patient). 18 patients (44.0%) had evidence of significant liver impair-
ment (at least grade A, according to Childs-Pugh classification). All patients
had baseline coagulation parameters available; 32 patients (78%) had a repeat
measurement within 24 hours of receiving PCC. Of those that had a repeat
measurement, the PT and APTT corrected to within 0.5 seconds of the refer-
ence range in 34.4% and 4.0% of patients, respectively. With the less stringent
target of correction to within 1.5x reference range, the PT and APTT corrected
in 75.0% and 71.9%, respectively.
Summary and Conclusions: In comparison to FFP, there are a number of
advantages to using PCC to correct coagulation abnormalities. It can be admin-
istered rapidly and, relative to FFP, incurs a low volume fluid load. These are
issues particular pertinent in the management of critically ill and decompen-
sated patients. Our data suggests that, at therapeutic doses, PCC is effective,
correcting routine coagulation parameters to with 1.5x of reference range in
the majority of patients. In combination with its clinical advantages, we suggest
this data supports wider advocacy of PCC use in acquired coagulopathies.
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VON WILLEBRAND FACTOR DEFICIENCY CORRECTED BY LUNG
TRANSPLANTATION.
A. Lario1,* R. Forés1, S. Gil1, J.L. Campo-Cañaveral2, D. Gomez-de-Antonio2,
R. Laporta3, M. Martín4, G. Anze1, N. Dorado1, J.L. Bueno1, R. Abad1,
C. Fernández1, A. Vázquez1, R. Cabrera1
1Hematology, 2Thoracic Surgery, 3Pneumology, Hospital Universitario Puerta
de Hierro Majadahonda (Madrid), Majadahonda (Madrid), 4Hematology, Hos-
pital Universitario La Paz, Madrid, Spain
Background: In experimental models with von Willebrand disease (vWD) pigs,
plasma von Willebrand factor (vWF) was significantly increased after lung trans-
plantation because lung endothelial cells strongly express vWF. However these
findings have not been confirmed in human beings.
Aims: To confirm that bilateral lung transplantation could correct a mild von
Willebrand defect.
Methods: A 26-year-old man, with mild bleeding episodes (epistaxis) and family
history (mother with menorrhagia), was diagnosed in November 2012 with type
1 vWD (FvW:Ag 39 IU/dL; FvW:RCo 44 IU/dL; FVIII 99%). The patient was
referred to our institution for lung transplantation as a result of cystic fibrosis.
The vWF deficiency was confirmed by low levels of vWF and a normal multimeric
plasma vWF pattern. Bilateral lung transplantation was performed in April 2013.
The mechanical ventilation time was 48 hours and PaO2/FiO2 was 358.
Ischemic times were 315 minutes (right lung) and 435 minutes (left lung). Ex
vivo lung perfusion was performed with Organ Care System (preservation time
120 minutes). FVIII/vWF concentrate was administered both during and after
surgery, without any relevant bleeding events. The patient developed primary
lung graft dysfunction grade 2 although he was extubated on the second post-
operative day with good oxygenation. However he developed progressive lung
infiltrates with respiratory failure and extracorporeal membrane oxygenation
(ECMO) was administered for 10 days. At hospital discharge in June 2013 he
was taking immunosuppression with oral tacrolimus, prednisone and mycophe-
nolate mofetil, which has continued until the present day (+22 months).
Tabella 1.
Results: Plasma vWF level increased during the postoperative days, presum-
ably due to endothelial injuries and the infusion of vWF concentrate. Laboratory
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tests post-lung transplantation demonstrated sustained normalization of all
parameters.
Summary and Conclusions: In the present case, bilateral lung transplantation
resulted in a sustained increase of plasma vWF levels produced by normal
lung endothelial cells that corrected the defect. To our knowledge, this is the
first case of von Willebrand deficiency corrected through lung transplantation.
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PREDICTING BLEEDING RISK IN PATIENTS ON VITAMIN K
ANTAGONISTS TREATMENT.
D. Benlaldj1,* A. Kamel1, M.A. Moueden1, F. Seghier1
1Hemobiologie, CHU ORAN, Oran, Algeria
Background: The patients on vitamin k antagonists, anticoagulant treatment
(VKA) have a high risk of bleeding which is difficult to evaluate and to predict. 
Aims: Assess the bleeding risk in patients on VKA using the ISTH/SSC scoring
system. And evaluated the efficiency of the scores: OBRI, HAS-BLED,
HEMORR2HAGES and ATRIA in predicting the risk of bleeding.
Methods: We have studied and evaluated the bleeding history of 57 patients
on VKA treatment. For each patients we calculate ISTH/SSC, OBRI, HAS-
BLED, HEMORR2HAGES and ATRIA score; this score was correlated with bio-
logical and clinical data. 
Results: 52% of the patients have a low bleeding risk (ISTH average score
after VKA treatment: 1.27), 39% of the patients have an intermediate bleeding
risk (ISTH average score after VKA treatment: 5.59), and 9% of the patients
have a high bleeding risk (ISTH average score after VKA treatment: 9.8). 79%
of the patients have a labile INR with a bleeding incidence estimated at 48.1%
per year, the incidence become 20% when the INR is not labile, whereas the
Major bleeding incidence is estimated at 2.5% per year. The scores: OBRI,
HAS-BLED, HEMORR2HAGES and ATRIA; have a low sensibility and speci-
ficity (sensibility <41% and specificity between 20% and 50%).
Summary and Conclusions: Good correlation was found between the high
score results (ISTH/SSC) and bleeding risk in the patients with Atrial fibrillation
on VKA treatment (INR [2-3]). The scores: OBRI, HAS-BLED,
HEMORR2HAGES and ATRIA have a limited ability to predict the bleeding risk.
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THE P2Y12 H1 HAPLOTYPE IS ASSOCIATED WITH IMPAIRED ADP
INDUCED AGGREGATION IN TWO PATIENTS WITH PLATELET-TYPE
BLEEDING DIATHESIS.
G. Soufla1,* E. Iliopoulou1, M. Katafygioti1, N. Matoula1, A. Angelidis1,
E. Melissari1
1Department of Haematology, Blood Transfusion Unit and and Haemostasis,
Onassis Cardiac Surgery Center, Athens, Greece
Background: At least two platelet receptors are required for full platelet acti-
vation and aggregation in response to ADP: P2Y1 that mediates a rapidly
reversible wave of aggregation and P2Y12 that is responsible for slowly pro-
gressive and sustained platelet aggregation. Markedly reduced and reversible
aggregation in response to (4μM) ADP (≈10%) was observed in two patients
free of any antiplatelet treatment with a bleeding diathesis suggesting an under-
lying molecular defect in P2Y12 receptor.
Aims: To investigate the above patients for molecular defects in the P2Y12 gene.
Methods: DNA & RNA extracted from patients’ whole blood were subjected to
PCR and RT-PCR respectively, followed by sequencing and real-time PCR.
Results: Both subjects had normal coagulation tests (fibrinogen, prothrombin
time and activated partial thromboplastin time), vonWillebrand factor antigen
and ristocetin cofactor activity but prolonged bleeding time (≥15min). Patient
KG had low platelet count (≈120x103/μL). Sequencing analysis of P2Y12 gene
revealed patient KG to be heterozygous for a non coding G-to-T transversion
(G52T) in exon 2 and an intronic T-to-C transition (i-T744-C). Therefore patient
KG carries both H1/H2 P2Y12 haplotypes. Patient DT exhibited no polymorphic
variation in these sites or at positions i-ins801A and i-C139T, indicating that the
patient carries two H1 alleles (H1/H1). Platelet P2Y12 mRNA, quantified by
real-time PCR in both patients, was expressed similarly to healthy blood donors’
platelets exhibiting normal aggregation in response to ADP. Sequencing analy-
sis of the P2Y12 cDNA revealed no sequence variations. 
Summary and Conclusions: In conclusion, no loss of function mutation or
transcriptional defect in the P2Y12 gene has been found in our patients. How-
ever, it has been published that the H2 and H1 haplotypes of P2Y12 gene are
associated with higher and lower maximal aggregation respectively in response
to ADP in healthy subjects. Therefore we can speculate that the presence of
the H1 P2Y12 haplotype could be associated with a poor ADP response leading
to bleeding diathesis in these subjects.
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PREGNANCY MANAGEMENT IN VON WILLEBRAND’S DISEASE
M. Vinogradova1,* T. Fedorova1, R. Shmakov2
1transfusiology, 2obstetrics, Federal State Budget Institution «Research Center
for Obstetrics, Gynecology and Perinatology», Moscow, Russian Federation
Background: Pregnancy and childbirth are considered as the situations pre-
disposing to a high risk of bleeding in women with von Willebrand disease
(VWD). A clinical vigilance and a treatment if necessary minimize the number
of complications during pregnancy and postpartum.
Aims: Establishment of algorithms for a management of pregnancy, delivery
and postpartum in VWD is crucial to pregnancy outcomes. We have been opti-
mizing strategies for the management of pregnant patients with VWD.
Methods: Since 2010 we have analyzed 24 pregnancies in 22 women with
VWD (previously diagnosed VWD-20, determined during pregnancy-2). VWD
Type 1 established in 16 patients, type 2 in 5 patients, type 3 in 1 case. All of
them underwent monitoring and a preventive treatment when necessary. The
laboratory assessment included complete blood count, activated partial throm-
boplastin time, prothrombin time, fibrinogen, von Willebrand panel (FVIII,
VWF:Ag, VWF:RCo), platelet aggregation studies and thromboelastography.
In addition, we examined the newborns to detect VWD.
The preventive treatment administered if analyses revealed hypocoagulation
signs or a clotting factor levels reduction. We used DDAVP during pregnancy
in type 1 on demand, a clotting factor concentrate (CFC) containing VWF until
the levels were above 40-50 IU/dl and a tranexamic acid.
Results: No bleeding events registered during pregnancy. Most women with
VWD type 1 developed an increase of clotting factor levels as a physiological
response to pregnancy. Only 4 (16,7%) cases required a regular CFC treatment
throughout pregnancy, including the patient with VWD type 3 received CFC all
observation time. Therapy on demand was performed in 9 (37,5%) cases. The
CFC preventive treatment during labour was performed in 8 (33,3%) cases, a
postpartum therapy - in 17 (70,8%) cases. Pregnancies resulted in a birth of the
full-term newborns in all 24 cases. No spontaneous miscarriage or neonatal
mortality has occurred. Caesarean sections were performed in 3 (12,5%) of
births. We detected VWD in 9 (37,5%) newborns. Despite the preventive treat-
ment, we observed one intraoperative hemorrhage in the case of placenta previa
and non-severe secondary postpartum hemorrhage (PPH) in 3 cases. Close
monitoring was conducted over 4-6 weeks postpartum for preventing delay PPH.
Summary and Conclusions: The risk of hemorrhagic complications during
pregnancy and postpartum in VWD may be minimized by applying the man-
agement algorithm including a preventive treatment. For women with low factor
levels the preventive treatment with CFC is necessary. Women with VWD need
pregnancy planning, clinical vigilance and observation by multidisciplinary team
during pregnancy, puerperium and postpartum.
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EFFICACY AND SAFETY PROFILE OF RIVAROXABAN FOLLOWING HIP
AND KNEE ARTHROPLASTY
A. Hua1, V. Loganathan1, J. Berger1, S. Patel1,* H. Kurunadalingam1,
S. Deplano1, M. Vizcaychipi1
1Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
Background: The incidence of venous thromboembolism (VTE) after hip and
knee arthroplasty has been quoted as 1.1% and 0.53% respectively despite
thromboprophylaxis. Furthermore, the incidence of myocardial injury after non-
cardiac surgery is 8.0%1. There is a burden of thromboembolic events in
orthopaedic patients during the perioperative period. Rivaroxaban is recommend-
ed as thromboprophylaxis following total hip and knee replacement surgery.
Aims: To investigate the efficacy and safety profile of rivaroxaban in patients
undergoing hip and knee arthroplasties.
Methods: Patients who underwent total hip or knee replacement surgery
between April 2013 and August 2014 were included in the retrospective study,
carried out in accordance with the UK Good Clinical Practice. Data regarding
patient characteristics and postoperative morbidity were collected using medical
records. Patients were followed up with telephone surveys to investigate any
bleeding events/adverse effects experienced. Primary efficacy was defined as
composite of pulmonary embolism (PE), deep vein thrombosis (DVT), myocar-
dial infarction (MI) and stroke. Safety profile was defined as major or minor
bleeding. Data analysis was performed using IBM SPSS statistical software.
Results: 445 patients were included in the study. Preliminary results are pre-
sented for a sub-cohort of 99 patients. PE occurred in three (3%) patients, of
which one patient died, and is higher compared to other studies1. No incidences
of DVT, MI or stroke were reported. One major bleeding event and seven minor
bleeding events occurred in five patients. The major bleeding event followed a
lobectomy and required blood transfusion. Minor bleeding events included epis-
taxis, wound, gastrointestinal and skin bleeds. There was a statistically signif-
icant association between diabetes and PE (p=0.02), and ischaemic heart dis-
ease and bleeding events (p=0.04) according to Fisher’s exact test.
Summary and Conclusions: Prophylactic management of VTE should be
individualised according to patients’ risk factors for thrombosis and bleeding. A
small percentage of patients experienced bleeding events and strategies for
reversal of rivaroxaban remain limited as there is no specific antidote currently
available. Future work includes long-term follow up of orthopaedic patients ini-
tiated on rivaroxaban and preventative strategies of VTE events.
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FACTOR V DEFICIENCY IN WEST OF ALGERIA: SINGLE CENTER
EXPERIENCE
M. Mohamed Amine1,* B. driss1, H. wassila1, S. fatima1
1Pharmacy Oran, Hemobiology Service, Oran, Algeria
Background: Factor V deficiency is one of the rare inherited bleeding disorders
the frequency in world is 1/ 106. But in algeria the high consanguinity rates
have increased the number of patients with Rare Bleeding Disorders (RBDs)
Aims: -It was established a clinical and biological classification of patients with
rare deficiency disorders. It was explored the relationship between coagulation
factor activity level and bleeding severity for this patients.
Methods: A retrospective study conduct from 2008 to 2014. It was concerned
63 patients with a mean age 29 years (range1 year to 73 years) and Sex ratio
♂/♀=1.17. We use assigned categories of clinical bleeding severity of The
European Network of Rare Bleeding Disorders (EN-RBD): 1. Asymptomatic:
No documented bleeding episodes. 2. Grade I: bleeding Bleeding that occurred
after trauma or drug ingestion (antiplatelet or anticoagulant therapy). 3. Grade
II: bleeding Spontaneous minor bleeding:bruising, ecchymosis, minor wounds,
oral cavity bleeding, epistaxis and menorrhagia. 4. Grade III: bleeding Spon-
taneous major bleeding: hematomas*, hemarthrosis, central nervous
system,gastrointestinal and umbilical cord bleeding.
Results: 15 patients (23.8%) of RBDs were diagnosed with Factor V deficiency,
the coagulation factor activity levels that were necessary for patients to remain
asymptomatic were: (39.58±13.56) %. Grade 1: (27.50±21) %. Grade 2: 12 %.
Clinical bleeding showed that the most common symptoms in patients with FV
deficiency were oral cavity bleeding followed by hemarthrosis.
Summary and Conclusions: There was no association between coagulation
factor activity level and clinical bleeding severity for FV. R2=0.143. Results of the
literature review suggest that the severity of symptoms is variable and correlates
poorly with laboratory phenotype. Platelets provide a concentrated supply of FV:
although most FV is present in plasma, approximately 20–25% of the circulating
FV is found within platelet a-granules. After a granule release upon platelet acti-
vation, FV can presumably bind immediately to surface receptors optimizing pro-
thrombinase complex activity. This probably protects some patients with FV defi-
ciency from severe life-threatening bleeding, and may explain the weak associ-
ation between laboratory phenotype and clinical severity.
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COMPOUND FACTOR V AND FACTOR VIII DEFICIENCY IN ALGERIA
D. Benlaldj1,* M.A. Moueden1, W. Homane1, F. Seghier1
1Hemobiologie, CHU ORAN, Oran, Algeria
Background: The frequency of the compound Factor V and factor VIII defi-
ciency is 1/1000000. The gene is located on chromosome 18. Level factor are
variable between 5% and 25%.
Aims: To assess the relationship between factor level and bleeding severity.
Methods: Retrospective study conducted for 7 years (2008 to 2014) in the west
of Algeria, 63 patients has been tested for diagnosis of rare bleeding disorder.
We use the Assigned categories of clinical bleeding severity of European Net-
work of Rare Bleeding Disorders (EN-RBD): 1. Asymptomatiqc (no documented
bleeding episodes). 2. Grade I bleeding (bleeding that occurred after trauma or
drug ingestion). 3. Grade II bleeding (spontaneous minor bleeding; bruising,
ecchymosis, minor wounds, oral cavity bleeding, epistaxis and menorrhagia).
4. Grade III bleeding ( spontaneous major bleeding ; hematomas, hemarthrosis,
central nervous system, gastrointestinal and umbilical cord bleeding).
Results: 16 patients (25.4%) diagnosed with compound Factor V and factor
VIII deficiency, 11 patients have factor level <20 % classified with severe form
and 05 patients had factor level betwene 20 and 40 % classified with moderate
form. According the proposition of europen network of rare bleeding disorder.
Regarding the clinical severity 3 are asymptomatic (factor level between 25
and 30%), 9 patients classified on grade 1 (factor level between 10 and 25%)
and 4 on grade 2 (factor level between 5 and 10%). 
Summary and Conclusions: A good corelation was found between factor
level (factor V and VIII) and the clinical severety (R2=0.83). Factor level <10%





IN VITRO FACTOR VIII ACTIVITY AFTER RECONSTITUTION WITH
DILUENT FLUID FOR CONTINUOUS INFUSION
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nal Medicine, Yonsei University Wonju College of Medicine, Wonju, 3Pediatrics,
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic Of
Background: Major surgery for hemophilia patients is very critical situation for
one’s life. For the successful result one’s blood coagulation factor level during
and after surgery is important. Continuous infusion method has merit of saving
product as much as 30%. Because the drug activity will be decreased gradually
after dilution even in vitro the latter portion of infusion will have decreased
activity also.
Aims: We evaluate in vitro factor VIII activity after reconstitution with diluent
fluid for continuous infusion.
Methods: We checked the in vitro activities on 0, 8, 16 and 24 hours after dilu-
tion with one commercial plasma derived FVIII product. And three commercial
FVIII products (2 recombinant FVIII and 1 plasma derived concentrates) were
used for in vitro FVIII:C activities at 0, 2, 4, 6, and 8 hours after reconstitution
in both the exposure to indoor light group and the light shield group.
Results: In vitro activity was gradually decreased to 91±5.3%, 80±6.9%, and
56±6.7% at 8 hr, 16 hr and 24 hr on room temperature and on room light expo-
sure respectively. Better results of 94±4.8%, 89±6.5% and 73±6.4% on light
shield were observed (p<0.001). In the three drugs, in vitro FVIII:C was
decreased from 0 to 8 hours after reconstitution (p <0.001). The decline of FVI-
II:C followed linear model (p<0.001). in vitro FVIII:C was 95.3±1.91% and
90.6±2.53% at 4 and 8 hours after reconstitution, respectively, in exposure to
room light group. On light shield group, FVIII:C was 95.4±1.12% and
90.9±1.67% at 4 and 8 hours, respectively (p=0.849).
Summary and Conclusions: We aware the longer in vitro dilution state the
lower factor activity. So, we have to adjust the required amount according to
the frequency of changing bottle for the best bleeding control during and after
surgery. Reconstitution of lyophilized powder with diluent every 4 hours is desir-
able to maintain effective blood factor level.
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FREQUENCY AND CHARACTERISTICS OF FACTOR VIII INHIBITORS IN
TUNISIAN HEMOPHILIA A: EXPERIENCE OF A SINGLE CENTER 
O. Kassar1,* M. charfi1, M. ghorbel1, C. kallel2, M. elloumi1
1hematology, 2laboratory of hematologie, Habib Bourguiba Hospital, university
sfax, sfax, Tunisia
Background: Development of an inhibitory antibody to factor VIII is a rare but
serious complication of hemophilia treatment of patients with hemophilia A.
Aims: The aim of this study is to determine the prevalence of inhibitors in
hemophiliacs patients and to analyse their characteristics in our center.
Methods: From May 2008 to May 2013, 75 patients with severe hemophilia A
admitted in department of hematology in Sfax from Tunisia were evaluated.
Those who had abnormal mixing study, antibody against FVIII were measured.
High titer inhibitor was defined as having a titer of >5 BU/ mL at any time. Data
were collected and analyzed. Our patients received treatment on-demand with
plasma-derived or recombinant FVIII and or cryoprecipitate.
Results: Of the 74 with hemophilia A enrolled in our study, 50 patients (68%)
were with severe form, 16 patients (21%) were with moderate form and 8
patients (11%) mild form. From this group, sixteen (21%) were developed
inhibitors. Frequency of inhibitors in severe, moderate and mild form were
respectively 26%, 19% and 0%. The mean age of patients at inhibitor devel-
opment was 15 years (3 -31years). Seven patients (44%) were high responders
while 9 patients (56%) were low responders. All low inhibitors have disappeared
spontaneously despite continued treatment with FVIII. One patient died by
severe bleeding and one patient developed compressive spinal hematoma and
keeps a flaccid paraplegia.
Summary and Conclusions: In our series the incidence of inhibitors in
Haemophilia A (21%) is similar to the literature (20 à 30 %). Inhibitors are more
frequently encountered in persons with severe hemophilia compared to those
with moderate or mild hemophilia. The median age of inhibitor development in
our series is higher than in developed countries (three years or less). Devel-
opment of an inhibitory remains a major problem in the management of hemo-
philia threatening the vital and functional prognosis in our patient population
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12 NOVEL MUTATIONS IDENTIFIED IN PATIENTS OF CONGENITAL
AFIBRINOGENEMIA IN PAKISTAN.
T. Nafees Sonia Khan1,* A. Naz1
1Coagulation and Hemostasis, National Institute of blood diseases and bone
marrow tranplantation, karachi, Pakistan
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Background: Consanguinity is a hot issue in multiple cultures around the globe.
Pakistan is included in the list where interfamilial wedlock is highly preferential
and enriched source of inherited bleeding disorders.
Aims: This study focuses to detect the mutation in fibrinogen gene ((FGA, FGB
&FGG) by DNA sequencing in Pakistani patients.
Methods: This descriptive and cross sectional study was conducted in Karachi
and Lahore and fully complied with the Declaration of Helsinki. Patients with
fibrinogen deficiency (tested by Fibrinogen functional assay from Laboratoire
Stago, Asnieres, France) were screened for mutations in the Fibrinogen gene
alpha (FGA), beta (FGB) and gamma (FGG) genes by direct sequencing. 
Results: Total 17 mutations have been identified in 13 patients. 10 mutations
were novel and identified in FGA, 4 in FGB and three in FGG. FGA gene muta-
tion is seemingly the most commonly occurring mutation in our population with
8 novel mutations followed by 2 novel mutations identified in FGB and two
novel mutations in FGG. Results were matched with wild type of FGA,FGB &
FGG using HGMD(http://www.hgmd.cf.ac.uk/ac/index.php).
Summary and Conclusions: Congenital afibrinogenemia is a rapid growing
problem in countries such as Pakistan where consanguinity is frequently prac-
ticed. In this study amongst 8 novel mutations in FGA gene, five are identified
as Missense mutation in FGA in our population which has not been reported
yet in literature. This study transpires the fact that mutations in FGA frequently
exist in local population followed by FGB and FGG mutations.
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EFFICACY AND SAFETY OF PROPHYLAXIS IN PREVIOUSLY UNTREATED
PATIENTS WITH SEVERE HEMOPHILIA A IN IRAN
M. Karimi1,* P. Eshghi2, S. Haghpanah1, Z. Zahedi1, B. Habibpanah2
1Hematology Research Center, Shiraz University Of Medical Sciences, Shiraz,
2Pediatric Congenital Hematologic Disorders Research Center, Shahid
Beheshti University of Medical Sciences, Tehran, Iran
Background: Hemophilia is an inherited bleeding disorder that is associated
with wide range of bleeding episodes. Primary prophylaxis is the best method
of treatment to save the health and quality of life especially in children. Recently
the low dose tailoring method of primary prophylaxis has been introduced for
Previous Untreated Patients (PUP).
Aims: To evaluate the efficacy and safety of low dose tailoring method of pri-
mary prophylaxis in PUPs with severe hemophilia A.
Methods: In this pre-post interventional study, 16 patients with severe hemo-
philia A (activity <1%) were included. All patients were attending at the two
main comprehensive care centers in Iran. Primary continuous modified pro-
phylaxis was used for patients with age less than 3 years old, after first and
before the second episode of obvious clinical bleeding in large joints or large
soft tissue hematoma or major bleedings. All the hemophilic subjects in our
study were previously untreated patients and randomly selected into two groups
receiving recombinant factor 8 concentrate (Kogenate Bayer) and plasma
derived (Emoclot Kedrion). Prophylaxis was started by 25-30 IU/kg once per
week and increased to twice or three per week if necessary according to defined
bleeding events for at least 50 exposure days (ED) or one year, each of
occurred later. None of the patients had positive titer of inhibitor at the beginning
of study. Descriptive data were presented as median and interquartile range
(IQR) and also summarized at table 1.
Results:: Median and IQR for age were 3 and 2.7 years respectively. Median
and IQR for age at diagnosis and age of starting prophylaxis were: 6 (5.7) and
9.5 (12) months respectively. Median and IQR for Annual Bleeding Rate (ABR)
of patients after prophylaxis were 1 and 2.75 episodes per year respectively.
Inhibitor was present in 5 patients (31%) after prophylaxis (patients number 2,
3 and 5: inhibitor titer =4; number 12: inhibitor titer =400; and number 13:
inhibitor titer =32).
Table 1. Clinical characteristics of previously untreated patients with
severe hemophilia A
Summary and Conclusions: Our study showed modified prophylaxis once
per week can be cost- benefit in comparison with other known protocols and
leads reduced morbidity in patients with severe hemophilia A comparing with
On Demand treatment. On the other hand, incidence of inhibitor was 31% in
our study which is comparable with previously published data (5-39%).
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DISTRIBUTION OF THE ALLELES HLA II CLASS IN UKRAINIAN
HEMOPHILIA A PATIENTS, DEPENDING ON THE INHIBITORS
O. Stasyshyn1,* V. Krasivska2, H. Makuch3
1Surgery, 1SI “Institute of blood pathology and transfusion medicine NAMS of
Ukraine”, 2Surgery, SI ‘Institute of Blood Pathology and Transfusion Medicine
of UNAMS”, 3Diagnosis of Hereditary Pathology, “Institute of hereditary pathol-
ogy NAMN of Ukraine”, Lviv, Ukraine., Lviv, Ukraine
Background: The development of neutralizing antibodies against factor VIII
and IX is the major complication in haemophilia care today. The antibodies
neutralize the biological activity of FVIII and FIX and render replacement ther-
apies ineffective. Antibodies against infused FVIII affect 20–30% of patients
with severe HA and usually occur in childhood within the first 20-50 exposure
days (ED) of therapy Antibodies are generated as a result of a cascade of
tightly regulated interactions between different cells of the innate and the adap-
tive immune system located in distinct compartments. Candidates for immuno-
genetic investigation are genes involved in the immune response such as
human leucocyte antigen (HLA) alleles. The HLA class II molecules are of par-
ticular interest because they present extracellular antigens (e.g. exogenous
FVIII) to the patient’s immune system. Previous immunogenetic studies in
severe HA have shown the implication of HLA alleles in inhibitors formation.
Aims: The aim of our study was to investigate a possible link between the
alleles HLA II class and the inhibitor and its type in Ukrainian haemophilia A
patients (pts)
Methods: The study included 47 haemophilia A pts, aged 3 to 65 years (13
children and 34 adults) who were divided into 3 groups: I - HA pts without
inhibitors (n=13); II –HA permanent inhibitor pts (n=20); III – HA transient
inhibitor pts (n=14). All non-inhibitor pts had more than 150 ED; Informed con-
sent was obtained from pts, children’s parents or adolescents. To measure the
FVIII activity and establish haemophilia diagnosis, the one-stage clotting assay
was performed. To detect inhibitors against FVIII, the Bethesda method was
applied. Genomic DNA was extracted from peripheral blood leukocytes by salt-
ing. Genotyping DRB1, DQA1 and DQB1 performed using PCR. Investigated
16 gene allele HLA-DRB1, 10 alleles of the gene HLA-DQA1 gene alleles and
19 HLA-DQB1.
Results: Statistical analysis of the results allowed to distinguish alleles asso-
ciated with inhibitor in patients with haemophilia A in Ukraine. To significantly
increase set for alleles DRB1*15:01 (χ2=4,61, p <0,0), DQB1*06:02 (χ2=4,61,
p <0,05), and is likely to significantly reduce DQB1*0302 (χ2=6,14, p <0,05).
This means that the alleles DRB1*15:01 and DQB1 *06:02 can be seen as
alleles - aggressors, and allele DQB1*03:02 rather as protectors allele. The
calculation showed that carriers of allelic groups DRB1*15:01 and DQB1*06:02
and increases the risk of inhibitor in patients with haemophilia 10 times each
(OR=10,7; CI 95%: 0,58-198,91) as opposed to carrier DQB1*03:02, which
reduces the risk of inhibitor 5 times (OR=5,5; CI 95%: 1,29-23,17).
Summary and Conclusions: The majority of associations of immune response
genes to the production of inhibitors in Ukrainian HA pts are related to HLA
class II alleles HLA- DRB1*15:01, DQB1*06:02 and DQB1*03:02 haplotype.
Further research must continue in a large group to determine the possible char-
acteristic of certain groups alleles and investigate their role in the development
of the FVIII inhibitor.
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THE RATIO OF LEUKOCYTE AND RED BLOOD CELL CLONES IN
PATIENTS WITH AA/PNH AND THEIR CORRELATION WITH LDH LEVEL
E. Shilova1,* T. Glazanova2, Z. Chubukina2, O. Rozanova2, K. Abdulkadyrov1,
L. Bubnova2
1Hematological department, 2lab. immunohematology, Russian Research Insti-
tute of Hematology and Transfusiology of the FMBA of Russia, St-Petersburg,
Russian Federation
Background: It is known that patients with AA in 70% and more can have
PNH-clone of various size: from minor clones to clones of considerable size
with the development of severe hemolysis. There are cases of discrepancy of
granulocyte and monocyte PNH-clone sizes in the same patients. In addition
relationship of leukocyte PNH-clone size with a level of LDH as indicators of
hemolysis is understood not enough.
Aims: Aim was to examine the ratio of granulocytic and monocytic PNH-clones
of patients with aplastic anemia associated with the PNH (AA/PNH) and assess
the relationship between the level of LDH and PNH-clone size among the dif-
ferent types of blood cells.
Methods: We heve examined 33 patients with AA/PNH, including 23 patients
in dynamics (total 78 analyses) with the definition of the size of PNH-clone
among white blood cells and red blood cells (RBC) using highly sensitive
method of 4-colour flow cytometry. The PNH-clone size, defined among the
granulocytes, was equal to or higher than 10% in 12 patients (Group 1) and
was less than 10% at 21 (Group 2).
Results: In most of the examined patients (19 of 33) the sizes of granulocyte
and monocyte PNH-clones did not significantly differ among themselves in the
same person. 13 patients have shown a higher percentage of monocyte PNH-
clone, including more than 10% difference in 5 patients: 4 in Group 1 and 1 –
in Group 2. The predominance of granulocytic PNH-clone was observed in 1
patient with a clone size within 20-30%. In a survey of the dynamics in the
absolute majority of patients trends persisted. In the whole group of patients
there were observed highly reliable correlation values of granulocyte and mono-
cyte PNH-clone size with LDH level (r=0.62 and r=0.74, respectively, p <0.01),
mostly due to the patients of Group 1. In Group 2 there persisted a correlation
between monocyte PNH-clone size and LDH level (r=0.61, p <0.01) and there
was no correlation between the granulocyte clone size and LDH level (r=0.07).
Worthy of note is the fact that in one third of this group of patients the size of
the monocyte PNH-clone was significantly higher than that among the granu-
locytes. Indicators of pathological clone size among RBC and ratio of type II
and III RBC could be variable in the same patient, depending on the presence
and intensity of hemolysis. But examination outside the periods of active hemol-
ysis in patients with clinical manifestation of PNH-clone identified general
trends. There was reliable correlation between the level of LDH and total RBC
PNH-clone (r=0.51, p <0.01) in the whole group of patients, mainly due to RBC
type III (r=0.51, p <0.01), whereas the relationship between the level of LDH
and RBC type II was much weaker (r=0.24). The relationship between the size
of granulocyte and total RBC PNH-clone was stronger in patients of Group 1
compared with that of Group 2 (r=0.53 and 0.46, respectively). On the contrary,
the relationship between the sizes of RBC clones type II and III was more pro-
nounced in patients of Group 2, compared to one in Group 1 (r=0.36 and 0.24,
respectively).
Summary and Conclusions: 1. In examined AA/PNH patients we have
revealed variability of the ratios PNH-clone sizes among granulocytes, mono-
cytes and different types of RBC. Noted more frequent prevalence of monocyte
PNH-clone compared to granulocyte one in patients with PNH-clone <10%.
2. In cases with the amount of granulocytic PNH-clone >10% there was a clear
correlation between the level of LDH (the primary intravascular hemolysis indi-
cator) with the value of the granulocyte and monocyte PNH-clone and RBC
type III (with an absolute deficiency of GPI-linked proteins). In cases of small
PNH clone (<10%) LDH correlated only with monocyte and RBC clones.
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VITAMIN D LEVELS OF CHILDREN WITH FANCONI ANEMIA
C. Albayrak1,* D. Albayrak1
1Pediatric Hematology Department, Samsun Ondokuz Mayis University Faculty
Of Medicine, Samsun, Turkey
Background: Fanconi anemia (FA) is a congenital syndrome associated with
chromosomal fragility and aplastic anemia. Conflicting data exist regarding
whether low bone mineral density is associated with FA. Factors that contribute
to development of peak bone mineral during critical periods of childhood and
adolescence include adequate calcium and vitamin D intake, general nutrition-
aladequacy, exercise, and normal hormonal and pubertal progression, along
with genetic factors. Severe vitamin D deficiency may cause myelofibrosis in
some children.
Aims: The aim of this study was to determine the frequency of vitamin D defi-
ciency and insufficiency in children with FA. 
Methods: None of the patients had previously received vitamin D supplemen-
tation. No patient had clinical or radiologic findings of rickets or seropositivity
of hepatitis C virus or HIV or had been made bone marrow transplantation.
Age, gender, serum level of ferritin, hemoglobin F, peripheric blood count, ALT,
AST, calcium, phosphor, alkaline phosphatase, 25-OH vitamin D, and parathor-
mon level were recorded. 25-OH vitamin D levels have measured by HPLC.
25-OH vitamin D level below 10 ng/ml is accepted as severe vitamin D defi-
ciency and between 10 and 19.99 accepted as vitamin D deficiency, 20 and
29.99 was vitamin D insufficiency. 
Results: Seventeen children with FA were included in the study. The median
age of the patients was 13 (range, 4–20) years. The median vitamin D level
was 11.73 ng/ml (range, 4.23–35.00). Vitamin D levels were below 10 ng/ml
(severe vitamin D deficiency) in 4 cases (23%), between 10 and 19.99 ng/ml
(vitamin D deficiency) in 10 cases (59%), between 20 and 29.99 ng/ml (vitamin
D insufficiency) in 2 cases (12%), and above 30 ng/ml (normal vitamin D level)
in 1 cases (6%). 
Summary and Conclusions: A majority of our patients with Fanconi anemia
(94%) had low vitamin D levels. Vitamin D levels will be different in different
geographic regions even in the same country. Our study is from the north region
of Turkey. New studies are therefore required from different regions. All centers
should determine the frequencies themselves and develop a prophylaxis policy
based on this data. We advise routine checking of vitamin D levels twice a
year and vitamin D supplementation to maintain its level between 30 and
100ng/ml.
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A PROPOSAL OF CLASSIFICATION FOR PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA.
A. Gaya1,* S. Brunet2, S. Piernas3, L. Armando4, A.C. Oliveira5, A. Rodriguez6,
D. Beneitez7, J.D.N. Ferreira8, N. Martinez-Cibrian1, U. Álvaro1
1Hematology, Hospital Clinic, 2Hematology, Hospital de la Santa Creu i Sant
Pau, Barcelona, 3Hematology, Hospital Parc Taulí, Sabadell, 4Hematology,
Hospital Arnau de Vilanova, Lleida, 5Hematology, Hospital Duran i Reynals,
ICO, Hospitalet de Llobregat, 6Hematology, Hospital Germans Trias i Pujol,
ICO, Badalona, 7Hematology, Hospital Vall d’Hebron, Barcelona, 8Hematology,
Hospital Joan XXIII, Tarragona, Spain
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic
stem cell disorder characterized by hemolysis, thrombosis and a frequent asso-
ciation with bone marrow failure syndromes. The size of the GPI deficient clone
(PNH clone) and the intensity of the hemolysis and pancytopenia vary widely
among patients and during the evolution of the disease. There is a general
agreement that the current PNH classification does not cover the spectrum of
these clinical manifestations and should be updated, especially in the eculizum-
ab era.
Aims: We propose a new PNH classification based on the clinical characteris-
tics of the patients and introducing the concept of “evolving PNH” in order to
allow a better identification of the differences in prognostic and treatment of
each subgroup. 
Methods: We propose to define four main PNH groups. (a) Predominantly
hemolytic with or without mild cytopenias, defined by: LDH>3 x ULN, retic-
ulocytes >150 x109/L, neutrophils >1.5 x109/L, platelets count>100 x109/L. (b)
Predominantly hemolytic with significant cytopenias, defined by: LDH>3 x
ULN, reticulocytes >150 x109/L, neutrophils <1.5 x109/L, platelets <100 x109/L.
(c) Predominantly hypoplastic with mild hemolysis, defined by LDH high
but<3 x ULN, reticulocytes high but <150 x109/L, and patients may have
hypoplastic bone marrow with significant cytopenias (as defined above). (d)
Subclinical, characterized by a PNH clone with no evidence of hemolysis, in
general in the context of a severe aplastic anemia (2 of the following 3 values:
neutrophils count<0.5 x109/L, platelets count<20 x109/L, reticulocytes<80
x109/L and bone marrow cellularity<25%) or a normal hemopoiesis.
Results: Thirty two patients (median age 35, range 6-71, years; males 63%)
diagnosed with PNH at 7 institutions between July 1979 and August 2013 have
been studied. At diagnosis, 12 (37.5%) patients were predominantly hemolytic,
7 (22%) predominantly hemolytic with significant cytopenias, 4 (12.5%) pre-
dominantly hypoplastic with mild hemolysis, and 9 (28%) subclinical PNH. Of
the 32 patients, 17 (53%) experienced an evolution of the disease along the
time, with clinical changes that modified their initial classification. Thus, 9 (28%)
patients presenting at diagnosis with severe aplastic anemia or with significant
cytopenias normalized the peripheral neutrohil and platelet values and evolved
into a more hemolytic disease, while 2 (6%) patients showed the opposite, a
progressive trend to an aplasia with decreasing hemolysis. Two (6%) patients
developed a myelodysplasia with 7q deletion, 2 (6%) patients evolved to a sub-
clinical PNH with normal neutrophil and platelet values and without hemolysis,
and 2 (6%) patients achieved a complete response after receiving a bone mar-
row transplantation. 
Summary and Conclusions: The proposed PNH classification was able to
classify all 32 PNH patients in four groups. It constitutes a dynamic classifica-
tion, showing that more than 50% of the patients change of category along the
time. Furthermore, this classification could be used to better define treatment
indications, according the predominance of hemolysis or aplasia, among dif-
ferent hospitals and groups interested in PNH.
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RABBIT ANTITHYMOCYTE GLOBULIN AT >3,5 MG/KG/DAY/X 5 DAYS FOR
TREATMENT OF ACQUIRED APLASTIC ANEMIA
C. Vallejo1,* A.J. González2, B. Xicoy3, Á. Bendaña4, B. Cuevas5, C. García6,
M.J. Requena7, O. Salamero8, L. Yáñez9
1Hematology, Hospital Universitario de Donostia, Donostia/San Sebastián,
2Hematology, Hospital Universitario Central de Asturias, Oviedo, 3Hematology,
Hospital Universitari Germans Trias i Pujol, Badalona, 4Hematology, Complejo
Hospitalario Universitario de Santiago, S. Compostela, 5Hematology, Hospital
Universitario de Burgos, Burgos, 6Hematology, Hospital General Universitario
de Alicante, Alicante, 7Hematology, Hospital Universitario S. Ochoa, Leganés,
8Hematology, Hospital Universitari Vall d’Hebron, Barcelona, 9Hematology,
Hospital Universitario M. Valdecilla, Santander, Spain
Background: Aplastic anemia (AA) is a life-threatening hematological condition
that can be cured with prompt and correct management, including combination
of the rabbit ATG Thymoglobuline (TG) plus cyclosporine A (CsA). However,
optimal dose of TG is still unknown.
Aims: To analyze outcome of a large series of patients treated with TG at >3,5
mg/kg/day/5 days plus long-term CsA (>1 year) (TG-3,5). 
Methods: Sixty-three AA patients (36 male, 27 female) treated with TG-3,5
were included in this retrospective analysis, across 22 centers. Median age
was 45 yo (2-78). Infection prophylaxis and dose of steroids used to prevent
serum sickness (SS) were administered according to each local center’s policy.
Response (complete [CR] plus partial [PR]) was assessed at days +90, +180
and at 1 year. 
Results: Early (≤4 months) mortality rate was 15,9% (10 patients from 6 cen-
ters, 7 of them due to infections). Late mortality (>4 months) was 0%. If we
excluded the 12 alive patients with follow-up <1 year, the overall response was
76,5% (39 out of 51). Five patients with no response at day +90 reached
response at day +180 or 1 year (late responders). 
Summary and Conclusions: Our series of AA patients treated with TG at >3,5
mg/kg/day/5 days plus long-term CsA showed: 1) Infectious early mortality in
around 1 out of 10 patients, which highlight the need to focus on infection pro-
phylaxis and limit the total dose of steroids employed after the 5 days of ATG
administration in patients who do not develop SS, as steroids may significantly
increase infectious complications. 2) 1-year overall response (CR plus PR)
superior to 75%. 3) An increase in response rate over time in a cohort of patients
(late responders). 4) Prospective randomized studies, as the ongoing Asia-
Pacific study, are warranted to find out the ideal dose of TG to treat AA patients.
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A STUDY OF THE MARKERS OF THROMBIN GENERATION AND
INFLAMMATION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN A
SUBSET OF PATIENTS SEEN AT A TERTIARY CARE CENTRE IN NORTH
INDIA
R. Dhawan1,* S. Varma1, P. Malhotra1, N. Varma2, J. Ahluwalia2
1Internal Medicine, 2Hematology, Post Graduate Institute of Medical Education
and Research (PGIMER), Chandigarh, India
Background: Data from studies on PNH patients from western countries and
few Asian countries suggest more hemolytic and thrombotic manifestations in
Caucasians compared to Asians. There is limited data reported on PNH from
the Indian subcontinent. 
Aims: Study of clinical features and outcomes of PNH in Indian population and
to measure the markers of thrombin generation and inflammation in PNH
patients presenting to our centre.
Methods: We studied disease characteristics, with emphasis on thromboem-
bolic complications in 18 patients with PNH who were registered in our depart-
ment between January 2004 and January 2014. Patients were sampled for
markers of hemostatic activation; thrombin-antithrombin complex (TAT), D-
Dimers, soluble P-Selectin (Sp-Selectin) and inflammatory cytokine Interleukin-
6 (IL-6). The samples were also collected for these assays from 35 age and
sex matched healthy control individuals in order to determine the cut off values
in Indian population. Plasma TAT, Sp-Selectin and IL-6 levels were measured
using commercial enzyme-linked immunoassays (Abcam TAT ELISA, Abcam
Inc, MA, USA; Human sP-selectin/CD62P ELISA & Human IL-6 Quantikine HS
ELISA, R & D Systems Inc, Minneapolis, MN, USA respectively). D Dimer was
measured with automated STA LIATEST immunoturbidimetric D-dimer assay
performed on the STA-Compact analyzer (Diagnostica Stago, France).
Table 1.
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Results: Thromboembolism was present in three (17%) PNH patients in our
study (two cerebral venous thrombosis and one portal vein thrombosis). All the
patients with thromboembolism had PNH clone size more than 85% at pres-
entation. The majority of the patients in our study (95%) fit criteria for classical
PNH. Bone marrow examination findings were correlated with clinical presen-
tation in 13 patients. Five (28%) patients had peripheral blood cytopenias ful-
filling the IAAAG criteria for aplastic anemia. However only one patient with
PNH/AA had decreased bone marrow cellularity and normal ME ratio. Periph-
eral blood cytopenias with increased BM cellularity were present in 4 (22%) of
patients. One of the two patients with anemia and thrombocytopenia had mas-
sive splenomegaly with hypersplenism secondary to portal vein thrombosis.
Two patients with pancytopenia had myeloid hypoplasia in addition to erythroid
hyperplasia in BM. The optimal cut-off values for TAT (2.9 ng/ml) & sP-Selectin
(58.41 ng/ml) were determined in our study population using Youden’s index.
IL-6 levels were not significantly elvated in PNH patients as all the patients
were on prednisolone therapy at the time of study. We found significant eleva-
tion of markers of thrombin generation (TAT and D-Dimer) and endothelial and
platelet activation (sP-Selectin) in patients with PNH in our study. A positive
correlation of TAT levels with sP-selectin and D-Dimer levels was observed in
our study suggesting a contributory role for platelet and endothelial activation
in activation of thrombosis in PNH. There was no correlation of hemolysis (LDH)
with markers of thrombin generation (D-Dimer, TAT) or platelet and endothelial
activation (sP-Selectin) in our study.
Summary and Conclusions: The prevalence of thromboembolism in PNH
reported in our study is similar to that reported from other Indian studies and
is comparable to the rates of thromboembolism reported in the western PNH
patients. We found significantly elevated markers of thrombin generation and
endothelial and platelet activation in PNH patients in our study. Further, there
was a lack of correlation between serum LDH and markers of thrombin gener-
ation suggesting that thrombin generation in patients with PNH occurs may be
through pathways independent of hemolysis.
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ELTROMBOPAG IS BENEFICIAL IN THE TREATMENT OF CHILDREN
WITH ACQUIRED APLASTIC ANEMIA
E. Atmatzidou1,* A. Vlachou1, K. Katsibardi1, N. Tourkantoni2, S. Kostaridou3,
A. Kattamis4
1Pediatrics Hematology-Oncology Unit, First Department of Pediatrics, Uni-
versity of Athens, 2Pediatrics Hematolgy-Oncology Unit, First Departmemt of
Pediatrics, University of Athens, 3Pediatrics Hematolohy-Oncology-Unit, 4Pedi-
atrics Hematology- Oncology Unit, First Department of Pediatrics, University
of Athens, Athens, Greece
Background: Acquired Aplastic Anemia (AA) in children is a rare disorder char-
acterized by peripheral blood pancytopenia and hypocellular bone marrow,
caused by immune-mediated processes. The first line treatment is allogeneic
bone marrow transplantation from an HLA-matched sibling donor. Patients not
eligible for bone marrow transplantation receive immunosuppressive treatment
(IST), with the most commonly used schema consisting of antithymocyte glob-
ulin, cyclosporine, and methylprednisolone with the optional addition of Gran-
ulocyte colony-stimulating factor (G-CSF). Eltrombopag is an oral thrombopoi-
etin mimetic, licensed for chronic immune thrombocytopenic purpura in adult
patients. Treatment of adult patients with AA with eltrombopag has been shown
to be beneficial. The use of eltrombopag in pediatric patients with AA has not
been reported.
Aims: To evaluate the hematologic response following eltrombopag use in chil-
dren with AA.
Methods: We report the use of eltrombopag in 4 children diagnosed with AA
treated in our unit during the past two years. The patient received the medica-
tion as off-label compassionate use and after having received approval from
regulatory authorities and Ethics committee. The patients were 3 males and 1
female, with their age being 6, 10, 15 and 16 years old, respectively. Possible
identifiable cause for AA was the use of non-steroid anti-inflammatory drugs in
one patient, while two patients presented with elevated transaminases, sug-
gestive of infectious or auto-immune etiology. All patients fulfilled criteria for
severe AA (absolute neutrophil count <500, platelet count (PLT) <20.000 /μL).
As they had no HLA-matched sibling donor, they received IST. Eltrombopag
was started at a dose of 100 mg daily per os, as they continued to have sub-
optimal platelet response, within 2 months after IST in the 3 patients, while the
4th patient started at 15 months after IST for persistent suboptimal response
and parental hesitation. Treatment was continued until they reach optimal
platelet count levels.
Results: Hematological response to the treatment with eltrombopag was
observed within the first weeks of treatment. All of the patients increased their
PLT levels at a percentage of >50%, and became platelet independent with
PLT counts>20.000/μL within the first month of treatment. Continuation of ther-
apy was related to continuous platelet improvement (figure 1). Neutrophil count
and hemoglobin levels paralleled platelet response. Duration of treatment was
at least for 6 months. One patient ended treatment after 6 months and is cur-
rently off Eltrombopag for 8 months with stable PLT counts>100.000/μl. The
other 3 patients continue to be on therapy, in 6, 7 and 8 months respectively.
Discontinuation of eltrombopag in one patient resulted in drop in the platelet
count. When the drug was restarted, the platelet count rose again. This obser-
vation verifies the direct effect of eltrombopag. No adverse events related to
eltrombopag use were observed.
Figure 1.
Summary and Conclusions: Eltrombopag use was clearly associated with
an increase in platelet count and possibly with a multilineage clinical response.
Addition of Eltrombopag should be considered in pediatric patients with AA.
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CHARACTERIZATION OF THE DNA-DAMAGE RESPONSE
DOWNSTREAM OF B-CELL RECEPTOR SIGNALING IN CLL
N. Nickel1,* A. Roth1, C.P. Pallasch1
1Innere Med. I - CECAD Research Center, Uniklinik Köln, Cologne, Germany
Background: Despite the considerable efforts which have been undertaken to
develop new treatment strategies, the classical chemotherapy is still indispen-
sable for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
Chemotherapeutic agents damage the genome of neoplastic cells which trig-
gers the DNA damage response (DDR) to either halt the cell cycle and repair
the damage or, if the extent of damage is beyond repair capacity, to send the
cell into apoptosis. However resistance against chemotherapy sooner or later
occurs and leads to a relapse of the disease. In order to develop new strategies
to overcome this resistance, a better understanding of the pro-survival signaling
cascades in CLL and their link to the DDR machinery is necessary. One impor-
tant pro-survival pathway in CLL is the PI3K/AKT pathway, which is activated
through B-cell receptor (BCR) signaling. Since the literature states several links
between AKT and the DDR, we hypothesize that AKT signaling downstream of
BCR activation interacts with the DDR also in B-CLL.
Aims: In the presented study we aim to clarify the importance of BCR signaling
and subsequent AKT activation for the resistance of CLL cells to classical
chemotherapy and try to identify molecular targets involved in DDR signaling
which respond to BCR activation.
Methods: We either stimulate the BCR by cross linking with soluble anti-IgM
antibodies or inhibit the receptor signal by blocking BTK (Ibrutinib) or PI3K (Cal-
101) in primary CLL cells to analyze the impact of BCR signaling on cellular
resistance towards genotoxic stress. We measure cellular survival by flow-
cytometry and activation of DDR signaling by immunofluorescence staining of
γ-H2AX as well as immunoblotting of p53, Chk2 and DNAPK.
Results: We observed no induction of DDR signaling by BCR stimulation alone,
but a clear activation of the investigated signaling molecules in response to
DNA damage induced by bendamustine. Stimulation with anti-IgM antibodies
clearly protects CLL cells from cell death induced by bendamustine and this
protective effect is abandoned by inhibition of BCR signaling with Ibrutinib or
Cal-101. However, the investigated DDR molecules show a very diverse acti-
vation pattern when genotoxic stress is combined with BCR stimulation. This
diversity became even more pronounced when also Cal-101 was added.
Summary and Conclusions: In CLL the BCR generates a distinct pro-survival
signal which protects the cells from apoptosis caused by genotoxic stress, how-
ever the activation of DDR signaling in response to BCR activation is not that
clear-cut. Since CLL is a very heterogeneous disease, our results potentially
reflect the existence of different CLL subgroups. We are currently subdividing
our patient samples according to different criteria, e.g. mutational status of the
immunoglobulin heavy chain, cytosolic calcium signaling in response to BCR
stimulation, deletion of chromosomes 11q or 17p or clinical response to treat-
ment in order to identify a correlation to the DDR patterns observed. 
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CD69 EXPRESSION POTENTIALLY PREDICTS RESPONSE TO
BENDAMUSTINE IN CHRONIC LYMPHOCYTIC LEUKEMIA 
A. Montraveta1,* E. Lee-Verges1, J. Roldan1, L. Jimenez1, S. Cabezas2,
G. Clot3, M. Pinyol4, S. Xargay-Torrent1, L. Rosich1, C. Arimany-Nardi5,
M. Aymerich6, N. Villamor6, A. Lopez-Guillermo7, P. Perez-Galan1, G. Roué1,
M. Pastor-Anglada5, E. Campo6, M. Lopez-Guerra8, D. Colomer8
1Experimental Therapeutics in Lymphoid Malignancies Group, IDIBAPS,
2Hematopathology Unit, Hospital Clinic, 3IDIBAPS, Barcelona, Spain,
4Genomics Unit, IDIBAPS, 5Departament de Bioquímica i Biologia Molecular,
Institut de Biomedicina, Universitat de Barcelona and Oncology Program,
CIBEREHD, 6Hematopathology Unit, 7Hematology Department, 8Experimental
Therapeutics in lymphoid malignancies group, Hematopathology Unit, Hospital
Clinic, IDIBAPS, Barcelona, Spain
Background: Bendamustine, a drug that combines the properties of an alky-
lator and a nucleoside analogue, is currently being used for the treatment of
chronic lymphocytic leukemia (CLL). Clinical responses are very heterogeneous
and no specific markers to predict drug sensitivity have been reported. 
Aims: The purpose of this study was to identify suitable biomarkers useful to
predict bendamustine response in CLL patients.
Methods: The in vitro response to bendamustine 25 µM at 24 hours was deter-
mined in peripheral blood mononuclear cells from 80 CLL cases by Annexin
V/PI labeling and flow cytometry. A gene expression profile was done in 38 CLL
samples in order to identify the differentially expressed genes (DEGs) between
the bendamustine-sensitive and the -resistant samples. Most relevant genes
were validated by qPCR in a larger cohort of 77 CLL cases and the correlation
of gene expression with bendamustine cytotoxicity was analyzed. The protein
levels of the genes showing the strongest correlation with bendamustine
response were then validated by flow cytometry. The effect of the microenvi-
ronment was also analyzed by co-culture with stromal cell lines.
Results: We found 416 DEGs between bendamustine-sensitive and -resistant
cases. The biological functions of these genes included cell-to-cell signaling
and interaction, cellular development, cellular growth and proliferation and cell
death and survival. According to the fold change, we selected 66 genes for val-
idation by qPCR, including 21 that showed a significant correlation with the in
vitro response to bendamustine. The combination of CD69 (CD69) and ITGAM
(CD11b) genes was the best predictor mRNA signature of response. When we
interrogated the predictive value of the cell surface protein expression of these
two molecules, we showed that the single expression of the activation marker
CD69 was the most reliable predictor of bendamustine sensitivity in CLL cells.
Importantly, a multivariate analysis revealed that the prognostic value of CD69
was independent from other biological and clinical CLL features, including Binet
stage, mutational IGHV status, previous treatment, deletions on 17p and 11q
and expression of ZAP-70, CD38 and CD49d. We also confirmed that the
chemoresistance mediated by the microenvironment was accompanied by an
upregulation of CD69 protein levels when CLL cells were cocultured with the
stroma. Likewise, tissue-derived CLL cells expressed higher CD69 levels than
their respective peripheral blood cell counterparts and, concordantly, were less
sensitive to bendamustine.
Summary and Conclusions: We have identified CD69 as a maker of ben-
damustine resistance in CLL patients. Thus, CD69 quantification by flow cytom-
etry may be useful to stratify patients who may receive bendamustine alone or
in combination regimens. Acknowledgements: This work has been funded by
Mundipharma Research.
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SERUM CHEMOKINES AND CYTOKINES IN CLL PATIENTS TREATED
WITH DUVELISIB, AN ORAL DUAL INHIBITOR OF PI3K-DELTA,GAMMA 
M. Douglas1,* K. Allen1, J. Sweeney1, S. O’Brien2, I. Flinn3, S. Horwitz4,
J. Byrd5, M. Patel6, B. Kahl7, F. Foss8, P. Porcu9, V. Kelly1, H. Stern1
1Infinity Pharmaceuticals, Cambridge, 2MD Anderson Cancer Center, Houston,
3Sarah Cannon Research Institute, Nashville, 4Memorial Sloan Kettering Can-
cer Center, New York, 5The Ohio State University Medical Center, Columbus,
6Florida Cancer Specialists, Sarasota, 7University of Wisconsin, Madison, 8Yale
Medical Group, New Haven, 9The Ohio State University, Columbus, United
States
Background: PI3K-δ and PI3K-γ play complementary roles in malignant B-
cells and the tumor microenvironment. Inhibition of PI3K-δ blocks cytokine-
mediated CLL proliferation, while inhibition of PI3K-γ blocks M2 macrophage
polarization and T-cell migration in vitro. Duvelisib, a dual oral inhibitor of PI3K-
δ,γ, has shown clinical activity in a phase 1 study in patients with hematologic
malignancies (Study IPI-145-02), including patients with relapsed/refractory
(R/R) CLL (O’Brien, ASH 2014). 
Aims: Examine changes in serum chemokines and cytokines from patients
with R/R CLL following treatment with duvelisib. 
Methods: Serum from 52 patients with R/R CLL and 30 healthy subjects was
analyzed for 72 analytes (cytokines, chemokines, and matrix metalloproteinas-
es) using Luminex xMAPÒ technology at baseline, Cycle 1 Day 8 (C1D8),
C2D1, and C3D1. Median change from baseline was analyzed for statistical
significance using a paired t-test with Bonferroni correction for multiple hypothe-
ses; threshold for reduction was ≤50% of baseline and for increase was ≥150%
of baseline. Comparison between CLL and healthy subjects utilized a 2-sample
t-test with Bonferroni correction.
Results: Following treatment with duvelisib, the median serum levels of 12
analytes decreased to ≤50% of baseline (p <0.0002) by C1D8. These included
CCL1, CCL3, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-6, IL-10, IL-12p40,
MMP-9 & TNFα. All of these were significantly elevated (p <0.0042) at baseline
in CLL patients compared to healthy subjects and reduced towards normal
range following duvelisib treatment. In addition, MMP1 was the only analyte for
which median serum levels increased above the threshold of ≥150% of baseline
(p <0.0002). Together, these 13 analytes were further explored for potential
associations with clinical efficacy. TNFα was significantly elevated (p <0.0013)
at C2D1 & C3D1 in patients who did not exhibit a nodal response.
Summary and Conclusions: Most of the analytes reduced following duvelisib
treatment are known to be involved in the communication between CLL cells
and the tumor microenvironment. Furthermore, one of these analytes (TNFα)
exhibited elevated levels at C2D1 and C3D1 in patients who did not achieve a
nodal response. Together, these data indicate that modulation of the tumor
microenvironment via PI3K-δ,γ inhibition may be an important mechanism of
action in supporting clinical activity of duvelisib in patients with CLL.
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TREG CELLS IN CLL: DEFECTIVE FUNCTION AND HIGH CD39
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Background: Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy
which is derived from monoclonal B-lymphocytes. Tumor reactive T cells were
determined in patients with CLL especially in early stages and it was suggested
that immunosuppressive mechanisms allow CLL cells to escape from immuno-
surveillance. Regulatory T cells (Treg cells) are defined as a subgroup of T
cells which express the markers CD4, CD25 and FOXP3. It was shown that
Treg cells can prevent autoimmune and inflammatory diseases and inhibit anti-
tumor responses. The numbers of Treg cells increase in other malignancies
and CLL. Possible mechanisms about Treg cells’ effects in immunoregulatory
activity include cell-cell contact dependent suppression, secretion of anti-inflam-
matory cytokines like interleukin 10, transforming growth factor beta, and accu-
mulation of pericellular adenosine. CD39 is another marker of Treg cells which
has ectoenzyme- ectonucleoside triphosphate diphosphohydrolase activity for
producing adenosine monophosphate (AMP). After production of AMP, another
ectoenzyme (CD73) hydrolyses this substrate for accumulating pericellular
adenosine which contributes to Treg cells’ suppressor activity and by binding
to its receptors on cytotoxic T cells (CTL) they can also suppress anti tumor
activity of CTLs.
Aims: In our study we have measured Treg cells in the peripheral blood of 39
CLL patients and 21 healthy controls (HCs) by using flow cytometry. We have
also evaluated the anti-proliferative effect of Treg cells on effector CD4 positive
T cells with co-culture.
Methods: Peripheral blood CD4+CD25+and CD4+CD25-T cells from patients
and HCs isolations were performed. Cells were co-cultured triplicate in anti-
CD3 coated 96 well plates at a ratio of 1:1 (5x103cells: 5x103cells) for 5 days
and medium supplemented with soluble CD28 at 5µl/ml concentration. Cross
mixing experiments were performed by co-culturing patients’ and HCs’ Treg
cells with the autologous and the converse CD4+CD25- cells either HCs or
patients. On the first day and the fifth day of culture WST-1 was performed in
order to measure proliferation. The measurements were performed in triplicate.
The results were evaluated according to the unpaired T-test by using SPSS
statistical program. The difference were indicated as statistically significant if
p<0.05 and highly significant if p<0.01.The proliferation index was calculated
according to the formula mentioned as [(Cell #)last-(Cell#)initial]/ [(Cell#)initial]
Results: As demonstrated in the table the percentages of CD4+CD25+and
CD4+CD25+FOXP3+cells were not different between patients and HCs. How-
ever the expressions of CD39 on CD4+CD25+cells are significantly higher in
patients than HCs. In addition, the cell percentage of CD39+cells in the popu-
lation of lymphocytes was found approximately equal to those of
CD4+CD25+cell population. The effect of Treg cells on effector T cells are
shown in figures We evaluated the proliferation index for CLL patients and
HCs. In this context, first, we compared proliferation index of
1:1(CD4+CD25high: CD4+CD25-) autologous cell co-culture versus 0:1
(CD4+CD25high: CD4+CD25-) cell culture in patients and HCs separately. We
demonstrated that patient CD4+CD25high Treg cells could not inhibit prolifera-
tion of autologous CD4+CD25- cells. In contrast, CD4+CD25highTreg cells from
HCs supressed the proliferation of their own CD4+CD25- significantly
(p=0,018). Second, we performed a cross-mixing experiment in which patient
and control regulatory CD4+CD25highcells were co-cultured with the converse
CD4+CD25- cells from either controls or patients. We compared proliferation
index of A) Patient CD4+CD25high:HCs CD4+CD25- (1:1) versus HCs
CD4+CD25- (0:1) B)HCs CD4+CD25high:Patient CD4+CD25- (1:1) versus
patient CD4+CD25- (0:1). We found that while patients Treg cells have no
inhibitor effect on HCs’ CD4+CD25- cells, in contrast HCs’ Treg cells could
inhibit the proliferation of patient CD4+CD25- cells however the difference was
not significant.
Figure 1.
Summary and Conclusions: CD4+CD25+cells are sensitive to toxicity
induced by ATP, high expression of CD39 on these cells can reduce this sen-
sitivity and this mechanism can provide survival advantage for Treg cells. In
addition, it can be possible that high expression of CD39 on Treg cells in CLL
can serve more AMP for CD73 which can result pericellular accumulation of
adenosine. It is probable that by this mechanism, inhibition of anti tumor activity
of CTL can be resulted as enhanced surveillance of malign CLL cells. On the
other hand we demonstrated defective function of Treg cells in co cultures in
CLL. An increased incidence of autoimmunity is a known entity in CLL. The
question is whether this defective cell-cell contact dependent suppression can
be responsible from this increased incidence.
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ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53
DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
USING PRIMA-1MET
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M. Trbusek1,2
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Background: In chronic lymphocytic leukemia (CLL), TP53 mutations repre-
sent the most adverse predictive and prognostic factor. As we have reported,
particularly poor prognosis is associated with missense mutations located in
DNA-binding motifs of the p53 protein. These alterations frequently lead to
accumulation of mutated p53 protein with presumably oncogenic properties.
Thus, the affected patients could potentially benefit from innovative therapy
targeted directly to the mutated p53 protein. PRIMA-1MET(Tocris Bioscience)
is a small molecule currently tested in clinical trials, which has been declared
to be able to change mutated p53 to wild-type (wt) conformation and rescue
its activity.
Aims: To test a possibility of subtle molecular manipulation with accumulated
mutated p53 in CLL cells using small molecule PRIMA-1MET.
Methods: CLL patients’ peripheral blood mononuclear cells (leukemic cells’
proportion over 85%) used for reactivation study were chosen from the cohort
characterized for TP53 status by FASAY and direct sequencing. The samples
were analyzed for p53 protein level by western blot (WB). A metabolic activity
(viability) after PRIMA-1MET treatment was determined by WST-1 assay. Impact
of 48 h PRIMA-1MET exposure on p53 protein level was analyzed by WB. The
p53 downstream genes’ induction was assessed by qRT-PCR.
Results: Firstly, the impact of PRIMA-1MET on CLL cells’ viability was assessed
to determine appropriate concentration range for the reactivation. We observed
clear concentration-dependent curve of viability in all studied samples (n=5)
between 0.5 and 4µM. Therefore, 2µM and 4µM were further applied for the
testing of reactivation at molecular level. Five out of eleven mutated samples
with high baseline p53 level showed clearly diminished or even absent p53
protein after 4µM PRIMA-1MET treatment and four other samples manifested
partially reduced level. The effects at 2µM were also apparent, but less pro-
nounced. The best response was observed for mutations p.Y205H, p.R248W,
and p.C275R, in which the p53 protein was completely eliminated even at 2µM
concentration. The p53 downstream genes’ expression was heterogeneous
among the samples, with the induction of CDKN1A (p21) and GADD45 being
much more prominent compared to PUMA. The expression induction reached
up to 11800% (p21) and 4500% (GADD45) in comparison with untreated control
set at 100%. The BAX and MDM2 genes’ expression was not increased after
treatment. This indicates that observed elimination of mutated p53 is not prob-
ably caused through the induction of the p53 basic negative regulator MDM2.
Concerning the specificity of observed effects with respect to TP53 status, we
noted the following: (i) in line with other studies, we noted similar impact of
PRIMA-1MET on both p53-wt and p53-mut samples’ viability, and (ii) certain
induction of p53 target genes was also evident in p53-wt samples. In addition,
we also analyzed 10 samples with TP53mutation, but without p53 protein sta-
bilization, for induction of the downstream genes. Again, the effects of PRIMA-
1MET were apparent, especially in case of p21 and GADD45.
Summary and Conclusions: We have been able to demonstrate that PRI-
MA-1MET can significantly diminish or even completely eliminate p53 protein
accumulated due to the high-risk mutations in TP53 gene. It still remains to be
elucidated, what is the specificity of the p53 pathway activation with respect to
TP53 status. Supported by grants NT/13519-4/2012 and MUNI/A/1180/2014.
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MICROVESICLES IN CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: Normal and malignant cells secrete extracellular microvesicles
(MV), usually defined as shedding membranous vesicles (50-1,000 nm diam-
eter) that are produced by budding from the plasma membrane. It has been
demonstrated that elevated levels of circulating MV in chronic lymphocytic
leukemia (CLL) are able to activate bone marrow stromal cells and, in turn, to
enhance production of VEGF, a pro-survival factor for CLL B-cells
Aims: We analyzed serum from untreated CLL patients searching for the num-
ber of circulating MV in order to test their possible prognostic role when evalu-
ated at diagnosis.
Methods: Sera from 101 CLL patients (mean age 70 years, range 41 – 89; 60
M, 41 F; 52 patients with A, 36 with B, and 13 with C Binet clinical stage, respec-
tively) were collected at diagnosis. Briefly, 1 ml of serum was processed with
serial centrifugations using Optima XE ultracentrifuge (Beckman Coulter): 2,000
x g for 15 min; 10,000 x g for 30 min; 100,000 x g for 70 min. Resulting pellets
were washed with pre-filtered (0.22 μm) phosphate buffer saline (PBS) and
centrifuged at 100,000 x g for 70 min. Pellets were suspended in 200 μl of pre-
filtered PBS. All steps of MV isolation were performed at 4°C. MV enriched pel-
lets were analyzed by a FACSCalibur (Becton Dickinson) cytometer using Cell
Quest software. Standard micro beads (0.3 – 0.9 – 3 μm) were used to define
the size limit for MV and their size assessment. Pre-filtered PBS was also used
to set the lower limit of MV gate. TruCOUNT beads (BD) were also added
immediately prior to analyze samples by flow cytometry to determine the num-
ber of MV/μl. To identify and characterize MV, allophycocyanin-conjugated anti-
CD19 monoclonal antibody and isotype-matched controls were used.
Results: A higher mean number of MV was found in CLL patients with respect
to 28 control healthy subjects (991.8±768.4/μl vs 270±325/μl; p <0.001). Of
interest, in CLL patients about 15% of MV were found to be CD19+. A higher
number of MV was found in patients with advanced clinical stage (Binet A+B
950/μl±770 vs C 1,234/μl±661, p 0.02), while a trend was observed with surface
expression of CD38, (p 0.06). No correlation was found according to CD49d
and ZAP-70 expression, IgVH mutational status and cytogenetics abnormalities
detected by FISH. A correlation was also found with respect to the number of
circulating B-lymphocytes, with either total and CD19+MV (r=0.23 and r=0.25,
respectively, p<0.05). Overall, patients who required therapy showed a more
elevated number of MV at diagnosis (1,333/μl±941) with respect to those who
did not (764/μl±565) (p 0.003). The time to treatment was longer in patients
with lower number of both total (p 0.05) and CD19+MV (p<0.05). Finally, overall
survival was shorter in patients with higher levels of total MV (p 0.001), while
the number of CD19+MV was not significant.
Summary and Conclusions: Our study suggests a possible prognostic rele-
vance of the circulating MV number detected at diagnosis in CLL patients. Inter-
estingly, it has been previously reported that: i) the majority of circulating MV is
platelet-derived (about 80%), while only a minority of them directly belongs to
endothelium (about 10%) or leukocytes (about 10%); ii) a phenotypic shift from
predominantly platelet/megakaryocyte-derived CD61+MV occurs in early
stages ,while more “leukemic” CD19+B-cell derived MV are seen in advanced
clinical stages; iii) in vitro stimulated CLL cells generate MV which preferentially
express CD52, but not CD19 antigen. In light of these observations, we are
currently evaluating the complete phenotype of the CD19-negative MV.
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CHANGES IN LYMPHOCYTE SUBSETS, ANGIOGENIC FACTORS AND
PLASMA CYTOKINES IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA DURING TREATMENT WITH OFATUMUMAB AND
LENALIDOMIDE
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L. Falchi1, J. Reuben2, J. Burger1, G. Calin3, A. Ferrajoli1
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Background: Chronic lymphocytic leukemia (CLL) is characterized by a com-
plex immune dysregulation. In CLL, lenalidomide exerts both a direct antitumor
effect and a pleiotropic activity on the immune system. The addition of an anti-
CD20 monoclonal antibody to lenalidomide is associated with improved clinical
responses in patients with CLL.
Aims: The aim of this study was to analyze the in vivo effects of the combination
of ofatumumab and lenalidomide on circulating T and NK cell numbers, and on
plasma levels of angiogenic factors, chemokines and cytokines.
Methods: Thirty-two patients with relapsed or refractory CLL were treated in a
phase II clinical study with ofatumumab and lenalidomide. Peripheral blood
mononuclear cells (PBMC) and plasma samples were collected at baseline
and after 3, 6, 9, and 12 months of therapy. Lymphocyte subsets were defined
by the expression of CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD25, CD56,
CD57, and Forkhead box protein P3 (FoxP3) by flow cytometry. PBMC from
34 age-matched healthy individuals were used as controls. A multiplex bead-
based immunoassay was used to quantify plasma concentration of bFGF,
VEGF, Trombospondin-1, IFN-γ, CCL2, CCL3, CCL4, IFNα2, and IL-12p70.
Clinical responses to therapy were assessed according to the 2008 International
Workshop on CLL criteria.
Results: Treatment with ofatumumab and lenalidomide decreased the number
of circulating T and NK cells. The greatest decrease was observed after 3
months of therapy as compared to baseline (median CD3+T cells 950/μl vs.
1830/μl, CD4+T cells 460/μl vs. 790/μl, CD8+T cells 460/μl vs. 700/μl, Tregs
50/μl vs. 80/μl, CD16+CD56+NK cells 120/μl vs. 160/μl, and CD57+CD56+NK
cells 32/μl vs. 70/μl; p≤0.02 for all comparisons). We hypothesized that T cell
number could impact the response to therapy, and therefore compared T and
NK cell populations in patients who achieved a complete response (CR) versus
those seen in non-responders (NR). We found that the baseline number of
CD4+T cells and CD57+CD56+NK cells was higher in CR patients as compared
to NR patients (median absolute number 1595/μl vs. 715/μl, p=0.04, and 358/μl
vs. 70/μl, p=0.02). We also compared baseline T and NK cell populations of
CR patients to healthy donors, and found that the former had significantly higher
numbers of CD16+CD56+and CD57+CD56+NK cells (median 356/μl vs. 80/μl,
p=0.03, and 358/μl vs. 29/μl, p=0.0008). Interestingly, baseline numbers of
CD16+CD56+and CD57+CD56+NK cells were comparable between NR patients
and healthy individuals. Plasma levels of bFGF, VEGF and IFN-γ were also
significantly decreased at month 3 compared to baseline in all analyzed patients
(p≤0.02 for all comparisons). No modulation of Trombospondin-1 levels was
detected. Consistently with our previous report in patients treated with lenalido-
mide as monotherapy, we observed significantly lower levels of circulating
CCL2, CCL3, CCL4, IFNα, and IL-12p70 during treatment in patients who
achieved CR, compared to NR (p <0.05 for all comparisons).
Summary and Conclusions: Patients with CLL achieving CR to treatment
with ofatumumab and lenalidomide have higher baseline numbers of CD4+T
cells and CD57+CD56+NK cells, suggesting that these cells play a key role in
response to therapy. The in vivo effect of this combination in modulating the
interactions between the microenvironment and the CLL clone is supported by
the induced changes in plasma angiogenic factors and cytokine levels.
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CD49D EXPRESSION IN TRISOMY 12 CLL HAS LITTLE PROGNOSTIC
POWER FOR SHORTER OVERALL SURVIVAL
P. Bulian1,* T.D. Shanafelt2, C. Fegan3, A. Zucchetto4, L. Cro5, H. Nuckel6,
L. Baldini5, A.V. Kurtova7, A. Ferrajoli7, J. Burger7, G. Gaidano8, G. Del Poeta9,
C. Pepper3, D. Rossi8, V. Gattei1
1Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferi-
mento Oncologico, Aviano, Italy, 2Mayo Research Center, Rochester, United
States, 3Cardiff University, Institute of Cancer and Genetics, Cardiff, United
Kingdom, 4IRCCS Centro di Riferimento Oncologico, Aviano, 5Ospedale Mag-
giore, IRCCS Ca Granda, Milano, Italy, 6University of Duisburg-Essen, Essen,
Germany, 7University of Texas, MD Anderson Cancer Center, Houston, United
States, 8Amedeo Avogadro University, Novara, 9Tor Vergata University, S.
Eugenio Hospital, Roma, Italy
Background: Trisomy 12 CLL cells have increased expression of many inte-
grins, including CD49d, compared with non trisomy 12 CLL. CD49d is one of
the most powerful prognostic markers in CLL and CD49d positive cases have
an average 23% reduction in OS at 10 years. The high fraction of CD49d pos-
itive cases would predict an high risk disease, in contrast with the intermediate
risk category assigned to the generic case bearing trisomy 12.
Aims: To verifiy if the high fraction of CD49d positive cases in trisomy 12 CLL
is still significantly correlated to shorter overall survival.
Methods: We performed a multi-center pooled analysis on 2157 untreated CLL
cases all evaluated by FISH for the common cytogenetic aberrations. Cases
were classified according to the hierarchical model of Dohner in the following
subgroups: 41% del13q (n=892), 28% negative (n=599), 14% trisomy 12
(n=303), 17% high risk (n=363, del17p or del11q). The following prognostic
variables were evaluated: IGHV mutational status, CD49d, CD38 and ZAP-70
expression. The endpoints overall survival (OS) and treatment free survival
(TFS) were correlated with prognostic variables by Kaplan-Meyer plots and
Cox regression analysis.
Results: The rate of death across cytogenetic subgroups was as expected:
10.5% in del13q cases, 14.3% in negative cases, 15.8 in trisomy 12, 26% in
high risk cases. By comparing low risk cytogenetic subgroups (del13q, negative
and trisomy 12) we found in trisomy 12 a remarkable higher fraction of cases
expressing CD49d, CD38, ZAP-70 and UM IGHV. This was most evident for
CD49d (78% of cases CD49d positive), one of the most powerful prognostic
markers in this setting. We compared the hazard ratio (HR) for death in trisomy
12 and negative cytogenetics subgroups, which shared a similar rate of death
and median follow-up (3.5 year trisomy 12, 4.7 years negative). By univariate
analysis all the variables had a significant HR, however, in trisomy 12 cases
the HR magnitudo and its statistical significance were lower for CD49d, CD38
and ZAP-70, with a barely significant p-value for CD49d (p=0.0489). By con-
trast, UM IGHV had a slight higher HR with the same level of statistical confi-
dence. By Kaplan-Meyer analysis, the 10-years OS rate of the few CD49d neg-
ative cases (84%) was superimposable to that of del13q/negative subgroups
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(82% and 76%). However, in multivariate analysis only UM IGHV remained a
significant predictor for shorter OS.
Summary and Conclusions: Our data suggest that in trisomy 12 CLL IGHV
mutational status may still be used for prognostic assessment, on the contrary
CD49d, CD38 and ZAP-70 expression lose their usual prognostic power. These
features, toghether with other characteristics, support the idea that CLL bearing
trisomy 12 constitute a CLL subgroup with a different biology from all other CLLs.
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MESENCHYMAL STROMAL CELLS IMPROVE SURVIVAL OF B-CLL
CELLS: ROLE OF CELL-CELL CONTACT AND SOLUBLE FACTORS IN
THE MICROENVIRONMENT
V. Trimarco1,* G. Chiodin1, E. Ave1, C. Gattazzo1, F. Frezzato1, V. Martini1,
F. Severin1, S. Imbergamo1, A. Cabrelle1, A. Visentin1, M. Facco1,
G. Semenzato1, L. Trentin1
1Department of Medicine, University of Padua, Padua, Italy
Background: The malignant behavior of chronic lymphocytic leukemia (CLL)
cells can be ascribed to intrinsic features involving an abnormal signal trans-
duction mediated by B Cell Receptors (BCR) and to factors originating from
the surrounding microenvironment in which CLL B cells engage complex inter-
actions with stromal cells. Mesenchymal Stromal Cells (MSCs) represent the
dominant population in CLL-marrow stroma and are involved in supporting
leukemic B cell survival and conferring drug-resistance. During last years, sev-
eral molecules have been developed to inhibit a variety of kinases in the BCR
signaling that are essential not only for activation of multiple survival pathways,
but also for migration and adhesion of B cells in the microenvironment.
Aims: The aim of this work was to evaluate how MSCs influence CLL B cell
behavior and whether Bafetinib, CAL-101 and Ibrutinib kinase inhibitors could
affect the MSC-CLL B cell cross-talk.
Methods: MSCs isolated from the BM of 50 CLL patients were expanded ex
vivo and characterized through flow cytometry analysis and differentiation cul-
tures (adipocytes and osteocytes). Freshly isolated CLL peripheral blood B
cells were co-cultured with MSCs. For experiments using kinase inhibitors, B
cells were treated with 5µM Bafetinib, 5µM CAL-101 and 5µM Ibrutinib. Apop-
tosis was measured by Annexin V test and western blotting analysis.
Chemokines and cytokines released in culture supernatants were collected for
the human Bio-Plex™ 27 plex Cytokine Assay.
Results: In presence of MSCs, we observed an extended survival of leukemic
B cells (60%±17.3 with MSCs vs 14%±11.7 with medium alone). Through a
transwell system to avoid lymphocyte-MSC direct contact, CLL B cell survival
in presence of MSCs was minimally reduced (60%±17.3 with MSCs vs
52.4%±23.5 with MSCs in transwell system), suggesting that the anti-apoptotic
effect is mainly ascribed to soluble factors produced by MSCs. In order to iden-
tify soluble factors responsible for the pro-survival effect, MSCs secretion profile
was evaluated before and after CLL B cells exposure. We observed a stronger
increase of IL-8, IL-15, CCL11 and CXCL10 production under co-culture con-
ditions, suggesting their potential involvement in leukemic B cell survival. More-
over, we found that MSCs were not able to rescue CLL B cells from apoptosis
induced by kinase inhibitors. In fact, CLL B cell viability co-cultured with MSCs
was: 84.7%±4.9% without inhibitors, 57.2%±14.9% with Bafetinib (p<0.01),
49%±16.5% with CAL-101 (p<0.01), and 38.2%±10.8% with Ibrutinib (p<0.001).
Summary and Conclusions: We demonstrate that MSC-CLL B cell co-culture
represents a reproducible in vitro system mimicking the in vivo bone marrow
conditions, pointing out that the heterogeneity of the disease is reflected also
by CLL B cell ability to respond to MSCs signals. Therefore, to identify patients
who may benefit from treatments targeting the cross-talk with supportive cells,
it is mandatory to test the effect of new therapeutic agents in the context of the
microenvironmental influence. For this reason, in our co-culture system we test-
ed the effect of Bafetinib, CAL-101 and Ibrutinib kinase inhibitors involved in
BCR pathway, finding that all the molecules were able to reduce CLL B cell via-
bility despite the MSCs presence. As a result of the ability of kinase inhibitors to
inactivate BCR signaling pathway, leukemic B cells lose not only their ability to
proliferate and survive but also their ability to home in, invade, and persist in the
lymphoid tissue, a necessary condition to pursue the eradication of the disease.
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QUANTITATIVE AND QUALITATIVE ANALYSIS OF REGULATORY T CELLS
(TREGS) IN B CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
E.D. Ioannidou1,* V. Bakou1, M. Vikentiou1, E. Konsta1, F. Kontsioti1, C. Kon-
tos2, D. Vasilatou1, A. Mpouchla1, K. Gontopoulos1, C. Roubakis1, G.
Stavroulaki1, N. Papanikolaou1, M. Atta1, E. Mpazani1, S. Papageorgiou1, S.
Kokkori3, E. Kyriakou3, G. Dimitriadis1, V. Pappa1
1Second Department of Internal Medicine and Research Institute, Attikon Uni-
versity General Hospital, 2Department of Biochemistry and Molecular Biology,
University of Athens, 3Hematology Laboratory, Attikon University General Hos-
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Background: T regulatory cells are immunosuppressive cells considered to
play an important role in cancer biology and autoimmunity by suppressing host
immune response and autoreactive lymphocytes respectively. Accumulated
data indicate a significant role of T cell dysfunction in the pathogenesis of CLL.
Aims: The scope of this study is the analysis of numerical and functional abnor-
malities of Tregs in B-CLL with the view to elucidate their role in the pathogen-
esis of the disease.
Methods: Treg cells derived from 28 untreated B-CLL patients with a median
age of 62 and 17 healthy donors were analyzed by Flow cytometry. Peripheral
blood was obtained from 15 patients with B-CLL. Mononuclear cells were iso-
lated using Ficoll-Paque gradient centrifugation. CD4+CD25+(Treg cells),
CD4+CD25- (T effectοr cells, Teff), CD5+CD19+(B-CLL) and CD5-CD19+(Normal
B, NB) cells were separated using magnetic antibody cell sorting. To test the
functionality of the assayed Tregs, the isolated cell populations were cultured in
a 96-well plate (Tregs, Teff, B-cll, NB cells, B-cll: Tregs in 1:20 ratio, B-cll: Teff
in 1:20 ratio, NB cells: Tregs in 1:20 ratio, NB cells: Teff in 1:20 ratio) and their
proliferative capacity was measured using the BrdU assay. To further analyze
the functional role of Tregs, peripheral blood was obtained from 12 patients with
B-CLL and 12 healthy donors. Mononuclear cells were isolated using Ficoll-
Paque gradient centrifugation. CD4+CD25+CD127dim/- (Treg cells),
CD5+CD19+(B-CLL) and CD5-CD19+(Normal B, NB) cells were separated using
magnetic antibody cell sorting and were co-cultured in a 96-well plate in a 1:10
ratio. The apoptosis of B cells was determined by the Annexin V/PI method.
Results: FACS analysis of the Treg cells resulted at the following observations:
The Treg absolute cell number (cells/μL), estimated either as the number of
CD4+CD25+CD127- cells or as the number of CD4+CD25+FoxP3+cells, was
significantly higher in patients’ samples than in controls (CD127- p=0.047,
FoxP3+p= 0.036). Annexin V expression in Treg cells from BCLL patients was
significantly lower compared to controls (p=0.027). The functional analysis of
Treg cells through BrdU assay and Annexin V/PI method indicated that CLL
Tregs were able to suppress the proliferation of Teff cells (p=0.002) and that
Teff cells were in turn able to significantly suppress the proliferation of B-CLL
cells (p=0.05). After the co-culturing of NB cells with Treg CLL cells, the apop-
tosis of NB cells was significantly increased compared to NB cells (16.10 vs
6.22, p<0,005). Likewise, when B-CLL cells were co-cultured with Treg CLL
cells, their apoptosis was significantly increased compared to control (24.06
vs 12.66, p<0,01). Interestingly, no significant alterations were observed after
culturing NB or B-CLL cells with Tregs from healthy donors.
Summary and Conclusions: In CLL patients, Treg cells are significantly higher
and present with lower apoptotic levels compared to healthy donors. The func-
tional analysis indicates that Teff cells suppress the proliferation of B-CLL cells
whereas they are suppressed by Tregs, indicating that increased Tregs
observed in CLL contribute indirectly to the proliferation of the CLL clone. More-
over, CLL Tregs, unlike Tregs from healthy donors, enhance the apoptosis of
both NB and B-CLL cells, suggesting the existence of distinct functional differ-
ences between CLL Tregs and their normal counterparts, which need to be
further elucidated.
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FCGAMMARIIB HOMMOAGREGATION CAN INDUCE A PROSURVIVAL
STATE IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS 
R. Bosch1,2,*, G. Ferrer3, R. Damle3, S. Gorlotov4, K. Rai5, E. Montserrat6,
J. Sierra1,2, N. Chiorazzi7, C. Moreno1,2
1Oncology/Hematology and Transplantation Laboratory, Biomedical Research
Institute Sant Pau (IIB-Sant Pau), 2Department of Hematology, Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain, 3Experimental CLL Research and
Treatment Program, The Feinstein Institute for Medical Research, Manhasset,
NY, 4MacroGenics, Rockville, MD, 5Hematology/Oncology, Oncology LIJ Med-
ical Center, Lake Success, NY, United States, 6Department of Hematology,
Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain,
7Experimental CLL Research and Treatment Program, The Feinstein Insitute
for Medical Research, Manhasset, NY, United States
Background: FcγRIIb is a low-affinity receptor that regulates B-cell activation
by inhibiting signalling from the B-cell receptor (BCR) in murine and normal B
cells. This inhibitory capacity depends on the colligation of FcγRIIb with BCR
and it is mediated by phosphorylation of SHIP and inhibition of the AKT pathway.
Besides this BCR-dependent inhibitory effect, in murine B-cells FcγRIIb has
been also implicated in delivering pro-apoptotic signals upon homoaggregation.
However, the effects of FcγRIIb hommoagregation have not been extensively
investigated in human normal-B cells and CLL cells.
Aims: To evaluate the effects of FcγRIIb signalling on viability, activation, and
proliferation of human CD19+normal B-cells and CLL cells. Also, to investigate
whether the SHIP/AKT pathway is involved in FcγRIIb hommoagregation sig-
nalling in these cells.
Methods: B-cells were isolated from cryopreserved PBMCs from 31 patients
with CLL (14 IGHV mutated, M-CLL, and 17 IGHV unmutated, U-CLL) and 10
healthy donors, cultured in RPMI 10% FBS in the presence or absence of the
novel and specific anti-human FcγRIIb mAb from Macrogenics. At 48 hours,
cell viability was determined as the percentage of AnnexinV/TO-PRO®-3 double
negative cells by flow cytometry, and cell activation was determined as the
percentage of CD69+cells. Cell proliferation was determined at 72 hours by
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using the Click-iT® EdU Alexa Fluor® 488 Imaging Kit. For signaling analyses,
reactions were stopped after 5 minutes of exposure, and total protein extracts
were performed to analyze the expression of phosphorylated SHIP and AKT
by western blot.
Results: In human CD19+normal-B cells and CLL cells, the hommoagregation
of FcγRIIb did not induce changes in B-cell viability nor in activation as com-
pared to basal levels. However, the FcγRIIb hommoagregation induced an
increase in proliferation at 72h in CLL cells from 15 out of 31 CLL samples and
in CD19+normal B-cells from 2 of 10 healthy donor samples (48.4% vs 20%,
p=0.152). Within CLL subgroups, 9 of 14 U-CLL and 6 of 17 M-CLL cases
responded with an increase in proliferation after FcγRIIb hommoagregation
(64.3% vs 35.3%, p=0.156). At the molecular level, we found that in 17 of 20
patients with CLL analyzed by western blot, CLL cells did respond to FcγRIIb
hommoaggregation with an increase in AKT phosphorylation, while in
CD19+normal-B cells, only 1 of 10 healthy donor samples did respond to FcγRI-
Ib crosslink with a slight increase of AKT phosphorylation (p<0.01). No signifi-
cant differences were observed between U-CLL and M-CLL cases, both groups
showing an increase AKT phosphorylation in 90% and 80% of cases, respec-
tively. SHIP protein did not appear to be involved in FcγRIIb hommoaggregation
signalling in CD19+normal-B cells and in CLL cells.
Summary and Conclusions: In contrast to what has been described in murine
B cells, the homaggregation of FcγRIIb in human normal B-cells and CLL cells
did not trigger B-cell apoptosis. Moreover, in CLL cells FcγRIIb hommoagrega-
tion induced AKT-phosphorylation activating signals, an effect that was not
observed in CD19+normal-B cells. Further experiments are needed to investi-
gate whether FcγRIIb stimulation may enhance CLL cells survival and thereby
contributing to the progression of the disease.
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CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE
TO DIRECT INHIBITION OF CHECKPOINT KINASE 1
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J. Malcikova1, E. Diviskova2, Y. Brychtova2, J. Mayer2, M. Trbusek1
1Department of Molecular Medicine, CEITEC, 2Department of Internal Medicine
- Hematology and Oncology, University Hospital Brno, 3Center of Biomolecular
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Background: Chronic lymphocytic leukemia (CLL) is incurable disease with
as yet no optimal treatment options, particularly for patients with mutations in
TP53 or ATM genes. Checkpoint kinase 1 (Chk1) is involved in molecular path-
ways preserving genome integrity in all cell cycle checkpoints (G1/S, intra-S,
G2/M) and also in non-dividing cells. SCH900776 (Schering-Plough) is highly
specific Chk1 inhibitor currently tested in clinical trials for selected solid tumors
and leukemia. We have prepared its potentially more metabolically stable ana-
log OH209EN1, which possesses highly unusual N-trifluoromethyl pyrazole
moiety. OH209EN1 phenocopies short interfering RNA-mediated Chk1 ablation
and greatly sensitizes tumor cells to nucleoside analogs.
Aims: (1) to assess the impact of direct Chk1 inhibition on CLL cells´ viability
using our innovative inhibitor, and (2) to correlate observed effects with the
presence of TP53 and ATM defects.
Methods: TP53 and ATM mutations were identified by next-generation
sequencing and Sanger sequencing. Deletions 17p and 11q were detected by
I-FISH. Peripheral blood mononuclear cells (CLL cells´ proportion over 85%)
were treated in 96-well plates using 500 000 cells/well. Cell lines were tested
the same way using 50 000 cells/well. The final viability after 72h inhibitor expo-
sure was assessed using metabolic WST-1 assay. Apoptosis (Annexin-V/PI)
was measured by flow-cytometry in full blood samples in lepirudin treated with
OH209EN1 for 24 h at 37oC, 5% CO2.
Results: Firstly we determined appropriate concentration range of OH209EN1
for viability testing using cell lines with known genetic status and healthy cells.
The LC50 values after 72h treatment were following: 80 nM for GRANTA-519
(MCL, ATM mutation), 250 nM for MEC-1 (CLL/PL, p53 mutation), and 300 nM
for NALM-6 (B-cell precursor leukemia, ATM/p53-wt). Negligible effect on three
healthy PBMNC cultures and three non-cancerous fibroblast cell lines was not-
ed up to 400 nM of the inhibitor. Further, Chk1 autophosphorylation on Ser-296
(Chk1 activation marker) was readily eliminated (on western blot) using 200
nM OH209EN1 in the cell line with high baseline autophosphorylation level
(NALM-6). According to these results, we used concentrations 100, 200, 300
and 400 nM of OH209EN1 for the testing in CLL cells. Fifty-four CLL cultures
were used and a clear concentration-dependent decrease of viability was noted
in the very most of them. At the highest concentration 400 nM, the final median
viability in individual genetic categories was following (listed according to sen-
sitivity): 33% in samples with ATM inactivation (mutation and 11q-; n=15), 44%
in samples with sole 11q- (n=10), 46% in samples with p53 inactivation (muta-
tion with/without 17p-; n=13), and 62% in samples having no ATM or TP53
abnormality (n=16). Interestingly, the inhibitor SCH900776 tested in parallel in
44 cultures showed substantially weaker effects with final median viability 80%.
The concentration-dependent (OH209EN1, 100-400 nM) induction of apoptosis
was clearly noted in two full blood samples from CLL patients, while no apparent
effect was observed in one tested healthy control blood.
Summary and Conclusions: Although CLL cells from peripheral blood are
non-dividing and exhibit rather low Chk1 expression, they manifest surprisingly
high intrinsic sensitivity to specific Chk1 inhibitor. This good response concern-
ing also ATM and TP53 mutated samples seems to be in contrast to non-can-





REGULATION OF CD38 BY IRF4 IN CHRONIC LYMPHOCYTIC LEUKAEMIA
H. Marr1,* L. Gaughan1, S.J. Tudhope1, J.M. Allan1
1Northern Institute of Cancer Research, Newcastle University, Newcastle on
Tyne, United Kingdom
Background: Chronic lymphocytic leukaemia (CLL) typically follows a very
heterogeneous course in different patients. A number of prognostic markers
have been determined in CLL, of which CD38 surface expression is one of the
most widely used, with positivity indicating a poorer outcome. Interferon regu-
latory factor 4 (IRF4) is a transcription factor with vital roles in B cell differenti-
ation. A single nucleotide polymorphism (defined by rs872071) in the 3’UTR
region of the IRF4 gene has been identified in genome wide association studies
as defining a strong common risk allele for development of CLL (OR=2.72 [1.93-
3.82 95% C.I.]). Interestingly, it is also significantly associated with CD38 pos-
itivity (p=0.004).
Aims: Given that the promoter and first intronic region of CD38 both carry per-
fect consensus binding sites for IRF4, we hypothesised that IRF4 plays a role
in the regulation of CD38 expression.
Methods: Chromatin immunoprecipitation (ChIP) was used to investigate bind-
ing of IRF4 to CD38 in a panel of immortalised B cell lines (TK6, MEC-1, SU-
DHL-6) and primary CLL samples. Primary cells were cultured on a CD40 lig-
and-expressing fibroblast layer in order to mimic the tumour microenvironment,
prior to ChIP. Short interfering RNA (siRNA) was used in B cell lines to generate
cells with transient knockdown of IRF4 protein. B cell lines were also transduced
with short hairpin RNA (shRNA) and then cloned on sloppy agar to generate
cell clones with constitutive IRF4 knockdown. Protein knockdown was con-
firmed by Western blotting. CD38 expression in knock down and wild type cells
was determined by flow cytometry, and the effects on cell proliferation and sen-
sitivity to cytotoxic agents were investigated by growth inhibition assay.
Results: ChIP demonstrated binding of IRF4 at CD38 in two out of three cell
lines (SU-DHL-6 and MEC-1). In both cases, binding at CD38 intron 1 was
consistently greater than the binding at the CD38 promoter, and this reached
significance in SU-DHL-6 (p=0.02). In contrast, binding at the CD38 intron 1
was negligible in TK6 cells. IRF4 knockdown slowed proliferation in TK6 cells
(p=0.02) and sensitized them to fludarabine-induced cytotoxicity. These effects
were not observed in the other cell lines. In addition, despite evidence of IRF4
knockdown confirmed by western blotting, there was no effect on surface CD38
expression in any of the cell lines. Co-culture of primary cells on a fibroblast
monolayer was associated with upregulation of IRF4 protein expression. ChIP
in these primary cells did not show consistent evidence of binding at the CD38
promoter or first intron. In separate experiments, IRF4 upregulation in primary
cells cultured on the fibroblast layer was not associated with any change in
CD38 expression.
Summary and Conclusions: These data suggest that IRF4 binds to CD38,
specifically at the first intron. IRF4 is known to bind its target genes as a het-
erodimer with Ets family transcription factors, and the cell-line specificity of the
IRF4-CD38 binding demonstrated here, suggests that the expression of IRF4
binding partners in cell lines may be relevant. Despite evidence of IRF4-CD38
interaction however, we were unable to demonstrate any impact of altered IRF4
expression (knockdown or upregulation) on surface CD38 expression. While
CD38 remains a potential therapeutic target in CLL, these data suggest that
IRF4 plays a relatively minor role in the functional regulation of surface CD38
in CLL.
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13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY
AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE
IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS
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versity, 3Department of Medical Genetics, 4Department of Internal Medicine –
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Background: In Chronic lymphocytic leukemia (CLL) four recurrent cytogenetic
aberrations with different prognostic impact are routinely tested: deletions 11q,
13q, 17p and trisomy 12. Their prognostic impact is generally described using
Dohner’s hierarchy: del17p >del 11q >tris 12 >normal >del 13q. The aberrations
are usually tested once at the diagnosis but their spectra can change during
disease evolution.
Aims: Repeated analysis of the four recurrent CLL cytogenetic aberrations
was aimed to monitor the changes in aberration distribution in the different dis-
ease stages.
Methods: Four common cytogenetic aberrations (deletions 11q, 13q, 17p, and
trisomy 12) were detected using interphase FISH analysis.
Results: Based on the disease course and therapy administration, CLL patients
were stratified into two groups: (A) patients with indolent disease – 16 %
(52/335), no treatment required, median follow-up 75 months; (B) patients with
progressive disease requiring therapy intervention either after an inactive phase
(56 %; 186/335; median time to first treatment 35 months; median follow-up
74 months), or soon after diagnosis (28 %; 97/335; median time to first treat-
ment 14 months, median follow-up 54 months). In total, newly acquired cyto-
genetic aberration was detected in 33 % (109) from 335 repeatedly tested
patients. In the indolent group A, 23 % (12/52) of patients gained a new aber-
ration during follow-up. In almost all cases (92 %; 11/12) the newly acquired
aberration was deletion 13q. In the progressive group B, patients were tested
repeatedly before the first therapy and during relapse where possible. 11 %
(30/283) of patients gained a new aberration already before therapy - 20 %
(6/30) at inactive phase and 80 % (24/30) at active phase of CLL. Del 13q
comprised 83% (5/6) of aberrations gained at inactive phase. The distribution
of aberrations gained at active phase of CLL was following: del 13q in 63 %
(15/24), del 17p in 17 % (4/24), del 11q in 13 % (3/24), and tris 12 in 7 % (2/24)
of cases. 71 % (200/283) of CLL patients were tested again in progression
after therapy. New chromosomal aberration was detected in 34 % (67/200) of
cases: del 13q in 61 % (41/67), del 17p in 28 % (19/67), del 11q in 16 % (11/67),
and tris 12 in 1 % (1/67).
Summary and Conclusions: In our study we showed that 33 % of repeatedly
tested patients acquired additional cytogenetic aberrations during the CLL
course. The most frequently acquired aberration was 13q deletion (66 %).
Regarding the disease activity, deletion 13q comprised 92 % newly acquired
aberrations among patients with indolent CLL without clinical manifestation of
the disease progression. Surprisingly, 13q deletion comprised 60 % of all aber-
rations acquired before therapy and 61 % of all aberrations acquired after ther-
apy also in the group with progressive disease. Our data suggests that the
proportion of the deletion 13q among newly acquired aberrations appears inde-
pendent on the disease activity and therapy intervention. In contrary, 17p dele-
tion acquisition increases with disease activity and foregoing therapy, 13 %
before vs. 28 % cases after treatment in progressive group. Supported by: IGA
MZCR NT13519, IGA MZCR NT13493, CZ.1.05/1.1.00/02.0068,
CZ.1.07/2.3.00/30.0009, NGS-PTL/2012-2015/no.306242, MSMT-CR (2013-
2015, no.7E13008)
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NOVEL NO-ASA DERIVATIVES ARE NEW PROMISING AGENTS IN THE
THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SOLID
CANCERS
H. Flamme1,* M. Krüger2, A. Berkessel2, M. Hallek1, K.A. Kreuzer1
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Background: CLL is characterized by an accumulation of B cells in the periph-
eral blood, bone marrow and lymphatic tissues. Patients harbouring inferior
prognostic markers as the 17p deletion or the TP53mutation show high resist-
ance to standard therapy in CLL. It is well known that NO-ASA (Nitric-oxide
donating acetylsalicylic acid) is a potential drug for the treatment of diverse
cancers by inducing apoptosis in vitro & in vivo.
Aims: Our main objectives were to determine whether NO-ASA is a specific
therapeutic substance in high risk CLL and further solid cancers. Further we
intend to illuminate the mechanism of its cytotoxic effect.
Methods: A group of 22 new developed NO-ASA derivatives were tested for
their efficacy to induce apoptosis on primary CLL cells and PBMCs of healthy
donors via Annexin V/7AAD assay. The anti-tumor effect analysis of the most
promising derivatives (B9, B12, B13) was enlarged to the analysis of diverse
cancer cell lines (SW480, MelJuso, HCC-44, SH2, COLO-407). In addition the
in vivo effect of B1 (para-NO-ASA), B9, B12 and B13 were analyzed via JVM3-
xenograft mouse model. To elucidate the biological mechanism of the deriva-
tives we performed a kinase array, Western Blots and immunofluorescence
analyses with a fluorescence coupled B9 (B20).
Results: The effective dose (and therefore the toxicity) in most of the NO-ASA
derivatives were significant lower in CLL cells compared to healthy PBMCs
(e.g. EC50 CLL: B9 1.3 µM, B12 1.05 µM, B13 1.08 µM; EC50 PBMCs: B9 93.4
µM, B12 55.4 µM, B13 77.2 µM). We detected a strong reduction of cell viability
in all tested cell lines and a cytotoxic effect even on TP53 mutated and pre-
treated CLL with the highest effects by B9 and B12. Derivative B9 and even
B12 demonstrated a strong anti-tumor efficacy in the xenograft mouse with a
maximal tumor inhibition rate of 65-70%. Cell imaging assumes that B20 might
be localized and acts in structures near the endoplasmatic reticulum. The
human phosphor kinase array and Western Blot analyses showed preliminary
results of the impact of the NO-ASA derivatives on the cell cycle checkpoint
signaling and the MAPKinase signaling pathway. After 3 h NO-ASA treatment
(B9, B12) on primary CLL cells the phosphorylation of the kinases p38 alpha,
MKK3/ MKK6, Chk2 and CREB were induced.
Summary and Conclusions: We showed that our new developed NO-ASA
derivatives (especially B9 and B12) are novel potential therapeutic drugs in
the treatment of CLL patients including these with bad prognosis. For the first
time we identified the three NO-ASA derivatives B9, B12 and B13 as potential
drugs for diverse solid cancers.
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A RETROSPECTIVE CASE CONTROL STUDY ASSOCIATING CHRONIC
LYMPHOCYTIC LEUKEMIA AND ITS SPECIFIC ABERRATIONS WITH
CERTAIN RISK FACTORS 
M. Karakosta1, E. Delicha1, G. Kouraklis2, K. Manola1,*
1NCSR “DEMOKRITOS”, 2Medical School, University of Athens, Athens,
Greece
Background: The role of environmental or occupational genotoxic exposure
in the development of Chronic Lymphocytic Leukemia (CLL) is limited and
inconclusive. In addition, no investigation has been conducted to elucidate the
putative role of lifestyle and occupational factors in the formation of CLL specific
chromosomal aberrations. 
Aims: Regarding the above, the present study examines through detailed
questionnaires the potential environmental and occupational chemical expo-
sure as well as the lifestyle and cancer family history of cases and healthy
controls to assess the contribution of specific risk factors to CLL incidence.
Moreover, these postulated risk factors are evaluated for the first time in respect
to CLL specific chromosomal abnormalities.
Methods: A total of 138 unselected patients diagnosed with CLL and 141 unre-
lated healthy men and women, age and sex matched to CLL cases, were
enrolled in this study. Face-to-face interviews were conducted on the study
participants using a standardized and structured questionnaire to obtain a life-
time demographic, occupational and medical history as well as other risk factor
information. In addition, cytogenetic analysis was performed on unstimulated
and stimulated bone marrow cells of all CLL patients at the time of diagnosis
so as to associate CLL chromosomal abnormalities with specific risk factors.
Study results were analysed using univariate and multivariate statistical analy-
sis to control the overall influence of risk factors.
Results: CLL was positively associated with certain lifestyle and medical/clin-
ical risk factors such as smoking (P=0.005), family history of CLL or other malig-
nancy (P<0.0001), episodes of pneumonia (≥1) within 5 years before CLL diag-
nosis (P=0.016) and exposure to medical radiation (P=0.003). Similarly positive
associations were revealed between CLL and occupational/environmental
chemical exposures including exposure to petroleum (P<0.0001), metals
(P=0.024), pesticides/chemical fertilizers (P<0.0001) and detergents
(P<0.0001). It was also observed that if someone is exposed to more than two
risk factors in lifetime, he/she is at ~1.5 fold greater risk of developing CLL
compared to those who have experienced only one toxic exposure (OR=1.42,
95% CI=1.17-1.73, P<0.0001). Analyses by specific risk factors and CLL chro-
mosome abnormalities showed that del(11q) and del(13q) were found more
frequent in patients having been exposed to pesticides (P=0.050) and rubber
(P=0.044) respectively while patients who had a father suffering from CLL or
other malignancies tended to carry more often del(11q), del(13q) and +12.
Summary and Conclusions: Our study provides evidence for the involvement
of genetic predisposition and exposure to specific occupational and lifestyle
risk factors in the onset of CLL. Moreover, it was indicated that the more differ-
ent risk factors one has been exposed to, the greater is the risk of developing
CLL. Notably, the association of certain risk factors with CLL specific chromo-
somal aberrations for the first time revealed positive correlations between dele-
tions of 11q and 13q and exposure to pesticides and rubber respectively. The
above results reinforce the idea that the interaction between specific exposures
and genetic predisposition may be a possible cause for the development of
CLL and its specific chromosomal abnormalities.
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HIGH RESOLUTION MELT (HRM) CURVE ANALYSIS OF P53 MUTATIONS
IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 
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E. Vandenberghe1,2
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Background: Disruption of p53 by deletion, mutation or both occurs in at least
10% of patients with chronic lymphocytic leukaemia (CLL) prior to first-line
treatment and is associated with both chemo-refractoriness and a short median
survival of 3-5 years. Del (17p) detected by FISH analysis identifies up to 80%
of p53 disrupted patients, but the remainder can only be confirmed by Sanger
sequencing, which is not feasible in a diagnostic molecular laboratory. p53 dis-
rupted patients follow a specific treatment pathway with alemtuzumab and allo-
geneic transplantation if <65 years, but more recently the novel, effective agents
ibrutinib and idelalisib have been licensed. The European research initiative
on CLL (ERIC) recommended screening all patients for evidence of p53 dis-
ruption prior to therapy.
Aims: To develop a pre-sequencing screening assay for p53 mutations, using a
high resolution melt (HRM) analysis to detect sequence alterations in exons 5-8
which harbour ≥95% of p53 mutations in CLL prior to confirmatory sequencing.
Methods: Consensus p53 PCR programme was employed to amplify exons
5-8 and optimise HRM analysis. The HRM predictive value and sensitivity were
evaluated using the cell lines (K-562 and JURKAT) and DNA from known
del(17p) patients of whom 80% will have a mutated second allele. We per-
formed HRM screening on 45 CLL patient blood samples (12 treatment–naïve
and 33 relapsed / refractory) and lymph node (LN) DNA from 4 patients with
Richter’s transformation (RT). Samples with an aberrant melt curve suggestive
of sequence alteration, was confirmed by bidirectional Sanger sequencing and
p53 mutation bioinformatics (COSMIC / Polyphen database) were used to
establish mutation frequency and its deleterious impact.
Results: The HRM assay sequence alteration detection sensitivity was 15%.
HRM analysis detected aberrant melt curves in 16/45 samples; 8/10 samples
(80%) had a del(17p) and 8/35 (23%) had no FISH-detectable deletion and all
cases were confirmed by sequencing. p53 mutations were detected in 8%
(1/12) of treatment-naïve and 33% (11/33) of relapsed / refractory patients
respectively. The 4 Richter’s patients had no mutations detected in blood; how-
ever, 3 of them had a mutation in LN DNA. Missense mutations affecting the
DNA binding site accounted for 83% of the p53 mutations and all were both
common and deleterious when compared to the COSMIC and Polyphen data-
base respectively.
Summary and Conclusions: We developed a consensus PCR amplification
and HRM protocol for p53 mutation detection. HRM methodology is a sensitive,
rapid and cost-effective pre-sequencing screening assay which reduces the
numbers of samples requiring sequencing with a sensitivity of 15%. Our p53
mutation detection results are comparable with reported data in the literature.
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ENDOSTEAL AND VASCULAR STRUCTURES OF BONE MARROW
STROMA IN CLL
N. Semenova1,* B. Stanislav1, R. Victor1
1Russian research institute hematology and transfusiology, Saint-Petersburg,
Russian Federation
Background: Normal hematopoiesis is carried out in close association with
stromal microenvironment, which forms the hematopoietic niche. Endosteal
and vascular elements of bone marrow stroma regulate the development of
HSC and lymphoid differentiation. The study of endosteal-vascular niche struc-
tural organization of the bone marrow allows to clarify the role of these entities
in the malignancy of hemolymphopoiesis.
Aims: To determine the morphofunctional features of stromal elements of
hematopoietic microenvironment that form hematopoietic niches in CLL.
Methods: Bone marrow core biopsies of 96 patients with CLL at the age 49-
73 years obtained before therapy were researched. Histological, histochemical,
morphometric and immunohistochemical methods were used. The statistical
significance was considered with p≤0,05 (Student criterion).
Results: On the bases of CLL patients spongy bone research, in bone marrow
parenchyma 3 types of lymphoid infiltration were detected: nodular (18 cases
- 18,8%), interstitial (26 cases - 27%), and diffuse (52 cases - 54,2%). The
distribution of bone marrow infiltration types by Rai stages was determined.
So, 3-4 stage was characterized by a predominance of cases with diffuse infil-
tration of the bone marrow, while 0-1 stage - by a predominance of nodular
infiltration. Interstitial infiltration was observed at all Rai stages (0 stage - 3
cases, 1 stage – 7 cases, 2 stage – 16 cases, 3 stage – 10 cases, 4 stage –
5 cases). Morphological signs of bone marrow stroma disorders were estab-
lished at all types of infiltration. Silver impregnation showed the increase num-
ber of reticulin fibers and the formation of reticular sclerosis foci in interstitial
and diffuse types of infiltration, including endosteal bone marrow areas.
Microvessels density increased with the progression of bone marrow infiltra-
tion. Vessels area in diffuse infiltration increased by almost 2 times in compar-
ison with the control group (17,9±3,7% instead of 9,1±1,2% in the control
group), in interstitial infiltration increased by 1,5 (13,1±1,2%), in nodular infil-
tration statistically significant changes were not found (12,3±2,5%), and, what
is especially important, the increase of vessels’ number in subendosteal
spaces was noted. Dependance of prognostic protein marker Zap70 expres-
sion from the density of microvessels was evaluated and statistically significant
correlation between these parameters (R=0,7, p <0.05, N=96) was noticed.
The Zap70 expression also correlated with the type of bone marrow infiltration:
in all cases of diffuse infiltration of bone marrow (n=52) most leukemic cells
were positive (>65%), in nodular infiltration (n=18) expression in the majority
of cases was not detected, interstitial infiltration of bone marrow (n=26) differed
by variable expression of Zap70. 6 cases of interstitial infiltration with lack of
expression of Zap70 (less than 15%), 4 cases with high expression (50-65%),
16 cases with moderate expression (30-45%) were noted. Analysis of
endosteal cells showed an increase in cells number per area unit in interstitial
(1,8±0,4 against 1,4±0,2 in the control group) and diffuse (2,3±0,7) infiltration.
The change of endosteal cells morphology was established too. The number
of cellular elements with elongated flattened nuclei shapes was decreased,
while increase in endosteal and subendosteal areas of stromal cells with large
light nucleus was noticed. Expression of the molecule CD146, which marks
the stromal cells endosteal and perivascular areas in diffuse infiltration was
also increased and was present in subendosteal areas almost everywhere
(10,2±1,3% vs. 2,5±0,3% in the control group).
Summary and Conclusions: Defects of endosteal-vascular structures of bone
marrow stroma testify to the participation of the hematopoietic niche in the neo-
plastic transformation of B-lymphocytes in CLL.
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NEW PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA:
PLASMA CCL3 (MIP-1Α)
D. Keskin1, S.N. Esatoglu2, M. Kutnu3, T. Elverdi1, A. Salihoglu1,*
A.E. Eskazan1, M.C. Ar1, S. Ongoren1, Z. Baslar1, Y. Aydin1, N. Tuzuner4,
H. Uzun3, T. Soysal1
1Hematology, 2Internal Medicine, 3Biochemistry, 4Pathology, Istanbul Cerrah-
pasa Medical Faculty, Istanbul, Turkey
Background: Chronic lymphocytic leukemia (CLL) is one of the most common
hematologic malignancies in adulthood. Prognostic markers are still needed to
aid therapy decision making. In response to BCR (B-cell receptor) activation,
CLL cells secrete the chemokine CCL3 (MIP-1α) [C-C motif Ligand
3/Macrophage Inflammatory Protein-1α], which affects tumor cell-microenvi-
ronment interactions. It is found that plasma CCL3 level is a useful prognostic
marker for risk assessment in CLL. 
Aims: We aimed to determine if there is any correlation between CCL3 plasma
levels and other prognostic markers in CLL patients, and if CCL3 has an impact
on overall survival (OS).
Methods: Between May 2012-2014, 99 CLL patients and 25 control cases
were included in the study. Peripheral blood samples were collected from both
groups. Age, gender, Rai, Modified Rai and Binet stages, lymphocyte count,
LDH level, β-2 microglobulin, CD38 expression, ZAP70 expression, del 17p
status, bone marrow involvement pattern and plasma CCL3 levels were report-
ed in the patient group. Age, gender and plasma CCL3 levels were reported in
control group. Plasma CCL3 level was measured by enzyme-linked immunosor-
bent assay (ELISA).
Results: The median follow-up time was 18 months in both groups. Median
age was 62.91±10.52 in CLL group and 67.92±12.28 in the control group. We
established that plasma CCL3 levels in CLL patients were higher than in the
control group (p=0.001). We divided CLL patients into two groups according to
high and low CCL3, based on ROC analysis (cut off value >35 pg/ml). We
found a positive correlation between high CCL3 level and β2-microglobulin
(r=0.220, p=0.042). Six patients in the CLL group with high CCL3 were dead
by the time of analysis, whereas no deaths occurred in the low CCL3 group.
Patients lost to follow-up had higher plasma CCL3 (p=0.047). OS of patients
with high CCL3 levels was found shorter. It was statistically determined that
OS decreased with increased CCL3 levels (r=-0.201, p=0.046). No correlations
were found between other prognostic markers. There was not any difference
in CCL3 levels between the treated and not treated patients (p<0.2). In sub-
group analysis, we noticed that splenomegaly was more common among
patients with high CCL3 level (p=0.025).
Summary and Conclusions: Plasma CCL3 level is an important prognostic
marker and is correlated with OS. The exact level of this chemokine in defining
disease course is not determined yet. Further studies are warranted to confirm
cut-off values of this chemokine and to make it one of the prognostic markers
in CLL. CCL3/MIPI-α might also have a role in the follow-up of the targeted
therapies of CLL.
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IMMUNOPHENOTYPE OF CLL CASES WITH STEREOTYPED BCR IS
CHARACTERIZED BY DECREASED CD23 EXPRESSION
V. Strugov1,* E. Stadnik1, T. Silina1, Y. Virts1, Y. Mirolubova1, A. Rumyantsev1,
P. Butylin1, A. Zaritskey1,2
1Hematology Institute, Federal North-West Medical Research Centre, 2Pavlov
First Saint Petersburg State Medical University, Saint Petersburg, Russian Fed-
eration
Background: About 1/3 of CLL cases is characterized by stereotyped motifs in
BCR structure apparently representing common antigen-driven selection of
malignant clones. It is conceivable that continuous antigenic stimulation would
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lead to certain surface immunophenotype changes in cases with BCR stereo-
typy. To the best of our knowledge no studies have tested this hypothesis so far.
Aims: To compare surface marker expression in CLL cases with or without
BCR stereotypy.
Methods: Out of 148 treatment-naïve participants of NORMA trial (id:
NCT02110394) 89 pts with diagnosis confirmed in a single centre by standard-
ized flow cytometry protocol and known IGHV/IGHD/IGHJ sequences were
analyzed. Most of these cases had typical CLL immunophenotype with bright
CD5, high CD23 (median 83,8%) and CD200 (median 98,8%) expression. In
few cases with low CD23 expression (N=3) mantle cell lymphoma was further
excluded by FISH with IGH/CCND1 t(11;14) probe. BCR stereotypy was deter-
mined according to ERIC recommendations. Levels of expression of surface
markers (in %) in stereotyped vs non-stereotyped cases were compared with
Mann-Whitney U test.
Results: Among 89 pts IGHV-UM cases prevailed (N=61; 68,5%). 19 (~21%)
pts had stereotyped BCRs. Most common subsets included #2 (N=6), #7 (N=4),
#8 (N=3) and #1 (N=2). Statistical analysis showed no differences in surface
expression of such markers as CD20, CD22, CD38, CD43, CD79b, CD200,
kappa or lambda among stereotyped and non-stereotyped cases. However,
BCR stereotypy was associated with significantly lower % of CD23 positivity
(median 64,55% vs 87,15%, p=.041).
Summary and Conclusions: Decreased surface expression of CD23 in CLL
cases with stereotyped BCR is shown for the 1st time. Ongoing antigenic stim-
ulation or increased TLR signaling could be possible explanations for this obser-
vation as published previously1,2. It is still unknown, whether underlining mech-
anism is downregulation of CD23 protein synthesis or increased shedding.
Other B-cell activation markers, sCD23 and, possibly, IgE levels should be
examined in the same manner.
References
1. Adelheid Dinkel et al. J Immunol. 1997 Sep 15;159(6):2678-84.
2. Leila Jackson et al. J Immunol 2009; 183:2585-2592.
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CD47 AGONIST PEPTIDES INDUCE PROGRAMMED CELL DEATH IN
REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS VIA PLCG1
ACTIVATION
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Background: Chronic lymphocytic leukemia (CLL), the most common adult-
hood leukemia, is characterized by the accumulation of abnormal CD5+B lym-
phocytes, which results in a progressive failure of the immune system. Despite
intense research efforts, drug resistance remains a major cause of treatment
failure in CLL, particularly in patients with dysfunctional TP53.
Aims: The objective of our work was to identify potential approaches that might
overcome CLL drug refractoriness by examining the pro-apoptotic potential of
targeting the cell surface receptor CD47 with serum-stable agonist peptides.
Methods: We performed in vitro cellular and molecular biology assessments
in primary CD5+B lymphocytes obtained from a cohort of 80 CLL patients, and
we assessed, in a CLL-xenograft mouse model, the in vivo capacity of the
CD47 agonist peptides to reduce tumor burden.
Results: Our in vitro approach shows that the CD47 peptide agonists enable
a Ca2+-mediated, caspase-independent PCD pathway that, sparing the normal
T and B lymphocytes, efficiently kills CLL B cells, including those from drug-
refractory patients (e.g., with dysfunctional TP53). This PCD pathway, molec-
ularly described here for the first time, involves a sequence of events initiated
by the triggering of CD47 by serum-stable peptide agonists and the subsequent
activation and phosphorylation at tyrosine 783 of the signal transduction protein
PLCγ1, an over-expressed protein in CLL. Further, PLCγ1 activation leads, by
means of the second messenger IP3, to ER stress, cellular Ca2+overload, mito-
chondrial damage, and B cell death. The in vivo data obtained in the CLL-
xenograft mouse model demonstrated that, by inducing PLCγ1-mediated, cas-
pase-independent PCD, the injection of CD47 agonist peptides significantly
reduced tumor burden.
Summary and Conclusions: Our work provides substantial progress in (i)
the development of serum-stable CD47 agonist peptides that are highly effec-
tive at inducing PCD in CLL, (ii) the understanding of the molecular events
regulating a novel PCD pathway that overcomes CLL apoptotic avoidance, (iii)
the identification of PLCγ1 as an over-expressed protein in CLL B cells, and
(iv) the description of a novel peptide-based strategy against CLL.
E1059
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JAPANESE PEOPLE LIVING IN SAO PAULO, BRAZIL
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Background: Monoclonal B-cell lymphocytosis (MBL) is defined by the pres-
ence of <5x109/L circulating clonal B cells in healthy individuals. In the general
population, the frequency of MBL varies from 5% to 12% in Western countries,
depending on the sensitivity of the method. High-count MBL (MBLhi) with chron-
ic lymphocytic leukemia (CLL)–like phenotype has been related to the progres-
sion to CLL at frequency of 1%/ per year. CLL shows clinical and epidemiolog-
ical differences among different ethnic groups including a low incidence in
Asian populations, even in those living in Western countries. MBL assessment
in individuals of Asian ancestry might contribute to clarify the pathogenesis of
CLL and its relationship with MBL.
Aims: To evaluate the frequency of MBL in healthy Japanese individuals living
in São Paulo.
Methods: 195 healthy adults without racial miscegenation were studied (medi-
an 66 years; range: 40-88 years; 57% female). Peripheral blood samples col-
lected in EDTA were analyzed in an 8-color flow cytometer. Cells were stained
after “bulky-lysed” using the following antibody combinations: sIgl & CD8/ sIgk
&CD56/ CD5/ CD19/ CD3/ CD38/ CD45 CD4 &CD20 and CD23/ CD10/
CD79b/ CD19/ CD5/ CD43/ CD45/ CD20. Median acquisition was of 5,000,000
events (648,250 to 7,933,086 events). A MBL clone was defined by the pres-
ence of >30 clustered events.
Results: The mean values  were: hemoglobin 14.6±1.3 g/dL (11.2-18.5 g/dL),
platelets 230±61x109/L (121-492x109/L), WBC 5.9±1.6x109/L (3.1-14.0x109/L),
lymphocytes 1.7 ±0.5 /L (0.6-4.0x109 /L), T lymphocytes 1.1±0.5x109/L (0.3-
3.4x109 /L), T CD4+0.7±0.4 x109 g/L (0.2-3.3 x109 g/L) and T CD8+0.3±0.2
x109 g/L (0.07-1.4 x109 g/L), CD4/CD8 ratio 2.7±1.6 (0.5 to 12.6 ), B cells
0.19±0.12x109/L (0.003-0.84x109 /L), sIgk/sIgl ratio 1.4±0.2 (0.6 to 3.5) and
plasma cells 0.005±0.015 x109/L (0-0.2 x109). MBL was detected in 7.7 % of
individuals (15/195), including 8.2% (10/122) of those cases where ≥5,000,000
cells were measured. All detected MBL clones had a CLL-like phenotype (in 9
cases a single clone was identified while 6 were biclonal). The median size of
the MBL clone was of 0.06% (0.01-19.8%) of B cells and 38.1x103 / L (2.0x103-
19.1x106/L). The frequency of MBL clones progressively increased with age:
4.6% (4/87) in individuals <65 years (GI); 6.2% (4/65) in subjects between 65
and 74 years (GII) and 16.3% (7/43) ≥75 years (GIII), while total B cells pro-
gressively decreased (mean x109/L) (GI=0.222±0.161, GII= 0.203±0.118 and
GIII=0.144±0.09) (p≤0.002 for GIII vs the other groups). The oldest individuals
(GIII) presented a higher frequency of MBL as compared to the others (16.3 vs
5.4%) and significantly lower number of total B cells (0.144±0.09 vs
0.214±0.144 x109 / L, respectively, p ≤0.001). Plasma cells also showed a ten-
dency to be reduced with age >75 years (0.0036±0.0039 vs 0.0052±0.018;
p=0.06). Additionaly, a trend to a positive correlation was also observed
between the size of the MBL clone and age (r=0.49, p=0.07).
Summary and Conclusions: The frequency of MBL in the Japanese individ-
uals living in Brazil is similar to that reported for Western populations but inferior
to that reported by Nieto et al (12%) using a technique with a similar sensitivity.
Of note, all cases corresponded to CLL-like MBL and showed a significant
increased frequency (as well as clone size) with age, most cases (13/15) having
clone sizes below the <0,5X109/L cutoff associated with risk of progression to
CLL. (Acknowledgments: FAPESP-proc n.2010/17668-6; CAPES; Hospital Sta.
Cruz and IOP/GRAACC).
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CHARACTERIZATION OF NORMAL AND PATHOLOGICAL LYMPHOID
POPULATIONS: VALIDATION OF A 10-COLORS FLOW CYTOMETRY
PROTOCOL FOR ROUTINE DIAGNOSIS
L. Rigollet1,* J. Stagnara1, A. Milhau1, L. Pellegrina1
1Laboratoire Biomnis, Lyon, France
Background: Multiparametric flow cytometry (MFC) has developed over last
years and 10-colors techniques are becoming routine, providing a great level of
information. Using markers of mutually exclusive expression, one can design pan-
els with even more markers than detectors available on the cytometer. Neverthe-
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less MFC remains a complex technique needing a thorough validation before it
can be used as a routine-test for diagnosis in hematology or immunology.
Aims: We developed a panel of only two tubes for screening and characteri-
zation of lymphoid abnormalities in blood or marrow samples. The “screening”
tube contained 11 markers in 9 colors: CD8+kappa-FITC / CD56+lambda-PE
/ CD3-ECD / CD5-PC5.5 / CD2-APC / CD7-AA700 / CD20+CD4-PacB / CD45-
KrO. The second tube, designed for B-cell malignancies, contains CD200-PE
/ CD23-ECD / CD5-PC5.5 / CD19-PC7 / CD10-APC / CD22-AA700 / CD38-
AA750 / FMC7-PacB / CD45-KrO. The aim of our study was to validate the
technical performances of these tubes, compared to our previous 5-colors tech-
nique, for correct characterization of lymphoid abnormalities.
Methods: The results obtained with this panel were compared with our previous
method which consisted in a 3 tubes screening panel: CD45-FITC / CD4-PE /
CD8-ECD / CD3-PC5 / CD2-PC7, CD45-FITC / CD56+CD16-PE / CD19-ECD
/ CD3-PC5 / CD7-PC7 and kappa-FITC / lambda-PE / CD19-ECD / CD5-PC5
/ CD20-PC7, and 2 tubes for B-cells malignancies: CD22-FITC / CD10-PE /
CD19-ECD / CD5-PC5 / CD38-PC7 and FMC7-FITC / CD23-PE / CD19-ECD
/ CD5-PC5. All antibodies were provided by Beckman Coulter except kappa
and lambda light chains (Dako) and CD200 (BD Biosciences). Almost 100 sam-
ples were tested including normal cases, benign unbalanced lymphoid popu-
lations (eg HIV) and various pathological contexts: CLL, other B-cell malignan-
cies, T-cell malignancies (eg Sézary cells, prolymphocytic T-cell leukemia) and
blastic infiltrations. Quality assessment samples were also assayed. We used
a Navios* (Beckman Coulter) cytometer and data were analyses with Kaluza*
software (Beckman Coulter).
Results: The results obtained with this 2-tubes method showed no discordance
with our previous technique. In addition, this new method provided a higher
level of information, as more markers could be assessed together. This allowed
a more accurate analyze of the lymphoid sub-populations, particularly in patho-
logical samples. The sensibility and specificity were thereby better with this
technique than with our previous 5-colors protocol. Although not expressly
designed for, the screening tube detected CD45- immature cells efficiently.
Summary and Conclusions: This 10-colors technique with one 11-markers
screening tube and one “Matutes”-tube for lymphocyte exploration provided
very satisfying results. Hence it was adopted in our lab for routine-use and sub-
mitted to accreditation. In addition to these technical issues, it is to note that
this technique saves human resources (less manipulations), cytometer
resources (faster acquisition) and reagents (no marker repeated in iterative
tubes), medico-economical cost being also of importance nowadays.
Chronic lymphocytic leukemia and related
disorders - Clinical
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CHEMOTHERAPY EXPOSURE AND SURVIVAL AMONG PATIENTS
DIAGNOSED WITH CHRONIC LYMPHOID LEUKEMIA
J. Kuiper1,* P. Musingarimi2, C. Tapprich3, F. Penning-van Beest1, M. Gaudig4
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands,
2Janssen Health Economics & Market Access EMEA, High Wycombe, United
Kingdom, 3Janssen Medical Affairs EMEA, 4Janssen Health Economics & Mar-
ket Access EMEA, Neuss, Germany
Background: Chronic lymphoid leukemia (CLL) accounts for approximately
30% of all lymphoid neoplasms and 12% of nodal lymphomas and is largely a
disease of older people. Currently, there are around 650 new cases of CLL per
year in the Netherlands.
Aims: To describe chemotherapy exposure, overall survival (OS) and progres-
sion-free survival (PFS) among patients diagnosed with CLL.
Methods: Data from the Eindhoven Cancer Registry (ECR), including data on
all newly diagnosed cancer patients, was linked on an anonymized patient-
level with the PHARMO Database Network that combines data from multiple
linked healthcare databases including in- and out-patient drug dispensing, hos-
pitalizations and clinical laboratory measurements. The PHARMO-ECR cohort
represents approximately 10% of the Dutch population. Patients diagnosed
with CLL between January 1, 1998-December 31, 2011 were included in the
source population. For a subset of patients with in-patient pharmacy data avail-
able, chemotherapy exposure after initial diagnosis was assessed. OS after
initial diagnosis was determined in the source population. For patients receiving
chemotherapy, OS was also determined after chemotherapy treatment as well
as PFS. Progression was defined based on 1) start of a different type of
chemotherapeutic agent and for a subset of patients also on 2) increase in the
number of blood lymphocytes by 50%, 3) decrease in Hgb level by >2 g/dl or
a Hgb of <10 g/dl, 4) decrease in platelet counts by >50% or a platelet count
of <100.000/ul. Survival was analyzed by the Kaplan-Meier method.
Results: In total, 624 patients were diagnosed with CLL in the study period.
Mean (±SD) age was 68 (±11) years and 62% was male. For 393 of the CLL
patients (63%), in-patient pharmacy data was available. Of these, 125 patients
(32%) received chemotherapy: 52 patients (42%) started chemotherapy within
6 months after initial diagnosis and 73 patients (58%) started chemotherapy
more than 6 months after initial diagnosis. Overall, median time from initial diag-
nosis until start of chemotherapy was 282 days. About 50% of the 125 patients
had one treatment line and about 25% had two lines of treatment. The most
common type of chemotherapy received as first and second line chemotherapy
was chlorambucil (71% and 48% for 52 patients starting chemotherapy within 6
months after initial diagnosis and 75% and 58% for 73 patients starting
chemotherapy more than 6 months after initial diagnosis). The second most
common type of chemotherapy received as first and second line chemotherapy
was R-CVP for patients starting chemotherapy within 6 months after initial diag-
nosis (13% and 15%) and fludarabine among patients starting chemotherapy
more than 6 months after initial diagnosis (10% and 17%). Five years after initial
diagnosis, 79% of all patients in the source population were still alive. The highest
mortality rate was observed within the first three months (9.2 (95% CI: 5.0-15.5)
per 100 person-years). Among patients receiving chemotherapy, 78% were still
alive one year after chemotherapy treatment. The median PFS from end of the
first treatment line was 27.4 months for patients starting chemotherapy within 6
months after initial diagnosis, and 16.8 months for patients starting chemother-
apy more than 6 months after initial diagnosis.
Summary and Conclusions: About one third of CLL patients received
chemotherapy, which mostly was chlorambucil. At 5 years, the majority of CLL
patients were still alive (79%). Among those receiving chemotherapy, the median
PFS ranged from 17 to 27 months, depending on the timing of chemotherapy.
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REAL-WORLD OUTCOMES OF PATIENTS WITH RELAPSED OR
REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
N. Lamanna1,* D. Hurst2, D. Latremouille-Viau3, R. Ionescu-Ittu3, A. Guerin3,
Y.M. Yim2, C. Reyes2
1Hematologic Malignancies Section/Herbert Irving Comprehensive Cancer
Center, New York-Presbyterian/Columbia University Medical Center, New York,
2Genentech, Inc., South San Francisco, United States, 3Analysis Group, Inc,
Montreal, Canada
Background: Patients (pts) with relapsed and refractory (R/R) chronic lym-
phocytic leukemia (CLL) and 17p deletion (del 17p) studied in clinical trials had
poor outcomes after standard CLL treatment (tx).
Aims: To describe best response, progression free survival (PFS), and overall
survival (OS) outcomes of R/R del 17p CLL pts receiving salvage tx in clinical
practice.
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Methods: An online medical chart review was used to collect data from 120
US oncologists/hematologists from 79 community and 41 academic sites on
408 adults with R/R del 17p CLL who started salvage tx from 2009 to 2014.
Pts characteristics were collected at R/R CLL diagnosis (dx). As reported by
physicians, del 17p was detected by FISH, and minimal residual disease (MRD)
by bone marrow aspirate and flow cytometry or PCR. Best response on 1st
and 2nd salvage tx, assessed according to local practice standards, and
response duration up to response loss or end of follow-up were reported.
Kaplan-Meier analyses from salvage tx initiation were used to estimate PFS
and OS rates. A sensitivity analysis was conducted among the subgroup of pts
who started salvage tx ≥1 year prior to study data collection (n=134).
Results: Of 408 R/R del 17p CLL pts, 54% were relapsed and 46% were
refractory to primary CLL tx. Median age was 64 years and 62% were male.
Among pts with reported information at R/R CLL dx, 72% had Rai stages III/IV
(292/406; 78% in relapsed, 65% in refractory pts), 21% had beta-2 microglob-
ulin ≥6 mg/L (69/322; 22%, 21%), 69% had unmutated IGHV (180/262; 71%,
66%), 27% had ≥20% cells with del 17p (98/362; 35%, 19%), and 28% had
ECOG ≥2 (114/403; 29%, 28%). Median time from R/R CLL dx to salvage tx
initiation was 0.4 month (range 0.0-39). Follow-up data after salvage tx initiation
was available for a median of 6 months (range 0.6-71). Outcomes are pre-
sented in the table.
Table 1.
Summary and Conclusions: In this large study describing real-world out-
comes of salvage tx in R/R del 17p CLL pts, refractory pts ppeared to have
lower physician-reported overall response rate, PFS, and OS after 1st salvage
tx as compared to relapsed pts. Despite CRs, response durations appeared




OUTCOMES OF ANTICOAGULANT OR ANTIPLATELET USE IN PATIENTS
WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR INDOLENT
NON-HODGKIN’S LYMPHOMA IN IDELALISIB TRIALS
S. Stilgenbauer1, J. Barrientos2, P. Ghia3, J. Pagel4, G. Salles5, J. Sharman6,
O. Gurtovaya7, Y. Kim7, B. Philip7, A.D. Zelenetz8, P. Hillmen9,*
1University of Ulm, Ulm, Germany, 2Hofstra North Shore–LIJ School of Medi-
cine, Hempstead, United States, 3Universita’ Vita-Salute San Raffaele and
Instituto Scientifico San Raffaele, Milano, Italy, 4Fred Hutchinson Cancer
Research Center and University of Washington, Seattle, United States, 5Hos-
pices Civils de Lyon and University Claude Bernard, Pierre Benite, France,
6Willamette Valley Cancer Institute and Research Center/US Oncology
Research, Springfield, 7Gilead Sciences, Foster City, 8Memorial Sloan Ketter-
ing Cancer Center, New York, United States, 9St. James’s University Hospital,
Leeds, United Kingdom
Background: Idelalisib (IDELA), a selective oral PI3Kδ inhibitor, is approved
for use in relapsed chronic lymphocytic leukemia (CLL; in combination with rit-
uximab [R]) and indolent non-Hodgkin’s lymphoma (iNHL; as monotherapy).
Both diseases occur mainly in the elderly, who have comorbidities that increase
thrombotic risk.
Aims: This post hoc analysis characterized the use and outcomes of antico-
agulant (AC)/antiplatelet (AP) therapy, which was allowed in IDELA registra-
tional clinical trials.
Methods: In the phase 3 Study 312-116 (NCT01539512), frail patients with
relapsed CLL (including those with any degree of thrombocytopenia) were ran-
domized to receive a combination of continuous IDELA 150 mg BID or placebo
(PBO) with 8 R doses. In the phase 2 Study 101-09 (NCT01282424), patients
with refractory iNHL received IDELA 150 mg BID until disease progression or
unacceptable toxicity. All patients provided informed consent. Grade 1, 2, and
≥3 bleeding events were analyzed using MedDRA preferred terms and CTCAE.
Results: The 2 trials included 343 patients. In the CLL study, 18 patients (16%)
on IDELA +R and 31 (29%) on PBO +R had grade ≥3 thrombocytopenia at
baseline. Concomitant AC/AP use was frequent (45% in each study); the most
common were aspirin, enoxaparin, and warfarin. AC/AP use was more frequent
in patients treated with IDELA +R vs PBO +R. The incidence of bleeding events
was similar with IDELA, IDELA +R, and PBO +R. Of the 28 patients receiving
warfarin, 9 had bleeding events (3 IDELA +R [all grade 1]; 2 PBO +R [all grade
1]; 4 IDELA patients [grade 1, n=3; grade 2, n=1). Grade ≥3 bleeding events
occurred in 1 IDELA +R, 1 PBO +R, and 3 IDELA patients.
Table 1.
Summary and Conclusions: AC/AP use involved 45% of the IDELA registra-
tional trial population. Overall, rates of bleeding events were moderate and
similar with IDELA +R vs IDELA +PBO; grade ≥3 events were uncommon.
There was no specific trend with regard to AC/AP and bleeding events in the
2 arms of the CLL study. Funded by Gilead Sciences.
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MODELING THE EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) AND WALDENSTROM’S MACROGLOBULINEMIA (WM)
IN FRANCE
X. Troussard1,* A. Herrera2, E. Cornet1, P. Solal-Céligny3
1Laboratoire d’hématologie biologique, CHU Caen - Hôpital de la Côte de
Nacre, Caen, 2Médecine interne immunologie, Hôpital Antoine-Béclère Cla-
mart, Clamart, 3Service d’Oncologie médicale, ICO site Paul Papin / ICO site
René Gauducheau, Angers / Saint Herblain, France
Background: Chronic lymphocytic leukemia (CLL) is a slowly progressing but
incurable disease and Waldenstrom’s Macroglobulinemia (WM) is a rare dis-
ease, representing 6% of lymphoproliferative diseases in France. Furthermore,
CLL and WM patients will eventually relapse after multiple lines of treatment,
leading to a high unmet medical need.
Aims: In 2014, there were few reliable publication sources of epidemiological
data for CLL and WM in France, particularly with regard to advanced stages.
In addition, epidemiology registries generally provide data on disease inci-
dence; however, no information can be directly obtained for the relapsed patient
population. At the same time, several new and effective therapies will be made
available to the Hematologist/Oncologist community and thus, there will be an
increase in the complexity of therapeutic algorithms. To address this, we under-
took an innovative modeling approach to answer the need of a greater under-
standing of the number of relapsed patients in need of new therapies. The
objective of the model was to determine the yearly incidence of first line and
later lines of therapy between 2015 and 2018 in CLL and WM patients; thus,
the model provides relevant data to determine the patient population size that
will be eligible for the new compounds and that could be implemented into a
prospective economic model.
Methods: First, we used the “Registre Régional des Hémopathies Malignes
de Basse-Normandie” (RRHMBN) to collect real world patient characteristics,
such as patient subgroups and tumor staging. The RRHMBN is dedicated to
Hematological malignancies and supported by official Health Authorities: “Insti-
tut National du Cancer“(INCA) and “Institut National de Veille Sanitaire” (INVS).
Then, we applied these findings to the French National Network of Registers
“FRANCIM” incidence and survival data. The analysis showed that in 2015,
the total number of patients estimated with stage A, B or C CLL is 3612, 671
and 384 respectively. In 2018, it is expected to reach 3778, 702 and 403
patients respectively. In 2015, the total number of patients with symptomatic
(20%) or asymptomatic +monoclonal gammopathy of undetermined signifi-
cance (80%) WM is estimated at 252 and 1008 respectively. In 2018, it is esti-
mated to reach 254 and 1018 patients respectively.
Results: The table below shows the yearly number of CLL and WM patients
eligible for treatment in first and subsequent lines of therapy as produced by
the model.
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Table 1.
Summary and Conclusions: Our modeling approach compensates for a lack
of real world information on relapsed CLL and WM. We have shown that there
is a significant number of relapsed patients who are in need of new treatments
in France. The model produces estimates for the number of patients in later
lines in need of novel therapies by 2018 and provides efficient prospective data
that can be integrated into medico-economic model development. Furthermore,
these data address a current medical need for the development of new CLL





MICRO-RNAS ASSOCIATED WITH PROGNOSIS IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) DO NOT IMPACT OVERALL SURVIVAL
IN PATIENTS WHO RECEIVE NONMYELOABLATIVE ALLOGENEIC STEM
CELL TRANSPLANT (NMAT)
I. Khouri1,* S. Anfossi2, R. Saliba1, J. Khoury2, L. St John1, J. Molldrem1,
J. Reuben2
1Stem Cell Transplantation and Cellular Therapy, 2Hematopathology, MD
Anderson Cancer Center, Houston, United States
Background: Noncoding RNAs play an important role in the pathogenesis of
CLL. Recent studies have shown that higher miR-155 levels (>56th percentile)
are associated with a lower overall survival (OS) (P= 0.0122) in CLL patients
treated with conventional chemotherapy regimens (Ferrajoli et al. Blood 2013;
122:1891). Others revealed that expression of miR-29b or miR-181b inhibits
the TCL1 oncogene (Pekarsky et al. Cancer Res 2006; 66:11590), whereas
high Tcl1 expression correlates with aggressive CLL phenotype showing unmu-
tated immunoglobulin variable region genes and ZAP70 positivity. However,
the clinical impact of the expression of these miRs in CLL patients who undergo
NMAT is unknown.
Aims: To assess the impact of miRs on overall survival in CLL patients under-
taking NMAT.
Methods: We identified 28 patients with relapsed/refractory CLL who had
received NMAT at our center between 2000-2010 and in whom pre-transplant
serum samples collected before initiating allogeneic conditioning were available.
We measured the serum levels of miR-155, miR-15a/16-1 cluster, miR-29b,
and miR-181b. Total RNA was isolated from 100 µL of serum using the Total
RNA Purification Kit and miRNA levels were measured by qRT-PCR (TaqMan
MicroRNA assays). Twenty fmol of synthetic C. elegans miRNA (cel-miR-39)
was spiked into each serum samples to normalize the experimental qRT-PCR
data (cel-miR-39 Ct mean±SD=17.777± 0.628). Relative miR levels were cal-
culated using the equation 2−ΔCt, where ΔCt=mean CtmiRNA – mean Ctcel-miR-
39, and Ct=threshold cycle.
Results: Patients had a median age of 59 years (range, 45-70). Median number
of prior therapies was 3 (range, 2-8). Eleven (39%) patients had a beta-2
microglobulin level of >3 mg/L. Ten of 12 (83%) patients with data that could be
evaluated had unmutated immunoglobulin variable-region heavy-chain gene,
and 4/19 (21%) had 17p13.1 deletion. At transplantation, 46% of patients had
refractory disease. The proportion of patients who received a matched related
and a matched unrelated donor was 68% and 32%, respectively. All patients
received nonmyeloablative conditioning with fludarabine, cyclophosphamide,
and rituximab as published previously (Khouri et al. Cancer 2011; 117:4679).
Graft-versus-host-disease prophylaxis consisted of tacrolimus and methotrex-
ate. Median follow-up time was 68 months (range, 43-141). The OS from the
time of NMAT was evaluated as a function of tiered relative miR levels (low,
below median; high, above median). Notably, none of the relative levels of the
miRs evaluated were associated with 5-year OS following NMAT (Table).
Table 1.
Micro-RNA OS associated with low-level OS associated with high-level P-value
miR-155 63% 50% 0.4
miR-15a 57% 57% 1.0
miR-16 43% 71% 0.2
miR-29b 52% 61% 0.7
miR-181b 60% 53% 0.9
Summary and Conclusions: Our data suggest that serum levels of miR-155,
miR-15a/16-1 cluster, miR-29b, and miR-181b do not impact 5-year OS in
relapsed/refractory CLL following NMAT. As such, other prognostic biomarkers
are needed in this patient group.
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THE OCCURRENCE OF OTHER MALIGNANCIES IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA
M. Todorovic Balint1,* A. Sretenovic1, V. Kecman2, D. Antic1, J. Jelicic1,
A. Bogdanovic1, J. Bila1, B. Andjelic1, V. Djurasinovic1, V. Vukovic1,
M. Smiljanic1, B. Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, Bel-
grade, 2Department of Internal Medicine, General Hospital, Pancevo, Serbia
Background: Chronic lymphocytic leukemia (CLL) is related with an increased
risk of developing different malignancies due to immunologic defects associated
with disease or therapy-related immunosuppression.
Aims: The aim of this study was to determine in patients with CLL type and fre-
quency of previously diagnosed malignanat disease MD (pMD), concomitant
MD (cMD), afterwards secondary MD (sMD), as well as patient’s outcome.
Methods: We have retrospectively analyzed clinical data of CLL patients who
were diagnosed at our institution from 1994 to 2010. Disease stage and treat-
ment were established after collecting clinical, laboratory, and pathological data.
Immunophenotypic diagnosis was verified by applying of CLL scoring system.
The study involves 471 patients (311 males/ 160 females) with median age at
diagnosis 64.3 (39-80).
Results: MDs were confirmed in 38 (8.1%) patients (24 males/14 females).
Presenting characteristics showed WBC>30x109/L in 30%, Rai stage III-IV in
13%, and LDH elevation in 23 % of patients. Immunophenotyping revealed
CD38 positivity in only 4/38 patients. The most frequent aditional MDs were
skin neoplasms in 9 (33.3%) patients comprising 5 cases of basocellular car-
cinoma, 2 of planocellular and 2 cases of melanoma. Other neoplasms were
colorectal carcinoma in 6 (22.2%), prostatic cancer in 4 (14.8%), lung cancer
in 3 (11.1%), bladder cancer in 2 (7.4%) and larynx cancer in 2 (7.4%) patients.
There was gender related distribution of MDs with the most frequent breast
carcinoma in females and prostatic carcinoma in males. Among males 3
patients had double MD, colorectal carcinoma associated with basocellular,
prostatic and laryngeal cancer. Regarding females, the frequency of MDs were
as following: breast carcinoma had 6 patients (42.8%), uterus and cervix car-
cinoma 3 (21.4%), colorectal carcinoma 2 (14.2%), kidney carcinoma 2 (14.2%)
and gastric carcinoma 1 (7.1%). Diagnosis of pMD noticed in 17 patients (9
males/ 8 females). Among this patients the most frequent pMD was breast car-
cinoma (5 patients), and afterward colorectal carcinoma (4 patients). Initial
treatment of pMD was only surgery in 8 patient, in 1 patients was combined
with chemotherapy, in 3 with hormone therapy, and finally in 3 patient with
radiotherapy. Single radiotherapy was performed in 2 patients. Median time for
appearing CLL after diagnosis of primary MD was 5 years. Regarding OS of
patients with CLL and previously diagnosed MDs, 5-years survival from pMD
was 68% with median OS of 23 years. In 11 CLL patients (6 males/5 females)
cMD was diagnosed and majority of them (90%) had stable CLL that didn`t
require medical treatment. Regarding patients with cMD, none of 11 patients
received any potentially mutagenic treatment previously. The OS of patients
with cMDs was 75% in the first year, with slowly dropping up to 60% in the 5-
years follow up. During CLL follow-up in 10 patients (9 males/1 females) was
diagnosed .sMD, which was appeared most frequently in the first 4 years (80%).
Previously 5 of them received chemotherapy (fludarabine based regimen).
From the diagnosis of sMD, median OS was 12 months, with 5-years survival
of only 25%.
Summary and Conclusions: CLL doesn’t have more aggressive nature after
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the treatment of previously diagnosed neoplasm and don’t affect the OS. In
patients with CLL and cMD the OS mainly depends on the behavior of con-
comitant malignancy. Finally, diagnosis of sMDs during CLL follow-up had an
effect on patient`s inferior outcome.
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MINIMAL RESIDUAL DISEASE IN HAIRY CELL LEUKEMIA: DOES IT
MATTER?
A. Santos Carreira1,* R. Pinto1, A. Carneiro1, F. Príncipe1, J.E. Guimarães1
1Hematology, Centro Hospitalar São João - Porto, Portugal, Porto, Portugal
Background: Hairy Cell Leukemia (HCL) is a fairly rare type of B-cell lympho-
proliferative disorder. Its prognosis is good compared to most common types
of leukemia but relapse remains a challenge. Minimal residual disease (MRD)
assessment is routinely performed in most centers using different approaches,
but its clinical usefulness is a matter of debate.
Aims: In an attempt to understand the impact of MRD evaluation in the natural
history of the disease and relapse risk, we have retrospectively reviewed all
patients with HCL diagnosed in our center and looked at how MRD measure-
ments correlated with patient outcome.
Methods: MRD was assessed by flow cytometry expression of CD19, CD25,
CD11c and CD103 as well as by marrow biopsy searching for minimal mor-
phological and/or immunohistochemical evidence of disease. MRD implied that
patients had achieved complete or partial remission (CR and PR, respectively)
with the treatment provided. For flow cytometry MRD positivity, two cut-off val-
ues were defined: more than 0.3% or 0.01% of HCL clone. CR was defined as
complete recovery of blood counts ie, hemoglobin>12g/dL in men and 11g/dL
in women, neutrophils >1500/uL and platelets >100.000/uL (with exception to
expected lymphopenia after chemotherapy courses), resolution of
splenomegaly in case it was present at diagnosis and, if not absent, minimal
morphological or immunohistochemical evidence of hairy cells in bone marrow
biopsy. PR was defined as at least a 50% improvement in any of these param-
eters, without criteria meeting CR.
Results: We analysed data from 29 patients diagnosed between 1991 and
2013, median follow-up was 108 months (range: 23-259 months). Male pre-
vailed (n=26). Median age at diagnosis was 54 years (range: 33-71). Most
patients (89.7%) were treated with cladribine upfront (dose 0.14mg/kg x 5
days). 25 patients (86.2%) entered CR. All other 4 patients achieved PR with
one cycle of cladribine. Flow cytometry MRD assessment and bone marrow
histology were available in 17 and 14 patients, respectively. Median flow cytom-
etry MRD positivity was 0.29% (range: 0-2.55%). Eight out of 17 patients had
a HCL clone greater than 0.3% and MRD was negative (<0.01%) in 4 patients.
Out of the 14 patients in whom MRD by histology was available, 6 proved to
be positive. Median progression free survival (PFS) was 11.8 years (±11.6%).
Relapse occurred in 12 patients (41.4%, n=12/29), of whom 2 had achieved
PR: five patients had flow cytometry MRD >0.3%, 2 were negative for the test
in question, whereas 4 had no MRD by histology. Moreover, we registered 6
relapses out of 13 patients who had a HCL clone greater than 0.01%, with the
remainder maintaining CR (n=5/13) or PR (n=2/13). Of notice, we encountered
only one relapse in 4 patients who had detectable MRD by both methods. We
could not establish any correlation between relapse risk and MRD detection
by any of the two methods used. Five-year PFS for patients with MRD >0,3%
and <= 0,3% was 88.9%(±10.5%) and 62.5% (±17.1%), respectively (p=0.356).
All but one patient (96.6%) continued alive at last follow-up.
Summary and Conclusions: HCL patients do not seem to behave differently
in terms of relapse incidence, PFS or overall survival, in respect to the presence
or not of MRD. Its assessment by flow cytometry and/or bone marrow histology
did not prove to be clinical meaningful in our analysis. Currently, clinical sur-
veillance and full blood count seem reasonable enough to accurately follow-
up HCL patients. Furthermore, MRD assessments bear relevant economical
costs and unnecessary stress to patients.
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ONE OUT OF FOUR TREATMENT-NAÏVE CLL PATIENTS IN TAIWAN
CARRY TP53 MUTATIONS: CLINICAL AND PATHOGENETIC
IMPLICATIONS
S.J. Wu1,* C.T. Lin1, A. Agathangelidis2, L.I. Lin1, P. Ghia2, H.F. Tien1
1National Taiwan University Hospital, Taipei, Taiwan, ROC, 2Università Vita-
Salute San Raffaele, Milano, Italy
Background: Previous studies have shown significant differences between
Taiwan and the West in terms of epidemiology and cytogenetic pattern of chron-
ic lymphocytic leukemia (CLL). Recently, technology advances have led to the
identification of previously unknown gene aberrations in CLL, some of which
have been shown of clinical relevance. The comparison of these molecular
genetic markers between Taiwan and the West may help clarifying the potential
difference in the disease between these different ethnic groups.
Aims: The study aimed at establishing the molecular genetic profiles of CLL
in the Taiwanese population and identifying the potential differences in this
low-prevalence ethnic region.
Methods: In a cohort of 74 patients with newly diagnosed CLL at the National
Taiwan University Hospital, we determined the usage and the mutational status
of the Immunoglobulin Heavy chain variable (IGHV) genes and the presence
of HCDR3 stereotypes, a frequent feature in western CLL. In addition, we also
screened for the presence of mutations in the TP53, NOTCH1, SF3B1, BIRC3,
and MYD88, genes recurrently mutated in CLL.
Results: In terms of IGHV gene usage, 56.4% of patients had somatic hyper-
mutations and in 10.2% of patients the HCDR3 sequences belonged to the
major stereotyped subsets, closely resembling the frequencies present in the
western population. That notwithstanding, the commonly used IGHV genes in
Taiwanese patients were different from those in Western patients as IGHV3-
07 and IGHV3-23 were over-represented (18.4% and. 16.3%, respectively),
whereas IGHV4-34 and IGHV4-39 were underrepresented, being absent in
the current cohort. In terms of molecular genetics, the frequencies of NOTCH1,
SF3B1, BIRC3 and MYD88 mutations were 9.7%, 9.7%, 1.6%, and 3.2%,
respectively, similar to the data derived from the West. In clear contrast, the
frequency of TP53mutation was significantly higher (24.2%) in Taiwanese CLL
patients than in western populations (5-10%); such a higher frequency is com-
patible with the higher 17p deletion rate and inferior survival outcomes in Asian
CLL patients reported previously. Similar to the data derived from the West,
TP53 mutation had a significant positive association with non-mutated IgHV
(p=0.011), TP53 and SF3B1 mutations were closely associated with 17p dele-
tion (p=0.010) and 11q deletion (p<0.001), respectively, and patients with
TP53/17p deletion or SF3B1 mutations had inferior overall survivals (p=0.007
and p<0.001, respectively).
Summary and Conclusions: The current study demonstrates a distinctly high-
er TP53mutation frequency that is in clear contrast with the features of CLL in
the Western countries and might explain the overall inferior outcome of CLL in
Taiwan, indicating a medical need for novel treatments in this region. The dis-
tinct usage of IGHV genes in this population may further suggest different
pathogenetic mechanisms with distinct antigenic elements acting in the natural
history of the disease that may predispose to genetic instability and the acqui-
sition of dismal genetic lesions.
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RETROSPECTIVE EVALUATION OF 83 PATIENTS WITH HAIRY CELL
LEUKEMIA TREATED WITH 3 DIFFERENT TREATMENT MODALITIES IN
THE LAST TWO DECADES: A SINGLE CENTER EXPERIENCE
S. Ongoren Aydin1,* A. E. Eskazan1, S. Berk1, I. Erdogan1, F.F. Yalniz1,
T. Elverdi1, A. Salihoglu1, M.C. Ar1, Z. Baslar1, T. Soysal1, B. Ferhanoglu2,
N. Tuzuner3, Y. Aydin1
1Department of Internal Medicine, Division of Hematology, Istanbul University
Cerrahpasa Faculty of Medicine, 2Department of Internal Medicine, Division of
Hematology, Koc University Faculty of Medicine, 3Department of Pathology,
Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Background: Hairy cell leukemia (HCL) is a rare mature B-cell neoplasm. Var-
ious treatment modalities have been used, and until the introduction of cladrib-
ine (2-CdA), splenectomy and interferon-alpha (INF-α) were the formerly con-
sidered standard therapies for HCL, which led to clinical and hematologic
responses. 2-CdA resulted in higher complete response (CR) rates and durable
remissions, and became the standard treatment modalities in most of the
patients.
Aims: The aim of this study was to retrospectively analyze the clinical outcome,
treatment responses, toxicities and survival of HCL patients treated in our insti-
tution with 3 treatment modalities (splenectomy, INF-α, and 2-CdA) between
1991-2014.
Methods: Eighty-three patients with HCL were included this study. We ana-
lyzed the outcome of different treatment modalities as well as different lines of
therapy among these patients. There were 12 patients with variant HCL (HCL-
v). The response rates of the 3 first-line treatment options were evaluated.
Patients were also divided into four subgroups according to the number of
treatments they had received. Group 1 included patients who received first-
line treatment. Group 2 consisted of patients who were treated with 2 lines of
treatment; Group 3 had patients who underwent 3 lines; and Group 4 included
patients with four lines of therapy. We used the criteria for response as
described by the Consensus Resolution. CR and partial response (PR) together
defined as overall response (OR), and any response other than a CR or PR
was considered as no response (NR). 
Results: Seventy-four patients (89%) were male, the median age was 49 years
(range, 31-76 years), with a median follow-up duration of 54 months (range, 1-
217 months). The median leukocyte counts of the HCL-v cases were 15.5 x
109/L and (range, 10.1-90.7 x 109/L). In 71 HCL cases, the median leukocyte
count was 3.03 x 109/L (range, 0.5-9.4 x 109/L). The median hemoglobin level
and platelet counts were 11 g/dL (range, 4-17 g/dL) and 51.5 x 109/L (range,
21-124 x 109/L), respectively. Splenomegaly was detected in 74% of the
patients, with hepatomegaly and lymphadenopathy 37% and 35% of the cases,
respectively. Seventy-three patients (88%) (Group 1) received 1st line treat-
ment, and 2-CdA was administered in thirty-two (44%), twenty-one patients
(29%) received INF-α and splenectomy was performed in 20 cases (27%)
(Table 1). The OR rates among 2-CdA, INF-α and splenectomy as a 1st line
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treatment option were 88%, 81% and 90%, respectively. Three patients (2-CdA
in two, INF-α in one) died due to infection during treatment. None of the patients
with splenectomy died due to post-operative complications. Twenty-nine
patients (Group 2) required 2nd line treatment due to relapsed/refractory dis-
ease. Seventeen patients received INF-α, 10 patients received 2-CdA and two
had splenectomy. Group 3 consisted of 9 patients, and 6 of them had INF-α,
two were given 2-CdA and one patient received rituximab (RTX). As a 4th line
of treatment one patient received RTX and one had fludarabine (Group 4)
(Table 1). During the follow-up, 10 patients died mostly due to refractory disease
and/or infections. Five patients were lost to follow-up. There were 64 infection
episodes, and most common infections were bacterial infections (pneumonia
in 12, tuberculosis in 8, febrile neutropenic episode in 7, soft tissue infection in
6, meningitis in one, and septic arthritis in one). Five patients had a secondary
malignancy of which 3 had occurred before the diagnosis of HCL.
Table 1. Summary of the different treatment modalities. (2-CdA, cladribine;
IFN-α, interferon-alpha).
Summary and Conclusions: These 3 treatment modalities were found to be
comparable regarding efficacy when used in the 1st line setting. First line
splenectomy was performed mostly prior to 2000, and nowadays 2-CdA and
INF-α are usually chosen as the 1st line treatment in most of the patients. Infec-
tions were the most common complication which can be observed both prior to
and during the treatment.
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TWO DECADES OF SINGLE-CENTER EXPERIENCE REGARDING THE
TREATMENT, PREDICTORS OF SURVIVAL AND CAUSES OF DEATH IN
PATIENTS WITH HAIRY CELL LEUKEMIA
D. Lekovic1,* M. Gotic1,2, N. Milic2,3, M. Perunicic-Jovanovic1, L. Jakovic1,
N. Kraguljac-Kurtovic1, J. Bodrozic1, M. Bogunovic1, M. Todorovic1,2,
I. Elezovic12, D. Tomin1,2B. Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Medical Faculty, 3Institute
for Medical Statistics, University of Belgrade, Belgrade, Serbia
Background: Treatment of hairy cell lekemia (HCL) is well established, how-
ever the predictors of survival and cause of death of these patients have not
been evaluated. Also, occurence of second malignancies in HCL patients is
matter of debate.
Aims: was to identify the parameters with an influence on survival as well as
causes of death of HCL patients.
Methods: Study included 137 patients who HCL were diagnosed and treated
at the Clinic for Hematology, CCS from January 1993 to December 2014. Eight
patients were diagnosed as HCL variant. We analyzed only patients with classic
HCL (129 pts) and their characteristics (age, gender, clinical and laboratory
parameters, immunophenotypic expression of HCL cells in peripheral blood,
histological characteristics of bone-marrow and type of therapy) as well as
development of second malignancies in terms of survival.
Results: Median age at the time of diagnosis was 54 years (IQR 20), with
dominance of male gender (82,9%). Regarding the therapy, one treatment-
line (TL) received 67 patients (51.9%), 2 TL 34 patients (26.4%), 3 TL 10
patients (7.8%) and four or more TL 14 patients (10.9%) resulting in 80.5% of
complete remissions (CR), 16.3% of partial remissions (PR) and 3.3% of non-
response (NR). Four patients were followed up only, without any treatment
(3%). Splenectomy was performed in 28 patients (21,7%). Purine analog
(cladribine) received 106 pts (82.2%) resulting in 82,5% CR, 16.5% PR and
1% NR. Seven patients with relapse of HCL after multiple treatments with
cladribine, received rituximab alone or in combination with cladribine resulting
in 6 patients with CR and in 1 patient with PR. After the median follow up of
86 months, 36 deaths were documented (27.9.%). The 5- and 10- years OS
was 90.2% and 70.9% respectively. Second malignancy during the follow-up
of HCL developed 17 patients (13.3%). Solid tumors occurred in 13 patients
while 4 patients developed second hematological malignancy. The causes of
death in HCL patients were as follows: active HCL (9 patients; 25%), cardio-
vascular disease (11 patients with coronary disease, cardyomyopathy and
heart failure; 30.6% and 4 patients with AIM; 11.1%), respiratory insufficiency
(2 patients; 5.5%), second malignancy (6 patients with solid tumors; 16,8%
and 2 patients with hematological malignancies; 5.5%) and concomitant dis-
eases (2 patients with active HCL and solid tumor; 5.5%). The mean age of
patients who died (63±10 years) was significantly higher than in living patients
(50±11years) (p<0.001). In univariate Cox regression model unfavorable pre-
dictors of survival were: age>55y (p<0.001), hemoglobin level<100g/L
(p=0.01), leukocyte count<2.8x109/L (p=0.001), sedimentation rate>30mm/h
(p=0.011) and occurrence of second malignancy (p<0.001). Regarding the
treatment, mortality of patients who did not receive cladribine was 74%, while
of those who received cladribine was 18% (p<0.001).
Summary and Conclusions: The cladribine treatment is effective with the
achievement of complete remission in over 80% of HCL patients. Patients with
multiple relapses have benefit with rituximab treatment. Also, the long-term fol-
low-up of HCL patients is important for evaluating the development of secondary
malignancies which this study highlights as one of main causes of death in
these patients.
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EVANS SYNDROME SECONDARY TO CHRONIC LYMPHOCYTIC
LEUKAEMIA IS ASSOCIATED WITH ADVERSE BIOLOGICAL FEATURES
AND OUTCOME
G. Carli1,* E. Falisi1, O. Perbellini2, E. Novella1, I. Giaretta1, I. Ferrarini2,
A. Sandini3, A. Ambrosetti2, F. Rodeghiero1, C. Visco1
1Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza,
2Department of Medicine, Section of Hematology, University of Verona, Verona,
3Department of Immunohematology, Genetics and Transfusional Medicine,
San Bortolo Hospital, Vicenza, Italy
Background: Secondary Evans syndrome (ES) is characterised by simulta-
neous or sequential development of autoimmune haemolytic anaemia (AIHA)
and immune thrombocytopenia (ITP), with a positive direct antiglobulin test in
the presence of an underlying aetiology. ES secondary to chronic lymphocytic
leukaemia (CLL) is an extremely rare occurrence, and its prevalence is
unknown. Conversely, isolated AIHA and ITP are much more common in
patients with CLL, occurring in 7-10% and 2-5% of patients, respectively.
Aims: Very few epidemiological and clinical data are available on ES secondary
to CLL. In this study, we collected clinical and biological data of patients with
ES secondary to CLL, and we compared them with patients developing isolated
ITP or AIHA.
Methods: We analysed the records of consecutive patients with CLL diagnosed
in two major Institutions from Veneto region between 2000 and 2014. All patients
met the CLL diagnostic criteria of National Cancer Institute Working Group. To
be included, patients with ES had to fulfill the international standardized criteria
proposed both for ITP and AIHA.
Figure 1.
Results: Overall, 860 patients with CLL were identified, and 25 (2.9%) devel-
oped ES. Additional 32 patients (3.7%) developed isolated ITP, and 63 isolated
AIHA (7.3%). Demographic and clinical characteristics at CLL presentation
(age, gender, Binet stage, median lymphocyte count) of patients developing
either ES, ITP or AIHA were similar among the three groups, and not different
from patients not developing autoimmune cytopenias (AIC). Of the three AIC,
isolated ITP was more frequently diagnosed concurrently to CLL presentation
(34% of patients developing this complication), as compared to ES (20%) or
AIHA (13%). ZAP70 expression was high (cut-off 20%) in 79% of patients with
ES, being significantly higher than in patients with no AIC (50%, p=0.01), but
similar to patients with isolated AIHA or ITP. Immunoglobulin heavy chain vari-
able region gene (IGHV) was un-mutated in 86% of patients with ES, which
was statistically higher than in patients with no AIC (41%, p=0.001), but also
compared to patients with ITP (60%, p=0.04) or AIHA (62%, p=0.04). Further-
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more, del(17)(p13) and TP53 gene mutations were significantly more frequent
in patients with ES (23% and 33% of tested patients, respectively) than in
patients with no AIC (5% for both, p=0.003). In terms of overall survival (OS),
patients developing ES had a significantly inferior OS than patients with no
AIC (Figure 1), but similar to patients with isolated AIHA or ITP. No impact on
OS was observed for patients with ES when divided according to time of onset
of AIC (simultaneous ITP and AIHA, ITP before AIHA or vice versa). However,
patients with ES diagnosed concurrently to CLL presentation had a significantly
inferior OS compared to patients developing ES later in the course of disease
(5 years OS 40% vs 74%, p=0.006). Treatment of ES was challenging, due to
the quite high rate of primary resistant forms, and frequent recurrences, often
requiring chemo-immunotherapy.
Summary/Conclusion: We showed that ES secondary to CLL is an infrequent
but not so rare occurrence, that similarly to AIHA and ITP was significantly
associated with unfavourable biological prognostic factors like ZAP70 expres-
sion, and un-mutated IGVH status. Furthermore, del(17)(p13) and TP53 gene
mutations were highly prevalent among patients with ES. Consequently,
patients with ES had poorer OS compared to patients not developing AIC, and
OS was even poorer when ES occurred concurrently to CLL diagnosis.
Chronic myeloid leukemia - Biology
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DETECTION OF BCR-ABL GENE MUTATIONS IN CHRONIC MYELOID
LEUKEMIA USING SENSITIVE LOW-DENSITY MICROARRAY APPROACH
T. Nasedkina1,2,* A. Ikonnikova1, Y. Yatsenko1, V. Ovsepyan3,
O. Kremenetskaya4
1Engelhardt Institute of Molecular Biology, 2Federal Scientific Clinical Center
of Pediatric Hematology, Oncology and Immunology named after Dmitrii
Rogachev, Moscow, 3Kirov Scientific Research Institute of Hematology and
Transfusiology, Kirov, 4National Research Center for Hematology, Moscow,
Russian Federation
Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell
disease characterized by the Philadelphia (Ph) chromosome and BCR-ABL
fusion gene coding for oncogenic tyrosine kinase. Imatinib mesylate, a tyrosine
kinase inhibitor (TKI) is used as a first line therapy in newly diagnosed CML
patients. However, imatinib resistance, usually due to BCR-ABL kinase domain
point mutations, remains an important problem in treatment of CML patient.
Different methods are used to analyze BCR-ABL point mutations, the common
ones are direct sequencing and allele-specific polymerase chain reaction (AC-
PCR). Direct sequencing is not very sensitive and can reveal 20-30% of mutant
sequence in the background of wild-type DNA. AC-PCR is patient material and
labour consuming while analysing a large number of point mutations. 
Aims: Development of rapid and sensitive microarray-based approach for rou-
tine clinical diagnostics of BCR-ABL kinase domain point mutations.
Methods: A low-density microarray for the analysis of BCR-ABL point mutations
has been designed and manufactured. Cytogenetically prepared fixed cells as
well as fresh blood samples of CML patients were taken after informed consent.
The procedure included RNA isolation and reverse transription-polymerase
chain reaction (RT-PCR) followed by hybridization on microarray with immobi-
lized probes able to discriminate between mutant and wild-type sequence. The
amplified DNA was labelled via incorporation of fluorescent triphosphates in
newly synthesized DNA strand. Fluorescent hybridization pattern was analyzed
using portable laser detector. To increase the sensitivity of the assay locked
nucleic acid (LNA) oligonucleotides were used to inhibit an amplification of
wild-type DNA.
Results: Fifteen mutations associated with imatinib resistance in 85% of CML
cases were included in the analysis: T315I, E255K, E255V, E255D, E255R,
M351T, G250A, G250E, Y253H, Y253F, F359I, F359C, F359L, F359V, M244V.
The microarray approach was validated using control CML samples with known
mutations or synthesized mutant DNA matrice. In total, 62 CML patients were
genotyped using the approach: 40 patients had chronic phase (CP) of the dis-
ease, 18 had accelarated phase (AP) and 4 patients had blast crisis (BC) man-
ifestation. Mutations were found in 15% (6/40) of patients with CP, 72% (13/18)
of patients with AP and 100% (4/4) of BC patients. Additionally, 2 of BC patients
carried simultaneously 2 mutations. The following mutations have been found:
T315I, E255K, E255V, E255D, M351T, G250A, G259E, Y253H, F359I, F359L,
M244V. Most frequent mutations were T351I, M351T and M244V. The microar-
ray genotyping data were confirmed by Sanger sequencing of selected sam-
ples. The sensitivity of the approach was experimentally tested. The method
allowed detecting 2% of mutant DNA in the background of wild-type DNA. All
CML patients carrying mutations developed imatinib resistance. 
Summary and Conclusions: A low-density microarray-based approach has
been developed to identify mutations in tyrosine-kinase domain of BCR-ABL
gene, leading to resistance against target therapy with imatinib. The method
includes RT-PCR following by allele-specific hybridization with immobilized
oligonucleotide probes. Fifteen BCR-ABL mutations which determine 85% of
imatinib resistant cases are included in the assay. The sensitivity of the method
allows detecting at least 2% of cells carrying mutations among cells with wild-
type BCR-ABL gene. The feasibility of the assay for routine clinical practice
has been demonstrated by genotyping of CML samples.
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ANTIPROLIFERATIVE AND APOPTOTIC EFFECTS OF PONATINIB AND ITS
EFFECTS ON MACROMOLECULAR CHANGES IN IMATINIB-SENSITIVE
AND RESISTANT CHRONIC MYELOID LEUKEMIA (CML) CELL LINES:
A MECHANISTIC APPROACH
M. Kartal Yandim1,* C. Ceylan2, E. Elmas2, Y. Baran1
1Molecular Biology and Genetics, 2Food Engineering, Izmir Institute of Tech-
nology, Izmir, Turkey
Background: Although effective treatment strategies have been invented for
CML therapy, CML patients have still developed resistance against tyrosine
kinase inhibitors used in the clinic. The most aggressive reason of resistance
in CML therapy is T315I mutation. Frontline therapeutics, imatinib, nilotinib,
and dasatinib cannot be effective in CML patients with T315I mutation. Pona-
tinib, approved in 2012 by FDA, is an effective inhibitor of BCR/ABL, even with
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the mutation T315I. However, the exact mechanism of ponatinib in CML has
been still unknown.
Aims: In this study, we aimed to examine apoptotic and antiproliferative effects
of ponatinib, and also its effects on macromolecules in imatinib-sensitive K562
human CML cell lines and 3 µM-imatinib-resistant K562/IMA3 CML cell lines
generated at our lab. In other words, we aimed to determine the potential mech-
anisms and structural metabolic changes activated by ponatinib-treatment in
CML cell lines.
Methods: K562/IMA3 cells were previously generated by selecting them under
increased concentrations of imatinib. The cells are resistant to 3 µM imatinib.
Cytotoxic effects of ponatinib on K562 and K562/IMA3 cells were determined
by MTT assay while apoptotic effects were assessed by examining the changes
in caspase-3 enzyme activity, loss of mitochondrial membrane potential (MMP),
and the localization of phosphatidylserine on the plasma membrane by Annex-
in-V staining. Cytostatic effects of ponatinib were determined by flow cytometry
after propidium iodide staining. Changes in macromolecules were determined
by Fourier Transform Infrared (FTIR) spectroscopy as the intensities of the sec-
ondary derivatives of the absorption bands.
Results: IC50 values of ponatinib for 72 h in K562 and K562/IMA3 cells were
found 1,72 nM and 28,5 nM, respectively. In order to examine the apoptotic
effects of ponatinib, K562 and K562/IMA3 cells were treated increasing con-
centrations of ponatinib (10-100 nM) for 72 h. Caspase-3 enzyme activity
changed 1,82- to 2,38-fold; and 1- to 1,45-fold in K562 and K562/IMA3 cells,
respectively, as compared to untreated controls. Ponatinib treatment also
caused changes in MMP by 1,3- to 3,56-fold; and 1- to 6,6-fold in K562 and
K562/IMA3 cells, respectively, as compared to untreated controls. Additionally,
ponatinib increased apoptotic cell population 1,96- to 8,47-fold in K562 cells in
response to 10-100 nM ponatinib; and also 7,75- and 9,64-fold in K562/IMA3
cells exposed to 50- and 100 nM ponatinib, respectively. Furthermore, cell cycle
analyses revealed that ponatinib arrested K562 and K562/IMA3 cells at G1
phase, and it also arrested K562/IMA3 cells treated with the highest concen-
tration at G2/M phase. Moreover, FTIR results showed that the transcription
rate observed as 994/969 cm-1 ratio (RNA/DNA ratio) decreased 13.79% in
K562/IMA3 cells. The glycogen/DNA ratio indicated by 1023/1021 cm-1 ratio
decreased in K562 cells by 8.15% whereas it increased by 16.67% in
K562/IMA3 cells. The intensity ratio of 1172/1011 cm-1 is accepted as the ratio
of cholesterol esters/DNA and it decreased in both types of the cells. The order
of the cellular DNA is expressed as 1069/1053 cm-1 decreased in K562 cells,
whereas increased in K562/IMA3 cells.
Summary and Conclusions: Under the light of these results, ponatinib could
affect strongly both imatinib-sensitive and resistant CML cells via cytotoxic,
cytostatic, and apoptotic ways in a dose-dependent manner. Moreover, our
results indicate that increasing concentrations of ponatinib causes significant
structural and organizational changes in both imatinib-sensitive and -resistant
K562 cells.
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COMPARATIVE ANALYSIS OF BCR-ABL AND VEGFR2 INHIBITORY
ACTIVITIES OF PONATINIB, AXITINIB, AND PF-114
J.M. Gozgit1,* F. Gonzalvez1, Y. Song1, T. Baker1, V.M. Rivera1
1ARIAD Pharmaceuticals, Inc., Cambridge, United States
Background: Resistance to tyrosine kinase inhibitors (TKIs) in patients (pts)
with chronic myeloid leukemia (CML) is frequently caused by mutations in the
BCR-ABL kinase domain. The T315I gatekeeper mutation (BCR-ABLT315I) con-
fers uniform resistance to all approved TKIs except ponatinib, which has demon-
strated deep and durable responses in heavily pretreated pts without or with
BCR-ABL mutations, including T315I. However, at a starting dose of 45 mg,
ponatinib treatment is also associated with an increased risk of arterial occlusive
events. Ponatinib also inhibits a number of other kinases that may contribute
to its adverse event profile, including VEGFR2. Recently, axitinib, a commer-
cially available VEGFR2 inhibitor, was reported to have preclinical activity
against BCR-ABLT315I, and PF-114, a close analog of ponatinib, was reported
to have T315I activity while exhibiting reduced inhibitory activity against VEG-
FR2.
Aims: To compare the anti-BCR-ABL and -VEGFR2 activities of axitinib and
PF-114 to that of ponatinib, and where possible, relate these potencies to clinical
PK parameters to address the potential for these compounds to be clinically
effective.
Methods: The potencies of ponatinib, axitinib, and PF-114 were assessed
using Ba/F3 cells whose viability was dependent on native BCR-ABL, BCR-
ABLT315I, or VEGFR2. IC50s for ponatinib and axitinib were compared to “clin-
ically effective” plasma concentrations (Ceff), which were derived using average
steady-state levels in patients treated at recommended starting doses (Cave
101 nM and 49 nM for 45 mg qd ponatinib and 5 mg bid axitinib, respectively),
and corrected for the functional effects of protein binding that we measured in
vitro (3.6-fold for ponatinib and 49-fold for axitinib). Analysis of crystal co-struc-
tures was used to assess detailed molecular ligand-protein interactions.
Results: Consistent with previously reported results, ponatinib potently inhibits
the activity of native and T315I-mutant BCR-ABL, as well as VEGFR2, with
IC50s ≤5 nM (Table). These IC50s are substantially below the Ceff of ponatinib
in patients (28 nM). Axitinib is a similarly potent inhibitor of VEGFR2, with an
IC50 (2 nM) that is close to its Ceff (1 nM). However, axitinib has substantially
lower activity against T315I and native BCR-ABL (IC50s 365 and 635 nM,
respectively). PF-114 inhibits native BCR-ABL (13 nM), though less potently
than ponatinib, and has substantially lower activity against not only VEGFR2,
but also BCR-ABLT315I (IC50s 201 and 538 nM, respectively). A plausible expla-
nation for this loss of potency is the introduction of an atom substitution into
PF-114 that creates a repulsive molecular interaction with a conserved structural
element in the hinge-binding region of the proteins.
Table: IC50 in Ba/F3 Cell Viability Assay (nM)
Native BCR-ABL BCR-ABLT315I VEGFR2
Ponatinib 1 5 3
Axitinib 635 365 2
PF-114 13 538 201
Summary and Conclusions: Neither axitinib nor PF-114 has a preclinical pro-
file that would suggest greater potential clinical benefit than ponatinib. Con-
centrations of axitinib required to inhibit T315I and native BCR-ABL substantially
exceed effective concentrations achievable in patients, and those required to
inhibit its clinically validated target VEGFR2. In generating PF-114, structural
modifications of ponatinib, designed to reduce its VEGFR2 activity, also result
in reduced potency against native BCR-ABL, and especially against BCR-
ABLT315I. A dose ranging trial aimed at evaluating the benefit/risk of ponatinib
treatment for patients with CML is planned.
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CD26 ANTIGEN IS SPECIFIC FOR LEUKEMIC STEM CELLS IN CHRONIC
MYELOID LEUKEMIA AND DISTINGUISHES PATIENT GROUPS WITH
DIFFERENT RATIOS OF LEUKEMIC AND HEALTHY STEM CELLS
M. Culen1,* M. Borsky2, V. Nemethova2, J. Smejkal2, T. Jurcek2, D. Dvorakova2,
B. Weinbergerova2, L. Semerad2, D. Zackova2, J. Mayer2, Z. Racil2
1Faculty of Medicine, Masaryk University, 2Department of Internal Medicine,
Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
Background: Putative leukemic stem cells (LSC) persist in chronic myeloid
leukemia (CML) patients during treatment and constitute risk of relapse. To
study LSC and develop a targeted therapy, it is necessary to define these cells.
Herrmann et al. (Blood 2014) recently proposed that CML LSC are defined by
expression of CD26. We therefore set to further confirm these results on a
larger group of patients.
Aims: To analyze the stem cell population in a wider cohort of chronic phase
CML patients based on CD26 expression and to analyze the disease burden
in sorted CD26- and CD26+stem cells.
Methods: For 25 consecutive de novo patient samples, we FACS sorted
CD45+34+38-/dim population into CD26- and CD26+cells fractions and ana-
lyzed the Ph burden in both fractions by FISH. Additionally, we re-analyzed the
FACS data and CD26 expression on SC using a more stringent CD45+34+38-
gate. Detection of BCR-ABL1 in sorted sub-fractions was performed using sin-
gle-cell nested RT-PCR.
Figure 1.
Results: We FACS sorted CD26- and 26+SC populations and analyzed the
percentage of Ph+cells in both fractions by FISH. This showed 96.2±9.3%
(mean±SD) Ph+cells in the supposed CD26+LSC fraction, and 40,0±42,0%
(mean±SD) Ph+cells in the CD26- fraction, regarded as HSC, which, however,
did not correspond with the results by Herrmann et al. We suspected that the
Ph positivity in CD26- fraction originated from cells with slightly higher CD38
expression (thus being CD38dim non-SC), included in the sorting to provide
enough cells for FISH analysis. Therefore, we performed a re-analysis of all
our FACS data with more stringent CD38- gate and re-analyzed the CD26
expression in the pure CD38- SC population. This revealed three clear CD26
SC expression profiles among the patients: 1 – dominant CD26- population; 2
– equal CD26- and +populations; 3 – missing CD26- population. The re-analysis
results therefore supported our previous theory; where, for example, the
patients analyzed with almost 100 % FISH Ph+cells in sorted CD26- fraction
had no or very few (0-11%) HSC after the re-analysis (Profile 3). This confirmed
that the FISH positivity in sorted CD26- fraction originated from the
CD38dim/26- non-stem cells and proved the concept that CD26 expression
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reflects Ph positivity only in the true hematopoietic CD34+38- compartment.
To provide a further proof, we analyzed 3 samples using a nested RT-PCR
protocol for single cell analysis. Here, we sorted 3-5 consecutive sub-fractions
(each constituting 5-20 cells) for both CD26- and +populations, ranging from
most CD38neg to CD38dim. CD26+population proved positive in all sub-frac-
tions, whereas in CD26- population, a weak BCR-ABL1 positivity could be
detected only for sub-fractions previously defined for re-analysis as CD38dim.
Summary and Conclusions: We have confirmed that CD26 based differenti-
ation of CML HSC and LSC (CD45+34+38-) is applicable irrespective of CD26
expression profiles, showing different HSC/LSC ratios, and proved the concept
that CD26 expression reflects Ph positivity only in strictly gated true hematopoi-
etic CD34+38- compartment. The results also show that simultaneous sorting
of pure CD26+LSC and CD26- HSC fractions from one patient will often be
unfeasible due to low cell number in either population. These findings extend
our knowledge on SC in CML and are important for further study and eradication
attempts of LSC.
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SPHINGOSINE-1-PHOSPHATE RECEPTOR 2/GQ/PHOSPHOLIPASE C
AXIS IS A NOVEL MECHANISM TO OVERCOME NILOTINIB RESISTANCE
IN T315I MUTATION EXPRESSING 32DCL3 MURINE CELLS
A. Adan Gökbulut1,* B. Ogretmen2, Y. Baran1
1Molecular Biology and Genetics, İzmir Institute of Technology, İzmir, Turkey,
2Department of Biochemistry and Molecular Biology, Medical University of
South Carolina, Charleston, United States
Background: Chronic myeloid leukemia is characterized by the Philadelphia
chromosome (Ph), encoding chimeric BCR-ABL with constitutive tyrosine
kinase activity. Although tyrosine kinase inhibitors (TKIs) provide great success
in the treatment, the development of resistance against TKIs is a main problem
in CML patients. Despite the expression of mutant forms of BCR-ABL such as
T315 mutation is a common reason for the development of nilotinib resistance,
the alterations in sphingolipid signaling pathway is an alternative significant
BCR-ABL1-dependent resistance mechanism. Some sphingolipid members
such as ceramide have apoptotic effects while others like sphingosine-1 phos-
phate (S1P) cause the development of drug resistance and induce cell growth.
Recently, we showed that sphingosine kinase-1 (SK-1)/sphingosine-1 phos-
phate (S1P)/ sphingosine-1 phosphate receptor 2 (S1P2)-mediated drug resist-
ance is related to inhibition of protein phosphatase 2A (PP2A), causing
increased stability of BCR-ABL1 (Salas et al. Blood 2011) However, specific
signaling cascade involved in this process remains unkown.
Aims: Determine the details of S1P2/PP2A mediated-TKI resistance in a mech-
anistic manner by identifying intermediate players between S1P2 and PP2A. 
Methods: BCR-ABL1 expressing 32Dcl3 cells, 32D-p210Bcr-Abl(wt) and 32D-
p210Bcr-Abl(T315I) were used. The antiproliferative effects of nilotinib, SK-1
inhibitor (PF-543), S1P2 inhibitor (JTE-013), phospholipase C inhibitor (U-
73122) and nilotinib/PF-543 and nilotinib/JTE-013 combinations on wt and
resistant cells were determined by MTT assay. Isobologram analysis was per-
formed using CompuSyn program. The mRNA and protein levels of BCR-ABL1,
SK-1 and S1P2 were checked by qRT-PCR and western blotting. Resistant
cells were also transfected with Gq peptide. The effect of U-73122/okadaic
acid (PP2A inhibitor) and Gq peptide/ okadaic acid combinations on BCR-ABL1
levels were evaluated by western blot.
Results: Vector transfected control cells do not give any response to nilotinib
while IC50 values were 8 and >500 nM for wt and resistant cells, respectively.
IC50 values for JTE-013 were calculated as 20 and 40 μM while that for PF-
543 were 8 and 30 μM, respectively. Nilotinib/PF-543 and nilotinib/JTE-013
combination studies showed strong synergistic effects on both cell types as
indicated by MTT assay and isobologram results. Although there is no signifi-
cant changes in BCR-ABL1 levels for wt and resistant cells, SK-1 and S1P2
levels increased in resistant cells. Combination studies caused significant
decreases in BCR-ABL1 protein levels in resistant cells comparing to untreated
control, PF-543 or JTE-013 alone treatments. Overall, these data suggest that
nilotinib resistance is not related to BCR-ABL1 overexpression, but related to
SK-1/S1P2 axis. Although U-73122 and Gq peptide treatments decreased
BCR-ABL1 protein, their combination with okadaic acid restored BCR-ABL1
protein levels. Therefore, SK-1/S1P2-mediated nilotinib resistance could be
overcome by activating PP2A through the inhibition of Gq and phospholipase
C, which are the newly identified players in this signaling.
Summary and Conclusions: Our data suggest that BCR-ABL1 levels
decreased by activating PP2A via Gq and phopholipase C inhibition, which is
a novel mechanism reported for the first time. This proposed mechanism of
nilotinib resistance could be a potential novel therapeutic target to overcome
nilotinib resistance.
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Background: The mechanism of action of imatinib is known to involve the
Fas-mediated apoptosis pathway. Consequntly inter-individual variations in
this apoptosis pathway might be associated with imatinib response or resist-
ance.
Aims: This study attempted to focus on 8 genotypes in the apoptosis pathway
including FAS (rs1800682, rs2229521, rs2234767 and rs2234978), FASLG
(rs763110), CASP10 (rs13006529), and APAF1 (rs1439123, rs2288713) and
analyzed their association with treatment outcomes including molecular
response with 4.5 log reduction (MR4.5), following imatinib therapy in 187 Kore-
an CML patients. 
Methods: Candidate genotypes were selected as non-synonymous SNPs in
exon regions with a minor allele frequency over 0.01 or based on the literature
review. The candidate SNPs were primarily evaluated for adequacy of Hardy-
Weinberg Equilibrium (HWE) using the Chi-square test. HWE and genotype
frequencies were calculated using Haploview software version 4.2 (Broad Insti-
tute, Cambridge, MA). For validation of the genetic effect, we performed internal
validation using a bootstrap algorithm.
Results: The GG/GA genotype in FAS (rs2234767) showed a higher rate of
MR4.5 than the AA genotype (at 5 years 59.7% vs 37.4%, p=0.013). Using a
bootstrap procedure for internal validation we confirmed that FAS (rs2234767)
correlates with MR4.5 (p=0.050). Multivariate analysis confirmed that the FAS
genotype (rs2234767) is an independent surrogate for MR4.5 (p=0.019, HR
0.43, 95% CI [0.22-0.87]).
Summary and Conclusions: In conclusion, the Fas/FasL signaling pathway
may represent the major pathway that mediates apoptosis in CML treated with
imatinib. SNP markers in the apoptosis pathway including FAS genotype
(rs2234767) can be potential surrogates for predicting deeper molecular
response after imatinib therapy.
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Background: Imatinib is, at present, the first-choice treatment for chronic
myeloid leukemia (CML) patients. Despite the impressive success of treatment
obtained with this drug, some patients show incomplete response or resistance
to Imatinib. The BCR-ABL oncoprotein, resulting from the BCR-ABL fusion
gene, characteristic of CML, is able to activate multiple signaling pathways,
including the NF-kB, mTOR and the proteasome pathways, which may provide
new therapeutic targeted alternatives in cases of resistance to Imatinib. Fur-
thermore, the altered expression of microRNAs, small RNA molecules that reg-
ulate gene expression, may influence the sensitivity and/or acquisition of resist-
ance to therapy. 
Aims: Our goal was to evaluate the influence of the expression levels of miR-
21, miR-125b, and miR-155 in CML cell lines sensitive and resistant to Imatinib,
as well as the therapeutic potential of new drugs such as Bortezomib, Partheno-
lide, and Everolimus.
Methods: In this work we used two CML cell lines, one sensitive to Imatinib
(K562 cells) and another resistant to Imatinib (K562 RC cells). Cell viability
was assessed by rezasurine assay and cell death by flow cytometry (annexin
V and propidium iodide) and through optic microscopy (May-Grünwald-Giemsa
staining). The expression of BAX, BCL-2, phosphorylated NF-kB, ubiquitin con-
jugates, and cell cycle analysis was performed by flow cytometry. The expres-
sion levels of AKT and AKT activation were analyzed by Western Blot. MiRNAs
expression was performed by qRT-PCR using commercial kits.
Results: Initially we observed that K562 RC cells had increased expression of
miR-21 and miR-125b as well as decreased expression of miR-155 in relation
to K562 cells. Bortezomib, Parthenolide and Everolimus were able to induce a
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decrease in cell viability in a time-, dose- and -dependent manner. Parthenolide
and Bortezomib induce a stronger cytotoxic effect on K562 cells resistant to
Imatinib, while Everolimus shows a higher cytotoxic effect on K562 cells sen-
sitive to Imatinib. These results may be related to the differential expression of
miRNAs observed in the cell lines. These compounds induce cell death pre-
dominantly by apoptosis and also induce cell cycle arrest. Furthermore, Borte-
zomib induced a decrease in NF-κB levels and an increase in ubiquitin levels
in both cell lines and may represent a possible therapeutic alternative for CML
patients resistant to Imatinib. Moreover, it was found that Parthenolide influ-
ences NF-κB levels in a dose and cell type-dependent manner, since small
doses induce a decrease of NF-κB in Imatinib-sensitive cells, while high doses
induce a decrease of NF-κB in the resistant cell line and an increase in the
sensitive cell line. Additionally, it was also observed that treatment with these
compounds was also able to modulate miRNAs expression levels, which can
influence therapy response.
Summary and Conclusions: In summary, miR-21, miR-125b and miR-155
expression levels could provide new biomarkers predictive of response to TKI
and/or new targeted drugs such as Bortezomib, Parthenolide and Everolimus
in CML. Moreover, these drugs may be new therapeutic approaches in CML,
specially Bortezomib and Parthenolide, namely as an alternative therapy in
CML patients with resistance to Imatinib. This work was supported by CIMAGO
and R. Alves is supported by the FCT fellowship FRH/BD/51994/2012.
E1080
A STUDY OF CELL CYCLE KINETICS AND OF KU80 EXPRESSION AS A
MARKER OF GENETIC INSTABILITY IN BONE MARROW MESENCHYMAL
STEM CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
V. Papadopoulou1,* I. Anagnostopoulos1, D. Koumpi1, C. Peste1,
D. Dimitroulis2, A. Galanopoulos3, M. Sofotasiou1, A. Pouli4, P. Tsaftaridis5,
P. Zervakis1, P. Diamantopoulos1, N. Viniou1
11st Department of Internal Medicine, Hematology Unit, University of Athens,
22nd Department of Surgery, Laiko Hospital, University of Athens, 3General
Hospital ‘’G.Gennimatas’’, 4’’Agios Savvas’’ Hospital, 5Hematology Clinic, Uni-
versity of Athens, Athens, Greece
Background: In chronic myeloid leukemia (CML), there is a well-characterized
lesion of the haemopoietic stem cell; however, mechanisms underlying disease
initiation and progression are unclear. Therefore, the role of bone marrow (BM)
stromal cells in disease pathogenesis merits further investigation. In myelodys-
plastic syndromes, BM mesenchymal stem cells (MSCs) were shown to have
a proliferation defect in comparison to BM MSCs of healthy individuals.
Aims: We first examined BM MSCs of CML for cytogenetic abnormalities. We
then studied kinetics of BM MSCs from CML patients and compared them to
those of BM MSCs from healthy controls. We also measured expression of the
Ku80 protein, a protein involved in non-homologous end joining of double strand
DNA breaks, as a marker of genetic instability. We compared Ku80 expression
among BM MSCs of CML patients, adipose tissue (healthy tissue) MSCs of
CML patients and BM MSCs of healthy individuals.
Methods: Samples of seven (7) CML patients (6 diagnosed in chronic phase
and 1 in blast crisis) were collected before onset of therapy, along with samples
of 4 healthy controls. MSCs were isolated from the mononuclear cell fraction
of BM or adipose tissue via a limited number of passages, removing non-adher-
ent-to-plastic cells. Purity of MSCs from haemopoietic cell contaminants (>94%)
was confirmed by flow cytometry; mesenchymal stem cells were positive for
CD90, CD73 and CD105 and negative for CD34, CD45 and CD14. Karyotyping
was performed in BM MSCs of CML patients. BrdU and 7-AAD staining of BM
MSCs to detect S-phase and apoptotic cells, respectively, was performed via
standard protocols and stained cell populations were analyzed with flow cytom-
etry. Cell lysates of BM and adipose tissue MSCs were used in standard SDS
electrophoresis. Western blotting with the use of Ku80 and actin antibodies
was performed.
Results: Karyotypes of BM MSCs of CML patients were normal. Percentage of
S-phase cells and apoptotic cells was compared between patient BM MSCs
(20,4% S-phase, 2,7% apoptosis) and control BM MSCs (19,3% S-phase, 4,6%
apoptosis). Mean values (t-test) did not have a statistically significant difference
(p=0,88% for S-phase percentage and p=0,92% for apoptosis). The ratio of
expression Ku80/actin, calculated by densitometry of Western blotting bands,
did not differ to a statistically significant degree among: patient BM MSCs, adi-
pose tissue MSCs and control BM MSCs (one-way ANOVA for 3 groups, p=0,28).
Summary and Conclusions: Bone marrow mesenchymal stem cells in CML
are known to lack the BCR-ABL fusion gene, but their properties and possible
contribution to disease pathogenesis have not been thoroughly researched.
This is the first study of kinetics of BM MSCs in CML in the literature. We have
shown that BM MSCs display a normal karyotype and have a proliferative and
apoptotic potential equivalent to MSCs of healthy individuals. We have addi-
tionally shown that expression of Ku80, a marker of genetic instability (double
strand DNA breaks), does not significantly differ between BM MSCs of patients
and those of adipose tissue MSCs or MSCs of healthy donors. Further research
is warranted on properties of MSCs in CML, also assessing whether these
properties can be exploited in bone marrow transplantation strategies.
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Background: Insensitivity to imatinib is a property exhibited by a population of
leukemic rare, primitive stem cells that are present in most chronic myeloid
leukemia (CML) patients, even in those with sustained undetectable molecular
residual disease (UMRD). It remains unclear whether such patients are defin-
itively cured or whether leukemic stem cells (LSCs) that persist in their bone
marrow represent a risk of disease recurrence. This suggests that the charac-
terization of LSCs by functional assays could be of interest in clinical practice.
Aims: To evaluate the burden of LSCs in TKI-treated patients. 
Methods: We evaluated the presence of LSCs in patients with CML at different lev-
els of molecular response induced by imatinib or nilotinib, and patients naïve of treat-
ment. All patients gave their informed consent. Bone marrow-derived CD34+cells
were used as initiators for 2-week CFU-C and 6-week long-term culture-initiating
cell (LTC-IC) assays. Their phenotype was defined using RT-qPCR on individual (8-
10 colonies per patient) and pooled colonies (24-30 colonies per patient). 
Results: In samples from newly diagnosed patients, BCR-ABL mRNA expres-
sion was measured in individual colonies from CFU-C assays (mean %BCR-
ABL/ABL=24.0, SD=7.3, n=4). However, in LTC-IC assays, BCR-ABL mRNA
only became detectable when measured in pools of 3-15 colonies (mean
%BCR-ABL/ABL =6.6%, SD=9.6, n=3). BCR-ABL mRNA levels were highly
variable in LTC-IC-derived pooled CFU-Cs, but still lower than in 2-week CFU-
Cs (ANOVA, p<0.05) (Figure 1a). In patients under TKIs treatment, BCR-ABL
transcripts were only detectable in LTC-IC-derived pooled CFU-Cs from patients
with a high burden of disease (n=7, %BCR-ABL/ABL in peripheral blood=1.1-
7.7%), whereas no BCR-ABL transcripts were detected either in individual
colonies from patients with a high burden of disease, nor in individual or pooled
colonies from patients with deeper responses (n=5). We observed a tendency
of reduction in BCR-ABL/ABL ratios in LTC-IC-derived CFU-Cs in accordance
with a reduction in disease burden, measured at peripheral blood and in
response to TKIs treatment (Figure 1b). On the other hand, the number of
colonies (expressed as the square root of no. colonies per 1,000 initiating cells)
obtained in LTC-IC assays was higher in patients showing a deep molecular
response (defined as at least MR4.0) than for patients with a high burden of
disease (at diagnose or with at least BCR-ABL/ABL of 1%) (ANOVA, p<0.01). 
Figure 1.
Summary and Conclusions: We observed a reduction in BCR-ABL/ABL ratios
in LTC-IC-derived pooled colonies compared to CFU-Cs in newly diagnosed
patients. Given that these patients have not received any TKI treatment, this
seems to be an intrinsic characteristic of primitive precursors, unrelated to expo-
sure to TKI selective pressure. On the other hand, as the burden of disease
was reduced by TKI treatment, lower BCR-ABL/ABL ratios were detected in
the primitive fraction, suggesting that the ability to detect rare residual LSCs in
TKI-treated patients will be limited by BCR-ABL expression levels. Despite that
measuring on pooled colonies may be masking a dilution effect, the same ten-
dency has been reported for HSCs and progenitor fractions isolated by sorting
(Kumari et al, Blood 2012, 119:530-539), further suggesting that LSCs are not
oncogene-addicted. Therefore, the results obtained in this work support the
hypothesis that evaluation of minimal residual disease in candidates for dis-
continuation studies would benefit from the measurement of Ph+primitive pre-
cursors cells at DNA level, so as to accurately assess LSCs persistence.
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Background: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative
disorder characterised by the presence of the BCR-ABL fusion gene. The gold
standard treatment for CML is the tyrosine kinase inhibitor (TKI) imatinib.
Although imatinib and second generation TKIs induce durable responses, TKI
resistance is a major issue and additional therapeutic options are still required.
Proteasome inhibitors have shown efficacy in the treatment of haematological
malignancies which has validated the ubiquitin proteasome system (UPS) as
a therapeutic target; there is now interest in targeting of specific components
of the UPS, such as E3 ligases and deubiquitinating enzymes. We have shown
previously that the proteasome inhibitors, bortezomib and carfilzomib, potently
induce apoptosis in imatinib-sensitive and -resistant CML cell lines and primary
CD34+CML cells, suggesting that CML cells may be sensitive to targeting of
other UPS components. Gene expression profiling of CML CD34+cells com-
pared to normal CD34+cells using UPS-specific microarrays (PIQOR) identified
that the E3 ligase TRIM32 was overexpressed in CML (p=0.02). TRIM32 is a
member of the TRIM family of RBCC proteins; it contains a RING finger domain,
one or two B-boxes, and a predicted coiled-coil domain. Studies have shown
TRIM32 to be involved in the ubiquitination and degradation of the tumour sup-
pressor proteins abelson interactor (ABI)-2 and p53. 
Aims: The aim of this study was to examine the expression of TRIM32 in CML
cell lines and investigate its effects on ABI-2 and p53.
Methods: TRIM32 expression in KCL22 and LAMA84 imatinib sensitive and
resistant CML cell lines was analysed by qPCR and Western Blotting. ShRNA-
mediated gene knockdown was used to analyse the effects of TRIM32 on cell
viability (CellTiter-Glo®) and cell cycle (flow cytometry analysis of propidium
iodide stained cells). Following knockdown, qPCR and western blotting were
used to validate the change in TRIM32 expression. Effects of TRIM32 knock-
down on ABI-2 and p53 were analysed by Western Blotting.
Results: Increased expression of TRIM32 was validated at both the gene and
protein level in CML cell lines compared to normal cells. Following knockdown
of TRIM32 expression with shRNA, a 14.8±8.8% decrease in cell viability was
determined with a statistically significant decrease (p= 0.009) observed in
KCL22-sensitive cells. This decrease in cell viability was associated with an
increase in the subG0 population in each CML cell line. TRIM32 knockdown
resulted in an increase in ABI-2 and an increase in p53 protein levels. Further-
more we show that combining knockdown of TRIM32 with imatinib and nilotinib
treatment increases the sensitivity of CML cell lines to theTKIs. 
Summary and Conclusions: In this study we demonstrate that TRIM32 is
overexpressed in CML cells at both the RNA and protein levels. Knockdown of
TRIM32 results in decreased cell viability and increased apoptosis. This was
associated with an increase in expression of the tumour suppressors ABI-2
and p53. TRIM32 knockdown also increased sensitivity of CML cells to TKIs.
Loss of ABI-2 has been previously shown to contribute to BCR-ABL+leukaemia
progression and suppression of p53 has been seen to enhance survival and
proliferation of CML. These studies suggest that TRIM32 may be a relevant
therapeutic target in CML and further study is warranted.
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Background: Advanced phase of chronic myeloid leukemia called blastic
phase or blast crisis (CML-BC) is incurable, despite success of targeted therapy
for the chronic phase CML (CML-CP). CML-BC is characterized by successive
increase in amount of blast cells in blood and bone marrow but pathogenesis
is still poorly understood. Majority of genomic studies are focused on detecting
clonal abnormalities, which arise during the progression of the disease and
are present only in advanced phase of the disease. However, recent findings
revealed, that in addition to the t(9;22) translocation, CML-CP at diagnosis may
already harbor a variety of sporadic genetic aberrations affecting the prognosis
and treatment.
Aims: We aimed at employing targeted deep-sequencing strategy to dissect
the underlying genetic cause of clonal evolution and rapid progression to
CML-BC in a patient who relapsed after allogeneic haematopoietic stem cell
transplantation (HSCT), developed lymphoid CML-BCs and died within 18
months.
Methods: Targeted enrichment strategy (NimbleGene SeqCap EZ Choice cus-
tom gene panel comprising almost 1000 genes) was applied followed by mas-
sive-parallel sequencing using the Illumina HiSeq1500 system and chemistry.
The data were processed by the CASAVA. Reads were mapped to the refer-
ence genome (hg19 build) using Burrows-Wheeler Aligner 6.2 and processed
using Genome Analysis Toolkit. The detected variants were annotated using
Annovar. Alignments were viewed with Integrative Genomics Viewer.
Results: Female patient (30-yrs old) was diagnosed with CML in 12/2005 (low
Sokal and Hasford score and no detectable clonal cytogenetic abnormalities
(CCA) additional to Philadelphia chromosome). Within 6 months from the diag-
nosis patient underwent allo-HSCT and achieved 100% chimerism and com-
plete cytogenetic remission (CCyR) but not a major molecular response (MMR).
After 4 months, patient relapsed with lymphoid BC with no detectable
BCR/ABL1mutation at that time. Despite intensive chemotherapy and imatinib
patient developed within few months 2nd BC and Y253H mutation in BCR-
ABL1 was detected. Then dasatinib was added to chemotherapy and patient
obtained partial remission. Unfortunately, 14 months after transplantation
patient developed 3rd BC with detectable BCR-ABL1 T315I mutation and died.
Since there were no CCA detected at any time point, we screened four sequen-
tial DNA samples (peripheral blood leukocytes): one from the time of diagnosis
and three samples from three consecutive BCs with targeted deep sequencing.
We detected a nonsense R320* RUNX1mutation, resulting in carboxyl-terminal
truncated RUNX1 protein in all 4 samples. Importantly, this mutation was
already present in the diagnostic sample, although the prevalence of mutated
clone was low (1%). In the BC samples RUNX1mut. clone rised and ranged
between 90% to 50% of CML blasts (Figure 1). We have also confirmed both
BCR-ABL1 mutations previously detected with standard sequencing. Interest-
ingly appearance of T315 clone in the 3rd BC was associated with lower fre-
quency of RUNX1mutated clone (Figure1). No BCR-ABL1 gene mutation was
detected by NGS sequencing in diagnostic sample nor in the 1st BC. Addition-
ally, missense mutation in ASXL1 (Q1102N) was detected in all samples, con-
sistent with observation in acute myeloid leukemia (AML),where mutations in
ASXL1 frequently co-occurs with RUNX1.
Figure 1. Frequency of RUNX1-mutated and BCR-ABL1-mutated clones
during progression and subsequent CML-BCs.
Summary and Conclusions: Deregulation of RUNX1 transcription factor by
chromosomal translocation or mutation are common events in haematological
malignancies, especially in AML. In CML-BC RUNX1 mutations have been
reported in few studies. We have shown that RUNX1mutation may be already
present in CML -CP at diagnosis and may potentially occur as a pre-leukemic
event prior to t(9;22) translocation (as also recently described by Schmidt et
al., Leukemia 2014; 28(12); 2292-9). Genetic screening of a large cohort of
patients at diagnosis may answer if presence of CML cells with RUNX1 muta-
tion at diagnosis confers a negative prognostic factor.
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Background: The identification of leukemia associated fusion genes is critical
for the correct diagnosis, choice of therapy and molecular monitoring of hema-
tological malignancies. Although usually inferred by cytogenetic analysis, the
precise identification of fusion genes typically requires specific PCR amplifica-
tion from cDNA and careful positioning of primers to enable detection of all
possible mRNA variants. Identification of gene fusions from genomic DNA is
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technically much more demanding since for many genes the breakpoints are
dispersed over large regions, for example >100kb in the case of ABL1. Never-
theless, the identification of genomic breakpoints provides some potential
advantages, for example patient-specific molecular monitoring using genomic
DNA enables the cellular burden of residual disease to be estimated much
more accurately than RT-PCR based methods. Furthermore, genomic DNA
assays facilitate much more sensitive detection of residual disease. We have
previously described long range PCRs (up to 10 kb) that amplify genomic break-
points of two fusions, BCR-ABL1 and FIP1L1-PDGFRA, with subsequent break-
point identification by more focused PCR and Sanger sequencing. It is expected
that new sequencing technologies will simplify this process, ideally allowing ab
initio identification of any fusion gene present from genomic DNA. The Oxford
Nanopore MinION is a miniature sensing system currently adapted for DNA
single molecule sequence analysis. A DNA strand passes through a nanopore
which registers a change in current allowing determination of nucleotide
sequence. The MinION device is currently being made available by Oxford
Nanopore though an early access program.
Aims: To assess Nanopore technology for sequencing long range PCR prod-
ucts to identify precise translocation breakpoints.
Methods: Long range PCR products encompassing genomic fusions were
amplified from BCR-ABL1 (n=4) and FIP1L1-PDGFRA (n=5) positive samples.
PCR products were processed according to the Oxford Nanopore genomic
DNA protocol which involves end repair, dA-tailing, ligation of adapter, HP motor
and tether. FIP1L1-PDGFRA fragments were sequenced using R6 flow cell
chemistry and BCR-ABL1 fragments using R7 chemistry. Samples were run
sequentially with washing between samples. Reads were aligned to the refer-
ence genome and split at their ‘soft’ or ‘hard’ clip sites using an in-house pro-
gramme. The resulting daughter reads were subjected to another round of
alignment in order to finely map fusion breakpoints.
Results: A median of 40 reads (range 7 - 458) passing internal quality control
were obtained per sample, of these 26% (11%>100%) were 2D reads i.e. were
read in both directions and therefore of higher quality. Median read length of
2D reads was 2980bp (range 318-7729) and consistent with PCR fragment
sizes. Only 2D reads were considered in subsequent analyses. During the initial
alignment phase 61% (33-100%) aligned to within 50bp of one of the amplifi-
cation primer sequences. The location of the breakpoints determined by
Nanopore sequencing were fully concordant with breakpoints determined by
focused PCR and Sanger sequencing in five samples, the remainder had insuf-
ficient read depth.
Summary and Conclusions: We conclude that LR-PCR and Nanopore
sequencing provides a rapid approach to characterize genomic breakpoints in
leukemia. Nanopore technology is rapidly improving and recent developments
promise improved accuracy, particularly for 2D reads.
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THE STUDY OF FUNCTIONAL ACTIVITY OF CD34 CELLS IN CML
PATIENTS WITH DIFFERENT RESPONSE TO IMATINIB THERAPY
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Background: It is believed that the reason of the leukemic clone cell resistance
to treatment with tyrosine kinase inhibitors in CML patients is mutations in the
genome of an early bone marrow progenitor cells that are CD34-positive. Such
cells, regardless of treatment, acquire ability to proliferation and differentiation.
This leads to the re-expansion of the CD34-positive cells.
Aims: was to determine the features of CD34 antigen expression in bone mar-
row (BM) and peripheral blood (PB) in CML patients with different response to
imatinib therapy using the results of hematopoietic cells culturing and the data
of flow cytometry.
Methods: We studied the BM samples of 41 CML patients in chronic phase of
disease treated with imatinib for at least 12 months. To determine the functional
activity of hematopoietic cells of patients in vitro culturing of BM mononuclear
cells in semisolid agar (“Difco”, USA). To assess the phenotypic characteristics
of hematopoietic cells of patients the method of direct cytometry was used. For
this purpose, BM mononuclear cells were stained with monoclonal antibodies
(Becton Dickinson, USA). 
Results: The results of cultivation suggest that in patients with an optimal
response to imatinib therapy the number of colonies was 1.8 times lower than
the number of those in the group of patients with suboptimal response to ther-
apy. In turn, in patients with failure of imatinib therapy the number of colonies
was the highest and was 2.1 times higher than the patients with optimal
response. In the case of clusters was recorded tendency to increase this indi-
cator in patients with suboptimal response and treatment failure. In addition,
the patients with inefficiency and suboptimal response to imatinib therapy had
the significantly higher proliferative potential than in patients with optimal
response. This may indicate that early progenitor cells dominated the more dif-
ferentiated cells which form clusters in the culture. In turn, in the BM of patients
who have increasing numbers of leukemic clone cells proliferation processes
dominate over the processes of differentiation that may be the cause of the
increase of the number of colonies in semisolid agar in vitro. The results of
cytometry analysis showed that in patients with the acquisition of resistance to
imatinib the number of CD34+cells increases in the BM and PB. It should be
noted, in patients with different response to therapy the number of CD34 antigen
in BM and PB was significantly different. This may indicate that during the pro-
gression of CML and during the acquisition of resistance to the drug by leukemic
clone cells the pool of early progenitor cells not only expands, but also, due to
the weakening of contacts between the cells of the microenvironment and
leukemic clone cells, the early progenitor cells fall in blood flow in large num-
bers, promoting a poorly differentiated hematopoietic cells in PB of patients. A
correlation analysis was conducted to identify the correspondence between
the number of CD34 cells in the BM and in PB of patients treated with imatinib.
These results indicate a direct correlation between the number of colonies and
clusters in semisolid agar in vitro and the number of CD34 cells in the patient
BM (R=0,83 and R=0,58, p<0.05). 
Summary and Conclusions: Thus, the number of CD34 cells in the BM of
patients increases with the acquisition of leukemic clone cells resistance to
imatinib. The correlation between the number of CD34 cells and the number of
cell aggregates in semisolid agar in vitro, which may be predictive method for
determining the future course of CML, shows the prognostic value of method
for determining the CD34 cells in the BM of patients; and a parallel increase of
their number in PB will allow to develop express methods for the detection of
individual patient response to imatinib therapy.
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TYROSINE KINASE INHIBITOR THERAPY INDUCES ALTERATIONS OF
CD137 AND CD137L EXPRESSION IN CHRONIC MYELOID LEUKEMIA
PATIENTS
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Background: CD137 (4-1BB, TNFRSF9) is a member of the TNFR superfamily
that provides expansion and survival signals to T cells. In addition to the ability
to costimulate T cells, CD137 ligand (CD137L) also signals back into antigen
presenting cells, promoting their activation and differentiation. Recently, CD137
has been proposed as a therapeutic target to improve and sustain anticancer
immune response. Expression of CD137 or CD137L was described in T
leukemia and B lymphoma activated cell lines, respectively, and soluble
CD137L has been found in sera of leukemia patients. However, the role of
these costimulatory molecules in hematologic malignancies is still unknown.
Aims: The aim of the present study was to evaluate CD137/CD137L role in Chron-
ic Myeloid Leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI).
Methods: In this study, approved by the Hospital and University Center of
Coimbra ethics committee, peripheral blood mononuclear cells from 60 patients
with CML, treated with imatinib mesylate and 39 blood donors were analyzed
for membrane expression (CD137 and CD137L) and intracellular cytokine (IFNγ
and TNFα) content in T (CD3+, CD4/CD8), B (CD19) and NK (CD3-CD56+)
cells using flow cytometry. In vitro 4-hours stimulation with LPS or PMA/iono-
mycin was performed in order to evaluate the impact on CD137/CD137L
expression. Soluble CD137 was analyzed by ELISA in patients sera and super-
natants of stimulation experiments. Gene expression profiling for cytokines
(IFNG, IL1B, IL2, IL4, IL6, IL10, IL12, TNFA, TGFB), granules (perforin,
granzyme and granulysin), caspases (CASP3 and CASP9) and reference
genes (ATP5B, SDHA and UBC) was performed for all samples. Additionally,
miRNA profiling was performed by RT-qPCR.
Results: Soluble CD137 was significantly increased in sera and supernatants
of in vitro stimulated PBMCs from CML patients. CD137 and CD137L were
found in T (CD4 and CD8), B and NK cells from CML patients. CD137 was
mainly expressed in CD8+T cells and CD137L was significantly detected in
CD4+T cells, but was also found in B and NK cells. Expression of CD137 and
CD137L positively correlated with TKI dose. These results were accompanied
by the increased production of IFN-γ. Gene expression of IFN-γ, granzyme B
and perforin was found to be upregulated in TKI-treated patients, compared to
TKI-naïve patients and healthy controls. Analysis of miRNAs that were predicted
as targeting TNFRSF9 and TNFSF9, revealed a significant increase of hsa-
mir-886-3p. The analysis of miRNAs associated with CD137 signaling pathway
and the induction of IFN-g via the ADAP-CBM signaling module (Lck, Fyn,
ADAP, CARMA/CARD11, Bcl-10, MALT1, c-Jun and IFN-γ) showed no corre-
lation in TKI treated CML patients.
Summary and Conclusions: Taking together, our results suggest that
CD137/CD137L signaling should be further investigated in CML patients under-
going TKI therapy to improve and sustain anticancer immune response.
Financial Support: FEDER (Programa Operacional Factores de Competitivi-
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dade – COMPETE) and FCT (Fundação para a Ciência e a Tecnologia) through
project PEst-C/SAU/LA0001/2013-2014.
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METABOLIC CHARACTERISTICS OF IMATINIB RESISTANT CHRONIC
MYELOID LEUKEMIA WITH T315I MUTATION
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Background: Imatinib resistant chronic myeloid leukemia (CML) cells made
by treatment of low dose imatinib in long period has known metabolic pheno-
types as more glycolysis and fatty acid synthesis compared with imatinib sen-
sitive cells. But metabolic characteristics of T315I mutant CML cells which
accounts for ~20% of the total burden in CML patients remains unknown.
Aims: Differenced metabolic characteristics of T315I mutant in CML cells could
provide opportunity as therapeutic target. Two human CML cell lines, KBM5
(imatinib-sensitive) and KBM5-T315I (imatinib-resistant) were analyzed to
assess metabolic phenotypes, including cell proliferation, oxygen consumption,
lactate production and redox state.
Methods: Metabolic phenotype between KBM5 and KBM5-T315I without ima-
tinib has been identified as the therapeutic target by molecular biologic methods
including measurement of cell viability, western blot and realtime-PCR.
Results: Unlike previously reported imatinib resistant cells, we found that
genetically mutated T315I cells showed decreased cell proliferation rate, lactate
production, fatty acid synthesis and Glucose-6-phosphate dehydrogenase
(G6PD), which is enzyme in the pentose phosphate pathway by maintaining
the level of the co-enzyme nicotinamide adenine dinucleotide phosphate
(NADPH), compared with KBM5 without imatinib. This result correlated with
decrease of cellular reactive oxygen species (ROS) and mRNA expression of
ROS scavengers, including SOD1, 2, catalase and enzymes related gulu-
tathione, which is an important antioxidant. Although basal mitochondrial oxy-
gen consumption had no difference between KBM5 and KBM5-T315I, mito-
chondrial maximal capacity and Isocitrate dehydrogenase 2 (IDH2) was higher
in T315I mutant.
Summary and Conclusions: Thus, we described changed specific metabolic
markers in T315I mutant in CML. Differenced metabolic characteristics of T315I
mutant might be considered for finding therapeutic target of imatinib resist-
ance.
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MISSPLICED GSK3Β TRANSCRIPT IS UNIVERSALLY EXPRESSED AND
CANNOT BE USED TO PREDICT BLAST CRISIS TRANSFORMATION IN
CHRONIC MYELOID LEUKAEMIA
L. Wang1,2,* G. Austin2, R. Clark2
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Background: GSK3β (glycogen synthase kinase 3β) has been shown to be
misspliced in its kinase domain in granulocyte/macrophage precursors (GMP)
in blast crisis (BC) samples of chronic myeloid leukaemia (CML). The misspliced
GSK3β could enhance β-catenin expression and self-renewal ability of CML
BC progenitors. Moreover it was also demonstrated that the misspliced GSK3β
was not detected by sequencing in more primitive CML blasts or normal sam-
ples.
Aims: Here we investigated the presence of the misspliced form of GSK3β
transcript in a broader population of peripheral blood white cell samples from
CML chronic phase (CP), blast crisis (BC), de novo Ph+acute leukaemia,
healthy volunteers and in vitro immortalised cell lines.
Methods: Peripheral blood white blood cells were separated and RNA was
extracted and cDNA synthesised. Long range RT-PCR was performed to ampli-
fy the full length of the GSK3β coding region. Nested PCR steps were subse-
quently used to amplify exons 1-6 and exons 5-12. In addition, nested PCR
steps were performed to amplify exons 6-10 and exons 10-12. PCR products
were then run on an agarose gel. Products on the agarose from selected sam-
ples were purified from the gel and cloned into p-GEMTeasy vector to be
sequenced. Allele specific real-time RT-PCR primers were designed to quantify
the transcript level of misspliced GSK3β (exon 8 and 9 deleted). The specificity
of the allele specific PCR primers were confirmed by PCR product direct
sequencing using both forward and reverse primers. The misspliced GSK3β
transcript levels were normalised to the levels of dominant GSK3β transcripts
(GSK3β with exon 9 deleted). The misspliced GSK3β to dominant GSK3β tran-
script ratio in KYO-1 cells was considered as an arbitrary unit of 1.0.
Results: It was found the misspliced GSK3β transcripts could be detected in
CML CP (6/12), BC (12/13), de novo Ph+acute leukaemia (7/9), the CML cell
lines KYO-1, LAMA84, the T cell leukaemia line Jurkat, and the hepatoma cell
line HepG2. The dominant GSK3β transcript in all samples tested was GSK3β
with exon 9 deleted. It was showed by using allele specific real-time RT-PCR
that CD34+cells separated from newly diagnosed CP CML had greater levels
of misspliced GSK3β than matched mononuclear cells (n=6, p=0.028, Wilcoxon
signed-rank test). For 9 cases of CML who had transformed to BC, the miss-
pliced GSK3β levels at BC stage were greater than those at the CP stage
(p=0.008, Wilcoxon signed-rank test). However no significant difference was
found between CML CP (n=50), CML BC (n=34) and de novo Ph+acute
leukaemia (n=15). Furthermore, at diagnosis of CP (prior to imatinib treatment),
there was no significant difference in misspliced GSK3β levels between patients
who achieved complete cytogenetic response after 12 months treatment
(n=26), those who had no cytogenetic response (n=23) and those who subse-
quently progressed to BC (n=6).
Summary and Conclusions: The misspliced GSK3β transcript can be detect-
ed at various levels in a wide range of cells from CML CP, CML BC and healthy
volunteers. Transcript levels of the misspliced GSK3β do not appear to be use-
ful as a prognostic marker to predict the progression of CML.
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Background: Bioactive sphingolipids, found in cellular membranes, are impor-
tant molecules that have vital roles affecting several cellular events such as
proliferation, apoptosis, senescence, cell cycle arrest, angiogenesis, and trans-
formation. Ceramide, the central molecule of bioactive sphingolipid metabolism,
is synthesized de novo by the activity of ceramide synthases (CERS1-6), where-
as clearence of ceramide is carried out by the activity of glucosylceramide syn-
thase (GCS) and sphingosine kinase 1 (SK1). While ceramide is a powerful
pro-apoptotic molecule, glucosylceramide generated from ceramide via GCS,
and S1P generated from ceramide via SK1 are powerful anti-apoptotic mole-
cules. Previous studies from our lab revealed that increased ceramide or
decreased GCS and SK1 levels in tyrosine kinase inhibitor (TKI)- sensitive and
–resistant CML cell lines result in trigger of apoptotic pathways while increased
intracellular GCS and SK1 levels trigger the pathways related to cell survival.
Additionally, for the first time, we revealed that sensitivity of CML cell lines
against TKIs can be increased via targeting bioactive sphingolipids. So far, there
is no study about the roles of bioactive sphingolipids in CML patient samples.
Aims: In this study, our goal was to determine the potential relation between
bioactive sphingolipids and disease progression in CML patients newly diagnosed,
TKI-treated and shown hematological response (HR), and also TKI-resistant. Our
additional goal was to confirm our previous data obtained in CML cell lines.
Methods: Bone marrows were harvested from CML patients with different disease
profiles, and mononuclear cells were isolated by lysis buffer. cDNA was synthe-
sized by reverse transcription from RNAs isolated from the cells. Expression levels
of CERS1, -2, -3, -4, -5, and -6, GCS, SK1, and BCR/ABL genes were analyzed
via quantitative real-time PCR. In this study, totally 66 CML patients including 33
newly diagnosed, 14 imatinib-treated, 2 nilotinib-treated, 3 dasatinib-treated, 6
imatinib-resistant, 1 nilotinib-resistant, 1 dasatinib-resistant, 1 dasatinib&nilotinib-
resistant, 2 imatinib&nilotinib-resistant, and 3 blastic phase were involved.
Results: Our results revealed that expression levels of CERS1-6 genes were
higher in the patients treated with TKIs and shown HR than the patients newly
diagnosed or TKI-resistant. GCS and SK1 expression levels were markedly
greater in TKI-resistant patients than that of newly diagnosed or TKI-treated
and shown HR. Moreover, comparison of the expression levels of the genes
mentioned above in bone marrow samples harvested from the particular
patients at once in six months periods showed that while CERS1, -2, -3, and -
6 expressions increased, GCS and SK1 expressions decreased by the time in
the patients treated with TKIs and shown HR. Additionally, GCS and SK1
expressions were found increased, whereas expression levels of CERS genes
decreased in the patients developing TKI-resistance.
Summary and Conclusions: The results of this study revealed for the first
time that there might be a strong relation between TKI-sensitivity or resistance
and the expression levels of bioactive sphingolipid genes in CML patients.
More importantly, our results demonstrated that expression levels of bioactive
sphingolipid synthesis genes might be decisive markers for predicting TKI-
resistance as well as novel targets for more effective therapy in CML patients.
Our project was supported by The Scientific and Technological Research Coun-
cil of Turkey with the Project number 111S392.
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Background: The best treatment strategy for patients with chronic myeloid
leukemia (CML) is still a matter of debate. Since the introduction of the BCR-
ABL tyrosine-kinase inhibitor (TKI) imatinib in 1998, CML patients have expe-
rienced a significant improvement in overall survival. Prior to the usage of TKIs,
the 10-year survival rate was 20%, therefore imatinib 400 mg nowadays is rec-
ommended as standard treatment. Currently, published evidence of second
generation TKIs also recommends dasatinib and nilotinib as first-line therapy.
However, direct head-to-head comparisons of second generation TKIs, which
are important for a clinical decision-making, are lacking.
Aims: To assess the benefits and risks of different initial treatment strategies
with TKIs for patients with CML in chronic phase and to provide patients and
physicians with a high-level evidence for treatment decisions.
Methods: Data sources: We developed sensitive search strategies for CEN-
TRAL, MEDLINE, and conference proceedings (searched from 1990 to
12/2014). Study selection and data extraction: Randomized controlled trials
that evaluated in at least one arm a regimen including a TKI as first-line therapy
in patients with CML in chronic phase. Two authors independently assessed
studies for eligibility. We extracted data and assessed quality of trials in dupli-
cate. The primary outcome was major molecular response (MMR). Secondary
outcomes included complete cytogenetic response (CCyR), overall survival
and adverse events. Data synthesis: Effect measures were risk ratios (RR) for
complete MMR, CCyR and adverse events, and hazard ratios (HR) for OS. We
pooled data using network meta-analysis. Direct comparisons within trials were
combined with indirect evidence from other trials by using a Bayesian random-
effects model. We evaluated both, the full network including all trials reporting
the outcome and a core network including only those regimens that were eval-
uated in at least two trials. Results are reported relative to imatinib 400 mg with
a RR <1 and HR >1 indicating superiority of imatinib 400mg. This project was
funded by the Federal Ministry of Education and Research, grant number:
01KG1112.
Results: The systematic search resulted in a database including 1,114 poten-
tially important references. Of those, 16 final RCTs from 209 publications were
identified and included into the network-analysis. These trials assessed the
effects of 14 various treatment arms and 18 comparisons for 6,314 patients
with CML. Nilotinib was associated with the highest chance to be best (41.9%)
in terms of MMR at 12 months (nilotinib 600 mg RR 1.99, 95%>credibility inter-
val (CrI) 1.45 to 2.74 and nilotinib 800 mg RR 1.85, 95%>CrI 1.24 to 2.78,
respectively) in the full network meta-analysis (see figure 1). This effect is even
more pronounced in the core network with a probability to be best of 83.1%.
Dasatinib 100 mg (RR 1.58, 95% Crl 1.16 to 2.13) and imatinib 800 mg (RR
1.45, 95% Crl 1.13 to 1.85) might be superior to imatinib 400 mg as well. All
other treatment strategies and the results for CCyR showed no statistically sig-
nificant difference to imatinib 400 mg. There are few events for OS, and thus
results are not conclusive (i.e.wide 95% CrI). Results regarding adverse events
will be reported in due course. Between-trial heterogeneity was negligible in all
three analyses (tau-square 0.01, 0.02, and 0.05, respectively).
Table 1.
Summary and Conclusions: The comparison of different first-line treatment
strategies for CML patients in this network meta-analysis shows a significant
and relevant nilotinib advantage over standard imatinib 400 mg treatment. This
analysis provides the currently best available evidence of different initial treat-
ment strategies for chronic phase CML patients and therefore adds valid and
important information for both, patients and physicians. However, some of the
regimens were only evaluated in one trial with a limited number of patients,
leading to imprecise results. 
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Background: Since the recent several reports have shown that imatinib (IM)
discontinuation can be employed in patients who had enough IM therapy and
undetectable molecular residual disease (UMRD) durations prior to IM discon-
tinuation, treatment-free remission (TFR) has emerged as a goal in chronic
myeloid leukemia (CML) treatment. Although UMRD with a sensitivity of 4.5
log for at least 2 years is required for a trial of TFR and factors associated with
a higher rate of sustained UMRD after IM cessation have found, precise iden-
tification of the minimum requirement for a safer, successful TFR and the under-
lying mechanism of sustained UMRD thus remains elusive. In addition, the
possibility of the second attempt to discontinue IM in patients with second sus-
tained UMRD who experienced loss of MMR after first IM discontinuation was
suggested.
Aims: The aim of this study is to identify predictors for safer, successful IM dis-
continuation and to explore additional contributing factors for sustained molec-
ular responses.
Methods: CP CML patients who were treated with IM for more than 3 years
and had undetectable levels of BCR-ABL1 transcripts determined by quantita-
tive reverse transcriptase polymerase chain reaction for at least 2 years were
eligible for Korean Imatinib Discontinuation (KID) study. In this analysis, the
patients with at least 6 months of follow-up were included, with the exception
of the patients who received IM for post-transplant relapse. In case of relapse,
defined as loss of MMR on 2 consecutive assessments, IM therapy was re-
introduced. If the patients re-achieved and maintained second UMRD for at
least 2 years, second IM discontinuation was allowed.
Results: A total of 92 patients (52 females, 40 males) with follow-up of ≥6
months were analyzed, with a median age of 49 years (range, 21-77). After a
median follow-up of 20.2 (range, 6.6-52.1) months after IM discontinuation, 46
patients (50%) lost UMRD. Of the 46 patients who lost UMRD but not MMR
exhibited different patterns of BCR-ABL1 kinetics; 7 patients spontaneously re-
achieved UMRD and 2 patients showed fluctuation of BCR-ABL1 transcript
under the level of 0.1% on IS, while the other 37 patients lost MMR by 2 con-
secutive analyses. Probabilities for sustained MMR at 12 months and 24 months
were 61.7% and 58.3%, respectively. All 37 patients who lost MMR were re-
treated with IM therapy for a median of 12.3 months (range, 0.3-41.4 months).
Among them, 30 patients re-achieved MMR at a median of 4.2 months (range,
0.5-11.1 months) after resuming IM therapy. In the univariate analysis, positivity
of digital PCR at screening, IM duration and UMRD duration before IM discon-
tinuation, and aggravation or newly development of musculoskeletal pain had
a higher probability of sustained MMR. In addition, three patients who re-
achieved and maintained second UMRD for 23.9, 25.3, and 25.3 months,
respectively entered into the second IM discontinuation, among whom 2
patients re-lost MMR after 2 months and 1 patients sustained MMR during 6
months.
Summary and Conclusions: Our data suggest the predictive factors for sus-
tained MMR which may provide additional information to guide clinical decisions
on the TFR study and the possibility of the second attempt to discontinue IM.
Overall, positivity of digital PCR at screening, both UMRD and IM duration, and
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IM withdrawal symptom were predictive factors for successful IM-off. Further
studies on underlying mechanisms about immunological control, minimal resid-
ual leukemia and stem cell biology during TKI-off study should be conducted.
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Background: In the tyrosine kinase inhibitor (TKI) era, imatinib is often the
first-line therapy for chronic myeloid leukemia (CML) patients in either the
chronic or the accelerated phases. However, even though second-generation
TKIs (TKI2) including dasatinib and nilotinib are appropriate options for patients
with disease progression to the accelerated phase following imatinib therapy,
allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only cur-
ative therapy. Nevertheless, the second-generation TKIs (TKI2) including nilo-
tinib and dasatinib can induce a faster and stronger molecular response and
may achieve better OS and PFS than first-generation TKIs. Meanwhile, great
progression has been achieved in human leukocyte antigen (HLA)-mis-
matched/haploidentical HSCT recently, the clinical results of which are com-
parable to that of matched sibling HSCT. Now, almost every patient can have
a donor. We recently reported that haploidentical HSCT affords a 4-year OS
rate of 73.3% for CML in AP. However, the efficacy of TKI2 has not been com-
pared with that of HSCT.
Aims: This study retrospectively analyzed the data from the Chinese CML
alliance database to compare the efficacy of TKI2 and HSCT for the treatment
of CML in AP.
Methods: This study retrospectively analyzed the efficacy of TKI2 and HSCT
for the treatment of CML in the accelerated phase. Ninety-three CML patients
registered in the Chinese CML alliance database from February 2001 to Feb-
ruary 2014 were enrolled. Patients were divided into the TKI2 (n=33) and allo-
HSCT (n=60) groups. Twenty-six patients toke Nilotinib as initial TKI2, 7 patients
toke Dasatinib as initial TKI2. Eleven patients exchanged to the alternative TKI2
after failure to one TKI2. Sixty patients received HSCT; 22 (36.7%), 35 (58.3%),
and 3 (10%) patients underwent allo-HSCT from an HLA-matched sibling donor,
HLA mismatched/haploidentical donor and unrelated donor respectively.
Results: All patients in HSCT group engrafted. Overall, 69.7% of patients had
hematological response, 48.5% had cytogeneic response, 45.5% had MMR.
to at least one of TKI2.. Sity (100%) patients achieved CHR and cytogenetic
response in HSCT group patients. The 5-year overall survival rate was signif-
icantly lower in the TKI2 group than the allo-HSCT group (42.9% vs. 86.4%,
P=0.002). The 5-year event-free survival rate was significantly lower in TKI2
group than the allo-HSCT group (14.3% vs. 76.1%, P<0.001). The 5-year pro-
gression-free survival rate was significantly lower in the TKI2 group than the
allo-HSCT group (28.6% vs.78.1%, P <0.001). Multivariate analysis showed
that male sex and TKI2 therapy were predictors of poor OS, while hemoglobin
<100 g/L and TKI2 therapy were predictors of poor EFS and PFS.
Summary and Conclusions: These results indicate allo-HSCT may be supe-
rior to nilotinib and dasatinib for adults CML patients in the accelerated phase.
Prospective trial is needed in the future.
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Background: Medication non-adherence (MNA) to tyrosine kinase inhibitors
(TKIs) occurs in around 30% of chronic myeloid leukemia (CML) patients. Elec-
tronically measured MNA to TKIs is associated with less favorable outcomes.
There are no proven strategies for improving adherence or identifying patients
at risk for non-adherence in CML. Modifiable risk factors for non-adherence
may guide intervention development yet have mainly been studied for imatinib
alone, based primarily on adherence measured by pharmacy refill records, pill
counts and subjective measures such as collateral and self-reports. Electron-
ically measured adherence to imatinib was reported primarily in the landmark
study by Marin et al, while electronically measured adherence to nilotinib and
dasatinib has not yet been reported. 
Aims: (1) To determine the period prevalence of electronically-assessed MNA
to TKIs; (2) To assess which factors are associated with MNA to TKIs.
Methods: We used baseline data of the TAKE-IT study (NCT01768689), a
prospective Israeli multicenter (N=4) pre-post adherence intervention study in
CML. A convenience sample of 56 adults with chronic phase CML receiving
imatinib, nilotinib or dasatinib, for ≥3 months before study inclusion were includ-
ed. Sample characteristics were as follows: median age, 60.5 [IQR 19] years;
prior disease duration, 43 [IQR 81] months; current TKI treatment duration, 34
[IQR 61] months; line of TKI treatment: 1st=62.5%, 2nd=28.5%, 3rd=9%; type
of TKI: imatinib 59%, nilotinib 18%, dasatinib 23%; optimal response at baseline
according to the ELN(2013) guidelines, 93%; membership in a CML advocates
(support) group, 50%. Period prevalence of TKIs adherence was assessed
using electronic monitoring during a 3 month period and expressed as a per-
centage of the prescribed doses taken over 3 months. Selected socio-demo-
graphic, patient, treatment, condition and healthcare system-related (according
to WHO taxonomy) risk factors of TKI MNA were assessed (For overview see
Table 1). Simple linear regression was used to identify risk factors associated
with TKIs MNA. Statistical significance was set at p<0.05.
Results: Median period prevalence of TKI adherence was 97.7% (IQR: 6.6%;
range: 48%>100%). We found the following sociodemographic factors, i.e.
younger age, Arab ethnicity (perhaps reflecting health inequalities), living alone;
patient related factor, i.e. non-membership in a CML advocates group; condition
related factor, i.e. prolonged duration of CML; treatment related factors, i.e.
advanced line of treatment, Nilotinib treatment; and healthcare system factor,
i.e. study center, to be significant predictors of TKI MNA (see Table 1). 
Table 1.
Summary and Conclusions: TKI adherence was high yet showed large vari-
ability. We identified several multi-level risk factors of TKI MNA, most of them
congruent with the chronic care literature. Half of the risk-factors identified are
modifiable and can thus guide intervention development in the future, optimally
targeting the different domains of the WHO taxonomy. Of special interest is
decreased adherence with Nilotinib, taken twice daily while fasting, as opposed
to imatinib and dasatinib. This may be a proxy for increased treatment com-
plexity, or for non-adherent patients receiving advanced lines of treatment due
MNA-driven failure of 1st line treatment. This must be taken in the context of
conflicting findings from previous studies comparing adherence between var-
ious TKIs. Study center may be a proxy for practice patterns or differences in
case mix treated. Non-membership in a patient’s advocate group as risk factor
for MNA is an interesting novel finding. Such groups might provide informational
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and other types of social support favoring adherence. In conclusion, our study
quantifies MNA to different TKI regimens and provides guidance for identifying
patients at risk, as well as ideas regarding which factors could be targeted for
intervention.
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Background: In the era of molecular hematology, the prognosis of BCR-
ABL+chronic myeloid leukemia (CML) is still based on three prognostic systems
including few clinical and hematological variables: age, platelet count, blast
cells, eosinophils, basophils (percentage in peripheral blood) and spleen size
(assessed by manual palpation; maximum distance in cm from costal margin).
The three prognostic systems are the Sokal score (Sokal et al, Blood
1984;63:789-799), the EURO score (Hasford et al, J Natl Cancer Inst
1998;90:850-858), and the EUTOS score (Hasford et al, Blood 2011;118:686-
692), based on the analysis of international, multicentric series of newly diag-
nosed, chronic phase (CP) CML patients, treated with conventional chemother-
apy (Sokal), interferon-alfa (IFNa)-based regimes (EURO), or imatinib-based
regimes (EUTOS), respectively.
Aims: In all the main studies exploring the efficacy of tyrosine-kinase inhibitors
(TKIs), at least one of these scores has been used: all three scores were able
to predict the response and/or the outcome, but the three scores are different,
and there is no agreement on which score may be more useful and should be
adopted. The aim of our analysis was to identify which score has been more
frequently used and which one is able to give more consistent results.
Methods: We reviewed the most relevant reports of the 13 important clinical
studies, published in peer-reviewed journals between 2003 and 2014. More-
over, we analyzed 559 patients enrolled within 3 multicentric prospective studies
conducted by the GIMEMA CML WP (NCT00514488, NCT00510926, obser-
vational trial CML023).
Table 1. Cytogenetic and molecular response according to Sokal, EURO
and EUTOS score in 13 selected clinical studies, published in
peer-reviewed journals between 2003 and 2014.
Results: The Sokal score was used in 12 studies, the EURO score in 2 studies,
the EUTOS score in 4 studies (Table 1). The results are difficult to interpret,
because sometimes only the p-values for differences (not the response rates),
and sometimes only the response rates (not the p-value) were reported. The
relationship between the risk and survival was analyzed in few studies: the
Sokal score was able to predict the survival in three studies (Hammersmith,
Czeck registry and Swedish registry), the EURO in only one study (Swedish
registry), and the EUTOS in no studies. Therefore, we tested all three scores
in 559 newly diagnosed CP-CML patients who were enrolled in GIMEMA studies
with imatinib front-line. No score was able to predict the early molecular
response. The complete cytogenetic response (CCyR) and the major molecular
response (MMR) rates by 1 year were better predicted by Sokal (p=.006 and.
001) and EURO (p=.002 and .002) scores than by EUTOS score (p=.009 and
.010). The rate of deep molecular response (MR4.0) by 6 years was better pre-
dicted by Sokal score (p<.001) than by EURO (p=.019) or EUTOS (p=.031)
score. The 6-year overall survival was better predicted by Sokal (p=.002) and
EURO (p=.003) score than by EUTOS score (p=.160).
Summary and Conclusions: There are no studies supporting the superiority
of any risk score over the others. The EUTOS score could be the first choice
because based on TKIs-treated patients. However, the Sokal score may still
be considered the reference risk score, because it has been validated in many
more independent studies, with more consistent results. All the three scores
could be refined introducing other biological variables (i.e. clonal chromosome
abnormalities in Ph+cells). However, more progress in CML biology is needed
to move from the era of clinical/hematologic prognosis to an era of molecular-
based prognosis.
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Background: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI)
that exhibits significant efficacy as first- or second-line treatment in patients
with chronic myeloid leukemia (CML). Superior rates of deeper molecular
responses were achieved with nilotinib vs. imatinib in patients newly diagnosed
with CML in chronic phase (CML-CP) in the ENESTnd trial. In addition, the 24-
month analysis of the ENESTcmr study demonstrated that switching to nilotinib
after a minimum of 2 years on imatinib led to increased rates of deeper molec-
ular responses vs. remaining on imatinib. Significantly more patients treated
with nilotinib achieved undetectable BCR-ABL1 by 24-month (32.7% on nilotinib
vs. 16.5% on imatinib; P =0.005).
Aims: To evaluate the efficacy of nilotinib in patients with CML-CP who have
achieved a major molecular response (MMR) with imatinib.
Methods: Patients with CML-CP who had achieved MMR but still had persistent
BCR-ABL positivity by real-time quantitative polymerase chain reaction (RQ-
PCR) on imatinib were eligible. Nilotinib will be taken twice daily (600 mg/day)
for 2 years. Thirty-five institutions in STAT study group participated. The study
was conducted in accordance with the principles of the Declaration of Helsinki.
Informed consent was written by all patients according to institutional guidelines.
The study was approved by all institutional review boards and registered with
ClinicalTrials.gov (number UMIN000005903). The primary objected of this mul-
ticenter phase II, single-treatment arm, open-label clinical study was to identify
the MR4.5 rate at 24 months after the initiation of nilotinib treatment. The molec-
ular response was evaluated according to the International Scale [IS] RQ-PCR
upon study entry and every 3 months thereafter. IS RQ-PCR was performed in
a central laboratory using a Molecular MD One-Step qRT-PCR BCR-ABL kit
(BML Inc., Kawagoe, Japan). At least 32,000 control gene (ABL) were required
for scoring deep molecular responses.
Figure 1-2.
Results: Between July, 2011 and December, 2012, 80 Japanese patients were
recruited, and 74 patients were evaluated in the study. The median age was
54.5 years. The ratio of men to women was 52:22. The median duration of
CML in patients was 68.9 months. The median duration of imatinib treatment
was 66.0 months. All patients showed MMR at the time of entry into the study
and the median time to MMR on imatinib therapy was 20.2 months. The pro-
portion of patients achieving deeper molecular responses (MR4, MR4.5)
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increased over time (Figure 1). The rates of MR4 in the evaluable patients
were 69% and 73% at 12 and 24 months, respectively, and the rates of MR4.5
were 28% and 49% at 12 and 24 months, respectively (Figure 2).
Summary and Conclusions: Switching to nilotinib led to deeper molecular
responses in patients with minimal residual disease on long-term imatinib ther-
apy. The results of our study suggest that switching to the more potent, selective
tyrosine kinase inhibitor nilotinib is beneficial in patients with minimal residual
disease after long-term imatinib therapy. Achievement of MR4.5 after switching
to nilotinib may enable a greater proportion of CML-CP patients to be eligible
for future discontinuation studies.
E1096
THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR
DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED
CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
Y. Najima1,* N. Iriyama2, S. Fujisawa3, C. Yoshida4, H. Wakita5, S. Chiba6,
S. Okamoto7, K. Kawakami8, N. Takezako9, T. Kumagai10, K. Inokuchi11,
K. Ohyashiki12, J. Taguchi13, S. Yano14, T. Igarashi15, Y. Kouzai16, S. Morita17,
J. Sakamoto18, H. Sakamaki1
1Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases
Center Komagome Hospital, 2Division of Hematology and Rheumatology,
Department of Medicine, Nihon University School of Medicine, Tokyo, 3Depart-
ment of Hematology, Yokohama City University Medical Center, Kanagawa,
4Department of Hematology, National Hospital Organization Mito Medical Cen-
ter, Ibaraki, 5Division of Hematology and Oncology, Japanese Red Cross Soci-
ety, Narita Red Cross Hospital, Narita, 6Department of Hematology, Faculty of
Medicine, University of Tsukuba, Ibaraki, 7Division of Hematology, Department
of Internal Medicine, Keio University School of Medicine, Tokyo, 8Department
of Hematology and Clinical Oncology, Kagawa Prefectural Central Hospital,
Kagawa, 9Department of Hematology, National Hospital Organization Disaster
Medical Center, 10Department of Hematology, Ohme Municipal General Hos-
pital, 11Division of Hematology, Department of Internal Medicine, Nippon Med-
ical School, 12Department of Hematology, Tokyo Medical University, Tokyo,
13Department of Hematology, Japanese Red Cross Shizuoka Hospital, Shizuo-
ka, 14Division of Clinical Oncology and Hematology, Department of Internal
Medicine, Jikei University School of Medicine, Tokyo, 15Division of Hematology
and Oncology, Gunma Prefectural Cancer Center, Gunma, 16Department of
Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo,
17Department of Biomedical Statistics and Bioinformatics, Kyoto University
Graduate School of Medicine, Kyoto, 18Tokai Central Hospital, Gifu, Japan
Background: Currently, as a second generation tyrosine kinase inhibitor, dasa-
tinib is one of the key treatment options for chronic myeloid leukemia (CML)
patients. Increase in lymphocyte counts, especially in the large-granular lym-
phocytes (LGLs), has been well investigated in patients treated with dasatinib
as a second line therapy, suggesting the correlation of increased LGL number
with the favorable outcome. However, lymphocyte dynamics in CML patients
treated with dasatinib as a first line therapy has yet to be clarified.
Aims: Elucidate the association between the lymphocyte dynamics after dasa-
tinib introduction and a favorable treatment response in newly diagnosed
patients with CML in chronic phase (CML-CP).
Methods: An open-label, multicenter, prospective clinical trial; D-First study
(ClinicalTrials.gov NCT01464411), enrolling patients with newly diagnosed
CML-CP was implemented to receive dasatinib 100mg/day. All patients were
followed-up for at least 18 months. BCR-ABL1 transcripts were quantified at 1,
3, 6, 9, 12, 15, and 18 months after initiation of dasatinib in all but one, harboring
the atypical undetectable BCR-ABL1 transcript. A deep molecular response
(DMR) was defined as BCR-ABL1 IS <0.01%. The incidence of lymphocytosis
was diagnosed if the number of peripheral blood (PB) lymphocyte counts
exceeded 3,600/μL on two occasions or more, after at least 4 weeks of dasa-
tinib initiation. Flow cytometry analysis was performed on each PB sample to
examine the phenotype of lymphocyte fractions.
Results: Of the 52 patients registered to the D-First study, 14 patients devel-
oped lymphocytosis and 29 patients achieved DMR by 18 months. The median
time from dasatinib induction to the first incidence of lymphocytosis was 7
months (range 1 – 16). The majorities of increased lymphocytes were morpho-
logical LGLs and were highly differentiated CD56+CD57+natural killer cells
(NK) or cytotoxic T lymphocytes (CTL) in most cases. Cumulative DMR rates
by 18 months were not significantly different between patients with lymphocy-
tosis and those without (50% vs 62%, P=0.53). However, total lymphocyte
counts at 1 month were significantly higher in patients with DMR by 18 months
compared to those without DMR (median 1,709/μL vs. 1,118/μL; P=0.018).
Furthermore, NK and CTL counts were significantly higher in patients with DMR
compared to those without DMR (P=0.009 for NK and P=0.005 for CTL). Using
the receiver operating characteristic curve, the optimal threshold in total lym-
phocyte, NK and CTL values at 1 month were calculated, indicating moderate
correlations (area under the curves were 0.70 in total lymphocyte, 0.72 in NK
and 0.74 in CTL) with the highest Youden’s index at 1,583/μL, 467/μL and
367/μL, respectively. When the patients were divided into 2 groups according
to those calculated thresholds, the cumulative DMR rates were significantly
better in higher value group compared to lower value groups (P=0.03 in total
lymphocyte, Figure 1 upper left; P=0.013 in NK, Figure 1 upper right and
P=0.007 in CTL, Figure 1 lower left). In contrast, regulatory T cell (Treg) counts
were significantly lower at 12 and 15 months in patients achieved DMR.
Figure 1.
Summary and Conclusions: Increased counts of total lymphocyte, NK and
CTL at 1 month after the initiation of dasatinib predicted better DMR rate in
newly-diagnosed CML-CP patients. Treg inhibition was also obvious in patients
with DMR at later time points, suggesting the dual effects of dasatinib on
immune system through the cytotoxic lymphocytes activation and Treg dereg-
ulation in different periods.
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Background: Detection of BCR-ABL1 e13a2 or e14a2 transcripts (major
breakpoint, M-BCR) of translocation t(9;22) (also known as the Philadelphia
chromosome) is important in CML monitoring tumor burden. The International
Scale (IS) was established to standardize reporting relative to a common base-
line. As newer TKI therapies create deeper responses, analytical sensitivity
has become a critical topic in investigations into TKI discontinuation, where
researchers require an assay that calls a molecular response (MR) of ≥4.5
logs below baseline (i.e. MR4.5 or 0.0032%IS).
Aims: Asuragen has developed a multiplexed RT-qPCR assay for the simul-
taneous amplification and detection of two BCR-ABL1 fusion transcripts (e13a2
and e14a2) and ABL1 (an endogenous control) using total RNA extracted from
human leukocytes. We evaluated the assay’s ability to meet current perform-
ance requirements for ease of use, sensitivity, and traceability to a higher order
standard reference material.
Methods: We tested whether this prototype BCR-ABL1 fusion quantification
assay could be an alternative to current clinical diagnostic tools for monitoring
CML patients for minimal residual disease. We compared patient test results
obtained with the Asuragen assay to our current clinical laboratory developed
test (LDT) to define correlation and concordance between the two methods.
Clinical and cell line RNA samples were used to study additional performance
characteristics of the Asuragen assay, including sensitivity (7-member human
RNA panel over 3 days), specificity (cell line RNAs and in vitro transcripts), lin-
earity (7-point human RNA dilution), precision (3-member human RNA panel
over 5 days), and clinical accuracy (20 human RNA specimens over 2 runs,
assessed against the LDT). EDTA blood-based RNA specimens were evaluated
for purity (OD260/280 >1.6) and concentration (100-500 ng/uL). Asuragen’s BCR-
ABL1 assay included all required RT and qPCR reagents in the kit. The RT and
qPCR were performed and analyzed on the ABI 7500 Fast Dx with software
version 1.4. RNA was provided as 7 different blends of BCR-ABL1 and ABL1
Armored RNA Quant® (ARQ) standards and controls to calibrate and control
the system. A single four-point standard curve using ARQ blends mimicked the
WHO Primary BCR-ABL1 reference materials. Assay-specific software was
used to automatically generate results reported in MR and %IS values.
Results: We found positivity in samples ≤MR4.5 (≥0.0032%IS) with human
CML positive RNA, indicating good analytical sensitivity. Despite deep analytical
sensitivity, the system maintains analytical specificity (non-M-BCR, non-CML,
and non-leukemic specimens produce true negative results). Linearity was
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demonstrated from LOQ to <MR1 (>10%IS). Technical replicates yielded
acceptable precision, including good %CV around the key clinical decision
points of 0.1%IS (MR3, MMR) and 10%IS (MR1, near PCyR). The Asuragen
assay showed good intra-laboratory correlation. Moreover, using assay com-
parison criteria proposed by Müller et al. (Leukemia 2009), the Asuragen assay
was considered comparable to our current LDT, suggesting good clinical accu-
racy (when treating the prior result in the LDT as truth).
Summary and Conclusions: The BCR-ABL1-targeting prototype improves
workflow with its streamlined reagent formulation, all inclusive contents, and
multiplex assay format. It facilitates assessment on the IS without conversion
(through integrated ARQ materials traceable to the WHO Primary reference
set), and generates results sufficient for studies in deep molecular responses.
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Background: Imatinib (IM) is remarkably effective in treating newly diagnosed
patients with chronic myeloid leukemia (CML) in chronic phase (CP). The long
term outcome is extremely important to assess the treatment efficacy and sta-
bility. To date, most of the available data come from studies in which some of
the patients were censored for diverse reasons. In the IRIS trial, at 8 year, 55%
of patients were still on IM and the overall survival (OS) was 85%. Other pub-
lished reports have shorter follow-up.
Aims: To evaluate the results of long term treatment in CML patients in a setting
where all events were recorded.
Methods: A total of 235 adult patients with CML in CP started IM from July
2000 till April 2007. Early CP was in patients with <1 year of pretreatment before
IM. At the time of therapy initiation 37% (86/235) patients were in early CP.
Common (ComCI) and current (CCI) cumulative incidences of complete cyto-
genetic response (CCyR), progression-free survival (PFS) and overall survival
(OS) were evaluated.
Results: Baseline demographics characteristics: median age: 42 years
(extremes 18-66 years); male sex: 49%; high Sokal, high Euro and high EUTOS
scores: 16%, 7% and 6%, respectively; clonal chromosomal abnormalities
(CCA) in Ph+cells: 7%. Median follow-up: 123 (9-162) months; still on IM treat-
ment: 54%; switched to TKI2: 34%; alive: 81%. The reasons for IM discontinu-
ation were: lack of efficacy (31%), death (12%), toxicity and other reasons (4%);
4% of patients were lost to follow-up. ComCI of CCyR in early CP and late CP
was 89% and 77%, respectively (p<0,0001). The CCI of CCyR in early CP was
higher than in late CP at all observation time. Switching to TKI2 allowed to
increase CCI in all group after 5 years therapy. The 12-year OS for early CP
and late CP was 90% and 74%, respectively (p=0,017); the 12-year PFS for
early CP and late CP was 94% and 77%, respectively (p=0,006).
Figure 1.
Summary and Conclusions: The available data on the very long-term out-
come of newly diagnosed CP CML patients treated frontline with IM are limited
to a company sponsored study (IRIS study). Until now, there are no available
data on the very long-term outcome of late CP CML patients treated with IM.
This study provided an unbiased overview of the long-term IM therapeutic
effects in early and late CP CML. IM more effective in early CP then in late CP
CML. Achieving and maintaining CCyR correlated with disease duration before
IM initiation. Switching to TKI2 allows to increase achieving and maintaining
CCyR in early and late CP CML
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Background: SIMPLICITY is an ongoing observational study of CP-CML
patients (pts) designed to understand the use of first-line (1L) imatinib (IM),
dasatinib (DAS) or nilotinib (NIL) in the United States (US) and Europe (Eu)
outside clinical trials (NCT01244750). Previous SIMPLICITY data (ASH 2013)
showed pts had 3.3 (±2.8) comorbidities (mean±standard deviation [SD]) at
start of 1L tyrosine kinase inhibitor (TKI; N=949); ≥1 baseline comorbidity report-
ed in >75% of pts, with >3 comorbidities in majority. 40.6% had cardiovascular
(CV) comorbidities at start of 1L TKI. Baseline comorbidity did not affect initial
TKI selection, although cautions regarding risks for specific adverse events
(e.g. cardiac and pulmonary) have been described for individual TKIs in pts
with pre-existing conditions.
Aims: This analysis focuses on the frequency of CV-related hospitalizations in
SIMPLICITY pts and describes these events by 1L TKI and TKI received at
time of hospitalization. Demographics and clinical characteristics of hospitalized
pts are compared with the total SIMPLICITY population.
Methods: SIMPLICITY includes three prospective pt cohorts treated with IM,
DAS or NIL as 1L therapy since 2010 and a historical cohort treated with IM
since 2008. Among hospitalizations reported through 22 Sept 2014, CV-related
hospitalizations were identified using preferred MedDRA terms in the CV cat-
egory. Based on events reported, events were categorized: valvular disease;
arrhythmia; cardiac failure; cardiac ischemic disease; and pericardial disorder.
TKI exposure was calculated from total duration on specified TKI regardless of
initial TKI.
Results: 1460 pts were enrolled prospectively on IM (n=415), DAS (n=416) or
NIL (n=376), and data collected retrospectively for IM (n=253). Over half of pts
were male (54.7%) and over half were from the US (66.7%). Median age
(interquartile range [IQR]) at 1L TKI was 56.0 (45.0–67.0) years and 31% of pts
were ≥65 years. Overall, 329 pts (22.5%) were hospitalized and 46 pts (3.2%)
had CV hospitalizations (retrospective IM: n=21; prospective IM: n=6; DAS: n=8;
NIL: n=11). Multiple CV hospitalizations were reported in 21.7% of CV hospital-
ized pts. Of pts with CV hospitalizations, median (IQR) age at 1L TKI was 70.8
(57.1–74.8) years; 60.9% were ≥65 years. Most pts were male (60.9%) and
from the US (82.6%); 62% were on 1L TKI at first admission. Median follow-up
from start of TKI to hospitalization was 370 days (retrospective IM, 484; prospec-
tive IM, 847; DAS, 105; NIL, 239 days) compared with 29.3 months for the total
SIMPLICITY population. Most frequent causes of CV hospitalization were cardiac
ischemic disease (34.6%), arrhythmia (30.8%) and cardiac failure (26.9%).The
rate of CV hospital admissions per 100 pt years exposure was 1.46 for all hos-
pitalized pts and was highest in the NIL-treated cohort (NIL: 2.61 compared with
0.77 [retrospective IM], 1.15 [prospective IM] and 1.15 [DAS]). The mean (±SD)
duration of hospitalization was 5.9 (±7.2) days.
Summary and Conclusions: In SIMPLICITY, few patients overall were hos-
pitalized for CV-related events. Pts with CV-related hospitalizations were older
than the total SIMPLICITY population. The highest rate of CV hospitalizations
per 100 pt years was in NIL-treated pts, while the observed rates for DAS and
IM patients appeared similar. Analysis of pre-existing CV co-morbidities in hos-
pitalized patients will be described.
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ESTIMATED GLOMERULAR FILTRATION RATES OF CHRONIC MYELOID
LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE
INHIBITORS (TKIS) IN DASATINIB TRIALS: DASISION (CA180-056),
CA180-034, AND CA180-035
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Background: As the survival of patients with CML has increased with the intro-
duction of BCR-ABL-targeted TKIs, more attention is being paid to the potential
long-term effects of chronic treatment. There is evidence that suggests individ-
ual TKIs may affect metabolic pathways such as glucose control, lipid levels,
and thyroid function (Breccia 2014, Leuk Res). In addition, imatinib has been
associated in two single center studies with decreased estimated glomerular
filtration rate (eGFR) over time, not reported with either dasatinib or nilotinib
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(Marcolino 2011, Ann Oncol; Yilmaz 2013, Blood, abstr 1488).
Aims: The objective of this analysis was to evaluate the long-term effects of
BCR-ABL-targeted TKIs on renal function in patients from three dasatinib phase
3 clinical trials: newly diagnosed patients with CML in chronic phase (CP) from
DASISION, imatinib-intolerant or -resistant CML-CP patients from CA180-034,
and imatinib-intolerant or -resistant patients with CML in accelerated/blast
phase (AP/BP) or Ph+acute lymphoblastic leukemia (ALL) from CA180-035.
Methods: This pooled trial analysis was conducted using final data reports
from each study: 5-year data from patients treated with first-line dasatinib 100
mg once daily (QD) or imatinib 400 mg QD in DASISION (NCT00481247;
N=519), 7-year data from patients treated with second-line dasatinib 100 mg
QD/50 mg twice daily (BID)/140 mg QD/70 mg BID in CA180-034
(NCT00123474; N=670), and 5-year data from patients treated with dasatinib
140 mg QD/70 mg BID in CA180-035 (NCT00123487; N=609). Modification of
Diet in Renal Disease (MDRD) values for eGFR were calculated for patients
aged ≥18 years using the formula: eGFR (mL/min/1.73 m²)=175 x (serum cre-
atinine)-1.154 x (age)-0.203x (0.742 if female) x (1.212 if African American).
Results: In DASISION, newly diagnosed patients started on imatinib and
dasatinib had a similar mean eGFR at baseline (89 mL/min/1.73 m2). The
mean eGFR with imatinib dropped approximately 9 mL/min/1.73 m² within the
first 2 weeks of treatment, and then stabilized over the remaining length of
the analysis (Figure 1). Conversely, there was a small increase in mean eGFR
with dasatinib at early time points that then returned to baseline levels for the
remainder of the analysis. In patients from CA180-034 and CA180-035 previ-
ously treated with imatinib, the baseline mean eGFR (79 mL/min/1.73 m2 for
dasatinib 100 mg QD in CA180-034 and 82 mL/min/1.73 m2 for dasatinib
140mg QD in CA180-035) was lower than that observed in DASISION (89
mL/min/1.73 m2). There was no difference in mean eGFR over time across all
dasatinib doses tested in patients from CA180-034. In CA180-035, where all
patients had advanced CML or ALL, a decrease in eGFR of approximately 10
mL/min/1.73 m2 in the year following dasatinib initiation was observed without
any long-term changes.
Figure 1. eGFR Over Time After the Start of Treatment in DASISION.
Summary and Conclusions: The renal profile of newly diagnosed CML
patients or imatinib-intolerant/resistant CML or Ph+ALL patients did not worsen
with long-term dasatinib treatment, regardless of CML phase. In DASISION,
the mean eGFR with imatinib decreased soon after treatment initiation to a
level consistent with the National Kidney Foundation (NKF) chronic kidney dis-
ease stage 2 (NKF Guidelines, 2002). Further analyses are ongoing to deter-
mine if there are any subpopulations of CML patients at risk, or other con-
founding factors, for developing renal dysfunction on TKIs.
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Background: Nilotinib (NIL) elicits rapid, deep MR as first- or second-line treat-
ment of patients (pts) with CML in chronic phase. However, the best treatment
for pts with suboptimal MR to first-line imatinib (IM) is not yet known. BIM poly-
morphisms (eg, BIM deletion [del] polymorphism at intron 2 or a single
nucleotide polymorphism [SNP; C465C>T at BIM exon 5]) reduce rates of MR
and increase the frequency of newly detected BCR-ABL1 mutations with IM
treatment, but little is known about how BIM affects pts receiving NIL.
Aims: SENSOR (NCT0104387) evaluated the efficacy and safety of switch to
NIL in Japanese pts with suboptimal MR (per 2009 European LeukemiaNet
criteria) to first-line IM. Here, we present final 24-mo data and results from a
BIM polymorphisms substudy.
Methods: In this multicenter study conducted in Japan, pts with suboptimal
MR to frontline IM (complete cytogenetic response but not major molecular
response [MMR] after ≥18 mo of IM) received open-label NIL 400 mg twice
daily for up to 24 mo. Laboratory tests were performed centrally. BCR-ABL1
transcript levels (using the International Scale with ABL1 as a control gene)
were assessed each mo (mo 1-3) and every 3 mo thereafter. BCR-ABL1 muta-
tion status was assessed by direct sequencing at baseline and retrospectively
analyzed at all these time points in pts without mutations detected. BIM poly-
morphisms were evaluated using a validated assay during or after treatment.
Progression-free survival (PFS) and overall survival (OS) were estimated using
the Kaplan-Meier method.
Table 1.
Results: Of 45 pts enrolled in the main study (Dec 2009-Feb 2012), 6 pts dis-
continued (3 had adverse events [AEs], 1 had disease progression, and 2 with-
drew consent). Median treatment duration was 22.1 mo (range, 0.1-22.7 mo).
Rates of MMR, MR4, and MR4.5at 24 mo were 66.7% (95% CI, 51.0%–80.0%),
11.1% (95% CI, 3.7%–24.1%), and 6.7% (95% CI, 1.4%–18.3%), respectively.
The cumulative incidence of MMR, MR4, and MR4.5by 24 mo was 75.6%,
13.3%, and 6.7%, respectively. Only 1 pt progressed or died; this pt had a
newly detected T315I mutation, progressed to blast crisis at 5.4 mo, and died
at 9.4 mo. Estimated 24-mo PFS and OS were 97.8% (95% CI, 85.3%–99.7%)
and 97.8% (95% CI, 85.3%–99.7%), respectively. Of 40 pts evaluated for BIM
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polymorphisms, 3 pts (7.5%) were heterozygous (hetero) for the BIM del, 10
pts (25.0%) had the C/T SNP, and 12 pts (30.0%) were hetero for the BIM del
and/or had the C/T SNP. Pts achieved MMR and acquired BCR-ABL1 point
mutations or splicing abnormalities regardless of polymorphism status, but no
pts with these BIM polymorphisms achieved MR4 or MR4.5(Table). Headache
(28.9%) and rash (26.7%) were the most common drug-related nonhematologic
AEs. The most common new or worsening laboratory abnormalities were
increased bilirubin (95.6%) and increased alanine aminotransferase (80.0%).
New or worsening hematologic abnormalities were decreased lymphocytes
(53.3%) and decreased hemoglobin (31.1%).
Summary and Conclusions: Upon switch to NIL, 66.7% of pts achieved MMR
at 24 mo, and 75.6% achieved MMR by 24 mo. Safety results were consistent
with those from other NIL studies. Pts achieved MMR regardless of BIM poly-
morphism status, but no pts with BIM polymorphisms achieved deeper MR.
Larger studies are required to determine how polymorphism of BCL-2-related
genes, including BIM, may affect clinical response to NIL in pts with CML.
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Background: In chronic myeloid leukemia (CML), achievement of optimal
responses by time point has improved long-term outcomes. In IRIS study, patients
who achieved major molecular response (MMR) at 18 months had event-free
survival (EFS) benefit, compared to those who achieved complete cytogenetic
response (CCyR) without MMR. However, the best treatment for these patients
is still not confirmed. By the previous studies, sustaining standard-dose of imatinib
(IM) is expected to yield less than 20 percent of additive MMR.
Aims: In this study, we investigated the efficacy of nilotinib (NIL) versus high-
dose IM versus sustaining standard-dose IM for CCyR patients with suboptimal
molecular response to frontline IM therapy.
Methods: Early chronic phase (CP) CML patients who have achieved CCyR
but no MMR after at least 18 months and up to 24 months ( 18 to 24 months)
on first-line IM therapy at a daily dose of 400 mg were divided into 3 treatment
groups; NIL 400mg BID (800 mg/day; group 1) vs IM 400 mg BID (800 mg/day;
group 2) vs IM 400mg QD (400mg/day; group 3). Group 1 and 2 patients were
selected in RE-NICE multicenter study and group 3 patients were selected with
the same inclusion criteria of RE-NICE. The efficacy endpoints are MMR rate
by 12 months and MMR rate and undetectable molecular residual disease
(UMRD) rates by 36 months. Safety profiles of each group were compared.
Patients showing lack of response (lack of complete hematologic response
(CHR) at 6 months, increasing WBC, no major cytogenetic response (MCyR)
at 24 months), loss of response (loss of CHR or MCyR) or intolerance to treat-
ment were allowed to switch to other treatment.
Results: With a data cut-off date of 12 Jan 2015, a total of 84 patients were
evaluated; 29 patients in NIL group (group 1), 29 patients in high-dose IM
group (group 2) and 26 patients in standard-dose IM group (group 3). With a
median follow-up of 36 months (range, 1-63), all patients in group 1 remained
in nilotinib treatment, 18 patients in group 2 switched to NIL 400mg BID due
to intolerance (n=4) and lack of response (no MMR; n=14). In group 3, with a
median follow-up of 13 months (range, 1-130), 16 patients switched to other
treatment due to intolerance (n=5) and lack of response (no MMR; n=10, treat-
ment failure; n=1) and 1 patient loss of follow-up after 9 months follow-up. Up
to now, three patients lost CCyR (1 in group 1, 1 in group 2 and 1 in group 3).
With an initial treatment 10 in 29 (35%), 8 in 29 (28%) and 5 in 26 (19%)
patients achieved MMR by 12 months, and 20 in 29 (69%), 10 in 29 (34%)
and 10 in 26 (38%) patients achieved MMR by 36 months in group 1, group 2
and group 3 respectively. Overall, 3 patients in group 1 (3/29, 10%) achieved
confirmed UMRD. Overall 3 years probability of MMR was higher in group 1
than the other two groups (81.0% vs 64.6% vs 64.0%, group 1, 2, 3 respec-
tively, group 1 vs 2, P=0.098, group 1 vs 3, P=0.020, group 2 vs 3, P=0.443).
Compare to other groups, the patients in group 2 showed higher toxicities,
such as leukopenia, anemia, thrombocytopenia, edema, fatigue, dyspnea and
hypophosphatemia.
Summary and Conclusions: Nilotinib 400mg twice daily treatment showed
better efficacy than high-dose or same standard-dose imatinib for the treatment
of patients who have suboptimal molecular response to initial standard-dose
imatinib. Additionally, a switch to nilotinib in suboptimal molecular responder to
imatinib would also be preferable option in terms of tolerability. Updated data
with longer follow-up duration will be presented in the meeting.
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Background: The molecular response at 3 months of tyrosine kinase inhibitor
(TKI) therapy for patients with chronic myeloid leukemia (CML) has prognostic
significance and, a BCR-ABL1 transcript level >10% on the international report-
ing scale (IS) at 3 months is associated with inferior outcomes. This finding
was confirmed by many groups with the original imatinib (OI) (Glivec®; Novartis,
East Hanover, NJ, USA), but never been tested for generic imatinib (GI). GI
was first introduced in Turkey in August 2012, and afterwards most of the
patients with chronic phase CML (CML-CP) were administered up-front GI
according to the reimbursement policy in Turkey. 
Aims: The first aim of this study was to evaluate the BCR-ABL1 (IS) transcript
levels at 3 months of GI treatment, and to demonstrate whether early molecular
response (EMR) had a prognostic impact on outcome among CML-CP patients
who receive GI in the first-line setting. The second aim was to compare these
findings to that of OI, in order to determine whether there was any difference
between group of patients receiving these two imatinibs. 
Methods: The testing for BCR-ABL1 (IS)was available in our institute after Jan-
uary 2010, so the study cohort consisted of 90 CML-CP patients who were diag-
nosed between 2010 and 2014. Patients’ demographics, Sokal risk scores and
follow-up periods were retrospectively noted from the patients’ files. Imatinib
response was evaluated according to the criteria recommended by the European
LeukaemiaNet (ELN). The cumulative major MR (MMR) and complete cytogenetic
response (CCyR) rates were calculated. Patients were divided into two groups
according to imatinib they consume; patients receiving OI were Group A, and GI
were Group B. Also these groups were further divided into two regarding the
BCR-ABL1 (IS) transcript levels at 3 months of imatinib as 10%≤and >10%.
Figure 1.
Results: There were 47 patients in Group A and forty-three in Group B. The
two groups were equally balanced regarding age, gender and Sokal risk scores
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(Table 1). But patients in Group A had significantly longer median follow-up
than patients in Group B (32.5 months vs. 13 months, p<0.001). BCR-ABL1
(IS) transcript levels at 3 months were available in 43 patients in Group A and
thirty-two in Group B. There were 31 patients in Group A with a BCR-ABL1 (IS)
transcript level 10%≤at 3 months whereas twelve patients had BCR-ABL1 (IS)
transcript levels >10%. In Group B, 20 patients had a BCR-ABL1 (IS) transcript
level 10%≤at 3 months and twelve had BCR-ABL1 (IS) transcript levels >10%
(Table 1). The cumulative CCyR and MMR rates in patients with BCR-ABL1
(IS) level 10%≤at 3 months were significantly superior than patients with BCR-
ABL1 (IS) level >10% both in Group A and B (Table 1). Also there were signif-
icantly more patients switching to 2nd generation TKIs (2GTKIs) due to resist-
ance in both groups among patients with a BCR-ABL1 (IS) level >10% at 3
months (Table 1). Two groups did not significantly differ regarding cumulative
CCyR and MMR rates as well as the number of patients with BCR-ABL1 (IS)
levels 10%≤and >10%. In Group B, among patients with BCR-ABL1 (IS) levels
10%≤at 3 months (n=20), sixteen had MMR but the remaining 4 patients had
a median follow-up of 8 months (range, 4-9 months) and 3 of them had CCyR
and one had partial CyR. Among patients receiving GI, event-free survival
(EFS) was significantly superior in patients with BCR-ABL1 (IS) level 10%≤at
3 months than patients with BCR-ABL1 (IS) level >10% (p=0.001) (Figure 1).
Table 1.
Summary and Conclusions: BCR-ABL1 (IS) transcript levels 10%≤at 3
months in CML-CP patients receiving generics had superior outcomes in terms
of cumulative CCyR and MMR rates as well as EFS when compared to patients
with BCR-ABL1 (IS) level >10%. And these findings were consistent with the
literature displaying similar results in patients receiving Glivec.
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Background: Ponatinib is a potent oral BCR-ABL tyrosine kinase inhibitor
(TKI) approved for patients with refractory chronic myeloid leukemia (CML) or
Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL)
and those with the T315I mutation in BCR-ABL1.
Aims: This retrospective analysis describes the efficacy and safety of ponatinib
(starting dose 45 mg once daily) in patients with a history of SCT prior to enroll-
ment in the ongoing phase 2 PACE trial.
Methods: Patients with CML or Ph+ALL who were resistant or intolerant to
dasatinib or nilotinib or who had the T315I mutation were enrolled in PACE
(NCT01207440). All patients gave informed consent. The PACE trial excluded
patients who underwent SCT <60 days before the first ponatinib dose, patients
with evidence of ongoing graft-versus-host disease (GVHD), and patients who
had GVHD requiring immunosuppressive therapy. Of 449 patients, 40 (9%)
had a history of SCT.
Results: Of 40 patients with a history of SCT, 12 (30%) had chronic-phase
(CP)-CML, 8 (20%) had accelerated-phase (AP)-CML, 11 (28%) had blast-
phase (BP)-CML, and 9 (23%) had Ph+ALL at study entry (PACE enrollment).
Median age was 48.5 years and median time since diagnosis was 3.8 years at
the time of the first dose. Most patients (73%) had received ≥3 TKIs, either
before or after SCT, prior to ponatinib treatment. Twelve patients (30%) had
T315I detected at baseline (1 CP-CML, 2 AP-CML, 5 BP-CML, and 4 Ph+ALL
patients). Twenty-five patients (63%) had an SCT ≤2 years (but ≥60 days)
before starting ponatinib, and 15 (38%) had an SCT >5 years before starting
ponatinib. Patients may have received intervening therapy between SCT and
ponatinib. As of 6 October 2014, median follow-up for these 40 patients was
12.6 months after start of ponatinib; median duration of ponatinib treatment
was 5.9 months. Median dose intensity was 39.9 mg/d and 45% of patients
had their dose reduced. The primary endpoint in CP-CML (major cytogenetic
response by 12 months) was achieved by 4 (33%) of 12 CP-CML patients. The
primary endpoint in AP-CML, BP-CML, and Ph+ALL (major hematologic
response by 6 months) was achieved by 3 (38%) of 8 AP-CML patients, 3
(27%) of 11 BP-CML patients, and 2 (22%) of 9 Ph+ALL patients. Major molec-
ular response at any time was achieved in 1 (8%) of 12 CP-CML patients, 1
(13%) of 8 AP-CML patients, 2 (18%) of 11 BP-CML patients, and 1 (11%) of
9 Ph+ALL patients. Vascular adverse events occurred in 6 (15%) of 40 patients
and included myocardial infarction (n=2), pulmonary embolism (n=2), angina
pectoris (n=1), cerebral ischemia (n=1), coronary artery disease (n=1), portal
vein thrombosis (n=1), superficial thrombophlebitis (n=1), and transient
ischemic attack (n=1). Additional data regarding SCT and other treatments
before ponatinib will be presented.
Summary and Conclusions: Ponatinib treatment induced responses in a sub-
stantial proportion of heavily pretreated Ph+patients with a history of SCT. Vas-
cular adverse events were observed in 15% of patients. Benefits and risks
should be considered when using ponatinib in patients with a history of SCT.
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Background: Advanced (ADV) Ph+CML patients (pts) have worse outcomes
vs chronic CML pts.
Aims: In this first report of bosutinib (BOS) activity in this cohort as fully
enrolled, we evaluate long-term efficacy and safety of BOS in ADV pts ≥4 y vs
≥1 y from last enrolled pt.
Methods: Ongoing phase 1/2 BOS study in 79 accelerated phase (AP) and
64 blast phase (BP) pts with prior tyrosine kinase inhibitor (TKI) failure. Informed
consent was obtained from all pts.
Table 1.
Results: For AP and BP pts, 18% and 3% remained on BOS at 4 y (vs 48%;
13% at 1 y; 1 y=48 wk); 57% and 28% newly attained or maintained baseline
overall hematologic response (OHR) by 4 y (most by 12 mo); 40% and 37%
attained/maintained major cytogenetic response (MCyR) by 4 y (most by 12
mo). Kaplan-Meier probabilities of maintaining OHR in responders at 4 vs 1 y
were 49% vs 78% (AP) and 19% vs 28% (BP); Kaplan-Meier MCyR probabil-
ities at 4 vs 1 y were 49% vs 65% (AP) and 21% vs 21% (BP). AP and BP pts
were treated for median 10.2 (range, 0.1–88.6); 2.8 (0.03–55.9) months. Most
common AEs were gastrointestinal (AP, 96%; BP, 83%), primarily diarrhea
(85%; 64%), which was typically low grade (grade 1/2: 96%; 93%), transient
(median duration/any grade AE: 2 [range, 1–910] d; 2 [1–211] d); no pt dis-
continued due to this AE. Newly occurring AEs arose mostly in y1; new car-
diac/vascular AEs occurring in y4 were pericardial effusion, sinus bradycar-
dia/1st degree atrioventricular block (same pt), and hypertension (all n=1);
those in y1 (>2 pts either cohort) were pericardial effusion (AP, n=4; BP, n=1),
tachycardia (n=2; n=4), hypertension (n=3; n=2; Table). Serious AEs occurred
in 56% AP and 58% BP pts, most commonly pneumonia (n=9; n=5). 11 AP
and 13 BP pts died within 30 d of last dose; 2 BOS-related (AP). Treatment
discontinuations were mostly due to progressive disease (AP, ≤1/>1 y,
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n=10/13; BP, n=29/3) and AEs in AP (n=16/5); death (n=6/0) and symptomatic
deterioration (n=6/0) in BP.
Summary and Conclusions: Durable response was seen in ~50% AP respon-
ders (~25% BP responders at y1, for whom BOS may be bridge to transplant);
toxicity was manageable with long-term treatment.
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Background: The growing number of TKIs available for CML increases com-
plexity in choosing therapy in non-research settings.
Aims: This study aims to determine patient (pt) characteristics & emergent
AEs that might underlie treatment choices.
Methods: TKI treatment episodes for adult CML pts from 1/2008 - 7/2014 were
identified in the MarketScan Commercial, Medicaid, and Medicare supplemental
databases. Pts were required to have ≥6 mos of enrollment prior to each TKI
episode and ≥1 pharmacy or medical claims for one of the TKIs on or after the
first CML diagnosis date. Analyses were retrospective and descriptive. Charlson
comorbidity index (CCI) and frequency of other key comorbid conditions prior
to each TKI episode were used to characterize patient baseline status (BL).
Corresponding treatment-emergent events were captured using the same diag-
nosis or treatment codes indicative of the conditions. Vascular occlusive (VO)
conditions include one or more of the following: myocardial infarction, conges-
tive heart failure (CHF), thrombotic events, acute coronary syndrome, peripheral
vascular, cerebrovascular, or coronary artery diseases. Median duration of
treatment was assessed using the Kaplan-Meier method.
Results: 4,166 TKI treatment episodes for CML were identified. Median follow
up was 13 months. Imatinib (IM) was most commonly used 1st line, dasatinib
(DAS) and nilotinib (NIL) 2nd line, and bosutinib (BOS) and ponatinib (PON)
3rd line. BOS pts had the most previous TKI episodes and were furthest from
initial diagnosis. They were the oldest, had the highest CCI, the most histories
of VO conditions, kidney diseases, and pleural effusion at baseline, but the
lowest rates of serious emergent AEs and discontinuation. With younger age
and lower CCI, PON pts had the highest incidences of treatment emergent VO
events and fluid retention, with the shortest treatment duration and highest
rates of discontinuation.
Table 1.
Summary and Conclusions: BOS appeared to be associated with lower risks
of serious AEs compared to other TKIs and suited to elderly pts with high
orbidities. It will be important to confirm the findings with larger sample sizes.
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Background: Chronic myeloid leukemia (CML) is a hematopoietic pluripotent
stem cell disease where myeloid cells lead to uncontrolled proliferation. Current
treatment of Ph (+) CML is based on the inhibition of tyrosine kinase inhibitors
(TKI), especially second-generation drugs. Majority of CML patients are male
and 46% of them are between 20 and 64 years of age. Therefore, it is con-
ceivable that inhibition of c-kit or PDGFR by TKI may have deleterious effects
on spermatogenesis or folliculogenesis, resulting in male or female subfertility.
In the first part of this study we showed the suppression of folliculogenesis
and prevention of spermatogenesis during the long-term nilotinib treatment. 
Aims: The aim of this part of our study is to determine the effect of nilotinib
on fertility and teratogenicity that is used routinely to treat CML. 
Methods: Here we present the results of testicular and ovarian changes after
nilotinib administration to five- week old male and female C57bI6 mice. Mice
received 0.4 mg of nilotinib per day dissolved in the drinking water for 2
months. Control group received only drinking water. Treatment dose was deter-
mined according to the clinical studies regarding the plasma concentrations
(20 mg/kg, orally).
Results: There were no differences in the fertility and live birth index, the sex
ratio or the frequency of survival to the time of weaning and also no evidence
of teratogenicity in the fetuses. Low birth weight fetuses were seen in the nilo-
tinib receiving female group whether the interruption of the drug during the
pregnancy. The pregnancy rates of the couples according to the case of the
using nilotinib or not were shown in Table 1. The pregnancy rates were reduced
to 75% in the case of male mice used nilotinib; to 60% in the case of female
mice used nilotinib; and finally to 25% in the case of both female and male
mice used nilotinib in the cohort. 
Table 1. The pregnancy rates of the couples
Summary and Conclusions: Although our results indicate that mice achieved
the pregnancy whether they used nilotinib, the pregnancy rates reduced sig-
nificantly compared to the control group in the study, especially if both female
and male mice used nilotinib together. According to limited information, the
potential consequences of the drug on developing fetus is still matter of debate,
all female mice have given birth to healthy baby in our study. In the third part
of our ongoing study, we are investigating the long-term effect of nilotinib on
baby mice.
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Background: Response to TKI is considered the strongest predictor of long-
term outcome in CML patients. As known, effective treatment overcomes the
negative impact of most prognostic factors, including Sokal score. Different
studies have demonstrated that early molecular response is strictly correlated
with outcome: infact, missing the 10% BCR-ABL landmark at 3 months predicts
inferior long-term survival. 
Aims: We investigated the dynamics of 3 months molecular “warning” CML
patients at 6 and 12 months landmarks; secondly, we sought to evaluate the
impact of Sokal score in the context of this unfavourable group
Methods: A total of 51 patients with BCR-ABL levels >10% at 3 months were
identified for the analysis from a cohort of 350 consecutive CML patients treated
with front-line standard dose imatinib (400 mg daily). “Optimal”, “warning” and
“failure” responses were stated according to ELN2013 recommendations. Com-
plete cytogenetic response (CCyR) was defined as 0% Ph+metaphases; major
molecular response (MMR) was defined as BCR-ABL <0.1%IS. TTF was meas-
ured from the start of imatinib to the date of any of the following events: pro-
gression to accelerated or blastic phase, death for any cause at any time, pri-
mary or secondary hematologic, cytogenetic or molecular resistance leading
to imatinib discontinuation. PFS was measured from the start of imatinib to the
date of progression to accelerated or blastic phase or death for any cause at
any time. Survival probabilities were estimated by the Kaplan-Meier method
and compared by log rank test; differences among variables were evaluated
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by the Fisher’s exact test or by Cochran–Mantel–Haenszel test
Results: The median age of patients was 56 years (range 25–81), with 33
males and 18 females. The median follow-up was 45.3 months (range 7–110).
The distribution of patiens according to the Sokal score was: 11 (21.6%) in the
low risk, 24 (47.1%) in the intermediate and 16 (31.4%) in the high risk group,
respectively. At 6 months, only 3 of 40 evaluable patients, 1 in each group
(11.1%, 5% and 9% respectively), improved their 3 months molecular response,
achieving an optimal response. 20 failures, defined as more than 10%IS BCR-
ABL transcript level, were recorded (1, 11 and 8 in low, intermediate and high
risk group respectively, P=0.008 comparing low vs other risk groups). At 12
months, 21 of 25 evaluable patients were considered failures; only 1 patient
gained an optimal response. 27.2%, 50% and 50% of low, intermediate and
high Sokal score patients failed to achieve a CCyR at any time (P=0.047),
while 72.7%, 45.8% and 31.3% of patients obtained a MMR (P=0.104), respec-
tively. Median time to CCyR and MMR was 12, 12.5, 24.5 months (P=0.21),
and 30, 25 and 22 months (P=0.21) for low, intermediate and high risk group
responding patients. Imatinib discontinuation rate, albeit remarkable in all Sokal
groups, was not significantly different (66.7% vs 78.3% vs 93.8% respectively,
P=0.22), as well as PFS (P=0.349), TTF (P=0.321) and OS (P=0.812). 9.1%,
12.5% and 25% of low, intermediate and high Sokal risk patients progressed
to AP/BC phase, respectively.
Summary and Conclusions: These data suggest that although non-low Sokal
score CML patients may experience a higher probability of early failure, long
term outcomes of molecular “warning” patients seem not to be significantly
influenced by Sokal risk. Therefore, 3-months BCR-ABL transcript level higher
than 10% IS appears to overcome non only the negative, but also the positive
prognostic impact of Sokal score. These observations warrant further confir-
mation in larger studies.
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Background: For the treatment of chronic myeloid leukemia (CML), higher
efficacy of tyrosine kinase inhibitors (TKI) has required accurate molecular
monitoring by standardized real-time quantitative polymerase chain reaction
(RQ-PCR). Although the standardization of RQ-PCR test has become particu-
larly important to increase the accuracy, each participating laboratory should
establish a laboratory-specific conversion factor through regular exchange of
a series of samples. However the process is very complicated and periodic
validation is needed to keep the stabilization of original conversion factors of
laboratories. Otherwise the measurement of BCR-ABL1 transcript by single
standardized laboratory can reduce many unnecessary processes and is able
to increase accuracy of result.
Aims: In this study, we evaluated the Korean centralized RQ-PCR program and
the result of molecular monitoring of CML patients in routine clinical practice.
Methods: Twenty four Korean university hospitals were agreed on a central-
ized assay performing in the Catholic University of Korea and the program
was started in October, 2012. EDTA tubes containing peripheral blood were
shipped to central laboratory within 24 hours and standardized RQ-PCR
assays were performed. To validate the result, we analyzed BCR-ABL1 tran-
script level and compared with ABL1 copy number for quality control of each
samples.
Results: Between October 2012 and November 2014, a total of 4,638 samples
from 1,545 CML patients were tested to measure the ratio of BCR-ABL1 to
ABL1 transcript level in international scale (IS). The ABL1 copy number was
more than 100,000 copies in 3,770/4,638 (81.3%), 32,000 and 100,000 copies
in 784 (16.9%), 10,000 and 32,000 in 43 (0.9%), and less than 10,000 copies
in 41 (0.9%) samples. Of 1,203 patients who were tested more than 2 times,
1,094 (90.9%) had appropriate copies of ABL1 for defining MR of each patient.
However, 109 (9.1%) in undetectable level were less than 100,000 ABL1 copies
which is inappropriate copies of ABL1 for defining MR5.0. Of 1,545 patients,
1,064 (69%) had MR3.0. Among them, 515 (33.1%) and 514 (33%) were in
MR4.5and MR5.0 respectively. Of patients achieving at least MR3.0, 98%
(n=1,043) and 87% (n=925) of patients had ≥32,000 and ≥100,000 ABL1 copies
respectively, and these were in the minimal requirement of ABL1 copy number
for defining MR4.5and MR5.0. 
Figure 1. Molecular response and Quality of RQ-PCR assay measuring
by ABL1 copy number (n=1,545).
Summary and Conclusions: Molecular monitoring using a centralization pro-
gram of BCR–ABL1 assay may provide stable and qualified results. Through
this program, more than 98%of samples met the minimum requirement of ABL1
copy numbers for at least MR4.5sensitivity and it can support for TFR studies
in the future.
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Background: Few data is available about long-term follow-up treatment and
outcomes with Tyrosine Kinase Inhibitors (TKI) in South American patients
(pts). Response to TKI is known as the most important predictor of outcome in
Chronic Myeloid Leukemia (CML). Early achievement of responses has also
been determined by many authors as predictor of long-term outcomes. How-
ever, major molecular response (MMR) is not a failure criterion at any time
point.
Aims: To identify predictive factors for achievement of deep molecular
response (MR) and improvement of failure-free survival (FFS). Secondary
objective was to determine whether late MMR acquirement impacts on FFS.
Methods: Pts were treated with various TKI modalities between 2000 and
2014. Cytogenetic analyses were performed with standard G-banding. Molec-
ular diagnostics for residual BCR-ABL transcripts followed the procedures and
definitions of Cross et al; and were performed in a standardized and accredited
laboratory. Confirmed MR4.0was defined as ≥4.0 log reduction of BCR-ABL
(detection ≤0.01%) on the international scale and determined by Rq-PCR in
two consecutive analyses. Overall survival (OS) was defined as the time
between diagnosis and death from any cause. FFS accounts for failure to
achieve response as defined by ELN, lost of complete cytogenetic response
(CCyR), accelerated phase and blast crisis. Adherence monitoring was
assessed by treating physician and reported in medical record.
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Results: Of 119 pts with diagnosed chronic phase CML, median age was 48
years (range, 16-82), 52% were males. The percentage of pts with low Sokal
risk score were 82%, 25% of pts had been previously treated with interferon.
Median follow-up was 89 months (mo) (range, 3-306). A total of 103 pts were
treated with 1st line imatinib (IM) 400mg daily and constitute the basis of the
analysis. The proportion of pts treated with IM who achieved CCyR or BCR-
ABL <1% within 6 mo and MMR within 12 mo was 84% and 38% respectively.
Median-time to achieve MMR and MR4.0was 2.6 and 3.6 years respectively. At
60 mo, FFS was 91% and OS 98%. Pts still on initial IM were 79% after 8 years.
By logistic regression analysis CCyR/BCR-ABL <1% within 6 mo, MMR within
12 mo and adherence resulted independent predictors for achieving MR4.0 (OR,
95%CI and p value are detailed in Table 1). In pts who acquired CCyR/BCR-
ABL <1% within 6 mo, MMR within 12, 24 mo and adherence >90%, FFS at 60
mo was higher than those who did not (Table 1). The sub-analysis determined
that pts ≤30 years had lower adherence than older pts (76% vs 94% p. 0.02).
Table 1. Predictors of Deep Molecular Response and FFS analysis in Pts
With CML treated With IM.
Summary and Conclusions: In our long-term follow-up population,
CCyR/BCR-ABL <1% within 6 mo, MMR within 12 mo and adherence constitute
early independent predictors for achievement of deep MR consistent with the
published literature. Although good responses are obtained with IM, some pts
still progress, this is the reason why it is necessary to identify those who will
relapse so as to consider a change in treatment to another TKI at a convenient
time point. Better results in terms of FFS were observed for pts who acquired
CCyR/BCR-ABL <1% within 6 mo, MMR within 12 mo and adherence >90%.
Nevertheless MMR within 24 mo does not seem to affect long-term outcomes
and further investigations, in a larger pt population, are needed to determine
when MMR must be considered a failure criterion. In terms of adherence, young
adults are particularly at risk and a new strategy may be needed in this special
subgroup of pts. Lack of adherence can prevent the long-term molecular objec-
tive of treatment. These results emphasize the validity, feasibility and harmo-
nization of molecular monitoring and treatment of CML worldwide.
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Background: Chronic myeloid leukemia (CML) treatment monitoring using
PCR based peripheral blood testing provides improved test sensitivity over
cytology but suffers from inadequate standardization due to variation inherent
in the existing PCR methodologies. Standardized Nucleic Acid Quantification
BCR-ABL (SNAQ-BCRABL) is a novel competitive template based peripheral
blood b2a2/b3a2 transcript abundance method. It uses mixtures of b2a2 or
b3a2 and GusB competitive templates and melting curve analysis to provide
desired quality controls to correct for procedural variation. 
Aims: A pilot study was conducted in CML patients to evaluate the imprecision
and linearity of two established real-time qPCR laboratory developed test (LDT)
and SNAQ for monitoring BCR-ABL.
Methods: Thirty six CML patients treated at our institution were enrolled in this
pilot study. Their peripheral blood sample were analyzed at MD Anderson
Molecular Diagnostic Laboratory and Cancer Genetics Institute for BCR-ABL
by LDT (L1 and L2) and SNAQ (S1 and S2) test respectively. The LDT methods
used TaqMan real-time assays to quantify BCR-ABL and ABL targets in cDNA
synthesized from WBC RNA isolated from the blood specimens. The SNAQ
method likewise used cDNA synthesized from WBC, but differs at the PCR
step by the addition of known quantities of competitive templates (b2a2 or b3a2
and GusB) to the cDNA prior to PCR amplification and melting curve analysis.
AccuGenomics’s SNAQ software imports the melting curve data, performs qual-
ity control and curve fitting analysis to generate a BCR-ABL report. The LDT
methods report %BCR-ABL/ABL results using International Standard, and the
SNAQ results were reported as %BCR-ABL/GusB. 
Results: Each test result (n= 36) was ranked against all the other samples
tested by the same method. The Pearson correlation between SNAQ and LDT
was met with correlations of 0.96, 0.96, 0.97 and 0.94 with L1 x S1, L1 x S2,
L2 x S1 and L2 x S2 respectively. ANOVA of log %BCR-ABL interlaboratory
results indicated a significant difference between LDT methods (p<0.0000001),
but not with the SNAQ methods between labs (p=0.98) (Figure1A). Imprecision
was estimated using the Bland-Altman method and the plot indicated that sam-
ple results from L2 had 1 outlier, which was excluded from analysis. All three
L1 difference plots (Figure1B & C) had a significant trend (p<0.007), requiring
regression correction prior to estimating variation. The linear regression analy-
sis, indicated L2 LDT was a large source of method bias.Post hoc analysis of
method agreement showed the SNAQ method did not generate any outliers
and had a 95% limit of agreement of ±3-fold between laboratories, whereas L1
and L2 LDT method had significant differences despite reporting in international
scale, with 95% limit of agreement of 2 to 20-fold. 
Figure 1.
Summary and Conclusions: In this pilot study, SNAQ methodology performed
well suggesting it might be able to overcome some of the limitations encoun-
tered by some of the LDT currently in clinical practice. Additional studies with
more patients and correlation with clinical outcomes are required to confirm
this observation.
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Background: In February of 2009 the Canarian registry of chronic myeloid
leukemias (CML) was created in order get a better insight of treatment
response, behavior and outcome in our region. For that purpose data from
patients treated in the 7 hospitals of the Canary Islands was collected.
Aims: The purpose of the study was to investigate the cardiovascular risk asso-
ciated with the use of Tyrosine Kinase Inhibitors (TKI) in the CML treatment.
Methods: Since 2009, 127 patients have been included. The series consisted
of 65 (51.18%) males and 62 (48.8%) females with a mean age at diagnosis of
54.64±16.37. 75 patients (59%) received Imatinib, 37 (29%) received Nilotinib
and 15 (12%) Dasatinib. We analyzed cardiovascular risk factors such as hyper-
tension (HTA), diabetes (DM), body mass index (BMI) and smoking. We esti-
mated the Framingham risk score (FRS) and researched the series retrospec-
tively for atherosclerotic events.
Results: Among risk factors to be considered in our series, we revealed that
55 patients (43.31%) were receiving concomitant drugs for hypertension, 34
patients (26.77%) had a concomitant DM, and 9 patients (7.09%) were smok-
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ers. According to WHO classification, 12 patients were classified as normal
weight (BMI<25), 32 patients were overweight (BMI 26≤30), 36 were obese
(BMI>30) and 47 unclassified because we couldn’t retrieve the BMI for the
whole series. At time of diagnosis 87 patients (68.5%) were classified as low
risk FRS category (<10% chance of suffering an atherosclerotic event), 19
patients (14.96%) as intermediate risk (10-20%) and 21 patients (16.54%) as
high risk (>20%). There were 9 patients (7.09%) who presented an atheroscle-
rotic event after treatment with a TKI of which 1 patient used Dasatinib (1/15)
(Cerebrovascular accident), 4 used Imatinib (6.67%) (2 aortic stenosis, 1 aortic
aneurism with bypass and 1 peripheral arteryoclusive disease (PAOD) with
ischemic ulceration) and 4 used Nilotinib (10.81%) (1 anterior ischemic optic
neuropathy, 1 intermittent claudication, 1 aortic stenosis accompanied with
intermittent claudication and 1 toe amputation). There was no significant dif-
ference in the incidence of the atherosclerotic events between Imatinib and
Nilotinib. Dasatinib patients were excluded due to the small series. The 9
patients with atherosclerotic events had high blood pressure levels, 2 of them
had the hypertension under contol and the rest (7 patients) had an uncontrolled
hypertension. There was a significant difference in incidence of the events
between patients with low risk FRS category (33.33%) and intermediate-high
risk FRS (66.66%) regardless the treatment (p=0.025). There was no significant
difference in patients with imatinib between low risk FRS (57.33%) and inter-
mediate-high risk FRS (42.67%), where 2 of the patients having atherosclerotic
events were classified as low risk FRS and the other 2 were classified as high
risk FRS. But in patients with nilotinib is a significant difference between patients
classified as low risk FRS (64.86%) and intermediate-high risk FRS (35.10%)
(p=0.005), where the 4 patients presenting atherosclerotic events were classi-
fied as high risk FRS.
Summary and Conclusions: Atherosclerotic risk factors in patients with CML
should be considered before the treatment with TKIs. Those patients with high
risk factors to which is decided treatment with Nilotinib despite the risk score
should also be closely monitored.
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THE RATE OF BCR-ABL DECLINE AS AN OPTIMIZED PREDICTOR OF
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Background: About 70% of chronic myeloid leukemia (CML) patients achieved
early molecular response (BCR-ABLIS ≤10% at 3-months) that led to 5-years
overall survival close to 95%. Nonetheless, CML patients remain heteroge-
neous group and several studies in recent years were aimed to personalize
treatment based on individual patients’ characteristics. Our group previously
put forward a hypothesis about the prognostic value of individual BCR-ABL
decline rate in the first three months of CML therapy1,2. The ratio BCR-ABL at
3 months to baseline had chosen as 0.1 as best cut-off value (sensitivity 83.33,
CI 62.6-95.3; specificity 66.67, CI 34.9-90.1) to predict MMR at 12 months.
Aims: The aims of this study were to validate our prognostic method in larger
group of patients.
Methods: Fifty-five patients (median age, 52 years; range 19-84; 24 male and
31 female) with chronic phase CML were included in the study. Distribution of
Sokal risk groups were as follows low-30 / intermediate-15 / high-10. Six
patients had EUTOS high-risk. Forty-two patients started treatment with Ima-
tinib 400 mg/day, 12 patients started with Nilotinib 600 mg/day and 1 patient
started with Dasatinib 100 mg/day. Median BCR-ABLIS transcript levels was
41.38% at diagnosis, range 3.39-3185.36%. The ratio of BCR-ABL levels at 3
months to baseline for each patient was calculated. In addition, we calculated
ratio of BCR-ABL levels at 3 months to BCR-ABL levels at 1 month for 13
patients. Comparison was made of the predictive sensitivity to achieve early
molecular response at 3 months (10% by IS). We estimated relative risk (RR)
the probability of achieving MMR, depending on the method of stratification of
patients. Statistical analysis was conducted with Fisher exact test.
Results: Twenty-six out of 34 patients (76.5%) with ratio of BCR-ABL levels at
3 months to baseline below than 0.1 achieved MMR at 12 months, while only
9 of 21 patients (42.9%) with ratio more than 0.1 had optimal response
(RR=0.41 (0.20 – 0.84); p=0.03). Ratio of BCR-ABL levels at 3 months to 1
month also showed good results with the same (0.1) cut-off value – 5 out of 6
patients (83.3%) with ratio BCR-ABL at 3 months to 1 month below than 0.1
achieved MMR, while only 1 patient (14.3%) with ratio more than 0.1 achieved
optimal response (RR=0.19 (0.03 – 1.19); p=0.05). Application of early molec-
ular response at 3 months (10% by IS) yielded worse discrimination results: 34
of 47 (72.3%) patients with BCR-ABL level ≤10% at 3 months had achieved
MMR at 12 months, whereas 2 of 8 (25%) patients with BCR-ABL>10% had
MMR at 1 year (RR=0.96 (0.62 – 1.49); p=0.78). Moreover, application of our
ratio cut-off value among patients with BCR-ABL level ≤10% at 3 months
allowed us to revealed additional 6 high-risk patients have not reached MMR
at 1 year of therapy, Figure1.
Figure 1.
Summary and Conclusions: Our study demonstrated that the individual BCR-
ABL decline rates from baseline to 3 months and to 1 month might be useful
prognostic markers that allowed detecting more patients at risk who had no
MMR at 1 year of treatment with using ABL as control gene. Also, the study
showed that the individual ratio of BCR-ABL levels might be studied as more
predictive landmark for change of TKI treatment even among patients that have
BCR-ABL levels ≤10% at 3 months.
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Background: Imatinib (IM) represents an important therapeutic option in
Chronic Myeloid Leukemia (CML). There are various clinical trials suggesting
safe IM discontinuation in CML patients with sustained major molecular
response (MMR), however, life-long therapy with IM is still the consensus rec-
ommendation. Therefore, there is increasing interest in identifying long-term
therapy associated toxicity of this treatment. There is lack of evidence regarding
the effect of long-term IM treatment on renal function.
Aims: To study the possible effect of IM therapy duration on renal function
impairment.
Methods: We studied a group of 48 patients (25 men, 23 women), 47 in
chronic phase (CP) CML, 40 (83%) of these patients with deep molecular
response (MR4.5), 1 patient with accelerated disease, receiving IM in the
course of their disease. Exclusion criteria was chronic renal disease at base-
line (estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73m2). The
median age was 51 (range 25-78) at the time when IM was started. The
median duration of IM treatment was 76,8 months (4,2 – 149,6), median total
follow-up was 84,1 months (4,2 – 152,6). 36 patients (75%) were previously
treated with interferon (IFN), median duration of treatment 29,4 months (4,2-
278,8). At present, 6 of these patients are receiving IFN together with IM
treatment. Laboratory data (creatinine, urea) and eGFR using CKD-EPI equa-
tion were obtained periodically from the start of IM treatment. Clinical infor-
mation about hypertension (HTA) and diabetes (DM), relevant for renal func-
tion assessment was collected.
Results: The mean baseline eGFR was 96,27±17 ml/min/1.73m2, mean eGFR
at last observation 77,55±25 ml/min/1.73m2, mean decrease between the base-
line and last eGFR 18,71 ml/min/1.73m2. During the follow-up, 5 patients devel-
oped Acute kidney injury (AKI), defined as increase in creatinine ≥0,3mg/dl, all
of them during the first month of IM treatment. There was the normalization of
creatinine and eGFR values in only 2 of these patients. 10 patients developed
chronic kidney disease, median age of this group was 64 (31-78), 1 patient
was diabetic and 6 patients had history of HTA. eGFR decreased significantly
with IM treatment duration (p<0,05). Age, HTA, DM or previous IFN treatment
were not significantly related to eGFR decrease.
Summary and Conclusions: Although IM is well tolerated and highly efficient,
its long-term effect on eGFR decrease and its mechanism are not well estab-
lished. We proved that IM treatment duration may be associated with important
eGFR decrease. Patients receiving IM should be monitored closely with regular
eGFR calculation.
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Background: Precise, mature data about real-world treatment efficacy in mod-
ern era of chronic myeloid leukemia (CML) are still missing. Moreover, true
incidence of persistent side effects of tyrosine kinase inhibitors (TKI) is rarely
reported in clinical trials.
Aims: To give a real picture of TKI treatment by analyzing detailed, prospective
database of all consecutive CML cases.
Methods: Data regarding all patients treated in the academic institution with
the catchment area of about 2 million people were analyzed according to the
European LeukemiaNet recommendations (Guilhot, Blood 2012). Diagnostic
and treatment protocols follow ELN and EUTOS recommendation/standard-
ization. TKI side effects were assessed according to CTCAEv4. 
Results: Two hundred and fourteen patients (median age 58 years, range 18-
92; 53.7% of males) with newly diagnosed CML in 2005 – 2014 underwent the
analysis: 194 patients (90.7%) in chronic phase (CP), 11 (5.1%) in accelerated
phase, 8 (3.7%) in blast crisis, and in 1 (0.5%) case the phase was unknown.
In total, 41 (19.2%) patients died during the follow-up (median 3.8 years, range
0.1-9.8): 22 patients due to CML activity, 13 patients due to causes probably
not related to CML, and in 6 cases the reason was unknown. The first line ther-
apy given to patients diagnosed in CP (Sokal high risk in 29.9%) was as follows:
imatinib, N=152 (78.4%); nilotinib, N=24 (12.4%); dasatinib, N=6 (3.1%); other,
N=7 (3.6%); none, N=5 (2.5%) due to death (N=3) and lost to follow-up (N=2)
before the treatment start. The median follow-up of 182 patients in CP treated
with 1st line TKI was 45.3 months (range, 5.2-115.8). Estimated cumulative
incidences of complete cytogenetic responses and major molecular responses
at 48 months were 92.2% and 89.2%, respectively. Estimated OS (defined as
the time from the start of TKI therapy to the death, with no censoring at the
time of therapy change) at 48 months was 89%. Estimated PFS, FFS, EFS,
and ATFS at the same time point were 89.9%, 74.5%, 67.4%, and 66.7%,
respectively. In total, 38.5% of patients permanently discontinued the first line
TKI. The reasons for discontinuation in group treated with imatinib (N=61/152;
40.1%) were resistance in 32/61 patients (52.4%), intolerance (13/61; 21.3%),
and other reasons (16/61; 26.2%; in 9 cases the reason was participation in
discontinuation trials, and in 5 patients non-CML related deaths). Reasons for
nilotinib discontinuation (6/24; 25%) were as follows: resistance (N=1), intoler-
ance (N=3), and other (N=2). Subsequent therapy after imatinib discontinuation
included dasatinib (N=19), nilotinib (N=16), and other (N=15). After cessation
of nilotinib, patients were treated with dasatinib (N=2), imatinib (N=2), and other
therapy (N=2). Analysis of imatinib and nilotinib clinical non-hematological tox-
icity incidence during the time revealed significant proportion of clinically rele-
vant events of grade 2-4, and their persistence during the whole follow-up
(Table 1).
Table 1. Incidence of clinical non-hematological toxicities during the time
of imatinib and nilotinib first line therapy.
Summary and Conclusions: About 10% of CML patients is diagnosed in
advanced disease and many newly diagnosed patients still die from leukemia.
Moreover, more than one third of patients in CP have changed the first line
therapy, mainly due to resistance, or intolerance. ATFS is a valuable parameter
covering all situations of treatment change. In patients who continue on origi-
nally chosen TKI, there is the evidence of clinically relevant adverse events
persistence in many of them, which can influence quality of life and can con-
tribute to drug non-compliance. More detailed analysis will be presented.
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Background: Attention of physicians caring for CML patients is seldom focused
on anemia as it was not shown to be an independent prognostic factor and it
may have different causes during the course of disease. The relevance of ane-
mia in routine clinical setting outside the clinical trials has not been sufficiently
covered. 
Aims: To evaluate the prognostic and clinical importance of anemia in CML
patients treated with imatinib using data from the international CML CAMELIA
Registry.
Methods: Retrospective analysis of all files of CML patients treated with first-
line imatinib in first chronic phase was performed. For the purpose of the study
anemia was defined by hemoglobin level lower than 120g/l. Single center survey
of quality of life using simple questionnaire in 32 CML patients with and 31
without anemia was performed. For statistical testing Mann-Whitney test and
Fisher exact test, for survival analysis Kaplan-Meier method with log-rank test
were used.
Results: Anemia was identified at diagnosis in 211 (45%) from the total cohort
of 469 patients in first chronic phase of CML treated with imatinib. Anemia was
not associated with initial cytogenetic findings (p=0.946) or age (p=0.125), but
strong correlation was found with higher risk scores in all prognostic systems
(Sokal, Hasford, EUTOS; p<0.001). Patients with anemia had significantly high-
er numbers of WBC (median=175.6 vs 48.0 p<0.001) and more frequent
splenomegaly (p<0.001). Response to the treatment was similar: major molec-
ular response was achieved in 72.5% and 68.7% of patients without and with
anemia, respectively. However, when assessing overall survival with the end-
point death caused by CML, anemia was associated with worse outcome (log-
rank test p=0.013). There were 23 deaths caused by CML among 31 dead
patients with anemia (74.2%) but only 11 out of 28 deaths (39.3%) in the group
of patients without anemia (p=0.009). During the treatment with imatinib anemia
was identified in 91 (19.4%) patients at one or more occasions. There was no
correlation with the anemia or risk scores at diagnosis. There was a trend
towards association of anemia with age over 60 years (24.4% vs 16.9%;
p=0.063). Anemia during the treatment was not associated with response to
treatment, but has significant impact on quality of life: patients spent more time
in bed (p=0.014), less time outside the flat or house (p<0.001), they suffered
more from dyspnea (p=0.022) and there were trends for lower Karnofski score
(p=0.057), unemployment (p=0.077) or sport capacity (p=0.079).
Summary and Conclusions: Anemia at diagnosis in CML patients from
CAMELIA Registry was a frequent finding and was associated with the high-
risk features. Despite the fact that response to treatment was not compromised
with anemia at diagnosis, a significant association was found with CML-related
death rate. During the treatment with imatinib, anemia was found in about 20%
of patients, affected more frequently elderly patients and had negative impact
on their quality of life.
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Background: The additional benefit of achieving major molecular response
(MMR) in patients with Complete Cytogenetic Response (CCyR) response is
still under debate, and therefore, patients with CCgR without MMR after 12
months of treatment are considered as a “warning” by European LeukemiaNet
(ELN) recommendations. Several clinical trials have shown how patients treat-
ed with imatinib front line and classified as late warning responders can benefit
from treatment changed to nilotinib in terms of improving molecular response.
However, there are no data regarding to treatment change to dasatinib in this
group of patients
Aims: To evaluate the efficacy and safety of treatment change to dasatinib in
patients treated with imatinib first line with late suboptimal response (patients
with CCyR without MMR after at least 18 months of treatment) by the ELN 09
recommendations
Methods: We are presenting preliminary results of the first 18 patients enrolled
in the phase II DASAPOST study (NCT01802450). Main inclusion criteria were
patients treated with late suboptimal response by the ELN09 (CCyR without
MMR after 18 months of treatment). Previous treatment with imatinib 600mg
(but not 800mg) was allowed. Median exposure to imatinib before dasatinib
was 5.1 years (1.8-12.2). Sokal risk groups % (L/I/H) was 22.5%, 55% and
22.5%. Median age was 56 years (34-77). Primary end point was the achieve-
ment of MMR after 6 months of dasatinib. Secondary endpoints were to assess
the efficacy of dasatinib in terms of depth and kinetics of molecular response,
as well as the relationship of response with lymphocyte alterations. Responses
evaluations were performed following indications of the ELN. All BCR-ABL/ABL
(IS) measurements were centralized in an EUTOS laboratory.
Results: Clinical: Eighteen patients have been enrolled in the study. Median
follow up at data cut-off was 262 days (21-380). Three out of 18 (16%) patients
had discontinued dasatinib due to side effects (pancreatitis, pleural effusion
and low grade, persistent side effects (fever, arthralgias, anemia and asthenia).
16/18 patients have been evaluated at 3 months, 12 at 6 months and 6 at 12
months. Cumulative incidences by ITT of MMR calculated by competing risks
by 3 and 6 months were 50 and 83%. However, for patients who reached the
6 months assessment frequencies of MMR and MR4.5 were 85% and 42%
respectively. No patient have lost CCyR while 1 patient in MR4.5 lost MMR. 1
patient had reduced dasatinib dose to 70mg due to congestive heart failure
(patient achieved and maintained undetectable molecular response). Immuno-
logical: Lymphocyte counts were done before and after dasatinib intake at
baseline, at 3 and 6 months, observing an increment of counts post intake in
most patients. At baseline the median increase post intake was 1,79 fold (
0,98-3,2). There was no significant association between this increment and
MMR at 3M (MMR at 6 months was not studied, as most patients obtained this
response at that timepoint).
Summary and Conclusions: Our study shows, for the first time to our knowl-
edge, that in patients treated with Imatinib and late suboptimal (warning)
responses, switch to Dasatinib induced MMR in 83% of the patients, although
16% discontinued treatment because of toxicity. No association was found
between lymphocyte “mobilization” post intake and response. Dasatinib
appears to have a good benefit/ risk ratio in this type of patients. More details
on the immunologic studies will be provided.
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Background: BCR-ABL1 tyrosine kinase inhibitors (TKIs) have been admin-
istered as fixed doses for adult patients with chronic myeloid leukemia (CML).
However, due to the wide inter-individual variability in the pharmacokinetics of
TKIs and increasing evidence supporting the relationship between drug expo-
sure and the efficacy and toxicity of these agents, there may be potential ben-
efits of TKI dose individualization based on body size. Radotinib is a selective
second generation BCR-ABL1 TKI and a phase 2 study was previously con-
ducted in patients with TKI failed CP CML.
Aims: Using the data from the phase 2 study, radotinib exposure-efficacy and
-safety relationship analyses were conducted to explore the dosing methods
that will potentially improve the efficacy and safety profiles of radotinib.
Methods: The efficacy and safety data were collected for 12 months after the
initiation of radotinib therapy from a multi-center phase 2 study conducted in
77 CP CML patients resistant and/or intolerant to other TKIs. All patients
received radotinib 400 mg twice daily until a dose-limiting toxicity (DLT)
appeared, after which the dose was reduced to 300 mg twice daily. The rela-
tionships between the body weight-adjusted dose (Dose/wt) and the probability
of achieving major cytogenetic response or experiencing DLT were explored
using a logistic regression method. The analyses were repeated using body-
surface-area-adjusted dose (Dose/BSA). Upon a stratification of the patients
based on Dose/wt or Dose/BSA, time-to-first DLT curves were compared using
a Kaplan-Meier method.
Results: Efficacy. No significant associations were found between radotinib
Dose/wt or Dose/BSA and major cytogenetic response at Months 1, 3 and 6.
Safety. Positive correlations were observed between radotinib Dose/wt and
the probabilities of first DLT occurrence at Months 3 (p=0.002), 6 (p=0.003), 9
(p=0.004), and 12 (p=0.007). Similar positive correlations were observed for
Dose/BSA. Statistically significant differences were evident in the Kaplan-Meier
curves of DLT between various Dose/wt groups, particularly between the
groups of Dose/wt <6 mg/kg and Dose/wt ≥6 mg/kg (p=0.008) with the median
time to first DLT being 259 and 83 days, respectively. At the cut-off of 6 mg/kg,
the patient weighs 66.7 kg. A 2-tier weight-based dosing method was recom-
mended to reduce the probability of DLT: radotinib 300 mg or 400 mg twice
daily for patients weighing ≤65 kg or >65 kg, respectively.
Summary and Conclusions: The probability of DLT increased without
improvement in efficacy as the Dose/wt or Dose/BSA of radotinib increased.
Therefore, a lower initial radotinib dose of 300 mg twice daily is recommended
for CP CML patients weighing ≤65 kg. A randomized clinical trial would be
needed to confirm the efficacy and safety of this alternative dosing regimen.
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Background: Kantarjian et al. reported in the phase 3 DASISION TRIAL that
519 patients with newly diagnosed CML-CP from 108 centers in 26 countries
were randomized to receive dasatinib (n=259) or imatinib (n=260). Of these,
23 % (120) were from the Latin America (LA) region (23 % Argentina, 9 %
Chile, 3 % Colombia, 15 % Peru, 19 % Brazil and 30% Mexico).
Aims: The main objective was to evaluate if LA results from DASISION TRIAL
can be considered similar to those obtained in the overall study.
Methods: DASISION (CA180-056; NCT00481247) is a signed IC 60 month-
Open Label Multinational randomized phase 3 trial comparing dasatinib 100
mg QD versus imatinib 400 mg QD in patients with CML-CP diagnosed within
3 months who had not received previous treatment for CML. All exposure, safe-
ty, and efficacy results described here were analyzed on the 120 LA patients
(all randomly assigned to receive dasatinib (n=63) or imatinib (n=57)) in com-
parison to the total patients treated (including Latin American patients), here
referred to as “all randomized”. The efficacy and safety were assessed by using
data obtained during the initial 3 years period of the trial.
Statistical Methods: Comparison of the rates was performed for p=0.05 (two-
tailed). Response (efficacy variables) and AEs rates were estimated with their
95% confidence intervals (CIs) when needed. The difference in rates between
the 2 treatment groups was tested by using Pearson Chi square Test. PFS and
OS by treatment group were estimated via the Kaplan-Meier product-limit
method. Due to the fact that the 120 LA patients is a subset of the planned
total enrolled population, every statistical analysis of LA was considered
exploratory.
Results: Treatment was discontinued due to disease progression in 4,8 % and
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7% of the cases, unacceptable toxicity in 3,2% and 8,8% of the cases in dasa-
tinib and imatinib groups respectively. Baseline characteristics and demograph-
ics of LA patients were relatively well balanced between the two treatment
groups and were similar to the overall study data with exception of baseline
high Hasford risk score in LA patients that was higher in both (dasatinib and
imatinib) treatment groups. At 36 months the rates of cumulative cCCyR, MMR
and PFS, OS and AEs rates for patients in either arm in LA patients and in all
randomized patients can be seen in Table below. AEs in LA and in all random-
ized patients will be described.
Table 1.
Summary and Conclusions: The results reported here suggest that the effi-
cacy profiles of dasatinib vs. imatinib in LA patients are similar to those seen in
the analysis of all patients worldwide. Exploratory comparisons of efficacy in
LA patients of dasatinib vs. imatinib arms yielded similar trends as observed in
all patients, having numerically higher rates of cumulative long-term response
rate values of cCCyR and MMR in dasatinib treatment Group. Both treatment
groups also experienced high rate values of PFS and OS after a 3-year follow-
up. Since small sample size in LA limits the strength of conclusions for efficacy
and safety, further exploration is needed to confirm any potential differences
compared with the total treated population in order to increase accuracy.
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Background: Imatinib is the standart of care in patients with chronic myeloid
leukemia (CML). Generic imatinib (GI) has been approved in the treatment of
CML in many countries including Turkey. We previously published our experi-
ence regarding the efficacy and safety of GI in patients with CML who started
tyrosine kinase inhibitor (TKI) treatment with original imatinib (OI) [Glivec] but
then had to switch to GI due to reimbursement policy [Eskazan AE, et al. Leuk
Lymphoma. 2014;55:2935-7]. Among our patient cohort, the efficacy and safety
of GI were comparable to those of OI. However the median duration of GI expo-
sure in that study was 12 months, shorter than the OI treatment duration prior
to switching.
Aims: The aim of this study was to update the efficacy and safety data of GI
among our chronic phase CML (CML-CP) patient cohort when used sequentially
after OI treatment with an extended follow-up. 
Methods: Our study cohort consisted of one hundred and forty-five patients
with CML-CP who were followed under OI with a median of 55 months (Figure
1). Patients on OI first switched to GI due to reimbursement policy after August
2012, and 80 patients switched to GI whereas sixty preferred to receive OI and
pay the price difference from their own pockets. After a median follow-up of 12
months, the data was first analyzed in October 2013, and the generics were
found to be at least non-inferior to the OI regarding efficacy and tolerability
when used subsequently [Eskazan AE, et al. Leuk Lymphoma. 2014;55:2935-
7]. We updated the data of this study after an additional follow-up of 16 months
in February 2015.
Results: Since the first analysis, 74 patients received GI with a median duration
of 15.5 months, and there were four patients who switched to 2nd generation
TKIs (2GTKIs) due to resistance and 4 patients were lost to follow-up. The
median of GI exposure in these patients after the first switch was 27 months
(range, 6-32 months). In the OI group, 60 patients received Glivec with a median
of 61 months and 13 months after the first switch and the first analysis, respec-
tively. There were 3 patients who switched to 2GTKIs (2 due to resistance, one
due to grade IV hepatitis), one patient was lost to follow-up, and one patient
quit OI due to a planned pregnancy. Twenty-seven patients receiving OI
switched to GI during the follow-up after a median of 10 months, and at the
time of the analysis, the study cohort consisted of 121 patients of which 28
were still on OI whereas ninety-three were receiving GI. All of these 121 patients
had durable major molecular respose (MMR), and none of the 27 patients who
switched from OI to GI lost their responses during the follow-up. There were no
imatinib dose reductions due to toxicities in both arms, and 4 patients had non-
hematological adverse events (AEs) (myalgia in 3 and gastrointestinal in one)
in the GI group whereas in the OI group there were 3 patients (myalgia in 2 and
one patient had both myalgia and hepatitis) with non-hematological AEs. Among
the twenty-seven patients who switched from OI to GI, two had grade I myalgia
after the switch.
Figure 1.
Summary and Conclusions: With an extended follow-up, generics were still
found to be comparable to Glivec regarding both efficacy and safety when used
subsequently. 
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Background: Generic imatinib (GI) has been approved in the treatment of
patients with chronic myeloid leukemia (CML)in many countries including
Turkey. Since there were limited data and some concerns about the efficacy of
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generics, we previously published our experience regarding the efficacy and
safety of GI when used in the up-front setting [Eskazan AE, et al. Br J Haematol.
2014;167:139-41]. Although the duration of GI exposure in this study was rel-
atively short, the efficacy and safety of GI were at least non-inferior to those of
original imatinib (OI) [Glivec].
Aims: The aim of this study was to update the efficacy and safety data of GI
among our chronic phase CML (CML-CP) patient cohort in the frontline setting
with a prolonged follow-up. 
Methods: We first analyzed the data of CML-CP patients who received up-
front Glivec and GI in February 2014 [Eskazan AE, et al. Br J Haematol.
2014;167:139-41] (Figure 1). There were 36 patients who started the tyrosine
kinase inhibitor (TKI) treatment had with OI, and twenty-six with GI. After medi-
an follow-up of 8.5 months and 20 months of GI and OI, respectively, we did
not find significant difference regarding efficacy and AEs between these 2
groups. During the follow-up, 8 patients switched from OI to GI due to reim-
bursement policy. We wanted to update the data of the initial cohort with an
additional follow-up of 12 months, and we also recruited new patients to the
study.
Figure 1.
Results: During the follow-up, 24 newly diagnosed patients were recruited in
the GI group whereas one patient started receiving OI (Figure 1). Nine patients
from the OI group switched to GI group due to reimbursement policy after a
median follow up of 24 months (range, 11-45 months). They were all in major
molecular response (MMR) at the time of the switch, and after a median of 7
months (range, 3-15 months) of GI expose, they all maintained their responses.
In the GI group, 20 patients from the initial analysis were still receiving GI after
a median of 20 months (range, 10-28 months), of which 15 had MMR, 4 had
complete cytogenetic response (CCyR), and one had partial CyR. Among the
24 newly diagnosed patients receiving GI, sixteen (67%) were male, and the
median age was 55 years. Low, intermediate and high Sokal risk score rates
were 47%, 47% and 6%, respectively. The median duration of GI treatment
was 8 months (range, 2-28). There were 11 patients with a follow-up of ≤6
months of which ten had complete hematologic response (CHR). Among the
8 patients with a follow-up of >6 and <12 months, 5 had CCyR and three had
MMR. Five patients had a follow-up duration of ≥12 months (median, 22
months), and all of them were in MMR. During the follow-up, patients who
needed to be switched to 2ndgeneration TKIs (2GTKIs) due to resistance in
the GI and OI groups were 3 and two, respectively. When the two groups were
compared regarding AEs, in the OI group the most common non-hematologic
AEs (all grades) were myalgia (n=8) and peripheral edema (n=4). The most
common hematologic AEs were thrombocytopenia (n=4) and neutropenia (n=1)
observed among patients in the OI group. In the GI group, the most common
non-hematologic AEs were peripheral edema (n=6), myalgia (n=5) and skin
reactions (n=3). The most common hematologic AEs in the GI group were
thrombocytopenia (n=3) and neutropenia (n=3). There was a patient in the GI
group who was switched to a 2GTKI due to grade III skin reaction. Also one
patient from the OI group switched to 2GTKI due to grade IV hepatitis. There
were 5 patients in the GI group who were lost to follow-up, and one patient
was lost to follow-up in the OI group. At the time of the analysis, after a median
follow-up of 16 months (range, 3-28 months), there were 37 patients who were
on up-front GI. Twelve patients who were still on frontline OI after a median fol-
low-up of 31 months (range, 19-55 months) were all in MMR.
Summary and Conclusions: GI was still non-inferior to OI regarding efficacy
and tolerability when used in the up-front setting among patients with CML-CP
with an extended follow-up.
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Background: Ponatinib is a potent pan-BCR-ABL tyrosine kinase inhibitor
(TKI). The phase 2 PACE study demonstrated that ponatinib is highly active in
heavily pretreated CP-CML patients, 58% of whom received ≥3 prior TKIs. Pre-
liminary evidence in the phase 3 EPIC study suggests that ponatinib has
improved efficacy over imatinib in newly diagnosed CP-CML, but with a higher
rate of arterial occlusive events at the doses studied. Fixed starting doses of
ponatinib (45 mg qd) and imatinib (400 mg qd) were used in these studies, but
the allowance for treatment interruptions and dose reductions, coupled with
frequent assessment of BCR-ABL levels, enabled high-resolution analysis of
dose-response relationships. 
Aims: To inform design of trials to optimize ponatinib dose, here we use a
novel approach, BARD (BCR-ABL Response-Dose association), to evaluate
associations between ponatinib dose and changes in BCR-ABL levels across
different lines of therapy.
Methods: BCR-ABL transcript levels were measured every 1-3 months in blood
samples from CP-CML patients in the PACE (N=267) and EPIC (N=154 [pona-
tinib] and 152 [imatinib]) studies, which had median follow-ups of 34.2 and 5.1
months, respectively. The change in BCR-ABL levels (expressed as 1/doubling
time [1/DT]) and average daily dose (based on patient daily dosing records)
were calculated for every measurement interval (window). 1/DT values were
analyzed for differences by t-test. An exponential growth/decay model was
used to transform the average 1/DT values, to BCR-ABL halving times. We
performed a series of analyses to demonstrate that including BCR-ABL/ABL
transcript values >10% IS does not strongly affect our conclusions; we will
present additional data using GUS to normalize the data.
Results: In newly diagnosed patients (EPIC), across all dose levels, BARD
analysis showed that BCR-ABL halving times induced by ponatinib and imatinib
were 13.8±1.2 and 27.1±2.4 days, respectively, consistent with the more rapid
molecular responses observed in the ponatinib arm. Within windows that includ-
ed only continuous dosing at starting dose levels, BCR-ABL halving times were
significantly more rapid with 45 mg ponatinib than 400 mg imatinib (p<0.0001)
(Table). Moreover, compared with 400 mg imatinib, BCR-ABL halving times
were also more rapid when average ponatinib dose levels were <15 mg
(p>0.05), 15 to <30 mg (p<0.02), and 30 to <45 mg (p<0.0001) (Table). In
heavily pretreated patients (PACE), across a similar timeframe as EPIC,
increased doses of ponatinib were also associated with a trend towards more
rapid decreases in BCR-ABL levels, although the rate of decrease induced by
45 mg ponatinib (halving time 28.1±4.8 days) was reduced compared with that
observed in newly diagnosed patients. Importantly, across the entire PACE
study, average daily doses of ponatinib as low as 10 mg were associated with
net decreases in BCR-ABL levels.
Table 1.
Summary and Conclusions: In newly diagnosed patients, ponatinib doses
as low as 15 mg induced more rapid decreases in BCR-ABL levels than 400
mg imatinib. The magnitude of BCR-ABL decreases induced by ponatinib in
heavily pretreated patients was reduced compared with newly diagnosed
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patients; nonetheless, ponatinib doses as low as 10 mg were still associated
with disease control overall. These analyses have helped inform the design of
studies aimed at optimizing the benefit/risk of ponatinib treatment for patients
with CML.
Gene therapy, cellular immunotherapy
and vaccination
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Background: Acute myeloid leukemia (AML) is the most common form of acute
leukemia in adults and current treatments remain unsatisfactory. Serious infec-
tions, resistance to therapy and relapses are the main causes of mortality
among these patients. The high frequency and severity of infections, even
before or during any chemotherapy, are probably due to a deep dysfunction of
adaptive immunity directly induced by the disease. T helper 17 cells (Th17)
play a key part in inflammatory response and autoimmune diseases, reducing
or promoting tumor growth and protecting against bacterial and fungal
pathogens. However, the role of Th17 cells in AML has not yet been clarified.
Aims: In our study we examine the relationship between Th17 cells, leukemic
cells, infections and immunocompetence. 
Methods: After obtaining the patient’s informed consent, peripheral blood was
collected from 30 newly diagnosed AML patients without infections and from
30 age-matched healthy volunteers (HV). Mononuclear cells (PBMCs) were
separated by density gradient centrifugation and CD4+cells isolated by negative
immunomagnetic depletion. Cells were cultured in complete medium, primed
for 24 h with IL-6 and for 5 h with PMA and ionomycin. An unstimulated control
was included for each experiment. After stimulation, cells were fixed, perme-
abilized and immunophenotyped for intracellular IFN-γ, IL-4 and IL-17A expres-
sion using the human TH1/TH2/TH17 phenotyping kit. For Treg analysis, naïve
PBMCs were stained with anti-CD4 FITC, anti-CD25 APC-Cy7 and then fixed,
permeabilized and stained with anti-FoxP3 APC. Appropriate isotype controls
were included for each sample. For cytokine secretion analysis, stimulated
CD4+cells were analyzed using human IL-17 and IL-10 secretion assay-detec-
tion kits. For co-culture assays, leukemic CD33+blast cells magnetically isolated
from patients and allogeneic CD4+cells obtained from HV were co-seeded in
1:1, 1:5 and 1:10 ratios and stimulated as previously described. At the end of
stimulation, T cell immunophenotypic and cytokine secretion analysis were per-
formed. Naïve CD4+cells were also stimulated for 24 h with C. Albicans pep-
tides, then depleted of IL-17-secreting cells and cultured for a further 24 h in
complete medium supplemented with C. Albicans peptides. T cells were then
analyzed for intracellular IFN-γ expression using the human TH1/TH2/TH17
phenotyping kit. A sample stimulated with C. Albicans for 48 h without depletion
of IL-17-secreting cells was added as control.
Results: In AML patients, compared to HV, we observed a strong increase in
Th17 cells that simultaneously released immunosuppressive IL-10, together
with a reduced frequency in Th1 and Th2 cells. Through the culture of AML-
derived CD4+cells with an infectious antigen (C. Albicans), we demonstrated
that Th17 cells selectively determined an immunosuppressive state, in terms
of a reduction in IFN-g production (Figure A). Moreover, all the changes
observed in T cells, and in particular in Th17 cells, were induced in vitro by
CD33+leukemic cells, as observed after co-cultures of healthy CD4+cells and
AML peripheral blasts (Figure B) and confirmed by restoration of the healthy
cytokine pattern after purification of patient T cells from CD33+cells.
Figure 1.
Summary and Conclusions: Our results show that altered Th17 cells actively
cause an immunosuppressive state in AML patients that may, considering the
long life of these cells, persist long enough to promote infections and probably
tumor escape. Th17 cells could thus represent a new target to improve AML
immunotherapy.
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Background: Several strategies have been under investigation for enhancing
antitumor activity in patients affected by a high risk solid or hematological malig-
nancies. The poor prognosis of these patients and the need to sustain antitumor
surveillance early after HSCT prompted the development of immune-based
therapies including the use of natural killer (NK). Currently, strategies to prepare
NK cell products include stimulation with IL-2 or other cytokines without any
pre-activation. The efficacy of these approaches is restricted by short-term per-
sistence and limited survival and effector function after adoptive transfer of the
NK cells into a patient. Recent studies in mice have shown that in vitro activation
with appropriate cytokines result in differentiation of long-lived NK lymphocytes
with memory-like properties.
Aims: Aim of this study was to investigate optimal culture conditions to induce
human memory-like NK cells both in autologous and allogeneic setting and to
analyze their lytic capacity against tumor cells (TC) or leukemia blasts (LB)
derived from onco-hematological patients.
Methods: The optimal culture conditions for ex vivo activation of human mem-
ory-like NK cells were established in allogeneic setting in 10 donors/recipients
pairs, using NK cells derived from HSCT donors and tested against leukemia
blasts (LB) derived from transplanted patients affected by acute myeloid or
lymphatic leukemia. For induction of memory like NK cells, NK cells isolated
from mononuclear cells of HSCT-donor by NK cell isolation Kit (Miltenyi Biotec)
were pre-activated for 16 hours with different concentrations of IL-12/IL-15/IL-
18, maintained in culture 7-10 days with IL-2 or IL-15 and then further activate
or not prior cryopreservation and evaluation of cytotoxic activity. NK cells were
alternatively activated overnight (ON) with IL-2 (control NK). During the various
phases and at the end of culture cell recovery, NK receptors and anti-tumor
cytotoxic activity of memory-like and control NK cells, were evaluated. 
Results: Donor-derived NK memory like displayed high levels of cytotoxic
activity against patients LB (mean: 53.7%, range 26-82 at effector:target ratio
of 30:1), while the levels of lysis against patients’ non malignant cells was
always less than 10% at E:T ratio of 30:1. Interestingly, this approach of acti-
vation with IL-12/IL-15/IL-18 makes NK cells endowed of high levels of anti-
tumor cytotoxic activity when compared with control NK cells activated ON with
IL-2 alone (mean 25%, range 12-33 at E:T ratio of 30:1). A surface marker
phenotype specific to memory-like NK cells has not yet been clearly identified
in mice, while in humans few studies have established some correlation
between surface phenotype of human NK-memory like and IFN-gamma pro-
duction. In agreement with these studies we confirmed that human cytokine
induced memory-like NK cells demonstrated increased expression of CD94,
NKG2A, NKp46 and CD69 compared with control NK cells from the same
donor. Preliminary experiments in murine model, obtained after transfer of
memory like and control NK cells derived from two different HSCT donors, sug-
gested that memory like NK cells persisted longer in the mice compared with
control NK cells. However, these data have to be confirmed in a larger number
of experiments, together with the ability of the transferred cells to maintain their
anti-tumor activity. Further experiments are in progress to determine the pos-
sibility of in vitro inducing memory like NK cells, able to efficiently kill TC, in
autologous setting, starting from NK cells isolated from patients affected by
solid tumors.
Summary and Conclusions: In the present study, we identified human NK
cells that exhibit enhanced anti-tumor cytotoxic activity after short-term pre-
activation with IL-12/IL-15/IL-18, followed by 7-10 days of in vitro culture with
IL-2 or IL-15 as compared with control NK cells. After confirmation that these
cells can persist and maintain their effector functions in vivo in both autologous
and allogeneic settings, this approach could be translated into future clinical
trials of adoptive NK cell therapy for cancer patients.
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Background: Hemophagocytic syndrome (HLH) is characterized by prolonged
and excessive activation of antigen-presenting cells (macrophages, histiocytes)
and CD8+T cells. This generates a severe hyperinflammatory condition and
organ damage including fever, cytopenia, splenomegaly, coagulophaty and/or
hypertrigliceridemia. HLH includes two different conditions: primary (or genetic
HLH) and secondary (or adquired), caused by infections, malignancy or autoim-
mune disorders. Histiocyte Society criteria have been widely used for diagnos-
ing HLH, however not all of them are usually present at the initial presentation.
HLH is a life-threatening disease which must be suspected and treated as early
as possible.
Aims: HLH is a rare and often fatal disease. Its incidence and main form of
presentation are not yet well known. This study aimed to evaluated the etiology,
clinical features and prognosis of HLH in our community.
Methods: A retrospective analysis was conducted through the medical files of
all patients with diagnosis of HLH between 2004 and 2014 in two different hos-
pitals. Clinical features, age, diagnostic criteria proposed by the Histiocyte Soci-
ety, etiology, treatment and evolution were analyzed. In our study 7 out of 28
patients did not meet the requested criteria due to the rapidly fatal evolution of
the disease.
Results: A total of 28 patients with a median age of 46.5 years were identified
(0,2 – 84 years), 19 male and 9 female (ratio 2.1/1). 12 were infection associ-
ated forms, 7 malignancy related, 5 due to autoimmune diseases and 4 were
of unknown etiology. Only secondary forms were analyzed. On the 21 patients
who met the diagnostic criteria, the clinical manifestations were fever (100%),
splenomegaly (66.6%), adenopathies (61.9%), ictericia (28.5%), edema
(28.5%) and neurological manifestations (19%). The laboratory findings were
hyperferritinemia (100%), cytopenias affecting two or more lines (90.5%),
hypertriglyceridemia (66.6%), liver enzyme alteration (52.4%), hypofibrinogen-
emia (47.6%), coagulopathy (38%), hypoproteinemia (38%), and hyponatremia
(28.5%). Hemophagocytosis was observed in 19 cases in bone marrow, only
1 case in the liver. The activity of natural killer lymphocytes was measured in
9 cases, and it was reduced in 5. Comparing the treatment regimens, 13 were
treated according to protocol HLH-04, in 8 of the underlying disease, a sup-
portive treatment was given to 7. The mortality due to HLH complications was
38% (8 patients), for non related complications 4.7% (3 patients). 52% expe-
rienced full recovery (11 patients).
Figure 1.
Summary and Conclusions: The incidence of HLH in our population can be
estimated between 2,1 and 2,8 cases /million. The majority were male (ratio
2.1/1). No primary forms were found in this analysis. The most common trigger
was infection which is consistent with the studies found in the literature. Out-
standing clinical manifestation were persistent fever and splenomegaly. Labo-
ratory data indicated that the most prevalent abnormality were hyperferritinemia
and cytopenia. The most used treatment regimen protocol was HLH-04 which
obtained acceptable tolerance and results. 
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HLA-PARTIALLY MATCHED CELLULAR THERAPY (STEM-CELL
MICROTRASPLANTATION) IN ACUTE MYELOID LEUKEMIA AND
MYELODISPLASTIC SYNDROMES
M.E. Martinez-Muñoz1,* R. Fores1, C. Regidor1, J.L. Bueno1, Y. Gutierrez1,
M. Garcia1, G. Bautista1, A. de Laiglesia1, N. Dorado1, J. Garcia-Marco1,
E. Ojeda1, A. Morales1, G. Anze1, C. Vilches1, R. de Pablo1, R. Cabrera1
1Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Majadahonda,
Spain
Background: Non-engraftment alloreactive cellular therapy has been proposed
as a treatment for acute myeloid leukaemia (AML). A host-versus-tumour effect
induced by graft-rejection has been suggested.
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Aims: To evaluate feasibility and safety of the microtransplantation in AML and
myelodisplastic syndrome (MDS) and estimate response rate, infections inci-
dence and the development of GVHD and alloreactivity.
Methods: We have performed 25 HLA-partially matched donor leukocyte infu-
sions (PM-DLI) infusions in 9 elderly patients (64-72 years old) with AML (6),
CMML (2) or RAEB (1) from 11 partially mismatched donors (9 haploidentical).
One or two apheresis of related donor peripheral mononuclear cells were col-
lected after G-CSF mobilization. The median number of MNC, CD34+,
CD3+and NK cells infused per course were: 3.16x108/kg (range 1.37-
5.51x108/kg), 3.29x106/kg (range1.42-6.58x106/kg), 1.15x108/kg (range 0.35-
2.42x108/kg), 0.94x107/kg (range 0.50-1.55x107/kg), respectively. Patients
received each PM-DLI following a conventional chemotherapy cycle (IA, HDAC,
MEC) or hypomethylant agent course. All patients except one received at least
two PM-DLI in each microtransplant. Expected NK cell alloreactivity, chimerism
and minimal residual disease were analyzed.
Results: The procedure was well tolerated, with a mild and transient “haploim-
munostorm syndrome” (fever, rash, diarrhea). Only the two patients with CMML
received corticosteroid. One patient suffered from early infusional reaction that
was resolved with support treatment. None of the patients showed acute or
chronic graft-versus-host disease (GVHD) or donor engraftment in chimerism
tests. No significant infections were observed. All AML/RAEB patients achieved
complete remission (CR). Four patients relapsed at 7, 9, 10 and 15 months
after the infusion; two of them achieved a second sustained complete remission
with another PM-DLI from a different donor (one of them had developed anti-
HLA antibodies). Currently, with a median follow-up of 11 months (range 1-25
months), six patients are alive and three died (one with CMML during the induc-
tion treatment and two due to leukemia progression).
Summary and Conclusions: Microtransplantation is a well tolerated procedure,
infectious complications are insignificant and the remission rates are encouraging,
in the absence of engraftment or GVHD. Patients can undergo a second micro-
transplantation from a different donor. Leukocyte infusions can be safely adminis-
tered following a hypomethylant agent course instead of conventional chemother-
apy. Despite of the promising results, larger patient cohorts are necessary to assess




UNTOUCHED GMP-GRADE PURIFIED ENGINEERED IMMUNE CELLS 
T. Straetemans1, C. Grunder1, S. Heijhuurs1, S. Hol1, I. Slaper-Cortenbach2,
H. Bonig3, Z. Sebestyen1, J. Kuball1,*
1Hematology / Laboratory of Translational Immunology, 2Cell Therapy Facility,
University Medical Center Utrecht, Utrecht, Netherlands, 3Institute for Transfu-
sion Medicine and Immunohematology, Johann-Wolfgang-Goethe University,
Frankfurt, Germany
Background: Engineering T cells with receptors to re-direct the immune system
against cancer has most recently been described as one of the scientific break-
throughs. However, a main challenge remains the GMP-grade purification of
immune cells selectively expressing the introduced receptor in order to reduce
potential side effects due to poorly or non-engineered immune cells.
Aims: By taking advantage of a model γδT cell receptor (TCR) naturally inter-
fering with endogenous TCR expression we aimed to develop a GMP-grade
method to obtain pure but untouched receptor engineered immune cells.
Methods: We designed the optimal retroviral expression cassette to achieve max-
imal interference with endogenous TCR chains. Following retroviral transduction,
non-and poorly engineered immune cells were efficiently depleted with GMP-
grade anti-αβTCR-beads. Next, the engineered immune cells were validated for
TCR expression, function and potential allo-reactivity in vitro against a panel of
tumor cell lines and primary tumors and in two humanized mouse models.
Results: The untouched enrichment of engineered immune cells translated
into highly purified receptor engineered cells with strong anti-tumor reactivity
both in vitro but also in vivo in two humanized mouse models. Importantly, this
approach also eliminated residual allo-reactivity of engineered immune cells.
Our data demonstrate that even with long-term suboptimal interference with
endogenous TCR chains such as in resting cells, allo-reactivity remained absent
and tumor control preserved.
Summary and Conclusions: All together, we present a novel GMP-grade
enrichment method of untouched engineered immune cells, which is potentially
applicable to all receptor-modified cells even if interference with endogenous
TCR chains is far from complete.
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EFFICIENT AND STABLE GENE TRANSFER INTO MESENCHYMAL STEM
CELLS
A. Bigildeev1,* N. Sats1, I. Shipounova1, N. Petinati1, V. Surin2, K. Cornils3,
T. Aranyossy3, B. Fehse3, N. Drize1
1lab. physiology of hematopoiesis, 2lab. genetic engineering, National Research
Center for Hematology, Moscow, Russian Federation, 3Research Dept. Cell
and Gene Therapy, University Medical Center Hamburg-Eppendorf, Hamburg,
Germany
Background: Mesenchymal stem cells (MSC) are attractive tool for gene ther-
apy due to their intrinsic properties. These cells produce long-living progeny,
differentiate into all mesenchymal lineages, and are easy to manipulate ex vivo.
Lentivectors have been shown to facilitate efficient transduction of rarely pro-
liferating cells.
Aims: The aim of this study was to evaluate the efficiency and stability of MSC
and progenitor-cell transduction by lentivectors in vitro and in vivo.
Methods: For in-vitro gene transfer, murine Dexter type long-term bone marrow
cultures (LTBMC) were infected 2 weeks after initiation by either a standard
LeGO-G2 vector (encoding eGFP gene under SFFV promoter) or a modified,
promoter-deprived vector (LeGO-G2pd) that was in some experiments barcod-
ed. The frequency of colony-forming unit fibroblast (CFU-F) was analyzed in
adherent cell layers (ACL) of LTBMC 2 weeks after infection. ACL were
trypsinized, and 500 cells/well were seeded in 96-well plates in aMEM with
20% FBS and 5 ng/ml bFGF. Infected LTBMC from each group were implanted
under the renal capsules of syngeneic recipients for the hematopoietic ectopic
foci formation. DNA was isolated from ACL, CFU-F, the inner cell mass of the
foci and the corresponding bone shells. The percent of marked samples was
assessed by PCR. For in-vivo gene transfer mice were injected with lentivirus
intrafemorally. The percent of marked ACL, CFU-F and foci formed was calcu-
lated 2-6 months after injection of lentivirus.
Results: Results are shown in Table. The percentage of cells in ACL marked by
lentivirus with eGFP expression was 17.6±5.9. About 25% of CFU-F from those
ACL were eGFP positive. Over half of all ectopic foci and corresponding bone
shells but only 5% of CFU-F from those foci were eGFP positive. Unlike in
LTBMC no eGFP fluorescence was detected in ectopic foci and CFU-F derived
from them. eGFP containing samples were revealed only by PCR. It has been
suggested that eGFP itself is immunogenic in vivo and CFU-F expressing eGFP
are eliminated by immune system of the recipients. So SFFV promoter was
deleted from the vector and LTBMC were infected with viruses lacking eGFP
expression. All bone shells developed from these implanted LTBMC were
marked. The abrogation of eGFP expression led to the increase of marked CFU-
F percentage within the ectopic foci up to 55%. The infection of LTBMC with
barcoded library provided the information of individually marked CFU-F from
infected ACL. Ectopic foci obtained from the infected LTBMC were also marked.
As ectopic foci are formed only by true MSC able to self-renew the presence of
foreign gene in the foci and CFU-F derived from them indicates the possibility
to transfer the genes of interest into MSC. It is important for the gene not to be
immunogenic. in vivo infection of MSC and CFU-F with vector w/o SFFV pro-
moter was effective as over half of LTBMC and ectopic foci carried foreign gene.
Table 1.
Summary and Conclusions: Our data suggest that MSC and stromal precur-
sor cells can be effectively and stably transduced in vitro and in vivo by lentivec-
tors. The genes of interest should not be immunogenic. Thus MSC can be used
as a reliable delivery system in gene therapy settings.
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IDENTIFICATION OF PREDICTIVE MARKERS OF IMMUNO-SENESCENCE
WITH FOCUS ON TUMOR SUPPRESSIVE GENES: HEALTHY DONORS
VERSUS PATIENTS DIAGNOSED WITH A LYMPHOPROLIFERATIVE
DISEASE
L. Dang1, K. Willard-Gallo2, H. Duvillier1, J.N. Lodewyckx1, S. Garaud1,
C. Gu1, S. Catherine3, D. Bron1,*
1Hematology, 2Molecular Immunology, 3Anatomo-pathology, Institut Jules Bor-
det (ULB), Bruxelles, Belgium
Background: Aging is associated with the functional alteration of multiple
organs including our immune system, thus affecting immune surveillance that
prevent the development of cancer. This is illustrated by the high median age
of most of the malignant hemopathies (MDS: 75y, AML: 70y, MM: 70y, NHL:
67y, CLL: 72y). In addition, aging is affecting other mechanisms of natural pro-
tection against cancer, resulting in poor DNA repair, telomere shortening, chro-
mosomal instability, altered intercellular communication, senescent environment
and loss in apoptosis-regulating genes. However, little is known in terms of
genetic or epigenetic modifications of tumor suppressive genes (TSG) in lym-
phocytes subsets.
Aims: 1.To identify predictive markers of immuno-senescence in T/B and NK
lymphocytes subsets, in a population of elderly patients with or without lym-
phoproliferative diseases (LPD): 2.To study tumor suppressor genes expression
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in lymphocytes subsets, according to age and diseases; 3.To Study the impact
of these factors on therapeutic responses and overall survival.
Methods: Healthy donors belonging to different ages groups and patients with
lymphoproliferative diseases (LPD) are recruited for immune status evaluation
after signed informed consent forms accepted by our ERB. Lymphocytes sub-
sets were analysed by flow cytometry (CD4, CD4RA, CD4RO,
CD4/CD25/FOXP3, CD8, CD19, CD16, CD56, CD197, CD27) before any treat-
ment. Each lymphocytes subset was isolated by the MASC isolation technology
for further molecular investigations. Tumor suppressor genes (TP53, PRDM1
and others) were quantified by RT-PCR on each purified lymphocytes subset.
Results: 21 healthy donors and 17 LPD (CLL and NHL) are currently prospec-
tively investigated and stratified according to ages and diseases. Absolute lym-
phocytes count was not significantly different among the different groups. In terms
of innate immunity, we found a significant lower number of NK celles (CD56+)
betwenn younger (<50y) and older (p=0 ,002) and between healthy donors and
patients (p=0,001). The functional tests are still on going. The CD4+/CD8+T cells
ratio was significantly increased in older patients (p=0,008). Among CD4+T cells,
CD4 memory and particularly T cenral memory lymphocytes were significantly
increased. CD3-/CD4+was also increaded. Quantitative RT PCR analysis
demonstrated a significant reduction in the TP53 gen expression in all pruified
lympocytes subgroups (CD4+, CD8+, CD19+, CD57+) when matched healthy
donors (>50yr) was compared with LPD patients (p=0,02). Thiese TP53 values
were inversely correlated with the expression of RPDM1 gene. Patients recruit-
ment is still on going and follow-up is too short to answer the tihrd objective.
Summary and Conclusions: our preliminary observations in a small series of
donors confirm that 1) both innate and adoptive immunities are affected by
aging: 2) Immuno-senescence is even more pronounced in patients compared
to matched healthy donors. The reason remains to be investigated. 3) down-
regulation of tumor suppressor gene such as TP53 is present in all lymphocytes
subsets and is correlated with aging.
E1131
CHRONIC EXPOSURE TO INTERFERON-ALPHA DRIVES MEDULLAR
LYMPHOPOIESIS TOWARDS T CELL DIFFERENTIATION IN MICE
M. Di Scala1,* I. Gil-Fariña1, L. Vanrell1, R. Sánchez-Bayona1, D. Alignani2,
C. Olagüe1, A. Vales1, P. Berraondo1, J. Prieto1, G. Gonzalez-Aseguinolaza1
1Gene Therapy, 2Department of Instrumental Techniques-Cytometry Unit,
CIMA, Pamplona, Spain
Background: Interferon-α (IFNα) is an antiviral, immunomodulatory and
antiproliferative cytokine which is produced in response to a variety of infectious
agents including viruses and bacteria. It constitutes a key component of natural
immunity linking innate and adaptive immune responses. In line with these
functions, IFNα has been utilized in the treatment of chronic viral infections
and diverse neoplastic conditions including hematological malignancies and
solid tumors. However, these activities are counterbalanced by the induction
of peripheral pancytopenia, which frequently limits its clinical use. 
Aims: Although a large amount of information exits about the beneficial and
deleterious effects of IFNα the modulation of hematopoiesis by IFNα still
remains poorly understood. This study aimed to investigate the consequences
of long-term IFNα treatment on blood cell homeostasis using a gene therapy
vector expressing this cytokine.
Methods: In this work, we analyzed the hematopoietic changes occurring in
mice subjected to chronic IFNα exposure. This was achieved by transducing
the liver of C57/BL6 mice with an intravenous injection of an adenoassociated
vector encoding IFNα (AAV-IFNα) to obtain sustained high serum levels of the
cytokine. Furthermore, the consequences of chronic IFNα exposure on lym-
phoid differentiation was assessed by transferring bone marrow cells from
IFNα-treated mice to Rag-/- mice. To understand the way IFNα modulates the
commitment of HSCs, we analysed by quantitative real time-PCR the expres-
sion levels of key transcription factors (TFs) involved in multipotent progenitors
(MPPs) lineage specification in total bone marrow (BM) cells, in purify Lin-
cKit+(LK) cells and in differentiated cells (Lin+). 
Results: Chronic IFNα exposure by AAV-IFNα injection induces a dramatic
change in the composition of the leukocyte population in the peripheral blood
and in the bone marrow. Here we found that (long-term hematopoietic stem
cells) LT-HSCs and (short-term) ST-HSCs are dramatically reduced in IFNα
treated animals causing a progressive and lethal pancytopenia indicative of
the exhaustion of the HSCs compartment. Moreover, long term IFNα treatment
guides multipotent hematopoietic progenitor cells toward a T cell fate. IFNα
directly downregulates both in vivo and in vitro the expression of B cell TFs in
lymphocyte precursor cells and this effect alters the differentiation of these
cells driving them to the production of T lymphocytes. 
Summary and Conclusions: In conclusion, our results demonstrate that long-
term exposure to IFNα exerts a complex impact on hematopoiesis, it compromises
the stemness of hematopoietic stem cells (HSCs) but also redirects the function of
the hematopoietic precursors cells triggering an unique genetic program in these
cells favoring the generation of T cells while blocking the development of B cells.
E1132
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Hematopoiesis, stem cells and microenvironment
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REQUIREMENT FOR PHOSPHOLIPASE C GAMMA 1 (PLCG1) IN
DEVELOPMENT AND MAINTENANCE OF HEMATOPOIETIC STEM- AND
PROGENITOR CELLS
P. Arreba-Tutusaus1,* T. Schnoeder1, T. Fischer1, F.H. Heidel1
1Department of Hematology and Oncology, Otto-von-Guericke University,
Magdeburg, Germany
Background: Hematopoietic stem cells (HSC) play a crucial role in the main-
tenance of hematopoiesis, balancing self-renewal capacity and differentiation
potential to form more committed progenitor cells. HSC homeostasis is highly
regulated by a complex network of signaling pathways and transcription factors.
Phospholipase C gamma 1 (Plcg1) is known as a key regulator of calcium sig-
naling which plays an important role in proliferation and differentiation of
immune. Upon activation by receptor and non-receptor tyrosine kinases, such
as T-cell receptor or JAK2, Plcg1 regulates the hydrolysis of phosphatidylinos-
itol 4,5-biphosphate, leading to the activation of various downstream pathways.
Several studies have reported Plcg1 to be essential for erythropoiesis during
murine embryonic development as well as for granulopoiesis in zebrafish mod-
els. Recently, our group provided first evidence for Plcg1 regulating maturation
of adult erythropoiesis. However, no previous study has investigated whether
Plcg1 is required for development or maintenance of hematopoietic stem cells.
Aims: In this study we aim to investigate the functional role of Plcg1 signaling
in fetal liver cells and adult hematopoietic stem- and progenitor cells using
RNA interference technology.
Methods: Fetal liver cells (FLC) were isolated from embryos at stage E13.5
while adult immature hematopoietic cells (Lin-Sca1+KIT+CD48-CD150+) were
sorted from 6-8 weeks C57/BL6 mice. Cells were transduced with either (non-
targeting) control shRNA or two different validated shRNAs targeting Plcg1. All
shRNAs were either GFP-labeled or selectable by puromycin. Colony-forming
potential was measured in methylcellulose medium and immunephenotype
was analyzed by flow cytometry. Functional potential of HSPCs was measured
in vivo using a short-term colony-forming unit spleen assay (CFU-S12) as well
as a long-term competitive repopulation assays. Engraftment capacity was
measured by a homing assay.
Results: Following Plcg1 knockdown, colony-forming capacity was significantly
reduced in fetal liver cells and adult HSC (when compared to non-targeting con-
trol). While fetal liver cells showed a significant erythroid maturation defect upon
Plcg1 knockdown in our previously published data, hematopoietic stem cells
revealed no maturation defect or lineage bias following inactivation of Plcg1.
Immunophenotypic analysis of colonies confirmed presence of all lineages at
reduced total numbers. To assess for HSC function we performed colony-forming
spleen assay and competitive repopulation studies in vivo. Here, loss of Plcg1
affected the functional potential of HSCs and fetal liver cells with significant
impairment of their colony-forming potential and repopulation capacity. This was
indicated by a drop in whole bone marrow chimerism below 10% at week 16-
20 post-transplantation. Again, lineage commitment was not affected, while a
reduction in HSPC abundance was observed. Inactivation of Plcg1 did not affect
homing of transplanted HSCs but effectively reduced proliferative potential.
Summary and Conclusions: Taken together, our data provide first evidence
that Plcg1 is required for HSPC homeostasis, since its genetic inactivation
negatively affects the functional capacity of HSCs. Ongoing experiments inves-
tigate the effects of Plcg1 on cell cycle activity and induction of apoptosis and,
aim to establish a mechanistic model to explain the observed phenotype.
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THE UTILITY OF FLUORESCENCE LIFETIME IMAGING IN ROUTINE BONE
MARROW SMEARS
I. Lorand-Metze1,* A.P. Racanelli2,3, C. Lenz Cesar4,5, M.A. Falconi6,
K. Metze2,7,8
1Internal Medicine, 2Laboratory of Analytical Cellular Pathology, 3National Insti-
tute of Photonics applied to Cell Biology ,(INFABIC), 4Institute of Physics,
5National Institute of Photonics applied to Cell Biology ,( INFABIC, 6Hematol-
ogy/Hemotherapy Center, 7Pathology, 8National Intitute of Photonics applied
to Cell biology (INFABIC), University of Campinas, Campinas, Brazil
Background: After excitation by a photon, a fluorophore will drop to the ground
state with some delay, according to exponential decay rates. This delay is called
lifetime. The new technique “fluorescence-lifetime imaging microscopy (FLIM)”
creates the image contrast with the help of the fluorescence lifetime values
(transformed in pseudo-colors) at each pixel of the two-dimensional microscopic
image and does not use the local concentration of the fluorophores or the emitted
spectrum. Now we can visualize microscopic structures based on differences
of their fluorescence decay rates, which depend on the physicochemical prop-
erties of the molecules, even when fluorescence is emitted at the same wave-
length. FLIM is a non-invasive technique, using low-potency lasers. Therefore
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it has been widely used in experimental settings with cell cultures or small organ-
isms. There are only very few reports on its application for diagnostic purposes
in routinely collected samples, such as bone marrow smears.
Aims: The aim of this pilot study was to investigate the utility of the FLIM tech-
nique for diagnostic purposes in routinely collected bone marrow smears.
Methods: We used non-stained routine bone marrow smears of 15 patients
after fixation with formaldehyde vapor. Images were obtained with a confocal
Zeiss Upright LSM780-NLO microscope equipped with a 63x oil immersion
objective and a HPM-100-40 Hybrid detector (Becker & Hickl), Image size was
512 x 512 pixels. The specimens were excited by a 405 nm pulsed diode laser
(80 MHz). In order to create equivalent images of the cytologic smears, pseu-
do-colors were attributed to different lifetime ranges. Images were compared
with the standard May-Grünwald-Giemsa (MGG) stained smears.
Results: In every case we obtained highly contrasted FLIM images, with clearly
distinguishable cellular elements. Photobleaching was rare. The obtained chro-
matin textures were somehow similar to that of the MGG images and permitted
to recognize the different types of hemopoietic cells. Erythrocytes were char-
acterized by the short lifetimes of their hemoglobin component. Cytoplasm and
the protein background showed intermediate lifetime values. Fluorescence life-
time of granulopoetic nuclei was considerably longer than in nuclei of erythrob-
lasts. Leukemic blasts of several types of acute leukemia showed considerable
variation, generally long lifetime values. In one case of Chediak-Higachi dis-
ease, the pathologic cytoplasmic granula were clearly distinguishable. Besides,
in that case, intracytoplasmic bacteria could be identified, which were not well
visible in the MGG stained smears.
Summary and Conclusions: The FLIM technique can be applied in routinely
acquired diagnostic bone marrow smears. No staining is needed. The images
are well contrasted, and permit proper identification of the cellular elements.
Different lifetime values of nuclear chromatin distinguish erythropoetic and gran-
ulopoetic lineage, thus suggesting relevant physicochemical differences of the
nuclear organization. Supported: FAPESP, CNPq 
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CORD BLOOD STEM CELLS BUT NOT ADULT STEM CELLS AFTER
TRANSPLANTATION OVEREXPRESS STEMNESS AND REPROGRAM-
MING GENES PARTIALLY OVERLAPPING THE SIGNATURE OF INDUCED
PLURIPOTENT STEM CELLS (IPS)
D. Cilloni1,* M. Podestà2, J. Petiti1, S. Carturan1, A. Bertaina3, F. Sabatini2,
V. Campia1, V. Gaidano1, P. Nicoli1, M. Berger4, F. Saglio4, G. Bandini5,
F. Bonifazi5, F. Fagioli4, L. Moretta6, F. Locatelli3, F. Frassoni2
1Dept Of Clinical and Biological Sciences, University of Turin, Orbassano,
2Stem Cell Laboratory, G.Gaslini Institute, Genova, 3Ospedale Bambino Gesù,
Rome, 4Ospedale Regina Margherita, Turin, 5Seragnoli Institute, Bologna,
6G.Gaslini Institute, Genova, Italy
Background: Hematopoietic stem cells (HCT) undergo tremendous expansion
and amplification during Hematopoietic Cell Transplant (HTC). To cope with
this challenge, HSC must activate several genes including those responsible
for self-renewal. 
Aims: To prove or disprove whether HSC decline or not in their proliferative
potentiality after HCT, we analyzed the expression of genes involved in self-
renewal and reprogramming in CD34+cells obtained from bone marrow cells
after the engraftment has been achieved.
Methods: Ninety-three genes, mainly involved in HSC regulation plus 30 gene
involved in epigenetic regulation, were analyzed in CD34+cells isolated from:
(i) Cord Blood (CB), (ii) normal Bone Marrow (BM), (iii) BM taken after umbilical
CB Transplant (UCBT), BM taken from (iv) adult or (v) children transplanted
with adult HSC. Expression data were compared among the five groups and
further with those obtained from iPS (induced pluripotent stem cells).
Results: Among the 93 genes analyzed, the following genes: DPPA2, LIN28,
NANOG, NESTIN, OCT4, SOX1 and SOX2 were found highly over-expressed
in CD34+cells isolated after UCBT with respect to CB or BM CD34+cells. The
level of expression of the above mentioned genes found in CD34+cells after
UCBT was similar to iPS cells. However, relevant differences in the expression
of several other genes were found between CD34+cells post-UCBT and iPS.
For instance, PTEN expression was 2 logs higher in UCBT CD34+cells than in
iPS. Protein analysis on CD34+cells confirmed the RNA data. Remarkably,
over-expression of genes overexpressed in CD34+cells after UCBT was not
observed in CD34+taken from BM after any other type of adult cell transplan-
tation. Moreover, we found about 2 logs over-expression of genes involved in
epigenetic control in CD34+cells taken from BM after UBCT when compared
to native CB CD34+cells.
Summary and Conclusions: CD34+cells taken from BM after UCBT over-
express fundamental genes involved in self-renewal and somatic cell repro-
gramming thus, partially acquiring the signature of iPS. These features are
unique since no other CD34+cell taken either from CB or adult BM or after any
hematopoietic adult cell transplantation shows similar pattern of gene expres-
sion. These findings open new perspectives: (i) toward a better understanding
of transplantation biology, (ii) toward governing gene expression in iPS to render
them safer for therapeutic purposes; (iii) in designing new methods to expand
HSC in more efficient and consistent manner.
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STROMAL CELL-DERIVED FACTOR-1 PLAYS IMPORTANT ROLES IN THE
REGULATION OF HUMAN EARLY B- AND T/NK-LINEAGE LYMPHOID
DIFFERENTIATION IN DIFFERENT MANNERS
H. Minami1,* K. Ohishi2, M. Masuya1, N. Katayama1
1Hematology and Oncology, Mie University Graduate School of Medicine,
2Blood Transfusion Service, Mie University Hospital, Mie University, Tsu city,
Mie prefecture, Japan
Background: Stromal cell-derived factor-1 (SDF-1) is shown to be essential
for B-lymphoid differentiation in mice. However, role for SDF-1 in human lym-
phopoiesis remains undefined. We previously reported that telomerized human
stromal cells support the differentiation of human hematopoietic progenitors to
CD45RA+CD7+CD10- T/NK- and CD45RA+CD7-CD10+CD19+B-lineage lym-
phoid precursors (Br J Haematol. 157:674-86, 2012). Because the stromal cells
produced SDF-1, we examined a role of SDF-1 in human early lymphoid differ-
entiation, using our coculture system.
Aims: In this study, we investigated whether and how SDF-1 regulates early
lymphoid differentiation from human hematopoietic progenitors to
CD45RA+CD7+CD10- and CD45RA+CD10+CD19+lymphoid precursors in the
presence of stromal cells.
Methods: CD34+lin-CD45RA-CD38lo hematopoietic progenitors were purified
from cord blood and cultured for 21 days either on hTERT-transduced human
bone marrow stromal cells or with conditioned medium (CM) collected from
cultures with stromal cells, in the presence of SCF, Flt3L, and TPO. To block
the binding of SDF-1 to CXCR4 receptor, anti-CXCR4 blocking antibody (Ab)
was added to the cultures. In some experiments, CD34+lin-CD45RA-CD38lo
cells were cultured with CM for 14 days and CD45RA+CD7+CD10- or
CD45RA+CD7-CD10+cells were isolated and incubated on stromal cells with
anti-CXCR4 Ab or isotype control. 
Results: In the cultures on stromal cells, anti-CXCR4 Ab significantly inhibited
the generation of CD45RA+CD7+as well as CD45RA+CD10+lymphoid precur-
sors from CD34+lin-CD45RA-CD38lo hematopoietic progenitors. Anti-CXCR4
Ab predominantly inhibited B-lineage differentiation in the cultures with CM.
We next examined the effect of anti-CXCR4 Ab on CD45RA+CD7+CD10- lym-
phoid precursors by culture on stromal cells. In control cultures, the number of
CD45RA+CD14- lymphoid cells including CD10+cells increased during 10 days
of cultures. However, in the presence of anti-CXCR4 Ab, the generation of
CD45RA+CD14- lymphoid cells including CD10+cells from
CD45RA+CD7+CD10- cells was suppressed, and few or no CD45RA+CD14-
cells were detected at day 10 after culture. Significant numbers of CD14+mono-
cytic cells were generated in both cultures. In the culture of CD45RA+CD7-
CD10+cells on stromal cells, anti-CXCR4 Ab inhibited their differentiation to
CD45RA+CD10+CD19+proB cells.
Summary and Conclusions: These data suggest that SDF-1 is important for
B-lineage differentiation regardless of presence of stromal cells but critical for
lymphoid differentiation from human early hematopoietic and CD7+lymphoid pre-
cursors in contact with stromal cells. These findings indicate that SDF-1 plays
key roles in early B- and T/NK-lineage lymphoid differentiation in different ways.
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COMPARISON OF SELF-RENEWAL EXPRESSION IN STROMAL IN VITRO
AND IN VIVO MICROENVIRONMENT MODELS – CRITICAL DIFFERENCES
AND THEIR IMPACT ON HEMATOPOIETIC SUPPORT FUNCTIONS
G. Horne1,* V. Campbell1, H. Wheadon1, T. Holyoake1, M. Copland1
1Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow,
United Kingdom
Background: The intricate relationship between the bone marrow (BM)
microenvironment and hematopoietic stem cells (HSCs), both normal and
malignant, is well established. Recent evidence highlights the importance of
the BM niche in governing stem cell behavior. Translational research is depend-
ent on understanding this relationship, utilizing both 2D and 3D in vitro co-cul-
ture experiments aiming to recapitulate this environment prior to in vivo studies.
The use of radiation and anti-proliferative agents on stromal cells is essential
in long-term co-culture. The effects of these treatments on hematopoietic sup-
portive function remain poorly understood.
Aims: (1) To define patterns of gene and protein expression of self-renewal path-
way components in in vitro co-culture models, using mesenchymal stem cells
(MSCs) and stromal cell lines; (2) To compare in vitro and in vivo models, using
CD34+CML-engrafted NSG mice. We hypothesized that radiation, anti-prolifer-
ative agents and confluency changes would be integral in altering hematopoietic
supportive function leading to incomparable results across models.
Methods: Human BM samples were collected from healthy donors and CML
patients (n=13) following informed consent. An unselected population of mononu-
clear cells was isolated to allow expansion of MSCs by plastic adherence. MSC
immunophenotype was confirmed as described (Mennan et al, 2013). Primary
CD34+CML cells were transplanted into sublethally irradiated (2.5Gy) 8week
old NSG mice (n=6). Mice were euthanized after 16weeks. Engraftment was
assessed using anti-human CD45 FACS analysis. Sorted CD45+cells were eval-
uated for BCR-ABL translocation by FISH. In vitro, M210B4, SLSL and HS5
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stromal cell lines were evaluated±irradiation (40Gy) or±mitomycin (10ng/mL);
varying confluency states were assessed. Gene expression of self-renewal
pathway components and downstream targets were analysed by Fluidigm qRT-
PCR. Protein expression was studied by IF and western blot.
Results: Between experimental models, significant variation in expression of
self-renewal pathway components was observed. Expression did not signifi-
cantly vary between normal and CML MSCs. Ageing MSC passage altered
these components, with upregulation in Notch (NOTCH2 p=0.0005, JAG1
p<0.0001, HES1 (ns)) between 4 subsequent passages. Unlike in vivo models,
there is limited expression of NOTCH4. The Hedgehog (Hh) pathway increased
with ageing MSC passage (SMO p=0.0002, GLI1 p=0.05). As expected, irra-
diation altered self-renewal expression in a time and cell-type dependent man-
ner, with most variation in M210B4. There was progressive downregulation of
Hh receptors, SMO (p=0.0005) and PTCH1 (ns). Within the Notch pathway,
there was initial upregulation followed by significant downregulation, particularly
in NOTCH2 (p=0.001). Ligands and downstream targets were unaffected. Mit-
omycin did not alter expression. Progressive confluency significantly increased
NOTCH1-4 expression in SLSL (p=0.03). However, unaffected ligand and
downstream targets suggested this was not due to cis-inhibition. Protein analy-
sis confirmed significant changes. Expression of both Hh and Notch varied
considerably from 2D in vitro models compared to in vivo murine models sug-
gesting further analysis is required in CML co-culture models.
Summary and Conclusions: Our data highlights the diversity between in vitro
co-culture models and the need to critically appraise these confounding factors
when developing 3D models and interpreting results in vivo. This will allow for
improved translation to clinical research. 
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BONE MARROW-DERIVED MSCS STIMULATED BY IFN-Γ INHIBITED THE
GROWTH OF TOXOPLASMA GONDII VIA UP-REGULATION OF GBP1
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Background: Mesenchymal stromal cells (MSCs) are a heterogeneous cell
population endowed with multi-lineage differentiation potential and extensive
immunomodulatory properties. MSCs have been successfully used for preven-
tion and treatment of immune disorders such as graft-versus-host disease.
Emerging preclinical studies suggest that MSCs might also protect against
infectious challenge. Toxoplasma gondii is an apicomplexan protozoan parasite
with a broad host range that is capable of causing significant disease in humans
and animals.
Aims: This study aimed to rule out the potential mechanism of human MSCs
against T. gondii.
Methods: Human bone marrow-derived MSCs (hMSCs) were pretreated for
24h with a series of concentrations of IFN-γ and then infected with T. gondii
strains of variant virulences (virulent RH/GFP and avirulent PLK/RED). RNA-
seq and westernblots were used to analyze gene and protein expression pat-
terns of hMSCs under IFN-γ-stimulated and unstimulated conditions. The intra-
cellular parasites (with fluorescence labeled) were counted microscopically at
multiple time points postinfection. The short hairpin RNA (shRNA) expression
was used to generate RNAi of GBP-1, GBP-2 and GBP-5.
Results: Human MSCs stimulated with IFN-γ were capable to inhibit the growth
of T. gondii (eg: at IFN-γ 10 ng/ml, the inhibition rates are 26.5% (RH/GFP) and
37.5% (PLK/RED) at 12 hr postinfection) in a dose-dependent manner. Com-
pared with the unstimulated MSCs (controls), IFN-γ treatment groups of 5, 10,
20 ng/ml inhibited T. gondii (RH/GFP) growth by percent of 17.7±7.9, 26.5±6.2,
30.0±7.7 (mean±SD, n=4) at 12 hr postinfection and the inhibition rates are
48.5±9.1%, 66.5±8.0% and 68.5±6.1% at 24 hr postinfection, respectively. In
the same concentrations of IFN-γ, the inhibition effect of MSCs on PLK/RED
strain was stronger than that on RH/GFP strain. Furthermore, After 48 hr postin-
fection, the ratio between parasites per parasitophorous vacuole (PV) containing
rosettes and single parasites in IFN-γ-stimulated MSCs was significantly
reduced compared with that in the unstimulated MSCs (p<0.01, p<0.01, p<0.001
for RH/GFP at IFN-γ 5, 10, 20 ng/ml, respectively). We also observed that the
resistance in hMSCs does not depend on IDO (p=0.59 for RH/GFP and p=0.45
for PLK/RED at IFN-γ 20ng/ml 24 hr postinfection). RNA-seq data showed that
IFN-γ-inducible p65 guanylate-binding proteins (GBPs) might play pivotal roles
in the inhibition of T. gondii growth. Reads per kilobase-pairs per million (RPKM)
mean values of GBP1, 2, 5 in IFN-γ-stimulated MSCs are 1093.3, 443.3, 348.2,
respectively. RNAi knockdown of GBP1 (but not GBP2, GBP5) in hMSCs result-
ed in significantly recovery of T. gondii growth from inhibition stimulated by IFN-
γ at 24 hr postinfection (p<0.01 and p<0.01 for RH/GFP and PLK/RED at 20
ng/ml level of IFN-γ, compared to shRNA control).
Summary and Conclusions: Human MSCs pre-stimulated with IFN-γ inhibited
the growth of T. gondii in a dose-dependent manner via up-regulation of GBP-
1 expression.
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SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY
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Background: Patients with Hodgkin lymphoma (HL) who progress after autol-
ogous hematopoietic stem cell transplantation (ASCT) have a dismal prognosis.
Therapeutic efficacy of conventional chemoradiotherapy is of little benefit and
only allogeneic stem cell transplantation (allo-SCT) is associated with prolonged
progression free (PFS) and overall survival (OS) in a proportion of eligible
patients. Monoclonal antibody drug conjugate Brentuximab Vedotin (BV) has
recently received approval for patients with HL who relapsed after, or are not
candidates for auto-SCT.
Aims: To retrospectively study the outcome of patients with HL who were treat-
ed with BV in Greece. The primary objective of our study was the estimation
of overall response rate as well as the PFS and OS of patients treated with BV. 
Methods: From June 2011 until August 2014, eighty patients with
relapsed/refractory HL received treatment with BV in Greece. Forty-three males
and 37 females with a median age of 32 years, range (18-77) were included in
this retrospective analysis. The median time from diagnosis to treatment with
BV was 35 months, range (5-245). Among the 80 patients, 61 (76%) received
BV due to relapse/progression after auto-SCT, 2 (2.5%) after failing both auto-
and allo-SCT, whereas 19 patients were treated with BV before auto-SCT, since
they were considered non-eligible for the procedure due to advanced age or
refractory disease. Fifty-four out of 80 (67%) patients had disease refractory to
induction treatment. The median number of treatments administered before
BV was 4, range (1-7). Refractoriness to treatment administered before BV
was observed in 52 out of 80 (65%) patients. BV was administered at a dose
of 1.8mg/kg every 3 weeks until disease progression or for a maximum of 16
cycles.
Results: At the time of this analysis, the median number of BV cycles admin-
istered was 6, range (1-6). Three patients died from progressive disease after
cycle 1, and therefore they were excluded from statistical analysis. The best
response achieved after BV was complete (CR) and partial remission (PR) in
14 (18%) and 31 (40%) patients, respectively. Nine (12%) patients had stable
disease (SD), while 23 out of 77 (30%) patients progressed during treatment
with BV. With a median follow up period of 9.5 months (range, 1-35) the median
PFS and the median OS were 10.5 and 31 months respectively (Figure 1). In
multivariate analysis: 1) refractoriness to treatment administered before BV
was associated with significantly reduced probability of achieving response to
BV [Odds Ratio=2.7, (95% CΙ 1.0 to 7.2), p=0.04], and 2) response to BV was
associated with significantly increased PFS [HR=0,14, (95% CI, 0,06 to 0,29),
p <0,0001] and OS [HR= 0,24, (95% CI, 0,07 to 0,77), p=0,017].
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Figure 1.
Summary and Conclusions: To our knowledge, this study is the second
largest study reported so far after the pivotal phase II trial which included 102
patients and resulted in the accelerated approval of BV. Although BV is a prom-
ising therapeutic option with an overall response rate of 58%, the median PFS
is only 10 months when BV is administered as a single agent. The therapeutic
efficacy of BV should be explored in different time settings such as, as salvage
before auto-SCT or as maintenance after SCT in order to consolidate estab-
lished responses. 
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EXPRESSION OF PD-I LIGANDS FOR CLASSICAL HODGKIN LYMPHOMA
PROGNOSIS
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Background: Classical Hodgkin lymphoma (cHL) is presente by some can-
cerous cells from germinal center B-cells and generality from non-malignant
reactive cells. Clinical outcome of cHL could be directly depended on pathways
between Hodgkin and Reed-Sternberg (HRS) cells and other cells in their
microenvironment. There is still much to learn in significance of the microenvi-
ronment in cancerous tumors and cHL especially. So, the main purpose of
study to evaluate importance of microenvironment expression.
Aims: To determine value of PD-L1 as a marker at prognosis and its association
with clinical outcome in cHL patients.
Methods: 49 patients with cHL were included in the analysis with stages IIA –
23, IIB – 3, III-IV – 23. Patients were treated by ABVD or BEACOPP 14/esc as
the first line therapyand radiotherapy by indications. cHL samples were received
from lymph node biopsies. PD-L1, PD-L2 expression levels were analyzed
using real-time RT-PCR. 
Results: For 49 patients OR rate after the first-line therapy was 93.9 % (47/49)
with a CR of 73.5 % (36/49) and PR – 22.4 % (11/49). Progression of the dis-
ease during the therapy was observed in 2 patients. Among the patients who
achieved a CR during the follow up (median – 24 months; range 12–36) – 9
had relapses. PD-L1 positive were 73.5% (36/49) of cHL cases and 26.5 %
(13/49) were PD-L1 negative. PD-L1 expression level was higher in nodular
sclerosis cHL and advanced stages of disease (p=0.19). PD-L2 expression
level was not associated with histological cHL variant, disease stage and clinical
outcome. ROC analysis revealed that PD-L1 expression level in tumor is an
important marker which is associated with clinical outcome of cHL patients
(Se=87.5 %; Sp=64.5 %; AUC=0.75; p=0.002). High PD-L1 expression was
associated with reduced progression-free survival (PFS) in cHL patients. The
2-year PFS rate for cHL patients with high PD-L1 expression was 47% com-
pared to 95% for low or absent of PD-L1 expression.
Summary and Conclusions: PD-L1 showed promising activity as a marker at
prognosis in patients with cHL. High expression of the PD-L1 is associated
with unfarouble clinical outcome in cHL patients.
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Background: Brentuximab vedotin, a CD30-targeted antibody-drug conjugate,
has conditional approval in Europe for the treatment of adult patients with
relapsed/refractory (R/R) CD30+Hodgkin lymphoma (HL), and systemic
anaplastic large cell lymphoma (sALCL). The European Medicines Agency
requires a post-authorisation safety study to further evaluate brentuximab
vedotin’s safety profile. ARROVEN is an ongoing, multi-centre, international,
prospective, observational study of R/R CD30+HL and sALCL patients treated
with brentuximab vedotin as part of routine clinical care. Currently available
data will be presented.
Aims: To evaluate the occurrence of serious adverse events (SAEs) and AEs
of special interest (AESI) in patients actively treated for R/R HL or sALCL with
brentuximab vedotin in routine practice; and to identify and describe potential
risk factors for peripheral neuropathy.
Methods: R/R CD30+HL or sALCL patients aged ≥18 years who are planned
to start or recently commenced brentuximab vedotin as part of routine clinical
care, are eligible. Data are extracted from information routinely recorded in the
medical record and no study visits or examinations are required. Follow-up
information and safety data are collected in conjunction with all routine visits,
every 3 months until death, withdrawal of consent, or loss of follow-up. The fre-
quency, intensity and relationship to treatment is evaluated for all SAEs and
AESIs considered related to brentuximab vedotin; peripheral neuropathy, neu-
tropenia, infections, hyperglycaemia, and hypersensitivity reactions.
Results: Between June 2013 and January 2015, 62 patients (mean age 47.6
years [range 19–82]) out of a target of 500 were enrolled across 21 sites; 39
(63%) had HL, and 18 (29%) had sALCL (5 [8%] unknown). Patients received
a median of 4 treatment cycles (range 1–12). AEs were reported in 45 (73%)
patients. The most common AEs (n≥4) were peripheral neuropathy (n=18),
infections (n=14), neutropenia (n=13), hypersensitivity reactions, and lethargy
(each n=4). There were no reported hyperglycaemia events. In the 18 patients
with peripheral neuropathy, all 21 events reported were categorised as ‘sensory,
motor, or other’; peripheral neuropathy risk factors were not evaluable at the
time of analayis. Grade ≥3 AEs were reported in 24 (39%) patients; grade ≥3
AEs in >1 patient were infections (n=8), neutropenia (n=6), and peripheral neu-
ropathy (n=2). Seven (11%) patients reported grade 4 toxicities. These included
infection (n=4), progression with sepsis (n=2), neutropenia (n=2), thrombocy-
topenia (n=1), and tumour lysis syndrome (n=1, sALCL patient). SAEs were
reported in 21 (34%) patients. This included 11 patients with drug-related SAEs;
the most common (n≥2) were infection (n=9), and peripheral neuropathy (n=4).
No cases of progressive multifocal leukoencephalopathy, Stevens-Johnson
syndrome, toxic epidermal necrolysis, or acute pancreatitis were reported. Two
patients discontinued brentuximab vedotin, 1 due to grade 5 multi-organ failure
during cycle 1, and 1 due to grade 3 left pleural effusion and grade 5 bronchop-
neumonia during cycle 4. There were 4 on-study deaths in total, due to pneu-
monia (n=3) and disease progression (n=1).
Summary and Conclusions: The severity and frequency of reported toxicities
in R/R HL and sALCL patients treated with brentuximab vedotin are consistent
with the known safety profile of brentuximab vedotin, and the pivotal phase 2
studies. These data indicate that brentuximab vedotin is manageable and tol-
erable in the conditionally approved indications.
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BRENTUXIMAB VEDOTIN (BV) AN EFFECTIVE TREATMENT FOR
TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY
(R/R) HODGKIN LYMPHOMA (HL)
S. Viviani1,* A. Guidetti1, S. Dalto1, A. Dodero1, L. Farina1, S. Bolis2, L. Rigacci3,
F. Zallio4, A. Busca5, B. Bruno5, N. Mordini6, G. Parvis7, P. Corradini1
1Hematology and Pediatric Onco-Hematology, FONDAZIONE IRCCS ISTITU-
TO NAZIONALE DEI TUMORI, Milano, 2Hematology, Azienda Ospedaliera San
Gerardo-Monza, Monza, 3Hematology Division, AOU Careggi, Firenze, 4Hema-
tology, Ospedale SS Antonio e Biagio, Alessandria, 5Oncology and Hematology,
AOU Città della Salute e della Scienza, Torino, 6Hematology Department,
Ospedale Santa Croce, Cuneo, 7Hematology, Ospedale San Luigi, Orbassano,
Italy
Background: Patients with R/R HL, who are refractory to ≥2 lines of salvage
chemotherapy, are generally considered ineligible for ASCT and have a very dis-
mal 2-year PFS. Furthermore, patients relapsing after ASCT need effective treat-
ment to eventually proceed to alloSCT. BV is a safe and highly effective treatment
in R/R HL after ASCT and 75% overall responses have been reported.
Aims: The aim of this retrospective study was to assess the efficacy of BV in
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inducing remission and enable R/R HL patients to proceed to ASCT or alloSCT.
Methods: Patients with R/R CD30-positive HL, treated with BV between Jan-
uary 2011 and April 2014 for failure of at least two prior therapies, when ASCT
was not considered a treatment option (Group A), or for failure following ASCT
(Group B), were included in this retrospective analysis. BV was given at the
standard dose of 1.8 mg/kg iv every 21 days in an outpatient setting. The pri-
mary endpoint of this study was to evaluate efficacy of BV to enable patients
to proceed to ASCT or alloSCT. Secondary endpoints included BV toxicity, Pro-
gression-free Survival (PFS) and Overall Survival (OS).
Results: Twenty R/R HL patients for Group A (ASCT-ineligible) and 25 patients
for Group B (ASCT failures) were identified. Main characteristics at start of BV
were as follows:
Table 1.
Characteristics Group A (n=20) Group B (n=25)
Males/Females 9/11 9/16
Median age (range) yrs 38 (20-76) 39 (18-64)
B Symptoms 7 9
Stage III-IV 10 11
Extra ±nodal involvement 9 11
Bulky disease (>7 cm) 7 4
Median number prior regimens (range) 4 (2-12) 4 (2-9)
Refractory disease after frontline therapy 15 17
A median of 6 BV cycles (range, 3 to 19) were administered. Overall response
rate in Group A and B was 75% and 64%, respectively; CR was documented
in 8 patients (40%) in Group A and 5 patients (20%) in Group B. Best response
was reported after a median of 3 cycles (range, 2-9). Three pts in Group A and
one in Group B, achieving a negative PET scan, by continuing BV therapy,
had PD and were considered transplant ineligible; one patient in Group B
refused alloSCT. BV enabled 7 patients in Group A (achieving CR: 5, PR:1,
SD:1) and 15 patients in Group B (achieving CR:3, PR: 8, SD:4) to receive a
transplant procedure. Nine patients (20%) had grade ≥3 adverse events (2
sensory peripheral neuropathy, 1 pneumonia, 6 neutropenia), no patient dis-
continued treatment due to toxicity. After a median follow-up of 14 months
(range, 1-36), median PFS was 5 months and median OS was still not reached.
For patients achieving CR or PR after BV and receiving ASCT (n=5) or alloSCT
(n=12), median PFS was 8 months. At 2 years OS was 70%, 53% and 60%,
for Group A, Group B and the entire patient population, respectively. 
Summary and Conclusions: These data confirm that BV is effective in heavily
pretreated R/R transplant ineligible HL patients, who have generally limited
conventional treatment options and a low median OS. BV may overcome
chemorefractoriness and enable patients to receive ASCT or allo-SCT, by omit-
ting the significant toxicity of multiagent chemotherapy regimens.
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Background: Some studies have shown that serum ferritin levels correlated
with tumor mass and closely followed disease activity in patients with hemato-
logic malignancies such as malignant lymphoma and acute leukemia. Studies
have also shown that elevated serum ferritin levels in cancer patients are asso-
ciated with a poor prognosis. Studies suggest that elevated pretransplantation
serum ferritin levels are associated with increased mortality and a lower trans-
plantation-related survival after allogeneic hematopoietic stem cell transplan-
tation and after autologous hematopoietic stem cell transplantation (ASCT) for
malignant lymphoma.
Aims: The aim of this study was to determine the relationship between pre-
transplantation ferritin levels and outcome following ASCT for Hodgkin lym-
phoma.
Methods: We performed a retrospective analysis the predictive value of pre-
transplantation serum ferritin (drawn within 60 days preceding transplant admis-
sion) of 136 consecutive adult patients who underwent ASCT for Hodgkin lym-
phoma (HL) at the Clinica Marly between January 1995 and December 2014,
was available for 136 patients ( 64%) who form the patient population for this
report. The normal range for ferritin in our laboratory is 10 to 500 ng/mL.
Results: The median pretransplantation ferritin for patients in this study was
658 ng/mL (range: 10 – 6352). Baseline ferritin 912 ng/mL as the cut off point
that best correlated with poor survival. Univariable analysis demonstrated that
number of prior chemotherapy regimens, disease status, and elevated ferritin
were significantly associated with overall survival (OS). On multivariate analy-
sis, a pre transplantation ferritin 912 ng/mL was associated with significantly
lower overall (OS; P: 0.025) and Disease Free Survival (DFS ; P= 0.002). Fer-
ritin 912 ng/mL was associated with a higher incidence of relapse (P=0.004)
and relapse mortality (P= 0.001). The median follow-up for surviving patients
is 44 months (range: 12 - 74). Multivariable analysis demonstrated that elevated
ferritin (P= .0022, HR 1.78, 95% CI 1.35 – 2.26) and, number of prior
chemotherapy regimens (P= 0.032, HR 1.63, 95% CI 1.12- 2.45) were signifi-
cant adverse prognostic factors for OS. Elevated ferritin (P= .021, HR 1.60,
95% CI 1.08-2.38) and disease status (P= .003, HR 2.05, 95% CI 1.45-2.71)
were also adverse factors for Disease Free Survival. 
Summary and Conclusions: Elevated levels of serum ferritin of 912 ng/mL,
number of prior chemotherapy regimens, disease status, may be an important
marker for predicting poor survival outcomes following ASCT for Hodgkin lym-
phoma. The present study cannot distinguish between a causal relationship of
elevated ferritin, through iron stores, on the malignancy and ferritin being a
surrogate for extent or aggressiveness of malignancy. Our results indicate the
need for studies designed to correlate an elevated ferritin with iron overload
and survival outcomes.
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Background: Hodgkin lymphoma, classic type (cHL) tissue is characterized
by an extreme disproportion between tumor (Hodgkin-Reed-Sternberg, HRS)
cells ranging from 0.1% to 10% and surrounding non-malignant microenviron-
ment cells. Last years brought an explosion of novel information about close
HRS-microenvironment cross-talk, which promotes a tumor growth. Numerous
studies tested the predictive value of microenvironment cells density using
immunohistochemistry (IHC) methods and many of them were focused on lym-
phoma-associated macrophages (LAM). High LAM density at time of diagnosis
was found to be an inferior prognostic factor. However, no studies were per-
formed on HRS cells density and HRS:LAM ratio analysis. 
Aims: To assess an impact of HRS cells density and HRS:LAM relationship
on disease development/prognosis in cHL, nodular sclerosis subtype using
novel automated scanning system of the total tumor sample area. 
Methods: We analyzed cHL tissues, obtained at time of diagnosis, in fourteen
patients with intermediate and advanced stages (KS IIB-IV). Six patients rep-
resented a relapsed/refractory (RR) cohort, eight patients were selected as
age-sex matched relapse-free (RF) controls. Paraffin-embedded biopsies were
prepared from pre-selected high-quality diagnostic samples stained with hema-
toxylin-eosin for morphology analyses and using CD30 (HRS) and CD68 (LAM)
for cell-density analyses. Tissue array analyses were performed using the Tis-
sueFAXS (TissueGnostics, Vienna, Austria) system that combines detailed
morphologic information offered by microscopy with the scientific accuracy of
multi-channel flow cytometry. Data were analyzed with TissueQuest software.
Each sample was previewed by scanning software and only significant tumor
tissue was manually gated for further analyses, excluding fibrotic (≥10 %),
necrotic or residual lymphatic structures. This area was considered as a Total
Tumor Sample (TTS) area.
Results: Mean TTS area covered 17.7±11.9 mm2 with mean total number of
cells 457,257±397,599. The mean TTS was not different in RF (17.9 mm2)
compared to RR cohort (19.2 mm2, p=0.86). There was a trend for higher cell
density in RF compared to RR cases (27,679 vs 20,861 cells per mm2, p=0.09).
Density of CD30+HRS cells was 2.4 fold higher in RF than in RR patients (429
vs 180 cells per mm2, p=0.055). Although mean density of CD68+LAM was
comparable in RF and RR group (2,372 and 2,716 cells per mm2, respectively,
p=0.66), a CD30:CD68 ratio was higher in RF (0.31) than in RR (0.07, p=0.044)
patients. The number of LAM per one HRS cell was 33.1 in RR, whereas only
12.1 in RF group (p=0.10). Our data showed that automated analysis of a TTS
area may overcome technical limitations caused by a tissue selection, hetero-
geneity in HRS and bystander cell distribution or tissue fibrosis/necrosis com-
paring to analysis of small tissue samples (2-3 mm2).
Summary and Conclusions: Cell distribution in cHL tissue is highly variable,
automated analysis of may bring more accurate cell-density results with lower
variance. We describe differences in HRS and total cell density in diagnostic
biopsies of relapse/refractory and relapsed- free cHL patients. Higher HRS:LAM
ratio in relapsed patient presume more potent HRS-microenvironment interac-
tion with the possible prognostic role.
Acknowledgement: supported by grant from the Faculty of Medicine and Den-
tistry, Palacky University Olomouc (IGA-LF-2015-001).
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Background: The treatment approach in Hodgkin Lymphoma (HL) is risk adopt-
ed. Thus, patients have to be stratified into certain risk groups based on clinical
stage and risk factors before selecting the appropriate therapy. In the past
decade, many studies were performed with the aim to identify reliable prog-
nostic biomarkers for HL. Among potentially very powerful biomarkers is con-
sidered the number of macrophages in tumor tissue, with negative prognostic
impact of their high content in tumor.
Aims: The aim of this study was to thoroughly evaluate high risk group of HL
patients according to number of macrophages in tumor tissue, in order to iden-
tify patients who potentially require more effective treatment approach.
Methods: The retrospective study was performed on selected patients with
newly diagnosed classical HL, initially treated with ABVD in the period 2000-
2008. The selection criteria was based on ROC curve analysis which deter-
mined 8 as the most appropriate cut off value for number of
CD68+macrophages in 1000x magnification high power field (hpf). The analysis
was performed on 61 patients with high number (higher or equal 8) of
CD68+macrophages/hpf. The examined parameters in survival and multivariate
analysis were presence of bulky disease, ESR≥50 mm/h, B symptoms, elevated
LDH and high IPS score (3-7).
Results: The median follow up was 71 months (range 2-162 months). The
median age was 31 yrs (range 17–84). Five-years overall survival (OS) was
68,9% and 5-years event free survival (EFS) was 54,1%. In univariate analysis
patients with ESR≥50 mm/h, B symptoms and elevated LDH had significantly
shorter OS (p=0.047, p=0.011, p=0.045, respectively), while there was a trend
toward worse OS in patients with bulky disease (p=0.058). EFS was significantly
shorter in patients with ESR≥50 mm/h, B symptoms, elevated LDH and high
IPS (p=0.047, p=0.044, p=0.017, p=0.033, respectively). Multivariate analysis
identified presence of B symptoms as the independent risk factor for poor OS
(p=0.018) and elevated LDH as the independent risk factor for poor EFS
(p=0.023).
Summary and Conclusions: The further stratification in high risk groups of
HL patients could be potentially useful for selecting the adequate treatment
approach. More effective treatment approach is potentially required in patients
with high number of CD68+macrophages with present B symptoms and/or ele-
vated LDH. Still, these have to be confirmed through randomized clinical trials.
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Background: Improvements in the treatment of Lymphomas have resulted in
an increasing number of long term survivors. This patient’s population is at risk
of developing late therapy related complications as cardiovascular diseases
and secondary cancers.
Aims: In our institution since September 2014 the Hodgkin’s (HL) and aggres-
sive non Hodgkin’s Lymphomas (NHL) long term survivors are followed up in
a dedicated clinic. This approach allows clinicians to better appreciate and
monitor not only signs and symptoms of the known hematologic disease but
also of other medical problems that can affect people undergone previous radi-
ation therapy and/or chemotherapy (survivorship). An additional target of this
project is to define a program of early detection of otherwise asymptomatic car-
diovascular, endocrine, respiratory, neurologic and oncologic disease. In this
work we focus on the preliminary results of screening of early cardiovascular
disturbances.
Methods: We collected data regarding cardiovascular diseases in 216 patients
and performed electrocardiographic and echocardiografic evaluation in 79
patients selected mainly according to the age, cardiovascular risk factor, time
from therapies, type and amount of antiblastic (antracyclines) and mediastinal
radiotherapy received.
Results: We analyzed data regarding 216 patients coming in our clinic from
15 September 2014 to 16 February 2015, 119 were affected by HL and 97 by
NHL. One hundred fifteen are females, 101 males; median age at observation
is 53 (range 22-89). All of them are in complete response for lymphoma for at
least 5 years from the completion of curative therapy. Thirty seven patients
(17%) had known cardiovascular problems developed after lymphoma treat-
ment (some of them had more than one defects): 9 isolated arterial hyperten-
sion, 14 ischemic cardiac disease, 4 valvular insufficiency, 1 dilatative car-
diomyopathy, 5 arrhythmia, 2 cardiac failure, 1 aortic ectasia, 2 cerebrovascular
ischemia. Electrocardiographic and echocardiografic evaluation has been per-
formed in 79 patients selected mainly according to the age, cardiovascular risk
factor, time from therapies, type and amount of antiblastic (antracyclines) and
mediastinal radiotherapy received. Thirty eight out of 79 (48%) showed previous
unknown cardiac disturbance: particularly 21 presented diastolic relaxation
abnormality, 15 valvular insufficiency and 5 aortic sclerosis of low-moderate
grade, 1 has low grade myocardic thickness and 3 arterial hypertension. The
median age of patients with cardiovascular abnormalities discovered during
the screening is 49 (range 32-70), 28 of them had received therapy for HL and
the other 10 for NHL.
Summary and Conclusions: Our analysis confirms that an high percentage
of patient survived to lymphomas can develop cardiovascular diseases. Their
monitoring can detect silent dysfunctions as diastolic relaxation abnormality
considered an early sign of cardiomyopathies.
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Background: In the past, the stomach has been thought to be the most com-
mon site of origin for extranodal marginal zone B-cell lymphoma of the mucosa
associated lymphoid tissue (MALT-lymphoma), with the large majority of cases
being associated with Helicobacter pylori (HP) infection.
Aims: As changes in clinicopathological characteristics and incidence have
been suggested by scattered reports, we have assessed characteristics and
outcome of patients with gastric MALT lymphoma from a tertiary referral cen-
ter.
Methods: Between 1999 and January 2015, a total of 320 consecutive patients
with MALT lymphoma were diagnosed, treated and followed at our institution.
We have retrospectively re-assessed all patients with gastric MALT-lymphoma
from this cohort in terms of stage, HP-infection, pathological characteristics,
treatment and outcome.
Results: In total, 116 / 320 patients (36%) with MALT lymphoma were of gastric
origin, while the large majority of patients had extragastric MALT lymphoma.
Only 4 /116 patients (3%) also had a diffuse-large B-cell lymphoma component
along with MALT lymphoma. Using a standardized staging regimen, we found
25 pts (22%) to have multiorgan-involvement, including 3 (2.6%) with bone
marrow involvement, while 91 had localized disease (78%). Out of 99 patients
with a fully tested HP-status, 34 (34%) were negative for HP and 65 positive.
Interestingly, 9 of these patients had been diagnosed before 2004 (9/49, 18%)
and 25 between 2004-2015 (25/50, 50%). In total, 40% of patients assessed
had monoclonal gammopathy, and plasmacytic differentiation was present in
31%. In addition, 29% of patients were found to have an underlying autoim-
mune disease, with chronic autoimmune thyroiditis being most common. In
terms of treatment, 76 patients (66%) had antibiotics as first line therapy, 31
systemic therapy (27%), while the remaining patients had surgery, radiation or
wait and see. After a median follow-up of 63 months, 85% (99/116) are alive,
while 17 (15%) have died. Transformation to DLBCL was only seen in one
patient after therapy, while 2 developed clonally unrelated nodal DLBCL. HP-
status was not associated with relapse following first line therapy (p=0.066),
and there was no difference in estimated time to progression between the two
cohorts. Interestingly, 14 HP-negative patients were treated with antibiotics
alone, resulting in 5 CR and 1 PR (46%), 5 stable disease and 3 progressions;
results of antibiotic treatment in HP negative patients were not significantly dif-
ferent for estimated time to progression (p=0.1) and progression following first
line therapy (p=0.38).
Summary and Conclusions: These results suggest that the rate of gastric
MALT lymphoma amongst the cohort of MALT lymphomas as a whole is
decreasing, while the rate of HP-negative gastric MALT lymphomas was much
higher (34%) than stated in the literature in the past. In addition, cautious
interpretation of our data suggests an increase of HP-negativity over the last
10 years. Surprisingly, a relevant percentage of patients can be managed with
antibiotic therapy alone without compromising patients`prognosis. Further
studies on the pathogenesis and therapy of HP-negative patients are needed
in order to optimize therapy and avoid overtreatment. In addition, our data
suggest that the risk of transformation to DLBCL in the course of the disease
is minimal.
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Background: In B-cells, phosphatidylinositol 3-kinase delta (PI3Kδ) mediates
cell survival and proliferation, and its activity is critical for retaining B cells in
lymphoid tissues. Idelalisib inhibits PI3Kδ in B-cell malignancies, and is indicated
for the treatment of 1st line 17p deleted and relapsed chronic lymphocytic
leukemia (CLL) in combination with rituximab. Idelalisib also demonstrated high
response rates in relapsed follicular lymphoma (FL) and small lymphocytic
leukemia (SLL). GS-9820 is a second-generation, PI3Kδ-inhibitor and was eval-
uated in B-cell malignancies including CLL and non-Hodgkin’s lymphoma (NHL).
Aims: The primary objective was to determine the maximum tolerated dose (MTD)
and to assess safety including the incidence and severity of elevated transaminase
levels, diarrhea and pneumonitis which are observed with idelalisib.
Methods: Subjects with relapsed B-cell malignancies and measurable lym-
phadenopathy (LAD) with ≥1 prior therapy received GS-9820 at doses of 50,
100, 200, or 400 mg, orally, twice daily (BID). The dose escalation stage (n=12)
had a 3+3 design and measured safety, efficacy and pharmacologic properties.
Additional subjects (n=27) enrolled in the dose expansion cohort at 400 mg
BID. Antitumor activity was evaluated every 2 months including CT scans, with
adjustments for redistribution lymphocytosis, consistent with PI3Kd inhibition.
Nodal PR (nPR) is defined as ≥50% reduction in LAD. Subjects received GS-
9820 until disease progression or unacceptable toxicity.
Results: As of July 2014, 15/39 subjects remain on treatment. Reasons for
discontinuation include disease progression (11), death (4) (all unrelated to
GS-9820), adverse events (AE) (14) and other (9). Response rates assessed
by independent review committee were; overall 33.3% (95%CI (19.1-50.2)),
for CLL subset (n=22) 33.3%, for NHL subset (n=17; 8 MCL, 4 DLBCL) 28.6%.
nPR in CLL subset was 84.6%. The median duration of response was not
reached and maximum duration of response was up to 11.9 months. No dose
limiting toxicities were reported. AEs (subject incidence >20%) were cough,
diarrhea, dyspnea, fatigue, peripheral edema and rash. Severe adverse events
(grade 3 or 4) reported by >1 subject were pneumonia (5, 12.8%), pyrexia (4,
10.3%) sepsis (2, 5.1%) and diarrhea (2, 5.1%). AEs considered related to
study drug by the investigator (subject incidence >10%) were pyrexia, dysgeu-
sia, diarrhea and increase in AST or ALT. Three subjects had elevations in
transaminase levels at grade 3 or 4 in the 400 mg BID dose cohort. No subjects
reported pneumonitis and 8 subjects reported pneumoniaa.
Summary and Conclusions: Interim analysis of this phase 1b study of GS-
9820 demonstrates clinical efficacy and safety comparable to idelalisib. Based
on the similarity to idelalisib, no further clinical development is planned. apneu-
monia included AEs of pneumonia, viral pneumonia, organizing pneumonia.
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Background: The purine analogue 2-chloro-deoxyadenosine (2CDA, cladrib-
ine) +/- rituximab (R) was successfully tested in MALT lymphoma patients
achieving remission rates of 80-100%. However, studies using 2CDA in other
indications have reported the potential for prolonged hematological side effects
and secondary malignancies. To date, there have been no data on long term
effects of 2CDA in MALT lymphoma patients.
Aims: In view of this, we have retrospectively analysed long term safety and
activity of 2CDA in MALT lymphoma patients.
Methods: From 1998-2004, 49 patients were treated with either 2CDA alone
(0.12 mg/kg i.v. d1-5, every 28 days) or R-2CDA (R 375 mg/m2 i.v. d1, 2CDA
0.1 mg/kg s.c. d1-4, every 21 days) for a maximum of six cycles. All patients
were treated within clinical trials and had undergone a standardised follow-up
(FUP) protocol (three-monthly for the first two years, then six-monthly for the
first five years, annually thereafter) minimizing a potential bias in the detection
of late sequels and relapses. This retrospective analysis had been approved
by the Ethical Board of the Medical University of Vienna.
Results: Patients included in this analysis had received either 2CDA alone
(n=17, 35%) or combined with R (n=32, 65%). The median age at treatment
start was 60 years. Response to treatment was 100% for 2CDA and 78% for
R-2CDA, respectively and the median number of applied cycles was four and
six, respectively. All documented relapses (n=17) occurred within a median
time of 13 (interquartile range; 10-42) and 15 (IQR; 8-33) months, suggesting
long term remissions in patients “outlasting” the initial post-treatment period.
After a median FUP of 55 months (IQR; 42-70) three of 49 patients aged 59,
70 and 77 had developed prolonged pancytopenia starting 1, 3 and 83 months
after treatment. All patients had a bone marrow biopsy and in one patient
myelodysplastic syndrome (MDS) was diagnosed. Two of three patients died
with ongoing panzytopenia after 14 and 89 months while the third recovered
to normal blood counts. Noteworthy, all three patients had received the maxi-
mum number of six cycles and in all 2CDA was not the sole treatment admin-
istered. Thus additional triggers for cytopenia/MDS cannot be ruled out. In one
patient, R-CHOP was given for relapse before MDS occurred while the other
two were pretreated with abdominal radiation or radioimmunotherapy. At the
time of analysis 35/49 (71%) are alive with 25/35 (71%) in ongoing complete
remission, two (6%) in ongoing stable disease, and eight (23%) free of lym-
phoma after 2nd line. Fourteen patients (29%) have died including two patients
who died after only one cycle of treatment due to unrelated reasons and one
patient who withdrew consent after four cycles. As reported, two patients died
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with pancytopenia 14 and 89 months after initiation of treatment. In addition
four patients died from secondary malignancies (gastric cancer, B-cell lym-
phoma, SCLC, skin cancer) after median 48 months (range; 12-93) and five
due to cancer-unrelated reasons after median 55 months (range; 11-124). Medi-
an overall survival was not reached (Figure 1: Survival curve for MALT lym-
phoma patients receiving cladribine treatment, n=49).
Figure 1.
Summary and Conclusions: After a median FUP of 55 months, 8/49 patients
(16%) treated with 2CDA for MALT lymphoma have developed a secondary
malignancy. In most of these cases, however, a causative role of 2CDA is rel-
atively unlikely given the nature and time of development of these cancers. In
addition, 3/49 patients had prolonged pancytopenia/MDS. While the number of
patients in our series is relatively small, these data suggest that with the high
rate of remissions and the fact that the median survival was not reached after
more than 5.5 years 2CDA might be safely applied also in terms of long term
toxicities. However, prolonged pancytopenia may occur particularly in older
patients.
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Background: NG MALT lymphomas may arise at any anatomic site. Recent
data suggest that primary localization may have an impact on patients’ clinical
course and outcome.
Aims: To investigate whether anatomic localization is associated with specific
disease features and outcome in a large series of NG MALT lymphoma patients
and to identify possible prognostic parameters. 
Methods: 185 patients, from 6 Hematology Units in Greece, with biopsy-con-
firmed NG-MALT lymphoma, were retrospectively analyzed. Survival probability
was estimated using the Kaplan-Meier method. 
Results: The main characteristics of the studied population are given in table
1. Fourteen different sites of involvement were recorded. The most common
were skin (22%), salivary gland (SG) (20%), ocular adnexa (OA) (13%) and
lung (12%). Seventy-two% presented with limited stage disease, while 78%
were classified as low risk according to IPI. A history of autoimmune disorders
was present in 24%, with Sjogren’s syndrome being the most common. Gas-
troscopy was performed in 87 pts; a MALT lymphoma was identified in 18%
and H.pylori (HP) (+) gastritis in 16%. Bone marrow was infiltrated in 12%.
Treatment was not uniform, comprised mainly of systemic therapies
[chemotherapy (CT) in 22%, Rituximab (R)-CT in 34%, R monotherapy in 9%,
IFN-a (3%)], local therapies (surgery in 13%, radiotherapy in 9%, R locally in
1%), while 6 pts (3%) were placed on follow up observation. Correlations of
anatomic site with specific disease features: 1. SG was more often associated
with advanced disease stage (p=0.001). 2. SG and thyroid had more often an
autoimmune background (p<0.001). 3. OA was strongly associated with HP(+)
gastritis (p=0.002). 4. Small intestine and lung had more frequently parapro-
teinemia (p=0.001). After a median follow-up time of 74 months (1-369) the
median failure free (FFS), overall (OS) and disease specific survival (DSS)
were 14,8, 25,5 and 25,5 years, respectively. Small intestine, lung and multiple
MALT site disease (>2) had a shorter median FFS compared to all other MALT
localizations (92 vs 197,7 months) (p=0.02). Patients could be grouped into 3
different risk categories according to their disease localization: Group 1 (skin,
large intestine, thyroid, SG and liver) had the most favorable FFS (median not
reached), group 2 (head and neck localization, breast, kidney and OA) had an
intermediate prognosis (median FFS 178 months), while group 3 (lung, small
intestine, thymus, bladder, brain and multiple MALT sites) were associated with
the worst outcome (median FFS 81,8 months) (p=0.013). Age<60 years was a
favorable factor for FFS (not reached vs 145,8 months) (p=0.034). IPI was a
strong prognostic factor for FFS: IPI 0/1 (median FFS not reached), IPI 2/3
(median FFS 37,9 months), IPI 4 (median FFS 8,6 months) (p<0,0001).
Table 1. Patients’ Characteristics.
Summary and Conclusions: NG MALT lymphomas display a highly favorable
clinical course and survival. The present study shows that certain anatomic sites
were highly associated with specific disease features. In addition lung, small
intestine and multiple MALT sites of involvement carried the most adverse prog-
nosis. Furthermore, age<60 and low IPI were associated with improved FFS.
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Background: Waldenström macroglobulinemia (WM) is a malignant indolent
incurable lymphoproliferative disease characterized by the association of the
evidence of a lymphoplasmacytic proliferation and a monoclonal component
of IgM. WM-related polyneuropathy (WM-PN) is its most frequent neurological
complication. WM-PN diagnosis is difficult and underestimated due to the het-
erogeneity of the mechanisms and of clinical presentations.The presence of
neuropathy is widely accepted as an indication for treatment in WM but the
choice and time of the appropriate therapy can be challenging due to different
toxicity profile of each option, the non-curable characteristic of the disease and
the heterogeneous response to treatment of different subtypes of neuropathy
Aims: The aim of our study was to present our local experience of the use of
fludarabine, as a single agent or in combination with rituximab or cyclophos-
famide (fludarabine-based chemotherapy) for the treatment of Waldenström
macroglobulinemia associated neuropathies.
Methods: Seventy patients with IgM monoclonal immunoglobulin and neu-
ropathy were addressed to our hematology department in the last 20 years: 27
patient were diagnosed with monoclonal gamapathy on undetermined signifi-
cance (MGUS) median age 67 years, 39 patients were diagnosed with WM,
median age 74 years and 4 patients with other low grade non Hodgkin lym-
phoma, median age 66 years. Treatment was proposed to 32 WM patients,
from whom 17 with fludarabine based chemotherapy. Our primary objective
was to evaluate the neurological response to treatment by clinical evaluation,
electromyography and the 10 points INCAT disability score, the secondary
objectives were the treatment-free survival (TFS) and the hematological
response.
Results: Of 17 patients (IPSSWM low- intermediate- high: 3-12-2), 13 started
treatment for neurological impairment only and 4 patients had in addition hema-
tological treatment criteria. All patients were treated with 4 to 6 cycles of
chemotherapy adapted to tolerance: 1 received RFC (rituximab-fludarabine-
cyclophosphamide) regimen, 11 received RF regimen, 5 received fludarabine
alone. Neurologically, 5 patients had pure axonal neuropathy; 11 patients pre-
sented demyelinating neuropathy and 2 patients demyelinating neuropathy
with secondary axonal lesions. In 8 patients anti MAG antibodies were detected
and 11 patients presented severe forms of neuropathy. The neurological
response after treatment: 11 patients presented clinical improvement, 5 patients
presented stable clinical disease, 1 patients dissociated response, the INCAT
score had significant improvement, more than 2 points, in 7 patients, and 1
point improvement in 4 patients. EMG registered only partial amelioration in 3
cases of axonal neuropathy and 1 case of non severe demyelinating neuropa-
thy. The hematological response: median peak reduction 75% (min 33%, max
100%). The median TFS for neurological or hematological criteria was not
reached, the mean TFS 92.5 months [min 68.3, max 116.7].
Summary and Conclusions: The fludarabine based chemotherapy for WM-
PN allows good control of the symptomatology and long treatment-free survival.
Further trials are needed to establish the optimal moment to treat in the evo-
lution of the neuropathy. 
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Careggi, Firenze, 9Hematology, Ospedale S. Chiara, Trento, 10SCDU Hema-
tology, Azienda Ospedaliera-Universitaria Maggiore della Carità, Novara,
11Hematology, Ospedali Riuniti Villa Sofia – Cervello, Palermo, 12Hematology
USD-TMO Adulti, AO “Spedali Civili”, Brescia, 13Hematology Unit, IRCCS
National Cancer Research Center “Giovanni Paolo II”, Bari, 14Oncology,
IRCCS-CRO, Aviano, 15Unit of Clinical and Experimental Pharmacokinetics,
Foundation IRCCS Policlinico San Matteo, Pavia, 16Hematology, DISM,
AOUSM Misericordia, Udine, Italy
Background: Rituximab (R)-chemotherapy induction followed by R mainte-
nance is the current standard of care for patients with follicular lymphoma (FL).
In recent years, several studies have investigated the optimal dose and sched-
ule of R based on pharmacokinetic (PK) data. These studies have proposed a
presumptive ‘active’ level of 25 µg/ml. However, scanty data are available with
regard to the PK of R during maintenance and its possible relationship with the
patients’ characteristics and outcome.
Aims: Here, we report the preliminary analysis of PK data correlated with
patients’ clinical characteristics and outcome during R maintenance.
Methods: Patients with grade 1, 2 or 3a FL in maintenance therapy with iv R
(375 mg/m2) administered every 2 (patients treated front-line) or 3 months
(after salvage immuno-chemotherapy) were investigated. R plasma trough
concentrations (Ctr) and the area under the curve (AUC) were determined
using a sensitive validated ELISA assay. PK data were then correlated with
the patients’ clinical characteristics and outcome.
Results: From March 2013 to March 2014, 101 patients have been recruited
by 12 FIL centers. The median age was 60 years (IQR 30-84) and 50 (48.5%)
were males. According to body mass index (BMI) 44 (43%) patients were over-
weight and 10.8% were obese. At study entry, 92 patients were in first complete
response (CR), 19/92 in second CR and 9 in partial response (PR), of whom
2 after salvage therapy. In 85/101 (group 1) and in 16/101 (group 2) patients,
R was administered every 2 or 3 months, respectively. After a median follow-
up of 23 months from the start of R maintenance, 91 patients were in CR, 3 in
PR and 7 had relapsed. The median Ctr level was 32 µg/ml (0.0 µg/ml – 200
µg/ml) in all patients, 33 µg/ml (0 µg/ml-188 µg/ml) in patients treated with R
every 2 months and 22.8 µg/ml (0 µg/ml-200 µg/ml) in patients treated every
3 months, respectively (p=0.7). A higher median R Ctr level (36 µg/ml vs 22
µg/ml, p=0.04) and a higher AUC (61.23 vs 41.9, p=0.011) were found in
females. No correlation between Ctr, AUC and BMI were documented, but a
trend towards higher levels were found in patients with a BMI <30 (Ctr=40.38
µg/ml vs 31.96 µg/ml, p=0.23; AUC=54.19 vs 42.55, p=0.13). This preliminary
analysis did not show any relationship between the quality of response (CR vs
PR), the outcome (response vs relapse) and the Ctr levels and AUC; however,
in a subanalysis of group 1, more patients with lower Ctr relapsed during R
maintenance (38.8 µg/ml vs 33.9 µg/ml, p=0.01) and, notably, 4/6 who relapsed
had Ctr levels under 25 µg/ml.
Summary and Conclusions: Our study confirms the favorable R PK profile in
female patients and in the 2 months administration scheme. At present, prob-
ably because of the relatively short follow-up and low number of events during
maintenance, no relationship between PK data and outcome has so far
emerged and a longer observation time is required.
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HYPOGAMMAGLOBULINEMIA AT LONG-TERM AFTER RITUXIMAB/
CHEMOTHERAPY TREATMENT FOR LYMPHOMA, AND USE OF
INTRAVENOUS IMMUNOGLOBULINS FOR RECURRENT INFECTIONS.
M. Ferraro1,* B. Sanchez-Gonzalez1, A. Esquerra1, F. Garcia1,
C. Fernandez-Rodriguez2, E. Torres1, A. Senin1, E. Gimeno1, A. Salar1
1Hematology, Hospital del Mar, 2IMIM, Barcelona, Spain
Background: Rituximab (R) is a monoclonal antibody against CD20 that caus-
es suppression of B-lymphocytes and may induce hypogammaglobulinemia,
with the subsequent increased risk of infections. B-cells usually recover within
6-12 months after R administration. Actually, many patients can be exposed to
rituximab during prolonged periods of time, either following maintenance or
because of retreatment. 
Aims: This retrospective study sought to evaluate (at long term) the kinetics
of gammaglobulins during the first 4 years after R treatment, the influence of
prolonged R exposition (following maintenance and/or second/third line treat-
ment) and its impact on the use of intravenous immunoglobulins (IVIG).
Methods: We identified 194 patients who received R or R-chemotherapy for
lymphoma between 2005 and 2011 in our Lymphoma Unit. Patient clinical his-
tories were evaluated with special interest in: type of R-chemo received, main-
tenance with R, use of other anti-CD20 monoclonal antibodies and treatment
at relapse. Quantitative serum immunoglobulin levels (sIg) prior to and at the
end of first line treatment and every 12 months was recorded, as well as need
for IVIG replacement therapy and relevant infectious events.
Results: median age of 67 years, 41 % female. Lymphoma types: aggressive
(58%), indolent follicular (29%), indolent non-follicular (13%). First R-containing
treatment: R (10%), R-purine analogs (6%) and R-chemo (84%). During the 4-
year study period, second-line treatment was administered in 71 patients (R:
13%, R-purine analogs: 13%, R-chemo: 52%, chemo without R: 22%) and, 53
and 10 patients received R as maintenance or Ibritumomab as consolidation,
respectively, in first or subsequent line of therapy. 85 patients had a total of
125 infectious adverse events: 53 during R or R-chemo (36% grade 1-2), 18
during R-maintenance (all but 1 grade 2) and 54 off R-therapy (39% grade 1-
2). Median lymphocyte count, gammaglobulin, and levels of IgG, IgA and IgM
are showed prior and post-therapy and at +12, +24 and +48 months:
Table 1.
Of note, prior treatment with R, 14% of patients had reduced levels of gamma-
globulins (<6.6 g/L) and 24.5% of patients had a level of IgG <700 mg/dL. In
the whole population, median levels of IgG, IgA and IgM were significantly
reduced at the end of the first treatment (p<0.0001, Wilcoxon test for paired
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samples), and also at months +12, +24 and +48. However, the kinetic of levels
of IgG-IgA-IgM was significantly different according to R exposition. Patients
receiving only one schema of R or R-containing chemo showed a faster recov-
ery with normal values of IgG, IgA and IgM at +12 months. Interestingly, patients
who received more than one treatment of R-chemo or R-maintenance after R-
chemo had a prolonged reduced levels of all gammaglobulins that remained
under normal values even at +48 months (figure 1). Even though 30% of cases
continued with reduced levels of IgG at +48 months, only 8 patients (4%) ulti-
mately required IVIG replacement. 
Figure 1.
Summary and Conclusions: Lymphoma patients receiving more than one
treatment of R or R-containing chemo and those receiving R-maintenance are
at increased risk of long-term hypogammaglobulinemia. With the increasing
use of R, it is important to monitor sIg levels even though the incidence of
symptomatic hypogammaglobulinemia that prompted IVIG administration is
infrequent.
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UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL,
DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT
OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES,
INCLUDING WALDENSTRÖM MACROGLOBULINEMIA
D. Siegel1,* J.L. Kaufman2, N. Raje3, J. Mikhael4, P. Kapoor5, S. Treon6,
J. Castillo6, L. Neuman7, M. Obreja7, I. Ghobrial6
1John Theurer Cancer Center at Hackensack University Medical Center, Hack-
ensack, 2Winship Cancer Institute, Emory University, Atlanta, 3Harvard Medical
School, Boston, 4Mayo Clinic, Scottsdale, 5Mayo Clinic, Rochester, 6Dana-Far-
ber Cancer Institute, Boston, 7Onyx Pharmaceuticals, Inc., an Amgen sub-
sidiary, South San Francisco, United States
Background: Oprozomib (OPZ) is an oral epoxyketone proteasome inhibitor
that has shown promising antitumor activity in a phase 1b/2 study
(NCT01416428) in patients with hematologic malignancies, including Walden-
ström macroglobulinemia (WM; Siegel et al., Blood 2014;124: abstract 1715).
In the phase 1b portion of the study, the maximum tolerated dose of single-
agent OPZ when administered once daily on days 1, 2, 8, and 9 of a 14-day
cycle (2/7 schedule) or on days 1–5 of a 14-day cycle (5/14 schedule) to patients
with hematologic malignancies was 300 mg/day and 240 mg/day, respective-
ly.
Aims: We present updated efficacy and safety results from patients with WM
enrolled in the phase 2 portion of the study.
Methods: Adult patients with hematologic malignancies who have relapsed
after receiving ≥1 line of therapy are eligible for enrollment. The primary objec-
tive of the phase 2 portion of the study (the target enrollment for the phase 2
portion is 66 patients with WM) is to determine the best overall response rate
(ORR; minimal response or better). In the phase 2 portion of the study, single-
agent OPZ is being administered once daily on days 1, 2, 8, and 9 of a 14-day
cycle (2/7 schedule: 240 mg/day during cycle 1; 300 mg/day thereafter if well
tolerated) or on days 1–5 of a 14-day cycle (5/14 schedule: 240 mg/day). All
patients provided informed consent. Efficacy and safety results are presented
for patients with WM in the phase 2 portion of the study.
Results: As of November 3, 2014, a total of 129 patients with hematologic
malignancies were enrolled in the phase 1b/2 study. Of those patients, 21 had
WM and were enrolled in the phase 2 portion of the study and treated with
OPZ. Four patients with WM were enrolled in the 2/7 dosing schedule; 17
patients with WM were enrolled in the 5/14 schedule. The median age of
patients was 64.5 years (range, 63–67 years) in the 2/7 schedule and 62 years
(range, 44–85 years) in the 5/14 schedule. The median number of prior regi-
mens was 2.5 (range, 1–8) in the 2/7 schedule and 3 (range, 1–7) in the 5/14
schedule. Preliminary median treatment duration was 6.6 weeks (range, 0.3–
8.1 weeks) in the 2/7 schedule and 8.1 weeks (range, 0.7–31.6 weeks) in the
5/14 schedule. All 21 patients with WM in the phase 2 portion were response-
eligible. The ORR in the 2/7 schedule was 25% (1 of 4 patients; 1 partial
response); the ORR in the 5/14 schedule was 53% (9 of 17 patients; 5 partial
responses and 4 minimal responses). The most common adverse events (AEs)
are shown in the Table. Grade 3 AEs occurring in >1 patient included nausea
and vomiting (2 patients each); there were no grade 4 AEs. Antiemetic medica-
tion was administered to 3 patients (75%) in the 2/7 schedule and 17 patients
(100%) in the 5/14 schedule. Four patients in each schedule (100% in the 2/7
schedule; 24% in the 5/14 schedule) received antidiarrheal medication. No on-
study deaths occurred in patients with WM. No patients enrolled in the 2/7
schedule and 7 patients (41%) enrolled in the 5/14 schedule discontinued treat-
ment due to an AE. Three patients (75%) in the 2/7 schedule and 11 patients
(65%) in the 5/14 schedule had ≥1 dose reduction due to an AE.
Table 1. AEs occurring in ≥30% of WM patients (by schedule)
Summary and Conclusions: Single-agent OPZ has promising antitumor activ-
ity in patients with WM. Enrollment in both treatment schedules is ongoing.
Updated results will be presented at the meeting.
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WHICH GUIDELINES TO TRUST? CRITICAL APPRAISAL OF CLINICAL
PRACTICE GUIDELINES FOR MANTLE CELL LYMPHOMA SHOWS HIGH
VARIABILITY AMONG RECOMMENDATIONS.
M. Marchetti1,* N.L. Liberato2
1Hematology - Oncology Unit, Hospital C. Massaia, ASTI, 2Internal medicine
Dpt, ASL-PAVIA, Casorate Primo, Italy
Background: Guidelines are evidence-based tools supporting everyday clinical
practice. Therefore, several national and international scientific and governa-
ment institutions regularly produce guidelines. Unfortunately, major inconsis-
tencies are usually found among basic recommendations, which limits both
applicability and harmonization. Some excellence institutions overcame such
a hurdle developing high-quality local clinical pathways. Nevertheless, guideline
representation through an ontology-based format may permit a greater insight
into inconsistencies and ambiguities.
Aims: In a pilot phase of a guideline harmonization project sustained by the
Italian Society of Hematology, we tested the comparability of guidelines for
frontline treatment of mantle cell lymphoma (MCL).
Methods: We applied the ADAPTE standard to search, appraise and compare
guidelines: those published in English language after the year 2010 were select-
ed. Clinical practice guidelines (CPG) reporting evidence levels and grading of
recommendations were listed separately from coonsensus statements and clin-
ical pathways. CPG quality was assessed by the standard tool AGREE. Finally,
we extracted implicit ontologies out of the recommendations and compared
them across guidelines.
Results: We retrieved 11 documents from 7 countries, including 5 clinical prac-
tice guidelines (CPG), 2 clinical pathways, 1 consensus statement and 1 hybrid
document. Four different grading systems for guidelines were adopted, only 2
of them using GRADE system. AGREE score for the 5 CPG ranged from 25%
to 57%, the weakest areas being applicability, editorial independence and
stakholders. The two CPG adopting GRADE system scored highest at AGREE
evaluation. Major inconsistencies among guidelines regarded the criteria used
to choose a therapy plan. Analysis of ontologies allowed us to classify the deci-
sional criteria suggested for prompting frontline choices into 7 classes: age,
performance status, comorbidity, biologic aggressiveness (blastoid variant, pro-
liferation index), clinical presentation (indolent disease, symptoms, nodal dis-
ease), prognostic score (MIPI, IPI), tumor burden (included stage). Each guide-
line incorporated only a small subset of the above decisional criteria and overlap
among guidelines was minimal. Rituximab-bendamustine and Rituximab-CHOP
were recommended as frontline therapy for transplant inelegible patients by all
the guidelines, however, only 2 of them transparently indicated a preference
ranking among therapies. Recommendations to other chemoimmunotherapies
(R-CVP, R-Chl, R-FC, R-CVAD/R-MA) were highly heterogeneous. Rituximab
maintenance was recommended by five out of five guidelines updated in 2014,
but the recommendation was usually not restitricted to patients treated with
frontline RCHOP. Radiotherapy was consistently recommended for stage I-II
disease, usually as consolidation after chemotherapy. Indication to ASCT con-
solidation in younger patient with advanced disease was not always stringent,
however it was in almost all the CPGs. Suggested induction regimen included
high-dose aracytin, except for one CPG suggesting the use of Rituximab-ben-
damustine. Only one CPG and one algorithm reported criteria for consolidation
allogeneic SCT in patients with a first complete remission. Three guidelines
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provided recommendations for management of compromised patients. No
guideline suggested the use of frontline regimens containing bortezomib, ibru-
tinib or idelalisib.
Summary and Conclusions: Inconsistency among guidelines does not reside
only in paucity of comparative high-quality evidence, rather, in lack of trans-
parent methods for linking evidence to recommendations, in disagreement on
ontologies and in empiric management of uncertainty. Guideline harmonization
projects may prompt an improvement of guideline quality and allow a more
critical adoption by physicians.
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CIRCULATING ADAMTS-13 IS REDUCED IN PATIENTS WITH
WALDENSTROM’S MACROGLOBULINEMIA AND IS ASSOCIATED WITH
INCREASED IGM LEVELS AND DISEASE FEATURES BUT NOT WITH THE
LEVELS OF VON WILLEBRAND FACTOR
E. Kastritis1,* E. Terpos1, M. Gavriatopoulou1, C. Skevaki2, E. Eleutherakis-
Papaiakovou1, D. Kalapanida1, M. Bakogeorgos1, M. Politou3, I. Papassotiri-
ou2, M. Dimopoulos1
1Department of Clinical Therapeutics, National and Kapodistrian University of
Athens, 2Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hos-
pital, 3Laboratory of Hematology and Blood Bank Unit, “Aretaieio” Hospital,
National and Kapodistrian University of Athens, Athens, Greece
Background: ADAMTS-13 is a protease, which cleaves the cell bound large
ultrapolymeric von Willebrand factor (vWF) strings. Circulating ADAMTS-13 is
primarily synthesized and released from hepatic stellate and endothelial cells.
Acquired functional deficiency of ADAMTS-13 results in excessive platelet
aggregation and disseminated vWF/platelet-rich thrombus formation. Hivert et
al (Blood 2012) and our group (ASH 2013, # 3194) have shown that increased
levels of vWF, the only known substrate of ADAMTS-13, are associated with
poor prognosis in patients with symptomatic WM. 
Aims: Our aim was to investigate the possible association of ADAMTS-13 anti-
gen (Ag) levels with features of WM and possible biologic implications of the
ADAMTS-13 / vWF interaction in WM patients’ prognosis. 
Methods: Our study included 42 patients with symptomatic WM who were
treated and followed in the Department of Clinical Therapeutics of the University
of Athens (Greece), 22 patients with asymptomatic WM and 19 healthy controls
of matched gender and age. ADAMTS-13 antigen levels were measured in
stored serum, collected at diagnosis and before initiation of therapy, using a
commercially available kit (R&D Systems, Minneapolis, MN, USA). 
Results: The median age of patients with symptomatic WM was 65 years
(range: 37-83 years) and 54% were males. Anemia (Hb<11.5 g/dL) was present
in 78%, platelet counts <100x109/L in 17%, beta2-microglobulin >3 mg/dl in
56%, while 7.5% had serum LDH ≥250 U/L and 58% had serum albumin <3.5
g/dL. Median serum IgM was 3340 mg/L (range 246-9563 mg/dL). According
to ISSWM, 22% had low, 43% intermediate and 35% high risk WM, respectively.
Reasons to initiate therapy included cytopenias in 42%, B-symptoms in 15%,
hyperviscosity in 12%, neuropathy in 10% and other reasons in 21%. Primary
therapy based on rituximab was given in 93% of the patients and 54% achieved
at least 50% reduction of IgM. Median ADAMTS-13 levels in patients with symp-
tomatic WM were 848 ng/ml (range 471-1622 ng/ml), in those with asympto-
matic WM were 875 ng/ml (range 280.5-1466 ng/nl) and in healthy controls
were 1170 ng/ml (range 770-1598 ng/ml). Thus, there was a significant differ-
ence of ADAMTS-13 levels between patients with either symptomatic or asymp-
tomatic WM and normal individuals (p<0.001 and p=0.002 respectively) but
there was no difference between symptomatic and asymptomatic WM
(p=0.934). There was a negative correlation between levels of ADAMTS-13
and levels of IgM (r=-0.544, p<0.001), beta2-microglobulin (r=-0.376, p=0.01)
and the infiltration of the BM by lymphoplasmatic cells (r=-0.338, p=0.03),and
a positive correlation with serum albumin levels (r=0.373, p=0.016). Accordingly,
in patients with hyperviscosity syndrome, serum ADAMTS-13 was lower
(p=0.04). There was no association of ADAMTS-13 levels and vWFAg levels,
in patients with either symptomatic or asymptomatic WM (p>0.5 for both). Thus,
a direct link between increased vWFAg levels, which are found in patients with
WM, and compensatory ADAMTS-13 levels cannot be supported by our data.
The levels of ADAMTS-13 had no prognostic association with overall or pro-
gression free survival in patients with symptomatic WM. 
Summary and Conclusions: This is the first evaluation of ADAMTS-13:Ag
levels in the serum of WM patients. Serum ADAMTS-13:Ag levels are lower
compared to healthy controls and inversely correlate with IgM levels, beta2-
microglobulin and the degree of bone marrow infiltration but do not increase in
compensation to increased levels of vWF Ag. 
E1157
DOES AGE ADJUSTED CHARLSON COMORBIDITY SCORE STRONGLY
PREDICT OUTCOME OF THE PATIENTS WITH FOLLICULAR LYMPHOMA
TREATED WITH IMMUNOCHEMOTHERAPY?
J. Jelicic1,* M. Todorovic1, B. Andjelic1, A. Sretenovic1, D. Antic1, J. Bila1,
D. Stanisavljevic2, V. Djurasinovic1, V. Vukovic1, M. Smiljanic1, B. Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology,
2Department of statistics, Faculty of Medicine, Belgrade, Serbia
Background: The clinical outcome of patients with follicular lymphoma (FL)
has been improved since the introduction of rituximab. However, the manage-
ment and optative outcome of patients with lymphoma is frequently complicated
by their comorbid conditions.
Aims: The aim of this study was to evaluate possible influence of comorbidities
on the overall survival (OS) of patients with FL, using correlation between clin-
ical outcome and comorbid status expressed through Cumulative Illness Rating
Scale (CIRS) and age adjusted Charlson comorbidity index (aaCCI).
Methods: A total of 140 patients (84 female/56 male) from age of 20-74 years
(median 52 years) were analyzed. Majority of patients (94.3%) were in
advanced clinical stage, III and IV according to the Ann Arbor classification.
Bulky disease was present in 35.7% patients, B symptoms in 67.1%, leukemic
phase of disease in 7.1% of patients. Bone marrow infiltration had 67.1%
patients and histopathological grade (Gr) 3 of disease had 25.6% of patients.
Regarding the Follicular Lymphoma International Prognostic Index 2 (FLIPI2),
low score was present in 4.4% patients, intermediate in 47.8% and high score
in 47.8%. According to CIRS (minimal score 14), 58.5% of patients were without
comorbid condition (CIRS 14) and 41.5% had at least one comorbidity
(CIRS≥15). In a view of aaCCI, 63.1% patients had aaCCI 0-2 and 36.9% had
aaCCI≥3.
Results: All patients were treated with immunochemotherapy including R-
CHOP protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, pred-
nisolone) applied in 92.1% of patients and R-CVP protocol (rituximab, vin-
cristine, prednisolone) applied in 7.9%. Partial and complete remissions were
achieved in 92.1% patients, and 7.9% did not respond to initial medical treat-
ment. There was no statistical difference regarding OS between patients who
were treated with R-CVP protocol comparing to patients treated with R-CHOP
(Log Rank χ21.436, p>0.05). According to the lymphoma grade, there was dif-
ference in 5–years survival between patients with Gr 1-2 and Gr 3 (Log Rank
χ2=5.291, p=0.06), 84% in patients with Gr 1-2 comparing to 68% in those with
Gr 3. The patients with B symptoms had poorer outcome with 5–years survival
of 78%, comparing to the patients without B symptoms whose 5–years survival
was 90% (Log Rank χ2=1.672, p˂0.05). Leukemic phase of lymphoma was
not in correlation with the worst outcome (Log Rank χ2=0.04, p>0.05), neither
was bulky disease (Log Rank χ2=1.672, p>0.05). The FLIPI2 was highly pre-
dictive in our group of patients (Log Rank χ2=20.361, p˂0.01). OS in patients
with CIRS≥15 after 1, 2 and 5 years was 92%, 87% and 80% respectively, and
98%, 95% and 89% for those with CIRS 14. Regarding aaCCI, OS in patients
with aaCCI≥3 after 1, 2 and 5 years was 94%, 82% and 76% respectively, and
97%, 93% and 88% for those with aaCCI 0-2. Multivariate analysis among
CIRS, aaCCI, lymphoma histopathological grade and FLIPI2, revealed that
only FLIPI 2 was independent prognostic parameter associated with worse OS
(HR=18.18, 95% CI 2.359-140.134).
Summary and Conclusions: In the rituximab era prognostic index FLIPI2 still
remains the most predictable value for OS in FL patients, while histopatholog-
ical Gr 3 illustrated the different, more biologically aggressive form of disease.
Among FL patients, aaCCI was associated with poorer outcome and should
be calculated in this population.
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TOXICITY AND EFFICACY OF BENDAMUSTINE IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) AND INDOLENT LOW GRADE
NON-HODGKINS LYMPHOMA (INHL); A MULTI-CENTRE OBSERVATION
OF REAL LIFE EXPERIENCE IN THE UK
D. Murray1,* K.C. Thein2, S. Basu3, P. Bassett4, S. Chaganti1, S. Paneesha5,
S. Shafeek2, V. Tandon6, S. Francis3
1Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust,
Birmingham, 2Clinical Haematology, Worcester Acute Hospitals NHS Trust,
Worcester, 3Clinical Haematology, Royal Wolverhampton Hospitals NHS Trust,
Wolverhampton, 4Statsconsultancy Ltd, Amersham, 5Clinical Haematology,
Heart of England NHS Foundation Trust, Birmingham, 6Clinical Haematology,
Walsall Healthcare NHS Trust, Walsall, United Kingdom
Background: Bendamustine has shown resurgence as a new ‘old’ drug effec-
tive in both CLL and iNHL with a favorable side-effect profile (Rummel MJ et
al, 2013, Lancet, 381:1203 & Fischer K et al, 2012, J Clin Oncol, 30:3209).
Data outside of the trial setting is lacking.
Aims: To analyze the response rate and toxicity of bendamustine in a large
heterogeneous cohort of patients treated in the United Kingdom.
Methods: We collected data on 161 patients treated with bendamustine over
2 years across 5 hospitals in the UK. Toxicity was assessed by red cell &
platelet transfusion, hospital admissions, G-CSF use during admission and
dose reduction. Univariate analysis of each factor assessed association with
response, toxicity, progression-free survival (PFS) and overall survival (OS).
PFS and OS were assessed by Cox regression.
Results: Mean age was 71 years (47-89). Diagnosis: CLL (n=108) and iNHL
(n=53). Bendamustine was front line therapy in 57 patients (35%), relapse ther-
apy in 104 (65%). ECOG performance status (PS) was 0-1 in 108 (67%)
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patients (range 0-3). Treatment was part of a trial in 19 patients (12%). Median
dose in CLL was 70mg/m2 and in iNHL 90mg/m2 (range 45-120), used as a
single therapeutic agent in 20%, and combined with rituximab in 76%. Sup-
portive therapy with septrin, anti-fungal and G-CSF was used in 64 (40%), 43
(27%) and 47 (29%) patients respectively. Improved response to bendamustine
in the whole cohort significantly correlated with front-line use (p=0.02) and lower
PS (p=0.01), but not age. In the CLL cohort, first line bendamustine overall
response rate (ORR) was 90%, complete response (CR); 51%. In the CLL
relapsed setting ORR was 76%, CR was 18%. Deletion of 17p and 11q did not
impact on ORR. In the iNHL cohort, first line bendamustine ORR was 100%,
CR was 53%. In the iNHL relapsed setting the ORR was 81%, CR of 28%.
Age, bulky disease, stage or bone marrow involvement did not affect ORR in
iNHL. Red cell transfusions were administered in 67 patients (43%), with higher
PS predictive of this (p=0.03). Of these patients, only 35 (53%) received irra-
diated blood. Platelet transfusions were administered in 23 patients (15%).
Admission during treatment occurred in 82 patients (53%), with male sex pre-
dictive of this (p=0.04). G-CSF administration during these admissions occurred
in 28 patients (19%), with a higher number of co-morbidities predictive of this
(p=0.008). Dose reduction after cycle 1 occurred in 17 patients (11%). Median
PFS in all patients was 17 months, median OS was 29 months. In CLL median
PFS was 16 months, median OS was 28 months. Deletion of 17p had no influ-
ence on OS (p=0.11) or PFS (p=0.25). In iNHL, median PFS was 21 months,
median OS was 66 months (see figure 1). Poor performance status (p <0.001)
and treatment in relapsed setting (p=0.04) predicted inferior PFS. In multivariate
analysis higher performance status (p <0.001), female gender (p=0.04) and
lower eGFR (p=0.004) predicted poorer OS.
Figure 1. Overall PFS and OS for iNHL and CLL.
Summary and Conclusions: Our data suggests bendamustine is an effective
therapy for CLL and iNHL. It delivers comparable efficacy to published trial data
even in non-trial patients, particularly in front-line therapy. Of note, response in
CLL was not affected by cytogenetic status. Similarly, response in iNHL was
not affected by bulky disease or marrow involvement. In our study we found a
high incidence of hospital admissions (53%) and blood product use. Several
factors including gender, performance status, co-morbidities and renal function
were found to independently correlate with toxicity. This study may help to
improve patient selection for this chemotherapeutic agent.
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MODELING THE EPIDEMIOLOGY OF FOLLICULAR LYMPHOMA (FL) IN
FRANCE
X. Troussard1,* A. Herrera2, E. Cornet3, P. Solal-Céligny4
1Laboratoire d’hématologie biologique, CHU Caen - Hôpital de la Côte de
Nacre, Caen, 2Service Médecine interne immunologie, Hôpital Antoine-Béclère,
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Background: As of 2014, there were few reliable publication sources of epi-
demiology data for Non-Hodgkin Lymphoma (NHL) in France, particularly with
regard to indolent forms such as Follicular Lymphoma (FL). In addition, epi-
demiology registries provide useful data on disease incidence but no information
is available on the number of relapsed FL patients. At the same time, new and
effective drugs will be made available to the Hematologist/Oncologist commu-
nity and thus, there will be an increase in the complexity of therapeutic algo-
rithms.
Aims: The innovative modeling approach intends to offer a better understanding
of the size of FL relapsed patient population in France. The objective of the model
was to determine the yearly incidence of FL patients in first line and later lines of
therapy between 2014 and 2018. Thus, the model provides relevant data to deter-
mine the patient population size that will be eligible for the new compounds and
that could be implemented into a prospective economic model.
Methods: First, we used the “Registre Régional des Hémopathies Malignes
de Basse-Normandie” (RRHMBN) to collect real world patient characteristics,
such as patient subgroups and tumor staging. The RRHMBN is dedicated to
Hematological malignancies and supported by official Health Authorities: “Insti-
tut National du Cancer“(INCA) and “Institut National de Veille Sanitaire” (INVS).
Then, we applied these findings to the French National Network of Registers
“FRANCIM” incidence and survival data. Thus, in 2014 the estimated number
of patients with low risks (FLIPI 0-1, 36%) or high risk (FLIPI ≥2, 64%) is 985
and 1750 respectively. In 2018, it is estimated to reach 1151 and 2048 patients
respectively. Afterwards, we applied progression free survival (PFS) results
from medical literature for each standard of care treatment. The analysis
showed that 36% of patients were classified FLIPI 0-1 and 60% of them had a
stage I or II and they did not receive any treatment. 90% of patients with stages
III/IV were treated by Rituximab alone (R) leading to a PFS equal to 26 months.
Others patients stages III/IV and 90% of FLIPI≥2 were treated with Rituximab
(R)−Cyclophosphamide (C)−Hydroxydaunorubicin (H)−Vincristine (O)−Pred-
nisone (P) leading to a PFS equal to 42.2 months. For the remaining 10% of
patients with FLIPI≥2, the Rituximab (R)−Cyclophosphamide (C))−Vincristine
(O)−Prednisone (P) regimen led to a PFS equal to 34 months.
Results: The table below shows the yearly number of FL patients eligible for
treatment in first and subsequent lines of therapy as produced by the model.
Table 1.
Summary and Conclusions: Our modeling approach compensates for a lack
of real world information on relapsed FL. We have shown that there is a signif-
icant number of relapsed patients who are in need of new treatments in France.
The model produces estimates for the number of patients in later lines in need
of novel therapies by 2018 and provides efficient prospective data that can be
integrated into medico-economic model development. Furthermore, these data
address a current unmet medical need for the development of new FL algo-
rithms that are required for the upcoming therapies in the relapsed setting.
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MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN’S LYMPHOMA
AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH
CONVENTIONAL CHEMOTHERAPY
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Background: Primary Hepatic (PHL) non-Hodgkin’s Lymphoma is a rare entity,
frequently associated with a poor prognosis. PHL was first described in 1965
by Ata el al and in 1986 Caccamo et al defined PHL as a localized lymphoma,
limited to the liver without extrahepatic involvement. Small series of PHL have
been reported, suggesting a non-fortuitous association with Hepatitis C Virus
(HCV) infection. The prognosis is believed to be dismal, with early recurrence
and short survival. To date, less than 150 cases have been published. 
Aims: Eleven adult consecutive patients observed in our Division from 1990 to
2013 (median age: 58 years) fulfilled the diagnostic criteria for Primary Hepatic
Lymphoma. 
Methods: Our series of patients were derived from 1083 patients with non-
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Hodgkin’s Lymphoma observed in our institution in the same period (i.e. with
a prevalence of 1.0% for PHL). We performed a study of the viral status and
the result of cytotoxic treatment. The disease occurred in middle-aged patients
(median age: 58 years). The main presenting complaint was right upper quad-
rant abdominal pain (4/11 patients). Tumor markers (Alfa-fetoprotein and CEA)
were normal in 8 patients tested. Liver scans demonstrated either a solitary
nodule or multiple lesions. Pathologic examination revealed diffuse large B cell
lymphoma in seven patients, two cases of follicular lymphoma, one of small
lymphocytic lymphoma and one case of T cell lymphoma. Eight patients (72%)
were HCV-positive. Eight patients were treated with CHOP regimen (6 CHOP
and 2 R-CHOP), two patients with R-FN, while a patient with a single focal
lesion underwent to surgical treatment. 
Results: The complete remission rate was 100% (11/11) after frontline therapy,
and only one patient relapsed but underwent remission after additional
chemotherapy courses; one of these patients, who had HCV-related cirrhosis,
died because of hepato-renal syndrome, and another one died because of
Acute Myeloid Leukemia. 
Table 1.
Summary and Conclusions: Our study confirms the rarity of PHL. In our Divi-
sion, the outcome of patients with PHL, who are treated with combination
chemotherapy, seems excellent. The frequent association of PHL with HCV
infection suggests a possible role of this virus in lymphomagenesis. HCV-infec-
tion does not appear to influence the outcome.
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Background: OAML(ocular adnexal mucosa-associated lymphoid tissue type
lymphoma) is uncommon but its incidence is constantly increasing. There have
been many attempts to identify prognostic factors for OAML. Recently, a new
staging system and treatment modalities have been developed.
Aims: We studied the clinical features of OAML and evaluated the effectiveness
of radiotherapy as a treatment modality. We also studied prognostic factors
correlated with overall and progression-free survival in patients with OAML.
Methods: Ninety-four patients who were diagnosed with OAML at Yeungnam
University Hospital between 1995 and 2014 were enrolled. Information on the
patient age, tumor location, symptoms, and biochemistry profiles were collect-
ed. Computed tomography (CT), magnetic resonance imaging (MRI), positron
emission tomography (PET), and bone marrow biopsies were performed in
order to establish the stage. Most patients were treated with external beam
irradiation (median dose 30 Gy). Treatment response was evaluated by using
orbital CT or PET. The progression-free survival was analyzed in patient sub-
groups classified according to tumor bilaterality, the Ki 67 index, and the TNM-
based stage.
Results: The median follow-up duration was 48 months (range 2–220 months).
The median progression-free survival was 42 months (range 2–202 months).
The median overall survival was 92.5 months (range 3–236 months). Seven
patients experienced relapses, and 5 patients died. The 5-year progression-
free survival and overall survival rates were 94.7% and 96.8%, respectively.
The relapse rate was 7.4%. In the radiotherapy-only group, 6 of 86 patients
had recurrences, but they achieved remission after additional treatment. Twelve
of the 86 patients in the radiotherapy-only group had remnant lesions, but a
remission rate of 92% was achieved even without additional treatment. Cervical
lymph node metastasis was identified in 1 of 84 patients who underwent imag-
ing, and bone marrow involvement was observed in 1 of 92 patients who under-
went biopsy. Lactate dehydrogenase and β2-microglobulin levels were not
found to be correlated with relapse. Statistical analysis did not identify any cor-
relation between progression-free survival and tumor bilaterality, the Ki 67
index, or the tumor stage.
Summary and Conclusions: Patients with OAML have a good prognosis.
Because of the high survival rate and low relapse rate of OAML, it is difficult to
identify prognostic factors that influence progression-free survival. Moreover,
owing to the rarity of patients with advanced stages of OAML, additional studies
are necessary to identify the economic benefits of performing thorough staging
procedures. We concluded that radiotherapy is a very effective treatment
modality for localized OAML, supporting the findings of previous studies.
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Background: Apart from localized gastric disease, there is no consensus on
standard initial treatment of mucosa-associated lymphoid tissue lymphoma. 
Aims: This study was launched to evaluate the use of Rituximab (R) alone or
Rituximab plus Chlorambucil (RC) in patients not previously given systemic
anticancer therapy.
Methods: All patients with histologically confirmed diagnosis of MALT lym-
phoma were selected from our data base. Only patients treated with R or RC
were analyzed and evaluated. The scheme: rituximab 375 mg/sqm weekly for
4 doses, then monthly for 4 infusions alone or in combination with chlorambucil
at the dosage of 0,1 mg/Kg/die for 45 days, then on days 1 to 15 monthly for
4 months.
Results: From January 2000 to February 2013, 136 patients with diagnosis of
MALT lymphoma were diagnosed and treated in our Institution, 76 of them uni-
formly treated with R or RC. The median age at diagnosis was 68 years (range
32-85). In 20 patients the disease was localized in conjunctiva; 17 in the stom-
ach; 14 in the lung; 13 in salivary glands; 3 intestine; 2 respectively in lacrimal
gland, liver, skin; 1 in breast, cheek and tongue. Stage was IA in 63 patients
(83%), IB in 1, IIA in 5 patients and IIB in 1, IIIA in 1 patient, IVA in 4 patients
and IVB in 1. Bone marrow biopsy was negative in 59 patients, positive in 5
and not performed in 12 patients. The proliferative index was evaluated in 50
patients with Mib1 monoclonal antibody: 42 patients showed less than 30% of
positivity and 8 had more than 30% of positivity. The diagnosis of MALT in 4
patients was associated with Sjogren Syndrome, in 4 patients with a positive
HCV and in 1 with sclerodermia. According to treatment, 61 patients were treat-
ed with Rituximab plus Chlorambucil; 15 were treated with Rituximab alone.
At the end of treatment 68 patients (89%) obtained a complete remission and
7 (11%) a partial remission with an overall response rate of 100%. With a medi-
an observation period of 65 months (range 1-158) the overall survival was
88%. 9 patients died, 6 for disease progression (3 after a relapse) and 3 for
causes not related to lymphoma. 12 patients (16%) relapsed, 8 of these patients
were retreated with Rituximab and obtained a new complete remission. Both
treatments were well tolerated without unexpected toxicities.
Summary and Conclusions: After a long follow-up the combination of Ritux-
imab and Chlorambucil or Rituximab alone proved to be low toxic, feasible and
effective therapy for MALT lymphomas.
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2Blood center, University Hospital Ostrava-Poruba, Ostrava-Poruba, 3Microbi-
ology, Faculty Hospital Olomouc, Faculty of Medicine and Dentistry, University
Palacky, Olomouc, Olomouc, Czech Republic
Background: Use of granulocyte transfusions (GT) in patients with hematologic
malignancy and prolonged neutropenia complicated with severe infection rep-
resents a strategy which positive and negative aspects are discussed.
Aims: To evaluate the efficacy and safety of GT applied over the last ten years
period (2005-2014). 
Methods: A single center retrospective analysis was performed. GT were col-
lected after stimulation with 40mg i.v. Solu-Medrol from unrelated AB0 and Rh
compatible donors. HLA compatibility was not evaluated and family donors
were not used. Separation was performed at Cobe Spectra - Caridian BCT
blood separator. GT were stored at room temperature and given to the patients
on the day of collection after irradiation of the packs with 32 Gy using Gamma-
cell 3000 Elan blood irradiator (Cs137). Decisions to give GT in individual
patients were made collectively after agreement minimally of 3 physicians (usu-
ally patients´ physician, head of the ward and head of Department). Decisions
to stop GT treatment were taken according to clinical response to GT and
degree of hematologic reconstitution. All patients were pre-medicated with
Hydrocortison 100mg i.v. given immediately prior transfusion.
Results: GT were given to 41 patients (15 female and 26 male) at age from 22
to 69 years (median 45.5). There were 26 cases of acute leukemia, 7 patients
with myelodysplastic syndrome, 5 patients with chronic lymphocytic leukemia
and 3 patients with lymphoma. In most patients disease was active at the time
of GT initiation (30; 73.2%), only 11 patients were in hematologic remission. 30
patients were after chemotherapy while 3 patients were after allogeneic
hematopoietic stem cell transplantation. Duration of severe neutropenia (less
than 0.5x109/l) was from 4 to 80 days (median 19 days). Antibiotics were applied
in all patients for 1 to 126 days (median 14 days) before initiation of GT. The
main clinical indications were soft-tissue inflammations (26 cases) and pneu-
monias (16). 14 patients have suffered from proven invasive fungal infections
(9 aspergilosis and 5 candidiasis) while coincident Gram-positive or Gram-neg-
ative sepsis was present in 9 and 16 cases, respectively, complicated in 12
patients with septic shock. Together 191 GT were given – in a single patient
from 1 to 17 GT (median 3.5). GT contained from 0.5 to 3.0x1010 granulocytes
per one transfusion unit (median 1.3x1010). No side-effects both in donors and
patients were recorded. Decrease of fever, complete resolution of infection and
clinical improvement after GT was observed in 36 (87.8%), 29 (72.5%) and 34
(82.9%) of patients, respectively. Clinical deterioration occurred in 6 (14.6%)
patients (4 – 9.8% – of these were fatalities). In six patients immediately after
GT treatment allogeneic stem cell transplantation was performed. We have not
observed any significant clinical consequences of GT in these patients after
transplantation, one patient transplanted with active disease died early after
relapse of acute leukemia while all other patients achieved full donor chimerism
with remission of hematologic disorder.
Summary and Conclusions: We can conclude, that in our hands GT harvested
from unrelated donors after stimulation with steroids and transfused in selected
patients with severe infections during prolonged neutropenia have a high effi-
cacy and safety and enabled not only successful management of infections in
most cases but also safe proceeding to allogeneic stem cell transplantation
leading to cure in a significant proportion of our patients. Acknowledgement:
Grant of IGA LF UP 01-2015.
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Background: Infection is the most common cause of treatment related mortality
in childhood acute lymphoblastic leukemia (ALL). Patients with ALL are prone
to infections especially during induction phase of treatment. 
Aims: Aim of the study is to determine incidence of common infections and
infectious agents in pediatric patients with ALL during induction phase of treat-
ment, and compare the infection frequency between the groups treated with
10 mg/kg or 20 mg/kg high dose methylprednisolone (MPZ). 
Methods: Pediatric patients newly diagnosed with ALL between 2008 and 2014
were enrolled. Patients were treated according to modified St Jude Total XV
Protocol, and they were randomized for high dose MPZ treatment, which was
given for seven days before induction treatment at a dose of 10 mg/kg or 20
mg/kg orally. A retrospective data review, from electronical database and paper
files, was performed. The incidences of diarrhea, pneumonia, neutropenic fever,
typhlitis, fungal infections, use of antifungal agents, mucositis, vancomycin
resistant enterococci colonization during induction phase were recorded. 
Results: A total of 154 patients with newly diagnosed ALL were included in the
study. Median age of patients at diagnosis was 5 (1-19) years. Neutropenic
fever occurred in 87 (56.5%) of patients (Table 1), 30 of patients had neu-
tropenic fever two or more times. Median duration of neutropenic fever was 2
(1-15) days. Microorganisms isolated in peripheral blood, central venous
catheter (CVC), or urine samples in 48 (31.2%) of the patients. In peripheral
blood cultures gram positive/negative ratio was 2.9, in CVC cultures this ratio
was 3. CVC infection was detected in 42 (27.3%) of patients. Fungal infection
was seen in 10 (6.5%) of patients. Infection related mortality occurred in 4
(2.6%) patients at induction, and one patient died due to tumor lysis syndrome
at the induction phase. Of the patients, 141 were available for comparison of
infection rates according to MPZ dose (78 received 10mg/kg, and 63 received
20 mg/kg MPZ). Only diarrhea frequency was statistically significantly more
common in group treated with 20mg/kg dose of MPZ (p; 0,02). 
Table 1. Infection rates in induction phase
   Characteristics n (%)
    Neutropenic fever 87 (56.5%)
    Catheter infection 42 (27.2%)
    Diarrhea 33 (21.4%)
    Mucositis 31 (20.1%)
    Pneumonia 26 (16.9%)
    Cellulitis, skin infections 14 (9%)
    Fungal infection 10 (6.5%)
    VRE colonization 13 (8.4%)
    Typhilitis 5 (3.2%)
Summary and Conclusions: Our study revealed that 56.5% of patients had
experienced neutropenic fever during induction phase. Catheter infections were
among the most common reason of infections. Gram positive bacterial infec-
tions were seen three times more frequent than gram negatives in both periph-
eral blood stream and central venous catheters. In our study majority of induc-
tion deaths was secondary to infections (4/5). Additionally, the higher doses of
MPZ had no impact on the rates of the various infections except for diarrhea
and diarrhea was more common among the dose of 20 mg/kg group that might
be related to oral application of the drug.
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Background: Guidelines recommend granulocyte-colony stimulating factor (G-
CSF) use to reduce the risk of neutropenic infections in patients receiving
chemotherapy (CT) and to enable full-dose delivery. ZOHé is a French prospec-
tive non-interventional, longitudinal study describing biosimilar filgrastim
(Zarzio®) use in routine practice, in patients receiving CT for solid tumor or lym-
phoid malignancies (LM).
Aims: To describe patients, Zarzio® treatment patterns, relative dose intensity
(RDI) maintenance and outcomes in the LM cohort.
Methods: Patients ≥18 years old receiving treatment for LM were recruited.
This analysis reports the impact in real life of EORTC guidelines on G-CSF
prophylaxis for chemotherapy-induced febrile neutropenia (CIN/FN). Zarzio®
treatment characteristics along with CT in terms of dose, day of initiation, dura-
tion and proportion of patients for which CT RDI was conserved (dose main-
tained in ≥85% of CT cycles) have been recorded. Data were collected at
Zarzio® initiation time and 3 months after inclusion.
Results: 633 evaluable patients were recruited from June 2013 to April 2014.
32 patients (5%) received a CT regimen associated with a FN risk ≥20% justifying
by itself the G-CSF prophylaxis. However, in patients receiving CT regimen with
FN risk of <10%, 10-20% or unknown, the vast majority (586, 97.5 %) had at
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least one risk factor for increased incidence of FN such as elderly patients (aged
65 and over) or advanced disease stage. Prophylaxis was initiated as either
primary or secondary in 427 (67.5%) and 206 (32.5%) patients respectively.
Zarzio® was started on average 6.5±2.2 days (median=6) after CT and given
for 5.9±1.7 days (median=5). Dosing was 30MIU/day in 80%, 48MIU/day in
20% of the cases. 16.7% of patients developed at least one Grade 3 or 4 CIN
episode of which 4.9% were febrile. CIN/FN-related hospitalizations were expe-
rienced by 5.7% of patients. 420 patients were evaluable for RDI (data collection
was optional): the majority of patients 85.2% had a preserved RDI over 3 months
follow-up (table). 37 non serious adverse events (AE) considered to be related
to G-CSF by the investigator were recorded. One AE led to a modification of
Zarzio® dose, 7 to Zarzio® treatment discontinuation.
Table 1. Relative dose intensity maintenance
Summary and Conclusions: In this routine practice French cohort BS filgras-
tim (Zarzio®) appears effective for RDI maintenance in the vast majority of the
patients. According to the EORTC guidelines, Zarzio® was initiated on primary
prophylaxis treatment in 67.5% of patients and mostly at day 6 after CT.
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BK VIRUS-HEMORRHAGIC CYSTITIS FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANTATION: CLINICAL CHARACTERISTICS AND UTILITY
OF LEFLUNOMIDE TREATMENT
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Background: BK virus-hemorrhagic cystitis (BKV-HC) is a potential cause of
morbidity and mortality in patients having undergone allogeneic stem cell trans-
plantation (Allo-SCT). 
Aims: We analyzed the clinical features of BKV-HC following Allo-SCT and
discussed the utility of leflunomode therapy for BKV-HC. 
Methods: From January 2005 to June 2014, among the 69 patients underwent
Allo-SCT in our institution, the patients who experienced BKV-HC were investi-
gated retrospectively. BK virus was confirmed by a qualitative PCR-based assay.
Severity of HC was graded as: grade 0 (no hematuria), grade I (microscopic),
grade 2 (macroscopic), grade 3 (macroscopic hematuria with presence of blood
clots), and grade 4 (macroscopic hematuria clots and renal impairment due to
urinary obstruction). Grade 3 and 4 were defined as high-grade HC. Complete
response (CR) was defined as complete improvement in symptoms without
hematuria; partial response (PR), downgrading of severity with persistent hema-
turia; no response (NR), unchanged or worsening urinary symptoms. 
Results: HC was observed in 30 patients (43.5%), and among them, 18
patients (26.1%) were identified as BKV-HC. The median patients’ age (12
males and 6 females) was 45 years (range, 13-63). The diagnosis of the
patients were acute myeloid leukemia (AML, n=11), aplastic anemia (n=4),
myelodysplastic syndrome (MDS, n=2), and non-Hodgkin lymphoma (n=1).
The donor types were a HLA-matched sibling donor for 6 patients, HLA-
matched unrelated donor for 9, and a haploidentical familial donor for 2. Nine
patients (52.9%) received myeloablative conditioning regimen. Seven (38.9%)
of patients received antithymoglobulin containing preparative regimen for in
vivo T-cell depletion. The median onset and duration of BKV-HC was on day
21 (range, 7-97) after transplantation and 22 days (range, 6-107). There was
no significant difference between the onset in patients with low-grade HC or
with high-grade HC (21 days vs 21 days, p=0.633). Half of the patients had an
acute graft-versus-host-disease (GVHD). Among them, seven (77.7%) patients
developed an acute GVHD after onset of BKV-HC and, conversely, 2 (22.3%)
patients developed a BKV-HC after the diagnosis of acute GVHD. Nine (50.0%)
patients had concomitant cytomegalovirus viremia. Eleven patients (62.1%)
had grade I-II HC and 7 patients (38.9%) had high-grade HC. Majority of the
patients received supportive treatment, including intravenous hydration and/or
blood transfusion. Urinary urethra catheter was inserted in 3 patients with grade
3 HC and 2 patients with grade 4 HC. After supportive care, treatment results
showed that 9 patients (50.0%) achieved CR, 4 patients (22.2%) PR, and 5
patients (27.8%) NR. Out of the 7 patients who had high-grade HC, 1 had CR,
1 PR, and 5 NR, respectively. Among the 5 unresponders, one died of BKV-
HC associated renal failure. The remaining 4 patients (3 AML and 1 high-risk
MDS) were treated with leflunomide and tolerated well, with 3 patients having
mild gastrointestinal symptoms, including anorexia and abdominal bloating.
After leflunomide treatment, 2 (50%) patients achieved CR and 2 (50%)
achieved PR. The median duration from the start of leflunomide therapy to
response was 13 days (range, 8–17). There was no recurrence of hematuria
in 2 patients achieving CR after discontinuation of leflunomide therapy.
Summary and Conclusions: BKV-HC was commonly observed in patients
with HC following Allo-SCT. In high-grade BKV-HC patients who fail supportive
care, leflunomide may be a feasible option without significant toxicity.
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Background: Febrile neutropenia(FN) is a known severe adverse event in
cancer patients undergoing chemotherapy. However, It is known that there is
a group of patients with FN who falls into low risk for developing severe com-
plications. 
Aims: To determine whether low risk FN can be managed with oral antimicro-
bials, we conducted prospective study to evaluate oral use of levofloxacin
(LVFX) .
Methods: We conducted a multicenter prospective study on cancer patients
with low risk FN. Eleven institutions participated in the study which was
approved by the institutional review board of each institution. Low risk was
determined based on the Multinational Association of Supportive Care in Can-
cer (MASCC) score. After chemotherapy, only those patients with a neutrophil
count of less than 500/μL, or less than 1,000/μL but expected to fall below
500/μL, and a recorded body temperature of over 38.0°C once or 37.5°C per-
sistently for 1 hour were enrolled in the study. It consists of two components,
i.e. either non-randomized treatment with LVFX or randomized treatment in
which patients received either oral LVFX or intravenous cefepime (CFPM), a
broad-spectrum cephalosporine. Primary endpoint is treatment success at 7th
day; success is defined as defervescence and improvement in clinical symp-
toms and laboratory results. Secondary endpoints are safety profiles for 7-day
study period and survival at 30th day.
Results: A total of 65 patients were enrolled. The results were analyzed as per
protocol parameters. In the CFPM group (n=24), treatment success at 7th day
was 66.7% (95%CI, 44.68-84.67), while In the LVFX group (n=41), it was 53.7%
(95%CI, 37.42-69.34). The difference was not statistically significant (p=0.304).
Serious adverse events were not observed in either group. All patients were
alive at 30th day.
Summary and Conclusions: The study did not show a significant difference
in effect or safety profiles between LVFX and CFPM in low risk FN, although
the number of patients was too small. However, since all patients in the LVFX
group survived at 30th day with no sequelae, oral use of LVFX could be con-
sidered a treatment option in low risk patients.
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LONGITUDINAL RISK OF HERPES ZOSTER IN PATIENTS WITH
NON-HODGKIN LYMPHOMA RECEIVING CHEMOTHERAPY: A
NATIONWIDE POPULATION-BASED STUDY 
S.F. Cho1,* W.H. Wu2, C.S. Chang3
1Division of Hematology & Oncology, Department of Internal Medicine, Kaoh-
siung Medical University Hospital, Kaohsiung Medical University, 2 School of
Medicine, I-Shou University, 3Division of Hematology and Oncology, E-Da Hos-
pital, Kaohsiung, Taiwan, ROC
Background: The outcome of patients with non-Hodgkin lymphoma (NHL)
was improved in recent decades, the treatment related adverse events on the
quality of life may be emerging as an issue.
Aims: This study aims to evaluate the incidence rate and risk factors of herpes
zoster in patients with NHL receiving anti-lymphoma treatment. 
Methods: This study was conducted using the National Health Insurance
Research Database (NHIRD) of Taiwan. The study cohort included patients
with NHL between 2002 and 2008. Propensity score matching was performed
to correct for sample selection bias. Logistic regression analyses were per-
formed to obtain odds ratios (ORs) and 95% confidence intervals (95% CIs)
for the risk evaluations. 
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Results: From 2002 to 2008, there were 3865 NHL patients with median age
of 55 years who received CHOP/CEOP or R-CHOP/R-CEOP as front-line treat-
ments; 2188 of these patients received CHOP/CEOP, and 1677 patients
received R-CHOP/R-CEOP. The overall incidence rate of herpes zoster was
12.21% (472/3865); 11.79% (258/2188) of the patients received conventional
chemotherapy and 12.76% (214/1677) of the patients received rituximab-con-
taining chemotherapy. For the patients who received conventional chemother-
apy, the risk factors included female gender, multiple courses of chemotherapy
and autologous hematopoietic stem cell transplantation. For the patients who
received rituximab-containing chemotherapy, the risk factors included female
gender, diabetes mellitus, multiple courses of chemotherapy, autologous
hematopoietic stem cell transplantation and higher accumulated rituximab dose.
The analysis of the cumulative incidence rate revealed that the majority of the
herpes zoster episodes occurred within the first two years after the diagnosis
of NHL. After adjusting for the propensity score matching, rituximab-containing
chemotherapy was not associated with a higher overall incidence rate of herpes
zoster (p: 0.155). However, the addition of rituximab to conventional chemother-
apy increased the short-term risk of herpes zoster with adjusted ORs of 1.38
(95% CI=1.05-1.81, p:0.021) and 1.37 (95% CI=1.08-1.73, p:0.010) during the
1-year and 2-year follow-up periods, respectively. 
Summary and Conclusions: This nationwide population-based study evalu-
ated the incidence rate and risk factors of herpes zoster in NHL patients who
were receiving anti-lymphoma therapy. The incorporation of rituximab into con-
ventional chemotherapy increased the short-term risk of herpes zoster.
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MACROPHAGES FROM SEPSIS SURVIVING MICE PRESENT DIFFERENTIAL
GENE EXPRESSION ASSOCIATED WITH AN IMMUNOTOLERANT
PROFILE
J.M. Mota1,* V. Wagatsuma2, J. Temporal3, F. Cunha4, H. Noushmehr2,
E. Rego1
1Clinics, 2Bioinformatics, 3Ribeirão Preto Medical School, University of São
Paulo, Ribeirão Preto, Brazil, 4Pharmacology, Ribeirão Preto Medical School,
University of São Paulo, Ribeirão Preto, Brazil
Background: Sepsis survivors are at a higher risk to present abnormalities of
the immune system and die of secondary infections caused by low virulence
pathogens. Such immunosuppressive state may favor tumorigenesis and exper-
imental data obtained in murine models showed that sepsis led to expansion
of regulatory T cells (Tregs) and macrophage polarization towards M2-like phe-
notype (characterized by high IL-10 production accompanied by low production
of IL-12 and associated with suppression of T cell responses). 
Aims: To report how sepsis affects the gene expression profile of macrophages.
Methods: C57Bl/6 mice were anesthetized and submitted to cecal and ligation
puncture to induce severe sepsis. Naïve mice were used as controls. All animals
received ertapenem 20 mg/kg ip. 6 h after surgery and bid for 3 days. Survivors
(50%) were killed for bone marrow harvesting at day 15. Macrophages were dif-
ferentiated using sarcoma L929 supernatant and adherent cells were collected
after 7 days. M1 and M2-macrophage were used as controls and polarized
through IFN-γ (50 ng/mL) plus LPS (10 ng/mL) and IL-10 (20 ng/mL), respec-
tively. Naïve mice were inoculated with bone marrow-derived macrophage
(BMDM) (10,000 cells) plus B16 melanoma (30,000 cells). Tumor growth and
survival were assessed. RNA from isolated BMDM was isolated by columns and
the cDNA was labeled and put in microarray slides. Data was analyzed using R
(version 3.1.2, 2014-10-3) and Bioconductor (version 2.14). Differential gene
expression was considered significant with a fold change of 20 for up and -2.0
for down-regulated genes and p <0.01. Pathway analyses were made through
Nextbio. Data were deposited at GEO database (code GSE64498).
Results: Tumor growth was increased and overall survival was reduced in the
group inoculated with BMDM from post-sepsis mice, compared with those who
received BMDM obtained from naïve mice. In the microarray analysis, a set of
64 genes were up-regulated and 94 genes were found to be down-regulated.
Genes related to innate immunity (e.g.Ccl5, Cxcl16, C3, Cfb, Ccr5 Tlr7 and Ccl8)
and interferon alpha/beta signaling (e.g. Oasl1, Ifit3, Ifit2, Irf7 and Ifit1) were in
general down-regulated. Also, several genes that encode chemotactic mediators
were up-regulated (e.g. Ccl2, Ccl7, Ccl12) in BMDM from post-sepsis mice.
Summary and Conclusions: BMDM obtained from sepsis surviving mice pres-
ent differential gene expression associated with an immunotolerant profile.
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VIRAL RESPIRATORY TRACT INFECTIONS IN CHILDREN WITH
MALIGNANCY: ISTANBUL PERSPECTIVE
Z. Karakas1,* S. Aydogdu1, A.G. Gencay1, E. Uysalol1, S. Karaman1,
A. Somer2, N. Salman2, S. Badur3
1Pediatric Hematology, 2Pediatric Infectious Disease, 3Microbiology, Istanbul
University, Istanbul Medical Faculty, Istanbul/, Turkey
Background: Viral infections can cause a variety of clinical pictures in children
on immunosuppression. RSV is the most commonly encountered viral respira-
tory pathogen in oncology patients, with parainfluenza virus (PIV) types 1, 3,
2, rhinovirus, influenza A and B following in order of decreasing frequency.
Aims: To evaluate the viral respiratory tract infections in children with malignancy
Methods: In this study, nasopharyngeal specimens were obtained from chidren
in our Hematology-Oncology clinic who had such respiratory symptoms as fever,
rhinorrhea, sneezing, cough or findings consistend with pneumonia on auscul-
tation or imaging and also from patients who shared a room with them. Appro-
priate antiviral therapy was instituted after evaluation of the samples, namely,
ribavirin po for 14 days for those positive for RSV and their roommates, and
oseltamivir po for 5 days for those positive for influenza and their roommates.
Results: Between October 1st 2013 and February 15th 2015, a variety of viral
respiratory pathogens were identified on specimens obtained on 32 occasions
from 26 patients who were admitted due to a variety of malignancies, namely,
acute lymphoblastic leukemia, acute myeloblastic leukemia and lymphomas.
The alarming symptom was cough in 19 episodes (59.3%), fever in 4 episodes
(12.5%), fever and cough in 9 episodes (%28.2). Pneumonia was diagnosed
through pysical examination and imaging on 8 episodes (%24.2). 14 patients
received ribavirin po, 6 patients received oseltamivir po and 15 of these
patients also received intravenous immunoglobulin due to an IgG level below
500 mg/dL. Most of our patients had mixed infections where 2,3 or 4 pathogens
were identified (RSV +PIV 2-3, hMPV +ADV, RSV +PIV4, RSV +rhinovirus,
RSV +HBovCor229 +CorHKU, Corona63 +Corona43 +CoronaHKU +rhi-
novirus, ADV +rhinovirus, rhinovirus +Corona 63, RSV +rhinovirus +HBov-
Corona229 +ADV +hMPV, coronavirus +influenza A). 11 of the patients had
rhinovirus, with 4 having rhinovirus only and 7 having rhinovirus and other
viruses), 9 had coronavirus (3 had coronavirus 43, 1 had coronavirus 229, 2
had coronavirus 63, 2 had coronaHKU), 10 patients had RSV, with 4 having it
in isolation and 6 having it as part of a mixed infection. 6 patients had parain-
fluenza viruses, with 4 having PIV only and 2 having a mixed infection. 2
patients each had human bocavirus, ADV and hMPV. 5 patients had influenza
A (4 were H1N1 and 1 was H3N2), one patient had influenza B. Six of our
patients got infected with different respiratory viruses at different times (Table).
Eight patiens were given antivirals despite their lack of symptoms as prophy-
laxis because they shared a room with an infected patient. One patient who
had familial hemophagocytic lymphohistiocytosis was younger than 6 months
and therefore could not receive ribavirin. One patient with ALL was positive
for CoronaHKU and H1N1, and received IVIG and oseltamivir and had to be
transfered to the intensive care unit due to respiratory distress, hypotension
and shock.
Table 1.
Summary and Conclusions: Viral infections of the respiratory tract can kill
immunocompromized children. Early diagnosis, close monitoring and treatment
with antivirals and IVIG for those infected with influenza A and RSV, and metic-
ulous supportive care for those infected with other viruses are needed to prevent
mortality.
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NEUTROPHIL CD64 INDEX AS A BIOMARKER OF EARLY SEPSIS IN
MALIGNANT HEMATOLOGIC DISEASE
S. yuxi1,* W. liru1
1Hematology, Fu-xing Hospital, Capital Medical University, Beijing, China, Bei-
jing, China
Background: Malignant hematologic disease with sepsis has been character-
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ized by high mortality and difficulties in diagnosis at early stage. A good bio-
marker may help us to improve the accuracy of diagnosis and to reduce the
mortality rate.
Aims: The aim of this study was to investigate the usefulness of neutrophil
CD64 expression in blood and procalcitonin (PCT) in the early diagnosis of
sepsis in malignant hematologic disease.
Methods: Ninety-seven hematological malignancies were enrolled in the study.
Sixty-three hematological malignancies were classified into three groups: no
infection (n=35), local infection (n=20) and sepsis (n=43). Another 20 healthy
people were included as a control group. Blood samples were collected within
24 hours after admission for neutrophilic CD64 index and neutrophilic CD163
index. Procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP) were
also determined in all groups. 
Results: CD64 index and CD163 index did not differ between control group
and no infection group (P>0.05); CD64 index were significantly increased in
the groups with local infection and sepsis compared to the group without infec-
tion (P<0.0001); CD64 index were also significantly increased in the group with
sepsis compared to the group with local infection (P<0.0001); The sensitivity,
specificity, overall area under the receiver operating characteristic curve of
CD64 index, CD163 index, PCT and hs-CRP for the diagnosis of early sepsis
were determined. CD64 index had the highest sensitivity of 68.9%, specificity
of 85% and overall area of 0.739 using a cut-off of > or =2.195. The cut-off val-
ue, highest sensitivity, specificity and overall area were 0.13ng/ml, 81.4%, 60%
and 0.732 for PCT, 30.15mg/L, 79.1%, 60% and 0.716 for hs-CRP, and
448.895, 88.4%, 30% and 0.535 for CD163 index.
Summary and Conclusions: We conclude that neutrophil CD64 index can
be incorporated with specific hematologic criteria as an additional marker for
diagnosis of early sepsis in hematological malignancies.
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FIVE CASES OF PNEUMOCYSTIS PNEUMONIA (PCP) INFECTION IN
PATIENTS FOLLOWING TREATMENT WITH BENDAMUSTINE/RITUX-
IMAB: PROPHYLAXIS SHOULD BE CONSIDERED AS STANDARD
PRACTICE
E. Groarke1,* T.M. Abkur1, M. Saeed1, S.Z. Ahmed1, R. McArthur1, J. Nally2,
M. Leahy1, H. O’Leary1, D. O’Keeffe1
1Department of Haematology, 2Department of Pharmacy, University Hospital
Limerick, Limerick, Ireland
Background: Pneumocystis pneumonia (PCP) is a life threatening infection
associated with immunocompromised patients. It was initially described in HIV
patients but is also well described following certain chemotherapy agents. It
has a high morality rate, particularly in non-HIV patients (35 – 50%)1. PCP pro-
phylaxis has been shown to effectively prevent PCP in at risk patients. Ben-
damustine is an alkylating chemotherapy agent, which is being increasingly
used in clinical practice, particularly in treatment of lymphoproliferative disorders
and myeloma. It is known to cause grade 3-4 lymphopenia in 74% of patients2.
At present there is no standard recommendation for PCP prophylaxis with ben-
damustine treatment.
Aims: Identify all cases of PCP following bendamustine treatment in our unit
and assess factors which increase the risk of infection.
Methods: Patients with a confirmed diagnosis of PCP who had received ben-
damustine were identified. Their case notes and investigations were reviewed.
Results: Seventy-two patients received bendamustine therapy between Novem-
ber 2009-February 2015. We identified five cases of PCP in our institution in
patients undergoing treatment with bendamustine / rituximab (6.9%). Four cases
of PCP occurred prior to routine introduction of PCP prophylaxis (August 2012)
and 1 case occurred subsequently in a patient whose prophylaxis had been
stopped. The patients infected consisted of 3 males and 2 females (average age
of 69.6 years). Two patients received treatment for low grade Non Hodgkin Lym-
phoma (NHL), 2 for Chronic Lymphocytic Leukmaemia (CLL) and 1 patient
received treatment for Waldenstrom’s Macroglobulinemia (WM). None of our
patients were on PCP prophylaxis at the time of infection. All infections were clin-
ically and radiologically suggestive of PCP and 4 were confirmed using quanti-
tative PCR on sputum samples. Four patients were undergoing treatment with
bendamustine / rituximab at the time of infection (ranging from cycle 1-3 of treat-
ment). One patient completed treatment twelve months earlier. All patients were
lymphopenic (<0.5) at time of infection (average 0.18), 2 patients had a sustained
lymphopenia (>2 weeks) prior to infection, and 4 had evidence of hypogamma-
globulinemia prior to infection (average IgG 3.48, IgA 1.49, IgM 2.82).
Summary and Conclusions: PCP infection is common following bendamus-
tine /rituximab treatment. It can occur during the first course of treatment and
it occured up to twelve months after treatment in our patient cohort. Patients
with severe lymphopenia (<0.5) and hypogammaglulinemia appear to be at
particularily high risk of PCP infection. We recommend that all patients who
receive bendamustine / rituximab treatment should be considered for PCP pro-
phylaxis from the start of treatment and it then should be continued until ade-
quate lymphocyte recovery occurs.
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SEVUPARIN DEMONSTRATES ANTI-ADHESIVE EFFECTS IN MALARIA
PATIENTS SUGGESTING ITS POTENTIAL CLINICAL BENEFITS IN
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Background: Microvascular obstruction is one of the main pathological events
leading to the development of severe falciparum malaria and pain during vaso-
occlusive crises (VOC) in sickle cell disease (SCD) patients. Excessive seques-
tration of falciparum infected red blood cells (IRBC) in malaria, and of sickle
blood cells (SSRBC) in SCD are typical features of severe states of these dis-
eases. The falciparum parasite and the SSRBC employ heparan sulfate (HS)
during the process of adherence to the endothelium and to other blood cells
causing obstructions of the blood flow. Inhibition of these abnormal cell and
pathogen interactions with sevuparin working as a decoy receptor could restore
a hampered blood flow and stop the parasite growth. Heparin and low molecular
weight heparins (LMWHs) have demonstrated clinical benefits in the treatment
of severe malaria (Munir M et al., Heparin in the treatment of cerebral malaria.
Paediatr Indones. 20, 47-50,1980) as well as of VOC in SCD (Qari MH et al.,
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin
in a double-blind randomized trial. Thromb Haemostat 98: 392-396, 2007);
however, the associated risk of bleeding limits their clinical use. Therefore,
sevuparin was designed to maintain the anti-adhesive properties of heparins
while minimizing the anti-thrombin-mediated anticoagulant activity. A 5-fold low-
er anticoagulant potency is found in sevuparin in comparison with LMWH. A
double blind, randomized Phase I study in healthy volunteers has previously
been completed.
Aims: A Phase I/II clinical study with sevuparin in patients with uncomplicated
falciparum malaria was conducted with the aim to demonstrate sevuparins
anti-adhesive effects.
Methods: The Phase I/II study consisted of an open labelled dose escalation
phase followed by an open labelled, randomized phase. The study was designed
to determine the tolerability and ex vivo efficacy of sevuparin when administered
as an iv injection as adjunctive therapy to atovaquone/proguanil (Malanil®) in
subjects affected with uncomplicated Plasmodium falciparummalaria, as com-
pared to Malanil® alone (control). Subjects were treated with 4 daily intravenous
(iv) injections of sevuparin during three consecutive days (12 doses).
Results: Sevuparin was found to be safe and well tolerated in patients with
falciparum malaria when given by iv injections as adjunct therapy with
Malarone®. Exploratory analysis revealed a potentially clinically meaningful
anti-adhesive effect since 1) mature IRBC previously being sequestered,
appeared in the circulating blood of sevuparin treated patients as compared to
controls, one hour after sevuparin injection (p=0.031) and 2) the number of
ring-stage IRBC was significantly decreased already one hour after the first
injection of sevuparin while the parasites continued to expand in control patients
not given sevuparin (p=0.022), suggests that the binding of malaria parasite
(merozoite) to RBC for invasion was inhibited. These effects are consistent
with previous in vitro results with sevuparin in both malaria and SCD related
experiments. Sevuparin has been found to block IRBC and SSRBC binding to
endothelium, and also to reverse already established blockade of the blood
flow during malaria sequestration and during vaso-occlusion related to SCD in
animals in vivo. In addition, sevuparin blocks the malaria merozoite invasion
into RBC in vitro. 
Summary and Conclusions: In the Phase I/II study in patients with uncom-
plicated falciparum malaria, sevuparin reverses the adhesion of blood cells
and pathogens to endothelium and other blood cells. These anti-adhesive
effects of sevuparin have the potential to normalize blood flow in indications
like severe malaria and VOC in SCD, which could impact the overall outcome
of these patients. Potentially sevuparin might have impact on other indications
were reversing and preventing vascular obstruction can improve the disease
status and progress.
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Background: In last 3 decades, success rate has been markedly increased in
childhood cancers; however, chemotherapy-related adverse events remain to
be an important issue. Oral mucositis, one of the toxic effects of chemotherapy,
is observed in 52-80% of the children receiving cancer therapy. Ankaferd Blood
Stopper (ABS) is an herbal product that is used as a hemostatic agent. In pre-
vious studies, it was shown that ABS has anti-microbial, anti-inflammatory
effects as well as positive effects on healing of tissue injury.
Aims: In our study, it was aimed to investigate effectiveness of ABS in prophy-
laxis and treatment of oral mucositis in patients receiving chemotherapy at
childhood. In addition, plasma levels of citrulline, a biochemical marker for
mucosal barrier injury, were measured and effectiveness of ABS therapy in
mucositis was correlated by quantitative data in addition to clinical assessment.
Methods: This was a randomized, controlled and open study which included
27 patients aged 4-17 years receiving chemotherapy regimens with strong
mucotoxic effect. The patients were asked to perform standard oral care (SOC)
upon first day of chemotherapy for 10 days and oral mucosa was assessed
daily upon completion of chemotherapy based on World Health Organization
scale for oral mucositis. In addition, blood samples were drawn immediately
before initiation of chemotherapy and at the period where mucositis became
most intensive. Same patients receiving same chemotherapeutic agents in the
second course of chemotherapy were asked to gurgle by using ABS four times
daily in addition to SOC. Mucosa ratings were performed before second
chemotherapy course and at the period where mucositis became most inten-
sive, and blood samples were drawn to measure citrulline levels in second
chemotherapy course.
Results: The study included 27 patients (mean age: 9.1±4.4 years; 15 boys
[56%]). Stages of oral mucositis were found to be significantly lower in the sec-
ond chemotherapy course given SOC plus ABS when compared to first
chemotherapy course given SOC alone (p=0.007). Mean plasma citrulline level
obtained before and after chemotherapy decreased from 44.08±11.20 to
23.99±12.16 nmol/mL in chemotherapy course given SOC alone (p<0.001)
while it decreased from 38.67±11.46 to 26.78±11.99 nmol/mL (p<0.001). When
extent of decrease in plasma citrulline level was assessed, it was greater in
courses given SOC alone compared to those given SOC plus ABS (p=0.009).
Summary and Conclusions: ABS can be considered to be an approach with
potential benefits, although its effectiveness hasn’t been proven in the prophy-
laxis and treatment of oral mucositis. Based on our results, ABS exhibited ben-
eficial effects in the prophylaxis and treatment of oral mucositis. However, mul-
ti-center experiences and further studies with larger sample size are needed
for introduction of ABS into primary oral care and treatment protocols of oral
mucositis.
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SAFETY OF BIOSIMILAR FILGRASTIM IN PATIENTS WITH LYMPHOMA
AND MYELOMA UNDERGOING NEUTROPENIA-INDUCING
CHEMOTHERAPY: A SUBANALYSIS OF THE NEXT STUDY 
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1Henri Becquerel Hospital, Rouen, 2Sainte-Anne Clinic, Strasbourg, 3Hôpital
Privé de l’Ouest Parisien, Trappes, 4Hôpital Morvan, Brest, 5Hospira France,
Meudon La Foret, France
Background: Febrile neutropenia (FN) is a major risk factor for infection-related
morbidity/mortality as well as a dose-limiting toxicity in patients (pts) undergoing
chemotherapy (CT). Biosimilar filgrastim (Nivestim™, Hospira Inc.) is a granu-
locyte-colony stimulating factor (G-CSF) licensed for the treatment of neutrope-
nia and FN induced by myelosuppressive CT.
Aims: NEXT (Nivestim™safety profile in patiEnts treated with cytotoXic CT in
real-life clinical pracTice) assessed the safety of biosimilar filgrastim in pts
undergoing CT for malignancies.
Methods: NEXT was a prospective, non-interventional, longitudinal, multicenter
study conducted in France to evaluate the safety of biosimilar filgrastim. Record-
ed data included demographic and clinical characteristics; treatment-related
data on efficacy and safety, such as adverse events (AEs) and FN. Pts were
monitored for 1–6 CT cycles with three visits at inclusion, during treatment, and
following CT. Here we present data for pts with lymphoma and myeloma.
Results: Of the total pts analyzed, 408 had lymphoma (mean age±standard
deviation (SD): 63.3±16.3 years [62.0% male]) and 47 had myeloma (mean
age±SD: 71.2±8.8 years [66.0% male]). At inclusion, the majority of pts had no
prior FN (lymphoma: 89.2%; myeloma: 76.6%); 27.5% of lymphoma pts and
59.6% of myeloma pts had prior CT, while 26.7% and 38.3% of lymphoma and
myeloma pts, had prior G-CSF therapy, respectively. Almost all pts received
biosimilar filgrastim prophylactically (lymphoma: 98.8%; myeloma: 97.9%). In
the group treated with curative intent, the median time to initiation of biosimilar
filgrastim therapy was 14.0 days after the start of the last CT cycle for both
lymphoma and myeloma pts; mean treatment duration±SD was 5.2±1.5 days
and 3.0±0.0 days for lymphoma and myeloma pts, respectively. In this group,
40.0% of lymphoma pts and 100.0% of myeloma pts received a dose of 30
MIU; all pts received subcutaneous (SC) administration of biosimilar filgrastim.
In the prophylactic group, the median time to initiation of biosimilar filgrastim
was 6 days and 6.5 days after the last CT dose for lymphoma and myeloma
pts, respectively; mean treatment duration±SD was 6.6±4.0 days and 5.9±4.5
days for lymphoma and myeloma pts, respectively. In this group, 72.5% of lym-
phoma pts and 78.3% of myeloma pts received a dose of 30 MIU; all pts
received biosimilar filgrastim by SC administration. Anti-infective prophylaxis
was reported in 42.9% of lymphoma pts and 67.4% of myeloma pts. In the pro-
phylactic group, 7.1% (95% confidence interval [CI] 4.9, 10.1) of lymphoma pts
and 10.9% (95% CI 4.3, 23.5) of myeloma pts experienced FN. More overall
pts with lymphoma experienced an AE than those with myeloma (21.5% vs
8.5%). The most common AEs (>5.0% of pts) were bone/muscular disorders
(lymphoma: 16.0%; myeloma: 4.3%) and muscle pain (lymphoma: 15.5%;
myeloma: 4.3%). In this analysis, 7.1% of lymphoma pts and 10.9% of myeloma
pts prescribed prophylactic treatment were hospitalized for FN and/or infection.
The mean duration of hospitalization±SD for FN and/or infection was 11.4±17.4
days for lymphoma pts (data not available for myeloma pts), <3% of pts had a
CT dose reduction (lymphoma: 2.8%; myeloma: 2.3%) and <12% of prophy-
lactic pts (lymphoma: 5.9%; myeloma: 11.4%) had a delay in administration of
CT due to FN and/or infection.
Summary and Conclusions: Biosimilar filgrastim was effective and well-tol-
erated in pts undergoing CT for hematological malignancies and is an alterna-
tive therapeutic option for pts with CT-induced neutropenia.
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R. Kim1,* Y.J. Choi1, J. Youk1, H. Park1, Y. Koh1,2, W.B. Park1, J.O. Lee2,3,
S.M. Bang2,3, I. Kim1,2, S.S. Yoon1,2, S. Park1,2
1Department of internal medicine, Seoul National University Hospital, 2Cancer
Research Institute, Seoul National University College Of Medicine, Seoul,
3Department of internal medicine, Seoul National University Bundang Hospital,
Bundang-Gu, Korea, Republic Of
Background: A serum galactomannan antigen (GM Ag) test has been used as
routine surveillance tool of invasive pulmonary aspergillosis (IPA) for hematol-
ogy patients who underwent allogeneic stem cell transplantation (alloSCT). In
an era of effective primary antifungal prophylaxis (PAP), the routine surveillance
of IPA with GM Ag test during alloSCT for hematologic malignancy need to be
re-evaluated.
Aims: The purpose of this study was to evaluate the efficacy of GM Ag test as
a routine surveillance tool for early detection of IPA in hematology patients
receiving alloSCT and PAP, especially with micafungin.
Methods: From 2013 to 2014, medical records of 111 patients who received
alloSCT for hematologic malignancy were analyzed. As an institutional protocol,
all patients underwent routine surveillance with GM Ag tests twice a week during
alloSCT, and received PAP with fluconazole or micafungin, if applicable. The
diagnoses with IPA were classified according to the European Organization for
Research on Treatment of Cancer/Mycoses Study Group (EORTC/MSG) cri-
teria. GM Ag tests with one of respiratory symptom/sign or fever at the same
time, were considered to have high suspicion of IPA, otherwise GM Ag tests
without any symptom/sign/fever were considered to have low suspicion of IPA.
Patient informed consent was waived because of the retrospective design of
the study.
Results: For 111 patients, a total of 681 GM Ag tests were performed (median,
4 per patient [range 1-21]). The incidences of breakthrough IPA were as follows:
583(85.8%) no IPA, 72(10.6%) possible IPA, 21(3.1%) probable IPA, and
4(0.6%) proven IPA. The optimal cutoff index of GM Ag for diagnosis of proba-
ble/proven IPA was found to be 0.8. Probable/proven IPA were diagnosed in
6(1.0%) tests with GM Ag index <0.8, and in 19(36.5%) tests with GM Ag index
≥0.8 (P<0.001). Sensitivity and specificity were 76.0% and 95.0%, respectively.
Of a total of 111 patients, PAPs with fluconazole and micafungin were performed
in 79(64.9%) and 28(25.1%) patients, respectively. The cumulative incidences
of probable/proven IPA at 3 months after completion of alloSCT were 1.5% in
PAP with micafungin, and 4.0% in PAP with fluconazole (HR 0.18, 95% confi-
dence interval 0.02-1.33, P=0.093, Log rank P=0.06). In patients receiving PAP
with fluconazole, 423 GM Ag tests were performed. Among them, 204(48.2%)
tests had low suspicion of IPA, and positive predictive value (PPV) was 33.3%.
The performance of GM Ag tests improved when there is high suspicion of IPA,
with PPV of 50.0%. In patients receiving micafungin prophylaxis, 136 GM Ag
were tested. 57(41.9%) GM Ag tests had low suspicion on IPA. They all had
GM Ag index <0.8, and no probable/proven IPA was diagnosed (NPV 100.0%,
PPV not applicable). 79(58.1%) GM Ag tests had high suspicion of IPA, in which
72(91.1%) had GM Ag index <0.8 with NPV of 100%. Of the rest 7(8.9%) tests
with GM Ag index ≥0.8, 2(2.5%) tests were proven to be probable/proven IPA
with PPV of 28.6%, and 5 (71.4%) tests were false positive.
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Table 1.
Summary and Conclusions: In comparison to PAP with fluconazole, patients
who received PAP with micafungin during alloSCT have lower incidence of
IPA. Most of GM Ag tests in PAP with micafungin were negative or false positive,
which renders routine surveillance of IPA by serum GM Ag tests less useful. 
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BIOSIMILAR FILGRASTIM IN PATIENTS UNDERGOING
NEUTROPENIA-INDUCING CHEMOTHERAPY: OVERALL RESULTS FROM
THE NEXT OBSERVATIONAL STUDY
F. Maloisel1,* S. Leprêtre2, D. Kamioner3, B. Christian4, H. Albrand5
1Sainte-Anne Clinic, Strasbourg, 2Henri Becquerel Hospital, Rouen, 3Hôpital
Privé de l’Ouest Parisien, Trappes, 4Hôpital Morvan, Brest, 5Hospira France,
Meudon La Foret, France
Background: Febrile neutropenia (FN) is a frequent and potentially serious
complication of cytotoxic chemotherapy (CT). Biosimilar filgrastim (Nivestim™,
Hospira Inc.) is a granulocyte-colony stimulating factor (G-CSF) approved in
France for the treatment of neutropenia and FN resulting from myelosuppres-
sive CT. Previous clinical trials have demonstrated similar efficacy and safety
of biosimilar filgrastim to the reference product (Neupogen®, Amgen Inc).
Aims: NEXT (Nivestim™safety profile in patiEnts treated with cytotoXic CT in
real-life clinical pracTice) evaluated the safety of biosimilar filgrastim in pts
undergoing CT for malignancies.
Methods: NEXT was a prospective, non-interventional, longitudinal, multicenter
study conducted in France to assess the safety of biosimilar filgrastim. Record-
ed data included demographic and clinical characteristics as well as treatment-
related data on efficacy and safety, including adverse events (AEs) and FN.
Pts were monitored for 1–6 CT cycles with three visits at inclusion, during treat-
ment, and following CT. Here we present the overall study results.
Results: Of 2114 pts enrolled in the study, 2102 pts were included in the analy-
sis (mean age±standard deviation [SD]: 63.5±12.7 years; 50.2% male). More
patients had solid tumors (75.0%) than hematological malignancies (25.0%).
At baseline, 92.5% of pts had no prior FN; 34.4% had previous CT; 20.2% had
received previous G-CSF therapy. The majority (98.2%) of pts received pro-
phylactic biosimilar filgrastim (primary prophylaxis: 91.0%; secondary prophy-
laxis: 7.3%). Of the pts receiving prophylactic biosimilar filgrastim, 79.9%
received a dose of 30 MIU and therapy was administered subcutaneously in
99.4% of these pts. In the prophylactic group, median time to initiation of biosim-
ilar filgrastim was 2 days after the last CT dose; mean treatment duration±SD
was 6.0±3.8 days. Anti-infective prophylaxis was reported in 14.5% of these
pts. The incidence of FN in this group was 4.9%, occurring a median time
(range) of 14.0 (-13.0–155.0) days following the first CT cycle. Infections were
reported in 3.1% of prophylactic pts, occurring a median time (range) of 23.5
(0.0–155.0) days following the first CT cycle. 4.9% of prophylactic patients
were hospitalized for FN and/or infection; occurring 5.5 (0.0–64.0) median
(range) days after initiating biosimilar filgrastim. 3.6% of pts were hospitalized
for FN and/or infection after the first CT cycle, with ≤1% patients hospitalized
for FN after each subsequent cycle. Reductions in CT dose due to FN and/or
infection occurred in 4.7% of patients receiving prophylaxis. During the study
20.4% of pts had ≥1 AE; 12.7% of pts reported muscle and/or bone disorders
and muscle pain (12.1%). The other most common AEs included gastrointesti-
nal disorders (5.5%), nausea (3.0%), general disorders and administration site
disorders (2.4%), diarrhea (2.3%) and headache (1.8%). Of the 205 physicians
who completed the questionnaire concerning treatment and prevention of CT-
induced FN, 73.1% routinely prescribed G-CSF therapy for prophylactic and
curative reasons. The most common reasons for prescribing biosimilar filgras-
tim were cost savings and comparable efficacy and safety.
Summary and Conclusions: Biosimilar filgrastim (Nivestim™) was effective
and well-tolerated in both the prophylactic and curative setting in patients under-
going chemotherapy for solid tumors and hematological malignancies. In real-
world practice, most physicians prescribed G-CSF therapy for prophylactic or
curative intentions in their patients receiving myelosuppressive chemotherapy.
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ORGANIZING PNEUMONIA IN HEMATO-ONCOLOGY PATIENTS: A
SOMEWHAT DISREGARDED DIFFERENTIAL DIAGNOSIS
G. Brás1,* M. Alpoim1, R. Pinto1, A. Carneiro1, F. Príncipe1, J. Guimarães1
1Serviço de Hematologia Clínica, Centro Hospitalar de São João, Porto, Por-
tugal
Background: Organizing Pneumonia (OP) is defined by clinical and imagio-
logical aspects of pneumonia, with histological pattern of intra-alveolar buds of
granulation tissue, consisting of intermixed myofibroblasts and connective tis-
sue. OP develops in the context of an immune deregulation, a perpetuation of
the inflammatory response in the presence of infection, autoimmune diseases
or drug exposure. In hemato-oncology, OP has been extensively studied in the
allogeneic transplant setting and, more recently, it has also been described in
lymphoproliferative diseases, myelodysplastic syndromes and chronic myelo-
proliferative diseases.
Aims: Analyze clinical characterisitics and outcomes of diagnosed OP in hema-
to-oncology patients, outside the allogeneic transplant setting.
Methods: Retrospective revision of biopsy-proven OP cases diagnosed in
patients with hematological diseases, in a Portuguese hospital centre, between
2005 and 2014.
Results: Ten cases with biopsy-proven OP were obtained. The median age
was 62 years (33-75) and 7 cases (70%) were male. The hemato-oncological
diagnoses were: Lymphoma (n=7; 70%); B-cell Acute Lymphoblastic Leukemia
(n=1; 10%); Myelodysplasia (n=2; 20%); Acute Myeloid Leukemia (n=2; 20%).
In two (20%), the OP diagnosis was made simultaneously with onset of hema-
tological disease, seven (70%) during chemotherapy and one (10%) during the
first 100 days after autologous transplantation. Prior to the OP diagnosis, none
was submitted to bone marrow allogeneic transplantation or pulmonary radio-
therapy. Clinically, nine (90%) patients had fever and nine (90%) had respiratory
insufficiency. Of the latter, three (30%) patients needed non-invasive ventilation
and two (20%) invasive ventilation. The thoracic CT scan reported findings vary-
ing between nodules (n=4; 40%), consolidations (n=3; 30%), interstitial infiltrates
(n=3; 30%), ground-glass opacities (n=3; 30%) and pleural effusions (n=3; 30%),
with findings overlapping in 9 (90%) cases. The perpetuation of an unfavorable
clinical course despite antimicrobial/antifungal therapy or the lack of typical CT
findings led to the decision of lung biopsy. Percutaneous transthoracic CT-guided
lung biopsy was performed in eight (80%) patients and thoracotomy in other
two (20%), with no procedure related complications. In terms of OP therapy,
corticosteroids were the choice in nine (90%) patients (n=5 isolated; n=4 in
association with azithromycin; n=1 no treatment), with clinical and imagiological
improvement in seven cases. Pulmonary aspergillosis was a non-confirmed dif-
ferential diagnosis in 5 (50%). Of the 4 OP exacerbations, 2 occurred with hema-
tological disease progression. Of the 6 (60%) deaths, 4 occurred with hemato-
logical disease evolution, 2 with OP exacerbation in association with sepsis/mul-
tiorganic dysfunction. The Overall Survival and the Exacerbation Free Survival
were 12 months and 4 months, respectively.
Summary and Conclusions: OP should be considered a differential diagnosis
of pulmonary lesions in hemato-oncological diseases. The lack of specificity of
the clinical and imagiological presentation, urges the need of considering the
lung biopsy in highly suspicious lesions. The correct diagnosis is essential to
begin the treatment with corticosteroids, which showed to be capable of rea-
sonable clinical and imagiological disease control in our series.
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THE EFFICACY OF POLYVINYLPYRROLIDONE – ZINC GLUCONATE AND
TAURINE GEL (GEL X) IN PROPHYLAXIS AND TREATMENT OF ORAL
MUCOSITIS IN CHILDREN TREATED WIH CHEMOTHERAPY
A. Colita1,2,* A. Bediman1, A. Colita3, C. Arion4
1Pediatric Hematology & BMT, Fundeni Clinical Institue, 2Pediatric Clinic, “Carol
Davila” University of Medicine and Pharmacy, 3Hematology @ BMT Depart-
ment, Coltea Hospital, 4Hematology @ BMT Department, Fundeni Clinical
Institue, Bucharest, Romania
Background: Polyvynilpyrrolidone-zn gluconate and taurine (GelX) is an oral
lubricating gel used in the management of oral mucositis (OM). OM is an impor-
tant medical and nursing problem secondary to use of chemotherapy, associ-
ated with oral pain and reduced oral intake, difficult to manage, especially in
young children, with important impact for quality of life and nutritional status.
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GelX forms an adherent barrier and cover the oral mucosa lesions, thus pro-
tecting the sensitive nerves endings and lubricating the oral tissue.
Aims: To evaluate the efficacy of Gel X as prophylactic or curative treatment
for children treated with chemotherapy for hematologic malignant diseases.
Methods: We conducted a single-centre prospective and observational study
in children with acute leukemias receiving chemotherapy according to the BFM
protocols. The parents signed the informed consent. The study was non-spon-
sored. In the prophylactic arm, the oral cavity nursing with GelX started on the
first day of chemotherapy and continued until the recovery from neutropenic
phase; for the curative arm, the oral cavity nursing started on the first day of
chemotherapy with other oral rinses and was switched to GelX after OM devel-
opment and continued until OM recovery. The oral rinses were recommended
to be used at least 3 times a day according to the product specifications. The
OM was assessed daily by the physicians using the WHO grading 0-4
(0=absent, 1= soreness and/or erythema, 2= erythema, ulcers and patient can
swallow solid food, 3= ulcers with extensive erythema and patient cannot swal-
low solid food, 4=mucositis to the extent that alimentation is not possible). We
performed also a patient assessment for pain (general, mouth and throat) VAS
scale 1-5 (1=no pain, 2=mild pain, 3=moderate pain, 4=severe pain, 5=very
severe pain) and saliva VAS scale 1-5 for a) swallowing ( 1=normal, 2=cannot
swallow certain solid foods, 3=can only swallow soft foods,4=can only swallow
liquid foods,5=cannot swallow), b) saliva amount (1=normal amount, 2=mid
loss of saliva, 3=moderate loss of saliva, 4=severe loss of saliva, 4=severe
loss of saliva, 5= no saliva) and c) consistency of saliva (1=normal, 2=slightly
thick, 3=moderately thick, 4=extremely thick, 5=saliva that dries in mouth or
lips). The tolerability of oral rinses was evaluated daily by the patients or parents
using the Visual Analog Scale (VAS) scoring 1-5: 1= tolerable without any prob-
lems, 2=satisfactory, 3= indifferent, 4= unsatisfactory, 5=intolerable. The OM
pain reduction and food intake improvement were assessed by the patients/par-
ents using the VAS scoring 1-5 (1=excellent, 2=good, 3=slight effect, 4=almost
no effect, 5=no effect at all). Basic statistics univariate analysis were performed
using statistical software with the Fisher’s exact test. The “P” values <0.05
were considered as statistically significant differences.
Results: A total of 15 patients were enrolled in this analysis, 8 in the prophylactic
arm (group A) and 7 in the curative arm (group B). Characteristics of the groups
were shown in Table 1. The OM maximum grade was higher in the B group
than in the A group, p=0,018. The patient/parent assessment of mouth pain
(p=0,01) and of saliva consistency (p=0,033) were significantly lower in the
prophylactic group. We also observed a significant difference regarding the
OM pain reduction (p=0,001), oral intake improvement (p=0,001) and use of
systemic analgesics (p=0,005). There were no difference in the median value
of tolerability of GelX rinses between the group A and B.
Table 1.
Summary and Conclusions: There are limited data regarding the use in chil-
dren as prophylactic or curative measures. In our study, the oral spray was
administered as prophylaxis or as curative treatment. Our results showed better
results in the OM development and quality of life in the prophylaxis arm. These
results, however, should be considered as informative and larger cohorts of
patients needs to be analyzed.
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INFECTION AND COLONIZATION BY CARBAPENEM RESISTANT
KLEBSIELLA PNEUMONIAE IN HAEMATOLOGY PATIENTS
M.D. Madrigal1,* C. Blazquez1, R. Saldaña1, V. Rubio1, S. Pérez-Cortés2,
M.D. López2, S. Garzón1
1Hematology, 2Infections disease, Hospital de Jerez, Jerez de la Frontera,
Spain
Background: Klebsiella Pneumoniae is a frequent nosocomial pathogen inhab-
iting the digestive tract. In the era of antibiotic resistance and multi-drug resistant
bacteria, the emergence and spread of carbapenem-resistant Klebsiella pneu-
moniae (CRKP),has become a major health concern for hospitalized patients.
Hematological patients are particularly prone to infection by CRKP due to a
combination of factors: prolonged neutropenia, recurrent use of chemotherapy
and broad spectrum antibiotics, severe mucositis, immunosuppression,
catheters.
Aims: Description an outbreak of CRKP colonization between May and Sep-
tember 2014 in our centre despite strict hygiene. 
Methods: Colonization (carrier state) was defined as the presence of at least
one rectal swab positive for CRKP. Eradication of colonization was confirmed
when three consecutive rectal swabs are negative after decontamination ther-
apy (after 3 days, 7 days and 1 month). Infection was defined as the presence
of the microorganism from blood cultures or other body site (urinary tract in
particular) with clinical signs. Carbapenemase detection was made by Hodge
test and disk diffusion, confirmed by specific PCR.
Results: 11 patients were identified as carriers CRKP over a period of 4 months.
(Patients characteristics are described in table 1). Colonization was followed
by a microbiologically documented infection in 5 patients (1 septic shock, 1
bacteraemia concomitant UTI and followed by septic shock, 1 bacteraemia,
catheter and soft tissue infection, 2 UTIs recurrent). As risk factors, four of
these patients had severe neutropenia and only one patient had a normal WBC
count, but suffered from gastrointestinal GVHD. All infected patients were ini-
tially treated with high doses carbapenem therapy administered by prolonged
infusion (3 hours) combined with gentamicin and/or fosfomicine and/or tigecy-
cline. In two episodes of bacteremia we used second-line treatment with cef-
tazidime/avibactam, with good safety profile and efficacy (negative cultures at
72 hours). The infection-related mortality rate was 40% (2/5).
Decontamination therapy consisted in oral gentamicin (80 mg/6h for 14 days),
if three days after rectal swab continued positive, treatment was started with
oral neomicine and estreptomicin (40/80 mg, 1 tablet/8h) or treatment was
repeated with gentamicin. 10 patients received decontamination therapy (1
patient developed septic shock and died before receiving treatment) being suc-
cessful in 5 of them (50%). It was necessary to repeat courses with an average
of two lines (1-4) and a median duration of 2 month (15days-6meses).
Table 1.
Summary and Conclusions: 1. In our center 5/11 colonized patients developed
infection. Our experience with ceftazidime/avibactam was favourable because
it managed to eradicate bloodstream infection. 2. We have done a good control
of the outbreak in only four months. Special health measures such as surveil-
lance with weekly rectal swabs, bed isolation and strict hygiene measures have
been very important in controlling the spread of the epidemic. 3. Hematology
patients need several courses of decontamination therapy to succeed.
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INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME/
ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE: REPORT
FROM A SINGLE CENTER
A.M. Quinto1,* E. De March1, M. Castelli1, G. Binotto1, G. Semenzato1,2,
F. Adami1
1Department of Medicine, Hematology and Clinical Immunology Section, Uni-
versity of Padua, 2Venetian Institute of Molecular Medicine, Padua, Italy
Background: Infections are common and potentially fatal events affecting
patients with myelodysplastic syndromes (MDS). Predisposing factors that are
likely to be associated with increased risk of infections in MDS patients are
neutropenia and/or neutrophil functional impairment; B-, T- and NK-cell defects;
secondary iron overload related to red blood cell transfusions; comorbidities;
treatment toxicity; previous severe infections. Few data are available on the
incidence and pathogens involved in infectious events, most of these originating
from retrospective studies or clinical trials with primary end points other than
infection. 
Aims: An Italian single Center real-life experience assessing the incidence,
risk factors and impact of infections on outcome of patients with MDS treated
with hypomethylating agents is herein reported.
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Methods: From March 2008 to October 2013, 50 patients, aged 40 years and
older (median age: 69, 40-84 years) with diagnosis of MDS (WHO2008 cate-
gories: 22.4% RA/RCMD, 32.6% RAEB-1, 28.5% RAEB-2, 12.2% CMML, 4%
AML), were treated with 5-azacitidine (75 mg/m2/die for 7 days every 4 weeks),
both in on-label and off-label drug use setting. Forty-four percent of patients
had intermediate-2 or high International Prognostic Scoring System, 68% were
neutropenic and 12% had high MDS-Comorbidity Index. Prophylactic antibiotics
were administered to 12 patients (24%), prophylactic antifungal to 17 patients
(34%) and granulocyte colony-stimulating factor was administered to 24
patients (48%).
Results: Median number of cycles received by a single patient was 5 (range
1-21); 48% received more than 6 cycles of therapy. 30.4% of the entire cohort
was considered responsive to treatment (14.4% hematologic improvement,
8% partial response, 8% complete response, according to IWG2006 criteria);
24% of patients achieved a stable disease. Out of 50 patients, 25 (50%) devel-
oped 25 infectious events (1 for each patient), during 325 treatment cycles
(7.7%); 14/25 (56%) events required hospitalization. Only one patient died from
an infectious complication. Twenty-two of 25 infectious events (84%) were bac-
terial, mostly pneumonia; 3 (12%) were fungal (invasive aspergillosis) and 1
(4%) was viral (H1N1). Infectious events did not significantly affect overall sur-
vival (27 vs 18 months, p=0.606), progression free survival (6.0 vs 6.1 months,
p=0.48) or overall response to therapy (13 vs 17.4%, p=0.693). However, no
complete responses were documented in the cohort of patients who suffered
from infectious episodes. In a univariate analysis, age, sex, low neutrophil
count, high comorbidity index, antibiotic prophylaxis and use of G-CSF were
not found to be associated with infections. Only high IPSS and the presence
of pancytopenia, seemed to be correlated with an increased risk for infections. 
Summary and Conclusions: Infectious events, specifically bacterial infections,
are one of the most frequent complications during therapy with azacitidine in
patients with MDS. These data suggest that there are not predisposing risk
factors for infection in patients except those connected with disease severity
(high IPSS and pancytopenia). Routine antibiotics, antifungal prophylaxis
and/or use of G-CSF appear not to reduce the incidence of infectious events.
Moreover, bearing in mind the risk of bacterial and fungal resistance associated
with extended use of anti-infective drugs, they should be used with caution in
selected subsets of MDS patients. 
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EVALUATION OF SERUM GALACTOMANNAN ASSAY FOR THE DIAGNOSIS
OF INVASIVE ASPERGILLOSIS IN CHILDREN WITH HEMATOLOGICAL
MALIGNANCIES
A. Jha1,* D. Bansal2, S. Prakash3, A. Chakraborty3
1Hematology-oncology, Bhaktapur Cancer Hospital, kathmandu, Nepal,
2Hematology-oncology, 3medical microbiology, PGIMER, Chandigarh, India
Background: Fungal infection is a major concern during treatment of hema-
tological malignancies. Establishing diagnosis is a challenge and often frustat-
ing for the treating physicians. Rapid and diagnostic test is valuable for timed
intervention. Galactomannan assay is a non invasive test, however it’s efficacy
needs to be validated in our population.Only few studies in Indian population,
hence to establish a clinically relevant cut off value this prospective study is
done.
Aims: Diagnostic efficacy of galactomannan assay (GA) for invasive aspergillo-
sis ( IA ) is variable. the cut off value is debated.
Methods: Children ≤14-years with hematological malignancies and fever were
enrolled prospectively. Blood sample for GMA was drawn on day of admission;
levels were measured with Platellia Aspergillus enzyme immunoassay. Diag-
nostic criteria were adapted from EORTC-MSG. GMA was evaluated at various
cut-offs, with proven, probable and possible episodes being considered as dis-
ease group.
Results: 100 febrile episodes in 78 patients were included. Mean-age was 6.1
years. Majority (75%) episodes were in patients with ALL, followed by AML
(17%). CT-scan-lung was performed in 23 episodes. BAL, transbronchial-lung-
biopsy and functional-endoscopic-sinus-surgery were performed in 2-episodes,
each. Post-mortem investigations included autopsy (1) and organ biopsies (6).
Diagnosis of IA was proven and probable in one case each. A possible diag-
nosis was made in 23 episodes; remaining 75 were categorized as “No IA”.
Other fungal infections diagnosed included mucormycosis (3), candidiasis (1)
and fusariosis (1). Best results were obtained with a cut-off value of 1.0, with
sensitivity, specificity, positive and negative predictive value of 60%, 93%, 75
and 87, respectively. With GMA >1.0 as cut-off, the probability of a positive test
to be true or false positive was 0.71 (95% CI: 0.48-0.88) and 0.28 (95% CI:
0.12-0.52), respectively. For a negative test, the probability of true negative
was 0.87 (95% CI: 0.78-0.93) and false negative was 0.13 (95% CI: 0.16-0.22).
The sensitivity dropped to 40%, at cut-off value of 1.5 and specificity was 38%,
at a cut-off of 0.5. Significant correlation of a higher GMA was observed with
pulmonary nodules (p=0.037), duration of Amphotericin >10-days (p=0.043)
and mortality (p=0.001).
Summary and Conclusions: Confirming the diagnosis of aspergillosis is a
challenge; this renders assessment of efficacy of GMA difficult. At a cut-off
value of 1.0, the sensitivity and specificity were 60% and 93%, respectively.
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ANIDULAFUNGIN THERAPY FOR HIGH RISK OF INVASIVE FUNGAL
INFECTION HEMATOLOGIC PATIENTS: ITS ROLE IN REAL-LIFE SINGLE
CENTER EXPERIENCE.
S. Lozano1,* P. Arregui1, A. Zabalza1, I. Aoiz1, M. Alvarellos1, A. Gorosquieta1,
K. Pérez de Equiza1, E. Olavarria1
1Haematology, Complejo Hospitalario de Navarra, Pamplona, Spain
Background: Anidulafungin in an echinocandin licensed for the treatment of
invasive candidiasis in adult non-neutropenic patients. This drug is neither
metabolized by the liver, nor has renal elimination. Liver dysfunction is common
after allogeneic stem cell transplantation and intensive chemotherapy. In our
hospital patients who fulfill criteria of high risk for Invasive fungal infection (IFI)
routinely receive antifungal prophylaxis with voriconazole. It has become routine
clinical practice to substitute voriconazole for anidulafungin in cases with hepat-
ic involvement of GVHD and/or liver toxicity manifested as elevated liver func-
tion tests (LFTs).
Aims: The aim of this study is to analyze the safety, toxicity and feasibility of
off label anidulafugin as prophylaxis and treatment of high risk of IFI hemato-
logic patients in a real life scenario.
Methods: We have retrospectively studied all episodes of adult high risk of IFI
hematological patients treated with anidulafungin in our hospital from March
2010 to October 2014. IFI was defined according to EORTC guidelines.
Results: Fifty patients were included, 38 were treated once, 9 twice and 3
thrice, thus 65 different therapy episodes were finally analized. Median age
was 50 years (IQR 39.2-61.2), with 63.1 % (n=41) cases being male. Most
(81.6%) had undergone allogeneic stem cell transplantation (Allo-SCT). The
most common baseline diagnoses were acute leukemia in 31 (47.7%) and non
Hodgkin´s lymphoma in 12 (8.3%). Fifty-five cases (85%) had no prior history
of IFI. The remaining ten cases previously had proven (n=3), probable (n=5)
or possible (n=2) IFI and therefore received secondary anti-fungal prophylaxis.
Anidulafungin was administered as prophylaxis in 48 episodes (73.9%), in 3
episodes for proven candidiasis (4.6%) and in 14 (21.5%) as empirical treat-
ment of IFI. Elevated LFTs was the most common cause to commence on
anidulafungin (n=46, 71.8%), in 19 of them (29.7%) voriconazole had to be
discontinued. Other reasons to start anidulafungin were chronic graft versus
host disease (n=6), voriconazole intolerance (n=4), hallucinations due to
voriconazole (n=3), candidiasis (n=3), and others (n=3). Median number of
days on therapy was 11 (IQR 5-19.5). Treatment with anidulafungin was well
tolerated in most of our patients (93.8%). The drug was withdrawn in three
cases: one due to acute kidney failure, one due to drug intolerance during infu-
sion and one due to progressive liver failure. Among the 48 cases receiving
anidulafungin as prophylaxis there were 36 with abnormal LFTs and 6 with
liver GVHD. In this very high risk of IFI cohort there were 3 proven (2 cases of
mucormicosis and one C.guillermondii candidemia), 2 probable and one pos-
sible IFI, during the duration of prophylaxis or in the week following the discon-
tinuation of anidulafungin. In addition, 4 more proven IFIs were diagnosed in
the following 100 days: one disseminated histoplasmosis (day 11), one C.krusei
candidemia (day 18), one pulmonary invasive aspergillosis (day 10) and one
esophageal candidiasis (day 36). All patients but the last one, had received
other anti-fungal agent after anidulafungin was discontinued. Nearly half of the
patients receiving anidulafungin as prophylaxis (45.8%) died during the 100
days follow up period, 2 of them (9.6%) due to IFI.
Summary and Conclusions: Anidulafungin is a safe and feasible alternative
to azole therapy, especially in patients with elevated LFTs or liver involvement
by GVHD. Further studies are needed to establish the role of anidulafungin in
this patient population.
E1184
LOW-RISK MYELODYSPLASTIC PATIENTS SUPPORTED WITH
ERYTHROPOIETIN PLUS LIPOSOMIAL IRON SHOWS A REDUCED
NUMBER OF FEBRILE EPISODES THAN PATIENTS WITH INTRAVENOUS
IRON SUPPORT.
G. Giordano1,* F. D’Amico2, A. Commatteo3, G. Berardi4, D. Berardi5,
B. Carabellese6, R. Gigli3, M. Magri3, A. Licianci3, L. di Marzio3
1medicine, Regional Hospital “A. Cardarelli”, Campobasso, 2Foundation “J.
Paul II”, campobaso, 3Regional Hospital “A. Cardarelli”, 4family medicine, Cam-
pobasso, 5University “La Sapienza”, Rome, 6nuclear medicine, Regional Hos-
pital “A. Cardarelli”, Campobasso, Italy
Background: Intravenous iron support simultaneous to erythropoietin admin-
istration improve response to erythropoietin in myelodysplastic patients. Oral
liposomal iron, bypassing normal intestinal mechanism of absorption, shows
similar effects, better than oral iron sulfate, usually poorly absorbed. Ther’are
many evidences that iron, useful for bacterial growth, might increase risk of
infection.
Aims: Aim of this study is to verify incidence of number of febrile episodes in
low-risk myelodysplastic patients without support or supported with erythro-
poietin (epo) only or with epo plus oral liposomal iron, oral iron sulfate or iv
sodium ferrigluconate.
Methods: This study is a retrospective, multicentric study.Between july 2008
and december 2014, 107 patients affected by low-risk refractory anemia were
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studied.Median follow-up was 24 months (R12-60).20 patients had no support,
27 epo support, 30 epo+liposomial iron (14 mg 2 tablets orally/day for 3
months), 15 epo+iron sulfate (525 mg2 tablets orally/day for 3 months), 15
epo+iv sodium ferrigluconate (62.5 mg iv in NS 100 ml in 1 h/day for 5
day/month).All patients supported with epo received calcium levofolinate 7.5
mg/day orally +Vitamin B12: 400 mg/day orally.Epo support was performed
with originator or biosimilar epo alpha or epo zed 40000 IU sc/week or with epo
beta 30000 IU sc/week.Statistical analysis was performed by Chi Squre test
and Fisher exact test.
Results: In group with no support median hemoglobin level was 9.5 g/dl (R8-
11). Median neutrophils count was 1000/mcl (R300-2500). Median packed red
blood cells unit (PRBCU) transfused was 0.2/month (R0-0.5). Median number
of febrile episodes/year was 1.5 (R0-2). In group supported with epo only medi-
an hemoglobin level after 3 month treatment was 11 g/dl (R7.5-12). Median
neutrophils count was 800/mcl (R400-1200). Median packed red blood cells
unit (PRBCU) transfused was 0.4/month (R0-0.7). Median number of febrile
episodes/year was 2 (R0-2).In group supported with epo+iron sulfate median
hemoglobin level after 3 month treatment was 10.5 g/dl (R8-12). Median neu-
trophils count was 750/mcl (R300-1100). Median packed red blood cells unit
(PRBCU) transfused was 0.3/month (R0-0.6). Median number of febrile
episodes/year was 3 (R0-3). In group supported with i.v. sodium ferrigluconate
median hemoglobin level after 3 month treatment was 12 g/dl (R9-13). Median
neutrophils count was 700/mcl (R250-1000). Median packed red blood cells
unit (PRBCU) transfused was 1.5/month (R1-3). Median number of febrile
episodes/year was 6 (R0-9). In group supported with liposomial iron median
hemoglobin level after 3 month treatment was 12.8 g/dl (R10-13). Median neu-
trophils count was 280/mcl (R150-1300). Median packed red blood cells unit
(PRBCU) transfused was 0.2/month (R0-1). Median number of febrile
episodes/year was 1 (R0-2).
Summary and Conclusions: Number of febrile episodes is low in each treat-
ment group. Febrile episodes seem not related to basal neutrophil count or
hemoglobin level reached after 3 month treatment. Number of febrile episodes
is higher in group with higher transfusion need and in group treated with i.v.
sodium ferrigluconate (p 0.02). Probably liposomial iron support provides a
reduced amount of non- transferrin bound iron that might block bacterial growth.
These data need confirmation on a larger cohort of patients.
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RISK FACTORS FOR FEBRILE NEUTROPENIA AND BLOODSTREAM
INFECTIONS IN RECIPIENTS OF HEMATOPOIETIC STEM CELL
TRANSPLANTS
I. Stoma1,* A. Uss2, I. Karpov1, N. Milanovich2, I. Iskrov2, I. Lendina2,
S. Vlasenkova2
1Belarusian state medical university, 2City clinical hospital №9, Minsk, Belarus
Background: Number and indications for Hematopoietic Stem Cell Transplan-
tations (HSCTs) in adults continue to grow worldwide. Febrile neutropenia (FN)
remains one of the most common complications in the HSCT patients. Blood-
stream bacterial infections (BSI) stay common causes of FN among neutropenic
patients. Choice of initial strategy of antibacterial treatment in FN patients is
based mainly on clinical and epidemiological risk factors, because of the low
frequency of culture isolation and reduced clinical manifestations of infection.
Aims: The aim of the study was to determine the risk factors for febrile neu-
tropenia or microbiologically proven bloodstream infection in adult patients
receiving HSCT.
Methods: 242 patients undergoing allogeneic or autologous HSCT at the
Belarus National Centre for Hematology and Bone Marrow Transplantation
from January 2013 to January 2015 were monitored and their clinical data was
reviewed. Age of the patients included in this study was 18-65 years, 42% of
them were male, 58% - female. The primary outcome was the episode of FN(ful-
filled criteria of Freifeld et al., 2011), the secondary outcome was microbiolog-
ically proven bacterial bloodstream infection (BSI). Isolation of pathogens was
performed by standard means with BacT/ALERT Standard Aerobic/Anaerobic
bottles and BacT/ALERT 3D automated microbial detection system, identifica-
tion and antibiotic resistance was studied with VITEK 2 system and disc-diffu-
sion methods.
Categorical variables were analyzed with χ2 test and Fisher’s exact test, and
continuous variables were analyzed with the Mann-Whitney U test and Odds
Ratio. A multivariate analysis with logistic regression was conducted for the
categorical variables with P-value ≤0,2 in previously performed univariate analy-
sis. Significant P-value considered to be <0,05.
Results: There were 87 patients with episodes of FN, the incidence of FN in
HCST recipients was 36%. Among them 39 patients had microbiologically proven
BSI, i.e. 16% of all HSCT recipients or 45% of those who had FN. Most of the
cases of BSI were caused by E. coli, Kl. pneumoniae, P. aeruginosa, A. bau-
mannii, Streptococcus spp.Among independent statistically significant risk fac-
tors for both FN and BSI were: profound neutropenia (OR 2,34, 95% CI 1,19-
13,24, p=0,012 for FN; OR 2,44, 95% CI 1,96-9,54, p=0,005 for BSI); neutrope-
nia duration >14 days (ОR 1,37, 95% CI 1,08-12,93, p=0,049 for FN; OR 1,68,
95% CI 1,14-8,73, p=0,045 for BSI) and active main disease on start of HSCT
procedure (OR 3,41; CI 2,32-8,63, p=0,01 for FN; OR 1,28, CI 1,04-3,81,
p=0,049 for BSI). Prior to HSCT patients colonization with ESBL-positive Enter-
obacteriaceae spp. and prior ICU hospitalization had a trend towards the statis-
tical significance as a risk factors of BSI, what may be proved by using larger
number of patients in the future studies (ОR 1,64, 95% CI 0,89-4,36, p=0,64 for
colonization; OR 2,31, 95% CI 1,27-6,41, p=0,72 for ICU hospitalization).
Summary and Conclusions: The above named risk factors and most common
pathogens should be taken into account when choosing a clinical approach to
empiric antibacterial treatment and prophylaxis in adult HSCT patients.
E1186
ANALYSIS OF 75 CASES OF ACUTE LEUKEMIA WITH INVASIVE FUNGAL
DISEASE
C. Wang1, Y. Fu1, Y.H. Tan1,*
1Tumor Center, First Hospital of Jilin University, Changchun, China
Background: Acute leukemia patients are susceptible to invasive fungal dis-
ease, proper diagnosis and treatment is important for reducing morbidity and
mortality.
Aims: To analyze the clinical characteristics of invasive fungal infections in patients
with acute leukemia (AL), explore the early diagnosis and prevention strategy.
Methods: Acute leukemia patients with invasive fungal disease (IFD) treated
in cancer center of the First Hospital of Jilin University from 2014 January -12
months were analyzed retrospectively according to the “criteria for the diagnosis
and treatment principles of hematological malignant patients with invasive fun-
gal disease (The Fourth Edition of China)”, the outcome of the disease and the
curative effect were analyzed simultaneously.
Results: In 211 cases of AL patients, 75 cases (35.5%) include 49 AMLs and
26 ALLs occurred IFD, the male to female ratio was 49:26, the median age
was 48 years old (883 years old). 73 cases were lungs IFD, 1 case was liver
and spleen IFD, 1 case was intestinal IFD. Among of the 75 cases, there were
1 case with proven IFD (blood culture positive for Candida), 8 cases with prob-
able IFD, 23 cases with possible IFD and 43 cases with uncertain IFD. Host
factors included neutropenia (70 cases, 93.3%), the application of hormone for
more than 3 weeks (10 cases, 13.3%), a history of previous fungal infection (4
cases, 5.3%), allogeneic transplantation (1 cases, 1.3%), prior application of
broad-spectrum antibiotics was confirmed in 69 patients (92%). 31 cases
(41.3%) showed specific CT signs, wherein the air crescent sign in 1 case, pul-
monary cavity in 1 case, liver and spleen buphthalmos sign in 1 cases, and the
rest cases showed compact, clear boundary lesions, including 5 cases with
halo sign. 30 cases (40%) of patients showed non-specific CT signs, such as
small nodules, multiple patchy shadow, ground glass shadow, emphysema or
bronchiectasis. Positive G test was found in 12 patients and positive GM test
was in 10 cases, of which both test positive was in 9 cases. All 23 patients with
possible IFD were identified as fungal infections according to the subsequent
treatment response and disease evolution, 23 cases (53.5%) was eventually
identified as fungal infection in 43 uncertain IFD patients, so in total 75 patients,
55 patients were eventually identified as fungal infection, accounting for 26.6%
of all patients with 211 leukemia patients. All 75 patients received antifungal
treatment, including 9 cases of target therapies, 46 cases of diagnosis driven
therapies, 20 cases of empiric therapies. 7 cases (77.8%) were effective in tar-
get therapies, 36 cases (78.3%) was eventually identified as fungal infection in
46 diagnosis driven therapies patients, in which 31 case (86.1%) were effective.
10 cases (50%) was confirmed with fungal infection in 20 empiric treatment
patients, and were all effective. The overall effective rate was 89.1% (48/55).
Summary and Conclusions: IFD is one of the main causes of infection in
acute leukemia patients. High resolution CT and G test, GM test were important
in the diagnosis of IFD. Early diagnosis and treatment is the key to improve the
efficacy of IFD. The application of “criteria for the diagnosis and treatment prin-
ciples of hematological malignant patients with invasive fungal disease (The
Fourth Edition of China)” can be a very good guide for the clinical diagnosis
and treatment.
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ACINETOBACTER BAUMANNII SURVEILLANCE MEASURES IN
HAEMATOLOGICAL MALIGNANCIES PATIENTS
V. Calafiore1,* E. Mauro1, C. Conticello1, T. Pollicino1, V. Zammit1, E. Spina1,
E. Martino1, M.C. Pirosa1, R. Manuele2, A. Imbriani3, P.F. Fiumara1,
F. Di Raimondo1
1Division of Hematology, 2Division of Infectious Diseases, 3Division of Micro-
biology, Azienda Policlinico-OVE, University of Catania. Via Citelli n. 6, 95124,
Catania, Italy
Background: Acinetobacter baumannii is a gram-negative, strictly aerobic,non-
fermentative coccobacillus that causes infections in immunocompromised and
chronically ill patients. Recently, it has emerged as a major cause of health
care-associated infections (HCAIs) in addition to its capacity to cause commu-
nity-acquired infections. It is associated with multidrug resistance and it is con-
sidered to be among the most difficult anti-microbial-resistant bacilli to control
and treat. Given to its antimicrobial resistance, treatment options are severely
limited, and to the best of our knowdlwdge there aren’t any controlled trials to
guide therapeutic choices. In severely ill patients multidrug-resistant Acineto-
bacter infections are associated with an extremely high morbility and mortality
rate. It is therefore necessary the developement of measures that can prevent
or early identify Acinetobacter infection.
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Aims: Despite the high proportion of infection related death, particularly sus-
tained by multidrug-resistant bacteria among wich A. Baumanii, there are only
few reports on Acinetobacter infection and measures to prevent and treat the
bacillus spread and infection in patients affected by haematological malignan-
cies. Moreover, these reports are case reports or describe small population of
patients. Here we describe our experience on Acinetobacter measures of early
detection.
Methods: Between January 2014 and December 2014 pharyngeal swabs
were performed on 139 haematological patients on the date of admission in
the hematology Section of Catania University and none was positive for Acine-
tobacter. We also performed 32 serial pharyngeal swabs on hospitalized
patients and when cases of Acinetobacter bacteraemia were detected (2 cas-
es) as empirical test to early detect contamination and treat positive sympto-
matic cases.
Results: Seven swabs were positive for A. Baumanii, all in heavily treated and
advanced stage patients (3 AML patients, 1 MM, 2 CLL, 1 LNH) and, of these,
3 patients died for concomitant complications, 2 patients developed Acineto-
bacter baumannii bacteremia that caused septic shock and death, and 2 were
successfully treated with inhaled colistin for the eradication of bacterium from
the respiratory tract, preventing bacteriemia. This method was not described
before and allows an early detection of the Bacillus. Moreover, it could be used
not only for cohorting patients but also as a signature marker for subsequent
clinical infections. In addiction, early treatment with aerosolized Colistin for the
eradication of MDRAB colonization in the respiratory tract resulted as salvage
therapy for the 2 patients described that are still alive after eradication.
Summary and Conclusions: In conclusion A. Baumanii colonization are dif-
ficult to manage in immunocompromised patients but an appropriate swabs
surveillance, application of strict infection control measures and use of
aerosolized Colistin therapy could be of help.
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DOES NEUTROPENIA AFFECTS HERPES VIRUS REACTIVATION IN
CRITICALLY ILL PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND
PNEUMONIA?
D. Tikhomirov1,* T. Garanzha1, V. Troitskaya2, T. Tupoleva1, T. Romanova1, G.
Galstyan3, E. Parovychnikova2, F. Filatov1
1Laboratory of Virology, 2Department of Hematology, 3Intensive care unit,
Hematology Research Center, Ministry of Health of the Russian Federation,
Moscow, Russian Federation
Background: Chemotherapy applied in hematological malignancies manage-
ment leads to blood cells count decreasing which in turn leads to a deterioration
in the condition of the patient. Leucocyte count diminishment involves not only
tumor cells but neutrophils as well. It can cause ICU admission. Neutrophils
are essential for immune regulation and opportunistic infection prevention.
Nevertheless life-threatening complications like nosocomial pneumonia and or
respiratory failure can occur within any granulocyte count during chemotherapy.
Herpes viruses tend to reactivate in immunodeficient person. Acute herpes
virus infection can cause lung injury.
Aims: The aim of the study was to estimate frequency of herpes viruses in
critically ill patients with hematological malignancies and pneumonia during
immunodeficiency
Methods: 38 critically ill patients with hematological malignancies suffered
from pneumonia were enrolled in the study: 18 with acute leukemia, 8 with
lymphoma, 8 with lymphoproliferative disorders and 4 with multiple myeloma.
23 of 38 were in immunodeficiency because of neutropenia. 5 also had reduced
levels of globulin. Another 15 of 38 had normal blood count and showed no
sights of immunodeficiency. HCMV DNA, EBV DNA, HHV DNA and HSV 1,2
DNA levels in bronchoalveolar lavage fluid (BALF) was measured by real-time
PCR.
Results: The frequency of detection of herpes virus DNA was almost twice as
high in immunodeficient patients than in patients with normal blood count (16
of 23 (70%) vs 7 of 15 (47%)). We observe HSV 1,2 DNA in 11 of 23 (48%)
BALF samples of nutropenic patient’s, HCMV DNA orEBV DNA in 6 of 23
(26%), HHV 6 DNA in 4 (17%). 5 samples contained 2 or more viral DNAs
simultaneously. As for patients without immunodeficiency, HCMV DNA was
detected in 4 of 15 (27%), HSV 1,2 DNA and HHV 6 DNA in 3 of 15 (20%),
EBV DNA in 2 of 15 (13%) BALF samples. Viral load varied depending on the
virus type and the patient’s immunity state. The vast majority of samples from
patients with neutropenia (14 of 16 (87.5%)) showed high DNA concentration
in BALF (more than 1000 copies/ml). In patients with no sights of immunode-
ficiency high viral load was detected in only 3 of 7 (42.9%) samples. Thus, the
frequency of high viral DNA level in BALF was two times higher for patients
with reduced neutrophils count and humoral immunodeficiency.
Figure 1
Summary and Conclusions: Obtained data show twice higher frequency of
herpes virus DNA detection in BALF of immunodeficient hematological patients.
Viral load is also higher if neutropenia occurs. This proves, granulocyte count
reduction can be associated with viral lung injury complications.
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NOCARDIA INFECTION IN PATIENTS UNDERGOING ALLOGENEIC STEM
CELL TRANSPLANTATION
M. Stamouli1,* A. Bouhla1, K. Girkas1, M. Atta1, N. Papanikolaou1,
C. Economopoulou1, C. Roubakis1, A. Vassilatou1, K. Godopoulos1,
E.D. Ioannidou1, K. Petevi1, E. Pessach1, S. Papageorgiou1, V. Pappa1,
E. Bazani1, P. Tsirigotis1
12nd Department of Internal Medicine Propaedeutic, Attikon University Hospital,
Haidari, Greece
Background: Patients undergoing allogeneic stem cell transplantation are at
increased risk of opportunistic infections. Nocardia, a gram positive bacterial
agent, is an uncommon cause of infection. The diagnosis of Nocardiosis can be
quite challenging because of technical difficulties (difficulty in obtaining adequate
samples and growing cultures). The disease usually presents in a subacute
manner in immunocompromised patients but its course is often life threatening.
Aims: The objective of this study was to record the incidence of nocardiosis in
patients who received stem cell transplants in our hospital and to describe their
clinical characteristics.
Methods: Seventy patients who had undergone allogeneic stem cell trans-
plantation between 2009 and 2014 were retrospectively evaluated. Reason for
transplant, graft vs host disease (GvHD), site of infection, pneumocystis jiroveci
prophylaxis, treatment regimens and outcome were recorded.
Results: In the above period of six years, 40 out of 70 patients developed graft
vs host disease (acute GvHD:24 cases, chronic GvHD:23 cases) that required
corticosteroid treatment. None of the remaining 30 patients developed nocar-
diosis. Of the 40 patients with GvHD, 35 patients received co-trimoxazole as
prophylaxis for pneumocystis jiroveci and five patients alternative prophylaxis
such as pentamidine and atovaquone. Again in the 35 patients who received
co-trimoxazole, no nocardiosis occurred, while three out of five patients (60%)
on alternative prophylaxis developed infection due to nocardia: osteomyelitis
in a man with acute lymphoblastic leukemia, disseminated disease (involving
the lung, brain, liver, spleen, kidneys and possibly the duodenum) in a man
with myelofibrosis and pulmonary nocardiosis in a woman with chronic myeloid
leukemia. The woman eventually died of nocardiosis. The two men with nocar-
diosis were successfully treated with adequate antibiotic combinations (one of
them is still under co-trimoxazole).
Summary and Conclusions: Though uncommon, nocardiosis should be kept
in mind when it comes to patients undergoing allogeneic stem cell transplan-
tation. Graft vs host disease and its treatment seriously affect the host’s immune
status and could increase patient susceptibility to the disease in this subgroup
of patients. Interestingly in our center all patients who were diagnosed with
nocardiosis were not receiving co-trimoxazole as prophylaxis for pneumocystis
jiroveci while none of the patients under co-trimoxazole prophylaxis ever devel-
oped any infection caused by Nocardia spp.
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INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
S. Ramos1,* M. Santos1, R. Tenreiro1, M. Pereira1, E. Cortesão1, L. Rito1,
M.L. Ribeiro1
1Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal
Background: Azacitidine (AZA) is the standard of care for high-risk myelodys-
plastic syndromes (MDS). Its mechanism of action includes demethylation,
cytotoxicity and the induction of apoptosis. Thus, cytopenias are a major prob-
lem during the first cycles of treatment, when hematological improvement has
not yet been achieved. The risk of infection in this period of treatment has been
demonstrated to be substantial. Indeed, in the AZA-001 trial, infections occurred
in about 50% of AZA-treated patients. The incidence and features of these
infectious complications has been addressed mainly in controlled clinical trials,
with highly selected patients, making it controversial to extrapolate the results
to “real life” patients.
Aims: We aimed to compare the incidence of infectious complications during
AZA treatment in a cohort of “real life” patients with the published data.
Methods: We retrospectively evaluated the incidence of infectious complica-
tions during AZA treatment in a cohort of patients with high risk MDS and Acute
Myeloid Leukemia (AML). 
Results: Fifty one patients started AZA treatment between 31/07/2006 and
24/03/2014. Median age at diagnosis was 69 years (49-83 yrs, 34 males, 17
females). Median age at the start of treatment was 71 years (49-83). There
were 44 MDS and 7 AML. MDS classification according to the WHO 2008 was:
Refractory cytopenia with multilineage dysplasia (n=10); Refractory anemia
with excess blasts 1 (n=12); Refractory anemia with excess blasts 2 (n=17);
Chronic Myelomonocytic Leukemia (n=4); Refractory anemia with ring sider-
oblasts (n=1). AZA was started at a median of 4.99 months from diagnosis in
a standard dose of 75 mg/m2, on a 5-2-2 schedule. A median of 5 (1-34) cycles
of AZA were delivered to each patient. In a total of 353 cycles, 31 (8.8%) infec-
tious episodes occurred in 12 patients (23.5%). The median time to first infec-
tion was 1.9 (0.2-41.9) months. Six patients (11.8%) had a single episode of
infection after a median of 3.2 months from the start of AZA (0.4-41.9 months).
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In the 6 patients who had two or more infectious episodes, the second one
occurred after a median of 4.7 (3.2-25.2) months from the start of AZA. The
median neutrophil count at the time of infection was 0.35 (0-16)/μL. In 17 of 31
(54.8%) infections, grade 3-4 neutropenia was present. In these 31 infectious
episodes, a positive microbiologic test was available in 11 cases (35.4%). Eight-
een bacteria and one fungus were isolated (table). Twenty-three hospitalizations
were required in 11 (91.7%) of the 12 patients who had infections, with a median
duration of 17 (2-59) days. The most frequent infection sites were the lungs
(32.2%) and the skin (19.4%). Infections were the attributable cause of death
in 7 hospitalized patients: five of them died due to pneumonia and 2 to fever of
unknown origin. Eighteen patients with MDS (38.3%) progressed to AML under
AZA, after a median of 7.5 (2.5-23.0) months. With a median follow-up of 16.3
(2.1-223.7) months, 15 patients were alive, resulting into a median overall sur-
vival of 20,5 (10,1-30,8) months.
Table 1.
Summary and Conclusions: We found a relatively high probability of infectious
complications following treatment of MDS/AML with AZA, especially pneumonia,
wich was also the main cause of death. However, in our cohort, the incidence of
infections (23.5%) was inferior of that related in the published data. We concluded
that in a setting of not highly selected patients, like our cohort, infections during
AZA treatment are not more incident than those described in the literature.
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FACTORS AFFECTING THE OUTCOME OF FEBRILE NEUTROPENIA IN
PATIENTS WITH HEMATOLOGIC MALIGNANCIES
H. Zawam1, W. Edesa1, R. Salama1,* M. Gaber2, M. Sherief3, C. Naseef1,
N. Ezzat 1
1Clinical oncology department, 2Clinical pathology department, 3Chemical
pathology department, Cairo university, Cairo, Egypt
Background: Febrile neutropenia(FN) is one of the most seroius complications
in patients (pts) with hematological malignancies.The prompt initiation of empirical
antiboitics within 1 hour of fever has lead to reduction of mortality and improvement
of survival .Several risk assesment guidlines have been adopted to identify pts as
low and high risk of complications.We conducted this single institution study to
determine specific risk factors that may affect the outcome in pts with FN.
Aims: To identify specific factors that may affect the response to treatment in
pts with febrile neutropenia.
Methods: During the peroid of 1st of April 2014 untill the end January 2015,
pts with hematological malignancies who presented to clinical oncology depart-
ment and developed FN during management were enrolled in this prospective
analysis. At the onset of fever, pts underwent complete physical examination,
in addition to blood culture, urine and stool culture. Computer tomography of
the chest and paranasal sinuses and serial galactomannan (GM) test were
requested in cases with uncontrolled fever or suspected invasive fungal infec-
tion (IFI).Polymerase chain reaction analysis of bacteria and fungi from the
blood and bronchoalveolar lavage were performed in selected cases.The data
were analyzed using chi-square test.
Results: One hundred and thirty five (135) pts were identified and analyzed.
The mean age was 38.5 years (range 14-76). 51% had acute myeloid leukemia,
36% acute lymphoblastic leukemia (ALL), non hodgkin’s lymphoma, chronic lym-
phocytic leukemia, and multiple myeloma were diagnosed in 7%, 4%, and 2%
respectively .According to Multinational Association for Supportive Care in Cancer
(MASCC) index, 80 pts (60%) were categorised as high MASCC score (<21),
while 55 pts (40%) had low MASCC score (>21). Blood culture was negative in
114 pts (84%), while it was positive in 21 pts(16%). Gram negative bacteria con-
stituted 60% of cases, while gram positive were 40 %.Serial GM test was positive
in 24 pts only (17%),88 pts (65%) did not receive antifungal agents. Fluconazole
was used as antifungal prophylaxis in the majority of pts (n=95)(71%), of those
who did not receive fluconazole (n=40), only 15 pts (37.5%) developed IFI and
were classified according to 2008 European organization for research and treat-
ment of cancer/invasive fungal infections cooperative group and the national insti-
tute of allergy and infectious diseases mycoses study group (EORTC/MSG) Con-
sensus; 12 pts had probable fungal infections,2 pts had possible fungal infections
and 1 patient had definitive fungal infection. The choice between first line antibi-
otics (ceftazidime, maxipime, imipenem) or antifungal (amphotericin, voricona-
zole) had no impact on the recurrence of FN attacks (P<0.08 and p<0.23 respec-
tively).In terms control of fever on 1st line antibiotics, there was statistically sig-
nificant difference in favour of low risk MASCC score (p<0.001),change of antibi-
otics due to uncontrolled fever was required in 62 pts (45%),there was a significant
difference between defervescence and low/high MASCC score (P<0.001). With
respect to first antifungal used, a significant correlation was observed between
low/high MASCC score and control on first antifungal therapy (P<0.006). In the
present study ,16 pts(12%) only were diabetics, there was no significant correla-
tion between diabetes and uncontrolled fever, prolonged neutropenia .Prolonged
FN (>7days) was observed in 40 % of pts ,the use of corticosteroids, and non
administration of granulocyte colony stimulating factor (G-CSF) were the pre-
dominant risk factors (P<0.001 ,P<0.002 respectively). In terms of mortality, only
pts with high MASCC score(n=11) (8%) had the worst outcome compared to low
score(n=1) (P<0.0001).
Summary and Conclusions: There are multiple factors that may affect the
outcome of pts with FN and it should be taken in considerations during mang-
ment of FN such as MASCC score, previous use of corticosteroid and G-CSF
adminstration during FN.
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VARIOUS PATTERNS OF HEPATITIS B VIRUS REACTIVATION IN B CELL
LYMPHOMA
A. Nakaya1,* S. Fujita1, A. Satake1, T. Nakanishi1, Y. Azuma1, Y. Fujita1,
M. Hotta1, H. Yoshimura1, K. Ishii1, T. Ito1, S. Nomura1
1First Department of Internal Medicine, Division of Hematology and Oncology,
Kansai Medical University, Osaka, Japan
Background: It has been reported that reactivation of hepatitis B virus (HBV)
could be fatal in patients with malignancy following systemic immunosuppressive
chemotherapy, especially combined with rituximab. The prophylactic nucleoside
analog therapy is recommended in the current guidelines to treat HBV reactiva-
tion in which the incidence of HBV reactivation was proved to be reduced. On
the while, how HBV reactivation exhibits clinical course in patients with lym-
phoma treated with rituximab-containing chemotherapy has to be elucidated.
Aims: To investigate various patterns of HBV reactivation in lymphoma patients
receiving Rituximab-contaionig chemotherapy.
Methods: We retrospectively analyzed 541 patients with B cell lymphoma who
were treated with rituximab-containing regimens between 2006 and 2013 at
Kansai Medical University Hospital. 
Table 1. Characteristics of 18 patients with HBV infection in B-cell
lymphoma.
Results: A total of 541 patients were studied. Most common subtype of lym-
phoma was diffuse large B-cell lymphoma. Among 541 patients, 14 patients
(2.5%) were hepatitis B antigen (HBs Ag) positive carrier. Among these 14 car-
riers, 12 patients whose HBV-DNA level was positive at diagnosis were treated
with nucleoside analog. Two patients whose HBV-DNA were undetected at
diagnosis, without prophylactic nucleoside analog, converted to reactivation
after the chemotherapy. Two patients who received prophylactic nucleoside
analog therapy developed breakthrough hepatitis long after diagnosis (median:
351 days). One-hundred and seven patients (19.7%) had occult HBV infection
(HBs Ag negative, HBc Ab positive or HBs Ab positive). Among occult patients,
5 patients converted to reactivation (de novo hepatitis) during the chemotherapy
and received nucleoside analog. All of these de novo hepatitis patients were
presented with hypogammaglobulinemia (median: 511 mg/dl) at reactivation.
Of all reactivated patients, 2 patients underwent autologous stem cell trans-
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plantation (ASCT). One was a carrier received prophylactic nucleoside analog,
and whose HBV-DNA became undetected, but she developed secondary reac-
tivation long after ASCT. The other was de novo hepatitis, he converted to late-
onset reactivation after ASCT. These two patients were also presented with
hypogammaglobulinemia (median: 301 mg/dl) at reactivation.
Summary and Conclusions: We achieved improvement on management
against HBV reactivation through the guideline to prevail on us to use prophy-
lactic nucleoside analog therapy. Here we addressed that HBV reactivation
could exhibit various patterns as we develop to treat lymphoma with new
immunosuppressive agents as well as hematopoietic cell transplantation.
Therefore, we have to pay attention to each pattern of HBV reactivations in
treating them beyond the guidelines.
LB2080
REACTIVATION OF HEPATITIS B INFECTION IN HAEMATOLOGY
PATIENTS RECEIVING RITUXIMAB THERAPY: EVIDENCE OF
SUB-CLINICAL ALT FLARES IN HBSAG-/HBCAB+ PATIENTS 
S. Mackenzie1,* S. Cheeseman1, L. Waters2, M. Scully1, K. Ardeshna1,
D. Linch1, J. Lambert1
1Department of Haematology, 2Department of HIV Medicine, University College
London Hospital, London, United Kingdom
Background: Reactivation of hepatitis B virus (HBV) following Rituximab therapy
is a well-recognized phenomenon. In patients with pre-existing serological mark-
ers of chronic (surface antigen positive [HBsAg+]) HBV infection, the rate of Rit-
uximab-associated HBV reactivation is approximately 80-100% in the absence
of nucleotide analogue (NA) prophylaxis. In patients with serological markers of
past infection (HBsAg-negative [HBsAg-]/core antibody positive [HBcAb+]), this
rate varies between 0% and 45%. European guidelines therefore recommend
that all patients are HBV serotyped (with HBsAg and HBcAb) prior to treatment
with Rituximab. Patients with active hepatitis B disease should not receive therapy
with Rituximab, and those with positive HBV serology but no active disease
should be referred to a hepatologist for specialist monitoring and therapy, includ-
ing measuring HBV DNA levels and starting prophylactic NA therapy.
Aims: To determine: i) the proportion of patients appropriately screened prior
to Rituximab and if HBsAg-/HBcAb+, the proportion tested for HBV DNA levels:
ii) the rate of ALT flares in the HBsAg-/HBcAb+ patients
Methods: Between January - October 2014, Haematology patients in a tertiary
level centre who received Rituximab were identified from the electronic pre-
scribing database. Pathology records were used to determine demographic
characteristics, evidence of HBV serotyping, HBV DNA levels and whether
HBsAg-/HBcAb+ patients received NA therapy. Patients with a high ALT at any
time following Rituximab were categorised into groups of ALT >50 or >150 IU/L.
Results: Of the 230 patients administered Rituximab, 82% had malignant diag-
noses and 18% non-malignant diagnoses. 166 patients (72%) underwent HBV
serotyping. Of these, 19 (11%) were HBsAg-/HBcAb+ and 2 were chronic
HBsAg+/HBcAb+ carriers. Of the HBsAg-/HBcAb+ patients, seven (33%) were
tested for HBV DNA at least once and none were positive. Both
HBsAg+/HBcAb+ patients had detectable HBV DNA. Four (21%) of the HBcAb+
and both the HBsAg+ patients were started on NA therapy. The proportion of
patients with an ALT >50 IU/L following Rituximab therapy was higher in the
HBcAb+ group compared to the HBcAb- group (47% vs 25% p = 0.04). There
was a trend to a greater number of patients with an ALT >150 IU/L in the HBcAb+
group compared to the HBcAb- group, but this was non-significant (21% vs.
13% p = 0.07). Of the 64 patients who did not undergo any HBV serotyping, 30
patients (18%) had an ALT of >150 and one developed an ALT of >1000 IU/L.
Summary and Conclusions: Although there were no patients with HBV DNA-
confirmed reactivations in the HBsAg-/HBcAb+ patients in this study, the higher
proportion of patients with an ALT >50 IU/L in the HbsAg-/HBcAb+ group sug-
gests that there were sub-clinical ALT flares in this group, and suggests that
the frequency of HBV DNA monitoring impacts on the measured reactivation
rate in previous studies. The study also highlights that increased awareness
amongst Haematology clinicians is needed to improve rates of HBV serotyping
prior to and monitoring for reactivation following Rituximab administration to
avoid preventable HBV-related complications.
Email address: scm104@ic.ac.uk
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USING PET/CT TO ASSESS FDG NODAL UPTAKE AND IMPACT OF
VIRAEMIA IN HIV-POSITIVE PATIENTS: A COMPARISON OF REACTIVE
LYMPHADENOPATHTY, MULTICENTRIC CASTLEMAN DISEASE AND
HIV-RELATED LYMPHOMA
S.C. Mackenzie1,* N. Ranganathan2, M. Noursadeghi1, S.G. Edwards2,
R. Miller2
1Division of Infection and Immunity, University College London Hospital, 2HIV
and Sexual Health , Mortimer Market Centre, Camden Provider Services, Cen-
tral and North West London NHS Foundation Trust, London, UK, London, Unit-
ed Kingdom
Background: PET/CT is a widely used imaging modality in the investigation,
diagnosis, staging and assessment of treatment response in patients with lym-
phoma and has an increasing role in investigating HIV-positive patients with
pyrexia of unknown origin (PUO). Its use in differentiating malignancy from
infection in the evaluation of intracranial lesions in the context of HIV, for exam-
ple, is well-recognized. HIV-related immunosuppression predisposes patients
to a number of additional phenomena however, including opportunistic infec-
tions, HIV-related reactive lymphadenopathy, immune reconstitution and the
lymphoproliferative disorder Multicentric Castleman disease (MCD). These can
lead to false-positive interpretations of malignancy, particularly in untreated
patients with high viral loads (VL) and therefore special consideration is required
when evaluating PET/CT in patients with HIV. There remains considerable
debate about which factors are most important in predicting the aetiology of
lymphadenopathy using PET/CT in the HIV setting. 
Aims: To compare PET/CT findings in HIV-positive patients with lymphoma,
reactive lymphadenopathy and MCD to identify differentiating factors. We aimed
to look specifically at the effect of VL on nodal and splenic characteristics and
used radiological parameters to assess this.
Methods: Patients with HIV who presented with PUO and who subsequently
had imaging with18F-FDG PET-CT were identified. Patients were categorised
into 4 groups after final diagnosis: i) reactive lymphadenopathy ii) MCD iii) HIV-
associated lymphoma and iv) confirmed infectious or other miscellaneous con-
dition; the latter group were excluded from analysis in this study. Electronic
records were used to record baseline demographic characteristics and CD4
count, plasma HIV load and ART status. All lymphoma and MCD diagnoses
were confirmed on biopsy and all patients with reactive lymphadenopathy had
extensive inpatient investigations which excluded an infectious or other aetiol-
ogy. PET/CT imaging was reviewed by a radiologist and SUVmax, distribution
of lymphadenopathy and liver-spleen ratio calculated.
Results: 80 patients were identified, of which 39 had HIV-related reactive lym-
phadenopathy, 26 had lymphoma and 15 had MCD. The mean age was 42
years and 74% were male. There were higher median SUVmax values among
patients with lymphoma compared to reactive lymphadenopathy and MCD
(12.0 vs. 5.6, p=0.0021, 12.0 vs. 5.7, p=0.0041, respectively). There was a
trend to higher median SUVmax values in the reactive lymphadenopathy group
with a detectable VL compared to the undetectable group, but this difference
was not significant (5.9 vs 4.0) and there was no difference between the MCD
and reactive lymphadenopathy groups. Reversal of the liver:spleen avidity ratio
was observed more commonly among those with detectable viral loads but did
not aid discrimination between diagnoses. 
Summary and Conclusions: This is the largest PET/CT series of HIV-positive
patients with fever and lymphadenopathy. Significantly higher SUVmax values
were observed among lymphoma cases and despite MCD being a lymphopro-
liferative disorder, showed similar median SUVmax values to reactive lym-
phadenopathy. There was no effect of high or low viraemia on SUVmax in patients
with both MCD or lymphoma which may be helpful clinically when serial PET/CT
imaging is available. Finally, this study confirms that both histological and radi-
ological evidence of HIV-related reactive nodal changes were seen even in
patients with complete serum virological suppression and this should therefore
be borne in mind when investigating HIV-positive patients for lymphoma.
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ANTIMICROBIAL-RESISTANT GRAM-NEGATIVE BACTERIA IN
BLOODSTREAM INFECTIONS IN PATIENTS WITH PEDIATRIC HEMATOLOGY
& ONCOLOGY AND PEDIATRIC BONE MARROW TRANSPLANTATION
UNIT
A. Akcay* D. Atay1, F. Erbey1, B. Varol2, D. Arman2, G. Ozturk1
1Department of Pediatric Hematology- Oncology and Bone Marrow Transplan-
tation Unit, Acibadem Univercity Medical Faculty, Acibadem Atakent Hospital,
2Department of Microbiology, Bahcelievler Medical Park Hospital, Istanbul, Turkey
Background: Patients with cancer are at high risk for infections caused by
antibiotic resistant gram-negative organism.
Aims: To survey blood cultures taken from the patients hospitalized in pediatric
hematology & oncology clinic and pediatric bone marrow transplantation unit
and inspect the antibiogram of antimicrobial-resistant gram-negative organisms.
Methods: The blood cultures taken from children hospitalized in pediatric hema-
tology & oncology and pediatric bone marrow transplantation clinics from April
2011 to April 2014 during fever and/or clinic infection existence were evaluated
retrospectively. The gram-negative organisms grew in the blood cultures and their
antibiograms were inspected. Antibiotic-resistance was classified as multidrug
resistant (MDR), extensively drug resistant (XDR) and pandrug resistant (PDR).
Results: Pathogen organisms had grown in 632 (12%) of 5287 blood cultures.
Among all of the organisms, 86.5% gram positive and 13.5% (n=85) gram neg-
ative organisms were identified. Forty-three (50%) of gram negative organisms
were antimicrobial-resistant. The anti-microbial resistant gram-negative organ-
isms identified in the blood cultures were Klebsiella pneumoniae (n=24; 11 with
ESBL resistant, 11 with MDR/XDR; and 2 with PDR), Acinetobacter baumannii
(9; 8 with MDR/XDR; and 1 with MDR), Pseudomonas aeruginosa (n=5; 4 with
MDR/XDR and 1 with MDR), Escherichia coli (n=5 with ESBL resistant).
Summary and Conclusions: In pediatric hematology-oncology patients,
bloodstream infections with antibiotic-resistant gram negative pathogens has
recently increased. They are associated with increased morbidity and mortality.
It is clear that the introduction of novel antibiotics will lead to improvements in
the treatment of MDR, XDR and PDR.
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CAR MEDIATES DIFFERENTIATION AND MIGRATION OF ERYTHROPOI-
ETIC PROGENITOR CELLS AND IS SPECIFICALLY DOWN-REGULATED
IN MDS
K. Bauer1,* S. Machherndl-Spandl2, S. Suessner3, M. Danzer3, J. Proell3,
J. Lauf4, G. Eisenwort1, W.R. Sperr1, H.-U. Klein5, G. Hoermann1, N. Häfner6,
M.C. Béné7, U. Platzbecker8, A. Weltermann2, C. Gabriel3, T. Lion1,
U. Germing9, P. Bettelheim2, P. Valent1
1Medical University of Vienna, Vienna, 2Elisabethinen Hospital Linz, 3Transfu-
sion Service of Upper Austria, 4Labor Europaplatz, Linz, Austria, 5University of
Muenster, Muenster, 6Jena University Hospital, Jena, Germany, 7CHU de
Nantes, Nantes, France, 8University of Dresden, Dresden, 9Heinrich-Heine-
University, Düsseldorf, Germany
Background: Myelodysplastic syndromes (MDS) are myeloid neoplasms char-
acterized by peripheral cytopenia, an accumulation of dysplastic cells in the
bone marrow (BM) and a high risk of transformation to acute myeloid leukemia.
Transfusion-dependent anemia develops in most patients. In the refractory
anemias the accumulation of dysplastic erythroid BM progenitor cells (EryPC)
which paradoxically accompanies peripheral anemia, is a typical finding. 
Aims: The biochemical basis of the maturation defect of erythroid cells and
their abnormal accumulation in the BM are still unknown. Therefore, we were
interested to examine abnormally regulated and functionally relevant genes
expressed in MDS EryPC.
Methods: In our study, we have established a screening program involving
mRNA expression profiling studies of EryPC in patients with low-risk MDS and
control BM samples obtained from patients with other BM neoplasms as well
as patients with unexplained cytopenia, normal BM or reactive/deficiency
cytopenias. EryPC were defined as CD45low/CD105+ cells and purified from
BM mononuclear cells by multicolor flow cytometry (MFC) and cell sorting.
mRNA expression profiles were analyzed by Affymetrix array technology and
confirmed for a panel of selected mRNA species by qPCR. 
Results: In mRNA- and MFC-validation experiments, we found that the major
Coxsackie-Adenovirus Receptor (CAR) is specifically down-regulated in
CD45low/CD105+ EryPC in MDS patients when compared to EryPC in normal
BM or other control cohorts. In line with this observation, the immature ery-
throblastic cell lines HEL, K562 and KU812 stained negative for CAR. Lentiviral
transduction of the full-length CAR gene into these cells resulted in a signifi-
cantly increased expression of various erythroid differentiation antigens, includ-
ing CD36, CD71 and Glycophorin-A as determined by flow cytometry and
qPCR. Furthermore, CAR transduction resulted in an increased migration of
HEL cells against a serum protein-gradient in a transwell assay. Transfection
with truncated variants of CAR did not result in an increased expression of ery-
throid antigens or an increased directed migration. 
Summary and Conclusions: In conclusion, our data show that CAR is a func-
tionally relevant molecule that promotes the expression of early erythroid dif-
ferentiation antigens on myeloid progenitor cells and their migration against
blood serum proteins. In patients with MDS, CAR is downregulated on EryPC,
which may have implications both in terms of the pathogenesis of the disease
and the application of this novel marker in diagnostic MFC algorithms. With
regard to functional consequences, we hypothesize that CAR-deficiency is
pathogenetically relevant as it may not only contribute to the maturation-defect
of EryPC in MDS but also to the related accumulation of erythroid cells in the
BM that is accompanying the peripheral anemia in these patients.
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RUNX1 MUTATION AND LOW RUNX1 TRANSACTIVATING ACTIVITY PRE-
DICT HIGHER RISK OF AML TRNASFORMATION AND INFERIOR
LEUKEMIA-FREE SURVIVAL IN CHRONIC MYELOMONOCYTIC LEUKEMIA
M.-C. Kuo1,2,* L.-Y. Shih1,2, S.-C. Tsai1, S.-T. Liang3, Y.-J. Huang1, Y.-S. Shih1,
T.-H. Lin1, C.-Y. Lai2, D.-C. Liang3
1Chang Gung Memorial Hospital, 2Chang Gung University, Taoyuan, 3Mackay
Children’s Hospital and Mackay Medical College, Taipei, Taiwan, ROC
Background: We have previously described a high frequency of RUNX1 muta-
tions in chronic myelomonocytic leukemia (CMML), the prognostic impact of
RUNX1 mutation and its biological activity on disease progression remain to
be investigated.
Aims: We aimed to correlate RUNX1 mutation status and its biological activity
with clinical features in patients with CMML as well as to determine the role of
RUNX1 mutants in secondary acute myeloid leukemia (sAML) transformation.
Methods: Bone marrow (BM) samples from 105 CMML patients at diagnosis
were examined for RUNX1 mutations by PCR-based analysis covering entire
coding sequences from exons 3 to 8 of RUNX1b gene. Additional 25 genes relat-
ed to the myeloid neoplasms were also analyzed. The RUNX1 mutant activity on
target C-FMS gene induction was determined by luciferase reporter assay. The
relative activity of each RUNX1b mutant was derived by measurement of
luciferase intensity of each transfectant and normalized with wt-RUNX1b. Pyrose-
quencing was used to measure allele burden of mutated genes. 
Results: Thirty-six of 105 patients (34.3%) with CMML had RUNX1 mutations,
33 of them had co-existing mutations, including 13 SRSF2, 10 ASXL1, 9 TET2,
8 EZH2, 6 NRAS, 5 CEBPα, 3 CBL, 3 SETPB1, 3 U2AF1, 3 SF3B1, 2 DNMT3A,
2 FLT3-TKD, and one each of IDH2, PTPN11, MLL-PTD, and CSF3R. The
RUNX1 mutants were grouped into high and low activity according to their rel-
ativet ransactivating activities (cut-off was 0.52), 30% of 103 CMML patients
had low RUNX1 activities. Both RUNX1 mutation and low biological activity
were significantly associated with lower platelet count, higher WBC count and
monocytosis, and higher BM blasts. Patients with low activity were younger
and had more CMML2 subtype. There was no correlation of hemoglobin level,
cytogenetics or IPSS-R with RUNX1 mutation status or mutant activity. Forty-
five patients progressed to sAML, 32 had matched paired CMML/sAML samples
available for clonal evolution analysis; 17 were positive for RUNX1 mutations
at both phases. The allele burden of RUNX1 mutations remained stable except
3 in which a new RUNX1 mutant clone emerged while the previous one declined
at sAML phase and accompanied the co-emergence of NRAS mutation and
FLT3-TKD in one each of them. In addition, RUNX1 mutant clones evolved in
another two patients and with the acquisition of IDH2 with FLT3-ITD and SRSF2
mutations, respectively in each of them during sAML progression. We also
found that one lost TET2 mutation and the other lost JAK2V617F during disease
progression. RUNX1 mutation was associated with an increased risk of sAML
transformation compared with non-mutated patients (58% vs 33%, P=0.021)
and shorter leukemia-free survival (LFS) (23.3±3.1 months vs 47.8±17.7
months, P=0.042) but with no impact on overall survival (12.5±3.2 months vs
13.2±1.5 months, P=0.147). CMML patients with low RUNX1 activities had a
higher risk of sAML transformation (64.5% vs 31.9%, P=0.004) and inferior
LFS (19.7±4.6 months vs 47.8 months, P=0.010) compared with high activity
group. By including additional gene mutations for outcome analysis, both
RUNX1 mutation status and biological activity were the most important prog-
nostic predictors.
Summary and Conclusions: Our results showed that RUNX1 mutation and low
RUNX1 transactivating activity predicted higher risk of sAML progression and
shorter LFS in CMML patients. (Grant support: NHRI- EX103-10003NI,
OMRPG3C0021, MMH-E-101009, MOST103-2321-B-182-015, and MOHW103-
TD-B-111-09).
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ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD
OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES
M. Velegraki1,* H. Koutala1, E. Rousaki1, A. Damianaki1, S. Mastrodemou1,
C. Pontikoglou1, H. Papadaki1
1Haemopoiesis Research Laboratory, University of Crete, School of Medicine,
Heraklion, Greece
Background: Immune deregulation is implicated in the pathogenesis of
Myelodysplatic Syndromes (MDS). Monocytes are an important part of the
innate immune system; circulating human monocytes are phenotypically and
functionally heterogenous. They typically express the CD14 antigen and are
divided in the CD16- (classical) monocytes and the CD16+ monocytes which
can be further subdivided in the CD14bright/CD16+ (intermediate) monocytes
and the CD14dim/CD16+ (non-classical) monocytes. Classical monocytes seem
to be involved in tissue repair while intermediate monocytes are mainly pro-
inflammatory. The role of the monocyte cell subsets in the pathogenesis/patho-
physiology of MDS has not been extensively studied.
Aims: The aim of this study was to investigate for quantitative abnormalities in
peripheral blood (PB) monocyte subsets of patients with MDS that might have
an impact on the pathogenesis/pathophysiology of the disease.
Methods: We have studied 44 patients with Very Low/Low risk MDS according
to the R-IPSS score and 31 age and sex matched healthy individuals. Four-
colour Flow Cytometry was used to assess the three monocyte subsets based
on their relative CD14 and CD16 surface expression. Furthermore, the Mean
Fluorescence Intensity (MFI) of the CCR2 and the CX3CR1 chemokine recep-
tors, which are characteristically expressed by monocytes, was determined in
each monocyte subpopulation.
Results: Analysis was performed within the CD14+ cell population. A significant
increase in the proportion of the CD16+ monocytes was observed in MDS
patients (26.4±15.4%) compared to normal controls (10.2±4.9%) (P<0.0001)
which was associated with a significant decrease of the CD16- monocytes in
patients (73.6±15.3%) compared to controls (89.8±4.9%) (P<0.0001). Among
the CD16+ monocytes, the most prominent increase was observed in the inter-
mediate CD14bright/CD16+ monocytes which were increased both as cell pro-
portions (22.1±13.8%) and absolute cell numbers (133.5±118.5/μl) in patients
compared to healthy controls (7.8±4.2% and 50.1±36.3/μl, respectively)
(P<0.0001 and P=0.0012, respectively). Furthermore, the percentages of the
CD14bright/CD16+/CCR2+ and the CD14bright/CD16+/CX3CR1+ cells, were
increased in MDS patients (19.2±14.2% and 16.2±13.3%, respectively) com-
pared to normal controls (6.9±3.2% and 7.4±4.8%, respectively) (P=0.0008
and P=0.0273, respectively). The CD14bright/CD16+ monocytes of MDS patients
consisted of a higher proportion of CCR2+ (91.8±6.4%) and a lower proportion
of CX3CR1+ (87.1±15.6%) cells compared to healthy individuals (87.7±6.7%
and 97.3±3.6%, respectively) (P=0.04 and P=0.001, respectively). Interestingly,
the MFI of CCR2 was significantly increased in the CD14bright/CD16+ mono-
cytes of MDS patients (12.9±3.2) compared to normal controls (7.2±2.4)
(P<0.0001) (Figure 1).
Figure 1.
Summary and Conclusions: We have showed for first time that patients with
lower risk MDS display significantly increased numbers of circulating
CD14bright/CD16+ monocytes which are also phenotypically altered. The pos-
sible involvement of this abnormal cell population in the excessive pro-inflam-
matory cytokine production and ineffective hematopoiesis of lower risk MDS is
currently under investigation.
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GLUTATHIONE S-TRANSFERASE P1 (GSTP1) PROMOTER HYPERME-
THYLATION IN MDS/AML: ASSOCIATION WITH SPECIFIC CHROMOSOME
ABBERATIONS
S. Zachaki1, A. Daraki1, M. Kalomoiraki1, C. Stavropoulou1, D. Koumbi1,
K. Manola1, A. Parcharidou2, P. Kollia3, C. Sambani1,*
1Health Physics, Radiobiology & Cytogenetics, NCSR “Demokritos”, Athens,
Greece, 2Bedford Hospital NHC, Bedford, United Kingdom, 3Department of
Genetics &and Biotechnology, Faculty of Biology, Athens, Greece
Background: Gene silencing by epigenetic alterations is a common event in
carcinogenesis. The GSTP1 gene is a well-known housekeeping gene involved
in carcinogen detoxification. Its expression has been linked to cancer incidence
and drug resistance. It has been reported to be the target of somatic CpG
island promoter hypermethylation in various types of human neoplasia, such
as prostate, breast and liver cancer. Recently, there is an ongoing preclinical
and clinical platform of drug discovery based on the activity of GSTP1 inhibitors
in stimulating multilineage differentiation of hematopoietic progenitors.
Aims: The aim of the study was to investigate the possible contribution of epi-
genetic inactivation of the GSTP1 gene in MDS and AML via DNA promoter
hypermethylation. We also assessed possible associations of GSTP1 methy-
lation pattern with specific chromosomal aberrations and the presence of A313G
GSTP1 germline inactivating polymorphism.
Methods: Our case-control study enrolled 116 patients [(62 MDS, 29 de novo
AML and 25 AML cases preceded by MDS (MDS-AML)] and 25 healthy donors.
Cytogenetic analysis of bone marrow samples was successfully performed for
all patients at diagnosis. Total genomic DNA was extracted from patients’ and
controls’ samples using the QIAamp DNA-extraction midi kit (Qiagen, Hilden,
Germany). GSTP1 promoter methylation status was studied by methylation-
specific PCR (MSP) using the CpG WIZ® GSTpi Amplification Kit (Chemicon,
Canada, USA). The A313G GSTP1 genotyping was performed by Real-Time
PCR on the Biorad CFX96 (Biorad, California, USA) using GoTaq® qPCR Mas-
ter Mix (Promega, USA).
Results: Our results showed that GSTP1 gene promoter was hypermethylated
in 39 out of 116 patients (33.6%). All control samples were found to be com-
pletely unmethylated. Hypermethylation of GSTP1 promoter was found in 21
out of 62 MDS (33.9%), 6 out of 29 AML (20.7%) and 12 out of 25 MDS-AML
cases (48.0%). A significantly increased frequency was observed in MDS
(p<0.001) and MDS-AML patients (p<0.001). The GSTP1 promoter hyperme-
thylation was not found to be associated with the A313G GSTP1 polymorphism.
Stratification of patients according to their cytogenetic findings revealed a sig-
nificantly increased frequency of methylated cases in the group of patients
showing a normal karyotype, as compared to those with an abnormal karyotype
(60.0% vs 38.9%, respectively). Among patients with an abnormal karyotype,
the most common chromosome aberrations were trisomy 8 (+8), -5/del(5q)
and -7/del(7q) followed by del(20q) and loss of Y chromosome (-Y). The higher
frequencies of GSTP1 hypermethylation were found in cases with -7/del(7q)
(45.0%) and -5/del(5q) (33.5%) (p<0.001).
Summary and Conclusions: The results indicate an important role of the
GSTP1 epigenetic silencing in MDS/AML pathogenesis, extending our knowl-
edge on epigenetic alterations of the GSTP1 gene in hematological malignan-
cies. The remarkably high frequency of GSTP1 promoter hypermethylation in
patients with chromosome 7 abnormalities is consistent with the use of DNA
demethylating agents in treatment of MDS with loss of chromosome 7. Further,
the findings might suggest that GSTP1 hypermethylation could be a potential
epigenetic biomarker for MDS response to treatment, mainly in cases under
treatment with GSTP1 inhibitors.
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CIRCULATING MICRORNAS IN PLASMA OF PATIENTS WITH MYELODYS-
PLASTIC SYNDROMES
M. Dostalova Merkerova1,* Z. Krejcik1, A. Hrustincova1, E. Ratajova1,
M. Belickova1, J. Cermak2
1Department of Genomics, 2Clinical Department, Institute of Hematology and
Blood Transfusion, Prague, Czech Republic
Background: Myelodysplastic syndromes (MDS) represent a wide range of
hematopoietic stem cell disorders characterized by ineffective hematopoiesis,
peripheral blood cytopenias, and a tendency to evolve into acute myeloid
leukemia. MicroRNAs (miRNAs) are short endogenous non-coding RNA mole-
cules that play an essential role in the regulation of gene expression at post-
transcriptional levels. Existence of miRNAs has been recognized not only in the
intracellular environment but it has recently been shown that these molecules
are also present in a wide variety of body fluids, including blood plasma. Cell
free miRNAs (referred to as circulating miRNAs) have been repeatedly proved
to function as new promising semi-invasive diagnostic markers of various types
of cancer but only little information is known about their deregulation in MDS.
Aims: In this study, we focus on alteration of miRNA levels circulating in plasma
of MDS patients with the emphasis on differences between low and high risk
disease.
Methods: Peripheral blood plasma was collected from 40 patients with untreat-
ed primary MDS and from 10 healthy, age-matched donors with no medical
history. Written informed consent was obtained from all tested subjects in accor-
dance with the Institutional Review Board. Total RNA was extracted from plas-
ma using Qiagen miRNeasy mini kit. Agilent Human miRNA Microarrays were
used to assess the amount of 2,006 human miRNAs in blood plasma from 13
MDS patients and 6 healthy donors. The microarray results were confirmed in
the complete set of samples by RT-qPCR.
Results: Statistical analyses identified significant differences in a plasma profile
of circulating miRNAs between different study groups. In MDS, 19 down-reg-
ulated and 25 up-regulated miRNAs were detected compared to healthy con-
trols. Some hematopoiesis and/or oncology-associated miRNAs were found
in the list of deregulated molecules, e.g. down-regulation of miR-92a-3p, miR-
142-3p/5p, miR-320a/b/d/e, and miR-451a, and up-regulation of miR-150-5p,
miR-188-5p, and miR-548q. Low-risk and high-risk groups of patients signifi-
cantly differed in levels of several miRNAs, namely in reduction of miR-185-5p
and miR-4306 and elevation of miR-548q, miR-623, miR-4707-5p, miR-4721,
and miR-4739 in high-risk patients.
Summary and Conclusions: Expression profiling of plasma miRNAs in
patients with MDS revealed several miRNAs with altered levels gradually
changing within the disease progression, suggesting that circulating miRNAs
may be new candidate molecular markers for monitoring of the disease.
This work was supported by the grant NT13847-4 from the Ministry of Health
of the Czech Republic. 
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IN VITRO CULTURE OF BM CELLS OF MDS PATIENTS AND CYTC POLY-
MORPHISMS CAN PREDICT THE IN VIVO HEMATOLOGICAL RESPONSE
OBSERVED DURING IRON CHELATION THERAPY WITH DEFERASIROX
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P. Niscola4, M. Crugnola5, A. Poloni6, M.T. Voso7, S. Fenu8, A. Pelizzari9,
F. Salvi10, D. Gioia10, E. Masiera10, E. Balleari3, G. Saglio1, F. Frassoni2
1Dept of Clinical and Biological Sciences, University of Turin, Orbassano, 2stem
cell laboratory, G. Gaslini Institute, 3dept of Internal Medicine, University of
Genova, Genova, 4S. Eugenio Hospital, Rome, 5University of Parma, Parma,
6University of Ancona, Ancona, 7University “Cattolica”, Roma, 8San Giovanni
Hospital, Rome, 9University of Brescia, Brescia, 10SS Arrigo e Biagio Hospital,
Alessandria, Italy
Background: Several studies showed that iron chelation therapy (ICT) can
induce hematological improvement and transfusion independence in a signif-
icant percentage of MDS patients. However, we do not have clinical or biological
parameters to identify patients with high probability of such hematological
response. 
Aims: The aim of the study was to identify either a molecular marker and/or
an in vitro assay to predict in vivo hematological improvement to deferasirox
treatment. 
Methods: 22 MDS patients from 9 Italian Centers were enrolled in the study.
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Five were RA, 4 RARS, 8 RCMD, 4 RAEB I, 1 CMML. In 6 of them ICT induced
RBC transfusion independence during the first 6 months of therapy, one expe-
rienced hematological improvement but he stopped therapy after few months
for progression. 
BM samples were collected from 22 patients before deferasirox treatment and
during follow up. BM cells were incubated with deferasirox 50 micromolar for
12 hrs and tested for colony formation in semisolid culture medium. In addition,
different mitochondrial genes, including COX1, COX2 and CytB were
sequenced in all the patients enrolled. 
Results: In 8 out of 22 patients (3 RA, 2 RARS, 2 RCMD, 1 CMML) the in vitro
incubation with deferasirox resulted in a significant increase of colonies (BFU-
E, CFU-GM and CFU-GEMM). (mean value of BFU-E: 9±4 before incubation
and 19±11 after incubation). Interestingly, 6 of these 8 patients who showed an
“in vitro” response experienced transfusion independence after in vivo treatment
with deferasirox. The responders continued to maintain the “in vitro response
“ throughout subsequent analysis during the follow-up. The other two 22 “in
vitro responder” could not be evaluated for in vivo response. 
By contrast patients who did not respond in vitro to deferasirox did not reduce
the transfusion requirement. In parallel we analyzed mtDNA in BM MNC cells
and we found a strict association between two polymorphisms of CytB (14766
and 15326) and the hematological response to deferasirox therapy. 
Summary and Conclusions: The hematological improvement during
deferasirox therapy in MDS patients can be predicted by colony assay after in
vitro incubation with deferasirox. Mitocondrial gene polymorphisms seems to
be associated with hematological response. Several other patients are under
evaluation and may confer further solidity to this correlation. At the same time,
new studies may shed new light on the mechanism of deferasirox activity.
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MUTATIONAL PROFILE IN MYELODYSPLASTIC SYNDROMES BY HIGH-
DEPTH NEXT GENERATION SEQUENCING AND CLINICAL RELEVANCE
M.T. Cedena1,* R. Ayala1, I. Rapado1, J. Martínez-López1
1Hematology, H. 12 Octubre, Madrid, Spain
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of clinical entities. Cytogenetic abnormalities are an important hallmark of prog-
nosis, but they are only present in 30-50% of patients. New technologies, such
as next generation sequencing (NGS), have found somatic mutations in a con-
siderable number of patients. 
Aims: To optimize the technique of high-depth NGS in our center, to compare
our preliminary results with the main previously published outcomes and to
define their clinical significance in SMD patients. 
Methods: We analyzed the mutational profile and copy number variation (CNV)
of 86 MDS patients, using the Ion Torrent Proton (Life Technologies) system
for NGS. We selected a library of 35 genes related to myeloid pathologies. An
optimal depth of coverage, median about 2000, and uniform sequence coverage
(92%) were reached, contributing to a high sensitivity. Additionally, clinical char-
acteristics were considered: sex, age, WHO classification, cytogenetic risk,
IPSS-R, and outcome. 
Results: Eighty six MDS patients, median age: 76 (range: 44-90), were select-
ed. The diagnosis, according to WHO classification, were: RA (4), RARS (9),
RCMD (32), RAEB1 (13), RAEB2 (11), MDS associated with isolated del5q (2),
CMML (12), and MDS/AML 20-30% blasts (3). Very low, low, intermediate, high
and very high risk categories according to IPSS-R were found in 23, 26, 11, 9,
and 15 patients, respectively. The median follow-up time was 12 month (range:
1-50). A total of 163 somatic mutations were found in 76 out of 86 patients
(88%). The more frequent mutations were: TET2 (21%), SF3B1 (19%), ASXL1
(15%), TP53 (13%), DNMT3A (13%), JAK2 (13%), RUNX1 (9%), EZH2 (8%),
ZRSR2 (7%), IDH1 (7%), CBL (6%), MLL (6%), IDH2 (6%), ETV6 (6%) and the
remainder had frequencies of ≤5%. The results are very similar to those than
have been previously published. CNV analyses showed alterations, gains or
losses of copies, in 65 out of 86 patients (76%). HRAS, involved in regulating
cell division, the erythroid transcription factor GATA1 and the transcriptional
regulator ATRX presented gains in an appreciable proportion of patients, 28%,
23% and 20%, respectively. In contrast, genes, such as KIT and TET2, pre-
sented losses of copies in 16% and 15% of patients. Considering the clinical
characteristics, SF3B1 mutations were associated to WHO classification and
IPSS-R; and TP53 mutations were associated to cytogenetic risk and to IPPS-
R. In univariate analysis, cytogenetic risk, IPSS, IPSS-R, WHO classification
and presence of TP53 mutations were associated with shorter survival. Patients
with TP53 mutations had a significantly poorer overall survival than those with-
out the mutation (median 7 m versus 38 m; P=0.001). In multivariate analysis,
only TP53 remained the independent prognostic factor for overall survival
(HR=5.2; 95% CI: 2.0-13.5; P=0.001).
Summary and Conclusions: Taking into account mutations and CNV, and using
methods of high-depth NGS, more than 95% of MDS patients present genetic
abnormalities. TP53 mutations, that were closely associated to high risk cytoge-
netic and poor prognosis categories of IPSS-R, remained the independent prog-
nostic factor for overall survival. In conclusion, high-depth NGS seems to be a
promising tool to improve our understanding of the genetic alterations in SMD in
order to consider them in future algorithms for diagnosis and prognosis.
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TS, MTHFR ANDxRCC1 GENETIC VARIANTS AFFECT THE CLINICAL
COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK
F. Loscocco1,* G. Visani1, E. Giacomini2, A. Ruzzo2, M.T. Voso3, E. Fabiani3,
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Background: Myelodysplastic syndromes (MDS) are hematologic neoplasms
characterized by ineffective hematopoiesis and an increased risk of transfor-
mation into acute myeloid leukemia. The pathogenesis and the outcome of
MDS is thought to evolve from accumulation and selection of specific genetic
or epigenetic events. We hypothesized that genetic variants in DNA repair, syn-
thesis or methylation genes may affect the clinical course of MDS patients.
Aims: To investigate the prognostic value of genetic polymorphisms in BER
system, DNA synthesis and folate-metabolizing genes on survival of MDS
patients.
Methods: We genotyped 113 MDS patients, 54 with IPSS low/int-1 receiving
only best supportive care (BSC) (low risk group) and 59 with IPSS int-2/high
treated with azacitidine (high risk group), for the following polymorphisms:
xRCC1 194 and 399, xRCC3 241, TS5’-UTR (2R/3R and G/C) and 3’-UTR
(6bp+/6bp-), MTHFR 677 and 1298, APE1 148. Genomic DNA was analyzed
by High Resolution Melting assay and restriction digests of PCR products.
Overall survival (OS) was calculated using the Kaplan-Meier estimate proba-
bilities, and differences between survival curves were analyzed by the log-rank
test. The association between genetic variants and survival was assessed using
stepwise logistic regression model.
Results: For all target genes, the distribution of genotypes was consistent with
the Hardy-Weinberg equilibrium. The median period of observation of patients
was 27 months for low risk group and 13 months for high risk group. In the low
risk group,xRCC1 399 GG [Hazard ratio (HR)=4.65; p=0.05], TS3’-UTR -6/-6
(HR=7.07; p=0.02), TS5’-UTR 2R/3G, 3C/3G, 3G/3G (HR=11.44; p=0.02) and
MTHFR 677 TT (HR=67.12; p=0.0001) variant alleles were associated with a
statistically significant adverse clinical outcome, if compared to the reference
groups. Interestingly, when we subsequently analyzed the association between
the genetic variants and OS in the high risk group, we found that 3 out of the 4
variants associated with an adverse outcome in the low risk group were still
significantly associated to lower survival even in the high risk group [XRCC1
399 GG (HR=5.71 p=0.002),MTHFR 677 TT (HR=8.58 p=0.0001), TS3’-UTR
+6/+6 (HR=0.097 p=0.004)]. Finally, we performed an exploratory analysis to
investigate the combined effect of the unfavorable genotypes on survival. In
the low risk group, the 3-year OS was 33% for those patients with ≥2 variant
alleles, as compared to 62.5%, and 100%, respectively, for those with 2 or 0/1
variant alleles. The predictive role of the combination of the adverse genotypes
on survival was confirmed also in the high risk group, suggesting that patients
with a higher number of genetic polymorphisms had a shorter survival. Inter-
estingly, treatment with azacitidine conferred a survival advantage to patients
with unfavorable genetic variants, resulting in the absence of a survival differ-
ence between low-risk patients treated with BSC only and high-risk patients
treated with azacitidine.
Summary and Conclusions: These data suggest, for the first time, that genetic
variants in TS, MTHFR andxRCC1 genes could independently modulate OS of
both low and high risk MDS patients, representing a possible new prognostic
marker able to provide guidance for clinical management of MDS patients.
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SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN
MDS AND AML PATIENTS
V. Guadagnuolo1,* C. Papayannidis1, I. Iacobucci1, M.C. Fontana1, G. Simonetti1,
A. Padella1, E. Imbrogno1, S. Paolini1, M.C. Abbenante1, S. Parisi1, C. Sartor1,
E. Ottaviani1, A. Ferrari1, M. Delledonne2, M. Malagola3, C. Filì3, D. Russo3
M. Cavo1, G. Martinelli1
1Department of Hematology and Medical Sciences “L. and A. Seràgnoli”,
Bologna University, Bologna, 2Department of Biotechnology, Verona, 3Unit of
Blood Diseases and Cell Therapies, Brescia, Italy
Background: Myelodysplastic syndromes (MDS) and acute myeloid leukemia
(AML) are a group of diseases of the elderly that initiates in a hematopoietic
stem cell and are characterized by clonal hematopoiesis and uncertain prog-
nosis, mostly due to cytogenetic background. In both diseases, 5-Azacitidine
(5-Aza) has been successful, inducing prolonged survival and delayed AML
evolution.
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Aims: To identify the genes mostly predictive of treatment response we use high-
throughput genomic analysis (SNP arrays and/or NGS-RNA-seq and/or NGS-
WES and/or GEP) in azacitidine-sensitive and resistant MDS/AML patients. Fur-
thermore, we sought to correlate the specific alterations with clinical outcome.
Methods: The high-density CytoScan HD Array (Affymetrix, Inc) includes 2.67
million markers for copy number analysis, with 750,000 SNP probes, and 1.9
million non polymorphic (based on Copy Number Variants, CNV) probes for
comprehensive whole-genome coverage. The results obtained by SNP Array,
were analyzed by Chromosome Analysis Suite (ChAS) v1.2 (Affymetrix Inc.):
using this software it is easy to distinguish between aberrations and artifacts,
moreover it let to discover which genes are involved in the disease and their
type of lesion (e.g. loss, gain, loss of heterozigosity, allelic imbalance, high
copy gain, homozygous copy loss). We used also another important software,
which is Nexus Copy Number™ v7.5 (BioDiscovery): it present the same fea-
tures of ChAS, but it also allows to compare two or more group of patients with
a statistical relevance.
Results: We treated 246 adult patients with MDS or AML: 214 patiens were
AML and 32 were MDS with a median age of 59 and 70 years, respectively.
Forty-five pts were treated with 5-Aza (32 MDS/13 AML), while 201 AML were
treated with conventional chemotherapy. Forty-five MDS/AML patients were
treated with at least one complete cycle of 5-Aza (75 mg/sqm/daily). SNP arrays
was done in 22/45 (49%), 13 pts were defined “insensitive/resistant”. Macro-
scopic CNAs affecting a complete chromosome or its arms were detected in 5
of 22 pts (23%), while classical cytogenetic was able to detect only two cases
of trisomy 8 (9%), suggesting superiority of SNPs array for CNAs identifications.
Chromosomic aberrations disease-related are more statistically frequent on
patients “insensitive” versus patiens “sensitive” (64% vs 35%) (p≤0.01). More-
over we found that from the median of chromosomic alterations lenghts (in kbp)
the group of “insensitive” MDS/AML patients to 5-Aza therapy present more
losses than “sensitive” ones. By Nexus Copy Number software, we identify 137
genes highly differentially gain (SIRPB1 and KIT with p ≤0.05) or loss (SIRPB1,
LCE1C, BCAS1, EXD3 with p ≤0.05) or LOH between “insensitive” versus “sen-
sitive” to 5-Aza (p ≤0.05). Among these genes, we focused on SIRPB1 (cytoband
20p13, 56Kbps), since it was loss on 14/22 (64%) “insensitive” pts (p=0,023)
and gain on 7/22 (32%) “sensitive” ones (p=0,0324), respectively. SIRPB1 com-
mon deletion region length is 27 kbps and the common amplified region length
is 30 kbps. By NGS-WES we analyzed 35/214 (16%) AML samples at diagnosis.
We found mutations in SF3B1, NPM1, CBL, RUNX1, BCOR, KIT, GATA2, IDH2,
KDM6A, KIAA1324L, PRIM2, RRN3, APOBR and again in SIRPB1 an heterozy-
gous missense variant (rs45545343; p. H/D).
Summary and Conclusions: We conclude that SIRPB1 is a promising marker
of response in patients with myelodysplastic syndromes and acute myeloid
leukemia treated with 5-Azaciditine.
Acknowledgement: Celgene, ELN, AIL, AIRC, progetto Regione-Università
2010-12 (L. Bolondi), FP7 NGS-PTL project.
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RPS14 EXPRESSION IN MYELODYSPLASTIC SYNDROME WITHOUT 5Q
DELETION
K. Quiroz 1,*C. Guillén 2R. Ayala 1J. Martínez 1
1Haematology, Hospital 12 de Octubre, 2Haematology, Hospital de Móstoles,
Madrid, Spain
Background: Reduced RPS14 expression in myelodysplastic syndrome
(MDS) with 5q deletion and the better prognostic of these patients are well
demonstrated, however the role of lower expressed RPS14 in MDS without 5q
deletion remains unknown.
Aims: We studied RPS14 expression in MDS patients without 5q deletion and
the role it plays in their prognosis and survival.
Methods: This study included bone marrow samples of 87 patients, 58 MDS
patients (15 with 5q deletion and 43 without 5q deletion), 4 myelomonocytic
leukemia, 12 chronic myeloproliferative disorders, 10 acute myeloid leukemia
patients and 3 healthy donors; between years 2000 and 2014. We used the
ABI PRISM® 7900HT (Applied Biosystems) detection system to quantify RPS14
expression. Statistical analysis was performed using the Statistical Package
of Social Sciences (SPSS 15.0). Survival was estimated by the Kaplan-Meier
method and compared with the log-rank test.
Results: Myelodysplastic syndrome and chronic myelomonocytic leukemia
patients showed RPS14 lower expression than acute myeloid leukemia, chronic
myeloproliferative disorders patients and healthy donors (p=0,08). MDS
patients with 5q deletion showed lower RPS14 expression when compared to
MDS patients without 5q deletion. The 56% (24/43) of MDS without 5q deletion
shown low RPS14 expression. The mean follow-up of the patients was 51
months (0,1-172). There was no significant difference for overall survival rate
between RPS14 lower and normal expression patients with MDS without 5q
deletion. Patients in Intermediate-1 group with RPS14 lower expression, had
longer overall survival than Intermediate-1 patients with RPS14 high expression
(81% vs 50%).p=0.08 (Figure 1).
Summary and Conclusions: Lower expression of RPS14 in MDS without 5q




AUTOPHAGY LEVEL WAS ABNORMAL IN PATIENTS WITH MYELODYS-
PLASTIC SYNDROMES
H. Wang1,* L. Guo1, Z. Shao1
1Hematology, General Hospital, Tianjin Medical University, Tianjin, China
Background: Myelodysplastic syndromes (MDS) are clonal hematopoistic
stem/preginitor cells disorders with cytopenia, myelodysplasia, ineffective
hematopoisis, and high risk transform to acute myeloid leukemia (AML). The
majority of patients are hepercelluar bone marrow while decreased peripheral
blood cells.
Aims: To explore the change of autophagy and its significance in the myelodys-
plastic syndrome (MDS) patients by detecting the expression level of Beclin 1,
mTOR, LC3 in bone marrow mononuclear cells (BMNC).
Methods: Thirty-eight patients with MDS and 26 non-malignant anemia
patients were enrolled in this study. The iron content of BMNC was detected
by iron staining. The level of reactive oxygen species (ROS) was detected by
flow cytometry. The quantity of autophagic vacuoles were detected by trans-
mission electron microscopy (TEM) and monodansylcadaverine (MDC) stain-
ing. The LC3 protein positive cells were counted by Immunofluorescence
assays. The expression of Beclin 1, LC3A, mTOR mRNA were measured by
real time PCR. The expression of Beclin 1 and LC3 proteins were detected by
Western blotting.
Results: (1) The iron particles appeared more in MDS patients when viewed
under a microscope and the intracellular iron content of MDS patients was also
higher than that of controls. (2) The ROS level of MDS patients was significantly
higher than that of controls. (3) The autophgic vacuoles of double membrane
that surrounds lysosomes appeared in MDS patients. (4) The percentage of
MDC positive cells was significantly higher in MDS patients than that of controls.
(5) The percentage of LC3 protein cells was also increased in MDS patients
(6.13%±1.03% vs 1.5%±0.58%, P<0.05. (6) The expression of Beclin 1, LC3A
mRNA in low-risk and intermediate-1 MDS were higher compared with controls
(3.61±3.02 vs 1.55±1.03 and 6.56±3.97 vs 1.21±0.95 respectively, both P<0.05.
The expression of mTOR mRNA was down-regulated in low-risk and interme-
diate-1 MDS compared with controls (0.39±0.37 vs 1.50±1.03P<0.05. There
were no significant difference in expression of Beclin 1 and mTOR mRNA
among the intermediate-2 and high-risk MDS and the controls. (7) The expres-
sion of Beclin 1 protein and LC3B were higher in MDS patients than that of
controls. 
Summary and Conclusions: The enhanced autophagy in low-risk and inter-
mediate-1MDS might be considered as a cell protective mechanism. The rel-
atively defective autophagy in intermediate-2 and high-risk MDS might con-
tribute to its progress to AML.
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Background: Myelodysplasic Syndrome (MDS) is considered a clonal
hematopoietic stem cell (HSC) disease, whereby the existence of changes in
these type of cells, besides being based on the aetiology of the disease can
also affect the progression to AML. Recently, a small subset of these cells was
identified with unique ability to auto renovate and differentiate into different lin-
eages of cancer cells that comprise the tumour, the cancer stem cells (CSC).
These cells have been identified in many types of cancers, in particular cancer
of the brain, breast, prostate, colon and pancreas, as well as in multiple myelo-
ma and leukaemia (leukemic stem cells, LSC). Moreover, the development of
MDS is accompanied by immune changes and production of antibodies and
cytokines, such as IL-6 and TNF-α. However, the evaluation of these cytokines
in the LSC and HSC has not been examined in patients with MDS.
Aims: To assess the relevance of IL-6 and TNF-α in HSC and LSC character-
ization, in MDS patients, in order to identify new prognostic and predictive mark-
ers as well as new therapeutic targets.
Methods: Analysis of clinical and analytical data of 102 patients with de novo
MDS. The distinction between HSC and LSC was performed by flow cytometry
using a panel of monoclonal antibodies conjugated with fluorescent probes in
the following combinations: CD34/CD117/CD123/GlP and CD34/CD11/CD123/IL-
6/TNF-α. All data were analysed using statistical tests (p<0,05).
Results: The sample consisted of 102 MDS patients with median age of 74 years
(22-89) and with a ratio Male/Female 0.8. The MDS subtypes according to the
WHO are: refractory cytopenia with multilineage dysplasia (RCMD) (n=52), refrac-
tory cytopenia with unilineage dysplasia (RCUD) (n=12), refractory anemia with
excess blasts (RAEB) -1 (n=8), RAEB-2 (n=8), refractory anemia with ringed
sideroblasts (RARS) (n=6), 5q- syndrome (n=4) and chronic myelomonocytic
leukemia (CMML) (n=12), with IPSS: low (n=37), intermediate-1 (n=39), inter-
mediate-2 (n=10) and high (n=1). Eleven patients progressed to AML: 7 patients
with RAEB-2, 2 patients with RCMD, 1 patient with RAEB-1 and another with
CMML. In our study we noticed an increase statistically significant in CD34+ cells
in MDS patients in more advanced stages (RAEB-2), as well as in cells that co-
express CD117, which can be related to the evolution of these patients to AML.
Furthermore, the increase in CD34+/CD117+ cells observed in patients with
RCMD may identify those who have a higher risk of leukemic transformation.
Analysis of stem cell also allowed the identification of two groups of cells, one
phenotypically ‘normal’ (HSC) and other with neoplastic characteristics (LSC)
that differentially express the inflammatory cytokines IL-6 and TNF-α in the several
MDS subtypes studied. The expression of IL-6 was observed in the HSC in RAEB-
2 and in the LSC in refractory thrombocytopenia subtype. TNF-α was also
observed in the HSC in CMML and in the LSC in RAEB-2 subtype. The presence
of both cytokines in patients with RAEB-2 (p <0.05) is marked, although IL6 pre-
dominates in HSC and TNF-α in LSC. On the other hand, the presence of stem
cells with the phenotype CD34+/ CD117+/IL-6+ may influence the progression to
AML (p <0.05), and is also associated with a decreased overall survival (p <0.05).
Summary and Conclusions: These results suggest the importance of IL-6
and TNF-α in distinguishing two groups of hematopoietic stem cells in MDS
patients, as they could influence the development and progression of the dis-
ease, as well as patient survival.
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DIAGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA
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Background: The diagnosis of chronic myelomonocytic leukemia (CMML)
relies on cytology and cytogenetics, and both play an important role in the prog-
nosis of this entity. Recently, other complementary tests such as flow cytometry
(FCM) have been incorporated in clinical practice and become especially rele-
vant in the diagnosis of doubtful cases.
Aims: The aim of this study was to analyze the discrepancies of the percentage
of monocytes and the sum of promonocytes plus blasts (PM+BL) between
cytology and FCM in CMML
Methods: In this study we carried out a retrospective analysis of the discrep-
ancies between the percentage of monocytes and the sum of promonocytes
plus blasts (PM+BL) at diagnosis, in cytological and FC bone marrow aspirate
reports of 17 CMML cases diagnosed at our institution between 2010 and 2014.
The diagnosis was stabilized according to the 2008 WHO classification. In order
to identify myeloid precursors, promonocytes, monocytes, dysplastic changes
in the monocytic population, and granulocytic maturation patterns by FCM, a
panel with the following antibodies in 2 tubes was used: CD16/CD13/CD34/
CD33/CD117/CD11b/CD45/HLA-DR and CD36/CD64/CD34/CD33/CD14/
CD11b/CD45/HLA-DR. The acquisition of cells was performed in a flow cytome-
ter BD FACSCanto II™ (BD Biosciences) and data were analyzed using Infini-
cytTM program (Cytognos). Statistical analysis was performed using SPSS
version 21.0. The interclass correlation coefficient (ICC) was used to assess
agreement between the 2 diagnostic methods and was interpreted as follows:
excellent ICC >0.9; very good ICC 0.7-0.9; good ICC 0.5-0.70; moderate ICC
0.3-0.50, poor ICC <0.30
Results: Table 1 summarizes patient’s characteristics, as well as the percent-
ages of monocytes and BL+PM assessed by cytology and FCM. It is worth not-
ing that most cases (15/17) were classified as CMML-1, and in the only 2
patients with CMML-2, the percentage of BL+PM detected by FCM was below
10%. FCM detected dysplastic alterations in all cases, being the most prevalent:
hipogranulation in mature neutrophils, abnormal maturation patterns in neu-
trophils, increased percentage of monocytes, and altered expression of mono-
cytic markers such as CD13 and CD33. We failed to find statistically significant
differences in the percentage of BL+PM detected by cytology or FCM respec-
tively (4 vs 2.8 P=0.2) neither in the percentage of monocytes (9 vs 10.7; P=0.2).
In addition, the concordance between the percentages of BL+PM (ICC=0.453)
and monocytes (ICC=0.488) by cytology and FCM was moderate.
Table 1. Patients characteristics and percentages of monocytes and
BL+PM assessed by cytology and flow cytometry.
Summary and Conclusions: FCM supported the diagnosis of CMML in all
our cases, and therefore should be implemented specially in unclear cases by
cytology. We could not find adequate concordance between cytology and FCM
in the determination of the percentage of BL+PM, and monocytes. Cytology
should still be considered the gold standard for the classification of CMML-1
and CMML-2 according to the 2008 WHO criteria.
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MOLECULAR PROFILE OF TRANSFORMED AND NON TRANSFORMED
INDIAN PATIENTS WITH MYELODYSPLASTIC SYNDROMES 
R. Chaubey1,* S. Sazawal1, M. Mahapatra1, S. Chhikara1, R. Saxena1
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Background: Myelodysplastic syndromes are characterized by bone marrow
failure and a risk of progression to acute leukemia. So far, blast counts and
cytogenetic abnormalities are known as major determinants of the risk for trans-
formation. Molecular pathogenesis and the molecular basis for its progression
to AML remain largely undefined. Although some case reports are available
but no molecular study from India is available on the transformed MDS cases.
Probably this is the only study with largest transformed MDS cases from Indian
subcontinent.
Aims: This study was an attempt to look for the molecular changes that may
be associated with transformation in MDS patients by comparing the molecular
profile of transformed and non transformed cases.
Methods: Both DNA and RNA were extracted from mononuclear cells from
patients Blood/ BM. Conventional cytogenetics was used for the detection of
karyotypic abnormalities. Nested PCR was used for the screening of RAS gene
mutations and RT-PCR was used to detect FLT3-ITD mutation and hTERT
expression respectively. Telomerase activity was measured by PCR-ELISA-
TRAP Assay. Methylation specific PCR was used to detect the methylation sta-
tus of TSGs (p15, SOCS-1, FHIT & Calcitonin).
Results: A total of 100 MDS patients were studied, progression was observed
in twenty one patients and no progression was found in 79 cases. Of the trans-
formed cases, two patients progressed from RA to AML, 10 patients from
RAEB2 to AML, 5 patients with RAEB-1 to AML, 1 patient with RAEB-2 to ALL,
2 patients with RA to RCMD and 1 patient with RAEB2 with del 5q to MF. The
median time of progression was 15 months (Range 1-16 months). Of these
progressed patients 6 were females and 15 were males. Median age of the
transformed patients was 48 years (range : 9-77 years) whereas for non trans-
formed 48 years (range :11-44 years).In non transformed patients favorable
cytogentics was more evident than transformed patients (p <0.03).FLT3 muta-
tions was not found in any patient or suppressor genes. The frequency of RAS
mutations were significantly higher in transformed patient as compared to non
transformed cases. Telomerase activity was significantly increased in trans-
formed patients (p<0.009). Of all the four tumor suppressor genes studied, fre-
quency of hypermethylation was significantly increased for the three genes in
transformed patients i.e., p15 (p<0.02), SOCS 1 (p<0.02), FHIT gene (p<0.02).
After multivariate analysis of all the factors, p15INK4b gene methylation was
found as an independent predictor for progression of disease (HR 5.15, 95%
CI, 1.64-16.1 p=0.005) (Figure 1).
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Figure 1. Frequency (%) of mutations within different WHO subtypes of
MDS.
Summary and Conclusions: Molecular profiling of the Myelodysplastic Syn-
domes may give the information about the transformation and prognosis of the
patients. Gene methylation may be one of the important factors in the process
of transformation. 
Myelodysplastic syndromes - Clinical
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MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHRO-
POIESIS STIMULATING AGENTS : EVALUATION OF ERYTHROPOIETIC
ASPECTS AND ANALYSIS OF RESPONSE
C. Cerchione1,* O. Vitagliano1, L. Simeone1, A.E. Pareto1, I. Soriente2,
A.M. D’Arco2, P. Danise2, F. Alfinito1, F. Pane1
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Nocera Inferiore (SA), Italy
Background: Erythropoiesis stimulating agents (ESAs) are the frontline treat-
ment in lowriskanemic MDS patients and an employment of this therapy in the
earlier stage of the disease can delay the need for RBC transfusion, hypothet-
ically by slowing the disease course. It is matter of debate whether the clinical
response is a result of proliferation and maturation of the dysplastic clone or
stimulation of residual normal erythropoiesis by ESAs.
Aims: Macrocytosis is one of the cytological hallmarks of dyserithropoiesis
in MDS : an analysis of the erythropoietic response to ESAs therapy in a
cohort of anemic non trasfusion-dependent MDS patients, enrolled in a ret-
rospective register, RECAMDS, subgroup of Italian MDS register, was per-
formed.
Methods: 137 patients, treated with standard-dose ESAs, have been retro-
spectively analyzed (Table 1). Data analysis was performed, according to IWG
2006 criteria, at the baseline, after three and six months of continuous treat-
ment, with a subanalysis of the patients according to WHO and R-IPSS risk
stratification. ESAs treatment was started at mean Hb concentration of 9.5
g/dl, mean serum EPO concentration : 41mU/L, after a mean time from diag-
nosis of six months (r.1-118).
Results: Overall response rate (ORR) was 83% (114/137) and no difference
among WHO and IPSS subgroups was found :76% achieved response after
three months of treatment, while other 7% after six months. 2 patients with sta-
ble disease (non responders IWG), in which treatment was continued, achieved
response after 9 months. In the macrocytic-responders group 87% exhibits
again macrocytosis after 3 months, while 13% become normocytic. In the nor-
mocytic-responders group 92% exhibits again normocytosis, while 4/52 (8%)
become macrocytic : in these 4 patients after three months there was a con-
temporary worsening in neutropenia and thrombocytopenia, with transfusion-
dependence, regarded as first signs of progression of disease. Non responders
were 23/137 (17%) : in the macrocytic-non responders group 89% exhibit again
macrocytosis after 3 months, while 11% become normocytic; in the normocytic
group 80% exhibits again macrocytosis, while 20% become normocytic : of
these 74% become transfusion-dependent at 6 months (median time to trans-
fusion 12 months : range 1-23).
Tablel 1.
Summary and Conclusions: These preliminary data can suggest that, in the
majority of MDS patients responsive to ESA treatment, the increase of hemo-
globin concentration occurs mainly stimulating erythroid production in MDS
clones; in the minority of patients probably it happens recruiting residual poly-
clonal erythropoiesis. It is interesting to note that stimulating effects of ESAs
last even when the expression of dysplasia progresses.
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PLASTIC SYNDROMES: RESULTS FROM A PROSPECTIVE STUDY
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P. Ghione2, R. Ghio1, F. Goretti4, E. Molinari1, O. Racchi5, M. Scudelletti6,
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Background: Myelodysplastic syndromes (MDS) are typical diseases of the eld-
erly. The most frequent symptom is anemia. Both age and comorbidities have a
relevant negative impact on the clinical outcome. In the case of a concomitant
cardiac disease, the presence of anemia and its related iron overload, frequently
observed in transfusion-dependent MDS pts, synergistically act with a harmful
effect on the probability of survival. It is not a case that cardiac disease is the more
common single comorbidity observed in the majority of MDS cohorts. Erythro-
poiesis stimulating agents (ESAs) have been demonstrated to reduce the trans-
fusion requirements in pts affected by MDS with low/Intermediate-1 IPSS. Anemia
appears to be strongly associated with cardiovascular morbidity and mortality.
Aims: Aim of our study is to investigate of early treatment with rHuEPO alpha
may reverse cardiac remodeling, improve Ejection Fraction (EF) and reduce
cardiovascular morbidity in “lower risk” MDS pts.
Methods: From January 2013 to January 2015, 40 MDS pts were included in
a prospective observational multicentric study; 15 females and 25 males, of
mean age 78 (range 61-92). According to the WHO 2008 classification, mor-
phological MDS diagnosis were as follows: 17% Refractory Anemia (RA), 55%
Refractory Cytopenia with Multilineage Dysplasia, 8% Refractory Anemia with
Ringed Sideroblasts, 2% del 5q syndrome, 17% Refractory Anemia with excess
of blasts-1. All pts had PSS low or int-1 risk and epo serum levels <500
mU/L.ESAs treatment was allowed when hemoglobin (Hb) was lower than 10.5
g/dL. All pts were analyzed with echocardiography before starting ESAs and
every 6 months during the treatment. All echocardiography measurements were
carried out according to the recommendations of the American Society of
Echocardiography by un external investigator. Left ventricular mass (LVM) was
calculated according to the Devereux formula and indexed to height. Left ven-
tricular hypertrophy (LVH) was defined by a LVM index >47 in women and >50
in men. We also analyzed comorbidity by CIRS and cardiovascular risk factors.
All pts were treated with rHuEPO alpha 40000 U weekly.
Results: At baseline all patients were transfusion-free and with mean Hb con-
centration of 9.66 g/dl. The rate of erythroid response to rHuEPO according to
IWG criteria 2006 was 54%. No thrombotic events was eported. One or more
comorbidity of any grade of severity was seen in 90% of pts at diagnosis. The
more common comorbidity was cardiac (62,5%). Cardiovascular disorders were
more frequent among older subjects (52% in >75y vs 30% in <75y), and among
males. The median EF at baseline was upper than 55% and half pts had normal
LVM. In 90% of pts with erythroid response EF was stable, in 10% improved
and in 0% decreased while LVM was reduced in 35% of pts. The EF improve-
ment and decrease of LVM was more evident in pts with cardiovascular comor-
bidities. None pts among “responders group” had cardiac comorbidity worsen-
ing ooor hospitalization. Anemia improvement and FE increase were associated
with an imanananprovement of quality of life (QOL). The median observation
time was 10 months (range 1-24). During the study period, 4 patients (10%)
have died, respectively: 2 sepsis, 1 hearth failure, 1 leukemia evolution.
Summary and Conclusions: rHuEPO alpha treatment is effective and safe also
in pts with cardiac comorbidities. In responders “lower risk” MDS pts, early treat-
ment has been shown to improve FE and reverse cardiac remodeling with con-
seguence a reduction of cardiovascular risk/ hospitalization and improvement
qment men uality of life. In pts with cardiac comorbidities the benefit of early treat-
ment was more evident. The aim of our ongoing prospective study is to demon-
strate the relationship between Hb levels, FE and LVM, cardiovascular events
and mortality. This correlation is more evident in patients with cardiac comorbidi-
ties. Further larger studies are warranted to confirm these data and to evaluate if
rHuEPO treatment could be worthwhile in term of cost-efficacy in the very old pts.
E1209
ACUTE MYELOID LEUKEMIA PROGRESSION IN ARGENTINEAN
PATIENTS WITH MYELODYSPLASTIC SYNDROMES.
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Background: At least, one third of patients with Myelodysplastic Syndromes
(MDS) develop Acute Myeloid Leukemia (AML) during the follow-up depending
on diverse prognostic factors and their respective group of risk. Once the leukemic
evolution occurs, the outcome of patients is very poor with short survival.
Aims: To analyze prognostic variables and scoring systems regarding leukemic
evolution in Argentinean population. Also, to test each category of risk trying to
access differences in terms of overall survival in patients with or without
leukemic evolution.
Methods: This is a multicentric retrospective study of 966 MDS patients (532
patients belonging to the Argentinean MDS Registry sponsored by de Argen-
tinean Society of Hematology and the remaining to a previous multicentric
study) diagnosed from 1981 to 2014. Patients were classified following FAB
and WHO criteria and 59 patients presented with secondary MDS. The median
age was 66.7 (14-95) years with 74.6% above 60 years, a male/female
(546/420) ratio of 1.3. During the follow-up (median: 18.3 months), 424 (43.9%)
died and 211 (25%) evolved to AML. BM transplanted patients were censored
till the moment of the procedure.
Results: Age (limit of 60 years), percentage of bone marrow blast (0-2, 3-4, 5-
9, ≥10%), hemoglobin level (<8, 8-<10, ≥10 g/dL), platelets (<50, 50-100, >100x
1012 /L) and neutrophil count (limit of 800 /μL), cytogenetic group of risk (accord-
ing to the IPSS-R), and red blood cell transfusion requirements were significant
predictive variables for leukemic evolution (Kaplan-Meier and Long-Rank test,
p<0.05). FAB and WHO classifications and scoring systems (IPSS, IPSSR)
also allowed us to differentiate groups of risk for evolution to AML.
The majority of prognostic categories showed statistical differences when we
tried to ascertain if patient that evolve to AML depict differences in term of sur-
vival when compared with patients that do not evolve (Table 1). However, higher
blast counts, worst cytogenetic findings and, correspondingly, higher IPSS and
IPSSR groups of risk showed similar survival regardless their leukemic pro-
gression. Among patients who died during the follow-up, those patients that
previously evolved to AML showed lower age (p<0.001), hemoglobin level
(p=0.022), neutrophil (p<0.001) and platelet count (p=0.015), and higher blast
percentages (p<0.001)
Table 1.
Summary and Conclusions: Clinical parameters, age, classifications and the
applied scoring systems were useful tools to evaluate prognosis in our series
that showed a similar rate of leukemic progression to previous reports. Inter-
estingly, the survivals in patients with higher blast percentages, worst cytoge-
netic findings and, correspondingly, higher IPSS and IPSSR groups of risk were
similar between patients with or without evolution to AML.
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PULMONARY INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYN-
DROMES RECEIVING AZACYTIDINE TREATMENT
R. Latagliata1,* F. De Angelis1, M.L. De Luca1, I. Carmosino1, F. Vozella1,
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Background: Azacytidine (AZA) is a demethylating agent widely used in the
treatment of patients with high-risk Myelodysplastic Syndromes (MDS). Pul-
monary infections represent the most frequent complication in these patients,
however, their incidence, etiology and impact in the overall outcome during
AZA treatment are still unclear. A major problem in the characterization of infec-
tions in MDS patients receiving AZA treatment is represented by the low level
of clinical and microbiological documentation being most of patients managed
on an outpatient basis.
Aims: Aim of this study was to evaluate the incidence and clinical role of pul-
monary infections in a cohort of MDS patients receiving AZA treatment in our
Institute, where the availability of a dedicated hematological emergency ward
made their access and their infective diagnostic work-up homogeneous in the
presence of fever or other infective clinical signs. 
Methods: We retrospectively evaluated 86 MDS patients (M/F 52/34, median
age 70 years, range 41-82) treated with AZA at our Institution from 04/2009 to
01/2015. All patients received AZA cycles at standard dosage (75 mg/m2 for 7
days every 28 days) as outpatients. Microbiological work-up included blood
cultures, culture from other sites, galactomannan assay from serum and from
sputum/bronchoalveolar lavage. 
Results: The total number of AZA cycles was 988, with a median of 8 cycles
per patient (range 1-56 cycles). There were 41 episodes of lung infection
documented by chest CT in 32 patients (37.2% of patients and 4.1% of AZA
cycles). Based on the above diagnostic work-up, pulmonary infiltrates were
considered of fungal origin in 9 cases (21.9%), associated to bacteremia in
3 cases (7.3%) and of unknown origin in the remaining 29 cases (70.7%). As
to the time of occurrence of lung infections, 12 episodes were documented
in the first 2 cycles of AZA treatment (14% of 86 patients), 13 after the cycles
3-5 (13.3% of 71 evaluable patients), and the remaining 16 episodes beyond
the fifth cycle of AZA treatment (29.6% of 54 evaluable patients) (Figure 1).
Overall, a pulmonary fungal disease was documented in 6 of 165 (3.6%)
cycles 1-2, in 1 of 196 (0.5%) cycles 3-5 and in 2 of 627 (0.3%) cycles since
cycle 6 (p=0.001). Out of 32 patients who developed a pulmonary infection
25 (78%) interrupted the AZA treatment within 3 months from the infectious
episode due to deterioration of clinical conditions, hematologic disease pro-
gression and/or death, including 8 of 9 (89%) patients who developed a pul-
monary fungal disease.
Figure 1. Incidence of pulmonary infections according to AZA cycles.
Summary and Conclusions: In conclusion, pulmonary infections are a com-
mon complication in MDS patients receiving AZA treatment, and are often asso-
ciated to an interruption of AZA therapy. Pulmonary fungal infections are more
frequently observed early during the first cycles of treatment. It should be
defined if the poor outcome of patients who develop pulmonary infections during
AZA therapy is an epiphenomenon of an immunologic deterioration associated
to the hematologic disease progression or is independently related to the com-
plication. If confirmed in other experiences, the results of our study raise the
issue of the need of an antibacterial and/or antifungal prophylaxis particularly
during the first months of AZA therapy. 
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Xicoy Cirici5, J.C. Caballero Berrocal2, F. López Cadenas2, I. Rodríguez
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1Hematology department, 2Hospital Universitario de Salamanca, Salamanca,
3Hospital de la Ribera, Valencia, Spain, 4Hematology department, Hospital de
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Background: Anemia is one of the most frequent abnormalities detected in
hemograms and it can be the first sign of MDS, especially in the elderly patients.
Diagnosis of MDS when anemia is the only abnormality can be complicated,
so the diagnosis is delayed until the degree of anemia becomes severe (trans-
fusion dependency) and/or other cytopenias/blasts appears.
Aims: To analyze the impact on the diagnosis of MDS among anemic patients,
by systematically and prospectively reviewing all hemograms performed in 3
centers in Spain.
Methods: We performed a prospective study within 69 days (Dec 2012-March
2013). Ethic committee approved the protocol as an observational study. All
hemograms performed in the laboratories (137,453 hemograms) were
reviewed. Those with Hb level <12g/dL and/or MCV >100 fL were selected
(2,702 patients). Surgery and oncology departments patients or with a known
disease causing anemia were excluded. In the second step, a complete periph-
eral blood analysis was performed (reticulocyte count, peripheral blood smear,
Vitamin B12, folic acid, ferritin, renal, thyroid and hepatic function). The results
were reviewed with the clinical history and if no cause of anemia/macrocytosis
was found, the patient was referred to the haematologist (n=221).
Results: From 137,453 hemograms, we selected 211 candidates to MDS screen-
ing. 133 final diagnoses have been made (see Table 1), included 12 MDS. 23
patients have currently been investigated. In 117 patients, we could not complete
the study due to comorbidity/age >90 years (N=99) or death (N=18).
Table 1.
Summary and Conclusions: This prospective approach is a reasonable
screening procedure in the hematological laboratories and will probably allow
us to diagnose the more relevant causes of anemia including MDS, early, avoid-
ing delay in providing the patients with the necessary intervention.
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Background: In 2009, azacitidine (AZA) was registered in Europe for the treat-
ment of transplant-ineligible patients with high-risk myelodysplastic syndromes
(HR-MDS). Population-based studies assessing its effectiveness compared
with that of conventional care regimens (CCRs) in daily practice are lacking.
Aims: In this population-based study, we assessed the effectiveness of AZA
on overall survival (OS) in HR-MDS compared with that of two CCRs.
Methods: We identified 515 transplant-ineligible, WHO-defined MDS patients
diagnosed between 2008-2011 from the Dutch PHAROS MDS registry, which
encompasses ~40% of the Dutch population (31 centers) and is notified by the
nationwide Netherlands Cancer Registry. The PHAROS MDS registry includes
data on patient features at baseline, classification, prognostication, treatment,
response to treatment and survival. All cases were confirmed by bone marrow
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examination. Overall, 151 (29%) patients were lower-risk and 113 (22%) high-
er-risk by IPSS. In the remaining 251 (49%) patients, an IPSS score could not
be computed mainly due to unperformed cytogenetics. CCRs were defined as
best supportive care (BSC) only, including treatment with growth factors, and
intensive chemotherapy (IC). OS was measured from time to HR-MDS diagno-
sis, which was estimated by the Kaplan-Meier method and compared by the
log-rank test. Unstratified Cox proportional hazard models were used to esti-
mate the hazard ratio (HR). Hematological response was assessed according
to the revised IWG-MDS criteria (Cheson 2006). Grade 3-4 adverse events
(AEs) were graded by CTCAE v3.
Results: Of all 113 HR-MDS patients, 65 received AZA, 32 BSC only and 16
IC. As expected from a real-world population, patients who received BSC only
were older and had poorer ECOG performance status (ie, ≥2) than patients
who received AZA or IC. Their median age (range) was 77 (52-88), 74 (55-83)
and 66 (52-75) years, and 25%, 3% and 0% had an ECOG score ≥2, respec-
tively. After a median follow-up of 14.7 months, the median OS (95% CI) was
17.6 months (15.1 to 24.7) in the AZA group versus 9.1 months (3.5 to 14.3) in
the BSC only group (HR 0.60, p=.027; Figure 1A) and 19.0 months (4.8 to
25.3) in the IC group (HR 0.73, p=.321; Figure 1B). One-year survival (95% CI)
was 72% (59% to 81%) in the AZA group versus 38% (21% to 54%, p=.005)
and 75% (46% to 90%, p=.935) in the BSC only and IC group, respectively.
AZA and IC were given for a median (range) of 7 (1-26) and 2 (1-3) cycles,
respectively, and BSC only for a median of 3.9 (0.0-26.4) months. Responses
of CR, PR and mCR were seen in 12%, 3% and 15% in the AZA group, 38%,
0% and 31% in the IC group and 0%, 0% and 0% in the BSC only group,
respectively. Further, hematological improvements were seen in 42%, 38% and
0% in the AZA, IC and BSC only group, respectively. Grade 3-4 anemia, throm-
bocytopenia and neutropenia, respectively, were seen during treatment in 48%,
52%, and 71% with AZA, 44%, 88% and 69% with IC and 44%, 40%, and 19%
with BSC only.
Figure 1.
Summary and Conclusions: In our population-based study, AZA prolonged
median OS compared with BSC only, but not with IC. Overall response rates
and grade 3-4 hematological AEs were similar with findings from the AZA-001
trial (Fenaux 2009). However, our real-world patient population experienced
poorer survival than reported in the AZA-001 trial. Population-based studies
provide data complimentary to findings from clinical trials and are important to
assess uptake and outcome of new interventions in daily practice and may be
part of guideline development. Our results, however, should be interpreted with
caution due to the modest patient numbers and the fact that population-based
studies are uncontrolled and confounded by indication.
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Background: Therapy-related myeloid neoplasms (t-MN) include therapy-relat-
ed acute myeloid leukaemia (AML), therapy-related myelodysplastic syndromes
(MDS) and therapy-related myelodysplastic syndrome/myeloproliferative neo-
plasms MDS/MPN) occurring as a late complication of cytotoxic chemotherapy
or radiation. t-MN is becoming increasingly common and known to be associ-
ated with poor outcomes.
Aims: To identify incidence, characteristics, treatment and outcomes of t-MN
patients in our centre.
Methods: We investigated the clinical characteristics, treatment and outcomes of
patients with t-MN diagnosed in a single centre between 2003 and 2014 and com-
pared with 198 de novo MDS patients for whom we have comprehensive data.
Results: Of 446 patients with AML (152) or MDS (294) diagnosed between
2003 and 2014, we identified 39 patients with features of t-MN (8.7%); 35
patients with t-MDS (11.9%) and 4 with t-AML (2.6%). Median age at presen-
tation and gender distribution were similar to de novo MDS with 25.6% of
patients under 65 years. The degree of cytopenias at presentation was greater
in t-MN group but the percentage of marrow blasts at diagnosis was comparable
between two groups. Twenty two patients (56.4%) had a prior haematological
malignancy, 10(25.6%) had solid tumours and 3 (7.7%) had cytotoxic therapy
for autoimmune disorders. Thirty four patients (87%) received chemotherapy,
12(31%) received radiotherapy and 7(18%) received combined chemotherapy
and radiation as primary therapy. The time from therapy to development of t-
MN was shortest for patients with haematological disorders (45.5 months) com-
pared to solid tumours (84.5 months) and autoimmune disorders (109 months).
Patients who developed t-MN after acute leukaemia had had topoisomerase II
inhibitors with other cytotoxic agents and were found to have the shortest laten-
cy (16.5 months) and overall poor survival. A higher proportion of patients with
higher risk cytogenetics were observed in t-MN group compared to de novo
MDS. Forty one percent of patients had a normal karyotype and were observed
to have better survival (31 vs 13 months). Improved survival was associated
with very low, low and intermediate risk IPSS-R. Twenty two patients received
best supportive care, 12 received Azacitidine and 5 received intensive
chemotherapy, of which 2 had allogeneic marrow transplantation. For patients
treated with Azacitidine, a median of 4 courses were given with 25% achieving
partial response, haematological improvement or stable disease. Median overall
survival for all patients was 14 months (0-122) compared to 30 months (0-156)
in de novo MDS. Survival declined markedly after two years and 5-year survival
was only 13.8%. Improved survival was associated with blast count <5%, prior
radiotherapy only, lower risk IPSS-R and a normal karyotype. Patients who
received Azacitidine had similar survival to those who were treated with inten-
sive chemotherapy (10.5 vs 14 months) (Table 1).
Table 1. Characteristics, survival and treatment of patients with t-MN.
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Summary and Conclusions: Patients with t-MN showed more adverse fea-
tures of MDS and cytogenetics hence have lower survival. A longer latency
period and better survival is observed in patients who received prior radiother-
apy only. Patients with low blast count at presentation, normal karyotype and
radiotherapy only as primary treatment had a survival advantage. The use of
IPSS-R can identify patients with good outcome and can be useful in risk-
adapted approach to management. Azacitidine is effective in selected patients
not fit for intensive therapies; however no survival advantage was noted in our
small cohort.
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CLINICAL FEATURES, TREATMENT DECISIONS AND TREATMENT OUT-
COMES OF PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
(CMML) IN THE REAL-WORLD: RESULTS FROM THE DUTCH POPULA-
TION-BASED PHAROS MDS REGISTRY
A. Dinmohamed1,* O. Visser2, W. Posthuma3, J. Wegman4, J. van Esser5,
V. Mattijssen6, S. Klein7, P. Wijermans8, M. van Marwijk Kooy9, G. Huls10,
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Background: CMML is a very rare hematological malignancy characterized
by features of both myelodysplastic syndromes and myeloproliferative neo-
plasms. Clinical practice guidelines for the management of CMML are ill-
defined due to the scarcity of CMML-specific phase 3 clinical trials. Clinical
characterization and clinical decision-making can be supported by information
gained from population-based studies.
Aims: To present clinical features, treatment decisions and treatment out-
comes of newly diagnosed CMML patients in daily practice in the Nether-
lands.
Methods: We identified 85 CMML patients (median age 74 years, age range
54-94 years, 63% males) diagnosed between 2008-2011 from the Dutch pop-
ulation-based PHAROS MDS registry, which encompasses ~40% of the
Dutch population (31 centers) and is notified by the nationwide Netherlands
Cancer Registry. For all cases, the diagnosis was confirmed by bone marrow
examination and classified according to WHO 2008 classification. The
PHAROS MDS registry includes data on patient characteristics at baseline,
classification, prognostication, treatment, response to treatment and survival.
Overall survival (OS) was measured from time of diagnosis until death or lat-
est follow-up.
Results: Of all patients, 72% were diagnosed in patients over 70 years of
age. The vast majority of patients had an ECOG performance score ≤1 (92%)
and ≥1 co-morbidity at diagnosis (84%). Overall, 84% patients had CMML-1
and 16% CMML-2. Cytogenetic assessments were performed in 52 (62%)
patients, of which 73%, 12% and 15% had good, intermediate or high-risk
cytogenetics based on the definition used in the CPSS (Such 2013), respec-
tively. Cytogenetic assessment decreased with older age from 83% in 18-
59-year-olds to 44% in over 80-year-olds (p for trend=.027). Data on ASXL1
mutational status were not available for patients diagnosed during the study
period of 2008-2011. A wait-and-see strategy was applied in 32 (38%)
patients, of which 11 (34%) ultimately started with therapy after a median of
8.9 months after diagnosis. Of 64 patients who received first-line therapy, 19
received hydroxyurea (HU) only, 19 transfusions only, 14 AZA, 11 EPO and
1 lenalidomide. Only 14 (22%) of 64 patients received second-line therapy:
9 received AZA, 2 HU, 2 transfusions only and 1 proceeded to an allograft.
With respect to treatment outcome, we assessed the outcome of first-line
AZA (n=14, median age 72.5 years; 93% ECOG score ≤1) vs first-line HU
without cross-over to AZA (n=15, median age 72 years; 87% ECOG score
≤1). Their characteristics are shown in Figure 1. Median OS (95% CI) was
19.9 (9.8-24.8) vs 8.2 (2.9-19.3) months in the AZA and HU treated group,
respectively (log-rank p=.078; Figure 1). AZA was given for a median (range)
of 5.5 (1-30) cycles and HU for a median of 5.1 (0.3-35.8) months. Hemato-
logical improvements per revised IWG-MDS criteria (Cheson 2006) were
observed in 29% and 0% in the AZA and HU treated group, respectively.
Summary and Conclusions: In our population-based study, risk-stratifica-
tion by means of cytogenetic assessment decreased with older age. Without
cytogenetics, accurate risk-stratification cannot be made, which possibly
could lead to inappropriate, risk-adapted management. Although limited by
small patient numbers, there was a trend towards higher median OS in
patients receiving AZA as opposed to those receiving HU only. In the absence
of CMML-specific phase 3 trials, population-based studies are important for




A NEW PROGNOSTIC INDEX TO PREDICT SHORT-TERM PROGNOSIS IN
MDS PATIENTS TREATED WITH AZACITIDINE; COMBINATION OF P53
EXPRESSION AND CYTOGENETICS
S. Nishiwaki1,* M. Ito2, S. Okuno1, Y. Harada1, S. Yamamoto1, T. Iwasaki1,
I. Sugiura1
1Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toy-
ohashi, 2Department of Pathology, Japanese Red Cross Nagoya First Hospital,
Nagoya, Japan
Background: Azacitidine (Aza) is a currently used demethylating agent for
myelodysplastic syndrome (MDS). Since Aza epigenetically modulates various
genes, there may be a new prognostic factor to predict outcome of MDS
patients treated with Aza. p53 is a tumor suppressor protein encoded by the
TP53 gene. Although it was reported that p53 expression was associated with
poor outcome in del(5q) myelodysplastic syndrome (MDS) patients treated
with lenalidomide, its value is controversial in MDS patients treated with Aza.
Aims: In this study, we intended to identify prognostic factors including p53
expression of bone marrow in the era of Aza for MDS.
Methods: We retrospectively analyzed 60 consecutive MDS patients treated
with Aza. To assess p53 protein expression, immunohistochemical analyses
of bone marrow clot sections were performed. Patients were categorized as
p53-positive when the percentage of p53-positive cells was 5% or more. The
prevalence of p53 expression was analyzed as a prognostic factor.
Results: Median age was 73 years old (range 48-90). In 29 patients, p53 was
positive. Numbers of patients according to the World Health Organization
(WHO) (2008) classification were 4 refractory cytopenia with unlineage dys-
plasia, 15 refractory cytopenia with multilineage dysplasia, 16 refractory anemia
with excess blasts with type 1, 14 refractory anemia with excess blasts with
type 2 and 11 acute myeloid leukemia, and those according to WHO classifi-
cation-based prognostic scoring system (WPSS) were 2 very low, 10 low, 9
intermediate, 24 high and 15 very high. There was no significant difference of
WPSS distribution between p53-negative and -positive patients. As to cytoge-
netic abnormalities, it was normal in 29 patients, complex or monosomy7 (poor
cytogenetics) in 14 and other abnormalities in 17. There was more patients
with poor cytogenetics in p53-positive cohort than those in p53-negetive cohort
(P=0.03). More patients in p53-negative cohort responded to azacitidine treat-
ment than those in p53-positive cohort according to International Working
Group response criteria revised in 2006 (42% vs 17%; P=0.04). Overall survival
(OS) was significantly lower in p53-positive patients compared with p53-nege-
tive patients (85% vs 59% at 12 months after the start of Aza administration;
P=0.006). Multivariate analysis demonstrated that p53-positive was a significant
prognostic factor for OS along with poor cytogenetics [p53-positive: Hazard
ratio (HR) 1.26, 95%CI 1.04-1.53; P=0.02, poor cytogenetics: HR 3.72, 95%CI
1.52-9.11; P=0.004]. We propose a new prognostic index to predict short-term
prognosis of MDS patients in the era of Aza; High: p53-positive and poor cyto-
genetics, Intermediate: p53-positive or poor cytogenetics, and Low: p53-nege-
tive and absence of poor cytogenetics. OS was significantly different among
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three groups according to this new prognostic index (Low 92%, Intermediate
65% and High 27% at 12 months; P<0.0001) (Figure 1).
Figure 1.
Summary and Conclusions: p53 expression of bone marrow was a significant
prognostic factor in MDS patients treated with Aza. In combination with cyto-
genetic abnormalities, it is possible to predict short-term prognosis.
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DIAGNOSIS, PROGNOSTICATION AND TREATMENT OF MYELODYS-
PLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: RESULTS FROM THE
DUTCH POPULATION-BASED PHAROS MDS REGISTRY
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Background: The Dutch Population-based HAematological Registry for Obser-
vational Studies (PHAROS) in MDS is established to document clinical features,
management and outcomes of newly diagnosed MDS patients in the Nether-
lands. The PHAROS registry documents data in addition to the minimal dataset
collected by the nationwide Netherlands Cancer Registry (NCR). The purpose
of the PHAROS MDS registry is to provide insight into the delivery of care to
MDS patients in order to improve the quality of diagnosis and management of
MDS patients in the Netherlands.
Aims: To assess clinical features, classification, prognostication and manage-
ment of newly diagnosed MDS patients in daily practice in the Netherlands.
Methods: We identified 536 WHO-defined MDS patients (median age 75 years,
age range 23-94 years, 60% males) diagnosed between 2008-2011 from the
PHAROS MDS registry, which covers ~40% of the Dutch population (31 cen-
ters) and is notified by the NCR. All cases were confirmed by bone marrow
(BM) examination. The PHAROS MDS registry includes data on patient char-
acteristics at baseline, classification, prognostication, treatment, response to
treatment and survival.
Results: Of all patients, the vast majority had an ECOG performance score ≤1
(91%) and ≥2 co-morbidities (57%). Further, 21% had received therapy for a prior
malignancy and 5% were transfusion dependent. In BM aspirates, the percentage
of erythroid, myeloid and megakaryocytic dysplasia (ie, <10% or ≥10%) was
reported in 35%, 45% and 30% of the records, respectively. Assessment of
ringsideroblasts was done in 70% of all BM aspirates. The degree of BM fibrosis
and CD34-positivity were assessed in 82% and 74% of all BM biopsies, respec-
tively. In 17% of all MDS cases, a MDS subtype could not be assigned. Cytoge-
netic assessments were performed in 61% of the patients, and decreased sharply
with older age from 78% in 18-59-year-olds to 43% in over 80-year-olds (p for
trend <.001). As a result, risk stratification could not be performed in a substantial
number of patients as cytogenetic data are essential to assess prognosis. In
patients with data available to assess prognosis by IPSS-R (n=268), 20%, 25%,
22%, 17% and 16% had very low, low, intermediate, high and very high risk MDS
at diagnosis. Overall survival by IPSS-R risk group is shown in Figure 1A. A total
of 64 (74%) of 86 patients aged <65 years received first-line therapy: 22%
received an allograft, 8% lenalidomide, 6% azacitidine (AZA), 14% growth factors,
13% intensive chemotherapy and 38% supportive care only (Figure 1B). Among
345 (77%) of 450 patients aged ≥65 years, the corresponding percentages were:
0%, 1%, 17%, 34%, 2% and 46 (Figure 1B). Data on subsequent treatment are
shown in Figure 1B as well. Of all 102 AZA-treated patients, 36% received AZA
outside the EMA-approved indication.
Figure 1.
Summary and Conclusions: We show that most patients from daily practice
do not undergo a full and proper diagnostic work-up, such as assessment of
dysplasia and cytogenetics, as recommended by previous and current Euro-
pean guidelines for the diagnosis of MDS (Malcovati 2013). Although treatment
options in MDS are limited, especially for the elderly, prognosis should at least
be assessed in order to accurately inform patients about their life expectancy
and to provide information on appropriate risk- and age-adapted treatment
options. Population-based registries, such as PHAROS, can be useful instru-
ments to evaluate guideline adherence. Also, they provide information comple-
mentary to findings from clinical trials as the latter usually addresses a small
minority of the general patient population.
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THE UTILITY OF GRANULOCYTE MATURATION PATTERNS ASSESSED BY
FLOW CYTOMETRY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYN-
DROME
S. Meisenberg1,* S. Bastow1, R. Ansell1, E. Bart-Smith1, G. Shah1, R. Johnston1,
T. Corbett1, T. Chevassut1, K. Boyd1, C. Dalley1
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sex, United Kingdom
Background: The routine role of flow cytometry (FC) in the diagnosis of
myelodysplastic syndrome (MDS) is currently limited to the quantitative meas-
urement of bone marrow (BM) CD34+ blast percentage. However, morphologic
diagnosis can be challenging, particularly when dysplastic changes in the mar-
row are subtle. The expression of specific antigens at various stages of normal
granulopoiesis is tightly controlled but dysgranulopoiesis may be associated
with variant antigen expression which can be identified by FC. 
Aims: 1) To assess the utility of variant granulocyte maturation antigen patterns
(GMAP) in supporting MDS diagnosis. 2) To develop an immunophenotyping
scoring system to rank dysgranulopoiesis. 
Methods: The BD FACsCanto II analyser™ and BD FacsDiva software™ were
used for acquisition and interpretation. A total of 60 BM aspirate samples from
adult patients were analysed; 31 controls (normal n=18, previous lymphoma n=5,
staging lymphoma n=1, paraproteinaemia n=3, myeloma n=3, systemic lupus
erythematosus n=1) and 26 confirmed MDS cases based on the standard WHO
diagnostic criteria. Three patients with subtle dysplastic BM, insufficient for diag-
nosis, were also included. The International Prognostic Scoring System for MDS
(IPSS-R) risk stratify patients with MDS; low risk n=16 (IPSS-R >1.5-3.0), inter-
mediate risk n=5 (IPSS-R >3-4.5) and high risk n=5 (IPSS-R >4.5-6). Antibodies
CD10, CD11b, CD13, CD16, CD34, and CD45 were added to aspirates. Param-
eters assessed were total CD34+ blast percentage, CD11b/CD16 GMAP,
CD13/CD16 GMAP, and four previously published scoring parameters1,2 which
include myeloblast%, B progenitor%, myeloblast vs lymphocyte CD45 ratio and
granulocyte: lymphocyte side scatter peak channel ratio. Each feature carries 1
point and a total score ≥2 is suggestive of changes often seen in MDS. 
Results: The majority of control subjects showed standard GMAP (Figure 1);
84% showed a uniform ‘biphasic’ pattern with CD13/CD16 and 81% showed a
uniform ‘orthogonal’ pattern with CD11b/CD16. Eighty-five percent of MDS
patients correlated with morphology by deviating from the standard ‘biphasic’
GMAP using CD13/CD16 whereas 77% deviated from the standard ‘orthogonal’
GMAP using CD11b/CD16. Of patients with low risk MDS, 63% had deviated
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GMAP with CD11b/CD16 and 69% had deviated GMAP with CD13/CD16.
Compared to control BM, all GMAP deviations in MDS patients presented as
a non-uniform pattern or as a reduction of CD11b and/or CD16 expression.
A GMAP score <2 was calculated in 90% of controls. A score ≥2 was seen in
85% of total MDS patients. A score ≥2 was seen in 75% of patients with low
risk IPSS-R. Interestingly, of 3 morphologically sub-diagnostic patients, 2 had
scores ≥2 and two had deviated GMAP using CD11b/CD16 and CD13/CD16.
Patients with low risk IPSS-R had a median GMAP score of 2, those with inter-
mediate risk IPSS-R had a median score of 4 whereas high risk IPSS-R patients
had a median score of 5.
Figure 1.
Summary and Conclusions: We have shown that GMAP has diagnostic utility
in MDS and that median GMAP scores may rank to IPSS-R score. Validation
of the GMAP and GMAP score using a larger MDS patient cohort, and refine-
ment by inclusion of FC assessment of dysmegakaryopoiesis is warranted. 
References
1. Ogata et al. (2009) Diagnostic utility of flow cytometry in low-grade myelodys-
plastic syndromes: a prospective validation study. Haematologica 94(8):
1066-1074.
2. Della Porta et al. (2012) Multicenter Validation Of A Reproducible Flow Cyto-
metric Score For The Diagnosis Of Low-Grade Myelodysplastic Syndromes:
Results Of A European LeukemiaNET Study. Haematologica 97: 1209-1217.
E1218
PATIENTS WITH THERAPY-RELATED CHRONIC MYELOMONOCYTIC
LEUKEMIA (TR-CMML) HAVE SHORTER MEDIAN OVERALL SURVIVAL
THAN DE NOVO CMML (DN-CMML): MAYO CLINIC EXPERIENCE
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Background: CMML is a malignant hematologic neoplasm characterized by
peripheral blood monocytosis and bone marrow dysplasia. The World Health
Organization (WHO) classifies therapy-related myeloid neoplasms (tr-MN) as
another category. It is known that tr-MNs tend to have a worse prognosis than
de novo MN (dn-MN). Tr-CMML is an under-described entity with scarce liter-
ature in comparison to dn-CMML.
Aims: To study the differences in clinical outcomes between tr-CMML and dn-
CMML patients. 
Methods: A retrospective single institution study chart review of cases with
CMML at Mayo Clinic Rochester between 1994- 2011 was performed. DN-
CMML, tr-CMML and leukemic transformation (LT) were defined according to
WHO classification (Swerdlow et al. 2008). Prior exposure to chemotherapy,
radiotherapy or both were defined as tr-CMML while lack of both as dn-CMML.
Cytogenetic risk was defined according to Such E. et al. (Hematologica 2011).
Appropriate IRB approval was obtained in accordance with the Helsinki decla-
ration. Comparison between group medians was done using Wilcoxon test, to
comparison values were done contingency and Onaway analyses (Means/Ano-
va/Pooled t), while survival estimates were calculated using Kaplan-Meier
curves JMP V10.
Results: Out of 265 CMML patients, 30 (11%) had tr-CMML. Median age was
72 years, with 19 (63%) patients being males. Labs at diagnosis included medi-
an white blood cell (WBC) of 16.8x109, hemoglobin (Hg) 10.5 g/dL, platelet
(PLT) 65x109, monocytes (Mon) 3.8x109, bone marrow (BM) blasts 4% (range
0-18), peripheral blood blasts (PB) 0% (0-7), Lactate dehydrogenase (LDH)
241 U/L. CMML-1 was found in 28/30 patients (93%) and CMML-2 in 2 patients
(7%). Splenomegaly was present in 7 (23%) patients and absent in 21(70%).
Two pts had splenectomy (7%). Cytogenetic were low 21 pts (72%), interme-
diate 2 (7%), and high in 6 (20%). LT was seen in 5 (17%) patients. When
evaluating prior therapy, 17(57%) patients were treated with chemotherapy
(CT), 6 (20%) patients were treated with radiotherapy (RT) and 7 (23%) CT+RT.
Out of 265 patients, 235(89%) had dn-CMML. Median age was 71, with 158
(67%) were males. Labs at diagnosis were median WBC 12x109, Hg 10.4 g/dL,
PLT 95x109(p=0.046), Mon 2.1x109, BM blasts% 4 (range 0-19), PB 0% (0-
19), LDH 222 U/L. CMML-1 was found in 210 pts (89%) and CMML-2 in 25 pts
(11%). Splenomegaly was present in 57 (24%) and absent in 166 (71%). Twelve
pts had splenectomy (5%). Cytogenetic were low 163 pts (71%), intermediate
31(13%), high 37(16%). LT was found in 26(11%) patients. Median overall sur-
vival was 30 months in dn-CMML vs 11 months in tr-CMML group (p=0.02).
Upon comparing LT between these groups, time to LT was 10 vs 11 months,
respectively (p=0.6). Median overall survival was in CT+ group 9 months, in
RT+ group 4.4 months and in CT/RT+ group 13 months (p=0.7).
Summary and Conclusions: Tr-CMML comprises a small portion of all CMML
cases (11%). Upon comparison, only lower platelets were found to be statisti-
cally significant compared to dn-CMML. Median overall survival in dn-CMML
group was longer than tr-CMML group but LT seemed to be similar in terms of
incidence and time to occurrence. Prior therapy (CT vs RT) in tr-CMML patients
did not effect median overall survival. Additional larger studies are needed to
confirm our results.
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Background: Hypomethylating agents (HMA) constitute an essential tool in
the treatment of myelodysplastic syndrome (MDS). The use of these drugs as
treatment for MDS was shown prolonged survival in MDS. However, there were
no definitive prognostic factors to predict survival or treatment outcomes after
using HMA in MDS. And guideline about HMA treatment recommend continu-
ous therapy because patients can be shown rapid progression if they stop the
treatment. However, in real clinical practice, many patients are impossible to
continue treatment of HMA because they have more problems such as comor-
bidities, old age, poor economics, etc than patients have those who enrolled
to clinical trials. 
Aims: The purposes of this study were to estimate porgnostic factors for sur-
vival in patients with MDS who were treated with HMA, and especially, to doc-
ument prognostic factors for HMA treatment free survival (TFS) in patients who
were stopped HMA without disease progression because of other causes such
as toxicities, cost, etc.
Methods: The medical records of this study were collected from nationwide
registry data which was performed in AML/MDS working party in South Korea.
Data from patients at fourteen university hospitals in South Korea between Jan
2001 to Oct 2013 were collected retrospectively. All included patients had been
diagnosed to MDS and they were treated with HMA such as azacitidine or
decitabine as front line therapy and they were treated continuously at least
four cycles. The evaluation of response were estimated by IWG response cri-
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teria. Early response was defined to be shown response after two cycles of
HMA treatment. The TFS was defined duration from the end date of HMA ther-
apy to the date of disease progression, relapse, or death from any causes. 
Results: The median age of the 217 patients was 68 years (range, 24-92 years)
and the male to female ratio was 1.8:1.0. 144 patients were treated with azacitidine
and 71 patients with decitabine. 109 patients stopped HMA therapy because of
disease progression and the others stopped HMA therapy without progression
because of other causes. The 5 years overall survival rates (OS) and TFS of patients
who were more than 65 years old, have blast counts more than 5% in bone marrow,
have poor cytogenetics, have higher risk of IPSS(International Prognostic Scoring
System), WPSS (WHO Classification-Based Prognostic Scoring System) and IPSS-
R (Revised International Prognostic Scoring System) were inferior than those of
patients less than 65 years old, blast less than 5% in bone marrow, good cytoge-
netics, lower risk of IPSS, WPSS, and IPSS-R (Table 1). Especially, the 5 years OS
and TFS of patients who stopped HMA therapy because of other cause without
disease progression were also inferior in bone marrow blast more than 5%, higher
risk of IPSS, WPSS and IPSS-R than those of patients who bone marrow blast
less than 5%, lower risk of IPSS, WPSS, and IPSS-R. However, patients who have
early good response including hematologic improvement, and more than stable
disease according to IWG response criteria, and early improvement of platelet
counts were also shown trends to be superior OS and TFS, but not shown significant
differnences (early good response vs not good response ; 70.2% vs 45.6%, p=0.228
(OS), 54.0% vs 46.0%, p=0.172 (TFS), and early platelet response vs not shown ;
70.2% vs 43.3%, p=0.179 (OS), 54.0% vs 43.4%, p=0.124 (TFS)). 
Table 1. Factors affecting OS and TFS (treatment free survival).
Summary and Conclusions: In our study, good prognostic factors for OS and
TFS were younger age (<65 years), blast counts in bone marrow (<5%), good
cytogenetics, lower risk of IPSS, WPSS, and IPSS-R. And in case of patients
who stopped HMA therapy without disease progression because of other caus-
es, they might be shown prolonged survival in less than 65 years old, blast less
than 5% in bone marrow, lower risk of IPSS, WPSS, and IPSS-R. However,
further studies are needed to determine more impressive clinical factors to pre-
dict survival in patients with MDS treated with HMA in clinical real practice.
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HYPOMETHYLATING AGENTS ARE EFFECTIVE IN SHRINKING
SPLENOMEGALY IN PATIENTS WITH CHRONIC MYELOMONOCYTIC
LEUKEMIA (CMML): MAYO CLINIC EXPERIENCE
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Background: CMML is a malignant hematologic neoplasm characterized by
peripheral blood monocytosis and bone marrow dysplasia. Cytoreductive ther-
apy (Hydroxyurea) and hypomethylating agents (HMA) (Decitabine (DAC) and
Azacitidine (AZA)) are the main therapy options. Splenomegaly is commonly
found in CMML patients. As of today, no consensus criteria for response in
CMML exist, and most clinicians use MDS International Working Group (IWG)
criteria (Cheson et al. 2006). Such criteria do not account for spleen response.
In addition, data is scarce on HMA effect on splenomegaly.
Aims: To study the efficacy of HMA on splenic size in CMML patients. 
Methods: A retrospective single institution study chart review of cases with
CMML at Mayo Clinic Rochester between 1994- 2011 was performed. Spleen
size was documented only via clinical examination. Due to lack of criteria on
splenomegaly response, we used “modified” splenic response criteria of inter-
national working group-myeloproliferative neoplasms research and treatment
(IWG-MRT) and European LeukemiaNet (ELN) consensus report for myelofi-
brosis (Tefferi A. et al. 2013). In our study, CR was resolution of splenomegaly
and PR was shrinkage over 50%. Patients with splenectomy were excluded.
Appropriate IRB approval was obtained in accordance with the Helsinki decla-
ration. Comparison between group medians was done using Wilcoxon test,
while survival estimates were calculated using Kaplan-Meier curves JMP V10. 
Results: Out of 269 CMML patients, 36 (13.4%) were treated with HMA. Median
age was 70 years, with 21(58%) patients being males. Labs at treatment included
median white blood cell (WBC) was 14.4x109, Hemoglobin (Hg) 10.2 g/dL,
platelet (PLT) 67x109, monocytes 3.36x109. CMML-1 was found in 26 patients
(72%) and CMML-2 in 10 patients (28%). When evaluated patients with treated
HMA therapy, 29(81%) patients were treated with DAC and 7(19%) patients
were treated with AZA. Median number of therapy cycles was 4.5. Out of 36
patients, 11(31%) had splenomegaly documented at time of start of HMA and at
follow-up. Median age was 66, with 7(64%) were males. Labs at treatment were
median WBC 39.3x109, Hg 10 g/dL, PLT 67x109, monocytes 3.37x109. CMML-
1 was found in 8 patients (73%) and CMML-2 in 3 patients (27%). Nine (82%)
patients had DAC and 2 (18%) AZA. Median number of therapy cycles was 4.
When evaluated pretreatment splenic size below left costal margin with physical
examination, median splen size was 6 cm (range 1-18 cm) while during treatment
best median spleen size was 2 cm (range 0-13cm). Among these patients splenic
complete and partial response (CR 3/PR 2) was 45% with rest having stable
spleen response (SR). Median cycles of therapy for CR/PR group was 5(range
4-6) versus 3 (range 1-6) in SR group. Median survival was 10 months in splenic
response positive (CR/PR) whereas 4.8 months in SR group (p=0.11).
Summary and Conclusions: HMA is frequently used for CMML patients. Sig-
nificant improvement was found on splenic size after HMA treatment for many
splenomegalic CMML patients. In addition splenic responders correlated with
longer length of therapy. Overall Survival in splenic positive response group
was longer than negative response group, but this did not reach statistical sig-
nificance, likely due to small number of sample. Additional larger studies are
needed to confirm our results.
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HEMATOLOGIC MALIGNANCIES, MOSTLY MYELODYSPLASTIC SYN-
DROMES AMONG 1740 INFLAMMATORY BOWEL DISEASE PATIENTS:
LONG TERM FOLLOW-UP DATA FROM A TERTIARY CENTER 
A. Salihoglu1,* N. Serin2, N. Esatoglu2, H. Yilmaz2, Y. Sengul2, I. Hatemi3,
Y. Erzin3, A. F. Celik3
1Hematology, 2Internal Medicine, 3Gastroenterology, Istanbul Cerrahpasa Med-
ical Faculty, Istanbul, Turkey
Background: It is not an uncommon situation that patients (pts) with inflam-
matory bowel disease (IBD) are referred to hematology for suspected hemato-
logic malignancies (HM). There is concern that IBD and medications especially
thiopurines and anti TNF agents used in the treatment may be associated with
increased risk of various HM. 
Aims: We aimed to describe IBD pts who developed HM. 
Methods: Retrospective review of medical records from all 1740 pts treated
for IBD at a single gastroenterology clinic from 1999 to 2014 was performed.
Pts with HM were further evaluated for the following parameters in the Table 1
and mean corpuscular volume (MCV) before azathioprine (Aza) use, MCV at
the time of HM diagnosis and duration of Aza treatment. Informed consent was
obtained from all pts.
Results: In total 6 pts (3/3, M/F) were identified with HM (5 MDS and 1 AML).
Characteristics of the pts are summarized in Table 1. Median ages at diagnosis
of IBD and HM were 38.5 (18-55) and 48.5 (29-59) respectively. All of these 6
pts except one had been exposed to Aza and 4 were treated also with anti
TNF. All 5 patients experienced leukopenia during Aza therapy. Median time of
Aza treatment duration was 10 (6-18) months. Median time between IBD and
HM was 6.5 years. At the time of IBD diagnosis MCV changed between 84-101
fl. Only 1 patient had a MCV >100 fl before Aza. At the time of HM diagnosis 4
pts had a MCV of >100 fl. Most of the pts (4/6) did not have active IBD at time
of HM diagnosis. Iron deficiency anemia with/without chronic disease anemia
was seen in 5 of 6 pts. Median hemoglobin was 11.7 (6.9-12.5) g/dl.
Table 1. Patients characteristics. AML, acute myeloid leukemia; Aza, aza-
thioprine; MDS, myelodysplastic syndrome; GIBD, gastrointestinal Behcet
disease; MTX, methotrexate; SSZ, salazopyrin; TNF, tumor necrosis factor.
Summary and Conclusions: Overall risk of myeloid malignancies mostly MDS
may be increased in pts with IBD either related to the disease itself or as a con-
sequence of its treatment. Pts with leukopenia during Aza and MCV >100 fl
(after exclusion of other causes) may be prone to develop HM and deserve
increased awareness. Concomitant iron deficiency may affect values especially
MCV and its increase.
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IMPACT OF AZACITIDINE ON RED BLOOD CELL ALLOINMUNIZATION IN
MYELODISPLASTIC SYNDROME
S. Ortiz Zuluaga1,* C. Villegas1, M.T. Orero1, K. Javier1, P. Pérez1, R. Collado1,
D. Ivars1, M. Roig1, I. Luna1, F. Carbonell1
1Hematology, Hospital General Universitario de Valencia, Valencia, Spain
Background: Reed blood cell (RBC) transfusion remains an essential com-
ponent for the management of patients with myelodisplastic syndrome (MDS).
Alloimmunization to RBC antigens is an important complication associated to
multiple transfusion. The incidence of alloimmunization in MDS ranges from
12 to 56%. Hipomethylating agents such as Azacitidine (AZA) and Decitabine
are standard care for the treatment of patients with MDS, however its impact
in RBC alloimmunization has not been evaluated.
Aims: The objective of this study was to examine whether AZA may influence
over the incidence of RBC alloimmunization in MDS.
Methods: Clinical and transfusion data regarding all consecutive patients with
MDS and secondary acute myeloid leukemia from MDS who received >6 RBC
concentrates between January 2009 and December 2014 were recorded. Data
included: diagnosis according WHO 2008 classification, RBC support, treat-
ment (AZA versus supportive care), alloantibody detection and identification,
and the time between first transfusion and evidence of alloantibodies. We com-
pare the data with that of MDS patients who received >6 RBC units between
1995 and 2008, previous to AZA approbation by EMEA. 
Results: A total of 59 patients (34 males/25 females) with a median age of 75
years (53-89) received ≥6 RBC units between 2009-2014. Twenty-seven
patients received AZA (75 mg/m2/day, 7 days without administration on the
weekend) when a median of 6 cycles (range 1-14). Thirty-two patients received
best supportive therapy (BSC) (RBC transfusions and erythropoietin when
baseline level is low). The median follow-up from first transfusion was 13
months for AZA group and 12 months for BSC group. We identified 6 cases
(18.8%) of alloimmunization in the BSC group and no cases in the AZA group
(p=0.02). The WHO 2008 subtype and alloantibodies specificities are showed
in Table 1. During a median follow-up of 23 months, the incidence of RBC
alloimmunization in 94 patients who received their first transfusion before 2009
was 14.9% (14 patients) without differences with the 2009-2014 group (6
patients: 10.2%) (p=0.39). We observed significant differences in number of
RBC units transfused between AZA group (median 24 units; range 6-212) and
BSC group (median 10.5 units; range 6-198) (p <0,005). The median RBC
units transfused per month was higher in AZA group (3.5; range 0.09-14) than
in BCS group (0.91; 0.17-21) (p=0.002). A higher number of RBC units were
transfused to patients in 1995-2008 group (median 36; range 6-307) compared
to 2009-2014 group (median 17; range 6-206) (p<0.001). However, they were
no significant differences in the median RBC units per month between groups.
The alloantibody free survival from first transfusion was significantly superior
in patients who received AZA (Figure 1) (Log-rank p=0,046).
Table 1. The WHO 2008 subtype and alloantibodies.
                          RCUD    RARS    RCMD    RAEB 1    RAEB 2     AML    MDS/MP    5q-
No. Patients             5           9          18            2             10           7             6            2
Alloantibodies         2           0           2             0              0            0             1            1
RCUD: Anti-C, Anti-D; RCMS: Anti-E, Anti-Kell; MDS/MP: Anti-Kell; 5q-: Anti-Kell.
Figure 1. Time to alloimmunization from first transfusion.
Summary and Conclusions: Patients with MDS who received treatment with
AZA form RBC antibodies at a lower rate than patients who received supportive
care. However, these results were not influenced by the period in which the
transfusion was performed. We suggest that the immunosuppression due to
AZA therapy could develop an immunological tolerance or no response to
incompatible transfusions.
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IRON CHELATION THERAPY IN MYELODYSPLASTIC SYNDROME (MDS)
IN ROUTINE CLINICAL SETTING: AN INTERIM ANALYSIS OF THE NON-
INTERVENTIONAL STUDY EXSEPT
F. Nolte1,* O. Rubanov2, R.-B. Kühn3, C. Schumann1, S. Kreil1, G. Metzgeroth1,
C. Johr4, S. Albrecht4, W.-K. Hofmann1
1Hematology and Oncology, University Hospital Mannheim, Mannheim, 2Office-
based Hematology/Oncology specialist, Hameln, 3Office-based Hematology/
Oncology specialist, Oldenburg, 4Novartis, Nuremberg, Germany
Background: MDS is a diverse group of hematopoietic stem cell disorders
with anemia as one of its major clinical features often leading to transfusion
dependency. A substantial proportion of MDS patients (pts) experiences iron
overload (IOL) due to chronic red blood cell transfusion. Although the impact
of IOL on morbidity and mortality in patients with MDS remains a matter of
debate, there is some evidence that iron chelation might be beneficial in this
patient group. Deferasirox (DFX) is an oral iron chelator, which has been shown
to be effective in removing excess iron from the body.
Aims: The study was planned to evaluate the feasibility, safety and effectivity
of the iron chelator DFX in a setting outside of clinical trials.
Methods: In the present non-interventional study EXSEPT, started in Aug 2010
and closed recruitment in Dec 2014 with a 2-year-follow-up-period still ongoing,
we have performed a subgroup analysis with interim data on 199 patients with
MDS and iron overload (data cut-off in Nov 2013). A total of 294 pts with IOL
due to different transfusion requiring diseases were enrolled in this prospective,
multicenter study. Efficacy was measured by change in serum ferritin (SF) dur-
ing chelation with DFX. All pts were treated with DFX according to the guidelines
for iron chelation therapy in pts with MDS. Within the first year, visits were
planned every 3 months and twice in the second year. Pts with at least 1 fol-
low-up visit were eligible for analysis and last observation was carried forward
defined as last visit. Dose groups of 5 mg steps were analyzed according to
the prescribed dose given.
Results: 190 pts with MDS and IOL were analyzed with 57% being male pts.
Median age was 74 years (range 14-93). The IPSS risk categories were avail-
able in 62% and were as follows: low in 19.5%, intermediate-1 in 26.8%, inter-
mediate-2 in 9.5% and high in 4.7% of the pts, respectively. Mean baseline SF
level was 2090 ng/mL (range 423 to 5840 ng/mL) and showed a moderate
mean reduction of 237 ng/mL during course of DFX treatment until last visit.
The reduction in iron burden differed within the initially planned dose groups
with no effective reduction in the dose groups <10 mg/kg (+207 ng/mL; mean
baseline 1759 ng/mL; n=27) and 10-≤15 mg/kg (-28 ng/mL; mean baseline
1750 ng/mL; n=16) compared to an effective reduction in the planned dose
groups 15-≤20 mg/kg (- 625 ng/mL; mean baseline 2236 ng/mL; n=14) and
20-≤25 mg/kg (-348 ng/mL; mean baseline 2094 ng/mL; n=46). Mean creatinine
levels increased slightly from baseline serum creatinine level of 0.90 mg/dL to
1.06 mg/dL at last visit. Adverse events were documented in 152 pts (80%).
DFX was generally well tolerated, with the most common adverse events being
gastrointestinal disturbances (15%), decrease in renal creatinine clearance
(8%) and blood creatinine increase (7%).
Summary and Conclusions: We performed this analysis to evaluate the safe-
ty and efficacy of DFX in a routine setting outside clinical trials. The results
demonstrated efficacious iron chelation using adequate doses of DFX in elderly
pts with MDS. Changes in SF were moderate possibly reflecting the early stage
of the study with limited data on pts with visits >6 months. Moreover, treatment
was possibly sub-optimal in pts with doses below 10 mg/kg/days, but no data
on the reason for the chosen dose were available. DFX was generally well tol-
erated, with the most common adverse events being gastrointestinal distur-
bances. This study with all its limitations due to the non-interventional nature
supports the results of previously conducted trials.
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HEMOCHROMATOSIS GENE MUTATIONS MAY AFFECT THE SURVIVAL
OF PATIENTS WITH MYELODYSPLASTIC SYNDROME
M. Lucijanić1,* V. Pejša1, Z. Mitrović1, T. Štoos-Veić2, A. Livun3, O. Jakšić1,
T. Vasilj1, M. Piršić1, V. Hariš1, R. Kušec3
1Hematology department, 2Department of Clinical Cytology and Cytometry,
3Clinical Institute of Laboratory Diagnosis, Divison of Molecular Diagnosis and
Genetics, Universitiy Hospital Dubrava, Zagreb, Croatia
Background: Myelodysplatic syndrome patients are at risk of developing an
iron-replete state and hemochromatosis due to frequent transfusion depend-
ency and characteristics of the disease itself.
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Aims: The recent availability of potent oral iron chelators is renewing an interest
in the assessment of the possible impact of HFE genetics in MDS.
Methods: 36 newly diagnosed patients with MDS were studied for parameters
of iron metabolism in addition to C282Y and H63D mutations of the HFE gene.
Results: Mutations were present in 11 out of 36 patients (31%), which was not
different from our general population and were equally distributed among MDS
subtypes. Mutated patients had higher ferritin levels (p=0.039) and lower TIBC
(p=0.018). Ferritin was found to be higher for the untransfused mutated patients
(p=0.017), but not for transfusion-dependent patients in whom ferritin levels
correlated significantly with the number of blood units received (p=0.04). There
was no difference in the number of blood units received between the mutated
and wild type patients. A new observation made was that the mutated patients
had a lower overall survival (OS) in addition to a poorer leukemia free survival
(LFS) (p=0.004 and p=0.003, respectively) (Figure 1).
Figure 1.
Summary and Conclusions: The HFE gene mutations are not more frequent
in MDS patients. Iron overload in mutated patients was higher. The effect of
mutations on survival could be mediated by changes in iron metabolism. The
HFE gentopye may predict MDS prognosis and there is a need for further stud-
ies. It remains a challenging question if HFE mutated MDS patients should be
considered for potent iron chelation therapy.
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P53 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
AT DIAGNOSIS AND FOLLOWING TREATMENT WITH AZACITIDINE 
S. Maung1,* N. Strahan1, R. Desmond1, J. McHugh1, C. Burke1, J. O’Loughlin2,
M. Jeffers2, H. Enright1
1Haematology, 2Cellular Pathology, Tallaght Hospital, Trinity College Medical
School, Dublin, Ireland, Dublin, Ireland
Background: The Myelodysplastic Syndromes (MDS) are a heterogeneous
group of malignant stem cell disorders characterised by ineffective and dysplastic
haematopoiesis resulting in a hypercellular and dysplastic bone marrow with a
risk in some patients of transformation to acute myeloid leukaemia (AML). Pre-
vious studies have demonstrated consistent correlation between immunohisto-
chemical staining for the tumour suppressor gene p53 (TP53) and the presence
of TP53 mutation identified by molecular methods including deep sequencing.
P53 expression has also been shown to have value as an independent prognostic
indicator in some haematological malignancies, including Del(5q) MDS.
Aims: Our study aimed to assess the prognostic impact of p53 expression in
bone marrow biopsies at diagnosis in MDS patients (n=47). We also set out to
assess the effect, if any, of treatment with the hypomethylating agent Azacitidine
on p53 expression.
Methods: Formalin-fixed paraffin embedded 4µm sections of bone marrow
trephines were stained with Dako p53 mouse monoclonal antibody (DO-007)
using standard protocol. Three hundred haematopoietic cells were manually
counted. Positive expression is defined as strong nuclear staining in at least
1% of the haematopoietic cells examined
Results: p53 expression (strong positivity in >1% of cells examined) was seen
in a significant number of patients (22%) at diagnosis of MDS (n=10). Using a
cut-off point of 5% of cells, strong positivity was identified in 14% (n=6). P53
expression was correlated with MDS WHO category and IPSS-R score. Strong
p53 staining in >5% of cells was associated with a significantly lower survival
rate. Not surprisingly, patients with known cytogenetic abnormalities involving
the short arm of chromosome 17 had particularly strong expression of p53.
Comparison of p53 expression in marrow biopsies prior to treatment and fol-
lowing 4 cycles of treatment in 25 patients treated with Azacitidine showed
varying patterns, with significant decrease in expression following treatment in
11 patients (44%). Patients with higher levels of expression had more substan-
tial decrease in expression post treatment. No association was observed
between changes in p53 expression and survival among Azacitidine treatment
group but this may be due to a small sample size (Figure 1).
Figure 1. Difference in P53 expression pre and post treatment with Azac-
itidine.
Summary and Conclusions: Immunohistochemical analysis of p53 expression
in marrow trephine biopsies shows significant promise for future use as a readily
available prognostic indicator with a short turn around time for patients with
MDS. Further research is warranted to assess the on the impact of Azacitidine
and other therapeutic agents on p53 expression, and to establish whether
immunohistochemical analysis of p53 expression might help predict either dis-
ease responsiveness or resistance.
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SUBGROUP ANALYSES OF A PHASE 3 STUDY IN PATIENTS WITH
MYELODYSPLASTIC SYNDROMES FAILING HMA TREATMENT: IDENTI-
FICATION OF A HOMOGENEOUS POPULATION WHO BENEFIT FROM
RIGOSERTIB THERAPY
G. Gaidano1,* U. Platzbecker2, K.-A. Kreuzer3, T. Bernal de Castillo4, L. Silverman5,
G. Garcia-Manero6, H. Loferer7, P. Fenaux8
1Amedeo Avogadro University of Eastern Piedmont, Novara, Italy, 2Universität-
sklinikum Dresden, Dresden, 3Universitätsklinikum Köln, Köln, Germany, 4Hos-
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7Onconova Europe GmbH, Munich, Germany, 8Hospital St Louis, Paris, France
Background: Myelodysplastic syndrome (MDS) is heterogeneous, with varying
categories and prognosis as defined by the Revised International Prognostic
Scoring System (IPSS-R; Greenberg 2012). Patients with higher IPSS-R scores
have worse clinical outcomes; those with Very High Risk (VHR) IPSS-R have
the worst prognosis, with most dying of bone marrow failure complications.
ONTIME was the first randomized study in patients with MDS failing
hypomethylating agents (HMAs), with overall survival (OS) as the primary end-
point. ONTIME enrolled RAEB-1, RAEB-2, RAEB-t and CMML patients previ-
ously treated with HMAs, with marrow blast count at entry of 5-30%. Thus, it
included a heterogeneous population of MDS patients. When the study was
designed, little information was available regarding the prognosis for patients
with MDS failing HMAs. Subsequently, Prebet and others showed a short sur-
vival expectancy (<6 months) for these patients (Prebet, JCO 2011; Jabbour,
Cancer 2010). ONTIME demonstrated a 2.3-month benefit in median OS
(mOS) in the ITT population that was not statistically significant (8.2 mo rigosert-
ib vs 5.9 mo BSC; p=0.33; HR=0.87; n=299). The study was well-balanced,
permitting post-hoc analyses of OS in defined subgroups of patients, including
those with the worst prognosis, based on the (i) types of failures of HMA ther-
apy, (ii) duration of exposure to HMA therapy, (iii) prognostic risk categories
per the IPSS-R, and (iv) cytogenetic aberrations.
Aims: We sought to identify MDS subtypes who may benefit from rigosertib
for a future clinical trial by defining a prospective patient population based on
data from ONTIME and biological rationale.
Methods: Distribution of OS in each risk category and each arm was estimated
by Kaplan-Meier method and log-rank test was used for treatment effect. Haz-
ard ratio was estimated by Cox regression.
Results: We analyzed OS in patients classified as Primary 5-Azacytidine (AZA)
Failures (patients who failed to respond to or progressed during AZA treatment)
or as Secondary AZA Failure (patients who responded and then progressed),
following Prebet 2011. The mOS was longer with rigosertib than with BSC
among the Primary AZA Failure patients (8.6 months vs 4.6 months; p=0.032;
HR=0.65) but not among patients classified as Secondary AZA Failure (5.5
months for rigosertib, 6.8 months for BSC; p=0.87; HR=1.05). In both treatment
arms, the IPSS-R results correlated with OS in this study. Among patients who
had VHR IPSS-R, the mOS was significantly longer with rigosertib than with
BSC (7.6 vs 3.2 months; p=0.0050; HR=0.56); in contrast to all other IPSS-R
risk categories (see Table 1). All of the patients with monosomy 7 and 66% of
those with trisomy 8 were also VHR IPSS-R. The analysis of karyotypic aber-
rations found that mOS was significantly longer with rigosertib than with BSC
for patients with the monosomy 7 (5.6 mo rigosertib vs 2.8 mo BSC; p=0.0033;
HR=0.24) or trisomy 8 (9.5 mo rigosertib vs 4.5 mo BSC; p=0.035; HR=0.34)
mutations.
Table 1. Overall survival by IPSS-R risk category (intention-to-treat).
Summary and Conclusions: We conducted in-depth analysis of ONTIME,
and found that patients with the worst prognosis at entry, and thus with the
greatest unmet medical need, appeared to benefit most from rigosertib treat-
ment; namely, those with Primary AZA Failure, VHR- IPSS-R, and monosomy
7. The duration of prior HMA treatment inversely correlated with survival benefit.
Based on these results, a new randomized prospective controlled study in this
high-risk MDS patient population comparing rigosertib to physician’s choice
will be conducted to confirm these important observations.
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PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING 
OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN 
SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS
L. Silverman1,* P. Fenaux2, A. Al-Kali3, M. Baer4, M. Sekeres5, G. Roboz6,
G. Gaidano7, B. Scott8, P. Greenberg9, U. Platzbecker10, D. Steensma11,
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Germany, 11Dana-Farber Cancer Institute, Boston, United States, 12Univer-
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va Therapeutics, Inc., Newtown, 17MD Anderson Cancer Center, Houston, Unit-
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Background: ONTIME was a randomized (2:1) controlled study of rigosertib
(RIG) vs best supportive care (BSC) in 299 pts with HR-MDS who had relapsed
after, failed to respond to, or progressed during treatment with hypomethylating
agents (HMAs). The study showed a non- significant trend favoring RIG in the
analysis of overall survival (OS). The Revised International Prognostic Scoring
System (IPSS-R) is a refinement of an earlier widely used index for risk assess-
ment and prognosis for MDS (Greenberg 2012). Here we present the results
of analyses in the subgroup of patients with very high risk (VHR) per the
IPSS-R.
Aims: To examine the utility of the IPSS-R and the correlation between baseline
characteristics and OS in a Phase III study of 2nd-line HR -MDS pts with IPSS-
R VHR.
Methods: A log-rank test was run on each baseline disease characteristic from
the 93 RIG and 41 BSC pts with IPSS-R VHR in the ONTIME study.
Results: Promising improvement (p<.01) with RIG on median OS vs BSC was
shown in several subgroups defined by baseline characteristics (see Table 1).
Overall, adverse events (AEs) were reported in 100% of RIG pts and 95% of
BSC pts with IPSS-R VHR. AEs ≥Grade 3 in ≥10% of pts were: anaemia (RIG
24%, BSC 11%), thrombocytopenia (21%, 11%), febrile neutropenia (17%,
11%), neutropenia (15%, 13%), pneumonia (12%, 13%).
Table 1. Median (months) OS by baseline disease characteristics in Pts
with IPSS-R VHR.
Summary and Conclusions: IPSS-R is a useful prognostic tool for 2nd-line
MDS pts. After HMA failure, MDS pts with IPSS-R VHR in certain subgroups
identified by baseline disease characteristics showed an OS advantage when
treated with RIG compared to BSC. Such characteristics should be considered
in the design of future 2nd-line studies in MDS patients with IPSS-R VHR.
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INCREASED IMMUNE ACTIVATION AND IMPAIRED CELL SUPPRESSION
ON MYELODYSPLASTICS SYNDROMES PROGRESSION
A. Perazzio1,2,* M.D.L. Chauffaille1,2
1Hematology, Unifesp, 2Hematology, Fleury Laboratory, São Paulo, Brazil
Background: The Myelodysplastics Syndromes (MDS) are characterized by
clonal proliferation of bone marrow cells with inefficient production. Its patho-
genesis is still unknown. Some patients present autoimmune phenomena and
abnormal immune function. Furthermore, some immune alterations remain
unexplained according to the disease progression
Aims: This study aims determine cell-mediate suppression by Treg in MDS
patients in 2 periods: zero and 12months
Methods: Peripheral blood of 38 patients was obtained initially (T0) and after
12 months (T12). Tregulatory (Treg) were sorted by flow citometry and cocul-
tured for 7 days with T effector cells (Teff) in different concentration (Teff isolated
with stimulation by phytohemagglutinin(Teff+PHA), Teff:Treg:1:1 and
Teff:Treg:8:1) to evaluate cell-mediate suppression by Treg and quantify inter-
leucines production (IL2, IL4, IL6, IL10, IL17, TNFa and IFNg) in culture super-
natant by CBA. Relative gene expression of IRF-1(exons 2 and 4/5) was detect-
ed by qRT-PCR in peripheral Treg cells and peripheral blood and gene expres-
sion of Foxp3 was detected only in peripheral Treg cells
Results: Treg number (T0=5,6x105±2,8 vs T12=4,8x105±2,60; p=0.3) and Teff
percentage (T0=16,8%±9,5 vs T12=13,1%±6,3; p=0.06) did not differ after 12
months, albeit there was a trend toward a decrease of Teff. Co cultures of
Treg:Teff 1:1 showed an increased Teff proliferation in T12 (41,9%±3,1) com-
pared to T0 (28,2%±4,7; p=0.02). The cytokine production was significantly
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IL17:p<0,001). Relative genetic expression of IRF-1 exon 4/5 was increased in
whole blood (T0=0,02±0,14 vs T12=0,99±0,2;p=0,001) and Treg (T0=0,07±0,07
vs T12=0,14±0,08; p<0.001) after 12 months. However, genetic expression of
exon 2 was only increased in whole blood (T0=0,002±0,01 vs T12=0,01±0,01;
p<0.001), while the genetic expression of Foxp3 in Treg did not present statis-
tical differences (T0=0,06±0,06 vs T12=0,07±0,12; p=0.57). Interestingly, a
moderate positive correlation between the genetic expression of Foxp3 and
IRF-1 exon 4/5 (R=0,659; p=0.002)
Summary and Conclusions: The increase of Teff proliferation and cytokine
production suggests an impairment of Treg suppression ability and might be
related to dysfunctions in inhibition by contact and inhibitory cytokine production.
The initial reduced expression of IRF-1 in MDS patients evolved with an impor-
tant increase during the disease progression. This gene is a powerful tumor
suppressor and its low expression may be associated to disease progression.
Moreover, IRF-1 is involved in several immune functions and high expression
was described in MDS patients with autoimmune manifestations, thus the
observed higher expression of IRF-1 might be associated to increased cytokine
production, like IFN. In mice, IRF-1 inhibits Foxp3 expression in Treg cells.
However, our results showed a positive correlation of IRF-1 exon 4/5 and Foxp3.
Thus it is possible that the high IRF-1 expression was disproportionally induced
by Foxp3 in MDS patients along disease progression
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IMMUNE EXACERBATION ON MYELODYSPLASTICS SYNDROMES
A. Perazzio1,2,* M.D.L. Chauffaille1,2
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Background: The Myelodysplastics Syndromes (MDS) are characterized by
clonal proliferation of bone marrow cells with inefficient production. However,
the pathogenesis is still unknown. Some patients present autoimmune phe-
nomena and abnormal immune function
Aims: This study aims to evaluate T cell function in MDS patients. Associated
to autoimmune manifestations and prognostic scores will be detailed and com-
pared to controls
Methods: The diagnosis of MDS was made according to WHO classification
including the analysis of peripheral blood/marrow cell morphology and kary-
otype, and patients were stratified for prognosis according to IPSS, IPSS-R,
WPSS. Peripheral blood from 38 MDS patients, 28 HC(healthy controls) and
17 AID (autoimmune disease composed by lupus and rheumatoid arthritis)
were obtained. Tregulatory (Treg) were sorted by flow citometry and cocultured
for 7 days with T effector cells (Teff) in different concentration (Teff isolated with
stimulation by phytohemagglutinin, Teff:Treg:1:1 and Teff:Treg:8:1) to evaluate
cell-mediate suppression by Treg and quantify interleukines production (IL2,
IL4, IL6, IL10, IL17, TNFa and IFNg) in culture supernatant by CBA. Relative
gene expression of IRF-1 was detected by qRT-PCR in peripheral Treg cells
and peripheral blood, and Foxp3 was detected only in peripheral Treg cells.
Antinuclear antibodies (ANA) were determined by indirect immunofluorescence.
Total complement (CH100) and C2 serum levels were determined by radial
immunohemolysis
Results: Treg number (x105cells) was not different in the MDS patients sub-
groups determined according to prognosis score: IPSS (high=4,9±1,1 vs
low=5,6±1,6; p=0,5), WPSS (high=5,8±2,2 vs low=5,2±0,4; p=0,29), and IPSS-
R (high=5,8±2,5 vs low=5,6±0,6; p=0,6). Hemoglobin serum levels was lower
in high risk (7,9mg/dL±1,2) compared to low risk patients (9,9mg/dL±0,2;
p=0.025), according to IPSS score. There was no difference in Treg number
(x105cells) according to the presence of normal (5±0,8) or abnormal karyotype
(6,5±1,2; p=0.12). Treg number (x105cells) was significantly higher in MDS
(5±2,8) than in HC (3,1±2,0; p=0.007) and AID (2,8±2,4; p=0.008). Peripheral
Teff percentage was similar in HC (20±8,3), MDS (13,3±9,0; p=0,27) and AID
(14±6,8; p=0,98). Suppression of proliferation Teff mediated by Treg cell was
decreased in the AID group compared to HC (p=0,03) and MDS (p<0.003).
Overall cytokine production detected in culture supernatant was decreased in
MDS, except for IL17, which was higher in AID (98,7pg/mL±155) compared to
HC (16,4pg/mL±49,3) and MDS (9,1pg/mL±95,7; p<0.001). The relative gene
expression of IRF-1 exon 2 (0,01±0,015 vs 0,001±0,01; p<0.02) and 4/5
(0,10±0,11 vs 0,02±0,14; p<0.01) in total peripheral blood were lower in MDS
patients compared to IAD. Additionally, relative gene expression of IRF-1 exon
4/5 in Treg cell was increased in AID (0,11±0,11; p=0,005) compared to
MDS(0,07±0,07) and HC (0,02±0,07; p=0,003). The relative gene expression
of Foxp3 in Treg cell was similar in the three groups (MDS=0,06±0,06 vs
AID=0,04±0,1 vs HC=0,04±0,04; p=0,96). MDS (46,2U/mL±2,1) patients pre-
sented lower CH100 than IAD (98,2U/mL±1,5; p=0,014). The frequency of ANA-
positive individuals was higher in MDS than in HC (p=0.029)
Summary and Conclusions: Our results showed that suppression of Teff cell
by Treg cell in MDS is similar to the controll, however the peripheral number of
Treg cell is higher than in HC and AID, suggesting that function might be
increased in MDS patients. One can hypothesize that it occurs secondarily, in
an attempt of controlling the disease immune hyper activation. Interestingly,
cytokine production was globally impaired in MDS, revealing a possible exhaus-
tion of immune system, emphasized by complement consumption
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LONG-LASTING HEMATOLOGIC RESPONSE TO AZACITIDINE IN
MYELODYSPLASTIC SYNDROMES: UPDATE OF CLINICAL RESULTS
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Background: Although Azacitidine (AZA) has proven effective in myelodys-
plastic syndromes (MDS), the duration of haematologic response is usually
limited (median: 13.6 months) (Fenaux 2009). The French Group (Itzykson
2011) identified some clinical and haematologic parameters (poor ECOG per-
formance status (p.s.), IPSS intermediate and poor risk cytogenetics, circulating
blasts, high transfusion need) independently associated with a a poorer out-
come, and these 4 criteria were integrated in a 3-risk-group prognostic score.
Aims: These data prompted us to retrospectively analyse our MDS pts treated
with AZA who showed a favourable long-lasting response to AZA (i.e.: duration
of response ≥20 months), in order to enucleate the clinical and hematologic
features of long-responder pts.
Methods: The type of response was defined according to IWG criteria (Cheson
2006): Complete Remission (CR), Partial Remission (PR), Marrow CR (mCR),
Hematologic Improvement (HI). The response duration was measured from the
date of achievement of a first response until the date of disease progression or
death. Overall Survival (OS) was measured from the start of AZA treatment. More-
over, we quantified the degree of phosphoinositide-phospholipase C (PI-PLC)
beta1 methylation and gene expression before and during AZA administration.
Results: From September 2004 in our Institution, 70 pts (50 males, median
age 70, range 37-87 yrs) were treated with AZA. 40/70 pts (57.1%) showed a
favourable response. 6 pts underwent allogeneic stem cell transplantation.
11/70 pts (15.7%, 27.5% of the responder pts) (4 males, median age: 68, range
60-84 yrs) showed a response duration ≥20 months. At AZA onset, WHO diag-
nosis was: RCMD-RS: 1 pt; RAEB-1: 4 pts; RAEB-2: 5 pts; MDS with Fibrosis:
1 pt. MDS was therapy-related in 3 pts. ECOG p.s. was <2 in all cases. IPSS
risk was: Low: 1 pt; INT-1: 3 pts; INT-2: 6 pts; High: 1 pt. WPSS risk was: Low:
1 pt; INT: 2 pts; High: 5 pts; Very High: 3 pts; IPSS-R risk was: Low: 2 pts; INT:
3 pts; High: 4 pts; Very High: 2 pts. IPSS cytogenetic risk was: Good: 5 pts;
INT: 4 pts; Poor: 2 pts. Transfusion need was high (≥4 RBC units/8 weeks) in
4 pts. No patient showed circulating blasts. Following Itzykson’s AZA prognostic
scoring system, the risk was: Low: 3 pts; INT: 8 pts. The pts received a median
of 24 (8-59) cycles of AZA (3 lower-risk pts discontinued therapy after 8th cycle).
The median duration of treatment was 35 (8-68) months. The best response
achieved was: CR in 6 pts; marrow CR+HI: 1 pt; HI: 4 pts. First Response and
Best Response were observed after a median of 1 (1-5) and 8 (1-12) cycles,
respectively. An abnormal karyotype persisted in 3 pts. The median duration of
response was 40 (21-75) months. In 8 pts, after the 1st 8 cyles, the intervals
between cycles were prolonged on average up to 8 weeks, and in 5 pts ery-
thropoietin was added during the maintenance therapy. Grade >2 non hema-
tologic toxicity was observed in 2 pts. In 8 pts the disease evolved into AML (4
pts), or into a more advanced MDS (2 pts), or into a chronic myeloproliferative
neoplasm (2 pts). 6 pts are still alive, and 2 pts are still maintaining the response
after 49 and 71 months, respectively. Median OS from the start of AZA was 50
(25-125) months. All the pts showed an increase in PI-PLCbeta1 expression,
that was maintained along with the hematologic response.
Summary and Conclusions: Our data show that a limited but significant fraction
of MDS pts show a long-lasting hematologic and molecular response to AZA.
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THE EFFICACY OF THE 5-AZACITIDINE IN THE THERAPY-RELATED
MYELOID NEOPLASIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE
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Background: Therapy-related myelodysplastic neoplasia (t-MDS/AML) is an
increasingly complication in patients (pts) treated with radiotherapy or
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chemotherapy for previous hematologic or solid tumors. Conventionally, these
pts are considered having a bad prognosis and allogeneic stem cell transplan-
tation is the gold standard therapy. However, this approach is often not
exploitable due to patient ineligibility or lack of stem cells donor. In these cases,
if pts had a medullar blast count below 30%, 5-azacitidine (5-AZA) may be a
suitable alternative. Very few data in this setting are available.
Aims: To evaluate the effectiveness of 5-AZA in this group of pts in the clinical
practice. To assess the influence of cytogenetic risk into the outcome.
Methods: A retrospective analysis of t-MDS/AML cases into a large cohort of
pts treated with 5-AZA in 10 centers in Lombardia region was performed. The
cytogenetic risk was evaluated in according to the recently developed cytoge-
netic system for Myelodysplastic Syndromes (Schanz JCO 2012) and used as
parameter in the prognostic score IPSS-R. Considering the small sample, the
“very low”, “low” and “intermediate” risk patients were evaluated together and
their survival was compared to the survival of the “high” or “very high” cytoge-
netic risk pts. Response to therapy was considered evaluable if pts had
reached, at the time of observation, at least 6 cycles of 5-AZA. The Kaplan
Meier method, followed by the Logrank test was applied to evaluate the survival,
starting from the beginning of treatment, and in relationship to the cytogenetic
stratification.
Results: From a population of 187 pts affected by a myeloid malignancy with
a medullar blast count <30% and treated with 5-AZA, data about 29 cases of
t-MDS/AML were carried out. Of these 16 were female and 13 were male.
Median age was 70 (range 40-87). Bone marrow blasts count was ≥20% in 2
cases, ≥10% in 10 cases and <5% in 3 cases. In 13 cases Red Blood Cells
transfusion dependence was present. In the other 16 cases median hemoglobin
level was 9.4 g/dl (range 8.6-12). Only 2 pts had platelet count (PLT)
<10.000/mm3, in other 10 case PLT were <50.000/mm3. In 7 cases neutrophil
count was less than 800/mm3. The median number of 5-AZA courses admin-
istered was 5 (range 1-20). A response to the treatment (including the cases
of “stable disease” maintenance) was achieved in 15 cases on 21 evaluable.
The median survival was 12.1 months (Figure 1a). The median survival of the
responders was significantly higher than the non responders one (23.8 months
versus 4.3 months; p=0.023, Figure 1b).
The cytogenetic analysis, at the starting therapy time, was available in 27 cases.
Considering the cytogenetic risk, the pts were divided as shown in Table 1.
Table 1.
Cytogenetic risk           Very Low           Low       Intermediate      High         Very High
Pts (n°)                             1                   8                  2                  7                 9
The survival of “very low”, “low” or “intermediate” cytogenetic risk pts did not
differ significantly from the survival of “high” or “very high” risk ones (p=0.1890;
Figure 1c).
Figure 1.
Summary and Conclusions: Treatment in t-MDS/AML patients with 5-azaci-
tidine seems to be effective to induce a response in these patients (71.4% of
evaluables). Responding pts had a significative benefit in overall survival. The
presence of a “high” or “very high” cytogenetic risk according to the IPSS-R
stratification did not influenced the survival.
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S. Papamichos1,* D. Margaritis1, E. Spanoudakis1, A. Christoforidou1,
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Background: Transposable elements (TEs) are known to promote genomic
plasticity by affecting both the expression patterns and the splicing motifs of
genes. Endogenous retroviruses (ERVs) represent remnants of ancient retro-
viral insertions into the host genome DNA that throughout the course of Verte-
brate evolution became fixed in the germ line. Human ERVs lack the ability to
retrotranspose however their long terminal repeats (LTRs) contain transcription
regulatory elements that, in the sense orientation, are functional and could be
adopted for use by nearby host genes. TNFSF11, the gene encoding for RAN-
KL, generates by alternative splicing two validated mRNA variants. TNFSF11
variant 1 (NM_003701.3) contains five exons and encodes for the membrane-
bound form of RANKL. Proteolytic cleavage of this transmembrane form allows
for the generation of a soluble form of the protein. TNFSF11 variant 2
(NM_033012.3) contains a set of alternate 5′ exons compared to variant 1,
lacks the exon encoding for the intracellular and transmembrane domains of
membrane-bound RANKL and can be directly translated into the soluble form
of RANKL protein. Originally identified in SCC-4 and T3M-1 Cl.2 squamous
cell carcinoma cell lines, it has been deduced that variant 2 is predominantly
expressed in malignant cell types. Interestingly, it has recently been suggested
that transcription of this variant is mediated via a distinct proximal promoter
sequence.
Aims: Highlight, via in silico analysis, that exon 1A of TNFSF11 variant 2 (sol-
uble RANKL mRNA, sRANKL) was evolutionary provided by an exapted ERV-
classI sequence. Show that transcription regulatory sequences of the putative
sRANKL proximal promoter were also provided by this genetic element as well
as by a nearby, upstream, TEs.
Methods: TNFSF11 and the genomic region spanning 5000 nts upstream were
downloaded from the NCBI Gene database and scanned for the presence of
TEs by RepeatMasker. TNFSF11 locus syntenic alignments of numerous mam-
mals were downloaded from the UCSC Genome Browser Database. The syn-
tenic DNA segments extracted were scanned by RepeatMasker. EMBOSS
Cpgplot was used to identify putative CpG islands located in the genomic region
spanning 5000 nucleotides upstream sRANKL transcriptional start site (TSS).
PROMO Version 3.0.2 software was used to evaluate transcription factor (TF)
binding affinity of the region spanning 250 nucleotides upstream sRANKL TSS;
assumed to include precious regulatory elements of the variant’s putative prox-
imal promoter. Only human factors and human binding sites were concidered,
applying a stringent maximum matrix dissimilarity rate of 7.
Results: TNFSF11 exon 1A locates in a region reported from RepeatMasker
to match a sense orientation LTR78 element, belonging to the ERV-classI fam-
ily. Thorough computational analysis, considering fragments of interrupted
repeats as joined by RepeatMasker, combined with in-depth phylogenetic
analysis strongly support that the genomic region ranging from 1638 nts
upstream to 3155 nts downstream sRANKL TSS was evolutionary provided by
a “TE cluster”; namely a region where older TEs, integrated into the host
genome, were interrupted by the insertion of younger ones. The genomic region
spanning 4000 nts upstream sRANKL TSS contains CpG-rich genomic content.
A CpG island was identified in this region, ranging from 2977 to 2775 nts
upstream sRANKL TSS. Of note, the DNA segment including the CpG island
was evolutionary provided by a LTR12C genetic element, locating short
upstream the “TE cluster”. The region spanning 250 nts upstream sRANKL
TSS includes many high-affinity TF binding sites. A putative binding site for
CREB1, a potent stimulator of TNFSF11 variant 1 expression, locates 41 nts
upstream sRANKL TSS. In addition, potential binding sites for factors inducing
gene transcription during T cell-dependent immune response (for example
STAT4 and NFATC2) as well as for factors regulating apoptosis and tumor-
suppression (TP53, IRF1) were identified (Figure 1).
Summary and Conclusions: Exaptation of an ERV-classI repeat allowed for
a novel TNFSF11 transcriptional pattern to occur. TEs, especially ERVs, are
known to represent common targets of DNA methylation. Transcription of these
genetic elements increases in the hypomethylated tumor microenvironment.
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In this context, the CpG-rich content of the region spanning 4000 nts upstream
sRANKL TSS, including the presence of a CpG island, could explicate the
observed preferential expression of sRANKL in malignant cells.
Figure 1.
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Background: Multiple myeloma (MM) survival improved dramatically with the
introduction of new therapies in the mid-late 2000s. These therapies essentially
transformed MM from an acute condition to a potentially manageable chronic
disease. The impact of further advances in MM therapy is uncertain, but can be
projected by analyzing historical data and expected future clinical trial outcomes.
Aims: The aim of the study is to estimate the current and future patient out-
comes in MM, specifically overall survival, using a novel approach.
Methods: For the historical perspective in the US (1990-2008), we calculated
overall survival for patients diagnosed in a given year (cohort OS) by analyzing
data from Surveillance, Epidemiology & End Results (SEER). For the predictive
analysis, we calculated cohort OS using a patient flow model by integrating
data from clinical trials, cancer registries and demographics as well as assump-
tions from key opinion leaders. We simulated progression of each cohort based
on treatment rates and time spent in each line of therapy. The resulting OS
curves were calibrated to 19 years of historical data.
Results: The median cohort OS in the US remained relatively static from 1990-
2001 at ~30 months, but increased by ~43% to 43 months in 2008. The median
cohort OS is expected to continue rising to ~72 months in 2022, which repre-
sents ~67% improvement from 2008 and ~140% improvement from 2001 (Fig-
ure 1). The life expectancy of patients diagnosed with MM in 2022 would thus
be ~75 years, but will still be shorter than the current ~86 year life expectancy
of the general population at the median diagnosis age at ~69 years. In European
geographies, we expect to see similar trends, albeit with a slight delay that
reflects the access restrictions and adoption patterns of novel therapies by
treating physicians.
Figure 1.
Summary and Conclusions: This analysis highlights the dramatic improve-
ments in MM survival since 2000 and the expected improvement in the future,
demonstrating the transformative impact and value of novel therapies. Over
the next few years, with better scientific understanding of MM and the use of
novel drug regimens, we expect to see additional improvement of ~67% in OS
for MM patients. Nevertheless, there is opportunity to further bridge the life
expectancy gap between the general population and MM patients.
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Background: Background: Recently, it was described that myeloma cells are
chronically exposed to hypoxic environment in the bone marrow. Although the
stabilization and nuclear localization of HIF-1 alpha protein in malignant plasma
cells, was confirmed in many studies, the hypoxia transcriptional signature was
not revealed thus far in MM patient. In fact, in order to determine such signature
it has to be demonstrated how the long term sorting process of CD138 positive
cells, conducted in the presence of oxygen, influences the expression of genes
triggered in hypoxic environment. 
Aims: Aim: To determine the stability of the hypoxia induced transcriptional
expression profile of malignant plasma cells applied to oxygen environment,
what mimics the condition during the sorting process of CD138 positive cells.
Our goal is to provide the bases for a proper determination of hypoxia signature
in multiple myeloma patients, taking into the consideration the influence of diag-
nostic procedure (CD138 cell sorting) on hypoxia-induced gene expression
changes in malignant plasma cells.
Methods: Methods: Malignant plasma cells were cultured in hypoxic environ-
ment for 16h. The proper hypoxic stimulation was confirmed by the presence of
HIF-1 alpha transcription factor in hypoxic cells by western blot and up-regulation
of established hypoxia target genes by RT-PCR. Among the analyzed gene (ADM,
BNIP3, VEGFA, PFKFB4, AK3L) we chose PFKFB4, as an excellent surrogate
marker of hypoxia in malignant plasma cells. Next, we determined the stability of
the hypoxia induced transcriptional expression changes of PFKFB4 in malignant
plasma cells applied to oxygen environment, mimicking the conditions during the
sorting process of CD138 positive cells. Upon indicated time points we analyzed
the influence of normoxic environment on hypoxia-induced stabilization of HIF-1
alpha (Western Blot) and on expression of hypoxia-induced PFKFB4 (RT-PCR).
The analysis was performed in the room temperature and in 40C. 
Results: Results: In our present study we identified PFKFB4, as an excellent
surrogate marker of hypoxia in malignant plasma cells. We demonstrated very
low expression of PFKFB4 in normoxic condition in all analyzed cell lines, oppo-
site to other established HIF-1 alpha target genes, which expression differs
between different cell lines. Importantly, PFKFB4 was strongly upregulated by
hypoxia in all tested multiple myeloma cell lines. Next, we determined the sta-
bility of the hypoxia induced HIF-1 alpha accumulation and hypoxia-induced
changes of PFKFB4 mRNA expression in malignant plasma cells applied to
oxygen environment, what mimics the condition during the sorting process of
CD138 positive cells. Our study revealed that HIF-1 alpha transcription factor
is stable for at least 6h in hypoxic cells applied to normoxic environment, pro-
vided they are kept in 40C. Nevertheless, however, in room temperature (RT),
the HIF-1 alpha transcription factor is not detected anymore upon 5 minutes in
normoxic environment. As for the hypoxia-induced transcriptional response,
we determined that PFKFB4 mRNA expression changes in malignant plasma
cells are significantly influenced by normoxic environment (RT), after the esti-
mated time required for CD138 sample preparation (from the bone marrow
aspiration to the step of RNA isolation of CD138 sorted plasma cells).
Summary and Conclusions: Summary and Conclusions: Our research
demonstrated that hypoxia-induced changes in the gene expression are not
stable in normoxic environment during the time required for the bone marrow
(BM) aspirate preparation. Thus, based on this study, we can conclude that the
delay in CD138 plasma cells analysis strongly influences the gene expression of
surrogate hypoxia markers in malignant plasma cells and only very strict labora-
tory practice allows the detection of hypoxia-induced transcriptional signature in
malignant plasma cells. Our study clearly points the approach, which should be
applied for BM aspirates to detect the hypoxia-induced gene expression profile. 
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Background: Multiple myeloma (MM) is a B-cell malignancy characterized by
the bone marrow (BM) accumulation of a clonal population of plasma cells,
which secretes a monoclonal IgH protein. The first step to the cure of MM is
achieving a clinical complete response (CR). However, a majority of patients
relapse in part due to the persistence of low levels of pathological plasma cells
after treatment (Minimal residual disease (MRD)), sometimes more 108 patho-
logic plasma cells. In addition, residual cells have a heterogeneous clonal archi-
tecture and clonal evolution. Accordingly, the technology employed to assess
MRD should not also be able to identify pathological clones, but also be able
to assess clonal evolution.
Next generation sequencing (NGS) allows the identification of clonogenic B or
T cells with high sensitivity and specificity and is suitable for detection of MRD
as shown recently in patients with chronic lymphocytic leukemia (CLL).
Aims: To present a new method for quantification of immunoglobulin (Ig) gene
clonal rearrangements from a polyclonal background by next generation
sequencing (NGS). To test the suitability of the method for minimal residual
disease (MRD) detection in Multiple Myeloma (MM) patients compared with
Flow Cytometry (FC) data.
Methods: We analyzed DNA from bone marrow samples of 50 patients (50
diagnostic samples and 76 follow-up samples). The method employs the
primers developed by BIOMED-2 for IGH (VDJ, DH-JH) and IGK (VJ and Kdel),
and a set of specific mathematical and bioinformatics tools.
First, we identified the clonal rearrangement(s) (clonotype) in the diagnostic
sample by fragment analysis and NGS. Second, we searched the NGS
sequences from follow-up samples to detect the presence of the clonotype
identified in the diagnostic sample.
PCR fragments shorter and longer than 250pb were sequenced with Proton
and PGM sequencers respectively (Ion Torrent) following manufacturer instruc-
tions (Life Technologies) with slight modifications.
Sensitivity was calculated with serial dilutions of samples of known MRD values
with polyclonal samples.
In follow-up samples we analyzed at least 1 µg of DNA to achieve a sensitivity
of 10-5 EMR values were calculated using the DIFF algorithm and the equation:
EMR=[Lc*(D/K)]/Lt2
Where: Lc sample clonal reads, Lt sample total reads, D ng of gDNA used for
PCR amplification, and k ng of gDNA per diploid cell.
Results: The sensitivity of the method is 10-5 for 150.000 cells. Reproducibility
is >90%. The linear correlation coefficient between NGS and FC data for diag-
nosis and follow-up samples was R=59 and R=0.51, respectively. The Pearson
correlation coefficient was 0.765, p<0.0001 for diagnostic and 0.716, p<0.0001
for follow-up samples. The Ig variable region usage identified by NGS was in
accordance with the described in the literature for MM.
Summary and Conclusions: NGS sequencing of Ig genes with the Ion Torrent
methodology is an effective technology to identify and quantify pathological
clonal cells in MM. It is a methodological and economical alternative to CF and
other methods for MRD follow-up.
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Background: Through the last years, the importance of HGF/MET signaling
related to Multiple Myeloma (MM) pathogenesis has been described. Because
of this, the inhibition of this signaling pathway could constitute a new therapeutic
target. Nowadays, there are lots of drugs whose mechanism of action is inhibit-
ing this signaling pathway.
Aims:-Analyze the mechanism of action that one MET inhibitor has on MM
patient’s plasma cells and MM cell lines. - Discover any possible synergism
combination among MET inhibitor and other antimyeloma drugs (Dexamatha-
sone, Lenalidomide, Bortezomib and Melphalan). - Evaluate the effect of MET
inhibitor on MM clonogenic cells.
Methods: Bone marrow plasma cells from: 44 MM patients at diagnosis, 8
patients without bone marrow infiltration and 6 MM cell lines, were studied.
MET and L1-MET expression was carried out on cDNA from plasma cells puri-
fied from all the samples. Levels of expression were quantified on the three
types of samples by SYBR assay; GUSB was used as control gene and MM
cell line U266 as control sample. Methylcellulose assays were carried out to
study the effect of MET inhibitor on MM clonogenic plasma cells. MET mutations
were studied by Next Generation Sequencing on MM plasma cells. Dose
response curves for cell viability of MM plasma cells and cell lines treated with
MET inhibitor, antimyeloma drugs or combination of both was stablished by
MTT assay. Combinations were carried out with IC30, IC50 and IC70 values
for each drug alone and plasma cell to study synergistic combinations.
Results: MM patients showed MET overexpression regarding to control bone
marrows that don’t have plasma cell infiltration (p-value=.0012). MM cell lines
MM1S and OPM2, were the most sensitive to MET inhibitor treatment (IC50 of
0.06 and 0.26 μM, respectively). These cell lines only showed MET expression.
L1-MET and MET transcripts were exhibited by RPMI, U266 and NCI-H929
MM cell lines and have higher IC50 values (3.6, 1.31, 1.09 μM, respectively).
This relation between L1-MET, MET levels expression and IC50 values were
also showed in MM patient’s plasma cells. We didn’t observe any mutation on
MET gene, so aberrant MET activation in MM is not due to activated mutations
on this gene but for MET overexpression. Besides that, MET inhibitor had cyto-
toxic effect on clonogenic plasma cells around IC50 values; we didn’t observe
any colony at higher concentrations of 0.02 μM MET inhibitor. MM cell lines
resistant to MET inhibitor presented synergism among the MET inhibitor and
anti-myeloma drugs (Dexamathasone, Lenalidomide, Bortezomib and Melpha-
lan), having high dose reduction index (DRI) (from 3.08 to 62.7) (Figure 1).
Figure 1. Cytotoxicity of MET inhibitor.
Summary and Conclusions: MET inhibition could be a new therapeutic option
in multiple myeloma. MET inhibition is synergistic with proteasome inhibitors
and immunomodultor drugs, as well as it kills clonogenic myeloma cells. L1-
MET transcript may be a biomarker in MM treated with MET inhibitors.
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INITIAL EVALUATION OF NOVEL DUAL PIM/PI3K AND TRIPLE PIM/PI3K/
MTOR INHIBITORS IN MULTIPLE MYELOMA
M. Reidy1,* M. vanDijk1, N. Keane1,2, M. O’Neill3, M.E. O’Dwyer1,2
1Apoptosis Research Center, 2Haematology, National University of Ireland,
Galway, Galway, 3Inflection Biosciences, Dublin, Ireland
Background: Multiple myeloma (MM) is characterised by clonal expansion of
malignant plasma cells in the bone marrow (BM). Despite significant advances
in treatment it remains incurable. This is largely due to the supportive role the
BM environment plays in migration, survival, proliferation and drug resistance.
BM microenvironmental signalling along with other factors such as treatment
with proteasome inhibitors (PI) can contribute to activation of the PI3K/AKT
survival pathway. Multiple small-molecule inhibitors have been developed to
target PI3K/AKT or mTOR kinases, but the efficacy of these drugs is likely to
be compromised by the stimulation of compensatory signalling pathways. The
redundancy of signalling pathways provides back-up mechanisms allowing
escape from targeted inhibition. One such compensatory pathway is that driven
by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR
and share several downstream molecular targets. As with PI3K/AKT, the BM
microenvironment plays a major role in PIM activation. PIM1 and particularly
PIM2 are known to be highly expressed in MM and play important roles in reg-
ulating MYC-driven transcription, apoptosis, cytokine signalling, cell proliferation
and protein translation. Combinations of separate PI3K and PIM inhibitors have
shown evidence of synergy in MM cell lines and animal models and a PIM
kinase inhibitor has recently shown activity in relapsed/refractory MM.
Aims: We wished to evaluate the activity of a novel family of kinase inhibitors
capable of inhibiting not only PIM kinases but also PI3K/AKT (dual inhibitors)
and PI3K/AKT/mTOR (triple inhibitors). 
Methods: We evaluated the in-vitro activities of a single pan-PIM (pPIMi), dual
PIM/PI3K (IBL-202) and triple PIM/PI3K/mTOR (IBL-301) inhibitor in a number
of MM cell lines alongside the pan-PI3K inhibitor GDC-0941 and the pan-PIM
inhibitor AZD1208. IBL-202 and IBL-301 are low nanomolar pan-PIM/PI3K and
pan-PIM/PI3K/mTOR inhibitors respectively. These dual and triple inhibitors
show excellent kinase selectivity profile against a panel of 456 kinases. Cell
viability was assessed using the Cell-Titre Glo assay and apoptosis was deter-
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mined using Annexin-V/PI staining. To examine the impact of the microenvi-
ronment on the efficacy of these compounds MM cells were co-cultured with
HS-5 stromal cells or in a hypoxic glove box (1% O2).
Results: Inhibiting PIM kinases and the PI3K pathway simultaneously using
IBL-202 was significantly more potent than a pan-PI3K inhibitor, GDC-0941
alone or pan PIM kinase inhibitors pPIMi or AZD1208. This was observed in all
MM cell lines tested and in addition for the compound IBL-301, a triple inhibitor
of PIM kinases, PI3K and mTOR. IC50 values were in the 0.5µM and 0.05µM
range for IBL-202 and IBL-301, respectively. In comparison pPIMi and GDC-
0941 scored an IC50 value between 5 and 10µM while the IC50 for AZD1208
was >20µM (Figure 1). In addition IBL-202 and IBL-301 caused a reduction in
pAkt and known PIM targets, pBad and pS6. Bortezomib caused a marked
increase in levels of PIM2 in MM cell lines. A combined treatment of IBL-202 or
IBL-301 with bortezomib resulted in a synergistic effect in these cell lines (CI<1). 
In an effort to mimic the tumour microenvironment MM cell lines were co-cul-
tured with the stromal cell line HS-5s. We observed strong induction of PIM2
in MM cells following co-culture. Co-culture protected MM cell lines against
bortezomib-induced cell death, while promoting the apoptotic effect of both IBL-
202 and IBL-301 with an increase in Annexin V positive cells from 15% to 40%.
This suggests that microenvironmental stimulation could potentially induce syn-
thetic lethality in the presence of these inhibitors. The tumour microenvironment
in MM patients is hypoxic compared to healthy controls. Hypoxic conditions led
to an increase in levels of PIM1 which is reported to regulate the surface expres-
sion of the CXCR4 receptor. The CXCR4 receptor is important for MM cell sur-
vival, migration and microenvironment interaction. We have observed a
decrease in levels of CXCR4 following treatment with IBL-202 in a dose depend-
ent manner. The dual and triple inhibitors are optimized with respect to their in
vitro ADME properties and have excellent oral bioavailability. In-vivo IBL-301
has been well tolerated, with no signs of toxicity even 20 times above the effi-
cacious dose in a transgenic (KRASV12NSCLC) mouse model. Testing of IBL-
202 in a relevant MM mouse model is planned in the near future.
Figure 1.
Summary and Conclusions: IBL-201 and IBL-301 show promising activity in
MM cellular models with increased potency compared to inhibitors targeting
PIM or PI3K alone and warrant further evaluation in this disease.
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PILOT ASSESSMENT OF PROXIMITY EXTENTION IMMUNOASSAY IN
PATIENTS WITH MONOCLONAL GAMMOPATHIES: PARALLEL EVALUA-
TION OF 92 CANCER-RELATED PARAMETERS IN BONE MARROW AND
IN SERA
J. Minarik1,* E. Kriegova2, P. Schneiderova2, J. Zapletalova3, P. Pusciznova1,
J. Hrbek4, Z. Hermanova2, T. Pika1, J. Bacovsky1, M. Herman4, V. Scudla1
1Department of Hemato-oncology, 2Department of Immunology, 3Department
of Biophysics and Statistics, 4Department of Radiology, Faculty of Medicine
and Dentistry of Palacky University and University Hospital Olomouc, Olomouc,
Czech Republic
Background: The assessment of prognostic factors in cancer is vital for correct
stratification and targeted therapy. In multiple myeloma, both tumor cells and
bone marrow microenvironment play an important role in pathogenesis, and
take part on the development and the extent of myeloma bone disease (MBD).
Aims: The aim of our project was to address the utility of Proximity Extention
ImmunoAssay technique (PEA) in patients with monoclonal gammopathies
instead of standard ELISA techniques in the assessment of tumor microenvi-
ronment parameters.
Methods: We assessed 92 cancer-related parameters from the Oncology I
96x96 protein biomarker panel (Olink, Uppsala, Sweden). The parameters are
known to be altered in various cancer types and are related to angiogenesis,
cell-cell signaling, growth control and inflammation. Both sera and bone marrow
samples were acquired from 30 patients with monoclonal gammopathies-25
patients with multiple myeloma (MM) and 5 individuals with monoclonal gam-
mopathy of undetermined significance (MGUS) taken at the time of
diagnosis.PEA is a sensitive and specific alternative of ELISA methods. For
each sample there are two different antibody probes labeled with A- and B-
oligonucleotides. Proximity of the oligonucleotide chains to the binding site
leads to PCR amplification of the signal with specific primers. For statistical
estimation we used Mann-Whitney U-test, Kruskal-Wallis test and Spearman
correlation analysis at p˂0.05 and Principal Component Analysis (GenEx,
SSPS).
Results: In 3 patients the data did not pass the quality control. In the rest 27
individuals we analysed parallelly bone marrow and sera analytes. In 58 ana-
lytes the levels in bone marrow and serum were significantly different, with up
to 38 fold difference (over 5 log scale), the rest 34 analytes had similar levels
in both bone marrow and sera. Out of the whole panel, 9 analytes were signif-
ically different when comparing individuals with or without the presence of renal
impairment. We found 19 proteins that significantly differed between MGUS
and MM in both serum and bone marrow. There were several perspective can-
didate biomarkers correlating with disease stage, extent of myeloma bone dis-
ease, M-protein type and therapeutic outcome, such as tartrate resistant alka-
linephosphatase-5 (TRAP-5), matrix metalloproteinase 1 (MMP-1), tumor necro-
sis factor (TNF), transforming growth factor alpha (TGF-α), Fas antigen ligand
(FasL), Fms-related tyrosine kinase 3 ligand (Flt3-L) or epithelial cell-adhesion
molecule (Ep-CAM).
Summary and Conclusions: Proximity ImmunoAssay is a very sensitive tech-
nique enabling parallel assessment of several analytes. Unlike ELISA, it has
many fold larger dynamic range, and is suitable for analyte levels beyond the
calibration curve. Out of the Oncology panel, 9 parameters were influenced by
renal impairment. Despite limited number of patients, we could trace several
potential candidates for the assessment of MM pathogenesis as well as for the
extent of myeloma bone disease.
Supported by the grant NT14393.
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THE USE OF MAGE C1 AND FLOW CYTOMETRY TO DETERMINE AND
MONITOR THE MALIGNANT CELL TYPE IN MULTIPLE MYELOMA
K. Wienand1,* K. Shires1
1Clinical and Laboratory Sciences, Division of Haematology, University of Cape
Town, Cape Town, South Africa
Background: Multiple Myeloma (MM) is a haematological malignancy, char-
acterised by the accumulation of neoplastic plasma cells in the bone marrow
(BM). Unfortunately, the full disease mechanism and exact malignant cell phe-
notype of this cancer remains unresolved. This affects effective MM treatment,
as it limits the development of target-specific drugs and importantly prevents
optimal detection of residual primary disease-causing cells. There is a definite
need to identify a common molecular marker that is expressed in the majority
of the diseased patients and directly associated to disease pathogenesis, there-
by allowing monitoring of the malignant disease-causing cell directly. Cancer
testis antigen MAGE C1 has been extensively studied in MM, is putatively
involved in the pathogenesis of the cancer and is expressed in >90% of symp-
tomatic MM patients at diagnosis, indicating a potential link to the malignant
cell phenotype and use as a minimal residual (MRD) marker.
Aims: The aim of this study was to use aberrant MAGE C1 expression to iden-
tify the malignant cell phenotype in MM using flow cytometry and then investi-
gate the use of this marker to monitor MRD in patients undergoing therapy.
Methods: BM and peripheral blood (PB) was collected from fifteen untreated
symptomatic MM patients at diagnosis, with PB also being collected every three
months over a two year period. Additional BM and PB samples were collected
from five healthy donors for comparison. Mononuclear cells were isolated using
density-gradient centrifugation, stabilized in 80% ethanol and analysed via flow
cytometry following incubation with relevant B-cell development cell-surface
markers and the nuclear-staining antibody MAGE C1.
Results: MAGE C1 expression was observed consistently in the early stem
cells (CD34+) and early pro-B to pre-B cells (CD34-/+/CD19+), as well as the
proliferating plasma cells in the MM BM and PB. The expression of MAGE C1
in the CD34+ cells suggests that these cells are the disease progenitors that
sustain the downstream accumulation of abnormal plasma cells. The reactiva-
tion of MAGE C1 expression in a sub group of these plasma cells may be
responsible for the proliferation, leading to a second disease mechanism that
accelerates plasma cell mass expansion. The expression of MAGE C1 in the
PB indicates that the malignant phenotype is also found in circulation and thus
could easily be used for MRD monitoring. Importantly, the changes in MAGE
C1 expression correlated to the decrease/increase in serum M protein, beta-2-
microglobulin and creatinine levels over the two year treatment period, con-
necting this cancer marker to disease pathogenesis and indicating a direct link
to active disease. It was further observed that current treatments are targeting
different cell populations not necessarily eradicating all the malignant cell types.
Summary and Conclusions: MAGE C1 was successfully used to determine
the malignant cell phenotype as well as to monitor MRD with specific B cell
markers via flow cytometry. MRD monitoring using PB is easily accessilbe to
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all MM patients compared to stressful BM biopsies. Furthermore, analysis of
PB using this assay is similar than current flow cytometry methods giving a
clear indication of the malignant cells found in circulation with better sensitivity
to residual disease. MAGE C1 expression in PB can provide clinicians with
access to the percentage of malignant cells in circulation prior to ASCTs as
well as other MM treatments in a time efficient manner in turn improving the
outcome of patients. 
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PERSONAL HISTORY OF INFECTIONS ASSOCIATED WITH AN
INCREASED RISK OF MONOCLONAL GAMMOPATHY OF UNDETER-
MINED SIGNIFICANCE (MGUS) AND MULTIPLE MYELOMA: A POPULA-
TION-BASED NESTED CASE-CONTROL STUDY
C. Mcshane1,* L.J. Murray1, O. Landgren2, M.C. Bradley3, C. Hughes4,
L.A. Anderson1
1Centre for Public Health, Queens University Belfast, BELFAST, United King-
dom, 2Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer
Center, New York, 3Cancer Prevention Fellowship Program, National Cancer
Institute, Maryland, United States, 4School of Pharmacy, Queens University
Belfast, BELFAST, United Kingdom
Background: Infections are a major contributor to the global cancer burden
and are a leading cause of morbidity and mortality in individuals with mono-
clonal gammopathy of undetermined significance (MGUS) and multiple myelo-
ma (MM). Both MGUS and MM are associated with immune dysregulation
which may not only increase the propensity to infection but may also act as a
trigger for the development of MGUS and/or progression to MM or associated
lymphoproliferative disorders.
Aims: To investigate the association between prior common community-
acquired infections and subsequent risk of MGUS and MM using the UK Clinical
Practice Research Datalink (CPRD).
Methods: Conditional logistic regression models were used to estimate odds
ratios (OR) and associated 95% Confidence Intervals (Cl) excluding the 12
month period prior to MGUS/MM diagnosis/control selection. Findings were
adjusted for a number of potential confounders including age at diagnosis,
comorbidities, autoimmune disease, prior cancer, and lifestyle variables. 
Results: In total, 4,654 MGUS and 3,801 MM patients matched to 23,101 and
18,991 controls respectively were identified. A personal history of infections
was associated with an increased risk of both MGUS and MM, with the
strongest associations observed for MGUS (MGUS: OR 1.32, 95% CI 1.23-
1.41; MM: OR 1.22, 95% CI 1.13-1.32). A number of infections, in particular
those affecting the respiratory tract were more commonly diagnosed in individ-
uals who later developed MGUS/MM. A dose response relationship was also
evident, with individuals more prone to infections more likely to later develop
MGUS/MM. 
Summary and Conclusions: The findings of this study suggest infections
may play an important role in the etiology of the plasma cell disorders and/or
be markers of an underlying immune disturbance. Further exploration of the
mechanisms involved may aid our understanding of the pathogenesis of MGUS
and MM.
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INFLUENCE OF ABC TRANSPORTERS’ GENETIC PROFILES IN THE
DEVELOPMENT OF MONOCLONAL GAMMOPATHIES
S.I. Fernandes1,2,3,* A.C. Gonçalves4, J. Jorge4, C. Geraldes5, R. Alves4,
A. Pires4, S. Veiga4, E. Cortesão5, L. Ribeiro5, A.B. Sarmento Ribeiro4
1University Clinic of Hematology, 2Applied Molecular Biology, Faculty of Med-
icine of University of Coimbra, Coimbra, 3Department of Biology, University of
Aveiro, Aveiro, 4Faculty of Medicine, University of Coimbra, 5University Clinic
of Hematology, University Hospital of Coimbra, Coimbra, Portugal
Background: Genetic variability inxenobiotic transport related proteins can
influence drugs’ efficacy and could contribute to the susceptibility to hemato-
logical conditions, such as Monoclonal Gammopathy of Unknown Significance
(MGUS) and Multiple Myeloma (MM). ABC (ATP-binding cassette) transporters
superfamily includes membrane proteins which function is to transport sub-
strates through intra- and extracellular membranes. MDR1 and MRP1 are
membrane transporter proteins that, besides the above described functions,
may play a role in development, progression and therapeutic outcome in sev-
eral hematological pathologies.
Aims: In this context, we investigated the relevance of polymorphisms in MDR1
(C3435T) and MRP1 (G1666A) genes as risk factors for the development of
monoclonal gammopathies, such as MGUS and MM, as well as their possibility
of prognostic risk factors.
Methods: This study included 145 patients diagnosed with monoclonal gam-
mopathies (GM) (68 MGUS, 77 MM) and 121 healthy controls (CTL). The
genetic profiles of MDR1 (C3435T) and MRP1 (G1666A) were assessed by
RFLP-PCR. The strength of association between polymorphisms and disease’s
development risk were estimated by odds ratio (OR) with 95% confidence inter-
val (CI 95%). The influence of these polymorphisms in the patients overall sur-
vival (OS) was calculated by Kaplan Meier method.
Results: Our results show that allele C from MDR1 is the most prevalent in
CTL (52.1%) and in MGUS (52.2%), while allele T is predominant in MM (52.0%).
Moreover, both alleles have the same prevalence in CTL (50.0%), and genotype
CT is the most common in all groups (CTL=46.3%; GM=62.8%; MM=70.1%;
MGUS=54.4%). As to MRP1 gene, we observed that allele A is the most frequent
in all groups (CTL=72.6%; GM=67.9%; MM=67.5%; MGUS=68.4%) and we
also perceived that the most common genotype is AG (CTL=54.8%; GM=51.7%;
MM=46.8%; MGUS=57.4%). After calculating the OR for individual genotypes
we realized that CC genotype from MDR1 is a protector factor for the develop-
ment of MM (OR=0.37; p=0.0093; CI95% 0.17-0.79) and CT genotype repre-
sents a risk factor for the development of GM in general (OR=1.9; p=0.0092;
CI95% 1.2-3.2) and for the development of MM (OR=2.7; p=0.0012; CI95% 1.5-
4.9). The Kaplan Meier analysis revealed that MM patients with the AA genotype
in MRP1 gene have a decreased overall survival in about 18 months (AA-
20.1±2.4 months; AG or GG-38.1±3.9 months; p=0.035).
Summary and Conclusions: This work suggests that MDR1 and MRP1 geno-
types can be predictive of the predisposition to the development and progres-
sion of monoclonal gammopathies. However, their role in therapy response
remains unknown.
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ANALYSIS OF RHOU AND RHOV EXPRESSION IN MULTIPLE MYELOMA
REVEALS A POSSIBLE CORRELATION WITH BONE MARROW DEPEND-
ENCE
S. Canovas Nunes1,2,* L. Quotti Tubi1,2, E. Mandato1,2, M. Carrino1,2, F. Zaffino1,2,
S. Manni1,2, R. Zambello1,2, F. Adami1, L. Trentin1,2, G. Semenzato1,2, F. Piazza1,2
1Department of Medicine, University of Padova, 2Venetian Institute of Molecular
Medicine, Padova, Italy
Background: Rho GTPases, in their active GTP-bound state, interact with
effector proteins controlling many biological processes: cytoskeletal regulation,
membrane trafficking, cell adhesion and polarization, transcriptional activity,
apoptosis and proliferation. The RhoUV subfamily consists of two atypical Rho
proteins: RhoU and RhoV that due to their spontaneous activation are normally
expressed at very low levels in most cell types and tissues. In Multiple Myeloma
(MM), a tumor microenvironmental niche, which protects MM cells from
chemotherapy and proapoptotic noxae, is created by the adhesion between pri-
mary malignant plasma cells and stromal cells. RhoU and RhoV GTPases are
able to alter cell-cell/cell-extracellular matrix adhesion, cell motility and actin
dynamics. Also, RhoU levels are known to be upregulated upon IL-6 stimulus,
which is a pivotal growth factor for malignant plasma cells. On these basis, we
hypothesize that changes in the expression of these GTPases and therefore in
their function could lead to dynamic alterations of MM-associated niche.
Aims: Analyze RhoU and RhoV expression and actin cytoskeleton dynamics
in normal B cells versus MM malignant plasma cells. Evaluate if changes in
the expression of these GTPases have an impact in adhesion,
migration/motility and structural features of MM cells. Study the role of RhoU
and RhoV in malignant cell-stromal cell adhesion and in the creation of pro-
tective bone marrow niches.
Methods: mRNA expression was analyzed by qRT-PCR in MM cell lines, MM
cells from patients and normal B cells from healthy donors. Malignant plasma
cells were isolated from bone marrow or peripheral blood of patients using
“EasySep CD138 positive selection kit”. Normal B cells were purified using
“EasySep human B cell isolation kit”. Fluorescence microscopy was performed
using Zeiss LSM 700 microscope. Staining was done with Phalloidin 594
(Abcam), rabbit anti-RhoU or RhoV (Abcam), goat anti-rabbit Alexa fluor 488
(Life Technologies) and DAPI (Vector).
Results: MM cell lines showed a significantly higher expression of RhoU and
RhoV as compared to normal B cells. While RhoV displayed the highest expres-
sion in stroma/IL-6-dependent cell line (INA-6), RhoU was expressed at high
levels in INA-6 but also in U-266, in this latter probably because of its autocrine
IL-6 production. Remarkably, RhoU and RhoV expression was actively modu-
lated when MM cell lines were co-cultured with stromal cells. MM patients also
showed a significantly higher expression of both proteins when compared to
normal B cells. Interestingly, in the stage of plasma cell leukaemia (PCL) RhoV
mRNA levels were high but RhoU levels seemed to be even lower than in nor-
mal B cells. Immunofluorescence showed that RhoU and RhoV colocalize with
actin in normal B cells while in INA-6 these were located both in the cytoplasm
and nucleus. Upon co-culture of INA-6 with stromal cells, RhoU accumulated
in the nucleolus. In freshly purified plasma cells from MM patients’ bone marrow,
RhoU and RhoV were found both in the cytoplasm and nucleus being RhoU
particularly abundant in the nucleolus. On PCL patients there was a very low
signal for both proteins and RhoV seemed to be present only in the cytoplasm.
Summary and Conclusions: RhoU and RhoV are widely over-expressed in
MM. Their expression seems to correlate with bone marrow dependence, being
that it decreases in more aggressive, bone marrow-independent stages where
malignant plasma cells are no longer dependent on the stromal signals. RhoU
and RhoV could be important in MM pathogenesis and suitable targets to dis-
rupt the MM plasma cell adhesion to protective bone marrow niches.
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GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-
MDSC) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOG-
ICAL DYSREGULATION OF MESENCHYMAL STEM CELLS (MSC) 
C. Giallongo1,* N. Parrinello1, D. Tibullo1, P. La Cava1, C. Conticello1, M. Cavalli1,
A. Chiarenza1, G.A. Palumbo1, A. Romano1, F. Di Raimondo1
1Division of Hematology, Azienda Policlinico-OVE, University of Catania, cata-
nia, Italy
Background: Granulocytic-Myeloid-derived suppressor cells (G-MDSC), a het-
erogeneous population of myeloid cells with peculiar immunosuppressive prop-
erties against T-cells due to increased levels of Arginase-1 (Arg-1), are increased
in Multiple Myeloma (MM), as recently described by our and other groups. MM
plasma-cells depend on the bone marrow microenvironment for the growth and
survival; important in this context is the role of mesenchymal stem cells (MSCs),
stromal adult stem cells with immunomodulatory properties.
Aims: Investigating the role of MSCs from MGUS and MM patients on expan-
sion and activation of G-MDSCs.
Methods: G-MDSC (CD11b+CD33+CD14-HLADR-) were evaluated by flow
cytometry and functional test, including the expression of the enzyme arginase
(ARG-1) and ability to suppress lymphocytes activation when co-cultured with
T-lymphocytes obtained from normal donors. Briefly, human peripheral blood
mononucleated cells (PBMCs) isolated from healthy volunteer donors were
cultured alone, with HD (n=6), MGUS (n=5) or MM MSCs (n=6) (1:100 ratio).
After one week, PBMCs were collected. G-MDSCs were then isolated using
anti-CD66b magnetic microbeads. The phenotype of G-MDSC was confirmed
by cytofluorimetric analysis. Their immunosuppressive capacity was analyzed,
evaluating T-cell anergy when co-cultured with autologous CFSE-labeled T
cells stimulated by phytohaemagglutinin (PHA).
Results: G-MDSC percentage in MM was greater than healthy controls
(61.2±1.6% versus 51.7±1.4%, p<0.001). We found a T-cell anergy dose- and
time-dependent driven by MM-G-MDSC, due to overexpression of ARG-1
(p=0.0012). Only MM MSCs-educated G-MDSC exhibited suppressor effect
with a reduction of T cell proliferation of about 34±9.6% (p<0.01) compared to
G-MDSC control (isolated from PBMCs cultured in medium alone). Notably,
neither MDSCs control nor myeloid cells co-cultured with HD or MGUS MSCs
showed suppressor activity on T cell proliferation. Using real time PCR, we
analyzed the expression of immune modulatory factors (Arg-1, NOS2, COX2,
TNFα, TGFβ, IL6, IL10, IL1β) by MSCs after 48 h of co-culture with PBMCs.
MM MSCs showed an increase of COX2, IL6, IL10, IL1β, TGFβ and NOS2
expression (p<0.05) compared to HD MSCs, suggesting that multiple mecha-
nisms are involved in MDSCs induction by MM MSCs. The same immune mod-
ulatory factors were investigated in MDSCs before incubation with T cells. MM
MSCs-educated MDSCs expressed higher levels of arginase1, NOS2 and IL6
(p<0.05) compared to MDSCs control.
Summary and Conclusions: MSCs from MM but not MGUS patients are able
to activate G-MDSCs with potential implication in immune escape that favours
plasma-cells growth, survival and resistance to drugs.
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MICRORNA PROFILE IN BONE MARROW FIBROBLASTS FROM
PATIENTS WITH MULTIPLE MYELOMA
V. Desantis1,* I. Caparrotta2, L. Beltrame2, L. Di Marzo1, S. Marchini2, I. Catacchio1,
M. D’Incalci2, A. Vacca1, M.A. Frassanito1
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policlinico di Bari, Bari, 2Department of Oncology, Istituto di Ricerche Farma-
cologiche Mario Negri, Milano, Italy, Mario Negri, Milan, Italy
Background: Multiple Myeloma (MM) is a plasma cell dyscrasia with specific
localization in the bone marrow that is almost invariably preceded by a Monoclonal
Gammopathy of Undetermined Significance (MGUS). Several studies have clear-
ly proved that a permissive microenvironment is required for MM to emerge.
Recently, we demonstrated that bone marrow fibroblasts (cancer associated
fibroblasts, CAFs) from 1st diagnosed MM patients show a relevant activated
phenotype that acts as a promoter for MM initiation and progression as well as
angiogenesis (1). The microRNAs (miRNA, miR) are a class of highly conserved
short non-coding RNA molecules that regulate gene expression at the post-tran-
scriptional level. They are involved in regulation of several biological processes,
including cell proliferation, differentiation, apoptosis, morphogenesis and metab-
olism. Specific miRNA expression signatures can distinguish cancer from benign
tissues and may provide the basis for developing new diagnostic and therapeutic
strategies. Despite numerous studies focused on the miRNAs profile in MM cells,
their analysis on CAFs has not been investigated yet.
Aims: We wondered whether miRNAs could play an important role in the func-
tional conversion of MGUS CAFs into the activated phenotype of the 1st diag-
nosed MM CAFs.
Methods: CAFs were purified from bone marrow aspirates of 15 patients with
MGUS and 15 patients with 1st diagnosed MM using appropriate microbeads,
and cultured in vitro until the second passage. 100ng of RNA enriched in miRNA
fraction were labeled and hybridized onto commercially array slides. Differen-
tially expressed miRNAs were analyzed with Rank Product algorithm. The
resulting p-values were corrected for multiple testing using the False Discovery
Rate (FDR) method by Benjamini and Hochberg. Results were validated using
quantitative real-time PCR.
Results: CAFs from 1st diagnosed MM patients show a different miRNA profile
compared to those from MGUS patients. Heighten differentially expressed miR-
NAs were identified: 8 were up-regulated, and 10 down-regulated.
Among the up-regulated miRNA, 5 were significantly up-regulated (miR-125b-
5p, miR-5100, miR-199a-5p, miR-214-3p and miR-27b-3p) and they were
engaged in tumor growth, differentiation, proliferation and drug resistance.
Among the down-regulated miRNA, 5 were significantly down regulated (miR-
4281, miR-4530, miR-4430, miR-6089 and miR-6087), and they were involved
in post-transcriptional regulation of gene expression for differentiation and
metastatic progression. In particular, miR-199a-5p and miR-214-3p play a major
role in fibroblast activation by targeting Caveolin1, a key player in TGFβ signal-
ing, and miR-125b-5p is involved in tumor drug resistance (Figure 1).
Figure 1.
Summary and Conclusions: These findings indicate that miRNA profile differs
between 1st diagnosed MM and MGUS patients and that the activated pheno-
type of 1st diagnosed CAFs might be related to the expression of specific miR-
NAs. Several studies are ongoing to identify a correlation between the differ-
entially expressed miRNAs and the activated phenotype of CAFs and their role
in the cross-talk between MM plasma cells and CAFs.
Reference
1. MA Frassanito et al. Leukemia 2014; 28:904.
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TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND
AND DEATH RECEPTORS: RELEVANCE IN THE PATHOGENESIS OF
MONOCLONAL GAMMOPATHIES
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Background: Tumor Necrosis Factor-related Apoptosis-inducing Ligand
(TRAIL) was identified in 1995 and, since then, growing interest has emerged
in oncology due to its reported ability to selectively trigger cancer cell death.
Pro-apoptotic TRAIL signaling is mediated through DR4 (also TRAIL-R1) and
DR5 (also TRAIL-R2) receptors. Despite intensive investigations very little is
known regarding expression of TRAIL and pro-apoptotic TRAIL receptors in
plasma cells (PCs) of patients (pts) with monoclonal gammopathies (MG). 
Aims: The aim of this investigation is to contribute to clarify the involvement of
TRAIL and death TRAIL receptors in the development of MG, in the progression
of MGUS to MM and in the prognosis of MM.
Methods: Between April 2010 and July 2013, we evaluated bone marrow PCs
from 125 pts with MG, 59 symptomatic multiple myeloma (MM), 66 monoclonal
gammopathy of uncertain significance (MGUS) and 11 healthy controls (Ctr).
PCs were analysed by flow cytometry and the 2 populations were identified by
gating CD138+/CD19- and CD138+/CD19+. We evaluated the expression of
TRAIL, TRAIL-R1 and -R2 with monoclonal antibodies in both populations by
flow cytometry. The results are expressed as percentage of PCs expressing
these proteins and expression levels in mean intensity of fluorescence (MIF).
Results: In our population, median age was 70 (39-86) years, 52% were male.
We found that the mean percentage of CD138+/CD19+ PCs expressing TRAIL
and TRAIL-R1 in MM (70,8% and 73%, respectively) is significantly higher than
in MGUS (54,8% and 46,1%, respectively) pts (p=0,0001) and in MGUS com-
pared to Ctr (46,2% and 13,2%; p=0,043 and p=0,0001, respectively); TRAIL-
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R2 was also higher in MGUS vs Ctr (56,7% vs 17%, p=0,0001). TRAIL expres-
sion level in PCs with the same phenotype was higher in MM (46,6±3,4 MIF)
than in MGUS (35,3±1,4 MIF) pts (p=0,026), as well as the level of expression
of TRAIL-R1 and -R2 in MM (32,7±1,1 MIF and 44,8±2,2 MIF, respectively)
and in MGUS (37,1±1,7 MIF and 60,9±1,9 MIF, respectively) pts compared to
Ctr (27,5±0,65 MIF and 24,8±0,7 MIF, respectively; p=0,0001). We also eval-
uated the expression of TRAIL and TRAIL pro-apoptotic receptors in
CD138+/CD19- PCs in MGUS and in MM pts. In MM, we found increased
expression levels of TRAIL and TRAIL-R2 in CD138+/CD19+ (46,6±3,4 MIF
and 44,8±2,2 MIF, respectively) compared to CD138+/CD19- (29,2±1,8 MIF
and 34,2±2 MIF, respectively) PCs (p=0,0001). Similar data were observed in
MGUS pts only for TRAIL-R2 (60,9±1,9 MIF in CD138+/CD19+ vs 54,8±2,4
MIF in CD138+/CD19- PCs; p=0,001). In our investigation, we also searched
for prognostic markers in MM pts and we found a significant better survival for
pts with a percentage of CD138+/CD19- PCs expressing TRAIL superior to
13,5% (p=0,008).
Summary and Conclusions: Our study showed that TRAIL and TRAIL pro-
apoptotic receptors, R1 and R2, are highly expressed in CD138+/CD19+ PCs
of MG pts compared to Ctr with increased levels in MM versus MGUS, sug-
gesting a significant role of these proteins in the development and progression
of MG. We also demonstrated a prognostic impact of TRAIL expression in MM
pts, with an improved prognosis associated with a higher percentage of
CD138+/CD19- PCs expressing TRAIL.
This work was supported by CIMAGO (project nº 23/09)
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THE NOVEL MOLECULE STK405759 HAS SELECTIVE CYTOTOXICITY
AGAINST MULTIPLE MYELOMA IN VITRO AND IN VIVO
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Background: Despite advances in treatment, including high-dose chemother-
apy and novel agents such as proteasome inhibitors and immunomodulators,
multiple myeloma (MM) remains incurable due to development of drug resist-
ance in the bone marrow microenvironment.
Aims: To evaluate the use of STK405759, a synthetic small molecule, as a
potentially novel drug for MM treatment in preclinical models. 
Methods: Cytotoxic activity of STK405759 was evaluated byxTT assay. Apop-
tosis and cell cycle were checked by flow cytometry. Protein expression was
assessed by Western blot. Histochemistry was used to evaluate apoptosis in
tumors of mousexenograft model.
Results: Our data show that STK405759 has a potent cytotoxic activity against
a wider variety of MM cell lines and patient-derived MM cells, regardless of
their sensitivity to conventional therapy or novel agents. In contrast, the viability
of normal peripheral blood mononuclear cells derived from healthy donors and
MM patients was not inhibited. Importantly, STK405759 induced cell death of
RPMIS cells co-cultured with HS-5 BMSCs. At low concentrations (nanomolar),
STK405759 triggered G2 cell cycle arrest and induced apoptotic cell death
associated with the cleavage of caspase-8 and poly (ADP-ribose) polymerase,
as well as down-regulation of the Mcl-1 anti-apoptotic protein. These biological
responses were associated with decreased AKT and CREB protein expression
in MM cell lines. Combination studies of STK405759 with bortezomib, lenalido-
mide or dexamethasone showed significant synergistic cytotoxicity in MM cells.
In vivo studies revealed decreased MM tumor burden and prolonged survival
of STK405759-treated mice as compared with controls. STK405759 induced
apoptosis of tumors cells from treated mice.
Summary and Conclusions: Our results from in vitro and in vivo studies
showed the anti-myeloma activity of STK405759 and provided the rationale
for further evaluation of STK405759 as monotherapy and combination therapy
for treating patients with MM.
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CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SINIG-
ICANCE CORRELATE WITH POOR PROGNOSIC FACTORS IN MULTIPLE
MYELOMA
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Y.K. Lee1
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Background: The prognosis of multiple myeloma (MM) depends on the under-
lying cytogenetic subtype. Recurrent cytogenetic changes including hyper-
diploidy of odd-numbered chromosomes, -13/13q- and balanced translocations
involving IGH have already been incorporated into risk stratification strategies
and are used in standard clinical practice. Nevertheless, MM often exhibits a
heterogenous and complex karyotype, and many other chromosomal abnor-
malities of uncertain clinical significance are observed.
Aims: We performed a comprehensive analysis for the relationship between
cytogenetic abnormalities of undetermined prognostic significance and known
prognostic factors in MM.
Methods: Conventional G-banding was performed in 333 newly diagnosed
MM. Karyotypes were described using the most recent version of the Interna-
tional System for Human Cytogenetic Nomenclature. Translocations with break-
points at p10, p11, q10, or q11 were all regarded as whole arm (centromere to
centromere) translocations. Poor prognostic indicators as follows: hemoglobin
(Hb) level <10 g/dL, calcium level >12 mg/dL, IgG level >7 g/dL or IgA level >5
g/dL, b2-microglobulin level >5.5 mg/L, and albumin level <3.5 g/dL. Creatinine
level >2 mg/dL, IgA type, lambda type, elevated free light chain level >100
mg/dL, abnormal kappa/lambda ratio of >4.0 or <0.5, and elevated LDH level
were also included.
Results: Among the 333 MM patients, 212 showed a normal or good/interme-
diate karyotype (195 with normal karyotype; 17 with abnormal karyotype asso-
ciated with good or intermediate prognosis); these served as the control group
in this study. The remaining 121 had other cytogenetic abnormalities (with or
without hyperdiploidy, or translocations associated with good or intermediate
prognosis). Chromosomes 1p (12.0%), 1q (18.9%), 6q (7.2%), 8q (6.9%), 11q
(5.4%), 12p (5.1%), 14q (9.3%) and 19q (5.1%).showed frequent abnormalities.
Common breakpoints were p10-12, p13, p22 in 1p, q10-12, q21, q25, q32 in
1q; q21, q25 in 6q; q10, q22, q24 in 8q; q10, q13 in 11q; p10-12 in 12p; q24,
q32in 14q and q10, q13.3 in 19q (Figure 1). Certain chromosomal abnormalities
were associated with known prognostic factors (p-value <0.05): 8q-IgA type;
1q-IgG level of >5 g/dL or IgA level of>3 g/dL; 14q-kappa or lambda type chains
>100 mg/dL; 1p, 1q, 6q, and 19q-Hb <10.0 g/dL; 1p and 12q-albumin <3.5
g/dL; 14q and 19q -creatinine >2.0 mg/dL; 1p, 1q, 6q, or 19q-b2-microglobulin
>5.5 mg/L; 1p, 8q, 11q, and 14q-calcium >12 mg/dL; 1p, 3p, 12p, or 14q-ele-
vated LDH level.
Figure 1. 
Summary and Conclusions: We analyzed the distribution and clinical signif-
icance of the less commonly occurring cytogenetic abnormalities for the first
time. Abnormalities in chromosomes 1p, 1q, 3p, 6q, 8q, 11q, 12q, 14q, and
19q were associated with clinical factors associated with a poor prognosis. Not
all chromosomes showing frequent aberrations correlated with prognostic fac-
tors, indicating that it is not the presence of a cytogenetic abnormality in itself,
but the particular chromosome(s) involved in the abnormality that is the key
factor that determines the initial clinical characteristics of MM
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PLASMA CELLS NEGATIVE SELECTION TECHNIQUE IN SAMPLES OF
PLASMA CELL DYSCRASIA PATIENTS. 
S. Verdesoto1, V. Escamilla1, M.T. Vargas De Los Monteros, 2O. Perez-Lopez1,
R.M. Morales-Camacho1, T. Caballero-Velazquez1, A. Rodriguez3, C. Prats-
Martin1, J. Martin1, M.L. Martino R. Duro3, R. Bernal1, J.A. Perez-Simon4,*
1Unidad de Gestion de Hematologia y Hemoterapia, 2Unidad de Gestion de
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Background: A 15-20% of plasma cells (PCs) is the main prerequisite for diag-
nosis of genetic abnormalities by FISH techniques in bone marrow interphase
plasma cell dyscrasia patients. Plasma cells (PCs) enrichment from bone mar-
row samples patients are frequently performed by the traditional method of
immunomagnetic separation (magnetic activated cell sorting, MACS) using
anti-CD138 MicroBeads. The main inconveniences of the MACS method are:
its high cost, it is unsuccessful if the percentage of PCs in the initial sample is
less than 5% and the PCs positive selection affect to the quality of the cells.
RosetteSep Human Multiple Myeloma Enrichment Cocktail The RosetteSep
500 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
enrichment cocktail cross-links unwanted cells in human bone marrow to mul-
tiple red blood cells (RBCs) using Tetrameric Antibody Complexes (TAC), form-
ing immunorosettes. This increases the density of the unwanted cells, in such
a way that they pellet along with the free RBCs when centrifuged over Ficoll-
Paque PLUS. Desired cells are never labeled with antibodies and are easily
collected as a highly enriched population at the interface between the plasma
and Ficoll-Paque PLUS. With this above negative selection cells technique, it
obtain a great quantity and high quality cells.
Aims: The aim of this paper is to find the optimal algorithm, results and advan-
tages in cost and pure and quality cell populations of the RosetteSep separation
technique for samples of 50 bone marrow plasma cell dyscrasia patients with
various percentages of neoplastic cells for applying FISH methods in these
diseases.
Methods: Specimens: We analysed 76 heparinized bone marrow aspirates
with known PCs dyscrasias for FISH diagnosis of genetic abnormalities. The
percentage of monoclonal PCs varied between 0.48 and 73.5% (mean 14.39%)
according to flow cytometry analysis on the previous study before PCs selec-
tion. The cytology analysis was used when the percentage was between 3 to
4%, to determine the PCs infiltration, when there was an infiltration ≥7% or
presence of cell nests the sample was processed. Cell separation: RosetteSep
technique was used for separation of PCs in all specimens. Briefly, we added
RosetteSep Multiple Myeloma Enrichment Cocktail at 50 μl/ml of bone marrow
aspirate sample, incubated 20 minutes at room temperature and diluted it with
an equal volume of Ficoll-Paque PLUS. After centrifuging for 20 minutes at
1200xg at room temperature we removed and washed the enriched cells from
the density medium (plasma interface). For all cases, enrichment was accom-
plished. Flow cytometry analysis: It was proved the percentage of PCs before
and after the separation. Enriched sample was stained with CD38-FITC and
CD45-V450 and acquired using a BD FACSCanto II. Percentage of PCs among
non-erythroid cells was obtained by Infinicyt software (Cytognos). FISH analy-
sis: FISH analysis was carried out following standard procedures on interphase
cells. The number of interphase cells analyzed were 200.
Results: 76 bone marrow samples were analyzed from patients with a range
age between 38-89 years old (mean 67 years old). 19 sample patients with
≤5% of preselected PCS by flow cytometry (0.48%>4.9%) showed hemodilution
(1 cases). Cytology analysis were carried out in spite of do the PCs selection
in the rest of the bone marrow samples with ≤5% PCs (6 cases); the PCs selec-
tion was realized when the samples showed a ≥7% of PCs and/or nest cells by
cytology. All samples were successfully separated. The median of PCs after
enrichment was 60.5% (range 45.93- 86.75%). We obtained results in all of 77
FISH samples analyzed.
Summary and Conclusions: The introduction of RosetteSep contributed
markedly in increasing the effectiveness of plasma cell separation from bone
marrow samples, mainly in samples with low plasma cell content where the
MACS method is not unsuccessful (<5%), its negative selection strategy
enabled us to obtain sufficient amounts of highly purified and quality PCs
required for subsequent diagnosis techniques proposed. On the other hand,
the above technique has a low cost as opposed to MACS. The increase in the
PCs concentration permits better FISH results incrementing the genetic abnor-
mality detections which have a high prognosis value in these pathologies.
Myeloma and other monoclonal gammopathies -
Clinical
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CT IS SUPERIOR TOx-RAY IN DIAGNOSING OSTEOLYTIC LESIONS IN
THE SPINE AND PELVIS: A PROSPECTIVE STUDY OF NEWLY DIAG-
NOSED MULTIPLE MYELOMA PATIENTS
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1Department of Internal Medicine, Section of Haematology. Institute of Regional
Health Research, University of Southern Denmark, Vejle Hospital, Vejle,
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Background: The presence of osteolytic lesions may define if a patient has
multiple myeloma needing treatment or smouldering myeloma, and once devel-
oped the skeletal damage tends to be irreversible. Thus, a sensitive examination
of the skeleton at diagnosis is of great importance for the decision to start anti-
myeloma treatment. Conventionalx-ray has been the method of choice in many
centres, despite increasing evidence that other imaging modalities may be
more sensitive, especially in the spine and pelvic areas.
Aims: In a prospective clinical trial we have compared low-dose Computed
Tomography (CT) head to head with conventionalx-rays for the demonstration
of osteolysis in the spine and pelvis in newly diagnosed multiple myeloma
patients. Simultaneously the value of adding 18-flourdeoxyglukose (18FDG)
Positron Emission Tomography (PET) and Single Photon Emission computed
tomography (SPECT) to CT was evaluated.
Methods: 35 previously untreated multiple myeloma patients (21 males, 14
females; mean age 64 (49-81)) were included in a prospective single centre phase-
II study evaluating the safety and efficacy of a five drug combination of doxorubicin,
cyclophosphamide, bortezomib, dexamethasone and lenalidomide. Informed con-
sent was obtained. At baseline the bone status of the patients was evaluated by
conventionalx-ray, CT, 18FDG-PET-CT and SPECT-CT. The presence of osteolysis
in the pelvis and spine was determined byx-ray and CT, and focal activity was
studied using PET-CT and SPECT-CT. The imaging was evaluated by a group of
dedicated experts.x-rays were evaluated independently from CT.
Results: CT was significantly more sensitive thanx-rays for detection of oste-
olytic lesions in both pelvis (p<0.01, n:32) and spine (p<0.05, n:32). Osteolysis
in the pelvis was diagnosed in 69% (24/35) of the patients by CT and only in
28% (9/32) of the patients byx-ray. Two patients were diagnosed with osteolysis
in the pelvis usingx-ray, which was not found at CT. In the first of these, PET
was also positive, and after retrospective comparison to a follow-up CT-scan
osteolysis was also recognized on the study CT. The second, had in addition
to a negative CT, also negative PET and SPECT, and after retrospective com-
parison to follow-upx-rays, the studyx-ray was considered as false positive due
to misinterpreting of intestinal air. In the spine osteolysis or malignant fractures
were diagnosed in 69% (24/35) of the patients by CT and in 38% (12/32) byx-
rays. In the spine none of the patients with osteolysis byx-rays had a negative
CT. Additionally, CT revealed three cases with imminent affection of the spinal
cord and one with extra medullary disease. In both spine and pelvis PET pos-
itive foci were found in 9% (1/11) of the negative CT-scans, while PET was
negative in 50% (12/24) of the positive CT-scans of pelvis, and in 48% (11/23)
of the positive CT-scans of spine (no corresponding PET of spine to one of the
24 positive CT-scans). SPECT was occasionally positive, in positive CT-scans
(spine:14/23, pelvis:8/21) but never in CT-negative, indicating that SPECT pos-
itivity may reflect enhanced bone remodelling in the respective areas. 
Summary and Conclusions: CT of the pelvis and spine diagnose significantly
more patients with osteolysis thanx-rays of the respective anatomical area, and
should be the preferred modality for the diagnosis of bone involvement in mul-
tiple myeloma. The additional value of adding the more expensive and time-
consuming 18FDG-PET or SPECT to CT was in this study low.
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Background: The combination of bendamustine, bortezomib and dexametha-
sone (BVD) demonstrated a high efficacy and a good tolerability in elderly
patients with relapsed and/or refractory multiple myeloma (RRMM). However,
severe infection was a major toxicity.
Aims: We reviewed clinical aspects and risk factors of severe infection occur-
ring in the IFM 2009 01 protocol.
Methods: The IFM 2009 01 protocol evaluated the BVD combination as 2nd-
line treatment in elderly patients (>65 years) with RRMM (Rodon P. et al.,
Haematologica 2015;100(2):e56-9). Twelve cycles were scheduled: 6 monthly
cycles followed by 6 cycles every 2 months. Patients did not receive any pro-
phylactic antibiotics. All adverse events were collected and graded prospec-
tively according to the National Cancer Institute Common Terminology Criteria
for Adverse Events (version 3.0). We report here an analysis of the episodes
of severe infection (grade 3 or more).
Results: Seventy-three patients were included. The median age was 75.8 years
(range 66-86). The median number of cycles administered was 7. The overall
response rate was 69.8%. The median progression-free survival was 10.8
months, and the median overall survival was 23 months. Twenty episodes of
grade 3 or more infection occurred in 17 patients (23.2%): lung and respiratory
tract infection 13 episodes, bloodstream infection 6 episodes and pyelonephritis
1 episode, respectively. A recurrence of lung infection was observed in 3 patients.
Fourteen episodes were diagnosed in the early phase of therapy (within the 4
first BVD cycles). Only 1 severe infection underwent during a chemotherapy-
induced neutropenic phase (absolute neutrophil count <1000/mm3). Fifteen
episodes occurred among 34 patients older than 75 years versus 5 episodes in
39 younger patients (p=0.0028). Sepsis was responsible of death in 5 of these
17 patients (29.4%), all occurring in the early phase of the BVD therapy.
Summary and Conclusions: Infection was a major severe adverse event in
elderly patients treated for RRMM in the IFM 2009 01 protocol, occurring in
approximately one quarter of the patients. Its incidence was significantly higher
in patients older than 75 years. Severe episodes of infection mainly occurred
in the early phase of treatment. The mortality rate was high. These findings
suggest that a systematic prophylactic use of antibiotics may be needed in this
population of patients.
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IMMUNOGLOBULIN HEAVY/LIGHT CHAIN IMMUNOASSAYS FOR
RESPONSE EVALUATION IN MULTIPLE MYELOMA: COMPARISON WITH
IMMUNOFIXATION, SERUM FREE LIGHT CHAIN, AND MULTICOLOR
FLOW- CYTOMETRY
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Background: Multiple myeloma (MM) patients are monitored to assess treatment
response. Serum immunoglobulin (Ig) heavy/light chain immunoassays are new
methods, which allow quantification of Ig light chain types (IgGκ, IgGλ, IgAκ, IgAλ).
Aims: We compared Ig heavy/light chain assays with standard methods for
response assessment, and evaluated advantages and limitations of this test.
We also studied whether the test predicted prognosis. 
Methods: 368 samples were obtained from 128 patients with IgG and IgA type
MM at Kameda Medical Center and Kanazawa University Hospital (median
age: 70 years, range: 44-89; median follow-up: 29 months, range: 0.9-189.6).
The proportions of patients in ISS stages 1, 2, and 3 were 24%, 37%, and
39%, respectively. Paraprotein type was IgG in 84 patients (59 IgGκ, 25 IgGλ)
and IgA in 44 (23 IgAκ, 21 IgAλ). Samples were taken at various times after
treatment and analyzed retrospectively by serum Ig heavy/light chain
immunoassays. Heavy/light chain ratio (HLCR) was calculated with Ig’κ (G or
A) as the numerator and compared to normal ranges (IgGκ: 3.84-12.07 g/L;
IgGλ: 1.91-6.74 g/L; IgGκ/IgGλ: 1.12-3.21; IgAκ: 0.57-2.08 g/L; IgAλ: 0.44-2.04
g/L; IgAκ/IgAλ: 0.78-1.94). The results were compared to serum protein elec-
trophoresis (SPEP), immunofixation electrophoresis (IFE), and serum free light
chain immunoassay (FLC). HLC-pair suppression was defined as uninvolved
immunoglobulin of the same isotype 50% below the lower limit of normal (IgGκ,
IgGλ, IgAκ, IgAλ). Residual neoplastic plasma cells (MM-PCs) in bone marrow
were assessed by multicolor flow cytometry (MFC) in 158 samples from 66
patients at very good partial response (VGPR), complete response (CR), and
stringent CR (sCR). MFC negativity was defined as <10-4 MM-PCs. Overall
survival (OS) and progression-free survival (PFS) were estimated by the
Kaplan-Meier method, and survival was compared using the log rank test.
Results: MM responses were assessed according to international response
criteria. Patients’ samples at various responses were: Before therapy, n=60
(16%); sCR, n=81 (22%); CR, n=30 (8%); VGPR, n=136 (37%); and PR, n=61
(17%). Normal HLCR was obtained at sCR, CR, VGPR and PR in 70 (86%),
29 (97%), 76 (55%) and 9 (15%) cases, respectively. Among PR samples with
normal HLCR, many SPEPs showed small M-spike with broad polyclonal peak.
In the sera from patients who achieved a CR or better, abnormal HLCR and
FLC ratio were seen at rates of 9.7% and 22.3%, respectively, and no sera
had abnormal value in both assays simultaneously. Among the patients who
achieved a VGPR or better, patients with a normal HLCR had fewer MM-PCs
than those with an abnormal HLCR (median 1x10-3.42 vs 1x10-3.04, respectively,
P=0.01). Shorter OS were shown in patients with highly abnormal HLCR; >100
or <0.01 at diagnosis than in those without (36.3 months vs not reached,
P=0.038). Longer OS were observed in patients who achieved HLCR normal-
ization at best response than in those who did not (not reached vs 119.7
months, P=0.0002). Presence of HLC pair suppression at best response was
associated with poorer OS, but that at diagnosis was not (Figures 1,2 and 3).
Figure 1. Highly abnormal HLCR at diagnosis is associated with shorter OS.
Figure 2. Abnormal HLCR at best response is associated with shorter OS.
Figure 3. HLC pair suppression at best response is associated with shorter
OS.
Summary and Conclusions: This study suggests the usefulness of HLC assays
for the assessment of MM response. Highly abnormal HLCR at diagnosis was a
poor prognostic factor. Abnormal HLCR and HLC-pair suppression at best
response were associated with poorer survival. Response assessment by SPEP
alone seems inaccurate, especially in patients with PR or VGPR with uninvolved
Ig recovery. HLC assay enables more accurate estimation of involved Ig quan-
tification, and should be used for response assessment in the near future.
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DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING
PARAMETERS CORRELATE WITH ANGIOPOIETIN-1/ANGIOPOIETIN-2
RATIO AND OTHER HIGH-RISK FEATURES IN PATIENTS WITH MULTIPLE
MYELOMA
E. Terpos1,* D. Matsaridis2, V. Koutoulidis2, F. Zagouri1, D. Christoulas1,
A. Koureas2, E. Kastritis1, L.A. Moulopoulos2, M.A. Dimopoulos1
1Department of Clinical Therapeutics, 2First Department of Radiology, National
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Background: Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) studies the kinetics of the distribution of paramagnetic contrast in the
microvessels and in the interstitial space of the studied tissue. It has been pre-
viously reported that DCE-MRI parameters correlate with increased angiogen-
esis and event-free survival of patients with multiple myeloma (MM) in the con-
ventional chemotherapy era.
Aims: The aim of this study was to evaluate the value of DCE-MRI in the era
of novel anti-myeloma agents and explore possible correlation with angiogenic
cytokines that have prognostic value in MM, such as the ratio of angiopoietin-
1/angiopoietin-2 (Angp-1/Angp-2).
Methods: We studied 46 MM, previously untreated, patients (24M/22F, median
age 67 years, range 33-88 years) at diagnosis (37 with symptomatic MM and
9 with smoldering MM-SMM) and 5 patients with MGUS. All patients underwent
MRI of the lumbar spine and DCE-MRI was performed. The following perfusion
parameters that were firstly described by our group (Moulopoulos et al., Ann
Oncol 2003;14:152-8) were evaluated: Wash-in (WIN), washout (WOUT), time-
to-peak (TTPK), time-to-maximum slope (TMSP) and WIN/TMSP (WTSP). All
these parameters can be obtained from the time-intensity curves and the first
derivative function [f(t)=d(DSE)/dt] of the EMG equation. The following serum
indices of angiogenesis were also measured on the day of MRI: VEGF, Angio-
genin (Ang), Angp-1 and Angp-2, using an ELISA methodology (R&D Systems,
Minneapolis, MN, USA).
Results: MRI evaluation of the spine revealed that 11 (23.9%) patients had
focal, 12 (26.1%) diffuse, 16 (34.8%) normal, and 7 (15.2%) had a variegated
pattern of marrow involvement. Symptomatic MM patients had increased WIN
values [median 18.7 sec-1, range (2-111 sec-1)] compared to SMM [5.7 (1.3-
30), p<0.05) and MGUS patients [1.7 (1.1-5), p=0.001]. TTPK values were
decreased and WTSP values were increased in both symptomatic MM [47 sec
(18-76 sec) and 0.47 sec (0.04-9.73 sec), respectively] and SMM [60.4 (36-98)
and 0.35 (0.02-1.01) respectively] MM patients compared to MGUS patients
[77 (67-120) and 0.04 (0.02-0.1), p<0.05 for all comparisons]. Only symptomatic
patients had decreased TMSP values [32 sec (11-56 sec)] compared to MGUS
patients [46 (41-71), p=0.004]. Patients with normal MRI pattern had increased
WIN, TMSP and WTSP values and decreased WOUT and TTPK values com-
pared to other patients (p<0.05 for all comparisons). The Angp-1/ Angp-2 ratio
was reduced in symptomatic MM patients [13.5 (1.8-39.7)] compared to SMM
patients (22.1 (9.9-32.3); p=0.017] and MGUS patients [64.2 (26.7-89.5);
p<0.001]. TTPK values correlated with serum Angp-2 (r=-0.330, p=0.018) and
Angp-1/Angp-2 ratio (r=0.361, p=0.009), as well as serum M-protein (r=-0.331,
p=0.02). WIN values correlated with M-protein (r=0.432, p=0.002), albumin (r=-
0.376, p=0.008), β2-microglobulin (r=0.335, p=0.021), hemoglobin (r=-0.309,
p=0.028) and serum creatinine (r=0.371, p=0.007). The median follow up of
symptomatic myeloma patients was 31 months and the median overall survival
was 67 months. All symptomatic patients were treated with novel agent-based
regimens. Thirteen patients progressed after first line therapy. There was a
trend for shorter time to progression in patients with low TTPK values (<upper
quartile, median TTP 44 months) compared to patients with high TTPK values
(median TTPK not reached, p=0.09).
Summary and Conclusions: DCE-MRI parameters, such as the TTPK, cor-
relate with increased angiogenic capacity, as reflected by the low ratio of Angp-
1/Angp-2, while others, such as the WIN, correlate with high risk features of
MM. Higher number of patients and longer follow-up is needed to reveal if DCE-
MRI can be of prognostic significance in the era of novel anti-MM agents.
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SERUM LEVELS OF VON WILLEBRAND FACTOR (VWF) BUT NOT OF
ADAMTS-13 PREDICT FOR EARLY DEATH IN PATIENTS WITH AL AMY-
LOIDOSIS, INDEPENDENTLY OF CARDIAC BIOMARKERS
E. Kastritis1,* M. Gavriatopoulou1, E. Terpos1, N. Simos2, N. Kanelias1,
E. Eleutherakis-Papaiakovou1, C. Pamboucas1, E. Psimenou1, E. Papadopoulou1,
S. Toumanidis1, M. Roussou1, A. Tasidou3, I. Papassotiriou2, M. Dimopoulos1
1Department of Clinical Therapeutics, National and Kapodistrian University of
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Background: The deposition amyloid fibrils composed of immunoglobulin light
chains in tissue microcirculation causes organ dysfunction in systemic light
chain (AL) amyloidosis. Light chains or of oligomers of light chains may also
have a direct toxic effect on cells such a myocardial cells or endothelia l cells.
vWF is mainly produced, stored and secreted by endothelial cells (ECs), is crit-
ical for thrombus formation but the secretion of vWF by ECs is also triggered
by several conditions and may reflect a state of “stimulation” of the endothelium.
ADAMTS-13 is a protease, primarily synthesized and released from hepatic
stellate and endothelial cells, which cleaves the cell bound large ultrapolymeric
vWF strings. Both vWF antigen (vWFAg) and ADAMTS-13 antigen levels have
been implicated as prognostic markers associated with cardiovascular events,
potentially reflecting endothelia dysfunction. Cardiac dysfunction is the main
determinant of prognosis in AL amyloidosis, but the role of endothelium has
not been studied. 
Aims: To evaluate the prognostic role of vWF and ADAMTS-13 in patients with
AL amyloidosis. 
Methods: Both vWFAg and ADAMTS-13 levels were measured in stored
serum, using commercially available assays, in 81 consecutive patients with
newly diagnosed AL amyloidosis who were treated in the Department of Clinical
Therapeutics (University of Athens, Greece) and in 30 age-matched healthy
controls.
Results: Median age was 68 years (range 42-82 years) and the median number
of involved organs was 2; heart was involved in 62% and kidneys in 74%. Medi-
an NTproBNP level was 2,318 pg/mL (range 33-75,000 pg/mL); 36% had
NTproBNP ≥4,000 pg/mL and 28%, 38% and 34% of patients had Mayo stage
-1, -2 and -3, respectively. Primary therapy based on bortezomib was given in
52%, on lenalidomide in 44%, while 4% received MDex. Median survival was
47 months; 3- and 6-month mortality was 12% and 20%, respectively. The
median serum level of vWFag in patients with AL amyloidosis was 181 (range
20-557) U/dL, significantly higher than in healthy controls (median: 84 U/dL,
range 48-124; p <0.001). Median ADAMTS-13 levels were similar between AL
patients and controls (median 1044 vs 1170 ng/ml, p=NS). There was no cor-
relation of vWF and ADAMTS-13 levels, and no association of vWFag levels
with renal, cardiac, nerve or liver involvement or with the levels of NTproBNP,
hsTnT or Mayo stage, eGFR, serum albumin levels or proteinuria or the levels
of involved free light chains. ROC curve analysie identified that levels of vWFag
within the top quartile (≥230 U/dL) were associated with a very poor outcome
(median survival 4 months vs 47 months, p=0.001). There was no association
of ADAMTS-13 levels with any outcome (early death or overall survival). In
multivariate analysis vWFag levels ≥230 U/dL were independently associated
with a high risk of death at 6 months (HR: 15, 95% CI 2.6-84, p=0.002) together
with NTproBNP ≥4,000 pg/mL (HR: 16.8, 95% CI 3- 94, p=0.001) and for overall
survival (HR: 2.64, 95% CI 1.2-5.8, p=0.01), along with NTproBNP levels ≥4,000
pg/ml (HR: 4.17, 95% CI 1.98- 8.8, p<0.001). Among patients with both
vWF≥230 IU/L and NTproBNP>4000 pg/ml, 75% died within 3 months from ini-
tiation of therapy.
Figure 1.
Summary and Conclusions: Serum vWFag levels in patients with AL amyloi-
dosis are elevated, without a compensatory increase of ADAMTS-13, are not
correlated with other features of the disease and are associated with a high
risk of early death independently of cardiac biomarkers. 
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CHEMOTHERAPY-INDUCED NEUROPATHY AMONG MULTIPLE MYELO-
MA PATIENTS AND THE INFLUENCE OF CHEMOTHERAPEUTIC AGENTS:
RESULTS FROM THE POPULATION-BASED PROFILES STUDY. 
A. Beijers1,* S. Oerlemans2,3, F. Mols2,3, M. Eurelings4, M. Minnema5, L. van
de Poll-Franse2,3, G. Vreugdenhil1,6
1Internal Medicine, Máxima Medical Center, Veldhoven and Eindhoven,
2Netherlands Comprehensive Cancer Organisation (IKNL), Netherlands Cancer
Registry, Eindhoven, 3CoRPS-Centre of Research on Psychology in Somatic
diseases, Department of Medical and Clinical Psychology, Tilburg University,
Tilburg, 4Department of Neurology, Spaarne Hospital, Hoofddorp, 5Department
of Hematology, UMC Utrecht Cancer Center, Utrecht, 6Departmen of Medical
Oncology, Maastricht University Medical Center, Maastricht, Netherlands
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a com-
mon adverse event of antimyeloma treatment, which may affect patients’ health-
related quality of life (HRQOL). Because there is no proven therapy for CIPN,
it is important to closely monitor the development of this side effect in order to
modify chemotherapy dose on time.
Aims: To evaluate the prevalence and severity of CIPN and the influence of
antimyeloma treatment with neurotoxic chemotherapy on the development of
CIPN among a population-based sample of multiple myeloma (MM) patients.
Methods: All MM patients diagnosed between 2000 and 2014 as identified by
the Netherlands Cancer Registry, location Eindhoven, and alive at questionnaire
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invitation, were eligible. 130 patients completed the EORTC QLQ-CIPN20 on
average 3.5 years after diagnosis (74% response). Data on chemotherapy reg-
imens, treatment response at time of the survey and dose reductions of
chemotherapy were extracted from the medical files. All patients gave written
informed consent.
Results: Patients received treatment with one (49%) or more (42%) neurotoxic
agents, including thalidomide (50%), bortezomib (48%), lenalidomide (39%)
and/or vincristine (7%). Overall, 54% of patients reported at least one neuropathy
symptom (‘quite a bit’ or ‘very much’ combined). The most reported neuropathy
symptoms during the past week were trouble getting an erection (46% of men),
tingling toes/feet (30%), numbness in toes/feet (20%), tingling fingers/hands
(19%) and trouble opening jars/bottles (19%). There were no differences in neu-
ropathy symptoms between patients who received treatment with only one vs a
combination of more neurotoxic agents. Patients who received chemotherapy in
the past 3 months reported a trend of more experienced neuropathy (64%), com-
pared to patients treated more than 12 months before (50%) (p=0.12). In addition,
they reported significantly more severe neuropathy with worse sensory scale
scores (mean 21 vs 12; p=0.01), respectively. Patients with relapsed or progres-
sive MM (n/N=35/130) received treatment in the past 3 months in 31%, and 51%
of patients reported CIPN. Of them 34% reported the highest (4th quartile) and
therefore worst sensory subscale scores. A dose modification of chemotherapy
was applied in 72% of patients, of whom 50% received a dose reduction because
of neurotoxicity. Dose modifications did not seem to adversely affect treatment
response rates.
Summary and Conclusions: CIPN is a common dose-limiting side effect
reported by more than half of patients with MM. The neuropathy is less severe
12 months after last treatment. However, patients with MM receive neurotoxic
treatment throughout a considerable period of life after diagnosis. Regardless
of the poor prognosis, 31% of patients with relapsed or progressive MM were
still actively treated with chemotherapy, with a high neuropathy symptom bur-
den, which may negatively affect their HRQOL.
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FRONTLINE INDUCTION THERAPY FOR MULTIPLE MYELOMA (MM) IN
REAL-WORLD CLINICAL PRACTICE: THIRD INTERIM ANALYSIS OF THE
MULTINATIONAL, OBSERVATIONAL EMMOS STUDY (NCT01241396)
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vicio Hematología y Oncohematología, Hospital Madrid Norte Sanchinarro,
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sitätsklinik Innsbruck Innere Medizin V-Haematologie & Onkologie, Innsbruck,
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Background: There is a lack of objective data on variation in treatment prac-
tices and outcomes for MM between countries.
Aims: The prospective, non-interventional EMMOS study was designed to
capture real-world data regarding treatments for MM at different stages of the
disease.
Methods: Consenting adult patients (pts) initiating any new line of therapy for
MM, irrespective of treatment line at study entry or type of therapy, were eligible
for inclusion in the EMMOS registry. A multi-staged site/pt recruitment model
was applied to minimize selection bias; enrolment was stratified by country,
region, and practice type. At baseline, pts’ medical and disease features, treat-
ment history, and remission status were documented. Prospective data regard-
ing treatment, efficacy, and safety (treatment-emergent adverse events
[TEAEs]) were electronically captured every 3 mos until 2 yrs after the last pt
enrolled. Responses were investigator-assessed; no predefined response cri-
teria were mandated. Here we report results from the third interim analysis of
the study, with a focus on frontline therapy in MM pts who had undergone stem
cell transplantation (SCT) at the time of data extraction.
Results: Between October 2010 and October 2012, 2353 pts were enrolled in
22 countries in Europe and Africa. Enrolment by practice type was 44% academic,
29% regional, 16% private, and 11% local clinics. The date of data extraction for
the present analysis was 29 December 2014, at which time 772/2353 pts had
undergone SCT in any treatment line. In the SCT population: pts’ median age at
MM diagnosis was 57.0 yrs (range, 25-74); 58% of pts were male; 13% had
severe renal impairment; and 71% had bone lesions. In 679 pts with available
staging data, 69% had ISS stage II/III disease (89% Salmon-Durie stage 2/3).
Median duration of follow-up from diagnosis was 40 mos (range, 4-345) and from
study entry was 28 mos (range, 0.4-46). The majority of pts (658/772; 85%)
underwent only a single SCT procedure during the course of their disease.
534/772 (69%) pts were recorded (retrospectively or prospectively) as having
received SCT in frontline. Prospective treatment data were available for 385 SCT
pts, of whom 297 (77%) had received SCT upfront and 88 (23%) had received
SCT in later lines. As part of their frontline treatment, 293 (76%) pts had received
bortezomib-based combinations and 92 (24%) had received non-bortezomib
combinations. Response rates to frontline therapy are summarized in the Table
1. Rates of higher-quality responses (very good partial response or better
[≥VGPR]) appeared higher with bortezomib-based compared with non-borte-
zomib-based frontline therapy (65% vs 49%). Safety data were analyzed in the
293 pts who had received bortezomib-based combinations in frontline. The most
common TEAEs were nausea (19%), diarrhea (18%), and pyrexia (17%). Periph-
eral sensory neuropathy and neuropathy peripheral were each reported in 28
(10%) pts. 12 (4%) pts experienced ≥1 serious TEAEs that were considered to
be at least possibly related to bortezomib.
Table 1. Best response to frontline therapy (response-evaluable popula-
tion, n=309)*.
Summary and Conclusions: Data from this real-world observational study
appear to reflect experience in the prospective clinical trial setting. Bortezomib-
based therapy was commonly used as part of frontline treatment in pts under-
going SCT in routine clinical practice, and produced substantial response rates.
No new safety signals for bortezomib were observed.
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ANALYSIS OF OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS
WITH 33 LINES OF THERAPY INCLUDING A PI AND AN IMID, OR DOUBLE
REFRACTORY TO A PI AND AN IMID USING REAL WORLD DATA
S. Usmani1,* A. Desai2, T. Ahmadi3, Y. Ng2, G. Sung2, M. Mehra2
1Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC,
2Janssen Global Services, Raritan, NJ, 3Janssen Research and Development,
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Background: Novel agents under evaluation for multiple myeloma (MM) treat-
ment show promising initial results. Interpretation of these findings is challeng-
504 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
ing due to limited information about the natural history of MM in relapsed
patients, particularly in patients treated with recently approved agents. Previ-
ously, an International Myeloma Working Group study determined the outcomes
of patients refractory to bortezomib and at least 1 IMiD (Kumar S et al. Leukemia
2012; 26: 149). Since then pomalidomide (IMiD) and carfilzomib (PI) have been
approved for relapsed and refractory MM in the United States (US).
Aims: To use real-world data to define the treatment landscape and natural
history of heavily pretreated MM by identifying a cohort of patients with MM
double refractory to a PI and IMiD or who had received ≥3 lines of therapy
(LOT; including a PI and IMiD).
Methods: The data source was the IMS LifeLink: IMS Oncology Electronic
Medical Records (EMR) Database (IMS Health Incorporated, all rights
reserved) comprising US patients only. Cohort identification of the initial pop-
ulation included patients from the index period of 2000-2011, excluding those
with prior cancer diagnoses. Approximately 88% of patients were diagnosed
with MM in 2006 or later. Patients who received ≥3 LOT (including a PI and
IMiD) and had shown disease progression within 60 days of completion of
the most recent regimen, or had disease refractory to both a PI and IMiD
were identified as the target population. MM drugs considered for regimen
analysis included PIs (bortezomib, carfilzomib), IMiDs (thalidomide, lenalido-
mide, pomalidomide), and chemotherapy/steroids (melphalan, cyclophos-
phamide, dexamethasone). Median overall survival (OS) was assessed based
on age; gender, ECOG status at last line of therapy; degree of refractoriness;
or prior LOT (≥6 vs <6).
Results: Of screened 4,030 patients with multiple myeloma, 101 were exclud-
ed for prior cancer diagnoses, 2,918 patients were available for regimen
analysis, and 500 met the criteria for the target population. Median ages at
diagnosis and eligibility were 66 and 70 years, respectively. At eligibility, 52%
were male and 26% had an ECOG score ≥2. Of the 500 patients, 177 received
≥3 prior LOT including a PI and IMiD. The remaining 323 (65%) patients met
the criteria of double refractory disease, 22% of whom were triple (n=61) and
quadruple (n=9) refractory. Overall, patients received a median of 3 (range,
1-25) prior LOT. All patients received 1 LOT after designation of eligibility,
298 received 2 LOT, and 169 received 3 LOT. Exposure to novel agents was
22% (carfilzomib, 16%; pomalidomide, 6%) at first LOT with >80% as a single
agent. Median OS for the full eligible population of 500 patients was 239
days. Median OS was significantly higher in patients aged <65 versus ≥65
years (289 vs 204 days; P <0.01), but was not significantly different by gender
(male, 228 days vs female, 260 days). Median OS was 228 days for double
refractory patients, 154 days for triple/quadruple refractory, and 350 days for
those that received ≥3 prior LOT including a PI and IMiD but were not double
refractory. Median OS was 239 days for ECOG score ≤2 versus 87 days for
ECOG score >2 (P <0.0001). Median OS was 274 days in patients with ≥6
prior LOT compared with 190 days in those with <6 prior LOT (P=0.09).
Summary and Conclusions: These real-world data confirm poor outcomes
in patients relapsed or refractory to current MM treatments and highlight the
unmet clinical need for novel therapeutic agents for the treatment of heavily
treated patients.
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Background: There are new tools for accurate follow-up and diagnosis assess-
ment in Multiple Myeloma (MM) patients. While the Free Light chain immunoas-
say (FLC) (Bindingsite, Birmingham, UK) is part of the mandatory response
assessment according to IMWG-criteria and recently one of the criteria for diag-
nosis, the role of the Heavy/Light Chain immunoassay (HLC), is still under
investigation with promissory results. Relapses in MM patients are frequent
and there is an especial interest in select therapy for consolidation/maintenance
after Autologous Stem Cell Transplantation (ASCT) and to detect early relapse
to optimize the therapy. We hypothesized that the combination of these tech-
niques could permit to detect early biological (non-symptomatic) relapses (EBR)
in these kind of patients.
Aims: To analyze the usefulness of HLC and FLC to detect EBR in MM after
ASCT in our hospital.
Methods: A retrospective study was performed including all consecutive
patients treated in our center, following these criteria: Diagnosed of secretory
MM, upfront-therapy including ASCT between May 2011-August 2014,
assessed with our protocol including FLC, HLC, serum and urine elec-
trophoresis (SPE, UPE) with immunofixation (IFX), previous to ASCT, after
12 weeks and every 3 months later with a minimum follow-up of 6 months
after ASCT. EBR was defined as an increase of 25% on M-protein (any
amount for patients on CR/SR) and/or an increase of >o=20mg/dl for FLC,
and/or 25% increase on involved HLC with abnormal ratio. For urine, an
increase >500mg/24 hrs of involved free-chain protein.
Results: Fifty-five patients were registered. Median follow-up 21 months. MF
ratio: 29/26, mean age 59.5 y (33-71). Immunoglobulin subtype: IgG-Kappa:
41.8% (23), IgG-Lambda: 23.6% (13), IgA-Kappa: 16.4% (9), IgA-Lambda:
7.3% (4), Bence-Jones-Kappa: 3.6% (2), Bence-Jones-Lambda: 7.3% (4).
Durie-Salmon Stage: IA: 13.5% (7), II-A: 32.7% (17), III-A: 44.2% (23), III-B:
9.6% (5), missing-data 3 case. All patients received Bortezomib based therapy
and MEL200 as conditioning regimen. Status pre-ASCT: minimal response:
12%, Partial Response (PR): 50.0%, very-good-PR (VGPR): 28.0%, complete
response (CR): 6% and string response (SR): 4.0%. After ASCT, evaluation
reveals that 13.0% achieved SR, 13.0% CR, 30.4% VGPR and 39.1% PR.
During follow-up, 27/50 (54.0%) patients who achieved at least PR after
ASCT, had a clinical relapse/progress, median PFS 24 months (19.8-28.1).
EBR were detected in 19/27 relapsed patients at median time 7 (2-19) months
before symptomatic relapse. The EBR were detected by FLCr (31.6%), HLCr
(21.0%), FLC+SPE (10.5%), FLC+IFX (5.2%), FLC+HLC+SPE (15.8%),
FLC+HLC+SPE+UPE (15.8%).
Summary and Conclusions: Both FLC and HLC are useful tools to detect
EBR, in our cohort in more than 50% of patients ahead other techniques. A
review of the criteria to re-introduction of therapy and research on this field
are warranted.
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Background: In the last decades, the median age at diagnosis of MM cases
and the proportion of very old patients (>80 years) have increased. However
they are underrepresented in clinical trials.
Aims: The objective of this study is to analyze the clinical features and out-
come of very elderly patients with MM and the impact of therapeutic advances
in this group of patients.
Methods: We conducted a retrospective analysis of patients with MM diag-
nosed at HGUV who were 80 years of age or older. The characteristics eval-
uated included ISS staging, hemoglobin, calcium, renal function, M-protein,
cytogenetic study and bone disease. We review treatment, response rate
(RR), early mortality and overall survival (OS), and we compare the outcome
with those of patients from 65 to 79 years old. 
Results: Among 311 patients with MM diagnosed at HGUV from January
1990 to December 2014, 70 (22.5%) were ≥80 years (median age 82.5 years,
range 80-93 years) and 166 (53.4%) between 65-79 years, 46% (n=32) males
and 54% females (n=38). The proportion of ≥80 years patients increase from
18% in 1990-1999 to 22.4% in 2000-2009 and to 25.6% in 2010-2014. Com-
pared to 65-79 years, octogenarian had more frequently ISS 2-3 (73 vs
89.6%, p=0.02) and renal impairment (56.9%vs67.2%;p=0.35), with a similar
incidence of severe RI (21.5% and 22.4% respectively). No significant differ-
ences were observed in hemoglobin, calcium, and bone disease between
both groups. Cytogenetic data were available for 43 patients (63.2%). The
incidence for del 17p was 2.4%, 4.9% for t(4;14) and 14.6% for del (13) in
≥80 years group and 4.5%, 9.1% and 6.8% respectively in 65-79 years. There
was no significant differences in proportion of smoldering MM between ≥80
years old patients (13.3%) and 65-79 years group (17.7%)(p=0.29). Data
from front line therapy were available for 59 patients. Fifteen patients (25.3%)
were considered unable to tolerate standard therapy, 4 (6.7%) received
steroid alone and 11 (18.6%) only supportive therapy. As first line treatment,
24 patients received melphalan-prednisone (MP) and 13 bortezomib-based
regimens (BBR) (with MP:6, Dexamethasone:5 or bendamustine:2). Overall
RR (≥partial response) was 44% in ≥80 years. RR were higher in 65-79 years
group (60.25%). The median follow up was 27 months in the younger group
and 15 months in ≥80 years. Early mortality (≤2 months) was 17.14% in octo-
genarians and 11.44% in the 65-79 years group. (p=0.236) The median OS
was 18 months for ≥80 years and 35 months for 65-79 years group (Log Rank
p=0.009). However, there was no significant difference when we excluded
patients without active treatment due to comorbid conditions or the smoldering
MM. In the subset of 65-79 years, patients treated with VMP had better OS
compared with MP (42 vs 29 months; p=0,026). However in the ≥80 years
group no significant difference in OS between patients treated with MP and
BBR was observed.
Summary and Conclusions: Our study evidences that octogenarian MM
patients shows shorter OS compared with old patients between 65-79 years.
The high rate of ≥80 years patients who are not fit for standard treatment
(25%), the high frequency of early mortality (17%) and advanced ISS staging
have a negative impact on survival. We have not observed an improvement
on OS with BBR in octogenarian patients, however the number of patients
was low. Beside the fact that we need more clinical trials that include octoge-
narian patients, we think that these patients are frail and need an especial
approach in terms of treatment and management.
haematologica | 2015; 100(s1) | 505
Vienna, Austria, June 11 - 14, 2015
E1259
RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLE MYELO-
MA TREATED WITH BORTEZOMIB: ROLE OF HEAVY/LIGHT-CHAIN
IMMUNEASSAY
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Background: Multiple Myeloma (MM) is characterized by multiples relapses,
for that reason the objective of MM therapy is to achieve the most deeper and
sustained response; actual approaches included a consolidation and/or a main-
tenance period with a close monitorization to assess the relapses and identified
the best moment to re-start the therapy. The routinely follow-up for minimal
residual disease in MM is based in the M-protein quantification by serum and
urine electrophoresis (SPE, UPE) with immunofixation (IFX). The incorporation
of Serum Free Light Chain Assay (FLC), and the quantification of paired clonal
and non-clonal immunoglobulins (HLC) in serum, offers the possibility to assess
the response to therapy more accurately detecting early non-symptomatic (bio-
logical) relapses (EBR).
Aims: To analyze the usefulness of HLC and FLC during MM follow-up to
detect EBR in patients who received Bortezomib-based first line therapy in MM
patients in our center.
Methods: Since January 2008 we have incorporate in the protocol for M-com-
ponents assessment the quantification of FLC, later the HLC; both at baseline
and in follow-up of MM. We have analyzed these parameters in all consecutive
patients diagnosed as secretory MM who complete at least 4 cycles of Borte-
zomib-based upfront therapy between Jan 2008-Jun 2014 in our center.
Results: A total of 135 MM patients started bortezomib-based therapy. Median
follow-up 25 months. Females: 40.7%, mean age 69.6 y (32-91). Subtype: IgG-
Kappa: 38.2%, IgG-Lambda: 9,8%, IgA-Kappa: 17.9%, IgA-Lambda: 15,4%,
IgDL: 1.6%, Bence-Jones-Kappa: 6,5%, Bence-Jones-Lambda: 8,9%, oligose-
cretory: 1.6%. Durie-Salmon Stage: IA: 9.8%, IB: 1.6%, II-A: 27.6%, IIB: 8.9%,
III-A: 21.1%, III-B: 21.1%. ISS: I: 25.2%, II: 32.5%, III: 23.6%. The 21.1% of
patients were not included in the analysis of response by uncompleted treat-
ment. Response at end of therapy: minimal response: 5.1%, PR: 44.3%, VGPR:
16.5%, CR: 14.4% SR: 7.2%, Failure: 12.5%. During follow-up 65.7% patients,
who achieved at least PR had clinical relapsed/progressed, in 86.9% of them,
a previous EBR were detected at a mean of 4.4 months before; methods who
detected BER: FLCr (28.8%), HLCr (13.5%), FLC+SPE+IFX (9.6%), FLC+IFX
(5.8%), FLC+HLC+SPE (28.8%), FLC+HLC+SPE+UPE (5.7%) Median PFS
20 months (12.8-27.1) Biological PFS: 18 m (12.1-23.8). 
Summary and Conclusions: Both FLCr and HLCr are sensitive and précised
tools to perform MRD assessment response in MM, in our cohort a 42.3% of
EBR were detected ahead of other techniques. More investigations on the role
of EBR for therapy initiation are necessary.
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MAJOR CARDIOVASCULAR EVENTS AND COMORBIDITIES IN PATIENTS
NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
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Background: Multiple myeloma (MM) is a common hematological cancer in
the United States and 62% of patients (pts) diagnosed with MM are aged ≥65.
While cardiovascular diseases (CVDs) are prevalent in the older population,
the prevalence of CVD and CVD risk factors in pts with newly diagnosed MM
(NDMM) have not been well described. In a Swedish study comparing the risk
of arterial thrombosis (coronary artery disease and cerebrovascular disease)
between 18,627 MM pts diagnosed between 1958 and 2006 relative to 70, 991
controls matched by age, sex, and county of residence, the risk of arterial
thrombosis was significantly increased at 1, 5, and 10 years of follow-up (hazard
ratio at 1 year=1.9; 95% confidence interval, 1.8-2.1). Mechanisms by which
MM pts may be at increased risk of arterial thrombosis are not well understood
and thus it is important to understand the prevalence of CVD comorbidities in
NDMM pts.
Aims: To describe and characterize the prevalence of prior CVD comorbidities
including major arterial events, in NDMM pts and to compare the prevalence
of these comorbidities in pts <75 and ≥75 years of age.
Methods: This was a descriptive analysis of NDMM pts aged ≥18 years with
Medicare/Medicare Part D coverage in the SEER-Medicare database from July
1, 2007 to December 31, 2009. Pts had continuous enrollment 6 months prior
to and 3 months after diagnosis and did not have renal disease requiring dial-
ysis. Comorbidities were identified using International Classification of Dis-
eases, 9th Revision-code-based algorithms.
Results: We identified 3,920 NDMM pts, of whom 1,937 (49.4%) were female,
2,770 (70.7%) were White, and 3,662 (93.4%) were ≥65 years at diagnosis
(1,457 (37.2%) were ≥age 75). A Charlson comorbidity score of 0 (lowest risk
for 10-year mortality) was present in 2,544 (64.9%) pts. Overall, 212 (5.4%)
and 130 (3.3%) NDMM pts had a previous diagnosis of acute coronary syn-
drome or myocardial infarction (MI) and prior diagnoses of stroke or transient
ischemic attack (TIA) were noted in 179 (4.6%) and 123 (3.1%) pts, respec-
tively. Heart failure (HF) was noted in 706 (18.0%) pts, atrial fibrillation in 382
(9.7%) pts, and conduction disorders in 323 (8.2%) pts. Of conditions associ-
ated with increased cardiovascular risk, 2,256 (57.6%) had hypertension, 2,109
(53.8%) had hyperlipidemia, and 706 (18.0%) had diabetes.
Most CVD comorbidities were more prevalent among those aged ≥75 (Table 1).
Table 1. Comorbidities Present in Multiple Myeloma Patients at Diagnosis
by Age <75 and ≥75 in the SEER-Medicare Database between July 1, 2007
and December 31, 2009 (N=3,920).
                                                         Overall                 <75 years                ≥75 years
                                                       N=3,920                N=1,851                  N=2,069
Comorbidity                                        N (%)                     N (%)                      N (%)
Acute coronary
syndrome/unstable angina                 212 (5.4)                 87 (4.7)                  125 (6.0)
Acute myocardial infarction                 130 (3.3)                 46 (2.5)                   84 (4.1)
Atrial fibrillation                                 382 (9.7)                104 (5.6)                278 (13.4)
Stroke                                               179 (4.6)                 66 (3.6)                  113 (5.5)
Transient ischemic attack                    123 (3.1)                 46 (2.5)                   77 (3.7)
Conduction disorders                         323 (8.2)                 88 (4.8)                 235 (11.4)
Diabetes                                          706 (18.0)              363 (19.6)               343 (16.6)
Heart failure                                     706 (18.0)              231 (12.5)               475 (23.0)
Hyperlipidemia                                2,109 (53.8)            990 (53.5)             1,119 (54.1)
Hypertension                                   2,256 (57.6)            994 (53.7)             1,262 (61.0)
Summary and Conclusions: While the background prevalence of major arte-
rial events (acute coronary syndrome, MI, stroke, TIA) was low, there were
large numbers of pts with other CVD comorbidities at MM diagnosis. Existing
HF at MM diagnosis was noted in 23% of those ≥75 years of age. Recognition
of these underlying CVD comorbidities may influence clinical management of
NDMM and may assist in understanding the pathogenesis of arterial throm-
boembolism in these pts.
E1261
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CATIONS OF USING BONE MARROW PLASMA CELL CONTENT AS A
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Background: Unlike the majority of malignancies, myeloma tumor burden can be
assessed either directly by the tumor cell content per bone marrow examination,
or indirectly by the quantity of paraprotein being secreted by the plasma cells. Con-
temporary response criteria primarily place primacy on the quantitation of serum
or urine monoclonal protein, or should these be inadequate, serum free light chain
levels. Bone marrow plasma cell content (BMPC) is currently a secondary metric
employed when the aforementioned are non-applicable, as in non-secretory myelo-
ma, as well as to characterize deep responses such as complete response.
Aims: To study the correlation between marrow plasmacytosis and monoclonal
protein levels, differential treatment effects, and possible implications of any
discrepancies. 
Methods: We identified 845 patients with newly diagnosed MM treated at Mayo
Clinic who demonstrated measurable disease by serum or urine M protein (1 gm/dl
and 200 mg/24 h, respectively) or by serum FLC (dFLC >=10 mg/ml); 628 (74%)
were evaluable by BMPC criteria. Comparisons were made between (i) treatment
responses based on IMWG criteria and BMPC change, (ii) variations of response
with respect to specific regimens, and (iii) the effect on survival outcomes.
Results: The median age of the group was 60.5 y; 59% were male, and 58%
were alive at the time of analysis. Initial therapy included conventional chemother-
apy (13%), dexamethasone (13%), IMiD based (44%), proteasome inhibitor (PI)
based (19%), or PI-IMiD combination (11%). When using IMWG criteria, 74%
demonstrated partial response, ranging between 58% for conventional therapies
to 94% with PI-IMiD combinations. Similarly, when using BMPC criteria for PR
per >=50% decrease, 73% of the evaluable patients achieved PR. Overall, 484
(80%) of the 604 patients who were evaluable by both BMPC and M protein
demonstrated concordant results by BM and M protein/FLC measurement. Of
the remaining 120 patients, 50 demonstrated PR solely by BMPC criteria, while
70 achieved PR by M protein/FLC measures only. When measurable BMPC was
defined as >=20%, 679 patients were evaluable by both measures, and the con-
cordance rate remained at 80%.  The ratio between serum M protein reduction
(%) and the BMPC reduction (%) was compared between conventional and novel
therapies. The ratio was significantly lower with conventional therapies (median
0.83) when compared to novel therapies (median 1.02), p <0.01. This suggests
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that the BMPC% does not decrement proportionately to the degree of decrease
in M protein with novel therapies, which could be consistent with a cytostatic
rather than a cytotoxic effect. The median OS for those with a concordant PR by
the two measures was superior compared to those who were discordant or not
in a PR by either system (p=0.02).
Summary and Conclusions: The current convention of identifying PR by spec-
ifying BMPC reduction by >50% with a baseline of >=30% is concordant with
M protein criteria for PR in 80% of this cohort. Using a lower threshold of 20%
BMPC at baseline had no demonstrable change in PR concordance. Superior
median OS was associated with PR concordance between both M protein and
BMPC assessments.
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Background: Light chain (AL) amyloidosis is caused by an accumulation of
misfolded proteins, resulting in dysfunction of vital organs (e.g., heart, kidneys,
liver, soft tissue). The protean clinical features of AL amyloidosis reflect its sys-
temic nature, and initial symptoms are often nonspecific (e.g., weight loss,
fatigue). Consequently, a correct diagnosis is frequently made only after the
disease has become advanced. Therapy is directed at the plasma cells that
produce the pathogenic proteins. In advanced disease, treatment may be asso-
ciated with significant adverse effects. 20% to 30% of patients die within 3 to 6
months of initiating therapy. Diagnosing the disease and accessing appropriate
therapy pose significant challenges, and there is a paucity of literature depicting
the patient experience. This not only impacts patients’ quality of life (QoL) but
likely also their survival. Such information may identify unmet clinical needs
and ways to improve patient care and disease outcomes.
Aims: The primary aims of this study were to identify the challenges in estab-
lishing a diagnosis of AL amyloidosis and to gain insight into the AL patient
experience.
Methods: Patients, family members, and caregivers were invited to participate
in an anonymous online survey through email and social media channels of
the Amyloidosis Foundation and an amyloidosis awareness group on Facebook.
The 16-question survey was developed by the authors and was available to
participants online from January 29 to February 5, 2015. Eight follow-up ques-
tions were sent via email to those who responded.
Results: A total of 507 persons completed the survey (patients, 57%; family
members, 34%; caregivers, 8%). Most responders were female (63%) and
between 50 and 69 years of age (63%). Average age at diagnosis was 57
years. Initial symptoms included fatigue, shortness of breath, weakness, neu-
ropathy, swelling of the legs, and enlarged tongue. The organs most frequently
involved included the heart (36%) or kidney (28%); 21% reported multiple organ
involvement. Time from initial symptoms to correct diagnosis was more than 1
year in 38% of responders; 31% met with 5 or more physicians before a correct
diagnosis was made (Figure 1). Diagnosis occurred at 144 institutions. 62% of
responders were evaluated at an amyloidosis center, and 43% received treat-
ment at an amyloidosis center. Almost half (40%) the responders reported
receiving no disease-specific information or education. Clinical trial information
was provided to only 24%. Almost half (46%) the responders would consider
enrolling in a clinical trial if they felt well informed; yet 45% did not know how
to enroll. Difficulty tolerating treatment was reported by 54% (93/173) of respon-
ders. Following therapy, no improvement in QoL was reported by 30%, with
some improvement and definite improvement reported by 40% and 30%,
respectively (175 QoL responses). Updated results will be presented.
Figure 1. Number of physician visits before establishment of a diagnosis.
Summary and Conclusions: A correct diagnosis of AL amyloidosis often
requires numerous physician visits to different medical specialists and often
occurs when disease is advanced. The responses obtained in this patient sur-
vey highlight the challenges experienced by patients with AL amyloidosis. These
data may identify opportunities to educate patients and physicians in order to
expedite diagnosis, facilitate appropriate disease management and access to
clinical trials, and ultimately improve patient survival.
E1263
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Background: Twenty percent to 40% of patients (pts) with multiple myeloma
(MM) exhibit renal impairment (RI), which is associated with poor outcomes
(Eleutherakis-Papaikovou et al., Leuk Lymphom, 2007; Knudsen et al., Eur J
Haematol, 2000). Two percent to 13% of these patients require dialysis (Blade et
al., Best Pract Res Clin Haematol, 2005). More than 95% of pomalidomide (POM)
is hepatically metabolized, and <5% is renally excreted as the parent drug; hydrol-
ysis products and phase I metabolites of POM are less potent with respect to
antimyeloma and immunomodulatory effects (Hoffmann et al., Cancer Chemother
Pharmacol, 2013). POM in combination with low-dose dexamethasone (LoDEX)
has shown efficacy in pts with refractory or relapsed and refractory MM (RRMM)
and moderate RI (creatinine clearance [CrCl] <30-44 mL/min; Siegel et al., Blood,
2012; Weisel et al., J Clin Oncol, 2013). However, POM+LoDEX has not yet been
fully studied in pts with severe RI (CrCl <30 mL/min; serum creatinine ≥3 mg/dL)
because these pts were excluded from prior trials.
Aims: MM-008 is a multicentre, open-label phase 1 study designed to assess
pharmacokinetics (PK) and safety of POM+LoDEX in RRMM pts and normal
or severely impaired renal function with or without dialysis.
Methods: Pts with RRMM (≥1 prior treatment [Tx]) and normal kidney function
or mild RI (creatinine clearance [CrCl] ≥60 mL/min; Cohort A-control arm),
severe RI (CrCl <30 mL/min) not requiring dialysis (Cohort B), and severe RI
requiring dialysis (Cohort C) were eligible. Cohort A received POM 4 mg, and
Cohort B received POM 2 or 4 mg on days 1-21 of a 28-day cycle, following a
3+3 dose-escalation design. Cohort B results informed the 4-mg dosage used
in Cohort C. All cohorts received DEX 40 mg (20 mg for pts aged >75 yrs) on
days 1, 8, 15, and 22. Tx continued until disease progression or unacceptable
toxicity. Dose-limiting toxicities (DLTs) were defined as: grade (Gr) 4 neutrope-
nia, febrile neutropenia, Gr 4 thrombocytopenia involving ≥30% decrease in
platelet count from baseline and requiring >1 platelet transfusion, Gr 3 throm-
bocytopenia with significant bleeding (requiring hospitalization and/or platelet
transfusion), Gr 4 infection, or ≥Gr 3 other non-hematologic toxicity related to
POM. Serial plasma samples were analyzed to generate PK parameters.
Results: Current data for 15 treated pts were available (8 in Cohort A, 3 in
Cohort B at 2 mg, and 4 in Cohort B at 4 mg). Median age was 66 yrs (range,
46-76 yrs), 60% (9/15 pts) were male, all had Eastern Cooperative Oncology
Group performance status 0 (6/15 pts) or 1 (9/15 pts), and a median time from
diagnosis of 3.8 yrs (range, 0.6-12.5 yrs). No DLTs were reported for any cohort
in cycle 1. The most common Gr ≥3 adverse events (AEs) were neutropenia
(47%), anemia (40%), infection (33%), and fatigue (13%). Median relative dose
intensity was consistent across cohorts (0.9-1.1). Mean dose-normalized expo-
sure (AUC0-24) is shown in the Figure 1. One patient in Cohort A discontinued
due to dyspnea and 1 discontinued due to pulmonary fibrosis; 1 in Cohort B 4
mg discontinued due to rash. No deaths have occurred during Tx or follow-up
visits at 28 days post-Tx discontinuation.
Figure 1.
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Summary and Conclusions: The ongoing prospective trial MM-008 is exam-
ining the PK and safety of POM+LoDEX in pts with RRMM and severe RI. Pre-
liminary PK data demonstrate similar mean dose-normalized exposure at a
clinical dose of 4 mg POM in pts with severe RI and no or mild RI. Preliminary
safety data and tolerability in this RRMM population are encouraging.
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MA: 15-YEAR EXPERIENCE AT A SINGLE CENTER
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Background: Allogeneic stem cell transplantation (allo-SCT) may cure multiple
myeloma (MM) but its role is still under discussion mainly for two reasons: the
high morbidity and mortality related to the procedure (TRM) and the impressive
results that can be attained with the new drugs.
We present our series of 29 patients with MM and an allo-SCT (2000-2015).
Aims: We present our results with Allo-SCT in a selected population and its
posibility to control the disease.
Methods: Patients: N=29 (16 female, 13 male). Median age at diagnosis: 45
years (range 21-56). ISS-1: 9 patients (31%), ISS-2: 7 patients (24.1%), ISS-
3: 13 patients (44.8%). Eighteen patients had previously received an autolo-
gous SCT (62%). The median time from diagnosis to allo- SCT was 494 days
(range 122-1,668). State of the disease pre-SCT: complete remission (CR): 7
(24.1%), very good partial remission (VGPR): 10 (34.4%), partial remission
(PR): 9 (31%), stable disease (SD): 2 (6.9%), progressive disease (PD) 1
(3.4%). Transplantation procedure: The conditioning regimen was myeloabla-
tive in 5 patients (17.2%); non-myeloablative in 24 (82.7%). Sixteen patients
(55.1%) had received radiotherapy as part of the conditioning regimen. Type
of donor: Related Adult Donor (RD): 21 (72.4%), Unrelated Adult Donor (UD):
5 (17.2%), Umbilical Cord Blood: 1 (3.4%), Haploidentical donor: 2 (6.9%). 
Results: Response at day 100+: CR: 14 (48.2%), VGPR: 4 (13.8%), PR: 4
(13.8%), SD: 1 (3.4%), PD: 3 (10.4%), Not Evaluable: 3 (10.4%). The cumula-
tive incidence of grade II-IV acute GVHD was 34.4% (10 patients), 7 of which
received an allo-SCT from RDs and 3 from UDs. The incidence of moderate-
to-severe chronic GVHD was 38% (11 patients). Two patients presented an
overlap syndrome. Eleven patients progressed (38%) and were treated with a
combination of anti-MM drugs and donor lymphocyte infusion. Ten patients
died (34.4%), 6 from transplant-related complications (20.6%) and 4 because
of MM progression. Nineteen patients are alive at the time of this report (65.5%),
10 of them in continuous complete remission (34.4%) having not required any
further treatment for their disease. Their current ECOG performance status is:
0-1: 12 patients (63.2%), ≥2: 7 patients (36.8%). The median overall survival
(OS) from diagnosis is 2,619 days (range 539-6,195). The median overall sur-
vival from allo-SCT is 1,951 days (range 25-5,963). 
Summary and Conclusions: Allo-SCT when performed in a selected popula-
tion of MM patients, has a low TRM even when using UD. A significant propor-
tion of patients remain disease-free for a long time. Patients progressing may
revert to a CR. The long OS of our series suggests a role of allo-SCT in the
control of the disease.
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Background: In multiple myeloma (MM) malignant plasma cells interact with
bone marrow (BM) microenvironment’s components and modify it, favoring in
multiple manners tha expansion of the clone. The genesis of new blood vessels,
in order to provide the suitable conditions for the expanding malignant mass is
a dynamic and complex pathological phenomenon with a major role in tumor
growth, invasion and disemination. 
Aims: The aim of the present study was to evaluate the expression of endoglin
in the BM of MM patients. An effort was made to correlate this marker with
mast cell dencity (MCD), the angiogenic cytokine angiopoietin-2(angiop-2) and
plasma cell nuclear antigen (PCNA).
Methods: BM microvascular dencity (MVD) was estimated by endoglin using
immunohistochemical methods in 57 patients with MM up to diagnosis. MCD
was evaluated with the same method. Circulating levels of angiop-2 were meas-
ured by ELISA in the same group of patients. Plasma cell proliferation index,
PCNA was estimated with immunochemical methods. The same parameters
were measured in 20 age- and sex-matched healthy controls. 
Results: We found that endoglin-MVD along with the MCD and serum levels of
angiop-2 and PCNA were increased significantly in patients with MM in compar-
ison to control group (p<0.001 in all cases). Angiop-2 serum levels were also
higher in advance disease stages(p<0.001). Similarly CD105 expression, MCD,
PCNA values were significantly increased in parallel with the stage of the disease.
CD105 expression correlated significantly with MCD(r=0.566, P<0.001), angiop-
2(r=0.399, p<0.002) while there was a trend to correlate with PCNA(r=0.0228,
p>0.08). All the measured parameters were higher in pre-treatment group in
comparison with the post-treatment group(p<0.001 in all cases).
Summary and Conclusions: Our results showed that angiop-2 and CD105
expression which reflect BM neovascularisation are increased in MM patients
and correlate positively with MCD values. This findings indicate that CD105
and MCD could be used as potential tumor markers for disease severity and
as possible target for MM treatment. 
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REFRACTORY MULTIPLE MYELOMA (RRMM): MM-024 EXTENDED
ACCESS PROGRAM (EAP)
Z. Cai1,* J. Jin1, F. Chen2, D.-B. Zhou3, L. Yu4, X. Ke5, X. Li6, D. Wu7, F. Meng8,
D. DeMarco9, J. Zhang9, J. Mei9, J. Hou10, X. Du11
1The 1st Hospital, Zhejiang University, Hangzhou, 2Xiangya Hospital of Central
South University, Changsha, 3Peking Union Medical College Hospital, 4The
301 Hospital-Chinese PLA General Hospital, 5Peking University Third Hospital,
Beijing, 6Shanghai 6th Hospital, Shanghai, 7The 1st Affiliated Hospital of Soo-
chow University, Suzhou, 8Nanfang Hospital of Southern Medicine University
in Guangzhou, Guangzhou, China, 9Celgene Corporation, Summit, NJ, United
States, 10Department of Hematology, Shanghai Changzheng Hospital, Shang-
hai, 11Guangdong General Hospital, Guangzhou, China
Background: In China, the Rd regimen is approved for use in relapsed/refrac-
tory multiple myeloma (RRMM) pts who have received ≥ 1 prior treatment (Tx).
Approval was based on the efficacy and safety of Rd demonstrated in the MM-
021 study, a phase 2 multicenter registration trial in which 199 pts were enrolled
(Hou, J Hematol Oncol 2013), and the global MM-009/MM-010 trials (Dimopou-
los; Weber, N Engl J Med 2007). MM-024 is an EAP initiated to provide con-
tinued Rd Tx for pts enrolled in MM-021, and as a follow-up on the long-term
safety of the Rd regimen.
Aims: To present updated safety and efficacy outcomes from the MM-024 EAP.
Methods: MM-024 comprises of Tx and safety follow-up phases. Eligible pts
for the Tx phase had participated in the MM-021 study, were still on Tx for ≥1
year (yr) and were progression-free. Pts received the same regimen of Rd as
in MM-021 (lenalidomide 25 mg/day on days 1-21, and low-dose dexametha-
sone 40 mg/day on days 1, 8, 15, and 22 of each 28-day cycle). Starting doses
of Rd were the same as the last doses received in MM-021 unless dose adjust-
ments were required prior to rollover, per protocol. Tx was continued until pro-
gressive disease (PD) or withdrawal due to toxicities, and pts were followed
for a maximum of 5 yrs (including 1 yr spent in MM-021). Pts who discontinued
Tx in MM-021, and those who discontinued the MM-024 Tx phase were entered
into safety follow-up phase. The primary endpoint was safety; secondary end-
points included progression-free survival (PFS) and overall survival (OS). All
efficacy endpoints were measured from the enrollment date of MM-021.
Results: Of the 199 pts in the MM-021 trial, 80 transferred into the MM-024
study (data cutoff November 5, 2014); 41 pts entered the EAP Tx phase, 15 of
whom are still receiving Tx. Overall, 26 pts discontinued Tx: 23 due to PD; 2
due to death; and 1 was lost to follow-up. Median follow-up for the treatment
cohort was 43.3 months (mos) from initial enrollment in MM-021. In the safety
population (n=80), median age was 59 yrs (range 35-76) and 28.8% of pts
were aged >65 yrs. Most pts (80.0%) had Durie-Salmon stage III disease at
baseline. All pts had received prior Tx for MM, median number was 4. A total
of 6.3% of pts had undergone surgery and 3.8% of pts had received radiation
Tx; 71.3% of pts had received prior bortezomib, 73.8% had received prior
thalidomide, and 51.3% had received both. In the treatment cohort (n=41) medi-
an PFS was 36 mos, median OS has not been reached. In the safety population
(n=80), 60% of pts had grade (Gr) 3-4 treatment-emergent adverse events
(TEAEs); among the most common TEAEs (all grades) were anemia (58.8%),
decreased neutrophil count (47.5%), upper respiratory tract infection (33.8%),
neutropenia (32.5%), fatigue (23.8%), and thrombocytopenia (18.8%). Gr ≥3
TEAEs included neutropenia (20.0%), decreased neutrophil count (13.8%),
anemia (11.3%), pneumonia (8.8%), and decreased white blood cell count
(7.5%) (Table 1). No TEAEs led to Tx discontinuation; however, TEAEs led to
lenalidomide dose reduction (7.5%), interruption (42.5%), or both (18.8%).
There were 2 second primary malignancies reported, one of which occurred in
the MM-021 study (solid duodenal tumor and nasopharyngeal carcinoma).
Summary and Conclusions: After 43.3 mos of follow-up in the treatment
cohort, median PFS was 36 mos; in the MM-021 final analyses (cutoff date
September 26, 2012) median PFS was 8.3 mos. The MM-024 safety profile
was comparable to MM-021. This indicates long-term use of Rd is well tolerated
and remains an effective Tx in Chinese pts with RRMM who have received
multiple prior Tx.
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Table 1. Gr 3-4 TEAEs reported in ≥3% of pts.
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STAT3 EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN YOUNG
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
S.-H. Jung1,* H.-W. Choi2, M.-G. Shin2, D.-H. Yang1, J.-S. Ahn1, Y.-K. Kim1,
H.-J. Kim1, J.-J. Lee1
1Department of hematology-oncology, 2Department of laboratory medicine, Chon-
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Background: The signal transduced and activator of transcription 3 (STAT3)
is a key signaling molecule implicated in the regulation of growth and malignant
formation, and is considered as prognostic marker in various type of cancer.
Aims: In this study, we investigated the prognostic significance of STAT3
expression in young patients with newly diagnosed multiple myeloma (MM). 
Methods: Ninety-four patients under the age of 65 years were enrolled between
June 2005 and March 2013. Dual immunochemical staining (IHC) for phospho-
tyrosine-STAT3 (PY-STAT3) and CD138 on paraffin-embedded bone marrow
sections at diagnosis was performed to evaluate tumor cell-specific PY-STAT3
expression. Patients with PY-STAT3 expression were classified into two groups
according to diffuseness of IHC staining (a cut off value -30%): weak or strong.
Results: PY-STAT3 was detected in 10 patients (10.6%) at diagnosis and three
showed strong-expression. Compared to PY-STAT3 negative patients, PY-STAT3
positive patients show higher C-reactive protein and serum calcium level at diag-
nosis. Over a median follow up of 38.9 months, PY-STAT3 positivity had predictive
value for progression-free survival (PFS) (P=0.001) and overall survival (OS)
(P=0.003). In addition, the median PFS was significantly shorter for strong-positive
patients than for other patients. (8.7 months in strong-positive vs 11.1 months in
weak-positive vs 23.0 months in negative patients, respectively, P <0.001). In 60
patients who received front-line autologous stem cell transplantation, PY-STAT3
positive patients showed poor PFS compared to PY-STAT3 negative patients
(4.2 vs 19.2 months, P=0.013). In the multivariate analysis, PY-STAT3 expression
was an independent prognostic factor for PFS (relative risk (RR) of 2.706,
P=0.014) and OS (RR of 3.091, P=0.044) in young patients with MM (Figure 1).
Figure 1. Kaplan-Meier survival curbes for progression-free survival and
overall survival according to PY-STAT3-positivity (A, B) and diffuseness
of PY-STAT3 expression (C, D).
Summary and Conclusions: These data suggested that PY-STAT3 positivity using
dual IHC method was significant prognostic marker in young patients with MM.
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HEPATITIS B REACTIVATION IN MULTIPLE MYELOMA PATIENTS WITH
RESOLVED HEPATITIS B UNDERGOING CHEMOTHERAPY 
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Background: Despite increasing reports of hepatitis B virus (HBV) reactivation
in multiple myeloma (MM), HBV reactivation in patients with resolved hepatitis B
[hepatitis B surface antigen (HBsAg)-negative/anti-hepatitis B core antigen anti-
body (anti-HBc)-positive] is still poorly characterized.
Aims: The aim of this study was to clarify its frequency and risk factors.
Methods:A total of 230 MM patients with resolved hepatitis B were retrospectively
reviewed for HBV reactivation and biochemical flare.
Results: During a median 2.4 years of follow-up, HBV reactivation was diagnosed
in 12 patients (5.2%). The cumulative rates of HBV reactivation at 2 years and 5
years were 5% and 8%, respectively. A baseline anti-HBs-negative status
(P=0.033) and high-dose therapy/autologous stem cell transplantation
[HDT/ASCT (P=0.025)] were significant risk factors that were positively associated
with HBV reactivation. In subgroup analysis of patients treated with HDT/ASCT
(n=127), a baseline anti-HBs-negative status was the only significant risk factor
for HBV reactivation (hazard ratio, 4.64; 95% CI, 1.47-14.7; P=0.009).
Summary and Conclusions: These data show that evaluation of anti-HBc is
needed for MM patients, and suggest that monitoring of HBV DNA should be
considered for patients with resolved hepatitis B undergoing HDT/ASCT, espe-
cially those who are anti-HBs-negative.
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POTENTIAL THERAPEUTIC TARGETS IN PLASMA CELL DISORDERS: A
FLOW CYTOMETRY STUDY
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Background: The discovery of new targets for tailored therapy is a major
improvement in oncology and tools for rapid and reliable detection of those targets
are essential. Clinical trials show the benefit of recently developed therapeutic
antibodies against antigens on malignant B-cells. Although the occurrence of
these antigens on malignant plasma cells is sporadic, targeting those antigens is
a therapeutic option in patients with plasma cell disorders.
Aims: The aim of this study was to assess plasma cell disorders cases for bio-
markers that have exhibited promise in targeted cancer therapy.
Methods: We retrospectively analyzed patients with amyloid light-chain (AL)
amyloidosis (n=30), monoclonal gammopathy of unknown significance (n=9),
smoldering myeloma (n=17), newly diagnosed symptomatic multiple myeloma
cases (n=25) and multiple myeloma cases in progressive stage of disease (n=22)
that were diagnosed in our clinic from Mai to October 2014. An analysis of CD52,
CD20, CD30, CD22, CD27, CD38, CD81, CD138 and SLAMF7 expression on
bone marrow plasma cells was performed by multiparametric flow cytometry.
Furthermore we studied FISH analysis data of all patients for t(11;14) in order to
correlate immunophenotyping and genetic parameters.
Results: The expression frequency of CD52, CD30 and CD22 on plasma cells
was similar to other studies (12-35%, 0-19% and 0-8%, respectively). Unexpect-
edly, we observed a high CD20 expression frequency on plasma cell in AL-amy-
loidosis up to 37% of all examined cases. t(11;14) correlated positively with CD20
expression on plasma cells in AL-amyloidosis (p=0.016). Furthermore, we found
that the expression level of SLAMF7 is decreased in advanced plasma cell dis-
orders (p=0.025) and that a diminished expression level of SLAMF7 is associated
with low expression of CD27 and CD81 on malignant plasma cells in newly diag-
nosed multiple myeloma.
Summary and Conclusions: This study provides a contribution to targeted ther-
apy options in plasma cell disorders. Particularly, it puts an emphasis on anti-
CD20 antibodies as therapeutic agents in AL-amyloidosis. Regarding the thera-
peutic options of the SLAMF7 antibody elotuzumab these data advise that target
expression diminished during the course of the disease and that analysis of
SLAMF7 expression before application of elotuzumab might help to estimate the
efficacy of elotuzumab in clinical trials.
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Background: Fms-like tyrosine kinase 3 (FLT3) ligand (FLT3-L) is a potent
hematopoietic cytokine that affects the growth and differentiation of progenitor
and stem cells both in vivo and in vitro. It is probably involved in early B cell
development.
Aims: The aim of the present study was to estimate the levels of FLT3L in
serum of patients with multiple myeloma(MM) and its relationship with param-
eters of tumor progression such as Ki-67, the bone marrow infiltration and B-
cell activating factor (BAFF)
Methods: We studied 52 newly diagnosed MM patients with mean age 67±8
years, of them 27 had IgG myeloma, 21 IgA and 4 light chain. According to ISS
10 were in stage I, 18 in stage II and 24 in stage III. 18 age and sex matched
healthy volunteers were used as control group. All assays were performed at
the end of the study, in order to avoid interassay variability. The detection of
biological parameters in the serum was performed by a solid-phase sandwich
ELISA. Immunohistochemical methods were used in order to determine Ki-67
proliferation index(Ki-67 PI).
Results: Our results indicate that the serum levels of FLT3L and BAFF and the
the expression of Ki-67 were significantly higher in patients with MM compared
to controls (p<0.001 for all cases). Moreover, the serum levels of FLT3L were
significantly different among the three stages of disease, with higher values in
advancing disease stage (p<0.001). Additionally, a positive correlation was found
between FLT3L and Ki-67 (p<0.001) and BAFF (p<0.003), while there was a ten-
dency to correlation between FLT3L and bone marrow infiltration (p<0.07)
Summary and Conclusions: Our results showed that FLT3L serum levels
were increasd in parallel with ISS stage. The correlation with parameters of
disease activity supports the involvement of FLT3L in the mechanisms of pro-
motion of MM growth. Its prognostic impact remains to be proven.
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THE ROLE OF DIAGNOSTIC DELAY IN MULTIPLE MYELOMA: “A DELAY
PARADOX”
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Background: The delay in the diagnosis of cancer can influence the outcome.
Little is known about the impact of diagnostic delay in multiple myeloma (MM). 
Aims: The aim of this study was to prospectively explore the impact of the
diagnostic delay in the outcome of newly diagnosed symptomatic MM patients
(NDMM). The primary objective was to describe the time in months (m) between
the first MM-related symptom and the diagnosis, and between diagnosis and
treatment initiation. The secondary objective was to determine whether times
to diagnosis and treatment influenced overall survival (OS).
Methods: The dates for the first MM-related symptom, date of diagnosis and
date of the induction therapy were recorded for all NDMM in our population-
based MM registry, along with variables of prognostic interest. The OS curves
were estimated by the Kaplan-Meier method.
Results: 215 consecutive NDMM patients were included in the study, 111 males
(51,6%) and 104 females, median age 65 years (12-89). Median OS was 31.3
(21.7-40.9) months (m). There were no significant differences in survival according
to sex. The median of diagnostic delay was 4 m (0.2-80). Mean delay for men
was 5.5 m and 6.6 m for women (p=ns). Patients with less than 4m of delay had
an OS of 19.8 m (11.4-28.2) whereas for those with delay of 4 m or higher, OS
was 50.3 m (p<0.001). According to sex, OS for patients with <4 vs ³4 m was 18.8
vs 80.9 m (p=0.001) and 20.4 vs 42.7 m (p=0.088), for men and women respec-
tively. Median time from diagnosis to treatment was 13 days. When comparing
prognostic factors in both groups, we found that patients with delay of <4 m had
ISS1 in 21.3% vs 34% (p=0,07), mean serum creatinine 2.3 vs 1.6 mg/dL (p=0.03)
and mean lactate dehydrogenase (LDH) 338 vs 240 U/L (p=0.009). No statistically
differences were found for free light chain involved-uninvolved ratio or high risk
cytogenetic abnormalities. The percentage of patients with isolated anemia, iso-
lated renal failure or a combination as MM-defining event was higher in the group
of <4 m of delay: 64.3%, 57.1% and 59.1% respectively.
Summary and Conclusions: We conclude that the apparent worse prognosis in
patients with early diagnosis (less than 4 m) is due to the presence in this group
of patients of poorer prognostic factors, in particular a deeper renal impairment,
higher levels of LDH and more advanced ISS stage. Early diagnosis in MM seems
to be associated to specific MM-defining events and a more aggressive disease.
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Background: High-dose chemotherapy followed by autologous stem cell trans-
plantation (ASCT) is a standard frontline therapy for multiple myeloma (MM).
Therapeutic options for patients (pts) with relapsed MM after ASCT include
novel agents, conventional chemotherapy or salvage ASCT (sASCT), with no
standard of care. 
Aims: To evaluate the efficacy and safety of novel agents incorporated into
sASCT. 
Methods: We retrospectively analyzed 66 MM pts who relapsed after up-front
single or double ASCT and received sASCT at four italian centres. 
Results: Induction therapy in preparation to up-front ASCT (single 67%, double
33%) consisted in conventional chemotherapy (35%) and was thalidomide-based
in 58% of pts. Best high-quality response to up-front ASCT included CR (43%)
and VGPR (32%). Median age at sASCT was 60 years. Median progression free
survival (PFS1) from upfront ASCT to relapse was 44 months. 72.7% of pts
received sASCT at first disease progression. Re-induction regimens were borte-
zomib (bort)-based (84.1%) and IMiDs-based (15.9%). Responses to re-induction
therapy included: CR 17.5%, VGPR 30.2%, ≥PR 82.5%. ORR was higher and
median time to response was shorter with bort-based in comparison to IMiDs-
based regimens, also adjusting for the treatment received as first line (88.2% vs
60%, p=0.049; 2.2 vs 4.2 months, p=0.01, respectively). 64% of pts already had
harvested stem cells for sASCT while 24 pts needed a further peripheral blood
stem cells (PBSC) mobilization. 41.7% of them received G-CSF plus plerixafor.
Overall, the median number of PBSC harvested was 3.5 (IQR: 2.9-4.9)x 106
CD34+/kg. High-dose melphalan was the standard regimen before sASCT and
was used at 200 mg/sm in 64.4% of pts. Responses to sASCT included: CR
43.9%, VGPR 33.3%, ≥PR 93.9%. 29% of pts improved from <CR before sASCT
to CR after sASCT (p=0.0001). With a median follow up of 2 years after sASCT,
39 pts (59.1%) experienced progression. Median PFS from sASCT (PFS2) was
17.3 months. PFS2 was significantly shorter in pts with PFS1 ≤24 months (9.6 vs
18.3 months, p=0.003), in pts who did not receive sASCT at first disease progres-
sion (9.7 vs 18.3 months, p=0.03), in pts with EMD (9.9 vs 18.3 months, p=0.008)
and in pts who received reinduction therapy with an IMiDs-based regimen (9.9 vs
18 months, p=0.01), also adjusting for treatment received as first line. In multivari-
ate analysis PFS1 ≤24 months (HR 0.21, CI 0.08-0.56) and the presence of EMD
(HR 6.6, CI 1.8-24.2) were associated with a shorter PFS2. 23 pts (35%) died
after sASCT, mainly due to disease progression (74%). TRM at day+100 was 3%.
Median OS from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respec-
tively. OS2 was significantly shorter in pts with PFS1 ≤24 months (14.2 vs 58.3
months, p=0.003), in pts who did not receive sASCT at first disease progression
(13.7 vs 58.3 months, p=0.008), in pts with EMD (13.9 vs 58.3 months, p=0.03)
and in pts who failed CR after sASCT (30 months vs not reached, p=0.006). In
multivariate analysis PFS1 ≤24 months (HR 0.26, CI 0.09-0.80) and CR after
sASCT (HR 0.27, CI 0.09-0.80) were associated with a shorter OS2.
Figure 1.
Summary and Conclusions: Novel agent-based sASCT is a safe and effective
procedure for relapsed MM. TRM is similar to that observed in the up-front set-
ting. Patients who are more likely to benefit from sASCT are those in first
relapse, with PFS1 >24 months and achieving CR. 
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Background: Smoldering multiple myeloma (SMM) is a plasma cell disorder
with no evidence of myeloma-related symptomatology (hypercalcemia, renal
insufficiency, anemia or bone lesions). SMM has a risk of progression to symp-
tomatic multiple myeloma (MM) of approximately 10% per year. However, this
risk is not uniform and several prognostic factors for the progression to MM
have been identified at diagnosis of SMM. The proportion of bone marrow plas-
ma cells (BMPC), the serum monoclonal protein level and the serum
immunoglobulin free light chain ratio (FLC) were identified by the Mayo Clinic
Group; the proportion of bone marrow aberrant plasma cells assessed by flow
cytometry plus immunoparesis were described by the Spanish Myeloma Group.
According to recommendations made by International Myeloma Working Group
(IMWG), a 24-h urine protein electrophoresis and immunofixation to identify
the presence of Bence Jones (BJ) proteinuria should be performed at diagnosis.
BJ proteinuria is a myeloma feature associated with renal function and tumor
burden as well. However, there is lack of evidence about the role of BJ protein-
uria in SMM as predictor marker of progression to MM.
Aims: The purpose of this study was to investigate the role of the presence of
Bence Jones proteinuria at diagnosis in SMM as predictor of progression to MM.
Methods: We reviewed the medical records of all patients diagnosed with SMM
in Castilla-León (western region of Spain), between 1983 and 2013, according
to the IMWG criteria defined in 2003. The primary endpoint was time to pro-
gression to MM.
Results: A total of 152 patients with SMM were included in the analysis. The
median age at diagnosis was 70 years (range: 34-90). The serum M-protein at
diagnosis ranged from 1 to 2.8 g/dL (median, 2.5). Seventy percent of SMM
patients were Ig G subtype. The proportion of bone marrow plasma cells ranged
from 1% to 55% (median, 14). Bence Jones proteinuria was detected at diag-
nosis in 41 patients (27%) and the average amount of BJ proteinuria was 280
mg in 24h urine. We identified 36 high-risk SMM patients(24%) with serum M-
protein greater than 3g/dL and more than 10% BMPC. Fifty eight patients (38%)
had more than 95% phenotipically abnormal plasma cells by flow cytometry
plus immunoparesis. The serum FLC ratio was assessed at diagnosis in 18
patients and it was abnormal (<0.26 or >1.65) in 15 patients (83%). FISH at
diagnosis was available in 41 patients. Four of them (10%) had high-risk cyto-
genetic abnormalities: t(4;14) or del 17p. The median follow-up for survivors
was 65 months. Progression to symptomatic MM occurred in 74 patients (49%).
The median time to progression (TTP) to MM in the whole series was almost 6
years. SMM with BJ proteinuria had a significantly shorter median TTP to active
disease as compared with patients without BJ proteinuria (21.7 months vs 88.3
months ;HR: 2.6, 95% CI: 1.6-4.4; p=0.001). The progression risk at 2 years in
the BJ group of SMM was 51%. Multivariate analysis selected BJ proteinuria
at diagnosis as an independent variable for progression to symptomatic MM
(HR: 2.47, IC 95%: 1.32-4.63; P=0.005). We identified 3 risk categories accord-
ing to amount of BJ proteinuria: 0 mg per 24h; up to 500 mg/24h; or greater
than or equal to 500 mg/24h, with a median TTP of 7, 3 and 1.1 years, respec-
tively (HR: 2.4; 95% IC (1.6-3.64); p <0.001).
Summary and Conclusions: The presence of Bence Jones proteinuria at
diagnosis in SMM patients is associated with significantly higher risk of pro-
gression to active MM (51% risk of progression at 2 years). Moreover, the pres-
ence of 500 mg or more of BJ proteinuria can be considered as a marker for
the identification of ultra high risk SMM.
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Background: In patients with MM, the choice of salvage therapy at first relapse
between re-treatment with the same drug of induction or change class of drug is
widely empirical and subjective even if PFS1 duration is usually highly thought of.
Aims: To analyze the outcome in terms of 2ndPFS and PFS2 of first salvage
therapies in patients with MM included in 2 prospective trials (VMP vs VMPT-
VT and MPR vs Mel-200) by comparing patients re-treated with the same new-
drug used in induction or with other new-drug class.
Methods: We analyzed 476 patients relapsed after first-line therapy that under-
went salvage therapies based on Bortezomib (126 pts), Lenalidomide (142
pts), Thalidomide (36 pts), chemotherapy (63 pts), autotransplant (92 pts) and
allogeneic transplant (7 pts). Out of these 476 patients, 311 meet the inclusion
criteria for this study that was re-treatment or change therapy with Bortezomib-
based or Lenalidomide-based therapy without transplantation.
Results: In the elderly group (257 pts), salvage therapy included bortezomib
(15%, 2ndPFS=8.8 months), lenalidomide (50%, 2ndPFS=16.6 months),
thalidomide (12%, 2ndPFS=8.6 months), chemotherapy (21%, median
2ndPFS=6.6 months). As regard younger patients (219 pts), 44% received
bortezomib (median 2ndPFS=7.2 months), 7% received IMiDs (median
2ndPFS=14.3 months), 41.5% bortezomib followed by autotransplant (media
2ndPFS=21.5 months), 3% received allotransplant (median 2ndPFS=35.7
months). Out of 311 patients considered for comparison of re-treatment vs
change therapy, 52 patients were re-treated (ptsR: 37 Bortezomib-based and
15 Lenalidomide-based) whereas 259 changed therapy (ptsC: 162 Lenalido-
mide-based, 97 Bortezomib-based). The 2 groups of patients were comparable
for the main prognostic factors (age, ISS stage, cytogenetic, renal function,
plasmocitoma and maintenance) and for follow-up (median 57.3 vs 56.2
months). PtsR received salvage therapy at a median time of 30.4 months (4.2-
64.4 months; <12 months=4 pts; 12-24 months=12 pts; >24 months=36 pts)
while ptsC after a median time of 25.1 months (1.2-63.9 months; p=0.001). In
the whole population, median 2ndPFS and PFS2 was 23.1 and 39.0 months,
respectively. Median 2ndPFS of ptsR was 8.8 months compared with 12.7
months of ptsC (p=0.038). Median PFS2 of ptsR was 39.9 months compared
with 38.8 months of ptsC (p=0.584). Splitting PFS1 duration in two periods, in
patients with a PFS1 duration up to 27 months, change of therapy allowed
2ndPFS and PFS2 significantly longer compared with those of re-treatment
(2ndPFS: 21 ptsR=5.3 vs 164 ptsC=10.2 months; HR=1.9, 95%CI=1.2-3.1,
p=0.006; 3yrsPFS2: ptsR=20% vs ptsC=34%, HR=1.5, 95%CI=1.0-2.5,
p=0.080) whereas, when PFS1 was longer than 27 months, 2ndPFS and PFS2
became similar between the two therapeutic options (2ndPFS: 31 ptsR=16.3
vs 95 ptsC=16.6 months, HR=1.2, 95%CI=0.6-2.1, p=0.614; 3yrsPFS2:
ptsR=90% vs ptsC=92%, HR=1.1, 95%CI=0.6-1.9, p=0.779).
Summary and Conclusions: Our data suggest that changing therapy seems
to be preferable at least until PFS1 is longer than that expected by a given reg-
imen while re-treatment may be consider behind this time to save drugs for
subsequent relapses. However, these results should be confirmed by a ran-
domized trial comparing these two strategies, at least for relapses occurring
between 2 or 3 year after diagnosis.
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AL AMYLOIDOSIS AND QUALITY OF LIFE OUTCOMES
R. Warsame1,* S. Kumar1, T. Carrie1, G. Morie1, M. Lacy1, B. Francis1,
H. Suzanne1, L. Nelson1, D. David1, L. John1, L. Yi1, P. Kapoor1, R. Go1,
S. Zeldenrust1, R. Kyle1, S.V. Rajkumar1, A. Dispenzieri1
1Hematology, Mayo Clinic, Rochester, United States
Background: Patients with light chain amyloidosis (AL) often have delayed
diagnosis and present with significant symptomatology; this in turn results in
decreased quality of life (QOL). With improving treatment options providing
longer survival, it is becoming increasingly important to assess treatment toxicity
and QOL. However there is a paucity of data in the literature of QOL in AL
patients. At Mayo Clinic, we employ a “Hematology Patient Reported Symptom
Screen” (HPRSS) at each visit, which is a three question assessment of fatigue,
pain and overall QOL.
Aims: Our objective was to determine if health related quality of life metrics
are prognostic in AL. 
Methods: We performed a retrospective chart review of newly diagnosed
patients with AL seen at our institution between 2009 and 2014 to collect clinical
data and HPRSS scores. HPRSS is scored on a scale of 0-10; 10 being the
worst for fatigue or pain, and 10 being the best overall QOL. The scores are
collected at each visit, and analyzed at diagnosis, 3 months, 6 months and 1
year. There were 322 patients identified with evaluable HPRSS scores. Only
those patients who died within the first year or had at least 12 months of fol-
low-up were included (n=305). 
Results: The median scores (interquartile range) for fatigue, pain, and QOL at
diagnosis were 6 (3,7), 2 (0,5), 5 (3,8), respectively. The median overall survival
(OS) for the entire cohort was 39.1 months, and 145 patients died in the first
year. There was a significant difference in baseline HPRSS between the 1-year
or better survivors and the early death patients in the domains of fatigue (5 [IQR
3, 7] versus 7 [IQR 5, 8], p<0.0001) and QOL (6 [IQR 4, 8] versus 5 [IQR 3, 7],
p=0.006), but not in the pain domain (2 [IQR 0, 5] versus 2 [IQR 0.5]). There
were significant baseline differences in the early death group for alkaline phos-
phatase, bilirubin, creatinine, and Mayo stage. On univariate analysis both fatigue
and QOL were prognostic for OS. On multivariate which included Mayo staging
and autologous stem cell transplant, only baseline fatigue remained an inde-
pendently prognostic value. In order to compare change in HPRSS scores over
time, we limited the subsequent analyses to those 126 patients who had both
baseline and 12 month measurements. QOL scores improved significantly 6 [IQR
3.5, 8] à 7 [IQR 5, 8] between the two measurements, two sided Wilcoxon signed
rank p=0.01, but there were no significant changes in fatigue scores (5 [IQR 2,
haematologica | 2015; 100(s1) | 511
Vienna, Austria, June 11 - 14, 2015
5]à 4.5 [IQR 3, 6], p=NS) or pain scores (2 [IQR 0,4]à 1.5 [IQR 0, 4], p=NS) over
time. Approaching the data slightly differently, one could score whether patients
HPRSS scores worsened by 1 point, remained stable, or improved by 1 point
over time. The respective proportions were: for fatigue, 37%, 20%, and 43%; for
QOL, 31%, 17%, and 52%; and for pain, 36%, 25%, and 39%. There was no dif-
ference in OS based on change or lack of change of QOL or fatigue, but patients
whose pain worsened had a significant better OS. (Figure 1)This was predomi-
nantly driven by those 67 patients who did not undergo ASCT and presumably
received bortezomib based therapy.
Figure 1. Change in HPRSS scores from diagnosis to 12 month of pain.
Summary and Conclusions: Patient reported fatigue and QOL are important
predictors of outcomes in newly diagnosed AL patients. These simple measures
can be incorporated in to routine clinical practice and should be considered an
important end point for future clinical trials. 
E1276
THE ROLE OF INITIAL 18F-FDG PET/CT IN PATIENTS WITH POEMS SYN-
DROME
J. Jang1, H. Cho1,* J.Y. Lee1, H. Park1, Y.D. Kim1, S.J. Kim1, Y.R. Kim1, J.-W.
Cheong1, Y. H. Min1, J.S. Kim1
1department of internal medicine, Yonsei University College of Medicine, Seoul,
Korea, Republic of
Background: In POEMS syndrome, the identification and biopsy of an
osteosclerotic lesion or a lymph node typical of Casleman’s disease is essential
to establish the diagnosis and plan appropriate treatment.
Aims: The aim of this study is to evaluate the usefulness to detect and select
lesions for the diagnostic biopsy in patients suspected POEMS syndrome
Methods: We reviewed 21 patients with POEMS syndrome retrospectively.
The 16 patients of them received an (18)F-FDG PET/CT scan using a Discov-
ery DSTe PET/CT scanner (GE medical Systems, Milwaukee, WI). All patients
also had undergone bone Ga-scintigraphy.
Results: We reviewed 21 patients with POEMS syndrome retrospectively. The
16 patients of them received an (18)F-FDG PET/CT scan using a Discovery
DSTe PET/CT scanner (GE medical Systems, Milwaukee, WI). All patients also
had undergone bone Ga-scintigraphy.
Results: The median age was 47.5 year and the ratio of male to female was 1.9.
The typical 5 features of peripheral neuropathy (100%), organomegaly (74%),
endocrinopathy (74%), M protein (100%), and skin change (84%) were observed.
Sclerotic bone lesions (81%) and extravascular volume overload (84%) were
also commonly observed. The high serum VEGF level at diagnosis was detected
in all tested patients (n=17). Although most cases of sclerotic bone were detected
by plainx-ray or Ga-scintigraphy, 5 of 17 cases were detected by only (18)F-FDG
PET/CT scan. Plasmacytoma was detected in 7 patients (33%). Except one
case, plasmacytoma were revealed by (18)F-FDG PET/CT scan. Multiple lesions
of plasmacytoma were detected in two patients. One patient who did not take
(18)F-FDG PET/CT scan showed bone pathology on Ga-scintigraphy and dis-
covered plasmacytoma by excisional biopsy. Castleman’s disease was suspected
on the (18)F-FDG PET/CT scan in two patients (10%) and one case was patho-
logically confirmed by biopsy. Of 16 patients who had undergone (18)F-FDG
PET/CT scan, 12 patients showed abnormal bone lesions or hypermetabolic
lesions. Sclerotic bone was seen in 11 patients, abnormal hypermetabolic focus
suspected plasmacytoma was seen in 6 patients, and multiple lymphadenopathy
with FDG uptake was seen in 2 patients. Plasmacytoma was confirmed by biopsy
in five patients and Castleman’s disease in 1 patient. In two cases of plasmacy-
toma, (18)F-FDG PET/CT scan revealed hypermetabolic abnormalities, which
were not detected by Ga-scintigraphy or plainx-ray. As the first line treatment, 12
patients received autologous stem cell transplantation (ASCT), 5 patients
received chemotherapy with or without radiation and four patients received high-
dose steroid, radiation or immune modulators only. Two of five patients with
chemotherapy underwent ASCT as second line treatment. The median follow-
up duration was 43.4month (11.2-99.8). Four-year overall survival rate was
74.5%. Six of seven patients with plasmacytoma received local radiotherapy with
systemic therapy (Table 1).
Table 1. Characteristics of 16 patients who had undergone (18) F-FDG
PET/CT scan.
Summary and Conclusions: (18)F-FDG PET/CT scan is useful in detecting
and selecting bone lesions and accompanying plasmacytoma or Castleman’s
disease for the reliable diagnosis of POEMS syndrome. Furthermore, this find-
ing has potential clinical application in therapy evaluation and follow-up as well
as diagnosis.
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TRIAL EFFICACY VS REAL WORLD EFFECTIVENESS IN FIRST LINE
TREATMENT OF MULTIPLE MYELOMA
J. Liwing1,* B.M. Heeg2, S. Karstorp1, M. Postma3, R. Silvennoinen4, M. Putkonen5,
P. Anttila6, K. Remes5, N. Abildgaard7, A. Waage8, H. Nahi1
1Department of Medicine, Karolinska Institutet, Stockholm, Stockholm, Swe-
den, 2Ingress-health, Rotterdam, 3Unit of PharmacoEpidemiology & Pharma-
coEconomics, Institute of Science in Healthy Aging & health caRE (SHARE),
Groningen, Netherlands, 4Kuopio University Hospital, Kuopio, 5Turku University
Hospital, Turku, 6HUS, Helsinkki, Finland, 7Department of Hematology, Odense
University Hospital, Odense, Denmark, 8Department of Hematology, St Olavs
Hospital, Trondheim, Norway
Background: Large randomized clinical trials (RCT) are the foundation of the
registration of newly developed drugs. A potential problem with RCTs is that
the inclusion/exclusion criteria will make the population different from the actual
population treated in real life. Hence, it is important to understand how the
results from the RCT can be generalized to a general population.
Aims: The primary aim of the present study was to assess the generalizability
of the large 1st line RCTs in Multiple Myeloma (MM) to the Nordic setting and
to understand potential difference and magnitude in outcomes between RCTs
and patients treated in standard care in the Nordics.
Methods: A retrospective analysis was performed on an incident cohort of
2960 MM-patients from 24 hospitals in Denmark, Finland, Norway and Sweden.
The database contained information on patient baseline characteristics, treat-
ments and outcomes. Data from relevant 1st line MM RCTs was selected from
the treatment MP (Waage, A., et al., Blood. 2010], MPT (Waage, A., et al.,
Blood. 2010) and VMP (San Miguel, J.F., et al., N Engl J Med, 2008) and base-
line characteristics were compared to newly diagnosed Nordic MM treated
patients. Potential difference in response and overall survival (OS) was esti-
mated by adjusting the RWE population to the RCT population using matching
adjusted indirect comparisons. Patients were matched on age (median approx-
imated to mean), gender, calcium, beta2-microglobulin and ISS score 3. These
variables were selected because they were reported in all trials and have pre-
viously been identified as having prognostic value.
Results: Patients in the Nordic database treated with MP (n=880) had a response
rate of (PD, NR, PR, VGPR, ≥nCR) of (13%, 39%, 38%, 6%, 4%). After matching
(n=347), the response rate was slightly worse (12%, 43%, 36%, 6%, 3%). This
can be compared to the response rate from the RCT of (7%, 53%, 33%, 3%,
4%). OS for Nordic MP treated patients was 2.67 years (2.25-3.17). After match-
ing the OS was 3.37 years (2.86-3.96) and this can be compared to the trial with
OS 2.40 years (2.23-2.66). Patients treated with MPT (n=283) in the Nordic coun-
tries had a response rate of (5%, 14%, 52%, 20%, 9%). After matching (n=179)
the response rate was slightly changed to (6%, 20%, 50%, 13% 11%). The cor-
responding RCT response results were 14%, 29%, 34%, 10%, and 13% respec-
tively. OS for Nordic MPT treated patients was 4.15 years (3.73- 4.74). After
matching the OS was 4.28 years (3.98-NA) years and compared to 2.42 years
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(2.08-3.17) OS observed in the corresponding trial. Patients treated with VMP
(n=59) in the Nordic countries had a response rate of (4%, 5%, 40%, 18%, 33%).
After matching (n=31) the response rate was improved to (8%, 11%, 28%, 8%,
45%). This corresponding response rates shown in the trial are 1%, 23%, 33%,
8%, and 33% respectively. OS for Nordic MP treated patients was 4.86 years
(3.79-NA). After matching the OS was 4.86 years (4.86-NA) and this can be com-
pared to the trial with OS 4.70 years. 
Summary and Conclusions: Surprisingly Nordic treated MM patients do very
well compared to, and even better than, patients treated in RCTs. Since the OS
for all tested treatments improves after matching to the RCT baseline character-
istics, patients recruited to the RCTs seems to be a bit better than ordinary Nordic
patents. The database used in the present study, and the used method, can be
valuable for generalizing the results to the Nordic setting and estimating potential
difference for future RCTs and Nordic MM treated patients. Future research should
include different data cuts to see whether the analyses are biased by differences
subsequent treatments applied in RCTs and clinical practice.
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HEAVY/LIGHT CHAIN IMMUNOPARESIS AS A NOVEL MARKER OF POOR
OUTCOMES IN SYSTEMIC AL AMYLOIDOSIS
S. Sachchithanantham1, O. Berlanga2, A. Alvi2, N. Wassef3, S. Mahmood1, R.
Sayeed1, J. Gillmore1, H. Lachmann1, C. Whelan1, P. Hawkins1, A.
Wechalekar1,*
1National Amyloidosis Centre, UCL, London, 2The Binding Site Group Ltd,
Birmingham, 3Biochemistry, Royal Free London NHS Foundation Trust, Lon-
don, United Kingdom
Background: Monoclonal free light chain (FLC) levels together with cardiac
biomarkers represent the basis of current risk-stratification models for AL amy-
loidosis, with high-risk patients demonstrating poor survival. However there
exists a need to identify new prognostic biomarkers that help assess outcomes,
particularly in patients surviving initial therapy. Suppression of heavy/light chain
(HLC) immunoglobulins has been shown to add prognostic value in plasma
cell dyscrasias, but similar studies in AL amyloidosis are lacking. 
Aims: To assess the frequency of HLC immunoparesis in AL patients and con-
trast the results in relation to outcome.
Methods: The study included 170 patients with systemic AL amyloidosis seen at
the National Amyloidosis Centre (London, UK). Serum samples were tested neph-
elometrically for FLC and heavy/light chain (HLC, i.e. IgGκ, IgGλ, IgAκ, IgAλ, IgMκ
and IgMλ) concentrations using Freelite® and Hevylite® assays, respectively (The
Binding Site Group Ltd, UK); and total immunoglobulins (IgG, IgA and IgM).
Immunoparesis was defined either by total immunoglobulin (Ig) measurements
as the concentration of any Ig class below the lower limit of normal (i.e. in g/L:
IgG<6, IgA<0.8, IgM<0.5; total Ig suppression), or by HLC immunoassays as
levels of any HLC isotype below the lower limit of their respective reference range
(i.e. in g/L: IgGκ<4.03; IgGλ<1.97; IgAκ<0.48; IgAλ<0.36; IgMκ<0.29; IgMλ<0.17).
Cardiac involvement was defined by the presence of amyloid deposits in tissue
biopsies and/or N-terminal pro-brain natriuretic peptide (NTproBNP) levels >332
ng/L. Survival studies were carried out using Kaplan-Meier curves with the log
rank test used to indicate significance. Median survival for all patients was 26.2
months, and for patients with cardiac involvement 14.8 months.
Results: HLC measurements identified immunoparesis of at least one HLC
isotype in 145 (85%) patients; and severe immunoparesis, defined as two or
more HLC isotypes suppressed by at least 50% below normal levels, in 29
(17%) patients. High monoclonal FLC levels (>180 mg/L, n=82(61%)) associ-
ated with shorter survival in all patients (median OS 14.8 vs 43.1 months;
p=0.05), but not in a landmark analysis of 127 patients alive at 6 months
(p=0.33). By contrast severe HLC immunoparesis associated with shorter sur-
vival in the latter group of patients alive at 6 months (20.2 vs 42.8 months;
p=0.09); with results approaching significance. In a subset analysis of 89
patients with cardiac involvement and alive at 6 months, severe HLC immuno-
paresis strongly impacted outcome (median survival 8.8 vs 29.9 months,
p=0.007) (Figure 1) whereas monoclonal FLC levels reported no significant
association (p=0.23). Systemic immunoparesis as determined by total Ig meas-
urements offered no prognostic information in any patient-group.
Figure 1.
Summary and Conclusions: HLC suppression is a common occurrence in
AL amyloidosis and may add to current models for the prognostication of
patients.
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ELEVATED FACTOR VIII LEVELS CARRY A POOR OVERALL SURVIVAL
IN NEWLY DIAGNOSED SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS
PATIENTS
S. Mahmood1,* A. Riddle2, S. Sachchithanantham1, T. Lane1, D. Foard1,
R. Sayed1, K. Patel1, M. Fontana1, T. Youngstein1, C. Youngstein1, M. Coyne1,
C. Whelan1, H. Lachmann1, J. Gillmore1, P. Hawkins1, K. Gomez2, A. Wechalekar1
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Background: Immunoglobulin light chains form amyloid fibrils and are deposit-
ed in different tissues in systemic light chain (AL) amyloidosis. Von Willebrand
Factor (vWF) is a multimeric adhesive glycoprotein which promotes platelet
adhesion to the subendothelium at sites of vascular injury and platelet-platelet
interactions under high shear-rate conditions. VWF acts as a carrier for FVIII,
acting to protect FVIII from rapid proteolysis.
Aims: To examine the coagulation factors, specifically FVIII, VWF antigen and
anti-thrombin in newly diagnosed systemic AL patients, and to assess the prog-
nostic utilities of these investigations.
Methods: One hundred patients with suspected AL amyloidosis referred to the
National Amyloidosis centre, London were prospectively examined between
May and December 2013. All patients underwent a detailed assessment for
organ involvement as per standard protocol. In addition, patients had blood
samples taken for baseline activated partial thromboplastin time (APTT), pro-
thrombin time (PT), thrombin time (TT), clauss fibrinogen, factor assays, protein
C, protein S and anti-thrombin levels, in conjunction with the Royal Free Hospital
based bleeding questionnaire. All assays were carried out using an ACL TOP™
coagulometer [Instrumentation Laboratory (IL), Bedford, USA], using each
patient’s frozen platelet poor plasma aliquots.
Results: The analysis included 70 newly diagnosed AL patients of the 100 sus-
pected systemic AL referrals. Examining this group, 41% male and the median
age 66.1 years (range 56.4-75), cardiac (70% with Mayo stage 3 in 40%), renal
(79%), liver (39%), PNS (13%) and ANS involvement (13%). Single organ
involvement was present in 27%, with greater than 2 organ involvement in 39%.
The bleeding questionnaire reported a bleeding score of 1 in 18.6% and greater
than 3 in 7%, with a variable duration of symptoms ranging from 1-60 months.
The sites of bleeding included cutaneous (n=17), oral (n=7), epistaxis (n=5),
haemarthrosis (n=1), muscle haematoma (n=1) and following surgery (n=2).
Coagulation screen abnormalities were present in 28.6% (excluding patients
on warfarin), with prolongation of the thrombin time in 48.6%. Interestingly, of
14 patients with an albumin less than 25mg/L, 57% had a low anti-thrombin
level, and by univariate analysis this factor was associated with survival (HR:
0.96, 95% CI 0.94-0.98, p<0.005). One striking finding was 94% and 91% had
elevated factor VIII and von Willebrand factor antigen, with median levels of
260 IU/dL (range 120-630) and 252 IU/dL (range 101-745) respectively. The
plasma metalloproteinase (ADAMTS 13) was normal in all patients. Examining
the prognostic significance of both VWF antigen and FVIII; a FVIII >280 IU/dL
was associated with a poor overall survival outcome, median survival 11.8 ver-
sus 17.1 months (p=0.013), illustrated in Figure 1.
Figure 1.
Summary and Conclusions: In newly diagnosed patients with systemic AL
amyloidosis, greater than 90% of patients had elevated VWF antigen and FVIII
levels, which may suggest increased platelet-platelet interactions within the
endothelium or potential sites of vascular injury that occur with immunoglobulin
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amyloid fibrils interacting at these sites. Examining these coagulation factors
independently, a FVIII>280IU/dL was associated with a significantly poor out-
come. Low anti-thrombin levels also statistically negatively impacted survival.
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FIRST REPORT OF A PROSPECTIVE STUDY ON WHOLE-BODY DYNAMIC
CONTRAST ENHANCED MRI IN NEWLY DIAGNOSED MYELOMA
PATIENTS TREATED WITH UP-FRONT AUTOLOGOUS TRANSPLANTA-
TION: DESCRIPTIVE STUDY AT BASELINE
K. Belhadj1,* A. Luciani2, P. Beaussart2, S. Bastuji-Garin3, C. Lin4, E. de Kerviler5,
B. Arnulf6, J. Dupuis1, F. Le Bras1, P. Zerbib2, B. Chafiq1, C. Haioun1,
A. Rahmouni2
1Hémopathies Lymphoïdes, 2Imagerie Médicale, 3Santé Publique, CHU Henri
Mondor, Créteil, France, 4Nuclear Medicine and Molecular Imaging Center,
Chang Gung Memorial Hospital, Taipei, Taiwan, ROC, 5Radiologie, 6Immunolo-
gie Clinique, CHU Saint-Louis, Paris, France
Background: Bone disease is the hallmark of multiple myeloma (MM). MRI is
the most sensitive non-invasive imaging technique for detection of bone marrow
involvement. It provides relevant information on the pattern of marrow infiltration
(focal and/or diffuse). Recent studies showed an independent prognostic value
of baseline whole-body MRI. Whole-Body Dynamic Contrast Enhanced MRI
(WB-DCE-MRI) provides functional parameters reflecting MM angiogenesis,
useful for patient staging and response assessment. Like PET/CT, WB-DCE-
MRI could be useful to evaluate MRD and to predict long-term outcomes.
Aims: To report the results of Whole Body Dynamic Contrast Enhanced MRI
(WB-DCE-MRI) in patients with newly diagnosed MM with CRAB criteria at
baseline. First results of the multi-centric cohort EVALICEMM (NCT01171430).
Methods: Patients were prospectively enrolled in this multi-centric IRB
approved study to investigate the role of WB-DCE-MRI to identify skeletal and
extra-skeletal lesions at baseline, and to assess with a second and third WB-
DCE-MRI, interim response (before high-dose therapy) and response at the
end of treatment (one month after autologous stem cell transplant). T1 and T2
signal intensity of focal lesions and bone marrow were analyzed together with
the DCE-MRI quantitative enhancement values of the bone marrow (BMEmax)
and of focal lesions (FLEmax). Extra-skeletal lesions and existence of epidural
lesions were also noted. We here report on the main findings at baseline.
Results: The main characteristics of the 79 patients enrolled between July 2010
and January 2014 who underwent WB-DCE-MRI at diagnosis are as follows:
median age of 59 y (range: 54-62), isotype IgG in 61%, IgA in 19% and light-
chain in 20% of cases, ISS stage I, II and III respectively in 45, 37 and 18% of
patients, median value of β2M was 3.5 mg/l (range 2.6-4.9) and adverse cyto-
genetic features (deletion 17p or t(4;14)) were observed in 13 of the 64 docu-
mented cases. At baseline WB-DCE-MRI, 52 patients (66%) presented with dif-
fuse bone marrow involvement together with focal lesions, 12 with diffuse bone
marrow involvement (15%) and 15 with focal lesions alone (19%). There was a
significant correlation between T1/T2 signal intensity abnormalities and the
dynamic enhancement parameters, both regarding focal lesions and bone mar-
row, with BMEmax significantly higher in patients with diffuse involvement (186%
vs 91%, p<0.001). Mean FLEmax in active lesions was 285%. Six patients (8%)
presented with extra-skeletal abnormalities (spleen n=3, muscle n=2, lung n=1)
and thirteen patients (17%) had epidural lesions. A correlation was observed
between BMEmax and International Staging System (p=0.003) and between
BMEmax and β2M level (p=0.0017). No significant correlation was observed
between BMEmax and adverse cytogenetic features.
Summary and Conclusions: At baseline, functional parameters derived
from WB-DCE-MRI are well correlated to T1/T2 bone marrow signal abnor-
malities. BMEmax appears to be correlated to ISS stage and to β2M level.
Extra-skeletal findings are present in 8% of patients which should advocate
whole body imaging.
E1281
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TION IN PATIENTS WITH NEWLY DIAGNOSED SYMPTOMATIC MULTIPLE
MYELOMA (MM) RECEIVING BORTEZOMIB (BTZ) -BASED REGIMENS
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Background: sFLC assay is an important tool for the diagnosis and monitoring
of MM, however data on prognostic significance in symptomatic MM treated
with novel agents are still limited.
Aims: We performed a retrospective analysis aimed at investigating the role
of sFLC evaluation over time as predictor of outcomes in newly diagnosed
symptomatic MM receiving btz.
Methods: Patients treated with a first line btz-based regimen and who had
sFLC assay serially evaluated were selected. sFLC assay (Freelite; The Bind-
ing Site, Birmingham, UK) was performed by BN II nephelometer (Date Behring,
Deerfield, IL, USA).
Results: 150 patients were available for analysis, 90 (60%) received btz incor-
porated into a program of auto transplant and 60 (40%) combined with conven-
tional chemotherapy. One-hundred and nineteen patients (79%) had a Ig secret-
ing MM, 28 (19%) a light chain only MM and 3 (2%) a non-secretory disease. At
baseline, 128 patients (85%) showed an abnormal sFLC ratio (sFLCR). After
treatment, 71 patients (47%) achieved a complete response (CR) and 113 (75%)
showed a normalization of sFLCR: of these 69 (61%) were in CR whereas 44
(39%) had a monoclonal-protein (M protein) still detectable by electrophoresis
or immunofixation (p<0.001). With a median follow-up of 31 months (mo), 59
patients (39%) progressed and 27 (18%) died. The median time to progression
(TTP), progression free survival (PFS) and overall survival (OS) were 44, 39 and
75 mo, respectively. At baseline, an involved/uninvolved sFLCR ≥100 (catego-
rized as high) resulted as the most powerful value for discriminating outcomes
of survival and was observed in 43% of patients. High and low sFLCR groups
were equally distributed between transplant and non-transplant regimens
(p=0.109). High baseline sFLCR correlated with Bence Jones isotype (p<0.001),
ISS stage III (p<0.001), higher bone marrow infiltration (p=0.003), higher creati-
nine (p=0.018) and beta-2-microgloblin level (p<0.001), lower haemoglobin con-
centration (p=0.003), and presence of del(13q) (p=0.001); whereas no correlation
was found with t(4;14) or del(17p). High sFLCR, compared to sFLCR <100, was
associated with a lower probability to normalize sFLCR after treatment (67% vs
81%, p=0.046), and shorter TTP (35 vs 50 mo, p=0.003) and PFS (32 vs 50 mo,
p=0.008), whereas the OS was similar in the two groups (81% vs 76% at 3 years,
p=0.36). Conversely, survival outcomes were significantly superior in patients
who achieved a normalization of sFLCR in comparison with those who failed this
objective with median TTP of 49 vs 18 mo, (p<0.0001), median PFS of 49 vs 17
mo (p<0.0001) and median OS of 75 vs 43 mo (p<0.0001), respectively. More-
over, achievement of sFLCR normalization maintained its prognostic value for
TTP (p=0.003) and PFS (p=0.003), along with achievement of CR (p=0.032 and
p=0.018, respectively) and ISS I/II (p=0.001 and p<0.001, respectively), by Cox
regression analysis. Finally, an involved/uninvolved sFLCR ≥100 was observed
in 38% of patients at relapse and was associated with earlier start of salvage
therapy, compared with sFLCR <100 (89% vs 64% at 3 mo, p=0.0426).
Summary and Conclusions: High sFLCR at baseline was associated with
shorter TTP and PFS, and at relapse with a short-lasting treatment-free phase.
Conversely, normalization of sFLCR after treatment was a robust prognostic
indicator of longer disease control, irrespective of achievement of conventional
CR. Evaluation of sFLC, in addition to M protein, allows to better define the
tumour burden throughout the course of the disease.
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EVALUATION OF THE CHROMOSOMAL ABERRATION PATTERN IN
IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS
M.-Y. Lee1,* K. Kim1, H.S. Kim1, J.Y. Lee1, S.H. Lim1, S.J. Kim1, G.Y. Lee1,
J.E. Lee1, J.-O. Choi1, J.-S. Kim2, H.-J. Kim3, S.-Y. Lee3, J.-H. Min4, E.-S. Jeon1
1Internal medicine, 2Pathology, 3Laboratory Medicine & Genetics, 4Neurology,
Samsung medical center, Seoul, Korea, Republic of
Background: Chromosomal aberrations of plasma cells are well recognized
as important pathogenetic and prognostic factors in multiple myeloma, whereas
it has remained unclear in immunoglobulin light chain (AL) amyloidosis in par-
ticularly Asian patients.
Aims: The purpose of this study is to identify prognostic cytogenetic risk factors
by interphase FISH in AL amyloidosis cohort patients in Korea.
Methods: A total of 184 patients with systemic AL amyloidosis were retrospec-
tively analyzed from April 1995 to August 2014 in Korea.
Results: Cytogenetic testing by interphase fluorescence in situ hybridization
(FISH) had been performed in 80 (44%) patients with AL amyloidosis, and 29
(36%) patients had abnormal FISH as follows; most common abnormality is
gain of 1q21 (18%) followed by t(11;14), deletion 13, t(4;14), deletion 17,
t(14;20) and t(14;16). Patients with abnormal FISH results had more bone mar-
row plasma cells (median 16.5 vs 30%, p=0.011). Median overall survival (OS)
was significantly longer in patients without gain of 1q21 (39.2 months) as com-
pared to in patients with gain of 1q21 (12.2 months, p=0.043). There was no
statistical significantly difference, but patients with t(11;14) or deletion 13 had
a shorter median OS (18.9 versus 36.3 months, p=0.367 or 15.2 vs 34.7
months, p=0.517).
Summary and Conclusions: In conclusion, our results suggest that detection
of gain of 1q21 is an adverse prognostic factor in patients with AL amyloidosis.
And further prospective and large studies of FISH test are warranted.
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IMPACT OF NF-KB EXPRESSION IN THE PROGNOSIS OF MULTIPLE
MYELOMA PATIENTS TREATED WITH BORTEZOMIB IN FRONTLINE REG-
IMENS
C. Geraldes1,2,3,* A.C. Gonçalves3,4, R. Alves3,4, E. Cortesão1,2,3, L. Ribeiro1,
J.M. Nascimento Costa3,5, A.B. Sarmento-Ribeiro1,3,4
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1Clinical Haematology Department, Coimbra University Hospital Center, 2Uni-
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and Oncobiology, 4Applied Molecular Biology and University Clinic of Hema-
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Background: Nuclear factor κappa B (NF-kB) is a heterodimeric transcription
factor that promotes transcription of several anti-apoptotic growth factors, pro-
teins, and cytokines, after its nuclear translocation. NF-kB is normally present
in the cytoplasm in association with its inhibitor, IkB. Bortezomib inhibits degra-
dation of Iκ-B and therefore blocks NF-kB activity. As NF-κB is highly expressed
in myeloma cells, its inhibition by bortezomib promotes their apoptosis. Borte-
zomib is frequently included in the frontline regimens to treat multiple myeloma
(MM) patients. However, the prognostic impact of NF-kB expression levels in
plasma cells from newly diagnosed MM patients, treated with bortezomib, is
largely unknown.
Aims: To analyze the expression levels of NF-kB in CD138+/CD19- and
CD138+/CD19+ plasma cells from MM patients, at diagnosis, and to determine
its impact in response and in overall survival of patients treated with bortezomib
as frontline regimen.
Methods: We evaluated 24 newly diagnosed MM patients, between April 2010
and April 2013, treated with bortezomib (+ dexamethasone,±cyclophos-
phamide) as first-line regimen. NF-kB expression levels were analyzed with
monoclonal antibodies by flow cytometry in CD138+/CD19+ and
CD138+/CD19- plasma cells from bone marrow samples collected at diagnosis.
NF-kB expression levels are mentioned in mean intensity of fluorescence (MIF).
Response evaluation was determined according to International Myeloma
Working Group response criteria. For statistical analysis, software IBM SPSS
Statistics v22 was used.
Results: Twenty-four patients (42% male) were studied, with a median age of
61 (41-75) years; 21/24 (88%) patients presented response to bortezomib. We
analyzed NF-kB expression levels in CD138+/CD19+ and CD138+/CD19- plas-
ma cells in patients with and without response to bortezomib (1 CR, 4 VGPR,
16 PR). According to our results, patients with response to bortezomib pre-
sented higher NF-kB expression levels in CD138+/CD19- plasma cells
(26,2±1,7 MIF vs 19,7±1,8 MIF; p=0,032). In CD138+/CD19+ plasma cells, we
didn’t find differences in NF-kB expression levels (38±2,3 MIF e 33,6±5,6 MIF,
respectively). Based on these results, we searched for a prognostic impact of
NF-kB expression levels in MM patients with response to bortezomib. Among
these patients, median NF-kB expression levels in CD138+/CD19- and
CD138+/CD19+ plasma cells were 26,2±1,7 MIF and 38±2,3 MIF, respectively
(p=0,0001). We also found that NF-kB expression levels higher than or equal
to 25 MIF in CD138+/CD19- plasma cells are associated to a longer survival:
median survival not reached compared with 26,1 months (95% CI; 22,4-29,8);
p=0,022, for NF-kB expression levels lower than 25.
Summary and Conclusions: Plasma cells from MM patients with different phe-
notypes present distinct NF-kB expression levels. Higher NF-kB expression levels
in CD138+/CD19- plasma cells are associated with increased response rates to
bortezomib and with a benefit in overall survival. These results suggest that NF-
kB expression levels in CD138+/CD19- plasma cells from MM patients might be
considered a potential biomarker for response to bortezomib and prognosis.
This work was supported by CIMAGO (project nº 23/09).
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CIRCULATING BCMA BINDING TO ITS LIGAND BAFF PREVENTS NOR-
MAL ANTIBODY PRODUCTION IN MULTIPLE MYELOMA PATIENTS
J. Berenson1,* E. Sanchez1, A. Gillespie1, N. Harutyunyan1, G. Tang1, J. Gottlieb1,
S. Vardanyan1, M. Li1, C. Andreu-Vieyra2, M. Ghermezi1, C. Wang1, J. Ben-Zvi1,
G. Garzio1, H. Chen1
1Hematology/Oncology, Institute for Myeloma & Bone Cancer Research,
2Hematology/Oncology, Oncotherapeutics, West Hollywood, United States
Background: A hallmark of multiple myeloma (MM) is the low levels of unin-
volved immunoglobulin (Ig) levels. B-cell maturation antigen (BCMA) is a recep-
tor expressed in mature non-malignant and malignant B lymphocytes, including
plasma cells. We previously demonstrated that BCMA is present in the serum
of MM patients and that its levels predict overall survival (Sanchez et al. Br J
Haematol 2012).
Aims: We hypothesized that circulating BCMA binds to its ligands, preventing
normal plasma cell development and antibody production in MM patients. 
Methods: BCMA-Fc and control Ig were obtained (R&D Systems). Human
BCMA and mouse BAFF, and mouse plasma IgA, IgA and IgM levels were
measured with ELISA (R&D Systems & Bethyl Laboratories). rhBCMA-mBAFF
complexes were determined using an ELISA. Plates were pre-coated with a
monoclonal mouse anti-BAFF capture Ab. Plasma samples were incubated
and an anti-human-BCMA detection Ab was added. Human serum IgA and IgG
levels were determined in MM patients using nephelometry (Immage 800, Beck-
man Coulter). Hevylite® Assays (Binding Site) were used to quantify the levels
of heavy-light chain isoform pairs.
Results: To determine the effects of human BCMA on plasma Ig levels in
immune competent mice, rhBCMA-Fc or control Ig-Fc (100 mg) was injected
into C57 Bl or Balb/c mice. rhBCMA-Fc resulted in significant decreases in IgA,
IgG and IgM levels. Decreases in IgA levels were observed when compared to
baseline levels on days 4 and 6 (P=0.0031 and P=0.0064, respectively), and
the controls (P=0.0087 and P=0.0221). Mouse IgG levels also showed a reduc-
tion compared to baseline (P=0.0023), the Ig-Fc (P=0.0014) and control
(P=0.0129) groups. IgM levels showed similar decreases when compared to
the untreated (P=0.0001) and Ig-Fc (P=0.0088) groups. We determined if rhBC-
MA-mBAFF complexes formed in vivo. Complexes were detected by ELISA at
high levels in plasma from mice dosed with BCMA-Fc, whereas none were
found in samples in control Ig-Fc or untreated mice. Next, we determined the
relationship of serum BCMA levels to uninvolved Ig levels in MM pts. For pts
with IgA (n=134) or IgG (n=313) MM, higher BCMA levels (≥100 ng/ml) corre-
lated with below normal levels of uninvolved IgG in IgA MM and uninvolved IgA
in IgG MM, whereas lower BCMA levels (<100 ng/ml) correlated with normal
uninvolved levels (P <0.0001). Using the Hevylite Assay, similar results were
observed BCMA levels compared to uninvolved IgG isoforms in both pts with
involved IgG lambda (n=62, P=0.0006) and IgG kappa (n=117, P <0.0001) MM.
Summary and Conclusions: We demonstrate the formation of circulating
BCMA-BAFF complexes in MM, and administration of recombinant BCMA to nor-
mal mice results in marked reductions in their antibody levels. We also show that
BCMA levels inversely correlate with uninvolved Ig levels in MM pts. Thus, the
lack of normal antibody production in MM pts results in part from circulating BCMA
binding its ligands, preventing production of normal antibody-producing cells.
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BORTEZOMIB CONSOLIDATION FOLLOWING ASCT FOR MULTIPLE
MYELOMA (MM) IMPROVES RESPONSE DEPTH, WITH ACCEPTABLE
TOXICITY AND PRESERVED QUALITY OF LIFE
N. Rabin1,*, C. Nicholas2, R. Owen3, B. Popova2, O. Schofield2, A. Rawston3,
R. de Tute3, J. Lyons-Lewis1, S. Moore4, D. Hughes5, K. Yong1
1Department of Haematology, University College London Hospitals, 2Cancer
Research UK and UCL Cancer Trials Centre, University College London, Lon-
don, 3Haematology Malignant Diagnostic Services, Leeds Teaching Hospitals,
Leeds, 4Department of Haematology, Royal United Hospitals Bath, Bath,
5Department of Haematology, Royal Free London Hospital, London, United
Kingdom
Background: Consolidation following autologous stem cell transplantation
(ASCT) may improve depth of response and prolong time to next treatment,
but there is no established standard of care.
Aims: To explore the effect on response depth, progression free survival (PFS)
and quality of life (QOL) in patients on a single arm phase 2 post ASCT borte-
zomib consolidation trial (BCT)
Methods: Bortezomib-naïve patients with at least stable disease were enrolled
3 to 4 months following ASCT, and received Bortezomib at 1.3mg/m2 (17 started
with IV, the rest with SC) on days 1, 8, 15, 22 of a 4-week cycle, maximum 8
cycles. Disease response (IMWG) was assessed at 3, 6 and 12 months post
ASCT. Minimal residual disease (MRD) by multiparametric flow cytometry was
assessed at the same time points from patient 15 onwards. Toxicity and QOL
(EORTC-QLQ-C30) were assessed at each cycle and end of treatment. PFS
and OS were measured from date of registration and estimated using the
Kaplan-Meier method.
Results: 40 patients were recruited December 2009-March 2014, 22 (55%)
were male. Median age was 61 years (range 43-69), isotypes were: 22 (59%)
IgG, 9 (24%) IgA, 1 (3%) IgD, 5 (14%) LC only, 1 NS and 2 unknown. Induction
regimens pre-ASCT were thalidomide (33 patients, 83%), idarubicin and dex-
amethasone (5 patients, 13%), and unknown in 2 (5%). All patients received
melphalan 200mg/m2 conditioning for ASCT. At trial entry, median time from
diagnosis and from ASCT were 11.0 months (8.6-18.1), and 3.4 months (2.7-
4.3) respectively. Of the 40 patients enrolled, 1 withdrew before treatment, 1
progressed in cycle 1, and 2 stopped treatment in/after cycle 1 (treatment relat-
ed adverse events); 36 patients (90%) completed more than 1 cycle of treat-
ment. A further 10 (25%) patients stopped treatment early, 5 due to toxicity (4
neuro-toxicity and 1 elevated alkaline phosphatase), 4 due to patient/physician
choice, and 1 for disease progression. 21 (53%) patients had a dose delay, 15
(38%) patients had a dose modification, and 28 (70%) at least one dose omitted.
A median of 8 cycles of trial treatment were received. After a median follow up
of 30.0 months, 25 patients (63%) are alive without progression, 13 (33%) are
alive having progressed, and 2 (5%) have died of MM. BCT improved response
depth in assessable patients who completed more than 1 cycle of treatment
(N=34): 4 (12%) ≥CR, 19 (56%) VGPR, 10 (29%) PR and 1 (3%) SD pre-treat-
ment, increasing to 7 (21%) ≥CR, 20 (59%) VGPR, 4 (12%) PR, 1 (3%) PD
and 2 (6%) N/A at 12 months post ASCT; 11 patients (32%) improved response.
Median PFS is 35.5 months (95% CI, 27.5-43.5), with a 2 year PFS of 77.7%
(95% CI, 62.8-92.6). 23 patients had MRD assessed at 3 or 6 months post
ASCT, of whom 18 had follow up samples at 12 months (end of consolidation).
Of these, 9 were MRD+ at the earlier time point, and 4 of these converted to
MRD- at 12 months. All MRD- patients remained MRD- at 12 months. Eleven
(28%) patients experienced a total of 15 grade 3 adverse events; 6 (neuropa-
thy), 4 (infection), 1 (fatigue), 1 (elevated alkaline phosphatase), 1 (hearing
impairment), 2 (haematological). In addition 1 patient had a grade 4 infection
(cycle 1, treatment discontinued) and 1 grade 4 back pain. EORTC-QLQ-C30
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scores for global health status, and physical, emotional and social functioning
did not change significantly throughout treatment.
Summary and Conclusions: Consolidation therapy using weekly Bortezomib
post ASCT is well tolerated and associated with a deepening of response,
including MRD- rate. This post-ASCT strategy deserves further study.
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SUPERIOR EFFICACY OF VTD OVER VCD BEFORE AND AFTER AUTOL-
OGOUS STEM-CELL TRANSPLANTATION IN NEWLY DIAGNOSED MUL-
TIPLE MYELOMA PATIENTS
M. Cavo1,* L. Pantani1, A. Pezzi1, F. Gay2, M.T. Petrucci3, F. Patriarca4,
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N. Cantore12, F. Morabito13, P. Sonneveld14, A. Palumbo2
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niti, Reggio Calabria, 6Azienda Ospedaliera Universitaria S.Martino, Genova,
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Background:A triplet bortezomib-based induction regimen and autologous stem-
cell transplantation (ASCT) are the current standard of care for young, newly diag-
nosed, multiple myeloma (MM) patients (pts). However, due to the lack of random-
ized trials comparing different regimens incorporating bortezomib, the treatment
choice is ultimately based upon physician’s preference or single center’s policy.
Bortezomib-thalidomide-dexamethasone (VTD) has been approved by EMA in this
setting. Bortezomib-cyclophosphamide-dexamethasone (VCD) is an alternative to
VTD, although efficacy results have not been backed by phase III studies.
Aims: To compare the efficacy of VTD vs VCD before and after ASCT.
Methods: 107 pts who were randomized to the VTD arm of the GIMEMA-
MMY-3006 study were compared with an equal number of Italian pair mates
who were treated with VCD and ASCT as part of the EMN02 trial. Baseline
case matching criteria were age (±2 years), ISS stage (1 vs 2 vs 3), presence
of t(4;14) and/or del(17p) positivity. Induction treatment consisted of three 21-
day cycles of either VTD (bortezomib 1.3 mg/m2 on d 1, 4, 8, and 11; thalido-
mide 100-200 mg daily; dexamethasone 40 mg on d 1, 2, 4, 5, 8, 9, 11, and
12) or VCD (bortezomib and dexamethasone as in VTD; cyclophosphamide
500 mg/m2 on d 1 and 8). Melphalan dose prior to ASCT was 200 mg/m2 (Mel-
200). Response was evaluated according to IMWG criteria.
Results: In comparison with VCD, VTD yielded a higher rate of ≥VGPR both
before (38% vs 60%, p=0.001) and after (63% vs 78%, p=0.014) ASCT, including
a significantly higher probability of CR (5% vs 19%, p=0.001, and 14% vs 39%,
p<0.001, respectively). Pts with t(4;14) and/or del(17p) had a significantly higher
probability to achieve ≥VGPR after VTD induction therapy as compared to those
receiving VCD (86% vs 43%, p=0.004). In pts with advanced ISS stage (2-3),
the superior efficacy of VTD over VCD was retained both before ASCT (CR: 25%
vs 5%, p=0.002; ≥VGPR: 67% vs 38%, p=0.001) and after ASCT (CR: 43% vs
11%, p<0.001; ≥VGPR: 85% vs 64%, p=0.007). Any grade 3-4 hematological
toxicity was higher with VCD vs VTD induction therapy (12% vs 5%). Grade ≥2
peripheral neuropathy (PN) (NCI CTCAE, version 3.0) was slightly, but not sig-
nificantly, higher for pts on VTD as compared to those on VCD (12% vs 9%,
p=0.19). However, when the threshold of grade ≥3 PN was considered, the dif-
ference between the two groups significantly favoured pts treated with VCD (2%
vs 7%, p=0.004), although it is worth noting that only a single pt on VCD and 2
pts on VTD discontinued treatment due to PN. No significant difference in the
median dose of CD34+ cells/kg infused to support Mel-200 was observed
between pts reveiving VTD or VCD (4x106 vs 4.5x106/kg).
Summary and Conclusions: The triplet VTD induction therapy was associated
with significantly higher pre-ASCT CR and ≥VGPR rates compared to VCD, con-
firming that VTD is one of the most active bortezomib-based induction regimens
in preparation for subsequent ASCT. The superior efficacy of VTD over VCD was
confirmed also after ASCT and was retained across subgroups of pts with ISS
stage 2-3 and a high-risk cytogenetic profile [t(4;14) and/or del(17p)]. Data from
the current analysis need to be confirmed by randomized studies designed to
prospectively compare VTD vs VCD induction therapy before ASCT.
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IMPACT OF SERUM ALPHA 1-ACID GLYCOPROTEIN (AAG), A POTENTIAL
PATIENT SELECTION MARKER FOR FILANESIB, ON SURVIVAL AND
RESPONSE TO CONVENTIONAL THERAPIES IN PATIENTS WITH
RELAPSED MULTIPLE MYELOMA (RMM)
S. Hussain1, R. Aitchison2, J. Regensburger2, A. Engebretson1, A. Dispenzieri1,
S.V. Rajkumar1, B. Tunquist3,* S. Kumar1
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Background: Serum AAG (orosomucoid) is an acute-phase reactant protein
that has been shown to correlate with disease stage as well as overall survival
(OS) in patients with multiple myeloma (MM). More recently, it has been pro-
posed as a response marker for patient outcome to filanesib (ARRY-520), a
novel kinesin spindle protein inhibitor undergoing evaluation for the treatment
of MM. To date, RMM patients with serum AAG concentrations >110 mg/dL
have not demonstrated objective responses to single-agent filanesib, while the
response rate for patients below this cut point is approximately 23%. It is
hypothesized that this lack of response may be caused by AAG binding to
filanesib, reducing free concentrations of serum filanesib, while having no
appreciable effect on other MM drugs.
Aims: The current study evaluated the prognostic value of AAG for OS, and its
ability to predict response in RMM patients treated with standard MM regimens.
Methods: AAG levels in plasma samples from patients with RMM who had
received at least one prior therapy (median 4 prior lines; range, 1 to 14) were
measured in a central laboratory (ICON Laboratory Services) using a validated
assay (Randox Laboratories). Patients were followed for objective response
to their next line of therapy and for overall survival. The relationship between
AAG concentrations and treatment outcomes were assessed with univariate
and multivariate analyses.
Results: AAG levels were measured in plasma from 247 patients (60% male,
median age 62 yrs) with RMM who had subsequent follow-up for OS. The
median time of plasma collection was 30 months after diagnosis of MM (range,
0.5 to 280 months). At the time of analysis, 60% of patients had died and the
median OS from date of plasma collection was 27.2 mos. The median plasma
AAG level was 81.1 mg/dL (range 25-266); 20% had high AAG (>110 mg/dL,
the cutoff used for filanesib study). AAG status correlated with the International
Staging System (ISS) prognostic index and other prognostic factors for MM
(e.g., LDH, β2M, number of prior regimens). In a univariate analysis, AAG
status was prognostic for OS: median OS was 16 mos for those with high AAG
compared with 30 mos for those with low AAG (hazard ratio=1.5; p=0.04). How-
ever, in a multivariate analysis that included other prognostic factors, the effect
of AAG on OS was not significant (HR=1.3, p=0.2). Importantly, there was no
correlation between patient AAG concentrations and objective response (≥PR)
to standard therapies initiated within 60 days following AAG measturement that
included stem cell transplant, treatment with proteasome inhibitors and/or
immunomodulatory agents (overall response rate=59% vs 55%, respectively,
for patients with low or high AAG, p=0.80).
Summary and Conclusions: In this retrospective study in patients with RMM,
plasma AAG concentration was not an independent prognostic factor for OS
or predictive of response to conventional MM therapies. These results suggest
that the value of AAG as a predictor for response may be unique to treatment
with filanesib amongst current myeloma therapies. This may be due to direct
binding of AAG to filanesib. The predictive and prognostic nature of AAG as a
patient exclusion biomarker for filanesib treatment is being evaluated in an
ongoing randomized study (NCT01989325).
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TEMATIC REVIEW AND META-ANALYSIS
K. Scott1 2,* A. Howman3, P.J. Hayden4, K. Wheatley3, A. Will5, I. Coyne2
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Background: Multiple myeloma is a plasma cell malignancy accounting for
approximately 1% of cancers diagnosed and 12% of haematological malignancies.
The first-in-class proteasome inhibitor, bortezomib, is commonly used in all myelo-
ma disease settings. We conducted a systematic review and meta-analysis to
evaluate the accumulated clinical evidence of bortezomib treatment of myeloma.
Aims: To assess the clinical benefits and side effects of bortezomib compared
to other therapies, doses, administration methods and treatment schedules.
Primary objectives were to assess effects of bortezomib on overall survival
(OS) and progression-free survival (PFS). Secondary objectives included
response rates (RR), adverse events (AE), treatment-related death (TRD) and
health-related quality of life (HRQoL).
Methods: We searched MEDLINE, the Cochrane Central Register of Con-
trolled Trials and EMBASE (till end of Nov 2014), conference proceedings and
clinical trial registries for randomised controlled trials (RCTs). Two review
authors independently extracted outcomes data and assessed risk of bias.
Hazard ratios (HR) and their confidence intervals (CI) were extracted for OS
and PFS and Odds Ratios (OR) for RRs, AEs and TRD. Trial authors were
contacted if summary statistics were missing. Log-rank statistics were estimat-
ed if not available. 
Results: Sixteen relevant RCTs involving 5630 patients were identified and
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12 trials included in the meta-analysis. Four trials of different doses, adminis-
tration and treatment schedules were reviewed qualitatively. Overall risk of bias
was considered to be generally low. We estimated OS benefit from 4118
patients (Peto OR=0.77 (95% CI: 0.69 to 0.86, P <0.00001) and PFS benefit
from 4344 patients (Peto OR=0.67 (95% CI: 0.61 to 0.72, P <0.00001) in favour
of bortezomib. Meta analysis of complete and overall RR also produced statis-
tically significant results in favour of bortezomib. Subgroup analyses by disease
setting revealed improvements in all outcomes. For therapy setting, a statisti-
cally significant benefit was observed in all outcomes except OS following con-
solidation therapy. Bortezomib treatment led to statistically significant increased
risks of thrombocytopenia, neutropenia, gastro-intestinal toxicities, peripheral
neuropathy, infection and fatigue. A greater risk of cardiac disorders was
observed in one comparison group (bortezomib vs no bortezomib with different
background therapy or vs other agents), however, no evidence of increased
risk of TRD. Only 4 trials analysed HRQoL and could not be meta-analysed. 
Summary and Conclusions: This systematic review and meta-analysis
demonstrates myeloma patients receiving bortezomib benefit in terms of OS,
PFS and RR. Bortezomib should be considered a standard therapy for myelo-
ma. However, we are unable to draw conclusions regarding optimal combination
therapy containing bortezomib. Further evaluation of the newer proteasome
inhibitors and more studies of HRQoL are also needed.
This abstract is based on a protocol of Cochrane Review published 11/11/2013,
Issue 11. Upon completion and approval, the final version is expected to be
published in the Cochrane Database of Systematic Reviews (www.the-
cochranelibrary.com).
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CAN OVERALL SURVIVAL BE IMPROVED IN ELDERLY MULTIPLE MYELO-
MA PATIENTS?
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1Ingress-health, Rotterdam, Netherlands, 2Department of Medicine, Karolinska
Institutet, Stockholm, Stockholm, Sweden, 3Unit of PharmacoEpidemiology &
PharmacoEconomics, Institute of Science in Healthy Aging & health caRE
(SHARE), Groningen, Netherlands, 4Kuopio University Hospital, Kuopio, 5Turku
University Hospital, Turku, 6HUS, Helsinkki, Finland, 7Department of Hematol-
ogy, Odense University Hospital, Odense, Denmark, 8Department of Hematol-
ogy, St Olavs Hospital, Trondheim, Norway
Background: The ongoing introduction of novel therapies for MM provides cli-
nicians and patients various treatment options in numerous lines of treatment.
Understanding the current treatment practices and the outcomes in different
age groups is of vital importance to understand whether these new treatment
should be used in patients from all age groups and where options for treatment
optimization exist.
Aims: (i) To describe treatment patterns and corresponding outcomes in terms
of response, time to next therapy (TTNT) and overall survival (OS) of Nordic
Multiple Myeloma (MM) patients with a focus on age. (ii) To investigate whether
age affected the patients’ probability of being treated with a conventional (e.g.
melphelan prednisone) or a novel treatment (bortezomib, thalidomide or
lenalidomide) and whether this treatment choice affected OS in the elderly.
Methods: A retrospective analysis was performed on incident 2960 MM-
patients from 24 hospitals in Denmark, Finland, Norway and Sweden. The data-
base contained information on patient baseline characteristics such as age,
gender, international staging system (ISS) stage, albumin, creatine, MM type
and response, TTNT and OS over eight lines of treatment. The patients were
stratified over three age groups (<65, 65<75 and ≥75) for which baseline char-
acteristics, treatments, response, TTNT and OS were reported. To validly com-
pare the effectiveness (OS) of novel vs conventional treatments in first line,
propensity score matching was used and also multivariate cox-regressions.
Results: Patients were on average 67 years old, 48% were male and 28%,
41% and 31% in ISS stages I, II and III, respectively. The chance of being treat-
ed with a conventional therapy increases with age in all lines of therapy. In first
line, 13% in younger patients <65 years and 72% of elderly patients ≥75 years
were treated with a conventional. Patients seemed to respond better on novel
therapies. In first line, patients aged ≥75 years treated with a conventional treat-
ment, novel treatment and stem cell transplantation had a 9%, 28% and 69%
probability on a ≥very good partial response respectively. Patients’ ≥75 with no
response or progressive disease on first line had a median OS of 1.54 years
whereas patients in the same age group with (near) complete response had a
median OS of 3.27 years. For patients aged ≥75 years, a matched treatment
comparison using propensity scoring showed significantly longer OS for novel
therapies 3.61 (2.66-6.44) years versus conventional therapies 2.14 (1.78-2.57)
years. Multivariate cox-regression models gave a similar result with an esti-
mated hazard ratio of 0.45 (0.24-0.98).
Summary and Conclusions: This paper shows that in this incident cohort eld-
erly patients are significantly more likely to be treated with a conventional MM
therapy than younger patients, while elderly patient do significantly benefit from
novel therapies in first line compared to conventional therapies in terms of
longer OS. Hence, there is a potential to improve therapy for and further
increase the OS among elderly MM patients with novel treatment options.
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PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ON SURVIVAL
OF PATIENTS WITH MULTIPLE MYELOMA
M. Granell1,*X. Calvo2, A. García3, L. Escoda4, C.M. Martínez1, M. Teixidó3,
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Background: The prognosis of patients with plasma cell leukemia (PCL) is
extremely poor. In multiple myeloma (MM) not fullfiling criteria of PCL, the find-
ing of plasma cells in peripheral blood is a marker for highly proliferative dis-
ease. The current definition of PCL requires the presence of an absolute periph-
eral blood plasma cell count >2x 109/L and >20% PC in differential white cell
count. Recently, it has been suggested a lower cut-off of ≥5% or ≥0.5x 109/L of
nucleated peripheral blood cells to redefine this entity.
Aims: To investigate whether the presence and number of circulating plasma
cells by morphology can be used as a predictor marker of survival in patients
with MM not fulfilling PCL criteria, trying to find the threshold to a new defini-
tion of PCL.
Methods: Three hundred and seventy patients (male/female 203/167; median
age 69 years, range 28-90) diagnosed with symptomatic MM or primary PCL
following the International Myeloma Working Group criteria between January
2008 and December 2012. For inclusion, peripheral blood smears at diagno-
sis had to be available for review. This study was conducted in four University
Hospitals from Catalonia. Clinical data including age, gender, Durie-Salmon
and ISS stage, initial treatment and follow up were collected from medical
records. Patients were treated according to local protocols. Wright-Giemsa
stained peripheral blood smears were systematically reviewed. A minimum
of 100 nucleated cells per smear were counted. Patients were classified in
three groups: MM-low group defined as <5% or <0.5x109/L circulating plasma
cells, MM-high group defined as 5% to 20% and/or 0.5x109/L to 2x109/L cir-
culating plasma cells, and PCL defined as >20% and/or >2x109/L circulating
plasma cells.
Results: Of the 370 patients studied, 357 (96.5%), 9 (2.4%) and 4 (1.1%)
were included in the MM-low, MM-high and PCL groups, respectively. Patients
in the MM-high group had lower platelet counts (median 91x109/L vs
214x109/L, p <.0001) and higher bone marrow plasma cells at diagnosis
(median 50% vs 39%, p=0.031) than the MM-low group. Median survival of
patients in the MM-low, MM-high and PCL groups were 52 (95% CI 42.4-
61.5), 7 (95% CI 4.0-9.9) and 12 (95% CI 3.1-20.8) months, respectively (Fig-
ure 1). MM-high group was associated with shorter survival (Hazard ratio
4.34, 95% CI 2.16-8.74) independently of age, Durie-Salmon stage and Inter-
national Staging System. Within the MM-low group, no differences were found
between patients with 0% circulating PC (N: 292, median survival 52 months,
95% CI 40.6-63.3) and 1% to 4% circulating PC (N: 65, median survival 53
months, 95% CI 31.7-74.2).
Figure 1.
Summary and Conclusions: The presence of either >5% or >0.5x109/L cir-
culating plasma cells in patients with MM has similar adverse prognostic impact
that PCL as currently defined. Despite the limited number of cases, our findings
support the perception that the definition of PCL should be revisited. The pro-
posal for this new threshold for PCL definition deserves confirmation in other
independent study.
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A POPULATION BASED STUDY OF NEWLY DIAGNOSED MULTIPLE
MYELOMA PATIENTS IN LATVIA (2007-2009 YEARS)
D. Auzina1,2,3,* S. Lejniece1,2, J. Nazarovs4, I. Strele5
1Department of Internal Diseases, Riga Stradins University, 2Chemotherapy
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Background: Multiple myeloma (MM) is the second most common hematologic
malignancy found in adult population. Specific end-organ damage caused by
the disease, such as renal disease, anemia and bone lesions are associated
with worse prognosis of MM patients.
Aims: To identify primary diagnosed MM patients from National Center of
Hematology with primary diagnosed MM between 2007 and 2009 and to ana-
lyze 5-year survival rate.
Methods: This retrospective 3-year study included 162 patients from National
Center of Hematology with primary diagnosed MM between 2007 and 2009.
Statistical analyses were performed using Graph Pad Prism 5, SPSS statistical
software (version 20). Survival curves were analyzed accordingly Kaplan-Meier
method and statistically compared using the log-rank test. 5-year survival rate
were analyzed for all group and for some subgroups. The survival factors were
analyzed without taking in to account the therapy received. During the time
period (2007- 2009), the novel agents in Latvia were not State paid and Velcade
was available only as a third treatment line. Autologus stem cell transplantation
was applied for just 12 patients.
Results: We have analyzed dates of 162 patients (n=66 (41%) males, n=96
(59%) females), with an age range from 48 to 85, mean age (Mean±SD) was
67.49±9.02 years. 47.5% of the patients were older than 70 years. The most
frequently reported symptoms were bone pain (51%) and fatigue (25%). MM
in 7% was diagnosed during routine blood tests. Most of patients (56%) were
in stage III (Salmon-Durie staging system), but 25% were in II stage and 19%
in I stage. M-protein in serum mean concentrations was 32.42±23.42 g/l (range
0-104), but in patients with III stage it was-48.83±25.36 g/l. Bone lesions had
56% (n=105) patients. >3 lytic bone lesions with vertebral fractures were detect-
ed in n=68 (42%) cases. Renal disease was proved in n=77 (48%) cases
(glomerular filtration rate (GFR) <60 ml/min/1.73m2). 12 patients with MM need-
ed hemodialysis. 3 patients were with extramedullary involvement. Five-year
survival rate in analyzed group was 25.9%.The median survival period for all
patients was 30.3 month (95% CI 24.8-35.9 month). Statistically better survival
was in patients under 70 years of age (p <0.001). The 5-year survival rate was
41.2% of patient <70 years, but in patients >70 years it was 9.1%. The most
important survival factor was stage of disease (Salmon-Durie). Better survival
was proved with early stage of MM. We didn’t find statistically significant survival
difference between 2nd and 3rd stage (p=0.274). Patients with 1st stage of dis-
ease 5 year survival rate was 51.6%, but 2nd-22% and 3rd-18.9%. The second
most important survival factor was renal disease with statistically significant
worse survival (p<0,001). The 5-year survival rate in patient group with renal
disease was 32.9%, but without it-18.2%. We found statistically significant sur-
vival difference between groups according to hemoglobin level. Patients with
Hb <85 g/L had statistically significant worse survival, than with Hb level 85 to
100g/L (p=0.016) and with Hb >100g/L (p<0.001). 5-year survival rate in
patients with Hb <85 g/L was 12.2%, but with Hb 85 to 100 g/L-22.2% and with
Hb >100 g/L-34.5%.
Summary and Conclusions: 1) 5-year survival rate for patients with primary
diagnosed MM from 2007 till 2009 in Latvia was 25.9%. 2) Important survival
factors for patients with MM were found to be age more than 70 years,
advanced MM stage (Salmon-Durie), renal disease and anemia. 3) MM in
Latvia was diagnosed at late stage (56% patients were at 3rd stage) with bone
lesions in 65% of cases and renal failure (48%).
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OUTCOME OF NEWLY DIAGNOSED SYMPTOMATIC MULTIPLE MYELO-
MA IN VERY ELDERLY PATIENTS (AGED 80 YEARS OR MORE)
N. Sgherza1,* A. Melaccio2, A. Iacobazzi1, R. Ria2, A. Vacca2, A. Guarini1
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Background: Multiple Myeloma (MM) is a plasma cell neoplasm typical of the
elderly, with a median age at diagnosis of 65 years. The increase in median
age in western countries has led to an increase in the incidence of this disease;
in addition the introduction of novel agents, such as the immuno-modulatory
drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib,
has considerably changed the therapeutic scenario both for young and elderly
patients with MM.
Aims: The aim of our study is a retrospective analysis of the outcome of very
elderly (80 years or more) patients with newly diagnosed symtomatic MM to
determine the characteristics of this subset of patients.
Methods: We collected data from 47 very elderly (80 years or more) patients
(M/F: 23/24) diagnosed and treated from January 2008 to December 2014. 
Results: Median follow-up was 31 months (range 6-98) after diagnosis. Median
age at diagnosis was 83 years (range 80-89) and PS was <2 in 37 cases (79%).
One or two concomitant diseases requiring specific treatments were present
in 29 patients (62%), and 3 or more concomitant diseases were present in 8
patients (17%). MM was IgG lambda in 9 patients, IgG k in 26 patients, IgA k
in 5 cases, IgA lambda in 4 cases, and micromolecular in 3 cases. According
to the ISS, 17 patients were classified as III stage, 10 as II stage and 20 patients
as I stage. Bone lytic lesions were present at diagnosis in 34 patients (72%),
representing the most CRAB feature. Anemia (median value: 8.4 g/dL) was
present in 32 patients (68%); hypercalcemia was present in 4 patients (8%)
and renal failure was present in 2 patients (4%). First line therapy was borte-
zomib (once-weekly administration)/dexamethasone in 10 patients (21%), mel-
phalan/prednisone +/- thalidomide in 9 patients (19%) and bortezomib/mel-
phalan/prednisone in 28 patients (60%). According to IMWG response criteria,
19 patients (40%) achieved CR, 12 (26%) achieved PR, 5 (11%) achieved
VGPR, and 8 (17%) achieved stable disease; 3 patients (6%) experienced pro-
gressive disease. Hematologic toxicity was infrequent but usually weak/mod-
erate (grades 1 & 2 on the WHO scale) and 24 patients received erythropoiesis-
stimulating agents. Extrahematologic toxicity was observed in 17 patients
(36%), and neuropathy was the most common adverse event for treatment. 25
patients (53%) had at least one disease progression since diagnosis and were
therefore switched to second-line therapy. The median time to first disease
progression was 21 months (range 6-58) since start of first-line therapy. Second
line therapy was bortezomib (once-weekly administration)/dexamethasone in
5 patients, and lenalidomide/dexamethasone in 20 patients. 5 patients received
bendamustine/dexamethasone as third line of treatment in disease progression.
31 patients (66%) are still alive for a median overall survival of 22 months
(range 7-92). 14 patients died due to disease progression and 2 died due to
causes not related to MM.
Summary and Conclusions: A study in a larger series of patients is warranted
but our experience showed that no upper age limit should be applied for the
administration of new drugs with MM; these treatments could be offered to
very elderly patients, including those with severe concomitant diseases. A study
in a larger series of patients is warranted but our experience showed that no
upperage limit should be applied for the administration of new drugs with MM;
these treatments could be offeredto very elderly patients, including those with
severe concomitant diseases.
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INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENEFI-
TIAL EFFECT OF NEW AGENTS IN THE TREATMENT OF NEWLY DIAG-
NOSED MULTIPLE MYELOMA (NDMM)
F. Escalante1,*S. Cerdá1, M. Fuertes2, V. Martínez-Robles1, B. Ballina1,
L. Villalobos1, P. Escribano1, J.-A. Rodríguez-Garcia2
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Background: Beneficial effect on survival after the introduction of high-dose
chemotherapy supported by hematopoietic progenitors and new therapeutic
agents (thalidomide, bortezomib and lenalidomide) in the treatment of NDMM
patients is recognized by the entire scientific community.
Aims: Evaluate the early introduction the new anti-myeloma agents is short-
term survival in NDMM patients.
Methods: Characteristics of patients: n: 322. Median age: 74 years (38-100).
Gender: male/female: 192/130. Age at diagnosis (ADx-years): A1 (<65): 82,
A2 (66-75): 108; A3 (>75): 132. Exposure to new agents according to ADx in
1st line and before 6 months: A1: 34 and 10 (54%), A2: 37 and 24 (52%) and
A3: 22 and 10 (24%) (p.01).
Results: The short-term survival (SV6 & SV12) is lower in patients Exposed
versus No-Exposed to new agents. SV6 & SV12 in Patients Exposed to new
agents is similar among the three age groups. This lack of difference is kept
until 24 months. Only statistically significant differences are observed in the
analysis at 3 years (SV36m of 81 vs 65/58%, p.01; no differences between the
2 groups over 65 years). Landmark: to avoid bias initial selection (characteris-
tics of patients, early mortality, palliative treatments in the “old-era”...) we have
performed an analysis excluding patients who had died before 6 months of
diagnosis. 72 patients (62 in group NO-Exposed and 10 in the Exposed) were
excluded. The SV12, SV24 and SV36 (%) according to age groups (<65, 66-
75,>75) were 97, 94, 93 (ns); 91, 82 and 79 (ns) and 84, 72 and 65 (p.02
between groups <and>65). The overall survival was 77 vs 56 vs 49 months
(p.018). In the subanalysis by age and exposure differences in SV short, medi-
um and long term are still maintained, with significant differences.
Summary and Conclusions: Early introduction of new therapeutic agents in
NDMM patients influence short-term survival independent of the age. 
This therapeutic approach achieves an effect not previously described: the
absence of differences in survival by age groups until 36 months from diagno-
sis. Better post-induction (intensification, consolidation, maintenance) treatment
in the group of non-candidate patients could improve these results. Recent
studies show the beneficial effect of “continuous” treatment in this group of
patients (GEM2005, MM-015, FIRST) (Figure 1).
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SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB: A REAL-LIFE
STUDY ON MULTIPLE MYELOMA PATIENTS
S. Mangiacavalli1,* F. Cocito1, V. Ferretti1, C. Cartia1, M. Cazzola1,2, A. Corso1
1Hematology, IRCCS Fondazione Policlinico San Matteo, 2Hematology, Uni-
versity of Pavia Fondazione Policlinico San Matteo, Pavia, Italy
Background: Intravenous Bortezomib (i.v. Bor) has emerged as a standard of
care for the treatment of patients (pts) with multiple myeloma (MM). Similar
efficacy and better safety profile have been showed with subcutaneous admin-
istration of Bor (s.c. Bor).
Aims: To compare efficacy and tolerability of standard marketing patented com-
bination regimens (1° line therapy with VTD/VMP, treatment at relapse with
VD) incorporating s.c. vs i.v. Bor outside clinical trials.
Methods: After local Ethic Committee approval, we reviewed data of 276 con-
secutive MM pts treated at our Hematologic division between July 2005 to
December 2014. We collected data regarding up-front (VTD/VMP regimen), as
well as treatment at relapse (VD regimen) with s.c./i.v. Bor. Standard criteria
were applied to evaluate response rate and toxicity.
Results: A) 1° line-VMP: 43 pts were analyzed, 15 with s.c. vs 28 with i.v. Bor.
Pts received similar number (N°) of cycle (5,5 (range 1-9) vs 5 (range 1-9),
p=0.605). There were no difference in terms of ORR (³PR, 73% vs 63%,
p=0.709) as well as of CR+nCR rate (27% vs 29%, p=0.53). Grade 3-4 Bor-
related toxicity rate were comparable: 11% vs 12% respectively for s.c. vs i.v.
administration (p>0,9). None of the pts in both group developed grade 3-4 Bor-
related peripheral neuropathy (PN). B) 1° line VTD (as induction before trans-
plant): 96 pts were analyzed, 15 with s.c. 81 vs with i.v. Bor. Pts received similar
N° of cycle (4 (range 1-5) vs 4 (range 1-6), p=0.9). There were no difference in
terms of ORR (³PR, 87% vs 84%, p>0.9) as well as of CR+nCR rate (7% vs
16%, p=0.22). Grade 3-4 toxicity rates were significantly lower with s.c. Bor
(none vs 34% respectively for s.c. vs i.v. administration (p=0,045)) with none
of pts treated with s.c. Bor developing grade 3-4 PN vs 7.7% in pts treated with
i.v. Bor. C) VD at relapse: 201 pts were analyzed, 28 with s.c. vs 173 with i.v.
Bor. Pts received similar N° of cycle (4 (range 1-8) vs 4 (range 1-9), p=0.27).
Pts receiving s.c. Bor had higher ORR (³PR, 69% vs 48%, p=0.05), in particular
we found a significantly higher rate of CR+nCR (19% vs 6%, p=0.02). Grade
3-4 toxicity rates were significantly lower with s.c. Bor (14 vs 43% respectively
for s.c. vs i.v. administration (p=0,045)) with none of pts treated with s.c. Bor
developing grade 3-4 PN vs 12.8% in pts treated with i.v. Bor.
Summary and Conclusions: This real life data confirms the efficacy and the
good toxicity profile of the subcutaneous administration of Bor in all settings of
patients. 
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THE AMPLIFICATION OF 1Q21 IS AN ADVERSE PROGNOSTIC FACTOR
IN CHINESE PATIENTS WITH MULTIPLE MYELOMA
L. Chen1,* W. Yu1, R. Zhang1, X. Qu1, H. Qiu1, R. Guo1, J. Li1
1Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu
Province Hospital, Nanjing, China
Background: The prognostic heterogeneity of multiple myeloma (MM) is largely
due to different genetic abnormalities. Cytogenetic analysis has revealed that
most of MM harbor chromosome aberrations. Amplification of 1q21 is one of
the most common chromosomal aberrations.
Aims: In the present study, we examined the amplification of 1q21 in Chinese
patients with newly diagnosed multiple myeloma and analyzed the relationship
between this genetic event and clinical features of patients.
Methods: Interphase fluorescence in situ hybridization (I-FISH) was applied to
detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM.
Results: 1q21 amplification (≥3 red signals) was found in totally 40 of 86
(46.5%) cases, among which 29 with 3copies of 1q21 and 11 with at least 4
copies of 1q21. There was no significant difference in sex, age, International
Stage (ISS), Durie-Salmon stage, immunoglobulin subtype, C-reactive protein,
erythrocyte sedimentation rate, β2-microglobulin, hemoglobin, platelet number
and albumin concentrations among those patients without1q21 amplification,
with 3copies of 1q21 and with at least 4copies of 1q21 (p>0.05). Further analysis
revealed a significant difference of overall survival (OS) (p=0.047) and pro-
gression-free survival (PFS) (p=0.001) among the three arms. Bortezomib could
not significantly improve the OS (p=0.626) or PFS (p=0.514) for patients with
at least 4 copies of 1q21.
Summary and Conclusions: These findings suggest that 1q21 amplification
especially more than 4 copies represents a factor for poor prognosis in MM
patients receiving Bortezomib-based regimens.
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USE OF EARLY CHANGES IN GENE EXPRESSION OF PLASMA CELLS
MAY PREDICT RESPONSE TO BORTEZOMIB IN PATIENTS WITH NEWLY
DIAGNOSED MULTIPLE MYELOMA
K. Liapis1,2,* T. Bagkratouni2, E. Kastritis2, S. Vasileiou3, F. Panitsas3, C. Liakou2,
E. Charitaki3, E. Bournakis2, E. Terpos2, S. Delimpasi3, N. Charchalakis3,
M.A. Dimopoulos2
1Haemato-oncology Unit, The Royal Marsden Hospital, The Royal Marden NHS
Foundation Trust, London, United Kingdom, 2Department of Therapeutics,
Alexandra Hospital, 3Department of Hematology, Evangelismos Hospital,
Athens, Greece
Background: Maximizing the response rate of first-line therapy (≥VGPR) in
multiple myeloma is prognostically important since it has been associated with
improved progression-free and overall survival. Molecular changes in plasma
cells after treatment with bortezomib caused by the in vivo interaction between
drug and tumor may be used as a predictor of response to therapy. Studies of
gene expression have revealed that certain genes associated with the protea-
some (PSMD4, BIRC5, KIAA1754) may represent clinically useful prognostic
factors.
Aims: We aimed to examine the use of early changes in the expression of
these genes as predictors of the quality of response to first-line bortezomib-
based therapy in newly-diagnosed multiple myeloma. 
Methods: We studied prospectively changes in the expression of three genes
(PSMD4, BIRC5, KIAA1754) induced by bortezomib and their possible corre-
lation with response rates, in 25 patients (16 men, 9 women) with newly-diag-
nosed multiple myeloma between March 2009 and March 2010. Monitoring
continued until January 2014. 19 patients received a combination of bortezomib
with dexamethasone (VD) and 6 received a combination of bortezomib, mel-
phalan, and prednisolone (MPV). Bortezomib was administered intravenously
with the classic biweekly regimen. Bone marrow aspiration and plasma cell
collection was performed at diagnosis (Day 0) and on the seventh day (Day
+7) of treatment (i.e., before the third dose of bortezomib). For the purposes of
comparison, we analyzed 5 patients who had thalidomide-based treatment (3
patients had thalidomide-dexamethasone, and 2 patients had thalidomide, mel-
phalan, and prednisolone). Selective isolation of CD138+ plasma cells was
performed with use of magnetic beads, confirmed with flow cytometry, and fol-
lowed by the isolation of RNA. We studied gene expression by means of RT-
PCR. The observed changes in gene expression were recorded as upregulation
(Up), downregulation (Down), or no change (No change). We used changes in
the expression of actin gene in order to normalize the variation in the expression
of the 3 genes in study. All patients gave written informed consent for the study.
Results: VGPR/CR reached 8 of 30 patients (26.6%), PR 15 of 30 patients
(50%), and SD/PD was seen in 7 of 30 patients (23.4%). We found that the
changes in the expression of the RNA of the BIRC5 gene (P=0.001) and
KIAA1754 gene (P<0.001) were associated significantly with the quality of
response to bortezomib-based treatment, whereas the changes in the expres-
sion of the PSMD4 gene were not associated with the quality of response to
bortezomib (P=0.132). In particular, an upregulation in the expression of
KIAA1754 was associated with the achievement of VGPR/CR, whereas a down-
regulation in the expression of BIRC5 was associated with an inferior response.
All patients who achieved VGPR/CR had the following BIRC5/KIAA1754 com-
binations: Down/Up or No change/Up. Patients in whom SD/PD was seen had
the following BIRC5/KIAA1754 combinations: Up/Down, Up/No change, and
No change/Down. Patients who reached a PR usually had BIRC5/KIAA1754
combinations: Up/Up, Down/Down, or No change/No change. We also found
that the expression of PSMD4, BIRC5, and KIAA1754 was not affected by
thalidomide-based treatment.
Summary and Conclusions: We found that the early changes (Day +7) in the
expression of BIRC5 and KIAA1752 genes were significantly associated with
the prediction of response to bortezomib-based treatment, but were not altered
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after treatment with thalidomide. These results are specific to the probability of
response to first-line bortezomib and, therefore, could be used as part of a risk
stratification system for early modification of first-line treatment in patients with
newly-diagnosed multiple myeloma. These data may have relevance for the
emerging concept of precision medicine.
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ANTI-GRP78 MONOCLONAL ANTIBODY PAT-SM6 IN REFRACTORY AND
EXTRAMEDULLARY MULTIPLE MYELOMA: PRECLINICAL AND CLINICAL
EVIDENCE FOR A COMBINATORIAL STRATEGY WITH NOVEL AGENTS
L. Rasche1,* V. Dubljevic2, C. Lapa3, J. Düll1, F. Hensel4, S. Knop1, A. Rosenwald5,
H. Einsele1, S. Brändlein5
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University Hospital Wuerzburg, 4Patrys GmbH, 5Pathology, University
Wuerzburg, Würzburg, Germany
Background: Despite enormous progress in multiple myeloma (MM) therapy
the development of effective therapeutic strategies for relapsed and drug refrac-
tory patients continues to represent an unmet medical need. We have devel-
oped an IgM monoclonal antibody (PAT-SM6) which interferes with Glucose
Regulated Protein 78 (GRP78), a heat shock protein frequently reported to be
involved in the mediation of drug resistance. In an initial phase I trial with heavily
pretreated MM patients, PAT-SM6 treatment showed a disease stabilization
rate of 33% when used as single agent. Objective responses according to the
IMWG criteria were not seen.
Aims: In this study we further evaluated PAT-SM6 in refractory MM disease. 
Methods: We used an in vitro drug combination model to investigate the effect
of PAT-SM6 in combination with other MM drugs. Immunohistochemical staining
with PAT-SM6 and control antibodies on bone marrow specimens and
extramedullary lesions was performed. PAT-SM6 was also tested in combina-
tion with Lenalidomide (Len) and Bortezomib (BTZ) on the basis of a compas-
sionate use program in one patient with refractory extramedullary MM after
informed consent.
Results: Immunohistochemical staining with PAT-SM6 showed stable GRP78
antigen expression throughout various stages of MM including cases with
extramedullary disease. Resistance to immunomodulatory drugs (Len) or pro-
teasome inhibitors (BTZ) did not affect GRP78 expression. Previous data
showed that treatment with single agent PAT-SM6 reduced tumor load and M
protein levels in a 5T33 murine model of aggressive MM in a dose dependent
manner. PAT-SM6 combined with MM drugs such as Len, BTZ, Carfilzomib
(CFZ) and Dexamethasone (Dexa) showed additive and synergistic effects in
some (but not all) tested MM cell lines when analyzed by the Chou Talalay
method. Interestingly, synergy was also observed in BTZ, Len and/or Dexa
resistant cell lines. A patient with plasmoblastic Len and BTZ resistant MM
experienced partial remission of intra- and extramedullary plasma cell tumors
after treatment with PAT-SM6 in combination with Len and BTZ. Remission
was not durable but repeated biopsies at progression showed preserved target
expression at the extramedullary sites giving hope that a prolonged or intensi-
fied antibody treatment can sustain remission in future patients.
Summary and Conclusions: The Anti-GRP78 antibody PAT-SM6 showed
promising activity in vitro and in a late stage MM patient with aggressive tumor
biology and drug resistance. Further studies focusing on refractory patients
using antibody combinations with novel agents are warranted to elucidate the
future role of PAT-SM6 in the treatment of MM.
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ACCURACY OF THE SERUM TOTAL LIGHT CHAIN RATIO AS A PREDIC-
TOR OF ABNORMAL SERUM FREE LIGHT CHAIN RATIOS
M. Pereira1,* N. Costa e Silva2, C. Geraldes1, L. Ribeiro1, F. Rodrigue 2
1Clinical Hematology Department, 2Clinical Pathology Department, Coimbra
University Hospital Centre, Coimbra, Portugal
Background: The identification and quantification of serum free light chains
(sFLC) with the determination of the kappa/lambda sFLC ratio has been shown
to be superior to serum total light chains (sTLC) and to the analysis of the uri-
nary excretion of light chains, in the diagnosis, management and follow-up of
plasma-cell dyscrasias. However, the price of the sFLC test can be much higher
than that of sTLC (reaching a five-fold difference, in our country). This difference
in cost means that the test is still frequently unavailable in lower-income coun-
tries, and in smaller Centers in middle-income countries.
Aims: We aim to determine the extent to which the determination of the sTLC
and of their ratio can be a surrogate marker for sFLC evaluation, as determined
by its sensitivity, sensibility and positive and negative predictive value (PPV
and NPV).
Methods: We analysed all samples processed in our Lab between the intro-
duction of the test in 01-09-2005 and 28-02-2015, selecting only those cases
with a simultaneous evaluation, in the same blood sample, of total kappa LC,
total lambda LC, free kappa LC and free lambda LC; any samples not fulfilling
this criterion were excluded. The reference interval used for the sFLC ratio
was 0.26-1.65 (inclusive), and 1.35-2.65 (inclusive) for the sTLC ratio. Border-
line deviations from the reference interval were defined as a decrease or
increase of 10% over the lower and upper limits of the reference interval,
respectively.
Results: We obtained 960 samples fulfilling the criteria defined above. The
sTLC ratios were abnormal in 76.7% of samples with an abnormal sFLC ratio,
but in only 31.3% of samples with a normal sFLC ratio (p<0.001). This reflects
an inter-rater agreement of 71.5% (Cohen’s kappa=0.42, p<0.0001). The sen-
sitivity of the sTLC ratio for the prediction of an altered sFLC ratio was, there-
fore, 76.6% (95% CI: 71.7-81.1%), with a specificity of 68.7% (95% CI: 64.9-
72.3%), a PPV of 56.2% (95% CI: 51.5-60.9%) and a NPV of 84.9% (95% CI:
81.5-87.9%). The area under the receiver operating characteristic (ROC) curve
(AUC) was 0.73, which represents a diagnostic test with a moderate accuracy.
Considering only samples with borderline deviations of the sFLC ratio, as
defined above, the percentage of abnormal sTLC ratios decreased to 66.7%
(remaining 31.2% in patients with normal sFLC ratios, p=0.002). For these bor-
derline cases, concordance decreased to 68.7% (kappa=0.06, p=0.0008).
Specificity was unaffected, at 68.7%; although the NPV increased to 98.6%
(95% CI: 97.0-99.5%), the PPV was only 5.7% (95% CI: 3.0-9.8%). Accuracy
was poor, with an AUC of 0.68. When the sFLC ratio was more than twice the
upper limit or less than half the lower limit of normal, the sensitivity of the sTLC
ratio increased to 83.3% (95% CI: 77.8-87.9%), while the NPV remained
acceptable at 91.9% (95% CI: 89.1-94.2%).
Summary and Conclusions: We found that the sTLC ratio is a test with a
moderate accuracy at identifying altered sFLC ratios, which are the current
gold-standard. Overall, sensitivity, specificity and PPV were fair; the NPV was
approximately 85%, which meant that only 15% of patients with a normal sTLC
ratio would in fact have an abnormal sFLC ratio. Although the accuracy of the
test was poor for borderline samples, its NPV was excellent at approximately
99%. These data suggest that, within the context of very limited monetary
resources, the sTLC ratio could optimize the allocation of resources, by helping
to exclude those patients who are unlikely to have an altered sFLC ratio, and
prioritizing the use of sFLC tests in those patients more likely to have abnormal
results.
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CLINICAL FEATURES, PROGNOSIS AND TREATMENT OUTCOME OF THE
OF THE EXTRAOSSEUS PLASMA CELL NEOPLASIA: PLASMACYTOMA,
MULTIPLE MYELOMA AND PRIMARY PLASMA CELL LEUKEMIA 
J. Jelicic1,* J. Bila1, V. Vukovic1, V. Djurasinovic1, B. Andjelic1, A. Sretenovic1,
M. Smiljanic1, D. Antic1, M. Todorovic1, B. Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, Bel-
grade, Serbia
Background: Extraosseous localizations of solitary plasmacytoma (ESP), or
symptomatic multiple myeloma (EMM) including primary plasma cell leukemia
(PCL), are rare presentations of plasma cell neoplasia (PCN).
Aims: The aim of this study was to analyse clinical characteristics, prognosis, and
treatment outcome in patients with extraosseous ESP, EMM and primary PCL. 
Methods: The study included analysis of the 560 newly diagnosed patients
with PCN for the past fourteen years, of which 42 patients (25 males/17
females, median age 57.5 years, range 19-74yrs) had extraosseous PCN. ESP
was diagnosed in 24 patients (57.2%), EMM in 12 (28.6%) and PCL in 6
(14.3%). Regarding the type of M protein, the distribution was as following:
IgG (50%), light chains (29.4%), IgA (11.8%), IgD (5.9%) and IgM (2.9%). Using
the immunofixation electrophoresis (IEF) and serum free-lite test (FLT), low
paraprotein concentrations were detected in 27/34 patients (79.4%). Non-
secretory disease was confirmed with negative IEF and normal FLT ratio in
8/24 patients (33.3%). The most frequent localizations of the extraosseus PCN
were: Oral cavity or pharynx (25%); Paravertebral tumours (16.7%); Muscle
infiltration of the thoracal/abdominal wall (13.9%); Salivary glands (8.3%);
Lymph nodes (8.3%); and maxillary sinus (8.3%). Less frequent localizations
were stomach, colon, and testis found in 1/42pts (2.4%). Majority of the patients
with EMM were diagnosed with clinical stage III (CS, Durie&Salmon, 76.2%).
Regarding International Scoring System (ISS), 66.7% patients with EMM had
ISS1-2, and 33.3% had ISS3. Renal impairment existed in 4 patients (9.5%).
Applied treatment was as follows: Radiotherapy (RT, 19% pts); chemothera-
py±RT (HT±RT, 54.8%pts); and HT+autologous stem cell transplantation
(HT+ASCT, 26.2%pts).
Results: Initial overall treatment response (CR/VGPR/PR) was achieved in
95.2% of analysed patients. In the group of patients with ESP, the 5-year sur-
vival was achieved in 90%pts, without reached median overall survival (OS).
Among 24 patients with ESP, 41.7% relapsed/progressed within first 4 years
of follow-up (range 1-14yrs). PD to symptomatic myeloma occurred in: 4/10pts
(40%) treated with RT; and in 6/14pts (42.9%) treated with RT±HT. Median OS
of the patients with ESP who progressed to MM was 113 months (95% CI,
70.216-157.469), with 5-year survival achieved in 58% pts, and 50 months of
median EFS. Patients with EMM had median OS 84 months (95% CI, 45.194-
122.806), and 5-year survival of 62% pts. Median EFS for this group was 48
months (95% CI, 43.467-52.533). The patients with PCL had the worst outcome
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with median overall survival (OS) of 36 months (95% CI, 4.564-67.436) (Log
Rank 3.864, p˂0.05), 5-year survival of 36% pts, and median EFS of 25 months
(95% CI, 5.539-44.461, Log Rank 7.923; p<0,05). There was no significant dif-
ference in the OS of the patients with EMM/PCL regardless the type of M protein
(Log Rank 1.127, p>0,05) or its concentrations (Log Rank 1.708, p>0.05), CS
(Log Rank 1.841, p>0,05) or ISS score (Log Rank 3.852, p>0.05), and
extraosseal localization (Log Rank 7.210; p>0,05).
Summary and Conclusions: In analyzed group, immature origin of the
extraosseus PCN is expressed through low-secretory features of predominantly
rare types of M protein. There is no difference in the course of ESP disease
regardless the treatment approach while primary PCL, as the principal repre-
sentative of extramedullary disease retains the most aggressive features
despite the introduction of novel therapies. 
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EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE
COMBINATION IN PATIENTS WITH POEMS SYNDROME PRE-TREATED
OR INELIGIBLE FOR HIGH-DOSE THERAPY: RESULTS OF A PROSPEC-
TIVE TRIAL
A. Nozza1,* E. Nobile-Orazio2, F. Adami3, F. Gallia2, B. Chiara4, F. Terenghi2,
A. Santoro1
1Hematology, Humanitas Cancer Center, 22° Neurology - Translational Medi-
cine, Humanitas Clinical and Research Center, Rozzano, 3Clinical and Exper-
imental Medicine -Hematology & Clinical Immunology, 4Department of Neuro-
sciences, University of Padova, Padova, Italy
Introduction: POEMS syndrome is a rare multisystemic disease. Several treat-
ments have been proposed for POEMS even if there is so far no controlled
study. Lenalidomide has anti-angiogenic activity through inhibition of VEGF
and TNF alpha.
Aims: This study plans to evaluate efficacy and toxicity of Lenalidomide in
POEMS. Lenalidomide 25 mg/day was given for 21 days in association with
weekly Dexamethasone 40 mg until progression or toxicity. Response to treat-
ment was assessed by a specifically prepared clinical scale which evaluates
ten hematological and clinical parameters(clinical response evaluation scale “,
CRES, range 0-20), as welll as by the Overall Neuropathy Limitations Scale
(ONLS), an expanded MRC sum score, the INCAT sensory sum score and
EMG, to evaluate neurological response. The primary end-point was the
response to therapy after six monthly cycles of RD. Pts were considered respon-
ders if they showed an improvement of at least 1 point in the ONLS scale and
at least 3 in the CRES scale.
Methods: From 10/09 to 10/14, we performed a pilot study with Lenalidomide
plus dexamethasone (RD) in 20 patients with POEMS - All Pts had a median
ONLS score of 4.5 (range 1-8), and monoclonal component (lambda restricted
in 88%) - Serum VEGF levels were >1000 pg/ml in all but two pts (88.9%) with
a median level of 4043 pg/ml (range 687-13856). Osteoscleoriotic bone lesions
were found byx-ray in 12 pts (67%), while Castelman Disease was histologicallly
confirmed in 2 pts. Skin changes were observed in 16 pts (89%),
hepatosplenomegaly in 14 (78%) pleural effusion, ascites or peripheral edema
in 6 pts (33%) and endocrine alterations in 16 (89%).
Results: Response evaluation after 6 months of RD was done in 16 out of 18
pts: 2 pts had dropped out during the first cycle (1 lost to follow-up, 1 for with-
drawal of informed consent): 15/18 of included pts (83.3%) completed the 6
cycles of therapy and were improved at six month in the clinical or neurological
scale or both, while one patient not improved and suspended the treatment
after 4 cycles. 13 pts (72.2%) had improved by at least 3 points in CRES, rang-
ing from 3 to 7 points (mean score at entry 10.36; mean score at six month
7.18; p=0.0006). 10 pts (55.6%) improved by at least one point in the ONLS
with an improvement ranging from 1 to 3 points (mean score at entry 4.3; mean
score at six month 3.6; p=0.0176), five remained stable and one patient had
deteriorated by two points. Six patients are still on treatment, after a median
follow-up of 33 months (range 10-52 months)- 5 Pts discontinued treatment for
complete response-stable disease after a median of 30 months (range 25-32
months) and only one relapsed 20 months later. In 4 pts the disease progressed
after 10, 21, 29 and 35 months. No patient discontinued treatment due to tox-
icity. Lenalidomide was reduced in 43% of patients mainly for haematological
toxicity (grade II-III), and dexamentasone was reduced in all patients, and
stopped in 30%. Has not been reported any thrombotic events or secondary
neoplasia in patients enrolled.
Summary and Conclusions: Conclusions: This prospective trail confirms that
lenalidomide is very effective and well tolerated in the majority of patients,
regardless of any previous treatments and it has a prolonged efficacy in POEMS
Syndrome.
Email address: andrea.nozza@humanitas.it
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HIGH PREVALENCE OF RAS PATHWAY MUTATIONS IN CMML PATIENTS
WITH HIGH COLONY GROWTH
K. Geissler1,* A. Zopf2, E. Jäger3, C. Gabriel2, P. Bettelheim4, P. Valent5
15th Department of Medicine, Hospital Hietzing, Vienna, 2Blood Transfusion
Service of Upper Austria, Austrian Red Cross, Linz, 3Department of Laboratory
Medicine, Medical University of Vienna, Vienna, 41st Department of Medicine,
Elisabethinen Hospital, Linz, 51st Department of Medicine, Medical University
of Vienna, Vienna, Austria
Background: Some time ago we reported that extensive in vitro formation of
colony-forming unit-granulocyte-macrophage (CFU-GM) without exogenous
growth factors is found in a subset of patients with chronic myelomonocytic
leukemia (CMML) (Geissler K et al. Leuk Res 1988). Subsequently we found
that this spontaneous myeloid colony formation depends on low endogenous-
ly produced granulocyte/macrophage colony-stimulating factor (GM-CSF)
concentrations in the culture system (Geissler K et al. J Exp Med 1996).
Moreover we have reported that CMML patients with high spontaneous CFU-
GM growth (>100/105PBMNC) have a worse prognosis compared to patients
with low CFU-GM growth (Sagaster V et al. Ann Hematol 2004). The
“RASopathies” are a group of genetic syndromes caused by germline muta-
tions in genes that encode components of the RAS signaling pathway includ-
ing NRAS, KRAS, NF-1, CBL, and PTPN11 (Niemeyer CM. Haematologica
2014). Besides their developmental defects they share a predisposition to
JMML. Molecular alterations of these components in murine hematopoietic
cells can lead to a CMML like disease in vivo and to spontaneous myeloid
colony formation in vitro due to hypersensitivity of granulomonocytic precur-
sors against GM-CSF (Wang J et al. Blood 2010). The significance of spon-
taneous CFU-GM growth in man regarding molecular aberration profiles in
CMML remains unknown.
Aims: Based on current knowledge we speculated that mutations in the RAS
signaling pathway may play a significant role in autonomous CFU-GM for-
mation in CMML.
Methods: In this study we reanalyzed CMML cells from our patients with
respect to the presence of molecular aberrations of RAS pathway components
and correlated the results with in vitro CFU-GM growth. For this purpose we
used deep DNA sequencing of 27 CMML associated genes.
Results: Our results show a high prevalence of RAS pathway mutations in
CMML patients with high spontaneous CFU-GM formation. Mutations in the
components of the RAS pathway were found in 12/15 (80%, NRAS 7, KRAS
1, NF1 2, CBL 2) CMML patients with high colony growth and in 2/9 (22%,
NRAS 1, CBL 1) patients with low spontaneous colony formation (p=0.008;
Fisher exact test). Mutations of RAS pathway components were mutually
exclusive. In all patients with RAS pathway mutations additional mutations
were observed in other genes, particularly in components of DNA methylation
and/or the spliceosome. Finally, as expected, we found a significant influence
of RAS pathway mutations and of high CFU-GM formation, respectively, on
overall survival in patients with CMML.
Summary and Conclusions: Our findings suggest that CMML with high
spontaneous colony growth is a RAS pathway-dependent malignancy which
may have clinical implications concerning prognostication and therapeutic
strategies aimed at targeting the hyperactive RAS signaling pathway in these
patients.
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ACQUIRED UNIPARENTAL DISOMY OF CHROMOSOME 14 IN MYELOID
MALIGNANCIES TARGETS THE IMPRINTED MEG3-DLK1 LOCUS
A. Chase1 2,* W. Leung1,2, W. Tapper1, A. Jones1, L. Knoops3, C. Rasi4,
L. Forsberg4, P. Guglielmelli5, V. Hall2, L. Chiecchio2, L. Docherty1,2, H. White1,2,
J. Score12, K. Zoi6, J. Dumanski4, A. Vannucchi5, D. Mackay1,2, N.C. Cross1,2
1School of Medicine, University of Southampton, Southampton, 2Wessex
Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United
Kingdom, 3Cliniques Universitaires Saint-Luc de Duve Institute, Université
catholique de Louvain, Brussels, Belgium, 4Department of Immunology, Upp-
sala University, Uppsala, Sweden, 5Department of Experimental and Clinical
Medicine, University of Florence, Florence, Italy, 6Biochemical Research Foun-
dation, Academy of Athens, Athens, Greece
Background: Whole or partial chromosomal acquired uniparental disomy
(aUPD) is a common finding in myeloid malignancies and typically acts to con-
vert a somatically-acquired heterozygous mutation to homozygosity with loss
of the normal allele. Examples are aUPD of chromosomes 4q, 7q and 9p asso-
ciated with mutations of TET2, EZH2 and JAK2 respectively. Several other
regions of recurrent aUPD have been identified; e.g. chromosome 14q aUPD
(aUPD14) is seen in about 1% of myeloid malignancies and also in population
cohorts of elderly individuals at a frequency of about 0.04%. Indeed, chromo-
some 14q is the most commonly affected region in such cohorts.
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Aims: To identify the molecular target of aUPD14.
Methods: Acquired UPD14 cases identified by SNP array analysis were
analysed by whole exome sequencing, MEG3 methylation by quantitative
methylation-specific PCR of bisulphited DNA and MEG3 and DLK1 expression
by RT-qPCR.
Results: Whole exome sequencing of six aUPD14 cases, of which 3 had been
diagnosed with a myeloid neoplasm and 3 had been picked up in a population-
based screen of elderly individuals, found no recurrent variants and therefore
we considered alternative possibilities. Inherited, constitutional UPD14 is asso-
ciated with Temple syndrome (maternal UPD) or Wang-Kagami syndrome
(paternal UPD), developmental disorders which result from inappropriate
expression of genes within the imprinted MEG3-DLK1 locus at 14q32. The
non-methylated maternal chromosome expresses the non-coding asRTL1,
MEG3, MEG8 genes as well as multiple miRNAs and snoRNAs, whilst the
methylated paternally inherited chromosome expresses the protein-coding
genes DLK1, RTL1 and DIO3. Since MEG3-DLK1 is deregulated in diverse
cancers (including overexpression of DLK1 in myelofibrosis) and this locus
falls within the minimal region of aUPD14, we investigated the possibility that
it might be the target of aUPD14. MEG3 methylation analysis was performed
on 22 cases with aUPD14 (21 with myeloid neoplasia, one healthy older indi-
vidual) and six cases with a myeloid neoplasia and trisomy 14. Of 8 cases with
aUPD14 estimated to affect >50% of cells i.e. a B-allele frequency >0.75, all 8
showed a methylation value three standard deviations above that of controls
indicating loss of the maternal chromosome and gain of the paternal chromo-
some (p<0.01). Loss of maternal chromosome 14 was also apparent in cases
with lower levels of aUPD14 and overall the degree of methylation imbalance
strongly correlated with the level of aUPD (r=0.76; p=0.0001). By contrast, no
consistent parental bias was seen in cases with trisomy 14. To determine if
MEG3 methylation is more widespread in myeloid malignancies, we examined
a further 48 CMML cases with unknown aUPD status and 48 MDS/MPN cases
known not to have aUPD14 by SNP array analysis. We identified three addi-
tional cases with increased MEG3 methylation of which two had no evidence
of aUPD by microsatellite analysis, thus suggesting alternative mechanisms of
MEG3-DLK1 deregulation. Using RT-qPCR we found increased DLK1 expres-
sion but no consistent change in MEG3 expression in two cases with aUPD14
compared to controls. Interestingly we also saw altered expression of DLK1
and MEG3 expression in myeloid neoplasias without aUPD14, further suggest-
ing that deregulation of the MEG3-DLK1 locus is not restricted to cases with
aUPD14.
Summary and Conclusions: We conclude that aUPD14 is a recurrent abnor-
mality targeting the imprinted MEG3-DLK1 locus, and that deregulation of this
locus may be more widely associated with myeloid malignancy, as well as
clonal hemopoiesis in apparently healthy older individuals.
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CIRCULATING ENDOTHELIAL CELLS (CEC) AS A SURROGATE MARKER
FOR EVOLUTION IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
M.L. Antelo1, N. Ramirez2, A. Angona3, A. Alvarez-Larran, 3E. Perez-Valderrrama2,
C. Mansilla2, M. Ciaurriz2, J. Rifon4, E. Olavarria5, M. Rodriguez-Calvillo1,*
1Haemathology and Hemotherapy, Complejo Hospitalario de Navarra,
2Navarrabiomed Fundacion Miguel Servet, Pamplona, 3Haemathology and
Hemotherapy, Hospital del Mar, Barcelona, 4Haemathology and Hemotherapy,
Clinica Universidad de Navarra, Pamplona, Spain, 5Haemathology and Hemo-
therapy, Hammersmith, London, United Kingdom
Background: The normal circulating endothelial cell (CEC) reference range
established in healthy donors is 1-20 CECs/mL blood. Changes in endothelial
cells play an important role in a variety of disorders including the classical
Ph-negative chronic myeloproliferative neoplasms (MPNs) Polycythaemia
vera (PV) and Myelofibrosis (MF). An elevated number of CECs has been
described in these diseases but also has lead to a wide variation in the report-
ed range of CECs.
Aims: The aims of the present study were: (1) To compare the quantification
of CECs in Ph-negative MPNs using two different platforms, Cell-Search sys-
tem-Veridex® and Polychromatic Flow Cytometry; (2) to establish variations
of CEC numbers in different risk-adapted MPNs according to time from diag-
nosis (for PV patients) and to DIPPS (for MF patients).
Methods: The study included 49 consecutive patients that were divided into
4 groups: PV up to 10 years from diagnosis (n=10), PV with less than 10
years from diagnosis (n=10), low DIPSS MF (n=9) and high DIPSS MF
(n=10). As a control group, 10 healthy blood donors (HC) were also studied.
Assessment of the circulating CECs by the Cell-Search system was per-
formed using a semiautomated fluorescence microscope. CD146+ cells
were immunomagnetically isolated and labeled with anti-CD105, CD45 and
nuclear stain DAPI. A camera is used to scan stained cells and evaluates
potential CEC candidates by image analysis software. Assessment of the
circulating CECs by flow cytometry was performed. using KDR, CD34, CD45
and CD133 monoclonal antibodies. Each analysis included 1,000,000
events.
Results: The statistical comparison of the CEC numbers showed significant
differences between PV patients and MF patients (Mann Whitney U test,
p<0.001) but also between Low and High DIPPS MF (p=0.022). Regarding
the flow cytometry population, statistical analyses found significance for the
same comparisons: p<0.001 between PV patients and MF patients and
p=0.009 between Low and High DIPPS MF. No statistically significant differ-
ences were found between patients with PV for either method. Both PV and
MF groups had a significant higher number of CEC compared to healthy
donors (p<0.001) (Table 1).
Table 1.
GROUP                                     CellSearch system                     Flow Cytometry
                                   CD146+CD105+CD45- (CEC/4ml)   CD34+KDR+133+ (%)
Control group                                 10.50 (3-26)           0.0006975 (0.000144-0.002331)
P. Vera up to 10 years                   58.50 (17-130)               0.0001345 (0-0.233905)
P.Vera >10 years from diagnosis     64.00 (9-507)                 0.0049305 (0-0.05922)
Low DIPPS MF                             84.00 (31-288)                0.0277855 (0-0.71932)
High DIPPS MF                          268.00 (69-7497)         0.153546 (0.00504-0.595544)
Summary and Conclusions: Our results suggest a role for CEC in the patho-
genesis of PV and MF and indicate that: (1) the CEC value could useful for the
evaluation of disease progression in PV and MF patients; (2) The standardized
method of CEC quantification (Veridex®) correlates with flow cytometry deter-
mination of this population.
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Background: Since the discovery of a point mutation in the Janus kinase 2
(JAK2V617F) gene in 2005, the concept of essential thrombocythemia (ET),
polycythemia vera (PV) and primary myelofibrosis (PMF) as separate disease
entities has been questioned and replaced by the hypothesis of a biological
continuum from ET over PV to PMF in JAK2V617F positive patients. Trans-
formations from ET to PV and of both entities to myelofibrosis are frequent
and the similarities between JAK2V617F positive ET and PV suggest that
overlap between them are more common than previously recognized. Recent-
ly, by performing unsupervised Principal Component Analysis (PCA) on gene
expression data from these three disease entities, we yielded further support
to a biological continuum from ET over PV to PMF with overlap between ET
and PV. However, no study has applied supervised classification to explore
the molecular classification of ET, PV and PMF which may add information
to the clinical diagnosis.
Aims: By using supervised classification methods, the aim of the study was
to investigate if ET, PV, and PMF can be separated into distinct groups and
to examine if an overlap between these three entities exists. 
Methods: Gene expression microarray studies have been performed on
whole blood from patients with ET (n=19; 9/10 patients JAK2V617F-/+), PV
(n=41; 1/40 patient JAK2V617F-/+), and PMF (n=9; 7/2 JAK2V617F-/+) using
Affymetrix HG-U133 2.0 Plus microarrays. A voting procedure involving
eleven different support vector machine learning algorithms SVM and KSVM
for pattern recognition were chosen for multi-class classification. The top 5-
100 genes were used to train the models with SVM/KSVM and leave one out
cross validation (LOOCV). A balanced accuracy and a significance level of
the classification methods were determined. The gene sets used in the clas-
sification procedure were subjected to functional analysis.
Results: In total, the 11 different SVM and KSVM classification algorithms
correctly predicted 15 of 19 (79%) patients with ET, 28 of 41 (68%) patients
with PV, and 8 of 9 (89%) patients with PMF. The classification models
showed a balanced accuracy of 79%. The performance of the classification
methods was highly significant (p=1x10-6). The results revealed that 4 of 4
misclassified patients with ET were classified as PV of whom 3 were JAK2
positive indicative of a possible transition towards PV. 10 of 13 misclassified
patients with PV were classified as ET and the remaining 3 as PMF. One of
9 patients with PMF was misclassified as ET. These results may add more
precise molecular phenotype information to the diagnosis. The resulting gene
sets used in the classification model included 117, 91, and 92 genes in ET
vs PV/PMF, PV vs ET/PMF, and PMF vs ET/PV, respectively. To explore the
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biology of the three gene sets using functional analysis, an association with
nucleotide binding, inflammation, metabolic process and secretory system
was shown in ET vs PV/PMF, plasma membrane, metabolic process, signal
transduction, and inflammation in PV vs ET/PMF, and immune system, signal
transduction, secretory system, and transcriptional regulation in PMF vs
ET/PV.
Summary and Conclusions: We have performed supervised classification
of gene expression data from patients with ET, PV, and PMF. Our data show
that ET, PV and PMF may be separated into distinct disease entities with
overlap between ET and PV providing further support to a biological contin-
uum from ET over PV to PMF. Moreover, our study may add important infor-
mation to the clinical diagnosis of ET, PV, and PMF.
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SERUM LEVELS OF MATRIX METALLOPROTEINASES AND THEIR TIS-
SUE INHIBITORS ARE ELEVATED IN JAK2V617F MUTATED COMPARED
TO CALR MUTATED MYELOFIBROSIS AND TRIPLE NEGATIVE ESSEN-
TIAL THROMBOCYTEMIA PATIENTS
L.T. Lima1,* D. Prudente Teixeira Nunes1, G. Wataru Gomes1, M.D.L. Chauffaille2,
M.R. Régis Silva3, C. Cilento Ponce3, F. Attié de Castro4, M. Cliquet5, M.T. dos
Santo6, M. Mitne Neto6, E.M. Guerra-Shinohara1
1Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical
Sciences, University of Sao Paulo, 2Department of Clinical and Experimental
Oncology, 3Department of Pathology, Federal University of Sao Paulo, Sao
Paulo, 4Department of Clinical, Toxicological and Bromatological Analyses,
School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo,
Ribeirao Preto, 5Department of Hematology, Hospital Complex of Sorocaba,
Catholic University of Sao Paulo, Sorocaba, 6Research and Development,
Fleury Group Inc, Sao Paulo, Brazil
Background: Myelofibrosis (MF) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) resulting from acquired hematopoietic
stem cell mutations. MF and ET patients may harbor JAK2V617F,
MPLW515K/L or calreticulin mutations (CALRMUT). The mechanism by which
mutant CALR alters cellular function to result in myeloid proliferation remains
unclear. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs)
are involved in tumor neoangiogenesis which plays important role in hema-
tological neoplasias progression and prognosis. 
Aims: To investigate expression of RNAm and serum levels of MMPs, TIMPs,
and plasma markers of angiogenesis (VEGFA and FGF2) according to
JAK2V617F and CALR mutational status in MPN patients.
Methods: Sixty-five MPN patients were studied: 21 primary MF (PMF), 23
ET, and 21 myelofibrosis post-ET (MPET). MPN diagnosis was defined
according to the 2008 WHO criteria. JAK2V617F, MPLW515K/L and MMP2,
MMP9, TIMP1 and TIMP2 gene expression were evaluated in peripheral
leukocytes by real time PCR, using TaqMan MGB probes. CALR mutations
were analyzed in JAK2V617F and MPL W515K/L negative samples by Sanger
sequencing method. Protein levels of MMPs, TIMPs, VEGFA and FGF2 were
measured Luminex technology. 
Results: The frequencies of JAK2V617F mutated patients were: 52% (N=11)
in PMF, 52% (N=12) in ET and 57% (N=12) in MFPET. CALR mutations were
detected in 38% (N=8) of PMF, 13% (N=3) of ET and 33% (N=7) of MPET
patients. One ET patient presented MPLW515L mutation. We found higher
protein levels of MMP9 in PMF JAK2V617F mutated patients (N=11) compared
with CALRMUT ones (N=8) (158.3 vs 55.8 ng/mL; P=0.023). MFPET
JAK2V617F patients (N=12) presented higher levels of MMP9 (131.0 vs 84.5
ng/mL; P=0.049), TIMP2 (119.8 vs 103.3 ng/mL; P=0.049), VEGFA (139.0 vs
11.16 pg/mL; P=0.008) and FGF2 (21.5 vs 6.6 pg/mL; P=0.027) compared
with CALRMUT (N=8). For ET, we found that triple negatives (N=6) showed
lower MMP2 (122.4 vs 156.6 ng/mL; P=0.048) and TIMP2 (97.5 vs 106.4
ng/mL; P=0.020) levels in comparison with JAK2 mutated (N=12). 
Summary and Conclusions: Our data proposes that JAK2V617F mutated
patients exhibit higher levels of proteins involved in angiogenesis compared
with CALR mutated and triple negative counterparts. These findings suggest
that CALR mutated and triple negative patients may present a less aggres-
sive course of the disease than JAK2V617F mutated ones. FAPESP
2012/12957-5.
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THE MUTATION OF THE SPLICING GENE SRSF2 PERFORMED BY HRM
SCREENING IN THE DIAGNOSIS OF CMML
M. Torres Ochando1,* C. Bilbao Sieyro1, M.T. Gómez Casares1, G. Santana
Santana1, T. Molero Labarta1
1Hematology, Dr. Negrin Hospital, Las Palmas, Spain
Background: Recent works associate the mutation of the splicing gene
SRSF2 (PRO95) with chronic myelomonocytic leukemia (CMML), a clonal
complex neoplasm that belongs to the group of myelodysplastic
syndromes/myeloproliferative neoplasms (MDS /MPN) of the 2008 WHO clas-
sification, reaching a prevalence of 40- 50%. This gene is located on chro-
mosome 17q25.1, is involved in the regulation of the stability of DNA and its
mutation coexists with others in a high prevalence.
Aims: The aim of this retrospective study was to analyze SRSF2 mutations
using high resolution melting (HRM) as a screening method, in a series of
patients diagnosed with CMML and its relationship with different variables
which will be discussed below.
Methods: We included 96 patients diagnosed and followed up between 2010-
2014: CMML (n=36, CMML-1, 78% (n=28), CMML-2, 22% (n=8). FAB:
Myelodysplastic 42% (n=15), myeloproliferative 58% (n=21)), MDS and AML
(n=50), other (n=10) (3 CLL, 2 thrombocytosis, 1 ITP, 1 HL, 3 MGUS). We
used DNA from total bone marrow nucleated cells. The samples were studied
by real-time PCR and HRM as a screening method. Primers were described
by Terra L.Lasho et al. (Blood 2012 120: 4168-4171) with a PCR product of
327 bp. By Melting analysis we obtained 2 possible results, mutated vs non
mutated. The analysis was done in duplicate, including C +, C- and wild type
reference. The positive cases were sequenced by Sanger method. We did
not observe false positives or negatives when we sequenced the results
obtained by HRM. Statistical analysis was performed by Clopper-Pearson
method for the analysis of the prevalence, Log Rank (Mantel-Cox), Breslow
(Generalized Wilcoxon), Tarone-Ware method for OS analysis, Mann-Whitney
test to compare the medians, student t-test was applied to compare means.
Results: 79.3% (23/29) of patients with CMML and 20.7% (6/29) of the
patients with MDS and AML presented SRSF2mut. None of the 10 patients
with other diagnosis showed mutations. We observed a significant association
(P<0.001) between SRSF2mut and CMML, in our series of patients. A bivari-
ate analysis was performed in the group of 36 patients with CMML, in relation
to the presence or absence of SRSF2mut (details on Table 1). SRSF2mut
prevalence in this subgroup was 63.89%. The mutational profile observed
(n=21) was p.Pro95His (n=10) p.Pro95Leu (n=4) p.Pro95Arg (n=3) 24bp del
(n=3). Karyotype at diagnosis was normal in 15 patients. The mean age at
diagnosis was 71 years, with no age difference observed in relation to
SRSF2mut (SRSF2mut=71.87 years vs SRSF2wt=69.54 years). A higher
prevalence of SRSF2mut was observed in myeloproliferative FAB variants
(71.4% (n=15) (P=0.310)) and type 2 OMS (75.0% (n=6) (P=0.682)). Hemo-
globin levels were similar in both groups (10.57 g/dl for SRSF2mut and 11.06
for SRSF2wt). The mean platelet count was lower for patients with
SRSF2mut, 125000/ul vs 205000/ul for SRSF2wt, (p=0.058). The median
survival time was 4 years (Me=5.1 years). The treatment and follow-up were
not homogeneous. There was no difference in survival between the two
groups (P=0.396). Of interest, 17 patients with CMML-1 WHO progressed to
type 2. All of them were SRSF2mut. Three patients progressed to AML, all
were SRSF2mut. One patient with CMML-1 (WHO) presented 2 spliceosome
mutations (SRSF2mut and SF3B1mut.).
Table 1.
Summary and Conclusions: We found a higher association between
SRSF2mut and CMML in our series of patients than others reported before,
maybe it depends on the use of HRM as a screening method. We found also
a tendency in the association of myeloproliferative FAB subtypes and type 2 of
WHO with SRSF2mut, as well as with a lower platelet count. Whether this
mutation is or not associated with increased aggressiveness of the disease
should be proved. Based on our results, detection of SRSF2mut by HRM
screening could be a useful diagnostic tool in CMML since is a feasible tech-
nique that could be easily performed in hematology diagnostic laboratories.
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FINDING MOLECULAR/EPIGENETIC SIGNATURES IN PHILADELPHIA NEG-
ATIVE MPNS: A NOVEL TOOL FOR STRENGTHENING DISEASE STATUS
CLASSIFICATION AND TAILORING PERSONALIZED DRUG STRATEGIES 
R. Garcia 1M. Roldan 2P. Altea 2M. Rivas 1A. Fernandez 1A. Rosell 1J. Ruiz
1M. Martin 2,*
1Hematology-Ibima, Hematology Department, Hospital Virgen de la Victoria,
Campus Teatinos SN 29010, Malaga, 2Molecular Oncology, GENYO. University
of Granada Centre for Genomics and Oncological Research, Granada, Spain
Background: Nowadays, there is a lack of data addressing possible epigenetic
alterations and their impact on disease status/evolution in Philadelphia-negative
myeloproliferative neoplasms (MPNs). Even so, a significant number of clinical
trials are currently using inhibitors of histone deacetylases, but little is precisely
known about the impact of histone modifications and chromatin remodeling in
MPNs (1). In line, only in a recent study has been shown a correlation between
phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts,
in a preclinical study using JAK2 (V617F)-driven disease models (2). In JAK2
mutant cells, it has been already proposed a prominent role of Akt/mTOR path-
ways besides Jak/Stat itself (3). Nonetheless, it is plausible to conceive that
the pathogenic mechanism operating in these cells might ensue from a complex
network of adaptational changes, affecting sequentially other signalling path-
ways such as Sonic Hedgehog. 
Aims: Hence, we propose that in MPNs, it would be crucial to find out combina-
torial profiles of molecular/epigenetic targets. Thus, the so-called “Molecular/Epi-
genetic Signatures”, would have the potential to address unresolved questions
in the prognosis and therapeutic of MPNs: i) establishing an improved starting
diagnostic profile at the molecular/epigenetic level; ii) potential capacity for better
disease prognosis; iii) implementation of tailored drug strategies according to
patient profiles; iv) novel tool for following up the therapeutic efficacy, providing
a guide to address “drug decision making” (including second line strategies). 
Methods: Accordingly, we studied molecular/epigenetic signatures in a
JAK2V617F CD34+ cell model, based on combinatorial profiles composed by:
Akt/mTOR activity; histone deacetylases (HDACs) activity; acetylated-lysine 4
of histone 3 (H3K4Ac); and Gli1 expression level, as a master transcription factor
in Sonic Hedgehog pathway. In addition, we aimed to test the effect of single and
double drug treatments on the proposed combination of markers using Ruxoli-
tinib, a JAK2 inhibitor; Panobinostat, pan-HDACs inhibitor; LDE225, antagonist
of the Sonic Hedgehog signalling downstream target Smoothened; BMK120, a
class I PI3K inhibitor; and Everolimus, an mTOR inhibitor (all the drugs kindly
provided by Novartis Pharma). Moreover, we aimed to address whether sequen-
tial drug additions in double-drug treatment strategies would provide significant
advantages versus classical combinatorial (simultaneous) additions.
Results: The molecular/epigenetic profiles investigated here shed novel sig-
natures with potential to establish a more detailed disease status diagnosis
(see supporting Figure for details). Moreover, the molecular/epigenetic signa-
tures correlated well with the impact on cell viability/proliferation of the different
drug treatments assayed in our cell model, thus turning out as a potent profiling
tool to test the efficacy of different therapeutic strategies. In addition, the
sequential drug strategies for Ruxolitinib+Panobinostat, and Ruxolitinib+
LED225, displayed clear advantage versus combined (simultaneous) additions,
based on a two ways effect: by improving its efficacy reducing cell viability/pro-
liferations capacity, and reducing drug toxicity side effects in control cells by
decreasing drug concentrations. Our data could open the pave to solve the
aforementioned unresolved questions in the prognosis and therapeutic inter-
vention of MPNs.
Figure 1.
Summary and Conclusions: Our data could open the pave to solve the afore-
mentioned unresolved questions in the prognosis and therapeutic intervention
of MPNs.
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TNIP1 AS A NOVEL REARRANGEMENT PARTNER FOR 5Q32 PDGFRB
IN EOSINOPHILIA-ASSOCIATED MYELOID NEOPLASM
A. Buijs1,* L. van der Veken1, S. Wittebol2
1Medical Genetics, University Medical Center Utrecht, Utrecht, 2Internal Med-
icine, Gelderse Vallei Hospital, Ede, Netherlands
Background: A 5q32 PDGFRB rearrangement is a diagnostic criteria for a
rare distinctive myeloproliferative neoplasm (MPN), often presenting with promi-
nent eosinophilia. Most common is a t(5;12)(q32;p13) resulting in an ETV6-
PDGFRB fusion mRNA. Variant translocations with a 5q32 PDGFRB gene
rearrangement present with other fusion genes. In all cases the result is an
aberrant, constitutive activation of the tyrosine kinase receptor. To date more
than 19 PDGFRB rearrangement partners have been reported. The identifica-
tion of PDGFRB-rearranged MPNs is of utmost diagnostic and therapeutic
importance, as in the pre-imatinib era acute transformation could occur within
a relatively short period of time. PDGFRB rearranged MPNs have been shown
to be sensitive to tyrosine kinase inhibitors such as imatinib.
Aims: Here we reported on a 76-years-old woman, recently presenting with a
MPN with leukocytosis, thrombocytosis, eosinophilia and mastocytosis.
Results: GTG banding of cultured bone marrow resulted in a normal female
karyotype. Eosinophilia prompted us to investigate the status of PDGFRA,
PDGFRB and FGFR1 by FISH analyses. Loss of a distal PDGFRB signal on
one chromosome 5 was demonstrated using 5q32 PDGFRB rearrangement
probes, suggesting either an interstitial deletion or an unbalanced translocation
involving 5q32 PDGFRB. Subsequent FISH analysis using a 5q subtelomere
probe was indicative for a deletion. SNP-array analysis (CytoSNP-850k;Illumi-
na) demonstrated an ~897 kb deletion likely with breakpoints within the 5q32
PDGFRB and 5q33.1 TNIP1 genes.
Summary and Conclusions: TNIP1 encodes TNFAIP3-interacting protein
1, a negative co-regulator of the NF-kB pathway. Loss-of-function mutations
in TNIP1 have been reported in diffuse large B-cell lymphoma (DLBDL), and
TNIP1 splice variants have been implicated in lymphoma and acute myeloid
leukemia (AML). The transcriptional orientation of TNIP1 and PDGFRB would
allow expression of a 5’ TNIP1-PDGFRB 3’ fusion mRNA, in line with other
PDGFRB gene fusions. The amino-terminal TNFAIP3-interacting protein 1
moiety that would be present in a TNFAIP3-interacting protein 1-PDGFRB
chimeric protein contains several coiled-coil domains, which is canonical for
dimerization and constitutive activation of the tyrosine kinase domain of
PDGFRB. The patient has started treatment using 400 mg of imatinib daily.
We will present on ongoing molecular characterization and treatment-
response of the MPN with this novel, cytogenetically cryptic TNIP1-PDGFRB
gene rearrangement. Our data underscore testing for cryptic rearrangements
in MPN with eosinophilia.
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ACTIVATED STAT5 AS NOVEL STEM TARGET IN JAK2 V617F POSITIVE
MYELOPROLIFERATIVE NEOPLASMS (MPN)
E. Hadzijusufovic1,2,3,* A. Keller2, F. Schur1, S. Cerny-Reiterer1,2, G. Hoermann4,
M. Mayerhofer5, C. Boudot6, F. Gouilleux6, L. Müllauer7, R. Moriggl8, P. Valent1,2
1Department of Medicine I, Medical University of Vienna, 2Ludwig Boltzmann
Cluster Oncology, 3Department of Internal Medicine, University of Veterinary
Medicine Vienna, 4Department of Laboratory Medicine, Medical University of
Vienna, 5Hanusch Hospital, Vienna, Austria, 6Faculté de Pharmacie, Université
de Picardie Jules Verne, Amiens, France, 7Department of Clinical Pathology,
Medical University of Vienna, 8Ludwig Boltzmann Institute for Cancer
Research, Vienna, Austria
Background: Myeloproliferative neoplasms (MPN) represent the most com-
mon myeloid neoplasms and have an increasing incidence in the Western
World. Three major categories of JAK2 V617F+ MPN have been defined by
the WHO: essential thrombocythemia (ET), polycythemia vera (PV), and pri-
mary myelofibrosis (PMF). Currently, drug therapies used in JAK2 V617F+
MPN are only able to suppress abnormal cell production for a certain time peri-
od but are not able to eradicate the disease, which may be due to resistance
of neoplastic stem cells (NSC). However, so far little is known about target
expression profiles in MPN NSC. The JAK2-STAT5 pathway has recently been
implicated as a potential target-pathway in CML NSC. This pathway also medi-
ates proliferation and survival in MPN cells. It has also been described that
mutated JAK2 leads to STAT5 overexpression and STAT5 activation in MPN.
However, little is known about expression and function of STAT5 in MPN NSC.
Aims: The aims of our project were to examine the expression of activated
STAT5 (pSTAT5) in putative CD34+/CD38- NSC in JAK2 V617F-transformed
MPN and to ask whether pSTAT5 serves as a therapeutic NSC-target.
Methods: We analyzed 32 bone marrow (BM) samples obtained from patients
with JAK2 V617F+ MPN, 17 BM samples obtained from patients with JAK2
V617F- MPN, and 7 non-reactive BM samples. Expression of pSTAT5 in NSC
was determined by flow cytometry. Furthermore, we employed two JAK2
V617F+ cell lines, HEL and SET-2. The effects of JAK2- and STAT5-targeting
drugs on proliferation were examined by measuring 3H-thymidine uptake, and
drug effects on apoptosis were examined by assessing the levels of activated
caspase-3 by flow cytometry. We used two STAT5 inhibitors, pimozide and
piceatannol, and four JAK2 inhibitors: AZD1480, TG101348, R763 and ruxoli-
tinib. In select experiments, the effects of STAT5- and/or JAK2 inhibitors on
primary MPN cells were examined.
Results: We have detected a significantly higher expression of pSTAT5 in
the putative CD34+/CD38- NSC fractions in our JAK2 V617F+ MPN patients
when compared to normal CD34+/CD38- BM stem cells. JAK2 V617F-
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patients showed no statistically significant difference in pSTAT5 expression
in the stem cell compartment compared to normal stem cells. As assessed
by flow cytometry, immunocytochemistry and Western blotting, HEL cells and
SET-2 cells were found to constitutively express pSTAT5, and that incubation
with STAT5- or JAK2 blockers leads to a decrease in pSTAT5 expression. In
addition, we found that all JAK2 inhibitors and all STAT5 inhibitors counteract
proliferation in HEL cells and SET2 cells, and in most instances these drugs
also induced apoptosis in these cell lines (IC50 and ED50 values are shown
in the Table 1). Similar effects were found when the targeting drugs were
applied on BM cells isolated from MPN patients. Again, all drugs tested were
found to suppress proliferation of MPN cells in a dose-dependent manner. In
one experiment, we examined the effects of the JAK2 blockers on
CD34+/CD38- cells in a BM sample isolated from a patient with ET. Here,
only TG101348 (5 µM, 48 hours) was able to decrease the numbers of NSC
significantly, whereas the other JAK2 inhibitors showed only slight effects on
CD34+/CD38- NSC.
Table 1.
Summary and Conclusions: In summary, our data show that NSC in JAK2
V617F+ MPN express pSTAT5, and that targeting of STAT5 may be a novel
interesting approach to control NSC expansion in these malignancies. Whether
drug-induced suppression of pSTAT5 in NSC is effective clinically remains to
be determined in clinical trials.
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PROGRESSION TO MYELOPROLIFERATIVE NEOPLASMS WAS ASSOCI-
ATED WITH MUTATIONS OF THE JAK2 AND CALR GENES IN PATIENTS
WITH IDIOPATHIC LEUKOCYTOSIS AND THROMBOCYTOSIS
N. Mori1,* K. Yoshinaga1, M. Ohwashi1, M. Shiseki1, J. Tanaka1
1Hematology, Tokyo Women’s Medical University, Tokyo, Japan
Background: Idiopathic leukocytosis and erythrocytosis are hematological dis-
orders without specific causes. Frequent V617F mutations on the JAK2 gene
have been reported in patients with polycythemia vera (PV), essential throm-
bocythemia (ET), and primary myelofibrosis (PMF). We also found JAK2 V617F
mutations in one of 11 patients with idiopathic erythrocytosis. Recently muta-
tions of the CSF3R, SETBP1, and ETNK1 genes have been found in chronic
neutrophilic leukemia and atypical chronic myeloid leukemia. Moreover an auto-
somal mutation was found in the CSF3R gene in a family with chronic neu-
trophilia. However, mutations associated with idiopathic leukocytosis and unex-
plained thrombocytosis have largely been unknown.
Aims: To elucidate the relevance of gene mutations, we analyzed mutations of
the CSF3R, JAK2, CALR, SETBP1, and ETNK1 genes in idiopathic leukocy-
tosis and thrombocytosis.
Methods: Leukocytosis is defined as a total white blood cell (WBC) count more
than two standard deviations above the mean, or a value greater than
11,000/μL. Those patients who satisfied the following criteria were included in
the study: leukocytosis (predominantly neutrophils); the absence of apparent
causes of leukocytosis; and documentation of the leukocytosis over a prolonged
period of time. The period of observation was 1 year or longer in most patients.
Those patients with unexplained persistent thrombocytosis (greater than
350,000/μL) who did not satisfy the criteria of ET (World Health Organization
classification) were included in the study. Neutrophils or mononuclear cells
were collected obtaining written informed consent from 16 patients with idio-
pathic leukocytosis (n=10), thrombocytosis (n=3), PV (n=1), and ET (n=2). Five
of the patients were males and 11 were females. Neutrophils from peripheral
blood were purified by dextran sedimentation followed by hypotonic lysis and
centrifugation with Ficoll-Conray. Mononuclear cells were isolated from bone
marrow by Ficoll-Conray gradient centrifugation. Genomic DNA was extracted
using the QIAamp DNA blood mini kit (Qiagen, Valencia, CA, USA). Mutations
within hot spots of the CSF3R, JAK2, CALR, SETBP1, and ETNK1 genes were
analyzed by direct sequencing in both directions using a 3730xL DNA Analyzer
(Life technologies, Carlsbad, CA, USA) and/or allele specific polymerase chain
reaction analysis. The current study was conducted within the guidelines and
with the approval of ethical committee.
Results: JAK2 V617F mutations were found in one of the 10 patients with idio-
pathic leukocytosis, one PV patient, and one of the two ET patients. No mutations
of the CSF3R, SETBP1, and ETNK1 genes were found in idiopathic leukocytosis,
thrombocytosis, PV or ET patients. Type 1 mutations of the CALR gene were
detected in two of the three unexplained thrombocytosis, and one of the two ET
patients. All of the three patients with the type 1 mutations of the CALR gene
were females. One idiopathic leukocytosis patient with JAK2 V617F mutation has
developed PV, whereas one idiopathic leukocytosis patient without the mutations
has developed leukemia. The other 8 patients with idiopathic leukocytosis have
a stable disease. One patient with unexplained thrombocytosis developed MF.
Summary and Conclusions: Our study suggests that idiopathic leukocytosis
and unexplained thrombocytosis are heterogeneous conditions regarding muta-
tions of the JAK2 and CALR genes and clinical courses.
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TO TAKE HOME: HOW MUCH VALUE IS LOW BURDEN OF JAK2 V617F
ALLELE MUTATION?
L. Torres-Miñana1,* M. Moreno1, N. Cruz1, C. Bilbao1, J. Gonzalez2, G. Santana1,
T. Gomez-Casares1, T. Molero1
1Hematology, 2Statistical Service, H. Dr Negrin GC, Las Palmas de GC, Spain
Background: The discovery of the JAK2 V617F mutation and its association
with distinct haematological and clinical characteristics has prompted studies
to assess the predictive value of JAK2 V617F and the allele burden for the
most common complications of Mieloproliferative neoplasm (MPN, like
Policitemic Vera -PV-, Essential Thrombocitosis -ET-, Myelofibrosis -MF-), and
its relationship with prognosis and survival. The studies support the contention
that quantification of JAK2 V617F allele burden might convey relevant clinical
information in well-defined categories of MPN cases. They also show that a
high JAK2V617F allele burden is associated with more severe disease with
lower hemoglobine, more prevalent massive splenomegaly, increased rate of
venous thrombosis (VT) and higher prevalence of bleeding events.
Aims: In this study we compare clinical and hematologic characteristics of
patients with low allele burden with the rest.
Methods: In this retrospective study, we selected peripheral blood samples of
89 patients with Ph-negative MPNs. 45 were men and 44 women, with ages
between 27 and 86 years old (mediane 53 years). We analyzed JAK2V617F sta-
tus, the allele burden and its relationship with hematologic and clinical parameters
like bleeding, deep vein thrombosis among others. The cutoff value for the allele
burden was set to ≥10% for high and intermediate levels and <10% for low levels.
JAK2 V617F mutation analysis was performed through High Resolution Melting
and Sanger sequencing. For the statistical analysis, patient’s characteristics were
compared by Fisher’s exact test for categorical variables, Mann-Whitney U test
for continuous variables and Shapiro. Wilk to check the normality of the data of
quantitative variables. All analyses were two sided, and significance was set at a
p- value of 0.05. SPSS statistical package (v. 15.0) was us.
Results: In our series 20.2% of the cases presented low allele burden (PV
1/46, ET 14/34, MF 3/9). The presence of low allele burden was not associated
with hematologic parametres compared to high and intermediate burden. In
PV, arterial thrombosis was detected in 0% of low buden cases compared to
high burden cases with 24% incidencie (p>0,05). On the same way, there was
VT in 20% of high burden cases versus 0% of low burden cases. On the other
hand, arterial thrombosis cases in patients with ET happened in 3% with low
budden and 6% with high and intermediate burden; in VT cases, there were
14.3% episodes in low burden and 20% cases with high and intermediate bur-
den. The allele burden was not associated with the necessity of transfusions,
phlebotomy or bleeding. In ET, patients with low allele burden presented lower
use of hydrea (p=0,035). We found that 16.7% of deaths presented low burden
in contrast to 83% with high and intermediate burden.
Summary and Conclusions:-According to our results, PV and TE patients
with low JAK2 V617F allele burden presented lower vein and arterial thrombotic
risk. - Patients with ET with low allele burden would require with lower frequency
hydrea treatment and it is probably relationated to myeloproliferative activity. -
We need to increase our series in order to confirm our results, nevertheless,
we believe that to get a better insight about the stratification of patients accord-
ing to mutant allele burden may be important to achieve a personalized and
more specific/effective treatment.
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CHRONIC INFLAMMATION BIOMARKERS IN MYELOPROLIFERATIVE
NEOPLASMS
V. Čokić1,* J. Santibanez1, D. Šefer2, S. Vignjević1, D. Marković1, M. Buač1,
D. Djikić1, M. Budeč1
1Institute for Medical Research, University of Belgrade, 2Clinic of Hematology,
Clinical Center of Serbia, Belgrade, Serbia
Background: Chronic inflammation contributes to the initiation and pathophysi-
ology of cancers, including myeloproliferative neoplasms (MPNs). Unfortunately
the new JAK1/2 inhibitors act only on symptoms and currently there is no cure
for MPNs. The recent JAK1/2 inhibitor trials in MPNs unexpectedly showed that
reducing inflammation can be more beneficial to patients than targeting gene
mutants. Among chronic inflammation biomarkers, TGF-β and IL-6 have a central
role, possessing both immunomodulatory and fibrogenic activities. TGF-β upreg-
ulates IL-6 and the levels of these cytokines are increased in MPNs.
Aims: We aim to evaluate the pro-inflammatory TGF-β, IL-6, NF-kB and anti-
inflammatory IL-10 signaling pathways in MPNs.
Methods: We analyzed 63 patients with essential thrombocythemia (ET), 92
with polycythemia vera (PV), and 50 with primary fibrosis (PMF), and per 10
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patients with secondary erythrocytosis and healthy controls. To evaluate the
proposed signaling pathways in CD34+ hematopoietic progenitors, of 20 MPN
patients, microarray analysis was used.
Results: Statistically significant leukocytosis was observed in PV vs secondary
erythrocytosis and in JAK2V617F mutation positive vs negative PMF patients.
Moreover, thrombocytosis was generally present in MPNs, while JAK2V617F
allele burden significantly decreased the level of thrombocytosis in ET and
PMF. Regarding TGF-β signaling related genes of hematopoietic progenitors:
transcription factor Dp-1 (TFDP1) was significantly decreased in PMF, while
cyclin-dependent kinase inhibitor 2B (CDKN2B) was increased in PV vs con-
trols. Also, bone morphogenetic protein receptor, type II (BMPRII) was
enhanced in ET and PV, whereas TGF-β receptor 1 in all MPNs. Regarding IL-
6 signaling pathway related genes: interleukin 6 signal transducer (IL6ST) and
mitogen-activated protein kinase kinase 1 (MAP2K1) were increased in ET
and PV vs healthy controls. Considering NF-kB signaling related genes: tumor
necrosis factor receptor superfamily (TNFRSF1A) and TNFRSF1A-associated
via death domain (TRADD) were increased in PMF and PV, respectively. In
addition, TNFRSF1A had more prominent overexpression in JAK2V617F muta-
tion positive patients than in MPN patients with no JAK2V617F mutation, reach-
ing statistical significance in ET. Analysis of IL-10 signaling pathway related
genes revealed significant increase of biliverdin reductase A (BLVRA) and
heme oxygenase 1 (HMOX1) in PV and ET, respectively.
Summary and Conclusions: The presented inflammation biomarkers will pro-
vide a better understanding of molecular mechanisms implicated in the devel-
opment and progression of MPNs.
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THE PRESENCE OF THE JAK2V617F POINT MUTATION AFFECTS
OSTEOCLAST FUNCTION IN PATIENTS WITH CHRONIC MYELOPROLIF-
ERATIVE NEOPLASMS
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Background: Myeloproliferative neoplasms (MPN) patients are at increased
risk for femoral fracture and the development of osteoporosis, compared to
age-matched population groups (1). The JAK2V617F is a gain of function point
mutation that occurs frequently in MPN patients and deranges many cellular
properties of their hemopoietic cells.
Aims: Therefore we speculate that genetically modified JAK2 can slightly mod-
ify osteoclast homeostasis, a gain of function that can be implicated in
increased bone resort ion and deregulation of the hematopoietic stem cell niche
in MPN patients.
Methods: Peripheral blood was drawn from 18 newly diagnosed MPN patients
(14 essential thrombocythemia, 2 primary myelofibrosis, 2 polycythemia vera
diagnosed according to 2008 WHO criteria) and from 4 age-matched normal
donors (ND). Osteoclast (OCL) forming assays were started from 2x105 posi-
tively selected monocytes. OCL were formed also under the presence of the
pan-JAK Inhibitor AG-490. Genomic DNA was extracted from the formed osteo-
clasts and the JAK2V617F/JAK2WT genomic DNA ratio was calculated by
using the Taqman based JAK2MutaQuant Kit (IPSOGEN). Comparisons
between groups were performed by using the Mann-Whitney for unpaired and
the Wilconxon Rank test for paired samples.
Results: OCLs formed from monocytes derived from heterozygous for the
JAK2V617F mutation (+/-) MPN patients, were significantly more compared to
those from the JAK2 wild type(WT) MPN patients and to ND as well [OCL per
10.000 monocytes, Median Value of osteoclasts (MV) (min-max) was for
JAK2V617F (+/-) MPN patients: 960 (159-3674), for JAK2 WT MPN patients:
204 (81-1286), p=0.03, and for ND was: 322 (215-522) and p=0.05 when com-
paring JAK2V617F(+/-) to ND, Mann-Whitney test]. The ratio of
JAK2V617F/JAK2WT genomic DNA was increased in OCLs compared to the
input monocyte cells. The median enrichment of OCLs for the JAK2V617F
mutated clone was 12% (3.3%>26% and p<0.01, Wilconxon Rank test). Com-
pared to ND OCLs from patients with JAK2V617F (+/-) are more susceptible
to JAK2 inhibition (Mann-Whitney test, p=0.03) but this was not statistically
significant for JAK2 WT MPN patients (Mann-Whitney test, p=0.1).
Summary and Conclusions: The acquisition of the JAK2V617F point mutation
in hematopoietic cells capable for osteoclastogenetic differentiation provides them
with increased OCL forming ability but these OCLs are concurrently becoming
more vulnerable to JAK2 kinase inhibition. This deregulation in osteoclast home-
ostasis can contribute to osteoporosis development in MPN patients and probably
in the mobilisation of hemopoietic progenitor cells towards the periphery.
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SEQUENCING FOR MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED
MUTATIONS
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Background: Classic myeloproliferative neoplasms (MPN) include poly-
cythemia vera, essential thrombocythemia and primary myelofibrosis and share
an association with molecular abnormalities such as JAK2V617F or CALR
mutations. Numerous somatic mutations have been identified in MPN patients
including mutations in signaling pathways, in epigenetic or splicing regulators,
and in oncogenes. Although the relationship between mutations and the patho-
physiology of MPN is not clear, some mutations are important for diagnostic
classification whereas others have prognostic relevance, making more preg-
nant the need for high throughput sequencing approaches. Next generation
sequencing (NGS) is capable of quickly allowing the assembly of a single mul-
ti-gene panel relevant to MPN, but as NGS becomes a clinical tool, a full under-
standing of the variables affecting sequencing analysis output is required.
Aims: In this multicentric study, we evaluated different NGS platforms 1) for
their robustness in the identification of mutations relevant to MPN diagnosis,
and 2) by comparing quantitative data for these variants.
Methods: Four laboratories participated in this study. All of them analysed 14
DNA samples from MPN patients. Two NGS platforms (MiSeq-Illumina (n=3),
PGM-Ion Torrent (n=1)) with different exon sequencing approaches (amplicon
sequencing (TSCA-Illumina (n=2), AmpliSeq-Lifetech (n=1) or Haloplex-Agilent
(n=1)) were evaluated. The gene panels slightly differed between groups, but
a common set of 10 genes was present in each center: JAK2, MPL, ASXL1,
TET2, EZH2, IDH1, IDH2, DNMT3A, LNK, SRSF2. Sequencing data were
analysed on each platform using local pipelines (VariantStudio-Illumina (n=2),
SureCall-Agilent (n=1) and IonReporter-life tech (n=1)) and compared between
laboratories with variant allele frequencies (VAF)>2% and depth>50X filters. 
Results: Comparative analysis of all labs found 32 mutations, all validated by
Sanger sequencing or allele-specific PCR, on 8 common genes. Twenty four
(75%) of these mutations on 6 genes were detected by all platforms with VAF
between 12% and 85%. The discrepancies between labs focused on 2 genes:
ASXL1 and SRSF2. PGM platform missed all deletions or duplications in ASXL1
gene (4/4). Low coverage was observed for SRSF2 hotspot point mutations in 2
platforms (AmpliSeq-PGM and TSCA-MiSeq). Three labs have integrated CALR
gene on their panel design, only the lab using SureCall analysis identified large
deletions in this gene. We observed a tight correlation of JAK2V617F VAF (23%
to 85%, n=9) among the different platforms (standard deviation average (SDA):
2.4, range: 0.37-3.94). In addition the different NGS technologies were well cor-
related with qPCR results (r²=0.86). Excepted for 2 frameshift variants in
DNMT3A and ASXL1, an excellent reproducibility was observed in quantitative
values of VAF (n=32 mutations) among participants (SDA: 4.35, range: 0.37-
19.5).
Summary and Conclusions: This inter-laboratory comparison demonstrates
that NGS is a reliable technology for mutations screening in MPN and would
permit a rapid molecular characterization. Moreover, we observed an excellent
accuracy of quantitative evaluation of VAF in particular with comparable results
between NGS and qPCR for JAK2V617F, and a good reproducibility regardless
platform characteristics and chemistry approaches. In summary, although cus-
tomized optimization to enhance variants detection remains necessary (low
depth, bioinformatics tools for indel detection), this comparative assessment
of NGS pipelines gives important insights into sequencing and analysis strate-
gies for routine hospital transfer. 
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A 7- GENE SIGNATURE DEPICTS THE BIOCHEMICAL PROFILE OF EARLY
PREFIBROTIC MYELOFIBROSIS
V. Skov1,* M. Burton2, M. Thomassen2, T. Stauffer Larsen3, C. Hasselbalch
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Background: The Philadelphia-negative myeloproliferative neoplasms include
essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofi-
brosis (PMF). Recent studies have shown that a large proportion of patients
classified as ET actually have prefibrotic myelofibrosis (pre-MF). Because prog-
nosis and likely in the future also treatment of both entities are different, it is
important to distinguish between them. According to the WHO classification,
bone marrow histology is a major component of the distinction between ET
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and pre-MF. However, the differential diagnosis between these two entities can
be challenging.
Aims: We aimed at identifying a simple gene signature-composed of a few
genes-which were able to distinguish true ET from pre-MF. 
Methods: Gene expression profiles have been generated on whole blood from
17 patients with ET using Affymetrix HG-U133 2.0 Plus microarrays. Seven
carefully chosen genes were used to develop a supervised classification model
to predict the signature of ET patients. The biochemical variables lactate dehy-
drogenase (LDH) and leukocyte count were used to divide patients into sub-
groups, taking into account that the leukocyte count may be elevated in ET
and pre-MF due to other factors than the myeloproliferation per se (e.g. inflam-
mation and other cancer), whereas the LDH is elevated in myeloproliferative
cancer only as a result of clonal myeloproliferation provided that other reasons
are excluded (e.g. liver disease and hemolysis). In addition, we a priori assumed
the leukocyte count to be normal in “genuine” ET (no increase in granu-
lopoiesis), whereas pre-MF is often associated with an elevated leukocyte count
and thrombocythemia. Bone marrow biopsies from 14 of the 17 patients were
evaluated by 4 independent hematopathologists. 
Results: Based on the LDH and leukocyte values, 9 patients were assigned to
the ET group and 8 patients were assigned to the pre-MF group; however, the
composition of patients in the LDH and leukocyte groups differed. Using LDH
as the clinical variable, the resulting 7-gene signature including MPO, CEA-
CAM8, CRISP3, MS4A3, CEACAM6, HEMGN, and MMP8 correctly predicted
8 of 8 patients in the pre-MF group (sensitivity 100%) and correctly classified
8 of 9 patients in the ET group (specificity 89%) and showed a balanced accu-
racy of 94%. Using the leukocyte value as the clinical variable, the 7-gene sig-
nature resulted in 62% sensitivity, 78% specificity, and a balanced accuracy of
70%. The performance of the 7-gene signature using LDH as the clinical vari-
able was tested against the bone marrow evaluation from the hematopatholo-
gists showing a concordance of 71%, 79%, 62%, and 38%. Gene ontology
analysis and literature research show that the 7 genes are involved in key
processes associated with the pathophysiology of MPNs. CRISP3, MMP8 and
MPO are neutrophile granula proteins that play important roles in immune and
inflammatory responses. CEACAM6 and CEACAM8 are involved in cell adhe-
sion, cellular invasiveness, angiogenesis, and inflammation. MS4A3 is a
hematopoietic cell cycle regulator, and HEMGN plays an important role in dif-
ferentiation, proliferation and hematopoietic development.
Summary and Conclusions: Supervised classification was able to distinguish
between ET and pre-MF with a balanced accuracy of 94%. Our findings suggest
that classification using LDH as the clinical variable may add support to the
clinical diagnosis of these two entities. Prospective studies of a larger cohort
of patients are being planned to substantiate LDH as a simple parameter in the
distinction between ET and pre-MF.
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PLATELET ANALYSIS INCREASES THE DETECTION OF MUTATIONS IN
TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS
A. Angona1,2,3,* C. Besses1,2, A. Alvarez-Larrán1,2,3, L. Camacho2, R. Longarón2,4,
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Background: Mutations in JAK2 (50-60%), CALR (15-30%) and MPL (1-5%)
have been identified in patients with essential thrombocythemia (ET). However,
there is still a percentage of ET patients (10-30%) who are wild-type for mutations
in these genes when isolated granulocytes or peripheral blood are analyzed. This
subgroup of patients called “triple-negative” has not been extensively studied
with regard to the presence of JAK2, CALR and MPL mutations in platelets.
Aims: To analyze JAK2V617F, CALR and MPL mutational status in platelets
from a cohort of triple negative ET patients.
Methods: From a whole cohort of 236 ET patients consecutively diagnosed in
a single institution, we included 33 ET patients (14%) lacking JAK2V617F
(determined by quantitative allele-specific PCR), MPL exon 10 mutations
(W515, S505; analyzed by Sanger sequencing) and CALR exon 9 mutations
(analyzed by PCR followed by fragment analysis) in granulocytes.
Mutational analysis. Platelet RNA was extracted with Trizol and 1ug total RNA
was reverse transcribed. The mutational analysis of JAK2V617F was performed
by quantitative allele-specific real time PCR. Analysis of exon 10 of the MPL
gene (S505, W515) was performed by next generation sequencing (NGS) (454
GS Junior, Roche), with a median coverage of 1335x (range 497-4863). Muta-
tions were confirmed by CAST-PCR. The mutational analysis of exon 9 of the
CALR gene was performed by PCR, using a 6-carboxyfluorescein labeled
reverse primer, followed by fragment analysis in a Genetic Analyzer 3500DX
(Applied Biosystems) or by NGS deep sequencing (454 GS Junior) with a medi-
an coverage of 1326.5x (range 607-1686).
Results: JAK2V617F was detected in 3 out of 33 (9.1%) patients analyzed,
with allele burdens of 16%, 20% and 33%. MPL mutations (W515L) were
detected in 3 out of 33 patients by NGS. Two cases with MPL W515L allele
burden of 12% and 26% in platelets were confirmed by CAST-PCR. The third
case with only a 3% of mutant allele burden was not confirmed. Interestingly,
the coexistence of JAK2V617F and MPLW515L was observed in one case with
a mutant allele burden of 16% and 12% respectively. Regarding CALR, two
cases showed deletions in exon 9 by NGS with allele burdens of 1% and 2%.
These mutations were not confirmed by fragment analysis.
Summary and Conclusions: In summary, we have confirmed the presence
of JAK2V617F and/or MPL mutations in 4/33 (12%) ET patients previously con-
sidered as triple-negative. Platelet analysis increases the sensitivity of driver
mutation detection in this subset of ET patients when compared to conventional
analysis on whole blood or isolated granulocytes. 
Acknowledgements. This study was supported in part by grants from ISCIII
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MAPK-JNK AND PI3K-AKT/PKB SIGNALING PATHWAY ACTIVATION
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Background: The classical BCR-ABL-negative myeloproliferative neoplasms
(MPN) are characterized by increased proliferation of hematopoietic precursors
in the bone marrow resulting in elevated numbers of terminally differentiated cells.
Despite the recent advances in the understanding of the biology of MPN, there
is still no curative treatment for MPN except for bone marrow transplantation.
The discovery of JAK-STAT constitutive activation in the majority of MPN patients
led to the development of clinical studies targeting MPN with Ruxolitinib, a JAK1/2-
specific inhibitor. However, despite achieving significant reductions in
splenomegaly and symptomatic improvement in MPN patients, JAK inhibition
failed to induce complete remissions and eradicate the malignant clone. In alter-
native, histone deacetylase inhibitors have shown success in the treatment of
several hematological malignancies but their efficacy in MPN is limited.
Aims: Given that both Ruxolitinib and the HDAC inhibitor Vorinostat fail to erad-
icate the neoplastic clone in MPN patients, we investigated the hypothesis that
the bone marrow stroma may confers resistance to these drugs by preventing
their cytotoxic effects on neoplastic cells.
Methods: We made use of a co-culture system in which MPN cell lines (SET-
2, HEL and UKE-1) are placed in direct contact with the HS-5 bone marrow
stromal cell line or its conditioned media. Upon exposure of MPN cells to the
bone marrow microenvironment and following treatment with different drugs,
the cells are harvested to analyze cellular viability, gene expression by quanti-
tative-PCR and signaling pathway activation by Western-blot.
Results: The treatment of the SET-2 cell line with both Vorinostat and Ruxolitinib
promoted apoptosis and decreased proliferation. However, apoptosis was signif-
icantly abrogated when SET-2 cells were cultured in the presence of a stromal
layer of HS-5 cells or HS-5 conditioned medium. The stroma protective effect
was maintained for up to 6 six days and was also dependent on drug concentra-
tion. The bone marrow stroma protective effect correlated with altered expression
in MPN cells of genes associated with inflammatory processes, apoptosis and
proliferation (CDKN1A, IER3, BIRC3, TNFRSF8, TNFRSF9, COX2, IL1B), and
with the activation of signaling pathways important for cellular homeostasis, such
as PI3K-PKB/Akt, MAPK-JNK, JAK-STAT and NF-κB as shown by increased
phosphorylation of PKB/Akt (Ser473); GSK3α/β (Ser9/Ser21); S6 (Ser235/236);
STAT3/5 (Tyr705/Tyr694) and p65/RELA (Ser536). Importantly, the pharmaco-
logical inhibition of PI3K-PKB/Akt and MAPK-JNK signaling pathways completely
abrogates the protective effect bone marrow stroma on SET-2 cells.
Summary and Conclusions: Overall, we show that bone marrow stroma pro-
tects MPN cells from the cytotoxic effects of two pharmacological agents of dif-
ferent classes: Vorinostat and Ruxolitinib. This protective effect is likely
achieved, through the up-regulation of genes associated with apoptosis (IER3,
BIRC3, TNFRSF9) and relies on the activation of pro-survival signaling path-
ways such as PI3K-PKB/Akt and MAPK-JNK. We did not observe any effects
of the bone marrow stroma on proliferation or differentiation, suggesting that
the main effect of bone marrow stromal cells is to prevent apoptosis of the neo-
plastic cells. Our results identify a possible cell non-autonomous mechanism
by which Ruxolitinib fails to eradicate the neoplastic clone in MPN patients and
may indicate novel therapeutic targets for MPN.
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Background: CALR mutations are detected in about 50% of persons of pre-
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dominately European descent with essential thrombocythemia (ET) or primary
myelofibrosis (PMF) with wild-type alleles of JAK2 and MPL. The role of CALR
mutations in the aetiology of ET and PMF is unknown and correlates between
CALR mutation, mutant allele burden and clinical features are being studied.
Aims: To study the frequency of CALR mutations and clinical correlates in Chi-
nese populations.
Methods: We studied 1088 Chinese with diverse myeloproliferative neoplasms
including ET (N=234) and PMF (N=50) without JAK2V617F or MPL exon 10
mutations. Detection of CALR exon 9 mutations was done by PCR amplification
followed by fragment length analysis and direct sequencing.
Results: CALR mutation was detected in 53% (95%CI, 46-60%) of subjects
with ET and 56% (95% CI, 41-70%) of subjects with PMF. 152 CALR mutations
were identified clustering into 15 types including deletions (N=8), insertions
(N=3) and complex indels (N=4). We also identified 9 new mutation (Figure1).
Mean (±SD) mutant allele burden was 31±12% (range, 0.5-69%). Persons with
PMF had higher CALR mutant allele burdens than those with ET (38±8% vs
29±12%; P<0.001). Amongst persons with CALR mutations, those with PMF
had different clinical features from those with ET.
Summary and Conclusions: These data may be useful for diagnosing ET
and PMF in Chinese who are about 40% of all persons with ET and PMF and
for monitoring therapy-response. They also highlight similarities and differences
in CALR mutations between Chinese and persons of predominately European
descent with these diseases.
Figure 1. Genomic positions of the 15 mutation types.
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ING PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS
V. Čokić1,* P. Mossuz2, R. Puri3, B. Beleslin-Čokić4, O. Mitrović-Ajtić1,
T. Subotički1, M. Diklić1, D. Leković5, M. Gotić5,6
1Institute for Medical Research, University of Belgrade, Belgrade, Serbia,
2Département d’Hématologie, Institut de Biologie et Pathologie, CHU Grenoble,
Grenoble, France, 3Division of Cellular and Gene Therapies, Center for Bio-
logics Evaluation and Research, Food and Drug Administration, Silver Spring,
United States, 4Clinic of Endocrinology, Diabetes and Diseases of Metabolism,
Clinical Center of Serbia, Belgade, 5Clinic of Hematology, Clinical Center of
Serbia, 6Medical faculty, University of Belgrade, Belgrade, Serbia
Background: The main target of activated phosphoinositide-3-kinase (PI3K)/AKT
is the serine/threonine kinase mammalian target of rapamycin (mTOR). JAK inhi-
bition, used in therapy of myeloproliferative neoplasms (MPNs), abolished the
activation of JAK/STAT and PI3K/mTOR signaling pathways.
Aims: We intend to reveal gene and protein markers of MPN pathogenesis,
with an accent to PI3K/AKT and mTOR pathway members and related genes.
Methods: Using cDNA microarray analysis of 25.100 unique genes, we studied
the gene expression profile of hematopoietic CD34+ progenitor cells and granu-
locytes obtained from peripheral blood of subjects with essential thrombocythemia
(ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The microarray
analyses of the hematopoietic progenitor cells and granulocytes were performed
from 20 MPN subjects: JAK2 positive ET, PV, PMF subjects, and JAK2 negative
ET, PMF subjects. The granulocytes for proteomic studies were pooled in 4
groups: PV with JAK2 mutant allele burden above 80%, ET with JAK2 mutation,
PMF with JAK2 mutation and ET/PMF with no JAK2 mutation.
Results: The number of differentially regulated genes was about two fold larger
in hematopoietic CD34+ progenitors compared to granulocytes. Thirty-six genes
(including RUNX1, TNFRSF19) were persistently highly expressed, while 42
genes (including FOXD4, PDE4A) were underexpressed both in hematopoietic
CD34+ progenitors and granulocytes. Using proteomic studies, significant upreg-
ulation was observed for MAPK and PI3K/Akt signaling regulators that control
myeloid cell apoptosis, differentiation and proliferation (GADD45B, CRIP1, SIPA1).
When the status of mTOR signaling pathway related genes was analyzed,
PI3K/Akt regulators were preferentially upregulated in hematopoietic progenitors
of MPNs, with downregulated major components of the protein complex EIF4F.
Summary and Conclusions: Molecular profiling of hematopoietic progenitors
and granulocytes of MPN determined gene expression patterns beyond their
recognized function in disease pathogenesis that included dominant upregu-
lation of PI3K/AKT signaling.
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WITH EPIGENETIC MECHANISMS IN NEOPLASTIC MAST CELLS
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Background: There is growing evidence that statins like simvastatin show
antileukemic activities (Bockorny and Dasanu, 2015). A multitude of experimental
studies have established their pro-apoptotic, anti-proliferative, anti-invasive, and
radiosensitizing effects. Although several cellular pathways activated by statins
have been identified, the precise mechanisms by which statins inhibit neoplastic
cell growth remain elusive and likely vary with the type of malignancy. Statins are
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors that act
on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl
pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP). Consequently, they
prevent posttranslational isoprenylation of small GTPases, and inhibit their activity.
In neoplastic cells, activated RAS-GTPase, the founding member of the gene
family, down-regulates the expression of the pro-apoptotic gene FAS via epigenetic
DNA-methylation by DNMT1 (Thaler et al., 2013). 
Aims: The aim of this study was to investigate possible epigenetic mecha-
nisms, which are responsible for the antiproliferative activity of statins on neo-
plastic mast cells.
Methods: Here we performed in vitro analyses from human mast cell leukemia
lines (HMC 1.1. and HMC 1.2.) following 3 days of simvastatin-treatment. For
comparative reasons a bisphosphonate-based inhibitor of the mevalonate path-
way (ibandronate) and a demethylating agent (decitabine) were used in phar-
macological concentrations. Modulation of gene expression from selected
genes, were analysed from gene chip data (Affymetrix) with respective bioin-
formatics tools (Pathvisio and GSEA) and confirmed and via real time PCR
and immune blotting.
Results: Dose response curves showed a significantly lower sensitivity of HMC
1.2 (EC50: 16.8 µM) as compared to HMC 1.1 (EC50: 3.5 µM). It remains to
be established, if this is associated with the Kit D816V mutation, which is only
present in HMC 1.2. Treatment with simvastatin upregulated the microRNA612
and down-regulated the epigenetic key enzymes DNMT1 and HDAC2. This
was associated with down-regulation of the repair mediator TYMS (thymidilate
synthase) and the associated metabolic pathway (one carbon/folate metabo-
lism, see Figure 1) as well as the BRCA genes, the latter being just observed
with simvastatin but not with ibandronate or decitabine, thus indicating a specific
effect of statin on DNA-repair.
Figure 1. One carbon metabolism pathway (green: down-regulation, red:
up-regulation).
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Summary and Conclusions: In conclusion this study shows that the antipro-
liferative effect of statins is associated with principal epigenetic mechanisms
including DNA-demethylation, histone modification as well as expression of
microRNA in mast cell leukemia lines, thus confirming similar data from solid
cancer cell lines (Karlic et al., 2015). It remains to be elucidated, whether statin-
mediated reduction of mediators for DNA repair is a possible cause or a con-
sequence of the observed epigenetic and antiproliferative mechanisms.
References
BOCKORNY, B. & DASANU, C.A. 2015. HMG-CoA reductase inhibitors as
adjuvant treatment for hematologic malignancies: what is the current evi-
dence? Ann Hematol, 94, 1-12.
KARLIC, H., THALER, R., GERNER, C., GRUNT, T.W., PROESTLING, K.,
HAIDER, F. & VARGA, F. 2015. Inhibition of the mevalonate pathway affects
epigenetic regulation in cancer cells. Cancer Genetics, in press.
THALER, R., SPITZER, S., KARLIC, H., BERGER, C., KLAUSHOFER, K. & VAR-
GA, F. 2013. Ibandronate increases the expression of the pro-apoptotic gene
FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol, 85, 173-85.
E1321
CD30 EXPRESSION ON NEOPLASTIC MAST CELLS IN SYSTEMIC MAS-
TOCYTOSIS-CORRELATION OF ASSESSMENT BY IMMUNOHISTOCHEM-
ISTRY AND MULTIPARAMETER FLOW CYTOMETRY WITH RESPECT TO
CLINICAL PARAMETERS
F. Bellos1,* K. Sotlar2, S. Schnittger1, C. Haferlach1, T. Haferlach1, W. Kern1
1MLL Munich Leukemia Laboratory, 2Institute of Pathology, Ludwig-Maximil-
ians-University Munich, Munich, Germany
Background: Systemic mastocytosis (SM) is a rare disease and clinical pres-
entation is highly variable from taking rather indolent to very aggressive courses,
seldom even with the presentation of mast cell leukemia. CD30 (Ki-1 antigen)
expression on neoplastic mast cells (MC) evaluated by immunohistochemical
staining (IH) on bone marrow (BM) biopsies has been reported to be present
in patients with more aggressive variants of MC. When assessed by multipa-
rameter flow cytometry (MFC) it might also contribute to improved diagnostic
accuracy. Only scarce data exists on correlation of CD30 expression detected
by MFC with clinical SM parameters.
Aims: To compare CD30 expression on MC of patients with SM detected by
either MFC or IH and to correlate results with patient characteristics and disease
characteristics as well as with cytogenetics (CG) determined by chromosome
banding analysis and with molecular genetics (MG).
Methods: We studied BM of 60 patients with SM by MFC. CD30 expression was
quantified by a five color staining assay with monoclonal antibodies against CD30,
CD45, CD117, CD2 and CD25. Aberrant MC were defined as CD117/CD45 pos-
itive cells with coexpression of CD2 and/or CD25. Mean fluorescence intensities
(MFI) of CD30 were determined in MC and correlated to CD30 MFI in lymphocytes
to derive CD30 index. For 22 patients data on MC infiltration and CD30 expression
by IH was assessed while CG and MG were done in 29 and 50 patients, respec-
tively. KITD816V mutation was analyzed using melting curve-based RNA mutation
analysis applying PNA clamping according to Sotlar et al. [Am J Pathol. 162:
737-746, 2003]. Expression of CD30 by MFC was correlated to results of CD30
expression by IH and results of CG and MG.
Results: 26 patients were male and 34 female. Median age was 61 years (20-
81 years). Aberrant karyotypes were found in 3 patients while 26 had a normal
karyotype. KITD816V mutation was found in 46/50 patients. In 6/60 patients con-
current hematological non-mast cell disease (AHNMD) was diagnosed. Mean
(±SD) MC infiltration was 20%±26% (range, 1.5%>85%) by IH and 0.5%±2.3%
(range, 0.01%>17%) by MFC. Mean (±SD) CD30 index was 20.5±24.3 (range,
3-154), mean (±SD) CD30 expression by IH was 9%±17% (range, 0%>70%).
Percentages of MC infiltration detected by IH and MFC correlated significantly
(p=0.002, r=0.819). No correlation of MFC CD30 index with age, sex, concomitant
AHNMD, grade of MC infiltration or percentage of CD30 positive MC by IH was
found. Interestingly, we detected a trend to higher CD30 index in patients with
KITD816V mutation (21.0±26.4 vs 10.9±9.4, n.s.) and a trend to lower CD30
index in patients with abnormal karyotype (11.6±10.3 vs 13.8±8.5, n.s.).
Summary and Conclusions: CD30 expression on neoplastic MC in patients
with SM is a dynamic parameter and can be assessed by MFC. CD30 expres-
sion may be stronger in patients harbouring KITD816V mutations compared to
those who do not. Patients with abnormal cytogenetics show a trend to lower
CD30 expression on MC. The expression of CD30 on neoplastic MC in patients
with SM should be further analyzed by MFC and IH in combination to substan-
tiate the present findings.
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INCIDENCE OF CALR MUTATIONS IN PATIENTS WITH CEREBRAL
VENOUS THROMBOSIS WITHOUT OVERT CHRONIC MYELOPROLIFER-
ATIVE NEOPLASM
E. Verger1,* I. Crassard2, B. Cassinat1, S. Bellucci3
1Cellular Biology Department, APHP St Louis, 2Neurology Department, 3Clinical
Hematology Department, APHP Lariboisiere, Paris, France
Background: In Myeloproliferative neoplasms (MPN) including Essential
Thrombocythemia (ET), Polycythemia Vera (PV) and Myelofibrosis thrombosis
is the main cause of morbidity and mortality. Venous thromboses are observed
in about 2 to 15 % of patients according to the MPN subtype. Venous throm-
boses at unusual sites are not exceptional and even typical of MPN as reported
affecting the splanchnic territory in 5-10 % of the patients with PV or ET and
the cerebral circulation reaching up to 1 % in ET. The JAK2V617F mutation is
present in 95% of cases with PV and 60% of cases with ET or Myelofibrosis.
With the discovery of this mutation, the diagnosis of MPN was greatly facilitated
and it was shown that a MPN at an early stage or even at a latent stage may
be responsible for the splanchnic thrombosis in a significant proportion of
patients. By contrast, the JAK2V617F mutation was very rare in patients with
cerebral venous thrombosis (CVT) and no patent signs of MPN, as we previ-
ously reported (Bellucci et al., 2008) in a series of 87 patients. Recently, muta-
tions in the CALR gene were reported in the majority of patients having MPN
with non-mutated JAK2.
Aims: We looked for the presence of JAK2V617F and CALR mutations in
patients with CVT and no hematological signs of patent MPN in order to see
whether CVT may reveal MPN at a latent stage in a particular subgroup of
patients. 
Methods: From September 2007 to April 2014, 167 patients with CVT were
included in our study: a patent MPN was carefully ruled out. Hematocrit was
checked to be repeatedly below 52 % in men and 48 % in women and the
platelet count to be repeatedly below 400G /L in order to rule out PV and ET
respectively, according to the WHO classification. Diagnosis of CVT was based
on magnetic resonance imaging (MRI) combined with MR venography and/or
helical cerebral CT venography. We looked for the JAK2V617F mutation using
an allele specific real-time PCR assay (Mutaquant®, Qiagen) and for the CALR
mutations using PCR followed by fragment analysis, which also allowed to cal-
culate the mutant allele burden.
Results: The JAK2V617F mutation was detected in 2 patients. In patient 1
(male, 56 years old) the allele burden was low at 0.5 %: an antiphospholipid
syndrome was evidenced requiring antivitamin K therapy. After a follow-up of
32 months no MPN was detected. In patient 2 (female, 21 years old) the
JAK2V617F mutation was also low at 3.2 %. CVT occurred concomitantly to
oestroprogestative intake. Blood counts were still normal 10 months after the
diagnosis of CVT. In 2 patients a type 1 CALR mutation (p.L367fs*46) was
detected. Patient 3 (male, 47 years old) had a venous recurrent thromboembolic
disease with a first deep venous thrombosis 2 years before the CVT and a
recurrence 22 months later. Patient 4 (female, 19 years old) presented with
CVT after oestroprogestative intake. The mutant CALR allele burden was low,
at 10 and 12% in patient 3 and 4 respectively. No MPN and no thrombophilic
abnormality were observed after a follow-up of 22 and 11 months in patient 3
and 4 respectively. 
Summary and Conclusions: The incidence of the JAK2V617F and CALR
mutations in patients with CVT without overt MPN was very low in this study.
In this large cohort of 167 patients JAK2V617F mutation occurred in 2 patients
(1.2%) and CALR mutations in 2 other patients. Interestingly all allele burdens
were low suggesting that these patients may be at an early stage of the disease
which may justify a prolonged follow-up. We do not recommend a systematic
research of these mutations in such patients but it may be helpful in some par-
ticular cases with CVT without any etiology. 
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COMPARISON OF THREE DIAGNOSTIC METHODS TO DETECT CALRETI-
CULIN MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
F. Girodon1,* J.-H. Park2, S. Ramla2, D. Bouchot2, M. Courtois2, M. Bas2,
S. Benali2, F. Bailly2, B. Favre2, J. Guy2, L. Martin3, M. Maynadié1, S. Carillo4
1Laboratoire Hématologie, Plateau Technique Biologie, Dijon, 2Laboratoire
Hematologie, 3service d’anatomopathologie, Plateau Techniqe de Biologie,
Dijon Cedex, 4laboratoire, CHU, Nimes, France
Background: Calreticulin (CALR) mutations have recently been reported in
70-84% JAK2V617F-negative myeloproliferative neoplasms (MPN), and this
detection has become necessary to improve the diagnosis of MPN.
Aims: The aim of our study was to compare in parallel on a large cohort of
ET patients three diagnostic methods [ High Resolution Melting (HRM) analy-
sis, product sizing analysis and Sanger sequencing] in the detection of CALR
mutations.
Methods: Based on the 2008 WHO diagnostic criteria, a total of 298 ET
patients from the hematology laboratory, University hospital in Dijon, France,
were retrospectively studied.
Results: Altogether, a JAK2V617F or a MPL exon 10 mutation was observed
in 179 (60%) and 13 (4.5%) patients, respectively. Finally 83 ET patients (33
males, 50 females) with a mean age of 63 y at the time of diagnosis (ranging
from 20 to 95 years) diagnosed from 2005 to 2013 did not harbor any mutation
and were considered as “double-negative” and thus tested using three molec-
ular methods for a CALR mutation. Using the HRM method, a positive curve
was noted in 54 patients, whereas no CALR mutation was observed in 28. Of
note, in one patient there was no DNA amplification. Using the product sizing
analysis, a CALR mutation was noted in 55 ET patients, and no mutation was
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seen in 28. Finally, using Sanger sequencing, 50 ET patients harbored a
CALR mutation, whereas no DNA amplification was noted in 4 samples. Tak-
ing altogether, a CALR mutation was noted in 56 patients and was of type 1
(leading to a deletion of 52 bp) or type 2 (leading to an insertion of 5 bp) in
28 (49%) and 20 (35%) patients, respectively. The 8 (16%) remaining muta-
tions were 2 deletions of 46bp, 1 deletion of 1bp, 1 deletion of 2bp, 1 deletion
of 25bp, 1 deletion of 33bp, 2 indel (1 insertion of 4bp and deletion of 2 bp
and 1 insertion of 5bp and deletion of 1 bp). A false negative test was
observed in 1, 2 and 2 in product sizing analysis, HRM method and Sanger
sequencing, respectively. The 2 false negatives cases in HRM had either
negative curves (patient #1) or curves with low amplitude (patient #2) contrary
to the product sizing analysis that showed the presence of one (patient #1)
or several mutant peaks (patient #2). Of note, in patient #2 the sequencing
analysis showed a 25bp deletion associated with an intron mutation. The 2
false negative cases in sequencing analysis had both positive curves in HRM
and mutant peaks in product sizing analysis however with low allelic burden
(13% and 8% respectively). The false negative case in product sizing analysis
had a deletion of 1bp that was not well separated from the wild type peak in
product sizing analysis despite the HRM curves were positive and the
sequencing analysis showed a deletion of 1 bp. The sensitivity for the HRM,
the product sizing analysis and Sanger sequencing was 96.4%, 98.2% and
89.3% respectively, whereas the specificity was 96.3%, 100% and 100%. In
our cohort, the product sizing analysis was the most sensitive method with
an easy interpretation, while the HRM was sometimes difficult to interpret.
On the other hand, when large series of samples were tested, HRM provided
results in a short delay in comparison to the other methods that required
more time. Finally the sequencing method, which is the reference method,
had the lowest sensitivity but allowed to describe precisely the type of the
mutations.
Summary and Conclusions: In routine laboratory activity, product sizing
analysis and HRM are globally similar to detect the CALR mutations and may
be used as first-line screening tests, followed by Sanger sequencing if posi-
tive to confirm and to determine the type of the mutations. 
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ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MOR-
GANA UNDER-EXPRESSION IN ACML
C. Panuzzo1,* G. Carrà1, S. Crivellaro2, R. Piazza3, U. Familiari2, S. Rocca4,
F. Fusella4, G. Saglio2, M. Brancaccio4, A. Morotti2
1Clinical and Biological Sciences, 2San Luigi Hospital, Turin, 3Dep. of Health
and Sciences, Monza, 4University of Turin, Turin, Italy
Background: Morgana/chp-1 is a chaperone protein regulating ROCK activ-
ity and it is involved in centrosome duplication and tumorigenesis. Morgana
+/- mice develop with age a fatal transplantable myeloproliferative disease
similar to aCML, presenting centrosome amplification as well as cytogenetic
abnormalities in bone marrow (BM). Notably, low morgana expression levels
were found in the BM of aCML-affected patients and in a portion of CML
Philadelphia positive patients. To assess whether morgana gene (CHORDC1)
mutations can be responsible for low morgana expression levels in aCML
patients we screened exome sequencing data obtained; no mutation were
detectable suggesting that more complex regulatory mechanisms are
involved in Morgana underexpression.
Aims: The aim of this study was to understand the mechanism responsible
of Morgana reducted expression in aCML in order to identify a new pathway
druggable to restore Morgana levels.
Methods: RNAs extracted from 9 primary aCML bone marrow samples col-
lected at diagnosis after informed consent was reverse transcripted in c-DNA
using random examers. The amplification products derived from Morgana
gene were purified using Gel Extraction System and sequenced with ABI
Prism 3100 Capillary Genetic Analyzer (Applied Biosystems). To evaluate
the amount of the wild type and alternative transcript, we used two specific
TAQMAN probes, one able to recognise only the wild type form and one
other able to recognise both the transcripts. Protein analysis were performed
by immunohistochemistry (IHC) experiments on formalin-fixed, paraffin-
embedded bone marrows. Exome sequencing was used to extend to a larger
portion of aCML patients and to analyze another pathology (AML) in order to
verify the specificity of this inactivation.
Results: In addition to the main Morgana mRNA we found the co-existence
of another transcript; direct sequencing of amplification products confirmed
the presence of an alternative transcript (AS) which lacks the entire exon 3
of Morgana; this phenomenon produces a change on the correct reading
frame and as consequence after 9 nucleotide the generation an earlier STOP
codon. The product of this new transcript isn’t a functional protein. Next we
decide to quantify this alternative transcript by using one probe able to rec-
ognize both the transcripts and one probe spanning the exons 4 and 5 of
Morgana and so able to recognize only the wild type form. We observed that
unlike the group of healthy donors all the aCML where Morgana wild type is
low have an high presence of alternative transcript. Surprisingly in the little
percentage of aCML with normal Morgana level the alternative splicing is not
significantly expressed. The generation of this AS colud be the mechanism
responsible of Morgana down-expression in aCML; in fact all the patients
with high alternative trascript shown very low level in Morgana protein,
analysed by IHC. All these data where confirmed by exome sequencing,
where the alternative transcript is observed on a large portion of aCML while
in 10 AML tested it is not detectable, suggesting the specificity of this type of
regulation in this myeloproliferative neoplasm
Summary and Conclusions: In this preliminary work, we identify one Mor-
gana AS responsible of aCML reduced Morgana expression. This could be
a consequence of mutations of those genes that are involved in the regulation
of the spliceosome even in the absence of spliceosome gene mutations,
alternative splicing of specific genes has also been reported with important
biological consequences and potential therapeutic opportunity.
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MUTATION ANALYSIS OF JAK2, MPL, CALR, ASXL1, TET2, IDH1, IDH2,
DNMT3A, AND SF3B1 IN MYELOPROLIFERATIVE NEOPLASM
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Background: Myeloproliferative neoplasms (MPNs) are blood diseases char-
acterized by clonal hematopoiesis, chronic excessive production of differenti-
ated blood cells and increased risk for thrombosis and secondary leukemic
transformation, which included polycythemia vera (PV), essential thrombo-
cythemia (ET) and primary myelofibrosis (PMF). JAK2 or MPL mutations are
found in 50-70% of patients with PMF or ET, whereas calreticulin (CALR) muta-
tions account for the majority of the remaining cases. However, MPN patients
often showed different clinical phenotype despite having the same mutation,
and other somatic mutations have been identified in some patients with MPN.
Aims: We evaluated incidence and clinical implication of several frequent
mutations in Korean MPN patients, including JAK2 V617F, JAK2 exon 12,
MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, and SF3B1.
Methods: We enrolled 87 Philadelphia negative MPN patients whose
archived peripheral blood or bone marrow sample collected at the time of
diagnosis or first referral were available. Mutations were analyzed by direct
sequencing and clinical data was collected retrospectively.
Results: We recruited 21 (25.8%) PV, 54 (59.6%) ET, and 12 (13.5%) PMF
patients. JAK2 V617F was the most frequently detected mutation accounting
for 69.0% (n=60) of MPN; 81.0% (n=17) of PV, 66.7% (n=36) of ET, and
58.6% (n=7) of PMF patients (Figure 1). JAK2 exon12 mutation was detected
in 1 PV patient. CALR mutations were found in 30.8% (n=8) of JAK2 mutation
negative MPN. It was not observed in PV, but one ET patient had CALR and
JAK2 V617F mutation concurrently. Mutations in ASXL1, TET2, DNMT3A,
and SF3B1 were also found in 9 (10.3%), 8 (9.2%), 4 (4.6%), and 1 (1.1%)
MPN patients, respectively, and these mutations were found exclusively with
CALR mutation. No MPL, IDH1 nor IDH2 mutation was detected in this cohort.
JAK2 V617F mutation was associated with the absence of symptom, high
leukocyte count, and low erythropoietin level with statistical significance.
Patients with CALR mutation had lower leukocyte count and hemoglobin lev-
el, and higher platelet count than patients who had JAK2 V617F mutation
only, or had neither CALR nor JAK2 V617F mutation. JAK2 V617F and CALR
mutation did not affect overall survival significantly. But patients with JAK2
V617F mutation and without CALR mutation seemed to have worse survival
than patients without JAK2 V617F mutation or with CALR mutation.
Figure 1. Mutational profile of 87 myeloproliferative disease.
Summary and Conclusions: It is first data of JAK2 V617F, JAK2 exon 12,
MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, and SF3B1 mutation in
Korean population. To validate of these clinical implication and prognostic value,
extension of patient number and follow up period would be warranted. 
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MARKERS OF CLONAL HEMATOPOIESIS IN PH-NEGATIVE MYELOPRO-
LIFERATIVE NEOPLASMS
L. Polushkina1,* I. Martynkevich1, V. Shuvaev1, E. Petrova1, M. Fominykh1,
L. Martynenko1, N. Cybakova1, M. Petrova1, E. Shabanova1, I. Zotova1,
T. Zamotina1, A. Zhernyakova1, K. Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: In 2013 several researchers published data describing recurrent
mutations-insertions and deletions-in 9th exon of CALR gene among patients (pts)
with Philadelphia -negative myeloproliferative neoplasms (Ph(-)MPN). Mutations
were not found in pts with polycythemia vera (PV). Frequency of CALR mutations
in pts with essential thrombocythemia (ET) and primary myelofibrosis (PMF) is
from 20 to 50%, respectively. Studies in mouse models showed JAK/STAT pathway
activation in cells expressing mutated CALR. It has been observed that mutations
in genes CALR, JAK2, MPL are mutually exclusive. Hence, mutations in 9th exon
of CALR gene can be regarded as a new marker of clonal hematopoiesis like
JAK2 and MPL mutations. Recent retrospective studies have shown that CALR-
ins/del burdening associated with milder disease and increased overall survival
(OS) compared with cases JAK2(+) or MPL(+) Ph(-)MPN.
Aims: The goal of our study was to determine frequency of JAK2, MPL, CALR
mutations in Ph(-)MPN pts and to analyze OS in groups with different clonal
markers and triple-negative.
Methods: We examined 182 pts with Ph(-)MPN: 76 pts with PV, 63 pts with ET
and 43 pts with PMF. The detection of V617F mutation of JAK2 for each patient
was done. JAK2V617F-negative pts with PV underwent the analysis of mutations
in 12th exon of JAK2 with direct sequencing. For JAK2V617F-negative pts with
ET and PMF investigation of 9th exon of CALR was carried out through high res-
olution melting (HRM) followed by direct sequencing of mutated samples. JAK2(-
) and CALR(-) samples were tested for MPL 515 codon mutations with PCR-
RFLP method. Karyotype research was done for patients with available bone
marrow samples.
Results: JAK2V617F mutation was determined in 74/76 (97,3%) PV pts, in 26/63
(41,27%) ET pts and in 21/43 (48,83%) PMF pts. 2/76 (2,7%) pts with PV had
mutations in 12th exon of JAK2. 515 codon mutations of MPL observed in 3/43
(6,97%) cases of PMF and in 3/63 (4,76%) cases of ET. Frequency of CALR
mutations among pts with PMF and ET was 20,63% (13/63) and 13,95% (6/43),
respectively. There was no reliable differences in OS in groups of pts with JAK2(+),
MPL(+), CALR(+) and without mutations (p=0.127) (fig.1), but it should be men-
tioned that 4 of 6 pts, who died pts had unfavorable karyotype (+7, +8, del(5q),
complex). It was not taken into account when determining OS. Interestingly, 3-
year OS in CALR-mutated group was 100% while OS in MPL(+) and triple-neg-
ative group was 67% and 80%, respectively.
Figure 1.
Summary and Conclusions: CALR mutations are highly specific marker of
clonal hematopoiesis along with JAK2 and MPL mutations. However, genetic
testing of clonal markers is insufficient. Only complex molecular genetic and
cytogenetic analysis of tumor cells has crucial importance for diagnosis and
prognosis of Ph(-)MPN.
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JAK2V617F MUTATION IN COMBINATION WITH ASXL1, DNMT3A, TET2,
U2AF1 AND RUNX1 VARIANTS IS ASSOCIATED WITH SEVERE CLINICAL
PHENOTYPES IN PRIMARY MYELOFIBROSIS
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Background: The past decade has witnessed a significant progress in the
understanding of the molecular pathogenesis of myeloproliferative neoplasms
(MPN). A large number of genes have now been implicated but their relative
importance, interactions and implications for prognosis remain unknown.
Aims: The aim of this study was to use a panel of mutations shown to be asso-
ciated with MPN to determine their relative importance and to identify driver
mutations and novel variants to elucidate the pathogenesis and predict survival
in patients with MPN in a multiracial country. 
Methods: We performed targeted sequencing on normal controls and patients
with MPN from 3 different races (Malay, Chinese and Indian) in Malaysia who
were diagnosed with polycythemia vera (PV), essential thrombocythemia (ET)
and primary myelofibrosis (PMF) according to the 2008 WHO diagnostic criteria
for MPNs. Patients from 3 tertiary-level hospitals were recruited prospectively
over 3 years and informed consents were obtained. DNA was extracted from
peripheral blood myeloid cells at diagnosis and high-throughput sequenced
using an Ion Torrent PGM and AmpliSeq targeting platform, with a panel of 26
MPN-related genes. 
Results: 22 patients (9 PV, 8 ET, 5 PMF) and 3 normal controls were recruited
into the study. 9 of 22 (40.9%) patients were Malay men and the median age
of the study population was 58y (range 26-75y). 19 of 22 (86.4%) patients har-
bored the JAK2V617F mutation which was detected in 9 (100%) PV, 5 (62.5%)
ET and 5 (100%) PMF patients; 7 of the 19 JAK2V617F positive patients (2
PV, 2 ET and 3 PMF) also harbored potentially pathogenic variants involving
the ASXL1, DNMT3A, TET2, U2AF1, and RUNX1 genes. 2 of the 3 JAK2V617F
negative ET patients had MPL exon 10 and TET2 mutations. Several novel
variants involving the DNMT3A, TET2, RUNX1, SH2B3 and CHEK2 genes
were identified in the study. The 3 PMF patients with JAK2V617F mutation in
combination with ASXL1, DNMT3A, TET2, U2AF1 and RUNX1 variants pre-
sented with severe clinical phenotypes, with marked anaemia, elevated leuco-
cyte counts, hyperferritinaemia, massive splenomegaly of >15cm,
hepatomegaly and debilitating constitutional symptoms. DIPSS-plus score was
intermediate-2 for 1 Chinese patient and high for 2 Malay patients who both
died within 2 years from diagnosis. None of these 3 patients developed throm-
bosis. However, 5 patients (3 PV and 2 ET) in the study who developed throm-
bosis all had the JAK2V617F mutation only. 3 ET patients developed bleeding.
2 of these patients had JAK2V617F mutation alone and 1 patient had a com-
bination of MPL exon 10 and a TET2 variant.
Summary and Conclusions: MPN in Malaysia is found predominantly in older
Malay men with a higher incidence of JAK2V617F positivity in the different sub-
types when compared to other studies. PMF patients who harbor the
JAK2V617F in combination with ASXL1, DNMT3A, TET2, U2AF1 and RUNX1
putatively pathogenic variants are found to have more severe clinical pheno-
types with very poor prognosis. Further studies are required to explore this
finding and the novel variants found in this study further. 
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GATA-1, BUT NOT FOG-1, FLI-1 OR CALR, IS UP-REGULATED IN ESSEN-
TIAL THROMBOCYTHEMIA INDEPENDENTLY FROM JAK2 AND CALR
MUTATIONS
C. Graham1, J. Lally1, L. Brown1, C. Rinaldi1,*
1Haematology, United Lincolnshire Hospital Trust and University of Lincoln,
Lincoln, United Kingdom
Background: GATA-1 is the founding member of the GATA transcription factor
family and it is essential for cell maturation and differentiation within the erythroid
and megakaryocytic lineages. We and others have demonstrated that elevated
GATA-1 expression is found in the bone marrow of Essential Thrombocythaemia
(ET) patients, independent of JAK2V617F and CALR mutations. GATA-1 is
able to coordinate lineage specification through its ability to bind both DNA and
protein partners that include; Friend of GATA (FOG-1) and the Friend leukaemia
integration 1 (FLI-1) transcription factors. FOG1 is vital for megakaryocyte
and erythroid lineage commitment and its expression largely overlaps spa-
tiotemporally with that of GATA-1. FLI-1 is an ETS family member that is
expressed at high levels in megakaryocytic progenitors. In conjunction with
GATA-1, FLI-1 targets those genes responsible for megakaryopoiesis. Calreti-
culin (CALR) is a calcium-binding protein involved in signaling and protein
expression that is believed to be responsible for clearing misfolded proteins
and involved in expression regulation. CALR mutations reported in myelopro-
liferative neoplasms create translation frameshifts in exon 9 which truncate the
C-terminal calcium binding domain and create a novel C-terminal peptide. Initial
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reports support CALR mutations as early and disease-initiating mutations that
favor expansion of the megakaryocytic lineage. CALR mutations are mutually
exclusive with JAK2 or MPL mutations.
Aims: We wanted to study the expression of GATA-1 in peripheral blood (PB)
of patients with ET, together with FLI-1, FOG-1 and CALR, trying to identify if
there is a common altered pathway and/or any correlation with JAK2 and CALR
mutational status.
Methods: PB specimens were collected from 36 patients diagnosed with ET,
17 JAK2 mutated (47%), 4 CALR (11%) mutated, 1 MPL mutated (3%) and 14
with no molecular abnormalities, and compared with a cohort of healthy volun-
teers. Samples were enriched for the mononuclear fraction by Ficoll separation.
Total RNA was extracted and analysed by Real Time PCR for GATA-1, FOG-
1, FLI-1 and CALR expression relative to the housekeeping gene GAPDH
using the2-ΔΔCTmethod.
Results: We confirmed the data obtained in bone marrow demonstrating that
GATA-1 is significantly up-regulated in ET patients also in PB and that GATA-
1 overexpression is independent from JAK2V617F and CALR mutations. How-
ever, the transcription factors FOG-1 and FLI-1 do not appear to be subject to
the same regulatory control in ET as that of GATA-1, remaining at the same
level of expression as the controls. Interestingly we also found a significant
downregulation in CALR mRNA comparing with controls and this is indipendent
from CALR mutation as well.
Summary and Conclusions: These results suggest that GATA-1 is specifically
deregulated in ET. GATA-1 overexpression is isolated and indipendent from its
co-factor FOG-1 or FLI-1. Very interestingly CALR is downregulated in ET sam-
ples indipendently from CALR mutation or JAK2 matation, however more data
are required to better understand the mechanisms of this deregulation. 
Myeloproliferative neoplasms - Clinical
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PEGYLATED INTERFERON TREATMENT IMPROVES SURVIVAL IN POLY-
CYTHEMIA VERA PATIENTS: A SINGLE CENTER EXPERIENCE
E. Crisà1,* K. Garvey1, G. Benevolo2, C. Aguzzi1, N. Barbara2, A. Borchiellini1,
E. Beggiato3, P. Manzini4, P. Francia di Celle5, L. Riera5, U. Vitolo2,
M. Boccadoro1, D. Ferrero1
1Hematology, University of Turin, 2Hematology, A.O.U. Città della Salute e della
Scienza, 3Hematology, A.O. Ordine Mauriziano di Torino, 4Laboratory Medicine,
5Department of Molecular Biotechnology and Health Sciences, A.O.U. Città
della Salute e della Scienza, Torino, Italy
Background: Polycythemia vera (PV) is a myeloproliferative disease with a
reported median survival of 14-15 years (Tefferi et al., 2014). The outcome is
mainly affected by thrombo-embolic events and evolution to myelofibrosis (MF)
and acute myeloid leukemia (AML).
Aims: The primary aim of the study was to evaluate the incidence of thrombo-
sis, MF and AML according to prognostic factors and therapeutic strategies in
a large series of PV patients. The secondary aim was to evaluate the outcome
and the variation in JAK2 allele burden in the patients treated with pegylated
interferon-alpha (peg-IFN-α).
Methods: Since 1995, 227 patients were consecutively diagnosed with PV at
the “A.O.U. Città della Salute e della Scienza” hospital of Turin. Hydroxyurea
(HU) was the first line treatment for the patients who required cytoreductive ther-
apy. Since 2006, we treated with peg-IFN-α the younger patients (age<65 years)
at high thrombotic risk or intolerant/resistant to phlebotomy. The use of alchilant
agents was limited to the oldest patients who were refractory/resistant to HU. 
Results: Median age at diagnosis was 66 years old and median follow-up was
8 years (13 to 244 months). Eleven% of patients presented with a thrombotic
event at diagnosis and no correlation with the blood count was found. Sixty-
nine% of patients were at high thrombotic risk for age or history of thrombosis,
however only the 13.3% of the whole cohort had a major thrombotic event dur-
ing follow-up. Major and minor thrombosis were statistically associated with
age over 60 and thrombotic history (p=0.034) but not with other cardiovascular
(CV) risk factors (hypertension, diabetes, smoking, hyperlipidemia) and the
treatment. Overall survival (OS) was longer than what reported in other studies,
with 90% and 58% of patients still alive at the median follow-up of 8 years and
at the maximum follow-up of 17 years, respectively. Regarding treatment, 97%
of patients received anti-platelet (89%) or anticoagulant agents (8%) and 86%
of patients received cytoreductive therapy, 88% with HU. Twenty-four patients
were treated with peg-IFN-α for at least 3 months (range 3-110) and their sur-
vival was longer than patients treated with HU (p=0.034) or with alkylating
agents (p=0.0023) (100% alive at the last follow-up). Even if peg-IFN-α was
available only from 2006, patients treated with peg-IFN-α had a median follow-
up from diagnosis similar to patients treated with HU (86 vs 97 months). Of
note, median age at diagnosis in the peg-IFN-α group was 53 and only 11% of
the patients had previous thrombosis. However, at multivariate analysis the
treatment with peg-IFN-alfa was confirmed to positively impact on survival,
regardless of the age and the thrombotic history. Moreover, a reduction of JAK2
quantitative burden was observed in 58% of the patients treated with peg-IFN-
α, an encouraging data considering that the median treatment duration was
still relatively short (median 26 months). Overall peg-IFN-alfa was fairly toler-
ated, with a discontinuation rate of 25%, as described in other studies (Quin-
tas-Cardama et al., 2006). Fifteen% of patients developed MF, a slightly higher
percentage than what reported by Tefferi et al. in 2014, but in line with data
previously published (Cervantes et al., 2008). The median MF-free survival
was 17,8 years. AML evolution occurred in 5.7% of patients only.
Summary and Conclusions: Our study confirmed some known prognostic
factors for thrombotic occurrence (age and thrombotic history) but no other CV
risk factors, probably due to the positive role of the anti-platelet therapy.
Peg-IFN-α is a promising therapy in PV, not only to control symptoms, but also
in a quantitative reduction of JAK2 mutation and OS improvement.
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TERT RS2736100_C POLYMORPHISM AS PREDISPOSITION FACTOR
FOR MYELOPROLIFERATIVE NEOPLASMS
K.P. Kiss1,* T. Krahling1, K. Balassa1, N. Meggyesi1, A. Bors1, J. Csomor2,
A. Batai2, G. Halm2, M. Egyed3, S. Fekete2, P. Remenyi2, T. Masszi2, A. Tordai1,
H. Andrikovics1
1Hungarian National Blood Transfusion Service, 2St. Istvan and St. Laszlo Hos-
pital, Budapest, 3Kaposi Mor Hospital, Kaposvar, Hungary
Background: The TERT rs2736100 single nucleotide polymorphism was found
to be a susceptibility factor for a variety of cancers (lung, glioma, bladder), and
recently for sporadic and familial myeloproliferative neoplasms.
Aims: The aim of our study was to investigate the role of TERT rs2736100
and JAK2 rs12343867 polymorphisms in a large cohort of Hungarian MPN
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patients regarding their frequency and their effect on clinical characteristics.
Methods: LightCycler melting analysis was applied to identify the risk allele of
TERT rs2736100_C and JAK2 rs12343867_C tagging 46/1 haplotype, in 209
polycythemia vera (JAK2 V617F positive PV), 281 essential thrombocytosis
(ET), 94 primary myelofibrosis (PMF) patients and 400 healthy individuals.
Results: In the ET cohort 148 (53%) JAK2 V617F, 95 (34%) CALR and 9 (3%)
MPL gene mutation positive and 29 (10%) triple negative cases; while in the
PMF cohort 51 (54%) JAK2 V617F, 25 (27%) CALR and 7 (7%) MPL gene
mutation positive and 11 (12%) triple negative cases were identified. Both genet-
ic variants showed increased allele frequencies in MPN patients compared to
controls (TERT rs2736100: 62.7±2.8% vs 48.8±3.5%, p<0.0001; OR [±95%CI]:
1.7 [1.5-2.1]; JAK2 rs1234386: 45.7±2.9% vs 29.8±3.2%, p<0.0001; OR
[±95%CI]: 2.0 [1.6-2.4]. Beside the allelic model, the difference remained sig-
nificant in all tested models (dominant, recessive, genotypic). Carriership of
the TERT rs2736100_C allele (dominant model) increased MPN susceptibility
equally in JAK2 V617F or CALR positive MPN patients (OR=2.8 [1.9-4.1] in
JAK2 V617F positive, OR=2.3 [1.3-4.1] in CALR positive groups, p=0.5 for
JAK2 V617F vs CALR positive groups comparison) as well as in PV, ET or
PMF subgroups. In contrast, the effect of the JAK2 rs12343867_C allele was
more pronounced in the JAK2 V617F positive group (OR=3.5 [2.6-4.8] in JAK2
positive, OR=1.6 [1.0-2.4] in the CALR positive groups, p=0<0.001 for JAK2
V617F vs CALR positive groups comparison). Combined hetero- or homozigos-
ity conferred even higher risk for MPN (combined heterozigosity: OR: 6.0 [3.4-
10.4], combined homozigosity: OR: 9.6 [4.4-21.1]). In the whole MPN cohort,
TERT rs2736100_C carriers displayed higher white blood cell count (9 vs 11
G/L, p=0.019) compared to homozygous AA patients. The frequency of different
complications (splenomegaly, venous and arterial thrombosis, myelofibrotic or
leukemic transformation) were not associated with the investigated TERT poly-
morphism either alone or in combination with the JAK2 haplotype.
Summary and Conclusions: In the present study, in an independent large cohort,
we confirmed that, TERT rs2736100_C polymorphism predisposes to the devel-
opment of MPN regardless of the molecular background or disease type.
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PATIENT SELF-CARE INTERVENTIONS: DO THEY IMPACT MPN-RELATED
FATIGUE?
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Background: The Philadelphia chromosome negative myeloproliferative neo-
plasms include essential thrombocythemia (ET), polycythemia vera (PV), and
myelofibrosis (MF). Fatigue is a prominent feature of these disease subtypes
which leads to reduced quality of life and impaired daily functioning. We have
previously evaluated the results of our initial phase I project evaluating fatigue
among MPN patients (Emanuel et. al. Blood 2013;a1595). Among the 879
online respondents, patients most often employed exercise, diet, social inter-
action, nutrition, rest, and relaxation techniques to reduce their fatigue. Despite
our previous efforts, little is known to date about the degree of relief obtained
from these specific fatigue-alleviating strategies.
Aims: The aim of this study is to evaluate fatigue-alleviating strategies in MRF.
Methods: A 70-item internet-based survey was developed and hosted by the
Mayo Clinic Survey Research Center. The survey was promoted online via mul-
tiple MPN-related webpages including the MPN Forum, MPN Net, MPN
Research Foundation, and MPN Voice during late February to March of 2014.
The MPN-SAF including the 10-item Brief Fatigue Inventory (BFI) was used to
assess disease burden (Blood. 2011 Jul 14;118(2):401-8). Fatigue was char-
acterized using a set of questions to evaluate timing, frequency, duration, trig-
gers, and impact on daily activities. Patients were queried as to whether they
had utilized individual interventions to alleviate fatigue and were asked to rate
the success of each intervention on a 1 (not at all successful) to 5 (very suc-
cessful) scale.
Results: Fatigue was prevalent and severe among survey respondents (BFI
24-hour worst fatigue item: score ≥1 95.3%, mean score 6.2 (SD=2.7)). Average
BFI score was 4.4 (SD=2.4). In selecting one or more times of day when fatigue
is most noticed, patients most often noticed their fatigue in the evening (44.0%)
or afternoon (42.4%), compared to the morning (17.7%) or continuously
throughout the day (23.4%). Fatigue triggers included physical work (58.8%),
stress (48.5%), exercise (41.6%), medications (25.2%), intellectual work
(24.3%), eating (16.9%) and sexual activity (6.6%). Approximately half of
patients felt that their fatigue was “about the same” over the last 6 months
(48.7%). However, large portion of patients felt that their fatigue had worsened
(40.7%), with only a minority of patients feeling that their fatigue had improved
(10.7%). Fatigue affected aspirations (64.5%), travel (61.0%), long term plan-
ning (58.3%), and vacation planning (57.2%). Most patients felt that fatigue
limited their normal daily activities (69.1%). Numerous self-care strategies were
implemented in order to reduce fatigue, including setting priorities, postponing
essential activities, exercise, and naps. Of these interventions, patients most
often felt that scheduling activities during peak energy times, pacing activities,
labor saving devices, and setting priorities were most efficacious in reducing
their fatigue (greater than 70% of patient attempting these strategies felt them
to be “very” or “somewhat” successful). Moderate/severe fatigue (categorized
as BFI score ≥4) was present more frequently in those who did not exercise as
compared to those who reported exercising at least once per week [188/248
(75.8%) vs 671/1181 (56.8%); p<0.001]. BFI score as compared to exercise
frequency per week is displayed in Figure 1. Exercise appears to have a dose
impact, as each level of physical activity is associated with lower fatigue. All
interventions except exercise and volunteer activities were attempted by a sig-
nificantly higher proportion of patients with moderate/severe fatigue than those
with none/mild fatigue level.
Figure 1. Box plot for BFI score by exercise frequency.
Summary and Conclusions: Overall patients with MPNs experience disabling
fatigue that greatly lowers their quality of life. This is the first published summary
evaluating the effectiveness of non-pharmacologic interventions utilized to alle-
viate fatigue among MPN patients. The unique role of exercise in alleviating
MPN related fatigue needs further prospective investigation. We plan to use
the results of this survey to inform an at-home interventional trial to investigate




ULTRA-DEEP SEQUENCING (UDS) ALLOWS MORE SENSITIVE DETEC-
TION OF THE D816V AND OTHER KIT GENE MUTATIONS IN SYSTEMIC
MASTOCYTOSIS
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Background: According to the World Health Organization (WHO) classification,
the diagnosis of Systemic Mastocytosis (SM) relies on bone marrow (BM) exam-
ination and is based on a major and four minor criteria. The somatic ‘autoacti-
vating’ point mutation D816V in the KIT receptor gene is one of the minor cri-
teria, founded in the great majority of patients (90%) and it plays a central role
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in the pathogenesis of the disease. Indolent Systemic Mastocytosis (ISM) is
the most common variant of SM, characterized by a very low MC burden and
associated with very different clinical pictures. A highly sensitive diagnostic
methods for D816V detection are required to assure an appropriate diagnosis
and to reduce false-negative results. The recent development of “ultra-deep
amplicon sequencing” (UDS) technologies has opened the way to a more accu-
rate characterization of molecular aberrations with higher sensitivity of screen-
ing for known and unknown mutations. 
Aims: Our aims were: i) to set-up and optimize a UDS-based mutation screen-
ing strategy of the KIT gene on the Roche GS Junior Instrument; ii) to test the
sensitivity of our UDS assay to detect the D816V mutation; iii) to investigate
the presence of additional KIT mutations in SM. 
Methods: We decided to take advantage of a next generation sequencing
approach to perform an UDS KIT gene mutation analysis on 24 bone marrow
(BM) samples from patients whit ISM that were negative for the D816V mutation
by Sanger Sequencing which has a sensitivity of 20%. Fusion primers were
designed to generate ten partially overlapping amplicon covering the whole
KIT transcript (exons 1-21) by RT-PCR. To determine the lower detection limit
of our UDS-assay, serial dilutions of the HMC-1 cell line (harboring the D816V
mutation) into an unmutated K562 cell line in ratios such as to simulate the fol-
lowing mutation loads were sequenced: 50%, 37.5%, 25%, 12.5%, 5%; 2.5%,
1.25%, 0.5%, 0.25%. 
Results: UDS of cell line dilutions showed a high accuracy of D816V mutation
detection and linearity of mutation calling over the entire range down to 0.25%.
The UDS technology allowed to detected the D816V mutation, below the lower
detection limit of Sanger Sequencing, with an abundance from 0.5% to 11%,
in 15/24 ISM patients. Two additional sequence variations were detected in a
large proportion of patients. These two variations included a 3bp in-frame dele-
tion in exon 15 (GenBankx06182.1: c.2164_2166delAGC; p.S715del) found in
12/24 patients and a 12bp in frame-deletion in exon 9 in all patients, whit an
abundance ranging from 83% to 97% (GenBankx06182.1: c.1550_1561del-
GTAACAACAAAG; p.G510_K513del). Previously published studies indicate
that the KIT Gly-Asn-Asn-Lys510-513+/- alternatively spliced located immediately
downstream to the extracellular KIT domain and KIT Ser715+/-, an interkinase
KIT domain, are expressed in normal human hematopoietic cell, leukemic cell
lines, acute myeloid leukemia blast and GISTs and represent rather a splice
variant of KIT transcript. Interestingly our results showed the presence of the
transmembrane domain M541L (GenBankx06182.1: c.1642A>C; p.Met541Leu)
KIT-activating mutation in exon 10, with an abundance of 50%, in addition to
D816V, in 3/24 ISM. This mutation is known to retain sensitivity to imatinib
mesylate (Figure 1).
Figure 1.
Summary and Conclusions: Our preliminary results suggest that our-UDS
based KIT gene mutation screening assay might be a reliable and sensitive alter-
native to conventional sequencing methods for the detection of the D816V. We
are now planning to investigate whether the greater sensitivity of UDS allows to
detect the D816V mutation in peripheral blood mononuclear cells from patients
with a suspected clonal mast cell disorder. These results could represent a start-
ing point to plan other extensive studies to better understand the exact role of
KIT receptor alterations in SM. Supported by ELN, AIL, AIRC, PRIN, progetto
Regione-Università 2010-12 (L. Bolondi), FP7 NGS-PTL project.
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Background: Ruxolitinib (RUX) is a JAK1/JAK2 inhibitor that proved superior
to best available therapy (BAT) in controlling hematocrit (HCT) and improving
splenomegaly and symptoms in patients (pts) with polycythemia vera (PV)
treated in the RESPONSE study. Because RESPONSE enrolled pts who had
an inadequate response to or unacceptable side effects with hydroxyurea (HU),
we performed a subgroup analysis to explore the efficacy of non-HU treatment
options in the BAT arm.
Aims: An exploratory analysis to compare key efficacy parameters of RUX
with HU and non-HU BAT in pts with PV who were resistant to or intolerant of
HU by modified ELN criteria.
Methods: RESPONSE is an open-label phase 3 study; pts with splenomegaly
(≥450 cm3 by MRI) who had HU-resistant disease or HU intolerance by modi-
fied ELN criteria were randomized 1:1 to RUX 10 mg bid or BAT. BAT included
single-agent HU, interferon, anagrelide, immunomodulators, pipobroman, or
no medication. HU was chosen based on the treating investigators’ judgment
that these patients could derive some benefit in the absence of more suitable
alternative treatments. All pts received low-dose daily aspirin. The primary com-
posite endpoint was the proportion of pts who achieved both HCT control with-
out phlebotomy (PBT) from wk 8 to 32 (with ≤1 PBT postrandomization and
prior to wk 8) and a ≥35% reduction in spleen volume from baseline at wk 32
by MRI. The proportion of pts who achieved a complete hematologic response
(CHR) at wk 32 was a key secondary endpoint. Symptoms were assessed
using the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-
SAF). Pts in the BAT arm could cross over to RUX starting at wk 32 if they had
disease progression or did not achieve the primary endpoint. The primary analy-
sis occurred when all pts reached wk 48 or discontinued.
Results: Overall, 110 pts were randomized to RUX and 112 to BAT. In the BAT
arm, 66 pts received HU as their initial treatment, and 45 pts received non-HU
treatment as their initial BAT (interferon, n=13; anagrelide, n=8; immunomod-
ulators, n=5; pipobroman, n=2; no medication, n=17); 1 BAT pt did not receive
study drug and was excluded from this analysis. Six pts changed BAT. Non-
HU treatment pts were pooled for analysis because few pts received any indi-
vidual treatment option as their initial BAT. Demographic characteristics were
generally well balanced across groups. The primary composite endpoint was
achieved in 1.5% of HU and 21% of RUX pts; no non-HU BAT pts achieved a
primary response. Larger proportions of pts receiving RUX achieved spleen
volume reductions, HCT control, CHR, and symptom responses than pts receiv-
ing HU- or non-HU BAT (Table 1). The proportion of pts who had PBT from wk
8 to 32 was substantially lower in the RUX arm than among pts receiving HU
or non-HU treatments in the BAT arm.
Table 1. Efficacy in patients who received RUX, BAT, HU BAT, and non-
UH BAT.
Summary and Conclusions: In the phase 3 RESPONSE study in pts with PV
who had an inadequate response to or unacceptable side effects from HU,
RUX treatment is effective in controlling HCT without PBT, decreasing spleen
volume, and improving PV-related symptoms when compared with HU and
non-HU standard treatment options.
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RISK OF PREGNANCY COMPLICATIONS AND EFFECT OF DIFFERENT
TREATMENTS IN WOMEN WITH ESSENTIAL THROMBOCYTHEMIA: A
RETROSPECTIVE MONOCENTER ANALYSIS OF 62 PREGNANCIES. 
S. Betti1,* E. Rossi1, T. Za1, A. Ciminello1, F. Bartolomei1, P. Chiusolo1,
V. De Stefano1
1Institute of Hematology, Catholic University, Roma, Italy
Background: A high rate of obstetric complications occurs in women with
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essential thrombocythemia (ET), with a consistent high risk of early fetal loss
and a probability of live births around 60%. A variety of therapeutic strategies
has been proposed, with a risk-driven intensity of treatment. The role of the
JAK2 V617 mutation as predictor of pregnancy complications and possible
therapeutic driver is controversial.
Aims: To assess in a retrospective cohort of ET patients the JAK2 V617F-relat-
ed risk of pregnancy complications and the efficacy of different treatments dur-
ing antepartum and postpartum periods. 
Methods: We analysed 62 pregnancies occurred in 38 women with ET
(median 2 pregnancies per woman, range 1-3) during the years 2001-2014.
The median age of the patients at diagnosis was 29 years (range 18-41);
the age at conception was >35 years in 33 pregnancies (53%). Nineteen
women (50%) carried the JAK2V617F mutation. Two of them had hepatic
vein thrombosis and TIA before first conception, respectively. One terminated
pregnancy, one blighted ovum and one miscarriage due to Turner syndrome
were excluded from further analysis. Antepartum treatment consisted of low
molecular weight (LMWH)+aspirin (ASA) in 32 pregnancies, ASA in 14,
LMWH in 6; seven pregnancies were left untreated. Interferon was admin-
istered during 9 pregnancies. The impact of different antepartum therapeutic
strategies was estimated by a multivariate proportional hazards regression
model over the weeks of gestation. Puerperium periods were defined as 6
weeks after delivery at ≥20 week of gestation and were treated with LMWH
in 45 of 51 cases.
Results: Among the evaluable pregnancies the rate of live births was 83%
(49/59); miscarriage occurred in 8, stillbirth in 2, abruptio placentae with
neonatal death in 1, intrauterine fetal growth retardation in 6. Overall, 17
obstetric complications (OC) were considered ET-related (17/59, 29%) and
occurred in 7 cases during LMWH+ASA (22%), in 2 during ASA (14%), 3
during LMWH (50%), and 5 in the untreated pregnancies (71%). No throm-
bosis complicated antepartum-periods. Antithrombotic treatment reduced
by 88% the risk of OC in comparison versus untreated pregnancies (odds
ratio, OR 0.12, 95%CI 0.02-0.69). The rate of OC was 43% in pregnancies
of JAK2 V617F-positive women (13/30) and 14% in the pregnancies of the
JAK2 V617F-negative women (4/29) (OR 4.77, 95%CI 1.33-17.18); however
after exclusion of the untreated pregnancies the risk associated with the
JAK2 V617F mutation was no more significant (OR 3.33, 95%CI 0.85-
13.00). A multivariate proportional hazards regression model including age
>35 yrs, JAK2 V617F mutation, and antepartum ASA, LMWH, and interfer-
on, retained only ASA as a variable associated with the outcome (OR for
complications 0.28, 95%CI 0.10-0.80, p=0.01). Among the 6 untreated puer-
perium periods, one was complicated by cerebral vein thrombosis (17%),
whereas no thrombosis occurred during the remaining puerperium periods
treated with LMWH. 
Summary and Conclusions: In ET patients JAK2 V617F is associated with
an increased risk of OC, which was prevented by treatment; namely, in this
cohort antepartum ASA was highly effective in preventing ET-related OC;
therefore, LMWH should be reserved only to women with additional risk fac-
tors for venous thromboembolism independent of ET. The rate of puerperi-
um-related venous thrombosis is high and prompts LMWH prophylaxis. 
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Background: The JAK2 V617F mutation, the thrombopoietin receptor mutation
MPL W515K/L and the Calreticulin (CALR) mutations are mutually exclusive in
essential thrombocythemia (ET) and support a novel molecular categorization
of ET. The most recently discovered CALR mutations account for up to 30% of
ET cases. 
Aims: In a retrospective study, we have examined the clinical phenotype and out-
come in a Belgian cohort of 165 ET patients in relation to their mutational status. 
Methods: A cohort of 107 JAK2 V617F negative ET cases diagnosed at several
Belgian hospitals was collected and analyzed for CALR and MPL mutations.
We also collected a control cohort of 58 JAK2 V617F positive ET diagnosed in
the University Hospitals Leuven and sequenced for CALR mutations. The medi-
an follow-up of the whole cohort of 165 patients was 8 years with a range of 1-
34 years.
Results: 62 (65.3%) JAK2 V617F/MPL W515K/L negative patients were car-
rying an indel in CALR, including 37 cases (59.6%) of Type 1
(c.1092_1143del) and 19 cases (30.6%) of Type 2 (c.1154_1155insTTGTC)
indels. We have also identified one ET patient positive for both CALR and
JAK2 V617F mutations. We compared the hematological and clinical features
between CALR +ve patients and JAK2 V617F +ve patients. This revealed
that CALR mutations are associated with younger age, male gender, higher
platelet counts, lower leukocyte counts, lower erythrocyte counts, hemoglobin
and hematocrit ratio. Dividing the CALR +ve group into Type 1 and Type 2
showed that CALR Type 1 was associated with male gender and higher
platelets compared to JAK2 V617F +ve patients. CALR mutant patients had
a better overall survival than the JAK2 V617F positive patients. However, in
the group of patients ≤60 years old CALR +ve group had a better overall sur-
vival over JAK2 V617F +ve group. Nonetheless, the group of patients older
than 60 years showed no difference in the overall survival between the CALR
+ve group and the JAK2 V617F +ve group. In our cohort, CALR +ve patients
present a higher risk of progressing to MF, but no difference in myelofibrosis-
free survival or leukemia-free survival was found (Figure 1).
Figure 1.
Summary and Conclusions: Our study confirms that CALR +ve ET is phe-
notypically distinct from JAK2 V617F +ve ET, with differences in the clinical
presentation and the disease course. CALR was also associated with better
overall survival, restricted to ET patients less than 60 years old. Our study
extends the growing body of evidence that CALR mutated ET has a distinct
phenotypic and hematological profile compared to the JAK2 V617F +ve group
and corroborates the observations from other similar studies.
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MUTATIONAL STATUS AND CARDIOVASCULAR COMPLICATIONS IN
PATIENTS WITH STRICTLY WHO 2008-DIAGNOSED ESSENTIAL THROM-
BOCYTHEMIA: A MONOCENTRIC STUDY
I. Bertozzi1,* E. Peroni1, G. Bogoni1, G. Coltro1, F. Fabris1, M.L. Randi1
1Dep. Internal Medicine-DIMED, University of Padova, padova, Italy
Background: Patients with essential thrombocythemia (ET) may carry JAK2,
MPL, or a calreticulin gene (CALR) mutation. The somatic mutations in CALR
are mutually exclusive with JAK2 and MPL mutations and is the second most
mutated gene in ET. Mutant CALR is a result of frameshift mutations, caused
by exon 9 deletions (type-1) or insertions (type 2). About 10% of ET patients
are still now triple negative (3NEG) for these mutations.
Aims: In the current study, we looked for phenotypic or prognostic differences
between ET patients stratified on the basis of their mutational status, the IPSET-
thrombosis (IPSET-T) score.
Methods: The study involved 183 patients (median follow-up 10.3 years
[range 0.2-31]) with a diagnosis of ET strictly fulfilling the 2008 WHO criteria.
All these patients are regularly followed twice a year at our Department. The
study was approved by the institutional Ethics Committee of Padua Hospital.
In agreement with the IPSET-T score, we assessed our patients’ thrombotic
risk based on: patient’s age at diagnosis; cardiovascular (CV) risk factors;
prothrombotic conditions and mutational status. Real-time quantitative PCR
for JAK2 and direct sequencing for MPL and CALR mutations were used.
Cox proportional hazard regression model was used for multivariable analy-
sis. MPL-mutated patients were not considered in the statistical analysis.
Results: Patients stratified by molecular status, IPSET-T score and cardio-
vascular events during follow-up are summarized in Table 1. The rate of
thrombosis during follow-up was 0.5% pats/year for low-risk patients, 2.3%
for intermediate-risk cases, and 5.1% for the high-risk group. After stratifying
patients by mutational status, the thrombosis rate was 4.2%, 1.6% and 0.7%
patients/year, respectively, for JAK2V67F, CALR (1.6% pats/y for CALR-1
and 1.5% pats/y for CALR-2) and 3NEG patients. In multivariable analysis
adjusted for sex and age at diagnosis the presence of JAK2V617F mutation
maintains a negative prognostic impact in predicting thrombosis both when
compared with CALR mutations (HR 2.6; 95% CI 1.2-5.5; p=0.013) and when
compared with triple negative (HR 5.3; 95% CI 1.3-22.5; p=0.022); no differ-
ences were demonstrated comparing CALR and 3NEG patients. The patients
distribution in agreement with IPSET-t score was similar in CALR type 1, type
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2 and 3NEG patients. Hemorrhages occurrence was similar in all mutational
groups.
Table 1.
Summary and Conclusions: It is known that ET patients carrying JAK2
mutation have a higher thrombotic risk compared to other ET having higher
hemoglobin and WBC counts. CALR mutated patients, in contrast, are asso-
ciated with higher platelet and lower hemoglobin and WBC counts. In our
cohort, CALR mutations as well as the absence of any known mutation
(3NEG) segregate with factors associated with a lower thrombotic risk. Inter-
estingly, all CALR type 2 and 84% of CALR type 1 have a low-intermediate
IPSET-T score and have a congruously lower rate of thrombosis during fol-
low-up. Therefore, CALR mutation does not have a negative impact on throm-
botic risk. We did not obtain a significant difference in hemorrhagic events
occurrence. Our data provide evidence that evaluation of JAK2, MPL, and
CALR mutation status is not only important for diagnosis but also for the
evaluation of thrombotic risk.
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CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH-
MYELOPROLIFERATIVE NEOPLASMS (MPN)
Y. Han1,* W. Zhang1, S. Zhao1, J. Qi1, J. Cen1, A. Sun1, C. Ruan1, D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Microparticles (MPs) are small membrane vesicles that are clas-
sified a as follow: platelet-derived MPs (PMPs), endothelial MPs (EMPs), red
blood cell MPs (RMPs) and tissue factor MPs (TF+MPs) based on their origins.
Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPN)
are disorders characterized by abnormal hematopoiesis, thrombosis and
JAK2V617F mutation. Although MPs are considered as biomarkers reﬂecting
procoagulant state in cancer patients, whether they exist in the patients with
Ph-MPN remains unclear.
Aims: Our objective in this study was to measure the variation of the four types
of MPs in the patients with MPN and to Figure out their correlations with
JAK2V617F mutation and some clinical complications, especially thrombosis
and splenomegaly. 
Methods: Ninty-two patients with MPN were enrolled in this study, including 60
essential thrombocythemia (ET), 20 polycythaemia vera (PV), and 12 primary
myelofibrosis (PMF). 30 healthy volunteers were selected as normal controls.
Venous blood wasanticoagulated with sodium citrate (1:9). Plasma samples were
measured by flow cytometry for RMPs, PMPs, TF+MPs and EMPs with phyco-
erythrin (PE)-conjugated monoclonal antibodies CD235a, CD61, CD142, and
CD62E, respectively. Forward scatter was set in scale using fluorescent micros-
pheres of 0.8μm and standard fluorescent microbeads (0~0.8μm) in diameter
were used to set the microparticle gate. Data were presented as mean and stan-
dard deviation. Meanwhile, genomic DNA was extracted from mononuclear cells
and amplified by allele speciﬁc polymerase chain reaction (PCR).
Results: (1) Levels of RMPs, PMPs, EMPs and TF+MPs in patients with Ph-
MPN was(135.2±291.60)/μl, (960.7±1539.1)/μl, (808.8±1244.5)/μl and
(103.2±303.6)/μlrespectively; they were all significantly higher than control group
(P<0.05). Moreover, levels of all four types of MPs in PMF group demonstrate
significantly higher than PV group (P<0.05), and RMPs in PMF group was sig-
nificantly higher than ET group (P<0.05).(2) Ph-MPN patients with thrombosis
complication showed higher levels of all four types of MPs than those without
thrombosis complication(P<0.01). (3) Ph-MPN patients with splenomegaly
showed higher levels of all four types of MPs than those without splenomegaly
(P<0.01). (4) All four types of MPs in the JAK2V617F mutation group were higher
than the group in which those patients without mutation (P<0.05).
Summary and Conclusions: Ph-MPN patients reveals higher levels of all four
types of MPs than normal controls, especially in patients complicated with
thrombosis or splenomegaly. MPs in PMF patients possess more obvious
increase than PV and ET groups. Patients with JAK2V617F mutation showed
higher levels of the four types of MPs than that without JAK2V617F mutation.
Consequently, MPs play an crucial role in the pathogenesis of Ph-MPN, and
the MPs released may promote the formation of thrombosis.
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MATRIX METALLOPROTEINASE 2,3,9,10 AND 13 GENE MUTATIONS IN
MYELOPROLIFERATIVE DISEASES
S. Maral1,* S.M. Bakanay2, O. Sahin Balçık3, E. Gündüz3, M. Albayrak4, A. Kosar5
1Hematology Department, 2Atatürk Research and Trainning Hospital, 3Turgut
Ozal Medical School and Hospital, 4Dışkapı Research and Trainning Hospital,
5Lokman Hekim Hospital, Ankara, Turkey
Background: Clonal myeloid disorders develop as a result of an acquired
mutation in the multipotent stem cells or early precursor cells. Matrix metallo-
proteinases (MMP) are proteolytic enzymes that play role in arrangement of
tissues, morphogenesis, wound healing and maturation. Additionally, they are
consigned in pathological pathway of tumor invasion, angiogenesis and metas-
tasis. The genetic polymorphisms may influence the functions of these
enzymes.
Aims: In this study the association of myeloproliferative diseases (MPD) with
polymorphisms in MMP2, MMP3, MMP9, MMP10 and MMP13genes were
investigated.We aimed to show is there any relationship with MMPs and dis-
ease prognosis and fibrosis of bone marrow.
Methods: Fiftyseven patients and 22 control cases were included in the study.
The study group was composed of 28 patients with polycythemia vera (PV),
12 patients with essential thrombocytosis (ET) and 17 patients with secondary
polycythemia (SP) patients. The ET and PV patients were diagnosed accord-
ing to 2008 WHO diagnostic criteria and they were either receiving medical
therapy and/or phlebotomy. DNA isolation was done from peripheral blood
samples by PureLink TM Genomic DNA Kit. MMP2 gene-735 C>T
(rs2285053), MMP3 gene -1612 5A → 6A (rs35068180), MMP9 gene
Gln279Arg (rs17576 G>A), MMP10 gene +180G>A and MMP13 gene -77A>G
polymorphisms were investigated. Polymerase chain reaction products of the
investigated gene region were observed in%3 agarose gel. Genotype was
determined by DNA sequencing after each polymorphism was recognized.
Results: The ratios of heterozygote patients for MMP2 were 39.3%in PV,
47.1% in SP, 41.7% in ET and 27.3% in control groups. Similarly, the ratios of
heterozygote patients for MMP3 were 38.3% in PV, 47.1% in SP, 33.3% in ET
and 68.2% in control groups, respectively. There was not any significant dif-
ference between groups regarding MMP2 and MMP3 mutations. The MMP9
polymorphism was most commonly reported in ET group (50%) while there
was not any MMP9 polymorphism reported in the control group (p=0.001).
There was not any statistically significant difference between groups regarding
the MMP10 polymorphisms. Heterozygote patients for MMP13 were deter-
mined as 71.4% in PV, 70.6% in SP, 75.0% in ET and 50.0% in control groups.
Heterozygote MMP13 patients were statistically significantly more common
in PV and ET groups than the control group (p=0.001).
Summary and Conclusions: We have determined that MMP9 gene
Gln279Arg and MMP13 gene -77A>G polymorphysms were associated with
ET while MMP13 -77A>G polymorphysms were associated with PV. The MMP
gene polymorphysims were not associated with SP development. Increased
number of megakaryocytes and increased thrombocyte outflow in ET patients
may be associated with increased MMP9 polymorphisms. On the other hand,
MMP13 polymorphisms may be associated with the acceleration of bone mar-
row fibrosis. Further studies are warranted to determine the association of
MMP9 and MMP13 polymorphisms in patients with MPD.
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KARYOTYPE OF CIRCULATING PROGENITOR CELLS OF MYELOID LIN-
EAGE COULD BE RELATED TO CLINICAL COURSE OF MYELOFIBRO-
SIS
R. Lozynskyy1,* M. Lozynska2, Z. Maslyak1, Y. Vyhovska1
1Hematological, Institute of Blood Pathology and Transfusion Medicine NAMS,
2Diagnostics of Hereditary Pathology, Institute of Hereditary Pathology of
NAMS, Lviv, Ukraine
Background: Granulocyte colony stimulating factor (G-CSF) is known to stim-
ulate mitosis of myeloid progenitors as well as non-committed stem cells that
could harbour hidden mutations and give rise to new pathological clones in
myelofibrosis (MF), especially leukemic. The level of circulating stem cells is
elevated during the disease progression. However, the total level of these
cells is low in peripheral blood (PB), and most of them don’t proliferate without
specific stimulation. Unfavorable karyotype of bone marrow (BM) is negative
prognostic feature of the pathological process in MF. Karyotype peculiarities
are revealed only in dividing cells using conventional cytogenetic methods,
but not in stem cells, and the information obtained during the investigation is
limited to BM, whereas the pathological cells are also presented in blood,
spleen and other organs. A lot of driver point mutations with impact on total
survival of the patients with MF are revealed. For instance, mutation as CALR
gene is related to favorable prognosis, and mutation of ASXL1 gene is related
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to poor outcome of the disease. However, there are no data confirming corre-
lation of unfavorable karyotype with mutation of ASXL1 or other genes in MF.
Aims: The aim of the study was to examine cytogenetic properties of myeloid
progenitor cells, circulating in the peripheral blood of patients with myelofibrosis.
Methods: The study group consisted of 34 patients with confirmed diagnosis
of both idiopathic, post-polycythemia vera, and post-essential thrombo-
cythemia MF. The PB was cultivated for 24 h with G-CSF in order to obtain
mitoses of circulating stem cells and to stimulate divisions of blast cells and
promyelocytes. Control analysis were performed in non-stimulated BM using
standard approaches. G-method of differential staining was used for cytoge-
netic studies of both PB and BM.
Results: Cytogenetic abnormalities were revealed in 47% of patients. The
spectrum of the most common anomalies obtained in this study included dele-
tions and translocations of chromosome 1, deletions of 5q and 20q, trisomies
of chromosomes 3, 8, 9, 12, monosomies of chromosomes 3, 5, 7, 9, 11, 13,
15, 17, and polyploidy. Karyotype of G-CSF-stimulated PB matched the BM
karyotype in most patients. Although there were some differences in propor-
tions between abnormal clones in the cases of mosaic karyotypes. Polyploidy
was more characteristic for the BM and was observed in 30% of cases that
included single polyploid metaphases, whereas incidence of polyploidy in the
PB was 6%. Most of the polyploidy metaphases were presented as tetraploid
ones, however, near-tetraploid, near-triploid and octaploid were also revealed
in some cases. The study of G-CSF-stimulated blood was successful for the
majority of patients in whom cytogenetic studies of BM failed. High mitotic
index according to cytogenetic analysis of PB with concomitant chromosome
abnormalities were accompanied by IPSS score >=2 and DIPSS score >=3
for other clinical indicators. If BM aspiration for cytogenetic analysis was unsuc-
cessful, but cytogenetic abnormalities were found in the study of PB, the dis-
ease course was unfavorable, because of appearance of transfusion depend-
ency, significantly increased leukocytosis with increasing changes in leuko-
gram, or even transformation to acute leukemia and death. The follow-up
within 1 year showed that the cytogenetic changes in PB in some cases were
preserved or further evolved with the appearance of additional chromosomal
abnormalities and worsening of the patient’s condition.
Summary and Conclusions: Cytogenetic studies of PB in MF using in vitro
stimulation with G-CSF could complement cytogenetic analysis of BM and
determination of the mutation status. The spectrum of anomalies obtained
during cytogenetic analysis of both G-CSF-stimulated PB and BM aspirate
are very similar. Therefore, the cytogenetic analysis of an in vitro G-CSF-stim-
ulated PB may be an acceptable alternative to repeated BM punctures in cases
of significant fibrosis that makes BM difficult or impossible to aspirate. Cyto-
genetic abnormalities in the blood of patients in our group were associated
with unfavorable course of MF. Collection of PB for cytogenetic analysis in
dynamics may become potential additional criterion for monitoring the effec-
tiveness of treatment and the disease progression. The absence of need to
repeat BM puncture is an additional factor that could contribute to greater
adherence of the patients to diagnostic and treatment procedures. Regular
monitoring of cytogenetic changes could help searching for chromosomal loci
with candidate genes involved in the disease progression.
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IPSET-THROMBOSIS BETTER IDENTIFIES THROMBOSIS FREE SUR-
VIVAL
Ö.G. Sevindik1,* S. Mersin1, A. Katgı1, S. Tunalı1, S. Medeni Solmaz1, C. Acar1,
I. Alacacıoğlu1, Ö. Pişkin1, M.A. Özcan1, F. Demirkan1, B. Ündar1, G.H. Özsan1
1Department of Hematology, Dokuz Eylul University, İzmir, Turkey
Background: Essential thrombocythemia (ET) is the most common among
the myeloproliferative neoplasms (MPNs). For better predicting the occurrence
of thrombotic events, an International Prognostic Score of Thrombosis for ET
(IPSET-Thrombosis) was recently developed.
Aims: We aimed to investigate the validity of IPSET-Thrombosis in a Turkish
patient cohort, and to compare the efficacy of IPSET-Thrombosis and conven-
tional risk scoring systems in predicting thrombosis free survival. 
Methods: We retrospectively evaluated the clinical characteristics and risk fac-
tors for thrombosis in 112 Turkish patients. Median thrombosis free survival
and Harrell C-Concordance indexes were calculated for both conventional and
IPSET-Thrombosis.
Results: Median age of 112 patients included in the study was 61 (27-90) years
at the time of diagnosis. When patients were stratified according to the con-
ventional risk stratification system, 43.8 % of patients were in low risk and
56.2% were in high risk group. 22.4% of low risk and 42.9% of high risk patients
had an at least one occasion of thromboembolic event. When patients were
stratified according to the IPSET-Thrombosis, 33% were in low risk, 26.8%
were in intermediate risk and 40.2% were in high risk group. Considering IPSET-
Thrombosis risk groups 5.4% of low risk, 26.7% of intermediate risk and 66.2%
of high risk patients had an at least one occasion of thromboembolic event.
Regarding IPSET-Thrombosis risk groups, 10 year thrombosis free survival
was 86.8% for low risk, 39.4% for intermediate risk and 32.9% for high risk
groups (p<0.001). Harrell C-concordance indexes of conventional and IPSET-
Thrombosis were 0.60 and 0.77 respectively (Figure 1).
Figure 1.
Summary and Conclusions: By validating the reproducibility of IPSET-Throm-
bosis in Turkish ET patients, we conclude that IPSET-Thrombosis identifies
thrombosis free survival better than the conventional risk stratification system.
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EFFICACY OF RUXOLITINIB IN MYELOID NEOPLASMS WITH PCM1-JAK2
FUSION GENE
I.C. Casetti1,* J.D. Milosevic2, E. Rumi3, D. Selleslag4, E. Lierman5, D. Pietra3,
C. Cavalloni1, M. Bellini1, C. Milanesi3, C. Astori3, R. Kralovics2, P. Vandenberghe5,
M. Cazzola1,3
1Deparmente of Molecular Medicine, IRCCS Policlinico San Matteo, Pavia,
Italy, 2CeMM Research Center for Molecular Medicine, Austrian Academy of
Sciences, Vienna, Austria, 3Department of Hematology Oncology, IRCCS Poli-
clinico San Matteo, Pavia, Italy, 4Department of Hematology, AZ Sint-Jan,
Brugge, 5Center for Human Genetics, KU Leuven/University Hospital Leuven,
Leuven, Belgium
Background: In September 2014 Schwaab et al. published two cases of myeloid
neoplasms associated with PCM1-JAK2 and BCR-JAK2 fusion genes treated
with ruxolitinib. While they reported a very good initial response for both cases,
relapse occurred after 18 and 24 months respectively. The authors concluded
that the response of myeloid disorders with JAK2 fusion genes to ruxolitinib is
short-lived, but that ruxolitinib may be an important bridging therapy prior to ASCT.
Aims: To report the follow-up of our two cases of myeloid neoplasms/Chronic
eosinophilic leukemia (CEL) with a PCM1-JAK2 fusion gene treated with Rux-
olitinib.
Methods: We monitored at 3, 6, 12, 24 and 36 months the number of
metaphases with t(8;9) through cytogenetics, the proportion of rearranged
nuclei through FISH, and the amount of PCM1-JAK2 fusion transcript through
quantitative real time PCR analysis.
Figure 1. The two lines represent the fold difference in transcript levels
normalized to the baseline sample considered as 100%.
Results: The first case was a 72-year-old male with a PCM1-JAK2 positive
CEL who gradually obtained a complete cytogenetic remission over a period of
15 months of therapy with ruxolitinib at a dose of 10- 20 mg bid. The hemato-
logical course of this patients beyond 15 months, under continued treatment
with ruxolitinib (10 mg, bid) was uneventful, with moderate anemia ((Hb>120
g/L) not requiring blood transfusions, with normal leukocytes and platelet counts
and normal eosinophil counts. Consecutive cytogenetic and FISH studies on
bone marrow showed complete cytogenetic remission. In addition, the meas-
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urement of disease burden by real-time quantitative RT-PCR showed a 2log
decrease at 34 months as compared with the disease burden at the start of
ruxolitinib. The last reevaluation was done three months before his death to
unrelated cardiac problems (septic endocarditis) 36 months after the start of
ruxolitinib, without- evidence of relapse. The second case was a 31-year-old
female affected with CEL. She started Ruxolitinib in 2011 at 15 mg BID and
obtained a complete clinical remission. She obtained a reduction of aberrant
metaphases and aberrant nuclei with t(8;9) and a marked reduction of the
PCM1-JAK2 fusion transcript. She is still alive in complete hematological remis-
sion. Both patients therefore achieved durable complete hematologic remis-
sions and cytogenetic response lasting for 3 year in each case respectively.
Figure 1 shows the marked reduction of the PCM1-JAK2 fusion transcript.
Summary and Conclusions: These cases demonstrate that the response of
myeloproliferative neoplasms with PCM1-JAK2 fusion genes can be long-lived,
without use of ASCT. 
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CLINICAL FEATURES OF JAPANESE POLYCYTHEMIA VERA AND
ESSENTIAL THROMBOCYTHEMIA PATIENTS HARBORING CALR,
JAK2V617F, JAK2EX12DEL, AND MPLW515L/K MUTATIONS
M. Okabe1,* H. Yamaguchi1, K. Usuki2, Y. Kobayashi3, E. Kawata3, J. Kuroda4,
S. Kimura5, K. Tajika6, S. Gomi6, N. Arima7, S. Mori8, S. Ito9, M. Koizumi10,
Y. Ito11, S. Wakita1, K. Arai1, T. Kitano1, F. Kosaka1, K. Dan1,12, K. Inokuchi1
1Department of Hematology, Nippon Medical School, 2Department of Hema-
tology, NTT Medical Center Tokyo, Tokyo, 3Department of Hematology, Japan-
ese Red Cross Kyoto Daini Hospital, 4Division of Hematology and Oncology,
Kyoto Prefectural University of Medicine, Kyoto, 5Division of Hematology, Res-
piratory Medicine and Oncology, Department of Internal Medicine, Faculty of
Medicine, Saga University, Saga, 6Department of Hematology, Yokohama
Minami Kyousai Hospital, Yokohama, 7Department of Hematology, Kitano Hos-
pital, Osaka, 8Hemato-Oncology Department, St Luke’s International Hospital,
Tokyo, 9Department of Medical Oncology, Iwate Medical University, Morioka,
10Department of Gastroenterology, Asahi General Hospital, Asahi, 11Depart-
ment of Hematology, Tokyo Medical University, Tokyo, 12Medical Education
Center, Ryotokuji University, Urayasu, Japan
Background: Myeloproliferative neoplasms (MPNs) are characterized by the
monoclonal proliferation of one or more lines of myeloid cells due to hematopoi-
etic stem cell abnormalities. MPNs involve hyperplasia of differentiated blood
cells and an increased risk of thrombosis, and can progress to leukemia. The
risk of complication of polycythemia vera (PV) and essential thrombocythemia
(ET) by thrombosis in Japanese patients is clearly lower than in western pop-
ulations, suggesting that genetic background such as race may influence the
clinical features.
Aims: This study aimed to clarify the relationship between genetic mutations
and haplotypes and clinical features in Japanese patients with PV and ET.
Methods: This study prospectively analyzed 74 PV and 303 ET patients who
were diagnosed at facilities which agreed to participate in this study. Compar-
isons were made with 232 normal controls. Mutation biased polymerase chain
reaction and direct sequencing were used to assess JAK2V617F,
JAK2Ex12del, MPLW515L/K mutations, and the single nucleotide polymor-
phisms, which are located near the JAK2V617F mutation, to determine JAK2
46/1 haplotype. CALR mutations were analyzed by direct sequencing of exon
9. Statistical analyses were performed with SPSS software (version 12.1.4).
Linkage analysis was performed with haploveiw ver.4.2.
Results: Genetic mutations in PV patients included JAK2V617F (93.2%; 69/74),
JAK2Ex12del (5.4%; 4/74), and MPL mutations (1.4%; 1/74). Genetic mutations
in ET patients included JAK2V617F (60.9%; 180/294), CALR (16.0%; 47/294),
and MPL (3.7%; 11/294) mutations. There were 57 ET patients (19.4%) who did
not have any of these mutations. There were no clinical differences, including
JAK2V617F allele burden, between PV patients harboring the various genetic
mutations. However, CALR mutation-positive ET patients had a significantly lower
WBC count (p=0.003), Hb value (p<0.001), Ht value (p<0.001), and NAP score
(p=0.015), and significantly more platelets (p=0.003), relative to JAK2V617F-pos-
itive ET patients and ET patients with no mutations. Compared to Type 1 CALR
mutation (p.L367fs*46 deletion)-positive ET patients, those with Type 2 mutations
(p.K385fs*47 insertion) had a significantly higher platelet count (p=0.048). The
single nucleotide polymorphisms rs12340895, rs10974944, rs12343867, and
rs1159782, which are located near JAK2V617F, exhibited linkage disequilibrium
between PV patients, ET patients, and normal controls. Compared to normal con-
trols, the frequency of the JAK2 46/1 haplotype was significantly higher among
patients with JAK2V617F (p<0.001), JAK2Ex12del (p<0.001), or MPL mutations
(p<0.001), whereas no significant difference was found among CALR mutation-
positive patients. The cumulative incidence of thrombosis from diagnosis of PV
and ET was 9.6% and 9.0%, respectively, after 10 years. The cumulative incidence
of thrombosis showed an increasing trend among PV patients aged ≥60 years
(p=0.098), but no significant difference was found in any of the other parameters
(history of thrombosis, WBC count, NAP score, 46/1 haplotype, various genetic
mutations. In ET patients, the cumulative incidence of thrombosis was significantly
higher among those with a history of thrombosis (with history: 18.0% in 10 years
vs no history: 7.0% in 10 years; p=0.043). JAK2V617F-positive patients had a
higher cumulative incidence of thrombosis (12.3%) relative to those with CALR
mutations (6.25%), the MPLW515L/K mutation (0%), or no mutation (0%),
although the differences were not significant.
Summary and Conclusions: The incidence of developing thrombosis after
an ET or PV diagnosis was about 9% each, which are lower than those
observed in western countries. We did not find a significant correlation between
CALR mutations and the 46/1 haplotype. JAK2V617F-positive ET patients and
CALR mutation-positive patients may have different mechanisms of occurrence
and clinical features of ET, suggesting the potential need for therapy stratifica-
tion in the future.
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BONE MINERAL DENSITY IN PATIENTS WITH ESSENTIAL THROMBO-
CYTHEMIA AND POLYCYTHEMIA VERA
S. Farmer1,* V. Shanbhogue2, S. Hansen2, C. Stahlberg2, A.P. Hermann2,
H. Vestergaard2, H. Frederiksen2
1Dept. of Haematology, 2Odense University Hospital, Odense C, Denmark
Background: Several systemic inflammatory diseases are associated with
osteoporosis and increased risk of fractures which at least in part may be
caused by low bone mineral density (BMD). Chronic inflammation is today a
model for cancer development and may also play an important role in the
pathology of chronic myeloproliferative neoplasms (CMPN). Patients with
essential thrombocythemia (ET) and polycythemia vera (PV) have an increased
risk of fractures in comparison with a matched background population as shown
in population based studies.
Aims: The aim of this study was to assess BMD in CMPN patients in a clinical
cross sectional study.
Methods: Patients with ET or PV according to WHO 2010-criteria International
Classification of Diseases, 10th revision were recruited from the Department
of Haematology, Odense University Hospital, Denmark. Dual energyx-ray
absorption (DXA) was used to measure BMD at the hip and the spine L1-L4.
Patients were compared with individuals from a cohort of healthy, Danish, Cau-
casian (n=499) recruited from the general population of the municipality in
Odense. Each CMPN patient was individually matched with a subject from this
cohort on age, sex, weight and height.
Results: 46 patients and 46 controls were included, 55% were females and
45 were men. Mean age was 56 years. The results of BMD measurements
were presented in the Figure 1 demonstrating that BMD measurement in both
hip and spine were comparable with the reference group.
Figure 1.
Summary and Conclusions: This study assessed BMD in CMPN patients
and compared results with healthy individuals. Results of the BMD measure-
ments in both hip and spine were comparable with the reference group. This
study does not explain the increased risk of fractures found in CMPN patients.
BMD alone may not be accurate in predicting fractures in CMPN, and our
results calls out for further studies with advanced imaging modalities or assess-
ment of biochemical bone turn over markers.
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PREVALENCE OF EOSINOPHILIAS (EOS), IDIOPATIC HYPERE-
OSINOPHILIA AND HYPEREOSINOPHILIC SYNDROME (HES) IN A LARGE
(ONE MILLION) POPULATION IN NORTH ITALY (THE ROMAGNA
GREATER AREA)
M. Rondoni1,* G. Poletti1, N. Tommasini1, M. Rosetti1, L. Baldrati1, F. Monti1,
M. Salvucci2, A. Lucchesi3, S. Tomassetti4, E. Ottaviani5, P. Savini6, E. Zuffa2,
P.P. Fattori3, G. Martinelli5, P. Tosi4, R.M. Dorizzi1
1Department of Clinical Pathology, Centro Servizi Pievesestina AUSL
Romagna, Pievesestina di Cesena (FC), 2Department of Hematology-Oncol-
ogy, Ravenna Hospital, AUSL Romagna, Ravenna, 3Department of Hematol-
ogy-Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
(I.R.S.T.), Meldola, 4Department of Hematology-Oncology, Ospedale “Infermi”
Rimini, Rimini, 5Department of Experimental, Diagnostic and Specialty Medi-
cine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna,
6Department of Internal Medicine, Faenza Hospital, Faenza, Italy
Background: The Eosinophilias (Eos) encompass a broad range of nonhema-
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tologic (secondary or reactive) and hematologic (primary, clonal) disorders.
Hypereosinophilia has been defined as a peripheral blood eosinophils (Eo)
count greater than 1,500/mm3 The HES is characterized by marked unex-
plained blood and tissue Eos and defined (1975) by Chusid’s criteria: (1) blood
Eo ≥1500/mm3 for longer than 6 months, (2) lack of evidence for parasitic,
allergic, or other known causes of Eos, and (3) presumptive signs or sympthoms
of organ involvement. Disease prognosis relies on identifying the origin of Eos.
The 2008 WHO establishes a semimolecular classification of eosinophilic dis-
orders (ED) based on the presence of recurrent molecular alterations
(PDGFRA, PDGFRB, or FGFR1), or of other clonal markers, and where HES
is a diagnosis of exclusion. The incidence and prevalence of ED and HES is
not well characterized, and also the frequency of PDGFRA rearrangement is
really unknown, with a high median rate of 23% from 8 clinical studies, that
probably depends from the selection bias of patients. 
Aims: The aim of this study was to investigate the prevalence of ED in the
Greater Romagna Area (AVR), an homogeneous large geographic area served
by the Italian National Health System (INHS). 
Methods: The Hub Laboratory (HL) of AVR serves more than one million
(1.124.866 in 2012) inhabitants living in an area of about 5000 square km in
North of Italy, that provides Laboratory Medicine service for all general practi-
tioners and for all the hospitals of the INHS. It includes hematology laboratory,
and genetic sections. The results of all the tests carried out by the HL since
2009, including the differential cell counts (DIFF), are stored in the LIS data-
base. We downloaded from the LIS the DIFF results obtained in 2012 and
selected the cases with ≥1.5x109/L Eo among the 574.380 unique individuals
with at least one DIFF. In order to verify if the first Chusid criteria for HES was
satisfied we searched for other DIFF requests in the semesters before and
after the selected cases and for Eo ≥1.5x109/L in these DIFFs. For this total
cohort of possible HES patients, we performed further data extraction from LIS
with the intent to exclude the more frequent causes of secondary Eos (e.g.
total IgE, fecal parasites, CRP, vitamin B12, bone marrow smears and cytoge-
netic). Moreover we matched the clinical records (InfoClin, LOG80, ONAMB)
of the uncertain cases for final diagnosis. 
Results: Of 574.380 unique individuals with one DIFF in 2012, 452 satisfied the
first Chusid’s criteria, and on these cohort we will performed our investigations.
Here we report the preliminary results on 44 patients (10% of the total cohort).
We excluded 27 patients with secondary Eos (61,3%), and 15 asymptomatic
patients no further investigated despite a persistent mild Eos (<2.5x 109/L), and
finally we identified 2 patients with sign and sympthoms of HES, with a prevalence
in the AVR of 0.034%. Of note, the 2 patients were male, and died in 3 and 15
months without evaluation of the presence of molecular rearrangements. 
Summary and Conclusions: The low prevalence of HES (<0.05%) is confirmed
by these preliminary data. With the completion of this analysis we will achieve a
better characterization of ED and, since we are investigating half of the resident
population of AVR, also the real prevalence of these rare diseases will be known,
including PDGFRA positive clonal disease, primary HES, but probably with the
exclusion of the ED with specific tissue Eos without peripheral Eos. 
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A SCORING SYSTEM BASED ON LEUKOCYTE ALKALINE PHOSPHATASE
ACTIVITY AND PERIPHERAL GRANULOCYTE PRECURSOR PERCENT-
AGE PREDICTS JAK2 V617F MUTATION IN PATIENTS WITH PRIMARY
MYELOFIBROSIS
R. Invernizzi1,* E. Travaglino1, L. Roma1, R. Bastia1, V. Rosti1, L. Villani1,
G. Bergamaschi1, F. Quaglia1, G. Barosi1
1IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Background: Patients with primary myelofibrosis (PMF) may carry mutations
of JAK2, MPL or CALR (calreticulin) gene. The genetic subtypes of PMF are
different as regards clinical course, disease progression and overall survival.
The mutation in the JAK2 gene consisting of a valine-to-phenylalanine change
at position 617 (JAK2 V617F) was reported in half and more of the patients.
This mutation increases JAK2 kinase activity and is significantly associated
with higher blood cell count, granulocyte activation and thrombosis risk.
Aims: Since increased leukocyte alkaline phosphatase (LAP) expression is
considered a granulocyte activation marker and variable LAP levels are found
in PMF, the aims of our study were to evaluate LAP activity in PFM patients
searching for possible correlations among LAP score, JAK2 V617F mutation
status, and clinical-pathological features; moreover, in patients treated with a
JAK1/2 inhibitor, to determine possible correlation between LAP levels and
degree of response to therapy.
Methods: We evaluated LAP activity by cytochemistry in peripheral blood
smears from 266 PMF patients at diagnosis, whereas JAK2 V617F mutation
status was assessed by polymerase chain reaction (PCR). On the basis of a
ROC curve analysis we defined a simple scoring system to predict JAK2 V617F
mutation with high sensitivity and specificity. Then, we prospectively tested this
score system in a new cohort of 105 PFM patients.
Results: JAK2 V617F mutation was identified in 162 patients (61%). In these
patients LAP scores were significantly higher than in nonmutated cases
(P<0.0001), without difference in relation to the allele burden. Score values above
the normal range were observed only in patients carrying the mutation. No cor-
relation was found between LAP score and white blood cell or platelet count,
hemoglobin concentration, splenomegaly, IPSS risk group, while there was a sig-
nificant inverse correlation between LAP score and peripheral granulocyte pre-
cursor percentage. A ROC curve analysis allowed us to identify a LAP score of
100 (AUC=0.81, 95% CI 0.76-0.86) and a peripheral granulocyte precursor per-
centage of 10 (AUC=0.80, 95% CI 0.64-0.79) as optimal cut-off to discriminate
mutated patients with good sensitivity and specificity (range 84-98%). On the
basis of these variables, we awarded 0 points (LAP score <100, or peripheral
granulocyte precursors ≥10%), 1 point (peripheral granulocyte precursors <10%)
or 2 points (LAP score ≥100), and developed a simple scoring system to predict
JAK2 V617F mutation. All cases with a score of 3 carried the mutation, while
94% of patients with a score of 0 showed a wild-type gene. Then, we prospectively
tested this score system in a new cohort of 105 PFM patients obtaining superim-
posable results. Nineteen PMF patients, 16 carrying the JAK2 V617F mutation
and 3 nonmutated, were treated with the JAK1/2 inhibitor Ruxolitinib. Eleven
patients had a ≥50% reduction in spleen volume, 2 cases achieved a modest
decrease in spleen size, whereas in 6 cases no spleen response was observed.
In all cases, LAP score significantly decreased during treatment (P=0.02); how-
ever, no correlation was found between LAP levels or peripheral granulocyte pre-
cursors percentages and response to therapy.
Summary and Conclusions: We confirmed the association between LAP lev-
els and JAK2 V617F mutation; moreover, we suggest a very simple, low expen-
sive and reproducible method based on old techniques to predict this gene
mutation.
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RUXOLITINIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA AND SYMP-
TOMATIC SPLENOMEGALY
K. Geissler1,* T. Rand2, E. Jäger3, A. Zopf4, G. Mitterbauer-Hohendanner3
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Background: In patients with myelofibrosis the JAK1/2 inhibitor ruxolitinib has
been shown to reduce splenomegaly and constitutional symptoms. Efficacy
was also seen in patients without the JAK2 V617F mutation suggesting that
some drug effects may be due to a general attenuation of cytokine signaling
(Ostojic A et al. Drugs Today 2011). In patients with chronic myelomonocytic
leukemia (CMML) symptomatic splenomegaly and constitutional symptoms
may be also a clinical problem and there is no generally accepted standard
treatment for the myeloproliferative form of CMML. In vitro findings by us
(Geissler K et al. J Exp Med 1996) and others (Padron E et al. Blood 2013)
suggest that divergent molecular aberrations in CMML seem to converge within
the GM-CSF signaling pathway. Since JAK2 is a sentinel kinase in this pathway
(Hansen G et al. Cell 2008) ruxolitinib may be an attractive drug in CMML.
Aims: Clinical observations from case reports may be helpful to support treat-
ment concepts.
Methods: We report our findings in 2 CMML patients with symptomatic
splenomegaly and constitutional symptoms receiving ruxolitinib off label.
Figure 1. Effect of ruxolitinib on spleen volumes in two patients with
chronic myelomonocytic leukemia.
Results: Patient 1 is a 75-year-old man with CMML-1 since 10/2011, JAK2
V617F mutation, progressive splenomegaly and constitutional symptoms
refractory to hydroxyurea. After informed consent ruxolitinib (2x20mg/d) was
started in 5/2013. Within 1 week constitutional symptoms subsided. CT con-
firmed a reduction in spleen volume of 48% at week 15 (Figure 1). Initiation of
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ruxolitinib was associated with a clear reduction of white blood cell (WBC)
counts without clinically relevant changes in platelet counts and hemoglobin
values. The patients response regarding splenomegaly and constitutional
symptoms is continuing without a clear decline in JAK2 V617F allele burden
(94.6% at week 0, 89.7% at week 67). Patient 2 is a 72-year-old man with
CMML-1 and mutations in NRAS, and SRSF2, respectively. Because of rapidly
increasing WBC counts (from 25990/mm3 to 62920/mm3 within 6 weeks),
symptomatic splenomegaly and constitutional symptoms the patient received
ruxolitinib (2x20mg/d) in 8/2012 after providing consent. Constitutional symp-
toms disappeared within 1 week. A reduction of spleen volume of 38% at week
15 and of 48% at week 21 of ruxolitinib therapy was observed (Figure 1). Ini-
tiation of ruxolitinib was followed by a stabilization of WBC counts with no
major hematological toxicity. Spontaneous relative to stimulated in vitro CFU-
GM formation, which has been shown by us to be GM-CSF-dependent
(Geissler et al. J Exp Med 1996), decreased from 101% before ruxolitinib to
36% at week 5. After 8 months the patient lost his response to ruxolitinib and
was treated with azacitidine. Having achieved a second transient response
he died 22 months after diagnosis due to progressive disease.
Summary and Conclusions: We show here for the first time spleen response
and disappearance of constitutional symptoms by ruxolitinib in 2 patients with
CMML. The response in patient 1 which was seen without reduction in the
JAK2 allele burden as well as culture data obtained during ruxolitinib therapy
in patient 2 are in line with the assumption that inhibition of GM-CSF-depen-
dent signaling may be at least in part responsible for these effects. Ruxolitinib
may be an interesting molecule to be systematically studied in patients with
CMML.
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CLINICAL DIFFERENCES IN ESSENTIAL THROMBOCYTHEMIA
PATIENTS WITH AND WITHOUT THROMBOTIC COMPLICATIONS
A. Zherniakova1,* V. Shuvaev1, I. Martynkevich1, L. Polushkina1, K. Abdulka-
dyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Thrombosis is the main factor causing disablement in essential
thrombocythemia (ET) patients. Currently, the connection between increased
blood platelets and leukocytes values, as well as JAK2V617F mutation pres-
ence and the risk of thrombotic events in ET is well-known.
Aims: The aim of this study is to analyze clinical characteristics in ET patients
with and without thrombotic complications.
Methods: The subject for this study were 218 patients who had been diag-
nosed at the Russian Research Institute of Hematology and Transfusiology
outpatient department over a period of 10 years (2003-2013). The ET patients
were divided into 2 groups: those with thrombosis (Thr+) (n=67) and those
without (Thr-) (n=151). During the study, the following parameters were
observed: age, sex ratio, blood test data, and the frequency of JAK2V617F
mutation. The Mann-Whitney U test for quantitative variables and the Chi-
square test with Yate’s contingency correction were used for statistical analy-
sis. Statistical significance was set at the p<0.05 level.
Results: In group Thr+ the following thromboses were observed: arterial 38
(56.7%), venous 21 (31.4%), and both 8 (11.9%). The majority of ET patients
with thrombosis had had thrombotic events before ET was established and 7
of them developed it during the follow-up (median follow-up=24 months). Other
variables were: group Thr+ median age 58.1 and group Thr- 59.6 years; sex
ratio in group Thr+ 44 (65.7%) female and 23 (34.3%) male, in group Thr- 117
(77.5%) female and 34 (22.5%) male (p=0.09). No statistical differences were
found in blood count analysis values at the point of ET detection. Mean values
(standard deviations): in group Thr+ hemoglobin-14.1 (20) g/dL, WBC-10.10
(3.75)x109/L, platelets-932 (407)x109/L and group Thr- hemoglobin-13.9 (16)
g/dL, WBC-9.86 (3.56)x109/L, platelets-914 (358)x109/L. JAK2V617F mutation
was detected in 84% of the ET patients in group Thr+ and in 48% of those in
group Thr- (p=0.004). The risk of thrombosis according to the IPSET-throm-
bosis scale in group Thr+ was as follows: low-7.6%, intermediate-20.9% high-
71.5% and 42.3%, 37.8%, 19.9% in group Thr- (p<0.0001).
Summary and Conclusions: ET patients show difference in thrombotic
events development. Risk factors for thrombosis include: age>60 years, car-
diac risk factors, thrombotic complications in patient case history, and
JAK2V617F mutation. JAK2V617F mutation and IPSET-thrombosis scores
assist in individualizing therapeutic strategy. This helps provide dynamic
thrombosis prevention, extend the patient’s life duration, and improve their
quality of life.
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LONG-TERM RESULTS OF PREDNISONE TREATMENT FOR THE ANE-
MIA OF MYELOFIBROSIS
J.-C. Hernandez-Boluda1,* A. Martínez-Trillos2, V. García-Gutiérrez3, F. Fer-
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Background: Corticosteroids are generally considered to have modest activity
in the treatment of the anemia of myelofibrosis (MF), but the available data
are limited.
Aims: To retrospectively evaluate the efficacy and long-term outcome of sin-
gle-agent prednisone, usually given after failure of other therapies, in MF
patients with severe anemia. In addition, to analyze the pre-treatment clinical
variables associated with the response to such therapy.
Methods: Among 511 patients diagnosed with primary MF (PMF: 345) or MF
evolving from a previous essential thrombocythemia (ET) or polycythemia
vera (PV) (post-ET/PV MF: 166) from 1978 to 2014, thirty cases (PMF: 27,
post-ET MF: 3) were eligible for the study. Initial prednisone dose was 0.5-1
mg/kg daily, with progressive tapering to the minimum effective dose in respon-
ders. Responses were assessed according to the revised International Work-
ing Group for Myelofibrosis Treatment and Research (IWG-MRT) consensus
criteria (Tefferi et al., Blood 2013).
Results: Median follow-up was 17.4 months (interquartile range [IQR]: 5.5-
29.1). Twelve patients (40%) achieved anemia response according to the
IWG-MRT criteria, after a median time of 1.1 months (IQR: 0.9-1.6) on treat-
ment. The median daily dose to attain the response was 45 mg (IQR: 22.5-
60), and the median daily maintenance dose in responders was 10 mg (IQR:
6-15). Median response duration was 12.3 months (IQR: 9.3-29.7). At univari-
ate analysis, constitutional symptoms and more than 2% circulating blasts at
treatment start had borderline statistical significance for a lower probability of
response. A platelet increase >50x 109/L was observed in 3 out of 11 patients
(27%) with baseline counts <100x 109/L. Median survival from prednisone
start was significantly longer in anemia responders (5.0 years, 95% CI: 3.5-
6.5, versus 1.5 years, 95% CI: 0.2-2.8; P=0.002).
Summary and Conclusions: Prednisone has clear therapeutic activity in the
anemia of MF and should be considered in patients failing conventional ane-
mia-treating agents.
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CLINICAL CHARACTERISTICS OF CALR MUTATIONS IN JAPANESE
PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 
Y. Sugimoto1,* K. Ohishi2, M. Ikejiri3, K. Nakatani3, M. Masuya1, T. Nobori3,
N. Katayama1
1Hematology & Oncology, Mie University, 2Transfusion Service, 3Laboratory
Medicine, Mie University Hospital, Tsu, Mie, Japan
Background: Recurrent CALR mutations were recently identified in myelo-
proliferative neoplasms patients without mutated JAK2 or MPL.
Aims: We analyzed these three mutations in Japanese patients with essential
thrombocythemia (ET) in our single institute and elucidated clinical character-
istics of patients with CALR mutation. 
Methods: Genomic DNA was isolated from granulocytes in peripheral blood
of 66 patients with ET. Mutational analyses of JAK2V617F, JAK2 exon 12,
CALR exon 9, and MPL exon 10 were performed with quenching probe
method or Sanger sequencing. 
Results: Our ET cohort (male/female, 35/31; age, 16 y.o.-85 y.o.; median
age, 63 y.o.) consisted of 30 (45.5%) patients with CALR exon 9 frame shift
mutation, 24 patients (36.4%) with JAK2V617F, 2 patients (3.0%) with
MPLW515, and 10 patients (15.2%) without these three mutations (triple neg-
ative). From genomic analysis of CALR mutations, all of them were heterozy-
gous and the details of CALR mutation type were as follows: type 1, 52-bp
deletion (n=15, male/female, 9/6); type 2, 5-bp TTGTC insertion (n=11,
male/female, 9/2); type 4, 34-bp deletion (n=2, male/female, 1/1); novel frame
shift deletions (c.1100_1152del53insG and c.1097_1130del34) (n=2,
male/female, 1/1). One of novel mutations is a single amino acid variant of
type 1 mutation and the other one is 2 amino acid variant of type 4 mutation.
Next, we compared the clinical parameters between CALR-mutated ET and
JAK2-mutated ET. CALR mutations were detected in the majority of male
patients and relatively younger female ET patients, while frequency of
JAK2V617F mutation was higher in elder female patients. Platelet counts of
CALR-mutated patients tended to be higher than those of JAK2-mutated
patients (1013x 109 /L vs 778x 109 /L, p=0.05). A progressive increase in the
number of platelets (>300x 109 /year) was observed in 7 out of 30 CALR-
mutated ET, but in only one out of 24 JAK2-mutated ET. However, thrombotic
events were not observed in 30 CALR-mutated patients, while they did occur
in 6 out of 24 JAK2-mutated patients and 3 out of 10 triple negative patients.
Significant difference was not observed between type 1 and type 2 CALR
mutations, regarding clinical characteristics because patient numbers were
small. Disease progression was observed in three out of eleven ET cases
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with CALR type 2 mutation about twenty years after diagnosis of ET: two
patients developed severe secondary myelofibrosis (MF), and one patient
developed acute myeloid leukemia (FAB M7). All of them were male with type
2 CALR mutation. Both of two secondary MF patients had cytogenetic abnor-
malities including 1q21 and 6p23. One of them is still alive after allogeneic
bone marrow transplantation, but the other patient died of hemorrhagic cere-
bral infarction due to tumor embolism. A patient with secondary leukemia con-
tained complicated karyotype including 1q32 abnormality and died of chemo-
refractory leukemia (Table 1).
Table 1. ET with transformation to severe MF or acute leukemia.
Summary and Conclusions: Platelet counts were higher and tended to
increase at a higher rate in patients with CALR-mutated patients than in those
with JAK2-mutated patients. However, incidence of thrombotic events was
significant lower in CALR-mutated patients. Disease progression was
observed in three male patients with type 2 CALR mutation and cytogenetic
abnormalities including 1q. It is reported that PMF patients with type 2 CALR
mutation exhibit comparably worse survival than those with type 1 CALR
mutation. Although patient numbers are limited, combination of CALR type 2
mutation and specific cytogenetic abnormalities might be related to disease
progression. 
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SIMULATION IN CONTINUING EDUCATION: IMPROVING HEMATOLO-
GIST EVIDENCE-BASED DECISIONS FOR MYELOPROLIFERATIVE NEO-
PLASM MANAGEMENT
E. Van Laar1,* D. Blevins2, R. Levine3, R. Mesa4
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Background: Due to the rarity of the disorders, many hematologists, espe-
cially those in the community setting, lack experience in diagnosis, treatment
and monitoring of myeloproliferative neoplasms (MPN). Prompt, accurate
diagnosis and appropriate initiation of treatment are important because poly-
cythemia vera (PV) and myelofibrosis (MF) are associated with shortened life
expectancy, serious complications, and impaired quality of life.
Aims: Underlying clinical practice gaps and educational needs were identified,
and a study was conducted to determine whether online, simulation-based
educational interventions could improve competence and performance of
hematologists in managing patients with MPN.
Methods: A cohort of US-practicing hematologists who participated in simu-
lation-based educational interventions was evaluated. The interventions con-
sisted of 4 cases presented in a platform that allowed learners to choose from
numerous lab tests and assessment scales as well as thousands of diag-
noses, treatments, and monitoring approaches. Participant clinical decisions
were analyzed using artificial intelligence technology, and instantaneous or
delayed clinical guidance was provided employing current evidence-based
and expert faculty responses. To assess the impact of simulation-based edu-
cation on clinical decisions, each participant’s decisions were collected after
clinical guidance and compared with that same individual’s baseline data. A
2-tailed paired T-test was used to determine statistical significance.
Results: The assessment sample consisted of 284 hematologists who made
at least 1 clinical decision within the simulation and proceeded to the final,
debrief section. As a result of clinical guidance provided through simulation,
significant improvements were observed in several areas of management of
patients with MPN, specifically: In PV: -11% improvement in the diagnosis of
PV (62% post intervention vs 56% baseline, P<.013); -109% improvement in
the selection of appropriate initiation of therapy (JAK2 inhibitor/interferon
alpha) for a patient with PV refractory to hydroxyurea (48% post intervention
vs 23% baseline, P<.001); -79% improvement in MPN symptom monitoring
for a patient with PV (50% post intervention vs 29% baseline, P<.001); In MF:
-29% improvement in the diagnosis of primary MF (63% post intervention vs
49% baseline, P<.002); -124% improvement in the selection of appropriate
initiation of therapy (JAK2 inhibitor) for a patient with primary MF (60% post
intervention vs 27% baseline, P<.001); -75% improvement in MPN symptom
monitoring for a patient with MF being managed with a JAK2 inhibitor (40%
post intervention vs 23% baseline, P<.001).
Summary and Conclusions: This study demonstrated the success of simu-
lation-based educational interventions on improving the evidence-based prac-
tice patterns of hematologists in the management of patients with MPN.
Despite the marked improvement in competence and performance, hematol-
ogist education needs specific to accurate MPN diagnosis, treatment selec-
tion, and symptom monitoring remain. The education gaps uncovered during
this intervention and the evolving treatment landscape outside of the United
States lay a foundation for future global education initiatives to bridge educa-
tion gaps in MPN.
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CLINICAL CHARACTERISTICS OF POLYCYTHEMIA VERA PATIENTS,
RECEIVING DIFFERENT TYPES OF THERAPY
D. Shikhbabaeva1,* V. Shuvaev1, I. Martynkevich1, A. Abdulkadyrova1, V. Udal-
eva1, T. Zamotina1, M. Fominykh1, R. Golovchenko1, I. Zotova1, L. Polushkina1,
K. Abdulkadyrov1
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Background: Achievements of fundamental sciences in study the pathogen-
esis of Polycythemia Vera (PV) made possible to create drugs with target
mechanism of action. It is important to determine indications for target drugs
with consideration their high cost and possible side effects.
Aims: Aim of study was to investigate clinical features of PV, receiving different
types of therapy.
Methods: 252 patients (pts) (147 female, 107 male), median age 59 years
(range 20-86), median of observation 6.1 year. Pts were divided into 4 groups:
phlebotomy and erythrocytapheresis (Phleb/Aph), therapy with hydroxyurea
(HU), with interferon-alpha (IFN), combined therapy with hydroxyurea and
interferon-alpha (HU+IFN). The endpoints were: clinical and laboratory fea-
tures, treatment outcomes, thrombosis incidence and overall survival (OS).
Responses to therapy were evaluated according to ELN criteria. Statistical
analysis was conducted with Kruskal-Wallis ANOVA and Chi-square tests.
Survival analysis was performed by Kaplan-Meier method with log-rank test.
Results: The Phleb/Aph group consisted of 36 pts with median age 57 years.
Baseline complete blood count (CBC): HB 18.6 g/dl (13.1-23.8), RBC
6.78x1012/l (5.36-9.30), HCT 57.6 (46.9-75.0), WBC 8.8x109/l (4.3-16.4), PLT
337х109/l (143-796). Splenomegaly was observed in 17%. Phleb/Aph proce-
dures performed with rate from 0.10 to 9.7 (mean 5.1) procedures per year.
Complete response (CR) was achieved in 5.5%, partial response (PR) in 67%,
no response (NR) was seen in 27.5% of patients. The outcome in myelofibro-
sis (MF) was observed in 2.8%. Thrombotic episodes occurred in 19%. The
HU group included 173 pts (median age 61 years). CBC data: HB 18.7 g/dl
(13.94-25.6), RBC 7.22x1012/l (5.22-10.29), HCT 59.3 (47.1-82.0), WBC
12.5x109/l (3.6-64.8), PLT 535х109/l (136-1642). Splenomegaly was observed
in 35%. Mean daily dose of HU was 0.7 (0.3-1.5) g. 7.5% achieved in CR,
76.5% had PR and NR in 16%. The MF transformation was observed in 3.5%.
Thrombotic incidence was in 6.6%. The IFN group consisted of 11 pts with
median 53 years. CBC: HB 17.6 g/dl (13.5-21.5), RBC 6.66x1012/l (5.90-7.48),
HCT 54.2 (43.0-64.2), WBC 12.3x109/l (3.6-23.7), PLT 562x109/l (312-1087).
Splenomegaly was detected in 64%. Mean weekly dose of IFN was 8.27 (4-
12) million IU. CR was achieved in 36%, PR in 36%, NR was seen in 28%.
The outcome in MF was observed in 28%. Thrombotic complications did not
occurred. The HU+IFN group consisted of 32 pts with median age 51 years.
CBC: HB 19.0g/dl (13.2-22.3), RBC 7.45х1012/l (5.17-9.99), HCT 60.4 (48.8-
72.8), WBC 11.0х109/l (5.1-21.0), PLT 549x109/l (171-1189). Splenomegaly
was observed in 53%. Mean daily dose of HU was 0.8 (0.5-1.5) g, mean week-
ly dose of IFN was 8.27 (6-30) million IU. CR wasn’t achieved in this group,
PR had 75% and NR in 25%. The outcome in MF was seen in 6%. Arterial
thrombotic episodes occurred in 6%. Statistically significant differences
between groups were obtained: age of patients (p=0.006), RBC(p<0.01), HCT
(p<0.01), WBC (p<0.01), PLT (p<0.01), splenomegaly (p=0.04), response to
therapy (p<0.01). Groups didn’t differ in the frequency of postPV-MF (p=0.23),
the overall frequency of thrombosis (p=0.19), arterial (p=0.56) and venous
(p=0.34) thrombosis, and OS (p=0.29).
Summary and Conclusions: PV is one of the most frequent myeloprolifera-
tive neoplasms with various clinical symptoms. The choice of therapy depends
on the patient’s age and clinical symptoms. The most of PV patients don’t
have a clinically significant response to therapy or achieve only a partial
response. This PV population might have perspective of improved treatment
results and OS with administration of targeted drugs in future.
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COMPLETE HEMATOLOGIC CONTROL WITH RUXOLITINIB IN PATIENTS
WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF
HYDROXYUREA
C.N. Harrison1,*T. Masszi2, P. Zachee3, F. Pane4, A.M. Vannucchi5,
S. Verstovsek6, M.M. Jones7, D.S. Hunter7, S. He7, J. Li8, M. Khan8, D. Habr8,
J.-J. Kiladjian9
1Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 2St.
István and St. László Hospital, Budapest, Hungary, 3ZNA Stuivenberg,
Antwerp, Belgium, 4University of Naples Federico II, Naples, 5University of
Florence, Florence, Italy, 6The University of Texas MD Anderson Cancer Cen-
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Paris Diderot, Paris, France
Background: Ruxolitinib (RUX) is a JAK1/JAK2 inhibitor that has shown supe-
riority over standard therapy for the treatment of PV for patients (pts) with an
inadequate response to or unacceptable side effects from hydroxyurea (HU).
RUX was well tolerated and effective in controlling hematocrit (HCT), decreas-
ing splenomegaly, and improving symptoms. PV is a trilineage disease, and
in addition to elevated HCT, pts often have elevated white blood cell (WBC)
and platelet (PLT) levels.
Aims: To explore the efficacy of RUX vs best available therapy (BAT) in con-
trolling HCT, WBC, and PLT levels in RESPONSE.
Methods: Pts with PV who were HU-resistant/intolerant by modified ELN cri-
teria and required phlebotomy (PBT) for HCT control were randomized 1:1 to
RUX 10 mg bid or BAT. The primary composite endpoint was the proportion
of pts who achieved HCT control without PBT from wk 8-32 (with ≤1 PBT wk
0-8) and a ≥35% reduction in spleen volume from baseline (BL) at wk 32. Pts
on BAT could cross over to RUX after wk 32. In this preplanned analysis of a
wk 80 data cutoff, hematologic parameters were assessed by BL level (HCT,
>45% and ≤45%; WBC and PLT, by BL quartile [Q1-Q4]).
Results: Pt characteristics (RUX, n=110; BAT, n=112) were well balanced
between groups. Median HCT was 43.3% vs 44.0% (RUX vs BAT); despite
having HCT control with PBT within 2 wk of randomization, many pts had HCT
>45% at BL (RUX, 25% [n=28]; BAT, 22% [n=25]); PLTs (median, 397 vs
444×109/L) ranged from: RUX, 100-1852×109/L (Q1, 250; Q3, 650); BAT, 78-
1604×109/L (Q1, 261; Q3, 654); and WBCs (median, 16.5 vs 16.3×109/L) from:
RUX, 3.0-67.0×109/L (Q1, 11.1; Q3, 22.5); BAT, 2.9-82.8×109/L (Q1, 10.4; Q3,
23.1). At data cutoff, 82.7% of RUX pts remained on treatment and no pts
remained on BAT (median exposure, 111 and 34 wk). As previously reported,
significantly more RUX pts achieved the primary composite endpoint (21% vs
1%; P<.0001) and complete hematologic response (CHR) at wk 32 compared
with BAT (24% vs 9% P=.003; Vannucchi NEJM 2015). These improvements
were durable in RUX pts, with probabilities of 0.96 and 0.69 of maintaining a
primary response and CHR at wk 80, respectively. In comparison to BAT pts,
more RUX pts achieved WBC ≤10×109/L (RUX: BL, 21%; wk 32, 41%; BAT:
BL, 21%; wk 32, 31%) and PLT ≤400×109/L (RUX: BL, 51%; wk 32, 61%; BAT:
BL, 46%; wk 32, 41%). For pts with uncontrolled HCT (>45%) at BL despite
PBT (Figure 1A), mean HCT in the RUX arm declined to <45% while mean
HCT for BAT-treated pts remained mostly >45% and above RUX-treated pts.
For pts whose HCT was <45% at BL, mean values in the RUX arm were also
consistently lower than in the BAT arm. Pts with near normal WBC or PLT
counts at BL (Q1, Q2) had levels that remained at or near BL values over the
course of treatment. For pts with higher WBC or PLT counts at BL (Q3, Q4),
mean values improved with RUX and were lower than with BAT. Pts with the
highest WBC counts at BL (Q4) had the largest reductions (Figure 1B), with
mean values in the RUX arm approximately 15×109/L or lower from wk 8
onward and those in the BAT arm >25×109/L. 
Figure 1. Mean (+/- standard erros) HCT, WBC, and PLT levels by baseline
categories and time.
Similar results were seen in pts with the highest PLT counts at BL (Figure 1C),
with mean values in the RUX arm reaching <500×109/L from wk 20 onward
while those in the BAT arm remained elevated.
Summary and Conclusions: In RESPONSE, long-term RUX treatment led
to control of HCT, WBC, and PLT levels, with the largest reductions for pts
with the most elevated values at BL. RUX provided durable and comprehen-
sive hematologic control in pts with PV who had an inadequate response to
or unacceptable side effects from HU.
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PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS
WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA
MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF
(POST-ET MF) 
T. Uno, S. Verstovsek1,* R. Mesa2, M. Talpaz3, E. Ritchie4, M. Wadleigh5,
O.M. Odenike6, C. Jamieson7, B. Stein8
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University of Michigan, Ann Arbor, MI, 4Cornell University, New York, NY,
5Dana Faber Cancer Institute, Boston, MA, 6University of Chicago Medical
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Background: NS-018 is an oral, selective, small molecule inhibitor of Janus
kinase 2 (JAK2)
Aims: The purpose of this study is to determine the safety and tolerability of
orally administered NS-018 in patients with PMF, post-PV MF, or post-ET MF
Methods: This multicenter, Phase 1/2, 3+3 dose-escalation study of NS-018
enrolled patients with IPSS intermediate-1, intermediate-2, or high risk PMF,
post-PV MF, or post-ET MF. Patients were ≥18 years, ECOG PS ≤2 and
required therapy. NS-018 was dosed orally QD or BID in 28-day cycles.
Responses were assessed according to IWG consensus criteria, changes in
spleen size by manual palpation and QOL with the Myelofibrosis Symptom
Assessment Form (MF-SAF). The Phase 1 portion of the study is completeand
is presented here.
Results: Patients: 48 patients were enrolled across 10 cohorts.
Patient characteristics: 37 PMF, 5 post-PV MF, 6 post-ET MF; median
age (range) 69.5yrs (38-83); M/F:29/19; 35 JAK2V617F+; and 22 pre-
viously treated with a different JAK2 inhibitor. Dosing and tolerability:
Dose levels included 75, 125, 200, 300 and 400 mg QD and 100, 200,
250, 300 and 400 mg BID. Systemic exposures based on Cmax were
approximately dose proportional across the tested range from 75 to
400 mg. At 400 mg QD/BID, NS-018 was not well-tolerable-based on
the proportion of drug-related neurologic AEs. Dizziness (Grade2 and
3), peripheral neuropathy (Grade1), headaches(Grade1), disturbance
in attention (Grade1), vertigo (Grade1), dysesthesia (Grade1), and
nervous system disorder (Grade1) were observed at 400 mg BID.
Dizziness (Grade1 and 3), paresthesia (Grade1), disturbance in atten-
tion (Grade1), and aphasia (Grade1) wereobserved at 400 mg QD. At
NS-018 doses <400 mg, 300 mg QD was better tolerated than 250 mg
or 300 mg BID, with a lower rate of neurologic AEs and discontinua-
tions due to AEs. For the 300 mg QDcohort (n=15), the most frequent
drug-related AEs across all grades were decreased platelet count
(≥Grade 3, 20%); Grade 3 related AEs were platelet count decreased
(13%) and dizziness (7%); and Grade 4 related AEs were platelet
count decreased (7%). Overall, 31 patients (65%) discontinued treat-
ment due to AEs (n=9), progressive disease (n=11), MD/patient deci-
sion (n=9), or no clinical benefit after 6 cycles (n=2). The AEs leading
to discontinuation included thrombocytopenia (Grade 4), transient
ischemic attack (Grade 2), muscle contraction involuntary (Grade 2),
dizziness (Grade 1), insomnia (Grade 1),neutropenia (Grade 3), elec-
trocardiogram QT prolonged (Grade 3), hemolytic anemia (Grade 3),
dizziness (Grade 2), dysphagia (Grade 2), nervous system disorder
(Grade 1), and hemolysis (Grade 3). Responses: Of 36 evaluable
patients with baseline splenomegaly ≥5 cm and treatment for ≥1 cycle,
20 (56%) patients showed ≥50% reduction in spleen size (confirmed
for ≥8 weeks in 16 patients). In addition, 12 patients showed splenic
clinical improvement (CI) for ≥8 weeks, 4 patients hemoglobin CI, and
1 patient platelet CI. Median (range) time to splenic response and
duration of response: 1 cycle (1-12) and 6 cycles (1-25). Splenic
reductions ≥50% are shown in the Table 1 for the specified patient
groups. Changes in MF-SAF and PK and PD results will be present-
ed.
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Table 1.
Summary and Conclusions: The RP2D dose was 300 mg QD. This dose
provided a durable dosing schedule,an acceptable safety profile,was associ-
ated with splenic size reduction and clinical improvement. Phase 2 is ongoing
and includes patients previously treated with a different JAK2 inhibitor.
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XRCC1 399GG GENOTYPE PREDICTS LONG LASTING CR AND SIGNIFI-
CANTLY LONGER OVERALL SURVIVAL IN RESISTANT LYMPHOMA
TREATED WITH BENDA-BEAM AND ASCT
G. Visani1,*F. Loscocco1, E. Giacomini2, A. Ruzzo2, P.M. Stefani3, S. Capria4,
P. Galieni5, F. Gaudio6, G. Specchia6, G. Meloni4, F. Gherlinzoni3, S. Falcioni5,
R. Gonella7, M. Gobbi7, B. Sarina8, A. Santoro8, F. Fuligni9, G. Nicolini1,
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Roma, 5Ascoli Piceno Hospital, Hematology, Ascoli Piceno, 6University of Bari
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Background: We demonstrated (Visani et al., Blood 2011, Blood 2014) the
efficacy of a new conditioning regimen with bendamustine, etoposide, cytara-
bine, and melphalan (Benda-BEAM) prior to autologous stem cell transplant
(ASCT) in heavily pretreated lymphoma patients (72% CR at 41 months after
ASCT; 3 years PFS 75%). Biological markers predicting response to Benda-
BEAM would significantly impact the clinical decision making. Cytotoxic activity
of Bendamustine is enhanced by inhibition of the base excision repair (BER)
DNA-damage response pathway, suggesting that the BER enzymes play a key
role in the repair of DNA damage caused by Bendamustine. Accordingly, we
evaluated the impact of the BER family genetic variants, in lymphoma patients
receiving the Benda-BEAM conditioning regimen pre-ASCT.
Aims: To evaluate the prognostic significance ofxRCC1 G399A,xRCC3 C241T
and ADPRT T2444C non-synonymous genetic variants on clinical outcome of
Hodgkin (HD) and non-Hodgkin (NHL) lymphoma patients treated with BeEAM-
ASCT.
Methods: All 43 patients with resistant/relapsed NHL (n=28) or HD (n=15),
enrolled in the clinical trial (EUDRACTnumber2008-002736-15), were analyzed.
Peripheral blood samples were available for somatic DNA extraction and geno-
typing analysis. Three Single Nucleotide Polymorphysms (SNPs) of BER genes
[XRCC1 399 (rs25487 G/A, Arg/Gln),xRCC3 241 (rs861539 C/T, Thr/Met),
ADPRT T2444C (rs1136410 T/C, Val/Ala)] were analyzed by PCR-HRM (High
Resolution Melting) assay and restriction digests of PCR products. Χ2 test and
Fisher’s exact test were used to analyze the association between the patho-
logical features and SNPs. All the candidate genotypes were evaluated to iden-
tify a potential correlation with overall survival (OS) using long-rank test and
Cox regression model. For all the target genes, the distribution of genotypes
was checked for Hardy-Weinberg equilibrium.
Results: In univariate analysis, thexRCC1 399 GG andxRCC3 241 TT geno-
type were associated with significantly longer overall survival (OS), if compared
with the other genetic variants (p=0.035, p=.0.025). Multivariate analysis con-
firmed the prognostic role ofxRCC1 GG on OS (p=0.005). Interestingly, all
patients carryingxRCC1 399 GG genotype reached CR, independently from
the disease type (HD and NHL), thus suggesting a possible positive predictive
role for thexRCC1 399 GG genotype in influencing both CR and OS of heavily
pretreated lymphoma patients. On the other hand, CR rate for patients bearing
thexRCC1 399 AA or GA genotype were 75% and 84%, respectively. Analyzing
pre-treatment features and genetic variants, we observed that patients carrying
the ADPRT 2444 CC or CT genotype had a chemoresistant disease, whereas
with TT genotype had a chemosensitive disease. Interestingly, the disease sta-
tus at transplant was a strong predictor of both PFS and OS in the clinical trial.
On the other hand, no association was found between the disease type or oth-
ers clinical features and SNPs in BER genes. 
Summary and Conclusions: xRCC1 399GG genotype is predictive for longer
duration of overall survival in lymphoma patients treated with Benda-BEAM
conditioning pre-ASCT. Moreover, the presence ofxRCC1 399 GG genotypes
was associated with the achievement of CR in 100% of patients carrying this
genotype.xRCC1 399 genotype could, thus, represent a biomarker in patients
with lymphoma, treated with Bendamustine BEAM regimen and ASCT.
Acknowledgements: supported in part by AIL Pesaro Onlus.
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FUNCTIONAL DEFECTS OF T CELLS OF LYMPHOMA PATIENTS AFTER
DIFFERENT CHEMOTHERAPY REGIMENS ACTIVATED BY THE BISPE-
CIFIC ANTIBODY AFM11
J. Düll1,* L. Rasche1, H. Einsele1, M. Topp1
1Medizinische Klinik II, Hämatologie, Würzburg, Germany
Background: Patients who suffer from hematological malignancies like B cell
lymphoma have to undergo chemotherapy. There is a high risk for a relapse or
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a refractory disease for older patients and patients suffering from MCL. Unfor-
tunately, there are only poor options for younger patients after autologous Stx
transplantation and for older patients who are not eligible for transplantation.
In this situation new immunotherapy and antibodies gain in importance. One
of them is the bispecific T cell engager CD19-CD3 antibody AFM11. The T
cells system of the patients seems to play a critical role in response or non-
response to T cell engaging antibodies.
Aims: We try to evaluate the T cell system of the patients after chemotherapy (R-
Benda, R-CHOP, HD-BEAM). As a preclinical study we explore the potential of
the TandAb antibody AFM11 in heatlhy donors and lymphoma patients to describe
the function and possible defects of patients T cells after chemotherapy.
Methods: We examine the blood of 32 patients with different lymphoma and
chemotherapies 6 weeks after their last chemotherapy. 17 healthy donors
donated blood for the control group. The lymphocytes are analyzed by multi-
color FACS staining. Absolut cell counts are calculated by the percentages in
the lymph gate in relation to the lymphocytes absolute number in the central
lab. For quantification of cytokines of the AFM11 engaged T cells CBA technol-
ogy was used. Proliferation assays were performed with CFSE dilution tech-
nique. For lytic activity a FACS based lysing assay was performed with Annexin
and PI readout. The effector to target ratio was decreased for higher sensitivity
of this assay to a ratio of 1:25 (E:T).
Results: A full immune recovery of the immune system of lymphoma patients six
weeks after chemotherapy is not verifiable. We find less CD3 cells (median 200
cells/µl -chemo group vs 1200cells/µl-healthy), NK cells (median 48-chemo group
vs 222 cells/µl-helathy) and no B cells in comparison to healthy donors. Regulatory
T cells-known as suppressor cells- are much higher in the R-Bendamustin and
HD-Beam group. These findings can be relevant for the treatment of patients with
a T cell engaged antibodies like bispecific antibodies with one CD3 component.
To clarify the function of the T cells we performed standardized T cell assays with
AFM11. There is no difference between healthy donors and patients regarding
the proliferation of T cells after AFM11 activation. T cells of patients after R-CHOP
and HD BEAM therapy produce high amounts of IL10 (average: 30pg/ml) in com-
parison to the R-Benda group (average: 10pg/ml). The IL2 production of patients
T cells treated with R-Bendamustin and HD -BEAM was reduced from 700pg/ml
(healthy donors and R-CHOP) to 300pg/ml. The specific lyse is 25% reduced in
patients after chemotherapy without any significance difference in the subgroups
of the different chemotherapy protocols. To investigate differences between the
subgroups and for a better sensitivity of the lysing assay we decreased the effector
to target ratio from 1:2 to 1:25. With this step we see reduced lysing capacity of
patients T cells after R-Bendamustin and HD BEAM treatment.
Summary and Conclusions: T cells of lymphoma patients after different
chemotherapy regiments are reduced and have functional defects. This may
affect the in vivo response to bispecific antibodies like AFM11. If this findings
correlate with the in vivo response will be evaluated in an ongoing phase I trial
with AFM11 in lymphomas.
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DESIGN AND DEVELOPMENT OF A NOVEL, HIGHLY POTENT AND
SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-215, AS POTENTIAL
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Background: The phosphatidylinositol-3-kinase δ (PI3Kδ) has emerged as a
promising target for the treatment of many hematological malignancies, such
as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL).
Recent clinical trials have demonstrated that Idelalisib, a specific PI3Kδ
inhibitor, achieved significant antitumor activity in CLL and NHL. However, Ide-
lalisib can have serious side effects, i.e. hepatotoxicity, severe diarrhea or coli-
tis, pneumonitis, and intestinal perforation. Therefore, there is an urgent need
to develop PI3Kδ inhibitors which entail diminished adverse events.
Aims: The aim of the study was to investigate the therapeutic potential of a
novel PI3Kδ inhibitor CPL-302-215 in hematologic malignancies.
Methods: Using knowledge-based drug design approach we have designed a
novel small molecule PI3Kδ inhibitor, CPL-302-215, structurally different from
other known δ-selective inhibitors. To establish the activity and the selectivity of
the compound among class I of PI3K lipid kinases and selected protein kinases,
we have used kinase activity assay, ADPGloTM. Additionally, the biological potency
and selectivity of a developed inhibitor was evaluated in a cell viability assays and
Western blot analysis in a number of hematological cell lines. Finally, using an in
vivo mouse model a bioavailability, as well as microsomal stability was assessed. 
Results: Our results indicate that CPL-302-215 inhibits PI3Kδ kinase with low
nanomolar concentrations (IC50=5,3nM) comparable to Idelalisib (IC50=4,1nM).
Additionally, CPL-302-215 exhibits exceptional selectivity over γ, β and α iso-
forms of PI3K (2080, 2000, and 63-fold, respectively) in comparison to Idelalisib
(27, 100 and 117-fold, respectively). Moreover, CPL-302-215 does not inhibit
protein kinases from the Celon Pharma’s selectivity panel at the concentration
of 1μM. In cell-based viability assays CPL-302-215 inhibits some NHL cell
lines. Western blot analysis has shown that CPL-302-215 significantly inhibits
phosphorylation of Akt in Raji cell line after anti-IgM stimulation (IC50<50nM).
Additionally, in a PI3Kγ-specific cell line RAW 264.7, compound selectivity has
been confirmed by showing no effect on Akt phosphorylation after C5a stimu-
lation up to the concentration of 5μM in opposite to Idelalisib which reduced
phosphorylation of Akt in 5μM. Analysis on microsomes (mouse, rat, dog and
human), showed that CPL-302-215 is showing virtually no CYP-mediated
metabolism. Therefore, a pharmacokinetics study was conducted to charac-
terize CPL-302-215 disposition in mice plasma. Orally (30mg/kg) and intra-
venously (10mg/kg) administered CPL-302-215 displayed attractive bioavail-
ability and reached appreciably high concentrations in plasma (p.o.
AUC=5,157μg/ml*h-1, Tmax=0,5h, Cmax=3,038μg/ml; i.v. AUC=2,492μg/ml*h-
1, Cmax=1,053μg/ml; F=82,82%). Currently, the therapeutic potential of CPL-
302-215 on primary cells from CLL patients is being evaluated. 
Summary and Conclusions: We have designed CPL-302-215-a very potent
and selective PI3Kδ inhibitor, both in the kinase- and cell-based assays. Pre-
clinical data from NHL cell lines indicate the therapeutic potential of CPL-302-
215 in hematologic malignancies. Moreover, our compound is very stable on
various species and has attractive bioavailability in mice. The activity and
unique selectivity of CPL-302-215 qualifies it for the consideration as a drug
with wide therapeutic window and limited side effects in clinical use.
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NR4A1 AND NR4A3 POSSESS FUNCTIONAL REDUNDANCY BY REGU-
LATING PRO-APOPTOTIC GENES IN AGGRESSIVE LYMPHOMAS.
A. Deutsch1,* B. Rinner2, K. Wenzl1, K. Troppan1, B. Pursche1, C. Beham-
Schmid3, P. Neumeister1
1Hematology, Internal Medicine, MUG, 2ZMF, MUG, 3Hematolpathology,
Pathology, MUG, Graz, Austria
Background: Recently, we described a significant down-regulation of NR4A1
(Nur77) and NR4A3 (Nor-1) -two members of the orphan nuclear receptors
acting together as critical tumor suppressor genes in acute myeloid leukemia-
in aggressive lymphoma. NR4A1 over-expression proved its pro-apoptotic func-
tion in aggressive lymphoma cells and its lymphoma suppressive properties in
vivo was demonstrated in axenograft mouse model.
Aims: Since the role of down-regulated NR4A3 in aggressive lymphomas is
unknown, we aimed to investigate the function of NR4A3 in lymphoid malig-
nancies.
Methods: For functional characterization NR4A3 was over-expressed in a
SuDHL4 lymphoma cell line by using an inducible lentiviral construct followed
by various apoptotic assays and by axenograft mouse experiment. To further
compare the transcriptional activity as nuclear receptor of NR4A3 to NR4A1,
both receptors were separately over-expressed in aggressive lymphoma cell
lines (Karpas-422 and SuDHL4 as GCB- cell line, RI-1 and U2932 as ABC-
cell lines) followed by mRNA expression analysis of intrinsic (BIK, BID, BMF,
Noxa, BAK, Bax, Puma, Bim, Bcl-2, Bcl-X and Mcl-1) and extrinsic (FasL, Fas,
Trail, DR4 and DR5) apoptotic genes. 
Results: Induction of NR4A3 expression led to a significantly higher proportion
of induced SuDHL4 cells undergoing apoptosis as demonstrated by DNA cleav-
age, Annexin V staining and increased caspase 3-7 activity suggesting func-
tional redundancy to NR4A1 in aggressive lymphomas. To test the tumor sup-
pressor function of NR4A3 in vivo, the stably transduced SuDHL4 lymphoma
cell line was further investigated in the NOD scid gamma (NSG) mouse model.
Induction of NR4A3 in SuDHL4 abrogated tumor growth in the NSG mice, in
contrast to vector control- and uninduced SuDHL4 cells, which formed massive
lymphoid tumors. Interestingly, mRNA expression analysis of apoptotic genes
in aggressive lymphoma cells demonstrated that NR4A1 and NR4A3 over-
expression induced Trail, Bim, Puma, BIK, BID and BAK in a similar pattern.
Summary and Conclusions: Our data demonstrate that NR4A3 has pro-
apoptotic properties which are functionally redundant to NR4A1 and define
NR4A3 as novel tumor suppressor in aggressive lymphomas.
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CD3+/CD8+/CD16+/CD56-/CD57+ T-LGLL REPRESENTS A DIFFERENT
SUBSET WITH DISTINCT CLINICAL AND BIOLOGICAL FEATURES
G. Barilà1,2,* A. Teramo1,2, G. Calabretto1,2, C. Ercolin1,2, A. Cabrelle2, E. Boscaro1,
M. Facco1,2, F. Piazza1,2, L. Trentin1,2, G. Semenzato1,2, R. Zambello1,2
1Dept of Medicine, Hematology and Clinical Immunology section, Padua University
School of Medicine, 2Venetian Institute of Molecular Medicine, Padua, Italy
Background: T-Large Granular Lymphocyte Leukemia (T-LGLL) is a chronic
and heterogeneous lymphoproliferative disorder characterized by clonal expan-
sion of CD3+ Large Granular Lymphocyte (LGL) with effector memory pheno-
type (CD3+/CD8+/CD57+/CD45RA+/CD62L-), although rare forms of CD4+
LGLL are described and characterized by CD4+/CD8-/dim expression. Most
patients present an indolent course but can become symptomatic due to the
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development of cytopenia, in particular neutropenia. At last, somatic activating
STAT3 mutations were discovered in approximately 30-40% of T-LGLL patients.
Aims: Aim of this study is the characterization of different clinical and biological
features of T-LGLL patients through evaluation of clinical, namely the presence
of neutropenia, and biological features including phenotypic analysis, the pres-
ence of STAT3 mutation, activation and expression of its target Mcl-1.
Methods: In 87 patients with diagnosis of T-LGLL, LGLs were analysed for the
presence of neutropenia and by flow cytometry using antibody for CD3, CD4,
CD8, CD16, CD56, CD57; DNA samples from these 87 patients were available
for STAT3 mutation analysis through Sanger sequencing and PCR ARMS for
Y640F and D661Y mutations. Western Blotting analysis for pSTAT3 Tyr 705,
STAT3 and Mcl-1 level was performed.
Results: A cohort of 87 patients affected by T-LGLL was studied by FACS analy-
sis; 56/87 (64%) patients were CD3+/CD4-/CD8+ T-LGLL (CD8+ T-LGLL) while
31/87 (36%) patients were CD3+/CD4+/CD8-/dim T-LGLL (CD4+ T-LGLL). STAT3
exon 21 somatic mutation analysis with Sanger sequencing and PCR ARMS
analysis was then performed and 30 out of 87 (34%) patients resulted mutated
(21 with Y640F, 7 with D661Y, 1 with D661V and 1 with N647I). All mutated
patients were in CD3+/CD4-/CD8+ group while all CD3+/CD4+/CD8-/dim patients
resulted wild type. Additional FACS analysis with CD16, CD56 and CD57 anti-
bodies was performed in CD3+/CD4-/CD8+ cohort identifying four distinct sub-
groups: CD16+/CD56-/CD57±subgroup (33/56, 59%), CD16-/CD56-/CD57+ sub-
group (5/56, 9%), CD16-/CD56+/CD57+ subgroup (15/56, 27%) and
CD16+/CD56+/CD57+ (3/56, 5%). Interestingly, 27/28 mutated patients were in
the CD16+/CD56-/CD57±subgroup while only one mutated patient fall in the
CD16-/CD56-/CD57+ subgroup. Patients with CD3+/CD8+/CD16+/CD56-
/CD57±phenotype presented higher level of pSTAT3 Tyr705 than other CD8+ T-
LGLL and CD4+ T-LGLL patients, but not significantly differences in STAT3 and
Mcl-1 level were found. Finally, mean ANC (absolute neutrophil count) in
CD3+/CD8+/CD16+/CD56-/CD57±was significantly lower than the remaining
CD8+ and CD4+ patients (800±547 vs 2744±1046, p<0,01).
Summary and Conclusions: In conclusion, a subgroup of patient characterized
by high frequency neutropenia, STAT3 exon 21 mutation and STAT3 activation
has been identified among the whole population of CD3+/CD8+/CD16+/CD56-
/CD57±T-LGLL. Interestingly, no significant differences in STAT3 level and his
downstream target Mcl-1 were found among different cell subsets. Taken together,
these data may suggest a causal relationship between STAT3 mutation and acti-
vation and the development of neutropenia. Further studies are in progress to
clarify the pathways involved in this setting.
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Background: T-cell large granular lymphocyte (T-LGL) leukemia is a heteroge-
neous disorder characterized by chronic expansion of cytotoxic T lymphocytes.
The World Health Organization (WHO) recognizes within its classification only
the indolent T-LGL leukemia (T-LGLL). However, several cases of aggressive T-
LGLL have been reported, presenting symptoms of acute illness,
hepatosplenomegaly, lymphadenopathy, lymphocytosis, anemia or thrombocy-
topenia. In these cases leukemic LGLs typically displayed a CD3+/CD8+/CD56+
immunophenotype. Recently, activating STAT mutations have been discovered
in T-LGLL patients, STAT3 mutations in 30-40% of T-LGLL indolent patients, while
STAT5b mutations were found only in very few cases, but these latters being
more frequently detectable in patients with severe clinical course.
Aims: We analyzed STAT5b mutation frequency in a series of 52 patients
affected by T-LGLL, with the aim to characterize the associated clinical and
biological features.
Methods: Immunophenotypic characterization was obtained by flow cytometer
analysis. STAT3 and STAT5b mutations were analyzed by Sanger sequencing.
FACSAria cell sorter was used to purify T-LGLs depending on their cell surface
markers. T-cell Receptor rearrangement was analyzed on DNA by PCR. Acti-
vation of STAT3 and STAT5b was evaluated by Western Blot analysis.
Results: Fifty-one patients showed the classical indolent T-LGLL, with neutrope-
nia, as the relevant clinical feature in 15 patients. One case showed an aggressive
clinical course presenting high leucocytosis with a doubling time of 4 weeks,
fatigue and moderate hepatosplenomegaly; no neutropenia were present at the
diagnosis. Mutation analysis did not reveal any STAT5b mutations in all the indo-
lent T-LGLL. On the other hand, two STAT5b mutations (N642H and Y665F)
were demonstrated in the aggressive case of T-LGLL. STAT5b mutations resulted
mutually exclusive with STAT3 mutations, reported in 17 cases. By Flow analysis,
all the patients with indolent T-LGLL have a LGL clone expressing CD57 antigen.
In STAT5b mutated patient proliferating cells were CD3+/CD8+/CD56+/CD57-
ve. By selecting for CD16 and CD158b antigens expression in LGLs of this
patient, three LGL subsets were recognized, namely a) CD158b+/CD16-, b)
CD16+/CD158b- and c) CD16-/CD158b- subsets. Performing mutation analysis
on sorted cells, CD158+/CD16- cell subset resulted STAT5b wild type, CD16-
/CD158b- subset showed both N642H and Y665F mutations and the small
CD16+/CD158- subpopulation carried Y665F mutation. By evaluation of TCR
rearrangement, all the three LGL populations were found monoclonally
rearranged. As expected, we found that patient’s LGLs displayed low level of
STAT3 activation and very high level of STAT5b activation as compared to indolent
T-LGLL cases, leading to an increased transcription of Bcl-xl.
Summary and Conclusions: In this report we demonstrated for the first time
the presence of intraclonal heterogeneity in a patient with aggressive STAT5b
mutated LGL leukemia, characterized by one immunodominant STAT5b mutat-
ed clone coexisting with additional smaller LGL expansions showing different
pattern of STAT5b mutation. The tight link between STAT5b mutations and the
aggressive form of T-LGLL supports the importance of STAT5b mutations in
the pathogenesis of this disease and indicates a new potential target for the
therapy of the aggressive T-LGLL.
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Background: Bone marrow involvement (BM) is a factor of poor prognosis for
diffuse large B-cell lymphoma (DLBCL). Bone marrow involvement is a poor prog-
nostic factor for patients treated with CHOP-like and with high-dose chemother-
apy. Bone marrow involvement in DLBCL by histology is detected in 10-30%
patients. The importance of B-cell clonality examination in bone marrow as a
prognostic and staging factor has not been yet described in the literature.
Aims: To evaluate the significance of the clonal immunoglobulin heavy chain
gene rearrangement analysis performed by PCR for identification of the bone
marrow involvement frequency and its value for staging and prognosis in
patients with de novo DLBCL treated with high-dose chemotherapy (HDC).
Methods: We performed a retrospective analysis, including 113 adult patients
(median age 45 years, range 17-69) with newly diagnosed DLBCL who were
enrolled in HDC protocol (mNHL-BFM-90 program or scheme R-DA-EPOCH/R-
HMA) since June 2007 till January 2015. 54 of the 113 patients had a GCB and
59-non-GCB phenotype; 23 pts (20%) had low IPI risk, 26 pts (23%) had low-
intermediate, 25pts (22%) had high-intermediate, 39 pts (35%) had high risk.
B-cell clonality was evaluated using PCR amplification by IGH (FR1, FR2, FR3)
and IGK (Vᴋ-Jᴋ, Vᴋ/intron-Kde) gene rearrangements with multiplex BIOMED-
2 primer sets and subsequent fragment analysis using ABI PRISM 3130 Genetic
Analyzer (Applied Biosystems).
Results: In 28 out of 113 patients, bone marrow involvement (25%) was revealed:
in 15 patients bone marrow involvement was identified by histological examination
and in 13 patients only by clonality of bone marrow. 13 patients with only B-cell
clonality in bone marrow were classified by IPI: 3 (23%) patients had high IPI, 7
(54%) patients-high-intermediate IPI and low-intermediate IPI-3 (23%) patients.
So, in 9% patients had to change the risk group according to bone marrow involve-
ment. In group of patients with only B-cell clonality in bone marrow (13 patients),
we performed immunohistochemical examination of bone marrow trephine biopsy.
In 7 (54%) of 13 cases we detected small number of СD20+ tumor cells in bone
marrow, in other 6 cases we didn’t prove bone marrow involvement by this exam-
ination. Univariate analysis of the entire cohort (n=113) revealed that age, IPI,
extranodal involvement and phenotype were not of prognostic significance (p
>0.05), but b-cell clonality in bone marrow was (p=0.05). In multivariate analysis,
detection of B-cell clonality in bone marrow was an independent predictor of OS
and relapse-free survival (RFS) (p ≤0.05). (Figure1A,B). OS, RFS in patients with
histological detection bone marrow involvement and with only B-cell clonality in
the bone marrow did not differ.
Figure 1.
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Summary and Conclusions: Detection of B-cell clonality in the bone marrow
seems to be an independent predictor of outcome in de novo DLBCL pts, treat-
ed with high-dose chemotherapy, while IPI and phenotype DLBCL cannot be
considered as risk factors for this group of patients. It seems reasonable to
include the detection of bone marrow B-cell clonality at primary diagnostics of
the DLBCL for staging and predicting response in HDC.
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Background: Multistep genetic alterations including microRNA(miRNA/miR)
are occurring during developing aggressive cancer. We have shown that some
tumor suppressive miRNAs including miR-150 and miR-16 were diminished in
metastatic cutaneous T-cell lymphoma (CTCL), and that miR-150 could inhibit
invasion and metastasis of CTCL cells by targeting a chemokine receptor CCR6
(Blood 2014). Furthermore, we recently found that when examined expression
of these miRNAs against early and advanced CTCL, miR-150 and miR-16
were decreased during disease progression. These findings suggest that dys-
regulation of these miRNAs is deeply associated with the pathogenesis of early
to advanced CTCL. 
Aims: The aim of this study was to determine the possible role of miR-16 and
miR-150 in the CTCL progression.
Methods: CTCL cell lines (My-La, HH, MJ, and Hut78) were employed for this
experiment. We established a mouse model which died after day 30-35 after
transplantation of CTCL cells into NOD/Shi-scid IL-2γnul(NOG) mouse due to
tumor cell invasion and metastasis, namely “CTCL mouse”. For in vivo admin-
istration of miRNA, miR-150 and/or miR-16 plus atelocollagen was injected
into tail vein of CTCL mice after day14 from CTCL cell transplantation. Injection
was conducted by every 5 days. 
Results: Firstly we examined in vivo transplantation of miR-16, miR-150 sta-
bly transduced CTCL cells into NOG mice, and found that not only miR-150
but also miR-16 transduced CTCL cells injected NOG mice showed significant
survival extentions than control mice. Interestingly, miR-16 transduced
showed stronger tumor inhibition capability than miR-150 transduced, despite
of lacking migration-inhibition capability. This result suggests that miR-16
might possess the other tumor suppressive function. Therefore we conducted
functional analysis of miR-16, and found that miR-16 could lead to strong
cellular senescence against CTCL cells. In miR-16 transduced CTCL cells,
p21, which is a key mediator of senescence, was strongly up-regulated in a
p53 dependent manner. Because it has been known that Bmi-1 negatively
regulates not only p16 but also p21, we examined Bmi-1 expression against
miR-16 transduced CTCL cells and found its down-regulation. This result
suggested that miR-16 directly regulate Bmi-1 against CTCL cells leading to
p21 up-regulation. To examine whether Bmi-1 could directly interact promoter
region of CDKN1A/p21 gene, we conducted cross-linking/chromatin immuno-
precipitation (ChIP) assay against CTCL cells, and demonstrated the direct
interaction. To examine whether miR-150 and/or miR-16 could lead tumor
inhibition in vivo, we conducted intravenous administration of these miRNAs
against CTCL mice. Though administration of either miR-16 or miR-150
extended survival of CTCL mice, use of both miR-150 and miR-16 yielded to
the most survival extension because miR-150 and miR-16 cooperatively can
inhibit distinct tumorigenic cascades of CTCL. Finally, we found that a histone
deacetylase inhibitor, vorinostat/SAHA, led CTCL cells to induce senescence
and migration inhibition with restoration of both miR-150 and miR-16, and
their target proteins.
Summary and Conclusions: miR-150 and miR-16 collaborate to inhibit
tumorigenic potential via down-regulating distinct tumor-associated cascades.
Our findings suggest that miR-150 and miR-16 could be, at least in part, epi-
genetically silenced during disease progression and their restoration as well
as vorinostat treatment could be key therapeutic strategy against CTCL.
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Background: Anaplastic lymphoma kinase-positive (ALK+) anaplastic large
cell lymphoma (ALCL) is an aggressive T-cell non-Hodgkin lymphoma type
characterized by the t(2;5) resulting in overexpression and activation of the
NPM-ALK oncogenic kinase. The NPM-ALK is known to activate multiple sig-
naling pathways including the phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR
and the JAK/STAT3 pathways resulting in cell cycle and apoptosis deregulation.
ALK+ ALCL is also characterized by strong AP-1 activity and overexpression
of two AP-1 transcription factors, CJUN and JUNB, which are upregulated by
NPM-ALK, and further contribute to ALCL oncogenesis.
Aims: We hypothesized that a biologic link between AP-1 activity and AKT
kinase may exist, which operates in ALK+ ALCL. Therefore, the purpose of
this study was to identify specific interactions of two AP-1 transcription factors,
JunB and cJun, with AKT1 gene promoter in ALK+ ALCL and in non cancerous
cell systems. In addition the biologic effects of AP-1 transcriptional control on
AKT gene were analyzed.
Methods: Three ALK+ ALCL cell lines (Karpas 299, SR-786 and SUP-M2), as
well as Jurkat and HEK293T cells were used in the study. AKT1 gene promoter
was analyzed using chromatin immunoprecipitation (ChIP), site-directed muta-
genesis, gene reporter assays and transient transfections. JunB and cJun
genes were knocked down using specific siRNA constructs. Quantitative real-
time RT-PCR and Western blotting were used to assess RNA and protein levels.
Cell proliferation, cell viability and colony formation assays were also applied
following gene silencing or pharmacologic inhibition studies.
Results: Using ChIP, reporter assays and site-directed mutagenesis, we show
that JUNB and cJUN bind directly to the AKT1 promoter at specific AP-1 binding
sites, thus inducing AKT1 transcription in ALK+ ALCL. Knockdown of JUNB
and CJUN in ALK+ ALCL cell lines downregulated AKT1 mRNA and promoter
activity and was associated with lower AKT1 protein expression and activation.
Of note, JUNB and CJUN seem to cooperate for the transcriptional regulation
of AKT1 gene. We also provide evidence that this is a transcriptional control
mechanism shared by other cell types even though it may operate in a way
that is cell context specific. In addition, STAT3-induced control of AKT1 tran-
scription was functional in ALK+ ALCL and blocking of STAT3 and AP-1 signal-
ing synergistically affected cell proliferation and colony formation.
Summary and Conclusions: Our findings uncover a novel transcriptional
crosstalk mechanism that links AP-1 and AKT kinase, which coordinate uncon-
trolled cell proliferation and survival in ALK+ ALCL. These mechanisms may
confer resistance to chemotherapy.
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Background: Adult T-cell leukemia (ATL) is a malignant disease caused by
infection with human T-lymphotropic virus type 1 (HTLV-1). Only about 2-5%
of HTLV-1-infected patients will develop ATL, and the response to chemother-
apy is extremely poor because of intrinsic or acquired drug resistance. Thus,
we hypothesized the existence of chemotherapy resistant leukemic stem cells
(LSCs) in ATL. Recently, LSCs with characteristics of self-renewal, tumori-
genicity, multipotency, asymmetric division, and drug- resistance were identified
and characterized in various types of solid tumors and leukemias. We have
previously identified ATL stem cell candidates in an ATL model using Tax trans-
genic (Tax-Tg) mice (Yamazaki et al., Blood 2009). It has been shown that the
HTLV Tax protein is crucial to initiate malignant transformation and spreading
of ATL. Recently, HTLV-1 bZIP factor (HBZ) was also identified as an important
factor in the development of ATL. HBZ transgenic (HBZ-Tg) mice also show
ATL-like lymphoma/ leukemia and are thought to be an ATL model mouse
(Satou et al., PLoS Pathog, 2011).
Aims: We aimed to identify and characterize ATL stem cells in the HBZ-Tg
mouse and compare their properties with ATL stem cells in the Tax-Tg mouse
to clarify the clonal evolution of ATL stem cells and molecular mechanisms
underlying ATL development and drug resistance.
Methods: We isolated and characterized splenic lymphomatous cells (named
Ht48) derived from HBZ-Tg mice, transplanted 1×107 Ht48 cells intraperitoneal-
ly into C57BL/6 mice to assess tumorigenicity. Then, we performed forescence
activated cell sorting (FACS) of Ht48 cells, and tested proliferative activity both
in vivo and in vitro analyseslu.
Results: The transplanted mice showed massive splenomegaly and died
within 25 days. The ATL cells had infiltrated into multiple tissues such as
spleen, liver, and ovary. To evaluate serial transplantability of Ht48 cells, we
performed nine consecutive serial transplantations. Ht48 cells regenerated
the ATL-like disease and regained the original phenotypes (CD4-CD8-/CD4-
CD8+/CD4+CD8+) after each transplantation. Next, we performed side pop-
ulation (SP) analyses to identify drug resistance. SP cells with high drug
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resistance existed among Ht48 cells. Interestedly, more than 40% of c-kit+
cells were enriched with SP cells, while less than 5% of c-kit+ cells compared
the other population. As expected, both SP and c-kit+ cells showed a high
proliferative activity in vitro and in vivo, and these cells could differentiate
into all lineages of ATL cells in vivo. These results suggest that c-kit expres-
sion is important to maintain ATL stem cell functions such as drug resistance
and high tumorigenicity in Ht48 cells. To characterize ATL stem cells in detail,
we divided c-kit+ cell fractions into four subpopulations and cultured the cells
for six days to clarify which population of c-kit+ cells are LSCs. We found c-
kit+/CD4-/CD8- cells possessed higher proliferative activity than any other
subpopulation. In addition, a neutralizing antibody against c-kit ligand (SCF)
inhibited ATL stem cell proliferation in vitro. ATL stem cell candidates gave
rise to all cell types in Ht48 cells in vivo. These data indicated that ATL stem
cells require an extrinsic signal from the niche to differentiate into all types of
ATL cells. Finally, we performed comprehensive gene expression analyses
of ATL stem cells in both HBZ- and Tax-Tg mice and identified some candidate
genes that can trigger and maintain LSC development.
Summary and Conclusions: We identified ATL stem cell candidates in HBZ-
Tg mice, and c-kit plays a key role in maintenance of LSCs and tumor devel-
opment in a mouse model of ATL.
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Background: Non-Hodgkin’s lymphoma (NHL) mostly includes mature B-cell
lymphomas, such as Burkitt lymphoma (BL), diffuse large cell lymphoma (DLB-
CL), and follicular lymphomas, which are all derived from germinal-center B
(GCB) cells. Despite recent advances in the drug development for lymphoma,
there are still patients with refractory and relapsed lymphoma. To analyze the
detailed molecular mechanisms during lymphomagenesis, we require appro-
priate mouse models, with short latency, in which monitoring the whole process
from the cell of origin to full-blown lymphoma is easy. 
Aims: To analyze the factors involved in mature B-cell lymphomagenesis,
we attempted to develop a new mouse model for lymphoma, originating from
GCB cells. 
Methods: Naive B-cells derived from C57BL/6 wild type (WT) or Ink4a/Arf-/-
mice were cultured ex vivo and stimulated with IL-4 and anti-CD40 antibody to
differentiate into GCB cells. GCB cells were retrovirally transduced with c-Myc,
which is highly expressed in most human lymphomas, and then transplanted
into sublethally irradiated syngeneic mice. Primary cultured lymphoma cells
were treated with the reagents described below. Human NHL cell lines including
4 Burkitt lymphoma (Daudi, Ramos, Raji, and Namalwa) and 9 DLBCL (DB,
Toledo, OCI-Ly19, WSU-DLCL2, SU-DHL6, NU-DHL1, NU-DUL1, OCI-Ly3,
and OCI-Ly10) were used.
Results: Approximately 60% of mice transplanted with Ink4a/Arf-/- derived c-
Myc-GCB cells, via intraperitoneal injection, exhibited splenomegaly and
enlarged lymph nodes in the axilla, inguinal, and intestinal regions, and even-
tually died. Mice transplanted with WT derived c-Myc-GCB cells did not show
any signs of lymphoma. Tissues from these mice showed mature B-cell
immunophenotype (B220+IgM+IgD+) and were histopathologically similar to
human BL. Remarkably, lymphoma cells from all mice did not show Fas expres-
sion at protein and mRNA levels in contrast to the original GCB cells that
showed high Fas expression. Furthermore, lymphoma cells, which sponta-
neously developed in all λ-Myc mice (a transgenic mouse carrying c-Myc under
the control of the Igλ light chain enhancer), showed no Fas expression. Fas is
a cell death receptor which has an important role in negative selection of GCB
cells, with self-reactive antibody and low-affinity antibody. To analyze the role
of Fas downregulation in lymphoma formation, Ink4a/Arf-/- GCB cells were
transduced with c-Myc and shRNA for Fas and then transplanted. All mice
transplanted with shFas-transduced GCB cells developed lymphoma and died
faster than mice transplanted with shControl-transduced GCB cells. To further
analyze Fas regulation in lymphoma cells, we carried out primary culture of
lymphoma cells. Fas expression was restored after CD40 ligand or anti-CD40
antibody treatments, suggesting that reduced CD40 signaling may be one of
the reasons for Fas downregulation. Further, we found that 11 out of 13 human
lymphoma cell lines, including 3 BL and 8 DLBCL, exhibited low expression of
Fas whereas 2 cell lines exhibited high expression of Fas that induced apoptosis
upon Fas ligand treatment. Among those Fas-downregulated cells, Fas expres-
sion was restored not only after CD40 ligand treatment, but also after a DNA
methyltransferase inhibitor 5-Aza-dC treatment or an HDAC-inhibitor TSA treat-
ment, indicating that Fas expression is also regulated by epigenetic mecha-
nisms in human lymphoma cells.
Summary and Conclusions: The findings in this study suggest that Fas down-
regulation is a crucial event for mature B-cell lymphomagenesis to escape from
immune surveillance and that restoration of Fas expression, such as anti-CD40
antibody treatment or epigenetic inhibitors, may be a promising strategy for
NHL treatment.
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Background: Mitochondrial membrane protein BCL2 is widely expressed in
many lymphoma entities but rarely in Burkitt lymphoma (BL). Expression of BCL2
can be considered as an indicator of diffuse large B cell lymphoma (DLBCL)
where morphology is unclear. Co-expression of BCL2 and MYC has been report-
ed to be an indicator of poor prognosis in DLBCL. Occasionally BCL2 expression
occurs in BL and in lymphomas with features intermediate between BL and DLB-
CL (intermediates). Gene expression profiling (GEP) has helped to define the
molecular features of BL (mBL). However, only few BCL2-positive BL have been
assessed by GEP in order to elucidate if their molecular pattern shifts to more
intermediate or DLBCL profiles.
Aims: To evaluate applicability of our recently developed BL and DLBCL molec-
ular classifier using formalin fixed and paraffin embedded (FFPE) tissue on diag-
nostically ambiguous cases. To understand to what extent BCL2 expression is
compatible with the diagnosis mBL. To assess the prognostic value of BCL2
expression in BL.
Methods: A cohort of 154 BL diagnosed by morphology, immunophenotype and
fluorescence in situ hybridization (FISH) for MYC and t(8;14)/MYC-IGH translo-
cations was analyzed for BCL2 expression by immunohistochemistry using two
different antibodies. These constructed a tissue microarray (TMA).
A group of 17 lymphomas (age range 3-24, median 11 years of age) with the
morphological an immunophenotypical features of BL but BCL2 expression (5%
>90% in lesion) were additionally labelled by GEP using RNA from FFPE material.
In 5 cases BCL2-positive and BCL2-negative areas of the biopsy block were
macrodissected and analyzed separately. To assess if BCL2 expression in mBL
correlated with poorer prognosis 43 further BL cases registered within the NHL-
BFM database were compared to the initial BCL2-positive mBL cohort for clinical
variables including outcome.
Results: In the TMA cohort BCL2 expression was detected in 21,3% (33/150) of
the cases. No differences in clinical features and outcome were detected between
BCL2-positive and BCL2-negative BL in 43 patients treated according to paedi-
atric NHL-BFM protocols. Using GEP, 13/17 (76,5%) cases were classified as
mBL and 4/17 (23,5%) as intermediates. The 5 lymphomas with spatial differ-
ences in BCL2 expression classified as mBL in both, BCL2-positive and BCL2-
negative areas. In this group of predominantly paediatric patients, none of the 4
intermediate cases relapsed according to clinical follow-up. 
Summary and Conclusions: Molecular classification indicates that lymphomas
with the clinical and pathological features of BL but expression of BCL2 display
molecular profiles compatible with mBL. BCL2 expression is not associated with
inferior survival in pediatric BL. Diagnostically ambiguous lymphomas by
histopathology and FISH can be reliably labelled by our GEP-based aggressive
lymphoma classifier in FFPE specimens.
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Background: CK2 is a serine-threonine protein kinase formed by the assembly
in a tetramer of two catalytic (a) and two regulatory (b) subunits. This enzyme
regulates a wide variety of cellular processes, including cell proliferation, differ-
entiation and survival. It is overexpressed and overactive in several solid tumors
and hematologic malignancies and promotes a “non-oncogene addiction” phe-
notype in cancer cells. Our and other groups have shown that B cell tumors, such
as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma,
rely on high activity of CK2 and are extremely sensitive to the cytotoxic effect of
CK2 inhibition induced either by gene silencing or with the clinical grade com-
pound CX-4945 (Silmitasertib). It is well known that the strength of the B cell
receptor (BCR) signaling influences mature B cell commitment and survival, and
is a powerful determinant of B cell derived lymphoma cell growth. CK2, through
a “lateral” regulation of BCR-dependent signaling cascades, could be involved in
normal and malignant BCR-elicited signaling. Indeed, B cell specific CK2b knock-
out mice, generated in our laboratory, display a marked reduction of follicular B
cells (FoB), suggesting a critical role of this kinase in FoB cell development and
maintenance.
Aims: We culled to investigate CK2 levels and activity in diffuse large B-cell lym-
phoma (DLBCL), an aggressive germinal center derived B cell tumor. Further-
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more, we intended to study the potential of combining CK2 inhibition with the
BCR blockade as a therapeutic option for this neoplasia.
Methods: Immunohistochemistry was performed on 4 μm-thick formalin-fixed
and paraffin-embedded sections. To inhibit CK2 we employed CX-4945, a selec-
tive ATP-competitive compound currently under scrutiny in phase I clinical trials.
To evaluate protein changes after treatments, cells were lysed and Western Blot
experiments carried out. To assess cell survival, MTT tests and AV/PI staining
were performed. Combination Index (CI) was calculated in accordance with the
Chou and Talalay method. To stimulate the BCR aIgM or aIgG antibodies were
used. Acquisition was done with FACS Canto and analysis with FlowJo software.
Results: CK2 was found to be over expressed in a series of primary samples of
activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL and in
ABC- and GCB-DLBCL cell lines as compared to normal counterparts. CK2 inhi-
bition with CX-4945 caused apoptosis of both types of DLBCL cell lines in a dose
dependent fashion even at low concentrations not toxic to normal B lymphocytes.
Moreover, CX-4945 boosted the effects of Fostamatinib, an effective BCR sig-
naling inhibitor, increasing malignant B cell death. Also, the downregulation of
CK2 catalytic activity led to a reduction in Ca++ release from endoplasmic retic-
ulum (ER) stores and impaired AKT activation after BCR stimulation.
Summary and Conclusions: Our study shows that CK2 levels and activity are
abnormally high in DLBCL, and its inhibition causes strong apoptosis of lymphoma
cells. CK2 is likely to lie downstream from chronic active and tonic BCR signaling,
presumably controlling AKT activation and Ca++ release from ER stores, two
critical events regulating B cell activation, survival and expansion. These findings
suggest that CK2 inhibition could target multiple sites of the BCR-dependent pro-
survival cascade, and could pave the way for the inclusion of CX-4945 in rational
drug combination therapies with BCR pathway inhibitors such as Ibrutinib and
Fostamatinib that are currently under clinical trials in DLBCL patients.
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INHIBITORS OF MTOR/PI3K/AKT PATHWAY EXTEND THERAPEUTIC
OPPORTUNITY IN WALDENSTRÖMS MACROGLOBULINEMIA CELLS
THAT DISPLAY RESISTANCE TO BOTH ABT-199 AND IBRUTINIB. 
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Background: Recent investigations support a role for constitutively active B-cell
receptor (BCR), and Toll-like receptor (TLR) signaling in the pathogenesis of
Waldenström macroglobulinemia (WM), a rare and indolent B cell disorder. Clin-
ically, mitigation of BCR signaling with the first in class BTK inhibitor, ibrutinib,
has shown promising results. However, clinical responses to ibrutinib alone are
less than optimal and development of ibrutinib-resistant disease is being recog-
nized as an important and impending dilemma. It has also been shown that Bcl-
2 family of anti-apoptotic proteins supports BCR/TLR induced proliferation and
survival of WM cells by prevention of apoptosis. This defective apoptotic signaling
is associated with aggressive clinical behavior, chemoresistance, and a poor
prognosis in many B-cell cancers, including WM. We have previously shown the
utility of disrupting pro-apoptotic Bcl-2 protein interactions in WM, chronic lym-
phocytic leukemia and multiple myeloma and that this functional interference
results in re-sensitization (or heightened sensitivity) of tumor cells towards
chemoimmunotherapy. As such, we examined the effects of ABT-199, a Bcl-2
specific small molecule inhibitor; in preclinical models of WM and found these
cells to be sensitive to ABT-199; an observation, which echoes early clinical effi-
cacy noted in WM patients part of a phase 1 clinical trial. As resistance to ibrutinib
is being noted in patients and early reports on ABT-199 suggest that resistance
to its activity is imminent, we established 1.) WM models resistant to ibrutinib, 2.)
WM models resistant to ABT-199 and 3.) WM models resistant to both ibrutinib
and ABT-199. These models were then used to delineate common survival path-
ways that may lend therapeutic cross-sensitivity in cells resistant to ibrutinib
and/or ABT-199.
Aims: To evaluate the effect of mTOR/PI3K/AKT inhibitors on WM cells resistant
to Ibrutinib and ABT-199. 
Materials and Methods: WM cell lines (BCWM.1, MWCL.1 and RPCI-WM1;
WT-WM cells) including their ibrutinib resistant (IR-WM), ABT-199 resistant
(ABTR-WM) or dual-ibrutinib/ABT-199 resistant (dual resistant WM) clones were
developed in the laboratory and used in this study.
Results:A comparison of expression pattern of Bcl-2 family members, Bcl-2, Mcl-
1, BCL-xL, A1 (anti-apoptotic members), Noxa, Puma, Bim (pro-apoptotic initiators)
and Bak and Bax (pro-apoptotic effectors), revealed that IR-WM cells and ABTR-
WM cells showed differential expression of Bcl-2 family members. Cell growth
(MTS) assays using ABT-199 indicated that IR-WM cells remain sensitive to ABT-
199 with an IC50 ranging between 2-4uM. ABT-199 induced a dose dependent
increase in MOMP with concomitant induction of apoptotic cell death in IR-WM
cells, the latter confirmed by observation of PARP-1 cleavage. ABT-199 induced
intrinsic apoptosis with the activation of caspase 9 and caspase 3 in all the cells
tested. This data indicated the Bcl-2 pathway as being relevant and essential in
IR-WM cell lines. Further, combined addition of ABT-199 with ibrutinib showed
synergistic cell death (as calculated using CalcuSyn software, Biosoft UK) in IR-
WM cells. However, prolonged and incremental exposure to ABT-199 in 1.) WT-
WM cell lines and 2.) in IR-WM cell lines resulted in outgrowth of tumor clones
that displayed resistance to both ibrutinib and ABT-199. Interestingly, these drug
resistant (IR-WM, ABTR-WM and dual-resistant) WM clones showed constitutive
activation of AKT. As such, we tested multiple inhibitors of the mTOR/PI3K/AKT
pathway (everolimus, LY294002 or MK2206) and observed a dose and time
dependent cytotoxicity in the aforementioned drug-resistant WM models.
Summary and Conclusions: Drug resistance in WM as in other B-cell cancers
is inevitable despite combination therapy and can result in development of tumor
clones that are cross resistant to multiple drugs. However, even in this complex
biological dynamic, these drug-resistant clones fortuitously may shift survival sig-
naling towards an alternative (but common) pathway, lending therapeutic cross-
sensitivity. Data from our ibrutinib, ABT-199 or dual-resistant preclinical models
affirms this notion and suggests these cells common preference for AKT-mediated
survival signaling when continual stress from ibrutinib and/or ABT-199 is applied. 
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HIGH THROUGHPUT IN VITRO COMBINATION SENSITIVITY SCREEN IN
HEMATOLOGIC MALIGNANCIES WITH DUVELISIB, A DUAL PI3K-
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Background: Phosphoinositide-3 kinases (PI3Ks) are key cellular signaling
proteins that act as a central node for relaying signals from cell-surface recep-
tors to downstream mediators. PI3K-δ and PI3K-γ isoforms are expressed in
normal leukocytes, as well as many hematological malignancies such as indo-
lent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL). Given the key role for PI3K-δ and PI3K-γ
in immune cell function, targeting these isoforms may provide opportunities to
develop differentiated therapies for the treatment of hematologic malignancies.
Duvelisib (IPI-145) is an oral dual inhibitor of PI3K-δ and PI3K-γ currently in
clinical development in hematologic malignancies.
Aims: In order to gain mechanistic insights into the cellular response to duvelis-
ib and identify novel combination pairings for duvelisib in a broad spectrum of
hematologic malignancies, a high-throughput pharmacology screen was con-
ducted. In vivo combination validation studies were also performed.
Methods: Duvelisib was evaluated alone and in combination with 35 com-
pounds comprising a diverse panel of standard-of-care agents and emerging
drugs in development for hematologic malignancies. Target and pathway
inhibitor redundancy was included to observe similar patterns of activity across
the cell line panel. These compounds were tested in 20 cell lines including dif-
fuse large B-cell (DLBCL), follicular, T-cell, and mantle cell lymphomas, and
multiple myeloma. Growth inhibition (GI) was measured by ATPLite (Perkin
Elmer) in a 6x6 or 9x9 dose combination matrix.
Results: Single agent activity was seen in 14 cell lines treated with duvelisib,
with a median GI50 of 0.59 µM. A scalar measure of the strength of synergistic
drug interactions (Synergy Score) was devised and filtering on scores exceed-
ing the mean self-cross plus twice the standard deviation revealed a synergy
hit rate of 19.3% across the matrix of drug combinations and cell lines. Synergy
was most prominent in DLBCL and follicular lymphoma cell lines and seen with
approved and emerging drugs used to treat hematologic malignancies, includ-
ing, but not limited to, dexamethasone, inhibitors of the B-cell receptor signaling
pathway, such as ibrutinib, and the BCL-2 inhibitor venetoclax (ABT-199). Syn-
ergy patterns were similar among agents that target the same molecules or
pathways helping to validate activities seen in combination with duvelisib. In
select cell line GI studies and in vivo DoHH2 lymphoma murinexenograft mod-
els, the combination of selective PI3K-δ and PI3K-γ inhibitors showed
enhanced effects compared to either inhibitor alone. Combination effects with
select drugs and duvelisib were also seen in DoHH2 murinexenografts.
Summary and Conclusions: These studies support enhanced activity of com-
bined PI3K-δ and PI3K-γ inhibition in lymphoma models and identified syner-
gistic pairings with the PI3K-δ and PI3K-γ inhibitor, duvelisib. These results
provide a rationale for exploring the combination of duvelisib and other thera-




ARTISAN PCR: HIGHLY RELIABLE IDENTIFICATION OF FULL-LENGTH
B-CELL RECEPTOR SEQUENCES
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Background: Full-length, error-free B-cell receptor (BCR) sequences are
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instrumental to study B-cell function in health, autoimmunity, and lymphoma.
Current amplification strategies are usually based on multiplex primers anneal-
ing to conserved upstream V segment regions. These primers obscure muta-
tions at their binding site and are prone to amplification bias or even complete
amplification failure (Koning et al., 2014). We designed an alternative assay
employing Anchoring Reverse Transcription of Immunoreceptor Sequences
and Amplification by Nested PCR (ARTISAN PCR).
Aims: To demonstrate improved success rate of full-length BCR identification
by ARTISAN PCR compared to multiplex strategies.
Methods: 39 EBV-transformed lymphoblastoid cell lines (LCL) were selected
for clonality by flow cytometry. In addition, biopsy material (peripheral blood,
bone marrow, lymph node, spleen, pleura) from 24 patients diagnosed with
either chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis,
Waldenström’s macroglobulinemia, multiple myeloma, follicular lymphoma,
mantle cell lymphoma, marginal zone lymphoma or Burkitt’s lymphoma (3
each) was selected. Poly(A)-RNA was isolated (Dynabeads; Invitrogen) and
subjected to 5’RACE cDNA synthesis (Smartscribe, Clontech) with gene-spe-
cific primers that anneal to the Ig constant region of interest. Anchor-tagged
cDNA was PCR-amplified with an anchor-specific forward primer and nested
constant region-specific reverse primers. Nested barcoding primers further
increased target specificity and enabled the combination of numerous PCR
products in one sequencing run. For comparison, cDNA was amplified by
conventional multiplex PCR (IGH FR1, IGK A, and IGL Clonality Assays,
Invivoscribe) utilizing generic primers designed to anneal to V and J regions.
EBV LCL amplicon libraries were sequenced on the PacBio platform (Pacific
Biosciences) at a minimum of 8 cycles. Lymphoma biopsy amplicons were
cloned and sequenced by Sanger sequencing.
Results: ARTISAN PCR on the 39 LCL yielded 52 clonal VDJ, 22 VJ-κ, and 39
VJ-λ sequences. 10 VJ amplicons were unproductive. In total, functional com-
plete BCRs were readily identified for all LCL, of which 27 were identified as
monoclonal and 12 as biclonal. By the Invivoscribe protocol, 6 VDJ, 1 VJ-κ,
and 10 VJ-λ were missed, corresponding to success rates of 88%, 95%, and
74%, respectively, compared to ARTISAN PCR. Complete BCRs were identified
for 38 of 51 (75%) LCL B-cell clones by Invivoscribe. ARTISAN PCR identified
a complete functional clonal BCR in all 24 lymphoma biopsies (7 IgM-κ, 13
IgM-λ, 2 IgA-λ 2 IgG-κ). With the Invivoscribe approach, a complete functional
clonal BCR was identified in 13 cases (54%). In 4 cases, no VDJ could be iden-
tified, and in 8 cases, no functional VJ. Neither in the LCL nor in the lymphoma
biopsies was a clonal amplicon found by the Invivoscribe assays that was
missed by ARTISAN PCR. Sequence analysis of the BCR obtained by ARTI-
SAN PCR revealed individual reasons for each instance of Invivoscribe assay
failure. In 19 instances, mutations in V or J primer binding sites led to deleterious
mismatches. In 9 cases, lack of a primer for the particular lambda V allele family
prevented VJ identification. In one case, a truncation obliterated the FR1 primer
binding site. The cumulative error rate (cDNA synthesis, PCR, sequencing) of
ARTISAN PCR was 1,26x10-4 in the LCL panel at a minimum of 8 cycles of
PacBio sequencing.
Summary and Conclusions: ARTISAN PCR permits reliable high-throughput
identification of full-length BCR transcripts and proves vastly superior to a com-
mercial assay based on multiplex primers.
E1371
NFKBIE MUTATIONS OCCUR IN 15% OF GCB DLBCL AND IN VARIOUS
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Background: Massively parallel sequencing technology in chronic lymphocytic
leukemia (CLL) has recently identified acquired recurrent somatic mutations in
the gene NF-ĸB inhibitor I kappa B epsilon (NFKBIE), a retrocontrol of NF-ĸB
signaling. NF-ĸB activity is a hallmark of various haematological malignancies,
and activating mutations in NF-ĸB transcription factors or upstream signaling
components such as CD79b, CARD11, or TNFAIP3/A20 are common findings
in lymphoid neoplasms. However, little is known regarding the prevalence of
NFKBIE mutations in lymphoid malignancies other than CLL.
Aims: Since gene mutations are rarely specific of a given tumor entity and
those identified in a given lymphoid malignancy are frequently found in other
diseases, we aimed to assess the presence and frequency of NFKBIE muta-
tions in a larger cohort of patients with lymphoid malignancies and to evaluate
the range of mutational burden. 
Methods: We investigated the mutational hotspot of NFKBIE in a series of 623
patients with lymphoid neoplasms. 113 chronic lymphocytic leukemias (CLL),
170 diffuse large B-cell lymphomas (DLBCL), 179 follicular lymphomas (FL),
57 mantle cell lymphomas (MCL), 94 T-cell acute lymphoblastic leukemias, 9
small lymphocytic lymphomas (SLL), and 1 mucosa-associated lymphoid tissue
(MALT) lymphoma were analyzed by Sanger sequencing or targeted deep
sequencing.
Results: Together, frameshift mutations in NFKBIE were detected in 24 out of
623 (3.9%) investigated patients. While NFKBIE mutations were rare in FL
(3/179=1.7%), MCL (1/57=1.8%), and T-ALL (1/94=1.1%) patients, a higher
frequency was detected in the CLL (6/113=5.3%), SLL (1/9=11.1%), and DLBCL
cohorts (11/170=6.5%). Furthermore, the only patient with a MALT lymphoma
in this series harbored a NFKBIE mutation. For 118 DLBCL patients, information
was available on the cell-of-origin subtype derived from the immunohistochem-
istry-based Hans classification. We found a high frequency of NFKBIE muta-
tions in the subgroup with germinal center B-cell-like (GCB) DLBCL
(9/59=15.3%), whereas only one of the 59 Non-GCB DLBCLs showed a NFK-
BIE mutation (1/59=1.7%; P=0.017 GCB vs Non-GCB in Fisher’s exact test).
Next, we evaluated the mutation burden of 12 NFKBIE mutated lymphoma
patients (6 CLL and 6 DLBCL based on DNA availability) by deep sequencing.
The mutation burden varied from 8% to 47% (mean coverage of 1260 reads
per patient sample). These data indicate that NFKBIE mutations may be part
of both major and subclone variations.
Summary and Conclusions: In summary, we show a 3.9% prevalence of
NFKBIE mutations in a large set of 623 patients with lymphoid malignancies.
NFKBIE mutations were most frequently found in CLL, SLL and DLBCL patients.
We further identified GCB DLBCL to harbor the highest prevalence of NFKBIE
mutations, reaching a frequency of 15.4%.
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NK CELLS CYTOTOXICITY IS AFFECTED BY VARIOUS BTK INHIBITORS
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Background: Targeting Bruton’s tyrosine kinase, due to a huge therapeutic
potential of ibrutinib, is becoming an attractive therapeutic approach in the treat-
ment of hematological malignancies derived from B-cells. However, we have
demonstrated that NK cell cytotoxicity, degranulation and cytokine secretion
are significantly impaired upon ibrutinib treatment (Bojarczuk et al., Leukemia
2014). Since NK cells are effectors in antibody dependent cell-mediated cyto-
toxicity (ADCC), which constitute one of the major mechanisms of anti-CD20
monoclonal antibodies widely used in hematooncology, in our ongoing studies
we are focused to determine in details the influence of various BTK inhibitors
on NK cells cytotoxicity, degranulation, cytokine expression and expression of
activatory NK cells receptors. 
Figure 1.
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Aims: The aim of the studies is to elucidate the influence of various BTK
inhibitors on the antitumor activity and phenotype of primary NK cells isolated
from blood samples of healthy volunteers as well as patients with leukemia
and lymphomas.
Methods: All experiments were performed fully in vitro using human primary
NK cells isolated from PBMC of healthy donors and NK cells from patients
with B-cell derived tumors. ADCC was determined using anti-CD20 mono-
clonal antibodies (rituximab, ofatumumab, obinutuzumab). To determine
cytolytic activity of NK cells we used CFSE/PI flow cytometry assay and/or
CD19 and PI staining to determine absolute counts of B cells. Cytokine secre-
tion and NK cells degranulation evaluated as the expression of CD107a on
the surface of NK cells were determined with flow cytometry upon incubation
with target cells for 4 h. Phenotype of NK cells pre-incubated with tested
compounds was determined with flow cytometry using antibodies conjugated
with fluorochromes.
Results: The initial results of the studies show that various BTK inhibitors differ-
entially regulate NK cells antitumor activity and affect phenotype of NK cells.
Interestingly, obinutuzumab-induced ADCC is not inhibited in the presence of
BTK inhibitors in contrast to type I anti-CD20 monoclonal antibodies (Figure 1).
Summary and Conclusions: Our studies are focused on better understand-
ing how newly approved inhibitors influence NK cells antitumor functions.
This knowledge is especially important in light of combination therapies when
monoclonal antibodies are used with small molecule inhibitors. On the basis
of our observations we conclude that combining obinutuzumab with BTK
inhibitors is a better therapeutic strategy than simultaneous combination of
type I anti-CD20 antibodies and BTK inhibitors. 
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Background: Follicular lymphoma (FL) is the second most frequent non-
Hodgkin lymphoma in western countries. Transformation into aggressive lym-
phoma continues being one of the worst events in the disease history. There
is a growing interest in connecting new approaches into the biological basis of
transformation and clinical application. IgH gene rearrangements in B lympho-
proliferative disorders have identified the preferential use of certain VDJH gene
segments, correlated in some cases with clinical prognosis. In this aspect,
transformed follicular lymphoma (tFL) has not been yet studied.
Aims: To study the IGHV gene usage and clinical features in patients diag-
nosed of tFL and to compare with FLs that do not undergo transformation, as
well as with diffuse large B-cell lymphoma (DLBCL), classified as GCB and
non-GCB by immunostaining according to Hans algorithm.
Methods: A total of 213 non-Hodgkin lymphoma (NHL) patients from a single
centre were included in the study, distributed in three groups: i) tFL patients
(n=32), most of them with paired samples at diagnosis and transformation
(n=25, 78%); ii) FL with no documented transformation at a median follow up
of 66 months (n=74); and iii) DLBCL patients (n=107; 44% GCB, and 56% non-
GCB). Clonal IGH rearrangements were amplified according to the BIOMED-
2 protocol and PCR products were sequenced. Germline IGH genes were iden-
tified using IMGT/V-QUEST database. Statistical comparisons were performed
using SPSS 20.0.
Results: Complete VDJH rearrangements were identified in 31 out of 32 tFL
patients (97%). In addition, other case was discarded due to the identification
of a different clone, and it was recorded as secondary NHL. A bias in the IGHV
gene usage was observed in tFL patients, with IGHV3-23 (20%), IGHV3-48
(17%), and IGHV4-34 (17%) genes accounting for 54% of the cohort. These
genes are common in both FL and DLBCL. However, and despite differences
were no statistical significant, a higher frequency of IGHV3-48 was shown in
tFL than in DLBCL (22% vs 6%), while IGHV4-34 showed higher frequency in
tFL than in FL (19% vs 8%). Moreover, IGHV4-34 was found only in the non-
GCB DLBCL subgroup. Regarding the clinical outcome, the average time to
transformation of tFL is 54 months (range 4-222 months). Interestingly, we
found a longer time to transformation in patients with IGHV4-34 as compared
with patients using other IGHV (99 vs 44 months, p=0.023). Finally, and inter-
estingly, only two patients have <2% SHM and both cases were composite of
FL+DLBCL at diagnosis.
Summary and Conclusions: Clonality analysis is necessary to discriminate
secondary NHL rather than tFL. IGHV in tFL gene usage is biased, similar to
those of DLBCL and FL, as expected. Patients using IGHV4-34 showed longer
time to transformation than other IGHV. This study should be considered as
preliminary, requiring larger and homogeneous cohorts.
Financial support: Health Research Program (RD12/0036/0069, PS0901382),
Health Council of Castilla y León (BIO/SA56/13, GRS265/A/08).
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Background: Plasmablastic lymphoma (PBL) is a rare B-cell lymphoma pref-
erentially occurring in immunosuppressed patients. Over the past few years
this highly aggressive lymphoma has significantly increased in incidence in
HIV-infected individuals from Southern Africa. Despite this increasing inci-
dence and highly aggressive nature, very few studies have addressed the
molecular pathogenesis of this lymphoma. These studies were limited to sin-
gle case reports and candidate-gene approaches, with only one study inves-
tigating the presence of copy number aberrations by an unbiased, though
low- resolution (1 Mb) BAC array approach. Thus, the molecular basis of HIV
associated PBL remains mostly unknown. We have previously characterized
a cohort of 45 patients with PBL of the oral cavity (31 with a documented HIV
positive status) for immunophenotypic features and well-known chromosomal
translocations. New to our study, was the finding of 7 cases (16%) with
rearrangements of both immunoglobulin heavy chain alleles. These double-
hit lymphomas underscore the aggressive nature of this disease in HIV infect-
ed individuals, stressing the need to elucidate its molecular pathology to
inform better treatment strategies.
Aims: To investigate genome-wide DNA copy number imbalances associated
with HIV related PBL using high-resolution molecular inversion probe (MIP)
arrays.
Methods: We used whole-genome molecular inversion probe arrays,
(OncoScan FFPE Express (MIP) platform, Affymetrix, Santa Clara, CA),
which generates high quality copy number data from formalin-fixed paraffin-
embedded (FFPE) samples, to investigate the genetic content of HIV asso-
ciated PBL on 30 FFPE specimens. MIP data were analyzed with the Nexus
7 Copy number software (Biodiscovery, Hawthorne, CA) using the SNP-
FASST2 segmentation algorithm and the Nexus default settings for signifi-
cance. Copy-number threshold was 2,5 for gain and 1,5 for losses.
Results: We observed a considerable variability in the number of aberra-
tions from one patient to the other ranging from 1 to over 100 aberrations
per sample. The sum of aberrations revealed that gains were more frequent
than losses and preferentially involved chromosomes regions 1q12qter,
6p22p21, 11q14qter, 12p, and chromosome 7. Analysis with the Genomic
Identification of Significant Targets in Cancer (GISTIC) software also iden-
tified multiple significant regions of gains and losses. The most significant
focal gain on 11p13, included the two genes CD44 and PDHX. The inter-
leukin IL10 and MAPKAPK2 genes, both involved in stress and inflammation
processes, were also amongst the most significant gains on chromosome
1q32.1. These gains were confirmed by fluorescence in situ hybridization
using BACs RP11-595K11 and RP11-343H5 that span these loci respec-
tively. MAPKAPK2 encodes for a kinase regulated through direct phospho-
rylation by p38 MAP kinase, as such it is involved in CD40-induced B-cell
proliferation and its up-regulation may favor B-cell proliferation. Losses were
less frequent. Of interest, we observed 2 significant focal losses at the com-
mon fragile sites FRA-16D and FRA-3B hosting the WWOX and FHIT genes
respectively. Deletions at WWOX and FHIT are the commonest aberrations
(85%) reported in primary effusion lymphoma, a disease closely related to
PBL (Figure 1).
Figure 1. Summary of copy number aberrations in 30 PBL samples.
Summary and Conclusions: Genome-wide DNA copy number imbalances
in HIV associated PBL specimens are heterogeneous in number from patient
to patient. Significant recurrent focal gains at 11p13 and 1q32.1 warrant fur-
ther studies aimed at determining their role in the pathogenesis of the
disease.
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EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO
SELECTIVE PI3K-Α, -Β, -Δ INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)
A. Zoellner1,2,* J. Arnd3, G. Hutter2, Y. Zimmermann2, W. Hiddemann1,2,
M. Dreyling1,2
1Internal Medicine III, Haematology and Oncology, LMU, 2Clinical Cooperative
Group Leukemia, 32Clinical Cooperative Group Leukemia, Helmholtz Center
Munich, Munich, Germany
Background: Immuno-chemotherapy is the current therapeutic standard in
MCL. However, new therapeutic approaches are urgently warranted in relapsed
and refractory disease.
Aims: Inhibitors of the different isoforms of the Phosphatidylinositol 3-kinase
(PI3K) show promising results in clinical trials and have been recently registered
for follicular lymphoma. We here investigate different PI3K inhibitors in mono
and combination treatment.
Methods: Established MCL cell lines (Granta519, Jeko1, Jurkat, Rec1) were
cultivated under standard conditions in RPMI1640 supplemented with fetal
bovine serum. Cells were exposed to A66 (PI3K-α inhibitor) (5µM), TGX-221
(PI3K-β inhibitor) (5µM), Idelalisib (PI3K-δ inhibitor) (5µM), Copanlisib (5µM)
and combinations of A66+Idelalisib and TGX-221+Idelalisib. Viable cells were
counted after 24h, 48h and 72h, using a cell viability analyser based on trypan
blue exclusion test. Additionally metabolic activity was tested after 48h and 72h
using a TTC-assay. Western Blot-experiments were performed in Granta519
and Jeko1 cell lines exposed to the inhibitor-combinations and Copanlisib
monotherapy). Similarly, cell viability of 4 patient samples was analysed after
72h exposure to A66, TGX-221, Idelalisib and Copanlisib (multiple concentra-
tions between 30 nM and 10 µM) using a luminescent cell viability assay based
on quantitation of ATP. Each experiment were performed in triplicates.
Results: Copanlisib significantly reduced cell growth in all cell lines (Granta519:
32%; Jeko1: 8%; Jurkat 16%; Rec1: 22%). Monotherapy with A66 (Granta519:
93%; Jeko1: 83%; Jurkat 89%; Rec1: 78%), TGX-221 (Granta519: 101%;
Jeko1: 86%; Jurkat 64%; Rec1: 71%) and Idelalisib (Granta519: 103%; Jeko1:
69%; Jurkat 63%; Rec1: 75%) showed much only moderate effects. Unexpect-
ed, the combination of TGX-221+Idelalisib (Granta519: 101%; Jeko1: 68%;
Jurkat 54%; Rec1: 77%) was not more effective than Idelalisib monotherapy,
additive effects were only observed in the control cell line Jurkat. In contrast,
the combination of A66+Idelalisib (Granta519: 95%; Jeko1: 35%; Jurkat 46%;
Rec1: 46%) showed synergistic effects in 3 of 4 cell lines and additive effects
in Granta519. TTC-assayshowed comparable results. In Western Blot analysis,
treatment with Copanlisib strongly influenced AKT(S) and GSK3α/β as well as
4E-BP1(S) and Rictor phosphorylation. In contrast, combination of Idelalisib
and A66 downregulated p42/44 and p38 MAPK. Finally, in patient samples
Copanlisib significantly reduced cell growth in all samples investigated so far
(0,625 µM-Pat1: 32%; Pat2: 17%; 0,5 µM-Pat4: 45%). In contrast monotherapy
with A66 (0,625 µM-Pat1: 80%; Pat2: 71%; Pat3: 83% Pat4: 109%), TGX-221
(0,625 µM-Pat1: 56%) and Idelalisib (0,625 µM-Pat1: 48%; Pat2: 72%; Pat3:
40%; Pat4: 98%) were significantly less effective.
Summary and Conclusions: Copanlisib is highly effective in both cell lines
and patient samples. Especiallythe combination of a and d inhibitor showed
strong synergism comparable but not achieving the activity of Copanlisib. These
results are due to different phosphorylation of PI3K downstream kinases which
may explain the observed high clinical activity of less selective PI3K inhibitors.
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WALDENSTROM MACROGLOBULINEMIA CELLS WITH PLASMACYTIC-
PREDOMINANT FEATURES ARE INSENSITIVE TO DISRUPTION OF B-
CELL RECEPTOR SIGNALING BUT RETAIN HEIGHTENED SENSITIVITY
TO PROTEOTOXIC STRESS
A. Paulus1, S. Akhtar2, X. Wang2, P. Wallace3, S. Ailawadhi2, S. Ansell4,
A. Novak4, M. Gertz4, R. Kyle4, P. Martin5, M. Coleman5, A. Chanan-Khan2,
K. Chitta2,*
1Cancer Biology, 2Mayo Clinic Florida, Jacksonville, 3Roswell Park Cancer
Institute, Buffalo, NY, 4Mayo Clinic, Rochester, 5Weill Cornell Medical College,
Cornell, United States
Background: In contrast to other B-cell malignancies, Waldenströms
macroglobulinemia (WM) is a unique clinicopathologic entity in which the tumor
compartment is comprised of a heterogeneous mixture of monotypic B-lym-
phocytes, lymphoplasmacytic cells and plasma cells. As such, anti-WM treat-
ment strategies to date have leveraged experience from other B-cell cancers
(comprising alkylating agents, anti-CD20 monoclonal antibodies) as well plasma
cell disease (proteasome inhibitors). Recently, the BTK-inhibitor, ibrutinib,
became the first drug to secure FDA-approval for treatment of WM. Ibrutinib
has shown remarkable clinical activity in patients with chronic lymphocytic
leukemia (CLL), a cancer of small mature B-cells but has been less effective in
patients with plasma cell disease such as multiple myeloma (MM) (Vij R et al.
ASH 2014). This observation carries important clinical and biological implica-
tions as the WM tumor compartment consists of both B-cells and plasma cells.
It is now increasingly being recognized that the phenotypic profile of the WM
tumor compartment can drastically shift after treatment with drugs that pre-
dominantly eradicate the B-lymphocyte population, resulting in a WM tumor
population enriched with plasma/plasmacytoid cells (Barakat et al., Am J Clin
Pathol 2011; Morice et al. Mod Pathol 2009). To evaluate if plasmacytic-WM
cells are sensitive to ibrutinib as well as the underlying molecular basis of
response, we utilized a molecularly validated WM model (RPCI-WM1) that dis-
plays plasmacytoid features (CD19lo/CD20lo/CD138high), is MYD88L265P+, and
was established from a WM patient who had received multiple lines of
chemotherapy (comparing against a WM cell line [BCWM.1] with B-lymphocyt-
ic-predominant features- CD19hi/CD20hi/CD138low).
Aims: To evaluate if plasmacytic-WM cells are sensitive to ibrutinib as well as
the underlying molecular basis of response.
Methods: Flow cytometry, western blot, mitochondrial membrane permeability
(MOMP) assay, RNA-Seq (Illumina Hi-Seq), micro-RNA profiling (Exiqon qPCR
array, real-time qPCR), methylation profiling (Infinium HumanMethylation 450K
array), whole exome sequencing (WES) and mate-pair sequencing.
Results: Cell viability and apoptosis assays confirmed our initial hypothesis,
revealing RPCI-WM1 cells as insensitive to ibrutinib (5uM) and contrastingly
demonstrated their sensitivity to a first in class 19S proteasome inhibitor,
VLX1570 (250nM), the latter causing immense proteotoxic stress and mito-
chondrial damage. Immunophenotype analysis demonstrated upregulation of
several antigens on RPCI-WM1, which are typically restricted to plasma cells.
Whole transcriptome profiling by RNA-Seq and gene pathway enrichment
analysis in RPCI-WM1 cells, showed differential changes where upregulated
genes were significantly enriched within the Protein Transport (p<1.8E-98) and
Response to Unfolded Protein Gene Ontology groups (p<5.9E-20); downreg-
ulated genes were significantly localized within the B-cell receptor-signaling
pathway (Broad MSigDB) (p<6.1E-14). As BCR signaling has been linked to
dysregulated expression of several micro-RNAs (miRs), we examined miR
expression in RPCI-WM1 cells and observed a decrease in several miRs, which
target and regulate components involved in BCR activation (notably miR-155).
To examine further epigenetic changes that may account for decreased BCR
signaling, we examined the global methylation profile of RPCI-WM1 and
BCWM.1 cells and noted hypermethylation of the promoter sites (200 base
pairs upstream) for a number of transcription factors involved in the BCR path-
way. Ongoing WES and mate-pair sequencing data is anticipated to reveal
additional molecular alterations that account for the divergent responses to
ibrutinib in WM cells that display predominantly plasmacytic features.
Summary and Conclusions: We have conducted a comprehensive
immunophenotype and genomic/epigenomic analysis of plasmacytic-WM cells
vs B-lymphocytic WM cells, using validated preclinical models representative
of the phenotypic heterogeneity present in the human WM tumor compartment.
Overall our data suggests that significant architectural differences between the
two tumor cell types account for their differential sensitivity to the BCR signaling
disruptor, ibrutinib or the novel 19S proteasome inhibitor, VLX1570. These find-
ings will be validated in primary patients-derived WM cells. Further, these obser-
vations provide rationale for optimizing (or sequencing) ibrutinib therapy in dis-
tinct subgroups of WM patients as based on the predominance of plasma/plas-
macytic WM cells, present in their individual tumor compartments.
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EVALUATION OF GENOMIC IMBALANCES AND MIRNA EXPRESSION IN
PATIENTS WITH MYCOSIS FUNGOIDES
F. Huaman Garaicoa1,2,3,* A. Roisman1, M. Arias4, C. Trila5, M. Fridmanis6, A.
Abeldaño4, S. Vanzulli7, M. Narbaitz2,3, I. Slavutsky1
1Laboratorio de Genética de las Neoplasias Linfoides, Instituto de Medicina
Experimental (IMEX), CONICET- Academia Nacional de Medicina, 2Laboratorio
de Patología, Fundaleu, 3Laboratorio de Patología, Instituto de Investigaciones
Hematológicas (IIHEMA), Academia Nacional de Medicina, 4Servicio de Der-
matología, 5Servicio de Patología, Hospital Dr. Cosme Argerich, 6Servicio de
Dermatología, 7Laboratorio de Anatomía Patológica, Instituto de Estudios
Oncológicos (IEO), Academia Nacional de Medicina, Buenos Aires, Argentina
Background: Mycosis fungoides (MF) is a clonally derived lymphoproliferative
disorder that preferentially involves the skin, which etiology and pathogenesis
remains elusive. Morphological and clinical features are not always accurate
enough to predict the disease outcome. Comparative genomic hybridization and
microarrays have shown imbalances of CDKN2A (p16) (9p21) and C-MYC (8q24)
genes, with probable prognostic value in this pathology. In addition, miR-155
overexpression was observed in several hematological and solid tumors, pro-
moting genomic instability, proliferation, and survival of malignant cells. 
Aims: In this study, we have evaluated CDKN2A losses and C-MYC gains and
their association with miR-155 expression, in patients with diagnosis of MF.
Results were correlated with clinicopathologic features of patients. 
Methods: The study was performed on formalin-fixed and paraffin-embedded
biopsies from 32 patients with MF (22 males; median age 62.3 years, range:
31-81 years): 28 cases showed tumor stage MF (T-MF), 13 of them in histologic
transformation to a large T-cell lymphoma (TR-MF) and 4 cases with follicu-
lotropic MF (F-MF) variant. FISH analysis using OTS9P21.3 (CDKN2A) and
OTS8Q24 (C-MYC) probes (LiVE-Lexel, Argentina), was performed. Gene
expression was quantified by real time PCR using TaqMan Gene Expression
Assays. Ten control samples from benign skin diseases were also evaluated.
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The study was approved by the local Ethics Committee. All individuals provided
their informed written consent. 
Results: FISH study was performed in 26 patients, 19 (73%) showed genomic
alterations (GA): 11 (42.31%) cases had CDKN2A deletion, 8 (30.77%) showed
C-MYC gains and 3 (11.54%) exhibited both anomalies. CDKN2A deletion was
observed in 7/13 (54%) TR-MF, 3/4 (75%) F-MF and 1/9 (11%) T-MF meanwhile
C-MYC gain was detected in 6/13 (46%) TR-MF and 2/4 (50%) F-MF. Thus,
GA rate was: TR-MF 92%, F-MF 75% and T-MF 11% (p=0.006). These aber-
rations were more frequent in trunk and lower limbs (75%) in contrast with
head, neck and upper limbs (25%) (p=0.012). Patients with GA showed higher
CD30+ by immunohistochemistry (56.25%) and progression to histological
transformation (75%) than cases with no alterations (NA) (10% and 20%,
respectively) (p<0.03). Clinical response to treatment was absent in 8/16 (50%)
of cases with GA vs 1/10 (10%) patients with NA (p=0.03). Although no signif-
icant differences were reached, mean LDH (532.6 UI) and Beta 2 microglobulin
levels (3.4 mg/L), median proliferation index (Ki-67) (62.86%) and extracuta-
neous relapse (25%) with respect to those with NA. In addition, the group with
GA showed shorter overall survival (96 months) compared to cases with NA,
that not reached the median survival (Log-rank p=0.04), indicating their asso-
ciation with poor outcome. Gen expression analysis showed miR-155 upregu-
lation in 27% TR-MF and 50% F-MF and in only 8% T-MF. No miR-155 expres-
sion was observed in controls. The correlation with FISH results found miR-
155 overexpression in 33% of patients with GA and 12.5% of cases with NA. 
Summary and Conclusions: Our results showed higher proportion of 9p21
losses than 8q24 gains in MF patients. TR-MF exhibited the highest frequency
of GA, supporting a role in the process of neoplastic transformation. Although
the number of F-MF is reduced in our series, this morphological variant would
seem to be associated to an increased frequency of genomic imbalances.
Moreover, our findings on miR-155 expression support its relation with genomic
instability and tumor development in this pathology.
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MULTIPLE INJECTIONS OF ANTIBODY-RADIONUCLIDE-CONJUTAGES
TARGETING CD37 INCREASES TOLERABILITY IN NUDE MICE BEARING
NON-HODGKIN LYMPHOMAxENOGRAFTS
H. Heyerdahl1,* A.H.V. Repetto-Llamazares1, J. Dahle1
1Research and Development, Nordic Nanovector ASA, Oslo, Norway
Background: CD37 is an internalizing transmembrane glycoprotein predomi-
nantly expressed by normal B cells and also B-cell malignancies, thus an inter-
esting target for targeted therapies. The novel anti-CD37 antibody-radionu-
clide-conjugate (ARC) 177Lu-DOTA-HH1 (BetalutinTM), containing the short-
ranged beta-emitter lutetium-177, is currently being tested as single injection
therapy in a clinical phase I/II trial for non-Hodgkin B-cell lymphomas.
Aims: The present work is the first to explore the anti-tumor efficacy and tol-
erability of multiple dosing of 177Lu-DOTA-HH1 in mice bearing non-Hodgkin
B-cell lymphomaxenografts.
Methods: Ten million Ramos human lymphoma cells were injected subcuta-
neously on flanks of in-house bread mice from the strain Hsd:Athymic Nude-
Foxn1nu. Tumor-bearing mice and mice without tumor for tolerability control
were given 2-4 weekly injections of 300 MBq/kg 177Lu-DOTA-HH1 i.v (n=16-
18 tumors in 10-11 mice, 3-4 non-tumor bearing mice). Control mice were given
4 injections of 0.9% NaCl (n=19 tumors in 10 mice, 3 non-tumor bearing mice).
Tumor size, body weight and hematology were monitored regularly after admin-
istration.
Results: A tumor growth delay was observed in all groups given multiple
injections. The delay was increased in the group given 3 injections compared
to the group given 2 injections due to the increased radioactive dose. Durable
complete regression >100 days was observed in 56% of the tumors in mice
given 3 injections, compared to 28% in mice given 2 injections. It was found
that 4 weekly injections of 300 MBq/kg 177Lu-DOTA-HH1 were above the
maximum tolerable dose, as 5 of 12 mice had to be euthanized at day 37
after initial injection due to radiation toxicity recognized by rapid weight loss
and severely reduced health condition in combination with low hematology
values. None of the 14 mice given 3 weekly injections of 300 MBq/kg 177Lu-
DOTA-HH1 needed to be euthanized due to radiation toxicity. An average
decrease in body weight of 5% was seen for this therapy group during injec-
tions, with continued increase of body weight observed one week after last
injection. Hematology analysis showed transient reduction in white blood
cells (WBC) and platelet counts in all mice receiving treatment with 177Lu-
DOTA-HH1, with NADIR values (WBC: 9-25% of baseline values; platelets:
22-44% of baseline values) occurring 1-2 weeks after last injection. Platelet
counts returned to baseline levels within 4-6 weeks and WBC within 7-9
weeks after last injection. A total injected activity of 900 MBq/kg was found
tolerable in this multiple injection regime, compared to previously published
single injection data showing a maximum tolerated dose of 400 MBq/kg and
50% toxicity-related deaths within 25 days after injection in nude mice given
800 MBq/kg (Repetto-Llamazares et al., PLoS ONE 2014).
Summary and Conclusions: Weekly injections increase tolerability of 177Lu-
DOTA-HH1 compared to high dosage single injection in nude mice, allowing a
higher total activity to be administered.
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OFATUMUMAB OVERCOMES CD59-DEPENDENT RESISTANCE TO COM-
PLEMENT-DEPENDENT CYTOTOXICITY IN HUMAN B-CELL LYMPHOMA
MODEL 
M. Dwojak1,* M. Bobrowicz1, M. Siernicka1, B. Pyrzynska1, K. Bojarczuk1,
J. Golab1, M. Winiarska1
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland
Background: Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the
treatment of CD20-positive lymphoid malignancies. Unfortunately, anti-CD20
immunotherapy is not without its obstacles. It turns out that nearly 50% of patients
do not respond to treatment or the resistance appears in the further course of ther-
apy. Accumulating evidence indicates that that resistance is related to the expres-
sion of membrane complement inhibitors, i.e. CD59 on the surface of target cells. 
Aims: The aim of this study was to evaluate the efficacy of the rituximab-or
ofatumumab-triggered complement-dependent cytotoxicity (R-CDC or O-CDC)
against CD59-overexpressing lymphoma cells and to determine the amount of
CD59 and CD20 which allows anti-CD20 mAbs to effectively trigger CDC.
Methods: Raji, human Burkitt’s lymphoma cell line, found to be CD59-neg-
ative, was chosen to create stable CD59-expressing cell line using pLVX-
IRES-Puro-CD59 lentiviral construct. Cell cloning by serial dilution was per-
formed to establish different populations of transductants with various CD59
expression and invariable CD20 expression. All experiments evaluating
expression of membrane antigens was performed with flow cytometry. The
effectiveness of anti-CD20 mAbs was assessed in a series of distinct clones
using MTT-reduction assay.
Results: The results show that CD59 expression, independently of CD20 level,
has a critical influence on R-CDC and negatively correlates with the capability
of rituximab to trigger the complement cascade (Figure 1A-D). To determine if
this inhibitory effect of CD59 can be surmounted, using a panel of different
clones we performed CDC assay with ofatumumab-a fully human anti-CD20
antibody. Interestingly, we observed that ofatumumab overcomes CD59-depen-
dent resistance of B-cell lymphoma cells (Figure 1E).
Figure 1.
Summary and Conclusions: Our study clearly shows that CD59 expression
level affects the efficacy of anti-CD20 monoclonal antibodies and this obser-
vation seems to be clinically relevant. We suggest that evaluation of CD59
expression should be included in the diagnostic panels for leukemia/lymphoma
immunophenotyping by flow cytometry. Moreover, determination of CD59 levels
can have far-reaching implications for the planning of clinical therapeutic reg-
imens. Since ofatumumab is capable to overcome a negative effect of CD59,
it is substantiated to include ofatumumab in therapeutic regimens for patients
with high CD59 expression. 
E1380
THE EXPRESSION OF FOXO4 REGULATES LYMPHOMA STEM CELL-
LIKE CHARACTERISTICS AND RESISTANCE TO TREATMENT IN B-CELL
NON-HODGKIN LYMPHOMA
K.J. Ryu1,* C. Park1, M. Hong2, Y.H. Ko3, W.S. Kim4, S.J. Kim4
1Samsung Biomedical Research Institute, Research Institute for Future Medicine,
2Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center,
3Pathology, 4Medicine, Samsung Medical Center, Seoul, Korea, Republic of
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Background: Although lymphoma cells are relatively sensitive to chemother-
apeutic agents, a subset of cells remains as being viable even during treatment.
This subset of lymphoma cells might have stem cell-like properties including
tumor initiating ability, and result in resistance to chemotherapy such as dox-
orubicin. However, there is limited data about the presence of lymphoma stem
cells and its association with treatment resistance. In this study, we used a
group of lymphoma cells that maintained the viability after the exposure to anti-
tumor agents including doxorubicin and phenylbutyrate as a model of cancer
stem cells because doxorubicin is the most commonly used chemotherapeutic
agent and phenylbutyrate, a histone deacetylase inhibitor is reported to induce
stem cell characteristics in cancer cell lines. 
Aims: We analyzed gene expression profiles and biological characteristics of
viable lymphoma cells during the treatment with high concentration of doxoru-
bicin and phenylbutyrate, and explored a potential marker for lymphoma stem
cells that are associated with treatment resistance. 
Methods: Human lymphoma cell lines including BJAB, Toledo (diffuse large B-
cell lymphoma), Daudi, and Raji (Burkitt’s lymphoma) were incubated with the
IC90 concentration of doxorubicin (300nM) or phenylbutyrate (8mM) for 48
hours. After incubation, viable cells were sorted, and analyzed for their resist-
ance to treatment. Gene expression profiles of those viable cells were evaluated
with cDNA microarray, and biological characteristics including stem cell-like
properties were also analyzed. Membrane proteomics was performed to explore
surface markers for lymphoma stem cells, and immunohistochemistry for can-
didate markers were performed in the paraffin tissue of patients with non-
Hodgkin B-cell lymphoma. 
Results: Lymphoma cells could maintain their viability after they were exposed
to the IC90 concentration of doxorubicin and phenylbutyrate for 48 hours in the
experiment with four types of B-cell lymphoma cell lines. These viable lym-
phoma cells sorted after their exposure to treatment showed resistance to treat-
ment and significantly better ability of colony formation and sphere formation
than control cells (P <0.05). The expression of stem cell-related genes including
OCT4, NANOG, and SOX2 was also increased in viable cells after treatment.
The comparison of gene expression profiles between survived cells after treat-
ment and control cells showed that 42 gene were up-regulated in both condi-
tions (doxorubicin and phenylbutyrate treatment). Among them, FOXO4 was
significantly overexpressed in viable cells. The expression of FOXO4 was con-
firmed with primary lymphoma cells derived from malignant effusion of three
patients with B-cell non-Hodgkin lymphoma. The amplification of FOXO4
expression in lymphoma cell lines also increased colony formation whereas
the knockdown of FOXO4 decreased the expression of OCT4, NANOG and
SOX2, and colony forming ability in lymphoma cells. The analysis of membrane
proteins in these lymphoma cells survived after phenylbutyrate treatment
showed increased expression of ENO1. The immunohistochemistry with paraf-
fin tissue of patients with B-cell non-Hodgkin lymphoma showed nuclear expres-
sion of FOXO4 and membranous expression of ENO1.
Summary and Conclusions: A small subset of lymphoma cells resistant to
treatment might have stem cell-like characteristics, and the expression of
FOXO4 might play a crucial role in their maintenance. The membranous expres-
sion of ENO1 in this small subset of lymphoma cells might suggest the proba-
bility of ENO1 as a stem cell marker in B-cell non-Hodgkin lymphoma.
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GLYCOLYTIC INHIBITOR 2-DEOXY-GLUCOSE SUPPRESSES CELL PRO-
LIFERATION IN NON-HODGKIN LYMPHOMA CELLS THROUGH DOWN-
REGULATION OF HIF-1 AND C-MYC
T. Wang1,* Y. Pang1, F. Chen1, H. Huang1, F. Xiao1, J. Zhong1, H. Zhong1
1Division of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong
University, Shanghai, China
Background: Metabolic reprogramming is linked to tumourigenesis, disease pro-
gression, clinical outcome and resistance to chemotherapy. However, the signifi-
cance of glycolytic metabolism in non-Hodgkin’s lymphoma (NHL) remains unclear.
Aims: To investigate the role of glycolysis in the pathogenesis of lymphoma
and the potential target for therapy. 
Methods: Cell proliferation and cytotoxicity were detected using Cell Counting
Kit-8. Glucose consumption was determined via glucose uptake assay. Lactic
acid generation was estimated using a lactic acid detection kit. Apoptosis and
cell cycle analysis were measured by flow cytometry. Real-time PCR was per-
formed to determine the levels of glycolysis-related genes. Cleavage of cas-
pase-3 and PARP-1 as well as expressions of HIF-1α and c-MYC were demon-
strated via western blot. 
Results: Activation of glycolysis-related genes was seen in malignant tissues
from patients with NHL, and a panel of NHL cell lines as well. Consistent with the
gene expression levels, multiple NHL cell lines exhibited the glycolytic metabolic
phenotype, suggesting a role of glycolysis in the pathogenesis of NHL. The gly-
colytic inhibitor 2-DG significantly suppressed the abilities of glucose consumption
and lactic acid production in NHL cell lines. In consert with suppression of the
metabolic phenotype, proliferation of NHL cell lines were significantly inhibited
by 2-DG in a time- and dose-dependent manner. In contrast, no difference was
observed in normal lymphocytes after 2-DG treatment. The Burkitt lymphoma
cell line Raji was less sensitive to 2-DG than other cell lines e.g. SU-DHL-4, DB,
Namalwa, Jeko-1. However, when cultured under hypoxia, the IC50 value of 2-
DG for hypoxic Raji cells was significantly lower compared with its normoxic coun-
terpart, accompanied by a more marked inhibition of cell proliferation, glucose
cosumption and lactic acid generation. Meanwhile, hypoxic Raji cells displayed
apoptosis induction after 2-DG treatment. Furthermore, down-regulation of HIF-
1α and c-MYC were observed only in hypoxic Raji cells (Figure 1).
Figure 1.
Summary and Conclusions: In conclusion, these results present novel insight
into critical roles of glycolytic pathway activation in NHL progression. Inhibition
of glycolytic pathway may provide a new therapeutic strategy for the treatment
of NHL.
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IMMUNOPHENOTYPIC CHARACTERIZATION AND CLINICAL BEHAVIOUR
IN CD19+CD5+ (NON-CLL) LYMPHOPROLIFERATIVE DISORDERS MUTAT-
ED AND UNMUTATED WITH AND WITHOUT T(11,14)
L. Lopez-Anglada1,* M. Alcoceba2, M. Garcia-Alvarez2, FJ. Diaz-Galvez3,
M. Bourgeois4, J.A. Queizan5, A. Ahmadi6, R.H. Cantalejo7, G. Martin8,
I.F. Graciani9, E. de Cabo3, M.C. Montes-Fernandez10, S. Fernandez-Ferrero11,
J.M. Alonso12, M. Gonzalez-Diaz2, M.B. Vidriales2
1Haematology, Hospital Universitario 12 de Octubre/ I+12, Madrid, 2Haematol-
ogy, Hospital Clínico de Salamanca/ IBSAL, Salamanca, 3Hospital del Bierzo,
Ponferrada, 4Hospital Clínico Universitario de Valladolid, Valladolid, 5Haema-
tology, Complejo Asistencial de Segovia, Segovia, 6Haematology, Hospital
Nuestra Señora de Sonsoles, Avila, 7Haematology, Hospital Santos Reyes,
Aranda de Duero, 8Haematology, Hospital Virgen del Puerto, Plasencia, 9Hos-
pital Río Hortega, Valladolid, 10Haematology, Hospital Virgen de la Concha,
Zamora, 11Haematology, Complejo Asistencial de León, Leon, 12Hospital Rio
Carrion, Palencia, Spain
Background: Mantle cell lymphoma (MCL), characterized by the presence of
t(11;14)(q13;q32), shows a typical immunophenotype CD19+CD5+ that can be
identified by flow cytometry (FC) and is easily distinguished from CLL. However,
cases with typical MCL-immunophenotype lacking t(11;14) are frequently
detected in the clinical routine. Further, clinical presentation could be variable
and may show a different IGHV mutational status. 
Aims: Characterize FC CD19+CD5+ (non-CLL) lymphoproliferative disorders
(LPD), trying to identify immunophenotypic profiles that may predict the presence
of t(11;14) and to find molecular differences associated to clinical behaviour.
Methods: We retrospectively reviewed a total of 98 patients with CD19+CD5+
(non-CLL) LPD detected by FC in the clinical laboratory of the University Hos-
pital of Salamanca (Spain), in which information of immunophenotype, cyto-
genetics, and molecular biology (MB) (bcl-1 and IGHV mutational status) was
available. The clonal B-cell population was detected in peripheral blood
(n=50), bone marrow (n=29) and/or lymph node (n=19). Erythrocyte-lysed
samples were stained with large panels of monoclonal antibodies, using 4-
color direct immunofluorescence technique according to previously described
methods, aimed to identify and characterize B neoplastic cells; the complete
diagnosis was performed with ancillary techniques as MB (bcl-1 and IGHV
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mutational status), karyotype and fluorescent in situ hybridization (FISH) for
t(11;14). 
Results: Out of the 98 samples with CD19+CD5+ immunophenotype (no CLL),
52% were t(11;14) positive (most of them studied by the tree techniques: 9%
Karyotype(Kt)+FISH+BM+; 11% Kt+FISH+BM-; 22% Kt-FISH+BM+; 47% Kt-
FISH+BM- and 11% Kt-FISH-BM+). FISH was the most useful technique, being
positive in 88% of the positive cases. 84% of the t(11;14) positive cases showed
typical CD22+/CD23- immunophenotype and bright expression of CD20+ and
FCM7+, CD38 expression was negative in 53% of the cases. Negative cases
for t(11;14) showed CD22+/CD23- in a slightly lower frequency (62%) being
more heterogeneous, but with similar expression of CD20; CD38 was positive
in a 33% of these cases. Concerning clinical behaviour and IGHV mutational
status, the percentage of mutated cases was higher among leukemic cases
(88%) than among nodal cases (35%), both with and without t(11;14). Despite
no differences in OS, unmutated cases could be associated with more aggres-
sive behaviour due to the need for earlier treatment (TTT median 15 days vs
29 months; p<0.001) and a higher progression risk (SLP median 52 months vs
NR; p<0.001). Among the 98 CD19+CD5+ (non-CLL) cases, 8 were non-clas-
sifiable chronic LPD, 4 were classified as SMZL, 4 as SLL, 2 as DLBCL, 1 as
FL and 79 as MCL. Overall, 75% of cases received therapy (of which 73% of
them had nodal behaviour; 27% leukemic behaviour). The time to treatment
was longer in leukemic than in nodal cases (median 82 months vs 15 days;
p<0.001).
Summary and Conclusions: Although typical MCL’s-immunophenotype cases
are frequently detected, t(11;14) is present only in half of the cases and there
is no clear difference in immunophenotype between cases t(11;14) positive
and t(11;14) negative. Despite no differences in OS, and taking into account
that patients were not treated uniformly, unmutated cases could be linked to
more aggressive behaviour due to the need for earlier treatment and to an
increased risk of progression, while mutated forms are generally presented as
a less aggressive disease.
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ANALYSIS OF THE IGVH SOMATIC MUTATIONS IN SPLENIC MARGINAL
ZONE LYMPHOMA
H.L. Julhakyan1,* B. Biderman1, A. Sudarikov1
1Hematological Scientific Center, Moscow, Russian Federation
Background: Splenic marginal zone lymphoma (SMZL), a specific type of
small B-cell lymphoma and characterized by a peculiar morphology with micron-
odular pattern of infiltration, biphasic cytology, and the almost constant pres-
ence of marginal zone differentiation.
Aims: The aim of our study to determine the immunoglobulin variable heavy
chain (IgVH) gene usage and somatic mutation patterns in a series of SMZL
patients and to correlate these findings with the clinical features and outcome.
Methods: Among a total of 125 SMZL patients diagnosed and followed up in
our Center during the last 14 years, 24 were included in the present study,
based on the availability of tissue specimens or frozen cell material. Diagnosis
was based on standard WHO criteria. In all patients, the diagnosis was based
on peripheral blood and BM findings. The baseline clinical and laboratory fea-
tures as well as follow-up and outcome were recorded for every patient.
Rearranged IgVH genes were amplified essentially in reactions that contained
only one of the 5’ leader region primers for the indicated 6 VH families and a
3’J primer. All PCR reactions were performed using appropriate positive and
negative controls.
Results: The studied population included 15 women and 9 men with a median
age at diagnosis of 60 years (range, 32 to 77 years). All patients had
splenomegaly, with a median spleen size of 10 cm below the left costal margin.
None of them had lymph node enlargement, except for the splenic hilar lymph
nodes. BM infiltration was evident in all patients, either by conventional mor-
phology and immunohistochemistry or by flow cytometry. B-symptoms were
present in all patients. Anemia (hemoglobin<12 g/dl) and thrombocytopenia
(platelets <100×109/l) were recorded in 14 and 7 patients respectively. Autoim-
mune hemolytic anemia was present in 3 patients, while paraproteinemia was
detected in 10 patients, being of the IgM isotype in all cases except one. Serum
lactate dehydrogenase (LDH) was elevated in 17, serology for hepatitis C was
negative in all patients. All patients underwent splenectomy as first-line therapy.
The rearranged VH genes identified for each case seemed to represent func-
tional rearrangements because no stop codons or crippling mutations were
identified. A comparison of the VH genes to reported germline sequences
revealed that 6 cases used the VH3 family VH gene segments, 2 the VH4 fam-
ily, 16 the VH1 family segments. The VH1 family genes V1-2 were used in 16
cases. In 4 out of 24 cases (16.67%), IgVH genes were in germline or near
germline configuration, whereas in 20 cases (83.33%), IgVH genes were
somatically mutated. We have shown no differences in clinical and laboratory
characteristics, immunophenotype, outcome or overall survival were found
between the mutated and unmutated cases. There was a trend for worse sur-
vival in unmutated versus mutated SMZL cases (median survival 70 vs.109
months), but the difference did not reach statistical significance.
Summary and Conclusions: Our analysis also showed the selective use of
VH1 family genes in a high proportion of SMZL cases (66.67%), while VH4
and VH3 family genes were represented at a lower frequency (8.33% and 25%,
respectively). The present study revealed that a significant fraction of SMZL
cases derive from naive B-cells with unmutated IgVH genes, thus indicating
that this is a heterogeneous group of disease with respect to its cellular origin.
A prognostic significance of mutation status was not observed in this study.
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FLOW CYTOMETRY IMMUNOPHENOTYPING AND CYTOLOGICAL
ANALYSES OF CSF: A COMPARISON OF PERFORMANCES FOR LYM-
PHOMATOUS CELL DETECTION 
M. Costopoulos1,* T. Belleville1, C. Settegrana1, K. Maloum1, Z. Azgui1,
M. Brissard1, P. Bonnemye1, S. Choquet2, K. Hoang-Xuan3, V. Leblond2,
H. Merle-Beral1, M. Le Garff-Tavernier1
1Biological Haematology Department, 2Hematology Department, 3Neuro-
Oncology Department, Pitie-Salpetriere Hospital, Paris, France
Background: Leptomeningeal involvement of lymphomas is a rare and aggres-
sive condition, mainly occurring in large B-cell lymphomas (DLBCL) and Burkitt
lymphomas. It is defined by the presence of malignant cells in the cerebrospinal
fluid (CSF) and can be prevented by intrathecal chemotherapy. The prevalence
of this affection is uncertain and may be explained by the various existing tech-
niques. Cytomorphological (CM) examination is considered to be the “gold
standard” but remains insufficiently sensitive due to the frequent sample pauci-
ty. Provided these limits, a multimodal investigation of CSF is required. Flow
cytometry (FCM) techniques tend to be more sensitive and specific. The
approach consisting of drawing the CSF sample on a TransfixTM tube is cur-
rently largely used for FCM and prevents early cell mortality.
Aims: The aim of our study was to assess the value of FCM in detecting CSF
disease in a large cohort of patients with aggressive lymphomas.
Methods: This retrospective study was conducted on all CSF samples referred
to our laboratory and coming from patients with primary cerebral lymphoma or
other non-Hodgkin lymphomas (NHL) between January 2013 and September
2014. We matched FCM and CM results obtained from the analysis of 204
CSF drawn (107 patients). In this purpose, 2 samples were collected: 1 ml for
CM analysis (with albumen added during cytospin and May Grünwald Giemsa
staining) and 1 ml on a Transfix-containing tube (Cytomark). A cytological sam-
ple was classified as negative or positive by CM evaluating lymphocyte features
defining lymphoid cells as typical or atypical. Immunophenotyping was per-
formed on a FACSCanto II (BD Biosciences) using an 8-colour panel (anti-
CD19, kappa, lambda, CD5, CD3, CD4, CD8 and CD45). A CSF sample was
considered as positive by FCM when a cluster of at least 20 events with
immunophenotypic features of neoplastic cells were detected. CM and CSF
results were treated in a double-blind manner.
Results: We confirm that Transfix-treated CSF prevent early cell mortality and
improves the quality of FCM tests. Identifying and analyzing cells by FCM remains
possible even if the total cell count is ≤1 leucocyte/µl in CM count (n=70). Overall,
178 (87%) samples showed similar results by CM and FCM with presence (n=25)
or absence (n=153) of lymphomatous cells. Seven percent of samples were clas-
sified as suspicious by one technique. Among them, 9 samples were positive by
FCM but negative by CM. This lack of accuracy is due to poor cellularity in the
CSF in patients with low-volume disease or to innocent aspect of neoplastic cells.
False negative cases occur because of low sensitivity of CM compared with
FCM. In contrast, three samples were positive by CM but negative by FCM. False
positive results by CM can be generated by the presence of confounding atypi-
cal-like reactive lymphocytes. On the other hand, false negative results by FCM
can be explained by the cell size (inherent cells parameter) particularly large
lymphocytes outside the scope of our analysis or by the loss of one gating marker. 
Summary and Conclusions: To date the debate pertaining FCM diagnostic
accuracy as well as prognostic impact when compared to CM examination is
still open. CSF is a biological sanctuary extremely accessible to FCM studies.
Our results suggest that FCM increases the sensitivity and specificity of lep-
tomeningeal disease detection. FCM is a well-reproducible quantitative method
suited for the identification of small cell populations. In conclusion, both meth-
ods should be applied concurrently for complementary diagnosis assessment
in patients with lymphomas.
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EXPRESSION OF SOXC CLUSTER AND MIR-17-92 POLYCISTRON IN
MANTLE CELL LYMPHOMA PATIENTS
A. Roisman1,* F. Metrebian2, D. Kohan3, H. García Rivello3, M. Narbaitz2,
E. Campo4, L. Hernández4, I. Slavutsky1
1Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experi-
menta. CONICET-Academia Nacional de Medicina, 2Departamento de Patología,
Instituto de Investigaciones Hematológica, ANM, 3Servicio de Patología, Hospital
Italiano, Buenos Aires, Argentina, 4Molecular Pathology., Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona., Spain
Background: Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoid
malignancy that accounts for approximately 6% of all non-Hodgkin´s lym-
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phomas. SOX4, SOX11 and SOX12 genes, constitute the SOXC family of tran-
scription factors involved in embryonic neurogen esis and tissue remodeling.
Among them, SOX11 shows aberrant expression in MCL, being considered a
new molecular marker of adverse prognosis in this pathology; meanwhile
recently it has shown that SOX4 can bind and regulate the promoter of Dicer,
a microRNA biogenesis factor. Furthermore, several studies have demonstrated
the oncogenic role of miR-17-92 cluster in hematological malignancies, being
scarce the information about the association between this cluster and SOXC
expression levels in MCL. 
Aims: In this study, we have performed a Gene Expression Analysis (GEA) of
SOXC cluster and their correlation with the expression of miR-17, miR18a, miR19b
and miR92a, members of the polycistronic oncomiR-17-92 in MCL patients. 
Methods: mRNA samples of 45 MCL patients (15 males; mean age: 56.7 years,
range: 34-71 years) and 12 normal controls were analyzed. Gene expression
was quantified by real time PCR using TaqMan Gene Expression Assays.
GUSB and RNU6B were used as housekeeping genes to normalize the expres-
sion of SOXC and miR17-92 clusters, respectively. The proliferation index was
evaluated by immunohistochemistry with the Ki67 antibody. The analysis of
mRNA expression data was done using the two-tailed Mann-Withney test. To
calculate the expression cut-off values with the highest sensitivity and specificity,
receiver operating characteristics curves were used. The study was approved
by the Ethics Committee of our Institution. All individuals gave their informed
consent. 
Results: The analysis of SOXC members showed upregulation, of SOX11 and
SOX12 in 60% and 71% patients, respectively, while SOX4 was downregulated
in 45% of cases, compared to normal controls. GEA of SOX11 and SOX12 showed
higher expression levels (2.1±0.24 and 3.1±0.16, respectively), with respect to
SOX4 (1.2±0.21) (p=0,006 and p<0.0001, respectively). Moreover, an inverse
relationship between the expression of SOX11 and SOX4 was detected
(p=0.0017), being the last one undetectable in patients with high expression of
SOX11. Regarding to the members of the miR17-92 cluster, miR17 and miR18a
were downregulated in 86% and 84.4% of our cohort, respectively; meanwhile,
miR19b and miR92a were upregulated in 95% of cases each, compared to con-
trols. GEA revealed that miR19a (3.24±0.1) and miR92a (2.59±0.1) exhibited
increased expression levels than miR17 (-2.7±0.15) and miR18a (-2.8±0.19)
(p<0.0001). A positive correlation between miR92a with miR17 (p=0.0001), miR18a
(p=0.0013), and miR19b (p<0.0001) mRNA levels, was observed. Moreover, we
found a positive correlation between SOXC members and miR18a expression
(p<0,012). In addition, patients overexpressing SOX11, SOX12 and miR92a
showed a higher percentage of Ki67 positive cells (37-41%), compared to cases
without expression, but without reaching significant differences. 
Summary and Conclusions: Our findings in MCL patients show for the first
time an inverse correlation in the expression profiles of SOX11 and SOX4
genes. Additionally, and to the best of our knowledge, we found new evidence
linking the differential expression pattern between SOXC genes and miR18a,
suggesting an interaction that could add new insights in the biologic character-
ization of this pathology.
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THE IMPACT OF MUTATION STATUS OF SOCS1 IN PATIENTS WITH HIGH-
GRADE DIFFUSE LARGE B-CELL LYMPHOMA.
O. Gavrilina1,* E. Zvonkov2, N. Siverina3, B. Biderman3, A. Sudarikov3,
E. Parovichnikova1, S. Kulikov4, V. Savchenko5
1Department of Hematological Oncology and BMT, 2Department chemotherapy
lymphomas, 3Laboratory of molecular hematology, 4Department of boistatistics,
5National Research Center for Hematology, Moscow, Russian Federation
Background: Suppressor of cytokine signaling 1 (SOCS1) is a negative reg-
ulator of JAK/STAT pathway. Nowadays there are studies that demonstrated
high frequency of SOCS1 mutations in patients with diffuse large B-cell lym-
phomas. There is only one publication about the prognostic value of SOCS1
mutations in DLBCL patients with CHOP-like therapy. 
Aims: To evaluate the frequency and prognostic impact of mutation status of
SOCS1 in patients with de novo high-grade DLBCL treated with high-dose
chemotherapy (HDC).
Methods: We performed a trial, including 22 adult patients (median age 40
years, range 20-66) with newly diagnosed DLBCL who were enrolled in HDC
protocol (mNHL-BFM-90 program) since July 2007 till January 2014. Their clin-
ical characteristics: m:f=9:13, extranodal involvement>1 in 13 (59%) patients,
bone marrow involvement in 5 (23%) patients, high proliferative activity Ki-
67>80% in 17 (77%) patients, GCB: non-GCB type=13:9, IPI risk>2 in 17 (77%)
patients. Mutations of SOCS1 were detected using sequencing PCR products,
which were received by single-round PCR. DNA for PCR was extracted from
sections of frozen tumor samples. Amplification of VH gene rearrangements to
control the tumor cells was performed by BIOMED-2 multiplex polymerase
chain reaction protocol.
Results: In 8 (36%) of 22 patients the SOCS1 mutations were detected. By
sequence analysis, we identified 18 (7 deletions, 11 single nucleotide substitu-
tions) SOCS1 mutations. We didn’t verify hotspots. Mutation status of SOCS1
gene didn’t correlat with clinical characteristics of patients.
The median follow-up time in 22 patients was 46 months (range: 5-65 month).
Four patients had died of the disease (~18%) and 18 patients were either alive.
Univariate analysis of the entire cohort (n=22) revealed that age, IPI, extranodal
involvement, Ki-67 and phenotype were not of prognostic significance (p >0.05).
In a multivariate analysis, detection of SOCS1 mutations in patients with high
grade DLBCL was an independent predictor for overall survival (OS) (p <0.05).
OS in DLBCL patients with SOCS1 mutations and without was 62,5% and 90%,
respectively. Event-free survival (EFS) was 62,5% and 71,4%, respectively.
(Figure1A-B). There was no difference in overall survival and event-free survival
in subgroups between SOCS1 deletions and SOCS1 single nucleotide substi-
tutions, between SOCS1 single mutation and SOCS1 multiple mutations.
Figure 1.
Summary and Conclusions: Though a group of analyzed patients is small,
however the detection of SOCS1 mutations seems to be an independent pre-
dictor of outcome in high grade DLBCL patients, treated with high-dose
chemotherapy, while IPI and phenotype DLBCL cannot be considered as risk
factors for this group of patients. It seems to be reasonable to continue a study
of mutation status of SOCS1 gene in high-grade DLBCL patients, because it’s
may be a single gene prognostic biomarker in DLBCL. If it will be confirmed,
this biomarker could determine an indication for autologous transplantation in
this group of patients as first-line therapy.
LB2092
CARDIAC GLYCOSIDES SELECTIVELY INDUCE HEMATOLOGICAL MALIG-
NANCY CELLS APOPTOSIS THROUGH NKA/IP3R SIGNALING PATHWAY
T. Wang1, J. Chen1, Y. Xu2, Y. Guo3, J. Ouyang2, J. Li2,*
1Nanjing University, 2Nanjing Drum Tower Hospital, Nanjing, 3the First People’s
Hospital of Changzhou, Changzhou, China
Background: Cardiac glycosides have been used to treat heart diseases for
centuries because of their inhibition effects on Na+/K+-ATPase (NKA). Recently,
more and more studies indicate that low doses of cardiac glycosides can inhibit
cancer cells proliferation and induce apoptosis, but there is no evidence suggests
which types of cancer cells are more sensitive to cardiac glycosides and until
now the anti-apoptotic mechanism is still not quite clear yet. In our previous work,
we found that low doses of cardiac glycosides without inhibition of NKA can trigger
intracellular signaling pathway (NKA/IP3R-Ca2+ oscillation-NF-kB) which regu-
lates cells proliferation and apoptosis. Here we found that Burkitt’s lymphoma
cells are the most sensitive cells to cardiac glycosides and the mechanism is that
Burkitt’s lymphoma cells overexpress c-myc which is regulated by cardiac glyco-
sides triggered signaling pathway (NKA/IP3R-Ca2+oscillation-NF-kB).
Aims: We attempt to elaborate on the following points: 1) The suppose that
cardiac glycosides regulate the activity of NF-κB and c-myc and induce Raji
cells apoptosis through NKA/IP3R-Ca2+ oscillation-NF-kB signaling pathway
will be certificated. 2) We set up Burkitt’s lymphoma animal model to investigate
cardiac glycosides anti-tumor activity in vivo study.
Methods: In vitro study: 1) Cells: 11 types of human malignant hematological
cell lines and 7 types of primary culture of human malignant hematological cells
were used. 2) Cardiac glycosides treatment: digoxin, digitoxin and ouabain
were used. 3) Cells Proliferation rate was measured by Cell Counting Kit-8. 4)
Cells apoptosis rate was detected and quantificated by Annexin-V-FLOUS
Staining Kit followed by flow cytometry. 5) NF-kB activity was measured by the
TransAM NF-κB p65 Kit. 6) NKAa1, IP3R and c-myc protein level were meas-
ured by western-blot, mRNA level were measured by realtime-PCR. In vivo
study: BALB/c-nu mice models of human Burkitt’s lymphoma were established
by injecting Raji cells subcutaneously. To study the effect of digoxin onxenograft
engraftment rate, digoxin was injected into the abdominal cavity daily 3 days
before or 1 day after tumor cells implantated into mice. Mice weight and volume
ofxenograft tumors were measured daily. Western Blot, immunohistochemical
staining and immunofluorescence staining were used to analyze c-myc protein
level ofxenograft tumors.
Results: 1) Low doses of cardiac glycosides can inhibit human malignant
hematological cells proliferation and induce apoptosis, Burkitt’s lymphoma cells
including primary culture cells and Raji cells are the most sensitive cells. 2)
Burkitt’s lymphoma cells overexpress c-myc not only protein level but also
mRNA level, NF-kB is over activated in Burkitt’s lymphoma cells. Cardiac gly-
cosides can decrease the c-myc expression level and inhibit NF-kB activity. 3)
Cardiac glycosides can increase Burkitt’s lymphoma cells NKAa1 expression.
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By using siRNA to knock down NKAa1, NKAa1 expression is decreased and
this abolish the anti-apoptotic effect of cardiac glycosides and also abolish the
effect of cardiac glycosides on c-myc and NF-kB activity. 4) In vivo study, by
using naked mice with hypodermic injection Raji cells to set up Burkitt’s lym-
phoma animal model. Digoxin reducedxenograft engraftment rate of Burkitt’s
lymphoma significantly if mice were treated with digoxin before tumor cell
implantation. Digoxin suppressed the growth of subcutaneous tumors at the
fifth day when mice were treated with digoxin after tumor established. This
effect lasted until the endpoint of the observation. Digoxin reduced c-myc pro-
tein expression of tumor cells.
Summary and Conclusions: Compare to other human malignant hematolog-
ical cells, Burkitt’s lymphoma cells are the most sensitive cells to cardiac gly-
cosides, this maybe because these cells overexpress c-myc which is regulated
by cardiac glycosides triggered signaling pathway (NKA/IP3R-Ca2+ oscillation-
NF-kB). Cardiac glycosides also have anti-tumor in vivo study. Burkitt’s lym-
phoma is a high grade malignancy, until now, there is no effective therapy
method. Our finding suggests a positive new medicine for the therapy of





FLOW CYTOMETRIC CHARACTERIZATION OF LEUKOCYTE SUBPOPU-
LATIONS IN BONE MARROW FROM UNTREATED PATIENTS WITH
GAUCHER DISEASE TYPE 1: PRONOUNCED T-CELL RESPONSE AND
STEM CELL DEFECT?
M. Klimkowska1,* E. Pawlowicz2, A. Jeppsson-Ahlberg1, M. Machaczka2
1Department of Clinical Pathology and Cytology, 2Hematology Center Karolin-
ska, Karolinska University Hospital, Stockholm, Sweden
Background: Gaucher disease (GD) is a lysosomal storage disease, with defi-
cient activity of glucocerebrosidase due to autosomal recessive mutations in
GBA1 gene. The defect causes ubiquitous macrophage infiltration in parenchy-
matous organs and bone marrow in all clinically distinguished phenotypes (GD
1-3), with additional nervous system involvement in type 2 and 3. Patients with
GD demonstrate a variety of abnormal immunological responses and tendency
to develop lymphoproliferative diseases. As the role of chronic inflammation in
GD-affected organs was postulated, the role of respective immunological cell
types is being discussed. Up till now studies focused exclusively on leukocyte
subpopulations and cytokine profiles in peripheral blood.
Aims: The study aimed to characterize leukocyte subsets in bone marrow aspi-
rates from treatment-naïve patients with Gaucher disease type 1 by multipara-
meter flow cytometry (FC), in comparison with data from healthy controls.
Methods: Twelve patients with GD1, previously untreated, followed at the
Karolinska University Hospital Hematology Center were enrolled (4 females,
8 males). Bone marrow aspirates were taken between 2008 and 2013, as a
part of routine clinical follow-up, and analyzed by flow cytometry. For com-
parison, bone marrow flow cytometry data on 12 healthy subjects, age and
sex matched to GD-patients, were retrieved from the database of Department
of Clinical Pathology and Cytology at the same institution. Samples were
routinely processed, stained with monoclonal antibodies (Beckton Dickinson,
DAKO), acquired using 4 color Canto A or 8 color Canto II cytometers (BD),
and analyzed using BD FACSDIVA™ software. Analysis included cells pres-
ent in mononuclear cell gate in each analyzed tube. The following cell pop-
ulations were highlighted in each subject: CD3+ T-cells and fractions (CD4+,
CD8+, CD4+/8+, CD4-/8-, T/NK-cells), CD56+/CD3- NK-cells, CD19+ B-cells
at different stages of maturation. Besides, CD34+ stem cells, CD117+ pre-
cursors, CD14+ monocytes and CD33+ mononuclear immature myeloid cells
were analyzed. For statistical analysis, Shapiro-Wilk test was used for veri-
fication of value distribution, and t-test and Mann Whitney U test for compar-
isons between groups.
Results: Median age was 55.5 years (mean 58.8±18.8) in GD patients and
57.5 yrs (57.6±17.3) in controls. Four GD patients were previously splenec-
tomized. Bone marrow aspirates from GD1 patients contained more T-cells
and respective fractions but the CD4/CD8 ratio was lower as compared to
healthy controls; the differences were however not significant. Patients with
GD1 had minimally fewer NK-cells, B-cells and plasma cells, with the exception
of the CD19+/CD5+ B-cell fraction. They had also significantly fewer CD34+
stem cells, with almost the same proportion of CD33+ or CD14+ cells as con-
trols. Splenectomized GD patients had significantly fewer precursor cells
(CD34+, CD117+) but more NK-cells as compared to non-splenectomized
ones. There were also non-significant trends for higher amounts of T-cell, B-
cell and monocytes in splenectomized patients (Table 1).
Table 1. Leukocyte subsets in bone marrow in flow cytometry analysis.
Summary and Conclusions: Presented findings provide for the first time an
overview of leukocyte subpopulations in GD1 patients who did not receive any
eznyme replacement or substrate reduction therapy. On the contrary to some
reports concerning lymphocyte subsets in peripheral blood from GD patients,
our data suggest a more pronounced T-cell response and possibly a stem cell
defect in the bone marrow of GD1 patients, where the actual Gaucher cells
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infiltrates are present. This trend was even more pronounced in splenectomized
patients, in whom the natural course of the disease varies from persons with
preserved spleen.
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FREQUENCY OF AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME IN
CHILDREN WITH CHRONIC IMMUNE CYTOPENIAS AND NEWLY DIAG-
NOSED LYMPHOMA
Z. Kaya1,* M. Isik1, E.U. Bagriacik2, F.G. Pinarli3, U. Kocak1, I. Yenicesu1,
T. Gursel1
1The Pediatric Hematology Unit of the Department of Pediatrics, 2Department
of Immunology, 3Department of Pediatric Oncology, Medical School Of Gazi
University, Ankara, Turkey
Background: Autoimmune lymphoproliferative syndrome (ALPS) is caused by
defective lymphocyte homeostasis resulting from mutations in FAS-mediated
apoptotic pathway. It is characterized by chronic non-malign organomegaly
and/or immune cytopenias and/or lifelong increased risk for lymphoma.
Although there are only 300 families that has been described all over the world,
the actual incidence is probably much higher than that. 
Aims: The aim of the present study was to investigate ALPS in children with
newly diagnosed lymphoma, chronic immune cytopenias with/without nonma-
lign organomegaly. 
Methods: We studied a total of 34 children, including newly diagnosed lym-
phoma (n:13), non-malign organomegaly in association with immune cytopenias
(n:6), chronic immune thrombocytopenic purpura (cITP) (n:10) and autoimmune
hemolytic anemia (AIHA) (n:5) which meet diagnostic criteria of proven and
probable ALPS. Their CD3+CD4-CD8- double negative T cells were isolated
from peripheral blood mononuclear cells and then analysed by flow cytometry
using anti-CD3, anti-CD4 and anti-CD8 coated magnetic beads. T cell apoptosis
was assessed in peripheral blood using flow cytometry and staining with Annex-
in V. Soluble Fas ligand (sFasL) and interleukin (IL-10) 10 levels were measured
using quantitative ELISA method. Other hematological and biochemical param-
eters were recorded from the patients clinical files.
Results: Eighteen (53%) of the 34 cases met the diagnostic criteria of proven
or probable ALPS. Frequencies of proven and probable ALPS were 38% and
15%, respectively. The distribution of underlying condition was lymphoma
(proven n:7) (21%), non-malign organomegaly (proven n:4, probable n:1)
(16%), cITP (proven n:1, probable n:3) (10%) and AIHA (proven n:1, probable
n:1) (6%). Elevated double negative T lymphocyte (>5%) and increased lym-
phocyte apoptosis ranged between 50-80% of all patients, but high sFasL
(>200pg/ml) and IL 10 (>20pg/ml) levels were found in only 10-30% of them.
Double negative T lymphocyte and lymphocyte apoptosis were significantly
higher in patients with lymphoma and non-malign organomegaly compared to
patients with cITP or AIHA (p<0.05). Ninety percent of lymphoma patients had
anemia and/or thrombocytopenia in association with hypergammaglobulinemia
which are secondary diagnostic criteria of ALPS.
Summary and Conclusions: Our data indicate that investigation of ALPS is
warranted in children with lymphoma presenting with hematologic abnormalities
at diagnosis, chronic non-malign organomegaly with immune cytopenias and
probably in cITP and AIHA developing organomegaly on follow up.
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PLASMA LEVELS OF PRESEPSIN (SOLUBLE CD14-SUBTYPE) AS A NOV-
EL PROGNOSTIC MARKER FOR HEMOPHAGOCYTIC SYNDROME
S. Nanno1,* H. Koh1, T. Katayama1, M. Hashiba2, A. Sato2, Y. Makuuchi1,
J. Nagasaki1, T. Yoshimura1, H. Okamura1, M. Nishimoto1, A. Hirose1,
M. Nakamae1, T. Nakane1, M. Hino1, H. Nakamae1
1Hematology, Graduate School of Medicine, Osaka City University, Osaka,
2Development Research, Mochida Pharmaceutical Co., Ltd., Shizuoka, Japan
Background: It is well known that hemophagocytic syndrome (HPS) is a rare,
potentially fatal cytokine-related disorder, caused by genetic factors or triggered
by infections, malignancies, autoimmune diseases and transplantation. Previ-
ous studies reported that soluble interleukin-2 receptor (sIL-2R), ferritin and
cytokines such as interferon-γ (IFN-γ), tumor necrosis factors-α (TNF-α), inter-
leukin (IL)-6 and IL-10 may be associated with the prognosis of patients devel-
oping HPS. Recently, presepsin (soluble CD14 subtype), a fragment of CD14
highly expressed on the membrane surface of monocytes/macrophages, has
been reported as a new diagnostic marker for sepsis (Endo S, et al. 2012). The
release mechanism is thought to be associated with phagocytosis of microor-
ganisms based on the animal data (Shirakawa K, et al. 2010). A phenomenon
wherein activated macrophages eat blood cells is commonly observed in
patients with HPS. We therefore hypothesized that presepsin may be a more
useful prognostic marker for HPS than previously reported markers.
Aims: Our purpose was to examine 1) whether presepsin was a superior prog-
nostic marker for HPS compared with sIL-2R, ferritin, IFN-γ, TNF-α, IL-6 and
IL-10, and 2) which combination of presepsin with one of the other markers
was a more useful predictor of survival when compared to any of the other
markers on its own.
Methods: We retrospectively analyzed consecutive patients with HPS, from
whom blood samples were obtained at our institution between April 2006 and
August 2014. We diagnosed HPS using the modified HLH-2004 criteria. Plasma
levels of presepsin were measured by the PATHFAST® Presepsin kit (LSI Medi-
ence Corporation, Japan) and serum levels of cytokines were determined by
the Bio-Plex Pro Cytokine Assay® system (Bio-Rad Laboratories, CA). We used
Cox models to investigate the association between the levels of these markers
at onset of HPS and day-90 mortality. In composite model analysis, using Cox
models, we compared the group of patients with a higher median value of pre-
sepsin and higher median values of each of the other markers, with the others
who did not have higher values for these markers.
Results: A total of 14 patients aged 22-65 years (median 46.5) were enrolled,
and 12 were evaluable, and of these, nine underwent allogeneic hematopoi-
etic cell transplantation. The median follow-up time in all patients and in sur-
vivors (n=4) was 250 days (range, 11-1185) and 900 days (343-1185), respec-
tively. In addition, the course of seven patients was complicated by the fol-
lowing infections at the onset of HPS: bacteria (n=2), fungus (n=3), virus
(n=1) and virus plus fungus (n=1). In univariable Cox models, there were no
significant variables: presepsin (Hazard ratio per 1 SD 1.3, P=0.53), sIL-2R
(1.4, P=0.28), ferritin (1.6, P=0.23), IFN-γ (1.4, P=0.30), TNF-α (1.1, P=0.81),
IL-6 (0.5, P=0.48) and IL-10 (1.5, P=0.32). However, only the combination of
presepsin (≥1,936 pg/ml) and sIL-2R (≥4,586 U/ml) was significantly associ-
ated with day-90 mortality (Hazard ratio 14.5, P=0.02), whereas no other
combination was significant (1.0, P=0.98 for ferritin-included model; 1.9,
P=0.53 for IFN-γ; 2.7, P=0.33 for TNF-α; 1.0, P=0.98 for IL-6; and 5.3, P=0.10
for IL-10, respectively).
Summary and Conclusions: Our results suggest that the composite model of
presepsin and sIL-2R levels at the onset of HPS, possibly a reflection of the
activation of macrophages and T cells respectively, may be a novel and powerful
predictor of the prognosis for HPS.
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INFECTIONS IN CHILDREN WITH CHRONIC NEUTROPENIA-A 13-YEAR
EXPERIENCE IN A TERTIARY CARE CENTER
M. Schmidt1,* S. Dumitras2, A. Ciobanu2, A. Ivanov2, I. Miron2
1Hemato-Oncology, “Sf.Maria” Children’s Hospital, 2Hemato-Oncology, “Sf
Maria” Children’s Hospital, Iasi, Romania
Background: Patients with severe congenital(SCN), autoimmune(AN) and
idiopathic neutropenia(IN) have frequent bacterial infections resulting in high
morbidity in early childhood. Few data on specific morbidity and mortality are
available in the literature for developing countries.
Aims: To describe incidence and type of infections requiring hospitalization
and antibiotic treatment in children with chronic neutropenia diagnosed in our
Department during a 13-year period.
Methods: Children less than 18 years of age presenting neutropenia
(ANC<1.000/µL in infants and ANC<1.500/µL in children) of >6 months duration
were evaluated. We reviewed the charts of all such patients seen at our center
from January 2002 to December 2014.Exclusion criteria were pancytopenia,
thrombocytopenia of less than 100.000/ µL, known hematologic malignancy,
previous chemotherapy.
Results: A total of 34 patients with chronic neutropenia were identified(15
females and 19 males).Six patients had severe congenital neutropenia(17%),
18 patients had AN(52%) and 10 patients had IN(33%). The median overall fol-
low-up was 5,2 years(range, 1-11,6 years). G-CSF was used only on
demand(febrile infections) in 15/34 patients, in all patients(100%) with
SCN,8/18(44%) patients with AN and 1/10(10%) patients with IN. All children
did not receive antibiotic prophylaxis. One patient with SCN underwent unre-
lated donor hematopoietic stem cell transplantation.In 7 of 18 children with AN,
neutropenia disappeared after a median of 18 months(range 10 to 54 months).
From birth to the last follow-up, a total of 120 infections requiring hospitalization
occurred in 21/34 patients.92/120 episodes were concentrated in 6/6 patients
with SCN, 19 episodes in 9/18(50%) patients with AN and 9 episodes in
6/10(60%) patients with IN. Microbiological characterization was possible in
23/120 episodes and showed Gram positive bacteria in 10 cases and Gram
negative bacteria in 13 cases. The most frequently occurring bacteria was
Staphylococcus aureus(9 cases),Escherichia coli(5 cases), Klebsiella pneu-
monia(2 cases) and Pseudomonas aeruginosa(2 cases), Enterococcus(2 cas-
es).Mouth infections(17%), pneumonia(16%), otitis(15%) and skin/subcuta-
neous infections(15%) were the most frequent localizations. During follow-up,
11 life-threatening infectious episodes occurred in 5 patients,10 of these
episodes occurred in patients with severe congenital neutropenia. The median
length of hospitalization was 14,3 days for the patients with SCN, 7,1days for
the patients with AN and 5,7 days for the patients with IN. No septic deaths
occurred. The median ANC before G-CSF was found 377/µl in patients with
SCN, 487/µl in patients with AN and 980/µl in patients with IN.
Summary and Conclusions: The majority of patients presented a benign clin-
ical course. The largest number of infectious episodes was in patients with con-
genital neutropenia. Oral cavity was the main involved site. Despite the fact
that antibiotic and G-CSF were used only on demand and not as prophylaxis,
no septic deaths were observed.
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OUTCOME OF LANGERHANS CELL HISTIOCYTOSIS IN CHILDREN
UNDER THE AGE OF 24 MONTHS- LCH-III PROTOCOL
M. Moschovi1,* M. Nikolaou1, A. Zampogiannis1, N. Tourkantoni1, J. Nikas2, C.
Hadjigeorgi2
1Hematology-Oncology Unit, 1st Department of Pediatrics, University of Athens,
2Radiology Department, Aghia Sofia Children’s Hospital, Athens, Greece
Background: Langerhans cell histiocytosis (LCH) is a rare childhood disease
with annual pediatric incidence 2-5 cases/1000000/year. It is most common
between 1 to 3 years of age. Prognosis is dependent upon the number of
organs involved, and the age of the patient at the onset of the disease.
Patients under the age of 24 months usually present with multisystem LCH
and have a potentially fatal outcome. Gastrointestinal tract involvement (GTI)
in LCH is a rare condition, typically noted in children less than two years of
age; 86% of reported patients presented GTI under one year of age; 59% of
reported patients have died within 18 months of diagnosis, suggesting a poor
prognosis.
Aims: The spectrum of clinical presentations and outcome of LCH in children
younger than 24 months of age was the aim of our study.
Methods: Eleven children, who were diagnosed with LCH in the first two
years of age and treated in our Unit, were enrolled in this study. The age
ranged from 26 days to 24 months (mean: 10 months). All patients were treat-
ed according to the LCH-III protocol and completed the chemotherapy regi-
ment at least 2-7 years ago. All patients remain in follow-up. 
Results: Five cases presented with multisystem disease in the first 6 months
of life, including intestine involvement, 3 cases had multiple bone lytic lesions
in rare sites, one case had periorbital mass and 2 cases had juvenilexan-
thogranuloma in the first month of life. All cases received chemotherapy
according to the LCH-III protocol. Four cases (36%) with multisystem disease
had reactivation within 8-12 months from the end of the chemotherapy and
achieved second remission. All the cases still remain in remission. 
Summary and Conclusions: 1) Although children with LCH under the age
of 24 months have a poor outcome, the new treatment protocols achieve a
higher survival rate for this patient group. 2) Reactivation of the disease is
still high (36%) and occurred in the first 12 months from the end of therapy.
The cases with reactivate disease had a second chance for stable remission.
3) In two cases, there was a rapid progression of the disease from the single
organ involvement, intestine and single bone lesion, respectively to the mul-
tiple organs involvement. 4) The rate of dissemination of the disease may
denote differences in the pathophysiology of the disease.
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HYPERTRYPTASEMIA OF UNCERTAIN SIGNIFICANCE: A NOVEL CON-
DITION DETECTED IN A SCREEN OF 1330 UNSELECTED CASES IN A
HEMATOLOGY CENTER
K. Blatt1,* S. Herndlhofer1, G. Hoermann2, W.R. Sperr1,3, P. Valent1,3
1Department of Internal Medicine I, Division of Hematology & Hemostaseology,
2Department of Laboratory Medicine, 3Ludwig Boltzmann Cluster Oncology,
Medical University of Vienna, Vienna, Austria
Background: In systemic mastocytosis (SM) and other myeloid neoplasms,
patients often have a slightly elevated serum tryptase (15-30 ng/ml). Howev-
er, an increased tryptase may also be found in allergic patients and some-
times even in healthy individuals.
Aims: In this study, we explored the relative distribution of cases with ele-
vated tryptase in various neoplasms and non-neoplastic states.
Methods: Tryptase-levels were measured in 1330 cases, including 914
patients with hematological neoplasms (myeloproliferative neoplasms, n=156;
myelodysplastic syndromes, MDS, n=241; acute myeloid leukaemia, AML,
n=317; SM, n=81; lymphomas, n=59; acute lymphoblastic leukaemia, n=26),
136 with non-neoplastic hematological disorders, 102 with non-hematological
conditions, and 178 healthy subjects.
Results: In healthy individuals, the median serum tryptase-level amounted
to 5.2 ng/ml. Elevated tryptase-levels were primarily found in myeloid neo-
plasm (SM: 90% of patients; AML: 38%; MDS: 25%). We also identified 15
cases (1.2%) in whom tryptase-levels were slightly elevated, but neither an
allergic disease nor a hematologic disease could be identified. The median
age of these 15 individuals was 44 years (range: 24-72 years) and the female-
to-male ratio was 2:1. The median tryptase-level at first presentation was
20.6 ng/ml (range: 14.5-35.5 ng/ml). In all cases, tryptase-levels remained
stable in the follow-up. Bone marrow examinations did not reveal any signs
of a myeloid neoplasm, and in none of the cases, an abnormal karyotype or
a KIT mutation at codon 816 were detected. Blood counts and differential
counts were normal in all cases, and no molecular aberrations were detected
by multiplex-PCR.
Summary and Conclusions: We have identified a cohort of apparently
healthy individuals with a persistently elevated tryptase-level. We propose
to call this condition hypertryptasemia of unknown/uncertain significance.
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AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME IN A FAMILY WITH 
PYRUVATE KINASE DEFICIENCY
M. Economou1,* A. Teli1, E. Papadopoulou1, A. Taparkou1, D. Adamidou2,
E. Farmaki1, A. Kattamis3
1First Department of Pediatrics, Aristotle University of Thessaloniki, 2Blood
Bank, Hippokration General Hospital, Thessaloniki, 3First Department of Pedi-
atrics, University of Athens, Athens, Greece
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare con-
genital disease caused by defective mediated FAS lymphocyte apoptosis and
characterized by non-malignant lymphoproliferation, hepatosplenomegaly,
autoimmune manifestations and increased risk for lymphoma. 
Aims: To describe the presence of ALPS in a family with pyruvate kinase
deficiency.
Methods: We report on a family with three boys and a girl with known pyruvate
kinase deficiency, followed at our outpatient clinic. The family was studied after
initial diagnosis of pyruvate kinase deficiency in the family’s first child. The boy
had an additional history of secondary to infection autoimmune haemolytic
anemia. His latest laboratory profile was compatible with a known mild
haemolytic anemia and a recently diagnosed hypergammaglobulinemia. Both
of his brothers presented splenomegaly and markers of mild haemolytic ane-
mia. In addition, however, both had a direct Coombs test and in one of them
extreme hypergammaglobulinemia was detected. Proband’s sister had only
haematological parameters of mild haemolytic anemia attributed to pyruvate
kinase deficiency, as did the father. Proband’s mother had a history of splenec-
tomy, autoimmune haemolytic anemia and immune thrombocytopenia, also
presenting with hypergammaglobulinemia.
Results: The family’s history of splenomegaly could be attributed to pyruvate
kinase deficiency, however, hypergammaglobulinemia and autoimmune man-
ifestations raised suspicion of ALPS. Peripheral blood lymphocytes analysis
by flow cytometry for double negative T cells revealed elevated circulating
TCRαβ+ cells in the proband, his mother and both of his brothers. In addition,
elevated levels of serum vitamin B12 were found. These findings reinforced
our suspicion for ALPS and blood sample was analysed for mutation in gene
coding for FAS for definitive ALPS diagnosis, which secured diangosis.
Summary and Conclusions: ALPS should be suspected in patients with per-
sistent splenomegaly and autoimmune manifestations as to achieve prompt
diagnosis and establish appropriate management. 
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THE RESEARCH PARAMETER NEUT-X IN VITAMIN B12 DEFICIENCY
E. Petridou1 A. Kotanidou1 A. Agorasti1,*
1Laboratory Haematology, General Hospital Ofxanthi, Xanthi, Greece
Background: The SysmexxE-5000 analyzer (using fluorescence flow cytom-
etry) provides a new parameter representing the structure of the neutrophils,
NEUT-X. High values of NEUT-X reflect the presence of hypersegmented giant
neutrophils. 
Aims: The aim of this study is to investigate the NEUT-X parameter in non
anemic patients with vitamin B12 deficiency. 
Methods: The patients enrolled in this study were recruited from a larger cohort
of patients who were referred to our laboratory for determination of vitamin B12,
folate or ferritin levels without anaemia (haemoglobin levels within the reference
intervals for age and gender). Exclusion criteria were pregnancy, C-reactive protein
levels >5 mg/L, white blood cells count >10,00x 103/μL and absolute neutrophil
cells count >6,00x 103/μL. 97 patients with vitamin B12 deficiency were included
in the study (patient group). 149 healthy individuals (matched in age and gender)
were randomly selected as a control group. Full blood count was performed with
SysmexxE-5000 analyzer, vitamin B12, ferritin and folate acid levels were deter-
mined by Roche Elecsys Systems (electro chemiluminescence technology).
Patients with vitamin B12 deficiency have had a blood film reviewed. Statistical
analysis: chi-square test, Student’s t-test and Mann-Whitney U test were applied.
Values of P <0.05 were considered to indicate statistical significance. 
Results: The two groups did not present a statistically significant difference in
haemoglobin levels (P=0,065), white blood cells count (P=0,429), absolute
neutrophil cells count (P=0,251), (Table 1), ferritin levels (P=0.623) and folate
acid levels (P=0,135), (data no shown). Patient group found to have significantly
higher NEUT-X values when compared with control group (P=0,013) (Table 1).
Table 1. Comparison between the two groups.
Hb: haemoglobin, WBC: white blood cells, Neut#: absolute neutrophil cells 
Data are presented as mean±SD. Patient group versus control group: P=0,013
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Summary and Conclusions: The increased NEUT-X value found in non ane-
mic patients with vitamin B12 deficiency reflects the hypersegmentation of the
neutrophils. NEUT-X parameter could be considered for the early diagnosis of
vitamin B12 deficiency, as the alteration of the morphological features of the
neutrophils (represented by high NEUT-X) is observed in a non anemic popu-
lation, with normal white blood cells count. 
E1395
CHRONIC NEUTROPENIA IN CHILDHOOD-EXPERIENCE FROM A SINGLE
CENTER
T.H. Karapınar1,* Y. Oymak1, Y. Ay1, S. Aydın Köker1, E. Töret1, F. Hazan2,
C. Vergin1
1Pediatric Hematology and Oncology, 2Genetics, Dr. Behcet Uz Children Train-
ing and Research Hospital, Izmir, Turkey
Background: Neutropenia is defined as the reduction in the absolute number
of neutrophils (ANC) in the blood circulation. Neutropenia is a relatively frequent
and often a secondary finding in childhood. It can be classified as acute or
chronic depending on its duration, lower or higher than 3 months. Acute neu-
tropenia is most commonly associated with viral infections, is often well tolerated
and normalizes rapidly, whereas chronic neutropenia (CN) has more complex
clinical manifestations. CN can be due to a heterogeneous group of diseases
in children. The differential diagnosis of CN often requires much time and a lot
of investigations.
Aims: The aim of the present study is evaluated the reasons and clinical man-
ifestations of the CN in childhood in a single children’s hospital.
Methods: Between October 2004 and April 2014, values of patients with CN
were evaluated retrospectively at the Dr. Behcet Uz Children Hospital. Patients
with chemotherapy-induced neutropenia, those secondary to lympho-myelo-
proliferative disorders, systemic autoimmune diseases, myelodysplastic syn-
dromes, and common variable immunodeficiency were excluded. Thirty-one
patients were diagnosed as CN. 
Results: All patients were followed up to maximum 114 months or until neu-
tropenia was recovered. The median duration of following was 29 months. The
median age of diagnosis was 21 months. Thirteen of the patients (41.9%) were
before the age of 12 months at initial diagnosis. Seven of 13 patients with ≤12
months at initial diagnosis (53.8%) were identified as congenital neutropenia
(CoN). There was no difference between the age >12 months and ≤12 months
at onset according to ANC at diagnosis. Twenty-two of all cases (70.9%) were
detected during acute infections. Hospitalization due to recurrent infections was
determined in 11 patients (35.5%). Most of the recurrent infections site was
lung (81.8%). CoN was identified in 14 patients (45.1%). Eight of 14 patients
(57.1%) required GCSF treatment and no advers effect of GCSF was seen in
any of these patients. Fifteen patients (48.3%) was considered as idiopathic
neutropenia. Interaction between idiopathic and congenital neutropenia groups
was evaluated. Whereas there was no difference for age, ANC or application
with infection at diagnosis, there was an difference for sex and spontane recov-
ery of neutropenia. Neutropenia was spontaneously recovered in 10 of all
patients (32.2%) during a follow-up of 7-52 months.
Summary and Conclusions: In current study, we found a higher congenital
neutropenia ratio in CN than other reports, it may be due to higher consan-
guineous marriages in our country. However, CN is a finding that required sev-
eral laboratory investigations, prolonged follow-up, and advanced molecular
analysis, it’s etiology can be remain idiopathic. 
E1396
STUDY OF ALPHA HEMOGLOBIN STABILIZING PROTEIN EXPRESSION
IN PATIENTS WITH Β THALASSEMIA AND SICKLE CELL ANEMIA AND
ITS IMPACT ON CLINICAL SEVERITY
M. Deghedy1,* H. Mahmoud2, I. Ragab1, A. Shoeib1, S. Abdel Ghani1
1Pediatrics, 2Laboratory Hematology, Ain Shams University, Cairo, Egypt
Background: The α hemoglobin stabilizing protein (AHSP) is an erythroid pro-
tein that specifically binds α-Hb and prevents its precipitation suggesting that
it may function to limit free α-Hb toxicities. Our aim was to study the level of
AHSP level in β thalassemia syndromes in relation to their clinical severity and
to compare it with its level in sickle cell anemia.
Aims: We compared patients with β-thalassemia (n=37), divided into β-tha-
lassemia major (BTM)(n=19) and β-thalassemia intermedia (BTI) (n=18) with
12 patients with sickle cell anemia.
Methods: Comparison as regards clinical severity, age at presentation, trans-
fusion dependency, initial hemoglobin electrophoresis, mean pre-transfusion
hemoglobin level, use of hydroxyurea and AHSP expression by real time quan-
titative PCR.
Results: Median AHSP was significantly higher in patients with sickle cell anemia
2275 (3898) compared to patients with thalassemia 283 (718), P=0.001, with no
significant difference in AHSP between BTM and BTI (P=0.346). It was signifi-
cantly higher in non-transfusion dependent patients with β thalassemia (NTDT)
compared to transfusion dependent ones (P=0.019), and in patients on hydrox-
yurea therapy (P<0.001). However, there was no significant difference in its level
according to clinical severity score (P=0.946) or splenectomy status (P=0.145).
Summary and Conclusions: AHSP Expression was higher in sickle cell ane-
mia versus thalassemia, with no significant difference between BTM and BTI.
Expression was higher in patients with NTDT and on hydroxyurea therapy.
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HEMOPHAGOCYTIC SYNDROMES IN SAUDI CHILDREN: SINGLE CEN-
TER EXPERIENCE
A. Alzahrani1,* G. Elyamany2, H. Elfaraidi1, N. Othman1, A. Shaker2, F. Al-Batniji 1,
M. Awad2, F. Alabbas1
1Pediatric Hem/Onc and BMT Department, 2Pathology and Laboratory Medi-
cine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare aggressive
and life-threatening syndrome of excessive immune activation due to cytokine
overproduction from excessively activated lymphocytes and macrophages. It
most frequently affects infants from birth to 18 months of age, but the disease
is also observed in children and adults of all ages. Chemo-immunotherapy-
based treatments have improved the survival of patients with HLH, but out-
comes of the patients are still unsatisfactory.
Aims: To evaluate patients’ characteristics, laboratory and molecular findings
and treatment outcome.
Methods: We retrospectively analyzed data of 11 HLH patients who were admit-
ted to the Pediatric Hematology Department of Prince Sultan Military Medical
City, Riyadh, Saudi Arabia between 2005 and 2014. HLH was diagnosed accord-
ing to the HLH-2004 diagnostic guidelines. We defined primary HLH as Patients
who were found to have a genetic abnormality and/or early-onset diseases (age
0-2 years) with family history were considered as having familial HLH.
Results: Patient characteristics are summarized in Table1.The median age at
onset of HLH is 12 months. There was female predominance (8/12). Consan-
guinity rates significantly were high (75%) and positive family history in 5 cases.
Of 12 patients, 9 were defined as primary, and 3 were secondary HLH (cases
4, 5 and 8). All patients met the criteria of HLH; at least five out of a total of
eight criteria. (Figure 1) To dates, 6 of the 12 patients are still alive (50%), 4 of
the patients died before HSCT, whereas one patient died of relapse after
matched unrelated donors and one lost follow up.
Table 1. Patient characteristics.
#         Age       Sex    Consanguinity   Family    Associated        HLH        Molecular        Treatment             HSCT      Outcome
                                                        history     Infection       criteria      Mutation                                         
1     4 months     M               +                 +                -                 6/8            PRF1            HLH 2004          Haplotype       Alive
2     4 months     M               +                 +              EBV              7/8           STX-11           HLH 2004               No            Died 
3    13 months    F                +                 +          Candida           5/8           STX-11           HLH 2004               No            Died 
4       3 years      M               -                  -       Dengue Fever       5/8          Negative          HLH 2004               No            Alive
5       8 years       F                -                  -              EBV              7/8         Not done         HLH 2004               No            Died 
6     2 months     F                +                 -                -                 6/8          Negative          HLH 2004          Haplotype      Alive
7    11 months    F                +                 +                -                 6/8           STX-11           HLH 2004           Cord SCT       Alive 
8       4 years       F                +                 -       Dengue Fever       5/8          Negative          HLH 2004               No     Lost follow up
9       7 years       F                +                 -                -                 5/8         Not done   Refused treatment         No            Died 
10   3 months     F                +                 -                -                 5/8            PRF1            HLH 2004          URD HSCT       Died 
11   6 months    M               +                 +    Gram +ve cocci     6/8           STX-11           HLH 2004         MRD HSCT      Alive
12     7 years       F                -                  -              HAV              6/8          Pending   HLH 2004 Anakinra   On therapy      Alive
Figure 1. Patient clinical and laboratory parameters.
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Summary and Conclusions: Hemophagocytic lymphohistiocytos is a serious
and potentially life threatening disorder in children and rarely in adults. Familial
HLH is the most common encountered type of syndrome. Chemotherapy reg-
imen is not ideal yet to control the disease. Bone marrow transplantation is the
only available cure. Awareness of the clinical symptoms and of the diagnostic
criteria of HLH is important as correct diagnosis with adequate treatment with
immunosuppressive /immunomodulatory agents in time can be life saving in
these patients. Research to uncover the gene responsible for the disease by
collaborative group is recommended.
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LONG TERM TREATMENT WITH CONTINUOUS LOW DOSE LENALIDO-
MIDE RESULTS IN PET/CT DOCUMENTED EXCELLENT PARTIAL REMIS-
SION IN A PATIENT WITH SEVERE MULTI-SYSTEMIC LANGERHANS
CELL HISTIOCYTOSIS 
A. Burchardt1,* D. Steiner2, M. Rummel1
1Hematology, 2Nuclear medicine, Universitätsklinikum Gießen und Marburg,
Gießen, Germany
Background: Langerhans cell histiocytosis (LCH) is a non malignant orphan dis-
ease of clonal dentritic cells with a possible affection of any organ. Diagnosis is
often difficult due to a wide clinical spectrum of presentation, ranging from a single
lesion right up to a multi-systemic disorder. Treatment options are consisting of
radiotherapy for bone lesions till conventional chemotherapy e. g. with cytarabin,
etoposide and vinblastin. In multi-systemic organ involvement cladribine (2-CdA)
is often used. Treatment with Thalidomide as could be a different option. In 2013
we already described a female patient (pat) achieving a complete remission of
localized LCH of the vulva with Lenalidomide (Len) treatment. Positron emission
tomography (PET), more specifically PET/CT has been well validated for staging
and treatment response monitoring in oncology patients (pts). The use of PET/CT
in LCH has been reported, but its use in adult pts is not well established. Especially
in adult pts with severe comorbidities like renal insufficiency it is a very useful tool.
In addition, other information like the metabolic activity defined as mean stan-
dardized uptake values (SUV) of LCH lesions can be very helpful.
Aims: Here we present the first pat with a multifocal aggressive and repeatedly
relapsing LCH with an outstanding response to continuous long term treatment
with low dose Len (10 mg every other day).
Methods: Case report.
Results:A 69 year old man with severe comorbidities (diabetes, renal insufficiency,
coronary heart disease) was diagnosed in Jun 2011 with multi-systemic LCH. In
between Aug 2011 and Dec 2011 he received 4 cycles of 2-CdA (0.14 mg/kg/BW)
and obtained only a partial remission (PR). In May 2012 he presented with a mul-
ti-systemic relapse/reactivation in different lymph nodes and involvement of other
organs like parotid gland, muscle, bone and testes. After histological confirmation
and PET/CT based staging in Jul 2012, first cycle of Len 10 mg/d for 21 days q 4
weeks was started. A few days later a substantial benefit with decreasing cervical
lymph nodes was noticed. Due to moderate leukocytopenia weekly G-CSF was
used. PET/CT in Dec 2012 showed again PR and due to a cardiac intervention
Len was stopped for 6 weeks. Due to a mild anemia, retreatment with Len 5 mg/d
was initiated in Feb 2013. Because of a slight lymph node decrease only, Len
dose was escalated up to 10 mg every other day as a continuous treatment option. 
PET/CT in Sept 2013 showed a mixed response, in May 2014 PET/CT showed
an acceptable remission with a SUV decrease in the LCH lesions. Current
PET/CT in Feb 2015 shows an excellent PR with only small residues sub-
mandibular and in left testicle (Table 1).
Table 1.
                                            PET/CT Jul 2012     PET/CT Sept 2013    PET/CT Feb 2015
Lymph node right neck [SUV]             15.1                         14.8                          2.8
Testicle right [SUV]                            12.0                          6.7                            0
Testicle left [SUV]                                0                             8.5                           4.9
Summary and Conclusions: We present a case of a highly effective treatment
with continuous low dose treatment of Len in a pat with multi-systemic LCH.
Long term treatment of Len is well tolerated without severe side effects. A dose
of 10 mg every other day appears to be very effective with manageable toxic-
ities. PET/CT based surveillance provides additional information of metabolic
activity in the LCH lesions and is a very helpful tool, especially in pts with
comorbidities like renal impairment.
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SUSTAINED INFLAMATORY CYTOKINES IN NAÏVE GAUCHER DISEASE:
A LINK WITH MULTIPLE MYELOMA?
M.M. Andrade Campos1,* J. Gervas-Arruga2, P. Giraldo3
1Traslational Research Unit. Ciberer. IIS-A, Hematology. Miguel Servet Uni-
versity Hospital., 2Traslational Research Unit. IIS-A., FEETEG, 3Traslational
Research Unit. CIBERER., IIS-A. FEETEG, Zaragoza, Spain
Background: Gaucher disease (GD), the most common lysosomal storage
disorders, (~1/100,000 habitants outside Ashkenazi population), is secondary
to the deficit of B-glucocerobrosidase activity leading to an accumulation of
glycil-ceramide in monocyte-macrophagic system, it characterized by a latent
chronic inflammation and expressed by hyperferritinemia, hypergammaglobu-
linemia, altered calcium homeostasis, metabolic syndrome and an imbalanced
pro-inflammatory cytokine expression. The incidence of Monoclonal Gammopa-
thy of Uncertain Significance (MGUS) and multiple myeloma (MM) and other
B-cell disorders is increased in type 1 GD (GD1) patients (3.5-12.5 folds). Pre-
vious reports have identified osteoclastogenesis induced by TNFa and others
cytokines like IL-6 in GD1 mouse models also some cytokines like MIP1a and
TNF have gained importance in the pathogenesis of MM-bone marrow microen-
vironment induced changes. Based on that we hypothesize that deregulation
of cytokines resulting from glucocerebroside accumulation may influence the
development of hematologic malignancies in GD1.
Aims: To analyze and compare a panel of proinflammatory cytokines profile
among MGUS, MM and GD1patients and correlate with outcomes.
Methods: A protocol was conducted with the Aragon biobank for select 4
cohorts of frozen stored plasma collected at least 5 years ago and with available
follow-up data: 36 MGUS (58.3% women, mean age: 75 years, range 53-89),
11 IgGk; 6 IgGL; 5 IgAk; 8 IgAL; 3 IgMk; 3 doble IgG+IgA. Forty-nine MM (42%
women, mean age 68 years, range 39-89), 20 IgGk; 5 IgGL; 8 IgAk; 5 IgAL, 8
ligth chain disease and 3 IgG+IgA. Concerning ISS classification 44.0% MM
patients had a score 1, and 31.7% score 3; thirty-eight naïve GD1 patients
(36.8% women, mean age 39.2 years, range: 17-79) and 71 healthy controls.
A panel of eight cytokines (IL4, IL6, IL7, IL10, IL13, MIP1α, MIP1β and TNF)
was tested (Luminex®100 platform, Millipore cytokine kits). Clinical and ana-
lytical data were obtained from the records of the Hematology Department and
from the Spanish Registry of GD (FEETEG). Non-parametric tests Mann-Whit-
ney-U and Kruskall-Wallis-H were used. Period of study: February-Sept 2014.
Results: After 5 years 21 MM and 8 MGUS patients had died (42.8%, 22.2%),
4 MGUS developed a MM (11.1%); 7 MM and 8 MGUS developed a second
tumour (14.2%, 22.2%). One GD1 patients developed a MM and 2 a solid tumour.
Cytokine analysis: significant difference (p<0.05) were observed in IL4; MIP-1α;
MIP-1β and TNFα values between controls, MGUS, MM and GD1 patients; Also
for IL13 in MM and GD1. MM and GD1 not showed differences in the median
values of IL4 and IL13. These groups showed significant differences in MIP-1α,
MIP-1β and TNFα values. In MM there are significant differences in IL4 and MIP-
1α between ISS 1 and ISS 3. In addition there are significant differences in MIP-
1α between IgGk vs IgAL and in MGUS patients who progressed to MM. Inside
the most expressed cytokines MM showed the highest MIP-1α values, but GD
naïve patients showed the highest inflammatory cytokines MIP-1β and TNFα
respect all cohorts (Table 1). There were not significant differences in cytokines
profile between patients that develop a second neoplasia.
Table 1. General overview (medians).
Summary and Conclusions: Cytokines produced in response to glucocerebroside
accumulation, could be a critical factor in the pathogenesis of MGUS and MM in
GD, both patients presents alterations on cytokines profiles, specially in MIP-1β,
TNFα and MIP-1α that could be a good biomarker to predict transformation to MM.
This work was partially sponsored by FIS PS12/01219 and Fundación Española
para el Estudio y Terapéutica de la Enfermedad de Gaucher (FEETEG) y otras
lisosomales and Fundación para el Estudio de la Hematología y Hemoterapia
en Aragón (FEHHA).
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AUTOIMMUNE HEMOLYTIC ANEMIA: DESCRIPTIVE STUDY OF 100 CASES
K. Zahra1,* N. Ben Sayed1, H. Regaieg1, N. Amri1, M. Zaier1, Y. Ben Youssef1,
A. Khelif1
1Hematology, Hopital Farhat Hached, Sousse, Tunisia
Background: Autoimmune haemolytic anemia (AIHA) is caused by autoanti-
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body-induced hemolysis (the premature destruction of circulating red blood
cells). Usually idiopathic, it is also associated with infection, lymphoproliferative
disorders, autoimmune diseases, and some drugs. 
Aims: Study the epidemiological, clinical, biological, etiological and therapeutic
aspects of AIHA. 
Methods: This is a retrospective and analytic study about 100 cases of AIHA
observed in the hematology and internal medicine departments of Sousse, over
a period of 14 years. In this work, we have tried to describe the clinical aspects
of these AIHA and evaluate the contribution of different diagnosis exploration
and therapeutic means used. 
Results: There were 40 men and 60 women (sex ratio=0.66) with a median
age of 51 years [14-87]. Regarding the medical history, 19 patients were hyper-
tensive, of whom 8 were receiving Methyldopa, 9 patients were diabetic, 7 had
thyroid dysfunction and 18 had a history of autoimmune disease. The circum-
stances of discovery were an anemic syndrome in 80 of patients, mainly due
to paleness and asthenia. Physical examination revealed icterus in 42 cases,
splenomegaly in 41 cases, hepatomegaly in 8 cases, lymph node in 16 cases
and fever in 21 cases. Concerning biology, regenerative anemia was normocytic
in 43 cases and macrocytic in 48 cases, thrombocytopenia below 100000/mm3
was observed in 13 patients. There were also biological signs of hemolysis:
hyperbilirubinemia in 70 patients, high LDH rate in 68 patients. Direct Coombs
test was positive for IgG in 55 cases, C in 12cases, Ig G+C in 20cases, IgA in
1 case, IgG+C +IgM in 4 cases and cold agglutinins search returned positive
in 8 cases. There was Evans syndrome in 14 patients. AIHA was idiopathic in
45 cases including 3 cases of pregnancy. In the other cases, it was secondary
to lymphoproliferative desorders in 20 cases, autoimmune disorders in 25 cas-
es, drug taking (Methyldopa) in 8 cases, associated with a myelodysplastic
syndrome Methyldopa in 1case and CMV infection in 1 case. The therapeutic
consisted of transfusion in 37 cases and all patients received corticosteroid
treatment in addition to folic acid therapy and etiological treatment in the non
idiopathic cases. A complete remission was obtained in 55 cases. In severe
cases of chronicity or relapse, immunosuppressive therapy was prescribed in
14 patients, anti-CD20 monoclonalantibody were prescribed in 8 patients and
splenectomy was performed in 3 patients. 
Summary and Conclusions: Glucocorticoids and/or intravenous immunoglob-
ulins are the mainstay of the treatment in the majority of patients with warm
AIHA. When these treatments fail, patients often require cytotoxic drugs or
splenectomy. The current research in many other autoimmune diseases that
can sometimes be associated with AIHA should still allow a better understanding
of the mechanisms involved in the occurrence of these diseases and to refine
treatments whose essential aim is to improve the effectiveness of both new
and already available treatments (including rituximab) in order to limit the use
of corticosteroids. 
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PROSPECTIVE STUDY OF PLASMA BIOMARKERS ASSOCIATED WITH
THE INFLAMMATORY RESPONSE IN TYPE 1 GAUCHER DISEASE
PATIENTS TREATED DURING ONE YEAR WITH VELAGLUCERASE ALFA
M. Andrade-Campos1,* J. Gervas2, I. Garcia3, O. Salamero4, P. Martinez-
Odriozola5, J.-A. Mendez6, F. Garcia-Bragado7, C. Fernández8, L.-I. Sancho-
Val9, H. Cano10, J. Perez11, J.-M. Hernandez-Rivas12, J.-F. Lorenzo13, M. Lopez-
Dupla14, M. Callao15, P. Giraldo2
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Josep Trueta Hospital, Girona, 8Haematology, Cabueñes Hospital, Gijon,
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Background: Background: It is wide accepted that Gaucher patients have an
impairment in their immune system, clinically reflected by a infections tendency
and biologically by a chronic inflammatory state. The role of cytokines in this
inflammatory state is partially known, and the modifications in this profile in GD
patients under enzymatic replacement therapy (ERT) are under investigation.
Our group has reported some changes on the cytokine profile in patients with
severe bone involvement1 and some inflammatory biomarkers of macrophage
activation related to the iron profile2.
The progressive infiltration by engorged macrophages led to a production of
proinflammatory cytokines into bone marrow microenvironment, altering of the
bone turnover, producing imbalance in cellular function, angiogenesis and
patchy infiltration by Gaucher cells. 
Aims: Aims: To explore the changes in the biomarkers of immune response in
a cohort of Spanish type 1 Gaucher disease patients (GD1) after one year on
Velaglucerase alfa therapy.
Methods: Patients and Methods: A total of 17 GD1 patients from 15 centers,
were included in a prospective protocol following these criteria: symptomatic
patients of both sexes, aged older than 4 years, naïve or previously treated but
without ERT at least one month previous to be included. The study included
blood counts, liver and spleen volume by MRI and bone marrow MRI evaluation
following S-MRI protocol, and determine bone mineral density by Quantiative
Ultrasound expressed by Z-score, and biomarkers: Chitotriosidase,
CCL18/PARC, ferritin, immunoproteins and the following cytokine profile: IL-
10, IL-13, IL-4, IL-6, IL-7, Mip1a, Mip1b,TNFa, performed at baseline and 12
months after therapy. The study was approval by ethical committees and
designed according Helsinki declaration rules; every one patient signed the
informed consent and commitment to use a safe contraceptive method during
the study period and 3 months after completion of treatment. Non-parametric
tests Mann-Whitney-U and Kruskall-Wallis-H were used. Period of study:
November 2011- April 2014.
Results: Results: General characteristics: 9 males, 8 females, mean age: 37.5
years (9-72). 3 splenectomized patients (17.6%); genotype: 3 N370S homozy-
gous one heterozygous for N370S/L444P and the rest heterozygous for
N370S/other. Seven patients (41.2%) have previous history of bone disease
complications. All patients received velaglucerase alfa 30U/kg iv every two
weeks for 1 year in every day clinical practice. Patients achieved an objective
response on disease goals, after normalization and/or stabilization in blood
counts and visceral volumes no significant variation were observed. Neverthe-
less a significant increase in the Z-score was observed after one year on
Velaglucerase alfa therapy. Respect to biomarkers, a reduction or stabilization
of CT activity and CCL/18 concentration were observed, also ferritine concen-
tration and serum free light chains do not show significant variation. The
cytokine profile showed a decrease in all inflammatory cytokines tested, how-
ever for Mip1a (p=0.027) and TNFa (p=0.023), a significant reduction were reg-
istered. Table1. No infusion reactions were reported, neither antibodies against
velaglucerase alfa.
Table 1. Comparative reduction of cytokines between baseline and 12
months.
Summary and Conclusions: Velaglucerase alfa is a well-tolerated therapy in
every day clinical practice. In our cohort we observed as part of the response
to therapy a significant decrease on the inflammatory state reflected through
the cytokine reduction.
Acknowledgements: This work was partially supported by a grant from Shire
and FIS: PS12/01219.
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A CASE OF INDOLENT SYSTEMIC MASTOCYTOSIS IN A GIRL TREATED
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Background: Mastocytosis refers to a group of myeloproliferative disorders
characterized by excessive proliferation and accumulation of mast cells in tis-
sues. It is rare in both adults and children and occurs in less than 0.01% of the
general population.
Aims: A 5-year old girl who was diagnosed as cutaneous mastocytosis by our
dermatology department when she was four months of age, was admitted to
our pediatric hematology department by hepatosplenomegaly. In physical exam-
ination, widespread maculopapuler and itchy lesions were determined.
Methods: The assessment of bone marrow aspiration was found to be consis-
tent with mast cells (rate >10%). Flow cytometry on bone marrow sample
revealed that there was CD117/CD25 positivity of 18.4% and CD117/CD2 pos-
itivity of 0.7%. Diagnosis of SM was verified by one major and one minor WHO
criteria: presence of multifocal, dense aggregates of mast cells in bone marrow
(major criteria) confirmed by expression of CD2, CD25, and CD117 in bone
marrow (minor criteria). Also serum tryptase level was 356 ng/ml (>20 ng/ml).
Results: We were diagnosed smouldering SM (a part of indolent SM) because
of high serum tryptase level, organomegaly, and infiltration of mast cells in the
bone marrow. During follow up, systemic anaphylaxis was determined and
treated for three times. We recommended the self-administration of epinephrine
on demand for anaphlactoid episodes. Treatment with montelucast, interferon
alfa-2a and methylprednisolon produced a marked and sustained reduction in
her symptoms, cutaneous lesion, and tryptase level (Figure 1A-B).
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Figure 3.
Summary and Conclusions: Consequently, we report on the first case of
indolent SM that was successfully treated with montelucast, interferon alfa-2a
and methylprednisolon in children.
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USEFULLNESS OF SERUM FERRITIN LEVEL >10,000 NG/ML TO DIAG-
NOSIS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN ADULTS.
E. Colorado Ledesma1,* M.M. Andrade Campos2, R. Rupay3, A. Montes-Limon1,
N. Espinosa1, N. Fernandez-Mosteirin1, C. Salvador Osuna1, P. Giraldo4
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Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare pathology
characterized for clinical and laboratory alterations secondary to an uncon-
trolled immune activation that lead a severe inflammation systemic status. HLH
can be congenital or acquired, idiopathic or secondary to infections, neoplasms
(specially hematologic neoplasms) or rheumatic diseases. The diagnosis of
HLH is based in the criteria determined by the Histiocyte Society, hyperfer-
ritinemia is a key criteria, it is specific for HLH in pediatric population; although
some reports had outstand the value of serum ferritin (SF) over 10,000 ng/mL
as the first suspicion clue for HLH. It is remarkable that HLH carry-on a mortality
rate around 90% and diagnosis in adults is difficult and the value of SF is not
fully established. Based on that, we perform a review to assess this aspect in
hospitalized adults patients with SF >10,000 ng/mL in our institution.
Aims: To identified adults patients with SF >10,000 ng/mL, assess the HLH
diagnostic criteria and describe the possible causes for high SF values and
the usefulness of this cut-off for HLH diagnosis.
Methods: A chart review was performed. All hospitalized-adults with a SF level
>10,000 ng/mL were selected to lead the retrospective assessment of the HLH
criteria using the clinical and laboratory data available in the electronic medical
registry. At the same time, selected patients were crossed with the transfusion
service to check transfusion records; also patients with family history of con-
genic HLH were excluded. For HLH diagnosis the presence of 5-6/6 following
criteria: >10,000 ng/dL SF, fever, splenomegaly, 2-3 cytopenias, hypertriglyc-
eridemia (>252 mg/dL) and bone marrow hemophagocytosis (BMH), (sCD25
and NK functionality studies were not available in our center). Period of study:
Jun-2009 to Jan-2015.
Results: A total of 78 patients were identified in the first screening for SF
>10,000 ng/mL; twenty-three patients full flied HLH criteria assessment. Mean
age: 53.91 y.o. (16-82). Male/female ratio: 12/11. According to criteria revision:
6 patients full flied 6/6 criteria and 18 patients 5/6 criteria. According to each
criteria all patients presented fever and hyperferritinemia; mean SF level:
28,938 ng/mL (12,606.9-61,557.0), Cytopenias: 22/23 patients presented it,
Mean values: Hb: 7.1 (2.3-12.5) g/dL, Absolute neutrophils count (17 patients
<1.00x103/mL): 0.19x103/mL (0.00-10.4), Platelets: 18 (1-90)x103/mL. Mean
serum triglycerides: 559 (252-1011) mg/dL, BMH: 13/17 patients with bone
marrow aspiration performed show BMH. Splenomegaly: 18/23 patients. At the
same time others biochemistry alterations (liver enzymes, LDH, bilirubin, coag-
ulopathy) were registered in all patients. Neurological, pulmonary and skin
alterations were recorded in 8, 9 and 3 patients. Possible etiologies of second-
ary HLH: infections: 7 cases, neoplasms: 12, both: 3 cases and other 1 case.
Mortality: the median time duration of the hospitalization were 23 days (3-60),
with the exception of 2 cases, one male with leishmaniosis and a female with
Evan’s syndrome and CMV infection are alive, the rest of the patients (91.3%)
died during the hospitalization period. 
Summary and Conclusions: HLH is a rare multisystemic syndrome with high-
er mortality rate, probably related with the difficulties during the diagnosis
process. In our cohort the value of ferritin levels >10,000 ng/mL was a good
biomarker to start the suspicion of the illness. More accuracy is necessary to
identified and treats this severe pathology. In case of acceptance a complete
review of all screened patients will be presented.
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DUSP4-MEDIATED ACCELERATED T-CELL SENESCENCE IN IDIOPATHIC
CD4 LYMPHOPENIA
A. Bignon1, A. Régent2, L. Klipfel1, L. Mouthon2, K. Balabanian1,*
1INSERM U996, Clamart, 2INSERM U1016, Paris, France
New Information: This work has been prepublished online as Blood First Edi-
tion paper, March 2, 2015; DOI 10.1182/blood-2014-08-598565. 
Background: Idiopathic CD4 lymphopenia (ICL) is a rare heterogeneous
immunological syndrome of unclear etiology. ICL predisposes patients to severe
opportunistic infections and frequently leads to poor vaccination effectiveness. 
Aims: Chronic immune activation, expansion of memory T cells and impaired
TCR signaling has been reported in ICL, but the mechanistic and causative
links remain unclear.
Methods: To gain insight into the functional pathways implicated in ICL patho-
physiology, we compared the gene expression profiles of CD4+ T cells sorted
from the blood of ICL patients and control groups of age-matched healthy sub-
jects and patients with CD4+ T-cell lymphopenia secondary to sarcoidosis.
These arrays enabled us to identify an ICL-related genetic signature with pre-
dominant involvement of two gene groups, one related to TCR response and
the other strikingly associated with T-cell aging. Among the first group, expres-
sion of the dual-specific phosphatase 4 (DUSP4), which negatively regulates
MAPK activation, was increased similar in this respect to CD4+ T cells from
elderly subjects. Functional studies further linked this overexpression to accel-
erated T-cell senescence in ICL.
Results: We showed that late-differentiated T cells in 20 ICL patients displayed
defective TCR responses and aging markers similar to those found in T cells
from elderly subjects. Intrinsic T-cell defects were caused by increased expres-
sion of DUSP4. Normalization of DUSP4 expression using a specific siRNA
improved CD4+ T-cell activity in ICL, as this restored TCR-induced ERK acti-
vation and increased the expression of the co-stimulatory molecules CD27 and
CD40L. Conversely, repeated TCR stimulation led to defective signaling and
DUSP4 overexpression in control CD4+ T cells. This was associated with grad-
ual acquisition of a memory phenotype and curtailed by DUSP4 silencing. 
Summary and Conclusions: These findings identify a premature T-cell senes-
cence in ICL that might be caused by chronic T-cell activation and a conse-
quential DUSP4-dependent dampening of TCR signaling.
Email address: karl.balabanian@u-psud.fr
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FINALLY A METHOD FOR ROUTINE DIAGNOSIS OF SOUTH-EAST ASIAN
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Background: South East-Asian Ovalocytosis (SAO), is a dominantly inherited
red cell membrane defect caused by a small deletion in exon 11 of SLC4A1,
the gene encoding band 3. The deletion is commonly accompanied by a mis-
sense mutation in exon 4 (p.Lys56Glu). The 9 amino acid-long deletion even-
tually results in a markedly increased rigidity of the red cell membrane. Never-
theless, individuals affected are usually clinically asymptomatic and only in
children slight haemolysis has been observed. Although, the homozygous state
of the mutation was believed to be incompatible with life, recently a homozy-
gous SAO child with severe dyserythropoietic anemia and distal renal tubular
acidosis has been described. The hall mark of the disease is the presence of
macro-elliptocytes, some with a transverse ridge across the central clearing,
on the blood smear (Figure 1C). This is currently the only way to reliable diag-
nose the disease. The condition is wide-spread in certain ethnic groups as the
condition protects against invasion of several malaria strains. However de pre-
cise Figure and incidence is unknown, as the investigation of the blood smear
is not part of daily routine laboratory practice.
Aims: To establish a highly specific method to diagnose SAO using the CELL-
DYN Sapphire automated haematology analyser.
Methods: EDTA samples of regular primary-care patients at our laboratory
were examined on the CELL-DYN Sapphire Haematology Analyser using the
complete blood cell count mode (CBC). Positive identification of SAO was fol-
lowed by measurements using the Reticulocyte mode (CBC+RETC) and blood-
smear analysis. To confirm our findings, anonymised EDTA samples were sub-
jected to osmotic gradient ektocytometry on the LoRRca MaXis and DNA analy-
sis of exons 4 and 11 of SCL4A1 and for typical cellular behavioural examina-
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tion by the automated Rheoscope Cell Analyser (ARCA). All cases sent were
positively confirmed as being a SAO-carrier, and the physician was subse-
quently notified on these results.
Results: Analysis of scatterplots generated by our routine blood cell analysers
revealed a small cluster of red cells in the 7/90° optical platelet scatterplot in
conjunction with a slightly lowered MCV (Figure 1A). Examination of these red
blood cells on a smear demonstrated typically SAO associated Macro-Ellipto-
cytes (Figure 1C). Analysis of the CBC+RETC mode showed a typical first
small peak close to the Y-axis followed by a broad asymmetric peak, displaying
the heterogenic distribution of the Cellular Heamoglobin Concentration (CHC;
Figure 1B). Using these two parameters we identified 32 SAO-carriers in our
population. SAO was confirmed by morphology, DNA, ektocytometric (Figure
1D) and Rheoscopic analysis. Comparison with other Haematology Analysers
revealed that this feature is probably due to the M.A.P.S.S. technique algorithm
which is unique for the CELL-DYN Sapphire.
Figure 1.
Summary and Conclusions: South East Asian ovalocytosis is a rare disease in
Europe and it is therefore difficult to study. We established a method by which
SAO can be easily and reliably diagnosed using routine laboratory haematology
parameters. When applied to a subpopulation in the Nothern part of the Nether-
lands, a considerable and higher than expected population of SAO carriers was
detected. This method can be used to prevent embryonic lethality or the severe




EFFICACY OF HIGH-DOSE METHYLPREDNISOLONE AS A FIRST-LINE
THERAPY IN ADULT PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC
PURPURA
K. Aydın1, E. Gürkan2,* F. Baslamisli2
1Dept of Internal Medicine, 2Dept of Hematology, Çukurova University Medical
School, Adana, Turkey
Background: Guidelines for the emergency treatment of clinically important
bleeding or prophylactic treatment before surgery/invasive procedures in ITP
patients recommend several approaches either as high-dose methylpred-
nisolone (HDP) or intravenous Ig (IVIG) and sometimes anti-D to provide a
safe platelet count. There are various reports suggesting that IVIG treatment
may result in a more rapid response thus more effective in these indications.
The recommendations are usually based on the results of few number of con-
trolled studies and more on individual experience. 
Aims: In this study we tried to compare the efficacy of high-dose methylpred-
nisolone with IVIG and conventional prednisolone (CDP) therapy as a firstline
treatment in adult patients with ITP. 
Methods: This retrospective study included 140 adults with either previously
untreated acute ITP (51) or persistent/chronic ITP (22/67) patients with an acute
attack. Patients with a platelet count <30x109/L or <50x109/L with a clinically
significant bleeding were treated either by CDP therapy (1 mg/kg/day until
response) or HDP (20 mg/kg/day for 3 days) or IVIG (1g/kg/day for 2 days). All
the patients in three groups continued treatment with oral prednisolone (1
mg/kg/d) until stable platelet count was reached. Steroids were then tapered
off in 4-6 weeks. Responses after the treatment and clinical course of the
patients were evaluated. 
Results: Of 140 patients enrolled initial platelet counts were similar in all treat-
ment arms. HDP was given to 92 (65,7%), IVIG to 32 (22,8%) and CS to 16
(11,4%) of patients. The median follow up patients was 21.5, 13.1 and 9.3
months in HDP, IVIG and CDP groups respectively (P<0.05). HDP received
patients showed the first response sooner (platelet counts ³30x109/L) compared
to IVIG and CDP patients which was 6, 10 and 12 days respectively (P<0.05).
Median platelet count at first response was similar between the three groups.
Long-term complete response (>6 months) was higher in HDP group (57.6%)
compared to IVIG (37.5%) and CS (25%) of patients (P <0.05). The initial treat-
ment choice did not effect the response type. Relapse rate after achieving
stable response was 62.8%, 81.3% and 88.9 % in HDP, IVIG and CDP group
patients but the differences were statistically insignificant (P >0.05). Overall a
negative correlation was observed between the response rates and age of the
patients in all of the three groups (R=-0.172, P=0.04). Long-term remission
rates also decreased as the patients become older in all the groups (R=-0,22,
P=0,02).
Summary and Conclusions: Our results support that HDP can be more com-
fortably proposed as firstline treatment in adult patients with ITP. Due to its
effectiveness, low cost, and convenience of use, high-dose methyl prednisolone
still seems to be the best choice as initial treatment in ITP.
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ELTROMBOPAG MAY BE USEFUL IN SECONDARY ITP PATIENTS IN CLIN-
ICAL PRACTICE
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Background: Eltrombopag is a thrombopoietin receptor agonist (TPO-RA)
approved for treating chronic primary ITP patients. Nevertheless, due to the
non-existence of clinical trials there are no clear efficacy and safety data of
eltrombopag in secondary ITP.
Aims: To evaluate the efficacy and safety results using eltrombopag for treating
secondary ITP patients in routine clinical practice in Spain.
Methods: 33 secondary ITP patients from 23 Spanish centers who had been
treated with eltrombopag and included in the Spanish Eltrombopag ITP Registry
were retrospectively evaluated. However, 5 patients were excluded from the
final analysis because three of them were aplastic anaemias, one was an
amegakaryocytic thrombocytopenia and another one was a acute myeloid
leukemia related thrombocytopenia.
Results: Our secondary ITP case series included nine hepatitis C virus-ITP, five
lymphoproliferative disorders, four systemic lupus erythematosus (SLE), three
HIV-ITP, two synchronous HCV-HIV-ITP, two psoriatic arthritis, one Evans Syn-
drome, one common variable immunodeficiency and one Sjögren syndrome.
The median age of our cohort was 54 (IQR, 35-66) years. There were 17 women
and 11 men. 25% of patients had a Charlson Comorbidity Index score of 2 or
more at diagnosis. The median time from secondary ITP diagnosis to eltrom-
bopag initiation was 36 (IQR, 1-76) months. The median number of therapies
before starting eltrombopag was 2 (IQR, 1-4), including rituximab (28%), romi-
plostim (17%) and splenectomy (10%). At the time of treatment start, 15 of 28
patients (53%) patients were receiving concomitant treatment for secondary ITP,
mainly including corticosteroids (31%) or immunoglobulins (21%). 7 of 28 (25%)
patients had bleeding symptomatology during the month preceeding the starting
eltrombopag. At eltrombopag initiation the median platelet count was 9x 109/L
(IQR, 6-15x109/L). 25 of 28 (89%) patients responded to eltrombopag treatment.
23 patients (82%) achieved a complete response (CR; platelet count
>100x109/L). To point out that 2 patients needed concomitant treatment with low
prednisone doses to achieve or maintain the response. It was a slight difference
between men and women regarding the response and complete response rates
obtained: men achieved 82% and 73% respectively meanwhile women achieved
94% and 83%. The proportion of patients achieving platelet response was quite
similar regardless the other studied parameters: age (87% and 92% for patients
<65 years-old and ≥65 years-old, respectively), use of concomitant ITP medica-
tion at baseline (87% and 93% for patients with and without concomitant baseline
ITP medication use) and bleeding at starting eltrombopag (100% and 87% for
patients with and without bleeding, respectively). Three patients achieved com-
plete response after only one month of tretament without relapsing afterwards.
In five patients splenectomy was made few months after eltrombopag treatment
(3 patients were in CR). Only two patients failed to achieve response with eltrom-
bopag treatment: common variable immunodeficiency and one HIV patients.
After a 9 months median follow-up, 15 patients maintain the response. Only 3
patients relapsed from their disease. Only two adverse events were reported: a
grade 2-3 cephalea in a SLE patient and a death caused by respiratory insuffi-
ciency in a HIV patient with a CR ITP at that moment.
Summary and Conclusions: Our case series describe the great efficacy and
safety results observed with the use of eltrombopag in our secondary ITP
patients. Our data suggest some diseases may not benefit from the use of
eltrombopag. However more studies are needed to confirm the possible use-
fulness of TPO-RAs in this variety of secondary ITP cases.
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ITP PATIENTS IN THE ASIA PACIFIC: ARE THEY DIFFERENT?
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by auto-antibody induced platelet (PLT) destruction and reduced
PLT production, leading to a low PLT count. The availability of robust epidemi-
ological and clinical data on ITP in regions outside Europe and the United
States is limited. The International ITP Registry is a prospective cohort study
which seeks to collect epidemiological and clinical data of recently diagnosed
primary ITP adult patients, predominantly from the Asia-Pacific region. The
International Registry has been established for >4 years.
Aims: To contrast and compare the International ITP Registry population with
the Intercontinental Cooperative Immune Thrombocytopaenia Study Group
Pediatric and Adult Intercontinental Registry on Chronic ITP (PARC-ITP Reg-
istry) adult population. The PARC-ITP Registry was selected as it represents
a prospective cohort including newly diagnosed ITP patients, with a comparably
sized adult cohort which is well established (>4 years) across the regions in
which epidemiological data is already available1.
Methods: Clinical and laboratory data from the International ITP Registry were
compared with clinical and laboratory data reported for adults enrolled in the
PARC-ITP registry. 
Results: At the time of this comparison 306 patients were enrolled across
10 countries in the Asia-Pacific, Middle East and Latin America regions in
the International ITP Registry with data available from 299 patients. The
PARC Registry had 340 adult patients enrolled in 31 countries across Europe,
Canada, United States, Latin America, the Middle East, and Asia. Patient
characteristics are presented in Table 1. The International ITP Registry has
a clear predominance of patients of Asian origin (68%) whereas the PARC-
ITP Registry population is principally Caucasian (63%). A female predomi-
nance is seen in both cohorts. Comorbidities were reported more often in
the International Registry group (67.5% vs 30%). Hypertension is the most
often reported comorbidity in both groups. Of the comorbidities related to
ITP diagnosis that are available for comparison, diabetes occurs more often
in the International Registry group and thyroid disease is reported at similar
rates in both groups (Table 1). Mean PLT count at baseline was 29.0x 109/L
(range 1-96x 109/L) in the International Registry group and 25.4x 109/L (range
0-133x 109/L) in the PARC Registry adults. Corticosteroids were the most
frequently used first-line treatment in both groups-68% in the International
Registry and 59% in the PARC-ITP Registry adults. IVIg is used in both pop-
ulations at much lower rates-18% in the International Registry and 6% in the
PARC-ITP Registry adults. Splenectomy is uncommon, with 13 patients in
our group having splenectomy, splenectomy is not reported on in the PARC-
ITP Registry publication. TPO-receptor agonist use is reported in the Inter-
national Registry group (n=23) but not reported on in the PARC-ITP Registry
group. Anti-D is reported both groups at rates <5%, and both groups have
similar rates of not treated patients (Table 1). Clinical signs of bleeding were
assessed by location in both Registries. The International Registry also
records severity of bleeding. Bleeding at any site was seen in 34% of patients
in the International Registry whereas PARC -ITP Registry reports manifesta-
tions of bleeding in 69% of adults.
Table 1. Patient characteristics.
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Summary and Conclusions: Comparative data showed similarities in gen-
der distribution, presenting platelet counts, diagnostic testing and first line
therapy, whereas differences occurred in co-morbidity, bleeding, and second
line therapies.
Reference
1. Kühne T, et al. on behalf of the Intercontinental Cooperative ITP Study Group.
Newly diagnosed immune thrombocytopenia in children and adults: a com-
parative prospective observational registry of the Intercontinental Coopera-
tive Immune Thrombocytopenia Study Group. Haematologica 2011;96(12):
1831-1837. doi:10.3324/haematol.2011.050799
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DEFICIENCY IN THROMBOTIC THROMBOCYTOPENIC PURPURA
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Background: Diagnostic and prognostic value of ADAMTS13 activity is con-
troversial. We previously reported the characteristics of severe ADAMTS13
deficiency in thrombotic thrombocytopenic purpura (TTP) and patients with
severe ADAMTS13 deficiency (Jang MJ et al., Int J Hematol 2011;93:163-9). 
Aims: In this study we updated it by adding more patients to know the clinical
characteristics of patients with severe ADAMTS13 deficiency at presentation.
Methods: One-hundred sixty nine patients with TTP from January 2005 to June
2014 were analyzed. ADAMTS13 activity and inhibitors were measured by
immunoblotting of degraded von Willebrand factor. Clinical information was ret-
rospectively collected and analyzed.
Results: Patients with severe ADAMTS13 deficiency at presentation had lower
serum creatinine levels (P<0.0001), lower platelet counts (P<0.0001), and high-
er total bilirubin levels (P=0.0001) than patients with non-severe ADAMTS13
deficiency. Treatment outcomes did not differ significantly between two groups
in response, remission, and mortality rate. After adjusting for clinical and labo-
ratory features, multivariate analysis revealed age over 60 year old is an inde-
pendent risk factor for TTP-associated mortality (P=0.0249). 
Summary and Conclusions: TTP with severe ADAMTS13 deficiency is a
unique subgroup characterized by lower platelet count and relatively good renal
function. The severity of ADAMTS13 deficiency at presentation does not have
prognostic significance.
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A PERSONALIZED REFERENCE INTERVAL FOR PLATELET COUNT
REDUCES THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA
AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY
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Background: The reference interval for platelet count currently in use in most
Western countries is 150-450 or 150-400x109 platelets/L. However, many
studies indicated that women have more platelets than men and platelet count
progressively decreases with ageing. Moreover, ethnicity-related differences
have been identified and the related genetic factors have begun to be
unveiled. 
Aims: To evaluate the outcome of a personalized reference range recently
identified by the study of 40,978 Italian healthy subjects and which takes into
account age and sex: 165-473x109 platelets/L, regardless of gender, under 15
years of age; 136-436 and 120-369x109/L in women and men, respectively,
between 15 and 64 years; and 119-396 and 112-361x109/L in women and men,
respectively, over 64 years (PLoS One 2013;81:e54289). 
Methods: The new personalized reference range was applied retrospectively,
in parallel to that presently in use of 150-450x109/L, to a series of 925 consec-
utive Italian patients admitted to a department of Internal Medicine. The inves-
tigated population was mainly composed of elderly subjects (mean age 74±14.2
years). Clinical records were used to identify the potential causes of thrombo-
cytopenia and thrombocytosis in each patient. The institutional review board of
the hospital approved the protocol, and all patients gave written informed con-
sent in accordance with the Declaration of Helsinki.
Results: The prevalence of thrombocytopenia was 21.3% with the traditional
reference range and 16.9% with the personalized one. Switching from throm-
bocytopenic to non-thrombocytopenic affected in most cases subjects without
any apparent cause of reduced platelet count, whose number dropped from 67
to 37. So, the personalized range reduced by 44.8% the number of subjects
with unexpectedly low platelet counts. Also a few patients with chronic liver dis-
orders turned from thrombocytopenic to non-thrombocytopenic. The prevalence
of thrombocytosis increased from 9.1% with the traditional range to 12.2% with
the personalized range, and switching always occurred in patients with potential
causes of high platelet count, the majority classified as affected by inflammatory
disorders.
Summary and Conclusions: The most relevant effect of personalized refer-
ence intervals for platelet count in elderly medical patients was the reduction
by nearly half in the proportion of subjects with an unexplained form of throm-
bocytopenia. Introducing the new range into the clinical practice is therefore
expected to prevent many subjects to receive a series of unnecessary and
expensive tests, this benefiting both involved people and the health system.
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Background: Detection of antibodies (Abs) against platelet GPIIb-IIIa and/or
GPIb-lX is a characteristic feature of immune thrombocytopenia (ITP) and Fc-
mediated clearance of platelet (plt) by splenic macrophages has so far been
addressed as the main mechanism of plt destruction. Recently, an Fc-indepen-
dent mechanism has been proposed which involves mainly anti-GPIb Abs (1)
which were shown to induce plt activation leading to GPIb desialyation. In turn,
plt lacking sialic acid (desialylated plt) are removed by the hepatic Ashwell-
Morell receptor (AMR or asialoglycoprotein receptor).
Aims: In order to test the clinical relevance of this novel mechanism of plt clear-
ance, plt kinetic studies and Ab type data were retrospectively reviewed in a
group of ITP patients (pts).
Methods: Charts of ITP pts who had data on both plt kinetic studies and Ab
testing were reviewed. Pts are enrolled in a local Italian database (REL-ITP
database), and informed consent to clinical data use is given at enrollment
Results: A total of 53 pts (M 24) were identified: 41 already splenectomized
between year 2000 and 2014, 12 evaluated for splenectomy. All pts underwent
or are candidate to splenectomy for steroid-dependent ITP; 1 pt only was pri-
marily refractory to steroids and IVIG treatment. All but 2 pts achieved a com-
plete response to splenectomy. 31/53 (58.4%) of pts tested positive to one or
more than one antiGP Abs. Results of platelet kinetic studies and Ab testing
are summarized in Table 1. Extra splenic clearance doesn’t differ significantly
(Fisher’s test p=0.531) between Ab negative or positive pts.
Table 1.
Summary and Conclusions: Recent data have proposed that Ab type may
determine plt fate in ITP by activating either Fc- or non Fc-mediated mecha-
nisms of plt clearance resulting in splenic or hepatic uptake respectively. How-
ever, our data on plt kinetic and Ab type do not support such a mechanism
being operative in ITP pts: no correlation was found between Ab type, number
(single vs multiple antiGP) of Ab positive test and site of plt clearance. On the
other hand, it is well known that plt desialylate as they circulate, thereby becom-
ing the primary AMR ligand. Desialylation also occurs when plt are activated
by a number of physiological stimuli (2). It may well be that AMR-mediated
hepatic plt clearance rather represents a physiological mechanism involved in
clearance of activated plt-a role for the AMR has been proposed in attenuating
the coagulopathy associated with sepsis (3-4)-and in the regulation of TPO
production by hepatocytes (5).
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DIAGNOSIS AND MANAGEMENT OF THROMBOTIC THROMBOCY-
TOPENIC PURPURA (TTP) IN AUSTRALIA-FINDINGS FROM THE FIRST
FIVE YEARS OF THE AUSTRALIAN TTP REGISTRY (2009-2014)
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Background: Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threat-
ening thrombotic microangiopathy. In 2009, the Australian TTP registry was
established and began collecting data on patients presenting with TTP through-
out Australia.
Aims: To summarise findings of the first five years (2009-2014) of TTP diag-
nosis and management from the Australian TTP registry. 
Methods: Registry data from June 2009 to October 2014 were reviewed.
Results: 57 patients were identified with TTP (ADAMTS13 <10%) accounting
for 72 clinical episodes. ADAMTS13 inhibitor testing was performed in 9/57
(16%) patients reflecting the limited availability of accredited testing facilities.
67/72 episodes were treated with therapeutic plasma exchange (PEX) with
cryodepleted plasma (40% episodes), fresh frozen plasma (36%) or a mixture
(22%). Exposure to plasma products was significant with a median exposure
of 55.9L per episode. PEX was not commenced until 2 or more days after date
of diagnosis in 15% of episodes. Adverse reactions to PEX were common with
documented allergic reactions (including life-threatening) in 21% of episodes.
Adjunctive immunosuppression was documented in 76% episodes (corticos-
teroid 71%, rituximab 39%). Platelets were transfused in 15% of episodes with
no documented adverse reactions.
Summary and Conclusions: Australian TTP registry data reveal a heteroge-
nous approach to the diagnosis & management of TTP in Australia from 2009-
2014. Identified areas for potential practice improvement include a standardised
approach to TTP diagnostic testing, improving access to timely PEX and a
more uniform approach to adjunctive immunosuppression and supportive care. 
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RECENT TIME TRENDS IN THE UPTAKE OF SPLENECTOMY IN ADULTS
DIAGNOSED WITH CHRONIC IMMUNE THROMBOCYTOPENIA: A
NATIONWIDE HISTORICAL COHORT STUDY IN DENMARK, 1996-2012
K. Cetin1, S. Wetten2,* C. Christiansen3, M. Nørgaard3, U. Heide-Jørgensen3
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by isolated thrombocytopenia leading to an increased risk of
bleeding. Low platelet counts in ITP result from both increased antibody-
mediated platelet destruction and decreased platelet production. Because
the spleen often removes circulating antibody-coated platelets and can be
the site of antibody production, splenectomy can be an effective treatment
option. Although it is generally viewed as a standard second-line treatment
in adults with ITP, splenectomy has its risks (perioperative and long-term),
and there are no clear clinical criteria (e.g., previous response to steroids)
that predict response. Additionally, spontaneous remissions are possible,
and newer nonsurgical second-line therapies are available. Some clinicians
and patients are therefore opting to avoid or defer splenectomy. We sought
to investigate recent trends in the uptake of splenectomy in adults with chronic
ITP (cITP) in Denmark.
Aims: To compare the rate of splenectomy in three time periods (1996-2001;
2002-2007; 2008-2012) in a cohort of adults diagnosed with cITP.
Methods: Using the Danish National Registry of Patients (DNRP), we included
all adults (≥18 years) diagnosed with cITP (≥2 ITP diagnoses made ≥180 days
apart) in Denmark from 1996 to 2012. The date of cITP diagnosis was defined
as the date of the first ITP diagnosis occurring ≥180 days after the initial diag-
nosis and after the patient’s 18th birthday. The DNRP was also used to identify
if and when patients had undergone splenectomy and the presence of comor-
bidities. We computed the cumulative incidence of splenectomy (treating death
as a competing risk) after a diagnosis of cITP by time period of diagnosis. Cox
proportional hazards regression analyses were used to assess whether the
hazard (rate) of splenectomy after a cITP diagnosis varied by time period of
diagnosis, adjusting for gender, age, and presence of comorbidities. Patients
were followed from the date of cITP diagnosis until 10 years post-cITP, death,
emigration, or end of follow-up in 2012.
Results: We identified 1,993 non-splenectomized adults diagnosed with cITP.
Women accounted for nearly 58% of the cohort; and 31%, 35%, and 34% of
patients were aged 18-40, 41-65, and ≥66 years, respectively, at the time of cITP
diagnosis. During a median follow-up of 3.9 years [range: <0.1-10.0], approxi-
mately 9% (n=177) underwent splenectomy. Among these patients, the median
time to splenectomy following the cITP diagnosis was 0.5 years (range: <0.1-
9.9). The 1- and 3-year cumulative incidence of splenectomy after the diagnosis
of cITP was lower in more recent time periods of diagnosis (Table 1). After adjust-
ing for gender, age, and comorbidities, patients diagnosed with cITP in 2008-
2012 were less than half as likely to undergo splenectomy compared with patients
diagnosed in 1996-2001 (adjusted hazard ratio: 0.4 [95% CI: 0.3-0.7]).
Table 1. Cumulative incidence of splenectomy in adults following a diag-
nosis of chronic ITP by time period of chronic ITP diagnosis.
Summary and Conclusions: Less than 10% of nearly 2,000 adults diagnosed
with cITP in Denmark from 1996 to 2012 underwent splenectomy during a
median follow-up of 3.9 years. The incidence of splenectomy after a diagnosis
of cITP was lower for patients diagnosed in more recent years.
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EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE
IVIG THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE
THROMBOCYTOPENIC PURPURA IN CHILDREN
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Background: High-dose intravenous immunoglobulin G (IVIG) is the first ther-
apy for childhood acute immune thrombocytopenic purpura (aITP). Individual
low-dose method has been applied in the Department of Pediatrics, Kyungpook
National University Hospital since 1984. We have reduced the daily dose from
400 to 200 mg/kg daily until platelet count (PLT) over 50,000/uL since 2000.
Aims: This study evaluated the efficacy of short term and very low dose IVIG
(VLD-IVIG) therapy according to individual clinical response.
Methods: Forty-six childhood ITP Patients who’s PLT less than 20,000/uL were
evaluated from January 2007 to December 2013. We treated them with VLD-IVIG
(200 mg/kg/day for 1~5 days) initially until rising PLT over 50,000/uL and then any
patients without the response were treated additional IVIG up to 2g/kg totally.
Results: The mean age of 22 male and 24 female ITP was 26 months. The
mean PLT was 8,300/uL at the time of diagnosis. Thirty nine patients responded
with VLD-IVIG only. Four patients needed only one day, 11 patients 2 days, 9
patients 3 days, 10 patients 4 days, and 5 patients 5 days of IVIG (200 mg/kg)
respectively. Six of 7 patients who did not raise PLT above 50,000 with VLD-
IVIG had response after full dose (total 2 g/kg). Only 1 patient did not response
with IVIG and needed corticosteroids and 1 patient recurred within 2 weeks
after therapy. The mean numbers of IVIG injection to 50,000/uL was 3 times
(621 mg/kg of dose). The mean PLT after therapy was 108,692/uL. The mean
duration to recover PLT more than 150,000/uL was 2 months. No patient was
diagnosed to chronic ITP. The mean follow-up duration was 24 months and
mean PLT was 336,410/uL at last follow-up date.
Summary and Conclusions: The short term VLD-IVIG therapy according to
individual clinical response is effective and is recommended for acute ITP to
reduce admission days and cost of high dose IVIG therapy.
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THE ROLE OF REGULATORY T CELLS IN IMMUNE THROMBOCYTOPE-
NIA OF CHILDHOOD
M. Stratigaki1,* G. Martimianaki1, N. Katzilakis1, P. Bourbaki1, M. Pesmat-
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Background: Immune thrombocytopenia (ITP) is one of the most common
blood diseases and the commonest acquired bleeding disorder in childhood.
Although the development of autoantibodies against platelet glycoproteins by
B cells remains central in the pathophysiology of ITP, dysfunctional cellular
immunity has also great importance. CD4+CD25+Foxp3+ T cells (Treg cells)
take part in the regulation of immune responses and maintenance of self-tol-
erance. It has been also shown that these cells play a key role in the patho-
genesis of autoimmune diseases.
Aims: The aim of this study was the determination of the sub-populations of
CD3+CD8+CD25+, CD3+CD4+CD25+, CD4+CD25high and CD4+CD25high-
Foxp3+ T cells in children with immune thrombocytopenia and the correlation
with the levels of platelets’ number and the disease phase.
Methods: Peripheral blood of 21 children, 12 with acute ITP (age range 5
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months-11 years) and 9 children (age range 8-16 years) with chronic immune
thrombocytopenia was studied. The percentage of regulatory T lymhpocytes’
subpopulations was estimated with flow cytometry. The median platelets’ num-
ber was 11900/μl in the group of acute ITP and 46600//μl for the patients in the
chronic phase of the disease.
Results: According to our findings between acute and chronic phase of immune
thrombocytopenia was not observed statistically significant difference in the levels
of CD3+CD8+CD25+, CD4+CD25high and CD4+CD25highFoxp3+ T cells sub-
populations. The levels of the CD3+CD4+CD25+ T cells sub-population were
statistical significantly reduced in children with acute immune thrombocytopenia
in contrast with children with chronic immune thrombocytopenia (2.94±0.68 vs
5.10±0.16, p=0.029). No statistically significant difference was observed in the
levels of regulatory T cells between diagnosis of immune thrombocytopenia and
the phase of recovery of number of platelets in normal values.
Summary and Conclusions: Between acute and chronic childhood ITP the num-
ber of CD3+CD4+CD25+ Treg cells was estimated with significant difference. This
reduction of the CD3+CD4+CD25+ Treg cells in acute ITP might be one of the
mechanisms implicated in the pathophysiology of the disease in children.
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INCIDENCE OF MALIGNANCY IN ADULT PATIENTS WITH AUTOIMMUNE
THROMBOCYTOPENIC PURPURA: A 12 YEAR SINGLE CENTER EXPERI-
ENCE
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Background: Autoimmune thrombocytopenia (ITP) is an autoimmune disorder
characterized by immune-mediated platelet destruction and suppressed platelet
production. Depending on the presence or absence of associated disease, ITP
is divided into primary and secondary types. Few studies have addressed the
association between ITP in adult patients and malignant neoplasms.
Aims: To estimate the incidence of malignant neoplasms in adult patients with
ITP.
Methods: All patients diagnosed with ITP and with a platelet count ˂ 100×109/L,
between September 2002 and January 2015 were included in the study.
Patients were retrospectively reviewed for diagnosis of malignancy, and inclu-
sion criteria included concurrent ITP or ITP preceding the diagnosis of a malig-
nant neoplasm within 1 year.
Results:A total of 86 patients (62 females and 24 males) were diagnosed between
2002 and 2015. Their ages ranged from 16 to 91 years with a mean (SD) of 35.7
(15.3) years. Among these patients, 13 (15.1%) developed malignancy during the
study period. The incidence of malignancy was significantly higher in males ≥30
years old than in males ≤30 years old. It was 6.9% among patients aged 31-50
years and 58.8% among patients aged ≥50 years. Hodgkin’s and marginal lym-
phoma were the most common cancers detected in this group of patients.
Summary and Conclusions: ITP had a strong association with malignant neo-
plasms, especially in male patients over 50 years of age. Hodgkin’s and mar-
ginal zone lymphoma were among the cancers strongly associated with ITP.
The results suggest that patients over 50 years of age with ITP should be exam-
ined for an underlying malignant condition. ITP may occur concurrently or pre-
cede the occurrence of malignant disease, which would have great diagnostic
significance. ITP may also be the first early sign of the disease. Thus, prompt
determination of the cause of ITP could be of great importance for the diagnosis,
monitoring and therapy of malignant neoplasms.
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AN OBSERVATIONAL CLINICAL PRACTICE STUDY OF ROMIPLOSTIM IN
PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
(ITP)-PLATON INTERIM RESULTS
G. Mihaylov1,* G. Kuchma2, J. Obernauerová3, B. Skopec4, Z. Sninska5,
N. Tzvetkov6, D. Niepel7, P. Černelč4
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Regional Hospital Mlada Boleslav, Mlada Boleslav, Czech Republic, 4Depart-
ment of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia,
5Department of Hematology and Blood Transfusion, University Hospital St.
Cyril and Metod, Bratislava, Slovakia, 6Clinic of Hematology, University Multi-
profile Hospital for Active Treatment “Dr. Georgi Stranski” EAD, Pleven, Bul-
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Background: The thrombopoietin-receptor agonist romiplostim is indicated for
adult splenectomised patients (pts) with ITP who are refractory to other treat-
ments and may be considered as second line treatment for adult non-splenec-
tomised pts where surgery is contra-indicated.
Aims: The aim of this ongoing study is to assess the use of romiplostim in clin-
ical practice in Bulgaria, Czech Republic, Slovenia, Slovakia, Romania and
Russia.
Methods: This international single-arm, non-interventional, multicenter, ret-
rospective and prospective study is enrolling adult pts with ITP, who have
received at least one application of romiplostim according to the licensed
indication. A period of 6 months prior to romiplostim initiation was documented
retrospectively from pt files; the prospective observation period started at the
time of romiplostim initiation. The total planned observation period is 2 years.
All pts provided written informed consent. Assessed parameters included pt
demographics, romiplostim application, dosage, adverse drug reactions
(ADRs) and reasons of discontinuations, concomitant ITP therapies, clinically
relevant bleeding events, and consumption of resources. Data from a proto-
col-defined interim analysis (IA) at 1 year of prospective observation are
reported here.
Results: 66 pts were analyzed for the IA (47% male, median age at romi-
plostim initiation 48 [range 19-82] years, splenectomized n=27, non-splenec-
tomized n=39). Of these, 58 (88%) completed 1 year of study, 8 (12%) dis-
continued from the study (adverse drug reactions n=1, administrative decision
n=2, lost to follow-up n=5). The median time from ITP diagnosis to romiplostim
initiation was 2.89 (0-42) years. 34 pts (51.5%) had received ≥3 prior ITP
therapies. During the 6 months before romiplostim initiation the event rate
per 100 pt years was 111 (95% CI 75.1, 156.8) for bleeding and 92 (95% CI
73.2, 113.0) for ITP-related hospitalizations. The median platelet count at
romiplostim start was 19.0 (range 1-411)x 10^9/L, increasing to 52.0 (range
2-361)x 10^9/L after 1 week and remaining above 50x 10^9/L for the period
until IA data cut-off at 1 year (Figure 1). During the 1-year observation period
for IA, pts received a median romiplostim dose of 2.13 (range 0.1-9.1)
µg/kg/week and a median of 31 (range 2-53) injections. The event rate per
100 pt years during the 1-year romiplostim treatment period was 58 (95% CI
39.0, 83.6) for bleeding (no grade 3/4 events) and 94 (95% CI 69.3, 125.4)
for ITP-related hospitalizations. 4 pts (6.1%) experienced a total of 11 ADRs,
with 2 pts experiencing 2 serious ADRs each (thrombosis, dysphagia, lym-
phocytosis, leucocytosis). 51 pts (77.3%) were hospitalized for 77 ITP-related
events during the 1 year observation period for IA for the following reasons:
platelet transfusion (n=5, 9.8%), ITP treatment administration (n=24, 47.1%),
bleeding event (n=14, 27.5%), infection-related (n=5, 9.8%), splenectomy
(n=7, 13.7%), ADR (n=1, 2.0%), other (n=21, 41.2%).
Figure 1.
Summary and Conclusions: These interim data show that platelet counts in
ITP patients treated with romiplostim in clinical practice increased and were
maintained within the desired range of 50-250x 10^9/L. The bleeding event
rate was lower during romiplostim treatment. Romiplostim was generally well
tolerated.
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MULTI-CENTER, PROSPECTIVE STUDY TO EVALUATE THE EFFICACY
OF “BIWEEKLY” ROMIPLOSTIM IN ADULT IMMUNE THROMBOCYTOPE-
NIA (ITP); PROLONGED DOSE INTERVAL ≥2 WEEKS IS NOT RECOM-
MENDABLE
S. Park1,* S.S.Y.2, J.H. Lee3, J.S. Park4, J.W. Lee5, J.H. Jang1
1Samsung Medical Center, 2Seoul National University Hospital, 3Asan Medical
Center, Seoul, 4Ajou University Hospital, Suwon, 5Seoul St. Mary’s Hospital,
Seoul, Korea, Republic of
Background: Romiplostim is recommended to administer weekly in adult
immune thrombocytopenia (ITP) patients. However, the optimal dose interval
has rarely been studied. 
Aims: This is a multi-center, prospective study to evaluate the efficacy of
“biweekly” romiplostim in maintaining platelet count ≥30x 109/L during 4 or more
weeks.
Methods: Treatment was started with weekly injection (starting dose, 1mcg/kg),
and the dose was escalated until achieving titrated dose that maintains platelet
count 50-200x109/L for 4 consecutive weeks. Then, patients moved to biweekly
schedule, and if platelet count became <30x 109/L, patients returned back to
weekly schedule. The process could be repeated twice. But platelet count <30x
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109/L on 2nd biweekly schedule, the study was finished after 4 weekly doses. 
Results: Between Jul 2013 and Dec 2014, a total of 18 patients were enrolled
(median platelet count, 14x109/L). After the 1st weekly schedule, 10 of 18
(55.6%) attained titrated dose of median 3mcg/kg and proceeded to 1st
biweekly schedule. However, all of them failed in maintaining platelet count
≥30x 109/L for at least 4 weeks, and returned back to 2nd weekly schedule.
8 of 10 were titrated (median, 5mcg/kg) and moved to 2nd biweekly romi-
plostim; 3 of 8 (37.5%) showed platelet counts ≥30x 109/L during 4, 8, and
10 weeks. However, all 8 patients eventually experienced drop of platelet
and entered onto the last stage; 2 (25%) almost did not respond to romi-
plostim at this time (Figure 1).
Figure 1. Overall treatment algorithm.
Summary and Conclusions: Lengthening the dose interval of romiplostim
more than a week is not desirable for stably maintaining the platelet count and
associated with fluctuating platelet response.
E1417
EFFECT OF THROMBOPOIETIN RECEPTOR AGONISTS ON COAGULA-
TION AND PLATELET ACTIVATION IN PATIENTS WITH IMMUNE THROM-
BOCYTOPENIA
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Background: Thrombopoietin receptor agonists (TPO) are effective treatment
in immune thrombocytopenia (ITP). Thrombotic events were reported in up to
6% of patients in TPO-agent trials in raising concerns of coagulation and platelet
activation.
Aims: To evaluate the effect of TPO-agents on coagulation and platelet activation. 
Methods: The study comprised 2 ITP cohorts. Cohort 1 (n=26) with sequential
blood samples at 0 (pretreatment) and 2, 6 and 12 weeks on treatment with
TPO. Cohort 2 (n=18) patients on long-term treatment with TPO-agents (>1
year) in whom blood samples were collected only once. Markers of coagulation
and fibrinolysis including endogenous thrombin potential (ETP) by calibrated
automated thrombography (CAT) assay, prothrombin fragments 1+2 (F1+2),
plasminogen activator inhibitor-1 (PAI-1) activity, and D-dimer as well as soluble
P-selectin as a marker of platelet activation were measured in all samples.
Healthy controls (n=20) were analyzed for P-selectin only.
Results: Mean age was 55 years (32% males). Nineteen patients were treat-
ed with romiplostim, 22 with eltrombopag and 3 with avatrombopag. Median
values of D-dimer, PAI-1, ETP (normalized against pooled normal plasma),
P-selectin and platelet counts are shown in the Table 1. Platelet counts
increased significantly after initiation of TPO treatment. No difference was
found between pretreatment and on treatment (both cohorts) values of D-
dimer, F1+2 or PAI-1. Median ETP at 6 weeks higher than pretreatment values
(p=0.042); remaining levels at 2 and 12 weeks and cohort 2 did not differ
from pretreatment. A statistically significant increase in P-selectin was found
shortly after initiation of TPO-agents (2 weeks)(p=0.002) and through 6
(p=0.0001) and 12 weeks (p=0.003) into treatment. A higher level of P-
selectin was also found in cohort 2 compared to pretreatment levels of
cohort1. Pretreatment levels of P-selectin did not differ from healthy controls
(mean 22.5 ng/mL) (p=0.4), however, all on treatment levels of P-selectin in
cohort 1 (p=0.002, 0.001, 0.008 respectively) and cohort 2 (p=0.006) were
significantly higher than healthy controls.
Table 1.
Summary and Conclusions: Conclusion: Evaluation of the coagulation and
fibrinolytic systmes shows that thrombopoietic agents cause no activation of
these systems confirming a previous study performed on eltrombopag. How-
ever, the finding of increasing soluble P-selectin during treatment with TPO
may indicate degranulation of alpha-granules and hence platelet activation. 
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SPLENECTOMY IN THE TPO MIMETIC ERA-STILL REASONABLE
APPROACH?
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Background: Immune thrombocytopenia (ITP) is an acquired, immunologi-
cally determined disease characterized by a decrease in platelet count and
the associated increased risk of bleeding. The spleen plays a major role in
the pathogenesis of ITP, it is the site of antibody production and often the
major site of antibody-mediated platelet destruction. Splenectomy was the
first method for ITP therapy and has long been the standard second-line
treatment for adults with ITP who do not respond to corticosteroids. Recent
advances in the understanding of etiopathogenetic mechanisms of ITP led
to the development of novel therapies and changed the role of splenectomy
in the management of ITP. 
Aims: Describe the population indicated for splenectomy (before and after
new guidelines). Evaluated efficacy and safety of splenectomy and therapeutic
possibilities for refractory patients.
Methods: We retrospectively analyzed the data of 98 patients with primary
ITP from four Czech hematological centers who underwent splenectomy
between years 1995 and 2014. The response was evaluated according to the
ITP International Working Group guidelines.
Results: In total, 98 patients (66% females) underwent splenectomy for ITP
between 1995 and 2014 in four Czech hematological centers. The median
age at diagnosis was 36 years (range 6-72) and median age at splenectomy
was 38 years (range 17-73). 56% patients who were splenectomized before
year 2010 had chronic ITP while 72% patients had chronic ITP if the splenec-
tomy was performed after year 2010. Minority of patients had newly diag-
nosed ITP, in a subgroup of patients splenectomized before year 2010 it was
19% and in a subgroup of patients splenectomized after year 2010 were
none with newly diagnosed ITP’s. While the median interval between diag-
nosis and splenectomy in patients who were splenectomized before 2010
was 13 months, the median interval in patients who were splenectomized
after 2010 was longer (32 months). After 2010, splenectomy was used most
often as a third-line treatment. 25 patients in our group underwent labelled
platelet scanning before splenectomy, majority of them had splenic uptake.
The median platelet count before splenectomy was 65x 109/l (range 1-330x
109/l). 77 patients (79%) were prophylactic vaccinated against encapsulated
bacterial pathogens. 61% of patients underwent splenectomy with an open
technique and 39% with a laparoscopic technique and the rate of laparo-
scopic splenectomies increased over time. Of the 98 patients, 10 (11%)
achieved a response (R) and 83 (84%) a complete response (CR), the overall
response rate was 95%. 28 (29%) patients relapsed after a median time 6
months (range 1-125). 8 patients (8%) experienced peri-operative and 3
patients (3%) post-splenectomy complications. In 33 patients (34%) splenec-
tomy was not successful because of the relapse or lack of response, but new
treatment options especially TPO mimetics improved the outcome of these
refractory patients.
Summary and Conclusions: Splenectomy is an effective treatment for ITP
with two thirds of patients achieving long-term response and still has a place
in the management of ITP. Recent trend is to postpone splenectomy until the
chronic phase of the disease.
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ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN SOME
IMMUNOREGULATORY GENES WITH IMMUNE THROMBOCYTOPENIA 
M. Pavkovic1,* S. Trkovska-Terzieva1, S. Genadieva-Stavric1, O. Karanfilski1,
T. Sotirova1, L. Cevreska1, A. Stojanovic1
1University Clinic for Hematology, Skopje, Macedonia
Background: Immune thrombocytopenia (ITP) is an autoimmune disease char-
acterized by thrombocytopenia due to platelet autoantibodies, causing an accel-
erated clearance of opsonized platelets by phagocytes. The etiology of ITP
remains unclear, but both genetic and environmental factors can have a role in
the development of ITP. 
Aims: The aim of our study was to investigate a possible association of some
single nucleotide polymorphisms (SNP) in genes for interleukin beta IL1β(-
511C/T), tumor necrosis factor beta TNFβ(+252G/A), tumor necrosis factor
alpha TNFα(-308G/A), cytotoxic T lymphocyte antigen 4 CTLA(+49 A/G), Fc
gamma receptor FCGR2A-H/R131 and FCGR3A-V/F158 with ITP.
Methods: We analyzed 125 adult ITP patients (35 men, 90 women) with median
age of 47(range 14-83) and 120 healthy matched controls. The median follow
up was 44 months (12-384). All 125 patients were initially treated with corticos-
teroids, 38 were splenectomized. Forty two (34%) patients had refractory or
unresponsive form of disease, according to the definition of the International
Working group for ITP. Genotyping was performed by using polymerase chain
reaction and restriction fragment length polymorphism methods. The distribution
of genotypes and allele frequencies were compared with a chi-squared.
Results: Our results demonstrated significantly different distribution of the
TNFβ(+252 G/A) genotypes and allele frequencies in patients with ITP (G/G=3,
A/G=38, A/A=84) comparing with controls (G/G=16, A/G=35, A/A=69), p=0.005
and p=0.009. We didn’t found significant differences in the genotype distribution
or allele frequencies for TNFα(-308G/A) and ILβ (-511C/T), p=0.363 and
p=0.845. There was significantly different genotype distribution and allele fre-
quencies for TNFα(-308G/A) between patients with unresponsive ITP (n=83;
G/G=75, A/G=8, A/A=0) and responsive ITP (n=42; G/G=30, A/G=11, A/A=1),
p=0.016 and p=0.009. There was no significant difference in genotype distri-
bution and allele frequencies for TNFβ(+252G/A) and ILβ(-511C/T) between
these two groups of patients. Our results demonstrated significantly higher fre-
quency of high affinity FCGR3A-158V allele in ITP patients comparing with
controls (47.2% versus 37.5%; p=0.037). We did not found significant differ-
ences in the allele frequencies for FCGR2A-131H/R, p=0.478. In the group of
patients with unresponsive and responsive ITP we found significantly different
genotype distribution and allele frequencies for FCGR3A, p=0.036 and p=0.008
respectively. Our results confirmed that, the combination of high affinity
FCGR2A-131H and FCGR3A-158V allele was more common in patients with
ITP than in control subjects (55% versus 40%; p=0.024). Analysis of CTLA-4
polymorphisms did not confirmed significant differences in genotype distribution
between ITP patients and controls, p=0.43. 
Summary and Conclusions: Results of this study, suggest possible role of
FCGR3A, TNF-β and TNF-α polymorphism in the etiology, development and
clinical form of immune thrombocytopenia.
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SWITCHING THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN
ADULT IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS: A RETROSPEC-
TIVE CASE SERIES
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Background: Availability of TPO-RA offers a new opportunity of treatment with
high response rates for ITP patients (pts). However, a small fraction of pts do
not respond or lose response-i.e. desired platelet (plt) count achieved but not
sustained over time-at follow-up or experience wide fluctuations in plt counts
with either romiplostim (R) or eltrombopag (E). Albeit rare, untoward effects
may lead to treatment discontinuation. Finally, pts preference may be an impor-
tant issue considering the different route and timing of administration of the
two drugs and the alimentary restrictions needed for proper E absorption. Avail-
ability of two TPO-RAs with different molecular structure and site of binding
within the TPO receptor, makes it appealing to try switching with the aim of
overcoming treatment limitations of either agent (1-3). 
Aims: Data on TPO-RA switch in everyday clinical practice are presented.
Methods: Charts of ITP pts receiving TPO-RAs at two collaborating Centers
were reviewed. All pts are enrolled in a local data-base and informed consent
to clinical data use is given at enrollment.
Results: A total of 59 pts received either R or E between Jan 2009 and Dec
2014. 14/59 (24%) underwent TPO-RA switch (Table 1). All pts had received
maximum product dose as per prescribing information prior to switch. Of the 5
pts switching because of lack of response to first TPO-RA, only 1 (#3) respond-
ed when switch from E to R, but developed neutralizing antibodies to R. Four
of 6 pts who lost response on first TPO-RA responded to the second TPO-RA;
the 2 non responders were splenectomized pts who had received multiple lines
of therapy prior to TPO-RA treatment. Both pts switched for plt count fluctuations
responded but one pt only achieved stable plt counts. Pts’s preference was the
reason for switching in one pt only who was receiving R; she did not respond
to E and was switched back to R regaining a response.
Table 1.
Summary and Conclusions: Availability of two TPO-RAs offers a safe and
often effective treatment alternative in pts not achieving the desired plt
response on either R or E. However, differently from published case series
(1-3) among our pts it seems that lack of response to either one of the two
available TPO-RA identifies a subgroup of pts least likely to respond when
switched to the second available TPO-RA. Similarly to reported series (1-3),
plt count fluctuation stabilize in approximately 50% of cases upon switching.
Finally, re-exposure to R (pt #14) was not associated with response loss,
which confirms our published observation (4) of absence of tachyphylaxis.
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A STUDY OF HUMAN KILLER CELL IMMUNOGLOBULIN-LIKE RECEP-
TOR(KIR) AND MULTI-DRUG RESISTANCE (MDR)GENE POLYMOR-
PHISMS IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA
N.M. El-beblawy1, N.S. Elbarbary1,* T.M. Kamal1, P.M. Mahmoud1
1Ain Shams University, Pediatric Department, Cairo, Egypt
Background: Childhood immune thrombocytopenia (ITP) is a common pedi-
atric hematologic disorder characterized by increased destruction of anti-
body-sensitized platelets with normal to increased megakaryocytes in the
bone marrow, as well as the presence of thrombocytopenia with otherwise
normal red cells and leukocytes, absence of splenomegaly and the absence
of other causes of thrombocytopenia. Although the etiology of ITP remains
unclear, it is generally accepted that both environmental and genetic factors
play an important role in the development of the disease.
Aims: To analyze the allelic and genotypic frequencies of MDR and KIR
genes polymorphisms in healthy and ITP Egyptian subjects. In addition we
assessed the potential role of these polymorphisms in relation to types of
ITP, progression of disease and response to different treatment modalities.
Methods: A total of 48 pediatric ITP patients (24 newly diagnosed, 24 chronic)
and 35 healthy controls were investigated via PCR-RFLP analysis for MDR1
and KIR2 genes.
Results: The frequency of MDR1 gene in patients and control was not sig-
nificant (P=0.090). CT genotype was the highest distribution among all ITP
cases(62.50% (n=30) and control (48.60%(n=17). There was a significant
difference in age at diagnosis of MDR1 gene with the CC genotype had the
eldest age and lowest initial platelets count (P=0.029 and P=0.004). The dis-
tribution of KIR2 gene among all ITP patients and controls was significant
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(P=0.026)with (KIRDL2-/KIRDS2-) genotype was the most prevalent among
patients.
Summary and Conclusions: The frequency of MDR1 polymorphisms were
not associated with susceptibility to the development and clinical progression
of the disease. However, KIR2 gene polymorphisms were independently
associated with childhood ITP in Egyptian patients with highest prevalence
among (KIRDL2-/KIRDS2-) genotypes.
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ROMIPLOSTIM AS A PREPARATION TREATMENT BEFORE SPLENECTO-
MY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
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E. Kuzub1
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Background: Splenectomy is used as a second line therapy for immune throm-
bocytopenia (ITP) in patients with corticosteroid resistance. The operation may
be risky for patients with a platelet count less than 30-40x 10(9/L) leading to
severe hemorrhagic complications. Massive platelet transfusion often leads to
immune complications. Moreover, it can be difficult to find retaining platelets in
enough supply to be able to provide to the patient. 
Aims: In the following trial romiplostim was used to reduce platelet transfusion
requirement in splenectomized patients over pre- and postoperative periods.
Methods: Over a 3-week period, 12 patients with ITP (7 females and 5 males
at age 26-42 years old) with a median platelet count of 7,3-7,5x109/L were
treated with romiplostim once weekly. 
Results: All that patients had resistance to corticosteroid therapy and bleed-
ing episodes such as epistaxis, gum bleeding or skin hemorrhages. Immune
globulin G therapy failed in hemorrhagic syndrome and did not cause the
increase in platelet count. After 3 injections of romiplostim all patients
demonstrated decrease of hemorrhagic manifestations. A median platelet
count were 148±52,9x109/L. All patients were splenectomized. Nobody of
them needed platelet transfusion in pre- or postoperative periods. No peri-
or postoperative complications have developed. In 10 patients a platelet
count increased up to 421±62,7x109/L on the second week after splenecto-
my. Two patients demonstrated a platelet count of 1457±132x109/L in 10
days after operation. In 4 weeks of treatment with heparin and hydroxycar-
bamide, their platelet count achieved the level of 402±37,5x109/L. No throm-
botic complications in all patients in postoperative period have developed.
Over next 11+-4,5 months all splenectomized patients had a complete clin-
ical and biochemical remission.
Summary and Conclusions: Thus, romiplostim could be recommended as a
preparation treatment before splenectomy in patients whose ITP does not
respond to corticosteroids, according to our material. However, a high risk of
thrombotic complications in postoperative period should be considered
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GLANZMANN THROMBASTHENIA IN CHILDREN : TWENTY FIVE YEARS
FOLLOW-UP
Z. Salcioglu1,* H. Sayilan Sen1, G. Aydogan1, F. Akici1, D. Tugcu1, Z. Baslar2
1Pediatric Hematology and Oncology Clinic, İstanbul Kanuni Sultan Süleyman
Education and Research Hospital, 2Internal Medicine, Hematology Department,
İstanbul University, Cerrahpaşa Medical School, İstanbul, Turkey
Background: Glanzmann Thrombasthenia is a rare bleeding disorder. The
cause of the disease is the qualitative or quantitative abnormalities of platelet
membrane glycoprotein GPIIb-IIIa complex. Severity and frequency of the
bleeding episodes may change from patient to patient.
Aims: In this report, clinical and laboratory features of 33 patients that were
followed between 1990-2015 were evaluated.
Methods: Information of patients were retrieved from patient files and from
the records contained in the electronic information processing environment
created after 2005.
Results: They were 16 males (48.5%) and 17 females (51.5%). The age of
onset was between 1 month and 7 years (mean 2.8 years). Familial consaguity
was present in 17 (51.5%) of the patients. Bleeding time was prolonged and
thrombocyte function tests were correlated with Glanzmann disease. Flow cyto-
metric tests were done in 27 patients. Type 1 disease was present in 5 (18.5%),
type 2 in 10 (37%), type 3 in 12 (44.5%) of the patients. The bleeding types
seen in our patients were as follows; oral mucosal bleedings 81.8%, superficial
skin bleedings 72.7%, epistaxis 66.6%, menorrhagia 15.1%, heamaturia 6%,
haemarthrosis 6% and intracranial bleeding 1.8%. Local therapies, antifibri-
nolytic agents, oral contraceptives and if severe bleeding is present thrombo-
cyte suspensions were given. For five of our patients with six bleeding attacks
rFVIIa was used. One of our patients died due to tuberculous pericarditis and
dilated cardiomyopathy.Follow up duration was between 1 and 24 years (mean
11.4 years). There was not any documanted alloimmunization. Thirty two of
our patients are still alive and being followed up.
Summary and Conclusions: In Turkey where consanguineous marriages are
common, patients with mild bleeding may be underdiagnosed. It is also known
that even diagnosed patients may seek help only when they have severe bleed-
ing problems. As a result; we believe that in order to diagnose these patients
as early as possible, to perform their follow-ups and scan their families and to
provide adequate patient education and genetic counselling, a nationwide pro-
gram should be organized.
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Background: The frequency of immune thrombocytopenia (ITP)-associated
diseases is not well known. The diagnostic values of the tests performed at
ITP onset in order to detect these diseases are discussed or unknown.
Aims: To compare the diagnostic value of the tests used at ITP diagnosis to
detect ITP-associated diseases in the overall ITP population, in the presence
of signs evocative of these diseases and in the absence of these signs. 
Methods: Study population was the patients included between June 2013
and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre
Midi-PyréneEN) registry. This multicenter registry is aimed at the prospective
follow-up of all incident ITP adults in the French Midi-Pyrénées region (3 mil-
lion inhabitants). Each investigator prospectively follows every patient newly
diagnosed for ITP in routine visit or hospital stay, providing informed consent
was received. ITP is defined in accordance with French guidelines: platelet
count <150x 109/L and exclusion of other causes of thrombocytopenia. Inves-
tigations performed at ITP diagnosis are recorded with their results. We
assessed their positivity rates in the entire cohort and depending on the clin-
ical and biological context. These rates were expressed in frequencies and
in number of patients needed to test (NNT) to observe one positive test.
Results: We included 113 patients. Median age was 65 years (range: 17-
95). Half of the patients were female, 24 (21.2%) had a secondary ITP, 58
(51.3%) had bleeding signs, median platelet count was 16x109/L (range: 1-
126) and 72 patients were treated for ITP within the month following the diag-
nosis. Bone marrow aspirate was performed in 87 patients. Four myelodys-
plastic syndromes (MDS) were found (2 refractory cytopenia with unilineage
dysplasia and 2 with multilineage dysplasia); these 4 ITPs had platelet count
<10x 109/L and responded to corticosteroids. The NNT to detect 1 MDS was
12 in case of anemia or neutropenia and 52 in case of isolated thrombocy-
topenia (among patients aged >60 years, NNTs were 10 and 25, respectively).
The NNTs for antinuclear antibodies (ANAs, tested in 92 patients without
known connective tissue disease, positive if titer≥1/160) were similar in case
of clinical signs of unknown connective tissue disease (NNT=2) or not
(NNT=3). Antiphospholipid antibodies were positive in only 1 lupus patient
(36 tested). The NNT for positive direct antiglobulin test (tested in 47 patients)
was 4 in case of anemia or low haptoglobin level, and 7 otherwise. The NNT
for hypogammaglobulinemias (<5g/L) on serum protein electrophoresis (test-
ed in 92 patients) was 23 in case of lymphopenia and 69 otherwise. No patient
had a history of repeated or severe infections. HCV, HBV and HIV were tested
in respectively 89, 97 and 86 patients, including 7 with elevated alanine
aminotransferase. No new infection was detected. The NNT for Helicobacter
pylori testing (n=11) was 2 in case of gastro-intestinal symptoms and 3 oth-
erwise. Thyroid stimulating hormone (TSH) or thyroid autoantibodies were
tested in 57 patients without history of thyroiditis. None had thyroiditis clinical
signs. Isolated autoantibodies or mild TSH abnormalities were found in 9
patients but no specific treatment was started.
Summary and Conclusions: Except for ANAs (whose presence may discuss
the use of hydroxychloroquine), NNTs were at least two-fold higher in case
of evocative context, discussing the systematic use of these tests. HIV, HCV
and HBV revealed by ITP seem very rare in France.
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Background: TTP is an acute, life threatening thrombotic microangiopathy
associated to a congenital or acquired deficiency of the von Willebrand factor
cleaving protease ADAMTS13. Limited data on utility of ADAMTS13 measure-
ments during pregnancy are available. 
Aims: Aim of this study was to evaluate the importance of closely monitoring
ADAMTS13 levels on pregnancy outcome.
Methods: Four consecutive pregnant women with TTP (2 congenital, 1
acquired and 1 with probably congenital) were enrolled into the study. ADAMTS-
13 activity (chromogenic assay), inhibitors (mixing studies), and anti-ADAMTS-
13 antibodies (ELISA) were measured in plasma. 
Results: Patient 1, a 35 y.o. woman with acquired TTP history not-related to
pregnancy had a TTP relapse at 21th week gestation (first pregnancy). A complete
ADAMTS13 activity deficiency associated to anti-ADAMTS13 auto-antibodies
was detected. Oral steroids and weekly plasma exchange (PEX) were started.
However, ADAMTS13 activity remained significantly low (<5%) and she prema-
turely delivered (25th week) an alive baby. At remission she had persistent
ADAMTS13 activity deficiency associated to auto-antibodies. Patient 2, a 21 y.o.
woman developed TTP during her first pregnancy (15th week). She had a com-
plete ADAMTS13 activity deficiency and no auto-antibodies, was successfully
treated with plasma infusion therapy plus steroids, and delivered on term a healthy
baby. At clinical remission, she had no ADAMTS13 activity and no auto-antibodies.
A possible congenital TTP diagnosis was hypothesized. About two years later
(May 2014) she was again pregnant. No ADAMTS13 activity or auto-antibodies
were detected, and at molecular analysis a compound homozygosity for two
novel ADAMTS13 mutations was found. She received prophylactic plasma infu-
sions and delivered (38th week) a healthy baby without disease manifestations.
Patient 3, a 28 y.o. woman with a HELLP syndrome history during her first preg-
nancy. She developed TTP during her second pregnancy, PEX treatment was
started, however cesarean section was performed at the 32th week because of
clinical worsening, with a successful outcome. She had a persistent low
ADAMTS13 activity levels with no auto-antibodies, and at molecular analysis a
compound heterozygosity for two novel ADAMTS13 mutations was found. Patient
4, a 30 y.o. woman developed TTP after her first pregnancy. After the delivery,
she developed severe thrombocytopenia, and an evaluation of ADAMTS13 levels
was performed. She had a complete ADAMTS13 activity deficiency and no auto-
antibodies. The inherited nature of severe ADAMTS-13 deficiency in this patient
was established by phenotype family analysis. The results of ADAMTS13 levels
of parents showed a moderate reduction in ADAMTS13 activity in the mother
(47%) and father (43%), associated with no antibodies. The genetic analysis is
under investigation. 
Summary and Conclusions: Our data endorse the utility of ADAMTS13 study
for differential diagnosis between congenital and acquired TTP and subsequent
type of treatment with either plasma infusion or plasma exchange. In addition,
our data indicate that the measurement of ADAMTS13 can represent an effec-
tive means to monitor women at risk of TTP recurrence in pregnancy.
Quality of life, palliative care, ethics and health
economics
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Background: Multiple myeloma remains an incurable cancer with evidence
that patients suffer more symptoms than in other haematological conditions.
Palliative care services are rarely involved.
Aims: We aimed to determine how symptom prevalence, severity and quality
of life as well as cost/health care utilisation change over time, and what demo-
graphic, clinical and social factors predict changes.
Methods: We recruited patients into a 14-site multicentre, longitudinal obser-
vational study, consenting patients at various stages of their illness (newly diag-
nosed, stable and progressive/relapsed disease). At baseline and then on up
to 4 occasions over eight months, patients completed self reported demograph-
ic, clinical, symptom, palliative, quality of life and service use questionnaires.
Clinical details were abstracted from medical records. We used myeloma-spe-
cific and generic, validated scales, including the Myeloma Patient Outcome
Scale (MyPOS), a quality-of-life questionnaire specifically developed for multiple
myeloma. We tested for predictors using multivariable analysis, adjusting for
confounders.
Results: 257 patients with multiple myeloma with a median age of 69 years
(range: 34-92) and on average 2.5 years post-diagnosis participated. 18.2%
were newly diagnosed, 47.9% had stable disease and 32.7% had relapsed dis-
ease or were in the advanced, palliative phase of illness. Patients reported a
mean of 5.1 (SD=2.7) symptoms. Over 70% had pain, 88.7% fatigue and 61.1%
breathlessness. The most burdensome symptoms in the advanced stages were
fatigue, poor mobility, pain, and tingling in the hand/feet. Over the eight months,
patients showed distinct trajectories according to whether they were in an early
or advanced treatment-interval or in an early or advanced treatment-free inter-
val. Trajectories of physical functioning did not follow other domains of quality
of life. The strongest predictors of higher levels of symptoms and health care
service use at the end of follow-up were initial scores on MyPOS, type of myelo-
ma, performance status and co-morbid conditions.
Summary and Conclusions: Burden of symptoms in multiple myeloma is high
and symptoms are not resolved even during the treatment-free intervals. Those
with a high symptom burden and with light chain disease are at increased risk
for poor HRQOL, should be monitored and could potentially be considered for
early referral to palliative care services.
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Background: Since the 1990’s, Non Hodgkin Lymphoma (NHL) has been
affected by profound changes with a better knowledge of the disease and new
therapeutic tools. Follicular (FL) and Diffuse Large B-cell Lymphoma (DLBCL)
were the first to benefit of these.
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Aims: To evaluate changes on survival in the general population; to compare
FL and DLBCL cancer mortality across European areas by studying the trend
of net survival; and estimating the effect of age and year at diagnosis on the
excess mortality hazard (EMR) in order to study the care management over
time.
Methods: FL or DLBCL diagnosed between 01-01-1996 and 12-31-2004,
and aged ≥15 years were selected from the EUROCARE-5 database. Vital
status was at 12-31-2008 (French registries at 12-31-2007). Registries that
covered the entire period were included and categorized into 5 areas (North-
ern, UK, Central, Eastern and Southern Europe). We estimated the 5-year
age-standardized net survival (5-year NS), using the Pohar-Perme’s estima-
tor. To model effects of covariate on the EMR, the flexible model of Remontet
et al. has been used in combination with a model-building strategy as pro-
posed by Wynant and Abrahamowicz.
Results: 13,988 FL and 25,320 DLBCL have been studied. An improvement
of the 5-year NS for the more recent year of diagnosis was observed. An
area disparity was evident within the last period [2002-04] with an age-stan-
dardized 5-year NS varying from 61%[54-69] to 75%[69-80] for FL and from
46%[43-50] to 58%[54-62] for DLBCL between Eastern and Northern Europe.
A significant effect of the year on the EMR was observed for all areas and
ages, except in Eastern Europe for DLBCL. The dynamic of the EMR varied
among areas and ages.
Summary and Conclusions: These results identify differences across
Europe. There remained an area-related difference in FL and DLBCL survival
especially in extreme ages (youngest and oldest patients) even if the gap
has reduced in recent years of diagnosis.
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Background: We previously predicted substantial efficiency and productivity
opportunities through the implementation of lean working practices and use
of a Therakos integrated photopheresis system (“Cellex”) for the administra-
tion of extracorporeal photopheresis (ECP). The challenge faced in
2013/2014 was to substantially increase the number of patients receiving
ECP with no increase in staff costs, together with a relocation of the ECP
unit.
Aims: The aim of this study was to implement lean working practices and
the use of integrated ECP systems to increase the number of patients who
could be treated without increasing nursing staff.
Methods: We implemented lean working practices and changed the config-
uration of our instruments to two Therakos “XTS” photopheresis systems and
four Therakos “Cellex” systems. This new process was implemented in the
St. Thomas ECP unit a few weeks before moving to Guys Hospital. We then
underwent a 5-day kaizen (rapid improvement) event shortly after moving
into the new ECP unit at Guys Hospital. We implemented a standardized
planning concept offering fixed appointment times depending on the type of
machine required and whether the patient could tolerate double-needle or
single-needle mode (Table 1). This standard approach enabled us to fill
vacant slots by telephoning “reserve” patients 1-2 days in advance, ensuring
that all slots were being filled and thus utilizing as much of our capacity as
possible.
Table 1.
Location     Treatment               Mon          Tue          Wed         Thu           Fri           Sat      Capacity  Capacity    Nurse       WTE
                                             11:30-     08:00-     08:00-     08:00-     08:00-     08:00-    Needed      Given
                                              20:00      20:00      20:00      20:00      20:00      18:00
Guys Hospital ECP unit
                “XTS” system            12:30       12:30      12:30      12:30       12:30      12:30        526          520           1          0.61
                     15:30                 15:30       15:30      15:30
              “Cellex” system          12:30       12:30                                                                329          312                       0.24
              (single-needle)           15:30       15:30
              “Cellex” system          12:30       09:00      09:00      09:00       09:00      09:00       2993       3016      2, 3, 4      2.63
             (double-needle)          15:30       12:30      12:30      12:30       12:30      12:30
                                                              15:30      15:30      15:30       15:30      15:30
Results: The weekly average increased from 43 treatments per week in 2012
to 63 per week in 2014-a 50% increase. A trend analysis was performed for
treatment numbers versus week number in the period May 2013 to May 2014
as illustrated in the plot below (Figure 1).
Summary and Conclusions: Implementation of these new practices has
meant that we are able to treat significantly more patients in the unit with the
same number of nurses. We continue to see an upward trend in treatment
numbers. We were able to eliminate Sunday sessions and treat the extra
patients in a 6-day week with the same number of nurses. The elimination of
working on Sunday has released funding towards the cost for the extra treat-
ments.
Figure 1. Trend analysis plot for ECP volumes at Guys Hospital May 2013-
May 2014.
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Background: A Comprehensive Geriatric Assessment (CGA) is currently
recommended to detect vulnerable cancer patients for whom chemotherapy
may lead to severe impairment on functionality, quality of life, or survival.
Although CGA is useful for a better management of older patients with unsus-
pected problems, little is known about the reliability of CGA to optimize the
therapeutic approach in patients with malignant hemopathies. Particularly,
the prognostic value of neuro-psychological parameters such as cognition,
in older patients with hematological malignancies admitted to receive
chemotherapy, are poorly investigated.
Aims: To assess in “clinically fit” (go-go and slow-go) patients with malignant
hemopathies, the reliability of different clinical parameters of CGA as a prog-
nostic tool to predict one-year overall survival (OS) treatment-related toxicity
and loss of autonomy after treatment. 
Methods: Between October 2010 and June 2013, CGA was proposed to 107
consecutive older patients (65+-yrs) with hematological malignancies, admit-
ted to the hospital and judged clinically fit, by their refereeing physicians, to
receive chemotherapy. An initial full-dose or reduced-dose chemotherapy
has been administrated to them according to a multidisciplinary team deci-
sion. Nutritional disorder was screened by MNA (<23.5). Psychological dis-
order was assessed by GDS-4 (>1) and HADS (>13) and cognitive impair-
ment by MMS (<27) and MoCA (<26). Log-rank test and multivariate Cox
proportional hazards model were used to predict one-year OS.
Results: Ninety patients -completely assessed by CGA- were evaluable for
one year OS; Non Hodgkin’s Lymphoma (53%), Multiple myeloma (16%),
Acute Myeloid Leukemia and Myelodysplastic Syndrome (15%), Chronic Lym-
phocytic Leukemia (14%) and Myeloproliferative Neoplasms (2%). Median
age is 74 (65-89) yrs. 56% are males. 80% were considered as “vulnerable”
when evaluated with CGA (≥2 impairments). During the first year of follow-
up, 28% (n=22) of older patients treated for hematological malignancies died.
Although the leading cause of death (82%) was the disease progression,
18% died due to toxicity related to treatment. Retrospectively, the CGA total
score (≥2 impairments) had no impact on the initial treatment choice and
was not predictive for one-year OS. In univariate analysis, nutritional
(p=0.946) and psychological disorders (p=0.884) were not associated with
OS. In a multivariate analysis, age (p=0.015; HR=1.1) and diagnosis
(p<0.001; HR=7.2), were major prognostic factors of OS. Regarding specific
CGA measures, the multivariate analysis showed that mild cognitive impair-
ment (evaluated with a MMS<27 and a MoCA<26) had the strongest prog-
nostic value (p=0.03; HR=3.6) for OS. The loss of autonomy after treatment
is still under-evaluation. In our “clinically fit” hematological patients, a poor
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CGA score does not translate into a worse survival, more likely because of
two reasons: the disease itself remains the major cause of death and malnu-
trition, a reversible impairment after effective treatments, strongly impacts
CGA. The objective of an effective screening tool should thus be the identifi-
cation of the population who could benefit from optimal treatment combined
with a comprehensive management of unsuspected specific problems.
Summary and Conclusions: Our observations in “clinically fit” older hema-
tological patients suggest that 1) the major cause of death is the disease
itself and the priority should be to identify all patients susceptible to benefit
from full dose chemotherapy 2) an abnormal CGA are not specific enough
and does not translate into a worse one year OS 3) some specific measures
factors in the CGA (such as cognitive impairment) are highly correlated with
one-year OS 4) age remain a continuous variable with a poor prognostic fac-
tor. Prospective trials are needed to further determine whether the combina-
tion of optimal treatment and improved management of impaired functions,
including cognition, could lead to a better OS.
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NOA PROGRAM INFLUENCING SURVIVAL IN CML PATIENTS FROM
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Background: Patient assistance program are a huge boon in the resource
constraint settings in aiding patients to combat malignant disorders from public
perspective. The average daily income in these countries is much lower than
the daily expenditure of the anticancer medication. The Novartis Oncology
Access (NOA) is a patient-access program sponsored by Novartis Oncology
and administered by The Max Foundation (MAX) that provides imatinib free of
charge to patients of chronic myeloid leukemia (CML) in resource-restricted
countries who are not able to afford this treatment. There is no study to-date
from India on the efficacy of this program. Also most studies from other coun-
tries/MAX have no control population for comparison.
Aims: To assess the role of NOA program on survival of CML patients. Our
objectives were to study OS in all CML patients enrolled either in NOA pro-
gram or on self-purchased medication. Subset analysis to study the role in
AYA, middle aged & elderly CML patients was also done. 
Methods: It is a single centre observational study from North India. Patients
of both sexes with diagnosed CML (ELN guidelines) aged more than 12 years
were included. Total of 1677 case files were screened of which 1241 patients
with complete records were analysed. This included 263 adolescents and
young adults (AYA) and 168 elderly CML patients. The patients were divided
into two arms-NOA arm (wherein patient was supplied with lifetime free med-
ication) and self-purchased (SP) arm (patients procured medication on own
expenses). Survival was analysed using telephonic calls, hospital records
and OPD visits over the last 3 months. Statistical analysis was done using
SPSS version 16.0.
Results: Amongst 1241 patients 67% of the patients were in the NOA arm.
The two groups were not significantly different in mean age, median delay in
diagnosis, median duration of hydrea therapy and median delay in starting
imatinib (Table 1). The average monthly income was significantly (p-0.001)
higher in SP arm (≈109€) than NOA arm (≈57€). The average cost for CML
therapy in our settings is approximately 60€ per month. The mean duration
of therapy was significantly (p-0.001) higher in NOA arm (1533.16+1055.35)
than SP arm (1080.53+982.82). Frequency of change in dose/type TKI was
significantly lower amongst patients under NOA (p<0.001). Cumulative Sur-
vival was much better in patients in NOA arm than SP arm, with the difference
being statistically significant (p<0.001) with the effect being pronounced only
in AYA-CML and adult CML, but not in elderly CML (Figure 1).
Table 1: Baseline characterstics.
Variable                                                               NOA                Not on NOA/Self Purchased    P value
                                                                         Mean             SD               Mean            SD
Age (years)                                                           38.59          19.12             41.45          19.55            0.108
Income (INR)                                                      4419.09      4721.14         8449.86     8508.875         0.001
Median Duration of Hydrea therapy (months)         7.0468         17.19             8.039          30.84            0.685
Delay in starting Imatinib from Diagnosis (days)     280.53        695.56           248.56        693.09           0.625
Delay in Diagnosis (days)                                     176.39       298.815          160.84       384.821          0.634
Mean Duration of Therapy (days)                          1533.16      1055.35         1080.53       982.82           0.001
Mean OS (days)                                                  1695.75      1204.21         1251.43     1113.186         0.001
Summary and Conclusions: Patient assistance programs being carried
out in a systematic manner would help in improving the outcomes of CML
patients. The retrospective nature of the study and uncertainty of exact com-
pliance of the patients were the limitations of the study. This study empha-




A MULTI-CENTRE COST COMPARISON OF INTEGRATED VERSUS “OFF-
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Background: A multicenter cost-analysis study of extracorporeal photopheresis
(ECP) providers at four centers was carried out to compare “off-line” and inte-
grated systems. Patients in these hospitals are treated with ECP for acute and
chronic graft versus host disease (GvHD), cutaneous T-cell lymphoma (CTCL),
solid organ transplantations, and various dermatological disorders. All four cen-
ters have the option of performing ECP using either an integrated system or by
using a selection of off-line systems.
The integrated Therakos photopheresis system delivers ECP via a unique one-
step process where the patient remains connected to the system for treatment.
This eliminates the risk of improper infusion and also alleviates the need for a
crossmatch of re-infused materials. The off-line system requires the removal
and isolation of the collected cells from the patient to a regulated cell manipu-
lation facility for further processing. According to European Guidelines for min-
imal cell manipulation, off-line procedures should be performed in a class A
laminar airflow cabinet located in a class D laboratory. During off-line” proce-
dures, cultures of the product for aerobic, anaerobic bacteria, and fungi should
be done immediately before reinfusion into the patient.
Aims: The aim of this study was to compare the cost of performing ECP using
the off-line systems versus the Therakos integrated system.
Methods: The additional costs of materials, overhead, and labor incurred by
use of the off-line system were considered in this study. For a meaningful cost
comparison it is important not to be misled by comparing the costs of off-line
kits and Therakos system procedural kits alone.
Results: The average cost of performing ECP using the off-line systems was
more expensive than the Therakos integrated system (€1,349.01 vs €1,285.81)
(Table 1).
Table 1.
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Summary and Conclusions: The substantial reduction in patient treatment
times offered by the Therakos integrated system improves patient quality of
life, increases staff capacity to undertake additional treatments, and decreases
bed retention time. In all four centers only one treatment per day can be carried
out per bed using the off-line systems compared to three treatments per day
per bed using the integrated system. The cost of performing ECP using the
Therakos integrated system is comparable to the cost of treatments using the
off-line systems.
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SICKLE CELL DISEASE
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1Lebanese American University, 2Lebanese University, Beirut, 3Nini Hospital,
Tripoli, Lebanon, 4University of Texas M D Anderson Cancer Center, Houston,
United States
Background: Sickle Cell Disease (SCD) is a common genetic disorder asso-
ciated with serious acute and chronic complications necessitating frequent hos-
pitalizations and heavily impacting on quality of life (QoL) of affected patients.
To date, there are no data on QoL of Lebanese patients with SCD. 
Aims: To assess Health Related QoL (HRQoL) of children with SCD through
self and proxy reporting of the PedsQL (4.0) questionnaire, compare it with
that of age matched healthy controls, and identify socio-demographic and clin-
ical factors that contribute to variation of QoL in SCD.
Methods: SCD children (age range 8-18 years) with no evidence of end organ
damage, stroke or mental disease from 2 comprehensive SCD centers in Northern
Lebanon and Beirut and healthy age sex-matched siblings (age range 8-16 years)
were included in this study. PedsQL4.0 was presented to the groups and general,
physical and psychosocial scores were calculated as previously described.
Results: 47 SCD patients (66% SS, 32% SB0, 2% SD, 49% males, 51% females,
mean age 12.3±3 years) and 30 sibling controls (53% males, 47% females, mean
age 12.6±2.3 years) were given the PedsQL (4.0) questionnaire. All patients had
received at least one transfusion. 93%, 74%, 59% of patients received folic acid,
penicillin or hydroxyurea (HU), respectively. Mean general (54±20 vs 78±13),
physical (49±25 vs 79±13) and psychosocial (57±19 vs 77±14) scores were sig-
nificantly lower in patients than their age-matched siblings (p<0.0001 for all three).
Patients receiving folic acid had significantly higher levels for general (56±18 vs
28±7), physical (51±24 vs 19±9) and psychosocial (59±19 vs 33±12) scores
(p<0.05). More females than males had a general score below the median (medi-
an=55.4) (p<0.05). There was a positive correlation between patients’ general
scores and each of psychosocial score and number of siblings (r=0.9, p<0.05).
Physical score was positively correlated with hemoglobin at presentation, age at
first transfusion and the number of siblings of the patients (r=0.9, p <0.05). Psy-
chosocial score was positively correlated with the age at first acute chest syn-
drome event (r=0.9, p<0.05). No significant impact of pain, hospitalization rate,
joint necrosis, osteomyelitis, total number of transfusions, HU or penicillin intake
on HRQoL scores could be detected. 
Summary and Conclusions: Lebanese children with SCD have significantly
decreased HRQoL compared to their siblings for all scores. The tendency for
higher scores among males compared to females patients may be attributed to
the more favorable nature of boys in Lebanese society. The strong association
between FA treatment and higher scores underscore the beneficial impact of this
inexpensive medication. The lack of impact of HU on HRQoL is surprising and
may be related to the small sample size and the suboptimal compliance with this
treatment in this patient group. Conclusively, the staggering difference among
patients and siblings warrants a strong intervention to improve patients’ QoL by
advising caregivers and parents about the importance of addressing early the
multiple psychosocial and physical challenges that patients with SCD face.
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IMPACT OF CARFILZOMIB ON HEALTH-RELATED QUALITY OF LIFE:
RESULTS FROM A PHASE 2 POST-HOC ANALYSIS OF SINGLE-AGENT
CARFILZOMIB (PX-171-003-A1) IN PATIENTS WITH RELAPSED AND
REFRACTORY MULTIPLE MYELOMA
D.S. Siegel1,* T. Martin2, M. Wang3, R. Vij4, A.J. Jakubowiak5, S. Lonial6,
S. Trudel7, K. Cocks8, D. Revicki9, E. Bacci10, S. Panjabi11, R.Z. Orlowski3,
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versity of California at San Francisco, San Francisco, 3MD Anderson Cancer
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Background: In the single-arm phase 2 study PX-171-003-A1
(NCT00511238), heavily pretreated patients (pts; median 5 prior lines of ther-
apy) with relapsed and refractory multiple myeloma (RRMM) who received sin-
gle-agent carfilzomib achieved meaningful clinical benefit as evidenced by
durable responses (Siegel et al., Blood 2012;120:2817-25). In addition, the tol-
erability profile of carfilzomib was found to be acceptable. In pts with RRMM
who have active symptoms, treatment-related toxicities, and multiple comor-
bidities, it is important to preserve health-related quality of life (HRQL) while
improving clinical outcomes.
Aims: To assess HRQL in pts treated with single-agent carfilzomib via the
Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-
Neurotoxicity (FACT/GOG-Ntx) questionnaire.
Methods: Pts with RRMM (N=266) previously treated with bortezomib and an
immunomodulatory agent (thalidomide or lenalidomide) were enrolled in the
single -arm phase 2 study PX-171-003-A1. Pts completed the FACT/GOG-Ntx
at screening and on day 1 of cycles 3, 5, 7, 9, and 11 and at the end of treatment
(EOT) visit. Minimally important difference (MID) thresholds for changes over
time (2 points for physical wellbeing [PWB], social wellbeing [SWB], emotional
wellbeing [EWB], and functional wellbeing [FWB]; 3 points for total FACT-G;
3.3 for the neurotoxicity [Ntx] subscale) were used to establish the proportion
of pts who improved, were stable, or worsened at each assessment. Longitu-
dinal effect sizes were calculated as change from baseline divided by the
pooled standard deviation. Change from baseline to best response in HRQL
was evaluated by response group.
Results: Median pt age was 63 years old (range, 37-87); 58% were male. Most
pts (80%) had progressed during their most recent therapy or within 60 days of
completing treatment. Pts who completed the FACT/GOG-NTX from screening
to cycle 3 dropped from 84.2% to 47.0% overall; however, expected completion
rate (pts alive and on treatment) was high throughout the study (≥72.3%). The
majority (n=169, 64%) had a HRQL assessment completed at baseline and dur-
ing at least 1 other assessment period. The majority of pts were considered
stable or improved at each assessment point over the study period using the
pre-specified MIDs. Specifically, the proportion who were stable or improved was
greatest for SWB (83% to 89%), EWB (79% to 89%), and Ntx domains (80% to
86%). A smaller majority of pts were stable or improved on the PWB (70% to
79%) and FWB (64% to 73%) domains. Longitudinal effect sizes showed some
small but clinically relevant improvements in EWB (0.26 to 0.39 from cycle 5)
and SWB (0.13, 0.20, and 0.10 at cycles 3, 7, and EOT, respectively). PWB had
declined moderately (-0.37) by the EOT visit, and there was a small reduction in
FWB at cycle 3 (-0.14) and EOT (-0.26). Pts with a partial response (PR) or better
had improvements in HRQL across all domains (Figure 1). Pts with stable disease
(SD)/minimal response (MR) or progressive disease (PD) had declining HRQL
on PWB and FWB domains. Pts with PD also demonstrated a decline on EWB
domain; SWB was not correlated with response.
Figure 1. FACT/GOG-Ntx acores by best response.
Summary and Conclusions: For the majority of pts with available assess-
ments, HRQL was maintained following treatment with carfilzomib. HRQL
scores generally correlated with response to treatment. The effect of carfilzomib
on HRQL is being assessed in randomised phase 3 trials.
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PATIENTS’ PERCEPTIONS OF RECEIVING A DIAGNOSIS OF A HAEMA-
TOLOGICAL MALIGNANCY, FOLLOWING THE SPIKES PROTOCOL
L. Dixon1,*
1Liverpool Medical School, Liverpool, United Kingdom
Background: Sharing potentially devastating news with a patient is often con-
sidered the most difficult task of a healthcare professional. The quality of the
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delivery of the bad news can have a direct impact on patients’ emotions and
adjustment to the condition; therefore doctors have a great responsibility.
Aims: The main aim of this study was to learn the theory behind breaking
bad news and discover patients’ perceptions of receiving bad news in the
haematology setting; including what they thought was done well and areas
that could be improved. The study was designed following the SPIKES pro-
tocol because it comprises the basic principles and provides a structure.
There is an ever increasing amount of literature available surrounding this
topic. Yet, there is a noticeable lack of research concentrating on the experi-
ence from the patient’s view.
Methods: A questionnaire was written based on the steps of the SPIKES model.
The questions were divided into sections. The first section, titled ‘patient demo-
graphics’, aimed to elicit personal information without comprising anonymity.
The next six sections represented the six steps of the SPIKES model. There
were a mixture of qualitative responses and multiple choice answers; however
the participants were always able to give qualitative responses if they felt there
were no multiple choice answers that represented their views. The participants
were asked the questions by interviewers, who documented their answers. The
interviewers were also available to explain the questions to the participants.
The questionnaire was attempted by 20 participants who were in/out patients
at Arrowe Park Hospital. The inclusion criteria for participation comprised a
diagnosis of a haematological malignant disease and treatment for the disease
at this hospital. Additionally, it was essential the patients gave voluntary and
informed verbal consent.
Results: Due to help from the interviewers, all of the 20 questionnaires attempt-
ed were completed and used in this study. The participants rated their experi-
ence: 55% said ‘excellent’; 25% reported ‘good’; 5% said ‘satisfactory’ and 15%
stated ‘poor’. ‘Poor’ was rated more commonly by women and participants
aged 45-64. Those who received their diagnosis within the past few years tend-
ed to have a better consultation. The main differences between the ‘excellent’
and ‘poor’ consultations include the doctor’s sensitivity and the patients having
their understanding checked. Problem areas include only 35% of patients were
asked their existing knowledge and 85% of consultations failed to discuss the
impact of the diagnosis on daily life. 
Summary and Conclusions: Overall, most patients were happy with their
consultation. The areas patients particularly praised were the set-up of the
consultation and how sensitively the news was delivered. The knowledge
section was done well generally, however it showed the greatest difference
between ‘poor’ and ‘excellent’ consultations; therefore should be improved
to standardise the experience. Other areas patients felt needed improvement
include the doctor determining the patient’s existing knowledge and what they
would like to know. With a poorer prognosis, doctors should work on reassur-
ance and conveying hope. Most consultations could be improved by the doc-
tor exploring the effect of the diagnosis on other areas of the patient’s life.
This study was limited by a small sample size and potential recall bias.
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IMPACT OF BURDEN OF THALASSEMIA MAJOR ON HEALTH RELATED
QUALITY OF LIFE IN OMANI CHILDREN
S. Tony1,* M. Sadoon1, M. Zachariah1, P.Y. Wali1
1Child Health, Sultan Qaboos University Hospital, Muscat, Oman
Background: The availability of oral iron chelators and new techniques for
detection of iron overload has markedly improved the prognosis and survival
of patients with beta thalassemia major. The chronic nature of the disease how-
ever poses a significant burden affecting many aspects of patient’s life such as
physical activities, family adjustments and school performance. As chronically
affected children are more vulnerable than adults and are less able to express
their concern, health related quality of life (HRQoL) serves as an important
domain for patients’ perception of the disease on physical and psychosocial
health functions. The impact of the disease on HRQoL in young Omani patients
with thalassemia has not been evaluated earlier.
Aims: We aimed to evaluate the HRQoL in Omani children with thalassemia
major by using Pediatric Quality of Life Inventory (PedsQL) 4.0 domain scores;
assess the domain scores based on child and parent reporting and correlate
the association between demographic-clinical characteristics and total PedsQL
scores in thalassemic children to improve health care.
Methods: This cross-sectional study was done at the pediatric thalassemia day
care center, Sultan Qaboos University Hospital Muscat, Oman from August 2013-
February 2014. All patients with thalassemia major (5-18 years) on regular hyper-
transfusion/chelation were included. Demographic and clinical information were
obtained from electronic patients’ records. The 23-item PedsQL 4.0 Generic Core
Scales with 4 Multidimensional Scales and 3 Summary Scores was used to
assess the HRQoL based on parent and child reports. The 4 Multidimensional
Scales included the essential core domains for pediatric HRQoL measurement:
physical functioning (8 items), emotional functioning (5 items), social functioning
(5 items) and school functioning (5 items). The 3 summary scores included the
physical summary score, psychosocial health summary score and the total scale
score. The physical summary score is the sum of all items of physical functioning
and the psychosocial health summary score is the sum of all items of the emo-
tional functioning, social functioning and school functioning. Appropriate forms in
Arabic were distributed to children (aged 5-7, 8-12 and 13-18 years) and parents.
Questionnaires were completed independently by children above 8 years and
their parents. Children aged 5-7 years were interviewed by nurses.Statistical
analysis was done using SPSS version 19.
Results: Patients’ perception: The mean total summary (73.57±18.46) and the
psychosocial health summary (74.55±18.25) scores were higher than the phys-
ical health summary score (72.26±22.34). School functioning score
(68.05±21.3) was the lowest, followed by emotional (74.85±19.8) and social
functioning (80.72±21.4) scores. Older patients were more likely to have higher
HRQoL compared to their younger counterparts. Caregivers’ perception: Similar
to the patients perception, mean total summary (76.36±19.84) and psychosocial
health summary (78.73±18.45) scores were higher than the physical health
summary score (69.91±19.86). School functioning score was the lowest
(69.71±18.96). In both groups gender had no significant association with
HRQoL scores. Both groups revealed that patients with pre-transfusion Hb lev-
els ≤9.5 and serum ferritin >1000 ng/ml had lower total summary score than
those with Hb levels >9.5 g/dl serum ferritin ≤1000 ng/ml (Table 1).
Table 1. Clinical and demographic characteristics of Omani patients with
thalassemia major.
Summary and Conclusions: Physical health function was more affected than
psychosocial health function from both patients’ and caregivers’ perspective.
School functioning domain was the most affected parameter of the psychosocial
summary score in both child and parent reports. Overall, children with higher
hemoglobin and lower serum ferritin levels scored better reflecting the signifi-
cance of adequate blood transfusion and optimal chelation in these patients.
Patients’ ratings of HRQoL were lower for themselves, suggesting the need for
emotional and social support. This study indicates that there is a need to
address children’s psychosocial and physical requirements in order to improve
their quality of life. There is also a need to improve the ability of schools to
adjust for the special needs of these children for better performance. 
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SYNDROMES WITH SEVERE THROMBOCYTOPENIA TREATED WITH
ELTROMBOPAG: INTERIM RESULTS OF A RANDOMIZED, PLACEBO-
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E.N. Oliva1,* V. Santini2, C. Alati1, G. Sanpaolo3, A. Poloni4, A. Molteni5,
F. Ronco1, G. Palumbo6, A. Marino1, S. Impera7, E. Balleari8, P. Salutari9,
P. Cufari1, I. Santacaterina1, P. Avanzini10, P. Niscola11, A.M. Liberati12,
A. Ricco13, F. Morabito14, A. Cortelezzi15, L. Fianchi16, F. Buccisano17,
P. Fenaux18, O. Beyne-Rauzy19, F. Rodeghiero20, F. Salvi21, R. Latagliata22
1A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, 2Azienda Ospedaliera Univer-
sitaria Careggi, Firenze, 3Ospedale Casa Sollievo della Sofferenza, San Giovanni
haematologica | 2015; 100(s1) | 575
Vienna, Austria, June 11 - 14, 2015
Rotondo, 4Università Politecnica delle Marche, Ancona, 5Ospedale Niguarda,
Milano, 6AOU “Policlinico-V. Emanuele”, 7Ospedale Garibaldi, Catania, 8Univer-
sità degli Studi di Genova, Genova, Genova, 9Ospedale Civile Spirito Santo,
Pescara, 10Arcispedale di Santa Maria Nuova, Reggio Emilia, 11Ospedale San-
t’Eugenio, Roma, 12A.O. Santa Maria, Terni, 13Policlinico Università di Bari, Bari,
14A.O. L’Annunziata, Cosenza, 15IRCCS Ospedale Maggiore Policlinico, Milano,
16Policlinico Gemelli, 17Policlinico Tor Vergata, Roma, Italy, 18Hôpital St Louis,
Paris, 19Pavillon des Médecines CHU Purpan, Toulouse, France, 20Ospedale
San Bortolo, Vicenza, 21A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria,
22Policlinico Umberto I, Università La Sapienza, Roma, Italy
Background: About 10% of low and Intermediate-1 risk (International Prog-
nostic Scoring System, IPSS) patients with myelodysplastic syndromes (MDS)
experience severe thrombocytopenia. Bleeding and the scarce efficacy of
platelet (PLT) transfusions drive research in novel treatments. Eltrombopag is
an oral agonist of the thrombopoetin-receptor (TPO-R) indicated for treating
chronic immune thrombocytopenic purpura. Eltrombopag’s potential in increas-
ing platelet (PLT) counts in lower risk MDS has not been evaluated. We present
interim results on the efficacy of eltrombpag in lower risk MDS with severe
thrombocytopenia in a Phase II, multicentre, prospective, placebo-controlled,
single-blind study (EQoL-MDS).
Aims: Primary endpoints are safety and efficacy of eltrombopag in low and inter-
mediate-1 IPSS risk. Secondary endpoints include changes in quality of life (QoL),
PLT transfusion requirement, incidence and severity of bleeding, and survival. 
Methods: Inclusion criteria are adult age; PLT<30 Gi/L; ECOG performance sta-
tus <4; ineligibility for, relapsed or refractory to other treatments; and naive to
TPO-R agonists. Eltrombopag/placebo (2:1) is administered at a 50 mg daily
starting dose with 50 mg increases every 2 weeks to maximum 300 mg to target
PLT 100 Gi/L. Dose interruptions or reductions are required for PLT >200 Gi/L or
adverse events. PLT response is defined as Response if: 1) baseline PLT>20
Gi/L: absence of bleeding and PLT≥50Gi/L; 2) baseline PLT<20 Gi/L: PLT>20
Gi/L and increase by at least 100%, not due to PLT transfusions; and Complete
Response if PLT≥100 Gi/L and absence of bleeding. QoL scores are evaluated
by the EORTC QLQ-C30 and by the MDS-specific instrument, QOL-E.
Results: Sixty-four patients (34 males) of mean age 67, SD±13 have been
randomized at the time of the present report. Thirteen patients had comorbidi-
ties. ECOG performance status was 0 in 24 cases, 1 in 37 cases, 2 in 2 cases
and 3 in one. According to the WHO 2008 classification, 19 patients had refrac-
tory cytopenia with unilineage dysplasia, 9 had refractory anemia with ringed
sideroblasts, 29 had refractory cytopenia with multilineage dysplasia (of which
15 with ringed sideroblasts), 5 had refractory anemia with excess blasts-1 and
2 were unclassified. IPSS score was low in 21 cases. Mean baseline platelet
(PLT) counts were 16 SD±9 Gi/L, mean hemoglobin levels 10.8 SD±2.6 g/dL
and mean white blood cell count was 5 SD±4 Gi/L. Twenty-two patients were
red blood cell transfusion-dependent. Thirty patients had a WHO bleeding scale
of 1, 6 experienced mild blood loss and 2 gross blood loss; 13 patients had
required PLT transfusions in the 8 weeks prior to randomization. Fifty-seven
patients were evaluable for response at 3 weeks. Of the 29 patients receiving
eltrombopag, 10 (32%) responded versus none in the placebo arm with a medi-
an PLT rise of 46±1 Gi/L (p=0.009). Poor QOL-E scores were registered in the
physical (N=33), functional (N=30), social (N=40), and fatigue (N=20) domains.
Significant improvements in fatigue were perceived by patients in the eltrom-
bopag arm from median QOL-E baseline score 73, interquartile range (IQR)
56-82, to median 81, IQR 62-91, at 3 weeks (p=0.006) and confirmed by the
EORTC QLQ-C30 scores (p=0.012). Though QOL-E social scores did not
change in the eltrombopag arm, there was a significant worsening in the place-
bo arm, from median 50, IQR 6-69, to median 25, IQR 13-50 (p=0.041), not
detected by the EORTC QLQ-C30.
Summary and Conclusions: Early after treatment initiation with eltrombopag,
one third of lower risk MDS patients with severe thrombocytopenia experience
significant improvements in PLT counts accompanied by improvements in fatigue.
E1437
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Background: Acute leukemia is a rare disease. However, it occurs all over the
world and there is a wide disparity in access to treatment. The French National
Health Insurance (NHI) is one of the most generous insurance systems in
Europe in providing care for foreign citizens. Since 2000, the NHI has provided
free health coverage for irregular aliens who have been in France longer than
3 months, called Aide Medicale d’Etat (AME). The AME assumes all health-
care costs with no charges. For foreigners who are in France for less than 3
months, there is also a critical care fund. 
Aims: We have been interested in evaluating the outcome of patients who
presented with acute leukemia while being in France with no health insurance
from a medical, social and economic point of view.
Methods: From 2006 to 2013, 52 irregular aliens with acute leukemia (AL)
were treated in the Saint-Louis Hospital in Paris (France). Medical and social
datas were collected by reading medical files and evaluating the computerized
medical records. To determine the treatment cost for each patient, the hospital
financial unit used an approach based on a day’s costs. In 2013, the cost of
one day of hospitalization in our hematology intensive care unit was €2,816.89
(US $3,764.82). We used an exchange rate of: €1=US $1.34.
Results: Fifty-two patients have been included (31 with an acute myeloid
leukemia (AML) and 21 with an acute lymphoïd leukemia (ALL)). Thirty-five of
them (67%) came in France after a diagnosis of AL in their country and 18
have already been treated before. The other patients already lived in France
illegally without a visa. Median age was 38,5 in the AML group and 31,2 in ALL
group. We first observed that these patients received an appropriate therapy,
based on intensive chemotherapy for the majority of them. For AML, the com-
plete remission (CR) rate was 80.6%, 48% of patients were able to receive
stem cell transplantation with a median time between CR and allogenic stem
cell transplantation (ASCT) of 143 days (71-158). For ALL, CR was 95.2%;
52% of patients were able to receive ASCT with a median time of 142 days
(91-681). Overall, the survival rate was 52% for AML and 50% for ALL, with a
median follow-up of 36 months. All patients were supported socially during
treatment and benefited all from the AME after three months in France. Nev-
ertheless, one-third of the patients lived in precarious conditions during their
treatment (No personal accommodation or socially isolation). Social situations
during treatment did not affect the outcome in our cohort. At follow-up, only 8
patients had returned to their countries. Long-term social data were available
only for 11/24 patients who stayed in France and in CR. They all had regularized
administrative situations but half of them still lived in precarious conditions. We
calculated the median total cost of care for the patients with AML to be €284,389
(US $381,081). The median total cost of care for the patients with ALL was
€314,421 (US $421,325). The economic portion of the study revealed that 38%
of the patients had a hospital debt of €2.16 (US $2.90) million in total.
Summary and Conclusions:Acute leukemia is a rare disease that requires expen-
sive care. There is a wide disparity in access to care, which causes migration to
countries where expensive and innovative agents are available. This study included
52 irregular aliens who benefited from the AME and were treated for acute leukemia
in France. Their outcome was similar to that of other patients with health coverage.
These foreign patients thus benefited from appropriate medical and social man-
agement, but this left a large financial impact on the hospital budget.
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PATIENT CENTERED CANCER SYMPOSIUM
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Background: A diagnosis of cancer leads to significant information require-
ments for patients to make health care decisions. In this situation, many patients
demonstrate a knowledge deficit that can translate to decreased quality of life,
personal life disruptions and decreased compliance. Through analysis of patient
centered cancer symposiums in 2013 and 2014, this deficit can be mitigated
by patient education. This requires identifying knowledge deficits and desired
information topics.
Aims: The aim of this study is to evaluate the impact of a patient centered
cancer symposium on the knowledge level, patient reported symptom burden,
and desired information from a broad population of cancer patients.
Methods: Surveys were distributed to the attendees of the “Living with and
Surviving Cancer” patient symposium in January 2015. Surveys included demo-
graphic data, EORTC QLQ-C30, Linear Analogue Self Assessment (LASA),
as well as a questionnaire evaluating disease comprehension, symptom bur-
den, information sources and desired topics of improved understanding.
Results: 113 patients completed the pre-intervention survey to date. The aver-
age age of participants was 64.7 years with a female predominance (55%).
Disease types included hematologic malignancies (N=50), breast cancer
(N=25), prostate cancer (N=17), bladder/renal cancer (N=10) and other solid
tumors (N=26). The majority of patients were greater than 3 years from cancer
diagnosis (48%). Most patients reported a history of cancer treatment (91%)
and half were undergoing cancer treatment at the time of the symposium (55%).
Most respondents reported “quite a bit” or greater comprehension of their dis-
ease (81%), screening tests (74%), making end of life decisions (73%), disease
monitoring tools (72%), nutrition (70%), disease symptoms (68%), common
side effects of chemotherapy (81%) and radiation therapy (68%), relationship
management (68%), and stress management (66%). The lowest percentage
of understanding (“quite a bit”/”very much”) was reported for financial consid-
erations (50%), fatigue management (49%), symptoms associated with relapse
(46%), pain management (38%), long term side effects of chemotherapy (33%),
and legal issues regarding disease and treatment (14%). A large proportion of
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participants indicated “quite a bit” or greater desire for increased understanding
of their disease (79%), risk factors (78%), screening tests (81%), nutrition
(84%), and symptom management (70%). To manage stress, participants
reported utilizing exercise (65%), spirituality (58%) and anti-anxiety medication
(21%). Similarly, to manage fatigue, participants reported utilizing exercise
(65%), yoga (13%) and spirituality (43%). Participants reported highest level of
stress directly following diagnosis (73%) while fatigue level was highest during
treatment (56%). Mean overall quality of life on the LASA was 7.6 (SD 1.79).
Reported mean overall quality of life in the past week based on the EORTC
QLQ-C30 survey was 5.1 (SD 1.16).
Summary and Conclusions: A cancer diagnosis creates a knowledge deficit
that can complicate the numerous decisions, directly or indirectly, related to
cancer care. Individuals diagnosed with cancer pursue information to improve
their disease understanding and management. A patient centered symposium
can serve as a forum to assess desired information and provide education in
hopes of easing the knowledge discrepancy experienced by patients and pos-
sibly improving their health care experience overall. Further results of cancer
knowledge and the impact of this intervention are being assessed.
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Background: CLL is the most common leukemia in the Western world and is
clinically characterized by peripheral blood B-cell lymphocytosis as well as lym-
phadenopathy, organomegaly, cytopenias and systemic symptoms in advanced
stages. All CLL patients eventually relapse and most require multiple treatment
regimens. Idelalisib, a potent, oral, selective inhibitor of PI3Kδ has been approved,
in combination with rituximab, for the treatment of adult patients with CLL who
have received at least one prior therapy. The cost-effectiveness of this and other
recently approved agents for common indolent lymphoproliferative disorders may
become a socio-economical concern in a large number of countries.
Aims: To assess the cost-effectiveness of idelalisib in combination with ritux-
imab compared to rituximab plus placebo in patients with relapsed/refractory
CLL from a Portuguese societal perspective.
Methods: The international cost-effectiveness model was adapted to Portuguese
health settings and is based around a partitioned survival approach, classifying
patients by survival status (alive/dead), and for those alive by disease status (pre-
or post-progression after prior therapy) (Figure 1). The model begins with 100%
of individuals in the pre-progression state. During any given cycle, patients can
be dead, alive in the pre-progression state or alive in the post-progression state.
Those in the latter state remain there until death (there is no modelling of remis-
sion). Costs and benefits are estimated at fixed time points (cycle length is one
week) for a fixed period of time (lifetime horizon). Costs and outcomes were dis-
counted at a 5% annual rate, as recommended by Portuguese guidelines. One-
way sensitivity analyses assessed the robustness of the model. Clinical efficacy
and safety data were based on the published results from the phase 3 idelalisib
plus rituximab clinical trial. Survival curves were extrapolated using a Weibull
function. Utility data was taken from published evidence. The consumption pattern
of outpatient resources (visits, medication, diagnostic exams, etc) was estimated
based on a geographically representative national expert panel. The experts
responded independently to a questionnaire sent by mail and the responses were
analyzed using the simple average of the values of the responses and excluding
any outliers, using the trimmed mean. The unit costs were taken from Portuguese
legislation and NHS references. Diagnosis-Related Groups database (DRG) for
2013 was used to estimate inpatient costs with adverse events (AE). Inpatient
episodes were identified using the appropriate code (ICD 9-CM).
Figure 1.
Results: Survival gains (measured as life years [LYs] and quality-adjusted life
years [QALYs]) were higher with idelalisib plus rituximab. Combination of ide-
lalisib to rituximab, compared with placebo plus rituximab, led to increased
direct costs (drug acquisition) but reduced the costs related to AEs and end-of-
life costs. Treatment with idelalisib plus rituximab yielded a gain of 2.51 QALYs,
5.16 LYG and an increase of € 82,189 in total cost, resulting in an incremental
cost-effectiveness ratio (ICER) of € 32,702 per QALY and € 15,935 per LY. Uni-
variate analyses showed that ICER values were robust and ranged from €
31,288 to € 34,176 per QALY when different parameters were varied.
Summary and Conclusions: The use of idelalisib plus rituximab in the treat-
ment of relapsed/refractory CLL, compared with rituximab plus placebo, is cost-
effective in Portugal.
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Background: Four years after the arrival of direct-acting anticoagulants onto
the market the controversy over their place in preventing embolisms during
non-valvular AF in relation to classical warfarin continues. A symptom of this
situation is the major differences over penetration of these drugs in different
European countries. A treatment that aimed to replace warfarin based on not
needing periodic controls of the level of anticoagulation has not quite settled.
Aims: In these past years we have encountered several analyses both from the
pharmaceutical industry and healthcare professionals from various disciplines
and public health managers on the efficacy, safety, advantages, disadvantages,
in short, on the efficiency of these drugs. However, this discussion has lacked
the opinion of users on those issues incumbent upon them; comfort, the value of
safety and their position on the cost of drugs both for them and for public health.
Methods: To bridge this gap we have undertaken a survey on the degree of
comfort or discomfort of dicumarinics for 1244 anticoagulated patients with
acenocumarol in the HUA and healthcare centres of this area. Four questions
were put to them on comfort in regard to professional activity and another four
related to family life; after these they were asked to classify their level of comfort
on a scale from 1 to 10. They were also asked whether they would prefer a
drug that does not require controls, whether they would prefer it to be more
expensive for public health, more costly for them and finally, whether it was
less safe in case of serious accidents.
Results: The results reveal that the average comfort level was 7.6 on a scale
from 1, maximum discomfort to 10, total comfort. The level of comfort was less,
6.6, for the youngest patients and in relation to professional activity. A total of
61% of patients would prefer to use a drug that did not require periodic controls.
This percentage would reduce to 47% in case it were more expensive for public
health and 31% more expensive for the patient. Finally, only 3.9% would prefer
this kind of drug if they were less safe in case of a serious accident. The results
show us a highly acceptable level of comfort, and it coincides with the fact that
only 61% would prefer a drug that does not require control. They also show us
that this preference reduces in relation to both the public and private cost and
a clear safety preference on comfort.
Summary and Conclusions: We believe that within the discussion on the
introduction of new anticoagulants, in addition to considering their efficacy, effi-
ciency, compliance and side effects, we would have to sound out the opinion
of users in regard to relevant topics such as the comfort, cost and safety as to
whether or not an antidote exists.
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Background: The AETHERA trial demonstrated that early consolidation treat-
ment with brentuximab vedotin (BV) post-ASCT significantly improved PFS in
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patients with Hodgkin lymphoma (HL). Peripheral neuropathy (PN) was the
most common adverse event. 
Aims: Here, we report the results of the Quality of Life (QoL) component of
the AETHERA trial. 
Methods: After ASCT, 329 patients were randomized to BV 1.8 mg/kg q3wk
or placebo for up to 16 cycles. The EQ-5D questionnaire, including the descrip-
tive system and visual analog scale (VAS), was administered at each cycle,
end of treatment (EOT), and q3 months during follow up until 24 months from
Day 1. Utility index value scores were calculated using the time trade-off (TTO)
method for US- and UK-based value sets. Differences between arms were
compared to the lower bound of an estimated minimally important difference
(MID) in cancer patients (Pickard et al. 2007).
Results: In both arms, EQ-5D scores declined from baseline to 24 months.
Slightly lower scores were seen with BV vs placebo from months 9-18, but this
resolved by end of follow up. In the analysis as randomized (US TTO), the dif-
ference between arms was <0.06 (MID) at all timepoints except for months 15
and 18. Scores by cycle were similar in the 2 arms; mean differences did not
reach the MID threshold. In both arms, scores for patients with progressive
disease (PD) per investigator were lower over time vs patients with no PD. In
the BV arm, scores for patients reporting PN were similar to those who did not.
Similar results were obtained with US- or UK-based value sets. EQ VAS scores
did not show an important difference between arms at any timepoint (Table 1). 
Table 1. US-indexed EQ-5D TTO scores.
Summary and Conclusions: As assessed using the EQ-5D questionnaire,
treatment with BV did not have a sustained impact on QoL in HL patients. In
both arms, decreased QoL was observed after progression. 
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Background: Multiple Myeloma (MM) is a chronic, virtually incurable, neoplastic
condition characterized by increasingly shorter periods of disease remission fol-
lowed by relapse. This reality, taken together with the fact that bone pain is one
of the clinical markers of disease, means that MM patients are frequent users of
palliative and hospice care. Historically, patient deaths took place at home, within
the family setting. However, in developed countries, patients are increasingly
spending their end-of-life twilight in a Hospital ward, often at the cost of a marked
decrease in quality of life. This loss of quality of life (QoL) is compounded by a
loss of dignity when patients die in Emergency Rooms, which are often crowded
and impersonal. 
Aims: This study aims to analyze the end-of-life period in a cohort of MM
patients in a tertiary referral Center in a middle-income country, to better char-
acterize the problem and help develop palliative and hospice care solutions to
improve the QoL and dignity of dying MM patients.
Methods: We analyzed a cohort of 372 MM patients diagnosed between 01-
01-2001 and 12-31-2014, for whom end-of-life data was available.
Results: After a median follow-up of 84.1 months, the median overall survival
for this cohort was 42.1 months. A total of 64.0% of patients died during the fol-
low-up period. Decedents were, on average, half-a-decade older than survivors
(73.4±0.7 vs 68.0±1.0, p<0.001). Among decedents, 29.8% died within the first
12 months of diagnosis, and 2.9% died 10 years (120 months) or more after
diagnosis; there were no differences in the age at death for the two groups, or
the intermediate (12-120 months) cohort (73.6±10.8, 74.9±9.2 and 70.5±12.3
years, respectively, p=NS). We found that 54.6% of patients died within our
tertiary referral Hospital setting (72.9±10.4 years vs 73.9±12.4, p=NS), corre-
sponding to 49.7% in a ward (Hematology or other) and 4.9% in the emergency
room floor, less than 12 hours after presentation to the Hospital. Longer sur-
vivors were more likely to die outside our Center (OS=48.9±122.9 months),
compared to patients dying in situ (30.7±27.9 months, p<0.001). Patients dying
in the ER were over a decade older (79.4±3.8 vs 67.4±9.0 years, p=0.04) than
patients dying in a ward; there was no difference in the length of disease
between the two groups.
Summary and Conclusions: In our real life cohort of patients treated in a ter-
tiary referral Center in a middle-income country, we observed a worrying trend,
with nearly 55% of patients dying away from home, in our Hospital. Notably,
nearly 5% of patients died in the Emergency Room, which is the least desirable
outcome for end-of-life quality and dignity.
While longer experience with the disease (reflected in longer survival) was a
predictor of death outside the Hospital, age failed to associate with in-Hospital
vs out-of-Hospital death. Age did, however, predict for death in the Emergency
Room floor, as opposed to death in the ward, perhaps reflecting a more restrict-
ed systemic reserve and a shorter exitus mortis.
Palliative and hospice care programs should address this reality, and develop
adequate alternatives to serve the population and improve end-of-life in chronic,
painful, neoplastic conditions.
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Background: To our knowledge, there is no published data to inform quality
of life of relapsed or refractory patients with iNHL. In oncology, cost-effective-
ness models often include three health states: progression free survival (PFS),
progressive disease (PD) and death, for which accurate utilities are needed.
Aims: In order to inform future HTA submissions, this study aims to review
and generate utility estimates for patients with previously-treated iNHL.
Methods: First, a literature search was conducted in MEDLINE and on UK HTA
websites. Thirty-two publications were screened and only one relevant study,
published in 2006, was identified (Wild et al). Utilities were estimated at 0.805
(SE=0.018) for PFS and 0.618 (SE=0.056) for PD. This study supported a NICE
STA, and was criticised for its small sample (33 patients had PD). As the retrieved
information was not recent and criticised, additional data collection through a
web-survey including socio-demographic and clinical questions, as well as the
EQ-5D, was considered. Remission was defined as no sign of active disease
and progression defined as a patient experiencing symptoms of the cancer. Given
the burden of iNHL in Europe, the questionnaire was conducted in France, the
United Kingdom, Germany, Italy and Spain. First, an analysis of utilities per health
state (i.e. remission and progression) of patients recruited to our study was per-
formed using the English tariff then, we combined the results of Wild et al. with
those of our study using a Bayesian approach. To do so, means and standard
errors reported by Wild et al. were used to specify prior distributions.
Results: The results of this web-survey show that the quality of life of a patient
with iNHL is impacted by disease progression. 82 patients were included in
the web-survey between the 25th of June 2014 and the 13th of August 2014
(i.e. 18 in Spain, 16 in France, 18 in the UK, 15 in Italy and 15 in Germany). All
of these patients were previously treated, and several of them received several
lines of therapy (i.e. 21 patients received 2 lines of therapy or more). The
patients with the highest utility scores were those who had experienced a remis-
sion of their disease (N=55, u=0.713, SD=0.31). Those patients who had the
lowest utility scores were those in progression (N=27, u=0.506, SD=0.35). The
mean utility increment in patients in remission compared to patients in pro-
gression was 0.207. Compared to Wild et al., this difference is wider in our
analysis (i.e. 0.207 compared to 0.187 in Wild et al.) and patient’ quality of life
was lower in both states of remission and progression as shown by our analy-
sis. Whilst in our study some patients were heavily treated, this information
was not recorded by Wild et al., which might explain the different results.
Summary and Conclusions: In the EU-5, the EQ-5D is a standardised and
validated generic instrument which can be used to elicit utility in iNHL patients.
This study confirmed that patient’ quality of life is higher in disease remission
than in progression. This study also shows how to use Bayesian statistics to
refine estimates already available in the literature, which can be of interest for
study questions related to small patient populations.
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THE IMPACT OF PALLIATIVE RADIOTHERAPY ON QUALITY OF LIFE IN
MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS
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Background: Multiple myeloma (MM) is still an incurable neoplasm of plasma
cells that accounts for approximately 10% of all hematological malignancies.
As a result, the most common clinical features of MM are diffuse osteopenia,
osteolytic bone destructions, pathologic fractures, hypercalcemia and bone
pain resulting from increased osteoclasts activity. Osteolytic lesions are detect-
ed in 70-80% of patients and increase the risk for pathological fractures, spinal
cord compression and requirement for surgery or radiotherapy to bone destruc-
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tions. Skeletal related events impair survival and undermine quality of life (QoL).
Radiotherapy, surgery and analgesics are required in order to overcome pain,
to evoke recalcification and to improve the QoL of MM patients.
Aims: To evaluate the impact of palliative radiotherapy on QoL in patients with
MM and painful bone destructions.
Methods: 46 patients (27 women and 19 men, median age: 69 years) with MM
and painful bone destructions were treated by palliative radiotherapy with 24
weeks follow-up. Patients completed QoL questionnaires including the EORTC
QLQ-C30 version 3.0 and EORTC QLQ-MY20 before treatment and after 4
weeks. The EORTC QLQ-C30 consists of 30 items on five functional scales, nine
symptom scales and a scale of global QoL. The EORTC QLQ-MY20 consists of
20 items on two functional scales and two symptoms scales. The patients’ single
items responses were linearly transformed to scores from 0 to 100 according to
the EORTC scoring rules. High scores on the functional scales indicate a good
functional status of the patient and high scores on global health status indicate a
high QoL, while high scores on symptoms scale indicate poor health condition.
We have analyzed the influence of clinical criteria (sex, age, clinical stage of dis-
ease, Karnofsky index, type of paraprotein, hemoglobin level, irradiated sites,
performed surgery, concurrent chemotherapy, pain score at admission, type of
pain medication) on QoL scores before and after radiotherapy.
Results: Before radiotherapy better functional scores (p=0,017) and lower symp-
toms scores (p=0,042) were observed in men, than in women. Significant higher
symptom scores were observed in patients with bone destructions in the spinal
column (p=0,038 and p=0,028) than in other affected sites. Better global health
status and functional scale were found in patients with mild pain score at the
admission (p=0.023 and p=0.031). Results showed that after radiotherapy emo-
tional function improved in patients older than 65 years (p=0.04), female
(p=0.005), receiving opioid analgesics (p=0.01), without surgery (p=0.008), in
patients with higher level (>82 g/l) of hemoglobin (p=0.007), with Karnofsky
index ≥60 (p=0.006), with concurrent chemotherapy (p=0.01), with severe pain
at admission (p=0.03), with irradiated spinal vertebral (p=0.001), in III clinical
stage of MM (p=0.005). Fatigue decreased in patients with severe pain at admis-
sion (p=0.01). Pain decreased in patients with higher level (>82 g/l) of hemoglo-
bin (p=0.03), with Karnofsky index ≥60 (p=0.05), in III clinical stage of MM
(p=0.05). Cognitive functioning improved in patients with higher level (>82 g/l)
of hemoglobin (p=0.05), with Karnofsky index ≥60 (p=0.02), without concurrent
chemotherapy (p=0.008), with severe pain at admission (p=0.05). Disease symp-
toms decreased in patients without concurrent chemotherapy (p=0.05), in III
clinical stage of MM (p=0.05). Global health status improved in patients with
IgM, IgD and light chains MM (p=0.04), with irradiated spinal vertebral (p=0.009).
Summary and Conclusions: Demographic and clinical criteria influence the
QoL characteristics before radiotherapy. Palliative radiotherapy improves




QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THE TURK-
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Background: Health-related quality of life (HRQoL) has become an important
outcome measurement in hematological malignancies. Different instruments
are introduced to accurately define and scale various quality of life items. QLQ-
MY20 is produced by EORTC to quantify HRQoL in multiple myeloma patients
and validated in different patient populations.
* Spearman correlation coefficients.
Aims: Our aim was to validate the quality of life questionnaire (QLQ)-MY20
instrument in patients with multiple myeloma (MM) in Turkey.
Methods: The Turkish versions of QLQ-C30 v3 and QLQ-MY20 instruments
were applied to patients who were diagnosed and treated at two tertiary centers
in Izmir, Turkey. Validity and reliability tests were performed. Test-retest was
carried out in a selected group of patients.
Results: 86 patients who were diagnosed with MM were included in the study.
Questionnaire completion rates were high, and instrument was well accepted.
Internal consistency tests demonstrated good convergent and divergent validity.
Regarding reliability analysis, cronbach’s α coefficients were all >0.7 for all
scales of both QLQ-C30 and QLQ-MY20 except functional cognitive scale of
QLQ-C30 questionnaire (Table 1).
Summary and Conclusions: Turkish version of QLQ-MY20 questionnaire is
reliable and valid for the assessment of HRQoL in patients with MM and can
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HODGKIN LYMPHOMA PROGRESSION POST AUTOLOGOUS STEM
CELL TRANSPLANT: EVALUATION OF HEALTHCARE RESOURCE UTI-
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Background: Brentuximab vedotin received approval for the treatment of
relapsed/refractory Hodgkin lymphoma (HL) after failure of autologous stem
cell transplant (ASCT) or ≥2 prior therapies. AETHERA is a randomized, dou-
ble-blind, Phase 3 study of brentuximab vedotin and best supportive care
(BSC) versus placebo and BSC for patients at increased risk of HL relapse
or progression following ASCT. Brentuximab vedotin consolidation therapy
post-ASCT substantially improved progression-free survival (PFS) per inde-
pendent review with a median PFS of 43 months in the brentuximab vedotin
arm compared with 24 months in the placebo arm (HR=0.57, P=0.001). The
most common treatment-emergent grade ≥3 adverse events (AEs) were neu-
tropenia (29% brentuximab vedotin vs 10% placebo), peripheral sensory neu-
ropathy (10% vs 1%), thrombocytopenia (4% vs 3%), peripheral motor neu-
ropathy (6% vs 1%), and anemia (4% vs 2%). Treatment discontinuation due
to AEs occurred in 33% vs 6% of patients, and 53 patients died on-study
(17% vs 16%). High risk patients who relapse post-ASCT often report a high
disease and treatment burden requiring healthcare intervention.
Aims: To compare the healthcare resource utilization (HRU) associated with
brentuximab vedotin and placebo for the treatment of patients at risk of HL
progression post-ASCT in the AETHERA trial.
Methods: HL patients aged ≥18 years at high risk for post-ASCT disease
progression, defined as a history of refractory HL, relapse or progression <12
months after frontline therapy, or extranodal involvement at the time of pre-
ASCT relapse, were eligible. Patients were randomized to receive brentux-
imab vedotin 1.8 mg/kg or placebo via IV infusion on day 1 of each 21-day
cycle, for a maximum of 16 cycles or until disease progression. All medical
care encounters that occurred from time of informed consent up to 24 months
post first study treatment were collected for the intent-to-treat population. The
total number of hospitalizations, outpatient visits, and the number of missed
days of work/other activity for patients or caregivers, were summarized by
treatment group.
Results: A total of 329 patients (median age 32 years [range 18-76]; 53%
male) were randomized to receive brentuximab vedotin (n=165) or placebo
(n=164) at 78 sites in the USA and Europe. There were 68 (41%) vs 61 (37%)
patients with ≥1 hospitalization on the brentuximab vedotin vs placebo arms,
respectively, with a total of 176 vs 198 hospitalizations. The hospitalization
rate per patient-year was 0.58 (95% CI: 0.49, 0.67) vs 0.65 (95% CI: 0.56,
0.74). The median duration of stay was 16 vs 26 days per patient. The most
common reasons for hospitalization were disease-related signs and symp-
toms (36% vs 40%) and AEs (29% vs 15%). There were 119 (72%) vs 133
(81%) patients with ≥1 outpatient visit, with a total of 2687 vs 3803 visits. The
haematologica | 2015; 100(s1) | 579
Vienna, Austria, June 11 - 14, 2015
outpatient visit rate per patient-year was 8.84 (95% CI: 8.51, 9.18) vs 12.43
(95% CI: 12.03, 12.82). The most common reasons for outpatient visits were
disease-related signs and symptoms (36% vs 42%) and AEs (22% vs 14%).
There were 85 (52%) vs 94 (57%) patients with ≥1 missed day of work/other
activity, with a median number of 15 vs 26 missed days. There were 7 (4%)
vs 24 (15%) caregivers with ≥1 missed day of work/other activity, with a medi-
an number of 7 vs 16 missed days.
Summary and Conclusions: Preliminary results suggest a trend toward
lower HRU with brentuximab vedotin compared with placebo. These data
prompt further investigation of the economic impact of early consolidation
post-ASCT with brentuximab vedotin in HL.
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ROW ANALYSIS: AN AUDIT OF SAMPLING TECHNIQUE AND SPE-
CIALISED HAEMATOLOGICAL TEST REQUESTING AT A HAEMATO-
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Background: There is little published data on ‘real-life’ practice of bone mar-
row assessment in haematology, particularly in publicly funded healthcare
systems where budgetary restraints and demonstrable cost-effectiveness
must be applied to high-quality evidence-based practice. The British Com-
mittee on Standards in Haematology (BCSH) outlines standards for biopsy
quality and additional specalised haematological testing (cytogenetics by flu-
orescent in-situ hybridisation (FISH) and G-banding, immunophenotyping by
flow cytometry). As knowledge of the prognostic implications of specialised
testing increases, there is greater tendency to order more costly tests (cur-
rently £200/€280 per immunophenotyping sample, £110/€150 for G-banding
to £441/€605 for myeloma FISH panel) without influencing clinical manage-
ment. 
Aims: The objective of this audit was to assess current practice in our busy
haemato-oncology unit against national guidelines and determine a pragmatic
approach to bone marrow assessment which is equitable, evidence-based
and deliverable within a restricted budget. 
Methods: Bone marrow reports on consecutive procedures undertaken
between January and October 2014 were examined (n=365) using the hos-
pital’s pathology database. Inadequacy of aspirate was defined by a report
stating ‘haemodilute and aparticulate’. 
Results: Indications for bone marrow included 23% acute leukaemia (AL)
diagnosis/response assessment, 21% cytopenias/suspected myelodysplasia
(MDS), 16% suspected multiple myeloma (MM), 15% lymphoma staging and
6% myeloproliferative disease. 19% aspirates were unfit for morphological
analysis. Trephine lengths were recorded in 82% of cases (range 1-38mm,
median 16mm) with only 50% exceeding the BCSH minimum standard
(16mm) and 11% deemed entirely inadequate for assessment. Approximately
£65,000/€90,000 in total was spent on specialised testing: £15,000/€20,000
on immunophenotyping and £50,000/€70,000 on cytogenetics. 34% of cases
had incorrect specialised tests sent. 20% and 13% of diagnostic AL samples
were sent without immunophenotyping and cytogenetics respectively. Cyto-
genetics and immunophenotyping were sent on 76% and 21% of MDS
requests and 63% and 14% of MM requests respectively: both recommended
in BCSH guidelines but rarely contributing to clinical management. 15% of
lymphoma staging requests were submitted for immunophenotyping and 9%
for cytogenetics without additional contribution to diagnosis. 
Summary and Conclusions: Our study suggests that special tests are fre-
quently missed or inappropriately requested with clinical and cost implica-
tions: an analysis against which there is little published data to compare.
Sample quality is often suboptimal and while often unavoidable highlights a
need for continuous assessment of operator skill. Current national and inter-
national guidelines increasingly request more specialised tests against the
backdrop of questionable clinical value and increasing financial restraints,
while national and international bodies recommend we ‘choose wisely’. This
challenges practicing clinicians to rationalise evidence-based best care, con-
sensual guidelines and budgetary contraints in an age of increasing scientific
discovery but with spiralling costs and increased scrutiny of healthcare eco-
nomics. 
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BLOOD AND PLATELET TRANSFUSIONS FOR HAEMATOLOGY
PATIENTS REQUIRING PALLIATIVE CARE: WHAT CAN UK HOSPICES
PROVIDE?
R. Ackroyd1, S. Ackroyd2,* R. Sheils3
1Palliative Medicine, Calderdale and Huddersfield NHS foundation Trust, Hal-
ifax, 2Haematology, Bradford Royal Infirmary, Bradford, 3Palliative Medicine,
Overgate Hospice, Halifax, United Kingdom
Background: There is increasing evidence that haematology patients benefit
from palliative care services. Often haematology patients require more inten-
sive supportive treatment including IV antibiotics, blood and platelet transfu-
sions, for symptom control and to maintain their quality of life, even near the
end of life. Specialist palliative care services in the UK may not always provide
these supportive treatments and this may be a barrier to haematology
patients needing palliative care.
Aims: To identify what blood products UK hospices are able to provide for
haematology patients
Methods: A mixed categorical and free text questionnaire was sent via email
to all Medical directors of adult hospices in the UK and Ireland with inpatient
services. 168 Questionnaires were sent.
Results: The response rate was 42% (n=70). Please see Table 1.
Table 1.
Provision of transfusion                                           Yes          Sometimes         No
RED CELL transfusion 9am-5pm, Monday-Friday      62 (94%)         4 (6%)            n/a
RED CELL transfusion out of hours                          15 (23%)       30 (45%)     21 (32%)
PLATELET transfusions 9am-5pm, Monday-Friday     38 (58%)         4 (6%)       24 (36%)
PLATELET transfusions out of hours                         11 (24%)       13 (28%)     22 (48%)
Summary and Conclusions: There was variation in what services are
offered by the palliative care units. Medical Staff being non-resident had impli-
cations for whether transfusions could be done out of hours. Although the
same training is required to administer red cells and platelets, more units
were able to provide red cell transfusions. There were misconceptions regard-
ing timing of platelet transfusions, storage and need for continuous agitation.
With further education hospices that provide red cell transfusions should be
able to provide platelet transfusions. Close working between haematologists
and palliative care with regard to transfusion decisions is important to embed
these supportive treatments in palliative care practice which ultimately can
improve patient care.
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COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAVIVUDINE
FOR PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI)
IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING
CHEMOTHERAPY
C. Cerchione1,* A. De Renzo1, M. Masarone2, C. Cimmino1, M. Raimondo1,
G. Signoriello3, M. Notarangelo1, G. Giagnuolo1, M. Persico2, F. Pane1
1Hematology, AOU “Federico II”, Napoli, 2Hepatology, Università di Salerno,
Salerno, 3Department of Statistical Sciences, Second University, Napoli, Italy
Background: Occult HBV infection (OBI) is defined by the persistence of
HBV in the liver without serum HBsAg and HBV-DNA. It represents a life
threatening event during immunosuppressive chemotherapies. An OBI occurs
in approximately 18% of HBcAb+ patients. International guidelines suggest
surveillance for HBV markers in immunosuppressed patients, in particular
monoclonal antibodies. In our study, the prevalence of OBI reactivation in
Non-Hodgkin Lymphoma (NHL), in 498 NHL patients in our centre of Southern
Italy, was 10.42% in HBcAb+ HBsAb- patients. In this work, we want to per-
form a cost-effectiveness analysis regarding the use of Lamivudine for the
prevention of reactivation in OBI in patients with Non-Hodgkin Lymphoma
undergoing chemotherapy with or without Rituximab. In fact, considering
guidelines and literature, universal prophylaxis should have been applied to
all HBcAb positive HBsAg negative patient. A cost-benefit issue arises : is it
more cost-effective to treat all the HBcAb positive HBsAg negative patients
with Lamivudine to prevent the OBI reactivation occurrence in a small quote
of them, or may it be more effective a “wait and see” protocol? 
Aims: Our idea was to perform a cost-effectiveness analysis, comparing the
costs of prophylaxis of an eventual HBV reactivation and the “monitoring”
approach that was used in our patient based on the international guidelines. 
Methods: We calculated the cost of prophylaxis with Lamivudine in a time
interval of twelve months, which encompasses the time of a standard Ritux-
imab-containing chemotherapeutic protocol and a minimum time of follow-
up. It has to be noticed that, very often, NHL patients need more than one
chemotherapy cycle to obtain NHL remission, and, sometimes, if they do not
obtain a complete remission, undergo to long-term “maintenance” treatments
with Rituximab. These patients (HBcAb positive) are at high risk of HBV reac-
tivations, due to long times of immunosuppression.
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Table 1.
Results: Nevertheless, even if our calculations underestimated the costs of
prophylaxis, the “monitoring approach” resulted cost- effective. Moreover, even
though in our series no serious events in terms of morbidity and/or mortality
occurred, in other literature reports a monitoring approach did not guarantee
patients survival. These detrimental results could be ascribed to the delayed
start of Lamivudine treatment if the monitoring is not adequately strict. Also, it
has been reported that performing only the transaminase monitoring should
not be acceptable to prevent severe reactivations. Our monitoring approach
resulted efficacious probably because of the monthly ALT assay was strictly
observed Table 1.
Summary and Conclusions: We report an advantage in the “monitoring”
approach even if, due to the retrospective nature of our study, we cannot draw
any firm conclusion on which should be the best approach (universal prophy-
laxis vs monthly ALT monitoring). A randomized controlled trial might be needed
to properly address this issue.
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DEMAND MANAGEMENT OF ANALYTICAL REQUEST IN ERYTHROPATH-
OGY SECTION OF A TERTIARY HOSPITAL
M.D.L.O. Abio Calvete1,* M.E. Botón Contreras1, M.C. Fernández Jimenez1,
J. Cuesta Tovar1, M.J. Murga Fernández1
1Hematología y Hemoterapia, Hospital Virgen de la Salud, Toledo, Spain
Background: The analytical requests to clinical laboratory have experienced
in the latest years changes increasing the amount of them. During 2010-2012
a significant increasing of the number of requests for erythroid maturation fac-
tors and of the number of repetitions of these factors in the same patient during
the same year were observed, coming from primary care centers (PCC). Given
this, an intervention was performed for a more efficient management of demand;
a corrective action was established from November 2011 on, to reduce the
number of unnecessary requests.
Aims: 1) Reduce the number of unnecessary requests for erythroid maturation
factors (ferritin, vitamin B12 and folate), without limiting the ability to request
testing by physicians, so no analysis of any of the requests made was denied.
2) Encourage the ordering physician awareness of the usefulness of certain
tests, the expenses incurred and diagnostic clinical advantage provided.
Table 1.
Requests                                          2010              2012              2013              2014
Ferritin                                             94876           126708          108045          107436
Folate                                               11685             32199             49278             47657
Cobalamin                                        11677             35856             51882             50069
Figure 1.
Methods: A descriptive and analytical study was conducted within 2 years
after developing corrective action (01/11/12-31/10/14). Requests of matura-
tional factors have been analyzed in the population covered by our center
(health area: 483 422 inhabitants), taking the total number of requests from
PCC of each test and the number of repetitions of them on the same patient
with a normal prior determination. This measure was taken to inform the
physician that with a normal result, there is no need to repeat the determina-
tion of these factors unless there are clinical changes that warrant. To that
end a comment was added next to the result when it was within normal limits:
“normal ferric profile (or cobalamin or folate). Repeat within one year only if
there are alterations in blood count, the patient is treated with iron, folate or
cobalamin, if clinical and/or laboratory changes or (in the case of ferric profile)
family history and/or hemochromatosis or hyperferritinemia in the patient”.
Also we have conducted briefings to primary care physicians about the meas-
ure and its results.
Results: After establishing the tool indicated at the end of 2011, a gradual
reduction in the total number of requests was observed (Table 1), but espe-
cially in the number of determinations to patients who had normal previous
result, especially if we consider the cut of 3 or more normal test. Note that no
longer exist patients with more than 5 determinations made in one year, as it
happened before (Figure 1). During the first year, a significant increase in
the number of requests for folate and cobalamin was observed. This fact
seems justified because in 2012 these tests were added to the computerised
requests of the PCC. Previously the physician had to remember to include it
and write it manually. Ferritin already existed in the prior computer application
and therefore the same effect doesn’t occur. Despite this increase, an effect
of the intervention can be observed since the first year: the number of patients
with 4 or more normal determinations decreased and afterwards the total
number of requests remains stable and the number of repeats with normal
previous result decreased as well.
Summary and Conclusions: The measure produced a greater decrease in
the total number of requests and subsequent repeats. The decrease was
more pronounced in the first year of its establishment. Subsequently seems
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to remain effective in controlling demand and thus health spending, so we
believe this tool should be maintained in the coming years to efficiently man-
age the requests for erythroid maturation factors.
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MICRO-COSTING STUDY OF RITUXIMAB SUBCUTANEOUS INJECTION
VERSUS INTRAVENOUS INFUSION IN DUTCH SETTING
J. Mihajlović1,2,* P. Bax1, E. van Breugel1, H.M. Blommestein3, M. Hoogen-
doorn4, W. Hospes5,6, M.J. Postma1,7
1Unit of PharmacoEpidemiology & Pharmacoeconomics, University of
Groningen, Groningen, Netherlands, 2Mihajlović Health Analytics, Novi Sad,
Serbia, 3Erasmus University, Rotterdam, 4Department of Haematology, Med-
ical Center Leeuwarden, Leeuwarden, 5Department of Pharmacy, Isala Clin-
ics, Zwolle, 6Department of Pharmacy, Ommelander Zorggroep, Win-
schoten/Delfzijl, 7Institute of Science in Healthy Aging & health caRE
(SHARE), University Medical Center Groningen (UMCG), Groningen, Nether-
lands
Background: Rituximab for subcutaneous (SC) administration has recently
been approved for use in common forms of diffuse large B-cell lymphoma
(DLBCL). This form of rituximab is supplied in ready-to-use vials that do not
require individual dose adjustment. It is expected that SC-injection will short-
en the treatment time per administration of rituximab in comparison with cur-
rently available intravenous (IV) infusion.
Aims: The goal of this study is to identify and compare all direct costs of IV
and SC rituximab given to the DLBCL patients in the Netherlands. 
Methods: Using a prospective, observational, bottom up, micro-costing study
we collected primary data on the direct medical costs of the preparation,
administration and acquisition of rituximab. Drug costs and spillage, labor
costs, material costs and remaining daycare costs were identified using stan-
dardized forms, structured using guideline prices and compared for the IV
and SC forms of rituximab. 
Results: Measurements were done on 53 administrations (33 IV and 20 SC).
The mean total costs of the IV infusion were €2174, and €1907 for the SC
injection. The estimated difference of €267 per administration was mainly
due to spillage costs and differences in chair time, related daycare costs and
drug costs.
Summary and Conclusions: Rituximab administered in the form of SC injec-
tion is less costly than its IV form. Taking into account their equal effective-
ness, favorable pharmacoeconomic profile of SC rituximab can result in sig-
nificant savings when transferred to the total DLBCL population in the Nether-
lands.
E1454
BIOSIMILAR FILGRASTIM FOR THE PREVENTION OF FEBRILE NEU-
TROPENIA IN ELDERLY DLBCL PATIENTS HAS COST EFFECTIVENESS
COMPEERED WITH ORIGINAL FILGRASTIM
N. Takezako1,* N. Sekiguch1, A. Nagata1, M. Kurimoto1, S. Noto1, A. Miwa1
1Hematology, Disaster Medical Center of Japan, Tachikawa, Japan
Background: According to American Society of Clinical Oncology guideline
on the use of granulo- colony-stimulating factors (G-CSF), primary prophy-
laxis is recommended for the prevention of febrile neutropenia (FN) in patients
who are at high risk based on age, medical history, disease characteristics,
and myelotoxicity of the chemotherapy regimen. G-CSF use allows a modest
to moderate increase in dose-density and dose-intensity of chemotherapy
regimens. Prophylactic G-CSF for patients with diffuse aggressive lymphoma
aged 65 years and older treated with R-CHOP should be given to reduce the
incidence of FN. A similar biologic medicinal product, commonly referred to
as biosimilar, is a copy version of an approved original biologic medicine
whose data protection has expired. Among of them, biosimilar filgrastim
have been approved and become available in Europe on the basis of com-
parable quality, safety and efficacy to the originator product. In Japan, biosim-
ilar filgrastim approved in 2013. However, biosimilar filgrastim has not been
used widely in Japan though it may have the reduction effect of costs. Here
we investigated the efficacy and the cost saving effect in use of biosimilar fil-
grastim.
Aims: To evaluate the efficacy and the cost saving effect in use of biosimilar
filgrastim.
Methods: From July 2013 to December 2014, our Institution used the biosim-
ilar filgrastim (Filgrastim BS®; Mochida Industrial Products, Tokyo, Japan),
at dosage of 75µg/day from day +10, for FN prophylaxis and hematological
recovery in elderly diffuse large B cell lymphoma (DLBCL) patient who
received R-CHOP therapy. These patients were retrospectively compared
with same elderly patients who received original filgrastim (Gran®; Kyowa
Hakko Kirin Co., Ltd, Tokyo, Japan), at dosage of 75µg/day from day +10 as
FN prophylaxis after R-CHOP (from April 2010 to June 2013). Comparisons
between qualitative variables were carried out using the χ2 test. Statistical
analyses were performed with the software package Stata version 11 (Stata
Corp LP, College Station, TX, USA). In all analyses, P values were 2-tailed,
and a P value less than 0.05 was considered to be significant.
Results: A total of 102 elderly patients with DLBCL were identified for this
study, comprising 41 patients treated with Filgrastim BS® and 61 treated with
Gran®. Comparisons of patient outcomes between groups are presented in
Table 1. There was no statistically significant difference among the two patient
cohorts. Mortality during therapy was similar in two group (p=0.647). Fur-
thermore, number of injection during one cycle was significant less in Fil-
grastim BS® group (4.2 vs 5.0; p <0.001). In addition, mean medical costs
during hospitalization were statistically lower in the Filgrastim BS® group
than in the Gran® group (1,356.3±94.1 vs 2,357.2±113.4 Euro; p <0.001).
Table 1.
Summary and Conclusions: According to our study, it is revealed that
biosimilar filgrastim (Filgrastim BS®) has similar efficacy and safety compared
with original filgrastim in febrile neutropenia prophylaxis after R-CHOP ther-
apy in elderly patients. This data confirm previous evidence that supports
the non-inferiority of biosimilar filgrastim in this setting. Furthermore, mean
medical costs during chemotherapy were statistically lower in the Filgrastim
BS® group than in the Gran® group. 
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IS CLINICAL TRIAGE EFFECTIVE? AN AUDIT OF OUTPATIENT REFER-
RALS TO THE HAEMATOLOGY DEPARTMENT AT NORTHWICK PARK
HOSPITAL, LONDON NORTHWEST NHS TRUST
M. Camilleri1,* F. Chowdhury1
1Haematology, Northwick Park Hospital, Harrow, United Kingdom
Background: The haematology service at Northwick Park Hospital is known
to be busy, with a minimum of seven follow-up clinics and five new patient
clinics running weekly. One Friday afternoon new patient session has been
introduced last year as a measure to keep up with the new outpatient referrals
that come to the department. In order to manage these referrals better, a
local consultant-led triage system screens and inputs each one onto a com-
mon departmental database. 
Aims: The aim is to increase the efficiency and safety of the outpatient serv-
ice by assessing the necessity of each referral and making sure patients are
seen within the right time frame by the appropriate clinician.
Methods: To assess this, an audit was carried out on all the new outpatients
referred to the haematology department at Northwick Park Hospital over a 6
month period. Data was extracted and analysed using simple descriptive sta-
tistical tools available on Microsoft Excel.
Results: There were 1016 referrals recorded from July 2014 to December
2014, with most cases being triaged within 1 to 3 days on receipt of referral.
14% of these were rejected, either because they were deemed inappropriate
(41%) or the patient would have benefitted from an alternative specialist review
(11%). Out of all the accepted referrals 24% needed the red cell service, 29%
required clotting advice and 34% of patients needed review at a white cell
clinic. 14% of haematology referrals had no specified reason documented.
74% of referrals come from primary care, with 55% coming directly from the
GP and another 19% via the Choose and Book patient scheme. The vast
majority of rejected referrals came from primary care (96%) with most clinical
questions requiring only simple advice, at times given over the phone. 71%
were direct GP referrals and 25% were Choose and Book electronic referrals.
Triaging cases to avoid unnecessary consultations is very likely to have pos-
itive financial implications, considering that costs of GP referrals to the NHS
come to £15 billion per year. 156 patients (15%) needed to be seen urgently
within a two week period, were the majority were referred due to a white cell
disorder (69%). Such cases constitute an average of 40% of a typical new
patient clinic list (2 slots out of 5 per clinic session), with an appreciable num-
ber of patients ending up requiring hospital admission for expedited work-up.
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Summary and Conclusions: With the ever rising demand for specialty refer-
ral, rationalizing the limited human and fiscal resources in secondary/tertiary
care is becoming important. Every hospital seeks to see the appropriate refer-
rals first; preventing unnecessary consultations whilst picking up urgent cases
early. This audit has shown that clinical triage and assessment has significant
strengths conveying several advantages. Filtering out inappropriate referrals
saves the GP money and prevents unnecessary waiting times. Also, referrals
can be directed to the most appropriate setting, making patient care more
efficient. With 2/3 of our urgent appointments being made up of white cell
disorders, a good triage system helps fast-track diagnosis of possible cancer.
Clinical triage, coupled with peer review and readily accessible consultant
feedback to GPs through letters or phone, may prove to be both cost- and
clinically-effective in today’s busy practice.
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PROGRESSION-FREE SURVIVAL AS THE PRIMARY ENDPOINT IN
ONCOLOGY TRIALS: ITS VALUE AND CREDIBILITY FROM DIFFERENT
STAKEHOLDERS’ PERSPECTIVES
C. Quinn1,* S. Palmer2, J. Bruns3, C. Grant1, D. Sykes1, S. Kaura4
1PRMA consulting Ltd, Fleet, 2Centre for Health Economics, University of
York, York, United Kingdom, 3Deutsche Krebsgesellschaft, Berlin, Germany,
4Celgene Corporation, Summit, New Jersey, United States
Background: The primary and secondary endpoints selected for oncology
trials have to meet the needs of diverse stakeholders: patient groups, clini-
cians, regulators, and health technology assessment (HTA) agencies, each
of whom considers trial outcomes from a different perspective. Progression-
free survival (PFS; time from randomization until progression or death from
any cause) is becoming a more widely accepted measure of treatment effi-
cacy, but there is tension between regulators and payors regarding its accept-
ability as a primary endpoint: payors still consider overall survival (OS; time
from randomization until death from any cause) the ‘gold standard’ because
of uncertainty about translating PFS gain to OS whereas regulators accept
non-OS endpoints in order to drive faster approvals.
Aims: The aim of this paper is to present and discuss PFS as a credible end-
point among different stakeholders, considering the heterogeneity in stake-
holder perspectives and preferences that needs to be accommodated in clin-
ical trial design and endpoint selection in order to provide adequate informa-
tion for all decision-makers.
Methods: We conducted a targeted review of the published and grey litera-
ture to identify regulatory and HTA guidance on PFS as an endpoint. We
identified examples of decisions by both regulators and HTA agencies in
which PFS data were presented as the primary outcome and compared the
assessment of the products by regulators and different HTA agencies. Afatinib
(A), erlotinib (E), and bevacizumab (B) were identified as examples of prod-
ucts for which decision-making appears to have been influenced by the use
of PFS data.
Table 1.
Cancer   Drug      FDA      EMA    NICE (UK)     TC (France)           G-BA (Germany)
NSCLC       A          Yes        Yes           Yes             ASMR 5       5 subgroups, benefit range:
                                                    + interim                            Indication of major benefit 
                                                    OS+PAS                            to added benefit not proven
                E          Yes        Yes           Yes             ASMR 4                         NA
                                                    + interim
                                                    OS+PAS
Ovarian      B          Yes        Yes           No             ASMR 4                         NA
                                                   Too much
                                                  uncertainty
Results: We identified several publications by regulatory and HTA agencies
that report PFS to be a valid and credible endpoint in oncology trials; its suit-
ability is determined by the type and stage of cancer. The magnitude of PFS
gain and the associated uncertainty are considered by all stakeholders, but
decision-making processes vary. Regulators assess the magnitude and cer-
tainty of survival gain in order to assess the risk-benefit profile. Clinicians
and patients use PFS data to make decisions about individual treatment
options. Payors use the data to assess the opportunity cost of recommending
one drug rather than another. This variation in processes is demonstrated in
the following decisions by regulators and HTA agencies for submissions
based on PFS data (Table 1). ASMR 4, minor improvement over standard of
care (SOC); ASMR 5, no improvement over SOC; NA, assessment not pub-
licly available; PAS, patient access scheme.
Summary and Conclusions: PFS is a valid and credible endpoint, and
measure of efficacy, in many oncology trials; by reducing trial length compared
with OS, efficiency is also improved and fewer patients exposed to a clinical
trial. Limitations associated with PFS are largely manageable. The value of
PFS needs to be consistently recognized by HTA agencies, and approaches
harmonized between HTA agencies and regulators.
E1457
IMBALANCES IN THE ANNUAL EHA CONGRESS. THE FUTURE OF
HAEMATOLOGY
J. Loza1,* A. Pereda1, P. Chavez1, I. Gonzalez1, A. Campeny1, E. Perez1,
R. Díez1, M. Quintana1, F. Rodriguez1, A. Mendizabal1, C. Menchaca1,
M. Ardanaz1, J. Guinea1
1Hematology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background: During the last EHA congress in Milan, our attention was
brought to the existing imbalance between the time and space dedicated to
oncohaematology in relation to other areas of haematology: red blood cell
series, haemostasis and transfusion.
Aims: We have proposed reviewing whether this imbalance is timely or main-
tained over the last few years.
Methods: we reviewed the weight of the various areas of haematology in the
last 10 EHA Congresses, based on book abstracts of communications that
can be consulted on the European Haematology Association’s official publi-
cation’s website. We have classified communications into six sections: onco-
haematology, red blood cell series, haemostasis, transfusion, transplant of
haematopoietic cells and various. We analysed their percentage weight and
time pattern.
Results: we detected that the participation of the RBC series varied between
4% and 6.9% with an average of 5.5%, haemostasis between 6.9% and
15.6% with an average of 9% and transfusion between 1% and 3.8% with an
average of 2.1%. Oncohaematology occupied between 42% in 2005 and
67.4% in 2014, with an average of 60%. Of the 10,868 communications pre-
sented between simultaneous sessions and posters, 60% referred to Onco-
haematology, 5.6% to RBC series, 9.1% to haemostasis, 2.1% to transfusion,
6.8% to transplant and 16.5% to various other issues: the taking part of
patients, management, efficiency of treatments, granulocytic function and a
long etc. of topics difficult to fit into the other five haematology areas. If we
analyse the parallel sessions, those aimed at oncohaematology varied
between 14 in 2005 to 27 in 2014 with an average of 20, which meant 64%
of the total sessions. However, only one session in 3 of the 10 congresses
was dedicated to transfusion (<1%). The study of the variation in the last 10
years revealed a gradual increase in the existence of oncohaematology in
congresses mainly from 2009, maintenance of the RBC series and haemosta-
sis in general below 10% and a trend towards a gradual disappearance of
transfusion. We only need point out that in the last 10 years there have only
been three parallel sessions which have tackled this field of our speciality.
Summary and Conclusions: We observed a gradual separation from
Haematology as a speciality in favour of oncohaematology, with a gradual
loss of the other three parts of the speciality, which could lead in the medium
term to reconsidering the survival of the Haematology speciality as we know
it today.
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HEMATOLOGY AND SOCIAL MEDIA: COMMUNICATION AND EDUCA-
TION IN THE MODERN ERA
E. Graves1,* A. McGregor1, J. Young1, R. Evans1
1Haematology, Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, Unit-
ed Kingdom
Background: Medical education, professional networking and communica-
tion are changing as social media becomes more integral to the lives of aca-
demics, doctors, health care professionals and patients. Social media (SoMe)
is gaining popularity as a platform for informal, user-directed learning; the
ease with which educational material and discussion can be accessed from
multiple devices is key to this.
Aims: We aimed to develop a hematology-oriented presence within SoMe.
We wanted to promote Hematology as a specialty willing to engage in inter-
national and truely multi-disciplinary dialogue via the most modern platforms.
We also wanted to create an educational dialogue that would allow interested
parties, from the smallest to largest institutions, to participate in teaching and
the dissemination of knowledge.
Methods: We chose Twitter, a free, widely used SoMe microblogging website
as it allows instant dissemination and discussion of educational material. Our
Twitter profile (@TeamHaem) contains a short biography of who we are and
our objectives. @TeamHaem established a Twitter presence by ‘following’
education and medical professionals, enabling us to see their status updates.
We subsequently asked them to ‘tweet’ about us; therefore gaining our own
followers. We created case-led discussions, which evolve over time and are
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designed to be topical and relevant to our followers, targeting their various
skill sets and levels of expertise. We used a blogging website to create the
backbone of our case and Twitter to lead the discussion. Images, such as
blood films, radiographs and marrow histology can be posted in addition to
links from journal articles. Any follower can contribute or can simply watch
the case developing. We react to followers’ suggestions and encourage evi-
dence-based discussion, closing each case with a summary. We moderate
discussion and explicitly refrain from offering medical advice. 
Results: @TeamHaem has been operational since 2012 and we currently
have 1296 followers from 112 countries around the world, including doctors,
nurses, students, pharmacists and biomedical scientists. We have published
32 interactive cases so far. We have also presented at medical education con-
ferences and participated in the twitter coverage of various hematology con-
ferences, including The Americal Society of Hematology 2014 congress which
was the topic of over 20,000 tweets. We have encountereed numerous diffi-
culties with this project, including technological literacy, compliance with con-
fidentiality and SoMe guidelines, time management and promotion of the serv-
ice to non-Twitter users. These obstacles have been overcome by following
published guidelines, seeking advice from senior colleagues, presenting at
local and national meetings and publishing in specialty specific newsletters.
Summary and Conclusions: Hematology is a specialty that is frequently
scientifically ground-breaking. Many in the field are interested in methods of
sharing knowledge and promoting the specialty, as well as learning from col-
leagues. @TeamHaem is an entirely novel programme which has succeeded
in developing an international network for professionals and students working
in Hematology. We have over 1000 followers from more than 100 countries
and continue to curate high quality educational networks and debate for the
Hematology community. 
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NARROWBAND ULTRAVIOLET-B PHOTOTHERAPY IN A PEDIATRIC
PATIENT WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
I. Eker1,* O. Gürsel1, M. Topdemir2, G. Açıkgöz3, O. Babacan4, A.E. Kürekçi4
1Pediatric Hematology, 2Pediatrics, Gulhane Military Medical Faculty, 3Der-
matology, 4Pediatric Hematology, Gülhane Military Medical Faculty, Ankara,
Turkey
Background: The advantage of narrowband UVB (NB UVB) phototherapy
for inflammatory skin diseases in adults and children is unquestionable, but
its use in graft versus host disease (GVHD) has been scarcely reported. 
Aims: We present here a 15 years-old boy, in whom complete and durable
remission was achieved with the addition of NB UVB. 
Methods: A 15 years old male patient with monosomy 7 positive bilineage
acute leukemia, underwent allogeneic peripheral blood stem cell derived
hematopoietic stem cell transplantation (allo-HSCT), from his full-matched
50 years old mother. Conditioning consisted of total body irradiation (12
Gy/total), cyclophosphamide (120mg/kg) and etoposide (30 mg/kg).
Methotrexate and cyclosporine were used for GVHD prophylaxis. 2.18x
106/kg CD34+ stem cells were transplanted. Full engraftment was achieved
with neutrophil, platelet and erythrocyte recovery being 16 days, 22 days
and 23 days respectively. He presented with overlap syndrome type GVHD
on the 30th day of transplantation with a score of 3 in the skin and a final
global assessment of severe GVHD. He was resistant to steroid, but remis-
sion was achieved with the combination of tacrolimus and mycophenolate
mofetil. He was in hematological complete remission with good health con-
dition and without immunosuppression for 2 months, until his second pres-
entation with overlap syndrome type GVHD on the 128th day of transplanta-
tion with a score of 3 in the skin and a final global assessment of ‘severe’
GVHD. A partial remission was achieved with methylprednisolon, but there
were not any response to treatment in his exfoliative skin lesions, especially
which were localized on his upper extremity and palmar face of his hands
(Figure 1). On the 132th day of transplantation NB UVB phototherapy was
started as an adjuvant therapy to steroid, tacrolimus and mycophenolate
mofetil. By means of a Waldmann UV-7002 K (Villingen-Schwenningen, Ger-
many) cabin NB UVB phototherapy was administered. Treatments were given
three times weekly and the starting dose was determined by the minimal ery-
thema dose with increments of 0.02 mJ/cm2 every two treatments. After the
10th treatment, complete remission was achieved and skin lesions were
totaly resolved in the patient who received a total of 2.94 j/cm2 therapy until
that time. He is on the 165th day of transplantation at the time of this report,
steroid therapy was discontinued. Tacrolimus and mycophenolate therapies
planned to continue with the goal of reaching the 30th NB UVB treatment.
Results: Narrowband UVB is controlled administration of UVB component
of sunlight. It is a method of treatment in which, UVB with 311-313 nm wave-
length is used to treat a wide range of inflammatory skin diseases, especially
psoriasis and vitiligo. In particular, phototherapy alters antigen presentation
and T-cell responsiveness in skin, primarily via inactivation of Langerhans
cell antigen-presenting capacity and secretion of immunosuppressive
cytokines.
Figure 1.
Summary and Conclusions: NB-UVB phototherapy is a useful adjuvant
therapeutic modality, effectiveness of which is proven in GVHD and can be
indicated in the treatment of patients with cutaneous GVHD as a nonaggres-
sive adjuvant therapy to immunosuppressive drugs.
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HEMOGLOBINOPATHIES WITH HIGH OXYGEN AFFINITY
W. Torres1,* M. García Roa1, A. Manubens1, M. Gutierrez Alvariño1, A. Pedraza
Navarrete1, D.S. Toral Ibarra1, P. Ropero Gradilla1, J.M. Nieto1, F. De la Fuente-
Gonzalo1, A. Villegas1, R.B. Martinez Martínez1, F.A. González Fernández1
1Hematologia y Hemoterapia, Hospital Universitario Clinico San Carlos de
Madrid, Madrid, Spain
Background: Hemoglobinopathies are the world’s most frequently found mono-
genic disorders. Depending on the replaced amino acid nature and its location
in the globin chain, changes will be observed in the hemoglobin molecules’ sta-
bility, solubility and function that finally lead to clinical haemoglobinopathies. In
the cases with high oxygen affinity, the decrease in the liberation of the oxygen
determines a secondary erythrocytosis.
Aims: In this work, we present 18 unrelated families of Caucasian race and of
Spanish origin, with eleven variants of hemoglobin or hemoglobinopathies with
high oxygen affinity, which were diagnosed in our laboratory.
Methods: The haemoglobinopathies were characterized either through elec-
trophoresis in an alkaline pH (8.6 pH) cellulose acetate, or an isoelectrofo-
cussing (IEF) in polyacrylamide gel (5.5-8.5 pH), or agar citrate (pH 6.0) elec-
trophoresis or reverse phase HPLC for globin chains or ionic exchange HPLC.
Hemoglobin function was established through P50 in the oxygen balance curve
plotted by a TCS Haemox-Analyzer (TCS Medical Products Co., Huntingdon
Valley, PA, USA). The molecular analysis was completed by automatic sequenc-
ing of the α and/or β genes’ PCR-amplified products using the ABI Prism TM
dRhodamine Terminator Cycle Sequencing Ready reagents kit (PE Applied
Biosystems, Foster City, AC) and the sequence was studied in an ABI Prism
310 Genetic Analyzer (PE Applied Biosystems).
Results: All the demographic data, hematrimetric results, P50 and chromatog-
raphy findings are summarized in Table 1.
Table 1.
Summary and Conclusions: Of the eleven haemoglobinopathies, in four (the
Hb San Diego, the Hb Johnstown, the Hb Malmö and the Hb Columbia-Missouri),
the change of amino acid affects zones of the contact a1b2; in two variants (the
Hb Strasbourg and the Hb Syracuse), it affects the unions with 2,3-DPG in the
central cavity; in the other two (the Hb Badalona and the Hb La Coruña), the cavity
of contact with the group heme is affected; in one (Hb Bethesda), it affects the
zone of contact a1b1; in another one (Hb Andrew-Minneapolis) it affects the
extreme C-terminal contacts of β chain and in the last one (Hb Olympia), the posi-
tion 20 of the chain in the helix B in the surface of the protein is affected. In all
cases, the change of amino acid, though of different form, facilitates that the qua-
ternary structure of the hemoglobin becomes stable in its relaxed configuration so
the transfer of oxygen and the P (50) value are decreased. All cases were sent to
our laboratory because of shown erythrocytosis. In the majority of them, the diag-
nosis was done during an analysis of routine or for being relatives of the first ones.
Although it is rarely diagnosed, the reported 18 families that show 11 different vari-
ants in the same geographic area lead us to think that the percentage of secondary
erythrocytosis in hemoglobinopathies of this type could be even higher and, there-
fore, their systematic detection should be emphasized in erythrocytosis of unknown
origin and, more so, when a family history is available.
E1461
TRANSFUSION-DEPENDENT HEREDITARY SPHEROCYTOSIS AND COM-
PLETE DISTAL RENAL ACIDOSIS: THE FIRST CASE WITH A HOMOZY-
GOUS EXON 12 C.1430C>A (P.SER477X) MUTATION OF THE SLC4A1 GENE
L. Kager1,2,* K. Boztug1,3, P. Zeitlhofer4, G. Fritsch2, M. Minkov5, B. Fahrner1,
A. Dossenbach-Glaninger6, O. Haas1,2,4
1St. Anna Children’s Hospital, Department of Pediatrics, Medical University
Vienna, 2Children’s Cancer Research Institute, 3CeMM Research Center for
Molecular Medicine of the Austrian Academy of Sciences, 4medgen.at GmbH,
5Pediatrics, 6Laboratory Medicine, Hospital Rudolfstiftung, Vienna, Austria
Background: Mutations in the SLC4A1 gene, which encodes a bicarbonate
anionic exchange protein (AE1 or Band 3), cause a rare and unique combination
of hereditary spherocytosis (HS) and distal renal acidosis (dRTA). The fast
majority of patients reported so far are compound heterozygotes. So far only
three types of homozygote mutations in this gene have been documented,
namely one with a p.V488M in exon 13 (Ribeiro et al., Blood 96:1602;2000),
one with a p.S667F in exon 16 (Toye et al., Blood 111:5380;2008) and another
one p.Ala858Asp in exon 19 (Fawaz et al., Europ J Haematol 88:350;2012).
Aims: To determine the genetic cause of complete dRTA in combination with HS.
Methods: A Turkish boy presented with a severe transfusion-dependent
hemolytic anemia, complete dRTA and a psychomotor developmental delay
since birth. Regular transfusions obstructed the establishment of a firm HS
diagnosis with a flow cytometric assay that is based on the reduced binding of
eosin-5-maleimide (EMA) to spherocytes. However, this test was abnormal in
his consanguine parents and his two siblings, who all had subclinical signs of
spherocytosis, despite normal RBC counts. These findings therefore prompted
us to screen the family for causative mutations in the SLC4A1 gene.
Results: Sequencing of the entire coding region revealed two homozygous
sequence changes in the patient, namely a disease-relevant nonsense mutation
c.1430C>A (p.Ser477X) in exon 12 and a disease-unrelated single nucleotide
polymorphism c.2312-48T>G (rs13306780). The nonsense mutation creates a
stop codon and results in a C-terminally truncated protein that only contains
the cytoplasmic domain and the first three trans-membrane segments. In accor-
dance with an autosomal recessive inheritance pattern of the disease, both
parents as well as his siblings were heterozygous carriers of this gene-disrupt-
ing sequence variant.
Summary and Conclusions: The respective p.Ser477X mutation was previously
found in only two heterozygous individuals with an incomplete form of dRTA. These
cases were identified when families with HS were screened with an urine acidifi-
cation test for this purpose (Rysava et al., Nephrol Dial Transplant 12:1869;1997),
whereas our patient is the first one who is affected by this mutation in a homozy-
gous form. The recurrence of this identical mutation in an apparently unrelated
family therefore may imply a common founder origin and proves that, if homozy-
gote, it produces the complete clinical picture of a severe transfusion-dependent
form of HS together with a complete dRTA. Whether the psychomotor development
delay is directly related to the mutation or presents a preventable consequence of
the hemolytic anemia and renal disturbance remains to be shown.
E1462
CHARACTERIZATION OF 6 HEMOGLOBINOPATHIES OCCURRING WITH
CYANOSIS AND/OR LOWERING THE OXIGEN SATURATION
W. Torres1,* M. Garcia Roa1, M. Gutierrez Alvariño1, E. Coria1, L. Sanchez
Noboa1, D.S. Toral Ibarra1, P. Ropero Gradilla1, F. De la Fuente Gonzalo1,
J.M. Nieto1, A. Villegas1, R.B. Martinez Martinez1, F.A. Gonzalez Fernandez1
1Hematologia y Hemoterapia, Hospital Universitario Clinico San Carlos de
Madrid, Madrid, Spain
Background: Structural hemoglobinopathies are the result of mutations in glo-
bin genes. In over 95% of cases the structural alteration corresponds to the
substitution of a single amino acid in the sequence of the globin chains. Until
now described over 1000 different variants being in most cases clinically and
phenotypically silents. However in some instances the amino acid change may
determine that the heme iron chain with the mutation this oxidized permanently
or submit a decreased affinity for oxygen enrolled in these situations with
cyanosis and/or decreased oxygen saturation.
Aims: In this work, we want to present the molecular characterization of six
variants of hemoglobin that his suspicion was conducted by the existence of a
decrease in oxygen saturation and/or cyanosis unexplained, which were diag-
nosed in our laboratory.
Methods: The haemoglobinopathies were characterized either through ionic
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exchange HPLC or reverse phase HPLC for globin chains. Hemoglobin stability
was determined using the isopropanol test, while the function was established
through P50 in the oxygen balance curve plotted by a TCS Haemox-Analyzer
(TCS Medical Products Co., Huntingdon Valley, PA, USA). The molecular analysis
was completed by automatic sequencing of the α and/or β genes’ PCR-amplified
products using the ABI Prism TM dRhodamine Terminator Cycle Sequencing
Ready reagents kit (PE Applied Biosystems, Foster City, AC) and the sequence
was studied in an ABI Prism 310 Genetic Analyzer (PE Applied Biosystems).
Results: All the demographic data, hematrimetric results, P50 and chromatog-
raphy findings are summarized in Table 1.
Table 1.
Summary and Conclusions: In the Hb M-Boston and M-Saskatoon changing
the distal histidine for tyrosine in α and β chains respectively and the Hb M-Hyde
Park changing the proximal histidine for tyrosine in anchoring the β chain Heme
group to both chains, determines the oxidation of iron the heme group perma-
nently to yield an electron and thus can not capture oxygen, this being the cause
of the decrease in oxygen saturation and cyanosis in these hemoglobinopathies.
In Hb Titusville changing aspartic for asparagine at position G1 α chain involved
in the contact α1β2 determines Hb stabilization conformationally deoxy T or so
has a low affinity for oxygen being the reason the decrease in oxygen saturation
and cyanosis. Hb Higashitochigi, the loss of a glycine in the helix B distorted
indirectly heme pocket at the end distal level of the distal histidine conformo-
cionales miss the relationships between helix B and helix E end which favors the
oxidation of iron central. In the Hb Arta the mutation affects segment CD is critical
in the transition from deoxy T or R configuration or oxy Hb, changing a pheny-
lalanine for cysteine at this level configuration favors what deoxy T and so deter-
mines a lower affinity for oxygen chain. The possibility of the presence of structural
hemoglobinopathies must be taken into account in cases of cyanosis and
decreased oxygen saturation unexplained. Although no clinical impact a confir-
mation saves people carrying extensive and unnecessary studies.
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IDENTIFICATION OF TWO NEW MISSENSE MUTATIONS AND A 5BP
DELETION IN THE ERYTHROID-SPECIFIC PROMOTOR OF THE PKLR
GENE IN TWO UNRELATED PATIENTS WITH NON-SPHEROCYTIC
HEMOLYTIC ANEMIA
L. Kager1,2,* M. Minkov3, K. Boztug1,4, P. Zeitlhofer5, B. Fahrner1, A. Dossen-
bach-Glaninger6, O. Haas1,2,5
1St. Anna Children’s Hospital, Department of Pediatrics, Medical University
Vienna, 2Children’s Cancer Research Institute, 3Pediatrics, Hospital Rudolfs-
tiftung, 4CeMM Research Center for Molecular Medicine of the Austrian Acad-
emy of Sciences, 5medgen.at GmbH, 6Laboratory Medicine, Hospital Rudolf-
stiftung, Vienna, Austria
Background: Pyruvate kinase (PK) deficiency is the most common form of
non-spherocytic hemolytic anemia (NSHA), which concurs with significant co-
morbidities. As an autosomal recessive disease it results from a variety of func-
tionally impairing mutations that are scattered over the entire coding region of
the PKLR gene, although they show a somewhat ethnicity- and region-specific
biased distribution. More than 200 different mutations have been documented
so far, but only two of these, which were functionally characterized in detail,
reside in the promotor region (Zanella et al. Brit J Haematol, 130:11, 2005).
Aims: To determine the genetic cause of a suspected PK deficiency.
Methods: We present two children from unrelated families, a five month-old
girl and a three-year old boy, who both suffer from severe transfusion-depen-
dent NSHA since birth. PK enzyme activity was not determined before initiation
of transfusions. However, this test still revealed a moderate reduced activity in
both the children’s healthy parents, who all had normal RBC counts. In consid-
eration of these clues, we Sanger sequenced the entire coding region of the
PKLR gene in the two patients and subsequently verified the parental inheri-
tance pattern of all identified sequence changes.
Results: Our mutation screening confirmed that both patients were compound
heterozygote carriers of causal PKLR mutations. The girl had a previously
recorded maternally-derived exon 9 (c.1174G>A; p.Ala392Thr) missense muta-
tion and a novel paternally-derived 5bp deletion in the promoter region (c.-39-
49_-39-45delTCTCT). The boy had two hitherto unknown missense mutations,
namely a maternally-derived c.907-908delCC (p.Pro303GlyfsX12) in exon 7
and a paternally-derived c.1381g>A (p.Glu461Lys) in exon 10. The ensuing
shift in the reading frame of the former prematurely interrupts amino acid syn-
thesis after AS 313 and truncates the protein, whereas the other one converts
a highly conserved amino acid from an acid to a basic one.
Summary and Conclusions: We succeeded to determine the genetic cause
of a suspected PK deficiency in two patients and thereby uncovered three
novel mutations in the PKLR gene, namely two missense ones in exons 7 and
10 and a 5bp deletion in its erythroid-specific promotor, which is so far only the
third one of its kind. The identification of underlying mutations is an essential
prerequisite not only for further functional studies that can provide important
insights into the respective disease mechanism but it also provides the neces-
sary basis for adequate counseling of the affected families.
E1464
HB PUERTA DEL SOL, HB VALDECILLA, HB GRAN VÍA, HB MACARENA,
AND HB EL RETIRO: DESCRIPTION OF 5 NEW HEMOGLOBINOPATHIES
F. De La Fuente Gonzalo1,* J.M. Nieto1, D. Velasco2, E. Cela3, E. Del Campo4,
A. Fernández-Teijeiro5, A. Escudero Soto6, R.B. Martínez Martínez1, A. Villegas1,
F.A. González Fernández1, P. Ropero Gradilla1
1Hematology, Hospital Clínico San Carlos, 2Laboratorio BR-Salud, Hospital
Infanta Sofía, 3Pediatria, Hospital Gregorio Marañon, Madrid, 4Analisis Clíni-
cos, Hospital Universitario Marques de Valdecilla, Santander, 5Oncohema-
tología Pediatrica, Hospital Universitario Virgen de la Macarena, Sevilla,
6Hematology, Hospital Gregorio Marañon, Madrid, Spain
Background: Structural hemoglobinopathies are due to mutations that cause
the change of the amino acid sequence of the protein chain. Some of these vari-
ants have altered electrophoretic mobility. They do not have a clinical impact but
can cause interference in the analytical determination of some parameters such
as the glycated hemoglobin in diabetic patients. Thalassemias are the most com-
mon monogenic disorders worldwide and represent a serious health problem in
areas where their incidence is high. The α-thalassemias are due to a deficiency
or absence of synthesis of the α-chain of hemoglobin (Hb). The defects in the
post-translational modifications produce hyper-unstable Hbs that are not detected
by most of electrophoretic or chromatographic methods available so far.
Aims: We shown 5 new α-chain Hb variants. One is a structural variant having
altered electrophoretic mobility and the other 4 are hyper-unstables and behave
as α-thalassemias.
Methods: We studied 7 patients, belonging to 6 unrelated families. The first 2
families were studied because they showed a peak of abnormal Hb during rou-
tine analytical assays. The other 4 families were studied because they had
microcytosis and hypochromia with normal Hb A2 and Hb F without iron defi-
ciency. Haematological data were obtained on a haematology analyzer. HbA2
and F quantification and the separation of abnormal Hb were performed by
ion-exchange HPLC. The abnormal Hb also was separated by capillary elec-
trophoresis. The study of the globin chains was performed by reversed-phase
HPLC. The most frequent mutations were ruled out by α-globin StripAssay.
The molecular characterization was performed by specific sequencing.
Results: The haematological parameters and the genotype of the studied sub-
jects are summarized in Table 1. The electrophoretic and chromatographic
studies are recruited in Table 2.
Table 1. Haematological parameters and genotype of the studied subjects.
Table 2. Chromatographic and electrophoretic studies.
586 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Summary and Conclusions: Hb Puerta del Sol has the same mobility than
HbS by IE-HPLC but a lower percentage. This variant has a normal blood count.
In the Hb Valdecilla the initiation codon is affected and the carrier shows a tha-
lassemia trait with anemia, microcytosis and hypochromia. This mutation is
also associated in trans to an heterozygous α+-thalassemia deletion. Within
the non deletional α-thalassemia, a very important group are those due to the
lack of stability of the α-globin chain, which causes the called hiper-unstables
Hbs. The three new Hbs (Gran Vía, Macarena and El Retiro) described in this
work are hiper-unstables although by different mechanisms. In Hb Gran Via,
instability could be due to the replacement of a Met (apolar) by an Arg (polar
positively charged) at position 13 of the B helix of the α2 chain. This mutation
alters the sequence of 6 residues (CD30-CD35) involved in the contact between
α1/β1 subunits Hb tetramer. In Hb Macarena, residue 119 of the α helix H chain
is affected, which has a key role interacting with the stabilizing protein alpha
chain of hemoglobin (AHSP). For Hb Macarena, its hiperinstability is probably
due to a decreased affinity for the AHSP. Most hemoglobinopathies are the
result of a point mutation, while only a few such as Hb El Retiro originate as a
result of small insertions or deletions. In Hb El Retiro a Val (apolar) is inserted
at position 122 (H5), therefore displacing a polar positively charged amino acid
(His) involved in α1/β1 contact. This could be the cause of instability of this
hemoglobinopathie. All these variants, although uncommon and privatives to
some families, reveal the complexity and variety of disorders that can be found
in the genes coding for Hb, having over 1000 different Hb variants described
to date. Some variants such as Hb Valdecilla, Hb Gran Vía, Hb Macarena and
Hb El Retiro, with significant clinical impact if associated with other forms of α-
thalassemia could lead to more serious forms of this group of pathologies as
is the Hb H disease. Therefore, it is important to maintain an adequate program
of screening of these diseases in countries where prevalence is high to prevent
the occurrence of severe forms.
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IDA AND ON THE TREATMENT OF IDA DNA DAMAGE: 8-HYDROXY-2-
DEOXYGUANOSINE LEVEL
B. Esen1, S. Akarsu2,* S. Aydin3
1University of Firat, Faculty of Medicine, Department of Pediatrics, 2University
of Firat, Faculty of Medicine, Department of Pediatric Hematology Oncology,
3University of Firat, Faculty of Medicine, Department of Biochemistry, Elazig,
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Background: Iron deficiency anemia (IDA) is a common and an important health
problem in developing countries. Ionized form is potentially dangerous while the
iron components which are in the form of inorganic components have an important
duty. Ionic iron causes damages at the cellular level by forming free radicals.
Therefore, decreases and increases in the level of iron have clinic significances.
Reactive Oxygen Species (ROS) lead to the formation of oxidative base damages
in DNA. Among these forms the most common one and the one which has the
best known mutagenity is 8-hydroxy-2’-deoxyguanosine (8-OHdG).
Aims: We aimed to determine IDA and its different forms of treatments’ (p.o.,
i.m., i.v.); probable oxidative damage on DNA by looking at the level of 8-OHdG.
In this way, we aimed to bring a new perspective to the treatment of IDA.
Methods: The total number of patients studied was 80 and 60 of them had IDA
and the rest were healthy control group. The patients were divided into 4 sub-
groups: (First group: Oral treatment (p.o.) group with 20 patients]; Second group:
Intramuscular treatment (i.m.) group with 20 patients]; Third group: Intravenous
treatment (i.v.) group with 20 patients]; Fourth group: Healthy control group 20
patients]. Blood and urine samples were taken from all patients totally four times;
just before the treatment, at the twenty-fourth hour of treatment, at the first week
of treatment and at the third month of the treatment. 8-OHdG levels detected in
blood and urine samples were compared with the control group. 
Results: Especially at the twenty-fourth hour of treatment and also at each stage,
statistical significance high was detected at the 8-hydroxy-2-deoxyguanosine
blood and urine level in i.v. group compared to other groups (p<0.05).
Summary and Conclusions: IDA and the treatment of it affect the level of 8-
OHdG. Oral iron therapy should be the top priority on children. If p.o. iron ther-
apy cannot be applied, i.m. iron therapy can be preferable. Intravenous iron
treatment might be chosen if the indications make a need.
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SEVERE NEONATAL JAUNDICE DUE TO A DE NOVO GLUCOSE-6-PHOS-
PHATE DEHYDROGENASE DEFICIENT CLASS I MUTATION
R. Del Orbe Barreto1,* B. Arrizabalaga2, L. Manco3, C. Bento4, L. Ribeiro4,
J.C. García-Ruiz2
1Biocruces Health Research Institute, 2Hematology, Cruces University Hospi-
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Background: G6PD deficiency is the most common human enzyme deficiency
worldwide. Acute hemolysis induced by exposure to oxidative stress, as infec-
tion, drugs or fava beans ingestion, is the most frequent clinical presentation,
however G6PD deficiency can be a major contributor to neonatal hyperbiliru-
binemia. To date different mutations causing chronic non spherocytic hemolytic
anemia (CNSHA) have been identified. Most of these class I mutations lead to
amino acids replacements close to the dimer interface and the “structural
NADP+”, suggesting that that the integrity of these regions is very important to
form stable dimmers. 
Aims: To report a case a of a newborn infant with severe G6PD deficiency
associated with a de novo G6PD class I mutation.
Methods:The patient was born by caesarean section after a 39 weeks gesta-
tion. Parents of Spanish origin were non-consanguineous and no family mem-
bers had a history of anemia or jaundice. A few minutes after birth the patient
developed clinical respiratory distress accompanied by skin pallor and jaundice.
Hb of 9 g/dL and data of extravascular hemolysis were evidenced. He required
a blood transfusion and later blood exchange transfusion at 15 hours of life for
hyperbilirubinemia (maximum of 17.4 mg/dL, mostly indirect). The episode was
associated with mild thrombocytopenia requiring transfusion of a platelet unit.
Biochemical analysis: All tests and evaluations were performed in accordance
with the Declaration of Helsinki and after parents’ informed consent given.
G6PD enzyme activity assays in the red blood cell hemolysates were performed
by quantitative spectrophotometer analysis according to the recommendations
of the International Committee for Standardization in Hematology (ICSH). DNA
analysis: Mutation screening of genes encoding erythrocyte enzymes, beta glo-
bin and membrane proteins was performed on a Next Generation Sequencing
platform (Ion Torrent PGM, Life technologies, Carlsbad, CA, USA). The founded
variants were confirmed by direct sequencing by dideoxy chain termination
reaction using the ABI PRISM BigDye Terminator v1.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, USA). Investigation of the new mutation was
assessed by bi-directional sequencing of G6PD gene in proband’s and mother’s
independent DNA samples obtained from EDTA peripheral blood, buccal cells
and hair. HLA-STR markers were analyzed in proband and relatives to confirm
mother-child genetic relationships using Luminex (Gen-Probe Transplant Diag-
nostics, Stamford, CT, United States).
Results: Enzymatic study was performed in the reference laboratory, in which
a G6PD deficiency was present (145 mU/109 RBC; normal value: 221-570
mU/109 RBC) and confirmed with a second quantification (<35 mU/109 RBC).
The sequencing analysis on the male proband, revealed a previously described
cytosine to timine transition at position c.827 on exon 8, resulting in the amino
acid change proline to leucine at the residue position 276 (c.827C>T;
p.Pro276Leu). The c.827C>T mutation was absent in the proband’s mother
genomic DNA, suggesting that this is a spontaneously occurring new genetic
alteration i.e., a de novo G6PD mutation. 
Summary and Conclusions: We report a case of a severe G6PD deficient
male with neonatal persistent jaundice accompanied by mild anemia and evi-
dence of extravascular haemolysis, requiring a blood transfusion and later
blood exchange transfusion at 15 hours of life for hyperbilirubinemia. NGS
analysis is a powerfull tool that let to conduct a comprehensive screening for
different diseases in a serious situation such as neonatal jaundice, where the
enzyme activity assays and peripheral morphology cannot provide sufficient
data to establish a diagnostic approach. In conclusion, this de novo
p.Pro276Leu mutation underlying a CNSHA phenotype (class I variant) maps
near the dimer interface of G6PD protein, and may severely compromise the
formation of the dimmer affecting enzyme stability and the steady-state level of
G6PD is so low, limiting for the survival of red cells even in the absence of any
oxidant challenge.
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THE CLINICAL FEATURES AND TREATMENT OF IRON OVERLOAD IN
PYRUVATE KINASE DEFICIENCY (PKD): DATA FROM THE PKD NATURAL
HISTORY STUDY (NHS)
D.H. Morton1, C. Knoll2, J. Rothman3, B. Glader4, E. Neufeld5, W. Barcellini6,
S. Eber7, H. Yaish8, J. Despotovic9, A. Thompson10, N. Usmani11, K. Nottage12,
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Background: Both transfusion-associated and transfusion independent iron
overload occur in individuals with congenital hemolytic anemias, particularly in
those with ineffective erythropoiesis. The prevalence and monitoring practices
differ by type of anemia, and these are not well described for PKD.
Aims: To describe the demographic features, co-inheritance of hereditary
hemochromatosis, iron monitoring, and chelation practices in transfusion
dependent and transfusion independent PKD patients (pts) with iron overload.
Methods: Between March 2014 and January 2015, 105 pts with PKD enrolled
on the PKD NHS at 14 IRB approved sites. For this study, baseline and retro-
spective enrollment data were included. Log10 transformation was applied to
liver iron concentration (LIC) by T2* MRI and ferritin values to improve normality.
Analysis of variance was performed to test for associations of LIC and/or ferritin
with categorical covariates of interest. General linear regression models were
used to identify the association of LIC and ferritin with continuous variables.
Analyses were performed in the overall cohort and repeated excluding the 46
Amish pts with a homozygous 1436G>A mutation. Significant results are report-
ed for those that were identified in either of the analyses.
Results: Of the 105 PKD pts, iron screening data were available for 71 (68%)
with ferritin [35/71 Amish] and 49 (47%) with LIC [40/49 Amish]. Ferritin was
significantly higher in pts who had a prior splenectomy, even after controlling
for transfusion history (p=0.01). Higher ferritin correlated with higher LIC (n=38;
p<0.0001, Figure 1); however, LIC was not significantly higher in pts with prior
splenectomy (p=0.23). In the 9 pts with available LIC measurements who had
never been transfused or only transfused for acute stressors, 7 had a LIC >4
mg/g dry weight (DW) liver. Based on clinical screening, 4 (3.8%) pts had a
homozygous mutation associated with hereditary hemochromatosis (HH), and
8 (7.6%) pts were heterozygotes. HH was not found to be significantly associ-
ated with an elevated ferritin (p=0.23) or LIC (p=0.80). Older age was signifi-
cantly associated with higher baseline ferritin (p=0.005).
21 non-Amish pts (20%) had received chelation therapy starting at a median age
of 11.4 years (range 1-44 years). Median ferritin and LIC at the start of chelation
were 1131 ng/ml (range 182-5630) and 8.3 mg/g DW liver (4.3-46), respectively.
Chelator types included: Deferoxamine (n=9), deferasirox (n=13), deferiprone
(n=2), and combination chelation (n=2). Of the 21 who received chelation, 5 had
complications: abdominal pain, ulcers, diarrhea, serum sickness, rash, kidney
stone, hearing loss, and/or vision loss. Only 1 pt had a LIC measured both before
and during/after chelation; thus, there is insufficient data to report efficacy by LIC.
Two pts had phlebotomy for iron removal with no improvement in ferritin or LIC.
Figure 1. Correlation of ferritin (ng/ml) and liver iron concentration (mg/g
dry weight liver) in the Pyruvate kinase deficiency natural history study
(n=38).
Summary and Conclusions: Iron overload assessed by ferritin or LIC was
common in all age groups regardless of transfusion history when monitored in
this cohort of PKD pts, but monitoring had not been performed in 30% of this
cohort. The efficacy of chelation in PKD is unknown, as most pts in this cohort
were not adequately monitored. Since the cohort in the NHS with iron testing
was mainly Amish, these results may not apply to PKD pts with other mutations.
Ferritin correlates well with LIC in this cohort; thus, regular ferritin testing starting
in early childhood could be considered to screen PKD pts for iron overload.
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THE QUESTIONING OF THE NEED FOR MONTHLY MONITORING OF PRO-
TENURIA AMONG PATIENTS WITH BETA THALASSEMIA MAJOR USING
DEFERASIROX
F. Gumruk1,* O. Unlu2, H. Kucuker2, A.D. Tutal1, T. Bayhan1, S. Unal1
1Hacettepe University, Division of Pediatric Hematology, 2Hacettepe Universtity,
Faculty of Medicine, Ankara, Turkey
Background: The major cause of morbidity and mortality among patients with
beta-thalassemia major (BTM) is transfusional iron accumulation in heart, liver
and endocrine organs and iron chelation is the mainstay of the treatment in these
patients. Deferasirox is an oral, once-daily active iron chelating agent and nephro-
toxicity is a common toxicity among users. Nephrotoxicity of deferasirox is usually
manifested with usually clinically significant rises in serum creatinin levels or
rarely with renal failure especially among patients with concomitant health prob-
lems. Proteinuria is also one of the potential adverse effects of deferasirox and
monthly follow-up for proteinuria is suggested by FDA and EMA. 
Aims: In this study, we aimed to investigate the necessity for monthly monitor-
ing for proteinuria among patients with BTM on deferasirox.
Methods: Thirthy-seven patients with BTM on deferasirox therapy were
enrolled. Median age of the patients was 23 years (4-39); 22 being females. At
the time of initiation of deferasirox all patients had normal serum creatinine,
glomerular filtration rate and spot urine protein/creatinine ratios. All patients
were monitored for proteinuria q3 or q4 weeks after initiation of deferasirox
with serum creatinin and spot urine protein/creatinine ratios throughout the
course of deferasirox treatment. The management of patients who developed
spot urine protein/creatinine ratio ≥0.8 were recorded.
Results: The median follow-up time of the 37 patients was 44 months. Through-
out this follow-up time 1490 times of testing was done for proteinuria detection.
Although all patients were ordered urine test at each visit (1987 order), 1490 of
the patients delivered their urine samples to laboratory; indicating a test compli-
ance of 75%. Of the patients, 7 (18.9%) developed significant proteinuria (ratio
≥0.8). Of the 1490 measurements, 12 tests (0.8%) were proteinuric. The risk of
proteinuria was higher at ages above a cut-off point of 23 years (p=0,019).
Patients who were on deferasirox at doses above 29 mg/kg/day were found to
have higher risk of proteinuria development (p=0.004). The patients who devel-
oped proteinuria had a concomitant rise in serum creatinine level more than 50%
of the serum creatinine level measured at deferasirox initiation. Of the proteinuria
occurences, three resolved after 1 week of drug cessation. The rest of the pro-
teinura cases resolved spontaneously in 1 to 3 visits of time, without any inter-
vention. None of the patients required hospitalization for proteinuria.
Summary and Conclusions: The compliance of the patients for monthly fol-
low-up proteinuria is not satisfactory. Additionally, the proteinuria usually
resolves without any complication or major intervention. Potentially more risky
groups (age above 23 years-old and dose above 29 mg/kg/day) might be sug-
gested to be followed monthly, other than monitoring all of the patients.
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CAUSES OF NEWLY DIAGNOSED ANAEMIA IN GENERAL PRACTICE:
THE RELEVANCE OF MCV
K. Stouten1,* J. Riedl1, P. Sonneveld2, M.-D. Levin1
1Albert Schweitzer hospital, Dordrecht, 2Erasmus MC, Rotterdam, Netherlands
Background: Anemia is a common finding amongst the elderly population and
its prevalence rises from about 5.6% in the age group 50-64 years to about
23.1% in the age group 85+ years. In recent years it has been shown anemia
is associated with increased mortality and morbidity and decreased quality of
life. Despite anemia being such a frequently encountered clinical problem, sur-
prisingly few data are available on the prevalence of the underlying causes.
Several studies on causes of anemia in the general population have been pub-
lished, but these generally included relatively small patient numbers and pro-
vided a limited analysis of underlying causes. A large cohort study of general
practice patients with newly discovered anemia was set up to allow for an
extensive analysis of the causes of anemia and to assess the validity of MCV-
based algorithms used for the diagnosis of the underlying cause.
Aims: To analyse the causes of anemia in general practice and assess the
validity of MCV-based algorithms.
Methods: Patients were included after presenting to one of the 63 participating
general practitioners with a newly diagnosed anemia (i.e. no diagnosis of ane-
mia in the preceding two years). Anemia was defined as hemoglobin level
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below 13.7 g/dL (8.5 mmol/L, men) and below 12.1 g/dL (7.5 mmol/L, women).
The inclusion period lasted from the 1st of February 2007 until the 1st of Feb-
ruary 2013. The follow-up period ended on the 1st of September 2013. Both
men and women were included when aged 50 years or older. A wide range of
parameters was analyzed for each patients to aid diagnosis. Two experts inde-
pendently reviewed the laboratory results of all patients and established the
underlying cause of anemia. In case of discordance, the experts deliberated
until a consensus was reached. The population was divided into age groups
(50-64, 65-74. 75-84 and 85+), class of anemia (based on MCV) and type of
anemia (based on hemoglobin). The differences between age groups, classes
and types were analyzed. 
Results: A total number of 2513 patients were included in the study, 1238
men (median age 72 years) and 1275 women (median age 77 years). A single
cause of anemia was found in 2284 patients (90.9%). Anemia of chronic dis-
ease was found 823 times (29.8%), renal anemia 340 times (12.3%), haemo-
globinopathy 17 times (0.6%), hemolysis 16 times (0.6%) and possible bone
marrow disease 105 times (3.8%). Vitamin B12 deficiency was found 115
times (4.2%), iron deficiency 516 times (18.7%) and folic acid deficiency 23
times (0.8%). Other causes were found 106 times (3.8%). The cause
remained unknown in 703 cases (25.4%). Iron deficiency and haemoglo-
binopathy were significantly associated with microcytic anemia, while anemia
of chronic disease and unknown were significantly associated with normocytic
anemia. Hemolysis, possible bone marrow disease, vitamin B12 and folic
acid deficiency and other causes were significantly associated with macrocytic
anemia. Apart from haemoglobinopathy, all causes were found in each class
at least once. Other observations included a prevalence of renal anemia rising
with age. In addition, anemia of chronic disease and unknown anemia were
associated with mild anemia, while iron deficiency and hemolysis were asso-
ciated with severe anemia. 
Summary and Conclusions: Several diagnostic algorithms developed for
determining the cause of anemia generally attribute a specific set of causes to
microcytic, normocytic and macrocytic anemia. Here it was shown causes of
anemia should not be excluded based solely on the MCV value, indicating
these existing algorithms should be reconsidered. 
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USEFULNESS OF LASER ASSISTED OPTICAL ROTATIONAL CELL ANA-
LYZER (LORRCA) IN THE DIAGNOSIS OF HEREDITARY HAEMOLYTIC
ANAEMIAS
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Background: Hereditary hemolytic anemias (HAs) are heterogeneous dis-
orders mainly due to defects of red cell (RBC) membrane and metabolism.
Hereditary spherocytosis (HS), elliptocytosis, and more rarely stomatocytosis
(dehydrated, DHSt and overhydrated), are caused by defects of cytoskeleton
or membrane permeability. Among RBC enzyme defects pyruvate kinase (PK)
deficiency is the most common, followed by glucose-6-phosphate isomerase
(GPI), and pyrimidine 5’-nucleotidase (P5’N) deficiency. Because of the rarity
and heterogeneity of these diseases, diagnosis may be often challenging,
notwithstanding the availability of a battery of laboratory tests. Ektacytometry,
and more recently, laser-assisted optical rotational cell analyser (LoRRca
MaxSis, Mechatronics Instruments, NL), able to measure RBC deformability
in osmotic gradient conditions (Osmoscan), is reported to be a useful tool in
the detection of RBC membrane disorders and in particular for the differential
diagnosis of HSt; few data are available in other haemolytic anemias.
Aims: To evaluate the diagnostic power of LoRRca MaxSis in the diagnosis
of RBC membrane disorders and other haemolytic conditions in a cohort of
84 patients with a confirmed diagnosis of haemolytic anemia of different cause
Methods: We analysed the Osmoscan curves in 54 cases with RBC membrane
disorders (47 HS, 7 DHSt), 17 cases with enzymopathies (11 PK, 4 GPI, 2
P5’N), 7 with congenital dyserythropoietic anemia type II (CDAII) and 6 patients
with paroxysmal nocturnal hemoglobinuria (PNH). Among them 5 HS, 2 PK, 3
GPI, 2 P5’N and 5 CDAII patients were splenectomysed. Normal ektacytometry
curves were obtained from 75 healthy control subjects. The evaluated param-
eters were: 1) Omin (osmolality at which the elongation index (EI) is minimal,
coinciding with the 50% haemolysis in osmotic fragility assays), 2) EImax (max-
imal deformability), 3) Ohyper (osmolality at ½EImax, representing cellular
hydration status). Moreover, patients’ curves were compared with a normal
control reference curve interval. All the analyses were performed on EDTA
blood sample, stored at 4°C and within 48h from collection.
Results: All the 47 HS (27 spectrin, 16 band3 deficiency and 4 with unde-
tectable defect at SDS-PAGE analysis) showed typical altered ektacytometry
curve, consistently with the reduced area of the curve and regardless the
biochemical membrane defect. (Figure 1a). The 7 DHSt patients displayed
the typical left-shift of the curve (Figure 1b). All GPI cases showed an altered
enlarged Osmoscan curve associated with significant increased Ohyper (Fig-
ure 1c). No alterations were found in not-splenectomised PK (n=9), CDAII
(n=2) cases, and in all PNH cases (Figure 1d). However, osmoscan curves
of splectomized PK (n=2), CDAII (n=5), and P5’N (n=2) patients fell in a
defined atypical area, regardless the pathology (Figure 1e).
Figure 1.
Summary and Conclusions: All the HS and DHSt patients analysed showed
diagnostic Osmoscan curves. Among the analysed parameters Omin and
EImax were more significantly altered in HS patients, whereas Ohyper was
significantly increased in GPI deficiency. For the first time abnormal Osmoscan
curve was described in GPI deficiency, offering a new tool for the diagnosis of
this rare enzyme defect. Splenectomy may interfere on the RBC deformability
evaluation, thus suggesting caution in the interpretation of curves. Osmoscan
analysis performed by LoRRca Maxsis represents a useful and feasible first
step screening test in the diagnosis of RBC membrane disorders and other
rare haemolytic anemias.
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IDIOPATHIC AND CONGENITAL ERYTHROCYTOSIS: A STUDY OF A
LARGE COHORT
M.L. Randi1,* E. Cosi1, E. Peroni1, M.C. Putti2, I. Bertozzi1, C. Santarossa1,
F. Fabris1
1Dept of Medicine-DIMED, 2Women’s and Children’s Health-SDB, Pediatric
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Background: Idiopathic Erythrocytosis (IE) is an absolute erythrocytosis (esti-
mated prevalence 1.1 casesx 1000 persons) without an identified cause and
its diagnosis is based on the exclusion of primary or secondary erythrocytosis.
Familial erythrocytosis (FE) are rare diseases sometimes recessively transmit-
ted and we and others have studied patients with congenital erythrocytosis (i.e.
VHL mutation) while the relatives carrying the same heterozygous mutation
show no signs of erythrocytosis. Therefore, FE may be diagnosed as IE, as
well as 1% of patients with Polycythemia Vera (PV) who do not carry a JAK2
mutation (JAK2-WT).
Aims: We tried to recognize, within a large cohort of patients with erythrocyto-
sis, simple features able to discriminate IE, FE and PV.
Methods: Over the last 20 years, we followed 99 patients with JAK2-wild-type
(JAK2-WT) erythrocytosis in whom a complete molecular study was available.
The molecular study was performed during follow up in all the patients diagnosed
before 2005. 78 patients were considered as IE after exclusion of secondary
causes of erythrocytosis or a negative family history; 21 patients have been clas-
sified as FE in the presence of a familial pattern or the demonstration of EPO-R,
PHD2, VHL or HIF1-2-alpha mutation. As controls we used 136 PV patients car-
rying JAK2V617F (allele burden 49±31%) or JAK2 exon 12 mutations. The Ethical
Committee of Padua Hospital approved the study. Nominal variables were com-
pared with thex2 test and continuous variables with the Mann-Whitney test. Logis-
tic regression model was used for multivariate analysis.
Results: The clinical and laboratory data of our patients, collected at diagnosis,
are summarized in the Table 1 (serum EPO [EPOs] in FE is extremely variable
and not considered in the statistical analysis). FE patients were significantly
younger in comparison with both IE and PV (p <0.001). In multivariate analysis,
low EPOs, high platelet count, thrombosis at or before diagnosis and
splenomegaly were confirmed as independent features non-suggestive for IE
when compared to PV. During follow-up no haematological progression to
myelofibrosis (MF) or acute leukaemia (AL) was observed in IE and FE, while
9 PV patients evolved in MF and 3 in AL. None of FE nor IE patient out of the
28 (35.9%) with a follow-up longer than 5 years nor the 12 (8.3%) with a FU
longer than 10 years progressed into an over PV.
Summary and Conclusions: This is a large cohort of IE and FE patients com-
pared with PV patients followed in a single centre. Our data suggest that, in a
patient with erythrocytosis associated with increased platelet count and/or
splenomegaly and suppressed EPOs, PV as to be suspected. In contrast, nor-
mal spleen, normal platelets count and no cardiovascular complications argued
haematologica | 2015; 100(s1) | 589
Vienna, Austria, June 11 - 14, 2015
against early forms of PV. This study confirms that IE is a common and indolent
form of erythrocytosis with a low risk of thrombosis. The role of phlebotomies
and low-dose aspirin is still debated, but cytotoxic drugs seem to be avoided.
We failed to identify simply clinical or laboratory data that can distinguish IE
and FE even if the latest is found often in very young people. The observation




LEFT VENTRICULAR GLOBAL FUNCTION INDEX AND LEFT VENTRICU-
LAR MASS VOLUME RATIO BY CMR: ASSOCIATION WITH HEART FAIL-
URE AND ARRHYTHMIAS IN THALASSEMIA MAJOR PATIENTS
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Background: Recently two novels indicators of left ventricular (LV) perform-
ance assessed by Cardiovascular Magnetic Resonance (CMR) have been
introduced: the LV global function index (LVGFI) and the LV mass/volume ratio
(LVMVR). The LVGFI combines LV stroke volume, end-systolic and end dias-
tolic volumes, as well as LV mass, integrating structural as well as mechanical
behaviour. Elevated LVMVR is indicative of concentric remodelling. A LVGFI
<37% and a LVMVR>1 were shown to be associated with the occurrence of
cardiovascular events in no-thalassemic populations.
Aims: This retrospective cohort study aimed to systematically evaluate in a
large historical cohort of thalassemia major (TM) in the CMR era whether the
LVGFI and the LVMVR were associated with a higher risk of heart failure and
arrhythmias.
Methods: We considered 812 TM patients (391 M, 30.4±8.6 years), consecu-
tively enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) network.
LVGFI and LVMRI were quantitatively evaluated by SSFP cine images. The
T2* value in all the 16 cardiac segments was evaluated and a global heart T2*
value <20 ms was considered indicative of myocardial iron overload (MIO).
Results: Eighty (9.9%) patients had a LVGFI<37% and, compared to the patients
with a normal LVGFI, they showed a significant higher frequency of heart failure
(43.8% vs 4.2%; P<0.0001) and of arrhythmias (7.5% vs 3.0%; P=0.036).
Patients with a LVGFI<37% had a significant higher risk of heart failure (odds-
ratio-OR=17.59, 95%CI=9.95-21.09; P=<0.001). The risk remained significant
also adjusting for the presence of MIO (OR=15.54, 95%CI=8.05-26.27;
P=<0.001). Patients with a LVGFI<37% had a significant higher risk of arrhyth-
mias (OR=2.62, 95%CI=1.03-6.66; P=<0.001). No adjustement was performed
since arrhythmias were not associated to MIO. Thirty (3.7%) patients had a
LVMVR≥1% and, compared to the patients with a normal LVMRI, they showed
a significant higher frequency of heart failure (20.0% vs 7.7%; P=0.015) but not
of arrhythmias. Patients with a LVMVR≥1% had a significant higher risk of heart
failure (OR=3.01, 95%CI=1.18-7.64; P=0.021). The risk remained significant also
adjusting for the presence of MIO (OR=3.44, 95%CI=1.31-9.01; P=0.012). In a
multivariate model including LVGFI, LVMVR and heart iron, the significant pre-
dictors of heart failure were a LVGFI<37% (OR=14.05, 95%CI=7.66-25.77;
P=<0.001) and a global heart T2*<20 ms (OR=1.94, 95%CI=1.08-3.47; P=0.026).
Summary and Conclusions: In TM patients a LVGFI<37% was strongly asso-
ciated with an higher risk of heart failure, independent by the presence of MIO.
Moreover, patients with a LVGFI<37% were more likely to have arrhythmias.
A widespread program using CMR exploiting its multi-parametric potential can
have considerable power for the early identification and treatment of patients
at risk for heart failure.
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Background: In 2004 seven Italian centers reported survival data for patients
with thalassemia major (TM) and showed that heart disease due to iron over-
load was the most common cause of death (Borgna et al. Haematologica 2004).
In the same years the accurate and noninvasive assessment of cardiac sidero-
sis was made possible in Italy by the introduction of the T2* cardiovascular
magnetic resonance (CMR).
Aims: We aimed to evaluate if the deployment of T2* CMR had an impact on
the mortality rate.
Methods: Four centers contributed to the present study, updating the data of
the enrolled patients until August 31, 2010. For the patients who died, the date
of the death represented the end of the study. 577 patients (264 females and
313 males) were included.
Results: One-hundred and fifty-nine (27.6%) patients died, 124 of whom
(77.9%) died before the year 2000. MRI was not performed in 406 patients
(70.4%) and no patient had been scanned before his/her death. Among the
survivors, MRI was not performed in the 59% of the cases (P<0.0001). The
absence of an MRI scan was a significant univariate prognosticator for death
(HR=43.25, 95%CI=11.32-165.33, P<0.0001). The study was restricted to the
patients dead after 2004 (19/159=12%) or followed until August 2010 (N=357).
In this subgroup of 376 patients, MRI was not performed in the 52.4% of the
survivors and in all dead patients (P<0.0001). The absence of a MRI exam
was reconfirmed as a strong predictive factor for death (HR=49.37,
95%CI=1.08-2263.24, P=0.046). The Kaplan-Meier curve is showed in Figure
1. The log-rank test revealed a significant difference in the curves (P<0.0001).
Figure 1.
Summary and Conclusions: Our data suggests that the use of T2* CMR,
that enables individually tailored chelation regimes reducing the likelihood of
developing decompensated cardiac failure, allowed the reduction of cardiac
mortality in chronically transfused TM patients.
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A NON-INTERVENTIONAL OBSERVATIONAL STUDY ASSESSING SAFE-
TY OF DEFERASIROX IN PATIENTS WITH HEMOGLOBINOPATHIES AND
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Background: A spectrum of large clinical programs has established the efficacy
and safety of the oral iron chelator deferasirox (DFX) in transfusion-dependent
patients with iron overload. We report the results from a multicenter, prospec-
tive, open-label, observational study reflecting the standard clinical practice in
thalassemia centers in Greece.
Aims: To assess the safety profile of DFX in transfusion-dependent patients
with iron overload.
Methods: Patients with hemoglobinopathies and transfusional iron overload,
baseline serum ferritin levels <4000 ng/mL, and for whom the physician decided
to initiate chelation with DFX under the local approved label and standard med-
ical practice, were included in the study. Patients with myelodysplastic syn-
dromes, severe cardiac siderosis (T2* <10 ms), left ventricular ejection fraction
<56%, serum creatinine (SrCr) >upper limit of normal (ULN), alanine amino-
transferase (ALT) ≥500 U/L, creatinine clearance (CrCl) <60 mL/min or signif-
icant proteinuria were not eligible. 
Results: Of the 230 patients enrolled, 226 were evaluated (4 patients were
excluded due to screen failures); a subset of the enrolled patients were pediatric
(age <16 years, n=24). Mean age was 35.1±13.8 (pediatric, 8.7±4.2; adults,
38.3±10.9) years. The most common underlying conditions for transfusional iron
overload were β-thalassemia major (66.8%, n=151), thalassemia intermedia
(17.7%, n=40), and sickle cell anemia (9.3%, n=21). Prior chelation treatment
was reported for 146 (64.6%) patients, most common being a combination of
deferoxamine and deferiprone (19.0%; n=43). None of the patients had prior DFX
exposure. Of the 226 evaluable patients, 179 completed the 12-month observa-
tion period, whereas 47 withdrew from the study prematurely. The 3 main reasons
for discontinuation were adverse events (AEs; 7.1, n=16), lost to follow-up (4.4%,
n=10), and consent withdrawal (2.2%, n=5). A total of 356 non-serious AEs were
reported in 103 (45.6%) patients, of which 167 AEs observed in 65 patients
(28.8%) were reported to be related to DFX. The most common non-serious AEs
related to DFX were increase in SrCr above ULN (8.4%), upper abdominal pain
(4.9%), and diarrhea (4.0%). Twenty-one (9.3%) patients experienced 56 serious
AEs (SAEs), of which 13 SAEs in 3 patients (1.3%) were reported to be related
to DFX, including gastrointestinal disorders (9 events), abnormal ALT, albumin
above ULN, musculoskeletal pain and cholecystectomy (all 1 event each). The
mean SrCr levels increased from 0.69 mg/dL at baseline to 0.74 mg/dL at 12
months, and the mean CrCL decreased from 127 mL/min at baseline to 123
mL/min (p<0.001 and p=0.015 for the mean differences, respectively). Transam-
inases (ALT and aspartate aminotransferase, [AST]) did not show an increase at
any point in time. Notably, while AST showed a decreasing trend at 12 months
(p=0.052), ALT decreased significantly at 12 months (p<0.001). Of the 15 patients
who underwent ocular examination, an improvement was seen in 1 patient, while
no changes were observed in the remaining patients. Of the 13 patients who
underwent auditory examination, an improvement was noted in 1 patient, 1 patient
showed deterioration, and 11 patients did not show any change.
Summary and Conclusions: This 1-year, multicenter, observational study
conducted in Greece, under standard clinical practice, showed that the safety
profile of DFX was consistent with previously published data.
Acknowledgement: We acknowledge the efforts of personnel from all sites,
involved in this study. Authorship was based on study enrollment.
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DESCRIPTIVE ANALYSES OF DEFERASIROX SAFETY AND EXPOSURE
IN PATIENTS AGED >65 VERSUS 18 TO ≤65 YEARS
N. Gattermann1, J.B. Porter2, C. Rose3, A. Bruederle4, J. Han5, N. Coello5,
M.D. Cappellini on behalf of EPIC study investigators6,*
1Heinrich-Heine-Universitat, Düsseldorf, Germany, 2University College London,
London, United Kingdom, 3Hôpital Saint-Vincent de Paul, Lille, France, 4Novartis
Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals, East Hanover, Unit-
ed States, 6Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy
Background: Patients discontinued from the EPIC study most frequently due
to adverse events (AEs). Discontinuation rates due to AEs were notably higher
in the MDS cohort (n=78/341, 22.9%; mean age 67.9 yrs) compared with the
overall EPIC population (n=153/1744, 8.8%; mean age 30.6 yrs); most fre-
quently due to gastrointestinal (GI)-related AEs (Gattermann et al. Leuk Res
2010). Altered drug exposure is known to be clinically relevant in elderly patients
for different drugs. It is hypothesized that differences in deferasirox pharmaco-
kinetics (PK) could contribute to observed differences in AEs.
Aims: 1. To determine whether there is a higher incidence of selected AEs in
elderly adult (>65 yrs) vs younger adult patients (18-≤65 yrs); 2. To investigate
whether variations in AE frequency were due to differences in deferasirox PK.
Methods: EPIC study design and inclusion/exclusion criteria have been previ-
ously described (Cappellini et al. Haematologica 2010). Patients initially received
deferasirox 10-30 mg/kg/day, depending on blood transfusions frequency, with
dose adjustments of 5-10 up to 40 mg/kg/day, based on 3-month serum ferritin
trends and safety markers. For this safety analysis, frequency of selected AEs of
clinical interest over 1 year (abdominal pain, diarrhea, nausea, vomiting, gas-
troenteritis, rash, renal-related) were summarized by age category. Relative risk
and 95% confidence intervals (CI) were estimated based on a non-modeling
approach. For PK analyses, steady state trough deferasirox concentration
(Ctrough,ss) and concentration measured 2 hours post-dose (C2hr) ‒ surrogates
for drug exposure (AUC) and peak levels (Cmax), respectively ‒ were described
by age category in all patients with available data, regardless of underlying dis-
ease, and in MDS patients only. A regression analysis of deferasirox dose-nor-
malized concentration versus age was also performed at Weeks 12 and 28.
Results: In total, 1079 patients ≥18 yrs were enrolled: n=837 aged 18-≤65 and
n=242 aged >65 yrs. Overall, 210/242 patients >65 yrs had MDS. The frequen-
cies and relative risks of reported AEs of interest are summarized (Table 1).
There was a significantly increased risk of diarrhea and renal AEs in patients
aged >65 vs 18‒≤65 yrs and a significantly reduced risk of rash. Distributions
of deferasirox dose-normalized Ctrough,ss and C2hr were comparable between
patients aged >65 vs 18‒≤65 yrs in the overall patient population with PK avail-
able (n=748) and within MDS patients only (n=232). There was no trend for
altered total drug exposure or peak levels between the two age categories.
Table 1. Frequencies and relative risks of reported AEs on interest in
younger adult (18-≤65 years) versus elderly adult (>65 years) patients in
the EPIC study.
Summary and Conclusions: There were differences in the deferasirox AE
profile between patients aged >65 vs 18‒≤65 yrs. Diarrhea was the only GI-
related AE significantly more frequent in patients >65 yrs; others did not differ
significantly. Renal AEs were also significantly more frequent in patients >65
yrs, possibly due to higher baseline serum creatinine levels, common in older
patients. AE variations did not appear attributable to differences in deferasirox
exposure as assessed by Ctrough,ss and C2hr. Therefore, this analysis does not
support the need for considering deferasirox dose adjustments based on dif-
ferences in drug exposure in elderly patients. Since the majority of elderly
patients had MDS, concomitant medications/underlying complications may
have influenced the AE profile, and should, therefore, be considered during
deferasirox therapy to anticipate and manage AEs.
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SERUM CYSTATIN C IN SICKLE CELL DISEASE: RELATION TO CARDIO-
VASCULAR DYSFUNCTION AND SICKLE CELL NEPHROPATHY
A. Tantawy1,* A.A. Adly1, E. Ismail2, M. Abd Elazeem1
1Pediatrics, 2Clinical Pathology, Ain Shams University, Sairo, Egypt
Background: Sickle cell disease (SCD) patients have ongoing hemolysis and
inflammation secondary to the sickling phenomenon. Many mechanisms con-
tribute to the complex pathophysiology of SCD, with dysfunction of the vascular
endothelium as a unifying theme. Renal dysfunction is a leading cause of mor-
bidity in sickle cell disease. Cystatin C has been recognized as a useful marker
of renal dysfunction and a strong predictor for risk of cardiovascular events. 
Aims: To determine the level of cystatin C in 53 children and adolescents with
SCD compared with 35 age- and sex-matched healthy controls and to assess
its relation to markers of hemolysis, iron overload, renal affection and endothelial
dysfunction.
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Methods: SCD patients in steady state were studied stressing on transfusion
history, hydroxyurea therapy, hematological profile, serum ferritin and urinary
albumin creatinine ratio (UACR). Cystatin C was measured by enzyme linked
immunosorbent assay (ELISA). Ecchocardiograhy was performed and carotid
intima media thickness (CIMT) of the common carotid artery was assessed
using high resolution ultrasonography. Heart disease was defined by at sys-
tolic left ventricle (LV) dysfunction (LV shortening fraction <30% or LV ejection
fraction <55%).
Results: Cystatin C levels were significantly higher in SCD patients com-
pared with control group (584.3±232.8 ng/mL versus 100.4±40.6 ng/mL;
p<0.001). SCD patients with nephropathy or heart disease had significantly
higher levels than those without (p<0.001 and p=0.041, respectively). Patients
who had history of frequent sickling crisis (>3 attacks/ year) had higher cys-
tatin C levels than those who were in steady state (p=0.034). SCD patients
on regular hydroxyurea therapy had lower cystatin C levels than untreated
patients (p=0.039). CIMT was elevated among SCD patients than controls
(0.64±0.12 mm versus 0.42±0.02 mm; p<0.001). Cystatin C was positively
correlated with corrected WBCs count (r=0.328, p=0.016), UACR (r=0.605,
p<0.001) and CIMT (r=0.588, p<0.001). The cutoff value of cystatin C at 580
ng/mL could differentiate SCD patients with and without nephropathy with
77.8% sensitivity and specificity of 84.6% while the cutoff value 650 ng/mL
could differentiate SCD patients with and without heart disease with 100%
sensitivity and specificity of 74.4%. 
Summary and Conclusions: Cystatin C may be considered a biological mark-
er for vascular dysfunction and subclinical atherosclerosis in SCD as reflected
by its positive correlation with CIMT. Serum cystatin C correlates with the level
of albuminuria and may be a reliable method to measure renal function in SCD.
Elevated Cystatin C levels would help in early crisis prediction and to identify
patients at risk of cardiac complications as well as monitoring the response to
hydroxyurea therapy. Further longitudinal studies are needed to verify the prac-
tical utility of Cystatin C measurement and validate the cutoff values for detec-
tion of cardiac and renal complications in SCD.
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DEFERASIROX IMPROVES LIVER FIBROSIS IN Β THALASSAEMIA
MAJOR PATIENTS. A 5 YEARS FOLLOW UP STUDY
E. Vlachaki1,* E. Sinakos1, D. Adamidou1, E. Gigi1, E. Chologitas1,
A.-K. Panteliadou1, F. Klonizakis1, E. Mandala1
1Ippokratio Hospital Thessaloniki, Thessaloniki, Greece
Background: β Thalassemia major (βTM) patients often develop liver fibrosis
due to transfusion related liver iron overload and/or hepatitis virus C (HCV)
infection. Transient elastography (TE) is a non-invasive method that accurately
measures liver stiffness (LSM) and therefore could serve as a helpful tool for
the fibrosis assessment.
Aims: To evaluate prospectively the liver fibrosis status in β TM patients being
chelated with deferasirox only and explore the contribution of iron overload in
liver fibrosis course.
Methods: We conducted a prospective 5 years (2008-2013) follow-up study in
22 βTM patients (9 males/13 females) with a median age of 32 (20-47) years.
All patients were HCV PCR negative and on regular transfusion regime (2 RBC
units every 15 days) retaining a pre-transfusion Hb level >9,5gr/dl, had no other
comorbidities and were not on other medications of known effect on LSM. Dur-
ing the study period 7 female patients had to discontinue chelation therapy for
16(12-18) months due to successful pregnancies and restarted deferasirox 12
(8-16) months before the 2nd fibrosis evaluation. Patients were assessed with
TE (LSM in kPa) at baseline-within 35(5-47) days after having been switched
to 35(30-40) mg/Kg deferasirox-and reexamined with the same method by the
same operator at 5 years. Readings of >8 kPa were considered indicators of
severe liver fibrosis. Serum ferritin levels (ng/ml) and MRI T2* liver and cardiac
imaging (using Anderson-Pennell protocol in ms) were concurrently run for the
evaluation of iron overload.
Results: When we analysed the whole group of patients we found a significant
positive correlation between ferritin changes and kPa fluctuation (p<0,004) and
a modest negative correlation among kPa and MRI T2* changes (p<0.06) during
the study period. Nevertheless there were no significant differences in mean
kPa, ferritin levels or liver MRI T2* readings between baseline and 5 years follow
up measurements (6.995 vs 6.573, 1133 vs 1035 and 8.21 vs 8.19 respectively).
Interestingly enough, when we excluded patients that discontinued deferasirox
from the analysis we found significant differences in the mean values of the
examined parameters {kPa: 7.5 vs 6.093 (p<0.035), MRI T2*: 6.5 vs 8.2
(p<0.05), ferritin: 1125 vs 941, at baseline and 5 years follow up respectively}.
In this subgroup there was also a consistent strong positive correlation between
kPa and ferritin fluctuations (p<0.009) and negative correlation with liver MRI
T2* changes, although not significant. In more details, 14 patients succeeded
complete or partial reversal of the liver fibrosis, including 4 with severe disease
at baseline, 1 remained stable and there was no case of progression.
Summary and Conclusions: Based on our data it seems that undisturbed
iron chelation with deferasirox could offer significant improvement in liver fibro-
sis as assessed by means of TE. This is also in line with a better control in iron
overload as shown by the decrease in ferritin levels together with the improve-
ment in liver MRI T2* succeeded throughout the 5 years treatment period.
Duration, compliance and other than the iron overload reduction possible
modes of action are open research fields in order to establish the use of
deferasirox in reversing or stabilizing liver fibrosis in βΤΜ patients.
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PREMATURE ATHEROSCLEROSIS IN CHILDREN WITH BETA- MAJOR
THALASSEMIA: NEW DIAGNOSTIC MARKER
L. Sherief1,* A. Ali1, O. Dawood2, H. Sherbiny3, M. Abd Alhady3, O. Abd Alazez4,
M. Nour3
1Pediatric Hematology & Oncology, 2Radiology, 3Pediatric, 4Biochemistry,
Zagazig university, Zagazig, Egypt
Background: Early vascular alteration, atherosclerosis and coronary artery
disease have emerged as important cardiovascular complications in beta-tha-
lassemia major (BTM) patients due to oxidative stress of iron overload.
Aims: were to assess the prevalence of premature atherosclerosis among
BTM patients, and to investigate the diagnostic value of serum osteoprotogrin
(OPG) as marker for atherosclerosis
Methods: This prospective cross-sectional study included ninety-eight children;
as sixty-five children with beta thalassemia major aged 5-18 years, on regular
blood transfusion regimen represented the patient group. While thirty-three
healthy children, with comparable age and gender, were assigned as control
group. All participants were evaluated for laboratory investigations including;
complete blood count, liver and kidney function tests, hepatitis B and C screen-
ing, C- reactive protein, lipid profile, serum ferritin and serum osteoprotogrin.
Carotid artery intima media thickness (CAIMT) was performed by duplex ultra-
sound for patients and controls.
Results: Our BTM patients were transfusion-dependent for as long as 8.5±3.8
years with significantly higher serum ferritin levels (2490±1579 ng/dl vs 83±32
ng/dl, p=0.001), and C-reactive protein (5.7±5.7 vs 0.9±0.9 when compared to
controls. Significantly higher serum triglyceride (128±20 vs 101±7 mg/dl,
p=0.009) and atherogenic index of plasma (0.45±0.12 vs 0.22±0.04, p=0.001)
were recorded in patients than comparisons. Carotid arteries intima media
thickness (CAIMT) of both side; were significantly increased for patients (Rt
0.62±0.2 vs 0.29±0.07 mm, p=0.001 & Lt 0.66±0.17 vs 0.29±0.05 mm, p=0.001)
when compared with healthy controls, and showed positive correlation with
body mass index (BMI), serum triglyceride, atherogenic index of plasma, and
serum osteoprotogrin levels. Assay of serum osteoprotogrin (OPG) revealed
significantly higher levels for thalassemia patients than healthy peers (427±102
vs 324±126 pg/ml, p=0.02). Of particular interest is the obvious positive corre-
lation between OPG levels and CAIMT of both sides (Rt r 0.54, p=0.001 &Lt r
0.479, p=0.001).
Summary and Conclusions: subclinical atherosclerosis started prematurely
in children with beta- thalassemia. Carotid artery intima media thickness
appeared to correlate well with serum osteoprotogrin. This finding highlighted
the possible validity of OPG assay as an early predictor of atherosclerosis in
thalassemia children
E1478
ASSESSMENT OF LIVER IRON CONCENTRATION IN PATIENTS WITH
THALASSEMIA MAJOR USING MRI TECHNOLOGY: FINAL RESULTS OF
A PROSPECTIVE COMPARATIVE STUDY BETWEEN T2* AND FERRISCAN
E. Voskaridou1,* M. Douskou2, D. Christoulas3, V. Komninaka1, M. Dimopoulou1,
M. Aliberti2, E. Terpos4
1Thalassemia and Sickle Cell Disease Reference Center, Laikon General Hos-
pital, 2Bioiatriki Medical Center, 3Department of Hematology, 251 General Air-
Force Hospital, 4Department of Clinical Therapeutics, National and Kapodis-
trian University of Athens, School of Medicine, Athens, Greece
Background: Iron overload is a significant complication of hemoglobinopathies.
Iron accumulates mainly into the endocrine glands, the liver and the heart leading
to potentially life-threatening events. The accurate monitoring of total body iron
is extremely important in patients with thalassemia major. Magnetic resonance
imaging (MRI) is the most accurate non-invasive technique for the evaluation of
iron overload in thalassemia patients. The MRI gradient echo (T2*), the reciprocal
of T2* (known as R2*) and the spin echo (T2) techniques have managed to quan-
tify tissue iron in the liver and the heart with high sensitivity. Another MRI method-
ology, which is firstly described by St. Pierre et al. (Blood 2005;105:855-61) eval-
uates liver iron concentration (LIC) using R2 (where R2=1/T2) signal decay rates,
commercially available as FerriScan. In that study there was a significant corre-
lation between R2 values and biopsy results. The FerriScan analysis produces
a map of liver iron and calculates a mean LIC measurement.
Aims: The aim of this prospective study was to compare the results of the LIC
evaluation obtained by conventional MRI and by FerriScan in patients with tha-
lassemia major.
Methods: We prospectively studied 21 patients (9M/12F, median age 45 years,
range 38-61 years) with thalassemia major who are followed-up in our Center.
All patients had MR examinations of the liver that were performed on a General
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Electric 1.5T Signa HDxt scanner (GE Healthcare, Milwaukee, USA). The pulse
sequence used to estimate the T2* relaxation time of the examined tissues is
a multi-echo fast gradient echo which has the ability to acquire 3 to 16 echoes
in a breath hold time of 12 to 18 sec. The post processing of the data is per-
formed with use of relevant software on a GE Advantage Windows 4.6 work-
station according to the relevant literature. On the same day serum ferritin was
measured, while LIC was evaluated using the FerriScan methodology. More
specifically, images were transmitted to the FerriScan Analysis Centre in DICOM
format, according to the FerriScan protocol. Images were analyzed off-site, as
previously described by St Pierre et al., and average LIC results were returned
electronically to our center.
Results: All patients were under oral chelation therapy at the time of evaluation.
Their ferritin levels were (mean±SD) 712±648 ng/ml. LIC based on T2* and R2*
values were 7.81±6.32 mg/g dry weight and 302±259 Hz, respectively. LIC values
estimated by FerriScan were 131±133 mmol/kg. There was a strong correlation
between R2* and FerriScan values (r=0.940, p<0.0001). Both R2* and FerriScan
values strongly correlated with ferritin levels (r=0.707, p<0.001 and r=0.721,
p<0.001 respectively). There was no superiority of one of the MRI techniques
versus the other regarding its correlation with serum ferritin (p=0.467).
Summary and Conclusions: This study demonstrated a very strong positive
correlation between R2* values and FerriScan-determined LIC. Furthermore,
we did not find any difference between the correlations of R2* or FerriScan
with serum ferritin. This may be the result of very effective chelation therapies,
as all our patients were under chelation treatment. However, if this result is
confirmed in a larger series of patients, it could potentially lead to more timely
patient results and cost savings as R2* is cheaper and easier to be performed
compared to FerriScan.
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25-OH VITAMIN D DOWN-REGULATES IN VITRO PRODUCTION OF ANTI-
ERITHROCYTE ANTIBODIES IN AUTOIMMUNE HAEMOLYTIC ANAEMIA
B. Fattizzo1,* A. Zaninoni1, J. Giannotta1, A. Cortelezzi2, W. Barcellini1
1UO Oncoematologia, Fondazione IRCCS Ospedale Maggiore Policlinico, 2UO
Oncoematologia, Fondazione IRCCS Ospedale Maggiore Policlinico e Univer-
sità degli Studi, Milano, Italy
Background: Vitamin D is a well known regulator of bone and calcium balance
that has multiple immune-modulating activities. Reduced levels of 25-OH vita-
min D have been found in various autoimmune diseases, such as systemic
lupus systemic lupus erythematous and multiple sclerosis, and its levels and
supplementation did correlate with disease clinical severity.
Aims: We evaluated a) the effect of vitamin D on the in vitro production of anti-
RBC autoantibodies in patients with autoimmune haemolytic anaemia (AIHA);
b) vitamin D levels, VDR expression and immunemodulatory cytokines.
Methods: Clinical and haematological parameters, serum samples and
informed consent were collected at the time of enrolment from January 2013.
25-OH vitamin D levels, VDR and IL-6, IL-10, IL-17, TNF-alfa and IFN-gamma
were evaluated in 40 patients and in 40 age and sex matched healthy controls,
using ELISA kits. Heparinized blood samples from 7 AIHA patients were tested
for anti-RBC production in unstimulated and PWM-stimulated 48h cultures with
or without vitamin D at increasing concentrations (10, 20 and 40 ng/mL). The
number of immunosuppressive therapy lines (steroids, immunosuppressors,
rituximab, splenectomy) were retrospectively collected.
Results: Laboratory features of the patients (15 males and 25 females; mean
age 58 years; 18 CAD, 18 WAIHA and 4 DAT negative AIHA) are shown in Fig-
ure 1a. Vitamin D levels were significantly reduced in patients versus controls,
regardless sex, age nor season at sampling. VDR was increased in patients
compared to controls; IL-6, IL-10, IL-17 and IFN-gamma serum levels were
higher in AIHA patients versus controls, whereas TNF-alfa was significantly
reduced. As shown in Figure 1b, vitamin D (at 10, 20, and 40 ng/mL) exerted
a dose dependent inhibition on in vitro production of anti-RBC antibodies, with
a delta% reduction of 6, 16 and 31 in unstimulated conditions, and 2, 1, 16 in
PWM-stimulated conditions, respectively. As regards treatment at sampling,
24 patients were under low dose steroids (e.g. 0,2-0,5 mg/Kg/day prednisone);
vitamin D status was comparable in treated and untreated cases. Retrospec-
tively, 2 cases were therapy naïve, 13 cases had been treated with steroid only,
15 cases with both steroid and a second line treatment (9 rituximab and 4
cyclophosphamyde), and 10 with more than 2 lines of therapy (4 splenectomy,
10 rituximab and 6 cyclophosphamyde). Vitamin D levels were significantly
lower in patients who had been treated with 2 or more lines of therapy (1,72±1
versus 2,78±2 ng/mL, p=0.04).
Summary and Conclusions: Vitamin D deficiency/insufficiency was observed
in patients with AIHA, both therapy naive or previously treated, with concomitant
alteration of immuno-modulatory cytokine levels. Moreover, we found increased
VDR expression, possibly reflecting an up-regulation due to ligand deficiency
or increased shedding because of reduced receptor recruitment. Vitamin D
deficiency was more evident in relapsed/refractory patients, suggesting a more
pronounced immune disregulation in these cases. In vitro studies demonstrated
a dose dependent inhibitory effect of vitamin D on the production of anti-RBC
auto-antibodies even at very low concentrations and suggested that vitamin D
supplementation may be useful in AIHA. 
Figure 1.
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A CROSS-SECTIONAL STUDY COMPARING DIFFERENT HEMATOLOGI-
CAL AND BIOCHEMICAL DISEASE MARKERS FOR CLINICAL DIAGNOSIS
OF IRON DEFICIENCY
D. Enko1,* H. Wagner2, G. Kriegshäuser1, R. Stolba1, G. Halwachs-Baumann1
1Institute of Laboratory Medicine, General Hospital Steyr, Steyr, 2Department
of Applied Statistics, Johannes Kepler University Linz, Linz, Austria
Background: Iron deficiency (ID) is a widespread condition throughout the
world. It is considered to be one of the most prevalent forms of malnutrition.
Heightened awareness of the adverse consequences of ID, such as changes
in cognitive development, immune function, energy metabolism or temperature
regulation, has renewed efforts to reduce the prevalence of this micronutrient
insufficiency. Nevertheless, no full international consensus exists on disease
markers to be used for assessing the human iron status. Furthermore, uncer-
tainty about the optimal epidemiologic approach and the quantitative measure-
ment of its severity still exists.
Aims: This study was conducted to compare performances of serum ferritin
and transferrin saturation (TSAT) with the soluble transferrin receptor (sTfR)/log
ferritin and reticulocyte hemoglobin content (CHr), also known as Thomas-plot,
to serve as biomarkers in patients with ID. Furthermore, separate logistic regres-
sion models, for patients without (C-reactive protein [CRP-] value ≤0.5 mg/dl)
and with acute-phase reaction (CRP-value >0.5 mg/dl) were used to predict
functional ID.
Methods: This cross-sectional study was approved by the Ethical Committee
of Upper Austria (Linz, Austria), and is in accordance with the current version
of the Helsinki Declaration. A total of 445 hospitalized adult patients with sus-
pected ID were investigated for complete blood cell count, ferritin, TSAT, sTfR,
sTfR/log ferritin ratio and CHr (i.e. Thomas-plot). All in all, 31.69% (n=141) were
male and 68.31% (n=304) were female. The median age was 70 years (range:
18-92). Patients below 18 years of age were excluded from the study. Descrip-
tive statistics were computed for the categorical and metric variables and to
compare different parameters and definitions of ID. Logistic regression models
for the probability of functional ID (CHr <28 pg) were constructed for all 445
patients, for 225 patients without (C-reactive protein [CRP] ≤0.5 mg/dL) and
220 patients with acute-phase reaction (CRP >0.5 mg/dL).
Results: Based on the Thomas-plot analyses, 153/445 (34.38%) patients were
identified with ID. When ID was diagnosed by means of serum ferritin levels
<30 ng/mL and TSAT levels <20%, 105/445 (23.60%) and 215/445 (48.31%)
patients were identified with ID, respectively. Based on the logistic regression
models for the probability of functional ID (CHr <28 pg), the sTfR/log ferritin
ratio showed the best positive predictive values (PPV) (62.50 and 64.41%) to
indicate functional ID in patients without as well as with acute-phase reaction
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compared to sTfR (58.14 and 61.67%), ferritin (32.50 and 32.86%) and TSAT
(26.74 and 42.86%).
Summary and Conclusions: In conclusion, the prevalence of ID in the study
population investigated here varied with marker selection and its definition.
Ferritin and TSAT demonstrated weaknesses in the detection of functional ID
(CHr <28 pg). Regarding the results of this work, for routine laboratory diagno-
sis, however, we suggest to use Thomas-plot analyses in combination with fer-
ritin single-marker measurements to efficiently identify patients with ID. 
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CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE III AND PRIMARY
HEMOCHROMATOSIS; COEXISTENCE OF MUTATIONS IN KIF23 AND HFE
M. Liljeholm1,* A.-L. Vikberg2, I. Golovleva2, A. Wahlin1
1Hematology, Department of Radiation Sciences, 2Department of Bio-
sciences/Clinical and Medical Genetics, University of Umea, Umea, Sweden
Background: Congenital dyserythropoietic anemia type III, CDA III, is a very
rare hereditary disorder. The disease is caused by mutation c.2747C>G,
p.P916R in KIF23, a protein with crucial role in cytokinesis, the final step of
mitosis. In the Västerbotten CDA III family, 48 individuals in 6 generations have
been diagnosed with CDA III. Secondary hemochromatosis, a clinical problem
in CDA I and II, has not been reported in CDA III. Absence of iron accumulation
in CDA III has been explained by intravascular hemolysis, leading to urinary
loss of iron. However, we have recently seen that some individuals in the
Västerbotten family, both CDA III positive and negative ones, have elevated
ferritin levels. The prevalence of primary hemochromatosis caused by muta-
tions in the HFE gene is high in northern Europe. 
Aims: To study the coexistence and clinical appearance of mutations in KIF23
c.2747C>G and HFE c.845G>A and c.187C>G in the Västerbotten family. 
Methods: DNA from 37 CDA III positive individuals and 21 of their CDA III neg-
ative siblings, was examined by PCR-TaqMan genotyping. HFE-genotype was
established concerning HFE c.845G>A and HFE c187C>G.
Results: Heterozygous mutation of HFE c.845G>A or c.187C>G was found in
18 CDA III positive individuals. Both mutations were found in six CDA III
patients. Nine of the CDA III negative siblings carried heterozygous mutations,
and two homozygous mutations of either of the examined loci of the HFE gene.
Two were found to have heterozygous mutations of both loci. Treatment with
phlebotomy to normalize ferritin and transferrin iron saturation (TSAT) was indi-
cated in the CDA III negative person with homozygous mutation of HFE
c.845G>A, in two CDA III positive individuals with single heterozygous muta-
tions (ferritin 1084 ug/L and 987 ug/L, TSAT 80% and 100%) and in one CDA
III positive patient with coexistence of HFE c.845G>A and c.187C>G (ferritin
700 and TSAT >55%). So far, phlebotomies have been performed without prob-
lems in spite of anemia. All patients were screened for diabetes. One CDA III
positive male with heterozygous HFE c.187C>G (ferritin 1084 ug/L, TSAT 80%)
was diagnosed with type II diabetes mellitus.
Summary and Conclusions: Mutations in one or two of the examined HFE-
loci were found in 65% of CDA III positive cases and in 62% of their CDA III
negative siblings. One CDA negative female with homozygous HFE c.845G>A
needed treatment with phlebotomy. Three patients with CDA III, heterozygous
HFE-mutations, and laboratory signs of iron overload have started treatment
with phlebotomy. Heterozygous mutation of the HFE-gene seems to be suffi-
cient to generate pathologic iron overload when occurring concomitantly with
a haemolytic disorder such as CDA III. Screening for primary hemochromatosis
should be performed in patients with congenital dyserythropoietic anemia.
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ERYTHROCYTE-DERIVED MICROVESICLE RELEASE DURING EX-VIVO
CARDIOPULMONARY BYPASS PROCEDURES
R. Huisjes1,* K. de Vooght1, C. Lau1, T.-J. van Laar2, M. de Jong2, M. Buijsrogge3,
W. van Solinge1, R. van Wijk1, R. Schiffelers1
1Department of Clinical Chemistry and Haematology, 2Division of Heart &
Lungs, 3Department of Thoracic Surgery, UMC Utrecht, Utrecht, Netherlands
Background: Cardiopulmonary bypass procedures (CPB) are commonly used
during heart surgery. The stressful conditions that this procedure imposes on
blood cells may cause damage leading to loss of cellular contents or vesicula-
tion of the cells. In this study we examined the effects of CPB in both an ex-
vivo and in-vivo set-up on erythrocyte behavior and erythrocyte-derived
microvesicle release.
Aims: To study the effects of CPB on deformability and phosphatidylserine
(PS) exposure of erythrocytes, the release of microvesicles (MVs) during this
procedure, and their ability to induce thrombin generation.
Methods: We investigated MV formation, in particular erythrocyte-derived MVs,
during ex-vivo CPB. In this set-up 150 ml of heparinized blood from 3 healthy vol-
unteers was hemodiluted and pumped through a membrane oxygenator back to
the venous blood reservoir. Osmotic gradient ektacytometry was performed to
study the deformability of erythrocytes after ex-vivo CPB. After ex-vivo CPB MVs
were purified by differential centrifugation from platelet-free plasma. Nanoparticle
Tracking Analysis (NTA), Western blot analysis, and hemoglobin measurements
were carried out to confirm the presence of MVs in whole blood from healthy vol-
unteers in this ex-vivo CPB model. The isolated MVs after ex-vivo CPB were
added to an automated thrombin generation test to determine its effects on blood
coagulation, whereas in this test the formed thrombin is able to split a substrate
to a fluorescent product. Microvesicle formation after routine CPB with patients
(n=30) samples was studied similarly as after ex-vivo CPB. 
Results: The number of erythrocyte-derived MVs after ex-vivo CPB
increased concomitantly with both the number of microcytic erythrocytes and
PS expression on erythrocytes as determined by flow cytometry. Despite this
vesiculation, deformability of the erythrocytes as determined by osmotic gra-
dient ektacytometry did not significantly alter during the ex-vivo CPB proce-
dure. The formed MVs were found to be able to stimulate thrombin formation,
thereby highlighting the potential contribution of MVs on side effects of CPB.
Remarkably, except for one sample, patient blood samples obtained after
CPB contained free hemoglobin but did not contain erythrocyte microvesicles
(MVs) (Figure 1).
Figure 1.
Summary and Conclusions: In this study we show that hemoglobin containing
erythrocyte-derived MVs are generated during an ex-vivo CPB procedure.
These nascent MVs are able to induce thrombin generation, we therefore
hypothesize that the reported diffuse inflammation after CPB could, at least
partly, be mediated by vesicles formed in blood. Patients samples after CPB
did not contain erythrocyte-derived MVs, possibly indicating high-clearance
rates of MVs in patient blood, suggesting that patients are at risk when clear-
ance systems (e.g. macrophages) get saturated. 
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HS-TROPONINE T RELATES WITH MYOCARDIAL IRON OVERLOAD IN
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Background: Myocardial iron overload (MIO) is the main cause of Heart failure
(HF) in β-thalassemia major (β-TM) patients. The transfusion-related hemo-
siderosis leads to myocardial damage thus influencing the clinical outcome.
Measurement of high sensitive-troponine-T (hsTnT) provides diagnostic and
prognostic information in patients with coronary artery disease, heart failure
and even in the general population. No data are available in literature about
hs-ThT and MIO in transfusion dependent thalassemia (TDT) patients.
Aims: We aimed to evaluate the relationship between MIO quantified by Mag-
netic Resonance Imaging (MRI)T2* and hs-ThT serum levels in a consecutive
cohort of 50 TDT patients enrolled into the MIOT network.
Methods: This pilot study recruited 50 consecutive TDT patients from June
2013 to January 2014 at Division of Haematology, Unit of Thalassemia, Uni-
versity of Catania, Italy. Male/Female ratio was 1:1; Median age was 32 years
(range 16-48). All of them were suffering from β-TM, except 2 male patients
suffering from Thalassemia Intermedia with Major-like phenotype. Myocardial
iron overload (MIO) was quantified by a multislice multiecho T2* sequence
(Meloni et al., Int J Cardiol, 2014). Biventricular function parameters were eval-
uated by cine images (Marsella M et al. Haematologica 2011). HF was defined
if clinically evident signs or symptoms were present. Raw data were expressed
as mean±standard deviation. Comparison between groups was performed
using the Mann-Withney test. Odds ratio were calculated with Chi2 test. Cor-
relation was performed using the Spearman correlation. Sensitivity and speci-
ficity were calculated with Receiver operating characteristic (ROC) analysis.
P<0,05 was considered as statistically significant.
Results: Median value of hs-TnT was 3,925 ng/L, ranged between 3 and 60,3
ng/mL (normal range 0-14). Overall, 5 patients presented levels of hs-TnT
greater than 14 ng/mL. 6 patients presented Heart Failure (HF), 1 with aug-
mented levels of hs-TnT. In our population we confirmed that both the presence
of a global Heart T2* <20 msec (Odds Ratio 15,6; 95%CI 2,25-108,12;
p<0,0001) and the number of cardiac segments with T2*<20msec was related
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with HF (Table 1). Presence of an HF related with higher levels of hs-TnT with
a cutoff value between 4,23 ng/L (sensitivity: 100%, specificity: 65,12%) and
5,2 (sensitivity: 83,3%, specificity: 67,44%) (AUC:0,7; p<0,01) (Figure 1). A
relationship was found between levels of hs-TnT and the number of myocardial
segments with T2* <20 msec (p=0,011), but not with the global Heart T2*
(p=0,85). However, clustering patients according to the presence of severe car-
diac siderosis (global heart T2*<20 msec), patients with significant iron overload
had levels of hs-TnT significantly greater than patients with global T2* ≥20 (5,74
ng/mL±9,15 vs 10,5±5 ng/mL; p<0,0001). 38 patients underwent biventricular
function evaluation. Of these, 22 (57,9%) had a left, right or biventricular dys-
function. In these patients there was a trend toward higher levels of hs-TnT
compared to patients without impairment (8,85±12,52 vs 4,49±4,19), without
reaching the statistical significance (p=0,068).
Table 1. HF vs occurrence of cardiac siderosis (defined as T2*<20msec).
Comparison between groups (Mann-Withney test).
                                                             Patients with HF     Patients without HF      p
                                                                     (N=6)                       (N=44)
Global heart T2* (ms)                                  35.55±10.58              16.89±5.57         0.001
Number of segments with T2* <20 ms            2.48±4.47                11.17±4.22         0.001
Figure 1.
Summary and Conclusions: Our findings suggest that in TDT patients, hs-
TnT would be a sensitive index of myocardial impairment consequent to iron
overload.
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DEFERASIROX, AND COMBINATION OF DEFEROXAMINE AND
DEFERIPRONE ON LIVER AND CARDIAC T2* MRI IN THALASSEMIA MAIOR
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Background: Cardiac complications due to chronic transfusion-induced iron
overload are the most common cause of death in patients with thalassemia
major. Successful treatment with iron chelators is required to prevent iron dep-
osition in various tissues.
Aims: The aim of this study is to compare iron chelation effects of deferoxam-
ine, deferasirox, and combination of deferoxamine and deferiprone on cardiac
iron load in these patients measured by T2* MRI.
Methods: 108 patients with thalassemia major aged over 10 years who had
iron overload in cardiac T2* MRI assay, were studied in terms of iron chelators
effectiveness and efficacy on reduction of myocardial siderosis. 104 completed
the treatment. The first group received only DFO, the second group only DFX,
and the third group a combination ofDFO and deferiprone. Myocardial iron was
measured at baseline and 12 months after the beginning of treatment through
T2* MRI technique.
Results: In the DFO group, myocardial T2* was increased from 12.0±4.1 ms
at baseline to 13.5±8.4 ms at 12 months (p=0.10). Significant improvement
was observed in myocardial T2* of theDFX group from 13.0±4.5 ms at baseline
to 17.5±7.1 ms at 12 months (p<0.001). In the combined treatment group,
myocardial T2* was increased from 11.6±3.8 ms at baseline to 16.8±9.9 ms at
12 months (p=0.001). These differences among the three groups were not sig-
nificant at the 12 months (p=0.09). A significant improvement was observed in
liver T2* at 12 months compared to baseline in the deferasirox group (p=0.01)
and the combination group (p=0.005), while this improvement was not signifi-
cant in the deferoxamine group (p=0.72). The most common reported adverse
effect in all three groups was mild and transient gastrointestinal side effects.
Summary and Conclusions: In comparison to deferoxamine monotherapy,
combination therapy with deferoxamine and deferiprone and deferasirox
monotherapy have a significant impact on reducing iron overload and improve-
ment of myocardial and liver T2*.
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MRI PROSPECTIVE SURVEY ON CARDIAC AND HEPATIC IRON AND CAR-
DIAC FUNCTION IN TRANSFUSION-DEPENDENT THALASSEMIA INTER-
MEDIA PATIENTS TREATED WITH DESFERRIOXAMINE, DEFERIPRONE
AND DEFERASIROX
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Background: Few studies have evaluated the efficacy of iron chelation ther-
apy in thalassemia intermedia (TI) patients.
Aims: Our study aimed to prospectively assess by quantitative Magnetic
Resonance imaging (MRI) the efficacy of the three available chelators in
monotherapy in transfusion dependent (TD) TI patients.
Methods: Among the 325 TI patients enrolled in the MIOT (Myocardial Iron Over-
load in Thalassemia) network, we selected 103 TI patients TD with an MRI fol-
low-up (FU) study at 18±3 months who had been received one chelator alone
between the two MRI scans. Iron overload was assessed by the T2* multiecho
technique. Hepatic T2* values were converted into liver iron concentration (LIC)
values. Biventricular function parameters were quantified by cine SSFP
sequences.
Results: Three groups of patients were identified: 27 patients (13 females,
mean age 40.12±10.31 years) treated with desferioxamine (DFO-mean
dosage 37.52±8.69 mg/kg/die), 23 patients (14 females, mean age
34.73±10.67 years) treated with deferiprone (DFP-dosage 71.70±14.46
mg/kg/die) and 14 patients (9 females, mean age 36.63±10.92 years) treated
with deferasirox (DFX-mean dosage 27.75±5.04 mg/kg/die). Excellent/good
levels of compliance were similar in the DFO (92.6%), DFP (100%) and DFX
(100%) groups (P=0.345). The mean starting age of regular transfusion was
14.73±15.89 years. At baseline in DFO group two patients (7.4%) showed a
global heart T2*<20 ms and one of them showed no cardiac iron at the FU.
At baseline in DFP group two patients (8.7%) showed a global heart T2*<20
ms and one of them showed no cardiac iron at the FU. All the 5 patients
(35.7%) under DFX therapy with pathological global heart T2* at the baseline
remained at the same status at the FU. The percentage of patients who main-
tained a normal global heart T2* value was comparable for DFO (100%), DFP
(100%) and DFX (88.9%) groups (P=0.164). Among the 46 patients with
hepatic iron at baseline (MRI LIC ≥3 mg/g/dw), the reduction in the MRI LIC
values was significant only in the DFO group (DFO: -3.39±6.38 mg/g/dw
P=0.041; DFP: -2.25±6.01 mg/g/dw P=0.136 and DFX: -0.36±5.56 mg/g/dw
P=0.875). The decrease in MRI LIC values was comparable among the
groups (P=0.336). The number of patients with a MRI LIC<3 mg/g/dw went
up from 10 (37%) to 11 (40.7%) in the DFO group, from 6 (26.1%) to 8 (34.8%)
in the DFP group and from 2 (14.3%) to 8 (57.1%) in the DFX group. The per-
centage of patients who maintained a normal MRI LIC value was comparable
for DFO (90%) vs DFP (50%) and DFX (100%) groups (P=0.191). In no group
there was a significant change in biventricular volumes, ejection fractions
and left ventricular mass index (Figure 1).
Figure 1.
Summary and Conclusions: Prospectively in transfusion-dependent TI
patients at the dosages used in the clinical practice, DFO and DFP showed
100% efficacy in maintaining a normal global heart T2* value while DFX had
100% efficacy in maintaining a normal LIC value. Further prospective studies
involving more patients with iron at the baseline are needed to establish which
is the most effective drug in reducing iron levels.
haematologica | 2015; 100(s1) | 595
Vienna, Austria, June 11 - 14, 2015
E1486
TISSUE DOPPLER IMAGING IN CHILDREN WITH SICKLE CELL DISEASE:
EVALUATION OF PULMONARY HYPERTENSION 
I. Youssry1,* A. El Sisi2, C. Ghobrial1, M.F. Shaltout2
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Background: The prevalence of Pulmonary Hypertension (PHT) in young chil-
dren with sickle cell disease (SCD) is unclear. However, early detection and
intervention of this potentially lethal problem may reverse the problem and pre-
vent its serious consequence. For diagnosing PHT in SCD, an elevated tricus-
pid regurgitant velocity (TRV) ≥2.5 m/s appears to have limitations in specificity.
However, new parameters characteristic of the right ventricular (RV) function
in patients with PHT by means of Tissue Doppler Imaging (TDI) may increase
the probability of a correct diagnosis of PHT.
Aims: Our aim was estimating the prevalence of PHT in children with SCD
and to assess the clinical, laboratory and cardiac parameters for correct diag-
nosis of PHT.
Methods: fifty SCD children with mean age 11.28±7.48 years and fifty healthy
control were enrolled. Various clinical and laboratory evidence of hemolysis
and inflamation were assessed. Conventional echocardiography and Tissue
Doppler Imaging were done for all patients and control. Pulmonary artery sys-
tolic pressure (PASP) was measured using TRV; the maximal transtricuspid
gradient was calculated according to the simplified Bernoulli equation.
Results: The frequency of PHT was 18%, 9/50 patients had TRV ranged from
2.51 to 3.59 m/s. The TDI showed evidence of diastolic dysfunction at the right
ventricle as evidenced by significant increase in Tricuspid Es, As and Es/As in
10 patients (20%). Nine out of these10 patients had TRV ranged from 2.51 to
3.59 m/s. Cases with PHT showed significant increase in aortic root diameter,
LVEDD and PA diameter than cases without PHT, p-value=0.024, 0.000, 0.000
respectively. Cases with PHT showed significant increase in RVET, PAT/RVET,
IVRT-LV, TRV and PASP than cases without PHT, p-value=0.005, 0.005, 0.001,
0.000, 0.000 respectively. The TDI showed significant increase in Tricuspid Es,
As and Es/As in cases with PHT than cased without PHT, p-value=0.019, 0.004
and 0.001 respectively. Furthermore, cases with PHT showed significant high
systolic blood pressure, high LDH level, high reticulocytic count, high builirubin
level, low Hb and high platelet count.
Summary and Conclusions: Tissue doppler imaging combined with Echocar-
diography may be useful in diagnosing PHT.
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Background: A certain degree of iron overload (IO) is sometimes seen in sub-
jects with β-thalassemia trait (βTT), a mild form of non-transfusion-dependent β-
thalassemia. The pathogenesis is unclear, but recently a population study in Sri
Lankan children has shown that βTT is characterized by mild hepcidin suppres-
sion due to increased erythropoietic activity (Jones E, Blood 2015). In individual
patients, this may be further aggravated by genetic (i.e. mutations in hemochro-
matosis genes) or acquired factors (e.g. alcohol abuse or non-alcoholic liver dis-
eases). Treatment of IO in βTT is problematic, since “standard” large-volume
phlebotomies are not feasible in mildly anemic subjects, as well as the lack of
approval of oral iron chelators and of specific guidelines. Deferoxamine (DFO) is
the only approved therapy, but it is poorly applicable because of inconvenient
parenteral administration and side effects. Sporadic case reports have suggested
the use of “mini-phlebotomies” in βTT patients with IO, but feasibility and efficacy
of such approach has not been evaluated in patients’ series.
Aims: This study has been designed to better characterize factors involved in
the development of relevant IO in βTT patients, and to evaluate feasibility and
efficacy of mini-phlebotomies to remove IO in this condition.
Methods: Up to now we have enrolled 17 consecutive βTT patients with IO
(14 males and 3 females, mean age 58 years) addressed to our tertiary referral
center for Iron Disorders in Verona (northern Italy). IO was documented through
increased ferritin levels (in most cases >1000 ng/ml, in repeated assays), and
either MRI or liver biopsy when indicated. All subjects gave written informed
consent. The study plan includes collection of detailed information about clinical
history through a structured questionnaire, measurement of serum hepcidin
by in-house mass spectrometry-based method, and a comprehensive genetic
analysis of the five hemochromatosis genes (HFE, HFE2, HAMP, TFR2,
SLC40A1) through next-generation-sequencing (NGS). 
Results: Mean Hb values were not uniform (9.5-13.5 g/dl), in agreement with
the known phenotypic variability of the βTT. A substantial alcohol consumption
(>100 g/day) appears a common acquired cofactor in βTT patients with IO, while
NGS (up to now performed in 13/17 patients) did not reveal potentially pathogenic
variants out of the known H63D in HFE. Nine patients started treatment with
“mini-phlebotomies” and four of them have reached the iron depletion. None of
the patients experienced a worsening of anemia during the treatment. 
Summary and Conclusions: In our region, the occurrence of clinically signif-
icant iron overload is not rare in βTT subjects, and is likely multifactorial in
most cases, with high alcohol intake and the H63D variant appearing as the
most frequent cofactors contributing to further hepcidin suppression. Prelimi-
nary results suggest mini-phlebotomies as a valuable approach for this peculiar
category of patients. 
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DIAGNOSIS OF FUNCTIONAL IRON DEFICIENCY: HEPCIDIN AS NOVEL
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Background: Hepcidin is a peptide hormone, which is produced in the liver
and excreted in the kidneys. It is considered as a key regulator of human iron
homeostasis, lowering the serum iron in the blood circulation by binding and
down regulating the iron exporter protein ferroportin in the basolateral site of
duodenal enterocytes and reticuloendothelial macrophages. High hepcidin
serum-levels decrease the iron transport out of the enterocytes as well as the
ability of macrophages to export recycled iron from senescent enterocytes.
Aims: The aim of the present study was to investigate, whether hepcidin is a
useful additional clinical biomarker to reflect the actual human iron status, espe-
cially functional iron deficiency (ID), as a state of inadequate iron supply to
erythropoietic precursor cells in the bone marrow despite the presence of stor-
age iron in the hepatocytes/macrophages.
Methods: This study was approved by the Ethical Committee of Upper Austria
(Linz, Austria), and is in accordance with the current version of the Helsinki Dec-
laration. All in all, 233 consecutive hospitalized adult patients with suspected ID,
were included. In total, 33.91% (n=79) were male and 60.09% (n=154) were
female. The median age was 69.0 (range: 20.0-93.0) years. Patients below 18
years of age were excluded from the study. All subjects were investigated for
hepcidin, reticulocyte hemoglobin content (CHr), soluble transferrin receptor
(sTfR)/log ferritin ratio (i.e. Thomas plot), sTfR, ferritin, transferrin saturation
(TSAT), C-reactive protein (CRP) and for complete blood cell count. The hepcidin
measurements were performed with the recently launched European Community
(CE)-marked enzyme-linked immunoabsorbent assay (ELISA) (Hepcidin-25
bioactive ELISA; DRG Instruments GmbH, Marburg, Germany). Functional ID
was defined as a CHr <28 pg. Separate logistic regression models were calcu-
lated with all potential biomarkers to evaluate and compare the predictive per-
formance with respect to functional ID in patients without (CRP ≤0.5 mg/dL) and
with (CRP >0.5 mg/dL) acute-phase reaction, respectively.
Results: The hepcidin measurements correlated with parameters of iron
metabolism. There was a positive correlation with serum ferritin (p <0.0001,
Pearson correlation coefficient 0.2608) and TSAT (p=0.0349, Pearson corre-
lation coefficient 0.1383), and a negative correlation with transferrin (p <0.0001,
Pearson correlation coefficient -0.6021), sTfR (p <0.0001, Pearson correlation
coefficient -0.3736), and iron (p=0.1617, Pearson correlation coefficient -
0.0920). There was also a positive correlation between CRP and hepcidin (p
<0.0001, Pearson correlation coefficient 0.2581). One hundred seventeen
patients with CRP >0.5 mg/dL showed a distinctly higher hepcidin median value
(35.60 [range: 4.27-80.03] ng/mL) as compared to 116 patients with CRP ≤0.5
mg/dL (18.55 [range: 3.77-73.01] ng/mL). With respect to functional ID, sTfR/log
ferritin ratio and sTfR were of better positive predictive value (PPV) (sTfR/log
ferritin ratio: 58.33 and 70.83%; sTfR: 60.00 and 60.00%) than when compared
to hepcidin (PPV: 37.74 and 42.86%) and ferritin (PPV: 27.54 and 46.15%) in
both subgroups.
Summary and Conclusions: In the logistic regression modelling and when
compared with the sTfR/log ferritin ratio or the sTfR measurements, hepcidin
as well as ferritin, both biomarkers are known as acute-phase reactants, were
only of low predictive value to reflect functional ID.
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CORRELATION OF GENOTYPE WITH PHENOTYPE IN BETA THALAS-
SAEMIA INTERMEDIA IN SRI LANKA
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Background: Previous studies on thalassaemia in Sri Lanka revealed that a
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third of patients attending thalassaemia clinics in Sri Lanka have intermedia
phenotype and has shown to be presented with a wide phenotypic diversity.
The majority of them have Hb E beta thalassaemia, but a significant minority
has been shown to have co-inheritance of beta thalassaemia minor with extra
alpha globin genes.
Aims: In our previous study we have studied a group of beta thalassaemia
intermedia patients without E beta thalassaemia for the molecular basis of inter-
media phenotype. In this study we investigated the possibility of correlating the
preliminary genetic analysis results in our thalassaemia intermedia study cohort
with the phenotype with aiming to unravel phenotypic diversity with genotypic
heterogeneity.
Methods: Fifty (50) unrelated thalassaemia intermedia patients were identified
from the five main thalassaemia centers in the Island with mostly presented to
the adult thalassaemia clinic at Ragama. Clinical severities of the intermedia
patients were assessed and they were categorized into “mild”, moderate and
severe phenotypic groups according to the clinical severity. DNA analysis of
the beta globin gene, alpha globin gene and SNPs of Hb F regulators were
performed by Southern blot analysis, GAP PCR, MLPA and DNA sequence
analysis of PCR products. 
Results: Seventeen (34%), of the total thalassaemia intermedia population were
homozygous or compound heterozygous for beta mutations. Five of the homozy-
gotes carried two mild beta alleles including a rare promoter mutation-90 C>T,
Hb variant alleles of Hb G-Szuhu and Hb G-Coushatta. Nine inherited with two
sever beta alleles with alpha gene deletions either one or two. Of the other three
individuals who carried two beta alleles with normal alpha gene, one had single
nucleotide polymorphismxmn I +/+. Individuals who had inherited with two mild
beta alleles and a sever mutation with Hb G-Szuhu and Hb G-Coushatta almost
invariably had a mild phenotype. Those individuals who had inherited two severe
beta alleles with alpha gene deletions invariably had a severe phenotype. It was
unable to explain the phenotype in two individuals in this group with the existing
genetic data. Thirty three (66%) of the total thalassaemia intermedia population
were heterozygous for beta mutations IVSI-5 G>C (n=12), IVSI-1 G>A (n=11)
being the commonest. Twenty eight of the heterozygotes carried excess alpha
genes and had a mild to moderate phenotype. In this group of individuals who
had inherited with single beta allele with normal alpha genes, the genetic study
could not explain the phenotype in five individuals.
Summary and Conclusions: Thalassaemia intermedia patients in Sri Lanka
showed a considerable heterogeneity both phenotypically and genotypically.
The clinical outcome of our thalassaemia intermedia patients were mostly
explained by the genotypes linked to the alpha and beta gene cluster. About
three fourth of the cases found with beta thalassaemia intermedia phenotypic
had mutations on the alpha and beta globin gene clusters. Co-inheritance of
additional alpha globin genes and beta thalassaemia minor was accounted to
be the most common finding for their clinical presentation. However in a minor-
ity, the existence of other causative genetic determinants remains to be molec-
ular defined.
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Background: Pain relief is the key point for patients admitted for sickle cell cri-
sis in emergency care units.We present a prospective monocentric trial aiming
to improve sickle cell patient support in our hospital
Aims: The primary objective was the evaluation of the pain relief in adult
patients admitted for sickle cell crisis in our emergency department. Upon
admission, a standard protocol based on international and local guidelines with
hyper-hydration and high doses of intravenous morphine was used. Morphine
was administered according to patient’s EVA (Analogic visual Evaluation) pain
scale. We in parallel conducted a hetero-evaluation of the patient’s pain by the
nursing team. The secondary objectives were the evaluation of morphine dose
required for pain relief, patient’s satisfaction and the length of hospitalization.
This study also comprised of an ancillary part aiming to determine a predictive
score of crisis severity based on standard laboratory parameters.
Methods: This observational prospective mono centric study was approved
by the local ethics committee. Written informed consent was obtained from
patients during routine hematology follow up visits or more rarely in the emer-
gency care setting. Patients were enrolled from February 2013 until February
2015. Pain was evaluated through EVA upon admission, after 1 hour, 3h, 6h
and then every 6 hour until pain relief. Patient satisfaction was analyzed with a
questionnaire developed by our psychologist and graded from 1 (very bad) to
5 (very good).
Results: 104 observations were obtained for 51 patients as some patients had
been hospitalized more than once. Mean waiting time before the start of treat-
ment was 18.6 minutes. More than 65% of patients waited less than 10 minutes.
Morphine doses used were less than those mentioned in literature and in our
local guidelines. Pain was systematically under scored by the nurse team (het-
ero EVA). Unexpectedly, women received significantly (p<0.001) more mor-
phine than men. Mean patient‘s satisfaction score was good (3.8).There was a
significant correlation between morphine dosage, waiting time until start of
treatment and patient satisfaction. We observed an improvement in patient sat-
isfaction as the study moved along. Analysis of laboratory data and length of
hospitalization are still ongoing.
Summary and Conclusions: The main aim of our study was to reinforce collab-
oration between the different teams taking care of patients in an emergency care
setting as well as during hospitalization. This multidisciplinary approach allows a
dramatic improvement in patient satisfaction during the study. A significant inverse
correlation was found between morphine dosage, waiting time until treatment and
patient satisfaction. We observed that continuous education of medical and para-
medical staff is mandatory to improve quality of care in this case.
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IMPROVING MACROCYTOSIS DIFFERENTIAL DIAGNOSIS BY RDW-SD
T. Nascimento1,* J.R. Pinheiro1, R. Barreira1, P. Ferreira1, J.P. Ferreira1,
A.T. Simões1, J. Azevedo1, S. Ramon1, J.C. Almeida1, M.L. Ribeiro1
1Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal
Background: Macrocytosis is defined as a mean corpuscular volume (MCV)
>100fL. Blood cells morphology and biochemical parameters are essential to
differentiate megaloblastic anemia (MA) from other causes of macrocytosis.The
red cell distribution width (RDW) evaluates the degree of anisocytosis. It can
be expressed as a coefficient variation of the MCV (RDW-CV).
Aims: The objectives of this study were to compare the sensitivity of RDW-CV
and RDW-SD to detect anisocytosis, in the presence of macrocytosis, and their
impact in the differential diagnostic of MA. 
Methods: We analyzed 152 samples with macrocytosis (78 with anemia; 74 with-
out; 26 suggestive of MA). They were divided in 8 groups: on chemotherapy,
hydroxyurea, alcoholic/hepatic disorders, hemolytic anemia, aplastic anemia,
myelodisplastic syndrome, hypothyroidism, and other disorders. The samples
were processed in HORIBA, Abbott and Sysmex instruments, in order to monitor
the reproducibility and the ability to screen out of range values. The reference
values were calculated for each equipment (150 blood donors). Data were ana-
lyzed with descriptive statistics, t-student, ANOVA, ROC (GraphPad Prism5).
Results: The objectives of this study were to compare the sensitivity of RDW-CV
and RDW-SD to detect anisocytosis, in the presence of macrocytosis, and their
impact in the differential diagnostic of MA. Reference values span from the mini-
mum to maximum obtained values: RDW-CV 12.03-14.49%; RDW-SD 36.5-
46.68fL. Hemoglobin(Hb) values were reproducible (p=0.8727), but MCV, RDW-
CV and RDW-SD differ significantly (p<0.0001). Patients with anemia: Hb median
10.2g/dL[5.4;11.7]; MCV105.8±7fL, RDW-CV14.9±2.4% and RDW-SD56.9±9.8fL;
patients without anemia: Hb median 13.5g/dL[12;16.8], MCV103±5.4fL, RDW-
CV13.3±1.2% and RDW-SD50.2±5.1fL. It was found more cases of MA in “other
disorders” group (n=10/63), followed by “hydroxyurea” (n=7/20), and “chemother-
apy” (n=4/28). MA and non-MA parameters means showed no significant differ-
ences (p>0.05). However, RDW-CV were borderline (MA 14.9±2; non-MA
15.8±3.1) and RDW-SD were elevated (57.3±11.1; 60±11.8, respectively). Regard-
ing to ROC analysis, it was found a better anisocytosis discrimination for RDW-
SD, since it presented a higher area under the curve (AUC) than RDW-CV (0.97
and 0.79, respectively). The best cut off for RDW-CV was 14.45% (sensitivity-
84.8%; specificity-82.69%) and for RDW-SD was 44.35fL, with improved results
for sensitivity and specificity (93.75% and 94.23%, respectively).
Summary and Conclusions: In macrocytosis, RDW-SD is more sensitive than
RDW-CV, improving anisocytosis discrimination. For this reason, RDW-SD may
become helpful when MA is considered, as it triggers, earlier than RDW-CV, an
alert that requires further actions, like blood smear review and vitamin B12/folic
acid quantification.
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PROSPECTIVE STUDY ON THE EFFECT OF FOK-I GENE POLYMORPHISM
ON BONE HEALTH IN YOUNG PATIENTS WITH B-THALASSAEMIA MAJOR
M. Dimitriadou1, A. Christoforidis1, L. Fidani2, M. Economou3,* V. Perifanis3,
A. Teli3, E. Vlachaki3, G. Katzos1
11st Pediatric Department, 2Medical Biology and Genetics, School of Medicine,
Aristotle University of Thessaloniki, 3Thalassaemia Unit, Ippokratio General
Hospital, Thessaloniki, Greece
Background: Low bone mass, a major cause of morbidity in patients with b-
thalassaemia major (b-TM) has a multifactorial pathogenesis with genetic fac-
tors greatly contributing to it. Fok-I vitamin D receptor (VDR) polymorphism
has been significantly related to low bone mineral density and can serve as a
useful genetic marker in predicting bone disease.
Aims: We sought to estimate the degree of genetic contribution of Fok-I gene
polymorphism of VDR to the evolution of bone mass in patients with b-TM
assessed with imaging techniques and biochemical parameters of bone metab-
olism over a period of two years.
Methods: Sixty-four children and young adults (33 males and 31 females) with
mean decimal age of 23.20±5.41 (range: 9.25- 32.41 years) were recruited in
this study. All patients were genotyping for Fok-I gene polymorphism and were
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assessed with both Dual energyx-ray Absorptiometry (DXA) and Quantitative
Ultrasound Sonography (QUS) at baseline and two years after. Z-scores were
calculated based on normal age and sex matched Caucasian population.
Metabolites of vitamin D, intact PTH, total calcium, inorganic phosphorous and
alkaline phosphatase were measured at the serum pre transfusion.
Results: No deviation of the genotype distribution from the Hardy-Weinberg
equilibrium was noticed: FF genotype accounted for 44.29%, ff genotype for
12.86% and heterozygosity (Ff) for 42.85%. A moderate proportion of patients
had decreased DXA Z-scores (Z-score ≤-2) predominately in total hip (31%)
and secondary in lumbar spine (15.6%). On the contrary, just a few patients
(7.8%) had decreased QUS values measured at tibia. Patients being homozy-
gous for the f allele had apparently higher BMD z-scores compared with those
carrying the F allele in homo- or heterozygosity, however, with a difference that
did not reached significance. Interestingly enough, a significant deterioration
in BMD Z-scores measured at femur (FF: p=0.004 Ff: p<0.001, ff: p=0.024)
and total hip (FF: p=0.022, Ff: p=0.005) was recorded for all type of genotypes,
except for ff genotype and with regards to the total hip DXA values. In contrast,
QUS values measured at tibia were significantly improved in patients carrying
the FF genotype (p=0.035). An increased prevalence of serum 25(OH)D3 defi-
ciency (59.4%) and 25(OH)D3 borderline (12.5%) was recorded. When stratified
according to 25(OH)D3 levels, no statistically significant difference in the evo-
lution of DXA or QUS parameters was observed. Regarding DXA Z-scores
measured at hip, a significant deterioration was recorded in all groups, inde-
pendently of the status of 25(OH)D3.
Summary and Conclusions: Fok-I gene polymorphism of VDR seems to
have an impact on bone health of patients with beta-thalassaemia major in
contrast to vitamin D levels. No level of agreement was observed between
the two imaging techniques in identifying thalassaemic patients with impaired
bone status.
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GROWTH DIFFERENTIATION FACTOR-15 AND CARDIOVASCULAR DIS-
EASE IN THALASSEMIA INTERMEDIA
A. Tantawy1,* A.A. Adly2, E. Ismail3, O. Yousef4, M. Ali2
1pediatrics, Ain Shams, 2Pediatrics, Ain Shams University, 3clinical pathology,
Ain Shams, 4Cardiology, Ain Shams University, Cairo, Egypt
Background: Heart disease is the leading cause of mortality and one of the
main causes of morbidity in β-thalassemia. Growth differentiation factor-15
(GDF-15), a member of the transforming growth factor-β superfamily, is a mark-
er of ineffective erythropoiesis in several anemias.
Aims: To determine the level of GDF-15 in children and adolescents with TI in
relation to clinical characteristics, iron overload, hemolysis and therapy and to
assess its value a potential marker for cardiovascular complications and sub-
clinical atherosclerosis.
Methods: Thirty-five TI patients without symptoms for heart disease were stud-
ied. Patients were subjected to detailed medical history and thorough clinical
examination with special emphasis on disease duration, evidence of renal,
hepatic or cardiac disease, splenectomy status. For transfusion status, patients
were classified as: transfusion-dependent (patients on regular-interval trans-
fusion protocols [once every 1-3 months for a pre-transfusion hemoglobin of
≥8 g/dL] initiated mainly for failure to thrive in childhood, bone deformities, pro-
gressive splenic enlargement, persistent worsening anemia; and non transfu-
sion dependent (patients who never received transfusion or required incidental
transfusions for transient severe anemia secondary to infections or surgery).
GDF-15 was measured and correlated to echocardiographic parameters and
carotid intima media thickness (CIMT).
Results: A total of 11 patients (31.4%) were splenectomized. By echocardiogra-
phy, 16 patients (45.7%) had pulmonary hypertension risk and 12 patients
(34.3%) had systolic left ventricular dysfunction. TI patients had significantly high-
er tricuspid regurgitation velocity (TRV), p<0.001, and lower left ventricular ejec-
tion fraction and fractional shortening than controls (p<0.001). CIMT was signif-
icantly increased among patients compared to controls (p<0.001). The median
(IQR) of GDF-15 level in TI patients was 1500 (1000-2850) pg/ml compared to
110 (80-200) pg/ml in controls (p<0.001). Transfusion dependent TI patients had
higher GDF-15 than non-transfusion dependent patients (p<0.001). TI patients
with splenectomy, pulmonary hypertension risk, and heart disease had higher
GDF-15 levels than those without. Hydroxyurea-treated patients had lower GDF-
15 levels than untreated patients. ROC curve analysis revealed that the cutoff
value of GDF-15 at 1500 pg/mL could differentiate patients with and without heart
disease with a sensitivity of 87.5% and specificity of 100%, AUC 0.945; p<0.001.
GDF-15 levels were positively correlated with age (r=0.463, p=0.005), disease
duration (r=0.567, p<0.001), transfusion index (r=0.767, p=0.005), indirect biliru-
bin (r=0.345, p=0.043), LDH (r=0.612, p=0.002) and serum ferritin (r=0.949,
p<0.001), while negatively correlated to hemoglobin (r=-0.408, p=0.015). More-
over, positive correlations were observed between GDF-5 and TRV (r=0.620,
p<0.001) as well as CIMT (r=0.499, p=0.024). 
Summary and Conclusions: Ineffective erythropoiesis as reflected by high
GDF-15 levels is the hallmark of disease process in TI. GDF-15 may be con-
sidered a risk marker for pulmonary and cardiovascular complications as well
as subclinical atherosclerosis in children and adolescents with β-TI. Levels are
closely related to markers of hemolysis and iron overload. Elevated levels of
GDF-15 may have clinical implications on treatment besides defining TI patients
at risk of cardiac complications. A marker of ineffective erythropoiesis as GDF-
15 may be a potentially valuable tool for monitoring the response to therapy,
thus, promote earlier intervention and improve clinical outcomes in TI patients.
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SOLUBLE FMS LIKE TYROSINE KINASE-1 (SFLT-1) : AN EARLY MARKER
FOR GLOMERULAR DYSFUNCTION IN SICKLE CELL NEPHROPATHY
I. Youssry1,* S. Makar2, R. Fawzy2, M. Wilson2, G. AbdAllah2, E. Fathy2,
H. Sawires2
1Head of the Pediatric Hematology & BMT unit, 2Faculty of Medicine, Cairo
University, Cairo, Egypt
Background: Given the potential role of angiogenesis in the pathophysiology
of sickle cell nephropathy (SN), novel biomarkers are needed for early diagno-
sis of SN before irreversible kidney damage. 
Aims: Our aim was to determine the relationship between serum level of the
anti-angiogenic factor soluble FMS-like tyrosine kinase-1 (sFLT-1) and other bio-
markers of renal damage as microalbuminuria (MA), for early diagnosis of SN.
Methods: 47 Sickle cell disease (SCD) patients and 49 healthy controls were
enrolled. Microalbumine was determined in patients’ urine sample. Blood sam-
ples were tested for sFLT-1, serum creatinine and various hemolysis and inflam-
mation markers. Also, peripheral blood monocyte expression of sFLT-1 was
measured using real time PCR.
Results: Serum level of sFLT-1 (pg/ml) in SCD patients was higher than the
control level (Median/range/IQR=142/ 60-1300/61 pg/ml vs 125/ 110-187/52
pg/ml respectively), (p=0.006). The median (range) of sFLT-1 level was higher
in SCD patients with MA compared to SCD patients with normoalbuminuria
(NA), 185(140-1300) vs 125(60-189) mg/g respectively), (p=0.004). There was
significant positive correlation between serum level of sFLT-1 and MA, lactate
dehydrogenase (LDH) and indirect bilirubin (r=0.59, 0.39, 0.30 & p=<0.001,
0.007, 0.041, respectively). The sensitivity of sFLT-1 in early detection of renal
affection in SCD was 93.6%, while the specificity was 68.6%. Finally, we iden-
tified the monocytes as a possible source of increased sFLT-1 in SCD patients.
Summary and Conclusions: sFLT-1 may constitute a novel renal biomarker
that can predict SN, enabling early diagnosis to prevent progression of renal
damage.
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ORAL IRON-BASED PHOSPHATE BINDER, FERRIC CITRATE, INCREAS-
ES IRON MEASURES IN DIALYSIS-DEPENDENT AND NON-DIALYSIS
DEPENDENT PATIENTS WITH CHRONIC KIDNEY DISEASE
S. Fishbane1,* L. Loram2, T. Ganz3
1Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Great
Neck, NY, 2Keryx Biopharmaceuticals, Boston, MA, 3David Geffen School of
Medicine, UCLA, Los Angeles, CA, United States
Background: Ferric citrate is an iron-based phosphate binder with demon-
strated significant improvement in serum phosphate control and in iron markers
including serum iron, transferrin saturation and serum ferritin in both dialysis
and non-dialysis (ND)-dependent CKD patients. 
Aims: We evaluated the temporal change in serum iron measures relative to
the amount of iron administered as ferric citrate in both ND-dependent CKD
and end-stage renal disease (ESRD) subjects.
Methods: In a previous 52-wk Phase 3 clinical trial evaluating efficacy and
safety of ferric citrate, a subset of dialysis subjects on ferric citrate did not
receive IV iron (n=48). Serum iron parameters were measured and% change
from baseline was calculated. Serum iron parameters were also evaluated in
subjects participating in a Phase 2 clinical trial of ND-dependent CKD patients
administered ferric citrate for 12 wk (n=61) to determine the safety and efficacy
of ferric citrate to control serum phosphorus and transferrin saturation (TSAT).
The subjects were not receiving IV iron or erythropoeisis stimulating agents
for the duration of the trial. In both trials, the percent change of serum iron
parameters was calculated per gram of iron administered (based on cumulative
dose for the duration of the trial). Each tablet of ferric citrate contains 210 mg
elemental iron and the dose of ferric citrate was titrated to control serum phos-
phorus to treatment target. 
Results: In both clinical trials, ferric citrate significantly improved serum iron
and TSAT levels with significantly increased hemoglobin in the ND-dependent
CKD subjects and maintained hemoglobin in the ESRD subjects. TSAT, hemo-
globin and iron administered in the ND-dependent CKD subjects are depicted
in the Figure 1 as mean±SEM. The percent change in serum iron in the ND-
dependent CKD subjects was 0.47±0.09% (mean±SEM) per gram of iron
administered as ferric citrate and% change in TSAT was 0.58±0.09% per g
iron administered. In the ESRD subjects, the% change in serum iron and TSAT
were lower than that seen in the ND-dependent CKD subjects at 0.05±0.02%
per g iron (mean±SEM) and 0.05±0.02% per g iron administered respectively.
The average dose of iron administered was 1.2 g/day for 12 weeks (~5-6
tablets/day of ferric citrate) in the ND-CKD subjects and 1.4 g/day (~7
tablets/day of ferric citrate) for 52 weeks in ESRD subjects.
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Figure 1.
Summary and Conclusions: Treatment with oral ferric citrate yielded signifi-
cant and sustained improvement in iron measures in both dialysis-dependent
and ND-dependent CKD subjects. The changes in both serum iron and TSAT
are small relative to the iron administered, attesting to low fractional absorption
of iron. In addition, the percent increase in iron parameters decreased over
time indicative of physiologic negative feedback mechanisms regulating the
amount of intestinal iron absorption.
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THE SPECTRUM OF Α-THALASSEMIA AND Β-THALASSEMIA MUTATIONS
IN SOUTH WEST IRAN
B. Keikhaei1,*
1Thalassemia, Health Institute,Research Center for Thalassemia and Hemo-
globinopathy, Ahvaz, Iran
Background: Carrier screening, genetic counseling, prenatal diagnosis and
aborted affected fetus are successful programs in reducing new delivery of β-
thalassemia major and severe form of α- thalassemia in Iran. As both alpha
and beta thalassemia are highly prevalent in south west Iran. The increasing
knowledge about mutation types might be an important guide for genetic coun-
seling sectors.
Aims: The purpose of this study is to detect the accurate frequency and type
of Alpha and Beta mutations in pre marital candidate couples.
Methods: A total of 600 couples (1200 individuals) were recruited in this study.
Five milliliter of EDETA and clot blood were drawn and obtained from each subject.
Cell blood count, Hemoglobin electrophoresis was done for everybody. The com-
mon deletional alpha thalassemia was determined by polymerase chain reaction
based direct amplification assay.DNA sequencing was done to detect beta and
non deletional alpha mutations. DNA study for beta mutation was performed on
each individual with MCV <80, MCH <27 and Hb A2>3.5.However, alpha mutation
was conducted with MCV <85, MCH <27.5 and Hb A2<3.5.
Results: The frequency of carrier state for beta thalassemia and alpha tha-
lassemia (silent, minor and Hb H) were 7 and 15% respectively. The mutation at
codon 36-37 (-T) was found the first mutation with a frequency of 21.2%. The
other mutations, at decreasing frequencies ranging from 18.3 to 1.1 were: IVS I-
110:18.3%,IVSII-I :14.8%,CD8 (-AA):5.6%,IVSI-I: 4.2%,CD 44(-C):
4%,CD5:4%,CD39(C-T):3.4%,IVS1-5:3.2%,CD8-9:2.6%,CD82=83:2.6%,-
28:2.6%,IVSI-6:2.4%,-88:1.9%,25bp del: 1.6%,IVSII-848:1.1%,IVSI-(-
24):1.1%,IVSI(-17):1.1. The prevalence of the other mutations was very rare. The
alpha mutations with a decreasing frequency was as follow:-α3.7 heterozygote:
38.2%,-α3.7 homozygote: 11.6%,-Med: 3.8%, CD 19:3.5%, Poly A4:2.5%,-α3.7/-
Med:2.5%,Poly A6:2.3%,-α4.2 heterozygote: 1.6%, IVSI -Donor site: 1.5%, 5NT-
del: 1.4%,-20.5:1.2%. The frequency of the other mutations was below 1%.
Summary and Conclusions: This study shows the high prevalence of alpha
and beta thalassemia in south west Iran. The most alpha and beta thalassemia
mutations were-α3.7 and CD 36-37 respectively. This is in concordance with
Amin Doosti-Irani et al. study. The most alpha thalassemia mutation is in the
line of most Iranian and Arabian countries studies. But the predominant beta
mutation in our study is not in the top list of Najmabadi H et al. study. Both
alpha and beta thalassemia are highly prevalent in south west Iran. The increas-
ing knowledge of health sectors about alpha and beta thalassemia frequency
and mutation types will enable them to manage better genetic counseling.
Key Words: South West Iran, Alpha mutation, Beta mutation.
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DO WE HAVE TO CHELATE PATIENTS WITH THALASEMIA MAJOR HAV-
ING FERRITIN LEVELS <500 ΜG/L?
G. Aydogan1,* Z. Salcioglu1, F. Akici1, H. Sen1, D. Tugcu1, M. Gokce1, A. Aycicek1,
G. Keskindemirci1, N.A. Ayaz1, C. Bayram1
1Pediatric Hematology, Kanuni Sultan Suleyman Education And Research Hos-
pital, Istanbul, Turkey
Background: In developing countries ıron load can be determined by meas-
uring ferritin levels. By following ferritin levels, alterations of iron status can be
predicted. The general recommendation is to decrease the dose of DFX or stop
chelation when the level of ferritin is <500 µg/L There is no study regarding the
use of deferasirox or deferipron at low ferritin levels. But case reports related
to iron toxicity with low ferritin levels had been published. 
Aims: So, we aimed to evaluate the toxicity due to chelation therapy at ferritin
levels of <500µg/L.
Methods: Children followed up at our pediatric hematology outpatient clinic
with the diagnosis of Thalasemia Major are involved to the study. The charts of
patients having regular blood transfussions and deferasirox therapy were
reviewed retrospectively and they were evaluated for hepatotoxicity and nephro-
toxicity when their ferrin levels were <500µg/L. 
Results: Of 21 patients, 22 times ferritin levels became <500 µg/L (106 µg/L -
495 µg/L). In 16 of these low levels of ferritin, chelation dose was decreased,
but in 6 of them the dose was not decreased due to the fact that te results were
brought late by the patients. The ages of patients under chelation therapy while
their ferritin levels were low was between 58 month and 21 years (median 9
years). Deferasirox was used in 20 patients, 1 patient was having deferipiron.
The duration that patients have ferritin <500µg/L was between 22weeks and
91 weeks. None of the patients had any clinical and laboratory (BUN, Kreatinin,
AST and ALT) derrangement.
Summary and Conclusions: Ferritin levels may change as a response to
inflammation, liver function abnormalities and ascorbate deficiency. There are
studies showing no significant correlation between cardiac iron load and ferrtin
levels. Even with moderately elevated ferritin levels iron toxcity may ensue.
So, it is a must to predict the toxicity of chelation therapy and continue chelation.
There was no clinical and laboratory influence of deferasirox therapy for patients
having ferritin <500µg/L. But larger controlled series are needed for saying
deferasirox therapy is safe at low ferritin levels.
E1498
KLF10 GENE EXPRESSION AS A SECONDARY MODIFIER IN BETA THA-
LASSEMIA AND SICKLE CELL DISEASE (SCD) PATIENTS AND A PHAR-
MACOGENOMIC BIOMARKER FOR HYDROXYCARBAMIDE TREATMENT
RESPONSE 
M. Elalfy1,* N. Elsherif1, T. Kamal2, N.H. Aly 1
1Pediatric Hematology and Oncology, 2Genetics, Ain Shams University, Cairo,
Egypt
Background: Many genes have been uncovered which could modify γ- globin
chain production and hence level of fetal hemoglobin (HbF) ameliorating the phe-
notype of beta hemoglobinopathies and SCD as well as the response to hydrox-
ycarbamide (HU). KLF10 indirectly increase gamma globin chain synthesis.
Aims: the aim of the study was to evaluate the frequency of different genotypes
for KLF10 gene in B-TM, B-TI,SCD patients compared to healthy controls via
DNA extraction and PCR and to assess its relation to disease phenotypes,
(HU), clinical and laboratory response.
Methods: This case control study included 80 patients; 48 beta thalassemia
major (B-TM), 16 sickle cell disease (SCD) and 16 thalassemia intermedia (B-
TI) patients (in a ratio 3:1:1), compared with 50 matched controls. All included
SCD and B-TI patients were on stable dose of HU therapy. Assessment of
KLF10 gene relation to phenotype was done using baseline HbF, transfusion
index, while evaluation of response to HU therapy was done through comparing
the frequency of vaso-occlusive crises and transfusion 2 years before and after
start of therapy as well as an increase more than 20% in baseline HbF level.
Results: The frequency of mutant KLF10 genotype and the mutant allele (T) was
significantly higher among B-TM (30%) compared to B-TI, SCD patients
(0%,7.1%)and control(6%) (p=0.04). There was no significant difference between
different KLF10 genotypes among B-TM patients as regards age at onset of dis-
ease, initial HbF%, transfusion index and mean pretransfusion Hb in last 2 years
prior to the study(p=0.12, p=0.08, p=0.73, p=0.59, p=0.42 respectively), nor between
homozygous SCD patients for normal KLF10 and mutant KLF10 gene as regard
age of onset of disease, the percentage of patients who suffered from avascular
necrosis, stroke, acute chest syndrome (p=0.69,p=0.27,p=0.18,p=0.15respectively).
Yet Homozygous SCD patients for normal KLF10 gene had significantly lower
TI/OR decrease transfusion frequency longer interval between transfusions
(p=0.002). The percentage of clinical and laboratory responders and non respon-
ders to HU between different KLF10 genotypes among B-TI, SCD patients was
comparable (p=0.679), (p=0.931). The frequency of mutant KLF10 genotype and
the mutant allele (T) was significantly higher among B-TM (30%) compared to B-
TI, SCD patients (0%,7.1%) and control (6%) (p=0.04). There was no significant
difference between different KLF10 genotypes among B-TM patients as regards
age at onset of disease, initial HbF%, transfusion index and mean pretransfusion
Hb in last 2 years prior to the study(p=0.12, p=0.08, p=0.73, p=0.59, p=0.42 respec-
tively), nor between homozygous SCD patients for normal KLF10 and mutant
KLF10 gene as regard age of onset of disease, the percentage of patients who suf-
fered from avascular necrosis, stroke, acute chest syndrome (p=0.69, p=0.27,
p=0.18, p=0.15 respectively). Yet Homozygous SCD patients for normal KLF10
gene had significantly lower TI/OR decrease transfusion frequency longer interval
between transfusions (p=0.002). The percentage of clinical and laboratory respon-
ders and non responders to HU between different KLF10 genotypes among B-TI,
SCD patients was comparable (p=0.679), (p=0.931). 
Summary and Conclusions: Although KLF10 gene has not a standalone role
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as an HbF modifier, yet our data supports its importance in ameloriating phe-
notype among beta hemoglobinopathies. Further evaluation of KLF10 gene
expression among B-TI, SCD patients as a potential pharmocogenomic marker
to differentiate between responder and non responder to HU is warranted. 
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THINKING OF HEREDITARYxEROCYTOSIS: THE FIRST STEP TO THE
DIAGNOSIS
M. Santos1,* B. Mesquita2, T. Maia1, H. Almeida1, C. Bento1, L. Ribeiro1
1CHUC, Coimbra, 2Centro Hospitalar Trás-os-Montes e Alto Douro, Vila Real,
Portugal
Background: Hereditaryxerocytosis (HX) or Dehydrated Hereditary Stomato-
cytosis is a rare autosomal dominant hemolytic anemia (1 in 50000 live births),
resulting from a red blood cell (RBC) membrane permeability disorder. HX has
a wide range of clinical phenotypes: while some patients are asymptomatic,
others have compensated hemolysis, with slight macrocytosis and reticulocy-
tosis, mild splenomegaly and/or gallbladder lithiasis. In spite of not requiring
frequent transfusion, most of the HX patients have iron overload. In the periph-
eral blood smear (PBS) a variable number of cup-cells can be observed, but
are frequently overlooked.
Aims: To review the clinical features and hematological parameters on patients
with HX in order to understand the most important steps to the diagnosis of
this rare disease, and also to show the high phenotypic variability of HX. 
Methods: Collection of all the clinical and laboratory data of all the patients
with HX diagnosis (confirmed by the presence of PIEZO1 mutations) followed
in our department.
Results: Our population consists in 7 patients, with male predominance (n=5)
and median age at diagnosis of 30 years (0-59). This group of patients showed
a heterogeneous disease phenotype: mean hemoglobin of 13,2 g/dL (10,4-
14,8), mean globular volume of 96,5fl (87,7-105), mean corpuscular hemoglo-
bin concentration of 34,6 g/dL (33,1-35,3), mean reticulocyte count of 232,8
G/L (94,9-600), mean total bilirrubin of 27,3 µmol/L (9-50), mean LDH between
normal values (330 U/L (99-493)) and ferritin of 574,7ng/ml (168-1489). On
clinical presentation only one patient showed the classical signs and symptoms
associated with HX, as can be observed in Table 1. One patient presented with
hidrops fetalis at birth but with Hb of 19g/dl and in a few weeks develops
hemolytic anemia with macrocytosis, reticulocytosis, hyperferritinemia and liver
and spleen enlargment while, in the opposite side of the clinical spectrum, 2
patients were asymptomatic, showing only a slight macrocytosis or reticulocy-
tosis and hyperferritinemia. The only common feature to all patients was the
presence of cup-cells in the PBS and 6/7 had hyperferritinemia. Five patients
had family history of anemia and/or hyperferritinemia.
Table 1.
Summary and Conclusions: Reviewing the data on these 7 patients with HX
due to PIEZO1 mutations we could observe a high phenotypic variability and
that the main steps to the diagnosis were the clinical suspicion and the identi-
fication of cup-cells in the PBS. The high association between HX and hyper-
ferritinemia misleads its diagnosis, which is overlooked on the etiological
workup of hyperferritinemia. In the era of molecular biology, we want to empha-
size the importance of the RBC morphology to the diagnosis of HX and the
current tendency to ignore the PBS observation is probably the main cause for
the disease underdiagnosis. The diagnosis of HX is essential because, unlike
the most congenital hemolytic anemia, the splenectomy is contraindicated,
since it is associated with severe thromboembolic disease.
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EFFECTIVENES OF MAGNETIC RESONANCE IMAGING FOR MEASURING
OF PITUITARY IRON OVERLOAD IN PATIENTS WITH THALASSEMIA
Y. Oymak1,* S. Okur2, T.H. Karapinar1, Y. Ay1, K. Demir3, M. Gurcinar4, S. Aydin
Koker1, N. Muminoglu5, E. Toret1, C. Vergin1
1Pediatric Hematology, 2Pediatri, Dr. Behcet Uz Children’s Hospital, 3Pediatric
Endocrinology, Dokuz Eylül University, 4Radiology, Bilrad MR, 5Pediatric Hema-
tology, Dr. Behcet Uz Children’s Hospitai, Izmir, Turkey
Background: In patients with b-thalassemia major iron deposition resulting
from complications related with morbidity and mortality. Iron accumulation starts
in the reticuloendothelial system and subsequently accumulates in all parenchy-
mal organs. One of the affected parenchymal organs is pituitary gland. Although
thalassaemic patients are chelated adequately, pituitary siderosis may lead to
hypopituitarism.
Aims: The aim of this study was to evaluate the magnetic resonance imagine
(MRI) signal intensity of pituitary gland if it was suitable to measure pituitary
siderosis.
Methods: The ratio of the average anterior pituitary gland signal intensity to
that of the pterygoid muscles and that of nasopharyngeal fat was assessed in
60 patients with b-thalassemia major by using signal intensity ratio of T1-weight-
ed MRI. All patients were taking deferasirox. In all patients, an endocrine eval-
uation was performed, including measurements of spontaneous gonadotropins,
thyroid hormones, growth hormone and insülin like growth factor. Also liver
iron content (LIC) was measured with R2 MRI.
Results: A total of 60(M/F=34/26) pediatric patients with mean age of
11.5±4.5(range 1.8-19.0) years were enrolled the study. The mean serum fer-
ritin level and LIC values were 1127.1±615.7 ng/ml and 2.1±1.2 mg iron/g dry
tissue weight (dw) respectively. Any patients had high LIC level. The measure-
ments of anterior pituitary gland wasn’t correlated median age of the patients
and median of other hormone levels. Only TSH level and pituitary-to-fat ratio
was correlated (r=0.32, p=0.033). Nine patients (15%) had pubertal retardation
and six patients (10%) subclinical hypotiroidsm. There wasn’t difference
between the patients who had and hadn’t hypotyroidism in terms of anterior
pituitary MRI. Also there wasn’t difference between the patients who had and
hadn’t pubertal retardation in terms anterior pituitary MRI.
Summary and Conclusions: Our data suggest that iron accumulation of ante-
rior pituitary gland measurement by using MRI wasn’t succesful. This may be
related that there were no patient who had high level of LIC. So the patients’
anterior pituitary glands may not be affected by iron accumulation due to priority
in iron accumulation of the reticuloendothelial system.
LB2089
ASSESSMENT OF THE EFFECTS OF ANEMIA ON CARDIOVASCULAR
FINDINGS IN OBESE ADOLESCENTS
Ö. Yıldırım1, T. Demircan2, Ö. Kızılca2, P. Kuyum3, M. Kır2, A. Abacı4, N. Ünal2,
N. Arslan3, E. Böber4, S. Yılmaz Bengoa5, H. Ören5,*
1Pediatrics, 2Pediatric Cardiology, 3Pediatric Gastroenterology, 4Pediatric
Endocrinology, 5Pediatric Hematology, Dokuz Eylül University Faculty of Med-
icine, İzmir, Turkey
Background: Obesity that develops during childhood is a major risk factor in terms
of cardiovascular diseases in further life. In obese adolescents, anemia may devel-
op due to inflammation of obesity and iron deficiency anemia and it may be a risk
factor that affects the cardiological progress negatively in these patients. 
Aims: The purpose of this study is to assess the effects of anemia on cardio-
vascular findings in obese adolescents by using echocardiography.
Methods: Twenty nine obese adolescent patients with anemia and 33 obese
adolescents without anemia who were 12-18 years old were echocardiograph-
ically investigated in the Pediatric Cardiology Outpatient Clinic. Thirty three
adolescents who had similar age and gender and whose body mass indexes
were between 3-85 percentiles were included as the control group. Patients
data were obtained from the relevant departments and the hospital patient
files. All patients were examined according to their cardiac risk factors, blood
pressures, pulse rates, and physical examination findings. Blood counts, liver
and renal function tests were noted. Serum iron parameters, thyroid function
tests, fasting glucose, lipid profiles, insülin, and CRP values of the obese ado-
lescents were recorded. The patients were examined according to their diet,
presence of intolerance to the effort, sleep apnea, thrombosis, and fatigue
symptoms. Echocardiographic parameters of all patients were examined.
Results: There were not any difference between groups in terms of age and
sex. Anemia was mild (mean Hb: 11.5±0.79 g/dL) in the anemic obese group.
Hypertension, presence of intolerance to the effort, and fatique were statistically
significantly high in both obese groups compared to the control group. There
was statistically significant difference between obese groups in terms of diet and
cardiac pulse rate. Anemic obese adolescents were dieting more in order to loose
weight and tachycardia was found at a higher rate. In laboratory examinations of
anemic obese and obese groups, a significant difference was detected in terms
of average values of ferritin, CRP, and fibrinogen. Ferritin was found significantly
low, CRP and fibrinogen levels were found significantly high in the anemic obese
group. According to M-mode echocardiographic examination results, a significant
difference was detected in terms of averages of interventicular diastolic diameter,
left ventricular posterior wall diastolic diameter, left ventricle mass, and left ven-
tricle mass index in obese patients compared to the control group; there was no
significant difference in these parameters between the anemic and nonanemic
obese patients. Ratio of mitral peak early diastolic flow velocity to peak early
diastolic myocardial velocity (Mitral E/E’) by tissue Doppler echocardiography
was slightly higher in both of the obese groups.
Summary and Conclusions: Early symptoms of subclinical left ventricular
diastolic dysfunction were detected in obese adolescents. Mild anemia did not
show any difference except higher cardiac pulse rate. Since severe anemia
may change the results and be one of the cardiovascular risk factors in obese
adolescents, it is necessary to avoid low iron diet programs in these children.
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ACTIVATION OF MONOCYTES AND DENDRITIC CELLS IN PATIENTS
WITH ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
E. Hofmann1,* P. Stein2, J. Dopheide3, H. Schild4, E.-M. Wagner1, M. Radsak1
1IIIrd Deparment of Medicine, 2Center for Thrombosis and Haemostasis, 3IInd
Department of Medicine, 4Institute of Immunology, Johannes-Gutenberg Uni-
versity Medical Center, Mainz, Germany
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the
treatment of choice for a variety of hematologic malignancies. Graft-versus-
host disease (GVHD) is a key contributor to treatment related morbidity and
mortality and consequently limits the efficacy of HSCT. GVHD may involve liver,
skin, gastrointestinal tract or other organs leading to severe and life-threatening
organ damage as well as to a high risk of opportunistic infections. Early diag-
nosis of GVHD and the consequent initiation of the adequate treatment are
important factors that contribute to a favourable outcome.
Aims: Several studies indicate that innate immune responses play an important
role in development of acute GVHD. Thus, we are interested in activation state
of monocytes and dendritic cells in HSCT patients asking whether there are
differences in activation of these cell types as early indicators of GVHD and
maybe useful for the early identification of patients at risk of developing GVHD. 
Methods: In this retrospective study, we analysed cryoconserved peripheral
mononuclear cells (MNCs) from 17 patients with acute GVHD and 16 patients
without GVHD. All patients had received HSCT after conditioning treatment
with fludarabine, melphalan and alemtuzumab and gave informed consent for
blood analyses. The following surface markers were analysed on monocytes
and dendritic cells (DCs) by multi-color flow cytometry using fluorochrome con-
jugated monoclonal antibodies: TREM-1, CD86, HLA-DR, CD16, CD14, CD83,
CD40, CD11c, CD123. In addition serum samples from a subset of 13 acute
GVHD patients and 8 controls were analysed by enzyme-linked immunosorbent
assay (ELISA) to detect soluble TREM-1 (sTREM-1). For statistical analyses,
two groups were compared by Pearson’s test for correlations and unpaired
Student’s t-test considering p<0.05 as statistically significant.
Results: In flow-cytometry analysis we found an increased expression of CD83
on plasmacytoid DCs (125.1 +/- 26.97 vs 38.06 +/- 20.65) as well as on myeloid
DCs (122.5 +/- 27.33 vs 10.13 +/- 12.86) in patients with acute GVHD. We
observed no differences in the expression of the surface markers (CD86, CD40,
TREM-1) on monocyte subpopulations. Nevertheless, sTREM-1 ELISA
revealed a significant difference between patients with acute GVHD and the
controls (244.7 +/- 35.89 vs 101.4 +/- 18.83). Laboratory parameters as C-
reactive protein (CRP) correlated positively with sTREM-1 levels in patients
with acute GVHD (r=0.692). Other laboratory parameters e.g. eosinophils or
platelets showed no significant differences between the groups.
Summary and Conclusions: We found an increased expression of CD83 on
DCs in patients with acute GVHD. Furthermore, sTREM-1 levels in this group
were significantly higher as well as CRP and s-TREM-1 levels showed a positive
correlation. Other parameters as eosinophils, platelets or monocyte phenotype
were not informative as markers for GVHD. However, the small number of
patients and the retrospective character of our study are currently limiting the
possibility to draw clearcut conclusions. Nevertheless, we conclude that ELISA
of sTREM-1 could be a new marker to identify patients and initiate early treat-
ment for GVHD, and warrant further prospective studies to evaluate the clinical
value of this new marker.
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COMPARISON OF CONDITIONING REGIMENS FOR RELAPSED/REFREC-
TORY LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION: BEAM VS HIGH DOSE ICE
A.K. Gunes1,* S. Dagdas1, F. Ceran1, M. Falay1, G. Ozet1, N. Zengin2
1Hematology, 2Oncology, Ankara Numune Training and Research Hospital,
ankara, Turkey
Background: High-dose chemotherapy in conjunction with auto-SCT is widely
recognized as the preferred modality of treatment for patients with relapsed or
refractory Hodgkin disease or non-Hodgkin lymphoma at the time of chemosen-
sitive relapse. Despite different drug combinations and conditioning regimens
before auto-SCT, the optimal choice is undetermined. Several studies have been
made to identify a regimen with superior antitumor activity and acceptable toxicity. 
Aims: In this retrospectical analysis, we compared the efficacy and the toxicity
of the BEAM and high dose ICE conditioning regimens in relapsed NHL and
relaps/refractory Hodgkin Lymphoma patients. 
Methods: A total of 83 patients with HL or NHL treated with Auto-SCT at our
center between 2004-2013 are analyzed retrospectively. Patients were con-
sidered eligible for transplantation, if they met the following inclusion criteria:
age between 16 and 65 years, ECOG performance status 0-2 (WHO (World
Health Organization)), left ventricular ejection fraction greater than 55%, crea-
tinine clearance greater than 60 ml/min and adequate lung and liver function.
The Bearman Regimen Toxicity Scale is specifically used to rate the complica-
tions caused by chemotherapy during hospitalization for SCT. 
Results: 52 patients (%62,7) received BEAM, 31 patients (%37,3) received
hd-ICE. Between two groups there is no difference by age, diagnosis, trans-
fused CD 34 yield, disease status at transplant, refractory case distribution,
ECOG score at transplant. The descriptive values are in Table 1. The Renal
toxicity in any grade BEAM group is%4 (1 grade I and 1 grade III) by the way
the renal toxicity in ICE group is%32 (6 with grade I, 1 with grade II, 3 with
grade III) (p=0,01). The GIS toxicity with any grade in BEAM group is%25 (10
with grade 1, 3 with grade 2) while in ICE GIS toxicity is%22,5 (4 with grade 1,
3 with grade 2) (p=0,415). The mucositis in BEAM group in any grade is% 26,3
while in ICE is%25 (p=0,857). Hepatotoxicity in BEAM group is%10, there is
no hepatoxicity in ICE group. (p=0,041). Transplant related mortality rate is%2,4
(2 patients, 1 BEAM group, 1 ICE group). The main cause of death in ICE
group is renal failure, while in BEAM group it is sepsis. In the BEAM group the
mean neutrophil engraftment occurred on 11,2 days (9-21 day) while in ICE
group 9,77 days (8-14 day) (p=0,047). The mean platelet engraftment in BEAM
group is 14,2 days (8-41 days) in ICE group the mean is 11,4 days (8-24 days)
(p=0,024)When the total patients analyzed, the CR rate in 100 days after trans-
plant in the BEAM group is%63,5, in the ICE group%45,2 (p=0,062).In refractory
Hodgkin group CR rate in 100.day, in BEAM group is%6,1, in ICE group% 7,1
(p=0,844). The partial remission rate for refractory Hodgkin group BEAM is%14,
ICE is%33,3 (p=0,047).1 year overall survival rate in BEAM group%87,2, in
ICE group% 90,4. 1 year PFS in BEAM group%72,7 in ICE
group%58.(p=0,039). If the refractory Hodgkin group is excluded 1 year PFS
in BEAM group%81,7, in ICE group%74,2. (p=0,345).In ICE group after 6,3
years follow-up, OS is%54, PFS is%45. In BEAM group after 6,3 year follow
up OS is%65,3 PFS%51,9. (p=0,041).
Table 1. Descriptive factors of BEAM and hdICE group.
Summary and Conclusions: Despite the common use of BEAM and hdICE
regimens as conditioning regimens for auto-SCT in patients with lymphoma,
there have been few reports comparing these two regimens.The high dose ICE
conditioning regimen provides us a shorter neutrophil and platelet engraftment
time, a lower hepatotoxicity and a higher response rate for refractory Hodgkin
patients whereas a marked increase in renal toxicity and a lower PFS and OS
in contrast to BEAM. According to our study analysis, Hd ICE as a conditioning
regimen for auto-SCT should be considered for refractory Hodgkin Lymphoma
patients. Prospective and randomized studies require defining the most efficient
conditioning regimens for relapsed/refractory lymphoma patients. 
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
NON-MALIGNANT HEMATOLOGICAL DISORDERS
Y. Elnahass1,* H.K Mahmoud1, M.A Samra1
1National Cancer Institute, Cairo, Egypt
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
from a geno-identical matched sibling (MSD) is one of the most successful
therapies in patients with non-malignant hematological disorders.
Aims: The aim of this study was to illustrate and report the out-come of allo-
HSCT in different non-malignant hematologicconditions treated at our Institute.
Methods: This study included 273 patients with severe aplastic anemia (SAA),
152 patients with B-Thalassemia major (BTM), 31 patients with Fanconi’s ane-
mia (FA), 20 patients with congenital immunodeficiency diseases (ID), and 13
patients with inherited metabolic disor-ders (IMD) allografted from a MSD. This
study included 273 patients with severe aplastic anemia (SAA), 152 patients
with B-Thalassemia major (BTM), 31 patients with Fanconi’s anemia (FA), 20
patients with congenital immunodeficiency diseases (ID), and 13 patients with
inherited metabolic disorders (IMD) allografted from a MSD. All donors were
siblings and at least 6/6 HLA matched. PBSC Donors were injected subcuta-
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neously with (G-CSF, 10ug/kg daily for 5 days) and mobilized PBSC was col-
lected the day of last injection. 
Results: In SAA, the 8-year overall survival (OS) of the whole group patients
was 74%. OS was significantly better in patients conditioned with fludarabine
and cyclophosphamide (Flu/Cy) than in those who received cyclophosphamide
and antithymo-cyte globulin (Cy/ATG) (p=0.021). Acute graft-versus-host disease
(aGVHD) grade II-IV occurred in 15% while chronic GVHD (cGVHD) occurred in
28%. In BTM, the 12-year dis-ease-free survival (DFS) of the whole group of
BTM patients was 72.4%. DFS was 74% for peripheral blood stem cell (PBSC)
group compared to 64% in the BM stem cell group. The inci-dence of graft rejec-
tion was significantly lower in patients who received PBSC than in those who
received BM (9% vs 25%) (p=0.036). AGVHD grade II-IV and cGVHD occurred
in 15% and 12% of the whole group of BTM patients respectively. In FA, the 5-
year OS was 64.5%. Graft rejection occurred in 10% of patients. Grade II-IV
aGVHD occurred in 16% while cGVHD occurred in 4%. In ID, the 5-year OS was
62%. Graft rejection occurred in two (10%) patients. Three patients (15%) devel-
oped grade II-IV aGVHD, 2 of them progressed. In SAA, OS was significantly
better in patients conditioned with fludarabine/ cyclophosphamide (Flu/Cy) than
in those who received Cy/ATG (p=0.021). Acute graft-versus-host disease
(aGVHD) grade II-IV occurred in 15% while cGVHD occurred in 28%. In BTM,
DFS was 74% for peripheral blood stem cell (PBSC) group compared to 64% in
the BM stem cell group. The incidence of graft rejection was significantly lower
in patients who received PBSC than in those who received BM (9% vs 25%)
(p=0.036). AGVHD grade II-IV and cGVHD occurred in 15% and 12% of the
whole group, respectively. In FA, the 5-year OS was 64.5%.Graft rejection
occurred in 10% of patients. Grade II-IV aGVHD occurred in 16% while cGVHD
occurred in 4%. In ID, graft rejection occurred in 2 (10%) patients. Three patients
(15%) developed grade II-IV aGVHD. In IMD, OS was 46% at 5 years. Graft
rejection occurred in 8% of patients.
Summary and Conclusions: Allo-HSCT provides a higher DFS rate over con-
ventional therapies for patients with non-malignant hematological disorders
with prolonged survival.
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FERTILITY IN OUR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANT PATIENTS: RESULTS FOR 23 YEARS OF EXPERIENCE 
P. Topcuoglu1,* P. Ataca1, E. Atilla1, S. Civriz Bozdag1, S.K. Toprak1, G. Gurman1
1Hematology, Ankara University School of Medicine, Ankara, Turkey
Background: Survival after allogeneic hematopoietic stem cell transplantation
(Allo-HSCT) has increased due to effective supportive treatment. Infertility is a
major late side effect after transplantation. However, healthy pregnancies and
births were reported previously.
Aims: In this paper, we aim to present our patients’ fertility after Allo-HSCT.
Methods: We retrospectively evaluated the fertility in 122 (14%) eligible
patients from 849 patients who underwent Allo-HSCT between 1989-2012 at
Ankara University Hematology Department and survived 2 years or more after
transplantation and desired pregnancy. We used Pearsonchi-square test to
compare groups. P<.05 was considered statistically significant.
Table 1. Distribution and comparison of fertile and infertile patients.
Parameters                                                     Fertility                 Fertility                   P
                                                                 Yes % (n=26)          No (n=96)
Diagnosis
Acute leukemia (AML, ALL, sec leukemia)      38.4% (10/26)     57.3% (55/96)         
0.014*
Chronic MPD (CML, PMF)                             42.3% (11/26)     28.2% (27/96)
Bone marrow Failure (AAA, PNH, MDS)          19.3% (5/26)        5.2% (5/96)
Others (Lymphoma, Myeloma)                         0% (0/22)           9.3% (9/96)
Relative vs non-relative donors                      100% (26/26)       96% (92/96)            0.88
Chemotherapy prior to ASCT                          77% (20/26)        93% (89/96)          
0.032*
Radiotherapy prior to ASCT                              0% (0/26)            3% (3/96)              0.45
Myeloablative conditioning regimen               96% (25/26)        90% (86/96)            0.48
TBI in conditioning regimen                            0.4% (1/26)         13% (12/96)            0.29
Acute GVHD                                                  35% (9/26)         39% (37/96)            0.82
Chronic GVHD                                              54% (14/26)        65% (62/96)            0.37
Disease relapse                                             12% (3/26)         31% (30/96)           0.04*
Results: In 122 patients (56 F/66 M), the mean age during Allo-HSCT in female
patients was 33.48±8.41, whereas 32.85±7.92 in male patients. 35 patients had
(29%) a child whereas 16 patients/patient partners (13%) had history of preg-
nancy complications prior to transplantation. The mean follow-up period after
transplantation was 119 months (range 18-300 months). From totally 31 preg-
nancies (23 partners of male patients vs 8 female patients), 6 of the female
patients (11%) and 20 of the male patients (30%), had a child after Allo-HSCT.
From 23 pregnancies of male patients partners, there were 4 abortus, 1 stillbirth,
1 gestational diabetes, 1 gestational hypertension; whereas from 8 pregnancies
of female patients there were 2 abortus, 1 preeclampsia, 1 gestational diabetes
were detected as pregnancy complications. The mean time from Allo-HSCT to
pregnancy was 68 months (range, 4-144) in male while 63 months (range, 8-
108) in female patients. All patients who had given birth after Allo-HSCT had
received transplants from full-match HLA sibling donors or relatives. 9 of 56
female patients (16%) had regular menstrual cycles after transplantation. Several
parameters compared between fertile vs unfertile patients were shown in Table
1.
Summary and Conclusions: Treatments prior to Allo-HSCT may have dam-
aging effects on gonadal tissue and induce infertility as previously reported.
The benign nature of the initial diagnosis, lack of chemotherapy regimen before
transplantation, early age and no relapse of the primary disease contribute to
fertility in our study. Unexpectedly, we found no relation between the myeloab-
lative conditioning regimen, radiotherapy prior to Allo-HSCT, TBI usage and
frequency, and development of acute and chronic GVHD with infertility. Fertility
preservation of recipients should be considered before transplantation.
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MESNA’S CONCENTRATION IN URINE CAN BE MAINTAINED BY CON-
TINUOUS INTRAVENOUS INFUSION OF MESNA: A BETTER METHOD TO
PREVENT HEMORRHAGIC CYSTITIS IN HSCT
Q. Jiang1,* H. Huang1, Q. Liu1, J. Sun1, H. Zhou1, Z. Fan1, Y. Zhang1, F. Huang1,
Y. Chai1, D. Xu1, Y. Lu2, Q. Wei1, G. Yu1, X. Li1, M. Dai1, N. Xu1, D. Zhou2,
H. Zhao2, K. Shen1, Y. Zhou1, Q. Zhang2, F. Meng1
1Department of Hematology, Nanfang Hospital, 2Southern Medical University,
Guangzhou, China
Background: The clinic protective effect of continuous intravenous infusion of
MESNA on cyclophosphamide-induced HC in HSCT has been demonstrated
by our team. But what is the mechanism? This work was supported by the
National Natural Science Foundation of China (No. 30901367, 31070866), Out-
standing Young Teachers’ foundation of SMU (C1031694).
Aims: To detect the MESNA’s Concentration in urine and serum, hoping to
illustrate the mechanism.
Methods: (1) In preliminary prospective study: 66 allogenic HSCTs were
prospectively randomized into the MESNA continuous i.v. (continuous) group
and the MESNA intermittent (0, 3, 6, 9h) i.v. (intermittent) group. (2) In retro-
spective study: 394 allogenic HSCTs were retrospectively analyzed between
both groups. (3) The MESNA concentration in urine and serum of both groups
were detected by HPLC. The three observation points of both group (n=5) were
as follows: Before CTX and MESNA, immediately after CTX administration,
12h after the beginning of CTX.
Results: (1) Preliminary prospective study (32 vs 34 cases) shows that HC
occurs 34.38% vs 0 within +30d (P=0.001), and 40.63% vs 5.88% within +60d
(P=0.002) between intermittent and continuous group. (2) Retrospective study
(160 vs 234 cases) shows that HC occurs 18.75% vs 7.26% within +30d
(P=0.001) and 28.13% vs 12.82% within +60d (P=0.000) between intermittent
and continuous group. The mean HC occurrence time are +19.77d vs +27.20d
(P=0.037), respectively. (3) The MESNA concentration in urine is as low as
zero in intermittent group 12h after CTX; while in continuous group, it varied
between (439.47±34.34) μM and (268.21±24.51) μM in urine, as well as
between (56.62±1.10) μM and (37.06±2.95) μM in serum.
Summary and Conclusions: Continuous i.v. of MESNA is efficient in the pre-
vention of HC in HSCT. Keeping enough MESNA concentration in urine is the
key factor in HC prevention.
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PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND EFFICACY
STUDY OF PLERIXAFOR IN CHINESE PATIENTS WITH NON-HODGKIN
LYMPHOMA (NHL)
J. Zhu1,* H. Chen2, Z. Li3, H. Chen4, J. Hu5, J. Li6, Y. Li7, Y. Su8, J. Wu7, R. Lai7,
X. Huang2
1Beijing Cancer Hospital, 2Peking University People’s Hospital, Beijing, 3Institude
of hematology & Hospital of Blood Disease, CAMS, Tianjin, 4307 Hospital of
PLA, Beijing, 5Shanghai Ruijin Hospital, Shanghai, 6Jiangsu Province Hospital,
Nanjing, 7Sanofi R&D, Beijing, China, 8Sanofi R&D, Bridgewater, United States
Background: Plerixafor, a small molecule antagonist of the chemokine recep-
tor 4, has been approved in US and Europe for use in combination with gran-
ulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells
to the peripheral blood (PB) for collection and subsequent autologous trans-
plantation in patients with NHL and multiple myeloma.
Aims: This study was designed to investigate for the first time the safety, phar-
macokinetics (PK), pharmacodynamics (PD) and efficacy profiles of plerixafor
with G-CSF in Chinese NHL patients.
Methods: Eligible NHL patients were given G-CSF (10 µg/kg/day subcuta-
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neously) for 4 days in the morning and randomized to receive plerixafor 240
µg/kg or placebo subcutaneously on the evening of day 4. Apheresis was initi-
ated around 1 hour after the next morning dose of G-CSF (approximately 9 to
10 hours post dosing of plerixafor/placebo). This regimen was repeated until
5x 106 CD34+ cells/kg were collected or for up to day 8. Venous blood samples
were collected at specific time points post the first dosing on the evening of
day 4 for assessing plasma plerixafor concentration and PB CD34+ cells count.
Patients with ≥2 × 106 CD34+ cells/kg collected, underwent pre-transplantation
chemotherapy followed by transplantation within 2 months.
Results: A total of 32 Chinese NHL patients [15 males, 17 females, median age
28 years, mean weight 68.5 kg, ECOG PS 0-1] were randomized and treated in
this study. Overall, the demographics and baseline characteristics of these
patients were similar in the 2 treatment arms. Plerixafor was rapidly absorbed
after the first subcutaneous administration in these patients with peak plasma
concentrations occurring at a median tmax of 0.47 hours and then declined with
a mean terminal half-life of 3.61 hours. Mean plasma Cmax, AUC0-10, AUC, CL/F
and Vz/F were 786 ng/mL, 2580 ng.h/mL, 3010 ng.h/mL, 5.73 L/h and 29.0 L,
respectively. The PB CD34+ cell count generally did not change significantly over
time following the placebo treatment. However, following the first plerixafor dosing
on day 4, a mean 2.1 to 2.7-fold increase of the PB CD34+ cell count from base-
line was observed from 2 to 10 hours with the maximum at 8 hours post dosing.
The incidence of adverse events was similar between the 2 treatment arms and
no unexpected adverse events were observed. 71.4% (10/14) patients in the
plerixafor plus G-CSF arm, and 5.6% (1/18) patients in the placebo plus G-CSF
arm achieved the target of ≥5x 106 CD34+ cells/kg collected.
Summary and Conclusions: The PK and PD profiles of plerixafor in Chinese
NHL patients were comparable to those of NHL patients observed in previous
studies. Plerixafor with G-CSF regimen was safe and effective in mobilizing
CD34+ cells for transplantation in these Chinese NHL patients.
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THE ROLE OF STEM CELL TRANSPLANTATION FOR PATIENTS WITH
CHRONIC MYELOID LEUKEMIA (CML) RESISTANT TO TYROSINE KINASE
INHIBITORS WITH BCR-ABL KINASE DOMAIN MUTATION T315I
E. Morozova1, J. Vlasova2,* B. Afanasyev3
1 Hematological Department, 2Daily Hospital, Hematological Department,
3Director, R.M. Gorbacheva Institute of Pediatric Oncology Hematology and
Transplantation St. Petersburg State Medical I. Pavlov University., St.Peters-
burg, Russian Federation
Background: Treatment of CML based on the use of tyrosine kinase inhibitors
(TKIs). Resistance to TKIs therapy is associated with the development of kinase
domain mutations. The threonine-to-isoleucine mutation at codon 315 of the
breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein
fusion Bcr-Abl (T315I) is insensitive to currently available TKIs. In 2012, ponatinib
(Iclusig®) was approved for treatment patients who have failed first-line therapy,
have the T315I mutation, or have progressed, and became an alternative to SCT.
Aims: Evaluate the role of Stem Cell Transplantation (SCT) in the treatment of
patients CML with T315I mutation.
Methods: 14 patients with TKI-resistant CML who had T315I mutations under-
went 16 transplantations. At the time of SCT, 5 patients were in chronic phase,
4 patients were in accelerated phase, 1 patient was in blast crisis phase; and
4 patients were in second chronic phase. All patients had received TKI and
had become resistant: 4 patients received imatinib, 6-nilotinib, 4-dasatinib. The
median time from CML diagnosis to SCT was 39 months (range, 14-119
months), and the median time from fist detection of T315I to SCT was 10
months (range, 4-72 months). In 6 cases, donors were HLA-identical siblings,
8-unrelated donors. 12 patients were male, 2-female, age was 17-55 years
(median 33.5 years).Conditioning regimen: in 4 cases was myeloablative, 12-
reduced-intensity conditioning. Source graft in 5 cases was bone marrow (BM),
9-peripheral stem cells (PBSC), 2 BM+PBSC.
Results: Survived 5 patients of 14. The best responses after SCT were a com-
plete molecular response (CMR) in 6 patients, and complete cytogenetic response
(CCyR) in 1 patient, The best outcome was for patients who underwent trans-
plantation in chronic phase, and all of those patients remained alive and in com-
plete molecular remission: 3 patients in the 1 st and 1-in the 2nd reached after
abolition of the basic immunosuppression and resumption of TKIs. In 1 patient
reported relapse after SCT and achieving CMR-progress in blast crisis phase,
currently under chemotherapy in combination with TKIs. Duration of observation
for living patients to date 1- 66 months, median 7 months. Overall survival of
patients who underwent SCT was 43.8%, with a median-up follow 7 months.
Summary and Conclusions: The current results indicated that SCT is an
effective strategy for patients with CML who have the T315I mutation, particu-
larly in earlier stages. 
E1508
GRANZYME B EXPRESSION IN T-REGULATORY CELLS ON DAY +14
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(ALLO-HSCT) IS A STRONG PREDICTOR OF ACUTE GRAFT-VERSUS-
HOST DISEASE (GVHD)
M. Drokov1,* E. Parovichnikova1, L. Kuzmina1, I. Galtseva2, Y. Muratova2,
K. Nikolay2, V. Vasilieva1, V. Savchenko1
1Bone Marrow Transplant Department, 2Flow Cytometry Department, NATION-
AL RESEARCH CENTER FOR HEMATOLOGY, Moscow, Russian Federation
Background: As we previously reported on ASH (ASH2014, №5871) : we
found out that percent of CD4+CD25highGranzymeB+ cells among CD4+cells
at day +30 after allo-HSCT in patients who never developed aGVHD was sta-
tistically higher (9,49%±2,79; p=0.003) than in patients at day of aGVHD onset
(3,8%±1,78) and who developed aGVHD in future after day +30 (3,38%±1,47).
Aims: Find an easy way to assess of aGVHD development
Methods: Peripheral blood samples were collected in EDTA-tubes at day +14
after allo-HSCT. Because of WBC mediana-0.28*109/L (0.02-0.8) we use PBMC
from 15 patients with hematological malignancies (AML=12, ALL n=1, LPD=1,
CML=1, CMML=1) after allo-HSCT (n=9 with standard immunosuppression
(MMF+CSA+ATG), and n=6 with cyclophosphamide (CY) on day+3,+4. All
patients in CY group was in advanced or high risk disease at a time before allo-
HSCT. The anti-CD4-APC-Cy7, anti-CD25-APC, anti-CD127-FITC and anti-
Granzyme B-PE (Becton Dickinson, USA) antibodies were used to determine T-
regulatory cells population as CD4+CD25high (Gregg et al., 2005) and
CD4+CD25highCD127low. We did not include anti-FoxP3 antibodies as FoxP3 is
not so specific in humans and particularly after allo-HSCT due to technical diffi-
culties, several isoforms and etc. CD4- lymphocytes (CD8+ and NK-cells certainly
containing granzyme B) were used as internal positive control. Geometric mean
fluorescence intensity (gMFI) was used to assess Granzyme B expression. 50000
of CD4+ cells were analyzed on a BD FACSCanto II (Becton Dickinson, USA).
Results: Four patients (26, 6%) (n=2 (22%) in standard IST group and n=2
(33%) in CY group) have developed aGVHD (II-IV) at a median time of +32
day (20-54) after HSCT. As we can see on chart 1: in a group with standard
immunosuppression therapy (IST) the level of Granzyme B was higher in
patients who never developed aGVHD in future (1653±273 gMFI units) in
CD4+CD25highCD127low and (1646±287) in CD4+CD25high cell population.
In a group without standard immunosuppression-only CY on day +3, +4 at dose
50 mg/kg. (Luznik et al., 2008) the results was inverse. Patients who developed
aGVHD in future have a higher level of Granzyme B expression (3716 gMFI
units in CD4+CD25highCD127low and 4673 gMFI units in CD4+CD25high pop-
ulation). This data show us that we can use low granzyme B expression in T-
regulatory cells on day +14 after allo-HSCT as aGVHD predictor only in a group
with standard IST (Figure 1).
Figure 1.
Summary and Conclusions: Despite the fact that the analyzed group is small,
we suggest that low expression of Granzyme B in Treg cells (despite assess-
ment method) after allo-HSCT in patients with standard IST may predict aGVHD
onset. This fact, of course, needs further investigation.
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THE ROLE OF TREGS AND TIM3 IN HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
C. Li1,* C. Ma1, X. Chen1, X. Yu1, H. Liu1, J. Ma1, L. Ye1, D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Tregs in DC-CIK infusion play a critical role in immunosuppressive.
Aims: (1) To detect CD4+CD25+CD127-T cells (Tregs) from DC-CIK, which
were infused to patients with high-risk or refractory hematologic malignancies
after allogeneic hematopoietic stem cell transplantation(allo-HSCT) and to dis-
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cuss the relationship between Tregs,Tim3 and aGVHD by detecting proportions
of Tregs and expression of Tim3 in patients’ peripheral blood.
Methods: (1) Detected the percentage of Tregs in DC-CIK by flow cytometry
and compared the occurrence of aGVHD with patients who developed aGVHD
but without DC-CIK infusion. (2) Sorted Tregs from DC-CIK by flow cytometry,
using MTT assay and mixed lymphocyte reaction to research the inhibition
function of Tregs from DC-CIK in vitro. (4) Detected the expression of Tim3 on
CD4+ T cells, CD8+ T cells, CD3-CD56+ cells and CD4+CD25+ T cells in
patients with or without aGVHD, respectively. 
Results: (1) 32 patients with high-risk or refractory hematologic malignancies
were treated with DC-CIK after allo-HSCT. 25 cases of DC-CIK were donor-
derived and 7 cases were receptor-derived. (2) When the percentage of Tregs
in DC-CIK was less than 5%, we defined as low proportion group, while high
proportion group was defined when the percentage was more than 10%.
5%>10% was defined as middle proportion group. 10 cases were in low propor-
tion group, 16 cases in middle proportion group and 6 cases in high proportion
group. (3) 4/32(12.5%) patients with DC-CIK treatment developed I-II aGVHD
and 3 of them were in low proportion group, 1 in middle proportion group.
10/27(37.03%) patients without DC-CIK treatment developed aGVHD. 7 of them
developed I-II aGVHD and 3 developed III-IV. The incidence and degree of
aGVHD in DC-CIK treatment group was significantly lower than none DC-CIK
treatment group (P<0.05). (4) The percentage of Tregs in patients with aGVHD
was lower than patients without aGVHD (P<0.05). (5) The Tim3 expression on
CD4+ T cells, CD8+ T cells and CD4+CD25+ T cells were higher in patients with
aGVHD than without aGVHD (P<0.05). While the expression was no significantly
difference in CD3-CD56+ cells between the two groups(P<0.05).
Summary and Conclusions: (1)DC-CIK infusion after allo-HSCT can reduce
the incidence of aGVHD and do not influence the effect of graft versus leukemia
(GVL) at the same time, thus being a promising method to improve the cure
rate of leukemia and providing a novel approach to cell biology treatment. (2)
Tregs negatively regulate immune reaction post allo-HSCT on the occurrence
and progress of aGVHD while Tim3 can promotes the occurrence and progress
of aGVHD through positively regulating immune reaction. Further research will
be needed to provide approach to reduce recurrence of aGVHD and gain more
methods on the preventation and treatment of aGVHD. 
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SUCCESSFUL STEM CELL MOBILIZATION AND AUTOLOGOUS STEM
CELL TRANSPLANTATION AFTER PRETREATMENT CONSISTING OF
BENDAMUSTINE, PREDNISONE AND BORTEZOMIB IN PATIENTS WITH
NEWLY DIAGNOSED MULTIPLE MYELOMA
W. Poenisch1,* M. Plötze1, B. Holzvogt1, M. Andrea1, T. Schliwa1, S. Heyn1,
G.N. Franke1, M. Jentzsch1, S. Leiblein1, S. Schwind1, T. Lange1, V. Vucinic1,
H.K. Al-Ali1, D. Niederwieser1
1Hematology/Oncology, University of Leipzig, Leipzig, Germany
Background: Bendamustine is a bifunctional alkylating agent with low toxicity
that produces both single- and double-strand breaks in DNA, and shows only
partial cross resistance with other alkylating drugs. Treatment of patients with
newly diagnosed multiple myeloma (MM) using bendamustine and prednisone
in comparison to melphalan and prednisone results in superior complete
response rate and prolonged time to treatment failure. So far, however, reliable
information on stem cell toxicity and mobilization of stem cells for autologous
stem cell transplantation (SCT) after induction treatment with a combination of
bendamustine, prednisone and bortezomib (BPV) is missing. 
Aims: Examining feasibility of induction therapy with Bendamustine, Prednisone
and Bortezomib (BPV) for Stem Cell Mobilization and Autologous Stem Cell Trans-
plantation in 35 Patients with newly diagnosed/untreated Multiple Myeloma.
Methods: A retrospective analysis of peripheral blood stem cell mobilization
and autologous SCT was performed in 35 patients with MM who had received
at least one cycle of a BPV induction therapy consisting of bendamustine
60mg/m2 on days 1 and 2, bortezomib 1.3mg/m² on days 1, 4, 8 and 11, and
prednisone 100mg on days 1, 2, 4, 8 and 11 between October 2008 and May
2014. The mobilization regimen consisted of cyclophosphamide 4 g/m2 and
G-CSF (2x5µg/kg). Apheresis was started as soon as peripheral CD34+ counts
exceeded 20x106/L with a harvest target of 8x106 CD34+/kg. The minimal
accepted target was 2x106 CD34+/kg. The transplantation conditioning therapy
consisted of melphalan 200mg/m2.
Results:A median number of two (range 1-5) BPV cycles were given. The majority
of patients (n=31, 89%) responded with 2 sCR, 5 nCR, 11 VGPR, and 13 PR.
Three patients had MR, and 1 SD. Stem cell mobilization and harvest was suc-
cessful in all patients. In 19 of 35 patients (54%) a single apharesis was sufficient
to reach the target. The median number of aphareses was one (range 1-4) and
the median CD34+ cell-count/kg was 13.5 (range 3.2-33.1)x106. All patients
received an autologous SCT. Engraftment was successful in 34 of 35 patients.
The median time to a leukocyte count >lx109/L was 11 days and the time to
untransfused platelet count of >50x109/L was 13 days. 34 patients (97%) respond-
ed after the autologous SCT with 11 sCR, 2 CR, 7 nCR, 7 VGPR, and 7 PR. The
progression free survival at 18 months was 87% and overall survival was 92%. 
Summary and Conclusions: Conclusion: Stem cell mobilization and autolo-
gous SCT is feasible in MM patients who have received BPV induction therapy. 
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MINIMAL RESIDUAL DISEASE MONITORING BY FLOW CYTOMETRY IN
CLL POST ALLOGENEIC STEM CELL TRANSPLANT (ALLOHSCT)
M. Sartor1,*, D. Gottlieb1
1Haematology, Weatmead Hospital, Sydney, Australia
Background: Recent studies have demonstrated improved outcomes in
patients with CLL who achieve MRD negativity within 12 months of alloHSCT.
Aims: We aimed to quantitate residual CLL after alloHSCT for the purposes of
directing post-transplant chemo-immunotherapy to optimise outcomes.
Methods: We recently published a method for a single tube 10 colour flow
cytometry assay to detect MRD in CLL and have used it for the quantitation of
MRD post alloHSCT in a cohort of 11 patients transplanted for CLL between
2011 and 2014 at our institution.
Results: Sixty-eight MRD assessments were performed (median 5 per patient,
range 1-13), the majority on PB (80%). Three patients died within the first 12
months post-transplant due to transplant related complications. Six patients
attained MRD negative status very early post-transplant (range 1-6 months) and
remain MRD negative and in remission at a median follow-up of 24 months (range
6-48 months). Two patients with persistent MRD at all times up to 12 months
post-transplant were treated pre-emptively in response to rising MRD by tapering
immunosuppression and administering escalating doses of DLIs, both without
and on the final occasion with a preceding cycle of lympho-depleting chemother-
apy. One patient has achieved MRD levels below 0.01% in PB within 22 months
post alloHSCT. The other patient (17p- disease) has responded to treatment and
has had stable residual disease up to 19 months post alloHSCT and now has
progressive disease and has started treatment with ibrutinib.
Summary and Conclusions: Monitoring MRD at regular intervals gives a
dynamic assessment of disease trends that is more meaningful than a single
MRD assessment at 12 months post-transplant and may be a better indicator
of disease trajectory. The application of MRD monitoring to guide pre-emptive
immune interventions or targeted therapies shows promise in preventing clinical
relapse post alloHSCT and warrants further investigation.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY
IMMUNE DEFICIENY DISEASES: A SINGLE CENTER EXPERIENCE
T. Patiroglu1,* M. Karakukcu1, H.H. Akar2, E. Unal1, M.A. Ozdemir1
1Pediatric Hematology, 2Pediatric Immunology, Erciyes University Medical Fac-
ulty, Kayseri, Turkey
Background: Primary immunodeficiency diseases (PID) are rare heteroge-
neous genetic disorders that can result in serious complications such as life-
threatening infections. Hematopoietic stem cell transplantation (HSCT) is the
only curative treatment for many of PID.
Aims: The aim of this study is to present the outcome of HSCT for PID in a
single center experience in Kayseri in Turkey.
Methods: Herein, we present a retrospective analysis of 20 patients who under-
went HSCT for PID from 2010 to 2015. The outcomes of PID patients were
analyzed retrospectively.
Results: In a 5-year period, 20 patients (Female=10, Male=10) with PID who
underwent HSCT were screened retrospectively. In the presented study, the
patients were included with combined immunodeficiency (CID) (n=6), chronic
granulomatous disease (n=2), hemophagocytic lymphohistiocytosis (n=4),
Griscelli syndrome type 2 (n=2), B-cell immunodeficiency plus bone marrow
failure (n=2), severe congenital neutropenia (n=1),x-linked lymphoproliferative
disease (n=1), T-cell deficiency plus relapsed Non-Hodgkin Lymphoma (n=1),
and leukocyte adhesion deficiency type 1 (n=1). Eleven patients, six patients,
two patients, and one patient received related HLA matched HSCT, haplo
HSCT, unrelated matched HSCT, and miss matched HSCT, respectively. The
median age of the diagnosis of PIDs was 10.5 months (3-33 months). The
median age of HSCT was 21 months (6-80 months). The median follow-up
was 3.5 months (range, 2-17 months). Eleven, six, and one patients received
matched, haploidentical, and mismatched HSCT have survival rates 73% and
50%, and 100% with overall survival of 65%, respectively. In the CID patients,
Immunoglobulin dependency has been observed only one patient with Artemis
gene defect. The mean neutrophil engraftment was 14.25±3.08 days. The
mean platelet engraftment was 24.7±11.4 days. The ratio of GVHD was 25%.
Summary and Conclusions: These results showed that haploidentical HSCT
as well as HLA-matched related HSCT may provide good results for PID again.
It may be concluded that HSCT can be performed with an encouraging outcome
in developing countries such as Turkey in patients with PID.
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DECITABINE BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN THE TREATMENT OF MDS RETROSPECTIVE
EFFICACY ANALYSIS
H. Zheng1, J. Wang1, J. Zhou1, P. Wang1, C. Fu1,* D. Wu1, A. Sun1, H. Qiu1,
Z. Jin1, Y. Han1, X. Tang1, X. Ma1
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1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: A retrospective analysis of decitabine bridge therapy followed
by allo-HSCT in 25 patients with MDS from July 2010 to December 2013, the
First Affiliated Hospital of Soochow University, Department of Hematology. 
Aims: To evaluate the efficacy of DAC (decitabine) bridge therapy followed by
allo-HSCT (allogeneic hematopoietic stem cell transplantation) in patients with
MDS.
Methods: We compared the 25 patients with the same period 33 patients who
receive other treatments followed by allo-HSCT,comparing patients’ mCR rate,
OS and GVHD after DAC bridge therapy. 
Results: With decitabine bridge therapy,64% patients achieved marrow com-
plete remission,and the control group was 15.1% (64% vs 15.1%) (P<0.05).
Decitabine bridging group of early transplant-related mortality than the con-
trol group (4% vs 18.2%), but the difference was not statistically significant
(P=0.106). To follow-up deadline, decitabine group mortality was 12%, the
control group was 30.3% (P<0.05). Decitabine group of 2-year OS was 83%,
the control group was 59% (P<0.05). Patients with IPSS intermediate-1
receiving decitabine bridging the OS rate was higher, and transplant-related
mortality rate less than the control group, the differences were statistically
significant. GVHD occurred decitabine bridging group was 56% and the con-
trol group aGVHD incidence of 48.5% (P=0.713). aGVHD extent decitabine
group is less than the control group (P<0.05). The incidence of occurrence
of cGVHD was 41.7% in the control group, the control group was 31.6%. 
Summary and Conclusions: decitabine bridging therapy followed by allo-
HSCT in the treatment of myelodysplastic syndrome is safe and effective.
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THE OUTCOMES OF HAPLOIDENTICAL HEMATOPOETIC STEM CELL
TRANSPLANTATION PERFORMED WITH UNMANIPULATED DONOR
STEM CELLS AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HIGH
RISK CHILDREN
M. Yesilipek1,* V. Uygun2, G. Karasu1, S. Cakı Kılıc3, H. Daloglu4, Ö. Özbörü3
1Pediatric Hematology, Bahcesehir University School of Medicine, Istanbul,
2Pediatric Hematology, Bahcesehir University School of Medicine, Antalya,
3Pediatric Hematology, Medicalpark Goztepe Hospital, Istanbul, 4Pediatric
Hematology, Medicalpark Antalya Hospital, Antalya, Turkey
Background: The patients who have a rare frequency of HLA group with a low
chance for a matched donor or need urgent HSCT, haploidentical transplanta-
tion from the relative donors promises as a good alternative. In recent years,
some of haploidentical transplantations are performed with unmanipulated bone
marrow or peripheral blood stem cells which the GVHD prophylaxis includes a
more intense chemotherapy approach. This approach is now more popular by
post-transplant high dose cyclophosphamide (PTCY). However, there is limited
experience in children.
Aims: In this study, we present the children who transplanted haploidentically
in our center, with unmanipulated bone marrow or peripheral blood stem cells
and GVHD prophylaxis with post-transplant high dose cyclophosphamide.
Methods: We assessed 16 HSCT in 15 patients retrospectively, who under-
went haploidentical related HSCT with unmanipulated bone marrow or periph-
eral blood stem cells and used post-transplant high dose cyclophosphamide
for GVHD prophylaxis. Five of patients were male and 10 were female
between 3.5-17 years old, median 9 years old. One patient was AML devel-
oped after Ewing Sarcoma and one was ALL progressed from CML. Another
patient was transplanted for aplasia developed after a haploidentical trans-
plantation from his mother which had performed with CD34 positive selection.
One patient underwent second haploidentical transplantation because of
relaps. Four patients were in the first complete remission, five were in the
second and three were in the third in the transplantation date. Donors were
their mother in ten transplantation, the father in five, and a sibling in one
patient. For the conditioning regimen BU+FLU+Etoposid was used for seven
patients and two patients with BU+FLU+ATG/, BU+CY+Mel,/BU+FLU+ATG
and FLU+CY+Mel, and one patient with BCNU+Etoposid+ARA-C+Mel. Fifty
mg/kg CY on the 3rd and 5th day and CsA or tacrolimus with MMF or MP
were also used for GVHD profilaxis. The source of stem cells was bone mar-
row in six transplantation while bone marrow and peripheral blood stem cell
were used in ten transplantation. The median count of TNC, MNC, CD34+
and CD3+ was 12,9x108 (4,1-39), 8,8x108 (4,8-14,3), 5,9x106 (2,5-16) and
2,9x108 (1,1-7,8), respectively.
Results: All patients engrafted with a median of 16 days (16-23) and 18 days
(11-37) for neutrophil and thrombocyte recovery, respectively. Grade 1 acute
GVHD developed in one patients, and grade 2 in 4 and 3 in 3 patients, while
limited chronic GVHD developed in two patients. Three patients had hemor-
rhagic cystitis and four developed VOD. Two patients were lost in the first 100
days because of sepsis (TRM 12, 5%). After 100 days, a patient died of pro-
gression of the primary disease and one patient was lost because of pneumo-
nia. One patient with diagnosis of Hurler showed graft rejection. The rest ten
patients (66.6%) are disease-free (OS is 73.3%) and on the follow up of median
10 months (between 4-20 months).
Summary and Conclusions: The advantages of using unmanipulated
hematopoetic stem cells are low laboratory costs, no worry for waiting for a
suitable donor, and less risk for graft failure or T cell deficiency. Our results are
consistent with these circumstances in our high risk patients and encouraging
for haploidentical HSCTs. However our results should be accepted as a pre-
liminary report with these few patients. We think that, it should be studied for
more patients and also for comparing with other haploidentical HSCT modalities
with longer follow up.
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THE EBMT RISK SCORE CAN PREDICT THE OUTCOME AFTER ALLO-
GENEIC HEMATOPOIETC CELL TRANSPLANTATION FOR ACUTE
MYELOID LEUKEMIA AMONG EGYPTIAN PATIENTS 
S. Desoukey1,* O. Fahmy1,2, H. Kamel3,4, A. Galal5, H. Messner5
1Internal Medicine, Hematology, Kasr Al-Ainy school of Medicine, Cairo Uni-
versity, 2Nasser Institute Hospital, 3Hematology and Oncology, National Cancer
Institute, 4Stem Cell Transplantation, Nasser Institute Hospital, Cairo, Egypt,
5Hematology and Oncology, Princess Margaret Hospital, Toronto, Canada
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a
potentially curative therapy for many patients diagnosed with acute myeloid
leukemia (AML). However, the success of this procedure has been limited by
high transplant-related mortality. Moreover, it is a high-cost procedure and can
present a financial challenge for patients and health care systems in developing
countries. Risk stratification and outcome prediction among AML patients receiv-
ing transplantation are required to guide decision making. The European Group
for Blood and Marrow Transplantation (EBMT) risk score, previously devised
for chronic myeloid leukemia, has been validated as a simple tool to predict the
outcome of allogeneic HSCT for other acquired hematological disorders includ-
ing AML.
Aims: The aim of this study was to evaluate the predictive validity of the EBMT
risk score to the outcome of allogeneic HSCT in a cohort of Egyptian patients
diagnosed with AML. 
Methods: This is a retrospective single-center observational study. It was con-
ducted using data of 291 consecutive patients diagnosed with AML and under-
went first allogeneic HSCT between January 1997 and December 2008 at
Nasser Institute Hospital. Patients diagnosed with AML-M3 were excluded.
Median age of all patients at time of transplantation was 21 years (range, 1 to
57 years); with 114 patients (39%) aged 18 years or younger and 113 patients
(39%) were female. HCT was performed in first complete remission for 209
patients (72%) and in second remission or beyond for 82 patients (28%).The
majority of patients (89.6%) received myeloablative condition regimen. All
donors were HLA-identical siblings. Peripheral blood stem cells were used as
graft source in 96.2% of patients. Median follow-up duration among survivors
was 12 months (range, 0-107 months). We calculated the EBMT risk score for
all the patients and the overall survival (OS) and transplant-related mortality
(TRM) were analyzed. Required parameters for the calculation of the score
were extracted from patients’ database and files.
Results: In univariate analysis the EBMT risk score was a significant variable
predictive of OS. Survival decreased with increasing EBMT risk score. The pro-
jected 2- year OS rates were 71%, 50%, 37%, 25%, and 0% for scores 0, 1, 2,
3 and 4/5, respectively (p<0.0001). The EBMT risk score also was highly pre-
dictive of TRM. The 2-year cumulative incidence of TRM rates were 23%, 48%,
54%, 65% and 100% for scores 0, 1, 2, 3, and 4/5, respectively, (P<0.0001). In
multivariate analysis the EBMT was confirmed as prognostic factor for both OS
(p=0.03, HR=0.5, 95%CI=0.27-0.92) and TRM (p=0.0007, HR=0.39,
95%CI=0.23-0.67) (Figure 1).
Figure 1. Probability of survival for patients who underwent allogeneic
HSCT for AML at Nasser Institute, by the EBMT risk score.
Summary and Conclusions: The EBMT riak score is shown to be predictive
of the outcome after allogeneic HSCT among Egyptian patients with AML
and can be incorporated into risk-adapted decision-making before trans-
plantation.
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FACTORS AFFECTING SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA
WHO RECEIVED DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF
FIRST RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
F. Kurnaz1,* L. Kaynar2, B. Eser3, F. Altuntas4, S. Sivgin3, C. Pala5, C. Sahin6,
A. Unal3, M. Cetin2
1Hematology, Harran University, Sanliurfa, 2Hematology, 3Erciyes University,
Kayseri, 4Ankara Yurtaslan Oncology Hospital, 5Hematology, Ankara Diskapi
Hospital, Ankara, 6Internal Medicine, Mugla University, Mugla, Turkey
Background: Leukemia relapse after allogeneic stem cell transplantation (SCT)
remains an important problem. Beside the best treatment option in patients with
relapsed acute leukemia is not certain; cytoreductive chemotherapy followed by
donor leukocyte infusion (DLI) is one of the treatment modality in relapse patients. 
Aims: In this study we evaluated the factors affecting on overall survival (OS)
in allogeneic SCT patients who received DLI after first relapse.
Methods: Acute leukemia patients who were in their first relapse after allo-
SCT were evaluated retrospectively. The data of 54 patients [26 acute myeloid
lekemia (AML) and 28 acute lymphoblastic leukemia (ALL)] between March
2004 and March 2013 was collected from patients’ files and also confirmed
with the data by computed file system. In this retrospective study 54 relapsed
patients in their first relapse after allo-SCT who received fludarabine based
chemotherapy followed by DLI were evaluated.
Results: The probability of OS after diagnosis for AML at 1, 3, 6, 12 and 24
months were 96%, 92%, 76%, 56% and 27%, respectively and for ALL were
100%, 92%, 81%, 62% and 25%, respectively. The median OS was 17 (1-66)
months for AML and 10 (3-39) months for ALL; there was not a statistically sig-
nificant difference between these patients (p>0,05) at the end of follow up. A total
of 10 patients developed acute GVHD after DLI (18.5%). GVHD was seen more
frequently in the patients who received more than one DLIs than the patients
who received only one DLI (p=0.7), there was not a significant increase at prob-
ability of OS in patients who had acute GVHD after DLIs (p>0.05). Increased
number of DLIs (p=0,001), and increased time period from transplantation to DLI
(p=0,005) were predictive for survival in cox multiple regression analysis. 
Summary and Conclusions: The chemotherapy regimens especially including
lymphocyte depleting agents, such as fludarabin, before DLI may be effective
in the treatment of patients with relapsed acute leukemia after allo-SCT. This
study showed that increased number of DLI improves the OS, and efforts to
enhance the number DLIs should be considered in leukemia patients that
relapsed after allo-SCT.
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CD4+ CELL COUNT ON DAY+30 PREDICT OVERALL SURVIVAL AND
TRANSPLANT RELATED MORTALITY IN ACUTE LEUKAEMIA PATIENTS
AFTER ALLOPBSCT
D. Pastore1,* M. Delia1, A. Mestice1, P. Carluccio1, A. Ricco1, A.V. Russo Rossi1,
C. Pasciolla1, P. Pinto1, S. D’Agostino1, C. Brunetti1, G. Specchia1
1Hematology with Transplantation, Policlinico, Bari, Italy
Background: Allogeneic peripheral stem cell transplantation (alloPBSCT) from
a related or unrelated donor is a well established strategy for patients with
acute leukaemia. However, this procedure is associated with increased mor-
bidity and mortality because of graft versus host disease (GvHD), immune
reconstitution impairment and a high risk of infections.
Aims: In our study we evaluated the lymphocyte subset recovery after alloPB-
SCT and its impact on transplant related mortality (TRM) and overall survival
(OS) in acute leukaemia patients.
Methods: We evaluated the immune reconstitution of CD3+/CD4+, CD3+/CD8+
and NK cells performed at 30, 100, 180 and 360 days after alloPBSCT in 122
patients with acute leukaemia. Patients were transplanted with unmanipulated
PBSC from an HLA matched related donor (MRD) (n=85) or an HLA (8/8) matched
unrelated donor(MUD) (n=37). Median age was 38 years (range 18-61); diagnoses
were acute myeloid leukaemia (n=96) and acute lymphoblastic leukaemia(n=26);
80% of patients underwent myeloablative conditioning (busulphan, cyclophos-
phamide in MRD and busulphan, cyclophosphamide and ATG in MUD) and 20%
underwent reduced intensityconditioning (busulphan, fludarabine, ATG).
Results: The median counts of CD3+/CD4+ were 98, 160, 200, 262 μl at 30,
100,180 and 360 days, respectively. The median counts of CD3+/CD8+ were
180, 350, 500 and 670 μl at 30, 100, 180 and 360 days, respectively. The medi-
an counts of NK cells were 110, 260, 270 and 260 μLat 30, 100, 180 and 360
days, respectively. Considering the entire patient population the median cell
count rose above 200 μl after day 180 for CD3+/CD4+ and after day 45 for
CD8+cells; the median NK cells count rose above 100 μl after day 30. The
median CD3+/CD4+ cell count on day +30 for the entire patient population
was 98 μl (range 20-190) and TRM at 2 years was significantly higher in
patients not achieving this CD4 cell count (38% vs 15%, p<0.001); patients
with a low CD3+/CD4+ count (<98 μl) on day +30 had a higher risk of dying of
infections (30% vs 11%, p>0.003). Median OS in patients not achieving CD4+
of 98 μl at 30 days was 40 months while median OS in patients with more than
98 CD4+ at 30 days was not reached. Univariate analysis at 100 days showed
a significant association between CD4 cell recovery and transplant from a relat-
ed donor (p=0.003), myeloablative conditioning (p=0.04) and absence of
aGvHD (grade II-IV)(p=0.002). In multivariate analysis, transplant from a related
donor (p=0.05) and absence of aGvHD(grade II-IV) (p=0.002) were significantly
associated with a better CD4 cell recovery. CD3+/CD8+ and NK cells recovery
did not correlate with a different TRM risk or OS.
Summary and Conclusions: Our results support the relationship between
immune reconstitution of CD4+, OS and TRM. The CD4+ cell count on day
+30 is able to predict OS and TRM after myeloablative alloPBSCT in acute
leukaemia patients. 
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HBV CLEARANCE IN HBSAG+ PATIENTS AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION IS HERALDED BY GVHD OF LIVER
T.-D. Tan1,* M.-C. Wu1, L.-W. Chiou1, A.-C. Feng2
1Hematology and Medical Oncology, 2Clinical Research and Statistics, Koo
Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan, ROC
Background: Alloimmune reaction has been reported to be effective in clearing
chronic hepatitis B (HBV) infection. However, the successful rates of HBV sur-
face antigen (HBsAg) clearance after allogeneic hematopoietic stem cell trans-
plantation are not clear.
Aims: We surveyed the seroconversion rate and chronologic change of HBsAg
titers retrospectively from the hematologic malignancy patients with HBsAg+
underwent allogeneic stem cell transplantation at our transplant unit.
Methods: Between 2001 ad 2013, we have twelve patients of HBsAg+ out of
210 patients undergoing allogeneic stem cell transplantation. All of them were
under anti-HBV prophylaxis with either lamivudine or entecavir and included
myeloablative or reduced intensity conditioning regimens for AML, ALL, NHL,
HL, and multiple myeloma patients.
Results: In these twelve HBsAg+ patients, 3 from HBsAg+ donors and one of
them got seroconversion with HBsAg cleared. The other 9 patients received
stem cells from HBsAg- and anti-HBsAb+ donors with 5 of them got successful
clearance of HBsAg and HBV DNA undetectable (55.5%) with the earliest sero-
conversion seen on sixth month after transplantation. Three of them got malig-
nant disease recurrence in the first year. None of our patients got symptomatic
flare of hepatitis B or even fulminant hepatitis. In four patients, we can see the
clearance of HBsAg is heralded by graft versus host disease with low or unde-
tected HBV DNA (Figure 1).
Figure 1. Disposition of HBsAg+ patients underwent allogeneic stem cell
transplant in cohort 1.
Summary and Conclusions: HBsAg+ hematologic malignancy patients can
attain high successful rate of seroconversion when underwent allogeneic stem
cell transplantation from HBsAg-/anti-HBsAb+ donors via graft versus host
effect. The risk of fulminant hepatitis flare is minimal in these patients whom
anti-HBV prophylaxis performed.
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OUTCOMES OF CORD BLOOD TRANSPLANTATION WITH NON-TOTAL
BODY IRRADIATION CONDITIONING REGIMEN CONSISTING OF FLU-
DARABINE AND BUSULFAN FOR PATIENTS WITH ADVANCED HEMA-
TOLOGYIC MALIGNANCIES
K. Tsuda1,* S. Sakaue1, Y. Takahashi1, T. Isshiki1, N. Takei1, K. Kobayashi1,
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Background: Cord blood transplantation (CBT) has increasingly become an
alternative therapy in patients who lack suitable related or unrelated donors
with advanced hematologic malignancies. Non-total body irradiation (TBI) con-
ditioning regimen has a high degree of usability for medical institutions where
TBI cannot be performed promptly. However, in contrast to bone marrow or
peripheral blood stem cell transplantation, the optimal non-TBI conditioning
regimen is not established in CBT yet. 
Aims: We investigated the outcomes of CBT with non-TBI conditioning regimen
consisting of fludarabine and busulfan in patients with advanced hematologic
malignancies.
Methods: Patients who underwent their first CBT using single unit umbilical
cord blood between April 2004 and December 2014 in Teikyo University Chiba
Medical Center and Tsukuba Memorial Hospital were included for the present
study. They were treated with non-TBI conditioning regimen consisting of flu-
darabine 30 mg/m2 for 6 days and busulfan 0.8 mg/kgx 4 for 2 or 4 days. Graft-
versus-host disease (GVHD) prophylaxis was provided by tacrolimus only.
Results: A total of 53 patients received CBT. The median age was 62 years old
(range, 26-74 years). Acute myeloid leukemia was the predominant diagnosis
(53%, n=28), followed by Non-Hodgkin lymphoma (n=8). The remaining diagnosis
included multiple myeloma (n=7), myelodysplastic syndrome (n=6), primary
myelofibrosis (n=2) and chronic myeloid leukemia (n=2). Only 16 patients (30%)
were in remission at transplantation. Median numbers of infused total nucleated
and CD34-positive cells were 2.9x 107 /kg (range, 1.9-5.5) and 0.58x 105 /kg
(range, 0.2-2.1), respectively. The cumulative incidence of neutrophil engraftment
was 62% (95% confidence interval [CI], 48%-74%), with a median time to recovery
of 23 days (range, 14-47 days). The cumulative incidence of grade II-IV and
grade III/IV acute GVHD was 22.9% (95% C.I., 12.5-35.0%) and 5.7% (95% C.I.,
1.5%-14.3%), respectively. Twelve patients developed chronic GVHD and the
cumulative incidence of chronic GVHD was 20.8% (95% C.I., 10.8-32.9%). At
one year, the cumulative incidence of treatment related mortality was 42%. The
leading cause of non-relapse mortality was infection (n=9) followed by graft failure
(n=3), acute GVHD (n=3), chronic GVHD (n=2) and hemorrhage (n=2). At one
year, overall survival was 25.0% (95% C.I., 13.9-37.6%). Univariate and multi-
variate analysis revealed that poorer overall survival was significantly associated
with age ≥70 (p<0.01). Overall survival at 1 year among patients younger than
70 years old was 28% (95% C.I., 15.8-42.0%) (Figure 1 and Figure 2).
Figure 1. The cumulative incidence of neutrophil engraftment.
Figure 2. Kaplan-Meier estimates of overall survival.
Summary and Conclusions: Our results suggest that conditioning regimen
with fludarabine and busulfan in CBT is a feasible option for patients younger
than 70 years in medical institutions where TBI cannot be performed.
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A PORTABLE MICROSCOPIC CELL COUNTER (ADAM II) FOR ENUMER-
ATING CD34+ CELLS
J.H. Oh1,* Y. Jung1, M.S. Kim1, S.R. Bong1, S.H. Hong1, J.Y. Kim1, H.J. Park1,
J.K. Hwang1, C. Chung1, C.S. Lim2, H. Koh3, Y.-H. Lee4
1NanoEntek, 2Department of Laboratory Medicine, Korea University Medical
Center, 3Department of Translational Medicine, Hanyang University Graduate
School of Biomedical Engineering, 4Department of Pediatrics, Hanyang Uni-
versity Medical Center, Seoul, Korea, Republic of
Background: Accurate determination of CD34+ cell numbers is of considerable
clinical importance and essential in the field of stem cell transplantation. Several
flow cytometry assays for enumerating CD34+ cell have been proposed, but
differences in gating methods between users lead to variability in the results.
Also flow cytometry assays require expensive instrumentation, have high
reagent costs, and, in most cases, are technically difficult. Therefore, a new
instrument that produces CD34+ cell counts more simply and reproducibly is
required.
Aims: We previously developed a new CD34+ cell counting device (Adam II)
that uses a microchip and microscopic cell counter. Our aim here was to eval-
uate the Adam II as a CD34+ cell counter by comparing it with a conventional
flow cytometer.
Methods: We used peripheral blood stem cell (PBSC) samples from 17
patients with hematological malignancies and 11 cryopreserved umbilical cord
blood (UCB) samples. Each individual donor provided written informed con-
sent prior to us obtaining the samples, and the study was approved by the
Institutional Review Board of Hanyang University Hospital. To assess the pre-
cision and linearity of the Adam II, CD34+ cell counts obtained with it were
compared with those from flow cytometry. For measurements, samples were
introduced into the Adam II CD34 tube containing lyophilized fluorescence
mixtures. The reacted samples were then loaded into the chips and read. For
flow cytometry, we used a Stem Cell Enumeration kit (BD Biosciences,
Franklin Lakes, NJ) to stain the samples, and the relative proportions of
CD34+ cells were obtained with a FACS Calibur (BD Biosciences). To assess
linearity, samples were serially diluted with mononuclear cells separated from
the peripheral blood of a healthy adult, and to assess reproducibility, some
samples were counted 10 times, and coefficients of variations (CVs) were
calculated.
Results: Linear regression analysis revealed a close correlation between the
data for CD34+ cell fractions (%) obtained with the Adam II and those obtained
with the FACS Calibur for both PBSCs (r2=0.98) and UCBs (r2=0.93). The two
methods also gave very similar results for the viability of the PBSCs (r2=0.94).
A dilution test of the Adam II method gave a linearity coefficient of r2=0.99, and
the method proved to be reliable in the samples serially diluted over the expect-
ed range: thus, four PBSC dilutions at CD34+ cell concentrations of 0.44, 0.18,
0.08 and 0.03% had CVs of 7.86, 13.66, 20.83 and 38.46%, respectively.
Summary and Conclusions: We have established a close correlation between
CD34+ cell counts and viability assays with the FACS Calibur and the Adam II.
This suggests that the Adam II CD34+ cell counting device could be useful for
stem cell assays given its advantages of reproducibility, accuracy, convenience,
and low expensive.
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LONG-TERM OUTCOMES FOLLOWING REDUCED-INTENSITY STEM
CELL TRANSPLANTATION: THE CRITICAL IMPORTANCE OF THE DEVEL-
OPMENT OF GRAFT-VERSUS-HOST DISEASE 
E. Nevill1,*R. Broady1, D. Hogge1, D. Forrest1, M. Barnett1, S. Nantel1, C. Toze1,
A. Gerrie1, K. Song1, S. Narayanan1, H. Sutherland1, J. Lavoie1, C. Dalley1,
M. Power1, E. Conneally1, Y. Abou Mourad1, T. Nevill1
1Leukemia/BMT Program of BC, Vancouver, Canada
Background: Allogeneic stem cell transplantation (AlloSCT) is the most effec-
tive treatment for a wide variety of hematologic diseases. The development of
reduced-intensity conditioning transplantation (RICT) has allowed alloSCT to
be used in patients (pts) of advanced age or with comorbidities. 
Aims: The study objective was to determine the incidence of acute/chronic
graft-versus-host disease (GVHD), treatment-related-mortality (TRM) and
relapse rate and to calculate Kaplan-Meier estimates of overall survival (KM
OAS) following RICT.
Methods: An IRB-approved retrospective chart and data base review was per-
formed on all pts that underwent RICT at Vancouver General Hospital between
05/01 and 12/13. Final analysis date was August 1, 2014.
Results: During the study period, 220 pts underwent RICT with all patients
signing IRB-approved consent forms; there were 150 males and 70 females
with median age of 58 years (range 18-68). Diagnoses were CLL (73 pts),
lymphoma (42 pts), AML (40 pts), myeloma (25 pts), MDS (10 pts), myelofi-
brosis (8 pts), CML (4 pts) or other (18 pts). A total of 232 RICT were per-
formed-209 pts had one, 11 pts had two [10 for graft failure (GF)] and 1 pt
had 3 (for GFx 2) RICT. Conditioning was Fludarabine (Flu)/Busulfan (Bu)
(71 pts), Flu/Cyclophosphamide (Cy) (64 pts), Flu/Bu/Campath (42 pts),
Flu/Bu/ATG (37 pts) or other (18 pts); GVHD prophylaxis was Cyclosporine
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and either Methotrexate (228 pts) or Mycophenolate (4 pts). Donor source
was matched related (MRD, 140 pts) or unrelated (MUD, 59 pts) and mis-
matched related (7 pts) or unrelated (MMUD, 26 pts). Following RICT, 59%,
53% and 42% of patients did not require red cell, platelet or any transfusion
support, respectively. Neutrophils >0.5 occurred a median of 18 days (range
0-138) post-RICT (19 pts never went <0.5). Acute GVHD occurred in 32% of
MRD, 38% of MUD and 58% of MMUD pts and chronic GVHD occurred in
72%, 55% and 54% of these cohorts, respectively. GF was identified 13 times
in 11 pts; 6 of these pts are alive and well. KM OAS after FluCy MRD RICT
is 41% at 10 years, 51% at 5 years after BuFlu MRD RICT and 53% at 5
years after MUD/MMUD RICT. There are 86 pts alive in continuous complete
remission (CCR), 85 pts relapsed (13 of whom are still alive in remission)
and 48 pts (21%) died of treatment-related complications (TRM). MUD/MMUD
pts receiving Campath had a lower incidence of acute (32%) and chronic
(44%) GVHD compared to those receiving ATG (62% and 76%, respectively)
but a higher incidence of relapse (50% versus 22%, respectively) and a lower
5-year OAS (48% versus 68%, p=0.14). In the entire cohort, 11% developed
acute GVHD only, 39% chronic GVHD only, 26% both and 24% neither. Out-
come was most favourable, and similar, for the “chronic only” and “both”
groups (combined N=151) with 78 pts (52%) in CCR; relapse and TRM
occurred in 45 (30%) and 27 (18%) pts, respectively (1 pt had GF). In the
“acute only” group, 7 pts (27%) remain in CCR, 12 pts relapsed (46%) and 6
pts (23%) experienced TRM (1 pt had GF). In the “neither” group, 30 pts
(55%) relapsed, 13 pts (24%) died of TRM, 11 pts (20%) had GF and 1 pt
(2%) remains in CCR. 
Summary and Conclusions: RICT results in long-term survival for many pts
with hematologic malignancies with similar outcomes seen with MRD and
MUD/MMUD. In the latter group, in vivo T-cell depetion with ATG is associated
with better outcomes than with Campath due to a lower risk of relapse with
ATG. Despite the morbidity associated with GVHD, its development (particularly
the chronic form) is critical to a successful outcome with RICT.
E1522
AUTOLOGOUS STEM CELL TRANSPLANT IN AL AMYLOIDOSIS: AN
EFFECTIVE TREATMENT FOR SELECTED PATIENTS
M. D’Adda1,* F. Schieppati1, S. Ferrari1, A. Belotti1, C. Pagani1, E. Cerqui1,
C. Bottelli1, D. Dalceggio1, G. Rossi1
1hematology, spedali civili, brescia, Italy
Background: High-dose melphalan (HDM) followed by autologous stem cell
transplant (ASCT) has been routinely used as a treatment option for systemic
light chain AL amyloidosis since the first report in mid-1990s. The high treat-
ment-related mortality (death before post-transplant day 100) reported in lit-
erature (11-40% in different papers) has decreased over the last years with
the improvement in patient selection. Particularly, in the largest Mayo Clinic
series of 422 subjects, patients with cardiac troponin-T <0.06 ng/L and NT-
proBNP <5000 ng/L had TRM <1%; besides, patients achieving hematologic
complete response/very good partial remission (CR/VGPR) had superior
overall survival than those achieving hematologic partial response (PR) and
no response.
Aims: To evaluate the outcome of the autologous stem cell transplant in
patients with AL Amyloidosis
Methods: Twenty-one ASCT were performed between 2001 and 2014 in 16
patients with AL amyloidosis (10 male and 6 female), in our center. The median
age at the time of ASCT was 58 years (range 38-68). Ten patients had 2 or
more involved organs. All 16 patients had: normal troponin-I value, NT-proBNP
<5000 ng/L, PS 0-1, cardiac ejection fraction over 50%, CO diffusion capacity
over 50%; three had creatinine clearance <50 ml/min. Five patients collected
stem cells after cyclophosphamide (1,5-4 g/m^2), the others after G-CSF alone.
Seven patients proceeded directly to ASCT without “induction therapy”. Five
patients received CyBorD (5/5 obtained hematologic PR, 3/5 organ response)
and 4 patients other induction regimen (without any response). Eleven patients
were treated with ASCT as 1st line therapy, 5 in 2nd or 3rd line. Patients received
melphalan 200 mg/m^2 (12 ASCT) or dose adjusted HDM (100-140 mg/m^2,
9 ASCT), depending on clinical decision. Five patients received double ASCT.
Results: Median follow up is 39 months (range 3-168); only 1 patient died (+48
months), for progression. All the others were alive at the last visit. Overall hema-
tologic and organ response rate after ASCT were 81% and 56%, without signif-
icant differences between patients treated with “induction therapy” before HDM
and patients that proceeded directly to ASCT. Two of 5 patients with double ASCT
improved response after second course (after 82 and 144 months follow up they
maintain a hematologic CR without organ involvement). Median hospitalization
for ASCT was 24 days (range 17-45), without any threatening-life side effect.
Eight of 16 patients needed new therapy for progressive disease after a median
follow up of 22 months (range 6-52): 5 of them had achieved hematologic PR
after ASCT, 1 patient achieved hematologic VGPR but no organ response and 2
had no hematologic response. Eight patients are in follow up without other therapy
after ASCT: 1 had optained no response, 2 hematologic PR, 1 VGPR and 4 CR.
These 4 patients in persistent hematologic CR performed ASCT as 1st line ther-
apy and 3 of them have long follow up (+82, +144, +168 months).
Summary and Conclusions: HDM followed by ASCT is an effective treat-
ment option in AL-amyloidosis, which may be effective even in patients non
responding to previous treatment with non myeloablative drugs. According
to the data of the literature, our experience suggests that a careful selection
of patients is critical for good outcomes and that particular cardiac biomarkers
(cardiac troponin-T <0.06 ng/L and NT-proBNP <5000 ng/L) are useful to
guide the choice of therapy. Also in our patients, hematologic CR after HDM
seems to be an important factor for long survival without other therapy. There-
fore, consolidation therapy (IMiDs and proteasome inhibitors) should be con-
sidered for patients who do not obtain at least a VGPR/CR after HDM. Finally,
in our experience the best results are in patients treated with ASCT as 1st
line therapy.
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TROUGH LEVEL MONITORING OF INTRAVENOUS BUSULFAN TO ESTI-
MATE THE AREA UNDER THE PLASMA DRUG CONCENTRATION-TIME
CURVE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT
RECIPIENTS
T. Nishikawa1,* E. Watanabe2, K. Ikawa3, Y. Kodama1, T. Tanabe1, Y. Shinkoda1,
Y. Okamoto1, Y. Kawano1
1Pediatrics, 2Clinical Pharmacy and Pharmacology, Graduate School of Med-
ical and Dental Sciences, Kagoshima University, Kagoshima, 3Clinical Phar-
macotherapy, Hiroshima University, Hiroshima, Japan
Background: Busulfan is an alkylating agent that plays an important role in
myeloablative preconditioning regimens in the setting of hematopoietic stem
cell transplantation (HSCT). A relationship between the busulfan dose intensity,
expressed as the area under the plasma busulfan concentration versus time
curve (AUC), and certain HSCT outcomes has been described. Although intra-
venous busulfan is considered to have a much more predictable pharmacoki-
netic profile than oral busulfan, there remains strong variation, particularly in
children. Therapeutic drug monitoring for appropriate dose adjustment is there-
fore recommended in all patients treated with regimens containing high-dose
busulfan.
Aims: Traditionally, the busulfan AUC is calculated using six plasma con-
centrations obtained within the six hours following busulfan infusion and
before the second dosing of busulfan (AUC0-∞). The application of fewer
samples to calculate the busulfan AUC would result in cost savings (workload,
assay costs) and reduce patient inconvenience related to obtaining blood
samples. In this study, we investigated the correlation between the busulfan
concentration and AUC0-∞ to determine the best clinical method for monitor-
ing the drug level.
Methods: Intravenous busulfan was infused via a central venous catheter for
two-hour periods every six hours for a total of 16 doses over four days. Follow-
ing the administration of a single dose of busulfan as a test dosing and the first
dosing of busulfan for the conditioning regimen, blood samples were collected
from each patient at six time-points (1, 2, 2.25, 2.5, 3 and 6 hours from the
start of the infusion). The busulfan concentrations in the plasma were measured
using high-performance liquid chromatography. The busulfan AUC from 0 to
infinity (AUC0-∞) was calculated according to the trapezoidal method using
MOMENT program, employing all six of the available data points. The relation-
ships between the AUC0-∞ and plasma busulfan concentrations obtained at
individual time points after intravenous administration were assessed using
Pearson’s correlation coefficient. Limited sampling strategies (LSSs) using one,
two, or three plasma busulfan concentrations were developed by multiple linear
regression. The associations between the actual AUC0-∞ and the predicted
AUC0-∞ based on LSS were described using the adjusted coefficient of deter-
mination (r2); values of >0.9 were considered to be acceptable. The degree of
bias and precision of the LSS was measured using the mean prediction error
(bias) and root-mean-squared prediction error (precision) methods. Bias and
precision values of <15% were considered to be acceptable.
Results: Pharmacokinetics samples (total: 46 AUCs) were collected from all
29 patients. The mean (±standard deviation) AUC0-∞ was 1,124 (±321) μM
min. The relationship between the AUC calculated using available all time-
points (actual AUC0-∞) and the AUC predicted using each one time-point at
1 hour (C1), 2 hours (C2), 2.25 hours (C2.25), 2.5 hours (C2.5), 3 hours (C3)
or 6 hours (C6) after the start of the two-hour infusion (predicted AUC0-∞).
The AUC0-∞ predicted based on C6 (trough level) was significantly correlated
with, and not statistically different from, AUC0-∞ (r2=0.929, P <0.0001, mean
bias 0.282% (95% confidence interval: -2.01 to 2.57), precision: 7.91%).
These results met the criteria for acceptability (adjusted r2 >0.9, mean bias
<15% and precision <15%). In contrast, the limited AUCs derived from the
other sampling points (C1, C2, C2.25, C2.5 and C3) did not meet the criteria.
LSSs using one- (C6), two- (C2 and C6), or three-sample (C2, C3 and C6)
were developed by multiple linear regression that showed excellent agree-
ment with AUC0-∞.
Summary and Conclusions: We created the LSSs using one, two, or three
time-point to estimate the AUC0-∞ in children receiving intravenous busulfan
prior to HSCT. These AUC0-∞ well predicted the actual AUC0-∞ with good pre-
cision and little bias. In single-point sampling strategies, the AUC0-∞ predicted
by the LSS (C6) and AUC0-∞ using the six data points demonstrated excellent
agreement.
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A BENDAMUSTINE CONTAINING FLUDARABIN-BASED REDUCED
INTENSITY CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN REFRACTORY/RELAPSED CLASSICAL
HODGKIN LYMPHOMA
N. Mikhaylova1,* M.O. Popova1, Y. Osipov1, E. Borzenkova1, E. Kondakova1,
M. Ivanova1, A. Kozlov1, V. Vavilov1, O. Slesarchuk1, I. Moiseev1, O. Pirogova1,
A. Alyanskiy1, E. Babenko1, M. Vladovskaya1, S. Bondarenko1, L. Zubarovskaya1,
B. Afanasyev1
1Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, First Pavlov State Medical University of Saint-Petersburg,
Saint-Petersburg, Russian Federation
Background: Autologous hematopoietic stem cell transplantation (autoHSCT)
is the standard treatment for pts with relapsed and refractory cHL (rr-cHL) but
20-30% responders to second line chemotherapy eventually have relapse. Allo-
geneic hematopoietic stem cell transplantation (alloHSCT) is a method with
high curative potential in rr-cHL, but the role of alloHSCT is still a subject of
controversy because of high treatment-related mortality (TRM) of myeloablative
conditioning regimens (CR). Reduced intensity conditioning (RIC) regimens
have emerged as a potential option with acceptable TRM in chemosensitive
pts. High toxicity of melphalan containing RIC in highly pretreated rr-cHL
induces to look for a new ways for CR. Bendamustin has a good safety profile
as a CR in non-Hodgkin lymphomas1 and showed high efficacy as a salvage
monotherapy in rr-cHL2. 
Aims: Efficacy and toxicity of a bendamustine containing RIC for alloHSCT in
pts with rr-cHL
Methods: For 3-year period (2012-2014) 13 pts with rr-cHL alloHSCT with a
bendamustine containing RIC have been performed. This RIC was modification
of BFR regimen1 and consist of intravenous (i.v.) fludarabine (Flu) at a total
dosage of 90 mg/m2 over three days and bendamustine (Be) i.v. at 130
mg/m2/day during the same three days. Primary end-points were
engraftment/rejection rate, organ toxicity, incidence of GvHD and infection com-
plication. Secondary end-points were a progression-free survival (PFS), overall
survival (OS) and treatment-related mortality (TRM) at 100 days and 2 years
after alloHSCT. Pts characteristics are outlined in Table 1.
Results: The engraftment was achieved in 100% of pts with median day +20
(14-44). Rejection was not registered. Cumulative incidence of mucositis grade
3-4 was 7,7%, severe renal toxicity-7,7%. There was no severe hepatic toxicity,
but VOD was observed in one patient. Infection complication: severe bacterial
infection/sepsis were registered in 15% of pts, CMV reactivation in two pts and
one of them had CMV reactivation before alloHSCT. Probable invasive
aspergillosis (IA) according EORTC/MSG criteria had 3 pts before alloHSCT.
The only one patient had relapse of IA at day +20. Two patient developed IA
after alloHSCT at days +100 and +235 which were associated with GvHD and
corticosteroid treatment. Cumulative incidence of aGvHD in study group grade
1-2 was 53%, 3-4-7,6%. Cumulative incidence of chGvHD was 38,5%, severe-
15%. There was no TRM at 2 years follow up. Progression-free survival at 100
days after alloHSCT was 76,9%, PFS at 2 years was 69,2%. Complete or partial
remission of HL at the moment of HSCT was associated with the best PFS at
2 years vs stable or progression disease (89% vs 25%, p=0,02). OS at 100
days and at 2 years after alloHSCT was 92,3%. One patient died from the pro-
gression of the underlying disease in early period after alloHSCT.
Table 1. Patient characteristics, n=13.
Summary and Conclusions: The FluBe RIC for alloHSCT had 100% engraft-
ment rate in our study group with acceptable toxicity and absence of TRM and
rejection. The administration of a bendamustine containing RIC was associated
with good PFS at day 100 (76,9%), as well with promising long-term OS (92,3%)
and PFS (69,2%), especially in chemosensitive pts (89% 2y-PFS).
Reference 
1. Khouri I. F. et all. BFR (bendamustine, fludarabine, and rituximab) allogeneic
conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelo-
suppression and GVHD // BLOOD, 2014, Vol. 124, No. 14: P 2306- 12
2. Ghesquieres H. et all. Clinical experience of bendamustine in relapsed or
refractory Hodgkin lymphoma: a retrospective analysis of the French com-
passionate use program in 28 patients, Leukemia & Lymphoma, 2013, Vol.
54, No. 11: P 2399-2404
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EFFICACY OF ORAL GLUTAMINE IN THE PREVENTION OF MUCOSITIS
IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION. EXPERIENCE OF A SINGLE CENTER
A. Santamaría López1,* L. Alvarez Pequeño1, R. Cidre López1, Á. Fernández
Fernández1, C. Albo López1
1Haematology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
Background: Mucositis is an inflammatory reaction produced by chemo and/or
radiotherapy, which affects the whole gastrointestinal tract. The main symptoms
are oral dryness, odynophagia, diarrhea and painful ulcerations. Glutamine is
a non-essential amino acid that helps to maintain the integrity of the digestive
tract. In high metabolic stress your intake exceeding the body’s synthesis capac-
ity and deficiency may occur. Some studies suggest that this amino acid can
prevent the onset of mucositis.
Aims: Analyze whether the use of oral glutamine supplementation decreases
the incidence of mucositis, severity and duration in patients undergoing
hematopoietic stem cell transplantation (HSCT).
Methods: A retrospective observational study was performed reviewing 274
hospital histories of patients undergoing HSCT inxeral Cíes Hospital, from 2002
to 2010 and from May to December 2014. Mucositis degree was evaluated in
patients who have received glutamine (YG) or not (NG) regarding the HSCT
type and conditioning regimen. The data was processing using R statistical
software using correlation matrices according the p Holms method.
Results: 147 males and 127 females were included, with a median age of 49
years (1-70). In the 191 autologous HSCT predominant diagnosis were myeloma
and lymphoma (87’4%), most of them receiving high doses of melphalan -BEAM,
MEL200- (79’6%). 83 were allogeneic HSCT and predominant diagnosis was
acute leukemia, receiving busulphan more than two days 42’2%, total body irra-
diation (TBI) 21’7%, reduced intensity conditioning (RIC) 22’9% and others 13’2%.
Mucositis was seen in 95’5% of the autologous HSCT, III-IV degree 43’1% and
35’3%, NG and YG groups respectively. 81’9% of allogeneic HSCT developed
mucositis, III-IV degree 42’9% vs 39’6%, NG vs YG. Mucositis degree, duration
and the use of opioids and parenteral nutrition (PTN) in both groups, as well as
mucositis depending on conditioning regimen are shown in Table 1. The TBI and
RIC groups were not evaluated by of the small number of patients in each group.
As shown in the Table 1 there is a significantly relation between the use of glut-
amine and reducing severe mucositis in autologous HSCT. Correlation is also
observed with duration of mucositis and opidoids use. Not so in the allogeneic
group in which no significant differences probably related to the sample size and
the existence of other factors that may influence their appearance are observed
(methotrexate use for GVHD prophylaxis, oral GVHD,…).
Table 1. Mucositis degree, duration, use of opioids and parenteral nutri-
tion in autologous and allogeneic HSCT, and grade of mucositis based
on conditioning regimens.
Summary and Conclusions: In the present study we have found a lower inci-
dence of severe mucositis in patients who have received glutamine undergoing
autologous SCT, so we would recommend its use. We cannot draw any con-
clusions from their use on allogeneic setting.
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THIOTEPA FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (AHSCT) IN SOLID TUMORS
R. Suzuki1,* Y. Takahasi2, M. Inoue3, H. Kanamori4, Y. Hashii5, H. Sakamaki6,
K. Kawa7, K. Kato8, Y. Atsuta9, S. Kojima2
1Cancer Center, Shimane University, Izumo, 2Pediatrics, Nagoya University,
Nagoya, 3Hematology, Osaka Medical Center and Research Institute for Mater-
nal and Child Health, Izumi, 4Hematology, Kanagawa Cancer Center, Yoko-
hama, 5Pediatrics, Osaka University, Osaka, 6Hematology, Tokyo Metropolitan
Komagome Hospital, Tokyo, 7Japanese Red Cross Kinki Block Blood Center,
Osaka, 8Pediatrics, Japanese Red Cross Nagoya First Hospital, 9Japanese
Data Center for HSCT, Nagoya, Japan
Background: Thiotepa (NN’N’’-triethylenethiophosphoramide) is a multifunc-
tional alkylating agent known to produce a significant anticancer effect in a
variety of hematological malignancies and solid tumors. Since its molecular
weight is as low as 189 g/mol, a good penetration of thiotepa to central nervous
system (CNS) has been reported. Because of the high concentration in cere-
brospinal fluid, thiotepa is recognized as one of the key agents for CNS tumors,
primary CNS lymphoma, and AHSCT. However, thiotepa is currently unavail-
able in Japan due to the problem in drug supply.
Aims: The aim of this study is to clarify the significance of thiotepa use for
AHSCT in solid tumors in Japan.
Methods: Data were retrospectively analyzed using Japan nation-wide data-
base by the Japan Society for Hematopoietic Cell Transplantation.
Results: Thiotepa was used for 1,083 of 3,850 patients who received AHSCT
for solid tumors. The median age was 9 years (renge: 0-71), and 679 patients
(63%) were younger than 16 years. The main indication was breast cancer
(314 of 444), primary CNS tumors (241 of 486), rhabdomyosarcoma (153 of
416), neuroblastoma (147 of 1,017), germ cell tumor (61 of 540), Ewing sarco-
ma (54 of 298) and hepatoblastoma (46 of 139). Various preconditioning regi-
mens were used, but the median dose of thiotepa was 600 mg/m3 of 12 mg/kg.
More than 80% of patients were treated in combination of alkylators.
Thiotepa+melphalan was the most frequently used regimen, with a total of 534
patients, particularly for CNS tumors, rhabdomyosarcoma, neuroblastoma,
germ cell tumor, and hepatoblastoma. Thiotepa+cyclophospamide with or with-
out other agents was used for 330 patients mostly for breast cancer.
Thiotepa+etoposide with or without other agents was used for 97 patients pref-
erentially for CNS tumors and Ewing sarcoma. The 5-year overall survival of
patients transplanted with thiotepa was 52%, and was significantly better than
that without thiotepa (48%, P=0.03). The survival benefit was evident in primary
CNS tumor (P=0.001), Ewing sarcoma (P=0.02) and rhabdomyosarcoma
(P=0.05), but not for other tumors including breast cancer, neuroblastoma,
germ cell tumor and hepatoblastoma (Figure 1).
Figure 1.
Summary and Conclusions: Thiotepa is potentially useful for certain solid
tumors as preconditioning for AHSCT. These findings should be confirmed in
prospective studies.
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DELAYED RECONSTITUTION AND IMMATURE PHENOTYPE OF NATURAL
KILLER(NK) CELLS FOLLOWING POSTRANSPLANT CYCLOPHOSPAMIDE
IN 30 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION
PATIENTS. A PROSPECTIVE ANALYSIS 
A.M. Pérez-Corral1,* D. Champ1, J. Anguita1, C. Pascual1, J. Gayoso1, M. Bastos-
Oreiro1, M. Kwon1, D. Serrano1, P. Balsalobre1, C. Martinez-Laperche1,
E. Sarmiento1, I. Buño1, J.L. Díez-Martín1
1Hematology, Gregorio Marañon Hospital, Madrid, Spain
Background: NK cells exert an important role in postransplant immune recon-
stitution, relapse prevention, infection control and graft versus host
disease(GVHD).They are the first lymphoid subpopulation to recover after a
conventional bone marrow transplantation.Their reconstitution and maturation
process resembles normal ontogeny, and is crucial for the development of their
functional capacities. Unmanipulated Haploidentical transplantation (Haploid
SCT) with postransplant cyclophosphamide is an emerging alternative for
patients with no identical sibling donor.
Aims: We prospectively analyse NK reconstitution post Haploid SCT in 30
patients comparing with simultaneous 8 patients with HLA identical sibling
donor (HLAid SCT), and its relationship with CMV reactivation and GVHD.
Methods: Between November 2012 and July 2014,30 patients received Haploid
SCT and 8 HLAid SCT in Gregorio Marañon Hospital.Peripheral blood was used
in all cases.GVHD prophylaxis included high dose Cyclophosphamide on
+3,+4/cyclosporineA/mycophenolatemofetil for Haploid and cyclosporine
A/Methotrexate for HLAid. Table1 shows patients characteristics,with no relevant
differences between the two groups, except for longer engraftment times and
lower acute GVHD incidence in Haploid group.For analysis of NK reconstitution
flow cytometry on FC500/Navios Beckman Coulter® was used. Total NK cells,
CD56 intensity and expression of NKG2A, NKp30, Nkp46 and NKG2D was stud-
ied at +15, +30, +60, and +90.For comparison Mann-Whitney U-test was used.
Results: Median NK cells/mm3 on +15 and +30 were significantly lower on
Haploid than HLAid group (0 (0-2) and 34,5 (16-177) vs 60 (52-125) and 230
(122,5-387,7); p<0.01),being similar on+60 and +90 (112 (52-225) and 147
(84,2-211,7) for Haploid vs 95 (42-119) and 101 (63,2-177,7) for HLAid; p
ns).NK cells reached normal levels on +30 in HLAid group,while in +60 in Hap-
loid patients.High percentages of immature CD56bright(CD56b) NK cells and
high expression of immature receptor NKG2A appeared on Haploid on +30
with further decrease (CD56b 77% (68.5-88.5), NKG2A 84% (77-93) on +30,
38% (25-48) and 72% (61-85,5) on +60, 35% (23-43) and 62%(53,7-77) on
+90). Compared with HLAid patients,CD56b cells and NKG2A expression were
significantly higher (p<0.05) on Haploid group on +30, +60 and +90. Expression
of activating receptors NKP46/ NKp30,and inhibitor NKG2D,linked to NK mat-
uration,were only decreased in Haploid group on +15 (p<0.05),with appropriate
expression and no differences on +30, +60 and +90.Expression of NKP46
tended to be higher in Haploid on +30 (81% (54,5-92,5) vs 59,5% (42,5-69,5)),
(p 0.05).In Haploid group, patients with acute GVHD II-IV had lower NK
cells/mm3 at +30 (Median 28,5 vs 132) and +60 (Median 67,5 vs 103) than
those with GVHD 0-I; p ns.No differences in receptor expression was detected
between patients with and without GVHD or CMV reactivation.
Table 1.
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Summary and Conclusions: After Haploid SCT with postransplant Cyclophos-
phamide NK cell reconstitution is delayed comparing with HLAid SCT,reaching
normal levels at +60. NK maturation in Haploid is also different. NK cells remains
in an immature phenotype with high proportion of CD56b NKG2A+ cells longer
than in HLAid patients. Interestingly cytotoxic capacity seems preserved, with
activating and inhibitor no KIR receptor expression, normally linked to maturation,
similar to HLAid patients from +30 onwards. Patients with clinically significant
GVHD had worse NK reconstitution in terms of lower total counts in the first 60
days. These observations bring interest about the possible benefit of early NK
infusions on Haploidentical setting to overcome this impaired NK reconstitution.
Acknowledgments: Foundation Mutua Madrileña.
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UTILITY OF CHIMERISM ANALYSIS IN DETECTION OF POST-TRANS-
PLANT DISEASE RELAPSE IN PATIENTS WITH MYELOID NEOPLASMS
UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENIC
HEMATOPOIETIC CELL TRANSPLANTATION
M. Hefazi1,* A. Al-Kali2, S. Hashmi2, K. Begna2, W. Hogan2, N. Gangat2, M. Litzow2,
D. Viswanatha2, M. Patnaik2
1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic,
Rochester, United States
Background: Reduced intensity conditioning (RIC) has expanded allogeneic
hematopoietic stem cell transplantation (allo-HCT) to elderly patients and to
those with additional comorbidities. However, relapse of myeloid neoplasms
after RIC allo-HCT remains a major problem. Although chimerism analyses are
frequently used for post-transplant surveillance, their utility in the detection of
relapse is controversial.
Aims: We sought to determine the utility of peripheral blood (PB) and bone
marrow (BM) chimerism analyses for the detection of post-transplant disease
relapse after RIC allo-HCT.
Methods:After IRB approval, consecutive patients with myeloid neoplasms (MDS
and AML) who underwent their first RIC allo HCT between 2005 and 2014 were
reviewed. Clinical and laboratory data were retrospectively abstracted. BM biop-
sies (including chimerism studies) that were done for post-transplant surveillance,
as well as concurrent CBC, and PB (sorted and unsorted) chimerism results that
were done within 5 days of the BM biopsies were analyzed.
Results: A total of 137 patients, 59% male, with a median age of 59 years (range
18-69), were identified. Ninety-two (67%) had AML and 45 (33%) had MDS. After
a median follow up of 19 months, 29 (21%) patients (21 with AML and 8 with
MDS) had disease relapse. Of these, 14 (48%) relapsed within the first 100 days,
8 (28%) between day 101 and 200, and 7 (24%) after day 200. A total of 316
bone marrow biopsies were reviewed. Of these, 53 (17%) were consistent with
disease relapse (41 with AML and 12 with MDS). As shown in the Table 1, full
donor chimerism was still present concurrent with BM relapse within a respectable
number of cases (32% of unsorted PB, 43% of lymphoid-sorted PB, 79% of
myeloid-sorted PB, and 15% of unsorted BM chimerisms). Furthermore, mixed
donor chimerism without the morphological or cytogenetic evidence of relapse
was also seen in 37% of lymphoid-sorted PB and 7% of unsorted BM chimerisms.
Unsorted BM and PB chimerisms had the best sensitivity for identifying disease
relapse (85% and 78%, respectively), whereas unsorted PB and myeloid-sorted
PB chimerisms had 100% specificity. CBC abnormalities preceded the relapse
in 25 (86%) out of the 29 patients, with circulating blasts in 13 (45%), isolated
thrombocytopenia in 10 (34%), and pancytopenia in 5 (17%), being early predic-
tive markers. Negative change in serial chimerisms prompted an evaluation for
possible relapse in only 1 (3%) patient. In 4 (14%) patients, relapse was not sus-
pected, but was diagnosed on a routine BM biopsy that showed only cytogenetic
relapse (3 patients) and at an extramedullary site (laryngeal chloroma) without
BM involvement (1 patient). The overwhelming majority of patients (15 out of 21
AML and 8 out of 8 MDS relapses) had circulating blasts at the time of relapse
confirmation on BM biopsy.
Table 1. Results of 316 concurrent* BM biopsy and chimerism studies
performed in 137 AML/MDS patients after RIC allo-HCT.
Summary and Conclusions: Chimerism studies, and in particular myeloid-
sorted PB chimerism, have a limited role in the detection of post-transplant
relapse in patients with myeloid neoplasms. Close monitoring of CBC results,
including early detection of thrombocytopenia, circulating blasts, and pancy-
topenia still remains a very effective strategy.
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BUSULFAN THERAPEUTIC DRUG MONITORING IS NEEDED IN POPULA-
TIONS WITH GENETIC HETEROGENEITY UNDERGOING ALLOGENEIC
STEM CELL TRANSPLANTATION
B. Al-Lawati1, M. Al-Khabori2,* M. Al-Zaabi1, S. Al-Kindi2, D. Dennison2,
M. Al-Huneini2, K. Al-Farsi2, M. Tauro2
1Pharmacy, 2Hematology, Sultan Qaboos University Hospital, Muscat, Oman
Background: Busulfan (Bu) based preparative regimens in allogeneic stem cell
transplantation are commonly used. Previous studies have shown that Bu at a
fixed dose of 3.2 mg/Kg/day (FBD) given intravenously decreases variability in
drug pharmacokinetics and this decreases the dependency on therapeutic Bu
drug monitoring (TDM). We hypothesized that in a population with genetic het-
erogeneity, like Oman, the FBD may not be adequate and TDM is still needed. 
Aims: Therefore, we planned to compare the Bu dose given using TDM with
the FBD of 3.2 mg/Kg/day. 
Methods: We retrospectively reviewed consecutive patients who received allo-
geneic stem cell transplantation at Sultan Qaboos University Hospital during
the period of January 2003 to December 2014. Included patients received intra-
venous Bu based preparative regimen using TDM. Patients with acute
leukemia, myelodysplasia, thalassemia major and sickle cell disease were
included in this study. We used Bland-Altman plot to compare the daily dose
between the TDM and FBD using 3.2 mg/day. We then normalized the dose
using patients’ weights (mg/Kg/day) and assessed the impact of age, gender,
weight, height and serum bilirubin on the difference between the normalized
TDM and FBD. 
Results: Sixty-one patients (Males 28, Females 33) with a median age of 16.5
y (Range: 2.7-55.9) were included. The median and the interquartile range (IQR)
for weight, height and serum bilirubin were 49 Kg (IQR: 23.2-62.5), 152 cm (IQR:
130-164) and 10 micromol/l (IQR: 4-17) respectively. Indication for transplantation
was acute leukemia/myelodysplasia in 30, sickle cell disease in 23 and tha-
lassemia major in 8 patients. The mean difference in daily dose between the
TDM based and FBD was 40 mg with clinically significant differences (Bland-Alt-
man agreement limits: -39 to 119; see Figure 1). The median normalized differ-
ence between the TDM based and FBD methods was 4.3 mg/kg/d (Range: 2.4-
8.1). In the multivariable linear regression model, weight (p=0.0278) and gender
(p=0.0288) were statistically significant predictors of the normalized difference
with a coefficient of determination of 47% for the model. 
Figure 1.
Summary and Conclusions: TDM remains important for appropriate dosing
of Bu in preparative regimens of allogeneic stem cell transplantation especially
in populations with genetic heterogeneity. Although, the gender and weight can
help predict the difference, the unexplained variance remains high. We recom-
mend Bu TDM to be used as a standard of care. 
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HEMATOLOGICAL RECOVERY AFTER INTRA-BONE MARROW CORD-
BLOOD TRANSPLANT WAS ENHANCED THROUGH LOCAL ENGRAFT-
MENT OF INJECTED SITE. A SINGLE CENTER PROSPECTIVE PHASE I/II
TRIAL IN JAPAN
N. Kurita1,* Y. Yokoyama1, S. Suzuki1, M. Seki1, M. Sakata-Yanagimoto1,
N. Obara1, Y. Hasegawa1, F. Frassoni2, S. Chiba 1
1Department of Hematology, University of Tsukuba, Tsukuba, Japan, 2Stem
Cell and Cell Therapy Lab, Istituto G. Gaslini, Genoa, Italy
Background: Cord-blood transplantation (CBT) is an effective option for hema-
tological diseases. However, high rate of graft failure and delayed engraftment
were the major limitations of CBT and as a consequence, CBT is associated
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with a high risk of morbidity and mortality. Intrabone-marrow CBT (iBM-CBT)
has been proposed as a measure which can solve the problems.
Aims: We conducted phase I/II prospective single-center trial of iBM-CBT with
15 cases to evaluate its safety and effectiveness. And another aim of this study
was to identify the site of early hematopoiesis after iBM-CBT.
Methods: 15 adult patients (median age 59 years, range 32-64) with hemato-
logical malignancies (AML, 8; ALL, 4; NHL,3) were enrolled in University of
Tsukuba Hospital, Tsukuba, Japan. Of them, three patients were not in remis-
sion. HLA matching was 5/6, and 4/6, for 5, and 10, respectively. Unwashed
units were used to avoid loss of the cord-blood cells. The cord blood was divid-
ed in four syringes, and was infused in the superior-posterior iliac crest bilat-
erally under general anesthesia for one case, or local anesthesia for fourteen
cases. Median transplanted cell dose was 2.8×107/kg (range 2.0-5.0). The pri-
mary endpoint was injection-related complication and the probability of hema-
tological recovery after iBM-CBT. Secondary endpoints included the incidence
of transplant-related mortality (TRM), acute GVHD, overall survival (OS), and
disease-free survival (DFS). We compared donor chimerism in the iliac bone
(the injected site) with that in the sternal bone (the remote site from the injection)
14 days after intra-bone marrow injection. This trial was registered on the UMIN
website, number UMIN000006175.
Results: Between October 2011 and July 2014, 15 consecutive patients under-
went iBM-CBT. Transient hypotension was observed after intrabone injection
in one case, which was thought to be due to vasovagal reflex and the sedatives.
The neutrophil recovery (≥0.5×109/L) and platelet recovery (≥5.0×109/L) were
seen in 14 cases (93%), and 13 cases (87%), respectively. The median time
to neutrophil and platelet recovery were 17 days (range 12-27) and 44 days
(range 32-99), respectively. Acute GVHD developed in 34% (grade II-IV), and
0% (grade III-IV). TRM within one year was not observed. Estimated 1-year
OS and DFS were 79% and 67%, respectively. The early donor chimerism was
significantly higher in the iliac bone (median 95.2%, range 67.3-99.7), where
cord blood had been injected, compared to the sternal bone (median 94.4%,
range 22.3-98.8) (P=0.006; Wilcoxon signed-rank test) (Figure 1).
Figure 1.
Summary and Conclusions: Our data suggest that iBM-CBT was well toler-
ated and can promote prompt hematological recovery. Local anesthesia is suf-
ficient to control pain associated with the procedure and the cord blood does
not have to be washed. The dominance of donor chimerism in the iliac bone
before engraftment suggests that local engraftment just after iBM-CBT con-
tributes to early hematopoiesis of the recipients.
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EXCELLENT LONG-TERM OUTCOME OF AUTOLOGOUS TRANSPLAN-
TATION WITH INTERMEDIATE-DOSE INTENSIVE MELPHALAN (100
MG/M2, MEL100) FOR MULTIPLE MYELOMA: A SINGLE CENTRE STUDY
K. Fukushima1,* T. Sudo1, T. Tamaki1
1Department of Hematology, Rinku General Medical Center, Izumisano, Japan
Background: It is generally accepted that high-dose melphalan therapy, fol-
lowed by autologous hematopoietic cell transplantation, should be the treatment
of choice in younger transplant-eligible patients with multiple myeloma (MM).
The optimal therapeutic approach in elderly patients with MM remains unclear.
Newer agents, including bortezomib and lenalidomide, have become available,
and their use should be considered in this population. We carefully evaluated
transplant-eligibility in both young and older patients (50s to 70s), and consid-
ered the treatment procedure: reduced intensity melphalan conditioning that
reported several study. Here we report on the excellent long-term outcome of
autologous tandem transplantation with intermediate-dose intensive melphalan
in patients with MM.
Aims: We aimed to determine the long-term efficacy, and associated adverse
events, of autologous tandem transplantation with intermediate-dose intensive
melphalan for MM.
Methods: We retrospectively analysed data from 37 patients, treated at our
institution with pre-planned 2 or 3 courses of intermediate-dose intensive mel-
phalan (100 mg/m2, MEL100) followed by peripheral blood stem cell (PBSC)
transplantation, between 2000 and 2009. Eligibility criteria for inclusion were
as follows: (1) histologically and clinically confirmed symptomatic MM; (2) aged
40-79 years; (3) transplant-eligible; (4) adequate organ function with Eastern
Cooperative Oncology Group performance status <3; and (5) provision of writ-
ten informed consent. The median age of patients was 60 years (range, 43-77
years). Pre-transplant disease status, according to the Durie and Salmon sys-
tem, was as follows: stage I (n=5), stage II (n=6), stage III (n=28). The rate of
response better than very good partial response (VGPR) was 29% at pre-trans-
plant with dexamethasone alone or VAD (Vincristine-Adriamycin-Dexametha-
sone) regimen. All cases of PBSC mobilization were performed with cyclophos-
phamide plus granulocyte-colony stimulating factor. Five patients underwent
allogeneic hematopoietic cell transplantation after tandem autotransplantation,
because of disease progression. 
Results: The 5-year overall survival (OS) was 50%, and cumulative incidences
of relapse and non-relapse mortality were 26% and 24%, respectively. All
patients who were followed up for more than 5 years post-transplantation are
alive. Complete remission was achieved in 16 (37%) patients. The median day
of neutrophil engraftment was day 11; there were no cases of engraftment fail-
ure. Only 2 patients died within 100 days post-transplantation (1 case of sepsis
and 1 case of disease progression). Surprisingly, survival during the follow-up
period was higher in patients carrying a 13 chromosome deletion (13q-) (10/11,
91%), compared with patients with a normal karyotype (9/26, 34%).
Summary and Conclusions: These data demonstrate the effectiveness of 2
or 3 courses of intermediate-dose intensive melphalan followed by stem cell
transplantation in older patients with MM. Thus, the MEL100 regimen is not
only feasible in older patients, but also prolonged overall survival. Patients with
a 13q deletion showed a particularly good response to this treatment, particu-
larly considering the poor prognosis often associated with such deletions.
Although recent data shows the potential of novel treatments such as protea-
some inhibitors and immunomodulating agents, the treatment protocol reported
here should be considered to achieve prolonged progression-free survival.
E1532
IMPACT OF DONOR AGE ON PERIPHERAL BLOOD AND BONE MARROW
HEMATOPOIETIC STEM CELL HARVEST
H. Cho1,* H. Park1, J. Lee1, J. Jang1, S.J. Kim1, Y. Kim1, J.S. Kim1, Y.H. Min1,
J.-W. Cheong1
1Internal Medicine, Yonsei University College of Medicine, Seoul, Korea,
Republic of
Background: Hematopoietic stem cell transplantation (HSCT) is still one of
the most important treatment modalities for the patients with hematologic malig-
nancies. For allogeneic HSCT, increasing difficulty in proper donor selection
leads to broaden the range of donor age than before. However, the exact
clinical impact of donor age on peripheral blood (PB) and bone marrow (BM)
hematopoietic stem cell (HSC) harvest is unclear.
Aims: This study was conducted to evaluate the impact of donor age on PB
and BM HSC harvest.
Methods: We retrospectively reviewed the yields of allogeneic PB or BM HSC
harvest from 384 healthy sibling or unrelated donors who donated their HSC
to adult patients receiving allogeneic HSCT at Severance hospital between
Jan. 2000 and Feb. 2015. For PB-HSCT, granulocyte colony-stimulating factor
(G-CSF), either filgrastim or lenograstim, was injected subcutaneously with
doses of 10 μg/kg/day either as a single or split from 4 days before harvest to
the end of the procedure.
Results: Among 384 donors, 290 (75.5%) donated PB HSC and 85 (22.1%)
BM HSC. Nine (2.3%) sibling donors provided both BM and PB stem cells due
to insufficient number of BM stem cell in initial harvest. Median age was 37
(range 14-73) years, and the number of donors with age <50 years was
244(84.1%), 50-59 years 34 (11.7%), and ≥60 years 12 (4.1%). Donors with
older age needed more sessions of harvest (Table 1. p=0.032) to complete the
harvest. The median CD34+ cell counts at the first day of harvest was also sig-
nificantly different according the age of donor; 4.03 (range 0.34-24.55)x 108 in
patients with age <50 years, 2.85 (range 0.16-10.21)x 108 in 50-59 year, and
1.89 (0.64-3.37)x 108 in ≥60 years (p <0.001). The median total CD34+ cells
collected were also reversely correlated with the age of donor (p <0.001). Two
of 12 (16.7%) donors over 60 year-old did not collect more than 1.4x 108 CD34+
cells finally which are probably needed to give >2.0x 106/kg CD34+ cells in
70kg recipients. The age of donors providing BM HSC was younger (median
33, range 13-56 years) than those providing PB stem cells. The number of
donors with age<50 years and ≥50 years was 88 (93.6%) and 6 (6.4%), respec-
tively. The median CD34+ cell counts at the first day of harvest were 1.56
(range, 0.06-8.11)x 108 and 1.08 (range, 0.31-1.37)x 108 in donors with age
<50 years and ≥50 years, respectively (p=0.015). The median counts of total
collected CD34+ cells after completion of harvest were 1.81 (range, 0.06-8.11)x
108 and 1.08 (range, 0.31-1.37)x 108, respectively (p=0.03). Median CD34+
cells/kg body weight of recipients were significantly higher in donors with
age<50 year than in those with age ≥50 years (2.59 vs 1.81x106, p=0.025).
Summary and Conclusions: This study showed that the majority of elderly
donor could provide sufficient PB or BM HSC for allogenetic HSCT, but number
of collected HSC was reversly correlated with the age of donor. Especially
because the risk of insufficient harvest was increased in PB HSC donor with
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age >60 and in BM HSC donor with age >50, more consideration should be
given in case of these elderly donors. 
Table 1.
E1533
BASELINE PERIPHERAL BLOOD CD34+ CELL COUNT DOES NOT INFLU-
ENCE PLERIXAFOR SUCCESS RATE
A. Ferreira Baptista1,* C. Geraldes1, M. Pereira1, R. Sofia1, C. Emília1,
A.I. Espadana1, M.L. Ribeiro1
1Serviço de Hematologia, Centro Hospitalar e Universitário de Coimbra, Coim-
bra, Portugal
Background: Plerixafor, a CXCR4 chemokine antagonist, has been shown to
significantly improve blood stem cell collection mediated by granulocyte-colony-
stimulating factor (G-CSF). Peripheral blood CD34+ cell counts (PB CD34+)
after different mobilization schemes have been shown to correlate with aphere-
sis yields and are widely used as the main variable to start apheresis. However,
doubts remain if there are predictive factors that can be used before starting
plerixafor administration in order to ration the use of this expensive drug.
Aims: To investigate if lower baseline PB CD34+ correlate with inferior collec-
tion success rates. 
Methods: We retrospectively analyzed 62 patients that received plerixafor
between 13-10-2008 and 31-12-2014. Five patients were excluded due to insuf-
ficient data. Plerixafor was given as part of a preemptive strategy or salvage ther-
apy after failure to mobilize or collect sufficient CD34+ cells following chemomo-
bilization. It is the standard operating procedure at our centre to target a collection
of 2 × 106 CD34+ cells/kg for lymphoma and of 4 × 106 CD34+ cells/kg-enough
for two autologous stem cell transplants (ASCT)-for multiple myeloma (MM)
patients. However, for the purpose of this analysis, the 2 × 106 CD34+ cells/kg
target was considered as a collection success for all patients. Plerixafor was
given at a dose of 0.24 mg/kg subcutaneously 11 hours prior to apheresis in con-
junction with G-CSF (10 µg/kg/day). Baseline PB CD34+ were determined after
4 G-CSF administrations and before the first plerixafor was given.
Results: Of the 57 patients, 33 (57.9%) were males. Median age was 57 years
[18-67]. In 12 patients (21.11%) the diagnosis was Hodgkin Lymphoma, in 14
(24.56%) Multiple Myeloma, in 30 (52.63%) Non-Hodgkin Lymphoma and in 1
(1.75%) Waldenström Macroglobulinemia. In 20 patients (35.09%), Plerixafor
was used preemptively. The PB CD34+ after the first plerixafor correlated with
the initial PB CD34 (r=0.60, p<0.001). The number of CD34+ cells collected
after the first apheresis also correlated with PB CD34+ at baseline (0.60,
p<0.001) and, to a higher degree, to the PB CD34+ after the first plerixafor
(r=0.78, p<0.001).The number of CD34+ cells collected after the first apheresis
was higher in patients with PB CD34+ ≥5 /mL at baseline (2.9±0.46 vs
1.8±0.29x10^6 cells /kg, p=0.02). The number of plerixafor administrations
needed to achieve a total collection of ≥2.0x106 cells/kg was higher in patients
with a baseline PB CD34+ under 5 /mL (2.1±0.13 vs 1.6±0.15, p=0.0094). The
percentage of patients achieving this goal after a single administration of pler-
ixafor was more than two-fold higher when the baseline count was ≥5 cells /mL
(47.8% vs 20.6%, p=0.030; 50.0 vs 25.0% for Myelomas and 47.1 vs 19.2%
for Lymphomas). However, the ratio of patients achieving a collection of
≥2.0x106 cells/kg both after the first apheresis (47.1% vs 56.5%, p=NS) and at
the end of all the aphereses with plerixafor (64,7% vs 78,3%, P=NS) was unaf-
fected by the initial PB CD34+. The optimal cut-off point to predict for better
collection results as defined above was 4.795 cells /mL at baseline, with a sen-
sitivity of 66.7% and a specificity of 61.1%.
Summary and Conclusions: In our series, higher baseline PB CD34+ corre-
lated with faster and higher PB CD34+ increase and therefore the need for a
lower number of apheresis. Nevertheless, it does not significantly influence the
probability of reaching our goal of sufficient CD34+ cells for one ASCT.
E1534
AUTOLOGOUS PERIPHERAL BLOOD CD34+ CRYOPRESERVED WITH
5% DIMETHYL SULFOXIDE COMPARED TO 10%: BETTER VIABILITY OF
CD34+ AND NO NEUROLOGICAL SIDE EFFECTS
V. Pavone1,* A. Mele1, A. Musarò1, R. De Francesco1, C. De Risi1, M.R. Mor-
ciano1, G. Greco1, M. Fina1, D. Carlino1, B. Rossini1, S. Sibilla1, S. Citiso1, E.
Prete1, B. Vannata1, M. Caputo1, L. Abbruzzese1
1Haematology and TMO, Hospital Card. G. Panico, Tricase (Le), Italy
Background: Dimethyl sulfoxide (DMSO) is extensively used as a cryoprotec-
tant in stem cell preservation, but is associated with toxicity and adverse reac-
tions in the transplant recipient. Cryopreservation using 5% DMSO instead of
10% DMSO is a strategy to reduce the adverse effects.
Aims: We compare the use of 5% DMSO versus 10% DMSO in terms of medi-
an and viability of CD34+ cells infused, haematological engraftment, number
of febrile neutropenia and treatment related mortality (TRM).
Methods: 118 consecutive patients with haematological malignancies submit-
ted to autologous transplant were included in the study. 81 (69%) were stored
in 10% DMSO (from January 2012 to September 2013) and 37 (31%) in DMSO
5% (from October 2013 to January 2015).
Table 1. Results of cryopreserved HPC and haematological recovery.
Results: Patients were similar in terms of median age, diagnosis, number of
previous treatments, disease status at transplant. Median time to transplant
from diagnosis was similar in the two groups but higher number of patients in
DMSO 10% were transplanted after one year from diagnosis (85% vs 43%,
p<0,001). Median of CD34+ cells infused was similar in the two groups, Table
1. Reduction in DMSO concentration to 5% was associated with higher CD34+
cells viability (99% vs 86%; p<0,008). No significant difference in median time
to neutrophil (ANC) and platelets (PLT) engraftment was demonstrated in the
two groups of patients, Table 1. DMSO concentration did not influence median
day of hospitalization and febrile neutropenia. No differences in terms of mucosi-
tis, diarrhea, renal or hepatic toxicity were observed. No neurological side
effects were observed in the group of patients with DMSO 5%, instead 3 events
(4%) were registered in the DMSO 10% group, (p=0,23). After 14 months of
median follow-up (range, 1-37), the estimated 1y TRM was 6% in the DMSO
5% vs 13% in DMSO 10%, p=0,45 (Figure 1).
Figure 1.
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Summary and Conclusions: Our results suggest that reduction in DMSO con-
centration to 5% was associated to higher viability of CD34+ cells infused without
affecting median CD34+ cells infused and haematological reconstitution. At the
same time, an equivalent 1y EFS was experienced between the two groups of
patients studied. Interesting, neurological side effects were not observed in
DMSO 5%. Further studies and longer follow-up is needed to evaluate fully effi-
cacy and long term safety of cryopreservation of cells with 5% DMSO.
E1535
SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTA-
TION IN MULTIPLE MYELOMA-RETROSPECTIVE STUDY
P. Silva1,* C. Pinho Vaz1, F. Campilho1, R. Branca1, L. Leite1, S. Roncon2,
A. Campos1
1Bone Marrow Transplant Service, 2Cell Therapy Service, Instituto Portugues
de Oncologia Francisco Gentil, E.P.E.-Porto, Porto, Portugal
Background: High-dose chemotherapy followed by autologous stem cell trans-
plantation (ASCT) is the main treatment of Multiple Myeloma (MM). However,
an alternative approach with tandem ASCT has been studied but response
rates, progression free survival (PFS) and overall survival (OS) are not well
established and conflicting results had been published.
Aims: Compare single versus tandem ASCT after high dose chemotherapy in
terms of responses, PFS and OS.
Methods: Retrospective study of all cases (n=176) of MM treated with high-
dose chemotherapy followed by ASCT (single or tandem) in our center during
six years (January/2008 to December/2014). The initial intention to treatment
was tandem ASCT. However, the majority of patients only had collected periph-
eral blood progenitor cells (PBPC) for one ASCT or refuse a second ASCT. We
performed a demographic and clinical survey of the population and evaluated
response to induction chemotherapy (before the ASCT) and to single or tandem
ASCT (2 and 6 months after ASCT) according to the criteria of the International
Myeloma Working Group (IMWG). We performed the analysis of OS and PFS
by the Kaplan-Meier method/log-rank test, Chi-square test.
Table 1. Main characteristics of study population.
Results: Fifty patients underwent tandem ASCT and 126 single ASCT with a
median follow-up of 42 months (9-132). Median age was 57 years (30-69) with
a slight male prevalence (51.1%). Tandem ASCT group had a lower median age
(54 vs 59, p=0.01) but no other demographic or clinical differences were found
between the two groups (Table 1). Type of response to induction chemotherapy
were also similar. After transplant, rates of response were also comparable
between the two groups: the tandem ASCT group had 56.2% complete response
(CR), 20.8% very good partial response (VGPR) and 22.9% partial response
(PR), while the single ASCT group had 62.3% CR, 11.3% VGPR and 25.5 PR
and 0.9% without a response (p=0.92). The PFS at 3 years and 5 years was
higher in patients undergoing tandem ASCT (75.8% vs 59.0% and 68.5% vs
33.3%, p=0.04), but showed no OS difference between the two groups: tandem
ASCT vs single ASCT at 3 and 5 years (100.0% vs 96.0% and 79.0% vs 74.2%,
p=0.27). These results were similar even after excluding CR to induction
chemotherapy: PFS at 3 and 5 years was 73.9% vs 49.1% and 67.2% vs 32.0%;
p=0.021; OS was, respectively, 100.0% vs 89.9% and 69.2% vs 70.0%, p=0.75.
Transplantation related mortality was absent in the two groups.
Summary and Conclusions: In our study, tandem ASCT improved PFS
when compared with a single ASCT, even in those who not achieved a CR
after the induction chemotherapy. However, it failed to significantly prolong
overall survival.
E1536
IS ALLOGENEIC STEM-CELL TRANSPLANTATION AN OPTION FOR
PATIENTS WITH ACUTE LEUKEMIA AND MYELODISPLASTIC SYN-
DROME TRANSPLANTED WITH ACTIVE DISEASE? A CENTER EXPERI-
ENCE
E. Perez-López1,* O. López-Godino1, M. Cabrero1, S. Alonso1, L. López-Corral1,
M. Diez-Campelo1, M.C. Cañizo1, L. Vazquez1, M.B. Vidriales2, M.D. Caballero1
1Universitary hospital of Salamanca, Salamanca, Spain, 2Hematology, Univer-
sitary hospital of Salamanca, Salamanca, Spain
Background: The prognosis of patients with refractory/relapsed acute
leukemia (rAL) or myelodisplastic syndrome (MDS) is poor. Although patients
with refractory disease are not good candidates for allogeneic hematologic
stem cell transplantation (HSCT), this could be the only curative option. Due
to the absence of reports on long-term follow up in this population, transplant
indication in those patients is a permanent focus of debate.
Aims: To evaluate the outcome and efficacy of salvage HSCT for rAL and MSD.
Methods: We examined retrospectively all the patients transplanted at our
Unit since1999 to 2003 who recived a HSCT in this situation.Diagnosis was in
74 patients (myeloid/lymphoblastic n=36/10) and MDS (n=28).Criteria of refrac-
toriness was defined as patients had never achieved a complete remission
(CR). Feasibility and efficacy of HCT was analyzed in terms of related mortality
(TRM), event free survival (EFS) and overall survival (OS).
Table 1.
Results: The main characteristics of the patients at transplant were: median
age 55 years (14-69); disease status at transplant: refractory 37 (50%), relapse
17 (23%), untreated 8 (10%) and aplastic 12 (30%); median of blasts at trans-
plant was 10% (5-72). 70 (94%) of the patients had evaluable pretrasplantation
cytogenetics: 12 favorable (16%), 29 intermediate (40%) and 29 unfavorable
(39%) (according MRC and IPSS-R). Median time from diagnosis to HCT was
7 months (1-160). All the patients but one engrafted. Median time to reach
>500 granulocytes and >20000 platelets were 17 (10 to 41) and 12 (6 to 70)
respectively. The incidence of acute-GVHD (aGVHD) was 61% (14% grade
III-IV) with median onset of 26 days (8-130); in evaluable patients, incidence
of chronic-GVHD (cGVHD) was 45% (24% severe) with a median onset of 163
days (84-451). (other characteristics in Table 1). Response to transplant was
evaluated at days +21 or 28, +56 and +100. At day +100: 43 patients (58%)
were in complete remission (CR), 13 (17%) have progressed and 18 (24%)
have died,mostly due to disease (n=12). With a median follow up of 30 months
among patients alive, the estimated OS and EFS at 6 monthsat 1 year and 3
years was 63%, 50%,37% and 47%, 38% and 30% respectively. The overall
TRM was 17% (10% at day +100). In the univariate analysis, to maintain CR
at +100 and to develop cGVHD were the only factors associated with a better
OS and EFS (p<0.05); these variables mantained their significance in the mul-
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tivariate analysis. Although patients with favourable cytogenetics findings had
a trend to a better relapse free survival as compared with intermediate and
unfavourable (74% vs 41%; p=0.1), we couldn’t demonstrate its impact in OS
and EFS in the univariate and multivariate analysis. Status disease at transplant
and blast percentaje has not significance in both OS and EFS also. The main
cause of death was progression disease (n=29, 40%). Median time to disease
progression was 183 days (6 to 4773). Considering those patients who were
on CR at +100, 76% of them (33/43) maintained the CR and 53% of them
(23/43) remained alive and disease free at last follow up to (156 months).
Analysing the influence of cGVHD in this selected group of patients on CR at
+100, the estimated probability of relapse at 1 year was 43% in those without
cGVHD (n=14) vs 11% in those who developed cGVHD (n=29) (p=0.02). 
Summary and Conclusions: Our results indicate that patients with rAL or
MDS could benefit from HSCT even with high leukemia burden and should be
considered as transplant candidates. We have shown that HSCT can induce
long-term disease remission and possibly cure in those who developed cGVHD
especially who are on CR at +100.
E1537
RETROSPECTIVE AUDIT OF A SINGLE CENTRE USE OF FRESH FROZEN
PLASMA WITH OR WITHOUT PLASMA EXCHANGE TO REDUCE ISOAG-
GLUTININ TITRES PRIOR TO MAJOR ABO MISMATCHED HAEMATOPOI-
ETIC STEM CELL TRANSPLANTS 
M.L. Tung 1,* C. Thow2, J. Mah2, T. G. Soh2, M. Poon Li Mei1, L.K. Tan1
1Haematology-Oncology, National University Cancer Institute, National Univer-
sity Health System, 2Department of Laboratory Medicine, National University
Hospital, Singapore, Singapore
Background: ABO major mismatched transplants are known to be associated
with various immune mediated complications such as immediate hemolysis,
delayed red cell engraftment and pure red cell aplasia. Reduction of incompat-
ible (recipient) isoagglutinins pretransplantation has been thought to reduce
the incidence of these complications, though the optimal strategy for this
remains unclear. Use of donor group fresh frozen plasma (FFP) infusions with
or without plasma exchange (PLEX) has been one of the strategies used, but
the literature on the safety and efficacy of this method has been sparse. 
Aims: The aim of our retrospective audit was to assess the efficacy of donor-
type FFP infusion on anti-A and/or B isoagglutinin reduction and clinical out-
comes associated with this strategy of isoagglutinin reduction. 
Methods: All patients undergoing major or bidirectional ABO-mismatched bone
marrow (BM), peripheral blood (PBSC), and cord blood (UCBT) hematopoietic
stem cell transplantation (HSCT) between 2010 -2014 were identified from our
institutional database. All patients received daily donor-type FFP infusion till
day of stem cell infusion if their antidonor isoagglutinin titres (Anti-A or Anti-B
titres) were ≥1:16, and PLEX was considered on the day of stem cell infusion
if the antibody titres remained ≥1:16. In addition, for all major ABO incompatible
HSCTs, the stem cell product was red cell-depleted, while for bidirectional ABO
incompatible HSCTs, the stem cell product was red cell- and plasma-depleted. 
Results: We identified 45 patients, 33 who received a major ABO mismatched
(73%) and 12 (27%) who had a bidirectional ABO mismatched HSCT during
this period (Table 1). Amongst these patients, 43 (96%) had an underlying
malignant disease whilst only 2 had a benign condition (Figure 1).
Table 1. ABO donor recipient pairs in the study.
Of the 45 patients identified, 29 patients (65%) required FFP with a median of
3871 ml (Range: 750ml-10 900 ml) received per patient. Median antibody titres
were 1:64 (Range: 32-1024) before intervention and 1:32 (Range: 2-256) post
intervention. Eight of the 29 patients had reduction of antibody titres to ≤16 and
did not need PLEX. Amongst the other 21 patients, 11 went on to receive PLEX,
while 10 did not due to either patient or physician choice. No significant major
side effects from FFP infusion was noted in all patients though 5 patients (17%)
suffered minor infusion reactions such as urticaria. No episodes of immediate
hemolysis or disseminated intravascular thrombosis were seen in any of the
patients at the time of the graft infusions. Incidence of pure red cell aplasia was
4% (n=2).  There were no significant major side effects from FFP infusion,
though 5 patients (11%) suffered minor reaction like urticaria. There were no
episodes of immediate hemolysis or disseminated intravascular thrombosis
seen in any patient at the time of ABO-incompatible graft infusions. Incidence
of pure red cell aplasia was 4% (n=2). There were 11 early transplant deaths
(24%) and 2 suffered graft failure (4%).
Figure 1. Indications for tranplant.
Summary and Conclusions: Our findings suggest that that the use of donor-
type FFP was safe, and was able to reduce anti-donor issoagglutinins by one
fold dilution (from median 1:64 to 1:32). Interestingly, despite only 50% of
patients who were recommended to receive PLEX actually receiving it, there
did not appear to be an increase in severe infusional reactions, hemolysis or
PRCA incidence in the patients in our study. Our findings confirm the safety
and efficacy of donor-type FFP in reducing isoagglutinin titres, but also ques-
tion whether the threshold at which PLEX is recommended may be raised
especially with the current concomitant use of red cell depletion in the stem
cell products.
E1538
BONE MARROW EOSINOPHILIA CORRELATES WITH TREATMENT OUT-
COMES BOTH AFTER AUTOLOGOUS AND ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Y. Georgieva1,* Y. Petrov2, B. Spassov3, G. Balatzenko4, P. Ganeva2,
V. Madzharova1, G. Mihaylov3, G. Arnaudov2, M. Guenova1
1Laboratory Haematopathology & Immunology, 2Department of Transplantation
of Hematopoietic Stem Cells, 3Clinical Hematology, 4Laboratory of Cytogenetics
and Molecular Biology, National Specialised Hospital for Active Treatment of
Haematological Diseases, Sofia, Bulgaria
Background: Many studies have shown the beneficial influence of eosinophils
(Eo) in diverse neoplasms independent of other standard prognostic factors.
Besides, eosinophilia in the blood and tissue is a common feature of graft
versus host disease (GvHD) and contributes to the allogeneic response, as
revealed in investigations in animal models and clinical observations. Data from
a number of cohorts indicate that elevated Eo blood counts could be associated
with better outcomes following allogeneic hematopoietic stem cell transplant
(HSCT). However, whether the degree of bone marrow eosinophilia influences
transplant outcomes has not been established yet, neither the significance of
eosinophilia after autologous transplantation.
Aims: The aim of the study was to evaluate how the existence and degree of
peripheral blood (PB) and bone marrow (BM) eosinophilia after auto-HSCT
and allo-HSCT influenced transplant outcomes.
Methods: A total of 310 consecutive pts who received HSCT at the National
Hematology Hospital, Sofia were included in this retrospective study. Auto-
HSCT was performed in 246 pts, 148 male and 98 female, at a mean age of
48.5 years (ranging 19-67), while allogeneic-in 64 patients, 45 male and 19
female, including 35 from related and 29 from unrelated donors, at a mean age
of 37.4 years (20-59). PB and BM Eo were evaluated at day 100 and at a next
time point depending on the follow-up schedule. Eosinophilia was defined as
an Eo count >0.5x10(9)/L in PB and >3.5% in the BM. Information about the
following events was recorded: peripheral cell engraftment, acute (a)GvHD and
chronic (c)GvHD, viral reactivation, and deaths. Overall survival (OS) was
defined as the time from transplantation until death from any cause.
Results: A biphasic pattern of eosinophilia was noted after HSCT. The first
peak occurred prior to day 100 then the second one, beyond day 100. At day
100 PB eosinophilia was detected in 4.9% of all pts, while increased BM Eo
were seen in 27.7%, without any correlation between PB and BM counts, with
no significant difference between auto- and allo-HSCT and regardless of the
donor type. No differences in engraftment, viral reactivation, aGVHD or cGVHD
depending on Eo counts were established. At this time point PB eosinophilia
did not correlate with OS in neither groups, however increased BM Eo were
associated with better outcomes in the overall cohort of allo-transplanted pts
(100% vs 51% OS in pts with low Eo, and median not reached vs 24 months,
respectively; log rank p=0.001). Beyond day 100 PB eosinophilia was rarely
seen in only 2.3% of all pts, while BM Eo were increased in 33.8% regardless
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of the type of HSCT. Similarly, PB eosinophilia did not correlate with OS in nei-
ther groups of pts, however increased BM Eo were associated with longer OS
both in auto-transplanted (100% vs 85.7% OS in pts with low Eo, mean 72 vs
63 months, respectively; log rank p=0.03), and in allo-transplanted pts (94%
vs 61.5% OS in pts with low Eo, mean 41 vs 27 months, respectively; log rank
p=0.007) (Figure 1).
Figure 1. Overall survival curves for patients with and without BM
eosinophilia beyond day 100.
Summary and Conclusions: Better outcomes could be expected in patients
with BM eosinophilia regardless of the PB Eo counts and the type of trans-
plantation. Interestingly, based on the results common mechanisms might be
speculated in allogeneic and autollogous HSCT, however the pathophysiology
behind eosinophilia remains to be investigated. Further studies are also war-
ranted to elucidate the causative mechanisms behind the clinical benefits of
increased eosinophils.
E1539
AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) FOR MULTIPLE MYELOMA WITHOUT CRY-
OPRESERVATION OF STEM CELL,SINGLE CENTER EXPERIENCE
M. Ramzi1,* R. Vojdani1, M. Karimi1, M. Dehghani1
1hematology and medical oncology, shiraz university of medical sciences, shi-
raz, Iran
Background: Hematologic malignancy currently represents the main indication
for HSCT. Clearly, autologous and allogeneic HSCT are established therapies
in many of hematologic malignancies. High dose therapy (HDT) supported by
autologous HSCT are the preferred choice for lymphoproliferative disorders
and multiple myeloma. Several clinical trials have shown the superiority of high-
dose therapy (HDT) and autologous stem cell transplantation over conventional
dose therapy for patients with multiple myeloma.
Aims: There is limited experiences with noncryopereserved autologous trans-
plantation.In this report we will describe our experiences with this method.
Methods: During 10 years we treated 152 patients with multiple myeloma
(mean age=53 range: 31-70) with a conditioning regimen of Melphalan 140-
200 mg/m2. Patients were treated by intensive chemotherapy followed by rein-
fusion of non- cryopreserved autologous stem cells. The source of stem cell in
all patients was peripheral blood. All apheresis products were kept in a con-
ventional blood bank refrigerator at 4°C for 2 -3days before infusion.
Results: The median time of hospitalization was 19days (range: 16-37).The
median time to platelet count >20×109/L was 14 days (range: 10-35). Also, the
median time to absolute neutrophil count >0.5 × 109/L was 11 days (range: 9-
22). All the 152 patients were engrafted and there was not graft failure in this
study group. Responses (complete and partial response) were seen in all the
152 patients. Transplant-related mortality in this study group was 1.3%.
Summary and Conclusions: All patients in our study showed hematopoietic
engraftment after receiving the HDT and non-cryo preserved stem cell. Accord-
ing to our experiences and results we concluded HDT and autologous stem
cell transplantation without cryopreservation is effective and safe method which
simplifies the procedure and is feasible and cost saving in our patients with
diagnosis of multiple myeloma.
LB2095
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
CHILDREN WITH HEMOPHAGOCYTIC SYNDROME: SINGLE CENTER
EXPERIENCE 
G. Ozturk1,* A. Akcay1, F. Erbey1, D. Atay1
1Department of Pediatric Hematology- Oncology and Bone Marrow Transplan-
tation Unit, Acibadem Univercity Medical Faculty, Acibadem Atakent Hospital,
Istanbul, Turkey
Background: Hematopoietic stem cell transplantation (HSCT) is the only cur-
ative treatment for patients with primary hemophagocytic lymphohistiocytosis
(HLH) and for patients with secondary HLH who fail to respond to therapy. 
Aims: To observe the conditioning regimen, efficacy, side effects of HSCT
for HLH. 
Methods: We retrospectively reviewed children with HLH who received HSCT.
From April 2011 to February 2015, a total of 15 allo-HSCT in 14 cases (9 were
females) were evaluated including 13 cases with familial HLH and a case with
secondary HLH related otoimmun disease who fail to respond therapy. The
median age was 19 months (3 months-9 yr). Eight patients received HLA-
matched related HSCT, five received HLH-match unrelated HSCT and two
received unrelated cord blood transplantation with conditioning regimen of
etoposide, busulphan, cycphosphamid and ATG (ATG in 13 pts). Cyclosporine
(in 9 pts) or cyclosporin and methorexate (in 6 pts) were used for prevention
of graft versus host disease (GVHD). 
Results: The mean overall survival time was 11 months (1-46 months). Eleven
patients were successfully engrafted. Acute GVHD occurred in 5 cases, includ-
ing 3 cases with skin, a case with skin+liver, and a case with gastrointestinal
GvHD. Chronic GVHD (cGVHD) occurred in 3 cases. Hepatic veno-occlusive
disease were developed in 6 (40%) patients. Five cases died after allo-HSCT.
Three patients died (reactivation of disease=1, infection=1, other=1) before
day +100, and another 2 patients died (reactivation of disease=1, infection=1)
after day 100. In four HSCT, failed to engraft (a case developed recurrent HLH
and died from infection after a second HSCT). 
Summary and Conclusions: The allo-HSCT is successful in treating primary
and secondary HLH who refractory to therapy.
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POST TRANSPLANT ERYTHROCYTOSIS IN ELEVEN CASES
S.K. Toprak1,* G. Pekcan1, P. Ataca1, E. Atilla1, S. Civriz Bozdag1, M. Kurt Yuksel1,
P. Topcuoglu1, M. Ozcan1, G. Gurman1
1Hematology, Ankara University School of Medicine, Ankara, Turkey
Background: Post transplant erythrocytosis (PTE) is not an expected compli-
cation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Only Mahmood et al. reported PTE in 3 aplastic anemia cases in literature. 
Aims: We aim to present 11 PTE diagnosed as; 4 acute myeloblastic leukemia
(AML), 2 paroxysmal nocturnal hemoglobinuria (PNH), 1 myelodysplastic syn-
drome (MDS), 2 chronic myeloid leukemia (CML), 1 primary myelofibrosis
(PMF), 1 fanconi aplastic anemia patient. 
Methods: We retrospectively evaluated 11 PTE patients from 945 allo-HSCTs
in our center.
Results: Patients’ characteristics are shown in Table. All patients are male.
They have transplanted from full matched related donors except one patient
has 1 mismatch and received stem cells from unrelated donor. PMF and fanconi
aplastic anemia patients received stem cells from bone marrow, others trans-
planted by peripheral blood stem cells. 1 CML patient relapsed after allo-HSCT
but followed in remission with tyrosine kinase inhibitors. None of them had
either leukocytosis or thrombocytosis. All of the patients had hyperviscosity
symptoms with no organomegaly. Erythropoietin levels in the upper limit of nor-
mal in all patients. No JAK2V617F mutation positivity was detected. 2/11
patients had bronchiolitis obliterans (BO) and 5/11 diagnosed as chronic liver
Graft vs Host Disease (GVHD) during follow-up. None of them are smokers.
All patients received cyclosporine (CsA) for GVHD prophylaxis.
Table 1.
Summary and Conclusions: Liver GVHD, BO and cyclosporine could lead to
secondary erythrocytosis however there is no evidence for causality. All of our
patients were male which is a risk factor for erythrocytosis similar to hyperten-
sion and smoking. Remarkably, all of the patient except one had erythrocytosis
a year after allo-HSCT. Further surveillance of the cases will improve our knowl-
edge over erythrocytosis.
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IMMUNOPHENOTYPIC CHARACTERIZATION OF HUMAN MOBILIZED
HEMATOPOIETIC STEM AND PROGENITOR CELLS: BIOLOGICAL AND
CLINICAL IMPLICATIONS
V. Giai1,* E. Saraci1, E. Marzanati1, C. Scharenberg2, P. Omedè1, E. Hellström-
Lindberg2, A. Palumbo1, B. Bruno1, M. Boccadoro1, D. Ferrero1
1Hematology Division, University of Torino, Torino, Italy, 2Center for Hematology
and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
Background: In the last years, peripheral hematopoietic stem and progenitor cells
(HSPC) have been widely used for transplantation procedures, instead of bone
marrow HSPC. The advantages consist in a quicker hematological and immuno-
logical reconstitution and in a reduced morbidity and mortality. Unfortunately, very
few is known about the proportions of HSPC in the peripheral CD34+ cells. 
Aims: In the present study, we intend to investigate the composition of circu-
lating HSPC subpopulations and analyze whether the differences in the number
of re-infused precursors could influence the hematopoietic engraftment after
an hematopoietic stem cell transplantation. 
Methods: Multicolor flowcytometry was run to examine 9 base-line peripheral
blood (PB) samples and 5 bone marrow (BM) samples from healthy donors
and 33 mobilized peripheral blood (mPB) samples from hematological patients
prior CD34+ cells harvesting.
Results: Common myeloid progenitors (CMP) showed a higher ratio in PB com-
pared to BM (47.8%±9.5 versus 27.6%±9.5) while granulocyte-macrophage pro-
genitors (GMP) were lower in PB compared to BM (10.3%±6.9 versus
23.8%±7.2). Progenitors fractions were equally distributed in BM (27.6%±9.5 for
CMP, 23.8%±7.2 for GMP and 27.6%±16.2 for megakaryocyte-erythroid progen-
itors -MEP). No significant differences were noticed between PB and BM
hematopoietic stem cells (HSC) (1.54±1.22 in PB versus 2.11±0.69 in BM) (Fig-
ure1a). Comparing base-line PB and mPB, no significant differences were shown
between the subpopulations (Figure1b). Among mPB samples, cyclophos-
phamide chemotherapy mobilized a higher ratio of CMP (61.1%±12.05) and a
lower percentage of GMP (11.09%±4.74) unlike patients who had received other
drugs (CMP 49.06%±14.12 and GMP 27.59%±10.92). No differences were found
in HSC proportions (Figure1c). In the two patients mobilized with the anti-CXCR4
Plerixafor instead of C-GSF only, more elevated proportions of GMP were
released: 37.8% in patient#1 and 33.8% in patient#2 compared to the average
16.31% of the “G-CSF only” mobilized samples (Figure1d). In the analysis of
CXCR4 expression among the subpopulations, we observed a significant higher
mean fluorescence intensity of this marker on GMP (Figure1e). Furthermore, a
strong correlation between the number of total peripheral CD34+ cells and mobi-
lized CMP, GMP and MEP was shown (Figure1f); no correlation was displayed
with mobilized HSC. White blood cells (WBC) count exhibited significant corre-
lation with the number of mobilized HSC (Figure1g), but not with CMP/GMP/MEP.
The next step was to detect possible relationships between the number of re-
infused progenitors or HSC and the hematological recovery in patients receiving
an auto-transplantation conditioned by high dose chemotherapy. A tendency to
inverse correlation was shown between the number of re-infused progenitors
and the days of aplasia (Figure1h-1m), as well as between the number of re-
infused CMP and MEP and platelet levels during aplasia time (Figure1o-1q).
Figure 1.
Summary and Conclusions: With these data, we confirmed the heterogeneity
of HSPC composition between PB and BM; chemo and mobilization regimens
can strongly influence the proportions of mobilized HSPC. Furthermore, the
number and type of re-infused progenitor could effect the engraftment kinetic
and the hematological recovery. Further studies on mobilized HSPC and the
correlation with clinical data will provide new sensitive tools for improving the
outcomes of hematopoietic stem cell transplantation. 
E1541
EXPRESSION OF TH17/TREGS AXIS ASSOCIATED REGULATORY FAC-
TORS IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE
Q. Liu1,* L. Xuan1, X. Wu2, L. Gao1, X. Wang2, Y. Li2
1Department of Hematology, Nanfang Hospital, Southern Medical University,
2Institute of Hematology, Medical College, Jinan University, Guangzhou, China
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is one of the most valid methods for the treatment of malignant hematological
diseases. Graft-versus-host disease (GVHD)which remains the main compli-
cation after allo-HSCT leads to the high transplant-related mortality. GVHD
occurs as a result of T cell activation. Acute GVHD (aGVHD) is suggested to
be predominantly related to T helper 1 (Th1) responses. Recent investigations
have discovered the possible role of Th17 cells and regulatory T cells (Tregs)
in the development of aGVHD. Th17 cells are found to have a direct role in the
development of aGVHD, and adoptive transfer of in vitro-differentiated Th17
cells is capable of inducing lethal aGVHD. Clinical and experimental studies
have suggested that Tregs could prevent and treat aGVHD, while preserve
graft-versus-tumor activity. However, the controls of Th17/Tregs axis on the
occurrence and development of aGVHD are not fully understood.
Aims: To investigate the expression levels and clinical significance of
Th17/Tregs axis associated regulatory factors in patients with aGVHD.
Methods: The expression levels of Th17/Tregs axis associated regulatory fac-
tors (IL-17A, IL-23R, RORc, STAT-1, STAT-3, Foxp3, CD25, CTLA-4, GITR and
TLR8) were analyzed in peripheral blood from 20 patients with aGVHD at the
following two time points (at the onset of aGVHD and two weeks after the treat-
ment), using real-time reverse transcription polymerase chain reaction with
SYBR Green I staining. Fifteen patients responded effectively to the treatment
within two weeks, and 5 did not respond within two weeks. Twenty healthy
donors were selected for the control. The β2-microglobulin gene was used as
an endogenous reference, and the relative mRNA expression level of each
gene was evaluated by the 2-ΔCt×100% method.
Results: The expression levels of RORc, STAT-1 and STAT-3 genes in the
untreated patients with aGVHD were significantly higher than that in the healthy
donors (P<0.001, P<0.001 and P<0.001), while the expression levels of IL-17A
and IL-23R genes were similar between the untreated patients with aGVHD and
the healthy donors (P=0.147, P=0.190). The expression levels of GITR and TLR8
genes in the untreated patients with aGVHD were also significantly higher than
that in the healthy donors (P=0.003, P<0.001). The expression levels of Foxp3,
CD25 and CTLA-4 genes were similar between the untreated aGVHD patients
and the healthy donors (P=0.298, P=0.934 and P=908). The expression level of
TLR8 gene in the patients with aGVHD was significantly decreased after effective
treatment (P=0.035). The expression levels of IL-17A, IL-23R, RORc, STAT-1,
STAT-3, Foxp3, CD25, CTLA-4 and GITR genes in untreated patients with
aGVHD had no significant change after effective treatment (P=0.778, P=0.875,
P=0.730, P=0.177, P=0.925, P=0.397, P=0.778, P=0.470 and P=0.638). The
expression level of Foxp3 gene was significantly decreased after ineffective treat-
ment (P=0.043). The expression levels of IL-17A, IL-23R, RORc, STAT-1, STAT-
3, CD25, CTLA-4, GITR and TLR8 genes were similar in patients at aGVHD
onset and after ineffective treatment (P=0.686, P=0.500, P=0.686, P=0.345,
P=0.225, P=0.345, P=0.345, P=0.893 and P=0.345).
Summary and Conclusions: Th17/Tregs axis associated regulatory factors
might influence in the occurrence and development of aGVHD
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MECHANISMS OF FATAL CARDIOTOXICITY FOLLOWING HIGH-DOSE
CYCLOPHOSPHAMIDE THERAPY AND A METHOD FOR ITS PREVENTION
T. Nishikawa1,* E. Miyahara1, K. Kurauchi1, E. Watanabe2, Y. Okamoto1,
Y. Kawano1
1Pediatrics, 2Clinical Pharmacy and Pharmacology, Graduate School of Medical
and Dental Sciences, Kagoshima University, Kagoshima, Japan
Background: High-dose cyclophosphamide (CY) is a mainstay in most condi-
tioning regimens for hematopoietic stem cell transplantation. Recently, admin-
istration of posttransplantation of CY in high doses has been attracting attention
as novel strategy for preventing graft-versus-host disease. CY is activated by
the hepatic cytochrome P-450 (CYP) enzyme system to form 4-hydroxy-
cyclophosphamide (HCY), which is in equilibrium with aldocyclophosphamide
(AldoCY). AldoCY decomposes to form cytotoxic phosphoramide mustard and
the byproduct acrolein. Alternatively, aldoCY is oxidized to the inactive metabo-
lite o-carboxyethylphosphoramide mustard (CEPM) by aldehyde dehydroge-
nase1 (ALDH1). The dose-limiting toxic effect of CY, observed only after admin-
istration of high doses, is cardiotoxicity.
Aims: Since the mechanism underlying this phenomenon has not yet been
elucidated, and no definitive risk factors have yet been identified, we investi-
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gated the cardiotoxic mechanisms of high-dose CY. To determine preliminary
mechanisms that may prevent the occurrence of CY-induced cytotoxicity in
H9c2 embryonic rat cardiomyocytes cell line, we also evaluated the protective
effects of potential cardioprotectant agents.
Methods: A rat cardiac myocardial cell line, H9C2, was exposed to CY metab-
olized by S9 fraction of rat liver homogenate mixed with co-factors (CYS9).
The degree of cytotoxicity was then evaluated by MTT assay, LDH release,
production of reactive oxygen species (ROS), and incidence of apoptosis. We
also investigated how the myocardial cellular effects of CYS9 were modified
by antioxidant N-acetylcysteine (NAC), isorhamnetin (ISO), and β-ionone (BIO)
a CYP inhibitor. Quantifying CY and CY metabolites, using LC/MS/MS, we
assayed culture supernatants of CYS9 with or without potential cardioprotectant
agents (PCA). In addition, we observed the cytotoxicity of CYS9 and the pro-
tective effects of PCA using a live-cell imaging system.
Results: Assay results for MTT showed that treatment with CY (125-500 μM)
did not induce cytotoxicity. CYS9, however, exhibited myocardial cytotoxicity
when CY concentration was 250 μM or more. After 250 μM of CY was metabo-
lized in S9 mix for 2 h, the concentration of HCY was 18±4, CEPM 27±5 μM, and
acrolein 31±1 μM. NAC, ISO, and BIO all inhibited CYS9-induced cytotoxicity.
When treated with ISO or BIO, metabolism of CY was significantly inhibited. Pre-
treatment with NAC, however, did not inhibit the metabolism of CY. Compared to
control samples, we observed no difference in HCY, a significant increase of
CEPM, and a significant decrease of acrolein. Furthermore, NAC pre-treatment
did not affect intracellular ROS levels produced by CYS9. Live-cell imaging also
confirmed that CYS9 induced acute cytotoxicity, which was inhibited by NAC.
Summary and Conclusions: We ascertained that, when metabolized in vitro
by S9, CY would produce similar levels of metabolic substance concentrations
as in vivo. When H9C2 was pre-treated with NAC, ISO, and BIO, each inhibited
cell damage by CYS9. When treated with ISO and BIO, we observed that CY
metabolism itself was inhibited. This result suggests that cardiac cell damage
may depend on individual differences in CY metabolic capacity. As preventative
drugs, however, both BIO and ISO seem likely to interfere with antitumor effects
and are thought to be unsuitable. Pre-treatment with NAC did not inhibit CY
metabolism: compared to control samples, while HCY concentration was sim-
ilar, CEPM concentration statistically significantly increased. Less acrolein,
however, was present after exposure to NAC. The increase in CEPM suggests
that scavenging of acrolein by NAC prevents inhibition of ALDH1. Consequent-
ly, through a mechanism related to its ability to inhibit acrolein, NAC may atten-
uate cardiotoxicity associated with high-dose CY.
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SCA1+ MESENCHYMAL STROMAL CELLS INHIBIT GRAFT-VERSUS-
HOST DISEASE IN MICE AFTER BONE MARROW TRANSPLANTATION
F. Wen1,* H.-J. Zhang1, W. Yin1, X. Hu1
1Department of Transfusion Medicine,xijing Hospital, the Fourth Military Medical
University,xi’an, China
Background: Mesenchymal stromal cells (MSCs) have therapeutic potential
for the prevention and treatment of graft-versus-host disease (GVHD). Although
the treatment of GVHD using MSCs has been studied in phase I/II and phase
III clinical trials, the results of clinical trials seem contradictory. MSCs comprise
several subpopulations, which have not been individually assessed for their
role in GVHD suppression. However, previously conducted pre-clinical exper-
iments or clinical trials for investigating the effects of MSCs on GVHD have
predominantly used MSCs mixtures. We speculate that the heterogeneity of
MSCs mixtures may be responsible for the contradictory outcomes of previous
studies. Some MSCs subpopulations may be immunosuppressive, whereas
others may be immune stimulatory. Therefore, it is necessary to explore the
therapeutic effects of MSCs subpopulations which remain unknown. Sca1 is a
marker expressed by hematopoietic progenitors and stem cells. Hu et al. pre-
viously identified bone-associated CD45-Ter119-CD31-Sca1+ cells as a com-
mon progenitor of niche mesenchymal cells in adults. Thus, Sca1 is also a cell
marker that is expressed by a primitive subpopulation of adult MSCs.
Aims: In this study, we aimed to assess the immunosuppressive effect of bone-
associated Sca1+ MSCs on acute GVHD (aGVHD) and elucidate the related
mechanisms in a MHC-mismatched mouse model of allogeneic hematopoietic
stem cell transplantation (HCT). 
Methods: The clinical manifestation of aGVHD was evaluated by the loss of
body weight, diarrhea, clinical scores, survival period and pathological changes
of target organs. The infiltration of T cells and the expression of CD80/86 in
target organs were analyzed by flow cytometry. The expression of CTLA-4 in
splenocytes was tested by Real-time PCR. 
Results: Our results showed that: (1) Non-cultured Sca1+ MSCs decreased the
severity of aGVHD and prolonged the survival period of allogeneic HCT recipients;
(2) The effect of Sca1+ MSCs on aGVHD was slightly better than that of MSCs
mixture, but not in a statistically significant way; (3) Infusion of Sca1+ MSCs
reduced donor T cell infiltration into GVHD target organs; (4) The expression of
CD80 and CD86 on splenic dendritic cells was decreased in Sca1+ MSCs injected
recipients; (5) The expression of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a
negative regulator of T cells, was elevated in the recipient splenocytes. 
Summary and Conclusions: Bone-associated Sca1+ MSCs subpopulation
suppressed GVHD and should be considered as a potential strategic treatment
of aGVHD.
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IN VITRO EXPANDED HUMAN CD4+CD25+FOXP3+ REGULATORY T
CELLS IN NUTRIENT-DEPRIVED MEDIUM AS A POTENTIAL ARMAMENT
IN THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE
T.-J. Chiou1,* T.-H. Chu1, S.-T. Chu2, W.-F. Tzeng3
1Division of Transfusion Medicine, Department of Medicine, Taipei Veterans
General Hospital and National Yang-Ming University School of Medicine, 2Insti-
tute of Biochemstry, National Taiwan Univeristy, Taipei, 3Department of Life
Science, Fu-Jen University, New Taipei City, Taiwan, ROC
Background: Allogeneic haematopoietic stem cell transplantation (HSCT) has
been used to treat some of haematological malignancies and inherited or
acquired non-malignant diseases. Unfortunately, graft-versus-host disease
(GVDH) occurred approximately 15% in transplant recipients and decreases
the success of allogeneic HSCT. At present, no effective treatment can com-
pletely prevent the GVHD from allogeneic HSCT patients. CD4+CD25+FoxP3+
regulatory T cells (Tregs) have been shown to be important in maintaining
immune homeostasis and preventing autoimmunity. However, 5% to 10% Tregs
could be measured in human CD4+ T cells and few Tregs would convert to
conventional activated T cells because of losing FoxP3 expression. It had been
reported to correlate with the occurrence and severity of GVHD in some study.
Aims: In order to study the potential use CD4+CD25+FoxP3+ Tregs for the
prevention of GVHD, we attempt to evaluate the better efficient method to
increase the number of induced Treg cells (iTregs) in the donor’s PB and sta-
bilize the FoxP3 in iTreg cells.
Methods: PBMC were prepared from blood of healthy donors by Ficoll-
Hypaque density gradient centrifugation. T cells were isolated by negative
selection. CD4+ cells were harvested, and then activated with anti-CD3/CD28
beads in the presence of IL-2, TGF-β and retinoic acid (RA) containing
RPMI1640 medium. During the Tregs induction, the activated T cells were per-
formed under low nutrient supplement (5% FBS) for three days then refreshed
the cells into the full nutrient supplement (10% FBS) for another four days. The
harvested cells were analyzed by flow cytometry method with fluorescence-
conjugated CD-antibodies, including CD4, CD25, CD127 and FoxP3. The pro-
tocol was shown in Figure 1A.
Figure 1.
Results: Our data showed that FoxP3+Tregs in PBMC were increased from
3.5% to 30% under IL-2 (20U/ml) and TGF-β (0.5ng/ml) containing medium,
after T cell activation. Most importantly, the number of FoxP3+Treg cells was
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increased from 30% to 50% with the 3-day-nutrient deprivation in advance,
comparing with the full nutrient supplement for 7 days. The addition of retinoic
acid (1mM) stabilized the FoxP3+ Tregs during this incubation period. Besides,
FoxP3+ and CD127 - shown in Figure 1B, the combination of RA and TGF-β
increased the functional iTreg cells to >70% (from 30% to 75% in this repre-
sentative data). Finally, activated T cells differentiated to FoxP3+ Treg cells
and stabilized by RA significantly, under this particular treatment.
Summary and Conclusions: Our study showed that the combination of IL-2,
TGF-β and RA in 3-day-nutrient-deprived medium could induce naïve
CD4+CD25+ cells to express and stabilize FoxP3 markedly. Further, we will
develop the iTreg suppression assay to clarify the biological function of iTregs
in vitro. GVHD mouse model will be established by using allogeneic HSCT to
verify iTreg’s function in vivo, too.
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PROGNOSTIC SIGNIFICANCE OF IMMUNOLOGIC RECOVERY AFTER
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IN PATIENTS WITH LYMPHOMAS
M. Cioch1,* A. Goracy1, D. Jawniak1, J. Manko1, M. Wach1, E. Wasik-
Szczepanek1, M. Hus1
1Department of Haematooncology and Bone Marrow Transplantation, Medical
University in Lublin, Lublin, Poland
Background: Autologous peripheral blood stem cell transplantation (APBCST)
is now established therapy for patients (pts) with refractory and relapsed lym-
phomas (Hodgkin lymphoma-HL and non-Hodgkin’s lymphoma-NHL). A lot of
factors influence on post transplant outcome: performance status, activity of
disease at time of APBSCT and chemosensitivity to salvage therapy. 
Aims: The aim of our study was the analysis of immunologic recovery after
APBSCT as another important factor with prognostic significance. 
Methods: A total 28 consecutive pts with lymphomas (16 with NHL and 12 with
HL) at Department of Haematooncology and Bone Marrow Transplantation at
Medical University of Lublin were recruited to this study. In NHL group there
were 5 female and 11 male (median age 50.5) and in HL group there were 7
female and 5 male (median age 27.5). The day before myeloablative regimen
blood samples for flow cytometry analysis were taken. In the transplantation
procedure pts were received BEAM (27 pts) or CBV (1 pt) regimen. Next blood
samples were taken at 30 and 100 day after transplantation procedure. At 100
day after APBSCT pts underwent clinical evaluation with CT or PET to establish
activity of disease (Complete Remission-CR or not Complete Remission-nCR). 
Results: Analysis of flow cytometry results compared with disease activity
showed at 100 day after APBSCT: higher level of T helper cells (CD3+CD4+;
CD3+CD4+CD45RO+; CD4+CD25high) in pts with CR compared with nCR
(p=0.0069; p=0.0025, p=0.0095); higher level of dendritic cells (BDCA1+CD19-
) in pts with CR compared with nCR (p=0.017), and higher level of T regulatory
cells (Foxp3+CD4+CD25high in pts with CR compared with nCR (p=0.0095).
Summary and Conclusions: Our analysis of immunologic recovery after APB-
SCT showed that CR status in pts with lymphomas is associated with higher
level of T helper cells, dendritic cells and T regulatory cells. Such ascertain-
ments encourages to searching new methods of immune reconstitution accel-
eration and enrichment of transplant source with those cells. 
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COMPARISON BETWEEN HEALTHY DONOR-DERIVED BONE MARROW
MESENCHYMAL STEM CELLS BM-MSCS AND HUMAN DERMAL FIBROB-
LASTS: IMPACT ON CLINICAL APPLICATIONS OF HMSCS
M. Al Bagami1,2,* H. Ouled Haddou1,2, I. Marcq1, V. Debuysscher1, C. Ossart2,
A. Regnier 2, J.-P. Marolleau1,2, H. Bouhlal1,2
1EA 4666, Lymphocyte Normal/Pathologique et Cancers Curs, CHU Sud, 2Ser-
vice Hématologie clinique-Thérapie cellulaire, CHU Sud, Amiens, France
Background: The results of clinical applications of human Mesenchymal Stem
Cells (hMSCs) depend on clinical and biological factors. The quality of stem cell
culture will affect success rate. Stem cell culture contamination by fibroblasts can
be happened. The identification of the differences between these two cell types
plays an important role to improve the quality of the therapeutic uses of hMSCs. 
Aims: Our present work is the first work to compare the phenotype and func-
tional properties of primary human Dermal fibroblasts HDF to hMSC from Bone
Marrow BM to reflect the impact of the possible contamination of bone morrow
derived hMSC (BM-hMSC) by fibroblasts.
Methods: In this study, hMSCs were obtained from the BM of (Healthy donor,
n=5) and compared to primary HDF. The following parameters were used for this
comparison: cell morphology, cell proliferation tests, cell cycle, immunophenotype,
pluripotent and differentiation capacity into osteoblastic and adipogenic lineages.
Genes expression profile was determined in BM-MSCs and HDF by Q-PCR.
Results: Our results show that both of BM-hMSCs and HDF cells have homoge-
nous fusiform, fibroblast-like appearance. Human derived fibroblasts showed, sig-
nificantly (p<0.001), high proliferative ability than hMSCs, which induces a short-
ening of doubling time (27.3-/+3h vs 44.5-/+ 8h for HDF and BM-MSCs, respec-
tively; p<0,0001). The analysis of cell cycle show that HDF cultures contained,
significantly p<0.001, two-fold higher cell number at synthesis stage (S) than in
BM-hMSC cultures. Both cell types share the same immunophenotypic feature
for these surfaces markers CD45(-), HLA-DR(-), CD73(+), CD90(+), CD105(+),
and CD166(+) but CD146 and CD10 were differently expressed on BM MSCs vs
HDF. Both of cell types have a potential to differentiate into osteoblastic and adi-
pogenic lineages showed by specific stains.This result was confirmed by the
expression levels of Runx2, PAL and Osterix (osteoblasts); and PPAR-γ2
(adipocytes). However, expression of these genes in osteoblasts and adipocytes
derived from HDF remains, significantly p<0.05, two times lower than the expres-
sion in osteoblasts and adipocytes obtained in BM-MSCs differenced cells.
Summary and Conclusions: Our results confirm the similarities of morphology
and phenotype of both HDF and BM-MSCs. The differentiation potential of BM-
MSCs can not be used to distinguish between HDF and BM-MSCs as we
showed that HDF could differentiate into other cell types as osteoblasts and
adipocytes. The genes expression profile in osteoblasts and adipocytes derived
from BM-MSCs and HDF can be used to distinguish between these tow cell
types as we found the genes expression in osteoblasts and adipocytes derived
from HDF were significantly lower than in BM-hMSCs. These results may
explain the unexpected results of hMSCs in therapeutic applications. In this
current study, new marker was identified to discriminate HDF from BM-hMSCs
in order to improve the quality of the therapeutic uses of hMSCs. 
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COMPARISON OF RED BLOOD CELL AND PLASMA DEPLETION EFFI-
CIENCIES OF TWO METHODS FROM CORD BLOOD: AUTOMATED SEPAX
(BIOSAFE) AND MANUAL CELLEFFIC (KANEKA)
P. Yurdakul1,* E.B. Gencer1, H.Y. Akin1, N. Sato2, C. Fricke3, M. Beksac1,4
1Cord Blood Bank, Ankara University Faculty of Medicine, Ankara, Turkey,
2Kaneka Corporation-Japan, Osaka, Japan, 3Kaneka Pharma Europe German
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Background: Volume reduction is a routine procedure in cord blood (CB) bank-
ing. Two major automated systems have been in use for depletion of excess
plasma and red blood cells (RBC) from CB, the most commonly used SEPAX
(Biosafe) and AutoXpress Platform (Thermogenesis) systems. Both automated
systems were proven to be efficient post processing, yielding high Total Nucle-
ated Cell (TNC) recovery rates as well as viabilities. Nonwoven matrices are
being used clinically as filters and scaffolds owing to their ability to trap cells. A
novel filtration system was described by KANEKA Corporation (Japan) for pro-
cessing of CB. This filtration system uses a nonchemical- coated/nonwoven
polyester fabric filter, which traps CD34+ cells through affinity without the need
of centrifugation or potentially toxic chemicals.
Aims: To compare Red Blood Cell and Plasma Depletion Efficiencies of Two
Methods from Cord Blood: Automated SEPAX (Biosafe) and Manual Celleffic
(Kaneka).
Methods: Twenty one CB units collected in utero from consented maternal
donors were included in the study. CBU plasma and red cell depletion was per-
formed either with only Celleffic or with both Sepax/Celleffic systems. CBUs
with below criteria were accepted: 1. CBUs with collection volumes of ≥40 mL
and ≤100 mL (with CPD) were chosen for Celleffic only group and CBUs with
collection volumes >100 mL were chosen for Sepax vs Celleffic comparison
group and processed as follows: CBU was split equally in half and after asses-
ment of pre TNC and pre CD34+ cell counts for each split bag, half of the initial
CBU was processed with automated SEPAX (Biosafe) and the other half with
Celleffic (Kaneka) 2. All CBUs and maternal donors were negative for infectious
disease markers 3. CBUs were processed within 48 hrs after collection. Post
process TNC, CD34+ cell, mononuclear cells (MNC), RBC and neutrophil recov-
ery rates as well as viability were assessed for all groups and compared for the
split CBUs. The comparative results of two processing methods were analysed
statistically using Student’s T-test.
Results: CBU with collection volumes ≤100 mL (n=12) were processed only with
Celleffic whereas CBU with collection volumes >100 mL (n=9) were processed
in both systems. There were no significant differences for any of the pre-process-
ing values of the parameters analyzed between two groups (Celleffic only and
Celleffic vs Sepax). Figure 1 indicates depletion and recovery results of variables
after processing with only Celleffic. Figure 2 denotes the comparison between
these two systems for the same five parameters. Celleffic was favorable in terms
of RBC depletion rates (p=0.008) while Sepax was found to be superior for post
TNC and MNC recovery rates (p=0.008 and p=0.015, respectively). There were
no significant differences between two systems regarding CD34+ hematopoietic
stem cell (HSC) recovery and NRBC cell depletion rates (p=0.674 and p=0.236,
respectively). Post processing TNC viability after Celleffic was slightly higher than
after Sepax (96% and 94%, respectively; p=0.017).
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Figure 1. Mean and SD values in percentages of cell recovery (TNC, HSC,
MNC, Neutrophil) or red blood cell depletion.
Figure 2. Comparison of two systems in terms of recovery or depletion.
Summary and Conclusions: The filtration method developed by Kaneka is
claimed to be simple, cost-effective, and nontoxic without requiring costly equip-
ment mostly suitable for developing laboratories with an average turn over
rate. This small sized prospective parallel study shows that both methods are
comparable in terms of HSC recovery. The Cellefic system has a higher red
cell depletion capacity whereas Sepax was more effective for TNC/MNC recov-
ery. Colony forming potential as well as post thaw viability/recovery rates of
both systems are currently being analyzed.
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THE EFFECTS OF -ADRENERGIC AGONIST OF ISOPROTERENOL ON
MIR-886-3P AND MIR-23A EXPRESSION IN HUMAN MESENCHYMAL
STEM CELLS
S. Kaviani1,* H. Zamani1, A. Atashi1, F. Parhizkar1
1Hematology, Tarbiate Modares University, School of Medical Sciences, Tehran,
Iran
Background: Mobilization of Hematopoietic Stem Cells (HSCs) for transplan-
tation and the importance of -adrenergic signals in induction of this process,
have been well investigated. However, little is known about the role of -adren-
ergic signals in mobilization of HSCs and factors influenced by these signals.
The chemokine Stromal Derived Factor 1 (SDF-1) which is expressed by
human bone marrow-derived mesenchymal stem cells (hMSCs), has a key
role in mobilization of HSCs and miR-886-3p and miR-23a can regulate the
expression of this chemokine. 
Aims: In this study, To investigate the role of miR-886-3p and miR-23a in mobi-
lization process, The expression of both miRNAs were evaluated in hMSCs
treated by Isoproterenol (a -adrenergic agonist).
Methods: In this study, hMSCs were isolated and cultured from human bone
marrow. After doing flowcytometric analysis, the cells were treated with 100 M
Isoproterenol. Total RNA was extracted at 12 and 48 hours post treatment, and
also from untreated hMSCs as a control. Then miR-886-3p and miR-23a
expression levels were quantified by quantitative Reverse Transcriptase PCR.
Results: The expression level of miR-886-3p was increased significantly at 12
and 48 hours post treatment (P<0.05). In addition, the expression level of miR-
23a was decreased at 12 hours post treatment and increased significantly at
48 hours post treatment (P<0.05).
Summary and Conclusions: Isoproterenol induces miR-886-3p in hMSCs.
miR-23a is firstly decreased and then increased by treating with Isoproterenol.
So both miRNAs can contribute in mobilization process.
Thrombosis and vascular biology
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SOLUBLE FMS-LIKE TYROSINE KINASE-1 IN CHILDREN AND ADOLES-
CENTS WITH THALASSEMIA INTERMEDIA: RELATION TO PULMONARY
VASCULOPATHY AND SUBCLINICAL ATHEROSCLEROSIS
A. Tantawy1,* A.A. Adly1, E. Ismail2, O. Yousef3, M. Ali1
1Pediatrics, 2Clinical Pathology, 3Cardiac, Ain Shams University, Cairo, Egypt
Background: The study of vascular biomarkers has greatly enhanced our
understanding of the underlying pathophysiology of atherosclerosis including
soluble biomarkers and physiological parameters such as measures of arterial
stiffness and endothelial function. The hypercoagulability in TI has been attrib-
uted to several factors, including a procoagulant activity of hemolyzed circulat-
ing red blood cells, increased platelet activation, coagulation factor defects,
depletion of antithrombotic factors, and endothelial inflammation. Iron-mediated
endothelial dysfunction may be mediated either directly through the inactivation
of endothelium-derived nitric oxide (NO) or indirectly through the promotion of
reactive oxygen species formation. Soluble fms-like tyrosine kinase-1 (sFLT-
1) is a member of the vascular endothelial growth factor receptor (VEGFR)
family. By adhering to and inhibiting VEGF and placenta growth factor, it
induces endothelial dysfunction.
Aims: We assessed the level of sFLT-1 in children and adolescents with TI,
correlating it with markers of hemolysis and iron overload as well as cardio-
vascular complications.
Methods: Thirty-five patients were studied stressing on history of cardiac dis-
ease, splenectomy, transfusion history and chelation/hydroxyurea therapy and
serum ferritin. sFLT-1 levels were measured by enzyme linked immunosorbent
assay. Ehocardiography and measurement of carotid intima media thickness
(CIMT) were done for all subjects.
Results: TI patients had significantly higher Tricuspid Regurgitation Velocity
(TRV) with lower ejection fraction and fractional shortening than controls
(p<0.001). CIMT was significantly increased among patients compared with
control group (0.43±0.02 mm versus 0.36±0.02 mm; p<0.001). sFLT-1 was
significantly higher in TI patients compared to control group (median [IQR],
110 [80-155] pg/mL versus 70 [60-90] pg/mL; p<0.001). Splenectomized
patients as well as those who had pulmonary hypertension had higher sFLT-
1 levels than those without (p<0.001). Hydroxyurea-treated patients had lower
sFLT-1 levels than untreated patients. Significant positive relations were
observed between sFLT-1 and indirect bilirubin (r=0.357, p=0.035) as well
as serum ferritin (r=0.879, p<0.001) while levels were negatively correlated
with hemoglobin (r=-0.398, p=0.018). TRV and CIMT were positively corre-
lated with sFLT-1 levels (p<0.001). ROC curve analysis revealed that the cut-
off value of of sFLT-1 at 110 pg/mL could differentiate patients with and with-
out pulmonary hypertension with a sensitivity of 86.96% and specificity of
100%, AUC 0.944; p<0.001.
Summary and Conclusions: Measurement of sFLT-1 as a marker of vascular
dysfunction in β-TI may provide utility for early identification of patients at
increased risk of pulmonary and cardiovascular complications. The relation
between sFLT-1 and CIMT provides a link between endothelial dysfunction
and subclinical atherosclerosis.
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ASSOCIATION OF THE DYNAMIC STATUS OF COAGULATION FACTORS
WITH L-ASPARAGINASE ADMINISTRATION IN THE INDUCTION PHASE
OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLAS-
TIC LYMPHOMA
Y. Kubota1,* Y. Ikeda1, C. Oyama1, T. Aoki1, K. Isobe1, M. Mori1, Y. Arakawa1,
R. Hanada1, K. Koh1
1Department of Hematology/Oncology, Saitama Children’s Medical Center,
Saitama, Japan
Background: Although L-asparaginase (L-asp) is one of the most important
medication used in pediatric acute lymphoblastic leukemia (ALL) and lym-
phoblastic lymphoma (LBL) treatment, it has been associated with several
adverse effects, including thrombosis. Thrombosis is caused by multiple factors,
including prothrombic properties of tumor cells, genetic factors, indwelling cen-
tral venous catheters, corticosteroids, and L-asp. L-asp plays a major role in
thrombosis because it reduces the synthesis of hemostatic factors in the liver.
The timing of thrombosis is generally late in the induction phase; however, little
is known regarding the dynamic status of hemostatic factors.
Aims: This study was conducted to analyze the dynamic status of hemostatic
factor levels in the induction phase of ALL treatment, including L-asp and to
determine the association between L-asp and thrombosis.
Methods: We retrospectively analyzed 69 pediatric patients (61 with ALL and
eight with LBL) who received Berlin-Frankfurt-Munster chemotherapy at a sin-
gle institution between October 2009 and November 2014. All patients received
an intramuscular injection of Escherichia coli-derived L-asp (5000 U/m2/injec-
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tion) on days 12, 15, 18, 21, 24, 27, 30, and 33. One patient had cerebral
venous thrombosis. Hemostatic factors analyzed in this study included fibrino-
gen (Fib), alpha-2-plasmin inhibitor (α2-PI), antithrombin-III (AT-III), plasminogen
(PLG), and platelets (Plt). Although platelets are not an L-asp dependent factor,
their levels were analyzed because of their association with hemostasis. We
analyzed the levels of each hemostatic factor at time point (TP)1 (at diagnosis),
TP2 (day 12, before the initial L-asp administration), TP3 (day 22, after the
fourth L-asp administration), and TP4 (after protocol Ia). Additionally, we ana-
lyzed the periods required by each hemostatic factor level to decrease below
the normal range and to recover to the normal range following the initial L-asp
administration; this is defined the period analysis. All data were analyzed by
one way analysis of variance.
Results: In TP1, Plt decreased below the normal range because of the myelo-
suppression of tumor burden. Fib increased above the normal range because
of the proinflammatory effects of tumors, while other factors were in the normal
range. In TP2, Plt levels remained suppressed, Fib decreased below the normal
range, and AT-III increased above the normal range, while α2-PI and PLG were
in the normal range. In TP3, the levels of all factors decreased. In TP4, Plt and
Fib levels recovered to the normal range, while AT-III, PLG, and α2-PI were
below the normal range. Our period analysis showed the following results:
median periods for each hemostatic factor that decreased below the normal
range were as follows: Plt, 0 days; Fib, 0 days; α2-PI, 3 days; AT-III, 5 days;
and PLG, 4 days. During the early induction phase, Plt and Fib levels decreased
significantly faster than AT-III and α2-PI levels (p <0.05). Additionally, the median
periods required by each hemostatic factor to recover to their normal ranges
were as follows: Plt, 21.5 days; Fib, 29 days; α2-PI, 29 days; AT-III, 30.5 days;
and PLG, 31 days. During the late induction phase, Plt levels recovered signif-
icantly faster than AT-III and PLG levels; Fib levels recovered significantly faster
than PLG levels (p <0.05).
Summary and Conclusions: During the early induction phase, bleeding risk,
rather than thrombosis, may increase because Plt and Fib levels decreased
below their normal ranges, which occurs faster than the decrease in the levels
of antithrombic factors, including AT-III and PLG. During the late induction
phase, the thrombotic risk may increase because of the faster recovery of Plt
and Fib levels as compared with that of PLG and AT-III levels. One patient
developed cerebral venous thrombosis on day 35 in protocol Ia, which con-
firmed our hypothesis. Therefore, clinicians need to be more cautious regarding
the possibility of thrombosis in the late induction phase.
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UPPER AND LOWER EXTREMITY DEEP VEIN THROMBOSIS IN CHIL-
DREN:A SINGLE CENTER EXPERIENCE
M. Cetin1,* S. Aytac1, T. Bayhan1, S. Unal1, B. Tavil1, B. Kuskonmaz1, F. Gumruk1
1Pediatric Hematology, Hacettepe University, Ankara, Turkey
Background: Deep Vein Thrombosis (DVT) in children can be caused by a
combination of several risk factors such as poor blood circulation, damage to
the veins and thrombophilia. 
Aims: Our aim is to evaluate the causes, risk factors and clinical outcome of
upper (UEDVT) and lower extremity (LEDVT) DVT in our center.
Methods: We retrospectively evaluate their clinical and laboratory results by
the way of searching their paper based & electronic files.
Results: Our database revealed 352 children having various types of thrombosis
between January 2009 to December 2014 and 70 out of 352 were diagnosed as
DVT. There were 44 male and 26 female with a median age of 60 months (min-
imum 1 month- maximum 216 months)in this group. The location of UEDVT
involved internal jugulary vein (n=16) and superior vena cava(SVC) (n=5) where-
as LEDVT include femoral and iliac veins(n=39), popliteal veins(n=10). More than
half of these DVTs were associated with a cathether related thrombosis on which
4/5 SVC, 15/16 jugulary vein thrombosis and 21/49 LEDVTs. All except 5 patient
having an underlying chronic diseases such as malignancy, nephrotic syndrome,
immune deficiency, congenital cardiac disorders, metabolic diseases. One out of
these 5 patient was diagnosed as a hereditary protein C deficiency after having
a recurrent LEDVT and pulmonary thrombosis. Recurrent thrombotic
episodes(n=13) was observed in 10 patients and 9 of these patient having LEDVT
had 12 recurrent episodes including (6 pulmonary thrombosis, 4 LEDVT, 1 renal
venous thrombosis and 1 sinevenous thrombosis). One patient who initially had
UEDVT experienced recurrent episode of SVC thrombosis. Factor V Leiden muta-
tion was found to be heterozygous in 15/50 and normal in 35/50. Homozygous
prothrombin 20210A mutation were detected in 2 out of 50 and 8/50 were het-
erozygous. Homozygous MTHFR C677T and MTHFR A1298C mutation was
found in 3/50 and 8/23 respectively. PAI 4G/5G heterozygous mutation was found
in 15/22 patient. Most of them(%65) initially treated with LMWH and TPA were
used as a thrombolytic agent in 6 of them without any complication. Vena cava
inferior filter was used in 3 patients having LEDVT. During the follow up period 2
had postphylepitic syndrome and 1 had an amputation and 9 patient deceased
because of the primary disesase.
Summary and Conclusions: Our single center experience showed that chil-
dren having spontenous DVT is very rare and most of these DVT episodes
were due to underlying disorder and associated risk factors (aquired and
hereditary).
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RECURRENCES AFTER SPLANCHNIC VENOUS THROMBOSIS: RISK
FACTORS AND EFFECT OF DIFFERENT TREATMENTS IN A RETROSPEC-
TIVE MONOCENTER COHORT OF 154 PATIENTS
V. De Stefano1,* F. Bartolomei1, A. Ciminello1, S. Betti1, T. Za1, P. Chiusolo1,
E. Rossi1
1Institute of Hematology, Catholic University, Roma, Italy
Background: Non-cirrhotic non-malignant splanchnic vein thrombosis (SVT)
is a rare clinical entity associated with heterogeneous underlying disorders;
chronic myeloproliferative neoplasms (MPN) and thrombophilia are the leading
systemic causes of SVT. Long-term treatment is a clinical challenge and the
optimal duration of anticoagulation is uncertain.
Aims: To assess in a retrospective cohort of non-cirrhotic non-malignant SVT
patients the risk factors for recurrent thrombosis and the efficacy of antithrom-
botic long-term secondary prophylaxis.
Methods: We analysed a retrospective cohort of 154 patients with a first SVT
referred to our Thrombosis Center between 1995 and 2014 (M/F 68/86, median
age at SVT 45 years, range 1-83); 12% of patients had hepatic vein thrombosis
and 88% thrombosis of one or more sites of the spleno-mesenteric-portal
venous axis. SVT was unprovoked in 84 patients (54%); inherited or acquired
thrombophilia was diagnosed in 56 patients (36%). Forty-seven patients (30%)
had diagnosis of overt MPN; JAK2 V617F mutation was present in 50 of 131
tested patients (38%). Long-term antithrombotic treatment was given to 112
patients: 80 (53%) were receiving anti-vitamin K treatment (AVK), 16 aspirin
(ASA) (10%), and 8 AVK+ASA (5%); 50 patients (32%) discontinued any pro-
phylaxis after 6-12 months of AVK treatment. The probability of recurrent throm-
bosis after SVT and the impact of different risk factors or treatments were esti-
mated by the Kaplan-Meier method and a multivariate proportional hazards
regression model. 
Results: During a total observation time of 748 years, 25 patients (16%) had a
recurrent thrombotic event: 15 a recurrent SVT, 7 a venous recurrence in other
sites, and 3 an arterial recurrence. The overall incidence of recurrences was
3.3% pts-years. The cumulative probability of recurrence was 6.1% at 1 year,
16.2% at 5 years, and 25.7% at 10 years. Recurrence occurred in 10 cases
during AVK treatment (2.1% pts-years) and in 15 cases without AVK (5.3% pts-
years). The univariate hazard ratio (HR) for recurrent thrombosis in patients with-
out AVK was double than in patients on treatment (HR 2.02, 95%CI 0.97-5.28).
A multivariate proportional hazards regression model having as dependent vari-
able the recurrence of thrombosis included as covariates gender, age >45 yrs at
SVT, family history of venous thrombosis, absence of provoking causes of SVT,
presence of thrombophilia, diagnosis of overt MPN, cytoreductive treatment, AVK
or ASA treatment. Male gender and age >45 years were associated with a higher
risk of recurrence (HR 2.6, 95%CI 1.04-6.53, and HR 1.18, 95%CI 1.18-8.97,
respectively); AVK treatment was significantly effective in preventing recurrences
(HR 0.35, 95%CI 0.13-0.91). A modified model with the variable JAK2 V617F
and without the redundant variable MPN was applied on the 131 patients checked
for the mutation, retaining only the presence of JAK2 V617F as positive predictor
of recurrence (HR 6.7, 95%CI 1.76-25.44) and confirming the efficacy of AVK
(HR 0.15, 95%CI 0.04-0.57). A sub-analysis of the patients with overt MPN or
carriers of JAK2 V617F confirmed the efficacy of AVK, whereas the use of ASA
had no significant impact in preventing recurrences.
Summary and Conclusions: In this monocenter cohort thrombophilia and
MPN/JAK2 V617F mutation were confirmed to be the systemic risk factors for
SVT more represented. Male gender, age >45 years, and the presence of JAK2
V617 mutation resulted independent risk factors for recurrence. Long-term
treatment with AVK decreased the rate of recurrences at least by 65% in the
overall cohort as well as in the MPN subgroup.
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THROMBIN INDUCES VASCULAR LEAKAGE THROUGH MACROPHAGE
MIGRATION INHIBITORY FACTOR AND AUTOPHAGY DURING SEPSIS
C.-H. Chao1,* H.-R. Chen2, T.-M. Yeh1
1Department of Medical Laboratory Science and Biotechnology, 2The Institute of
Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan, ROC
Background: Sepsis is a disease, of which the systemic inflammation-induced
vascular leakage and disseminated intravascular coagulation leads to multiple
organ failure. Thrombin, a serine protease mediating critical pathological roles
during sepsis, not only activates coagulation cascades but also acts as a
cytokine to induce vascular hyper-permeability and inflammation. In previous
study, it has been demonstrated that thrombin could induce endothelial cells to
secret macrophage migration inhibitor factor (MIF). MIF is another critical pro-
inflammatory cytokine secreted in sepsis, and it has also been indicated to
induce the formation of autophagy. However, the interplay between MIF and
autophagy on thrombin-induced vascular hyper-permeability during sepsis has
not yet been revealed. 
Aims: We aim to investigate whether thrombin-induced vascular hyper-per-
meability is through MIF-mediated autophagy in sepsis.
Methods: Human microvascular endothelial cell line (HMEC-1) was co-treated
with thrombin with or without MIF/autophagy inhibitors and the permeability
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was monitored by real-time cell analyzer (RTCA) and trans-well permeability
assay in vitro. We also used lipopolysaccharide (LPS)-intraperitoneally injected
mice as endotoxemia mice model to test whether MIF and autophagy inhibitors
could rescue LPS-induced vascular leakage and septic shock. To measure
vascular leakage level of endotoxemia mice model, Evans blue dye was
intraperitoneally injected into mice and the vascular leakage of the mice was
determined by the concentration of Evans blue dye in peritoneal lavage.
Results: We found that thrombin activity in plasma was significantly increased
in endotoxemia mice. In addition, treating HMEC-1 cells with thrombin could
induce MIF secretion and autophagy formation within 30 minutes and accom-
panied with VE-cadherin translocation. Next, we used MIF and autophagy
inhibitors to rescue endothelial barrier dysfunction. Blocking MIF by ISO-1,
p425 and anti-MIF antibodies could rescue thrombin-induced endothelial hyper-
permeability both in RTCA and trans-well assay. Blocking the autophagolyso-
some formation by bafilomycin A1 (BafA1) and chloroquine (CQ) partially block
thrombin-induced endothelial hyper-permeability in RTCA. Co-treatment of
PI3K inhibitor (3-methyladenine, 3-MA) or ROS scavenger (N-acetyl-L-cysteine,
NAC) with thrombin effectively attenuated thrombin-increased endothelial per-
meability in trans-well permeability assay.In addition, inhibition of MIF could
block the thrombin-induced autophagy, revealing that thrombin-induced
autophagy is mediated by MIF. Furthermore, in endotoxemia mice model, peri-
toneal injection of LPS increased the MIF secretion, while bovine serum albu-
min (BSA) did not show similar effect. Injection of ISO-1 and BafA1 with LPS
eliminated LPS-induced vascular leakage, indicating that this effect was medi-
ated by MIF and autophagy.
Summary and Conclusions: Our results suggest that thrombin-induced vas-
cular hyper-permeability is mediated by MIF and autophagy and this study may
provide potential therapeutic target for treating sepsis in the future.
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BLOOD RHEOLOGY DISTURBANCES INCREASES VTE-RISK IN CHIL-
DREN WITH ACUTE LYMPHPBLASTIC LEUKEMIA
I. Kolesnikova1,* E. Roitman2, S. Roumyantsev1
1FSCC of Pediatric Hematology Oncology and Immunology, 2Pirogov Russian
National Research Medical University, Moscow, Russian Federation
Background: Central hemodynamics and blood rheology disorders are well-
known factors leading to thrombosis. High risk of venous thromboembolism
(VTE) have accompanied acute lymphoblastic leukemia (ALL) like another
malignancies. Besides the chemotherapy has negative effect on cardiac func-
tion which can lead to blood velocity decrease. And hemorheological changes
could be caused due to proinflammatory cytokines negative influence on red
blood cells aggregability.
Aims: To investigate blood rheology features as VTE risk factor in children
with acute lymphoblastic leukemia.
Methods: The study’s population consist 48 children (age <17.6 y.o.). In all
patients we investigated BNP level. Whole blood viscosimetry (shear rates 5-
300 s-1), plasma viscosimetry (shear rates 250 s-1), erythrocytes aggregability
and deformability were investigated. All patients had not any symptomatic
organs failures. 
Results: From 48 patients 1) in 8 cases BNP was elevated more 82 ng/L (up
to 208 ng/L), and 2) in 6 patients had thrombosis and three from them were
with increased BNP. All cases thrombi had revealed at the area of central
venous line. All patients had normal plasma viscosity (1,1-1,5 mPa*s) and
unimpaired erythrocyte deformability. Despite it whole blood viscosity was
increased by shear rates 5-300 s- and mainly by shear rates 5-75 s-1(eta by
5s-1: 4,2-7,9 mPa*s; eta by 75s-1: 2,3-4,1 mPa*s). The last assumes erythro-
cytes hyperaggregability in all patients.
Summary and Conclusions: As a whole, hemorheological profile is impaired
moderately in children with ALL. Totally increased blood viscosity and erythro-
cytes hyperaggregability and hidden ventricle overload (presumably, this is a
temporary) signed by elevated BNP allows together to aggravate circulatory
disorders. We assume that the revealed hemorheologic features could be one
trigger to start of VTE despite standard antithrombotic prevention in children
with acute lymphoblastic leukemia. The study is continued now.
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ADAMTS-13 A NOVAL MARKER LINKING BETWEEN MICRO AND
MACRO- VASCULAR DISEASE IN YOUNG TYPE -1 DIABETES PATIENTS 
A. Tantawy1,* M. Salem1, A.A. Adly1, Y. Dawish2
1Pediatrics, 2clinical pathology, Ain Shams University, cairo, Egypt
Background: Several observations that vascular damage and endothelial dys-
function occur early in the course of diabetic microangiopathy have been report-
ed.The net effect of all these changes is to convert the endothelium from a
thromboresistant to a thrombogenic surface and, consequently, impairment of
coagulation and of anticoagulant pathways. Recently it was demonstrated ele-
vated level of VWF in type1 diabetics which is degraded by a metallo protease,
ADAMTS-13. It’s hypothesized that elevated VWF level was due to reduced
level of ADAMTS-13. Deficiency of Von Willebrand factor (VWF)-cleaving pro-
tease (ADAMTS13) causes platelet thrombosis in the microcirculation.
Aims: to determine whether diabetic micro-angiopathy was associated with
abnormally modulated haemostasis and to demonstrate whether a correlation
existed between the thrombotic tendency, as measured by ADAMTS-13 levels
and macrovascular complications measured as dyslipdemia and CIMT.
Methods: Seventy children and adolescents with type 1 diabetes attending the
Pediatric Diabetes Clinic, Pediatric Hospital, Ain Shams University were com-
pared with 40 age- and sex-matched healthy controls. The mean age of patients
was 12.6±4.9 years and with a M/F ratio of 1.2/1.Detailed medical history with
special emphasis on disease duration and insulin therapy, thorough clinical exam-
ination,blood pressure (BP) measurement, as well as screening for diabetic com-
plications, was performed. Laboratory assessment of high-sensitivity C-reactive
protein, Lipid profile, albumin/creatinine ratio, renal functions and glycosylated
hemoglobin (Hb A1c) were assayed. Carotid intima-media thickness was meas-
ured using ultrasound as well as ADAMTS 13 level using ELISA technique.
Results: The mean cIMT was higher in diabetics than controls (0.6 mm±0.1 vs
0.4 mm±0.1, p=0.000). Moreover, it was higher in diabetics with positive microal-
buminuria compared to normo-albuminuric patients (mean 0.7 mm±0.1 vs 0.6
mm±0.1, p=0.018). cIMT was found to positively correlate with: age in diabetics
(r=0.76, p=0.000,), body mass index (r=0.82, p=0.000). In diabetics, mean aggre-
gate cIMT positively correlated with duration of diabetes (r=0.66, p=0.000), mean
systolic blood pressure SDS(r=0.82, p=0.000) as well as Hb A1c (r=0.40, p=0.004)
and correlated negatively with high density lipoprotein -cholesterol (HDL-C)
(r=−0.88, p=0.000).The mean ADAMTS-13 serum levels were significantly lower
in diabetics compared to controls with the lowest values in complicated patients.
Mean ADAMTS-13 levels were negatively correlated with ACR(r=2.1,p<0.05),
mean CIMT(r=1.9,p<0.01), HbA1c (r=2.4,p<0.05)and mean random blood glu-
cose(r=2.7,p<0.001). Moreover mean ADAMTS 13 levels were negatively corre-
lated with TG,TC,high sensitivity CRP and LDL(p<0.01). Multiregression linear
analysis showed that, UACR, and hs-CRP were independently related to
ADAMTS 13 levels in type 1 diabetics (p<0.05).The mean ADAMTS 13 levels
were related to severity of MVCs as patients with combined or more than one
MVCs had significantly lower levels compared to patients with single MVCs.
Summary and Conclusions: ADMTS13 levels were eleveted and young type1
diabetics and related to metabolic control, dyslipidemia, CIMT as well as sever-
ity of MVCs.
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PROGNOSTIC SIGNIFICANCE OF THE ABSOLUTE MONOCYTE COUNTS
IN LUNG CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM
G.-W. Lee1,* S.-I. Go1
1Internal Medicine, Gyeongsang National University School of Medicine, Jinju,
Korea, Republic of
Background: Lung cancer is one of the most prevalent types of cancer in which
VTE occurs among malignancies presenting with VTE. Advanced disease stage,
elderly, adenocarcinoma, smoking history, comorbidities, and chemotherapy have
been reported to be risk factors for VTE in patients with lung cancer. VTE in lung
cancer is associated with an increased risk of mortality
Aims: We investigated the clinical significance of the absolute monocyte count
(AMC) as a predictor of the response to anticoagulation and survival in lung
cancer patients with venous thromboembolism (VTE).
Methods: We retrospectively reviewed 1,707 patients with pathologically
proven lung cancer who visited the hospital between July 2008 and May 2014.
Among them, the clinical data of patients newly diagnosed with VTE and treated
with anticoagulation were compared between the low and high AMC groups
according to the median value of AMC (640/μL) at the time of VTE diagnosis.
Results: The incidence of VTE was 7.9% during the study period. Most of the
patients had non-small-cell lung cancer (82.1%), stage IV (64.2%), and pulmonary
thromboembolism (76.1%) and were incidentally diagnosed with VTE (76.9%).
The patients’ characteristics and laboratory values were not significantly different
between the low and high AMC groups. Among patients available for evaluation
of the response to anticoagulation, the high AMC group was significantly more
refractory to anticoagulation than the low AMC group (no response to anticoagu-
lation: 21.7% vs 6.8%, respectively; p=0.044). Additionally, the high AMC group
showed worse overall survival (OS) than the low AMC group (median: 9.6 months
vs 5.9 months; p=0.038). On multivariate analysis, high AMC, low albumin, and
advanced stage were independent poor prognostic factors for OS.
Summary and Conclusions: High AMC is associated with refractoriness to
anticoagulation and poor prognosis in lung cancer patients with VTE.
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PREDICTIVE POTENTIAL OF MARKERS OF COAGULATION, FIBRINOL-
YSIS AND ANGIOGENESIS IN CANCER PATIENTS
E.A. Beleva1,* T. Deneva2, E. Karaslavova3, V. Popov1, J. Grudeva1
1Clinical Oncology, Medical Faculty, 2Clinical Laboratory, Faculty of Pharmacy,
Medical University-Plovdiv, 3Faculty of Biology, Plovdiv University “Paisii Hilen-
darski”, Plovdiv, Bulgaria
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Background: In cancer setting hemostatic system exhibits recognized
pleiotropic effects in the processes of tumor initiation, growth, metastasis and
angiogenesis. However, the predictive potential of various hemostatic markers
regarding treatment efficacy and disease progression remains disputable.
Aims: To determine dynamics of the procoagulant activity of tissue factor bear-
ing microparticles (MP-TF) throughout chemotherapy, its correlation to levels
of soluble urokinase plasminogen activator receptor (suPAR) and angiopoietin-
2 (Ang-2).
Methods: Single institution prospective observational study including 128 can-
cer patients who underwent chemotherapy in 2013/2014 for breast (44), lung
(28), colon (37), ovarian (19) cancers. Patients were subsequently followed up:
before chemotherapy (ChTh) initiation, after three cycles, after six cycles and
three months post therapy cessation. A control group of 30 healthy volunteers
was studied as well. Written informed consent was obtained from both study
groups. Serum levels of suPAR and Ang-2 were determined by ELISA and MP-
TF procoagulant activity was measured by a combined immune-chromogenic
method (Zymuphen MP-TF).
Results: MP-TF procoagulant activity was twice higher in cancer patients com-
pared to controls (0.9421vs.0.4300 pg/ml, p<0.0001). Sequential testing of MP-
TF in patients with lung, colorectal and ovarian cancers revealed decrease in
their procoagulant activity during treatment followed by a significant rise in activ-
ity after therapy cessation (0.9421 vs 1.4103 pg/ml, p<0.0001). No significant
dynamics in MP-TF was observed in patients with breast cancer (0.9814 vs
0.8733 pg/ml, p=0.785). SuPAR and Ang-2 showed marked two- to threefold
decrease during ChTh that is sustained after its cessation. MP-TF activity cor-
relates negatively with suPAR and Ang-2 (ρang2 -0.259, ρsuPAR -0.296,
p=0.0001). All three markers had AUC >0,70 and therefore could be identified
as reliable diagnostic tool for the presence of malignant disease. Amongst them
MP-TF had greatest potential as independent predictor (Beta 0,408, p<0.0001).
Summary and Conclusions: MP-TF procoagulant activity, suPAR and Ang-2
could serve as surrogate markers for biologic activity and therapeutic efficacy.
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DURABLE LONG TERM REMISSIONS WITH EARLY USE OF RITUXIMAB IN
PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
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Background: Adult onset acquired thrombotic thrombocytopenic purpura (TTP)
is a life-threatening disease mediated by autoantibodies directed against
ADAMTS13. Therapeutic plasma exchange (TPE) and immunosuppressive
therapies have largely remained the mainstay of treatment. Several studies
have reported promising results with early use of rituximab. 
Rituximab is a safe and effective treatment for newly diagnosed TTP, and has
shown in a prospective, multicentre trial to decrease the number of plasma
exchanges (PEX) required to achieve remission, to decrease the length of inpa-
tient stay and to reduce the risk of relapse by over 80% when compared to his-
torical controls. 
Aims: We report our experience with early use of rituximab in patients with initial
severe manifestations (cardiac or neurological involvement) or those who were
failing to show early response to TPE from a tertiary care centre in Saudi Arabia.
Methods: This is retrospective data of ten patients with TTP who received rit-
uximab either for refractory disease or sever manifestations of TTP since 2006
to 2014 at our teritary care hospital, saudi Arabia.
Results: Total of ten patients with TTP received rituximab either for refractory
disease or sever manifestations of TTP since 2006 to 2014.There were six
females (60%) and four males (40%). The median age was 33±12.08. Nine of
the ten patients (90%) had neurological involvement ranging from headache,
dizziness, confusion, seizures and focal neurological signs. Four patients (40%)
had renal impairment. Two patients (20%) had associated systemic lupus ery-
thematosis(SLE). Five patients (50%) were refractory to plasma exchange while
the rest received early rituximab due to cardiac or neurological involvement at
treating physician’s discretion. Four patients received Rituximab within 5 days
of diagnosis. Seven patients received weekly four doses of Rituximab at
375mg/m2 while two patients received eight and five doses weekly. One patient
with SLE received two doses at 1000mg each as per Rheumatology protocol
for the benefit of treatment of concurrent SLE. Nine out of ten (90%) achieved
complete response; no subsequent relapses occurred with median follow-up
of 16 months (range, 6-62 months). There was one death during the early
course of disease due to delayed presentation. Number of mean plasma
exchanges in early rituximab group who received Rituximab within five days
was 13.5 while it was 17.4 in those who received later than day 5. Number of
mean total plasma volumes exchanged in early Rituximab group were 11.1
(range 7.8-15.5) compared to 16.15 in later group (range 11.2-25.2). There
were no serious immediate complications noted. On longer term clinical follow
up, we have not found any increased tendency of infections or any case of
leukoencephlopathy.
Summary and Conclusions: The results suggest that early use of Ritux-
imab is associated with decrease number of plasma exchanges, increased
duration of remission and decreased risk of relapse with excellent safety
profile as suggested by earlier studies. We also noticed maximum benefit
is seen if Rituximab given at the earliest. We need further randomized con-
trolled trials testing efficacy of upfront Rituximab. Based on these observa-
tions, our group is planned for prospective study for the early use of
rituximab.
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Background: In vitro studies show that thrombodynamic (TD) method is sen-
sitive for anticoagulant effect of low molecular weight heparins (LMWH), but
there is still no information of its utility in anticoagulation monitoring in children
with deep venous thrombosis (DVT) during active cancer treatment.
Aims: to assess anticoagulant effect of LMWH in children with DVT using
Thrombodynamic assay.
Methods: Twenty-one children aged 5 months to 13 years with objectively
confirmed DVT during active cancer treatment were enrolled in this prospec-
tive observational study. All children were prescribed for LMWH treatment
starting with 100 IU/kg/bid on the day of thrombosis detection. Anti-Xa activity
and novel global hemostasis test Thrombodynamics were used to assess
coagulation status in all patients before and on the 4th day of anticoagulation.
Hypercoagulability in TD was defined when clot growth velocity (V) was above
reference range, hypocoagulability -when V was below reference range. For
all calculations, OriginPro 8.0 (Microcal Software, Northampton, MA, USA)
have been used.
Results: The day of thrombosis detection 13 patients had hypercoagulability
in TD: V=30.3-45.5 um/min (median 33,9 um/min, normal range is 22-29 um/min
in children), while 8 had normal results. After 4 days of LMWH therapy TD
revealed significant shift (*P<<0.05, pair-sample t-test) to hypocoagulability
range: V=6.3-33.9 um/min (median 9.7 um/min); anti-Xa activity=0.14-0.79
IU/ml (median 0.43 IU/ml). There was a strong correlation between anti-Xa
activity and value of 1/V during LMWH treatment: Spearman correlation
coeff.=0.77 (Sign. 0.0001).
Summary and Conclusions: Thrombodynamics reveal significant shift from
hypercoagulability range on thrombosis to hypocoagulability in consequence
of anticoagulant treatment with LMWH that is in good agreement with anti-Xa
activity.
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CRP, D-DIMER, LEUKOCYTE, BLAST AND PLATELET COUNTS AT THE
TIME OF ALL DIAGNOSIS AS POSSIBLE BIOMARKERS FOR EARLY
CEREBRAL VEIN THROMBOSIS
S. Mertanen1,* O. Laine2, M. Rämet2, M. Vesanen3, E. Elonen1, U. Wartiovaara-
Kautto1
1HUCH Cancer Center, Division of Hematology, Helsinki University Central
Hospital, Helsinki, 2Department of Internal Medicine, Tampere University Hos-
pital, Tampere, 3Department of Internal Medicine, Turku University Central Hos-
pital, Turku, Finland
Background: Thrombotic complications in cancer patients are mostly venous,
cerebral vein occlusion (CVT) representing often the most drastic conse-
quences in patients’ lives. A majority of thromboses occurs during the first
months following ALL diagnosis and introduction of treatment (Vu et al. 2015).
They possibly have an adverse impact on the overall survival (Ku et al., 2009).
Older age, presence of a catheter, comorbidities as well as introduction of
asparaginase (ASP) have been linked to deep venous thrombosis in leukemia
patients. However, very limited data exists on biomarkers already available at
diagnosis of ALL predicting the risk of thrombosis during the early treatment
course of ALL.
Aims: We performed a multicenter retrospective study aiming at character-
izing the incidence and patterns as well as possible predictive factors for
thrombosis during the multiagent treatment of ALL before allogenic stem cell
transplantation.
Methods: We reviewed the charts of 161 consecutive patients diagnosed with
ALL and recruited to a national treatment study (ALL2000) in four university
hospitals and one central hospital in Finland during years 2000-2012.
Results: In all, 31 patients (19%) suffered from thrombosis during the three
months follow-up time. 13 (42%) of the thromboses occurred within two
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months after ALL diagnosis. 32% (n=10) of the thrombotic events were local-
ized in patients’ cerebral veins detected by MRI and seven of them took place
remarkably early in the treatment course and before the introduction of ASP
(cycle 3, day 8). None of the patients with CVT had been diagnosed with
leukemia in central nervous system. Plasma CRP, fibrinogen degradation
product (DD), and blood hemoglobin, leukocyte, blast and platelet counts
recorded at ALL diagnosis were also investigated. In patients acquiring throm-
bosis a trend, nearly reaching statistical significance, towards a lower platelet
count and higher CRP, DD, leukocyte and blood blast count at leukemia diag-
nosis was detected. This was even more pronounced in patients who suffered
from CVT.
Summary and Conclusions: A large proportion of thromboses possibly affect-
ing regular ALL treatment and patients’ survival occurs very early after the
leukemia diagnosis despite low platelet counts at diagnosis and during the
multiagent cytostatic treatment. At diagnosis, high CRP, high DD, high leukocyte
and high blood blast count as well as low platelet count possibly reflect the
role of ALL disease itself in provoking thrombosis, especially CVTs. In order to
confirm these findings prospective studies are still called for.
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CHILDREN WITH CEREBRAL INFARCT DUE TO CRANIOCERVICAL
ARTERIAL DISSECTION IN A SINGLE CENTER
S. Aytac1,* K. Karli Oguz2, M. Cetin1, F. Gumruk1
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Ankara, Turkey
Background: Children with craniocervical arterial dissection is being recog-
nized increasingly in the recent years and it is reported to be associated with
a high morbidity rate in the childhood period. Treatment is challenging however
anticoagulation and antiplatelet treatment are the treatment options. CAD is
an important cause of childhood arterial ischemic strokes which occured
between 7.5%>20%.
Aims: Our aim is to evaluate our patients who had had arterial ischemic stroke
secondary to craniocervical arterial dissection in our center.
Methods: We retrospectively reviewed our patients who had had arterial
ischemic stroke secondary to craniocervical arterial dissection. All of these
patients’ diagnoses were based on cranial and neck magnetic resonance (MR)
imaging, MR angiography and computed tomography (CT) angiography in
presence of appropriate clinic setting and a past history of trauma.
Results: Of the 305 children with thrombosis diagnosed in our center, 64 were
acute arterial cerebral thrombosis and of those 4(6.2%) patients were diag-
nosed as arterial dissection. In all of these patients past history revealed a
trauma and all patients had evidence of cerebral ischemia at the time of diag-
nosis. Hereditary prothrombotic risk factors were homozygout MTHFR in 2
patient and heterozygout FV Leiden mutation in one patient. Recurrent stroke
was not observed in our group.
Summary and Conclusions: Long term mortality rates of childhood onset
arterial ischemic stroke were reported as 2-11% and overall rate of intracranial
hemorrhage was shown to be about 5% in this group of patients. In our ischemic
stroke group, cervicocranial dissection rate (6.2%) seems to be lower than the
rate reported in the literature which may be up to 20% of strokes in childhood
and adolescence. This may be due to underdiagnosis of these patients, in that
diagnosis should be based on primarily clinical suspicion and vascular imaging
of the neck and brain. Children who developed neurological abnormalities after
a blunt trauma to the head and/or neck should alert the physicians to have the
possibility of carotid artery injury. It is important to remember that ischemic
infarcts are usually not visible on CT during the first 12 hours of the acute
stage. Cranial MR imaging especially with introduction of the diffusion-weighted
imaging have been much more sensitive in detection of the acute ischemic
lesions.Furthermore detection of extracranial dissections usually require
demonstration of an intramural thrombus which is hyperintense on subacute
stage especially on fat-saturated T1-weighted imaging or an intimal flep as a
linear structure traversing the lumen.
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A BESPOKE ‘APP’ FOR THE INVESTIGATION AND MANAGEMENT OF
DEEP VEIN THROMBOSIS 
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Background: Deep vein thrombosis (DVT) is a common condition that may
lead to potentially fatal complications, such as pulmonary embolism. The
development of an application, the ‘app’, guides clinicians to the appropriate
diagnostic management and treatment for patients with suspected DVT in
acute setting. The ‘app’ offers guidance on the two-level DVT Wells score,
D-dimer measurement and ultrasound imaging requests. It uses formal clin-
ical decision rules in conjunction with blood tests to enable a more structured
clinical diagnosis of DVT. It offers guidance on the management and treat-
ment of DVT covering contraindications/cautions for anticoagulation therapy,
prescription dosing and patient counselling information. Information from the
‘app’ is pre-populated in the discharge summary facilitating discharge with
accurate summary of investigations and management. The ‘app’ has been
developed in accordance with hospital and national guidelines with an aim
to standardise the pathway ensuring patient quality and safety.
Aims: To improve the pathway for the investigation and management of
patients with suspected DVT with electronic technology to ensure patient safety,
quality and experience.
Methods: Stakeholders (clinical, radiology and nursing staff; information and
‘app’ development teams) agreed on the vision and requirements such as
objectives; data metrics for diagnosis, management, patient and staff satis-
faction, workflow and time; clinical aspects (ward area, patient exclusions,
pathway); ethics approval and technical system (user device, software, serv-
er, network, configuration criteria, access rights) to deliver an electronic deci-
sion-support safety system, in an ‘app’ format, to guide clinicians to the appro-
priate diagnostic investigations and treatment for patients with suspected/con-
firmed DVT. Timelines for implementation phrases and go-live date were set.
Stages for development, testing, installation, further validation, training and
monitoring were performed. Supporting materials and user guides were cre-
ated. The ‘app’ will be trialled for 3 months to assess benefits and perform-
ance compared to the current paper system using a DVT proforma. This time-
frame will provide feedback whether our vision is delivered and if our strate-
gies are working for better patient care, accurate and relevant investigation
and appropriate management. 
Results: Audit results for investigation and management of DVT (WS: Wells
Score; USS: Ultrasound): 92% (47/51) of patients had a history and exami-
nation recorded; 18% (9/51) of patients had a WS; 100% (6/6) of patients
with a DVT likely WS had USS within 4 hours of request or therapeutic enoxa-
parin and USS within 24 hours; No (0/2) patients with DVT likely WS had a
repeat USS 6-8 days with positive D-Dimer and negative USS; 100% (3/3)
of patients with DVT unlikely WS had a D-Dimer test; 50% (1/2) of patients
with DVT unlikely WS and positive D-dimer had USS within 4 hours or ther-
apeutic enoxaparin and USS within 24 hours; 100% (4/4) of patients with
confirmed DVT had appropriate anticoagulation therapy.The audit showed
the lack of documentation of the two-level DVT Wells score, thus difficult to
evaluate whether patients were management appropriately due to limited
data available and confirming non-compliance to hospital guidance. Results
will be compared to an audit post implementation of the ‘app’.
Summary and Conclusions: Clinical teams are aware the current paper sys-
tem is not effective and have developed and introduced a novel decision-sup-
port pathway, in an ‘app’ format, to guide the clinician step-by-step for appro-
priate investigation and management of suspected and confirmed DVT, with a
mission to ‘see, feel and change’.
References
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EFFICACY OF THROMBOPROPHYLAXIS IN THE PREVENTION OF
THROMBOSIS IN PREGNANCY. EFFECTS ON THE INCIDENCE OF
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P. Llamas2
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Background: The etiology of gestational vascular complications (GVC) is
not accurately known, however it has been proposed that activation of
haemostasis may cause poor placental development and thrombosis.
Antithrombotic prophylaxis with LMWH and/or aspirin could prevent the devel-
opment of CVG by controlling of hemostasis during pregnancy.
Aims: To analyse the type and dose of thromboprophylaxis in a group of
pregnant women. To study the relationship between antithrombotic prophy-
laxis and GCV development.
Methods: We studied 162 pregnant women referred to the Hematology con-
sultation in HURJC and HUFJD. All of them were pregnant at the time of
consultation. Thrombotic and CVG risk factors were estimated and it was
decided to have expectant management or to start prophylaxis with LMWH
+/- aspirin, according to our protocol. The following data were collected: pro-
phylactic medication and dose, obstetric history, history of miscarriages, his-
tory of thrombosis, prior pregnancy complications and thrombophilia.
Results: The mean age was 35.7 years (range=22-43); mean gestational
age at first visit was 12.6 weeks. 51.2% (n=83) women had no living children;
and 69.9% (n=114) had have abortions. 63.6% (n=103) were referred with a
history of abortion, 72.7% (n=83) in the 1st trimester, 18.5% (n=10) in the
2nd and 8.8% (n=21) in the 3rd. In addition, 70 women had other pregnancy
complication history: preeclampsia (8.5% n=6), implantation failure (18.6%
n=13), and fetal death (22.8% n=16). In this group 19.8% (n=32) had at least
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one thrombotic event before pregnancy. 58% (n=94) had thrombophilia:
13.8% C677T homozygous, 26.5% FV Leiden, 16% PT20210A and 8.5%
AFS. 47 patients (29%) had complications during pregnancy or childbirth.
49% of newborns experienced some complications, being the most common:
prematurity (n=27) and low weight (n=15). There was no perinatal death. Risk
factors (previous thrombosis, maternal age, recurrent miscariages, presence
of thrombophilia) were studied and treatment was prescribed as indicated. In
53.3% of the patients prophylaxis was started in the first trimester). LMWH
prophylaxis was effective in preventing thrombosis during pregnancy, (statis-
tically significant p <0.0001). 108 (88.5%) of women treated with LMWH had
a live birth. Although didn´t found no statistically significant relationship
between antithrombotic phrofilaxys and prevention of abortions or fetal loss,
87.9% (n=73) women with no living children who received LMWH prophylaxis
during pregnancy were able to have a live birth (p=0.394). 
Summary and Conclusions: In our study group LMWH prophylaxis was
effective in preventing thrombosis. Although there is no statistically significant
relationship between antithrombotic prophylaxis and prevention of abortions
or fetal loss, 87.9% of women with no living children who were prescribed
with LMWH were able to have a live birth.
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THROMBIN GENERATION (TG) POTENTIAL AND ACTIVATED PROTEIN C
(APC) RESISTANCE IN PATIENTS ON CHRONIC ORAL ANTICOAGULANT
THERAPY WITH VITAMIN K ANTAGONIST (VKA)
C. Verzeroli1,* M. Marchetti1, C. Giaccherini1, V. Milesi1, L. Barcella1, A. Falanga1
1Immunohematology and Transfusion Medicine, Hospital Papa GiovannixXIII,
Bergamo, Italy
Background: Atrial fibrillation (AF) and cardiac valvular prosthesis (CVP)
expose patients to high risk of stroke that significantly contribute to morbidity
and mortality. In these diseases despite the clinical beneﬁt of oral anticoag-
ulation with VKA (i.e. Warfarin) for thrombosis prevention, major bleeding
may be frequent and devastating. The dose of VKA is determined for each
patient by monitoring the Prothrombin-International Normalized Ratio (PT-
INR). Some recent studies showed that, though with in therapeutic range PT-
INR some patients can suffer serious bleeding complications or recurrent
thromboses, suggesting that PT-INR do not always reflect the real bleeding
or thrombotic risk and therapeutic effect of VKA.
Aims: This prospective study aim to characterize the TG potential in a group
of AF or CVP patients on VKA, in order to investigate whether a correlation
exists between TG and PT-INR and whether TG might be useful to identify
subjects at higher bleeding risk.
Methods: Thirteen patients with AF (6M/7F, median age 77 years, (59-86))
and 7 patients (7M, median age 65 years (58-76)) who underwent CVP inter-
vention were enrolled at the Hemostasis and Thrombosis Center of Papa
GiovannixXIII Hospital, Bergamo, Italy, after gave informed written consent.
All patients were on VKA treatment. To be included into the study the patients
should have at least 65% in-range PT-INR in the previous year and 100%
in-range PT-INR in the previous 3 months. Enrolled patients were prospec-
tively followed up for one year. TG was performed by the Calibrated auto-
mated thrombogram (CAT) in platelet-poor plasma collected at the same
day of PT-INR control (13 samples/each patient). TF 5pM was used as a
trigger of TG assay. TG curves were described in terms of lag-time, endoge-
nous thrombin potential (ETP), peak height and time to peak (ttP). ETP-
based APC resistance was evaluated by CAT assay in the presence of 2 nM
APC and results expressed as normalized APC sensitivity ratio (nAPCsr).
Thirty healthy subjects (14M/16F) with no antiplatelet, anticoagulant or, for
women, no oral contraceptives or hormone replacement therapies, acted as
a control group. 
Results: TG assay showed that lag-time and ttP were significantly prolonged
while ETP and peak height were significantly lower in patients compared to
controls (p<0.01), particularly in CVP patients. PT-INR correlate positively
with lag-time (R=0.58, p<0.000) and ttP (R=0.61; p<0.000) and negatively
with ETP (R=0.78; p<0.000) and peak height (R=0.78; p<0.000). The corre-
lation between PT-INR and ETP and peak remain statistically significant also
after correction for age. Interestingly, patients with similar PT-INR showed
wide differences in TG value. nAPCsr, fixed at 1 in controls, was significantly
(p<0.01) reduced in patients (0.6±0.14) suggesting that patients on VKA
were more sensitive to the anticoagulant activity of APC. During follow-up,
a total of four bleeding events were registered: two minor bleedings in AF
patients, and two bleedings (one minor and one major) in CVP patients: all
these patients presented with in-range PT-INR but very low TG potential. 
Summary and Conclusions: The variability of TG values in patients with
similar PT-INR and the occurrence of bleeding complications in patients with
in-range PT-INR but very low thrombin generation values, suggest that TG
assay can be more sensitive in detecting a hemorrhagic phenotype. This
strategy can be useful in monitoring those patients initiating and/or receiving
multiple antithrombotic drugs.
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ONIST ORAL ANTICOAGULANTS (NOACS) AND THEIR IMPLICATION IN
THE PERIOPERATIVE SETTING. RESULTS FROM THE “REAL LIFE”
COHORT
I. Valcarce1,* P. Olivera1, V. Pons1, V. Cortina1, L. Lopez-Andreoni1, G. Artaza1,
F. Bosch1, A. Santamaria1
1Department of Hematology, University Hospital Vall d’ Hebron, Barcelona,
Spain
Background: The use of NOACs has increased especially in elderly patients
polymedicated. The drug-drug interactions and polypharmacy are a significant
problem mainly affecting the geriatric population. Some studies have considered
this issue, but most of them focused only on relevant interactions. It is important
to evaluate the impact of polymedication on NOACs patients in special situa-
tions such as the perioperative setting and to determine whether some of the
commonly used drugs may modulate the anticoagulant effect of NOACs. 
Aims: To determine the degree of polypharmacy and the incidence of possible
drug interactions between daily used drugs and NOACs in perioperative setting
and whether they affect NOACs plasma concentrations or not. 
Methods: From June 2014 to December 2014 we consecutively reviewed 33
patients diagnosed of atrial fibrillation treated with NOACs that needed to under-
go a surgical procedure. Perioperative management was performed following
the PM guidelines from the Spanish Forum of anticoagulants and Anaesthesia.
NOACs plasma concentrations were measured the day of the procedure using
the Direct Thrombin Inhibitor Assay from IL (Bedford-MA-USA) for Dabigatran
and the Technoclone anti-Xa assay from Technoclone (Vienna-Austria) for
Rivaroxaban and Apixaban. Every drug each patient had daily taken was
recorded and assessed considering the drug transport (P-glycoprotein) and
metabolism either if they are cytochrome substrates, inhibitors or inducers. 
Results: A total of 33 patients were included. Median age was 74 years (range
61-94), 17 (51.5%) were female. From them, 8 patients received dabigatran, 20
rivaroxaban and 5 apixaban.The number of medications consumed ranged from
2 to 16 and averaged 6.9 (SD+/-3.13) drugs per patient. The most frequent were
proton pump inhibitors, hypogycemics, antihypertensive, statins and beta-block-
ers. A considerable number of routine taken drugs share the cytochrome for its
metabolization with NOACs, none of them are strong inhibitors or inducers of
cytochrome or transport P-glycoprotein as if to provoke a change on NOACs
plasma concentrations. We just found five drugs that modulated the NOACs
effect (Amiodarone, Atorvastatin, Carvedilol, Diltizem and Omeprazole). Some
of the considered moderate inducers or inhibitors of either cytochrome or P-gly-
coprotein did not show any modulation of NOACs plasma concentrations. No
association between the number of taken drugs and bleeding events was found. 
Summary and Conclusions: In a real clinical setting we found that the com-
monly used drugs would have little impact on NOACs plasma concentrations.
So we might conclude that NOACs are safe in polymedicated patients, even in
special situations such as the perioperative setting.
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IMMOBILIZATION AS A RISK FACTOR IN VENOUS THROMBOEMOLISM.
DIFFERENCES BY SEX AND AGE
A. García Raso1,* C. Miranda2, T. Arquero3, S. Monsalvo3, R. Vidal3, R. Mata3,
P. Llamas3
1Hematolgy, Health Care Institute Fundación Jiménez Díaz, Madrid, 2Hema-
tolgy, Rey Juan Carlos University Hospital, Mostoles, 3Hematolgy, Fundacion
Jimenez Diaz University Hospital, Madrid, Spain
Background: Many studies recognize the importance of immobilization as a
risk factor for venous thromboembolism (VTE), the OR ranging from 5.5 to 11.1
depending on the series. Retrospective studies have shown that 59% of cases
of VTE occur in hospitalized patients (35% for nonsurgical causes). It has also
been reported that 42% of pulmonary embolism (PE) initiated during hospital-
ization. Blood flow in the venous valves is slow, especially in the lower limbs;
an effect is accentuated with immobilization. This is the reason why a prolonged
bed rest may be a risk factor.
Aims: Study immobilization as a risk factor for venous thromboembolism, and
analyze differences according to the characteristics of the patient and the throm-
botic event
Methods: We studied 438 patients with VTE. In this group immobilization was
defined as non-surgical patients bed-ridden at least four days, two months prior
to the diagnosis of thrombosis.
Results: 53% (n=232) of patients included in the study were male and 47%
(n=206) female, with a mean age of 55.2 (±17.9) years. The distribution of
patients according to thrombosis localization was: DVT-LL 49.4% (n=217),
26.9% PE (n=118), DVT+PE 8.8% (=39), DVT-UL 2.3% (n=10), SVT 3.9%
(n=17) and VT-UL 8.7% (n=38). Immobilization was determined as a trigger
and risk factor for thrombotic event in 32 patients (7.4%), and was associated
with the development of venous thrombosis with an OR of 2.84 (CI 95%: 1.35
to 6.71, p=0.0048). The relationship with VTE according to thrombosis local-
ization is shown in Table 1. Immobilization was a risk factor for SVT and DVT-
UL. Immobilization was a risk factor for thrombosis in men but not in women
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(Table 2). In addition, it was a risk factor for patients younger than 55 years but
not in older patients (Table 2).
Table 1. Association between immobilization thrombosis localization.
GROUP                                                  OR              CI (95%)                                 p
TVP-MMII                                               3,46           (1,54-8,53)                            0,002
TEP                                                       1,60           (0,48-4,90)                            0,427
TVP-MMII+TEP                                        6,94           (2,16-21,3)                             0,02
TV-LI                                                      1,99           (0,29-8,43)                            0,425
Table 2. Association between immobilization and VTE. Analysis by sex
and age.
GROUP                                                  OR              CI (95%)                                 p
Women                                                  2,40           (0,84-2,58)                           0,1054
Men                                                      3,33           (1,21-11,7)                           0,0181
<55 years                                              6,90           (1,95-43,8)                           0,0013
≥55 years                                              1,53           (0,60-4,42)                           0,3822
Figure 1.
Summary and Conclusions: Immobilization is an important risk factor for the
development of thrombotic events with greater relevance in male and younger
patients.
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PROPHYLAXIS FOR VENOUS THROMBOEMBOLIC DISEASE IN PREG-
NANCY AND POSTPARTUM PERIOD
S. Grille1,* V. Castro1, P. Turcatti1, D. Mussio1, G. Laporte2, F. Medici2, C. Senatore2,
C. Rodriguez2, G. Vitureira2, L. Sosa3, W. Lauría2, C. Guillermo1, L. Diaz1,
M. Stevenazzi1
1Catedra de Hematologia, 2Clínica Ginecotologica B, 3Clínica Médica, Hospital
De Clinicas. Facultad De Medicina. Universidad De La Republica, Montevideo,
Uruguay
Background: Venous thromboembolism (VTE) remains one of the leading
direct causes of maternal death. Risk stratification is difficult and recommen-
dations for prophylaxis have low grade of evidence. Risk factors for VTE and
prophylaxis guidelines have been highlighted by the Royal College of Obste-
tricians and Gynaecologists (RCOG). Thromboprophylaxis is a cost-effective-
ness way to reduce VTE high morbi-mortality. 
Aims: To determine the risk factors of VTE during pregnancy and postpartum
period present in our population, and to assess compliance with a written alert
used in our clinical practice.
Methods: We conducted a prospective, descriptive and analytical study at Hos-
pital de Clinicas, Montevideo, Uruguay between 1/2014 to 2/2015. We enrolled
hospitalized pregnant and puerperal patients and stratified them, through a written
alert in the medical record, in high, intermediate or low risk for VTE. We used a
local modification of the RCOG guidelines (2009) to identify those patients at
risk and to guide prophylaxis with low-molecular-weight heparin (LMWH).
Results: We included 348 patients in whom the risk stratification for VTE
through written warning and according thromboprophylaxis were performed.
38,2% (n=133) were pregnant and 61,7% (n=215) were puerperal. Median
age: 23 years (range 15-43). 3,4% (n=12) were at high risk and 36,4% (n=127)
at intermediate risk. All high risk patients received adequate pharmacological
prophylaxis with LMWH. Of the 127 intermediate-risk patients, 66,9% (n=85)
received adequate pharmacological prophylaxis. VTE was developed in only
1 patient of the intermediate group who received prophylaxis with LMWH. Non
bleeding complications were observed.
Summary and Conclusions: Awareness of the thrombotic risk, as conferred
by an easy and suitable risk assessment has the potential to improve VTE pro-
phylaxis in pregnancy and puerperal patients. In our service, 39,8% of admitted
patients had criteria for pharmacological prophylaxis for VTE.
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THE CALIBRATED AUTOMATED THROMBOGRAM AS A USEFUL TOOL
IN DETERMINATION OF PROTHROMBOTIC PHENOTYPE
V. Shmeleva1,* O. Matvienko1, S. Kapustin2, V. Kobilyanskaya1, T. Morosova1,
L. Papayan1
1Laboratory of Blood Coagulation, 2Laboratory of Biochemistry, Russian
Research Institute of Haematology and Transfusion, St-Petersburg, Russian
Federation
Background: The assessment of prothrombotic phenotype is important to
determine optimal primary and secondary prophylaxis in patients with throm-
bophilia. Application of integral global assays promises to be useful in this
aspect. The Calibrated Automated Thrombography (CAT) is known to deter-
mine haemostatic misbalance and it reflects the action of both procoagulant
and anticoagulant factors. 
Aims: Aim of our study was to determine intermediate phenotype in asympto-
matic carriers of known prothrombotic mutations and in thrombophilic patients
with diagnosed thrombotic complications. 
Methods: Genotyping was done by PCR and restriction fragment length poly-
morphism analysis. Factor I 455 G/A, factor II (FII) 20210 G/A, factor V 1691
G/A (FVLeiden), factorxII 46 C/T, PAI-I 675 4G/5G, TPA 311 I/D, GpIa 807 C/T,
GpIbα 434 C/T, GpIIIa 1565 T/C, platelet receptor P2RY12 H1/H2, MTHFR
677 C/T, endothelial nitric oxide synthase 786 T/C, ApoE E2/E3/E4, AGT 704
T/C, ACE 287 I/D and angiotensin receptor 1 1166 A/C polymorphisms were
detected. Homocysteine (Hcy) was measured by high-performance liquid chro-
matography with fluorescence detection. Hyperhomocysteinemia (HHcy) was
defined as Hcy levels more than 95% percentile measured in age and sex
matched control group. Lupus anticoagulants (LA) were diagnosed according
to the SSC-ISTH criteria: a sensitive APTT, the DRVVT, and confirmatory tests.
Activities of FVIII, protein C and antithrombin were measured. The study
involved 100 persons: 85 patients with VTE and/or recurrent pregnancy loss
and 15 asymptomatic carriers of known prothrombotic mutations-7 FVLeiden
heterozygous, 6 FII20210G/A heterozygous and 2 double heterozygous. CAT
was done according to Hemker et al. at 5 pM TF and 4 μM phospholipids in
platelet poor plasma (PPP) with PPP plasma+/-TM reagent. 
Results: From the parameters of the thrombin generation curve (Lag time,
endogenous thrombin potential (ETP), peak thrombin (PT), time to peak), as
well as ETP and PT inhibition, no one showed significant correlation with
FVIII activity, studied polymorphisms and/or HHcy. None of the patients
demonstrated antithrombin or protein C deficiency. Among 85 patients with
VTE and/or recurrent pregnancy loss 18 patients had FV Leiden (FVL) muta-
tion, 5-FII20210G/A mutation, 1 was heterozygous for both mutations, 5 had
LA, 10-increased FVIII activity, 19-moderate HHcy. Significant correlation
with LA (p<0,05) was found for lag-time (R=0,45), ETP (R=-0,45) and PT
(R=-0,44) both in presence and absence of TM. ETP and PT reduced in the
presence of TM. Values below 21% for ↓ETP and/or 14% for ↓PT i.e. activated
protein C resistance (APCR) were found in 100% of FVL and LA patients,
90% of asymptomatic carriers of FVL and 50% of patients with increased
FVIII. Abnormal ↓PT was more sensitive to detect APCR. FII 20210G/A car-
riers demonstrated increased ETP (i.e. >2114 nMmin in the absence of TM
and >1433 nMmin in the presence of TM-values above 95% persentile of
controls) in 80% of cases. APCR was found by CAT in 20% of FII 20210G/A
carriers. 
Summary and Conclusions: We consider CAT to be useful in evaluating
haemostatic abnormalities in thrombophilia patients. In cost-effectiveness
aspect in a number of cases it could be preferable to a standard approach that
includes a wide panel of genetic and functional tests. Clinical utility of abnormal
CAT results in asymptomatic carriers of factor V Leiden and prothrombin
G20210A mutations needs further elucidation, but we suggest that an integrated
approach defining an individual’s intermediate phenotype could help in identi-
fying individuals with high risk for thrombotic event that would benefit from
active primary thromboprophylaxis.
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LMWH PROPHYLAXIS THROMBOTIC EVENTS IN HODGKIN LYMPHOMA
PATIENTS
A. Poletaev1,* A. Balandina1, V. Kopelevich2, I. Shitareva2, F. Ataullakhanov1,
S. Kravchenko2
1Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and
Immunology named after Dmitry Rogachev, 2National Research Center for
Hematology, Moscow, Russian Federation
Background: Patients with Hodgkin Lymphoma(HL) have a high risk of venous
thrombotic complication. LMWH is used for thrombosis prophylaxis throughout
the therapy. However this prophylaxis do not prevent all thrombotic complica-
tions thus routine laboratory monitoring is not recommended for low-dose
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LMWH. The problem of adequate laboratory diagnostic to identify high-risk
group and to prevent thrombotic complications is still remains.
Aims: The aim of this was to examine the state of hemostatic system in primary
patients with HL and to identify the number of thrombotic risk factors (RF) in
these patients. The evaluation of the effectiveness of heparin therapy remains
important.
Methods: Twenty four primary patients (median 31 yr, 18-60 yrs, 12 men
and 12 women), staging by Ann Arbor II-8, III-7, IV-9 patients, were enrolled
in this study. The number of thrombotic RF by NCCN scale is from 3 to 7. The
patients were treated by ВЕАСОРР-14. LMWH was administered in doses
70-113 IU/kg 2 times a day. aPTT, PI, TT, fibrinogen and D-dimer levels, and
the global hemostasis assays Thromboelastography (TEG) and Thrombody-
namics (TD) were performed to evaluate the hemostatic state of patients on
diagnosis (before oral contraceptives for women), on 1 and 8 day of all
chemotherapy cycles.
Results: Hypercoagulation was detected in 75% of primary patients with at
least one of the tests before treatment (45% by TD, 55% by TEG, 16% by
aPPT), 40% by TEG and TD, 20% by aPPT and TD, 13% by aPPT and TEG.
D-dimers were higher in 33% of patients. Throughout the chemotherapy cycles
in patients with ineffective LMWH prophylaxis was revealed the
significant(p<0.05) increase in global assays parameters (TD V(velocity)>25
um/min, TEG alpha>40 deg) and in D-dimer level compared to patients with
effective prophylaxis (medians 387ng/ml (min 62-max 5109) and 195ng/ml (min
53-max 3571) respectively). Blood samples were collected after 4 hours of
LMWH injection. Despite low-dose LMWH prophylaxis the D-dimer level was
significantly(p<0.05) increased from 1 cycle (median 213 ng/ml, min 71-max
5109) to 8 cycle (median 349ng/ml, min 79-max 4376) of chemotherapy.
Summary and Conclusions: Primary patients with HL revealed hypercoagulation
by global hemostasis assays, TD and TEG, before chemotherapy. Despite LMWH
prophylaxis nearly 40% of patients remained hypercoagulation state by global
hemostatic assays and D-dimer level. The combination of global assays parame-
ters, D-dimer level and thrombotic RF is prospective in indicating high-risk group
and monitoring and correction of LMWH prophylaxis in patients with HL.
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CATALASE С−262Т GENE POLYMORPHISM AS A POSSIBLE RISK FAC-
TOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF
NORTH-WESTERN RUSSIA
S. Kapustin1,* V. Shmeleva2, L. Aleksanyan3, N. Saltykova4, S. Svitina3,
V. Soldatenkov4
1Russian Research Institute Of Haematology And Transfusiology, Saint-Peters-
burg, Russian Federation, 2Laboratory of Hemostasis, 3Laboratory of Biochem-
istry, 4Surgery Department, Russian Research Institute Of Haematology And
Transfusiology, Saint-Petersburg, Russian Federation
Background: The role of genetic mechanisms in most cases of venous throm-
boembolism (VT) is still unclear. We have recently shown, that in addition to
known molecular determinants of inherited thrombophilia, genetic variations asso-
ciated with endothelial dysfunction (ED) could be involved in pathogenesis of VT.
Oxidative stress is an important mechanism of ED development which occurs
due to imbalance between reactive oxygen species production and antioxidant
system activity. Catalase is an important enzyme of antioxidant system which
activity depends on the variation(s) in the promoter of the respective gene.
Aims: To evaluate the role of catalase С−262Т gene polymorphism as a pos-
sible risk factor for VT in the population of North-Western Russia.
Methods: Retrospective study involved 300 patients with VT (147 men and
153 women, mean age 42.3±12.6 years) and 203 sex- and age-matched
healthy controls (HC). All individuals originated from the North-Western region
of Russia and gave informed consent for participation in the study. Catalase
С−262Т gene polymorphism was discriminated by PCR-RFLP technique. The
differences in genotype distributions between the groups were estimated by
Fisher`s exact test. Odds ratios (OR), their 95% confidence intervals (CI) and
p-values were calculated using the GraphPad Prism software.
Results: Catalase −262Т allele was more frequently seen in VT patients than
in HC (44.3% vs 34.9%, OR=1.5; 95% CI: 1.0-2.1; p=0.042). Heterozygosity
for this polymorphism was present in 39.0% of VT cases compared to 30.0%
in controls (OR=1.5; 95% CI: 1.0-2.2; p=0.046). Catalase −262Т allele occurred
more frequently in the group of 200 patients with early-onset disease (at age
45 or less) than in those who suffered from the first VT episode after 45 years
old (46.0% vs 40.0%, respectively). The frequency of homozygous −262ТT
genotype was 2-fold higher in young patients than in those with late-onset VT
(6.5% vs 3.0%, respectively). When compared to HC group, the presence of
the catalase −262Т allele has been proved to be a significant risk factor for VT
development in young patients originated from the North-Western region of
Russia (OR=1.6; 95% CI: 1.1-2.4; p=0.026). At the same time, the difference
between the group of patients with late-onset VT and HC for the proportion of
individuals positive for −262Т variant was not statistically significant (40.0% vs
34.9%, respectively, OR=1.2; 95% CI: 0.8-2.0; p=0.45).
Summary and Conclusions: We suggest that catalase С−262Т gene poly-
morphism is a possible risk factor for VT development in young patients from
the North-Western region of Russia.
Transfusion medicine
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EVALUATION OF ABO BLOOD GROUP DISCREPANCIES IN A TERTIARY
CARE CENTRE IN SPAIN
M. Tenorio1,* G. Moreno1, A. Jiménez1, V. García Gutiérrez1, C. Anabelle1,
C. Maria1, H. Pilar1, J. López-Jiménez1
1Haematology and Haemotherapy, Hospital Ramón y Cajal, Madrid, Spain
Background: ABO incompatible blood transfusion is associated with major
morbidity and mortality. Solving ABO discrepancies is an essential step towards
a safe transfusion practice.
Aims: To evaluate the frequency, main causes and clinical impact of ABO blood
group discrepancies detected in our hospital in a two-year period of time.
Methods: We retrospectively analyzed all ABO discrepancies recorded in
Ramón y Cajal Hospital Blood Bank from 1st January 2013 to 31st December
2014. The results included both in-patients and out-patients but not blood
donors. ABO blood group determination in our centre includes forward and
reverse group using column agglutination technology (AutoVue Innova, 0.8%
Affirmagen A1, B Grouping Red Blood Cell, and ABO/Rh Reverse cassette).
When ABO discrepancies are detected, sample and reagent suitability is
checked and the cited automatized test is then repeated. Once confirmed, man-
ual red cell (Anti-A, Anti-B Diagast) and serum (A1, B cells Affirmagen 3.5%,
Ortho Clinical Diagnostics) tube testing at different temperatures (immediate
centrifugation, room temperature and at 4ºC) is performed. If unexpected pos-
itive reactions are seen in the serum test, a 3-cell antibody screen (Surgiscreen,
Ortho Clinical Diagnosis) is also carried out. When relevant, antibody identifi-
cation panels (11- cell microcolumn Liss-Coombs and papain-treated red cells
panels, DianaGel-Grifols), direct antiglobulin test (polyspecific and monospecific
anti-IgG and C3d, Menarini reagents) and adsorption and elution tests (acid
glycine elution or 56ºC elution) were also undertaken. When necessary, sam-
ples were sent to the Blood Regional Centre for molecular analysis. The causes
for the discrepancy were assessed as well as the clinical impact of the subse-
quent resolution of the ABO blood group problem.
Results: A total of 155 patients presented ABO discrepancies. The main causes
for the discrepancy were: ABO major incompatibility allogeneic stem cell trans-
plantation (ASCT) (9.7%), ABO minor incompatibility ASCT (12.3%), both major
and minor incompatibility ASCT (1.3%); “A” subgroups (6.5%), out-of-group
transfusion (2.6%), acquired immunodeficiencies (18.7%), alloantibodies
(3.2%), autoantibodies (2.6%), cryoagglutinins (4.5%), technical errors (11%),
age-related (6.5%) and others (19.4%). In the “A” variants group, 6 A2B were
detected (5 with anti-A1 active at 37ºC) and 4 A2 were detected (2 with anti-A1
active at 37ºC). The alloantibodies identified were anti-M (n=4) and anti-H (n=1).
The “others” group consisted of samples with diminished serum testing results
in column agglutination technology but normal reverse grouping in test tube at
lower temperatures (4ºC). Solving ABO discrepancies lead to specific blood
unit selection and preparation in 51 patients through antigen phenotype match
(n=5), compatible blood cross-match (n=49), not allowing O transfusion (anti-
H: 1 case) and pre-warming of blood and minimizing low temperatures during
cardiac surgery (1 cryoagglutinin with cardiac valve surgery). No hemolysis
was observed in the patients who received blood transfusions.
Summary and Conclusions: Currently, ABO incompatible ASCT is the main
cause of ABO discrepancy in our hospital followed by acquired immunodefi-
ciency and by technical issues. Automatized ABO discrepancies should be con-
firmed in test tube method and at low temperatures in the serum test. ABO dis-
crepancy resolution lead to specific transfusion practice decisions in about a
third of these patients.
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USE OF A PEGYLATED CARBOXYHEMOGLOBIN BOVINE IN SEVERE
LIFE-THREATENING ANEMIA 
R. Jubin1,* J. Berryman1, R. Prince1, H. Misra1, A. Abuchowski1
1Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, United
States
Background: Patients who cannot receive blood transfusions in the presence of
severe anemia can sustain significant morbidity and mortality. Religious beliefs
and hemolytic reactions are the most common reasons for not transfusing a
patient. Pegylated bovine carboxyhemoglobin (Sanguinate; SG), a therapeutic
drug, has been used in 5 such patients including a patient who developed a
severe hemolytic reaction following stem cell transplantation. SG is a therapeutic
drug designed to carry carbon monoxide (CO) and oxygen in the mammalian
vasculature for delivery to tissues to synergistically treat inflammation and vaso-
constriction and other comorbidities characterized by tissue hypoxia. 
Aims: Perform post-hoc analysis of clinical findings; their relationship to indi-
vidual patient diagnosis/associated comorbidities and SG intervention.
Methods: Five patients with hemoglobin (Hb) levels under 3.5 g/dL were treated
with repeated doses of SG. Diagnoses included AML, hemolytic reaction, acute
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chest syndrome and sickle cell crisis. Patients ranged in age from 19 to 61. A
unit of SG consists of 500 mL (40 mg/mL). Total doses ranged from 1 unit/day
for 2 to 4 days up to 8 units given over 9 days. 
Results: No adverse events associated with SG were reported. Each investi-
gator reported clinical improvements in their patient following administration of
SG, despite continuing low Hb levels. The number and size of allowed blood
draws were restricted; therefore analysis of clinical chemistries was limited.
Patients with reported extreme fatigue or neurological deficit each demonstrat-
ed increases in responsiveness or self-reported comfort within close temporal
association with SG treatment. One patient had a significant increase in cere-
bral oximetry and another showed improvements in cerebral blood flow meas-
ured by TCD. A patient with hyperhemolysis reported feeling well with no pain
and no shortness of breath despite severe anemia (Hb 2.5) and had improved
mobility following a total of 8 units of SG. A patient who had undergone a stem
cell transplant developed immune hemolytic anemia, with resulting extreme
fatigue and tachycardia. He received 4 once-daily units of SG, during which
time his heart rate normalized and was reported to be alert and oriented. 
Summary and Conclusions: Evidence indicates that SG has potential thera-
peutic benefit in patients who have life-threatening anemia and cannot receive
blood transfusions for personal or medical conditions. As vasoconstriction,
inflammation, and oxygen deprivation are significant factors in severe hemol-
ysis and ischemia, SG through the therapeutic actions of CO and oxygen may
interrupt the ischemic cascade and improve clinical symptoms of hypoxia due
to severely low hemoglobin levels. The improved clinical status in these patients
suggests that SG has potential utility in patients with severe anemia who are
unable to receive blood transfusions. Since submission to ASCO2015, preclin-
ical and in vitro studies with SG have been shown to demonstrate anti-inflam-
matory activity as well as active CO and oxygen transfer. SG is currently in
clinical development. A protocol is under development to treat patients for whom
blood transfusion is not an option.
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CLINICAL COURSE AND OUTCOME OF NEWLY DIAGNOSED ACUTE
LEUKEMIA PATIENTS PRESENTED WITH HYPERLEUKOCYTOSIS IN
THAILAND: A 10-YEAR SINGLE-CENTER RETROSPECTIVE STUDY
A. Khuhapinant1,* T. Naorungroj1
1Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Background: Hyperleukocytosis is defined as peripheral WBC count ≥100x
109/L or blast count ≥50x 109/L. It is one of the most emergent life-threatening
conditions in acute leukemia (AL) and confers early and high mortality, low
complete remission (CR) rate and high relapse rate. Patients with hyperleuko-
cytosis may suffer from vascular infiltration of CNS and lungs, and fatal bleeding
in vital organs. Most such patients belongs to monoblastic subtype of acute
myeloid leukemia (AML). Current treatment would include prior intensive leuka-
pheresis followed by intensive chemotherpy.
Aims: To study an incidence, clinical and laboratory presentation, treatment
modalities and outcome of newly diagnosed AL patients presented with hyper-
leukocytosis.
Methods: This was a retrospective, descriptive chart review study. All newly
diagnosed AL patients presented with hyperleukocytosis in Siriraj Hospital,
Mahidol University, Thailand during 2000-2009 were included. Data collection
comprised demographic data, presenting clinical manifestation, initial WBC
and blast count, chemistry panel, types of AL (AML, acute lymphoblastic
leukemia (ALL) and subtypes), treatment modalities with complications, and
outcome including overall survival (OS) and disease-free survival (DFS).
Results: Of all 1,232 AL patients, 136 patients (66 male) were collected. Medi-
an age was 46.52 years (range 13-87), and AML:ALL was 118:18 of which M4,
M1 and M5 were the majority subtypes (34, 26 and 20, respectively). Normal
karyotype was found in 48 of 74 patients. Presentation (%) with fever, alveolar
hemorrhage, hypoxemia, acute respiratory distress syndrome, ischemic and
hemorrhagic stroke, headache, dizziness/ vertigo, blurred vision, and abnormal
bleeding were 29.4, 2.9, 12.5, 3.7, 2.9, 2.2, 12.5, 4.4, 6.6 and 42.6, respectively.
Median WBC and blast count (x 109/L) were 201.42 (58.59-978.00) and 159.90
(0.54-806.40), respectively. Only 129 patients received treatments with either
leukapheresis (2), chemotherapy (120) or combination of both (7). CR rate
was 34.85% after front-line treatment, and median OS and DFS were 2.86 and
7.87 months, respectively. Major causes of death (%) were infection, bleeding,
stroke and respiratory failure for 47.8, 16.2, 5.1 and 5.1, respectively.
Summary and Conclusions: Hyperleukocytosis as initial presentation in acute
leukemia is associated with poor prognosis and overall survival. More rapid,
emergent and appropriate treatment is required to improve outcome.
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DETECTION OF UNEXPECTED RED CELL ALLOANTIBODIES BY THE
ENZYME/NACL GEL TEST ONLY
A. Argyrou1,*F. Vakos1, K. Kamitaki1, K. Manta1, A. Podaras1, C. Kiriakopoulos1,
M. Kokkinou1, C. Maraki1, A. Gafou1
1Blood Bank, General and Oncology Hospital “Agioi Anargyroi”, Athens, Greece
Background: In the patient’s pretransfusion testing, the antibody screening
helps in detecting the presence of significant red blood cell (RBC) alloantibod-
ies. Performing a low ionic strength solution (LISS) indirect antiglobulin test
(IAT) at a minimum couple of donor’s reagent RBC expressing all the clinically
significant antigens, is considered as the only obligatory step. The additional
step of hemagglutination testing by using enzyme treated RBC could further
contribute in determining the presence of unexpected alloantibodies.
Aims: The determination of the frequencies/ specificities of “enzyme only”
detected RBC- alloantibodies in the routine RBC antibody screening. 
Methods: In a general hospital of 300 beds (>80% oncology patients), 10523
blood samples, were submitted for routine pretransfusion testing, during a 41-
months-period (11/2010- 5/2014). According to National Blood Bank Center’s
guidelines for blood group serology, all samples were tested for ABO blood group,
RhD antigen and RBC unexpected alloantibodies. The RBC antibody screening
was carried out with a 3-cell panel RBCs LISS IAT on Liss/Coombs cards, and
also with an enzyme test (ET) with a 3-papaine-treated-cell panel on NaCl cards,
according to the manufacturer’s instructions. In the case of a positive screening
test result, an antibody identification test was carried out, using an 11-cell panel
LISS IAT and an 11 papaine-treated cell panel test (ET). Results were considered
“inconclusive” either when there was no specific alloantibody identified or when
the test reaction was too weak to interpret accurately. A positive screening test
followed by a negative panel investigation was considered “false positive” result.
The inconclusive results, the false positive ones, as well as the cases of autoan-
tibodies were categorized as “unwanted positive reactions”.
Results: During the study period, 10523 samples were tested. Positive RBC
antibody screening (positive IAT/ positive ET, or negative IAT/ positive ET) was
recorded in 168 patients. Negative IAT/ positive ET screening was found in
54.76% of them (n=92, 47.8% men, 52.2% women). A history of previous trans-
fusion, was recorded in 50 patients (54.34%), while 34 (36.95%) of them had
never been transfused before and 8.69% (n=8) had an unknown history of
transfusion. A history of labor or miscarriage was recorded in 44 women
(91,66%). The frequencies/specificities of RBC antibodies detected only by the
ET technique are shown in Table 1.
Table 1.Frequencies and specificities of RBC antibodies detected with
the ET technique only.
Summary and Conclusions: 1. The ΕΤ technique helps in detecting clinically
significant RBC alloantibodies (e.g. anti Jkb) which could be missed if we used
the IAT technique only (early phase of alloimunization? low- titter antibodies?). 2.
Larger studies could lead to more data about the frequency/ specificity of detected
RBC alloantibodies and help in defining the necessity or not of performing the ET
technique in general patient population or among specific subpopulations.
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SUCCESSFUL COMPATIBLE PHENOTYPE TRANSFUSION PROTOCOL
TO PREVENT ALLOIMMUNIZATION IN SICKLE CELL DISEASE
S. Redondo Velao1,* A. Pérez-Corral1, E. Cela2, V. Pradillo1, C. Pascual1,
C. Beléndez2, C. Garrido1, C. Coomonte1, C. Falero1, J.L. Díez- Martín1,
J. Anguita1
1Hematology, 2Gregorio  Marañón Hospital, Madrid, Spain
Background: Transfusion of red blood cells (RBCs) is used to treat and prevent
complications of sickle cell disease (SCD). Alloimmunization to non-ABO anti-
gens is commonly encountered in part due to antigen disparity between blood
donors and patients for ethnic reasons and in part due to the frequency of pro-
inflammatory factors present at time of transfusion. 
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Aims: We report our experience in one single reference center. 
Methods: We retrospectively analyzed pediatric patients with SCD and at least
one RBC transfusion in Gregorio Marañón Hospital (pediatric reference center
for SCD patients in Madrid) through a query of blood bank database. Patients
were excluded if they were alloimmunized prior to be transfused in our center.
Transfusion indications included acute complications, therapy for prevention
cerebral vascular events and pre-stem cell transplantation. Since 2009 a pedi-
atric RBC matching protocol is applied at our blood bank for every new SCD
patient who is going to have a hypertransfusion regimen. It entails matching for
ABO, D, C, E, c, e and Kell. Before first transfusion, fully phenotype is performed
(ABO, D, C, E, c, e, Kell, Jka, Fya and S) and registered in the database. If fur-
ther alloimmunization occurs extended matching is employed. 
Results: A total of 32 patients (19 males, 13 females) with HbSS and history
of one or more RBCs transfusion between 1998 to 2015 were included; 23
were African, 8 African-American and 1 Asian. The median age of the first
transfusion was 4 years (5 months-16 years). Of the 32 patients, 13 (40.63%)
were on chronic transfusion therapy for prevention cerebral vascular events
(6) or pre-stem cell transplantation (7); 19 (59.37%) were transfused because
of acute complications such as acute chest syndrome (6), splenic sequestra-
tion (6), vaso-occlusive crisis (4) and acute febrile illness (3); 11 received
bone marrow transplantation and 19 were on chronic Hydrea treatment; of
the 32 patients, 24 (75%) were transfused under the pediatric RBC matching
protocol, and 8 (25%) were transfused matching only ABO and D. Median
transfusion per patient was 11.5 RBCs (1-57) with total transfusions of 482
RBCs resulting in the formation of 5 new RBC alloantibodies in four patients
(AntiKpa, AntiM+S, AntiK, AntiFya). The global alloinmunization rate was
1.037% per 100 units transfused and the alloinmunization under pediatric
RBC matching protocol was 12.5% per patient; no case was associated with
hemolytic transfusion reaction. The characteristics of alloimmunized patients
are shown in Table 1. The median number of RBCs transfused pre new anti-
body was 3 (2-17) and there was no clear association between the number
of units transfused and alloinmunization. Of the 4 alloimmunized patients, 2
were on chronic transfusion and 2 were transfused due to acute complica-
tions, 3 of them were transfused with Rh (C,E,c,e) and Kell matched RBCs,
and the other one was transfused before the matching protocol was use. 
Table 1. Characteristics of alloimmunized patients with SCD (N=4).
Summary and Conclusions: As previously described, we confirm that limited
RH (C,E,c,e) and K phenotype matched transfusion could be enough to suc-
cessfully reduce the incidence of alloantibody production in SCD. With this pro-
tocol we manage a very low alloinmunization rate (1.037% per 100 units trans-
fused), with only 5 alloimmunizations in 4 patients which did not jeopardize
subsequent transfusions. This scenario allows routine transfusion protocols to
prevent SCD complications.
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THE MIRNA PROFILE OF PLATELETS STORED IN A BLOOD BANK AND
ITS RELATION TO CELLULAR DAMAGE FROM STORAGE
T. Pontes1,* C. Moreira-Nunes1, J. Maués2, L. Lamarão3, J.A. Lemos3,
R. Montenegro1, R. Burbano1
1Institute of Biological Sciences, 2Human and Medical Genetics, Federal Uni-
versity of Pará, 3Laboratory of Genetics and Molecular Biology, Foundation
Center for Hemotherapy and Hematology of Pará_HEMOPA, Belém, Brazil
Background: Millions of blood products are transfused each year, and many
lives are directly affected by transfusion. Platelet concentrate (PC) is one of
the main products derived from blood. Even under good storage conditions,
PC is likely to suffer cell damage. The shape of platelets changes after 5 to 7
days of storage at 22°C. Taking into consideration that some platelet proteins
undergo changes in their shape and functionality during PC storage.
Aims: Characterize the most highly expressed miRNAs in PC using high cov-
erage sequencing, examine quantitative changes in miRNA levels during and
after storage in a blood bank and validate by real-time quantitative polymerase
chain reaction (RQ-PCR) most expressed miRNAs in 40 PC bags tubes to pro-
pose candidate miRNAs as biomarkers of PC storage damage.
Methods: Sixteen PC bags were collected and each PC bag tube was cut into
six equal pieces to perform experiments with platelets from six different days of
storage. Thus, on the first day of storage, 1/6 of the tube was used for miRNA
extraction, and the remaining 5/6 was stored under the same conditions until
extraction of miRNAs on each the following five days. Samples were sequenced
on an Illumina Platform to demonstrate the most highly expressed miRNAs. Two
miRNAs, mir127 and mir320a, were selected from miRnome and two were select-
ed based on literature to validated by real-time quantitative PCR (RQ-PCR).
Results: Our sequencing results suggests the use of the miRNAs mir127 and
mir320a as biomarkers to assess the “validity period” of PC bags stored in
blood banks for long periods. Preliminary validation results suggest statistical
difference the four selected miRNAs from the fourth day storage (p<0.05). Thus,
bags can be tested on the 5th day of storage for the relative expression levels
of this miRNAs (Figure 1).
Figure 1.
Summary and Conclusions: We suggest using candidate miRNAs as molecular
biomarkers of storage damage that can be used as tools to evaluate the quality
of stored PC. The use of miRNAs as biomarkers storages damage is unprece-
dented and will contribute to improved quality of blood products for transfusions.
E1577
MONITORING HEMOSTATIC POTENTIAL OF PLATELETS DURING STOR-
AGE OF PLATELET CONCENTRATES FOR TRANSFUSION
C. Giaccherini1,* M. Marchetti1, C. Verzeroli1, C.J. Tartari1, L. Russo1, A. Vignoli1,
E. Diani1, B. Woodhams2, A. Falanga1
1Immunohematology and Transfusion Medicine, Hospital Papa GiovannixXIII,
Bergamo, Italy, 2Haemacon ltd, Bromley, United Kingdom
Background: Platelet concentrates (PCs) are extensively used either prophy-
lactically to prevent bleeding in onco-hematology patients with thrombocytope-
nia, or therapeutically to control active bleeding. For a successful transfusion,
platelets in PCs should have a good hemostatic potential to have an effective
and immediate action.
Aims: In this study we evaluated variations in platelet activation and aggrega-
tion properties during standard storage of PCs and the influence of blood group
on these changes. 
Methods: Seventy pooled buffy-coat-derived PCs (O group=43, A group=27)
were analyzed on the day of preparation (D0) and after 3 day-storage (D3) at
22°C on lateral agitation. Platelet aggregation was assessed by Born method
(300,000 plts/ul) in response to collagen (5mg/ml), TRAP-6 (40mM) or arachi-
donic acid (1mM). Levels of degranulation markers (Platelet factor 4 (PF4), β-
Thromboglobulin (β-TG), Thrombospondin-1 (TSP-1) and Vascular Endothelial
Growth Factor (VEGF)), together with soluble form of membrane surface pro-
teins, i.e. P-selectin and glycoprotein V (sGPV), were evaluated in PC super-
natants by ELISA. Data were analyzed according to blood group and statistical
analysis performed using SPSS statistic data editor.
Results: Platelet aggregation potential after three days of storage was signif-
icantly (p<0.01) decreased in response to TRAP-6 (-35%) and collagen (-
58.5%). Moreover, platelets from A group showed lower aggregation capacity
to all agonists used, both in D0 and D3, compared to those from O groups
(p=ns). Analysis of PC supernatants showed that levels of the soluble form of
the two platelet membrane surface molecules, P-selectin and GPV, significantly
(P<0.01) increased from D0 to D3, respectively of 49% and 123%, probably
due to platelet degranulation and to the presence of protease activity in PC
bags. Similarly, level of α-granule proteins significantly (p<0.01) raised during
storage. We observed marked differences in percentage increment according
to the type of α-granule proteins and blood groups analyzed. Particularly, PF4
and β-TG, which levels significantly (p<0.001) correlates (r=0.932), raised
respectively about 140% and 110%, and the increase was higher in A group;
TSP-1 level increased only about 33% and mainly in O group; finally, VEGF
level raised about 180% in both blood groups. All these data suggest the occur-
rence of a differential and regulated release of platelet α-granules subsequent
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to activation. A significant (p<0.05) inverse correlation was found between the
decrease of aggregation potential induced by TRAP-6 and the increase in PF4
(r=-0.335), β-TG (r=-0.415) and sGPV (r=-0.420) levels.
Summary and Conclusions: During storage, platelets become activated and
change their hemostatic phenotype; this reflects in an increased release of α-
granules content and a lower ability to aggregate in the presence of agonists.
Platelets of A group seem to be more sensitive to these phenomena. The sig-
nificant correlation found between degranulation and platelet aggregation sug-
gests that measurement of these proteins can be a valuable surrogate of
platelet aggregation for evaluation of platelet hemostatic potential. Further stud-
ies are required to define the strength of these markers to identify PCs that
could not display a full functionality and reactivity in the recipient.
E1578
INDIVIDUALIZED GCSF/PLERIXAFOR PBSC MOBILIZATION SCHEDULE
ALLOWS SUCCESSFUL HARVEST ALSO IN POOR MOBILIZERS LYM-
PHOMA PATIENTS
M. Postorino 1,* A. Lanti2, E. Fiorelli3, A. Zizzari1, L. Pupo1, D. Nasso1, L. Giannì1,
S. Vaccarini1, L. Franceschini1, G. Paterno1, M. Rizzo1, G. Guiducci3, F. Meconi1,
I.M. Onnis1, V.M. Rapisarda1, F. Buccisano1, G. Adorno3, M. Cantonetti1
1Ematologia, Dipartimento di Biomedicina e Prevenzione, Università Tor Ver-
gata, 2SIMT, Policlinico Tor Vergata, 3Immunoematologia, Università Tor Ver-
gata, Rome, Italy
Background: Autologous peripheral blood stem cell (PBSC) transplantation
has a fundamental role in first line treatment of multiple myeloma (MM) and
has been shown to improve complete remission and overall survival rates in
relapsed Non Hodgkin Lymphomas (LNH). GCSF with or without chemotherapy
represents the conventional PBSC mobilization regimen; according to standard
criteria apheresis start at level of 20x10^6/L CD34+ cells. Nevertheless, 10%
to 20% of patients fail the harvest of an adequate amount of PBSCT.
Aims: The combined administration of Plerixafor and GCSF at steady state or
during haematological recovery after chemotherapy allows a sufficient PBSC
harvest even in this group of poor mobilizers. In fact, many authors demon-
strated that, in poor mobilizers, CD34+ PBSC reach a peak 9 hours after pler-
ixafor administration and in this time-frame the CD34+ cell count may become
sufficient to start apheresis. The aim of our study was to assess the feasibility
and safety of a regimen combining GCSF (10 µg/kg, on days 1-4) and plerixafor
(0,24 mg/kg on day +4), with leukaphereses started at a lower level of circu-
lating CD34+ cells (10x10^6/ L).
Methods: Patients and methods: Between July 2014 and February 2015 we
enrolled 10 pts affected with LNH. Seven were male e 3 female, median age
was 48 (range 36-62). Seven pts were proven and 3 were predicted very poor
mobilizer. The CD34 mobilization profile was evaluated by testing CD34+ levels
every 3 on day +4 of CGSF alone (6 patients) or starting on day +10 during
recovery post DHAP chemotherapy (3 patients). In case an increase of CD34+
cells of at least 10 /microl was not reached, we administered plerixafor on day
+5. Thereafter we tested CD34+ count every 3 hours and we began leuka-
pheresis as soon as CD34 count reached 10/mL.
Results: Results: All patients successfully performed leukaphereses and
reached the target value of CD34 (2.x 10^6/kg) with one (in 5 pts) or two (5
pts) procedures. Median value of cd34+ cells/ul at +3, +6, +9, +12 hours at
day +5 were 15.5, 15.8, 19.11, 16.8, respectively; median value of CD34 har-
vested at day +5 was 1.7x 10^6/kg (range 0,86-7,63). Five pts needed a second
plerixafor dose and apheresis and the median value of CD34/ul at +3, +6, +9,
+12 hours were 13, 8.7, 8.27, 7.5, respectively; median value of CD34 har-
vested at day +6 was 1.2x 10^6/kg (range 0.61-3.18). In the overall series the
median value of CD34 harvest was 2.66x 10^6 CD34/kg (range 1.97-7.67). 5
pts underwent to PBSC transplantation and the median of neutrophils and
platelets engraftment were 12 and 18 days respectively.
Summary and Conclusions: Conclusion: An early (hour +3) evaluation of
CD34+ levels after plerixafor allows detecting early CD34 increase that would
be missed with standard monitoring protocols (hour +12). Moreover the early
evaluation of Cd34 mobilization profile starting on day +4 allows identifying
patients who are predicted to become poor mobilizers so that a further dose of
plerixafor may be added to standard schedule. This strategy may be successful
in rescuing patients that, according to standard criteria, would never reach the
minimum level of CD34+ cells to start leukaphereses.
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GENETIC RISK FACTORS IN HUMORAL IMMUNE RESPONSE TO
PLATELET ANTIGENS HLA AND HPA SYSTEMS IN MULTITRANSFUSED
HEMATOLOGICAL PATIENTS 
L.L. Golovkina1,* T. Pushkina1, P.E. Mikhaylova2, A.V. Savchenko3
1Immunohematology, 2Chemotherapy of Hemoblastosis and Bone Marrow Fail-
ure, 3General Head, National Research Centre for Hematology of Ministry of
Healthcare Service Russian Federation, Moscow, Russian Federation
Background: Humoral immune response to alien antigens reduces number
of compatible and, hence, safe blood components transfusions. Alloimmuniza-
tion of recipients to HPA (Human Platelet Antigens) and HLA (Human Leukocyte
Antigens) I class antigens is one of the common immunological complications
in platelet transfusions. Molecules HLA II class play an important role in the
initiation of humoral immune response as amino acid structure of peptide-bind-
ing sites of immune cells influences on presentation of alien peptide to Т-lym-
phocyte’s receptors. HLA-restricted mechanisms of alloimmunization are not
investigated enough in transfusiology.
Aims: to investigate the association of the HLA and HPA genotypes with anti-
body formation to HLA and HPA systems in multitransfused Russian hemato-
logical patients.
Methods: serums of 228 multitransfused patients [100 with aplastic anemia
(АА) and myeloproliferative syndrome (MDS), 76 with acute myeloblastic
leukemia (AML), 52 with acute lymphoblastic leukemia (ALL)]; DNAs of 178
the same patients (57 with АА and MDS, 44-with ALL, 77-with AML). All inves-
tigated people were of Eastern European origin.HLA-DRB1,-DQB1 (low and
high resolution) (Dynal, Protrans, BAG) and НРА-1,-2,-3,-4,-5,-6,-15 genotyping
by PCR-SSP (BAG, Protrans). Patients were initially screened for HLA class I
using standard microlymphocytotoxic test; and for HPA antibodies using ELISA
with native and modified (without HLA) platelets. HPA-typed platelets were
used for detection of anti-HPA antibodies specify. The statistical calculation
was performed using Chi-square and Fisher exactly (in small groups) criteria,
p value <0,05 were considered significant. HLA haplotype were estimated via
maximum-likelihood analysis using the Arlequin software version 3.5.
Results: Alloimmunization to HLA and to HPA was detected in 70% patients
with AA and MDS, 35,5% patients suffering AML, and 15% patients with ALL.
Antibody formation depends on disease’s forms which range on alloimmu-
nization frequency as follow: АА-AML-ALL. Parallel investigations of HLA
antibody formation and HLA genotyping were carried out in 124 patients (39
AA+MDS, 36 ALL, and 49 AML) from whom only 48 made HLA antibodies
(20 AA, 22 AML, and 6 ALL). Risk factors for anti-HLA antibody formation
were established as HLA-DQB1*02 and HLA-DQB1*03:01 with closely linked
genes of superfamily HLA-DRB3*01 (HLA-DRB1*03,-*11,-12,-*13,-*14):
18/20 AA and 13/22 AML patients with anti-HLA and 6/19 AA and 7/27 AML
without anti-HLA were HLA-DQB1*03:01 positive (p<0,001 and 0,04 accord-
ingly). Absolute marker of alloimmunization to HLA was haplotype HLA-
DRB1*13:03,-DQB1*03:01: 5/20 patients with AA (p=0,047), 4/22 patients
with AML (p=0,035) and 3/6 patients with ALL (p=0,01) were positive for this
one. 10/22 AML patients with antibodies and 4/27 without those were HLA-
DQB1*02 positive (p=0,027). Genes HLA-DRB1*15 and HLA-DQB1*06 had
protective effect for anti-HLA antibody formation in AML patients: 13/27
patients without HLA antibodies and 3/22 with antibodies were HLA-DRB1*15
positive (p=0,015); according HLA-DQB1*06 the relation was as 19/27 and
7/22 (p=0,016). Parallel investigations of HPA antibody formation and HLA
typing were carried out in 114 patients (46-AA+MDS, 56-ALL, and 12-AML)
from whom only 33 made HPA antibodies. We could detect the antibody spec-
ifies in 24 patients. Haplotypes of predisposition for specific HPA antibodies
formation were determined as follow: to anti-HРА-1b in HPA-1a/1a patients-
HLA-DRB1*07:01,-DQB1*02; to anti-НРА-5b in HPA-5a/5a patients-HLA-
DRB1*13:01,-DQB1*06 and HLA-DRB1*13:03,-DQB1*03:01, to anti-HPA-2b
in HPA-2a/2a patients-HLA-DRB1*15,-DQB1*06:02/*06:14.
Summary and Conclusions: HLA tissue type profiles together with HPA typing
will be informative in predicting the alloimmunization in multitransfused patients.
It’s very important in patients needed long term platelet transfusion support.
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STUDY OF AN ALTERNATIVE PYROGEN TEST FOR BLOOD PRODUCTS
USING MONOCYTE ACTIVATION TEST
J.H. Kim1,* C.-Y. Ahn1
1Blood Product Team, National Center for Lot Release, NIFDS, Ministry of
Food and Drug Safety, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Background: Blood product such as plasma derivatives is a drug manufactured
by separating plasma protein components. For example, human serum albumin,
immunoglobulin, coagulation factor etc. are plasma-derived preparations. Cur-
rently the rabbit pyrogen test is practiced for national lot release of final blood
derived products. However, the replacement of rabbit test needs to be considered
due to the high consumption of animals and ethical issues. While it costs many
lives of rabbits, it does not line with the international trend which argues for min-
imization of animal testing, also represented as 3R. There also has been a need
of replacement due to its impossibility in quantification of pyrogen, and also to its
sensitivity to condition of animals and technique of examinant.. In this study, we
established an assay method of alternative pyrogen test for final blood derived
products using monocyte activation test as a quality control.
Aims: The aim of our study was to develop an alternative in vitro pyrogen test
for final blood derived products.
Methods: Three organizations including MFDS collaborated for this joint
research about monocyte activation test. We established the assay protocol of
monocyte activation test according to the EP 2.6.30. In this research, human
cryopreserved blood was used as a cell source of human monocyte and fever
inducing cytokines were measured by ELISA method to determine the pyro-
genisity of the samples. Three organizations shared the established protocol
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and conducted the monocyte activation test for WHO-endotoxin international
standard and representative non-endotoxin pyrogenes from gram positive bac-
teria, fungi. And then we also applied the assay method to final plasma derived
preparations. We confirmed the possibility to replace of the rabbit pyrogen test
by conducting the preliminary test.
Results: As a result, we established conditions and test method of monocyte
activation test for endotoxin and non-endotoxin pyrogen standards. And we
confirmed that not only endotoxin from gram negative bacteria but also non-
endotoxin pyrogenes from other origins were detected by monocyte activation
test using human cryopreserved blood and cytokine IL-1beta, IL-6 and TNF-
alpha ELISA kit. In addition, we conducted monocyte activation test (MAT)
based on human fever reaction to study on the possibility of its application to
final blood products. Furthermore, data showing that MAT is capable of covering
the total pyrogens and applicable to blood derived products.
Summary and Conclusions: By this study of alternative pyrogen test, espe-
cially monocyte activation test for national lot release of complete blood prod-
ucts, we predicted substitutability of the rabbit pyrogen test. The results of the
research will be used as baseline data for introduction of in vitro pyrogen test
which is mainly inspected for safety of blood product, and will also contribute
to blood product quality improvement. However, further study is needed to con-
firm that the developed method can be used as an official quality control test.
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INFILTRATION OF PLATELET RICH PLASMA OBTAINED IN OPEN SYS-
TEM IN PATIENTS WITH EPICONDILITIS
A. García Raso1,* A. Fernandez Bravo2, S. Sanchez3, T. Arquero3, B. Gutierrez2,
E. Fontoira4, M.V. Rodriguez3, G. Bermejo2, C. Fernandez2, P. Llamas 3
1Hematolgy, Health Care Institute Fundación Jiménez Díaz, 2Rehabilitation,
3Hematolgy, 4Radiology, Fundacion Jimenez Diaz University Hospital, Madrid,
Spain
Background: There is evidence that the infiltration of PRP improves function
and pain in patients with chronic epicondylitis and is an alternative before con-
sidering surgical treatment.
Aims: To assess the efficacy and safety of treatment with platelet-rich plasma
obtained in an open system in a group of patients with epicondylitis.
Methods: We included patients with a diagnosis of chronic epicondylitis (>6
months) with persistent pain despite proper rehabilitation treatment. All
patients had rehabilitation; patients with persistent symptoms after four
months were referred to the Interventional Rehabilitation Unit. A shoulder
ultrasound was ordered to all patients, to exclude major elbow tendon ruptures
and determine the degree of damage. They were evaluated according to the
DASH scale before and after infiltration to estimate the results objectively.
The infiltration was performed with ultrasound control. PRP was obtained
from 12x3ml tubes of PB with 3.2% sodium citrate. Additionally, we obtained
blood samples from each patient to carry out serology (HBsAg, anti-HIV type
1 and 2, HCV S, techniques HCV genomic nucleic acid amplification, syphilis,
ABO group, regular antibodies). The samples were processed using a two
sequential centrifugation, keeping them at room temperature. All manipula-
tions were performed under sterile conditions in laminar flow cabin within a
C/D room. The samples were processed immediately after extraction in the
Blood Bank.
Results: To date, 12 patients have been treated with PRP. They received a min-
imum of 1 and a maximum of 3 infiltrations. All patients showed tendon thickening,
decreased echogenicity and neovascularization in the ultrasound. In 6 cases intra-
substance rupture was found and one patient had microcalcifications. 9 patients
had symptoms improvement (considered as a reduction of at least 25% in the
DASH scale), that is 75% of the treated patients. In these 9 patients ultrasound
improvement was documented 4 months after the end of the PRP treatment.Only
one patient had a minor complication: a presyncopal episode after infiltration with-
out hemodynamic instability. There are no other adverse reactions or complications
associated with PRP treatment in the 12 month follow-up.
Figure 1.
Summary and Conclusions: Infiltration with PRP in patients with epicondylitis
refractory to conservative treatment is safe and effective and can be considered
as an option prior to surgery. In our patients signs of clinical and ultrasound
improvement (tendon regeneration mediated by the PRP) was found one month
after the first infiltration. Obtaining PRP in an open system has proved safe in
the treatment of these patients.
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PREVALENCE AND TRENDS OF HBV, HCV, AND HIV SEROLOGICAL AND
NAT MARKERS AND PROFILES IN SAUDI BLOOD DONORS
W. Elbjeirami* H. Al-Jedani1, N. Arsheed1, N. Elnagdi1, H. Abou Eisha1,
A. Abdulwahab2, N. Abd Alltif1, E. Hezam1, F. Al-Allaf1
1Laboratory and Blood Bank, 2Hematology Department, King Abdullah Medical
City, MAKKAH 21955, Saudi Arabia
Background: Epidemiologic studies on the prevalence of transfusion-trans-
mitted infections (TTIs) in Saudi Arabia (SA) regions are limited.
Aims: This study investigated prevalence of HBV, HCV, and HIV using both
serological and nucleic acid testing (NAT) methods to determine temporal and
geographic trends among blood donors in Makkah. Our secondary objective
was to realize the most suitable NAT format, without compromising sensitivity
of NAT results by using individualized or mini-pool testing.
Methods: Serologic and NAT screening records of 22,963 blood donors from
January 2011 to December 2014 were evaluated for HBsAg, Anti-HBc, Anti-
HCV, Anti-HIV, HBV-DNA, HCV-RNA, and HIV-RNA. Prevalence rates were
calculated for TTIs per hundred donations and additional analysis was con-
ducted to examine donor profiles associated with positive serologic and NAT
results. Known viral loads (<20 IU/ml for each HBV and HCV and <50 copies/ml
HIV) diluted in negative plasma at 1:2, 1:4, 1:6, and 1:8 were evaluated by NAT
screening.
Results: The overall serological prevalence of HBs-Ag, anti-HBc, anti-HCV,
and anti-HIV were 0.7, 6.7, 0.44, and 0.07%, while molecular HBV-DNA, HCV-
RNA, and HIV-RNA overall prevalence were 0.72, 0.05, and 0.03% respectively.
There was a gradual decline in percentage of infected donor blood based on
combined serological and/or NAT screening from 8.3% in 2011 to 6.8% in 2014
with an overall 7.4% (n=1,689) infected by one or more TTI during the period
under study. The prevalence of HBV, HCV and HIV was unevenly distributed
among different regions in SA. Analysis of donor serologic and molecular pro-
files revealed solitary anti-HBc- positive was the highest (6%) donor profile fol-
lowed by anti-HBc-positive/HbsAg-positive/HBV-DNA positive donor profile at
0.6%, and solitary anti-HCV at 0.4%. Simulation of mini-pool NAT format by
dilution of known viral loads at 1:6, resulted in 70% reduction in HBV detection,
50% for HCV, and 40% for HIV.
Summary and Conclusions: This is the first study to provide current data col-
lectively comparing prevalence and trends of HBV, HCV, and HIV serologic
and nucleic acid markers amongst Saudi blood donors. Makkah boasts one of
the lowest TTIs prevalence in SA and to surrounding countries. The majority of
seropositive and NAT-reactive blood donors are in a state of acute, chronic or
resolved HBV infection. Individual donor NAT is the ideal methodology that
should be applied in SA where diluted samples could compromise clinical sen-
sitivity and blood safety.
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PLASMA EXCHANGE FOR ACUTE HUMORAL REJECTION OF RENAL
ALLOGRAFT AFTER ABO-MATCH KIDNEY TRANSPLANTATION: 5-YEAR
EXPERIENCE IN A UNIVERSITY HOSPITAL
I. Parra Salinas1,* V. González Rodríguez1, A. Gutiérrez Dalmau2, J. Gimeno
Lozano1, J. A. Gracia1, P. Delgado Beltran1, J. A. Garcia-Erce3
1Dept. of Hematology and Hemotherapy, 2Dept. of Nephrology, Miguel Servet
Universitary Hospital, Zaragoza, 3Dept. of Hematology and Hemotherapy, San
Jorge Hospital, Huesca, Spain
Background: Acute humoral rejection (AHR) of renal allograft after ABO-match
Kidney Transplantation (KT) is one of the main causes of acute graft dysfunction
and had a high risk of allograft loss. This entity often pose challenge to nephrol-
ogists and hematologists during practice.
Aims: To analyze the safety and effectiveness of plasma exchange (PE) in
patients with AHR in our department. 
Methods: Retrospective review of PE procedures carried out over 5 years
(2008-2012) in patients with AHR. We collected clinical and analytical data and
defined response as a reduction greater than 25% from nadir initial values of
serum creatinine (SC), Stable graft function as decrease of less than 25% or
increase over 25% of nadir initial values of SC and no response as a rise greater
than 25% of values. Early response: response with 3 or less procedures of PE.
Graft failure: restarting of hemodialysis.
Results: 15 patients (8♀y 7♂), median age: 44,64 (29-76) y-o. Median time
between KT and AHR: 10,8 (0,57-148,7) months. Five patients had also histo-
logical findings of Acute Cellular Rejection (n=3), Chronic Humoral Rejection
(n=2) and Tubular Acute Necrosis (n=1). Treatments before PE: monoclonal
antibody anti-cd20 in 3 cases (in one case with MTPD bolus). Simultaneous
treatments: none (n=1), IVIG (n=1); IVIG with MTPD bolus (n=2); IVIG with
anti-cd20 (n=6), IVIG, MTPD and anti-cd20 (n=4); IVIG, anti-cd20 and Borte-
zomib (n=1). Median procedures done on each patient: 6 (5-12). During this
period time 109 procedures were performed, we observed 7 sessions (6,4%)
with technique-related adverse events, none of them was severe. One patient
achieved Response and eleven Stable graft function. These 12 patients had
the highest values of serum creatinine before PE (3,5 mg/dL vs 2,2 mg/dL,
p=0,041) and a late development of AHR (38,3 vs 4,7 months after KT,
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p=0,035). Variables related with better responses were, initial hypertension
(p=0,046) and immunosuppressive therapy before PE (p=0,024). At the end of
follow up, eight sustained graft function. Five patients reached early response.
These patients were mainly women (57,1%), all of them had hypertension and
more than 2 antibodies (see Table) in the immunohematological study before
PE. At the end of follow up, three of them sustained graft function. After PE, all
patients had immunosuppressive therapy (Tacrolimus, MF and Prednisone)
and in one case, there was necessary to add a dose of anti-cd20. Only in two
cases, antibodies turned negative after PE (1 for Class I and 1 for Class II).
Random urine Protein/Creatinine ratio was normal in all patients before and
after PE. There were no important differences between values of white blood
cells, hemoglobin, platelet count, pH or albumin before and after PE. During
2,7 (0,21 - 6,24) years of follow up, three patients died (1 of unknown cause
and 2 of infectious cause), one of them with functional graft. One out of 12
patients alive, had been transplanted for a second time (32 months after PE
completion), and 33,3% had graft failure. Other abbreviations used (alphabet-
ical order): Abs: Antibodies, DSA: Donor specific antibodies, IGIV: Intravenous
Immunoglobulin, MF: Mycophenolate, MTPD: Methylprednisolone.
Table 1. Immunohematological study previous and after plasma exchange
(PE).
Summary and Conclusions: Eighty percent of our series achieved response
and 33% of them in an early way. These results are maintained long-term.
Therefore, although AHR is a serious complication for transplant recipients,
PE improve results regards renal graft survival, and is a safe therapeutic
method. In addition, we observed that there is no correlation between response
and the presence of antibodies in the immunohematological study.
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GENE THERAPY USING TRAIL-SECRETING HUMAN ADIPOSE TISSUE
DERIVED MESENCHYMAL STEM CELLS (AD-MSCS) AGAINST LEUKEMIA
S. Solali1,* S. Kaviani2, M. soleimani2
1Tabriz University of Medical Science, Tabriz, 2Tarbiat Modares University,
Tehran, Iran
Background: Mesenchymal Stem Cells (MSCs) are a group of adult stem cells
naturally found in the body. These cells were reported from many sources.
Bone marrow and adipose tissue are two main sources of human MSCs. MSCs
have attracted considerable attention in the fields of cell and Gene Therapy
due to their intrinsic characteristics and ability to differentiate into multiple lin-
eages. Whereas BM has been the first recognized source of MSC, adipose tis-
sue represents a valid reservoir of mesenchymal progenitors. Adipose tissue
can be obtained in relevant amount and easily processed to release large num-
bers of adipose-derived MSC (AD-MSC). These cells may offer efficient tools
for cell-based Gene Therapy approaches.
Aims: In this study, we evaluated whether AD-MSC could deliver TRAIL for
leukemic cells treatment and induce apoptosis in leukemic cells.
Methods: Human AD-MSCs were isolated, characterized and transduced with
a lentiviral vector encoding secretory tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). TRAIL protein production verified by western blotting.
TRAIL-ADMSCs were Co-cultured with HL-60 and AML-M3 patients MNCs.
Apoptosis induction was studied by flow cytometry using annexin-FITC. We
also studied MSCs migration potential by Trans-Well method.
Results: In coculture experiment of TRAIL secreting MSCs with leukemic cells
we observed TRAIL-AD-MSC targeted HL-60 cells and AML-M3 mononuclear
cells (MNCs). We observed significant apoptosis inducing potential by TRAIL-
ADMSC in HL-60 cells and AML patients’ mononuclear cells (MNCs) compared
to control once (P<0.05). Maximum apoptosis induction in HL-60 cells was 25%
which shows most of these cells have resistance to TRAIL induced cell death.
Whatever in patients MNCs maximum induction of apoptosis was 45%. in vitro
coculture experiments on Trans-well plate’s migration assays showed that HL-
60 cells culture but not FBS lacked growth media, supported the migration of
hMSCs and enhanced their migration (P<0.05).
Summary and Conclusions: We found that stably TRAIL transduced ADMSCs
could serve as constant source of TRAIL production. However this treatment
modality didn’t completely induced apoptosis in all HL-60 or MNCs nevertheless
it indicate needs for finding cotreatments appropriate to type of resistance
mechanism. We also observed that leukemic cells are able to production and
releasing cytokines which cause migration of AD-MSCs toward leukemic cells
and also AD-MSCs have relevant receptors on the cell surface to respond such
cytokines. In conclusion these results suggest that human AD-MSCs have
potential use as effective delivery vehicles for therapeutic genes in the treatment
of hematologic malignancies.
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PEDIATRIC TEL-AML1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
PATIENTS SHOW INCREASED MN1 EXPRESSION
M. D. Yener1,* M. Numata2, S.S. Ekmekçi3, M. Aydın3, G. Grosveld2, U. Özbek3,
Ç. Güleç4, S. Anak4, S. Karaman4, G. Öztürk5, M. Akbıyık5, A. Kandilci1
1Molecular Biology and Genetics, Gebze Technical University, Gebze, Kocaeli,
Turkey, 2Genetics, St. Jude Children’s Research Hospital, Memphis, United
States, 3Department of Genetics, Institute for Experimental Medicine, 4Pediatric
Hematology Division, Istanbul Medical Faculty, 5Medical Park Hospitals, İstan-
bul, Turkey
Background: The MN1 (Meningioma 1) gene is overexpressed in certain sub-
types of acute myeloid leukemia (AML), including patients carrying transloca-
tions inv(16)(CBFB-MYH11) and t(8;21)(AML1-ETO) which target the core-
binding factor (CBF) transcription factor complex. In consistence, ectopic MN1
expression in mouse bone marrow (BM) cells cultured under myeloid conditions
results in increased myeloid colony forming activity and myeloid leukemia.
Despite this growing body of evidence describing MN1’s involvement in AML
development, it is unknown if MN1 also plays a role in the pathogenesis of lym-
phoblastic leukemia.
Aims: We aimed to determine expression level of MN1 in pediatric B-ALL as well
as effect of ectopic MN1 expression on primary mouse Pro B/pre B-cells in vitro.
Methods: Engogenous MN1 expression in BM samples of 73 pediatric B-ALL
patients and healthy controls (n=9), as well as in FACS isolated primary mouse
pro B/pre B-cells, were analyzed using RT-qPCR. MN1 was overexpressed in
mouse pro B/pre B-cells using retrovirus and followed by methocult assays.
Results: Here we showed that compared with control BM, MN1 expression
was increased (2-fold or more) in 29 out of 73 (40%) pediatric B-ALL patient
BM. Additional analysis of MN1 expression in sub-groups within our cohort car-
rying different chromosome translocations showed that carriers of t(12;21)(TEL-
AML1) (n=27), targeting CBF, expressed significantly more MN1 than both
healthy controls (P=0.02) and the group carrying the t(9;22)(BCR-ABL) (n=9)
(P=0.001). In addition, there was a trend of increased MN1 expression in TEL-
AML1positive patients (18 out of 27) as compared with patients that are negative
for this translocation (n=30). Retroviral MN1 overexpression increased the
colony forming activity of mouse Pro B/Pre B cells in vitro.
Summary and Conclusions: Our results suggest that deregulated MN1
expression contributes to the pathogenesis of pediatric B-ALL. Further inves-
tigation into the clinical and biological significance of elevated MN1 expression
in TEL-AML1positive leukemia might provide insight into additional molecular
mechanisms contributing to B-ALL and may lead to improved treatment options
for patients.
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SCREENING FOR VARIATIONS IN EXONS 9, 10 AND 12 OF CD22 GENE
IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
D. Aslar1,* D.F. Akın1, M. Mumcuoglu1, U. Ezer2, E. Kurekci2, N. Akar3
1Lösante Cancer Research and Genetics Laboratory, 2Lösante Hospital,
3TOBB ETU Hospital, Ankara, Turkey
Background: CD22, a B cell specific transmembrane protein, have commonly
seen in hematological malignancies and plays a role in B cell survival, prolifer-
ation, and differentiation via B-cell receptor (BCR). BCR is an inhibitory co-
receptor of B cells and B cell precursors that acts as a negative regulator of
multiple signal transduction pathways critical for B cells. CD22 signaling is
mediated through interactions with kinases and phosphatases which connect
the cytoplasmic domain via phosphorylated tyrosine residues that locate within
TAM and TIM motifs. CD22 protein SHP-1 (Src homology 2 domain-containing
tyrosine phosphatase) function deficient mice showed disruption of the SHP-1
signaling network that can result in defective maturation in development of B-
cell lymphoproliferative state and apoptosis. Studies of human CD22 demon-
strated that its variations could cause CD22 molecule with inadequate functional
and disturbance of mRNA expression. CD22 is expressed in 90% of chronic
lymphoblastic leukemia patients, in 60-70% of B cell lymphoma patients, in
100% of hairy cell leukemia patients, in 96% of childhood acute lymphoblastic
leukemia patients. Precursor B Cell Acute Lymphoblastic Leukemia (precursor
B-ALL) the largest subset of acute lymphoblastic leukemia (ALL), is the most
common form of childhood cancer. B cell expression of CD22 makes this a
great target for the treatment of leukemia. CD22 that is located on chromosome
19q24 contains 14 exons. Studies by using DNA sequencing method were
detected several homozygous mutations (transversions/transitions, deletions,
and insertions) between exon 12 and intron 13 in CD22 gene and this region
was called “mutational hotspot”.
Tabella 1. Charcaterization of the variants in CD22 gene.
Aims: In this study we aimed to screen exon 9, 10 and 12 of CD22 gene that
is mutational hotspot region in children with precursor B-ALL and to find possible
genetic variations for molecular hematological analysis in childhood ALL.
Methods: In this study we aimed to screen exon 9, 10 and 12 of CD22 gene
that is mutational hotspot region in children with precursor B-ALL and to find
possible genetic variations for molecular hematological analysis in childhood
ALL. Study population consisted of 115 patients aged between 1 and 15 years
who were admitted to Lösante Hospital with the diagnosis of precursor B-ALL.
Blood samples were collected with EDTA-containing tubes and DNA was
extracted from peripheral blood and bone marrow leukocytes with MagNA Pure
automatic DNA isolation instrument (Roche Diagnostics, Manheim, Germany).
Amplification of gene was performed by PCR and all samples were screened
for the variants by SSCP. Samples showing band shifts were directly sequenced
on an automated sequencer (Beckman Coulter, USA).
Results: We detected 7 variants in CD22 gene in our study population. There
were no variants at exon 9. We report a novel mutation at exon 10 of CD22
(T2199G). The most of CD22 variants were described in exon 12; intron
A2538G (rs4805119), intron A2646G (rs4805120), intron C2642G
(rs10413526); intron G2557A (rs10406539); intron C2612G (rs10413500); exon
G2318A (rs10406069). Table 1 shows summary of CD22 variant profiles.
Summary and Conclusions: The detected variants in this study seem to be
the first screening results of studied gene in childhood precursor B-ALL patients
in our country. Identified variants in the CD22 exons encoding the cytoplasmic
domain could disturb mRNA stability and splicing mechanism of gene. Thus, a
truncated CD22 protein or reduced expression levels of an intact protein might
lead to development of leukemia. These results need to be confirmed by further
exons on a larger number of patients.
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COMPARISON OF THE IMMUNOPHENOTYPE OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA AT DIAGNOSIS AND RELAPSE
E. Zengin1,* S. Aylan Gelen1, S. Çakı Kılıç1, U. Demirsoy1, M. Karadoğan1,
G. Gacar2, G. Beyazıt2, N. Sarper1
1Pediatric Hematology, 2Stem Cell and Gene Therapies Research/Aplied Cen-
ter, Kocaeli University, Kocaeli, Turkey
Background: Lineage switch was reported in relapsed acute leukemia. 
Aims: Leukemia-associated immunophenotypes in patients with acute lym-
phoblastic leukemia (ALL) at diagnosis and relapse were investigated.
Methods: The immunophenotype of leukemia cells from 28 relapsed patients
at diagnosis and relapse was detected by four-color flow cytometry (FCM).
Isolated testicular relapse was excluded. Antibodies used in the panel were
CD2, CD3, cyCD3, CD5, CD7, CD13, CD14, CD15, CD33, CD10, CD19, CD20,
CD22, cyCD79a, CD34, CD117, MPO, TdT, glicophorin A, CD41 and HLA-DR.
The classification was according to the European group for the immunologic
group. Cut-off for positive antigens was ≥20%.
Results: Mean age at the diagnosis was 7.57±4.32 years and 71.43% (n=20)
of the patients were male. Median time from diagnosis to relapse was 25
months (6 -138 months). According to BFM criteria 11, 9 and 8 patients had
very early, early and late relapse, respectively. Sites of relapse were isolated
bone marrow in 19, bone marrow and testis in 5, bone marrow and central
nervous system (CNS) in 3 and isolated CNS in 1 patient. At presentation pre-
cursor B-ALL, T-ALL, and mix lineage leukemia was detected in 21, 3 and 4
patients respectively. Immunophenotypic switch occurred in 28.57% (n=8) of
the relapsed patients (two patients from precursor B-ALL to T-ALL, three
patients from precursor B-ALL to mix lineage leukemia, one patient from pre-
cursor B-ALL to AML-M5; and of the two patients with mix lineage leukemia
one switched to precursor B-ALL and the other to T-ALL). There was no relation
between immunophenotypic switch and site and time of relapse. HLA-DR
expression decreased at relapse (50.99±32.01% at diagnosis, 38.67±27.4%
at relapse, P=0.029). However, CD33 and TdT expression increased at relapse
(CD33 from 34.02±32.26% to 58.05±31.28% and TdT from19.83±24.84% to
44.0934.86±%; p values were 0.006 and 0.031, respectively.
Summary and Conclusions: There are many hypotheses in lineage switch
as physiological plasticity of the original clone or emerging of a new clone or
expansion of secondary clone after eradication of the dominant clone by
chemotherapy. In the present study, immunophenotypic switch was detected
about one fourth of the patients at relapse. In addition, there were significant
differences in the expression levels of HLA-DR, CD33 and TdT. Their clinical
implications require further study.
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FREQUENCY OF COPY NUMBER ABNORMALITIES IN COMMON GENES
ASSOCIATED WITH BCP-ALL CYTOGENETIC SUBTYPES IN BRAZILIAN
CHILDREN
T.C. Barbosa1,* C.F.G. Andrade1, E.T.P. Granado1, I. M.Q. Magalhaes2,
G.R. Neves3, A. Gadelha4, G.e.g. Filho5, M.S. Souza6, R. Melaragno7,
M. Emerenciano1, M.S. Pombo-de-Oliveira1
1Pediatric Hematology-Oncology Program, Instituto Nacional de Câncer, INCA-
RJ, Brazil, Rio de Janeiro, 2Hospital da Criança José Alencar, Brasília, 3Hos-
pital Sarina Rolin, São Paulo, 4Hospital Napoleão Laureano, 5Instituto de
Hematologia da Paraíba, João Pessoa, 6Hospital Regional de Mato Grosso
do Sul, Campo Grande, 7Hospital Santa Marcelina, São Paulo, Brazil
Background: Copy number alterations (CNAs) in genes committed to B-cell
precursors have been associated with poor survival in subgroups of B-cell pre-
cursor acute lymphoblastic leukemia (BCP-ALL).
Aims: Therefore, the aim of this study was to determine the frequency of gene
deletions and the significance of copy number alterations in IKZF1, CDKN2A/B,
PAX5, EBF1, ETV6, BTG1, RB1, CSF2RA, IL3RA and CRLF2 within a cohort
of Brazilian pediatric BCP-ALL patients.
Methods: Bone marrow and peripheral blood aspirates samples from 274
BCP-ALL patients were analyzed prior to any oncological treatment (period
2004-2011). The inclusion criteria were the quality of the frozen diagnostic
material, having at least 30% blast cells, patients with ≤18 years old at the time
of BCP-ALL diagnosis. The exclusion criteria were acute leukemia in children
with Down syndrome, samples collected in heparin, and DNA of insufficient
quality. DNA was analyzed by the SALSA multiplex ligation-dependent probe
amplification (MLPA) kit (P335-A4). IKZF1 deletion results were confirmed
using a P202 IKZF1 SALSA MLPA kit. The age at diagnosis and white blood
cell (WBC) count were the criteria for assigning prognostic risk of ALL, accord-
ing to the National Cancer Institute (NCI). The disease risk associated with
CNA occurrence across overall and subgroups of patients was determined by
calculating odds ratios (ORs) with a 95% confidence interval (CI). Overall sur-
vival (OS) was defined as the time from diagnosis to last event (death or alive).
The OS analysis were obtained by the Kaplan-Meier method and log-rank test.
Results: Deletions/amplifications in at least one gene were identified in 83%
of the total series. In children older than two years, there was a predominance
of CNAs involving deletions in IKZF1, CDKN2A and CDKN2B, whereas IL3RA
and CSF2RA had deletions that were found more frequently in infants (P<0.05).
Multiple gene deletions occurred in the same patients. Sixty-three patients had
both CDKN2A and CDKN2B deletions (P<0.01). Deletions of CDKN2A and
CDKN2B also coincided significantly with deletions in PAX5 (P<0.01) and IKZF1
(P<0.05). IKZF1 deletions were also found concomitantly with BTG1 and EBF1
deletions (P<0.05 and P<0.01, respectively). ETV6 deletions overlapped with
PAX5, BTG1, EBF1 (P<0.01) and CRLF2 deletions (P<0.05). Based on the
cytogenetic subgroups, favorable cytogenetic subgroups (i.e. ETV6-RUNX1
and hyperdiploiy) showed more deletions than other subgroups, specifically
ETV6 deletions (P<0.05). TCF3-PBX1 was frequently deleted in RB1, and an
absence of deletions was observed in IKZF1 and genes localized to the PAR1
region. IKZF1 deletions (P=0.01, 30.2 months, 95% CI 8.5-52.0) and RB1 dele-
tions (P<0.01, 16.8 months, 95% CI 0.0-46.1) confered poorer OS to standard
risk patients.
Summary and Conclusions: The results corroborate previous genome-wide
data and are an important validation of the impact of IKZF1 deletions in the
prognosis of BCP-ALL. The obtained results emphasize the need for including
screening of submicroscopic alterations as additional markers for risk stratifi-
cation, especially in standard risk patients.
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PROGNOSTIC VALUE OF GLUCOCORTICOID RECEPTOR GENE
POLYMORPHISMS AND MRNA EXPRESSION IN ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA.
A. Bedewy1,* S. Elmaghraby1, W. Elbendary2
1Hematology, Alexandria University, Alexandria, 2Clinical Pathology, Military
Medical Academy, Cairo, Egypt
Background: Therapeutic protocols used in adult acute lymphoblastic
leukemia (ALL) are widely variable. However, glucocorticoids (GC) are essential
components in its treatment. The antineoplastic actions of glucocorticoids can
be partially attributed to glucocorticoid-induced apoptosis.
Aims: The aim of this study was to evaluate the distribution of the 3 prominent
glucocorticoid receptor gene polymorphic variants (BclI, N363S, and
ER22/23EK) among controls and Philadelphia-negative adult ALL patients. In
addition, we aimed to investigate the association between glucocoticoid recep-
tor mRNA isoforms expressions and the response to induction chemotherapy
in the studied patients.
Methods: Fifty-two adults with newly diagnosed Philadelphia-negative ALL,
aged 18 to 75 years and 30 healthy control subjects were enrolled in this study.
Genotyping of BclI, N363S, and ER22/23EK polymorphisms was carried out
by polymerase chain reaction restriction fragment–length polymorphism. Glu-
cocoticoid receptor mRNA isoforms expressions were assayed by quantitative
real time PCR.
Results: Fifty-two newly diagnosed Philadelphia-negative adult ALL patients
were enrolled with a median age of 34 years (range 18-75). They were 35
(67.3%) males and 17 (32.7%) females. The incidences of BclI, N363S, and
ER22/23EK polymorphic variants were 44.2%, 5.8% and 1.9% among patients
and were 33.3%, 6.7% and 6.7% among controls, respectively with no statis-
tically significant difference. The allelic frequencies of the mutant allele of BclI,
N363S, and ER22/23EK polymorphisms in patients were 0.15, 0.02, and 0.004,
respectively. The different genotypes of the polymorphisms were not related to
glucocorticoid resistance. No association was found between the studied
parameters and the expression of beta glucocorticoid receptor (GR) isoform.
The alpha GR expression was associated with complete remission (P=0.03).
Compared to GC sensitive patients, the expression of gamma GR mRNA was
significantly higher in GC resistant patients (P=0.032). Moreover, the expres-
sion of gamma GR mRNA was significantly higher in non-responders versus
responder patients(P=0.019).
Summary and Conclusions: The BclI polymorphic variants of the GR gene
are the most frequent compared to N363S and ER22/23EK polymorphisms in
Philadelphia-negative adult ALL patients. Polymorphisms of the GR gene were
not associated with the sensitivity to glucocorticoids. Higher alpha GR and
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lower gamma GR expressions were associated with achievement of complete
remission while higher expression of gamma isoform was associated with glu-
cocorticoid resistance. Our data suggest that pretreatment glucocorticoid recep-
tor isoforms expression levels can be useful in predicting response to gluco-
corticoids and in anticipating achievement of complete remission in Philadel-
phia-negative adult ALL patients.
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EFFECTS OF SIRT6 INHIBITORS ON ACUTE LYMPHOBLASTIC T CELL
LEUKEMIA
S. Boero1,* A. Poggi2, A. Nencioni1
1Dipartimento di Medicina Interna e Specialità Mediche DIMI, Università degli
Studi di Genova, 22Unit of Molecular Oncology and Angiogenesis, IRCCS AOU
San Martino-IST, Genoa, Italy
Background: Sirtuins are NAD(+)-dependent deacetylases with documented
roles in gene expression, metabolic pathways, apoptosis, cell survival, DNA
repair, development, inflammation, and healthy aging. SIRT6 is a sirtuin family
member which has been implicated in the control of glucose uptake and metab-
olism, cell metabolism, genomic stability and DNA repair, and in inflammation.
Aside for the observation that SIRT6 chromosomal locus is a region prone to
chromosomal breaks in human acute myeloid leukemia, no data are available
concerning the possible involvement of SIRT6 in leukemogenesis.
Aims: Herein, we have selected a series of novel and specific quinazolinedione
small molecules SIRT6 inhibitors named S602, S603, and S610 and we have
analyzed their in vitro effects on the T-ALL cell line Jurkat upon stimulation with
anti-CD3/CD28 antibodies coated immunomagnetic beads to mimic tumor
microenvironment signaling of the T-ALL cells.
Methods: After 24, 48 and 72 hours of stimulation in presence or absence of
SIRT6 inhibitors we performed: a) a viability test with propidium iodide to deter-
mine whether these inhibitors affect cell survival; b) an assay for evaluating the
content of ATP to determine whether the inhibitors alter the mitochondrial meta-
bolic activity and therefore proliferation; c) an ELISA for TNF-α released on
harvested supernatants
Results: We found that none of these inhibitors induced cell death or inhibited
cell proliferation at concentrations raging between 10 and 100 µM. On the con-
trary, a strong and concentration dependent inhibition of TNFα production trig-
gered by CD3 and CD28 co-engagement was observed. Notably, a marked
reduction in intracellular ATP levels in Jurkat cells treated with the SIRT6
inhibitors could also be detected after a 72 h incubation.
Finally, SIRT6 inhibition resulted in a decrease in TNFα production in Jurkat
cells line triggered through CD3 and CD28 co-engagement
Summary and Conclusions: Altogether, these findings suggest that inhibitors
of SIRT6 can selectively affect the synthesis of ATP and thus the metabolic
state of T-ALL cells. These inhibitors could be an useful tool when used together
with pro-apoptotic anti-blastic drugs because of their complementation activity,
affecting different molecular targets that are relevant for T-ALL cell growth.
In addition, TNFα production inhibition is expected to favorably affect the tumor
microenvironment and to reduce invalidating systemic manifestations of dis-
ease, such as fever and cachexia, which typically worsen the clinical outcome
of T-ALL patients.
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ROLE OF FLOW-CYTOMETRIC IMMUNOPHENOTYPING IN PREDICTION
OF BCR/ABL GENE REARRANGEMENT IN ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA
F. Corrente1,* S. Bellesi1, E. Metafuni1, P. L. Puggioni1, S. Marietti1, A.M. Ciminello1,
T. Za1, L. Laurenti1, F. Sora’1, S. Giammarco1, L. Pagano1, S. Sica1,
V. De Stefano1, P. Chiusolo1
1Hematology, Policlinico A. Gemelli UCSC, Rome, Italy
Background: Among B-cell precursor acute lymphoblastic leukemia (B-ALL),
t(9;22) (q34;q11) responsible for BCR/ABL fusion transcripts is the most com-
mon cytogenetic abnormality that occurs in around 20-30% of adult patients
(pts). BCR/ABL-positive (BCR/ABL+) B-ALL has been typically associated with
high expression of myeloid antigen such as CD13, CD33, CD66c. We analyzed
44 adult patients with B-ALL diagnosed in our center from December 2004 to
December 2013, with a median age of 46 ys (range 13-78), 23 males and 21
females.
Aims: The purpose of this study was to establish by immunophenotyping which
combination of antigens was most predictive for BCR/ABL gene rearrange-
ment.
Methods: Flow-cytometric data were acquired by immunophenotypic B-ALL
definition panels performed using FACSCanto cytometer and BDFACSCanto
software. Arbitrary cutoff of 20% analyzed events that were brighter than the
control stain, was required for an antigen to be considered positive. Levels of
BCR-ABL fusion transcript were quantified in RT-PCR assay. Comparison
between two groups were performed using the Mann–Whitney U (MWW) and
Chi-square tests (CSQ) or Fisher exact test (FET) for continuous and dichotom-
ic variables, respectively. Measure of association was expressed by Odds Ratio
(OR). Cut-off value for the marker was selected using receiver operating curves
(ROC). Multivariate analysis was performed using Logistic Regression (LR). P
values lower than 0.05 were considered statistically significant (SPSS 15.0 ver-
sion).
Results: BCR/ABL transcript was identified in 21 pts (47.7%). CD10 and CD34
was positive in the totality of BCR/ABL+ cases. BCR/ABL+ pts exhibited a
greater median percentage of CD10 (96.8% vs 88.6%, MWW, P=0.030) and
CD34 (98.3% vs 92.3%, MWW, P=0.013) expressions, but a lower median per-
centage of CD38 expression (92.6% vs 99.0%, MWW, P=0.001) than pts with
BCR/ABL-. Considering Median Fluorescence Intensity (MFI), BCR/ABL+ cas-
es presented a higher CD10 MFI (median of MFI, 11295 vs 1972, MWW,
P=0.001) and a lower CD38 MFI (median of MFI, 919 vs 6747, MWW, P=0.006)
than their counterpart. No significant difference were observed in CD34 MFI
values comparison. By calculating ROC, the best cut-off for CD10 MFI was
5159 (AUC=0.787, 95% CI: from 0.65 to 0.92) and for CD38 MFI was 6284
(AUC=0.750, 95% CI: from 0.60 to 0.90). These cut-off values provided a sen-
sitivity of 80% and a specificity of 74% for CD10 and a sensitivity of 83% and
a specificity of 54% for CD38. Categorized CD10 MFI and CD38 MFI presented
a strong association with BCR/ABL rearrangement [CSQ, P<0.001, OR 12.75
(95% CI: from 3.06 to 53.19); P=0.010, OR 0.14 (95% CI: from 0.03 to 0.59),
respectively]. CD66c positivity was more frequent in BCR/ABL+ pts than in the
others (81% vs 45%, FET, P=0.016). The co-expression of CD66c with CD13
or CD33 was more frequently present in BCR/ABL+ pts (44% and 39%, respec-
tively) than in BCR/ABL- (13% and 6%, respectively)(FET, P=0.04). The sen-
sitivity and the specificity of CD66c as sole marker were 81% and 55%, respec-
tively. In opposite, the co-expression of CD66c/CD13 or CD66c/CD33 showed
a lower sensitivity (44% and 39%, respectively) and a greater specificity (88%
and 94%, respectively). Multivariate analysis in which categorized CD10 MFI
was combined with categorized CD38 MFI and CD66c expression showed that
CD10 was an independent predictor for the presence of BCR/ABL rearrange-
ment (LR, P=0.003).
Summary and Conclusions: We suggest a screening panel predictive for
BCR/ABL rearrangement in B-ALL by using the combination of CD38, CD10,
CD34, CD66c, CD13 and CD33 expressions.
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EVALUATION OF MULTIPLEX LIGATION DEPENDENT PROBE
AMPLIFICATION FOR IDENTIFICATION OF ACUTE LYMPHOBLASTIC
LEUKEMIA WITH AN INTRACHROMOSOMAL AMPLIFICATION OF
CHROMOSOME 21 IN A BRAZILIAN POPULATION
G. Fuka1,* T.M. Farias-Vieira1, L. Hummel1, C.B. Blunck 1, J.C. Santoro1,
E. Terra-Granado1, T. Conceição Barbosa1, M. Emerenciano1,
M.S. Pombo-de-Oliveira1
1Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
Background: An intrachromosomal amplification of chromosome 21 (iAMP21)
defines a unique subgroup of B-cell precursor acute lymphoblastic leukemia
(BCP-ALL). The finding of three or more extra copies of the RUNX1 gene by
fluorescence in situ hybridization (FISH) is internationally used to define of an
iAMP21. Recently, genomic profiling of chromosome 21 has been suggested
for assisting the identification of an iAMP21.
Aims: In this work, we aimed to test the multiplex ligation-dependent probe
amplification (MLPA) SALSA P327-A1 probe set for evaluating copy number
alterations (CNA) on chromosome 21.
Methods: A series of consecutive diagnostic samples from Brazilian childhood
BCP-ALL patients collected between the years 2002 to 2012 were selected
according to availability of material of good quality providing that bone marrow
aspirates harbored at least 30% of blast cells. The MLPA SALSA P327-A1
probe set was employed to detect an iAMP21 (MRC Holland, Amsterdam, The
Netherlands). Test fragments of the P327-A1 probe set were designed to detect
CNA of 24 genes distributed from centromeric to telomeric regions (q11.2-
q22.3, 14.668-46.356) of chromosome 21. Relative copy numbers were
obtained after normalization of peaks against cord blood derived controls. Rel-
ative peak heights between 0.75 and 1.3 were considered normal, while those
below 0.75 and above 1.3 indicated losses or gains of genomic material, respec-
tively. FISH was performed using the “LPH012 TEL/AML1 Translocation, Dual
Fusion Probe”, designed to detect the ETV6/RUNX1 fusion gene. Cases were
considered positive for an iAMP21 when ≥5 RUNX1 FISH signals were
observed in at least 7% of metaphase nuclei (standard deviation +/- 2%).
Results: In 74 out of 368 BCP-ALL patients, gain of genetic material on chro-
mosome 21 was detected. MLPA peak profiles segregated patients into three
groups by hierarchical clustering. Next, patient material was subjected to FISH.
Cells with ≥5 RUNX1 FISH signals (n=9) were considered as “true iAMP21”.
By contrast those with 3-4 RUNX1 signals (n=35) or a normal RUNX1 FISH
pattern (n=6) probably acquired additional copies of an intact chromosome 21,
even though not detectable by FISH in all cases. Peak ratios of RUNX1 and
DYRK1A genes, located within the common region of amplification (CRA), were
in “true iAMP21” patients higher, an opposite pattern was observed for telomeric
SNF1LK and TFF1 genes. Since we observed variations in MLPA peak heights
between different patients, the correlation between RUNX1, DYRK1A, ETS2
and ERG gene load and expression was tested. For illustration we stepwise
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arranged cases from the lowest to the highest MLPA peak ratios and depicted
corresponding delta CT (threshold cycle) values. Positive correlation between
the MLPA peak ratios and CT values were observed, since those patients with
high MLPA peak ratios were the ones with low gene expression. This observa-
tion particularly held true for the genes RUNX1, DYRK1A, and ERG.
Summary and Conclusions: Altogether, we confirmed that aberrations on
chromosome 21 represent a high level of complexity and individuality and pro-
vided evidence for the existence of gene regulatory mechanisms that might
modulate the expression of amplified genes. In BCP ALL with an iAMP21 we
consider MLPA tests highly desirable for data replication of array based com-
parative genomic hybridization analyzes. MLPA profiles of high peak ratios of
CRA genes might be especially helpful in case identification whenever
metaphase nuclei for FISH are not available. However, we want to stress that
a precise separation of BCP-ALL with an iAMP21 from hyperdiploid ALL with
additional copies of chromosome 21 is still under revision. Control fragments
binding on chromosomes that are usually over represented should be included
in next generation MLPA probe sets.
PB1593
CIRCADIAN RHYTHM OF MELATONIN IS PRESERVED AT DIAGNOSIS
AND DURING TREATMENT IN PEDIATRIC PATIENTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
A. Vlachou1,* A. Kattamis1, D. Perrea2, I. Papassotiriou3, N. Tourkantoni1,
S. Polychronopoulou4
1Division of Pediatric Hematology-Oncology, First Department of Pediatrics,
University of Athens, 2Laboratory for experimental surgery and surgical
research N.S Christeas, University of Athens, 3Department of Clinical Biochem-
istry, 4Department of Pediatric Hematology-Oncology, Aghia Sophia Childrens
Hospital, Athens, Greece
Background: Melatonin, the main hormone secreted by the pineal gland in
the human brain, has a strong impact on the sleep-wake cycle and is consid-
ered to be the general moderator of circadian rhythm and through this of several
biological functions. It has also been shown to neutralize a number of free rad-
icals and to enhance the activity of several antioxidative enzymes. Patients
with acute lymphocytic leukemia (ALL) show significantly deranged oxidation
homeostasis due to both the leukemic burden and the therapy. Alterations of
circadian rhythm of melatonin secretion on these patients either at diagnosis
or during therapy could enhance oxidative stress or affect bioavailability and
efficacy of therapeutic agents.
Aims: Aim of the present study was to elucidate whether melatonin maintains
its diurnal variation among pediatric patients with ALL from diagnosis and
throughout their treatment. Additionally, correlation of melatonin’s level with
the oxidative/antioxidant status of these patients was also evaluated.
Methods: Twelve patients (median age 6.5 years old) with intermediate risk
B-ALL, treated according to BFM-ALL95 protocol, were included in this study.
Morning (10 am) and night (10 pm) samples were collected from each patient
at 7 different time points, with a median follow up time being 8 months. More
precisely, blood samples were collected at the time of diagnosis, at the end
of the first part of Induction, at the beginning and at the middle of Consolida-
tion and Reinduction cycles and before starting Maintenance therapy. Mela-
tonin levels were measured in serum by an Enzyme Linked Immunofluores-
cent Assay (ELISA). Total oxidative stress was estimated by colorimetric
assay by measuring the total quantity of lipid peroxides present in serum.
Total antioxidative serum capacity was estimated by photometric assay by
adding a specific quantity of hydrogen peroxide in the sample and then meas-
uring the remaining amount, not neutralized by the natural antioxidants in
the serum.
Results: Melatonin’s secretion retained its circadian rhythmicity with higher
levels (9.72±7.39 pg/mL) at night and lower during the day (8.1±6.19 pg/mL)
throughout the study (P<0.05). In this respect, intrapatient AM and PM levels,
as well as their difference were stable. Total Oxidative Capacity showed an
inverse circadian rhythm pattern with higher levels measured in the morning
(612.79±329.56 μmol/L) and lower in the night (531.50 ±321.75 μmol/L) sam-
ples (P<0.001). Of note the highest levels of oxidative stress (913.30 ±277.26
μmol/L) were measured at the time of diagnosis (P<0.001). This was the time
point with the lowest, though not statistically significant, melatonin concentra-
tion. Moreover, morning levels of melatonin correlated with the oxidative versus
anti-oxidative ratio (r 0.23, P<0.05).
Summary and Conclusions: This study depicts, for the first time to our knowl-
edge in the literature, the daily variations of melatonin and oxidative stress in
pediatric patients with ALL. Our results showed that melatonin levels maintain
their circadian rhythm in our pediatric patients with ALL, both at diagnosis and
throughout treatment. Furthermore, we portrayed that oxidative capacity exhib-
ited a similar inverse circadian rhythm, also retained throughout the study.
However, oxidative status presented significant fluctuations between distinct
measurements, probably related to leukemic burden and the type and intensity
of therapy. The above data are of significant importance as many physiological
processes, like hormonal secretion and pharmacodynamics, are affected by
the body’s circadian rhythms.
PB1594
IMPLEMENTATION OF 8 COLORS MULTIPARAMETRIC FLOW CYTOMETRY
(8-MFC) IN THE DIAGNOSIS AND MONITORING OF PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL) IN A SINGLE CENTER
A. Alonso1,* M. Camós2, S. Rives1, A. Català1, R. Berrueco1, A. Ruiz-LLobet1
M. Mesegue2, M. Trabazo1, R. Malatesta2, N. Vega-Garcia2, M. Torrebadell2
1Pediatric Hematology. Department of Hematology and Oncology, 2Hematology
Laboratory, Hospital Sant Joan de Déu, Fundació Sant Joan de Déu, University
of Barcelona., Barcelona, Spain
Background: ALL is the most common childhood malignancy and the leading
cause of pediatric cancer-related mortality. Minimal residual disease (MRD) is
a powerful predictor of outcome in childhood ALL and allows stratification of
patients into prognostic risk subgroups and the application of risk-directed ther-
apy. MRD assessment is routinely performed by flow cytometry and quantitative
real-time polymerase chain reaction (qRT-PCR).
Aims: the aim of our study was to implement 8-MFC to diagnose ALL and
monitor MRD using EuroFlow Consortium approach and evaluate its correlation
with molecular techniques.
Methods: a descriptive study of childhood ALL diagnosed in a single center
between September 2013 and February 2015 and treated according to Spanish
Pediatric Hemato-Oncology Society SEHOP-PETHEMA-2013 protocol. The
initial diagnosis was established with the monoclonal antibodies panels pro-
posed by the EuroFlow Group. Detection of MRD was based on leukemia-
associated immunophenotype (LAIP) observed at diagnosis. Fusion genes
ETV6-RUNX1, TCF3-PBX1 and BCR-ABL1 were analyzed by qRT-PCR fol-
lowing the guidelines of the Europe Against Cancer program.
Results: twenty-six patients were included (17 males, median age 6.5 years,
range 1.1-16.7 years). Twenty-one cases were B-cell precursor ALL (B-pre-
ALL) in common stage (CD10+) and 5 patients had T-cell ALL in cortical
(CD1a+) stage. The most frequent LAIPs identified in B-pre-ALL were cross-
lineage antigen expression (studying CD13, CD15, CD123 and CD66) and
asynchronous antigen expression. ETV6-RUNX1 rearrangement was detected
in six patients and TCF3-PBX1 rearrangement was observed in three cases.
All patients had a good response to prednisone at day +8 and the evaluation
on day +15 by morphology showed persistent disease (≥5% blasts) in 4 B-pre-
ALL cases. At the end of induction IA all patients (24 cases evaluated) achieved
morphologic remission (<5% blasts). The MRD by 8-MCF on day +15 was neg-
ative (<0.01%) in 8/26 cases (5 B-pre-ALL and 3 T-ALL), on day +33 in 21/24
cases and on day +78 in all cases (18 cases evaluated). Two follow-up samples
were not evaluable by qRT-PCR analysis. The MRD study by qRT-PCR was
concordant with the 8-MFC in 17/19 samples. In a patient with TCF3-PBX1
rearrangement the MRD on day +33 was negative by 8-MCF but positive by
qRT-PCR (ratio TCF3-PBX1/ABLx104 3 copies) but the assessment on day
+78 was negative in both. In addition, a patient with ETV6-RUNX1 rearrange-
ment had a negative MRD on day +33 by 8-MCF but qRT-PCR still detected a
very low number of copies (ratio ETV6-RUNX1/ABLx104 4.9 copies). The eval-
uation on day +78 for this patient is still pending.
Summary and Conclusions: implementation of MFC-8 has optimized the
diagnosis and monitoring of MRD using less amount of sample for the analysis,
representing a significant improvement in pediatric care. Furthermore, a good
correlation of the MFC-8 MRD levels with molecular results was observed
(89.5% of cases), suggesting a good complementarity of both techniques.
Thus, MFC-8 confirms as a simple, fast and very useful tool to diagnose and
follow MRD with high sensitivity in pediatric ALL patients.
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ABERRANT BAFF-R EXPRESSION AFFECTS APOPTOSIS RATE OF B
LYMPHOBLASTS AFTER CORTICOSTEROID TREATMENT
E. Sevdali1, M. Zamanakou1, A. Germenis1, M. Speletas1,*
1Department of Immunology and Histocompatibility, University of Thessaly,
School of Health Sciences, Faculty of Medicine, Larissa, Greece
Background: BAFF and APRIL play crucial role in the survival, maturation
and homeostasis of peripheral B-cells through their interactions with BAFF-R,
TACI and BCMA receptors. While the BAFF/APRIL cytokine axis lacks func-
tional roles in early stages of normal B cell development, recent evidence indi-
cates that malignant lymphoblasts aberrantly express receptors of the BAFF-
system (predominantly BAFF-R), suggesting a new role for these molecules in
acute lymphoblastic leukemia (ALL) biology. 
Aims: The aim of this study was to uncover any possible effect of BAFFR
aberrant expression on the in vitro survival capacity of malignant lymphoblasts
after treatment with conventional chemotherapeutic drugs.
Methods: Two ALL cell lines were included in the study͘: the pre-B-ALL cell
line 697, expressing BAFF-R and carrying the E2A-PBX1 chromosomal translo-
cation and the T- ALL Jurkat cell line, characterized by the absence of expres-
sion of any BAFF/APRIL receptor (served also as a negative control). Cells
have been treated in the presence of chemotherapeutic agents that are cur-
rently being used in ALL therapeutic protocols (aracytine and dexamethasone).
The hypotoxic dose of these drugs (aracytine: 0.08-40.0 μg/mL, dexametha-
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sone: 0.01-200.0 μg/mL) was determined by evaluating the apoptosis rate of
cells with flow cytometry, using an Annexin V-FITC/7-AAD kit (Beckman-Coul-
ter), according to the manusfacturer’s instructions. In order to determine if the
presence of BAFF could affect the survival of ALL cell lines, cells have been
treated with exogenous BAFF (5 ng/mL-800 ng/mL), in combination or not with
one of the above agents.
Results: Dexamethazone induced apoptosis of both cell lines in a dose-depen-
dent manner. Interestingly enough, exogenous BAFF significantly increased
the dexamethasone-induced apoptosis of 697 cells; this effect was also obvious
in the lowest dose of BAFF (5ng/mL). As expected, exogenous BAFF did not
affect the rate of dexamethasone-induced apoptosis in Jurkat cells, which did
not express BAFF-R. Concerning aracytine, treatment of both cell lines with
BAFF did not alter the apoptosis rate caused by the drug itself.
Summary and Conclusions: The aberrant expression of BAFFR might play
a crucial role in ALL biology and treatment.
Acute lymphoblastic leukemia - Clinical
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THE EFFECT OF PROLIFERATION INHIBITION AND APOPTOSIS OF BRD4
INHIBITORS JQ1 ON PH POSITIVE ACUTE LYMPHOCYTIC LEUKEMIA
CELL AND ITS MECHANISM
M. LiangMing1,* W. XiaoZhen1, W. Tao1
1Hematology, Shan Xi Da Yi Hospital, Taiyuan, China
Background: It has been widely demonstrated that BRD4 knockdown or inhi-
bition by JQ1 is associated with c-MYC downregulation and antileukemic activ-
ity. leading to suppression of the transcriptional program linked to proliferation
and survival.
Aims: We evaluated the effect of proliferation inhibition and apoptosis of brd4
inhibitor JQ1 on Ph positive acute lymphocytic leukemia(Ph+ ALL) cell and its
mechanism.
Methods: different concentrations of JQ1 are used on SUP-B15 cell and pro-
liferation inhibition level were detected by MTT assaythe cell apoptosis rate
were determined by flow cytometry(FCM) the expressions of BCR – ABLmRNA
brd4mRNA mycmRNA P53mRNA were detected by real-time fluorescent quan-
titative PCR(RT-PCR). 
Results: different concentrations of JQ1 can all inhibit SUP-B15 cell prolifera-
tion, inducing cell apoptosis apoptosis rate was significantly increased com-
pared to control group, and depend of time and dose. half inhibitory concentra-
tion of 72h is about 1.0 umol/L.At the same timeJQ1 can down regulation
BCR-ABLmRNA,brd4 mRNA, myc mRNA transcription levels, and up regulation
the transcription level of p53mRNA.
Summary and Conclusions: JQ1 as brd4 inhibitor can down regulation the
expression of brd4, thus affecting its downstream gene myc and p53, at the
same time it can changeover the express of BCR-ABL,further achieve inhibition
of cell proliferation, inducing cell apoptosis.
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THE EFFECTS OF JQ1 ON SUP-B15 CELL NOTCH1 PATHWAY AND ITS
MECHANISMS 
M. Liangming1,* W. Yan1, W. Tao1
1Hematology, Shan Xi Da Yi Hospital, Taiyuan, China
Background: Philadelphia chromosome-positive (Ph+) acute lymphoblastic
leukemia (ALL) has a poor prognosis. Advances of treatment due to the tyrosine
kinase inhibitor imatinib have improved the cure rates.
Aims: The study was aimed to investigate the inducing effect of JQ1 on the
apoptosis of Ph(+) human ALL Cell(SUP-B15),and whether the regulation of
Notch1 pathway involved in the effect of JQ1 on SUP-B15 cells.
Methods: The SUP-B15 cell were treated with different concentrations of JQ1
for different time.The cell proliferation was analyzed with cytotoxicity test(MTT
method).Cell cycle was detected by fluorescence microscopy and flow cytom-
etry. The expression of Notch1 pathway was detected by real-time quantitative
PCR by MSI2 Notch1 Hes1mRNA.
Results: The results indicated that JQ1 could significantly inhibite the viability
of SUP-B15 cells treated with 0-4μmol/L in does-and time-dependent
manner.JQ1 could induce S cycle arrest in does-dependent manner which was
statistical different from the control at the same time (P<0.05).MIS2 Notch1
Hes1mRNA expression was down-regulated by JQ1 which was statistical dif-
ferent from the control(P<0.05)
Summary and Conclusions: It is concluded that JQ1 could potently inhibit
the growth and proliferation of SUP-B15 cells and the Notch1 pathway might
be one of the important apoptosis mechanisms in Ph(+) ALL cells induced by
JQ1.
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IS BERLIN-FRANKFURT-MUNSTER (BFM) REGIMEN FEASIBLE FOR
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA:
RETROSPECTIVE ANALYSIS OF OUTCOME OF ADULT ALL TREATED
WITH BFM AND HPER-CVAD PROTOCOLS
I. Alacacioglu1,* S. solmaz1, H. Ozsan1, B. PAyzin2, G. Sevindik1, C. Acar1,
A. Katgi1, F. Ozdemirkan2, O. Piskin1, M. A. Ozcan1, B. Undar1, F. Demirkan1
1Hematology, Dokuz Eylul University Faculty of Medicine, 2Hematology, Katip
Celebi Universty Ataturk Research And Training Hospital, Izmir, Turkey
Background: Multiple induction regimens have been developed for adult
patients with acute lymphoblastic leukemia (ALL). But none have been directly
compared in a prospective randomized trial.
Aims: In this report, we want to evaluate outcome of our adult ALL patients
treated with BFM-like and Hyper-CVAD protocols retrospectively and also eval-
uate the feasibility of BFM protocol in adult patients in case of efficacy and tol-
erability.
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Methods: In this study, we want to evaluate outcome of our 50 adult ALL
patients treated with Berlin-Frankfurt-Munster (BFM) (20 patients) and Hyper-
CVAD (30 patients) protocols between march 2006 and october 2012.
Results: The median age was 25 years in BFM, 30.5 years in Hyper-CVAD
group with M/F ratio 15/5 and 17/13 respectively. 45% of patients in BFM group
and 30.3% of patients in Hyper-CVAD group were under age of 25. The majority
of cases were B cell in origin (80% in BFM, 70% Hyper-CVAD group). Complete
remission after induction therapy was achieved in 95% and 96% of the patients,
respectively. Median follow-up time was 37 months. Five-year survival rate
was higher in BFM group with respect to Hyper-CVAD group (59%x 34%).
There were also no complication which can cause a delay during Hyper-CVAD
regimen. Both chemotherapy were well tolerated. None of patients died due to
drug related toxicity. Only mild liver enzyme elevations were seen as toxicity in
BFM which didn’t cause any delay in therapy.
Summary and Conclusions: BFM regimen seems to be feasible for adult
patients with ALL in case of tolerability and efficacy especially in young adults.
PB1599
THE RESULTS OF BFM 95 PROTOCOL IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE FROM
TURKEY
U. Ezer1,* M. Ozturk1, F. Sirin1, N. Sonmez1, S. Tasdelen1, D. Aksen Ezer1,
E. Akkaya1, D.F. Akin1, M. Mumcuoglu1, A. E. Kurekci1
1Losev Losante Hematology Hospital, ANKARA, Turkey
Background: In the past, acute lymphoblastic leukemia (ALL) treatment suc-
cess was 20-30%. But in the last three decades this rate has been increased
by over 80%. This success achieved by contemporary protocols, improvements
in the infrastructures, supportive treatments, and social and psychological sup-
ports. Over the last decade, our country has reached the same success level
as other developed countries. ALL BFM 95 protocol is commonly used for pedi-
atric ALL in European countries and also in Turkey.
Table 1. Demographic characteristics and treatment results of the 147
children receiving ALL-BMF-95 protocol.
Aims: We would like to present our results of 147 pediatric ALL patients who
were treated with this protocol in our hospital within a 10-year period.
Methods: One hundred and forty-seven children with acute lymphoblastic
leukemia (ages 1-14) who were treated with ALL BFM 95 protocol in the
Lösante Hospital between the years 2000 to 2009 were reviewed. The risk
groups were defined by the age and leukocyte count at diagnosis, steroid
response of 8th day, bone marrow aspiration results of 15th and 33th day and
cytogenetics/genetic alterations.
Results: Demographic characteristics, distribution of risk groups and survival
rates for children with ALL receiving ALL BFM 95 protocol are shown in Table
1. The standard risk group showed excellent results with a rate of 100% for
both EFS and OS. The rates of EFS and OS for B-cell ALL are around 90%
when the SR and IR groups were taken together whereas they were 55.88%
and 58.82 for HR group. The event free survival (EFS) and overall survival
rate (OS) for 123 patients with B-cell phenotype were 82.25% and 83.1%,
respectively. The rates of OS of T-cell IR and HR groups were 86.66% and
50%, respectively. Twenty-four patients with T-cell phenotype achieved 73.91%
five-year OS and 69.56% EFS rate. Overall, five-year survival rate of 147
patients who received treatment in our center was 81% and event-free survival
rate was 77% that is comparable to published results so far. Regarding the
white blood cell count (WBC), the rates EFS and OS are higher in patients
with low WBC (<20 000/µL). During high dose corticosteroid treatment, 8
patients showed hypertension and six patients showed hyperglycemia. Later
on, patients who showed hyperglycemia diagnosed with diabetes mellitus and
insulin treatment was initiated. One patient developed aseptic necrosis on
femur two years after chemotherapy. PRES Syndrome was seen in two
patients. Regarding the distribution of the patients included in the risk groups,
we found that number of our patients in SR group were lower (19% vs 35%),
equal in IR group (51% vs 53%), and higher in HR group (30% vs 12%). This
result may be due to referred patients diagnosed with ALL to our center from
other medical centers. We proudly observed that the rates for EFS and OS in
our ALL-BFM 95 SR group were 100%. This excellent outcome could be
explained by successful planning of the current chemotherapy protocol by BFM
group and implementation of appropriate supportive treatments. Additionally,
our treatment results of other risk groups suggest that our success rates are
comparable to the results of centers using ALL-BFM 95 protocol in European
countries and our country.
Summary and Conclusions: We are pleased to know that ALL-BFM 95 pro-
tocol improved survival in childhood ALL. However, the development of new
strategies is still necessary in order to prevent relapses and to improve sur-
vival.
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NO ADVANTAGE OF ALLOGENEIC STEM CELL TRANSPLANTATION
OVER MAINTENANCE CHEMOTHERAPY AS POST-REMISSION THERAPY
IN ADULT PATIENTS WITH B-ACUTE LYMPHOBLASTIC LEUKEMIA IN
OUR CENTRE
M. Alpoim1,* G. Brás1, R. Pinto1, A. Carneiro1, F. Príncipe1, J.E. Guimarães1
1Serviço de Hematologia Clínica, Centro Hospitalar de São João, Porto, Por-
tugal
Background: The optimal post-remission therapy for adult acute lymphoblastic
leukemia (ALL) patients is not well established. Although allogeneic stem cell
transplantation (allo-SCT) has been used in adult ALL for more than 20 years,
its role remains controversial as demonstrated by conflicting results in many
studies.
Aims: Compare allo-SCT vs maintenance chemotherapy as post-remission
therapy in adult B-ALL patients.
Methods: We retrospectively analyzed 64 patients with de novo B-ALL in a
single centre from 2006 to 2014.
Results: The median age at diagnosis was 47 years [17-70], 25(39.1%)
patients with ≤40 years. The median white blood count (WBC) was 9x109/L
[1.0-254] and 17(26.6%) patients had hyperleucocytosis (>30x109/L). Forty
(62.5%) cases corresponded to common-B ALL, 20 (31.3%) to a pre-B ALL
and 4 (6.2%) were pro-B ALL. Thirty-three (51.6%) patients had an unfavorable
karyotype: t(9,22) in 31 (48.4%) patients, t(4,11) in 1 (1.6%) and hypodiploidy
in 1 (1.6%) patient. Thirty-four (53.1%) patients received remission induction
therapy with the HOVON 100 ALL/EORTC 06083 protocol (nonexperimental
arm), 24 (37.5%) with the Hyper-CVAD protocol and 6 (9.4%) with CLG/EORTC
58951 protocol. In cases of Philadelphia chromosome–positive (Ph+) ALL, all
patients received tyrosine kinase inhibitors (TKI) (in addition to multiagent
chemotherapy). Sixty-two (96.9%) patients achieved complete remission (CR)
after either one (90.6%, n=58) or two (6.3%, n=4) courses of induction therapy.
Four patients (6.25%) died during consolidation treatment (2 related to toxicity
of chemotherapy and 2 due to early relapse). Among 58 (90.6%) patients who
completed consolidation therapy, 30 (51.7%, n=30/58) received allo-SCT
(matched related donor, n= 23 and unrelated donor, n=7) and 28 (48.3%,
n=28/58) were treated with maintenance chemotherapy. In patients receiving
allo-SCT, 12 (40%, n=12/30) had ≤40 years and 19 (63.3%, n=19/30) were
Ph+ ALL. The mortality rate in patients submitted to allo-SCT was 56.7%
(n=17/30) and the majority (52.9%, n=9/17) of patients died in CR. In patients
treated with maintenance chemotherapy, the mortality rate was 42.9%
(n=12/28) and the main (75% n=9/12) cause of death was disease relapse.
The median follow-up was 27 months [1-108]. The disease-free survival (DFS)
and overall survival (OS) rates at 3 years of the all cohort were 41.1% (+/-
6.7%) and 48.4% (+/-6.7%), respectively. Comparing Hyper-CVAD protocol
with HOVON 100 ALL/EORTC 06083 protocol, no differences statistically sig-
nificant were found for RC vs NR (P=0.270), DFS (P=0.741) or OS (P=0.411).
According to allo-SCT vs maintenance chemotherapy comparisons, no signif-
icant differences were observed for DFS (P=0.167) and OS (P=0.259) even
including only Ph+ ALL patients in the analysis (DFS for Ph+ ALL allo-SCT vs
Ph+ ALL chemotherapy-P=0.539; OS for Ph+ ALL allo-SCT vs Ph+ ALL
chemotherapy-P=0.857). Additionally, when patients with ≤40 years were ana-
lyzed as a separate group, we failed to observe any statistical difference
between the two post-remission therapies in terms of DFS (P=0.575) and OS
(P=0.780).
Summary and Conclusions: Our study does not demonstrate any advantage
for allo-SCT compared with maintenance chemotherapy as post-remission
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therapy in adult B-ALL even in those patients with Ph+ or ≤40 years. In our
analysis the non-relapse treatment-related mortality in patients submitted to
allo-SCT was very significant. Although our series was small, it represents the
results of daily clinical practice, where graft-versus-host-disease and serious
infections are major challenges.
PB1601
A PEDIATRIC TREATMENT REGIMEN FOR PHILADELPHIA NEGATIVE
ACUTE LYMPHOBLASTIC LEUKEMIA IN ADOLESCENTS AND YOUNG
ADULTS IS FEASIBLE IN THE REAL-LIFE SETTING – SAFETY ANALYSIS
IN A SINGLE-CENTER SERIES
M. Koehler1,* F. Gonçalves1, J. Lobato1, J. Desterro1,M. D. J. Frade1, A. Nunes1,
M. Gomes da Silva1
1Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil,
Lisboa, Portugal
Background: There is considerable evidence that pediatric (PED), high inten-
sity chemotherapy protocols may improve clinical outcome in adolescents and
young adults (AYA) with Acute Lymphoblastic Leukemia (ALL). Toxicity, which
is more frequent and severe in older patients (pts), is a key issue, limiting the
potential benefits and becoming more evident outside clinical trials.
Aims: We evaluated the feasibility and safety of a PED regimen – the Dana-
Farber Cancer Institute Consortium Protocol (DFCI) 05-01-in Ph- AYA ALL pts
receiving treatment (Tx) in an adult Hematology reference center.
Methods: We conducted a retrospective analysis of all adverse events (AE)
occurring during the DFCI 05-01 regimen in a series of consecutive AYA pts
treated at our institution, with a focus on Grade 3-5 CTCAE toxicities and special
interest side effects with at least a possible relationship to Tx.
Table 1. 
Results: 22 Ph- ALL pts (median age 18 yo, range 15-42, 68.2% males), diag-
nosed between 2007 and 2014, were treated according to the DFCI 05-01 pro-
tocol. 54.6% were<20 yo, 13.6% 20-29 yo, and 31.8% were 30-42 yo. B-ALL
was diagnosed in 11 (50%), T-ALL in 8 (36.4%), and T Lymphoblastic Lym-
phoma in 3 (13.6%). Only 1 case had detectable blast cells in diagnostic spinal
tap (<5/ul). At the end of induction (IND) 20 (91%) pts achieved CR, 2 had
refractory disease, being excluded from the analysis after this point, and 4 B-
ALL cases had high MRD levels (≥0.001) assessed by RQ-PCR. Based on
cytogenetics and molecular response at day 32, 7 (31.8%) pts moved to the
very high-risk group and received intensified Tx according to protocol. 2 relaps-
es occurred before maintenance and 2 pts died of refractory disease shortly
after starting salvage regimens. 2 Tx-related deaths were observed. With a
median follow up of 37 months, 16 pts (72.7%) are alive in CR1: 5 completed
the protocol, 8 had an allogeneic stem-cell transplant after Consolidation II,
and 3 are still under Tx. Table1 depicts the grade 3-5 toxicities and asparaginase
(ASP) specific related toxicities observed during a median of 11 months of Tx
per pt. No deaths were observed during IND and infectious complications were
the most frequent AE: 9 pts (40.9%) developed febrile neutropenia with 7 con-
firmed bacteremias. Overall, infections were the most relevant reported AE dur-
ing Tx, with 2 grade 5 events. 2 episodes of reversible AKD (not requiring renal-
replacement therapy) during high dose MTX Tx were seen. 10/14 evaluable
pts (71.4%) who initiated the 30-week ASP course were able to receive 26 or
more IM E. coli ASP equivalent doses, with one of the ASP formulations –
native E. coliASP, PEG-L-ASP, or Erwinia L-ASP. 4 musculoskeletal AEs were
observed, including 3 cases of avascular necrosis, and 1 bone fracture, possibly
related to corticosteroid therapy.
Summary and Conclusions: Increased toxicity in AYA is the limiting factor for
the use of intensified therapeutic regimens in ALL. We did not observe unex-
pected grade 3-4 AE, nor an unacceptable high incidence of these events,
compared to literature. Tx-related mortality was also equivalent (9%). In this
series ASP tolerance was acceptable: the incidence of major ASP-related tox-
icities was similar to older children, with a proportion of pts completing at least
26 weeks of high-dose ASP only slightly lower than described in PED popula-
tions (71.4% VS 88%). The application of tolerable, PED protocols may improve
the outcome of adult ALL.
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THE EFFECTS OF THIOPURINE METHYLTRANSFERASE
POLYMORPHYSMS (TPMT*2, TPMT*3B, TPMT*3C, TPMT*3A) AND ITS
CYTOPLASMIC ENZYME LEVELS ON MYELOSUPPRESSION IN
CHILDREN WITH ALL TREATED WITH 6-MERCAPTOPURINE.
Y. Mortazavi1,* M. Jafarian2, S. Alavi3, M. Hedayati4
1Pathology, 2Molecular Medicine and Genetics, Zanjan University of Medical
sciences, Zanjan, 3Pediatric congenital hematologic disorders research center,
Shahid Beheshti University of Medical Sciences, 4Hematology, Tehran Mofid
Hospital, Tehran, Iran
Background: Thiopurine Methyltransferase (TPMT) prevents the toxic effects
of thiopurine drugs such as 6-mercaptopurine and neutralizes its side effects
such as myelosuppression. This enzyme methylates toxic metabolites and
leads to their inactivation.
Aims: The aim of this study was to evaluate TPMT gene polymorphisms
(TPMT*2, TPMT*3B, TPMT*3C, TPMT*3A) and detection its cytoplasmic
enzyme levels and myelosuppression and hepatotoxicity effects in children with
acute lymphoblastic leukemia (ALL) treated with 6-MP.
Methods: 98 patients with standard risk paediatric ALL in maintenance phase
were selected. PCR-RFLP method was performed to detect mutations in exon7
(460G>A; TPMT*3B), and in exon 10 (719A>G; TPMT*3C). TPMT*2 (238G>C)
allele, in exon 5 was analyzed by allele-specific PCR method. Exons 7 and 10
in 19 patients and exone 5 of 2 patients were also sequenced to confirm the
results obtained by PCR-RFLP and AS-PCR methods. The enzyme level of
70/98 patients was assessed by ELISA. Then Correlation between genotype,
phenotype and side effects such as myelosuppression and hepatotoxicity was
analyzed by statistical methods.
Results: Frequency of TPMT*1\*3B genotype was 1.1% and the frequency of
TPMT*3B allele variant was 0.71%. No allele variant was detected in TPMT*2
and TPMT*3C,*3A, *4, *7, *8, *10 (4 allele variants (TPMT *4, *7, *8, *10) were
analyzed by sequencing). The concentration of enzyme was low in 8 (11.4%)
individuals. There was no meaningful association between phenotype and
genotype of TPMT enzyme. A significant correlation was found between low
concentration of TPMT enzyme and myelossuppresion (P=0.04, leucopenia,
P=0.02 neutropenia ). There was no statistical difference between low and nor-
mal concentration of TPMT enzyme and hepatotoxicity (P=0.12).
Summary and Conclusions: The results of this study showed that there is a
relationship between low enzyme concentration and myelosuppression in some
patients who were treated with 6-MP. Therefore, to avoid some side effects of
6-MP such as myelosuppression, studying common and rare TPMT gene vari-
ant as well as measurement of TPMT enzyme level is recommended.
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MULTICOLOR FLOW-CITOMETRY IS A CHEAP AND RELIABLE PREDICTOR
OF RELAPSE RISK IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS,
RETROSPECTIVE DATA FROM REAL LIFE EXPERIENCE.
F. Guolo1,* P. Minetto1, G. Pastori1, D. Guardo1, L. Giannoni1, A. Kunkl2,
M. Clavio1, N. Colombo1, R. Grasso1, F. Ballerini1, M. Miglino1, R. M. Lemoli1,
M. Gobbi1
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2Department of Pathological Anatomy, IRCCS AOU San Martino-IST,
Genoa, Italy
Background: Many studies have shown the prognostic value of minimal resid-
ual disease (MRD) evaluation in Acute Lymphoblastic Leukemia (ALL). Nowa-
days, most of the modern therapeutic protocols include risk-oriented and MRD-
driven consolidation program. MRD is usually evaluated by multicolor-flow
cytometry (MFC) and RQ-PCR for VDJ rearrangements. The latter method is
significantly more sensible but is quite expensive and complex, and usually
requires a great amount of time. MFC is cheaper and quicker, and it is currently
applied in most induction protocols, where is performed at fixed timepoints.
However, few data are available on MFC MRD value outside clinical trials,
where often response assessment timing greatly varies between different induc-
tion schedules and different patients.
Aims: The aim of the present study is to evaluate if MFC-MRD maintains prog-
nostic significance in the real life therapeutic experience, outside clinical trials
and with different induction schedules.
Methods: We retrospectively analyzed outcome of 132 consecutive ALL
patients, treated in our centre in the last 10 years. Median age was 44.5 years
(range 15-82 years). Induction regimens included Hyper-CVAD, standard three
or four drug induction, with or without L-Asparaginase, and TKI with or without
chemotherapy for Philadelphia positive ALL. Relapse-free survival (RFS) was
calculated from the time of diagnosis until last follow-up or documented
leukemic relapse. Patients were censored upon allogeneic transplantation.
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MFC MRD levels were evaluated on bone marrow samples after first induction
cycle, at a median of 36 days after diagnosis (range 28-52). A positive MFC
MRD was defined by the presence of no less than 25 clustered leukemic
cells/105 total events (threshold of 2.5x10-4 residual leukemic cells) at four-
color flow-cytometry. 
Results: Sixteen patients (12,1%) died during induction, mainly because of
infectious events. Of remaining 116 patients, 101 (84%) achieved complete
remission (CR). None of the analyzed variables significantly influenced CR
probability. After a median follow-up of 58 months, 63 relapses were observed.
The probability of disease relapse was significantly increased by leukocytosis
at diagnosis, omission of L-Asparaginase and MFC MRD positivity after first
cycle (P=0.003, P=0.047, P=0.048, respectively, Fig.1). Specifically, relapse
rate in MFC MRD negative patients were very low (5/25 MFC-MRD negative
patients, 25%), when compared to the whole cohort. MFC value resulted inde-
pendent from ALL lineage, induction schedule, sex and age. High dose
Methotrexate administration conferred a borderline advantage on RFS
(P=0.066). Multivariate RFS analysis disclosed low WBC count and inclusion
of L-Asparaginase as the strongest predictor of longer RFS, however without
reaching statistical significance (P=0.061).
Figure 1. RFS according to MFC MRD.
Summary and Conclusions: Risk adapted consolidation and transplant timing
has recently shown high efficacy in many MRD-driven clinical trial. Our data con-
firm that evaluation of MRD by MFC on bone marrow samples is a cheap, relatively
simple and a reliable predictor of relapse risk, even outside clinical trials. Basing
on those findings, MFC MRD evaluation could be a valid surrogate of RQ-PCR
for VDJ rearrangement, with potential clinical utility especially in those setting
where access to expensive molecular techniques is difficult, allowing to apply risk
adapted consolidation even if molecular MRD methodic are not available. 
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PREGNANCY IS NOT AN EXCLUSION CRITERIA FOR THE TREATMENT
ACCORDING TO THE ADULTS ACUTE LYMPHOBLASTIC LEUKEMIA
PROTOCOL ALL-2009: RESULTS OF THE RUSSIAN ALL STUDY GROUP
(RALL)
V. Troitskaya1,* E. Parovichnikova1, A. Sokolov1, S. Makhinya2, G. Galstyan3,
G. Kliasova2, A. Zvereva4, Z. Fidarova1, O. Gavrilina1, A. Sidorova1,
S. Novikov3, T. Kaporskaya5, V. Lapin6, O. Latyshkevich4, V. Savchenko2
1Department of Hematological Oncology and BMT, 2National Research Center
for Hematology, Moscow, Russian Federation, 3Department of anesthesiology
and Intensive therapy, National Research Center for Hematology, 4Centre of
Family Planning and Reproduction, Moscow, 5Irkutsk Clinical Regional Hospi-
tal, Irkutsk, 6Yaroslavl regional hospital, Yaroslavl, Russian Federation
Background: Acute lymphoblastic leukemia ALL accounts for about a third of
acute leukemias diagnosed during pregnancy. Pregnancy is a common exclu-
sion criteria for any clinical trial. RALL study group decided to include the preg-
nant women with ALL in the multicenter clinical trial ALL-2009 (ClinicalTrials.gov
public site; NCT01193933). The protocol is based on non-intensive but non-
interruptive treatment. 
Aims: To evaluate efficacy and toxicity the ALL-2009 protocol for pregnant
women with ALL.
Methods: From Jan 2009, till Dec 2014, 30 centers enrolled 263 Ph-negative
ALL pts, among whom there were 13 pregnant women (3-in 1st; 3- in the 2nd
and 7-in 3rd trimester of pregnancy) from 3 hematological centers. The median
age was 28 (18-32) years. B-cell ALL was diagnosed in 6 (46%) and T-cell ALL-
7 (54%) patients. 10 patients (77%) were attributed to a high-risk, 3 (23%)-to a
standard risk group. The treatment according the protocol ALL-2009 was carried
out without deviations except the shift of L-asparaginase for later phases of
treatment (after delivery) and applying intrathecal injections without methotrexate
for those in whom chemotherapy was started during pregnancy. Medical abortion
was performed in 3 patients at the 1st trimester (10-11 weeks of gestation) during
the prephase (7 days with prednisolone 60 mg/m2). 3 patients at 36-40 weeks
of gestation were delivered before treatment and prephase was initiated after
2-3 days after delivery. All others (n=7) were started with chemotherapy during
pregnancy (at 16, 19, 25, 28, 29, 31 and 34 weeks of gestation).
Results: All pregnant women were refractory to prednisolone defined by more
than 25% of bone marrow blasts after 7 days of prephase. So dexamethasone
was used for all further treatment. One patient is on the induction now, so CR
rate was evaluated in 12. CR was achieved in 10 of 12 (83,3%), in 7 after the 1st
phase and in 3 – after the 2nd induction phase. 2 patients had refractory ALL and
died from the disease. There were no differences in the frequency of infections,
duration of neutropenia, transfusion support during induction in comparison with
common ALL pts. In 3 pts of those who were treated during pregnancy delivery
was carried out after the 1st induction phase, in 2 – during the 2nd phase, in 1 –
after the 2nd phase. Gestational age at delivery was 34 weeks (33-39 weeks). At
time of delivery 4 pts were and 2 were not in CR. One pregnant woman is still on
the induction treatment. The median interval between the last administration of
cytostatic drugs and delivery was 6 days (1-20 days). The median time from
delivery to continuation of chemotherapy was 16 days (11-44 days). Chemother-
apy duration during pregnancy constituted 5-9 weeks. Totally 9 children were
born at a median gestation time – 36 weeks (33-40). All are alive at a median 9
months (8-60 mo) and healthy. Allo-HSCT was performed in 2 pts, auto-HSCT-
2. There were 2 relapses and 1 death in CR. The OS and DFS constituted 62%
and 53% at 3 years, and these results did not differ from the other pts treated
according ALL-2009 protocol (60% and 57%, respectively).
Summary and Conclusions: Our data demonstrate that ALL in pregnant
women is characterized by higher frequency of T-cell phenotype and high risk
disease, most cases occurred in the 2nd and 3rd trimester, CR rate is 83%. All
born children are well. Long-term survival does not differ from that of the other
patients on this protocol. So pregnancy should not be considered as an exclu-
sion criteria for our protocol that is non-intensive, non-interruptive and easily
reproducible.
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FOURTEEN YEARS EXPERIENCE WITH THE EORTC 58951 PROTOCOL
FOR THE TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA IN THE SOUTH OF TUNISIA
M. Medhaffar1,* I. F1, B. A. I1, H. S1, J. I2, S. I3, G. M1, K. O1, B. H1, K. F1, E. M1,
1Hematology, Hedi Chaker Hospital, 2Hematology, Habib Bourguiba Hospital,
3Hematology, Institut Pasteur, Sfax, Tunisia
Background: Childhood acute lymphoblastic leukemia (ALL) is an hematologic
malignancies with high rate of cure. We report the experience of the department
of clinical hematology of Sfax for the treatment of childhood ALL with the
EORTC 58951 protocol.
Aims: we report the results of fourteen years treatment of childhood acute
lymphoblastic leukemia with the EORTC 58951 Protocol
Methods: From January 2000 to December 2013, we retrospectively studied
the outcome of all childhood ALL treated with the EORTC 58951 pediatric pro-
tocol. For those patients we studied the leukemia characteristics (sex ratio,
white blood cell counts WBC, blast’s phenotype, cytogenetic abnormalities)
and response to treatment: response to prophase, remission rate, risk group
stratification, treatment related mortality (TRM) (induction and post induction
death) and survival (overall survival OS, event free survival EFS and disease
free survival DFS: calculated for patients in complete remission). We complete
the analysis by a comparison between two periods P1 and P2 (P1: 2000-2006
and P2: 2007-2013). 
Results: From January 2000 to December 2013, 160 children were treated
with the EORTC 58951 protocol. Median age was 6 years (range: 13 months
to 15 years). Sex ratio M/F was 1.4. WBC counts less than 10 G/l, from 10 to
100 G/L and more than 100 G/L were observed respectively in 42, 42 and 16%
of cases. The blast’s phenotype was B in 70% and T in 30%. Cytogenetic
abnormalities were noted in 48% of cases. A good response to prophase was
noted in 84% and complete remission in 97% of cases. The EORTC risk group
stratification was Low Risk (LR) in 6.5%, Average Risk1 (AR1) in 45%, Average
Risk2 (AR2) in 25.5% and Very High Risk (VHR) in 23%. TRM was 9%: induc-
tion rate death was 7% and post-induction rate death was 2%. Seven patients
from VHR group with familial donor underwent allograft. The relapse rate was
23% of all patients in remission; 10% for LR group, 22% for AR1 group, 17%
for AR2 group and 37.5% for VHR group. At 5 years of follow up, OS, EFS and
DFS were 67, 64 and 74% respectively. We compared two periods, we noted
less TRM and less relapse in P2 with respectively (2% vs 14%) and (19% vs
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28%), so we have a good survival at 5 years in P2 (OS: 75% vs 58%, EFS:
73% vs 55% DFS: 79% vs 68%).
Summary and Conclusions: Childhood ALL in our institut were characterized
by a poor presentation at diagnosis: male sex, leucocytosis more than 100 G/L,
T phenotype and bad response to prophase are frequent compared to the occi-
dent reports. EFS are acceptable in our study but still less than observed in lit-
erature (85-90%). We have noted an improvement in the survival rates during
the second period P2 this could be explained by improved support treatment
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WHAT IF YOU FAIL? IMPACT OF UNSUCCESSFUL CYTOGENETIC ANALYSIS
ON TREATMENT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL): A TERTIARY CARE SINGLE CENTRE ANALYSIS FROM INDIA
C. Philip1,* M. J. John1, A. Mathew1, S. Singh1
1Clinical Haematology, Haemato-Oncology and Bone Marrow (Stem Cell)
Transplantation, Christian Medical College & Hospital, Ludhiana, India
Background: Cytogenetic findings are important in predicting prognosis; and
are an obligatory tool in stratifying patients for treatment assignment in ALL.
The large studies in ALL have reported between 10-30% of cytogenetic failure.
The impact of cytogenetic failure on treatment outcomes in this group with ALL
has not been sufficiently explored.
Aims: To determine the differences in clinical features and treatment outcomes
in patients with ALL based on the success of karyotype analyses.
Methods: We undertook a retrospective study to evaluate the impact of cyto-
genetic failure on treatment outcomes in patients with a diagnosis of ALL (Burkitt-
excluded) treated at our tertiary care center from January 2009 till December
2014. Cytogenetic failure was used to define analyses that could not be per-
formed in the laboratory due to no mitoses or non-informative morphology. Risk
stratification and treatment was based on the BFM95 protocol for patients’ ≤15
years and GMALL in the older patients. Standard of care diagnostic tests and
supportive care was administered to all patients. The cytogenetic data was
retrieved from the original reports of the laboratory performing the analyses at
our centre. Only cytogenetic studies sent to the laboratory were included for
analyses. Clinical details were ascertained through patient admission records
and discharge cards. The collected data was analyzed using SPSS.
Figure 1.
Table 1. Socio-demographic characters, clinical features and laboratory
parameters in newly diagnosed patients (N=54).
Results: A total of 76 admitted patients were diagnosed with ALL. Of these 54
(71.1%) continued with treatment. Bone marrow was sent for cytogenetic analy-
ses in 33 of these patients. There were no significant differences observed in
terms of socio-demographic and baseline laboratory parameters among the
two groups based on the success of cytogenetic analyses (table1).The Event
Free Survival (EFS) and Overall Survival (OS) were lesser in patients with cyto-
genetic failure than in those who had a successful karyotype analyses (Figure
1). With a mean follow up of 32 months, the EFS at one year in those with cyto-
genetic failure was significantly lower than those with a successful karyotype
analyses (P=0.008). When compared against the outcomes of patients with
adverse karyotype (t (9; 22) or >3 abnormalities), those with cytogenetic failure
had a significantly lower EFS (P=0.022).
Summary and Conclusions: Risk stratification in ALL has not defined the opti-
mal strategy in patients with cytogenetic failure. Unsuccessful cytogenetics
likely predicts a poor outcome. This needs to be further explored by facilitating
the inclusion of these patients as a group in clinical trials. 
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THE FREE RADICAL OXIDATION ROLE IN THE DEVELOPMENT OF
ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN PATIENTS WITH
ACUTE LEUKEMIA IN THE PRESENCE OF CONCOMITANT ISCHEMIC
HEART DISEASE
T. Lymanets1,* I. Skrypnyk1, G. Maslova1,
1Chair of Internal Medicine #1, Ukrainian Medical Stomatological Academy,
Poltava, Ukraine
Background:Anthracycline antibiotics (AA) are included into the most modern
acute leukemia (AL) treatment regimens. The AA assignment in polychemother-
apy (PCT) programs contributes to the clinical-hematological remission per-
centage growth, and the improvement of pts survival. However, the formation
of anthracycline-induced cardiotoxic effects can be significant limiting factor of
PCT full dose conducting, which certainly leads to reduced effectiveness of
anticancer therapy. In this aspect particularly important becomes the assess-
ment of the heart tissue injuries potential risks. The incidence of cardiotoxicity
depends on the cumulative dose (CD) of AA. The generally toxic AA CD is 550
mg/m2 for doxorubicin. An additional risk factor for anthracycline cardiotoxicity
is considered to be the concomitant ischemic heart disease (IHD). The imbal-
ance between generation and inactivation mechanisms of aggressive free rad-
icals as a risk factor of heart tissue AA-induced injury in patients with AL with
concomitant ischemic heart disease remain insufficiently studied.
Aims: To assess the prooxidant-antioxidant imbalance status in patients with
AL in the dynamics of AA treatment taking into account concomitant IHD.
Methods: The study involved 41 patients with acute leukemia (acute lym-
phoblastic leukemia-13 pts, acute myeloid leukemia-28 pts), aged 16–72 years,
23 (56%) men and 18 (44%) women, which PCT included AA. Patients were
divided into two groups according to the presence of concomitant IHD: I (n=24)
– without concomitant IHD; II (n=17) – with the concomitant IHD. The general
condition assessment of pts of the both groups was performed twice: before
specific therapy and after reaching AA cumulative dose from 100 to 200 mg/m2.
The POL processes activity was determined by the malondialdehyde (MDA)
level, the antioxidant protection (AOP) – the serum catalase concentration.
Results: Before treatment in patients of group I without concomitant IHD the
MDA concentration in serum exceeded the upper limit of normal in 1.2 times,
the catalase level – in 1.1 times. In patients of group II with concomitant IHD the
MDA level was increased in 1.46 times with the simultaneous tendency to reduce
the catalase concentration in serum compared to normal, indicating that the
exhaustion of antioxidant protection on the IHD background. Upon reaching the
AA CD of 100-200 mg/m2 MDA concentration in serum was in 1.54 times higher
in pts of group II compared with pts of group I (4.81±0.38 mmol/l vs 3.12±0.28
mmol/l; P<0.05). Simultaneously, with the presence of concomitant IHD in pts
of group II the catalase level in serum was in 2.1 times lower in comparison with
pts of group I (72.5±8.7 mkkat/l vs 33.8±3.2 mkkat/l; P<0.05).
Summary and Conclusions: Therefore, concomitant ischemic heart disease
in patients with AL during the treatment AA is an additional risk factor for car-
diotoxicity, due to exhaustion antioxidant protection system and deepening
imbalance between the formation and inactivation of free radicals.
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OUTCOME OF ADOLESCENTS AND YOUNG ADULTS WITH ACUTE
LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC PROTOCOL:
62 CASES
F. I1,* M. Medhaffar1, B. A. I1, H. S1, K. O1, B. H1, K. F1, E. M1
1Hematology, Hedi Chaker Hospital, Sfax, Tunisia
Background: Several retrospective studies have confirmed that adolescents
and young adults (AyA) with acute lymphoblastic leukemia (ALL) treated with
pediatric protocols have better outcomes than similarly aged patients treated
with adult protocols. We reported results and feasibility of a pediatric-based
protocol (EORTC 58951) in adolescents and young adults.
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Aims: Pediatrics protocols improve the outcome of adiolescents and adults
acute lymphoblastic leukemia
Methods: From January 2000 to December 2013, 62 patients aged 16 to 30
years with newly diagnosed ALL were treated, in the department of clinical
hematology of Hedi Chaker Hospital, according to the pediatric protocol EORTC
58951. Further leukemia characteristics (Sex, White Blood cell count, Blasts
phenotype, Cytogenetic results), we studied the protocol results: response to
prophase, risk group stratification (average: AR1 and AR2, very high: VHR),
treatment related mortality (TRM), remission rate, relapse rate and 5 years
survivals (overall OS, event free EFS and relapse free survival RFS).
Results: Sixty two AyA ALL were treated with the pediatric protocol. The
patients were 38 males and 24 females (SR=1.58). 34% had a WBC>100 G/l.
A T blast phenotype was noted in 53% of cases. Nineteen patients (30.5%)
had poor response to pophase. Fifty two patients (86%) received AR2 (52%)
or VHR (34%) arm induction. Fifty seven patients (97%) achieved CR. Two
patients failed to achieve complete respond after 2 courses of chemotherapy.
Induction death was noted in 8%. Consolidation death was noted in 17%.
Relapse was observed in 25%. Five years OS, EFS and RFS were respectively
48, 48.5 and 65%.
Summary and Conclusions: This study showed that pediatric protocol can
offer good results concerning CR and DFS to adolescent and young adult ALL.
However OS and EFS, sure better than adult ALL treated during the same peri-
od by adult protocol (OS= 14%, EFS=14% and DFS= 40%) was not satisfactory
because the high toxic mortality rate. 
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HIGH RISK CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA GROUP
TREATED WITH THE EORTC58951 PROTOCOL: RESULTS AND
OUTCOME
M. Medhaffar1,* F. I1, G. M1, K. O1, B. H1, K. F1, B. A. I1, H. S1, E. M1
1Hematology, Hedi Chaker Hospital, Sfax, Tunisia
Background: More than 80% of children with acute lymphoblastic leukemia
(ALL) can be cured, but subsets of patients have significantly worse outcomes.
In this study we analyzed the clinical, biological features and therapeutic results
of patients treated with high risk group of the EORTC protocol.
Aims: Report the outcome of high risk childhood acute lymphoblastic leukemia
group
Methods: From January 2000 to December 2013, 160 patients with ALL aged
less than 16 years were treated by the EORTC protocol in the Hematologic
department of Hedi Chaker Hospital, from those 37 patients were treated by
high risk group (VHR). The VHR group includes patients with poor prednisone
response at day 8 (more than 1000 blasts/mm3 on the blood smear), those
with defavorable cytogenetic abnormalities (t (9,22), t (4,11)...) and those with
complete remission after two courses of chemotherapy. From those patients
we analyzed the clinical and biological features (Age, sex, blood count, cyto-
genetic abnormalities and blasts phenotypes) and therapeutic results (remis-
sion rate, rate relapse, overall survival (OS), event free survival (EFS) and dis-
ease free survival (DFS) at 5 years follow up).
Results: In our study, thirty seven children were treated with VHR group of the
EORTC protocol (23%). The median age of patients was 9 years (ranged 2-15
years). Sex ratio H/F=1,64. The median WBC count at diagnosis was 55.8 G/L
(ranged from 2 to 400 G/L). There were 51% with B-cell ALL and 49% with T-
cell ALL. Cortico-resistance was the only high risk factor in 23 patients, absence
the remission after induction in 8 patients and only cytogenetic abnormalities
in 4 patients. The cortico-resistance at day 8 was observed in 65% of patients.
Five children (13.5%) were treatment failure after two courses of chemotherapy.
The complete remission was obtained in 32 children (86%), among them 12
relapsed (37.5%). The post induction death was noted in 2 patients. Only 7
patients (16%) underwent allograft from familial donor. At 5 years follow-up,
the OS, EFS and DFS were respectively 46%, 43% and 54%.
Summary and Conclusions: The frequency of high risk group in our study is
more than those observed in the literature (12 to 16%). The poor 5 years sur-
vivals (OS=46%, EFS=43%) are related to the high rate of relapse. Improve-
ment of outcome can be obtained by enlargement of donor source: unrelated
and cord blood. 
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CLINICAL CHARACTERISTICS AND CYTOGENETIC ABNORMALITIES OF
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: SINGLE
INSTITUTE EXPERIENCE FROM SAUDI ARABIA
N. Alkhayat1,* G. Elyamany2, Y. Elborai1,3, O. Alsharif1, M. Awad2,
O. Alsuhaibani2, I. Ben-Abdallah Bouhajar2, E. Al Mussaed4, M. ALshahrani1
1Pediatric Hem/Onc and BMT Department, 2Pathology and Laboratory Medi-
cine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, 3Pediatric
Hem/Onc and BMT Department, National Cancer Institute, Cairo University,
Cairo, Egypt, 4Department of Basic Science, Princess Nourah Bint Abdulrah-
man University College of Medicine, Riyadh, Saudi Arabia
Background: Childhood Acute Lymphoblastic Leukemia are generally char-
acterized by recurrent molecular and cytogenetic abnormalities; the identifica-
tion of those abnormalities is clinically important because they are considered
significant risk-stratifying markers.
Aims: Currently, no sufficient data exist regarding cytogenetic abnormalities
and treatment outcome in Saudi pediatric ALL patients. Ninety-two cases of
childhood ALL were examined to determine cytogenetic profile, and did corre-
lations to other biologic factors.
Methods: Patients. From 2004 to 2014, we reviewed all cases with established
diagnosis of childhood ALL. Of the 92 patients, 82 were B-lineage ALL, and 10
T-cell ALL. All patients were treated by UKALL 2003 protocol and risk stratified
according previously published criteria. Cytogenetic Analysis. Chromosome
banding analysis and fluorescence in situ hybridization (FISH) were used to
detect genetic aberrations. Analysis of FLT3mutations. Bone marrow or blood
samples were screened for FLT3mutations (internal tandem duplications, ITDs
and point mutations, D835) using polymerase chain reaction methods (PCR).
Results: Figure 1 and Table 1. Summarize patient’s characteristics and
patient’s outcome. Cytogenetic analysis showed chromosomal anomalies in
59 out of 92 cases with overall incidence 64.1%.The most frequent chromoso-
mal anomalies in ALL were trisomy 21, t(9;22), and t(12;21). Our data are in
accordance with those published showed that FLT3 mutations not common in
ALL patients (4.7%) and have no prognostic relevance in pediatric ALL patients
while t(9;22) and MLL gene rearrangements were signs of a bad prognosis in
childhood ALL, with high rate of relapse, shorter overall survival; (P=0.031)
and event-free survival (EFS) was also worse(P=0.040) compared to standard
risk group.
Tabella 1. Cytogentic abnormalities detected in our study.
Available for Karyotype                                                28 normal 
                                                                                 11 abnormal
Available for Fish                                                                n=83
t (9;22)                                                                          10 (12%)
t (12;21)                                                                        8 (9.6%)
MLL                                                                                6 (7.2%)
MYC                                                                                2 (2.4%)
t (1;19)                                                                          1 (1.2%)
+21                                                                              11 (13.3%)
Del 12p                                                                            5 (6%)
+6                                                                                  1 (1.2%)
+9                                                                                  3 (4.6%)
+8                                                                                  1 (1.2%)
-19                                                                                 1 (1.2%)
Hyperdiploid                                                                    6 (7.3%)
Pseudotriploidy                                                                2 (3.1%)
Tetraploidy                                                                        1 (1.5
Figure 1. Patient characteristics and FLT3 mutations.
Summary and Conclusions: Our data are in accordance with those published
and confirm that the frequency of cytogenetic abnormalities and their prognostic
relevant were comparable to those reported in the literature. FLT3 mutations
not common among Saudi ALL and occur in low percentage and had no prog-
nostic relevance as in AML and did not affect clinical outcome.
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IMPACT OF DURATION TO COMPLETE INDUCTION IN ACUTE
LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE FROM
INDIA
C. Philip1,* M. J. John1, A. Mathew1, S. Singh1
1Clinical Haematology, Haemato-Oncology and Bone Marrow (Stem Cell)
Transplantation, Christian Medical College & Hospital, Ludhiana, India
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Background: The improvement in event free survival in Acute Lymphoblastic
leukemia(ALL) corresponds to advances in chemotherapy and supportive care.
However despite these breakthroughs, the intensity of the chemotherapy pre-
disposes patients to cytopenias and infections. These result in a break from
the protocol and delay in induction completion. In a resource restricted setting
where a major constraint to therapy remains the cost, it is important to analyze
the factors to optimize treatment. The impact of duration to complete the initial
intensive induction on survival needs analysis. 
Aims: To evaluate the clinical characteristics and outcome of patients with a
diagnosis of ALL (Burkitt- excluded) admitted at our tertiary care center. 
Methods: We undertook a retrospective study on patients with ALL (Burkitt-
excluded) admitted at our tertiary care center. Induction chemotherapy con-
sisted of standard induction as in the BFM95 protocol for patients’ ≤15 years
and GMALL in the older patients. In addition to the chemotherapy; standard of
care diagnostic tests and supportive care was administered to the patients.
The data was retrieved from the patient admission records and discharge cards.
The collected data was analyzed using SPSS.
Results: A total of 76 admitted patients were diagnosed with ALL during this
period. Of these 54 (71.1%) continued with treatment (Fig 1A). The median age
of newly diagnosed patients was 20 years (range: 1-65) and there were 53
(69.7%) males. In the treated patients, B-ALL was seen in 37(68.5%).The other
baseline features are as depicted in Table1. The mean duration of induction
chemotherapy was 30.4(± 5.3) days. A microbiologically documented infection
was seen in 11(20.4%) and the induction was delayed more than the mean
duration in 14 (37.8%). With a mean follow up of 15 months, the Event Free sur-
vival at one year in those with delay in completion of induction was 68.2%±15.4
and not statistically significant from those without a delay (Fig 1B). A similar con-
clusion was seen in the pediatric subgroup analysis (Data not shown).
Table 1. Descriptive baseline demogrphic characteristics in newly
diagnosed patients with ALL.
Figure 1. Newly diagno
Summary and Conclusions: In conclusion there are challenges in the man-
agement of ALL in India. One fourth of the patients decline treatment in view of
financial constraints. In those who proceed with induction, there occurs a delay
in one third. These delays do not appear to impact the event free survival in
ALL. More analysis of prevalent practices will help tailor therapy in resource
restricted settings.
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COST EFFECTIVE APPROACH IN FLOWCYTOMETRY BASED
IMMUNOPHENOTYPE OF ACUTE LYMPHOBLASTIC LEUKEMIA. A
TERTIARY CENTRE EXPERIENCE FROM AIIMS, NEW DELHI, INDIA
P. Tanwar1,* A.R. Singh1, R. Gupta1 S. Bakhshi2, l. Kumar2
1Laboratory Oncology Unit, Dr B.R.A.Institute Rotary Cancer Hospital, 2Medical
Oncology, Dr B.R.A.Institute Rotary Cancer Hospital, all India Institute of Med-
ical Sciences, New Delhi, India
Background: The diagnosis of acute lymphoblastic leukemia is based on mor-
phology, cytochemistory, cytogenetics and immunophenotyping. In an under
resource setting and sparsely insurance covered nation like India, the cost of
investigation and treatment is one of the major barrier between disease and its
curative management. With primary objective of establishing, the cost effective
diagnostic panels without compromising the quality, we used primary screening
antibodies panel comprising of major pan-lineage markers. This was followed
by extensive secondary antibodies panel comprising of more lineage specific
markers to reach a final diagnosis. In this study, we evaluated, the cost effective
role of five-color primary screening antibodies to reach to the final conclusive
diagnosis without compromising the quality of analysis.
Aims: Evaluation of the cost effective role of five-color primary screening antibodies
panel in flowcytometry based immunophenotyping of Acute Lymphoblastic Leukemia.
Methods: A total of 234 newly diagnosed cases of Acute Leukemia from Jan
2013 to Jan 2015 were included in this study. All these cases were stratified to
their respective lineages with the panel of primary screening antibodies com-
prising of cytoplasmic myeloperoxidase (MPO), cytoplasmic 79a (c79a), CD34,
cytoplasmic CD3 (c3) and CD45.Once the lineage has been screened, then
extensive secondary panel of antibodies with more specific marker of B-cell, T-
cell and myeloid lineage were used to conclude for final diagnosis
Results: Of all the cases (234) evaluated 206(88%) were successfully identified
on primary screening panel only, 28/234(17%) cases failed to show any specific
lineage in primary screening panel. These 28 cases included 23/187(12%) B-
ALL and 5/47(10%) cases of T-ALL
Summary and Conclusions: The five-color primary screening antibodies panel
was very cost effective in identifying correct lineages in majority i.e. 88% of all
cases. The absence of lineage specific marker was the most common reason
for failure of the predictive power of the primary panel
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OVERALL-SURVIVAL, DISEASE-FREE SURVIVAL AND COMPLETE
RESPONSE RATE IN ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS IN
COLOMBIA
E. Castillo1,* A. M. Castellanos2, M. E. Pierre3, J. Prada-Arismendy4
1Hematology and Oncology Unit, Hospital Manuel Uribe Angel, Envigado,
2Hematology and Oncology Department, Fundación Cardio-Infantil, 3Hematol-
ogy and Oncology Department, Hospital Militar Central, Bogotá, 4Grupo de
Investigación e Innovación Biomédica, Instituto Tecnológico Metropolitano,
Medellín, Colombia
Background: The ASR incidence of acute lymphoblastic leukemia (ALL) in
U.S. is 1.6 cases per 100,000, with 6,050 de novo cases per year and 1,440
deaths estimated during 2012. ALL accounts for 80% of all acute leukemias in
children, with 3-years overall-survival (OS) around 80%. In adults, ALL is
responsible of 20% of acute leukemias, with 3-year OS around 40%. In Colom-
bia, the statistics are poor. Globocan and National Cancer Institute of Colombia
estimated approximately 2,500 cases of leukemias in 2012, with an ASR inci-
dence of 6.3 per 100,000 and an ASR mortality of 4.8 per 100,000. Taking into
account these dates, approximately 73% of patients diagnosed with any kind
of leukemia in Colombia die. Treatment response rates and OS data in Colom-
bia are even scarcer; the study of the National Cancer Institute found a complete
response (CR) rate of 64% and 3 years OS of 0%.
Aims: To determine the CR rate to treatment, disease-free survival (DFS) and
(OS) in adults with ALL treated with different chemotherapy protocols in Hospital
Militar Central (HMC) (Bogotá, Colombia) between 2006-2012.
Methods: A retrospective study was made on newly diagnosed ALL patients
who came to HMC from January 2006 to December 2012. Descriptive statistics
and cross-tabulation were used to describe patient characteristics. Mann-Whit-
ney analyses were used to determine between-group differences. OS and DFS
were analyzed with Kaplan- Meier method.
Results: Thirty-four patients older than 15 years were diagnosed with de novo
ALL. Mean age was 28.5 years-old; 55.9% of cases had between 15 to 24
years-old. 23.5% of patients were older than 35 years- old, of which 25% had
t(9;22). Mean leukocyte count was 38,490/uL (1500-367.000/uL). Anemia was
present in 86.7% and 20.6% of patients had normal platelet count.
Twenty-six patients (76.5%) showed B-cell lineage, while T-cell lineage was
found in 5 cases (14.7%). Ten patients (38.5%) with B-cell lineage had leukocyte
count ≥ 30,000/µL (avg. 82,318/µL). All patients with T-cell lineage had leuko-
cyte count less than 100,000/µL (avg. 17,536/µL). Karyotype was normal in 22
cases (64.7%). 80% of patients with abnormal karyotype had t(9;22), of which
66.7% had hyperleucocytosis. Twenty patients (58.8%) were at high risk for
systemic relapse, (presence of one or more of the following: hyperleucocytosis
≥ 30,000/ul in B-cell phenotype, hyperleucocytosis ≥100.000/uL in T-cell phe-
notype, age ≥ 35 years, CD20 positivity >20% and t(9;22). The other molecular
risk factors are not available in Colombia. The most frequent chemotherapy
protocol used was GMALL (35%) followed by FRALLE 93 (29%). Two patients
(5.9%) died during induction phase. Twenty-eight cases (82.3%) entered CR
after induction therapy. Minimal residual disease was evaluated by flow cytom-
etry in 17 patients (60.7%), being positive in 10 (58.8%) and negative in 7
(41.2%). From 28 patients who entered CR after induction therapy, 9 cases
relapsed; 88.9% of relapses occurred during first 12 months. Mean time to
relapse was 7.4 months. All patients who relapsed received second-line protocol
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(R HyperCvad, HyperCvad, BFM Retz, IDA-FLAG and ALL R3) and only 3
responded (42.8%). OS and DFS at the first year was 92% and 84.8%, respec-
tively. The OS and DFS to 3 years was 29.5% and 32.4%, respectively.
Summary and Conclusions: Comparing data previously obtained by National
Cancer Institute between 2001-2005, this study shows improved CR rates and
OS in ALL in Colombia during recent years. However these data are still less
favorable than those obtained in studies from developed countries.
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SUPPRESSION OF ADRENAL AXIS FUNCTION AFTER HIGH-DOSE
STEROID THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA IN IRAN
S. Ansari1,* M. Sabzechian2, A. Kiumarsi1, T. Rostami1, F. Rouhani3
1Hematology, Iran University, 2Hematology, Baghiyatollah University, 3Iran Uni-
versity, Tehran, Iran
Background:A 4 weeks course of high-dose glucocorticoids (GCs) may cause
prolonged adrenal suppression even after a 9 days tapering phase.
Aims:.In this study, adrenal function and signs and symptoms of adrenal insuf-
ficiency were prospectively assessed in children with acute lymphoblastic
leukemia (ALL) after induction treatment with high-dose prednisone.
Methods: In 42 children with newly diagnosed ALL, a baseline serum cortisol
level was assessed and after receiving a 28 days of high dose prednisone
according to the BFM 2009 protocol ad a 9 days tapering phase, serum cortisol
level was assessed again and thosel was normal underwent low-dose adreno-
corticotropic hormone (LDACTH) stimulation 24 h after the last tapered steroid
dose. Signs and symptoms of adrenal insufficiency were recorded during the
observation period. All patients except one who was excluded had normal basal
cortisol values at diagnosis.
Results: Twenty-four hours after last GC dose, morning cortisol was reduced
in 15 (36.5%) patients. LDACTH testing showed adrenal suppression in 17
(41.4%) patients.
Summary and Conclusions: High-dose GC therapy in ALL children may cause
adrenal suppression even after a tapering phase. Laboratory monitoring of cor-
tisol levels and steroid coverage during stress episodes may be indicated.
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EVALUATION OF BONE MINERAL DENSITY IN YOUNG ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS: A SINGLE CENTER
EGYPTIAN EXPERIENCE 
G. Elgohary1,* I. Asfour1, N. Moustafa1, H. Abdelbary1, H. Dief1, M. Refaee1,
M. Tolba1
1Adult Haematology, Ain Shams University, Cairo, Egypt
Background: Bone health and the loss of bone density are impor tant clinical
concerns for patients with cancer who may be at risk for primary osteoporosis
because of aging and other risk factors. They may have the added risk for can-
cer treatment-induced bone loss (CTIBL), which also could be termed second-
ary osteoporosis related to therapy and cancer as in acute lymphoblastic
leukemia (ALL).
Aims: To assess bone mineral density in young adult patients with ALL at pres-
entation and after induction therapy, to determine whether disease and/or
chemotherapy can affect bone density
Methods: 25 Adult patients aged 20-45 years, with newly diagnosed ALL, pre-
senting to Ain Shams University hospitals were recruited to this cross-sectional
prospective study if they were eligible for induction therapy.All patients were
evaluated according to published international guidelines for assessment of
new acute leukemia patients. In addition, bone mineral density (BMD) was
evaluated by using dual-energy X-ray absorptiometry (DXA) for all studied sub-
jects at presentation and at D28 for evaluable patients. Measurements were
performed at the lumbar spine (L2 to L4) and the left femoral neck using a
Lunar DPX-L scanner. Bone mineral density was expressed in grams per
square centimeter (g/cm2). Lumbar spine and femoral neck BMD was evalu-
ated in all patients at diagnosis and after receiving induction chemotherapy. T-
score was used to describe BMD (normal, osteopenia or osteoporosis) accord-
ing to WHO classification.All patients except those who had mature B cell ALL
received induction according to Holtzer protocol, while Patient with mature B-
cell ALL received hyperCVAD chemotherapy (cycle A).
Results: 25 patients with newly diagnosis of ALL were recruited into this
prospective study. Mean age was 30.32 (20-45 years), male: female ratio was
3:2. Presenting features include anemia (80%), bleeding tendency (52%), fever
(52%) and hyperleucocytosis (32%). Extra medullary infiltration was detected
in 3 patients, testis (n=1) and Central nervous system (n= 2).Sixteen patients
(64%) had Pre-B ALL, one patient (4%) had Pro-B ALL, two patients (8%) had
mature B ALL and six patients (24%) had T ALL. Clonal chromosomal abnor-
malities was detected in 4 patients (complex chromosomal abnormalities in
one patient and t (9; 22) in 3 patients). 21 were evaluable at day +28. Seventeen
patients (68%) were in complete remission and four patients (16%) had refrac-
tor leukemia.None of the patients had osteoporosis either in the pre or post
treatment evaluation (T-score<-2.5). Seven patient (28%) fulfilled the WHO cri-
teria for osteopenia in the lumbar spine at diagnosis (T- score -1 to -2.5). At
post-treatment evaluation, ten patients (40%) were found to have osteopenia
as assessed at the lumbar spine. Yet the difference in bone density at the lum-
bar spine did not reach statistical significance (p-value >0.05). There was sta-
tistically significant reduction in the BMD at the left femoral neck, in the post
treatment evaluation as compared to the pre treatment evaluation, with p-val-
ue<0.001.We have tried to correlate the bone density (BMD,T score, Z score)
in femoral neck to several clinical variables in a multivariate analysis (age, sex,
extra medullary disease, and Ph chromosome). However, we did not find any
statistically significant correlation with any of the previous factors.
Table 1. Bone mineral density BMD pre- and post tratment values at the
lumber spine and the left femor neck.
Summary and Conclusions: Skeletal morbidity, characterized by bone pain,
osteonecrosis, fractures, loss of mobility, bone deformation, or osteopenia, is
frequently encountered in patients affected by ALL. Clinically important sites
for evaluation of osteopenia/ osteoporosis in adult are the lumbar spine (L2-
L4), and femoral neck. Larger sized studies are required to draw more firm
conclusions and to design screening and prophylactic programs.
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ANALYSIS OF THE EFFICACY OF CCLG-ALL2008 PROTOCOL ON THE
ADOLESCENTS AND YOUNG PATIENTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA
Y. Lang1, C. Wang2, S.J. Gao2, Y.H. Tan2,*
1Dermatology Department, 2Tumor Center, First Hospital of Jilin University,
Changchun, China
Background:Acute lymphocytic leukemia is a kind of heterogeneous disease,
the prognosis of the pediatric patients was significantly better than that of adults.
Adolescent and young adult (AYA) patients could adopt pediatric or adult
chemotherapy regimens. In recent years, some studies showed pediatric like
regimens could improve the prognosis of AYA ALL patients. 
Aims: Analysis of efficacy and safety of the pediatric ALL chemotherapy regi-
men CCLG-ALL2008 on adolescents and young ALL.
Methods: 15 to 30 years old ALL patients treated with CCLG-ALL 2008 regimen
from January 2008 to December 2013 in our cancer center was retrospectively
analyzed. CR rate on day 14 and day 28, relapse-free survival, overall survival
and the relativity between the clinical characteristics and RFS were analyzed.
The chemotherapy related toxicity was assessed with WHO criteria. The
informed consents of each patient was obtained before the treatments.
Results: 21 cases of adolescent ALL included 13 males and 8 females were
analyzed, with a median age of 18 years old and 18 cases with median-risk
and 3 cases with high-risk according to regimen CCLG-ALL2008. 14 days CR
rate was 90.5% and 28 day CR rate was 100%, median CR time were 14 days
(14 to 28d), median cytogenetic remission time was 2 months, 17 patients
reached molecular biology remission with a median time of one month. Three
cases relapsed and 1 patient was lost in follow-up, five cases underwent
hematopoietic stem cell transplantation. 2-year OS rate was 100.0% and 2-
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year RFS rate was 66.6%; Univariate and multivariate analysis showed that
the presence of extramedullary infiltration was unfavorable factors of 2-year
RFS. Neutropenia was observed in 17 patients (81%), neutropenia fever
occurred in 12 cases (57.1%) and were documented with infection, including 2
(9.5%) pneumonia and 5 sepsis (23.8%). 4 degree of thrombocytopenia
occurred in 13 patients (61.9%) and coagulation abnormalities occurred in 16
patients (76.2%), Non-fatal bleeding occurred. 1-2 grade toxicity occurrence
rates in heart, liver and kidney and gastrointestinal were 33.3%, 61.9%, 23.8%
and 71.4% respectively. 
Summary and Conclusions: The regimen of CCLG-ALL2008 has obtained
good curative efficacy in AYA ALL patients, and the toxicity was easily tolerated.
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EVALUATION OF ENDOCRINE LATE COMPLICATIONS IN CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA SURVIVORS
C. Bayram1,* N. Yarali1, A. Fettah1, F. Demirel2, A. Kara1, B. Tunc1,
1Pediatric Hematology, 2Pediatric Endocrinology, Ankara Children’s Hematology
and Oncology Hospital, Ankara, Turkey
Background: Improvement in long-term survival in patients with acute child-
hood leukemia has led to the need for monitorization of chemotherapy related
morbidity and mortality. 
Aims: This study aimed to evaluate long-term endocrine compliations in acute
lymphoblastic leukemia survivors.
Methods: Sixty patients diagnosed with acute lymphoblastic leukemia between
December 2003 and May 2009 at Pediatric Hematology Clinic, Ankara Chil-
dren’s Hematology and Oncology Education and Research Hospital, who were
in remission for at least two years, were evaluated retrospectively for endocrine
complications. 
Results: There were 31 male and 29 female patients, while 55 of them were
diagnosed with precursor B-cell ALL and 5 of them with T-cell ALL. Median age
of the patients at the time of diagnosis, at the time of chemotherapy completion
and at the time of study was 5 years (range:3-7,8 years), 8 years (6,2-10,8
years) and 11.7 years (range: 10-14.9 years), respectively and median duration
of remission was 4 years (range: 2.5-5 years). At least one complication was
observed in 81,6% of patients. Vitamin D insufficiency / deficiency (46,6%),
overweight / obesity (33,3%) and dyslipidemia (23,3%) were the most three
frequent endocrine complications. Other complications seen in our patients
were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin
resistance (11,7%), hypertension (8,3%), failure to thrive (6,7%), thyroid function
abnormality (5%), precocious puberty (3,3%) and decreased bone mineral den-
sity (1,7%), respectively. There were no statistically significant correlation
between endocrine complications and age, sex and radiotherapy.
Summary and Conclusions: A high frequency of endocrine complications
were observed in the current study. It is estimated that about two-thirds of can-
cer survivors will experience at least one late adverse effects and more than
40% may have a severe, disabling or life-threatening condition or may die 30
years after cancer is diagnosed as a result of their cancer and it’s therapy. The
high frequency of late effects necessitates long-term surveillance of this popu-
lation to better understand the incidence of late-occurring events and defining
high-risk features that can facilitate developing intervention strategies for early
detection and prevention.
PB1618
ANALYSIS OF THERAPY RESULTS IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKAEMIA. A SINGLE CENTER EXPERIENCE IN
TURKEY
T. Patiroglu1,1,* M. A. Ozdemir1, E. Unal1, K. Degirmenci1, M. Karakukcu1
1Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey
Background: Prognosis of children with acute lymphoblastic leukemia (ALL)
which the most common cancer in childhood, has improved in the last years.
Aims:
Analysis of treatment outcome and identification of prognostic factors in children
treated for acute lymphoblastic leukaemia (ALL).
Methods: The patients diagnosed for ALL in our Hospital of Kayseri-Turkey
between 2000-2014 were evaluated retrospectively. Children were treated
according to the protocol of BFM-90 (Berlin-Frankfurt-Münster). Patients were
classified into standart-risk (SR), medium-risk (MR) and high-risk (HR) group
according to initial leukaemic burden, early treatment response, genotype of
leukemia.
Results: A total number of 341 children aged 4 monts -17 years (median age
5.45 years) were diagnosed for ALL in our Hospital of Kayseri-Turkey between
2000-2014. Children were treated according to the protocol of BFM-90 (Berlin-
Frankfurt-Münster).Duration of the chemotherapy was two years. Treatment
results were evaluated in 341 children. With a median follow-up of 7 years,
event-free-survival (EFS) was 85.4% and overall survival 86.4%. Relapse was
diagnosed in 14.6% of the patients.
Summary and Conclusions: Large progress has been made in the treatment
of acute lymphoblastic leukaemia of childhood and adolescence over the ana-
lyzed period of 14 years. Our results for children with acute lymphoblastic
leukaemia are similar to the results in the other BFM study-Group.
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IS CD45 EXPRESSION LEVEL RELATED TO HIGH RISK DEFINITION IN
CHILDHOOD PEDIATRIC B ALL?
D. Albayrak1,* C. Albayrak2
1Pediatric Hematology Department, Samsun 19May University Faculty Of Med-
icine, 2Pediatric Hematology Department, Samsun Ondokuz Mayis University
Faculty Of Medicine, Samsun, Turkey
Background: Two report shows CD45 brightnes of childhood ALL blast is asso-
ciated with poor prognosis. Borowitz et al showed that bright CD45 expression
was associated with a poor prognosis in BCP-ALL patients treated according
to theprotocols of the Pediatric Oncology Groupstudy group and Cario et al
also in ALL-BFM-2000 protocol.
Aims: In the present study, we assessed the relation of brightness of CD45 expres-
sion in pediatric ALL patients treated according to he ALL-IC-BFM 2009 protocol.
Methods: The brightness of CD45 expression was compared in ten patients of
high risk group and ten patient of standart and intermediate groups. In the ALL-
IC BFM 2009 trial, the high-risk group was defined by poor prednisone response
on treatment day 8, FCM blast ratio >%10 at day 15 and BCR-ABL OR MLL
positivity. The brightness of CD45 expression was evaluated as mean floures-
ence index (MFI).
Results: CD45 MFI was 710,2 for blast, 13784,6 for normal lymphocytes, 0,056
for blast/lymphocytes in hr group, CD45 MFI was 590 for blast, 7904,4 for nor-
mal lymphocytes, 0,082 fr blast/lymphocytes in hr group. The differenceb
between groups was not significantly different.
Summary/Conclusion: In conclusion, the CD45 brightnes of childhood BCP-
ALL did nod have any additional contribution to high risk stratification. This
result is different from previous reports. New reports is required to solve this
debate.
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T315I CLONE SELECTION IN A PHI+ ALL PATIENT UNDER MAINTENANCE
PONATINIB 
J. Noetzli1,* M. Gavillet1, S. Masouridi-Levrat2, A. Priovolos Hughes1, C. Abbal3,
O. Spertini1
1Hematology, CHUV, Lausanne, 2Hematology, HUG, Geneva, 3LCH, CHUV,
Lausanne, Switzerland
Background: Ponatinib is a third generation tyrosine kinase inhibitor (TKI)
approved for the treatment of chronic myeloid leukemia (CML) or Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with T315I or
resistant/intolerant to other TKIs. Serious vascular adverse events have been
reported at the dosage of 45 mg once daily suggesting that a reduction in the
dosage of ponatinib may be advisable.
Aims: We present here the case of a Ph+ ALL in 2nd relapse who achieved a
molecular remission with ponatinib 30 mg/day. To decrease the risk of vascular
complications, ponatinib dosage was reduced to 15 mg/day during maintenance
therapy. We examined whether this ponatinib dosage is sufficient to prevent
molecular relapse.
Figure 1.
Methods: Residual disease was measured by RQ-PCR and BCR-ABL muta-
tions were detected by Sanger sequencing. 
Results: This 39-year-old patient was diagnosed in 2008 with a Ph+ ALL (Fig-
ure 1). He was first treated with imatinib (GRAALL/GRAAPH 2005 trial) and
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then successively with dasatinib, nilotinib and bosutinib because of intolerance
or resistance and finally with ponatinib. Due to liver toxicity, ponatinib was given
at 30 mg/day as maintenance therapy. One year after the second transplant,
while the patient was still in CR, an unexpected high rate of ponatinib-induced
vascular events was reported. According to recommendations made for CML
in major molecular response, the maintenance therapy was reduced to 15
mg/day. Six months later, a molecular relapse was identified in bone marrow
and Sanger sequencing revealed a T315I mutation in BCR-ABL kinase domain
(KD). The patient was treated with steroids, a single dose of vincristine (1,4
mg/m2) and ponatinib 45mg once daily. Fifteen days later, MBCR-ABL level
was reduced by 1 log and sequencing showed the concomitant presence of
wild-type and T315I BCR-ABL KD. Donor lymphocyte infusions were started.
Three months later, the MBCR-ABL/ABL ratio was 0,025%. Presently, 6 months
after the 2nd relapse, the patient is in complete molecular remission, without
graft versus host disease.
Summary/Conclusion: We report here the clinical course of a Ph+ ALL patient
who was treated with ponatinib 15mg/day, as maintenance therapy, and devel-
oped a BCR-ABL T315I mutation leading to leukemia molecular relapse. This
clonal evolution was reversed, without adverse effects, by increasing ponatinib
dosage to 45mg/day suggesting that ponatinib dose reduction may not be
appropriate in Ph+ALL maintenance therapy. 
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A RETROSPECTIVE ANALYSIS OF COMPLICATIONS OBSERVED IN
CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING
CHEMOTHERAPY 
A. Canbolat Ayhan1,* C. Timur1, O. Kalaycık1, A. Yoruk1
1Pediatric Hematology, Medeniyet University Goztepe Education And Research
Hospital, Istanbul, Turkey
Background: ALL is the most common cancer in the paediatric age group. In
recent years, through the use of intensive chemotherapy together with improved
supportive care, the 5-year survival rate has increased above 85%. Despite this
high survival rate, completing the entire therapy regimen is challenging because
of the severe complications that interrupt the chemotherapeutic process. A minor
proportion of patients can be expected to complete chemotherapy without expe-
riencing serious complications during chemotherapy.
Aims: We aimed to evaluate the complications that we observed in children
with acute lymphoblastic leukaemia (ALL) during the remission induction, con-
solidation, and reinduction phases of chemotherapy retrospectively.
Methods: We analysed the clinical records of 128 patients with ALL who were
diagnosed and treated in the Department of Pediatric Hematology of Istanbul
Medeniyet University Goztepe Training Hospital between August 2009 and
April 2014. 
Results: Of these documented complications, 53.05% were in males, 46.95%
in females; 32.26% were in standard-risk, 45.52% in medium-risk, 22.22% in
high-risk group of patients. Common documented events were pneumonia
(25%), therapy-induced hyperglycemia (16.40%) therapy-related hepatitis
(15.62%), generalized tonic-clonic seizures (14.84%), anaphylaxis to asparag-
inase (14.06%), hypertension (13.28%), varicella zoster infection (13.28%),
renal tubulopathy (12.5%). Time of complications was induction phase in
32.62%, consolidation in 19.35%, HR blocks in 18.28%, reinduction 29.75%
during the phases. Mortality rate due to complications was 13.28%.
Summary and Conclusions: Therapy-related complications can limit the sur-
vival rates in children with ALL. To minimize the treatment burden, even very
rare complications must be considered and treated promptly with a multidisci-
plinary approach.
Acute myeloid leukemia - Biology
PB1622
BONE MARROW MESENCHYMAL STROMAL PRECURSOR CELLS FROM
ACUTE MYELOID LEUKEMIA PATIENTS ARE DAMAGED BY LEUKEMIC
CELLS AND THE PROCEDURE OF ALLOGENEIC BONE MARROW
TRANSPLANTATION
T. Sorokina1,* N. Petinati2, I. Shipounova2, A. Bigildeev2, N. Drize2, L. Kuzmina1,
E. Parovichnikova1, V. Savchenko3
1High dose chemotherapy, depressions of hematopoiesis and bone marrow
transplantation dept., 2Physiology of Hematopoiesis laboratory, 3General direc-
tor, National Research Center for Hematology, Moscow, Russian Federation
Background: Leukemic cells and high dose chemotherapy affect both
hematopoietic and stromal precursor cells. Changes in the hematopoiesis
occurring in acute myeloid leukemia (AML) are well characterized, however,
the mechanisms of alterations in stromal microenvironment during the debut
of AML and pre-transplantational conditioning are still obscure.
Aims: This study aimed to analyze the alterations in the characteristics of
human multipotent mesenchymal stromal cells (MSC) and their more differen-
tiated progeny – fibroblastic colony forming units (CFU-F) derived from the
bone marrow (BM) of AML patients.
Methods: 18 newly diagnosed and 20 patients who underwent allogeneic bone
marrow transplantation (alloBMT) were included in the study after informed
consent. BM was aspirated prior to any treatment in the newly diagnosed group,
before the conditioning and at 6 time points during 1st year after alloBMT in
the corresponding group. MSC were cultured in aMEM with 10% fetal calf
serum. Cumulative MSC production was counted after 3 passages. CFU-F
concentration was analyzed in standard conditions. The relative expression
level (REL) of different genes was measured by TaqMan RQ-PCR. As a control
MSC and CFU-F from 88 healthy donors were used.
Results: The CFU-F concentration in the BM of newly diagnosed AML patients
was 1/3 of the donor’s (8.7±3.7 versus 25.8±3 per 106 nucleated cells,
P=0.0008). There were no correlation between CFU-F concentration and blast
count in the patients BM samples. So the decrease in CFU-F concentration
could not be explained by mere substitution of stromal cells by blasts, but rather
it reflects the action of leukemic cells on the stromal microenvironment. In the
remission BM CFU-F concentration restored (26.7±7.2 per 106 BM nucleated
cells). After the alloBMT CFU-F concentration in patients’ BM decreased 3-9
fold during the next year of observation. The decrease at each time point was
highly significant comparing to donors. Similar picture was observed in MSC
features. Cumulative cell production in cultures of newly diagnosed AML
patients was half to donor’s (5.03±0.8x106 versus 7.6±0.8x106, P=0.07). MSC
from the BM of patients before alloBMT were also slightly and insignificantly
lower than from healthy donors (5.9±1x106). In patients after alloBMT cumula-
tive MSC production decreased 1.3-5.2 fold during the next year. The decrease
at almost each time point was significant comparing to donors. Gene expression
analysis revealed that in MSC of new diagnosed patients the expression of
FGF2 and VEGFA significantly decreased, while REL of CSF1, FGFR1, JAG1,
PPARG, PDGFRA and PDGFRB-increased. In remission REL of FGF2 and
LIF were twice as high as donor’s, after alloBMT the expression of FGF2 was
mainly elevated. However, REL of CSF1, PDGFB, VEGF and VCAM1 was sig-
nificantly decreased at the most time points after alloBMT. It seems that expres-
sion profile of MSC at manifestation of AML reverses in the remission but still
does not achieve normal levels.
Summary and Conclusions: During the AML development leukemic cells
alter the stromal precursor cells leading to the decrease in their proliferative
ability, in the level of expression of some regulatory genes and in the number
of CFU-F in the BM. Chemotherapy used for induction the remission restores
the stromal precursor cells incompletely. Conditioning regiments used for the
alloBMT significantly damage both types of studied stromal precursors, and
the effect lasted at least for 1 year. Thus, both AML cells and chemotherapeutic
treatment affect BM hematopoietic microenvironment.
PB1623
CHARACTERIZATION OF KMT2A (MLL) CHROMOSOMAL BREAKPOINTS
L. Zejskova1,* R. Plachy1, T. Jancuskova1, D. Hardekopf1, J. Stika1, M. Ondrackova1,
N. Kosyakova2, T. Liehr2, A. Zavrelova3, P. Zak3, V. Petecukova4,
J. Novak4, T. Kozak4, S. Pekova1
1Laboratory synlab genetics s.r.o., Synlab Genetics s.r.o., Prague, Czech
Republic, 2Institute of Human Genetics, Jena University Hospital, Jena, Ger-
many, 34th Department of Internal Medicine-Hematology, Charles University
Hospital and Faculty of Medicine, Hradec Kralove, 4Internal Clinic of Hematol-
ogy, University Hospital Kralovske Vinohrady, Prague, Czech Republic
Background: The KMT2A gene (MLL, mixed lineage leukemia) is located at
chromosome region 11q23. Chromosomal rearrangements involving the human
MLL gene are associated with development of childhood, adult and therapy-
related acute leukemia. The presence of certain MLL rearrangements is an
646 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
independent prognostic factor and patients are usually treated according to
high-risk protocols. Minimal residual disease (MRD) detection provides an
objective assessment of treatment response and enables risk stratification of
patients. However, MRD assays using MLL fusion transcripts as molecular
markers usually do not provide sufficiently sensitive detection of residual
leukemic cells. 
Aims: Identification of the unique chromosomal breakpoints of the MLL gene,
which is necessary for the design of a quantitative real-time PCR (qPCR) DNA-
based MRD assay.
Methods: For the identification of patient-specific MLL breakpoint sequences
we used two different technical approaches. The first approach was long-range
PCR followed by sequencing of the PCR products. The second approach includ-
ed a combination of conventional chromosome microdissection, amplification
of the microdissected material, next-generation sequencing, long-range PCR
and sequencing of the final PCR products. Patient-specific sequences of the
chromosomal breakpoint were used to develop MRD assays and enabled us
to perform sensitive monitoring of MRD using qPCR in six acute leukemia
patients.
Results: We identified unique breakpoint sequences in five patients with acute
myeloid leukemia and one patient with acute lymphoblastic leukemia at the time
of diagnosis. Using first approach (i.e. long-range PCR followed by sequencing
of the PCR products) we detected MLL/AF6, MLL/AF9 (two patients) and
MLL/ELL. A combination of conventional chromosome microdissection, amplifi-
cation of the microdissected material, next-generation sequencing, long-range
PCR and sequencing of the PCR products was used for identification of MLL/AF10
and MLL/AF4 breakpoints. Identification of unique breakpoint sequences was
followed by the design of sufficiently sensitive qPCR MRD assays. The MRD lev-
els of residual leukemic cells correlated with clinical outcome. 
Summary and Conclusions: MLL breakpoints could be identified by various
methods (e.g. inverse PCR, panhandle PCR). Our results show other approach-
es for identification of unique MLL breakpoint sequences, which can be utilized
for the design of the leukemia-specific assay for DNA-based MRD monitoring
in patients with acute leukemia.
PB1624
MUTATIONAL PROFILE STUDY OF ADULT DE NOVO ACUTE MYELOID
LEUKEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS)
E. Onecha1,* I. Rapado1, S. Barrio1, N. Castro2, R. Alonso2, J.M. Sanchez2,
P. Martinez-Sanchez2, J. Martinez Lopez2, 3, R. Ayala2,3
1Hematologia Traslacional-Biologia Molecular, 2Servicio De Hematologia, Hos-
pital Universitario 12 De Octubre, 3Universidad Complutense De Madrid,
Madrid, Spain
Background: AML is a highly heterogeneous pathology with a variety of sub-
types stratified function of cytogenetic and molecular markers. To date, the
major prognosis criteria is cytogenetics, however the 40-50% of de novo
patients have normal karyotype. Recent sequencing techniques such as NGS
allow us to identify the mutational profile, to decide the diagnosis and risk strat-
ification of patients and to personalize therapy. 
Aims: To identify the mutational profile of AML and to correlate with the patient’s
survival data.
Methods: A cohort of 65 AML patients who were treated with intensive
chemotherapy was selected. Mediam age at diagnosis was 52 years (range:
18-79), male:female ratio 30:35; 53 patients had de novo AML, 10 s-AML fol-
lowing MDS or MPN, and 2 t-AML; median leukocytes was 36.8x109/L. Cytoge-
netic results were available in 64 cases and categorized according to MRC
(Blood 2010): favorable in 6 (9.4%), intermediate in 44 (68.8%), and adverse
in 14 (21.9%). We performed targeted gene sequencing by NGS (Ion Torrent
Proton System–Life Technologies) using a panel of 33 genes implicated in
leukemia prognosis; in addition, FLT3 internal tandem duplication (ITD) was
detected by GENSCAN and NPM1 mutation was detected by qPCR.
The discrete variables of patients with and without analyzed gene mutations
were compared using the X2 test. Kaplan-Meier survival curves and Long-rank
test were used for estimation of survival and difference between groups
Results: On average, 90,8% of the target sequence showed a mean depth
coverage around 1300. We discovered 140 non-synonymous mutations which
118 were somatic single nucleotide variants (SNVs) and 22 small insertions
and deletions (Indels) in coding regions. No mutations were detected in 5 sam-
ples, 14 samples presented 1 mutation, and the others 46 samples present 2
or more mutations. TET2 was the most frequently mutated gene (33,8%), fol-
lowed by DNMT3A (26,2%), NPM1 (26,2%), FLT3 (21,5%), NRAS (20%), FLT3-
ITD (18,5%), KMT2A (16,9%), IDH2 (13,8%), RUNX1 (13,8%), EPOR (12,8%),
KRAS (12,8%), ASXL1 (9,2%), IDH1 (9,2%) and the others genes had a fre-
quency below 8%. Mutations in ASXL1 (P=0.005), KRAS (P=0.033), JAK2
(P=0.061) and ZRSF2 (P=0.019) were associated with secondary AML.
DNMT3A (P<0.001) and ZRSF2 (P=0.005) mutations with NPM1 mutations.
DNMT3A and ETV6 mutations with FLT3 ITD AML (P=0.041 and 0.029 respec-
tively). AML patients who present TP53 or TET2 mutations showed a statistically
non-significant correlation with death (P=0.103 and 0.062 respectively), in con-
trast IDH2 mutations were more frequent among alive patients (P=0.061).
RUNX1 mutations were associated with female gender (P=0.023), and these
and TP53 mutations were associated with refractoriness (P=0.009 and
P=0.001, respectively). EZH2 and TET2 mutations were associated to AML
patients >55yrs (P=0.011 and 0.025 respectively). In contrast to KRAS muta-
tions that were detected mainly in patients<55yrs (P=0.090). Median RFS was
significantly longer in female (28.5 vs 10.8months, P=0.017) and also in
patients<55 years (18.9 vs 10.8 months, P=0.026). Median OS was significantly
longer in patients<55 years (18.9 vs 11.8 months, P=0.038). No significant dif-
ferences in RFS in function of analyzed gene mutations were found, but we
observed that the median OS was significantly shorter in mutated TET2 patients
(8.4 vs 18.8 months, P=0.049).
Figure 1.
Summary and Conclusions: NGS is a useful technique to classify groups in
AML with biological and prognosis implications. These results support the role
of TET2 as an important poor prognostic biomarker in AML. This study was
funded by Instituto Carlos III (PI13/02387)
PB1625
CD81 AS NEW POTENTIAL MARKER IN ACUTE MYELOID LEUKEMIA
S. Guihard1,* T. Boyer2, C. Roumier2, P. Peyrouze1, F. Gonzales1,
C. Preudhomme2, C. Roche-Lestienne3, M. Cheok1
1UMR-S1172, 2Hematology institute, Centre de Biologie-Pathologie Pierre-
Marie Degand, 3Genetic institute, Jeanne de Flandre Hospital, Lille, France
Background: AML is a heterogeneous disease at both the phenotypic and
molecular level with a variety of distinct genetic alterations giving rise to the
disease. This heterogeneity extends to the leukemic stem cell (LSC), with this
dynamic compartment evolving to overcome various selection pressures
imposed upon it during disease progression. Since LSC are thought to be resist-
ant to current chemotherapeutic regimens and mediate disease relapse, their
study may have profound clinical implications. Various markers have been
described to characterize the LSC. CD81 antigen belongs to the tetraspanin
family (33 members in mammals) which are cell surface transmembrane pro-
teins and may be involved in the re-entry of hematopoietic stem cells into qui-
escence.
Aims: In this project, we plan to investigate the role of CD81 in the hetero-
geneity of AML, its potential to induce tumor dormancy and if this is character-
ized by resistance to chemotherapy.
Methods: In order, to study CD81 expression on primary leukemic blasts, we
designed a MFC panel (CD36, CD81, CD33, CD90, CD123, CD34, CD38,
CD45).Cell surface marker expression was measured in fresh or thawed bone
marrow samples from adult patients with AML at diagnosis (n=122) or at relapse
(n=10) using the above mentioned panel. This is a retrospective study to test
the prognostic value of CD81, in comparison with other markers of LSC/HSC,
for survival (overall survival, event free survival, relapse free survival). AML
was diagnosed between 2010 and 2013 at the CHRU of Lille. To further study
the function of CD81, we will use AMLxenografts. Blasts obtained from newly
diagnosed AML, were FACS sorted based upon high CD45 intensity and were
then directly injected into NSG mice. After engraftment, the mice were sacri-
ficed, and the bone marrow and spleen were analyzed by flow cytometry. Serial
engraftment is performed by injecting one part of the blast cells into a subse-
quent NSG mouse.
Results: We performed the analysis on 122 diagnosis bone marrow samples
and we found that 35% of the samples were positive for CD81 expression.
Classification by CD81 expression predicts OS and EFS in AML (EFS: P=0.012;
OS: P=0.0066). 23 primary AMLs have been injected and 8 of them produced
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serial engraftments. Yet, we did not find any difference in phenotype between
the AMLxenografts and the AML diagnosis. However, the phenotype of the
blasts differ between bone marrow and spleen (P= 0.027).
Summary and Conclusions: Our preliminary results show that CD81 may
have an important role in AML as their expression on blast cells predicts worse
clinical outcome (OS and EFS) in this pathology. Furthermore, we have put in
place and phenotypically validated AMLxenografts, and we will be able to study
the functional role of CD81 in AML in the near future. Nevertheless, the impact
ofxenografts in general and in particular with regard to CD81 on prognosis will
be studied once we have sufficient follow-up time and numbers of patients
analyzed and injected into NSG mice.
PB1626
DEOXYCYTIDINE KINASE IS DOWN-REGULATED UNDER HYPOXIC
CONDITIONS AND CONFERS RESISTANCE AGAINST CYTARABINE IN
ACUTE MYELOID LEUKEMIA
N. Degwert1,* E. Latuske1, G. Vohwinkel1, M. Klokow1, H. Stamm1,
C. Bokemeyer1, W. Fiedler1, J. Wellbrock1
1Hematology and Oncology, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
Background: Leukemia initiating cells reside within specialized niches in the
bone marrow where they undergo complex interactions with different stromal
cell types. The bone marrow niche is characterized by a low oxygen tension
resulting in high expression of hypoxia-inducible factor 1 alpha (HIF-1α).
Expression of HIF-1α has been shown to represent a negative prognostic factor
in acute myeloid leukemia (AML).
Aims: In the current study, we investigated the impact of hypoxic versus nor-
moxic conditions on the sensitivity of AML cell lines and primary AML blasts to
cytarabine.
Methods: AML cell lines HL60, Kasumi-1, MOLM-13, OCI-AML5, MV4-11 and
KG-1 as well as primary blasts from AML patients were cultured under normoxic
and hypoxic conditions (oxygen content of 20% vs. 6%, respectively). After an
adaptation period of three days, cells were plated for proliferation and colony
formation assays to investigate the susceptibility to cytarabine (Cell Pharm
GmbH, Bad Vilbel, Germany). Proliferation and colony formation was deter-
mined after 3 and 7 days of cytarabine treatment, respectively. Using quanti-
tative RT-PCR analysis, we investigated the mRNA expression of deoxycytidine
kinase in AML cells cultured under normoxic vs. hypoxic conditions for 3 days.
AML cells under hypoxic conditions were additionally treated with the HIF-1α
inhibitor BAY87-2243 (Selleckchem, Houston, TX).
Results: AML cells cultured under 6% oxygen were significantly more resistant
to cytarabine compared to cells cultured under normoxic conditions in prolifer-
ation assays. HL60 cells were the most susceptible cells to the drug-induced
growth inhibition under hypoxic conditions for cytarabine concentrations
between 10 nM and 1000 nM. Although less pronounced, Kasumi-1, MOLM-
13, OCI-AML5 and MV4-11, also showed the hypoxia-induced resistance to
cytarabine. Only in KG-1 cells, no significant differences in growth inhibition
could be detected under normoxic vs. hypoxic conditions. Furthermore,
increased sensitivity to cytarabine under normoxia could also be observed in
primary AML samples (n=5). Response to cytarabine under normoxic vs. hypox-
ic conditions was also analyzed by colony formation assays for several AML
cell lines using cytarabine concentrations ranging from 25 nM to 100 nM.
Colony numbers at day 7 of cytarabine treatment were significantly higher at
6% oxygen than at normoxia. Interestingly upon cultivation under hypoxia, the
expression of the cytarabine-activating enzyme deoxycytidine kinase was
down-regulated in all analyzed AML cell lines and primary AML samples rep-
resenting a possible mechanism for resistance to chemotherapy. Furthermore,
the down-regulation of deoxycytidine kinase could directly be associated with
HIF-1α as treatment with its inhibitor BAY87-2243 hampered the down-regu-
lation of deoxycytidine kinase expression under hypoxic conditions.
Summary and Conclusions: In conclusion, our data reveal that the hypoxia-
induced down-regulation of deoxycytidine kinase might represent one mecha-
nism of drug resistance to cytarabine in acute myeloid leukemia.
PB1627
MUTATED REGIONS OF NUCLEOPHOSMIN 1 ELICIT CD8+ T-CELL
RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
A. Sun1,* Z. Cheng1, G. Chen1, X. Yang1, D. Wu1
11the First Affiliated Hospital Of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Stimulating lymphocytes from healthy donors by DCs loaded
with NPM1mutpeptides in vitro in order to induce specific cellular immune
responses against the peptides.
Aims: Detecting the NPM1mut peptide specific T-cell in peripheral blood of
patients with NPM1mut positive acute myeloid leukemia (AML), to provide a
theoretical basis for immune therapy of AML.
Methods: 1. newly diagnosed patients of AML underwent gene mutations
screening routinely. 2. peripheral blood mononuclear cells (PBMCs) were iso-
latedfrom healthy donors with HLA-A* 0201 or A*1101 and NPM1mut positive
AML patients in complete remission. 3. Inducing differentiation of PBMCs into
DCs. 4. Generation of NPM1-specific cytotoxic T cells. 5. ELISPOT analysis
and intracellular staining.
Results: 1. In the Han Chinese population, the most common alleles of HLA-
A loci were A* 1101, A*2402, and A*0201 allele. 2. Through prediction of the
aforementioned software, HLA-A*0201 restricted wild type NPM1 amino acid
sequences (DLWQWRKSL), mutated NPM1-A/D amino acid sequences
(AIQDLCLAV), and HLA-A*1101 restricted mutated NPM1-A/D amino acid
sequences (AVEEVSLRK) were synthesized. There were no proper epitopes
for either HLA-A*1101 restricted wild type NPM1 protein or HLA-A*2402 restrict-
ed wild type and mutated NPM1 protein. 3. Expression of surface antigens of
DCs on day 7 were as follows: CD14(2.6%), CD80(43.4%), CD83(7.8%),
CD86(99.9%), HLA-DR(67.1%), which was consistent with DCs phenotype.
4. About 10 days after DCs were co-incubated with their own PBMCs, the num-
ber of lymphocytes increased significantly, especially in the NPM1mut peptide
pulsed group. On day 7 of co-incubation, ELISPOT analysis results of all sam-
ples were negative. However, 3 cases’ ELISPOT results were positive for the
mutated peptide holes on day 14, in contrast, the results of the wild type peptide
holes were negative. The NPM1mut peptide-specific T lymphocytes positive
rate [=(average number of spots in mutated peptide holes-the average number
of spots in negative control holes)/total lymphocytes per hole] was about
1/2500. Intracellular staining showed that in the aforementioned 3 cases, the
proportion of CD8+IFN-γ + cells of the mutant peptide group was higher than
either the wild type peptide group or negative control group, but there was no
difference between the later two groups. 5. 6 peripheral blood samples of
patients with NPM1mut +AML were performed ELISPOT analysis, with only 1
case (16.7%) showing a approaching positive result. 
Summary and Conclusions: NPM1mut peptide pulsed DCs can stimulate their
own PBMCs from healthy donors in vitro to produce mutated NPM1 specific T
lymphocytes, and it is expected to be used as immune therapy of AML. The
mutated NPM1 specific CTL in NPM1mut+AML patients are almost undetectable
that indicates immune system have been comprised because of chemotherapy
and disease, and can not responses to antigens efficiently. Perhaps AML
patients can accept CTL transfusion from their relatives. Our study provide an
experimental basis for cellular immunotherapy of AML.
PB1628
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF BONE MARROW
MESENCHYMAL STEM CELLS OF PATIENTS WITH ACUTE MYELOID
LEUKEMIA
M. Al Bagami1,2,* I. Marcq1, H. Ouled Haddou1, V. Debuysscher1,
M.N. Lacassagne2, L. Garcon1,3, H. Bouhlal1,2, J.P. Marolleau1,2
1EA 4666, Lymphocyte Normal/Pathologique et Cancers CURS, CHU Sud,
2Service Hématologie clinque-Thérapie cellulaire, CHU Sud, 3Hématologie,
CHU Sud, Amiens, France
Background: Mesenchymal stem cells MSC are main cells found in bone mar-
row BM microenvironment. They play a major role in hematopoietic stem cell
HSC niche. These niches support acute myeloid leukaemia AML cells prolifer-
ation and differentiation.Many studies showed the protection of AML cells from
chemotherapy induced apoptosis by BM microenvironment. The mechanism
of this protection is still unclear.
Aims: Our present work is to compare the phenotype and functional properties
of AML BM-MSCs to normal MSCs from BM to identify new mechanisms could
help to improve the treatment of AML.
Methods: MSC were obtained from the BM of patients with AML and healthy
donors (n=5 per group). Following parameters were used for: cell morphology,
cell proliferation test, cell cycle, immunophenotype, differentiation capacity into
osteoblastic and adipogenic lineages. Gene expression profile was determined
by Q-PCR. 
Results: 4/5 of AML BM-MSC have heterogenous morphology and 1/5 has
homogenous fusiform, fibroblast-like appearance. AML BM-MSC show, signif-
icantly (P<0.05), low proliferative ability than normal BM-MSC, which induces
an increase of doubling time (62,8-/ + 7h and 44,5-/ + 8h for AML and normal
BM-MSC, respectively; P<0,01). The analysis of cell cycle show that the num-
ber of cells in AML BM-MSC cultures in G2/M phase, significantly P<0.05,
reduced by 50% compared to normal BM-MSC cultures. However, Both of Nor-
mal and AML BM-MSC have similar immunophenotype profile (positive: CD90,
CD73, CD105, CD166 and CD146; negative: HLA-DR, CD34, CD45). Both of
cell types have a potential to differentiate into osteoblastic and adipogenic lin-
eages showed by specific stains. This result was confirmed by the expression
levels of Runx2, BMP2 and ALP Alkaline phosphatase (osteoblasts); and
PPAR-γ2 (adipocytes). However, expression of these genes in osteoblasts
derived from AML BM-MSC remains, significantly P<0.01, lower than the
expression in osteoblasts obtained in normal BM-MSC differentiated cells. 
Summary and Conclusions: The proliferative capacity of MSC obtained from
the BM of patients with AML are limited and have a heterogenous morphology
although the expression of phenotypic markers remains unchanged compared
to normal BM-MSC. More significantly, the capacity to differentiate into
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osteoblasts is reduced in AML BM-MSC. This result suggest that, the bone
quality obtained by AML BM-MSC is affected. Therefore, there is an influence
on the endosteal microenvironment and that could affect the behavior of CD34
HSC in the endosteal niche. 
PB1629
EVIDENCES OF A DNMT3A DEPENDENT CYTOSTATIC EFFECT OF 
S-ADENOSYLMETHIONINE ON OCI-AML3 CELLS
K.A. von Hohenstaufen1,* B. De Servi2, M. Meloni2
1Liber Augustalis, Independent Biomedical Research Association, 2Vitroscreen,
in vitro Research Laboratory, Milan, Italy
Background: AML with mutated NPM1 and its cell line OCI-AML3 carry the
NPM1 mutation A and the heterozygous R882C mutation of the DNA (cytosine-
5-)-4 methyltransferase 3 alpha (DNMT3A). The mutant DNMT3A protein exerts
a dominant negative inhibition on the wild type protein resulting in focal
hypomethylation. Of note, AML with mutated NPM1 harbors a distinct methylation
profile among AML subtypes. S-adenosylmethionine (SAM) is a universal methyl
donor and a coenzyme of DNMT3A. SAM has been used in the clinical practice
as an antidepressant drug with very limited side effects. There are growing evi-
dences of the antineoplastic activity of SAM in vitro and in murine models of
solid cancers. Recently, the combination of SAM with demethylating agents
showed an interesting in vitro synergistic cytotoxicity on breast cancer cells.
Figure 1.
Aims: To explore the effect of SAM on OCI-AML3 cells and its dependence on
DNMT3A activity.
Methods: We used the MTT assay to test the cytostatic effect of SAM iodide
(Sigma-Aldrich, St. Louis -MO) on OCI-AML3 cells (DSMZ Leibniz Institut,
Braunschweig -Germany). The cells were treated with SAM for 24h. Untreated
and treated cells were tested in triplicate for each SAM concentration. Results
were expressed as percentage of cells viability compared to the control (i.e.
OCI-AML3 untreated cells). The Apoptosis assays were performed after 24h
and 72h of SAM treatment using the Tali®Apoptosis Assay Kit–Annexin V Alexa
Fluor®488/Propidium Iodide (Invitrogen, Carlsbad, CA) for cells staining, and
the Tali Image Based Cytometer (Invitrogen) for cells counting. In order to verify
if the observed effect was mediated by DNMT3A, we repeated the MTT assay
after DNMT3A silencing with a predesigned SiRNA directed against DNMT3A
(SiRNA ID HSS176224, life technologies). Transfection was performed on trip-
licates cultures with lipofectamine RNAiMax (Invitrogen) and transfection effi-
ciency calculated by BLOCK-IT AlexaFluor Red Fluorescent Oligo (Ambion-
life Technologies). DNMT3A knock-down was verified by RTPCR (TaqMan
Applied Biosystem ABI7500; Taqman primer/probes for DNMT3A,
Hs01027166_m1). 
Results:A significant dose dependent reduction of the cells viability was evident
for SAM concentrations equal or superior to 500µM, with an IC50 of 500µM
(Figure 1a). Since a Cmax of 211µM (SD 94) after single intravenous infusion
of SAM was previously reported in healthy volunteers, we tested SAM concen-
tations close to 211µM, and observed a significant reduction of the cells viability
with SAM 200µM (62,74% viable cells) and SAM 300µM (53.32% viable cells),
(data not shown). The apoptosis assay at 24h and 72h of SAM treatment,
showed no significant increase in the amount of apoptotic cells, (data not
shown), however a dose dependent decrease of the percentages of living cells
was observed which was considered congruent with the results of the MTT
tests. The MTT assay was repeated testing at the same time DNMT3A silenced
and non-silenced OCI-AML3 cells. SiRNA transfection efficiency was 80%.
Gene knock-down was confirmed by a DNMT3A expression of 39% compared
to the non-silenced cells. In the MTT assay with SAM 500 µM (24h) the non-
silenced cells showed a significant reduction of the cell viability (49,8% viable
cells), while no effect was observed in the DNMT3A silenced cells (97,5% viable
cells) (Fgure 1b). 
Summary/Conclusion: SAM shows in vitro cytostatic activity on OCI-AML3
cells, at concentrations close to the blood concentrations achievable in humans.
These preliminary results are in line with other studies using similar SAM con-
centrations in solid tumors cell lines. The MTT assay performed after DNMT3A
knock-down demonstrated that the cytostatic effect of SAM on OCI-AML3 cells
is specifically mediated by DNMT3A. This finding suggests that modulating the
activity of DNMT3A with supraphysiological concentrations of its substrate can
induce cell growth inhibition in AML cells with heterozygous DNMT3A mutation.
SAM should be further investigated as a potential antileukemic compound in
AML with NPM1 and DNMT3A mutations.
PB1630
CLINICAL SIGNIFICANCE OF DIFFERENT GATA-2 MUTATION TYPE IN
ACUTE MYELOID LEUKEMIA
S. Zhang1,*
1Hematology, Ruijin Hospital of Shanghai Jiao Tong University School of Med-
icine, Shanghai, China
Background: Cytogenetic and gene abnormalities are considered to be the
most important prognostic factors of acute myeloid leukemia(AML) patients.
Gene mutations such as internal tandem duplications (ITDs) or tyrosine kinase
domain (TKD) of FMS-like tyrosine kinase 3 (FLT3), C-KIT, neuroblastoma RAS
viral oncogene homolog gene (NRAS) have been considered to belong to class
involving signal transduction, nucleophosmin gene (NPM1), the
CCAAT/enhancer binding protein α gene (CEBPA) or the mixed-lineage
leukemia (MLL)gene, which can be affected either through chromosomal
translocation or via an intragenic partial tandem duplications (PTDs) to form a
fusion gene to class those causing impaired differentiation. GATA-2 is a zinc-
finger(ZF) transcription factor and play important roles in hematopoiesis in
many cell lineages.
Aims: To evaluate the prognostic value of GATA-2 mutation in acute myeloid
leukemia (AML) patients, we performed sequence analysis to see if GATA-2
mutation play important role in AML leukemogenesis.
Methods: We performed sequence analysis to detect GATA-2 mutation in 135
AML patients. We also performed luciferase assay and Western-Blot assay to
analyze the biological function of mutant GATA-2.
Results: A total of 5 (3.7%) different GATA-2 mutations were detected in 135
patients. The mutation types of GATA-2were GATA-2W10C(tgg>tgt, Trp→Cys),
GATA-2S277N(agc>aac, Ser→Asn), GATA-2P304H(cct>cat, Pro→His), GATA-
2 R362Q(cga>caa, Arg→Gln), GATA-2 V369A(gtc>gcc, Val→Ala). Luciferase
assay showed the transcription activity of GATA-2 G320D was significantly lower
than that of wt GATA-2(P<0.05), whereas the activity of GATA-2 P304H and
GATA-2 R362Q was slightly lower than wtGATA-2 (P>0.05). The result of West-
ern-Blot showed that the expression of GATA-2 protein in GATA-2
P304H(P=0.002) was significantly higher while GATA-2 R362Q or GATA-2 G320D
mutants was lower than wt GATA-2 (P=0.02 and P=0.004, respectively).
Summary and Conclusions: GATA-2 mutation is a rare mutation in AML
patients. The mutations located in zinc-finger domain may contribute to AML
leukemogenesis.
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DETECTION OF TET2, KRAS, AND CBL VARIANTS BY NEXT GENERATION
SEQUENCING IN CHILDHOOD ACUTE MYELOID LEUKEMIA
D.F. Akın1,* D. Aslar1, M. Mumcuoglu1, U. Ezer2, M. Bahce3, E. Kurekci2,
N. Akar4
1Lösante Hospital Cancer Research and Genetics Laboratory, 2Lösante Hos-
pital, 3Gene-Lab Genetic Diseases Diagnosis Center, Ankara, Turkey, Gene-
Lab Genetic Diseases Diagnosis Center, 4TOBB-ETU Hospital, Ankara, Turkey
Background: Acute myeloid leukemia (AML) is a heterogeneous clonal neo-
plasm characterized by accumulated genetic aberrations, which result in
enhanced proliferation, block in differentiation, increased survival of the
leukemic blast cells and variable response to therapy. During the past decades,
a number of recurrent cytogenetic and molecular genetic abnormalities have
been identified in AML such as t(8;21), inv(16), FLT3, NPM1, CEBPA, Ten-
Eleven-Translocation 2 (TET2), Kirsten rat sarcoma viral oncogene homolog
(KRAS), and Casitas B-cell lymphoma (CBL). Mutations in TET2 gene could
contribute to leukemogenesis by altering epigenetic regulation of transcription
via DNA methylation. The incidence of TET2 mutations is approximately 10-
20% in AML. RAS mutations, especially KRAS, represent about 90% of can-
cer-associated mutations. RAS proteins play a major role in cell signaling path-
way of cell proliferation, differentiation, and survival. KRAS mutations are the
most frequently seen and found in 10-15% of these patients. CBL is a mam-
malian gene encoding the protein CBL which is an E3 ubiquitin-protein ligase
involved in cell signaling and protein ubiquitination. These mutations have also
been observed in 1% of AML.
Table 1. Demographic characteristics and TET2, KRAS, and CBL variants
of children with AML
Aims: In this study, we aimed to screen whole TET2, (KRAS) and (CBL) genes
by using Next generation sequencing (NGS) analysis to find new possible
genetic markers in children with AML.
Methods: Study population consisted of eight patients aged between 1 and
15 years who were admitted to Lösante Hospital for Children with leukemia
with the diagnosis of AML. The Patient characteristics of the cases are shown
in Table 1. Blood samples were collected with EDTA-containing tubes and DNA
was extracted from peripheral blood and bone marrow leukocytes with MagNA
Pure automatic DNA isolation instrument (Roche Diagnostics, Manheim, Ger-
many). We utilized NGS to study three candidate genes at TET2, KRAS and
CBL. All coding exons of TET2 (exons 3 and 11) were presented by 27 ampli-
cons. Beside, two primer pairs were amplified known mutational hotspot regions
to describe the RING finger domain and linker sequence for CBL (exons 8 and
9) and KRAS (exons 2 and 3).
Results: We detected 16 variants in TET2, 2 variants both KRAS and CBL.
The most of TET2 variants were described in the largest exon 3 and 11; 1842
G>- (6/8 patients, 75%) and 1088 C>T (5/8, 62,5%) variants, 5162 T>G(5/8,
62,5%) in exon 3 and exon 11 of TET2, respectively. 310 A>C (7/8 87,5%) vari-
ation was the highest among the variants in intron 2 of KRAS. 1347 T>- in exon
8 of CBL was detected 6/8 patients (75%).Table 1 summarizes the association
of patients’ characteristics and variants of TET2, KRAS and CBL profiles.
Summary and Conclusions: In this study, we screened the mutations of
TET2, KRAS and CBL genes in pediatric AML patients. We used an amplicon
based sequencing method to find possible new genetic markers for leukemia
diagnosis. TET2, KRAS andCBL genes were selected based on recent studies
on genetic abnormalities in AML and other hematologic malignancies. In 8
patients, we report novel mutations at TET2 and CBL genes. Seven of 16 sub-
stitutions were missense mutations in the exon and UTR regions. These muta-
tions may result in truncated translation of protein. In conclusion, we found that
TET2mutations are more frequent than KRAS, and CBLmutations in pediatric
AML in this study. The usage of NGS to search for TET2, KRAS, and CBL
mutations might be fruitful, however, these results need to be confirmed by
further studies on a larger number of patients.
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IMPACT OF LEUKEMIA STEM CELL FREQUENCY AT DIAGNOSIS ON
SURVIVAL IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS
A. Kamel1,* N. El-Sharkawy1, E. Kandeel1, M. Hanafy1, M. Samra2
1Clinical Pathology, 2Medical Oncology, NCI, Cairo University, Cairo, Egypt
Background:Acute myeloid leukemia (AML) is a heterogeneous disorder with
treatment results much inferior to acute lymphoblastic leukemia. Treatment
failure is largely attributed to the persistence of leukemia stem cells (LSCs)
which are less accessible and hence less responsive to chemotherapeutics.
The classical LSC phenotype is CD34+/CD38-; however LSCs express other
markers especially CD123 and CD133 which may be even earlier than CD34.
We hypothesized that CD123 and CD133 may be better markers of LSCs and
that higher frequency of LSCs at diagnosis may be associated with shorter
survival.
Aims: To evaluate CD123 and CD133 as LSC markers as compared to the
standard CD34+/CD38- and to study the impact of LSCs frequency at diagnosis
on overall survival (OS) and disease free survival (DFS) in adult AML as well
as correlate the LCS frequency with other findings at diagnosis.
Methods: The study was performed on 84 newly diagnosed AML patients includ-
ing 51 Males and 33 females with an age range of 18-70 with a median of 31.5
years. Two 4 color panels of monoclonal antibodies were used:
CD45/CD34/CD38/Cd123 and CD45/CD133/CD90/Cd33 and analyzed on
Navios Coulter Flow Cytometer. Cell populations with different surface markers
were calculated using the prism function of the soft ware. Results were correlated
to other parameters at diagnosis. The median value for each marker alone and
in different combinations (panels) was used to divide the cohort into high and
low expressers. Patients were treated by (3+7) protocol; they were followed up
for a period of 0.2-24 with a median of 5.5 months and evaluated for OS and
DFS. The study was performed according to the guidelines of Helsinki declaration
for studies performed on human beings and approved by the Institution Review
Board (IRB) of the National Cancer Institute, Cairo University. An informed signed
consent was obtained from all study subjects before enrollment.
Results: Single markers or panels expression were not correlated to age, gen-
der, percentage PB or BM blasts, Hb level, TLC or platelet count.
Among the studied single markers CD123 and CD133 high expression was
associated with shorter OS (P=<0.001 and<0.006 respectively) and DFS
(P=<0.001). Among the panels, CD123+/CD34+/CD38- was the best discrim-
inator for OS (P=0.005) followed by CD123+/CD34- /CD38+ (P=0.025) and
CD34+/CD38- (P=0.025). For DFS CD123+/CD34+/CD38- and CD123+/CD34-
/CD38+ were both associated with shorter DFS (P=<0.001); CD34+/CD38-
population level at diagnosis had no significant impact on DFS.
Summary and Conclusions: The classical phenotype of CD34+/CD38- is not
inclusive; LSC may be present among CD34- and/or CD38+ populations.
CD123 and CD133 are sensitive markers, even better than CD34+/CD38-, for
the detection of LSC. Higher frequency of leukemia stem cells at diagnosis is
associated with shorter OS and DFS. 
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NOVEL TETRACYCLINE TIGECYCLINE EFFECTS ON HEMATOLOGICAL
MALIGNANCIES VIA CASPASE 3,9 PATHWAY AND NFKB PATHWAY
H. Shigemi1,* T. Yamauchi1, Y. Tanaka2, I. Sakamaki1, M. Ohkura1, H. Naiki3,
H. Iwasaki4, T. Ueda1
1Hematology and Oncology, 2Molecular and Biochemistry, 3Molecular Pathol-
ogy, 4Infectious Disease, University of Fukui, Faculty of Medical Science, Fukui,
Japan
Background: Novel tetracycline derivative tigecycline has an antibiotic effect
against a wide range of microorganisms including an activity in multi-resistant
drug infections and modulates the production of cytokines and chemokines.
FDA approved it for the treatment of complicated infections in 2005. Besides it
might affect hematological malignancies. Skrtic et al. reported tigecycline’s
anti-leukemia activity in TEX cell lines and M9-ENL-1 cell lines. The phase I
clinical trial has undergone in USA.
Aims: We examined the anti-leukemic effect and elucidated the mechanism
of tigecycline. Furthermore, we confirmed tigecycline is also effective on cytara-
bine resistant (AraC-R) HL60 cell line and clofarabine resistant (CAFdA-R)
HL60 cell line. Two cell lines showed 200-fold and 100-fold resistant to parental
HL60 cells, respectively.
Methods: To assess the effects of tigecycline on cell viability in acute myeloid
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leukemia HL60 cell line, acute lymphocytic leukemia CEM cell line, multiple
myeloma U266 cell line and chronic myeloid leukemia K562 cell line, XTT assay
was performed. Annexin-PI assay, sub G1 analysis in cell cycle were performed
using by flowcytometry in HL60 and CEM cell line. Apoptosis related protein
(caspase 3, 8, 9, Bax, Bad, Bclxl, Bcl2) and the phosphorylation of IKKα/β,
NFκB were detected by Western Blotting. The effectiveness of tigecycline on
AraC-R HL60 cell line and CAFdA-R HL60 cell line, those have been estab-
lished in our laboratory, were evaluated. Sensitivities on Bcl2 inhibitor (ABT737)
and NFkB inhibitor (BAY11-7821) in HL60, CEM, AraC-R HL60 and CAFdA-R
HL60 cells, were also examined.
Results: 1) The cell viability was measured at 72 hours by XTT assay. The val-
ues of Inhibition Concentration 50% (IC50) of tigecycline in HL60, CEM, K562
and U266 cells were 5.0µM, 2.5µM, 2.7µM and 21.2µM respectively. It was
shown that tigecycline was cytotoxic to leukemic cells. 2) Tigecycline induced
apoptosis in a dose- and time- dependent manner. In addition, sub G1 analysis
showed that tigecycline suppressed S phase in cell cycle. 3) Tigecycline sup-
pressed the expression Bcl2 in a time-dependent manner and inhibited the phos-
phorylation of NFκB in HL60 cells and CEM cells. Tigecycline activated cas-
pase3, 9. 4) We examined the effectiveness of tigecycline on AraC-R HL60 cells
and CAFdA-R HL60 cells. The values of IC50 of tigecycline were 6.7 µM (AraC-
R) and 2.0 µM (CAFdA-R). ABT737 and BAY11-7821 displayed more effective
on resistant cells compared to HL60 parental cells. The values of IC50 of ABT737
were 881nM (Parental), 73.3nM (AraC-R), 68.4nM (CAFdA-R). Those of BAY11-
7821 were 2.4 µM (Parental), 1.1 µM (AraC-R), 1.5 µM (CAFdA-R).
Summary and Conclusions: Tigecycline showed an anti-leukemic effect on
HL60, CEM and K562 cell lines. Tigecycline is presently used for the treatment
of certain infections. Pharmacological concentration of tigecycline is useful for
treatment of cancer and leukemia. Targeting caspase3, 9 pathway and NFκB
pathway, tigecycline induced apoptosis. Furthermore, tigecycline were cytotoxic
to both resistant cells. That means tigecycline could be used as the new strategy
for treating the recurrent and resistant leukemia. ABT737 and BAY11-7821 also
could be new agents, however, they have not been approved for the clinical
use. Interestingly, ABT737 showed collateral sensitivity to the resistant cells.
Tigecycline mechanically has both effects on leukemic cells. In short, tigecycline
might give a marked improvement in anti-leukemic chemotherapy.
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GENE EXPRESION MARKERS PANEL IN POSTTRANSPLANT RELAPSES
EVALUATION
A. Shakirova1,* I. Barkhatov1, O. Shakirova2, O. Smykova1, V. Teplyashina3,
Y. Gudozhnikova3, S. Bondarenko1, L. Zubarovskaya1, B. Afanasyev1
1R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, First Pavlov State Medical University of St.Petersburg,
2St.Petersburg State Polytechnic University, St.Petersburg, Russian Federation,
3R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, St.Petersburg State Polytechnic University, St.Petersburg,
Russian Federation
Background: It is known that up to 50 percent of cases of acute myeloid
leukemia (AML) does not have informative genetic markers. At the same time,
the studies of donor chimerism do not fully indicate the degree of tumor cells
elimination and not always allows to estimate the risk of post-transplant relapse.
Thus, finding of universal markers allowing for adequate therapy in post-trans-
plant period, is quite important. WT1, BAALC, EVI1 and PRAME gene expres-
sion analysis is one of the possible approaches is this field.
Aims: Evaluation of WT1, BAALC, EVI1, PRAME gene expression markers
significance in assessment of posttransplant relapse likelihood of acute myeloid
leukemia.
Methods: Our study included 63 patients with AML (1 to 60 years old) (M0-
2pts, M1-11pts, M2-13pts, M3-2pts, M4-21pts, M5-11pts, M6-1pt, M7-2pts )
who underwent allogeneic transplantation of hematopoietic stem cells (allo-
HSCT). In 24 patients myeloablative conditioning regimen were used, 39 –
received reduced toxicity protocols. Assessing the levels of WT1, BAALC, EVI1,
PRAME gene expression and the level of chimeric transcripts was performed
by means of RQ-PCR with normalization for ABL gene expression. For the
donor chimerism monitoring a panel of STR-markers was used.
Results:As based on gene expression in healthy donors, we have established
cut-off overexpression (gene exp. / ABL exp. X100) values for the genes: WT1
– 250, EVI1-10, BAALC – 20, PRAME-200. For the present patient setting, we
found no statistically significant differences in WT1, BAALC, EVI1, PRAME
genes expression between the patients with different FAB variants of AML.
However we were able to identify a trend to higher values of PRAME and
BAALC gene expression in patients with M1 variant, and WT1 gene values
among patients with M4 variant of AML. In patients who underwent transplan-
tation in relapse state, we have noted a significant overexpression of EVI1
(P=0.006), WT1 (P<0.001), BAALC (P<0.001). A similar trend was observed
for PRAME gene (P=0.08). EVI1 gene overexpression was revealed for 6
patients (33%), WT1 in 13 cases (72%), BAALC in 10 patients (55%) and
PRAME in 4 patients (22%). When comparing the data on chimeric transcripts
expression, we detected a correlation between expression levels of the studied
genes and chimeric transcripts (PML-RARa and RUNX1-RUNX1T1, P<0.05)
as well as with donor chimerism levels. At the same time, we did not find this
relationship, when comparing with data about of expression of a CBFB-MYH11
chimeric gene. When evaluating the test sensitivity and specificity analysis we
revealed a bellow-cutoff value of the expressed genes in presence of the
chimeric transcript less than 2%.
Summary and Conclusions: Evaluation of universal gene marker expression
is an attractive approach for assessing efficiency of therapy in patients with
AML. Thus, their use in early diagnostics of relapse in post-transplant period is
quite promising. However, due to low specificity caused by basal expression in
normal cells, futrher application of these markers is limited, when detecting
minimal residual disease levels.
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PROGNOSTIC VALUE OF HEMATOGONES IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION
M. Hassanein1,* R. Haggag1, S.M. El Shorbagy 1, H. F.Ebian2
1Medical Oncology, 2Clinical Pathology, Zagazig University, Zagazig, Egypt
Background: Hematogons (HGs) are normal bone marrow cells; that may
reflect the quality of the bone marrow response to chemotherapy. Many studies
have focused on the role of HGs in acute leukemia.
Aims: In our study, we investigated the prognostic value of HGs expression in
patients with AML in first complete remission. 
Figure 1. Overall-survival according to HGs status.
Methods: A total of 65 patients with non- promyelocytic AML, in first complete
remission were enrolled in this study, and four color flow cytometry was used
to quantify Hematogones. We identify the HGs detectable group as those who
had more than or equal to 0.01% HGs in bone marrow aspirated sample.
Results: HGs were detectable in 25 patients’ marrow samples, and they were
significantly associated with cytogenetic risk (P=0.01). After a median follow-
up of 17.6 months, patients with detectable HGs had better DFS and OS than
those with undetectable levels (P=0.013 and<0.001; respectively) and only 3
patients with detectable HGs in marrow remission samples experience relapse.
On multivariate analysis, the HG ≥0.01% is an independent predictive value
for DFS (P< 0,0001), and OS (P<0,007), but number of chemotherapy cycles
to achieve CR and poor cytogenetic had significant prognostic effect on DFS
but not on OS.
Summary and Conclusions: we can concluded that AML patients in first com-
plete remission with HGs ≥0.01% have better DFS and OS.
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THE MICROARRAY GENE PROFILING ANALYSIS OF ACUTE
PROMYELOCYTIC LEUKEMIA CELLS IN RESPONSE TO FISETIN AND
HESPERETIN
A. Adan Gökbulut1,* Y. Baran1
1Molecular Biology and Genetics, İzmir Institute of Technology, İzmir, Turkey
Background: Flavonoids are reported to prevent the initiation, promotion and
progression of cancer by making changes in various signaling pathways.
Although several treatment options exist for acute promyelocytic leukemia
(APL), it is not cured effectively due to the development of drug resistance and
intolerance and its heterogenic nature. Thus, it is important to develop novel
natural treatment approaches in order to improve outcome. Fisetin and hes-
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peretin, bioactive flavonoids, found in fruits and vegetables have been reported
to be promising novel antioxidants with their potentials as chemopreventive/
chemotherapeutic agents in several cancer types such colon, breast and
prostate cancers. However, there is no information about the precise mecha-
nisms by which fisetin and hesperetin exert their antileukemic effects.
Aims: We intented to explain the molecular mechanisms and global gene
expression patterns modulated by fisetin and hesperetin using genome-wide
microarray analysis in APL cells.
Methods: Illumina Human HT-12v4 beadchip microarrays (San Diego, CA) were
used to assess global gene expression. Poly-A tail mRNA isolated from fisetin
and hesperetin treated HL60 APL cells was converted to biotin labelled c-RNA.
The data obtained after hybridization of c-RNA to beadchips was analyzed using
Illumina GenomeStudio software to cluster genes. The list of differentially
expressed genes constrained by p-value<0.05 and at least 2.0 fold change was
obtained. Affected genetic networks were determined by using the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) and Ingenuity Pathway Analysis (IPA).
Results: A total of 54 and 1608 genes were significantly regulated (P<0.05) in
20 and 50 μM fisetin treated HL60 cells, respectively. Fold change analysis
displayed that TXNIP, TFPI, miRNA1974, ID1 and ID3, HSPA1B and IDH1
were altered genes in both 20 and 50 μM fisetin-treated HL60 cells. On the
other hand, MAP3K1, Caspase 4 and LASS6 were the examples of upregulated
genes while LONP1, STAT5A and STAT3 and JAK1 were some of specifically
downregulated genes in 50 μM fisetin treated HL60 cells. KEGG and IPA analy-
sis displayed that MAPK, JAK/STAT and PI3K/AKT signaling pathways and ID
signaling pathway were examples of the most altered networks. Moreover,
HL60 cells treated with 100 and 150 μM hesperetin changed the expression of
130 and 691 genes (P<0.05), respectively. SASH1, MT1F and SPRR2D were
common upregulated genes while TUBB1, ID3, ID1, NMU, FGFR3 and S100P
were common dowregulated genes in both 100 and 150 μM hesperetin treated
HL60 cells based on fold change analysis. Futhermore, 150 μM hesperetin
induced more genes that were either upregulated or downregulated as com-
pared to 100 μM hesperetin. TXNIP, MT1A, MAP3K1 and SPRR2F were some
of upregulated genes while RPS25, C-MYC, TUBA1C were the examples of
downregulated genes. ID signaling pathway, translation-, gluconeogenesis-
and mitosis-related networks, TGF-β and MAPK pathways were the affected
signaling networks based on KEGG and IPA analysis.
Summary and Conclusions: Our data show that fisetin and hesperetin trigger
growth inhibitory and apoptotic effects by modulating the expression of genes
involved in cellular processes. The genetic networks identified in this study
enlight some important biological pathways that are altered by fisetin and hes-
peretin while giving a list of candidate genes that could be targeted for APL
therapy. In conclusion, we determined the molecular mechanisms by which
fisetin and hesperetin exert pleiotropic effects on APL cells.
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CHARACTERISTICS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
AND MYELODYSPLASTIC SYNDROMES WITH MONOSOMAL
KARYOTYPE
I. Kostroma1,* S. Gritcaev1, I. Martinkevitch2, Z. Chubukina3, L. Martinenko2,
M. Ivanova2, N. Potichonova4, K. Abdulkadyrov1
1Hematological clinic, 2Cytogenetic laboratory, 3Immunological laboratory,
4Clinico-morphological laboratory, Russian Institute of Hematology and Trans-
fusiology, St.Petersburg, Russian Federation
Background: It has been shown previously that monosomal karyotype (MK)
is associated with bad prognosis in patients with acute myeloid leukemia (AML)
and myelodysplastic syndromes (MDS). At the same time there are ambiguous
data about relationship of MK with other clinical and biological features of AML
and MDS.
Aims: To characterize clinical, morphological and cytogenetic signs of AML
and MDS patients that are associated with MK.
Methods: A retrospective analysis of 44 patients with AML and 33 patients
with MDS was done. To diagnose AML and MDS the criteria of WHO classifi-
cation was used. Karyotype was studied by standard method. The cases with
t(8;21), t(15;17), and inv(16) were excluded from the analyses.
Results: The median age of AML and MDS patients was 64 (17-84) y and 63 y
(28-81), accordingly. Number of patients with therapy-related AML and MDS was
11.4% and 12.1%, accordingly. In the MDS group there were 3 (9.1%) patients
without excess of bone marrow (BM) blasts and 30 patients had ≥5% BM blasts.
So the ratio was 1:10. The most frequent monosomies were -5, -7, and -18
regardless of the diseases. The number of monosomies in individual patients
was ranged from 1 till 7. In the AML group the number of cases with ≥3 mono-
somies was more frequent event in patients ≥60 y than in patients<60 y: 46.4%
vs 18.7%; P=0.02. There was correlation between the number of monosomies
and AML patients’ age: r=0.308; P<0.05. Specific CD expression different from
the typical myeloid blasts’ phenotype was not found. Median overall survival (OS)
of AML and MDS patients were 6 and 8 months, accordingly. Nevertheless there
were some long-liver patients: 4 with AML (12-171 mo) and 2 with MDS (20, 38
mo). Three of the AML patients were treated with chemotherapy only and the
period of follow-up without relapse were 52, 119 and 171 months. Their karyotype
did not characterize by any iterant chromosomal aberration. AlloSCT was realized
to the fourth AML patient. Long-liver MDS patients had variant without excess of
BM blasts and died after AML transformation or pancytopenia’s intensification.
Summary and Conclusions: Monosomal karyotype is the cytogenetic finding
that is not associated with patients’ age, negative influence of the previous
therapy or specific CD expression on the BM blast. But it may be more often
event in the group of advanced MDS. AML patients with monosomal karyotype
have to be treated aggressively as there is a chance of long relapse-free and
OS after standard intensive chemotherapy.
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MORPHOFUNCTIONAL STATE OF U-937 TREATED WITH PROTEIN
KINASES INHIBITOR MALEIMIDE DERIVATIVE IN COMBINATION WITH
PHORBOL-12-MYRISTATE-13-ACETATE
I. Byelinska1,* L. Garmanchuk2, V. Rybalchenko1
1Research sector “Membranology and Cytology”, ESC “Institute of biology”,
2Biochemistry, ESC “Institute of biology”, Taras Shevchenko National University
of Kyiv, Kyiv, Ukraine
Background: Maleimide derivative (MI-1, 1-(4-Cl-benzyl)-3-Cl-4-(CF3-pheny-
lamino)-1Н-pyrrole-2,5-dione synthesized in Taras Shevchenko National Uni-
versity of Kyiv, Ukraine) is a competitive inhibitor of PDK1, VEGF16, SW-620)
in vitro and in vivo decreases the number of colon tumors and normalizes an
increased number of monocytes and platelets in blood of rat with 1,2-dimethyl-
hydrazine-induced colon carcinogenesis. MI-1 inhibits proliferation and mitotic
activity, activates apoptosis, causes shift of cells from G2/M+S to Go/G1 stage
of human monocytic cells U-937. 
Aims: The aim of this study was to investigate the effects of MI-1 on the mor-
phofunctional state of U-937 in combination with agonist protein kinase C phor-
bol-13-miristat-13-acetat.
Methods: Cells U-937 were incubated (5% CO2, 100 humidity, 37 oC) in 96
well plates in RPMI-1640 («Sigma», USA) with 10% FBS («Sigma»), 2 mM
Glutamine and 40 μg/mL gentamicin. MI-1 at final concentration of 0.008 mM
or 0.016 mM in combination with 100 nM phorbol-12-myristate-13-acetate
(PMA) were added to cell cultures and incubated for 24 or 48 hours. The num-
ber of live and dead cells was calculated in hemocytometer with 0.1% trypan
blue staining. Percent of apoptotic, mitotic or necrotic cells was calculated per
1000 cells in cytospin prepared specimens after Pappenheim’s stained. SPSS
16.0 One-Way ANOVA followed by Hochberg and DunnettT3 tests were used.
Mean and SD are presented. 
Results: MI-1 at 0.008 mM with 100 nM PMA tended to reduce proliferation of
U937 by 22% (0,67±0,18; P=0.064), at 0.016 mM and PMA reduced prolifera-
tion by 35% (0,56±0,12; P=0.004) in comparison with PMA only (PMA-control
0,86±0,13) after 24 hours exposure. Number of dead cells didn’t differ between
the indicated groups (0,08±0,03, P=0.944; 0,12±0,03, P=0,12 vs. PMA-control
0,07±0,05). Extension of treatment for 48 hours with 0.008 mM of MI-1 and
PMA reduced proliferation by 40% (0,57±0,13; P<0.001), with 0.016 mM-by
62% (0,36±0,09; P<0.001) vs. PMA-control (0,95±0,13). Number of dead cells
at 0.008 mM of MI-1 (0,08±0,04; P=0.94) didn’t differ from the control
(0,10±0,04), at 0.016 mM-increased (0,32±0,09; P=0.008). MI-1 at 0.008 mM
and PMA tended to increase by 26% (2,57±0,32%; P=0.245) and at 0.016 mM
increased the number of apoptotic cells in 8,5 times (17,17±2,52%, P=0.018)
vs. PMA only (2,03±0,31%). The number of apoptotic cells was increased after
48 hours exposure of MI-1 and PMA (10,17±0,15%, P=0.001; 10,73±0,64%,
P<0.001 respectively) vs. PMA-control (2,00±0,53%).MI-1 at both investigated
concentration with PMA decreased the number of mitotic cells (1,90±0,10%,
P=0.005; 1,60±0,10%, P=0.001 respectively) vs. PMA-control (2,50±0,10%)
after 24 hours exposure. 48 hours exposure of MI-1 at 0.008 mM and PMA
reduced by 20% (1,07±0,15% P=0.526), at 0,016 mM-by 47% of the mitotic
cells (0,70±0,10%, P=0.125) vs. PMA-control (1,33±0,31%). The number of
necrotic cells after 24 exposure of MI-1 at 0.008 mM and PMA (2,63±0,15%,
P=0.001) lower from the PMA-control (5,10±0,36) and tended to reduce at
0.016 mM (4,27±0,31%, P=0.060) but after 48 hours exposure tended to
increase (1,90±0,36% P=0.592, 2,17±0,40% P=0.060) vs. PMA (0,87±0,31%).
Summary and Conclusions: MI-1 in combination with PMA reinforces oppres-
sion proliferation activity of U-937, reduces mitotic activity and activates apop-
tosis through inhibiting of VEGFR-, EGFR- and of non-receptor PDK1-, Src-
and Syk- kinases that are involved in hematopoiesis.
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CLINICAL CHARACTERISTICS OF PATIENTS AFFECTED BY ACUTE
MYELOID LEUKEMIA RESISTANT TO PRIMARY INDUCTION CHEMOTERAPY:
AN ANALYSIS OF 385 CASES FROM A SINGLE INSTITUTION
S. D’Ardia1,* E. Messa2, B. Allione1, E. Audisio1, S. Aydin1, A. Castiglione3,
G. Ciccone3, C. Frairia1, E. Maffini4, B. Nicolino1, U. Vitolo1
1Hematology, Città della salute e della Scienza, Torino, 2Internal medicine, Car-
magnola Hospital, Carmagnola (Torino), 3Statistic Department, 4Hematology,
Torino University, Torino, Italy
Background: patients (pts) affected by acute myeloid leukemia (AML) resistant
to a first line treatment are a relatively small group with a very poor prognosis.
There are few data about clinical and molecular features predictive of primary
induction failure (PIF) at baseline. Ravandi observed in a series of 1597 AML
patients that higher age, unfavourable cytogenetic, high white blood cells (WBC)
count at presentation were associated with PIF while they failed to identify any
association with molecular abnormalities such as FLT3 mutations.
Aims: aim of our work was to evaluate clinical and molecular features of PIF
AML patients at baseline in order to identify any possible clinical characteristics
predictive of PIF.
Methods: Clinical and molecular data at baseline of 385 pts affected by AML
fit for standard chemotherapy from 2000 to 2013 were collected in a prospective
manner in our institution. The distribution of patients’ characteristics were sum-
marized using percentiles, for continuous variables, and percentages and fre-
quencies for categorical variables. In order to test difference in distribution of
patients’ characteristics according to PIF we performed the Wilcoxon rank sum
test for continuous variables and the χ2 test for categorical variables. We per-
formed a logistic regression analysis to identify risk factors associated of failure
to achieve complete remission after induction treatment.
Results: 104 (27%) out of 450 pts resulted refractory to the first line treatment.
Clinical characteristics at baseline were as follows: median age 58 (± 19) years,
207 out of 385 pts were male. 25,8% of patients who achieved complete remis-
sion showed organomegalies versus 28,6% of PIF pts. High WBC count at pres-
entation was evident in 22% of PIF versus 23,9% of controls. Median platelets
count at presentation was similar in the two subgroups: 60 in controls versus 48
in PIF pts. Cytogenetic risk was as follows: 9% of controls and 2,3% of PIF pts
were low risk, 23,8% of controls and 39,1% of PIF patients were high risk, the
remaining pts were intermediate risk. The majority of the pts (64%) were treated
by standard dose anthracycline based induction regimen, while 26% were treat-
ed by fludarabine based regimen and 10% were treated by high dose chemother-
apy. At univariate analysis age, unfavourable cytogenetic risk and fludarabine
based regimen were predictive factors of induction failure (OR 1,02, 2.05 and
1,77 respectively with 1,01-1,04, 1,22-3,45 and 1,09-2,87 95% CI) while NPM
mutated status, high dose ARA-C regimen and favourable cytogenetic risk were
associated with complete remission (OR 0,33, 0,4 and 0,23 with 0,1-1,07, 0,17-
0,99 and 0,05-1,02 95% CI). We failed to identify a statistically significant asso-
ciation with WBC, platelets count and FLT3 status and PIF status.
Summary and Conclusions: In our experience the only predictive factors of
PIF in adults affected by AML are higher age and unfavourable cytogenetic at
baseline. Flt3 status is confirmed not to be a molecular marker of treatment
failure while NPM mutation seems to have a positive predictive value but the
data need to be confirmed in a larger series of cases. Even if our study is only
observational, our data showed that pts treated by conditioning regimen based
on high dose ARA-C showed a better outcome than pts who underwent flu-
darabine based induction chemotherapy. Further studies are needed in order
to identify more clinical and biological factors predictive of primary treatment
failure at baseline. 
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EFFICACY OF DECITABINE IN 10-DAY REGIMEN IN ELDERLY PATIENTS
WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE
CHEMOTHERAPY
B. Moreno De Gusmao1,* I. Esteves1, M. Petrolli1, J. Hyppolito1, F. Santos1,
F. Ferreira1, G. Perini1, R. Helman1, N. Hamerschlak1
1Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
Background: Currently the hypomethylating agents (azacitidine, decitabine)
are safe and effective alternative treatment for patients with acute myeloid
leukemia (AML) that do not fit for intensive chemotherapy treatments. Several
studies have been described the modification of the treatment regimen with
hypomethylating agentes. We analyzed the effectiveness of decitabine in
patients with acute leukemia not eligible for intensive therapy.
Aims: The objective of this study is to analyze the safety and efficacy of using
decitabine in 10-day regimen.
Methods: We reviewed 11 patients with AML treated with DEC between June
2010 and January 2015. The schedule was DEC 20 mg/m2x 10 days in induc-
tion therapy. Patients who achieved remission cytological (defined as<5% blasts
in the bone marrow aspirate) received consolidation therapy with DEC 20
mg/m2x 5 days until progression and the remaining patients received a re-
induction before start consolidation therapy.
Results: 36.4% were de novo AML 63.6% were secondary AML (2 myelofibro-
sis, 4 MDS and CMML 1). All patients were male with a median age of 82 years
old (range 69-86) and 36.4% patients had cytogenetic abnormalities in diagno-
sis according to European Leukemia Net (ELN): 6 patients were favorable risk,
intermediate risk 1 and 3 high-risk. 54.5% patients had>30% blasts and 45.4%
received treatment previously. 91% of patients had some comorbidities. A medi-
an of 6 cycles (range 1-10) were administered in total 57 cycles of decitabine.
All patients had adverse effects during treatment, the most frequent febrile neu-
tropenia (63%) and there was an early death (<8 weeks) associated with liver
failure in a patient previously diagnosed. According to ELN, with induction in
10 days, we had a global response rate of 72.7% (2 CR with cytogenetic remis-
sion; 2 CR, 4 CR with incomplete hematologic recovery, 1 PR and 3 patients
with refractory disease. Secondary AML, transfusion dependence and number
of blasts>30% at diagnosis, had no effect on treatment response induction. In
our study 6 patients died because disease progression infection. Median fol-
low-up of 340 days (range 148- 1506 days) with OS of 63% in 1-year and 45.5%
during the follow up with a DFS of 45.5%.
Summary and Conclusions: In our experience, decitabine in 10-day regimen
in elderly patients is safe and very effective, even in poor prognosis patients.
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INTENSITY OF CHEMOTHERAPY INFLUENCING AN OVERALL SURVIVAL
OF PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS
I. Djunic1,* M. Virijevic1, N. Suvajdzic-Vukovic2, A. Novkovic3, M. Mitrovic4,
N. Colovic2, A. Vidovic2, D. Tomin2
1Department of acute leukemias, Clinic for Hematology, Clinical Center of Ser-
bia, 2Department of acute leukemias, Clinic For Hematology, Clinical Center of
Serbia, Medical Faculty of Belgrade University, 3Clinical Hospital Center
“Zemun”, 4Clinic For Hematology, Clinical Center of Serbia, Medical Faculty of
Belgrade University, Belgrade, Serbia
Background: Acute myeloid leukemia (AML) is common disease in people
aged >70 years. While the best management of AML is based mainly on inten-
sive chemotherapy (CT) in younger patients, are still remains a matter of con-
troversies in the elderly. In elderly AML patients, intensive CT is often poorly
tolerated and gives scanty results.
Aims: The aim of this study was to identify the patients with AML not eligible
for CT and who could be suitable only for supportive care.
Methods: This single-center study involved 68 patients aged >70 years (range
71-85) with nonpromyelocytic AML during follow-up of 5 years. Patients were
treated by three type of therapeutic regimen with various intensity: CT (induction
therapy with daunorubicin 30 mg/m2 on day 1 and 3 and cytarabine 100 mg/m2
given for 5 days; or mitoxantrone 10 mg/m2 and etopozide 100 mg/m2 given
for 5 days), paliative therapy (Hydroxiurea, Etoposide or 6-mercaptopurine per
os) and supportive therapy (transfusions). Comorbidities were evaluated by
using the hematopoetic cell transplantation-specific comorbidity index (HCT-
CI). Performance status (PS) was evaluated by Eastern Cooperative Oncology
Group (ECOG), ranged 0-4. Cytogenetic risk group was assessed by reco-
mandation of Europian LeukemiaNet (ELN). The following parameters were
estimated as risk factors for treatmement with CT: age >75 years, leukocytope-
nia (white blood count<4x109/L), thrombocytopenia (platelet count<50x 109/L),
higher absolute peripheral blasts (>5x 109/L), ECOC PS (<2 vs ≥ 2), ELN cyto-
genetic risk group, and HCT-CI (<3 vs ≥ 3). Risk factors were identified using
the univariate and multivariate analysis.
Results: In this group of patients, 16 pts treated with CT, 24 pts treated with
palliative and 28 pts with supportive therapy. In group of patients treated with
CT, univariate analysis showed that the following risk factors were significant
for OS: leukocytopenia (P=0.039), thrombocytopenia (P=0.043), higher
absolute peripheral blasts (P=0.002), ECOG PS ≥ 2 (P<0.001) and HCT-CI ≥
3 (P< 0.001). Multivariate analysis indicated HCT-CI ≥ 3 as the most important
risk factor for poor OS of patients treated with CT: P<0.001, relative risk
(RR)=3.689; 95% confidental interval (CI)=1.817-7.489. Patients with leukcy-
topenia and HCT-CI ≥ 3 were separated in single group and in this group (17
pts) most benefit for OS had patients treated only with supportive therapy:
P=0.043, RR=0.382, CI=0.131-1.115.
Summary and Conclusions: Elderly AML patients with cytopenia and comor-
bidities are not suitable for intensive CT. In these patients supportive care need
to be concidere as a choise of therapy because the intensive CT has a poor
influence on its OS.
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MYELOID SARCOMA: CLINICAL FEATURES AND OUTCOMES AFTER
INTENSIVE TREATMENT, TEN YEARS EXPERIENCE AT A SINGLE
CENTRE.
F. Pavesi1,* M.G. Carrabba1, C. Messina1, M. Ponzoni2, R. Milani3, P. Ronchi3,
L. Vago1, E. Sala1, B. Gentner1, M. Tassara3, S. Marktel1, M. Morelli1,
M.T. Lupo-Stanghellini1, J. Peccatori1, C. Corti1, F. Ciceri1, M. Bernardi1,
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2Pathology Unit, 3Immuno-hematology and Transfusion Medicine, IRCCS San
Raffaele Scientific Institute, Milan, Italy
Background: Myeloid Sarcoma (MS) is a rare neoplasm composed of imma-
ture myeloid cells potentially occurring in any extramedullary organ, most com-
monly in the lymph node and soft tissues. MS develops before, concurrently
or after the diagnosis of acute myeloid leukemia (AML), but can rarely occur
without bone marrow infiltration by leukemia. MS is associated with poor out-
come. The rarity of this presentation has been an obstacle to characterize its
clinical features and prognosis.
Aims: The aim of the study was to analyze characteristics, treatments and
overall survival of all patients presenting with MS.
Methods: We retrospectively reviewed medical record of patients who pre-
sented with MS to our institute from 2004 through 2015. In total 28 patients
with MS were identified.
Results: Thirteen patients had a MS at disease onset, 2 as primary sarcoma
and 11 associated with AML, 15 developed MS at relapse of AML, 9 patients
had only extramedullary relapse (EM), 6 also bone marrow involvement (table
1). The median age of patients at MS presentation was 45 years (range 22-
76). The most commonly involved site for patients with MS at disease onset
was abdomen (gastrointestinal tract and kidney.) Six out of 13 patients had
cytogenetic abnormalities involving chromosomes 8, 21, 16, Y; karyotype was
normal in 3/13 and complex in 2/13. Cytogenetic was not available in 2/13 cas-
es. Eleven out of 13 patients with MS at diagnosis received allogeneic stem
cells transplantation (alloSCT) as post-remission treatment and 2 patients were
treated with palliative chemotherapy due to old age. After a median follow-up
of 560 days (range 108-3715) 8/13 patients (61%) are alive and 6/13 (46%)
are disease free. Among the 15 patients who have developed a MS at AML
relapse the most frequent location was paravertebral (table 1) The median age
at presentation was 46 years (range 22-65). Seven out of 13 available cytoge-
netic analysis were normal, 5 complex and 1 was t(8;21) plus delY. The median
time from AML diagnosis to EM relapse was 657 days (range 308-2312) and
in 14/15 cases EM occurred after alloSCT, with a median time to relapse of
444 days (range 254-3195). Salvage treatment of these patients: 6 alloSCT, 3
immunotherapy, 4 chemotherapy, 2 palliative radiotherapy. At last follow up
three out of 15 patients (20%) are alive and in complete remission from AML
and MS (median follow-up was 350 days, range 39-1847).
Table 1. Sites of Myeloid Sarcoma.
Summary and Conclusions: With this study we provide a single institution
experience of MS management and outcome. Our Institution is a referral centre
for alloSCT thus explaining the high rate of alloSCT in this series. Our data
support alloSCT as part of first line treatment of MS after chemotherapy. EM
relapse of AML after first line therapy has a poor prognosis even after intensive
treatment. The high rate of EM relapse after alloSCT (14/15) suggests that MS
may represent a form of post alloSCT AML immune escape not necessary
related to sarcomatous presentation at onset. Larger multicenter studies are
needed to better and more fully assess outcomes of these patients.
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PRELIMINARY RESULTS OF ACUTE LEUKEMIA EPIDEMIOLOGICAL
ESTIMATIONS BASED ON CLINICAL REGISTIRY DATA IN RUSSIA
Z. Akhmerzaeva1,* S. Kulikov2, M. Rusinov2, L. Gavrilova3, E. Zotina4,
A. Pristupa5, N. Vopilina6, E. Borisenkova7, E. Parovichnikova8
1Acute leukemia department, 2Biostatistic department, National Research Cen-
ter For Hematology, Moscow, 3Hematological Department, Saransk Clinical
Hospital, Saransk, 4Hematological Department, Kirov Clinical Hospital, Kirov,
5Hematological Department, Ryazan’s Clinical Hospital, Ryazan, 6Hematolog-
ical department, Tambov regional clinical hospital, Tambov, 7Hematological
department, Kaluga regional clinical hospital, Kaluga, 8BMT department,
National Research Center For Hematology, Moscow, Russian Federation
Background: The incidence of acute leukemia (AL) in US and European coun-
tries is about 5 per 100000 according data from cancer registries. Russian
Federal Сancer Register reported AL incidence rate across the country as
about 3 per 100000. Russian Hematology Society in 2013 initiated the AL pop-
ulation based registry study in which participated 8 regions of Russia Federa-
tion. The primary goal was to pre-registry patients for clinical studies, and sec-
ondary-to evaluate the epidemiology of AL. 5 regions were included into analy-
sis of epidemiology statistics. The criteria were the fullness and reliability of AL
cases registration. Also, only regions with one big hematological center accu-
mulating all AL cases were chosen. All new cases were recorded on-line into
special Web based data capture system. 
Table 1.
Aims: To evaluate the age-gender specific incidence, profile and other epi-
demiologic characteristics AL in Russian regions. 
Methods: The registry was started at 1st April of 2013 and is ongoing. 
Results: 169 new ALL cases from Kirov, Ryazan, Kaluga, Tambov regions and
Mordovia republic (4,7 M of population) were included into analysis. The dis-
tribution by AL subtypes was following: AML-109 (74,6%), ALL - 31 (21,2%),
APL-5 (3,4%), other-1 (0,7%). Median age was for AML-59 (17-85), ALL - 38
(18-80), APL 54 (38-60) years. Gender female/male proportions in AML were
– 18/13, in ALL - 54/55, in APL - 4/1. 105 (62,5%) patients are alive; 58(34,5%)-
died, 5 (3%) were withdrawn. The incidence rate estimates by region are listed
in Table1. Two regions (Kirov region and Mordovia) with longest duration of
registration were taken for age specific incidence calculations. Incidence of AL
by age is following: in 15-19 age group – 0.90; in 20-39 age group – 1.13; in
40-59 age group – 2.45; in 60-79 age group – 3.54; in 80-99 age group – 2.18.
Total crude incidence in this two regions is 2.09, standardized by WHO popu-
lation – 1.87.
Summary and Conclusions: The first estimations of AL epidemiology in
selected Russian regions was made based on direct registration data from
hematological centers. The incidence rate estimations are less than expected.
Some explanations may be: incomplete registration of cases, under -diagnos-
tics of AL, non-admission of AL patients to hematological center.
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AML-PATIENTS FROM A SOCIALLY DISADVANTAGED ENVIRONMENT
SHOW POORER THERAPEUTIC OUTCOME
A. Kaifie1,* T. Lunau2, N. Dragano2, E. Jost1, T. H. Brummendorf1, S. Wilop1,
M. Crysandt1
1Department for Hematology, Oncology, Hemostaseology and SCT, Medical
Faculty, RWTH Aachen University, Aachen, 2Institute for Medical Sociology,
Medical Faculty, University of Dusseldorf, Dusseldorf, Germany
Background: The socioeconomic status (SES) is strongly associated with the
development and clinical course of several malignant and non-malignant dis-
eases. Only few studies examined the clinical outcome of AML patients in rela-
tion to indicators of the social environment at their area of residence, showing
divergent country-specific results. So far, no evaluation of area level social dif-
ferences for survival in AML-patients has been conducted in Germany.
Aims: The aim of the study was to investigate if the social environment in the
area of residence is related to complete remission and overall survival of indi-
vidual AML-patients in the city of Aachen.
Methods: All patients who were treated with a confirmed diagnosis of AML
from 1996-2014 at the University Hospital in Aachen were assessed retrospec-
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tively (n=139). Clinical and prognostic parameters like age at diagnosis, sex,
cytogenetic risk group, primary or secondary AML, curative or palliative intention
of treatment were recorded. Patients were assigned to geographical areas
using administrative area codes. We classified the social status at the area of
residence using area-specific socioeconomic indicators (e.g. proportion of
unemployed, crime rate). Based on this index we divided the sample into
patients living in high or medium SES areas and those living in low SES areas.
Survival analyses were performed using Kaplan-Meier estimator and Log-rank
test. Furthermore univariate and multivariate Cox-regression analyses were
conducted.
Results: First of all, the distribution of prognostic factors (age at diagnosis,
cytogenetic risk group, therapeutic intention) was assessed for the two social
environments. No significant differences were detected. Survival analyses for
all patients and defined subgroups (stratified by age and therapeutic intention)
were performed. Younger patients (≤65 years) who received induction therapy
with a curative intention showed a significant difference in overall survival
(P=0.0084) between the two social spaces (Figure 1).
Figure 1.
In the assessment of the clinical course, patients from a social disadvantaged
environment reached significantly less often a complete remission (23.1% vs.
12%, P=0.0039).
Summary and Conclusions: Similar to several solid tumors the socioeconomic
environment in the area of residence was significantly related to the clinical
course in younger patients with AML. A detailed evaluation of the underlying
mechanisms is needed for the improvement of this unsatisfactory situation. As
these are findings from analyses not specified in advance confirmation with
independent data is needed.
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FAVORABLE EFFECT OF PRIMING WITH GEANULOCYTE
COLONY-STIMULATING FACTOR IN REMISSION INDUCTION OF
HYPOCELLULAR ACUTE MYLOID LEUKEMIA
N. Colovic1,* Y. Palibrk1, G. Jankovic1, M. Colovic1
1Internal medicine, Medical Faculty University Belgrade, Belgrade, Serbia
Background: The hypocellular variant of acute leukemia is very rare atypical
leukemia which mainly occurs in older patients. It ussually has a myeloid phe-
notype. Survey of Pub Med have shown that there are no guidelines in the
world literature for the treatment of such subtype of AML. The effect of G-CSF
priming has not been investigated as a key constituent of remission induction
chemotherapy in this cohort of patients. We point out the need for such contri-
bution of world centers to show the best way for good outcome of these rare
subtype of acute myloid leukemia.
Aims: The aim was to evaluate the results of treatment with different protocols.
Material and methods. We retrospectively analyzed all hypocellular acute
myeloid leukemias which were treated in ten years period, between january
1990 and december 2010 at the Clinic of Hematology, Clinical Center Belgrade.
All diagnostic criteria were met: pancytopenia with blasts in peripheral blood,
less than 20% of bone marrow cellularity and more than 20% of blastas in bone
marrow which were myeloperoxidase positive responding to myelod phenotype.
There were 30 patients, 18male 12female. The median age of the patients was
58,9 years (ranging from 32-76 years) and median cellularity of bone marrow
of this group of patients was 16%. Only one patient had myelodysplastic syn-
drome as antecedent disorder. No one of presented patients received prior
chemoradiotherapy for non-hematopoietic neoplasms.
Results:All patients at presentation had leucopenia ranging from 0.3-2.0 (with
SD 0.4). The distribution according to FAB Classification were as follows: 5
patients(pts) had M0 (16%), 11 pts M1 (36%), 6 M2 (20%), M4 1pts(3% ), M5a
2 pts( 6%) and M7 1 pts (3%) and 4 patients had unclassified acute myeloid
leukemia. The ECOG performance status was: 17 patients had favorable per-
formance status (1 PS was in 4 pts and 2 in 13 pts – 56,6%), status 3 in 8 (26,6
%) and 4 in 5 (1.3%). Sixteen patients had a normal diploid karyotype (or –Y in
one), in seven patients cytogenetic analyses were inadequate, in four patients
it was not done, in one 47XY, der(13)/46,XY, and another 46,XX, t(8;20) ad
finally 46,XX,add(9)(p24)[6]/46,XX[14] was found. AML M1 was the most com-
mon subtype. Followed by M2 and M5a. Twelve patients received priming with
G-CSF followed by standard 3+7 regimen, 5 patients GCSF plus small doses
of cytosine arabinoside, 8 patients only support and 5 patients hydoxiurea.
Thirteen patients (43%) achieved a complete remission, 11 treated with G-CSF
followed by standard induction chemotherapy and 2 patients treated with GCSF
and low doses of cytosine arabinoside. Disease free survival was from 4 months
to 72 months (median 14 months). On multivariate analysis overall survival,
remission duration and event free survival were comparable to other patients
with acute myeloid leukemia.
Summary and Conclusions: This report describes a cohort of patients with
hypocellular AML characterized by prominent cytopenias, older age, low bone
marrow cellularity, cytogenetic findings and distribution of morphologic subtypes
similar to normocellular AML. We found that patients treated with priming G-
CSF achieved the best CR rate and OS which were statistically significantly
longer(Log rank P<0.0001) (P<0.008) then the rest of the cohort patients.
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MOLECULAR ANALYSIS OF FUSION POINTS AND RELATIVE
EXPRESSION OF MEIS1, EVI1, HOXA5 AND FLT3 IN MLL-MLLT10
HARBORING AML PATIENTS
S. Burillo-Sanz1, R. Morales-Camacho2,M. T. Vargas2, T. Caballero-Velazquez2,
I. Perez de Soto2, A. Rodriguez3, E. Carrillo2, C. Prats-Martín2, R. Bernal2,
J. A. Perez-Simon2, *J. R. Garcia-Lozano1
1Inmunology, 2Hematology, HUV del Rocio, 3Hematology, HUV del Rocio y
HUV Macarena, Sevilla, Spain
Background: A frequently occurring chromosomal aberration in acute
myeloblastic leukemia (AML) is a translocation involving the mixed lineage
leukemia (MLL) gene at 11q23 with one of more than 70 partner genes
described to date. Although, in general, MLL rearrangements are related with
a poor outcome, there are great differences based only on the translocation
partner of MLL. Up to 15% of all MLL rearrangements in AML are due to MLLT10
fusions. MLL-rearrangements result in an upregulation of HOX transcription
factor genes. Moreover, EVI1 and MEIS1 upregulation are significantly asso-
ciated to a poor prognosis in AML and not all MLL-rearranged leukemia cases
overexpress these genes.
Aims: In this work we report on the molecular analysis and gene expression
profiling for MLL-MLLT10 AML. 
Methods: MLL gene fusion was detected by cytogenetics; FISH with LSI MLL
dual color, Break Apart probe, and WCP 10 and 11 probes; reverse transcription
PCR (RT-PCR) and sequencing. Gene expression was analyzed by real-time
PCR in a reaction with specific primers and SybrGreen. Relative quantification
was performed by 2-DDCt method. We include analysis of two MLL-MLLT10
harboring leukemias of the FAB-M5 subtype. Both patients obtain complete
remission (CR) with positive MRD and disease relapse 4 months after diagno-
sis. Patient 1 die 3 months after transplantation and second one is currently
receiving rescue chemotherapy.
Figure 1. Gene upregulation in MLL-MLLT10 harboring AML.
Results: Patient 1 cytogenetic analysis revealed 46,XY,del(10)(p12),add(11)
(q23)[20]. FISH analysis using MLL locus specific probe showed a 73% of an
uncertain pattern with two nearby split signals. Metaphase FISH with WCP con-
firmed that chromosome 10 material was present at 11q and that the chromo-
some 11 material had not been transferred elsewhere in the genome. Patient
2 presented a 46,XX[20], and the same MLL FISH pattern that patient 1. Molec-
ular analysis for the MLL-MLLT10 fusion demonstration was performed based
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on the presence of NG2 by flow cytometric analysis and a FISH pattern sug-
gesting a gene insertion in 11q23. The cDNA was used in multiplex PCR reac-
tions for detection of the MLL-MLLT10 fusion, and PCR product was
sequenced. In patient 1, a mRNA fusion between exon 7 of 5’ MLL mRNA and
exon 15 of 3’ MLLT10 mRNA was detected, with frame conservation and the
whole sequence of both exons (GenBank ID: KF778381). The breakpoint
described here is unusual in 10;11 rearrangements and the same fusion at
mRNA level was previously described in only one case. In the second case,
the same RT-PCR analysis revealed an mRNA fusion between exon 8 of 5’
MLL mRNA and exon 16 of 3’ MLLT10 mRNA. This MLL-MLLT10 fusion was
first described in patient C from Chaplin, et al. 1995. Gene expression analysis
showed overexpression of HOXA5, FLT3 and MEIS1 in both cases but EVI1
was only overexpressed in patient 1.
Summary and Conclusions: Molecular studies are required for MLL-MLLT10
detection in cryptic rearrangements and, as illustrated in this work, for the iden-
tification of new MLL-MLLT10 fusion points. Gene expression analysis shows
overexpression of MEIS1 in both MLL-MLLT10 patients, previously related to
poor outcome, and EVI1 only in patient 1.
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PREVALENCE AND PROGNOSTIC IMPACT OF IDH1 AND IDH2
MUTATIONS AMONG CYTOGENETICALLY NORMAL AML EGYPTIAN
PATIENTS 
S. Aref1, M. El-Ghonemy1, M. El Baiomy2,*
1Hematology Unit, Clinical pathology Department, 2Medical Oncology and
Hematology Unit, Oncology Center Mansoura University, Mansoura, Egypt
Background: Acute myeloid leukemia (AML) is a clonal malignant disease of
haematopoietic tissue caused by somatic mutations in genes that control nor-
mal cell proliferation and differentiation.The molecular genetic alterations is
one of the most important prognostic factors that have been identified in AML
and the role of this genetic alterations has been emphasized by the 2008
revised WHO classification of AML like FLT3, NPM1, and CEBPA. The isocitrate
dehydrogenases (IDHs) are enzymes that catalyze oxidative decarboxylation
of isocitrate into ketoglutarate by using NAD or NADP as a cofactor to yield
NADH or NADPH, respectively.
Aims: This study aimed to evaluate the clinical impact and prognostic relevance
of IDH1 and IDH2 mutations among cytogenetically normal AML patients.
Methods: Two hundred and eleven patients were assessed for the presence
of IDH1 and IDH2 mutations by sequencing.
Results: IDH1 mutation was detected in 18 out of 211 AML patients (8.5%)
and IDH2 mutation was detected in 22 out of 211 AML patients (10.4%). The
IDH1 mutant cases were more older age, female, with high platelet count (P
0.01), high bone marrow blast cells count (P 0.002) and the NPM1 mutation
was more common in wild versusmutated groups (81.1% vs 18.9% respectively
with P<0.001). The IDH2 mutation was more common in older age, normal
karyotyping (P 0.001), with low WBCs count (P 0.003) and high platelets count
(P<0.001). The induction of remission rate wasn’t significantly associated with
neither IDH1 nor IDH2 mutation status. Patients with mutant IDH1 showed
poor OS versus patients with wild type (6 vs 9 months respectively; P 0.07),
however there was no statistically significant relation between IDH2 mutation
and OS. In this study, there was 24 patients with CN-AML patients (ie: NPM1
mutation and without FLT3 mutation), IDH1 mutation in this group showed sig-
nificantly shorter overall survival versus patients with IDH1 wild (5 vs 13 months
respectively; P 0.02).
Summary and Conclusions: IDH1 and IDH2 mutations occur in 8.5% and
10.4% respectively in AML patients which is a minor subset of the newly diag-
nosed cases and these mutations have an association with molecular and cyto-
genetic status. We recommend molecular testing for IDH1 and IDH2 mutations
to confirm the role of these mutations as novel genetic markers in risk stratifi-
cation of AML patients in a larger study.
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ACUTE ANTHRACYCLINE CARDIOTOXICITY IN ACUTE MYELOID
LEUKEMIA DURING INDUCTION CHEMOTHERAPY: ROLE OF
ECHOCARDIOGRAPHY
M. Aggarwal1,* P. Mishra1, A. Saxena2, S. Gupta2, S. Tyagi1
1Hematology, 2Cardiology, All India Institute Of Medical Sciences, New Delhi,
India, New Delhi, India
Background:Anthracyclines are used in induction treatment of acute myeloid
leukemia. However, they cause dose-dependent cardiac dysfunction through
generation of reactive oxygen species, mediated by topoisomerase -IIb in car-
diomyocytes and forming complexes with intracellular iron, leading to lipid per-
oxidation and DNA damage. Due to low potential for regeneration in cardiac
myocytes, these changes are likely irreversible. Early detection of cardiotoxicity
is important before changes become clinically overt. Left ventricular ejection
fraction (LVEF) has been the main indicator of cardiac dysfunction but impair-
ment in LVEF is detected only after considerable myocyte loss has occurred.
So, more sensitive tools to detect these alterations are warranted.
Aims: To study acute cardiac toxicity of anthracycline in acute myeloid leukemia
(AML) patients by serial echocardiographic parameters during induction
chemotherapy. 
Methods: The prospective study included newly diagnosed AML patients.
Patients with history of previous anthracycline exposure were excluded. AML
induction therapy consisted of daunorubicin 60 mg/m2/day for 3 days and
cytarabine 100 mg/m2/day for 7 days. All patients were assessed by echocar-
diography at start and end of induction chemotherapy and after 3 days of
daunorubicin. Parameters on M mode, Doppler and tissue Dopper modes at
mitral valve (lateral) and septum were recorded.
Table 1.
Results: A total of 32 patients of AML were enrolled with median age of 21
years (range 7-57 years) and 18 males (56.2%). Median leucocyte count was
6300/uL (range 300-380,000). 16 patients (50%) had fungal infection during
induction and 14 patients expired (44%). Cardiac chamber dimensions were
not altered during induction. Doppler parameters: E velocity decreased in AML
patients (P value 0.023). A velocity did not changed significantly. E/Ashowed
overall decreasing trend (P value 0.09). Tissue Doppler parameters: Em lateral
decreased (P value 0.005) in AML patients. Em septal decreased from baseline
to post chemotherapy echo (P value 0.04). Am lateral dropped from baseline
to post chemotherapy echo in AML patients (P value 0.001). Sm lateral and
septal were not altered significantly. Isovolumetric contraction time was signif-
icantly increased from baseline to post chemotherapy echo (P value 0.019).
Ejection fraction did not show significant changes during induction.
Summary and Conclusions: Significant changes occur in various Doppler
and tissue doppler parameters during induction chemotherapy reflecting under-
lying diastolic dysfunction due to anthracycline induced cardiotoxicity. Ejection
fraction is relatively insensitive tool to ascertain these early changes. It is sug-
gested that these patients be followed up with repeated ECHO to find improve-
ment or worsening of these changes before any overt clinical symptoms due
to heart failure develop. Early interventions can be planned before overt heart
failure in consultation with cardiologists especially while planning treatment for
patients with relapsed disease or transplantation.
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ELLIPTICINES DRIVE LEUKAEMIA CELL DEATH VIA MITOCHONDRIAL
ROS
e.g. Russell1,* E.C. O’Sullivan2, F.O. McCarthy2, T.G. Cotter1
1School of Biochemistry and Cell Biology, 2Department of Chemistry, University
College Cork, Cork, Ireland
Background: Ellipticine is an anticancer agent which induces cell death by
multiple mechanisms of action1. Unfortunately, this compound and its ana-
logues have limited solubility and have been associated with several toxic
effects which has hampered their clinical development. A panel of novel ellip-
ticine isomers was designed and synthesised with the aim of evaluating their
cytotoxic effects2. A preliminary NCI 60-cell screen demonstrated that these
compounds display promising anti-tumour activity across a number of different
cancer cell types, particularly leukaemia cell lines. 
Aims: We examined the effect of these derivatives in detail on the acute
myeloid leukaemia (AML) cell line, MV4-11. The most cytotoxic compound, 7-
formyl-10-methylisoellipticine was identified from this panel. The mechanism
by which this compound induces its cytotoxic effects was investigated.
Methods: Cell cycle was monitored by flow cytometry. Cell number and viability
was measured by dye exclusion. Confocal microscopy was used to visualise
compound accumulation. Protein levels were evaluated by Western blotting.
Reactive oxygen species (ROS) levels were measured by flow cytometry using
the ROS probes dihydroethidium and MitoSOX.
Results: Cell cycle analyses revealed that the compounds had a range of dis-
tinctive cell cycle effects3. 7-formyl-10-methylisoellipticine showed the most
promise with respect to cytotoxic activity. We demonstrated that this compound
killed cells by apoptosis which is mediated by an induction of reactive oxygen
species (ROS). In a cell, mitochondria and NAPDH oxidase (NOX) are the
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major sources of ROS. Previous research in our laboratory has shown that
NOX derived ROS is critical for cell survival4. ROS inhibitors were employed
to reveal the origin of the ROS. Our study suggests that the compound gener-
ates ROS in mitochondria which ultimately leads to its cytotoxic effect. Inter-
estingly synergistic effects are seen when 7-formyl-10-methylisoellipticine is
used in combination with a NOX inhibitor as well as the clinically used AML
chemotherapeutic, daunorubicin. 
Summary and Conclusions: This study provides detailed cellular information
on the potential use of isoellipticines as chemotherapeutic agents. By probing
the mechanism of action of this novel compound class we have uncovered a
potential clinical application in the field of adjuvant therapy. We are currently
investigating the effects of the compound in a pre-clinical AML mouse model.
References
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TREATMENT OUTCOME OF CHILDREN WITH DE NOVO AML GROUPED
BASED ON RISK FEATURES AND TREATMENT RESPONSE
K.H. Yoo1,* Y.B. Choi1, K.W. Sung1, H.H. Koo1, J.W. Lee2, N.G. Chung2, B. Cho2,
H.K. Kim2, H.J. Baek3, H. Kook3
1Pediatrics, Samsung Medical Center, SUNGKYUNKWAN University School
of Medicine, 2Pediatrics, The Catholic University of Korea College of Medicine,
Seoul, 3Pediatrics, Chonnam National University Hwasun Hospital, Gwangju,
Korea, Republic Of
Background: Approximately 80-100 children are newly diagnosed as AML in
Korea. The survival rate of pediatric AML has improved due to intensified well-
designed chemotherapy, better supportive care, risk-based treatment adapta-
tion and allogeneic HSCT. However, relapse still remains the leading cause of
events, which accounts for 30 to 40%. Because pediatric AML is a heteroge-
neous disease and only some subgroup of patients benefits from allogeneic
transplantation in 1st CR, risk-adapted treatment strategy is needed.
Aims: This multicenter pilot study was aimed to evaluate the feasibility of new
treatment protocol based on risk stratification for newly diagnosed pediatric de
novo acute myeloid leukemia (AML).
Methods: Patients with acute promyelocytic leukemia and AML of Down syn-
drome were excluded. Risk features were defined as follows: 1) low risk features
(LRF): inv(16)/t(16;16), t(8;21) without c-kit mutation, or with normal karyotype
in the presence of NPM1 or CEBPA mutation without FLT3/ITD mutation; 2) high
risk features (HRF): -5, 5q-, -7, 3q abnormalities, t(8;16), t(6;9), t(16;21), t(6;11),
t(10;11), AMKL without t(1;22), complex karyotype, or FLT3/ITD mutation; 3)
standard risk features (SRF): all the others. A new chemotherapy regimen was
developed which consisted of 2 induction and 4 consolidation cycles. Treatment
responses were determined according to the marrow response at the end of
each induction as good response (CR-CR), delayed response-1 (PR [blast
5~15%]-CR), delayed response-2 (NR [blast>15%]-CR), refractory (PR/NR-
PR/NR), and early relapse. Patients were allocated into either favorable (FG),
intermediate (IG), or poor (PG) prognostic group considering both risk features
and treatment response. Patients in FG were not allocated to transplantation.
Results: Fifty-seven patients were enrolled. There were 13 patients (22.8%)
with LRF, 22 (38.6%) with SRF, and 22 (38.6%) with HRF. The overall CR rate
following 2 cycles of induction was 87.5%. One patient (1.8%) died during
induction therapy. Eight patients relapsed of whom 6 were in PG, 1 in IG, and
1 in FG. Twenty-three patients underwent allo-HSCT. With a median follow-up
of 13 mo, the estimated 2-y overall survival and event-free survival of all patients
were 91% and 71%, respectively.
Summary and Conclusions: Although follow-up duration is short, our new
treatment protocol based on risk stratification seems effective.
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PROGNOSTIC SIGNIFICANCE OF INTRACELLULAR SURVIVIN IN
MYELOID BLAST CELLS AS AN INHIBITOR OF APOPTOSIS IN EGYPTIAN
ADULT ACUTE MYELOID LEUKEMIA (AML) PATIENTS
M.O. Azzazi1,* M. Mattar2, S. Ezz El-Arab1, H. Hegab1, R. Ibrahim1,
W. Elsalakawy1, N.N. mostafa1, M. Shazly1
1hematology and BMT., Ain Shams University, 2hematology and BMT., Cairo
University, Cairo, Egypt
Background: The balance between cell death and cell viability is important in
tissue homeostasis. Abnormalities in the control of apoptosis play an important
role in tumorigenesis (Altieri Cancer 2013). Survivin is one of eight members of
the inhibitor of apoptosis protein family (IAP) that, regulates, integrates cell divi-
sion and suppresses apoptosis. Over expression of several IAPs has been
detected in various hematological malignancies, including acute leukemias,
myelodysplastic syndrome, chronic myeloid leukemia, and many types of lym-
phoid malignancies, such as chronic lymphocytic leukemia and diffuse large B-
cell lymphoma. Many publications revealed significant correlation between a
high level of IAPs, especially of XIAP and survivin, and tumor progression con-
tributing to leukemogenesis due to deregulated apoptosis. The expression of
survivin may be a general feature of cancer and alone or with other antiapoptosis
genes such as Bcl-2, survivin may extend the viability of transformed cells and
regulate their susceptibility / resistance to apoptosis-based therapy. For this rea-
son survivin may provide an ideal therapeutic target for its selective expression
in neoplasia. Survivin shuttles between the nucleus and the cytoplasm, it effec-
tively inhibits apoptosis, by binding to second mitochondrial activator of cas-
pase.Expressed during embryonic development and by many cancer cell
types,but not in the differentiated normal tissue,survivin is implicated in control
of cell survival and regulation of mitosis in cancer(Coumar et al. Cancer 0013).
Aims: To assess expression of survivin in Egyptian AML patients, and its cor-
relation to outcome, impact on progression, and survival.
Methods: 120 adult Egyptian patients with AML (52 females and 68 males)
were recruited and followed up for 2 years, (mean age:42.1±13.1years), 16
patients had AML-M0, 32 AML- M1,32 AML- M2, 12 AML- M3, 16 AML -M4 and
12 AML-M5 (FAB classification ). A control group of 60 age and sex matched
normal healthy volunteers was included.All enrolled patients were treated
according to our unit ongoing induction and consolidation regimens(NCCN
guidelines). Patients were followed up for two year and outcome was designat-
ed as either favorable or unfavorable.Detection of intracellular Survivin antigen
in myeloid blast cells was done by flow cytometry on bone marrow samples at
D0, D28 and then every 6 month (Kim et al Ann Lab Med 2013).
Figure 1. 
Results: Survivin expression was higher in AML patients at D0 and D28 com-
pared to healthy controls (P=0.001),highest survivin level were seen in AML
M5 (FAB subtypes) followed by AML M4,then by AML M1, AML M0, AML M3
and AML M2 subtype. A statistically significant positive correlation was found
between age of patient at diagnosis and Survivin expression, also between
survivin level at D0 and at D28 among responders patients (P=0.001), also
between D0-survivin level of AML patients with favorable response compared
to patients with unfavorable response (P=0.005), survivin expression positively
correlated with CD15, CD14 and CD11c expression. No statistically significant
correlations were found between survivin expression and sex, or with results
of cytogenetic studies,nor with AML FAB subtypes. There was statistically sig-
nificant negative correlation between survivin level and with Complete remission
(CR),overall survival (OS) Figure -1. EFS, and PFS. CR and post induction
response to chemotherapy occured in patients with negative survivin expression
more than in patients with positive survivin expression (P=0.005),and after 2
year follow up patients with positive survivin expression relapsed more
(P=0.015). 
Summary and Conclusions: Survivin is important factors involved in control
of apoptosis in malignant cells. Survivin expression was found to be higher in
elderly AML patients compared to younger patients group, A statistically signif-
icant negative correlation was detected between survivin level at D0 and
CR,OS,EFS, and PFS. Being preferentially and highly expressed in cancer
cells, with little expression in normal tissues,makes it an attractive therapeutic
target to inhibit cancer growth by inhibiting extrinsic and intrinsic apoptotic path-
ways and confers resistance to apoptosis by directly suppressing caspase
activity.
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EVALUATION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID
LEUKEMIA WITH NPM1 MARKER
N. Alizadghandforoush1,* F. Nadali2, S. Rostami1, B. Chahardouli1, H. Ghadimi1,
A. Ghasemi1, K. Alimoghaddam1, A. Ghavamzadeh1
1Hematology, Oncology, and Stem Cell Transplantation Research Center,
Tehran University of Medical Sciences, 2 Hematology, School of Allied Medical
Sciences, Tehran university of Medical Sciences, Tehran, Iran
Background: Minimal residual disease (MRD) tests provide early identification
of hematologic relapse and timely management of acute myeloid
leukemia(AML)patients. Approximately 50% of AML patients do not have clonal
chromosomal aberrations and categorize as a cytogenetically normal acute
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myeloid leukemia (CN-AML). Molecular markers are useful in the dissection of
this heterogeneous group of AML patients into prognostically different sub-
groups. About 60% of adult CN-AML have a mutationin exon 12 of the NPM1
gene. This mutation is specific for malignant clone and potentially is a good
marker of MRD. 
Aims: In this retrospective study, we set up a NPM1quantitative test and then
AML patients carrying NPM1mut were followed up for MRD monitoring.
Methods: In this study, we prepared plasmids containing a cDNA fragment of
the NPM1 and ABL genes by PCR cloning. ABL served as a control to compen-
sate for variations in the quality of the RNA and for differences in the efficiency
of the reverse transcription reaction the plasmids were used to construct stan-
dard curves quantitation of each of the target and control genes. Eleven patients
were analyzed using established method. Serial PB /and or BM samples (71
samples ) were taken in1-3 month intervals (mean 1.5-month intervals) and
median follow up duration after chemotherapy was 11 months (5- 28.5 months).
Results: In this study, we developed RNA-based RQ-PCR to quantitation of
NPM1 mutation A with sensitivity of 10(-5). NPMmut transcript levels were
expressed as a percentage ratio of NPMmut to ABL transcripts. The percent of
NPMmut/ ABL level showed a range between 132 and 757 with a median of 383.5
in samples at diagnosis. The median NPMmut transcript level log reduction was 3
log.Relapse occurred in 45% of patients (5 cases), All cases at diagnosis demon-
strated the same mutation at relapse. In patients who experienced relapse, Log
reduction levels of NPM1 mRNA transcript after therapy were 4(2 patients),3(two
patients) and 1 log(1 patient). Totaly NPMmut level showed less than 5 log reduction
in all of them, Whereas this reduction was 5-6 log in other patients.
Summary and Conclusions: Despite the limitations of this study in terms of
sample size and duration of follow up, it showed the accuracy of set up for
detection of mutation and this marker has worth for following up at different
stages of disease. Because of high frequency, stability, specificity to abnormal
clone and high sensitivity, NPM1 is a suitable marker for monitoring of NPMc+
AML patients. 
PB1653
DECITABINE AS THE FIRST-LINE TREATMENT FOR ELDERLY PATIENTS
WITH ACUTE MYELOID LEUKEMIA; A SINGLE CENTER EXPERIENCE IN
KOREA
J. Lee1,* H. Park1, H. Cho1, J. Jang1, S. J. Kim1, Y. Kim1, J.S. Kim1,
J.W. Cheong1, Y.H. Min1
1Internal Medicine, Yonsei University College of Medicine, Seoul, Korea,
Republic Of
Background: Decitabine, a DNA hypomethylating agent, was approved by the
European Union for the treatment of elderly patients with acute myeloid
leukemia (AML) who are not candidates for standard induction chemotherapy
in 2012, but the role of decitabine for remission induction is still controversial.
Recently, Korean Food and Drug Administration also approved decitabine as
the first-line treatment for as same indication as of EU. 
Aims: Through this study, we want to share our recent experience of decitabine
for the treatment of elderly AML patients.
Methods:Among patients who were diagnosed with AML except acute promye-
locytic leukemia from Jan. 2014 at Severance hospital in Korea, 16 patients
treated with decitabine as the first-line therapy for remission induction were
evaluated retrospectively. All patients were treated with at least one course of
decitaibine at an initial dose of 20 mg/m2 intravenously daily for 5 days in 28-
day cycles. Patients showing complete response (CR) or partial response (PR)
could continue to decitabine therapy, and those showing no response (NR) or
loss of response (LOR) could be considered treatment failure and received
second-line treatment. 
Results: The median age of total patients was 73.5 (range, 68-82) years, with
9 patients 65–74 years and 7 over 75 years. Cytogenetic risk assignment based
on the National Comprehensive Cancer Network criteria was favorable in 3
patients (18.8%), normal karyotype or other intermediate-risk in 11 (68.8%),
poor-risk in 1 (6.3%) and unknown in one. The median follow-up duration after
diagnosis was 138 (range, 39-310) days. Median and mean number of cycle
was 3 and 3.75 (range, 1-8), respectively, and 2 patients received total 8 cycles.
Fifteen (93.8%) patients completed the second cycle, and 9 were evaluated for
response. CR was achieved in 2 patients (22.2%) after the second cycle and in
additional 2 patients after the fourth cycle, for an overall response rate (ORR)
of 33.3%. LOR was shown in 2 patients. Eight patients discontinued decitabine
treatment due to NR or LOS in 5 (62.5%) and side effects in 3 (37.5%). Grade
3-4 febrile neutropenia was developed in 7 (43.8%), grade 2-3 fatigues in 3
(18.8%), and grade 3-4 heart failure in 1 (6.25%). The estimated median overall
survival (OS) was 302 (95% CI, 83.5-520.5) days. The pretreatment character-
istics that differed significantly between responders and non-responders was
age (P=0.042) and serum ferritin level (P=0.016). Age and serum ferritin level
were younger and lower in responder than in non-responder.
Summary and Conclusions: In our experience, 5-day decitabine treatment
has efficacy in elderly patients with AML considered unfit for conventional
chemotherapy with 33.3% of CR rate and 10 months of median OS. Further
study will be objected to discover good clinical determinants and biomarker to
select patients who may drive greater benefit from decitabine.
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THE EFFECT OF SERUM IRON TESTS AND IRON OVERLOAD ON
TRANSPLANTATION-RELATED COMPLICATIONS AND PROGNOSIS IN
ACUTE LEUKEMIA 
U.Y. Malkan1, G. Gunes1, H. Demiroglu1,* H. Goker1, I. Haznedaroglu1,
S. Etgul1, T. Aslan1,S. Balaban1,O. Ozcebe1,N. Sayinalp1,S. Aksu1,Y. Buyukasik1
1Department of Internal Medicine, Division of Hematology, Hacettepe Univer-
sity, School of Medicine, Ankara, Turkey
Background: Many studies have investigated impacts of serum iron parameters
and/or radiological evidence of systemic iron overload on stem cell transplantation
in acute leukemia.Some of them aimed to discover if iron overload might have
any detrimental effect on the transplantation. On the other hand some other stud-
ies were interested in negative prognostic sign of hyperferritinemia irrespective
of body iron status. Unfortunately, some of the studies evaluating iron overload
in transplant setting did not precisely show the patients with iron overload, mainly
due to inadequacy of radiological methods in relatively mild hemosiderosis and
ignoring consideration of transferrin saturation along with hyperferritinemia for
elimination of non-iron overload etiologies of hyperferritinemia.
Aims: Herein, we aimed to investigate the the effect of serum iron tests and
iron overload on transplantation related complications and prognosis in acute
leukemia with adequate methodology.
Methods: Patients who undergone allogeneic stem cell transplantation for
acute leukemia in Hacettepe University Medical School Department of Hema-
tology were screened retrospectively in order to find cases with serum iron
tests within 9 months before transplant. Serum iron (SI), total iron binding
capacity (TIBC) and ferritin levels had been measured. Transferrin saturation
was calculated by dividing serum iron level to TIBC.
Results: There were 84 patients suitable for inclusion. Important baseline char-
acteristics and rates of the endpoints are presented in Figure 1. When various
ferritin plus TS cut-off values presented in Table 1 were investigated for a possible
relationship with major transplant results only ferritin>2000 + TS>45% was found
to have an association with VOD at borderline significance (P=0.067) (Table 1).
Table 1. The relationship between iron overload and major transplant
results
                              Ferritin >2000 and TS >45%P value
                           Yes                                       No                                     
aGVHD                    2                                          12                                 0.410
cGVHD                    3                                          11                                 0.813
VOD                        2                                          12                                 0,067
OS                   69.6±12.5                             69.5±7.3                            0,603
DFS                 61.5±13.4                             62.5±7.2                            0.729
Table 2. Baseline characteristics and rates of the endpints.
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Summary and Conclusions: There are many studies reporting about the
impact of iron overload on stem cell transplantation. Unfortunately only ferritin
level was used to detect iron overload in these studies. There are many condi-
tions associated with increased serum ferritin level (eg. Inflammation, infection,
macrophage activation, liver injury, etc...) Therefore an increased ferritin level
should not be considered as iron overload by itself. The laboratory sign of iron
overload is ferritin elevation in the presence of an increased transferring satu-
ration.Iron overload was investigated by radiological tests in some studies.
Although this method is an optimal one in apparent iron overload, it might miss
iron overload in early stages. There are some studies which investigated the
association between iron overload and post-transplant prognosis using an
acceptable method to define iron overload. Some of them found a relationship
between iron overload and post-transplant survival. On the other hand some
others did not. Interestingly the relationship between iron overload and VOD,
probably the most expected specific transplant complication in patients with
liver injury, was not reported in any of these studies considered to have ade-
quate methodologies for detection of iron overload. In conclusion, we observed
a possible relationship between iron overload and post-transplant venoocclusive
disease. We did not confirm other post-transplant complications reported in the
literature. It must be noticed that although many studies intended to investigate
the relationship between iron status and transplant outcomes, only a few of
them really looked for the effect of iron overload.
Aggressive Non-Hodgkin lymphoma - Clinical
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IS THERE A PLACE FOR TOTAL TUMOR RESECTION OF PRIMARY
CENTRAL NERVOUS SYSTEM LYMPHOMA IN PATIENTS WITH GOOD
PERFORMANCE STATUS?
J. Jelicic1,* M. Todorovic1, D. Antic1, J. Bila1, B. Andjelic1, V. Djurasinovic1,
A. Sretenovic1, V. Vukovic1, M. Smiljanic1, B. Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, Bel-
grade, Serbia
Background: The outcome of the patients with primary diffuse large B cell
lymphoma of central nervous system (PCNSL) still remains poor. The prog-
nostic value of available prognostic scores need to be validated as well as the
surgical approach since the improvements made in the field of neurosurgery.
Aims: The aim of this study was to evaluate treatment approach and the validity
of the International Extranodal Lymphoma Study Group (IELSG) score of the
patients with PCNSL.
Methods: This study involves 30 patients (13 males/17females) with a median
age of 53.5 years (range 29-72 years). The patients presented usually with
more than two different symptoms which mostly reflected tumor location, and
were as following: headache (13 patients), hemiparesis (13 patients), neu-
ropsychiatric (11 patients), dysarthria (8 patients), nausea and vomiting (5
patients), visual symptoms and vertigo (5 patients), and other symptoms occa-
sionally. Five patients (16.7%) had B symptoms, 5 patients (16.7%) had bone
marrow infiltration and 13 patients (43.3%) had deep tumor location. According
to the Eastern Cooperative Group performance status (ECOG), 9 patients
(30%) had ECOG 1–2 and 21 patients (70%) had ECOG 3–4. Regarding the
International Prognostic Index (IPI), low score was present in 44.4% of patients,
low intermediate in 26%, high-intermediate in 22.2% and 7.4% of patients had
high IPI score. The prevalence of the IELSG score was as following: low score
had 17.4% of patients, intermediate had 65.2% and 17.4% had high IELSG
score. Treatment options included total tumor resection in 13 patients (43.3%),
partial tumor resection in 10 patients (33.3%) and biopsy only in 7 patients
(23.3%). A customized de Angelis protocol based on high doze methotrexate
with/without whole brain irradiation was applied in all patients.
Results: The median overall survival (OS) was 41 months. Median event free
survival was 36 months. Overall treatment response was achieved in 22
patients (73.4%), 8 patients (26.6%) had primary resistant disease with lethal
outcome within 5 months. Statistical analyzes showed that the patients with
ECOG≥3 had worst prognosis than the patients with ECOG 1–2 (Log Rank
χ211.722, p˂0.01). Median OS in the group of patients with ECOG 1-2 was 62
months and 23 months in the group of patients with ECOG 3-4 (95% CI 3.118-
42.882). The IPI didn`t show prognostic significance in the patients with PCNSL
(Log Rank χ2 0.274, P=0.601), however the IELSG score significantly predicted
survival in these patients (Log Rank χ2 12.755, P˂0.01). The patients who
underwent an open surgery with total tumor reduction had significantly longer
OS (median 62 months) in comparison to the patients who had partial tumor
reduction or biopsy only (Log Rank χ2 5.692, P=0.017) and whose median OS
was 23 months (95% CI 1.634-44.366).
Summary and Conclusions: Despite that total tumor resection is not standard
procedure in the patients with PCNSL, according to our data, it should be con-
sidered in patients with good performance status and surgically accessible





UNRECOGNIZED RENAL INSUFFICIENCY AMONG NON-HODGKIN
LYMPHOMA PATIENTS TREATED WITH R-CHOP: EVALUATION OF
PREVALENCE, CHARACTERISTICS AND EFFECT ON REGIMEN
RELATED TOXICITY
A. Leader1,2,3,* S. Kaptzon2, M. Maor2, G. Itchaki1,3, O. Cohen2, L. Vidal1,3,
A. Gafter Gvili1,3, E. Joffe1,3, M. Lishner2,3
1Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin
Medical Center, Petah Tikva, 2Department of Medicine A, Meir Medical Center,
Kfar Saba, 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background: Estimated glomerular filtration rate (eGFR) is more accurate
than serum creatinine (SCR) in assessing renal function. The IRMA study
demonstrated a 50% prevalence of decreased eGFR despite normal SCR,
coined as “unrecognized renal insufficiency (RI)”, among patients with solid
malignancies. Unrecognized RI potentially may have an impact on treatment
toxicity. In a recent study, breast cancer patients with unrecognized RI receiving
cyclophosphamide and doxorubicin had an adjusted OR of 3.56 for regimen-
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related toxicity. However, little is known regarding its prevalence and clinical
implications in hematologic malignancies.
Aims: To determine the prevalence of unrecognized RI and its association with
treatment toxicity in non-Hodgkin lymphoma (NHL) patients treated with ritux-
imab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).
Methods: Patients ≥ 18 years with normal pre-treatment SCR (<1.3 mg/dl)
and NHL treated with R-CHOP every 21 days at our institute’s hemato-oncology
unit (1/1/2005 – 31/8/2013) were included in this retrospective cohort. Patients
who had previous chemotherapy or total bilirubin ≥ 3mg/dl were excluded. The
eGFR was calculated from pre-treatment SCR, using Cockcroft-Gault (primary
analysis), aMDRD and CKD-EPI equations. Joint primary outcomes were neu-
tropenic fever and premature treatment termination, while dose reduction after
cycle 1 (>20%), dose delay (≥7 days), any hospital admission and death, were
secondary outcomes. Rates of treatment toxicities were compared between
eGFR groups as defined by NKF-KDOQI and KDIGO guidelines, using
Kendall’s Tau.
Table 1. Baseline characteristics of study partecipants with a comparison
between e GFR groups (based on Cockcroft Gault formula).
Results: 94 patients fulfilled the study criteria, reaching the planned sample
size. Seventy percent had unrecognized RI distributed evenly among CKD
stage 2 and 3. CHOP dose reduction ≥10% from cycle 1 was associated with
lower eGFR groups (57% of patients with CKD3 vs 7% in CKD1), as was lower
BMI. These were the only statistically significant differences in patient charac-
teristics between CKD stages (Table 1). Patients with CKD 3 were older than
patients in CKD 2 and CKD 1, although the difference was not statistically sig-
nificant (P=0.134). There was no difference in rates of neutropenic fever (overall
29.8%, P=0.68) or other regimen-related toxicities between eGFR groups. Pre-
mature treatment discontinuation was most frequent in the lowest eGFR group
(P=0.03) in univariate analysis using Cockcroft Gault equation (but not with
aMDRD OR EPI_CKD), but lost statistical significance after multivariate analy-
sis. Thirty percent of patients had baseline dose reductions ≥ 10%. They were
older (P<0.001) and with a lower eGFR (70% vs 22.7% CKD3, P<0.001), but
had similar outcomes.
Summary and Conclusions: Most NHL patients treated with R-CHOP have
unrecognized RI. The absence of an association between eGFR and treatment
toxicity among these patients is in contrast to findings from solid malignancies.
This may indicate that relatively subtle changes in renal excretion of cyclophos-
phamide do not carry clinical significance in this potent multidrug regimen. This
could also be a false negative result, reflecting the much more common pre-
planned dose reductions in older patients with lower eGFR. Thus, in this pop-
ulation, unrecognized RI is common and had no effect on treatment toxicity
when chemotherapy doses were reduced in older patients with lower eGFR,
at the hematologist’s discretion. Further research is needed to determine
whether lower eGFR is indeed associated with treatment toxicity in a large
cohort of older patients receiving full R-CHOP dose intensity, or whether it is
merely a marker of older and frailer NHL patients with normal SCR.
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OCCURRENCE OF DERMOPATHY BY TREATMENT WITH ANTI-CCR4
ANTIBODIES FOR ADULT T-CELL LEUKEMIA
G. Eguchi1,* S.I. Kawaguchi1, A. Konishi1, K. Yamamoto1, T. Yamaguchi1,
Y. Maeda1
1Hematology, National Hospital Organization Osaka Minami Medical Center,
Kawachinagano, Japan
Background: Human T-cell leukemia virus type I (HTLV-I) is a human retrovirus
that is an etiologic agent of adult T-cell leukemia/lymphoma (ATL/ATLL). The
poor outcome of adult ATL is mainly because of an intrinsic resistance of the
leukemic cells to conventional or high doses of chemotherapy and severe
immunosuppression. The CC-chemokine receptor 4 (CCR4) is expressed in
almost ATLL cells. Thus, anti-CCR4 antibodies can be used as a treatment
strategy for ATLL. Mogamulizumab (MOG), which is a defucosylated anti-CCR4
monoclonal antibody, showed good results even in patients with recurrent ATLL
in phase I or II studies. MOG has strong antibody-dependent cellular cytotoxicity
(ADCC). The common adverse events in the phase II study were infusion reac-
tion and skin rashes. In our study, MOG inhibited the growth of ATL cells and
induced remission. CCR4 is expressed not only in ATL cells but also in non-
ATL regulatory T cells (Treg). After treatment with MOG, the population of Treg
decreased significantly, which boosted the antitumor activity. MOG treatment
was associated with the risk of viral infection as an opportunistic infection and
skin disturbance (dermopathy). 
Aims: In this study, we observed the effects of MOG as CCR4-specific ADCC
against CCR4-positive ATL cells. At the same time, frequency of opportunistic
viral infection including active CMV infection and severe skin disturbance (der-
mopathy) have been observed.
Methods: Patients were eligible for enrollment in the study if they were at least
18 years of age, had previously untreated ATL, and recorded a World Health
Organization (WHO) performance status (PS) of 0-3. Fourteen patients diag-
nosed with acute type ATL were selected for this study. In the present study,
we treated 14 patients with ATL who were resistant to chemotherapy using
MOG monotherapy. 
Results: All patients showed CR with a marked decrease in the number of
ATL cells. These results suggested that MOG was effective in chemotherapy-
resistant ATL patients. No rearrangement of TCRαβ gene was observed, which
indicated molecular CR. Skin disturbance (dermopathy) was found 9 cases of
14 ATL patients treated with MOG monotherapy. The skin rash spread through-
out her body with bulla and skin biopsy was performed, and diagnosed as
Stevens–Johnson syndrome (SJS)(Figure) in 2 patients of them. Administration
of steroid and intravenous immunoglobulin was performed, and SJS gradually
improved. Further, in other patients, grade 2 and 3 dermopathy was found,
and the patients were treated with glucocorticoid steroid. CMV infection was
detected using C7-HRP methods. CMV infection was diagnosed in 5 patients
of 14 MOG treated ATL patinets. One of the patients died because of severe
CMV infection despite of adequate treatment
Summary and Conclusions: Thus, physicians should be aware of CMV infec-
tion and development of immunocompromised condition after MOG monother-
apy. In that case, specific anti-CMV treatment for CMV reactivation should be
recommended. Moreover, We have to find out the skin rash as soon as possible
after treatment with MOG and it should be recommended quick administration
with glucocorticoid. Further study for the dermopathy should be considered.
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THE ROLE OF PROGNOSTIC AND COMORBIDITY INDEXES IN PATIENTS
WITH DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH
IMMUNOCHEMOTHERAPY
J. Jelicic1,* M. Todorovic1, D. Antic1, J. Bila1, B. Andjelic1, D. Stanisavljevic2,
V. Djurasinovic1, A. Sretenovic1, V. Vukovic1,M. Smiljanic1, I. Petkovic3, I. Vrbic3,
B. Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology,
2Department of statistics, Faculty of Medicine, Belgrade, 3Hospital of Knez
Selo, Clinical Center of Nis, Nis, Serbia
Background: The influence of comorbidities in patients with diffuse large B-
cell lymphoma (DLBCL) in the rituximab era has been modestly investigated.
Different comorbidity scoring systems are available for cancer patients.
Aims: In order to evaluate the impact of comorbidities on the overall survival
(OS) we have performed retrospective analyses of clinical records of the
patients with DLBCL treated with R-CHOP, R-EPOCH and R-CVP protocol.
The following comorbidity scores were used: Cumulative Illness Rating Scale
(CIRS), Charlson Comorbidity Index (CCI), age adjusted CCI (aaCCI) and
Hematopoietic-Cell-Transplantation Comorbidity Index (HCT-CI)
Methods: A total of 378 patients (195 female/183 male) were included in the
study. Median age was 58 years (range 18-80). Elderly population (70 years
and older) represented 20.2% of analyzed group. According to the Ann Arbor
classification, stage I, II, III and IV had 51patients (13.5%), 129 (34.1%), 72
(19%) and 129 (33.3%), respectively. Bulky disease was present in 88 patients
(23.3%) and B symptoms in 248 patients (65.6%). Regarding Eastern Coop-
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erative Group (ECOG) performance status (PS), 23.7% of patients had ECOG
PS ≥ 2. The most frequent extranodal localization were bone marrow (27.2%
of patients) and gastrointestinal tract (28.8% of patients). Revised International
Prognostic Index (R-IPI) was represented as low score in 70 patients (18.5%),
intermediate in 203 (53.7%) and high in 105 (27.8%). Approximately 55% of
patients didn`t have any comorbidity. Regarding comorbidity indexes (CI), CIRS
≥ 17 had 4% of patients (minimal score was 14), CCI ≥ 3 had 3.2%, aaCCI ≥ 5
had 34.1%, and HCT-CI ≥ 2 had 31.2% of patients. The patients were treated
with R-EPOCH protocol (13 patients, 34.4%), R-CVP (22 patients, 5.8%), and
R-CHOP (343 patients, 90.7%).
Results: Complete and partial remission were achieved in 334 (88.4%) of
patients and 44 patients (12.6%) had primary resistant disease. The prognostic
value of R-IPI was highly statistically significant (Log Rank χ2 53.569, P<0.01).
The patients with ECOG PS ≥ 2 had poorer outcome than the patients in good
PS (Log Rank χ2 33.075, P<0.01). In patients with CIRS ≥ 17 median OS was
30 months (95% CI 10.147-49.859) comparing to the patients with CIRS 14-16
whose median OS was not reached (Log Rank χ2 10.046, P<0.01). The patients
with CCI ≥ 3 had poorer outcome (median OS of 24 months, 95% CI 0.00-
50.877) than the patients with CCI 0-2 (Log Rank χ2 12.659, P<0.01). The
patients with HCT-CI≥2 had significantly poorer outcome than the patients with
low CI (Log Rank χ2 8.041, P<0.01). OS in patients with HCT-CI≥2 after 1, 2
and 5 years was 69%, 63% and 49% respectively, and 89%, 81% and 72% for
those with HCT-CI 0-1. The patients treated with R-CHOP and R-EPOCH pro-
tocol had statistically significant better OS than the patients treated with R-CVP
protocol (Log Rank χ2 8.754, P<0.01). Multivariant analysis (CIRS, CCI, aaCCI,
HCT-CI, therapeutic approach, R-IPI) revealed that the most predictable factor
for OS was R-IPI (P<0.0001).
Summary and Conclusions: Comorbidities are an independent prognostic
parameters for worse OS in patients with DLBCL treated with immunochemother-
apy. Omission of the antracyclines due to the frailty, older age or high comorbidity
score leads to significantly poorer outcome. Finally, in the rituximab era prognosis
is appreciably influenced with the value of initial R-IPI.
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THE COMBINATION OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE
(ICE) WITH OR WITHOUT RITUXIMAB IS SAFE AND EFFECTIVE SALVAGE
THERAPY FOR ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL
LYMPHOMA
N. Sarid1,* E. Joffe1, L. Gibstein1, I. Avivi1, A. Polliack1, C. Perry1, Y. Herishanu1
1Hematology, Tel Aviv Sourasky Medical Center, tel aviv, Israel
Background: Elderly patients are under-represented in clinical trials, especially
in studies evaluating intensive salvage combinations for relapsed or refractory
diffuse large B-cell lymphoma (DLBCL). Yet, the risk of developing non-hodgkin
lymphomas increases with age, with approximately 50% of patients are diag-
nosed above the age of 65 years. This leads to uncertainty regarding the risks
and benefits of these treatments, and can have a substantial impact on treat-
ment decisions.
Aims: To evaluate a 10-year single-center experience and results of therapy
using the ifosfamide, carboplatin and etoposide±rituximab (ICE±R) as a salvage
regimen in elderly patients with DLBCL. 
Methods: This a retrospective single-center study evaluating the efficacy and
tolerability of ICE±R regimen used for the treatment of elderly patients (>70
years) with relapsed or refractory DLBCL. The ICE±R regimen consisted of
etoposide (100 mg/m2) on day 1-3, carboplatin (dose=5x [25+creatinine clear-
ance], capped at 800mg) and ifosfamide (5000 mg/m2, mixed with an equal
dose of MESNA administrated by continuous infusion over 24 hours) on day
2±rituximab (375 mg/m2) given on day 0, as reported previously.
Data were collected from medical records. Adverse events (AEs) graded
according to the Common Terminology Criteria for Adverse Events version 4.0.
Disease response was defined according to the revised response criteria for
malignant lymphoma. Clinical endpoints were defined according FDA guidance.
The study was approved by the local institutional Helsinki ethics committee.
Results: Between October 2003 and June 2014, a total of 32 patients (21
women and 11 men) with DLBCL older than 70 years, were treated in our insti-
tute with the ICE±R regimen. Median age of the entire cohort was 75.6 years
(range 70.6-87.1). Most of the patients had an Ann Arbor stage IV disease
(56%, n=18), an intermediate-high to high sIPI (63%, n=20), a low Carlson
comorbidity index (0-1 in 81%, n=26), and an excellent ECOG score (0-1 in all
cases). In 27 patients (84%) the dosage of the chemotherapy was reduced,
with a median dose reduction of 25% (range 0-50%). ICE±R was administered
in all, except one case, as an in-patient therapy and all received G-CSF as pri-
mary prophylaxis. The overall response rate observed was 53.1% with a com-
plete response of 40.6%. After median follow-up of 12 months, the median pro-
gression free survival (PFS) and overall survival (OS) were 3.9 months and
17.0 months, respectively. Patients who responded to ICE±R (including cases
followed by autologous stem-cell transplantation) achieved median PFS of 47.2
months and OS of 78.9 months. Previous response to first-line therapy
appeared to be the strongest predictor of response, PFS and OS to second-
line treatment. Following treatment with ICE±R, an attempt to harvest peripheral
blood stem cells was performed in 8 patients. Harvesting was successful in
seven patients (>2.5x106 of CD34 cells/Kg) of which six (19%) proceeded to
autologous stem-cell transplantation (ASCT). Patients ineligible for ASCT that
responded to ICE±R (n=11) were treated with extended cycles of ICE±R (medi-
an of 4 cycles per patient), and achieved median PFS of 18.9 months and OS
of 21.7 months. ICE±R was generally well tolerated and major toxicity related
mostly to hematological adverse events. 
Summary and Conclusions: ICE±R is a safe regimen and achieves high
response rates in elderly patients with relapsed or refractory DLBCL. Response
to first-line therapy is the strongest predictor of response to ICE±R. Patients
with chemosensitive disease, who are not transplant-eligible, should be con-
sidered for extended treatment with this regimen. 
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SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA: CLINICAL
CHARACTERISTICS AND SURVIVAL STUDY OF 21 THAI PATIENTS IN A
SINGLE INSTITUTION
J. Julamanee1,* K. Kayasut2, A. Lekhakula1
1Department of Internal Medicine, 2Department of Pathology, Prince of Songkla
University, Songkhla, Thailand
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a
rare lymphoma subtype which is commonly associated with hemophagocytic
syndrome (HPS) and had an aggressive clinical course. The incidence of SPT-
CL is high in Asian countries including Thailand. Due to the rarity of the disease,
there are limited data on the clinical characteristics and optimal therapeutic
approaches of this entity.
Aims: The aim of this study was to characterize the clinical features, treatment
outcomes, and survival of SPTCL in Thai patients at a single institution.
Methods: Twenty-one patients diagnosed as SPTCL according to WHO clas-
sification 2008 were enrolled from January 2001 to December 2014 in Songk-
lanagarind Hospital. All tissue specimens were reviewed by hematopathologist.
The demographic, clinical, treatment, and outcomes data were collected for
analyses.
Figure 1. 
Results: The median age was 33 years (range 22-64 years) and 12 patients
were female. Lesions usually presented as multifocal subcutaneous nodules
or masses in 90%, commonly at lower extremities and trunk. Nine patients had
extra-cutaneous manifestations. The common sites of involvement were liver,
spleen, and lymph nodes. None of the patients had HPS in this study. Most
patients had a good ECOG performance score (90%) and low prognostic scores
(IPI low to low-intermediate in 71% and PIT score 0-1 in 90%). Fifty-seven per-
cent of the patients had limited stage of disease. B symptoms occurred in 57%
and elevated LDH level in 86%. Nineteen (90%) patients were treated with
chemotherapy, CHOP chemotherapy was used in 85%. Only one patient was
treated with radiotherapy. Of the 20 patients evaluated, the overall response
rate was 85% with 75% complete remission. Nevertheless, progressive disease
occurred in 8 patients, including 5 patients who had obtained complete remis-
sion. With median follow-up time of 52 months, the median OS and RFS were
unreached. The 5-year OS and RFS were 80% and 68%, respectively. No sig-
nificant prognostic factors were identified in this study.
Summary and Conclusions: SPTCL frequently affected young females.
Lesions typically presented as multifocal subcutaneous nodules or masses on
trunk and lower extremities. Patients responded well to CHOP chemotherapy
with long-term survival outcomes.
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CLINICAL FEATURES AND TREATMENT OUTCOMES IN NON-HODGKIN’S
LYMPHOMA IN CHILDHOOD: 24 YEARS EXPERIENCE OF A SINGLE
CENTER
F. Akici1,* D. Tugcu1, G. Aydogan1, Z. Salcioglu1, H. Sayilan Sen1, A. Akcay1,
A. Kiyak1, M. Gokce1, S. Sander2, O. Dogan3
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Vienna, Austria, June 11 – 14, 2015
1Pediatric Hematology-Oncology Clinic, 2Pediatric Surgery Clinic, Kanuni Sul-
tan Suleyman Training and Research Hospital, 3Division of Pathology, Istanbul
Medical Faculty, İstanbul, Turkey
Background: Non-Hodgkin’s lymphomas (NHL) of childhood and adolescence
are a heterogeneous group of malign diseases originating from the lymphoid
cells. NHL usually responds to the polychemotherapy and survival rates in NHL
have increased significantly in the last decades.
Aims: This study aims was to evaluate and compare the demographic data
and treatment results of childrens with NHL treated and therapeutic efficacy of
modified NHL German Berlin Frankfurt Munster (BFM) protocols in our center
retrospectively.
Methods: 115 children (79 male, 36 female) from January 1990 to September
2014, new diagnosed with NHL were enrolled to the study. The patients were
stratified by risk factors and treated either with a modified B-nonB NHL BFM-
90 (before 2004) or BFM-95 (after 2004) protocols. (Until September 1993,
lymphoblastıc patients recived LSAL2, non lymphoblastıc NHL patients recived
COMP ) and the use of 1 or 3 g/m2 of methotrexate instead of 5 g/m2/24 h was
the only important modification in BFM-90 protocol. 
Results: Demographic results: the median age 7 years(range: 3-14.5years)
were treated in the center with median 81 months follow-up. Histopathologic
subtypes were:24 lymphoblastıc, 11 anaplastic large cell, 80 nonlymphoblastic
Burkitt/diffüz B cell. 3 patients (3%) were in stage I, 19 patients (17%) in stage
II, 64 (56%) in stage III, and 29(24%) in stage IV. The most common initial pri-
mary tumor location sites were abdomen (58%), head and neck (18%) and
thorax (15%).The median LDH level at diagnosis was 790U/L(224-10300).
Treatment results: 32 patients (24 progressive disease, 6 toxicity, 2 seconder
neoplasm)died.7 patients were follow-up. The 10-year overall survival (OS) for
all patients was 72%, and event-free survival (EFS) was 67% respectively. 10
year survival was 100,89,76,51% in stage I,II,III, and IV. The 10-year OS rates
in modified BFM-90 and in BFM-95 protocols were 66% and 84%; the 10-year
EFS rates in these 2 protocols were 60% and 84%, respectively (P=0.061 for
OS, P=0.049 for EFS).Survival rates were significantly higher in patients receiv-
ing modified BFM regimen, than in ones COMP and LSA2L2
Summary and Conclusions: Survival rates in the whole group are in parallel
with advances attained in the world in NHL.The significantly higher survival
rates achieved in patients with advanced stage non lymphoblastic patients
receiving modified BFM(1 g/m2MTX) may be due to the decreased toxicity
seen in this group and to the advences in supportive care in the last decade.
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FAVORABLE PROGNOSTIC PARAMETERS IN TREATMENT OF AIDS
RELATED LYMPHOMA PATIENTS; TEN YEAR SINGLE CENTRE
EXPERIENCE
B. Mihaljevic1,2, M. Smiljanic1,* D. Jeftovic2,3, J. Ranin2,3, D. Salemovic3,
M. Todorovic1,2, J. Bila1,2, B. Andjelic1,2, V. Djurasinovic1, A. Sretenovic1,
V. Vukovic1, J. Jelicic1, D. Antic1,2,
1Lymphomas, Clinic of Hematology Clinical Centre of Serbia, 2Faculty of Med-
icine, Belgrade University, 3AIDS Department of the Institute for Infectious and
Tropical Disease, Clinical Center of Serbia, Belgrade, Serbia
Background: AIDS-related lymphomas (ARL) are frequent complication of
HIV infection, due to progressive CD4+ T-lymphocytes depletion and subse-
quent immune impairment. HIV-positive patients (pts) have up to 200-fold
increased incidence for non-Hodgkin lymphomas (NHLs). Most ARLs are
aggressive forms of B-NHLs. Usually pts presents with advanced disease, and
prognosis is generally poor. Previous studies reported International prognostic
Index score (IPI) ≤2 as significant predictive factor for overall survival (OS).
Current standard in ARL patient’s treatment is concomitant combined antiretro-
viral therapy (ART) and chemotherapy. 
Aims: The aims of this study were to detect prognostic factors and estimate
benefit of concomitant ART and chemotherapy for ARL patients OS.
Methods: We enrolled 37 ARL patients in our study. All were treated at the
Clinical Centre of Serbia, Belgrade in period 2004-2014. Thirty-two pts had an
aggressive NHL. Indolent NHL and Hodgkin disease were diagnosed in 2 cases
each, unclassified lymphoma in 1 case. Concomitant ART (same in all cases)
and chemotherapy was applied in 30 cases, chemotherapy only in 4, neither
ART nor chemotherapy in 3 cases.
Results: We found that use of concomitant ART and chemotherapy (P=.009,
DF=1), IPI risk score ≤2 (P=.031, DF=1) and LDH level ≤400IU (P=.028, DF=1)
were significant for OS (10 months, 2-102). Same parameters were confirmed
as positive OS predictors in univariate survival analysis (P=.020, 95.0%CI for
RR 0.141-0.847; P=.046, RR 1.013-4.813; P=.097, RR 0.875-4.25 respective-
ly). In multivariate analysis concomitant ART and chemotherapy remained sig-
nificant for OS (P=.012, RR 0.120-0.774).
Summary and Conclusions: Our results suggested necessity for prompt use
of concomitant ART and chemotherapy in ARL treatment, in order to improve
OS. Most ARLs are very aggressive, both in terms of histology and clinical
course, but pts without advanced disease seems to have better OS rate when
treated this way.
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TOXICITY AND EFFICACY OF LMBA-02 PROTOCOL IN THE TREATMENT
OF BURKITT’S LYMPHOMA AMONG THE MOROCCAN ADULT
POPULATION
S. Regragui1,* S. Jennane1, S. Amelal1, K. Doghmi1, M. Mikdame1
1Clinical hematology, Militarian Hospital of Rabat, Rabat, Morocco
Background: The geographical position of Morocco, straddling Europe and
sub-Saharan Africa gives the Burkitt lymphoma equitable distribution between
the endemic and the sporadic form. 
Aims: The objective of this study is to evaluate the toxicity and the efficacy of
LMBA02 Protocol on the Moroccan population.
Methods: This is a retrospective study including all patients managed in our train-
ing for Burkitt’s lymphoma and treated using the LMBA02-Mabthera protocol.
Results: A total of 18 patients were included. The median age was 44 years,
with a range of 16-70 years. The rate of men was more likely higher than
women with a sex ratio [M/F] of 1.6. Diagnosis delay was 3 months average.
At diagnosis, 39% of patients had abdominal localization, 33.3% had a
mandibular one, 16.6% had a neurological localization and 11% had a marrow
infiltration. Two patients (11%) were infected with human immunodeficiency
virus. 39% were in stage III and 39% in stage IV Murphy. 50% of patients had
systemic symptoms. All patients were treated according to the protocol
LMBA02- Mabthera. The overall response rate (OR) was 83.2% with a com-
plete response rate (CR) of 66.6% and a partial response (PR) to 16.6%. The
treatment-related mortality (TRM) was 16.6%. The overall survival rate was
62% at 6 months, 50% at 1 year and 36% at 2 years; when analyzing it in
terms of age, there is a 2-year survival of 75% among patients under 40 years
and 14% in patients over 40 years (P<0.05). The main causes of death are
dominated by treatment-related toxicity (37.5%), resistance to first-line treat-
ment (37.5%) and relapse of the disease (25%). Both mortality risk factors are
age and cure spacing due to the toxicity of treatment.
Summary and Conclusions: Despite its effectiveness, the treatment-related mor-
tality of LMBA02-Mabthera protocol in patients over 40 years is considered high.
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ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED
MYCOSIS FUNGOIDES/SEZARY SYNDROME
E. Atilla1,* P. Ataca1, S. Civriz Bozdag1, S.K. Toprak1, M. Kurt Yuksel1,
P. Topcuoglu1, B.N. Akay2, H. Sanli2, G. Gurman1, M. Ozcan1
1Hematology, 2Dermatology, Ankara University School of Medicine, Ankara,
Turkey
Background: T-cell lymphomas are heterogeneous group of diseases that
account for<10% of non-Hodgkin lymphomas. The prognosis for patients with
most forms of T-cell lymphoma is generally poor. Mycosis fungoides (MF) and
Sezary Syndrome (SS) are cutaneous T cell lymphomas. Several studies have
suggested that allogeneic hematopoietic stem cell transplantation (HSCT) may
improve survival in advanced MF and SS. 
Aims: We aim to present the outcome of our patients with MF or SS who
underwent HSCT
Methods: We retrospectively evaluated totally 8 patients, 5 advanced stage
MF and 3 SS who underwent peripheral HSCT rescue at Ankara University
Department of Hematology from Oct 2012 to Oct 2014. Three MF patients had
large cell transformation at pre-transplantation period. All of the patients
received at least three lines of therapy prior to HSCT (Table). Two out of 8
patients were transplanted from unrelated HLA one antigen or allele mismatch
donors whereas other 6 patients had fully matched siblings. All of the patients
had refractory disease prior to HSCT, 6 of 8 patients received reduced intensity
conditioning regimen (Fludarabine-Cyclophosphamide-TBI +/-ATG) while 2
patients received myeloablative conditioning regimens including Cyclophos-
phamide plus total body irradiation. Peripheral blood was the stem cell source
in all the patients. For graft-versus host disease prophylaxis, patients received
cyclosporine plus methotrexate or mycophenolate mofetil except one patient
in whom metal-prednisolone was used due to renal toxicity.
Table 1. Patient characteristics.
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Results: The median age of the group was 59 years (range 49-61). The median
time from diagnosis to HSCT was 3 years (range 1-11 years). The Sorror HCT-
CI scores prior to HSCT were listed as: 2/8 score of 0, 3/8 score of 1, 3/8 score
of 2. The patients achieved engraftment at a median of 12 days after HSCT
(range 0-22). We evaluated the disease response in only 6 patients because two
patients died of the early transplant-related mortality in 16th day of the transplan-
tation due to fungal or Acinetobacter infection. Disease responses after the trans-
plantation could evaluated in only six patients as follows: 2 complete remissions,
2 very good partial remission (VGPR), and 2 minimal responses. We obtained
complete remission in one patients with VGPR after developing acute GvHD.
Acute GvHD developed in 57.1% of the patients (4/7). Chronic GvHD was detect-
ed in 3 out of 5 patients surviving longer than 100 days after the transplantation.
Early transplant-related mortality was seen in 25%. Our follow-up was changing
between 16 days and 769 days. The possibility of two-year progression free and
overall survival was 37.5%±1.7% and 62.5%±1.7%, respectively.
Summary and Conclusions: Our results in a small patient group suggest that
allo-HSCT is an effective treatment in the patients with advanced stage refrac-
tory MF/SS.
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INCIDENCE OF THROMBOTIC EVENTS IN PRIMARY MEDIASTINAL
B-CELL LYMPHOMA AND ITS INFLUENCE ON THE OUTCOME OF THESE
PATIENTS: EXPERIENCE OF SINGLE CENTER
J. Hidalgo1,* C. Carpio1, B. Merchan1, J. Castellví2, O. Salamero1, P. Abrisqueta1,
A. López1, F. Bosch1
1Hematology, 2Pathology, University Hospital Vall d’Hebron, Barcelona, Spain
Background: Primary Mediastinal B cell Lymphoma (PMBL) is a lymphoid
neoplasm that accounts for 2% to 4% of non-Hodgkin lymphomas (NHL).
Because of its particular features (fibrosis, large mediastinal mass, pericardial
and/or pleural effusion) is included in the Large B-cell lymphomas (LBCL) with
special features category. PMBL presents usually with superior vena cava syn-
drome (SVCS) and thrombotic events of the mediastinal circulation although
the real prevalence of these events have not been accurately reported in the
literature. 
Aims: The main objective of the study was to determine the incidence of these
thrombotic events and how this complication influences the outcome of patients
diagnosed with PMBL. 
Methods: Thirty-one patients consecutively diagnosed with PMBL in a single
center between 1995 and 2014 were included. After reviewing the pathology,
the demographic and clinical characteristics of the series were recorded and
evaluated, paying particular attention to the thrombotic events.
Table 1. 
Results: The median age at diagnosis was 34 years (range: 17 to 56) and 61%
were female. The median of the largest diameter of the mediastinal mass was
98 mm (range: 50-150 mm), 26% had extranodal involvement (most frequently
associated with adjacent structures) and 52% had SVCS. Ten patients (32%)
had thrombotic events, 90% detected at diagnosis. There were no differences
between the clinical characteristics (sex, age, larger diameter of the mediastinal
mass, SVCS presence or extranodal involvement) between patients with or with-
out thrombotic events. With a median follow-up of 71 months (range: 1-183) we
did not find any difference between patients with or without thrombotic events
regarding the response to therapy and the outcome (PFS and OS), Table 1.
Summary and Conclusions: The prevalence of thrombotic events in PMBL
reported in our study is higher than the one described in other types of lym-
phomas. Nevertheless, response to therapy and outcome seems not to be
influenced by this complication.
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ALCOHOL INTAKE AND SMOKING HABITS HAVE NO MAJOR IMPACT ON
THE SHORT TERM SURVIVAL IN PATIENTS WITH DIFFUSE LARGE
B-CELL LYMPHOMA
P. Svenssen Munksgaard1,* T. Christoffer El-Galaly1, E. Bekric2,
C. Brieghel Mortensen3, K. Buchardi Jensen4,M. Bøgsted5,M. Dahl Bendtsen5,
M. Tang Severinsen1
1Department of hematology, Aalborg University Hospital, Aalborg, 2Department
of hematology, Odense University Hospital, Odense, 3Department of hematol-
ogy, Copenhagen University Hospital, Copenhagen, 4Department of hematol-
ogy, Holstebro Hospital, Holstebro, 5Department of Clinical Medicine, Aalborg
University, Aalborg, Denmark
Background: Individual lifestyle factors such as smoking and alcohol intake
are common in the Western world and modify the risk of several cancer types,
including non-Hodgkin lymphoma (NHL). However, less is known about the
impact of these lifestyle factors on survival once the lymphoma has arisen. 
Aims: To examine the prognostic impact of smoking and alcohol intake on
overall survival (OS) in patients with newly diagnosed DLBCL treated with
immunochemotherapy.
Methods: This retrospective study included adult patients with newly diagnosed
DLBCL seen at the hematology centers of Aalborg (2003-2010), Holstebro
(2006-2012), Odense (2006-2012), and Copenhagen (Rigshospitalet, 2010-
2012). All patients had been treated with R-CHOP/CHOP-like regimens. Patient
lists were obtained from the Danish Lymphoma registry (LYFO). The LYFO
contains detailed information on a wide range of clinico-pathological features
as well as complete follow-up data. Medical records were retrieved and
reviewed for information on smoking habits, alcohol consumption, and comor-
bidities. Overall survival (OS) estimates were made using the Kaplan-Meier
method. The impact of lifestyle and comorbidity on OS was evaluated with sim-
ple and multiple Cox models with inclusion of the standard international prog-
nostic index (IPI) risk groups and comorbidities.
Results: A total of 502 DLBCL patients had available information on smoking
and alcohol intake and were included in the present study. Patients were cate-
gorized as low-risk (26%), low-intermediate (24%), intermediate-high (26%) and
high risk (18%), according to the IPI. Never smokers accounted for 43% of the
patients, former smokers 31%, and current smokers 26%. A low alcohol intake
(<3 standard drinks per week) was noted in 33% of the patients, a moderate
intake (3-14 standard drinks per week) in 55%, and heavy drinking (>14 standard
drinks per week) in 11%. The Table shows the impact of lifestyle on outcome. In
male patients, both current and former smoking were associated with a lower 3-
year OS. Smoking habits did not influence survival in female patients. However,
the associations between smoking and OS were attenuated after adjusting for
comorbidities, which suggest that the effects of smoking were at least partially
mediated by excess comorbidity in these patients. Participants with a moderate
alcohol intake had the highest 3-years OS (71%), whereas heavy drinkers had
the lowest 3-years OS (60%), but alcohol consumption did not have impact on
survival in univariate or multivariate Cox analyses.
Table 1. 
Summary and Conclusions: Overall, smoking habits and alcohol intake had
no significant impact on the short term survival in this large cohort of uniformly
treated DLBCL patients. However, current and former smoking were associated
with a strong trend toward inferior OS, which is possibly mediated by excess
comorbidity in this subset of patients.
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UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION OVERCOMES
A NEGATIVE IMPACT OF MALE GENDER IN HIGH-RISK DIFFUSE LARGE
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Background: Combining rituximab to combination chemotherapy (R-CHOP)
has significantly improved overall survival (OS) of patients with diffuse large B-
cell lymphoma (DLBCL), but high-risk patients stratified according to the inter-
national prognostic index (IPI), non-germinal center B cells (non-GCB) subtype,
and male patients have shown inferior treatment outcomes. Although the first-
line treatment of patients with DLBCL is R-CHOP irrespective of the risk-group,
there have been few studies evaluating the role of upfront ASCT as consolida-
tive treatment strategy for high-risk DLBCL patients.
Aims: To investigate the role of upfront ASCT as consolidation after R-CHOP
chemotherapy according to the gender in newly diagnosed advanced stage
DLBCL patients.
Methods: We performed a multicenter retrospective analysis of 204 newly
diagnosed DLBCL patients between January 2008 and December 2013.
Patients who were younger than 65 years of age with advanced stage (Ann
Arbor stage III or IV) and elevated serum lactate dehydrogenase were included.
All the patients completed 4 to 8 cycles of planned R-CHOP chemotherapy
and achieved at least PR after completion of planned R-CHOP chemotherapy.
Results: The median age at diagnosis was 50 (range 22-64) years and 111
(54.4%) patients were male. Median follow-up for surviving patients was 42
(range 4-115) months. Seventy-five (36.8%) patients underwent upfront ASCT
as consolidation. Fifteen (11.6%) patients in the non-ASCT group (n=129) under-
went ASCT after relapse. The 3-year OS and PFS rate for all patients were 78.8%
and 68.4%, respectively. In multivariate analysis, non-CR after R-CHOP
chemotherapy and non-upfront ASCT was associated with shorter OS (hazard
ratio (HR) 2.57; 95% CI 1.34-4.95; P=0.005 and HR 2.97; 95% CI 1.38-6.40;
P=0.005, respectively). Non-ASCT was also associated with shorter PFS in mul-
tivariate analysis (HR 2.26; 95% CI 1.25-4.07; P=0.014). Among the male
patients, upfront ASCT showed superior OS and PFS compared to the non-
ASCT group (P=0.016 and P=0.024, respectively). GCB subtype compared to
the non-GCB subtype showed better PFS in male patients (P=0.026), but there
were no difference in OS and PFS in male patients who received upfront ASCT.
In female patients, non-CR after completion of chemotherapy was associated
with shorter OS on multivariate analysis (P=0.024). However, survival differences
in OS and PFS according to the disease status after the completion of chemother-
apy were not observed in female patients who received upfront ASCT. 
Figure 1. 
Summary and Conclusions: Upfront ASCT as consolidation after R-CHOP
chemotherapy overcomes a negative impact of male gender and non-GCB
subtype in male patients with high-risk DLBCL. Among female patients with
high risk DLBCL, upfront ASCT after R-CHOP chemotherapy may overcome
a negative impact of non-CR response to initial therapy. Additional data com-
paring with new regimens such as additional use of rituximab are necessary to
find out the exact role of upfront ASCT.
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HIGH NEUTROPHIL LYMPHOCYTE RATIO AT DIAGNOSIS IDENTIFIES
DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH POOR CLINICAL
OUTCOME
B. Spassov1,* G. Balatzenko2, D. Vassileva3, G. Mihaylov1, S. Toshkov2,
M. Guenova4
1Department of Clinical Hematology, 2Laboratory of Cytogenetics and Molec-
ular Biology, 3Laboratory of Nuclear Medicine, 4Laboratory of Hematopathology
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eases, Sofia, Bulgaria
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
type of non-Hodgkin lymphoma (NHL) and is a biologically heterogeneous dis-
ease. At present, the stratification of DLBCL patients is performed by the revised
international prognostic index (R-IPI). However, some preliminary data suggest
the important role of inflammation in cancer biology. It has been assumed that
systemic inflammatory response has prognostic significance in a wide range
of different cancer types including NHL. The neutrophil to lymphocyte ratio
(NLR) in the peripheral blood has been proposed as a prognostic factor in can-
cer patients. However data regarding the prognostic significance of NLR in
DLBCL patients is quite limited.
Aims: To evaluate the prognostic significance of baseline NLR in a cohort of
newly diagnosed DLBCL patients treated with chemoimmunotherapy.
Methods: Data from 254 DLBCL patients, at a median age of 58.6 years
(range, 19-82 years), diagnosed between 2007 and 2014, were evaluated ret-
rospectively. The patients were treated with R-CHOP. The NLR cutoff value for
survival analysis determined by receiver operation characteristics (ROC) curve
in the whole patients’ cohort was 3,01. The prognostic influence of the NLR
and other factors including age, lactate dehydrogenase (LDH), β2 microglobulin
(β2 M), R-IPI and Ann Arbor stage at diagnosis on 5-year overall- (OS) and dis-
ease-free (DFS) survival was studied by Kaplan–Meier curves. To evaluate the
independent prognostic relevance of NLR, univariate and multivariate Cox
regression models were applied.
Results:A significantly higher proportion of patients with NLR above 3,01 had
elevated levels of LDH and β2 M (64% vs 28.8% and 75% vs 53.1%, respec-
tively), advanced disease stage (III – IV) (48.2% vs 31.1%), high risk (R-IPI 3-
5) disease (9.3% vs 32.2%) in comparison to patients with NLR below the
cutoff value. Patients with high NLR at diagnosis experienced an inferior 5-
year OS (38.5% vs 74.4%, P<0.001) and 5-year DFS (61.8% vs 77.7%,
P<0.001). By multivariate analysis, an independent significant association
between high NLR and poor clinical outcome in terms of OS (harard ratio
[HR]=1.99, 95% confidence interval [CI], 1.07-3.71, P=0.03) and DFS
(HR=2.58, 95% CI, 1.04-6.43, P=0.04) was identified.
Summary and Conclusions: Our data suggest that NLR at diagnosis provides
useful independent prognostic information to assess clinical outcomes in DLBCL
patients treated with R-CHOP. Further studies are required to confirm these results.
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COMBINATION OF CHEMOTHERAPY AND RADIATION IMPROVE THE
PROGNOSIS OF PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE
TONSIL
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C.W. Choi8, J.S. Kim9
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Busan Paik Hospital, Busan, 7Internal Medicine, Hallym University College of
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Background: Non-Hodgkin lymphoma of the Waldeyer’s ring is a relatively rare
entity and the tonsil is the most frequently involved site. The majority of tonsil
lymphomas are of B-cell origin and the most common histological type is diffuse
large B-cell lymphoma (DLBCL). Treatment approaches that have used include
chemotherapy (CTx) alone, radiation (RT) alone, and combination of both.
Aims: We reviewed our data and evaluate treatment outcome of patient with
primary diffuse large B-cell lymphoma of the tonsil.
Methods: Retrospective review of 114 stage I-II DLBCL patients treated with
curative intent between 1995 and 2010. Forty-five (39.5%) patients had stage I
disease and systemic symptoms (B-symptoms) were present in only 7 (6%)
patients. Seventy-two (65.5%) patients were treated with CTx alone, whereas
the remaining 38 (34.5%) received treatment with a combination of CTx and RT.
Chemotherapy was CHOP-based, with R-CHOP in 80 patients (70%). Median
involved-field RT dose was 3,960 cGy, with 96% receiving more than 3,000 cGy. 
Results: The median age was 59 years and the majority of patients (61%)
were males. Low risk disease: low to low intermediate by International prog-
nostic index (IPI) was 97.3% and only 10 (8.8%) patients had high serum lactate
dehydrogenase (LDH) level. Overall CR rate was 73.5% and seven (13.5%) of
the patients who had achieved CR had recurred. The median follow up was 28
months (34 months for CHOP-treated, 23 months for R-CHOP). Disease-free
survival (DFS) and overall survival (OS) were 43.9% and 42.5%, respectively.
Significant prognostic factors included: age ≥60 year-old (OS: 93.1% vs. 74.1%,
P=0.011; DFS: 83.3% vs. 80.6%, P=0.160), LDH >upper normal limit (OS:
664 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
88.2% vs. 72.9%, P=0.003; DFS: 86.8% vs.20.0%, P<0.001), IPI>0 (OS: 90.0%
vs. 55.9%, P=0.007; DFS: 86.5% vs. 64.0%, P=0.034) and combination of CTx
and RT (OS: 79.6% vs. 48.2%, P=0.025; DFS: 72.6% vs. 48.5%, P=0.038).
Germinal center (GC) and non-GC phenotype were not predictors of outcome
in localized primary DLBCL of the tonsil. Combination chemotherapy-treated
patients with rituximab did not show a significantly better OS and DFS than the
combination chemotherapy-treated patients without rituximab. On multivariate
analysis; LDH >upper normal limit (DFS: hazard ratio [HR], 14.958; 95% CI,
2.474-90.432, P=0.003; OS: HR, 9.341; 95% CI, 1.635-53.361, P=0.012), and
combination of CTx and RT (DFS: HR, 0.088: 95% CI, 0.009-0.834, P=0.034;
OS: HR, 0.112; 95% CI, 0.014-0.918, P=0.041), retained statistical significance. 
Figure 1.
Summary and Conclusions: The DFS and OS rates were significantly better
for patients receiving combination of CTx and RT. A combined treatment, con-
sisting of CTx and RT results in a satisfactory outcome in patients with localized
primary DLBCL of tonsil.
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TREATING HIV-RELATED NON-HODGKIN LYMPHOMA IN SEVERELY
IMMUNOCOMPROMISED PATIENTS, IN THE CART ERA. A SINGLE
CENTER EXPERIENCE.
A. Re1,* S. Casari2, C. Cattaneo1, A. Peli1, D. Dal Ceggio1, F. Castelli2,
A. Scalzini3, G. Rossi1
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Background: Low CD4+ lymphocyte count at diagnosis, in patients (pts) with
HIV-related non-Hodgkin’s lymphoma (NHL), is associated with poor clinical
outcome, mainly due to low treatment tolerability. Severely immunocompro-
mised pts are frequently excluded from clinical trials. Moreover, several authors
claim that Rituximab should be held in pts with very low CD4 count due to the
increased risk of infections
Aims: To define the outcome of severely immunocompromised HIV positive
(+) pts with NHL in the real-life, in terms of possibility to receive treatment with
curative intent, treatment-related mortality (TRM), complete remission (CR)
rate and survival
Methods: All consecutive HIV pos pts diagnosed at our Institution from Jan
1997 to Dec 2013 (cART era) with aggressive systemic NHL and CD4+ lym-
phocyte count<100/mcl (CD4<100) at lymphoma diagnosis were considered.
Histology included DLBCL, Burkitt, plasmablastic or other aggressive lym-
phomas. Pts’characteristics, treatment response and long-term outcome were
compared with the concomitant series of HIV-related NHL pts with CD4+ lym-
phocyte count >100/mcl (CD4>100). Each pt was treated with standard state-
of-the art in lymphoma and HIV care at the time of diagnosis, or enrolled in
prospective trials. After 2001 all pts with CD20+ NHL received Rituximab com-
bining chemotherapy (CT)
Results: Since 1985 to 2013 198 HIV pos pts were diagnosed at our Institution
with NHL, 84 in the pre-cART era (1985-1996) and 114 in the cART era (1997-
2013). The proportion of pts with CD4<100 during the cART era was 35% vs
63% in the pre-cART era (P=.0002). The clinical characteristics of the 2 groups
(CD4>100 vs CD4<100) are shown in table 1. Significant differences included
worse performance status (PS) and more pts with B symptoms in CD4<100
group and a greater proportion of pts on cART at NHL onset in CD4>100 group.
The proportion of pts with CD4<100 we treated with curative intent was 63%
vs 97% in pts with CD4>100 (P<0.0001). Pts were excluded from curative treat-
ment for poor PS, major infections and/or severe comorbidities. After a follow-
up of 60 ms (1-204), the 5y-overall survival (OS) of the 2 groups of pts was
31% (CD4<100) and 60% (CD4>100) (P=0.003). However, analysing pts who
underwent CT, CR rate was similar (54% for CD4<100 and 64% in CD4>100;
P=0.6). TRM was respectively 21% and 9% and included mainly infectious
events. Overall, 14 pts (58%) died in CD4<100 (cause of death: NHL 7 pts,TRM
5,HCV cirrosis 1 and unknown 1) and 29 (41%) in CD4>100 group (NHL
19,TRM 6,lung cancer 1,car crush 1,suicide 1 and drug overdose 1). Response
duration was not different (85% and 84% at 5 years). A trend towards worse
OS and PFS were seen in pts treated with CD4<100 (38% vs 62% and 39% vs
52%) (P=NS). Fifteen pts with CD4<100 (DLBCL 11 and Burkitt 4) received
Rituximab combining CT, while 6 pts (DLBCL 5 and Burkitt 1) did not. The CR
rate for pts who received Rituximab was higher (60% vs 33%, P=NS) with sim-
ilar TRM (20% vs 17%), and median OS and PFS of 19 vs 4.5 ms and 17 vs
4.5 ms (P=NS).
Summary and Conclusions: After the advent of cART the proportion of
severely immunocompromised pts with HIV-related NHL has significantly
decreased. In our single center experience, a substantial proportion of them
could not receive adequate treatment and OS remained poor. However, if prop-
erly treated with standard immunochemotherapy, the CR rate was similar to
pts with less immunocompromise, with chance of favourable long-term out-
come. TRM was not negligible. Rituximab appears feasible in this setting and
it seems to improve CR rate and possibility of long-term survival.
Table 1. Comparison between characteristcs of patients with CD4+
limphocyte count more or less than 100 at lymphoma diagnosis.
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Background: Rituximab in combination with cyclophosphamide, vincristine,
doxorubicin and prednisolone (R-CHOP) has been a standard treatment for
patients with diffuse large B cell lymphoma (DLBL). Although complete response
(CR) rate is up to 60~70%, 10~20% patients remained in PR after R-CHOP.
Patients with PR are relatively chemo-sensitive compared to primary refractory
diseases, but predictive factors and treatment strategy for these patients are in
controversy. 
Aims: We investigated the characteristics and prognosis for the patients who
achieved PR after the first-line R-CHOP to analyze the survival of these patients
and to define the prognostic factors affecting the clinical outcome of this specific
patient group.
Methods: We performed a retrospective multicenter study on behalf of the
Consortium for Improving Survival of Lymphoma (CISL). Patients who achieved
PR by Cheson response criteria, and who had available PET scans at the end
of R-CHOP were enrolled. Clinical parameters before and after R-CHOP were
obtained to evaluate whether the patients’ dynamic condition after treatment
could predict the outcome. For survival analysis, PFS2 (from the date PR was
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documented to disease progression or death) and OS2 (from the date PR was
documented to death) were used. 
Results: A total of 88 patients were enrolled. Median age was 53.5 years (21-
88), and the number of patients with initial stage III-IV was 64 (72.7%). The
International Prognostic Index (IPI) score at diagnosis was >2 in 46 (52.3%).
At the time of PR documentation, secondary IPI scores (IPI2) assessed after
R-CHOP were 0 in 33 (37.5%), 1 in 27(30.7%), and >1 in 28 (31.8%). The
Deauville scores of PET scans after R-CHOP were ≤2 in 24 (28.2%), 3 in 26
(30.6%), ≥ 4 in 35 (41.2%), and unknown in 3 cases. As a second-line treat-
ment, local radiation to residual lesion without any systemic treatment was per-
formed in 33 (38.6%) patients. Intensive chemotherapy such as salvage
chemotherapy or upfront ASCT was performed in 42 (47.7%) patients. Four
(4.5%) patients received less intensive therapy such as rituximab or other oral
agents. With a median follow up of 47.8 months, 3-year PFS2 and OS2 rates
were 57.9% and 68.1%. In the univariate analysis, age, bone marrow involve-
ment, lymphopenia, and high IPI score at diagnosis were significantly associ-
ated with poor PFS2 and OS2. High IPI2 score (≥1) and the Deauville score
(≥4) were significantly associated with worse PFS2 (P=0.001 and P=0.029,
respectively). In the multivariate analysis, high IPI2 was an independent pre-
dictive factor for PFS2 (HR 2.40, 95% CI 1.08-5.269, P=0.031) after adjustment
with initial IPI (P=0.163), bone marrow involvement (P=0.005), lymphopenia
(P=0.124) at diagnosis and the Deauville score after R-CHOP (P=0.338). For
overall survival, high IPI2 score was also associated with poor OS2 in univariate
analysis (P=0.013), but not the Deauville score (P=0.134). Only the initial IPI
score >2 (P=0.041) and bone marrow involvement at diagnosis (P=0.001)
remained significant in the multivariate analysis model.
Figure 1.
Summary and Conclusions: IPI2 in patients with DLBL who achieved PR
after R-CHOP was an important predictive factor for further survival outcomes.
This suggests that the patient’s condition and residual tumor burden might be
helpful when we are planning the next treatment.
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SURVIVAL BENEFIT OF HEMATOPOIETIC STEM-CELL TRANSPLANTION
FOR PTCLS: A RETROSPECTIVE COMPARISON STUDY BETWEEN
CONVENTIONAL CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
FOR PTCLS FROM A CHINESE CENTER
H. Huang1,* Q. Wang1, Z. Jin1, D. Wu1
1The First Affiliated Hospital of Soochow University, Suzhou, China
Background: Peripheral T-cell lymphomas (PTCLs) are rare malignancies
with poor outcome after conventional chemotherapy. The role of stem cell trans-
plantion in the treatment of PTCLs is still unclear. 
Aims: Here, we present the result of a comparison study between conventional
chemotherapy and stem cell transplantation for PTCLs in our centre.
Methods: From July 2004 to July 2014, 104 cases were analyzed retrospec-
tively, including age, IPI score and morbid state before transplantion. 52 patients
underwent HSCT including angioimmunoblastic T-cell lmphoma (n=15),
anaplastic large cell lymphoma (n=14), PTCL not specified (n=12), NK/T cell
lymphoma (n=11). In this group, 43 patients were IPI≥3-4). Thirty-three patients
(63.5%) received autologous stem-cell transplantion (autoSCT) and nineteen
patients (36.5%) received allogeneic stem-cell transplantion (allo-SCT). Before
stem-cell transplantation, 43 Patients were in complete remission (CR), 2
patients were in partial remission (PR), 7 patients were not-remission(NR). In
conventional chemotherapy group, 52 patients (median age, 49.5 years, IPI≥3-
4: 40 patients ) only received conventional chemotherapy. Primary outcomes
of progression-free survival (PFS), and overall survival (OS) rates were esti-
mated by using the Kaplan-Meier method.
Results:After a median follow-up of 23.5 months, K-M analysis showed that the
5-year PFS for HSCT and chemotherapy were 60% and 30%(P=0.006), the 5-
year OS were 65% and 33% (P=0.007) (Fig 1), respectively. These results sug-
gested that frontline stem cell transplantation for high-risk PTCLs may improve
treatment outcome. The 5-year PFS for autoHSCT and alloHSCT were 60% and
58%(P=0.074). The 5-year OS were 62% and 61% (P=0.074) (Fig 2). There
were no significant survival differences between the auto-HSCT and allo-HSCT.
Figure 1. Progression-free survival an overall survival by transplantation
and conventional chemotherapy for PTCLs.
Figure 2. Progression-free survival an overall survival by auto-HSCT and
allo-HSCT fot PTCLs.
Summary and Conclusions: The results of this retrospective study suggest
that HSCT have great advantange copared to conventional chemtherapy on
long-term survival in peripheral T-cell lymphomas. However, the resullt of auto-
HSCT and allo-HSCT seems to have no difference. Therefore, autoHSCT
should be considered to be the first -line therapy in peripheral T-cell lymphomas,
especially for those patients with high risk factors.
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PERIPHERAL ABSOLUTE MONOCYTE AND LYMPHOCYTE COUNTS AT
DIAGNOSIS PREDICT SURVIVAL IN PATIENTS WITH PRIMARY NODAL
DIFFUSE LARGE B-CELL LYMPHOMA
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Background: Diffuse large B-cell lymphoma (DLBCL) is a biologically hetero-
geneous disease with primary nodal and extranodal origin. At present, the strat-
ification of DLBCL patients is performed by the revised international prognostic
index (R-IPI). However, some preliminary data suggest the important role of
blood monocytes and lymphocytes in cancer biology. It has been assumed that
baseline levels of peripheral absolute lymphocyte (ALC) and monocyte (AMC)
counts have prognostic value in solid tumors. However, data regarding their
impact on clinical outcomes of DLBCL patients are limited.
Aims: To evaluate the prognostic significance of baseline ALC and AMC in a
cohort of newly diagnosed DLBCL patients treated with chemoimmunotherapy.
Methods: Data from 255 DLBCL patients, at a median age of 58.6 years
(range, 19-82 years), diagnosed between 2007 and 2014, were evaluated ret-
rospectively. Primary nodal and extranodal lymphoma were detected in 60.4%
(154/255) and 39.6% (101/255), respectively. The patients were treated with
R-CHOP. Values<1.0x 109/L for ALC and >0.8x 109/L for AMC were considered
abnormal and applied to stratify patients in the present study. The prognostic
influence of the ALC and AMC, and other factors including age, lactate dehy-
drogenase (LDH), β2 microglobulin (β2 M), R-IPI and Ann Arbor stage at diag-
nosis on 5-year overall- (OS) and disease-free (DFS) survival was studied by
Kaplan–Meier curves. To evaluate the independent prognostic relevance of
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ALC and AMC, univariate and multivariate Cox regression models were applied.
Results: The median ALC at diagnosis was 1.74x 109/L (range 0.28–7.16x
109/L) and abnormal ALC were detected in 16.8% (42/255) of the patients. A
significantly higher proportion of patients with ALC<1.0x 109/L had elevated
levels of LDH and β2 M (76.2% vs 36.1% and 86.8% vs 57.6%, respectively),
advanced disease stage (III – IV) (60.9% vs 34.9%), high risk (R-IPI 3-5) dis-
ease (43.9% vs 15.8%) in comparison to patients with ALC ≥ 1.0x 109/L. The
median AMC at diagnosis was 0.59x 109/L (range 0.28–7.16x 109/L) and AMC
>0.8x109/L were detected in 24.3% (62/255). Similarly, a significantly higher
proportion of patients with abnormal AMC had elevated levels of LDH and β2
M (59.7% vs 37.3% and 76% vs 60.1%, respectively), advanced disease stage
(III – IV) (52.4% vs 34.9%), high risk (R-IPI 3-5) disease (36.8% vs 15.5%) in
comparison to patients with AMC ≤0.8x 109/L. Patients with abnormal ALC at
diagnosis experienced an inferior 5-year OS (18% vs 64.7%, P<0.001) and 5-
year DFS (48.9% vs 78.2%, P<0.001). Patients with abnormal AMC at diagnosis
experienced an inferior 5-year OS (60% vs 79.2%, P=0.002) and 5-year DFS
(53.6% vs 80.4%, P=0.001). However, regarding nodal and extranodal origin
of lymphoma the analysis revealed that only primary nodal DLBCL patients
with abnormal baseline ALC and AMC experienced inferior 5-year OS and 5-
year DFS. Moreover, an independent significant association between abnormal
ALC and poor clinical outcome in terms of OS (hazard ratio (HR) 2.14, 95%
confidence interval (CI) 1.13-4.06, P=0.019) and DFS (HR 5.88, 95% CI 2.00-
17.25, P=0.001) was identified by multivariate analysis only in primary nodal
DLBCL patients.
Summary and Conclusions: Our data suggest that ALC and AMC in peripheral
blood at diagnosis predict survival in primary nodal DLBCL treated with R-
CHOP. However only ALC is independent, poor prognostic factor for DFS and
OS, and can be used in combination with other prognostic features to better
predict the outcome of these patients.
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S. Ostojić-Kolonić3, V. Pejša5, D. Nemet2
1Hematology, University Hospital Centre Osijek, Osijek, 2Hematology, Univer-
sity Hospital Centre Zagreb, 3Hematology, Clinical Hospital Merkur, Zagreb,
4Hematology, University Hospital Centre Rijeka, Rijeka, 5Hematology, Clinical
Hospital Dubrava, 6Hematology, University Hospital Centre Sestre Milosrdnice,
Zagreb, 7Hematology, University Hospital Centre Split, Split, Croatia
Background: B-large cell lymphoma (B-LCL) is the most common form of NHL.
5-year survival rates vary between 40 and >90% depending on prognostic fac-
tors but the importance of many of them is disputed. Those found most impor-
tant and reproducible in the pre-rituximab era were included in the IPI. Since
the original description, various variants of this index have been published.
Aims: To reassess the value of the IPI, revised IPI (R-IPI), age-adjusted IPI
(aaIPI), stage-adjusted IPI and different possible clinical prognostic factors in
an unselected population of patients with B-LCL receiving rituximab containing
front-line therapy.
Methods: 371 patients diagnosed with B-LCL during 2007 and 2008 and treat-
ed with rituximab plus chemotherapy in 16 Croatian hematology departments
were included in this study. Patients were registered at the time of treatment
start, and data on demographics, clinical features and laboratory parameters
collected. Follow-up was performed yearly. The study was approved by the
Croatian Central Ethics’ Committee. Prognostic values of IPI, R-IPI, aaIPI,
stage-adjusted IPI, individual factors used in indices (age, PS, LDH, stage,
number of extranodal organs involved), bulk, gender, anemia, bone marrow
infiltration and the presence of B symptoms were evaluated with respect to
overall survival (OS) and progression-free survival (PFS) were evaluated. Sur-
vival analyses were performed using the Kaplan-Meier method and compar-
isons using the log-rank test. Multivariate analysis is ongoing.
Results: 5-year OS and PFS of the whole cohort were 50% and 49.5%. Signif-
icant negative prognostic factors in univariate analyses for OS and PFS were:
age>65, LDH high, PS>1, stage>2, Hb<120 g/l, male gender, bone marrow infil-
tration and presence of B symptoms. Number of involved extranodal sites and
presence of bulky disease did not influence prognosis. Regarding prognostic
indices, conventional IPI was most useful, distinguishing 4 categories with rea-
sonable proportions of patients. R-IPI was less useful; the differences in PFS
between the three prognostic categories were significant, but there was no dif-
ference in OS between patients with scores 0 and 1-2. aaIPI distinguished only
two categories; patients with score 0 had excellent prognosis, while there was
no difference in outcomes between those with scores 1 and 2-3. Stage adjusted
IPI distinguished three prognostic groups, but very few patients had a score 0.
Summary and Conclusions: Our study suggests that conventional IPI remains
the most useful prognostic index. Bulky disease does not seem to be of prog-
nostic importance, probably because of widespread use of adjuvant radiother-
apy to initial bulky sites after immunochemotherapy. As seen in some other
studies, men have a worse prognosis, possibly related to differences in ritux-
imab metabolism. Additional negative prognostic factors include anemia, B
symptoms and bone marrow infiltration, possibly as markers of aggressive sys-
temic disease.
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CLINICAL IMPACT OF EARLY RECOVERY OF POST-TRANSPLANT
PERIPHERAL BLOOD ABSOLUTE LYMPHOCYTE COUNT ON THE
OUTCOME OF FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION
FOR DIFFUSE LARGE B-CELL LYMPHOMA
Y. Kim1,* J.Y. Lee1, H.S. Park1, J. Jang1, S.J. Kim1, J.W. Cheong1, Y.H. Min1,
J.S. Kim1
1Yonsei University Severance hospital, Seoul, Korea, Republic Of
Background: Several studies have shown that lymphopenia, which is consid-
ered a surrogate marker of immunological incompetence, has considered as
an adverse prognostic factor in Non-Hodgkin`s lymphoma (NHL). Recently, it
has been suggested that early recovery of an absolute lymphocyte count (ALC)
at 2-3 weeks following therapy has been associated with superior progression-
free survival (PFS) and overall survival (OS) in patients who received autolo-
gous stem cell transplantation (ASCT) for NHL,. However, the prognostic sig-
nificance of early recovery of peripheral ALC following frontline ASCT in diffuse
large B-cell lymphoma (DLBCL) remains unclear.
Aims: The purpose of this study was to investigate the prognostic role of early
recovery of peripheral ALC after ASCT in patients with DLBCL who underwent
frontline ASCT.
Methods: We retrospectively evaluated 51 patients who underwent ASCT for
DLBCL at Yonsei University Severance Hospital between January 2006 and
2014. All patients were treated with R-CHOP (rituximab-cyclophosphamide,
doxorubicin, vincristine, and prednisone) every 3 weeks for 3 to 8 cycles as
first-line therapy and received frontline ASCT as consolidation. Most patients
(n=40) received intravenous busulfan-based conditioning chemotherapy. The
ALC at the time of D+14 after ASCT was obtained. Receiver operating charac-
teristics (ROC) analysis was performed to determine the optimal cut-point for
the ALC.
Figure 1.
Results: The study population included 51 patients with a median age of 53
years (range, 19-66 years). Fourty-six (90.2%) had stage IV disease according
to the Ann Arbor staging system. Most patients (87.3%) were younger than 60
years. Thirty-five (68.8%) patients had B symptoms. International prognostic
index (IPI) was low in 2 (4%), Low-intermediate in 15 (30%), high-intermediate
in 25 (50%) and high in 8 (16%). Pre-transplant disease status was complete
remission (CR) in 30 (58.8%) patients and partial remission (PR) in 21 (41.2%)
patients. The median ALC at D+14 after ASCT was 0.43x 109/L (range, 0.03-
1.57x 109/L). The ROC curve analysis identified 0.36x 109/L as the cutoff value
of ALC at D+14 for predicting relapse with an area under curve of 0,759 (95%
CI, 0.628-0.890, P=0.020). When comparing the baseline clinical characteristics
of patients with an ALC at D+14 of ≤0.36x 109/L (low ALC group, n=19) and
>0.36x 109/L (high ALC group, n=32), no significant difference was found
between two groups, except for a female dominance and presence of B symp-
toms at diagnosis in the low ALC group. The median survival of patients follow-
ing ASCT was 49.4 months (range, 4.4-101.9 months). In a univariate analysis
from the time of ASCT, it appears that high ALC at D+14 was associated with
a better OS (HR=0.083; 95% CI 0.010-0.694, P=0.022) and PFS (HR=0.086;
95%CI 0.010-0.720, P=0.024) and event-free survival (EFS) (HR=0.283; 95%
CI 0.082-0.971, P=0.045). Multivariate analysis revealed that high ALC at D+14
was a good prognostic factor for OS (HR=0.086; 95%CI 0.008-0.979, P=0.048).
Summary and Conclusions: The early recovery of ALC at D+14 after ASCT
can be regarded as a good prognostic marker in patients with DLBCL who
underwent frontline ASCT.
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INVESTIGATION OF SEROUS EFFUSIONS WITH FLOW CYTOMETRY
O. Salim1, U. Iltar1,* O. K. Yucel1, R. Erdem1, M. Ulubahsi1, L. Undar1
1Hematology, AKDENIZ University, Antalya, Turkey
Background: In current clinical practice serous effusions are evaluated by
cytopathologic, chemical and microbiologic examinations. As well as infections
and inflammatory diseases, serous body fluids can also be observed in
hematopoietic and solid neoplastic diseases. Flow cytometry(FC) is well estab-
lished as a critical and quick diagnostik tool used routinely in the diagnosis of
hematopoietic neoplasms by fine-needle aspiration and an alternative diag-
nostic method for the evaluation of serous body fluids. 
Aims: The aim of this study was to investigate immunophenotypic analysis of
serous body fluids by FC.
Methods: During the time period of 2010-2014, a total of 79 consecutive serous
effusion specimens (45 pleural, 33 peritoneal, 1 pericardial ) of 76 cases (40
female, 36 male, 24-84 years of age) were investigated with the six-color FC
(FACSCanto II, BD Biosystems, San Jose, USA) in the Division of Hematology
Laboratory at Akdeniz University Hospital. We retrospectively analyzed these
datas.
Results: FC was positive for definitive immunophenotypic evidence of a
hematopoietic malignancy in 3 of 45 pleural fluid specimens (Diffuse Large B-
cell lymphoma(1 case), Burkitt’s lymphoma(1 case), T-cell Acute Lymphoblastic
Leukemia / Lymphoma(1 case)) and 3 of 33 peritoneal fluid specimens (T-cell
prolymphocytic leukemia(1 case), diffuse large B-cell lymphoma(1 case),
Burkitt’s lymphoma(1 case)(Figure 1)). Subsequent tissue studies confirmed
the diagnosis of a hematopoietic neoplasm in these seperate six cases.
Figure 1.
Summary and Conclusions: Cytopathologic evaluation may lay long espe-
cially in the diagnosis of aggressive lymphomas which requires urgent evaluation
and treatment. Immunophenotypic analysis of serous body fluids by FC can
provide better access to early diagnosis and also accurate clinical staging.
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EVALUATION OF MINIMAL RESIDUAL DISEASE AND USAGE OF
TARGETED THERAPY IN PEDIATRIC PATIENTS WITH ANAPLASTIC
LARGE CEL LYMPHOMA
K. Katsibardi1,* A. Vlachou1, N. Tourkantoni1, E. Atmatzidou1, S. Kostaridou1,
A. Kattamis1
1Hematology-Oncology Unit, 1st Department of Pediatrics, “Aghia Sofia” Chil-
dren’s Hospital, Athens, Greece
Background: Anaplastic large cell lymphoma (ALCL) is an aggressive T cell
non-Hodgkin lymphoma, characterized by an increased risk of relapse. Its pres-
entation maybe cutaneous or systemic. It is classified on the basis of the
expression of anaplastic lymphoma kinase (ALK) protein, which carries the
translocation t(2;5)(p23;q35) and results in the specific fusion gene Nucle-
ophosmin (NPM-ALK). In 50% to 60% of patients with NPM-ALK–positive
ALCL, NPM-ALK–expressing cells can be detected in peripheral blood and
bone marrow samples by qualitative reverse-transcriptase polymerase chain
reaction (RT-PCR). ALCL is designated by the uniform expression of CD30,
making this surface antigen a target for immunotherapeutic approaches. 
Aims: The purpose of the present report was the evaluation of minimal residual
disease in children with ALCL and its usage in guiding treatment with targeted
therapy, namely the anti-CD30 antibody-drug conjugate, Brentuximab vedotin. 
Methods: RT-PCR for NPM-ALK was performed in bone marrow or peripheral
blood samples in two pediatric patients with NPM-ALK–positive ALCL, at reg-
ular time points. 
Results: The first patient is an 11-year-old girl with systemic NPM-ALK–positive
(lymphadenopathy, skin, orbit and central nervous system involvement). She
achieved remission and completed chemotherapy based on the AEIOP proto-
col. Three months after treatment completion she presented with disseminated
relapse and required ventillatory support. She started targeted treatment with
Brentuximab vedotin. She promptly responded to the treatment and she was
able to be weaned off ventillatory support within 3 days after the infusion. The
patient entered clinical and radiological remission (MRI and PET scan) with
Brentuximab vedotin given at dose of 1.8 mg/kg IV every 3 weeks. She received
a total of 6 cycles and subsequently underwent mega-therapy with autologous
bone marrow transplantation rescue. Six months after transplantation, RT-PCR
for NPM-ALK became positive, while the patient remained in clinical remission
and the imaging examinations were negative for disease. Brentuximab vedotin
was reinstituted and she entered molecular remission with negative minimal
residual disease after the 5th cycle. The second patient is a 9-year-old boy with
systemic NPM-ALK–positive ALCL, presenting with an abdominal primary
mass. He completed chemotherapy and is monitored by radiological examina-
tions and RT-PCR for NPM-ALK at regular time points. Minimal residual disease
in this patient remains negative six months after the end of therapy. 
Summary and Conclusions: Recent advances in the treatment of adult
patients with NPM-ALK–positive ALCL have led to better follow up and expand-
ed options of therapeutic modalities, especially for patients who relapse. Early
detection of relapse by assessing minimal residual disease with molecular
techniques seems to be superior to classical clinical risk features, identifying
a high risk for overt relapse group of patients, which can be amenable by alter-
native therapeutic approaches. In conclusion, the potential use of minimal resid-
ual disease detection and second-line treatment like the novel antibody-drug
conjugate, Brentuximab vedotin, warrant further evaluation for pediatric patients
with CD30-expressing ALCL.
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PERFORMANCE OF THE NGS-BASED LYMPHOTRACK® IGK ASSAY:
IDENTIFYING AND MONITORING CLONALITY IN LYMPHOPROLIFERA-
TIVE DISEASE
Z. Xie1,* K. Hutt1, W. Huang1, M. Klass1, J.E. Miller1
1Invivoscribe Technologies, Inc., San Diego, United States
Background: During B-cell development functional immunoglobulin genes are
assembled from individual V, D, and J gene segments to generate V-D-J com-
binations of length and sequence that are unique for each cell. Rearrangements
within IGH occur first, followed by IGK. Along with the Vk and Jk segments,
there are other elements in the IGK loci that can be involved in recombination.
The Kde can rearrange to Vk gene, but also to an isolated RSS in the Jk-Ck
intron (INTR). If IGK rearrangements that produce functional IgH/IgK molecules
are not successful, rearrangement proceeds within the other immunoglobulin
light chain (IGL) locus. Leukemia and lymphomas originating from the malignant
transformation of individual lymphoid cells generally share one or more of these
cell specific or “clonal” gene rearrangements. Assays that identify clonal lym-
phocyte populations in clinical specimens are used on a routine basis to assist
in the diagnosis of lymphoproliferative disease.
Currently, most IGK clonality assays use multiplex PCR followed by capillary
electrophoresis. However, these methods often do not provide sufficient ana-
lytical sensitivity and are incapable of identifying the specific rearranged DNA
sequence data required to track clones in follow up testing. The emergence of
cost-effective, next-generation sequencing (NGS) platforms and development
with associated bioinformatics tools have resulted in powerful new approaches
for clonality detection and monitoring.
Aims: To establish the performance of a sensitive, robust and reliable NGS
assay formatted for the Illumina® MiSeq instrument that includes the bioinfor-
matics tools to identify clonal IGK gene rearrangements and the corresponding
specific V-J DNA sequence information.
Methods: LymphoTrack® IGK Assay (Invivoscribe, Inc., San Diego, CA USA)
uses a single PCR multiplex master mix to amplify each sample (24 indices,5
reactions each, are included in each kit).The amplicons were purified using
the AMPureXP system and purified equimolar amounts of amplicons were
pooled to generate a library. A portion of the library was sequenced on a MiSeq
instrument using the MiSeq v2 Reagent kit (500 cycles). The MiSeq data was
analyzed using LymphoTrack® bioinformatics software, which generated fre-
quency distributions and identified the rearranged DNA sequences.
Results: Data generated with the LymphoTrack® IGK Assay and bioinformatics
software identified clonality and corresponding DNA sequences of IGK Vk-Jk,
Vk-Kde, and INTR-Kde gene rearrangements. The results obtained generally
were concordant with results of testing with capillary electrophoresis. The assay
demonstrated excellent linearity, sensitivity, and reproducibility using contrived
samples. This assay was used to test genomic DNA from peripheral blood,
bone marrow and FFPE specimens. In addition, this NGS testing approach
identified the specific break point sequence of the INTR element.
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Summary and Conclusions: A comprehensive NGS assay has been devel-
oped for the Illumina MiSeq platform that identifies clonal IGK Vk-Jk, Vk-Kde
and INTR-Kde rearrangements and the associated specific DNA sequences.
The assay can be used both to detect and monitor clonal populations.
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PRIMARY CENTRAL NERVOUS SYSTEM POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISORDER (PTLD-CNS) IS AN EBV-RELATED
DISEASE WITH GOOD RESPONSE TO ISS REDUCTION AND
RADIOTHERAPY: SINGLE-CENTER STUDY OF 16 CASES
E.M. Cavalcante1,* G.F. Perini1, J. Garibaldi Jr1, A.M.D. Penna1, J.C. Vargas1,
J.O.M. Pestana2, O.C.G. Baiocchi1
1UNIFESP-Federal University Of São Paulo, 2Hospital do Rim e Hipertensão,
São Paulo, Brazil
Background: Post-transplant lymphoproliferative disorders are a heterogenous
group of diseases occurring in the setting of post-transplant immunossupres-
sion. Clinically, extranodal involvement is common, and it occurs in the CNS in
approximately 7-15% of cases. Most data on PTLD-CNS are based on case
series/reports, with an exception of a multicenter study of 84 patients. In this
group, PTLD-CNS showed to be a poor prognosis, late-ocurring EBV-associ-
ated disease. We retrospectively analyzed 16 cases of PTLD-CNS in Hospital
do Rim, Sao Paulo, Brazil.
Aims: To analyze the cases of PTLD with CNS involvement diagnosed on our
center over the past 17 years.
Methods: From 1998 to 2014, a total of 11,284 kidney transplants were per-
formed at Hospital do Rim e Hipertensão/UNIFESP (Federal University of São
Paulo). We retrospectively analyzed cases of PTLD with CNS involvement
diagnosed over the past 17 years. Only confirmed cases of PTLD with available
clinical and epidemiological data were included.
Results: From 1999 to 2014, a total of 20 patients were diagnosed with PTLD-
CNS. Four patients were excluded from the analysis due to conflict data. Among
16 patients, the median age at time of diagnosis was 40, with a male:female
ratio of 0,77:1. 56% of patients received ATG at the time of transplant. Regard-
ing immunossupression (ISS), all patients received Prednisone, 37,5% received
FK, 43,7% received MMF, and 56,2% received CSA. The median time of trans-
plant to PTLD was 93 months, with 25% patients with polymorphic PTLD and
75% with monomorphic PTLD (DLBCL). Regarding EBV positivity, 14/16 were
EBV+, with 1 EBV- and 1 inconclusive. All patients had ISS reduction, 43% of
patients received brain radiotherapy. Only 1 patient received high dose
Methotrexate. 75% of patients responded to treatment. No death related to
lymphoma progression was observed: four patients died, all of them due to
infectious complications, and none of them during therapy. 
Summary and Conclusions: In our population, CNS-PTLD was an EBV-relat-
ed disease with good response to ISS reduction and radiotherapy, with most
patients achieving responses. No death due to disease progression was
observed. Late effects of brain radiation, however, should be taken in account
when deciding the best therapy for this rare complication of transplant.




CIRCUMCISION AND COMPLICATIONS IN ADOLESCENT AND ADULT
PATIENTS WIITH HEMOPHILIA IN SOUTHERN PART OF TURKEY
I. Sasmaz1,* B. Antmen1, B. Guvenc2, B. Karagun1, Y. Kilinc1, A. Aridogan3
1Pediatric Hematology, 2Hematology, 3Urology, Çukurova University, Adana,
Turkey
Background: Circumcision is the oldest and most frequent surgical procedure
in the world and especially in Turkey as is seen in the other Islamic countries
because of religious and traditional pressures. The world health organization
defines an adolescent as any person between ages 10 and 19. The social pres-
sures are very strong in adolescent patients and especially adult patients. In
this study, we aim to report the experience of circumcision at Çukurova Univer-
sity in total 36 adolescent and adult patients with hemophilia between 1994
and 2013.
Aims: We retrospectively reviewed medical records of 33 hemophilia patients
without inhibitors and 3 hemophilia patients with inhibitors who had been cir-
cumcised. Before the year 2000, factor concentrates were given before and
after circumcision for 6-7 days. After 2000, we used fibrin glue together with
factor concentrates for only 3 days. By-passing agents were used for circum-
cision in hemophilia patients with inhibitors.
Methods: We retrospectively reviewed medical records of 33 hemophilia
patients without inhibitors and 3 hemophilia patients with inhibitors who had
been circumcised. Before the year 2000, factor concentrates were given before
and after circumcision for 6-7 days. After 2000, we used fibrin glue together
with factor concentrates for only 3 days. By-passing agents were used for cir-
cumcision in hemophilia patients with inhibitors.
Results: 33 patients with hemophilia were circumcised in our centre under
general anesthesia except for 3 patients who were given local anesthesia. Eight
of 33 hemophilia patients (24,2%) without inhibitors had 5 mild and 3 moderate
bleeding complications. A few patients had significant bleeding despite ade-
quate factor replacement. Two of three hemophilia patients with inhibitors had
2 mild bleeding complications.
Summary and Conclusions: Our experience showed that circumcision for
patients with hemophilia should be carefully performed by surgeons together
with pediatric hematologist under appropriate conditions in hemophilia centers
which has comprehensive coagulation lab.
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MONITORING OF TREATMENT WITH BYPASSING AGENTS IN PATIENTS
WITH ACQUIRED AND CONGENITAL HAEMOPHILIA WITH INHIBITORS
USING ROTEM: A SINGLE-CENTRE EXPERIENCE
A. Balta1,* M. Tornemo1, V. Radulovic1, F. Baghaei1
1Coagulation Department, SAHLGRENSKA University HOSPITAL, Gothen-
burg, Sweden
Background: Acquired and congenital haemophilia with inhibitor against FVIII
or FIX are usually managed with bypassing agents, such as recombinant factor
VIIa (rFVIIa) and activated prothrombin complex concentrates (APCC). To be
able to evaluate and predict the clinical effects of treatment with bypassing
agents, global coagulation assays could be useful monitoring tools. One of the
currently leading candidate methods for this purpose is thromboelastography/
rotational thromboelastometry (TEG/ROTEM ).
Aims: Our purpose is to evaluate the changes in ROTEM parameters during
treatment with bypassing agents and its correlation with the clinical effect.
Methods: In this retrospective study 11 haemophilia patients were included (age
5-85 years). Four (n:4) were patients with congenital severe haemophilia A with
inhibitors and seven (n:7) were patients with acquired haemophilia A. Recorded
total 15 bleeding episodes, acute or associated to surgical procedures and all of
the patients treated with APCC. Monitoring of global hemostasis was performed
with ROTEM assay, before and after bypassing agent administration.
Results: Excellent and good haemostatic effect was demonstrated in 87% of
patients. One patient had adverse effect complicated with thrombosis. Accord-
ing to ROTEM analysis in NATEM the average of clotting time (CT) before and
after APCC administration was 2110 sec and 888 sec respectively. Furthermore
the clot stability was evaluated with maximum clotting firmness (MCF) param-
eter and that was 11 mm and 62 mm before and after APCC administration
respectively.
Summary and Conclusions: The results of this single-centre report demon-
strates, in a limited number of patients, improvement in ROTEM parameters
(CT and MCF in NATEM) after APCC administration. In the most of the cases
these results accompanied with good or excellent clinical response (87%) in
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bypassing agent treatment. According to our data the ROTEM method could
be a useful monitoring tool to predict the efficacy of treatment with bypassing
agents in haemophilia patients with inhibitors. Undoubtedly further studies
should be performed with adequate number of patients in order to reinforce
our conclusion.
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RARE BLEEDING DISORDERS IN OMANI CHILDREN: A SINGLE CENTER
EXPERIENCE
M. Elshinawy1,2,* A. Rawas1, Y. Wali1
1Pediatric hematology, SQUH, Muscat, 2Pediatrics, Faculty of Medicine,
Alexandria University, Alexandria, Egypt, Oman
Background: Rare bleeding disorders (RBDs) are autosomal recessive het-
erogeneous group of inherited coagulation factor deficiencies, with a preva-
lence varying between 1:500,000 and 1:2,000,000. Remarkably, there is a
paucity of data on RBDs from the Middle East. Despite education and social
modernization, Oman still has a high prevalence of consanguineous marriage,
reaching more than 50% of all registered marriages. Being mostly autosomal
recessive, RBDs are expected to be relatively high in such community com-
pared to western countries.
Aims: The aim of the current work is to study the demographic characteristics,
clinical presentations and management of RBDs in Omani pediatric patients.
Methods: Retrospective data analysis of all children diagnosed with inherited
coagulation factor deficiencies in Pediatric Hematology Unit, Sultan Qaboos
Universsity Hospital, Muscat, Oman from January 2009 till December 2014.
Results: Deficiencies of fibrinogen, FV, FVII, FX and FXIII were diagnosed in
16 pediatric patients (7 males and 9 females), accounting for 9.5% (16/169) of
all children with inherited coagulation factor deficiencies. The age ranged from
3 days to 6 years and consanguineous marriages were found in 13/16 cases
(81.3%). The clinical spectrum varied from mild mucocutaneous bleeding to
serious sight-threatening retrobulbar and intraocular hemorrhage with subse-
quent unilateral enucleation. As an initial presentation, intracranial hemorrhage
occurred in 5/16 cases (31.3%). Two patients (12.5%) suffered from global
developmental delay due to severe intracranial hemorrhage in early infancy.
Four patients (3 with FV deficiency and 1 with FXIII deficiency) are on regular
prophylaxis. The detailed demographic data, clinical presentations, complica-
tions and management of all patients are shown in Table 1.
Table 1. Demographic data and clinical characteristics of pediatric
patients with rare bleeding disordes.
Summary and Conclusions: In conclusion, children with RBDs constitute
almost one tenth of cases of hereditary coagulation factor deficiencies in our
center. They have some unique features in terms of severity, clinical profile
and the need for prophylaxis early in life. We recommend establishing a nation-
al/regional registry of RBDs in collaboration with other centres in Oman and
the Middle East. This will serve to identify the epidemiology, clinical presenta-
tions, genotype-phenotype correlation and therapeutic options of such rare,
yet significant disorders in this part of the world.
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COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY
WITH A NOVEL MISSENSE MUTATION IN MCFD2 GENE
A. Wang1,* X. Liu1, J. Wu1, Z. Sun1
1Hematology, Anhui Provincial Hospital; Anhui Provincial Hemophilia Treatment
Center, Hefei, China
Background: Mutations in LMAN1 or MCFD2 genes cause a rare autosomal
recessive bleeding disorder, which was named combined FV and FVIII defi-
ciency (F5F8D). Encoded proteins by MCFD2 and LMAN1 genes which may
form a Ca2+-dependent cargo receptor complex have been confirmed to par-
ticipate in the transport of FV and FVIII from the endoplasmic reticulum (ER)
to the Golgi. We made a diagnosis F5F8D by findings of decreased FV and
FVIII levels in a Chinese family.
Aims: Try to study the molecular mechanism of the disease and observe the
clinical features and treatment in this family.
Methods: We do a molecular genetic analysis in the family. All the exons of
LMAN1 and MCFD2 genes were PCR amplified and sequenced.
Results: We found a novel missense mutations p.Asp81Ala in MCFD2 gene
in a Chinese family. The patient was homozygous missense mutation for
Asp81Ala in exon 3 of MCFD2 gene, while his father and one of his sisters
were heterozygous. LMAN1 gene in this family was revealed no additional
mutations.
Summary and Conclusions: The presence of consanguineous marriage in
the family played an important role in the cause of this disease. The Asp81
missense mutations reported in MCFD2 to date was carried out from the many
patients, like Asp81Tyr and Asp81Asn, while the mutations ‘Asp81Ala’ have
not previously been reported. Therefore, It seems likely that the mutation in
the Asp 81 is a hot region, The Asp81 residue replacement by Ala most likely
disrupts the MCFD2–LMAN1 cargo receptor complex.
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SURGICAL MANAGEMENT OF ELECTIVE SURGERY IN PATIENTS WITH
MILD HAEMOPHILIA FROM A SINGLE INSTITUTION
L. Lacalle1,* N. Espinosa1, A. Segura1, J. M. Calvo1, N. Fernandez1,
P. Delgado1
1HUMS, Zaragoza, Spain
Background: There is a spectrum of severity of haemophilia, defined as ‘mild’,
‘moderate’ or ‘severe’ according to the plasma levels of FVIII or FIX activity. Mild
haemophilia may not be diagnosed until a minor surgery causes prolonged bleed-
ing. Although general surgery in patients with ‘mild’ haemophilia has become
more common, the surgical literature concerning these patiens remains limited.
Aims: The purpose of this single centre retrospective study was to investigate
perioperative management and outcome of mild haemophiliac patients under-
going different surgical procedures.
Methods: For this study, we revised 12 mild hemophilia patients, who underwent
31 surgical procedures between 2008 and 2014 at our institution. Classification
into minor/major surgery was carried out according to the BUPA system. We
analized the hematologic diagnosis, type of surgery, genetic mutation linked to
haemophilia, treatment undertaken to correct the bleeding disorders, the dose
and duration of clotting factor administrated and post-surgical complications.
Results: We revised a total of 31 surgical procedures performed in 12 mild
haemophilia patients, 9 Haemophilia A (HA) and 3 Haemophilia B (HB). Median
age at surgery 37 years (range: 20-54). No patients received an anticoagulatory
prophilaxys for perioperative management. Among this haemophiliac group, 5
patients (41.6%) were hepatitis C seropositive who did not receive antiretroviral
therapy. We didn´t found any seropositive for HIV or other viral disease. Molec-
ular study was available in 7 patients (6 HA and 1 HB). 6 patients showed mis-
sense mutations: exon 14 (p.Arg698Trp), Exon 7 (p.Val 266Ala), Exon 2
(c.6374G>A), exon 12 (p.Arg593Cys), Exon25 (p.Asp2267Gly) and Exon 3
(p.Asp82Glu) and exon 2 (c.6374G>A) in 1 HB patient. Data about surgery,
pre and post procedure treatment are seen in Table 1, 23 (74.2%) were minor
and 8 (25.9%) were major surgery. Loco-regional anaesthesia was performed
in 22 (70.9%) procedures. 8 (66.7%) patients (6 HA/2 HB) underwent more
than one surgical procedure. Pre and post-procedure dose of factor replace-
ment treatment were adjusted according WFH guidelines. Plasma derived FVIII
was employed in 2 patients during 4 procedures and recombinant FVIII or FIX
were employed in 9 patients. Desmopressin alone and tranexamic acid alone
were employed in 2 patients who underwent dental extraction (no wisdom
tooth). Regarding minor procedures, 20 patients received Tranexamic Acid IV
on postoperative days 1, 2 and 3. Before surgery, 1 patient who underwent 1
surgical procedure (dental extraction) showed a baseline factor level 5%>10%,
6 patients (12 procedures) showed factor levels 10%>20%, 5 patients levels
21%>30% (16 procedures) and 2 patients (2 procedures) 31%>40%. One HB
patient (3.2% of all procedures) with a baseline factor level of 7.6% developed
local bleeding after dental extraction although preoperative dose of recombinant
FIX was administered, and he required one additional dose of recombinant
FIX. No inhibitor development was observed.
Table 1.
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Summary and Conclusions: Surgical procedures in patients with mild
haemophilia can be performed with low hemorrhagic morbidity rates when there
is good haematological support and appropriate hemostatic treatment. There
was no association between the type of product used in perioperative period
and inhibitor development in our group of patients. It is important that minor
surgery should be scheduled to use desmopressin analogs +/- antifybrinolytics
agents instead of recombinant clotting factor VIII/IX to minimize the risks of
therapies and reduce overall treatment costs.
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CHANGES IN THE HEMOSTATIC SYSTEM IN PATIENTS WITH APLASTIC
ANEMIA
V. Kobilyanskaya1,* S. Bessmeltsev2, E. Shilova2, T. Morozova1
1Hemostasiological Laboratory, 2Hematological department, Russian Research
Institute of Hematology and Transfusiology of the FMBA of Russia, St-Peters-
burg, Russian Federation
Background: Introduction. Since the first description by Paul Arliam acquired
aplastic anemia (AA) over 100 years ago, but today this disease remains in the
spotlight hematologists and physicians in adjacent fields. AA-a serious disease
of the blood system, resulting from damage to the stem cells (precursors of all
blood cells), resulting in a profound inhibition of normal hematopoiesis with the
development of pancytopenia. One of the main clinical manifestations is hem-
orrhagic syndrome caused by thrombocytopenia. Moreover, the clinically sig-
nificant hemorrhagic syndrome is observed usually only with severe thrombo-
cytopenia. In connection with this, is of great interest the study of the compen-
sating functions of the system of hemostasis in AA – patients.
Aims: The search for diagnostic markers hypercoagulation status in patients
with AA. 
Methods: The research material was venous blood 25 patients (17 men and 8
women, mean age 38±0,5), with a diagnosis of aplastic anemia”. Plasma level
of hemostasis was evaluated in the following coagulation tests: activated partial
thromboplastin time (APTT), prothrombin time Quick (PT), thrombin time (TT),
the concentration of fibrinogen (Fg), the activity of the factor VIII activity of
antithrombin (AT). The control group consisted of 40 clinically healthy men and
women of similar age.
Results: Compared to the normal performance of screening tests (APTT, PV,
TV, FG) in 18 (72%) of 25 patients reported a significant increase in the activity
of factor VIII, which is usually regarded as an indicator hypercoagulation state
of hemostasis (189,8%±96,5% against normal value 119,0%±30.5%, P<0,001).
However, in 8 (44%) of 18 patients with elevated factor VIII revealed reduced
levels of antithrombin, which amounted to 68% (fluctuations from 74% to 62%).
However, clinical manifestations hypercoagulation syndrome (thrombosis and
thromboembolism) single patient not were observed.
Summary and Conclusions: Thus, in patients with AA showed increased
activity of factor VIII and decreased levels of anti-thrombin. Whether these indi-
cators markers hypercoagulation state, or is it a manifestation of compensatory
functions, which prevent severe hemorrhagic complications in this category of
patients. Research in this direction continues.
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FACTOR VII DEFICIENCY IN WEST ALGERIA
D. Benlaldj1,* M. Moueden1, W. Homane1, F. Seghier1
1HEMOBIOLOGIE, CHU ORAN, oran, Algeria
Background: Factor VII deficiency is one of the rare inherited bleeding disor-
ders, the frequency is 1/500000. His molecular study is very interesting because
of its rarity.
Aims: The objectif of this study was to describe the bleeding tendencies and
the variation of factor VII level.
Methods: Retrospective study coducted for 7 years (2008 to 2014) in the west
Algeria. 63 patients has been tested for diagnosis of rare bleeding disorder.
we use the assigned categories of clinical bleeding severity of European Net-
work of Rare Bleeding Dsorders: 1. Asymptomatic (no document bleeding
episodes). 2. Grade I bleeding (bleeding that occured after trauma or drug
ingestion). 3. Grade II bleeding (spontaneous minor bleeding, bruising, ecchy-
mosis, minor wounds, oral cavity bleeding, epistaxis and menorrhagia). 4.
Grade III bleeding (spontaneous major bleeding, hematomas, hemarthrosis,
central nervous system, gastrointestinal and umbilical cord bleeding).
Results: 18 patients (28.57%) diagnosed with factor VII deficiency, 06 patients
have factor level<10% classified with severe form, 01 patients had factor level
between 10 and 20% classified with moderate form and 11 patients have factor
level >20%, according the classification of Europen Network of Rare Bleeding
Disorders. Regarding the clinical severity 10 patients are asymptomatic (factor
level >30%), 07 patients classified on grade II (factor level between 01 and
40%) and 01 patients on grade III (factor level<5%). The oral cavity bleeding
(25%) and hematoma (17%) are the frequent bleeding symptom in our patients.
The molecular study performed for 05 patients from the same family revealed
a mutation c.430+78 G>A and polymorphism IVS7H7 in the homozygous state
(02 patients ), in the heterozygous state (03 patients). 
Summary and Conclusions: Not corelation found between factor VII level
and the clinical severety. This results are according the literature database.
The diagnosis of factor VII deficiency is depending the laboratory testing (level
factor depending to the reagent) and the bleeding severety define the disease. 
The mutation c.430+78 G>A and polymorphism IVS7H7 are described in the
literature and involved in the modulation rates of factor VII. 
PB1689
ANGIODYSPLASIA IN A CHILD AS A CAUSE OF LOWER
GASTROINTESTINAL BLEEDING FOLLOWING HEMATOPOIETIC STEM
CELL TRANSPLANTATION, WHICH WAS SUCCESSFULLY CONTROLLED
BY ANGIOEMBOLIZATION
I. Eker1,* O. Gürsel1, O. Babacan1, O. Koç2, M.S. Uğurel3, A.E. Kürekçi4
1Pediatric Hematology, Gulhane Military Medical Faculty, 2Pediatrics, 3Radiol-
ogy, 4Pediatric Hematology, Gülhane Military Medical Faculty, Ankara, Turkey
Background: Gastrointestinal complications are common following hematopoi-
etic stem cell transplantation (HSCT); however angiodysplasia is not well char-
acterized in terms of its association with HSCT and only a few reports of
angiodysplasia in transplant recipients are available, all of them are adults. 
Aims: Here we report a 7 years old child with a massive lower gastrointestinal
bleeding, caused by angiodysplasia (vascular ectasia) following HSCT. To our
knowledge, this is the first reported pediatric case demonstrating the association
of angiodysplasia with HSCT and successfully controlled by angioemboliza-
tion.
Methods: The patient was a 6-year-old boy who underwent HSCT for relapsed
acute lymphoblastic leukemia. He was in remission at the time of transplant.
Preparative regimen consisted of 12 Gy total body irradiation and 60 mg/kg
etoposide. He received 2,4x106/kg CD34+ stem cells from his well-matched
father (one antigen mismatched at HLA-C). Cyclosporin was administered for
GVHD prophylaxis. Full engraftment was achieved with neutrophil, platelet and
erythrocyte recovery being 13, 20 and 27 days respectively. On the 14th day
of transplantation grade IV acute graft-versus-host disease (GVHD) was devel-
oped (skin stage III, liver and gastrointestinal tract stage IV). Skin manifestations
were resolved, but liver and gastrointestinal GVHD went on depite prednisolone
therapy and the increase of cyclosporin. However, thrombotic microangiopathy
(TMA) was developed on the 19th day and resolution was not achieved despite
the switch of cyclosporin to mycophenolate mofetil. He underwent therapeutic
plasma exchange sessions on alternate days. The resolution was achieved
after 14 sessions, liver GVHD was also resolved, but gastrointestinal symptoms
went on with recurrent massive gastrointestinal bleeding despite therapies
including octreotide, recombinant human coagulation Factor VIIa and third party
mesenchymal stem cells. The localization of the gastrointestinal bleeding could-
n’t be identified despite nuclear medicine scan, endoscopy and colonoscopy.
The localization of the bleeding couldn’t be identified with transcatheter arteri-
ography also, but there were seen angiodysplastic lakes in branchs of celiac,
gastroduodenal and superior mesenteric artery (Figure1). With the suspicion
of these lakes may be the origin of bleedings, superselective embolization was
performed and gastrointestinal bleeding episodes were resolved completely
without any complication. Occult gastrointestinal bleeing was also became neg-
ative after ten days of the embolization and he was discharged on the 130th
day of HSCT.
Results: In the literature on the subject, it is observed that HSCT associated
gastric vascular ectasias are with a prior TMA episode and suggested that local
endothelial injury and subsequent local thrombosis in TMA may obstruct sub-
mucosal blood vessels and eventually lead to development of vascular ectasia.
The fibrin thrombi and/or ectasia in mucosal vessels observed histologically in
these patients supported their hypothesis 
Summary and Conclusions: In conclusion, angiodysplasia is a rare but impor-
tant cause of recurrent intestinal bleeding in children and should be kept in
mind as a diagnostic possibility especially in HSCT patients who have a history
of TMA. Early diagnosis of this rare lesion is important to avoid a possible fatal
outcome and thus the physician should be aware of this lesion as a rare cause
of intestinal bleeding in children.
Figure 1.
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RELATION BETWEEN INHIBITOR PRODUCTION AND BCLI/INTRON 18
AND VNTR ST14 POLYMORPHISMS IN A IRANIAN POPULATION WITH
HEMOPHILIA A 
N.B. Mirbehbahani1,* A. Rashidbaghan2, S. Livani1, A. Khosravi1
1Golestan University of Medical Science, Gorgan, 22Medical Biology Research
Center, Kermanshah University, Kermanshah, Iran
Background: According to several reports, 20-30% of severe hemophilia A
and 1-3% of severe hemophilia B patients develop inhibitors. There is a col-
lection of mutations related to production of inhibitor in hemophilia A.
Aims: In factor VIII gene that is associated hemophilia A, the most useful poly-
morphisms are bi-allelic that are formed by a single nucleotide substitution.
Identifying these mutations can help to diagnosis the susceptible people for
this disorder. Here, two of these mutations were studied in Iranian Hemophilia
with inhibitor production.
Methods: We have 150 patients with hemophilia and rare bleeding disorders
in our center. It was studied all of patients with hemophilia A from our center.
Inhibitor was tested for all of them and cases with inhibitor >0.5 BU determined.
20 patients from 80 had inhibitor. BclI/intron 18 and VNTR st14 polymorphisms
of factor VIII gene were analyzed in 20 patients of hemophilia A with inhibitor.
DNA was extracted from whole blood. RFLP and usual PCR techniques were
done for BclI/intron 18 and VNTR st14, respectively. Results: In this population,
55% had a restriction site on BclI. All of patients were homozygote for VNTR
st14 and just one allele was observed.
Results: In this population, 55% had a restriction site on BclI. All of patients
were homozygote for VNTR st14 and just one allele was observed. 
Summary and Conclusions: The observed BclI/intron 18 was quite high in
our cases in comparison other hemophilias without inhibitor. But, the heterozy-
gosity rate for VNTR st14 was different in our study in comparison with other
hemophilias without inhibitor. Therefore BclI/intron 18 can increase risk of pro-
duction of inhibitor in Iranian population.
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SEQUENTIAL THERAPY WITH ACTIVATED PROTHROMBIN COMPLEX
CONCENTRATES AND RECOMBINANT FVIIA IN PATIENTS WITH SEVERE
HAEMOPHILIA A, INHIBITORS AND LIFE THREATENING BLEEDING
M. Mitrovic1,2,*P. Miljic1,2, A. Darko1,2, B. Jelena1, L. Daniejla1, I. Elezovic1,2
1Clinic of Hematology, Clinical Center of Serbia, 2Faculty of Medicine, Univer-
sity of Belgrade, Belgrade, Serbia
Background: Haemophilia patients with inhibitors can develop bleeding
episodes refractory to monotherapy with either recombinant factor VIIa (rFVIIa)
or activated prothrombin complex concentrates (APCC). These bleeds are often
very difficult to treat and can result in significant morbidity. For such patients,
therapies with sequential administration of standard doses or concomitant
administration of lower dose of rFVIIa and APCC have been suggested. How-
ever, treatment with a combination of these agents is not widely practiced. 
Aims: To present our experience of sequential therapy with rFVIIa and APCC
in patients with severe haemophilia A, inhibitors and life threatening bleeding. 
Methods: We reviewed the medical records of all the inhibitor patients for
whom sequential therapy was prescribed, defined as having received both
APCC and rFVIIa within 6 h of each other.
Results: Case 1) A 19 year’s old patient with sever haemophilia A and previously
detected inhibitor (11 BU) developed intracranial hemorrhage. He was treated
with rFVIIa in dose 90 μg/kg/2 h. Due to very bad venous access central venous
catheter was inserted with rVIIa (120 μg/kg every 2 hours, 2 dose). Four hour
after surgery massive neck oedema and breathless developed. CT scan showed
diffuse large neck muscle and soft tissue hematoma. Therapy with APCC 100
U/kg/12h and rFVIIa 90 μg/kg every 2 to 3 hours resulted in bleeding control.
After 12 h of sequential usage, therapy was continued with rFVIIa. Case 2) A 35
year’s old patient with sever haemophilia A and previously detected inhibitor
(220 BU) developed spontaneous mediastinal and pericardial bleeding, without
sings of tamponade. He was treated with APCC 100 U/kg/12h. Two days after
admission haemoglobin level decreased from 134 to 78 g/L. CT showed massive
mediastinal bleeding complicated with pleural effusion. Therapy was continued
with rFVIIa 90 μg/kg every 2 hours, APCC 100 U/kg/12 h and blood transfusion.
After 24 h of sequential usage therapy was continued with APCC. Case 3) A 19
year’s old patient with sever haemophilia A and previously detected inhibitor
(20 BU) was prepared for tooth extraction with rFVIIa (90 μg/kg). Extraction was
complicated with massive subconjuctival, infraorbital and buccal hematoma with
difficult swallowing. Dose of rFVIIa was increased to 120 μg/kg every 2 hours,
without effect. Sequential therapy with rFVIIa 90 μg/kg/2 hours and APCC 100
U/kg/12 h was continued and bleeding was stopped. After 24 h of sequential
therapy treatment was continued with APCC. Symptoms and sings of thrombosis
and disseminate intravascular coagulopathy, as well as d dimer elevation were
not seen in our patient’s during sequential therapy.
Summary and Conclusions: Our report confirms efficacy and the safety of
short course sequential rFVIIa and APCC for the management of life threaten-
ing bleeding refractory to monotherapy with APCC or rFVIIa. However, con-
trolled trials with a larger number of patients are required to further assess the
safety, efficacy and cost benefit of this treatment.
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PREOPERATIVE SCREENING FOR BLEEDING DISORDERS: OUTCOME
OF EVALUATION IN CHILDREN WITH ABNORMAL TESTS
A. Rajendran1,* J. Scott2
1Pediatric Hematology Oncology, Sri Ramachandra Medical College and
Research Institute, 2Pediatric Hematology Oncology, Sei Ramachandra Med-
ical College and Research Institute, Chennai, India
Background: Children prior to invasive procedures undergo screening tests
with platelet count and basic ciagulation studies like prothrombin time (PT),
Partial Thromboplastin Time (PTT) to identity children with bleeding disorders
Aims: This study aims at studying the outcome of these children with abnormal
screening tests or positive bleeding history
Methods: Case records of children who satisfy the inclusion criteria and eval-
uated in the last 5 years (2009-2014) were analyzed for the final diagnosis and
surgery details.
Results: Twenty seven children were evaluated during this five years period
due to abnormal screening tests or positive bleeding history. Twenty three chil-
dren tested to have a bleeding disorder with variable severity. Three children
did not have any bleeding disorder on evaluation. Two had positive lupus anti-
coagulant and therefore prolonged PTT. The above five children underwentre-
quired surgery without excess bleeds. Te diseases picked up during evaluation
of children with abnormal screening tests or positive bleeding history were
hemophilia (5), von Willebrand disease (type3>type1) (5), mild factor 7 defi-
ciency, mild platelet function disorder(2), Bernard Soulier syndrome (2) and
Glanzmann’s thrombasthenia. One third of these cjildren underwent surgery
with appropriate component replacement. 
Summary and Conclusions: These inexpensive screening tests coupled with a
good bleeding history is an essential tool to screen children for bleeding risk. This
is especially important in children who would have never been challenged till date
and this will definitely prevent critical bleeding which might be life threatening.
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SUBSTITUTION WITH RECOMBINANT ACTIVATED FACTOR VII
(NOVOSEVEN) IN A PATIENT WITH CONGENITAL COMBINED DEFICIENCY
OF FACTOR VII AND FACTOR X DURING SURGERY OF LUNG
TUMOR-CASE REPORT
V. Milosevic1,* M. Mitrovic1,2, P. Miljic1,2, M. Jurisic3,4, D. Subotic2,5, I. Elezovic1,2
1Clinic of hematology Clinical Center of Serbia, 2Faculty of Medicine University
of Belgrade, 3Clinic of Oral Surgery Clinical Center of Serbia, 4Faculty of Dental
University of Belgrade, 5Clinic of Thoracic Surgery Clinical Center of Serbia,
Belgrade, Serbia
Background: Combined deficiency of coagulation factors is considered as an
extremely rare bleeding disorder (RBD) inherited in an autosomal recessive
pattern. Combined FX et FVII deficiency appear also associated with coagu-
lation-unrelated abnormalities (carotid body tumors, mitral valve prolapse, atrial
septal defect, ventricular septal defect, thrombocytopenia absent radius- TAR
syndrome, mental retardation, microcephaly and cleft palate).
Aims: The purpose of our case report was to evaluate therapy options for pre-
vention of bleeding in patient with hereditary combined deficiency of FVII and
FX who underwent surgery.
Methods: Application recombinant activated factor VII (NovoSeven) in patient
with congenital combined deficiency of factor VII and factor X during surgery
of lung tumor.
Results: A 19-year- old woman admited to the hospital due to preparation
treatment before teeth extraction. Combined deficiency of factors VII and X
has been diagnosed when she was 14 years old (27% FVII, FX 50%). In early
childhood was noted the delay in physical development, with spastic parapare-
sis and brachydactyly on foot. Cytogentics analysis showed a normal female
karyotype. Her sister also has a combined deficiency of FVII and FX with mental
retardation. Patient had surgery operation of echinococcus cyst at age of 15
years, and teeth extraction on several occasions. Prior to teeth extraction
patient received fresh frozen plasma (FFP), recombinant activated factor VII
(rFVIIa) and antifibrinoyitic. Intervention proceeded without complications. Few
months later, she was admited for teeth extraction (15 and 16) in general anes-
thesia, due to mental retardation. During the administration of FFP she devel-
oped severe allergic reactions with intensive urticaria, and anesthesiologist
has not consented the intervention done. After 15 days the patient received
rFVIIa 20μg/kg b.w. (2mg i.v.) and tranexamic acid imidiately before teeth
extraction. It was performed without complications (25% FVII, FX 43% before
therapy). Two days after the intervention, the patient had chast pain. ECG, car-
diospecific enzymes and D-dimer were in the reference values. X-rays and CT
of the chest showed a tumor in the left lung diameters 55x51x43 mm, which
could corresponded as tumor or echinococcus cyst. In December 2014, under-
went resection of lung tumor with preoperative application of rVIIa in a dose of
672 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
2 mg i.v (20μg/kg b.w) The therapy was continued at the same dose at 12 h
following 5 days to remove the drain. The levels of FVII were from 80% to 130%
during the treatment. Histopathology examination showed hamartoma. During
and after the surgical intervention she had not unexpected bleeding complica-
tions.
Summary and Conclusions: Therapy options for prevention of bleeding in
patients with hereditary combined deficiency of FVII and FX, who underwent
surgery, can be concentrate of rFVIIa, in dosage 20μg/kg, as the treatment of
choice.
PB1694
PREVELANCE OF H PYLORI INFECTION AND RISK OF GIT BLEEDING IN
EGYPTIAN HAEMOPHILIC PATIENTS 
N. El Husseiny1,* M. kassas2, L. Issac2
1Heamatology Department, 2Kaser El Eini University, Cairo, Egypt
Background: : H pyelori is endemic in Egypt and present a main cause of
gastrointestinal bleeding. 
Aims: Aim of this study was to evaluate the prevalence of Helicobacter pylori
infection in hemophilic patients, and to assess its impact on gastrointestinal
bleeding associated with this infection in such patients. 
Methods: Methods: we prospectively investigated the prevalence of H. pylori
infection in 40 Egyptian patients with hemophilia A,B and von Willebrand syn-
drome and 20 male subjects were included. Every patient and control subject
in the study was tested one time for H. pylori stool antigen by ELISA. All patients
and control subjects were tested for occult blood using Guaiac-based fecal
occult blood test.
Results: Twenty eight out of 40 patients were H. pylori positive (70%); and 12
out of 20 control subjects were H. pylori positive (60%). The odds ratio is 1.55,
95% CI (0.6162 to 3.9269), Significance level P=0.3497. Among 28 H.pylori
positive patients, 5 patients tested positive for occult blood (17.9%). Among
the 12 H.pylori positive subjects in the control group, only one tested positive
for occult blood (8.3%). Odds ratio for Occult bleeding in H pylori positive
patients and control was 2.39: P=0.4504. None of the H. pylori negative patients
or control subjects had a positive occult blood disease.
Summary and Conclusions: Conclusion: We concluded that in patients with
hemophilia, H. pylori should be considered as an important cause of GI bleed-
ing. The recurrence of the infection and GI bleeding can be prevented with
eradication of H. pylori. Screening test for H. pylori would be needed in patients
with hemophilia in endemic areas.
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HEMOPHILIC PSEUDOTUMOR OR TUMOR? DIAGNOSTICS AND
TREATMENT CHALLENGES
M. Smiljanic1,* M. Mitrovic2,3, D. Antic1,3, I. Elezovic2,3
1Lymphomas/Department of hemostasis, 2Department of hemostasis, Clinic of
Hematology Clinical Centre of Serbia, 3Faculty of Medicine, University of Bel-
grade, Serbia, Belgrade, Serbia
Background: Hemophilic pseudotumor is characterized by slowly expanding,
encapsulated mass. It develops as a result of extra-articular musculoskeletal
hemorrhage, in 1-2% of hemophiliacs. Hemophilia treatment has significantly
improved, bringing the opportunity for age-related morbidities development,
including malignancies. Sometimes after imaging diagnostics, surgery is nec-
essary for differential diagnostics.
Aims: To present hemophiliac patient with large tumor mass, initially suspected
for hemophilic pseudotumor. Pathohistological finding of tumor biopsy revealed
HCC metastasis with HCV infection. We discuss treatment option for such
patient.
Methods: Single case report.
Results: Hemophilia B with F IX 1% was diagnosed at the age of 15. Forty
years later, our patient was diagnosed with HCV infection and he received sub-
sequent antiviral therapy. After four years, following abdominal CT finding (liver
necrotic lesions) and presence of elevated serum alpha-fetoprotein (AFP, 174
ng/mL), HCC diagnosis was established. Trans-arterial chemoembolization
(TACE) was opted as treatment choice but prior to intervention, right forearm
painful swelling occurred. Since MRI finding of right arm and shoulder showed
large tumor mass in humeroscapular region with severe osteolytic lesions of
the right humerus, hemophilic pseudotumor was highly suspected. F IX con-
centrate substitusion was applied but with no obvious therapy response. Sub-
sequently, tumor biopsy was performed and it revealed HCC metastasis. PET
scan finding confirmed this metastasis as solitary. Several treatment options
were discussed. Since HCC is known to be poor radiotherapy responder, and
it would only be applied to metastasis, we excluded this treatment. Second
generation tyrosin kinases inhibitors that would have a certain degree of sys-
temic effect were not available in our country. Radical surgery that included
right hand amputation was also excluded, due to a very high perioperative risk
and present comorbiditiy (Diabetes mellitus type 2). Patient was subsequently
treated with palliative therapy. Five months later, lethal outcome occurred, after
severe bleeding in humeroscapular region. 
Summary and Conclusions: A leading cause for HCC in hemophilia is HCV
chronic infection. Extra hepatic metastases occur in approximately half of HCC
patients, and in our case tumor biopsy revealed very unusual HCC metastasis.
If HCV infection is diagnosed it has to be treated. Due to the high risk for HCC
in hemophilia, regular ultrasonography should be performed. When pseudotu-
mor is suspected, HCC possibility should also be investigated. HCC should be
surgically treated in its early stage.
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ASSESSMENT OF EFFICIENCY OF DIFFERENT PLASMA DERIVED FVIII
CONCENTRATES IN BLEEDING CONTROL-HEMOPHILIA PATIENTS’
PERSPECTIVE
J. Bodrozic1,* I. Elezovic1, D. Antic1, D. Lekovic1, M. Mitrovic1, P. Miljic1
1Clinic of Haematology, Clinical Center of Serbia, Belgrade, Serbia
Background: Patients in Serbia are usually switching between different plasma
derived FVIII concentrates (pdFVIII), dependent on their market availability. We
observed that some of the patients expressed a personal impression that there
is a difference in efficiency of different factor concentrates in achievement of
bleeding control. 
Aims: To investigate is there any difference regarding efficiency in achievement
bleeding control in hemophilia A patients between different pdFVIII concen-
trates, based on analysis of subjective assessments recorded in patients diaries
Methods: We extracted the data from a personal patient diary of eight adult
patients, average age of 29, with severe form of hemophilia A about sponta-
neous joint bleeding episodes, while they were on a low dosage tertiary pro-
phylaxis. Over a 4-year observation period from January 2010 to March 2014,
our patients received, twice a week, the same dosage (15U/kg) of pdFVIII. Dur-
ing this time they switched between five different pdFVIII, dependent on the
availability at that specific point of time. For every bleeding episode we recorded
the type of pdFVIII applied, pain intensity, graded from 1 to 10, time necessary
for the bleeding to stop measured in hours and overall subjective assessment
of the therapy efficiency (OSA). OSA was graded from 1, meaning that patient
considered therapy completely ineffective, to 10, meaning that bleeding stopped
immediately after treatment.
Results: Eight patients received first plasma derived FVIII concentrate (pdFVI-
II1) during altogether 88 months, second (pdFVIII2) 83 months, third (pdFVIII3)
68, fourth (pdFVIII4) 79 and fifth (pdFVIII5) during 82 months. For pdFVIII1
average bleeding frequency per month was 0.53, for pdFVIII2 0.52, pdFVIII3
0.52, pdFVIII4 0.59, pdFVIII5 0.58. Mean time for bleeding to stop while using
different pdFVIII was 6.15, 5.88, 6.08, 5.91, 6,02 hours. Average OSA was 6.0,
7.38, 6.67, 6.0, 6.9, for each pdFVIII respectively. In multivariate logistic regres-
sion analysis, OSA, was highly influenced by the time necessary for the bleed-
ing to stop (OR=0,108 CI 0,068-0,147), but not with used pdFVIII concentrate.
Summary and Conclusions: According to our results, the type of pdFVIII
applied didn’t have any influence on OSA as well as the pain intensity. The
OSA was dependent only on the length of bleeding episode. 
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FACTOR XIII DEFICIENCY WITH INTRACRANIAL HEMORRHAGE 
N. B. Mirbehbahani1,*
1Golestan University of Medical Science, Faculty of Medicine, Gorgan, Iran
Background: Congenital factor XIII (FXIII) deficiency is a rare autosomal reces-
sive coagulation disorder. This congenital disorder is associated with poor
wound healing, spontaneous abortion, life-long tendency towards spontaneous
bleeding and a high risk of potentially life-threatening intracranial hemorrhage.
Aims: Routine prophilaxis with FXIII concentrate is recommended in all indi-
viduals with FXIII levels of<1 IU/dl from the time of diagnosis and in some
severely affected patients with FXIII levels of 1-4 IU/dl.Therefore reliable assays
for FXIII are necessary not only for the diagnosis of deficiency state but also to
guide prophilaxis and replacement therapy in patients during times of increased
risk. In Iran, ureaclot lysis test (FXIII screen) is the most available test and reli-
able assays are not accessible because of limitations of laboratory equipment.
Hence, we recommended prophilaxis in any cases with abnormal FXIII screen
and history of intracranial hemorrhage.
Methods: In here, it is reported the clinical course and outcome of 38-month
old boy with intracranial hemorrhage that successfully managed and received
prophilaxy with fibrogammin® P. He had a history of recurrent spontaneous
bleeding or bleeding after trauma in extremities from birth. He admitted at 27
month of age in hospital due to gluteous hematoma after muscle injection. He
was tested for PLT, PT, PTT, INR, fibrinogen (clauss method) and FXIII screen
(ureaclot lysis test). He had abnormal FXIII screen test and other tests were
normal. He managed with fresh froze plasma before diagnosis and recom-
mended for on demand therapy after diagnosis
Results: He admitted at 30 months of age due to headache and vomiting. Brain
CT scan revealed intracranial hemorrhage. He was treated with fibrogammin® P.
The prophylactic substitution therapy with fibrogammin® P 20 IU/kg every 4 weeks
performed and he is free from bleeding episodes. Nugent et al, 2012, studied on
41 patients with congenital FXIII deficiency. Fibrogammin® P was administrated
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intravenously at an initial dose of 40 IU/kg every 4 weeks, with dosing adjusted
to maintain a trough FXIII activity level of 5-20%. No spontaneous bleeding
episodes requiring FXIII treatment were reported during the study.
Summary and Conclusions: According to inaccessibility to reliable assays of
FXIII in Iran we recommended prophilaxy with fibrogammin® P in all cases with
intracranial hemorrhage.
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FACTOR II DEFICIENCY IN WEST OF ALGERIA : SINGLE CENTER
EXPERIENCE
M. amine1,* H. wassila1, B. Driss1, S. fatima1
1pharmacy oran, hemobiology service, Oran, Algeria
Background: Factor II deficiency is one of the rare inherited bleeding disorders
the frequency in world is 1/ 2*106. But in algeria there is high consanguinity
rates have increased the number of patients with Rare Bleeding Disorders
(RBDs)
Aims: It was established a clinical and biological classification of patients with
rare deficiency disorders. It was explored the relationship between coagulation
factor activity level and bleeding severity for this patients.
Methods: A retrospective study conduct from 2008 to 2014. It was concerned
63 patients with a mean age 29 years (range1 year to 73 years) and Sex ratio
♂/♀=1.17. We use assigned categories of clinical bleeding severity of The
European Network of Rare Bleeding Disorders (EN-RBD): 1. Asymptomatic :
No documented bleeding episodes. 2. Grade I : bleeding Bleeding that occurred
after trauma or drug ingestion (antiplatelet or anticoagulant therapy). 3. Grade
II : Spontaneous minor bleeding:bruising, ecchymosis, minor wounds, oral cav-
ity bleeding, epistaxis and menorrhagia. 4.Grade III : bleeding Spontaneous
major bleeding: hematomas*, hemarthrosis, central nervous system,gastroin-
testinal and umbilical cord bleeding.
Results: 06 patients (09.5%) of RBDs were diagnosed with Factor II deficiency,
Clinical bleeding showed that the most common symptoms in patients with FII
deficiency were oral cavity bleeding(34%), followed by hematomas(17%), epis-
taxis (17%) .
Summary and Conclusions: Any association between bleeding manifesta-
tions and residual FII coagulant activity in plasma was found, but is very difficult
to ascertain this association because the small number of reported cases.
However, 03 patients with FII coagulant activity<10% reported to be associated
with severe bleeding manifestations grade II and III.and a weak direct correla-
tion between laboratory severity and the age at first bleed was noted. 
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RESISTANT THROMBOSIS WITH STANDARD HEPARIN TREATMENT:
ANTI-THROMBIN III DEFICIENCY
Y. Altuner Torun1,* M. C. Serbetci2, G. Poyrazoglu3
1Pediatric hematology, 2Pediatrics, 3Pediatric neurology, Kayseri education
and research hospital, Kayseri, Turkey
Background: Sinus vein thrombosis is a type of stroke anda multifactorial dis-
ease that usually manifested by non-specific symptoms in children.In most
cases there is an underlying prothrombotic risk factors or a combination of
many clinical reasons. The prevalence of antithrombin III deficiency in patients
with thrombosis incidence is 0.02%, as this rate in normal populations is 1%.In
this article, we will discuss a case with antithrombin III deficiency that he do
not receive the standard heparin treatment. A twenty years old male patient
with sudden onset of headache, dizziness, nausea and vomiting was admitted
to our clinic.His physical examination and vital findings were stable. His cranial
MRI showed thrombosis of superior sagittal sinus and the left transverse and
sigmoid sinuses.Clexane(enoxaparin) started 2x1 mg/kg/daily and contunied
for 15 days.There was not any recanalization in the thrombosis veins on his
repeated cranial MRI after the 15 days treatment.The patient’s anti-thrombin
III activity was 34.8% as other normal thrombophilia tests. Antithrombin III defi-
ciency was diagnosed. Coumadin(warfarin) treatment was started due to inef-
fective low molecular weight heparins. The possibility of antithrombin III defi-
ciency should be considered when a low molecular weight heparin therapy is
not effective in the follow up patients with the diagnosis of thrombosis. Sinus
vein thrombosis is a type of stroke anda multifactorial disease that usually man-
ifested by non-specific symptoms in children.In most cases there is an under-
lying prothrombotic risk factors or a combination of many clinical reasons. 
Aims: The prevalence of antithrombin III deficiency in patients with thrombosis
incidence is 0.02%, as this rate in normal populations is 1%.In this article, we
will discuss a case with antithrombin III deficiency that he do not receive the
standard heparin treatment.
Methods: A twelve years old male patient with sudden onset of headache,
dizziness, nausea and vomiting was admitted to our clinic.His physical exam-
ination and vital findings were stable. His cranial MRI showed thrombosis of
superior sagittal sinus and the left transverse and sigmoid sinuses.
Clexane(enoxaparin) started 2x1 mg/kg/daily and contunied for 15 days. There
was not any recanalization in the thrombosis veins on his repeated cranial MRI
after the 15 days treatment. The patient’s anti-thrombin III activity was 34.8%
as other normal thrombophilia tests. Antithrombin III deficiency was diagnosed. 
Results: Antithrombin III deficiency was diagnosed. Coumadin(warfarin) treat-
ment was started due to ineffective low molecular weight heparins. 
Summary and Conclusions: The possibility of antithrombin III deficiency
should be considered when a low molecular weight heparin therapy is not effec-
tive in the follow up patients with the diagnosis of thrombosis.
PB1700
LUPUS ANTICOAGULANT-HYPOPROTHROMBINEMIA SYNDROME IN A
7-YEAR OLD GIRL: A CASE REPORT
T. Patiroglu1,* E. Yılmaz1, E. Unal1, M. Karakukcu1, M.A. Ozdemir1
1Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey
Background: Lupus anticogulant (LA) can be associated with bleeding as a
consequence of hypoprothrombinemia.
Aims: We present the report of a patient with hemorrhagic symptoms in com-
bination of hypoprothrombinemia and LA.
Methods: A 7 year-old girl was admitted with epistaxis for 5 days. On physical
examination, she had scleral icterus, echimosis and hepatomegaly. The com-
plete blood count was normal expect hemoglobin of 47 g/l. The coagulation
screening showed a prolonged prothrombin time (PT) (60.8 s) and activated
partial thromboplastin time (aPTT) (118.6 s). Although a packed fresh frozen
plasma was administered to the patient, the prolonge of PT and aPTT contin-
ued. Therefore, the mixing study was performed but both PT and aPTT did not
improve.
Results: Factor assay revealed a low prothrombin level (4,46% ). The lupus
anticoagulant and anti nuclear antibody were found positivity but anti DS-DNA
was negativity in advanced laboratory examination of patient respectively. Fur-
ther evaluation revealed the presence of immunoglobulin (Ig) G an M anticar-
diolipin antibodies, IgG and IgM anti-β-2-glycoprotein antibodies, IgG and IgM
anti phosphotydilserin antibodies. After 5 days of mega dose methylpred-
nisolone (30 mg/kg/d) was administered to the patient, PT(13.6 s) and a PTT
(38.4 s) were measured normal and directly Coombs test was found negatively.
Therefore, mega dose methylprednisolone treatment was stopped. One month
after stopping of the treatment with mega dose methylprednisolone she had
again both prolonged PT and aPTT, and the positivity of directly Coombs test.
In this period, it was revealed the presence of immunoglobulin (Ig) G an M
anticardiolipin antibodies, IgG and IgM anti-β-2-glycoprotein antibodies, IgG
and IgM anti phosphotydilserin antibodies. Hence, the patient re-treated with
steroid. Her family asked the follow-up in another hospital.
Summary and Conclusions: The low dose immunosuppresive treatment in
the patients with LA and hypoprothrombinemia is necessary to continue for the
long time.
PB1701
NEW BIRTHS OF CHILDREN WITH HEMOPHILIA: REPORT FROM A
SINGLE CENTER
M. Economou1,* A. Teli1, V. Gourtsa1, G. Lakkaki1, S. Vakalopoulou2,
V. Garipidou2
1First Department of Pediatrics, 2Hematology Department, Second Propedeutic
Department of Internal Medicine, Aristotle University of Thessaloniki, Thessa-
loniki, Greece
Background: Great progress has been reported during recent years on pre-
natal diagnosis of several congenital diseases, including hemophilia. In addi-
tion, pre-implantation techniques have enabled couples at risk to give birth to
healthy babies. In Greece, genetic counseling is offered in specialized centers
to all women carriers of hemophilia who opt to seek advice.
Aims: The aim of the present study was to report on new births of hemophilic
children in Central-Northern Greece during the last 5 years (January 2010-
December 2014).
Methods: Patient records of the Pediatric and Adolescent Center for Hemor-
rhagic Diseases were retrispecively studied. The Center is one of the 2 pediatric
hemophilia centers in Greece, following all patients aged under 18 years, living
in the area of Northern and in parts of Central Greece. New births in the given
5 year period were recorded, as well as data regarding age of diagnosis, dis-
ease severity, family history and prenatal counseling. 
Results: During the study period 12 new patients with hemophilia A were born,
8/11 with severe hemophilia, 2/11 with moderate hemophilia and 2/11 with the
mild form of the disease. Overall, 8/11 had a positive and 3/11 a negative family
history. In none of the cases was prenatal screening performed, even though
6/8 cases with a known family history were associated with severe hemophilia
and in one case death due to the disease in a very young age was reported.
Mean age of diagnosis in the a positive history group was 9.8 months (3 days
– 3 years), while in 3/8 cases bleeding episodes preceded laboratory investi-
gation. In the negative family history group diagnosis was reported at an earlier
mean age (8.5 months, 7 months-12 months), in all cases diagnosis following
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a bleed. In one of the 3 patients with a negative family history, the mother was
pregnant to a second baby-also a hemophiliac- when she was informed of the
diagnosis of the first child, but the family did not opt for prenatal screening. 
Summary and Conclusions: New births of hemophilia are still recorded, even
in cases with known-even severe-family history. This could be attributed to the
knowledge of progress in the management of hemophilic children, as well as
to religious issues. Weaknesses in the health system’s provision of information
regarding availability of prenatal counseling cannot be ruled out. 
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SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT
THERAPY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE
TO NOVEL HOMOZYGOUS MUTATION IN LMAN1
A. Wang1,* X. Liu1, J. Wu1, Z. Sun1
1Hematology, Anhui Provincial Hospital; Anhui Provincial Hemophilia Treatment
Center, Hefei, China
Background: Surgical operations in congenital coagulation factor deficiencies’
patients will increase risk of perioperative bleeding if without adequate replace-
ment therapy. After adequate replacement therapy, patients with hemophilias
can have successful experience of surgical operation. Patient with congenital
combined FV and FVIII deficiency (F5F8D) can also have successful percuta-
neous coronary intervention after replacement therapy. There are rare reports
about successful surgical operations in patients with F5F8D without adequate
replacement therapy.
Aims: We reported that a patient with combined FV and FVIII deficiency had
successful abdominal operation without replacement therapy and analyzed the
molecular mechanism of the disease for the patient.
Methods: Before the diagnosis of the combined FV and FVIII deficiency, a 35
years old female patient was admitted for abdominal operation due to hydros-
alpinx and chocolate cyst of ovary. We do a molecular genetic analysis in the
family. Peripheral blood DNA was extracted. All the exons of LMAN1 and
MCFD2 genes were PCR amplified and sequenced.
Results: Although with prolong activated partial thromboplastin time and pro-
thrombin time, the patient underwent successful abdominal operation without
replacement therapy. She tolerated well for abdominal operation therapy without
increase risk of perioperative bleeding. Molecular analysis showed that the
patient has a novel homozygous deletion mutation in exon 12 of LMAN1
(1456delGTG).
Summary and Conclusions: Our results suggest that a F5F8D patient with
homozygous deletion mutation in exon 12 of LMAN1(1456delGTG) can safely
undergo abdominal operation therapy for hydrosalpinx and chocolate cyst of
ovary without fresh frozen plama and recombinant FVIII replacement therapy.
Bone marrow failure syndromes incl. PNH - Clinical
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SERUM FERRITIN IN PATIENTS WITH APLASTIC ANEMIA RECEIVING
COMBINED IMMUNOSUPPRESSIVE THERAPY.
Z. Fidarova1,* E. Mikhaylova1, V. Dvirnyk1, V. Troitskaya1, E. Parovichnikova1,
V. Savchenko1
1chemotherapy of hemoblastoses and bone marrow transplantation, Research
Center of Hematology of Russian Ministry of Health, Moscow, Russian Feder-
ation
Background: Iron metabolism disorders in patients with AA are not only related
to disease pathogenesis but to regular red blood cells (RBC) transfusions. 
Aims: Analyze iron parameters before immunosupressive therapy, in time of it
(meaning RBC transfusions dependence retained) and in remission phase.
Methods: A total of 85 patients from 18 to 65 years old were enrolled: 41 males
and 44 females at age from 18 to 65 years old. Patients were followed up from
1 month to 3 years. Severe forms of AA were detected in 59 patients, non-
severe in 26 pts. All patients received immunosupressive therapy (ATG +
cyclosporine). Serum ferritin level (SF) was applied as the main iron overload
(IOL) indicator (N 11-160 ng/mL). Depending on obtained results all patients
were divided into 3 groups. Group 1 patients had SF evaluation prior to com-
bined immunosupressive therapy (n=47), these patients were split into sub-
groups 1A and 1B: 1A subgroup patients (n=16) received<20 transfusions in 1-
4 months prior to the study, 1B subgroup patients (n=31) received >20 trans-
fusions in 2-19 months prior to the study. Group 2 patients (n=20) retained long
term RBC transfusion dependence in spite of continued immunosupressive
therapy. Group 3 patients (n=20) demonstrated good immunosuppressive ther-
apy response, therefore developed significant hematological improvement and
became transfusion independent. 
Results: In patients of 1A subgroup SF median was 303 ng/mL (range 40-
1483 ng/mL), in 1B Group-722 ng/mL (range 105-4950 ng/mL) with significant
difference between SF levels received (P=0.025). Group 2 patients had SF
median of 1018 ng/mL (range 250-6300 ng/mL), and Group 3 patients were
notable for lower SF levels with SF median of 480 ng/mL (range 15-1500
ng/mL). Significant differences recorded when comparing Group 1 SF levels of
and Group 2 patients data (P=0.004) as well as Group 2 and Group 3 patients
SF levels (P=0.014).
Summary and Conclusions: It was discovered that iron metabolism disorders
have been detected in almost all AA patients prior to immunosupressive therapy
start and then progressed in time of ongoing RBC transfusions. Notable high
SF levels of maintained for a long time after patients became transfusion inde-
pendent. These data suggest chelation therapy is valuable not only for trans-
fusion dependent AA patients but may also be useful in remission patients with
retained laboratory signs of iron overload.
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DIAGNOSTIC, THERAPEUTIC AND EVOLUTIVE ASPECTS OF ACQUIRED
APLASTIC ANEMIA: ABOUT A RETROSPECTIVE STUDY OF 107 CASES
F. Kallel1,* H. Bellaaj1, C. Maha1, G. Manel1, S. Mseddi1, H. Rekik2, 
M. Mdhaffar1, O. Kassar1, M. Elloumi1
1Hematology Department Sfax Hospital, 2centre De Transfusion Sanguine,
Faculté De Médecine De Sfax Unité De Recherche, Sfax, Tunisia
Background: The acquired aplastic anemia (AAA) is a rare but serious and
severe disease. Evolution could be fatal by medullary isuffisance ‘s complica-
tions.
Aims: We found it useful to carry out a retrospective study over a period of 16
years and to analyze the diagnostic, therapeutic and evolutive characteristics
of myelosuppression in southern Tunisia.
Methods: Our study is retrospective, it has enrolled the acquired aplastic ane-
mia patients diagnosed and monitored in the hematology department of Sfax
hospital over 16 years from january 1998 to december 2013. 107 cases were
collected.The date of point was fixed to January 2015. The etiological diagnosis
contained a careful history, a study of medullary and constitutional karyotype,
a search for HPN clone, viral serology....overall survival was carried out accord-
ing to Kaplan Meier method.
Results: 107 cases of acquired aplastic anemia were collected, they were 60
men and 47 women with a median age of 27 years (range 2-81 years). The cir-
cumstances of discovery were hemorrhagic syndrome, anemic syndrome and
fever respectively in 7%,% and11% of cases. Our patient’s distribution accord-
ing to Camitta) score showed 38% AAA moderate, 31% severe AAA and 31%
very severe AAA. The etiological investigation has revealed negative in 85
patients (79%) and labeled idiopathic. It showed a toxic agents or viral infections
as in postseronegative hepatitis respectively in 7% and 11% of patients. Two
patients have had AM / HPN.In addition to symptomatic treatment, specific
treatment concerned 99 patients. It involved the allogenic bone marrow (allo-
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graft), ciclo associated with SAL, ciclo only and androgen.The therapeutic
results according to the used therapeutics are detailed in the following table.
Table 1.
Summary and Conclusions: The acquired aplastic anemia is a rare and seri-
ous disease. It is a therapeutic emergency requiring a carefull etiological inves-
tigation and early management with effective therapeutic.
PB1705
CONTRIBUTION OF FLOW CYTOMETRY IN THE BALANCE SHEET OF
ACQUIRED APLASTIC ANEMIA
M. Charfi1,* H. Bellaaj1, F. Kallel1, M. Ghorbel1, H. Rekik2, M. Mdhaffar1,
O. kassar1, M. Elloumi1
1Hematology, Hedi Chaker Hospital, 2Hematology, Regional Center of Blood
Transfusion, Sfax, Tunisia
Background: Flow cytometric immunophenotyping has become the gold stan-
dard for the diagnosis and monitoring of Paroxysmal hemoglobinuria(PNH).
PNH results from acquired somatic mutation of the phosphatidylinositol glycan
complementation class A (PIG-A) gene, leading to partial or complete absence
of the glycosylphosphatidylinositol (GPI) anchor that is responsible for linking
a large number of proteins to the cell membrane. 
Aims: The aim of our work is to detect and quantify by flow cytometry (FC)
PNH clones in aplastic anemia (AA) patients.
Methods: From January 2001 to december 2013,we have evaluated 103
patients with aplastic anemia. The presence of a PNH clone was assayed by
peripheral blood flow cytometry on granulocytes(CD16) and monocytes(CD14).
The diagnosis of PNH was retained by the presence of a deficit clone greater
than or equal to 50% of white blood cells. The PNH clone is considered small
if >5%, and major if >30%.
Results: Among all AA patients, 15% patients had the PNH clone. Ham’s test
was performed in ¾ of cases. Anemia was present in all patients with PNH-AA
syndrome. Among them,80% had severe aplastic anemia. Bone marrow trans-
plantation (BMT) concened 21% of patients with PNH-AA syndrome. three
patients with PNH-AA syndrome died by severe thrombotic accident, progres-
sion to acute leukemia and severe anemia.
Table 1.
                                  Patients number                     Percentage
Major HPN clone                     5                                         5%
Small HPN clone                    10                                       10%
No clone HPN                        88                                       85%
Total                                       103                                     100%
Summary and Conclusions: The flow cytometry on granulocytes is a useful
method to diagnose and characterize PNH. This test is good for early detection
of PNH clones in AA patients at initial diagnosis. PNH clone search using spe-
cific erythroid markers (CD 55 and CD59) should improve the specificity of our
results.
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CLINICAL MANIFESTATIONS AND TREATMENT OUTCOME OF FANCONI
ANEMIA: RESULTS OF A SINGLE CENTER
B. Koc1, N. Ozdemir1,* B.S. Koc1, G. Dikme1, H. Apak1, T. Celkan1
1Pediatric Hematology Oncology, ISTANBUL University, Cerrahpasa Medical-
Faculty, Istanbul, Turkey
Background: Fanconi anemia is an inherited disease characterized by con-
genital malformations, pancytopenia, cancer predisposition, and sensitivity to
cross-linking agents. The molecular diagnosis of Fanconi anemia is relatively
complex for several aspects including genetic heterogeneity.
Aims: The aim of this study is to characterize clinical manifestations and treat-
ment of Turkish patients with Fanconi anemia (FA) at our center.
Methods: The medical records of 16 FA patients diagnosed at Istanbul Uni-
versity, Cerrahpasa Medical Faculty from 2006 to 2014 were retrospectively
reviewed.
Results: The median age at diagnosis was 6,5 years (6 months-12 years). Nine
of them were male and 7 of them were female (M/F: ). Two of them were brother
and sister. All patients showed evidence of marrow failure and one or more
physical stigmata. Most common findings were cafe-u-lait, hypopigmented
lesions, thumb anomaly and renal anomalies. Chromosome breakage tests
were positive in 12 out of 12 available patients and 2 of them had mosaism in
the chromosome breakage tests. The median follow-up duration was 63 (7-112)
months. None of the patients underwent stem cell transplantations (SCTs). All
patients were alive by the end of the study. None of the patients developed
leukemia. Androgens were used in 7 patients for treatment. Two of the patients
received erythrocyte suspension and 1 of them received thrombocyte suspen-
sion.
Summary and Conclusions: We provide information of FA patients at our
center. A nation-wide FA registry that includes information of the genotypes of
is required to further characterize ethnic differences and provide the best stan-
dard of care for FA patients.
PB1707
CHRONIC LIVER DISEASE WITH HYPERSPLENISM PRESENTING AS
PANCYTOPENIA
H. Ryu1,* J.Y. Moon1, Y.S. Choi1, I.C. Song1, D.Y. Jo1
1Department of Internal Medicine, School of Medicine, Chungnam National
University, Daejeon, Korea, Republic Of
Background: Hypersplenism is one cause of pancytopenia. Chronic viral hep-
atitis and liver cirrhosis are prevalent in Asian populations and often result in
splenomegaly and hypersplenism.
Aims: In this study, we reviewed and analysed the diagnostic process of chronic
liver disease associated with hypersplenism initially presenting as pancytope-
nia.
Methods: Patients with chronic liver disease with hypersplenism who initially
presented with bicytopenia or pancytopenia from January 2002 to December
2013 at Chungnam National University Hospital were enrolled. The patients’
characteristics and laboratory investigation findings at the time of diagnosis
were analysed retrospectively.
Results: Nineteen patients with a median age of 61.5 years (range, 43–77
years) were enrolled, accounting for about 3% of patients presenting with bicy-
topenia or pancytopenia during the study period. All patients were first seen by
a haematologist. In 12 patients (63.2%), bicytopenia or pancytopenia was inci-
dentally found during a health check-up at a local clinic. A history of liver disease
was limited to six patients (31.6%), and one patient (5.3%) was a carrier of the
hepatitis B virus. Hepatitis B surface antigen and anti-hepatitis C antibody were
detected in four (21.1%) and seven (36.9%) patients, respectively. Eighteen
(94.7%) patients exhibited one or more abnormalities among the aspartate
transaminase level, alanine transaminase level, alkaline phosphatase level,
total bilirubin level, albumin level, and prothrombin time. All patients exhibited
hepatic dysfunction and splenomegaly on Tc-99m phytate liver scintigraphy;
therefore, all were diagnosed with liver cirrhosis accompanied by hyper-
splenism. The causes of the cirrhosis were hepatitis B in four patients (20.0%),
hepatitis C in seven (36.9%), alcohol consumption in two (10.5%), chronic
heart failure in one (5.3%), and an autoimmune disorder in one (5.3%). No
clear aetiology was found in four (20.0%) patients. Of 15 patients with liver cir-
rhosis who underwent a bone marrow study, 2 (13.3%) were confirmed to have
aplastic anaemia in addition to hypersplenism. Myelodysplastic syndrome and
megakaryocytic hyperplasia were reported in three (20.0%) and two (13.3%)
patients, respectively, and were later confirmed to be reactive changes of hyper-
splenism.
Summary and Conclusions: Chronic liver disease accompanied by
splenomegaly and hypersplenism should be highly suspected when bicytope-
nia/pancytopenia and abnormalities in chemistry coexist in the same patient,
even in those with no history of liver disease or who are negative for viral hep-
atitis markers. The Tc-99m liver scan is a simple but highly efficient investiga-
tional tool for these patients.
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IMPLEMENTATION OF MINIMAL RESIDUAL DISEASE IN CHRONIC
LYMPHOCYTIC LEUKEMIA ON REUNION ISLAND
I. Kittler1,* R. Letestu2, P. Zunic3, A. Clabé4
1Laboratoire HLA, CHU de La Réunion, Saint-Denis, Réunion, 2Laboratoire
d’hématologie, Hôpital Avicenne, Paris, 3Hémato-oncologie, CHU de La Réu-
nion, Saint-Pierre, France, 4Laboratoire d’hématologie, CHU de La Réunion,
Saint-Pierre, Réunion
Background: Emerging data strongly indicate that quantification of Minimal
Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) appears to
be a powerful predictor of progression-free and overall survival, regardless of
the clinical response, type of therapy and known biological markers. Two meth-
ods are currently available for assessing complete remission according to the
international consensus and IWCLL guidelines, i.e. allowing to detect one malig-
nant cell in 10.000 leukocytes. These approaches are either based on specific
immunoglobulin heavy chain rearrangement in each clone (RQ-ASO IgH-PCR)
or on the unique immunophenotype profile of CLL cells using multiparameter
flow cytometry.
Aims: Our aim was to assess complete remission in CLL on Reunion Island.
The assay had to be not as complex, expensive and time-consuming as previ-
ously published techniques. This study describes the different steps in imple-
menting and optimising an eight-colour flow cytometry MRD assay in peripheral
blood.
Methods: Our work is based on an antibody panel designed by the ERIC expert
group (www.ericll.org) including the following combination:
CD81/CD79b/CD22/CD19/CD43/CD20/CD5/CD3. The malignant clone is iden-
tified among normal B cells thanks to 15 scattergrammes combining six CLL
highly characteristic markers. Tumor cells typically express CD5, dim CD22,
dim CD20, dim or negative CD79b, CD43, dim or negative CD81. In order to
reach a higher specificity and sensibility for detection of CLL cells, we have
been working on three different approaches: modification of sample preparation
procedure, introduction of a new brilliant fluorochrome for the violet laser line
and optimisation of data analysis strategy. Once the implementation of the
assay had been carried out, we studied performance criteria according to
learned societies, considering clinical relevance and practical feasibility.
Results: After modifying the eight-colour protocol, we achieved a precise esti-
mation of the number of total leukocytes events by excluding unlysed cells
(SSC/CD43 dot plot), erythrocytes debris (CD81/CD19 dot plot) and doublets
(FSC-A/FSC-H dot plot). This new gating algorithm allows us to calculate the
number of CLL cells events as a percentage of total leukocytes, according to
international guidelines. The intersection of 16 regions of interest contribute
further to clearly define the CLL population by minimizing the error of inclusion
risk. Analysis of ten healthy donor blood has been carried on to assess the limit
of detection, which is 5.3. The application of this new data analysis strategy
achieves a sensitivity of 5x10-6 after acquiring one million leukocytes. Perform-
ance criteria proved mostly satisfying: imprecision, accuracy, carryover and
specimen stability meet the standards we set.
Summary and Conclusions: We have developed on Reunion Island a flow
cytometric technique reliable and sensitive enough to detect the presence of
less than one CLL cell in 100.000 leukocyte. This 8-colour assay reduces sub-
jectivity, sample requirements and time taken for acquisition and analysis, com-
pared with 4 and 6-color assays. It also presents the advantage of requiring
less specialized equipment and being not as expensive as the sensitive PCR
methods.
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THE EFFECT OF THE RETINOIC ACID DERIVATIVE, ACITRETIN, ON
CHRONIC LYMPHOCYTIC LEUKEMIA CELL VIABILITY, MIGRATION AND
APOPTOSIS.
S. Elsir Mohammed1,* B. Hennessy2, J. Quinn3, P. Thornton1, O. Aslan2,
A. Eustace2, P. Murphy3
1Haematology, 2Molecular Medicine, Royal College Of Surgeons OF Ireland,
3Haematology, Beaumont Hospital, DUBLIN, Ireland
Background: Retinoids modulate the activity of a large number of genes
through binding to the retinoic acid receptor (RAR/RXR) resulting in a variety
of molecular and biochemical consequences. The role of retinoids in different
malignancies has been extensively explored. However little is known about
their effect on lymphoid malignancies.
Acitretin is a synthetic retinoid which has been shown to induce cell differenti-
ation, and apoptosis in squamous cell carcinoma, where it was shown to induce
apoptosis of malignant squamous cells without effecting normal epithelial cells.
Aims: We aimed to investigate the effects of Acitretin on the CLL like cell line
MEC-1 and on primary CLL cells.
Methods: Peripheral blood samples were obtained from 28 CLL patients who
gave written informed consent (14 treatment naïve, 14 with relapsed disease).
The CLL like cell line MEC-1 was obtained and experiments were performed
on these and on primary CLL cells, freshly isolated from whole blood using a
density centrifugation technique. Viability assays were performed using the
Celltitre96 AquousOne® MTS assay. Migration assays were performed on the
Boyden chamber platform where migration of acitretin treated cells toward the
chemokine CXCL12 was compared to untreated controls. Apoptosis was meas-
ured using FACS analysis of CLL cells treated with 10microM Acitretin for 24
and 72hrs. Treated cells and vehicle controls were labelled with Annexin 5 and
Propidium Iodide to detect early apoptotic cells and dead cells.
Results: Acitretin significantly reduced proliferation of MEC-1 cells at drug con-
centrations of up to 25µM (28.6% mean reduction, P=0.0002).
Acitretin reduced the proportion of viable CLL cells in 5 out of 7 patients as
compared to control in cells from treatment Naïve patients (18% mean reduc-
tion, P=0.0001), at drug concentrations up to 20 µM. Furthermore, one clinic
patient with early stage CLL was commenced on acitretin for control of squa-
mous cell carcinoma of the skin. His lymphocytosis was found to have resolved
3 weeks into treatment. His lymphocyte count continued to be normal 1 year
into follow up. However, acitretin had no effect on viability of cells from relapsed
patients. Acitretin also had a variable effect on cell migration whereby it reduced
the ability of cells to migrate towards the chemokine CXCL12 in 2 out of 5
patient samples and did not appear to effect migration of the cells in 3 patient
samples. Acitretin does not appear to significantly affect the rate of early apop-
tosis in the primary cells as measured by the proportion of Annexin V/Propidium
Iodide labelled cells. Future analysis of additional primay cell lines will further
substantiate these results.
Summary and Conclusions: The retinoid derivative acitretin reduced the pro-
liferation rate of MEC-1 cells and the viability of primary CLL cells from treatment
Naïve patients in vitro, but had a variable effect on cell migration and did not
appear to effect early apoptosis.
Our findings show a potential effect of retinoids in early CLL however the mech-
anism and clinical significance needs to be further defined.
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MIMICKING THE TUMOR MICROENVIRONMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA IN VITRO CRITICALLY DEPENDS ON THE
TYPE OF B CELL RECEPTOR STIMULATION
A. Rombout1,* S. Lust2, F. Offner2, E. Naessens1, B. Verhasselt1, J. Philippé1 
1Department of Clinical Chemistry, Microbiology and Immunology, 2Department
of Internal Medicine, Ghent University, Ghent, Belgium
Background: The B cell receptor (BCR) plays a key role in the crosstalk
between chronic lymphocytic leukemia (CLL) cells and the tissue microenvi-
ronment, which favors disease progression by promoting proliferation and drug
resistance. In these protective niches in the bone marrow and secondary lym-
phoid organs, the BCR becomes activated and sets a signaling cascade in
motion that contributes to the survival and expansion of the malignant clone.
In vitro studies of this crosstalk investigating downstream signaling and func-
tional effects of BCR ligation often report contradictory results, in part due to
the lack of a standardized protocol for BCR stimulation in CLL. 
Aims: Our aim was to define a biologically relevant and robust in vitro stimu-
lation method with regard to cellular phenotypic and transcriptional responses.
Methods: We evaluated mRNA (MYC, FOS, LPL) and protein (CD54, CD19,
CD62L, CD184) expression of genes modulated by BCR triggering in IGHV
mutated and unmutated CLL cells, after stimulation using soluble or immobilized
anti-IgM antibodies from different brands. 
Results: The effect of BCR stimulation on gene and protein expression was
comparable in all CLL patients, irrespective of IGHV mutation status, as previ-
ously reported by us. However, immobilized anti-IgM stimulation elicited clear
and robust changes in gene and protein expression, whereas the response to
soluble anti-IgM was far less obvious. 
Summary and Conclusions: These results show that the method of BCR
stimulation is of major importance regarding responsiveness of CLL cells in the
context of the tumor microenvironment, while genetic differences in the BCR
pathway are less critical. 
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ANALYSIS OF MONOCYTES SUBPOPULATIONS WITH CYTODIFF™* IN
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
S. Lugovskaya1, E. Sukhacheva2,* F. Dukov1, E. Naumova1, M. Pochtar1,
V. Dolgov1
1Russian Medical Academy of Postgraduate Education, Moscow, Russian Fed-
eration, 2Beckman Coulter Eurocenter, Nyon, Switzerland
Background: During last decade 3 sub-populations of monocytes have been
described in the human blood: classical, intermediate and non-classical mono-
cytes, which can be differentiated with flow cytometry based on the expression
of CD14 and CD16. The involvement of monocyte subpopulations in different
pathological processes also was described, including sepsis, HIV infection,
haematologica | 2015; 100(s1) | 677
Vienna, Austria, June 11 – 14, 2015
tuberculosis and cardiovascular disorders. Very limited information available
about monocyte sub-populations in Chronic Lymphocytic Leukemia (CLL), but
according to literature they seem to be important for tumor progression and
immune suppression in CLL.
Aims: The aim of our study was to compare CD-16 negative and CD16-positive
monocytes in CLL patients and in normal individuals. Also we aimed to compare
the groups of CLL patients with bad and good prognosis.
Methods: 58 patients with confirmed diagnosis of CLL were included in the
study at the time of diagnosis. The comparison group included 307 blood
donors. EDTA-anticoagulated blood sample were analyzed with CytoDiff™*
panel according to the recommendation of the supplier. The CytoDiff™* panel
is a 5-color / 6-marker reagent that provides an extended 18-part white blood
cell differential from whole blood specimens by flow cytometry (Beckman Coul-
ter). Among other WBC sub-populations, CytoDiff™* is able to provide the
count of CD16-positive and CD16-negative monocytes (@M+ and @M-) in
peripheral blood. The expression of CD38 on lymphocytes was used as prog-
nostic marker for CLL patients.
Results: The absolute number of classical CD16-negative monocytes (@M-)
was similar in donors and in CLL patients (503 cells/mcl vs 510 cells/mcl respec-
tively). When compared to normal individuals, patients with CLL were charac-
terized by higher absolute count of CD16-positive monocytes (@M-, 40
cells/mcl vs 30 cells/mcl, P=0.0007), higher proportion of CD16-positive mono-
cytes among all monocytes (@M+/Total Mono; 8.8% vs 5.8%, P<0.0001) and
lower proportion of CD16-negative monocytes among all monocytes ((@M-
/Total Mono; 94.2% vs 91.3%, P<0.0001). Within the group of 58 CLL patients
we identified patients with unfavorable prognosis (n=16) based on the CD38
expression (>6%). In patients with bad prognosis CytoDiff™* results revealed
higher proportional (0.24% vs 0.175%, P=0.1346) and absolute (63 cells/mcl
vs 38 cells/mcl, P=0.166) count of CD16-positive monocytes, but the difference
did not reach the statistical significance.
Summary and Conclusions: CytoDiff™* analysis is very efficient tool to mon-
itor the monocyte subpopulations in various pathologies, including CLL. The
exact role of CD16-positive monocytes in CLL and their significance remain to
be investigated on a larger cohort of patients. *Not available in the United
States and other geographies. For research use only. Not for use in diagnostic
procedures. @-Research Use Only (RUO) parameters
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ASSOCIATION OF CD38, ZAP-70, CD49D AND CXCR4 EXPRESSION IN
CHRONIC LYMPHOCYTIC LEUKEMIA
I. Milosevic1,2,* S. Popovic2, A. Savic2, I. Urosevic2, N. Rajic2, D. Agic2, I. Savic2 
1Department for internal medicine, Medical faculty of Novi Sad, 2Clinic for
hematology, Clinical Center of Vojvodina, Novi Sad, Serbia
Background: Chronic lymphocytic leukemia is disease with very heterogeneous
clinical course, some patients have long survival without treatment, while others
have short survival in spite of intensive treatment. Therefore is important to predict
clinical outcome at the time of diagnosis and to plan adequate therapy. Classic
prognostic parameters is based on tumor size and are not valid for prognosis in
the early clinical stages. CD38, ZAP-70, CD49d and CXCR4 are involved in cell
signalization and interactions with microenvironment. This molecules conduct
proliferative and anti-apoptotic signals and contribute to the development of the
disease and resistance to treatment. Expression of CD38, ZAP-70, CD49d and
CXCR4 correlates with active subpopulation of leukemic clone and can predict
course of the chronic lymphocytic leukemia at the time of diagnosis.
Aims: Aim of the study was to determine if there is a correlation of CD38, ZAP-
70, CD49d and CXCR4 expression in chronic lymphocytic leukemia and if there
is a correlation between expression of these antigens with clinical and labora-
tory parameters.
Methods: 40 patients with chronic lymphocytic leukemia was analysed before
treatment. Expression of CD38, ZAP-70, CD49d and CXCR4 was detected by
immunocytochemical staining. Correlation of expression of the CD38, ZAP-70,
CD49d, CXCR4, and correlation between expression of these antigens and clin-
ical and laboratory parameters were tested with standard statistical methods.
Results: Median age of patients was 61,8 years; 14 patients were in Binet
stage A, 14 in Binet stage B and 12 in Binet stage C. Median total lymphocyte
count was 38,8x10.9/l. Among all patients, CD38 positive were 45%, ZAP-70
positive 55%, CD49d positive 52,5% and mean percent of CXCR4 positive cells
was 57,2% cells. There were statistically significant correlations between CD38
and ZAP-70 positivity, CD38 and CD49d positivity, and ZAP-70 and CD49d pos-
itivity. There were also correlation between percentage of cells which express
CD38, ZAP-70 and CD49d, and correlation between percentage of cells which
express CD49d and CXCR4. Expression of ZAP-70 correlate with advanced
clinical stage and hepatomegaly, expression of CD49d with hepatomegaly, and
expression of CD38 with number of lymph nodes and splenomegaly.
Summary and Conclusions: In our study, expression of CD49d in chronic
lymphocytic leukemia cells strongly correlates with expression of CD38 and
ZAP-70, and CD49d expression correlates with CXCR4 expression, suggesting
cooperation of these molecules in leukemic cell functions.
Chronic lymphocytic leukemia and related
disorders - Clinical
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CHROMOSOMAL ABERRATIONS BY FLUORESCENCE IN SITU
HYBRIDIZATION IN JAPANESE CHRONIC LYMPHOCYTIC LEUKEMIA:
CLLRSG-01 STUDY.
J. Takizawa1,* S. Aoki2, R. Suzuki3, N. Nakamura4, K. Ohshima5, K. Izutsu6,
A. Utsunomiya7, J. Suzumiya3
1Hematology, Endocrinology and Metabolism, Niigata University Faculty of
Medicine, 2Clinical Oncology, Niigata University of Pharmacy and Applied Life
Sciences, Niigata, 3Cancer Center, Shimane University Hospital, Izumo,
4Pathology, Tokai University, Isehara, 5Pathology, Kurume University, Kurume,
6Hematology, Toranomon Hospital, Tokyo, 7Hematology, Imamura Bun-in Hos-
pital, Kagoshima, Japan
Background: Chronic lymphocytic leukemia (CLL) is the most common
leukemia in Western countries but is very rare in Asian countries, including
Japan. There are few reports about immunophenotypes, chromosome aberra-
tions and mutations of immunoglobulin heavy chain gene variable region
(IGVH) in Japanese CLL patients.
Aims: Hence we have conducted a nationwide registry study (CLLRSG-01)
from January 2011 to clarify the characteristics of Japanese CLL patinets. We
present here the interim results of prospective study.
Methods: Seventy-five untreated patients with indolent B-cell neoplasms met the
inclusion criteria: (i) absolute lymphocyte counts of 5000/ul or more in the peripheral
blood; or (ii) abnormal lymphocytes of 20% or more in the peripheral blood. The
morphological examination was carried out according to the WHO classification by
diagnostic committee. “Atypical CLL” was determined according to the morphology
by the FAB classification, but this term does not mean atypical expression of surface
immunophenotype. Immunophenotyping was performed using flow cytometry with
a panel of antibodies including CD5, CD19, CD20, CD21, CD22, CD23, CD38,
CD69, FMC7 and ZAP-70. The immunophenotypic score was calculated based
on the CLL scoring system proposed by Matutes et al.We investigated del(13q14),
del(11q22), del(17p13), and trisomy 12 using interphase fluorescence in situ
hybridization (FISH). Cases with mantle cell lymphoma were excluded by FISH
with t(11;14) probe and/or the overexpression of CCDN1 by immunostaining.
Results: According to the morphologic review of peripheral blood smear, 41
patients (55%) were classified as typical CLL, 12 (16%) as atypical CLL and
22 (29%) as other indolent B-cell tumors (others) including 8 hairy cell leukemia.
The immunophenotypic profile demonstrated that the frequency of expression
of CD5, CD21, CD23 and CD69 in CLL (typical and atypical) group was higher
than that of others. The Matutes’ CLL scoring system showed that 27 patients
(51%) with CLL had higher values (5 or 4) whereas 21 patients (95%) with oth-
ers had lower score values (0-3) (P=0.004). There was no significant difference
between the typical and atypical CLL in this scoring system. Of the 75 patients
analyzed by FISH, 44 (59%) had at least one aberration. The most frequent
abnormality was del(13q14)(37%), followed by trisomy 12 (23%),
del(11q22)(7%), and del(17p13)(7%). Del(17p13) was not detected in patients
with CLL, but was detected in 5 patients (23%) with others. Among CLL
patients, atypical morphology was shown to correlate with ZAP-70 expression
and trisomy 12 by FISH analysis in comparison with typical CLLs.
Summary and Conclusions: The present study demonstrated immunophe-
notypic and cytogenetic characteristics of CLL in Japan. Our results have shown
that Japanese CLL has atypical immunophenotypes and similar chromosomal
aberrations as those in Western countries. Our results should be confirmed by
further Japanese and Western collaborative study.
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AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE
TREATMENT IN CLL PATIENTS
F. Autore1, I. Innocenti1, G. D’Arena2, M. Coscia3, P. Mondello4, R. Pasquale1,
S. Sica1, L. Laurenti1,* 
1Catholic University of the Sacre Heart, Rome, 2IRCCS Centro di Riferimento
Oncologico della Basilicata, Rionero In Vulture, 3University of Turin, Torino,
4University of Messina, Messina, Italy
Background: Immune dysregulation with autoimmune phenomena, especially
autoimmune haemolytic anaemia (AIHA), is a common complication over the
lifetime of CLL patients. Therapy-related haemolysis in CLL was first described
in 1966 in patients treated with radiotherapy or alkylating agents. Drug-induced
haemolytic anaemia mostly related to the use of fludarabine has been often
reported, even if the use of monoclonal antibody with chemotherapeutic agents
could reduce the incidence of haemolytic episodes. Bendamustine is an alky-
lating agent composed by benzimidazole ring which is similar to some purine
analogs; for these reasons the haemolysis generated by bendamustine should
be similar to that induced by fludarabine. To date, this complication was rarely
reported in association with bendamustine.
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Aims: We reported the experience of 4 Italian haematological centres focusing
on AIHA during treatment with bendamustine plus rituximab (BR) in patients
affected by CLL.
Methods: We included in the study all CLL patients who underwent BR treat-
ment as front-line or successive treatment for progressive disease. All patients
who experienced AIHA during or after BR treatment were described. AIHA was
diagnosed as reduction of haemoglobin level with positivity of haemolysis tests.
Results: One hundred-thirty CLL patients were treated with BR in our four cen-
tres. Of these, 61 patients were treated for progressive CLL as first-line therapy
and 69 patients as second-line therapy. No patient experienced autoimmune
phenomena when bendamustine was used with rituximab as part of front-line
therapy. On the opposite in CLL patients treated with BR as second-line therapy,
5 episodes of AIHA were reported as shown in Figure 1. The prevalence of
bendamustine related AIHA in patients who underwent to BR treatment as sec-
ond line therapy was 7.2%. Three of five patients who experienced AIHA had
positive DAT, AIHA or immunological autoantibodies at the onset of CLL. Three
cases used fludarabine based regimens as front-line therapy. Three of five
patients developed DAT positive AIHA; low median lymphocytes count
(1000/mmc) and the use of rituximab could justified DAT negative AIHA in two
patients. The onset of AIHA was observed during the BR treatment in 4 patients
and at the end of planned therapy in 1 patient. The course of AIHA was mild, it
responded to steroid or rituximab therapy and it was solved in a few days.
Table 1. Characteristics and biological profile of AIHA/CLL patients.
Summary and Conclusions:All 5 patients experienced bendamustine related
AIHA during or after BR treatment as second line chemotherapy. Our experi-
ence confirms the literature data in which 9 of 10 cases of bendamustine related
AIHA in CLL patients reported, appeared after second or further treatment.
Patients who experienced previous autoimmune phenomena or underwent flu-
darabine as front-line therapy, probably for its similitude in the drug structure to
bendamustine, showed an increase risk of AIHA. AIHA is probably due to deple-
tion of CD4 cells which can lead to failure to control auto-reactive T-cells that
are free to create autoimmunity. The course of bendamustine related AIHA was
mild, it could be quickly solved in a few days with the use of immunosuppressive
agents as steroid or monoclonal antibodies. In conclusion BR is safe and effec-
tive regimen in CLL patients, a care observation should be taken in patients in
which BR was used as second or further line therapy. Previous autoimmune
phenomena, prior use of fludarabine and CD4 depletion could explain the
increased incidence of bendamustine related AIHA. 
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SIMILAR EPIDEMIOLOGICAL TRENDS OF LYMPHOID MALIGNANCIES
AND THEIR RESPECTIVE PRECURSOR LESIONS IN TAIWAN
P.Y. Hsieh1,* S.C. Lin1, C.T. Lin2, C. Fazi3, S.J. Wu2, P. Ghia3, C.S. Chuang4 
1Far Eastern Memorial Hospital, New Taipei City, 2National Taiwan University
Hospital, Taipei, Taiwan, ROC, 3Università Vita-Salute San Raffaele, Milano,
Italy, 4Chi-Mei Hospital, Tainan, Taiwan, ROC
Background: Based on epidemiological studies, it is well known that Taiwan
differs from the Western countries in terms of incidence of lymphoid malignan-
cies with follicular lymphoma (FL), multiple myeloma (MM), and chronic lym-
phocytic leukemia (CLL) being much less prevalent The respective incidence
rates are around one-fourth, one-third, and one-sixth of the one in the US. For
these reasons, it is of interest to evaluate whether also their respective precur-
sor conditions, i.e., circulating t(14;18)-IGH/BCL2 translocation, monoclonal
gammopathy of unknown significance (MGUS), and monoclonal B-cell lympho-
cytosis (MBL) are also less common in Taiwan. 
Aims: To know the epidemiology of the preursor conditions of lymphoid malig-
nancies in Taiwan.
Methods: We screened 300 healthy Taiwanese individuals with the median age
of 43 (range 23~73) for the presence of IGH/BCL2 translocation in peripheral
blood mononuclear cells by polymerase chain reaction. In another cohort of 302
healthy individuals with the median age of 53 (range 23-79), the screening for
the appearance of MGUS by serum immunofixation and MBL by flow cytometry
were done. The results were compared to the data from Western cohorts.
Results: In line with the epidemiological findings on the actual diseases, the
prevalence rates of all three precursor conditions appear significantly lower in
the Taiwanese population with 10.7% (32/300) of the cases positive for circu-
lating IGH/BCL-2 translocations, 1.3% (4/302) positive for MGUS, and 1.3%
(4/302) positive for MBL, as compared with the frequencies of more than 50%
for circulating IGH/BCL-2 translocation, 3~5% for MGUS, and 3.5~7% for MBL
in the Western populations. The differences, however, were similar to those
observed for the incidence rates of FL, MM, and CLL, respectively, between
Taiwan and the West. For MGUS and MBL, the numbers of positive cases were
too small for analyses in terms of age. In the case of circulating IGH/BCL2
translocations, the prevalence in the healthy population was higher in middle-
aged to older people than in young adults (6.3% in the 3rd decade, 6.6% in the
4th decade, 13.8% in the 5th decade and 10.6% in the 6th decade), similar to
the age-distribution pattern of FL.
Summary and Conclusions: The present study demonstrates lower rates for
pre-neoplastic conditions in the Taiwanese population, i.e. of the presence of
the circulating t(14;18)-IGH/BCL2 translocations, MGUS, and MBL that is in
line with the known lower frequency of their respective lymphoid neoplasms as
compared to Western populations. These results confirm the role of the pre-
cursor conditions during the natural history of the actual diseases and the pre-
neoplastic nature of these manifestations. Unraveling the molecular and genetic
features of circulating IGH/BCL2 translocations, MGUS, and MBL in healthy
Taiwanese population will be key to understand the pathogenetic mechanisms
responsible for the lower frequencies of FL, MM, and CLL as compared to the
Western populations.
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PROGNOSTIC TESTING PATTERNS IN PATIENTS (PTS) WITH CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN US PRACTICES FROM THE
CONNECT® CLL REGISTRY
A. Mato1, C.R. Flowers2, C.M. Farber3, M.A. Weiss4, T.J. Kipps5, M.F. Kozloff6,
C. Nabhan7,* I.W. Flinn8, D.L. Grinblatt9, N. Lamanna10, K. Sullivan11,
P. Kiselev12, E.D. Flick13, K.A. Foon12 A.S. Swern12, J.P. Sharman14
1Center for Chronic Lymphocytic Leukemia, University of Pennsylvania,
Philadelphia, 2Emory University, Atlanta, 3Morristown Memorial Hospital, Carol
G. Simon Cancer Center, Morristown, 4Thomas Jefferson University, Philadel-
phia, 5Division of Hematology-Oncology and Central Office of CLL Research
Consortium, Moores Cancer Center, University of California San Diego, La
Jolla, 6Section of Oncology/Hematology, Ingalls Hospital, Harvey, 7The Uni-
versity of Chicago, Chicago, 8Sarah Cannon Research Institute, Tennessee
Oncology PLLC, Nashville, 9NorthShore University HealthSystem, Evanston,
10Leukemia Service, Hematologic Malignancies Section, Department of Med-
icine, New York-Presbyterian/Columbia University Medical Center, New York,
11Celgene Corporation, Overland Park, 12Celgene Corporation, Summit, 13Cel-
gene Corporation, San Francisco, 14Willamette Valley Cancer Institute, US
Oncology, Springfield, United States
Background: Genetic aberrations detected by fluorescence in situ hybridization
(FISH) and cytogenetic (CG) testing provide important prognostic information
for CLL pts. The identification of genetic abnormalities has particular relevance
in choosing immunochemo- or kinase inhibitor therapies, allogeneic stem cell
transplantation, or clinical trials for CLL pts.
Aims: To analyze factors influencing decisions to perform FISH or CG testing
in CLL pts.
Table 1. 
haematologica | 2015; 100(s1) | 679
Vienna, Austria, June 11 – 14, 2015
Methods: Connect® CLL is a large, prospective, longitudinal, multicenter, obser-
vational registry of 1494 CLL pts at 179 community (1311 pts), 17 academic (155
pts), and 3 government (28 pts) sites. Pts were enrolled within 2 months of initi-
ating any line of CLL-directed therapy (LOT). Univariate (UV) and multivariate
(MV) logistic regression analyses were conducted to identify characteristics asso-
ciated with a decision to perform genetic testing at LOT 1 and at LOT ≥ 2.
Results: Baseline characteristics for the cohort were as follows: 63.8% of pts
were male and the median age was 69 years (range 22–99). The median time
from diagnosis to inclusion in the registry was 3.7 years (range 0–32) and
92.7% of pts had an ECOG PS score of ≤1. FISH or CG was performed at
study enrollment in 861/1494 (58%) pts (36% CG, 49% FISH, 28% both). 65%
of 889 pts were tested for FISH/CG prior to LOT1, 50% of 260 in LOT2, 45%
of 345 in LOT≥3. Of 861 pts tested at enrollment, 29% had FISH/CG retested
with a subsequent LOT. In UV analyses (14 predictors), FISH/CG were more
often performed at academic sites (p 0.005), in pts age ≤75 (p 0.0002), at
enrollment at LOT1 vs. LOT ≥2 (P<0.0001), in private insurance pts (p 0.002)
and Rai stage ≥2 (P<0.0001). Table 1 describes independent predictors of per-
forming genetic FISH/CG testing stratified by LOT (LOT1 vs. LOT≥2) and prac-
tice setting (all practice settings vs. community-government settings only).
Summary and Conclusions: Our results indicate that only a fraction of CLL
pts are tested/re-tested for genetic alterations by FISH/CG. Given the signifi-
cance of identifying del17p or complex CG in selecting each LOT, these results
indicate a need for increased awareness of the importance of this testing in
clinical practice.
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VALUE OF CIRCULATING GALECTIN-3 FOR PROGNOSIS OF CARDIO-
VASCULAR EVENTS IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA IN REMISSION
B. Samura1,*
1Zaporizhzhia Regional Clinical Hospital, Zaporizhzhia, Ukraine
Background: Perivascular leukocyte infiltrates and endothelial damage are
vital in the development of chronic lymphocytic leukemia. As cell-to-cell inter-
actions are critical in the processes of chronic lymphocytic leukemia, galectin-
3 have become of interest as novel regulators of inflammation. Galectin-3 is
produced by activated macrophages and it is predominantly expressed in sub-
clinical atherosclerosis, unstable and stable coronary artery disease, heart fail-
ure. Therefore, galectin-3 is not only key player in inflammation and as well as
in tumor progression by displaying intracellular and extracellular activities. How-
ever, the predictive role of galectin-3 in stable patients with chronic lymphocytic
leukemia in remission is not understood.
Aims: Evaluate the prognostic value of circulating galectin-3 for cumulative
survival in patients with chronic lymphocytic leukemia in remission.
Methods: One hundred fifty six out subjects with chronic lymphocytic leukemia
in full or partial remission were enrolled in the study. Diagnosis and staging of
chronic lymphocytic leukemia were defined by current clinical practice guidelines.
All subjects gave their written informed consent to participation in the study.
Observation period was up to 12 months. Blood samples for biomarkers meas-
urements were collected. ELISA method for measurements of circulating level of
galectin-3 was used. Hemodynamic evaluation was performed by transthoracic
echocardiography. Echocardiography in B-mode was performed accordingly to
Recommendation of American Society of Echocardiography on the scanner
“MyLab 50” (Italy) using a transducer with a frequency of 2.5-3.5 MHz.
Results: Two hundred sixteen cumulative clinical events occurred in 51
patients (32,7%) within the follow-up, with their distribution being as follows: 7
deaths, 122 cardiac arrhythmias, 16 cardiac ischemic events, 3 strokes, 30
chronic heart failures and 38 hospital admissions for cardiovascular reasons.
Medians of circulating levels of galectin-3 in free-events subject cohort and
subjects cohort with cardiovascular events were 5,16 ng/mL (95% confidence
interval [CI]=4,74-5,56 ng/mL) and 16,40 ng/mL (95% CI=14,80-18,01 ng/mL)
(P<0.001). In multivariate logistic regression circulating VE-catherin independ-
ently predicted cumulative cardiovascular events (odds ratio [OR]=1,13; 95%
CI=1,07–1,25; P=0.003) within 12 months of observation period. Results of
the study showed that exaggerated circulating level of galectin-3 in patients
with chronic lymphocytic leukemia in remission may consider biomarker with
power predictive value for cardiovascular events whether for tumor progression
did not. Probably it may be related with small size of the study or short-term
period of the observation. However, association of galectin-3 with tumor pro-
gression was not found. Author think that it is needed more studies with higher
statistical power to be recognized prognostic potential of Gal-3 in two directions:
cardiovascular outcomes and tumor progression.
Summary and Conclusions: Among patients with chronic lymphocytic
leukemia in remission increased circulating galectin-3 associates with increased
cumulative cardiovascular events within 12 months.
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EFFICACY AND TOLERABILITY OF PENTOSTATIN CYCLOPHOSFAMIDE
RITUXIMAB (PCR) REGIMEN IN ELDERLY, “SLOW-GO” CHRONIC LYM-
PHOCYTIC LEUKEMIA (CLL) PATIENTS. A MONOCENTRIC EXPERIENCE
S. De Lorenzo1,* M. Barone1, F. Rivellini1, C. Califano1, V. Belsito Petrizzi1,
M. Langella1, C. Ingenito1, P. De Prisco1, A. Campana1, V. Iovino1, C. Trezza1,
A.M. D’Arco1
1U.O. Oncoematologia, Ospedale A.Tortora, Pagani, Italy
Background: Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia and primarily affects the elderly. Treatment of CLL has evolved sig-
nificantly in recent years. There is currently no standard of care for patients
with CLL older than 70 years or patients with co-morbidities and an impaired
physical condition (“Slow go”). These patients may be offered a mild
chemotherapy regimen: chlorambucil or dose-reduced fludarabine or ben-
damustine. Dose-modified combination regimens such as Fludarabine,
Cyclophosphamide, Rituximab (FCR)-Lite seem to deliver the FCR therapy
with a lower toxicity, but this combination still has to be tested on a large scale,
in less fit patients. Similarly, the use of pentostatin, cyclophospamide, rituximab
(PCR) was investigated to achieve a reduced toxicity, with promising results,
both in pretreated CLL patients than in frontline.
Aims: Starting in December 2010, we selected elderly patients with “slow-
go” CLL to evaluate efficacy and safety of PCR regimen in this subset.
Methods: To date, we observed 16 cases of “slow-go” elderly CLL, most were
high risk patients. They were treated with PCR regimen consisting of pento-
statin (P:2mg/m2), cyclophospamide (C:600 mg/m2) and rituximab (R:375
mg/m2) on day 1 (21-day cycles). Dose 1 of R was given on day 8 (Cycle 1)
and was increased to 500 mg/m2, from cycle 2. The dose of pentostatin was
increased to 4 mg/m2, from cycle 3, in the absence of grade III-IV hematologic
toxicity. This PCR regimen was given on a 21-day, 6-cycle schedule. Support
from granulocyte colony-stimulating growth factor was provided, as required.
Patients received prophylaxis with cotrimoxazole and lamivudine (as required).
Results: 13 patients (82%) were treated in frontline and 3 patients (18%) at
relapse. The median age was 73 years and 88% were 70 years older. 69%
(RAI stages 3-4) and 100% (Binet B-C). Cytogenetics showed Trisomy 12
(31%) and 13q14 deletion (19%). No other cytogenetic abnormalities were
detected. IgVH status resulted “unmutated” in 81% of cases. All patients had
comorbidities and 87% had a Creatinìne Clearance (CrCl)<70 ml/min. The
overall response rate (ORR) on the whole population was 88%, complete
response (CR):25%, partial response (PR):63%. The ORR in frontline was
85%, CR(31%), PR(54%). All patients completed the planned six courses of
PCR, without dose reductions or delayed. Toxicities were: grade III-IV neu-
tropenia (18%) and anemia (6%); grade II thrombocytopenia (18%), grade II
nausea (31%), grade II constipation (6%), grade II hypertransaminasemia
(6%). We didn’t observe severe or prolonged infections or other toxicities.
There were no significant differences in the number of cycles administered,
need for dose reductions, grade 3-4 toxicities in patients with CrCl<70 ml/min.
At a median follow-up of 29 months (range: 6-44), the median progression
free survival (mPFS) was 17.6 months (range: 3-42), 75% of patients are
alive, 3 patients (25%) died for cardiovascular disease, respectively after 6,
12 and 12 months and 1 patient for severe pneumonia after 3 months from
the end of therapy.
Summary and Conclusions: Therapeutic strategies for “slow-go” patients
with CLL are still lacking, especially for elderly patients. In previous studies,
PCR regimen demonstrated activity, both in frontline and at relapse. Moreover,
PCR seems feasible and safe because loaded from toxicities less than FCR
regimen. In our experience, PCR was well tolerated in elderly and “slow-go”
CLL, also in patients with CrCl<70 ml/min. Then, PCR may be a treatment
option in this subset of patients.
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IMMUNE THROMBOCYTOPENIA IN B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA
K. Alexandrova1,* M. Velizarova2, E. Hadjiev3, A. Stanchev4, D. Popova5
1Department of medical oncology, Gustave Russy Cancer Campus, University
Hospital, Paris, France, 2University Hospital Alexandrovska, Sofia, Bulgaria,
3Clinic of Hematology, University Hospital Alexandrovska, Sofia, Bulgaria,
4The Royal Oldham Hospital, Oldham, United Kingdom, 5Military Medical
Academy, Sofia, Bulgaria
Background: Chronic Lymphocytic leukemia (CLL) is sometimes associated
with autoimmune cytopenia: autoimmune hemolytic anemia (5-25% of cases)
and immune thrombocytopenia (1-8% of cases)]. The effect of immune throm-
bocytopenia (ITP) on the clinical outcome and survival of patients with CLL is
controversial.
Aims: The aim of the study was to correlate of ITP-CLL evidence with biolog-
ical features, phenotypic and cytogenetic abnormalities and disease outcome
in patients with B-CLL.
Methods: We studied 175 patients with B-cell CLL. All patients were diag-
nosed according to the revised criteria of the National Cancer Institute-spon-
sored Working Group (NCI-WG) on Chronic Lymphocytic Leukemia (CLL) and
were classified according to the Rai staging system. Twelve of them (6.9%)
were with immune thrombocytopenia (IT). The diagnosis of immune thrombo-
cytopenia was based on the presence on unexplained fall in platelet count
to<100x109/L and on more than two indirect parameters: evidence of normal
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bone marrow function (normal or increased megakaryocytes in bone marrow),
no splenomegaly and no chemotherapy within the last month. The patients
with thrombocytopenia due to bone marrow suppression (lymphocytes over
80% in bone marrow) were excluded from this analysis.
Results: Among clinical and biological variables, neither age, gender, tumor
mass nor Rai stages at CLL diagnosis were significantly associated with ITP
development. The ITP occurrence was significantly associated with ZAP-70
positivity (7/12; 58.3%). In contrast ZAP-70 was found in 44 of 119 B-CLL cases
(27%, P=0.028). CD38 and P53 expressions was significantly higher (75% and
41.7%, respectively; P=0.038 and P=0.013, respectively) than in CLL without
ITP (44% and 11.2%). Based on available FISH data, we found that among 12
cases with deletion of (11)(q22-23) region only one (9%) developed ITP. There
was no statistical significance (p>0.05) between ITP development and cytoge-
netic deletion (13)(q14). The median overall survival of CLL-ITP patients was
significantly shorter -68.6 months (95% CI: 49.5-87.6 months) than the patients
without ITP -111 months (95% CI: 104.7-117.4 months; P=0.016) and overall
survival dropped rapidly and was in stable rate after 12 months since the diag-
nosis. ITP cases had an increased risk of disease progression and mortality
risk over 3 fold above the patients without ITP (P<0.001, P<0.05, respectively).
CLL-ITP patients showed shorter median free of treatment period-2.08 months
(95% CI 0-5.99), compared to CLL without ITP-45.10 (95%CI 36.50-53.70).
Summary and Conclusions: ITP-CLL is associated with a higher frequency
of poor prognostic markers such CD38, ZAP-70 and P53 expressions and
shortened free of treatment period and overall survival.
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IMPACT OF CLINICAL AND BIOLOGICAL VARIABLES ON TIME TO FIRST
TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
A. Giordano1,* P. Curci1, R. Rizzi1, T. Perrone1, A. Cimmino2, A. Mestice1,
G. Nardelli1, B. Daraia1, V. P. Gagliardi1, F. Albano1, G. Specchia1
1Hematology with Transplantation, 2Anatomic Pathology, University, Bari, Italy
Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease
with variable outcome. The identification of factors that could predict the clinical
course of CLL is a crucial objective. Recently, prognostic models involving a
set of clinical and biological risk factors have been proposed to evaluate the
association with the time before initiating treatment and the prognosis for
patients with CLL.
Aims: In our study we investigated time to first treatment (TFT), measured as
the time elapsed between diagnosis and first treatment, and its relation with
clinical and biological parameters and overall survival.
Methods: We retrospectively evaluated patients (pts) with de novo CLL treated
at the University Hospital of Bari (Italy) between April 2006 and February 2013.
At diagnosis pts were studied for clinical characteristics and biological prog-
nostic factors: age, β-2 microglobulin, absolute lymphocyte count, sex, Rai
stage, number of lymph node groups involved, pattern of bone marrow involve-
ment, splenomegaly, mutational status of the immunoglobulin heavy chain
gene variable region (IGVH), cytogenetic abnormalities detected by FISH.
Median time to first treatment was calculated for all pts, divided into two groups
according to Median time to first treatment. The first group included pts treated
within 40 months from diagnosis; the second group pts treated after 40 months
from diagnosis. Univariate analyses of each group were performed to evaluate
the correlation between the clinical variables and time to treatment. In addition,
overall survival was calculated and compared in the two groups.
Results: In total, 69 pts were included; 42 in the group of pts treated within
40 months from diagnosis, and 27 in the group treated after 40 months. 
Statistically significant differences were seen between the 2 groups regarding
the pattern of bone marrow involvement (diffuse versus other patterns of mar-
row involvement; P=0.05), number of lymph node groups involved, (one versus
more than one; P=0.01); mutational status of the immunoglobulin heavy chain
gene variable region (IGVH) (mutated versus unmutated; P =0.05), cytogenetic
abnormalities by FISH (21 pts with 13q14 in the group of TFT >40 months and
2 in the group of TFT<40 months; P:0.01). No statistically significant difference
was seen among the other clinical variables and TFT. Moreover, comparing
the OS of the group with TFT >40 months with OS of the group with TFT<40
months, statistically significant difference was observed (P:0.01).
Summary and Conclusions: In our study the pattern of bone marrow involve-
ment, the number of lymph node groups involved, the mutational status of the
immunoglobulin heavy chain gene variable region and the cytogenetic abnor-
malities could help to recognize at diagnosis a subset of patients that may
show rapid evolution to progressive disease. Multicentric studies and larger
cohorts of patients are warranted to confirm these preliminary data.
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INCIDENCE OF SECOND CANCER IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKAEMIA: 19 YEARS EXPERIENCE FROM SINGLE
CENTRE.
O. Seimeni1,* S. Koumas1, C. Prokopiou1, N. Neokleous1, F. Tsolakis1
1hematology, Limassol General Hopsital, Limassol, Cyprus
Background: Patients with chronic lymphocytic leukaemia (CLL) have a higher
incidence of second malignancies than the general population.
Aims: Our study aims to present the incidence in our population and predicting
whether stage and previous chemotherapies could have a negative impact on
the number of second cancer in patients of CLL at our Hospital.
Methods: We retrospective evaluated 178 patients of CLL registered at General
Hospital of Limassol, in Cyprus over a period of 19 years (1995-2014). A second
malignancy was defined as another malignancy at the time of diagnosis or dur-
ing follow up.
Table 1. Results of study in parathensis there is the report of deaths relat-
ed to second cancer (dead patients w/o cancer+dead patients with can-
cer).
Results: There were 178 patients, 75 females and 103 males. The average
age, was 67 years (34-94 years). The common presenting features were lym-
phocytosis 86%, lymphadenopathy 82%, splenomegaly 20%, and
hepatomegaly 7%. Analysing data for all the patients, at diagnosis, 79% were
early stage, (Rai stage 0- 46,3%, Rai stage I- 14,7%, Rai stage II-18%) and
21% of cases were in advanced stage, (Rai stage III- 18,6%, Rai stage IV-
2,4%). Twenty seven percent of patients received treatment at presentation or
at disease progression, including chlorambucil, fludarabine, rituximab and ben-
damustine based regimens. During the follow up, we noticed 27 cancers, includ-
ing two haematological malignancies along with cancer of breast, uterus, lung,
prostate, colon, skin, pancreas renal and larynx. We also found two high grade
transformation (Richter syndrome), two cases of prostate infiltration and one
case of breast infiltration by chronic lymphocytic leukaemia (Table I). Median
time between CLL and second cancer diagnosis was 5.01 years (0-16 years).
According to correlation analysis, neither advanced stage nor previous
chemotherapies influenced with statistical significance the incidence of second
malignancy in patients with CLL in our Hospital. Moreover the second tumour
did not predisposed shortness of patient’s survival and chemotherapy has no
impact in the time of cancer diagnosis.
Summary and Conclusions: The incidence of second cancer is 15,3% in our
population. Advanced stage and previous chemotherapies have none impact
in this incidence and did not influenced the survival of the patient, comparing
with the survival of the non-cancer patients. Unfortunately, the majority of our
patients has diagnosed before the facility for molecular and cytogenetic analysis
became feasible in Cyprus, that didn’t let us to include modern prognostic fac-
tors in our study.
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HYPOGAMMAGLOBULINEMIA AND INFECTIOUS EVENTS IN CHRONIC
LYMPHOCYTIC LEUKEMIA
M.J. Mendes1,* G. Ferreira1, H. Saturnino1, J.C. Almeida1, L.F. Araújo1,
M. Duarte1, M.L. Ribeiro1
1Hematology, CHUC, Coimbra, Portugal
Background: Infections are a major cause of morbidity and mortality in Chronic
Lymphocytic Leukemia (CLL), related to humoral and cellular immune deregu-
lations due to the disease itself and enhanced by immunosuppression associ-
ated to treatments. Hypogammaglobulinemia is the most common chronic
immune defect in CLL, related to duration and stage of the disease, and corre-
lates with the frequency and severity of infections observed in these patients.
Aims: Analyze and compare the frequency and type of infectious episodes
requiring hospital admission in a population of patients diagnosed with CLL,
with and without hypogammaglobulinemia.
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Methods: Retrospective analyses of the clinical files of patients with CLL diag-
nosed between January 2004 and August 2014.
Results: Between January 2004 and August 2014, 151 patients were diag-
nosed with CLL. Twenty-five patients (16.6%) developed hypogammaglobu-
linemia, 6 at the time of diagnosis. The mean time from diagnosis of CLL to the
development of hypogammaglobulinemia in the remaining patients was 38.2
months (min=4; max=97). Patients with a serum IGg<5g/L and recurrent or
severe infections received IVIg replacement therapy. In the group with
hypogammaglobulinemia (n=25), the median age at diagnosis was 71 years
(min=50; max=88); 14 men (56%) and 11 women (44%). The initial staging
(Rai) was 0 in 11 patients (44%), I in 8 patients (32%), III in 3 patients (12%)
and IV in 3 patients (12%). The initial approach was watchful waiting in 16
patients (64%), with 9 patients (36%) requiring treatment. Sixteen patients
(64%) required hospital admission related to infectious intercurrences, with
25.6 days as mean time of hospitalization (min=1; max=133). The total number
of documented infections was 47 (mean of 3 episodes/patient; min=1; max=9):
upper and lower respiratory tract infection in 14 patients (87.5%), urinary tract
infection in 6 patients (37.5%); gastroenteritis, lower and upper limb cellulitis,
oral candidiasis and febrile neutropenia in 2 patients each (12.5%). One patient
developed cryptococcal meningitis and one patient developed septicemia. In
the group without hypogammaglobulinemia (n=126), the median age at diag-
nosis was 70 years (min=37; max=93); 73 men (58%) and 53 women (42%).
The initial staging was 0 in 90 patients (71.4%), I in 24 patients (19%), III in 6
patients (4.8%) and IV in 7 patients (5.6%). The initial approach was watchful
waiting in 113 patients (89.7%) and treatment in 13 patients (10.3%). Twenty-
two patients (17.4%) required hospital admission due to infectious events, with
a mean time of 15.55 days (min=1; max=69) and a total number of 37 infections
(mean of 1.7 episodes; min=1; max=5): upper and lower respiratory tract infec-
tion in 12 patients (54.5%), urinary tract infection in 6 patients (27.3%); gas-
troenteritis, septicemia and cellulitis in 3 patients each (13.6%); febrile neu-
tropenia in 2 patients (9.1%). One patient developed a rickettsia infection.
Summary and Conclusions: The two groups were similar in terms of age
and sex distribution. The proportion of patients staged III and IV was higher in
the group with hypogammaglobulinemia. The percentage of patients with infec-
tious events requiring hospital admission was significantly higher in the group
with hypogammaglobulinemia (64% vs 17.4%). Fungal infections were only
present in the group with hypogammaglobulinemia. A higher number of infec-
tious events in this group required a longer time of hospital admission, reflecting
their severity. Therefore, it is important to monitor immunoglobulin levels and
to administer immunoglobulin replacement therapy in these patients.
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CUMULATIVE ILLNESS RATING SCALE (CIRS) – AN INDEPENDENT
PROGNOSTIC PARAMETER FOR CHRONIC LYMPHOCYTIC LEUKEMIA
PATIENTSʼ PRETREATMENT STRATIFICATION 
V. Vukovic1,* D. Antic1,2, M. Todorovic1,2, J. Bila1,2, B. Andjelic1,2,
V. Djurasinovic1, A. Sretenovic1, J. Jelicic1, B. Mihaljevic1,2
1Lymphoma center, Clinic for Hematology, Clinical Center of Serbia, 2Medical
Faculty, University of Belgrade, Belgrade, Serbia
Background: Most of data about the clinical outcome of patients with chronic
lymphocytic leukemia (CLL) come from patients participating in clinical trials.
Such trials typically have strict eligibility criteria based on performance status
and organ function. Little is known about the organ function of unselected
patients (i.e., regardless of whether they are eligible for trials). Adult comorbidity
evaluation-27 (ACE-27), Cumulative Illness Rating Scale (CIRS) and
hematopoietic cell transplantation comorbidity index (HCT-CI) are comorbidity
indexes that take concurrent presence of nonmalignant diseases into account
when explaining survival. They differ in both the number and categorization of
comorbidities.
Aims: We investigated the prognostic significance of three comorbidity indexes
in adition to standard prognostic tools in a sample of 74 patients with CLL.
Methods: We retrospectively evaluated the impact of ACE-27, CIRS and HCT-
CI in a cohort of 74 adult patients with chronic lymphocytic leukemia (HLL)
treated with Fludarabine-Cyclophosphamide combination. Also we tested
impact of standard prognostic tool available in daily practice as age, gender,
Rai/Binet clinical stage, LDH level, type of bone marrow infiltration and CD38
expression. Patient and survival data were acquired from inpatient hospital
records. Cox hazard regression model was used to analyze overall survival
according to standard prognostic factors and comorbidities classified by the
ACE-27, CIRS and HCT-CI.
Results: Median follow up of our group was was 5 years (60 months) while
median overall and progression free survival was 72 and 32.5 months, respec-
tively. We found a significant association between CIRS and bone marrow infil-
tration pattern and overall survival (P=0.037; RR=2.0; 95%CI for RR 1.1-4.0
for CIRS>15 and P=0.014; RR=2.3; 95%CI for RR 1.2-4.5 for diffuse type of
bone marrow infiltration). Other two comorbidity indexes – ACE-27 and HCT-
CI and standard prognostic factors did not outperform the survival model, while
in multivariate analysis CIRS>15 and diffuse type of marrow infiltration
remained the most important predictors of overall survival (P=0,009 and
P=0,004, respectively). We developed a new scoring system based on the
CIRS score value and bone marrow infiltration pattern. Patients with CIRS≤15
and without diffuse type of marrow infiltration were of low risk (score 0), patients
with CIRS>15 or diffuse bone marrow infiltration pattern corresponded with
intermediate risk (score 1), while patients with both CIRS>15 and diffuse type
of bone marrow infiltration represented high risk group (score 2). Median overall
survival for patients with score 0, 1 and 2 was 96, 82 and 34 months, respec-
tively, which makes this new score a good predictor of mortality among patients
with chronic lymphocytic leukemia (P<0.001; RR=2.6; 95%CI for RR 1.5-4.5).
Figure 1.
Summary and Conclusions: In our group of adult CLL patients the overall
survival is associated with the presence of comorbidities defined by the CIRS
index. CIRS and type of bone marrow infiltration present a superior comorbidity
risk-adjustment model for CLL survival prediction.
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SIDE EFFECTS AFTER RITUXIMAB INFUSION IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA
G. D’Arena1,* S. De Lorenzo2, M.L. Vigliotti3, I. Innocenti4, M. Cimminiello5,
V. Simeon6, G. Farina3, V. Patella7, F. Autore8, V. De Feo9, P. Musto10,
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4Hematology Chair, Catholic University of Sacred Hearth, Rome, 5Hematology
Unit, “S. Carlo” Hospital, Potenza, 6Laboratory of Preclinical and Translational
Research, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero
in Vulture, 7Allergology Unit, “S. Maria della Speranza” Hospital, Battipaglia,
8Hematology Chair, Catholic University of Sacred Heart, Rome, 9Pharmacology
Department, University of Salerno, Salerno, 10Scientific Direction, IRCCS Cen-
tro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Background: The anti-CD20 monoclonal antibody rituximab is approved for
the treatment of non-Hodgkin’s lymphomas (NHL) and chronic lymphocytic
leukemia (CLL). Infusional side effects are commonly seen during rituximab
administration, mostly in the first cycle and in patients with high tumor load.
Severe adverse events (SAE) may also occur, following which the drug needs
to be definitively stopped in some cases. Very recently, Norin et al, have report-
ed data of a Swedish national observational study focusing on SAE occurring
in patients with CLL who underwent rituximab treatment (Leuk Res, 2015).
These Authors evaluated 96 patients and found that 58% of them experienced
at least one adverse drug reaction (ADR) during the first cycle. Only 5 patients
(5%), however, reported grade ≥ 3 ADRs, with one grade 4 reactions. Only 2
patients had a leukocyte count >50.000/mL and no correlation between leuko-
cyte count and ADR grade was found.
Aims: Starting in October, 2014, we are conducting a retrospective Italian mul-
ticenter study aiming to evaluate the incidence of side effects in patients treated
in the last 5 years at our Institutions with rituximab for their hematologic malig-
nancies or autoimmune disorders. We choose to focus on ADRs occurred in
CLL patients aiming to evaluate the incidence of infusional side effects and,
possibly, its correlation with clinico-biological features evaluated immediately
before to start therapy. 
Methods: To date, 130 patients have been evaluated: 60 with CLL, 34 with non-
Hodgkin’s diffuse large B-cell lymphomas, 33 with non-Hodgkin’s indolent lym-
phomas, 1 with Hodgkin’s lymphomas with lymphocyte predominance, and 2
with autoimmune disorders (1 immune thrombocytopenia and 1 acquired hemo-
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philia A). Sixty patients with immunologically typical CLL were evaluated (40 were
male and 20 female; mean age was 66,4 years, range 46-86; 1 patient with Rai
stage 1; 29 patients stage 2; 17 stage 3; and 13 stage 4). Rituximab was given
as first line treatment and variously combined with different drugs, the most used
being fludarabine, cyclophosphamide, chlorambucil and bendamustine.
Results: Twenty-three patients (38%) experienced an adverse event during
the first infusion of rituximab, while 37 patients (62%) did not. Overall, 13
patients (57%) had grade 1, 7 (30%) grade 2, 1 (4%) grade 3, and 2 (9%) grade
4 ADRs, according to National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE). No correlation was found with age, gender, con-
comitant presence of an autoimmune hemolytic anemia, spleen and lymph
node involvement, platelet count, and type of associated-chemotherapy. Degree
of bone marrow infiltration (p 0.03) and the concomitant infusion of rituximab
plus chemotherapy with respect to a delayed administration (p 0.007) were sig-
nificantly associated with the occurrence of ADRs. Quite surprisingly, patients
with more elevated hemoglobin levels (p 0.02) and those with lower peripheral
lymphocyte counts (p 0.03) displayed a greater risk to develop ADRs; these
last patients also showed more severe ADRs. Most of side effects were easily
managed. In the majority of cases rituximab was temporarily stopped, while
steroids and anti-histaminic drugs were given. The monoclonal antibody was
then safely re-started with a less rapid infusion. Only one patient definitively
stopped rituximab treatment, due to grade 4 ADR (shock and dyspnea).
Summary and Conclusions: Overall, in our multicenter experience, side
effects after rituximab were commonly seen in CLL patients during the first infu-
sion. However, they were mostly limited to grade 1 and 2 (mild-moderate) and
were easily managed. Rituximab was generally re-administered during the
same course of the treatment. Only very few patients experienced severe infu-
sion-related ADRs and rarely the monoclonal antibody had to be definitively
stopped. Clinico-biological variables, including pharmacogenomic parameters,
that could be useful in predicting the development of infusional side-effects are
warranted in order to identify patients at higher risk for ADR and to develop
appropriate preventing therapies.
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EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIA ON REUNION
ISLAND
I. Kittler1,* P. Zunic2, R. Letestu3, A. Clabé4
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Background: Chronic Lymphocytic Leukemia (CLL) is the most common type
of leukemia diagnosed in the Western world. The causes of its occurrence
remain unclear: environmental factors are involved, such as farming related
and chemical exposures. Family history of any hematological malignancy may
also increase risk of CLL. Reunion Island is an 874.000 inhabitants tropical
French overseas department located in the southwestern Indian Ocean.
Because of its insularity and the significant interbreeding population, this terri-
tory lends itself to genetic peculiarities. The fraction of people of each ethnicity
is not known exactly. A 2002 regional report estimated the distribution of different
ethnic groups as 33% Persons of mixed race, 27% Caucasians, 20% Indians,
17% Africans and 3% Chinese.
Aims: In the absence of previous epidemiological study, we conducted a com-
prehensive review of epidemiological, prognostic and therapeutic characteristics
of CLL Reunionese patients over a period of ten years, between 2004 and 2013.
Methods: Inclusion criteria were as follows: any French patient having a per-
manent residence on Reunion Island and matching the NCI/WG diagnosis cri-
teria for the 2004-2008 period, or the IWCLL diagnosis criteria for the 2009-
2013 period. Monoclonal B-cell lymphocytosis as well as small lymphocytic
lymphomas were not included in the study. Variables analyzed were age at
diagnosis of CLL, sex, prognostic markers (ZAP-70, lymphocyte doubling time,
B2-microglobulin, and where available del (17p13)), stage at diagnosis and
treatment intervention.
Results: A total of 134 cases of CLL were identified in this study. The age-
standardized incidence rate was 1.23 per 100.000 with a male/female sex ratio
of 1.98:1. Median age at diagnosis is 63 (range, 38-93 years). 37.3% of patients
were under 60 years. A majority of CLL diagnosis (86.3%) were discovered
incidentally after a blood cell count is performed for another reason. More
patients were at early stage (Binet A) versus advanced (Binet B or C) at the
time of CLL diagnosis (77% versus 23%). Median absolute lymphocyte count
at diagnosis was 11.7 G/L. When treatment was indicated (30%), 2/3 patients
(12%) received immunochemotherapy as first-line treatment. The median time
to treatment was 21.9 months. The overall survival at 5 years is 85%.
Summary and Conclusions: All CLL diagnosis in Reunion Island are carried
out a priori in one of the two Hospital Centers existing on the island, which are
the only facilities able to perform blood lymphocytic immunophenotyping by
flow cytometry. The French National Network of Registers FRANCIM analyses
together CLL and small lymphocytic leukemia: the 2012 incidence rate on the
whole French territory is estimated at 4.4 and 2.2, in men and women respec-
tively, per 100,000. CLL incidence seems twice to three times lower on Reunion
Island. Despite a comparison bias between national and Reunionese statistics,
the difference appears significate. This Reunionese peculiarity might be
explained either by genetic factors related to a highly mixed population, or by
environmental factors. Another hypothesis which might explain the low CLL
incidence would be an under-use of public and private medical facilities by the
Reunionese, in particular elderly people. Besides, sharing between Binet clas-
sification stages is the same as the one reported in the literature. No significant
differences were identified in overall survival compared with European CLL
patients. The low CLL incidence observed on Reunion Island is probably due
to multiple factors and requires further investigations. The determination of
each patient’s ethnic origin shall highlight a possible under-representation of
one or several population categories.
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SECONDARY MALIGNANCIES AFTER FCR AND FC TREATMENT IN
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. А SINGLE
CENTER STUDY.
T. Byalik1,* O. Timofeeva1, Y. Ryabukhina1, V. Larionova1, E. Osmanov1
1Oncohematology, N.N. Blokhin Russian Cancer Research Center, Moscow,
Russian Federation
Background: The combination of fludarabine, cyclophosphamide and rituximab
(FCR) improved response rates and prolonged both overall survival (OS) and
progression-free survival (PFS). On the basis of CLL8 trial FCR has become
the standard treatment for fit patients with CLL.
Aims: In this report we presents of follow up results of FCR and FC therapy
and adverse events as secondary malignancies.
Methods: 117 patients (50 previously untreated and 67 with relapsed and
refractory) received six courses of FCR or FC. Median age was 56,5 (range
28-73) for FCR group and 57 (range 38-76) for FC group. 52 patients were in
Binet stage B and 15 in stage C for FCR group, 38 patients were in Binet stage
B and 12 in stage C for FC group. OR was 91% with CR rate 57% for FCR
group, 86% and 50% for FC group.
Results: At follow up period 120 months median overall survival in FCR group
was 61,3 month, in FC group – 44,6 months, in previously untreated FCR group
median OS was 89 months and OS was not reached for previously untreated
FC group, progression-free survival were 42,4 months for previously untreated
FCR group and 24,4 month for previously untreated FC group (P=0,01). Infec-
tion complications III-IV grade were appeared in 15 patients: 4 (6%) for FCR
group and 11 (22%) for FC group. 5 patients died due to infection: 2 patients in
FCR group (2,9%) and 3 patients in FC group (6%). Secondary malignancies
were occurred at 10 patients (8,5%): 6 patients in FCR group (8,9%) and 4 –
in FC group (8%). Of these 10 patients, 5 patients (4,2%) had a solid tumor
(lung, bladder, colon), 1patient (0,8%) had a melanoma, 4 patients (3,4%) had
a Richter transformation.
Summary and Conclusions: FCR chemoimmunotherapy is highly effective
in patients with CLL. The frequency of secondary malignancies was 8,5%.
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IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: A SINGLE CENTRE
EXPERIENCE
J. Russell1,* C. Gomez2, K. Bowles3, G. Turner3, S. Sadullah2
1Department of Medicine, Norfolk and Norwich University Hospital, Norwich,
2Department of Haematology, James Paget University Hospital, Gorleston,
3Department of Haematology, Norfolk and Norwich University Hospital, Nor-
wich, United Kingdom
Background: Ibrutinib, a first-in-class Bruton’s Tyrosine Kinase inhibitor, was
available to National Health Service patients with relapsed/refractory Chronic
Lymphocytic Leukaemia (CLL) through a Named Patient Supply (NPS) program
from April to September 2014, funded by Janssen Pharmaceuticals. Approxi-
mately 600 patients with CLL were enrolled in the United Kingdom (UK). The
James Paget University Hospital treated 23 patients with CLL through the NPS
(including 10 patients from the Norfolk and Norwich University Hospital).
Aims: To evaluate the therapeutic response to ibrutinib in the clinical setting
compared to clinical trial data.
Methods: Therapeutic response was assessed in October 2014 using clinical
and laboratory data. The patient group was 65.2% male, with a median age of
74 years (range 45–89) and a median of 3 prior lines of therapy (range 1-6).
Cytogenetic analysis was available for 20 (87%) patients. Five (25%) patients
had 17p deletion, four (20%) had 13q deletion, three (15%) had trisomy 12p, two
(10%) had 11q deletion, and six (30%) had no detectable abnormalities. Five
patients were excluded from the analysis, including four who had received less
than eight weeks of treatment and one who had withdrawn from the NPS early.
Results: Out of 18 patients, comprising a total of 242 drug-weeks, there was
one (5.6%) Clinical Complete Response (CR), four (22.2%) Partial Responses
(PR), nine (50%) Partial Responses with Lymphocytosis (PR+L), two (11.1%)
with Stable Disease (SD), one (5.6%) with Disease Progression (DP) and his-
tological transformation, and one (5.6%) death from sepsis. The Overall
Response Rate (including PR+L patients) was 78%. Notably, both the patient
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in Clinical CR and the patient with histological transformation had 17p deletion.
Common side-effects included diarrhoea (16.7%), upper respiratory tract infec-
tions (11.1%), low platelet counts (<30x109/L in 5.6%), and lymphocytosis
(>two-fold increase in 22.2%). None were treatment-limiting.
Summary and Conclusions: These encouraging early results must be inter-
preted cautiously, but they suggest that Ibrutinib has similar efficacy and side-
effect profiles in the clinical setting as it does in clinical trials.
Chronic myeloid leukemia - Biology
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COMBINED EFFECTS OF PI3K INHIBITOR, COPANLISIB WITH ABL
TYROSINE KINASE INHIBITORS IN PH-POSITIVE LEUKEMIA CELLS
S. Okabe1,* T. Tauchi1, Y. Tanaka1, S. Katagiri1, K. Ohyashiki1
1Department of Hematology, TOKYO MEDICAL University, Shinjuku-Ku, Japan
Background: ABL tyrosine kinase inhibitor (TKI), imatinib and second-gener-
ation ABL TKIs, nilotinib and dasatinib have demonstrated the potency against
chronic myeloid leukemia (CML) patients. However, resistance to ABL TKI can
develop in CML patients due to BCR-ABL point mutations. Moreover, ABL TKIs
cannot eradicate leukemia stem cells (LSCs), thus, TKIs do not appear to lead
to a cure the diseases. Therefore, new approach against BCR-ABL mutant
cells and LSCs may improve the outcome of BCR-ABL-positive leukemia
patients. Phosphoinositide 3-kinase (PI3K) pathway regulates cell metabolism,
proliferation and survival. Furthermore, aberrant activation of PI3K signaling
pathway has been shown to be important in initiation maintenance of human
cancers. Copanlisib, also known as BAY80-6946 is a potent pan-class I PI3K
inhibitor against PI3Kα and PI3Kδ with potential anti-neoplastic activity. Copan-
lisib is being investigated in a pivotal phase 2 clinical trial against hematological
malignancies such as malignant lymphoma.
Aims: We hypothesized that targeting PI3K, in combination with ABL TKI,
would result in enhanced therapeutic activity in Philadelphia chromosome (Ph)-
positive leukemia cells including T315I mutation and ABL TKI resistant.
Methods: We investigated the combination therapy with a copanlisib and an
ABL TKIs (imatinib, nilotinib and ponatinib) by using the BCR-ABL positive cell
line, K562, murine Ba/F3 cell line which was transfected with T315I mutant,
nilotinib resistant K562, ponatinib resistant Ba/F3 cells and primary samples.
Results: 72 h treatment of copanlisib exhibits cell growth inhibition against
K562 cells in a dose dependent manner. The treatment of imatinib, nilotinib
and ponatinib exhibits cell growth inhibition partially against K562 cells in the
presence of feeder cell line, HS-5. We found that mRNA of PI3K subunit, p110δ
is significantly increased after a co-culture with HS-5 in K562 and primary CD34
positive CML samples. We examined the intracellular signaling after treatment
of copanlisib. High concentration of copanlisib reduced the phosphorylation of
BCR-ABL, Crk-L and S6 ribosomal protein. Activity of poly (ADP-ribose) poly-
merase (PARP) was increased. Phosphorylation of BCR-ABL, Crk-L and S6
ribosomal protein was reduced after imatinib and copanlisib treatment. We
investigated the copanlisib activity against T315I positive cells. Copanlisib
potently induced cell growth inhibition of Ba/F3 T315I cells. Combined treatment
of Ba/F3 T315I cells with ponatinib and copanlisib caused significantly more
cytotoxicity than each drug alone. Phosphorylation of BCR-ABL and Crk-L was
reduced and cleaved PARP was increased after ponatinib and copanlisib treat-
ment. To assess the activity of copanlisib and ponatinib, we performed to test
on CML tumor formation in mice. We injected nude mice subcutaneously with
Ba/F3 T315I mutant cells. A dose of 20 mg/kg/day p.o of ponatinib and 6
mg/kg/three times per week i.p of copanlisib inhibited tumor growth and reduced
tumor volume compared with control mice. We examined the intracellular sig-
naling of tumor model. Phosphorylation of Crk-L and S6 ribosomal protein was
reduced and cleaved PARP was increased. Treatments were well tolerated
with no animal health concerns observed. We also found that the treatment of
copanlisib exhibits cell growth inhibition against Ba/F3 ponatinib resistant cells,
K562 nilotinib resistant cells and primary samples.
Summary and Conclusions: Our preclinical results indicated that adminis-
tration of the PI3K inhibitor, copanlisib may be a powerful strategy against ABL
TKI resistant cells and enhance cytotoxic effects of ABL TKI against those Ph-
positive leukemia cells.
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DISTINCT ASSOCIATIONS BETWEEN UGT1A1 GENE PROMOTER
POLYMORPHISM AND HYPERBILIRUBINEMIA IN CML PATIENTS
TREATED WITH NILOTINIB AND RADOTINIB
S. Kim1,* S.Y. Choi 1, S.E. Lee2, H.L. Yoo1, Y.J. Oh1, M.Y. Lee1, E.J. Jang1,
M.Y. Choi1, M.M. Jang1, D.W. Kim1,2
1Cancer Research Institute, The Catholic University of Korea, 2Department of
Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul,
Korea, Republic Of
Background: Second-generation BCR-ABL tyrosine kinase inhibitors (2nd gen-
eration TKIs) including nilotinib (NIL) and radotinib (RAD) are approved for the
treatment of newly diagnosed and other TKI failed chronic myeloid leukemia
(CML). Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene pro-
moter polymorphism, distinct number of TA repeats in promoter, has been
reported for an association with hyperbilirubinemia on nilotinib therapy (Singer
et al. Leukemia (2007) 21, 2311–2315). However, the distribution of UGT1A1
(TA)7 repeat polymorphism differs greatly between Caucasians and Japanese,
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namely, the frequency of UGT1A1(TA)7 repeat polymorphism is high in Cau-
casians, whereas it is low in Asians (Beutler et al. Proc. Natl. Acad. Sci. USA
95 (1998) 95, 8170–8174).
Aims: The aim of this study was to investigate the association between
UGT1A1 gene promoter polymorphism and hyperbilirubinemia in Korean CML
patients treated with NIL and RAD as a frontline therapy.
Methods:A total of 94 newly diagnosed chronic phase CML patients who treated
with frontline NIL (n=42) and RAD (n=52) was screened for UGT1A1 promoter
polymorphism genotype analysis. We used the High Pure PCR Template Prepa-
ration Kit (Roche, Germany) to prepare genomic DNA from whole blood and geno-
typed by direct sequencing of the 253- to 255-bp fragments produced by PCR. 
Results: The (TA)6/(TA)6 homozygote and (TA)6/(TA)7 heterozygote were seen
in all genotyped population and frequency of (TA)6/(TA)6 homozygote was
77.7% (73/94) in our patients. (TA)6 /(TA)6 homozygote predominated with
78.9% of the alleles in the RAD group and 76.2% in the NIL group. Relative
risk for each genotype presented in Table 1, with hyperbilirubinemia defined as
CTCAE grade 2 or greater observed at any post-baseline point. The relative
risks for 6/6 genotype versus 6/7 genotype was 3.9 with 95% CIs of (0.7, 20.3)
in the RAD group compared with 10.5 (2.0, 54.3) in the NIL group and NIL
group showed significantly high association with UGT1A1 gene promoter poly-
morphism (P<0.05).
Table 1. Relative risk calculations prevalcence of hyperbilirubinemia.
Summary and Conclusions: This finding suggests that UGT1A1 gene pro-
moter polymorphism may be an important determinant of hyperbilirubinemia in
CML patients with NIL therapy, but not in RAD. However other mechanisms
should be explored in patients who have significant hyperbilirubinemia with
RAD therapy. Updated data with longer follow-up duration will be presented in
the meeting
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IMPACT OF MULTIDRUG RESISTANCE GENE 1 (MDR1) C3435T
POLYMORPHISM ON CHRONIC MYELOID LEUKEMIA RESPONSE TO
TYROSINE KINASE INHIBITORS
Y. Elnahass1,* M. mattar2, H. El Leithy2
1Clinical Pathology, National Cancer Institute, 2Cinical hematology, School of
Medicine, Cairo, Egypt
Background: Single nucleotide polymorphisms (SNPs) of multiple drug resist-
ance (MDR1) gene are associated with altered P-glycoprotein (p-gp) activity
and contribute to resistance to tyrosine kinase inhibitors (TKIs) in chronic
myeloid leukemia (CML).
Aims: We aimed to demonstrate the association between MDR1 gene C3435T
polymorphism and molecular response in newly diagnosed chronic phase (CP)
CML patients to standard dose upfront imatinib and nilotinib therapy.
Methods: MDR1 C3435T was genotyped using polymerase chain reaction
Restriction Fragment Length Polymorphisms (PCR-RFLP) at diagnosis. BCR-
ABL1 transcripts level was measured by Real Time Quantitative polymerase
chain reaction (RQ-PCR) at diagnosis then every 3 months. 
Results: This study included 74 Philadelphia (Ph’) positive CP-CML patients;
38 males and 36 females. Median age at diagnosis was 38 years (18-78). Medi-
an BCR-ABL1 level was 101%. Forty patients received imatinib (54%) while 34
received nilotinib (46%). Optimal response at 12 month was 35% in the imatinib
arm versus 80% in the nilotinib arm (P=0.001). The frequency of MDR1 SNP
C3435T was 46%, 32% and 22% for CC, TT and CT genotypes, respectively.
Optimal response at month 12 differed significantly between imatinib and nilo-
tinib among patients with MDR1 C3435TT genotype (11% versus 83%, respec-
tively, P=0.002) while less significant difference was found between the two
drugs in CC and CT genotypes (35% vs. 75% and 60% vs. 83%, respectively,
P=0.042 & P=0.588).
Summary and Conclusions: MDR1 C3435TT may be used as an additional
criterion for initiating nilotinib instead of imatinib as front line therapy for CP-
CML patients. We demonstrated the usefulness of MDR1 SNP polymorphism
in the identification of CML patients who may or may not respond optimally to
imatinib.
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DIFFERENTIAL EXPRESSION OF ABCF2 IN NEWLY DIAGNOSED AND
DASATINIB-TREATED CHRONIC MYELOID LEUKEMIA PATIENTS
B. Ribeiro1,* R. Ferreira1, R. Silveira1, Â. Fachel2, S. Verjovski-Almeida2,
B. Vergílio1, D. Albuquerque1, C. Souza1, K. Pagnano1
1Hematology and Hemotherapy Center, University of Campinas-UNICAMP,
Campinas, 2Departamento de Bioquímica, Instituto de Química, Universidade
de São Paulo, São Paulo, Brazil
Background: ABCF2 was previously identified by our group as genes differ-
entially expressed in CML patients which are resistant to imatinib, in samples
collected before and after dasatinib treatment (responsive and resistant) in a
microarrays analysis study (SILVEIRA, RA et al. Hematology;19(1):31-41,2014).
ABCF2 gene is a member of the ATP binding cassette (ABC) transporter family
and although its function is not clear, studies with colorectal and breast cancer
showed an association of low expression of ABCF2 and poor prognosis and
non-response to palliative chemotherapy. The role of ABCF2 in CML patho-
genesis is unknown. 
Aims: The aim of this study was to analyse the expression profile of ABCF2 in
CML patients without previous treatment, in CML patients treated with dasatinib
(after imatinib failure) and in healthy donors.
Methods: Total RNA extraction of mononuclear cells from peripheral blood,
transcription to cDNA, and qPCR were performed to analyze differential gene
expression. ACTB and GAPDH were used as endogenous control. geNorm
program was used to estimate the gene expression in arbitrary units (A.U.).
Results were expressed as median and compared using non-parametric tests
(Mann Whitney or Kruskal-Wallis). We evaluated 13 healthy donors (control
group) and 39 CML patients treated with dasatinib in second line after imatinib
failure: 25 responsive to dasatinib, all with complete cytogenetic response
(CCyR), 15 of them with major molecular response (MMR) and 14 patients
resistant to dasatinib. We also analyzed 9 samples collected at CML diagnosis
from the group that was responsive to dasatinib. Only one patient of this group
had no sample available after dasatinib treatment. 
Results: ABCF2 expression was down-regulated in the newly diagnosed CML
samples and in patients treated with dasatinib compared to control group (0.15
[0.05 – 0.91] versus (vs.) 0.35 [0.04 – 3.07] versus (vs.) 2.5 [0.61 – 4.84] P<
0.0001). There was no difference of expression between patients at diagnosis
and patients treated with dasatinib (all patients) (P=0.09). However, ABCF2
expression was significantly lower in CML dasatinib-resistant patients when
compared to dasatinib-responsive patients with MMR (0.35 [0.05 – 2.21] versus
(vs.) 1.19 [0.14 – 3.07] P=0.02). The expression of ABCF2 was down-regulated
in 8 CML patients at diagnosis and its expression increased after treatment
with dasatinib in patients that achieved MMR (0.22 [0.06 – 0.91] versus (vs.)
1.20 (0.14 – 2.73] P=0.049).
Figure 1.
Summary and Conclusions: ABCF2 is down-regulated in newly diagnosed
CML when compared to the healthy donors and to dasatinib treated patients.
On the other hand, up-regulation of ABCF2 was observed after treatment in
patients which achieved MMR with dasatinib. ABCF2 might be involved in
mechanisms associated with the development of CML or resistance. Further
studies are necessary to clarify the role of ABCF2 in CML. 
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DIDO 2 LOW EXPRESSION IN CML IS LINKED TO APOPTOSIS
RESISTANCE
M. Coelho1,* A.P. Marsola1, S. Burin1, M. Rocha-Junior1, A. Ferreira1,
S. Haddad1, B. Simões2, R. Panepucci3, C. Martinez4, F. Castro1
1Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP, 2Faculdade
de Medicina de Ribeirão Preto-USP, 3Fundação Hemocentro de Ribeirão Preto,
Ribeirão Preto, Brazil, 4Centro Nacional de Biotecnologia-CSIC, Madrid, Spain
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neo-
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plasm which patients are diagnosed by the BCR-ABL1 oncogene presence.
BCR-ABL1 encodes Bcr-Abl, a tyrosine kinase protein responsible for CML
pathogenesis and apoptosis impairment. CML patients are treated with tyrosine
kinase inhibitors (TKI). However resistance to TKI have been described and
can be associated with Bcr-Abl dependent and independent mechanisms.
Therefore new therapeutic targets and CML pathogenesis, including the pos-
sible involvement of DIDO, should be investigated. DIDO is a gene that
encodes transcription factors of apoptosis-inducing genes and has three dif-
ferent isoforms: DIDO 1, 2 and 3. In physiological conditions DIDO is present
in small concentrations in cytoplasm, but during the process of apoptosis its
protein expression rises and then it is translocated to the nucleus. Increased
expression of DIDO is therefore associated with the induction of apoptosis
process. In myeloproliferative diseases DIDO is defined as a tumor supressor
gene. Expression changes of isoforms 2 and 3 were already described in the
pathophysiology of myeloid neoplasms. 
Aims: To evaluate the association between apoptosis resistance and Dido
expression by the quantification of the expression of DIDO 1, 2 and 3 genes in
CML patients in chronic and advanced phases and in healthy subjects.
Methods: 39 CML patients (median age = 45 years; 19 women and 20 men)
and 16 controls (median age = 35 years; 10 women and 6 men) were studied.
Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density gra-
dient method and the mRNA was extracted by Trizol® method. The cDNA was
synthesized by High Capacity cDNA Reverse Trasnscription® Kit in conventional
PCR and gene expression analysis of isoforms 1, 2 and 3 of DIDO gene was
performed by real-time PCR (Applied Biosystems 7500 Real Time PCR®). The
results were expressed as relative units of expression. The gene expression
comparison of DIDO1, 2 and 3 between health subjects and patients in different
stages of the disease was assessed by Mann-Whitney statistical test.
Results: The DIDO 2 expression was lower in advanced stages (median=1.352
and P=0.0130) in comparison to controls (median=4.886 and P=0.0130). Com-
parison of isoforms 1 and 3 expression between CML patients and controls
yielded no significant differences.
Summary and Conclusions: The results indicate that DIDO 2 low expression
may be linked to apoptosis resistance in CML patients. In addition the results
also suggest a different role for each of the three different gene isoforms in CML.
PB1733
DOWN-REGULATION OF MIR-203-B IN IMATINIB-RESISTANT CHRONIC
MYELOID LEUKEMIA PATIENTS
N. Ryabchikova1, G. Safuanova1,* I. Minniakhmetov2, A. Karunas2, B. Yalaev2,
E. Shut2, R. Latypov2, E. Khusnutdinova2
1Bashkir State Medical University, 2IBG USC RAS, UFA, Russian Federation
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder
characterized by the expression of the BCR-ABL oncoprotein, which is essential
for the pathogenesis of the disease. Imatinib, an ATP-competitive selective
inhibitor of BCR-ABL, has unprecedented efficacy for the treatment of CML.
Nevertheless resistance to imatinib is observed in over 30% cases of CML.
Several cellular and genetic mechanisms of imatinib resistance have been pro-
posed, including overexpression of the BCR-ABL gene, the tyrosine kinase
domain mutations, pharmacokinetic and pharmacodynamic factors.
Aims: The purpose of this study was to investigate the mechanisms of resist-
ance to imatinib in CML patients.
Methods: We have analyzed mRNA level of BCR-ABL gene by quantitative
real time RT-PCR in 114 patients and have studied BCR-ABL mutations in
patients with high level of expression of fusion gene. Mutation status was stud-
ied by direct sequencing of BCR-ABL cDNA samples.
Results: BCR-ABL mutations were founded in 16 (32%) patients with resist-
ance to imatinib treatment. The mutation spectrum included four missense
mutation: M351T (7 cases), T315I (4), T315I+M351T (2), M244V (1) and H396R
(1). Next we conducted a search for microRNAs specifically targeting 3’UTR
of BCR-ABL, using the miRBASE program to scan human genome
(http://microrna.sanger.ac.uk/) and analyzed microRNAs expression profile.
The down-regulation of miR-203-b (25-fold), mir-323 (4-fold) and miR-196-b
(2-fold) in the group of patients with resistance was discovered.
Summary and Conclusions: In conclusion, our data showed that mutations
in the BCR-ABL kinase domain may cause, or contribute to, resistance to tyro-
sine kinase inhibitors in CML patients, but resistance mechanisms might also
be regulated by microRNAs.
PB1734
A GENOME-WIDE ANALYSES OF DIFFERENTIALLY EXPRESSED GENES
AND RELATED NETWORKS AFFECTED BY FISETIN AND HESPERETIN
IN CHRONIC MYELOID LEUKEMIA CELLS
A. Adan Gökbulut1,* Y. Baran1
1Molecular Biology and Genetics, İzmir Institute of Technology, İzmir, Turkey
Background: Diet is an important determinant of cancer risk based on various
epidemiologic and case control studies. Therefore, there is a great interest to
investigate bioactive food components for their cancer preventive and thera-
peutic potentials. Fisetin and hesperetin are members of the flavonoid polyphe-
nols, found in several plant species. They have a wide range of pharmacological
properties including antioxidant, anti-inflammatory and anticancer effects. Their
chemopreventive/chemotherapeutic potentials were investigated in several
cancer types such as colon and prostate cancers, however, the exact mecha-
nisms of fisetin and hesperetin actions are not known in CML.
Aims: We aimed at determining the underlying molecular mechanisms of fisetin
and hesperetin induced growth inhibitory effects in K562 CML cells based on
changes in global gene expression patterns using genome-wide microarray
analysis.
Methods: Expression profiling is accomplished using the Human HT-12v4
beadchip microarrays (Illumina, Inc.). Total RNA isolated from fisetin and hes-
peretin treated K562 CML cells was converted to biotin labeled cRNA, which
were hybridized to beadchips. The BeadChips were analyzed using Illumina’s
Genome Studio in order to cluster genes. We obtained the list of differentially
expressed genes based on p-value<0.05 and at least 2.0 fold change. Affected
genetic networks were determined by using the Kyoto Encyclopedia of Genes
and Genomes (KEGG) and Ingenuity Pathway Analysis (IPA).
Results: A total of 553 and 1734 genes were significantl regulated (P<0.05) in
50 μM and 100 μM fisetin treated K562 cells, respectively. Both 50 and 100
μM fisetin treatment resulted in the upregulation of common genes such as
NFKBIA, NOXA, p21 and GADD45B. We also found each fisetin concentration
altered expression of specific genes. For instance, 50 μM fisetin upregulated
NFKBIZ and GADD45A while 100 μM fisetin treatment resulted in the upregu-
lation of CDKN2D/ p19, TXNIP and SMAD5. Furthermore, MYC, MYB, C-KIT,
TUBA1A and TUBAL3 were some of common downregulated genes after 50
and 100 µM fisetin treatment. 100 μM fisetin also caused downregulation of
important genes such as FOXK1, FOXA2 and BCL-XL. Apoptosis modulation,
TP53 network, TNF-α, KIT receptor and JAK/STAT signaling, adhesion net-
works, growth hormone receptor signaling and angiogenesis were modulated
networks. On the other hand, a total of 1659 and 1201 genes were significantly
changed (P<0.05) in 100 and 150 μM hesperetin treated K562 cells, respec-
tively. DUSP1, CDKN1A, GADD45B and BIM were the examples of common
upregulated genes in 100 and 150 μM hesperetin treatment. On the other hand,
100 μM hesperetin also upregulated some other genes such as p27, CASP4,
DUSP5 whereas 150 μM hesperetin upregulated MT1A, DUSP3 and NFKBIA.
STAT5A, TUBA1A, MYB, KIT, EPCAM and PCNA were the examples of com-
mon downregulated genes in 100 and 150 μM hesperetin treatment. 100 μM
hesperetin treatment also resulted in the downregulation of EEF1G, POLR2B
and STAT3. Furthermore, 150 μM hesperetin treatment downregulated genes
such as MCM10, ABCC4 and POLE2. Translation initiation and elongation net-
works, replication and trancription networks, EGF, JAK/STAT and KIT receptor
signaling pathways, growth hormon receptor signaling and PI3K pathway were
altered networks.
Summary and Conclusions: Fisetin and hesperetin trigger apoptosis and
growth suppression via affecting various significant targets in K562 cells, which
could open the usage of new strategies together with fisetin to overcome diffi-
culties in CML treatment. 
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A STATE OF THE ART CUSTOM “DUPLEXED” REAL TIME PCR ASSAY
FOR MINIMAL RESIDUAL DISEASE MONITORING OF CHRONIC MYELOID
LEUKEMIA USING LOCKED NUCLEIC ACID PROBES.
S.K. Joshi1,* P. Subramanian1, S. Chaudhary1, P. Tembhare1, S. Gujral1,
S. Gaware1, H. Doshi1, N. Patkar1
1Hematopathology, Tata Memorial Centre, Kharghar, India
Background: In India treatment of Chronic Myeloid Leukemia (CML) is sup-
ported through an International Patient Assistance Program in which imatinib
mesylate is provided to economically disadvantaged patients free of cost. As a
result most of these patients opt for treatment and need regular molecular mon-
itoring. However, commercial kits for BCR-ABL monitoring are cost prohibitive
for our patients. It is also currently recommended to test for BCR-ABL copy
numbers in triplicates to ensure making confident calls at low levels placing fur-
ther economic strain in resource constrained settings especially if all quality
control measures are to be followed. In that context it is required to develop
cost effective BCRABL monitoring technologies. Globally, a majority of centres
use the EAC protocol for CML, an assay that suffers from background noise.
We addressed these problems by modifying the legacy real time PCR (qPCR)
process. We cloned a duplex qPCR compatible plasmid that enables us to mul-
tiplex BCRABL and ABL reaction in a single well using FAM- black hole
quencher1 (BHQ1) and HEX-BHQ1 probes modified with locked nucleic acids
(LNA). 
Aims: To develop a custom duplex PCR compatible plasmid and develop and
standardize a LNA probe based assay for BCR-ABL and ABL.
Methods: A 1600bp amplicon from a newly diagnosed CML (E13A2) patient
into a pJET1.2/blunt cloning vector. This was linearized and using Avogadro’s
number an estimate of copy numbers were arrived at and a standard curve
was created. Accuracy of dilutions were confirmed by using Ipsogen’s stan-
dards. Using Modified EAC protocol: BCR-ABL probe was truncated to 16
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nucleic acids labelled with FAM and BHQ1 with three LNA modifications where-
as the ABL probe was 19 nucleic acids (HEX and BHQ1) with 4 LNA modifica-
tions. Calibration to the WHO calibrator was done using a secondary standard
(Asuragen Inc) to derive an international scale conversion factor. Assay preci-
sion was monitored using two levels of controls in the duplex assay (median
NCN 0.1% and 0.05%). We compared the normalized copy number (NCN)
derived from the duplex assay with the simplex assay in 87 samples of CML
(NCN ranging from 0.002 to 108.5, median 0.14%).
Results: The plasmid was successfully cloned and confirmed by sanger
sequencing. The duplex assay did not lead to loss of MMR in any patient also
we did not face any issues with false positivity. We found a good correlation
between the simplex and duplex assay (r2=0.97). In all runs, slope was between
-3.2 to -3.6, R2>0.98. The international scale conversion factor was 0.79. Over
60 runs the BCRABL assay has a CV of 38.9% and 48.1% for high and low
precision controls.
Summary and Conclusions: This assay has enabled us to maintain a high
level of quality control (runs in triplicates, precision, no template as well as no
reverse transcription controls) yet process 22 samples per run. As a result the
cost of the assay is low. We would be happy to share this plasmid to other
users from resource constrained setting such as ours. To the best of our knowl-
edge, this is first paper to use LNA probes for CML minimal residual disease
(MRD) monitoring. The use of a duplex PCR enables us to significantly
decrease the cost of the assay ($5/patient) yet maintain a high standard of
quality control.
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EXPRESSION LEVELS OF JAK/STAT SIGNALING GENES IN NEWLY
DIAGNOSED, DRUG SENSITIVE AND RESISTANT CHRONIC MYELOID
LEUKEMIA PATIENTS
Y. Kiraz1,* G. Saydam2, F. Şahin2, I. Kozanoğlu3, H. Özdoğu 3, Ö. Pişkin4,
M.A. Özcan4, F. Avcu5, A. U. Ural6, A. Ünal7, Y. Baran1
1Molecular Biology and Genetics, İzmir Institute of Technology, 2Hematology,
Ege University, İzmir, 3Hematology, Baskent University, Adana Research and
Application Hospital, Adana, 4Hematology, Dokuz Eylul University, İzmir,
5Hematology, Gülhane Military Medical School, 6Hematology, Bayındır Hospital,
Ankara, 7Hematology, Erciyes University, Kayseri, Turkey
Background: Jak/STAT is a major intracellular signaling pathway that involved
in immune response, cancer development (mostly leukemias) and
hematopoiesis by stimulating cellular growth, proliferation and differentiation.
This pathway relies on transmition of outside signals into the cells through cell
membrane. The Jak/STAT mechanism composed of 2 main components includ-
ing Janus kinase (Jak) and signal transducers and activators of transcription
(STAT) proteins. Janus kinases, have four different types (Jak1, Jak2, Jak3 and
Tyk2), found as an inactive form and associated with receptor protein on the cell
membrane whereas there are seven types of STAT protein (STAT1, STAT2,
STAT3, STAT4, STAT5A, STAT5B, STAT6) that are located in cytoplasm and
activated by Jak kinases. The system is started with conformational change and
trans-activation of Jak proteins by a signal from a number of cytokines. This
activation is followed by STAT phosphorylation at tyrosine residue in transacti-
vation domain of STAT protein. Phosphorylated STAT proteins become dimerized
by interacting phosphotyrosine of one STAT and SH2 domain of another STAT,
as a result, they either affect different pathways and cause signaling cascades
or move into the nucleus and directy activate their target genes involved in pro-
liferation, differentiation, cell growth, cell death or survival. Abnormal activation
of Jak/STAT signaling pathway proteins are found in many types of hematological
malignancies including AML, MDS, B-cell lymphomas and CML.
Aims: Despite high efficiency of tyrosine kinase inhibitors, the success of ther-
apy is limited to multidrug resistance phenomenon. Recent developments in
drug resistance mechanism in CML showed that many molecular interactions
and signaling pathways are involved in mediating TKI resistance in patients.
Jak/STAT signaling pathway is one of these pathways that have significant
roles in various cellular mechanisms including leukemia initiation and drug
resistance. The aim of this study is to examine the relationship between expres-
sion levels of Jak/STAT genes and clinical outcome of chronic myeloid leukemia
(CML) patients who are newly diagnosed; treated with imatinib, nilotinib or
dasatinib; responded positively to TKIs; imatinib, nilotinib or dasatinib resistant;
or lost of their molecular response. 
Methods: This study including 14 newly diagnosed CML patients, 5 patients
who are CML diagnosed and treated with imatinib, 1 patient who positively
responded to imatinib, 1 patient who lost molecular response, 1 imatinib resist-
ant patient and 1 patient who has both imatinib and nilotinib resistance.
Mononuclear cells were isolated from bone marrow samples of the patients
and total RNAs were isolated, mRNAs were converted into cDNAs and expres-
sion levels of JAK1-3, TYK2, STAT1-4, STAT5A-B and STAT6 genes were
detected by Real-Time PCR.
Results: The results showed that expression levels of Jak3, STAT1-4 and
STAT5A genes had higher in TKI resistant patients, compared to other patient
groups. Expression levels of STAT5B, JAK1 and JAK2 genes were higher in
newly diagnosed and positively responded patients than in resistant patients
while expression levels of TYK2 was lower in imatinib-treated patients.
Summary and Conclusions: It was demonstrated for the first time that there
is a relation between the clinical outcome of CML patients and expression levels
of JAK-STAT genes that could make this signaling pathway a new target for
more effective treatment of CML.
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PLASMA AND LEUKOCYTE METABOLOMICS AND METABOLISATION
STUDY OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
R. Karlíková1, K. Mičová1, M. Hrdá1, J. Široká1, I. Vrobel1, A. Gardlo1,
L. Najdekr1, D. Friedecky1,2,3,* E. Faber4, T. Adam1,2,3
1Institute of Molecular and Translational Medicine, Faculty of Medicine and
Dentistry, Palacký University in Olomouc, 2Laboratory of Inherited Metabolic
Disorders, Faculty of Medicine and Dentistry, Palacký University in Olomouc,
University Hospital Olomouc, 3Department of Clinical Chemistry, University
Hospital Olomouc, 4Department of Hemato-Oncology, Faculty of Medicine and
Dentistry, Palacký University in Olomouc, University Hospital Olomouc, Olo-
mouc, Czech Republic
Background: Metabolomics refers to the interpretation of information-rich data
with the aim to understand metabolic processes and to find changes in metabo-
lite levels as a potential biomarkers of the disease. Due to drug metabolizing
enzymes several bioactive or toxic metabolites of tyrosine kinase inhibitors are
produced. Therefore determination of drug metabolites may have clinical rele-
vance and could be helpful for treatment adjustment. 
Aims: The first aim of this work was to examine the influence of tyrosine kinase
inhibitors and hydroxyurea on the leukocyte and plasma metabolite profiles
from patients with CML compared with healthy controls. The second aim of this
work was profiling of imatinib metabolites in plasma from patients with chronic
myeloid leukaemia.
Methods: Leukocytes and plasma samples from healthy controls (n=10),
patients before treatment (n=9), treated with hydroxyurea (n=5), imatinib (n=24),
dasatinib (n=8) and nilotinib (n=10) were prepared from whole blood and
metabolites were extracted by the chloroform/methanol/water mixture. Analysis
of 400 metabolites was performed using high performance liquid chromatogra-
phy (Ultimate 3000, Dionex) coupled with tandem mass spectrometry (QTRAP
5500, AB Sciex). Metabolites were quantified using MultiQuant 3.0 software
and statistically evaluated in R programme language with statistics packages.
For metabolisation study plasma samples were taken from patients on treat-
ment by imatinib (24h after dose of 400 mg). Separation of imatinib metabolites
was performed on Phenomenex Kinetex C18 column using UltiMate 3000 RS
(Thermo Scientific) liquid chromatography. For detection in full scan mode and
MS2 fragmentation experiments Orbitrap Elite mass spectrometer (Thermo Sci-
entific) based on exact mass measurement was used. Data were evaluated
using MetWorks 1.3 SP3 and Mass Frontier 7.0 software.
Results: Total 170 metabolites were identified on the basis of its transition and
retention time in all leukocyte and plasma samples. Significant changes in
metabolic pathways were found. Both unsupervised and supervised statistic
methods (PCA, PLS-DA, OPLS-DA, cluster analysis) separated all the studied
groups. In plasma samples more than 90 potential metabolites in concentration
range of 4 orders of magnitude were found. All metabolites were identified by
exact m/z values and confirmed by MS2 and MS3 exact m/z fragmentation
experiments. Changes in profiles of several metabolisations between patients
were followed.
Summary and Conclusions: In this study metabolome of human leukocytes
and plasma was defined and changes of metabolite levels were observed in all
groups of patients compared to healthy controls. High Resolution Mass spec-
trometry using Orbitrap principle is able to detect and confirm high as well as
low intensive metabolites and its fragments. Tyrosine kinase inhibitor – Imatinib
offers complex metabolite profile. It has diagnostic potential for individualized
treatment of patients with adverse effects or resistance on treatment. The work
was supported by grant of IGA Ministry of Health, Czech Republic NT12218-
4/2011. 
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TO THE DIFFERENTIAL DIAGNOSIS OF ACUTE MYELOBLASTIC
LEUKEMIA AND CHRONIC MYELOID LEUKEMIA STARTED WITH BLAST
CRISIS 
T. Saralidze1,* T. Saralidze2, T. Shvelidze3, B. Metreveli4
1 Faculty of Medicine, AIETI Medical School, 2Department of Internal Medicine,
Tbilisi State Medical University, 3Clinical Laboratory, 4Department of Gynecol-
ogy, Medical Center “JUNONA”, Tbilisi, Georgia
Background: Despite the achievements of modern medicine sometimes there
is a problem to differentiate chronic myeloid leukemia (CML) started with blast
crisis from acute myeloblastic leukemia (AML), especially in the cases of Ph
chromosome negative or BCR-ABL1- negative cases. Even in the presence of
this marker one should have taken in mind that there are cases of Ph + AML
as well.
Aims: The aim of our study was to precise the diagnose in patients with blast
cells in peripheral blood and prominent hepato- and splenomegaly suspicious
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on CML and reveal additional criteria for the diagnosis of CML started with
blast crisis.
Methods: To solve this problem we have used peripheral blood and bone mar-
row cell culture method worked out by us. This method supports propagation of
blast cells specific for each form and variant of leukemia and enables to reveal
the malignant clone according to morphocytochemical investigation or pheno-
typing in vitro proliferating cells (Shvelidze, Saralidze et al.Atlas of Hematology,
2013. http://www.e-bookland.ge/Books/medical/ATLAS-of-HEMATOLOGY). We
investigated peripheral blood and bone marrow cell cultures of 5 patients with
CML presented with blast crisis at the time of diagnosis, 8 patients with CML at
chronic stage, 2 patients with CML in accelerated phase and 7 patients with
AML (3 cases of AML without maturation and 4 cases of AML with maturation).
Results: Our studies showed that in all cases of AML proliferation of blast cells
is confirmed by abundance of blast cells in cultures during 2 weeks of cultivation
and appearance of maturation part of them up to promyelocytes and myelo-
cytes and rarely to the band neutrophils in late cultures. On contrary, in the
cases of CML presented with blast crisis as well as in the cases of CML at
chronic stage, rapid maturation of blast cells up to band neutrophils is obvious
from the beginning of cultivation. Just from the second day of cultivation in cul-
tures of patients with CML disappearance of blast cells and abundance of band
and segmented granulocytes, mainly neutrophilic, but eosinophilic and
basophilic also are observed (Figure 1). It must be noticed that from 2 patients
with CML in accelerated phase in one case majority of cells in culture were
matured granulocytes, that is characteristic for CML, while in another case cul-
ture material was presented by abundance of immature myeloid cells –
myeloblasts, promyelocytes and myelocytes and a few band and segmented
granulocytes that pointed to tumor progression. In the last case treatment was
not effective at all. Figure 1. Abundance of band neutrophils with ring nuclei. 2-
day- bone marrow culture of a patient with CML started with blast crisis. Rapid
maturation of blast cells up to band neutrophils in vitro enabled to diagnose
CML. May-Grünwald –Giemsa stain. Х 1000.
Figure 1.
Summary and Conclusions: Results of our study show that blood and bone
marrow culture data of patients with CML can be successfully used as additional
criteria for the differentiation of CML started with blast crisis from AML as far as
in cultures of patients with AML abundant proliferation of blast cells is observed,
whereas in the cases of CML started with blast crisis rapid maturation of blast
cells up to band neutrophils from the beginning of cultivation is obvious. Abun-
dance of immature cells in blood or bone marrow cultures of patients with CML
points to tumor progression in spite of the clinical stage of disease and represents
a bad prognostic marker. Cytochemical study or immunophenotyping of prolifer-
ated in vitro cells can help to determine the type of new proliferative clone.
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USEFULNESS OF THE TEMPUS™ BLOOD RNA STABILIZATION SYSTEM
FOR OPTIMIZING RNA EXTRACTION METHOD FROM WHOLE BLOOD,
MEASURING AND REPORTING ABL TRANSCRIPTS LEVELS IN CHRONIC
MYELOID LEUKEMIA.
R. Lukackova1,* M. Eckertova1, I. Hojsikova1
1Genetics, Medirex, Bratislava, Slovakia
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder
of blood stem cells. More than 95% of patients with detected translocation
t(9;22) is characterized by the fusion between exons e13 or e14 of BCR gene,
which are located in major breakpoint cluster region (M-bcr) and exon a2 of
ABL gene. These fusions are described as b2a2 (e13a2) and b3a2 (e14a2).
Because patients treated with tyrosine kinase inhibitors achieve lower levels
of detectable disease, quantification of BCR-ABL transcripts with quantitative
RT-PCR has become an essential tool in chronic myeloid leukemia monitoring.
Major molecular response (MMR; i.e., a ≥3-log reduction in BCR-ABL transcript
levels) is used in current treatment guidelines to assess prognosis. Recent evi-
dence suggests that deeper molecular responses (≥4-log reductions in BCR-
ABL transcript levels), particularly when attained early during treatment, may
have even better correlation with long-term outcomes, including survival and
disease progression. Therefore, quantitative measurement of BCR-ABL tran-
scripts in blood and bone marrow both aids in the initial diagnosis of CML is
essential for routine post-therapy minimal residual disease monitoring. Estab-
lishing methods for secure long-term storage of RNA is critical to realize MRD
monitoring. We describe the results of RNA stability in the same set for whole
blood RNA collecting in Tempus Blood RNA tubes and tubes with EDTA.
Aims: All the steps of the preanalytical phase (blood collection, conservation
and procedures of isolation RNA) are influencing on the number of copies of
the ABL control gene in the analysis of BCR/ABL transcripts. Our aim was to
show the differences in the stability of the RNA using EDTA tubes and tubes
with a special stabilizing solution Tempus (TempusTM VACUETTE® Blood RNA
Tube) for the collection of peripheral blood and bone marrow in CML.
Methods: Various kits for stabilizing the RNA at the time of blood collection
were developed: Ambion RNA later (Applied Biosystems) and the new Tempus
Blood RNA kit (Applied Biosystems). The Tempus Blood RNA kit (VACUETTE®
TempusTM Blood RNA Tube) uses tubes containing a proprietary blend of
reagents based on a patented RNA stabilization technology. In order to evaluate
the Tempus Blood RNA kit, it was compared to unstabilized EDTA blood pro-
tocol. The RNAs extracted by the different methods were assessed for quantity
control gene (ABL) and fusion gene transcripts BCR-ABL by QRT-PCR. After
extraction, both RNA purity were measured by using both, the ratio A260/280,
no significant changes in these ratios were observed in either system. The
integrity of RNA after extraction was confirmed using the Agilent 2100 Bioan-
alyzer and was indicated by the RIN.
Figure 1.
Results: Our results strongly suggest the superiority of the stabilization system
special tubes over the unstabilized EDTA blood. Tempus tubes are preventing
the degradation of RNA at the time of the preanalytical phase during genetic
analysis of CML patients. Using Tempus tubes we have achieved increased
stability of RNA, which has a direct impact on increasing the number of copies
of the ABL control gene (3-4 times) for the analysis of BCR/ABL and thus ulti-
mately increases the sensitivity of QRT-PCR method. Tempus blood RNA sys-
tems have been shown to provide efficient stabilization of the blood RNA for
several days at room temperature. Comparison of expression levels of ABL
control gene in RNA (10 patients) extracted by EDTA or Tempus Blood RNA
system. ABL expressions are expressed as copy number. P-value: in blood
P<0.0001 and in bone marrow P<0.0101 (t-test).
Summary and Conclusions: In summary, molecular response measured by
BCR-ABL QRT-PCR provides important prognostic information for the man-
agement of patients with CML treated with TKI therapies. The deeper molecular
response (MR4, MR4.5, and MR5) that is necessary to enroll a patient in a trial
aiming at treatment-free remission (TFR).
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IMMUNE MONITORING OF THERAPEUTIC EFFICACY IN CHRONIC
MYELOID LEUKEMIA
P. Rodrigues Santos1,2,* P. Couceiro2, J. Almeida2, A. Diniz1, V. Alves1,
L. Růžičková3, P. Freitas-Tavares3, M. Santos-Rosa1
1Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra,
2Lab Imunologia e Oncologia, Centro de Neurociências e Biologia Celular,
3Hematologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Background: Different effects on the immune system are reported at the diag-
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nosis and during therapy depending on Tyrosine Kinase Inhibitors (TKI) and
interferon-alpha protocols. Some of these are dose-dependent effects. At pres-
ent time, several clinical trials are establishing also the safety parameters for
cessation of therapy in a selected group of Chronic Myeloid Leukemia (CML)
patients. Although there is no consensus for laboratory evaluation of immune
response for clinical trials, the Human Immunophenotyping Consortium (HIPC)
aims at the standardization of protocols based on multicolor flow cytometry
(Maecker et al. Nat Rev Immunol 2012).
Aims: The current study aimed at the evaluation of the immune status in treated
CML patients to establish addtional efficacy parameters of different therapeutic
strategies.
Methods: We used an extended 10-parameter panel for the analysis of T cells
(Th1, Th2, Th17, Tregs), B cells (including plasmablasts), monocytes (classical
and non-classical), dendritic cells (myeloid and plasmacytoid) and NK cells
(CD56bright and CD56dim) in CML immune monitoring. Additionally, activation
and maturation profile, as well as memory status was investigated for T and B
cells. Intracellular cytokine staining, phosphorylation studies, response to mul-
tiple stimuli and gene expression profiling of relevant sorted cells was also per-
formed for evaluation of immune response in these patients. Deep analysis of
specific subsets (NK, NKT and γδ T cells) and pathways (CD137, PD-1, CD96,
CD226, TIGIT) were explored.
Results: Significant impact on NK cells, NKT and Th17 cells was observed in
CML patients undergoing therapy with TKI. Maturation and activation status of
different lymphocyte subsets was found affected by therapy. Optimal response
was found associated to immune response robustness of CML patients.
Summary and Conclusions: In conclusion, CML successful treatment is highly
influenced by the immune response and an immune-based monitoring could
be an important tool in the near future. 
Financial Support: FEDER (Programa Operacional Factores de Competitivi-
dade – COMPETE) and FCT (Fundação para a Ciência e a Tecnologia) through
project PEst-C/SAU/LA0001/2013-2014.
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EARLY BCR-ABL REDUCTION IS PREDICTIVE OF BETTER EVENT FREE
SURVIVAL IN CHRONIC MYELOID LEUKEMIA NEWLY DIAGNOSED
PATIENTS TREATED WITH ANY TKIS
C. Fava1,* G. Rege-Cambrin2, I. Dogliotti1, E. Gottardi1, P. Berchialla3,
B. Di Gioacchino2, F. Crasto1, R. Lorenzatti1, A. Volpengo1, F. Daraio1,
C. Fantino1, G. Saglio1
1Department of Clinical and Biological Sciences, University of Turin, 2Division
of Internal Medicine and Haematology, AOU San Luigi, Orbassano, 3Depart-
ment of Clinical and Biological Sciences, University of Turin, Turin, Italy
Background: Treatment of chronic myeloid leukemia (CML) aims at obtaining
optimal response, as defined by international recommendations. As more tiro-
sine kinase inhibitors (TKIs) are now available, much attention has been paid
to the identification of early prognostic markers during treatment. A strong pre-
dictive value has been observed for early molecular response, with BCR-ABL
ratio ≤10% at 3 months (mos), and BCR-ABL ratio ≤1% at 6 mos, being pre-
dictive for overall survival and event-free survival (EFS). Recently, the velocity
of early BCR-ABL transcript elimination, namely the halving time, has shown
to represent an additional prognostic index.
Aims: To evaluate the prognostic significance of the 3 mos time-point in our
population.
Methods: We retrospectively analyzed the population of CML-CP pts treated
in our Division, selecting pts who had a quantitative molecular evaluation at 3
mos. EFS was estimated with Kaplan-Meier method. Log-rank test was used
to identify significant differences between curves. ROC analysis was used to
calculate the optimal halving time thresholds for discriminating between out-
comes. ABL was used as control gene.
Table 1. Responses and events according to BCR-ABL transcripts at 3
months
Figure 1. Event free survival by BCR-ABL levels at 3 months.
Results: 50 CML-CP pts, with a median follow-up of 57,5 mos (31-110.5) were
analyzed. 36 pts (72%) were male, 14 (28%) female. Median age at diagnosis
was 59 years. 33 pts were treated frontline with imatinib, 10 with nilotinib, 4
with dasatinib and 3 were enrolled in the GIMEMA rotational protocol nilo/ima.
76% of patients had a transcript ≤10% at 3 mos. 37 pts had the 6 mos evaluation
and 39 pts had the 12 mos evaluation. 3/7 pts who had a transcript >10% at 3
mos had a transcript ≤1% at 6 mos (Table 1). None of the patients with a tran-
script >10% at 3 mos achieved an MR3 at 12 mos, compared to 50% in the
other group (P=0.007). 14/50 pts had an event, defined as lack or loss of optimal
response as per ELN recommendations, with a statistically significant difference
among groups (94.6% in the group with 3 mos BCR-ABL >10% vs 66.7% in
the group with BCR-ABL ≤10%, by 12 mos, P<0.001; 84.6% in the >10% group
vs 41.7% in the ≤10% group, by the median time of follow-up, P<0.001) (Figure
1). No progressions occurred. 12 pts had to change drug because of an event
(6 shifted to dasatinib, 6 to nilotinib), 3 for intolerance (1 shifted to dasatinib, 2
to nilotinib). Excluding these pts, in the group of pts >10% at 3 mos the proba-
bility of achieving a long-term MR4 was more than 60% lower compared to the
other group [HR 0.36 95% CI (0.10;1.27)]. The halving time thresholds for dis-
criminating between EFS was 25.5 days (specificity 84.8% and sensitivity of
83.3%; AUC 85.9%). None of the pts with a transcript >10% at 3 mos had a
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halving time<25.5 days. Among pts with a transcript ≤10%, those with a halving
time<25.5 days had an EFS of 93% vs 50% with a halving time >25.5 days (P
=0.012). Those with a halving time<25.5 days had a reduction of risk of event
of 92% (HR 0.08; 95% CI (0.02;035)). All pts were alive at the last follow-up.
Summary and Conclusions: Three different drugs, imatinib, dasatinib and
nilotinib. are commercially available for frontline treatment of newly diagnosed
CML. Clinicians are allowed to decide which of these therapies is most suitable
for each pt, based on comorbidities, Sokal risk and age of the pt. Irrespective
of the TKI used, the achievement of a BCR-ABL transcript ≤10% influences
the outcome of the pts. Interestingly, we confirmed the importance of halving
time in discriminating pts with the best outcome.
PB1742
GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC
IN THE MANAGEMENT OF CML
S. Aksu1, S.H. Aktimur2, D.Ç. Arica3, H. Atay2, O. Bektas4, Y. Buyukasik1,
H. Demiroglu1, E. Eliacik1, M. Esme5, H. Goker1, A. Hacihanefioglu6,
S. Karakus3, S. Kilickap7, E. Koca3, U.Y. Malkan1, O.I. Ozcebe1, N. Sayinalp1,
P. Tarkun6, M. Turgut2, I.C. Haznedaroglu1
1Hematology, Hacettepe University, Ankara, 2Hematology, Ondokuz Mayıs Uni-
versity, Samsun, 3Hematology, Başkent University, Ankara, 4Hematology,
Konya Research Hospital, Konya, 5Internal Medicine, Hacettepe University,
Ankara, 6Hematology, Kocaeli University, Kocaeli, 7Oncology, Hacettepe Uni-
versity, Ankara, Turkey
Background: Unsustainable drug prices in chronic myeloid leukemia (CML)
and cancer may be causing harm to patients. Advocating for lower drug prices
is a necessity to save the lives of patients who cannot afford them (Experts in
CML. Blood. 2013; 121(22):4439-4442). The patent date of imatinib mesylate
in USA has just expired in January 2015. Patent expiration dates for imatinib
may be different in different countries/regions. In Turkey, generic imatinib prepa-
rations are currently present. The only concern for generic imatinib is its efficacy
over the original drug, Glivec or Gleevec. 
Aims: The aim of this multi-center study is to assess the efficacy of generic
imatinib over Glivec in terms of hematological, cytogenetic, and molecular
responses in CML. 
Methods: This work is designed as multicenter and retrospective study
Figure 1. The ratio of drugs that were preferred by the clinicians for each
evaluation.
Results: In this study, the retrospective data of 120 Turkish CML patients
receiving imatinib from six different CML centers across Turkey were analyzed
(68 females, 56.7%; 52 males, 43.3%). The mean age was 53 years (21-81).
The most frequent ECOG performance status was “0” (65%). The distribution
of genders between centers was similar. At the study onset, 86.7% of the
patients (n=104) were using original molecules, and 13.3% of the patients
(n=16) were using generic molecules. Original (86.7%), 16 generic imatinib
mesylate. The patients were evaluated at 4 different time points for change of
medication and efficacy. The mean period between each evaluation was 9
months. Initial evaluation showed that a patient who was using only original
molecule, switched to second generation tyrosine kinase inhibitor (TKI) treat-
ment. In this period, hematological response (HR) was observed in 99.2% of
the patients, cytogenetic response (CR) was observed in 88.7% of the patients
(47 of 53), and molecular response (MR) was observed in 75% of the patients.
For each evaluation, the ratio of drugs that were preferred by the clinicians is
shown in Figure 1. According to Figure 1, clinicians had a tendency to prefer
generic molecules in each sequent visit, and this change rate was significant
(P<0.001). The rate of using generic molecules was 13.3% in the initial evalu-
ation, 20.8% in the second visit, 41.7% in the third visit, and 43.3% in the fourth
visit. The rates of switching from original molecule to generic molecule, from
original molecule to second generation TKI, and from generic molecule to sec-
ond generation TKI are shown in Table 1. Accordingly, 11 patients, who were
using original molecules during all cohort, switched to second generation TKI.
On the other hand, only 1 patient, who was using generic molecules, switched
to second generation TKI. Response to treatment is shown in Figure 2.
Figure 2. The ratio of CML treatment of the four evaluation points.
Table 1. The rates of switching from original molecule to generic mole-
cule, from original molecule to second generation TKI, and from generic
molecule to second generation TKI.
Summary and Conclusions: Therefore, we did not find any significant differ-
ence in HR, CR, and MR for original and generic drugs in each visit. Based on
this data, generic imatinib mesylate is as effective as original Glivec in the
management of CML.
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IMPACT OF TYROSINE KINASE INHIBITORS (TKIS) ON THE FERTILITY
OF CHRONIC MYELOID LEUKEMIA PATIENTS (CML) IN A SINGLE
CENTER IN ALGERIA
B. Yamina1,* T. Souad1, A. Mohand Tayeb1
1Hematology, EHS ELCC CAC Faculty of Medicine, University Blida 1, Blida,
Algeria
Background: TKIs have dramatically modified the outcome of CML patients
giving opportunity to 10% of patients that are in age to procreate to have a
parental project.TKIs stopping leads to the relapse. We count the event of
pregnancy and its evolution among patients with CML at Chronic Phase treated
with TKIs in the two sexes at Blida in Algeria. 
Aims: To evaluate in the two sexes fertility of patients treated by tyrosine kinase
inhibitors.
Methods: Of 231 CML patients treated by TKIs, 29 pregnancies were noted
among 19 women; we analyze the time of exposure to the TKIs before and at
the time of the pregnancy and the hematologic, cytogenetic and molecular sta-
tus before and after the pregnancy.
Results: Pregnancy of the spouse: - Husbands treated by Imatinib (IM): 10
cases, median age=34 years; IM (400mg/d); median time of exposure
(MTE)=23 months; No interruption of IM before the conception; 3 early abor-
tions; 12 pregnancies carried out in the term; 12 alive new-born without mal-
formation. - Husbands treated by Dasatinib: 2 Cases (100mg/d; MTE before
the conception (BTC)=12 months, not treatment stopping before the design;
02 pregnancies carried out in the term; 2 alive new-born, no malformations.
- Husbands treated by Nilotinib: 1 case (800 mg/d), MTE BTC=12 months, no
stop of TKI before the conception; 1 pregnancy carried out in the term; 1 new-
born living any malformation. Pregnancies not planned in 0 3 women treated
by Imatinib: median age=31 years; median time of impregnation BTC : 19
months (4, 24, 39); Cytogenetic profile: CCyR=2 patients, MMR: 1 pt; no treat-
ment stopping before the conception; exposure time to the IM of 6, 8 and 12
weeks; Evolution of the pregnancy without incidents; childbirth at 35 weeks=2
pts, 1 Caesarian (after acceleration phase); 03 alive new-born of weight (2400-
3500 gr) without malformations; Evolution of the CML: loss of the hematologic
remission at 20 weeks=3 patients of which one acceleration, relayed by inter-
feron; No breast feeding; resumption of IM=3 pts, one blast phase (AML5)
treated by Nilotinib, which died after 12 months; 2 pts with HR and CCyR after
12 months of recovery. Pregnancies planned in 5 women treated by Imatinib:
4 (G0P0), 01 (G2P1); median age=29 years; sokal high=2 pts: Intermediary=3
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pts; MTE BTC=48 months (30-60) with IM 400 mg/d; cytogenetic profile=5
CCyR, 2 MMR 4.5 and 2 MMR 4; stop of IM BTC =5 pts, from 01 to 05 months;
2 early abortions 1 month from stopping; 5 pregnancies 3 to 5 months after
stopping IM; Evolution of the pregnancy: without incidents, of which one treated
by interferon; Childbirth: in the term = 4 pts; 5 alive new-born (twin) without
malformations; 1 in progress; breast feeding: 3 pts (1 month); Evolution of
CML=CHR maintained at 37 weeks=4 patients, a loss of the CHR; resumption
of IM=4 Pts, MMR in one pt after 12 months of recovery OS=75 months; 3 still
of evaluation, OS=61 months (46-83). Pregnancy in woman treated by Dasa-
tinib: 30 years, sokal: Intermediary; G0P0; MTE BTC: 18 months, Cytogenetics:
CCyR; no treatment stopping before the conception; pregnancy not planned;
exposure time: 4 weeks; lost of follow up until the childbirth, new-born alive
without malformations, Evolution of the CML: loss of HR; Resumption of Dasa-
tinib, HR after 2 months, CCyR after 3 months, OS=65 months
Summary and Conclusions: Infertility is not an side effect of the TKIs; the
major molecular response made it possible to carry out a pregnancy without
relay, a non-response requires a relay and exposes to the risks
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SECOND REPORT OF ARAB LEUKEMIA NET (ALN) REGISTRY FOR CML
IN THE MIDDLE EAST &NORTH AFRICA REGION(AFME).PART II RESULTS
OF ADDITIONAL CHROMOSOMAL ABNORMALITIES(ACAS) IN EGYPT, A
MULTICENTER RESULTS. 
M.O. Azzazi1,* M. Mattar2, A. El Ghandour3, M. El Sorady3, S. Shehata4,
A. El Nahass5, H. Hegab1, R. Ibrahim 1, NN. Mostafa1, H. Ellithy2, M. Shazly1
1Hematology and BMT., Ain Shams University, 2Hematology and BMT., Cairo
university, Cairo, 3hematology and BMT., Alexandria university, Alexandria,
4Oncology and Haematology,, University of Assiut, Assiut, 5Clinical Pathology.,
cairo university, Cairo, Egypt
Background: The first ALN report1 demonstrated that age-specific rates for
CML in Egypt and Arab nations are lower by at least two decades compared to
western populations1. Geographic and ethnic variations contribute to the vari-
ability of incidences among CML registries2. ACAs were reported in 5% of CML
patients in chronic phase (CP). At diagnosis considered by ELN as a “warning”
requiring careful patient monitoring, while ACAs emerging during treatment are
considered by WHO classification as accelerated phase (AP) CML.ACAs influ-
ence response to Imatinib and outcome of TKI therapy. The occurrence of ACAs
and additional mutations besides Ph chromosome(Ch) indicates that the
leukemia has become at least partially BCR-ABL independent by secondary
genetic acquisitions 2.Although the underlying mechanisms of resistance /dis-
ease progression are not fully understood for all ACAs, some are well identified
as poor prognostic factors. such as the acquisition of additional Ph chromosome
which might confer resistance via increasing the kinase activity of BCR-ABL3,
the isochromosome 17q i(17q) which leads to inactivation of the tumor sup-
pressor gene p53 and impedes the response to Imatinib via allowing the dam-
aged cells to escape the DNA repair machinery of p53 and thus escape cell
growth arrest or apoptosis, the extra 8 which is known to lead to c-Myc over
expression that enhances the transformation of BCR-ABL positive cells or
allows rapid growth of leukemic cells, and the extra 19 which might hinder Ima-
tinib activity via hypermethylation / inactivation of neoplastic transformation
silencing gene promoters such as ATG16L2 gene promoter4. 
Aims: 1) To Release data of second ALN report concerning epidemiology of
CML in Egypt, after enrolling 6 new centres,228 patients and adding ACAs to
evaluate disease and clonal evolution. 2) Investigate the low mean age of CML
in Egypt and the role of ACAs.
Methods: We analyzed data of 578 CML Egyptian patients (302 male and 276
female) followed-up for 5 years. Data were collected from 10 centers according
to ELN2 and EUTOS recommendations2-3 by using a multicenter web based
data registery portal, the ALN. (www.aln-afme.com). Chromosome banding
analysis and FISH were performed according to the International System for
Human Cytogenetic Nomenclature. we tested for ACAs defined as “major route”
namely trisomy 8, duplication of Ph chromosome, i(17q), and trisomy 19.21.FISH
was performed on at least 200 cells on bone marrow cells prepared according
to cytogenetic techniques and by using DNA probes that hybridize at the BCR
and ABL regions. RT-PCR, and real-time quantitative PCR were performed.
Results: Patients Median age was 43y, (40y for males, 41y for females), The
age specific rates were highest for the age group of 30-35 years. Female
patients presented with lower hemoglobin, higher platelet counts and smaller
spleen size (P<0.0001). 98%of patients achieved CH respone,89% CYR,87%
CYR,and 83% MMR. At diagnosis 87% patients were in CP-CML, 8.1% in AP
and 4.9% in blastic phase. Sokal score: Low risk 57.8% Intermediate24.5%
and High in 17.7%. EURO (Hasford) score (59% Low risk, 28.4% Intermediate
risk and12.6% High risk). 42% of patients received first generation TKI, 54%
second generation TKI, and 4% needed therapies plus TKI). Transplantation
rate was 19%, PFS and OS were equal in female and male patients. ACAs
were found in 62(11%) patients, they had lower cytogenetic and molecular
response rates and longer response time to TKI and inferior outcome. ACAs
were more frequent in younger, Imatinib resistant patients, and in blast phase.
We identified loss of Y Ch in 18 patients (29%), trisomy 8 in 7 (11%), trisomy
19 in 12 (19%), i (17q) in 12(19%), other different single abnormalities in 8
patients (13%), complex karyotype with double ACAs in only 5 patient (8%).Four
patient showed variant Ph Ch: t(9;22;22)(q34;q11;q11). Deletion of der(9) Ch
in 17 cases (27%): (10 cases with loss of Y Ch, case with del(20)(q11q13), and
3 case with t(X;13)(q13;q32)). The cytogenetic and molecular response rates
were uniformly lower in patients with ACAs, CCgR and MMR rates were signif-
icantly lower in patients with ACAs (68% vs 89% and 55% vs 86% respectively),
responses were significantly slower in patients with ACAs, 54 patients presented
with ACAs at diagnosis while 8 patients developed or acquired ACAs while on
treatment.
Figure 1.
Summary and Conclusions: The importance of ethnicity and gender differ-
ences in relation to disease incidence, and prognosis are major health policy
focus2.To investigate the low mean age of CML in Egypt and evaluate role of
ACAs on disease and clonal evolution, we analyzed CML data of 10 Medical
Centers in Egypt. We identified 62(11%) cases with clonal ACAs. ACAs are
more frequent in younger patients and adversely affected time and response
rates to Imatinib treatment they were related to lower cytogenetic and molecular
response rates and longer response time toTKI and inferior outcome and lower
overall survival.
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Background: Thrombocytosis is a common feature in chronic myeloprolifera-
tive disorders. The incidence of thrombocytosis in CML is reported to be around
30 to 50%. Extreme thrombocytosis defined as a platelet (PLT) count >1.000x
109/l is uncommon in CML as well as isolated thrombocytosis.
Aims: Our aim is to study the clinical management and the therapeutic
response of CML with extreme thrombocytosis.
Methods: From January 2001 to January 2015, 1314 patients affected by CML
were followed in 15 different Italian hematological centers. We diagnosed 78
CML with extreme thrombocytosis at onset (5.9%); we conducted the study on
70 pts who have at least 6 months of follow-up and were in chronic phase; 2
pts in blast phase and in accelerated phase were excluded from the analysis.
Results: Our patients were 48 females and 22 males with a median age of 59
years (range 18-84). At diagnosis, median hemoglobin level was 11.6 g/dl,
median WBC 32.7x 109/l and PLT count 1.466x 109/l. The Sokal score was
high in 44 (62.9%), intermediate in 21 (30%) and low in 5 (7.1%). According to
Hasford score 47.5% pts resulted high, 30.5% intermediate, 22% high; Eutos
score available in 48/70 pts was high in 13 (27.1%) and low in 35 (72.9%). Pts’
characteristics are summarized in Figure 1. PCR analysis showed the presence
of p210 in all cases and the absence of JAK2 V617F mutation in 28 out of 30
pts (42.9% of all the pts) who performed the test. At diagnosis we registered 5
thrombotic/hemorrhagic episodes: 1 superficial thrombosis, 1 subarachnoid
hemorrhage, 1 metrorrhagia, 1 epistaxis and 1 purpura. None of the two JAK2
positive patients showed thrombotic/hemorrhagic episodes. All but six pts
received initial treatment with hydroxyurea and allopurinol. One patient under-
went PLT apheresis. PLT count was generally unresponsive to initial treatment.
Upfront treatment was imatinib in 53 pts, nilotinib in 11 pts and dasatinib in 6
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pts. PLT count normalization was rapidly achieved after introduction of TKIs.
Hematological response was reached at a median of 1 month, complete cyto-
genetic response after a median of 3 months (range 3-36) in 62/65 evaluable
pts, and major molecular response in 53 out of 64 evaluable pts after a median
of 9 months (range 3-101). Of the 53 pts who started imatinib 7 pts shifted to
nilotinib for resistance (3 primary and 4 secondary), 3 to dasatinib for primary
resistance, 1 to ponatinib for primary resistance and 2 pts are not on TKI at
this time for intolerance. Four of these pts dead for causes independent from
CML (1 pt for myocardial infarction, 1 pt for GVHD post-transplantation and 2
pts for second tumor at 3, 9, 38 and 147 months respectively) and 3 pts were
lost during follow-up. Three patients of the 11 who started nilotinib stopped
treatment with TKIs for resistance or intolerance, 1 shifted to dasatinib for sec-
ondary resistance. Sixty-three patients (90%) are alive, 58 of them on TKIs (33
imatinib, 14 nilotinib, 10 dasatinib, 1 ponatinib) at a median follow up of 65
months (range 7-168).
Table 1. Characteristics of patients and laboratory findings.
Summary and Conclusions: The prevalence of extreme thrombocytosis in
CML is 5.9% in a large multicenter observational study. Cytoreduction with
hydroxyurea was not able to achieve normalization of PLT count, however pts
with extreme thrombocytosis were easily and rapidly managed by TKIs. CML
pts with extreme thrombocytosis resulted similar to the CML population con-
sidering the response to TKIs and low number of thrombotic/hemorrhagic com-
plications. Patients on at least major molecular response are 48 out of 55 evalu-
able (87.3%) at a median follow-up of 65 months.
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Background: Ponatinib is a potent, multitargeted tyrosine kinase inhibitor with
proven efficacy in resistant Philadelphia chromosome–positive (Ph+) leukemia.
Aims: This analysis reports elevated BP and adverse events of HTN in phase
1, 2, and 3 trials of ponatinib in patients with leukemia.
Methods: Ponatinib safety and efficacy were evaluated in patients with
relapsed/refractory hematologic malignancies in the ongoing phase 1 trial, in
heavily pretreated chronic myeloid leukemia (CML)/Ph+ acute lymphoblastic
leukemia (ALL) patients in the ongoing PACE (phase 2) trial, and in newly diag-
nosed chronic-phase CML patients in the terminated EPIC (phase 3) trial of pona-
tinib vs imatinib. All patients gave informed consent. Phase 1 and EPIC, but not
PACE, excluded patients with uncontrolled HTN (defined as untreated
systolic/diastolic >150/>100 mm Hg in phase 1 and >140/>90 mm Hg in EPIC).
Elevated BP was defined by the single highest BP measurement (systolic/dias-
tolic): grade (G) 1/pre-HTN 120–139/80–89 mm Hg, G2 140–159/90–99 mm Hg,
G3 ≥160/≥100 mm Hg. HTN adverse events were reported by investigators.
Results: Elevated BP was frequent at trial entry (Table 1). G1/G2–3 rates were
44%/42% in phase 1, 37%/47% in PACE, and 51%/19% with ponatinib vs
52%/12% with imatinib in EPIC. Any increase in BP grade from baseline was
also frequent, with rates of 74% in phase 1, 68% in PACE, and 68% with pona-
tinib vs 51% with imatinib in EPIC. In PACE, estimated systolic/diastolic BP
increases over time were low, at 2.3/0.7 mm Hg per year. HTN adverse events
were reported in 38%, 28%, 18%, and 2% of patients in phase 1, PACE, and
the EPIC ponatinib and EPIC imatinib arms, respectively. Hypertensive crisis
was reported in 2 patients in PACE and in 2 patients in the EPIC ponatinib
arm. HTN adverse events did not lead to discontinuation or death. Few patients
had dose modifications for HTN adverse events (0% in phase 1, 5% in PACE,
and 3% with ponatinib vs 0% with imatinib in EPIC). A retrospective multivariate
analysis of pooled patients showed that HTN adverse events were significantly
associated with ponatinib dose intensity.
Table 1. Baseline BP and Any Increase in BP Gradea on Study.
aBased on single highest BP measurement; b<120/<80 mm Hg. Baseline BP
was missing for 1 patient in the EPIC imatinib arm.
Summary and Conclusions: Increase in BP was frequently observed in pona-
tinib trials, including in patients on imatinib. Rates of HTN adverse events were
relatively lower and seen primarily with ponatinib. While associated with pona-
tinib dose intensity, HTN adverse events rarely led to change in leukemia ther-
apy. Given BP variability, investigator reporting of HTN adverse events may be
a more reliable indicator of clinically meaningful HTN.
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Background: Imatinib therapy has drastically changed the prognosis for
patients with chronic myeloid leukemia (CML). Confirmed deep molecular
response predicted significantly higher survival probabilities and no patient
with confirmed deeper molecular response (i.e. MR4.5) has experienced pro-
gression (Hehlmann R et al. J Clin Oncol. 2014). However, even after 8 years
of imatinib administration, the cumulative incidence of ≥2 years of undetectable
BCR-ABL1 (Stable MR4.5) was 36.5% (Branford S et al. Blood. 2013). On the
other hand, second generation tyrosine kinase inhibitor, nilotinib has been
shown to be a more potent inhibitor of BCR-ABL than imatinib (Saglio G et al.
N Engl J. 2010). Another study shows that patients with CML-CP with persistent
minimal residual disease (MRD) on imatinib who switched to nilotinib experi-
enced deeper confirmed molecular responses compared with those who
remained on imatinib, and these responses were stable (Hughes P, et al. Blood
2014). Dasatinib, another second generation tyrosine kinase inhibitor also
induces fast and deep cytogenetic and molecular responses that translate to
better outcomes (Jabbour E et al. Blood 2014). However, it is not clear that
dasatinib has a potential for achieving further molecular response after switch-
ing. Here, we conducted a multicenter, prospective ‘CMR-CML’ study and
observed molecular response of CML-CP patients treated with dasatinib.
Aims: The primary endpoint of our study was complete molecular response
(CMR) rate by 18 months after switching to dasatinib.
Methods: For the assessment of molecular response, a quantification of BCR-
ABL transcripts by RQ-PCR analysis was applied. The analysis of BCR-ABL
transcripts were performed at registration, 1, 3, 6, 9, 12, 15, and 18 months
after switching to dasatinib. Measurement of BCR-ABL transcripts was per-
formed as described previously (Yoshida C et.al. Int J Clin Oncol.2013). Unde-
tectable level of BCR-ABL transcript (<50 copies/µgRNA), which is equivalent
to 4.16-log reduction, was defined to be CMR in this study. Comparisons
between the qualitative variables were carried out using the χ2 test. These sta-
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tistical analyses were performed with the software package Stata version 11
(Stata Corp LP, College Station, TX, USA). For all analyses, the P values were
2-tailed, and a P value less than 0.05 was considered to be significant.
Figure 1.
Results: From August 6, 2011 to January 17, 2013, a total of 21 patients with
CML-CP with persistent MRD after at least 2 years of imatinib therapy assigned
in our study. Five patients were excluded because of several reasons. Finally,
16 patients were registered in this trial. The median age at registration was 50
years (range, 25-70 years), and 11 were men and 5 were women. All patients
received a dosage of 100mg/day dasatinib once daily. All patients achieved
CMR within 18 month. There were 4, 5, 1 patients obtained CMR by 1, 3, and
6 months respectively in 16 evaluable patients (Figure). Ten patients kept
CMR at 16 month and 6 patients lost CMR (2 patients widowed this trial, 3
patients was suffered from recurrence). We investigated the possible associ-
ations between the achievement of early CMR and a number of baseline vari-
ables, including age, sex, lymphocyte count, International Scale (IS), and dura-
tion of imatinib therapy. There was higher cumulative incidence of CMR at 1
month when patients with a low IS at registration were compared with those
with a high IS (0.013 vs 0.034 P=0.0201). Duration of imatinib therapy was
significantly longer in patients who obtained CMR in 1 month (106±21 months
vs 55±10 months P=0.0322). There was no difference in the frequency of
female sex, age, lymphocyte count. Dasatinib therapy was well tolerable and
toxicities were almost low grade. Non-hematological toxicities were liver dys-
function (grade 1 or 2, 43%), pleural effusion (grade 1 or 2, 37%), dyspnea
(grade 1, 12%; grade 3, 6%), and gastrointestinal bleeding (grade 1, 12%).
Hematological toxicities were anemia (grade 1or 2, 75%; grade 3, 12%), neu-
tropenia (grade 1 or 2, 43%; grade 3, 6%), and thrombocytopenia (grade 1 or
2, 37%; grade 3, 12%).
Summary and Conclusions: This pilot study shows dasatinib has the ability
to obtain further deep molecular response for the patients who do not achieve
stable undetectable BCR-ABL1 after long-term imatinib therapy. Based on this
study, randomized control study should be attempted in the future.
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Background: Tyrosin kinase inhibitors (TKI) treatment in CML has is standard
of care, however, its treatment goals have become more stringent are directed
by response kinetics. Since standardized BCR-ABL transcript monitoring has
been established the ELN recommendations guide treatment according to the
achieved molecular response. Clinical trials have demonstrated the predictive
value of early molecular response with respect to consecutively achieved deep
responses which in turn would allow for about half of the patient to remain in
treatment free remission. In addition, the duration of sustained deep molecular
response has recently been shown to be associated with a lower relapse rate
after treatment discontinuation. Although second generation TKIs (2G-TKIs)
are of superior efficacy in inducing deep molecular response the majority of
patients in routine care are still receiving imatinib.
Aims:Assessing the current status of treatment and response thereto is a pre-
requisite to ascertain a high quality of disease management and to guide physi-
cians to future treatment options for their patients. This registry aims to reflect
the real life situation of CML treatment in Austria.
Methods: The Austrian CML registry is a database project under the patronage
of the ASHO approved by an ethics committee. It is focused on diagnostic
parameters, e.g., conventional cytogenetics and/or FISH, BCR-ABL transcript
levels, blood counts, general laboratory parameters, CML phase, concomitant
diseases, CML specific treatment and including stem cell transplantation and
adverse effects. Participating centres can contribute patient data after having
obtained written informed consent.
Results: We summarize the CML registry data as of March 2015 and focus on
treatment response. The CML registry cohort comprised a total of 434 patients
with a median number of 4581 follow-up visits. At diagnosis 87.9%, 8.3% and
0.7% of evaluable patients were in early, late and secondary phase, respec-
tively, whereas only 2.1%, 0.7% and 0.2% were in accelerated phase, myeloid
and lymphatic blast crisis, respectively. First line treatment was imatinib, nilotinib
or dasatinib in 301, 21 and 8 evaluable cases, respectively. The majority of
patients had an optimal response according to ELN criteria at the last evaluable
follow up (Figure1). We will present the results of the currently running final
update on the registry cohort.
Figure 1.
Summary and Conclusions: The majority of patients fulfils the ELN 2013 cri-
teria for optimal response. For years imatinib has been for years the mainstay
of treatment and continues to be so. However, the use of 2G-TKIs has
increased. The main focus of this registry for 2015 will be the percentage of
patients reaching a sustained deep molecular response.
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Background:According to NCCN and ELN Guidelines, the monitoring of BCR-
ABL1 transcript levels is central to care of Chronic Myeloid Leukemia (CML)
patients. Previous studies have shown that, in the US, a high proportion of
CML patients do not receive the recommend frequency of BCR-ABL testing.
Efforts have been made to standardize technical aspects of monitoring, but a
large degree of variation remains in many other aspects of the BCR-ABL testing
process, for example test requisition and result reporting. Therefore physicians
are required to collect, assimilate and interpret a large amount of, often tech-
nical, information associated monitoring CML patients. 
Aims: The aim of this study was to quantify the variation in the BCR-ABL testing
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pathway, from test availability through to result reporting. An additional objective
was to use a national database to analysis testing rates for CML patients. 
Methods: Insurance claims data and independent information from clinical
laboratories were used to map and evaluate the current US BCR-ABL1 testing
landscape. This study included analysis of test availability (including geographic
reach), test request forms, turn around times (TAT), cost (as billed by the lab-
oratory), methodology, sample reports and number of tests performed and
billed.
Results: Between June 2013 and May 2014, BCR-ABL1 testing was offered
by 209 US clinical laboratories, of which, 137 laboratories conducted the testing
in-house. The remaining 72 laboratories sent this testing to 26 laboratories, 22
of which were used by only a single referring laboratory. Geographic spread of
the laboratories was not uniform, e.g. 16 laboratories in California whereas
only one laboratory in each of 9 other states. 21% of laboratories stated they
report on the International Scale (IS), with 77% not providing this critical infor-
mation. Only 30% (6/20) of test request forms specified transcript types for
which testing is available. TAT and cost varied from 2-14 working days and
$187-$497 respectively. Only 22% (4/18) of laboratory reports included full test
methodology details, graphical representation of historical results and clear
interpretative comments in line with current NCCN guidelines. The testing fre-
quency of CML patients was found to be<1 test per annum, much lower than
current guidelines recommend. 
Summary and Conclusions: Availability of quantitative BCR-ABL1 testing
appears to be adequate in the US, however, our data show that in those states
with fewer laboratories offering BCR-ABL quantitation, a physician is less likely
to have access to a laboratory offering testing on the International Scale. The
heterogeneous landscape for BCR-ABL1 testing is likely contributing to insuf-
ficiently-informed testing choices, testing frequency and, ultimately, treatment
choices. The inadequate and inconsistent information available for physicians
poses a barrier to supporting them in choice of testing laboratory and in deter-
mining actionable outcomes from patient test results. A more uniform and inte-
grated approach is needed to better support physicians and to ensure optimal
patient care.
PB1750
CORRELATION OF DASATINIB PHARMACOKINETICS WITH CLINICAL
RESPONSE AND ADVERSE EVENTS IN NEWLY DIAGNOSED CHRONIC
MYELOID LEUKEMIA CHRONIC PHASE
A. Mita1,* M. Miura2, T. Niioka2, M. Abumiya2, T. Kobayasi1, S. Takahshi1,
Y. Kameoka1, T. Yoshioka1, N. Takahashi1
1Department of Hematology, Nephrology, and Rheumatology, Akita university
graduate school of medicine, 2Pharmacy, Akita university hospital, Akita, Japan
Background: The second-generation tyrosine kinase inhibitor (TKI) dasatinib
is used as the first-line therapy for newly diagnosed chronic myeloid leukemia
(CML). However, some patients fail to respond or become intolerant to dasa-
tinib. Several studies have shown a relationship between pharmacokinetics of
dasatinib and molecular responses or significant adverse events.
Aims: To investigate pharmacokinetics of dasatinib and to identify an influence
of transporter gene polymorphisms on dasatinib treatment in newly diagnosed
CML patients.
Methods: Fourteen patients treated with dasatinib from whom were obtained
a total of 118 pharmacokinetic profiles were enrolled in this study. Dasatinib
plasma concentrations from samples obtained just prior to and 1, 2, and 4 h
after oral dasatinib administration were analyzed by liquid chromatography-
tandem mass spectrometry. Genotyping of 10 single nucleotide polymorphisms
(SNPs) in genes involved in dasatinib pharmacokinetics (ABCG2, ABCB1,
CYP3A5*3, SLC22A1, ABCC2) was performed by PCR-RFLP. The study pro-
tocol was approved by the Ethics Committee of Akita University Hospital, and
all recipients gave written informed consent.
Figure 1.
Results: In this study, associations between dasatinib concentration, clinical
response, adverse event, and 10 SNPs were investigated among newly diag-
nosed chronic phase CML patients. Seven patients achieved major molecular
response (MMR) at 3 month and the other 7 patients did not. The plasma con-
centration at 2 h (C2h) or the maximum plasma concentration (Cmax) of dasa-
tinib was significantly higher among patients with a MMR at 3 month than those
without (P=0.051, P=0.035, Figure 1). Among 118 pharmacokinetics profiles,
there were 8 adverse events of pleural effusion in 4 patients. Although there
was not a significant difference in plasma trough concentration of dasatinib
(C0h) between groups with pleural effusion and without (P=0.350), it was
observed in patients with more than 1.4 ng/mL of C0h which could be translated
into 2.8 nM (Figure 2). 5 patients have ABCG2 421C/C and 9 patients have
ABCG2 421C/A. There were significant differences of plasma concentration at
2 h (C2h) after dasatinib administration between two groups (P=0.019). How-
ever, the other SNPs were not associated with dasatinib pharmacokinetics in
this study.
Summary and Conclusions: Higher dasatinib C2h/max was associated with
the likelihood of achieving a MMR at 3 month in our small CML patient cohort.
Additionally, pleural effusion was not observed in patients with lower dasatinib
trough concentration. Although a prospective study with a larger patient popu-
lation is necessary to validate these findings, in addition to BCR-ABL1mutation
analysis, our data indicate that clinical dasatinib blood-level testing may improve
the efficacy and the safety of dasatinib therapy among newly diagnosed CML
patients.
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«FLAG» REGIMEN IS EFFECTIVE FOR CHRONIC PHASE INDUCTION FOR
CHRONIC MYELOID LEUKEMIA BLAST CRISIS.
E. Romanova1,* L. Girshova1, E. Goryunova1, N. Siordia1, V. Ivanov1,
D. Motorin1, E. Lomaia1, A. Zaritskey1
1Hematology department, Federal North – West Medical Research Centre, St-
Petersburg, Russian Federation
Background: Only hematopoetic stem cell transplantation (HSCT) should be
curative in chronic myeloid leukemia blast crisis (CML BC). It seems that few
patients obtain stable second chronic phase (CP) on monotherapy with tyrosin
kinase inhibitors (TKI)and then might be switched to HSCT. We suggest that more
patients may benefit with high doses of cytostatics in combination with TKIs. 
Aims: To evaluate whether high doses of cytostatics in combination with TKIs
may allow to obtain more stable response and switch more patients to HSCT.
Methods: We studied the results of different therapeutic approaches for CML
BC in 19 patients (9 females and 10 males) with median age 43 years at the
moment of the BC onset (range 21-63). CML was initiated in BC in 4 pts, where-
as other pts develop BC on TKIs therapy. Median time from CML diagnosis
was 44,5 mo (range from 1,7 to 139 mo). Type of BC was myeloid in 9, lymphoid
in 7 and nondifferenciated in 3 pts. Pts were treated with FLAG based regi-
men+TKI (n=8), low dose chemo+TKIs or mono TKI (n=11). All pts obtained
monoTKIs before FLAG regimen. The therapy was intensified due to lack or
loose of second CP. 8 pts had SCT. Type of SCT was 4 unrelated alloSCT, 2
related alloSCT, 2 haploidentical SCT. 5 pts after FLAG and 3 pts after low
dose chemo or monoTKIs undergo SCT.
Results: Second CP was obtained in 7/ 8(87.5%) patients after FLAG and
only in 3/11 (27%) pts after low dose chemotherapy induction (P=0,02). More-
over 3 and 2 pts after FLAG induction have CCyR and MMR, accordingly. No
pts on other therapies reach CCyR. 3 patients were undergone HSCT after 1
of FLAG course. Other patients received one or more FLAG consolidation.
Consolidation did not lead to stable CP. All patients had rapid increase of blast
count. There are no differences in duration of response in patients with low
and high dose cytostatic therapy. The median time to HSCT from BC onset
was 12 mo (range from 5,6 to 94 mo). The probability of survival is higher for
transplanted patients vs not transplanted patients (25% vs 15%, p 0,014). 50%
patients are alive after HSCT with median overall survival time after HSCT
14,5 mo (range from 4,4 to 38 mo). Median time to HSCT in alive and dead pts
was 6,6 and 12,8 mo accordingly. There were no differences in overall survival
after HSCT between treatment groups.
Summary and Conclusions: HSCT should be the goal of treatment strategy
in BC CML. FLAG regimen in combination with TKIs is effective for CP induction
and allow us to switch more pts to HSCT in compare with less aggressive
strategies. Intensive chemo+TKIs may be able pts to reach CCyR or even
MMR, but the responses are unstable and whether pts should obtained several
courses of chemo for response deepening is questionable. It seems that pts
should undergo HSCT as soon as possible after CP induction.
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FLOW CYTOMETRY-BASED ASSAY FOR DETECTION OF BCR-ABL
FUSION PROTEIN IN BLOOD CELLS FROM CML PATIENTS
L. Löf1,* U. Strömberg2, U. Landegren3, M. Kamali-Moghaddam3
1Uppsala University, 2University Hospital, 3Departement of Immunolgy, Genet-
ics and Pathology, Uppsala University, Uppsala, Sweden
Background: Chronic myeloid leukemia (CML) is currently diagnosed using
RT-PCR and/or FISH to reveal the presence of the fusion mRNA transcripts
for BCR-ABL, or of the characteristic Philadelphia chromosome. RT-PCR is
also used to monitor the effects of treatment by sensitively measuring tran-
scripts representing minimal residual disease (MRD). It has not been possibly
to use flow cytometry to identify the neoplastic cells but such a method would
be helpful in the workflow of a hematopathology lab.
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Aims: We have now developed a method that successfully detects and enu-
merates cells harboring the fusion protein BCR-ABL by flow cytometry in CML
patients. 
Methods: The method uses the in situ proximity ligation assay (PLA) (Söder-
berg et al 2006, Leuchowius et al 2009), where two antibodies target the BCR
and the ABL part, respectively, of the fusion protein. The antibodies are
equipped with DNA oligonucleotides that – when brought in proximity – guide
the formation of a circular DNA molecule as a template for localized DNA ampli-
fication through rolling circle amplification (RCA). Each RCA-product is then
labeled with around 1,500 fluorophore-coupled DNA oligonucleotides, allowing
cells to be detected by flow cytometry.
Results: The method has proven very sensitive, able to detect very low number
of cells in patient samples, and it allows identification of patients in relapse at
a very early state. We have analyzed 25 CML patient samples using PLA-based
flow cytometry, and the results were compared to the routine RT-PCR analysis.
More than 50% of the analyzed samples were positive for both methods, rang-
ing from 75 IS% down to 0.03 IS% for the RT-PCR. Five of the samples were
positive only in RT-PCR, while three were positive only in the PLA method. 
Summary and Conclusions: Since the method is developed for readout with
flow cytometry all the advantages with multicolor fluorescence analysis can be
achieved simultaneously. In addation, the method allows for standard cytolog-




LOW HEMOGLOBIN LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH
WORSE TREATMENT RESPONSES AND EVENT FREE SURVIVAL IN
CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE RECEIV-
ING TYROSINE KINASE INHIBITORS
P.S. Ko1,* Y.B. Yu1, M.H. Hung1, J.P. Gau1, C.J. Liu1, L.T. Hsiao1, M.H. Chen1,
J.H. Liu2, T.J. Chiou3, C.Y. Liu1, C.H. Tzeng1
1Division of Hematology and Oncology, Department of Medicine, 2Division of
Oncology, Department of Medicine, 3Division of Transfusion Medicine, Depart-
ment of Medicine, Taipei Veteran General Hospital, Taipei City, Taiwan, ROC
Background: SPECIAL;Despite progress in prognosis of patients with chronic
myeloid leukemia in the era of tyrosine kinase inhibitors (TKI), values of current
available three prognostic scoring systems, namely Sokal, Hasford and EUTOS
scores, for predicting survival outcomes and treatment response remained
inconclusive. Current Sokal and Hasford score developed in pre-TKI era and
they both included many baseline clinical variables but without baseline hemo-
globin levels, a seldomly discussed variable. The value of baseline hemoglobin
levels for predicting treatment responses and survival outcomes might be wor-
thy to be reevaluated.
Aims: This study aims to exam the role of hemoglobin level at diagnosis in
association with survival outcomes and treatment responses in chronic myeloid
leukemia patients in chronic phase (CML-CP) receiving frontline TKIs and to
validate the three scoring systems.
Figure 1.
Methods: SPECIAL;A total 172 consecutive patients with CML-CP patients
were screened retrospectively from January 2001 to April 2014. Patients who
previously recieved interferon-alpha or any chemotherapeutic agents or in com-
bination with TKIs treatment, patients who were lost follow-up within 3 months
of diagnosis, and patisnts who had no adequate data to calculate baseline risk
socres were excluded. 143 patients were enrolled to further analysis after
screening. The cut-offs of baseline hemoglobin level were defined as 12.3 mg/dl
for male and 9.0 mg/dl for female sperately in consideration for gender differ-
ence in hemoglobin levels by adopting the receiver oprator characteristic (ROC)
curve method.
Results: With a median follow-up of 54.0 months, 5-year overall survival (OS),
progression-free survival (PFS), and event-free survival (EFS) were 87.5%,
85.9% and 66.8%. We found Sokal and Hasford, but not EUTOS score were
predictive for difference in EFS and PFS; however, none of the three scoring
systems were predictive for difference in OS. Lower baseline hemoglobin levels
was an independent adverse factors for EFS (hazard ration 2.06; 95% confi-
dence interval 1.12-3.78, P=0.019) and associated with worse treatment
responses: the proportion of patients with lower versus higher hemoglobin levels
achieving optimal responses were 52.2% vs 71.1% for 3-month early molecular
response (P=0.021), 20.0% vs 51.4% for 6-month complete cytogenetic respone
(P<0.001), and 18.0% vs 45.1% for 12-month major molecular response
(P<0.001). Furthermore, combining hemogobin level and Sokal score further
distinguised a population at risk for worse EFS and treatment responses.
Summary and Conclusions: The results highlights the need for revisiting tra-
dition CML scoring systems in the TKI era and suggests baseline hemoglobin
levels at diagnosis might be considered for new scoring systems. 
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NILOTINIB RESULTS IN IMPROVED RATES OF MOLECULAR RESPONSE
IN TURKISH NEWLY DIAGNOSED CML-CP PATIENTS: A 24-MONTH
UPDATE
G. Saydam1,* I.C. Haznedaroglu2, L. Kaynar3, A.S. Yavuz4, R. Ali5, B. Guvenc6,
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B. Undar13, S. Dagdas14, O.M. Ayyildiz15, B. Uçar16, I.M. Dag16, O. Ilhan17
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Hacettepe University Medical Faculty Hospital, Ankara, 3 Hematology Division,
Erciyes University Medical Faculty Hospital, Kayseri, 4Department of Internal
Medicine, Hematology Division Istanbul University Istanbul Faculty of Medicine,
Istanbul, 5Department of Internal Medicine, Hematology Division Uludag Uni-
versity Medical Faculty, Bursa, 6Department of Internal Medicine, Hematology
Division Cukurova University Medical Faculty Hospital, Adana, 7Department of
Internal Medicine, Hematology Division Eskisehir University Osmangazi Medical
Faculty Hospital, Eskisehir, 8Department of Internal Medicine, Hematology Divi-
sion Istanbul University Cerrahpasa Medical Faculty, 9Department of Genetics,
Istanbul University Institute for Experimental Medicine, Istanbul, 10Department
of Internal Medicine, Hematology Division Karadeniz Technical University Med-
ical Faculty, Trabzon, 11Hematology Department, Okmeydani Training and
Research Hospital, Istanbul, 12Department of Internal Medicine, Hematology
Division Gaziantep University Medical Faculty, Gaziantep, 13Department of
Internal Medicine, Hematology Division Dokuz Eylul University Medical Faculty,
Izmir, 14Department of Internal Medicine, Hematology Division Ankara Numune
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Hematology Division Dicle University Medical Faculty Hospital, Diyarbakir,
16Novartis Oncology, Istanbul, 17Hematology Department, Ankara University
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Background: Nilotinib, a more potent and selective BCR-ABL-1 inhibitor than
imatinib is approved by FDA and EMA for the treatment of newly-diagnosed
Ph+ CML patients in the chronic phase (CML-CP).
Aims: The aim of the present study was to evaluate the efficacy and safety of
nilotinib in a Turkish population of newly-diagnosed Ph+ CML-CP patients.
Methods: The study was a multicenter, open-label, single-arm phase II clinical
trial. All patients were to be treated with nilotinib (AMN107, Tasigna®) 300 mg
BID for 24 months. 
Table 1. Baseline characteristics and molecular responses of the study
patients.
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Results: As of April 30, 2014, of the 96 patients out of a total 112 enrolled that
had 24 month follow-up, 77 completed active treatment period. General char-
acteristics of the patients at baseline and molecular response by 24 months
are presented in Table 1. Cumulative major molecular response rates at 3rd,
6th, 9th, 12th, 15th, 18th, 21st and 24th months were 23.4%, 47.9%, 56.4%,
61.7%, 71.9%, 79.2%, 82.2%, and 80.2%, respectively. For the assessment of
deeper molecular responses (defined as transcript levels of BCR–ABL on the
International Scale [BCR–ABLIS] ≤0.0032%]), complete molecular response
with a 4·5 log reduction required at least 32000 control genes. According to
this evaluation, within 24 months follow-up 19 patients achieved MR4.5 (19.7%)
by 12 months whereas 45 patients achieved increased MR4.5 (46.8%) ratio
by 24 months in out of 96 patients. Out of 96 patients, 39 patients had tempo-
rally or permanently discontinued treatment. Permanent discontinuation rate
due to adverse event was 9.6% (9 patients) which was the most common rea-
son among all patients (19.8%>19 patients) who permanently discontinued
during 24 months. Thrombocytopenia was the most frequent (10.4%) AE, fol-
lowed by hyperbilirubinemia (8.3%) and increased lipase level (7.3%). Despite
published peripheral arterial occlusive disease (PAOD) reports related to nilo-
tinib usage, there were no PAOD events reported at our cohort.
Summary and Conclusions: By 24 months, in Turkish patients with newly
diagnosed CML, the cumulative MMR rate was 80.2%. Only one progression
occurred, during the first year of therapy. Additionally results showing that
46.8% of these patients achieving MR4.5 by 2 years suggest that high efficacy
was achieved with nilotinib, an approved first-line therapy for newly diagnosed
chronic phase of CML (CP-CML) and can be an option for future candidate
CML treatment regimen. Treatment free remission approach for the patients
with sustainable responses during long term follow-up. This study contribute
to well established nilotinib profile for chronic phase CML patients which is a
licensed alternative for the treatment of newly diagnosed Ph+ CML-CP in
Turkey.
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INCIDENCE OF SECOND NEOPLASMS IN PATIENTS WITH CHRONIC
MYELOID LEUKEMIA ANALYSED IN THE FRAME OF INTERNATIONAL
RESEARCH PROJECT EUTOS POPULATION BASED STUDY IN RUSSIAN
FEDERATION
O.V. Lazareva1,* E. Chelysheva1, I. Tischenko2, M. Galayko3, V. Pepelyaeva4,
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Background: Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid
leukemia (CML) gives hope for a durable disease free survival. Therefore long-
term effects of TKI treatment should be studied. A significant event for CML
patients (pts) is the development of other tumors, second neoplasms (SN)
which can be defined as prior malignancies (pM) if detected before CML diag-
nosis and second malignancies (sM) which occur after the CML diagnosis dur-
ing TKI treatment.
Aims: To evaluate the incidence and variants of SN in CML pts treated in
clinical practice in Russian Federation (RUS).
Methods: We included 199 CML pts from 7 centers of 6 administrative districts
of RUS into RUS part of EUTOS PBS-study. The inclusion criteria were: Ph’/bcr-
abl-positive CML diagnosed in 1.10.2009-31.12.2012 verified by cytogenetic/
molecular data, age of pts ≥ 18 years (y). Median (Me) age was 50(18- 82)y, sex
ratio M/F(%) was 100/99 (50/50)pts. At the time of diagnosis phases of CML were
the following: chronic phase (CP) in 187(94%)pts, accelerated phase in 11 (5,5%)
pts, blast crisis in 1(0,5%) pts. Me time from diagnosis to imatinib (IM) therapy
was 0,6 (0,5-15) months (mo). Pretreatment before IM was the following: hydrox-
yurea in 99 (50%) pts; IFN-α in 2 (1%) pts. Me follow-up since the CML treatment
start was 35.2 (0,5-85)mo (Me for n=192; 7pts were without TKI therapy).
Results: Total rate of sN was 7% (14 of 199 pts). Two of those cases were sM
revealed at 22mo (Encephaloma) and 23mo (adenocarcinoma of the colon)
after diagnosis of CML, respectively. These 2pts died due to progression of sM
after 29 and 32 mo of CML diagnosis respectively. A pM before CML diagnosis
was in 6% (12 of 199 pts). Their Me age was 69(33-73)yy, sex ratio (M/F)
4/8pts. The Me time from diagnosis of a pM to CML diagnosis was 61 (28-
429) mo. The pMs were: breast cancer (4/12 of cases), cancer of uterus and
ovaries (2/12 of cases), rectal cancer, tumor of the upper third of the shoulder,
kidney cancer, prostate cancer, basal cell carcinoma of the eyelid, GIST. Me
time of IM therapy was 36 (7- 49)mo. Most of the pts among 12 cases had
good results of TKI therapy: 7pts achieved major (4/7) and complete molecular
(3/7) response (Me 13 (extr.6–30) mo). Three out of 12 pts with pM in anam-
nesis died (2 pts not achieved even hematologic response). Pts with sM
achieved complete and partial cytogenetic response to 12mo of IM therapy.
Mortality in the whole group of 199pts was 15,6% (31cases) and 5 of them
(2,5%pts) or 35% (5 of 14 pts) died due to SN progression: 3pts with sM+ 2pts
with pM, all 5 were in CP CML.
Summary and Conclusions: Identified cases of SN and CML combination
underline a need for understanding the relationship between CML, other malig-
nancies and their therapy. Assosiation of sM annd CML needs deeper analysis
during longer observation time.
PB1757
OUTCOME OF FRONTLINE TREATMENT WITH GENERIC IMATINIB
ACCORDING TO ELN 2009 BASED NATIONAL GUIDELINES. EXPERI-
ENCE FROM University CLINIC OF HEMATOLOGY, CLINICAL CENTER
OF SERBIA, BELGRADE
A. Bogdanovic1,* V. Milosevic2, D. Lekovic2, V. Djordjevic2, J. Jovanovic2,
M. Dencic Fekete2
1Outpatient&Diagnostic Dept, Clin Hematology CCS, Faculty of Medicine, Unv
Belgrade, 2Outpatient&Diagnostic Dept, Clinic of Hematology CCS, Belgrade,
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Background: Serbia was the first country in Europe introduced generic imatinib
(ANZOVIP®, Actavis). Lot of concerns and many issues were arisen by general
and medical public, especially by patients knowing reports about treatment
failures. All patients in Serbia were switched to the same drug together with
newly diagnosed patients. To realize real efficiency of the drug, we made eval-
uation of newly diagnosed patients only.
Aims: Retrospective analysis of response to generic imatinib in frontline treat-
ment.
Methods: As the largest institution, Clinic of Hematology CCS, we analyzed
cohort of 49 patients with CML in chronic phase, frontline treated by generic
imatinib from August 2012 to March 2014. All patients were treated according
to ELN 2009 based National guidelines with regular cytogenetic follow up and
molecular monitoring after 12 months (after CCgR). In all patients the follow
up of treatment was at least 6 month.
Results: Our 49 patients, had median age of 47yrs ranging from 24 to 74yrs.
There were 31 male and 18 female patients. In all patients CHR was achieved
within 3 months of treatment. In 17 pts after their approval, we have performed
early cytogenetic evaluation at 3 mths: 3/17 pts was without mitoses, 10/17
pts (58%) had Ph<35%, and 4 were non responders (Ph from 50-100%).
According to our National guidelines evaluation at 6 and 12 months were per-
formed. At 6 months, 23/49 pts achieved CCgR (46.9%), 38/49 (77.5%) was
in majorCgR (ELN 2009 optimal), and 9/49 pts had insufficient response (no
major CgR). At 12 mths similar evaluation revealed 26/49 pts achieving CCgR
(53%), and ELN 2009 suboptimal response was noted in 7/49 pts (14.3%).
Unfortunately we have also noted that some patients lost their previously
achieved response after one year of treatment. Also 3 patients developed sud-
den blast phase. Taken together failure >12 mths was in 5+3 pts (16%). Besides
7 pts (14.3%) never achieved optimal response by 400mg imatinib up to one
year of treatment. Seven patients (14.3%) were treated by imatinib escalation
(800mg), and 4 achieved CCgR. 9 pts were treated with second line nilotinib
(failure by ELN 2009) and 5 of them achieved secondary CCgR. From other
four patients without optimal response to nilotinib, 3 of them were sent to BMT.
Molecular evaluation was performed at M12 and M18 from start of the treat-
ment. Due to technical reasons it was performed in more than half of the
patients, 30 of 49 (61%), and optimal molecular response at M12 of M18 was
achieved in 25 of 30 analyzed patients (at least MR3) but in 5 patients MR3
was not achieved even they are in continuous CCgR up to at M18.
Summary and Conclusions: Our pilot data are based on small number of
patients from single center, but provided data that generic imatinib used in Ser-
bia (ANZOVIP) is not much inferior to branded imatinib. Larger series of patients
from whole Serbia (e.g. 90-100) will provide more accurate data about efficiency
of generic imatinib in the first line treatment.
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THIRD-LINE TREATMENT WITH 2ND GENERATION TYROSINE KINASE
INHIBITORS (TKIS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
WHO FAILED TWO PRIOR TKIS: A SINGLE CENTER EXPERIENCE OF 21
PATIENTS 
A. Salihoglu1, A. E. Eskazan1,* V. Suzan2, S. Savci2, I. Erdogan1, S. Berk1,
F. F. Yalniz1, T. Elverdi1, M. C. Ar1, S. Ongoren Aydin1, Z. Baslar1, Y. Aydin1,
N. Tuzuner3, U. Ozbek4, T. Soysal1
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Internal Medicine, 3Department of Pathology, Istanbul University Cerrahpasa
Faculty of Medicine, 4Department of Genetics, Istanbul University Institute of
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Background: Although most of the chronic phase chroic myeloid leukemia
(CML-CP) patients do well under imatinib (IM), some quit IM due to resistance
and/or intolerance. 2nd generation tyrosine kinase inhibitors (2GTKIs) (dasatinib
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(DAS) and nilotinib (NIL)) can be used in patients who have intolerance and
resistance to IM, and approximately 50% of patients failing to respond to pre-
vious treatments may respond to 2GTKIs. Limited data is available, displaying
the outcome of CML patients who failed two lines of TKI, and received 2GTKIs
as a 3rd-line treatment option.
Aims: The aim of this study is to report our single center experience on CML
patients who received 2GTKIs as a 3rd-line treatment option.
Methods: Two hundred and nine CML-CP patients who were diagnosed
between 1999-2013 and received IM were evaluated. Patients’ demographics,
Sokal risk scores, treatment outcomes and durations, and the follow-up periods
were noted from the patients’ files retrospectively. Patient monitorization was
performed according to European LeukemiaNet (ELN) recommendations, and
in case of resistance, mutational analysis was performed. The cumulative inci-
dence of major molecular response (MMR) and complete cytogenetic response
(CCyR) rates during the follow-up periods were calculated. The choice of
2GTKIs depended on mutational status and comorbidities of the patient, and
the disease phase at the time of the switch (i.e. in patients with blastic crisis
(BC), DAS was the treatment choice). Also in Turkey DAS was in the market
before NIL became available, so at that period of time, DAS was the only option
for 2nd-line TKI treatment.
Table 1.
Results: One hundred and twenty-two patients were male (58%), and the median
age was 44 years (range, 18-92 years). The rates of low, intermediate and high
Sokal risk scores were 44%, 39% and 17%, respectively. One hundred and sev-
enty-eight patients (85%) were in early CP (ECP), whereas 31 (15%) were in late
CP (LCP). One hundred and forty-four (68.9%) of the patients had only received
IM as a TKI treatment, of which 129 (61.7%) were still on IM after a median fol-
low-up of 86 months (range, 13-142 months) at the time of the analysis. The
cumulative MMR and CCyR rates under IM were 73.6% and 79.9%, respectively.
Sixty-five patients (31.1%) received 2GTKIs, of which 45 had DAS and twenty
received NIL as 2nd-line treatment. One patient having an allogeneic hematopoi-
etic stem cell transplantation (AHSCT) after IM failure received DAS for the post-
transplant relapse. Among patients receiving DAS, BC was the reason for starting
treatment in 5, and nine patients receiving 2nd-line DAS, and one patient receiving
2nd-line NIL died due to BC. Two patients underwent AHSCT after receiving 2nd-
line DAS+chemotherapy, of which one died due to disease progression and the
other one remained in remission. The cumulative MMR rates under 2nd-line DAS
and NIL were 40% and 55%, respectively. Twenty-one patients (15 NIL and 6
DAS) received 2GTKIs as a 3rd-line treatment, and at the time of the analysis, 13
patients were still on treatment, five and 3 patients had to stop therapy due to
intolerance and resistance, respectively. During the follow-up, four patients died
(3 due to disease progression, and one after AHSCT) (Table 1). Eight patients
had 3rd-line treatment for less than 6 months (median 2.5 months), and the
remaining 13 had a median follow-up of 22 months under 3rd-line 2GTKIs. Ten
patients achieved MMR after a median of 22.5 months (Table 1). Among patients
who were refractory to 2nd-line treatment (n=10), only three had gained MMR
and one achieved CCyR, whereas 7 of the remaining eleven had achieved and/or
maintained MMR under 3rd-line 2GTKI treatment where switching from the 2nd-
line treatment was due to intolerance.
Summary and Conclusions: 2GTKIs can be a reasonable choice for the 3rd-
line treatment even in patients who are resistant to prior 2 lines of TKI treatment,
especially when 3GTKIs are not available and AHSCT is not an option.
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PDGFRB SUSTAINS THE “WITHDRAWAL SYNDROME” AFTER IMATINIB
DISCONTINUATION
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Background: The Swedish group reported that 30% of patients who stopped
imatinib presented by the first 2 months musculoskeletal pains, localized to
shoulders and hips or extremities, like a rheumatic polymyalgia (Richter J, JCO
32: 25 -2014). Some of these cases have been described as sensitive to parac-
etamol, whereas other patients need long-term treatment with corticosteroids.
Aims: The aim of this study was the strict molecular and clinical follow-up of
patients who stopped imatinib for intolerance in order to do a precocious diag-
nosis and start an appropriate treatment for this “withdrawal syndrome”. 
Methods: Seven patients discontinued imatinib in 2014 at the Hematology Unit
of the Pisa University; median age was 70 years (range 54-75); all patients
received imatinib for more than 3 years, with a median time from diagnosis of
10 years. Initial Sokal risk score was low in 4 patients, intermediate in 2, and
high in one patient; EUTOS score was low in all cases, except for one. All
patients were in deep molecular response (at least MR4.5) from a minimum of
24 months at the moment of discontinuation. Treatment was interrupted
because of non-hematological toxicities (PAOD, bleeding, alopecia, eyes, liver,
skin toxicity). BCR-ABL1/ABL1 IS ratio was monitored by quantitative PCR
every month. Reactive C protein, interleukin-2, interleukin-10, TNFa, PDGFb,
VEGF, and interferong were measured in the plasma by ELISA.
Results: Two of our 7 patients developed the “withdrawal syndrome” after 2
and 3 weeks from the imatinib discontinuation, respectively. They presented
muscolo-skeletal pains, localized to shoulders, arms and hip; these symptoms
were graded as 2. The C-reactive protein serum level was normal in one case
and only slightly increased in the other one; lactate dehydrogenase and protein
electhrophoresis were normal in both cases. None of the 7 patients lost the
deep molecular response during the follow-up (median 6 months, range 3-11
months). Interleukin-2, interleukin-10, TNFa, IFNg, and VEGF were in the nor-
mal range; interestingly, in both patients presenting the “withdrawal syndrome”
PDGFRb resulted increased (2.5 fold higher than the highest value in the normal
range). Both these patients did not respond to paracetamol 1g trice/day, thus
corticosteroids were given (16 mg methyl-prednisolone per day), with tapering
within 8 weeks up to 4 mg. Both patients showed a clear improvement within
days; after 8 weeks steroid was discontinued, but symptoms, even if milder,
reappeared. Both patients still receive 4 mg/day. PDGFb in this phase was still
high, even if significantly reduced in respect of the onset of the syndrome.
Summary and Conclusions: Our study confirms, even if in a limited experi-
ence, the feasibility of the TKI discontinuation, but also the presence of the
“withdrawal syndrome”. It is well known that imatinib inhibits PDGFRb; PDGFRb
has been also reported to contribute to synovitis by re-directing synovial fibrob-
lasts toward a more aggressive phenotype (Rosengren S, 2010), and increased
expression of PDGFb was also detected in the inflamed synovia, supporting its
relevant role in the inflammatory processes (Reuterdhal C, 1991).
Consequently, we could hypothesize that the discontinuation of imatinib, stop-
ping the PDGFRb inhibition, could activate the PDGF-mediated arthalgias. 
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CROSSING OF BLOOD-PLACENTAL BARRIER BY TYROSINE KINASE
INHIBITORS USED FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA:
THEORETICAL AND PRACTICAL ASPECTS
E. Chelysheva1,* A. Zeifman2, G. Chilov2, D. Guranda3, S. Mordanov4,
K. Kazakbaeva5, S. Saliev5, E. Polushkina6, A. Turkina1
1Scientivic Advisory Department of Chemotherapy of Myeloproliferative disor-
ders, Federal State Funded Institution National Research Center for Hematol-
ogy of the Ministry of HealthCare of the Russian Federation, 2FSBI Institution
of Organic Chemistry of Russian Science Academy named after N.D.Zelinsky,
3Farm innovation technologies Ltd, Moscow, 4FBEI HPE Rostov State Medical
University of Healthcare Ministry of Russian Federation, Rostov, Russian Fed-
eration, 5Research Institute of Hematology and Blood Transfusion MOH of
Uzbekistan, Tashkent, Uzbekistan, 6FSBI Scientific Center of Obstetrics, Gyne-
cology and Perinatology of Healthcare Ministry named after V.I.Kulakov,
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Background: The issue of safe usage of tyrosine kinase inhibitors (TKIs) in
chronic myeloid leukemia (CML) patients on late stages of pregnancy is unclear.
TKI ability to cross the blood-placental barrier (BPB) in humans and association
with the adverse effects is rarely evaluated in practice due to rareness of cases
and ethical reasons. The obtained data are scarce. We hypothesized whether
BPB crossing can be predicted by a model based on molecular physicochemical
properties of available TKIs.
Aims: To compare the theoretical calculations of BPB crossing of TKIs used
for CML treatment with the data obtained in practice and association with clinical
outcomes.
Methods: The relative rate of TKIs penetration through BPB was evaluated by
so called clearance index (CI) in comparison with antipyrine as free passive
diffusion reference with CI=1. The CI of imatinib, nilotinib, dasatinib and bosu-
tinib. was estimated using Quantitative Structure-Activity Relations (QSAR)
approach (Hewitt et al, Environ Res, 2007) according to the equation (picture
1). Concentration of imatinib in available cases was simultaneously measured
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at labour in blood plasma of mother, cord blood and homogenized placenta by
HPLC-mass spectrometry technique. Information of therapy and pregnancy
outcomes was taken from Russian CML pregnancy registry and local database
of Uzbekistan.
Results: Calculated CI values for imatinib, nilotinib, dasatinib, bosutinib were
0,36, 0,33, 0,44 and 0,67 correspondingly showing moderate but not negligible
rate of BPB transfer compared to antipyrine. In 3 of 17 women with CML who
received TKI (15 imatinib, 2 nilotinib) since 2nd-3rd trimester (due to lack of
response) imatinib concentration was measured. The fetal:maternal ratio
ranged from 0,12 to 0,25 and imatinib concentration in placenta was higher
than in maternal blood (Table 1). All 17 newborns had no birth abnormalities,
low weight<2500 g was in 6 cases. In 5 of 6 cases infants were born preterm
at week 35-37, their further development was normal.
Table 1. Concentration of imatinib measured at labour and fetal:maternal
ratio.
Imatinib concentration, ng/ml fetal:maternal 
maternal blood placenta cord blood
ratio of case
plasma
1 896,5 ND 109,5 0,12
2 897,5 1095 226 0,25
3 520,6 702,10 115,5 0,22
Figure 1.
Summary and Conclusions: A simple QSAR model based on diffusion-like
properties of TKIs used for CML treatment showed the moderate rate of BPB
transfer compared to antipyrine. Data obtained at practice showed reduced
level of imatinib in cord blood plasma and higher level in placenta compared
to maternal blood. Factors which were not accounted in the theoretical model
(active transportation mechanisms, extensive metabolic clearance at the fetal
side) might specifically prevent TKIs from crossing BPB. Cases of preterm
delivery with low weight of children in mothers who got TKIs during pregnancy
need further evaluation.
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ACHIEVING EARLY OPTIMAL RESPONSE IS ASSOCIATED WITH BETTER
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC
MYELOID LEUKEMIA TREATED WITH IMATINIB OR NILOTINIB AS
FRONTLINE THERAPY
Q. Jiang1,* H.B. Wang2, X.D. Mo1, L. Yu1, X.J. Huang1
1Peking University People’s Hospital, 2Peking University Clinical Research
Institute, Beijing, China
Background: Tyrosine kinase inhibitors (TKIs) as the first-line therapy have
improved the outcome of patients with chronic myeloid leukemia in chronic
phase (CML-CP). Health-related quality of life (HRQoL) is becoming increas-
ingly recognized as an important component of the management of CML.
Aims: To prospectively assess the HRQoL in newly-diagnosed patients with
CML-CP treated with imatinib or nilotinib and to identify the factors associated
with the HRQoL outcomes.
Methods: From June 2011 to July 2011, 59 newly-diagnosed patients with
CML-CP from Peking University People’s Hospital, who were enrolled in the
ENESTchina trial, were randomly assigned to receive imatinib 400 mg daily
(n=27) or nilotinib 300 mg BID (n=32). Response to first-line TKI therapy was
assessed according to European LeukemiaNet 2013 recommendations for the
management of CML. HRQoL was measured with the Short Form 36 Health
Survey (SF-36) at baseline and every 3 months during the 3 years follow-up.
Fisher Exact tests or chi-square tests were used to compare subjects treated
with imatinib or nilotinib. The Kaplan-Meier method was used to assess statis-
tical significance in the time-to-event analyses. The longitudinal change in
HRQoL was further analyzed in a mixed model approach to linear regression
for repeated measurements.
Results:Among the 59 patients (35 man and 22 women), the median age was
37 years (range, 18-74 years). Patients in the two treatment arms were compa-
rable in terms of demographics (e.g. gender, age, education and house register),
clinical characteristics (e.g. Sokal risk score and interval from diagnosis to treat-
ment) and HRQoL scores at baseline. With a median follow-up of 37 months
(range, 11-38 months), patients in the nilotinib arm had significant higher cumu-
lative incidences of complete cytogenetic response (P=0.0077) and major
molecular response (P=0.0248) compared with those in the imatinib arm. Higher
proportions of optimal responses at 3 months (81.5% vs. 68.8%, P=0.263), 6
months (77.8% vs. 62.5%, P=0.204) and 12 months (51.9% vs. 37.5%, P=0.269)
were also observed in the nilotinib arm, but without statistical significance.
Patients in the two arms had similar rates of event-free survival (84.4% vs.
85.2%, P=0.958), progression-free survival (88. 9% vs. 87.5%, P=0.893) and
overall survival (100% vs. 90.6%, P=0.199 at 3 years. Regarding HRQoL,
although there was no difference on the SF-36 physical and mental assessments
between patients in the two arms during the follow-up, role-physical functioning
subscale was improved in patients treated with imatinib (P=0.0421) over time,
furthermore, social functioning (P=0.0293) and mental component summary
(P=0.0043) were improved in those treated with nilotinib. In total population,
patient characteristics at baseline (including gender, age, education, house reg-
ister and Sokal risk score), TKI used (imatinib vs. nilotinib) and early responses
to TKI therapy (optimal response vs. non-optimal response) at 3, 6 and 12
months was analyzed in order to identify the independent factors affecting the
HRQoL. Multivariable analyses by mixed model showed that patients with uni-
versity graduate or above was associated with better vitality (P=0.0468), achiev-
ing optimal response at 3 months improved physical functioning dramatically
(P<0.0001), and achieving optimal response at 6 months (P=0.0432) or 12
months (P=0.0483) improved social functioning remarkably.
Summary and Conclusions: Imatinib or nilotinib as the first-line therapy
improved the HRQoL of CML-CP patients significantly, especially for those
achieving optimal response at 3 months, 6 months or 12 months.
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“REAL-LIFE” FRONTLINE DASATINIB TREATMENT IN UNSELECTED
ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA 
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Background: Dasatinib has been recently licensed for first line treatment of
patients with chronic myeloid leukemia (CML). However, very few data are
available as to toxicity and efficacy of dasatinib in unselected elderly CML
patients. 
Aims: To address this issue, we revised a “real-life” cohort of 54 CML patients
in chronic phase aged >65 years treated with frontline dasatinib in 24 Italian
Centers from 6/2012 to 12/2014 focusing on toxicity and efficacy data. 
Methods: The main clinical features of the patients at diagnosis were as fol-
lows: M/F 27/27, median age 75.4 years [interquartile range (IQR) 70.6 – 79.5),
median Hb 12.3 g/dl (IQR 11.1 – 13.6), median WBC 51.5x 109/l (IQR 28.1 –
100.0), median PLTS 430x 109/l (IQR 233 – 770). According to Sokal risk clas-
sification, 2 patients (3.7%) were low risk, 32 (59.3%) intermediate risk, 15
(27.8%) high risk while 5 (9.2%) were not classificable. 30/54 patients (55.5%)
had ≥ 2 comorbidities requiring concomitant therapies: according to ECOG
scale, performance status at baseline was 0 – 1 in 46 patients (85.1%) and 2
in 8 patients (14.9%). 
Results: Median interval from diagnosis to dasatinib start was 23 days (IQR
14 – 35). Dasatinib starting dose was 140 mg/day in 1 patient (1.8%), 100
mg/day in 40 patients (74.1%) and<100 mg/day in 13 patients (24.1%), respec-
tively. After a median period of treatment of 13.7 months (IQR 6.4 – 20,6) all
patients were evaluable for toxicity; on the whole, grade 3 – 4 hematological
and extra-hematological toxicities were reported in 5 (9.2%) and 9 (16.6%)
patients, respectively. Overall, 9 patients (16.6%) permanently discontinued
dasatinib due to toxicity (2 patients in the first 3-month period of treatment and
7 beyond that period). Pleural effusions of all WHO grades occurred in 10
patients (18.5%): in 4 of them the pleural effusion occurred during the first 3-
month period of treatment. As to treatment efficacy, 5 patients were considered
too early to be evaluated (<3 months of treatment) and 49 were evaluable for
cumulative response; on the whole, 45/49 patients (91.8%) achieved complete
cytogenetic response (CCyR) and 33/49 (67.3%) also a major molecular
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response (MMolR). Response to treatment at different time-points is shown on
Table 1. After a median period of observation from dasatinib initiation of 15,5
months (IQR 9.2 – 24.7), only 1 patient died from unrelated cause (senectus)
while in MMolR: cumulative event-free survival (EFS) at 12 months was 82.4%
(95%CI 71.3 – 93.5).
Table 1. 
Summary and Conclusions: Present data shows that dasatinib could have a
major role in the treatment of unselected patients aged >65 years; indeed,
dasatinib seems very effective and has a favourable safety profile also in elderly
subjects with comorbidities.
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QUALITY OF LIVE IN PATIENTS WITH CML: QUESTIONNAIRE BASED
STUDY
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Medicine, Seoul, 6Seoul National University Bundang Hospital, Seongnam,
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Background: With imatinib therapy, the survival of patients with CML has
improved dramatically. In recent years, second generation TKI (2G TKI) led to
more increased responses. Despite the demonstrated superiority of efficacy
and toxicities as previous treatments, several adverse events of TKIs remain.
Because CML treatment is lifelong, it is important for patients to maintain adher-
ent to treatment. Correlations between poor adherence to TKI treatment and
adverse events and quality of life (QoL) have been demonstrated among CML
patients in clinical settings. The FACT-leu is a validated tool that measures
leukemia-specific and more general QoL concerns. However, there are few
studies about QoL of CML patients in Korea.
Aims: Therefore, we evaluated the QoL of CML patients treated with TKIs.
Methods: The CML working party of the Korean society of Hematology was
produced by the questionnaire included the questions of FACT-leu. We distrib-
uted the questionnaire over the online or offline. QoL of patients with CML was
analyzed using these questionnaires.
Results: A total of 384 patients responded to the survey between March 2014
and June 2014. Patients with high compliance of TKI (taking 90% or more
drugs) were 88.28% and lower compliance (taking 70% or less drugs) were
1.82%. In queries about poor adherence to TKI therapy, most common cause
was forgetfulness (18.49%). FACT-Leu scale was higher in patients with 2G
TKIs than imatinib (122.9±22.65 vs 116.0±25.00 (P=0.005)). Female, older
patients showed meaningful worse QoL in FACT-leu scale.
Summary and Conclusions: In 2G TKI era, QoL of CML patients seemed that
is better than before. Additional prospective studies are warranted using ade-
quate measuring tool of QoL.
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SAFETY AND USEFULNESS OF REDUCING THE DOSE OF IMATINIB TO
300 MG IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH SUS-
TAINED DEEP MOLECULAR RESPONSE.
S. Redondo Velao1,* I. Pérez Sánchez1, C. Laperche1, I. Buño1,
J.L. Díez-Martín1, S. Osorio Prendes1,
1Hematology, Gregorio Marañón Hospital, Madrid, Spain
Background: Tyrosine kinase inhibitors have dramatically changed the treat-
ment of CML and nowadays most of the patients are able to achive sustained
deep molecular responses in this setting. This scenario has led to an increasing
interest on therapy discontinuation studies but this strategy is not recommended
outside clinical trials
Aims: We have reduced the dose of Imatinib (IM) from the standard 400 to
300 mg/day, in some patients with deep and stable deep responses in order to
improve tolerability and costs of the treatment. In this analysis we review
whether this strategy was safe and clinically useful. 
Methods: Patients with chronic phase CML that decreased IM 400 to 300
mg/day at least during 3 months and who had molecular responses analyzed
before and after the change were retrospectively selected from our database.
BCR-ABL ratio was measured by automated means (GeneXpert, Cepheid, CA,
USA) according to the International-Scale. Hematological parameters such as
hemoglobin level and mean corpuscular volume were also analyzed before
and after the IM dose change. Data were analyzed using SPSS v11.0.
Table 1. Patient’s responseti IM 300MG/DAY (N=13).
Results: A total of 13 patients (7 males, 6 females) with chronic-phase CML
diagnosed between 1998 and 2012 were included in the present study. Median
age at diagnosis was 67 years (range 23-78). According to Sokal score, 3 were
high risk, 4 intermediate and 6 low; according to EURO score, 1 was high risk,
6 intermediate and 6 low; according to EUTOS score, all were low risk. First
line treatment was IM 400 mg in 10 (76.9%), IM 600 mg in 1 (7.1%) and Inter-
feron-alpha in 2 (16%). The reason for dose reduction was toxicity in 6 patients
(46%): neutropenia (2), pancytopenia (2), limb edema (1) and heart failure (1).
In all of them the adverse event improved after lowering the dose. All patients
that reduced the dose due to toxicity were at least in CCR. In the other 7 patients
(54%) the dose was reduced because of sustained deep response; RM4.5 or
better and undetectable disease (>RM4.5 with UD). Median time in >RM4.5
with UD, prior to dose reduction was 24.4 months (range 12-33; Table 1). Medi-
an time of treatment with 300 mg/day was 12 months (range 4-117). Comparing
molecular response before dose reduction and at last follow up, 3 patients
improved and 10 maintained it; if we compared molecular response before the
dose reduction and the worst response during follow up, just 3 patients wors-
ened (2 from RM4 and UD to MMR, and 1 from RM4.5 and UD to RM4 with
detectable disease), but none of this changes were clinically relevant. The
median hemoglobin increase was 1.2 g/dl (range 0.4-2.3; P=0,054). The median
decrease in mean corpuscular volume was 3.7 fL (range 0.4-11.5; P=0,006)
(Wilcoxon Test). With this univariate analysis we cannot rule out that other con-
current causes could contribute to this hematological change. Additionally, there
was an economical benefit derived from the dose reduction, since 334 accu-
mulated months of treatment with IM 300 mg/day, produced savings of 357.046
Euros (savings for 13 patients would be of 166.764 Euros per year). Out of the
13 patients, 12 continue with 300 mg, and one patient died due to causes not
related to CML
Summary and Conclusions: In our experience IM dose reduction due to med-
ical decision or toxicity in patients with sustained deep response has been safe,
clinically useful and economically beneficial. This could be a useful strategy in
some patients with deep responses until treatment discontinuation could be
recommended in common clinical practice.
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INFLUENCE OF CYP3A5 AND SLCO1 ON IMATINIB RESPONSE AMONG
EGYPTIAN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID
LEUKEMIA.
S. Aref1, M. El-Ghonemy1, M. El Baiomy2,*
1Hematology Unit, Clinical pathology Department, 2Medical Oncology and
Hematology Unit, Oncology Center Mansoura University, Mansoura, Egypt
Background: Imatinib (IM) was approved as a molecular target drug that selec-
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tively inhibits Bcr-Abl tyrosine kinase which causes Philadelphia-positive chron-
ic myeloid leukemia (CML) and so far been the first-choice treatment in CML
with excellent results. However, only a proportion of patients achieve major
molecular response. Hence, the need to find whether there are some factors
that affect the response to treatment is essential. Although IM pharmacokinetics
is influenced by several enzymes and transporters, little is known about the
role of pharmacogenetic variation in IM metabolism.
Aims: This study aimed to investigate the frequencies of mutational status of
CYP3A5 and SLCO1 in CML patients undergoing imatinib treatment and to
determine whether these two genes could predict the response to imatinib ther-
apy in CML patients.
Methods: We investigated the mutational status of SLCO1 and CYP3A5 by
Polymerase Chain Reaction followed by restricted fragment length polymor-
phism in 62 Philadelphia positive newly diagnosed Egyptian CML patients in
chronic phase. All patients received imatinib therapy and were followed for at
least one and half years. The response to imatinib therapy was evaluated by
recording the hematological response, cytogenetic response at 6 month, and
molecular response at 12 month of imatinib treatment according to the Euro-
pean Leukemia Net criteria.
Results: 11 patients were excluded from the study as they showed treatment
failure to imatinib at 6 month of treatment so they were shifted to 2nd line TKIs.
Six (54.5%) out of these 11 patients were mutant for CYP3A5 while five were
wild, however four (36.3%) out of them were mutant for SLCO1 and seven
patients were wild type. The remaining 51 patients who continued in the study
showed that the mutant CYP3A5 was more common with low hemoglobin level
(P 0.03) and low platelets count at diagnosis (P 0.001) however, there was no
relation between SLCO1 mutational state and patients characteristics. Also
there was no relation between mutational state of either CYP3A5 or SLCO1
with the sokal score of the patients at diagnosis. Patients with mutant CYP3A5
showed suboptimal cytogenetic response to imatinib at 6 month versus patients
with wild type (P 0.07). At 12 month of imatinib treatment, 74.1% of patients
with mutant CYP3A5 had no MMR versus 66.7% of patients with wild type had
MMR (P 0.004). However there was no significant relation between mutational
state of SLCO1 with neither cytogenetic response at 6 month nor molecular
response at 12 month of imatinib treatment. 
Summary and Conclusions: CYP3A5 mutant gene was associated with poor
imatinib efficacy while the SLCO1 was not associated with the response to
imatinib treatment in Egyptian patients with CML in chronic phase.
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IS GENERIC MESILATE OF IMATINIB LESS INFERIOR THAN GLIVEC?
ANALISYS IN BRAZILIAN COHORT
P. Cappelletti1,* S. Bonecker1, R. Bittencourt1, J. Dobbin2, A. Moellman2,
I. Zalcberg1
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Background: The improvement of the treatment for LMC patients after the
introduction of tyrosine kinase inhibitor (TKI) Imatinib (Glivec®, Novartis) speaks
for itself. After the developed of Glivec, others TKIs became available on the
market. These new drugs, however, come to market with prices to astronomical
levels. The introduction of therapies with generic drugs is extremely relevant.
In Brazil, mesilate of imatinib (IM) become available in a generic formulation
(gIM) by January 2014 with a productive development partnership signed Far-
manguinhos/FIOCRUZ, Vital Brazil Institute and Cristália Pharmaceutical
Chemicals.
Aims: The objective of this study was analyzed our Brazilian CML patients
cohort and evaluate the molecular response of these patients before and after
the exchange of the drug (Glivec vs. gIM) and monitoring a small group of CML
patients considering only gIM as first line therapy. 
Methods: We analyzed and compared two different groups. The first one has
171 patients who start with Glivec as first line therapy and followed them
between 2001 and 2014. All these patients switched to gIM in 2014. The second
group has 11 patients who started the treatment with gIM in 2014. For those,
the follow-up was 12 months. 
Results: The median time follow-up for patients whom start Glivec was 5.4
years (1.1 – 13.8), while on the other group was 0.4 (0.3 – 1) years. We
observed a slight predominance of female on the Glivec first line therapy cohort.
Most of the patients (96.8%) were diagnosed in chronic phase in both group;
96.8% and 92.3% respectively. Considering the group who start with Glivec as
front line therapy before switch to generic, 9.9% (17/171) of the patients lose
MR during the treatment. One of them presented a L452I mutation. In spite of
that, they still switch to gIM. Among 17 patients, 5 (29.4%) gain MR after switch
to generic IM. At this time, these 17 patients are excluded from subsequent
analyzes. After switch to gIM, 5.8% of the patients (9/154) lost MMR response
or more. Three of them acquire a mutation, 1 patient at 7 months and the other
2 patients, 3 months after change the treatment: L273M, L387M and F359V.
L387M mutation was already described as sensitive to IM. F359V-mutated cell
lines demonstrated decreased sensitivity to imatinib compared with CML cell
lines wild type. One patient present E453A mutation before change the drug.
The median time to lose response was 7 months. Only 3.3% (5/154) of the
patients gain MR after change to generic IM. We had 11 patients in our cohort
who star the treatment with generic IM. Taking account the 3 months cutoff,
72.7% (8/11) of the patients presented levels ≤10% BCR-ABL1 transcripts and
5 of these 8 patients (62.5%; 5/8) achieved MMR at 12 months. None of them
discontinuous the treatment.
Summary and Conclusions: In our patient cohort of “good responders”, taking
into account that all of the patients who had to switch to second generation
TKIs were excluded from this study, the generics were at least non inferior to
the original drug in terms of maintenance of response state, efficacy and toler-
ability when used in the upfront setting, as well as when used subsequently.
Prospective studies are needed to address the effectiveness of generic IM in
CML patients.
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Background: Vitamin D deficiency is a common problem all over the world.
Growing evidence suggest that there is connection vitamin D and cardio-meta-
bolic disease and cancer. Low-circulating 25-hydroxy vitamin D (25-OH-D) has
been associated with various malignancies, although it remains unclear
whether vitamin D deficiency exerts as a causal effect on the development of
malignancies.
Aims: In this study we aim to evaluate whether there is link between circulating
25-OH-D levels and molecular response in chronic myeloid leukemia (CML)
Methods: Subjects : A total of 61 patients with CML (31 women, 30 men) were
recruited in this cross-sectional study from hematology clinics of Katip Celebi
University Ataturk Training and Research Hospital between June 2014 and
September 2014.The study was approved by the human research ethics com-
mittee of the hospital and informed consent was obtained from all participants.
Vitamin D status as defined; severe deficiency ≤10 ng/mL; deficiency 10-20
ng/mL; insufficiency 20-30 ng/mL; sufficiency ≥30 ng/mL (1). Treatment
responses were evaluated according to the ELN recommendations. Statistical:
All analyses were performed using the Statistical Package for the Social Sci-
ences Software, version 18.0 (SPSS Inc., Chicago, USA). In view of the sub-
jects number for each groups, patients were divided into two groups according
to their vitamin D levels (group 1 ≤10 ng/mL, group 2 >10 ng/mL) and two
groups were compared with clinic and laboratory feature using Mann-Whitney
U test. Among the groups difference in gender distribution was analyzed byx2
analysis. To evaluate vitamin D levels on molecular response, we used binary
logistic regression analysis. In the model, molecular response was defined as
a dependent variable and subjects were categorized to their vitamin D levels;
≤10 ng/mL an >10 ng/mL and also which were added the analysis as a cate-
gorical variable. To clarify effect of potential confounders; sokal score, gender
and type of treatment, we added these variables in the model as a consecu-
tively. All reported confidence interval (CI) values are calculated at the 95%
level. A two-sided p value of<0.05 was considered statistically significant.
Results: According to the vitamin D levels; 37 (60.7%) patients had ≤10 ng/mL,
19 (31.1%) patients had 10-20 ng/mL and 5 (8.2%) patients had 20-30 ng/mL.
In our study population no subjects had sufficient vitamin D levels. In unadjusted
logistic regression models, increased vitamin D levels were significantly asso-
ciated with molecular response. After adjusting potential confounders, this asso-
ciation was slightly diminished but it is still remained
Summary and Conclusions: In present study, we demonstrated for the first
time that lower circulating 25-OH-D levels were independently associated with
molecular unresponsive in subjects with chronic myeloid leukemia after adjust-
ing for potential confounders.There are some limitations to the current study.
The size of study population was relatively small and the cross-sectional design
of the study cannot prove causality. These findings are initial and provoking,
but this association should be verified in another larger population using a
prospective-cohort design. Taken together, our results indicate for the first time
that decreased circulating 25-OH-D levels were associated with molecular
unresponsive in patients with CML. 25-OH-D may contribute to molecular
response in the patients
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ANALYSIS OF MINIMAL RESIDUAL DISEASE AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC MYELOID
LEUKEMIA (CML) BY REAL-TIME QPCR FOR BCR-ABL GENE AND ITS
CORRELATION WITH RELAPSE
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Background: hronic myeloid leukemia (CML) is a clonal bone marrow disease
characterized by the presence of the Philadelphia chromosome, resulting from
translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid
gene., which encodes tyrosine kinase proteins and regulate cell growth. The
development of targeted therapies for the treatment of this disease, such as
imatinib mesylate, changed the landscape treatment of CML. Hematopoietic
stem cells transplantation (HSCT) still remains the only curative modality of
therapy. After HSCT, relapse can be observed even very late. The amount of
leukemic cells in relapse (molecular, cytogenetic or hematologic) and relapse
phase are the main prognostic factors found, and the response to the interven-
tions (infusion of donor lymphocytes or imatinib mesylate) are best when
relapse is identified early. The use of real-time PCR for the detection of BCR-
ABL gene for monitoring of recurrence in patients after HSCT shows a good
alternative of tracking disease, however cut-offs which would define relapse
are not yet established in the literature. Besides, there have been recent
changes in the PCR methodology including the padronization of an international
scale, used as monitorization for TKI therapy. Few studies evaluated this
method for monitoring patients after HSCT. 
Aims: The main objective of this study is assessing the significance of the
results of real-time PCR for quantification of BCR-ABL gene in patients previ-
ously diagnosed with CML who underwent HSCT. The intention is to analyze if
the results of this test are reliable predictors of the risk of disease recurrence
and what is the range of values that is considered at increased risk for relapse,
which would allow early intervention. 
Methods: We retrieved databases and records of 57 patients diagnosed with
CML who were treated with HSCT from 2003 in the HC-UFPR. Type of relapse
(hematology or cytogenetic ) and correlation with BCR-ABL values obtained by
real-time PCR, is the primary endpoint. 
Results: We identified 57 patients which received HSCT from 2003-2014. All
them had been molecularly monitored by Real Time Q-PCR and have more
than one value measured. 21 patients had positive Q-PCR results. From those,
17 had persistent positive results, and 12 of them ultimately relapsed. Four
patients had intermitent low values of BCR-ABL and so far no one of them
relapsed. No patient with persistent negative brc-abl relapsed. IS ratio of
patients who relapsed were significantly higher than those who didn’t relapse,
which had IS showing 2-3 log reduction. Patients with intermitent low values of
BCR-ABL had IS showing 3 log reduction altenating with negative results. 
Summary and Conclusions:Although there were changes in BRC-ABL tech-
niques, real time Q PCR can be used for monitorization of relapse after trans-
plant. Persistent positive results highly correlated with relapse within the present
cohort of patients. However, low levels aternated with negative results did not
resulted in a higher rate of relapse. Patients with persistent negative measuses
did not relapse at all.
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MONITORING CLINICAL CARDIOLOGY WITH TRANSTHORACIC
ECHOCARDIOGRAPHY AND ELECTROCARDIOGRAPHY IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE
INHIBITORS SECOND GENERATION
M. Ayala1,* I. Bonilla2, J. Domínguez3, X. Aquino3, A. Flores4,
1Hematology & BMT Unit, Hospital de Especialidades, CMN “La Raza”, 2Car-
diology, Hospital de Especialidades, CMN “La Raza”, IMSS, 3Consulmed,
4Signufarma, México, Mexico
Background: Long term prognosis of patients with chronic myeloid leukemia
(CML) has significantly improved during the “age of tyrosine kinase inhibitors”,
though the occurrence of adverse events on medium and long term in patients
with chronic comorbidities, of which cardiopulmonary and metabolic diseases
must be routinely evaluated, has become a clinical concern albeit the cardiac
safety profile has been prospectively investigated. During the phase II and III
clinical trials of both first and second-line therapy, we reported our experience
in cardiologic monitoring of patients with CML treated with second-generation
TKI (nilotinib and dasatinib) on second-line therapy.
Aims: Identify clinical, electrocardiographic and transthoracic echocardiogram
alterations in CML patients treated with nilotinib or dasatinib.
Methods: Clinical evaluation, electrocardiograms and transthoracic echocar-
diogram were performed to all CML patients on treatment with nilotinib or dasa-
tinib during the period between October 2010 and January 2015, at the begin-
ning of treatment and every 6 and 12 months after that according to the occur-
rence or not of abnormalities detected at baseline. The exclusion criteria were;
clinically significant cardiac disease (congestive heart failure), left ventricular
ejection fraction (LVEF) < 45%, past myocardial infarction or unstable angina
(during the last 12 months), resting bradycardia (< 50 beats/min), left bundle
branch block, ventricular bypass, acquired or congenital long QT syndrome
(including family history), QTcF interval >450 msec, patients taking medications
that could extend the QT interval and those who could not discontinue their
treatment before initiating nilotinib or dasatinib. The doses used of tyrosine
kinase inhibitors were 400 mg every 12 hours for nilotinib and 100 mg every 24
hours for dasatinib per os.
Results: Baseline characteristics and electrocardiogram and transthoracic
echocardiogram abnormalities are shown on table 1, along with the identified
changes in the monitoring during treatment of the clinical, electrocardiogram
and transthoracic abnormalities recorded.
Table 1. 
Summary and Conclusions: The cardiac adverse events in patients with CML
undergoing treatment with second-generation TKI are not common and may be
related to factors independent from treatment like age, cardiopulmonary and
metabolic comorbidities and pharmacological interactions. Treatment was dis-
continued on those patients with recurrent PAH on dasatinib dose adjustment,
though there was a temporary suspension in one nilotinib patient due a severe
PAH, extended QT syndrome was not observed in any of the patients, however
8 patients undergoing treatment with dasatinib (16%) showed PAH (2 severe, 2
mild, and 4 slight), 5 were temporary suspensions and 2 resulted in definitive
suspensions due severe PAH; In our experience the results do not differ signif-
icantly from the international publications. To our knowledge is the first report to
adverse events in México for PAH secondary to second-generation TKIs.
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EVALUATION OF PLURIPOTENT MARKERS IN CELLS OBTAINED FROM
DIFFERENT HUMAN HEMATOPOETIC SOURCES
D.D. Çelik1,* S. Kuruca1, M. Aktan2, Z. Çelebi3
1Department of Physiology, 2Internal Medical Science, Demartment of Hema-
tology, İstanbul University Faculte of Medicine, 3Gynecology and Obstetrics,
Zeynep Kamil Women and Children Diseases Training and Research Hospital,
İstanbul, Turkey
Background: Clinical use of hematopoetic stem cells (HSC) is a developing
field for treatment of most hemoglobinopaties, hereditary blood diseases and
cancers. Even though use of HSC’s are practical they are not as effective as
pluripotent stem cells (PSC). In last years the thought of possible presence of
PSCs in other adult tissues has become an attractive research area for search
and isolate of PSCs from adult tissues.
Aims: In our study we refined cell populations using different isolation methods.
Cells obtained from three different human hematopoetic sources and analysed
for expression of pluripotent markers like NANOG, OCT3/4 and SSEA4.
Methods: Human peripheral blood (PB), apheresis material (AM) and cord
blood (CB) were used as hematopoietic sourses. Two isolation method per-
formed to all materials. 1) Total mononuclear cells obtained by eryhtrocyte lysis
method. 2) MNC layer and erythrocyte layer were isolated with ficoll density
gradient method. The presence of pluripotent markers such as NANOG,
OCT3/4 and SSEA4 and their celullar location were detected with immunoflu-
orescence staining in all three layers. Also western blotting method used for
determinig NANOG and OCT3/4 protein expression.
Results: The results obtained from western blotting and immunofluorescence
methods showed expression of NANOG, OCT3/4 and SSEA4 proteins in PB,
AM and CB. And also immunofluorescence images demonstrated cytoplasmic
and nuclear presence of these proteins. OCT3/4 protein of immunofluorescence
determinations showed cytoplasmic locations in all layers. Futher investigations
need to be done for enlighten this protein function in hematopoetic cells
because OCT3/4 has different isoforms. NANOG protein showed cytoplasmic
location in PB and AM, both cytoplasmic and nucleic location in CB. Western
blotting results indicated that NANOG protein create a ladder pattern mostly
cause of post-translational modifications. NANOG ladder pattern also changed
between layers. These findings showed different layers had different post-
translational modifications so different type of NANOG protein.
Summary and Conclusions:As a result, these findings showed that it is nec-
essary to investigate the function of PSC markers in differentiated adult cells.
Another conclusion is, among the lysis and ficoll density gradient method, lysis
method has the highest cell recovery amount.Consequently, this study provided
us new informations and viewpoints about expression of PSC markers in adult
tissues.
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ALTERATIONS IN THE BONE MARROW MICROENVIRONMENT CAN
ELICIT DEFECTIVE HEMATOPOIESIS: COMPARISON OF APLASTIC ANE-
MIA, CHRONIC MYELOID LEUKEMIA AND NORMAL BONE MARROW.
M. Park1,* C.J. Park2, S. Jang2, D.Y. Kim3, J.H. Lee3, J.H. Lee3, K.H. Lee3,
Y.H. Lee4
1Department of Pediatrics, College of Medicine Chungbuk National University,
Cheongju, 2Department of Laboratory Medicine, 3Department of Internal Med-
icine, Asan Medical Center, University of Ulsan College of Medicine, 4Depart-
ment of Pediatrics, Hanyang University Medical Center, Hanyang University
College of Medicine, Seoul, Korea, Republic Of
Background: Normal hematopoiesis involves complex interactions between
hematopoietic cells and the bone marrow (BM) microenvironment. Examples
of extremes at both ends of dysregulated hematopoiesis are BM failure in
aplastic anemia (AA) and myeloproliferative disease such as chronic myeloid
leukemia (CML). The specific causes of and mechanisms involved in dysreg-
ulated hematopoiesis are unknown.
Aims: To better understand the interactions between hematopoiesis and the
BM microenvironment, we investigated changes in the hematopoietic stem cell
(HSC) compartment and the BM microenvironment of patients with AA (n=10),
CML in chronic phase (n=10) and normal marrow (n=10).
Methods: BM biopsy specimens were analyzed by semiquantitative immuno-
histochemistry (mean positive cell number/high power field) for osteopontin,
osteonectin, osteocalcin, nestin, stromal-derived factor-1 (SDF-1) expression,
and to identify endothelial cells, lymphocytes (CD3, CD4, CD8, CD20, CD56),
macrophage (CD169), and HSCs (CD34, CD117).
Results: The lowest numbers of HSCs were in AA specimens, and the highest
numbers were in CML specimens. The highest numbers of T and B lymphocytes
were found in normal control specimens (P<0.01). Natural killer (NK) cells were
occasionally observed in the AA specimens, but were absent from the CML and
control specimens (P<0.01). Macrophages were absent from the CML speci-
mens, whereas the number of macrophages (P<0.01) was highest in the AA
specimens. There were significant differences between the stromal cell compo-
nents of AA specimens and CML specimens. Numbers of cells positive for osteo-
pontin (P<0.01), SDF-1 (P<0.01) and nestin (P<0.01) expression were higher
in the AA than in the CML specimens. No nestin+ cells were observed in CML
specimens. Numbers of cells positive for osteocalcin (P<0.01) and osteonectin
(P=0.015) expression were higher in CML than in AA specimens. The highest
numbers of endothelial cells were in CML specimens (P<0.01).
Table 1. 
Summary and Conclusions: The BM of AA patients demonstrated increased
numbers of macrophages and NK cells, which could result in cytotoxic and/or
immune-mediated marrow damage; or, alternatively, be a consequence of HSC
injury. The BM of CML patients demonstrated decreased numbers of SDF-1-
expressing and absence of nestin-expressing cells, which may result in reduced
homing of HSCs and proliferation of malignant hematopoietic cells. There were
significant differences between AA and CML specimens in the numbers of cells
expressing osteoblast-derived extracellular proteins such as osteopontin,
osteocalcin and osteonectin. Our findings suggest that changes in the compo-
nents of the BM microenvironment might be related to defective hematopoiesis
that may lead to BM failure and/or myeloproliferative disease.
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ENDOPLASMIC RETICULUM STRESS RESPONSE IN G6PC3 DEFICIENT
WHITE BLOOD CELLS 
R. Pittner1,* G. Kriván2, Z. Lédeczi1, T. Kardon1
1Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis
University, 2Pediatric Hematology and Stem Cell Transplantatio, Szent László
Hospital, Budapest, Hungary
Background: Severe Congenital Neutropenia type 4 (SCN4) is a rare autoso-
mal recessive disease due to mutations in the glucose-6-phosphatase beta
(G6PC3) gene. G6PC3 is a typical metabolic enzyme in the endoplasmic retic-
ulum (ER) suggested hydrolyzing glucose-6-phopshate (G6P) in glucose and
phosphate. This enzyme catalyzes the final step of glycogenolysis in non glu-
coneogenic tissues like neutrophils. In the lumen of ER glucose-6-phosphate
can be metabolized by hexose-6-phosphate dehydrogenase (H6PD) as well,
which is responsible for ER redox homeostasis. The first diagnosed patient in
our country has a non-sense mutation in the first exon at position W73Term
causing a lack of G6PC3. Beyond severe inborn neutropenia and consequent
inflammatory episodes the phenotype comprises other anomalies including
congenital heart defects, urogenital anomalies prominent superficial veins,
facial dysmorphism, growth and developmental delay. 
Aims: The question arises as to what kind of disturbances can cause a defect
of a metabolic enzyme leading to developmental malignancies-beyond affecting
neutrophils? Since data are already presented in G6PC3 KO mice, we were
interested in the differences or similarities between human and rodent WBC-s.
Methods: Whole blood from healthy and patient with SCN4 was collected and
purified obtaining total white blood cell (WBC) fraction. Enzymatic and West-
ern-blot measurements were made on these protein samples.
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Results: Neutrophils from G6PC3-deficient WBC-s proved the lack of G6PC3
on Western blot, and also on the enzymatic level. Surprisingly we could not
identify any metabolic aberrations in G6PC3-deficient WBC-s. G6PC3 deficient
cells showed increased level of Grp78 and phosphorylated eIF2-α compared
to the control one. Other ER stress enzymes are still under investigation. Inter-
estingly H6PD was also decreased in the mutant cells vs. control cells. 
Summary and Conclusions: Lack of G6P reduction or hydrolysis suggests
that endoplasmic reticulum stress can be responsible for increased apoptosis
in G6PC3-deficient neutrophils. However, the involvement of the PERK-eIF2α-
ATF4 signaling pathway in SCN4 is still unclear, these alterations may at least
in part be responsible for the phenotype of G6PC3 deficiency. Our results sug-
gest that trying to maintain the ER redox environment with small molecules,
like ascorbic acid, may help in neutrophil granulocyte surviving. We continue
our investigations towards this direction. This work was supported by the Hun-
garian Scientific Research Fund OTKA 101226
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EXPANSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC STEM
CELLS ON BIOCOMPATIBLE NANOFIBER SCAFFOLDS USING
CO-CULTRE SYSTEM WITH BONE MARROW DRIVED MESENCHYMAL
STEM CELLS 
M. Mokhtari1,* A. Atashi2, M. Soleimani3
1PhD student of hematology, Department of hematology, Faculty of medical
sciences, 2Assistant professor of hematology, Department of hematology, Fac-
ulty of medical sciences, 3Associate professor of hematology, Department of
hematology, Faculty of medical sciences, Tarbiat Modares University, tehran,
Iran
Background: Hematopoietic stem cell transplantation (HSCT) is a therapeutic
approach in treatment of hematological malignancies and inability of the bone
marrow. Umbilical cord blood (UCB) known as an alternative for hematopoietic
progenitor/stem cells (HPSC) for in allogeneic transplantation. The advantage
of this source of HPSC is the low aptness of GVHD due to low number of T
lymphocytes. The main hindrance in application of HPSC derived from umbilical
cord blood is the low number of stem cells in the cord blood. So, ex vivo expan-
sion of HSCs is the useful approach to overcome this restriction.
Aims: The aim of using this systems is to produce appropriate amount of
hematopoietic stem cells, which have the ability of transplantation and long
term hematopoiesis.
Figure 1.
Methods: The routine system of hematopoietic stem cells expansion is using
expansion cytokine cocktail including, SCF, TPO and FLT3L in 2- Dimensional
(2D) microenvironment. In this microenvironment cells only affected by
cytokines and there is not any influence of cell – cell interactions. Synthetic
biomaterials such as nanofibers based on Polyethersulfone(PES) is used to
produce synthetic niches. These 3D structures leads to activation of adhesion,
proliferation and differentiation of CD34+cells with highly similarity to bone mar-
row microenvironment. Considering the important role of mesenchymal cell lin-
eages in the bone marrow hematopoietic stem cells fate through the production
of secretory factors andcell-cell interactions, in this study we used mesenchymal
stem cells seeded on the bottom surface of the nanofiber scaffolds to provide
their supportive role in hematopoietic stem cell proliferation during the three-
dimensional culture system.Accordingly, we set up four culture systems consist
of two-dimensional (2D), three-dimensional (3D),two dimensional + co-cultured
by mesenchymal stem cells (2D-CO) and three-dimensional + co-culture by
mesenchymal stem cells(3D-CO). We sorted CD34+ cell by MACS technology
and the cells were cultured in StemSpan serum-free medium containing
SCF+TPO+Flt3L.
Results: The results of this study showed that coculture of HPSC with MSC in
three dimensional scaffold could able to expand of CD34 cells with minimal dif-
ferentiation in comparison to other systems.
Summary and Conclusions: Establishing a cell culture system with maximum
similarity to the bone marrow microenvironment lead to improve culture condi-
tions and proliferation of hematopoietic stem cells. this include three-dimen-
sional (3D) nanofiber scaffold system and use of chemical molecules existing
in matrix of bone marrow.also given important role of mesenchymal stem cells
in fate of hematopoietic stem cells,using this cell resulted improved proliferation
of hematopoietic stem cells.it is recommended to additional studies for more
investigate the required characteristics of stem cells for bone marrow trans-
plantation and evaluate enhanced abilities of this system.One of the challenges
in this system is the harvesting hematopoietic stem cells amidst of of fiber scaf-
folds and mesenchymal stem cells.To overcome this problem, use of biodegrad-




EFFECTS OF STORAGE IN PARAMETERS OF FULL BLOOD COUNT (FBC)
D. Gunawardena1,* S. Jayaweera2, D. Lokumarakkala3, G. Madhubhashini3
1Heamatology, 2Depertment of Allied Health Sciences, 3Department of Allied
Health Sciences, University of Sri Jayawardenapura, Colombo, Sri Lanka
Background: It is common knowledge that the FBC has to be analyzed as
soon as possible to get an accurate result. However due to the heavy workload
and the increase demand for FBC, a delay before analysis is seen many times.
Therefore it is vital to know the storage effects that are likely to affect the FBC.
Aims: FBC is a laboratory test which is routinely done as one of the first steps
in the diagnostic workup. There is often a post collection interval before analysis
of results where external factors such as storage temperature, and the duration
of sample storage can affect the results. This study analyses the storage effects
of components of FBC at different temperatures over time.
Methods: A descriptive cross sectional study was conducted in the laboratory
of CSTH. K2EDTA blood samples were randomly taken from 102 apparently
healthy individuals aged between 20-70 years. Baseline measurements were
analyzed within 30 min of collection through a fully automated haematology
analyzer Sysmex SX 500i. Samples were divided into 3 portions and each of
them was kept at 4±2ᵒC, 23±2ᵒC and 31±2ᵒC up to 48hrs. All were repeatedly
analyzed after 6hrs, 24hrs, and 48hrs. Statistical analysis was conducted using
SPSS 17.O.
Results:Among parameters of the FBC, red cell count and haemoglobin were
stable at 40 C, 23±2ᵒC and 31±2ᵒC throughout the study (48 hrs).White blood
cell count (WBC) was increased at 31±2ᵒC and 23±2ᵒC. Machine refused to
read the differential count of some samples after 24hr of storage. Neutrophil
and Basophil counts were significantly increased with time throughout the study
in all temperatures. Storage caused a significant decline in platelet count and
an increment in MPV at all temperatures after 6hr. (P<0.05). At 40C MCV and
RDW were decreased whereas it was significantly increased at RT and 23±2ᵒC. 
Summary and Conclusions: In order to prevent variability in FBC parameters,
it is preferred to analyze the blood sample as soon as possible. For an accurate
platelet count, samples should be analyzed within 6hr. Haemoglobin remains
stable at any temperature even at 48 hr. Neutrophil count keeps increasing
with storage time at different temperatures. Differential counts were rejected
by the machine in most cases after 1day of storage.
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CLINICAL OUTCOME OF VERY REFRACTORY HODGKIN’S LYMPHOMA
F. Gaudio1,1,* F.E. Laddaga1, F.E. Laddaga1, T. Perrone1, T. Perrone1, P. Pinto1,
M. Leo1, C. Bitetto1, M.S. De Candia1, G. Ingravallo2, P. Pedote3, D. Pastore1,
G. Specchia1
1Hematology, University of Bari, 2Patology, University of Bari, 3Radiology, Uni-
versity of Bari, Bari, Italy
Background: Although Hodgkin’s lymphoma (HL) is largely curable with first-
line therapy, approximately one-third of patients will not have a complete
response to frontline treatment or will subsequently relapse. Only in 50% of
these patients will effective salvage be achieved with conventional therapies.
The prognosis is particularly poor for those patients who are refractory or
relapse following an autologous stem cell transplant (ASCT). Reduced-intensity
conditioning (RIC) is increasingly used as a potentially curative option.
Aims: We performed a retrospective analysis of 25 adult patients (15
women/10 men) with HL, who relapsed within 12 months or had progressive
disease after ASCT, in order to analyze clinical outcome.
Methods: Disease status at ASCT was complete remission in 7 patients (28%),
sensitive disease in 14 (56%), and refractory disease in 4 (16%). Median time
from ASCT to relapse was 7 months (range 0.5-11); 12 patients (48%) had
stage 3-4 at relapse/progression. B symptoms were present in 40% of the
patients, bulky disease in 20% and extranodal involvement in 56%. Treatments
following relapse/progression were the standard BEACOPP regimen in 10
patients (40%), 2nd ASCT in 5 (20%), brentuximab vedotin without further ther-
apy in 2 (8%) and RIC in 8 (32%); the therapeutic regimens used as a “bridge”
to RIC were brentuximab vedotin in 6 (24%) and bendamustine in 2 (8%).
Results: Overall response rate was 64%, including 36% complete remission
and 28% partial response. Progression occurred in 24% and 12% had stable
disease. No difference in response rate was found among the treatment regi-
mens. RIC was administered in 8 patients (4 in complete and 4 in partial remis-
sion). Estimated overall survival at 40 months was 72% for the whole popula-
tion, 88% for patients who underwent RIC and 58% for those who did not. Esti-
mated progression-free survival at 40 months was 50%; 62% for the RIC group
and 42% for the non RIC group. After a median follow-up of 36 months (range
3-84), 18 of the 25 patients are alive (72%) and 11 (44%) still in complete
remission (45% of them underwent RIC).
Summary and Conclusions: Patients with HL who fail ASCT have a very poor
prognosis, and the goal of treatment should be to ultimately refer them to RIC.
Even if several questions are still open, this approach should be proposed for
these poor prognosis patients. Brentuximab vedotin is useful in order to reduce
the disease burden before RIC.
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THERAPEUTIC RESULTS OF TUNISIAN NATIONAL HODGKIN
LYMPHOMA PROTOCOL :MDH2008 UNICENTRIC EXPERIENCE ABOUT
71 PATIENTS
F. Kallel1,* S. Mseddi1, C. Maha1, B. Hatem1, K. Olfa1, H. Ben Salah2, G. Manel1,
M. Moez1, G. Lilia2, F. Imen1, B.A. Imen1, E. Moez1
1Hematology department sfax hospital, 2Radiotherapy SFAX Hospital, Faculté
de Médecine de SFAX Unité de Recherche, SFAX, Tunisia
Background: Hodgkin lymphoma(HL) is a curable hemopathy. Several groups
have established management protocols for this disease. The Tunisian group
has adopted a third version of a national consensus: MDH2008
Aims: assessment of therapeutic response of hogkin lymphoma treated
according the national protocol HL 2008.
Methods: Between Mai 2009 and decembre 2013,71 patients were enrolled
in HL-2008 protocol (a third version of prospective trial) at the haematology
department of Hedi Chaker hospital (Sfax). HL-2008 defined 5groups : G1 :
favorable early stage, G2 : unfavorable early stage, G3 : advanced stage and
localised stage with mediastinal bulk(MTI>0.35), G4 : early stage in elderly
patients, G5 : advanced stage in elderly group. We recommanded 2 cycles
ABVD+radiotherapy (IFRT) for G1, 4 cycles of ABVD + IFRT for G2, 8cycles
of BEACOPP (4 escalated+ 4 baseline) for G3. Elderly groups recieved 6 and
8 cycles of ABVD for G4 and G5 resectively. Early assessment of response
was recommanded after 2 cycles in each group and an escalation to BEA-
COPP-R took place if response was less than 75%. The date of point is in jan-
uary 2015. Our study determine therapeutic response, the overall survival (OS),
event free survival (EFS), relapse free survival (RFS) and factors forecast
which influenced these survivals.
Results: Median age was 33 years (range16-82) with sex ratio=0.87. 62% of
patients were treated in G3, 21% in G2, 7% in G5, 6% in G1 and 4% in G4.
86% of patients were in complete response after the first line therapy. 7% of
patients were refractory. OS, EFS, RFS were respectively 91%, 82% and 92%.
5 relapse were noted. There were grade 3-4 hematological toxicities only in
patients treated with BEACOPP. 3 toxic deaths were noted 1 with escalated
BEACOPP and two with ABVD treating elderly(G5). In univariante study,
chemosensivity (2cure) and therapeutic response at the end of treatment were
2 predictive prognostic factors for OS (P=0.01, P<0.001), EFS (P<0.001,
P<0.001). Bulky mediastinal disease was a significant adverse prognostic factor
for the EFS and the RFS (P=0.03, P=0.009). 
Summary and Conclusions: Comparatively to the second version, intensive
chemotherapy for unfavorable HL(advanced stage and bulky medaistinal dis-
ease with stage II), RFS and OS are better. 
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SECOND NEOPLASMS IN LONG SURVIVORS OF HODGKIN’S
LYMPHOMA: A RETROSPECTIVE ANALYSIS IN A SINGLE CENTER
B. Rosado1,* A. Garcia1, J.A. Queizan1, S. Valencia1, C. Olivier1, R. Fisac1,
C. Navarro1, M. Vargas2, J.M. Hernandez1
1Hematology, 2Psychiatry, General Hospital of Segovia, Segovia, Spain
Background: Prolonged survival in patients with Hodgkin’s Lymphoma (HL)
seems to be associated with an increased risk of developing secondary malig-
nancies. 
Aims: Ours objectives were to describe and analyze incidence of secondary
malignancies, to detect predictors and their overall survival.
Methods: Single-center retrospective analysis of patients diagnosed and treat-
ed for LH in the period 1975 to 2015, at the General Hospital of Segovia (Spain).
Statistical analysis was performed using SPSSâ (v.15).
Results: 101 patients were analyzed. Median age was 33 years [10-88]. 59.4%
were male. 60% had an advanced stage at diagnosis (IIB-IV). The most com-
mon histology was nodular sclerosis (n=48). 82.2% patients had a favorable
prognosis (Hasenclever ≤2). 87.1% patients were treated with chemotherapy
(schedule ABVD the most used). 62.5% of patients received radiotherapy (RT)
as first-line therapy. 10 patients only received RT as single therapy. The median
follow-up was 88 months [0-422]. 16 second malignancies were detected. Medi-
an onset was 10 years [2-26]. Differences in median onset between hemato-
logic malignancies and non-hematologic (4 vs16 years) were observed, but
the difference was non stadistical significantly, perhaps due to small sample
size. Comparing patients with secondary neoplasia against the global serie,
only the stage (P=0.013) and number of deaths showed significant differences
(P=0.005). Cumulative incidence (CI) was 35% at 300 months (CI in second
malignancies is shown in Figure 1). The median overall survival stimated was
310 months in global serie (patients with second neoplasms: 300 months).
Nowadays, 71 patients (70.3%) still alive, but only 6 affected by second neo-
plasia are alive.
Figure 1.
Summary and Conclusions: HL is considered curable in a high percentage
of patients, but carries a incidence of second malignancies in long survivors
with an increased risk at 25 years of diagnosis, as happened in our series of a
single center with median onset of 16 years. A previous publication (Kg, AK.
Blood, 2014) describe an increased risk of hematologic neoplasia in patients
who had received chemotherapy with alkylating agents type MOPP plus exten-
sive radiotherapy later or with the combination chemotherapy (ABVD-MOPP).
We found similar data in our serie featuring 2 cases who were treated with
MOPP and mantle type RT, and other 2 with ABVD-MOPP. Another publication
showed higher risk associated with BEACOPP schedule, results against to our
findings: None of the 11 patients who received BEACOPP (standard or scalat-
ed) developed second neoplasia. In any case, the absence of these neoplasms
along the track (last hematologic neoplasia in 1996), may be due to the change
in therapeutic schemes and extent of RT (field involved vs extend field). Patients
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who developed non-hematological malignancies, 8 were treated with RT (all
type Mantle). Therapeutic schemes were different, but in those patients who
did not receive RT, all except one received ABVD scheme, no differences in
both arms. Appearance of secondary neoplasms in field radiation is to be
expected, as shown in our serie; however, there is also an increased risk in
patients treated with alkylating agents.
In our retrospective study of single center, stage at diagnosis proved to be a
predictor factor of development of second neoplasia related with higher mor-
tality. Therefore, our data resemble previously publications as increase in the
CI throughout evolution. Secondary malignancies may be lower with actual
therapeutic schemes although longer follow-up would be necessary.
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ENDOCRINOPATHIES AND SECOND MALIGNANCIES IN LYMPHOMA
SURVIVORS: A SINGLE CENTRE EXPERIENCE
M.P. Simula1,* A.M. Mamusa1, S. Usai1, E. Angelucci1
1Struttura Complessa di Ematologia e Centro Trapianti. Ospedale Oncologico
di Riferimento Regionale. Cagliari, Italia, ASL Cagliari, Cagliari, Italy
Background: Improvements in the treatment of both Hodgkin’s and non
Hodgkin’s Lymphomas (HL and NHL) have resulted in an increasing number
of long term survivors. But this patient’s population is at high risk of developing
serious late therapy related complications that can negatively affect their lives
or lead them to an early death. The most common secondary diseases in the
people cured from lymphomas are cardiovascular diseases, second malignan-
cies (mainly solid tumours) and endocrinopathies that in the majority of the
cases are thyroid dysfunctions.
Aims: In our institution the HL and aggressive NHL long term survivors are fol-
lowed up in a dedicated clinic since September 2014. Here we report prelimi-
nary data on second malignancies and thyroid dysfunctions.
Methods: We have collected retrospective data on thyropathies and second
tumours in 216 lymphoma survivors.
Results: We have analyzed data regarding 216 patients coming in our clinic
from 15 September 2014 to 16 February 2015, 119 were affected by HL and
97 by NHL. One hundred fifteen are females, 101 males; median age at obser-
vation is 53 (range 22-89). All of them are in complete response for lymphoma
for at least 5 years from the completions of curative therapy. Thirty patients (28
females and 2 males) had thyropathies (13.8%),namely hypothyroidism inter-
esting 25 of them and multinodular goiter in 5 cases. Twenty six had a previous
HL but only 4 developed endocrinopaties after a NHL. According to lymphoma
therapies, 26 (24 HL and 2 NHL) of them had neck and/or mediastinal radio-
therapy. They are the 26.5% of all receiving irradiation in the chest and neck;
the other 4 did not had radiotherapy. Twenty four patients (11%) experienced
a second cancer, 3 of them had 2 neoplasms, so we documented 27 second
tumours. They were: 8 breast, 7 skin basocellular, 3 colon and sigma, 3 thyroid,
2 prostatic, 1 lung, 1 bladder carcinoma, 1 testis and 1 cutaneous appendages
cancer. Regarding the previous therapies all but 2 the females with breast can-
cer had undergone to mediastinal radiotherapy; 5 out of 7 with cutaneous can-
cer developed the lesion in the sites of previous irradiation; 1 out of 3 with
thyroid cancer had mantel radiotherapy, the one with lung cancer had MOPP
chemotherapy and mantle radiotherapy; no one of the intestinal cancers had
abdominal radiotherapy, the one with urinary cancer had abdominal radiother-
apy and MOPP/ABVD regimen. Median age of breast cancer in our setting is
50.5 (range 38-70). The median time between diagnosis of lymphoma and
diagnosis of second malignancy was 21 years (range 5-41).
Summary and Conclusions: Our data confirm the incidence of thyroid dis-
eases in lymphoma survivors particularly in people with prior HL. In our Depart-
ment we described also numerous cases of second neoplasms in the lymphoma
survivors population. That outline the importance of a plan for early diagnosis
of cancers in this setting of patients.
Indolent Non-Hodgkin lymphoma – Clinical
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CLINICAL AND OUTCOME IN PATIENTS WITH ALK POSITIVE AND
NEGATIVE ANAPLASTIC LARGE-CELL LYMPHOMA 
A. Ramirez-Ibarguen1,* B. Acosta-Maldonado1, S. Rivas-Vera1
1Hematology, Instituto Nacional de Cancerologia, Mexico, Tlalpan, Mexico
Background: Anaplastic large-cell lymphoma (ALCL) accounts for approxi-
mately 3% of non-Hodgkin´s lymphomas (NHL). It is a peripheral T-cell lym-
phoma characterized by expression of CD30. Currently the WHO recognized
two kinds of ALCL based on anaplastic lymphoma kinase (ALK) expression. In
previous studies, ALK positive ALCL was associated with younger patients and
a better prognosis. The International Peripheral T-Cell Lymphoma Project Study
reported a 5 year overall survival of 70% and 49% in ALK positive and ALK
negative ALCL respectively. 
Aims: To study the clinical characteristics and outcomes of patients with sys-
temic ALK-positive and negative ALCL in our population.
Methods: We retrospectively analyzed 39 consecutive cases of ALCL referred
and treated at the Instituto Nacional de Cancerologia, México 
Results: A total of 1951 charts of NHL patients from 2008 to 2013 were
reviewed. ALCL was confirmed in 49 (2.5%). Ten patients had primary cuta-
neous anaplastic lymphoma, thus 39 patients were analyzed.
Twelve patients were ALK-positive (33%) and 27 (77%) Alk-negative. Median
aged was 26 (17-48) vs 47 years (22-76) respectively (P=0.40). Clinical char-
acteristics are shown in table 1. There were not significance differences
between groups. Seventeen patients achieved a CR (44%), 3 (8%) partial
responses, 5(13%) had refractory /relapsed disease and 14 patients (36%)
could not be evaluated for response, 12 died before treatment completion. The
median follow up was 39 months with an overall survival (OS) of 47%, median
EFS was not reached. The multivariate analysis for OS in all group identified
B2-microglobulin ≥2.7 mg/dL as the only prognosis factor (P=0.01). No differ-
ence in overall response, overall survival or event-free survival was found in
relation with ALK status.
Table 1.
ALCL ALK negative n(%) ALCL ALK positive n(%) p
Range, y
<40 7 (29) 8 (67) 0.71
≥40 17 (71) 4 (33)
Performance status 0-1 12 (52) 7 (70) 0.45
Ann Arbor stage III-IV 19 (83) 9 (75) 0.67
B symptoms 19 (83) 11 (92) 0.64
Bulky disease 9 (39) 6 (50) 0.53
Extranodal disease 11 (48) 5 (42) 0.72
Albumin ≤3.5 mg/dL 15 (65) 8 (89) 0.38
DHL elevated ≥213 UI/L 13 (56) 6 (67) 0.70
Hemoglobin ≤10 g/dL 4 (17) 3 (33) 0.37
Lymphocyte ≤1200 cel/mm3 15 (65) 7 (78) 0.68
2microglobulin ≥2.7 mg/dL 11 (50) 7 (78) 0.23
IPI score 0.56
Low/ Low-intermediate 9 (39) 5 (50)
High-intermediate/ High 14 (61) 5 (50)
Treatment
CHOP 13 (72) 6 (54) 0.039
CHOEP - 4 (36)
Other 5 (28) 1 (9)
Radiotherapy 6 (25) 7 (58) 0.050
Overall response (CR+PR) 10 (71.4) 8 (88.9) 0.61
Relapsed 7 (29) 2 (17) 0.68
3 years OS 49.5% 70% 0.38
10 months EFS 50% 80% 0.15
Summary and Conclusions: Interestingly, we found no difference in outcome
between Alk positive and negative patients. There are controversial reports about
the prognostic significance of ALK status in ALCL. Gascoyne and cols. reported
a 5 years OS of 93% vs 37%. However a GELA study did not find such a differ-
ence, while an elevated B2-microglobulin was a poor prognostic factor (OS 84%
vs 22%). We also found B2-microglobulin to be a significant prognosis factor.
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BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN FIRST LINE/
RELAPSED HCL: A SINGLE CENTRE EXPERIENCE
M. Pelosini1,* R. Riccioni1, E. Capochiani1
1Hematology, Ospedali Riuniti di Livorno, Livorno, Italy
Background: Hairy Cell Leukemia (HCL) is a low grade Non Hodgkin lym-
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phoma that presents with cytopenia and splenomegaly. Diagnosis is confirmed
by the presence of lymphocytes CD103, CD25, CD11c positive on bone mar-
row. Treatment is based of purine analogs with which patients reach an hema-
tological response. However relapse still occurs suggesting the presence of
residual disease. Recently it has been discovered the presence of B-RAF V600
mutation in HCL, and experience with B-RAF inhibitor had shown major
responses. Bendamustine experience in hematologic neoplasms lead to clinical
and long lasting response, especially in low grade lymphomas. The drugs acts
as an alkylating agent but it shares some characteristic with purine analogs. 
Aims: We previously observed its promising clinical activity with MRD eradi-
cation as well, here we report updated results. 
Methods: We treated a total of 9 patients (2011-2014) with bendamustine (60-
70 mg/ m2 days 1,2 ) in association with rituximab (375 mg/m2 day 3). Cycles
were repeated every 28 days up to 6 cycles. Before and after treatment patients
had an abdomen ultrasound and bone marrow evaluation. Complete response
was considered absence of marrow involvement and splenomegaly post treat-
ment. MRD was evaluated by cytometry or IgH rearrangement with Pcr tech-
niques. Patients’ characteristics are summarized in Table 1.
Results: Treatment was well tolerated in all patients, with neutropenia (grade
2) and skin toxicity (grade 2). One patient had to stop treatment due to pul-
monary embolism. We did not observe any serious infective complication. Over-
all response rate (ORR) was 100% with 7/9 complete response (CR) and 2/9
partial response (all in patient with relapsed disease). After a median follow up
25,7 months patients are all alive without any relapse. In evaluable patients
MRD eradication has been achieved in 5/9 cases Patients treated at diagnosis
obtained 100% CR and were MRD negative.
Table 1.
Summary and Conclusions: Here we confirmed our first report on bendamus-
tine in HCL with a longer follow up and additional cases. Results are encour-
aging and this approach is well tolerated also in elderly patients. Data of ben-
damustine in HCL as first line therapy are not yet described in literature and in
our experience results are at least comparable to those with purine analogs.
First data on MRD are interesting as well. Future will bring B-RAF inhibitors
which are not still available and with whom resistance has already been
described, but in the in the meanwhile bendamustine could be suggested as a
treatment option for HCL patients.
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EXPERIENCE WITH VEMURAFENIB IN THE TREATMENT OF HAIRY CELL
LEUKEMIA 
E. Sari1,* K. Baghy2, I. Kovalszky2, C. Bödör2, H. Rajnai2, J. Csomor2, Z. Nagy1,
J. Demeter1
11st Department of Internal Medicine, 21st Department of Pathology and Exper-
imental Cancer Research, Semmelweis University, Budapest, Hungary
Background: Targeted inhibitory therapy with first line BRAF-inhibitors has been
used successfully in HCL patients refractory to or relapsing following previous
lines of therapy, including cladribine and rituximab. Careful selection of eligible
patients is mandatory since vemurafenib might cause secondary skin malignan-
cies, photosensitivity, QTc-prolongation, liver enzyme elevations and arthralgia.
Nevertheless, vemurafenib treatment has the advantage of perfect oral bioavail-
ability, possibility of outpatient treatment, and the lack of hematological toxicity.
Aims: Treatment of relapsed/refractory hairy cell leukemia patients is a chal-
lenging task. We report on our experience gained with vemurafenib, a treatment
option targeting the disease-defining genetic event, the BRAF V600E mutation.
Methods: Since 2012 January, six out of our 75 hairy cell leukemia patients
were found to be refractory to at least two or three lines of therapy or relapsed
repeatedly following previous treatments and thus were candidates for vemu-
rafenib treatment. The National Institute for Quality and Organizational Devel-
opment in Healthcare and Medicines permitted the off label use of vemurafenib
in each case. All patients were male, median age was 67 yrs (40-83). One
patient was refractory to four previous lines of therapy, the other patients
relapsed, on average three times (2-6), and were ineligible for cladribine treat-
ment (4/6 patients) or had cladribine-intolerance (1/6). Before starting vemu-
rafenib, every patient underwent a dermato-oncological and ophtalmological
screening. Treatment was planned for 56 days with 240 mg BID regime. Three-
four months after treatment splenic ultrasound and bone marrow biopsy were
performed to assess the response.
Results: Treatment lasted for 56 days, starting dosage was 240 mg BID. Three
of six patients had no complaints during therapy. In two cases asymptomatic
and reversible indirect hyperbilirubinaemy was detected without any other clin-
ical signs of hemolysis of hepatic transaminase elevation. Dosage modification
(240 mg once a day) was indicated in a patient with reversible grade 1 toxico-
derma. In one case treatment was interrupted arbitrarily by the patient after 14
days because of grade 3 arthralgia. In another patient vemurafenib was with-
hold for 10 days because of community acquired pneumonia. Treatment
responses were as follows: partial remission in 4/6, minor response 1/6, and
still not evaluable in a recently treated patient A 83 year old patient received
vemurafenib treatment for only 10 days when he had to be hospitalised due to
progressive cardiac decompensation anaemia, renal insufficiency and hyper-
uricaemy. The patient died a few days later due to cardiac cause, an autopsy
report was not available. Interestingly, in an 80-ys-old patient vemurafenib
treatment resulted in gradual and stable normalisation of blood counts while
the degree of bone marrow infiltration decreased from the initial 90% only to
70% at three months after having finished therapy. With a median follow up
time of 12 (1-22) months until now we observed no overt relapse in our HCL
patients treated with vemurafenib.
Summary and Conclusions: Vemurafenib offers a feasible outpatient treat-
ment option for relapsed/refractory patient without hematologic toxicity. Ques-
tions to be answered in prospective studies are the optimal dosage and duration
of vemurafenib, retreatment and the possibility to combine treatment with a
MEK inhibitor.
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PREVALENCE OF HEPATITIS B REACTIVATION IN PATIENTS WITH
INDOLENT NON HODGKIN LYMPHOMA CD20+ DURING MAINTENANCE
THERAPY WITH RITUXIMAB
G. Giagnuolo1,* M. Raimondo1, C. Cimmino1, R. Della Pepa1, S. Luponio1,
G. Beneduce1, C. Cerchione1, M. Masarone2, M. Persico2, F. Pane1,
A. De Renzo1
1Hematology Division, Department of Biochemistry and Medical Biotechnology,
university of Federico II, Naples, 2Internal Medicine and Hepatology Unit, Uni-
versity of Salerno, Salerno, Italy
Background:Anti CD20 antibody (Rituximab) based chemotherapy regimens
increase the HBV reactivation risk although sporadic HBV reactivation cases
are reported in patients on maintenance with Rituximab single therapy. We
evaluated how many reactivation occurred among patients Hepatitis B core
antigen positive (HBcAb+) and Hepatitis B surface antigen negative (HBsAg-)
who received maintenance therapy with Rituximab.
Aims: The aim of this study is to assess the prevalence of HBV reactivation
among patients HBcAb+/HBsAg- during maintenance therapy with Rituximab.
Methods: Here we report our experience about 98 patients with indolent non
Hodgkin Lymphoma CD20+ who received maintenance therapy with Rituximab
(schedule: 375 mg/mq every 2 months for 2 years) from January 2007 to Jan-
uary 2015. Patients received different chemotherapy regimens during induction:
45% (44/98) with R-CHOP, 34% (33/98) with R-FN, 13% (13/98) R-Bendamus-
tine, 3% (3/98) with R-Fludarabine, 3% (3/98) with R-Leukeran and 2% (2/98)
with Rituximab monotherapy. We performed blood tests for HBV (HBsAg,
HBsAb, HBeAg, HBeAb, HBcAb) in all patients before starting maintenance
therapy and liver function tests before each administration of Rituximab. None
of these patients received prophylactic therapy with antiviral drugs during induc-
tion and maintenance therapy.
Results: 32% of the patients (32/98) were HBcAb positive. 58% of the patient
(57/98) completed therapy with Rituximab and 30% of them (17/57) were
HBcAb positive; one of these patients occurred HBV reactivation. 42% of the
patients (41/98) are still in maintenance therapy and 36% of them (15/41) were
HBcAb positive with risk of HBV reactivation too.
Summary and Conclusions: In patients HBcAB+/HBsAg- treated with Ritux-
imab in single therapy is indicated the prophylaxis with lamivudine. In our single
centre experience HBcAB+/HBsAg- patients didn’t received therapy with antivi-
ral drugs during maintenance therapy with Rituximab; one of our patient
occurred HBV reactivation. In terms of cost-benefit, we reported an advantage
in the monitoring approach that was used in our patients in respect to universal
prophylaxis with a total savings of about € 3.400,00 for each patient. More
study are necessary to estabilish the clinical utility of prophylactic therapy with
lamivudine during the maintenance therapy with Rituximab.
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ARE THE FOLLICULAR LYMPHOMAS CURABLE DISEASES? RETRO-
SPECTIVE STUDY ON 146 PATIENTS WITH AT LEAST 10 YEARS OF
OBSERVATION
L. Rigacci1,* F. Lancia1, S. Kovalchuk1, L. Mannelli1, G. Benelli1, B. Puccini1,
A. Bosi1
1Haematology, AOU Careggi, Firenze, Italy
Background: Follicular lymphomas are usually defined as incurable diseases
with a natural history characterized by several relapses. This study was
launched to evaluate how many patients, after a long observation period, don
not relapse or do not experience a new chemotherapy treatment.
Aims: We aim to identify which clinical characteristics or therapeutical
approaches are associated with this cohort of favourable patients.
Methods: All patients with histologically confirmed diagnosis of follicular lym-
phomas grade I-II or IIIa were selected from our data base starting from January
2000 untill December 2004 in such a way to have at least 10 years of obser-
vation for alive patients. We divided patients in two cohorts, cohort 1 with
patients relapsed or progressed and cohort 2 with patients never relapsed or
progressed.
Results: From January 2000 to December 2004, 146 patients were diagnosed
and treated in our Institution. Thirteen patients were excluded from the analysis,
8 because of lost to the follow-up and 5 did not obtained at least a partial remis-
sion. Finally 133 patients were selected for the study. The median age at diag-
nosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone
marrow biopsy was positive in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI
3 in 40 and FLIPI 4 in 15 patients. According to treatment 96 patients were
treated with antracycline containing regimens, 24 with fludarabine containing
regimens and 13 were observed or treated with radiotherapy. Rituximab was
used in 92 patients, as sequential treatment in 70 or chemotherapy combined
in 22; 41 patients did not use rituximab. Patients relapsed or progressed rep-
resent cohort 1 (85 patients) and those without relapse or progression represent
cohort 2 (48 patients). The statistically significant differences between the two
cohorts were: elderly patients (P 0.05), symptomatic patients (P 0.05), FLIPI
and FLIPI2 high score (P 0.005), lack of complete remission (P 0.0000) all
observed in cohort 1. The overall survival with a median period of observation
of 115 months (range 2-185) was 71%, considering the two groups the overall
survival in cohort 1 was 62% with a median of 142 months and it was 94% in
cohort 2 with median not reached. In univariate analysis normal value of beta2
microglobulin (P 0.05) and the use of rituximab (P 0.01) were associated with
a better overall survival; in multivariate analysis treatment with rituximab man-
teined a statistically significance.
Summary and Conclusions: In conclusion this retrospective monocentric
study confirms that about one third of follicular lymphoma patients could be
considered cured particularly if rituximab was used in the treatment. At the
present time all patients with follicular lymphoma are treated with combined
immuno-chemotherapy, moreover after induction therapy patients are started
on manteinance. We can therefore hope for the future in an improvement of
survival results.
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A RETROSPECTIVE ANALYSIS OF SPLENIC MARGINAL ZONE
LYMPHOMA: PROGNOSTIC FACTORS, ROLE OF WATCH AND WAIT, AND
THERAPEUTIC APPROACHES IN THE RITUXIMAB ERA
S. Perrone1,* G.M. D’Elia1, G. Annechini1, P. D’Urso1, C. Stefanizzi1, R. Foà1,
A. Pulsoni1
1Hematology, Department of Cellular Biotechnologies and Hematology.,
Sapienza University, Rome, Italy
Background: Splenic marginal zone lymphoma (SMZL) is an indolent lym-
phoma recognized as a distinct entity in the WHO classification. Arcaini’s scoring
system (Blood, 2006)-based on Hgb<12 g/dL, albumin<3.5 g/dL, elevated LDH-
is useful to stratify patients prognostically. Given the lack of standard criteria
guiding treatment initiation, the watch and wait (W&W) approach in asympto-
matic patients is recommended. In symptomatic patients it has been suggested
that, apart from splenectomy, rituximab +/- chemotherapy is the best option.
Aims: The aims of our study were to identify risk factors at diagnosis, to assess
the progression rate within a W&W strategy, and to analyze the outcome of dif-
ferent therapies in the post-rituximab era.
Methods: : We retrospectively examined the clinical files of 83 patients with
SMZL managed at our center in Rome between 2000 and 2013. Patients were
stratified according to Arcaini’s scoring system. Asymptomatic patients were
managed with a W&W policy. Splenectomy was performed in 21 patients with
a symptomatic spleen enlargement and limited bone marrow or nodal involve-
ment. Patients not eligible for a splenectomy or with a more generalized disease
were treated with chemotherapy alone (12) and, after its introduction, with rit-
uximab + chemotherapy (R-chemo) (8).
Results: The median age at diagnosis was 66 years. The male/female ratio
was 1.1. HCV antibodies were positive in 3.7% of cases. The 10-year overall
survival was 93% (CI: 84.7-100%). Notably, no patient died of disease progres-
sion. The 5- and 10-year progression-free survival (PFS) were 77% and 62%,
respectively. In univariate analysis, negative predictors of a worse PFS were
splenomegaly (>18 cm) and bone marrow infiltration (>30%). Patients with a
low Arcaini score had a better 5-year PFS (87%) than those with an intermediate
(76%) or high (44%) risk score (P value=0.01). Fifty asymptomatic patients
underwent a W&W program. The median PFS of this population was 45 months;
at 10 years, 17% of patients are still on W&W (Figure 1). Sixty-five patients,
either at diagnosis or after a W&W period, were treated; those treated with
splenectomy or R-chemo first line had similar results, while those treated only
with chemo had an inferior outcome. However, when analyzing separately
patients with a score<1, splenectomy alone resulted in a highly significant PFS
advantage compared to the other treatment approaches (Figure 2).
Figure 1.
Figure 2.
Summary and Conclusions: This real-life single center study offers an insight
into the natural history of indolent SMZL, confirming its very good prognosis. We
found a negative prognostic impact of a marked splenomegaly and marrow infil-
tration. At variance from previous reports, we did not observe a high prevalence
of HCV, especially as this is a Center/South-Italian case series. Moreover, we
confirm that Arcaini’s staging system, that defines 3 separate risk groups, is a
powerful prognostic stratificator. The W&W approach allows a median PFS of 45
months, longer than that reported in follicular lymphoma patients. Finally, our
data confirm the inferiority of chemotherapy alone against splenectomy and R-
chemo. The subgroup of low risk patients treated only with splenectomy fared
very well. For such patients, splenectomy could remain the best first-line approach
even in the rituximab era. Prospective studies are needed to confirm these results.
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SINGLE-AGENT IBRUTINIB DEMONSTRATES LONG-TERM ACTIVITY AND
SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY WALDEN-
STRÖM’S MACROGLOBULINEMIA
R. R. Furman1,* E. Bilotti2, T. Graef2
1Division of Hematology and Medical Oncology, Weill Cornell Medical College,
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Background: Bruton’s tyrosine kinase (BTK) is an essential component of the
B-cell receptor pathway and functions via the activation of downstream signals
mediating B-cell growth, adhesion, and survival. Ibrutinib, a first-in-class, once-
daily, oral, covalent inhibitor of BTK, has emerged as an attractive treatment
option for patients with Waldenström’s macroglobulinemia (WM). Recently,
ibrutinib was approved by the FDA for the treatment of WM, representing the
first FDA-approved agent in WM. The first-in-human trial of ibrutinib was an
open-label, phase 1 study in patients with relapsed/refractory (R/R) B-cell malig-
nancies including WM (Advani, J Clin Oncol. 2013) and demonstrated encour-
aging activity of ibrutinib (75% overall response rate) in WM, thus initiating fur-
ther studies.
Aims: To report long-term activity and safety outcomes of ibrutinib in 4 patients
with R/R WM who enrolled in this phase 1 study and then continued into an
extension study.
Methods: All patients provided written informed consent before enrollment.
Four patients with R/R, histologically confirmed WM and adequate hematologic,
renal, and hepatic function received oral ibrutinib between 560 mg/day and
12.5 mg/kg/day until progressive disease or unacceptable toxicity. Patients
were required to have IgM levels ≥1000 mg/dL with bone marrow infiltration.
After 6 months of therapy, patients with objective response or stable disease
were rolled over from the parent study (PCYC-04753) into the extension study
(PCYC-1103-CA) at a fixed dose of ibrutinib 560 mg daily. Adverse events
(AEs) were assessed by NCI CTCAE v3.0. In the 1103 study, only data on AEs
grade ≥3, serious AEs (SAEs), and AEs leading to dose modification or dis-
continuation were captured. Disease response assessments included labora-
tory assessments (serum IgM) and radiographic imaging when applicable. Best
clinical response was assessed per the 3rd International Workshop of WM
(IWWM).
Results: Three of 4 WM patients achieved durable partial responses accom-
panied by ≥50% reductions from baseline in IgM levels (~80% to 90%), which
reached a plateau after 1 year of therapy. Responses are ongoing after 4 years
of therapy with no evidence of progression in other clinical features attributed
to WM. Additional clinical improvements included sustained increases or sta-
bilization in hemoglobin levels (without the use of erythropoietic growth factors
or transfusion); reduction in lymphadenopathy (present in 3 of 4 patients at
baseline); and improvement in hematocrit over time. Grade 3/4 AEs included
neutropenia (1 patient) and thrombocytopenia (1 patient), and SAEs included
febrile neutropenia (2 patients), pneumonia and pneumonitis (1 patient), and
atrial fibrillation (1 patient). In addition, the same patient experienced a second
episode of grade 2 atrial fibrillation (not an SAE), leading to dose modification
to ibrutinib 420 mg daily. All grade 3/4 AEs and SAEs were resolved without
sequelae and were assessed by the investigator as unrelated to ibrutinib.
Summary and Conclusions: This case series is the first to demonstrate
extended activity and tolerability of ibrutinib in R/R WM, accompanied by early
and rapid decline in IgM levels and increase in hemoglobin levels. Single-agent
ibrutinib induced profound and durable responses, with a favorable safety pro-
file, in this difficult-to-treat patient population—consistent with findings of a
phase 2 trial (Treon, IWWM, 2014).
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BENDAMUSTINE IN ELDERLY PATIENTS WITH INDOLENT
NON-HODGKIN’S LYMPHOMA: A REPORTED EXPERIENCE IN ROUTINE
PRACTICE ON 76 PATIENTS
A. Razurel1,* S. Amorin2, M. Tiv3, M. Zine2, L. Biard3, S. Harel2, P. Brice3,
I. Madelaine1, C. Thieblemont2
1Pharmacy, 2hemato-oncology, 3Biostatistics and Medical Information, Saint-
Louis Hospital, Paris, France
Background: The combination of bendamustine and rituximab (RB) has been
shown to be an appropriate option for first line treatment or treatment for
relapsed / refractory patients (pts) with indolent non-Hodgkin’s lymphoma (NHL)
and Chronic Lymphocytic Leukemia (CLL). 
Aims: The objective of this retrospective study was to compare the toxicities
of RB between pts<65y and ≥ 65y among pts with indolent NHL or CLL in
relapse. 
Methods: Analysis was performed retrospectively on pts treated with RB
between January 2009 and December 2013 in relapse. The treatment consist-
ed of rituximab (375 mg/m2 D1) and bendamustine (90 mg/m2 D1-2) every 28
days. Fisher and Wilcoxon tests were used, and the probability of adverse
event (AE) during cure was compared according to the age in generalized
linear mixed models. 
Results: Among the 76 pts included, 41 pts (54%) were<65y (median age=
57y, range 33-64), and 35 pts (46%) ≥65y (median age= 74y, range 65-80). In
the cohort of pts<65y, 33 pts presented with indolent NHL (24 FL, 6 MZL, 2
SLL, 1 tricholeucocyte), 7 pts CLL, 1 MCL. In pts ≥65y, 26 pts presented with
indolent NHL (15 FL, 7 MZL, 3 SLL, 1 Waldenström), 8 pts CLL and 1 MCL.
The PS was ≥2 in 18% of pts<65y vs 32% of pts ≥65y, with high LDH in 29%
vs 53% of pts. The median number of prior treatments was 4 in<65y and 6 for
≥65y. Fifty-seven (75%) pts received at least 4 cycles of RB and 34 (45%) pts
at least 4 cycles, corresponding to 344 cycles overall (179 (52%) in pts<65y
and 165 (48%) in pts ≥ 65y). Eighty-six percent of pts had at least one AE
during their treatment, wich was G3/4 in 47% of the pts. The occurrence of
G1/4 AE per cycle was 51% in the whole cohort without significant difference
between age groups (53% and 49%, respectively in pts<65y and pts ≥65y,
P=0.65). Among them, AE was noticed grade (G) 3/4 in 50 cycles corresponding
to 28 (16%) cycles in pts<65y and 22 (13%) in pts ≥65y (P=0.64). Hematotox-
icity was present in 29 pts (70%)<65y and 27 pts (77%) ≥65y. Probability of
hematotoxicity per cycle was 20% for<65y and 18% for ≥ 65y (P=0.70). Throm-
bocytopenia and neutropenia were the most frequent G3/4 hematotoxicity,
occurring in 12% and 17% of the pts<65y and pts ≥65y respectively. Nausea
affected 34% of pts<65y vs 43% pts ≥65y. Twenty-seven percent of pts<65y
and 31% pts ≥65y developed infections. Pulmonary toxicities G1/4 with bron-
chitis were rare (3% per cycle) but significantly more frequent in pts ≥65y, 5%
per cycle compared to pts<65y, 1% per cycle (P<0.036). A dose adjustment
was required for 10 pts (24%)<65y related to thrombocytopenia in 7 pts; the
same happened to 12 pts (34%) ≥65y, because of thrombocytopenia, deep
neutropenia, cutaneous rash G3, maculopapular rash, severe sepsis or diges-
tive disorder. Treatment was discontinued in 13 (32%) pts<65y (4 pancytopenia,
2 thrombocytopenia, neutropenia G4, 1 severe sepsis and 1 pneumonitis) and
in 11 (31%) pts ≥65y (4 fever infections (bronchitis), 2 febrile aplasia, 1 cuta-
neous rash G3, 1 pancytopenia, 1 thrombocytopenia, 1 mucositis G3 and 1
gastrointestinal intolerance) (P=1). 
Summary and Conclusions: The toxicities of RB combination and their prob-
abilities do not differ significantly with the age, except for respiratory disorders.
Bronchitis G1/2 appears to occur more frequently in pts ≥ 65y. This has to be
noticed in the perspective of association of BR with new agents such tyrosine
Kinase inhibitors that may increase this risk of pulmonary toxicity in elderly
patients.
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INCIDENCE OF SECONDARY PRIMARY NEOPLASM IN A COHORT OF
PATIENTS WITH FOLLICULAR LYMPHOMA. A SINGLE CENTER REPORT
M. M. Andrade Campos1,* E. Colorado Ledesma2, N. Espinosa3, P. Giraldo4 
1Traslational Research Unit. CIBERER. IIS-A, Hematology. Miguel Servet Uni-
versity Hospital., 2Hematology, 3Miguel Servet University Hospital., 4Trasla-
tional Research Unit. CIBERER., IIS-A. FEEHA, Zaragoza, Spain
Background: Follicular lymphoma (FL) account approximately one third of all
non-Hodgkin lymphomas, it is know that primary affect males and white popu-
lation; also is established that any patient diagnosed for a primary cancer have
an increased risk to be diagnosed for a second primary neoplasm (SPN),
respect to follicular lymphoma there are few reports about a 25% increased
risk for all non-Hodgkin lymphomas not related with histologic subtype. Although
is recognized that chemotherapy, radiotherapy and radioimmunotherapy (RIT)
increased this risk; there are recent reports about the use of radioimmunother-
apy with 90Y-Ibritumomab-Tiuxetan (90Y-IT) that show an increased risk for
SPN. RIT is available in our center since 2005 and we have been accumulated
a long experience. Considering this we analyze our data and compare the inci-
dence of SPN in all patients with FL treated in our institution with different
schedules including or not 90Y-IT.
Aims: To analyze the incidence of second primary neoplasm in FL patients
diagnosed and treated in our center, searching for relationship with RIT
Methods: A chart review was carried using the registry of diagnosed patients,
from the Department of Hematology, all consecutive patients diagnosed of Fol-
licular lymphoma of any grade according to WHO since 2001 were included, a
review of clinical records: demographic and clinical data, incidence of previous
cancer and therapies, SPN (basocellular skin and in situ cervix carcinoma were
excluded), number of chemotherapies, relapses, therapy with 90Y-IT, actual
status and cause of dead were recorded. 
Results: A total of 251 FL patients were registered, Male/female ratio: 107/144,
mean age 59.9 years (15-86), Stage I: 7.2%, II: 11.0%, III: 24.1%, IV: 57.8%,
FLIPI: Low-risk: 62.15%, Intermedium: 13.9%, High-risk: 10.3%. A 27.8% of
patients receiving two or more chemotherapy schedules, 10,5% had underwent
an auto-SCT. 100 patients (39.8%) received 90Y-IT (55 as a 2nd or 3rd line of
therapy and 45 as a consolidation therapy). The mean follow-up for all patients
is 108 months (median 49 m). Respect to incidence of neoplasms we found
that 38 (15.1%) patients have a registry of at least 2 primary cancers, in 16
(42.1%) of them FL diagnosis were the second primary neoplasm. In the 22
patients who developed a SPN after FL diagnosis, 11 had been received two
or more lines of therapies and 5 of them including RIT.
According to relationship with 90Y-IT, in 3 SPN were diagnosed before the use
of RIT and in one at the same time of RIT, and in 8 patients the diagnosis of
SPN occur after RIT at a mean time of 32.3 months. For all patients the SPN
were recorded at a mean time of 24.5 months after FL diagnosis.
Summary and Conclusions: Even this work is a single institution reports,
summarize relevant information outside clinical trials about the incidence of
second primary neoplasm in one cohort of follicular lymphoma patients treated
(100) or not (151) with 90Y-IT. In our experience 90Y-IT not increase signifi-
cantly the risk of SPN. A more exhaustive analysis will be presented in case of
acceptance.
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COMBINATION OF FLUDARABINE, MITOXANTRONE, DEXAMETHASONE
AND RITUXIMAB (R-FND) IN THE TREATMENT OF INDOLENT NON-
HODGKIN B CELL LYMPHOMA-RETROSPECTIVE STUDY OF 60 CHINESE
PATIENTS
T. Chan1,* G. Harinder Singh2, H. Yu Yan1, T. Eric Wai Choi2, K. Yok Lam3
1Department of Medicine, 2Department of Medicine, 3Medicine, Queen Mary
Hospital, Hong Kong, Hong Kong
Background: Indolent non-Hodgkin B cell lymphomas (NHL) are a group of
lymphoid malignancies that typically follows a protracted clinical course with
frequent relapses. Although it is generally considered incurable, effective treat-
ment regimens exist. The combination of fludarabine, mitoxantrone and dex-
amethasone (FND) resulted in high complete remission (CR) rate in the pre-
rituximab era. Data are scarce on whether the addition of rituximab (R-FND)
would result in a better CR rate or longer remission. Moreover, this combination
has never been properly evaluated in Chinese patients, a population that report-
edly has a much lower prevalence of indolent NHL.
Aims: To determine the efficacy of RFND regimen in indolent lymphomas in
Chinese patients
Methods: Consecutive patients who are diagnosed with indolent NHL (follicular
lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and low
grade B cell lymphoproliferative disease (B-LPD) not otherwise classified) were
recruited into this retrospective study from January 2012 to December 2014.
The R-FND regimen (Rituximab 375mg/m2 on D1, Fludarabine 40mg/m2 daily
D1-3, mitoxantrone 10mg/m2 on D1 and dexamethasone 20mg daily D1-5) was
used as frontline treatment in our institution. Baseline demographic data were
collected. Response rate and toxicity of the regimen was evaluated. Overall sur-
vival and progression free survival was analyzed using Kaplan-Meier method.
Results: Sixty patients (29 men, 31 women) (follicular, N=22; marginal zone lym-
phoma, N=27; lymphoplasmacytic lymphoma, N=4; B-LPD not otherwise classi-
fied, N=7) at a median age of 61 years were treated, with R-FND given as frontline
therapy in 50 patients and salvage therapy in 10 patients. Stage III/IV disease
occurred in the majority of the cases (N=42, 70%). The median follow up time
was 23 months. Complete remission (CR) was achieved in 49 out of 59 evaluated
patients (83.1%), and partial remission (PR) in 8 patients (13.6%), giving an over-
all response rate (ORR) of 96.7%. The response was also durable, with a pro-
gression free survival at 2 years of 81.3%. The overall survival at 2 years was
93.4%. Haematological toxicities were the most common adverse effects, with
grade III/IV anaemia, neutropenia and thrombocytopenia being 10%, 88% and
17% respectively. Clinically significant cytomegalovirus (CMV) reactivation
occurred in 8 patients (13%) with 2 of them developing CMV retinitis.
Summary and Conclusions: R-FND is a highly effective regimen with high
CR rate and long duration of remission. However, due care should be taken
with respect to haematological toxicity.
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A MULTICENTER, RETROSPECTIVE ANALYSIS OF LOW-GRADE
PRIMARY FOLLICULAR LYMPHOMA OF THE GASTROINTESTINAL
TRACT: TREATMENT AND OUTCOME 
J.Y. Lee1,* H. Cho1, J.W. Cheong1, Y.H. Min1, S.I. Lee2, C. Suh3, Y. Park4,
D.H. Yang5, J.S. Kim1
1Internal medicine, Severance hospital, Seoul, 2Internal medicine, Dankook
University College of Medicine, Cheonan, 3Oncology, University of Ulsan Col-
lege of Medicine, Asan Medical Center, 4Internal medicine, Korea University
College of Medicine, Seoul, 5Hematology-Oncology, Chonnam National Uni-
versity Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic Of
Background: Primary gastrointestinal (GI) follicular lymphoma (FL) has been
regarded as a relatively rare malignant disease, accounting for 1-3.6% of pri-
mary non-Hodgkin lymphomas of the GI tract. The primary FL of the GI tract
occurs most often in middle-aged adults with a 2:1 female predominance. The
most frequent primary occurrence location is duodenum. The low-grade primary
FL of the GI tract which is especially located at duodenum characterized as an
indolent. Although the various therapeutic strategies have been developed for
FL, there is no definite guideline for the treatment of low-grade primary FL of
the GI tract.
Aims: In this study, we analyzed our experience of low-grade primary FL of the
GI tract according to the treatments.
Methods: A total of 12 patients who diagnosed as a low-grade primary FL of
the GI tract between June 2005 and June 2014 from 5 institutions in Korea
were retrospectively analyzed. Low-grade primary FL of the GI tract was defined
as Lugano stage I or II and WHO histologic grade 1 or 2. Endoscopy and
immunohistochemical pathologic work-up were performed at diagnosis. The
patients were classified according to the treatment strategies such as watch &
wait group (n=4) and treatment group (n=8). Treatments included various
chemotherapies (CTx) and radiotherapy (RTx).
Results: Median age was 44 years (range, 33-66) and a female predominance
was observed (male:female=4:8). All patients had an Eastern Cooperative
Oncology Group (ECOG) performance score of 0 or 1. The most common rea-
son for initial evaluations of primary FL of the GI tract was health screening
(n=10, 83.3%). Only two patients received initial evaluations due to GI symp-
toms. The small intestine, especially the 2nd or 3rd portion of duodenum was
the most common primary site of involvement (n=8, 66.6%). There were similar
clinical characteristics between the two groups. Exceptionally, white blood cell
(WBC) count (P=0.024) at diagnosis was higher in the treatment group. The
primary site of involvement was not different between the two groups. However,
the only primary site of the watch & wait group was duodenum (n=4, 100%). In
the watch & wait group, the maintenance of stable disease status was observed
in all patients. However, one patient in the watch & wait group eventually
received additional RTx after the initial observational period of 19.4 months
according to the decision of the attending physician. In the treatment group,
two patients received CTx such as CVP (cyclophosphamide, vincristine and
prednisone, n=1) or CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisone, n=1) and six patients received RTx (median 3600 cGy, range,
2520-4140). These eight patients in the treatment group achieved complete
remission (CR) after treatment, but one patient with low-grade primary FL of
the rectum who received 6th cycles of CVP CTx relapsed at 30.5 months after
achieving 1st CR. She received 4 cycles of weekly rituximab monotherapy and
re-achieved CR. After a median follow-up of 33.1 months (range, 3.6 to 107.7
months), all 12 patients were alive.
Table 1. Clinical characteristics of primary follicular lymphoma of the GI
tract.
Summary and Conclusions: In this study, we confirmed that the watch & wait
strategy was safe in low-grade primary FL of duodenum. In addition, radiation
alone also was an appropriate strategy for the low-grade primary FL of the GI
tract. However, close monitoring would be necessary for the patients with non-
duodenal site of the low-grade primary FL. Further studies with more patients
would be needed to confirm appropriate treatment strategies for the low-grade
primary FL of the GI tract.
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RITUXIMAB INDUCES HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH
NON HODGKIN LYMPHOMA
R. Della Pepa1,* A. De Renzo1, A. Pecoraro2, S. Luponio1, G. Giagnuolo1,
G. Beneduce1, I. Migliaccio1, M. Raimondo1, N. Pugliese1, D. Salvatore1,
C. Cimmino1, F. Pane1, G. Spadaro2
1Hematology, 2Medical Translational Science, Federico II University, Naples,
Italy
Background: Rituximab (R) is a monoclonal antibody that binds the CD20
antigen on all peripheral B cells. Its favorable toxicity profile and effectiveness
have led to its wide use in induction and maintenance regimens for Non Hodgkin
Lymphoma (NHL). 
Aims: This retrospective single center study aimed to evaluate the hypogam-
maglobulinemia (hypoIg) associated with R use.
Methods: We performed serial quantitative serum immunoglobulin (SIg) con-
centration at the baseline, after chemotherapy, during and after R maintenance
therapy.
IgG, IgA and IgM deficit were respectively defined by level below 700 mg/dL,
70 mg/dL and 40 mg/dL. Symptomatic patients were defined as having 2 or
more non-neutropenic infections in a 6-month period after or during R. 
Results: 123 patients with indolent NHL and SIgG studies were analyzed,
47,1% were relapsed or refractory. The median age of patients was 60 years
(range: 28-80). The histologies included follicular lymphoma (FL) (n=77), small
lymphocytic lymphoma (SLL) (n=14), marginal zone lymphoma (ML) (n=20),
mantle cell lymphoma (MCL) (n=12). Patients received a median of 13 doses
of R (range: 6-27). The median follow-up of surviving patients was 4,4 years.
Before treatment with R, 11/123 (8,9%) had low SIgG levels (5 FL, 1 MCL, 4
SLL, 1ML) and 3/11 (27,2%) required, during R maintenance treatment, Intra-
venous Immunoglobulin (IVIG) administration. After R-chemotherapy, IgG defi-
ciency appeared in 29/123 (28,4%), 2/29 needed IVIG. After or during R main-
tenance 25/123 (20,3%) showed IgG deficiency after a median of 9 R cumula-
tive doses; the deficit occurred in the 80% (20/25) within the fourth R mainte-
nance dose and in no one after the sixth R administration. In this category,
10/25 (40%) were symptomatic and 4/25 (16%) required IVIG. All 10 patients
who needed IVIG showed at least two Ig isotypes deficiency.
Summary and Conclusions: We observed that R administration was associ-
ated with a high risk of hypoIg. In addition, we found that the number of R doses
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correlated to the development of symptomatic hypoIg. Finally we observed that
the risk of hypoIg increased in patients who received maintenance R. The deci-
sion to introduce therapy with IVIG in non-neutropenic patients was related to
repeated episodes of infection. HypoIg often is underestimated also for the
presence of confounding symptoms. Our study suggests that the baseline and
periodic Ig monitoring should be considered in these patients subset.
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LONG TERM OUTCOME OF PATIENTS WITH GASTRIC MARGINAL ZONE
LYMPHOMA RECEIVING FLUDARABINE, MITOXANTRONE AND RITUX-
IMAB AS FIRST-LINE TREATMENT
E. Cencini1,2,*A. Fabbri2, G. Bartalucci2, L. Schiattone2, A. Gozzetti2, F. Lauria1,
M. Bocchia1,2
1Hematology, University of Siena, 2Hematology, Azienda ospedaliera univer-
sitaria senese, Siena, Italy
Background: Gastric mucosa-associated lymphoid tissue (MALT) B-cell lym-
phoma represents the most frequent localization of extranodal marginal-zone
lymphoma (MZL), characterized by a well established association with Heli-
cobacter pylori (HP) infection. The first-line treatment for HP positive patients
is HP eradication therapy; however, there is no consensus on the standard
management for patients with HP negative or persistent disease after HP erad-
ication. Current approaches include radiation therapy, chemotherapy and
immunotherapy with rituximab, either alone or in combination. Despite the activ-
ity of many alkylating agents and nucleoside analogues against MALT lym-
phoma, evidence about the superiority of a specific regimen toward others is
still lacking. 
Aims: in this study we have investigated long-term efficacy and safety of flu-
darabine and mitoxantrone in association with rituximab (R-FM) as first-line
treatment for gastric MALT lymphoma with HP negative or persistent disease
after HP eradication.
Methods: A cohort of 13 patients (M/F: 5/8; median age 65 yrs) diagnosed
with gastric MALT lymphoma by gastroscopy biopsies and treated between
August 2005 and March 2012 was retrospectively analyzed. All patients com-
pleted staging with whole body CT scan and bone marrow (BM) biopsy. Five
patients had stage I disease, 7 stage II and 1 stage IV, HP was positive in 9/13
patients. Induction treatment consisted of fludarabine (25mg/m2 i.v. on days 2
to 4), mitoxantrone (10mg/m2 i.v. on day 2) and rituximab (375 mg/m2 i.v. on
day 1), administered for up to 6 cycles every 28 days. Final response assess-
ment including esophagogastroduodenoscopy with random biopsies and CT
scan was done 4-6 weeks after completion of therapy according to the 2007
Revised Response Criteria. During follow-up period CT scan was performed
together with esophagogastroduodenoscopy every 6 months for the first 2
years (annually for stage I patients). Thereafter, endoscopy was performed
annually until the 5th year, after this period the patients continued only clinical
follow-up.
Results: All patients (13/13, 100%) achieved a complete remission (CR), a
median of 4 cycles (range 3-6) of R-FM were given and all were evaluable for
response and toxicity. Treatment-related toxicities were mainly hematologic,
with grade 3-4 neutropenia observed in 11/13 patients (84.6%), grade 2 throm-
bocytopenia and anemia in 1 and 2 patients, respectively. All but one cases
required secondary neutropenia prophylaxis with filgrastim, 1 patient had grade
3 febrile neutropenia. The same patient was hospitalized while on treatment
because of non-neutropenic fever with detection of Candida Albicans by stool
culture; 2 months later experienced CMV reactivation, too. Two patients devel-
oped prolonged pancytopenia, with slow recovery after about 12 months. Grade
II nausea was documented in 4/13 patients, no other adverse events occurred.
After a median follow-up of 60 months (range 24-110) all patients were alive,
1/13 had disease relapse after 8 months and received total gastrectomy; esti-
mated 9-year progression-free survival and overall survival were 92.4% (Figure
1) and 100%, respectively.
Figure 1.
Summary and Conclusions: This small series of homogeneously treated
patients suggests R-FM regimen has a high long-term efficacy as frontline
treatment for gastric MALT lymphoma. However, the high incidence of grade
3-4 hematological toxicity makes this treatment less safe compared to the pre-
viously published results of other regimens such as rituximab in combination
with chlorambucil or bendamustine. It could remain a suitable option for patients
with advanced-stage disease, while exluding stage I.
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THE ROLE OF FLOW CYTOMETRY IN THE DIAGNOSIS AND FOLLOW UP
OF GASTRIC LNH
S. Luponio1,* A. De Renzo1,M. Romano2, A. Miranda2, D. Sgambato2,M. Raia3,
G. Scalia3, R. Della Pepa1, F. Pane1, L. Del Vecchio3
1Division of hematology, university Federico II, 2Department of Clinical and
Experimental Internal Medicine, AOU, SUN, 3Biotecnologie Avanzate, CEINGE,
Naples, Italy
Background: The diagnosis of lymphoma is mainly based on morphology, but
the diagnostic accuracy is greatly increased by the use of ancillary techniques
like immunophenotyping, citogenetic and molecular tests. This multiparametric
approach is recommended by WHO classification.
Aims: To evaluate the role of flow cytometry in the study of gastric biopsies
with suspect of NHL. We have assessed the validity of integration of histological
and cytometric assays to optimize diagnosis of lymphoproliferative diseases
and to lower the number of inconclusive cases at histological exam. The aim
of flow cytometry was to define lineage and clonality of lymphoid proliferation,
thus giving a support to final assessment.
Methods: 27 patients with primary gastric lymphoma underwent, from January
2007 to June 2010, to double gastric biopsy at diagnosis or during follow up.
Diagnosis was MALT in 15/27 (56%), DLBCL in 8/27 (30%) and other histolog-
ical type in 4/27 (14%). Every patient underwent complete staging and the
stage was I/E in 12/27 and II/E in 15/27. Therapy was antibiotic eradication of
HP in 5/27 and chemo-immunotherapy in accordance with guidelines. Samples
for histology were fixed with formalin and stained with HE, then tested by anti-
bodies for CD3, CD5, CD10, CD20, CD21, CD23, CD30, CD38, CD43,
CD45RO, CD79a, CiclinaD1, BCL-2, BCL-6, Ki67, EMA, κ e λ. Samples for
flow cytometry were put in saline, sent to laboratory within thirty minutes and
processed with standard methods. A cytometric pattern was defined as patho-
logical if there was an evident atypical assempbly of B or T lymphoid antigens
along with clonal restriction for Ig light chains or TCRVβ repertoire. 
Results: We have carried out 36 biopsies in a population of 27 patients and
we obtained a final diagnosis in all cases. Diagnosis was: NHL in 9/36 (8 MALT
and 1 follicular lymphoma), plasmacytoma in 1/36, and benign conditions in
the remaining 26/36. In all cases there was strict concordance between the
two methods, but in one single cases positivity of flow cytometry led to histo-
logical revision and, finally, to full concordance. 
Summary and Conclusions: This study demonstrated that flow cytometry is
an easy and reliable diagnostic tool for gastric lymphoma: assumed that its
goal is to assess lineage and clonality, it is fast, sensitive and specific. It is syn-
ergistic to histology, especially in difficult cases like biopsy performed during a
revaluation after chemotherapy or antibiotic therapy, or reactive conditions
where lymphoid infiltrates can mimic lymphoma. Histological diagnosis certainly
remains the gold standard for lymphoma diagnosis but flow cytometric typing
can usefully support histology to reach a correct diagnosis in 100% of cases. 
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IMPROVED DETECTION OF CHLAMYDOPHILA PSITTACI DNA IN
OCULAR ADNEXAL MALT LYMPHOMA WITH PCR OPTIMIZATION
C. Yoo1,* D.H. Yoon1, J. Choi2, Y.S. Park2, C. Suh1
1Oncology, 2Pathology, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea, Republic Of
Background: The pathogenic association between Chlamydophila psittaci
(Cp) infection and ocular adnexal MALT lymphoma (OAML) has been suggest-
ed, but large geographic variation (0-87%) has been reported in the prevalence
of Cp infection in patients with OAML. Although its cause has not been eluci-
dated fully, this geographic discrepancy may be in part due to the methodolog-
ical biases or suboptimal PCR.
Aims: Therefore, we examined the detection rates for Cp DNA in patients with
OAML according to the different PCR condition.
Methods: Six OAML patients diagnosed between April 8, 2014 and August 11,
2014 were included in this study. DNA was extracted from paraffin-embedded
tissues and touchdown enzyme time release (TETR)-PCR was performed to
identify Cp DNA as previously reported (Madico et al., J Clin Microbiol
2000;38:1085-93). Then, we performed TETR-PCR with modified annealing
temperature (beginning at 67C vs 62C in original protocol) using same extract-
ed DNA samples. 
Results: Four (67%) patients were male and median age was 50 years (range,
41-77 years). The primary site of OAML was conjunctiva in 4 (67%) patients
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and orbital soft tissue in 2 (33%) patients. At presentation, each 3 (50%) patients
were diagnosed as stage I and IV, respectively. In initial TETR-PCR according
to the original protocol, Cp DNA was detected in none of 6 patients. When
TETR-PCR was performed with modification of annealing temperature, Cp DNA
was identified in 4 (67%) patients. Direct sequencing could be performed in 3
of 4 positive cases, and specificity of amplified fragments was confirmed. 
Summary and Conclusions: PCR optimization with modification of annealing
temperature could improve the detection of Cp DNA in patients with OAML.
Future prospective validation in a larger sample size is necessary.
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SYMPTOMATIC BONE INVOLVEMENT IN WALDENSTROMS
MACROGLOBULINAEMIA
S. D’Sa1,* K. Rajesparan2, J. Kothari3, C. Yeomans1, W.K. Wong4, C. House2
1Cancer Division, 2Radiology, UCLH NHS Foundation Trust, London, 3Haema-
tology, Oxford University Hospitals, Oxford, 4Haematology, UCLH NHS Foun-
dation Trust, London, United Kingdom
Background: Bone involvement by Waldenstroms macroglobulinaemia (WM)
is very uncommon. The presence of bony lesions may point towards possible
high-grade transformation, or the diagnosis of a different IgM paraprotein-pro-
ducing disorder (e.g. IgM myeloma).
Aims: We describe symptomatic skeletal involvement in 4 cases of previously
diagnosed WM patients and evaluate the diagnostic value of bone biopsy to
allow tailored management decisions to be made.
Methods: Four patients with WM were evaluated when they developed pro-
gressive bony pain, using MRI, PET-CT and bone biopsy. An image-guided
biopsy of affected bone was performed in each case and the results were cor-
related with their bone marrow histology and other clinical and laboratory data.
Patient characteristics are shown below:
Table 1.
Figure 1.
Results: In all cases, patients were investigated due to unrelenting bone or
joint pains, including shoulder & upper arm (24 months); knee (6 months); ankle
and lower limb (6 months); knees (8 months) with limitation of movement and/or
joint swelling. The bone disease was evident at the outset, at 12, 18 and 38
months from diagnosis respectively; 1 patient had newly diagnosed WM need-
ing treatment, 2 had evidence of progressive disease 6 and 14 months post
last treatment and the 4th patient had achieved a minor response to therapy at
the time of bone disease. MRI scans demonstrated abnormal intraosseous sig-
nal characteristics in the affected bones in all cases which enhanced with con-
trast and showed low signal intensity on the T1 weighted sequences and areas
of high signal intensity on the T2 weighted sequences. PET-CT scans were
performed in 3 cases and showed patchy diffuse uptake correspomding with
MRI signal abnormality in 2 cases, but no focal tracer uptake in the third case.
There was no evidence of osteolysis on the CT component. Biopsy of affected
bones demonstrated a heavy infiltrate (70-90%) of lymphoplasmacytic lym-
phoma with identical characteristics to the iliac crest biopsy. In all cases, the
bones were diffusely infiltrated by CD20+ cells, with a scattering of CD138+
cells. There was no evidence of transformation to high grade disease in any
case. Blood work showed a median Hb of 120 g/L, median platelets 270x 109/L,
median M-protein of 17 g/L (range 5-22 g/L), raised alkaline phosphatase and
LDH in 1 patient, and normocalcaemia in all. All 4 went on to receive chemoim-
munotherapy (patient A also had radiotherapy to the humerus) which improved
the bone symptoms in 2, but too early to assess in 2, and are alive with a
median follow up is 7 months (range 1-20).
Summary and Conclusions: In our cohort of 4 patients who developed symp-
tomatic bone disease there was appendicular skeletal infiltration by lympho-
plasmacytic lymphoma; the possibility of skeletal disease in WM should be
considered patients with bone or joint pain and the significance of bone disease
in WM deserves further characterisation. Image-guided bone biopsy helps to
confirm the diagnosis and rule out transformation to high grade lymphoma or
an alternative diagnosis of IgM myeloma.
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BORID REGIMEN IN PATIENTS WITH MANTLE CELL LYMPHOMA
I. Erdogan1, A. E. Eskazan1,* D. Cuhadar Ercelebi2, S. Berk1, F.F. Yalniz1,
T. Elverdi1, A. Salihoglu1, M.C. Ar1, S. Ongoren Aydin1, Z. Baslar1, Y. Aydin1,
N. Tuzuner3, T. Soysal1,
1Department of Internal Medicine, Division of Hematology, 2Department of Inter-
nal Medicine, 3Department of Pathology, Istanbul University Cerrahpasa Faculty
of Medicine, Istanbul, Turkey
Background: Mantle cell lymphoma (MCL) is seen in predominantly elderly
and male patients, and responsive to chemotherapy but usually remission peri-
ods are short. There is no standart treatment regimen but addition of rituximab
to treatment protocols increased response rates. Bortezomib has been shown
to have synergistic effect with rituximab and alternative combination regimens
[eg. BORID (bortezomib-rituximab-dexamethasone)] have been implemented.
Aims: To evaluate the effect of BORID regimen to prognosis and survival in MCL. 
Methods: We investigated 15 patients diagnosed MCL between 2001-2014 in
our clinic and treated with BORID regimen during follow up because of relapsed
disease. Demographic data collected from patient files retrospectively.
Table 1.
Results: 73% of patients were male, and the median age was 65 years (range,
46-73 years). All of the patients were in advanced stage (III-IV) at diagnosis and
according to MIPI score all patients were high risk. Mean hemoglobin level was
10.7 g/dL (range, 6.2-14.8 g/dL). Mean leukocyte and lymphocyte counts were
8.900x 109/L (range, 2.79-561 x 109/L) and 2.2 x 109/L (0.7-522 x 109/L), respec-
tively. LDH was normal in seven (47%) patients and high in 8. Ki-67 index was
examined in 9 patients, and it was >%50 in 3. Median number of treatments
prior to BORID was 2 (range, 1-5) and median BORID cycle was 3 (range, 1-6).
Treatment regimens are listed in Table 1. BORID was discontinued after first
cycle in 3 patients (20%) because of side effects; 1 patient had tumor lysis syn-
drome, 1 had elevated liver enzymes and 1 grade 4 polyneuropathy. Response
rates for BORID were as follows: 1 patient was non-responsive and lost the fol-
low-up after two cycles, 1 patient was partial responsive after 6 cycles and she
received 12 courses of BORID totally, after all she had complete response. 1
patient lost the follow up after 3 cycles, 1 had tumour lysis syndrome and died
after first course of BORID, 1 patient had progression and CNS involvement
after 3 cycles, 1 patient had hepatotoxicity and lost the follow-up after first course,
2 patients had partial remission, 6 patients were non-responsive and one of
them died because of pneumosepsis after second course of BORID, 1 patient
had grade 4 polyneuropathy after first cycle but she remained progression free
for 23 months. 4 patients received SCT (3 autologous, 1 autologous and allo-
geneic), and median survival was 41 months (range, 7-152 months).
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Summary and Conclusions: Cure in MCL is not possible with current treat-
ment strategies. Combination of bortezomib and rituximab may be appropriate
treatment regimen in relapsed MCL especially for patients who are not candi-
date for SCT or with comorbidities, but to evaluate the efficacy and toxicity of
BORID in relapsed MCL prospective studies are needed.
Infectious diseases, supportive care
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THE MANAGEMENT OF INVASIVE FUNGAL INFECTION WITH
POSACONAZOLE ORAL SUSPENSION MAINTENANCE TREATMENT
FOLLOWING INTRAVENOUS ANTIFUNGAL REGIMENS IN ROUTINE UK
CLINICAL PRACTICE (MAINTAIN)
H. Ahir1, C. Craddock2,*N. Duncan3, C. Loughran4, D. Cooper5
1Market Access, Merck Sharp & Dohme Limited, Hoddesdon, 2Haemato-oncol-
ogy, 3Queen Elizabeth Hospital, Birmingham, 4University Hospitals Leicester,
Leicester, 5Merck Sharp & Dohme Limited, Hoddesdon, United Kingdom
Background: There are limited data on the use of posaconazole oral suspen-
sion (POS) as a maintenance treatment for invasive fungal infection (IFI) fol-
lowing initial treatment with an intravenous (IV) antifungal agent/s.
Aims: To describe a population of patients who received POS following previ-
ous IV antifungal treatment for possible, probable, or proven IFI and describe
the IV antifungal agents prescribed in those patients, prior to POS, the rationale
for initiating POS maintenance therapy, and the dose and duration of POS
received.
Methods: A retrospective analysis of 25 consecutive eligible adult patients
who received oral POS following IV antifungal treatment was conducted in
three hematology centers in the UK. Study data were obtained from hospital
records, including patient case notes and hospital administrative and clinical
databases. Data is presented as descriptive statistics.
Results: Description of patient population: The patient population reported in
this analysis comprises 25 adults with a median age of 54 years (interquartile
range [IQR]: 43-61 years), of whom 15 were male and 22 were defined as
White British. The most common primary diagnosis was acute myeloid
leukaemia (n=13). 7 patients had a previous IFI prior to the case under review;
7 had documented long-term immunosuppression, and 17 patients were stem
cell transplant recipients. Antifungal treatment: 12 out of 25 patients received
prophylaxis prior to this episode of IFI. All patients were given IV antifungal
treatment prior to the initiation of oral POS maintenance treatment. The two
most commonly prescribed IV antifungal treatments prior to POS initiation were
either caspofungin or liposomal amphotericin B. The most common reasons
for treatment initiation were; persistent temperature and suspicious CT result.
For the majority of the patients who were subsequently prescribed POS the
center attributed rationale for doing so, was to “facilitate hospital discharge”
(n=16). All 25 patients received POS at the normal recommended dose; of the
19 patients with a recorded stop date, the median duration of POS therapy
was 27 days (IQR: 15-87.5 days). Table 1 shows the mean number of diag-
nostic and monitoring tests of those patients that had the specified test.
Summary and Conclusions: This analysis suggests that in a UK patient pop-
ulation diagnosed with hematological malignancy and receiving treatment for
an IFI, POS is frequently used following iv therapy, as a step-down treatment.
Physicians most frequently stated that this treatment decision was to allow the
early discharge of patients from hospital. The sample size although relatively
small, has similar demographics to already published data. Use of POS, by
allowing the discontinuation of iv therapy, may reduce the burden on hospital
resources and may deliver considerable cost savings to the NHS by decreasing
length of stay. Furthermore, other benefits may include allowing patients to
receive treatment at home, in their preferred environment, where appropriate
and also reduce the risk of nosocomial infections.
PB1798
IMMUNOLOGICAL MEMORY OF HEPATITIS B VACCINE IN CHILDREN
WITH CANCER
M. Zakaria1,* A. Al Alakhras1, M. Atfy1, M. AI Amin2, N. Abdallah1
1pediatrics, 2Clinical pathology, zagazig university, zagazig, Egypt
Background: Children with cancer are at risk of severe infections especially
who have not completed their primary immunizations. Immune competence
decreases not only due to chemotherapy-induced neutropenia, but also due to
the reduction of serum antibody titers gained from previous immunizations.
Hepatitis B infection in cancer patients occurs as a result of recurrent blood
transfusions and also due to suppressed immune system. The national immu-
nization program plays an important role in decreasing subsequent hepatitis B
infection in children with cancer, however, the efficacy of the immunization
strategies employed is questionable.
Aims: We aimed at evaluating the acquired immunity from the routine hepatitis
B vaccination in cancer patients after recovery of their immune system.
Methods: case control study was conducted on 22 patients with cancer(13
males,9 females, mean age 7.2±3.14 years) who were registered in and fol-
lowed up at pediatric oncology unit of Zagazig university hospital and who com-
pleted their standard chemotherapy at least 6 months prior to the study. Twenty
two age and sex matched healthy children were enrolled as a control group.
Data abstraction form was designed to capture the appropriate information
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from the individual medical records including full clinical, transfusion and labo-
ratory data.. HBsAb and HBcAb concentrations were determined in the patients
and healthy subjects serum by ELISA. HBs AB titer >10 mIU/mL was considered
as baseline protective titer for preventing HBV infection.
Results: The frequency of non immune subjects in children with cancer was
significantly higher than those in healthy children (P-value=0.001),where anti-
HBs antibody titer was more than 10 mIU/mL in 54.5% of patients and less
than 10 mIU/mL in 45.5% of patients. While in healthy controls, 90.9% had
antibody titer more than10 mIU/mL and 9.1% had antibody titer less than
10mIU/mL. No significant relation was found between loss of immunity against
HBV and age of patient, type of cancer and duration of chemotherapy.
Summary and Conclusions: Children with cancer who received chemother-
apy are at increased risk for HBV infection. HBV revaccination should be con-
sidered at least six month post-intensive chemotherapy.larger studies still need-
ed to confirm our finding.
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THE EVALUATION OF FEBRILE NEUTROPENIA EPISODES IN
CHILDHOOD MALIGNANCY; SINGLE CENTER EXPERIENCE
E. Toret1,* T. Karapinar1, I. Devrim2, Y. Ay 1, B. Demirag1, Y. Oymak1, B. Gunes1,
M. Bulut1, D. İnce1, C. Vergin1
1pediatric hematology-oncology, 2pediatric infectious diseases, Izmir Dr Behcet
Uz hospital, Izmir, Turkey
Background: Febrile neutropenia (FN) is an oncologic emergency that may
cause serious complications or death. Rapidly diagnosis and empirical antimi-
crobial therapy can decrease morbidity and mortality in FN. Agents for empirical
therapy have choosen by clinicians must be bacterisidal, broad-spectrum and
least toxic. Guidelines and current studies have anticipated about high risk fac-
tors and empirical therapy in FN.
Aims: To evaluation of febrile neutropenia episodes (FNEs) in our clinic is
aimed in current study.
Methods: We retrospectively analyzed data of 131 FNEs of 48 patients who
were admitted to the Pediatric Hematology and Oncology Department of Dr.
Behçet Uz Children’s Hospital, Izmir, Turkey between January 2012 and
March2014.
Results: The median age at diagnosis of FNEs was 7.4years (3 months-17
years). Thirty-two of the 48 patients were male and 16 were female. The diag-
nosis were leukemia at 31, lymphoma at 2 and solid tumor at 15 of patients.
Seventy-four per cent of 131 FNEs were determined in patients with leukemia.
Focus of clinical infection were determined in 78% of episodes. The distribution
of infection’s focus were shown at figure 1. Thirty of FNEs (23%) were docu-
mented microbiologically and 60% of them were gram negative bacteria, 30%
of them were gram positive bacteria and 10% of them were fungus. Empirical
antibiotherapy was applied with monotherapy in 28% of episodes as monother-
apy with piperacillin-tazobactam. Piperacillin-tazobactam was also used in 47%
of FNEs as duotherapy with aminoglycosides. Other empirical antibitherapy
choose were 16% meropenem and 9% cefoperasone-sulbactam. Empirical
antifungal was applied in 10% of episodes. Modification of therapy was made
as adding antibiotics in 37% (adding aminoglycoside or glycopeptide) or chang-
ing antibiotics in 22% (changing to meropeneme) of FNEs. Fourty-eight per
cent of FNEs had got response with monotherapy or duotherapy like controlled
fever with clinical stabilization. Fever control was provided in 72% of episodes
in first 72 hours and also in 83% of episodes in 5 days. Two of 48 patients (4%)
were died during neutropenic fever due to pneumonia.
Figure 1. The distribution of infection’s focus.
Summary and Conclusions: This study presents clinical findings of patients
with FN in childhood malignancy at single center. FNEs were the most in
leukemia than the other malignancy. In current study, we identified that we mod-
ificated to therapy in FNEs and this value is higher then expected. Even so,
fever control rate of us was successfull in FNEs for initial 5 days. This study will
contribute to rapidly and efficacious empirical therapy can decrease morbidity
and mortality in FNEs.
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AFTER ADMISSION TO INTENSIVE CARE UNIT NON-TRANSPLANT
PATIENTS WITH HAEMATOLOGIC MALIGNANCIES HAVE BETTER
SURVIVAL OUTCOME THAN RECIPIENTS OF HAEMATOPOIETIC STEM
CELL TRANSPLANTATION
T. Knight Asorey1,* Y. Corcía Palomo2, J. Garnacho Montero2,
F. Márquez- Malaver1, I. Montero Cuadrado1, J. Falantes Gónzalez1,
R. Parody Porras1, J. Gonzalez Campos1, M. Martino Galiana1,
D. Gallo Cavero1, L. Martín Villén2, J. Pérez Simón1,3 I. Espigado1,3
1Haematology and haemotherapy Service, Hospital Universitario Virgen del
Rocio- Virgen del Macarena, 2Intensive Care Unit, Hospital Universitario Virgen
del Rocio, 3University of Seville and Instituto de Investigación Biomédica de
Sevilla (IBiS), Sevilla, Spain
Background: Patients with haematological malignancies admitted to Intensive
Care Units (ICU) have a high mortality rate and poor survival. Identifying pre-
dictors of mortality and survival may be useful for clinical decision making and
can help to improve survival. The differences in mortality rate and survival out-
comes between recipients of haemoipietic stem cell transplant (HSCT) and
non-transplant haematologic patients have been poorly studied.
Aims: to compare survival rate after intensive care management between recip-
ients of haematopoietic stem cell transplant and non-transplant patients with
haematologic malignancies.
Methods: prospective observational study of all consecutive patients with
haematologic malignancies admitted to the ICU. Patients have been undergone
an HSCT or not. Period: December 2012 through April 2014. Variables that
were analyzed included: demographics, haematological disease, stage of the
haematological disease, main reason for admission into the ICU, critical score
evaluation (APACHE II y SOFA), organ failure, organic support therapy, death
rate in the ICU and in hospital during the following 28 days after admission.
Comparisons of quantitative and qualitative variables between independent
groups were analyzed by Student t-test, or Mann-Whitney U test for non-nor-
mally distributed variables, and chi-square test, Fisher’s exact test in 2x2 tables,
depending on sample size.
Results: 63 consecutive patients were included and their data analyzed. Twenty
seven have undergone an HSCT and 36 did not. HSCT recipients tended to be
younger [median age 51 (34-55) vs. 57 (43-66); P=0,01] and they were admitted
to the ICU in a worst clinical condition [SOFA: 10 (8-14) vs. 8 (4-11); P=0,01]
and APACHE II [26 (19-29) vs. 21 (16-28); P=0,3]. The most frequent cause of
admission to the ICU was respiratory failure (77,8%), without differences
between both groups (P=0,5). However, recipients of HSCT needed more fre-
quently invasive mechanical ventilation (IMV; P=0,007) and suffered signifi-
cantly more liver failure (77,8% vs. 30, 6%; P<0,001) and renal failure (85,2%
vs. 44,4%, P<0,001). Haemodynamic failure was also more frequent in the
HSCT recipients than in non-transplant patients (88, 9% vs. 63, 9%; P=0, 02).
Hospital mortality rate 28 days after ICU admission of patients with HSCT was
higher (92,6%) than for non-HSCT patients (44,4%; P<0,001). There were no
significant differences between both groups in the rest of analyzed variables
Summary and Conclusions: recipients of an haemopoietic stem cell transplant
have a significantly higher mortality rate and worst survival than non-transplant
haematologic patients after intensive care admission. The causes for such an
outcome could be the worst clinical condition at ICU admission, more need for
invasive mechanical ventilation and higher rate of organ failure in HSCT recip-
ients. Knowing the reasons for these differences merit further investigation and
may help to improve survival of both settings of patients
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INVASIVE PULMONARY ASPERGILLOSIS IN ACUTE LEUKEMIA:ABOUT
57 CASES
O. Kassar1,* A. miled1, M. ghorbel1, H. bellaaj1, H. fourati2, W. ketata3,
M. mdhaffar1, F. cheikhrouhou4, S. hdijji1, M. elloumi1
1hematology, 2radiology, 3pneumology, 4Laboratory of Parasitological-Mycolo-
gy, university sfax, sfax, Tunisia
Background: Invasive pulmonary aspergillosis (IPA) is a serious fungal infec-
tion and it’s associated with high mortality. 
Aims: In this study, we evaluate the incidence and treatment outcome of IPA
in acute leukemia (AL).
Methods: Our retrospective study included patients with novo acute leukemia
(ALL or AML) under which occurring IPA during chemotherapy following in
department of Hematology CHU Hédi CHaker Sfax between January 2009 and
December 2013. The treatment of acute leukemia is based in chemotherapy
and /or corticosteroids, and it is done in conventional rooms.Invasive pulmonary
aspergillosis was diagnosed based on the revised definitions of invasive fungal
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disease from the EORTC/MSG clinical, microbiological and radiological criteria.
Accordingly, the patients were diagnosed as having “proven,” “probable,” or
“possible” IPA.For this, a Clinical data including clinical manifestations, diag-
nostic results, and treatment was collected for every patient.
Results: We analyzed 247 patients with acute leukemia. IPA was diagnosed
in 57 patients.the incidence of IPA was 23% during 5 years. The average age
was 29 years old (3-53 years old). All our patients had at least 3 criteria accord-
ing to EORTC/MSG (neutropenia<500 / mm3 and prolonged, fever despite
broad-spectrum antibiotics and immunosuppressive agents in the previous 30
days). The aspergillus antigenemia was positive in 26 patients (45%).The bron-
cho-alveolar lavage (LBA) was done in 22 cases including (38%). For this,
patients with aspergillosis were diagnosed with probable IPA in 45%, possible
IPA in 46.5% and proven one in 5 cases (8.5%). All patients were treated with
amphotericin B and relay by voriconazole. The Evolution was favorable in 28
cases (49%) with early deaths in 10 patients (18%). Twenty patients (35%) are
alive with an average decline about 1 year.
Summary and Conclusions: The prevalence of the IPA in our series is higher
than the literature (15%) because patients are treated in conventional rooms.
The prevalence of proven IPA in our study is very low because of the difficulty
of histological documentation (technic problem and deep thrombocytopenia).
Wherever; the precocity of diagnosis by TDM imagery and the treatment with
voriconazole have improved the mortality rate in our series.
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DIAGNOSTIC UTILITY OF ADDING SERUM GALACTOMANNAN TEST TO
STANDARD TECHNIQUES OF DIAGNOSING INVASIVE FUNGAL
INFECTION IN PATIENTS OF ACUTE LEUKEMIA WITH NEUTROPENIA 
P.K. Singh1,* R. Maiwall2, Y. Dabas3, P.C. Misra1, T. Seth1, I. Xess3,
M. Mahapatra1
1Hematology, All India Institute of Medical Sciences, 2Hepatology, Institute of
Liver and Biliary Sciences, 3Microbiology, All India Institute of Medical Sciences,
New Delhi, India
Background: Invasive fungal infection (IFI) (esp. Invasive Aspergillosis) is
very common in patients of acute leukemia undergoing induction chemother-
apy. Case fatality rates are approximately 50-60% in various studies. It is usu-
ally diagnosed as probable case based on CT, as per EORTC/MSG criteria.
Serial Galactomannan (GM) monitoring can be helpful in diagnosing IFI early.
Aims: To study the diagnostic & prognostic significance of weekly Serum
Galactomannan level monitoring and the development of invasive fungal infec-
tion based on radiological imaging.
Methods: Prospective single centre cohort study which included 100 patients
of acute leukemia with neutropenia. Weekly GM levels were done with CT
chest done as and when clinically indicated. Results of GM levels were com-
pared with CT positivity at any time point during the phase of neutropenia. GM
levels were also assessed to predict the survival.
Results: Patients of acute leukemia with neutropenia (mean age 248 years,
62% males) were followed for a period of 1 month of which 37% patients
expired with median day of expiry 40 days. ALL and AML patients were 34 and
66%, respectively with fever being most common (92%) presenting symptom.
49% patients had evidence of fungal pneumonia on the basis of CT chest with
median day of positivity was 12 days (IQR 3-16 days). 74% patients had GM
positive value at any time point out of which 20% had persistent GM index
positive. Highest value of GM index was 0.701 at day 14 correlating with nadir
ANC of 30/cumm at day 14. GM levels were positive in 43%, 63%, 69% and
54% patients at day 0, 7, 14 and 21, respectively. The median GM levels at
day 7 (0.8 vs 0.4; P=0.001), 14 (0.87 vs 0.49; P=0.00) and 21 (0.92 vs 0.46;
P=0.00) were higher in CT positive group as compared to CT negative group.
There was a significant negative correlation between ANC and GM levels
(P=0.007). High GM levels at day 7 (p value=0.018) and day 14 (p value<0.001)
were predictor of development of invasive fungal infection on 1st or 2nd CT.
Low GM levels at day 14 (1 vs 0.63; P<0.001) and post induction CR status
(98% vs 8%; P<0.001) were significantly associated with better survival.
Summary and Conclusions: High GM levels at day 7 were predictor of devel-
opment of invasive fungal infection on CT. High GM levels negatively correlates
with the degree of neutropenia. Low GM levels at day 14 and post induction
CR is associated with better survival.
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INFECTIOUS COMPLICATIONS AFTER AUTOLOGOUS HEMATOPOIETIC
TRANSPLANTATION:EARLY AND LATE EVENTS
M. J. Requena1,* G. Amores1, M. Diaz Goizueta1, C. Payamps1, N. Fontarigo1,
M. Berberana1, P. Sanchez Godoy1
1Hematology, Hospital Severo Ochoa, Madrid, Spain
Background: Infectious complications occur in most patients receiving high
dose therapy (HDT) and autologous stem cell transplantation (ASCT) both dur-
ing neutropenia,related to the conditioning regimen and later on due to gradual
immunological reconstitution of lymphoid and immune effector cells.
Fatal infections are rare, but they represent a mayor cause of morbidity and
treatment related mortality. 
Aims: We retrospectively analyzed the incidence and type of infections
(early:day (d) 0-100, late:from d 100) after ASCT for haematological malignan-
cies at our hospital from January 2002 to February 2015.
Methods: We studied 103 ASCT performed to 98 patients: 62 males and 41
females;median age:55 years (23-69); the diagnosis were: 42.7% Multiple
Myeloma, Non Hodgkin Lymphoma(follicular 10.67%,Large cell B diffuse
10.67%,T 5.8%,anaplastic 0.97%,plasmablastic 0.97%),Hodgkin Lymphoma
19.4%,amyloidosis 1.9%, acute myeloid leukaemia 5.8%, acute lymphoblastic
leukaemia 0.97%. Conditioning regimens were:BEAM 19.4%, escalated CBV
28.1%,melfalan 41.7%,BUMEL 2.9%,BEA 5.8%,other 1.9%.
All patients received antibiotic and antiviral prophylaxis during conditioning and
for at least 6 months.Vaccinations were administered as stated in EBMT guide-
lines.(one dose of polysaccharide pneumococcal vaccine at 7m).
Results: Early infections: 94.2% patients have febrile neutropenia; fever of
unknown origin represented 44.3% of episodes, the documented infections
were as follows:see table 1. We have a fatal sepsis caused by multirresistant
pseudomonas aeruginosa.Mortality due to infection:1.03%. Late infections: 75
episodes were recorded in 43 patients. Mortality due to infection was 7.14%.
The incidence of Herpes zoster reactivation was11.2% at 6m(3-48) postrans-
plantation; 54.5% were receiving corticosteroids and 36.2% had relapsed. Uri-
nary tract infections 12.2% at 57.5m(10-117). Bacterial Pneumonia:20.4% at
43m(4-78);50% received corticosteroids and 65% had relapsed. Influenzae
pneumonia 2%at 27.5 m(14-41).Invasive fungal infections(aspergillus) pneu-
monia 3.1%: 2 probable,1 proven at 31.5m(4-59).Oropharyngeal candidiasis
3.1% at 45.5m (10-86). Pneumococal infection: 8.2% at (45.5m (15-76):(5 inva-
sive pneumococcal disease:1 arthritis, 3 bacteriemic pneumonia,1meningitis),
3 pneumonia; 2 patients have multiple episodes;mortality rate was 25%;50%of
patients had progressed.and 62.5% received corticosteroids. Catheter related
infections: 5.1% at 17m(4-46). Gastroenteritis 3.1%(1 campylobacter, 2 clostrid-
ium difficile) at 13m (7-23). 1(1.02%)episode of bacteriaemia by Listeria mono-
cytogenes without focal infection at 8m. 1(1.02%)Visceral Leishmaniasis at
33m. Cryptosporidium infection 3.1% (1 systemic, 2 diarrhea) at 40.5m(8-73).
Table 1.
Summary and Conclusions: Our incidence of infectious complications during
neutropenia period is similar to that previously described in literature. The inci-
dence of fungal infections is low. 43.8% of our patients suffered late infections
and the mortality was 16.2%.Herpes zoster is an important cause of morbidity
late after ASCT. Pneumococcal infections stand out due to its continuous occur-
rence late after transplantation and its high mortality; perhaps the use of the
13-valent pneumococcal conjugated vaccine could help to prevent it. Constant
surveillance and prompt therapy must be held for infections, even late after
autologous transplantation.
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RITUXIMAB-ASSOCIATED HEPATITIS B VIRUS (HBV) REACTIVATION IN
LYMPHOPROLIFERATIVE DISEASES: CASE REPORTS
S. Bougherira1,* M.E.H. Meghadcha2
1hematology, 2Infectious Disease, faculty of medecine, university hospital of
Annaba, Annaba, Algeria
Background: Reactivation of hepatitis B virus (HBV) after rituximab-based
chemotherapy regimens in patients with B chronic lymphoproliferative disorders
is well-recognized as a potentially serious complication in HBV immune
patients. It has been observed in patients positive for hepatitis B surface antigen
(HBsAg) and in HBsAg negative patients who had HBV infection in the past.
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The risk of HBV reactivation differs according to both the patient’s HBV infection
status prior to systemic chemotherapy and the degree of immunosuppression
due to chemotherapy. The overall incidence of reactivation with use of rituximab
is unclear, but ranges from 2% to 35% of patients.
Aims: To discuss the relationship between Rituximab-based therapy and B
hepatitis reactivation, and to estabilish the management of hepatitis associated
with the use of Rituximab, prevention and treatment. 
Methods: We conducted a prospective study on nine patients with lymphopro-
liferive diseases, whom treated with Rituximab, in our institution from 2013 to
2014. Data were collected and analysed from medical records. We were
focused on risk factors for HBV reactivation, clinical characteristics, biological
data and management. Lymphoproliferative histologies were diffuse large B-
cell lymphoma (n = 3), follicular lymphoma(n=1) CLL (n=2), mantle-cell lym-
phoma (n=1), and marginal zone lymphoma (n=2). All patients received Ritux-
imab-containig chemotherapy: FCR (Fludarabine, Cyclophosphamide, Ritux-
imab), and R-CHOP (Rituximab-Cyclophosphamide, Doxorubicine, Vincristine
and Prednisone). Four patients were HBV positve; one of them was treated by
pegylated Interferon and was completely recovered before starting Rituximab.
Results: The median age at diagnosis was 56 years (rang 37-72), and seven
patients were male. HBV screening data were available for all patients at base-
line. 4 patients were HBsAg positive, five of them were HBsAg negative. The
time from last rituximab to reactivation was 3 months (range 0–12), HBV reac-
tivation occured usually at the completion of chemotherapy (upper than 3
months after the last dose of Rituximab), for 3 patients in the periods between
cycles (median occurrence was 17 days). Clinical manifestations of hepatitis B
reactivation were variable and ranged from asymptomatic to acute hepatitis (2
patients). Serum transaminase (ALT, AST) levels were elevated, high total biliru-
bin and hepatitis serology tests revealed reappearance of HBsAg and hepatitis
B e antigen (HBeAg), loss of anti-HBsAb, and positivity for hepatitis B virus
(HBV) DNA (3 patients were HBV DNA negative). Lamivudine and entecavir
(nucleoside analogues) were the most antiviral used for the treatment of HBV
reactivation. Six patients were treated : 05 of them received Lamuvidine
schudeled at 100 mg daily. Entecavir was prescribed for one patient who
received previously Interferon. The remaining 3 (33% patients) were HBsAg
negative and anti-HBsAb negative and anti-HBcAb positive, did not undego
treatment and they were closely monitored for HBsAg, anti-HBsAb, HBV-DNA,
and transaminase levels. The hepatitis flare was controlled (improvement of
liver function tests, reduction of HBV DNA levels) and treatment was well tol-
erated. At the last follow-up, two patients died because of fulminant hepatitis
and severe peumonia
Summary and Conclusions: Rituximab-based therapy may cause serious
HBV-related complications and even death, by increasing the risk of HBV reac-
tivation both in inactive carriers and those with resolved HBV. Baseline HBV
serology is recommended for all patients receiving immuno-chemotherapy reg-
imen, and HBsAg positive patients should receive anti-HBV prophylaxis to
decrease virus reactivation and death rates.
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DIAGNOSTIC VALUE OF PLASMA LEVELS OF PRESEPSIN (SOLUBLE
CD14-SUBTYPE) FOR FEBRILE NEUTROPENIA IN PATIENTS WITH
HEMATOLOGIC MALIGNANCIES
H. Koh1,* T. Katayama1, M. Hashiba2, A. Sato2, M. Kuno1, Y. Makuuchi1,
T. Takakuwa1, H. Okamura1, A. Hirose1, M. Nakamae1, M. Hino1, H. Nakamae1
1Hematology, Graduate School of Medicine, Osaka City University, Osaka,
2Development Research, Mochida Pharmaceutical Co., Ltd., Shizuoka, Japan
Background: Previous studies reported that procalcitonin (PCT), C-reactive
protein (CRP) and cytokines such as interleukin (IL)-6 and IL-8 may be useful
as biomarkers of bacterial infections in the management of febrile neutropenia
(FN). CD14, one of the surface markers in monocytes/macrophages, is a
lipopolysaccharide-binding protein complex receptor, and its fragment “pre-
sepsin (soluble CD14-subtype)” has recently been reported as a novel diag-
nostic biomarker of infection, especially sepsis (Endo S, et al. 2012). However,
the superiority of this test in FN, compared with the other markers, is unknown.
Aims: The purpose of the study was to examine whether presepsin was a
superior diagnostic marker for bacterial infections in comparison with PCT,
CRP, IL-6 and IL-8.
Methods: We prospectively evaluated the utility of these biomarkers in patients
with hematological disorders who developed FN during chemotherapy between
Nov 2013 and Feb 2014. FN was defined as an axillary temperature ≥ 37.5 
recorded once with a neutrophil count<500/μl or<1,000/μl with an expected
decline to<500/μl. Patients were closely and frequently monitored to assess
precisely differences in kinetics among these markers. Thus, blood samples
for these measurements were collected simultaneously at the following time
points: once before chemotherapy as a control, 3 times per week until onset of
FN after chemotherapy, at onset of FN, at 8, 16, 24, 48 and 72 hours after the
onset of FN, and every 48 hours after that until resolution of fever, in accordance
with the protocol. Plasma presepsin was determined by the PATHFAST® Pre-
sepsin kit (LSI Medience Corporation, Japan). Serum levels of CRP, PCT and
cytokines were measured by nephelometry, electrochemiluminescence
immunoassay and the Bio-Plex Pro Cytokine Assay® system (Bio-Rad Labo-
ratories, CA), respectively.
Results: A total of four patients aged 29–54 years were enrolled and four FN
episodes were evaluable. The underlying diseases were acute leukemia in
three patients and one case of non-Hodgkin’s lymphoma. Concerning the cause
of FN, Patient no.1 (P1), P2, P3 and P4 were finally diagnosed as having a
fever of unknown origin, suspected drug fever, clinically documented local infec-
tion and Staphylococcus aureus bacteremia, respectively. The number of times
each of these patients was sampled was 18, 17, 18 and 15 respectively. A
result was considered to be positive if it met the following criteria: 314 pg/mL
for presepsin, 0.30 mg/dl for CRP, 0.05 ng/mL for PCT, and the levels of the
baseline controls sampled before chemotherapy for both IL-6 and IL-8, respec-
tively. The presepsin peak levels from the onset of FN to 24 hours in P1, P2,
P3 and P4 were 330, 148, 348 and 460 pg/mL, respectively. The corresponding
levels of CRP, PCT, IL-6 and IL-8 in P1, P2, P3 and P4 were 1.8, 6.0, 11.9 and
4.9 mg/dl; 0.04, 0.34, 0.36 and 0.22 ng/mL; 14 (baseline, 27), 107 (23), 69 (25)
and 24 (8.4) pg/mL; and 52 (62), 787 (58), 56 (150) and 26 (13) pg/mL, respec-
tively. In P2, where no infection was suspected, presepsin was the only marker
that did not increase. This suggests that presepsin might be useful to differen-
tiate infectious from non-infectious causes of FN.
Summary and Conclusions: Our results suggest that presepsin may be more
useful than CRP, PCT, IL-6 and IL-8 in the management of FN, especially when
attempting to rule out the presence of serious bacterial infections.
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EFFECTIVENESS OF SUPPORTIVE THERAPY WITH LOW-DOSE
LENOGRASTIM FOR B-CELL LYMPHOMAS
A. Nagata1,* N. Sekiguchi1, M. Kurimoto1, S. Noto1, N. Takezako1
1hematology, Disaster Medical Center, Tachikawa, Japan
Background: To date, over 30 kinds of malignant lymphomas have been clas-
sified by the WHO classification. Although R-CHOP chemotherapy is currently
considered the standard therapy for B cell lymphoma, the beneficial effects of
G-CSF, namely, decreases in the number of neutrophils, the prevention of
febrile neutropenia, and maintenance of the treatment interval, have also been
reported. We performed R-CHOP therapy in our hospital between 2009 and
2014 and assessed its curative effects based on the number of neutrocytes
when combined with three G-CSF agents (filgrastim, nartograstim, and
lenograstim), which were used as supportive therapy in our hospital.
Aims: We would like to confirm whether the usage of G-CSFs which are fil-
grastim, nartograstim, and lenograstim is considered a safe supportive therapy
for R-CHOP chemotherapy.
Methods: White blood cell counts were measured before administering G-CSF
to a total of 177 patients scheduled for the next cycle of R-CHOP chemotherapy
in our hospital between February 2009 and February 2014. The effectiveness
and side effects of the 3 drugs were examined through analysis of variance.
Results: The median age of patients who underwent a total of 177 cycles of
R-CHOP chemotherapy was 61 years old. The Filgrastim group was signifi-
cantly older than the Nartograstim and Lenograstim groups (Filgrastim: 75±5
years old (P=1.64×106), Nartograstim: 61±17 years old, Lenograstim: 58±12
years old). The proportion of females was high in the nartograstim group
(P=0.004). No significant difference was observed the incidence of infiltration
to the bone marrow between the Nartograstim and Lenograstim groups. LDH
levels were significantly lower (LDH: 200±24mg/dL, P=0.036) in the Filgrastim
group immediately prior to chemotherapy. Furthermore, white blood cell counts
before the next course of chemotherapy were significantly lower in the Filgrastim
group (WBC: 4352±1412/µL, P=0.006), whereas no significant difference were
observed between the Nartograstim and Lenograstim groups.
Summary and Conclusions: It was difficult to directly compare filgrastim with
the other 2 drugs due to the large number of elderly patients in the study hos-
pital. On the other hand, no significant differences were observed in effective-
ness between nartograstim and lenograstim and no influence was noted on
the white blood cell count immediately prior to the next course of chemotherapy.
We herein confirmed that no significant differences existed between the Nar-
tograstim and Lenograstim groups; therefore, the usage of these agents is con-
sidered a safe supportive therapy for R-CHOP chemotherapy.
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INVASIVE FUNGAL INFECTION IN ACUTE LEUKEMIA PATIENTS-A
SINGLE CENTER EXPERIENCE
A. Dascalescu1,* G. Butura2, A. Dascalu2, I. Antohe1, C. Burcoveanu2,
C. Danaila1,
1Hematology, University of Medicine and Pharmacy “Gr.T.Popa”, 2Hematology,
Institutul Regional de Oncologie, Romania
Background: Invasive fungal infection (IFI) is one of the most severe compli-
cations that apppear in patients with acute leukemia. The outcome of the acute
leukemia is significantly influenced by the presence of severe fungal infection
during induction, consolidation or salvage therapy.
Aims: To evaluate the outcome of patients with proven or probable IFI at diag-
nosis or during therapy. We analyzed the risk factors for invasive fungal infection
in our study group.
haematologica | 2015; 100(s1) | 715
Vienna, Austria, June 11 – 14, 2015
Methods: We evaluated 91 patients diagnosed with acute leukemia during a
2 year period between March 2012 and October 2014. Of the 91 patients includ-
ed, 63% was diagnose with acute myeloid leukemia. Median age at diagnosis
was 52 years old. The number of episodes of febrile neutropenia in all patients
and the appearance of probable or confirmed invasive fungal infections in the
course of these episodes was analyzed. 
Results: In our cohort the incidence of IFI during 90 episodes of febrile neu-
tropenia analyzed was 18,6%. More than 50% of invasive fungal infection
appeared after induction chemotherapy and the median duration of neutropenia
grade IV OMS at this patients was 22 days. Infection with Aspergillus spp. was
the most frequent diagnosed fungal infection (14 patients). Invasive candidiasis
was diagnosed in only 3 patients. The most common location was the lung. 2
patients were diagnosed with probable cerebral aspergillosis. Despite the good
response of azole based therapy in majority of patients, 5 patients required sec-
ond line of antifungal therapy and death appear in 4 patients with invasive fungal
infection. In our study group the only risk factor which statistic significantly influ-
enced IFI risk was duration of neutropenia more than 21 days (P=0,006).
Summary and Conclusions: IFI is an important cause of morbidity and mor-
tality in patients diagnosed with acute leukemia. The high percentage of patients
with invasive fungal infection after induction chemotherapy (9,9% in our study)
with significantly delays in subsequent consolidation courses is a important
issue. Correct assessment of the risk of infection in these patient populations
associated with appropriate prophylactic measures can significantly reduce
the risk of these forms of infection. 
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INFECTION HISTORY MAY BE USED TO PREDICT OF BENEFIT OF IVIG
THERAPY IN HYPOGAMMAGLOBULINAEMIC HAEMATOLOGY PATIENTS
L. Paxton1, P. Crispin1,2,* C. Hawkins1,3
1Australian National University Medical School, Canberra, 2Haematology,
3Immunology, Canberra Hospital, WODEN, Australia
Background: Intravenous immunoglobulin (IVIg) has been shown to reduce
the risk of infections in unselected patients with hypogammaglobulinemia sec-
ondary to hematological malignancies. It is not known whether a history of
infections can predict benefit from IVIg and can therefore by used to select
patients for therapy
Aims: To determine the risk of serious infections when selecting hematological
patients for IVIg based on a history of infections and IgG levels.
Methods: A retrospective review of the rate of hospitalisation for infections
before and during IVIg therapy in hematological malignancy patients selected
for therapy on the basis of serious or recurrent infections was conducted.
Results were compared with hypogammaglobulinemic haematology patients
not selected for therapy. Characteristics of the groups were compared with
Chi-squared tests and event rates expressed as rate ratios with estimated vari-
ance to determine 95% confidence limits.
Results: A total of 35 treated patients were treated with IVIg for 1194 months
and had 776 months of observations prior to starting treatment. By comparison
57 patients with low IgG levels were identified with hypogammaglobulinemia
(IgG<7g/L) who did not require IVIg, with the total observational period being
2587 months. The untreated group had fewer cases with severe hypogamma-
globulinemia (51% v 77%, P<0.01) but were otherwise similarly matched for
diagnosis, age and sex. The treated group showed a rate of hospitalisation for
bacterial infection of 0.42 per patient year prior to treatment, reducing to 0.14
(relative risk 3.1 (1.6-5.9) for infection prior to treatment). The risk of infection
prior to treatment also compared favourably to the 0.08 hospitalisation per patient
year in those never treated (relative risk 5.5 (3.0-10)). An IgG level of<4g/L did
not predict rates of infection compared with an IgG level >4g/L in either the
untreated group or the treated group prior to the commencement of IVIg. 
Summary and Conclusions: In this retrospective study, selecting hypogam-
maglobulinemic hematology patients to have IVIg given or withheld on the
basis of a history of infections appears safe and effective. 
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IMPACT OF POSACONAZOLE PROPHYLAXIS ON INVASIVE FUNGAL
INFECTION, ASPERGILLUS GALACTOMANNAN AND PERSISTENT
FEBRILE NEUTROPENIA DURING AML INDUCTION THERAPY: A
SINGLE-CENTER, REAL-LIFE EXPERIENCE
V.S. Sampath1,* A. Tso Ching Yee1, L.K. Lee1, S.Z. Fong1, P. Kuperan1,
Y.C. Lim1, J. Rajendran1, C.A. Gallardo1, K.H. Ong1
1Haematology, Tan Tock Seng Hospital, Singapore, Singapore
Background: Posaconazole prophylaxis has been shown to prevent invasive
fungal infection(IFI) in acute myeloid leukaemia (AML) patients during induction
therapy. The role of serum aspergillus galactomannan(GM) in diagnosis of
invasive fungal infection and the optimal management of persistent febrile neu-
tropenia during posaconazole prophylaxis is less clear.
Aims: The aims of this study are to determine in patients having AML induction
chemotherapy with posaconazole prophylaxis, the incidence of IFI, the role of GM
in diagnosis and premptive antifungal treatment and the management of persistent
febrile neutropenia for more than 96 hours despite broad-spectrum antibiotics.
Methods: We collected prospective data on 22 consecutive patients undergo-
ing AML induction chemotherapy with posaconazole prophylaxis between
August 2013 and November 2014. Induction chemotherapy comprised
duanorubicin 45-90 mg/m2 for 3 days and cytarabine 100 mg/m2 for 7 days.
Oral posaconazole was started on day 1 of chemotherapy. Patients not in com-
plete remission received salvage reinduction chemotherapy. Serum posacona-
zole levels were not done. GM was performed once or twice weekly.Patients
who had persistent febrile neutropenia for more than 96 hours despite broad
spectrum antibiotics were investigated with computed tomography. Respiratory
consult for broncho-alveolar lavage was discretionary. Empirical antifungal ther-
apy was commenced if the patient was clinically unstable or had radiological
findings of probable IFI.
Results: IFI(aspergillus flavus sinusitis) was diagnosed in 1 out of 22 patients
(4.55%) during the first cycle of induction chemotherapy. Probable invasive
pulmonary aspergillosis was diagnosed in one patient during salvage
chemotherapy. Both infections were fatal. Both patients had radiological find-
ings but negative serum GM levels and diarrhoea at the time of diagnosis. One
patient had a single positive serum GM (GM index of 0.9) two weeks prior to
the diagnosis of IFI but was deemed to be false-positive as he was afebrile
and asymptomatic. Serum GM was done on 179 occasions but was positive
only once (0.56%) which was deemed false-positive. Persistent febrile neu-
tropenia for more than 96 hours despite broad spectrum antibiotics were seen
in 17 patients (77.27%). Computed tomography showed radiological findings
suggestive of chest infection in 9 patients (40.9%) and sinusitis in 3 patients
(13.63%). Positive blood cultures were seen in 10 patients with febrile neu-
tropenia (45.45%). 4 patients(18.19%) had antifungal treatment. BAL was per-
formed in one patient and did not reveal any specific microbiology.
Summary and Conclusions: Posaconazole is effective antifungal prophylaxis
in AML patients undergoing induction chemotherapy. Diarrhoea may impair
posaconazole absorption and may have lead to invasive fungal infection in the
two patients but posaconazole levels were not done. Therapeutic drug monitoring
may be useful as IFI are uncommon with adequate levels. Serum GM is not
useful in the diagnosis and initiation of preemptive antifungal therapy with
posaconazole prophylaxis. Persistent febrile neutropenia should not be auto-
matically an indication for empirical antifungal therapy in all patients. Individu-
alised decision making is needed in this context. Assessment of serum posacona-
zole levels, computed tomography, broncho-alveolar lavage with BAL galac-
tomannan and the clinical status of the patient may be the best approach to
initiate antifungal therapy with posaconazole prophylaxis in persistent febrile neu-
tropenia of unknown origin. Empirical antifungal therapy is an alternative option
but may increase treatment cost and drug resistance. Invasive fungal infection
in the setting of posaconazole prophylaxis is difficult to treat and often fatal.
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THE EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS INHEMATO-
LOGIC ADULT PATIENTS IN WROCLAW University HOSPITAL, POLAND
M. Biernat1,2, D. Urbaniak-Kujda1, K. Kapelko1,* U. Nawrot3, M. Laszkowska1,
J. Dybko1, T. Wróbel1, K. Kuliczkowski1
1Department and Clinic of Haematology, Blood Neoplams and Bone Marrow
Transplantation, 2Department of Microbiology, 3Department of Pharmaceutical
Microbiology and Parasitology, Wroclaw Medical University, Wroclaw, Poland
Background: The invasive fungal infections (IFIs) are associated with a very
high mortality in hematologic patients mainly because of asymptomatic course
and delayed diagnosis. 
Aims: The aim of the study was to analyze the clinical feature and outcome of
invasive fungal infections in adult patients diagnosed and treated in Wroclaw
Medical University.
Methods: The retrospective analysis of patients with hematologic malignancies
and patients undergone hematopoietic stem cell transplant (HSCT), who were
hospitalized in our hospital between January 2011 and December 2014, was
performed. Proven, probable and possible IFIs were diagnosed according to
the definitions of EORTC/IFICG. Galactomannan and mannan antigens were
detected by ELISA whereas culture of pathogenic fungi was based on EUCAST
recommendations.
Results: In analyzed period, invasive fungal infection was diagnosed in 55
patients, of which 34 (62%) was proven, 19(34,5%) probable, and 2(3,5%) pos-
sible. Aspergillosis was diagnosed in 50/55 patients, candidosis in 3/55 patients,
mucormysosis in 1/55, and cryptococcosis in one patient (1/55). The major
pathogens isolated form clinical specimens were: Aspergillus fumigatus
(21/55,38.2%), Aspergillus flavus (2/55, 3.6%), Aspergillus niger (1/55, 1.8%),
Absidia (1/55, 1.8%), Mucor (1/55, 1.8%), Candida glabrata (3/55, 5.5%). In two
patients two different Aspergillus spp. (A. fumigatus and A. flavus) were identified
from lower respiratory tract. The infection was mostly localized in lungs
(48/55,87.2%), and central nervous system (4/55, 7.3%). Disseminated infection
was noted in two patients (3/55, 5.5%). IFIs were most common in patients with
acute myeloid leukemia (27/55, 49%) and patients undergone HSCT (8/55,
14.5%). The major risk factors in this patients were prolonged neutropenia and
degree of immunosupression. A total of 39 patients (71%) died.
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Summary and Conclusions: The most common pathogen of invasive fungal
infection in the cohort of hematologic patients was Aspergillus fumigatus. Con-
stant monitoring of the epidemiologic trends and insights in timing of fungal
infections in this patients may help to improve the effective prevention and
treatment strategies. 
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A COMPARISON OF IMMATURE GRANULOCYTE (IG) PARAMETER
BETWEEN A HEMATOLOGY ANALYZER AND MANUAL MICROSCOPY
P. Tsiatsiou1,* D. Lazaridou1, E. Evaggelou1, P. Mauroidaki1, M.A. Fotiadou1,
T. Karamitopoulou1, L. Skoura1, A. Nikolaidou1
1Clinical Microbiology, AHEPA University Hospital, Thessaloniki, Greece
Background: Left shift in granulopoiesis, has been seen in cancer or infection.
An accurate marker has been IG (immature granulocyte which includes promye-
locytes, myelocytes and metamyelocytes), blasts and bands are excluded from
the measurement. In the peripheral blood smear, the appearance of immature
granulocytes (IG) is a common finding in infection, inflammation, hematologic
malignancy disorders and other factors that stimulate the bone marrow such
as Growth-Stimulating Factors (G-CSF). Also, increased granulation in neu-
trophils indicates serious infection or patients undergoing chemotherapy.
Aims: To compare the manual IG with the IG provided from an automated
hematology analyzer. 
Methods: A total of 143 unselected whole-blood samples were collected in
tubes with K3-EDTA and were analysed in approximately 3 h of collection.
Patients who had their blood counts monitored on a daily basis were excluded.
The automated IG% results (a percent of the total white blood count) provided
from the hematological analyzer (Sysmex-XE 5000) were divided into three
groups IG<1 (61 samples), IG 1-10 (61 samples), IG >10 (21 samples) and
compared to manual IG counts. The first two groups were similar in regard to
sex (39 males-22 females) and age (8-86 years avg=59,4 years). In the third
group there were 14 males and 7 females, the age was 18 to 88 years
(avg=58,4 years). The peripheral blood smears, from flagged reported samples
(Imm Gran), were stained with May-Grünwald- Giemsa by Sysmex SP-100
slide system. The immature granulocytes and granularity of the neutrophils,
were generated by two expertised physicians. Mean value comparison using
paired t-tests was used in order to examine the statistical significance among
the groups. The significance level was defined as P<0.05. All statistical analysis
was performed using SPSS 20 and Mc Excel 2010.
Results: In the first group with the automated IG<1, the manual IG count was
zero, so there was an agreement between visual microscopy and SYSMEX
XE-5000. In the second group there was also an agreement in comparison to
the manual IG. The difference of the mean values of IG1-10 between the man-
ual IG and the automated IG is not statistically significant (p-value >0,05) show-
ing that there is no difference between the two methods. In the third group
there was a difference. The manual IG percentage revealed a higher number
of immature granulocytes than the automated IG. The difference between the
microscopic and manual results increased with increasing levels of IG. In the
third group, the number of specimen was very low so, in order to acquire reliable
results, a larger number of samples should be generated. 
Summary and Conclusions: Immature granulocytes (IG) are a predictive use-
ful parameter for the presence of infection, sepsis, inflammation, treatment with
oncolytic drugs or bone marrow activation. For blood samples whose IG was
>1%, a microscopic examination should be operated. In addition, taking into
consideration IG% as a marker, a serious number of spurious blood film reviews
might be reduced and minimized. Also, the implication to shorter turn-around
times would enhance the diagnostic effectiveness.
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VORICONAZOLE AND CASPOFUNGIN COMBINATION THERAPY IS
EFFECTIVE AND SAFE FOR PROBABLE AND POSSIBLE INVASIVE
PULMONARY FUNGAL INFECTION IN PEDIATRIC ACUTE LEUKEMIA
J.M. Lee1,* Y.T. Lim1, K.H. Suh1, S.Y. Kim1, Y.K. Kim2, C.H. Lee2
1Pediatrics, 2Laboratory Medicine, College of Medicine, Yeungnam University,
Daegu, Korea, Republic Of
Background:Aspergillus species have emerged as an important cause of life-
threatening infections in immunocompromised patients. Despite timely diag-
nosis and appropriate antifungal therapy, clinical outcome might be disappoint-
ing, necessitating treatment with a combination of antifungal agent.
Aims: in this study, we report the efficacy of voriconazole and caspofungin in
pediatric acute leukemia.
Methods: We identified 30 pediatric acute leukemia patients who received the
combination of CAS and VRC for invasive fungal infection (IFI) from April, 2009
to May, 2013 in pediatric department of Yeungnam university hospital. Medical
records of patients were reviewed and analyzed retrospectively. We analyzed
data that included the following: Demographic characteristics, underlying dis-
ease and disease state, radiological findings and outcome in patients with IFI.
Results: Of the 30 consecutive patients who receive CAS and VRC during
study period, 8 patients were not evaluable for the following reasons: pneumo-
nia not attributed to fungus (n=3), non-infectious pulmonary infiltration (n=5). 
The study group comprised 11 boys and 11 girls, with mean age was 7 years
(range, 0.8-13.3) years. Underlying diseases were acute lymphoblastic
leukemia (ALL) in 11 of these patients, acute myeloid leukemia (AML) in 11 of
patients. No patient had received hematopoietic stem cell transplantation nor
immunosuppressive treatment at the onset of IFD. IFD were classified as prob-
able in 9 (41%) and possible in 13 (59%) patients, respectively. All but 1 patients
had received previous empirical antifungal monotherapy with conventional
amphotericin B, liposomal amphotericin B and fluconazole (range 1-21 days)
before start of VRC and CAS combination therapy. One patient had started de
novo combination antifungal therapy. The median duration of VRC and CAS
combination therapy was 45 (range, 5 – 99 days) days. Loading and mainte-
nance dose of CAS were 63.1±7.7 mg/m2 and 47.2±6.0 mg/m2 respectively.
Those of VRC were 5.9±0.5 mg/kg and 3.6±0.60 mg/kg respectively. The sur-
vival rate of 100 days after initiation of combination therapy is 90.9%. Twenty
patient (90.9%) had response to combination therapy. (19 complete response
and 1 partial response). Age, sex, underlying disease, disease state, treatment
phase, oxygen and intravenous immunoglobulin therapy did not affect overall
response and overall survival by univariate analysis. VRC and CAS combination
therapy was well tolerated except for 2 patents. Two had mild increased in liver
enzyme.
Figure 1.
Summary and Conclusions: Voriconazole and caspofungin combination ther-
apy is effective and safe treatment for serious invasive pulmonary fungal infec-
tions in pediatric acute leukemia
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POSACONAZOLE AS PRIMARY PROPHYLAXIS REDUCES INVASIVE
FUNGAL INFECTIONS IN AML PATIENTS: A SINGLE CENTRE MATCHED
PAIRED ANALYSIS
P. Minetto1,* F. Guolo1, G. Pastori1, L. Giannoni1, D. Guardo1, D. Avenoso1,
M. Clavio1, M. Miglino1, R. M. Lemoli1, M. Gobbi1
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCSS AOU San Martino-IST, Genoa, Italy
Background: Prevention and prompt treatment of invasive fungal infections
(IFI) in acute myeloid leukemia (AML) patients can improve overall survival by
reducing infection-related mortality and allowing to receive full planned
chemotherapy in a timely manner. 
Aims: Since January 2013, AML patients undergoing intensive chemotherapy
in our institute and potentially eligible for bone marrow transplantation received
posaconazole (PSZ) as IFI prophylaxis. The aim of the present study was to
evaluate tolerability and efficacy of PSZ and to optimize our clinical practice.
Methods: From January 2013 to October 2014, 35 patients treated for newly
diagnosed AML in our institute received PSZ for antifungal prophylaxis.
Non promyelocytic AML patients received a fludarabine, cytarabine and idaru-
bicin containing regimen (FLAI) as first line treatment. M3 AML patients were
treated according to GIMEMA AIDA 2000 protocol.
PSZ was given at the standard dose of 200 mg for 3 times/day, concurrently
with a fat snack or with at least 100 ml of an acidic drink. Because of unpre-
dictable absorption rates PSZ serum levels (TDM) were assessed routinely
according to a validated high-performance liquid chromato-graphic (HPLC)
method as described. To detect factors affecting PSZ exposure we analyzed
each period of hospitalization as a single independent event.
We retrospectively compared through a matched-paired analysis 22 non M3
AML patients treated with PSZ as IFI prophilaxys to a control historical series
of 22 patients who had received fluconazole (FLC) or itraconazole (ITZ). Of 22
patients in PSZ cohort, 18 received subsequent induction cycle 2 and 6 received
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consolidation therapy, therefore accounting for a total of 46 episodes of pro-
longed neutropenia. In FLC/ITZ arm 22 patients received cycle 2 and 6 received
consolidation therapy, for a total of 50 episodes of prolonged neutropenia.
Matching variables were sex, age, response to induction. Patients median age,
sex and days of severe neutropenia were not significantly different between
the two cohorts. The incidence of IFI and the days of empirical or targeted
intravenous antifungal therapy were analyzed.
Results: PSZ showed a good tolerability profile with no serious adverse events
clearly related to prophylaxis occurring. A median number of 3 TDM for each
period of hospitalization was performed (range 2-6). The achievement of a
plasmatic PSZ concentration >0,7 mcg/mL is considered optimal for prophylaxis
efficacy; in 39/65 (60%) episodes of hospitalization and treatment, with at least
two TDM, the threshold PSZ serum concentration was reached, with stable
plasmatic levels. Median PSZ plasmatic value at first assessment was 0.73
mcg/mL (range 0.1-3.9). The strongest negative factors affecting PSZ absorp-
tion are the temporary discontinuation of prophylaxis and the concomitant
assumption of proton pump inhibitors. No proven or probable IFI were observed
in the PSZ cohort. Data coming out from the matched paired analysis demon-
strated a significant reduction in IFI incidence in our institution: 0% in PSZ
cohort Vs 12% (6 proven/probable IFI episodes over 50 severe neutropenic
periods) in FLC/ITZ cohort (P<0.05). Mean days of targeted/empirical intra-
venous antifungal therapy for single patient in PSZ cohort was 0 days Vs 2.2
days in FLC/ITZ cohort (P<0.05).
Summary and Conclusions: Our clinical experience confirms the benefit and
potential cost-effectiveness of primary prophylaxis with PSZ in AML patients
receiving intensive treatment, as no patients in PSZ cohort experienced IFI
nor received empirical intravenous antifungal therapy. 
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IMPACT OF CHEMOTHERAPY REGIMENS WITH ESCALATED ANTHRA-
CYCLINES ON INCIDENCE OF FEBRILE NEUTROPENIA IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA
I. Iskrou1,* I. Stoma1, I. Lendzina2
1cells transplantation, 2Hematological, City Clical Hospital №9, Minsk, Belarus
Background: Modern chemotherapy schemes of acute myeloid leukemia
include remission of induction regimens with escalated doses of anthracyclines
(escalated “7+3” regimen). Changes in incidence of febrile neutropenia are not
clear in patients receiving remission induction regimen “7+3” with escalated
anthracycline dose (90mg̸m2 ) comparing to standart “7+3” chemotherapy reg-
imen(45mg̸ m2 ).
Aims: The aim of the study was to assess the influence of “7+3” chemotherapy
regimen with escalated anthracyclines on incidence of febrile neutropenia in
patients with acute myeloid leukemia comparing to standard “7+3” chemother-
apy regimen.
Methods: 56 hospitalization episodes of patients with acute myeloid leukemia
on chemotherapy from March 2013 to January 2014 were reviewed. Incidence
of febrile neutropenia (fulfilled criteria of Freifeld et al., 2011) was compared in
the groups receiving standard “7+3” regimen and “7+3” with escalated anthra-
cyclines. Groups were comparable by age and gender characteristics and
adjusted for other possible confounders. 
Results: No statistically significant difference in incidence of neutropenia in
patients receiving the escalated “7+3” regimen comparing to the standard one
was found (71% to 70% accordingly, P=1, exact Fisher’s criterion). 
Summary and Conclusions: Use of “7+3” chemotherapy regimen with esca-
lated anthracycline dose in treatment of acute myeloid leukemia does not
increase the risk for development of febrile neutropenia in patients. 
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PREDICTORS OF OUTCOME AND SEVERITY IN ADULT FILIPINO
PATIENTS WITH FEBRILE NEUTROPENIA
R.E. Villalobos1,* M.G. Yu1, R. Berba1
1Department of Internal Medicine, Philippine General Hospital, Manila, Philip-
pines
Background: Febrile neutropenia carries a significant mortality rate of 5-21.5%,
warranting early recognition and institution of appropriate therapy. In the Philip-
pines, there is a lack of studies on prognostic factors that predict poor outcome
in patients with febrile neutropenia. It is important to identify these factors to
recognize patients who will benefit from early aggressive therapy and closer
monitoring.
Aims: The study aimed to describe the clinical, laboratory, and microbiologic
profile of adult Filipino patients with febrile neutropenia, and to determine spe-
cific parameters that are potentially associated with severe outcomes, compli-
cations, and mortality.
Methods: This is a retrospective study of adult febrile neutropenia patients,
regardless of cause, admitted at the Philippine General Hospital from January
2010-October 2014. Patients were described in terms of clinical, laboratory,
and microbiologic presentation, and stratified according to the presence or
absence of severe outcomes. Prognostic factors were then identified using
univariate and multivariate logistic regression analysis. 
Results: A total of 115 febrile episodes in 102 patients were identified. There
was no difference in median age or gender ratio between the complicated and
non-complicated groups; leukemia (48.7%) was the most common primary
underlying disease in both groups. Most patients (50.43%) had infections of
the respiratory tract, with Gram negative organisms predominating in the com-
plicated group. The factors that significantly predicted poor outcome in the uni-
variate analysis were non-treatment/relapse of the underlying disease (OR
2.28; 95% CI, 1.04-4.98; P=0.040), prolonged fever >7 days prior to admission
(OR 3.24; 95% CI, 1.16-9.01; P=0.024), non-recovery from neutropenia (OR
2.17; 95% CI, 1.01-4.68; P=0.048), and severe thrombocytopenia<50,000/uL
(OR 3.45; 95% CI, 1.52-7.84; P=0.003.) Meanwhile, completeness of antibiotic
therapy significantly predicted a better outcome (OR 0.26; 95% CI 0.12-0.57;
P=0.001.) Using the factors that reached significance in the univariate analysis,
subsequent multivariate analysis yielded prolonged fever (OR 2.43; 95% CI,
0.77-7.74), isolation of a pathogen on cultures (OR 2.69; 95% CI, 1.04-6.98),
and nadir absolute neutrophil count (ANC)<100 during admission (OR 1.96;
95% CI, 0.75-5.12) as significant predictors of poor outcome. The factors that
significantly correlated with better outcome were granulocyte colony-stimulating
factor (G-CSF) use (OR 0.31; 95% CI, 0.11-0.85) and completeness of antibiotic
therapy (OR 0.26; 95% CI, 0.10-
Summary and Conclusions: Adult febrile neutropenia patients with prolonged
fever >7 days prior to admission, known pathogen on cultures, and nadir
ANC<100 during admission were at significant risk of developing worse out-
comes, whereas those with G-CSF use and complete antibiotic therapy were
significantly associated with better outcomes. These prognostic variables might
be useful in identifying patients that need more intensive treatment and closer
monitoring. 
PB1816
CHEMOTHERAPY-INDUCED NEUTROPENIA AMONG PEDIATRIC
CANCER PATIENTS IN EGYPT: RISKS AND CONSEQUENCES
T. Hassan1,* M. Badr1, H. Sakr1, M. Al Malky1, W. Al-Saeed1
1pediatrics, Zagazig university, zagazig, Egypt
Background: Chemotherapy –induced neutropenia (CIN) is the major dose-
limiting toxicity of systemic chemotherapy, and is associated with substantial
morbidity, mortality and costs. 
Aims: The aim of the current work was to identify risk factors that may predis-
pose pediatric cancer patients, treated with myelo-suppressive chemotherapy,
to CIN and associated sequels.
Methods: 113 neutropenia episodes were analyzed, risk factors for CIN were
classified into; patient-specific, disease-specific and regimen specific while
consequences associated with CIN were divided into infectious and dose mod-
ifying sequels. Both risks and consequences were analyzed to target high risk
patients with appropriate preventive strategies.
Results: 28% of our patients presented with single neutropenia attack while
72% of them experienced recurrent attacks during their treatment cycles. Mean
absolute neutrophil count (ANC) was 225.5±128.5 (109/L), ranged from 10-
497(109/L) started at 14.2±16.3 days (ranged 2-100) after the onset of
chemotherapy and resolved within 11.2±7.3 days either with (45.1%) or without
(54.9%) granulocyte colony stimulating factor (G-CSF).No significant associa-
tion could be found between any patient character or disease stage and the
risk for CIN. However, certain malignancies (ALL, Neuroblastoma and Burkitt’s
lymphoma) and certain regimens (induction blocks for ALL, AML) had the worst
myelotoxic effect with severe and prolonged neutropenia episodes. G-CSF sig-
nificantly shortened the neutropenia episodes and enhanced bone marrow
recovery. Febrile neutropenia was the leading complications among our cases
(73.5%), associated with several documented infections particularly mucositis
(54.9%), respiratory (45.1%), GIT (38.9%) and skin (23.9%) infections. 6% of
our cases died of infection –related complications. Neutropenia was responsible
for treatment discontinue (13.3%), dose delay (13.3%), and dose reduction
(5.3%) of our patients. The mean cost for each episode in our service was
9386.5±6688.9 Egyptian pounds (L.E) which represented a significant burden
on health care providers.
Summary and Conclusions: Although this study is preliminary survey with
relatively small number of patients, our findings are relevant to clinical care of
pediatric cancer patients in our region. Special attention to CIN prevention
should be directed to hematologic malignancy cases especially at early cycles.
Severe and prolonged neutropenia are life-threatening events that need
aggressive management.
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MENTAL DISORDERS OBSERVED DURING THE APPLICATION OF
VORICONAZOLE
D.E. Vybornykh1,* G. Klyasova1, E. Mikhailova1, L. Kuzmina1, V. Troitskaya1,
O. Pokrovskaya1, E. Urnova1, M. Drokov1, E. Parovichnikova1
1National Research Center for Hematology, Moscow, Russian Federation
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Background: Among the side effects of the drugs from the group of antifungal
agents voriconazole are the mental disorders by different psychopathological
registers.
Aims: The aim was to study the typology of mental disorders and therapeutic
approaches in the event of psychosis in patients with hematological diseases
complicated by fungal infection, during the application of voriconazole.
Methods: There were studied 15 patients with various hematological diseases
(AML, ALL, MM, AA) by the clinical method in the period from 2006 to 2014, in
which observed the development of mental disorders during therapy with voricona-
zole in connection with invasive fungal infections (aspergillosis, candidiasis).
Results: Of the 15 patients, 11 demonstrated hallucinatory syndrome. Devel-
opment hallucinosis in most cases within 1-2 days underwent almost stereotyp-
ical dynamics-the formation of psychopathological disorders began with demon-
strations insomniac disorders (violation of falling asleep, frequent awakenings),
joined by vivid nightmares with disturbing content, accrued unexplained anxiety,
persistent daytime (4 patients of the 11 alarm combined with hypothymia
(depressed mood). Then, against the clear consciousness and stored criticism,
manifest verbal perceptual deception by type of acoasma (hiss, scratches) or
elementary functional hallucinations (addressed to the patient isolated words or
phrases arising on a background of real sounds of medical equipment or per-
sonnel speech), which gradually became more complicated. With closed eyes
formed visual hallucinatory disorders that were in the nature of sensuous vivid-
ness, and were represented by a set of bright, moving images of people and
(rarely) animals of normal size or reduced. It is noted high involvement of the
patient in what is happening-“people” were talking among themselves and with
the patient, “commented” his actions and thoughts. There was not noted the
increasing of anxiety on the background of experienced by patients deceptions
of perception. In 4 patients, hallucinatory disorders are not formed and mental
disorders limited by insomniac, anxiety disorders and hypothymia and had more
short-term character than in the previous group of patients. Described disorders
in patients persisted for 6±2 days on average. Formation of described psy-
chopathological disorders occurred on the background of significant somatogenic
asthenia caused by severe hematologic malignancies and its complications
(including infectious origin) and intoxication by chemotherapeutic agents. In the
history of the patients showed no manifest psychopathological disorders. Treat-
ment of mental disorders in the studied patients was phased. The aim of the
first phase was psychosis reduction, the second – the support treatment to pre-
vent relapse of psychotic disorders. Preference was given to intravenous admin-
istration of psychotropic drugs (in most cases – through a central venous
catheter) that correspond to the guidelines for the management of patients with
haematological diseases. In hallucinatory disorders the main therapeutic inter-
vention focused on the first stage; the treatment have a short duration and
include the use of butyrophenone antipsychotics (haloperidol 10 mg / day). In
necessary of the rapid sedation or relief the anxiety/insomniac disorders
diazepam was administered in therapeutic scheme (20 mg/day).
Summary and Conclusions: During the application of voriconazole the mental
disorders may occur (most often formed hallucinatory syndrome) that require
psychopharmacological correction.
Myelodysplastic syndromes - Biology
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IN VITRO EVALUATION OF A BACTERIAL BIOLUMINESCENT REPORTER
ASSAY FOR ASSESSMENT OF RESPONSE TO DECITABINE
A. Aruomaren1,* K. Page1, C. Stratford-Smith2, V. Salisbury2, M. A. Smith3,
M. Ruddock4, A. Martin4, C. Reid4, J. Lamont4, H. Alloush1, J. May1,
E. Anderson1
1Centre for Research in Biosciences, 2University of the West of England, Bristol,
3Royal Marsden NHS Foundation Trust, Surrey, 4Randox Laboratories Ltd,
Belfast, United Kingdom
Background: Decitabine (DAC) is a cytidine analogue and hypomethylating
agent used in the management of patients with myelodysplastic syndrome
(MDS) and increasingly in acute myeloid leukemia (AML). Cellular uptake via
the hENT1 transporter and subsequent phosphorylation by deoxycytidine
kinase (dCK) produces the active metabolite decitabine triphosphate (DAC-
TP). DAC-TP is incorporated into DNA, where it covalently binds to and inacti-
vates DNA methyltransferases (DNMTs), leading to hypomethylation and poten-
tial re-expression of silenced tumour suppressor genes. DAC is also known to
have a direct cytotoxic effect on leukaemic cells. DAC has been compared
extensively with the related compound azacytidine (AZA) clinically. Only 10-
20% of intracellular AZA is converted to DAC-TP leading to hypomethylation,
compared with 100% DAC-TP from DAC. Trials have shown AZA to be clinically
favourable, indicating that a lower intracellular concentration of DAC-TP could
be beneficial. Current opinion is that DAC may be useful following appearance
of resistance to AZA. Therefore a tool that could assist in predicting individual
patient benefit from treatment with DAC is needed, particularly considering
associated costs to healthcare services for this drug (~$80,000 pa per patient).
Aims: This study aimed to assess the feasibility of detecting DAC and DAC-TP
using a previously validated biosensor sensitive to the cytidine analogue cytosine
arabinoside (ara-C) (Alloush et al., Clin Chem. 2010;56(12):1862-70). Biosensor
HA-1 is a cdd-deficient, bioluminescent bacterium with inducible expression of
human dCK that is specific for toxic analogues of cytidine. Biosensor HA-1 has
been formulated into an assay capable of predicting response to treatment within
8-hours and is currently undergoing clinical evaluation for ara-C.
Methods: Direct application of DAC to biosensor HA-1 using a clinically relevant
dosing range (0.1-10 mM) equivalent to 15-150 mg/m2 resulted in a dose-
dependent increase in light output, with maximum 2.6-fold increase over control.
A concurrent decrease in bacterial growth was observed as previously noted
with ara-C, confirming intercalation of bacterial DNA with DAC-TP. Direct com-
parison of DAC with ara-C demonstrated an equivalent response by biosensor
HA-1 for both time to peak (5.25 hours) and scale of increase of light output
Results: Subsequently leukaemic cell lines, HL-60 and K562 were exposed to
DAC (0-10 µM) to assess whether DAC uptake and metabolism to DAC-TP
during the initial 1-hour post-dosing would predict cytotoxicity at 72 hours.
Assessment of cytotoxicity of DAC performed following daily dosing of DAC
(0.1 – 10 mM) on HL-60 and K562 cells over a 72-hour period indicated that
HL-60 cells were more susceptible to DAC-induced cytotoxicity than K562 cells.
Concurrent assessment of accumulation of parent DAC and DAC-TP using
biosensor HA-1 indicated that K562 cells produced more DAC-TP than HL-60
cells in the initial 1-hour post-dosing with DAC (≥1 mM), implying that the cyto-
toxicity observed may be more related to accumulation of parent DAC than
metabolite. Previous in vitro studies have observed that the IC50 concentration
of DAC is associated with maximal hypomethylation, indicating that DAC-TP
could be responsible for the suppression of proliferation observed
Summary and Conclusions: Studies are on-going in our laboratory to directly
assess DAC-TP using biosensor HA-1 and compare with hypomethylation in
cell lines and patient blasts to define the intracellular drug kinetics of DAC, and
further dissect the role of parent drug and metabolite in DAC-mediated toxicity.
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LOW RPS14 EXPRESSION IN THE NON 5Q- MYELODYSPLASTIC
SYNDROMES 
S. Grassi1, E. Ciabatti1, M. Rousseau2, F. Guerrini1, N. Cecconi1, G. Cervetti1,
P. Musto3, F. La Rocca4, D. Cilloni5, V. Gaidano5, I. Petrini6, A. Poloni7,
G.A. Palumbo8, S. Galimberti1,*
1Clinical and experimental Medicine, 2UO Hematology University of Pisa, Pisa,
3IRCCS-CROB, Rionero in Vulture, Italy, 4Laboratory of Preclinical and Trans-
lational Research, IRCCS-CROB, Rionero in Vulture, 5Oncology, Division of
Hematology and Internal Medicine, Turin, 6Department of Translational Medi-
cine, Pisa, 7Department of Clinical and Molecular science, Division of Hema-
tology, Ancona, 8Hematology-AOU “Policlinico-V.Emanuele, Catania, Italy
Background: The RPS14 gene, located on chromosome 5 and involved in the
ribosomal protein synthesis, has been reported as a causal factor in the 5q-
syndrome, where its up-regulation during treatment with lenalidomide has been
associated with best responses. RPS14 expression in non-5q-MDS was report-
ed in 53%>71% of cases. Interestingly, in low and intermediate-1 IPSS sub-
groups, patients with lower RPS14 expression had longer OS.
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Aims: The aim of this study was to assess the RPS14 expression in a larger
series of non-5q- MDS patients.
Methods: A total of 112 patients, 45% females and 55% males, with a median
age of 71-year (range 19-89), were enrolled in 5 different Italian institutions
from March 2010 to October 2014. Nine patients were affected by CMMoL; the
prognosis of the remaining 103 cases was determined according to the IPSS
in low (36%), intermediate-1 (31%), intermediate-2 (21%), and high risk (12%).
About 40% of cases were affected by RCMD, 24% by RAEB-2, and 13% by
RA. Twelve bone marrow samples from healthy donors have been used as
normal references.
Results: In healthy donors, the mean RPS14 expression was 0.94±0.26; in the
whole MDS series, it was 0.57±0.42. In comparison with healthy controls, the
52% of MDS cases showed lower RPS14 expression levels: 79% in the RA,
56% in the RAEB1, 44% in the RAEB-2, and 41% in the RCMD subgroups.
When patients were stratified according to the IPSS, in the half of the low, inter-
mediate-1 and intermediate-2 cases RPS14 was under-expressed, opposite to
one third of the high risk and 13% of the CMMoL patients only. No relationships
with age or sex were observed. To evaluate if the haploinsufficiency would be
responsible of the low expression of RPS14 gene, we performed the copy num-
ber assay on 32 MDS, 15 healthy donors, and 3 patients with 5q- syndrome: in
91% of cases the copy number assay excluded the haploinsufficiency.
Summary and Conclusions: Our study showed in a large series of patients
that a lower RPS14 expression interests the half of the non-5q- cases, espe-
cially those affected by RA and at low and intermediate IPSS risk. Other authors
previously reported that low expression of RPS14 was not due to promoter
hypermethylation. Here we demonstrated that also the haploinsufficience is
not the cause of the RPS14 low expression. Moreover, our findings suggest a
possible role for lenalidomide in non-5q- MDS, especially in low risk patients.
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MOLECULAR MAPPING OF THE PDGFRB/SPTBN1 GENE FUSION
TRANSCRIPT AS A RESULT OF THE T(2;5)(P16.2;Q33.1) IN AN IMATINIB
MESYLATE-RESPONSIVE MDS 
D. Koumbi1,* P. Kollia2, S. Samara22, M. Psyllaki3, V. Pappa4, S. Zachaki1,
A. Daraki1, M. Kalomoiraki1, K. Manola1, G. Pantelias1, H. Papadaki3,
C. Sambani1,
1Health Physics, Radiobiology & Cytogenetics, NCSR “Demokritos”, 2Depart-
ment of Genetics and Biotechnology, Faculty of Biology, Athens, 3Department
of Hematology, University Hospital of Crete, Heraklion, 4Hematology Unit, 2nd
Dept. of Internal Medicine, Athens, Greece
Background: PDGFRB is a member of the tyrosine kinase family and
PDGFRB gene rearrangements, already reported in myeloproliferative neo-
plasms (MPN), lead to its constitutive activation, ultimately affecting cell prolif-
eration and migration. Patients with PDGFRB rearrangements respond to ima-
tinib mesylate therapy. The t(2;5)(p16.2;q33.1) (PDGFRB/SPTBN1) has been
reported only in one case of atypical MPN. SPTBN1 is a cytoskeletal protein
with a role in mitotic spindle assembly.
Aims: The aim of the study was to fully characterize the partner fusion gene
products formed as a result of the t(2;5)(p16.2;q33.1), encountered for the first
time in a MDS patient.
Methods: A 78-years-old man presented for investigation of macrocytic anemia
in 2012. Bone marrow smear showed mild dysplastic features in the granulo-
cytic and megakaryocytic series. Bone marrow biopsy showed 60% cellularity
and 4% CD34+ cells. The findings were consistent with MDS diagnosis. One
year later, a new biopsy showed 23% CD34+ cells and dyserythropoiesis. The
patient was administrated imatinib mesylate and since July 2014 has achieved
hematological remission. Following karyotypic analysis on bone marrow cells,
interphase and metaphase FISH studies with specific BAC probes (UCSC
Genome Bioinformatics, Source Bioscience) were performed in order to refine
the chromosome breakpoints and detect the partner genes. RP11-
100O5/RP11-368O19 BAC probes encompassing the PDGFRB gene at 5q33.1
and RP11-423Ν19/RP11-1022E1 BAC probes flanking the SPTBN1 gene at
2p16.2, were fluorescently labeled by nick-translation and used as dual-color
break-apart probes. For the molecular characterization of the partner genes,
5’ rapid amplification of cDNA ends, followed by single step 5’RACE PCR was
performed using a 5’Gene Racer primer (Life Technologies) and a reverse
primer for PDGFRB exon 15. Second step PCR was carried out with a 5’Gene
Racer nested primer and a reverse nested primer for PDGFRB exon 15. Fol-
lowing cloning, sequence analysis of the PCR products was conducted to fully
characterize the fusion transcripts.
Results: At diagnosis the karyotype was: 46,XY,t(2;5)(p16;q33)[20]/46,XY[5].
iFISH detected PDGFRB and SPTBN1 gene rearrangements in 56% of the
cells. Based on those results, the patient was administrated imatinib mesylate
and has favorably responded thus far. Metaphase FISH revealed translocation
of 5’ PDGFRB at 2p16.2 and fusion with the 3’ SPTBN1 onto derivative chro-
mosome 2. Accordingly, the 5’ of SPTBN1 was translocated at 5q33.1 and
fused with the 3’ PDGFRB onto derivative 5. For the molecular characterization
of the fusion gene transcripts, cloning and sequencing of the 5’RACE PCR
products, showed that SPTBN1 exons 1-3 were fused to PDGFRB exon 12
onto derivative chromosome 5.
Summary and Conclusions: Cytogenetics identified the PDGFRB/SPTBN1
fusion gene generated from the rare translocation t(2;5)(p16.2;q33.1). Thorough
molecular mapping analyses revealed that the genomic breakpoints were locat-
ed at exon 3 of SPTBN1 gene and exon 12 of PDGFRB gene, leading to a
PDGFRB/SPTBN1 fusion transcript comprising exons 1-3 of SPTBN1 gene
and exon 12 of PDGFRB gene onto derivative chromosome 5. Importantly, the
involvement of tyrosine kinase gene PDGFRB in t(2;5), encountered for the
first time in a MDS case, prompted the administration of a successfully tai-
lored-based signal transduction therapy (imatinib mesylate) to the patient.
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EVALUATION OF P53 PROTEIN EXPRESSION IN MYELODYSPLASTIC
PATIENTS: PROGNOSTIC IMPACT IN A SINGLE CENTRE EXPERIENCE
A. Ricco1,* A. napoli2, P. carluccio1, A.V. Russo Rossi1, C. pasciolla1, M. leo1,
A. franco1, B. daraia1, V. carluccio1, A. cellamare1, G. specchia1,
1Department of Emergency and Transplantation, Hematology Section, 2Depart-
ment of Emergency and Transplantation, Pathology Section, University of Bari
Medical School, Bari, Italy
Background: AML follwing MDS has a very poor outcome, so accurate pre-
diction is essential, expecially in patients who could potentially be cured by
stem cell transplantation. A strong association between p53 protein expression,
the TP53 mutation and an adverse outcome has been reported in various
hematologic malignancies including MDS. Strong nuclear staining of the p53
protein by immunhistochemistry (IHC) has been used as a surrogate marker
for TP53 gene mutation in hematologic and other malignancies; a strong cor-
relation of p53 nuclear expression with TP53 mutation has also been demon-
strated.
Aims: To assess the role of p53 expression in MDS patients as a new prog-
nostic tool, as well as its feasibility in routine clinical practice, we analyzed the
prevalence of p53 expression in a cohort of 62 consecutive bone marrow (BM)
biopsies from patients with MDS at diagnosis, and correlated our findings to
other validated prognostic markers and clinical outcome
Methods: The DO-7 antibody (DakoCytomation, Denmark), which labels both
wild and mutant-type p53 proteins, was used to detect p53 expression (a col-
orectal carcinoma positive control was included on each slide). Diagnosis
according to the 2008 WHO Classification was: isolated del (5q) in 4 cases,
RA in12, RARS in 5, RCMD in 8, RAEB-1 in 15, RAEB-2 in 18.
Results: Among patients with strong p53 immunostaining in ≥1% of BM cells,
we found significant correlations with BM blasts (70% RAEB-1/2, vs 32% in
negative cases). IPSS-R cytogenetic risk was int/poor/very poor in 36% of pos-
itive and 0% in negative IHC cases. IPSS score was int-2/high in 54% of
patients with strong positivity vs 20% in negative cases. BM fibrosis was present
in 70% of positive vs. 30% of negative IHC cases. Transfusion dependency
was observed in 50% of patients with p53 strong expression vs. 20% of neg-
ative cases. Moreover, we found that strong p53nuclear expression was asso-
ciated with a significantly worse outcome (87% disease progression plus
leukemic evolution vs. 20% in negative cases) and shorter median OS (18
months vs. 35 in negative cases).
Summary and Conclusions: Our data indicate that IHC p53 protein expres-
sion, evaluated in bone marrow biopsies by a widely available method, is a
highly predictive marker and thus a helpful tool in risk assessment and the
decision making process in MDS.
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MYELODYSPLASTIC SYNDROMES: AN INTEGRATED WORKUP FOR A
CORRECT DIAGNOSIS
E. Ciabatti1,2,*A. Valetto3, V. Bertini3, F. Guerrini1, S. Grassi1, M.I. Ferreri3,
A. Guazzelli3, A. Azzarà1, I. Petrini4, P. Simi3, M.R. Metelli1, M. Petrini1,
S. Galimberti1
1Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa,
2GenOMec, University of Siena, Siena, 3Medicine Laboratories, AOUP, Pisa,
4Translational Research and New Technologies in Medicine, Oncology, Uni-
versity of Pisa, Pisa, Italy
Background: The diagnosis of MDS is determined by bone marrow’s histology
and is integrated by conventional cytogenetic (CC) analyses that, although,
are unable to show chromosomal abnormalities in about 30% of cases. Array
Comparative Genomic Hybridization (aCGH) detects copy number aberrations
in half of MDS diploid by CC. Recently, TET2, ASXL1, EZH2, CBL, IDH1/IDH2,
DNMT3A, and UTX mutations have been described in MDS.
Aims: Therefore, we evaluated the prognostic and predictive implications of
FISH, aCGH and mutation assays when added to CC. 
Methods: Fifty patients, 15 females and 35 males, with a median age of 72-
year (range 39-88) were enrolled in a single institution (Hematology Unit, Uni-
versity of Pisa, Italy), between March 2013 and October 2014. Patients’ prog-
nosis was determined according to IPSS in low (42%), intermediate-1 (33%),
intermediate-2 (17%) and high risk (8%). Samples were evaluated by CC includ-
ing, conventional karyotyping and FISH for chromosome 5, 7, PDGFRA, and
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PDGFRB. Moreover, aCGH was performed using SurePrint G3 Human CGH
Microarray, 8x60K (Agilent), and mutations of TET2, TP53, ASXL1, and EZH2
were determined using qBiomarker somatic mutation PCR array (Qiagen).
Results: After FISH analysis, additional copy number losses of chromosome
3 and 5 were observed in 1 and 2 cases, respectively. According to aCGH, 20
patients (40%) showed copy number aberrations (Table). Seventeen patients
had a mutation: 12 in TP53, 4 in ASXL1 and 1 in TET2 sequence.
Table 1.
Summary and Conclusions: 1) The study showed the reduction of CC failures
(only 16%); 2) Because of FISH results, a patient received azacitidine and
another one lenalidomide; 3) Three MDS patients with copy number aberrations
detected exclusively by aCGH progressed in acute leukemia being lethal: one
patient had copy number loss of chromosome 3, one had copy number losses
of chromosomes 8 and Y and the last one had copy number loss of ETV6 locus.
4) One patient with TET2 mutation did not respond to the azacitidine. Three
out of 4 patients with ASXL1 mutation had a good response to epoietin. TP53
mutations were observed in 12 cases of which 2 developed acute leukemia, 2
were resistant, and 2 sensitive to epoetin. In conclusion, our results support
the relevance of an integrated work-up for MDS and provide a preliminary esti-
mation of copy number aberration and mutation frequencies. The prognostic
role of aCGH and somatic mutations needs to be determined in properly sized
series.
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CD38 EXPRESSION ON CD34+ BONE MARROW CELLS (BM) AS A TOOL
IN LOW GRADE MYELODYSPLASTIC SYNDROMES (MDS)
R. Siguenza1,1,* M.H. Bañas1, I. Casas1, F. Ibañez1, N. Bermejo1, J.M. Bergua1,
M.J. Arcos1, J. Prieto1, M.L. Martin Mateos1, C. Cabrera1, F.D.A. Perez Leal1
1Hematología, Hospital San Pedro de Alcantara, Cáceres, Spain
Background: The diagnosis of MDS can be difficult, especially in the absence
of markers of clonality. Flow cytometry (FCM) has tried to be a useful tool but
the methods described so far are poorly standardized and time-consuming. 
Aims: Recently, a study has shown that a reduced expression of CD38 in the
CD34 + BM cells below a threshold value diagnosed low-grade MDS with high
sensitivity and specificity, (Goardon et al, Haematologica, 2009, 94:. 1160-
1163). Our aim was to test the effectiveness of this method.
Methods: We analyzed 140 BM samples sent to our laboratory between 2012-
2015 with suspected MDS. The samples were processed within 24 hours of
aspiration and were labeled with an antibody panel that included CD45-FITC,
CD34-PE-Cy5 CD38 PE, CD10 PE-Cy7, CD117-APC and CD19-APCCy7. A
sufficient number of nucleated cells was acquired on a FACSCanto (Becston
Dickinson) flow cytometer and CD38 expression was analyzed in CD34 +
myeloid and lymphoid blasts. The expression of CD38 was quantified as a ratio
as the MFI of CD38 on CD34 + cells divided by the MFI of isotype control stain-
ing. The result was considered pathological below the threshold value described
in the study (CD38 IMFR<110)
Results: Of the total of 140 patients, 71 patients were diagnosed with MDS
using current WHO criteria (2008): 39 RCDM, 7 RCUD, 2 AR, 10 CMML, 3
RAEB-1, 7 RAEB-2, 1 RARS,1 5q-, 1 MDS / MPD. In them, the ratio CD38
IMFR gave altered in 46 (64.5%). (Media 95.2, range 10.3-314.1). 69 patients
did not meet criteria for SMD, of which 61 (88.4% patients) had a normal ratio
(mean 145.9, range: 63.8-808.8).
In our case, the test gave a sensitivity of 64.5% and a specificity of 88.4% in
the diagnosis of MDS.
Summary and Conclusions: Our results confirm that CD38 expression is
reduced in CD34 + cells from MDS patients and may be helpful in the diagnosis
of low-grade MDS.
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COMPARISON BETWEEN CYTOMORPHOLOGY AND CYTOGENETIC
ANALYSIS FOR THE DIAGNOSIS OF MYELODYSPLATIC SYNDROME IN
COHORT OF 374 PATIENTS 
E. Lestang1,* J. Delaunay1, O. Theisen2, Y. Le Bris2, M. Eveillard2, P. Peterlin1,
P. Chevallier1, P. Moreau1, C. Godon2, M.C. Béné2, S. Wuilleme2,
1Service d’hématologie clinique, 2Laboratoire d’hématologie, Hôtel Dieu, CHU
de Nantes, Nantes, France
Background: Cytogenetic analysis is an essential step to establish the prog-
nosis in patients with myelodysplastic syndrome (MDS). In our center, the inves-
tigation of cytopenia includes a systematic cytogenetic analysis.
Aims: The aim of this work was to compare the efficiency in first intention of
bone marrow morphologic analysis to karyotype analysis to reach the diagnosis
of myelodysplastic syndrome.
Methods:A monocentric cohort of patients investigated for one or more cytope-
nia(s) was analysed. Patients diagnosed with MDS with blasts excess, acute
leukaemia, bone marrow localization of lymphoma or solid tumor were exclud-
ed. Blood, bone marrow smears morphology and karyotype were compared
according to the final diagnosis (MDS, immune, metabolic, inflammatory, con-
genital cytopenia).
Results: Between 2010 and 2013, samples of 374 patients were analysed.
Median age of the whole cohort was 66.8 y.o (1-91). 72% of patients had one
cytopenia (mostly anaemia in 50%), 20% were bicytopenic and 8% were pan-
cytopenic. Analysis of bone marrow smears revealed no dysplasia, a uni-or
multi-lineage dysplasia or an abnormality of cellularity in respectively 53%, 42%
and 5% of cases. Cytogenetic disclosed a normal karyotype in 84% and at
least one abnormality in 16% of patients. Loss of Y chromosom, recurring
abnormalities and del 5q were the most frequent karyotype abnormalities
respectively 7%, 3,7%, 3%. The diagnostic of MDS was retained in 105 patients
(29%) whereas 269 patients (71%) were classified as having a differential diag-
nosis of cytopenia (immune, metabolic, inflammatory, congenital). MDS sub-
types were refractory anemia (49%), refractory cytopenias with multilineage
dysplasia (20%), refractory cytopenia with unilineage dysplasia (17%), refrac-
tory neutropenia (1%), refractory thrombopenia (3%), del 5q syndrome (4%)
and MDS-unclassified (6%). In group of MDS patients compared to non-MDS
patients, blood test revealed a deeper anaemia (10.2 vs 11 g/dL, P< 0.0001),
a higher mean corpuscular volume (94 vs 89 fL, P<0.0001), a higher red-cell
distribution width (15.15 vs 13.8, P<0.0001). Then, bone marrow cytomorphol-
ogy showed more often at least one lineage dysplasia 86.7% vs 30% without
dysplasia (P<0.0001) and at least one karyotype abnormality in 32.6% vs 10%
without abnormality (P<0.0001). Finally, table 1 summarizes sensitivity, speci-
ficity, positive predictive (PPV) and negative value (PNV) of morphological and
cytogenetic analyses for the diagnosis of MDS
Table 1.
Summary and Conclusions: For the diagnosis of myelodysplastic syndrome,
cytomorphology of bone marrow is more sensitive but less specific than cyto-
genetics. Our results suggest that in case of cytopenia without blast excess or
malignant infiltration, blood and bone marrow smears microscopic examination
could be performed frontline and cytogenetic examination could be delayed at
the time of morphology confirmation after 1 to 3 months.
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MYELODYSPLASTIC SYNDROMES IN PATIENTS AFFECTED BY
AUTOIMMUNE DISEASES
C. Baldini1, E. Elefante1, E. Cioffi1, F. Ferro1, R. Vagelli1, M. Rousseau2,
E. Ciabatti2,3, R. Talarico1, M. Mosca1, S. Galimberti2,*
1Clinical and experimental Medicine, UO Rheumatology University of Pisa,
2Clinical and experimental Medicine, UO Hematology University of Pisa, Pisa,
3GenOMec, university of Siena, Italy
Background: Background: Several immunological abnormalities have been
reported among patients affected by myelodysplastic syndromes (MDS). On
the other hand, a relatively limited number of studies have explored the occur-
rence of MDS during the course of systemic autoimmune diseases (AD)
Aims: Aim of the study: to estimate characteristics and frequency of MDS
among patients with systemic autoimmune diseases (AD).
Methods: Methods: A retrospective systematic search through the electronic
health records of patients admitted at the Rheumatology University Medical
Center from 2009 and 2014 who were concomitantly evaluated by the Division
of Hematology was performed to select those patients with systemic AD and
MDS. To refine the search the ICD-9-CM diagnosis code for MDS was utilized.
Medical charts of eligible patients were retrieved and data were collected with
regard to demographics, type of AD, AD duration, prior treatments, bone mar-
row biopsy, and cytogenetic profile. Categorical variables were compared using
chi square test and Fisher’s test; continuous variables were compared using
Student’s t-test. A 2-tailed value of P<0.05 was taken to indicate statistical sig-
nificance.
Results: Results: Out of the medical records of 3800 patients, we identified
23 patients with AD and MDS. Patients’ median age at the diagnosis of MDS
was 65 years, with a 1.09:1 female to male ratio. Rheumatoid arthritis and
seronegative arthritis were the most frequent underlying AD condition (7/23,
30%) followed by large and small vessel vasculitis (7/23, 30%), Systemic Lupus
Erythematosus (3/23, 13%), Sjogren’s syndrome and myositis (2/23, 8%).
Moreover, one patient was affected by Systemic Sclerosis and one by Behçet’s
syndrome. Anemia (21/23, 91%) was the most common hematologic presenting
abnormality, followed by thrombocytopenia (9/23, 39%) and neutropenia (8/23,
35%). Three patients out of 23 presented with a trilineage cytopenia (13%). In
the majority of the patients the diagnosis of MDS was subsequent to that of
AD, with a median period between the two diagnosis of 4 years. Prior to MDS
diagnosis, about one third of the patients received cytotoxic drugs, among
which MTX was the most commonly prescribed (5/23, 22%) followed by aza-
thioprine and cyclophosphamide (2/23, 8%). Regarding MDS, the most com-
mon diagnosis was refractory anemia with excess of blasts (RAEB I and II)
(4/16, 25%) followed by sideroblastic anemia (2/16, 12%) and refractory anemia
(2/16, 12%). A progression to leukemia was documented in 2 patients.
Summary and Conclusions: Conclusions: Our study is limited by its retro-
spective design. However, our results documented that the frequency of MDS
in AD is not negligible and might be suspected especially in older patients pre-
senting with “unexplained” cytopenias.
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HYPERFERRITINEMIA IS ASSOCIATED WITH IMPAIRED SURVIVAL IN
PATIENTS DIAGNOSED WITH MYELODYSPLASTIC SYNDROMES
RESULTS FROM THE FIRST POLISH MDS REGISTRY 
A. Waszczuk-Gajda1,* J. Dwilewicz-Trojaczek1, K. Mądry1, J. Drozd-Sokolowska2
B. Stella-Holowiecka3, R. Machowicz1, A. Mital4, A. Obara5,
A. Szmigielska-Kaplon6, A. Sikorska7, A. Kolkowska-Lesniak7, E. Subocz8,
W. Mendrek9, M. Szczepanska10, M. Biedron11, A. Jachalska12, E. Wasilewska13,
M. Wojciechowska14, R. Guzicka-Kazmierczak15, E. Wiater1, A. Kopacz16,
K. Katinas17, W. Kruger17, A. Dawidowska18, D. Zawirska19, Z. Salamanczuk19,
A. Swiderska20, S. Gornik21, M. Sedzimirska22, M. Soroka-Wojtaszko23,
A. Nowicki24, W.W. Jedrzejczak1
1Department of Hematology, Oncology and Internal Diseases, Public Central
Teaching Hospital, Warsaw Medical University, 2Department of Hematology,
Oncology and Internal Diseases, Public Central Teaching Hospital Address:
1a, Banacha Str., 02-097 Warsaw, Warsaw, 3Department of Haematology and
Bone Marrow Transplantation, Silesian Medical University,, Katowice, 4Depart-
ment of Hematology and Bone Marrow Transplantation, Medical University,
Gdansk, 5Department of Hematology, Holycross Cancer Center, Kielce,
6Department of Hematology, Medical University, Lodz, 7Department of Hema-
tology, Institute of Hematology and Transfusiology, 8Department of Hematology
and Internal Diseases, Military Institute of Medicine, Warsaw, 9Department of
Hematology and Bone Marrow Transplantation, Silesian Medical University,,
Katowice, 10Nicolaus Copernicus Specialist Municipal Hospital, Nicolaus
Copernicus Specialist Municipal Hospital, Torun, 11Department of Hematology,
Blood Neoplasms and Bone Marrow Transplantation, Medical University, Wro-
claw, 12Department of Hematology, Medical University, Bydgoszcz, 13Depart-
ment of Hematology, Medical University, Bialystok, 14Department of Hematol-
ogy, Regional Specialist Hospital, Olsztyn, 15Department of Hematology,
Pomeranian Medical University, Szczecin, 16Department of Hematology, Voivo-
dal Specialistic Hospital, Rzeszow, 17Department of Internal Medicine, J. Strus
Hospital, Poznan, 18Department of Oncology and Hematology, Central Clinical
Hospital of the Ministry of Interior, Warsaw, 19Department of Hematology,
Jagiellonian University, Krakow, 20Department of Hematology, Provincial Hos-
pital, Zielona Gora, 21Department of Internal Diseases, Hospital in Zamosc,
Zamosc, 2220Lower Silesian Centre for Cellular Transplantation, 20Lower Sile-
sian Centre for Cellular Transplantation, Wroclaw, 23Department and Division
of Hematooncology and Bone Marrow Transplantation, Medical University in
Lublin, Lublin, 24Department and Division of Hematology, Medical University
in Poznan, Poznan, Poland
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal stem cell disorders characterized by ineffective hematopoiesis, cytope-
nias and risk of progression to acute myeloid leukemia (AML).
Aims: The influence of serum ferritin concentration on survival and acute
myeloid leukemia transformation in MDS patients remains controversial. The
data for Central European population is scarce and so far there is no description
for Poland. Aim of this study was to perform an retrospective analysis of rela-
tionship of ferritin concentration with red blood cell transfusion dependency,
survival and acute myelogeneous leukemia transformation.
Methods: We retrospectively evaluated data of the 819 MDS patients (58%
male; median age 70 years), included in the MDS Registry of the Polish Adult
Leukemia Group (PALG). Analysis was performed for 190 patients diagnosed
with MDS maximal 6 months before inclusion to registry in order to avoid selec-
tion bias (shorter survival of higher risk MDS patients).
Results: Patients with hyperferritinemia higher than 1000 ng/l versus patients
with ferritin concentration lower than 1000 ng/l had median survival of 320 days
vs 568 days respectively (p log-rank=0.014). It was shown that the following
factors significantly worsened survival: ferritin concentration higher than 1000
ng/l (P=0.0023; HR=2.94), RBC-transfusions dependence (P=0.0033; HR
2.671), platelet transfusions dependence (P=0.0033; HR 2.671), hemoglobin
concentration lower than 10 g/dl (P=0.0036; HR 2.97), platelet count lower
than 10 G/l (P=0.0081 HR=5.04), acute leukemia transformation (P=0.0081;
HR 1.968).
Summary and Conclusions: Taking into account relatively low number of
patients in previous studies exploring the topic of hyperferritinemia in MDS
patients, the study provides important insights.
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HIGH P53 PROTEIN EXPRESSION IS ASSOCIATED WITH WT1 MRNA LEV-
EL AND DISEASE STAGE PROGRESSION IN PATIENTS WITH
MYELODYSPLASTIC SYNDROME.
E. Yamazaki1,* M. Enaka2, S. Koyama1, H. Takahashi1, Y. Nakajima1,
T. Miyazaki1, T. Tachibana1, K. Ohashi2, N. Tomita1, Y. Ishigatsubo1
1Department of Internal Medicine and Clinical Immunology, Yokohama City
University Graduate School of Medicine, 2Department of Pathology, Yokohama
City Univeresity Hospital, Yokohama, Japan
Background: Myelodysplastic syndrome (MDS) is a heterogeneous disease.
Several clinical findings were reported as prognostic markers. Identification of
p53-positive cells by immunohistochemistry in bone marrow (BM) was demon-
strated to correlate with presence of TP53 mutations, indicative of poor prog-
nosis. Wilms’ tumor gene (WT1) mRNA expression was associated with the
WHO classifications and risk evaluation of MDS. But there was no report about
correlation between p53 expression and WT1 mRNA level.
Aims: We assessed BM biopsy specimens for p53 expression by immunohis-
tochemistry in association with other clinical parameters including WT1 mRNA
expression in adult MDS patients.
Methods: We performed a retrospective study involving 29 BM biopsy samples
from 24 patients with MDS between 2013 and 2014. The percentage of p53
staining positive cells was assessed based on a total manual count of 1000
BM hematopoietic cells. Clinical parameters were corrected from patient med-
ical charts.
Results: The study included 17 males and 7 females. The median age at pro-
cedure was 71 years (range, 28-84). Five patients received sequential BM
biopsies when clinical findings changed. According to WHO 2008 classification
of MDS, 14 specimens were RCMD, 3 were RCMD-RS, 6 were RAEB-1 and
6 were RAEB-2. The result of cytogenetic analysis of 26 samples, showed
complex karyotypes with more than 3 abnormalities found in 7 samples includ-
ing 4 of complex karyotype with -5/5q-, isolated del5q was not found in this
cohort and 11 were normal karyotype. Nine patients (11 specimens) were treat-
ed with azacitidine after first biopsy. With the median post-procedure follow up
of 5.7 months (1-23.3 months), leukemic transformation and death occurred in
one patient (two specimens) and two patients (three specimens), respectively.
Positive rate of p53 expression in BM was as follows;<1%, 5 specimens; 1-
3%, 8; 3-5%, 4; 5-10%, 4; >10%, 8. In 5 patients with sequential biopsies, p53
expression level of first sample was lower than it of second sample except in
one patient who received azacitidine treatment after first biopsy. WT1 mRNA
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expression level in peripheral blood (PB) was as follows;<100 copies, 11; 101-
1000copies, 8; >1000 copies, 6; 4 patients were not tested for WT1 mRNA
level at the time of BM biopsy. Higher level of p53 expression was significantly
associated with greater WT1 mRNA expression level in PB (r=0.40, P=0.05),
complex cytogenetic abnormality (r=0.64, P<0.001), increasing with WHO2008
classification (r=0.68, P<0.001), IPSS (r=0.50, P=0.01), and IPSS-R (r=0.53,
P=0.006). But it was not associated with percentage of CD34 positive cells in
BM. In spite of short duration of follow-up time, high level of p53 expression
was associated with overall survival (r=0.54, P=0.003). 
Summary and Conclusions: High p53 protein expression in BM is associated
with WT1 mRNA expression level and disease stage progression. It can be a
predictor of survival in adult MDS.
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BONE MARROW OSTEOPONTIN AS A PROGNOSTIC FACTOR IN
MYELODYSPLASTIC SYNDROME
S. Kim1,* Y.S. ji1, J. Yun1, H.J. Kim2, K.H. Kim3, H.J. Kim1, S.C. Lee2, S.B. Bae2,
C.K. Kim1, N.S. Lee3, K.T. Lee2, S.K. Park1, J.H. Won3, D.S. Hong1
1Division of Hematology & Oncology, Soonchunhyang university hospital,
Bucheon, 2Division of Hematology & Oncology, Soonchunhyang university hos-
pital, Cheonan, 3Division of Hematology & Oncology, Soonchunhyang university
hospital, Seoul, Korea, Republic Of
Background: Osteopontin, a glycophosphoprotein encoded by a single gene
on chromosome 4q13, is expressed and secreted in numerous human cancers
and plays a role in tumor progression and metastasis. Also, high osteopontin
level is associated with shortened survival in hematologic malignancies. Bone
marrow (BM) osteopontin levels are currently not reported, and relationship
between BM osteopontin and the clinical course of disease has not been
demonstrated in myelodysplastic syndrome (MDS).
Aims: The objectives of present study were to investigate 1) the prognostic value
of BM osteopontin, 2) whether osteopontin level in response to chemotherapy can
be used to predict therapeutic response in patients with newly diagnosed MDS.
Methods: From July 2012 to February 2014, 24 patients [12 with refractory
cytopenia with multilineage dysplasia (RCMD) and 12 with refractory anemia
with excess blasts (RAEB)] were enrolled. The RAEB patients were treated
with hypomethylating agent, while RCMD patients received supportive care.
The patients with RAEB were divided into three separate groups: in marrow
complete remission (mCR), in progression of disease (PD), and in stable dis-
ease (SD) after chemotherapy. The levels of BM osteopontin were analyzed at
the time of diagnosis from RCMD and RAEB patients, and after 3 cycles of
hypomethylation chemotherapy from RAEB patients. The BM samples obtained
at the time of diagnosis in RCMD patients, and at the time of diagnosis and
after chemotherapy in RAEB patients. 
Results: Osteopontin levels were significantly higher in the RAEB group com-
pared to the RCMD group (120.62±20.42 vs. 62.62±7.40 ng/mL, respectively;
P<0.001). Osteopontin levels did not change significantly with chemotherapy
response (Figure 1).We analyzed the association between osteopontin levels
at diagnosis and survival in RCMD and RAEB patients. RCMD patients were
divided into two subgroups with high (≥ 63.1 ng/mL) and low (< 63.1 ng/mL)
osteopontin levels at diagnosis. The osteopontin level had no significnat impact
on survival among thess subgroups (P=0.157 for each variable; Figure 2).
RAEB patients also were divided into two subgroups with high (≥ 115.3 ng/mL)
and low (< 115.3 ng/mL) osteopontin levels. The low osteopontin level had a
trend toward survival advantage (P=0.087 for each variable; Figure 3).
Figure 1. BM osteopontin level in response to chemotherapy in RAEB
group.
Figure 1. BM osteopontin level and survival in RCMD group. The patients
were divided into two subgroups with high (≥63.1 ng/mL) and low (<63.1
ng/mL) osteopontin levels at diagnosis.
Figure 1. BM osteopontin level and survival in RAEB group. The patients
were divided into two subgroups with high (≥115.3 ng/mL) and low (<115.3
ng/mL) osteopontin levels.
Summary and Conclusions: The present study demonstrated that RAEB
patients have higher levels of marrow osteopontin than RCMD patients, and
that these patients tend to show a shorter survival. In RAEB patients, the low
osteopontin level had a trend toward survival advantage. Thus, these result
may contribute to the understanding of the role of marrow osteopontin as the
prognostic factor in MDS patients.
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HIPERFERRITINEMIA IN MYELODYSPLASTIC SYNDROME (MDS)
PATIENTS - RETROSPECTIVE STUDY FROM A SINGLE CENTRE
EXPERIENCE
M. Ionita1,* I. Ionita1, L. Cheveresan1, V. Todorescu1, C. Ionita1, D. Calamar1,
D. Oros1, H. Ionita1
1Hematology, University of Medicine and Pharmacy “Victor Babes” Timisoara,
Timisoara, Romania
Background: Most myelodysplastic (MDS) patients have anemia and many of
them require red blood cells (RBC) transfusions leading to iron overload. Hema-
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tological improvement (HI) during iron chelation therapy (ICT) was first pointed
out more than twenty years ago. This phenomenon seems to be more frequent
after introduction of Deferasirox. The most simple test assessing iron overload
is serum ferritin concentration.
Aims: Assessment of hyperferritinemia incidence in MDS patients at the
moment of MDS diagnosis, and correlation between ferritin level and AML
transformation in patients diagnosed with MDS.
Methods: The retrospective data collection from a single center experience
(Department of Hematology County Hospital, Timisoara, Romania) between
December 2003 and December 2012 included 121 patients (68 men and 53
women) with MDS. All the patients had complete blood count and serum ferritin
level, and complete follow-up data.
Results: Ferritin level above 1000 ng/mL was found in 38 patients (31%)
(Group 1) and ferritin level ≤1000 ng/mL in 83 patients (69%) (Group 2). Most
patients with significant hiperferritinemia, were RBC transfusion dependent
(81% of patients). Among patients with ferritin level ≤1000 ng/mL, 38% were
RBC transfusion dependent. Serum hemoglobin concentration was lower in
Group 1 patients in comparison with Group 2 patients (7,5 g/dL vs 9,4 g/dL,
P<0,001). The most frequent MDS subtype in Group 1, were patients with
refractory anemia (RA) (30%), compared with patients with ferritin ≤1000
ng/mL-15% (P<0,04). According to IPSS score, there were no differences
between studied groups. Median follow up was 12 months. There was an
improved overall survival (OS) in RBC transfusion independent patients com-
pared to RBC transfusion dependent patients, but mean OS was not signifi-
cantly statistically different in studied groups. No correlation was found between
ferritin level and time to AML transformation.
Summary and Conclusions: Hiperferritinemia >1000 ng/mL does not influ-
ence survival and time to AML transformation in MDS patients. The most fre-
quent MDS subtype in patients with ferritin level>1000 ng/mL was MDS RA.
Among patients with ferritin level >1000 ng/mL, 81% were RBC dependent.
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EPIDEMIOLOGICAL, CLINICAL, THERAPEUTIC AND PROGNOSTIC
FEATURES OF MYELODYSPLASTIC SYNDROM IN FARHAT HACHED
HOSPITAL SOUSSE TUNISIA.
H. Rgaieg1, K. Zahra1,* N. Ben Sayed1, B. Achour1, Y. Ben Youssef1,
M. Romdhani1, M. Zaier1, A. Khelif1
1hematology, Hopital Farhat Hached, SOUSSE, Tunisia
Background: The myelodysplastic syndrom (MDS) is a frequent entity in
hematology. The clinical manifestations are characterized mainly by hemor-
rhagie, anemia or infection. An early diagnosis is essential in order to initiate
an appropriate management to improve the prognosis of this affection.
Aims: The aim of our study is to report the epidemiological, clinical and ther-
apeutic features of patients with MDS.
Methods: This retrospective analysis included 114 patients with MDS who
were treated and followed between 2005 and 2013. 
Results: The sex ratio was 1.The median age was71 years with a range from
11 to 99 years. Three patients had a family history of hematological diseases,
and two had a personal history of neoplasia treated with chemotherapy and
radiotherapy. The circumstances of discovery were an anemic syndrome, hem-
orrhagic syndrome and hemorrhagic syndrome in 68.7%, 5.2% and 2.6% of
cases, respectively. The blood count showed anemia in 89.5% with VGM>100fl
in 48.7% of cases, thrombocytopenia in 61.4% of cases, and leukopenia in
24.3% of cases. The myelogram showed dyserythropoiesis, dysgranulopoiesis,
dysmegacaryopoiesis in 44.3%, 65,2% and 44.3% of cases, respectively. The
karyotype was normal in 75.4% and abnormal in the remaining cases. Accord-
ing to the latest WHO classification, refractory anemia, sideroblastic anemia,
refractory anemia with excess blasts, refractory anemia with excess blasts type
2, 5q- syndrome, refractory cytopenia with multi line and unclassifiable in
26.4%, 7%, 22.4%, 20%, 1.7%, 2.6%, and 20%, respectively. According to the
IPSS, patients were classified very low risk, low risk, intermediate risk, high
risk and very high risk in 10%, 36%, 30%, 17% and 7%, respectively. The man-
agement was symptomatic with red blood cell transfusions in 66% of cases,
platelet transfusion in 56% of cases. The MDS was stable in 51% of cases and
transformed into acute myeloid leukemia (AML) in 12, 3% of cases and only
5.26% of patients received chemotherapy. Only one patient aged 30years was
underwent allograft of hematopoietic stem cell transplantation and two patients
received revlemid. The overall survival at 2 years was 59% and 48% at 5 years.
Summary and Conclusions: Specific treatment for the kind of MDS should
be started early in order to improve the management and prognosis of these
patients.
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A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN
ZETA (BIOSIMILAR OF EPO ALPHA ) IN LOW RISK MYELODISPLASTIC
PATIENTS
G.A. Palumbo1,* C. Vetro1, C. Consoli1, F. Dell’Aria2, V. Di Giacomo3,
V. Di Martina1, E. Schinocca1, I. Amico1, L. Tambè1, P. Spina1, S. Siragusa2,
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Background: Erytropoietin (EPO) is a valuable option in the treatment of low
risk myelodisplastic syndrome (MDS). Since the expiration of EPO alpha patent,
epoietin biosimilars are becoming an increasingly important therapeutic option
as anti-anemic drugs. Clinical efficacy and safety of biosimilar EPOs have been
demonstrated in renal failure and chemotherapy anemias, but not in the treat-
ment of myelodisplasic syndrome (MDS) patients.
Aims: Our study was designed to evaluate safety and efficacy of erythropoietin
zeta (Retacrit, Hospira), a biosimilar of EPO alpha, to treat anemia of low risk
MDS, such as low and Intermediate-1 (Int-1) patients according to International
Prognostic Scoring System (IPSS ).
Methods: We collected data from 32 MDS patients (14 males, 18 females),
aged 58-84 (median 76.5), treated with EPO zeta in Sicily. According to WHO
classification, 15 out of 32 subjects were diagnosed as refractory anemias
(RA), 13/32 as refractory cytopenias with multilineage dysplasia (RCMD) and
4/32 as refractory anemias with excess blasts-1 (RAEB-1, bone marrow
blasts<10%). Considering cytogenetic subgroups, karyotype was favourable
in 28 out of 32 patients while was intermediate in the remaining 4. According
to IPSS risk stratification, 17/32 patients were classified in the low risk group
and 15/32 in the Int-1. Four patients were transfusion dependent before anti-
anemia treatment with EPO. To start EPO treatment: 1) Emoglobin (Hb) had
to be below 10 g/dl; 2) Serum iron, folate and B12 vitamin had to be in the in
the normal range or corrected before therapy onset; 3) the maximum allowed
transfusional need was of 3 units of packed red blood cells (PRBC) per month
in the 90 preceding days; 4) serum EPO levels had to be below 500 UI/mL.
Patients were treated with EPO zeta, 40.000 U s.c./week. After 8 weeks,
whether there was no or suboptimal response (raise in Hb of less than 1.5 g/dl
and/or no transfusion independence), EPO dose was raised to 80.000 U
s.c./week. Treatment was continued for 24 weeks.
Results: Patients were considered as responders either when Hb levels raised
of at least 1.5 g/dl from basal levels (and this data had to be confirmed in two
consecutive evaluations) or when there was at least a 50% reduction of the
trasfusional needs as evaluated before starting EPO. Responders were 23 out
of 32 patients (71.9%); for 9/23 responders (39%) EPO dose had to be raised
to 80.000 U/week to obtain the best results. No side effects greater than G1
according to WHO were reported in our cohort of patients during the 24 weeks
treatment period.
Summary and Conclusions: In our series, efficacy of EPO zeta in low risk
MDS patients was consistent with that reported in the literature using the orig-
inator EPO alpha in similar patient populations. Larger prospective randomized
studies comparing originator and biosimilar EPOs will provide a definitive
answer. However, biosimilar EPO zeta seems to be a good option to treat ane-
mia in low risk MDS, thus saving resources considered its favourable pharma-
co-economic profile.
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MANAGEMENT OF MYELODYPLASTIC SYNDROMES:EXPERIENCE OF
MILITARIAN HOSPITAL OF RABAT MOROCCO
A. Sanae1,* J. selim1, R. safae1, D. kamal1, M. Mohammed1
1clinical hematology, militarian hospital Mohammed V Rabat, Rabat, Morocco
Background: Myelodysplastic syndromes (MDS) are a disorder of hematopoi-
etic stem cell that affects essentially old population. 
Aims: In this study we aim to show characteristics of management of MDS in
our department and give a small example about Moroccan way to treat them
with a few resources.
Methods: This is a retrospective study including all patients managed in our
training for MDS since 2006 to February 2015.
Results: A total of 78 patients were included. The median age was 65.94 years;
the rate of men was more likely higher than women with a sex ratio [M/F] of
1.7. At diagnosis, the international prognosis scoring system (IPSS) was cal-
culated for only 85, 89% (67 patients), 41.79% (28 patients) had low risque,
35.82%(24 patients) had intermediate 1 IPSS,14.92% (10 patients) intermedi-
ate 2,just five patients had a high risque with range of 7%.Reviesed IPSS(R-
IPSS) was also calculated for only 61 patients (78%),9.8% had a very low R-
IPSS,44.26% had low risque,29.5% had intermediate risque,10 patients had
high (9%) and very high (6,55%) risque. Concerning management, we decided
to wait and see for 41% of patients, 34.6% needed best supportive care, Ery-
thropoietin was prescribed for 28% of our patients, 21.7% received Azacithidine,
three of our patients had Hydroxyurea,one of them had Thalidomide, and only
two of them have been selected to have an allo stem cell l transplantation.
Overall Follow up is about 42 months. The overall survival rate was 77, 78%
at 2 years, and 44, 44% at 5 years.
Summary and Conclusions: Despite our few resources our results are the
same of most publications concerning survivals in MDS.
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THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL
REAL LIFE EXPERIENCE 
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10Hematology, Istituto Europeo di Oncologia, Milan, Italy
Background: The myelodysplastic/myeloproliferative disorders (MDS/MPN),
according to the World Health Organization classification, include cases that
have clinical, laboratory, and morphologic features intermediate between
myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). This
is an infrequent entity and there is few data in the literature regarding treat-
ment.
Aims: To evaluate the efficacy of 5-azacitidine (5-AZA) treatment in patients
(pts) affected by MDS/MPN disorders.
Methods: A retrospective analysis of the MDS/MPN pts, into a large cohort of
MDS or AML with blast<30% subjects, treated with 5-AZA in 10 centers in Lom-
bardia region was performed. Response to therapy was considered evaluable
if pts had reached, at the time of observation, at least 6 cycles of 5-AZA. The
Kaplan Meier method was applied to evaluate the survival.
Results: From a population of 187 pts, data about 9 cases of MDS/MPN were
carried out. Of these 4 were female and 5 male. Median age was 65 (range 23-
81). Median bone marrow blasts was 5% (range 2-15); in two cases blasts
were over 10%. In 3 pts Red Blood Cells transfusion dependence was present.
In the other 6 cases median hemoglobin level was 10.2 g/dl (range 9-15). Only
1 patient had Platelet count (PLT) <10.000/mm3, in 3 case PLT was
<50.000/mm3 and in 2 cases PLT was >300.000/mm3. In 3 pts the Neutrophil
count was ≥ 10.000/mm3, in 1 case was<1500/mm3. The median number of 5-
AZA courses administered was 6 (range 5-20). A response to the treatment
(including the cases of “stable disease” maintenance) was achieved in 5 cases
on 7 evaluable. The median survival was 10 months (Figure 1).
Figure 1.
Summary and Conclusions: This abstract is intended to be only a descriptive
report of a disease entity rarely considered. The small sample size does not
allow to draw any conclusion about the observed population. Nevertheless, the
response rate to 5-AZA therapy seems to indicate a trend of efficacy and, there-
fore, the interest in collecting new data to make a significant analysis.
PB1834
CHARACTERISTICS OF BLASTS IN THE PERIPHERAL BLOOD AND
BONE MARROW SAMPLES OF THE PATIENTS WITH MDS TREATED WITH
5-AZACITADINE 
H.T. Mya1,* L. Lopéz Anglada1, J. Caballero1, F. López Cadenas1, J. Pérez
Lopéz1, M. Vidriales1, A.M. Garcia-Sancho1, N. Puig1, J. Alonso2, B. Albarrán2,
C. Olivier3, J. Gonzalez Hurtado4,M. Castellanos5, M. Cañizo1, M. Diez Campelo1
1Haematology, Hospital Universitario de Salamanca, Salamanca, 2Haematol-
ogy, Hospital Rio Carrión, Palencia, 3Haematology, Hospital General de
Segovia, Segovia, 4Haematology, Hospital Virgen Del Puerto, Plasencia,
5Haematology, Hospital Clinico de Valladolid, Valladolid, Spain
Background: Identification of the blast population in the patients with MDS
has been improved in the recent years with the application of multiparametric
flow cytometry (MFC).
Aims: The aim of our study was to fully characterize the blasts in the peripheral
blood (PB) and bone marrow (BM) of the patients with MDS, by MFC before
and after the treatment with 5-Azacitadine (5-AZA).
Methods: Patients with MDS, suitable for the treatment with 5-AZA were select-
ed by the participating centers after the approval of the ethic committee. BM
and PB samples were analyzed by BD FACSCanto flow cytometer before and
after the treatment with 5-AZA. For each sample, detailed analysis with Euroflow
leukemia orientation tube and acute myeloid leukaemia panels were performed
(Table 1). A minimum of two million events were acquired. Infinicyt software ver-
sion 1.8 (Euroflow member version) was used to analyze the acquired data files.
Results: Thirteen patients have consented to participate in the study from Jan-
uary 2011 to December 2014. Eight patients had normal cytogenetics and the
remainder had one to three abnormal clones with del 5q, del 20q, trisomy 8
and del 11q. All patients had advanced MDS, either RAEB-1 or RAEB2 at 5-
AZA treatment and received at least 3 cycles of 5-AZA before the reassess-
ment.There were 13 pre and post 5-AZA BM samples and 8 pre and post 5-
AZA PB samples. The pre 5-AZA blast count by flow cytometry ranged from
2.5 to 14% in the bone marrow and post 5-AZA blast count from 0.48% to 13%.
By applying the Euroflow panels, the blast population with the same expression
pattern as in the marrow was detected in the peripheral blood samples of all
patients, with the lowest post treatment peripheral blood blast count being
0,02%. The blasts were uniformly positive for CD117, HLADR, dim CD45,
CD13, CD33 and CD34 except one patient with negative CD34 expression.
They did not express granulocytic or monocytic maturation markers in all
patients, with MPO expression found only in 28% of the tested samples. Dim
CD71 and dim CD123 expression was noted in ten patients whereas aberrant
CD7 expression in three patients, CD56 in one patient and CD22 in one patient
were noted. None of the patients had cCD3 or CD19 expression.
Table 1. Monoclonal antibodies used to analyze the blasts of in bone mar-
row and peripheral blood samples
Tubes            FITC PE PerCP5.5 PECy7 APC APCH7 PB PO
Tube 1          CD16 CD13 CD34 CD117 CD11b CD10 HLA-DR CD45
Tube 2          CD35 CD64 CD34 CD117 IREM-2 CD14 HLA-DR CD45
Tube 3          CD36 CD105 CD34 CD117 CD71 CD33 HLA-DR CD45
Tube 4          cTDT CD56 CD34 CD117 CD7 CD19 HLA-DR CD45
Tube 5          CD15 7.1 CD34 CD117 CD22 CD38 HLA-DR CD45
Tube 6    CD42b/CD61 CD203c CD34 CD117 CD123 CD4 HLA-DR CD45
Tube 7          cMPO cCD79b CD34 CD19 CD7 cCD3 HLA-DR CD45
Summary and Conclusions: The myeloblasts in the study patients demon-
strated more immature immunophenotypic features with rare expression of
maturation markers, consistent with the previous findings in advanced MDS.
MFC can accurately identify the blast population of the same immunophenotypic
features as that of the BM samples, in the PB samples at diagnosis and post
treatment. Assessing the evolution of the characteristic blast population in the
PB samples by multiparameter flow-cytometry may be an interesting and useful
approach in the patients with MDS during the post-treatment period.
PB1835
SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF
INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND
ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
R. Stringer1,* D.T. Rider2, D.J. Newman2, D.R. Grace2
1Brighton and Sussex Medical School, Brighton, 2East Sussex Healthcare NHS
Trust, Eastbourne, United Kingdom
Background: The hypo-methylating agent, 5-azacitidine, is used to treat chron-
ic myelomonocytic leukaemia (CMML), intermediate and high-risk myelodys-
plastic syndrome (MDS) and acute myeloid leukaemia (AML) with 20-30%
blasts in patients unsuitable for high intensity treatment. Our centre is one of
the largest users of azacitidine in the South East of England, reflecting the pre-
dominantly elderly population served.
Aims: To evaluate overall survival (OS) of patients treated with 5-azacitidine at
our centre. Comparison of OS for MDS and AML groups and according to cyto-
genetic prognostication. Also to compare local prescribing practice with 2011
guidelines published by the National Institute for Clinical Excellence (NICE).
Methods: A retrospective analysis of medical records for all patients treated
with four weekly cycles of 5-azacitidine (75mg/m2) for 7 days. Patients were
grouped according to diagnosis (MDS, CMML or AML) and cytogenetic classi-
fication as per the 5-group MDS Revised International Prognostic Scoring Sys-
tem (IPSS-R).
Results: Forty-two patients (n=19 AML, n=22 MDS, n=1 CMML) were identified
from a 40 month observation period. Mean age was 71 (range 43-84). The
median time from diagnosis to treatment was 17 days. The mean number of
cycles received was 6 (range 1-23). Eighteen patients were diagnosed and
received 5-azacitidine after treatment for a previous haematological malignancy:
relapsed AML (n=7); transformed MDS (n=4); myeloproliferative disorder (n=3);
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MDS following AML treatment (n=2); chronic lymphocytic leukaemia (n=1);
myeloma (n=1). Kaplan-Meier analysis revealed an OS of 9.77 months for all
42 patients (95% CI 6.55-12.98). OS for MDS patients was 12.11 (CI 7.69-
16.5). OS for MDS subgroups according to cytogenetic prognostic groups
‘good’, ‘intermediate’, ‘very poor’ and ‘unknown’ were 15.7 (n= 9, CI 7.7-23.7),
8.25 (n=4, CI 6.44-10.05), 3 (n=4, CI 0.23-5.77), and 10.6 (n=5, CI 2.48-18.72),
months respectively. The ‘good’ cytogenetic group had significantly longer OS
compared to ‘bad’ cytogenetics, P<0.001. OS for AML patients was 6.34 (CI
2.02-10.7) significantly worse when compared to all MDS patients, P=0.001.
Twenty-nine patients (69%) met NICE approval criteria. Treatment outside the
criteria was due to either no alternative available (9), instruction from regional
transplant centre (3) or as part of a trial (1). Treatment within NICE recommen-
dations showed significantly improved survival (P=0.001) with a mean of 13.27
months (CI 9.32-17.23) compared to 2.73 (CI 1.84-3.67). 
Summary and Conclusions: Treatment with 5-azacitidine for AML and MDS
gave OS of 12.11 and 6.34 months respectively in our elderly population with
limited alternative therapeutic options. Favourable prognostic cytogenetics and
treatment within national guidelines led to superior survival in this sample.
PB1836
PROGNOSIS IN MDS – CAN SERUM ERYTHROPOIETIN BE OF HELP?
R. Tenreiro1,* E. Cortesão1, S. Ramos1, M. Pereira1, P. César1, J. Carda1,
M. Gomes1, L. Rito1, E. Magalhães1, A.C. Gonçalves1, N. Costa e Silva1,
C. Geraldes1, A.B. Sarmento Ribeiro1, J. Nascimento Costa1, L. Ribeiro1
1Clinical Hematology, Coimbra University Hospital Center, Coimbra, Portugal
Background: Myelodysplastic syndromes (MDS) are a heterogeneous entity
characterized by dysplasia, hypercellular bone marrow, cytopenias and a risk of
transformation to acute leukaemia (AL). Treatment is mainly based in the Interna-
tional Prognostic Scoring System (IPSS). In the last few years a lot has been writ-
ten about MDS prognosis, with new scores for survival increasing in complexity
making their use in everyday practice somewhat difficult. Although other prognostic
factors, for instance, bone marrow fibrosis, LDH and β2-microglobulin elevation
are readily available to clinical practice, others like gene mutations TP53, EZH2,
ETV6, RUNX1, NRAS, ASXL1, SRSF2, U2AF1 and SF3B1 are not so easy to
obtain. Two retrospective studies show a benefit in survival in patients treated with
erythropoietin (Epo)±G-CSF, however without an impact on progression to AL.
Aims: We aimed to study the prognostic impact of serum Epo at diagnosis in
a cohort of MDS patients.
Methods: We analyzed the records of 102 patients with de novo MDS between
October 2009 and March 2014. Clinical and laboratorial data were collected
and overall survival (OS) was estimated stratified according their serum Epo
level: low vs normal vs<100 mUI/mL vs 100-500 mUI/mL vs ≥ 500 mUI/mL.
Results: The patients had median age of 74 years, with a Male:Female ratio of
0.8. According to the WHO classification, MDS subtypes where distributed as
follows: Refractory Cytopenia with Multilineage Dysplasia (RCMD) (n=52),
Refractory Cytopenia with Unilineage Dysplasia (RCUD) (n=12), Refractory Ane-
mia with Excess Blasts (RAEB)-1 (n=8), (RAEB)-2 (n=8), Refractory Anemia with
Ring Sideroblasts (RARS) (n=6), 5q- Syndrome (n=4) and Chronic Myelomono-
cytic Leukaemia (n=12). Thirty seven patients presented with low IPSS score,
39 with intermediate-1, 10 with intermediate-2 and 1 with high score. The mean
erythropoietin was significantly lower in RCMD patients when compared to other
MDS subtypes (P<0.05). Eleven patients (7 RAEB-2, 2 RCMD, 1 RAEB-1 and 1
CMML) progressed to AL. Their mean erythropoietin value was higher than in
patients who did not evolve (P<0.05). We found that patients with elevated serum
Epo had significantly lower survival rates than those with normal Epo levels
(P=0.0336). The predictive value of serum Epo was maintained after Cox regres-
sion adjustment for LDH, age, IPSS, R-IPSS, hemoglobin, neutrophils, platelets,
ferritin, β2-microglobulin and bone marrow blasts. In multivariate analysis, the
independent survival predictors were serum Epo (P<0.001), ferritin (P<0.001),
β2M (P=0.008) and marrow blast percentage (P<0.001).
Summary and Conclusions: In the present study, serum baseline erythro-
poietin was identified as in independent poor prognostic factor, with higher val-
ues in patients with progression to AL and decreased OS.
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CHRONIC MYELOMONOCYTIC LEUKEMIA IS CHARACTERIZED BY
HYPOADIPONECTINEMIA AND HYPORESISTINEMIA INDEPENDENTLY
FROM THE IGF-I SYSTEM: A CROSS-SECTIONAL STUDY
M. Dalamaga1, A. Lekka2,*, K. Karmaniolas3, G. Sotiropoulos2, J. Chamberland4,
M. Triantafilli2, L. Tzianoumis5, C. Mantzoros4
1Clinical Biochemistry, University of Athens, School of Medicine, Attikon Gen-
eral University Hospital, 2Laboratory of Hematology, 3Department of Internal
Medicine, NIMTS Hospital, Athens, Greece, 4Division of Endocrinology, Dia-
betes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, United States, 5Hematologic Clinic, Ygeias Melathron, TYPET,
Athens, Greece
Background: Accumulating evidence supports a role for obesity in the etiology
of hematologic malignancies. Obesity may be also linked to chronic
myelomonocytic leukemia (CMML), a hematologic malignancy combining pro-
liferative and dysplastic characteristics, through altered adipokine secretion,
one of which, adiponectin, presents a protective role in several malignancies,
including leukemia and lymphoma.
Aims: In this cross-sectional study, we investigated the association of circulat-
ing adiponectin and resistin with CMML in relation to insulin-like growth factor-
I (IGF-I), a hormonal system which is implicated in several human malignancies
including leukemia.
Methods: Blood samples were collected from 14 cases with incident, histolog-
ically confirmed CMML and 70 healthy controls (1 patient versus 5 controls)
who came for an annual check-up examination without any neoplastic and
infectious conditions, matched on gender, age and year/month of diagnosis
(±1 month) between 2004 and 2012. Informed consent was obtained from all
participants. Serum adiponectin and resistin were determined respectively by
radioimmunoassay (LINCO Research Institute, St Louis, MO). High molecular
weight (HMW) adiponectin was measured using ELISA (ALPCO Diagnostics,
Salem). IGF-I and IGFBP-3 concentrations were measured using an immuno-
radiometric assay kit (DSL, Webster, TX) The statistical analysis of the data
was performed using IBM-SPSS® version 22 for Windows.
Results: CMML cases presented significantly higher height and weight than
control subjects (P<0.001), while differences of body mass index (BMI) were
only of borderline significance (P=0.10). Lower serum total or HMW adiponectin
and/or resistin levels were independently associated with higher risk of CMML
adjusting for age, gender, BMI and serum IGF-I levels (p≤0.05). In particular,
CMML was characterized by hypoadiponectinemia (total adiponectin in CMML
patients: 12.5±8.8 μg/dL versus controls: 16.3±7.9 μg/dL, P=0.05) and hypore-
sistinemia (resistin in CMML patients: 12.1±6.2 ng/mL versus controls: 21.9±32.7
ng/mL, P=0.013). Total adiponectin exhibited a positive correlation with HMW
adiponectin both in CMML cases and controls (r=0.83, P<0.001; r=0.88,
P<0.001, respectively). Although, total and HMW adiponectin were both signif-
icantly reduced in CMML, HMW did not offer any substantial additional predictive
value over total adiponectin. Serum IGF-I was not significantly and independ-
ently associated with CMML in multivariable analysis adjusting for age, gender,
date of diagnosis, BMI and history of lymphohematopoietic cancer (P=0.56).
Summary and Conclusions: Total and HMW adiponectin may present a pro-
tective role in CMML by suppressing proliferation of myeloid cell lineage, where-
as resistin levels may be decreased via a compensatory mechanism due to an
upregulation of other inflammatory factors etiologically and ontologically linked
to CMML. Further studies are needed to confirm these associations and to
explore the mechanisms underlying adiponectin’s role in myelopoiesis and
leukemogenesis.
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THE HETEROGENEITY OF MYELODYSPLASTIC SYNDROME WITH
CHROMOSSOME 5 ABNORMALITIES: THE PROGNOSTIC IMPACT OF
BLAST COUNT, KARYOTYPE, P53 PROTEIN EXPRESSION AND
TRANSFUSION DEPENDENCY
G. Brás1,* A.R. Pereira2, M. Alpoim1, R. Pinto1, E. Fonseca3, F. Príncipe1,
J. Guimarães1
1Serviço de Hematologia Clínica, Centro Hospitalar de São João, Porto, 2Esco-
la de Ciências da Saúde, Universidade do Minho, Braga, 3Serviço de Anatomia
Patológica, Centro Hospitalar de São João, Porto, Portugal
Background: Deletion of the long arm of chromosome 5 [del(5q)] is the most
prevalent cytogenetic abnormality in patients with Myelodysplastic Syndrome
(MDS) and is frequently associated with good prognosis. However, MDS with
del(5q) is a heterogeneous entity in terms of survival and/or progression to
Acute Myeloid Leukemia (AML). The analysis of the proposed Revised Inter-
national Prognostic Scoring System (R-IPSS) for MDS reinforces the impor-
tance of blast count, karyotype and number and degree of cytopenias to define
high-risk subgroups with worse prognosis. More recently, the presence of TP53
mutation and/or high P53 protein expression by immunohistochemistry (IHC)
has been proposed as additional markers of poorer outcome in MDS with chro-
mosome 5 abnormalities.
Aims: Assess the prognostic impact of blast count, number of additional cyto-
genetic abnormalities, transfusion dependency and p53 IHC expression, in
MDS with del(5q).
Methods: We retrospectively analyzed 18 patients diagnosed with MDS and
del(5q) at our centre, between 2005-2014, in which a bone marrow histology
was available. All patients were evaluated for R-IPSS, transfusion dependency
and P53 protein expression by bone marrow IHC. A high blast count was
defined by the presence of >5% of blasts cells in bone marrow smear. A high
number of chromosome abnormalities was defined by >=2 abnormalities
besides del(5q). A positive p53 IHC expression was defined by the presence
of >5% p53 positive cells observed on the histology of bone marrow. Transfu-
sion dependency was defined as no period of eight consecutive weeks without
red blood cell (RBC) transfusions.
Results: The median of age was 69 (55-81) years and 11 (61%) patients were
male. The MDS WHO-classification was: RCMD n=3 (16,7%), RAEB-1 n=3
(16,7%), RAEB-2 n=5 (27,8%) and MDS with isolated del(5q) n=7 (38,9%). In
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terms of R-IPSS evaluation, patients were stratified as: Very Low n=1 (5,6%),
Low n=6 (33,3%), Intermediate n=2 (11,1%), High n=2 (11,1%) and Very High
n=7 (38,9%). For the relevant prognostic parameters analyzed, frequencies
were: n=8 (44,4%) had >5% of blasts, n=4 (22,2%) had >=2 chromosome
abnormalities besides del(5q), n=16 (88,9%) had transfusion dependency and
n=9 (50%) had >5% of p53 IHC protein expression. Overall Survival (OS) and
Progression to AML Free Survival (PFS) were significantly worse for patients
with >5% of blast count (OS: 5 months vs 39 months, P<0.05; PFS: 5 months
vs 32 months, p>0.05) and for those with >=2 chromosome abnormalities
besides del(5q)(OS: 6 months vs 36 months, P<0.05; PFS: 5 months vs 29
months, P<0.05). Those differences were also observed in multivariate analysis
(P<0.05). A trend towards a worse OS and PFS was observed for transfusion
dependency (OS: 21 months vs 48 months, P=0.18; PFS: 17 months vs 44
months, P=0.12) and >5% of p53 IHC protein expression (OS: 19 months vs
30 months, P=0.37; PFS: 18 months vs 21 months, P=0.75).
Summary and Conclusions: The presence of a high blast count and other
chromosome abnormalities besides del(5q) define subsets of worse prognosis
in MDS with del(5q), despite of this being classically considered a chromosomal
abnormality associated with good prognosis. There is also a trend for a poor
prognosis in patients with transfusion dependency and positive p53 IHC protein
expression. The absence of a statistical significant difference in OS and PFS
for these patients subsets might be due to the low number of patients in this
cohort.
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COMPLEX KARYOTYPE CHANGES ARE THE STRONGEST PREDICTOR
OF OUTCOME OF ALLOGENEIC TRANSPLANTATION IN
MYELODYSPLASTIC SYNDROME
J. Radocha1, A. Zavrelova1, P. Belohlavkova1, M. Lanska1, B. Visek1, P. Zak1,* 
1University Hospital Hradec Kralove, 4th Department of Medicine-Hematology,
Hradec Kralove, Czech Republic
Background: Complex karyotype has been recently reported as one of the
predictors of poor outcome of allogeneic transplantation in patients with
myelodysplastic syndrome (MDS). Current opinions challange transplantation
as a curative option in these patients.
Aims: To evaluate impact of complex karyotype changes of MDS in setting of
allogeneic stem cell transplantation
Methods: We evaluated all consecutive patients with all stages of MDS trans-
planted at our center from 2007-2014. Patients parameters, demographic data,
disease status, pretransplant remission status, type of transplantation and kary-
otype has been evaluated as possible factors influencing outcome of trans-
plantation.
Results: Overall 22 patients (12 males, 10 females, median age 56 years, 32-
66 years) were analysed. Disease status was as follows: 12/22 were MDS
related AML, 4/22 RAEB-2, 3/22 RAEB-1 and 3/22 RA or RCMD. Majority of
patients (20/22) underwent transplant from matched unrelated donor, 2/22 had
sibling donor. Conditioning was intended myeloablative in 13/22 patients and
reduced intensity in 9/22. 14 patients reached hematologic CR before trans-
plant. Five (5/22) patients had complex karyotype changes. The median fol-
low-up was 3 months. Median overall survival was not reached, survival at 5
years was 56%. The strongest predictors of outcome were: CR before trans-
plant (median survival 4.5 months vs. not reached, P=0.0997, trend only), stage
of the disease (AML and RAEB-2 vs. others, median survival 18 months vs.
not reached, P=0.0361) and komplex karyotype changes (meadian survival
4.5 months versus not reached P=0.0044).
Summary and Conclusions: Complex karyotype changes, disease stage and
remission status are probably the most singificant factors which influence the
outcome of allogeneic transplantation in MDS. The possibility of transplant for
these patients is a matter for debate since the outcome remains dismal.
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AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML):
POSSIBILITY OF IMPROVED RESPONSE AND SURVIVAL
P. Niscola1,* A. Tendas1, L. Cupelli1, D. Piccioni1,M. Giovannini1, L. Scaramucci1,
E. Abruzzese1, T. Caravita1, T. Dentamaro1, L. Morino1, B. Neri1, D. Renzi1,
A. Siniscalchi1, M.M. Trawinska1, P. de Fabritiis1
1Hematology, Sant’Eugenio Hospital, Rome, Italy
Background: CMML is a clonal disease characterized by high rate progression
to AML. Treatment is not curative traditionally and allo-SCT remains the only
option, although in a minority of patients. Recently, significant clinical benefits
by hypomethylating agents have been reported.
Aims: To evaluate efficacy and toxicity of azacitidine on CMML. 
Methods: Fourteen patients with a median age of 75 (60-85) and several co-
morbidities were evaluated; 5/14 (37%) aged >80 years. Median PS was 70%
(range 50-90). According to WHO, 10, 2 and 2 patients presented CMML-2,
CMML-1 with severe and symptomatic cytopenias and CMML-related AML
with<30% BM blasts, respectively. Six patients had proliferative CMML, 7 were
transfusion-dependent at the start of azacitidine and two had abnormal kary-
otype. Three patients had CMML secondary to low risk MDS; one patient pre-
sented a therapy-related CMML. Previous therapies were: intensive chemother-
apy (1), ESA (6) and hydroxyurea (8); 4 patients were treatment-naïve. The
interval between diagnosis and the start of azacitidine was 2 months (0.3 – 18)
and the median number of courses was 12 (2-33). Treatment was well-tolerated
and with no remarkable side effects. Responses were evaluated according to
2006 IWG.
Results: Thirteen patients were evaluable for response after the fourth cycle
of azacitidine; the remaining patient developed AML after the second cycle of
therapy. Five patients (36%) achieved CR and 6 (43%) PR with an ORR of
78%; two patients presented a primary failure to azacitidine. After a median fol-
low-up of 19 months (5-46), 6 patients (3 in PR, 2 in CR and 1 with AML) are
still alive, with an OS from CMML diagnosis and the start of azacitidine treatment
of 25 and 17 months, respectively. Among responding patients, 1 is alive and
well 120 days after unrelated allo-SCT. Six patients progressed to AML: 1 was
primarily unresponsive to azacitidine and 5 progressed after 17 (5-40) months
from the start of therapy. Among the 8 deceased patients, 5 died from AML pro-
gression and 3 because of complications related to pre-existing cardiac comor-
bidities (2 patients), or secondary lung cancer (1 patient).
Figure 1. Overall survival from the start of azacitidine.
Summary and Conclusions: Despite the limited number of cases, the results
are encouraging, considering age and the complexity of the patients. The ORR
of 78% and the unfavorable prognosis of our comorbid patients reinforce the
existing evidence, making azacitidine the most appropriate treatment of CMML
in the real life setting.
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CIRCULATING TOTAL LEPTIN, LEPTIN RECEPTOR AND FREE LEPTIN
INDEX LEVELS IN CHRONIC MYELOMONOCYTIC LEUKEMIA: A CROSS-
SECTIONAL STUDY
M. Dalamaga1,1, A. Lekka2,* M. Triantafilli2, G. Sotiropoulos2, J. Chamberland3,
K. Karmaniolas4, L. Tzianoumis5, C. Mantzoros3
1Clinical Biochemistry, University of Athens, School of Medicine, Attikon General
University Hospital, 2Laboratory of Hematology, NIMTS Hospital, Athens,
Greece, 3Division of Endocrinology, Diabetes and Metabolism, Beth Israel Dea-
coness Medical Center, Harvard Medical School, Boston, United States,
4Department of Internal Medicine, NIMTS Hospital, 5Hematologic Clinic, Ygeias
Melathron, TYPET, Athens, Greece
Background: Recent evidence suggests that overweight/obesity may be impli-
cated in the etiology of hematologic malignancies, including myelogenous
leukemia and myelodysplastic syndromes. A strong asociation of
overweight/obesity with insulin resistance, characterized by hyperinsulinemia,
has been well documented. There is evidence that insulin resistance is impli-
cated in several malignancies associated with excess body weight. Leptin and,
particularly, free leptin, the biologically significant form of leptin, reflecting accu-
rately the body fat mass, regulate glucose and lipid metabolism by ameliorating
insulin sensitivity and decreasing intracellular lipids. 
Aims: In this cross-sectional study, we investigated the potential association
of leptin and free leptin with chronic myelomonocytic leukemia (CMML), a hema-
tologic malignancy combining proliferative and dysplastic features, after adjust-
ing for a potential confounding effect of age,gender, date of diagnosis (matching
factors) a well as withbody mass index (BMI), family history of lymphohe-
matopoietic cancer (LHC) and serum insulin.
Methods: Blood samples were collected from 14 cases with incident, histolog-
ically confirmed CMML and 70 healthy controls (in an analogy of one patient
versus five healthy controls) who came for an annual check-up examination
without any neoplastic and infectious conditions, matched on gender, age and
year/month of diagnosis (±1 month) between 2004-2012. Informed consent
was obtained from all study participants. Serum leptin and insulin were deter-
mined by radioimmunoassay (Linco Research Institute St Louis MO, and Milli-
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pore Co Billerica, MA respectively). Serum leptin receptor levels (sOB-R) levels
were measured using a commercially available ELISA (BioVendor R&D, Brno,
Czech Republic). Free Leptin Index (FLI) was calculated as the ratio of leptin
to sOBR. The statistical analysis of the data was performed using IBM-SPSS®
version 22 for Windows.
Results: CMML cases presented significantly higher height and weight than
control subjects (P<0.001), while differences of BMI were only of borderline
significance (P=0.10). Serum insulin was significantly higher in cases than con-
trols (P=0.05). CMML cases exhibited a significant total and free hypoleptinemia
in comparison to controls (total leptin in patients with CMML: 13.2±16.3 ng/mL
versus controls 24±21.1 ng/mL, P=0.005; FLI in patients with CMML: 0.81±1.6
versus controls: 2.84±5.4, P=0.04). Moreover, CMML cases exhibited signifi-
cantly lower serum levels of sOB-R than controls (P=0.04). In multivariate
analysis, subjects with total and free hypoleptinemia presented significantly
higher odds for CMML after adjusting for age, gender, date of diagnosis, BMI,
family history of LHC and serum insulin levels. 
Summary and Conclusions: This study raises the hypothesis that leptin which
reflects overall fat mass and insulin may be associated with CMML. Leptin’s
major physiological role is to signal inadequate rather than excess energy
stores, and hypoleptinemia found in a small but significant percentage of obese
humans is associated with hyperinsulinemia and impaired T-cell function. Fur-
ther mechanistic, interventional and epidemiological studies are needed to con-
firm these findings and to explore whether leptin may mediate the effect of
body fat distribution on insulin resistance and leukemogenesis risk.
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ASSOCIATION OF THYROID HORMONES AND AUTOIMMUNE THYROIDITIS
WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
M. Dalamaga1, M. Triantafilli2, G. Sotiropoulos2, K. Karmaniolas3,
L. Tzianoumis4, A. Lekka2,*
1Clinical Biochemistry, University of Athens, School of Medicine, Attikon Gen-
eral University Hospital, 2Laboratory of Hematology, 3Department of Internal
Medicine, NIMTS Hospital, 4Hematologic Clinic, Ygeias Melathron, TYPET,
Athens, Greece
Background: Thyroid disease has been associated with increased incidence
of leukemia, myelodysplastic syndrome (MDS) and lymphoma. No previous
study has investigated whether thyroid disease and especially autoimmune
thyroid disease (ATD) is associated with chronic myelomonocytic leukemia
(CMML), a hematologic malignancy which has been classified as a subtype of
MDS but was recently demonstrated to be a distinct entity combining prolifer-
ative and dysplastic features.
Aims: In this case-control study, we investigated the potential association of
thyroid hormones and ATD with CMML.
Methods: Our study included 14 cases with incident histologically confirmed
CMML and 70 controls (one patient versus five controls) who came for an
annual check-up examination without any neoplastic and infectious conditions,
matched on gender, age and year/month of diagnosis (±1 month) between
2004-2012. All participants were submitted to clinical and ultrasound thyroid
evaluation. Informed consent was obtained from all study participants. Serum
free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), thyroglobulin
and thyroperoxidase antibodies (anti-TG and anti-TPO) were determined using
electrochemiluminescence on Cobas e411 analyzer (Roche, Basel, Switzer-
land). The statistical analysis of the data was performed using IBM-SPSS®
version 22 for Windows.
Results: Mean serum levels of fT3 and fT4 were significantly higher in CMML
patients than in controls (fT3 in patients with CMML: 3.6±0.3 pg/mL versus
controls: 2.9±0.42 pg/mL, P<0.001; fT4 in patients with CMML: 1.7±0.29 ng/dL
versus controls: 1.4±0.28 ng/dL, P<0.001). The prevalence of anti-thyroid anti-
bodies (anti-TG and anti-TPO Ab) was significantly higher in CMML patients
than in controls (P<0.001). On the contrary, mean TSH serum levels were sig-
nificantly lower in CMML patients than in controls (TSH in patients with CMML:
1.56±0.6 μΙU/mL versus controls: 2.9±0.4 μIU/mL, P=0.001). The frequency of
family history of thyroid disease (first degree relatives) in CMML patients was
similar with that reported by controls (P=0.52). Finally, the prevalence of clinical
thyroid disease-especially ATD-was higher in patients with CMML than in con-
trols (P=0.06, though not statistically significant at α=0.05).
Summary and Conclusions: We have found biologically plausible and empir-
ically strong evidence that thyroid hormones, thyroid disease and especially
ATD may be associated with CMML. Further larger prospective studies are
needed to confirm this association and explore underlying interactive mecha-
nisms between thyroid hormones and thyroid autoimmunity with myelopoiesis
and leukemogenesis.
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EFFICACY OF AZACITIDINE IN MDS AND AML WITH PROLIFERATIVE
FEATURES
A. Almeida1,* F. Pierdomenico1
1IPO Lisboa, Lisbon, Portugal
Background: Azacitidine is a hypomethylating agent with demonstrated effi-
cacy in high risk myelodysplastic syndromes (MDS), chronic myelomonocytic
leukemia (CMML) and acute myeloid leukemia (AML). The trials that have led
to its approval for these indications excluded patients with leucocytosis and
most observational studies suggest that it is less efficacious in patients with
proliferative disease. 
Aims: We present a single-centre retrospective analysis of the efficacy of azac-
itidine in 18 with MDS, CMML and AML with proliferative features and compare
these with a similar cohort of patients with non-proliferative disease.
Methods: Data was collected retrospectively from clinical files following ethical
committee approval
Results: The cohort with proliferative disease, defined by a leukocytosis
>13x109/L, had a median age at diagnosis of 67 years; 55% were men. WHO
2008 diagnosis was MDS in 2 patients, AML in 8 patients and CMML in 8
patients. At diagnosis, the median hemoglobin was 8.9 g/dL (range 6.5-13.0),
median WBC was 34.7x109/L (range 12.7-95.0) and median platelet count
89x109/L (range 12-695). Bone marrow blast percentage was >10% in 72% of
patients; median 19% (range 1.2-98) Karyotypes were normal in 44%, inter-
mediate risk in 27% and poor risk in 29%. Azacitidine was used as single agent
as first line therapy with no prior cytoreduction in all patients. Patients started
treatment a median of 2.3 months following diagnosis. Marrow response was
assessed after the 6th cycle. Treatment was continued until progression in all
cases. A median number of 8 cycles were administered. Marrow assessments
were available in 16 patients. Responses were documented in 6 patients, of
which 1 was complete and 5 were partial. Stable disease at time of assessment
was seen in 4 patients and progression in 6. Transfusion independence was
achieved in 8 of 10 patients who were previously transfusion-dependent. Four
patients only received 1 cycle of treatment due to progression in 3 and pneu-
monia in one. Normalization of WBC was achieved in all but the former 4
patients after a median of 2.3 cycles. All patients had died by the time of analy-
sis, 16 due to progression, one due to pneumonia and one due to cerebral
haemorrhage. Median overall survival was 15.85 months. The median survival
of the comparator non-proliferative group was 11.58 months. This was not sig-
nificantly different from that of the proliferative group (15.85 vs 11.58 months,
respectively; log rank test: P=0.25).
Summary and Conclusions: These results support the use of azacitidine in
patients with proliferative disease, increasing treatment options in these
patients.
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CHARACTERISTICS, TREATMENT, OUTCOMES AND SURVIVAL OF IRISH
PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKAEMIA (CMML)
S. Maung1,* C. Burke2, J. Bains2, M. Coyne2, R. Desmond2, J. McHugh2,
H. Enright2
1Haematology, Tallaght Hospital, Trinity College Medical School, Dublin, Ire-
land, 2Haematology, Tallaght Hospital, Trinity College Medical School, Dublin,
Ireland
Background: CMML is classified as a myelodysplastic/myeloproliferative neo-
plasm (2008, WHO). Compared with other haematological malignancies it is
an uncommon disorder, and there are few large studies regarding outcome.
Approximately 9.5% of patients registered with the Irish National Registry for
Myelodysplastic Syndromes (MDS) between 2007 and 2014 had CMML.
Aims: We evaluated the treatment, outcome and survival for 29 Irish patients
with CMML.
Methods: We evaluated presenting symptoms, diagnostic findings, cytoge-
netics and treatment received including blood transfusions, haematopoietic
growth factors, hypomethylating agents, chemotherapy and transplantation.
Results: The median age at diagnosis was 75 years (range 56-89) with male:
female ratio of 1.9:1. Nineteen patients (65.5%) were asymptomatic at pres-
entation and 10(34.5%) had constitutional symptoms, bleeding, and/or
splenomegaly. Apart from monocytosis in all patients, features at presentation
included anaemia (65.5%), thrombocytopenia (55%), leukocytosis (45%), neu-
tropenia (20.5%), raised LDH (68.9%) and splenomegaly (17%). Peripheral
blasts were present in 5 patients, all of whom subsequently developed Acute
Myeloid Leukaemia (AML). JAK2V617F mutation was negative in all patients
tested (n=9). Seven patients (44%) had CMML-2 and 21(72.4%) CMML-1.
Ninety three percent of patients had a hypercellular marrow. Evidence of dys-
plasia (93% dyserythropoiesis, 86% myeloid dysplasia, 72% megakaryocytic
dysplasia) and increased reticulin fibrosis (73%) were noted. Only 7 patients
(24.1%) had cytogenetic abnormalities, including trisomy 8 (n=2), t(8;21) (n=1),
Monosomy 7 (n=1), trisomy 19 (n=2) and –Y (n=2). Seventeen patients (58.6%)
received active management including Azacitidine (n=11), intensive AML-type
induction therapy (n=2), allogeneic marrow transplant (n=1) and Hydroxycar-
bamide (n=6). Seven (24.1%) patients received transfusion support only. Ery-
thropoietin was given in 7 patients (24.1%) and G-CSF in 2. Sixteen patients
(55%) required transfusion at diagnosis. Twelve patients (72%) required red
cells and 13(68%) required platelets during the course of illness. Eight of 11
patients treated with Azacitidine remained transfusion dependent. Median sur-
vival was 20 months (0-154 months). Transformation to AML was seen in 7
patients (24.1%). Survival for patients who received Azacitidine was 22 months
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(11 to 154) with a median treatment cycles of 18 (3-33). One patient has been
on Azacitidine for 7 years and remains alive 13 years after diagnosis. Median
survival of patients who received Hydroxycarbamide and AML-type induction
were 11.5 and 22 months respectively. Only one patient (with monosomy 7)
received allogeneic transplantation but died 12 months later due to AML. Sur-
vival was 32 and 15 months respectively for patients with normal/ good risk
karyotype and those with adverse cytogenetics and 18 months and 21 months
respectively for those who received active management and those managed
by best supportive care.
Summary and Conclusions: A significant number of CMML patients are diag-
nosed incidentally and the majority of patients are asymptomatic at diagnosis.
The classical finding of splenomegaly is not always present. All male patients
were anaemic at diagnosis. Adverse risk cytogenetics was less frequently encoun-
tered but indicated poor outcomes. Most patients were transfusion dependent
and two thirds of patients were managed actively, mainly with Azacitidine.
Myeloma and other monoclonal
gammopathies - Biology
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PI3K GAMMA/DELTA AS A NOVEL TARGET FOR THE TREATMENT OF
MULTIPLE MYELOMA
R. Piddock1,* G. Pillinger1, M. Auger2, S. Rushworth1, K. Bowles1,2
1Norwich Medical School, University of East Anglia, 2Norfolk and Norwich Uni-
versity Hospital Trust, Norwich, United Kingdom
Background: Inhibiting tumor proliferation by targeting specific tyrosine kinases
has proved an effective and well tolerated strategy in a number of hematological
malignancies. Phosphoinositide-3-kinases (PI3K) are an enzyme group that
generates phosphatidylinositol 3, 4, 5-triphosphate which provides a membrane
docking site for the tyrosine kinase AKT (also known as protein kinase B). The
class 1 PI3K isoforms (p110α/β/γ/δ) are known to be involved in the carcino-
genesis and chemotherapy resistance of many cancers types, with p110δ and
p110γ specifically being enriched in the hematopoietic system. The aberrant
activation of the PI3K-AKT pathway has previously been shown to be active in
Multiple Myeloma (MM) where it functions as a pro-survival signaling pathway.
IPI-145 (Duvelisib) is a PI3K p110δ and p110γ inhibitor which at 25mg twice a
day dosing is reported to achieve a plasma steady-state concentration of 0.9
μM and plasma peak concentration (Cmax) of 2.4 μM.
Aims: Here we investigate the effects of IPI-145 on MM pro-survival signaling,
proliferation and bone marrow stromal cell (BMSC) and SDF1 mediated plasma
cell migration using drug concentrations achievable in vivo.
Methods: To investigate the role of PI3K p110δ and p110γ subunits in regulating
MM survival and migration we used PI3K pharmacological inhibitor IPI-145
(PI3K δγ inhibitor) with LY295002 (Pan PI3K inhibitor) and CAL101/Idelalisib
(PI3K p110δ inhibitor) as controls. CellTiter-Glo was used to measure survival
and transwell permeable plates with 8.0µM pores for migration assays. Western
blotting was used to examine the role of BMSC, SDF-1 and IL-6 in regulating
AKT and MAPK activation in MM cells in response to PI3K δγ inhibition.
Results: The PI3K δγ inhibitor IPI-145 reduced survival of MM cells at 1uM.
IPI-145 triggered cytoxicity was associated with pAKT inhibition. IPI-145 also
inhibited MM cell growth in response to IL-6 and bone marrow stromal cell co-
culture. Furthermore we found that IPI-145 inhibited the migration of MM cells
responding to BMSC and SDF-1 stimulation. Finally, we report that IPI-145 can
inhibit SDF-1 induced AKT phosphorylation and downstream signaling.
Summary and Conclusions: IPI-145 inhibits MM cell survival and migration
at concentrations achievable in vivo. The results reported here provide a molec-
ular mechanistic rationale for the clinical evaluation of IPI-145 in MM patients.
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BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1
AND YKL40 EXPRESSION 
D. Tibullo1,* M. Di Rosa1, C. Giallongo1, P. La Cava1, N. Parrinello2, A. Romano1,
C. Conticello1, F. Puglisi1, G. Sapienza1, G. A. Palumbo1, F. Di Raimondo1
1Division of Hematology, azienda ospedaliera universitaria policlinico Vittorio
Emanuele, University of Catania, 2Division of Hematology, azienda ospedaliera
universitaria policlinico Vittorio Emanuele, azienda ospedaliera universitaria
policlinico vittorio emanuele, Catania, Italy
Background: Osteolytic bone disease is a common manifestation of multiple
myeloma (MM) that leads to progressive skeleton destruction and is the most
severe cause of morbidity in MM patients. It results from increased osteolytic
activity and decrease osteoblastic function. Activation of mammalian chitinases
CHIT1 and YKL40 is associated with osteoclast (OCs) differentiation and bone
digestion.
Aims: In the current study, we investigated the effect of two Bortezomib’s con-
centration (BO) (2.5 nM and 5nM) on osteoclastogenesis by analyzing regula-
tion of chitinase expression. 
Methods: In order to obtained the OCs, the conditioned medium was supple-
mented with 25 ng/mL soluble rhRANK ligand (Peproteck, BDA, Italy) and 20
ng/mL rhM-CSF (Peproteck, BDA, Italy), for 21 days w/o Bortezomib (2.5nM or
5nM). The medium was replaced every 3 days. Cells and supernatants were
harvested every 3 days for enzymatic assay, qRT-PCR, immunofluorescence
and Western blotting. The supernatants were stored at − 20 °C. To confirm that
macrophages achieved OCs differentiation, suitable markers were analyzed by
qRT-PCR. Finally, in order to evaluate the ability of MM cell lines (U266) to digest
bone, dentine discs were added to the wells before cell seeding. U266 cultured
with conditioned medium (without BO) for 24 h were used as a control.
Results: OCs exposition to BO was able to inhibit the expression of different
OCs markers such as RANK, CTSK, TRAP and MMP9. In addition BO-treat-
ment reduced CHIT1 enzymatic activity and both CHIT1 and YKL40 mRNA
expression levels and cytoplasmatic and secreted protein. Moreover,, immuno-
fluorescence evaluation of mature OCs showed that BO was able to translocate
YKL40 into the nucleus, while CHIT1 remained into the cytoplasm. Since MM
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cell lines such as U266, SKM-M1 and MM1 showed high levels of CHIT1 activ-
ity, we analyzed bone resorption ability of U266 using dentin disc assay. After
3 days of incubation, we observed that U266 cells were able to form resorption
pits on a dentin disc. Silencing the chitinase proteins in U266 cell line with spe-
cific siRNAs, resulted in pits number reduction on dentine discs
Summary and Conclusions: In conclusion we showed that BO decreases
osteoclastogenesis and reduces bone resorption in OCs and U266 cell line by
modulating the chitinases CHIT1 and YKL40. These results indicate that chiti-
nases may be a therapeutic target for bone disease in MM patients.
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POLYMORPHISM WITHIN THE BFGF PROMOTER REGION IS ASSOCIATED
WITH DISEASE PROGRESSION AND RESPONSE TO CHEMOTHERAPY
IN PATIENTS WITH MULTIPLE MYELOMA
T. Wróbel1,* A. Butrym1,2, P. Lacina3, J. Rybka1, K. Gembura3,
K. Bogunia-Kubik3, G. Mazur4
1Dept. of Hematology, Blood Neoplasms and Bone Marrow Transplantation,
2Dept. of Physiology, Wroclaw Medical University, 3Laboratory of Clinical
Immunogenetics and Pharmacogenetics,, L. Hirszfeld Institute of Immunology
and Experimental Therapy, Polish Academy of Sciences, 4Department of Inter-
nal, Occupational Diseases and Hypertension, Wroclaw Medical University,
Wrocław, Poland
Background: Vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) play an important role in the initiation of angiogenesis. 
Aims: We aimed to assess whether polymorphisms located within the genes
coding for these key angiogenic activators (VEGF (rs3025039; C>T) and bFGF
(rs308395, G>C)) contribute to disease susceptibility and/or progression in
patients with multiple myeloma (MM) and response to chemotherapy. 
Methods: For this purpose, 133 patients with MM and 122 healthy individuals
were typed for the VEGF and bFGF alleles by PCR-RFLP technique.
Results: Patients and controls presented with similar distributions the VEGF
and bFGF alleles and genotypes, thus none of the polymorphisms was asso-
ciated with the risk of MM. However, it was observed that patients presented
with stage I-II of the disease (according to the Durie-Salmon criteria) more fre-
quently carried the bFGF-923G allele as compared to patients in stage III of
MM (0.31 vs 0.16, P=0.052) and healthy controls (OR=2.010, P=0.040). Pro-
gression of the disease after first line chemotherapy was more frequent among
patients carrying this allelic variant (6/32 vs 4/88, P=0.022).
Summary and Conclusions: Clinical course of disease in patients with mul-
tiple myeloma is associated with a polymorphism within the bFGF promoter
region.
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PLASMA CELLS CULTURE OPTIMIZATION FOR CYTOGENETIC STUDY
IN MULTIPLE MYELOMA 
M. Peris1, C. Palacio2, J. Hidalgo3,* M. Gironella3, F. Bosch3, M.R. Caballin4,
M. Ortega1
1Cytogenetic Laboratory, Department of Haematology, 2Cytometry Laboratory,
Department of Haematology, 3Department of Haematology, Hospital Universi-
tary Vall d’Hebron, 4BAVE. Antropology Unity, University Autonoma of
Barcelona.UAB, Barcelona, Spain
Background: Multiple myeloma (MM) is a malignant disease characterized
by clonal proliferation of plasma cells (PC) and their accumulation in the bone
marrow (BM). Cytogenetics alterations have a remarkable prognostic value in
patients with MM. But the main limitation of the karyotype study is that PC have
a low proliferative index, and conventional cytogenetics methods allow to detect
chromosomal alterations in only 20-40% of cases at diagnosis. For this reason
the eligible diagnostic technique is the iFISH in selected PC. Selected PC cyto-
genetics cultures studies are not found in the literature
Aims: To optimize the conventional cytogenetic study by the selection of PC
Methods: In 32 patients with PC neoplasms (19 MM at diagnosis, three MM
after treatment, five MM at relapse, three smoldering MM (SMM) and two mon-
oclonal gammopathy of undetermined significance (MGUS)) a PC negative
selection with the commercial kit RosetteSep® Human Multiple Myeloma Cell
Enrichment Cocktail (Stemcell®) and the culture (SCP) was performed. In par-
allel, a conventional culture (N-SCP) as a control was performed in 27 patients.
To evaluate the technique efficiency, in both cultures, the%CP post-culture and
the detection of chromosome alterations were compared
Results: It was observed that the PC negative selection prior to culture signif-
icantly increased the%CP post-culture (54% SCP vs 16.9% N-SCP) in all PC
neoplasms (P=0.02) and significantly increased the detection of chromosome
aberrations (75% SCP vs 37,5% N-SCP) (P=0.022). It was also confirmed the
possibility to perform the iFISH technique in addition to karyotype and the
increase in the percentage of interfasic nuclei with genetic alterations in SPC
culture(71% SCP vs 16% N-SCP)
Summary and Conclusions: The PC selected culture is a viable, simple and
effective technique that allows the conventional cytogenetic study with an
increase of chromosomal aberrations detection in patients with PC neoplasms
(75%) and also allows iFISH study
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THE ROLE OF FLT3-LIGANT IN THE PROGRESSION OF MULTIPLE
MYELOMA: CORRELATION WITH ANGIOGENIC CYTOKINES.
M. Kokonozaki1,* M. Devetzoglou2, G. Tsirakis2, C. Vasilokonstantaki2,
I. Stagakis2, F. Psarakis2, E. Moraitaki2, E. Nioti2, M. Alexandrakis2
1Laboratory of Haematology, 2PAGNI, heraklio crete, Greece
Background: Background.Multiple myeloma (MM) is a malignant proliferation
of monoclonal plasma cells, resulting in a variety of clinical manifestations
including osteolytic bone lesions, anemia, hypercalcemia and renal failure.
Angiogenesis, the formation of new blood vessels from existing blood vessels,is
an essential component in the growth and progression of MM. Fms-like tyrosine
kinase 3 (Flt3) ligand (Flt3-L) is a potent hematopoietic cytokine that is probably
involved in early B cell development and it is expressed by endothelial cells.
Aims: Aims.The aim of the present study was to evaluate serum levels of cir-
culating FLT3-L in newly diagnosed MM patients and to estimate if there is any
relationship between FLT3-L and known markers of angiogenesis such
as,TNFa,HGF, and the expression of CD105 on endothelial cells.
Methods: Methods.We studied 56 newly diagnosed MM patients (26 female
and 30 male with mean age 64.5±12.3 years), according to ISS.15 had stage-
I disease,19 stage -II and 22 stage- III. We also studied 20 healthy persons as
control group.TNFa,HGF and FLT3-L serum levels,were determinate by a sol-
id-phase sandwich ELISA,using commercially available kits.CD105 expression
was determinate by immunohistochemical methods.
Results: Results.FLT3-L,TNFa,HGF and expression of CD105 values,were
significantly higher in MM patients compare to controls(P<0,001 in all
cases),TNFa,FLT3-L,HGF and CD105 values,were also significantly higher
with advancing disease stage(P<0,001 in all cases). We also found significant
correlations between FLT3-L serum levels with expression of CD105 values
(r=0,459,P<0,0001),TNFa (r=0,458,P<0,0001) and HGF (r=0,537,P<0,0001).
Summary and Conclusions: Conclusion.There is a growing evidence that
FLT3-L has a significant role in the progression of MM.Serum levels of the
angiogenic cytokines TNFa,HGF and the expression of CD105 wich reflect
bone marrow neovascularisation,are increased in MM patients and correlated
strongly with FLT3-L values this findings indicates that FLT3-L serum levels
could be used as a potential tumor marker for disease severty and angiogen-
esis.
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SYNERGISTIC APOPTOTIC EFFECTS OF BORTEZOMIB AND
METHYLSTAT ON DIFFERENT MULTIPLE MYELOMA CELL LINES
N. Kaci1, Y. Kiraz1,* Y. Baran
1Molecular Biology and Genetics, İzmir Institute of Technology, İZMİR, Turkey
Background: Several treatment strategies are used for multiple myeloma
(MM), because of the high heterogeneity of MM, it still remains an incurable
disease and it gives different clinical response against the therapeutic agents
and drugs. Bortezomib, proteasome inhibitor, is an anticancer agent used for
the treatment of multiple myeloma while methylstat is a demethylase inhibitor
having anticancer potential. Until now, the effects of methylstat have been
reported in breast and oesophageal cancer types. However, there is no study
on multiple myeloma cells (MM). 
Aims: In this study, we investigated antiproliferative and apoptotic effects of
methylstat alone or in combination with bortezomib on U266 and ARH77 cells.
We also examined the genes involved in methylstat induced apoptosis.
Methods: Cytotoxic effects of bortezomib and methylstat on U266 and ARH77
cells were demonstrated by MTT cell proliferation assay. To understand the
apoptotic effects of these agents, loss of mitochondrial membrane potential
and changes in caspase-3 enzyme activity were investigated by using JC-1
dye based-method (Cayman Chemicals, USA) and caspase-3 colorimetric
assay kit (BioVision Research Products, USA) while phosphatidylserine local-
ization was investigated by Annexin V assay. Cell cycle analysis in response
to Bortezomib and Methylstat alone or in their combination were measured by
flow cytometry. Changes in expression profiles of 84 genes underlying apop-
tosis and cell cycle control, in response to Methylstat were determined by
Human Cancer Pathway Finder RT2 Profiler PCR Array System (SABio-
sciences Corporation, USA).
Results: There were dose- and time- dependent decreases in cell proliferation
in response to bortezomib and methylstat based on the results of MTT assay.
IC50 values were calculated from cell proliferation plots and found to be 41 nM
and 19 nM for U266 and ARH77 cells in respons to bortezomib, respectively
while they were 2.2 µM and 4.2 µM for U266 and ARH77 cells in response to
methylstat, respectively. On the other hand, combination studies showed that
IC50 values decreased as compared to bortezomib and methylstat alone and
were calculated as 0.5 nM and 0.6 nM for U266 and ARH77 cells, respectively.
To evaluate the apoptotic effects of agents, JC-1, caspase-3 and Annexin-V
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analysis were performed. Combination of bortezomib with methylstat showed
more effect on apoptosis as compared to any agent alone and untreated control
group. Also, cell cycle analysis was performed to detect the DNA contents of
cells. Combination of bortezomib and methylstat arrested cells at the S phase.
The fraction of cells in S phase increased accordingly. Previous data demon-
strated that combination of agents caused apoptosis and it could be cell cycle-
dependent. Human Cancer Pathway Finder RT2 Profiler PCR Array System
results of this study had shown that 1.1 µM and 2.2 µM methylstat treatment
caused upregulation of FASLG, NGFR, TNF, TNFRS10B and TNFRS1B apop-
tosis- triggering genes in U266 cells and BCL2L11, CSP7, TNFRSF21 and 2.1
µM and 4.2 µM methylstat treatment caused TNFSF8 apoptosis- triggering
genes in ARH77 cells in a dose-dependent manner. Furthermore, there were
significant decreases in the expression levels of AKT1, AVEN, BAG1 BCL2L2
and RELA anti-apoptotic genes in U266 cells and NFKB1 anti-apoptotic gene
in ARH77 cells in response to increasing concentrations of methylstat.
Summary and Conclusions: In conclusion, all results showed that the effects
of bortezomib in combination with methylstat on U266 and ARH77 MM cells
had significant decreases in proliferation and triggered apoptosis. Lots of genes
and pathway in the cell were affected by methylstat treatment so methylstat
might be used as candidate agent for the treatment of MM after in vivo analyses. 
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MYELOMA OVEREXPRESSED (MYEOV) ONCOGENE: AN ANCIENT
TRANSPOSABLE ELEMENT EXAPTATION EVENT ALLOWED FOR THE
PRODUCTION OF A HUMAN-SPECIFIC PEPTIDE.
S. Papamichos1,* D. Margaritis1, E. Spanoudakis1, A. Christoforidou1,
Z. Bezirgiannidou2, E. Vlachaki3, S. Vakalopoulou4, G. Koutra5, S. Dapdapi6,
A. Rampotas1, I. Kotsianidis1
1Department of Haematology, Medical School, Democritus University of Thrace,
2Blood Transfusion Center, University Hospital of Alexandroupoli, Alexan-
droupolis, 3Thalassaemia Unit, Hippokration General Regional Hospital, 4Sec-
ond Propedeutic Department of Internal Medicine, Medical School, Aristotle
University of Thessaloniki, Thessaloniki, 5Cardiac Intensive Care Unit, General
Hospital of Kavala, Kavala, 6Thalassaemia Unit, University Hospital of Alexan-
droupoli, Alexandroupolis, Greece
Background: It has formerly been suggested that the high incidence of cancer
in human, as compared to non-human primates, could likely be related to mal-
adaptations during the recent evolutionary past. MYEOV, an oncogene in mul-
tiple myeloma (MM), was recently characterized as a human-specific protein-
coding gene of de novo origin from long non-coding RNA. In 2010, MYEOV
expression was documented in primary MM cells and in purified plasma cells
from patients with monoclonal gammopathy of undetermined significance how-
ever was scarcely detected in bone marrow plasma cells and was absent in
normal plasmablasts or memory B cells. In addition, the gene was identified as
causally involved in promoting MM cells propagation.MYEOV has the potential
to encode for two protein isoforms, namely for a 313 amino acid peptide
(MYEOV-313) and for a shorter one (MYEOV-255). Solid Western-blot assays
support the production of both the proteins while MYEOV-313 expression has
been validated in patients with MM. Both the peptides seem to be directed to
the membrane nonetheless are of, yet, unknown function.
Aims: Illuminate, via in silico analysis, the evolutionary path leading to MYEOV.
Highlight that a captivating exaptation event of an ancient transposable element
(TE) significantly contributed to the creation of MYEOV gene structure.
Methods: BLASTN search against the GenBank human genomic database
and BLASTP search against the GenBank nonredundant protein database were
used to exclude MYEOV origination via gene duplication and to verify unam-
biguous MYEOV orthologs. MYEOV orthologs annotated in the respective data-
bases from NCBI and Ensembl were identified by searching with the gene
name. Whole-genome shotgun (WGS) sequence contigs, including within the
DNA segments used to curate the reference genomic sequences of MYEOV
orthologs, were downloaded from the NCBI Gene database. The WGS
sequence contigs were used to build MYEOV locus alignment blocks between
human and the 11 species with annotated orthologs, via BLASTN. Each align-
ment block was manually scrutinized for validating the primary open reading
frame (ORF) of the annotated orthologs. Search for MYEOV upstream ORFs
was performed with the ORF Finder program.MYEOV splice site analysis was
performed with the Human Splicing Finder Version 2.4.1 program. MYEOV was
scanned for the presence of TEs by Repeat Masker. MYEOV locus syntenic
alignments of numerous Vertebrates were downloaded from the UCSC Genome
Browser Database (UCSC GBD). The automated alignments were used to
extract syntenic DNA segments in numerous mammals that flank MYEOV-313
start codon. The DNA segments extracted were scanned by RepeatMasker. 
Results: MYEOV BLASTN search yields no significant similarity with any other
coding sequence in the human genome. Syntenic alignments, extracted from
the UCSC GBD, signify that the DNA segment where MYEOV locates emerged
in Eutherian mammals. An important mutational event occurred in Catarrhini
resulting in the de novo gain of a translatable ORF in a genomic region that
seems noncoding in other species. That is the acquisition of a MYEOV-255
start codon. During evolution in the Catarrhini genome, MYEOV acquired a
gradually elongated translatable ORF, a gradually shortened translation-regu-
latory upstream ORF, as well as introns and alternatively spliced mRNA variants.
During Homo / Pan separation time, a momentous point mutation was intro-
duced in human resulting in the acquisition of MYEOV-313 start codon. Accord-
ingly, many of the automated annotations of MYEOV orthologs, provided by
the NCBI and Ensembl automated pipelines, contain inaccuracies. MYEOV-
313 start codon is included in a genomic region reported from RepeatMasker
to match a TE of the L2 family. The RepeatMasker match appears degenerated
however in-depth phylogenetic analysis verified the presence of the L2 repeat
in syntenic DNA segments in many mammals. 
Table 1.
Summary and Conclusions: MYEOV is a Primate Orphan Gene. MYEOV-
255 is conserved in Hominines while MYEOV-313 represents a human-specific
peptide. MYEOVwas characterized as a human-specific de novo gene because
the existence of two protein isoforms was not specifically addressed. MYEOV-
313 start codon was evolutionary provided by a L2 TE. Could this rare exapta-
tion event represent a human mal-adaptation, is a tantalizing possibility. Accord-
ingly, MYEOV-313 biological role warrants further research, especially because
targeting a human-specific peptide could theoretically cause less adverse
effects than targeting components of evolutionary conserved signaling cas-
cades.
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EXPRESSION OF MULTIDRUG RESISTANCE GENES IN PATIENTS WITH
NEWLY DIAGNOSED AND REFRACTORY MULTIPLE MYELOMA 
Y. Chernykh1,* A. Golenkov1, S. Shushanov2, E. Rybalkina2, T. Mitina1,
E. Trifonova1, L. Vysotskaya1, E. Kataeva1
1The State Budgetary Healthcare Institution of Moscow Area “Moscow’s region-
al research clinical institute n.a. M.F. Vladimirskiy”, 2FGBU Russian Cancer
Research Center named after N. N. Blokhin Russian Academy of Medical Sci-
ences, Moscow, Russian Federation
Background: The myeloma cells have the phenomenon of multidrug resistance
(MDR), which reduces the effects of chemotherapy. The better understanding
of the molecular genetic mechanisms of development of MDR may lead to the
development of the individual criteria of prediction of response to cytotoxic
treatment of patients with multiple myeloma. 
Aims: To determine the expression of four genes associated with MDR, such
as MDR1, MRP1, LRP, and BCRP in relation to treatment status. We studied
the aspirate of bone marrow of patients with multiple myeloma before cytotoxic
treatment and in the resistant group of patients. 
Methods: The study included 33 patients (16 men and 17 women) with a diag-
nosis of multiple myeloma stage 3 by Durie-Salmon system. The age of the
patients ranged from 50 to 78 years. 14 patients were investigated before the
start of cytostatic treatment. In 19 patients the bone marrow studied after treat-
ment alkylating-containing combinations at the time of registration of resistance
to the given therapy. The mRNA expression of the genes was determined by
semiquantitative RT-PCR (polymerase chain reaction with reverse transcription)
in the mononuclear fraction of the bone marrow aspirate.
Results: Generally, the incidence of mRNA expression of the studied genes
MDR in a group of untreated patients was high. The MDR 1 mRNA expression
was detected in 93% (13/14) of the samples, the mRNA of the gene MRP 1
was detected in 79% (11/14). The BCRP mRNA expression was detected in
100% of the investigated samples. The expression of mRNA of the gene LRP
was identified in 71% of the studied cases (10/14). In the group of patients
after treatment the expression of mRNA of genes MDR1, MRP 1, BCRP was
detected in 100% of cases, and the LRP mRNA levels detected in 16/19 (84%)
of the samples. The expression level of mRNA of each of the tested MDR genes
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in all studied patients was different. The average value of the expression a
total of 4 MDR genes in the group of untreated patients was 3.5±0.72 points.
In group of pretreated patients value of the expression has increased to 6.3±
0.54points (P=0.004). 
Summary and Conclusions: The expression of mRNA of MDR MRP 1, MDR
1, BCRP, LRP was determined in patients with untreated multiple myeloma.
The intensity of gene expression increases in resistant patients.
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IL-4 AND IL-6 GENE POLYMORPHISMS IN PATIENTS WITH MULTIPLE
MYELOMA FROM THE NORTHWEST FEDERAL DISTRICT OF RUSSIA
A. Pavlova1,* I. Sokolova1, L. Bubnova1, S. Bessmeltsev2, I. Pavlova1
1Immunohaematology laboratory, 2Deputy director for science, Russian Insti-
tute of Haematology and Transfusion, Saint-Petersburg, Russian Federation
Background: It is a well known fact that interleukin 6 (IL-6) stimulates the pro-
liferation of neoplastic plasma cells and acts as an osteoclast-activating factor
(plays an important role in the development of the bone disease), whereas
interleukin 4 (IL-4) suppresses growth of multiple myeloma (MM) by inhibiting
the synthesis of IL-6. Single nucleotide polymorphisms (SNPs) in the regulatory
regions of cytokine genes may affect on the transcription and production of the
cytokines that can effect on the development of various diseases. 
Aims: The aim of this study was to identify SNP in different regions of IL-6 (-
174G/C, nt565G/A) and IL-4 (-1098T/G, -590T/C, -33T/C) genes associated
with the development of MM among the residents of the Northwest Federal
District of Russia as well as determination of the bone lesions severity.
Methods: We analysed 43 MM patients with the median age 69 years. Patients
were divided into two groups depending on the detected changes in the bones:
1st group (19 patients)-with severe osteolytic bone lesions (III stage of the
Durie-Salmon staging system); 2nd group (24 patients) – with manifestations
of osteoporosis and isolated pockets of osteolytic bone lesions (II stage of the
Durie-Salmon staging system). The control group consisted of 40 healthy unre-
lated Caucasoid blood donors (median age 54 years). All analysed people
were from the Northwest Federal District of Russia (St-Petersburg). Genomic
DNA was extracted from the peripheral blood and both IL-4 and IL-6 gene
genotyping was performed by the use of PCR-SSP.
Results: Based on the genotyping results of IL-4 -1098T/G we found that in
general cohort of patients with MM genotype frequencies were not significantly
different from each other except for the IL-4 -1098GG genotype which was not
detected in the group of healthy people but was registered in the group of
patients with a frequency of 0.05. When we analysed data for IL-4 -590T/C the
genotype frequency of IL-4 -590TC in patients was two times lower than in
control group (0.25 vs. 0.53). Although genotype IL-4 -33TT in MM patients
with manifestation of osteoporosis occurs three times often than in control
group (0.33 vs. 0.10 respectively). Some differences in IL-6 -174GG genotype
frequencies in patients with MM were observed: in a total group of patients-
0.47 (0.53 in the 1st group and 0.42 in the 2nd group) against 0.13 in the control
group. Сonversely, the IL-6 -174GC genotype was more frequent in the group
of donors than in the group of patients with severe osteolytic lesions (0.70 vs.
0.26 respectively). Similar pattern was observed for IL-6 nt565GA genotype-in
control group this genotype was noticed more frequently (0.80) than in patients
(from 0.26 in the 1st group and 0.42 in the 2nd group). However, IL-6 nt565GG
genotype frequency was less common in healthy people compare to patients
with MM (0.13 to 0.49 respectively). Finally, IL-6 nt565GG was significantly
higher in patients with severe osteolytic bone lesions than in patients with
symptoms of osteoporosis and in the control group (0.53 vs. 0.46 and 0.13
respectively).
Summary and Conclusions: Thus, our results allow to describe some geno-
types as markers associated with the development of MM such as IL-4 -33TT,
IL-6 -174GG and IL-6 nt565GG. Furthermore, IL-6 nt565GG genotype is asso-
ciated with the development of severe osteolytic lesions in multiple myeloma.
Myeloma and other monoclonal
gammopathies - Clinical
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HIGH LEVELS OF SERUM ANGIOGENIC GROWTH FACTORS AND MAST
CELL DENSITY IN THE DEVELOPMENT OF MULTIPLE MYELOMA
R. Vyzoukaki1,* M. Devetzoglou2, M. Kokonozaki1, A. Papadopoulou1,
A. Boula3, E. Nioti1, A. Alegakis4, M. Alexandrakis5
1Laboratory of Haematology, 2Department of Haematology, University Hospital
of Heraklion Crete, 3Division of Haematology, Venizeleion Hospital of Heraklion
Crete, 4School of Medicine, University of Crete, 5Laboratory of
Haematology,Department of Haematology, University Hospital of Heraklion
Crete, Heraklion, Greece
Background: Bone marrow angiogenesis is involved in the pathogenesis and
progression of certain haematological malignancies, like multiple myeloma
(MM). Increased mast cell density (MCD) in bone marrow (BM) produces var-
ious mediators promoting MM progression with multiple manners.
Aims: The purpose of this study was to evaluate the involvement of BM MCD,
and angiogenic cytokines such as angiopoietin-2(angiop-2), angiogenin (ang)
and metalloproteinase-9(MMP-9) in MM disease progression.
Methods: We studied 70 newly diagnosed MM patients, 38 males, 32 females,
mean age 57±14,5 years.According to ISS 20 were in stage I, 28 in stage II
and 22 in stage III. 20 age and sex matched healthy volunteers were used as
control group. The immunohistochemical expression stage of mast cell
thryptase was measured in BM biopsy samples in order to estimate MCD, while
angiop-2, MMP-9 and ang values were measured in serum by a solid phase
sandwich ELISA.
Results: There are significant differences in levels of MCD, Angiop-2 and ANG
(P<0,001 for all cases) but no significant differences in MMP-9(P=0,538)
between patients and controls. All of the measured parameters were also in
parallel with ISS stage(P<0,001 for all cases). Moreover BM MCD correlated
positively with angiop-2, MMP-9, and ang (P<0,0001 for all cases).
Summary and Conclusions: Mast cells are increased in MM BM and they
participate in many aspects of the disease. They release various mediators,
increasing directly and indirectly myeloma growth.It has been also established
that disease progression in MM is accompanied by increased BM angiogenesis.
Overall mast cells and angiogenic growth factors seem to be important factors
in MM biology and disease progression.
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MAST CELL DENSITY AND CIRCULATING BIOMARKERS OF BONE
DISEASE INCREASE SIMULTANEOUSLY WITH PROGRESSION OF
HUMAN MULTIPLE MYELOMA
R. Vyzoukaki1,* M. Kokonozaki1, P. Kanellou2, K. Pappa3, P. Spatharaki1,
S. Masud1, D. Stafylaki1, M. Tzardi4, M. Alexandrakis5
1Laboratory of Haematology, 2Department of Haematology, University Hospital
of Heraklion Crete, 3Department of Internal Medicine, Venizeleion Hospital of
Heraklion, 4Department of Pathology, 5Laboratory of Haematology, Department
of Haematology, University Hospital of Heraklion Crete, Heraklion, Greece
Background: Multiple myeloma (MM) is a neoplastic disorder characterized
by clonal proliferation of plasma cells in the bone marrow. Many circulating
biomarkers posses variable roles in the pathogenesis of bone disease causing
bone distruction. Mast cells (MCs) can produce, store and release many kinds
of chemical mediators with angiogenic properties. MCs accumulation has been
associated with enhanced tumor growth.
Aims: The purpose of the study is to estimate the participation of RANK-ligand,
matrix metalloproteinase 9 (MMP-9), N-terminal telopeptide (Ntx), carboxyter-
minal propeptide of type 1 collagen (PICP) and mast cell density(MCD) in the
process of bone disease in MM patients.
Methods: We studied fifty-two newly diagnosed MM patients, 28 males, 24
females, mean age 64 years. The types of monoclonal proteins were 27 IgG,
18 IgA, 7 light chain, according to ISS:15were in stage I, 18 in stage II, 19 in
stage III. Twenty age- and sex-matched healthy subjects were used as control
group. We measured serum levels of sRANKL, MMP-9 and Ntx in urine sam-
ples by a solid-phase sandwich ELISA, and MCD in bone marrow biopsy sam-
ples by immunostaining. Radiographic examination including skull, pelvis, long
bones and cervical, thoracic, and lumbar spine was carried out in all patients
as a routine staging procedure.
Results: MCD, RANKL and Ntx were significant higher in untreated myeloma
patients in comparison to healthy controls (P<0,001 for all cases). All values were
increasing in parallel with ISS stage (P<0,001 for MCD, RANKL, MMP-9 and
Ntx). There are significant correlations between MCD and MMP-9, RANKL and
Ntx (P<0,001 for all cases). No correlation between MCD and PICP was found.
Summary and Conclusions: In conclusion, our results underline that MCD is
an important factor responsible for the enhancement of bone involvement in
MM. The positive correlation between MCD and circulatin biomarkers of bone
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disease support the involvement of mast cells in the biology of myeloma cell
growth. Moreover MCD could be used as a marker of disease activity. 
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SUCCESSFUL TREATMENT OF PATIENTS WITH NEWLY
DIAGNOSED/UNTREATED LIGHT CHAIN MULTIPLE MYELOMA WITH A
COMBINATION OF BENDAMUSTINE; PREDNISONE AND BORTEZOMIB
(BPV) 
W. Poenisch1,* H. Mrachacz1, N. Khoder1, M. Plötze1, B. Holzvogt1, M. Andrea1,
T. Schliwa1, S. Heyn1, G. N. Franke1, R. Krahl1, M. Jentzsch1, S. Leiblein1,
S. Schwind1, V. Vucinic1, D. Niederwieser1
1Hematology/Oncology, University of Leipzig, Leipzig, Germany
Background: Patients with light chain myeloma have frequently a light chain
tubular cast nephropathy, which can lead to severe renal impairment.
Aims: Both bortezomib and bendamustine have been identified as quickly act-
ing, effective and well tolerated drugs and might therefore constitute an ade-
quate combination regimen for patients with newly diagnosed/untreated light
chain multiple myeloma.
Methods: Between September 2009 and March 2014, 20 patients with newly
diagnosed/untreated light chain multiple myeloma were treated with bendamus-
tine 60mg/qm on days 1 and 2, bortezomib 1.3 mg/qm on days 1,4,8 and 11,
and prednisone 100mg on days 1,2,4,8 and 11 once every 21 days. 5 patients
(25%) had a moderate or severe renal dysfunction (eGFR 15–59ml/min) and 9
patients (45%) a renal failure/dialysis (eGFR<15ml/min).
Results: The median number of the BPV-treatment was 2 (1-5) cycles. 19
patients (95%) responded after at least one cycle of chemotherapy with 3sCR,
4nCR, 5VGPR, and 7PR. The myeloma light chains decreased rapidly, reach-
ing the best response after the first cycle in 8 and after the second cycle in
additional 9 patients. 16 patients discontinued therapy after median 2 cycles
of BPV treatment to receive autologous (n=13) or autologous/allogeneic SCT
(n=3). All together 10/14 patients with at least moderate renal failure improved
their renal function (4CRrenal, 2PRrenal, 4MRrenal). 3 of the 6 dialysis-depen-
dent patients became dialysis-independent.With a median follow up of 23
months of the surviving patients, median PFS and OS for patients at 24 months
were 90% and 95%, respectively. The most common severe side effect was
grade 3-4 leukocytopenia in 25% of the patients. Grade 3-4 thrombocytopenia
was observed in 15% of the patients. Moderate to severe infection were seen
in 4 patients.
Summary and Conclusions: We conclude that BPV is effective and well tol-
erated in patients with newly diagnosed/untreated light chain multiple myeloma.
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THE FREQUENCY OF CYTOGENETIC ABNORMALITIES AND THEIR
IMPACT ON OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA.
A. Garifullin1,* S. Voloshin1, I. Martynkevich1, S. Bessmeltsev1, L. Martynenko1,
E. Kleina1, G. Salogub2, E. Karyagina3, A. Schmidt1, A. Kuvshinov1,
K. Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, 2Saint-Peters-
burg Pavlov State Medical University, 33City Hospital N15, Saint-Petersburg,
Russian Federation
Background: Cytogenetic analyses, including fluorescence in situ hybridization
(FISH) is integral part of stratification in patients with multiple myeloma on risk
groups. Detection of specific abnormalities optimizes treatment strategy for life
expectancy improvement. The impact of the mixed specific genetic aberrations
on the overall survival (OS) is studied.
Aims: To estimate the OS in patients with multiple myeloma, according to risk
stratification.
Methods: 133 patients were prospectively assessed (median age 61 years,
range 26-93; male: female ratio – 1:1.27) with newly diagnosed multiple myelo-
ma. Cytogenetic and FISH analyses were determined in all patients for search
of genetic abnormalities. Cytogenetic studies were performed on bone marrow
samples using standard GTG-method. Metaphase FISH analyses were per-
formed according to the manufacturer’s protocol with use of DNA probes: LSI
13(RB1)13q14, IGH/CCND1, IGH/FGFR3, LSI TP53 (17q13.1) (Abbott). Strat-
ification of patients was carried in risk groups according to the molecular clas-
sification mSMART 2.0 Patients with nonspecific genetic abnormalities were
included in standard risk group. Patients with complex karyotype (3 and more
chromosomal aberrations) and who has 2 specific chromosomal abnormalities
were included in certain group-mixed specific genetic aberrations risk group.
Results: Genetic abnormalities in newly diagnosed multiple myeloma were
detected in 49.5% (56/113). The occurrence frequency of t(11;14) was 26.5%
(n=30), del(13q) – 22.1% (n=25), t(4;14) – 7.1% (n=8), del(17p) – 7.1% (n=8).
73/113 (64.4%) patients was in standard risk group, 17/113 (15,0%) – interme-
diate risk, 8/113 (7,1%) – high risk and 15/113 (13,3%) – with mixed specific
genetic aberrations risk. 5-years OS in standard risk group was 70%, in inter-
mediate risk-84% (P=.42), in high risk – 36.5% and in group with mixed specific
genetic aberrations – 68.7% (P=.036).
Figure 1.
Summary and Conclusions: Genetic abnormalities are important prognostic
factors in patients with multiple myeloma. Identification of specific genetic mark-
ers, which included into high risk group, is a reason for search of optimal strat-
egy of therapies. The obtained data need in further analysis taking into account
age and variants of anti-myeloma therapies. 
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THE DYNAMICS OF SERUM CROSSLAPS AND SCLEROSTIN LEVELS
CORRELATES WITH TREATMENT RESPONSE IN MULTIPLE MYELOMA
PATIENTS WITH THE PRESENCE OF MYELOMA BONE DISEASE
J. Minarik1,* Z. Hermanova2, P. Petrova3, P. Pusciznova1, T. Pika1, J. Bacovsky1,
J. Zapletalova4, V. Scudla1
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Olomouc, Olomouc, Czech Republic
Background: We performed a prospective study in patients with multiple
myeloma (MM) and monoclonal gammopathy of undetermined significance
(MGUS) aimed at the behavior of 13 selected parameters of myeloma bone
disease (MBD).
Aims: The aim of our study was to assess the behavior of selected parameters
of MBD with respect to therapeutic response.
Methods: Altogether we assessed a cohort of 51 patients: 31 patients with
newly diagnosed active MM who responded to treatment reaching at least par-
tial remission (PR) after 4 cycles of chemotherapy, 10 patients with refractory
MM (progression or not reaching PR after 4 months), and two control groups –
5 patients with smoldering MM and 5 individuals with MGUS. The selected
parameters of MBD were as follows: serum calcium (Ca), phosphorus (P), pro-
collagen-I N-terminal propeptide (PINP), carboxyterminal telopeptide of type I
collagen (ICTP), cross linked C-telopeptide (CTX), osteocalcin (OC), parathor-
mone (PTH), calcitonine (C), 25-hydroxyvitamin D (D2), 1,25 dihydroxyvitamin
D (D3), bone fraction of alkaline phosphatase (bALP), sclerostin (Scl) and matrix
metallopeptidase 9 (MMP9). In the whole cohort we performed the analysis of
MBD parameters at the time of diagnosis (before start of chemotherapy in
active MM) and after 4 months. We assessed the behavior of the parameters
with respect to treatment response. The patients were treated using bortezomib
or thalidomide based regimens. All patients with MBD received bisphospho-
nates and adequte calcium support. In patients undergoing autologous stem
cell transplantation the follow-up results were acquired 4 months after the diag-
nosis but before the transplantion. For statistical estimation we used Wilcoxon
pair test at p ˂ 0,05, and McNemara test of symetry at p ˂ 0,05.
Results: We detected significant decrease of CTX (M 0,649 vs. 0,413ug/l;
P=0,014) and sclerostin (M 44,4 vs. 40,6pmol/l; P=0,030) together with significant
increase of parathormone (M 26,0 vs. 60,0pmol/l; P=0,0005) after 4 months of
therapy in patients responding to initial treatment. All the other assessed param-
eters were without significant change. In patients with refractory MM there was
no significant change in any of the assessed parameters. Similarly, there was no
significant change in any of the assessed parameters in the control groups, i.e.
in patients with smoldering MM, and there was only boderline significant decrease
of Ca (M 2,42 vs. 2,28 mmol/l; p =0,042) in MGUS individuals.
Summary and Conclusions: Despite appropriate anti-resorption therapy, there
is no change in the parameters of MBD in patients with MM who failed to respond
after 4 months of treatment. Patients who respond to therapy have significant
decrease of sclerostin and CTX suggesting their auxiliary clinical potential in
the assessment of bone turnover in MM patients. With support of NT14393.
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POST-AUTHORIZATION SAFETY OF LENALIDOMIDE + DEXAMETHA-
SONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE
MYELOMA: EARLY SAFETY REPORT OF TURKISH PASS STUDY
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tal, Ankara, 24Celgene Turkey, Istanbul, 25Ankara University Medical Faculty,
Ankara, Turkey
Background: Prognosis of patients with multiple myeloma (MM) has improved
with the use of novel agents in the past decade. The data on real-world safety
of these agents is limited. Following its regulatory approval in 2010, lenalido-
mide is now commonly used in the relapsed/refractory multiple myeloma
(RRMM) setting in Turkey.
Aims: This post-authorization observational study is designed to define the
safety profile of lenalidomide + dexamethasone therapy under routine real-
world clinical practice by characterizing and identifying the incidence of adverse
events (AE) of special interest in RRMM patients in Turkey.
Methods: Patients aged ≥18 years with RRMM and started on lenalidomide +
dexamethasone treatment were included in the study. Patients who had previ-
ously received lenalidomide and discontinued or who had a treatment inter-
ruption for ≥4 weeks were excluded from the study. Thromboprophylaxis was
allowed but not required. AEs were graded according to NCI-CTCAE (version
4.03) grading.
Results: As of January 30, 2015, 119 patients across 24 institutions in Turkey
were enrolled. Of those, results of 111 patients with available data are going to
be presented in this early safety report. Median follow-up was 19.9 weeks
(range, 1.4–56.4). Median age was 62 years (range, 29–85) and 56.8% were
male. Among 98 of the patients whose ECOG status were recorded at entry,
81 (82.7%) had good performance status (ECOG score 0–1) and 17 (17.3%)
had an ECOG score of 2–4. Median number of prior therapies was two (29.7%
had one prior therapy, 53.2% had two prior therapies and 17.1% had ≥3 prior
therapies). Fifty-four (48.6%) patients had received autologous stem cell trans-
plantation. The overall incidence of peripheral neuropathy at the baseline was
30.6%. Starting dose of lenalidomide was 25 mg in 85 (76.6%) patients, while
15 mg, 10 mg, and 5 mg were the initial dose in 10 (9.0%), 11 (9.9%), and 5
(4.5%) patients, respectively. Dose modifications were required in 13 (11.7%)
patients. Prophylaxis for thromboembolism was performed in total of 37 (33.3%)
patients with aspirin (n=21), heparin (n=15) and warfarin (n=1). Overall, 46
Grade 3-4 AEs were observed in 41 (%36.9) patients and 70 (63.1%) patients
were free of Grade 3-4 AEs. Grade 3–4 neutropenia, pneumonia, anemia, and
thrombocytopenia developed in 8.1%, 5.4%, 3.6%, and 1.8% of patients,
respectively. VTE was reported only in one patient (Grade 2). Among 111
patients, 69 (62.2%) are still receiving lenalidomide + dexamethasone while
42 (37.8%) patients discontinued treatment (AEs : 12 [10.8%], death: 10 [9.0%],
progression: 6 [5.4%], and other reasons: 14 [%12.6]). No second primary
malignancy was reported.
Summary and Conclusions: Early safety data confirmed known AEs of
lenalidomide plus dexamethasone therapy in RRMM patients in Turkey. Longer-
term follow-up of AEs in this study will provide better characterization of AEs.
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LIFE-THREATENING BOWEL PERFORATION WHILE ON THALIDOMIDE-
BASED TRIPLET REGIMEN FOR MULTIPLE MYELOMA: A RETROSPEC-
TIVE CASE SERIES
P. Sriskandarajah1,* F. Scott1, S. Muthalali1, J. Mercieca1
1Haematology, Epsom and St Helier Hospital, Carshalton, United Kingdom
Background: Thalidomide is an oral agent which has demonstrated significant
anti-myeloma activity resulting in improved progression-free and overall survival
rates in newly diagnosed multiple myeloma (MM) patients. The mechanisms
of action of Thalidomide are complex and thought to include both antiangiogenic
and immunomodulatory properties. However, as well as targeting neoplastic
plasma cells, Thalidomide can affect other organ systems resulting in toxicities.
These have been well documented and supportive measures are currently
incorporated into our daily clinical practice to counteract these. However, there
are other adverse effects which have been recorded as uncommon, including
diverticular perforation. Recent figures have suggested that<1% patients treat-
ed between 2004-2012 reported this to the Food and Drugs Administration
(FDA). However, contradictory to these findings, we have noticed an increasing
number of patients within our trust presenting with this life-threatening compli-
cation. Furthermore, this complication has not been observed in patients receiv-
ing other types of anti-myeloma treatment, including Bortezomib, Lenalidomide
and Bendamustine. 
Aims: To study the association between Thalidomide and diverticular perfora-
tion in patients with Multiple Myeloma. 
Methods: A retrospective case series was performed examining all MM patients
who received Thalidomide, either as a single agent or in a combination regimen,
between 1st January 2007 and 31st December 2014 at Epsom and St Helier
Hospital. Patients who developed diverticular perforation while on Thalidomide
were identified and further data collected. This included demographics, co-
morbidities, disease response (according to the International Myeloma Working
Group Response Criteria), time interval between current cycle of treatment
and diverticular perforation, and patient outcome.
Results: A total 118 patients received Thalidomide of which 6 (5%) developed
diverticular perforation. Interestingly, 3 of these patients had presented in the
last 12 months. The median age for this group was 69 years (range 56-86
years) with equivalent numbers of males and females. None of the patients
were known to suffer with gastrointestinal disease, although one patient did
have associated renal amyloidosis. All 6 patients received Thalidomide as part
of a triplet regime with Dexamethasone and either Cyclophosphamide or Borte-
zomib for newly diagnosed multiple myeloma. The median number of cycles
received was 4 (range 2.5 – 6) with 5 out of the 6 patients achieving a disease
response. Response rates included 1 Complete Response (CR), 1 Very Good
Partial Response (VGPR) and 3 PRs. Five patients received 100mg Thalido-
mide with 20mg Dexamethasone, while one patient was taking 200mg Thalido-
mide with 40mg Dexamethasone. All 6 patients were receiving thrombopro-
phylaxis throughout their treatment. Median time to presentation with divertic-
ular perforation was 24 days (range 14-37) from day one of their current cycle.
At presentation the median nadir neutrophil count was 5.1x109/L (range 1.1-
14.4x109/L). All 6 patients were managed surgically with subsequent bowel
biopsies confirming diverticulitis. Five patients made a good post-operative
recovery and were discharged. Three later received further treatment of which
one patient was rechallenged with Thalidomide while the other two patients
received Bortezomib instead. Two patients did not receive further treatment
and are currently under active surveillance. 
Summary and Conclusions: Our case series demonstrates that Thalidomide-
associated diverticular perforation is far more prevalent than previously report-
ed. Given the increasing use of this drug caution should be exercised by clini-
cians, particularly in patients with a known background of diverticular disease.
Further research to establish the molecular mechanism by which Thalidomide
induces diverticular perforation should be performed.
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HYPERCOAGULABILITY AND ITS ASSOCIATION WITH METABOLIC AND
PRO-INFLAMMATORY MARKERS OF CARDIOVASCULAR RISK IN
PATIENTS WITH MULTIPLE MYELOMA
I. Dzis1,*
1Hematology, Institute Of Blood Pathology and Transfusion Medicine, Lviv,
Ukraine
Background: Patients with multiple myeloma (ММ) have an increased risk of
thrombotic complications. The incidence of venous thromboembolism in
patients with MM ranges from 3% to 10%. Hypercoagulability is one of prog-
nostic biomarkers of venous and arterial thrombosis.
Aims: To identify associations between blood markers of coagulation activation,
systemic inflammation, lipid and protein metabolism in patients with MM to
elaorate prognostic markers of thrombotic events.
Methods: Our study involved 22 patients with MM, 14 men and 8 women aged
46-81 years, and a control group of 16 healthy people. Parameters of hemo-
stasis, systemic inflammation, protein and lipid metabolism were studied. In
statistics, Mann-Whitney test and Kendall’s tau correlation were used. Medians
and interquartile intervals were used to describe parametric data. 
Results: In the group of patients with MM, markers of hypercoagulability, such
as increased levels of fibrin monomer and D-dimer were found in 77.3% of
cases. Frequencies of other cardiovascular risk factors were the following:
overweight/obesity – 81.8%, hyperuricemia – 45.5%, atherogenic dyslipidemia
with higher than optimal levels of low density lipoprotein cholesterol (LDL-Ch)
and low levels of high density lipoprotein cholesterol – 68.2%, increased inflam-
matory markers CRP and IL-6 – 77.3%. There were significantly higher levels
of fibrinogen – 5,35 (3,93-6,87) g/L vs 3,80 (3,49-4,40) g/L (P=0,005), fibrin
monomer – 6 (4-10) mg/dL vs 3 (3-3,5) mg/dL (P=0,002) and D-dimer – 90,05
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(32,9-487,8) ng/mL vs 21,55 (18,96-35,50) ng/mL (P<0,001) in comparison
with the control group. Fibrinogen levels correlated positively with body mass
index (BMI) (τ=0.63, р=0.001), levels of total cholesterol (τ=0.44, р=0.004),
LDL-Ch (τ=0.42, р=0.006), albumin in percentage (τ=0.43, р=0.007), and cor-
related negatively with total protein (τ=-0.41, р=0.01) and M-protein levels (τ=-
0.35, р=0.029). Fibrin monomer levels correlated positively with fibrinogen
(τ=0.51, р=0.001), IL-6 (τ=0.51, р=0.001), triglycerides levels (τ=0.47, р=0.002),
albumin in percentage (τ=0.38, р=0.018), and correlated negatively with M-
protein (τ=-0.34, р=0.034) and IgA levels (τ=-0.56, р=0.034). D-dimer levels
correlated positively with triglycerides levels (τ=0.32, р=0.035). Thus, in myelo-
ma patients, increased BMI, systemic inflammation and atherogenic hyperlipi-
demia promotes hypercoagulability. Laboratory data of more severe disease
stage according to parameters of protein metabolism were associated with less
significant features of hypercoagulability.
Summary and Conclusions: To predict the risk of arterial and venous throm-
bosis in patients with MM it is advisable to determine BMI, blood levels of fib-
rinogen, fibrin monomer, D-dimer, CRP, IL-6, and lipid fractions.
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BORTEZOMIB IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA:
THE EXPERIENCE OF A CENTER
M.J. Mendes1,* G. Ferreira1, H. Saturnino1, M. Duarte1, J.C. Almeida1,
L.F. Araújo1, M.L. Ribeiro1
1Hematology, CHUC, Coimbra, Portugal
Background: The therapeutic approach of Multiple Myeloma (MM) has been
marked by two great advances: the possibility of hematopoietic stem cell trans-
plantation in eligible patients and the use of new active drugs, such as Talido-
mide, Bortezomib and Lenalidomide.
Aims: Analyze the follow-up of a group of patients with MM submitted to regi-
mens including Bortezomib in the first line, evaluate the response to the treat-
ment, analyze the overall survival (OS), duration of response (DOR) and time
to progression (TTP).
Methods: Retrospective analyses of the clinical files of patients with MM, diag-
nosed between January 2009 and December 2014, undergoing treatment with
protocols including Bortezomib in the first line. Response criteria after treatment
according to the International Myeloma Working Group (IMWG). Statistic analy-
ses using SPSS 22.
Results: Between January 2009 and December 2014, 65 patients were diag-
nosed with MM, 34 of which (52,3%) were treated with first line Bortezomib
(CyBorDexa in 29; BorDexa in 3; VMP in 2). The median number of cycles
administered was 8,5. The median age at diagnosis was 65,6 years (min=42;
max=79), 18 were females (52,9%) and 16 males (47,1%). The mean follow-
up time was 1,9 years. At diagnosis 31 patients (91,2%) presented anemia, 24
bone disease (70,6%), 19 renal impairment (55,9%) and 11 hypercalcemia
(32,4%). According to the ISS, 10 patients were low risk (ISS 1) (29,4%), 10
patients intermediate (ISS 2)(29,4%) and 14 high risk (ISS 3)(41,2%). Six
patients were eligible for transplant consolidation (17,6%). In 5 patients disease
progression occurred during treatment (14,7%) and 3 are still under treatment.
Response after treatment completion was accessed in 26 patients: PR=13
patients (50%), CR=9 (36,4%), VGPR=3 (11,5%) and sCR=1 (3,9%). Eleven
patients progressed (42,3%) with a median TTP of 15,81 months and mean
DOR of 9,09 months, 2 of them had reached VGPR and 9 PR. Five patients
died. The 5-year overall survival was 85,3%.
Summary and Conclusions: The use of Bortezomib in the regimens CyBor-
Dexa, BorDexa and VMP was effective in the majority of the patients, with
response rates and overall survival mimicking the literature. In 58,8% of patients
the ISS risk was low and intermediate; all the high risk patients presented renal
impairment. Most of the patients completed treatment, 29/34 with CyBorDexa
protocol, 86,4% reaching PR or CR. Among the responding patients, 15 (57,7%)
have not progressed after a mean follow up time of 14 months. Although being
widely used for its good tolerance and low toxicity, in several studies the CyBor-
Dexa protocol showed inferior results compared with other multiple-drug pro-
tocols, such as VTD (Bortezomib, Talidomide and Dexa) or VRD (Bortezomib,
Lenalidomide and Dexa). Currently, ongoing clinical trials will hopefully define
the new standard of care in Multiple Myeloma, namely for the transplant eligible
patients.
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BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOLLOWED BY
AUTOLOGOUS TRANSPLANTATION AS FIRST LINE TREATMENT IN
MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE
J.M. Arguinano1,* M. Zudaire1, E. Pena1, I. Aoiz1, M. Hamdi1, M. Mateos1,
M. Ardaiz1, M. Viguria1, M. Rodriguez Calvillo1, A. Gorosquieta1,
M. Sanchez Anton1, I. Quispe1, P. Arregui1, M. Montoya1, P. Garcia Ramirez1,
M. Alvarellos1
1Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain
Background: A three drug induction regimen followed by autologous trans-
plantation is considered the best approach in multiple myeloma patients who
can endure that procedure. Despite scarce evidence available, the combination
of lenalidomide, bortezomib and weekly dexamethasone (VRd) has been widely
adopted, probably due to more favourable toxicity profile as compared to borte-
zomib, thalidomide and dexamethasone
Aims: To review our center’s experience in using VRd protocol and autologous
transplantation as first line therapy in multiple myeloma patients
Methods: Multiple myeloma was diagnosed according to IMWG criteria, as
well as response assessment. All patients fit enough to undergo transplantation
were treated with VRd combination, as previously described by Richardson et
al, except for weekly administration of 40 mg dexamethasone. Four cycles
were initially scheduled, but two additional cycles could be administered if less
than partial response was achieved. Only patients with creatinine clearance
below 50 mL/min were excluded. At least partial response was required to pro-
ceed to transplantation. Postransplant consolidation with two cycles of borte-
zomib and dexamethasone was administered in case of partial response, as
well as lenalidomide maintenance in order to achieve complete response
Results: From April 2011 to February 2014 a total of 19 patients were treated
according to this protocol. Median age at diagnosis was 58 years, ranging 32
to 70. ISS score was 1 in 7/19, 2 in 7/19 and 3 in 5/19. One patient required
second line therapy due to lack of response to VRd induction, but proceeded
to transplant once a partial response to DT-PACE was achieved. Other patient
did not receive transplantation because of significant cardiac amyloid deposi-
tion. Stem cell mobilization yielded enough cells for the procedure in all patients
despite lenalidomide usage. Responses after VRd induction therapy were com-
plete response (CR) in 5/19, very good partial response (VGPR) in 4/19 and
partial response (PR) in 10/19. A total of 18 transplantation procedures were
performed, conditioned with melphalan 200 mg/m2 in 15 patients; the other 3
received 140 mg/m2 because of renal impairment (one patient) and poor toler-
ability to previous therapies (2 patients). Time to engraftment, infectious and
non-infectious complications were similar to those previously reported. No
deaths occurred during the procedure or immediately thereafter. Response
after transplantation was CR in 13/18 (strict in 11/13), VGPR in 2/18 and PR in
3/18. Transplant upgraded the response in 9 out of 18 patients (50%). Only
three patients required posttransplant consolidation and four received lenalido-
mide maintenance. After a median follow up of 28 months, a total of 11 patients
(61%) have experienced relapse after a median of 18 months from start of
treatment. Only 7 of them, (39%) have experienced clinical or paraprotein
relapse requiring second line therapy. Median progression free survival is 22
months. No second neoplasms have been detected so far
Summary and Conclusions: VRd induction followed by autologous transplan-
tation is a safe and effective therapy for newly diagnosed multiple myeloma.
Half of the patients upgraded their response after transplantation, making it an
essential part of therapy. Despite excellent responses achieved, relapse is still
the main cause of failure
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BONE MARROW PLASMA CELLS ASSESSMENT AFTER INDUCTION
THERAPY DOES NOT IMPACT ON PERIPHERAL BLOOD STEM CELLS
MOBILIZATION IN MULTIPLE MYELOMA PATIENTS IN THE NOVEL
AGENTS ERA
C. Nozzoli1,* E. Antonioli1, M. Staderini1, I. Donnini1, F. Bacchiarri1, S. Urbani1,
R. Saccardi1, S. Guidi1, A. Bosi1
1Hematology and stem cell transplant center, AOU CAREGGI, Florence, Italy
Background: Over the past 10 years, novel agents (NA), including immunomod-
ulatory drugs and proteasome inhibitors, have been increasingly incorporated
in front line multiple myeloma (MM) treatment. Induction with NA did not nega-
tively affected the efficacy of stem cell harvest in some studies. Few data are
available on the prognostic role of residual bone marrow plasma cells (BMPC)
assessment on peripheral blood stem cell harvest after induction therapy with
NA in MM patients undergoing autologous stem cell transplant (ASCT).
Aims: The aim of this retrospective single-center study was to determine the
impact of BMPC, quantified before peripheral blood stem cell (PBSC) mobi-
lization, on the efficacy of CD34+ cells collection and number of leukapheresis.
Methods: This retrospective study concerned 132 newly diagnosed MM
patients who underwent ASCT in the Hematology Unit in Florence from January
2006 to January 2015. Induction therapy included dexamethasone with thalido-
mide (TD) and/or bortezomib (VTD, VD). Patients who were refractory to induc-
tion therapy were excluded from the study. Bone marrow biopsy was performed
before PBSC mobilization and residual plasma cells were evaluated after
CD138, kappa and lambda immunostaining. All patients were mobilized with
cyclophosphamide (EDX) 3 or 4 gr/m2 followed by G-CSF 5-10 μg/kg daily sub-
cutaneously from day 2 until the end of the collection procedure. Leukapheresis
was scheduled to start on day 10 and be performed until at least 2.0×106 CD34+
cells/kg were collected. Patients who failed G-CSF mobilization received pler-
ixafor. CD34+ cells counts were assayed using a single platform method. Sta-
tistical analisys was made by Mann-Whiney test.
Results: Median age was 59 (range, 37-68), 48 patients (37%) were females;
81 patients (61%) received VTD as induction therapy (3-7 cycles) while 39 (30%)
received TD (3-8 cycles) and 12 (9%) received VD (4-6 cycles). After induction
therapy 18 (14%) patients obtained a complete response, 62 (47%) had a very
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good partial response, 49 (37%) a partial response, and 3 (2%) a minimal
response. BM biopsy was performed in all patients: in 67 (51%) the BMPC
were<5% of the total cellularity, whereas in 40 (30%) the BMPC were between
5% and 20% and in 25 (19%) the BMPC were over 20%. All patients proceeded
to chemo-mobilization: 16 (12%) with EDX 3 gr/m2 and 116 (88%) with EDX 4
gr/m2. No grade ≥3 toxicities were recorded. In 98 patients (74%), the mean
number of CD34+ cells collected was 12.2×106/kg (range 2.8-57.2x106/kg) within
1 leukapheresis; 23 (17%) patients needed a second procedure to collect a
mean CD34+ cells count of 7.3×106/kg (range, 2.0-16.2x106/kg), whereas 7
patients (5%) required 3 or 4 procedures and collected 4.4×106/kg (range, 2.3-
7.4x106/kg) (P=ns). A total of 4 (3%) patients, all females, aged 49-61 years
(median age 60 years), received plerixafor. In 2 patients, the mean number of
CD34+ cells was 5.8x106/kg collected in 1 day, in 2 other patients leukapheresis
was repeated 3 times to collect 6.9x106 cells/kg. The BMPC percentage was
not significantly correlated with the mean CD34+ cells counts or with the numbers
of leukapheresis. The CD34+ cells count was significantly higher in patients
younger than 55 (n=47; mean 12.7×106/kg, range 4.9-36.8) than in the older
patients (n=85; mean 9.6×106/kg, range 2.0-57.2) (P<0.001). Furthermore the
mean CD34+ cells count was significantly higher in patients treated with VTD
(n=81; mean 11.8×106/kg, range 2.7-57.2) vs those treated with TD (n=39; mean
8.2× 106/Kg, range 2.0-21.2).
Summary and Conclusions: The residual BMPC percentage did not adverse-
ly impact on CD34+ collection in our study. Younger age and VTD induction
were associated with higher CD34+ cells counts.
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CURRENT MANAGEMENT OF MULTIPLE MYELOMA TREATMENT IN
SPAIN: MEETINGS OF EXPERTS FROM 41 HOSPITALS
M.V. Mateos1,* J. de la Rubia2, J. Martínez3, J.A. Pérez Simón4, T. Garrido5
1H. Universitario Salamanca, Salamanca, 2H. Dr. Peset, Valencia, 3Hospital
12 de Octubre, Madrid, 4Hospital Virgen del Rocío, Sevilla, 5Amgen, S.A.,
Barcelona, Spain
Background: The outcome of patients with multiple myeloma (MM) has
improved significantly due to the introduction of autologous hematopoietic stem
cell transplant (ASCT) and, subsequently, with the introduction of new drugs.
However, the optimal sequence of treatments is unknown and, in Spain, there
are no national MM treatment guidelines. 
Aims: The purpose of the expert meetings was to obtain updated information
about the most commonly used treatment strategies in Spain outside clinical
trials.
Methods:A total of 5 expert meetings attended by 43 hematologists were held
in November-December 2014. The treatment algorithms published by Ludwig
et al. (The Oncologist 2014) were used as the basis for the discussions. Infor-
mation was obtained on the most commonly used treatments in 3 different sce-
narios: 1) front line in patients who are candidates for ASCT, 2) front line in
patients who are not eligible for ASCT, and 3) first relapse.
Results: Most patients are not candidates for ASCT (50-70%). The most fre-
quently used induction regimens before transplant (4-6 cycles) are triple therapies
(86%), bortezomib/thalidomide/dexamethasone (VTD) being the most common
(79%), followed by bortezomib/doxorubicin/dexamethasone (PAD) (36%), borte-
zomib/cyclophosphamide/dexamethasone (VCD)(32%), lenalidomide/borte-
zomib/dexamethasone (RVD)(14%), and cyclophosphamide/thalidomide/dex-
amethasone (CTD)(4%). When triple therapy cannot be used due to access
restrictions or patient characteristics, bortezomib/dexamethasone (VD) is gen-
erally administered. Most centers (53%) do not administer consolidation after
ASCT. If consolidation is administered, the regimen is usually the same as in
induction. Maintenance treatment after transplant is used only in selected cases
and centers and usually consists of lenalidomide for 2 years (47%)(exceptionally
until progression), thalidomide for 1 year (26%) or bortezomib (21%). In non-
transplant candidates, the front-line regimen most commonly administered is
(VMP)(97%). Maintenance is not usually administered. After the first relapse, a
second transplant is considered if the remission lasted ≥18 months and if patients
have good performance status. Retreatment with the same initial regimen (20-
60% cases) is reserved for patients with a treatment-free interval >12-18 months
or in whom the progression-free survival is greater than the median for the reg-
imen. Otherwise, physicians prioritize inclusion in clinical trials or treatments with
authorized drugs with a different mechanism of action, such as lenalidomide and
dexamethasone (50-60%). If no new drugs are used in induction (8%), borte-
zomib-based regimens are usually administered (77%).
Summary and Conclusions: Although there is considerable inter-center and
inter-region variability in the treatment of MM in Spain, partly explained by dif-
ferent patient characteristics or restrictions on access to some drugs, pre-ASCT
induction and front line treatments without ASCT are quite consistent. Following
the first relapse, treatment is more variable and individualized. 
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OUTCOME IMPROVEMENT IN IGD MULTIPLE MYELOMA WITH AGGRES-
SIVE CLINICAL FEATURES: IMPACT OF NOVEL DRUGS
L. Torti1,* S. Pulini1, A.M. Morelli1, F. Bacci2, P. Di Bartolomeo1
1Department of Hematology, Transfusion Medicine and Biotechnology, Clinical
Hematology, “Spirito Santo” Civic Hospital, Pescara, 2Department of Hematol-
ogy and Oncological Sciences, Section of Hematopathology, S. Orsola-Malpighi
Hospital, University of Bologna, Bologna, Italy
Background: IgD Multiple Myeloma (MM) is one of the rarest type of MM, rep-
resenting almost 2% of all myeloma cases. It has been reported a poorer out-
come of this variant when compared with other subtypes, with an aggressive
course, high incidence of bone complications, extramedullary disease and
resistance to chemotherapy. These data come from small retrospective studies
mainly before the introduction of bortezomib and immunomodulatory drugs. 
Aims: We describe aggressive and unusual clinical course of IgD MM, with a
good outcome after hematopoietic-stem-cell transplantation (HSCT) and “nov-
el-agent” therapy.
Methods: We present four female patients with aggressive IgD MM diagnosed
in our Department; they received chemotherapy with novel agents alone or fol-
lowed by autologous hematopoietic stem cell transplantation (HSCT).
Results: Mean age was 56 yrs. All patients had multiple bone lesions, two of
them a serum creatinine >2 mg/dl and hypercalcemia; two patients showed
extramedullary involvement and multiple lymphadenopathy, two of them
showed chromosomal abnormalities. Bone-marrow biopsy revealed more than
40% clonal plasma cells. Three women showed LDH superior to normal values.
Three young patients underwent autologous HSCT upon conditioning
chemotherapy with melphalan 200 mg/m2: in two cases it was preceded by
bortezomib-thalidomide based induction therapy; the third patient received VAD
induction and she was treated with bortezomib for recurrent disease. The fourth
older patient receveid melphalan, bortezomib and steroids based regimens. A
relapse was observed in this patient with progressive paraplegia; MRI revaled
an extramedullary tumour of 68x 57 mm extended from D5 to D7, with need of
irradiation plan-treatment. Chemotherapy consisted of Lenalidomide and Dex-
amethasone. All these four patients presented an atypical clinical onset, but
they all obtained a CR after treatment, which is still present after various months
(median overall survival 55 months). Despite heterogeneity of the population
studied, use of the novel drugs both in first line therapy and relapsing disease
has been shown to achieve an improvement in overall survival.
Figure 1.
Summary and Conclusions: The IgD MM is really different from IgG and IgA
MM; it could be interesting to discover if the clinical picture and the course of
illness could be somehow related to the class of M-component. IgD MM could
be considered a different kind of neoplasia, with high kinetic proliferation rate
and peculiar biologic aspects. Probably new cytogenetic aberrations, as pre-
sented in our population (trysomy of chromosome 5 and 9 in two patients)
could explain this different biology and behavior. Nowadays IgD myeloma is
still a challenging matter. Half of our patients with IgD MM presented
extramedullary plasmacytoma, a rare and poorly understood entity. It is not
known which mechanisms are involved in the hematogenous myeloma spread
and how can myeloma cells growth and survival at extramedullary sites. There-
fore in a patient with fever, lymphoadenopaties and high LDH levels we should
consider this kind of aggressive myeloma as differential diagnosis with lym-
phoproliferative disorders. Nevertheless, after the introduction of different novel
agents the clinical course and prognosis of IgD MM seems to have improved
in particular with novel drugs in combination with autologous HSCT. All our
patients are in CR after treatment and are currently being monitored at our
centre. Our results were obtained in a few patients and an international collab-
orative trial is needed to confirm these findings.
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USE OF FLC AND HLC RATIOS FOR DIAGNOSIS AND MONITORING OF
MONOCLONAL GAMMOPATHIES
A. Gagliardi1,* C. Carbone2, A. Russo2, R. Cuccurullo1, A. Lucania1,
P. Della Cioppa1, L. Mastrullo1, C. Tommasino2
1ASL NA1 -Centro U.O.C. Ematologia Ospedale San Gennaro-NAPOLI, 2ASL NA1
-Centro U.O.C. Patologia Clinica Ospedale San Gennaro-NAPOLI, Napoli, Italy
Background: Monoclonal Gammopathies are characterized by the presence
of a serum monoclonal component (MC), either an intact immunoglobulin, a
free light chain, or a combination of both. Measurement of FLC with Freelite®
is standard practice and it is recommended by IMWG guidelines. Recently,
Hevylite™ heavy light chains (HLC) assays were introduced to specifically tar-
get junctional epitopes between the heavy and light chains of intact
immunoglobulins, allowing the independent quantification of the involved Mon-
oclonal Component and uninvolved, polyclonal background.
Aims: In our Department we have used FLC and HLC for diagnosis and mon-
itoring of Monoclonal Gammopathies, particularly in Multiple Myeloma patients
this method is useful for monitoring of disease.
Methods: from January 2012 to March 2014 we collected 300 samples from
90 patients and assessed the diagnostic and monitoring performance of
Hevylite® A and G assays in 7 transplanted patients, 17 non eligible patients
and 18 relapsing patients, receiving a combination therapy with VTD; PAD;
MPV or Len/Dexa. We selected 3 emblematic case studies
Results: Hevylite® absolute values and ratio demonstrated high sensitivity and
specificity with respect to Freelite and serum protein electrophoresis, serum
immunofixation. The combined use of Hevylite® A and G with Freelite® was partic-
ularly useful in dubious cases with more than one MC or with co-migrating compo-
nents, and in the course of monitoring to assess the independent change of FLC
and HLC, possibly reflecting the presence of clonal heterogeneity in our cohort. 
Summary and Conclusions: Freelite and Hevylite are independent, useful
markers to monitor the MC and to assess with greater specificity and sensibility
the effect of therapy, thereby providing clinical support. More studies are needed
to assess the prognostic potential of Hevylite in SMM and MGUS patients.
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IMPACT OF PG-SGA SCORE ON SURVIVAL IN PATIENTS WITH MULTIPLE
MYELOMA
H.S. Kim1,* M.Y. Lee1, J.Y. Lee1, S.H. Lim1, K. Kim1, S. Kim1
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of
Background: Disease-related weight loss is relatively common in patients with
newly diagnosed multiple myeloma, but there are limited data on the impact of
nutritional status on survival. 
Aims: Using the Patient-Generated Subjective Global Assessment (PG-SGA)
score, we retrospectively explored the effect of malnutrition on the survival of
multiple myeloma patients. We also investigated the relationship between PG-
SGA score prior to chemotherapy and clinical manifestation, in patients with
multiple myeloma.
Methods: Analysis was performed on a retrospectively assembled cohort of
216 multiple myeloma patients diagnosed between October 1, 2002, and Octo-
ber 31, 2013. A total of 216 myeloma patients were subdivided into three groups
based on PG-SGA scores.
Results: Twenty-three percent (50/216) patients had a PG-SGA score 9 or
over, indicating severe malnutrition requiring specialist nutrition intervention.
BMI and serum LDH were independently associated with PG-SGA scores
(P<0.05). The median survival times were not reached in nourished patients
with PG-SGA score 0-3, 58.7 months in moderately malnourished patients with
PG-SGA score 4-8 and 35.0 months in severely malnourished patients with
PG-SGA score ≥9 (P=0.001). Multivariate analysis showed that PG-SGA score
≥9 patients compared with PG-SGA score 0-3 patients (HR 2.347, 95% confi-
dence interval [CI] 1.271-4.334; P=0.006), International Staging System (ISS)
stage III compared with ISS stage I (HR 2.360, 95% CI 1.271-4.379, P=0.007)
and autologous stem cell transplantation (HR 0.388, 95% CI 0.248-0.606,
P<0.001) were associated with overall survival.
Summary and Conclusions: In conclusion, higher PG-SGA score prior to
chemotherapy was associated with reduced survival among patients with mul-
tiple myeloma. Nutritional evaluation should be integral part of the clinical
assessment of MM patients and PG-SGA score would be an appropriate tool
to evaluate nutritional status.
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BING NEEL SYNDROME, ABOUT A CASE REPORT AND REVIEW OF
LITTÉRATURE
S. Bougherira1,*
1Hematology, faculty of medecine, university hospital of Annaba, Annaba, Algeria
Background: Waldenstrom’s Macroglobulinaemia (WM) is is defined by the
World Health Organization as an IgM secreting “lymphoplasmacytic lymphoma,
characterized by BM infiltration, and occasionally lymph nodes and spleen.
The most frequent neurological complication of Waldenström’s macroglobu-
linemia is IgM-mediated polyneuropathy. Direct tumor cell infiltration of the nerv-
ous system is extremely rare and better known as the “Bing and Neel Syn-
drome” (BNS), that was first described in 1936.
Aims: We describe a patient with a long history of WM presenting Bing and
Neel syndrome revealed by convulsion.
Methods: 68-year-old man was followed up in our department since September
2002 for a typical WM. A first complete remission was obtained with CHOP. In
March 2007, he relapsed, and a second complete remission was obtained with
chlorambucil. FCR therapy regimen (fludarabine, cyclophosphamide and ritux-
imab) was used on July 2011. In March 2014, the patient presented with per-
sistant headaches, episods of convulsion, blurry vision and disorders of mem-
ory. Computerized tomography of the brain showed a tumor mass multifocal
supratentorial with edema. Brain magnetic resonance imaging displayed pachy-
meningeal regions of enhancement with associated FLAIR hypertensity on T2-
weighted sequences. Examination of the cerebrospinal fluid (CSF) showed a
lymphocytic meningitis with an increase of the CSF protein, and a normal CSF
glucose. The patient did not undergo biopsy. The staging including full body
scan, bone marrow aspiration, and bone marrow biopsy was normal, no
organomegaly, meaning stable WM. Our patient underwent successful treat-
ment with MPV-A regimen chemotherapy of Methotrexate 3,5 g/m² D1/ Vin-
cristine 1,4 mg/m² max 2,8 D1/Procarbazine 100 mg/m² D1to D7(cycles 1, 3,
& 5)-5 cycles repeated every 15 days, at final a closing course with AraC 3g/m²
D1 and D2 without radiation therapy.
Results: The evolution was characterized by disparition of clinical symptoms,
a marked regression of lesions on MRI and normalization of CSF analysis. The
patient is still alive with free-symptoms in December 2014, last scheduled visit.
Summary and Conclusions: BN syndrome is a very rare complication of WM
that should be considered in patients with neurologic symptoms and a history
of WM. A brain MRI and histologic analysis may be a good supportive tool to
diagnose Bing-Neel syndrome.There is still no consensus on the treat-
mentstrategies to use in BNS.
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DAY-100 BONE MARROW TREPHINE FOLLOWING AUTOLOGOUS STEM
CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: HOW USEFUL
ARE THE RESULTS? 
B. Catherine1, R. Byers2, E. Rothwell1, M. Saif1, F. Dignan1, J. Thachil1,*
B. John1, T. Eleni1, R. Krishna1
1Haematology, 2Histopathology, Manchester Royal Infirmary, Manchester, Unit-
ed Kingdom
Background: Bone marrow trephine samples are routinely assessed from
patients following autologous stem cell transplantation (SCT) for Multiple Myelo-
ma (MM) 100 days after the procedure
Aims: The aim of this study is to assess the clinical value of the day 100
trephine biopsy and to see if it offers additional information when compared to
serological markers.
Methods: We analysed the pre-transplant and day 100 (d100) post-transplant
bone marrow trephines for a series of consecutive patients (n=64) who under-
went autologous stem cell transplant between June 2013 to August 2014. Only
patients who had adequate pre- and post-transplant trephine biopsies taken
were included in the study (n=46). Pre-transplant state was categorised as
either complete response (CR) or as partial response (VGPR/PR groups) as
defined by the International Myeloma Working Group (Uniform Response Cri-
teria for MM). At d100 the bone marrow trephine results and corresponding
serum paraprotein and light chain values were analysed. The concordance
between these sets of results was determined
Results: Prior to transplant, 34 patients were in VGPR/PR and 12 in CR. Over-
all, the bone marrow trephines showed no change in 34/46 patients. There was
an improvement in 11/46, while poor regeneration was noted in 1/46. In all
patients with CR (n=12), there was no change in the d100 trephine results.
However, paraprotein became detectable in 7/12. 5/12 remained in CR. In the
VGPR/PR patients (n=34), d100 trephine showed no change in 22/34, 11/34
showed an improvement, 1/34 showed poor regeneration. Out of the 11 that
showed improvement, 4/11 showed concordant improvement in the serum
markers (paraprotein and/or light chain levels), 1/11 showed worsening of serum
markers, 5/11 showed no change and 1/11 had no d100 serum markers avail-
able. In the VGPR/PR group, 2/34 had progressive disease according to serum
markers; of these, one had no change in the trephine while the other showed
improvement. 10/34 showed improvement in the serum markers; of these, 4/10
showed concordant improvement in the trephine samples. 21/34 showed no
change in serum markers, of which 15/21 showed no change in the trephine,
5/21 showed improvement, 1/21 had poor regeneration. There were no d100
serum markers available for one patient. Overall, no progression was seen in
all d100 trephines compared to pre-transplant sample, while progression was
seen in 9/46 serum markers at d100 compared to the pre-transplant levels
Summary and Conclusions: Data from this study demonstrates that based
on the bone marrow trephine results in isolation, patients who had received
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SCT for MM did not require a change to clinical management. There was no
progression noted in any d100 trephine biopsy sample, although 9/46 patients
showed progression in serum markers. Although this study is too early to
assess any longer-term predicative value of d100 marrow assessment, we
would propose routine day 100 bone marrow trephine biopsies for MM patient’s
post autologous SCT contributes little additional clinical value and could be
omitted with little risk to the patient. It may be more appropriate to follow up
such patients using serum paraprotein and/or light chain levels alone.
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OUTCOME OF POMALIDOMIDE THERAPY IN RELAPSED / REFRACTORY
MYELOMA: A UK MULTI-CENTRE EXPERIENCE
N. Maciocia1,* F. Sharpley2, E. Belsham3, H. Renshaw4, S. Schey4,
S. Cheesman1, A. Cerner1, A. Rismani1, S. D’sa1, M. Streetly5, B. Reuben4,
M. Jenner3, K. Ramasamy2, K. Yong1, N. Rabin1
1Haematology, University College London Hospitals NHS Foundation Trust,
London, 2Haematology, Oxford University Hospitals NHS Trust, Oxford,
3Haematology, University Hospital Southampton NHS Foundation Trust,
Southampton, 4Haematology, King’s College Hospital NHS Foundation Trust,
5Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, United
Kingdom
Background: Pomalidomide is licensed in Europe for patients with relapsed /
refractory myeloma, who have received at least two prior therapies including
lenalidomide and bortezomib and who have progressed on their last therapy. In
the phase 3 NIMBUS study, pomalidomide and dexamethasone was associated
with longer progression free (PFS, 4.0 vs 1.9 months) and overall survival (OS,
12.7 vs 8.1 months) compared to dexamethasone alone (San Miguel et al 2013). 
Aims: To assess the clinical efficacy of pomalidomide in a real-world setting in
several large treatment centres in the UK.
Methods: Patients had measurable disease (IMWG criteria) and received at
least 1 cycle of pomalidomide with dexamethasone. Disease response was
assessed as per IMWG and high risk disease defined as ISS II/III plus t(4;14)
+/- del(17p) (IMWG criteria). PFS and OS were measured from start of poma-
lidomide therapy and estimated using Kaplan-Meier method.
Figure 1. A) Progression-free survival and B) overall survival of all patients.
Results: Seventy-nine patients were identified, of whom 62 (78.5%) were suit-
able for inclusion in response analyses. All patients received pomalidomide (2-
4mg days 1-21) with weekly dexamethasone, 30/79 (38%) received another
agent(s) [clarithromycin (23), cyclophosphamide (9), carfilzomib (1), bortezomib
(1)]. Patient characteristics were as follows: median age 67 years (range 40-
89); isotypes were: 43 (55%) IgG, 19 (24%) IgA, 15 (19%) LC only. Median time
from diagnosis was 4.9 years (range 0.5 to 18); median prior lines of therapy
was 4 (range 1 to 8). Prior therapies included lenalidomide (100%), bortezomib
(98%), thalidomide (84%), and autologous stem cell transplantation (61%). Sev-
enty-three patients (92%) were refractory to their last therapy, and 58 (73%)
were refractory to both bortezomib and lenalidomide. Median follow up was 6.4
months (0.92-34.5). Median number of cycles was 4 (range 1-32), and median
daily dose was 4 mg. Fifteen patients (19%) had dose reductions. In those with
a GFR<45ml/min at baseline, 50% (7/14) started at a dose<4mg. Overall
response (≥ PR) was 53%, VGPR 5%, and at least stable disease was achieved
in 58/62 (94%). PFS was 4.3 months (Figure 1A), and OS was 13.7 months
(Figure 1B). Impaired renal function (GFR<45ml/min, 14 patients) did not appear
to influence PFS (4.0 months vs 4.5 months, P=0.44), or OS (10.8 vs 13.7
months, P=0.80). High risk FISH was present in 11/40 (28%) patients, who had
comparable outcomes to standard risk patients: PFS 3.6 months vs 4.5 months,
(P=0.70) and OS 11.3 vs not reached (P=0.19). Inclusion of a third agent at
start of therapy (14 patients) did not appear to confer benefit (PFS 4.3 vs 4.0
months, P=0.40, OS 7.8 vs 13.7 months P=0.37). In eight patients with bio-
chemical or clinical progression on pomalidomide/dexamethasone, a third agent
was added, and 7 achieved SD/PR. Grade 3/4 non-haematological toxicities
occurred in 27/79 (34%) patients: pneumonia, 15 patients (19%) and neutropenic
sepsis, 9 patients (11.4%) being the most common. Grade 3/4 neutropenia
occurred in 28 patients (35%) and thrombocytopenia in 17 patients (22%).
Summary and Conclusions: Pomalidomide is an effective treatment in
relapsed / refractory myeloma, with survival outcomes comparable to reported
results from the phase 3 NIMBUS study. Impaired renal function and adverse
genetics do not appear to influence outcomes. The addition of a third agent
should be explored prospectively.
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THE IMMUNOPHENOTYPIC CHARACTERISTICS OF CD19 POSITIVE
MYELOMA AND ITS PROGNOSTIC IMPACT
H.T. Mya1,* N. Puig1, M.B. Vidriales1, M. Díez-Campelo1, J.J. Pérez Morán1,
J. Flores-Montero2, A.M. Garcia-Sancho1, N.C. Gutiérrez1, M.V. Mateos1,
E. Ocio1, M. Cañizo1, A. Orfao2, R. García Sanz1
1Haematology, Hospital Universitario de Salamanca, 2Flow cytometry, Univer-
sidad de Salamanca, Salamanca, Spain
Background: Clonal plasma cells (CPCs) in multiple myeloma were usually
characterized by negative CD19 expression by multiparametric flow cytometry
(MFC). However, positive CD19 expression in CPCs was noted in some cases
with the reported incidence ranging from 0 to 8%. Positive CD19 expression in
CPCs could complicate the minimal residual disease (MRD) assessment by
high sensitivity MFC as the majority of polyclonal plasma cells (PPCs) retained
CD19 expression. In addition, CD19 positive myeloma patients were reported
to have a poorer clinical outcome in the group of patients treated with induction
chemotherapy followed by autologous stem cell transplantation.
Aims: We aimed to review the immunophenotypic features of CD19 positive
myeloma patients in comparison with that of CD19 negative cases to determine
specific immunophenotypes which could be useful for MRD assessment. The
prognostic impact of positive CD19 expression on clinical outcome in patients
treated with the regimens including novel therapies was also evaluated.
Table 1.
738 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
Methods: A retrospective review of newly diagnosed myeloma patients in a
single centre was performed for the period of Jan 2006 to Jan 2015. The clinical
data was retrieved from the patient information system of the institution as well
as by reviewing the clinical records. Multiparametric flow cytometry analysis
was performed by BD FACSCalibur™ for four colour analysis and BD FAC-
SCanto™ flow cytometer for eight colour analysis. CD19, CD45, CD38, CD138
and CD56 expression was determined for all patients and for those cases where
eight colour analysis was applied, CD27, CD28, CD117 and CD81 expression
was studied. All the FCS data was analysed using infinicyt software. Plasma
cells were identified by primarily gating on CD38 and CD138 positive cells.
Mean fluorescent intensity of CD19 expression on plasma cells was compared
with that of B-lymphocytes to determine positive or negative expression. It was
considered a positive expression if 20% of the CPCs were positive.
Results: A total of 157 newly diagnosed multiple myeloma patients were
reviewed. The incidence of CD19 positive myeloma cases was 4.46%. Out of
7 patients who were CD19 positive, four patients had homogeneous strong
positive expression while the remainder had heterogeneous dim positive
expression. Baseline demographics of the patients, ISS, immunoglobulin sub-
types and clinical parameters at presentation i.e. related organ and tissue
impairment, LDH, albumin,beta2 microglobulin levels and cytogenetic risks
were similar in both CD19 positive and CD19 negative myeloma patients (Table
1). CD56 expression was 100% and 74% positive in CD19 positive and negative
myeloma patients respectively (P 0.12). There was a higher percentage of pos-
itive CD81 expression (80% vs. 37.3%, P 0.056) and higher percentage of neg-
ative CD27 expression (60% vs. 35.9%, P 0.276) in CD19 positive cases though
it did not reach statistical significance. No statistically significant difference in
overall survival was found with a median OS of 56 and 75 months for CD19
positive and negative cases respectively (P 0.847).
Summary and Conclusions: In our study, CD19 expression was associated
with a 100% positive CD56 expression, a higher positive CD81 expression and
a higher negative CD27 expression rate even though statistical significance
was not reached due to few numbers of patients in the cohort. This could be a
useful finding for MRD assessment of the patients as well as to differentiate
CPCs from PPCs in MGUS or smoldering myeloma by MFC. In the current
cohort, we did not demonstrate a poorer prognostic impact of CD19 positive
expression. This could be explained by the difference in the treatment era of
the study patients where almost all the patients eligible for treatment received
one or more novel therapeutic agents, compared to previous cohorts. Prospec-
tive studies with larger cohorts may further elucidate the significance of CD19
positive myeloma.
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BURDEN OF MULTIPLE MYELOMA IN THE UNITED KINGDOM
M. Raluy-Callado1,* D. Lambrelli1, E. Merinopoulou1, S. Panjabi2
1Evidera, London, United Kingdom, 2Onyx Pharmaceuticals Inc., an Amgen
subsidiary, San Francisco, United States
Background: The introduction of novel agents for the treatment of multiple
myeloma (MM) in recent years has been shown to lead in improvements in
response and overall survival. However, real world evidence studies on the
burden of disease are limited and outdated.
Aims: To describe patient characteristics of newly diagnosed MM patients in
the United Kingdom (UK) and to assess disease burden in terms of healthcare
resource use.
Methods: Retrospective primary care data from the Clinical Practice Research
Datalink (CPRD) linked to the Hospital Episode Statistics (HES) was used.
Adult patients with a first diagnosis of MM between Jan 2008-Dec 2012 were
identified. Patient characteristics including comorbidities were described at date
of diagnosis (index date). Disease-related symptoms, complications and
adverse events were described during follow up, as well as primary and sec-
ondary care resources, including GP visits and hospitalisations.
Results: In the CPRD cohort, 1,457 newly diagnosed MM patients were iden-
tified and followed up on average for 2.1 years. Of those, 910 (62.5%) were
linked to HES (CPRD-HES cohort). Mean age in the CPRD cohort was 71
years (SD: 11.6) and 54.8% were male. Body mass index (BMI) recorded in
the 12 months prior diagnosis for 48.5% of the patients was on average 27,
classifying them as obese or overweight. The most common comorbidities iden-
tified in whole medical history prior diagnosis were renal disease (25.5%),
chronic pulmonary disease (19.6%), other malignancies excluding MM (17%)
and diabetes without complications (13.1%). During the follow–up period, renal
insufficiency was the most common disease symptom (annual incidence: 176.5
per 1,000 patients). Side effects including constipation, vomiting, diarrhoea,
syncope, skin rash, and venous thromboembolism were observed at a rate
greater than 10 per 100 patients in the first year after diagnosis. GP visits
around diagnosis increased from a rate of 4.5 visits/patient (95% Poisson Con-
fidence Intervals [CI]: 4.4-4.6) in 12 to 6 months prior to 8.4 (CI: 8.2-8.5) in the
6 months post diagnosis, and remained high for the entire follow up period
(rate: 6.4; CI: 6.4-6.5). Demographic and clinical characteristics of the CPRD-
HES cohort were comparable to the overall CPRD cohort; mean age at diag-
nosis was 71 years (SD: 11.7). A majority (86.6%) of patients in the CPRD-
HES cohort incurred at least one hospitalisation post diagnosis (Figure 1). Most
hospitalizations were day case admissions (85.6%), with inpatient admissions
(14.4%) accounting for the remainder. On average, 4.4 day case admissions
per patient per year (SD: 8.8) were encountered in the post-diagnosis period,
while the average length of stay for inpatient admissions was 9.8 days
(SD=11.85).
Figure 1. Average number of hospital admissions (inpatient and day cas-
es) per patient during 6-month periods prior and post index date (Poisson
CI)
Summary and Conclusions: Renal disease and respiratory conditions are
common presenting comorbidities among MM patients. The management of
disease symptoms, complications and adverse events as well as severe comor-
bidities leads to increased resource use in both primary and secondary care
settings.
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TIME TO ONSET AND DURATION OF INDUCTION THERAPY AND ASSO-
CIATED FACTORS AMONG NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS
A. Yusuf1,2,* T. Bovitz1, T. Matlon1, W. Werther3, D. Felici3, M. Mahue3,
K. Bridges3, Y. Peng1
1Chronic Disease Research Group, 2University of Minnesota, Minneapolis,
3Onyx Pharmaceuticals Inc., an Amgen Subsidiary, South San Francisco, Unit-
ed States
Background: While early start of induction chemotherapy may improve treat-
ment outcomes for patients with cancer, little is known about time to treatment
onset and duration of induction therapy in newly diagnosed multiple myeloma
(NDMM) patients.
Aims: We examined onset and duration of induction therapy and associated
factors including age, gender, race, index year, stem cell therapy, and drug reg-
imen in NDMM patients in the United States. 
Methods: Using Medicare 20% data, we created a cohort of adult (≥18 years)
NDMM patients (2008-2010) who initiated therapy with defined medications
within 1 year of cancer diagnosis. Induction therapy regimens were categorized
as bortezomib-based, immunomodulator (IMiD)-based, bortezomib-IMiD-based,
or corticosteroid-based. Median number of days from diagnosis to therapy
onset and of therapy duration were examined overall and for associated factors
in a univariate approach using the Kruskal-Wallis test.
Table 1.
Results: We identified 1455 NDMM patients. Overall, median (IQR) number of
days to therapy onset from diagnosis and of therapy duration were 26 (12-64)
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and 195 (113-349), respectively. Neither days to onset nor duration varied sig-
nificantly by age, sex, or race. Days to onset decreased from 29 to 21 days
from 2008 to 2010, respectively (P<0.0001), but therapy duration was similar
across years ranging from 188 to 214 days (P=0.06). Although days to onset
were similar for patients who did (25 days) and did not (26 days) receive stem
cell therapy (SCT; P=0.52), median therapy duration was 25% longer at 202
days for those who did not (P<0.0001). Onset was more rapid (21, 24, and 20
vs. 31 days) and duration longer (203, 257, and 258 vs. 129 days) for patients
treated with bortezomib-, IMiD-, and bortezomib-IMiD-based regimens com-
pared to those treated with corticosteroid-based regimens, respectively. Duration
of therapy was longer for patients who did not receive SCT compared to those
who did for bortezomib-based (209 vs. 156 days), IMiD-based (284 vs. 124
days), and bortezomib-IMiD-based (291 vs. 142 days) regimens, respectively.
Summary and Conclusions: We observed differences in time to onset and
duration of induction therapy by index year, SCT status, and choice of regimen,
and found no racial or sex differences. The clinical implications of these findings
are unknown. Further studies are warranted to better understand the observed
differences. 
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SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN
VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE
MYELOMA
R. Castelli1,* G. Pantaleo2, P. Gallipoli3, P. Gallipoli3, M. Arquati4, M.A. Wu4,
G. Lambertenghi Deliliers5, M. Cicardi4
1Hematology, 1 Department of Pathophysiology and Transplantation University
of Milan, and Department of Haematology IRCCS Ca’ Granda Policlinico, Milan,
Italy, 22 UniSR-Social.Lab, Faculty of Psychology, Vita-Salute San Raffaele
University of Milan, Italy, Milan, Italy, 3Department of Haematology, Adden-
brooke’s Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK,
Cambridge, United Kingdom, 44Department of Biomedical and Clinical Sci-
ences Luigi Sacco, University of Milan, Luigi Sacco Hospital Milan, Milan, Italy,
University of Milan, 5Fondazione Matarelli Milan, Fondazione Matarelli, Milan,
Italy
Background: Despite recent advances in therapy, multiple myeloma (MM)
patients eventually relapse and become refractory to treatment with a median
survival ranging from 6 to 9 months. Over the last decade, the introduction of
new front-line agents, such as the immunomodulatory drugs (IMIDs) thalido-
mide and lenalidomide and the proteasome inhibitor, have led to an increase
in survival in MM by achieving deeper levels of responses and prolonging the
duration of remission. Bortezomib (bort)–dexamethasone (dex) is an effective
therapy for relapsed/refractory (R/R) MM, but few data are available for elderly
patients. Although MM affects people of all ages, more than 60% of MM patients
are older than 70 years of age (median age at diagnosis 70 years), and the
number of new patients is expected to double worldwide by 2030
Aims: To evaluate efficacy and toxicity of bort-dex treatment in elderly R/R
MM patients.
Methods: From 2006 to 2015 we performed a retrospective, observational
study to detect the efficacy and tolerability of bort-dex in a cohort of 81 elderly
patients with R/R MM. Patients were treated with bortezomib at the dose of
1.3 mg⁄m2 on days 1, 4, 8, 11 every 3 weeks up to 6–8 cycles alone or in asso-
ciation with dexamethasone at the dose of 20 mg on the day of bortezomib
administration and on the subsequent day. Responses were assessed accord-
ing to the International Myeloma Working Group (IMWG) criteria
Results: Median age of study population was 73 years (range 65-89 years).
Fifty-three (65. 4%) of patients achieved at least a partial response, including
8 patients (11%) with Complete Response (CR) and 9 patients (12.5%) with
very good partial response (VGPR). The median number of prior lines of ther-
apy was 2. The median number of cycles of bort-dex was 6 (range 1-11). Thir-
ty-nine patients (48%) received bortezomib intravenously, 42 (52%) received
bortezomib subcutaneously. Fifty patients (61.7%) had received immunomod-
ulatory drugs. The median duration of response, time to next therapy and
treatment free intervals were 8, 11 and 5 months. The duration of response
was significantly longer for patients achieving CR⁄VGPR than for those achiev-
ing PR (7.3 vs. 3.8 months, P=0.03). After a median follow up of 24 months,
78 patients showed disease progression and 70 patients died. Median Time
to progression (TTP), progression free survival (PFS) and overall survival
(OS) of the whole population were 8.9, 8.7 and 22 months respectively. The
most relevant side effect was peripheral neuropathy (PN), occurring in 38
patients.
Summary and Conclusions: The depth of response to bortezomib and clinical
benefit are known to be strictly related in younger MM R/R patients. Our data
highlight that bort-dex is highly effective and tolerable in fit elderly patients,
thus justifying the efforts to obtain deeper responses to therapy also in this
subset of patients. However, awareness of the risk of short living haematolog-
ical responses to bort-dex salvage therapy (both in young and in old patients)
should lead to thorough evaluation about the need of a maintenance therapy
with other agents such as lenalidomide or pomalidomide in order to achieve
sustained responses.
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LEVELS OF UNINVOLVED IMMUNOGLOBULIN PREDICT CLINICAL
STATUS AND PROGRESSION FREE SURVIVAL FOR MULTIPLE
MYELOMA PATIENTS
J. Berenson1,* N. Harutyunyan1, S. Vardanyan1, M. Ghermezi1, J. Gottlieb1,
A. Berenson1, C. Andreu-Vieyra2, M. Li1, C. Wang1, G. Tang1, E. Sanchez1,
J. Ben-Zvi1, G. Garzio1, H. Chen1
1Institute for Myeloma & Bone Cancer Research, 2Oncotherapeutics, West
Hollywood, United States
Background: The levels of monoclonal immunoglobulins (M-Igs) are used to
monitor multiple myeloma (MM). HevyLite® +(HLC) assays are able to discrim-
inate between uninvolved and M-Ig levels.
Aims: We evaluated the levels of involved and uninvolved HLC, their ratios
and differences and their relationship to outcomes among 189 MM patients.
Methods: Serum samples were analyzed using the HLC assays, and results
were correlated with clinical status (complete response (CR), ≥ partial response
(PR),<partial response, and progressive disease (PD)). Comparisons were made
using student’s t, Mann-Whitney, and Fisher’s tests. PFS was calculated using
Kaplan-Meier analysis. All tests were double-tailed and P-values determined.
Results: The patients were 62% IgG and 38% IgA with a median age of 66
years, b2 microglobulin 3.27 mg/L, albumin 3.8 g/dl, and median follow up of
72.5 months. Patients with PD had higher involved HLC levels, lower unin-
volved HLC levels, higher ratios of involved/uninvolved HLCs and greater dif-
ferences between them compared with patients with ≥ PR (all with P<0.0001).
A higher proportion of patients in ≥ PR had normal uninvolved HLC levels than
patients with<PR (P<0.0001). Additionally, patients in CR were more likely to
have normal uninvolved HLC than those with below normal levels (P<0.0001).
Similarly, patients in CR were more likely to have normal HLCs than in PR
(P=0.0040). Patients with normal uninvolved HLCs showed a longer PFS (45
months) than those with less than normal levels (11 months; P=0.0019).
Patients with normal involved HLC levels had longer PFS (33 months) than
patients with involved HLC above the normal range (11 months; P=0.0405).
Summary and Conclusions: We show that involved/uninvolved HLC ratios,
differences between them, involved and uninvolved HLC levels correlate with
clinical status for MM patients. Patients with normal uninvolved levels or normal
involved HLC levels have a longer PFS.
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SUBCUTANEOUS BORTEZOMIB IS AS EFFECTIVE AND LESS NEURO-
TOXIC THAN INTRAVENOUS BORTEZOMIB: ANKARA University EXPE-
RIENCE
B. Ateşağağlu1,* P. Topçuoğlu1, M. Merter1, M. Sungurlu1, Ö. Şener2,
M. Beksaç1
1Department Of Hematology, 2Department Of Neurology, Ankara University,
Ankara, Turkey
Background: Bortezomib is a proteasome inhibitor which has proven potent
activity against malignant plasma cells.Peripheral polyneuropathy (PNP)is one
of the most frequent, non-hematologic adverse effects (AE) of Bortezomib often
requiring dose modification or discontinuation.
Aims: Although the initial report by Moreau et al demonstrating the advantages
and safety of subcutaneous use which led to the approval,this route of appli-
cation is not being widely used in Turkey.Here we aimed to present our expe-
rience on the incidence of Bortezomib induced neuropathy (BiN)comparing
two approved routes of administration.
Methods: After 2012 s.c.administration has become an accepted approach in
our clinic for patients presenting with BiNin addition to dose reduction as rec-
ommended in the package.Weekly administration is the second step that fol-
lows if PNP does not improve.After 2013 s.c.has become the preferred
approach for NDMM too.We retrospectively analyzed 129 consecutive patients
diagnosed with Multiple Myeloma at Ankara University School of Medicine
Department of Hematology between 2008-2013 and had completed at least
three cycles of a Bortezomib containing protocol either at diagnosis or at
relapse. Hospital records were screened to evaluate the incidence ofBiN, dose
adjustments arising from AEs of Bortezomib and outcome measures.We com-
pared the frequencies of AEs and treatment outcomes between patients who
started treatment with s.c.versus i.v.administration of Bortezomib.We also ana-
lyzed outcomes following conversion from iv to sc too.Statistical analysis were
performed using the SPSS for Windows,Version 16.0
Results: Baseline demographics,disease characteristics or number of previous
lines of therapy were similar between patients receiving s.c.or i.v. treatment
(Table-1). De novo subcutaneous Bortezomibwas given to 58 patients during
induction;16 patients converted from i.v.tos.c route following diagnosis of
BiN(n:9) or due to change in adminstration policy(n:7).s.c.groupconsisted of
74 patients.55 Patients completed Bortezomib treatment only i.v.The median
cumulative dose of Bortezomib was 15.6 (range 5.2-44.8) and 18.3 (range 5.2-
62.4) mg/sq.m. among sc and iv groups (P=0.72).Neurologic adverse effects
are summarized in Table-1.The median cumulative Bortezomib dose to onset
of any grade of PN was 20.8 (range 3.9-41.6) and 20.8 (range 5.2-44.8)
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mg/sq.m. to onset of PN with sc and iv group (P=0.69)respectively. Although
statistically not significant dose reduction was required more often among
patients in the iv group.Eight of the nine patients who converted to sc following
onset of BiN had a improvement in symptoms with change in route and weekly
administration.None of the patients experienced severe AEs related to s.c.
administration or discontinued treatment. Rash at injection site was the most
frequent AE which was lasting for 3 days maximum and easily tolerable.The
progression-free survival (PFS) and OS between arms were also similar. 
Table 1.
Summary and Conclusions: These results confirmed the safety and equal
efficacy of sc Bortezomib compared to iv administration.Based on our results
we recommend s.c. administration to avoid dose reduction requirement and
discontinuation arising from neurotoxicity.
PB1878
CANCER-TESTIS ANTIGEN SLLP1 REPRESENTS A PROMISING TARGET
FOR THE IMMUNOTHERAPY OF MULTIPLE MYELOMA
S. Yousef1, J. Heise2, N. Lajmi2, T. Luetkens1, N. Kröger2, D. Atanackovic1,*
1University of Utah/Huntsman Cancer Institute, Salt Lake City, United States,
2University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Background: Most patients with Multiple Myeloma (MM) will relapse after an
initial response and eventually succumb to their disease. This is due to the per-
sistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM)
and immunotherapeutic approaches could contribute to eradicating these remain-
ing cells. We evaluated SLLP1 as a potential immunotherapeutic target for MM.
Aims: Our goal was to evaluate cancer-testis antigen SLLP1 as a potential
target for the immunotherapy of Multiple Myeloma.
Methods: We determined SLLP1 expression in myeloma cell lines and 394 BM
samples from myeloma patients (n=177) and BM samples from healthy donors
(n=11). 896 blood samples and 64 BM samples from myeloma patients (n=263)
and blood from healthy donors (n=112) were analyzed for anti-SLLP1 antibodies.
Seropositive patients were evaluated regarding SLLP1-specific T cells.
Results: Most cell lines showed SLLP1 RNA and protein expression while it
was absent from normal BM. Of 177 patients 41% evidenced SLLP1 expression
at least once during the course of their disease and 44% of newly diagnosed
patients were SLLP1-positive. Expression of SLLP1 was associated with
adverse cytogenetics and with negative prognostic factors including the
patient’s age, number of BM-infiltrating plasma cells, serum albumin, β2-
microglobulin, creatinine, and hemoglobin. Among patients treated with allo-
geneic stem cell transplantation those with SLLP1 expression showed a trend
towards a reduced overall survival. Spontaneous anti-SLLP humoral immunity
was detectable in 9.5% of patients but none of the seropositive patients evi-
denced SLLP1-specific T cells. However, antigen-specific T cells could readily
be induced in vitro after stimulation with SLLP1.
Summary and Conclusions: SLLP1 represents a promising target for the
immunotherapy of MM, in particular for the adoptive transfer of T cell receptor-
transduced T cells.
PB1879
ASSESSMENT OF INDIVIDUAL THROMBOSIS RISK ON THE CAPRINI
SCALE IN MULTIPLE MYELOMA PATIENTS UNDERGOING PERIPHERAL
BLOOD STEM CELL MOBILIZATION. 
E.S. Urnova1,* M. Gracheva1, L. Mendeleeva1, O. Pokrovskaya1, L. Kuzmina1,
I. Tarandovskii1, S. Vasiliev1, E. Gemdzhian1, M. Soloviev1, M. Firsova1,
M. Nareyko1, E. Parovichnikova1, V. Savchenko1
1Hematology Research Center, Russian Ministry of Health, Moscow, Russian
Federation
Background: Patients (pts) with multiple myeloma (MM) face an high risk of
thrombosis. We are talking about pts-related, disease-related and therapy-relat-
ed risk factors. Meanwhile no specific scale exists to assess the risk of throm-
botic complications for MM pts. We suppose that the Caprini scale is the most
comprehensive instrument for validation of individual risk factors and it can be
used not only for surgery pts.
Aims: The study was aimed to investigate the blood coagulation status in MM
pts depending on the individual risk assessment on the Caprini scale before
and during peripheral blood stem cell (PBSC) mobilization.
Methods: The study’s sample consisted of 30 pts-candidates for high dose
chemotherapy. There were 19 males and 11 females at the age of 27 – 64
years (median 55). After bortezomib-containig induction therapy 7 of them
achieved PR, 16 – VGPR and 7 – CR. PBSC mobilization was performed by
using cyclophosphamide (CY, 4g/m2) and granulocyte colony-stimulating factor
(G-CSF, 5mcg/kg/day). According to the internal protocol all pts had prevention
heparin-sulphate continuous infusion (in initial dose 500 IU/hour), starting the
day before CY introduction and stopping the next day after finish last PBSC
collection. All pts were assessed with Caprini model. Hemostasis analysis was
performed 5 times and included validation the results of activated partial throm-
boplasin time (APTT, 25 – 38 sec) and concentration of D-dimer (0 – 500 mkg/l).
Hypercoagulation was considered in cases when APTT<25 sec and D-dimer
>500 mkg/l. And hypocoagulation was estimated by data APTT >38 sec. Sta-
tistical analysis was performed with SAS 9.1 (using the GLM procedure).
Figure 1.
Results: This group of pts had 3-6 (mean 4,4±0,96) scores on the Caprini
scale. Initially (before heparin administration) APTT evaluation showed normal
coagulation in 26 pts and hypocoagulation in 4 pts (mean 34 sec; 95% CI 32 –
36 sec). D-dimer was normal in 25 pts and increased in 4 cases (mean 309,8
mkg/l; 95% CI 170,0– 449,5 mkg/l). APTT had significantly (P<0,05) changed
to hypocoagulability on the next day after starting thromboprophylaxis and in a
state of agranulocytosis became 39 sec (95% CI 36 – 46 sec) and 40 sec (95%
CI 36 – 50 sec) respectively. On the next day after CY infusion, APTT was sta-
tistically significantly decreased (P<0,05) reaching 34 sec (95% CI 32 – 37
sec). On the day of PBSC collection the mean APTT was 38 sec (95% CI 37 –
43 sec). Concentration of D-dimer was not modified in response to heparin or
CY infusion or in a state of agranulocytosis and it icreased (P<0,05) reaching
476 mkg/l (95% CI 326-626 mkg/l) on the day of PBSC collection. Thrombotic
complications were detected in 2 pts from a very high risk group (>5 score) on
the Caprini scale. The analysis of our results showed statistically significant
increase of (P=0,01) concentration of D-dimer in pts with the score of 5 or 6
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compared pts with the score of 3 or 4 score (figure 1). Pts in CR demonstrated
no significant difference in coagulation status compared to pts in VGPR or PR.
Summary and Conclusions: The possibility to use the Carpini scale to assess
an individual risk of thrombotic complications for patients with MM has been
confirmed clinically and by results of laboratory tests.
PB1880
REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PAT-
TERNS IN US PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE
MYELOMA (MM) 
L. Viana Nicacio1, G. Calkins1, M. Curtis1, J. Kohansimeh1, F. P. Lindberg1,
K. Larrabee1, A. Jaskiw1, R. N. Feinstein1,M. Terry1, L. Plotkin1,M. L. Palladino1,
A. Krishna2,*R. J. Green1
1Flatiron Health, New York, 2Novartis Pharmaceuticals, East Hanover, United
States
Background: The introduction of proteasome inhibitors (PIs) and immunomod-
ulatory drugs (IMiDs) has improved survival of patients (pts) with R/R MM.
However, there is little real-world data on PI, IMiD, and autologous stem cell
transplantation (ASCT) use.
Aims: The aim of this study was to describe recent US multiple myeloma treat-
ment patterns through August 2014.
Methods: Pts with R/R MM were selected from a longitudinal, nationally-rep-
resentative electronic medical record (EMR) database (Flatiron Health). MM
diagnoses were confirmed by physician (MD) notes. Pts were required to
progress after 1st line (1L), ≥ 1 visit after 2010, and ≥ 3 months follow-up post-
progression. Data were integrated from structured and unstructured EMR
sources: disease class from laboratory results and confirmed in MD notes and
ASCT status from MD notes. 
Results: We identified 607 pts with R/R MM (median age, 70 years; 32%<65
years). Most pts were male (57%), Caucasian (63%), and had IgG myeloma
(66%). Of the 117 pts who received an ASCT, the most common 1L regimens
were RVD 44%, VD 14%, RD 11%, and CyBorD 9%. In non-ASCT pts, the
most common 1L regimens were VD 27%, RVD 16%, RD 14%, and CyBorD
7%. Overall, 29% of pts received both mechanisms of action (MOAs; PIs and
IMiDs) in 1L. Of pts exposed to either a PI or IMiD in 1L who went on to receive
2L, 62% switched from PI to IMiD or IMiD to PI, and 30% continued with the
same MOA. MOA switching was highest in ASCT pts who received 1L PI (73%
received an IMiD in 2L, 23% continued on PI). By 3L, 79% of non-ASCT pts
had been exposed to both MOAs vs. 96% in ASCT pts. Treatment utilization is
shown in Table 1. 
Table 1.
Summary and Conclusions: PIs and IMiDs are the most prevalent MOAs
used in R/R MM in the US. Most patients receiving a single MOA in 1L go on
to receive the other MOA in 2L, suggesting a perceived clinical benefit of switch-
ing MOA. Most patients have been exposed to both MOAs by 2L (67%) or 3L
(83%), suggesting a possible need for treatment options with novel MOAs.
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REAL-WORLD BORTEZOMIB USAGE PATTERNS AMONG PATIENTS
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA 
G. Calkins1, J. Kohansimeh1, A. Krishna2,*, R.J. Green1, M. Curtis1,
F.P. Lindberg1, A. Jaskiw1, K. Larrabee1, M. Terry1, R.N. Feinstein1, L. Plotkin1,
M.L. Palladino1, L. Viana Nicacio1
1Flatiron Health, New York, 2Novartis Pharmaceuticals, East Hanover, United
States
Background: The 2012 FDA approval of subcutaneous (SC) bortezomib (BTZ)
was based on non-inferior efficacy and reduced toxicity vs intravenous (IV)
administration of BTZ. While differences in BTZ toxicity are attributed to route,
dose, schedule, and duration, little is known about BTZ use in recent real-world
practice in the US. 
Aims: This study aimed to examine the real-world use of bortezomib in
relapsed/refractory multiple myeloma patients in the US.
Methods: Patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
were selected from a longitudinal, nationally-representative electronic medical
record (EMR) database (Flatiron Health). MM diagnoses were confirmed by
physician (MD) notes. Pts were required to have disease progression following
1st line of therapy (LOT), ≥1 visit after 2010, and ≥3 months follow-up post-
progression. Pt-level data were integrated from structured and unstructured
EMR sources: transplant status abstracted from MD notes and IV/SC admin-
istration data merged with oral data from MD notes. We evaluated BTZ usage
among these pts with R/R MM.
Results: We identified 607 pts with R/R MM; among these pts, 542 (89%)
received BTZ. There were 830 LOTs containing BTZ. Initiation with SC vs IV
BTZ increased over time (2011: 13% SC; 2012: 64% SC; 2013: 76% SC; 2014:
71% SC). Among BTZ initiations after 2012, 34% of those starting IV BTZ later
switched to SC (7% of SC BTZ initiations later switched to IV). Across all BTZ
initiations, 47% started at a schedule of >once per week (1×/wk); the rate was
higher in earlier LOTs and transplant recipients (Table 1). BTZ initiations starting
at 1x/wk were associated with longer duration (4.9 vs. 4.0 months, P=0.02),
fewer dose reductions (26% vs. 40%, P<0.01) and similar cumulative total dose
(median of 20.8 vs. 22.3 mg/m2, P=0.24) than BTZ initiations starting at >1x/wk.
Table 1.
Summary and Conclusions: To our knowledge, this is the first real-world
study evaluating evolving patterns of BTZ use in pts with R/R MM in the US.
There was increased SC administration after 2012, longer duration of treatment
among those starting at 1x/wk, and fewer dose reductions among those starting
at 1x/wk; all which may be associated with toxicity management. 
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RISK OF THROMBOTIC EVENTS IN PATIENTS WITH NEWLY DIAGNOSED
(NDMM) AND RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
TREATED WITH LENALIDOMIDE BASED THERAPY: A SINGLE CENTRE
EXPERIENCE
J. George1,* A.J. Mahdi1, H.I. Sati1
1Haematology, Singleton Hospital, ABMUHB, Swansea, United Kingdom
Background: Thrombotic events (TEs) are a known complication of lenalido-
mide (LEN) therapy in patients with multiple myeloma. Venous thrombopro-
phylaxis has been recommended to reduce this risk. There is paucity of infor-
mation regarding the risk of arterial TEs in this group of patients. Furthermore
the difference in the risk and pattern of TEs between the NDMM and RRMM
patients exposed to LEN therapy has not been assessed in clinical trials.
Aims: To compare the incidence and nature of arterial and venous TEs
between NDMM and RRMM patients receiving LEN based therapy. Identifica-
tion of patients at risk by correlation with thrombopropyhlactic measures, LEN
dose, duration of treatment and additional anti-myeloma therapy.
Methods: We conducted a retrospective analysis of patients receiving LEN
based therapy between September 2009 to January 2015 in Singleton Hospital,
ABMUHB, UK. Patients were identified from our electronic prescribing system
(ChemocareÓ) and correlated with clinical notes.
Results: A total of 81 patients were identified (NDMM: n=34; RRMM: n=47).
The mean age at the start of treatment was 64.3 years (range 45-85 years)
and 69.4 years (range 48-86 years) for NDMM and RRMM groups respectively.
Thromboprophylactic measures were identified in 33 (97.1%) and 39 (83.0%)
of NDMM and RRMM patients respectively. A total of 12 TEs were noted
(NDMM: n=6, 17.6%; RRMM: n=6, 12.8%). Arterial TEs were noted in 3 patients
(8.8%) of the NDMM group compared to only 1 (2.1%) patient in the RRMM
group. The arterial TEs in the NDMM group were 2 TIA’s and one popliteal
artery thrombosis. One of the NDMM patients developed the arterial TIA whilst
on LEN monotherapy in the absence of additional risk factors for arterial throm-
bosis. In the RRMM group, one patient who had a previous history of TIA,
developed an ischaemic stroke resulting in dense hemiplegia despite dual anti-
platelet therapy. There were 3 (8.8%) venous TEs (all below knee DVTs) in the
NDMM group compared to 5 (10.6%) in the RRMM group (2 PEs, 2 proximal
lower limb DVT and 1 distal DVT). The mean LEN dose of those having TEs
was 22.5mg and 18.3mg in NDMM and RRMM groups respectively. The mean
time to TEs was 3.0 months in NDMM patients and 5.8 months RRMM groups
from the start of LEN therapy. All but one patient was on dexamethasone at
the time of TE.
Summary and Conclusions: Our analysis confirms the thrombotic risk of LEN
therapy both in NDMM and RRMM patients. There was a trend towards an
increase in arterial TEs (8.8% vs 2.1%) in NDMM compared to RRMM patients.
Hence LMWH in combination with anti-platelet therapy may be warranted in
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NDMM patients. Larger prospective studies are required to define optimal
strategies of TEs prophylaxis in patients with multiple myeloma receiving LEN
therapy.
PB1883
PRESENTING FEATURES AT DIAGNOSIS OF MULTIPLE MYELOMA IN AN
ISRAELI COHORT: PATIENTS YOUNGER THAN AGE 50 YEARS REPRE-
SENT A SPECIAL GROUP WITH A HIGH FREQUENCY OF T (11; 14).
A. Duek1,* L. Trakhtenbrot1, A. Avigdor1, A. Nagler1, M. Leiba1
1Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel
Background: Multiple myeloma is uncommon in persons younger than the
age of 50. Conflicting reports have been published concerning the presenting
features in this age group. The question regarding characteristics in presenta-
tion is clinically relevant since significant differences in biological features have
been demonstrated in several malignancies.
Aims: We analyzed the presenting features of patients with multiple myeloma
aged younger than 50 years currently treated in our center. 
Methods: Patients fullfilling diagnostic criteria for multiple myeloma currently
treated in our center and younger than the age of 50 were included for analysis.
The following information was available: age, sex, date of birth, date of diag-
nosis, type, percentage of BM inflitration, FISH, serum levels of immunoglob-
ulins free light chains, hemoglobin, creatinine, albumin,and b2 microglobulin,ISS
stage, bone lytic lesions, proteinuria, and plasmocytoma 
Results: Of the total of 23 patients studied, median age was 42 years (37.5-
47), with 36.3% younger than 40. In accordance with previously published stud-
ies1, the patients were more frequently male (81.8%), had favorable features
such as low International Staging System (ISS) (78.6% ISS I-II) as well as rel-
atively small frequency of adverse prognostic factors including hemoglobin
<10gr/dL (33.3%), serum creatinine >2mg/dL (16.6%), albumin <3.5m/dL
(44.4%), b2 microglobulin >3.5mg/dL (42.8%), and calcium >10mg/dL in only
27.7% of cases. However, most of the cases (71.42%) showed bone marrow
plasma cell infiltration >30% and bone lytic lesions were present in 88.2% of
cases. As usually described, the most common isotype was IgG (47.6%) while
that of light chain myeloma was higher than frequently reported (40.9%). FISH
analysis was available in 22 patients. Surprisingly, t (11; 14) was present in 13
cases (59.1%). This is significantly higher than the normally reported frequency
of this translocation (15 to 20%) in myeloma patients2-3 (binomial test with
P<0.001, equal than 0.02, respectively). Patients carrying such abnormality
were younger (mean age of 40 year vs. 46 year), had lower b2 microglobulin
values (mean 3.1mg/dL vs 5.2mg/dL), lower serum FLC kappa (38.6 vs
150mg/dL), lambda (8.3 vs 47mg/dL), and FLC ratio (4.82 vs 24.75 mg/dl).
Moreover, the group revealed more plasma cell infiltration (75% vs. 47.5%),
higher proteinuria (2.9gr/day vs 0.19gr/day), and only 20% of these patients
suffered from plasmocytomas. Patients younger than 40 did not show differ-
ences in any of parameters evaluated.
Summary and Conclusions: In summary, our cohort of young myeloma
patients from a single center showed at presentation a less aggressive disease
(low ISS stage, and low frequency of b2 microglobulin higher than 3.5mg/dL,
hypercalcemia, anemia and renal failure), as previously suggested1. Interest-
ingly, we found a higher frequency of t(11;14) by FISH analysis in this age
group. The data may support the fact that t (11;14) is present at the earliest
stage of plasma cell dyscrasias4. Further studies are needed to evaluate the
different biological nature of Multiple Myeloma in this age group.
References
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EPIDEMIOLOGIC AND CLINICAL CHARACTERISTICS OF MULTIPLE
MYELOMA IN FIVE REGIONS OF RUSSIAN FEDERATION
L. Mendeleeva1,* M. Soloviev1, O. Pokrovskaya1, E. Volodicheva2, L. Anchukova3,
S. Men’shakova4, S. Osunihina5, V. Voitsehovskiy6, V. Savchenko7
1Bone Marrow Transplant Department, National Research Center for Hema-
tology of Ministry of Healthcare Service Russian Federation, Moscow, 2Hema-
tology, Tula Regional Hospital, Tula, 3Hematology, Vologda Regional Hospital,
Vologda, 4Hematology, Tver’ Regional Hospital, Tver’, 5Hematology, Clinical
Hospital №4 of Mordoviya Republic, Saransk, 6Hematology, Amur regional hos-
pital, Blagoveshensk, 7National Research Center for Hematology of Ministry of
Healthcare Service Russian Federation, Moscow, Russian Federation
Background: Multiple myeloma (MM) is an incurable hematological disease
previously associated with poor prognosis and survival rates. MM accounts for
15% of all hematologic malignancies and 2% of all malignancies. In Europe it
affects about 4 per 100 000 individuals each year. The total number of patients
in Russian Federation is still unknown. Epidemiological cancer registries are
institutions for the collection, storage, processing, analysis and interpretation
of data on the incidence and prevalence of cancers within defined registration
areas. The data from the cancer registries also forms an indispensable basis
for further studies into the assessment of early detection measures and popu-
lation-based care of tumour patients.
Aims: To define epidemiologic and clinical characteristics of MM in 5 different
regions in Russian Federation.
Methods: 170 patients with multiple myeloma from 5 different regions of Russ-
ian Federation (Tul’skaya region, Vologodskaya region, Tverskaya region, Mor-
doviya republic and Amurskaya region) diagnosed from January 01, 2009 to
January 01, 2012 were included in the study. Data regarding these patients
were extracted from prospectively maintained databases and review of medical
records. Follow-up information on these patients was collected prospectively
and entered at the time of each visit. Response was defined according to IMWG
criteria. Kaplan-Meier analysis was used for analyzing overall survival. The cut-
off date for the interim analysis was January 22, 2014.
Results: Among 170 pts, there were 68 men and 102 women, aged from 42 to
86 years (median 61 year). 48,9% of pts were less than 60 years. There were
55% pts with myeloma G, 19% with myeloma A, 13% with light-chain myeloma,
1% with myeloma D, 3% with myeloma M, 2% with non-secretory myeloma, 5%
pts with diclonaly myeloma and in 2% of pts the type of MM was not defined. 85
(50%) pts were in stage III, 77 (45%) pts were in stage II and only 8 (5%) of pts
in stage I. At the time of diagnosis 36 (21%) pts had signs of renal failure (serum
creatinine more 177 mmol/l). Information about treatment and treatment respons-
es was available in 153 cases. 97% of pts proceeded induction therapy: 84%
pts – bortezomib-containing treatment, 13%-conventional therapy and 3%
refused of treatment. High-dose therapy with autologous stem cell transplanta-
tion was performed only in 14 cases due to remoteness from transplant centers.
Overall response was achieved in 68% of pts, among them complete remission
– in 26%. Absolute 5-year overall survival rate in our group was 37%±6,3%
(median 41,7 months). No difference was seen in overall survival between men
and women. There was a trend of increase of 3-year overall survival in pts diag-
nosed in 2011 in compare with pts diagnosed in 2009 (65,5% vs 46,4%). 71of
170 pts are still alive. The main reasons of deaths were disease progression
(70%), concomitant illnesses (21%) and inflectional complications (5%).
Summary and Conclusions: Our study showed that the median of age of pts
with newly diagnosed MM in Russian Federation is 10 years less than in Europe
and USA. Absolute 5-year overall survival rate in our pts is 37% that is compa-
rable with MM pts in Germany (39%).
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BENDAMUSTINE IN THE MANAGEMENT OF RELAPSED AND REFRAC-
TORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
C. Cerchione1,* L. Catalano1, A.E. Pareto1, S. Basile1, L. Marano1, I. Peluso1,
L. Simeone1, O. Vitagliano1, S. Palmieri2, S. Rocco2, F. Ferrara2, F. Pane1
1Hematology, AOU “Federico II”, 2Hematology, AORN “A.Cardarelli”, Napoli,
Italy
Background: Bendamustine is a bifunctional alkylating agent, with low toxicity,
that produces both single- and double-strand breaks in DNA, and shows incom-
plete cross resistance with other alkylating drugs, proved to be effective either
in relapsed or refractory and in new diagnosed MM as single agent or combined
with steroid and has also additive/synergistic activity with bortezomib.
Aims: Here we evaluate the efficacy and tolerance of bendamustine in combi-
nation with bortezomib-dexamethasone in patients with relapsed and refractory
multiple myeloma, whose prognosis is severe, so that there is a strong need
for new options for the management of these patients. A retrospective analysis
of patients with relapsed and refractory MM, who had received bendamustine
as salvage therapy, has been performed.
Methods: 39 patients, 21 males, 18 females, with advanced multiple myeloma,
treated with several lines of treatments, and refractory to all the lines previously
performed, received a schedule Bendamustine-based. Median age at diagnosis
was 57 years (r.36-82) while age at start of treatment was 62 years (r.37-83),
and median number of prior lines of treatment was 6 (r.2-11). ISS was equally
distributed, and cytogenetic characteristics were evaluable in 9 patients, only
two of whom had cytogenetic abnormalities, and in particular one of them had
del13q and in the other one was observed t(11;14). All the patients had previ-
ously been treated with schedule containing bortezomib and lenalidomide, while
90% of them had been treated with melphalan, 77% with cyclophosphamide
and 34% with anthracyclines, and 30% had also received radiotherapy. 58% of
patients had undergone at least to a single autologous stem cell transplantation.
Last treatment before bendamustine was a bortezomib-based regimen in 39%,
an IMIDs- based regimen in 49% (a combined bortezomib/IMIDs-based regimen
in 27%), while 12% of patients had received other chemotherapies. All patients
were relapsed and refractory to last therapies received.
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Results: Only patients completing at least two courses of Bendamustine were
considered for analysis. A total of 128 cycles was administered (median 3, range
2-9). Bendamustine was variously associated to bortezomib (66%), or IMIDs
(25%) and only in 9% it was combined only with dexametasone. In our schedule,
Bendamustine was given, at a median dose of 90 mg/sqm (range total dose :
120-180) on day +1 and +2 every 28 days. Median OS from diagnosis was 56.5
months (range 6-145), while median OS from start of Bendamustine was 6.5
months (range 2-30). 16/39 patients went in progressive disease during treat-
ment, 2/39 patients died for other causes (one for cardiovascular disease and
the other one had a gastric cancer). Grade 3 transfusion-dependent anemia
occurred in 31% while in 46% grade 3 neutropenia occurred. No severe extra-
hematologic toxicity was observed, only grade 1 gastrointestinal side effect
(nausea), treated by common antiemetic drugs. According to IMWG response
criteria, after a median follow up of 6 months (r.2-30), 1 patient achieved a com-
plete response, 1 patient achieved a VGPR and 21 out of 39 evaluable patients
achieved a partial response after a median time of 2 months with an overall
response rate of 59% and 12 patient were considered in stable disease, which
can be considered an impressive result in this subset of patients. In particular,
for 4 patients of this study, Bendamustine treatment was, after having achieved
a PR, a bridge to second autologous stem cell transplantation, and for one
patient a bridge to allogenic stem cell transplantation.
Summary and Conclusions: In conclusion, Bendamustine has shown signif-
icant efficacy in a particularly severe setting of patients, relapsed and refractory
to almost all available therapeutic resources, and in particular cases it could
be considered as a bridge to a second autologous or to allogeneic BMT.
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ROLE OF HEAVY/LIGHT CHAIN ASSAY, ALONE AND IN COMBINATION
WITH FREE LIGHT CHAIN ASSAY AND MINIMAL RESIDUAL DISEASE, IN
MYELOMA PATIENTS WHO ACHIEVE COMPLETE RESPONSE AFTER
FIRST LINE TREATMENTS 
F. D’Auria1, T. Statuto1, F. Larocca2, V. Simeon2, R. Guariglia3, G. Pietrantuono3,
O. Villani3, G. Mansueto3, T. Izzo3, C. Criscuolo3, G. D’Arena3, P. Musto4,*
1Laboratory of Clinical Research and Advanced Diagnostics, 2Laboratory of
Pre-Clinical and Translational Research, 3Unit of Hematology and Stem Cell
Transplantation, 4Scientific Direction, IRCCS, Referral Cancer Center of Basil-
icata, Rionero In Vulture (Pz), Italy
Background: The International Myeloma Working Group (IMWG) guidelines
recommend the use of protein electrophoresis, serum/urine immunofixation
and free light chain (FLC) assay for assessing response to treatment in multiple
myeloma (MM). In this setting, flow cytometry (FC) is emerging as a useful,
though difficult to standardize, additional tool to detect minimal residual disease
(MRD). Furthermore, the novel heavy/light chain (HLC) assay has recently
become available to improve quantification of IgG and IgA MM isotypes. 
Aims: To evaluate the effect of HLC ratio, FLC ratio and MRD on clinical out-
come of MM patients achieving immunofixation negative complete response
(CR) after first line therapy, according to IMWG criteria. 
Methods: We followed a prospective cohort of 25 patients with MM (14 males,
11 females; median age 63.2, range 43-82; 14 IgG and 11 IgA) who had
achieved CR after initial treatments including novel agents, with (n. 11) or with-
out (n. 14) autologous stem cell transplantation (AuSCT). CR was identified
after 6 induction cycles in patients not eligible for AuSCT and after AuSCT in
those undergoing such a procedure. Sera samples were tested for HLC and
FLC ratios by commercially available immunonephelometry kits, while bone
marrow samples were analyzed by multiparametric FC for assessing MRD,
using a home-made method based on a combination of CD138, CD38, CD56,
CD19, CD45, CD20, and CD117 monoclonal antibodies. MRD was defined
negative if< 10 neoplastic plasma cells were detected in a 100.000-event file.
The Kaplan-Meier method was used to plot and calculate progression free sur-
vival (PFS ) and overall survival (OS). Variables were analysed by log-rank
test and p-value<0.05 was considered statistically significant.
Results: At CR detection time, 18 patients showed normal HLC ratio, 11 had
normal FLC ratio (thus they were in “stringent” CR), and 13 had negative MRD.
After a median follow-up of 42 months, 12 patients remain in CR and 13 have
relapsed, 11 of whom are deceased. Overall, though neither HLC or FLC
assays, nor MRD evaluation, alone or in different combinations, showed a sta-
tistically significant influence on the clinical outcome, a trend toward a better
PFS (81% vs 50%) was observed in patients with sCR, particularly in those
with IgA subtype (100% vs 35%), where normal HLC also identified a subgroup
with more favorable outcome (PFS 67% vs 41%). Interestingly, PFS was lower
in patients with both abnormal HLC and FLC ratios than in those with only
abnormal FLC (40% vs 55%, respectively). 
Summary and Conclusions: Our preliminary and still numerically limited expe-
rience suggests that HLC might have a prognostic role in patients with IgA MM
in CR and might enhance the negative effect of abnormal FLC on PFS estimate.
A larger number of patients and an extended follow-up are required for achiev-
ing more robust data.
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IMPACT OF INITIAL CHEMOTHERAPY RESPONSE AND PRETRANS-
PLANT DISEASE STATUS BEFORE AUTOLOGOUS TRANSPLANTATION
ON SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA
F. Yalniz1,* T. Elverdi1, E. Celik1, S. Berk1, I. Erdogan1, A. Salihoglu1,
A.E. Eskazan1, C. Ar1, S. Aydin1, Z. Baslar1, Y. Aydin1, T. Soysal1
1Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
Background: High dose chemotherapy with autologous stem cell transplan-
tation (ASCT) has been considered the standard of care for multiple myeloma
patients and has been shown to increase both overall survival (OS) and pro-
gression free survival (PFS). However, the significance of initial treatment
response and the significance of pretransplant disease status are not clear
whether the depth of response influences the OS or PFS.
Aims: In this retrospective study we aimed to evaluate the significance of initial
chemotherapy response and pretransplant disease status on PFS and OS.
Methods: We identified 127 myeloma patients who underwent ASCT between
1997- 2014 at Istanbul University Cerrahpasa Medical Faculty. Five of them
were excluded from the study due to missing first line response data. Remaining
122 were grouped according to the first line chemotherapy responses, as sub-
optimal and optimal. Standard International Myeloma Working Group criteria
were used for classifying disease responses and defining progression of mul-
tiple myeloma. Suboptimal response to first line pretransplant therapy was
defined as a failure to achieve at least a VGPR following the first line
chemotherapy. Demographic variables and disease related variables were giv-
en in Table 1. PFS and OS of patients in the 2 study cohorts were compared
using Logrank test (Table 3)
Results: 127 patients treated with high dose chemotherapy and ASCT between
1997-2014 were included in the study. Median follow up time is 56 months. Of
these patients, 56% (n:68) failed to achieve an optimal response following the
first line chemotherapy. Most of these patients received second line chemother-
apy before proceeding to ASCT. Subsequent to additional chemotherapy, 37%
(n:46) underwent ASCT. The overall survival of patients responded as CR or
VGPR is 53 months.
Figure 1.
Summary and Conclusions: In conclusion, for patients achieving less than a
VGPR response following initial chemotherapy, additional chemotherapy
improved depth of response, but was not associated with survival benefit. Fur-
thermore we found no impact of initial treatment response on PFS and OS.
This might be explained by the increased efficacy of new agents.
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NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK
ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS
TREATED UPFRONT WITH NOVEL AGENTS
A. Romano1,* N. L. Parrinello1, M. L. Consoli1, S. Forte1, C. Conticello1,
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A. Corso 2A. Pompa 2K. Noonan3, I. Borrello3, F. Di Raimondo1,
1Division of Hematology, Azienda Policlinico-OVE, Catania, 2Divisione di Ema-
tologia, IRCCS FOndazione San Matteo, Pavia, Italy, 3Department of Oncology,
Johns Hopkins University, Baltimore, United States
Background: Recent reports identify the ratio between absolute neutrophils
count (ANC) and absolute lymphocyte count (ALC), called NLR,as predictor of
progression free survival (PFS) and overall survival (OS) in cancer patients. 
Aims: We retrospectively tested NLR in a cohort of 309 newly diagnosed MM
patients treated upfront with novel agents. 
Methods: NLR was calculated using data obtained from the complete blood
count (CBC). PFS and OS were evaluated. 
Results: Median NLR was 1.9 (range 0.4-15.9). Higher NLR was not due to
ISS stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS esti-
mates were, respectively, 18.2% and 36.4% for patients with NLR ≥ 2 versus
25.5% and 66.6% in patients with NLR<2. NLR ≥ 2 reduced PFS for ISS stage
I and OS significantly for stages I and III, but not stage II. Among younger
patients (age<65 years, N=179), NLR ≥ 2 had a negative prognostic impact on
both PFS and OS, in all ISS stages. By combining ISS stage and NLR in a
model limited to young patients, we found that 19% of the patients were clas-
sified as very-low risk group, and 70% and 11% were in standard-risk and very-
high risk groups, respectively. The 5-year estimates were 39.3%, 19.4% and
10.9% for PFS and 95.8%, 50.9% and 23.6% for OS for low, standard and high
risk groups, respectively.
Summary and Conclusions: We found NLR as predictor of PFS and OS in
MM patients treated upfront with novel agents. NLR can be combined with ISS
staging system allowing a better identification of patients with dismal outcome. 
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MULTIPLE MYELOMA IN ELDERLY AFRO-CARIBBEAN PATIENTS
TREATED WITH MEPHALAN PREDNISONE AND THALIDOMIDE IN MAR-
TINIQUE;A RETROSPECTIVE STUDY
A. Lok1,* J.C. Meniane2, V. Vinh Hung3, J. Baudin4, C. Joachim4, J. Macni4,
P. Escarmant3, L. Majoubi5, M. Razakanaivo6, A. Brebion2, P. Moreau1
1Hematology, CHU Nantes, Nantes, France, 2Hematology, 3Oncology,
4AMREC, CHU Martinique, Fort de France, Martinique, 5CHU Villejuif, Villejuif,
France, 6CHU Martinique, Fort de France, Martinique
Background: In African-Americans (AA), the incidence of multiple myeloma
(MM) is twice as high as in Caucasians. Only few studies have focused on
overall survival. A recent population-based study comparing white and AA sub-
jects showed a better survival in AA patients over a entire study period ranging
from 1973 to 2005. However, significant survival improvement after the current
era of intensive treatment or new therapies was only seen among whites, with
smaller, non-significant change seen among blacks.This study hypothesized
that the disparities in improvement in outcome observed could be related to a
lower response to new therapies in AA patients. In Martinique, a French overseas
department, the vast majority of the population is of Afro-Caribbean origin.
Aims: Our aim was to assess the characteristics, progression-free (PFS) and
overall survival (OS) of this ethnicity subgroup.
Methods: We conducted a retrospective study on transplant-ineligible patient,
newly diagnosed with MM who were treated in the Hematology Department of
Fort de France in Martinique between 2007 and 2012.
Figure 1.
Results: During this period, the Martinique Association for Epidemiological
Research on Cancer revealed an incidence of 8/100,000 inhabitants per year.
Fifty four patients were not eligible for autologous stem cell transplantation and
had been treated with melphalan, prednisone and thalidomide as part of front-
line therapy.The patients had a median age of 80 years, with ISS stage III doc-
umented in 48%. The overall response rate was 76%. With a median follow up
of 35 months, PFS and OS were 28.9 months and 48.6 months.
Summary and Conclusions: Compared to metropolitan France, our results
show a higher incidence and a similar outcome in this population, despite an
advanced age and disease status at diagnosis. No data have been published
focusing only on the outcome of AA or African-Caribbean elderly patients treated
with combination therapies that include novel agents. Our study highlights find-
ings which had so far not been described and do not support the hypothesis
that AA patients had a lower response to new therapies.
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WALDENSTROM’S MACROGLOBULINEMIA EXPRESS B-CELL MATURA-
TION ANTIGEN AND SERUM LEVELS CORRELATE WITH DISEASE
STATUS AND CONVENTIONAL M-PROTEIN AND IGM LEVELS
J. Berenson1,* S. Vardanyan1, E. Sanchez1, M. Li1, C. Wang1, A. Gillespie1,
M. Spitzer1, A. Shvartsur1, N. Harutyunyan1, G. Garzio1, G. Tang1, J. Said2,
H. Chen1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, 2Pathology
and Laboratory Medicine, Geffen School of Medicine at the University of Cali-
fornia at Los Angeles, Los Angeles, United States
Background: Waldenström’s macroglobulinemia (WM) is an incurable B-cell
lymphoplasmacytic lymphoma. B-cell maturation antigen (BCMA) is expressed
on malignant B cells and we have previously shown that serum BCMA levels
are elevated in multiple myeloma (MM) patients and correlate with disease sta-
tus in multiple myeloma (MM) patients.
Aims: Our objective was to determine whether BCMA is present in WM; and,
furthermore, whether its serum levels also correlate with disease status and
track with conventional tumor markers for patients with WM.
Methods: Data was obtained on 20 WM patients who received treatment in a
single clinic specializing in monoclonal gammopathies. Mann-Whitney analysis
was used to measure statistical significance (P<0.05). Immunohistochemical
staining and flow cytometric analysis was used to determine the expression of
BCMA on WM cells.
Results: First, we found that BCMA is highly expressed on the surface of tumor
cells from the bone marrow of WM patients using both immunohistochemical
and flow cytometric analysis. Next, we compared serum BCMA levels from
untreated WM patients (n=9) to healthy individuals (n=14), and the levels were
markedly higher in WM patients (P<0.0001). Next, BCMA levels in WM patient
sera were also correlated with disease status at the time during which the sam-
ple was collected. Serum from patients achieving >partial response (n=7)
showed significantly lower levels of BCMA than samples from patients with sta-
ble disease (n=4) or progressive disease (n=7; P=0.003 and P=0.0003, respec-
tively). Additionally, the BCMA levels of seven WM patients were correlated
with the serum M-protein and IgM levels of these patients during the course of
their therapy. Changes in serum BCMA levels correlated with changes in serum
M-protein as well as IgM levels.
Summary and Conclusions: These results indicate that BCMA is present on
the malignant cells from WM patients and serum levels of this protein can be
used as a potential marker for tracking the course of their disease.
PB1892
EXTRA MEDULLARY RELAPSE AFTER ALLOGENEIC BONE MARROW
TRANSPLANTATION FOR MULTIPLE MYELOMA (MM)
L. Torjemane1,* M. Chelli2, N. Abdejlil1, I. Safra3, H. Kaabi4, A. Lakhal5,
R. El Fatmi1, S. Ladeb1, H. Slama4, T. Ben Othman1
1Hematology, Centre National de Greffe de Moelle Osseuse de Tunis, Bab
Saadoun, 2Radiology, Institut Kassab de Tunis, 3Hematology, Institut Pasteur
de Tunis, Tunis, 4Immunology, 5Hematology, Centre National de Transfusion
Sanguine de Tunisie, Bab Saadoun, Tunisia
Background: The role of allogeneic stem-cell transplantation (allo-SCT) in
treatment of myeloma patients is still controversial. Allo-SCT consolidates treat-
ment by virtue of its graft-versus-myeloma (GvM) effect and results in a higher
rate of molecular remission and lower risk of relapse. However, in our experi-
ence we observed extra-medullary relapse (EMR) which can be reversed by
new post-transplantation strategies. 
Aims: The goal of our study is to evaluate the frequency, aspects and the prog-
nosis of EMR after a tandem auto-allogeneic bone marrow transplantation (allo-
BMT) for MM.
Methods: Our study is retrospective about 25 patients with MM who underwent
allo-BMT between February 1998 and December 2013 in the “Centre National
de Greffe de Moelle Osseuse de Tunis”. The median age at transplant were 42
years (range; 31-49). Conditioning regimen were oral or IV Bu 14-Cy (n=23),
Fludarabine-TBI (n=2). All patients received cyclosporine with methotrexate as
graft-versus-host disease (GVHD) prophylaxis; one patient received in addition
mycophenolate mofetil. Responses were assessed using the IMWG criteria.
EM relapse was defined as the presence of plasmocytoma evidenced by med-
ical imaging techniques and secreting the same monoclonal component while
the myelogram is normal and hematopoiesis was of donor type.
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Results: After allogeneic –BMT, eight patients (32%) are alive after a median
follow up of 36 months (range 2- 168 months). Nine patients (36%) died from
toxicity mainly related to GVHD and its complications. Eleven patients (44%)
relapsed (n=9) or progressed (n=2) after ABMT. In eight patients (8/11; 72%),
relapse was extra medullary with histological confirmation in 2 patients. Compo-
nent monoclonal was IgG lambda (n=4), IgA lambda or kappa (n=2), IgG kappa
(n=1) and light chains lambda (n=1). The median time between allogeneic- BMT
and EM relapse was 29 months (range 3-132 months). The status of the disease
before allograft was CR (n=4), PR (n=4). Six patients had a tumor mass adjacent
to bone, 2 patients have soft tissue involvement or multiple organs involvement
(pancreas, kidney and abdomen). There were no evidences of medullary involve-
ment at the time of relapse. Molecular and cytogenetic chimerism was performed
in 5 patients and they were of donor type. Seven patients were treated by
chemotherapy (bortezomib or lenalidomid; n=4) and / or radiotherapy (n=6).
Three patients from them (3/8; 37.5%) are alive after a median follow-up of 156
months (range; 132-168) with partial (n=1) or complete remission (n=2).
Summary and Conclusions:After allogeneic BMT, patients are at risk of TRM
and extra medullary relapse. The effect GvM seems to be limited to the bone
marrow. New treatments options (lenalidomide/bortezomib) in combination with
radiotherapy seems controlling the disease.
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CLINICAL PROGNOSTIC FACTORS OF LONG TERM SURVIVAL ΙΝ MUL-
TIPLE MYELOMA
A. Tsakiridou1,* P. Lampropoulou1, A. Anastasiadis1, G. Papageorgiou1,
D. Stoumbos1, I. Patsias1, C. Gekas1, M. Kotsopoulou1, P. Repousis1,
A. Megalakaki1,
1Clinical Heamatology, Anticancer METAXA Hospital, PEIRAUS, Greece
Background: Multiple myeloma prognosis may correlate with the patient’s
clinical characteristics as well as biologic variables of the malignant clone.
In the mid 90’s with the systematic use of high dose melphalan and ASCT the
average survival rate was 3-4years,while after 2007 with the indroduction of
immunomodulatory agents and proteasome inhibitors, life expectancy exceed-
ed the limit of 7-8 years.At the same time the impact of the molecular features
of the malignant cell in prognosis was strongly validated and acknowledged.
Aims: In this cohort we present patients diagnosed with multiple myeloma
before 2006, who remain alive at least eight years after the initial diagnosis.The
purpose of the study was to identify common clinical characteristics of favorable
prognosis among long term survivors independently of cytogenetic or molecular
abberations.
Methods: The present study included 26 patients(19males,7 females) diag-
nosed with multiple myeloma between 2000-2005 in our institution.The median
age at the time of diagnosis was 57(44-75 )yrs.Αmong the cases reported 10
were IgGk, 4 IgGλ,3IgAk, 3IgAλ,3 light chain(λ), 2 non secretory and one had
tripple M-component(IgGk/IgAk/IgDk). The majority of patients (25/26) were
eligible of treatment initiation according to the current criteria (presenting with
CRAB).23 patiens were diagnosed with bone disease,14 had anemia,11 pre-
sented with renal insufficiency and 3 with hypercalcemia.In 6/26 patients MGUS
preceeded the diagnosis for more than 12 months. At staging by Salmon Durie
15/26 were at stage III,6 at stage II,5 at stage I,while according to ISS 6/26
were at stage III.Classical cytogenetic analysis was performed in bone marrow
speciments for 20/26 patients and all had a normal karyotype. 23/26 received
VAD or VAD-Caelyx regiments.Two received melphalan -steroids combination
and one bortezomib-steroids.Palliative radiotherapy was applied to all patients
having bone disease (23/26).19/26 received high dose melphalan and autolo-
gous transplant while 5 of them were submitted to a second transplantation
(tandem) and 15 reached complete remission after transplantation.22/26 fol-
lowed a maintenance schedule with thalidomide.
Results: 15 out of 26 patients remain in complete remission 9-15 years after
diagnosis,while 3 are alive with relapsed or progressive disease.8 patients died
>8-14 years after diagnosis(7 died from disease complications and one from
an irrelevant cause).Although no statistical analysis can be performed in this
sample,two different subgroups are revealed:the first subgroup consists of 15
patients of younger age (median 54),no comorbidities,with bone disease as
the main clinical feature,who were treated with high dose melphalan and ASCT
and achieved CR according to the contemporary response criteria.The latter
subgroup included 9 patients of older age with previous MGUS diagnosis (most-
ly IgGk),whose survival exceeded the average life expectancy.
Summary and Conclusions: A clinical profile of younger age,lower ISS, pro-
longed PFS is compatible with long term survival. ISS appears to have higher
prognostic value than Salmon Durie.Even in the era of novel treatment agents
clinical characteristics of the patient may indicate survival benefits although the
use of cytogenetic or molecular analysis when available has become mandatory.
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THE ROLE OF THE UPTAKE PATTERN OF 18F-FDG PET/CT AND 99MTC-
MIBI IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH MULTIPLE
MYELOMA
I.G.H.L. Metze1,* R.J. Ferrari2, G.B. Duarte3, C. Mosci2, C.D. Ramos2
1Internal Medicine, 2Radiology, 3Hematology/Hemotherapy Center, University
of Campinas, Campinas, Brazil
Background: for staging of myeloma it is important not only to measure the
total tumor mass but also to localize the lesions in order to treat special local-
izations
Aims: to compare the image patterns of 18F-FDG positron emission computed
tomography/ computed tomography (PET/CT) with those of 99mTc-MIBI single
photon emission tomography/CT (SPECT/CT) at diagnosis in plasma cell neo-
plasms (MM) and evaluate the relation of this pattern with risk factors, therapy
response and patients’ progression-free survival (PFS).
Methods: Eighteen newly diagnosed MM patients were enrolled. PET/CT and
SPECT/CT were included in the diagnostic work-up, reporting focal lesions
and diffuse bone marrow involvement. One patient had a solitary plasmacytoma
and was not evaluated for response. Patients gave informed consent.
Results: Eleven patients (61%) were male. Median age: 57 years (37-84);
albumin 3.4 g/dL (2.16-4.2), beta-2-microglobulin: 4.2 mg/L (0.4-29.4), calcium
9.8 mg/dL (7.8-15), serum creatinine 0.85 mg/dL (0.6-2.4). No patient was on
dialysis. According to ISS, 2 patients were stage I; 6 were stage II, and 10
were stage III. One case fulfilled criteria for plasma cell leukemia and 1 had a
solitary plasmocytoma. Patients received CTD (12 patients); MPT (3 patients);
CVD and Dexa-Tal (one case each). PET/CT and SPECT/CT, were concordant
for presence (11) or absence (4) of a diffuse pattern. In the last ones, two
showed positive foci in PET/CT. PET was able to detect >84 (extramedullary
in six cases) while SPECT/CT detected only 10 focal lesions (extramedullary
in one case). Intensity of 99mTc-MIBI uptake as well as the number of foci seen
in PET/CT had an inverse correlation with hemoglobin values but not with ISS.
A very good partial remission was seen in 5 patients and 2 had a complete
remission. After a median follow-up of 12 months (1-19), 4 patients had pro-
gressed and 3 patients (17.6%) died during the follow-up. The 12 month pro-
gression free survival for diffuse pattern of PET/CT and SPECT/CT was not
statistically different, although none of the patients with a negative SPECT/CT
had progressed.
Summary and Conclusions: in this preliminary study, 18F-FDG PET/CT
detected more focal lesions (including extramedullary lesions) and 99mTc-MIBI
was able to measure the intensity of diffuse BM involvement. Both techniques
should be used together, especially in clinical studies, as they give comple-
mentary information. Concerning therapy response, the time of observation is
rather short, and no relation with PFS and OS was found yet.
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BENDAMUSTINE-BASED THERAPY RELAPSE/REFRACTORY MULTIPLE
MYELOMA PATIENTS: FIRST IMPRESSIONS IN RUSSIA
S. Voloshin1, S. Bessmeltsev1, T. Zagoskina2, A. Garifullin1,* N. Kotova3,
E. Kariagina4, K. Kaplanov5, N. Medvedeva3, A. Kuvshinov1, L. Stelmashenko1,
K. Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, 22Kirov’s Institute of Hematology and Transfusiology, Kirov, 33City Hospital
Number 31, 44City Hospital Number 15, Saint-Petersburg, 55Volgograd Region-
al Clinical Oncology Dispensary Number 1, Volgograd, Russian Federation
Background: Relapsed and refractory (R/R) multiple myeloma (MM) consti-
tutes a specific and unmet medical need. Median survival ranges from as little
as 6 to 9 months, and responses to treatment are characteristically short. In
patients with R/R MM after therapy of bortezomib and/or immunomodulators
(IMiDs) a bendamustine-based treatment can be used as “salvage”.
Aims: Examine efficiency of bendamustine-based chemotherapy in R/R MM
patients.
Figure 1.
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Methods: In this retrospective analysis we have identified 32 patients with R/R
MM by means of case research, who have been bendamustine-based treated
at Hematological Clinics of Russian Federation since 2011. Median age was
67 years, the female/male ratio was 2.5:1. After in median 2 lines of prior therapy
(range: 1-7) patients received in median 3 (range: 1-9) cycles of bendamus-
tine-based therapy. Bendamustine dosage was 70-120 mg/m2/day on days 1
and 2 of a each 28-day cycle until progressive disease or intolerability. Ben-
damustine was administered as monotherapy in 12% of patients, whereas 88%
received concomitant steroids (group Bendamustine (B), n=17). Bendamustine
with dexamethasone and bortezomib or IMiDs (BBD, BRD, BTD) was evaluated
in 15 patients with R/R MM (group Bendamustine-plus (B+)). Primary end point
was overall response rate (ORR). Secondary end points were time to progres-
sion (TTP), overall survival (OS), and toxicity.
Results: ORR in both group was 59.2%: 22.2% partial response (6.7% in group
B vs. 41.7% in group B+, р<0.05), stable disease 37.0% (26.7% vs. 50.0%,
accordingly, р>0.05). Median TTP was 9.7 months (4.1 mo in group B vs. 7.2
mo in group B+, р=0.02)) (pic). Median OS was 25.4 months in group B, but in
group B+ median OS is not reached. Hematologic toxicity was in 25.0% of
patients: grade 3/4 anemia was noted in 9.4%, grade 3/4 thrombocytopenia
was noted in 6.3%, and grade 3/4 infections were noted in 21.9%.
Summary and Conclusions: Bendamustine-based therapy is active and well
tolerated in patients with relapsed/refractory multiple myeloma.
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THE IMPORTANCE OF IMMUNOPHENOTYPIC COMPLETE REMISSION
AFTER INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
ON PROGRESSION/RELAPSE FREE SURVIVAL
T. Zabranska1,* A. Jungova1, P. Jindra1
1Department of Hematology and Oncology, Charles University Hospital in
Pilsen, Pilsen, Czech Republic
Background: Multiple myeloma (MM) is a malignant, essentially incurable
desease caused by malignant transformation of B-lymphocytes. Depth of
achieved remission appears to correlate with the duration of desease control.
Therefore there are cumulative data supporting the importance of the molecularly
or imunophenotypically defined remission (absence of minimal residual disease-
MRD). MRD in bone marrow may be detected by flow cytometry (with a threshold
sensitivity at a level of 1x10-4). Immunophenotypic complete remission (iCR) is
defined by fulfilling requirements of conventional CR along with negative test of
free light chains in serum and absence of myeloma cells in the bone marrow by
examination of at least 10 cells using >4-color flow cytometry.
Aims: To verify the importance of iCR after induction therapy in patients with
MM on progression/relapse free survival (PFS).
Methods: Retrospective analysis of 25 patients with MM consecutively diag-
nosed in 2010-2013, who achieved conventional CR after induction therapy
and were examined by flow cytometry to evaluate eventual presence of MRD
in bone marrow (according to EMN – European myeloma network).
Results: Our cohort of patients comprised 14 men and 11 women, the mean
age was 60 years. Patients were treated with induction chemotherapy contain-
ing thalidomide in 12/25 (48%) and bortezomib in 13/25 (52%) and all patients
subsequently received highdose chemoterapy (HD-Melphalan 200 mg/m2) sup-
ported by autologous stem-cell transplantation. A total of 8 patients (32%) in
conventional CR after induction therapy achieved also iCR (the MRD-ve), while
17 patients (68%) had still by flow cytometry detectable MRD in bone marrow
at a level of 1x10 to 1x10-2-4 (MRD +ve). Immunofenotypic data after autolo-
gous transplantation are not available. Between the two groups was no statis-
tical difference in sex (P=0.34), cytogenetic risk group (P=0.63), or type of
induction chemotherapy (P=0.73). The median PFS for MRD+ve was 23
months (12-48) and for MRD-ve 35 months (15-57), however difference in the
median PFS between the two groups was not statistically significant (P=0.73).
Summary and Conclusions: Our data indicated a trend towards a longer PFS
for patients MRD-ve, however absence of statistical signification may be caused
by the relatively low number of patients and eventually by the efect of subse-
quent HD-chemotherapy. The study with longer follow-up of more patients with
flow cytometry-monitoring in all stages of treatment (also after HD-Melphalan)
is thus waranted.
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RAPID EFFICACY OF LENALIDOMIDE PLUS DEXAMETHASONE FOR
POEMS SYNDROME: ASSESSMENT OF FOUR PATIENT’S CLINICAL
OUTCOME
S. Kalayoglu-Besisik1,* M. Ayer2, E. Osmanbaşoglu3, E.S. Torun1, O. Arslan1,
O. Dogan4
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Istanbul, Turkey
Background: The POEMS syndrome (coined to refer to polyneuropathy; PNP),
organomegaly, endocrinopathy, M protein, and skin changes) is a rare disorder
and characterized by elevated vascular endothelial growth factor (VEGF) levels.
The treatment for POEMS syndrome is mostly derived from regimens that have
shown efficacy in other plasma cell dyscrasia, such as lenalidomide which
reduces proinflammaotory and proangiogenic cytokines.
Aims: We report the efficay of a combination of lenalidomide and dexametha-
sone (Ld) in four patients with POEMS syndrome.
Methods: Four patients (M : F, 3 : 1)(age ranf-ge: 37-56 years) had been diag-
nosed as having POEMS syndrome. Serum VEGF level elevation could be
documented only in one patient. The common main complain were fatique and
weight loss which defined the reason that Internal Medicine speciaist were the
first physicians. Two of the patients had severe PNP which inhibits normal daily
activity and led to need assistance for walking. Two patients had severe
extravascular volume overload as pleural effusion and ascite. As endocrinopa-
thy, all of them had hypogonatorophic hypogonadism and hypocortisolemia
among hypothyroidism and mild diabetes. Hyperpotasemia, mild increased
serum creatinine level and hyponatremia were noted as biochemical changes.
Only two patients had hyperpigmentation and acanthosis nigrigans. Treatment
was started with lenalidomide (25mg, days 1-21) and dexamethasone (40mg
weekly) following approvement for reimbursement. All patients received venous
thrombosis prophylaxis.
Results: Massive ascite and also pleural effusion dramaticaly diminished and
disappeared with the time. All of the patients put on weight and biochemistry
was normalized. With intensive physical and occupational therapy, there was
also steady improvement of the pateint’s motor function. Two patients were
agree to collect autologous peripheral blood stem cell harvesting but decide
for delayed transplantation. One patient had needed radiotherapy for the pain
related with bone lesions. The patient’s serum free light chain ratio became
normalized but M-protein was still detectable with immunfixatipn.
Summary and Conclusions: Our experience suggest that Ld therapy is not
only realtively safe but also a promising option for POEMS syndrome.
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CASE REPORT: CEREBRAL LIGHT CHAIN DEPOSITION DISEASE (LCDD)
F.I. Ibañez Camacho1,2,* V. Cabanas-Perianes1, J. Monserrat Coll1,3,
A. Rábano Gutiérrez4, B. Cuartero-Perez5, J. Ros De Sampedro6, A. Sanchez
Salinas2, M. Blanquer Blanquer2, M. Berenguer2, J.M. Moraleda Jimenez2,7
1Hospital Universitario Virgen de la Arrixaca, Murcia, 2Hematology, Hospital
Universitario Virgen de la Arrixaca, 3Hospital Virgen Arrixaca, Murcia, Murcia,
412Departamento de Neuropatología y Banco de Tejidos, Fundación Cien,
Instituto de Salud Carlos III, Madrid, 5Neurosurgery, Hospital Universitario Vigen
de la Arrixaca, 6Neurosurgey, Hospital Universitario Virgen de la Arrixaca, 7Cat-
edrático Facultad de Medicina, Universidad de Murcia, Murcia, Spain
Background: Light chain deposition disease (LCDD) is a rare monoclonal
gammopathy characterized by the systemic deposition of non-amyloid
immunoglobulin light chains causing a progressive accumulation of extracellular
material with varying degrees of organ impairment. Although LCDD mainly
affects the kidneys (it manifests as proteinuria and/or renal insufficiency) the
involvement of other organs (e.g., heart, central nervous system and peripheral
nerves) is very common. We present the case of a patient with a newly diag-
nosed cerebral restricted λ LCDD.
Aims: We present the case of a patient with a newly diagnosed cerebral restrict-
ed λ LCDD. 
Methods: A 49 -year-old female was admitted to our hospital with progressive
loss of coordination in her right hand and some in her left leg for 3 months,
associated with mayor depression, headaches and constitutional symptoms
(asthenia, weight loss and anorexia). Clinical examination revealed a decrease
in the strength and the sensitivity in the right hemisphere 4/5. Her complete
blood count showed a mild anaemia (Hb 114 g/L) and trombocytopenia
(122.000/uL) with total leukocyte in the normal range. Calcium was normal.
Liver and renal function was also normal. Serum and urine protein electrophore-
sis did not reveal any monoclonal protein spike. Immunofixations were negative.
Nephelometry was performed showing a decreased of IgA and IgM levels with
a normal IgG. Serum λ free light chains were 6.98 mg/L with a normal or K/λ
ratio (K/λ:). The MRI study was made to the patient in order to discard a central
nervous system (CNS) neoplasm. The MRI revealed a space occupying diffuse
lesion in left front parietal. Histological examination with hematoxylin and eosin
of the resected tumor demostrated an amorphous eosinophilic deposits in white
and grey matter of the brain without plasmacytic cells. These deposits were
positive for λ-light chain antibody by immunohistochemistry. To rule out other
plasma cell dyscrasias, bone marrow aspiration (BMA) and fine-needle aspira-
tion of abdominal fat pad (FPFNA) were assessed. BMA showed a 3% of plas-
ma cells (PC). Flow cytometry did not evidence monoclonal PC. FPFNA was
negative to amyloid. With these data, Multiple Myeloma (MM) and Primary Sys-
temic Amyloidosis (PSA) were discarded and the diagnosis of λ cerebral LCDD
was made. The patient received conditioning regimen consisted of BEAM:
BCNU 300 mg/m2 (d-6) cytosine arabinoside 200 mg/m2/d and VP-16 200
mg/m2/d (d-5 to d-2) and melphalan 200 mg/m2 (d-1) followed by autologous
stem cell transplantation (ASCT). Currently (After 3 months of ASCT) the patient
has been improved her strength and sensitivity.
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Results: LCDD is a rare monoclonal gammopathy and it is less common involv-
ing CNS. As in other neurological disorders, the clinical presentation (epilepsy,
cognitive impairments, hemiparesis,headaches.) depends mainly on the loca-
tion of deposition and not on the histological finding. Although chemotherapy
including an alkylating agent, radiotherapy or steroids have been reported in a
few cases, the standard treatment has not yet been clearly established. ASCT
has been reported as a feasible strategy in LCDD. We choised BEAM condi-
tioning regimen in order to cross the blood-brain barrier. The median overall
survival is approximately of 4 years. Prognostic factors for LCDD include age,
presence of concomitant MM or PSA. Nowadays, there is not enough data
about the management of brain LCDD and more information is needed describ-
ing the efficacy of the different treatments.
Summary and Conclusions: We choised BEAM conditioning regimen in order
to cross the blood-brain barrier. The median overall survival is approximately
of 4 years. Prognostic factors for LCDD include age, presence of concomitant
MM or PSA. Nowadays, there is not enough data about the management of
brain LCDD and more information is needed describing the efficacy of the dif-
ferent treatments.
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EXTRAMEDULLARY BREAST PLASMACYTOMA ACCIDENTALLY
DIAGNOSED PRECEDING AGGRESSIVE SYSTEMIC RELAPSE: AN
UNUSUAL AND RARE MANIFESTATION OF RECURRENCE OF MULTIPLE
MYELOMA
L. Torti1,* S. Pulini1,1, E. Sabattini2, F. Bacci2, A. M. Morelli1, P. Di Bartolomeo1
1Department of Hematology, Transfusion Medicine and Biotechnology, Clinical
Hematology, “Spirito Santo” Civic Hospital, Pescara, 2Department of Hematol-
ogy and Oncological Sciences, Section of Hematopathology, S. Orsola-Malpighi
Hospital, University of Bologna, Bologna, Italy
Background: Extramedullary (EM) plasmacytoma is a plasma cell neoplasm
of the soft tissues that may occur with or without bone marrow and systemic
involvement. EM disease is an uncommon manifestation in Multiple Myeloma
(MM) and can either accompany newly diagnosed disease or more frequently
develop with relapse. It seems to have a different pathogenesis from the
medullary involvement and represents an independent poor prognostic factor
with high rate of mortality. Myeloma of the breast is a rare entity not completely
understood, with only a few reported cases in the literature not providing any
statistical information.
Aims: We present a patient with extramedullary breast plasmacytoma diag-
nosed incidentally during breast plastic surgery for long-term history of fibro-
cystic disease. This unexpected diagnosis was shortly thereafter followed by
a severe systemic medullary and extramedullary recurrence, treated with
chemotherapy and radiotherapy.
Methods: A 44 year-old woman was diagnosed with IgG lambda MM stage
IIIA ISS3, showing deletion of 17 and 13 chromosome detected by FISH and
without bone or EM lesions. She was affected by MGUS from 14 years and
had undergone right nephrectomy for renal cancer five years before. VTD ther-
apy was started (total 4 cycles) followed by double autologous HSCT obtaining
a VGPR. She remained in remission of disease for 14 months until mastopexy
breast surgery. Surprisingly the histopathological examination of the breast tis-
sue was consistent with diagnosis of plasmacytoma. Strangely, both the ultra-
sound and the breast MRI showed no nodular areas. Molecular examination
confirmed the presence of monoclonal lambda positive plasma cells achieved
through analysis of the rearrangement of the immunoglobulin heavy chain
genes by PCR.
Results: A subsequent disease restaging showed an unexpected massive
skeletal bone marrow and extramedullary involvement. PET/CT revealed patho-
logical accumulation in the femoral heads, left iliac bone, gluteal muscles,
pelvis. X-rays demonstrated multiple lytic lesions of right and left humerus,
pelvis and D2 vertebral wall. MRI showed massive effusion in the left iliac bone
with multiple lytic lesions extending up to gluteal muscles. She presented high
level of LDH and 30% of atypical bone marrow CD56 negative plasma cells.
She underwent radiotherapy on her pelvis and was treated according with PAD
regimen (4 cycles). Nowadays patient is currently undergoing therapy; autolo-
gous and allogenetic HSCT are being evaluated.
Summary and Conclusions: EM is prevalent in genomically defined high-risk
MM with shorter overall survival. Some autopsy studies have shown extraskele-
tal involvement in approximately 50-70% of patients with MM. EM disease
seems to be prevalent in patients treated with novel agents, although this find-
ing is not confirmed and could be due to the increased survival of patients with
new drugs. The mechanisms of extramedullary spread are poorly understood;
a decreased expression of integrins and loss of CD56 have been described,
which could cause disease dissemination. Several papers have described
relapses of MM occurring from different subclones of plasma cells from those
of initial diagnosis. Recently, it has been speculated the presence of Circulating
Myeloma Tumor Cells (CTCs), that constitute a subpopulation of clonal plasma
cells associated with aggressive disease. They are characterized by downreg-
ulation of adhesion molecules, might transit in the peripheral blood and colonize
other sites during the patients’ resting and remission period. One might ask
some questions: some recurrent MM could be firstly an awakening of dormant
MM circulating clones? Which are the mechanisms for hematogenous spread
and EM involvement? These and others are unanswered questions; interna-
tional collaborative trials are necessary to better understand EM dissemination
and discover optimal treatment.
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TAZ GENE FROM HIPPO PATHWAY IS OVEREXPRESSED IN POLY-
CYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA PATIENTS
M. Cacemiro1,* N. Nunes1, R. Tognon2, E. Souto3, F. Traina4, L. Pontes4,
L. Perobelli3, P. Prata4, B. Simões4, F. Castro1
1Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP, Ribeirão Preto,
2Universidade Federal de Juiz de Fora, Governador Valadares, 3Hospital Estad-
ual de Transplantes Euryclides Zerbini, São Paulo, 4Faculdade de Medicina
de Ribeirão Preto-USP, Ribeirão Preto, Brazil
Background: Polycythemia vera (PV), essential thrombocythemia (ET) and
primary myelofibosis (MF) are myeloproliferative neoplasms (MPN) character-
ized by the increase of mature hematopoietic cells of one or more of the myeloid
series proliferation. MPN may present theJAK2V617F mutation which occurs
in 95% of PV patients and 50% of ET and MF patients. The JAK2V617F muta-
tion constitutively active STAT3 transducer protein, which is related to apoptosis
resistance and myeloproliferation in MNP. Although all the molecular knowlegde
about MNP pathogenesis, these diseases do not have an efficient therapy.
Thus, more studies related to MPN pathophysiology and description of new
therapeutic targets, such as the molecules from Hippo pathway are relevant.
The Hippo signaling pathway has been defined as a tumor suppressor pathway
responsible for regulating the proliferation, differentiation and cell death. This
pathway is composed ofMST1/2, WW45, Lats1/2, Mob1 and YAP/TAZ proteins
present in mammals.
Aims: To compare the TAZ gene expression among PV, ET, MF patients and
controls (CTRL) subjects.
Methods: The leukocytes were obtained from peripheral blood of 23 PV
patients (median age=60 years; 13 men and 10 women), 21 ET patients (medi-
an age=62 years; 10 men and 11 women), 21 MF patients (median age=64
years; 16 men and 5 women) and 23 CTRL (median age=58 years; 6 men and
17 women). The leukocytes were separated by Voluven gradient method. The
RNA were extracted by Trizol® method and the cDNA were synthesized using
High Capacity cDNA reverse transcription kit®. The gene expression was
assessed by a real time PCR and the results were expressed as relative units
of expression (RUE). 
Results: Moreover, in PV patients the TAZ expression is higher in those
JAK2V617F-negative patients. 
Summary and Conclusions: The results indicate that TAZ gene may con-
tribute to PV and ET pathogenesis since TAZ is well known for their regulation
by the Hippo pathway acting as a transcriptional co-activator inducing expres-
sion of cell-proliferative and anti-apoptotic genes via interactions with specific
transcription factors. Supported by FAPESP process 2014/04234-9
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ABCB1 AND SLC22A1 MRNA EXPRESSIONS ARE INCREASED IN A
HOMOZYGOUS JAK2V617F CELL LINE TREATED WITH JAK INHIBITOR
G.W. Gomes1,* F.A. de Castro2, D.P.T. Nunes1, L.T. de Lima1, A.C. Rodrigues3,
R. Tognon Ribeiro4, E.M. Guerra Shinohara1
1Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências
Farmacêuticas, Universidade de São Paulo, Sao Paulo, 2Departamento de
Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Far-
macêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto,
3Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universi-
dade de São Paulo, Sao Paulo, 4Departamento de Farmácia, Faculdade de
Farmácia, Universidade Federal de Juiz de Fora/Campus Avançado, Gover-
nador Valadares, Brazil
Background: Pharmacokinetics of many anticancer drugs is affected by drug
transporters as ABCB1, ABCG2 and SLC22A1. These molecules are respon-
sible for cell uptake (SLC22A1) or efflux (ABCB1 and ABCG2) of severalxeno-
biotics and are widely distributed in many tissues. Several studies have shown
their role in resistance and toxicity to chemotherapeutic agents. Dysregulation
of JAK-STAT pathway is considered a hallmark of myeloproliferative neoplasms
(MPN), and disruption of this pathway may result from mutations such as
JAK2V617F. Therefore, therapies targeting the inhibition of JAK proteins have
been developed. However, the impact of JAK-STAT pathway inhibition over
ABCB1, ABCG2 and SLC22A1 gene expression in MPN cells has not been
investigated yet. 
Aims: To evaluate the effect of JAK-STAT pathway inhibition in the expression
of drug transporters ABCB1, ABCG2 and SLC22A1 in JAK2V617F positive cell
line HEL92.1.7.
Methods: Erythroleukemia homozygous JAK2V617F cell line HEL92.1.7 was
treated with 1 µM of JAK Inhibitor I (Merck/Calbiochem, Darmstadt, Germany),
an ATP-competitive inhibitor of JAK proteins, for 24h. Western blot was used
for verifying JAK-STAT pathway inhibition by inactivation of STAT-5. Quantitative
real time-PCR and flow cytometry analysis were used to assess ABCB1,
ABCG2 and SLC22A1 mRNA and protein expression, respectively, in JAK
inhibitor-treated cells and in vehicle-treated control cells.
Results: JAK-STAT pathway was inhibited by treatment with 1 µM of JAK
Inhibitor I for 24h, confirmed by non-detection of phosphorylated STAT-5.
ABCB1 and SLC22A1 mRNA expressions were increased after treatment
(median of 1.58 and 1.64 fold change, respectively), however, no difference
was observed between ABCB1, ABCG2 and SLC22A1 protein expression in
cells treated with 1 µM of JAK Inhibitor I for 24h and controls (P>0.05 for all).
Summary and Conclusions: Our data suggest that JAK-STAT pathway inhi-
bition could modulate mRNA expression of drug transporters ABCB1 and
SLC22A1 in MPN cells. Further studies with longer periods of treatment may
confirm this proposition and help to elucidate the effect of JAK-STAT pathway
in ABCB1, ABCG2 and SLC22A1 protein expression.
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INCIDENCE OF CALR MUTATIONS IN COHORT OF MPD PATIENCE FROM
RUSSIAN FEDERATION
P. Butylin1,* N. Matuhina1, A. Silutina1, N. Siordia1, E. Lisina2, O. Senderova3,
A. Zaritskey1
1Hematology Insitutte, North-West Federal medical research center (Almazov
institute), Saint-Petersburg, 2Hematology, Chuvash republic regional clinical
hospital, Cheboksary, 3Hematology, Irkutsk regional clinical hospital, Irkutsk,
Russian Federation
Background: Since discovery of mutation in 9th exon of the CALR gene in
2013, molecular diagnostics of ET and PMF by analysis of JAK2V617F, CALR
and MPL515L/K mutations became standard in many of the research centers
in the world. In this study we are for the first time reporting incidence of above-
mentioned mutations in patients from Russian Federation.
Aims: This study aimed to reveal incidence of mutation in calreticulin encoding
gene in patients with myeloproloferative deseases: PV, ET, PMF.
Methods: Patients: DNA from peripheral blood of 103 patients diagnosed with
PV, ET, and PMF tested for the mutations. Patients group was sex balanced
54F/49M. Average age was 52 years. For JAK2V617F and MPL515L/K detec-
tion allele specific real-time PCR with specific primers set were used (Genotech-
nology, Russia). CALR mutations were detected by Sanger sequencing of the
C-end coding region, as described earlier (1). 1. Nangalia J, et al., Somatic
CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N
Engl J Med. 2013 Dec 19;369(25):2391-405.
Results: Results of patints test presented in table. We did not found any cases
with simultaneous appearance of two mutations in one patient. PMF patient
with MPL515L mutation also have co appearence of BCR-ABL chimera. Cal-
reticulin mutations were mostly type1 -deletions of 52 bp (15 cases), type 2-
insertions of 5bp (4 cases) and deletions other than 52bp (2 cases). CALR
mutated patients were no younger than average – mean 57 years old (from 20
to 77). Also, we did not observe any significant correlation between type of the
mutation and age/sex/complications.
Table 1.
Summary and Conclusions: Incidence of the JAK2V617F, CALR and
MPL515l/L in studied patient group is similar to the one reported in European
centers. We did not find correlation of CALR mutation status with younger age,
as described previously. No thrombotic events were found in ET patients with
CALR mutations. 
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CALR GENE MUTATIONS IN MOROCCAN PATIENTS IN ESSENTIAL
THROMBOCYTHEMIA: FIRST REPORT
M. Kerbout1,* E.M. Mahtat2, S. Jennane2, W. Smaili3, A. Sefiani3, K. Doghmi4,
M. Mikdame5
1Clinical HematologyDepartment, 2Clinical Hematology, Military Hospital
Mohammed V, 3Département de Génétique Médicale,, Institut National d’Hy-
giène, 4Clinical Hematology Department, Mlitary Hospital Mohammed V, 5Clin-
ical hematology department, Military Hospital Mohammed V, Rabat, Morocco
Background: Since 2005, the discovery of the somatic mutation V617F in
exon 14 of the Janus Kinase 2 gene (JAK2) was the front-line molecular tool
for the diagnosis of Myelproliferative neoplasms (MPN) of which essential
thrombocythemia (ET). In addition, detection of genetic alteration in the 10th
exon of the myeloproliferative leukemia gene (MPL) plays a significant role in
the pathogenesis of ET. However, about 40% of patients did not carry any of
these markers and the diagnosis of ET remained a major challenge. Towards
the end of 2013, somatic mutations in the 9th exon of the gene encoding cal-
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reticulin (CALR) were revealed to be responsible of MPN in around 80% of ET
patients who don’t carry the JAK2 or MPL mutations. 
Aims: This discovery have improved and simplified the accuracy of diagnosis
of patients with ET worldwide, and opened the door to a better understanding
of the disease pathogenesis. In this study, we present the 1st mutational profiles
in CALR gene assessed in Moroccan Patients.
Methods: 25 Moroccan patients from Clinical Hematology Department of the
Military Hospital Mohammed V were reviewed for having ET. All patients had
a CBC with elevated platelet count; We searched magakaryocytes proliferation
at the bone marrow biopsy for only 8 patients. The bcr-abl transcript was neg-
ative for all patients. The mutational status for exon 10 of MPL gene has not
been evaluated in any of our patients. We evaluate somatic mutation V617F in
JAK2 gene and mutations in 9th exon of CALR.
Results: Patients ages were between 23 and 75 years, 13 of them were
female. Discovery circumstances ranged from fortuitous discovery to thrombotic
or hemorrhagic manifestations. Median platelet countat diagnosis was 1 027
578 /mm3. Molecular assessment of the somatic mutation V617F in JAK2 gene
was positive in eight, negative in 13 patients, 4 patients were not evaluated.
Among the 13 “JAK2 negative” patients mutations in 9th exon of CALR were
evaluated in 11 patients and were detected in four of them (36.3%). All the
variants found were insertion/deletion mutations; All mutations were found
between positions 1142 and 1157 in the coding DNA sequence (cDNA).
Patients with intermediate and high risk received therapy such as hydroxyurea
(13 patients), anagrelide (2 patients), pipobroman (4 patients) to lower the
platelet count.
Summary and Conclusions: CALR gene mutations discovery represented a
major milestone in the diagnosis of ET that would be highly considered in the
revision of the WHO classification of MPN. Up to date, comparative studies on
the treatment of CALR mutated patients with ET were not yet reported and fur-
ther studies should help to explore this area.
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ET BUT NOT PV ARE ASSOCIATED WITH POLYMORPHISM ARG399GLN
XRCC1 IN PATIENTS OF THE KRASNOYARSK TERRITORY
A. Gorbenko1,* M. Stolyar1,2, T. Subbotina1,2, E. Vasiliev3, I. Olkhovskiy1,4
1Krasnoyarsk Branch of the Federal State-Funded Institution «National
Research Center for Hematology» of the Ministry of Healthсare of the Russian
Federation, 2Siberian Federal University, 3Krasnoyarsk regional hospital, 4Kras-
noyarsk Scientific Center of the Siberian Branch of the Russian Academy of
Sciences, Krasnoyarsk, Russian Federation
Background: The associations between the Arg399Gln polymorphism in X-
ray repair cross-complementing gene 1 (XRCC1) gene and the risk of hema-
tological malignancies have been extensively investigated. In the subgroup
analysis by ethnicity and cancer types, significant association was found in
Asians but not in Europeans (Du L e.a. 2015 PMID: 25619474). No data on
any it association with Ph-negative myeloid neoplasms.
Aims: The purpose of this study was to evaluate the association between
XRCC1 Arg399Gln and Ph-negative myeloid neoplasms risk in patients of the
Krasnoyarsk Territory.
Methods: In this study was included 134 cases with ET -75 V617F JAK2 (+),
31 CALR(+) and 5 MPL(+), 91 patients was included with PV -79 V617F
JAK2(+). The control group (n= 114) consisted of healthy individuals. The
XRCC1 polymorphism was detected in DNA isolated from peripheral leucocytes
using PCR-based Taqman assay using a “iQ iCycler” 5.0. We used two pairs
of primers (F: GTA-AGG-AGT-GGG-TGC-TGG-ACT-GT; R: GTC-TGA-CTC-
CCC-TCC-AGA-TTC-C) and two probes (A allele: FAM-CTG-CCC-TCC-CAG-
AGG-TAA-GGC-CTC-BHQ1; G allele: HEX-CTG-CCC-TCC-CGG-AGG-TAA-
GGC-C-BHQ1).
Results: Our data are shown in the table. The additive model of Arg399Gln
was associated with Essential Thrombocytemia (ET) risk. Conversely, no sta-
tistical association was found with Polycythemia vera (PV).
Table 1.
Summary and Conclusions: The differences were found in the association
between the polymorphism PV and ET to suggest Arg allele of the Arg399Gln
polymorphism prevents the loss of homozygosity typical to PV.




A PRESENTING NEUTROPHIL COUNT MORE THAN 75% IS A PREDICTOR
OF THROMBOSIS AT DIAGNOSIS BUT IS ASSOCIATED WITH LESS
THROMBOSIS SUBSEQUENTLY IN PATIENTS WITH POLYCYTHAEMIA
VERA
G. Kam1,* M. Kam2, Z.Y. Myint1, H. Than1, G.C. Wong1, A. L. Ang1, R. Yiu1,
L.H. Lee1, C. Chuah1
1Department of Haematology, 2Division of Medicine, Singapore General Hos-
pital, Singapore, Singapore
Background: Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN)
characterised by elevated haemoglobin and thrombotic tendency. Leukocytosis
has been demonstrated to be a risk factor for thrombosis in PV. However, the
white cell subtype implicated in thrombosis in PV has not been evaluated. 
Aims: In this study we examined the role of presenting neutrophil levels in PV
patients with thrombosis.
Methods: We retrospectively reviewed the case records of 163 patients with PV
for thrombotic events in our institution’s MPN registry. This is an institutional
review board approved registry that utilises REDCap, an electronic data capture
tool for research studies. Thrombotic events considered were ischaemic heart
disease, cerebrovascular accident, peripheral arterial disease, retinal artery occlu-
sion, thrombosis of the splanchnic circulation and venous thromboembolism.
Results: Median age of diagnosis was 58years; 58.3% were male. 32 patients
presented with a thrombotic event at diagnosis of PV. 12.5% of events were
venous. Patients with a thrombosis at diagnosis were more likely to have risk
factors for atherosclerotic disease (31.3% vs. 8.4%, P=0.012), have a higher
presenting white cell count (15.2x 109/L vs. 13.6x 109/L, P=0.04) and to be
treated with cytoreduction (90.6% vs. 71.8%, P=0.026). Patients with a throm-
bosis at diagnosis had a higher presenting neutrophil percentage of 82% (vs.
76.4%, P=0.002) and median absolute neutrophil count (ANC) (12.1x 109/L vs.
10.1x 109/L, P=0.017) than patients who did not. Based on receiver operating
characteristic (ROC) analysis, a cut-off neutrophil percentage of 75% was
derived for further analysis. 80.6% of patients who presented with thrombosis
at diagnosis had a neutrophil count ≥ 75%, whereas 57.3% of those who did
not, had a presenting neutrophil count ≥ 75% (P=0.016). On logistic regression,
adjusting for gender, age ≥ 60 at diagnosis, prior thrombosis and presence of
atherosclerotic disease risk factors, a presenting neutrophil percentage ≥ 75%
(Odds ratio (OR) 3.36, 95% CI 1.25-9.03, P=0.016) and presence of athero-
sclerotic disease risk factors (OR 4.43, 95% CI 1.21-16.18, P=0.024) were pre-
dictors for thrombosis at diagnosis. Over a 5.4year median follow up, 31 throm-
botic events occurred in 28 patients. Six patients who presented with thrombosis
had subsequent events. Paradoxically, less patients who had a thrombotic event
on follow up had a presenting neutrophil percentage ≥ 75% than patients who
did not have thrombosis on follow up (34.6% vs 67.4%, p =0.002). Of patients
who had a thrombosis after diagnosis, 57.1% were on cytoreduction compared
to 74.8% of those who did not develop thrombosis (P=0.059). 10 and 20year
thrombosis-free survivals were better in patients with presenting neutrophil per-
centage ≥ 75% than those with lower presenting neutrophil counts: 91.4% vs.
47.6% and 64.9% vs. 35.7% (P=0.001) respectively. On multivariate analysis,
in a model including gender, age ≥ 60 at diagnosis, atherosclerotic disease risk
factors, prior thrombosis, use of cytoreduction, thrombosis at diagnosis and pre-
senting neutrophil ≥ 75%, a presenting neutrophil level ≥ 75% was significant
(Hazard ratio 0.25, 95% CI 0.11-0.6, P=0.002).
Summary and Conclusions: More patients who presented with a thrombotic
complication at diagnosis had a presenting neutrophil count ≥ 75%. A present-
ing neutrophil count ≥ 75% and presence of risk factors for atherosclerotic dis-
ease were predictors of thrombosis occurring at diagnosis. However, for follow
up thrombotic events, a presenting neutrophil ≥ 75% was associated with less
thrombosis.
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WT1 EXPRESSION IN PH-NEGATIVE MYELOPROLIFERATIVE DISEASES
N. Siordia1,* E. Lomaia1, P. Butylin1, N. Matyhina1, K. Bogdanov1, E. Lisina1,
A. Zaritskey1
1Hematology, Federal North-West Medical Research Centre, Saint-Petersburg,
Russian Federation
Background: Expression of Wilms tumor antigen (WT1), which encodes a
transcription factor, is significantly increased in tumor cells of the kidney, testes,
ovaries, breast and certain hematological malignancies. WT1 is overexpressed
in many patients with acute myeloid leukemia and in the absence of more spe-
cific molecular markers can be used for monitoring of minimal residual disease.
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The rate and significance of WT1 overexpression in chronic myeloproliferative
diseases (MPDs) currently remains unclear
Aims: The aim of this study was to evaluate the incidence of overexpression
of WT1 gene in MPDs.
Methods: Peripheral blood samples from 52 (male n= 33, female n=19) patients
with polycythemia vera (PV), essential thrombocythemia (ET) and primary or
post-PV/post-ET myelofibrosis were evaluated for WT1 expression. Patients’s
characteristics at the time of evaluation is presented in the table 1. WT1 expres-
sion was performed by quantitative PCR, using a standard set ProfileQuant
Wt1 kit, PCR analyzer «Rotor- Gene 6000”. Normal reference range in periph-
eral blood considered is 0.00-50.00 WT1/104 ABL copies.
Results: WT1 overexpression was observed in 25/52 (48%) patients. It was
found in all patients with myelofibrosis (primary or post-PV/post ET). No patients
with PV or ET have WT1 overexpression. The mean level of WT1 gene expres-
sion was 714 WT1/104 ABL copies in MF (range, 171-6000), 4.0 WT1/104 ABL
copies in PV (range 1.1-17), and 8.32 WT1/104 ABL copies in ET(range, 1.8-
14). We did not find any significant correlation of WT1 expression level with
either mutation status of Jak2, MPL and CALR genes or clinical data (age, gen-
der, DIPSS risk groups, median time from MF diagnosis).
Table 1.
Summary and Conclusions: WT1 gene was overexpressed in all MF, includ-
ing post-PV/post-ET cases, but was normal in PV and ET patients. It seems
that WT1 gene overexpression could be potential marker for prediction of bone
marrow fibrosis development in patients with PV/ET. Whether the level of
expression of WT1 is correlated to grade of fibrosis is a subject of our investi-
gation.
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MULTICENTER-RETROSPECTIVE ANALYSIS OF TURKISH PATIENTS
WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
G. Saydam1,* I.C. Haznedaroglu2, N. Akad Soyer3, D. Cekdemir4, M. Yilmaz5,
A. Unal6, O. Bilgir7, O. Ilhan8, F. Ozdemirkiran7, F. Sahin1
1Hematology, Ege University Hospital Internal Medicine, Izmir, 2Hematology,
Hacettepe Univ, Ankara, 3Hematology, Ege University Hospital Internal Medi-
cine, Bornova, 4Hematology, Sakarya EAH, Sakarya, 5Hematology, Gaziantep
Univ., Gaziantep, 6Hematology, Erciyes Univ, Kayseri, 7Hematology, Bozyaka
EAH, Izmir, 8Hematology, Ankara Univ., Ankara, Turkey
Background: Chronic Myeloproliferative neoplasms (CMPN) are Philadelphia-
negative malignancies characterized by a clonal proliferation of one or several
lineages. According to WHO classification, CMPNs include Polycythemia Vera
(PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF).
Aims: The aim of this report was to determine the demographic features, dis-
ease characteristics, JAK mutational status, treatment strategies, and survival
rates of 708 patients with CMPN from 8 centers in Turkey.
Methods: Across all of Turkey, 8 centers were enrolled in the study. We retro-
spectively evaluated 708 patients’ results with CMPN. 
Results: The JAK2V617F mutation was found positive in 75.11% of patients
with PV, in 51.5% of patients with ET and in 50.4% of patients with PMF. Throm-
bosis occurred in 20.65% of patients with PV, arterial in 21 (47.7%) cases and
venous in 23 (52.2%). Thrombosis was observed in 15.12% of patients with
ET, arterial in 30 (50.8%) cases, venous in 27(45.8%) and two (3.4%) patients
suffered both arterial and venous thrombosis. Approximately ten percent of
PMF patients suffered from thrombosis, arterial in 7 (6.7%) cases and venous
in 3 (2.9%). Bleeding at diagnosis occurred in 7.5% of PV patients, in 9% of ET
patients and in 10.4% of PMF patients. Six hundred and eight patients (85.9%)
had a cytoreductive therapy. The most common used drug was hydroxyurea
(75.1%). Hydroxyurea was used 79.3% of PV patients, 57.1% of PMF patients,
and 77.7% of ET patients in the first-line treatment. Interferon was used 5.1%
of PV patients, 1.9% of PMF patients, and 5.1% of ET patients. Cytoreductive
therapy was changed in 198 (28% of all) patients. In the second-line treatment,
the most common used drug was anagrelide (147 of 198 patients). Anti-platelet
therapy was used in 553 (78.1%) patients. Splenectomy was performed in 10
(1.4%) patients. Eight PMF patients (1.1% of all CMPN patients) were treated
with allogeneic stem cell transplantation. Progression to acute leukemia and
secondary myelofibrosis were observed in 0.6% and 11.3% of all patients,
respectively. The median follow- up was 38 months (0-322) and overall survival
(OS) was 86.7% at 10 years in all patients. Among the 213 PV patients, the
median follow- up was 3.5 months (0-322) and the OS was 89.7% at 10 years.
In 390 ET patients, the median follow- up was 35 months (0-280) and the OS
was 98.5% at 10 years. Among the 105 PMF patients, the median follow-up
was 15.5 months (0-229) and the OS was 82.5% at 10 years.
Summary and Conclusions: Our patients results is compatible the literature
except the frequency of JAK2V617F mutation in PV patients. Hydroxyurea was
the most common used cytoreductive therapy in our country. 
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INCREASED PLATELET COUNTS AT DISEASE DIAGNOSIS IS RELATED
WITH EARLY INTRODUCTION OF CYTOREDUCTICTION AND REDUCED
EVENT-FREE SURVIVAL IN YOUNG ADULT PATIENTS WITH ESSENTIAL
THROMBOCYTHEMIA.
E. Spanoudakis1,* C. Zagoridis1, S. Guliamtzi1, D. Margaritis1, I. Kotsianidis1,
1Democritus University of Thrace, Alexandroupolis, Greece
Background: ET is not such an innocent disease in young adults. Most throm-
botic events occur during diagnosis and almost half of the initially asymptomatic
patients will have an event during the course of their disease
Aims: Herein, we analyzed retrospectively the medical records of 33 ET
patients diagnosed below the age of 45 years and followed in a single institution
from 1992 to 2014.
Methods: Management was left at the discretion of the treating physician but
antithrombotic agents were used from disease diagnosis in all patients. Among
33 young adult patients 11 were males and 22 females. 18 patients were fol-
lowed for a median period of 94,5 (range 45-178) months and left untreated
and they were included in group A. While cytoreductive treatment was intro-
duced in 15 patients included in group B. Among 15 treated patients cytore-
duction was introduced from disease diagnosis in seven patients and in eight
during the course of their disease after a median period on observation of 36
months (ranging from 6 to 168).
Results: We separated our patients into two groups according to the need to
start any cytoreductive treatment and try to discover patient’s characteristics at
diagnosis that can predict the early use of cytoreductive treatment.
Splenomegaly of any grade was palpated in 3/18 (16.5%) patients in group A
and in 2/15(13%) in group B, P=0,796. Although hematocrit levels were equal
between the two groups [42,7%(34,7-47,6) in group A and 40,7%(37,3-46) in
group B, P=0,84] as were also and the leucocyte counts [ 7,85 (5,6-13,2) X 103
pcm in group A and 9,73 (4,7-11,7) X 103 in group B P=0,6], the median values
of platelet counts at diagnosis was significantly higher in group B compared to
group A [805(490-2300) X 109 pcm vs 604,5(490-921) X 109 pcm, P=0,012].
Fibrosis (grade I) at the initially performed bone marrow biopsy was met at
higher percentages in patients allocated in group B 40% (6/15) in group B
and11% (2/18) at group A, P=0,03. JAK2V617F was detected in 40% (6/15) in
group B and 50% (9/18) in group A, P=1. According to the IPSET-thrombosis
scoring system in group A most patients had low thrombotic risk 10/18, 7/18
had intermediate thrombotic risk and 1/18 had high thrombotic risk. In group B
7/15 had low thrombotic risk, 3/15 intermediate and 5/15 had high thrombotic
risk. In the total cohort of 33 young ET patients platelet counts at disease diag-
nosis can predict reduced Event free Survival (EFS). As an event were consid-
ered thrombohemorhagic complications, development of myelofibrosis and the
need to start cytoreductive treatment. 10 year EFS was for patients with platelet
counts<600x 109 pcm 89% for platelet counts between 600-800 X 109 pcm
66% and for platelet counts>800 X 109 pcm was 22%, P=0.003, Kaplan-Mayer,
LogRANK test. On the contrary the presence of grade-I fibrosis was not asso-
ciated with reduced EFS.
Summary and Conclusions: In young ET patients increased platelet counts
at disease diagnosis can predict an eventful disease journey with early need
for the use of cytoreductive treatment and reduced EFS.
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INCIDENCE AND CLINICAL CORRELATION OF CALR MUTATIONS IN
PATIENTS WITH JAK2/MPL NEGATIVE ESSENTIAL THROMBOCYTEMIA
(ET) AND PRIMARY MYELOFIBROSIS (MF). A SINGLE INSTITUTION
COHORT REVIEW.
H. Saturnino1, M. Coucelo1, M. Mendes1,* G. Ferreira1, M. Duarte1, L. Araujo1,
J. Almeida1, M. Ribeiro1, B. Celeste1
1Serviço de Hematologia, Centro Hospitalar Universitário de Coímbra, Coimbra,
Portugal
Background: The recent description of CALR mutations occurring in ET and
MF greatly contributed to the diagnostic evaluation of ph- Myeloprolyferative
Neoplasms (MPN). The CALR gene encodes the endoplasmic reticulum Ca2++-
binding chaperone-Calreticulin. Exon 9 CALR somatic insertions and deletions
have been reported and the most frequent variants are Type-1, 52-bp deletion
(p.L367fs*46), and type-2, 5-bp TTGTC insertion (p.K385fs*47), representing
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about 80% of the cases. These mutations have also been reported as favorable
prognostic factor on ET thrombosis-free patients, particularly the type-1.
Aims: To evaluate CALR, JAK2 and MPL mutations in a group of ET and MF
patients and to correlate clinical and analytical data. 
Methods: We actualized a retrospective analysis of 115 patients (pts) diagnosed
MPN: 88 ET and 27 MF (according to WHO2008 criteria), with a mean follow-
up time of 8 years (3 moths-31 years). JAK2V617F mutation was assessed by
ASO-PCR and real-time quantitative PCR, mutations in exon 10 MPL and exon
9 CALR by PCR-sequencing in blood or bone marrow samples.
Results: In ET group (39males/49females), 59,1% (52) were JAK2 positive;
20,5% (18) CALR 4,5% (4) MPL and 15,9% (14) were negative for
JAK2/CALR/MPL- “triple negative”. The CALR type-1 mutation was detected
in 11/18, the type-2 in 6/18 and one patient harbored the p.K375Rfs*49 muta-
tion. Comparing JAK2, CALR and triple negative pts, CALR had a male dom-
inance and higher mean platelet (PLT) counts (P=0.02), JAK2 pts had higher
hemoglobin (Hb) levels (P=0.04) and triple negative pts presented at younger
age (P=0.002). Analyzing the CALR subgroups, there is a trend to an older
age and a higher PLT count in type-2 mutation group and an incremental dif-
ference on PLT counts comparing to JAK2 (P<0.001). There were no differ-
ences in leukocyte (WBC), serum ferritin and erythropoietin levels. Regarding
hematological response to cytoreduction we did not observe differences within
CALR pts. Thrombosis occurred in 24/88 ET, 18 previously or at diagnosis;
21/52 JAK2: 2 of splanchnic veins both associated to prothrombotic factors (1
HTZ Factor V Leiden (FVL), 1 HTZ PRT20210G/A/FVL); 3/18 CALR all type-
1 and 2 associated to prothrombotic factors FVL (1) and HTZ PRT20210G/A
(1). One CALR (type-2) and 4 JAK2 pts progressed to MF, one of them to AML.
Eleven patients deceased: 6 JAK2, 3 CALR (type-1) and 2 triple negative. The
MF pts (15M/12F) were 55,6% (15) JAK2, 33,3% (9) CALR : 6/9 type-1, 3/9
type-2; 7,4% (2) MPL and 3,7%(1) triple negative. About 70% of JAK2 pts had
an allelic burden >50%. We observed a higher WBC count in JAK2 compared
to CALR (P=0.04) and no differences in Hb, PLT, serum ferritin and EPO values.
Thrombosis occurred in 3 JAK and 1 CALR type-1. There were 3 deaths 2
JAK2 and 1 CALR type-1.
Summary and Conclusions: In this cohort of MPN, 58,2% (67/115) have
JAK2V617F mutation, 23,5% (27/115) CALR and 5,2% (6/115) MPL. In 13,1%
(15/115) we found no JAK2/MPL/CALR mutation. Exon 9 CALR mutations, the
second most prevalent marker in ET pts, are associated to higher PLT counts
and lower Hb levels comparing to JAK2. Comparing CALR subgroup, ET pts
with type-1 mutations had more thrombotic events, most of them in association
to prothrombothic factors while type-2 presented with higher PLT counts and
only a type-2 pt progressed to MF. There were no differences in cytoreduction
response. The impact of the different type of CALR mutations on natural history
of ET and MF pts are not yet completely elucidated. Nevertheless, these muta-
tions constitute a molecular marker of ph- NMP and offer an important tool in
the diagnostic pathway ET and MF. 
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CALRETICULIN V/S JAK2 MUTATION CHARACTERISTICS IN ESSENTIAL
THROMBOCYTOSIS IN ASIAN AND NON-ASIAN POPULATION: A META-
ANALYSIS 
H.R. Kourie1,* L. Ameye1, M. Paesmans1, D. Bron1
1Jules Bordet Institute, Brussels, Belgium
Background: 2014 was marked in myeloproliferative neoplasms by the dis-
covery of Calreticuline mutation in essential thrombocytosis and primary
myelofibrosis. Many papers were published describing the clinical, biological
and epidemiological characteristics of this mutation compared to JAK2 mutation
in ET. A meta-analysis of these studies was necessary to confirm the different
characteristics of this new mutation in Asian and non-Asian populations.
Aims: The aim of this study is to evaluate the epidemiological, clinical and bio-
logical characteristics of patients with essential thrombosis having JAK2 or
Calreticuline mutation and to compare the particularity of these mutations in
Asian and non-Asian population. 
Methods: 8 studies published from December 2013 to October 2014 met the
inclusion criteria of this meta-analysis: three of them in Asian population and
five in non-Asian population. More than 2307 patients diagnosed having ET
either with Calreticuline or JAK2 mutation were included. The epidemiological,
clinical and biological characteristics of those patients at diagnosis (age, sex,
hemoglobin level, white blood cells count, platelet counts, risk of thrombosis
and hemorrhage, transformation to myelofibrosis or leukemia ) were compared
according to the positivity of JAK2 or Calreticuline mutation and to the race
(Asian and non-Asian).
Results: The incidence of Calreticuline is 25% in ET patients in Asian and
non-Asian subgroups. JAK 2 mutated ET patients are older than Calreticuline
mutated patients with a mean difference of 6.9 years in all included patients,
5.3 years in Asians and 8.5 years in non-Asians. JAK2 mutated patients are
less likely to be men when compared to calreticuline mutated patients in non-
Asians with an OR =0.49; this OR was 1 in Asians. Hemoglobin level and white
blood cell count was higher in JAK2 mutated patients compared to Calreticuline
mutated patients in all sub-groups, while platelet count in JAK2 mutated
patients was significantly lower. The risk of thrombosis was higher in JAK2
mutated patients compared to Calreticuline mutated patients at diagnosis and
during the follow-up in all sub-populations with an OR>2 in all groups. The
transformation to primary myelofibrosis was lower in JAK2 mutated patients,
while there was no-significant difference in leukemia transformation, presence
of splenomegaly at diagnosis and risk of hemorrhage.
Summary and Conclusions: With those specific characteristics, Calreticuline
mutation will probably be added as diagnostic criteria of ET and will be considered
a new prognostic factor affecting the treatment and the management of ET.
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TWO NOVEL CALRETICULIN MUTATIONS IN A TURKISH PATIENT WITH
PRIMARY MYELOFIBROSIS: C.1116DELA AND C.1120A>C 
S. Güvenç1,* V.S. Hançer2, N. Uslu1, M. Arat3, R. Küçükkaya1
1Hematology, 2Molecular Biology and Genetics, Istanbul Bilim University,
3Hematology, Florence Nightingale Hospitals, Istanbul, Turkey
Background: With the discovery of somatic frameshift mutations in exon 9 of
the calreticulin (CALR) gene, approximately 90% of myeloproliferative neo-
plasm (MPN) patients have gained a chance of genetic diagnosis. CALRmuta-
tions were first identified exclusively in JAK2-MPL negative essential thrombo-
cytemia (ET) and primary myelofibrosis (PMF) at a rate of 60-88%, accounting
for 1/4 to 1/3 of all patients with ET and PMF. CALR mutations that reported in
the literature, consist of somatic insertions, deletions or both which always
leading to an one base pair shift in the open reading frame and produce a
novel C-terminal amino acid sequence that impair the function of calreticulin.
As of today, more than 50 different types of mutations have been reported.
The 2 most common mutations accounting for 85% of mutated cases are either
a 52-bp deletion (Type 1; c.1099_1150del; L367fs*46; 44%–53% of cases) or
a 5-bp insertion (Type 2; c.1154_1155insTTGTC; K385fs*47;32%–42% of cas-
es). The remaining 15% include various other infrequent mutations that are
often unique or found in a few patients.
Aims: Here we present another two CALR mutations in one patient with PMF
that is not reported before.
Patient: The patient is a 46 year old man who is suffered from low back pain
that have started 6 months ago. MRI scan of lumbosacral region revealed
sacroileitis at the left side and he referred to a rheumatologist for further inves-
tigations. Anemia (hgb 10,8 g/dl) and thrombocytosis (700x109/L) with high
LDH level (351 U/l) were found in initial tests. The other tests for a possible
rheumatologic disease including HLA-B27, were all negative and the patient
was admitted to hematology clinic. Physical examination was almost normal
with no sign of organomegaly. Spleen size was also normal in the abdominal
ultrasound. Peripheral blood smear showed dacrocytes, occasional myelocytes
(1%) and metamyelocytes (1%). Bone marrow biopsy showed diffuse, grade
3-4 reticulin fibrosis with atypical proliferation of megakaryocytes and increased
cellularity consistent with PMF. BCR-ABL, JAK-2 V617F, and MPL 515L/K tests
were found to be negative.
Methods: Genomic DNA was extracted from whole blood using a commercial kit
(HibriGen Biotech R&D, Istanbul, Turkey). Exon 9 of the CALR gene was amplified
using Forward ACAACTTCCTCATCACCAACG and Reverse GGC-
CTCAGTCCAGCCCTG primers. PCR reaction was performed using 2X PCR
master mix (HibriGen Biotech R&D, Istanbul, Turkey), primers and 25-30 ng
genomic DNA. Direct Sanger sequencing of amplified fragments were performed
using BigDye Terminator Cycle Sequencing kit v3.1 and an ABI3130xl sequencer
(Applied Biosystems, Foster City, CA, USA). Our results were evaluated using
the BLAST (http://www.ncbi.nlm.nih.gov/BLAST) and SeqScapeTM v2.0 (Applied
Biosystems, Foster City, CA, USA) software packages. Mutation was confirmed
on a second DNA sample isolated from a duplicate tube of blood followed by
sequencing in both forward and reverse directions. All nucleotide numbers refer
to the wild type cDNA sequence of CALR (NM_004343) as reported in Ensembl.
Results: Electropherogram of CALR exon 9 of the patient was shown in figure
1. Due to a 1bp deletion in codon 372 c.1116delA (D373fs*57) and c.1120 A>C,
reading frame has changed in codon 373 and there after. 
Figure 1.
Summary and Conclusions: To date 55 different CALR mutations have been
described. Here we report two new CALRmutations [1bp deletion; c.1116delA
(D373fs*57) and c.1120 A>C] in a same patient with PMF. These mutations
have occured in exon 9 of the CALR gene, and changed the aminoacid
sequence of C domain starting with aminoacid residue 372; which will interfere
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with calcium binding capacity of the molecule. The identification of new CALR
mutations will improve our understanding of the pathophysiology of MPN, and
will help to find new theraupetic targets.
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ESSENTIAL THROMBOCYTEMIA IN CHILDREN – CLINICAL, HEMATO-
LOGICAL, MOLECULAR AND THERAPEUTICAL ASPECTS – SINGLE
CENTER EXPERIENCE
A. Colita1,2,*, M. Asan1, C. Dobrea3, M. Dragomir4, D. Coriu5, C.V. Arion6,
A. Colita7,
1Pediatric Hematology & BMT, Fundeni Clinical Institue, 2Fundeni Pediatric
Clinic, Carol Davila University of Medicine & Pharmacy, 3Hematology, 4Molec-
ular Biology, Fundeni Clinical Institue, 5Hematology, Carol Davila University of
Medicine & Pharmacy, 6Fundeni Pediatric Clinic, Fundeni Clinical Institue,
7Hematology, Coltea Hospital, Bucharest, Romania
Background: Essential thrombocytemia (ET) is an extremely rare disease in
children, with an incidence of 1-4 cases/10 million people/year. ET can be pres-
ent as sporadic or familial disease and exclusion of secondary thrombocytemia
is mandatory. There are few data about ET in children. Some studies showed
a lower incidence of JAK2 mutation in children compared to adults.
Aims: The purpose of this study is to evaluate the clinical manifestations and
follow-up of children with ET.
Methods: We performed a retrospective study of 5 children with ET, followed
between 2008-2014 in the Fundeni Clinical Institute, Bucharest. Diagnosis con-
sisted of: a) tests to exclude secondary thrombocytosis; b) tests to exclude
other malignant thrombocytosis and c) specific tests: JAK2V617 PCR analysis,
calreticulin, C-MPL, bone marrow examination, cytogenetic analysis. The WHO
2008 criteria for ET were used. Thrombopilia screening was performed with –
PC, PS, AT, APC-R analysis; in case of positive screening for thrombophilia,
PCR assay for MTHFR 677, FVL, FII was recommended.
Results: Five patients, 4F/1M were diagnosed with ET at ages 7- 15 years
(median 8 years). One case was familial ET and 4 were sporadic ET. The
platelet count at diagnosis was 700-2500x 109/L. Three cases showed extreme
thrombocytemia (>900x109/L), 2 cases moderate thrombocytemia (700-
900x109/L), one case with mild thrombocytemia (450-700x109/L). Clinical man-
ifestations at diagnosis: 2 cases had cephaleea, 1 case cephaleea and severe
abdominal pain, 1 with cerebral thrombotic event and hemiparesis and 1 asymp-
tomatic case. Three out of 5 cases were JAK2 positive. BM biopsy revealed in
all cases hypercellularity, giant megakaryocytes, absence of reticulin fibrosis.
The karyoype was normal in all cases. One case was MTHFR heterozygote.
Treatment consisted of α-Interferon followed by anagrelide, due to severe symp-
toms persistence, in a JAK2 negative case, first-line anagrelide in all 3 JAK2
positive cases and hematologic monitoring in the ET familial case. Anagrelide
treatment reduced the platelet count in all cases, and controlled the symptoms,
but 1out of 4 patients developed ischemic stroke despite treatment. No sec-
ondary effects were recorded.
Summary and Conclusions: We observed severe clinical symptoms in 4/5
pediatric ET cases. Some pediatric studies suggested that JAK2 positive cases
have a severe course and could be considered distinct disorders. It is necessary
to asses which child with ET really needs cytoreductive therapy, as already
defined for adults.
PB1914
TYPE 1 CALR MUTATION IMPROVES DIAGNOSIS OF PREFIBROTIC
IDIOPATHIC MYELOFIBROSIS (MF0)
B. Martino1,* C. Labate2, D. Ielo1, D. Rotilio1, C. Mammì2, C. Laganà2, F. Ronco1
1Hematology, 2Genetic, Ospedali Riuniti, Reggio Calabria, Italy
Background: CALR mutation discovery improves essential thrombocythemia
(TE) and idiopathic myelofibrosis (MI) diagnosis. Over 36 CALR type mutations
have been found, but only two types (type 1: del52bp and type 2: ins5bp) are
present in 80% of the patients. It seems that type 1 mutation is frequently asso-
ciated to fibrosis and that it has a worse impact on overall survival than type 2
mutation. Diagnosis of a prefibrotic state (MF0) presents histological diagnostic
difficulties. MF0 has a worse prognostic impact than TE with regard to throm-
botic risk, and a higher risk towards MI and acute leukemia evolution. For this
reason a new type of identification of a group of patients is very useful. 
Aims: The aim of this study was to evaluate CALR mutations in patients with
MI and TE JAK2-negative and MPL-negative and the type of CALR mutations
frequently associated to MF0.
Methods: We studied 47 patients CALR-positive, 21 with TE and 26 with MI.
12 out of 26 with MI were classified as MF0 on the basis of the histological
examination of bone marrow biopsy. Debut features have been evaluated for
WBC, Hb, PLT, LDH, peripheral CD34, spleen. Fragment analysis of PCR exone
9 CALR gene was performed.
Results: Type 1 mutation was present in 6 out of 21 patients (30%) with TE
and in 19 out of 26 patients (73%) with MI. In the subgroup of MF0, 9 patients
out of 12 (75%) were positive to del52bp. Conversely, type 2 mutation was
present in 15 patients out of 21 (70%) with TE and in only 7 patients out of 26
(27%) with MI. Of the 12 patients with MF0, 3 patients (25%) were positive to
ins5bp. Statistical analysis was negative for WBC, Hb, PLT, LDH, peripheral
CD34 and spleen and not statistically significant between these 3 groups of
patients.
Summary and Conclusions: It was recognized that CALR mutation has a
better impact with respect to the complications of myeloproliferative neoplasm
Ph1 negative. It is still unclear the role of del and ins mutations of CALR gene.
In our experience, type 1 mutation is more representative in “fibrotic” phenotype
as it is demonstrated the higher frequence of del 52bp in MF0 patients than in
MI patients. This allowed us to better identify MF0 clinical features, in that a
particular clinical attention for MF0 is required, being different from TE.
Keywords: MF0, CALR, CALR mutations, TE
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TET2 MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY
MYELOFIBROSIS
C. Turan1, S. Güvenç1,* V. S. Hançer2, F. Hindilerden1, M. Arat3, R. Küçükkaya1,
1Hematology, 2Molecular Biology and Genetics, Istanbul Bilim University,
3Hematology, Florence Nightingale Hospitals, Istanbul, Turkey
Background: Myeloproliferative neoplasms other than CML are grouped as pol-
icytemia vera (PV), essential trombocythemia (ET) and primary myelofibrosis
(PMF). By the identification of JAK2617f mutation in 2005; the explanation of the
clonal proliferation in 90-95% of PV, 50% of ET and 50% of PMF have been pos-
sible. Thereafter JAK exon-12 mutations for PV and MPL mutations for ET and
PMF have been defined. However the clonal proliferation in approximately half
of the ET and PMF cases have been undetermined. One of the many mutations
which could have a role in the pathogenesis is TET2 mutations. TET2 mutations
were found positive in 15% of PV, 4-11% of ET and 19% of PMF patients. Some
studies also showed that TET2 mutations have prognostic value.
Aims: Our aims are the determination and clinical relevance of TET2 mutations
in patients with ET and PMF which are following in our clinic. 
Methods: 35 ET ve 10 PMF patiens are included according to WHO criteria.
Patients’ demographic informations, clinical and laboratory findings were reg-
istered. DNAs were isolated from venous blood samplings and all exons of the
TET2 gene were analyzed by Sanger based sequencing method. Informed
consent was obtained from all patients. In addition to descriptive statistics,
datas were evaluated for the comprasion of two groups with t test, chi-square
test and Odds Ratio.
Results: TET2 mutations were found in 47,5% (16/35) of ET patients and 70%
(7/10) of PMF patients. Six mutations were defined: I1762V, M1907T, L1721W,
H1778A, C1298Y and Q1828X. Of these, L1721W and I1762V have possibility
of being a genetic polymorphism. The frequency of TET2 mutation was not sta-
tistically different between sex and age. We demonstrated a correlation between
initial spleen size and TET2 mutations for patients with ET (P=0.011). Increased
bone marrow fibrosis is also found in bone marrow biopsy examination in TET2
mutation-positive ET patients (P=0,011). Furthermore, complications including
arterial thrombosis and bleeding are found more frequent in TET2 mutations
positive ET and PMF patients (for ET relatively OR:2,59, for PMF relatively
OR:1,7, OR:1,6). Togetherness of JAK2V617F and TET2 mutations associates
bigger spleen size (P=0,001) and increased risk of arterial thrombosis and
bleeding in patients with ET and PMF (for ET, relatively OR:3,85, OR:2,8; for
PMF, relatively OR:3,67, OR:3,67). 
Summary and Conclusions: We herein found higher rates of TET2 mutations
in patients with ET and PMF. Positivity of TET2 mutations are correlated with
especially spleen size and the rate of fibrosis for patients with ET; and these
mutations increase the risk of arterial thrombosis and bleeding. For patients
with PMF, positivity of TET2 mutations increase spleen size and the risk of arte-
rial thrombosis and bleeding. Togetherness of JAK2V617F and TET2 is asso-
ciated with increased risk of complications. We conclude that to know the TET2
mutations in ET and PMF can give information about disease progression and
complications thus may identify a high-risk subgroup of MPN patients. 
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VORINOSTAT MAY OFFER LONG TERM CONTROL OF DISEASE IN
THERAPY RESISTANT ESSENTIAL THROMBOCYTHAEMIA
S. Alimam1,* D. Radia1, M.F. McMullin2, H. Hasselbalch3, C.L. Andersen3,
C. Harrison1
1Department of Haematology, Guy’s & St Thomas’ NHS Foundation Trust, Lon-
don, 2Department of Haematology, Belfast City Hosptial, Belfast, United King-
dom, 3Department of Haematology, Roskilde University Hospital, Roskilde,
Denmark
Background: Vorinostat, a histone deacetylase (HDAC) inhibitor has shown
promise in a number of haematological malignancies including myeloma, lym-
phoma and myelodysplastic syndromes. Inhibition of histone deacetylases leads
to arrest of tumor cell growth, differentiation and increased apoptotic cell death.
The role of HDAC inhibitors in myeloproliferative neoplasms were described by
Guerini et al (2008) who demonstrated the arrest of proliferation in polycythaemia
vera (PV) and essential thrombocythaemia (ET) haemopoietic cells.
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Aims: We describe our experience using Vorinostat as an alternative agent in
therapy resistant ET.
Methods: A phase II study evaluating vorinostat in ET and PV reported early
discontinuations due to adverse events, and poor tolerability (Andersen et al
2013). Two patients at our institution continued vorinostat in a compassionate
use programme following this phase II study. We describe herein their on-going
responses.
Results: Patient 1, a 54 years old male with CALR positive ET since 2001
complicated by a left internal capsule infarct, chronic kidney disease and leg
ulcers whilst on hydroxycarbamide (HU). Despite dose escalation he was unre-
sponsive to standard therapy with HU and anagrelide (ANA). On initiation of
vorinostat 400 mg daily, his Haemoglobin (Hb) concentration was 103g/L (130
– 150g/L), leukocyte count 12.3x 109/L (4.0 – 11.0x 109/L), platelet count was
978x 109/L (150-400x 109/L), and creatinine was 151 umol/L (59-104 umol/L)
(EGFR 42). Shortly following commencing on Vorinostat, there was a notable
decline in his renal function to 201umol/L (EGFR to 29), thus a dose reduction
to 300 mg daily was made with satisfactory control of platelet count. The only
side effect he reported was dysgeusia, which did not impact on his activities of
daily living. He has now been on Vorinostat for 51 months; over this time, the
vorinostat dose was gradually reduced with overall stable platelet count control.
His current maintenance dose is 100 mg/200 mg alternate days with a platelet
count of 367x109/L at last clinic visit. Renal function has remained stable
throughout therapy; the most recent creatinine level was 171umol/L (EGFR
36). The second patient, a 53 year old male also had CALR positive ET, diag-
nosed in 2004. He had a history of a previous cerebrovascular accident and
was symptomatic from his ET; his main complaints were profound pruritus and
fatigue. Both blood counts and symptoms were resistant to treatment with
busulphan, HU, interferon and ANA. When vorinostat was initiated his Hb con-
centration was 128g/L, leukocyte count 5.3x109/L and an unstable platelet
count that ranged between 315 – 947x109/L. To date the patient has been on
vorinostat 52 months with minimal side effects. Vorinostat 300mg/400mg alter-
nate days has reduced his symptom burden and maintained the platelet count
below 800x 109/L with no thrombotic or haemorrhagic events. Renal function
has remained stable; creatinine level on commencing therapy was 77umol/L
(EGFR 92) increasing to 104umol/L (EGFR 64) at last clinical visit.
Summary and Conclusions: Although displaying two contrasting clinical
courses on vorinostat, both patients have demonstrated a prolonged clinical
response with symptom and platelet count control. Therefore, we conclude
that vorinostat may offer selected patients resistant to standard therapy an
alternative agent in ET when options are often extremely limited.
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UTILITY OF NEXT-GENERATION SEQUENCING FOR INTEGRATED
MOLECULAR PROFILING OF PRIMARY MYELOFIBROSIS USING ION
TORRENT PGM SYSTEM
V. Shivarov1,* M. Ivanova2, E. Naumova2
1Laboratory of Clinical Immunology, Sofiamed University Hospital, 2Department
of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria
Background: In the last decade a number of genes have been reported to be
recurrently associated with primary myelofiborsis (PMF). While some mutations
such as JAK2 V617F and MPL exon 10 mutations are easily detectable by
conventional molecular genetics methods other mutations are more difficult for
screening because of lower frequency and being scattered along large genomic
ranges. On the other hand, newly developed approaches for next-generation
sequencing (NGS) provide an affordable solution for targeted multiplex rese-
quencing of up-to several hundreds of amplicons.
Aims: Here, we aimed at the development and validation of a novel custom
panel for targeted resequencing of PMF samples using the Ion PGMTM System
(Ion Torrent, USA).
Methods: We designed a pool of 424 primers for amplification of 212 amplicons
covering 99.46% of the exonic regions of 9 human genes as follows: ASXL1,
EZH2, CALR, RUNX1, SETBP1, SF3B1, SRSF2, TET2 and U2AF1. Initial test-
ing of the panel performance was done on Ion PGMTM machine using PGMTM
316 v2 chips on 8 DNA samples from PMF patients (6 males, 2 females, median
age 61.5 years). Sequences alignment, variants calling and annotation were
performed using Ion Reporter software.
Results: We identified a total of 22 nonsynonymos somatic coding variants in
7 out of 8 samples. The most frequently mutated gene was TET2 (6 mutated
samples out of 8). Two patients had mutations in SRSF2, and CALR, EZH2
and SETBP1 were found mutated in one sample each. No mutations in RUNX1,
SF3B1 and U2AF1 were found. Overall, mutations rate was consistent with
previous reports on PMF molecular profiling.
Summary and Conclusions: This small proof-of-concept study confirms the
feasibility of Ion Torrent systems for resequencing of clinically relevant muta-
tions in myeloid malignancies such as PMF. It can be particularly useful in
cases without the most frequent clonal markers in PMF such as JAK2, MPL
and CALR mutations.
Acknowledgements: The authors are thankful to Dr. Nina Petkova and Dr.
Evgenii Hadzhiev for providing the clinical samples as part of the project
ID_09_157 (National Science Fund, Bulgaria).
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HYPEREOSINOPHILIA: A CENTER’S EXPERIENCE
I. Conde1,* D. Alves1, S. Matos2, B. Polo1, E. Espada1, A. Ferreira1, S. Silva1,
I. Pereira1, M. Neves1, H. Martins1, S. Mendes1, J. Amaral1, A. Alho1, F. Velosa1,
S. Valle1, C. Lopes1, M.J. Costa1, G. Esteves1, C. Martins1, F. Lourenço1,
R. Moreno1, L. Guerra1, J. Raposo1, J. Alves do Carmo1
1Hematology and Bone Marrow Transplantation, Hospital de Santa Maria,
2Genomed, Molecular Medicine Institute, Lisbon, Portugal
Background: Hypereosinophilias comprise a very heterogenous group of
haematologic alterations. They are usually secondary to diseases affecting
various organ systems, although they may also have clonal or idiopathic aeti-
ologies. The differential diagnosis is crucial and has significant implications
that affect the therapeutic decision. According to the World Health Organization
Classification (WHO) 2008, clonal hypereosinophilias are included in lymphoid
and myeloid neoplasms associated with eosinophilia and platelet-derived
growth factor receptor alfa (PDGFRA), platelet-derived growth factor receptor
beta (PDGFRB) or fibroblast growth factor receptor 1 (FGFR1) abnormalities.
Screening for rearrangements of these genes to document clonal eosinophilias,
in which the tyrosine kinase inhibitor Imatinib has demonstrated effectiveness
as a first-line agent, is fundamental since the treatment of reactive hypere-
osinophilias and idiopathic Hypereosinophilic Syndrome (HS) is, respectively,
that of the underlying condition and systemic corticosteroids.
Aims: Analysis of patients with peripheral blood (PB) or bone marrow (BM)
hypereosinophilia screened for PDGFRA and PDGFRB gene rearrangements
and evaluation of response to treatment.
Methods: Retrospective analysis of patients with PB (>1500/uL) or BM (>5%)
hypereosinophilia screened for PDGFRA and PDGFRB gene rearrangements,
between 2008 and 2014.
Results: PDGFRA and PDGFRB gene rearrangements were screened in 23
patients with hypereosinophilia: of these 12 had secondary aetiologies and 11
were primary. Of the secondary eosinophilias, 4 were due to parasitic infesta-
tion, 4 allergic, 2 lung diseases, 1 systemic mastocytosis and 1 T cell lym-
phoma. Of the primary eosinophilias (11): 4 patients had PDGFRA rearrange-
ments, 2 of them associated with T-ALL; 2 had PDGFRB rearrangements; 3
had HS; 1 had chronic eosinophilic leukemia and 1 myeloproliferative neo-
plasm. Out of the 6 patients with PDGFRA or PDGFRB rearrangements, 1 died
before starting treatment, 1 had no criteria for therapy iniciation and all 4 treated
with Imatinib (100-400mg/day) had good tolerance and hematologic response
with 2 achieving molecular response. The median eosinophil count at presen-
tation was 1780/uL (Q1 382.5; Q2 1787.5).
Summary and Conclusions: Our data is in agreement with the literature
regarding the incidence of primary hypereosinophilias and the therapeutic effi-
cacy of Imatinib, with response rates >80%.
Disclosure of Interest: none declared
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HOW DIAGNOSTIC AND THERAPEUTIC APPROACHE CHANGED IN THE
LAST DECADES IN THE PHILADELPHIA NEGATIVE MPN PATIENTS OF
THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)
L. Gugliotta1,* A. Iurlo2, G. Gugliotta1, A. Tieghi3, A. Candoni4, M. Lunghi5,
A. Dragani6, E. Antonioli7, P.R. Scalzulli8, V. Martinelli9, B. Martino10,
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Background: The last decade starts for the patients with Philadelphia Neg-
MPN after the JAK2 mutations discovery (2005), the Italian guidelines for
Essential Thrombocythemia therapy (2004), and the WHO classification (2001) 
Aims: To evaluate how the diagnostic and therapeutic approach changed in
the clinical practice in the last decade.
Methods: The patients of the Registro Italiano Trombocitemie (RIT) diagnosed
before and after 2005 were compared by considering demography, clinico-bio-
logical characteristics at diagnosis, and the initial treatment approach.
Results: The 2418 analyzed patients were diagnosed (PVSG or WHO criteria)
before 2005 (Group I, n 1230, 51%) and after 2005 (Group II, n 1188, 49%).
The patients of Group II, as compared with those of Group I, had at diagnosis
older age (median 60 vs 55 y, p60 y in 50% vs 41%, P<0.001), higher rate of
comorbidities (56% vs 49%, p 0.002), and lower median PLT count (748 vs
786x109/L, P< 0.001). No significant differences were found for gender (males
38% vs 38%), prior thrombosis (20% vs 20%), prior hemorrhage (4.9% vs
5.6%), CV general risk factors (71% vs 68%), symptoms (41% vs 41%),
splenomegaly (25% vs 23%), hepatomegaly (22% vs 24%), WBC count (medi-
an 8.7 vs 8.5x109/L; >10x109/L 28% vs 27%), and HCT level (median in males
44.8% vs 44.1%; median in females 41.5% vs 41.0%). The bone marrow biopsy
in the first year was performed more frequently (76% vs 67%, P<0.001). The
test for JAK2 mutation was performed in 89% of Group II patients, and, a pos-
teriori, in 72% of Group I patients (P<0.001). The patients of Group II had a
higher rate of JAK2 V617F mutation (62% vs 56%, p 0.015), and of allele bur-
den<25% (65% vs 51%, P<0.01). Moreover, the patients of Group II had a
higher rate of standard high thrombotic risk (57% vs 49%, P<0.001).During the
first year after diagnosis, an antiplatelet (+ or-cytoreductive) treatment (almost
always low dose aspirin) was started more frequently in the Group II (65% vs
48%, P<0.001), particularly (P<0.001) in patients at low thrombotic risk (stan-
dard and IPSET-Th). Similarly, a cytoreductive (+ or-antiplatelet) treatment was
started more frequently in the Group II (57% vs 50%, p 0.002), particularly
(74% vs 68%, p 0.013) in patients with high thrombotic risk (standard and
IPSET-Th). In the Group II, as compared with Group I, the rate of hydroxycar-
bamide use was higher for patients over 60 y (71% vs 63%, P<0.01) and lower
for those below 40 y (8% vs 14%, P<0.05), while the rate of anagrelide use
was higher for patients below 40 y (6.4% vs 2.7%, P<0.05).
Summary and Conclusions: The patients of the RIT diagnosed after 2005,
compared with those diagnosed before, although were older, had more fre-
quently a bone marrow biopsy at diagnosis. They had lower platelet count,
higher rate of JAK2 V617F mutation, and higher rate of high thrombotic risk.
No significant differences were found for gender, prior thrombosis, CV general
risk factors, symptoms, splenomegaly, WBC count. During the 1st year, they
were treated more frequently with antiplatelet drugs (particularly if at low throm-
botic risk), and with cytoreductive drugs (particularly if at high thrombotic risk).
The hydroxycarbamide use increased in older patients, while the anagrelide
use increased in younger ones. In conclusion, in the real life of the RIT centers,
a significant improvement of the diagnostic and therapeutic approach was doc-
umented in the last decade.
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ATHEROSCLEROSIS AND RELATED FACTORS IN PATIENTS WITH
PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEO-
PLASMS
M. Demir1,* E. Umit1, S. Uyanik1, V. Ermis2, S. Tuncel2, G. Pamuk1
1Hematology, 2Radiology, Trakya University Faculty Of Medicine, Edirne Turkey,
Edirne, Turkey
Background: Cardiovascular diseases,thrombohemorrhagic complications,
bone marrow failure due to myelofibrosis and leukemic transformation are the
major causes of mortality and morbidity in patients with Philadelphia negative
chronic myeloproliferative neoplasms (MPNs). Chronic inflammation is also
suggested to play a role in the development of atherosclerosis in this group of
patients.
Aims: We aimed to evaluate the prevalance of subclinical atherosclerosis in
patients with essential thrombocythemia and polistemia vera with the terms of
conventional risk factors like lipid profile and carotid intima media thickness
(CIMT).
Methods: 100 patients with Philadelphia negative chronic MPN and 50 age and
gender matched healthy controls were enrolled in our study. We determined the
lipid profile, fasting blood glucose, body mass index and CIMT of both groups.
Results: Mean age of patient group was 58.46 years (26-86 years). 44 were
female (44%) and 56 were male (56%). In the control group, mean age was
58.68 years (37-67 years), 24 were female (48%) and 26 were male (52%).
Duration of disease was 1 to 14 years (mean 5.81). In the medical history of
patients venous thromboembolism was present in 10 patients (10%) and arterial
thromboembolism was present in 28 patients (28%). 1 patient had diabetes
(1%) and 34 patients had hypertension (34%). Levels of cholesterol, LDL, HDL,
triglyceride, fasting blood glucose and body mass indexes were similar in both
groups. Over 1 cm thickness was accepted as plaque. Plaque was observed
on the right in 3 patients (%3) while on the left in 8 patients (%8). No patients
had plaque on both carotid arteries. In the control group, 3 patient had plaque
on the right carotid artery (6%) and 2 patient had on the left carotid artery (4%,
total 10%). CIMT was related with age, disease duration, body mass index,
levels of total cholesterol, LDL and absolute leucocyte count while not related
with gender, fasting blood glucose, levels of HDL, triglyceride, hemoglobin,
hematocrite and thrombocytes. Logistic regression analysis of age, disease
duration and presence of plaque showed a relation with disease duration and
presence of plaque (P=0.001). In patients with a history of arterial thrombosis,
6 had plaque (21.4%) while in patients with a history of venous thrombosis, 5
was observed to have plaque (50%), though no relation was observed with
logistic regression analysis.
Summary and Conclusions: During the course of chronic MPNs, a chonic
inflammatory process with thromboembolic complications is certain. Develop-
ment of subclinical atherosclerosis is related with traditional risk factors like
hypercholesterolemia as well as disease duration independent of age.
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RELATIONSHIP BETWEEN HUMAN PLATELET ANTIGEN-1 GENE
POLYMORPHISM AND ASPIRINATED PLATELETS IN PATIENTS WITH
ESSENTIAL THROMBOCYTHEMIA
R. Cacciola1,* E. Gentilini Cacciola2, A. Cipolla2, M. Torre2, E. Cacciola2
1Experimental and Clinical Medicine, 2Institute of Haemostasis, Catania, Italy
Background: Essential thrombocythemia (ET) is a myeloid neoplasm charac-
terized by platelet activation and thrombotic risk. Aspirin (ASA) is the standard
therapy to prevent the thrombosis. It is reported that thrombocythaemic patients
have ASA insentivity. It is debated if inherited thrombophilia induces the throm-
bocythemic platelet activation and, hence, the ASA platelet insensitivity.
Aims: Therefore, we evaluated human platelet antigen-1 (HPA-1) gene poly-
morphism, as thrombophilic molecular mutation associated with platelet hyper-
function, platelet count, b-thromboglobulin (b-TG) and platelet factor 4 (PF4),
as markers of platelet activation, the platelet functional activity (PFA) as indicator
of ASA platelet sensitivity and the maximum clot firmness (MCF), as indicator of
aspirinated platelet contribution to clot firmness. We studied 48 patients (4 men,
8 women; mean age 51 years, range 32-70) with ET according to WHO criteria.
Methods: The mean duration of disease was 11 years. All patients were on
ASA 100 mg once daily. Fifty subjects served as controls. The genotype HPA-
1 was determined using a commercialized polymerase chain reaction kit with
sequence-specific primers. Platelets were measured by automated analyzer.
b-TG and PF4 were determined by ELISA. ASA platelet sensitivity and MCF
were measured by Platelet Function Analyzer (PFA-100) and by ROTEM delta,
respectively.
Results: Of 48 patients, 36 were HPA-1a/1a and 12 were HPA-1a/1b. The
mean platelet count was 462±240x109/L. All patients had high b-TG and PF4
(244±15 IU/mL vs 20±11 IU/mL and 162±56 IU/mL vs 6±2 IU/mL, respectively)
(P<.0001 and P<.0001, respectively), prolonged C/EPI closure time (CT, unit:
s, n.v. 84-160 s) (252±48 s) and normal MCF (MCF, unit: mm, n.v. 50-72 mm)
(71±2 mm).
Summary and Conclusions: These findings suggest that HPA-1 gene poly-
morphism does not inhibit aspirinated platelets sensitivity in patients with ET.
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BIOMARKERS FOR PREDICTION OF THROMBOSIS IN PATIENTS WITH
ESSENTIAL THROMBOCYTHEMIA (ET)
M. Podolak-Dawidziak1,* I. Prajs1, K. Kuliczkowski1
1Hematology and Bone Marrow Transplantation, Wroclaw Medical University,
Wroclaw, Poland
Background: Arterial or venous thrombotic events occurs in 15% of essential
thrombocythemia (ET) cases at presentation and in 10% to 20% during the
disease course. The pathogenesis of thrombosis in ET is multifactorial and not
yet clear. Prevention of thrombohaemorrhagic events is the important goal of
the ET therapy. 
Aims: The aim of this study was to examine biomarkers for prediction of pos-
sible prothrombotic condition in patients with essential thrombocythemia.
Methods: Diagnosis of ET based on the WHO criteria (2008). The study was
approved by the Ethics Committee of the Medical University of Wroclaw and
was performed in accordance with the Declaration of Helsinki. Each patient has
been tested using Ceveron alpha (Technoclone) for fibrinogen (F) (Fibrynogen
Reagent, Technoclone), factor VIII (Siemens test), D-dimer (Technoclone), pro-
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tein C (PC) (TECHNOCHROM® Protein C, Technoclone), activated protein C
resistance (APCR) (APC Restance Kit Technoclone), thrombin generation and
microparticles (MPs) (TECHNOTHROMBIN® TGA (Technoclone). The activation
markers thrombin-antithrombin complexes (TAT) and prothrombin fragment F1+2
(F1+F2) were determined by ELISA using kits from Enzygnost micro, Simens).
Testing for the factor V Leiden mutation (FVL mutation) and prothrombin gene
mutation was accomplished by the PCR on peripheral blood leukocyte DNA.
Materials: The study group consisted of 45 patients with ET (13 males and 32
females; mean age 61) and 45 healthy subjects (28 males and 17 females;
mean age 62). The JAK2V617Fmutation was present in 25 ET patients. Twen-
ty-one patients experienced thrombotic events, 12 had arterial thrombosis
(myocardial infarction in 6, TIA in 3, and peripheral arterial disease in 3 and 8
had deep venous thrombosis in 8 patients. Out of 45 ET patients 35 were treat-
ed with anagrelide and 8 with hydroxyurea.
Results: In ET patients the median level D-dimer was significantly higher com-
pared to control (183.2 vs 18.5 ng/mL; P=0.00018), but not fibrinogen level,
TAT, F1+F2, FVIII activity and protein C activity. Neither thrombin generation
(TG) nor microparticles (MPs) were elevated in ET patients. Five of 45 ET
patients had the activated protein C resistance (APCR), and in two of them the
heterozygous type of FVL was confirmed. Prothrombin gene mutation was not
present in the ET group.
Summary and Conclusions: Conclusions: D-dimer has been shown as a
valuable biomarker for prediction of thrombotic events in patients with essential
thrombocythemia, and the knowledge of carriership of FVLeiden can be used
in the individual thrombosis risk assessment.
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CLINICOPATHOLOGIC CHARACTERISTICS OF UNCLASSIFIABLE
MYELOPROLIFERATIVE NEOPLASMS
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Background: According to WHO classification 2008, myeloproliferative neo-
plasm, unclassifiable (MPN-U) is defined as neoplasms that has MPN features
but fails to meet the criteria of any specific MPN entities, or that has two or
more characteristics of MPN entities. Accurate diagnosis of each MPN sub-
group is important because each subgroup could show different clinical cours-
es; leukemic transformation rate at 20 years is estimated at<10% for poly-
cythemia vera (PV) and<5% for essential thrombocythemia (ET) and fibrotic
transformation rates are slightly higher (Tefferi A. Am J Hematol 2015;90:162).
The prognosis of primary myelofibrosis (PMF) is significantly poor, compared
with those of PV or ET. 
Aims: The clinicopathologic characteristics of MPN-U are needed to be cleared
so that we could assign MPN-U to specific subtypes, if possible. The purpose
of this study was to identify characteristics of laboratory findings, bone marrow
pathology, genetic aberrations and clinical course in MPN-U. 
Methods: The study group included 8 patients diagnosed as having MPN-U
based on WHO 2008 criteria from 2000 to 2014. Median follow up period was
59 months (range 8-91 months). The mutation analysis of JAK2, MPL and
CALR was performed by real time PCR or direct Sanger sequencing. Whole
genome single nucleotide polymorphism array (SNP-A) (SNP 6.0, Affymetrix,
CA) based karyotyping and target exome sequencing (Ion AmpliSeq Compre-
hensive Cancer panel, Life Technologies) were performed according to man-
ufacturer’s instructions. 
Results: Five patients with thrombocytosis (450-991x106/L) and normal or
mild leukocytosis(7.6-14.9x106/L) showed upper normal hemoglobin (16.1-
17.4 g/dL in 2 men, 15.9-16.1 g/dL in 3 women), but, not met PV criteria of
WHO 2008 (Hb >16.5 g/dL for women and 18.5 g/dL for men). Hypercellularity
with trilineage proliferation for ages was found in 4 patients and megakaryocytic
atypia was found in 1 patients. All patients showed normal karyotype and JAK2
V617Fmutation. Of them, two patients showed one or more mutations in addi-
tion to JAK2 : 1 patient had JAK2, DNMT3A, and C-KIT; 1 patient JAK V617F
and CSF1R. In the other hand, a 73-year old female patient with high hemo-
globin (Hb 16.3 g/dL) had neither JAK2 V617F nor CALR mutation and the
laboratory findings were as follows; WBC 15x106/L, platelet 1,290x106/L, low
levels of erythropoietin and panhyperplasia with megakaryocytic atypia. There
was no one progression showing hemoglobin levels which met the criteria for
typical PV during follow up period. Taken together, these patients didn’t meet
the hemoglobin criteria for PV, but we can’t exclude the possibility of pre-PV
phase. In two patients developed myelofibrosis, the initial laboratory findings
met neither the criteria of PMF nor ET fully. One patient (55-year old female)
developing myelofibrosis at 33 months after initial diagnosis showed CALR
mutation and copy neutral-loss of heterozygosity of 19p13.3-p13.12 region
(including CALR gene) by SNP-A based karyotyping. The other laboratory find-
ings were as follows: Hb 13.8 g/dL, WBC 6x106/L, platelet 1,626x106/L,
increased LDH, normocellularity for ages and megakaryocytic atypia. The other
patient (62- year old female) developing myelofibrosis at 6 months showed
dual mutations of MPL and SF3B1, Hb 13.0 g/dL, WBC 17x106/L, platelet
930x106/L, increased LDH, hypercellularity for ages, but not significant
megakaryocytic atypia. These findings suggested that these two patients may
be prefibrotic stage of PMF at initial diagnosis.
Summary and Conclusions: This study suggests that MPN-U could include
pre-PV or prefibrotic-PMF. Therefore, the pathologists need to assign a more
specific diagnosis in MPN-U and further follow up study is recommended to
provide a more precise classification in MPN-U patients. 
PB1924
IS THERE A ROLE FOR A NEW REGISTRY IN PV? EARLY ASSESMENT
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Background: A new MPN registry,based on the database of available patient
data and a disease specific questionnaire were conducted and used in several
Hungarian hematology centers.
Aims: The aim of the survey was to collect data of Philadelphia negative MPN
patients, in order to establish a Hungarian MPN registry.
Methods: There was close cooperationbetween hematologists and information
technicians (IT) experts to create an easily evaluable questionnaire. Data of
classical MPN patients were collected from Hungarian centers. The thrombotic
risk and the risk adapted treatment characteristics were stratified according to
the Landolfi criteria. In this review the data of 408 patients (57% male) regis-
tered as having PV,were analysed. The data entry (Table 1)started at 2014
and the centers entered their patients data, diagnosed between 1989-2014.
Results: There were 820 evaluable MPN patients till the initial assesment
deadline(15th Feb 2015) In the 408 evaluable PV pts the average time from
diagnosis was 7.6 years, and about 50% of them were diagnosed more than
5 years ago. The number of evaluable cumulative patient years was 3016. 
Among the 408 PV patients there were 80%(327) JAK2 V617F posi-
tive,13%(52) of them were JAK2 V617F negative. JAK status was missing in
7%(29)of patients.The detailed analysis of the JAK negative group revealed
that 6 of them had an elevated hemoglobin + 2 positive minor criteria, fulfilling
the 2008 WHO criteria, therefore they had proven PV.The other 67 patients
did not fulfill the WHO diagnostic criteria of PV,they were identified as ÷insuf-
ficient” and therefore their data have not been included into the present eval-
uation. According to the Landolfi thrombotic risk stratification there were 73
patients stratified as low/moderate risk. They have to be treated with phleboto-
my and ASA only. 44 (60%) of them were treated with phlebotomy and only
25(34%) with ASA. 45(62%) of them were treated with cytoreductive drugs-
mainly with hydroxyurea 36pts(49%), 1 with a JAK inhibitor,1 with
anagrelide,and 1 with HU+anagrelide+ASA combination. Seven pts.(10%)
received interferon-alfa. Among them 8 thrombotic events and no transforma-
tion was observed, thus, according to the Landolfi risk treatment criteria,
patients in this group were overtreated. In the high /extremely high risk group
there were 260 patients. 35% had thrombotic events prior to diagnosis. 32%
had a thrombotic event after the diagnosis. Disease transformation has been
found in 10% of the patients (MF 22 pts, AML 2 pts, lymphoproliferative neo-
plasia in two patients.) 6% of registered PV patients had bleeding episodes 
Figure 1.
Summary and Conclusions: The main aim of the questionnaire was to create
a national registry of MPN patients and to help our colleagues how to stratify
the thrombotic risk and to choose the proper treatment. To date it remains
unanswered whether low risk patients need cytoreductive treatment to prevent
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thrombotic events? Our data show an increase of thrombotic events in low risk
patients treated with cytoreductive drugs (8 pts treated with cytoreductive drugs
versus no patient treated with phlebotomy and ASA), thus arguing against treat-
ing these patients with cytoreductive drugs.Our results show the risk of throm-
botic and hemorrhagic complications in PV to be comparable to published
results. Based on our data we are convinced that the new national registry
helps to give a good feedback about our diagnostic and treatment habits in PV.
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Background: Considering and realising the remarkable heterogeneity of MPN
care in Hungary an MPN Working Group has been established in year 2012. 
Aims: The Hungarian MPN Working Group created our MPN Registry in 2013,
the aims were: (1) to gain epidemiological, diagnostic, therapeutic data, to
follow up complications and disease transformations. (2) to investigate the
adherence to the WHO/2008 diagnostic criteria and to the Landolfi therapeutic
guidelines, to gain insight into vascular and haematological complications.
(3)Try to identify crucial issues and possible gaps, and promote internationally
accepted, standard care in MPN.
Methods: The basis of the Hungarian MPN registry was the former Regional
Centre of the Hungarian Academy of Sciences, Veszprém. The questionnaire
had been thoroughly updated regarding the 2008 WHO diagnostic criteria (mor-
phology, mutations, etc.)with focus on complications, risk stratification and treat-
ment. The electronic platform can be continuously updated as needed by our
steering committee (new molecular results e.g. calreticulin mutations can be
included). All haematologists using the system are entitled to initiate search
and association analysis. Our MPN Registry is legally permitted by our author-
ities (ETT-TUKEB).
Results: During the two active years of the Hungarian MPN Registry 15 of our
major or smaller haematological centers provided patient data, alltogether
reaching the evaluable patient number of 820. Even if some major centers data
are still missing probably our data are representative enough to characterize
MPN patient care in our country. The most important data are summarised in
Table. I. The complex multiparametric analysis of vascular events (venous,
arterial, minor, major) correlation with haematocrit, cell counts (platelet, leuko-
cyte, monocyte), Landolfi score, traditional vascular risk factors, treatment
modalities will be presented in details. We detected some shortcomings regard-
ing the diagnostic evaluation of some JAK2V617F negative PV and some
myelofibrosis cases, this will be shown in a separate poster (M. Egyed et al.)
Treatment modalities have been analysed in depth, both regarding treatment
modalities (i.e. phlebotomy, ASA, cytoreductive drugs, interferons, JAK
inhibitors,etc.) and in the context of cell counts, vascular complications and risk
stratification. Even if the observation was short, we found interesting transfor-
mation patterns in PV (408 patients): myelofibrosis 22, MDS-AML in two
patients, secondary lymphoproliferative disease in two patients.
Table 1.
Summary and Conclusions: 1. We have created a national MPN Registry
covering a large part of Hungary. The database is operational, online, user-
friendly, easily adjustable to the new professional needs. It is convenient for
complex search, correlation and other multiparametrical analysis. The data col-
lected so far are in concert with the international epidemiological data. 2. In
addition, it gives a valuable reflection on the adherence to the diagnostic and
therapeutic standards, revealing some heterogenities. The Hungarian MPN
Working Group decided to help small centers to render better diagnostic pos-
sibilities (rare genetic alterations and determination of von Hippel Lindau muta-
tion). The Steering Committee tries to facilitate patient enrollment to new MPN
drug multicenter trials, too. 3. The early results of our database clearly show
that important correlations could be made or further confirmed regarding vas-
cular events, cell counts, monocyte number, etc. In spite of the short observation
period patients with non-myeloid transformation were also found deserving fur-
ther attention.
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Background:An increase of allele burden and development of homozygosity with
the JAK2 gene V617F mutation is well-known in polycythemia vera (PV) patients
(Vannucchi AM et al, Leukemia 2008). However, the homozygosity development
of specific for PV mutations in JAK2 exon 12 has been much less studied.
Aims: The aim of this study was detection and quantification of JAK2 exon 12
allele burden in JAK2 V617F- negative PV patients using a pyrosequencing
method.
Methods: The 10 DNA samples from JAK2 V617F- negative patients with con-
firmed clinical diagnosis and bone marrow morphological features have been
selected. The informed consents from these patients were obtained. The
nucleotide sequencing of the JAK2 exon 12 fragment was performed by pyrose-
quencing method as described in (Mironov K et al, Spravochnik zav clin lab,
2011). The routine sample preparation and PCR kits («AmpliSens», Russia)
we used. Pyrosequencing was carried out with «PyroMark Q24» using «Pyro-
Mark Gold» kit («Qiagen», Germany). To verify the presence of mutations, the
DNA sequences extracted from the clinical samples were cloned into pGem-T
vector using standard protocol («Promega», USA), and obtained clones were
sequenced using reagents and equipment of the «Applied Biosystems» (USA).
Results: Among 10 of JAK2 V617F-negative PV patients, a N542-E543del
mutation of JAK2 in exon 12 has been detected in one 62-year old male patient.
On the onset of the disease in July 2013 he had a pronounced plethoric syn-
drome, Hb 204 g/l, HCT 49.9%, RBC 6.43х1012/l, WBC 8.0х109/l, PLT
250х109/l. The level of JAK2 exon 12 N542-E543del allele burden was 19%.
The patient was treated phlebotomy only and did not received any cytoreductive
treatment during 18 months. After these 18 months, the patient characterized
with presence of moderate splenomegaly, level of Hb 171 g/l, HCT 61.3%, RBC
9.03х1012/l, WBC 7.47х109/l, PLT 500х109/l. The level of JAK2 exon 12 N542-
E543del allele burden was increased up to 68%.
Summary and Conclusions: A pyrosequencing with «PyroMark Q24» was
able to identified mutations in JAK2 exon 12 and it demonstrated a possibility
that N542-E543del mutation is evolving into homozygous form in the same
manner as described for the JAK2 V617F mutation.
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Background: JAK2 and MPL mutation play an important role in diagnosis of
myeloid proliferative neoplasm (MPN). Another key marker in the molecular
diagnosis of MPNs, mutations in CALR, was recently reported. Known muta-
tions are all located at exon 9 and they are somatic mutations of deletion or
insertions; the two commonest abnormalities account for 80-90% of CALR
mutations, whereas lesions are highly heterogeneous in the remaining 10-20%.
Aims: Almost previous reports analyzed CALR mutations using Sanger
sequencing. However, sequencing method can’t be used easily in every labo-
ratory condition. Authors want to make an easy system to detect CALR muta-
tions which is available in small laboratory without sequencing machine. We
investigated the screening PCR to detect CALR mutations in Korean patients
with thrombocytosis and compared the results with Sanger sequencing.
Methods: Bone marrow DNA samples were obtained from 83 patients with
thrombocytosis. Screening PCR primer sets were designed to detect the wild
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type (product: 357 bp), type 1 mutation (product: 302 bp) and type 2 mutation
(product: 262 bp) in one reaction (Figure 1). And Sanger sequencing was done
in hot spot region.
Results: JAK2V617F was detected in 36 patients (33 ET, 1 PMF, 1 MPN, U,
and 1 MDS/MPN, U) (Table 1). Two kinds of CALR mutation, type 1
(c.1092_1143del) and type 2 (c.1154_1155insTTGTC) were detected in 16 ET
and 1 PMF patients. In ET group, mutational frequencies were 62.3% for
JAK2V617F and, 30.2% for CALR, 5.7% for dual positive and 13.2% for dual
negative. Among the ET patients without JAK2V617F, frequency of CALR
mutation was 80%. The frequency of type 2 CALRmutation (8/16, 50.0%) was
higher than type 1 (6/16, 37.5%). Interestingly, one patient with both mutations
(1/16, 6.3%) was identified and novel mutation pattern (c.1123_1132delinsTGC)
was detected by only Sanger sequencing. Any mutation was not detected in
reactive disease group.
Table 1. The frequency of JAK2 and CALR mutations in different patient
groups 
*Type 1: 6 patients (37.5%); Type 2: 8 patients (50.0%); Type 1 & Type 2: 1 patient (6.3%)
and novel mutation: 1 patient (6.3%)
Abbreviation: ET; essential thrombocythemia, PMF; primary myelofibrosis,
MDS/MPN,U; myelodysplastic syndrome/myeloproliferative neoplasm, unclas-
sifiable, MPN,U; myeloproliferative neoplasm, unclassifiable, HES; hypere-
osonophilic syndrome, Reactive; reactive disease group with non-hematologic
malignancy.
Figure 1.
Summary and Conclusions: Screening PCR could detect the 94.1% (16/17)
of mutation cases, and this method showed the concordant result with Sanger
sequencing in the case of type 1 and type 2 mutations. One novel mutation
was only identified with Sanger sequencing. Our system can’t detect single
base pair substitution or small base insertions like the mutation of this case;
however, the frequency of these mutations is very rare. Therefore, this Screen-
ing PCR would be useful in small laboratory condition as a screening test for
detection of CALR mutations.
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Background: Myeloproliferative neoplasms are a group of clonal disorders
that arise from a transformation in a hematopoietic stem cell. These disorders
consist of essential thrombocytosis (ET), primary myelofibrosis (PMF) and poly-
cythemia vera (PCV). Several therapeutic agents have been used in the past
to treat these disorders. Treatment strategies for these patients must consider
the possibility of long-term survival, morbidity from thrombotic complications,
transformation into myelofibrosis with myeloid metaplasia or acute myeloid
leukemia, and the effect of specific therapies on the incidence of leukemic
transformation and on pregnancy.
Aims: At Drexel University, a significant number of patients were treated with
busulfan and were thought to have a more favorable clinical course and
increased survival in comparison to other agents. In our study we analyzed the
outcomes of patients treated in the practice of I. Brodsky Associates diagnosed
with ET, PCV and PMF, who received a variety of treatment modalities, and
compared their clinical courses to determine if there is a superior treatment.
Methods: This study is a retrospective cohort study in which we examined the
medical records of patients treated for the diagnoses of ET, PCV and PMF at
Hahnemann Hospital-Drexel University College Medicine in the practice of I.
Brodsky Associates from January 1960 to December 2013. The following vari-
ables were measured and compared: age of the patient; sex of the patient;
demographics; cytogenetics; family history; baseline hemoglobin level, hema-
tocrit level, platelet count and WBC count; JAK 2 V617F mutation status; initial
erythropoietin level, red cell mass, oxygen saturation, presence of
splenomegaly and B12 level; Bone marrow biopsy results; thrombohemorrhagic
complications; transformation to acute leukemia, progression to myelofibrosis
and development of secondary malignancies; and treatment with busulfan,
aspirin with or without clopidogrel, anegralide, hydroxyurea, and phlebotomy
Results: One hundred ninteen patients charts were reviewed. Twenty-four
patients were given aspirin. One progressed to myelofibrosis (4%), seven
patients were noted to have recurrent thrombotic episodes in the form of TIA,
CVA, DVT/PE, and MI (29%). Thirty four patients were given Busulfan. Four
patients progressed to myelofibrosis with MM (11%) and one patient progressed
to CML (3%). Six patients were noted to have thrombotic events in the form of
CVA, MI, subclavian vein thrombosis and carotid artery stenosis (17%). Twenty
six patients were given hydroxyurea. One patient’s course was complicated by
Hodgkin’s lymphoma (4%), four patients progressed to acute leukemic blast
crises (15%), and three patients progressed to myelofibrosis (11%). Eight
patients were noted to have multiple thrombotic events in the form of CVA,
DVT, TIA, splenic vein thrombosis, and renal artery stenosis (31%). Twenty
four patients were given Busulfan and Hydroxyurea together during their course
of treatment. Fourteen patients were noted to have multiple thrombotic events
in the form of PVT, SMV thrombosis, PE, TIA, Budd Chiari syndrome and LE
arterial thrombosis (58%). Two patients progressed to CML blast crises (8%)
and three patients developed myelofibrosis with MM (12%). Eleven patients
were treated with only phlebotomy. Five patients progressed to myelofibrosis
with MM (45%). Two patients were noted to have thrombotic events that includ-
ed MI or TIA (18%)
Summary and Conclusions: Our study set out to discover if this unique treat-
ment correlated with improved survival and less treatment toxicity. Busulfan
and hydroxyurea given together proved to have the lowest rate of progression
to leukemia and myelofibrosis when compared to other standard therapies.
Patients treated with hydroxyurea and intermittent busulfan, were shown to
have the best long-term outcomes. This suggests that physicians should
include the use of busulfan in treating myeloproliferative neoplasms
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Background: ET is a chronic myeloproliferative neoplasm, characterised by
the presence of thrombohemorrhagic events (THE), the evolution to myelofi-
brosis and acute myeloid leukemia. The mutation of JAK2 exon 14 V617F is
detected in 70% of the patients, and it is related to more THE and a higher
number of leukocytes and platelets.
Aims: To analyze the thrombotic (T) and bleeding (B) clinical and analytical
profile in patients with ET.
Methods: Clinical files of a sample of patients diagnosed of ET from 1990 to
2014 in our hospital, and that were evaluated in our center consultations for 12
months were reviewed. Demographic and analytical variables, type and THE’s
location, and the treatment received were analyzed.
Table 1.
Results: 101 patients were valued, 34 ♂ (33.7%) and 67 ♀ (66.3%). Mean age
at diagnosis 59.32 (♂ 56.53 and ♀ 60.73). A higher prevalence of male (38.2%
vs 19.4%) was observed in patients between 45 and 65 years, in contrast to the
group of ≥65 years where prevalence in women was higher (65,7% vs 52,9%).
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39 events T in 35 patients, 29 arterial (74.3%) and 10 venous (25.7%) which is
shown in the data table. T pre diagnosis: 6 in legs, 10 brain, 5 coronary, 1 throm-
bosis in lower cava, 1 central retinal vein, 78 without thrombosis. Post-diagnosis:
1 in legs, 5 brain, 9 coronary, 1 thrombosis in lower cava, 85 without thrombosis.
51 patients (50.5%) were JAK2 positive (+) and 24 of those presented T (61.5%
of the total T), with regard to 7 in group JAK2 negative (-) (results were not avail-
able in 8 patients). 16 T (41.02%) were observed during the evolution of disease
in 12 patients (11.9%), 4 of these patients didn´t received cytorreductive treat-
ment, 14 antiplatelet therapy and 2 anticoagulantion. B was observed in 16
patients (5 JAK2 +/11 JAK2 -) mainly located in ORL mucous membranes and
genitourinary. At diagnosis no significant differences were observed between
hematologic values and development of T, however, patients who had developed
B events had a higher platelet counts (>900x 109/L).
Summary and Conclusions: THE define the natural evolution of ET. B events,
as shown in literature, are more frequent on mucous membranes levels and in
patients with higher platelet counts. We observe a higher frequency of these
events in patients JAK2-. A third of the patients developed T events in our series
reaching values around 50% in JAK2+, with an incidence of arterial T similar
to prospective studies. Despite antithrombotic prophylactic treatment after diag-
nosis and during the evolution of the disease, 10% of the patients developed
T which suggests that a better stratification and control the T risk is needed.
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JAK-INHIBITORS COULD INDUCE HEPCIDIN DOWNREGULATION IN
PATIENTS WITH MYELOFIBROSIS
R. Del Orbe Barreto1,* B. Arrizabalaga1, L. Posada1, M.I. Moreno2, M.J. Moran2
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Background: Iron homeostasis is dysregulated in primary myelofibrosis (PMF),
given the high prevalence of anemia, need for red blood cell (RBC) transfusions,
and disease-associated inflammatory state. Recent data published by Par-
danani et al. (Am. J. Hematol. 88:312–316, 2013) show that hepcidin levels in
patients diagnosed with Myelofibrosis (MF) are considerably elevated (MF
patients median 156,3 pg/mL, Healthy patients median 13,5 pg/mL) and are
strongly correlated with serum ferritin levels and even increased hepcidin levels
were associated with shortened survival.
Aims: To appraise serum hepcidin levels in MF patients treated with JAK
inhibitors.
Methods: Plasma hepcidin levels were measured in six patients diagnosed
with Myelofibrosis, all of them with intermediate-2 or high IPSS-risk, were on
treatment with a JAK-1/JAK-2 inhibitor (Ruxolitinib) at least 6 months prior. All
patients with transfusion dependence were receiving iron chelation therapy
(except patient 1). The methodology for hepcidin measurement was DRG Hep-
cidin-25 (bioactive) ELISA kit. It is a solid phase enzyme-linked immunosorbent
assay (ELISA) based on the principle of competitive binding (DRG Instruments
GmbH, Germany). The microtiter wells are coated with a monoclonal (mouse)
antibody directed towards an antigenic site of the hepcidin-25 molecule.
Endogenous hepcidin-25 of a sample competes with a hepcidin-25-biotin con-
jugate for binding to the coated antibody. After incubation, the unbound conju-
gate is washed off and a streptavidin-peroxidase enzyme complex is added to
each well. After incubation, unbound enzyme complex is washed off and sub-
strate solution is added. The blue color development is stopped after a short
incubation time, turning the color from blue to yellow. The absorbance of each
well is determined at 450 nm with a microtiter plate reader. The intensity of
color developed is reverse proportional to the concentration of hepcidin in the
sample. A standard curve is calculated using a 4PL (4 Parameter Logistics)
curve fit. The concentrations of the samples can be read directly from this stan-
dard curve. Data from serum ferritin level, transferrin saturation index and trans-
fusion dependence was collected from their medical records.
Results: The results are summarized in the table.
Table 1.
                    Serum Hepcidin Serum Ferritin          Transferrin Transfusion
                                                Saturation Index requirements
Patient 1+          94 ng/mL 8825 ng/mL              107.2% 4 units / month
Patient 2             12 ng/mL 223 ng/mL                45.4%
Patient 3             40 ng/mL 1235 ng/mL               95.6% 3 units / month
Patient 4             24 ng/mL 116 ng/mL                20.9%
Patient 5+         138 ng/mL 2091 ng/mL               60.4% 4 units / month
Patient 6             23 ng/mL 862 ng/mL                43.9%
*median serum Hepcidin in control cohort: 9.8 ng/mL. 
+Dead.
Summary and Conclusions: In our cohort of patients diagnosed with Myelofi-
brosis we can observe elevated levels of hepcidin and its direct correlation with
serum ferritin levels. In turn, we realize the hepcidin levels represent a negative
prognostic factor in survival of these patients. Comparing hepcidin levels
observed in our patients with the data published by Pardanani et al we can
infer that Ruxolitinib plays a role in lowering serum hepcidin level.
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LEUKOCYTOSIS AS A RISK FACTOR FOR THROMBOTIC COMPLICA-
TIONS IN PATIENTS WITH PHILADELPHIA (PH)-NEGATIVE MYELOPRO-
LIFERATIVE NEOPLASMS 
E. Simonovic1,* V. Colic1
1Internal, General Hospital Leskovac, Leskovac, Serbia
Background: Myeloproliferative neoplasms (MPNs) are a group of clonal
hematopoietic stem cell malignancies, characterized by overgrowth of one or
more blood lines with normal or nearly normal maturing of those cells in the
bone marrow and extramedullary hematopoietic organs. MPNs are acquired
prothrombogenic conditions. The mechanism of increased predisposition to
thrombosis in myeloproliferative neoplasms is not clear enough. Elevated leuko-
cyte count is an independent prognostic factor for the development of throm-
bosis. It is considered that activated neutrophils bind platelets influencing the
increased expression of tissue factor and activation and damage of endothelial
cells, especially in JAK2V617F-positive patients.
Aims: The aim of this paper is to monitor the leukocyte count as a potential
risk factor for the development of thrombotic complications with patients with
Philadelphia-negative Chronic Myeloproliferative Neoplasms.
Methods: During the five-year period we followed up the occurrence of throm-
botic complications and the leukocyte count in 109 patients of both sexes aged
between 30 and 78 years, with a diagnosis of Ph-myeloproliferative neoplasms.
Patients were classified into the following groups: 1. Group with Polycythemia
Vera (PV) (51); 2. Group with Essential Thrombocythemia (ET) (28); 3. Group
with Idiopathic Myelofibrosis (IMF) (21); 4. Group with myeloproliferative neo-
plasm unclassified (MPNs) (29). We used methods of clinical, laboratory, ultra-
sound and CT scans.
Results: The leukocyte count ranged from 2,2-17,1x109/L. The highest leuko-
cyte count was recorded in the group of patients with PV and MPNs (P<0.001)
and the lowest in the group of patients with the IMF (P<0.01). Between the
group of patients with PV and MPNs there were not any statistically significant
differences noticed in the leukocyte count. The highest percentage of thrombotic
complications (arterial and venous) is in a group of patients with ET and MPNs
(P<0.01) and then in the group with PV (P<0.05). Thrombotic complications in
those groups were more frequent in percentage with patients with leukocytosis,
but statistical significance was found only in the group with MPNs.
Summary and Conclusions: Leukocytosis may be considered as a potential
risk factor for thrombosis in patients with myeloproliferative neoplasms, espe-
cially with PV, ET and MPNs. It is necessary to continue follow-up of these
patients and to increase the number of subjects as well. Follow-up of the
patients with neoplasms unclassified is of special importance, which showed a
high prevalence of leukocytosis and thrombotic complications, and all with the
aim to continue their further differentiation.
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TREATMENT WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR
SECONDARY MYELOFIBROSIS: SINGLE CENTER EXPERIENCE 
D. Sotiropoulos1,* G. Papaioannou1, M. Iskas1, G. Karavalakis1, Z. Bousiou1,
A. Athanasiadou1, M. Gaitatzi1, N. Stavroyianni1, C. Lalayanni1,
T. Touloumenidou1, V. Kalaitzidou1, A. Anagnostopoulos1
1Hematology & HCT Unit, G. Papanikolaou Hospital of Thessaloniki, Thessa-
loniki, Greece
Background: Myelofibrosis is one of the classical Philadelphia negative myelo-
proliferative neoplasms (MPNs), either appearing de novo (primary MF[PMF])
or following a previous ET or PV (post-ET or post-PV MF). The disease is
essentially the same. The therapeutic landscape of MF has changed with the
introduction of JAK inhibitors.
Aims: To evaluate the efficacy and safety of ruxolitinib treatment in patients
with MF.
Methods: Eighteen patients with MF (12 male and 6 female), median age 62.5
(33-75) years old were evaluated: 7 with PMF, 5 post PV, 3 post ET, 3 post
MPN-U. Median follow up since ruxolitinib initiation was 4 (1-33) months, where-
as total follow up since diagnosis was 5 (2-19) years. JAK2 mutational status
was available in 14/18 patients, 12/14 being positive for the V617F mutation.
Cytogenetic study was available in 12/18 patients, 8 of them having normal
karyotype, 2 with deletion of long arm of chromosome
20 [del(20)(q13.1)], one with trisomy 8 and one with complex karyotype
[48,XX,+8,+9,t(12:14)(q24.1:q24)]. According to dynamic international prog-
nostic scoring system (DIPSS) upon ruxolitinib initiation, risk group was low in
2, intermediate-1 (int-1) in 4, intermediate-2 (int-2) in 7 and high in 5 patients.
Results: Spleen volume (SV) reduction was observed in 11/18 (61%) patients
with a mean SV reduction of 33.7%. Constitutional symptoms subsided in all
patients within 2 weeks of ruxolitinib initiation. Fifteen out eighteen patients had
weight gain and quality of life improvement. Hematologic toxicity involving ane-
mia and thrombocytopenia was observed in 6/18 (33%) and 2/18 (11%) patients
respectively. Red cell transfusion was required in one patient. Dose adjustment
with dosage de-escalation was required in 2 patients due to platelet count
decrease or preexisting thrombocytopenia, while upgrading and dosage esca-
lation in 3 patients was performed due to platelet count increase (6th, 8th and
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12th week). Low dose hydroxyurea administration was continued as concomi-
tant medication in post-PV and post-MPN-U MF patients.
Summary and Conclusions: JAK inhibitors, such as ruxolitinib, have signifi-
cantly improved the treatment of MF. The clinical experience of the drug has
shown that it is generally well tolerated. Long term effects and impact on dis-
ease natural history remain to be further studied through diligent monitoring.
Non-Hodgkin & Hodgkin lymphoma - Biology
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OUT OF EPIGENETIC CONTROL: REGULATION OF MIR23A~27A~24-2 IN
B CELL NON-HODGKIN LYMPHOMA AND CLASSICAL HODGKIN
LYMPHOMA 
S. Eberth1,* N. Klytta1, T. Lusansky2, A. Rosenwald3, R. Siebert4, H. Drexler2,
H. Quentmeier2
1Junior Research Group Molecular Cancer Research, 2Human and Animal Cell
Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell
Cultures, Braunschweig, 3Institute of Pathology, University of Würzburg,
Würzburg, 4Institute of Human Genetics, Christian-Albrechts University, Kiel,
Germany
Background: Recent publications suggest an important role for microRNAs in
B-cell differentiation, maturation and malignant transformation. Epigenetic and
genetic alterations are supposed to contribute to the deregulation of microRNA
expression in lymphoma.
Aims: We sought to identify microRNAs which are deregulated in B-cell lym-
phoma due to epigenetic alterations and aimed to test these for subtype-specific
DNA methylation patterns.
Methods: Using a microRNA expression array, we screened for microRNAs
inducible by the DNA demethylating agent 5-Aza-2’-deoxycytidine (Aza) in B
cell non-Hodgkin lymphoma (B-NHL) cell lines. Putative Aza-induced microR-
NAs were shortlisted by harboring CpG islands in their 5’-region. Array data
were validated with quantitative real-time PCR on the level of primary, precursor
and mature microRNAs. To determine any correlation of DNA methylation and
histone acetylation cell lines were treated with suberoylanilide hydroxamic acid
(SAHA) or Trichostatin A (TSA) in combination with Aza. DNA methylation was
analyzed by methylation specific PCR and bisulfite sequencing of respective
CpG islands in a panel of B-NHL and classical Hodgkin lymphoma (cHL) cell
lines together with primary B-NHL samples and healthy controls.
Results: Of the 872 microRNAs represented on the microarray 15 (1.7%) were
induced >1.5-fold by Aza in follicular lymphoma (FL) cell line SC-1, 31 (3.6%)
were activated in mantle cell lymphoma (MCL) cell line JEKO-1. Altogether
11/15 miRNAs are located downstream of a CpG island in SC-1 and 20/31 in
JEKO-1, rendering them potentially susceptible to silencing via DNA methyla-
tion. Transcriptional validation of mature and precursor microRNAs identified
the microRNA cluster MIR23A~27A~24-2 which was inducible by both DNA
demethylating agents and histone deacetylase inhibitors. Analysis of
MIR23A~27A~24-2 in a panel of B-NHL and cHL cell lines revealed that its
expression was inversely correlated with the DNA methylation status of its 5’-
region. Burkitt lymphoma (BL) and FL cell lines were methylated and mainly
negative for miR-23a, miR-27a and miR-24 expression. In contrast, most MCL
and all cHL cell lines analyzed expressed these microRNAs and were not
methylated. Diffuse large B cell lymphoma (DLBCL) cell lines showed a more
heterogeneous picture. Notably, these in vitro data are in accordance with the
methylation status of the MIR23A~27A~24-2 5’-region in primary samples:
23/29 BL patient samples were methylated, compared to 4/10 DLBCL samples
and only 1/9 MCL samples. Peripheral blood mononuclear cells and tonsils
from three healthy controls were all methylated at the MIR23A~27A~24-2 5’-
region, indicating that loss of epigenetic silencing might be the aberrant event
in lymphomatous entities like MCL and cHL. 
Summary and Conclusions: The microRNA cluster MIR23A~27A~24-2 is fre-
quently downregulated due to DNA methylation in BL, FL, and some DLBCL,
but is demethylated and highly expressed in MCL and cHL. Future investiga-
tions need to test the eligibility of this microRNA cluster as a potential diagnostic
or prognostic biomarker in B-NHL and cHL.
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PRELIMINARY STUDY ON THE MECHANISM OF CCL5/RANTES IN
DIABETIC PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
J. zhang1,* H. hu1, F. he1,2
1Hematology, 2Jinhua Hospital of Zhejiang University, jin hua, China
Background: The chemokine RANTES/CCL5 is an inducible, secreted inflam-
matory cytokine of small molecular weight, and has functions of chemotaxis
and activation of T cells and mononuclear cell. The protein among them, con-
taining 68 amino acid residues and its molecular weight being 8kd, is mainly
formed by NK cells and T lymphocytes, and plays an important part in immunity
to the tissue damage, infection and tumor.
Aims: The purpose of this experiment is to investigate the mechanism of
chemokine CCL5 in diabetes mellitus with diffuse large B cell lymphoma (DLB-
CL), and to investigate the action of CCL5 gene from molecular level, cell level
and animal level and partial molecular mechanism, in order to provide experi-
mental data with reference value for the function mechanism of CCL5 in dia-
betes with DLBCL.
Methods: Normal human B cells and DLBCL cells were cultured in vitro, and
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RT-PCR was used to detect the expression of CCL5 mRNA; human diffuse
large B lymphoma cell lines and rat diffuse large B cell lymphoma cell lines
A20 were cultured in two kinds of sugar concentration of 5mmol/L and
30mmol/L, RT-PCR was applied for the detection of the expression of CCL5
mRNA respectively; BALB/ c mice were intraperitoneal injected streptozotocin
(STZ) of small dose to construct diabetic rats model, and cell lines with a stable
low expression of CCL5 and high expression of CCL5 were established via
lentiviral transfection technology. The three kinds of cell lines of low expression
of CCL5, high expression of CCL5 and un-transfection were injected subcuta-
neously in the diabetic BALB/c mice and normal blood glucose BALB/c mice,
then were observed about the rate and the time of tumor formation and tumor
size and texture; the expression of CCL5 in each group was detected by tumor
tissue routine HE staining and immunohistochemistry; peripheral blood from
mice in each group was extracted to detect the expression of CCL5 in peripheral
blood by ELISA.
Results: 1. DLBCL cell lines of Ly1, Ly8, Ly10 are cultured in vitro, the expres-
sion level of CCL mRNA in each group is higher than the normal B cell(P<0.05);
2. Glu30mmol/L cultivate human DLBCL cell strain Ly1, Ly8, Ly10 and mice
DLBCL cell strain A20, after culturing for 2W, the CCL5mRNA are all higher
than the one cultured by Glu5mmol/LP<0.05 ; 3. Through injecting the dia-
betic mice by lower expression CCL5, high expression CCL5, none transfection
cell lines A20, the diabetic mice’s tumor formation rate is A1: 93.3%; A2: 60%;
A3: 66.6%, the tumor forming time are respectively A1: 7.0±0.85d; A2: 9.5±2.8d;
A3: 9.0±1.8d. Higher than the normal blood sugar mice’s tumor forming rate
B1 20% B2: 20%; B3: 46.6%, the tumor forming time are respectively B1:
12±1.3d; B2: 14±2.5d; B3: 12 ±4.2d; 4. Using the immuno-histochemistry to
detect the diabetic mice tumor forming tissue CCL5’s expression, and the result
is higher than the normal blood sugar mice’s tumor tissue;5. The result of ELISA
detecting the diabetes mice’s CCL5 expression is higher than the mice with
normal blood sugar in the peripheral blood.
Summary and Conclusions: 1. Human DLBCL cell strain’s expression of
CCL5mRNA are higher than the normal B cell; 2. High concentrated glucose
cultivate human DLBCL cell strain and mice DLBCL cell strain’s CCL5mRNA is
higher than the low sugar cultivate one, this shows in the high glucose environ-
ment, the DLBCL tumor cell can produce more CCL5; 3. The high expression
CCL5’s cell strain is more easily to form tumor in the body than the low expres-
sion CCL5’s cell strain, the tumor grow faster; and at the same condition, the
diabetes mice are more easily to form the tumor than the normal mice; 4. The
expression of CCL5 in the tumor forming tissue of the diabetic mice is higher
than the tumor forming tissue of the normal mice; 5. The expression of CCL5
in the serum of the diabetic mice is higher than the normal mice. 
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INFILTRATING T-CELLS IN HODGKIN LYMPHOMA LYMPH NODES: A NEW
BIOLOGICAL MARKER RELATED TO DISEASE OUTCOME
S. Alonso1,* D. Julio1, J. C. Caballero1, D. Caballero1, E. Zato2, P. MJ2, G. J3,
A. Barez4,5, M. Vidriales1, A. Orfao1, M. Gonzalez1, R. Garcia-Sanz1
1Hematologia, Hospital Universitario de Salamanca, Salamanca, 2Hematologia,
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Background: Hodgkin lymphoma (HL) is the most frequent cancer in adoles-
cent and young adults (AYA). It is considered a curable tumor, but still many
patients do not favorably respond or quickly relapse after responding to the
current chemotherapy. Most widely used prognostic guides still fail to accurately
identify those patients with very poor prognosis. Recently, microenvironment
has been a main focus of interest for define risk and disease outcome. Few
studies have analyzed the role of CD4+ T-helper cells (THs) and macrophages.
Results about cytotoxic T cells remain controversial.
Aims: To analyze the role of the amount of CD8 assessed by flow cytometry
in the outcome of patients diagnosed of HL.
Methods: Fresh samples from lymph the node biopsy were obtained during
diagnostic process in 80 patients. Single cell suspensions were prepared after
homogenizing these samples. Immunophenotyping was made by flow cytometry
with standard methods as a tool to help in the diagnosis, which was finally got by
standard pathological methods. Clinical data were collected retrospectively from
clinical courses and statistical comparisons were performed using SPSS 20.0.
Results: Ratio male/female was 52/46, and median age 37 year (12-85). Forty-
six patients (60%) patients had advanced-stage disease (III, IV, B or Bulky dis-
ease). Histologic diagnoses were: nodular sclerosis n=58 (73%), mixed cellu-
larity n=10 (12%), lymphocyte rich n=5 (6%), and lymphocyte depletion n=2
(3%), and finally nodular lymphocyte predominance n=5 (6%).The distribution
of cases according to IPS prognosis was: good 16%, intermediate 49%, and
poor 35%. Considering the total lymphocyte number, CD8+ T cells median
value of was 15% (2-75). 76 patients received therapy with ABVD+/-radiother-
apy (RT) and 2 with RT alone. With a median follow up of 5 years, freedom
from treatment failure (FFTF) was longer for females (P=0.05), patients achiev-
ing complete response to 1st line therapy (P<0.001) and cases with >15%
CD8+ cells (P=0.018). This superiority was maintained when only advanced-
stage cases were evaluated (P=0,035), as well as in patients with Bulky dis-
ease, where all patients with >15% CD8+ remained free from treatment failure
(P=0.08). In multivariate analysis, response to therapy and having >15% CD8+
were the parameters with independent statistically significance.
Figure 1.
Summary and Conclusions: An increased number of infiltrating CD8+ cells
in the microenvironment of HRS cells assessed by FCM is associated with
superior FFTF in classic HL and could be considered as a new biomarker for
risk stratification. Prospective studies must be performed to confirm these
results and further understanding of their role in microenvironment. 
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ROLE OF HLA SPECIFICITIES IN FOLLICULAR LYMPHOMA
M. Alcoceba* 1,* M. García-Álvarez* 1, S. Alonso-Álvarez* 1, I. Prieto-Conde1,
C. Jiménez1, M. E. Sarasquete1, M. C. Chillón1, A. Balanzategui1,
R. Maldonado1, M. Hernández-Ruano1, A. Antón1, R. Corral1, N. Puig1,
A. Martín1, M.B. Vidriales1, N. Gutiérrez1, M.D. Caballero1, R. García-Sanz1,
L. Marín1, M. González1
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Spain
Background: Follicular lymphoma (FL) is the most common indolent lym-
phoma, accounting for ~20-30% of all non-Hodgkin (NHL). It is an incurable
disease with frequent relapses and shorter response to further treatments,
developing drug resistance. Recently, using GWAS, polymorphisms in 6p21.3
region were related to susceptibility to develop NHL, including FL. The role of
the HLA system in antigen presentation could be related to susceptibility and
disease control. Previous studies show an association between HLA alleles
and/or haplotypes and NHL. However, information regarding FL is little.
Aims: To analyze the role of HLA specificities in development and prognosis of FL.
Methods: A total of 149 consecutive patients from a single centre diagnosed
of FL between 2000 and 2012 were included in the study. Grade 3b FL or those
cases with DLBCL areas were not considered. Healthy donors (n=1940) from
the CyL Bone Marrow Donors Registry as control group. HLA typing of class I
(–A, –B y –C) and II (–DRB1 y –DQB1) at low resolution level were performed
according to the EFI methodology. Allelic frequencies were estimated by direct
counting. Phenotypic frequencies between groups were compared with the
Fisher test, considering P<0.05 as statistical significant. P-value were corrected
(Pc) according to the number of valid comparisons (Bonferroni correction). Sur-
vival analyses were carried out using Kaplan-Meier. Differences between curves
were estimated using the log-rank test (SPSS 20.0).
Results: There were no statistical differences in specificities frequencies of HLA
class I. However, a higher incidence of HLA-DRB1*01 was observed in patients
than in donors (46% vs. 19,5%, P<0,0001, Pc<0,0013). The median follow-up
of the series was of 75 months. A total of 82% of the patients received treatment
for FL, 68% of them with Rituximab. Those patients receiving a CHOP-like plus
Rituximab regimen and carrying the HLA-DRB1*13 had worse 10-year OFS
(54% vs. 85%, P=0.05) compared with patients without this specificity.
Summary and Conclusions: The present study suggest an association
between HLA-DRB1*01 and FL development, in line with previous studies.
However, this study should be considered as preliminary, requiring higher sam-
ple size.
Financial support: Health Research Program (RD12/0036/0069, PS0901382),
Health Council of Castilla y León (BIO/SA56/13, GRS265/A/08).
* Equal contribution
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DIFFERENTIAL EXPRESSION OF ROBO1 IN MANTLE CELL LYMPHOMA,
CHRONIC LYMPHOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA.
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Background: Mantle Cell Lymphoma (MCL) is a B-cell neoplasm that repre-
sents 6%-9% of malignant lymphoma in Western Europe. MCL is characterized
genetically by the translocation t(11;14) leading to overexpression of the cell
cycle protein Cyclin D1 distinguishing MCL from other lymphomas. The out-
come is extremely heterogeneous, supporting the need for new molecular
markers to clarify the disease cause as well as assisting in diagnosis and prog-
nosis. Chronic lymphocytic leukaemia (CLL) is the most common leukaemia of
adults in Western countries. The mutational status of the IgH-V genes envis-
ages here the prognosis along with mutations in a number of genes including
p53, notch1, sf3b1, and birc3. Nevertheless, there is still a need for new mark-
ers for prediction of survival and treatment strategy in CLL. Recent next gen-
eration sequencing (NGS) studies have pinpointed a number of candidate
genes that harbor mutations in clonal B cell neoplasms among others, the
ROBO1 gene (1). We likewise identified mutations in the ROBO genes in a
pair of monozygotic twins with monoclonal B-cell disorders (2). The ROBO
gene family consists of the genes ROBO1-4 which encode single pass trans-
membrane proteins involved in neuronal migration across the midline and fetal
brain development. These genes have previously been associated with several
malignancies though only a single study, to our knowledge, -directly associated
ROBO1 with lymphomas (3).
Aims: The aim of this project is to investigate ROBO1 as a new molecular
target in patients suffering from MCL, CLL and acute myeloid leukemia (AML).
We explored the mRNA expression patterns of the gene and compared the
expression to a cohort of healthy individuals.
Methods: Blood samples from 20 patients with MCL, 20 patients with CLL and
20 patients with AML were collected at diagnosis. In addition blood samples
from 20 healthy individuals were employed. The qPCR assay Hs00268049_m1
(Applied Biosystems, Foster City, CA, USA) targeting the specific ROBO1
mRNA was applied in triplicates on a MX3005 (Agilent Technologies, Santa
Clare, CA, USA) and the quantitative range of the assays was determined. β-
glucoronidase (GUS) and β-2-microglobulin (B2M) were employed as reference
genes and the cell line K562 was used as positive control. ∆Cq was calculated
as Ave(Cq, target gene) – Ave(Cq, reference genes). The non-parametric
Mann-Whitney U test was used to evaluate significant difference between the
groups (Figure).
Results: We identified a significant difference between the expression of
ROBO1 in MCL versus healthy individuals (P=0.0002), between CLL and
healthy individuals (p =<0.0001) and between AML and healthy individuals (p
=<0.0001). Interestingly, three MCL patients displayed remarkably high expres-
sion of ROBO1 compared to the rest of the cohort (Figure).
Figure 1.
Summary and Conclusions: Using a qPCR assay, specifically targeting
ROBO1 mRNA we found a significantly difference in the expression level in
the MCL, CLL and AML cohorts compared to the healthy individuals. There
has previously been a report on promoter methylation of ROBO1 in MCL with
impact on prognosis (3). Methylation of the promoter CpG islands could explain
the significant difference in expression that we observed. However, whether
the difference in expression of ROBO1 solely derives from promoter methyla-
tion or is due to mutations in the gene needs to be further explored. Perspec-
tives of using the expression profile of genes like ROBO1 as additional tool for
prognosis are interesting in these B-cell neoplasms with very heterogeneous
outcome.
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CXCR4 WHIM-LIKE MUTATIONS ARE A RARE EVENT IN DIFFUSE LARGE
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Background: MYD88 p.L265P mutation has been recently reported to have
predictive value for worse response and survival in diffuse large B-cell lym-
phoma (DLBCL). In lymphoplasmacytic lymphoma (LPL), that is characterized
by a high presence of the MYD88 p.L265P change, different mutations in the
C terminus of the CXCR4 gene have been lately described. These alterations,
that affect almost a 30% of LPL cases, are similar to those found in the WHIM
syndrome and virtually all of them coexist with the MYD88 p.L265P alteration,
modifying the clinical presentation and outcome of the disease.
Aims: To study the occurrence of CXCR4 WHIM-like mutations in adult patients
with DLBCL and their possible association with other frequent mutations affect-
ing the MYD88 (p.L265) and CD79B (p.Y196) genes.
Methods: We analysed the mutational status of CXCR4 and CD79B in a series
of 101 DLBCL (19 of them harbouring the MYD88 p.L265P mutation) diagnosed
in our institution according to the WHO 2008 diagnostic criteria for lymphomas.
DNA samples extracted from FFPE tissue were used and macrodissection was
performed in those cases where tumoral tissue represented less than the 50%
of the sample. The presence of the MYD88 p.L265P mutation was assessed
by allele-specific real time-PCR. The mutational status of CXCR4 was deter-
mined by direct Sanger sequencing of the C terminus of the gene (aminoacidic
positions Glu288 to Ser352, according to the NCBI reference sequence
NM_003467.2). Mutations affecting the tyrosine 196 at the ITAM motif of CD79B
were studied also by direct Sanger sequencing of the targeted region.
Results: A total of 101 DLBCL cases (54 male; 47 female) with a median age
of 71 years (range 25-88) were included in the study. According to the Hans’
immunochemistry-based algorithm, 48% of the cases were ABC-type and 52%
were GCB-type. CD79B p.Y196 mutations were found in 10 patients. Consis-
tently with previous studies, most of the cases of the MYD88 p.L265P positive
group (n=19) were ABC-type lymphomas (74%) and presented a primary extra-
nodal origin (68.4%) besides of being more enriched in CD79BY196 mutations
than the MYD88 wild-type group (36.8% vs 3.7%, P<0.001).
Only one case with a mutation in the CXCR4 gene was detected in the MYD88
p.L265P positive group (5.26%) whereas no CXCR4 mutations were found
within the MYD88 wild-type cases. The alteration consisted in the c.C1000T
heterozygous substitution, leading to a nonsense mutation at the arginine 334
(p.R334*) and coexisted with a mutation in the CD79B ITAM motif (p.Y196C).
Noteworthy, this mutation represents a rare CXCR4 WHIM-like alteration also
in LPL, where the most frequent altered position is, by far, the serine 338.
Regarding the clinical features of the mutated case, the patient was a 71 years
old male that presented an ABC-DLBCL with primary testicular origin. After 26
months of follow-up, the patient has not presented monoclonal component,
bone marrow affectation or any other meaningful alteration.
Summary and Conclusions: Our study shows that the CXCR4 WHIM-like
mutations are a rare event in DLBCL, even within those patients bearing the
MYD88 L265P mutation, despite the recently shown correlation between these
two molecular alterations in patients with LPL. Although these findings require
further validation in larger studies, these results suggest that the pathogenic
events driven by the MYD88 L265P mutation might differ among both diseases.
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Veterinary Medicine, LMU, Munich, Germany
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
subtype of canine lymphoma and shows significant similarities in its clinical
and biological presentation to human DLBCL. Since the majority of canine
DLBCL appears to have genetic parallels to the human Activated B-Cell (ABC)
subtype of DLBCL, analysis of the biology and evaluation of possible treatment
targets in canine DLBCL could supply valuable insights about the disease.
Aims: Here we demonstrate the expression of hallmark kinases of the B-cell
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receptor pathway in the canine DLBCL cell line CLBL-1. Further we investigated
the treatment with B-cell receptor pathway interacting compounds such as BTK
inhibitor Ibrutinib and PI3K inhibitor Idelalisib and substances lately known for
their anti-lymphoid activity.
Methods: Established canine DLBCL (CLBL-1) and T-cell lymphoma (CL-1)
cell lines were cultivated under standard conditions in RPMI and exposed to
ascending doses of Idelalisib, Ibrutinib, Temsirolimus, BX-912, Ku-63764, Enza-
staurin and Bortezomib. Cell proliferation was determined after 48 hours based
on WST cell proliferation assay. Western blotting was performed after 24h. All
experiments were performed at least in triplicates.
Results: In Western blot analysis kinases hallmarking the B-cell receptor- PI3K-
AKT pathway (AKT, PDK, PI3K, mTOR) and their phosphorylated isoforms
were detected in CLBL-1 cells. Furthermore untreated CLBL-1 cells expressed
p42/44, p38, MEK, GSK alpha and GSK beta and their phosphorylated isoforms
as well as the cyclins CDK2, CDK4, CDK7, CDK9 but no cyclin D1. Significantly,
treatment with only 1,25nM Ibrutinib induced in WST analysis a growth reduction
to 45%, with 1µM arresting growth thoroughly. The PI3K-delta inhibitor Idelalisib
showed dose dependent effects: 0,6µM reduced cell growth to 41%, whereas
5µM reduced proliferation to 13%. The mTor inhibitor Temsirolimus showed
high efficacy: 1,25nM Temsirolimus reduced cell proliferation to 38%, while the
mtorc1/mtorc2 inhibitor Ku-63794 induced at the dose of 0,25µM a reduction
to 49%. CLBL-1 was also sensitive towards other compounds with anti-lymphoid
activity such as the PDK-1 inhibitor BX-912 (0,25µM; 20%), the PKC inhibitor
Enzastaurin (1,25µM; 52%) and the proteasome inhibitor Bortezomib (5nM;
50%). To identify B-cell receptor pathway specific mechanisms the T-cell lym-
phoma cell line CL-1 was treated as control. Increasing doses of Ibrutinib, Ide-
lalisib and Enzastaurin (up to 5µM) and Temsirolimus (up to 20nM) did not have
significant effects.
Summary and Conclusions: The detected activated B-cell receptor pathway
in CLBL-1 and the sensitivity towards small molecule inhibitors targeting this
pathway indicates the similarity to human ABC DLBCL. This data strongly sup-
ports the relevance of canine DLBCL as model for its human counterpart. 
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Background: Several types of T-cell lymphomas are characterized by a high
risk of relapse after standard chemotherapy. It continues to be reasonable to
investigate potential targets for immunotherapy in T-cell lymphomas. CTG are
expressed in some hematologic malignancies. Nowadays there are a few infor-
mation about the CTG expression in T-cell lymphomas. 
Aims: To investigate the expression profile of CTG in T-cell lymphomas.
Methods: We used RQ PCR to evaluate mRNA expression of CTG’s HAGE,
NY-ESO-1, MAGEA1, PASD1, SCP1, SEMG1, SPANXA1, SSX1 and PRAME
relatively gene Abl. Systems of specific primers and fluorescent probes were
used for each gene. mRNA has been extracted from peripheral blood (PB),
marrow (BM) and lymph nodes (LN). mRNA has been extracted from 4 samples
of LN, 4 PB and 5 BM of 6 patients with Angioimmunoblastic T-Cell Lymphoma
(AITL); 2 samples of LN, 3 PB and 3 BM of 6 patients with T-cell lymphoma,
not otherwise specified (PTL-NOS); 4 samples of LN, 5 PB and 3 BM of 5
patients with Anaplastic Large Cell Lymphoma ALK-positive (ALTCL ALK+); 2
samples of PB and 3 BM of 3 patients with Anaplastic Large Cell Lymphoma
ALK-negative (ALTCL ALK-). Statistical analysis was carried out using χ2.
Results: We observed the PRAME (in 1 of 4 cases) and SSX1 (1/4) expression
in LN of patients with AITL. SCP1 (1/4), SEMG1 (1/4) and SSX1 (2/4) were
expressed in PB of these patients. SCP1 (1/5), SEMG1 (1/5), SPANXA1 (1/5)
and SSX1 (2/5) were expressed in BM of patients with AITL. We detected
GAGE (1/2) SEMG1 (1/2) SSX1 (1/2) and PRAME (2/2) in LN, GAGE (1/3),
SEMG1 (1/3), SSX1 (1/3) and PRAME (2/3) in PB of patients with PTL-NOS.
It is interesting that GAGE, SEMG1, SSX1 and PRAME were expressed togeth-
er in LN and PB of one patient. There wasn’t any CTG expression in BM of
PTL-NOS patients. PASD1 (1/4), SCP1 (2/4) and PRAME (4/4) mRNA were
expressed in LN; NY-ESO-1 (1/5), PASD1 (1/5), SCP1 (1/5), SEMG1 (2/5),
SPANXA1 (1/5) and PRAME (2/5) were expressed in PB, GAGE (1/3), NY-
ESO-1 (1/3), PASD1 (1/3), SCP1 (2/3), SEMG1 (2/3), SPANXA1 (1/3) and
PRAME (1/3) were expressed in BM of ALTCL ALK+ patients. SCP1 (1/2) and
SPANXA1 (1/2) were expressed in PB and GAGE (1/3), SCP1 (1/3) and
SEMG1 (1/3). Expression of CTG occurred only in BM of patients with histo-
logically proven tumor involvement. PRAME expression was observed in LN
more frequently, than in PB (P=0,0841) and BM (P=0,0194). All other CTG
were expressed with similar frequency in LN, PB and BM.
Summary and Conclusions: T-cell lymphomas have a different CTG expres-
sion profile. PRAME expression was predominantly observed in lymph nodes
and could be considered like a potential target in relapsed or resistant cases
of T-cell lymphomas.
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CD26 AND CD39 IN THE REGULATORY MICROENVIRONMENTS OF
LYMPHOMA AFFECTED LYMPH NODES
R. Di Gaetano1,* V. Gasparetto1, B. Callegari1, M.A. De Benedetto1, R. Sartori1,
E. Scarpa1, N. Maschio1, G. Tagariello1
1Haematology, Castelfranco Veneto Hospital, Castelfranco Veneto, Italy
Background: In previous reports we have described that lack of CD26 on the
surface of activated CD4+T (CD38+ ) in the microenvironment of Hodgkin lym-
phoma (HL) suggest a T-reg immunosuppressive activity. Other studies have
shown that low expression of CD26, associated with adenosine deaminase
(ADA), and the presence of CD39, ectoenzyme associated with hydrolysis of
extracellular ATP, might be responsible for the generation of adenosine recog-
nized as a major mechanism of T-reg for the suppression of anti-tumor immune
responses and for successful tumour escape.
Aims: Significant amount of non-clonal cells infiltrating HL is an excellent model
to analyze the para-neoplastic cellular elements of the tumor microenvironment.
The scope of this study was to perform lymphocyte immunophenotyping by
flow cytometry (FC) from lymph node samples suspected of lymphoma with
the scope of verify biomarkers of enzymatic activity favorable to the proliferation
of neoplastic cells.
Methods: We have examined the relationship between the expression of CD26
and CD39 by FC on CD4+T and measured its expression on CD4 + T subset
correlating to the CD26 and CD38 in 52 samples of lymph nodes (6 HL, 30 non
Hodgkin lymphoma (NHL) and 16 non malignant nodes (BN).
Results: HL samples show statically differences compared to BN in the expres-
sion of CD26 (12% vs 42%; P<0,0002), CD38 (72% vs 20%; P<0,0005), CD39
(42% vs 14%; P<0,05). When compared to NHL there is a confirmation signif-
icance in CD26 (12% vs 37%; P<0,0007), in CD38 (72% vs 25%; P<0,0009) in
contrast to CD39 (42% vs 26%; P<0,3). Among NHL cases, there were 6 relaps-
es, that we have compared to HL: CD26 (42% vs 12; P<0,02); CD38 (23% vs
72%; P<0,04); CD39 (30% vs 42%;P<0,7).
Summary and Conclusions: Data confirm the activated profile (CD38+) that
distinguishes HL-infiltrating cells from NHL and BN. It is more evident in HL,
but in NHL microenvironment there is a tendency to a reduction of the expres-
sion of CD26 on CD4+T cells compared with BN; this, correlated with CD39
increase, might suggests an enzymatic activity with a significant adenosine
accumulation in NHL too. Although the small size of the cohort, the pattern of
relapsed seems similar to HL. This mimics the regulatory microenvironments
that strengthens the neoplastic cells to manipulate its surrounding to avoid host
immune attack suggesting a possible resistance to treatment.
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DETECTION OF MYD88 L265P IN PATIENTS WITH DIFFUSE LARGE
B-CELL LYMPHOMA
A. Sidorova1,* E. Zvonkov1, A. Sudarikov1, N. Severina1, N. Gabeeva1,
A. Kovrigina1, V. Troitskaya1, V. Savchenko1
1National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, Russian Federation
Background: The mutation of the myeloid differentiation primary response
gene 88 (MYD88) at amino acid position 265 leading to a change from leucine
to proline (L256P) is present in approximately one-third of patients (pts) with
activated B-cell–like types of diffuse large B-cell lymphoma (ABC-DLBCL) and
rarely occurs in pts with other subtypes of DLBCL. Considering the published
data, patients with MYD88 DLBCL treated by standard chemotherapy (CHOP
and CHOP-like regimens), was associated with an unfavorable outcome.
Aims: To identify the clinical and prognostic value of the MYD88 L256P muta-
tion in pts with ABC-DLBCL who received treatment in the National Research
Center for Hematology during 2008-2014.
Methods: Thirty-two newly diagnosed pts with ABC-DLBCL were selected for
the study. The diagnosis of ABC-DLBCL was established according to the World
Health Organization 2008 classification. DNA from 28 cryopreserved and 4 for-
malin-fixed paraffin-embedded tumor samples were available for our study. The
screening for MYD88 L256P mutation was performed by Sanger sequencing
and allele-specific PCR. 
Results: Thirty-two pts with ABC-DLBCL (median age 54,5 years (range 18-
74), 18 males and 14 females) were tested for MYD88 mutation. MYD88 L265P
mutation was found in 28,2% (9/32) of pts. There was just a slight predominance
of the female sex for MYD88 L265P positive group (5:4) as compared to MYD88
negative group (9:14). According to the Ann Arbor classification, approximately
55% pts had stage IV of the disease in both groups. Sixty-six percent of the pts
with MYD88 mutated DLBCL were classified as the high risk group by the inter-
national prognostic index (IPI) vs 8 (34,8%) pts MYD88 unmutated DLBCL. In
addition, 17 of 23 pts (73,9%) with MYD88 wild type DLBCL had elevated lactate
dehydrogenase (LDH) levels versus 100% of pts with MYD88-positive DLBCL.
Among MYD88 positive group 5/9 (55,6%) pts had extranodal lesions: central
nervous system, skin, gastrointestinal tract, adrenal gland, bone and soft tissue,
as compared to cases without MYD88 DLBCL 8/23 (34,8%). The clinical char-
acterictics of the pts are summarized in Table 1. All pts received high-dose
chemotherapy, 6/9 MYD88 mutated pts achieve complete remission after initial
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treatment, one of them experienced disease relapse with nasopharynx, bone
marrow, vertebral involvement 45 months after the diagnosis, median follow-
up was 41 (range 11-83) months. Three pts had died of progressing lymphoma.
Out of 23 pts with MYD88 wild type DLBCL, 17 pts achieved complete remis-
sion (median follow-up 54 months, range 11-90), 2 pts had early relapse and
4 pts were refractory. Overall survival (OS) was better in pts with MYD88 unmu-
tated DLBCL than pts with MYD88 positive DLBCL (5-year OS, 72% vs 42%).
Table 1.
Summary and Conclusions: Our study has demonstrated that the presence
of MYD88 L256P mutation in pts with ABC-DLBCL is associated with worse
OS probability. An analysis of treatment outcomes revealed no statistically sig-
nificant differences in OS because of the small number of pts enrolled in study.
MYD88 L265P DLBCL presented with higher number of extranodal involve-
ment, IPI high risk and older age as compared to MYD88 wild type DLBCL.
We plan to increase patient recruitment in our research, continue to analysis
MYD88 mutation in ABC DLBCL and try to improve treatment strategy in
patients with poor-prognosis DLBCL.
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T REGULATORY CELLS IN CHILDHOOD MALIGNANCIES
N. Katzilakis1, G. Martimianaki1, M. Stratigaki1,* E. Stiakaki1
1Pediatric Hematology-Oncology, University of Crete, University Hospital of
Heraklion, Heraklion,Crete, Greece
Background: T regulatory cells (T regs) participate in the maintenance of
immunological self-tolerance and according recent studies play an essential
role for the control of antitumor immune responses. The utility of T regs as
prognostic factors and targeted treatment strategies in different cancers is
under immense investigation. 
Aims: The study of T regulatory cells’ subpopulations CD4+CD25high and
CD4+CD25highFOXP3+ in the peripheral blood of children with malignancies
(lymphomas and soft tissue sarcomas) at diagnosis, during therapy and after
treatment completion as well as of children with autoimmune cytopenias.
Methods: Mononuclear cells were isolated from peripheral blood (PBMCs) of
children with malignancies at diagnosis (Md, n=9), during therapy (T, n=8) and
at the end of treatment (ET, n=26) as well as of children with autoimmune
cytopenia (CP, n=6) by density gradient centrifugation. A multi-color flow cytom-
etry panel was used for the validation of T reg subpopulations using CD4-PC5,
CD25-PE and the intracellular FOXP3-FITC monoclonal antibodies. The panel
for the estimation of CD4/CD8 ratio included CD45-PC7, CD3-FITC, CD4-PE
and CD8-PC5.
Results: The findings of our study revealed that the levels of CD4+CD25high
and CD4+CD25highFOXP3+ subpopulations of T regulatory cells were low at
diagnosis of malignancies. According to our analysis an increase of
CD4+CD25high and CD4+CD25highFOXP3+ levels (0.5±0.094 vs 1.08±0.187,
P=0.015 and 0.390± 0.087 vs 0.84±0.173, P=0.049 respectively) were
observed during treatment administration and a new reduction of the above
subpopulations after treatment completion (1.08±0.187 vs 0.62±0.062, P=0.034
and 0.84±0.173 vs 0.46±0.063, P=0.031 respectively). T reg CD4+CD25high-
FOXP3+ cells were also elevated during treatment compared to cytopenias
(0.84±0.173 vs 0.36±0.065, P=0.041). No statistically significant differences
were estimated from the comparison between the group of cytopenias and the
diagnosis of malignancies as well as the end of treatment. In addition CD4/CD8
ratio was significantly higher at diagnosis of malignancies compared to treat-
ment period and the end of treatment group (2.13±0.299 vs 1.29±0.207,
P=0.043 and 2.13±0.299 vs 1.4±0.085, P=0.019 respectively).
Summary and Conclusions: In childhood malignancies studied the levels of
T regulatory cells were estimated low at diagnosis and after treatment comple-
tion whereas were elevated under treatment as a result related to immunosup-
pression. 
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ASSOCIATION OF SELECTED GENE POLYMORPHISMS WITH PROGNO-
SIS AND TREATMENT RESULTS IN FOLLICULAR LYMPHOMA PATIENTS
E. Tothova1,* A. Kafkova2, L. Klimcakova3, J. Duras4, J. Salagovic3, R. Hajek5
1Dpt of Clinical and Medical Biophysics, LF UPJS, 2Dpt.of Hematology, HEMKO
l.t.d, 3Dpt of Medical Biology, LF UPJS, Kosice, Slovakia, 4Dpt of Hematoon-
cology, FNO and OU, 5Dpt of Hematooncology, FNO and LF OU, Ostrava,
Czech Republic
Background: Biological studies suggest that a host immunologic environment
plays a major role in follicular lymphomagenesis, which is partly determined by
host genetic background. Cytokines are key regulators of immune function and
regulation, they are highly polymorphic, and have been implicated in lymphoma
etiology and prognosis. To date, few studies addressing the association of poly-
morphisms with prognostic indicators and results of the treatment in follicular
lymphoma have been carried out.
Aims: We analyzed the effect of polymorphisms of selected genes on some
indicators of prognosis, response to treatment regimen and survival rate.
Methods: We genotyped 4 single nucleotide polymorphisms (SNPs) from 44
candidates’ cytokine and immune genes in 64 follicular lymphoma patients who
had participated in our study. Baseline clinical data and survival rates were
obtained from cancer registry files. Genotyping of polymorphisms (IL2 rs
2069762, IL12B rs 3212227, FCGR2A rs 1801274, C1QA rs172378) was per-
formed by the method of analysis of melting curve according to real time PCR
by using Eco Real-Time PCR system. Statistical analysis was executed by
using statistical software SPSS with the use of following tests: chi-kvadrat test,
Fisher exact test, Kaplan-Meier analysis and Cox regres model. P=0.05 was
considered as level of statistical significance. Following genetic models were
tested: codominant, recessional and dominant.
Results: The median age at diagnosis was 53 years (range, 23–76), 41%
men, 37% of patients were in high risk, 8 (12.5%) patients died during the fol-
low-up, with a median follow-up of 59 months (range, 29 – 79 months) for sur-
viving patients. The dominant genetic model, IL12B allele carriers rs 3212227G
had achieved in comparison to TT homozygotes significantly more complete
remissions after first-line treatment (95.5% vs 67.6%, P= 0.018, Fisher exact
test). Other 3 polymorphisms were not associated with 1.line treatment (R-
CVP, R-CHOP). Statistical significance limit was observed for the association
with mortality rate for the recessional genetic model, while the carrier homozy-
gotes CC polymorphism rs 2069762 IL2 showed a pattern of higher mortality
rate, compared to carriers of allele A (40% vs. 12%, P=0.144). In the Kaplan-
Meier survival analysis, we observed significantly shorter time for overall sur-
vival (OS) in the group CC homozygotes compared to carriers allele polymor-
phism IL2rs2069762 (34 vs 166 months; P<0.001); this difference between
genotypes remained statistically significant after adjustment to age and sex in
the Cox regression model (P=0005).
Summary and Conclusions: In summary, the results of the project have
shown an association of several polymorphisms to response to treatment, mor-
tality and survival rates. For the most important prognostic consider polymor-
phism IL12B rs3212227, where the G allele was associated with higher fre-
quency of achieving complete remission in the group followed. Given the small
number of patients in the study, for the final analysis and possible use of the
results in practice it is necessary to evaluate larger population of patients with
follicular lymphoma.
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BRAF-V600E AND P53 MUTATION AS A POTENTIAL PROGNOSTIC
MARKERS OF REMISSION DURATION
I. Kryachok1,* T. Skrypets1, O. Novosad1, N. Khranovska2, N. Svergun2,
O. Grabovoy2, S. Antoniuk2
1Oncohematology, 2Experimental oncology, National Cancer Institute, Kiev,
Ukraine
Background: Langerhans Cell Histiocytosis (LCH) is an orphan disease of
clonal dendritic cells which may affect any organ of the body.It is most often
diagnosed in childhood, but can occur at any age. Clinically, LCH manifesta-
tions range from isolated bone lesions to multisystem disease, with outcomes
ranging from spontaneous remission to progressionon therapy. Morphologically,
LCH cells are for CD1a and/or CD207 (Langerin), S-100 positive. Recent iden-
tification of cancer-associated mutation BRAF V600E and p53 in LCH cases
provided molecular evidence of the neoplastic nature of LCH. 
Aims: To investigate the frequency of BRAF V600E and correlation with p53
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mutations in histiocytosis, and it clinical significance as a potential biomarker
of early relapse or refractory disease. 
Methods: Formalin-fixed, paraffin embedded (FFPE) tissuegenotyped for
BRAF-V600E mutations with allele-specific, real-time PCR assays and immuno-
histochemistry (IHC) with moAb p53 in order to study an expression of tumor
protein p53.
Results: During last 5 years in our Institute we diagnosed 5 cases of LCH. All
patients have multisystem LCH and were immunohistochemically positive for
S-100, CD1a. Patients received the same therapy: 6 cycles of chemo according
to LCH – 1 study protocol: etoposide – 150 mg/m2 i.v. (day 1-3), methylpred-
nisolone – 30 mg/kg i.v. (day1-3). We assessed BRAF-V600E status in FFPE
samples from all 5 patients (4 men and 1 woman, age between 23-55 years
old, median age 39 y.o). BRAF-V600E mutation was found only in one patient.
P53 was found at the same patient with positive BRAF-V600E. Compared with
patients in which mutation of BRAF-V600Eand p53 have not been identified,
this patient demonstrated early relapse (in 6 months after treatment). Two
patients without mutation had late relapse (in 46 and 24 months – median 35
months), 1 patient had transformation in Hodgkin’s lymphoma (in 12 months)
and 1 patient is still in remission (for 36 months).
Summary and Conclusions: BRAF V600E and p53 mutations were found in
1 out of 5 patients with LCH. This patient had short remission duration in com-
parison with patients without BRAF and p53 abnormalities. Probably BRAF
and p53 could be considered as a potential prognostic markers of remission
duration. 
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LYMPHANGIOGENESIS AND ANGIOGENESIS IN DIFFUSE LARGE B-CELL
LYMPHOMA: RELATIONSHIP WITH CLINICAL FEATURES AND
TREATMENT OUTCOME
A. Korycka-Wolowiec1,* E. Ziolkowska1, D. Jesionek-Kupnicka2, A. Wosztyl3,
M. Danielewicz4, T. Robak1, D. Wolowiec5
1Department of Hematology, 2Department of Pathology, Medical University of
Lodz, Lodz, 3Hematology Department, Holycross Cancer Center, Kielce,
4Department of Patomorphology, Medical University of Lodz, Lodz, 5Depart-
ment of Hematology, Medical University of Wroclaw, Wroclaw, Poland
Background: Formation of new blood and lymphatic vessels, called angio-
and lymphangiogenesis, is essential for the development and dissemination of
malignant tumors, including diffuse large B-cell lymphomas (DLBCL). It was
demonstrated that the main lymphangiogenesis-involved cytokines:VEGF-C,-
D and their receptor VEGFR-3 are expressed in the majority of DLBCL cases.
Our previous studies revealed that VEGF-D serum concentration has a negative
impact on the overall survival of DLBCL patients, however the influence of lym-
phangiogenesis on the clinical picture and treatment outcome assessed directly
by a mean vascular density (MVD) and mean lymphatic vessels density (LVD)
has not been studied so far.
Aims: The aim of our study was to evaluate the angiogenesis and lymphan-
giogenesis in DLBCL lymph nodes in relationship to the clinical features and
the serum VEGF-C,-D, VEGFR-3 and bFGF levels at diagnosis, in order to
assess the predictive value of those cytokines as to the complete remission
(CR) achievement after standard R-CHOP treatment.
Methods: The study was performed in 31 (21 M, 10 F) DLBCL patients NOS
type, aged 26-84 yrs (mean 67,5±13,6) from the Holycross Cancer Center,
Kielce, Poland. 14 patients were classified as GCB, and the remaining 17 were
non-GCB. For each patient blood count, serum LDH activity, b-2microglobulin,
albumin and CRP concentrations were determined. The clinical stage of the
disease and the general condition were determined according to the Ann Arbor
classification, ECOG and the IPI staging system. The patients received 6-8
courses of the standard 21-R-CHOP regimen, and 10 of them achieved CR, in
one case no data on remission were not obtainable. The cytokines serum con-
centration was established by ELISA method. The angio- and lymphangiogen-
esis were assessed in the DLBCL lymph nodes by immunohistochemical stain-
ing with anti-CD34 and D2-40 (a marker of lymphatic endothelium) antibodies.
MVD and LVD was estimated in three selected hot spots by two independent
investigators. As a control, MVD and LVD in a group of 11 inflammatory lymph
nodes were determined. Statistical analysis was performed using Mann-Whit-
ney test and the Spearman rank correlation coefficient. The p value less than
0.05 was assumed as statistically significant.
Results: For the whole group of patients, the mean MVD and LVD were
126,7±51,1/mm2 and 99,6±81.6/mm2, respectively. For the reactive lymph
nodes the respective values were 197.1±43,0/mm2 and 84.4±19,2/mm2. MVD
was significantly higher in reactive than in neoplastic lymph nodes (P=0.002).
There was also a significant difference in MVD between complete as opposed
to not complete remission patients (144.0±37.6/mm2 and 117.9±56.7/mm2;
P=0.03). We did not find any relationship between LVD and the clinical param-
eters studied. MVD displayed no relationship either with clinical features or with
treatment issue. We also found no correlation between the cytokines serum
concentration and the extent of either angiogenesis or lymphangiogenesis.
Summary and Conclusions: Although the extent of lymphangiogenesis seems
to be similar in DLBCL and non-neoplastic lymph nodes, the LVD may be a
negative predictive factor with regard to the treatment of DLBCL with R-CHOP
immunochemotherapy. Although our results do not support the usefulness of
serum concentration of VEGF-C, -D, VEGFR-3 and bFGF as surrogate markers
of angiogenesis and lymphangiogenesis in DLBCL, further studies on this issue
would be worthwhile. The work was supported from a grant of Medical Univer-
sity of Lodz (503/1-093-01/503-01).
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OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUAN-
TIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO
SECTIONS OF 4 MM TISSUE ARE REQUIRED
O. Alishlash1,* A. Pettitt1, S. Coupland1, K. Lin1
1Department of Clinical and Molecular Cancer Medicine, University of Liverpool,
Liverpool, United Kingdom
Background: Activation induced cytidine deaminase (AID) induces genomic
alterations required for immunoglobulin SHM degradation and CSR in normal
B cells. The mutagenic effects of AID may also contribute to genomic instability
and adverse outcome in B-cell malignancies. We sought to address this ques-
tion by measuring levels of AID mRNA and protein in formalin fixed paraffin
embedded (FFPE) biopsy samples from patients with follicular lymphoma (FL).
Since measuring specific mRNAs in FFPE samples is notoriously challenging
owing to RNA
Aims: in this study, we aimed to first optimise the conditions for mRNA extrac-
tion, cDNA synthesis and qPCR amplification. 
Methods: 8 FFPE tissue samples stored in a local FL tissue bank for 0.5 – 14
years were used for this optimisation. Using 2 sections of 4μm-thick tissue, we
found that a better yield of RNA was obtained with the Qiagen RNeasy FFPE
Kit as compared to the Promega ReliaPrep™ FFPE Total RNA Kit (2 μg vs 0.9
μg in average).
Results: The yield was further increased (65%) by modification of the
deparafinization procedure. Using random primers for cDNA synthesis com-
bined with a pair of qPCR primers targeting a 100-bp sequence spanning two
exons, we found that AID mRNA was consistently and reproducibly detected in
both recently obtained and old FFPE samples. Applying our method to artificially
degraded RNA extracted from B-cell line cells, we found that AID mRNA levels
were not changed when the RNA integrity number (RIN) varied between 2.1
and 10. Applying this criterion to archived FFPE samples from patients with FL
that had been stored for between 0.5 and 5 years allowed us to successfully
quantify AID mRNA levels in 33/56 (59%) cases. To validate our findings, levels
of AID mRNA were compared to levels of AID protein detected in all of the 33
samples by IHC; a significant positive correlation (P<0.001) was observed.
Summary and Conclusions: In summary, we have shown that a sufficient
quantity of mRNA for RT-qPCR can be extracted from only two sections of
4mm-thick FFPE tissue if an optimised protocol is applied. Our findings are rel-
evant not only to the measurement of AID but to all situations where mRNA
quantification is required and tissue availability is a limiting factor.
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TRANSAMINASES AND THE INFLUENCE OF SILYMARIN IN EPIRUBICIN
CHEMOTHERAPY REGIMENS IN MICE
S. Alciona1,2,* H. Anca3, M. Eftimie4,5, C. Coralia1,2
1Hematology, Clinical emergency county hospital of arad, 2Hematology, 3his-
tology, 4gastroenterology, Vasile Goldis Western University of Arad, 5gastroen-
terology, Clinical emergency county hospital of arad, arad, Romania
Background: Epirubicin is a chemotherapeutic drug used in the haematological
malignancies regimens. Epirubicin forms a complex with DNA, with consequent
inhibition of nucleic acid (DNA and RNA) and protein synthesis. Epirubicin is
cytotoxic in vitro to a variety of established murine and human cell lines and
primary cultures of human tumors. It is extensively and rapidly metabolized by
the liver, one of the reported toxicities being the hepatotoxicity. Serum amino-
transferase elevations occur in up to 40% of patients on antraciclin therapy.
There are some natural compounds that have been investigated for their
hepatoprotective effects. 
Aims: The scope of this study was to evaluate the hepatotoxicity of epirubicin
as seen through the elevation of transaminases and in parallel to evaluate the
protective effect of silymarin in mice treated with epirubicin and silymarin.
Methods: The study included 6 mice experimental lots (first lot with no treat-
ment, the second lot treated with epirubicin alone, the third and the forth lots
treated with epirubicin and silymarin 50 and 100mg/day, the fifth and sixth lots
treated with silymarin alone, 50 and 100mg/day). 
Results: The results showed that in the epirubicin treated lot, the level of ASAT
was increased compared to the lots treated with epirubicine and silymarine or
silymarine alone (P=0,0111 for the lot treated with epirubicin and also 50mg
silymarine/day, P= 0.0374 for the ot treated with epirubicin and also with 100mg
silymarine/day). Concerning the ALAT, we haven’t found any statistical signifi-
cant results in the compared lots.
Summary and Conclusions: As a conclusion, silymarine could have a hepatic
protective effect when taken in the same time with the epirubicin included reg-
imens in mice.
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ERYTHROPOIETIC RESPONSE TO A LIGAND TRAP OF ACTIVIN RECEP-
TOR II IN CULTURES FROM Β-THALASSEMIA PATIENTS
S. Flotta1,* P. Delbini1, G. Graziadei1, A. Marcon1, V. Sung2, M.D. Cappellini1,3
1Internal Medicine Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy, 2Celgene Corporation, San Francisco, United States,
3Department of Clinical Sciences and Community Health, Università degli Studi
di Milano, Milan, Italy
Background: The hallmark of β-thalassemias is ineffective erythropoiesis lead-
ing to anemia and tissue hypoxia. Activin has been shown to affect the erythro-
poiesis in the late-stage of maturation. Sotatercept [ACE-011; Celgene Corpo-
ration (Summit, NJ, USA)], a recombinant activin receptor type IIA ligand trap,
binds with high affinity activin A/B and other members of the transforming
growth factor β-superfamily. In animal models, RAP-011, a murine ortholog of
ACE-011, reverses bone loss and increases hemoglobin and hematocrit by
acting indirectly on the late stages of erythropoiesis and in a mouse model of
β-thalassemia, RAP-011 was shown to improve anemia and the quality of ery-
throid cells. 
Aims: The aim of our study is to further explore the molecular mechanisms
underlying the effect of RAP-011 on erythropoiesis in erythroid progenitor cell
cultures from β-thalassemia patients at different stages of differentiation and
maturation.
Methods: CD34+-enriched cells were isolated from peripheral blood of β-tha-
lassemia patients and healthy donors by immunoselection. CD34+ cells were
cultured in the presence or absence of RAP-011 (50 and 100 µg/mL) for 14
days in two conditions: liquid standard cultures and HS5 stromal cell line co-
cultured with CD34+ cells. CD34+ liquid cultures in medium from HS5 cells
conditioned with RAP-011 (CM) were also set up. Conditioned medium was
assayed for apoptosis activity and cytokine content by ELISA. In the co-cul-
tures, the erythroid cells were rescued as non-adherent cells in supernatant
(NAC), phase-bright cells adhering to the surface of HS5 cells (PBC) and
phase-dim cells beneath the stromal cells (PDC). At day 14 erythroid cells were
evaluated for cell number and viability, differentiation (Glycophorin/CD71/CD34)
and gene expression profile.
Results:At day 14, there were no significant differences in cell number, viability
and immunophenotype between untreated liquid cultures and those treated
with RAP-011 (either derived from β-thalassemia and control subjects). In β-
thalassemia co-cultures, no relevant differences in cell number and viability of
the three cell fractions, in presence or absence of RAP-011 were observed;
whereas the cell surface marker Glycophorin was more highly expressed in
NAC (1.5-fold, P<0.05) and PDC (3.6-fold, P<0.001) treated with RAP-011 in
comparison to untreated fractions. Similar results were observed in controls.
In CM cultures, RAP-011-treated erythroid precursors from β-thalassemic
patients expanded significantly compared to untreated cells (6.5-fold vs 3.1-
fold). No significant differences were found in controls. High levels of anti-
inflammatory, anti-apoptotic cytokines (SICAM-1, Bcl-2 and Bcl-xL) and factors
that favour erythroid differentiation (MCP-1 and GRO-a) were detected in CM.
At day 14 in presence of RAP-011, GATA1 expression increased (P<0.005)
while GATA2 and α-globin expression decreased in erythroid thalassemic cells.
In control subjects, no significant differences were observed. In β-thalassemic
CM and co-cultures treated with RAP-011, GATA1 mRNA production was
strongly induced (P<0.001), while the levels of GATA2 and α-globin mRNA
were significantly lower (P<0.005). Similar results were observed in controls.
Summary and Conclusions: Our results suggest that RAP-011 didn’t directly
affect erythroid maturation, but probably acted through bone marrow-derived
factors. Furthermore, RAP-011 seemed to recruit quiescent CD34+ cells with
more primitive properties (NAC and PDC), stimulating them to differentiate with
an especially marked effect on erythroid maturation. 
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DACRYOCYTES ARE A COMMON MORPHOLOGIC FEATURE OF AUTOIM-
MUNE AND MICROANGIOPATHIC HEMOLYTIC ANEMIA
C. Robier1,* D. Klescher1, G. Reicht2, O. Amouzadeh-Ghadikolai3,
F. Quehenberger4, M. Neubauer2
1Central Laboratory, 2Department of Internal Medicine, 3Department of Psy-
chiatry, Hospital of the Brothers of St. John of God, 4Medical University of Graz,
Graz, Austria
Background: Dacryocytes are teardrop- or pear-shaped erythrocytes which
are usually found in peripheral blood smears of patients with primary or sec-
ondary myelofibrosis as well as infiltrative neoplastic disorders of the bone
marrow. Such a teardrop poikilocytosis has rarely been observed in blood
smears of patients with autoimmune (AIHA) and microangiopathic hemolytic
anaemia (MAHA). The prevalence of dacryocytes in AIHA and MAHA has not
been examined to date.
Aims: The aim of this study was to determine the prevalence of dacryocytes
in peripheral blood films of patients with AIHA and MAHA.
Methods: We compared the dacryocyte counts in blood smears stained
according to the May-Grünwald-Giemsa technique between 20 subjects with
AIHA (n=9) and MAHA (n=11) with those from 21 controls having normal periph-
eral blood counts and lacking signs of hemolysis. The dacryocytes, defined as
erythrocytes tapered to a point at one end, were counted as cells per 20 high
power fields (HPF) at 630-fold magnification.
Results: In AIHA, MAHA and controls, dacryocytes were found in 89% (8/9),
91% (10/11) and 19% (4/21) of the blood smears, respectively. The medians
and ranges of the dacryocyte counts per 20 HPF were 24 (0-89), 11 (0-50) and
0 (0-1). The rates of dacryocyte positivity and the dacryocyte counts between
the samples of hemolytic anemias and controls differed statistically highly sig-
nificant (P<0.0001).
Summary and Conclusions: The results of this study indicate that dacryocytes
are commonly apparent in blood smears of patients with AIHA and MAHA. Knowl-
edge of this frequent feature may be beneficial in clinical routine diagnosis.
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SCREENING OF GAUCHER DISEASE TYPE 1 IN NON-ASHKENAZIC
POPULATION – A PILOT PROJECT IN MORAVIAN-SLESIAN REGION
L. Stejskal1,* C. Bodzásová1, E. Tothová1,2Z. Kučerová1, J. Bizoňová1,
M. Janušková1, J. Vaculova3, Z. Zetková4, N. Rytiková5, M. Mičaníková6,
R. Hájek1,2
1Department of Haematooncology, University Hospital, 2Faculty of Medicine,
University of Ostrava, Ostrava, 3Department of Haematology, Hospital in
Frýdek Místek, Frýdek Místek, 4Department of Clinical Haematology, Hospital
in Nový Jičín, Nový Jičín, 5Department of Haematology, Hospital in Krnov,
Krnov, 6Departement of Haematology, Multicipal Hospital in Ostrava, Ostrava,
Czech Republic
Background: The patients with Gaucher disease (GD) type 1, although it is
the most common lysosomal storage disease, have probably not met the pri-
mary care doctors not even once in 10 years. This may cause that GD patients
have been passing through the years in a specialized clinic under different
diagnosis and they are not being treated properly. With regard to the incidence
of GD 1: 60000 in our Moravian-Silesian Region (with approx. 1,3 mil. people),
should be 20 persons with GD type 1. But there was only one patient with GD
in National Center for the treatment of GD in the Czech Republic till December
2013. Based on a successful pilot project of GD diagnosis that was solved by
our colleagues in Italy, under the leadership of prof. Cappellini (*), we decided
to implement similar in our conditions. (*) Motta I. et al., A Multicenter Obser-
vational Study For Early Diagnosis Of Gaucher Disease In Patients With
Splenomegaly and/Or Thrombocytopenia, Poster ASH 2013
Aims: Our aim is to highlight this rare diagnosis, on which we should think
more in the differential diagnosis of hepatosplenomegaly and thrombocytope-
nia, particularly in all the unclear cases.
Figure 1.
Methods: We have used Dried Blood Spot (DBS) cards (attached) to detect
beta-glucosidase enzyme activity in patients with splenomegaly (palpable
spleen or ultrasound examination demonstrated over 12 cm) and/or thrombo-
cytopenia (platelets below 130x 10/9/l). In the case of thrombocytopenia, at
least 1 more condition must be met: the current anemia, MGUS or polyclonal
gammopathy, bone pain history, or past history of splenectomy. We excluded
individual with criteria: A) known hematological malignancy, B) proven cirrhosis
of the liver or hemolytic anemia incl. hemoglobinopathy.
Results: For 10 months (from May 2014 to February 2015) we enrolled 15
patients (9 male, 6 female) from hematology clinics in Moravian-Silesian
Region. The reasons for testing were: 27% (4/15) splenomegaly, 27% (4/15)
thrombocytopenia and 46% (7/15) both of them. During this period all 15 DBS
test were negative, none patient was diagnosed with GD.
Summary and Conclusions: We are continuing to search for the patients with
GD to may put these patients the chance of timely and adequate treatment to
prevent serious complications and restrictions on their quality of life.
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GAUCHER DISEASE LATE COMPLICATIONS IN AN ITALIAN FAMILY
C. Carbone1,*
1Hematology, Ospedali Civili Brescia, BRESCIA, Italy
Background: Gaucher disease is a genetic disorder, autosomal recessive,
due to the lack of an enzyme in the metabolic pathway of phospholipids. The
deficiency of glucocerebrosidase leads to accumulation of glucocerebroside in
macrophages in the spleen, liver, bone marrow, bone, and other tissues/ organs.
Its manifestations are still highly subject to different penetrance.
Aims: We know in Gaucher patients there is major incidence of neoplastic dis-
eases and of Parkinson’s disease.
Methods: We describe an Italian family, composed of 5 brothers, where we
can observe all described complications.
Results: In this family only one member is healthy. The first brother, suffering
from Gaucher (diagnosis 58 years old), never treated, at the age of 64 years
developed acute lymphoblastic leukemia with a rearranged karyotype, was
treated with supportive care and he died of infection after a few months in 2004.
The sister, born in 1941, received diagnosis in 2004 with her brothers.She was
already affected of a neurological form of juvenile-onset Parkinson’s disease.
Treated for about 2 years with enzyme replacement therapy, she manifested
improvement in haematological parameters but simoultaneously she showed
a rapid deterioration of psychophysical performance. Brother n° 3 (b. 1949)
received the diagnosis of Gaucher disease in 2004. He was treated with
enzyme, in 2011 he developed acute myeloid leukemia, and he died in 2012
after chemotherapy. The last brother, born 1952, is currently in treatment without
complications, with stable disease.
Summary and Conclusions: The history of this family confirms the data of
higher incidence of neoplasms and Parkinson’s disease reported in the litera-
ture. It confirms, also, the reduced expectance of life of Gaucher patients.
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PRIMARY HEMOPHAGOCYTIC SYNDROME IN PEDIATRIC
S. guemghar1,* C. kaddache1, F. sadaoui1, H. mesbaiah1, A. lamraoui1
1university of BLIDA, Clinical of pédiatric BLIDA, Blida, Algeria
Background: Hemophagocytic syndrome (HS) is a clinical-biological entity
characterized by exaggerated and uncontrolled immune response. It can be
primary or secondary. Serious illness that can develop life-threatening and
imposing the initiation of urgent specific treatment. The existence of a family
history, consanguinity and an early start is very suggestive of primitive forms
and reports to various forms of immunodeficiencies. We relating 6 cases of pri-
mary HS hospitalized in our department over a 4 year period.
Aims: Records of patients with HS
Methods: Retrospective study from December 2009 to December 2014, 6 chil-
dren with primary HS were collected, the diagnosis was made on the criteria of
histiocyte society, 2007.
Results: There are 4 boys and 2 girls with an average age of 23 months (range
2 months-6 years). The clinical picture is dominated by fever and poor general
condition (100% of cases), organomegaly (hepato splenomegaly) control tissue
infiltration by histiocytes, was found in all cases. Neurological involvement is
present in 3 patients. The pigmentation abnormality is found in 3 cases. Very
contributive biology revealed a healthy cytopenia at least 2 bloodlines (100%
of cases), fibrinogen is decreased in 83% of cases associated with a lower TP.
Ferritin sensitive and specific test HS is greater than 500 microg / l in 5 cases.
Medullary smear showed hemophagocytosis and confirms the diagnosis in all
cases. Genetics is made in 3 cases. The underlying etiologies were: 3 cases
of syndrome Chediak-Higashi (CHS), 2 cases of familial hemophagocytic lym-
pho- histiocytosis probable, probable case of Purtilo syndrom type 2. These
surges haemophagocytosis were triggered by EBV infection in 3 cases. The
combination of corticosteroids and immunosuppressive have been established
in all cases, and in 03 cases an anti CD20, no child has received marrow trans-
plant. The evolution was fatal for 4 children in an array of multi-visceral failure
(2 CHS and 2 family HLH). A case has developed autoimmune cytopenia.
Summary and Conclusions: Primary HS remains a serious disease with a
poor prognosis, 70% mortality was observed in our series. Hope lies in the
realization of a bone marrow transplant for our patients in Algeria
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CONTRIBUTION OF BLOOD SMEAR IN THE DIAGNOSIS OF STORAGE
DISEASES: REPORT OF A CASE OF NIEMANN PICK’S DISEASE
N. Haddad1,* S. Guemghar2, S. Bouchrit2, A. Lamraoui2, R. Belouni1,
C. Kaddache2
1central laboratory, 2pediatric departement, BLIDA Hospital, Faculty of
Medecine, BLIDA, Algeria
Background: Lysosomal storage diseases are rare constitutional diseases
due to deficiency of a lysosomal protein that causes the blockage of a catabolic
pathway of macromolecules. These conditions result in the accumulation of
non-degraded metabolites in various tissues including the hematopoietic tissue.
Their classification is based on the nature of the accumulated substance
(mucopolysccharides, sphingolipids, neutral lipids, oligosaccharides...) and the
protein in question anomaly. There are: the Gangliosidoses, Gaucher disease
and Niemann-Pick disease. Niemann Pick’s disease is associated with abnor-
mal transport of cellular lipids inducing an accumulation of cholesterol and gly-
cosphingolipids in the brain (type A +++) and other tissues. There are 3 types
according to the presence (type A) or absence (type B), progressive presence
(type C) neurological manifestations.
Aims: We report the case of a 50 days old infant hospitalized at the pediatric
department for exploration of a fever in the long term with hepatosplenomegaly.
Methods: The blood count shows a bicytopenia: aplastic anemia hypochromic
microcytic to 6 g / dL with moderate thrombocytopenia 118 G / L. The exami-
nation of the blood smear then highlights a population of abnormal lymphocytes
containing large and multiple vacuoles. The anomaly appears vacuolated lym-
phocytes with enough evidence to we can assert its pathological nature and
distinguish visible microvacuoles sometimes in normal lymphocytes.
Results: These clinical characteristics (hepato splenomegaly) and biological
(presence of vacuolated lymphocytes) are evoke a lysosomal storage disease.
Bone marrow smer confirms the pathological origin of these vacuoles and
shows the presence of foam cells and bulky loads that oriented towards the
diagnosis of the Niemann Pick’s disease.
Summary and Conclusions: The storage diseases include the often poorly
understood diseases. In this context, the detection of inconstant cytologic anom-
alies in blood and bone marrow smears, permitting a rapid screening, is an
important step in the diagnostic approach.
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ETIOLOGICAL EVALUATION OF PATIENTS WITH VENOUS THROMBOEM-
BOLISM
E. Saribacak Can1,* H. Okutan2
1Hematology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital,
2Hematology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital,,
Ankara, Turkey
Background: Etiological Evaluation of Patients with Venous Thromboem-
bolism.
Aims: Venous thromboembolism (VTE) is the common name for all pathological
thrombosis in venous circulation. It commonly occurs deep veins of lower
extremities; and more rarely in upper extremities, pelvis and in other veins. The
most important component of VTE which poses a threat to life is pulmonary
embolism. It is determined that pulmonary embolism is deadly disease, and
30% of the patients with pulmonary embolism die within the 30 days, and exactly
the same proportion of patients (30%) die within following 8 years due to chronic
complications such as recurrent attacks or pulmonary hypertension. Hospital-
ization is one of the most important factors which acutely trigger the pulmonary
embolism. The purpose of this study is to perform etiological examination of
the patients who apply to the department of hematology of our hospital and
who are diagnosed with venous thromboembolism.
Methods: In this study, we prospectively evaluated the factors, which can play
a role for etiology, in outpatients of our hospital, who were diagnosed with VTE
and who received hospitalized treatment during 2009 – 2012.
Results: The patients with venous thromboembolism, 83 in total, ranged in age
between 18 and 50 years with an average age of 38,1±10,1. 35 of the patients
were men (42,2%) and 48 (57,8%) were women. According to the classification
of thrombosis localization in the patients, pulmonary embolism was detected in
34 patients (41,0%), DVT in 29 patients (39%), SVT (sinus ven thrombosis) in
9 patients (10,8%), RVT (retinal ven thrombosis) in 7 patients (8,4%), and
intraabdominal ven thrombosis in 4 patients (4,8%). In the classification of throm-
bosis localization of the patients with venous thrombosis according to the age
groups, there was a statistically significant difference among the age groups in
terms of pulmonary embolism (P=0,028), and localization of pulmonary
embolism was more frequent in the age group of >40 compared to ≤30
(P=0,008). No statistically significant difference was determined among the age
groups for the frequency of localization for DVT (P=0,325). There was a statis-
tically significant difference among the age groups for sinus thrombosis
(P=0,005), and frequency of sinus thrombosis was higher for the age groups of
≤30 and >40 compared to the age group of 31-40 (P=0,010 and P=0,017). When
the findings were evaluated as normal/heterozygote+homozygote for FV Leiden,
there was a statistically significant difference among the age groups (P=0,026),
and the rates of heterozygote/homozygote was lower for the age groups of ≤30
and >40 compared to the age group of 31-40 (P=0,013 and P=0,035). No sta-
tistically significant difference was detected for prothrombin gene mutation
(P=0,090). When inherited and acquired thrombophilia factors were studied in
the patients with recurrent abortus history, FV Leiden heterozygote (16,7%) was
determined in 8 patients, FV Leiden homozygote (6,3%) in 3 patients, prothrom-
bin gene mutation heterozygote 1 (2,1%) in 1 patient, AT3 deficiency (2,1%) in
1 patient, high level of D-dimer (6,3%) in 3 patients, high level of fibrinogen
(8,3%) in 4 patients, high level of homocysteine (8,3%) in 4 patients, ANA positive
(8,3%) in 4 patients, AntiDsDNA positive (4,2%) in 2 patients, AKAIGM positive
4 (8,3%) in 4 patients, AKAIGG positive (4,2%) in 2 patients.
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Summary and Conclusions: Venous thromboembolism is a frequently seen
at the clinic practice with high mortality and morbidity. The patients must be
evaluated with appropriate methods, and their diagnosis must be made at an
early stage. Moreover, inherited and acquired risk factors must be systemati-
cally evaluated in an appropriate manner. This evaluation proposes anticoag-
ulant therapy for risky cases and determines duration of the therapy. 
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HEMATOLOGY MEETS ONCOLOGY: AN INTERESTING CASE OF
SPLENOMEGALY AND CYTOPENIA AFTER SURGICAL RESECTION AND
CHEMOTHERAPY FOR COLORECTAL CANCER
M. Haas1,* P. Rexrodt2, H.J. Schlitt3, U. Vehling-Kaiser1
1Practice for Hematology, Oncology and Palliative Care, 2Practice for Radiology
and Radiotherapy, Landshut, 3Department of Surgery, University Hospital of
Regensburg, Regensburg, Germany
Background: Hematology and oncology are increasingly becoming different
specializations with own experts in their fields.
Aims: The current case from a rural oncologic practice in Germany shows an
interesting cross-link between surgery, oncology and hematology.
Methods: A 38 year old woman underwent R0 resection of an adenocarcinoma
of the ascending colon in 2001. Afterwards she was treated with 4 cycles of
adjuvant chemotherapy with 5-fluorouracil/folinic acid/oxaliplatin. In 2005 recur-
rent disease with liver metastasis in the right liver lobe was diagnosed and
was treated by a right hemihepatectomy. One year after the partial liver resec-
tion, a splenomegaly of 18cmx 5cm became evident, but did not cause any
symptoms. The blood count then showed a slight tri-cytopenia with leucocytes
2.8 G/L, hemoglobin 11.3 g/dl and thrombocytes 85 G/L, which was interpreted
as associated with previous chemotherapy. In frequent follow-up visits, there
has been no sign of relapse of colorectal cancer up to now. The splenomegaly
remained constant with recovered values for leucocytes and persistent throm-
bocytopenia around 100G/L. The patient was fully active without any problems
due to splenomegaly. In 2013, the patient increasingly suffered from left-sided
abdominal pain and fatigue, the spleen then was 20cm in size. Thrombocyte
count had occasionally dropped below 50 G/L. Bone-marrow puncture was
performed showing no signs of dysplastic syndrome or other malignancy. In
August 2014, the spleen was 23 cm in longest diameter. A CT-scan showed
signs of portal hypertension with pronounced collaterals, possibly due to con-
striction of the inferior vena cava and/or left hepatic vein, as a potential com-
plication of the liver-resection in 2005. A gastroscopy confirmed oesophageal
varices. The patient was transferred to a university hospital for further diag-
nostics and potential placement of a portosystemic shunt. Left hepatic vein
stenosis could not be substantiated by venous catheter pressure measure-
ments. As a definite reason for portal hypertension was not clear with no evi-
dence for liver cirrhosis or fibrosis, the patient was advised for splenectomy for
symptom relief.
Results: To avoid splenectomy, as preferred by the patient and the treating
hemato-oncologist, the case was again discussed with the surgeon. It was
concluded to initially perform a side-to-side spleno-renal shunt. After construct-
ing the shunt, a significant reduction of blood-flow through the portal vein direct-
ly after surgery was observed. Only three months after the intervention, the
spleen had shrunk from 24cm to 16cm accompanied by an increase in throm-
bocytes above 100 G/L and significant improvement of symptoms.
Summary and Conclusions: Splenectomy could finally be avoided and the
patient showed a significant improvement in symptoms after construction of
the shunt. The current case illustrates the necessity of close networking
between different disciplines and especially the treating physicians in rural
areas and specialists at highly specialized centers.
Platelets disorders
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FLOW CYTOMETRY ANALYSIS OF BONE MARROW HEMATOPOIESIS IN
PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
G. Shubinsky1,2,3,* Y. Kapelushnik2,4, A. Abu-Koider4, O. Pikovsky2,3,
T. Gershberg1, I. Dulman1, I. Levi2,3
1Flow Cytometry Unit, Hematology Laboratory, Soroka University Medical Cen-
ter, 2Faculty of Health Sciences, Ben-Gurion University of the Negev, 3Institute
of Hematology, 4Department of Pediatric Hemato-oncology, Soroka University
Medical Center, Beer Sheva, Israel
Background: Immune thrombocytopenia (ITP) is a clinically and pathogenet-
ically diverse autoimmune disorder resulted from antibody and/or T-cell medi-
ated destruction of platelets and insufficient platelet production by immunolog-
ically affected megakaryocytes. The studies of bone marrow (BM)
hematopoiesis in ITP show morphologically normal marrow with increased
number of megakaryocytes in many patients. Abnormal levels of plasma throm-
bopoietin, interleukin 6 and some other hematopoietic cytokines were recently
reported in patients with ITP, and these suggested a disorder of cytokine reg-
ulation with possible consequences for BM hematopoiesis. BM examination is
usually unnecessary for patients with ITP, but flow cytometry (FC) study of BM
is needed in some thrombocytopenic patients to exclude non-immune causes
of cytopenia. The data of multi-parametric FC analysis in these patients repre-
sent a good opportunity to determine morphologically undetectable abnormal-
ities in BM hematopoiesis at ITP.
Aims: The aim of current study was to examine hematopoiesis in patients with
ITP by FC analysis of their BM.
Methods: FC records of eleven adult and seven pediatric patients with non-
treated primary ITP from our database were enrolled for retrospective analysis.
Different types of hematopoietic progenitor cells, B-lineage, myeloid and nucle-
ated erythroid cells of different maturity were counted in BM of patients with
ITP using several eight-color staining protocols and multi-parametric FC analy-
sis. The data from ITP patients were compared with the data from hematolog-
ically normal adult (n=29) and pediatric (n=7) BM.
Results: Differential count of BM cells by FC detected the elevated numbers
of total CD34+ hematopoietic progenitors, CD34+/cytoCD79a+/nuTdT+ B-lin-
eage progenitors, CD34+/CD33+ committed myeloid progenitors and probable
increase of early erythroid progenitors (erythroblasts) in adult patients with ITP
when compared with normal adult BM and BM from patients with idiopathic
cytopenia of undetermined significance as pathological control. FC showed an
increased fraction of CD10+/CD20+/nuTdT- immature B cells and increase of
total population of B cells in BM of adult patients with ITP. In contrast to adult
patients, a reduced number of B cells was found in BM of pediatric patients
with ITP, and it resulted from decrease of B-cell progenitors and immature B
cells. FC revealed no other significant differences between BM of pediatric
patients with ITP and age-related controls.
Summary and Conclusions: The present data suggest an acceleration of
hematopoiesis in adult patients with ITP and address the question of its poten-
tial role in the pathogenesis of disease. Opposite changes in the composition
of BM B cells in adults and children may reflect a different pathogenetic role of
B cells and BM lymphopoiesis in the adult and pediatric ITP.
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IDENTIFICATION OF INCIDENT CASES OF GAUCHER DISEASE IN
PATIENTS CONSULTING FOR SPLENOMEGALY AND/OR THROMBOCY-
TOPENIA IN SPECIALIZED MEDICAL SERVICES IN COLOMBIA THROUGH
THE USE OF A SELECTION ALGORITHM
J.N. Marun Chagin1, G.J. Davd Tarud1, Y.P. Jimenez2, W.A. Barcenas Narvaez2,
R.D. Salazar3, D.I. Molina4, J.D. Villanueva5, J.G. Duque6,* C. Mejia7,
A.C. Rubio Marin6
1Colombia, Cecac, 2Colombia, Bonnadona, Barranquilla, 3Colombia, Astorga,
Medellin, 4Colombia, IPS Medicos Internista de Caldas, Manizales, 5Colombia,
Caimed, Barranquilla, 6Colombia, Caimed, 7Colombia, Genzyme Colombia,
Bogota, Colombia
Background: Gaucher disease (GD), categorized by its low frequency as rare
disease is an autosomal recessive lysosomal storage disorder, characterized
by deficiency of the enzyme acid beta-glucosidase. The prevalence is
1:40,000/100,000 live births in the general population and 1:500 live births
among Ashkenazi Jewish (Grabowsky G.,2004). Data from the International
Gaucher Registry (GR), 2010 have included 5828 patients, reporting that 15.6%
(911) of the patients are from Latin America. GD has great variability in the
severity and organ involvement, being usually of nonspecific clinical charac-
teristics, leading to late diagnosis, with irreversible complications.
Splenomegaly and thrombocytopenia are the two most common manifesta-
tions, revealed in 2008 on the GR, which reported 86% cases with moderate
to severe splenomegaly and 60% thrombocytopenia at the time of diagnosis,
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and these are the reasons why patients are referred in the first instance to
hematology. Considering the diagnosis of GD after other diagnostic hypotheses
have been ruled out. The consensus of international experts in the management
of patients with GD, established a diagnostic algorithm that is specially intended
for specialists (Mistry et al 2010). The diagnostic algorithms of straightforward
implementation, to support medical specialties in Latin America for early diag-
nostic suspicion of GD is required.
Aims: To identify new cases of GD in a selected population referred to Hema-
tology, Pediatric Hematology, Pediatrics, Genetics and Internal Medicine serv-
ices with a history of splenomegaly and/or thrombocytopenia, which are param-
eters of the diagnostic algorithm for the general population, based on the rec-
ommendations of the article by Mistry, et al (Figure 1).
Figure 1.
Figure 2.
Methods: Multicenter, descriptive study, in active recruitment process with non-
probabilistic sampling by convenience. Currently, the study has 16 specialized
medical centers in Hematology, Pediatrics and Internal Medicine in Colombia.
Eligible patients are those with documented thrombocytopenia<150,000 mm3
according to Mistry algorithm, or splenomegaly defined as palpable spleen ≥1
cm below the costal rim or diagnosed by ultrasound, Nuclear Magnetic Reso-
nance and Computed Tomography. Patients with prior diagnosis of GD,
splenomegaly due to portal hypertension, documented hematologic malignancy
or hemolytic anemia/ thalassemia were excluded. All patients were compiled
information from their medical history and the determination of the activity of
the enzyme beta-glucosidase, was performed. The study has an expected dura-
tion of 12 months of recruitment for each center.
Results: Since February 2014 (many of the patients were admitted in Novem-
ber and December), 27 patients have been recruited, of which analysis of enzy-
matic results report was obtained in 12 patients (7 women and 5 men) with
median age of 9 years in a range of 1.33 to 79 years. All patients of non-Ashke-
nazi origin reported 50% of splenomegaly, among other symptoms and signs
(Figure 2). It was recorded from the total sample analyzed, 91.7% of thrombo-
cytopenia, and an enzymatic report of a patient with evidence of a positive cor-
relation with chitotriosidase levels (Figure 3).
Figure 3.
Summary and Conclusions: The results of this study are in early stages of
development, and its analysis is based on a limited sample. Nevertheless there
is evidence that the algorithm offers support to specialists in our environment
to detect new cases of GD. We will expect to recruit more patients and sites
during year 2015 to provide more power to the results of this clinical study.
Acknowledgements: We thank Genzyme Colombia for financial support and
CAIMED Colombia for coordination of the study.
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CORRELATION OF CLINICAL FEATURES AND OUTCOME IN CHILDREN
WITH IMMUNE THROMBOCYTOPENIA 
S.J. Kim1,2,* H.S. Ahn1,2, H.S. Choi1
1Pediatrics, Seoul National University Bundang Hospital, Seongnam, 2Medi-
cine, Seoul National University, Seoul, Korea, Republic Of
Background: Immune thrombocytopenia (ITP) is the most common cause of
abrupt onset thrombocytopenia in an otherwise healthy child. Many efforts have
been made to identify patients at risk of developing persistent or chronic ITP. 
Aims: The aim of this research was to investigate the relationship of clinical
features and outcome of patients receiving intravenous immunoglobulin (IVIG),
with the intent of identifying prognostic factors.
Methods: During the period between January 2009 and July 2014, we retro-
spectively analyzed 94 children newly diagnosed with ITP who received IVIG
treatment. Medical records of all patients were reviewed retrospectively. CBCs
with differential counts were obtained at diagnosis, 1, 3, 6, and 12 months. 
Results: Ninety four patients aged between 1.3 months and 15 years (median
27.3 months) were enrolled. Multivariate analysis showed that patient gender,
age at diagnosis, history of viral infection or vaccination prior to disease onset
and IVIG dosage was not statistically correlated with platelet recovery at 6 and
12 months. Also, hemoglobin count, total leukocyte count (TLC), absolute neu-
trophil count (ANC), and absolute lymphocyte count (ALC) at diagnosis was
not correlated with patient outcome. However, early platelet count recovery of
≥ 100,000/µl at 1 and 3 months after IVIG treatment was significantly correlated
with platelet recovery at 6 (P<0.001 and P<0.001, respectively) and 12 months
(P=0.014 and P=0.019, respectively). 
Summary and Conclusions: To date, there is no consensus regarding the
management of acute ITP, however IVIG use to expedite the recovery of a
platelet count adequate for hemostasis is commonly practiced for newly diag-
nosed ITP children. The results of this study indicate that early platelet count
recovery was the only significant prognostic factor associated with a short
disease duration and favorable outcome. Further investigation of a larger
pool of patients is warranted to validate these findings and an understanding
of the pathophysiological mechanism underlying this association is needed
to properly identify prognostic factors of patients at risk of developing per-
sistent or chronic ITP.
Key words: immune thrombocytopenia (ITP); children, prognostic factor, out-
come.
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THERAPY WITH RITUXIMAB AND TPO-RA IN THE REAL-LIFE CLINICAL
PRACTICE OF ITP
V. Rancitelli1,*
1Internal Medicine, University of Padua, Padova, Italy
Background: The classical therapeutic approach for Immune Thrombocy-
topenic Purpura (ITP), provides the use of corticosteroids and intravenous
immunoglobulins (IVIg) as first line treatment and, in case of refractoriness,
the splenectomy as second line therapy. Since more than ten years other two
drug regimens with Rituximab and TPO-ra, are available for the ITP treatment
but their precise location in the stages of the disease is still debated.
Aims: Goal of this study was to evaluate, retrospectively, the use and efficacy
of Rituximab and TPO-ra in the real-life practice of ITP to define the best time
for their use.
Methods: The response to Rituximab and TPO-ra was investigated in patients
treated (21 and 15 ITP patients respevtively) between May 2004 and February
2015 at our ward. The response was evaluated in terms of efficacy (CR*= Com-
plete Response >100 pltx 109L, PR= Partial Response >50 pltx 109L, MR=
Minimal Response >30 pltx 109L, NR= None Response <30 pltx 109L or no
change from the baseline platelet count) and duration (SR**= Sustained
Response >6 months, PeR= Persistent Response >3 months, TR= Transitory
Response <3 months).
Results: The results are summarized in Table 1 and Table 2. Overall response
to Rituximab was 62% and to TPO-ra was 67%. The response rate in Rituximab
group decreases significantly if it was used as second line of treatment (69%)
rather than as third (23%) or fourth (8%) line. Our results don’t show the same
trend for the TPO-ra group where the response seems to be independent from
the time of use and from the previous treatments (40% of rat response in sec-
ond line; 40% in the third line; 20% in the fourth line). 
Table 1. Efficacy and duration of the response
Table 2. Relationship between response and previous treatments
Summary and Conclusions: The overall response is than clearly higher when
Rituximab was used in an early stage of ITP showing a marked trend to ineffi-
cacy in the chronic and multi-refractory phases. Actually we can’t say the same
thing for TPO-ra. Prospective and multicenter studies about the use of these
drugs in acute ITP should be performed to validate these results.
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INCREASED PRODUCTION OF ROS BY PLATELETS IN EXPERIMENTAL
CIRRHOSIS 
P. Romecín D1,* N. Marin Atucha1, D. Iyu1, J.E. Millan1, F. Garcia-Candel2,
E. Garcia2, C. Ortiz1, J. Garcia Estañ1
1Fisiología, Universidad de Murcia, 2Hematology, Hospital Universitario Virgen
de la Arrixaca-España, Murcia, Spain
Background: Despite the endogenous coagulopathy of cirrhosis, some
patients experience venous thromboembolism. Previous studies in experimen-
tal cirrhosis by bile duct ligation (BDL) have shown a platelet hyperactivity, sim-
ilar to humans with biliary cirrhosis disease (Clin.Sci., 2007,112(3):167-74). In
these experiments we have found abnormal intracellular Ca2+ homeostasis
and alterations in the metabolism of homocysteine (Hcy) that may contribute
to those platelet alterations (J. Hepatology 2009, S280). The role of ROS in
this platelet hyperactivity is not known. 
Aims: Investigate agonist-induced production of ROS in platelets of bile duct
ligated rats and the effects of chronic folic acid treatment (an essential cofactor
in the metabolism of homocysteine (Hcy)).
Methods: Cirrhosis was induced in rats by bile duct ligation (BDL) and sham-
operated rats were used as control. The experiments were performed after 21
days (without ascites) and 28 days (BDL group with ascites) after surgery.
Platelet rich plasma aggregation in response to ADP (5µM) was analyzed using
a lumiaggregometer. To analyze ROS, by fluorescence spectroscopy, platelet
suspensions were washed and incubated with CM-H2DCFDA acetyl ester and
stimulated with thrombin (0.3U/mL), ADP (5µM) and homocysteine (Hcy, 50-
200µM). In some experiments, sham and BDL rats were treated with folic acid
(8 mg/Kg/day in drinking water). 
Results: Platelet stimulation with thrombin and Hcy induced an increase in
ROS production that was of greater magnitude in platelet from BDL rats than
in control. Ascites reduced aggregation response and increased ROS produc-
tion. Chronic treatment with folic acid decreased more platelet aggregation and
ROS production in BDL than in control group.
Summary and Conclusions: Folic acid show antiaggregant actions in cirrhotic
rats due in part to attenuation of a high ROS production and might be used for
prevention of venous thromboembolism in liver cirrhosis. But, with proper con-
trol, due to the folic acid reduces platelet aggregation excessively in cirrhosis
with ascites and can produce increased maintenance of gastrointestinal bleed-
ing due to portal hypertension characteristic of this disease.
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STUDY OF IMMATURE PLATELET FRACTION AND POTENTIAL ROLE IN
DIFFERENTIATING VARIOUS CAUSES OF THROMBOCYTOPENIA
A. Khuhapinant1,* E. Utchariyaprasit1
1Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Background: Immature platelets are newly released reticulated platelets into
circulation. They can be measured using a specifically designed automated
hematology analyzer as immature platelet fraction (IPF). IPF was shown to be
high in immune thrombocytopenic purpura (ITP) due to rapid clearance and
enhanced production of platelet. In aplastic anemia (AA), IPF was lower
because of low platelet production rate. Utilization of this parameter to differ-
entiate causes of thrombocytopenia between underproduction and peripheral
destruction has been proposed. There is no IPF data on other diseases with
similar mechanisms such as hypersplenism, Evans syndrome (ES), thrombotic
thrombocytopenic purpura (TTP), or chemotherapy-induced bone marrow sup-
pression (CIBMS).
Aims: To measure IPF in healthy Thai volunteers, and patients with thrombo-
cytopenia from various causes and to compare IPF from different thrombocy-
topenic mechanisms i.e. underproduction (AA, CIBMS) and peripheral destruc-
tion/ sequestration (ITP, TTP, ES, hypersplenism).
Methods: This was a prospective, cross-sectional, observational study. Each
EDTA-anticoagulated blood from Thai healthy volunteers (NL; 51) and throm-
bocytopenic patients (67) (platelet count<150x 109/L) with known diagnosis of
AA (14), CIBMS (22), ITP (20), TTP (2), ES (3) and hypersplenism (6) was
analyzed by Sysmex XE-5000 for complete blood count, reticulocyte parame-
ters (percentage, absolute count and fluorescent ratio), IPF, and mean platelet
volume (MPV). Peripheral blood smears were simultaneously examined for
RBC, WBC and platelet morphology. Clinical parameters were collected on
fever, anemia, jaundice, bleeding status with/ without ecchymosis, and con-
current therapy for thrombocytopenia.
Results: Mean platelet number (x 109/L) for NL, AA, CIBMS, ITP, TTP, ES and
hypersplenism were 277.25, 27.21, 35.55, 50.20, 54.50, 22.67, and 63, respec-
tively. Negative correlation between platelet number and IPF value was shown
in which the lowest median IPF (%) was found in NL (1.50; 0.6-4.5) compared
among underproduction (2.95; 0.7-24.8) and peripheral destruction group (4.80;
0.2-25.7). In each underproduction subgroup, median IPFs (%) for AA and
CIBMS were 4.25 (1.8-24.8) and 2.50 (0.7-15.5). In each peripheral destruction/
sequestration subgroup, median IPFs (%) were 5.45 (0.2-25.7), 4.90 (2.4-7.4),
8.90 (4.8-11.4), and 3.95 (1.3-17.2) for ITP, TTP, ES and hypersplenism,
respectively. A cut-off absolute immature platelet count value of more than
1,000x 109/L was proposed to differentiate peripheral destruction from under-
production mechanism with sensitivity and specificity of 75.2% and 63.9%,
respectively. 
Summary and Conclusions: IPF is a simple, reliable parameter and can
potentially be used to differentiate mechanisms causing thrombocytopenia.
More beneficial roles of IPF are expected.
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PROPHYLAXIS OF FETO-MATERNAL ALLOIMMUNE THROMBOCYTOPE-
NIA (FMAIT) WITH ENRICHED INTRAVENOUS IMMUNOGLOBULINS (IVIG)
AND CORTICOTHERAPY 
G. Dine1,* E. Nacoulma1, S. Brahimi1, N. Ali-Ammar1, S. Misra1, S. Vergnolle1,
Y. Rehn1
1Hematologie, Hopital des Hauts Clos, TROYES, France
Background: FMAIT can lead to serious complications such as intracranial
hemorrhage. The current consensus is to initiate first line prophylactic treatment
with IVIg and corticotherapy. We describe 2 cases of successful prophylactic
treatment of FMAIT with enriched IVIg and corticotherapy. Infusion of enriched
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IVIg is interesting to the quality of life in outpatient setting. Time of infusion is
faster than standard IVIg.
Aims: Ms VH born in 1982 gave birth normally to a 2.130 g girl in 2005. In
2008 a second pregnancy was medically terminated during week 30 because
of fetal hydrocephalus. The post expulsion evaluation identified FMAIT caused
by incompatibility of parental HPA1 and HPA3 platelet groups and anti-platelet
alloantibodies against HPA1a/a and HPA3a/a. In 2009 this woman begin a third
pregnancy and was treated prophylatically with lyophilized IVIg (Tegeline 5%,
1 g/kg bodyweight) from the 16th week combined with Prednisolone (60
mg/day) from week 30. A healthy 2.070 g girl was delivered by caesarean sec-
tion during week 33. This woman initiated 2 new pregnancies in 2011 and 2013
treated with prophylactic infusion of enriched IVIg (Privigen 10%, 1 g/kg body-
weight) from week 19 combined with Prednisolone (60 mg/day) started during
week 32. In 2011 she gave birth by caesarean section at 37 weeks to a 3.370
g girl. In 2013 a scheduled caesarean section was performed on week 37 and
a 2.460 g girl was born.
Methods: Ms SA born in 1973 is mother of 1 child with no reported clinical
issues. During her second pregnancy in 2014, thrombocytopenia was observed
at the 5th month with a maternal platelet count of 35 000/mm3. FMAIT is diag-
nosed with parental HPA5 incompatibility and anti-platelet alloantibodies against
HPAa/b. Prophylactic treatment with enriched IVIg (Privigen 10%, 1 g/kg body-
weight) was started during week 18. Platelet count of 190 000/mm3 was
observed 2 weeks after. Prednisolone (40 mg/day) was started during week 32.
A caesarean section was performed on week 38 with birth of a 2. 800 g boy.
Results: Owing to the morbidity of FMAIT IVIg prophylactic treatment with cor-
ticotherapy is nowadays considered a standard approach. IVIg are generally
intiated during weeks 16 – 18 of pregnancy and continued until planned cae-
sarean section 2 – 4 weeks before the due date. The current consensus on the
IVIg dose is 1 g/kg bodyweight per week. Corticotherapy is regularly combined
with IVIg from week 30. Interest of enriched IVIg concerns particularly the quality
of life of these patients.
Summary and Conclusions: To our knowledge this is the first report of FMAIT
treatment with enriched IVIg preparation which was well tolerated and effective
consistent with the profile of standard IVIg. Prophylactic treatment of FMAIT
depends on identification of risk factors from previous pregnancies with diagnosis
by laboratories experienced in biological platelet testing. Management must
involve close multidisciplinary collaboration between obstetrics team and hema-
tologists experienced in IVIg use. Surveillance mainly involves fetal echographic
monitoring and maternal biological parameters follow-up. Based on our experi-
ence use of enriched IVIg in women at high risk of FMAIT is efficient and safe.
PB1964
BORTEZOMIB IN THE MANAGEMENT OF ACUTE TTP – DIFFICULTY IN
MONITORING PROGRESS
R. Low1,* T. Dutt2
1Haematology, Royal liverpool Hospital, 2University of Liverpool, Liverpool,
United Kingdom
Background: Thrombotic Thrombocytopenic Purpura (TTP) is a rare but life
threatening condition that has an untreated mortality of 90%. It is characterised
by the presence of autoantibodies against the von Willebrand factor cleaving
enzyme ADAMTS13.(1) Therapeutic plasma exchange (PLEX) remains the
mainstay treatment – adjuvant immunosuppressant therapy with rituximab is
also required in some patients.(2) 
Aims: We report the case of an acute acquired TTP that did not respond to
PLEX or rituximab however rapidly responded to the proteasome inhibitor, com-
monly used in multiple myeloma, bortezomib. 
Methods: The case is of a 59 year old gentleman who presented with vomiting,
progressive dizziness and double vision. Acute TTP was confirmed and the
patient was commenced on once daily PLEX to which he had an inadequate
response. He was subsequently initiated on twice daily PLEX and prescribed
four doses of rituximab. Again only a partial response was observed, so based
on case report data, a course of bortezomib was trialed alongside the twice
daily PLEX. 
Results: A relatively quick recovery in platelet count was observed, and
although difficult to interpret the ADAMTS13 inhibitor titre and ADAMTS13 activ-
ity normalised. The patient was discharged 57 days post diagnosis and has
remained stable since. 
Summary and Conclusions: This case supports the use of bortezomib as an
adjuvant therapy in the management of acute TTP where PLEX and rituximab
have been ineffective. Flow cytometry conducted on this patient’s bone marrow
post-rituximab revealed a normal CD19 count supporting the failure of ritux-
imab in this case. One potential reason that is important to consider, is that
effect of twice daily plasma exchange on the pharmacokinetics of rituximab,
evidence suggests peak plasma concentrations are difficult to achieve during
PLEX.(3) The PLEX also made it difficult to monitor progress with bortezomib,
as both ADAMST13 and its inhibitor titre were unreliable representations of
disease activity.
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IMMUNE THROMBOCYTOPENIA: AN EGYPTIAN EXPERIENCE IN MAN-
AGING ADULT PATIENTS WITH ITP 
D. El Demerdash1,* M. Mattar1, N. El Hussieny1
1Internal Medicine (Clinical Hematology Unit), Cairo University, Cairo, Egypt
Background: Idiopathic thrombocytopenic purpura (ITP) is a heterogeneous
clinical disorder characterized by immune-mediated platelet destruction, it may
present both as an acute, self-limiting condition and as a recurrent (chronic)
form. The clinical differences between newly diagnosed and chronic ITP sug-
gest the existence of different pathophysiological mechanisms in the two forms.
Aims: We aimed to study the clinical, laboratory parameters as well as
response to therapy in Egyptian adults with ITP.
Methods: We investigated 108 Egyptian patients with immune thrombocytope-
nia who were registered in clinical hematology unit, internal medicine depart-
ment, Cairo university, Egypt during period between 2013 and early 2015
through history, physical examination, laboratory tests including CBC, reticulo-
cyte ounts, ESR, PTT, PT, virology markers; CMV IgM, EBV IgM, HCVAb,
HBsAg and HBcAb, ANA, Lupus anticoagulant, anticardiolipine, H pylori antigen
in stool and TSH and response to therapy including response to rituximab and
thrompopoietin agents recently introduced as line of therapy in our center.
Results: We had investigated 108 ITP patients, Female (n;89) were 82% while
male were 18%, The median age at the time of diagnosis was 30 years and its
range was (14–70) years, Duration of disease ranged between (3 months-21
years) where the median duration was 2.5 years, 45% were newly diagnosed,
44% had chronic ITP and 10% had persistent ITP. Bleeding symptoms were
present in 88% (the frequency of various bleeding symptoms were as follows:
cutaneous bleeding 79%; gingival hemorrhage 33%; epistaxis 30.5%; vaginal
bleeding 27.7%; melena 3.7%; hematuria 4.6%; 1.8% fresh bleeding per rectum
and post-partum hemorrhage 0.9%), The median platelet count at the time of
diagnosis was 15,000/ mm3 where 38.8% patients had a platelet
count<10,000/mm3, ANA was positive in 13.8%, and anti-DNA was positive in
1.8% of ITP patients who had symptoms and signs fulfilling criteria to diagnose
SLE. APL antibodies were positive in 4.8% who also had history either of throm-
bosis or abortion. HBsAg was negative in all studied patients where anti-HCV
antibody was positive in 13.8% of patients, also 15.7% of our patients had pos-
itive H pylori antigen in stool with silent gastritis, 2.7% had positive anti EBV
IgM with high titer and none of studied patients had positive anti CMV IgM.
Regarding the thyroid functions 6.4% had abnormal functions where 3.7% of
ITP patients had overt hypothyroidism. Also the onset of disease was related
to pregnancy in 12% of ITP patients. Regarding Treatment and follow-up; There
was an indication for treatment in 96% of patients, Of the 104 ITP patients who
were given first-line therapy (corticosteroid 1mg/kg/day PO), there was com-
plete response (CR) in 40.3% and 59.7% patients were nonresponsive to ther-
apy. Patients who had failure of response to 1st line of therapy were given a
2nd line of therapy and the details of it were as follow (splenectomy was done
in 16,1% and CR was 3%, 14% received rituximab and CR was 60%, 3%
received (TPO) agonist; Eltombopag and CR was 100%, 45% received com-
bined azathioprine and steroid therapy and CR was 64%, 4.8% received triple
therapy in form of steroid, azathioprine and danazole where CR was 66%, 8.1%
received vincristine and CR was 20% and 5 patients received anti H pylori triple
therapy and CR was 20% ) 
Summary and Conclusions: Most ITP patients were females and investigating
2ry causes of ITP cases even when there is no clear symptoms of the 2ry cause
is very important and may be a rising issues in future. Using another agents as
2nd line therapy rather than splenectomy they proved its value although it still
need more time and number of ITP patients to prove its efficacy that’s why our
study still ongoing recruiting more chronic ITP patients to represent our single
center Egyptian experience.
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MUTATION ANALYSIS AND CLINICAL SPECTRUM IN PATIENTS WITH
BERNARD SOULIER SYNDROME: A SINGLE CENTER EXPERIENCE
H. Tokgoz1,* U. Caliskan1, A. Pecci2
1Pediatric Hematology and Oncology, Necmettin Erbakan University Meram
Medical Faculty, Konya, Turkey, 2Dept of Internal Medicine, University of Pavia,
Pavia, Italy
Background: Bernard Soulier Syndrome (BSS) is a rare inherited disorder of
platelet function due to absence of obviously decreased expression of the
platelet Gp Ib-V-IX receptor. This complex plays a critical role in hemostasis by
initiating platelet adhesion and subsequent activation at the site of injured ves-
sel. Due to rarity of disease, there are reports only a few cases about the rela-
tionship between phenotype and genotype. 
Aims: We aimed to evaluate clinical and genetic characteristics of the patients
with BSS diagnosed at our department.
Methods: Five patients with BSS diagnosed at department of Pediatric Hematol-
ogy, Necmettin Erbakan University, Meram Medical Faculty, were enrolled the
study. The diagnosis of patients was based on low platelet count, presence of
giant platelets and aggregometric studies. Flow cytometry to assess the surface
Gp Ib-V-IX complex showed reduced expression. Clinical manifestations and lab-
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oratory investigations of the patients were evaluated. We also analyzed the coding
regions of genes GpIBA (NM-ooo173,4), GpIBB (NM-000407.4_ and GpIX (NM-
000174.3) using DNA samples of affected patients and their family members.
Results: Four of the patients have mutation in GpIBB gene. Two patients have
c.233T>G (p.Leu78Arg) in GpIBB gene. Two patients have
c.[470T>A(+)472_473del(CT)] (p.Leu157GlnfsX151) in GpIBB gene. One
patient has c.1A>C in GpIA gene. Clinical and laboratory findings of the patients
are summarized in table 1. 
Table 1.
Summary and Conclusions: Patients with BSS often suffer from mucocuta-
neous bleedings. All of our cases are female. Menorrhagia is the major problem
for girls at the age of menstruation. One patient, who carrying the mutation of
c.[470T>A(+)472_473del(CT)] (p.Leu157GlnfsX151) at GpIBB gene, had expe-
rienced spontaneous splenic rupture and successfully treated with conservative
approaches such as transfusion of erythrocyte and thrombocyte suspensions.
Three different mutations were identified in 5 patients. All of them are previously
described mutations. Larger collaborative studies are needed to describe rela-
tionship between clinical phenotype and genotype.
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THE EVALUATION OF OXIDATIVE STRESS IN CHRONIC IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
A.M. Gaman1,2,* M.A. Gaman3
1Hematology, Filantropia City Hospital, 2Pathophysiology, University of Medi-
cine and Pharmacy of Craiova, Craiova, 3”Carol Davila” University of Medicine
and Pharmacy, Bucharest, Romania
Background: Chronic Idiopathic Thrombocytopenic Purpura (ITP) is an
autoimmune disease characterised by a low platelet count determined by an
increased platelet destruction or a decreased platelet production. Oxidative
stress, defined as an imbalance between the reactive oxygen species and the
antioxidant defence system, plays an important role in the pathophysiology of
autoimmune diseases determined by DNA, protein and lipid oxidation.
Aims: To evaluate if oxidative stress is involved in the pathogenesis of chronic ITP.
Methods: We studied 28 patients with chronic ITP hospitalized in the Clinic of
Hematology of Craiova (Romania) between 2012 and 2014 (group A). The A
group was compared to 30 healthy people who represented the control group
(group B). Both free oxygen radicals and total antioxidant capacity were eval-
uated by FORT (Free Oxygen Radicals testing) and FORD (Free Oxygen Rad-
ical Defence) tests from a single drop of capillary blood, at the time of diagnosis,
before the administration of any drug. The normal value of FORT was less
than 2.3 mmol/L H2O2 and the normal value of FORD was in between 1.07-
1.53 mmol/L. The statistical analysis was performed and a p value ≤0.001 was
considered significant. 
Results: A statistically significant difference was determined for both FORT
and FORD levels between the two groups. The FORT and FORD levels were
higher in group A compared with group B.
Summary and Conclusions: We believe that oxidative stress is involved in
the pathophysiology of the chronic ITP. When free oxygen radicals become
excessive and surpass the total antioxidant defence capacity, they are destruc-
tive and attack the fundamental cellular components such as proteins that may
be highly immunogenic and induce autoantibody production which is involved
in platelet destruction.
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EVALUATION OF A FLOW CYTOMETRIC PLATELET COUNT METHOD
M.N. Ben Naoum1,* H. Lazreg1, A. Adda1, M. Hamadi1
1Department of Hemobiology, Etablissement Hospitalier et Universitaire (EHU)
‘‘1er Novembre 1954’’, oran, Algeria
Background: The platelet count is an important orienting test for clinicians to
diagnose various pathologies and in the therapeutic monitoring of patients, this
is why the accuracy of the results is essential and any measurement faults
may leads the clinician to errors in the diagnostic and the treatment.
Aims: We tried to use the high precision of flow cytometry in the platelet count.
In this respect we adapted a simple method and tried it.
Methods: We compared the platelet count obtained by flow cytometry based
on red blood cells/platelet ratio with 2 automated hematology analyzers. : one
with impedance principle and another with optical principle. The flow cytometric
count is performed after labeling platelets with specific monoclonal antibody
(CD61), then the red cells/platelet events ratio is determined on a forward scat-
ter/Fl1 cytogram and the platelet count is calculated from the number of red
blood cells obtained precisely by an hematology analyzer. A total of 105 blood
samples were analyzed including 3 levels quality control: 45 samples with a
normal platelet count, 29 samples with a low platelet count and 31 samples
with a high platelet count.
Results: The correlation of the results of the platelet count obtained by the 3
methods is excellent for samples with normal and low platelet count. However
the impedance hematology analyzer shows less accuracy in the high platelet
count samples. The stability of the flow cytometric platelet count over the time
is good. The mean of the CV over the time is 08%, which is accepted in bio-
logical analysis.
Summary and Conclusions: Finally, we suggest using the flow cytometric
platelet count as a gold standard since the other methods have a large margin
of error and we need exactly results to manage thrombopenic patients. 
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THE BURDEN OF GAUCHER DISEASE: A REVIEW OF THE LITERATURE
L. Nalysnyk1,* T. Eagleton1, A. Hamed1
1Genzyme, a Sanofi company, Cambridge, United States
Background: Gaucher disease (GD) is a rare, genetic lysosomal storage dis-
order caused by a deficiency in the enzyme β-glucocerebrosidase. This enzy-
matic deficiency leads to progressive accumulation of the substrate glucosyl-
ceramide in organ tissues resulting in debilitating hematologic, visceral, and
skeletal manifestations that span a wide spectrum of disease severity and
adversely impact patients’ quality of life. Glucosylceramide accumulation in
macrophage lysosomes of the liver, spleen, and bone marrow leads to anemia,
thrombocytopenia, hepatosplenomegaly, and bone disease as defining clinical
signs. Three subtypes of GD are recognized: type 1 (GD1, non-neuropathic),
type 2 (GD2, acute neuropathic), and type 3 (GD3, sub-acute/chronic neuro-
pathic), with GD1 being most prevalent. Diagnosis of GD relies on clinical pres-
entation, heightened diagnostic suspicion and exclusion of other hematologic
diseases. Enzyme assay to measure deficiency of β-glucocerebrosidase in
leukocytes is the definitive diagnostic test. However, owing to low disease
awareness and symptoms that overlap with other diseases, diagnostic delay
is common, which substantially impairs patient care.
Aims: To better understand the burden of GD, a comprehensive review of the
published literature was conducted.
Methods: MEDLINE, EMBASE, CENTRAL, and conference proceedings lit-
erature sources published in English between January 1990 and February
2013 were searched for relevant publications. Eligible studies were primarily
of observational design and examined the disease epidemiology, clinical and
socioeconomic disease burden of GD and the impact of current treatment
options.
Results: Overall, 2034 citations were identified through a systematic search
of databases, conference abstracts, and manual searches of published reviews.
Full text was reviewed in-depth for 177 relevant studies and a total of 97 pub-
lications were summarized. In the reviewed studies, the standardized incidence
and prevalence of GD in the general population varies from 0.30 to 5.80 per
100,000 and 0.33 to 1.75 per 100,000, respectively, and GD1 is the predomi-
nant type in most regions. The risk of mortality is highest in GD patients who
present younger than age 5 years and generally increases after age 55; the
life expectancy is lower than the general population. Prior to treatment, anemia
was present in 11–75% and thrombocytopenia in 20–62% of GD patients in
the reviewed studies. Prevalence of splenomegaly and hepatomegaly varied
widely among small samples of patients with untreated GD (15–96% and 10–
86%), respectively. Bone pain and bone crises were reported frequently in
studies of patients with untreated GD (8.0–64.2% and 3.4–24.2%), respectively.
Parkinson’s disease and cancer were frequently reported medically important
comorbidities among patients with GD.
Summary and Conclusions: GD is a rare, chronic disease associated with
significant disease burden to patients and their families. Signs and symptoms
of Gaucher disease can be nonspecific and are often suggestive of hematologic
abnormalities, including neoplasms. Disease awareness is of critical importance
in facilitating clinical diagnosis and optimal management. Current treatment
options for GD include enzyme replacement therapy or substrate reduction
therapy. However, there are still medical unmet needs and further research is
needed in this area.
772 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
PB1970
IMPACT OF THE ABNORMALITIES IN IMMUNOGLOBULIN LEVELS IN THE
EGYPTIAN PATIENTS WITH ITP
T.E.E. Abouzeid1,* E. Azmy1, M.S. Elghonemy2, S. Aref2, S. Abd Elaziz2,
A. Elsabaagh3
1Hematology, 2Clinical pathology, 3Micrbiology, Mansoura Oncology Center,
Mansoura, Egypt
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune dis-
order that characterized mainly by a low platelet count and absence of any
apparent initiating and/or underlying cause of the thrombocytopenia. ITP is
associated with a loss of tolerance to platelet antigens and a phenotype of
accelerated platelet destruction with impaired platelet production. Common
variable immunodeficiency (CVID) is a mixed group of disorders characterized
by decreasing the Immunoglobulins (Igs) and an increased susceptibility to
repeated infections, autoimmunity and malignancies. Both ITP and autoimmune
hemolytic anemia (AIHA) are autoimmune disorders which can be seen together
with CVID.
Aims:. This study aimed to assess the immune system deregulation in the form
of measuring the immunoglobulins (Igs) levels in patients diagnosed as ITP
and correlates the relation of these levels to the initial platelet counts, severity
of the disease, treatment response and clinical outcome.
Methods: Across-section study was done on 105 patients’ age range from 10-
61 years, with newly diagnosed ITP at the Oncology Center Mansoura Univer-
sity over the past 2 years.
Results: The patients with IgA level below or equal to median had good
response to stander treatment (steroids, intravenous Ig (IVIG), or intravenous
anti-D), while the patients with a higher IgA level than median showed excellent
response with stander treatment (P=0.02). Subjects with High IgA levels asso-
ciated with increased major bleeding but not platelet count. Low IgM levels
associated with failure to response to stander treatment and platelet count but
not major bleeding. Changes in IgG levels wasn’t associated with either
response to treatment nor bleeding tendency or platelet count.
Summary and Conclusions:. We recommend initial measure of immunoglob-
ulin level in patients with ITP to help us in the treatment protocol for each
patient.
Quality of life, palliative care, ethics and health
economics
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UNMET NEED FOR TREATMENT RELAPSES IN MANTLE CELL LYM-
PHOMA: DECREASING INTERVALS BETWEEN SEQUENTIAL TREAT-
MENT LINES IN THE US
S. Le Gouill1,* J.Y. Chen2, D. Mahmoud3, H.X. Hu3, R.L. Wade2
1Haematology Department, CHU Nantes and UMR892 INSERM, Nantes,
France, 2Health Economics and Outcomes Research, IMS Health, Plymouth
Meeting, 3Global Market Access, Celgene Corporation, Summit, United States
Background: No large scale description of sequential treatment (tx) lines and
time to the next treatment (TTNT) exists for mantle cell lymphoma (MCL).
Aims: This study evaluated first, second, and third tx lines (1L/2L/3L) and TTNT
for US patients in the usual care setting.
Methods: MCL patients (pts) were identified from the IMS PharMetrics Plus
database (>100 million US pts) having ≥2 medical claims (ICD-9-CM 200.4x)
at least 30 days apart in 2008-2012 (the first diagnosis date as the index), no
MCL claims in the 6 months pre-index and continuous enrollment in the health
plans for ≥3 months post-index. The 1L therapy was defined as all MCL tx
administered within 90 days of tx start. A new tx line was defined as addition of
a new agent ≥90 days from tx start, or when tx was restarted following a 90 day
gap in therapy. For ASCT pts, TTNT to 2L was the duration from ASCT proce-
dure date to the start of subsequent tx; for non-ASCT patients and ASCT pts
post-2L, TTNT was the time between the initiation of current line tx to the begin-
ning of next line tx. Rituximab (R) monotherapy was not considered a new tx
line when initiated within 12 months post any tx line.
Results: Of the 872 pts in the study, 172 (19.7%) received ASCT, 628 (72.0%)
were males and mean age was 63.3 years. Comparison between transplanted
and non-transplanted pts revealed ASCT pts were younger (median: 56.8 vs
64.9 years). Compared to non-transplanted pts, ASCT pts had also fewer
comorbidities calculated by Charlson Comorbidity Index (mean: 1.63 vs 2.44).
Within 1L, the majority (52.9%) of ASCT pts received tx regimens containing
anthracycline + R, followed by regimens containing cyclophosphamide or vin-
cristine +/- R (18.6%). The most frequent 1L tx regimens for non-ASCT pts
were anthracycline +/- R (30.7%), R monotherapy (19.9%) and bendamustine
+/- R (13.9%). The most common tx regimens in 2L contained R monotherapy
(32.3%), bendamustine +/- R (21.9%), bortezomib +/- R (16.8%) and other
chemotherapy +/- R (24.3%), and the most common regimens in 3L contained
bendamustine +/- R (29.4%), R monotherapy (20.2%), bortezomib +/- R
(14.3%), and other chemotherapy +/- R (23.5%). Of the pts not followed to
TTNT (n=538), median follow-up time in days was 517 from the start of 1L tx,
304 from 2L tx, and 243 from 3L tx. The median TTNT to 2L was 349.5 days
for pts who relapsed after ASCT (n=54) and 421.5 days for relapsed non-ASCT
pts (n=280). For all relapsed/refractory pts, median TTNT was 403.5 days from
1L to 2L (334 pts); 272 days from 2L to 3L (119 pts), and 213 days from 3L to
4L (41 pts).
Summary and Conclusions: Within each tx line, there was substantial varia-
tion in treatment regimens. The decreasing interval from one line of therapy to
the next line of therapy suggests that once patients relapse, they deteriorate at
an increasing pace. Taken together, the current results suggest an unmet need
exists for effective treatment of patients that relapse.
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A TRANSITION FROM USING “OFF-LINE” TO INTEGRATED PROCE-
DURES FOR PERFORMING EXTRACORPOREAL PHOTOPHERESIS: A
COMPARISON OF COSTS AND EFFICIENCIES
N. Azar1, M. Ouzegdouh1, N. Goncalves1, N. Mouayas1, C. Cherat1,
M.J. Chollet1, V. Leblond1, J. A. Button2, P.M. Button2,*
1Groupe Hospitalier, Pitié Salpêtrière, Paris, France, 2ProcEx Solutions Ltd,
Wales, United Kingdom
Background: The Hemobiotherapy Department at Pitié Salpêtrière Hospital
has been providing extracorporeal photopheresis (ECP) procedures for patients
presenting with graft versus host disease (GvHD) and cutaneous T-cell lym-
phoma (CTCL) since November 2011 and for lung transplant rejection patients
since June 2013. Initially, an “off-line” system was used for all procedures, and
in the first 12 months we carried out a total of 225 treatments. At the end of
2012 we commenced a transition from the off-line system to a Therakos inte-
grated photopheresis system. In 2013 we carried out a total of 527 ECP pro-
cedures with 397 using the integrated system. At the start of 2014, the unit was
thought to be close to capacity so we participated in a ProcEx Solutions work-
flow assessment where we successfully implemented improved ways of man-
aging the increasing demand with the same number of nurses in the unit. Then,
in 2014 we transitioned to performing all procedures using the integrated system
and a total of 797 treatments were performed.
Aims: The aim of this study was to compare the cost and efficiency of perform-
ing ECP using the off-line system versus the Therakos integrated system.
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Methods: An activity-based costing method was applied to provide an accurate
and meaningful cost comparison between administration of ECP using the off-
line method or the integrated system. This was important so as to not be misled
by comparing the costs of off-line and integrated system procedural kits alone.
Results: The cost of performing ECP using the off-line system was more
expensive than the Therakos integrated system (€1,429 vs €1,265) resulting
in a cost avoidance of €131,242 for 2014 by performing all ECP treatments on
the integrated system. Of note, the lymphocyte PHA and OKT3 inhibition tests
mean scores were 99.2% (Integrated system) and 97.4% (off-line system),
respectively. Off-line (Macopharma) Integrated (Therakos) Collection of leuko-
cyte concentrate (PTC) €173.75 €1,009.20 Biologic analysis (patient) €59.00
€59.00 Biologic analysis (cell collection) €31.05 — Transportation of cells to
CT area €7.76 — Irradiation of leukocyte concentrate €616.55 — Biologic
analysis (irradiated cells) €76.00 — Transportation of cells to ward €7.76 —
Injection (triple access) €12.00 — Personnel costs €108.00 €40.50 Bed reten-
tion cost/treatment (per hours used) €337.50 €156.00 Total cost €1,429.37
€1,264.70Number of treatments in 2014 797 Cost per treatment €1,429.37
€1,264.70 Total cost in 2014 €1,139,208 €1,007,966 Difference in cost (2014)
€131,242.
Summary and Conclusions: The transition from off-line to the Therakos inte-
grated system proved beneficial in terms of cost and ease of implementation.
The integrated system has resulted in efficiency gains in terms of the number
of patients who can be treated in a day with the same number of nurses being
employed. For hospitals considering a transition from off-line methods where
cost is a barrier, activity-based costing should be applied to gain an accurate
understanding of the true situation. Also, reimbursement factors should be con-
sidered when making a judgement; the off-line system allows significantly fewer
treatments, so reimbursement levels received by the treatment center will be
substantially reduced.
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INNOVATION IN ONCOLOGY: WHY FOCUSING ONLY ON BREAK-
THROUGH INNOVATION MAY BE COUNTER-PRODUCTIVE
C. Quinn1,* S. Palmer2, J. Bruns3, J. M. Borras4, C. Grant1, D. Sykes1, S. Kaura5
1PRMA consulting Ltd, Fleet, 2Centre for Health Economics, University of York,
York, United Kingdom, 3Deutsche Krebsgesellschaft, Berlin, Germany, 4Depart-
ment of Clinical Sciences, University of Barcelona, Barcelona, Spain, 5Celgene
Corporation, Summit, New Jersey, United States
Background: Innovative oncology products are routinely perceived to be those
that offer a substantial increase in overall survival (OS), usually above a certain
threshold. However, this growing emphasis on significant OS gain (break-
through innovation), to the exclusion of other clinical and non-clinical gains,
undervalues new products and may not capture aspects of treatment that are
important to patients. Clinicians, patient groups, and manufacturers argue that
progressive innovation in other domains needs to be considered and valued in
regulatory and health technology assessment (HTA) decisions. 
Aims: The aim of this paper is to bridge the perspectives on progressive inno-
vation and the approaches taken to measure and value innovation among dif-
ferent stakeholders at all levels of drug approval, appraisal and access.
Methods: We conducted a targeted literature search for definitions of innova-
tion in academic and grey literature, covering regulatory, HTA, and industry
bodies. Current/proposed OS thresholds were applied to standard of care
(SOC) therapies in colorectal cancer (CRC) and non-small cell lung cancer
(NSCLC).
Results: The magnitude of OS benefit consistently emerges as key in the def-
inition of innovation from policy (e.g., England’s Cancer Drugs Fund) and clinical
(e.g., American Society of Clinical Oncology [ASCO]) perspectives. Regulators
and HTA agencies do not provide clear consistent definitions, however. Empha-
sis is increasingly on ‘clinically meaningful’ change in survival, expressed as
minimum thresholds: OS gain >2.5months, HR>0.8; progression-free survival
gain >3months, HR>0.5. Only one of six CRC products approved since 2000
met the OS threshold published by ASCO of three to five months (Ellis et al.
2014) whereas survival has doubled in that time. None of the products
approved for NSCLC since 2005 met the OS threshold, for 3.25 to 4 months,
while survival in patients receiving first-line treatment for advanced NSCLC
has also doubled.
Summary and Conclusions: Innovation should not be defined solely on one-
time large survival gains but should be evaluated according to the value pro-
vided to patients and health systems. Smaller sequential gains in clinical benefit
and improvements in quality of life, safety, convenience, and system efficiency
should be considered in assessing value and innovation. Products that have
smaller outcome gains can be combined to provide an amplification of effec-
tiveness. Similarly, small incremental advances can lead to significant
improvemments over time. If the focus moves too far towards breakthrough
innovation, these treatment opportunities will be lost. Progressive innovation
in these aspects provides opportunities for immediate benefit, including survival
until the next therapy is available, and may uncover new clinical pathways with
significant cumulative benefit over time. Recognition of this ‘option value’ for
future health and research advances is needed. Focussing only on break-
through OS gains Regulatory and HTA agencies should balance clinical and
economic gains and societal and patient preferences when evaluating innova-
tion in a new therapy.
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IMPACT OF THE ECONOMIC CRISIS IN GREECE ON THE MANAGEMENT
OF THALASSEMIA PATIENTS
A. Teli1,* V. Gourtsa1, S. Theodoridou2, M. Economou1
1First Department of Pediatrics, Aristotle University of Thessaloniki, 2Hemo-
globinopathy Prevention Unit, Hippokration General Hospital, Thessaloniki,
Greece
Background: Economic crisis has had a major impact on public health in
Greece during the last 5 years, negatively affecting both ability for health insur-
ance coverage and availability of medical and laboratory services. As all
patients suffering from chronic illnesses, thalassemia patients have had to live
with and try to overcome relevant difficulties. 
Aims: Purpose of the present retrospective study was to evaluate the impact
of economic crisis on management of thalassemia patients for the 5 year crisis
period (January 2010-December 2014) in a single pediatric institution. 
Methods: A total of 17 multi-transfused pediatric patients participated in the
study. Patient data assessed included annual heart and liver MRI T2* meas-
urements, transfusion frequency, chelation therapy, as well as mean annual
pre-transfusional hemoglobin and ferritin level. Changes in family working sta-
tus of the patients as well as in insurance coverage ability were recorded. 
Results: Mean study population age was 10.5 years (range 6.5-18 years),
with a baseline mean pre-transfusional hemoglobin of 9.5g/dl, a mean ferritn
value of 1380ng/mL, a mean heart Τ2* of 32m (20-58ms) and a mean liver T2*
of 7.4ms (3.1-26ms). No significant change in pre-transfusional hemoglobin
was recorded during the study period, as all patients continued their regular
transfusion program. All patients continued chelation therapy during follow-up.
Changes in chelation therapy during study period were only based on medical
criteria and were not related to economic issues. With regards to ferritin levels,
13/17 patients showed an improvement, with an overall statistically significant
improvement in the mean value at the end of study. As to iron concentration,
15/17 patients improved their liver measurements and 2/17 remained stable.
Out of 17 patients, 8 improved their heart measurements, 2 remained stable
and 8 showed decrease in heart values – however, in only one case did the
measurement reach an abnormal value, consistent with mild heart siderosis.
With regards to insurance ability, 3/17 patients lost coverage due to parents’
unemployment, but Social Security provided free services, enabling patients
to continue regular transfusions and chelation treatment.
Summary and Conclusions: Although Greece has seriously suffered during
the last years because of the economic crisis, provision for health has managed
to survive-at least for patients suffering from chronic illnesses, such as thalassemia.
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PREVALENCE OF TRANSFUSION TRANSMITTED INFECTIONS IN INDI-
VIDUALS WITH THALASSEMIA IN PAKISTANI POPULATION
H. Yasmeen1,2,* S. Hasnain1,2
1Department of Microbiology and Molecular Genetics, University of the Punjab,
Lahore Pakistan, Lahore, 2Department of Microbiology and Molecular Genetics,
The Women University, Multan, Multan, Pakistan
Background: Individuals suffering from thalassemia requires regular transfu-
sion in absence of expensive stem cell transplant treatment. However, repeated
or frequent blood transfusion along with post transfusion hepatitis intensifies
the severity of disease and it continues to be a problem in these high risked
individuals.
Aims: Present study undertaken at multicenter of Pakistan aims to estimate
the prevalence of blood transfusion transmitted infections (TTI) in individuals
suffering from beta thalassemia. 
Methods: In a cross-sectional study, after consents 350 individuals suffering
from beta thalassemia excluding patients of any other blood disease were inter-
viewed for different epidemiological parameters e.g. Gender, age, transfusion
history, family and personal history from October 2012-December 2013.
Haematological parameters such as RBC indices and quantification of haemo-
globin were recorder retrospectively. Individuals were screened for transfusion
transmitted infections (TTI) mainly anti-HIV, HBsAg and anti-HCV. 
Results: Out of 300 thalassemic individuals 47% (142/350) were infected with
TTI including 78 males and 64 females. The seroactivity for HCV was highest
93% (133/142) followed by for HBV 6.3% (9/142) and no seroactivity for HIV.
Beta thalassemia major (>95%) was most common followed by thalassemia
intermedia (<5%) and few structural variants (<1%) e.g. HbS and HbH. When
compared to the normal age span, it was observed that only 3.14% (11/350)
of the patients crossed the second decade of their life. Early onset disease
(before 6 months) was more common (24%; 124/350) than the late onset e.g.
above 36 months (06%; 21/350). 
Summary and Conclusions: Short life span and high number of HCV/ HbBAg
status depicts that in a country like Pakistan insufficient facilities, poor man-
agement and compromised socioeconomic status are deteriorating the disease
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status. More multicenter studies covering cities from different regions of country
are needed in developing preventive measurements at regional and national
level. 
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THE QUALITY OF LIFE OF ANEMIC PATIENTS WITH LYMPHOPROLIFER-
ATIVE DISORDERS TREATED WITH RED BLOOD CELL TRANSFUSIONS
AND ERYTHROPOIESIS-STIMULATING AGENTS
N. Romanenko1,* A. Romanenko2, M. Zenina1, N. Potikhonova1,
K. Abdulkadyrov1
1Clinical Hematology, Russian Research Institute of Hematology and Transfu-
siology, FMBA of Russia, 2Clinical Neurology, Children Hospital of St. Olga,
Saint-Petersburg, Russian Federation
Background:Although haematological toxicities, such as anemia, are common
in lymphoproliferative disorders (LPD), no clear consensus exists on the use
and impact of Erythropoiesis-stimulating agents (ESA) and Red blood cells
transfusions (RBCsT) on quality of life (QoL).
Aims: To assess alteration of QoL in anemic patients with LPD treated with
RBCsT and ESA.
Methods: There were included 131 anemic patients with LPD (multiple myelo-
ma, low-grade non-Hodgkin’s lymphoma, chronic lymphocytic leukemia). Medi-
an age of patients was 67 years (range 24-85). All persons were divided into
two groups: 1st group included patients (n=54) treated with RBCsT, 2nd (n=77)
– treated with ESA. Posetive response for ESA considered as achievement of
hemoglobine concentration 120 g/L or increase Hb ≥ 20 g/L. QoL was studied
with Functional Assessment of Cancer Therapy Anemia subscale (FACT-An)
and Fatigue subscale (FACT-F).
Results: In the 1st group of patients treated with RBCsT (in average 3.7±0.3
Units) concentration of Hb increased from 70.0±1.6 g/L to 93.1±1.2 g/L. Statisti-
cally significant improvement of their QoL was found in FACT-An subscale – from
41.1±2.0 (95% Cl=37.1-45.0) to 34.2±2.1 (95% Cl=30.0-38.3) points (P<0.001;
n=54). Improvement of QoL was also found in FACT-F subscale – from 30.2±1.4
(95% Cl=27.8-32.9) to 23.2±1.5 (95% Cl=19.8-26.9) points (P<0.0001; n=54). In
the 2nd group positive response for ESA-therapy was found in 52 (67.5%) out of
77 patients: 39 (50.6%) patients achieved the Hb concentration 120 g/L and 13
(16.9%) ones increased Hb more than 20 g/L. The patients with positive response
increased the Hb concentration significantly from 88.4±1.4 g/L to 123.1±2.4 g/L
(P<0.0001; n=52). We found out improvement of QoL in both subscale: in FACT-
An – from 34.5±1.7 (95% Cl=31.1-37.9) to 30.1±1.6 (95% Cl=26.9-33.2) points
(P<0.001; n=52) and in FACT-F – from 22.8±1.3 (95% Cl=20.3-25.4) to 19.7±1.2
(95% Cl=17.3-22.1) points (P=0.013; n=52).
Summary and Conclusions: Both RBCsT and ESA-therapy are able to
increase Hb concentration considerably and improve QoL. However the RBCsT
patients had more severe anemia and over a period of its correction the RBCsT
patients’s planned level of Hb was less than ESA-patietnts’s one therefore their
final QoL was less. So using the ESA-therapy can increase higher Hb concen-
tration and improve QoL more than RBCsT. It’s indicating importance of ESA-
therapy not as alternative RBCsT method of anemia’s correction but also as a
way to prevent decreasing of the Hb induced by toxic effect of chemotherapy
and as a method of anemia treatment with which a normal Hb level can be
achieved.
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VITAMIN D DEFICIENCY IN SURVIVORS OF CHILDHOOD ACUTE
LEUKEMIA
S. Tasdelen1,* M. Öztürk2, F. Şirin2, N. Sönmez2, Y. Cıvır1, Ü. Ezer2,
M. Mumcuoğlu3, A. Kürekçi2
1Clinic laboratory, 2Pediatric hematology/oncology, 3Genetic laboratory, Lösante
Hospital, Ankara, Turkey
Background: Vitamin D plays an important role in calcium and bone metabo-
lism. It also exerts some biological effects in regulatory systems including host
defense, inflammation and immunity. Vitamin D deficiency is to be a worldwide
problem, especially in developing countries. Low serum levels of 25-hydroxy-
vitamin D (25(OH)D) have been associated with a number of diseases like car-
diovascular diseases, diabetes, cancer, and infections. However, recent studies
demonstrated evidence for vitamin D in preventing the development of many
diseases including cancer. 25(OH)D is formed by hydroxylation of cholecalcif-
erol in microsomes of hepatocytes. The serum concentration of 25(OH)D is
used to determine vitamin D status in the body.
Aims: The prevalence of subclinical vitamin D deficiency has been reported to
be higher in adult survivors of childhood cancer (1). However, the data on this
subject are scarce.In this study, we aimed to determine the frequency of vitamin
D deficiency/insufficiency in acute leukemia patients who completed treatment.
Methods: Serum 25(OH)D levels of leukemia survivors were measured using
liquid chromatography-mass spectrometry (LC-MS) technique who were fol-
lowed-up at Late Effect Clinic in Lösante Hospital between January 2013 and
December 2013. According to criteria published by Mısra M et al. the serum
25(OH)D levels<15-20 ng/mL is considered insufficiency, or deficiency if<15
ng/mL or severe deficiency if ≤10 ng/mL for children and adolescents (2,3).
According to criteria published by Kuchuk NO et al. the serum level of 25(OH)D
was considered insufficiency if the level was ≤30 ng/mL and deficiency<10
ng/mL for young adults. (3,4)
Results: Two hundred and forty-eight patients (113 female and 135 male) aged
between 3 and 31 were recruited. Of these, 233 patients had acute lymphoblas-
tic leukemia (ALL), 12 acute myeloid leukemia (AML), and 3 myelodysplastic
syndrome (MDS).Treatment completion times were between 2 months and 17
years. The results of serum 25(OH)D levels in survivors of childhood leukemia
are shown in Table 1. Overall, 95 children and adolescents (38.1%) had normal
levels of 25(OH)D whereas only two young adults older than 21 years (10.5%)
had normal levels.
Table 1. Distribution of 25-hydroxy-vitamin D Levels after Chemotherapy
According to Age.
Summary and Conclusions: The results of the current study showed that
vitamin D insufficiency/deficiency is an important problem in survivors of
leukemia even in a country which the rate of sunlight exposure is high. Studies
in recent years, which show that vitamin D deficiency plays an important role
in many diseases, including cancer, emphasize the importance of detection of
the insufficiency/deficiency of Vitamin D and the necessity of the planning the
corrective treatment. Vitamin D deficiency is a health problem that concerns all
age groups. Vitamin D inadequacy is now an internationally recognized health
problem and survivors of neoplastic diseases may be at even higher risk than
healthy children, adolescents, and adults. Thus, the measurement of vitamin D
level in survivors of neoplastic diseases seems mandatory during their follow-
up.(3,5).
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THE RULE OF QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS
PATIENTS WITH ACUTE MYELOID LEUKEMIA IN A MONOCENTRIC EXPE-
RIENCE
C. Buquicchio1,* L. Ciuffreda1, T. Santeramo1, P. Mongelli1, R. Miccolis1,
D. Diomede1, G. De Sanris1, G. Tarantini1
1Ematologia, Ospedale Dimiccoli, Barletta, Italy
Background: In older patients the concept of frailty is changing, infact actually
it’s necessary to analize not only the age and the comorbidities but also how
the tumoral pathology involve and modify the performance status of the patient
s(generally calculated by karnosky, IADL and ADL scale)
Aims: We investigated the value and utility of a simple and fast questionnaire
about physical and mental quality of life (SF12 Standard V1) administered to a
group of elderly consecutive patients with acute myeloid leukemia in our single
center.
Methods: During the years 2013-2015 twenty consecutive patients with acute
myeloid leukemia (AML) and age >65 years treated with hypomethylating agents
(azacitidine 75mg/m2 for seven consecutive days each twenty-eight days) com-
piled a simple questionnaire(SF12 Standard V1) with twelve questions to deter-
mine and quantify the degree of physical and mental fitness/frailty at the onset
of AML and during the treatment(each six months with a monitoring an year.
Results: We observed that the patients with higher score at the questionnaire
(major impairments in physical activity and mental discomfort) had a poor out-
come, while patients with lower score at AML onset or score improvement of
6th months questionnaire(during treatment) predicted longer overall survival
(median 200 days versus 600 days;p0.03) and better response to therapy (over-
all response vs non response p0.04).
Summary and Conclusions: The quality of life questionnaire could help to
have a more complete vision of the pathology in those vulnerable patients and
to take therapeutic decision (non intensive care versus intensive care)consid-
ering the reversibility of frailty caused in part of the acute leukemia.Clinical
trials are necessary to confirm the rule predictor of this quality of life question-
naire for overall survival and response to therapy in a large population of older
AML patients.
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HALOPERIDOL CURES COGNITIVE DYSFUNCTION; THE MECHANISM
OF ACTION IS EXPLAINED.
M. Van Hoef1,*
1Transplant Creations, Amsterdam, Netherlands
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Background: Cognitive disorders occur in the course of life threatening situ-
ations such as deportation and diseases such as cancer and are often asso-
ciated with acute stress and post traumatic stress disorders induced by the
treatment received. A battery of function tests have been used to assess cog-
nitive disorders but cure for these disorders is not known.
Aims: Cognitive dysfunction has been reported after cancer treatment and
after hematopoietic stem cell transplantation. The observations in this case
lecture how to proceed in patients with similar conditions in the treatment of
cancer. 
Methods: The subject experienced a life changing situation of major impact
that induced a cognitive disorder, which expressed itselves in difficulty writing
letters, documents and composing presentations; moreover she reported her
capacity after deportation to be 10% of her former capacity (1). At a conference
in 2013 a video was presented of a patient who had been treated for breast
cancer who had the same cognitive disorder, being difficulty writing.
Results: Treatments that impact life drastically induce stress that may result
in acute stress disorders, posttraumatic stress disorders and cognitive impair-
ment. The subject was initially not treated and noticed slow improvement; how-
ever the old level of functioning was not reached and work finally resulted in
burnout. Although time off work improved the status it was not until haloperidol
was instated that she noticed improvement of writing skills after about three
weeks of treatment. A few years later upon new exposure to stress she noticed
a decrease in capacity that could not be overcome with rest and requested
reinstatement of haloperidol. She reported recovery in about three weeks after
start of therapy. The subject first received haloperidol at a dose of 5 mg/day
which was too high and induced extrapyramidal side effects. The dose was
reduced to 2 mg/day, which was well tolerated. Although the subject had been
advised to take the drug life long she stopped after nine to ten months and
remained well. The second time haloperidol was prescribed at 2 mg/day and
well tolerated and the function recovered in about three weeks. The subject
took the drug four months and alternated 2 mg and 1 mg every other day. Since
stopping the subject‘s status has remained well.
Summary and Conclusions: Biochemical studies have demonstrated that
stress increases dopamine turn over in the prefrontal cortex, which is associ-
ated with cognitive deficits (2). Haloperidol is a dopamine receptor antagonist
and administration reverses cognitive impairment.Van Hoef MEHM. Successful
treatment of stress induced cognitive impairment with haloperidol; evaluation
also warranted in hematopoietic stem cell transplantation. The observations
described hereabove warrant evaluation of haloperidol as treatment for cogni-
tive disorders that may develop in the course of treatment for cancer; although
these are generally attributed to chemotherapy, the mechanism of action may
rather be attributable to stress induced biochemical changes in the brain. In
prescription of the drug, doctors should inform the recipient what to expect
from the drug, that treatment is temporary, that they can relapse and that at a
dose of 2 mg/day driving capacity is affected.
References:
1. Van Hoef MEHM. Hematology and Leukemia 2015; doi 10.7243/2052-434X-3-1.
2. Amsten AF, Goldman-Rakic PS. Arch Gen Psychiatry 1998;55(4):362-8.
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DEVELOPMENT OF A PROGRESS TEST BASED ON THE EHA CURRICU-
LUM AND EHA CV PASSPORT, USED FOR YEARLY EVALUATION OF
HEMATOLOGY RESIDENCY IN SWEDEN
J. Ungerstedt1,* A. Eriksson2, E. Ölander3, E. Bergfelt2, M. Liljeholm3,
H. Lind Kristjanssdottir1, T. Erger1, D. Erixon3, C. Isaksson3, G. Birgegård2
1Department of Medicine, Karolinska Institute, Stockholm, 2Department of Med-
ical Sciences, Uppsala University, Uppsala, 3Department of Medicine, Umeå
University, Umeå, Sweden
Background: In Sweden, after 5.5 years of medical school and 18-21 months
of general internship, you can pursue a residency in internal medicine and
hematology, which takes an additional 6.5-7 years. The Swedish Hematology
Association (SHA) [AE1] appointed a Work Unit (WU) of resident hematologists
lead by two senior colleagues with a vast teaching experience, to develop a
yearly progress test for evaluation of hematology residents in Sweden. The
framework for the progress test was the EHA curriculum and EHA CV Passport,
which divides the Hematology Specialty into eight large parts, with subunits to
systematically cover the whole field of Hematology.
Aims: The aim for the WU was to develop a yearly MCQ based progress test,
based on the eight parts of the EHA CV Passport, and to launch it among
Swedish resident hematologists, with a questionnaire to fill out along with the
assessment.
Methods: Individuals or groups of Swedish experts, e.g. the National Diagnostic
Groups, were asked to produce a number of multiple choice (MCQ) questions.
The questions were read, revised and sorted by the WU, after which 75 MCQ
questions, covering the eight major fields of the EHA CV Passport, were select-
ed. The test was available via the SHA homepage, www.sfhem.se for one week
in October 2014, whereafter the test was removed and the answers posted
online. Instructions were to complete the test within 2 hours, and when answers
were available, sit down and discuss with a clinical mentor, and fill out an internet
based questionnaire on your impressions of the MCQ test.
Results: Among 77 listed resident physicians in the SHA registry, 54 (70%)
answered the questionnaire. Out of these, 83% had completed the test. All
except one valued the subjective usefulness of the test to high/very high, and
interestingly, 37 of 54 reported that their test result would contribute to them
actively re-planning their education in some way, mostly by adding courses in
specific subjects, or by increasing literature studies. 67% had not yet gone
through the test with mentor, but almost all claimed that they would do so in
the near future. There was an even spread in years of education, with 21 in the
beginning, 10 in the middle, and 23 physicians at the end of their residency. All
but two residents acknowledged that they would do the test again next time it
is given, to assess progress on an individual level. Comments from residents
were that the test was well received, the questions adequate to assess skills,
and helpful to point out weaknesses to work on.
Summary and Conclusions: There is a need for continuous evaluation of
acquired skills during residency. The Swedish MCQ progress test reflecting
the EHA CV Passport was well received by the resident doctors and may be
an appropriate tool for yearly progress evaluation.
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ANDRAL NETWORK: OPEN ACCESS SOLUTION FOR BEST CYTOLOGI-
CAL EXPERTISE
V. Leymarie1,2,* F. Trimoreau2, D. Lusina3, J.M. Martelli4, F. Delhommeau5,
A.C. Galoisy6, F. Geneviève7, J.F. Lesesve8, O. Crepin9, S. Daliphard10,
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pital, Melan-les-Mureaux, 5Department of Hematology, Saint-Antoine University
Hospital, Paris, 6Laboratory of Hematology, Hautepierre University Hospital,
Strasbourg, 7Laboratory of Hematology, University Hospital, Angers, 8Depart-
ment of Hematology, University Hospital, Nancy, 9Laboratory of Hematology,
Local Hospital, Bethune, 10Laboratory of Hematology, University Hospital,
Rouen, 11French Speaking Group of Hematology, Paris, 12Laboratory of Hema-
tology, Côte de Nacre University Hospital, Caen, France
Background: In hematology, the microscopic analysis of cellular morphology
of blood, bone marrow, lymph node… samples remains the first important stage
for diagnosis and patient follow-up. In our field, the application of information
technology has allowed remarkable developments: iconographic databases,
e-learning systems, automated systems of classification of blood cells, and
cytological web-review of clinical protocols. However, the cytological diagnosis
itself has yet to really benefit from the great possibilities offered by modern
technology.
Aims: In this aim, the French speaking Group of Cellular Hematology in part-
nership with the College of Hematology established the open access solution
of “tele-expertise” in cytology: the ANDRAL network.
ANDRAL proposes remote expert decision-making support in cytology: for any
transmitted request for classification, an image file with a clinical/biological
form is submitted. The network then allows remote classification and diagnosis
to be obtained by opinion of two expert reviewers within 24h. 
Methods: The ANDRAL network is accessible on www.gfhc-reseau-andral.fr.
It is free and accessible to both hospital and the private biologists. ANDRAL is
linked to a group of 45 international expert reviewers, who assure by paired
review, continuous cytological care service. Globally, the system satisfies the
strictest requirements regarding medical data exchange in terms of security,
confidentiality, and sample/patient traceability.
Results: From October 2012 through August 2014, the network recorded more
than 300 registrations with approximately 40% from private biologists, 60%
from biologists practicing in a local or university hospital. 15% of the subscribers
(n=42) practiced outside of France. Over the same period, more than 200
dossiers were submitted. 70% were de novo diagnoses; 15% were urgent
requests. Image files were selections of images and rarely wide field images.
The requests were variable ranging from benign to malignant pathologies and
common occurrences to rare hemopathies. The average time of request man-
agement was 1h50min, and the time to obtain a classification was on average
6h00min. The ANDRAL network also features specific evaluation tools which
allow for follow up activity and also allow the measure of the quality of service
provided.
Summary and Conclusions: Today, the assessments and the perspectives
offered by ANDRAL network are real and very encouraging. In term of assess-
ments, the constant and rapid increase of membership, the incredible motiva-
tion of all the expert reviewers and the high quality of exchanges are highlights.
Several developments are further committed: collaboration with other networks
and other countries and the development of a permanent economically feasible
medical model. For the hematologists involved in morphological diagnoses,
the ANDRAL network is a working example of cooperative function of which
the first results are very encouraging.
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PREVALENCE AND TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
IN GERMANY: AN ANALYSIS OF SICKNESS FUNDS 
J. Tomeczkowski1,* M.K. Leisten1, H. Metin1, J. Fleischmann1, C. Tapprich1
1Janssen-Cilag GmbH, Neuss, Germany
Background: No central registries for patients with mantle cell lymphoma
(MCL) exist in Germany.
Aims: The objective of this analysis was to determine the number of patients
with MCL diagnosed (with or without other diagnoses of cancer) and to char-
acterize the types of treatment being utilized and care settings using sickness
funds claim data.
Methods: This analysis evaluates data from 1,771,225 beneficiaries in 2012
from different statutory sick funds (SHI). MCL patients were identified by ICD-
10 C83.1, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemother-
apy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number
(PZN) 9999092 and/or operating and procedure code (OPS) 854*.
Results: 78 patients with a diagnosis of MCL (C83.1) could be identified
(4/100.000). Overall gender ratio was 76.9% male and 23.1% female. Additional
oncological diagnoses were found in 43.6% of patients. 20.7% had malignant
neoplasms of ill-defined, other secondary and unspecified sites (C76-80), 17.2%
had malignant neoplasms of digestive organs (C15-26), 13.8% had melanoma
(C43-44), 10.3% had neoplasms of uncertain behavior, polycythemia vera and
myelodysplastic syndromes (D37-48), 8.6% had malignant neoplasms of uri-
nary tract (C64-68) and malignant neoplasms of lip, oral cavity and pharynx
(C00-14) (multiple diagnoses possible). The outpatient diagnosis rate was
64.1%, inpatient rate 15.4% and in- and outpatient 20.5%. From a total of 78
patients 44 (56.4%) patients received chemotherapy (40 men [90.9%] and 4
women [9.1%]) in 2012. 25.0% of patients received both out- and in-patient
treatment, 65.9% received out-patient treatment and 9.1% in-patient treatment.
Identification of the administered substances was possible when ATC codes
were reported. The most commonly used treatments were rituximab (34.7%),
bendamustine (14.9%), cyclophosphamide (11.9%), vincristine (8.9%), doxoru-
bicine (21.8%) and other treatments (21.8%) (multiple treatments possible).
Summary and Conclusions: Prevalence and gender ratio 3:1 was consistent
with previously reported1,2. Most patients were diagnosed and treated as out-
patients. Other oncological disorders are higher than in chronic lymphocytic
leukemia³. About half of the patients were treated with chemotherapy within a
year.
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THE SOUTHERN TRANSYLVANIA HEMATOLOGICAL PATIENTS’ OPINION
ON THE QUALITY OF MEDICAL CARE
R.-G. Mihaila1,* L. Mondoc2, C. Salcudean2, V. Baldovin2, N.M. Stopici2
1Faculty of Medicine, Lucian Blaga University of Sibiu, 2Emergency County
Clinical Hospital Sibiu, Sibiu, Romania
Background: The interest about the opinion of our patients on various aspects
of health management has become a constant in our work, helping us to
improve our activity.
Aims: To find the opinion of our patients on the quality of medical care.
Methods: A transversal study was performed on a sample of 214 consecutive
hospitalized patients in our Hematology department in January 2015 who
responded to a questionnaire on the quality of medical care. The results were
analyzed and they have allowed conclusions that we hope to have implications
for clinical practice.
Results: The mean age of surveyed patients was 61,79+/-16,05 years. Dis-
tribution by gender: women 51,19%, men 48,81%. Most surveyed patients
(92.8%) believe that regular consultations in hematology service is a useful
opportunity for drug doses adjustment and early detection and treatment of
possible recurrences. Most of them (84.14%) believe that the time interval
between two successive control consultations is suitable and only 8.33% think
it is too short. It is gratifying that all surveyed patients believe that the attitude
of physicians towards them is polite and 94.04% of them think that nurses are
polite, too. However, the lack of courtesy of nurses was observed by 5.95% of
respondents. Most patients (83.33%) think that the time established by the
doctor for patient consultation is long enough, 3.57% of them consider that it
is too short. All surveyed patients said they had been informed by their doctor
on the diagnosis of hematological disease,the therapeutic plan has been
exposed to them, and they understand its necessity. Most patients (94.04%)
are satisfied with the results of treatment, and the rest do not know. The pos-
sible adverse effects of transfusions were explained to 82.82% of them. A per-
centage of 13.64% of them said they did not receive such information, and
4.55%-did not remember about this. While 82.82% of them admited to having
read and signed a transfusion consent before they were transfused, 15.91%
of them said they did not remember hereof. A proportion of 83.33% of surveyed
patients is satisfied with the conditions of hospitalization and 14.29% of them
are not. A proportion of 11.9% of them would like the medical staff to offer
more attention to them. If they had to decide again in what hematology depart-
ment in the country to be hospitalized and treated, 100% of respondents would
still come in Sibiu.
Summary and Conclusions: Although most patients are satisfied with the
medical care they have expressed several opinions that may contribute to
increase their quality: a more polite attitude of the nurses, more time dedicated
by physicians for consultation, explaining the possible adverse effects of trans-
fusion to all patients, additional efforts to improve the conditions of hospitaliza-
tion, more attention offered to the patient and their needs, greater concern for
the introduction of innovative therapies. The fact that, despite the reported
imperfections, patients prefer to be hospitalized again in our service, means
that the general opinion is favorable and that they trust the provided medical
services, which are perfectible.
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LIPOSOMIAL IRON IMPROVES FATIGUE IN PATIENTS WITH MYELODYS-
PLASTIC SYNDROMES AS REFRACTORY ANEMIA. MULTICENTRIC
STUDY.
G. Giordano1,* F. d’amico2, A. commatteo3, G. berardi4, D. berardi5,
B. carabellese6, R. gigli3, M. magri3, A. licianci3, L. di marzio3
1medicine, Regional Hospital “A. Cardarelli”, Campobasso, 2Foundation “J.
Paul II”, campobaso, 3Regional Hospital “A. Cardarelli”, 4family medicine, Cam-
pobasso, 5University “La Sapienza”, Rome, 6nuclear medicine, Regional Hos-
pital “A. Cardarelli”, Campobasso, Italy
Background: Fatigue is the most invalidating symptom in neoplastic disease.
Fatigue frequently is linked to an iron deficiency. In inflammatory diseases as
myelodysplastic syndromes fatigue might be linked to a functional iron deficiency
with elevated ferritin level and a saturation of total iron binding capacity<20%.
Aims: Aim of this study is to verify if liposomial iron support in myelodysplastic
syndromes as refractory anemia improves fatigue perception in patients with a
saturation of total iron binding capacity<20%.
Methods: Between june 2011and december2014,20patients affected by refrac-
tory anemia were studied. Median follow-up was12 months(R10-24).Patients
were randomized1:1 to receive in groupA alpha erythropoietin
40000IUsc/week+calcium levofolinate7.5mg/day orally+Vitamin
B12:400mg/day orally.In group B patient received liposomial iron14mg1 tablet
orally/day+alpha erythropoietin 40000IUsc/week+calcium
levofolinate7.5mg/day orally+Vitamin B12:400 mg/day orally.In group A median
age was60 years(R65-70),M/F:8/2.In groupB median age was66 years(R60-
75),M/F:6/4.Caryotype was normal in groupA andB patients.Median level of
haemoglobin was 9 g/dl in group A(R8.5-11) and8.8g/dl(R8.5-11.5)in group
B.Fatigue was measured with Modified Fatigue Impact Scale (FISC-Fisk 1994).
Results: Patients in group A reached a median hemoglobin level of11.5g/dl
after 3 month of therapy and referred a median FISC score of74 (R65-80).
Patients in group B reached a median hemoglobin level of12.5g/dl after 3 month
of therapy and referred a median FISC score of54 (R42-68).
Summary and Conclusions: Liposomial iron support improves fatigue per-
ception in patients with refractory anemia. This study needs confirmation on a
lager cohort of patients.
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MOLECULAR CHARACTERIZATION OF BETA GLOBIN GENE OF THA-
LASSEMIA REVEALS NEW AND RARE MUTATIONS IN PAKISTANI POP-
ULATION
H. Yasmeen1,2,* S. Hasnain1,2, S. Toma3, N. Killeen3, L. Foroni3,4
1Department of Microbiology and Molecular Genetics, University of the Punjab,
Lahore, 2Department of Microbiology and Molecular Genetics, The Women
University Multan, Multan, Pakistan, 3Department of Medicine, Imperial College
Healthcare NHS Trust, Hammersmith Hospital, 4Centre for Haematology,
Department of Medicine, Imperial College London, London, United Kingdom
Background: Imbalance in synthesis of α- or β- chains of hemoglobin results
in thalassemia that has clinically diverse manifestations ranging from asymp-
tomatic to regularly transfusion dependent individuals. More than 200 deletions
or point mutations have been identified that impair transcription, processing,
or translation of α- or β-globin mRNA. In Pakistan, a carrier rate of 5 to 7%
demands communal preventive measures such as carrier identification, genetic
counseling and prenatal diagnosis. 
Aims: Present multicentre study undertaken in four cities of Pakistan examines
the frequency and spectrum of alpha and beta thalassemia in Pakistani population. 
Methods: 161 seronegative beta thalassemia patients, identified on the ground
of haematological parameters, were screened for mutations of the Alpha (HBA2
and HBA1) and Beta (HBB) genes and G Gamma (HBG2) Globin gene XmnI
polymorphism using a combination of Multiplex Gap PCR, Sanger sequencing
and RFLP PCR.
Results: Among 16 mutations identified in the beta gene, HBB:c.27_28insG
(p.Ser10Val) was the most prevalent. α-3.7 and α-4.2 deletions were also found
in coinheritance with beta thalassemia mutations. Rare mutations such as
HBB:c.-138C>T and HBB:c.315+1G>A were also identified. Interestingly, one
novel mutation (HBB:c.-148T>A), two rare variants (HBB:c.332T>C
(p.Leu111Pro) and HBB:c.92G>C (p.Arg31Thr) and a novel association
(HBB:c.92G>C (p.Arg31Thr)/HBB:c.-92C>G) were also reported for the first
time in our study in the Pakistani population. HBG2:c.-211C>T base-pair sub-
stitution (historically described as -158 Gγ XmnI polymorphism) was present
in 36% of the patients analysed.
Summary and Conclusions: Such comprehensive studies revealing some
rare mutations are essential for prenatal screening and control of this highly





HEME EXPORT AND HEME DEGRADATION DURING MURINE ERY-
THROPIESIS
S. Petrillo1,* D. Chiabrando1, S. Mercurio1, L. De Franceschi2, A. Camporeale1,
L. Silengo1, F. Altruda1, E. Tolosano1
1Department of Molecular Biotechnology and Health Sciences, University of
Turin, Turin, 2Department of Medicine, University of Verona, Verona, Italy
Background: Erythropoiesis is the biological process that consumes the high-
est amount of body iron for heme synthesis. Heme accumulation within differ-
entiating erythroid cells is crucial for globin genes expression and hemoglobin
production. Recently, a role for heme oxygenase (HO)-1and Feline Leukemia
Virus subgroup C Receptor (Flvcr)-1 genes in the control of cytosolic heme
during erythropoiesis has been reported. HO-1 is the inducible enzyme respon-
sible for heme degradation. Flvcr1 gene encodes for two heme exporters,
Flvcr1a and Flvcr1b, localized at the plasma and mitochondrial membrane,
respectively. Flvcr1 plays a crucial role in erythropoiesis since loss of both
Flvcr1a and Flvcr1b in mice and zebrafish results in anaemia. Moreover, we
demonstrated that Flvcr1b is required along all phases of erythropoiesis while
Flvcr1a is important for the expansion of committed erythroid precursors but
dispensable for their differentiation.
Aims: The aim of this work was the elucidation of the interplay between heme
export and heme degradation during erythropoiesis. 
Methods: We isolated erythroid sub-population from murine bone marrow and
analyse the expression of Flvcr1 isoforms and HO-1. Moreover, we compared
HO-1 level observed in wild-type mice to that of conditional knock-out mice
that do not express Flvcr1a and Flvcr1b in bone marrow. The same analysis
was performed on the fetal liver of mouse embryos carrying alleles that differ-
entially affect Flvcr1a and Flvcr1b expression.
Results: Our data indicated different profiles of expression for HO-1, Flvcr1a
and Flvcr1b during erythropoiesis. Moreover, when Flvcr1a or Flvcr1b were
lost, HO-1 resulted up-regulated.
Summary and Conclusions: These results suggest that during erythroid dif-
ferentiation, heme export and heme degradation control different pools of heme.
PB1988
HEME, INFLAMMATION AND PARKINSON’S DISEASE
R. Gozzelino1,2,*
1Chronic Diseases Research Center, Lisbon, 2Instituto Gulbenkian de Ciência,
Oeiras, Portugal
Background: Heme is a metallo-compound, essential for the survival of most
organisms. However, the ability of the central iron (Fe) atom, contained within
its protoporphyrin ring, to participate in the Fenton chemistry and generate
highly reactive hydroxyl radicals renders heme potentially toxic. Under inflam-
matory conditions, the release of heme from hemoproteins leads to unfettered
oxidative stress, a deleterious effect allowing this molecule to sensitize
parenchyma cells to undergo programmed cell death. We previously demon-
strated that heme critically contributes to the pathogenesis of immune-mediated
inflammatory diseases, by promoting the activation of the c-Jun N-terminal
kinase signaling transduction pathway in response to pro-inflammatory agonists
released in the course of the infection. The deleterious effect of heme is asso-
ciated to tissue damage and disease severity, as upon hemolysis its release
into circulation dictates the outcome of infectious diseases.
Aims: As infectious and inflammatory diseases are often associated to a certain
degree of vascular leakage, it is possible that under these conditions the cyto-
toxicity of heme may affect also organs of restricted accessibility, such as the
brain, thus increasing the risk and severity of neurodegenerative diseases.
Methods: This hypothesis has been investigated in mice by assessing whether
the peripheral exogenous administration of heme or the release of heme upon
exposure to immune-mediated inflammatory diseases enhances the severity
of Parkinson’s disease.
Results: Preliminary data demonstrates that heme triggers neurodegeneration
and enhances the susceptibility to Parkinson’s disease.
Summary and Conclusions: The protective effect of heme scavengers and
proteins counteracting the pro-oxidant reactivity of Fe in preventing the devel-
opment of Parkinson’s disease suggests that heme cytotoxicity may critically
contribute to this disorder.
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GHRELIN GENE POLYMORPHISM IN IRON DEFICIENCY ANEMIA
E. Bahadir1, S. Akarsu2,* E. Onalan Etem3
1University of Firat Faculty of Medicine, Department of Pediatrics, 2University
of Firat Faculty of Medicine, Department of Pediatric Hematology Oncology,
3University of Firat Faculty of Medicine, Genetics, Elazig, Turkey
Background: Iron deficiency anemia (IDA) is the most common in infancy and
childhood hematologic diseases. It is seen in all age groups. Nutrition plays an
important role in the development of IDA which is the most common cause of
nutritional anemia. In our country, IDA has been determined in 12.7% of children
between 4-months and 18-years old. One of the clinical features of IDA is loss
of appetite and nutrition plays a major rol in IDA. Ghrelin stimulates appetite
and food intake. It is considered that appetite and eating behavior are controlled
with complex mechanisms by certain areas located at hypothalamus in central
nervous system (CNS). The neurons containing ghrelin involved in appetite
were found at arcuate nucleus of hypothalamus. Ghrelin at this localization
controlles food intake. In addition to becoming hunger hormone, ghrelin regu-
lates eating behavior and weight balance. Also ghrelin, before and after fasting,
controlles behavioral, metabolic and gastrointestinal adaptations. The signifi-
cant positive correlation was found between body iron and ghrelin levels. Ghre-
lin levels progresively decrease from iron decrease to development of IDA.
Aims: The frequency of ghrelin gene polymorphism was aimed to be investi-
gated in children diagnosed as IDA and healthy control group. In this way, we
aimed to determine ghrelin gene polymorphism in healthy children of our soci-
ety. It was aimed which determined polymorphisms are seen more frequently.
Thus, we aimed to determine difference between the ratios of healthy children
and children with IDA. Among children with the same nutrition manner, common
living conditions, we aimed to answer question that the real reason of IDA
development may be occurance of a polymorphism at ghrelin gene.
Methods: In our study, total 57 children with IDA, 27 female (47.4%) and 30
male (52.6%), and 57 healthy control group were assessed. -501 promoter,
arg51Gln, Leu72Met, and Gln90Leu polymorphisms at ghrelin gene were stud-
ied in patients and contol group.
Results: In terms of -501 A/C polymorphism at ghrelin gene, A allele was found
statistically significant in patients group (P<0.05). For promoter -501 A/C poly-
morphism, the frequencies of genotype was not different from the control group
(P<0.05). When genotype and allele frequencies were compared with control
group for Arg51Gln, Leu72Met and Gln90Leu polymorphisms, there is no sta-
tistically significant difference (P<0.05).
Summary and Conclusions: We suggest that ghrelin gene may play an impor-
tant role in IDA immunogeneticy. Also we think that studies are needed to be
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done in both Turkish population and other populations for the determiation of
other polymorphisms in this gene which may contribute to this disease. To verify
our data, the same polymorphisms should be futher investigated in patients
with IDA in different populations by more futher studies. We suggest that
increased promoter -501 variant frequency in ghrelin gene may be one of he
mechanisms involved in etiopathogenesis of IDA.
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RESPONSIVENESS TO PARENTERAL IRON THERAPY IN THE DIFFER-
ENTIAL DIAGNOSIS FROM UNEXPLAINED REFRACTORY IRON DEFI-
CIENCY ANEMIA TO IRON-REFRACTORY IRON DEFICIENCY ANEMIA 
M. Akin1,* H. Sarbay2, S. Guler2, C. Cicek2, Y. Balci2, A. Polat2
1Pediatric hematology, 2Pamukkale University, denizli, Turkey
Background: We evaluated responsiveness to parenteral Iron therapy in the
differential diagnosis from unexplained refractory iron deficiency anemia to iron-
refractory iron deficiency anemia.
Aims: We evaluated responsiveness to parenteral Iron therapy in the differential
diagnosis from unexplained refractory iron deficiency anemia to iron-refractory
iron deficiency anemia.
Methods: This study analyzed responses to IV iron sucrose therapy given to
15 children with unexplained refractory IDA who were unresponsive to oral iron
therapy.
Results: Ferritin, MCV, MCH and Hb values were normal range in 10 patients
at 6 weeks following the first therapy. The increase in Hb, MCH, MCV, and ferritin
values were ranging from 2.6 to 3.5g/dL, 1.7 to 4.2 pg, 2 to 9 fL and 13 to 25
ng/mL in table 1, respectively. In five patients, Hb, MCH and MCV mean (range)
values [11.2 g/dL (11-12.2), 24.5 pg (24-25.6) and 67fL (65-70)] were nearly nor-
mal but ferritin mean (range) values [ 9.8 ng/mL (8-11)] were below normal. The
increase in Hb, MCH, MCV and ferritin were ranging from 2.6 to 3.5g/dL,7 to 4.2
pg, 2 to 9 fL and 5 to 12 ng/mL, respectively. Children with IRIDA in previous our
study, Hb, MCH, MCV and ferritin values increased 6 weeks after the first ther-
apy. The increase in Hb was 0.8–2.7g/dL and that of MCH, MCV, and ferritin
values were 1.7–4.2 pg, 2–9 fL, and 13–25 ng/mL, respectively.
Summary and Conclusions: Intravenous iron therapy increased rapidly blood
parameters in children with unexplained refractory IDA. The hematologic
response to IV iron therapy should be used differentiation from unexplained
refractory IDA to IRIDA.
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PHENOTYPIC PROFILE OF PAROXYSMAL NOCTURNAL HÉMOGLOBIN-
URIA CLONES BY FLOW CYTOMETRY IN BLIDA, ALGERIA.
O. Salima1,* T. Souad1, A. Mohand Tayeb1
1Hematology, EHS ELCC CAC Faculty of Medicine, University Blida 1, Blida,
Algeria
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, geneti-
cally acquired, life-threatening disease. We report 24 cases of PNH diagnosed
and followed by flow cytometry (FC).
Aims: To evaluate the size of PNH clones and their clinical impact
Methods: The PNH clone was required in the event of bone marrow aplasia
with or without hemolysis, of regenerative haemolytic anemia with negative
direct Coombs test, in case of Myélodysplastic syndrome, in case of unex-
plained cytopenia and in thrombosis. The research of the clone by FC is carried
out by analysis of the following monoclonal antibodies: Flear, CD59, CD14 with
gating on the CD45, CD64 and on Glycophorin A; the clone was required on
the red cells, neutrophil graulocytes (NG) and monocytes. We judged that the
patients (pts) has a HPN clone when the deficit is >5% on at least two markers
highlighted on two different lines. PNH clone was diagnosed among 151 pts
since August 2009. A monitoring by CMF is ensured in the event of absence of
deficit or a very moderate deficit or concerning only one line.
Results: On 151 analyzed cases, absence of HPN clone in 127 cases (84,2%);
ln 24 cases (15,8%), a deficit ≥ two markers in two lines or more was present.
They are 10 women and 14 men; sex ratio=1,4, median age=41 years (21-58).
PNH clone was found in bone marrow aplasia: 15/67 cases (22, 4%), hemolytic
anemia with negative direct coombs: 2 /28 case (7,1%), other hemolysis : 2/11
cases (18%), thrombosis: 2 /21 (9,5%), bone marrow aplasia in pregnancy: 1/3
cases (33%), myelodysplastic syndrome : 02/14 cases (14.3%) and cytopénia:
0/6 cases. Types of HPN: type II: 2 cases (8,4%), type III: 16 (66%), mixed
type: 6 cases (25%). The median rate of deficit of the CD59 on red cells=31.7%
(5-72), of the CD59 on neutrophil granulocytes = 58,7% (7-99) and of Flear
carried out in 11 cases=61.42% (6-98) and the deficit on the monocytes was
required in 8 cases, the median rate of the deficit of CD14=77.7% (22-97) and
of Flear (4 cases)=72,2% (19,4-92,1). In monitoring: appearance of the PNH
clone in 1 case, increase in the size of clone in 4 cases, initially lower than 2%,
and in a case the clone has doubled of size from 54% to 98% after 6 months
and the patient developed a wide thrombosis. In 13 cases, a moderate deficit
of a marker was noted on only one line.
Summary and Conclusions: In our study HPN clone was noted in 14% of the
cases of MDS which joined the literature.
In the group where moderate deficit was observed, biological signs of hemolysis
were absent; the indication of a follow-up of the size of HPN clone is then nec-
essary and must include an assessment of hemolysis repeated with evaluation
of the LDH; that is checked in our study since in 04 cases of increase size of
the clone, a thrombosis occurred in one case.. B. Höchsmann showed after
follow-up of 155 cases a significant increase of the clone in 28% of cases.
The application of FC, enabled us to make the diagnosis of PNH. Moreover it
determined the phenotypic profile of PNH clones in our area and specified their
size; it is also very useful for the follow-up of the patients. It remains a key
examination in the diagnosis of the PNH and in some cases it will be necessary
to repeat research of the clone after a first negative analysis in particular in the
event of bone marrow aplasia and of hemolysis associated, and also in the
event of small clone to follow its evolution.
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IRON AND TRANSFERRIN IN CHLDREN WITH SIDEROPENIC ANEMIA
V. Grajqevci-Uka1,* R. Macastena-Maxhuni1, B. Abrashi1, F. Selimi1
1hemato-oncology, university clinical centre kosova, prishtina, Kosovo
Background: Introduction: Sideropenia means lack of iron within the organism.
As the result of the absence of the iron the synthesis of hemi decreases in
hemoglobin. Sideropenic anemia is the most common anemia to children
because of the specific metabolic needs associated with growth and develop-
ment. Anemia as a lack of iron is charachteriszed by a defect in the synthesis
of hemoglobin and as a result of that we end up to a reduction of the red blood
cells (micro cells), and to a reduction of amount of hemoglobin (hypochromic).
Aims: The purpose of the paper: was the presentation of cases with sideropenic
anemia to our patients.
Methods: Materials and methods: Within the study we had 200 children con-
sisting of all age groups, hospitalized in the Pediatric Clinic, in hemato-oncology
department. The diagnosis is done based on the past history, physical exami-
nation, and laboratory analysis. The test of iron and transferrin is done using
the electronic modern method.
Results: Results: Regarding the age of children diagnosed with sideropenic
anemia, the most endangered age group was 0-1 years where 113 cases or
(56.1%) were diagnosed, whereas the ages with lower risk were ages 7-15
years which consisted of 18 cases or (5.6%). Further on, according to settle-
ments, we did not have many differences. From villages we have had 109
cases (54.5%), while from the cities 91 cases (45.5%). Male children dominated
by 107 cases (53.5%), whereas females consisted of 93 cases (46.5%). In
terms of nutritional status, eutrophic children dominated by 131 cases (65.6%).
Moreover, according to iron values of 1-2.9 micromoles/L have been presented
14 cases (70%), and of 6-10 micromoles/L 108 cases (54.0%) have been pre-
sented. By nominal values of UIBC transferrin have been 187 cases (93.5%),
while those with higher values of TIBC consisted of 128 cases (64.8%).
Summary and Conclusions: Conclusion: Based on our data, it is obvious that
sideropenic anemia is not rare to our children, however it tends to be quite fre-
quent. A very important part to this disease we consider some factors such as:
socio-economic low status, the low level of parental education, and the nutri-
tional manner.
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MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE FOR PREDIC-
TION OF CARDIAC COMPLICATIONS IN THALASSEMIA INTERMEDIA: A
PROSPECTIVE MULTICENTER STUDY
A. Pepe1,* A. Meloni1, P. Giuliano2, F. Terrazzino3, M. G. Neri1, C. Gerardi4,
A. Pietrapertosa5, G. Roccamo6, A. Ciancio7, V. Positano1, N. Giunta2
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2U.O. Car-
diologia, 3U.O.C. Radiologia, “ARNAS” Civico, Palermo, 4Ospedale “Giovanni
Paolo II” ASP Agrigento-Distretto di Sciacca, Sciacca (AG), 5Servizio Regionale
Talassemie, Policlinico di Bari, Bari, 6Unità di Prevenzione e Cura delle Mic-
trocitemie, PO di S.Agata di Militello (ASP-ME), S.Agata di Militello (ME), 7 Day
Hospital di Talassemia, Ospedale “Madonna delle Grazie”, Matera, Italy
Background: Cardiovascular Magnetic Resonance (CMR) has an established
role in managing and predicting prognosis of patients with Thalassemia Major
(TM). Thalassemia Intermedia (TI) is a milder variant of beta-thalassemia show-
ing a different clinical and prognostic profile; pulmonary hypertension (PH) is
a more common complication in TI patients.
Aims: We prospectively determined the predictive value of CMR parameters,
including measurement of right ventricular mass, for cardiac complications in TI.
Methods: We considered 342 TI patients enrolled in the Myocardial Iron Over-
load in Thalassemia network; about half of them (178/302, 58.9%) became
transfusion-dependent in the adult age. Myocardial and liver iron overload were
measured by T2* multiecho technique. Atrial dimensions, left and right ventricular
mass and systolic function were quantified by cine SSFP images. Late gadolin-
ium enhancement (LGE) images were acquired to detect myocardial fibrosis.
Results: Twenty-three patients were excluded because a cardiac complication
was present at the time of first CMR, so we prospectively followed 319 patients.
All 319 patients were white, with a mean age at time of their first scan of
38.02±11.69 years and 165 (51.7%) of them were females. Mean follow-up
time was 52.24±24.87 months (median 54.64 months). Cardiac events were
recorded in 22 patients (6.9%): heart failure (HF) in 1 patient, arrhythmias in
12 patients, pulmonary hypertension (PH) in 7 patients and myocardial infarc-
tion (MI) in 2 patients. The mean time from the first MR scan to the development
of a cardiac complication was 30.77±23.48 months and 8 (36.4%) cardiac
events occurred within the first year of follow-up. Significant myocardial iron
overload (global heart T2*<20 ms), ventricular dilation, right ventricular (RV)
hypertrophy, myocardial fibrosis and atrial dilation were identified as univariate
prognosticators. In the multivariate analysis the independent predictive factors
were RV hypertrophy (HR=24.12, 95% CI=5.09-114.12, P<0.0001) and
myocardial fibrosis by LGE (HR=6.59, 95% CI=1.33-32.67, P=0.021). The Fig-
ure displays the Kaplan–Meier curves showing the impact of each predictive
factor on the development of cardiac complications. The log-rank test revealed
a significant difference in the curves for each predictor factor (RV hypertrophy:
P<0.0001 and myocardial fibrosis: P<0.0001).
Figure 1.
Summary and Conclusions: For the first time we studied the prognostic value
of right ventricular mass as part of multiparametric CMR imaging in a population
of TI patients. Both RV hypertrophy and fibrosis detected by LGE were inde-
pendent predictive factor for cardiac complications. Measurement of RV mass
should be part of the multi-parametric CMR study of patient with thalassemia
intermedia.
PB1994
A PROSPECTIVE MRI STUDY OF CARDIAC AND HEPATIC IRON AND
CARDIAC FUNCTION IN NON-TRASFUSION-DEPENDENT THALASSEMIA
INTERMEDIA PATIENTS TREATED WITH DESFERRIOXAMINE
A. Meloni1, M.G. Neri1, M. Benni2, P. Bitti3, C. Fidone4, R. Sarli5, V. Santamaria6,
D. De Marchi1, G. Valeri7, P. Preziosi8, V. Positano1, A. Pepe1,*
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Servizio
di Immunoematologia e Centro Trasfusionale, Policlinico S. Orsola “L. e A.
Seragnoli”, Bologna, 3Servizio Immunoematologia e Medicina Trasfusionale,
Dipartimento dei Servizi P. O. San Francesco. ASL Nuoro, Nuoro, 4U.O.S. di
Microcitemia, Az. Osp. Civile, O.M.P.A. di Ragusa, Ragusa, 5Centro
Microcitemia, ASL Taranto Presidio Ospedaliero Orientale “M. Giannuzzi”,
Taranto, 6 Immunologia e Centro Trasfusionale, ASP Vibo Valentia, Vibo Valen-
tia, 7Dipartimento di Radiologia, Azienda Ospedaliero-Universitaria Ospedali
Riuniti “Umberto I-Lancisi-Salesi”, Ancona, 8 U.O.C. Diagnostica per Immagini
e Interventistica, Policlinico “Casilino”, Roma, Italy
Background: In thalassemia intermedia (TI) patients no observational study
prospectively evaluated in the real life the efficacy of the desferrioxamine (DFO)
therapy in removing or preventing iron overload from the heart and the liver by
T2* Magnetic Resonance Imaging (MRI).
Aims: The efficacy endpoint of this study is represented by the changes in
cardiac T2* values, MRI LIC (liver iron concentration) values and biventricular
function parameters in non-transfusion dependent (NTD) TI patients after 18
months of desferrioxamine therapy.
Methods: Among the 325 TI patients enrolled in the MIOT (Myocardial Iron
Overload in Thalassemia) network, we selected 129 TI patients NTD. We con-
sidered 29 patients who had been received DFO alone between the two MRI
scans. Cardiac iron overload was assessed by the multislice multiecho T2*
technique. Hepatic T2* values were assessed in a homogeneous tissue area
and converted into LIC. Biventricular function parameters were quantified by
cine SSFP sequences. Myocardial fibrosis was evaluated by late gadolinium
enhancement (LGE) acquisitions.
Results: Mean age was 39.69±8.12 years and 14 (48.3%) patients were
females. Patients started regular chelation therapy at a mean age of
21.92±15.89 years. The mean administered dosage of DFO via subcutaneous
route was 38.46±10.27 mg/kg body weight on 3.32±1.54 days/week. The per-
centage of patients with excellent/good levels of compliance to the chelation
treatment was 82.1%. At baseline only one patient showed cardiac iron over-
load (global heart T2*=15.23 ms) but he recovered at the FU (global heart
T2*=26.93 ms). All patients without cardiac iron maintained the same status at
the follow-up (FU). Eighteen patients (62.1%) had hepatic iron overload (MRI
LIC ≥3 mg/g/dw) at the baseline. For this subgroup, the baseline and the FU
LIC values were, respectively, 9.15±7.97 mg/g/dw and 7.41±6.28 mg/g/dw.
The reduction in MRI LIC values was not significant (P=0.102). Out of the 11
patients with a baseline MRI LIC<3 mg/g/dw, only one (9.1%) showed hepatic
iron at the FU. The Figure shows the evolution of different hepatic iron overload
risk classes between the baseline and the FU. Due mainly to technical reasons,
cardiac function was assessed at both baseline and FU MRIs in 24 patients.
At baseline all patients had a normal LV ejection fraction (EF) and 4 of them
showed a reduced LV ejection fraction (LVEF) at the FU. No patient had a
pathological RV EF. No significant change between the two MRIs was detected
in biventricular volume indexes, biventricular EFs and LV mass index. For 21
patients the presence of myocardial fibrosis was investigated at both baseline
and FU MRIs, and this subgroup was considered. Three (14.3%) patients had
myocardial fibrosis at the baseline, all with a non ischemic pattern. At the FU
two new occurrences of non-ischemic myocardial fibrosis were detected.
Figure 1.
Summary and Conclusions: In this small population of sporadically or non
transfused TI patients, the DFO therapy showed 100% efficacy in maintaining
a normal global heart T2* value. As regards as the hepatic iron overload, the
DFO therapy did not prevent the transition to a worst class in 2 patients. More-
over, the DFO therapy did not prevent the worsening of the LV function and the
occurrence of new myocardial fibrosis.
PB1995
THE ROLE OF NITRIC OXIDE IN SLEEP OF ADULTS PATIENTS WITH
SICKLE CELL DISEASE 
A.C. Cabanas-Pedro1,* S.S. Matsuda1, S. Roizenblatt2, M.G. Mouro3,
T.P. Biassi1, J.R. Reinfelderon Jr4, E.M.S. Higa3, S. Tufik4, M.S. Figueiredo1
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1Clinical and Experimental Oncology, Hematology and Bloor Transfusion Divi-
sion, 2Department of Medicine, Internal Medicine Division, 3Department of Med-
icine, Nephrology and Emergency Division, 4Department of Psychobiology,
UNIFESP/ Escola Paulista de Medicina, Sao Paulo, Brazil
Background: Nitric oxide (NO) is widely implicated in the modification of the
sleep-wake states and, in obstructive sleep apnea, decreased NO levels have
been implicated as possible mechanisms for development of cardiovascular
diseases. Previous studies have shown that sleep disorders are prevalent in
sickle cell disease (SCD) patients, and it is well known that NO plays a signif-
icant role in the pathophysiology of this disease. 
Aims: The aim of the present study was to analyze the relationship between
NO and sleep disorders in a group of SCD patients. 
Methods: Steady-state adult patients with SCD followed at Ambulatory of
Hereditary Anemias from Escola Paulista de Medicina/UNIFESP were invited
to this study. Exclusion criteria were: chronic blood transfusion, pregnancy, and
vaso-occlusive episodes and transfusion in the last three months. Sleep disor-
ders were evaluated by standard overnight multichannel polysomnography
(Somnologica, EmblaTM). NO plasma samples were determined by chemilu-
minescence using Model 280 Nitric Oxide Analyzer (NOATM) from Sievers
Instruments, Inc. (Boulder, CO, USA). This study was approved by Ethical Com-
mittee, and all patients agreed to participate.
Results: 64 consecutive patients were enrolled, 33 (51.6%) males, with median
(range) age of 28 (19–60) years. 42 (65.6%) had sickle cell anemia in use of
hydroxyurea (SS-HU), 13 (20.3%) SS without HU, and 9 (14.1%) SC disease.
The NO median concentration was 71.75 uM (40.5–243.5), with no difference
among SS-HU, SS and SC patients (P=0.40). According with median level of
NO, the patients were divided in two groups: G1 ≤71.75 and G2 >71.75uM.
Among the sleep parameters analyzed, only two showed significant difference
when compared G1 with G2: AHI – apnea-hypopnea index: 3.1(0–43.2) vs. 0.8
(0–10.4) (P=0.008), and DI – desaturation index: 5.1 (0–106.3) vs. 3.3 (0–29.9)
(P=0.011). Considering the normal values of AHI and DI (≤5 and ≤10, respec-
tively), we found association between lower levels of NO and AHI (OR=5.05,
95%CI: 1.25-20.43, P=0.03), and between lower levels of NO and DI (OR=3.81,
95% CI: 1.04–13.95, P=0.07).
Summary and Conclusions: Obstructive sleep apnea is, probably, the most
known sleep-disordered breathing (SDB). It is a multifactorial process that leads
not only to chronic intermittent hypoxia and sleep fragmentation, but also to
increased cardiovascular morbidity. NO plays a contributory role in the patho-
physiology of this process. Interestingly, SDB and SCD present many aspects
in common, like chronic inflammatory status, endothelial dysfunction, and lower
levels of NO. Moreover, SDB is prevalent in SCD and there is a relationship
between NO level and SCD manifestations. The AHI and DI are important index-
es related to SDB and risk of cardiovascular morbidity. The fact that we found
both indexes altered in SCD, especially in patients with lower levels of NO,
confirm that SCD patients suffered from sleep disturbances, and implies that
NO is probably associated with it. This is one of the first studies about sleep
disorders in adult patients with SCD, reinforcing the need of more studies in
this field. 






LESSONS FROM VERY SEVERE, REFRACTORY AND FATAL PRIMARY
AUTOIMMUNE HAEMOLYTIC ANAEMIAS
W. Barcellini1,* B. Fattizzo2, A. Zaninoni3, F. Nesa3, A. Zanella3, A. Cortelezzi4
1U.O. Oncoematologia, Fondazione IRCCS Ospedale Maggiore Policlinico,
2U.O. Oncoematologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, 3UO Oncoematologia, Fondazione IRCCS Ospedale Maggiore Poli-
clinico, 4UO Oncoematologia, Fondazione IRCCS Ospedale Maggiore Policlin-
ico e Università degli Studi, Milano, Italy
Background: Autoimmune haemolytic anaemia (AIHA), usually classified as
warm (WAIHA), cold (CAD), mixed, and atypical forms, is a greatly heteroge-
neous condition both in terms of clinical presentation and response to treatment,
varying from mild/fully compensated to very severe, life-threatening and fatal.
Aims: To describe acute and very severe cases of AIHA who displayed multi-
drug refractoriness and related complications.
Methods: 13 consecutive patients were identified among 157 primary AIHA
followed from 1996 to 2014 at our institution. Patients were selected on the
basis of very severe clinical presentation (Hb<6 g/dL, 51 cases) and require-
ment of at least 3 lines of therapy [steroids +/- IVIG, splenectomy, various
immunesuppressants, plasma-exchange (PEX) and erythropoietin, 13/51].
Results: Table 1 shows the clinical characteristics of patients: 7 cases were
direct antiglobulin test (DAT) positive with IgG+C antisera, 4 with IgG, and 1
with C; 1 case was DAT negative. All displayed marked intravascular haemol-
ysis, 8 inadequate reticulocytosis, and 6 immune thrombocytopenia. Thrombotic
events occurred in 8 patients (of whom 4 pulmonary embolism and 3 dissemi-
nated intravascular haemolysis) and acute renal failure in 3. All patients (but a
Jehovah witness) received transfusions and steroids +/- intravenous
immunoglobulins, 11 rituximab, 9 immunosuppressants, 5 PEX, 3 erythropoietin
and 5 underwent splenectomy. Seven cases (54%) were fatal. In most cases
death was due to infections and multiple organ failure, and was related with
multi-treatment, particularly splenectomy, and with concomitant thrombocy-
topenia. Thrombotic complications were not fatal, and occurred more frequently
in splenectomised cases.
Table 1.
Summary and Conclusions: The challenging AIHA cases described showed
a greatly unpredictable clinical course. Evans syndrome and previous splenec-
tomy, particularly when performed after multiple immunosuppressive therapies,
were associated with poor prognosis. Rituximab, when promptly administered,
was effective in solving the clinical emergency in most cases unresponsive to
steroids and transfusions. Plasma exchange and erythropoietin were valuable
options. Above all, in very severe AIHAs a scrupulous and continuous attention
by experienced clinicians is required in order to avoid a delay in potentially life-
saving strategies.
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THE CORRELATION BETWEEN CAROTID ARTERY INTIMA MEDIA THICK-
NESS AND ANTIOXIDATIVE ENZYMES ACTIVITIES IN CHILDREN WITH
IRON DEFICIENCY AND IRON DEFICIENCY ANEMIA
H. Aslaner1, Y. Altuner Torun2,* C. Karakurkcu3, A.B. Ergul1
1Pediatrics, 2Pediatric Hematology, 3Biochemistry, Kayseri Education and
Research Hospital, Kayseri, Turkey
Background: Lipid peroxidation increased in iron defiency anemia (IDA) as a
result of increase capasity of oxydant and also decreases of antioxydant cap-
asity. Though there are many studies that damaged antioxydant activity affects
atherogenonosus in IDA; there are not any studies over intima-media thickness
of carotid artery (CIMT).
Aims: The aim of this study is to assess the antioxydant enzym activity in iron
defiency (ID) without anemiea and thickness of carotid intima media as an early
indicator of premature of atherosclerosis.
Methods: In this study, we searched for the relationship between carotid inti-
ma-media thickness and antioxidant enzyme activities in adolescents with iron
deficiency or IDA. The study was performed on 71 children aged 11 to 17 years
old including 25 children with ID, 25 children with IDA and 21 healthy children.
Complete blood count, the serum levels of iron and iron binding capacity, ferritin,
lipid profile, glutathione peroxidase, glutathione reductase, paraoxonase activity
were carried out. The CIMT were assessed by using echocardiography. All
blood tests and CIMT were reevaluated after three months oral ferric iron treat-
ment in the group with iron deficiency anemia.
Results: We founded significantly lower paraoxonase activity in groups of iron
deficiency and iron deficiency anemia (P<0.05), but there was not a difference
between this two groups. In addition, glutathione peroxidase and reductase
activities were similar (p>0.05). CIMT in ID and IDA were higher than the control
group (P<0.05), but there was not a difference between this two groups. After
the iron treatment, significantly increased PON, GSH-Px, GSH-R activities
(P<0.05) and CIMT were decreased. It has been determined that a significant
correlation between PON enzyme activity and levels of hemoglobin, serum
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iron, ferritin, serum transferrin saturation. Moreover, there was an inverse cor-
relation between carotid intima thickness and levels of hemoglobin, ferritin,
and serum transferrin saturation. It was also revealed PON was negatively cor-
related with CIMT in IDA group (P<0.05, r: -0.410).
Table 1.
Table 2.
Summary and Conclusions: We think that impaired antioxydant capasity
exist during iron defiency without anemia and this lead up to atherosclerosis.
In addition, iron defiency even if not anemia should be treated to prevent pre-
matüre aterosclerosis
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A COMMON GENETIC VARIANT OF THE TMPRSS6 GENE INFLUENCES
THE SUSCEPTIBILITY TO IRON DEFICIENCY ANAEMIA IN PORTUGUESE
WOMEN 
L. Goncalves1,* A. Miranda2, R. Faria1, L. Correia3, P. Faustino1
1Departamento de Genética Humana, Instituto Nacional de Saúde Doutor
Ricardo Jorge (INSA), 2Departamento de Promoção da Saúde, Instituto
Nacional de Saude Doutor Ricardo Jorge, 3Departamento de Bioquímica e
Biologia Humana, Faculdade de Farmácia da Universidade de Lisboa, Lisboa,
Portugal
Background:Anaemia is a worldwide blood disorder affecting about one-quar-
ter of the world’s population. Iron-deficiency anaemia (IDA) is the most common
type of anaemia and is caused by inadequate iron availability for haemoglobin
synthesis. The disorder development can be attributed to nutritional factors,
namely to an iron deficiency diet. However, genetic variants may also be
involved. Genome-wide association studies have suggested that common vari-
ants in the liver-expressed TMPRSS6 gene might modulate haematological
phenotype and iron status. This gene encodes for a membrane-bound serine
protease, matriptase-2, that plays an essential role in down regulation hepcidin,
the key regulator of iron homeostasis. One of the suggested genetic variant is
the SNP rs855791 c.2207 C>T, p.Ala736Val.
Aims: The objective of this work was to evaluate whether the SNP rs855791
in TMPRSS6 gene may influence IDA susceptibility in Portuguese women.
Methods: The SNP rs855791 (c.2207 C>T, p.V736A) was characterized at
DNA level, using an allele specific amplification approach, in 25 Portuguese
women presenting IDA (mean age=38 years) and in another 89 women without
IDA, corresponding to the normal control group (mean age=39 years).
Results: We have found that the frequency of the three genotypes at SNP
rs855791 is different between the two groups of women. The CC genotype fre-
quency (736A) is lower in the IDA group than in controls and, inversely, the TT
genotype frequency (736V) is higher; (P=0.037). Also, the TT genotype is asso-
ciated with low haemoglobin level (P=0.036), serum iron (P=0.009) and trans-
ferrin saturation (P=0.015). 
Summary and Conclusions: The genotype TT at SNP rs855791 within the
gene TMPRSS6 is associated with the lowest haemoglobin levels and serum
iron parameters of the studied women. Moreover, it is more frequent in the IDA
group. Therefore, we can conclude that this variant is a genetic risk factor to
develop IDA, which corroborates results obtained by previous studies in other
populations. So, this study has revealed that the TMPRSS6 gene, besides its
association with the rare iron deficiency iron refractory anaemia (IRIDA), has
also an important role as genetic modifier of common iron-related disorders.
The polymorphism p.Ala736Val effect is probably due to a partial impairment
of matriptase-2 and, consequently, to an increased expression of hepcidin
which perturbs iron absorption in the duodenum as well as iron recycling by
macrophages. Partially funded by FCT: PEst-OE/SAU/UI0009/2013 and Pest-
OE/SAU/UI4013/2011.
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LONG TERM FOLLOW-UP OF HYDROXYUREA IN SICKLE CELL DISEASE
B. Mohamed1,* B. Faiza1, C.L.1, K. MOURAD1
1Deprtement de Médecine, Faculté de Médecine. Unicersité Saad Dahleb, Bli-
da, Algeria
Background: Hydroxyurea (HU) is considered to be the most successful drug
therapy for severe sickle cell disease (SCD) and has many characteristics of
an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit
through multiple mechanisms of action. HU emerged as an important thera-
peutic option for children and adolescents with recurrent vaso-occlusive events
and sustained long-term benefits were documented
Aims: To assess long term effects of hydroxyurea therapy in infants and adults
with sickle cell disease (all types)
Methods: Since 2000, there were 54 SCD patients treated with HU, 39 SS
14S/βthal and 1 SC: Mean age at inclusion was 12+/-4.4 years (4 – 22 y), just
3 patients was aged above 40y at the inclusion, sex ratio: 29F/25M. Thirty
night included for standard criteria (more than 3 severe crisis pain/year and/or
recurrent acute chest syndrome >1 ACS/y) and 7 because of severe chronic
anemia (baseline of hemoglobin lower than 6g/dL), 2 for complex red cell allo-
immunization, 1 for delayed posttransfusional hemolysis, 1 invalidant priapism,
2 association with auto-immun disease(sarcoidosis, Systemic lupus erythe-
matosus), 1 history of stroke with transfusional difficulties, 1 for nephropathy
and renal failure (creatinine 18 mg/mL). 13 patients have been splenectomized
before the inclusion; Avascular Necrosis of hips was noted in 5 patients. Fer-
ritine in 27 patients polytransfused (more 20 blood units) was 3700 ng/mL. The
median daily dose of HU was 18 mg/kg (14 to 22 mg/kg/d)
Results: After a follow-up of 9 years(5 to 14 years), we observed a significant
decreased (P<0,0001) of severe and recurrent acute pain crisis (5,5→0,7/y)
and Acute chest syndrome (1,5→0,3/y), need of blood transfusions (8→2/year),
days of hospitalization (17→3/y). Sustained clinical benefits for the most
patients received long-term HU treatment. Total hemoglobin increase was
1,1g/dl (0.5 à 2.5). In the subgroup of 7 patients treated for severe anemia, the
mean hemoglobin level was 6.6±0.5 g/dL prior to HU and increased to 8.2±1.5
g/dL after 1 year of therapy. The iron chelation Deferroxamine (30mg/kg/j, 3j/7)
and phlebotomy, performed in 11 patients when Hb level was upper 9g/dl). We
noted some severe events: acute priapism in 4 patients (1 shunt caverno-
spongieux),4 hip osteonecrosis. We deplored 7 deaths: recidive of stroke (1),
sepsis (1), ACS (2), progressive renal failure (1), acute hepatic sequestration
(1), undetermined (1). Five were lost to follow-up after a median of 48 months.
Very young patients treated have been associated with excellent growth and
development. Sexual maturation, including menarche, has occurred without
apparent delay. No severe side effect was related to HU treatment, which was
discontinued in children mainly for transient neutropenia or thrombopenia,
hypersplenism or acute splenic sequestration, followed by splenectomy(9 cas-
es) or non-compliance (2 cases). Four women were pregnant after 8 years of
HU. Long-term clinical benefits have also been observed wth improved quality
of life. Ferritin levels were decreased with significant decline in group of patients
treated with Deferroxamine and/or phlebotomy (3700→950 ng/mL).
Summary and Conclusions: Long-term exposure to HU seems associated
with significantly reduced mortality, perhaps by reducing long-term end organ
damage and does not appear to be associated with increased risk of secondary
malignancies nor myelodysplasic syndrome. Our experience, mainly in children
allows us to consider that this drug is a very potent therapeutic option for the
management of severe forms of the disease, particularly in countries with lim-
ited blood supply. An updated national registry is highly needed to further
assessment.
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GEOGRAPHICAL DIFFERENCES IN IRON OVERLOAD AND IRON CHELA-
TION PRACTICES IN ANEMIA PATIENTS: BASELINE RESULTS FROM THE
TRANSFUSIONAL HEMOSIDEROSIS REGISTRY STUDY (TORS)
N. Siritanaratkul1,* J. W. Lee2,M. Pehlivan3, E. Volodicheva4, Q. Jiang5, F. Grifi6,
B.S. Ko7, R. Wong8, V. Louw9, A. Khelif10, A. El-Ali11, A. Losco11, O. Ilhan12
1Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand,
2The Catholic University of Korea, Seoul, Korea, Democratic People’s Republic
Of, 3Medical Faculty, Department of Hematology, Gaziantep University, Gazian-
pet, Turkey, 4Tula Regional Clinical Hospital, Tula, Russian Federation, 5Peking
University People’s Hospital, Beijing, China, 6Centre Hospitalier Universitaire
Annaba, Annaba, Algeria, 7National Taiwan University Hospital, Taipei, Taiwan,
ROC, 8The Chinese University of Hong Kong, Shatin, Hong Kong, 9University
of the Free State, Bloemfontein, South Africa, 10Farhat Hached University Hos-
pital, Sousse, Tunisia, 11Novartis Pharma AG, Basel, Switzerland, 12Depart-
ment of Hematology, Ankara University School of Medicine, Ankara, Turkey
Background: Data describing transfusion practices and diagnoses of iron
overload as well as iron chelation in patients with anemia across geographical
regions are limited. A prospective epidemiological study may provide further
insights into clinical practices for these conditions.
Aims: This prospective, multinational, non-interventional study, aimed to (1)
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evaluate the differences in baseline characteristics among early diagnosed
patients with anemia requiring chronic transfusion therapy; (2) assess the extent
of iron overload and patterns of care surrounding the use of iron chelation ther-
apy in different geographical regions.
Methods: Patients aged >2 years requiring chronic transfusion therapy with
newly diagnosed anemias (<12 months from diagnosis), including thalassemia,
low and intermediate-1 myelodysplastic syndromes (MDS), aplastic anemia
(AA), Diamond-Blackfan anemia (DBA) and other transfusion-dependent ane-
mias were enrolled. Patients were recruited from Turkey, Russia and South
Africa as well as from countries within the Asia-Pacific and Middle East regions.
Patients with secondary or therapy-related MDS; intermediate-2 or high-risk
MDS; or acute leukemia were excluded. Patients were evaluated at baseline
and at follow-up visits according to the standard practice for up to 3 years or
until death. At baseline, patient demographics and details of iron overload and
iron chelation therapy use were assessed. Transfusional hemosiderosis was
defined as ≥1 serum ferritin measurement >1000 ng/mL after onset of transfu-
sion therapy; or a liver iron concentration (LIC) >2 mg Fe/g dry weight; or if
serum ferritin or LIC measurements were not available, evidence of ≥20 units
of red blood cell transfusions.
Results: Of the 564 patients (including patients aged ≤18 years, n=57) recruit-
ed, majority had a diagnosis of MDS (58.5%, n=330), followed by AA (31.2%,
n=176), other transfusion-dependent disorders (6.2%, n=35), β-thalassemia
major (2.0%, n=11), β-thalassemia intermedia (1.1%, n=6), sickle cell anemia
(0.5%, n=3) and DBA (0.4%, n=2). The mean age (±SD) of the patients was
51.9±23.87 years (range, 2-92); 49.5% (n=279) were male. At study entry,
>70% of patients in all countries, except Thailand (45.7%), were receiving trans-
fusion therapy. Overall, 29.4% (166/564) patients and 36.8% (21/57) pediatric
patients were assessed as having iron overload during the study; extent of iron
overload across countries varied and ranged from 7.4% (6/81) in Thailand to
83.3% (10/12) in Hong Kong. Patients receiving drug therapy only were less
likely to be assessed for iron overload (1.2% [1/86]) than patients receiving
erythrocyte transfusion (33.0% [33/100]) or erythrocyte transfusion and drug
therapy (38.1% [131/344]). Overall, 39% of the population received iron chela-
tion therapy and ranged from 9.2% (11/119) in China to 100.0% (12/12) in Hong
Kong. Despite receiving iron chelation therapy, 56.4% (124/220 patients) were
documented as having iron overload (Figure 1).
Figure 1.
Summary and Conclusions: In this large observational study, MDS was the
most common disease type enrolled. Majority of patients received transfusion
therapy across countries; consequently there was a proportion of patients that
had iron overload. Despite a large percent of patients receiving transfusion
therapy and having developed iron overload, there was a broad spectrum of
iron chelation use. Notably, over half of patients still had iron overload despite
receiving chelation therapy. Overall, these results suggest that iron overload
management practices may still be suboptimal in many parts of the world. Fur-
ther studies are required to clearly understand these geographical differences
in management of transfusion–dependent anemias.
PB2003
CHRONIC HCV INFECTION AND HEMOSIDEROSIS AMONG EGYPTIAN
THALASSEMIA PATIENTS: THE ROLE OF HOMA INDEX
M. Hamdy1,* M. mokhles2, D. fikry3
1pediatric hematology, cairo university, 2internal medicine, national center for
research, 3clinical pathology, national research center, cairo, Egypt
Background: Hepatitis C virus (HCV) is a major cause of chronic hepatitis C
(CHC) which increases the risk for insulin resistance, glucose intolerance and
type 2 diabetes. Egypt has the highest reported rates of HCV infection espe-
cially among chronically transfused patients. Abnormal glucose tolerance is
common in multitransfused thalassemia and is attributed to early impaired beta
cells function with increasing insulin resistance (IR). The HOMA index (home-
ostasis model assessment) has been extensively used to investigate insulin
resistance in CHC
Aims: to detect insulin resistance in transfusion dependent thalassemia major
patients and to evaluate its possible link to chronic hepatitis and iron overload
Methods: : Fifty nine Egyptian thalassemia major patients were divided into
hepatitis C (HCV) positive (group A; n= 39) and HCV negative thalassemics
(group B; n=20) by HCV antibody and RNA. Thalassemia patients were com-
pared to 20 age and sex matched HCV positive (non thalassemic) patients
(group C). Blood samples were withdrawn from all patients for assessment of
HOMA index, serum ferritin, AST and ALT
Results: : Abnormal HOMA test was evident in 30.8% (n=12) of group A and
40% (n=8) of the control group while none of group B had abnormal test. Sig-
nificant results of HOMA-IR was observed between the three groups (P=0.029)
and between group B and each of groups A and C (P= 0.012, 0.043 respec-
tively) while no difference was observed between HCV positive thalassemics
and control group (P=0.99) Positive correlation (P=0.038) was observed
between HOMA- IR and AST but no correlation to age or serum ferritin level
Summary and Conclusions: Chronic Hepatitis in transfusion dependent tha-
lassemia major patients is a major risk factor for insulin resistance in these
patients
PB2004
MRI BRAIN IN YOUNG EGYPTIAN SICKLE CELL DISEASE PATIENTS:
RELATION TO CEREBRAL BLOOD FLOW AND NEUROPSYCHOMETRIC
EVALUATION
A.A.G. Tantawy1,* M.H. El Rakawy2, S. A.Mohamed2, A.A.Z. Dewedar2,
A.A.N.A. Aziz2, S. Abdel Ghani1
1Pediatric Department, 2Neuropsychiatry, Faculty of Medicine,Ain Shams Uni-
versity,Cairo,Egypt, Cairo, Egypt
Background: Stroke is an important and common complication of sickle cell
disease (SCD), affecting children as well as adults.
Aims: To evaluate the prevalence of abnormal MRI brain in sickle cell disease
(SCD) patients and its relation to transcranial Doppler findings and the results
of neurosychometric evaluation
Methods:A cohort of 30 SCD patients aged less than 18 years were recruited
from the Children’s Hospital, Faculty of Medicine, Ain Shams University, Cairo,
Egypt, examined in the steady state.Patients were subjected to full clinical and
neurological examination and psychometric evaluation using Wechsler intelli-
gence scale and Benton visual retention test, laboratory investigations including
CBC,Hb electrophoresis,serum ferritin, MRI brain,transcranial Doppler ultra-
sonography for MCA,ACA,PCA,ICA,vertebral artery and basilar artery.
Results: The cohort included 12 males and 18 females, mean age 11+/-3.5
years., including 14 splenectomized patients. Abnormal MRI findings were pres-
ent in 7/30 patients(23.3%), as tiny cortical infarctions in 5 patients (all were
asymptomatic) and large infarctions in two patients (both had previous history
of stroke). The presence of abnormal MRI was not related to age,sex,family
history of SCD or stroke,neurological symptomatology,abnormal findings on
neurological examination,or frequency of blood transfusion. Abnormal brain
MRI was significantly related to frequency of sickling crises (P=0.002), surgical
splenectomy (P=0.002), HDU therapy (P=0001), scholastic retardation
(P=0.0001), impaired Penton visual perception (P=0.0001), impaired attention
(P=0.001), impaired comprehension (P=0001), hematocrit value(P=0.001),
HbS%(P=0.0001), HbF%(P=0.001), Total WBCs count(P=0.0001), absolute
neutrophil count(P=0.0001), serum ferritin(P=0.0001).Abnormal MRI was relat-
ed to cerebral blood flow in MCA (P=0001)and ICA (P=0001) but not related to
cerebral blood flow in ACA,PCA, vertebral artery and basilar artery.
Summary and Conclusions: Conclusion: In patients with SCD,the neurologist
should not only rely on standard neurological examination,but should add cere-
bral doppler and neuropsychometric assessment tools as soft signs to identify
even minor MRI lesions and to identify the children at risk of stroke
PB2005
THE PREVALENCE OF ANEMIA, IRON DEFICIENCY AND IRON DEFICIEN-
CY ANEMIA, AND THEIR ASSOCIATION WITH HEAVY METALS IN BLOOD
AND NUTRITIONAL INTAKES IN KOREAN WOMEN AGED 10 YEARS OR
OLDER 
S.K. Kim1,* Y.J. Seo2, D.H. Lee2
1Dept. of Pediatrics, 2Department of Biomedical Sciences, Inha University Hos-
pital, Incheon, Korea, Republic Of
Background: Anemia, iron deficiency (ID) and iron deficiency anemia (IDA)
continue to be common disorders in the world. 
Aims: This study was aimed at assessing the prevalence of anemia, ID and
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IDA in apparently healthy Korean women aged 10 years or more. We also
aimed at verifying an association of heavy metals in blood or nutritional intakes
with ID and IDA. 
Methods: We used the fifth Korea National Health and Nutrition Examination
Survey (KNHANES V; 2010~2012) data by the Korea Centers for Disease
Control and Prevention. This study was performed on 10,169 Korean women
including 1,232 anemia, 2,030 ID and 690 IDA subjects. Prevalence and 95%
confidence intervals (CI) were calculated using the SAS Survey Procedures.
Logistic regression analyses were performed to identify significant factors that
affect the risks of ID and IDA.
Results: The overall prevalence rate of anemia, ID and IDA was 12.4%, 23.11%
and 7.7%, respectively, between 2010 and 2012 in Korean women. The most
prevalent age groups for anemia were ≥ 70 (17.8%) and 19-49 years (15.0%).
The women of 15-18 (36.5% for ID; 10.7% for IDA) and 19-49 years (32.7%
for ID; 11.3% for IDA) were most prevalent for ID and IDA. The risks of ID and
IDA conferred by the blood cadmium level were significant (OR=3.03, 95%
CI=2.45-3.75, P<0.0001 for ID; OR=3.14, 95% CI=2.41-4.10, P<0.0001 for
IDA). Vitamin D intake showed significant protective effects of ID and IDA
(OR=0.96, 95% CI=0.94-0.98, P=0.0004 for ID; OR=0.94, 95% CI=0.91-0.98,
P=0.0015 for IDA).
Summary and Conclusions: This study shows that the prevalence of anemia,
ID and IDA was relatively high in late adolescents and reproductive ages, and
there has been minimal improvement in the burden of anemia and IDA com-
pared with the previous data. The cadmium in blood was found to increase the
risk for ID and IDA, however, vitamin D intake contributed to prevent the risk
for ID and IDA. Our findings indicate that systematic health systems between
policymakers and specialists are needed to control anemia, ID and IDA.
PB2006
EFFICACY OF DEFERIPRONE IN THALASSEMIA: POSSIBLE ROLE OF
UGT1A6 GENETIC POLYMORPHISM AND NON-GENETIC FACTORS
A.L. Ang1,* M. Hae Tha1, Y. Zhao2
1Haematology, 2Singapore General Hospital, Singapore, Singapore
Background: Deferiprone(DFP) is an oral iron chelator widely used in tha-
lassemia(thal) patients(pts). It is mostly glucuronidated by liver UGT1A6 to an
inactive metabolite before renally excreted. UGT1A6 polymorphism has been
studied as a potential cause for variability in DFP’s efficacy. No significant(sig)
effect of UGT1A6 polymorphism was shown on the single-dose pharmacoki-
netics of DFP in healthy volunteers, while another study on β thal major pts
treated with DFP showed an association of UGT1A6 single nucleotide poly-
morphism(SNP) 541A>G with lower ferritin. There are no studies on UGT1A6
polymorphism’s association with MRI-T2*, which allows more specific meas-
urement of DFP response by non-invasive liver and heart iron quantification. 
Aims: Determine associations of UGT1A6 genetic polymorphism and other
non-genetic factors with MRI-T2* responses to DFP in thal.
Methods: Thal pts(aged ≥18 years) who had ≥1 year of DFP and at least two
MRI-T2* of ≥1 year apart for assessment of DFP response were enrolled after
consenting for UGT1A6 DNA analysis. 3 common non-synonymous
SNPs(19T>G, 541A>G, 552A>C) and 1 synonymous SNP(105C>T) of
UGT1A6 were detected by sequencing PCR-amplified target DNA segments.
Data on MRI-T2* response to DFP was retrospectively collected and analysed
for associations with UGT1A6 SNPs/haplotypes and other non-genetic fac-
tors(gender, race, splenectomy, baseline cardiac/liver T2*, type of thal, trans-
fusional iron load, DFP and concomitant deferoxamine(DFO) doses). Liver T2*
was converted to liver iron concentration(LIC). Improvement in cardiac T2*(if
baseline cardiac T2*<20ms) or LIC without discrepant changes in correspon-
ding LIC or cardiac T2* were considered to have responded to DFP.
Figure 1.
Results: 32 pts(Chinese 56%, Malay 35%, Indian 3%, others 6%) were treated
with median 6(1-11) years of DFP at median average dose of 68.2(24.4-93.3)
mg/kg/day. 53% received concomitant DFO at median average dose of
23.1(11.4-40.6) mg/kg/day; 84% was regularly transfused, with median trans-
fusional iron load of 0.4(0.1-0.6) mg/kg/day. Genotypic frequency was
UGT1A6*1/*1: 75%, UGT*1/*2: 18.8%, UGT*1/*4: 6.2% (UGT1A6*1=wild type
haplotype; UGT1A6*2=variant haplotype with SNPs 19T>G, 541A>G, 552A>C;
UGT1A6*4=variant haplotype with SNPs 19T>G and 552A>C). In addition,
15.6% were heterozygous for 105C>T SNP. On multivariate analysis, splenec-
tomy(OR 0.002, 95% CI[0.000, 0.697], P=0.04) and UGT1A6 variant haplo-
types(*2 or *4) without concurrent 105C>T(OR 0.016, 95% CI[0.000, 0.766],
P=0.03) independently associated with absent DFP response. The median rate
of LIC improvement was 2.7(-12.0 to 10.1) mg/g dw per year after excluding 2
patients with discordant liver and cardiac T2* changes. On multivariate analysis,
thal major(-2.8, 95% CI[-5.5, -0.04] mg/g dw per year, P<0.05) and UGT1A6
variant haplotypes without concurrent 105C>T (-4.8, 95% CI[-7.8, -1.7] mg/g
dw per year, P<0.01) independently associated with poorer LIC improvement
rate (see Figure). Other analysed factors did not have sig independent asso-
ciations with DFP response and LIC improvement rate(P>0.15).
ISummary and Conclusions: Splenectomy decreases iron storage capacity,
might lead to iron redistribution to other organs and poorer MRI-T2* responses
to DFP. Thal majors had poorer DFP response than other types of thal likely
due to higher body iron load. The poorer DFP response observed in our pts
with UGT1A6 variant haplotypes (and no concurrent 105C>T) was contrary to
expectations since recombinant UGT1A6 variants have slower in vitro DFP
glucuronidation rates than wild type. One possibility is UGT1A6 variants have
different in vivo activities on DFP since conflicting activities of recombinant and
liver UGT1A6 allozymes are reported for other substrates. Concomitant
105C>T appeared to negate the adverse impact of UGT1A6 variants on DFP
response in our pts. in vitro, this SNP increased mRNA stability despite no
amino acid changes. This might influence mRNA or enzyme protein stability in
vivo for heterozygotes of UGT1A6 variants, leading to changes in DFP metab-
olism and efficacy. More studies on UGT1A6 SNPs’ clinical impact and inter-
actions with other factors on DFP’s efficacy are needed for better insights into
individualisation of DFP therapy for thal.
PB2007
CHARACTERISTICS OF FEBRILE CONVULSIONS OF PEDIATRICS
RELATED TO IRON DEFICIENCY IN EAST DELTA OF EGYPT
M. Fathy1, M. Zakria1, N. Rafaat2, S. Al Esh3, U. El Safy1,*
1Pediatric Hematology and Oncology, 2Biochemistry, 3Clinical Pathology,
Zagazig University, Zagazig, Egypt
Background: Iron is clearly important for brain development as well as for
prevention of anemia, and more study is warranted to understand its role in
these common neurodevelopmental disorders.Iron deficiency has also been
associated with alterations in synaptic neurotransmitter systems including nor-
epinephrine, dopamine, serotonin, glutamate and gamma-aminobutyric acid
(GABA). Febrile seizures may reflect different facets of altered brain excitability
that is enhanced by iron deficiency and also influenced by genetic factors.
Aims: To find the association between iron deficiency anemia and febrile con-
vulsions among children aged 6 to 36 months presenting at Pediatric Hema-
tology and Oncology out patients clinic of Zagazig university hospital- Zagazig
city – Egypt, from January 20011 to December 20014..As well as to find char-
acteristics of febrile convulsion with iron deficiency in Pediatrics.
Methods: A total of 200 patients fulfilled the study criteria of febrile seizure
and 100 patients with any febrile illness without convulsion. These were divided
into two groups with children having febrile seizures comprised the cases
(Group I) while those having only febrile illness with no seizures comprised the
controls (Group II). Both matched for age and gender. Workup for seizures [
History and complete neurological and developmental examination.EEG and
MRI according the need for each case] and iron deficiency anemia [ CBC-
Serum iron – Serum Ferritin- Total Protein Iron Binding Capacity – Serum Cal-
cium ionized and total ] were done and data was analyzed using SPSS version
10. According to iron deficiency, Group I had been subclassified into Group IA
with iron deficiency and Group IB without iron deficiency. Any case with abnor-
mal calcium level and those with MRI findings were excluded.
Results: A total of 24% of group I had iron deficiency (ID) and 16% had iron
deficiency anemia (IDA), compared to 17% and 12% of controls respectively.
There was significant decrease of Hb level, serum iron, serum ferritin and total
iron binding capacity in children with febrile convulsion than that of controls.
There was significant decrease age, HB conc, serum iron, ferritin and total pro-
tein iron binding capacity in group IA than group IB. One attack of febrile con-
vulsion at presentation was significant higher in group IA than group IB. Dura-
tion of convulsion was significantly lower in group IA than group IB.
Summary and Conclusions: Serum Iron, Total Protein Iron binding capacity
and Plasma ferritin level were significantly lower in cases as compared to con-
trols suggesting that iron deficient children are more prone to febrile seizures.
The characteristics of iron deficiency related febrile convulsions were young
age [9-21 month], short duration [not exceed 3 minutes],usually first attack,high
with non-breast fed baby.
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PREVALENCE AND CLINICAL SIGNIFICANCE OF XMNI ΓG-158 (C/T)
POLYMORPHISM IN AN EGYPTIAN COHORT OF SICKLE CELL DISEASE
PATIENTS
M. El-Ghamrawy1,* M. Khorshied2, A. Tosson3, N. Babiker3
1Pediatric Hematology, 2Clinical & Chemical Pathology, 3Pediatrics, Faculty of
Medicine, Cairo University, Cairo, Egypt
Background: Sickle cell disease (SCD), well-known for its clinical and hema-
tologic variability, comprises a heterogeneous group of hemoglobin genotypes
where affected individuals have sickle hemoglobin (HbS). This considerable
clinical heterogeneity among SCD patients is still not well understood. Genetic
variants that modulate fetal hemoglobin (HbF) level have a strong impact on
ameliorating the clinical phenotype.
Aims: The current study aimed to evaluate the prevalence of Xmn1 γG-158
(C/T) gene polymorphism in an Egyptian cohort of SCD patients and to inves-
tigate the possible association between this polymorphism and HbF level.
Methods: This case control study included 111 Egyptian SCD patients aged 1-
21 years (mean age 11.08±5.5 years; 77 HbSS and 34 S/β thalassemia) and
100 age and gender matched unrelated healthy controls. All subjects were
recruited only after informed consents were freely obtained from their guardians.
Genotyping of Xmn1 γG-158 (C/T) polymorphism was performed by polymerase
chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
Results: In our cohort, wild genotype Xmn1 (-/-) was the most prevalent
(91.9%), while polymorphic genotypes whether heterozygous or homozygous
(-/+ and +/+) were detected in 8.1% of SCD patients; six (6/77-7.8%) were
HbSS and three (3/34-8.8%) were S/β thalassemia. No statistically significant
differences were detected between SCD patients and controls or between
HbSS and S/ β-thalassemia patients regarding prevalence of Xmn1 polymorphic
genotypes (P=0.50 and 0.73 respectively). Baseline hemoglobin, HbF level
and mean corpuscular volume were significantly higher in patients harboring
polymorphic genotypes (P=0.01, 0.001 and 0.04 respectively). We found no
significant effect of γG-158 (C/T) polymorphism on age of first transfusion,
vasoocclusive crisis frequency or transfusion frequency (P=0.067, 0.778 and
0.053 respectively). Although HbF level was significantly higher in patients with
polymorphic genotypes (19.24±7.0 vs. 9.06±7.45, P<0.001), Xmn1 γG-158
(C/T) polymorphism did not seem to influence HbF levels in patients receiving
hydroxycarbamide (P=0.68, 95% Confidence interval= 5.08-7.68). By multiple
regression analysis, only baseline HbF correlated independently with elevation
of HbF in response to hydroxycarbamide therapy (P<0.001, 95% Confidence
interval=0.75-1.31).
Summary and Conclusions: Egyptian sickle patients have low frequency of
Xmn1 γG-158 (C/T) polymorphism. The presence of Xmn1 γG-158 (C/T) poly-
morphism had positive influence on HbF level.
PB2009
ELECTIVE CHOLECYSTECTOMY IS ASSOCIATED WITH INCREASED
MORBIDITY AND MORTALITY IN PATIENTS WITH SEVERE THA-
LASSEMIA: A RETROSPECTIVE CASE CONTROL STUDY
A. Premawardhena1,* R. Fernando1, S. Kumarage2, N. Nishad1, I. de Silva3
1Medicine, 2Surgery, University of Kelaniya, 3Hemals Thalassaemia Unit,
Teaching Hospital Ragama, Ragama, Sri Lanka
Background: Haemoglobin disorders including thalassemia and sickle cell dis-
ease are often complicated with gall stone formation. The co-existence of
Gilbert’s syndrome together with these diseases further increases the risk of
gall bladder disease. Some of these patients develop symptomatic disease
which necessitates surgical intervention. At present the timing of cholecystec-
tomy for thalassemia is no different from that of the general population with the
exception of removal of the gall bladder at the time of splenectomy. This is no
longer the case in sickle cell disease where, laparoscopic cholecystectomy is
recommended even in asymptomatic patients. This practice however has not
been extended to other types of haemoglobin disorders.
Aims: 1.To assess the perioperative complications of patients with thalas-
saemia during cholecytetomy and to compare it with non thalassaemics who
undergo the procedure. 2. To see if there is enough evidence to recommend
elective cholecystectomy for thalassaemics.
Methods: We retrospectively studied case notes of thalassemia patients who
had cholecystectomy (cases) in two of the biggest thalassaemia centres in Sri
Lanka and also of 62 non-thalassaemics (controls) with gall bladder disease
who had been scheduled to have gall bladder surgery in the same hospitals
and looked at their peri-operative complications.
Results: 98 out of 540 (18%) thalassaemics in the two centres had gall stones.
Mean age of cases was 26.8 (SD 10.9) years and of controls 47.5 (SD 19.7)
years. 19 (19%) thalassaemics with gall stones had undergone cholecystecto-
my. Ten patients had cholecystectomy simultaneously with splenectomy. The
majority of non-thalassaemic “controls” had laparoscopic cholecystectomy
53/55 (96.3%) whilst the patients with thalassaemia were mostly operated with
laparotomy 13/19 (68%). There was a significant excess complications occur-
ring in both early (42.11 vs. 18.1%) and late (31.5 vs. 12.7%) phases in the
thalassaemic patients compared with the controls.
Among the early complications, sepsis (10.5% vs. 1.8%) and liver abscess for-
mation (5.2 vs. 0%) was significantly different in the groups, adversely affecting
the thalassaemics. Recurrent abdominal pain was more common among the
thalassaemics as a late complication (P<0.05). Six thalassaemic patients with
gall stone disease died during this study, 5(5%) while awaiting surgery and
1(1%) after surgery. There were no deaths among the controls. Out of the
deaths, 3 (50%) were directly attributable to gallstone disease. In all three sep-
ticemia precipitated heart failure. We found a significant increase of both early
and late post-surgical complications in the thalassemia group and also
increased mortality most of which was related to severe sepsis. Higher peri-
operative mortality and morbidity were seen among symptomatic thalassaemic
patients with gall stone disease undergoing cholecystectomy. This seems to
suggest a strong case for supporting elective cholecystectomy in thalassemics
before they develop symptoms.
Summary and Conclusions: We suggest that laparoscopic elective chole-
cystectomy be considered for non-sickle, thalassemia patients too who have
asymptomatic gall bladder disease, in an attempt to reduce this morbidity and
mortality.
PB2010
EFFICACY AND SAFETY OF DEFERASIROX IN SINGLE VS DIVIDED
DOSAGE IN THALASSEMIC CHILDREN.
S. Kakkar1,* P.P.C. Sobti2, A. Kalra3
1Pediatrics, Hemato-oncology unit, Dayanand Medical College, Ludhiana,
2Pediatrics, hemato-oncology unit, Christan Medical College, Ludhiana, 3Pedi-
atrics, Dayanand Medical College, Ludhiana, Ludhiana, India
Background: Iron chelation has improved the prognosis in thalassemia major.
DFX had been the recent oral iron chelator in use. Dose-dependent effect of
DFX had been observed in many studies. Initially it was used at 20 – 30
mg/kg/day but efficacy proved to be better when used at higher doses of 30 –
40 mg/kg/day with good tolerability. Ferritin levels tended to be high even on
DFX (30 – 40 mg/kg/day) with good compliance, so safety and efficacy of higher
doses (40 – 50 mg/kg/day) in once daily vs two daily doses needed to be com-
pared.
Aims: To study the efficacy and safety of DFX (40-50 mg/kg/day) in single vs
divided doses in thalassemic children
Methods: The prospective study was conducted in thalassemia ward of Depart-
ment of Pediatrics, Dayanand Medical College and Hospital, Ludhiana from
Jan 2013 to June 2014. Patients were randomly allocated in two groups, Group
A & Group B. Both took DFX in doses of 40 – 50 mg/kg/day, group A once daily
doses and group B in two divided doses. Efficacy was studied in terms of
change in ferritin levels, cardiac & liver MRI T2 * values and LVEF. Safety profile
was studied in terms of gastrointestinal side effects, rash and change in serum
creatinine values, SGPT and GFR.
Results: Serum ferritin levels reduced in both the groups viz. Group A
(2692.5±1232.35 ng/mL to 1959.5±696.19 ng/mL p value=0. 07), Group B
(2766.2±897.51 to 2569.9±762.6 ng/mL ;p value=0.38) with significant differ-
ence between the two groups at the end of study (P=0.05).Liver MRI T2* values
improved in group A (2.1±1.50 to 3.1±1.84 ms; P= 0.096)as compared to group
B (2.8±1.84 to 2.2±2.71 ms; P=0.70). Mean LIC decreased in group A
(17.4±7.83 mg/g dw to 12.4±8.05 mg/g/dw; P= 0.197) as compared to group B
(15.3±10.42 mg/g dw to 22.1±11.93 mg/g/dw; P= 0.340 ).Overall mean cardiac
MRI T2 * values decreased (30.5±10.30 ms to 24.5±4.94 ms; P=0.202 ) in
group A and (31.7±14.78 ms to 20.5±11.78 ms; P=0.167) in group B but
remained within normal limits. No change in LVEF was observed. No significant
adverse effects were noted with 40–50 mg/kg/day dose of DFX. There was
increase in liver transaminases (SGPT) levels (64.4±54.0 to 34.5±14.1 mg/dl
in group A; P= 0.05) and (97.9±79.3 to 61.9±39.2 mg/dl ;P= 0.134) in group B
Summary and Conclusions: DFX is safe in higher dosages (40 – 50
mg/kg/day) and once daily dosage is more efficacious as compared to twice a
day dosage schedule.
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MICROPARTICLE PROFILE DURING PAINFUL CRISIS AND NON-CRISIS
PERIOD IN SICKLE CELL ANEMIA
A. Atmis1, I. Sasmaz1,* B. Antmen1, B. Karagun1, Y. Kilinc1
1Pediatric Hematology, Çukurova University, Adana, Turkey
Background: Sickle cell anemia is a disease which is characterized with
hemolytic anemia, hypercoagulopathy and painful crisis. Microparticles are 0,1-
1 µm sized little membrane particles which are derived during activation or
apoptotic phase of cell cycle. It is reported that microparticles are increased in
many systemic disease including sickle cell anemia.
Aims: In this study we aimed to investigate the role of microparticles on clinical
state and prognosis during crisis and non-crisis periods in sickle cell anemia
patients.
Methods: Twenty nine patients, following by Çukurova University Department
of Pediatric Hematology, are included in this study. Blood samples were col-
lected in 26 of these patients in non-crisis period. Control group was formed
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with 18 healthy children without any systemic disease. Complete blood count,
hemoglobin electrophoresis and biochemical parameters were studied in both
groups. Also patients’ total microparticle levels, erythrocyte (CD235a), endothe-
lia (CD106), monocyte (CD14) particle levels and tissue factor expressing
(CD142) microparticle levels were studied by flow cytometry and whole data
was statistically analyzed.
Results: Hemoglobin and hematocrit levels were significantly low in sickle cell
anemia patients (P<0,001). Levels of HbS were significantly high during crisis
period comparing with mean HbS levels during non-crisis period (P<0,001).
Total microparticle levels were significantly high in sickle cell anemia patients
with painful crisis comparing with control group (P<0,05). Erythrocyte and
monocyte microparticle levels were significantly high in patients with painful
crisis comparing with non-crisis periods (P<0,05). Endothelial and tissue factor
expressing microparticle levels were high in patiens with crisis comparing to
non-crisis period but this was not statistically significant (p>0,05). There was
not any significant relation with microparticle levels and femur or humerus head
avascular necrosis (p>0,05). There was not any significant relation with fre-
quency of crisis and microparticle levels (p>0,05). Microparticle levels were
low in patients whose were taking hydroxiurea treatment comparing with not
taking hydroxiurea treatment but this was not statistically significant (p>0,05).
Summary and Conclusions: As a result we found high levels of total micropar-
ticle, erythrocyte and monocyte microparticles in sickle cell anemia patients
during painful crisis period. These microparticles may be role in pathophysio-
logical process of crises in SCA patient. We need further studies in order to
understand the effect of microparticles on prognosis of sickle cell anemia.
PB2012
TRANSIENT RED CELL APLASIA “THE GIFT OF PROGRESS”
N. Vaynyuskaya1,*
1Hematological, State Children Hospital 1, Saint-Petersburg, Russian Feder-
ation
Background: “What we call progress is the replacement of one trouble to
another”,H.Ellis. Modern technologies that enabling blood transfusion even in
utero, possibilities to identify new viruses and so on that is a background why
doctors have to solve previously never-existing problems.Transient aplasia cri-
sis is an often situation for the pediatric hematologist in Russia. It would seems
strange, but we have decided to unite under this name two quite different noso-
logical forms:hemolytic disease of the newborn,complicated with an absence
of reticulocytosis, and transient erythroblastopenia of childhood. 
Aims: To analyze the clinical features and management of aplasia crisis in
children with hemolytic disease of newborns, complicated with an absence of
reticulocytosis and children with transient erythroblastopenia.
Methods: There were reviewed medical histories of 62 patients (16 babies
with hemolytic disease of the newborn, complicated absence of reticulocytosis,
46 children with transient erythroblastopenia of childhood). We have evaluated
duration of hospitalization, number of transfusions,the connection of the disease
with infection, therapeutic options. Period of evaluation was since 2009 to 2014
years.
Results: Children with hemolytic disease of the newborn were aged from 0 to
3. Children with transient erythroblastopenia of childhood were aged from 12
months to 5 years.The length of hospitalization of children ranged from 16 days
to 35 days, the average was 24 days, and from 9 to 25 days on average 16
days, respectively.Children with hemolytic disease of the newborn were closely
observed immediately after birth, and were admitted to hospital in adequate
time. Only 12 of the 46 children with transient erythroblastopenia of childhood
were applied to hospital immediately after infection. During the observation
period the number of patients with transient erythroblastopenia of childhood
increased from 7 (2009) to 15 (2014).Children with hemolytic disease of the
newborn has increased from 3 (2009) to 5 (2014).6 children with hemolytic
disease of the newborn required intrauterine transfusions, 9 children required
exchange transfusion immediately after birth, 12 babies needed transfusion
during the first month of life.There were 21 child with transient erythroblastope-
nia of childhood that required blood transfusions because of the hemic hypoxia
signs.In 18 children with transient erythroblastopenia of childhood was verified
acute viral infection (6 EBV,2 Parvovirus 19,4 CMV, 5 herpes virus type 6,1
herpes type 1).In children with hemolytic disease of the newborn, complicated
by aplastic crisis, acute viral infections has not been found. Two children with
severe long regenerating form of hemolytic disease of the newborn held a bone
marrow biopsy, to 44 patients with erythroblastopenia was also made this
study.According to the results of myelogram in all patients there was excluded
systemic blood diseases. All patients with hemolytic disease of the newborn
received drugs of erythropoietin from 5 to 15 injections depending on the sever-
ity of the condition. Reticulocytosis crisis was reached in an average of 4-5
injections. All patients with erythroblastopenia received B group vitamins, 16
children received a course of prednisolone. Children with erythroblastopenia
had normalization of blood count at 12-25 day.
Summary and Conclusions: Transient aplasia crisis, that presented by nor-
mochromic aregenerating anemia, is severe, but in the modern world, treatable
condition. Duration and severity of hemolytic disease of the newborn regener-
ating status is determined by prenatal transfusion therapy. Severity and length
of transient erythroblastopenia of childhood is determined by the etiology of
the infectious agent and the time of anemia status. Parvovirus B19 is not the
only reason for the erythroblastopenia of childhood.Both of these diseases are
relatively benign conditions, it can pass without trace, but in view of the high
transfusion dependence it requires further study and observation. Regularly
blood tests after birth and diseases can help to find this conditions earlier and
to reduce transfusion rate. 
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IL28B GENE POLYMORPHISMS IN EGYPTIAN PEDIATRIC PATIENTS
WITH SICKLE CELL DISEASE: PREVALENCE AND RELATION TO SPON-
TANEOUS CLEARANCE OF HCV
S. Mohammed Mousa1, M. El-Ghamrawy2,* H. Gouda1, M. Khorshied1,
D. Abd Elsalam Ahmed1, H. Shiba1
1Clinical and Chemical Pathology, 2Pediatric Hematology, Faculty of Medicine,
Cairo University, Cairo, Egypt
Background: Egypt has the highest prevalence of hepatitis C virus (HCV)
worldwide. Patients with sickle cell disease (SCD) are exposed to the risk of
HCV infection. Genetic polymorphisms in IL28B gene have been associated
with spontaneous HCV clearance.
Aims: To determine the prevalence of both HCV infection and IL28B gene
polymorphisms among pediatric patients with SCD and to explore the relation
between IL28B gene polymorphisms and spontaneous HCV clearance.
Methods: Seventy SCD patients were screened for HCV antibody. All patients
were recruited only after informed consents were obtained freely from their
guardians. Detection of IL28B polymorphisms (rs 12979860 SNP and rs
12980275 SNP) was done using Taqman QRT-PCR and sequence specific
primers PCR respectively. HCV RNA was measured in sera of HCV positive
patients using quantitative real time PCR.
Results: Sixteen patients (23%) were positive for HCV antibodies. Nine
patients (56.3%) had undetectable HCV RNA in serum (spontaneously cleared)
and 7 patients (43.8%) were not cleared. Genotypes CC/CT/TT of rs12979860
were found in 30 (42.9%), 29 (41.4%) and 11 (15.7%) while rs12980275
AA/AG/GG were found in 8 (11.4%), 59 (84.3%) and 3 (4.3%). There was no
significant difference in the frequency of IL28B (rs 12979860) genotypes
between HCV patients who cleared the virus and those with persistent viremia
(P=0.388). In addition, frequency of IL28B (rs12980275) genotypes did not dif-
fer between the two groups (P=0.438).
Summary and Conclusions: Egyptian sickle cell disease patients have high
prevalence of HCV. IL28B gene polymorphisms are not associated with spon-
taneous clearance of HCV in this cohort of Egyptian children with sickle cell
disease.
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GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY: CLINICAL AND
MOLECULAR CHARACTERIZATION OF 10 CASES 
E. Fermo1,* C. Vercellati1, P. Bianchi1, A.P. Marcello1, S. Aytac2, M. Cetin2,
A. Zaninoni1, A. Zanella1, W. Barcellini1
1UOS Fisiopatologia delle Anemie, UO Oncoematologia, fondazione IRCCS
Ca Granda Ospedale Maggiore Policlinico, Milano, Italy, 2Department of Pedi-
atric Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) is a dimeric
enzyme that catalyses the reversible isomerisation of glucose-6-phosphate
(G6P) to fructose-6-phosphate (F6P), the second reaction step of glycolysis.
GPI deficiency, transmitted as an autosomal recessive trait, is the second most
common erythro-enzymopathy of anaerobic glycolysis, after pyruvate kinase.
GPI deficient patients are affected by chronic non-spherocytic hemolytic anemia
of variable severity; in rare cases mental retardation or neuromuscular symp-
toms have also been reported. The gene locus encoding GPI is located on
chromosome 19q13.1 and contains 18 exons. So far about 60 cases of GPI
deficiency have been described, and 35 mutations have been reported at the
nucleotide level.
Aims: We report the clinical, haematological and molecular characteristics of
10 GPI deficient cases
Methods: 10 patients (6 males, 4 females) from 9 families, with a median age
at admission of 7 yrs (range 1-51) were studied. Eight patients were of Italian
origin and 2 were Turkish. Haematological parameters and red cell enzyme
activity were determined according to standard methods. The entire coding
region of the GPI gene was amplified by PCR and automatically sequenced.
Results: Main clinical and haematologic parameters and results of the molec-
ular characterization are reported in Table 1. All patient displayed anaemia at
birth or in the early infancy; neonatal jaundice was observed in 4 patients, 3 of
whom required exchange transfusion. All patients needed blood transfusion in
childhood: 3 regularly (every 4-8 weeks), the remaining occasionally in con-
comitance of haemolytic crises due to infections. Splenectomy, performed in 5
patients, did not lead to normalization of anaemia, only resulting in a slightly
increase of Hb levels (0.5-1 g/dL) but it eliminated transfusion requirement;
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bilirubin levels increased after splenectomy in 3 cases. No patient needed trans-
fusions in adulthood; however, two underwent chelation therapy for iron over-
load. None showed neurological signs. Eleven different mutations were found
in GPI gene, 4 of them never described before (c.311 G>A, c.307C>G,
c.269T>C, c.1066G>A); all the new mutations affect highly conserved residues,
were not detected in Ensembl and 1000 genomes database, and were predicted
to have pathogenic effects by Polyphen, SIFT analysis. In particular, mutation
Asp356Asn falls in a region involved in the sugar isomerase domain and dimer-
dimer interface, and it is part of active site, further suggesting its drastic effect.
In one patient we were unable to find the second mutation; however, the loss
of heterozygosity at the cDNA level suggested the presence of a null mutation
of the paternal GPI allele
Table 1.
Summary and Conclusions: We characterized the largest series of GPI defi-
cient patients so far reported. Patients present with moderate/severe anaemia
that improve with aging. The study confirms the great heterogeneity of the
molecular defect. Although neurological impairment is sometime reported in lit-
erature in GPI deficiency, none of the cases here described displayed extra-
haematological symptoms.
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ASEMPTOMATIC NEPHROTOXICITY IN PATIENTS WITH TRANSFUSION
DEPENDENT BETA THALASSEMIA
Z. Karakas1,* A. Annayev1, A. Yalçıner2, S. Emre3
1Pediatric Hematology/Oncology, Istanbul University, 2Duzen Laboratory, 3Pedi-
atric Nephrology, Istanbul University, Istanbul, Turkey
Background: There is few information about nephrotoxicity than other organ
damages in patients with transfusion-dependent Beta thalassemia(TDT). Crea-
tinine levels are not sensitive indicators and do not change unless renal injury is
significant. Cystatin C(Cys-C) is a marker to predict glomerular dysfunction with
higher sensitivity and specificity than serum creatinine and creatinine clearance.
Aims: The aim of this study was to evaluate renal tubular and glomeruler func-
tions with Glomerular Filtration Rate(GFR), Beta 2 microglobuline(B2 MG),
mean fractional Na excretion (FENe) and cystatin C in patients with TDT.
Methods: Fifty patients with TDT who were being followed up at Istanbul Uni-
versity, Istanbul Medical Faculty, Thalassemia Center between January 2014
and May 2014, were included in this study after the approval of the ethical com-
mittee and informed consents were signed by patients. The mean age was
18.4±11.8 years (28 female and 22 male, age range:2-45 years). Thirty healthy
volunteers with matched age and sex were also evaluated as the control group.
Patients with known renal disease were excluded from our study. The patients
were evaluated using GFR, FENe for glomerulopathy and serum Cys-C and
urine β-2 MG for tubulopathy. These results were compared with the controls.
Serum Cys-C and urine β-2 MG were measured by a latex particle-enhanced
nephelometric immunoassay (DadeBehring, Liederbach, Germany).
Results: We studied 50 patients, all of them have normal GFR according to
age.Thirty patients (60%) had at least one sign of glomerulopathy and tubu-
lopaty. Twenty-seven of 50 patients (55%) had higher serum Cys-C values
(mean : 0,75+0,12) compared with controls (mean:0,66+0,09), P<0.001) while
no patient had increased levels of serum Cr according to age. There was a lin-
ear relationship between Cystatin C and GFR. When we evaluated the etiology
of glomerulopathy and tubulopathy, we found that; there were no statistically
significant differences between pretransfusion Hb, ferritin, liver iron overload,
cardiac iron overload, and cystatin C, β-2 MG, FENe and GFR. Cystatin C
increases with the age, the beta-2 MG and FENe does not change with age.
27 of 30 patients with renal injury (90%) had an increased Cys-C levels com-
pared to the control group. Forty-two of 50 patients (84%) used Deferasirox
(DFX), 8 (16%) used Deferipron (DFP). When patients were evaluated with
respect to chelation they received, nephrotoxicity was determined in 22 of 42
patients using DFX (52%). Only FENe level in 2 of these patients, only Cys-C
level in 11, both FENe and Cys-C levels in 2, both B2 MG and Cys-C levels in
4, all three parameters had increased in 3 of these patients. Nephrotoxicity
was detected in 7 of 8 patients (85%) using DFP. Only Cys-C level increased
in 4 of these patients (57%), only FENe level increased in 1, both B2 MG and
Cys-C levels had increased in 2 of these patients. Also, Cys-C level increase
was detected in one TDT patient who didn’t receive any chelator yet. In patients
receiving DFX, nephrotoxicity was more obvious and related with dosage.
Figure 1.
Table 1.
Summary and Conclusions: Nephrotoxicity in thalassemia patients is reported
with rate of 4-80% and is multifactorial, even if DFX receiving patients have
more risk, all TDT patients should be evaluated with Cys-C for early identifica-
tion of asymptomatic nephrotoxicity. We suggest intermitten evaluations (at
least every 6 months) with Cys-C in addition to routine renal function tests to
diagnose and prevent major renal injury in patients with TDT.
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SPURIOUSLY LOW PULSE OXIMETRY SATURATION ASSOCIATED WITH
HEMOGLOBIN SYDNEY IN A CHILD AND RELATIVES: IDENTIFICATION
OF THIS UNSTABLE HEMOGLOBIN MAY AVOID UNNECESSARY TESTING
AND HOSPITAL ADMISSIONS
S. Rives1,* A. Català2, M. Fernández-Sevilla3, R. Berrueco2, M. Camós4,
M. Torrebadell2, T. Toll2, A. Alonso2,M. Mesegué2,M. Trabazo1, V. Santa-María2,
A. Ruiz-Llobet2, A. Blanco5, D. Benéitez6
1Pediatric Hematology. Department of Hematology and Oncology, 2Hospital
Sant Joan de Déu de Barcelona. Fundació Sant Joan de Déu. Universitat de
Barcelona, Barcelona, Spain, 3Pediatric Department, 4Hematology Laboratory,
Hospital Sant Joan de Déu de Barcelona. Fundació Sant Joan de Déu. Univer-
sitat de Barcelona, 5Hematology Molecular Genetics Department. Hematology
Department, Hospital Vall d’Hebron, 6Erythropathology Unit. Department of
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Hematology, Hospital Vall d’Hebrón, Barcelona, Spain
Background: Pulse oximetry is a noninvasive method to measure hemoglobin
oxygen saturation and is widely used in different medical settings. Very few variant
hemoglobins have been associated with unexpectedly low SpO2. We describe
a new family with the unstable hemoglobin Sydney associated to artifactually
low SpO2, which, to our knowledge, has not been reported as a cause of this
phenomenon. Identification of these rare hemoglobinopathies may avoid cardiac
and pulmonary testing, unnecessary treatments and even hospital admissions.
Aims: To describe the association of Hemoglobin Sydney with artifactually low
SpO2.
Methods: HPLC analysis with the VARIANT II equipment and CDM software
(Bio-Rad) and acid and alcaline electrophoresis (HYDRASIS, SEBIA HIS-
PANIA) were performed on the hemoglobin of the index case and his father.
PCR amplification of the exons 1, 2, 3 and adjacent intronic regions was per-
formed on the HBB gene (betha-hemoglobin gene) and sequence analysis of
the amplified region. 
Results: A 19-month-old male and his father had low pulse oxygen saturation
measured by pulse oximetry (SpO2), which was not confirmed by arterial blood
oxigen measurement (SaO2) in the child (index case). The child was referred
by his primary care pediatrician to the Emergency ward because of bron-
chospasm that, in spite of salbutamol nebulizations and oxygen did not improve
SpO2 (87%). He was admitted to the hospial ward and treated with salbutamol,
corticosteroids and oxygen. A chest XR and cardiac ultrasound were performed
which were normal. He had mild compensated hemolysis (hemoglobin 125g/L,
VCM 94 fL, reticulocytes 4.5%, haptoglobin<40 mg/L. SaO2 was 96% (FiO2
21%) when SpO2 was 85%. The patient’s father, grand-father and aunt had
history of chronic hemolysis due to an unstable hemoglobin, not further char-
acterized. The grand-father had a history of splenectomy. A hemoglobinopathy
causing this falsely low SpO2 was suspected and confirmed. Both the patient
and his father had anomalous hemoglobin peaks on HPLC that did not separate
at all from HbA1 and DNA sequence analysis exhibited a mutation in het-
erozigosity in the HBB gene (Beta 87 (E11) Val>Ala) consistent with Sydney
hemoglobin. The artifactuosly low SpO2 may be due to abnormal absorption
peak measured by pulse oximeter.
Summary and Conclusions: Hemoglobin Sydney is a known unstable hemo-
globin which can result in an artifactually low oxygen saturation measurement with
pulse oximetry, previously not reported. To describe this association is important in
order to avoid unnecessary tests in patients with this rare hemoglobinopathy.
PB2017
FREQUENCY OF MUSCULOSKELETAL AND OTORHINOLARYNGOLOGIC
MANIFESTATIONS IN CHILDREN WITH B- THALASSEMIA
A. Abo Elsoaud1, M. Hesham2, M. Beshir 2,* D. Atta1, W. Elsaeed2, M. Mortada1,
H. Kelani3, M. Hassan3, N. Ezzeldin1
1Rheumatology department, 2Pediatrics department, 3E.N.T department, Fac-
ulty of Medicine, Zagazig University, Egypt, Zagazig, Egypt
Background: Beta-thalassaemias have a wide variety of musculoskeletal sys-
tem manifestations. Spinal involvement related to disease course and treatment
is common in patients with thalassemia syndromes. Also, a high frequency
sensorineural hearing loss is observed in a large percentage of patients during
intensive Desferrioxamine therapy.
Aims: To study the clinical and radiographic skeletal changes in transfusion-
dependent beta-thalassaemia patients and to present a comprehensive
overview of spinal involvement in those patients.
Methods: this cross sectional study was carried out on 240 patients with b-
thalassemia major who came weekly for blood transfusion at the hematology
outpatient clinic of Pediatric Department at Zagazig University hospital during
a period from 2012-2013. In all patients studied, detailed history regarding
musculoskeletal involvement was taken and locomotor examinations were per-
formed. Also, preliminary auditory perceptual assessment of patient’s voice
and careful laryngeal examination. All patients underwent all routine laboratory
investigations (CBC, Serum iron and ferritin, Liver and renal functions ), Imaging
study with standing anteroposterior and lateral X-rays of the spine,Ultra sonog-
raphy on affected knee (s) joint, augmentation and documentation of the glottic
picture and high-fidelity voice recording and acoustic analysis was done.
Results: locomotor system involvement was found in 56 patients (23.3%).
Most frequent complaints were arthralgia and low back pain in 21.3% and 6.3%
of patients respectively. Scoliosis was detected radiologically in 8 patients
(3.3% ). The most common curve pattern in thalassemia was the left lumbar
(62.5% ) followed by the right lumbar (37.5). Ultrasonography of affected knee
(s) joint showed synovitis, effusions, signs of metaphysis dysplasia and
increased power Doppler signals in (23.8%,14.3%,85.7%,19% respectively ).
There was mild to moderat laryngeal congestion nearly in all cases but the
vocal fold mobility (crico-arytenoid joint) is not affected.
Summary and Conclusions: Patients with beta thalassemia have a variety of
musculoskeletal problems and spinal involvement is common. Further studies
will be needed to detect the risk factors involved in the development of these
musculoskeletal problems.
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STUDY OF GROWTH DIFFERENTIATION FACTOR 15 IN EGYPTIAN
PATIENTS WITH BETA THALASSEMIA
M. El Tagui1, M. Hamdy2,* D. Mosallam2, N. Sowelam3
1pediatric hematology, 2pediatrics, 3clinical pathology, cairo university, cairo,
Egypt
Background: The thalassemia syndromes represent the most common causes
of ineffective erythropoiesis. The increased but ineffective erythropoiesis result-
ing in tissue iron overload induces numerous endocrine diseases, hepatic cir-
rhosis, cardiac failure and even death. Growth Differentiation factor 15 (GDF-
15) is a member of the transforming growth factor β super family. It was recently
studied as a marker of ineffective erythropoiesis in different types of anemia.
Aims: Our objective was to study the serum level of GDF- 15 in β thalassemia
major (TM) and thalassemia intermedia patients (TI) and to correlate it to the
iron status and different clinical and laboratory parameters in these patients
Methods: twenty five thalassemia major patients (mean age of 12.08± 4.6
years) and 25 thalassemia intermedia patients (mean age of 9.3± 4.7 years)
were randomly selected from the hematology clinic of the children hospital at
Cairo University together with 30 age and sex matched healthy controls. All
patients were subjected to thorough history taking and clinical exam. Blood
samples were withdrawn for the assessment of complete blood count, liver
function tests and serum ferritin. Estimation of GDF-15 level was done using
ELISA technique.
Results: On comparing the level of GDF-15 among the 3 groups, it was sig-
nificantly elevated in the TM group (8769.6±3560 pg/mL) versus the TI group
(7090±3656 pg/mL); P< 0.05 and versus the control group (385.1±244); P<
0.05. GDF-15 showed positive correlation to the age of starting chelation among
TM patients; P= 0.04 and negative correlation to the frequency of transfusion
and hemoglobin level in the TI group; P= 0.001.
Summary and Conclusions: GDF-15 in our study represent a first step for its
use as a biomarker in thalassemia patients. Future studies with large number
of patients are needed to confirm this hypothesis.
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EFFECT OF IRON FORTIFIED FORMULA FEEDING IN THE SECOND 6
MONTHS OF LIFE ON IRON STATUS AND ZINC LEVELS
H. Apak1, N. Ozdemir1,* G. Tuysuz1, B. Kutlubay1, E. Erginoz2, M. Kucur3
1Pediatric Hematology Oncology, 2Statistics, 3Biochemistry, ISTANBUL Uni-
versity, CERRAHPASA MEDICAL FACULTY, Istanbul, Turkey
Background: Malnutrition, iron deficiency anemia, zinc deficiency and asso-
ciated conditions are among the significant health problems of infancy espe-
cially in developing countries. The influence of nutrition types on iron deficiency
has not been adequately studied.
Aims: The aim of this sudy is to investigate the relationship between iron status
and zinc levels in infancy and type of milk consumed.
Methods: All infants were exclusively breatfed in the first 6 months life. All
mothers were recommended to start complementary foods at 6 months of age.
Infants, without a nutritional problem, weighing over 10th percentile and con-
tinue to be breastfed in addition to adequate complemantary foods were
enrolled in the control group (n: 45), babies weighting over 3rd percentile, did
not get adequate complementary foods and an iron fortifed formula was added
to the diet were included in the study group (n: 39). All infants were followed-
up monthly for 3 months. Hemoglobin, ferritin, iron, iron binding capacity and
zinc levels were assessed in relation to the type of milk.
Results: Mean hemoglobin values were similiar in the two groups at the end
of 3 months of follow-up. Mean ferritin values increased from 53,2±41,8 mg/L
to 64,7±89,7 mg/L in the study group, while decreased from 42,8±34,0 mg/L to
34,6±29,3 mg/L in the control group. In the study group, significantly higher
levels of ferritin were measured in the last assessment, compared to the control
group. There was no difference in the zinc levels between breastfed and for-
mulafed babies. 
Summary and Conclusions: An increase in the iron stores of iron fortifed for-
mula fed infants was observed during the follow-up period
PB2020
DO PANCREATIC FUNCTIONS PREDICT CARDIAC AND LIVER IRON
LOADING IN TRANSFUSION-DEPENDENT BETA THALASSEMIA MAJOR
PATIENTS USING CARDIOVASCULAR AND LIVER T2-STAR (T2*)MAG-
NETIC RESONANCE ?
G.M. Mokhtar1, W.E. Ibrahim1, N.S. Elbarbary1,* R.M. Matter1, A.S. Ibrahim2,
S.M. Sayed1
1Ain Shams University,Pediatric Department, 2Ain Shams University,Depart-
ment of Clinical Radiology, Cairo, Egypt
Background: In Egypt, b-thalassemia is the most common genetically deter-
mined chronic hemolytic anemia. Regular and frequent red blood cell transfu-
sions have significantly increased the life expectancy of patients with b-TM.
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The transfusions reduce some of the consequences of anemia, such as growth
deficit. However, when no appropriate chelation therapy is available, patients
accumulate iron in the heart, liver, spleen, pancreas, and endocrine glands,
leading to progressive organ dysfunction.
Aims: To assess the correlation between cardiac and hepatic T2*MRI findings
with the endocrine and exocrine pancreatic functions in known β-TM patients.
Methods: A total of 44 children and adolescents β-TM patients and 44 healthy
controls were investigated via: serum amylase, lipase, triglyceride index, oral glu-
cose tolerance test, and T2* MRI to assess iron content in the heart and liver.
Results: Overt diabetes was found in 9.4% and 45.5% of patients had impaired
fasting glucose. Median cardiac T2* was 22ms (12-31 ms) and LIC was 6ms
(4-9 ms). CardiacT2* was less than 10ms in 21.4% indicating heavy load with
iron in cardiac tissues. There is a significant decrease in serum amylase (87.5
vs. 63.5 IU/L, p =0.003) and lipase (94 vs.70 IU/L, P=0.056) among enrolled
patients in comparison to control group. Thalassemic diabetic showed low
serum amylase (32.5 vs. 59.5,P=0.0005),serum lipase (39.5 vs. 68, P=0.0007),
low cardiac T2* was found (7 vs. 22 ms,p =0.0006) and low LIC (2 vs.
6ms,P=0.0006) than other β-TM patients without diabetes. Inverse correlation
was found between triglyceride index with cardiac T2*(r= -0.376, P=0.014) and
low LIC (r=-0.376, P=0.014 respectively) but not with serum lipase (r= -
0.099,P=0.533), (r= -0.222,P=0.1570) and serum amylase (r =-0.191P=0.225),
(r=-0.053 ,P= 0.738 ) respectively. In Egypt, β-thalassemia is the most common
genetically determined chronic hemolytic anemia.
Summary and Conclusions: Follow up of thalassemic patients with impaired
fasting glucose together with intensive chelation therapy may help to prevent
the development of cardiac and hepatic siderosis.
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USEFULNESS OF DUAL-ENERGY CT FOR DETECTION OF LIVER IRON
DEPOSITION IN TRANSFUSION-DEPENDENT PATIENTS
H. Kobayashi1,* N. Yoshimura2, T. Kasami1, T. Katagiri1, H. Nemoto1,
K. Kawamoto1, T. Ushiki3, Y. Shibasaki4, M. Moriyama5, J. Takizawa1, M. Narita6,
H. Sone1, M. Masuko4
1Hematology, Endocrinology and Metabolism, 2Radiology, Niigata University
Faculty of Medicine, 3Transfusion Medicine and Regenerative Medicine Bio-
science Medical Research Center, 4Stem Cell Transplantation, Niigata Univer-
sity Medical and Dental Hospital, 5Medical Oncology, Niigata University Faculty
of Medicine, 6Hematology and Oncology, Graduate School of Health Sciences,
Niigata, Japan
Background: Chronic red blood cell transfusions lead to iron overload, which
has been implicated in the development of serious complications. Liver iron
concentration (LIC) is considered an indicator of total body iron stores, and the
measurement of T2* values by MRI represents a standard noninvasive tech-
nique to evaluate LIC. However, some limitations are associated with MRI,
such as its high cost and the overestimation of LIC. Although the application of
CT, which is easy to use and widely applied to measure LIC, needs to be con-
sidered, conventional single energy CT (SECT) also has limitations for the
detection of LIC due to normal variations in CT attenuation, predominantly in
patients with mild iron overload. Moreover, SECT fails to detect iron in fatty liv-
ers, which has an inverse effect on attenuation by lowering CT numbers. Dual-
energy CT (DECT) is used to obtain additional information on tissue composition
over that provided by SECT. This technique is based on substances showing
different densities with two different energies, with each substance displaying
its own energy-dependent change in CT attenuation. However, the role of DECT
in the detection of LIC remains to be clarified. 
Aims: The aim of this study was to examine whether DECT represented a
novel and useful technique for the detection of LIC.
Methods: Eight transfusion-dependent patients underwent liver DECT using a
dual-source 128-slice CT system, serum ferritin levels were measured, and
liver MRI was performed. DECT images were acquired using a tube voltage
pair of 140 kV and 80 kV or 140 kV and 100 kV, and the three-material decom-
positions of fat, soft tissue and iron. All patients provided informed consent.
Patient 1 was a 54-year-old male with MDS (RCMD-RS). Patient 2 was a 66-
year-old female with AML with MRC in 1st CR. Patient 3 was a 47-year-old
female who had undergone renal transplantation for chronic renal failure.
Patient 4 was a 65-year-old male with AML with MRC receiving iron chelation
therapy. Patient 5 was a 47-year-old male with AML in 3rd CR. Patient 6 was a
52-year-old female with AA. Patient 7 was a 63-year-old male with AIHA. Patient
8 was a 56-year-old female with AML in 2nd CR. All patients had long transfusion
histories and received red blood cell transfusions of at least more than 12 U.
Results: Serum ferritin levels in patients 1 to 8 were 961, 2168, 7875, 795,
1921, 5104, 2401, and 2916 ng/mL, respectively. Although patient 8 with fatty
liver, which was confirmed by abdominal ultrasonography, showed hypodensity
on SECT images, liver iron deposition was detected on DECT images. All
patients showed diffuse severe hypointensity on MRI T2*-weighted images.
Patients 1, 2, and 3 also showed severe diffuse iron deposition on DECT
images. However, patients 4, 5, 6, and 8 showed mild focal iron deposition,
while patient 7 did not show iron deposition on DECT images.
Summary and Conclusions: Our results suggest that DECT has the ability to
detect liver iron deposition in transfusion-dependent patients more precisely
than MRI. DECT may be a new tool that can overcome the limitations of MRI.
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INCIDENTAL DETECTION OF HAEMOGLOBIN VARIANTS DURING GLY-
CATED HEAMOGLOBIN ANALYSIS
E. Petridou1, A. Kotanidou1, A. Agorasti1,*
1Laboratory Haematology, General Hospital of Xanthi, Xanthi, Greece
Background: The presence of a haemoglobin variant (Hb variant) influences
the glycated haemoglobin (HbA1c) analysis in a method-depending manner
and may erroneously lead to underestimated HbA1c measurements by high
performance liquid chromatography (HPLC).
Aims: The aim of this study is the retrospective registration of the cases of Hb
variant detected during HbA1c analysis by HPLC, in order to reevaluate the
use of this specific method. 
Methods: All patients who had their HbA1c levels determined in our laboratory
during the period of time from 01-01-2004 to 31-03-2013 were included in the
study. The measurements of HbA1c were performed by automated reversed
phase cation exchange HPLC on an ADAMS™ A1c HA-8160, ARKRAY® ana-
lyzer. All Hb variant cases found during routine HbA1c analysis and further
identified with HPLC analyzer (HLC-723 G7 β-Thalassemia Mode, TOSOH®)
were recorded. Only one HbA1c result per patient was included in the study.
Results: Out of a total of 12617 patients, 122 (54 men & 68 women) was found
to have Hb variant. In particular, 83 patients (68,03%) had Hb-O Arab (1 hom-
ogyzous & 82 heterozygous), 36 patients (29,5%) had HbS (heterozygous),
two patients (1,64) had HbJ (heterozygous) and one patient (0,82%) had HbD
(heterozygous). The determination of HbA1c was impossible in the case of
homozygous O-Arab (no s-A1c peak detected). In all cases, the presence of
Hb variant was first diagnosed during the routine HbA1c analysis. 
Summary and Conclusions: The analysis of HbA1c using the HPLC method
is a simple and reliable screening test for Hb variant. The incidental finding of
haemoglobinopathy is very important, because old people that usually suffer
from diabetes mellitus, probably did not have previous haemoglobinopathy
investigation. Furthermore, homozygous O-Arab and heterozygous HbS pres-
ent a significant clinical importance. As the measurement of HbA1c can poten-
tially be affected by the presence of a Hb variant, and in order to avoid mis-
management of diabetes mellitus (pre-diabetes, diagnosis, monitoring) in indi-
viduals with Hb variants, the visual inspection of chromatograms obtained from
HPLC analysis for the detection of additional peaks is recommended. The lab-
oratory should report the presence of Hb variant with the HbA1c result.
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CHARACTERIZATION OF CHRONIC GRAFT-VERSUS-HOST-DISEASE IN
MALIGNANT HEMATOLOGICAL DISORDERS AFTER USING G-CSF-
PRIMED BONE MARROW AS A SOURCE OF HEMATOPOIETIC STEM
CELLS FOR ALLOGENEIC TRANSPLANTATION 
P. Guzman1,* E. Leon1, M. Rivera1, R. Terrazas1, C. Balderas1
1Hematology-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición,
Salvador Zubirán, Mexico, Mexico
Background: A major complication of allogeneic stem cell transplantation (allo-
SCT) is chronic graft-versus-host disease (cGVHD). Risk factors for the devel-
opment of cGVHD include prior acute GVHD, increasing patient age, and use
of a parous female donor for a male recipient. GVHD is also associated with
significant morbidity and mortality, commonly requiring long-term immunosup-
pressive therapy after allo-SCT. It has been documented that the use of G-
CSF-primed bone marrow as a source of hematopoietic stem cells decreases
the frequency and severity of cGVHD.
Aims: To describe the frequency and characteristics of cGVHD in 35 patients
who underwent allogeneic, G-CSF-primed bone marrow transplantation, at
INCMNSZ, from November 1998 to December 2014.
Methods: A retrospective analysis was performed in 35 patients who underwent
allogeneic, G-CSF-primed bone marrow transplantation, describing the char-
acteristics and outcome of 12 of them who developed cGVHD, using the Sta-
tistical Software Package SPSS v21.0.
Results: Twelve out of 35 patients who underwent allogeneic, G-CSF-primed
bone marrow transplantation, from November 1998 to December 2014, devel-
oped cGVHD (34.2%). Median age was 33 years (range 16-49), and 60% were
male. The patients had a following range of underlying diseases: acute lym-
phoblastic leukemia (LLA, n=4, 33.3%), myelodysplastic syndrome (n=5,
41.6%), chronic myeloid leukemia (CML, n=2, 16.6%), and acute myeloid
leukemia (AML, n=1, 8.3%). Median infused CD34+ stem cell dose was 2.04x
106/kg. All patients received conditioning with busulphan and cyclophosphamide,
and prophylactic immunosuppression with methotrexate (10 mg/m2 days 3, 6,
and 11) and cyclosporine A (CsA 5mg/kg) for the first 4 months. The median
interval from transplantation to occurrence of cGVHD was 275.3 (range, 101-
1359) days. 83.3% of the patients had limited cGVHD (10/12). Among the risk
factors associated with cGVHD we identified the following: five male patients
were given grafts from female donors, 2 patients with CML developed cGVHD
after donor lymphocyte infusion, three patients previously experienced acute
GVHD, and only one patient had an antigen mismatch (9/10). In 11 patients
(31.4%), hepatic dysfunction was consistent with elevation of transaminases
and alkaline phosphatase. Nine patients developed skin involvement charac-
terized by exanthema; 6 had mucous lesions: 2 patients lichen reticularis, 2
developed ulcers, and one leukoplakia. None of the patients had pulmonary or
ophthalmic lesions. Initial treatment included steroids in all patients, without
complete response and additional Immunosupressive therapy was prescribed
including: CsA, sirolimus, mycophenolate mophetyl, cyclophosphamide, ruxoli-
tinib, and imatinib. Median time of duration of immunosuppression therapy was
12.9 months (range, 3-41) with an overall response of 66% (8/12 patients).
GVHD associated mortality occurred in one patient, and one patient was lost
during follow up. At last follow up, the remaining 10 patients were alive and 8
were out of immunosuppressive therapy without evidence of GVHD.
Summary and Conclusions: Using G-CSF-primed bone marrow as a source
of hematopoietic stem cells for allo-SCT is associated with a different pattern
of cGVHD tissue impairment, characterized by skin and liver involvement, in
most cases mild and limited. At least two immunosuppressive therapy
approaches were needed to induce clinical remission. Further studies including
a larger number of patients are required in order to validate this strategy.
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IMPACT OF PLATELETS ALLOIMMUNIZATION IN ALLOGRAFT
S. Astati1,* S. Maury2, M. Mikdame1
1Service d’Hématologie Clinique,, Hôpital Militaire d’Instruction Mohammed V,
Rabat, Maroc, Rabat, Morocco, 2Service d’Hématologie Clinique et de thérapie
cellulaire, Hôpital Henri Mondor, Créteil, France
Background: The prolonged thrombocytopenia after hematopoietic stem cell
transplantation (HSCT) present factor of poor prognosis. There causes are
varied and complex; whose platelet alloimmunization, which is responsible for
refractoriness platelet transfusions.
Aims: The objective is to demonstrate the impact of mismatches between
donor and recipient for human platelet antigens (HPA) on recovery of platelet
counts after transplantation.
Methods: A retrospective analysis of 96 patients transplanted at the Department
Hematology at Hospital Henri Mondor, Creteil, between January 2011 and Decem-
ber 2013 was performed. Only geno and pheno-identical HSCT are studies.
Results: We tested each of the four HPA systems (HPA1, HPA3, HPA5 and
HPA15), the platelet recovery in recipients “aa” as they receive HSC donor
“aa” or “ab or bb”. We demonstrated no significant differences between groups
with or no mismatch HPA, compared at 1, 3, 6, and 12 months after graft. While
there was a trend (P=0.07) in HPA3 system at 24 months to transplant. In
HPA5 system, the differences were in the expected direction without statistically
significant.
Summary and Conclusions: It would be important to demonstrate the impact
of mismatch HPA on platelet recovery in a most important sample of patients
to prevent the onset of refractoriness to platelet transfusions in the course of
allogeneic haematopoietic stem cell.
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CLINICAL IMPACT OF HEPATITIS B SURFACE ANTIGEN POSITIVITY IN
PATIENTS UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
H.G. Yi1,* M.H. Lee1, J. Hong2, J. Park2, J.H. Lee2, S.H. Kim3, S.K. Park3,
D.S. Hong3, C.S. Kim1
1Internal medicine, Inha University, School of Medicine, 2Internal medicine,
Gachon University, School of Medicine, Incheon, 3Internal medicine, Soonchun-
hyang University, School of Medicine, Bucheon, Korea, Republic Of
Background: Hepatitis B virus (HBV)-related events could increase in patients
who have HBV before or after allogeneic hematopoietic stem cell transplanta-
tion (HSCT) due to their immunosuppressive status because of their primary
diseases, conditioning regimens, immunosuppressive agents, and immature
immune reconstruction. However, the consensus of the risk of HBV status and
prophylactic or therapeutic strategies for these patients were not settled yet.
Aims: We intented to search the clinical impact of HBV surface antigen (HBS
Ag) positivity in patients undergone allogeneic hematopoietic stem cell trans-
plantation.
Methods: We reviewed clinical information of HBS Ag-positive patients who
had been treated with allogeneic HSCT for various hematologic diseases to
evaluate the influence of HBsAg positivity to the clinical outcomes. A total of
398 patients who had been treated with allogeneic HSCT between January
1998 and November 2014 in three domestic institutes of Korea were enrolled
in this study.
Results: Eleven patients (2.8%) were HBsAg-positive among 398 patients
treated with allogeneic HSCT. The diagnosis were acute myeloid leukemia
(N=3), acute lymphoblastic leukemia (N=1), non-Hodgkin lymphoma (N=1),
myelodysplastic syndrome (N=2), severe aplastic anemia (N=3), and acute
biphenotypical leukemia (N=1). Ten patients were HBsAg-positive before HSCT,
and one patient became seroreversion after HSCT due to HBsAg-positive
donor. Seven patients (63.6%) were given prophylactic antiviral agents (lamivu-
dine, N=4; entecarvir, N=3). Three patients (27.3%) experienced chronic active
hepatitis (CAH) after HSCT, which was controlled well with antiviral agents. Of
three CAH patients, two had not been give any HBV prophylaxis during HSCT.
Sinusosidal obstruction syndrome (SOS) occurred in 3 patients (27.3%), and
one died of SOS. Acute liver graft-versus host disease (GVHD) occurred in 4
patients (36.4%); and chronic liver GVHD did in 2 (18.2%). Interestingly, one
patient whose donor had HBs antibody (HBsAb) lost HBsAg after HSCT.
Summary and Conclusions: HBsAg positivity could increase the risk of the
incidence of chronic active hepatitis after allogeneic HSCT. However, it seems
not to influence markedly to the overall clinical outcomes of HSCT including
survival, SOS or liver GVHD. Loss of HBsAg might be expected if the donor
has HBsAb. Further large-scaled studies designed to identify the risk of HBsAg
positivity and the optimal strategy for HBsAg-positive patients is required.
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THE ROLE OF HLA HIGH RESOLUTION TYPING IN UMBILICAL CORD
BLOOD TRANSPLANTATION
A. Sun1,* S. Yang1, J. He1, C. Xu1, H. Qiu1, Z. Jin1, X. Tang1, C. Fu1, X. Ma1,
D. Wu1
1The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hema-
tology, Suzhou, China
Background: 1s smdy was pur10sed to investigate me clillical value of HLA
mtchjn2(10w and tIigh I esolution)aJld its effect on outcome of the patients
received umbilical cord blood_ransplantation(UCBT). This study was purposed
to investigate the clillical value of HLA matching(low and high resolution) and
its effect on outcome of the patients received umbilical cord blood transplan-
tation(UCBT)
Aims: To analyze HLA matching(low or high resolution ) on outcomes of umbil-
ical cord blood transplantation(UCB) and the value of clinical application.
Methods: From October 2010 to July 2012,26 patients were selected umbilical
cord blood transplantation in our hospital,in the absence of a suitable HLA-
identical sibling donor or alternative donors.We examined the effects of HLA
matching (low or high resolution ) on engraftment of leading, engraftment,graft-
versus-host disease (GVHD), infection and mortality.Performed mainly by
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sequence-specific oligonucleotide probe (SSOP) methods, sequence-based
typing (SBT) methods and high resolution sequence-specific primers(SSP)
methods,retrospective HLA matching of cord blood,typed at high resolution for
HLA-A,-B, -C, -DRB1, -DQ, and -DP and low resolution for HLA-A,B,DRB1. 
Results: Compared single UBC units transplantation with double UBC units,the
hematopoietic reconstitution rate was 88% vs 56%.The median total nucleated
cells(TNC) of single and double cord blood was 5.5×107/kg, when
TNC≥5×107/kg could promote neutrophil recoveries (P<0.05). The UBC units
were a 6/10 HLA high resolution match or better with each other could promote
UCB implantation advantaged P<0.05, accelerate platelet recovery P<0.05 and
reduce more risk of acute GVHD (grade III -IV) P<0.05. There are different
between the group 5-6/6 HLA low resolution and 3-4/6.but no statistical differ-
ence P>0.05.
Summary and Conclusions: The HLA High resolution typing can select the
better UCB than HLA low-resoulution. It has important clinical value on pro-
moting hematopoietic reconstitution and reducing complications after UCB
transplation.
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WHICH IS THE MOST ADOPTABLE PROGNOSTIC MODEL FOR DIFFUSE
LARGE B CELL LYMPHOMA TREATED WITH R-CHOP FOLLOWED BY
AUTOLOGOUS TRANSPLANTATION?
M. Lee1,* S.Y. Kim1, I. Kim2, Y.K. Kim3, J.A. Kim4, Y.S. Kim5, H.S. Lee5, J. Park6,
S.J. Kim7, H. Shim8, H.S. Eom9, B.B. Park10, J. Lee11, S.K. Park12,
J.W. Cheong13, K.W. Park14
1Internal Medicine, Konkuk University Medical Center, 2Internal Medicine, Seoul
National University Hospital, Seoul, 3Internal Medicine, Chonnam National Uni-
versity Hwasun Hospital, Hwasun, 4Medicine, The Catholic University of Korea
College of Medicine, Seoul, 5Medicine, Kosin University Gospel Hospital,
Busan, 6Medicine, Gachon University Gil Hospital, Incheon, 7Medicine, Sam-
sung Medical Center, Seoul, 8Medicine, Wonkwang University Hospital, Iksan,
9Medicine, National Cancer Center, Ilsan, 10Medicine, Hanyang University Col-
lege of Medicine, Seoul, 11Medicine, Daegu Fatima Hospital, Daegu, 12Medi-
cine, Soonchunhyang University Hospital, Bucheon, 13Medicine, Yonsei Uni-
versity College of Medicine, Seoul, 14Medicine, Dankook University Hospital,
Cheonan, Korea, Republic Of
Background: The ideal prognostic model has not been developed for patients
with diffuse large B cell lymphoma (DLBCL) treated with rituximab combined
with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell
transplantation (Auto-SCT).
Aims: Among the currently adoptable prognostic models for DLBCL, we inves-
tigated to find out which one is the most adoptable one for DLBCL treated with
R-CHOP followed by upfront Auto-SCT.
Methods: We retrospectively evaluated survival differences between the risk
groups based on the International Prognostic Index (IPI), the age-adjusted IPI
(aaIPI), the revised IPI (R-IPI) and the National Comprehensive Cancer Network
IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with
R-CHOP followed by upfront Auto-SCT.
Results: Patients had either stage I/II bulky disease (6.3%) or stage III/IV dis-
ease (93.7%). The median age at diagnosis was 50 years (range, 22-66 years).
37 of 63 patients (58.7%) belonged to the IPI high-intermediate or high risk
group. 48 of 63 (76.2%) received 6 or more cycles of R-CHOP. The median
time to transplantation was 7.2 months (range, 3.4-40.3 months). At the time
of Auto-SCT, 74.6% and 25.4% of patients achieved complete (CR) and partial
remission (PR) after R-CHOP, respectively. As a whole, the 5-year overall (OS)
and progression-free survival (PFS) were 78.8% and 74.2%, respectively. The
5-year OS and PFS rates according to IPI, aaIPI, R-IPI, and NCCN-IPI did not
differ in statistical significance between the risk groups of each prognostic model
(P values for OS: 0.255, 0.185, 0.881, and 0.803, respectively; P values for
PFS: 0.177, 0.832, 0.295, and 0.609, respectively). 
Summary and Conclusions: There is no ideal prognostic model among the
currently adoptable ones for CD20-positive DLBCL treated with R-CHOP followed
by upfront Auto-SCT. A new prognostic model is necessary to identify those who
will gain the maximum benefit from upfront Auto-SCT in the rituximab era.
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EAM (ETOPOSIDE, CYTARABINE, MELPHALAN) BEFORE AUTOLOGOUS
STEM CELL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR RESIST-
ANT/RELAPSED HODGKIN LYMPHOMA PATIENTS
A. Bekadja1,* R. Bouhass1, S. Osmani1, M. Brahimi1, S. Talhi1, N. Yafour1,
A. Arabi1,
1Hematology and cell therapy, University hospital Oran, Oran, Algeria
Background: High-dose chemotherapy (HDT) followed by autologous stem
cell rescue has become the standard of care for patients with relapsed, chemo-
sensitive Hodgkin lymphoma (HL). A BEAM regimen is widely used conditioning
regimen for autologous stem cells transplant (ASCT) in patients with lymphoma
because of its acceptable toxicity and high effectiveness. Adverse events asso-
ciated with BEAM are related in part to BICNU.
Aims: On 2011-2012, we started a pilot study designed as follows: Etoposide
800 mg/m2 J-5 to J-2, Cytarabine 1000 mg/m2/12h, J-5 to J-2 and Melphalan
140 mg/m2 J-1 as the conditioning regimen to ASCT for resistant/relapsed HL
patientsto evaluate the safety and the efficacy of this regimen with high dose
Cytarabine.
Methods: Seventeen patients, seven males and ten females, 17 to 51 years
old (median, 28 years), with HL were consecutively treated in our center.
Regarding the stage of disease, four patients were in early stage (I-II), thirteen
in advanced stage (III-IV) and concerning their status at ASCT, thirteen were in
complete remission, three in partial response and one presented a refractory
disease. A median number of 3,73x106 CD34+ cells/kg (range, 2, 97-6, 15)
were re-infused.
Results: All patients had a full hematopoietic reconstitution. Median time to
achieve neutrophils >500 /μl was 13 days (range: 9-19) and median time to
achieve an unsupported platelet count >20,000/μl was16 days (range: 14-25).
Toxicities included grade 4 hematologic in all patients, grade 3 mucositis in 4,
grade 3 infectious in 2. Among 16 patients evaluable, fifteen patients (94%)
achieved CR; one patient had progressive disease post-ASCT.Fivepatients
died: one within the first 100 days that followed transplantation, one after pro-
gression of disease and three after relapse. After a median follow up of 37
months (2-45) (End point: 31/12/2014), the overall survival was 70% at 45
months, the DFS was 75% at 45 months and 12 patients are alive in continuous
CR (80%).
Summary and Conclusions: In conclusion, this pilot studyof EAMas condi-
tioning regimen seems to be safeand effective for heavily pre-treated Hodgkin
lymphoma patients. Although these outcomes are encouraging, our results
need to be confirmed by more other studies.
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CLINICAL IMPLICATION OF ΓΔ+ T CELL RECOVERY AFTER ΑΒ+ T CELL
DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTA-
TION IN CHILDREN WITH HEMATOLOGIC MALIGNANCY
J.K. Suh1, J.J. Seo1,* S.W. Lee1, K.N. Koh1, Y.U. Cho2, E.S. Choi1, S. Jang2,
H.J. Im1, C.J. Park2
1Pediatrics, 2Laboratory medicine, ASAN MEDICAL CENTER, Seoul, Korea,
Republic Of
Background: Human γ + T cells exhibit an ability to kill tumors but do not rec-
ognize major histocompatibility complex, thus have shown limited risk of graft-
versus-host disease (GVHD).
Aims: The purpose of this study were to determine antitumor efficacy of γ + T
cells in children with hematologic malignancy after αβ+ T cell depleted hap-
loidentical hematopoietic stem cell transplantation (haplo-HSCT).
Methods: Ten children (6 males, 4 females, median age 12.3 years) with hema-
tologic malignancy received haplo-HSCT after ex vivo depletion of αβ+ T cells
between May 2012 and December 2013 at AMCCH. Of 10 patients, 1 had ETP-
ALL in CR2 who relapsed after MSD-HCT, 1had MLL in relapse after 2 rounds
of URD-HCT, 5 had AML [2 CR1, 2 CR2, 1 non-remission (NR)], 2 had JMML
(1 CR1, 1 NR), and 2 had NHL (1 CR2 and 1 CR3) who relapsed after AUTO-
HCT. The median number of CD34+, αβ+, γ + and CD3+ cells infused was 10.6x
106/Kg, 6.3x 105/Kg, 2.1x 107/Kg and 22.9x 106/Kg, respectively. Proportion of
TCR γ + T cells in T lymphocyte were analyzed by using Gallios flow cytome-
ter™ (Beckman Coulter, Fullerton, CA, USA) after HSCT.
Results: All 10 patients engrafted and 1 patient experienced grade IV acute
GVHD without treatment related mortality. At a median follow-up period of 387
days (range, 208-766), 5 patients (1 ETP-ALL, 1 MLL, 2 AML, 1 NHL) relapsed
at the median 131 days (range, 42-234) after haplo-HSCT. The median dose
of infused γδ+ T cell for 5 patients without relapse and 5 with relapse were 2.2x
107/Kg and 1.8x 107/Kg. The median proportion of γ + T cells after HSCT was
higher in non-relapsed patients than in relapsed patients. (69.4% vs 29.3% at
1 month, 44.2% vs 6.2% at 2 months and 36.8% vs 9.1% at 3 months post-
transplant) At a median follow-up of 12 months probability of 1 year relapse-
free survival was 48.0%, and probability of 1 year overall survival was 78.8%.
Summary and Conclusions: These findings suggest a correlation between
an increase in the proportion of γ + T cells and improved relapse-free survival
after αβ+ T cell depleted haplo-HSCT. However, further studies including
prospective large numbered trial are needed to confirm our results. 
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EXTRACORPOREAL PHOTOPHERESIS AS A TREATMENT FOR ACUTE
AND CHRONIC GRAFT VERSUS HOST DISEASE. A SINGLE CENTER
EXPERIENCE IN SPAIN
J. Fonseca-Cipagauta1,* V. García Gutierrez1, S. Pérez-Gala2,
P. Herrera-Puente1, A. Chinea-Rodriguez1, M. Calbacho-Robles1,
G. Moreno-Jiménez1, M.C. Tenorio-Nuñez1, A. Jiménez-Martín1,
N. Revilla-Calvo1, I. Saavedra-Tapia1, J. López-Jiménez1
1Haematology Department, 2Dermatology Department, Hospital Universitario
Ramón y Cajal, Madrid, Spain
Background: Graft versus host disease (GvHD) is the most important cause
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of mortality and morbidity in patients who have undergone allogeneic stem cell
transplantation. Currently, high-dose steroid is the first line of therapy in this
disease. Nevertheless, there are no guidelines or agreement about the second
and subsequent lines of treatment, so this still remains a matter of discussion.
Extracorporeal photopheresis (ECP) has shown to be an effective and safe
option to treat GvHD.
Aims: To evaluate the efficacy and safety of ECP in GvHD treatment in our
center.
Methods: Since 2011 we have treated with ECP (Therakos System) a total of
25 patients with acute GvHD (aGvHD) (group 1) (n=12) and chronic GvHD
(cGvHD) (group 2) (n=13) with refractory disease to two or more previous lines
of therapy. Patients in group 1 were treated with weekly cycles and response
was evaluated at week 6-8 after treatment was started. Patients in group 2
were treated every 2 weeks and response was evaluated at month 3-4. In
group 1 Complete Response (CR) was defined as resolution of all symptoms,
Partial Response (PR) as improvement of at least one grade compared to
baseline and, Non Response (NR) when patients did not accomplish any of
the other definitions. In group 2 CR was defined as symptom resolution with
immunosuppressant treatment discontinuation, PR as improvement of more
than 50% over baseline and/or reduction of more than 50% in immunosup-
pressant treatment, Minimum Response (MR) as improvement less than 50%
over baseline and/or immunosuppressant reduction between 25-50% and Pro-
gression (PG) as clinical worsening or new organ involvement. The Modified
Glucksberg classification was used to stage aGvHD and the NIH criteria to
stage cGvHD.
Results: GvHD staging was 16%, 42% and 42% for grade II, III and IV respec-
tively in group 1 and 8%, 38% and 54% for mild, moderate and severe in group
2. Group 1 was treated with a median of 6 cycles (1-12) and group 2 with a
median of 9 cycles (3-22). The responses in group 1 was CR= 25%, PR= 33%
and NR= 42% and in group 2 was CR= 15%, PR= 54%, MR= 8% and PG=
23%. The mortality rate was 67% for group 1 and 54% for group 2. The main
causes of mortality were infections (88% and 57% for group 1 and 2) and GvHD
progression (12% and 29% for group 1 and 2). The only complication associ-
ated to ECP was catheter infection (2 cases).
Summary and Conclusions: In our experience, ECP has proven to be a safe
and effective treatment for patients with aGvHD and cGvHD. Prospective stud-
ies are required to establish indications and treatment guidelines.
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EFFECT OF COMORBIDITIES ON HEMATOPOIETIC STEM CELL TRANS-
PLANTATION OUTCOME IN ADULT PATIENTS WITH DIFFERENT HEMA-
TOLOGIC DIEASES :SINGLE CENTER EXPERIENCE IN EGYPT
A. El afifi1, M. elzimaity1, N. mostafa1, M. M. Moussa1,* G. shams eldin1,
R. magdy1, A. abdelaziz2, N. shalaby2, H. saber1
1Internal Medicine, Hematology and BMT unit, 2clinical pathology, Ain Shams
University, Cairo, Egypt
Background: Background Heamtopoeitic Stem cell transplantation (HSCT)
is a procedure that can restore marrow function for patients who have had
severe marrow injury, replacement of marrow by disease, or abnormalities of
the immune system..It is either autologous or allogenic. It has become increas-
ingly important to optimize pre-transplant risk assessment in order to improve
HCT decision making and clinical trial assignments. Single-organ comorbidity
involving liver, lung, heart, or kidney before HCT has been traditionally found
to cause organ toxicity after HCT. The HCT-comorbidity index (HCT-CI) has
provided better prediction of HCT-related morbidity and mortality than other
non-HCT-specific indices
Aims: The aim of this work is to study the impact of various pretransplant
comorbidities on outcome of patients who had undergone either-allogenic or
autologous HSCT -in relation to treatment related mortality and disease related
mortaliy with specific emphasis on overall survival.
Methods: A retrospective study was conducted at the bone marrow Trans-
plantation Unit, of internal medicine department Ain Shams University on 119
patients who were transplanted either by autologous or allogenic HSCT
(matched or mismatched related donor). All of them were aged >18ys.and had
different types of hematologic diseases; the most frequent being AML(34.4%)
followed by multiple myeloma(17.6%) then ALL(16.8%) and lymphoma (10.9%)
whereas,aplastic anemia,MDS,CML and biphenotypic leukemia.collectively
were20.1%.They were either in complete or partial remission according to the
type of disease. They were categorized according to HCT-CI into mild score
(0) 43 patients (36.2%), moderate score (1-2) 60 patients (50.4%) and severe
score (≥3) 16 patients (13.4%). The study data were collected from medical
notes, pathology reports and laboratory data.
Table 1.
Results: There was statistically significant relation between HCT-CI and overall
survival (p 0.012), disease free survival (p 0.007), mortality(p 0.047 ). and the
incidence of graft failure.(p 0.034). Comparison between different HCT-CI
scores as regard overall survival (Kaplan- Maier curve): P<0.05S-
Figure 1.
Summary and Conclusions: In our study, we could conclude that the HCT-
CI is a better predictor to detect the influence of comorbidity in patients with
hematologic disorders on mortality, overall survival and disease free survival
post HCT.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELODYSPLAS-
TIC SYNDROME
A. Sabrina1,* B. Malek1, T. Amina1, M. Farih1, B. Rachida1, R. Nadia1,
B. Mounira1, A.O. Dina1, B. Hanane1, Z. Sara1, M. Hanane1, B. Fatiha1,
A.A. Nacera1, T. Farida1, A. Naima1, B. Fateh1, A.N. Redouane1,
H. Rose Marie1
1Pierre and Marie Curie Center, Algiers, Algeria
Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic dis-
orders characterized by ineffective hematopoiesis, marrow dysplasia with
cytopenias, abnormal blasts and variable rates of transformation to acute
myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation
(HSCT) currently is the only potentially curative therapy for MDS. However,
since most patients with MDS are older than 60 years, few are candidates for
myeloablative transplantation. We present in this study our experience in HSCT
for MDS.
Aims: Between May 2001 to June 2014 (13 years period), twenty two pts with
MDS underwent allogeneic HSCT with HLA- identical sibling donors. The medi-
an age of the pts is 35,5 years (11-58), the Sex ratio is 1,44 (13M/9F), according
to WHO classification 2008 (RA : 01, RA with del 5q : 01, RA with ring siderob-
lasts: 01, refractory cytopenia with multilineage dysplasia: 07, RA with excess
blasts-1: 07, RA with excess blasts-2 : 05), 20pts were transfusion-dependent
before transplantation. Median time from diagnosis to allogeneic HSCT was
17, 2 months (7-52).
Methods: Myeloablative conditioning (MAC) was employed in 08pts and the
reduced intensity conditioning (RIC) in 14pts. GVHD prophylaxis consisted of
association of Cyclosporin and Methotrexate according to Seattle protocol. All
pts received G-CSF mobilised peripheral blood stem cells, with a median
CD34+ cell count : 5 ,8.106 /Kg (3,18-19,9). At 31 December 2014, a median
time of follow-up is 41, 5 months (6-135).
Results: Neutropenia occured in all pts and the median duration of aplasia
was 14 (7-23) days. Median time to achieve neutrophils count >0,5.109/l :
13,5days (11-23) and platelets >20.10ç/l : 13 days (9-35). Twenty pts (90%)
required red blood cells transfusions (9, 9 units/pt) and 20 pts (90%) needed
platelet transfusions (6 units/pt). Acute GVHD was observed in 05 cases
(22,7%) grade II-IV and chronic GVHD in 07 pts (31,8%) of whom 5 with an
extensive form.One pt (4,5%) relapsed at 4 months. 12 pts (54,5%) are still
alive in complete remission, 10 pts (45,5%) died (4 : early severe infection, 1 :
VOD, 1 : MAT, 3 : acute GVHD, 1 after relapse). The overall survival (OS) and
the Disease free survival (DFS) are respectively 52, 4% in all pts. The OS and
DFS for RIC group are 53, 9%.
Summary and Conclusions: This study, after a long follow-up, suggests that
allogeneic HSCT is the treatment of choice for pts with advanced stage MDS
and pts with dependent transfusion. Relapse seems low (4,5%) in our study
and no difference in term of OS between MAC and RIC group. The advantage
of RIC is the possibility of HSCT for pts up to 60 years of age and older.
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HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTA-
TION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR HIGH
RISK PEDIATRIC LEUKEMIA. EXCELLENT ENGRAFTMENT AND
ENCOURAGING LEUKEMIA FREE SURVIVAL
A. Karduss-Urueta1, G. Suarez1,* R. Perez1, J. Betancurt2, M. Ramirez2,
J.A. Jimenez1, L.R. Gomez1, P. Reyes1, M. Gonzalez1, A. Cardona3,
C.L. Hurtado4, H. Deossa4, C. Fernandez4
1Bone Marrow Transplantation, Instituto de Cancerologia-Clinica las Americas,
2Critical Care Unit, Clinica Las Americas, 3Research Unit, Instituto de Can-
cerologia, 4Bone Marrow Transplantation, Clinica Las Americas, Medellin,
Colombia
Background: T cell replete haploidentical stem cell transplantation with post-
transplantation cyclophosphamide (PTCy) has shown encouraging results for
the treatment of hematologic malignancies; its main advantage is that almost
every patient will have a donor. But this technique has been explored mainly in
adults and using bone marrow as a cellular source
Aims: To present our experience using T cell replete haploidentical peripheral
blood stem cell transplantation (TCR-Haplo-PBSCT) with PTCy for high risk
pediatric acute leukemia
Methods: Donors were mobilized with filgrastim 5 ucg/kg/BID for five days,
the PBSC were collected with one large volume apheresis procedure. The con-
ditioning consisted of fludarabine 150 mgs/m2, busulfan 4-8 mgs/kg and Total
Body Irradiation 400 cGy (Flu Bu TBI) or fludarabine 150 mgs/m2, melfalan
100-140 mgs/m2 and TBI 200 cGy(Flu Mel TBI); on days +3 and +4 PTCy 50
mgs/kg/day was given followed by cyclosporin and mycophenolate starting day
+ 5. All patients received post transplant filgrastim beginning on d + 6.
Results:After a signed informed consent, 18 patients, were transplanted; medi-
an age was 11.5 years (range 6-16), 8 were girls, the diagnosis were: acute
lymphoblastic leukemia 8 patients, acute myeloid leukemia 9 and blastic phase
of chronic myeloid leukemia one. 22% were in CR1, 39% in CR2 and 39% in
CR3 or with refractory disease. Flu Bu TBI conditioning was given in 14 cases
while Flu Mel TBI in 4. A median of 10 million/kg of CD34+ cells were infused.
The engraftment rate was 100%, median time to achieve 500 neutrophil or
more was 15 days (range 14-20), 1 patient out of 18 died without platelet recov-
ery, the remaining had a self- sustained platelet count of 20.000 or more at a
median of 14 days (range 10-21). Chimerism at day + 100 was available in 14
cases, all of them had full donor hematopoiesis. The cumulative incidence of
aGVHD II-III and extensive cGVHD was 37.5% and 27% respectively. The
median follow-up is 13.5 months (range 1-24), 4 patients have died, the causes
were; pneumonia (n:1) and relapse of leukemia(n:3), other 2 have relapsed
but are alive receiving low intensity chemotherapy. The cumulative incidence
of transplantation related mortality is 5.6% and the 2 years actuarial overall
survival and event free survival are 79.8% and 58.7% respectively
Summary and Conclusions: The use of TCR-Haplo-PBSCT with PTCy for
treating pediatric acute leukemia is promising; it is associated with low trans-
plantation related mortality, very good engraftment rate, acceptable incidence
of GVHD, despite the use of peripheral blood, and encouraging leukemia free
survival. It deserve more studies
PB2034
HIGHER DOSE CD34+ CELLS AFFECT ABSOLUTE IMMATURE PLATELET
COUNT BEFORE ENGRAFTMENT AND PLATELET COUNT AFTER
ENGRAFTMENT IN CORD BLOOD TRANSPLANTATION: A SINGLE-INSTI-
TUTIONAL STUDY
K.I. Iwama1,*
1Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan
Background: Platelet recover is important to successful allogeneic stem cell
transplantation and platelet is the last to be regenerated in bone marrow after
stem cell transplantation. Especially, platelet increase is far slower in cord blood
transplant(CBT). Recent retrospective studies suggested CD34+ cell and total
nucleated cell affect blood cell recover. However, the impact of CD34+ cells
dose on each blood cell lineages is not be sufficiently investigated. In addition,
these studies mainly focus on engraftment. 
Aims: Therefore, we analyzed cases in our database to evaluate the impact of
CD34+ cell and total nucleated cell on each blood cell lineages in consecutive
patients who were treated with CBT and achieved platelet engraftment over
the past 6 years at our institution in Tokyo, Japan.
Methods: We included 95 consecutive patients treated at our institution
between April 2008 and May 2014. The study population consisted of 58 male
and 37 female patients with a median age of 53 years old (range: 16-69). Patient
in this cohort underwent CBT as a part of therapy for myeloid
malignancies(N=52) and lymphoid malignancies (N=43). 38 patients were treat-
ed with Flu+Cy+TBI(2gy), and 29 patients were treated with Flu+Bu+TBI(2Gy),
and 29 patients were treated with AraC+CY+TBI(12gy). All patients received
calcineurin inhibitor plus MMF for GVHD prophylaxis. Due to the influence of
blood transfusion on blood cell counts and overall estimation of each blood cell
movement, each blood cell lineages, and absolute Immature platelet
count(ABPC) were assessed by the 5-day moving average,and then we
checked movement of the 5-day moving average between patients receiving
higher doses of CD34+ cells and patients receiving lower. The 5-day moving
average was calculated from the time of day4 after transplantation until day
100 or death from any cause or the date on which the patient was received
next chemotherapy. 
Results: Among 95 patient, 69 patieunt achieved platelet engraftment. The
median CD34+ cells doses and total nucleated cells doses were 0.8*10^5/kg
and 2.0*10^7/kg. Among patients’ age, total cell count and CD34 cell count in
donor cord blood and disease status and conditioning regimen, disease status
and myeloablative regimen impacted on pletelet engraftment on multivariate
analysis. But, as shown figure 1, the curve of ABPC in patients receiving higher
doses of CD34+ cells is highter than the other from day +30 to day +50, and
the curve of platlet counts in platelet patients receiving higher doses of CD34+
cells were raising after day +40. In patient who attained platelet engraftment,
only age and CD34 cells affect over all survival rate.
Figure 1.
Summary and Conclusions: The results of the present study highlighted the
importance of CD34 cells on platelet recover and CD 34+ cell can be prognostic






COMPARATIVE ANALYSIS OF FILGRASTIM, BIOSIMILAR FILGRASTIM
AND LENOGRASTIM AS PERIPHERAL BLOOD CD34+ MOBILIZATION
DRUG FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
B. Soria1,* P. Ubierna2, J. Rodríguez-López1, A. Iglesias1, J. Mesa1,
I. González-Perera3, G. González-de-la-Fuente3, M.T. Hernández-García1,
J.M. Raya1
1Hematology and Hemotherapy, Hospital Universitario de Canarias, 2Hema-
tology and Hemotherapy, Medicina-Universidad de La Laguna, 3Pharmacy,
Hospital Universitario de Canarias, La Laguna, Spain
Background: There are different strategies to mobilize peripheral blood CD34+
cells in oncohematologic patients that will receive an autologous stem cell trans-
plantation (ASCT). As mobilizers drugs (G-CSF), in addition to the original fil-
grastim (Neupogen®) and lenograstim (Granocyte®), since 2012 we have a
biosimilar filgrastim (Nivestim®). 
Aims: Our objective was to compare the effectiveness and cost of these drugs
in our hospital during the past six years.
Methods: We retrospectively analyzed patients undergoing peripheral blood
CD34+ apheresis between January 2009 and December 2014. The collected
data included: age, sex, disease (acute leukemia, plasma cell neoplasm, NHL,
Hodgkin lymphoma and solid tumor), number of lines of prior chemotherapy,
prior use of purine analogs or alkylating agents or radiotherapy, type of mobi-
lization (G-CSF alone, associated with cyclophosphamide or mega-CHOP, or
associated with disease-specific chemotherapy) days of administration and
daily dose of G-CSF. As for the apheresis procedure: leukocytes, hematocrit,
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platelets, percentage of mononucleated cells, percentage of CD34+ cells and
CD34+ cells/µL in blood just before apheresis; total number of volemias and
processed volume, total number of apheresis per mobilization, process time
and obtained CD34+ cells (x106/Kg, target >2), and cost per total mobilization
procedure. If ASCT was done, we also collected infused CD34+ cells, day to
achieve a neutrophil count >500/µL and platelets >20,000/µL. For statistical
analysis, SPSS was used.
Results: We studied 201 patients, mean age 50 years (range 2-71) and 64%
males, and we used filgrastim in 85 cases, biosimilar 66 and lenograstim 50.
There were no significant differences among the three groups for any of the
analyzed variables, except for the total number of apheresis per mobilization
(the lowest with biosimilar, 1.7, and the highest with filgrastim, 2.1; P=0.009),
the number of lines of prior chemotherapy (biosimilar 1.4, lenograstim 1.5 and
filgrastim 1.9; P=0.006) and the cost in euros per total mobilization procedure
(biosimilar 200, lenograstim 531, and filgrastim 602; P<0.001). Average CD34+
cells in the final product was 6.7x 106/Kg (range 0.2 to 40.2) for mobilization
and similar with all three drugs (P=0.38). In 25 cases (12%), CD34+<2x 106/Kg
were obtained. ASCT was performed in 103 patients (51%) and no differences
in infused CD34+ cells, days to achieve neutrophils >500/µL or platelets
>20,000/µL (for the two last, average 11 and 17, respectively), were observed.
Summary and Conclusions: In our experience we found no differences
between the three analyzed drugs in terms of number of CD34+ cells obtained
at the final product of apheresis, or hematopoietic recovery after ASCT. How-
ever, for the biosimilar drug fewer apheresis for mobilization procedure were
needed, and a significantly lower overall cost was observed. 
PB2038
FROM HLA TYPING TO ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION: BARRIERS AND OUTCOME
L. El Halabi1,* R. shamieh1, C. soussain1, S. glaisner1, S. malak1
1hematology, Rene Huguenin/Institut Curie, saint cloud, France
Background: Despite the advent of newer targeted and immune therapies,
allogeneic hematopoietic cell transplantation (HCT) still offers an advantage in
terms of disease free survival, overall survival and quality of life in appropriate
settings.
Aims: Several studies have elucidated the heterogeneity in HCT practice
among individual physicians, transplant centers and different countries. In our
institution, we conducted a retrospective analysis describing and evaluating
the outcome of patients for whom an allogeneic HCT was discussed or planned.
Methods: From 2007 till the end of 2014, an HLA typing was done for 156
patients treated for different hematological malignancies at Centre Rene
Huguenin/ Institut Curie, France. We reviewed the files of these patients for
the type of malignancy, the reason why HLA typing was done, the major barriers
to allogeneic HCT and the different outcomes.
Figure 1.
Results: Among the 156 patients, 27.5% had acute myeloid leukemia, 5.8%
acute lymphoblastic leukemia, 0.6% biphenotypic leukemia, 1.9% plasmacytic
leukemia, 15.4% multiple myeloma, 7.1% hodgkin lymphoma, 16.1% non
hodgkin lymphoma, 7.7% chronic lymphocytic leukemia, 12.8% myelodysplas-
tic syndrome, 5.1% myeloproliferative neoplasms. Of these, 14.1% were typed
before complete risk stratification of the disease, 37.2% for the presence of
high risk factors (e.g karyotype, molecular markers, ...), 17.3% because their
disease was refractory to primary treatment or had an early relapse, 30.8% for
late and multiple relapses, and 0.6% upon patient’s request. Fifty nine patients
or 37.8% underwent allogeneic hematopoietic cell transplantation and 7.1%
are currently being evaluated by the committee. The median age of the patients
undergoing allogeneic HCT was 53 years (19-67years) and those for whom an
HLA typing was done was 57 years (19-72years). Median time from HLA typing
to HCT was 7 months ranging from 1 to 14 months. For the remaining patients,
in 31.4% of the cases, allogeneic HCT was finally not indicated due to favorable
prognosis, 25.6% didn’t have a matched donor, 15.1% were ineligible because
of refractory/resistant disease and 15.1% were also ineligible because of high
risk comorbidities. In 10.5% of cases, the patients refused to undergo HCT
and 2.3% were lost to follow up. In terms of outcome, the patients with no indi-
cation to HCT due to a favorable prognosis had a significantly better survival
than all others. Patients ineligible to HCT with a refractory/resistant disease
had the poorer outcome. The group of patients undergoing allogeneic HCT
had a lower relapse rates (10.1%) compared to those who didn’t have a
matched donor or who refused transplantation (22.5%) but there was no sig-
nificant difference in survival between these groups possibly due to a transplant
related mortality of 20.4%.
Summary and Conclusions: In patients for whom HCT was discussed in our
institution, a favorable prognosis was the main cause for not undergoing HCT.
The major barriers were lack of matched donors, patient’s refusal and significant
comorbidities. Our results show that current risk stratification of the hemato-
logical malignancies correlates well with the patients outcome. Clear criteria
for allogeneic HCT are still lacking especially with the advent of new targeted
therapies and the persistence of a significant transplant related mortality and
morbidity.
PB2039
HYPERBARIC CHAMBERS APPLICABLE IN THE TREATMENT OF HEM-
ORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELLS FROM UNRE-
LATED DONORS.
D. Urbaniak-Kujda1, J. Dybko1, K. Kapelko1,* M. Biernat1,2, M. Laszkowska1,
T. Wróbel1, K. Kuliczkowski1
1Department and Clinic of Haematology, Blood Neoplams and Bone Marrow
Transplantation, 2Department of Microbiology, Wroclaw Medical University,
Wroclaw, Poland
Background: Hemorrhagic cystitis (HC) is a diffuse inflammation of the bladder
of an infectious or non-infectious etiology, causing bleeding of the bladder
mucosa. Medications: (busulfan, endoxan, idarubicin, carboplatin), radiation,
viruses, chemicals may be the cause of HC. HC occurs after approximately 35
days after stem cell/bone marrow transplantation and continues for approxi-
mately 23 days. Symptoms of cystitis may be caused by defect in the inflam-
matory response and increase the permeability of glycosaminoglycan layer,
which covers the bladder mucosa, form a physiological barrier. There are no
explicit guidelines defining appropriate treatment. Hyperbaric therapy (HBO)
has been recognized clinically in the treatment of HC in the past 15 years. It is
a non-invasive method involving the operation of 100% oxygen under increased
pressure, which penetrates poorly perfused areas, patient exposure to 100%
oxygen-saturated tissue oxygen efficiently.
Aims: We reviewed the records of 5 patients with HC who received hyperbaric
oxygen as an adjunctive treatment.
Methods: We retrospectively analyzed the effectiveness of HOT in 5 patients
in the years from 2012 to 2014. Among patients there were 3 men, aged from
31 to 41 years and 2 women aged from 40 to 43 years. Patients characteristics
is shown in Table 1.
Table 1.
Abbreviations: C= cyclosporine, Tym= tymoglobuline, Gluc=glucocorticoids,
MUD=matched unlrelated donor, MTX=methotrexate
Table 2.
Results: Clinical presentations of 5 patients with haemorrhagic cystitis. The
median time to onset of HC after allogeneic stem cell transplantation was 22
days (range, 11-55 days). In one patient, the symptoms did not appear until
the day 55 after transplantation. Despite immunosuppressive therapy, all
patients had macroscopic hematuria and GvHD. The BKV and ADV DNA were
detected in urine and plasma samples in 2 patients, ADV DNA was detected
in urine and plasma in 2 other patients, and in the one patient, BKV was detect-
ed in both samples, respectively. The patients were treated with HOT (2.5
atmospheres for 60 minutes, 5 days per week) after treatment failure of bladder
drainage flow, hyaluronic acid administered intravesically, as well as antiviral
treatment. All patients showed complete resolution of hematuria and eradicaton
of the virus after a median of 13 sessions (range, 11-30) of HOT. 
Summary and Conclusions: Hyperbaric oxygen therapy may be an alterna-
tive and promising therapy in the treatment of severe hemorrhagic cystitis.
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THE IMPACT OF INDUCTION THERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION IN MULTIPLE MYELOMA ON TREATMENT OUT-
COMES: A SINGLE CENTER EXPERIENCE
V.P. Pop1,* O.A. Rukavitsin1, S.V. Shamansky2
1Federal State Budgetary Institution Main Military Clinical Hospital named after
ac. N.N. Burdenko of the Ministry of Defense of the Russian Federation, 2Fed-
eral State Budgetary Scientific Institution Russian Cancer Research Center
named after N.N. Blokhin Russian Academy of Medical Sciences, Moscow,
Russian Federation
Background: Treatment of symptomatic multiple myeloma (MM) in patients
(pts) eligible for ASCT is a main approach, which can lead to a complete erad-
ication of the tumor, improving or deepening of response, as well as increased
survival rates.
Aims: The primary aim was to assess whether induction therapy and ASCT
was associated with improved results on anti-tumor response and overall sur-
vival (OS). We also evaluated the impact of renal impairment and advanced
stage of MM on OS in pts that underwent of ASCT.
Methods: The study included a cohort of pts with MM who underwent of ASCT
for the period from 2001 to 2014. Induction therapy prior to ASCT included
VAD-regimen and bortezomib-containing regimens with subsequent high-dose
cyclophosphamide therapy. OS and progression free survival (PFS) estimated
by the Kaplan-Meier method.
Results: The analyzed group consisted of 71pts with primary diagnosed MM
(48 males/23 females; mean age 53.1 yrs (range 34-69). IgG MM was diag-
nosed in 39pts (55%), IgA MM in 13 (18%), Bence Jones myeloma in 16 (23%),
primary plasma cell leukemia in 3pts (4%). In accordance with clinical stage,
(Durie B.G.M. and Salmon S.E.) pts were distributed as follows: IA-2 (2.8%),
IIA-23 (32.4%), IIB-2 (2.8%), IIIA-21 (29.6%), IIIB-22 (31%). Induction therapy
was VAD in 28pts (39.4%), bortezomib (VDD, VD) in 40 pts (56.4%), and VAD-
like and VD in 3 pts (4.2%). The median of follow-up was 26.7m (3.1-126.2m).
The cohort studied performed 83 ASCT. 12pts received 2 ASCT including
planned tandem ASCT (n=6) and 2nd ASCT due to progression (n=6). Before
the 1st ASCT complete response (CR) was observed in 21pts (29.6%) including
8 stringent CR, which was preserved when restaging after 3m. We identified
improving the quality of response from a very good partial response (VGPR)
and partial response (PR) to CR in 16 (37.2%) of 43pts after ASCT. 5pts with
stable disease (SD) reached VGPR and PR. Of the 2pts transplanted in early
biochemical relapse, 1 was reached CR, and the 2nd developed clinical relapse.
Before the 2nd planned tandem ASCT performed with an interval of 3m (2-
5m), in 3 of 6pts were reported CR, which hasn’t changed during 3m. Of the
remaining 3pts the achieved VGPR and CR preserved in 2pts. VGPR and PR
was noted before the 2nd ASCT after relapse/progression in 5pts; 3m later 1
patient achieved CR, and 4pts showed no change. A patient with signs of dis-
ease progression after the 2nd ASCT achieved SD. The impact of induction
therapy (with or without bortezomib) did not affect the results of survival
(P=0.57). Renal impairment and advanced stage of MM as a poor prognostic
factors also had no effect on the survival rate after ASCT (P=0.1). PFS and OS
after ASCT (n=71) was 19.6m and 45.2m, respectively. OS from the diagnosis
of MM was 58.5m. OS after 1st-line therapy (n=62) was 69m compared to 29m
after 2nd-line (n=9), P=0.02. Median PFS after the 1st and 2nd line therapy did
not differ (P=0.14). OS was significantly greater in the group of pts with CR
after induction therapy (n=21) than with PR (n=43): 94 m vs 43 m, P=0.04.
PFS for pts with CR before transplantation also exceeded PFS in pts with PR
(34m vs 16m, P=0.05).
Summary and Conclusions: The depth (degree) of response to induction
therapy was positively associated with survival rates. ASCT followed by high-
dose chemotherapy demonstrated improving responses in a substantial pro-
portion of patients not only after the first ASCT but also after the second ASCT
(tandem or due to relapse of MM), which confirms the important role of ASCT.
No survival benefit was seen for patients treated with ASCT in different regimens
of induction chemotherapy and if they have renal impairment.
PB2041
THE INFLUENCE OF HAPLOTYPE HLA-BW4 IN EVOLUTION AFTER HSCT
D. Bratu1,* I. Constantinescu2, A. Moise2
1Haematology, 2Immunogenetics, Clinical Institute Fundeni, Bucharest, Romania
Background: Continuing to study haplotypes of patients like ligands for inhibito-
ries and activatories donors KIR allele in HSCT,it is an evidence that haplotypes
can be protective or not against postHSCT complication,like ligand or not.
Aims: Haplotype HLA-BW4 is described in literature like,,bad,, haplotype.We
try to demonstrate the influence of this haplotype at patients with acute leukemia
after HSCT.
Methods: Eighteen pairs patients-donors are evaluated :patients with acute
leukemia,lymphoblastic and non-lymphoblastic and their genoidentics
donors.Eleven patients have HLA-BW4 haplotype,seven HLA-BW6(absence
of HLA-BW4) Following the impact of inhibitory KIR3DL1 and activatory
KIR3DS1 on survival and complication development,we proved the protective
effect of absence of HLA-BW4 haplotype,HLA-BW6,respectively.The source of
HSCT was PBSC.The method used was PCR-SSP (Innotrain DIAGNOSTIK
GMBH,Dynal BIOTECH PEL-FREEZE )The complications like graft versus host
disease acute and chronic,relapse,TMA and the recovery with leucocytes and
thrombocytes are followed
Results: Absence of HLA-BW4 haplotype(HLA-BW6,respectively) is protective
for both types of leukemia,the patients survival is 100% in presence of
KIR3DS1(activatory allele) and with statistical significance (sig<0,05) and 83%
in presence of KIR3DL1(inhibitory allele) Is protective against relapse, TMA,
aGVHD, leucocytes and thromboytes recovery,with statistical significance in
presence of KIR3DS4,and also in presence of KIR3DL1 is protective against
aGVHD,TMA and relapse,also thrombocytes recovery,without statistical signif-
icance.
Summary and Conclusions: Absence of HLA-BW4 improve survival and pro-
tect against most complication at patients with acute leukemia and related
donors with 100% allele match,in presence of both types of KIR alleles and
confirme the ”missing ” ligand theory.
PB2042
MATCΗED UNRELATED DONOR HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION OFFERS LONG-TERM SURVIVAL IN ABOUT HALF OF
ADULTS WITH HAEMATOLOGICAL MALIGNANCIES. THE GREEK EXPE-
RIENCE.
D. Karakasis1,* I. Batsis2, F. Panitsas1, V. Pardalis1, Z. Bousiou2, E. Xenou1,
S. Karakatsanis1, M. Linga3, P. Kalogiannidis2, A. Xirokosta1, A. Kaisari1,
D. Mallouri2, E. Triantafyllou3, E. Giannaki2, A. Loidoris1, M. Bouzani1,
C. Smias2, I. Markou1, J. Apostolidis1, S. Gigantes1, A. Spyridonidis3,
I. Sakellari2, I. Baltadakis1, A. Anagnostopoulos2, N. Harhalakis1
1BMT Unit, Evangelismos Hospital, Athens, 2BMT Unit, Papanikolaou Hospital,
Thessaloniki, 3BMT Unit, University Hospital Patras, Patras, Greece
Background: Allogeneic haematopoietic stem cell transplants (HSCT) are
steadily increasing in number due to the enhanced availability of matched unre-
lated donors (MUD) over the last decade. The results of MUD-HSCT have
improved considerably, mainly due to the introduction of high-resolution molec-
ular HLA typing for donor selection. Currently, more than 50% of allogeneic
HSCT are done with MUD worldwide. 
Aims: The aim of this study is to retrospectively analyze the outcomes in a
cohort of adult patients, who underwent MUD-HSCT for hematological malig-
nancies at three major transplant centers in Greece. 
Methods: From 01/2001 until 12/2013, 331 patients (M/F: 197/134) underwent
MUD-HSCT for acute myeloid leukemia (n= 148), acute lymphoblastic leukemia
(n= 74), non-Hodgkin’s lymphoma/chronic lymphocytic leukemia (n=28),
myelodysplastic syndrome (n=26), chronic myeloid leukemia (n=21), Hodgkin’s
lymphoma (n=20), myelofibrosis (n=7), or other haematological malignancies
(n=7). The median age of patients was 40 (range, 14-66) years. Median time
from diagnosis to transplantation was 13 (range, 2-235) months. Disease Relat-
ed Index (DRI) was low, intermediate or high/very high in 11%, 66% or 23% of
cases, respectively. EBMT risk score was ≤3 in 38% and ≥4 in 62% of patients.
The comorbidity-age index was ≤1 in 58.4%, and ≥2 in 41.6% of recipients.
The conditioning regimen was myeloablative in 252 (76%) or reduced intensity
in 79 (24%) of procedures. Peripheral blood was the source of graft in 92% of
cases. Donor/recipient HLA allele match at HLA-A, -B, -C and -DRB1 loci was
8/8, 7/8 or<7/8 in 51%, 47% and 2% of cases, respectively. in vivo T cell deple-
tion with antithymocyte globulin or alemtuzumab was performed in 58% of cas-
es. The combination of tacrolimus and methotrexate was used for GvHD pro-
phylaxis in 234 (71%) patients.
Results: Engraftment was achieved in 97% of patients. The incidence of acute
and chronic GvHD was 42.5% and 55.5%, respectively. The cumulative inci-
dence (CI) of treatment related mortality (TRM) was 26% and 33% at 1 and 3
years post transplant, respectively. CI of relapse was 25%. With a median fol-
low-up of 36.5 months, 3-year event free survival (EFS) and overall survival
(OS) were 44% and 47%, respectively. The major prognostic factors for OS in
multivariate analysis were EBMT score (≥4 vs. ≤3, 37.4% vs. 64.1%, HR: 2.32,
P<0.001), comorbidity-age index (≥2 vs. ≤1, 32.6% vs. 59.7%, HR 1.81,
P<0.001), DRI (high/very high vs. intermediate/low, 26.3% vs. 54.3%, HR:
1.79, P<0.004) and HLA match (≤7/8 vs. 8/8, OS 40% vs. 56.1%, HR: 1.68,
P<0.002).
Summary and Conclusions: MUD-HSCT is an effective therapeutic option
for adults with haematological malignancies, and offers long-term survival in
about half of them. Apart from age and comorbidities, the outcome greatly
depends on HLA match and disease stage at transplant. Therefore, timely refer-
ral of patients for MUD-HSCT early in the course of disease may further improve
the results.
PB2043
COMPARISON OF ORAL BUSULFAN (BU) AND INTRAVENOUS BU THER-
APY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR HEMATOLOGICAL MALIGNANCY IN CHILDREN AT A SINGLE INSTI-
TUTION
K. Isobe1,* K. Koh1, Y. Ikeda1, C. Oyama1, T. Aoki1, Y. Kubota1, M. Mori1,
Y. Arakawa1, R. Hanada1
1Hematology / Oncology, Saitama Children’s Medical Center, Saitama, Japan
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Background: Busulfan (BU) is a frontline agent in the hematopoietic stem cell
transplantation (HSCT); however, severe complications including sinusoid
obstructive syndrome (SOS) have been reported, particularly with oral admin-
istration. Since intravenous BU (i.v. BU) was introduced in 2006, some reports
have demonstrated i.v. BU reduces hepatic complication such as SOS and
treatment related mortality in adults. However, there have been few studies in
pediatric populations comparing i.v. BU and oral BU (p.o. BU).
Aims: The purpose of this study was to determine the efficacy and safety of
i.v. BU in children.
Methods: We retrospectively analyzed 38 cases of hematological malignancy
in which HSCT was performed with myeloablative dose of BU between January
2000 and March 2014.
Results: Twenty-six cases received p.o. BU and 12 cases received i.v. BU. The
median age at HSCT was 5 years (range, 3months-17 years). The median over-
all follow up was 777.5 days (range,7 -4893 days), 1400 days (range, 7-4893
days) in the p.o. BU group, and 459.5 days (range, 33-2360 days) in the i.v. BU
group. Diagnosis of hematological malignancies were as follows: 11 AML, 10
ALL (5 infan) and 5 others in the p.o. BU group, and 10 ALL (4 infant) and 2 oth-
ers in the i.v. BU group. Disease status at HSCT with BU were as follows: 14
cases (36.8%) were CR1 overall, 11 cases (42.3%) in the p.o. BU group, and 3
cases (25%) in the i.v. BU group (P=0.32). Overall survival (OS) at 1 year was
52.5% overall, 56% in the p.o. BU group, and 50% in the i.v. BU group (P=0.83).
Event free survival (EFS) was 35% overall, 42.8% in the p.o. BU group, and
33.3% in the i.v. BU group (P=0.35). Relapse rates at 1 year were 27.5% overall,
21.4% in the p.o. BU group, and 41.7% in the i.v. BU group. Non relapse mortality
at 1 year was 26.3% over all, 26.9% in the p.o. BU group, and 25.0% in the i.v.
BU group. SOS occurred in 6 cases (15.8%) overall, 4 (15.4%) in the p.o. BU
group, and 2 (16.7%) in the i.v. BU group (P=0.92). Adverse events above grade
3 included pulmonary complications such as interstitial pneumonia is 3.8% (2/26)
in the p.o. BU group, while 50% (6/12) in the i.v. BU group. We also analyzed
OS and EFS, cumulative incidence of relapse, non-relapse mortality of patiens
with no prior HSCT (n=23) in this cohort. There were no statistically significant
differences in OS, EFS, cumulative incidence of relapse or non-relapse mortality
between p.o. BU (n=16) and i.v. BU (n=7) among patients with no prior HSCT.
Figure 1.
Summary and Conclusions: In summary, our analysis demonstrated no dif-
ference in OS and EFS at 1 year or probability of SOS between myeloablative
i.v. BU and p.o. BU doses for the treatment of hematological malignancies.
Recent reports have demonstrated i.v. BU can improve the outcome following
HSCT in adult. However, retrospective analysis of a large number of pediatric
HSCT cases in Japan found no significant benefit of i.v. BU on the survival prob-
ability (M Kato et al.Biol Blood Marrow Transplant 2013; 19: 1690-1694). Our
study corroborated these result; however, this was a retrospective study with
different patients backgrounds. These are the major limitations of this study. In
terms of adverse events, pulmonary complication was more frequent with i.v.
BU than that with p.o. BU. This result may be due to the proportion of infantile
cases at a high risk of pulmonaly complications with BU included in this study.
Although i.v. BU is considered the gold-standard, i.v. BU does not confer benefit
on survival probability and is still associated with severe complications including
SOS and interstitial pneumonia. It is important that complications arising from
the use of i.v. BU are fully elucidated by long term observational studies and the
accumulation of evidence regarding the outcomes following i.v. BU use.
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THE NUMBER OF ANTI-MYELOMA DRUGS IN PRIOR TREATMENT REG-
IMENS DOES NOT NEGATIVELY AFFECT THE SUCCESS OF AUTOLO-
GOUS CD34+ HEMATOPOIETIC STEM CELL MOBILIZATION
M.I. Pereira1,* M. Santos1, A.L. Pinto1, L. Ruzickova1, A. Roque1, R. Tenreiro1,
D. Mota1, A.S. Batista1, A. Ribeiro1, J.P. Carda1, C. Geraldes1, E. Cortesão1,
A. Espadana1, L. Ribeiro1,
1Clinical Hematology Department, Coimbra University Hospital Centre, Coim-
bra, Portugal
Background: Post-induction Autologous Hematopoietic Stem Cell (HSC)
Transplantation (aHSCT) remains the standard of care for multiple myeloma
pts (MM) who are fit enough to tolerate it. Although treatment guidelines favour
transplantation after induction, recent drug developments have lead to pro-
longed survivals and the ability to salvage patients who were not transplanted
at diagnosis, and who now present at aHSCT Centers, referred from hospitals
with differing practices regarding the timing for autologous HST and the proto-
cols used. While it is known that prior treatment can adversely affect the suc-
cess of HSC collection, consensus is lacking on whether this is only due to the
myelotoxicity of the drugs used, or also to the type of regimen chosen.
Aims: We aim to clarify the influence of the type of prior antimyeloma regimens
on the success of HSC collection in a real world sample of newly-diagnosed
and previously treated patients (pts).
Methods: We analysed 96 MM pts undergoing their first aHCT. HSC collection
success was evaluated by the number of peripheral blood autologous CD34+
cells (“PB CD34”), per kilogram, available for infusion at the first transplant
(“Number of Cells”).
Results: The median overall survival was 104.5 m after a median follow-up of
59.1 m. Overall, 68.8% of pts underwent their first aHSCT after 1st line therapy,
23.9% after 2nd line and the remaining 7.3% after 3rd line or greater. The mean
Number of Cells infused was 3.4±1.9x10^6, 3.3±1.7, and 2.6±0.7, respectively,
P=0.05. The regimens received prior to apheresis ranged from doublets up to
seven-drug associations (VBMCP/VBAD), and included alkylator-, bortezomib,
IMID- and anthracycline-based therapies. Considering pts undergoing aHSCT
after 1st line, 40.9% were treated with doublets, 47.0% with triplets and 12.1%
with associations of ≥4 antimyeloma agents. Pts receiving doublets were trans-
planted with a larger number of PB CD34 cells (4.1±2.6 vs 3.0±1.1x10^6,
P<0.001), compared to pts receiving ≥3 drug-associations. Within the same
cohort, the 57.6% who were treated with alkylator-based regimens were trans-
planted with a lower Number of Cells than pts treated with alkylator-free protocols
(3.0±1.0 vs 4.1±2.6x10^6, P<0.001). In contrast, neither the presence of anthra-
cyclines nor of bortezomib in the 1st line regimen influenced the success of
apheresis; the 21.1% of pts treated with anthracycline-based regimens were
infused with 4.1±1.7x10^6 cells vs 3.3±1.9 (P=NS) in pts without anthracyclines;
the 74.2% of pts treated with bortezomib-based regimens received 3.4±2.0x10^6
cells vs 3.8±1.7 (P=NS) in pts without bortezomib. Only 7.6% of pts received
one of the IMIDs at 1st line in our cohort, limiting our analysis. We found that
0% of doublet-regimens included alkylators, compared to 96.8% of triplets and
100% of ≥4 drugs (P<0.001). Taking this into account, after multivariate analysis
the number of drugs used lost its predictive value, while only the presence of
an alkylator maintained its effect over the success of HSC collection.
Summary and Conclusions: We found that the presence of an alkylator in
the 1st line regimen negatively impacted HSC collection success, as expected
from its myelotoxic effects. Neither the anthracyclines nor proteasome-inhibitors
influenced the success of HSC collection. While there was a significant differ-
ence favouring the use of doublets prior to apheresis, this was due to the higher
likelihood of the inclusion of an alkylator in higher-number drug-associations.
Our results support the option of saving alkylators for advanced-lines of treat-
ment, in pts who have not yet undergone HSC collection.
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HIGH INCIDENCE OF NEUROLOGICAL COMPLICATIONS IN SICKLE CELL
DISEASE UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION: EARLY DIAGNOSIS CAN CHANGE THE PROGNOSIS
R. Helman1,2,* J. Fernandes1, M. Diniz1, F. Kerbauy1, L. Kerbauy1,
E. ChapChap1,M. Brumati1, N. Halley1, A. Azambuja1, J.M. Kutner1, A. Ribeiro1,
N. Hamerschlak1
1Hematology, Hospital Israelita Albert Einstein, 2Hematology, Santa Casa São
Paulo, Sao Paulo, Brazil
Background: Hematopoietic stem cell transplantation (HSCT) was offered pri-
marily as a therapeutic option for severe sickle cell disease in the context of
myeloablative matched sibling donor transplants over the last two decades
and helped to establish the benefits of transplantation for this disorder. In recent
years, the transplant community has set out to explore ways to make stem-cell
transplantation more available to patients with the disease, define indications
and better timing, and offset toxicities with novel approaches to conditioning
and better supportive care. In this context, neurological complication such as
stroke and blood flow alterations in cerebral artery constitute the main indica-
tions of HSCT but neurological complications are the main causes of TRM in
D+100 and is important to find ways to prevent this problem.
Aims: Describe early neurological complications in sickle cell patients under-
going related HSCT on single center and its following after the early diagnosis.
Methods: Seven patient undergone related HSCT for sickle disease from 2011
to 2013. All patients filled inclusion criteria in the study and signed agreement
term. Seven HSCT were developed in the period, being four males. The aver-
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age age was 13 years old (7-24). The HSCT indications were previous stroke,
cerebral flow alteration on Doppler, acute chest syndrome and alloimunization.
All patient were on blood transfusion therapy. The conditioning regimen was
BuCy + ATG and the GVHD prophylaxis was MTX and CSA. Related donors
were chosen with 10/10 HLA match and graft source marrow
Results: The median of the neutrophil engraftment was D+ 25 and the platelets
engraftment was in D+60. Two patient died, one by intestinal and liver GVHD
on D+120, and another with sagittal sinus thrombosis and hemorrhagic stroke
on D+3. Other two patients showed PRES syndrome related to cyclosporine
use. The patients showed generalized seizures with tomographic neurological
alteration. After the imunossupressor change to tacrolimus and the change of
Phenytoin to Lamotrigine, the patient had total resolution of neurological com-
plications without development of neurological sequelae. Patients who used
Lamotrigine since the beginning of the conditioning have not shown neurological
alterations. 
Summary and Conclusions: The PRES Syndrome and Stroke are two of the
main causes of mortality related to the use of calcineurin inhibitors. Patients
with sickle disease have shown endothelial and cerebral microcirculation
changes, which made them highly susceptible to neurological complication. The
control of blood pressure, maintenance of 50.000 platelets level and the use of
Lamotrigine as prophylaxis of seizures seems to decrease the risk of neurological
complications. Prospective studies with lamotrigine as primary prevention of
PRES Syndrome must be performed. Patients with severe neurological alteration
as vessels stenosis more than 90% and Moya-Moya Syndrome must be better
evaluated before the conditioning because of high TRM risk. 
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THE COMPARISON OF LENOGRASTIM AND FILGRASTIM IN ALLOGENE-
İC STEM CELL TRANSPLANTATİON: EFFECTS ON BONE MARROW STEM
CELL PRİMİNG 
A. Fettah1,* N. Özbek1, F. Azik1, B. Tavil1, M. Ozguner2, Z. Avcı1, P. Isik1,
N. Yarali1, D. Uckan1, B. Tunc1
1Pediatric Hematology and Bone Marrow transplantation Unit, 2Stem Cell
Research Laboratory, Department of Pediatric Hematology, Ankara Children’s
Hematology and Oncology Research Hospital, Ankara, Turkey
Background: Hematopoietic stem cell transplantation from HLA-matched sib-
lings improved long-term survival of the children with hematologic malignancies
and bone marrow failure syndromes.Recombinant human granulocyte colony
stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells for allo-
geneic and autologous hematopoieitc stem cell transplantation. 
Aims: In this study, we aimed to compare the efficacy profile of different G-
CSF agents including biosimilar filgrastim (Leucostim®) and lenograstim (Gra-
nocyte®) on bone marrow stem cell mobilization in healthy donors 
Methods: A total of 29 healthy donors were enrolled in the study and analysed
retrospectively. Fifteen donors received biosimilar filgrastim and fourteen donors
received lenograstim. The dose and duration of G-CSF treatment was 10
ϻcgr/kg/dose for 3 days and similar between two groups. Post-G-CSF white
blood cells, harvested stem cell volume, number of total nucleated cells (TNC)
and CD34+ cells, CFU-GM colony number has been compared between
biosimilar filgrastim and lenograstim groups.
Results: There were 16 (55.2%) male and 13 (44.8%) female donors. The
median age and body weight of donors was 12.5±10.2 years and 37.1±19.3 kg
respectively. The median number of post G-CSF white blood cells (x103/ϻL)
[32.6 (28-41.2) vs. 37.3 (25.7-40), P=0.663], harvested total stem cell volume
(cc) [437 (385-850) vs. 643 (324-1018), P=0.694], number of total nucleated
cells(x108/recipient kg) [6.4 (5.1-8.7) vs. 7.1 (5.1-8.6), P=0.861], CD34+ cells
(ϻL) in the harvested stem cell [183 (104-272) vs. 160 (93-259), P=0.801],
number of CD34+ cells (x106/recipient kg) [3.1 (2.1-5.2) vs. 2.6 (2.3-5.5),
P=0.930], CFU-GM colony number (x104/recipient kg) [13.2 (8-15.4) vs. 14.1
(9.8-25.6), P=0.538] were similar between filgrastim and lenograstim groups. 
Summary and Conclusions: In conclusion, the current retrospective study
shows that biosimilar filgrastim and lenograstim are similar in terms of efficacy
for the mobilization of bone marrow hematopoietic stem cells in healthy donors. 
PB2047
FACTORS RELATED TO THE FINAL NUMBER OF CD34+ CELLS
OBTAINED BY APHERESIS FOR AUTOLOGOUS STEM CELL TRANS-
PLANTATION: EXPERIENCE IN 181 CONSECUTIVE PROCEDURES IN A
SINGLE CENTER
B. Soria1,* A. Martín-Martín1, J. Rodríguez-López1, C. De Bonis1, A. Iglesias1,
J. Mesa1, M. Tapia2, M.T. Hernández-García1, J.M. Raya1
1Hematology and Hemotherapy, Hospital Universitario de Canarias, La Laguna,
2Hematology and Hemotherapy, Hospital General de La Palma, Santa Cruz
de La Palma, Spain
Background: The successful mobilization of hematopoietic progenitors
(CD34+) for autologous stem cell transplantation has been associated with the
number of cycles of previous chemotherapy (CT), recent administration of CT
(<3 months), prior use of purine analogs or alkylating agents, radiotherapy,
age, marrow involvement by the disease, and leukopenia or thrombocytopenia
before mobilization. 
Aims: Our objective was to analyze our experience on CD34+ cell collection
by apheresis in the past 5 years, focusing in what factors are implicated in a
better or worse final product.
Methods: We retrospectively analyzed all consecutive mobilization procedures
performed in our department between 2009 and 2014. Analyzed data included:
age, sex, underlying desease (acute leukemia, plasma cell neoplasm, small
cell NHL, aggressive NHL, Hodgkin’s lymphoma or solid neoplasm), type of
used G-CSF (filgrastim, biosimilar filgrastim or lenograstim), type of mobilization
(G-CSF alone, associated with cyclophosphamide or mega-CHOP CT, or dis-
ease-specific CT), number of previous CT lines, prior radiotherapy or purine
analogs or alkylating agents, marrow involvement at diagnosis, percentage of
CD34+ cells and CD34+ cells/μL in blood just before apheresis, and CD34+
cellsx 106/kg at the final product. For statistical analysis (SPSS adapted to Win-
dows) we used the Pearson correlation coefficient, ANOVA and Tukey HSD
test for multiple comparisons.
Results: We studied 181 patients, mean age 51 years (range 3-71) and 64%
males. We found that the type of G-CSF, the number of previous lines, the use
of purine analogs or alkylating drugs, and marrow involvement at diagnosis did
not influence significantly in the final number of CD34+ cells obtained. In the
other hand, we observed a tendency to a poorer final product in older patients
(P=0.09) or when there was a history of radiotherapy (P=0.062). Significantly,
the richest final product was achieved in patients with Hodgkin’s disease com-
pared with poorer in those affected of acute leukemia, plasma cell neoplasm
or small cell NHL (P=0.012). Similarly, a higher number of CD34+ cells were
collected in patients mobilized with disease-specific CT, compared with the
other types of mobilizations (P=0.006). Finally, as expected, the pre-apheresis
mononuclear cells and CD34+ cell percentages, and circulating CD34+ cells/μL,
were directly related to the achieved final product (P=0.004, P<0.001 and
P<0.001, respectively).
Summary and Conclusions: In our experience, the factors that most influ-
enced the amount of CD34+ cells harvested by mobilization and apheresis,
are the type of hematologic disease (from most to least favorable: Hodgkin’s
disease, solid tumors, aggressive NHL, small cell NHL, plasma cell neoplasms
and acute leukemia) and type of mobilization scheme used (the best product
was obtained with disease-specific CT, and worst with G-CSF alone). To a less-
er extent, the patient’s age and history of radiotherapy may also influence the
final product.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING
FLUDARABINE, MELPHALAN, TOTAL BODY IRRADIATION AS REDUCED-
INTENSITY CONDITIONING REGIMEN FOR MYELOID MALIGNANCIES IN
A SINGLE INSTITUTION.
T. Nemoto Anan1,* R. Watanabe1, T. Tomikawa1, M. Sagawa1, T. Tabayashi1,
Y. Kimura1, Y. Takahashi1, M. Tokuhira1, M. Kizaki1
1Department of Hematology, Saitama Medical Center, Saitama Medical Uni-
versity, Kawagoe, Japan
Background: Traditional transplant conditioning regimens have a limiting factor
regarding co-morbidities or old age. Therefore, reduced intensity conditionig
(RIC) regimens have been increasingly used since RIC regimens have lower
rates of severe toxicity. Although RIC regimen for allogeneic hematopoietic
transplants (allo-SCT) have become common usuful strategy for high risk
myeloid malignancy, optimal conditioning regimen has not been established. 
Aims: To define the role of RIC and MAC condition for patients with myeloid
malignancy.
Methods: We retrospectively compared long-term outcomes of 38 consecutive
transplants for adult patients with high-risk myeloid malignancy. Fifteen out of
38 patients who were older age (55 year-old) or unfit received RIC regimen
consisting of fludarabine (125mg/m2), melphalan (80mg/m2) and total body
irradiation (TBI) (4Gy). Twenty-three patients received MAC regimens contain-
ing TBI (12Gy). All transplants received uniform strategy of graft versus host
disease (GVHD) prophylaxis. 
Results: All patients achieved engraftment in RIC comparing with 2 patients
were engraftment failure in MAC. High level of treatment related toxicities was
observed in patients with MAC rather than RIC. Compared with MAC, relapse
rate was higher in RIC. Overall 2-year survival rate and relapse free survival
were 42.3%, 36.7% in RIC and 43.5%, 39.1% in MAC respectively. Grade III to
IV of acute GVHD were occured 6.6% in RIC and 30.4% in MAC, chronic GVHD
were appeared 46.6% in RIC and 34.7% in MAC. In unitivariate analysis, good
performance status (PS) and disease status CR, In multivariate analysis, dis-
ease status CR was the only prognostic variable for prolonged OS in high risk
myeloid malignancy.
Summary and Conclusions: Our retrospective study, RIC was feasible and
survival benefit was obtained in same level MAC. Lower tumor burden before
transplantation but not conditioning intensity nor patient age intensity influenced
longer survival. Although our study was small size of patient population, larger
prospective randomized study should be required.
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EFFICACY OF COMPLEMENT MODULATING THERAPIES IN ALLOGENE-
IC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC
MICROANGIOPATHY
I. Herraez1,* L. Bento1, A. Sampol1, A. Gutierrez1, A. Novo1, C. Ballester1,
L. Garcia1, J. Besalduch1
1hematology, hospital son espases, palma de mallorca, Spain
Background: Thrombotic microangiopathy (TMA) is a rare but potentially dev-
astating complication of allogeneic stem cell transplantation (allo-SCT). Its
pathophysiology remains poorly understood. Mechanisms associated with TMA
include loss of endothelial cell integrity induced by intensive conditioning reg-
imens, immunosuppressive therapy, irradiation, infections or graft-versus-host-
disease (GVHD). Management and treatment strategies of MAT remain chal-
lenging. Strategies as the discontinuation of calcineurin inhibitors or plasma
exchange have limited efficacy. Eculizumab could be a promising complement
targeting therapy for allo-SCT associated TMA.
Aims: To describe our experience with eculizumab in two cases of TA-TMA.
Methods: Post-allo-SCT TMA was diagnosed according to diagnostic criteria
(International Working Group Definition for TMA (2007)). All patients received
Tacrolimus (T) and Sirolimus (S) as immunosuppressive therapy. ADAMTS13
and serum C3 complement were analysed in all patients.
Results: 2 patients with TA-MAT are described: Case 1: 53 year old woman
diagnosed with refractory Hodgkin Lymphoma who underwent allo-SCT from a
sibling donor. TA-TMA was diagnosed on day +34 post-allo-SCT. This patient
had a severe kidney injury and neurologic disfunction and the blood tests con-
firmed an overdose of inmunosupressives. TMA treatment consisted in S and T
withdrawal and plasma exchange with no response. ADAMTS13 was normal
and serum C3 level was low. Induction therapy with 4 doses of Eculizumab was
initiated with resolution of renal function and improvement of hemolysis param-
eters. Due to the excellent response we did not complete the maintenance treat-
ment. Case 2: 52 year old woman diagnosed with AREB-II who underwent allo-
SCT from a sibling donor. TMA was diagnosed on day +26 post-allo-SCT. This
patient had a severe kidney injury, alveolar hemorrhage and the blood tests
confirmed an overdose of inmunosupressives. ADAMTS13 and C3 were normal.
The TMA treatment consisted in S and T withdrawal and plasma exchange with
no response. Finally, induction therapy with Eculizumab was initiated. The
patient received only 1 dose when normal C3 was confirmed and also because
of the good evolution of renal function and hemolytic parameters.
Summary and Conclusions: Allo-SCT associated TMA is an uncommon but
devastating complication of HCT. The pathogenesis is unclear. Although T and
S have been implicated as risk factors for TA-TMA, there is no solid evidence
supporting the discontinuation or dose reduction of these medications. Recent-
ly, it has been observed that both the classical and alternative complement
pathways may be involved in TA-TMA, supporting the potential use of comple-
ment modulating therapies as Eculizumab in patients at highest risk for the
worse outcomes. It poses certain challenges such as the reported difficulty of
achieving therapeutic levels in critically ill HSCT patients, limited availability in
certain countries and significant cost associated with this therapy. We achieved
good response with the use of Eculizumab in one patient who had serum C3
low levels. Novel TMA biomarkers, reflecting predisposition for injury to specific
organs, need to be identified in order to aid earlier TA-TMA.
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PULMONARY FUNCTION TESTS (PFTS) PRIOR TO AUTOLOGOUS STEM
CELL TRANSPLANT AS PREDICTOR OF PULMONARY COMPLICATIONS
AND SURVIVAL IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES
O. Annibali1,* F. Chiodi1, S. Scarlata2, S. Santangelo2, C. Sarlo1, D. Armiento1,
E. Cerchiara1, S. Ferraro1, M. C. Tirindelli1, R. Antonelli Incalzi2, W. Arcese3,
G. Avvisati1
1Hematology Unit, 2 Geriatric Unit of Respiratory Pathophisiology, University
Campus Bio-Medico Roma, 3Hematology Unit, University Tor Vergata on behalf
of Rome Transplant Network (RTN), Rome, Italy
Background: Autologous Stem Cell Transplantation (ASCT) represents a stan-
dard-of-care for Multiple Myeloma patients eligible to receive high-dose
chemotherapy, Lymphoma patients undergoing second-line treatments and for
a small proportion of Acute Leukemia patients. Although all canditates to an
ASCT are carefully evaluated for their eligibility with a complete screening of
clinical, laboratory, imaging and functional tests to check comorbidities, global
organ function and infections, pulmonary and infective complications are a sig-
nificant cause of morbidity and mortality after ASCT. However, the relationship
between pre-transplant Pulmonary Function Tests (PFTs), development of post-
ASCT complications and mortality is unknown.
Aims: The aim of this study was to evaluate the role of pre ASCT PFTs on
post-ASCT complications and mortality
Methods: We collected data for 88 patients undergoing ASCT between March
2008 and February 2015 in our Institution. Complete PFTs were obtained in 62
patients (74% males; median age 57 yrs, range, 18-69): Multiple Myeloma
n=44, Non-Hodgkin Lymphoma n=18, Hodgkin Lymphoma n=4, Acute Myeloid
Leukemia n=1). ASCT was performed as first line treatment in 42 (67%)
patients, after first relapse in 17 (28%) and as salvage treatment after ≥2
relapse in 3 (5%). Previous regimens including drugs known to induce pul-
monary toxicity, such as bortezomib and bleomycin had been administered to
34/62 (55%) patients
Results: Of the 62 transplanted patients, 9 (13.4%) had abnormal PFTs at
baseline (5 obstructive and 4 restrictive PFTs) and 19 (28.4%) had two or more
major chronic comorbidities (metabolic and cardiovascular disease). Infective
complications occurred in 40/62 (64.5%) and respiratory complications in 9/62
(14.5%) cases. After a median follow-up of 25 months (range, 4-111), 48 out of
62 patients (77,4%) are alive. Post-ASCT respiratory complications were signif-
icantly higher (97% vs 83%; P=0.05) in patients with reduced pre-ASCT FEV1.
Summary and Conclusions: To reduce the risk of respiratory complications
after ASCT, these patients might benefit from the use of a reduced intensity
conditioning.
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COMPLETE RESOLUTION OF EXTENSIVE CHRONIC GRAFT-VERSUS-
HOST DISEASE WITH IBRUTINIB
R. Kamble1,* G. Obi1, A. Schollof1, G. Carrum1
1Hematology Oncology, CAGT Baylor College of Medicine and Houston
Methodist Hospital, Houston, United States
Background: Chronic graft versus host disease (cGvHD) is mediated donor
T cells. The role of B cells in the pathogenesis of cGvHD is increasingly rec-
ognized. Two murine studies have explored the role of ibrutinib in cGVHD-like
syndromes, one in which there is T cell driven sclerodermatous cGvHD and a
second in which there is Ab driven multiorgan system cGvHD that includes
bronchiolitis obliterans. 
Aims: We herein document a complete response of extensive chronic graft-
versus-host disease (cGvHD) to a Bruton’s tyrosine kinase (BTK) inhibitor,
ibrutinib. 
Methods: Following approval from Institute Review Board, patient disease and
transplant related variables were studies in a single patient who received Ibru-
tinib for post- allogeneic transplant relapse of mantle cell lymphoma (MCL). NIH
criteria for cGvHD diagnosis and staging were followed for disease assessment.
Results: A 41 years old female with primary refractory MCL underwent mis-
matched unrelated donor allogeneic hematopoietic stem cell transplantation
in December 2011 (ablative conditioning with CY/TBI and alemtuzumab,
graft=6.6x 106/kg CD-34+ cells, tacrolimus alone for GVHD prevention). Fol-
lowing engraftment on day 11, she developed grade III acute GvHD involving
the skin and gut on day 17 of transplantation that persisted beyond 100 days
post-transplant. Her cGvHD was treated with steroids, but remained active and
extensive. Despite persistent cGvHD and 100% donor chimerism she relapsed
in July 2012. Treatment with radiation, bendamustine and rituximab failed. By
December 2013, the patient had extensive cGvHD manifesting as scleromatous
skin thickening, oral ulcers and sclerosis of the buccal mucosa, ocular dryness
and diarrhea, and was started on ibrutinib1 560 mg once daily for relapsed
MCL. After 8 weeks of therapy, cGvHD had begun to improve. Oral steroids
were reduced and ultimately stopped after 26 weeks of ibrutinib; after 30 weeks
treatment all cGvHD manifestations resolved completely. A complete remission
for MCL was documented at 8 weeks of ibrutinib initiation. Currently she con-
tinues to be on 560 mg daily ibrutinib without cGvHD exacerbation or MCL
relapse for 22 weeks and 52 weeks, respectively. 
Summary and Conclusions: Our report provides the evidence for BTK inhi-
bition led complete cGvHD resolution and supports exploration of its role in
future clinical trials.
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RIC WITH BUSILVEX 4 DAYS OF ONCE-DAILY 100MG/M² WITH FLUDARA-
BINE AND ANTITHYMOCYTE GLOBULINS PRIOR TO ALLOGENEIC STEM
CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK HEMATOLOG-
ICAL MALIGNANCIES.
J. Elcheikh1,* A. wanquet1, R. crocchiolo1, S. furst1, A. granata1, C. faucher1,
R. devillier1, S. harbi1, C. lemarie1, B. calmels1, R. bouabdallah1, N. vey1,
P.J. weiller1, C. chabannon1, L. castagna1, D. blaise1
1Transplantation, Institut Paoli Calmettes, Marseille, France
Background: The optimal intensity of myeloablation delivered as part of a
reduced-intensity/toxicity conditioning (RIC/RTC) regimen to decrease the recur-
rence rate, without increasing non relapse mortality (NRM), remains to be estab-
lished and the disease control remains a major challenge. The introduction of
RTC regimens has allowed allogeneic hematopoietic cell transplantation to be
performed in patients who were previously considered too old or otherwise unfit.
Aims: When busulfan Pharmacokinetic is not available the optimal dose is dif-
ficult to determine. In this perspective we made the hypothesis that decreasing
the daily dose can be safer and efficient in high risk patients.
Methods: We studied the outcome of 27 patients (median age, 50 years; range,
21-65 years) with hematological malignancies were included. The conditioning
regimen based on busulfan at a dose of 100 mg/m2 /day intravenously for 4
days, fludarabine at a dose of 30 mg/m2 /day for 5 days, and antithymocyte
globulins at a dose of 2.5 mg/kg/day for 2 days. Patient, disease and transplant
characteristics are shown in Table 1.
Table 1.
Results: No patients experienced graft rejection. The median HCT comorbidity
index score was 2 (range, 0 to 5). With a median follow-up of 13 months (range,
3-16months), the cumulative incidences of grade 2 to 4 acute graft-versus-host
disease (GVHD) and chronic GVHD (all grades) were 43% (95% CI, 26%>60%)
and 44% (95% CI, 20%>68%), respectively. The Kaplan-Meier estimates of
overall and disease-free survival at 1 year were 63% (95% confidence interval
[95% CI], 42%>84%) and 49% (95% CI, 27%>71%), respectively. At 1 year,
the cumulative incidence of recurrence/disease progression was 32% (95%
CI, 12%>52%). Non relapse mortality (NRM) was 4% and 19% at day 100 and
at 1 year respectively. Patient age, diagnosis, donor type, sex, presence of
comorbidities, and the Hematopoietic cell transplantation-specific comorbidities
index did not appear to have any statistically significant impact on NRM, recur-
rence/disease progression, disease-free survival, or overall survival.
Summary and Conclusions: This well-tolerated conditioning platform can lead
to long-term disease control The RTC regimen used in the current study
appeared to be safe, with a low NRM rate at 1 year noted among high-risk
patients, and efficient disease control, warranting prospective phase 3 trials.
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VENOUS THROMBOEMBOLISM (VTE) IN CHILDREN WITH CANCER AND
HEMATOLOGICAL DISORDERS; 16 YEARS OF EXPERIENCE IN A GREEK
CENTER
M. Ampatzidou1,* H. Pergantou2, H. Platokouki3, H. Papachristodoulou1,
V. Dendrinos1, E. Rigatou1, L. Petrikkos1, V. Papadakis1, S. Polychronopoulou1
1Department of Pediatric Hematology-Oncology, 2Hemophilia Center and
Hemostasis Unit, “Aghia Sophia” Children’s Hospital, 3“Aghia Sophia” Chil-
dren’s Hospital, Hemophilia Center and Hemostasis Unit, Athens, Greece
Background: Guidelines addressing the management of venous thromboem-
bolism (VTE) in pediatric cancer and hematological patients remain heteroge-
neous while the identification of independent risk factors for VTE, represents
a major challenge that may help in refining prevention and treatment strategies. 
Aims: Our aim is to define characteristics, treatment and outcome of pediatric
hematology-oncology pts with proven VTE and illustrate possible risk factors
and genetic predisposition.
Methods: Data from all pts with benign or malignant hematological disorders
and solid tumors consecutively diagnosed and treated at the Department of
Pediatric Hematology-Oncology (N=532,1999-2014) have been retrospectively
recorded and analysed. Pts with superficial thrombosis were excluded from
the study. 
Results: In our cohort, a total of 32 pts (median age 5.7 yrs, range 1.1-18.6)
developed VTE with the following disease background: acute lymphoblastic
leukemia(14), T-lymphoblastic lymphoma(2), RAEB-T/acute myeloid
leukemia(1), nephroblastoma(3), neuroblastoma(3), hemophagocytic lympho-
histiocytocis(1), autoimmune hemolytic anemia(2) and other rare solid
tumors(6). In our cohort, 21 pts had high risk disease features and 6 pts pre-
sented with bulky mediastinum involvement. Median time of VTE occurrence
from disease diagnosis was 129 days (range 0-4244). 25/32 pts developed
DVT during the intensive chemotherapy regimen (16 not in CR). Most com-
monly used drugs within the last 30 days from DVT diagnosis were Asparagi-
nase and steroids, followed by VCR, MTX, CPM and cisplatin. 13/32 pts had
undergone major surgery and no pt received hormone therapy. In 26/32 pts
CVL was placed; median time between CVL placement and VTE occurrence
was 60 days (range 0-1352). VTE diagnosis was symptom-driven (n=16) or
incidental finding (n=16); in 15 pts VTE was CVL-related (4 with infection) and
6 cases presented in tumor adjacent areas. The most common VTE sites were
right atrial and jugular veins (16), subclavian veins and superior vena (2), kidney
and inferior vena cava (6), pulmonary embolism (2), femoral and iliac vein (3),
cerebral sinovenous thrombosis (5) [ischemic cerebral infracts, cavernous sinus
(after XRT), upper sagittal and transverse sinus], with some patients presenting
with multiple VTE sites. Additionally, 2 pts presented with VOD, as well. WBC
or PLTs count at diagnosis did not have a statistically significant impact on the
probability of VTE. Thrombophilia evaluation that was performed in 16/32 pts
did not reveal an increased incidence of predisposing factors [factor G20210A
variant homozygous or heterozygous (1/1), heterozygous MTHFR variant (8),
elevated FVIII (7)]. Treatment consisted mainly of sc LMWHs as anticoagulation
therapy in 28/32 pts. Median time of treatment duration was 6 months (range
3-12) and was guided by the continuing presence of CVL, CR status and until
establishing vascular patency and stable imaging findings. Within a median
follow-up time of 33.8 months (range 2.1-195.1) no VTE recurrence occurred
while overall survival was 78.12% with morbidity not related to VTE.
Summary and Conclusions: In our study, VTE was not very common among
our pediatric haematology-oncology pts and continuation of chemotherapy was
feasible in all cases, with no VTE recurrence. Furthermore, thrombophilia eval-
uation neither revealed an increased incidence of predisposing factors nor
altered our therapeutic decisions; thus, extensive baseline screening or DVT
prophylaxis are not supported in pediatric pts who can be successfully diag-
nosed and treated with current recommendations. 
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ARTERIAL ISCHEMIC DISEASE AND CONGENITAL THROMBOPHILIA
TESTING IN YOUNG PATIENTS: DO OR NOT DO?
M.M. Moreno Vega1,* I. Balda Aguirre1, T. Molero Labarta1
1Hematology, Universitary Hospital of Gran Canaria Dr. Negrín, Las Palmas
de Gran Canaria, Spain
Background: Cardiovascular disease (CVD) includes coronary, renal, cerebral
and peripheral artery atherosclerosis and ischemia. It may be caused by several
cardiovascular risk factors (CVRF), the most are acquired and modifiable like
high blood pressure, smoking, diabetes, obesity or high blood cholesterol, and
others unchangeable factors like age or family history of premature illness.
Many researchs which have investigated association between congenital
thrombophilia (CT) and CVD have obtained positive and negative results. In
spite of the doubtful utility of CT analysis in these cases, it is not infrequent its
request for young patients with CVD.
Aims: Our aim in this research is to assess CT prevalence in young patients
(less or equal than 55 years old) with CVD and comparing to observed in
patients with venous thrombotic disease with same age and that has been
described in general population.
Methods: Sequential and retrospective analytical study of 149 patients (68
men and 81 women) ≤55 years old with arterial isqhemic event in different vas-
cular areas whom were made CT analysis that included: Antithrombin (AT) and
functional chromogenic Protein C (PrC), Functional coagulative Protein S (PrS)
and immunological PrS; resistance to Activated Protein C and molecular analy-
sis of factor V Leiden (FVL) and Prothrombin G20210A (FIIG20210A) by PCR.
Data were taken from database of our Unit.
Results: Mean age at presentation was 42.9 years (18-55). Ischemic location
was cerebral in 122 cases, 16 cardiac and 11 peripheral cases. Twelve patients
(8%) presented postivie CT: six of them were heterozygous FIIG20210A muta-
tion (4.02%), four heterozygous FVL mutation (2.6%) and one case was positive
for type I PrS deficiency (0.67%); a patient presented double thrombophilia
(FIIG20210a and PrS deficiency). Eight of twelve patients with TC (66,6%) pre-
sented some CVRF and the patient with double thrombophilia was taking oral
contraceptives and she was obese, smoker, diabetic and hypertensive. Com-
paratively, CT prevalence in other previous research of ours about 253 young
patients with venous thrombotic disease was 26.8%.
Summary and Conclusions: Congenital thrombophilia prevalence in young
patients with CVD is not higher than in general population. Congenital throm-
bophilia positive result did not trigger any change in therapeutic attitude and it
is the reason why its routing testing in arterial thrombosis cases presents little
or no use.
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EFFICACY OF TREATMENT WITH ASPIRIN IN THE PREVENTION OF
RECURRENT THROMBOTIC EVENTS
A. García Raso1,* M. Carolina2, S. Monsalvo3, R. Mata3, R. Vidal3, E. Askari3,
P. Llamas1
1Hematolgy, Health Care Institute Fundación Jiménez Díaz, 2Hematolgy, Rey
Juan Carlos University Hospital, 3Hematolgy, Fundación Jimenez Diaz Uni-
versity Hospital, Madrid, Spain
Background: The risk of recurrent venous thromboembolism persists for sev-
eral years after the interruption of anticoagulant treatment. The role of aspirin
in the primary prevention of venous thromboembolism has been evaluated by
different groups. In these studies, treatment with low-dose aspirin (100 mg /
day) was associated with a reduced risk from 20-50%. The benefit of antiplatelet
therapy for secondary prevention of VTE was evidenced by the results of WAR-
FASA study.
Aims: To evaluate the efficacy of aspirin for the prevention of recurrent venous
thromboembolism after treatment with vitamin K antagonists in an unselected
group of patients with VTE.
Methods: 105 patients with VTE referred to the Hematology consultation during
last year were included, the mean age of the group was 52.83±18.40 (63.8%
were women, n=67). From each patient cardiovascular risk factors and the
location of thrombosis were collected. Aspirin administration was decided
depending on the presence of cardiovascular risk factors. Aspirin was pre-
scribed in patients with 2 or more risk factors.
Figure 1.
Results: The characteristics of the population and the result of the comparison
of both groups are shown in Table 1. The mean follow-up period after discon-
tinuation of OAT was 35.96±19.49 months, after which 15 cases of recurrent
thrombosis (14.3%) and 31 cases of post-thrombotic syndrome (29.5%) were
diagnosed. Figure 1 shows the distribution of patients according to the location
of the thrombosis. The mean duration of OAT was 12.63±9.79. 87.6% of
patients (n=92) were treated with acenocoumarol and 12.4% were treated with
LMWH (n=13). Finally, 49 patients were treated with low dose aspirin (46,7%).
In this group 20.4% (n=10) patients had recurrent VTE, compared to the
patients not prescribed with aspirine 8,9% (n=5) (P=ns). The number of PTS
diagnosed was similar in both groups (26.8% (n=15) vs 32.7% (n=16);
P=0.6577). VTE Aspirin No aspirin p Age 52,83±18,40 55,45 ±16,06
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50,54±20,10 0,1735 Dyslipemia 32,7 (33) 41,7 (20) 24,5 (13) 0,1049 Smoke
24,8 (26) 18,4 (9) 30,4 (17) 0,2327 Obesity 15,2 (16) 16,3 (8) 14,3 (8) 0,9855
Hypertension 26,7 (28) 30,6(15) 23,2 (13) 0,5261 DM 3,8 (4) 6,1 (3) 1,8 (1)
0,3370 CVD 5,0 (5) 6,1 (3) 3,6 (2) 0,0491.
Summary and Conclusions: The results we obtained are consistent with those
published in the WARFASA study, although we found no statistically significant
difference in the recurrence rate. It would be interesting to extend this study
including a larger population and review the selection criteria to choose patients
who may benefit with aspirin treatment; and also a prospective analysis of the
evolution of the patients treated with low-dose aspirin.
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RESISTANCE TO ACTIVATED PROTEIN C AS PATHOGENIC MECHANISM
UNDERLYING THROMBOSIS ASSOCIATED WITH LUPUS ANTICOAGU-
LANTS
V. Shmeleva1,* O. Matvienko1, V. Kobilanskaya1, S. Kapustin2, Y. Namestnikov1,
L. Papayan1
1Laboratory of Blood Coagulation, 2Laboratory of Biochemistry, Russian
Research Institute of Haematology and Transfusion, St-Petersburg, Russian
Federation
Background: Resistance to activated protein C (APCR) is associated with high
risk of venous thromboembolism (VTE). After the factor V Leiden (FVL) mutation
was found as the main cause of APCR little attention is paid to the role of
acquired APCR. An acquired resistance to activated protein C has been previ-
ously shown in patients with antiphospholipid antibodies. The Calibrated Auto-
mated Thrombography (CAT) is now considered to reflect patients phenotype
better than traditional coagulation tests. When thrombomodulin (TM) is used
thrombin generation (TG) becomes sensitive to all disorders of the PC system.
Aims: Aim of our study was to evaluate the prevalence of acquired APCR and
its reasons in patients with VTE manifestation under the age of 45 years. 
Methods: The study involved 35 patients (M/F 15/20, mean age 37,0±9,0 yr)
with early manifestation of VTE and 30 controls. All patients received vitamin
K antagonists (VKA) treatment at least for 6 months, 18 of them were still on
VKA. TG was measured according to Hemker et al. with fluorogenic assay, at
5 pM TF and 4 μM phospholipids in platelet poor plasma (PPP) with PPP plas-
ma+/-TM reagent (Thrombinoscope BV, Maastricht, The Netherlands). 
Results: Endogenous thrombin potential (ETP) and peak thrombin (PT) were
markedly reduced in the presence of TM. None of the patients had increased
ETP measured as values above 95th percentile in controls (i.e. >2114 nMmin
in the absence of TM and >1433 nMmin in the presence of TM). Lupus antico-
agulants (LA) were found in 5 patients. From parameters derived from the
thrombin generation curves measured both with and without TM significant cor-
relation with LA (P<0,05) was found for lag-time (R=0,45), ETP (R=-0,45) and
PT (R=-0,44) both in presence and absence of TM. Normal ranges of ETP and
PT inhibition calculated in controls were 21-62% and 14-51% respectively. Val-
ues below 21% for ↓ETP and/or 14% for ↓PT (i.e. APRC) were found in 20
(57%) of samples. In the studied group 100% of patients with FVL demonstrated
APCR phenotype. So, in 50% of cases APCR was due to FVL mutation (10
patients, among them 2 patients with acquired protein C deficiency on VKA
treatment). As for the rest 50% of detected APCR cases 25% (5 patients) were
associated with LA, 10% (2 patients) with isolated increased FVIII activity, 10%
(2 patients) with prothrombin G20210A mutation and increased FVIII activity.
The reasons of APCR in the rest 5% of cases need further elucidation. APCR
was found in 100% of LA samples. Importantly all these patients had protein C
activity within the normal range. Abnormal PT inhibition seemed the most sen-
sitive to detect APCR. Abnormal PT inhibition was found in all patients, contrary
to ETP inhibition-50% cases with FVL and 75% with LA.
Summary and Conclusions: In conclusion LA was the most prevalent cause
of acquired APCR in our patients. Beta2 glycoprotein I, anti-prothrombin anti-
bodies and lupus anticoagulants previously demonstrated association with
APCR, determined by classic activated partial thromboplastin time-based tests.
We used a novel integrated approach with calibrated automated thrombography
made in parallel with and without TM. This modification of the thrombin gener-
ation test allows effectively detecting APCR and LA even in patients on vitamin
K antagonists treatment, that is very important for clinical practice. APCR in
patients with lupus anticoagulants is strongly associated with thrombotic com-
plications; it was demonstrated by CAT in all patients with VTE manifestation
under the age of 45 years and LA laboratory phenotype. Acquired APCR could
be the main pathogenic mechanism underlying thrombosis associated with LA.
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RELATIONSHIP BETWEEN ANTIPHOSPHOLIPID SYNDROME CLINICAL
MANIFESTATIONS AND MULTIPLE POSITIVE ANTIPOSPHOLIPID ANTI-
BODIES
R. Siguenza1,* N. Bermejo1, I. Casas1, F. Ibañez1, M.H. Bañas1, J.M. Bergua1,
M.J. Arcos1, J. Prieto1, M.L. Martin Mateos1, C. Cabrera1, F.D.A. Perez Leal1
1Hematología, Hospital San Pedro de Alcantara, Cáceres, Spain
Background: The Antiphospholipid syndrome (APS) is characterized by the
development of thrombosis and/or pregnancy complications in addition to the
persistent presence of antiphospholipid antibodies (APLS): Lupus Anticoagu-
lant, Anticardiolipin antibodies, Anti-beta 2 GP1 antibodies. At this moment, is
not well known that risk factors could be associated to any clinical manifesta-
tions of APS.
Aims: We investigated if there are relationship between the different clinical
manifestations of APS and the presence of cardiovascular risk factors, hered-
itary and acquired thrombophilia or multiple positive APLS.
Methods: Retrospective we investigated the relationship between clinical man-
ifestations and the presence of cardiovascular risk factors, hereditary and
acquired thrombophilia or the existence of multiple positive APLS in 65 patients
consecutive diagnosed of APS in our hospital from 1 February 2000 to 31 Jan-
uary of 2015. The patients ages were between 21 to 88, gender 53.8% male
and 46.2% females. 43 patients present cardiovascular risk factors (26 smokers
24 hypertension, 22 dyslipidemia, 3 Diabetes Mellitus), 21 patients with throm-
bophilia (8 hyperhomocysteinemie, 2 antithrombine deficiency, 3 protein S defi-
ciency, 1 protein C deficiency, 4 FV Leiden mutations and 3 prothrombin
G20210A mutation), 17 patients with triple APLS (TP) and 48 with one/double
APLS (ODP). 37 patients presented venous thrombosis (22 deep vein throm-
bosis, 6 pulmonay embolism, 9 both), 15 patients with arterial thrombosis man-
ifestations (2 arterial thrombosis, 3 myocardial infarction and arterial thrombosis,
10 cerebrovascular accident), 4 with pregnancy complications, and 9 with com-
bined complications (arterial/venous thrombosis/pregnancy complications). The
statistical analysis was performed with Chi2 test realized by JMP 9, being sta-
tistically significant P<0.05.
Results: We found statistically significant difference between the presence of
TP and the development of arterial thrombosis (OR 0.16 y IC 95% 0.03 – 0.76 
P=0.01).
Summary and Conclusions: Our data show an association between TP and
development of arterial thrombosis in APS patients. We did not found associ-
ation between one or multiple positivity on APLS and the other clinical mani-
festations of APS, and the presence or not of cardiovascular risk factor or throm-
bophilia with clinical manifestations of APS.
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THE INFLUENCE OF CYP2C9 AND VKORC1 GENE POLYMORPHISMS ON
THE RESPONSE TO WARFARIN IN EGYPTIANS
A. Bedewy1,* S. Showeta2, M. Hasan2, L. Kandil3
1Hematology, alexandria university, 2Biotechnology, Institute of Graduate Stud-
ies and Research, 3Biochemisty, Pharos university, Alexandria, Egypt
Background: warfarin is the most commonly used drug for chronic prevention
of thromboembolic events and stroke, it also ranks high among drugs that cause
serious adverse events. The narrow therapeutic index coupled with substantial
inter-individual variability in warfarin dose requirement puts patients at increased
risk for hemorrhagic events, and the variability in dose requirements has been
attributed to inter-individual differences in medical, personal, and genetic factor.
Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagu-
lant effect of warfarin by catalyzing the conversion of the pharmacologically
more potent S-enantiomer to its inactive metabolites. Warfarin exerts its anti-
coagulant effect by reducing the regeneration of vitamin K from vitamin K epox-
ide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase.
This protein is encoded by the recently identified vitamin K epoxide reductase
complex subunit 1 gene (VKORC1).
Aims: The current study aimed to investigate the pharmacogenetic effect of
CYP2C9 and VKORC1 gene polymorphisms on the patients response to war-
farin.
Methods: This study was carried out on 100 cases starting warfarin treatment.
Informed consent was obtained from each subject or patient prior to participating
in this work. The mean daily dose of warfarin (mg) was calculated from patient’s
medical records. For each patient,<10% variability in warfarin dose and a target
international normalized ratio (INR) within the therapeutic target range (2–3)
and for patients having valve replacement and recurrent pulmonary embolism
target was (2.5-3.5), were required for at least 3 months for one of the following
indications (Deep vein thrombosis, Pulmonary embolism, cerberovascular
stroke and Myocardial infarction ) prior to inclusion in the study. Molecular
genetic study was performed to determine CYP2C9*2, CYP2C9 *3, and the
VKORC1 1639G >A genetic polymorphisms. The genotypes were determined
with the tetraprimer amplification refractory mutation system (T-ARMS) using
specific outer and inner primers. Plasma warfarin determination was performed
using rapid flouremetric assay.
Results: The median age of the studied cases as shown in table 1 was 49
years (range, 33–68).The males represented 56% of the cases while the
females represented 44%. The body mass index of the patients ranged from
19.81 to 42.44. The plasma warfarin concentration ranged from 2.19-10.98
µg/mL with a median 3.52 µg/mL. The patients were stratified into three different
groups based on their maintenance dose (>2.5 mg is the low dose group, ≤2.5
mg to 7 mg is the standard dose group and >7 is the high dose group). The
INR ranged from 2 to 4 wth a Mean of 2.58±0.62(SD).The incidence of
supratherpeutic INR was presented in 11% of the cases. Thromboembolic com-
plications occurred to 7% of the cases. While 8% of the cases experienced
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major bleeding. The majority of the patients receiving high maintenance dose
(>7 mg/day) had combined non VKORC1*2 and homozygous wild-type
CYP2C9 (CYP2C9*1*1) alleles, representing 52.2% of the high dose group
while the majority of the patients recieving low maintenance dose are carriers
of the Variant (AG + AA)/ Wild (*1/*1) representing 55.6% of the low dose
group.These results were statistically significant with p value<0.001. With
respect to Incidence of supratherapeutic INR, a significantly increased risk
occurred in patients carrying the CYP2C9 variant in the multivariate logistic
regression model. Also with respect to thromboembolic complications and inci-
dence of supratherapeutic INR, higher risk was observed in patients carrying
combined VKORC1 Variant (AG + AA) and CYP2C9 Variant (*2/*3).
Summary and Conclusions: Data from our study suggest that together with
clinical factors, VKORC1 and CYP2C9 polymorphisms are important contrib-
utors to warfarin dosing and may help predict adverse effects in Egyptian
patients.
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ASSOCIATION OF FACTOR V LEIDEN G1691A AND PROTHROMBIN
GENE G20210A MUTATION WITH ADVERSE PREGNANCY OUTCOMES
S. Asad1,* B. Moiz1
1Pathology and Microbiology-Section haematology, Aga Khan University Hos-
pital, Karachi, Pakistan
Background: Familial defects and polymorphisms of clotting cascade proteins
protein S, protein C, factor V Leiden G1691A and factor II G20210A are linked
with increased risk of thromboembolism which is better known as inherited
thrombophilia. Thrombophilia causes deep venous thrombosis, pulmonary
embolism and is strongly associated with poor pregnancy outcomes. Patho-
physiology of these outcomes is thought to involve thrombosis in uteroplacental
blood flow hence, anticoagulation therapy can potentially improve obstetric
outcome in females with thrombophilias. To date, there is limited data from this
region on the role of these genetic abnormalities causing adverse pregnancy
outcomes.
Aims: Determine the association of factor V Leiden G1691A and prothrombin
gene G20210A mutation with adverse pregnancy outcomes.
Methods: It was a case control study, conducted at clinical laboratory, section
of haematology, and PCR-RFLP technique is used at multi-disciplinary laboratory,
Aga Khan University Hospital. Females with adverse pregnancy outcomes who
came to obstetrical clinic were included in the study as cases. Adverse pregnancy
outcomes included recurrent pregnancy loss (defined as >2 first trimester mis-
carriages or one or more second trimester miscarriage), severe pre-eclampsia,
placental abruption, intrauterine growth restriction and still birth. Control samples
are selected from females with ≥ 2 consecutive normal pregnancies. Calculated
sample size is 172 which comprise of 86 cases and 86 controls.
Results: Overall mean age of all subjects was 28.5 years (±4.9). Mean age of
cases was 29.3 (±5.17) years and of controls was 27.6 years (±4.5). 73 (84.8%)
cases had recurrent pregnancy loss, 12 (13.9%) had pre-eclampsia, 8 (9.3%)
had IUGR while placental abruption and still birth was present in 2 (2.3%)
cases each. 10 (11.6%) cases had more than one adverse pregnancy out-
comes. 19 (22.09%) cases had >4 pregnancy losses. Among cases, 40 (46.5%)
females had previous live births and 9 (10.4%) were pregnant at the time of
sample collection. Two cases with recurrent pregnancy loss (P=0.155 OR=0.49)
showed heterozygous mutation of factor V Leiden G1691A and while no muta-
tion identified in the control arm. Heterozygous prothrombin gene mutation was
identified in one case with recurrent pregnancy loss (P= 0.316 OR=0.497) while
none of the control exhibited this mutation.
Summary and Conclusions: This is a small sample sized study which does
not support a significant association between inherited thrombophilia mutations
and adverse pregnancy outcomes. The apparent lack of association may be
reconciled by the low numbers of subjects recruited.
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LONG-TERM ANTICOAGULATION WITH DABIGATRAN IN PATIENTS WITH
SEVERE LACTOSE INTOLERANCE
N. Bermejo1,* R. Sigüenza1, F. Ibañez1, M.H. Bañas1, I. Casas1, F.D.A. Perez
Leal1, J. Bergua1
1Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain
Background: Chronic anticoagulation is realized mainly with vitamin K antag-
onists (VKA), but the use of VKA is problematic in patients with severe lactose
intolerance. Dabigatran is currently the only available lactose-free oral antico-
agulant, however its use in patients with lactose intolerance has not been
described.
Aims: Evaluate long-term anticoagulation with dabigatran in patients suffering
lactose intolerance.
Methods: We present two patients with severe lactose intolerance on long-term
anticoagulation with VKA, that were transitioned from VKA to dabigatran because
the treatment with VKA worsened symptoms of their lactose intolerance. Case
1. A 75-year-old female was diagnosed with nonvalvular atrial fibrillation. Long-
term anticoagulation with VKA was started for stroke prevention. Two weeks
later, the patient was admitted by recurrence of acute diarrhea in the setting of
her lactose intolerance, well controlled so far. VKA was replaced by dabigatran
and fifteen months later, she remains asymptomatic. Case 2. A 40-year-old female
was diagnosed with antiphospholipid syndrome (APS) when she experienced a
non provocated acute left upper extremity venous thrombosis. She was started
on anticoagulation with VKA with an INR target of 2.5 and had no recurrence of
thrombosis. However, VKA therapy was complicated by frequent episodes of
diarrhea that the patient suffered from several years. She was evaluated by a
gastroenterologist and was diagnosed with lactose intolerance. Due to progres-
sive worsening gastrointestinal clinical despite a lactose free diet, three years
later she was transitioned from VKA to dabigatran. One year later, she is asymp-
tomatic and has not suffered thromboembolic recurrence. We present two
patients with severe lactose intolerance on long-term anticoagulation with VKA,
that were transitioned from VKA to dabigatran because the treatment with VKA
worsened symptoms of their lactose intolerance. Case 1. A 75-year-old female
was diagnosed with nonvalvular atrial fibrillation. Long-term anticoagulation with
VKA was started for stroke prevention. Two weeks later, the patient was admitted
by recurrence of acute diarrhea in the setting of her lactose intolerance, well con-
trolled so far. VKA was replaced by dabigatran and fifteen months later, she
remains asymptomatic. Case 2. A 40-year-old female was diagnosed with
antiphospholipid syndrome (APS) when she experienced an unprovoked acute
left upper extremity venous thrombosis. She was started on anticoagulation with
VKA with an INR target of 2.5 and had no recurrence of thrombosis. However,
VKA therapy was complicated by frequent episodes of diarrhea that the patient
suffered from several years earlier. She was evaluated by a gastroenterologist
and was diagnosed with lactose intolerance. Due to progressive worsening gas-
trointestinal clinical despite a lactose free diet, three years later she was transi-
tioned from VKA to dabigatran. One year later, she is asymptomatic and has not
suffered thromboembolic recurrence. 
Results: Our patients with lactose intolerance on long-term anticoagulation
with dabigatran have not experienced gastrointestinal symptoms or throm-
boembolic complications months after transitioning to dabigatran. 
Summary and Conclusions: Switching from VKA to dabigatran for patients
with lactose intolerance seemed clinically reasonable, but until results of
prospective randomised trials are available, we recommend caution in using
dabigatran in patients with APS.
PB2061
THE PENETRANT FEATURE OF VENOUS THROMBOEMBOLISM IN FAM-
ILIES WITH INHERITED THROMBOPHILIA FROM NATURAL ANTICOAG-
ULANT DEFICIENCY IN KOREA
Y.J. Jung1,* D.K. Kim2, S.H. Kim1, H.J. Kim1
1Department of Laboratory Medicine and Genetics, 2Department of Medicine,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Korea, Republic Of
Background: Inherited thrombophilia is a genetic predisposition to develop
venous thromboembolism (VTE) from either deficiency of natural anticoagu-
lants (NA) or increased procoagulant activity. Deficiencies of NA such as protein
C (PC), protein S (PS) and antithrombin (AT) are relatively common in Asian
populations. It has been acknowledged that the development of VTE is affected
by various factors other than genetic predisposition such as environmental
influences and other modifiers.
Aims: The purpose of this study was to investigate the penetrance of VTE in
families with inherited thrombophilia from NA deficiency in Korea.
Methods: The authors reviewed the family history and family study results in
a cohort of consecutive patients with VTE from genetically confirmed NA defi-
ciency between January 2005 and December 2014 at a single tertiary institution
in Seoul, Korea.
Results: A total of 87 probands were VTE patients with PC (N=44), PS (N=21),
or AT (N=22) deficiency confirmed by molecular genetic tests (mean age: 40
years; 62 men and 25 women). The family history of the parents was available
in 78 probands, and a positive VTE history was ascertained in 7 (9%). Family
study was performed in both or either one of the parents in 10 probands, and
11 parents of either side (mean age: 55 years; 4 fathers and 7 mothers) were
confirmed to have the same mutation as in the probands. Among them, 2 had
a history of VTE (18%).
Summary and Conclusions: To our knowledge, this is the first study to inves-
tigate the family history of VTE in a large cohort of probands with genetically
confirmed NA deficiency. The results demonstrated a low penetrance of VTE
in the parents of the probands, even in genetically confirmed cases. The data
suggested that the environmental factors (possibly generation-dependent) have
implications for the index of suspicion in inherited thrombophilia and genetic
counseling in VTE patients. A further study involving siblings of the probands
is believed to better delineate the penetrance feature.
PB2062
A LOCAL PROCESS AND MANAGEMENT FOR HOSPITAL ASSOCIATED
VENOUS THROMBOEMBOLISM EVENTS
S. Patel1,* S. Deplano1, F. Matthey1
802 | haematologica | 2015; 100(s1)
20thCongress of the European Hematology Association
1Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
Background: In 2005 a House of Commons Health Committee in England
reported an estimated 25000 avoidable deaths occur annually in the UK from
hospital associated venous thromboembolism (VTE)1. There is ongoing work
in England to develop up-to-date and accurate statistics about incidence and
death from hospital associated VTE although this is difficult due to often clinically
silent nature of VTE and a decrease in post-mortems in recent years. Root
cause analysis (RCA) is required for all confirmed cases of pulmonary embolism
and deep vein thrombosis associated by patients in hospital, with an aim to
reduce avoidable death, disability and chronic ill heath from VTE2.
Aims: To implement a process for identification and management of hospital
associated VTE events (HATs). To determine incidence of HATs and potentially
preventable HATs. To identify contributory factors for potentially preventable
HATs
Methods: Support from senior Executives were essential in prioritising VTE as
a patient safety quality improvement objective. RCA tools were developed to
explore the how, the what, and most importantly the why of HAT. RCA will iden-
tify contributory factors and inform an action plan developing solutions with
monitoring to prevent reoccurrence. The VTE RCA team is multidisciplinary
with Consultant Haematologist, Anticoagulation Pharmacist, lead clinician, clin-
ical governance and radiology departments. Weekly imaging reports are sent
by the radiology team. Reports are screened to identify new VTE diagnosis.
Patient records are reviewed to establish whether the VTE event is hospital
associated. Lead clinicians are requested to complete the RCA tool to determine
whether the HAT was potentially preventable. An action plan is implemented to
address contributory factors.
Results: From April 2014-January 2015, 6 potentially preventable HATs iden-
tified. Interventions to address contributory factors for HATs were: A ‘Preventing
Harm’ group was introduced to investigate omitted doses of thromboprophy-
laxis, without clinical omission. An electronic report was created for ‘prescribed
but not given’ medications, by ward. Agency nursing staff were given access to
the electronic prescribing system to allow for documentation of medications
given. VTE ward rounds introduced on medical, surgical and obstetric wards
to review VTE risk assessment completion and accuracy, and whether throm-
boprophylaxis is appropriate. A summary report of findings/learning points is
circulated to division. Risk assessment and guidance for patients with lower
limb immobilisation was updated with appropriate management. Patient agree-
ment to investigation or treatment consent form updated to include VTE as a
significant, unavoidable or frequently occurring risk related to surgical proce-
dures. WHO checklist updated to define if thromboprophylaxis is required and
if prescribed. Educational support for accurate VTE risk assessments at booking
appointments for antenatal women, to identify those at risk requiring antenatal
thromboprophylaxis. Audits performed to assess whether patients receive ver-
bal/written information on VTE prevention.
Summary and Conclusions: The VTE team implemented a robust and sus-
tainable system for identifying and analysing HATs with feedback to depart-
ments. Successful interventions are embedded into clinical practice to reduce
HATs. Key messages: Continuous VTE awareness, education and stewardship,
Robust action plans to drive and excel performance, Real-time reporting, Main-
tain VTE momentum – cause some noise about VTE prevention.
PB2063
INHERITED AND AQUIRED THROMBOPHILLIAS IN WOMEN WITH REC-
CURENT PREGNANCY LOSS- OUR EXPERIENCE
E. Miljkovic1,* D. Markovic1, M. Vucic1
1Clinical Center Nis, Nis, Serbia
Background: Inherited thrombophilias are the leading cause of maternal throm-
boembolism and are associated with an increased risk of certain adversy preg-
nancy outcomes including second and third trimester fetall loss, abruptions,
severe intrauterine growth restriction and early onset severe preeclampsia.
The antiphospholipid antibody syndrome (APS) is an acquired autoimmune
thrombophyllia in which vascular thrombosis and/or reccurent pregnancy losses
occur in patients having laboratory evidence for antibodies againts phospho-
lipids or phospholipid-binding protein cofactors in their blood. Pregnant women
with these highly thrombogenic conditions are at very high risk for both throm-
boembolism and adverse pregnancy outcomes.
Aims: Aim was to determine the presense of inherited or acquired throm-
bophillias in women with reccurent pregnancy losses (RPL).
Methods: Women with RPL were tested for heterozygosity for the factor V Lei-
den and prothrombin G 20210A mutations, homo and heterozygosity in the
type 1 plasminogen activator inhibitor gene (PAI-1) and the thermolabile variant
of the methylentetrahydrofolate reductase gene (MTHFR). They were also test-
ed for deficiencies of protein C, protein S and antithrombin, as well as for
antiphospholipid antibodies-anti beta 2 glycoprotein I antibodies, anticardiolipin
antibodies and lupus anticoagulant assays.
Results: From January 2011 till January 2015 260 women were tested for the
presense of inherited or acquired thrombophillias because of reccurent preg-
nancy loss or treatment of infertility. Median age of patients was 33.4 (19-45).
Six women (2.3%) was negative for both inherited or APS and others (97.7%)
were positive. Criteria for APS fullfilled 57 patinets (21.9%), 8 patients (3%)
had only APS and 49 patients (97%) had APS with some of inherited throm-
bophillias. 246 patients (94.6%) were positive for one or more inherited throm-
bophillias. 99 patients (38.1%) were positive for one inherited thrombophillia: 4
(1.5%) for Factor V Leiden, 2 (0.7%) for prothrombin G 20210A, 47 (18%) for
MTHFR and 46 (17.7%) for PAI-1. 133 patients (41.1%) were positive for 2, 13
patients (5%) for 3 inherited thrombophillias. 105 patients (40.3%) with low
molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone had success-
fully pregnancy outcome-live birth.
Summary and Conclusions: Some form of thrombophillia-inherited or
acquired was found in most of tested women with reccurent pregnancy loss
(97.6%) and 163 patients (62.7%) had more then one thrombophillia. With ade-
quate anticoagulant therapy patients with these conditions had chance for suc-
cessfully pregnancy outcome.
PB2064
INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH
INTRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE
IN TURKEY
T. Patiroglu1,* G. Koç2, M. Canpolat3, E. Unal1, S. Doğanay2, M. Karakukcu1,
M.A. Ozdemir1
1Pediatric Hematology, 2Pediatric Radiology, 3Pediatric Neurology, Erciyes Uni-
versity Medical Faculty, Kayseri, Turkey
Background: Intracranial venous thrombosis (IVT) is a rare condition in child-
hood, with a wide variety of clinical features and etiologies.
Aims: We aimed to describe the inherited prothrombotic risk factors in children
with IVT, confirmed by neuroimaging.
Methods: The retrospective study involved reviewing the records of patients
who were admitted to our hospital during the years of 2010-2014. The patients
diagnosed as having IVT, confirmed by neuroimaging were investigated for the
common thrombophilia markers, such as protein C (PC), protein S (PS),
antithrombin III (AT III), factor V G1691A and prothrombin 620210A mutations,
methylenetetrahyrafolate reductase (MTHRF) C677T, and MTHFR A1298C
genotypes.
Results: The clinical manifestations in 18 patients with IVT included headache,
seizures, cranial nerve palsy, and hemiparesis. Transfer sinus thrombosis was
the commonest site (50%) followed by diffuse sinus thrombosis (31.25%). Two
patients had PC deficiency. Furthermore, one of them had homozygous MTHFR
C677T genotype. No patient had PS and ATIII deficiencies, and prothrombin
620210A mutations. Eleven patients showed the MTHFR genotype (homozy-
gous C677T, n=4, heterozygous C677T, n=5, heterozygous A1298 C, n=2);
and 1 patient was carrier of heterozygous factor V mutation.
Summary and Conclusions: Early diagnosis by fast and safe radiological
methods (neuroimaging of the brain), investigation of thrombophilia markers
and the appropriate anti-clotting therapy in acute phase may prevent death due
to IVT at the pediatric age.
PB2065
PAIN AS UNIQUE MANIFESTATION OF HIGH TITER ANTI-PF4/HEPARIN
ANTIBODIES.
M. Nagy1,* L. Alberio1
1Hematology, CHUV, Lausanne, Switzerland
Background: A 68 years old male patient was addressed for hematological
care in the context of polycythemia vera, a recent proximal deep vein thrombo-
sis, and a newly diagnosed rectal tumor requiring resection. The patient had
been known for polycythemia vera for 10 years, was treated by hydroxycar-
bamid and aspirin, and presented stable blood counts. A recently diagnosed
left femoro-popliteal thrombosis had been treated by dalteparin. One week after
the initiation of anticoagulation he signaled the apparition of extreme, burning
pain in the distal region of the thrombosed leg and in the right hand, always
starting 1 hour after each injection of dalteparin. The pain persisted for a couple
of hours and was not responsive to anti-inflammatory and analgesic treatment.
The switch of the low molecular weight heparin (LMWH) to nadroparin did not
affect the pain. Clinical examination showed discrete lower limb edema pre-
dominantly in the affected side, without sign of ischemia. Imaging did not show
an extension of the thrombosis. Discrete thrombocytopenia (137 G/l) was the
only anomaly of blood count. Coagulation tests were normal. 
Aims: To describe laboratory findings and clinical course of this unsusual case.
Methods: Because of the consistent temporal relation of the pain to the admin-
istration of LMWH and the slight degree of thrombocytopenia, anti-PF4/heparin
antibodies were assessed. The IgG-monospecific ELISA was highly positive
(OD 1.86; cut-off : 0.32). The HIPA test performed in a reference laboratory
was negative even if the local ELISA was also highly positive. 
Results: Nadroparin was immediately changed to fondaparinux, which allowed
prompt and complete resolution of the pain. After one month of fondaparinux
treatment a Doppler control of the thrombosis showed thrombus persistence
without complete canalization. Blood counts showed discrete anemia and
thrombocytosis, and the anti-PF4/heparin antibody level decreased to OD 1.45.
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The rectal surgery was performed with no complication 36 hours after the last
dose of fondaparinux and anticoagulation was resumed in the post-operative
phase with argatroban followed by fondaparinux 3 days later. At last follow-up,
1 month after surgery the patient was still on fondaparinux, free of pain and
the anti-PF4/antibody level had further decreased (OD 0.98).
Summary and Conclusions: Because of the temporal relation of the patient’s
symptoms with the administration of LMWH and the steady decline of anti-
PF4/heparin antibodies after switch to fondaparinux, we consider this the first
case report of high titer anti-PF4/heparin antibodies uniquely presenting with
post-injection pain. We propose that clinicians should be aware that the pres-
ence of high titer anti-PF4/heparin antibodies might be related to otherwise
unexplained pain after injection of low-molecular weight heparins. In our case,
switch to a non-heparin based anticoagulation lead to an immediate disap-
pearance of the post-injection pain.
Transfusion medicine
PB2066
PREVENTING UNNECESSARY TRANSFUSIONS DURING ELECTIVE PRO-
CEDURES
A. Niblock1,* K. Donnelly2, L. Henderson3, A. Ruiz2, J. McCormick2
1haematology, Belfast City Hospital, Belfast, 2Altnagelvin Area Hospital, Lon-
donderry, 3Orthopaedics, Altnagelvin Area Hospital, Derry, United Kingdom
Background: In 2013 the UK chief medical officers iniative Patient Blood Man-
agement superseded Better Blood Transfusion. Patient Blood Management is a
multidisciplinary, evidence-based approach to optimising the care of patients who
might need blood transfusion. Patient Blood Management puts the patient at the
heart of decisions made about blood transfusion to ensure they receive the best
treatment and avoidable, inappropriate use of blood and blood components is
reduced. Reduced blood usage will reduce demand, therefore less pressure on
Northern Ireland Blood Transfusion Service. In turn will mean less shortages and
more blood available for emergencies. If a transfusion is avoided then there is
no risk of a transfusion reaction. Safest blood transfusion is the one not given.
Aims: Can blood transfusions be prevented during elective procedures?
Methods: A surgical list of all elective hip replacements was obtained between
01/09/2013 and 31/12/2013. Preoperative assessment including baseline
haemoglobin was recorded. Post operative complications including haemoglo-
bin drop and blood transfusions were looked at.
Results: 68 patients underwent elective hip replacements during this time. 5
patients underwent post operative blood transfusions 12/68 had pre operative
haemoglobins<120g/l 56/68 had pre operative hb >120g/l 0% of patients with a
pre operative hb >120g/l required a blood transfusion. 5/12 patients with a pre
operative hb<120g/l required at least 1 unit of packed red cells post operatively.
Summary and Conclusions: All patients with a hb<120g/l at present are not
being added to the elective hip replacement list until their anaemia is investi-
gated and managed appropriately. General Practitioners received a letter indi-
cating that the pre operative assessment has detected anaemia, also enclosed
is guidelines regarding the investigation of anaemia. Once the patients anaemia
has been treated or hb optimised the patient is returned to the waiting list.
The safest blood transfusion is the one not received.
PB2067
PROGRESSIVE DECLINE OF HBSAG SEROPREVALANCE IN BLOOD
DONORS IN NORTHERN TURKEY: THE TWENTY ONE-YEAR EXPERI-
ENCE 
D. Albayrak1,* C. Albayrak1
1Pediatric Hematology Department, Samsun Ondokuz Mayis University Faculty
of Medicine, Samsun, Turkey
Background: The high prevalence of HBV, HCV, HIV-1/2 and treponema pal-
lidum carriers among blood donors has the unpleasant results for cost- effec-
tive, transfusion security and contagious disease. 
Aims: The aim of this study was to determine the seroprevalence of HBV,
HCV, HIV-1/2 and treponema pallidum in blood donors who applied to our
Blood Bank in an twenty one –year period retrospectively. 
Methods: The single donations and first time donation of repeat donors entered
statistical analysis. HBsAg, anti-HCV treponema pallidum and anti-HIV-1/2
screening tests were performed using ELISA kits. 
Results: Between 1994 and 2015, total 267,242 blood donation records at the
Blood Banks of University were retrieved. Of them 206,027 were first time
donors. HBV, HCV, HIV-1/2 and treponema pallidum seroprevalences among
these first time donors were analyzed. The mean seroprevalence of HBsAg
was 3.6% between 1994 and 2000 years. The rate of HBsAg positivity was
unchanged in these seven years. But prevalence began to decrease in 2001.
The positivity rates were 3.7% in 2000 and 3.1% in 2001. This difference was
significant statistically. This declining continued progressively in later years and
the rate dropped to 0.5% in 2014. 
Summary and Conclusions: This retrospective study showed a significant
and progressive decline in the HBsAg seropositivity while no apparent change
were those of HCV, HIV and T. Pallidum among blood donors in Northern
Turkey at last thirteen years. The drop in HBsAg seroprevalence is probably
multifactorial such as public education activities and use of mandatory dispos-
able injectors.
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